METHODS 0 NOUN T
Ten 0 NUM T
healthy 0 ADJ F
volunteers 0 NOUN F
were 0 VERB F
enrolled 0 VERB F
in 0 ADP F
a 0 DET F
randomized 0 VERB F
, 0 PUNCT F
double-blinded 0 VERB F
, 0 PUNCT F
placebo-controlled 0 VERB F
, 0 PUNCT F
crossover 0 ADP F
trial 0 NOUN F
in 0 ADP F
which 0 ADP F
they 0 PRON F
received 0 VERB F
an 0 DET F
infusion 0 NOUN F
of 0 ADP F
saline 0 NOUN F
, 0 PUNCT F
remifentanil 0 ADJ F
, 0 PUNCT F
or 0 CCONJ F
alfentanil 0 NOUN F
for 0 ADP F
120 0 NUM F
min 0 NOUN F
. 0 PUNCT F

The 0 DET T
age- 0 NOUN F
and 0 CCONJ F
weight-adjusted 0 VERB F
infusions 0 NOUN F
( 0 PUNCT F
determined 0 VERB F
with 0 ADP F
STANPUMP 0 NOUN T
, 0 PUNCT F
a 0 DET F
computer 0 NOUN F
modeling 0 PUNCT F
software 0 NOUN F
package 0 NOUN F
) 0 PUNCT F
were 0 VERB F
given 0 VERB F
to 0 PART F
achieve 0 NOUN F
three 0 NUM F
predicted 0 VERB F
constant 0 ADJ F
plasma 0 NOUN F
levels 0 NOUN F
for 0 ADP F
40 0 NUM F
min 0 NOUN F
each 0 ADP F
of 0 ADP F
remifentanil 0 NOUN F
( 0 PUNCT F
0.75 0 NUM F
, 0 PUNCT F
1.5 0 NUM F
, 0 PUNCT F
and 0 CCONJ F
3 0 NUM F
ng/ml 0 NOUN F
) 0 PUNCT F
and 0 CCONJ F
alfentanil 0 NOUN F
( 0 PUNCT F
16 0 NUM F
, 0 PUNCT F
32 0 NUM F
, 0 PUNCT F
and 0 CCONJ F
64 0 ADP F
ng/ml 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

Mood 0 PUNCT T
forms 0 NOUN F
and 0 CCONJ F
psychomotor 0 NOUN F
tests 0 NOUN F
were 0 VERB F
completed 0 VERB F
, 0 PUNCT F
and 0 CCONJ F
miosis 0 NOUN F
was 0 VERB F
assessed 0 VERB F
, 0 PUNCT F
during 0 ADP F
and 0 CCONJ F
after 0 ADP F
the 0 DET F
infusions 0 NOUN F
. 0 PUNCT F

In 0 ADP T
addition 0 NOUN F
, 0 PUNCT F
analgesia 0 NOUN F
was 0 VERB F
tested 0 VERB F
at 0 ADP F
each 0 DET F
dose 0 NOUN F
level 0 NOUN F
using 0 VERB F
a 0 DET F
cold-pressor 0 NOUN F
test 0 NOUN F
. 0 PUNCT F

RESULTS 0 ADJ T
Remifentanil 0 NOUN T
had 0 PUNCT F
prototypic B-MENTAL ADJ F
micro-like I-MENTAL ADJ F
opioid I-MENTAL NOUN F
subjective I-MENTAL ADJ F
effects I-MENTAL NOUN F
, 0 PUNCT F
impaired B-MENTAL VERB F
psychomotor I-MENTAL NOUN F
performance I-MENTAL NOUN F
, 0 PUNCT F
and 0 PUNCT F
produced 0 PUNCT F

A 0 DET T
double-blind 0 ADJ F
placebo 0 NOUN F
controlled 0 VERB F
trial 0 NOUN F
of 0 ADP F
piracetam 0 NOUN F
added 0 VERB F
to 0 ADP F
risperidone 0 NUM F
in 0 ADP F
patients 0 NOUN F
with 0 ADP F
autistic 0 ADJ F
disorder 0 NOUN F
. 0 PUNCT F

It 0 PRON T
has 0 PUNCT F
been 0 PUNCT F
reported 0 VERB F
that 0 ADP F
autism 0 NOUN F
is 0 VERB F
a 0 DET F
hypoglutamatergic 0 ADJ F
disorder 0 NOUN F
. 0 PUNCT F

Therefore 0 ADV T
, 0 PUNCT F
it 0 PRON F
was 0 DET F
of 0 ADP F
interest 0 NOUN F
to 0 PART F
assess 0 NOUN F
the 0 DET F
efficacy 0 NOUN F
of 0 ADP F
piracetam 0 NOUN F
, 0 PUNCT F
a 0 DET F
positive 0 ADJ F
modulator 0 NOUN F
of 0 ADP F
AMPA-sensitive 0 ADJ T
glutamate 0 NOUN F
receptors 0 NOUN F
in 0 ADP F
autistic 0 ADJ F
disorder 0 NOUN F
. 0 PUNCT F

About 0 PUNCT T
40 0 NUM F
children 0 NOUN F
between 0 ADP F
the 0 DET F
ages 0 NOUN F
three 0 NUM F
and 0 CCONJ F
11 0 NUM F
years 0 NOUN F
( 0 PUNCT F
inclusive 0 PUNCT F
) 0 PUNCT F
with 0 ADP F
a 0 DET F
DSM 0 NOUN T
IV 0 NUM T
clinical 0 ADJ F
diagnosis 0 NOUN F
of 0 ADP F
autism 0 NOUN F
and 0 CCONJ F
who 0 ADP F
were 0 ADP F
outpatients 0 ADJ F
from 0 ADP F
a 0 DET F
specialty 0 NOUN F
clinic 0 NOUN F
for 0 ADP F
children 0 NOUN F
were 0 VERB F
recruited 0 VERB F
. 0 PUNCT F

The 0 DET T
children 0 NOUN F
presented 0 VERB F
with 0 ADP F
a 0 DET F
chief 0 ADJ F
complaint 0 NOUN F
of 0 ADP F
severely 0 ADV F
disruptive 0 ADJ F
symptoms 0 NOUN F
related 0 VERB F
to 0 ADP F
autistic 0 ADJ F
disorder 0 NOUN F
. 0 PUNCT F

Patients 0 NOUN T
were 0 VERB F
randomly 0 ADV F
allocated 0 VERB F
to 0 ADP F
piracetam 0 NOUN F
+ 0 SYM F
risperidone 0 NUM F
( 0 PUNCT F
Group 0 NOUN T
A 0 NOUN T
) 0 PUNCT F
or 0 CCONJ F
placebo 0 NOUN F
+ 0 SYM F
risperidone 0 NUM F
( 0 PUNCT F
Group 0 NOUN T
B 0 NOUN T
) 0 PUNCT F
for 0 ADP F
a 0 DET F
10-week 0 NOUN F
, 0 PUNCT F
double-blind 0 ADJ F
, 0 PUNCT F
placebo-controlled 0 VERB F
study 0 NOUN F
. 0 PUNCT F

The 0 DET T
dose 0 NOUN F
of 0 ADP F
risperidone 0 NUM F
was 0 VERB F
titrated 0 VERB F
up 0 CCONJ F
to 0 ADP F
2 0 NUM F
mg/day 0 NOUN F
for 0 ADP F
children 0 NOUN F
between 0 ADP F
10 0 NUM F
and 0 CCONJ F
40 0 NUM F
kg 0 NOUN F
and 0 CCONJ F
3 0 NUM F
mg/day 0 NOUN F
for 0 ADP F
children 0 NOUN F
weighting 0 CCONJ F
above 0 ADP F
40 0 NUM F
kg 0 NOUN F
. 0 PUNCT F

The 0 DET T
dose 0 NOUN F
of 0 ADP F
piracetam 0 NOUN F
was 0 VERB F
titrated 0 VERB F
up 0 CCONJ F
to 0 ADP F
800 0 NUM F
mg/day 0 NOUN F
. 0 PUNCT F

Patients 0 NOUN T
were 0 VERB F
assessed 0 VERB F
at 0 ADP F
baseline 0 NOUN F
and 0 CCONJ F
after 0 ADP F
2 0 NUM F
, 0 PUNCT F
4 0 NUM F
, 0 PUNCT F
6 0 NUM F
, 0 PUNCT F
8 0 NUM F
and 0 CCONJ F
10 0 NUM F
weeks 0 NOUN F
of 0 ADP F
starting 0 PUNCT F
medication 0 NOUN F
. 0 PUNCT F

The 0 DET T
measure 0 NOUN F
of 0 ADP F
the 0 DET F
outcome 0 NOUN F
was 0 VERB F
the 0 DET F
Aberrant B-OTHER ADJ T
Behavior I-OTHER NOUN T
Checklist-Community I-OTHER NOUN T
( I-OTHER PUNCT F
ABC-C I-OTHER NOUN T
) I-OTHER PUNCT F
Rating I-OTHER PUNCT T
Scale 0 NOUN T
( 0 PUNCT F
total 0 ADJ F
score 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
ABC-C B-OTHER NOUN T
Rating I-OTHER PUNCT T
Scale I-OTHER NOUN T
scores 0 NOUN F
improved 0 VERB F
with 0 ADP F
piracetam 0 NOUN F
. 0 PUNCT F

The 0 DET T
difference 0 NOUN F
between 0 ADP F
the 0 DET F
two 0 NUM F
protocols 0 NOUN F
was 0 VERB F
significant 0 ADJ F
as 0 ADP F
indicated 0 VERB F
by 0 ADP F
the 0 DET F
effect 0 NOUN F
of 0 ADP F
group 0 NOUN F
, 0 PUNCT F
the 0 DET F
between 0 ADP F
subjects 0 ADJ F
factor 0 NOUN F
( 0 PUNCT F
F 0 NOUN T
= 0 SYM F
5.85 0 NUM F
, 0 PUNCT F
d.f 0 PUNCT F
. 0 PUNCT F

= 0 SYM F
1 0 NUM F
, 0 PUNCT F
P 0 NOUN T
= 0 SYM F
0.02 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
changes 0 NOUN F
at 0 ADP F
the 0 DET F
endpoint 0 NOUN F
compared 0 VERB F
with 0 ADP F
baseline 0 NOUN F
were 0 ADJ F
: 0 PUNCT F
-11.90 0 NOUN F
+/- 0 SYM F
3.79 0 NUM F
( 0 PUNCT F
mean 0 NOUN F
+/- 0 SYM F
SD 0 NOUN T
) 0 PUNCT F
and 0 CCONJ F
-5.15 0 ADJ F
+/- 0 SYM F
3.04 0 NUM F
for 0 ADP F
group 0 NOUN F
A 0 NOUN T
and 0 CCONJ F
B 0 NOUN T
respectively 0 ADV F
. 0 PUNCT F

A 0 DET T
significant 0 ADJ F
difference 0 NOUN F
was 0 VERB F
observed 0 VERB F
on 0 ADP F
the 0 DET F
change 0 NOUN F
in 0 ADP F
scores B-OTHER NOUN F
in I-OTHER ADP F
the I-OTHER DET F
ABC-C I-OTHER NOUN T
Rating I-OTHER PUNCT T
Scale I-OTHER NOUN T
in 0 ADP F
week 0 NOUN F
10 0 NUM F
compared 0 VERB F
with 0 ADP F
baseline 0 NOUN F
in 0 ADP F
the 0 DET F
two 0 NUM F
groups 0 NOUN F
( 0 PUNCT F
t 0 NOUN F
= 0 SYM F
6.017 0 NUM F
, 0 PUNCT F
d.f 0 PUNCT F
. 0 PUNCT F

= 0 SYM F
38 0 NUM F
, 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.0001 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
results 0 CCONJ F
suggest 0 VERB F
that 0 ADP F
a 0 DET F
combination 0 NOUN F
of 0 ADP F
atypical 0 ADJ F
antipsychotic 0 ADJ F
medications 0 NOUN F
and 0 CCONJ F
a 0 DET F
glutamate 0 NOUN F
agent 0 NOUN F
such 0 PUNCT F
as 0 ADP F
piracetam 0 NOUN F
, 0 PUNCT F
might 0 VERB F
have 0 CCONJ F
increase 0 DET F
synergistic 0 ADJ F
effects 0 NOUN F
in 0 ADP F
the 0 DET F
treatment 0 NOUN F
of 0 ADP F
autism 0 NOUN F
. 0 PUNCT F

Use 0 NOUN T
of 0 ADP F
an 0 DET F
inspiratory 0 ADJ F
impedance 0 NOUN F
threshold 0 NOUN F
device 0 NOUN F
on 0 ADP F
a 0 DET F
facemask 0 VERB F
and 0 CCONJ F
endotracheal 0 ADJ F
tube 0 NOUN F
to 0 PART F
reduce 0 ADJ F
intrathoracic B-PHYSICAL DET F
pressures I-PHYSICAL NOUN F
during 0 ADP F
the 0 DET F
decompression 0 NOUN F
phase 0 NOUN F
of 0 ADP F
active 0 ADJ F
compression-decompression B-PHYSICAL NOUN F
cardiopulmonary I-PHYSICAL ADJ F
resuscitation I-PHYSICAL NOUN F
. 0 PUNCT F

INTRODUCTION 0 NOUN T
Use 0 NOUN T
of 0 ADP F
an 0 DET F
inspiratory 0 ADJ F
impedance 0 NOUN F
threshold 0 NOUN F
device 0 NOUN F
( 0 PUNCT F
ITD 0 NOUN T
) 0 PUNCT F
significantly 0 ADV F
increases 0 NOUN F
coronary 0 ADJ F
perfusion 0 NOUN F
pressures 0 NOUN F
and 0 CCONJ F
survival 0 NOUN F
in 0 ADP F
patients 0 NOUN F
ventilated 0 VERB F
with 0 ADP F
an 0 DET F
endotracheal 0 ADJ F
tube 0 NOUN F
( 0 PUNCT F
ETT 0 NOUN T
) 0 PUNCT F
during 0 ADP F
active 0 ADJ F
compression-decompression 0 NOUN F
cardiopulmonary 0 ADJ F
resuscitation 0 NOUN F
. 0 PUNCT F

We 0 PRON T
tested 0 VERB F
the 0 DET F
hypothesis 0 NOUN F
that 0 ADP F
the 0 DET F
ITD 0 NOUN T
could 0 PUNCT F
lower 0 PUNCT F
intratracheal 0 VERB F
pressures 0 NOUN F
when 0 ADP F
attached 0 VERB F
to 0 ADP F
either 0 CCONJ F
a 0 DET F
facemask 0 VERB F
or 0 CCONJ F
ETT 0 NOUN T
. 0 PUNCT F

METHODS 0 NOUN T
An 0 DET T
active 0 ADJ F
and 0 CCONJ F
sham 0 ADJ F
ITD 0 NOUN T
were 0 VERB F
randomly 0 ADV F
applied 0 VERB F
first 0 VERB F
to 0 ADP F
a 0 DET F
facemask 0 VERB F
and 0 CCONJ F
then 0 ADV F
to 0 ADP F
an 0 DET F
ETT 0 NOUN T
during 0 ADP F
active 0 ADJ F
compression-decompression 0 NOUN F
cardiopulmonary 0 ADJ F
resuscitation 0 NOUN F
in 0 ADP F
13 0 NUM F
out-of-hospital 0 ADJ F
cardiac 0 ADJ F
arrest 0 ADV F
patients 0 NOUN F
in 0 ADP F
a 0 DET F
randomized 0 VERB F
, 0 PUNCT F
double-blinded 0 VERB F
, 0 PUNCT F
prospective 0 ADJ F
clinical 0 ADJ F
trial 0 NOUN F
. 0 PUNCT F

The 0 DET T
compression-to-bag-valve 0 PUNCT F
ventilation 0 NOUN F
ratio 0 NOUN F
was 0 ADP F
15:2 0 PUNCT F
. 0 PUNCT F

Airway 0 NOUN T
pressures 0 NOUN F
( 0 PUNCT F
surrogate 0 ADJ F
for 0 ADP F
intrathoracic 0 PUNCT F
pressure 0 NOUN F
) 0 PUNCT F
were 0 VERB F
measured 0 VERB F
with 0 ADP F
a 0 DET F
pressure 0 NOUN F
transducer 0 NOUN F
. 0 PUNCT F

A 0 DET T
sham 0 ADJ F
and 0 CCONJ F
an 0 DET F
active 0 ADJ F
ITD 0 NOUN T
were 0 VERB F
used 0 VERB F
for 0 ADP F
1 0 NUM F
min 0 NOUN F
each 0 CCONJ F
in 0 ADP F
a 0 DET F
randomized 0 VERB F
order 0 NOUN F
, 0 PUNCT F
first 0 ADJ F
on 0 ADP F
a 0 DET F
facemask 0 VERB F
and 0 CCONJ F
then 0 ADV F
on 0 ADP F
an 0 DET F
ETT 0 NOUN T
. 0 PUNCT F

Statistical 0 ADJ T
analyses 0 NOUN F
were 0 VERB F
made 0 VERB F
using 0 VERB F
Friedman 0 NOUN T
's 0 PUNCT F
and 0 CCONJ F
Wilcoxon 0 NOUN T
's 0 PUNCT F
rank-sum 0 NOUN F
tests 0 NOUN F
. 0 PUNCT F

RESULTS 0 NOUN T
For 0 ADP T
the 0 DET F
primary 0 ADJ F
end 0 NOUN F
point 0 NOUN F
, 0 PUNCT F
mean 0 NOUN F
+/- B-PHYSICAL SYM F
sd I-PHYSICAL NOUN F
maximum I-PHYSICAL NOUN F
negative 0 ADJ F
intrathoracic B-PHYSICAL PUNCT F
pressures B-PHYSICAL NOUN F
( 0 PUNCT F
mm 0 NOUN F
Hg 0 NOUN T
) 0 PUNCT F
during 0 ADP F
the 0 DET F
decompression 0 NOUN F
phase 0 NOUN F
of 0 ADP F
cardiopulmonary B-PHYSICAL ADJ F
resuscitation I-PHYSICAL NOUN F
were 0 VERB F
-1.0 0 NUM F
+/- 0 SYM F
0.73 0 NUM F
mm 0 NOUN F
Hg 0 NOUN T
with 0 ADP F
a 0 DET F
sham 0 ADJ F
vs. 0 CCONJ F
-4.6 0 NUM F
+/- 0 SYM F
3.7 0 NUM F
mm 0 NOUN F
Hg 0 NOUN T
with 0 ADP F
an 0 DET F
active 0 ADJ F
ITD 0 NOUN T
on 0 ADP F
the 0 DET F
facemask 0 NOUN F
( 0 PUNCT F
p 0 NOUN F
= 0 SYM F
.003 0 NUM F
) 0 PUNCT F
and 0 CCONJ F
-1.3 0 NUM F
+/- 0 SYM F
1.3 0 NUM F
mm 0 NOUN F
Hg 0 NOUN T
with 0 ADP F
a 0 DET F
sham 0 ADJ F
ITD 0 NOUN T
vs. 0 CCONJ F
-7.3 0 ADP F
+/- 0 SYM F
4.5 0 NUM F
mm 0 NOUN F
Hg 0 NOUN T
with 0 ADP F
an 0 DET F
active 0 ADJ F
ITD 0 NOUN T
on 0 ADP F
an 0 DET F
ETT 0 NOUN T
( 0 PUNCT F
p 0 NOUN F
= 0 SYM F
.0009 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Decompression B-PHYSICAL NOUN T
phase 0 PUNCT F

Effect 0 NOUN T
of 0 ADP F
spinal 0 ADJ F
versus 0 CCONJ F
general 0 ADJ F
anesthesia 0 NOUN F
on 0 ADP F
bladder B-PHYSICAL NOUN F
compliance I-PHYSICAL NOUN F
and 0 CCONJ F
intraabdominal B-PHYSICAL ADJ F
pressure I-PHYSICAL NOUN F
during 0 ADP F
transurethral 0 ADJ F
procedures 0 NOUN F
. 0 PUNCT F

STUDY 0 NOUN T
OBJECTIVE 0 NOUN T
To 0 PROPN T
evaluate 0 NOUN F
the 0 DET F
influence 0 NOUN F
of 0 ADP F
spinal 0 ADJ F
versus 0 CCONJ F
general 0 ADJ F
anesthesia 0 NOUN F
on 0 ADP F
bladder B-PHYSICAL NOUN F
compliance I-PHYSICAL NOUN F
and 0 CCONJ F
intraabdominal B-PHYSICAL ADJ F
pressure I-PHYSICAL NOUN F
in 0 ADP F
elderly 0 ADJ F
males 0 NOUN F
undergoing 0 VERB F
elective 0 ADJ F
transurethral 0 ADJ F
resection 0 NOUN F
of 0 ADP F
the 0 DET F
prostate 0 NOUN F
. 0 PUNCT F

DESIGN 0 NOUN T
Prospective 0 ADJ T
, 0 PUNCT F
randomized 0 VERB F
, 0 PUNCT F
open-label 0 NOUN F
study 0 NOUN F
. 0 PUNCT F

SETTING 0 ADJ T
Teaching 0 ADJ T
hospital 0 NOUN F
. 0 PUNCT F

PATIENTS 0 NOUN T
21 0 NUM F
ASA 0 NOUN T
physical 0 ADJ F
status 0 NOUN F
I 0 NUM T
, 0 PUNCT F
II 0 NUM T
, 0 PUNCT F
and 0 CCONJ F
III 0 NUM T
patients 0 NOUN F
at 0 ADP F
least 0 ADV F
18 0 NUM F
years 0 NOUN F
of 0 ADP F
age 0 NOUN F
, 0 PUNCT F
undergoing 0 VERB F
transurethral 0 ADJ F
surgery 0 NOUN F
. 0 PUNCT F

INTERVENTIONS 0 NOUN T
According 0 PUNCT T
to 0 ADP F
a 0 DET F
computer-generated 0 VERB F
randomization 0 NOUN F
schedule 0 NOUN F
, 0 PUNCT F
patients 0 NOUN F
were 0 VERB F
allocated 0 NUM F
to 0 ADP F
one 0 PUNCT F
of 0 ADP F
two 0 NUM F
groups 0 NOUN F
. 0 PUNCT F

In 0 ADP T
Group 0 NOUN T
Spinal 0 ADJ T
( 0 PUNCT F
S 0 NOUN T
) 0 PUNCT F
, 0 PUNCT F
10 0 NUM F
mg 0 NOUN F
of 0 ADP F
hyperbaric 0 ADJ F
tetracaine 0 NOUN F
was 0 VERB F
administered 0 VERB F
intrathecally 0 ADV F
. 0 PUNCT F

In 0 ADP T
Group 0 NOUN T
General 0 VERB T
Anesthesia 0 NOUN T
( 0 PUNCT F
GA 0 NOUN T
) 0 PUNCT F
, 0 PUNCT F
patients 0 NOUN F
received 0 VERB F
, 0 PUNCT F
fentanyl 0 NOUN F
intravenous 0 ADJ F
( 0 PUNCT F
i.v 0 NUM F
. 0 PUNCT F

1 0 NUM F
to 0 ADP F
2 0 NUM F
micrograms/kg 0 NOUN F
and 0 CCONJ F
propofol 0 NOUN F
i.v 0 NUM F
. 0 PUNCT F

1.0 0 NUM F
to 0 ADP F
2.0 0 NUM F
mg/kg 0 NOUN F
for 0 ADP F
induction 0 NOUN F
of 0 ADP F
anesthesia 0 NOUN F
. 0 PUNCT F

Thereafter 0 ADV T
, 0 PUNCT F
a 0 DET F
laryngeal 0 ADJ F
mask 0 NOUN F
airway 0 NOUN F
was 0 NOUN F
inserted 0 VERB F
and 0 CCONJ F
, 0 PUNCT F
with 0 ADP F
spontaneous 0 ADJ F
ventilation 0 NOUN F
, 0 PUNCT F
anesthesia 0 NOUN F
was 0 VERB F
maintained 0 VERB F
by 0 ADP F
administering 0 NOUN F
isoflurane 0 NOUN F
( 0 PUNCT F
end-tidal 0 NOUN F
0.7 0 NUM F
% 0 SYM F
to 0 ADP F
1.2 0 NUM F
% 0 SYM F
) 0 PUNCT F
and 0 CCONJ F
70 0 NUM F
% 0 SYM F
nitrous 0 ADJ F
oxide 0 NOUN F
( 0 PUNCT F
N2O 0 NOUN T
) 0 PUNCT F
in 0 ADP F
oxygen 0 NOUN F
. 0 PUNCT F

Intraabdominal 0 ADJ T
pressure 0 NOUN F
and 0 CCONJ F
bladder 0 NOUN F
compliance 0 NOUN F
were 0 VERB F
recorded 0 VERB F
prior 0 PUNCT F
to 0 ADP F
the 0 DET F
induction 0 NOUN F
of 0 ADP F
anesthesia 0 NOUN F
and 0 CCONJ F
immediately 0 ADV F
before 0 ADP F
the 0 DET F
onset 0 NOUN F
of 0 ADP F
the 0 DET F
surgical 0 ADJ F
procedure 0 NOUN F
. 0 PUNCT F

MEASUREMENTS 0 ADP T
AND 0 CCONJ T
MAIN 0 ADJ T
RESULTS 0 NOUN T
The 0 DET T
two 0 NUM F
groups 0 NOUN F
were 0 VERB F
demographically 0 ADV F
comparable 0 ADJ F
. 0 PUNCT F

In 0 ADP T
Group 0 NOUN T
S 0 NOUN T
, 0 PUNCT F
mean 0 VERB F
bladder 0 NOUN F
compliance 0 NOUN F
was 0 VERB F
significantly 0 ADV F
( 0 PUNCT F
p 0 NOUN F
= 0 SYM F
0.003 0 NUM F
) 0 PUNCT F
higher 0 PUNCT F
and 0 CCONJ F
mean 0 NOUN F
intraabdominal B-PHYSICAL ADJ F
pressure I-PHYSICAL NOUN F
significantly 0 ADV F
lower 0 PUNCT F
( 0 PUNCT F
p 0 NOUN F
= 0 SYM F
0.007 0 NUM F
) 0 PUNCT F
when 0 ADP F
compared 0 VERB F
to 0 ADP F
baseline 0 NOUN F
preanesthetic 0 ADJ F
values 0 NOUN F
. 0 PUNCT F

In 0 ADP T
Group 0 NOUN T
GA 0 NOUN T
, 0 PUNCT F
mean 0 VERB F
intraabdominal B-PHYSICAL ADJ F
pressure I-PHYSICAL NOUN F
significantly 0 ADV F
( 0 PUNCT F
p 0 NOUN F
= 0 SYM F
0.006 0 NUM F
) 0 PUNCT F
decreased 0 ADP F
when 0 ADP F
compared 0 VERB F
to 0 ADP F
baseline 0 NOUN F
preanesthetic 0 ADJ F
recordings 0 NOUN F
. 0 PUNCT F

Following 0 VERB T
the 0 DET F
induction 0 NOUN F
of 0 ADP F
general 0 ADJ F
anesthesia 0 NOUN F
, 0 PUNCT F
a 0 DET F
small 0 ADJ F
change 0 NOUN F
in 0 ADP F
bladder B-PHYSICAL NOUN F
compliance I-PHYSICAL NOUN F
was 0 VERB F
noted 0 VERB F
. 0 PUNCT F

However 0 ADV T
, 0 PUNCT F
statistical 0 ADJ F
significance 0 NOUN F
was 0 VERB F
not 0 ADV F
reached 0 VERB F
. 0 PUNCT F

Data 0 NOUN T
were 0 VERB F
analyzed 0 VERB F
and 0 CCONJ F
compared 0 VERB F
using 0 PROPN F
Student 0 NOUN T
's 0 PUNCT F
t-test 0 NOUN F
( 0 PUNCT F
p 0 NOUN F
< 0 SYM F
0.05 0 NUM F
was 0 VERB F
considered 0 VERB F
statistically 0 ADV F
significant 0 ADJ F
) 0 PUNCT F
. 0 PUNCT F

CONCLUSION 0 NOUN T
Both 0 CCONJ T
spinal 0 ADJ F
and 0 CCONJ F
general 0 ADJ F
anesthesia 0 NOUN F
induced 0 VERB F
a 0 DET F
significant 0 ADJ F
decrease 0 NOUN F
in 0 ADP F
intraabdominal 0 ADJ F
pressure 0 NOUN F
. 0 PUNCT F

While 0 ADP T
both 0 CCONJ F
techniques 0 NOUN F
were 0 VERB F
associated 0 VERB F
with 0 ADP F
an 0 DET F
increase 0 NOUN F
in 0 ADP F
bladder 0 NOUN F
compliance 0 NOUN F
, 0 PUNCT F
statistical 0 ADJ F
significance 0 NOUN F
was 0 VERB F
demonstrated 0 VERB F
only 0 ADV F
in 0 ADP F
the 0 DET F
spinal 0 ADJ F
anesthesia 0 NOUN F
treatment 0 NOUN F
group 0 NOUN F
. 0 PUNCT F

The 0 DET T
effects 0 NOUN F
of 0 ADP F
a 0 DET F
24-h 0 NOUN F
psychological 0 ADJ F
training 0 DET F
program 0 NOUN F
on 0 ADP F
attitudes B-MENTAL NOUN F
, 0 PUNCT F
communication B-MENTAL NOUN F
skills I-MENTAL NOUN F
and 0 CCONJ F
occupational B-MENTAL ADJ F
stress I-MENTAL NOUN F
in 0 ADP F
oncology 0 NOUN F
: 0 PUNCT F
a 0 DET F
randomised 0 VERB F
study 0 NOUN F
. 0 PUNCT F

The 0 DET T
usefulness 0 NOUN F
of 0 ADP F
psychological 0 ADJ F
training 0 DET F
programs 0 NOUN F
( 0 PUNCT F
P.T.P 0 ADP T
. 0 PUNCT F
) 0 PUNCT F

in 0 ADP F
health 0 NOUN F
care 0 NOUN F
settings 0 NOUN F
devoted 0 VERB F
to 0 ADP F
cancer 0 PUNCT F
care 0 NOUN F
is 0 NOUN F
beginning 0 ADV F
to 0 PART F
be 0 PUNCT F
recognised 0 VERB F
but 0 CCONJ F
their 0 ADJ F
content 0 NOUN F
, 0 PUNCT F
form 0 NOUN F
and 0 CCONJ F
effectiveness 0 NOUN F
need 0 PART F
further 0 ADJ F
investigation 0 NOUN F
. 0 PUNCT F

Seventy-two 0 NUM T
oncology 0 NOUN F
nurses 0 NOUN F
were 0 VERB F
randomly 0 ADV F
assigned 0 VERB F
to 0 ADP F
a 0 DET F
24-h 0 NOUN F
P.T.P 0 VERB T
. 0 PUNCT F

or 0 CCONJ F
to 0 ADP F
a 0 PUNCT F
waiting 0 PUNCT F
list 0 NOUN F
period 0 NOUN F
. 0 PUNCT F

Attitudes B-MENTAL ADV T
were 0 VERB F
assessed 0 VERB F
by 0 ADP F
a 0 DET F
semantic B-MENTAL ADJ F
differential I-MENTAL ADJ F
questionnaire 0 NOUN F
, 0 PUNCT F
occupational B-MENTAL ADJ F
stress I-MENTAL NOUN F
was 0 VERB F
assessed 0 VERB F
by 0 ADP F
the 0 DET F
Nursing B-MENTAL PUNCT T
Stress 0 NOUN T
Scale B-MENTAL NOUN T
and 0 CCONJ F
communication B-MENTAL NOUN F
skills I-MENTAL NOUN F
were 0 VERB F
assessed 0 VERB F
by 0 ADP F
standardised 0 DET F
videotaped 0 ADJ F
role-playing B-MENTAL ADP F
exercises B-MENTAL NOUN F
. 0 PUNCT F

These 0 ADP T
were 0 VERB F
used 0 VERB F
to 0 PART F
compare 0 NOUN F
trained 0 VERB F
( 0 PUNCT F
T.S 0 NOUN T
. 0 PUNCT F
) 0 PUNCT F

and 0 CCONJ F
control 0 NOUN F
subjects 0 NOUN F
( 0 PUNCT F
C.S. 0 ADV T
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
results 0 ADV F
show 0 VERB F
a 0 DET F
significant 0 ADJ F
training 0 DET F
effect 0 NOUN F
on 0 ADP F
attitudes B-MENTAL NOUN F
( 0 PUNCT F
P 0 NOUN T
= 0 SYM F
0.05 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
especially 0 ADV F
on 0 ADP F
those 0 ADP F
related 0 VERB F
to 0 PUNCT F

Surgery 0 NOUN T
of 0 ADP F
aphakic 0 NOUN F
retinal 0 ADJ F
detachment 0 NOUN F
. 0 PUNCT F

In 0 ADP T
a 0 DET F
prospective 0 ADJ F
study 0 NOUN F
84 0 NUM F
patients 0 NOUN F
with 0 ADP F
aphakic 0 NOUN F
retinal 0 ADJ F
detachment 0 NOUN F
were 0 VERB F
treated 0 VERB F
either 0 PUNCT F
by 0 ADP F
local 0 ADJ F
scleral 0 ADJ F
buckling 0 ADP F
alone 0 ADJ F
or 0 CCONJ F
combined 0 VERB F
with 0 ADP F
an 0 DET F
encirclement 0 NOUN F
. 0 PUNCT F

The 0 DET T
rate 0 NOUN F
of B-PHYSICAL ADP F
surgical I-PHYSICAL ADJ F
reattachment I-PHYSICAL VERB F
of I-PHYSICAL ADP F
the I-PHYSICAL PUNCT F

Correlation 0 NOUN T
between 0 ADP F
in 0 PUNCT F
vivo 0 ADJ F
humoral 0 ADJ F
and 0 CCONJ F
in 0 ADP F
vitro 0 ADJ F
cellular 0 ADJ F
immune 0 ADJ F
responses 0 NOUN F
following 0 VERB F
immunization 0 NOUN F
with 0 ADP F
hepatitis 0 NOUN F
B 0 NOUN T
surface 0 NOUN F
antigen 0 NOUN F
( 0 PUNCT F
HBsAg 0 NOUN T
) 0 PUNCT F
vaccines 0 NOUN F
. 0 PUNCT F

To 0 ADJ T
study 0 NOUN F
the 0 DET F
regulation 0 NOUN F
of 0 ADP F
the 0 DET F
human 0 NOUN F
immune 0 ADJ F
response 0 NOUN F
to 0 ADP F
hepatitis 0 NOUN F
B 0 NOUN T
surface 0 NOUN F
antigen 0 NOUN F
( 0 PUNCT F
HBsAg 0 NOUN T
) 0 PUNCT F
we 0 PRON F
have 0 VERB F
carefully 0 DET F
monitored 0 PUNCT F
the 0 DET F
in 0 PUNCT F
vivo 0 ADJ F
humoral 0 ADJ F
and 0 CCONJ F
in 0 ADP F
vitro 0 ADJ F
cellular 0 ADJ F
immune 0 ADJ F
responses 0 NOUN F
to 0 ADP F
HBsAg 0 NOUN T
in 0 ADP F
50 0 NUM F
subjects 0 NOUN F
receiving 0 VERB F
four 0 NUM F
doses 0 NOUN F
of 0 ADP F
hepatitis 0 NOUN F
B 0 NOUN T
vaccine 0 NOUN F
according 0 VERB F
to 0 ADP F
a 0 DET F
0 0 NUM F
, 0 PUNCT F
1 0 NUM F
, 0 PUNCT F
2 0 NUM F
, 0 PUNCT F
12 0 NUM F
month 0 NOUN F
vaccination 0 NOUN F
scheme 0 NOUN F
. 0 PUNCT F

Twenty-three 0 NUM T
subjects 0 NOUN F
were 0 VERB F
given 0 VERB F
a 0 DET F
plasma-derived 0 VERB F
vaccine 0 NOUN F
( 0 PUNCT F
Hevac 0 NOUN T
B 0 NOUN T
) 0 PUNCT F
and 0 CCONJ F
27 0 NUM F
received 0 VERB F
a 0 DET F
recombinant 0 ADJ F
HBsAg 0 NOUN T
vaccine 0 NOUN F
( 0 PUNCT F
yeast-derived 0 PROPN F
; 0 PUNCT F
Engerix-B 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
humoral 0 ADJ F
and 0 CCONJ F
cellular 0 ADJ F
immune 0 ADJ F
responses 0 ADV F
were 0 VERB F
measured 0 VERB F
before 0 ADP F
vaccination 0 NOUN F
( 0 PUNCT F
day 0 NOUN F
0 0 NUM F
) 0 PUNCT F
; 0 PUNCT F
6 0 NUM F
days 0 NOUN F
after 0 ADP F
the 0 DET F
second 0 ADJ F
dose 0 NOUN F
( 0 PUNCT F
day 0 NOUN F
36 0 NUM F
) 0 PUNCT F
; 0 PUNCT F
6 0 DET F
days 0 NOUN F
( 0 PUNCT F
day 0 NOUN F
66 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
2 0 NUM F
months 0 NOUN F
( 0 PUNCT F
day 0 NOUN F
120 0 NUM F
) 0 PUNCT F
and 0 CCONJ F
10 0 NUM F
months 0 NOUN F
( 0 PUNCT F
day 0 NOUN F
365 0 PUNCT F
) 0 PUNCT F
after 0 ADP F
the 0 DET F
third 0 ADJ F
dose 0 NOUN F
and 0 CCONJ F
1 0 NUM F
month 0 NOUN F
after 0 ADP F
the 0 DET F
fourth 0 ADJ F
dose 0 NOUN F
( 0 PUNCT F
day 0 NOUN F
395 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Based 0 VERB T
on 0 ADP F
the 0 DET F
kinetics 0 NOUN F
of 0 ADP F
the 0 DET F
humoral 0 ADJ F
immune 0 ADJ F
responses 0 NOUN F
, 0 PUNCT F
the 0 DET F
vaccinees 0 PUNCT F
could 0 VERB F
be 0 VERB F
classified 0 VERB F
into 0 ADP F
fast 0 ADP F
, 0 PUNCT F
intermediate 0 ADJ F
and 0 CCONJ F
slow/non-responders 0 PUNCT F
. 0 PUNCT F

Based 0 VERB T
on 0 ADP F
the 0 DET F
magnitude 0 NOUN F
of 0 ADP F
the 0 DET F
immune 0 ADJ F
response 0 NOUN F
( 0 PUNCT F
anti-HBs 0 NOUN F
titre 0 NOUN F
) 0 PUNCT F
on 0 ADP F
day 0 NOUN F
395 0 NUM F
, 0 PUNCT F
the 0 DET F
vaccinees 0 PUNCT F
could 0 VERB F
be 0 VERB F
divided 0 VERB F
into 0 ADP F
high 0 ADJ F
( 0 PUNCT F
> 0 PROPN F
or 0 CCONJ F
= 0 SYM F
2000 0 NUM F
U 0 NOUN T
l-1 0 NOUN F
) 0 PUNCT F
and 0 CCONJ F
low 0 ADJ F
( 0 PUNCT F
< 0 PROPN F
or 0 CCONJ F
= 0 SYM F
2000 0 NUM F
U 0 NOUN T
l-1 0 NOUN F
) 0 PUNCT F
responders 0 NOUN F
. 0 PUNCT F

A 0 DET T
close 0 ADJ F
correlation 0 NOUN F
between 0 ADP F
the 0 DET F
kinetics 0 NOUN F
and 0 CCONJ F
the 0 DET F
magnitude 0 NOUN F
of 0 ADP F
the 0 DET F
humoral B-PHYSICAL ADJ F
immune I-PHYSICAL ADJ F
response I-PHYSICAL NOUN F
was 0 VERB F
observed 0 VERB F
. 0 PUNCT F

The 0 DET T
in 0 PUNCT F
vivo B-PHYSICAL PUNCT F
anti-HBs I-PHYSICAL NOUN F
response I-PHYSICAL NOUN F
was 0 VERB F
measured 0 VERB F
using 0 SYM F
commercially 0 ADV F
available 0 ADJ F
immunoradiometric 0 ADJ F
assays 0 NOUN F
. 0 PUNCT F

The 0 DET T
in 0 PUNCT F
vitro B-PHYSICAL ADJ F
cellular I-PHYSICAL ADJ F
immune I-PHYSICAL ADJ F
response I-PHYSICAL NOUN F
was 0 VERB F
measured 0 VERB F
using 0 VERB F
an 0 DET F
HBsAg-specific 0 ADJ T
lymphoproliferation 0 NOUN F
assay 0 NOUN F
. 0 PUNCT F

Because 0 PUNCT T
of 0 ADP F
interassay 0 NOUN F
variability 0 NOUN F
the 0 DET F
results 0 CCONJ F
were 0 VERB F
considered 0 VERB F
as 0 PUNCT F
dichotomous B-OTHER ADJ F
variables I-OTHER NOUN F
( 0 PUNCT F
proliferation 0 NOUN F
versus 0 CCONJ F
non-proliferation 0 NOUN F
) 0 PUNCT F
for 0 ADP F
further 0 PUNCT F
data 0 NOUN F
analysis 0 NOUN F
. 0 PUNCT F

A 0 DET T
statistically 0 ADV F
significant 0 ADJ F
correlation 0 NOUN F
was 0 VERB F
observed 0 VERB F
between 0 ADP F
the 0 DET F
kinetics 0 NOUN F
and 0 CCONJ F
magnitude 0 NOUN F
of 0 ADP F
the 0 DET F
humoral 0 ADJ F
immune 0 ADJ F
response 0 NOUN F
on 0 ADP F
the 0 DET F
one 0 NUM F
hand 0 NOUN F
and 0 CCONJ F
the 0 DET F
in 0 PUNCT F
vitro 0 ADJ F
anti-HBs 0 NOUN F
response 0 NOUN F
on 0 ADP F
the 0 DET F
other 0 ADJ F
hand 0 NOUN F
. 0 PUNCT F
( 0 PUNCT F

ABSTRACT 0 ADP T
TRUNCATED 0 PUNCT T
AT 0 ADP T
250 0 NUM F
WORDS 0 NOUN T
) 0 PUNCT F

Salmeterol 0 NOUN T
plus 0 CCONJ F
fluticasone 0 NOUN F
propionate 0 NOUN F
versus 0 CCONJ F
fluticasone 0 NOUN F
propionate 0 NOUN F
plus 0 CCONJ F
montelukast 0 NOUN F
: 0 PUNCT F
a 0 DET F
randomised 0 VERB F
controlled 0 VERB F
trial 0 NOUN F
investigating 0 VERB F
the 0 DET F
effects 0 NOUN F
on 0 ADP F
airway B-PHYSICAL NOUN F
inflammation I-PHYSICAL NOUN F
in 0 ADP F
asthma 0 NOUN F
. 0 PUNCT F

BACKGROUND 0 NOUN T
Few 0 ADJ T
studies 0 NOUN F
have 0 ADP F
compared 0 VERB F
treatment 0 NOUN F
strategies 0 NOUN F
in 0 ADP F
patients 0 NOUN F
with 0 ADP F
asthma 0 NOUN F
poorly 0 ADV F
controlled 0 VERB F
on 0 ADP F
low 0 ADJ F
dose 0 NOUN F
inhaled 0 VERB F
corticosteroids 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
little 0 DET F
is 0 VERB F
known 0 VERB F
about 0 ADP F
the 0 DET F
effects 0 NOUN F
of 0 ADP F
different 0 ADJ F
treatments 0 NOUN F
on 0 ADP F
airway 0 NOUN F
inflammation 0 NOUN F
. 0 PUNCT F

In 0 ADP T
this 0 DET F
double-blind 0 ADJ F
, 0 PUNCT F
placebo-controlled 0 VERB F
, 0 PUNCT F
parallel 0 ADJ F
group 0 NOUN F
study 0 NOUN F
, 0 PUNCT F
we 0 PRON F
compared 0 VERB F
the 0 DET F
effects 0 NOUN F
of 0 ADP F
salmeterol 0 NOUN F
plus 0 CCONJ F
fluticasone 0 NOUN F
propionate 0 NOUN F
( 0 PUNCT F
FP 0 NOUN T
) 0 PUNCT F
( 0 PUNCT F
Seretide 0 NOUN T
; 0 PUNCT F
SFC 0 NOUN T
) 0 PUNCT F
and 0 CCONJ F
FP 0 NOUN T
plus 0 CCONJ F
montelukast 0 NOUN F
( 0 PUNCT F
FP/M 0 NOUN T
) 0 PUNCT F
on 0 ADP F
sputum B-PHYSICAL NOUN F
inflammatory I-PHYSICAL ADJ F
markers I-PHYSICAL NOUN F
, 0 PUNCT F
airway B-PHYSICAL NOUN F
responsiveness I-PHYSICAL NOUN F
, 0 PUNCT F
lung B-PHYSICAL NOUN F
function I-PHYSICAL NOUN F
, 0 PUNCT F
and 0 CCONJ F
symptoms B-PHYSICAL NOUN F
in 0 ADP F
adult 0 NOUN F
asthmatics 0 NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
Sixty-six 0 ADJ T
subjects 0 NOUN F
were 0 VERB F
randomised 0 VERB F
to 0 ADP F
SFC 0 NOUN T
or 0 CCONJ F
FP/M 0 NOUN T
for 0 ADP F
12 0 NUM F
weeks 0 NOUN F
. 0 PUNCT F

The 0 DET T
primary 0 ADJ F
outcome 0 NOUN F
was 0 VERB F
changes 0 NOUN F
in 0 ADP F
neutrophil 0 NOUN F
, 0 PUNCT F
eosinophil 0 NOUN F
, 0 PUNCT F
macrophage 0 NOUN F
, 0 PUNCT F
lymphocyte 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
epithelial 0 ADJ F
cell 0 NOUN F
levels 0 NOUN F
in 0 ADP F
induced 0 DET F
sputum 0 NOUN F
. 0 PUNCT F

Additional 0 ADJ T
outcomes 0 NOUN F
included 0 ADP F
the 0 DET F
change 0 NOUN F
in 0 ADP F
other 0 ADJ F
sputum 0 NOUN F
markers 0 NOUN F
of 0 ADP F
airway B-PHYSICAL NOUN F
inflammation I-PHYSICAL NOUN F
, 0 PUNCT F
airway B-PHYSICAL NOUN F
responsiveness I-PHYSICAL NOUN F
, 0 PUNCT F
symptom B-PHYSICAL NOUN F
control I-PHYSICAL NOUN F
, 0 PUNCT F
and 0 CCONJ F
lung B-PHYSICAL NOUN F
function I-PHYSICAL NOUN F
. 0 PUNCT F

RESULTS 0 NOUN T
Both 0 PUNCT T
treatments 0 NOUN F
had 0 PUNCT F
no 0 DET F
significant 0 ADJ F
effect 0 NOUN F
on 0 ADP F
induced 0 VERB F
sputum B-PHYSICAL NOUN F
inflammatory I-PHYSICAL ADJ F
cells 0 NOUN F
, 0 PUNCT F
although 0 ADP F
there 0 PUNCT F
was 0 VERB F
a 0 DET F
trend 0 NOUN F
for 0 ADP F
a 0 DET F
reduction 0 NOUN F
in 0 ADP F
sputum B-PHYSICAL NOUN F
eosinophils I-PHYSICAL NOUN F
. 0 PUNCT F

Both 0 CCONJ T
treatments 0 ADJ F
significantly 0 ADV F
improved 0 PUNCT F
airway B-PHYSICAL NOUN F
responsiveness I-PHYSICAL NOUN F
, 0 PUNCT F
whereas 0 ADP F
SFC 0 NOUN T
generally 0 ADV F
led 0 PRON F
to 0 ADP F
greater 0 PUNCT F
improvements 0 NOUN F
in 0 ADP F
symptom B-PHYSICAL NOUN F
control I-PHYSICAL NOUN F
and 0 CCONJ F
lung B-PHYSICAL NOUN F
function I-PHYSICAL NOUN F
than 0 PUNCT F
FP/M 0 NOUN T
. 0 PUNCT F

FP/M 0 NOUN T
led 0 VERB F
to 0 ADP F
significantly 0 ADV F
greater 0 PUNCT F
reductions 0 NOUN F
in 0 ADP F
sputum B-PHYSICAL NOUN F
cysteinyl I-PHYSICAL NOUN F
leukotrienes I-PHYSICAL ADJ F
than 0 PUNCT F
SFC 0 NOUN T
( 0 PUNCT F
treatment 0 NOUN F
ratio 0 NOUN F
1.80 0 NUM F
; 0 PUNCT F
95 0 NUM F
% 0 SYM F
CI 0 NOUN T
1.09 0 PUNCT F
, 0 PUNCT F
2.94 0 PUNCT F
) 0 PUNCT F
. 0 PUNCT F

CONCLUSION 0 NOUN T
Both 0 PUNCT T
treatments 0 NOUN F
led 0 VERB F
to 0 ADP F
similar 0 ADJ F
control 0 NOUN F
of 0 ADP F
eosinophilic B-PHYSICAL ADJ F
airway I-PHYSICAL NOUN F
inflammation I-PHYSICAL NOUN F
, 0 PUNCT F
although 0 ADP F
PEF 0 NOUN T
and 0 CCONJ F
symptom 0 NOUN F
control 0 NOUN F
were 0 VERB F
better 0 PUNCT F
with 0 ADP F
SFC 0 NOUN T
. 0 PUNCT F

STUDY 0 NOUN T
NUMBER 0 NOUN T
: 0 PUNCT F
SAM40030 0 NOUN T
( 0 PUNCT F
SOLTA 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
value-congruence 0 ADJ F
model 0 NOUN F
of 0 ADP F
memory 0 NOUN F
for 0 ADP F
emotional B-MENTAL ADJ F
experiences I-MENTAL NOUN F
: 0 PUNCT F
an 0 DET F
explanation 0 NOUN F
for 0 ADP F
cultural 0 ADJ F
differences 0 NOUN F
in 0 ADP F
emotional 0 ADJ F
self-reports 0 NOUN F
. 0 PUNCT F

In 0 ADP T
3 0 NUM F
studies 0 NOUN F
, 0 PUNCT F
the 0 DET F
authors 0 NOUN F
found 0 VERB F
support 0 NOUN F
for 0 ADP F
the 0 DET F
value-congruence 0 ADJ F
model 0 NOUN F
that 0 ADP F
accounts 0 NOUN F
for 0 ADP F
cultural 0 ADJ F
variations 0 NOUN F
in 0 ADP F
memory 0 NOUN F
for 0 ADP F
emotional B-MENTAL ADJ F
experiences I-MENTAL NOUN F
. 0 PUNCT F

In 0 ADP T
Study 0 NOUN T
1 0 NUM F
, 0 PUNCT F
the 0 DET F
authors 0 NOUN F
found 0 VERB F
that 0 ADP F
in 0 ADP F
the 0 DET F
made-in-the-U.S. 0 NUM F
scenario 0 ADJ F
condition 0 NOUN F
, 0 PUNCT F
European 0 ADP T
Americans 0 PUNCT T
were 0 VERB F
more 0 ADV F
accurate 0 ADJ F
than 0 PUNCT F
were 0 VERB F
Asian 0 ADJ T
Americans 0 VERB T
in 0 ADP F
their 0 PUNCT F
retrospective B-MENTAL ADJ F
frequency 0 NOUN F
judgments B-MENTAL NOUN F
of I-MENTAL ADP F
emotions B-MENTAL NOUN F
. 0 PUNCT F

However 0 ADV T
, 0 PUNCT F
in 0 ADP F
the 0 DET F
made-in-Japan 0 NUM F
scenario 0 ADJ F
condition 0 NOUN F
, 0 PUNCT F
European 0 ADP T
Americans 0 PUNCT T
were 0 VERB F
less 0 ADV F
accurate 0 ADJ F
than 0 PUNCT F
were 0 VERB F
Asian 0 ADJ T
Americans 0 PUNCT T
. 0 PUNCT F

In 0 ADP T
Study 0 NOUN T
2 0 NUM F
, 0 PUNCT F
the 0 DET F
authors 0 NOUN F
demonstrated 0 VERB F
that 0 ADP F
value 0 NOUN F
orientation 0 NOUN F
mediates 0 NOUN F
the 0 DET F
CulturexType B-MENTAL NOUN T
of B-MENTAL ADP F
Event 0 NOUN T
congruence B-MENTAL NOUN F
effect 0 NOUN F
. 0 PUNCT F

In 0 ADP T
Study 0 NOUN T
3 0 NUM F
( 0 PUNCT F
a 0 ADP F
daily 0 ADJ F
event 0 NOUN F
sampling 0 PUNCT F
study 0 NOUN F
) 0 PUNCT F
, 0 PUNCT F
the 0 DET F
authors 0 NOUN F
showed 0 VERB F
that 0 ADP F
the 0 PUNCT F

Randomized 0 VERB T
clinical 0 ADJ F
trial 0 NOUN F
comparing 0 VERB F
laparoscopic 0 PUNCT F
and 0 CCONJ F
open 0 ADJ F
surgery 0 NOUN F
in 0 ADP F
patients 0 NOUN F
with 0 ADP F
rectal 0 ADJ F
cancer 0 NOUN F
. 0 PUNCT F

BACKGROUND 0 NOUN T
The 0 DET T
laparoscopic 0 ADJ F
treatment 0 NOUN F
of 0 ADP F
rectal 0 ADJ F
cancer 0 NOUN F
is 0 VERB F
controversial 0 ADJ F
. 0 PUNCT F

This 0 DET T
study 0 NOUN F
compared 0 VERB F
surgical 0 ADJ F
outcomes 0 NOUN F
after 0 ADP F
laparoscopic 0 ADJ F
and 0 CCONJ F
open 0 ADJ F
approaches 0 NOUN F
for 0 ADP F
mid 0 NOUN F
and 0 CCONJ F
low 0 ADJ F
rectal 0 ADJ F
cancers 0 NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
Some 0 PUNCT T
204 0 NUM F
patients 0 NOUN F
with 0 ADP F
mid 0 NOUN F
and 0 CCONJ F
low 0 ADJ F
rectal 0 ADJ F
adenocarcinomas 0 NOUN F
were 0 VERB F
allocated 0 VERB F
randomly 0 ADV F
to 0 ADV F
open 0 ADJ F
( 0 PUNCT F
103 0 NUM F
) 0 PUNCT F
or 0 CCONJ F
laparoscopic 0 ADJ F
( 0 PUNCT F
101 0 NUM F
) 0 PUNCT F
surgery 0 NOUN F
. 0 PUNCT F

The 0 DET T
surgical 0 ADJ F
team 0 NOUN F
was 0 ADV F
the 0 DET F
same 0 PUNCT F
for 0 ADP F
both 0 PUNCT F
procedures 0 NOUN F
. 0 PUNCT F

Most 0 DET T
patients 0 NOUN F
had 0 PUNCT F
stage 0 NOUN F
II 0 NUM T
or 0 CCONJ F
III 0 NUM T
disease 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
received 0 CCONJ F
neoadjuvant 0 PUNCT F
therapy 0 NOUN F
with 0 ADP F
oral 0 ADJ F
capecitabine 0 ADJ F
and 0 CCONJ F
50-54 0 NUM F
Gy 0 NOUN T
external 0 ADJ F
beam 0 VERB F
radiotherapy 0 NOUN F
. 0 PUNCT F

RESULTS 0 NOUN T
Sphincter-preserving 0 PUNCT T
surgery 0 NOUN F
was 0 VERB F
performed 0 VERB F
in 0 ADP F
78.6 0 NUM F
and 0 CCONJ F
76.2 0 NUM F
per 0 ADP F
cent 0 ADJ F
of 0 ADP F
patients 0 NOUN F
in 0 ADP F
the 0 DET F
open 0 ADJ F
and 0 CCONJ F
laparoscopic 0 ADJ F
groups 0 NOUN F
respectively 0 ADV F
. 0 PUNCT F

Blood B-ADVERSE-EFFECTS NOUN T
loss I-ADVERSE-EFFECTS NOUN F
was 0 VERB F
significantly 0 ADV F
greater 0 PUNCT F
for 0 ADP F
open 0 PUNCT F
surgery 0 NOUN F
( 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.001 0 NUM F
) 0 PUNCT F
and 0 CCONJ F
operating B-OTHER VERB F
time I-OTHER NOUN F
was 0 VERB F
significantly 0 ADV F
greater 0 PUNCT F
for 0 ADP F
laparoscopic 0 ADJ F
surgery 0 NOUN F
( 0 PUNCT F
P 0 NOUN T
= 0 SYM F
0.020 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
and 0 CCONJ F
return 0 ADJ F
to 0 ADP F
diet 0 NOUN F
and 0 CCONJ F
hospital B-OTHER NOUN F
stay I-OTHER NOUN F
were 0 VERB F
longer 0 PUNCT F
for 0 ADP F
open 0 PUNCT F
surgery 0 NOUN F
. 0 PUNCT F

Complication B-ADVERSE-EFFECTS NOUN T
rates I-ADVERSE-EFFECTS NOUN F
, 0 PUNCT F
and 0 PUNCT F

[ 0 PUNCT F
Improving 0 PUNCT T
wound B-PHYSICAL NOUN F
healing I-PHYSICAL VERB F
after 0 ADP F
nose 0 NOUN F
surgery 0 NOUN F
by 0 ADP F
combined 0 VERB F
administration 0 NOUN F
of 0 ADP F
xylometazoline 0 NOUN F
and 0 CCONJ F
dexpanthenol 0 NOUN F
] 0 PUNCT F
. 0 PUNCT F

BACKGROUND 0 NOUN T
The 0 DET T
aim 0 NOUN F
of 0 ADP F
this 0 DET F
study 0 NOUN F
was 0 VERB F
the 0 DET F
examination 0 NOUN F
of 0 ADP F
efficacy 0 NOUN F
and 0 CCONJ F
tolerability B-OTHER NOUN F
of 0 ADP F
an 0 DET F
application-form 0 NOUN F
of 0 ADP F
the 0 DET F
new 0 ADJ F
combination 0 NOUN F
of 0 ADP F
Xylometazoline 0 NOUN T
with 0 ADP F
Dexpanthenol 0 NOUN T
( 0 PUNCT F
Nasic 0 NOUN T
) 0 PUNCT F
versus 0 CCONJ F
Xylometazoline 0 NOUN T
alone 0 ADJ F
. 0 PUNCT F

PATIENTS 0 NOUN T
AND 0 CCONJ T
METHODS 0 NOUN T
Randomized 0 PROPN T
verum 0 ADJ F
controlled 0 VERB F
parallel-group-comparison 0 ADJ F
of 0 ADP F
two 0 NUM F
weeks 0 NOUN F
treatment 0 NOUN F
of 0 ADP F
a 0 DET F
nasal-spray 0 NOUN F
. 0 PUNCT F

61 0 NUM F
inpatients 0 NOUN F
with 0 ADP F
the 0 DET F
diagnosis 0 NOUN F
Rhinitis 0 NOUN T
following 0 VERB F
nasal 0 ADJ F
operation 0 NOUN F
were 0 VERB F
included 0 VERB F
in 0 ADP F
this 0 DET F
study 0 NOUN F
and 0 CCONJ F
30 0 NUM F
patients 0 NOUN F
were 0 VERB F
treated 0 VERB F
with 0 ADP F
verum 0 ADJ F
and 0 CCONJ F
placebo 0 NOUN F
each 0 PUNCT F
. 0 PUNCT F

The 0 DET T
assessment 0 NOUN F
of 0 ADP F
nasal-breathing-resistance B-PHYSICAL NOUN F
according B-OTHER CCONJ F
to I-OTHER ADP F
scores I-OTHER NOUN F
was 0 VERB F
defined 0 VERB F
as 0 ADP F
target-parameter 0 NOUN F
. 0 PUNCT F

Confirmatory 0 ADJ T
statistical 0 ADJ F
analysis 0 NOUN F
was 0 VERB F
carried 0 VERB F
out 0 PUNCT F
according 0 PUNCT F
to 0 ADP F
Wilcoxon-Mann-Whitney-U 0 ADV T
two-sided 0 ADP F
at 0 ADP F
alpha 0 NOUN F
< 0 SYM F
or 0 CCONJ F
= 0 SYM F
0.05 0 NUM F
. 0 PUNCT F

MAIN 0 ADJ T
OUTCOME 0 NOUN T
MEASURE 0 NOUN T
The 0 DET T
superiority 0 NOUN F
of 0 ADP F
the 0 DET F
combination 0 NOUN F
of 0 ADP F
Xylometazoline-Dexpanthenol 0 NOUN T
nasal-spray 0 NOUN F
versus 0 CCONJ F
Xylometazoline 0 NOUN T
nasal 0 ADJ F
spray 0 NOUN F
could 0 VERB F
be 0 VERB F
proven 0 VERB F
for 0 ADP F
the 0 DET F
target-parameter 0 ADJ F
as 0 PUNCT F
clinically 0 VERB F
relevant 0 ADJ F
and 0 CCONJ F
statistically 0 ADV F
significant 0 ADJ F
. 0 PUNCT F

The 0 DET T
clinically B-OTHER ADV F
proven I-OTHER VERB F
efficacy I-OTHER NOUN F
is 0 VERB F
emphasized 0 PUNCT F
by 0 ADP F
good 0 ADJ F
tolerability B-OTHER NOUN F
of 0 ADP F
both 0 PUNCT F
treatments 0 NOUN F
. 0 PUNCT F

Due 0 PUNCT T
to 0 ADP F
easy 0 PUNCT F
handling 0 PROPN F
of 0 ADP F
the 0 DET F
nasal-spray 0 NOUN F
a 0 DET F
good 0 ADJ F
compliance B-OTHER NOUN F
was 0 VERB F
confirmed 0 VERB F
. 0 PUNCT F

CONCLUSION 0 NOUN T
Distinct 0 ADJ T
improvement B-PHYSICAL NOUN F
of I-PHYSICAL ADP F
symptoms I-PHYSICAL NOUN F
in 0 ADP F
patients 0 NOUN F
following 0 VERB F
nasal 0 ADJ F
operations 0 NOUN F
underlines 0 PUNCT F
the 0 DET F
efficacy 0 NOUN F
of 0 ADP F
both 0 CCONJ F
medications 0 NOUN F
. 0 PUNCT F

With 0 ADP T
respect 0 NOUN F
to 0 ADP F
the 0 DET F
tolerability B-OTHER NOUN F
therapy 0 NOUN F
with 0 ADP F
the 0 DET F
combination 0 NOUN F
is 0 VERB F
more 0 DET F
beneficial 0 ADJ F
in 0 ADP F
comparison 0 NOUN F
to 0 ADP F
the 0 DET F
alternative 0 ADJ F
therapy 0 NOUN F
. 0 PUNCT F

The 0 DET T
result 0 NOUN F
of 0 ADP F
this 0 PUNCT F
controlled 0 VERB F
clinical 0 ADJ F
study 0 NOUN F
confirms 0 VERB F
that 0 ADP F
the 0 DET F
combination 0 NOUN F
Xylometazoline-Dexpanthenol 0 NOUN T
is 0 VERB F
an 0 DET F
enlargement B-OTHER NOUN F
and 0 CCONJ F
improvement B-OTHER NOUN F
of I-OTHER ADP F
effective I-OTHER ADJ F
medicinal 0 ADJ F
treatment 0 NOUN F
of 0 ADP F
rhinitis 0 NOUN F
following 0 ADP F
nasal 0 ADJ F
operation 0 NOUN F
in 0 ADP F
comparison 0 NOUN F
to 0 ADP F
therapy 0 NOUN F
with 0 ADP F
Xylometazoline 0 NOUN T
alone 0 ADJ F
. 0 PUNCT F

RESPECT-PTSD 0 NOUN T
: 0 PUNCT F
re-engineering 0 PUNCT F
systems 0 NOUN F
for 0 ADP F
the 0 DET F
primary 0 ADJ F
care 0 NOUN F
treatment 0 NOUN F
of 0 ADP F
PTSD 0 NOUN T
, 0 PUNCT F
a 0 DET F
randomized 0 VERB F
controlled 0 VERB F
trial 0 NOUN F
. 0 PUNCT F

BACKGROUND 0 NOUN T
Although 0 ADP T
collaborative 0 ADJ F
care 0 NOUN F
is 0 VERB F
effective 0 ADJ F
for 0 ADP F
treating 0 VERB F
depression 0 NOUN F
and 0 CCONJ F
other 0 ADJ F
mental 0 ADJ F
disorders 0 NOUN F
in 0 ADP F
primary 0 ADJ F
care 0 NOUN F
, 0 PUNCT F
there 0 PUNCT F
have 0 ADP F
been 0 PUNCT F
no 0 DET F
randomized 0 VERB F
trials 0 NOUN F
of 0 ADP F
collaborative 0 ADJ F
care 0 NOUN F
specifically 0 ADV F
for 0 ADP F
patients 0 NOUN F
with 0 ADP F
Posttraumatic 0 ADJ T
stress 0 NOUN F
disorder 0 NOUN F
( 0 PUNCT F
PTSD 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

OBJECTIVE 0 NOUN T
To 0 PROPN T
compare 0 NOUN F
a 0 DET F
collaborative 0 ADJ F
approach 0 NOUN F
, 0 PUNCT F
the 0 DET F
Three 0 NUM T
Component 0 NOUN T
Model 0 NOUN T
( 0 PUNCT F
3CM 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
with 0 ADP F
usual 0 ADJ F
care 0 NOUN F
for 0 ADP F
treating 0 VERB F
PTSD 0 NOUN T
in 0 ADP F
primary 0 ADJ F
care 0 NOUN F
. 0 PUNCT F

DESIGN 0 NOUN T
The 0 DET T
study 0 NOUN F
was 0 ADV F
a 0 DET F
two-arm 0 NOUN F
, 0 PUNCT F
parallel 0 VERB F
randomized 0 VERB F
clinical 0 ADJ F
trial 0 NOUN F
. 0 PUNCT F

PTSD 0 NOUN T
patients 0 NOUN F
were 0 VERB F
recruited 0 VERB F
from 0 ADP F
five 0 NUM F
primary 0 ADJ F
care 0 NOUN F
clinics 0 PROPN F
at 0 ADP F
four 0 NUM F
Veterans 0 PUNCT T
Affairs 0 PUNCT T
healthcare 0 NOUN F
facilities 0 NOUN F
and 0 CCONJ F
randomized 0 ADP F
to 0 PART F
receive 0 NOUN F
usual 0 ADJ F
care 0 NOUN F
or 0 CCONJ F
usual 0 ADJ F
care 0 NOUN F
plus 0 CCONJ F
3CM 0 NUM F
. 0 PUNCT F

Blinded 0 VERB T
assessors 0 NOUN F
collected 0 VERB F
data 0 NOUN F
at 0 ADP F
baseline 0 NOUN F
and 0 CCONJ F
3-month 0 NOUN F
and 0 CCONJ F
6-month 0 NOUN F
follow-up 0 NOUN F
. 0 PUNCT F

PARTICIPANTS 0 ADP T
Participants 0 NOUN T
were 0 VERB F
195 0 NUM F
Veterans 0 NOUN T
. 0 PUNCT F

Their 0 PUNCT T
average 0 PUNCT F
age 0 NOUN F
was 0 VERB F
45 0 NUM F
years 0 NOUN F
, 0 PUNCT F
91 0 NUM F
% 0 SYM F
were 0 ADP F
male 0 NOUN F
, 0 PUNCT F
58 0 NUM F
% 0 SYM F
were 0 VERB F
white 0 CCONJ F
, 0 PUNCT F
40 0 NUM F
% 0 SYM F
served 0 VERB F
in 0 ADP F
Iraq 0 NOUN T
or 0 CCONJ F
Afghanistan 0 NOUN T
, 0 PUNCT F
and 0 CCONJ F
42 0 NUM F
% 0 SYM F
served 0 VERB F
in 0 ADP F
Vietnam 0 ADV T
. 0 PUNCT F

INTERVENTION 0 NOUN T
All 0 PUNCT T
participants 0 NOUN F
received 0 VERB F
usual 0 ADJ F
care 0 NOUN F
. 0 PUNCT F

Participants 0 NOUN T
assigned 0 DET F
to 0 ADP F
3CM 0 PUNCT F
also 0 ADV F
received 0 CCONJ F
telephone 0 NOUN F
care 0 NOUN F
management 0 NOUN F
. 0 PUNCT F

Care 0 NOUN T
managers 0 NOUN F
received 0 VERB F
supervision 0 NOUN F
from 0 ADP F
a 0 DET F
psychiatrist 0 NOUN F
. 0 PUNCT F

MAIN 0 ADJ T
MEASURES 0 NOUN T
PTSD B-PHYSICAL NOUN T
symptom I-PHYSICAL NOUN F
severity I-PHYSICAL NOUN F
was 0 VERB F
the 0 DET F
primary 0 ADJ F
outcome 0 NOUN F
. 0 PUNCT F

Depression B-PHYSICAL NOUN T
, 0 PUNCT F
functioning B-PHYSICAL VERB F
, 0 PUNCT F
perceived B-PHYSICAL DET F
quality I-PHYSICAL NOUN F
of I-PHYSICAL ADP F
care I-PHYSICAL NOUN F
, 0 PUNCT F
utilization B-OTHER NOUN F
, 0 PUNCT F
and 0 CCONJ F
costs B-OTHER NOUN F
were 0 VERB F
secondary 0 ADJ F
outcomes 0 NOUN F
. 0 PUNCT F

KEY 0 NOUN T
RESULTS 0 NOUN T
There 0 CCONJ T
were 0 VERB F
no 0 DET F
differences 0 NOUN F
between 0 ADP F
3CM 0 CCONJ F
and 0 CCONJ F
usual 0 ADJ F
care 0 NOUN F
in 0 ADP F
symptoms 0 NOUN F
or 0 CCONJ F
functioning 0 SYM F
. 0 PUNCT F

Participants 0 NOUN T
assigned 0 DET F
to 0 ADP F
3CM 0 CCONJ F
were 0 VERB F
more 0 ADV F
likely 0 ADJ F
to 0 PART F
have 0 PUNCT F
a 0 DET F
mental B-MENTAL ADJ F
health I-MENTAL NOUN F
visit I-MENTAL NOUN F
, 0 PUNCT F
fill 0 PUNCT F
an 0 DET F
antidepressant 0 NOUN F
prescription 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
have 0 PUNCT F
adequate B-OTHER PUNCT F
antidepressant I-OTHER NOUN F
refills I-OTHER NOUN F
. 0 PUNCT F

3CM 0 NUM F
participants 0 NOUN F
also 0 ADV F
had 0 PUNCT F
more 0 DET F
mental B-MENTAL ADJ F
health I-MENTAL NOUN F
visits I-MENTAL NOUN F
and 0 CCONJ F
higher 0 PUNCT F
outpatient B-OTHER ADJ F
pharmacy I-OTHER NOUN F
costs I-OTHER NOUN F
. 0 PUNCT F

CONCLUSIONS 0 DET T
Results 0 PUNCT T
suggest 0 VERB F
the 0 DET F
need 0 NOUN F
for 0 ADP F
careful 0 ADJ F
examination 0 NOUN F
of 0 ADP F
the 0 DET F
way 0 NOUN F
that 0 PUNCT F
collaborative 0 ADJ F
care 0 NOUN F
models 0 NOUN F
are 0 VERB F
implemented 0 VERB F
for 0 ADP F
treating 0 VERB F
PTSD 0 NOUN T
, 0 PUNCT F
and 0 CCONJ F
for 0 ADP F
additional 0 ADJ F
supports 0 VERB F
to 0 PUNCT F
encourage 0 VERB F
primary 0 ADJ F
care 0 NOUN F
providers 0 NOUN F
to 0 PART F
manage 0 NOUN F
PTSD 0 NOUN T
. 0 PUNCT F

Comparison 0 NOUN T
of 0 ADP F
non-invasive 0 ADJ F
methods 0 NOUN F
for 0 ADP F
the 0 DET F
assessment 0 NOUN F
of 0 ADP F
haemodynamic 0 ADJ F
drug 0 NOUN F
effects 0 NOUN F
in 0 ADP F
healthy 0 ADJ F
male 0 NOUN F
and 0 CCONJ F
female 0 NOUN F
volunteers 0 NOUN F
: 0 PUNCT F
sex 0 NOUN F
differences 0 NOUN F
in 0 ADP F
cardiovascular 0 ADJ F
responsiveness 0 NOUN F
. 0 PUNCT F

1 0 NUM F
. 0 PUNCT F

The 0 DET T
study 0 NOUN F
was 0 VERB F
performed 0 VERB F
to 0 PART F
determine 0 NOUN F
the 0 DET F
sensitivity 0 NOUN F
and 0 CCONJ F
short-term 0 NOUN F
and 0 CCONJ F
day-to-day 0 NOUN F
variability 0 NOUN F
of 0 ADP F
a 0 DET F
novel 0 ADJ F
technique 0 NOUN F
based 0 VERB F
on 0 ADP F
laser 0 NOUN F
interferometry 0 NOUN F
of 0 ADP F
ocular 0 ADJ F
fundus 0 NOUN F
pulsations 0 ADJ F
and 0 CCONJ F
of 0 ADP F
non-invasive 0 ADJ F
methods 0 NOUN F
for 0 ADP F
the 0 DET F
quantification 0 NOUN F
of 0 ADP F
haemodynamic 0 ADJ F
drug 0 NOUN F
effects 0 NOUN F
. 0 PUNCT F

An 0 DET T
additional 0 ADJ F
aim 0 NOUN F
was 0 VERB F
to 0 PART F
assess 0 NOUN F
sex 0 NOUN F
differences 0 NOUN F
in 0 ADP F
haemodynamic 0 ADJ F
responsiveness 0 NOUN F
to 0 ADP F
cardiovascular 0 ADJ F
drugs 0 NOUN F
in 0 ADP F
male 0 NOUN F
and 0 CCONJ F
female 0 NOUN F
healthy 0 ADJ F
volunteers 0 NOUN F
. 0 PUNCT F

2 0 NUM F
. 0 PUNCT F

Ten 0 NUM T
males 0 NOUN F
and 0 CCONJ F
nine 0 NUM F
females 0 NOUN F
( 0 PUNCT F
age 0 NOUN F
range 0 NOUN F
20-33 0 NUM F
years 0 NOUN F
) 0 PUNCT F
were 0 VERB F
studied 0 VERB F
in 0 ADP F
a 0 DET F
double-blind 0 ADJ F
, 0 PUNCT F
randomized 0 VERB F
, 0 PUNCT F
cross-over 0 NOUN F
trial 0 NOUN F
. 0 PUNCT F

Simultaneous B-PHYSICAL ADJ T
measurements I-PHYSICAL NOUN F
from 0 ADP F
systemic 0 ADJ F
haemodynamics 0 NOUN F
, 0 PUNCT F
laser 0 NOUN F
interferometry 0 NOUN F
of 0 ADP F
ocular 0 ADJ F
fundus 0 NOUN F
pulsations 0 NOUN F
, 0 PUNCT F
systolic 0 ADJ F
time 0 NOUN F
intervals 0 NOUN F
from 0 ADP F
mechanocardiography 0 NOUN F
, 0 PUNCT F
a/b 0 PUNCT F
ratio 0 NOUN F
from 0 ADP F
oxymetric 0 ADJ F
fingerplethysmography 0 NOUN F
and 0 CCONJ F
Doppler 0 NOUN T
sonography 0 NOUN F
of 0 ADP F
the 0 DET F
radial 0 ADJ F
artery 0 NOUN F
were 0 ADP F
used 0 VERB F
to 0 PART F
describe 0 VERB F
the 0 DET F
haemodynamic 0 ADJ F
effects 0 NOUN F
of 0 ADP F
cumulative 0 ADJ F
, 0 PUNCT F
stepwise 0 DET F
increasing 0 PUNCT F
intravenous 0 ADJ F
doses 0 NOUN F
of 0 ADP F
phenylephrine 0 NOUN F
, 0 PUNCT F
isoprenaline 0 ADV F
, 0 PUNCT F
sodium 0 NOUN F
nitroprusside 0 NOUN F
and 0 CCONJ F
of 0 ADP F
placebo 0 NOUN F
. 0 PUNCT F

3 0 NUM F
. 0 PUNCT F

Laser 0 NOUN T
interferometry 0 NOUN F
detected 0 VERB F
the 0 DET F
isoprenaline-effects 0 NOUN F
at 0 ADP F
the 0 DET F
lowest 0 PUNCT F
dose 0 NOUN F
level 0 NOUN F
of 0 ADP F
0.1 0 NUM F
micrograms 0 NOUN F
min-1 0 NOUN F
with 0 ADP F
a 0 DET F
high 0 ADJ F
signal-to-noise 0 ADJ F
ratio 0 NOUN F
. 0 PUNCT F

The 0 DET T
reproducibility 0 NOUN F
of 0 ADP F
measurements 0 NOUN F
under 0 ADP F
baseline 0 NOUN F
was 0 VERB F
high 0 ADJ F
, 0 PUNCT F
no 0 DET F
changes 0 NOUN F
were 0 VERB F
observed 0 NUM F
after 0 ADP F
systemically 0 ADV F
effective 0 ADJ F
doses 0 NOUN F
of 0 ADP F
phenylephrine 0 NOUN F
or 0 CCONJ F
sodium 0 NOUN F
nitroprusside 0 NOUN F
. 0 PUNCT F

Systolic 0 ADJ T
time 0 NOUN F
intervals 0 NOUN F
were 0 VERB F
sensitive 0 ADJ F
and 0 CCONJ F
specific 0 ADJ F
for 0 ADP F
isoprenaline-induced 0 VERB F
effects 0 NOUN F
, 0 PUNCT F
PEP 0 NOUN T
and 0 CCONJ F
QS2c-measurements 0 NOUN T
had 0 VERB F
high 0 ADJ F
reproducibility 0 NOUN F
. 0 PUNCT F

Fingerplethysmography 0 NOUN T
proved 0 PROPN F
a 0 DET F
sensitive 0 ADJ F
measurement 0 NOUN F
for 0 ADP F
the 0 DET F
detection 0 NOUN F
of 0 ADP F
the 0 DET F
vasodilating 0 VERB F
effects 0 NOUN F
of 0 ADP F
sodium 0 NOUN F
nitroprusside 0 NOUN F
, 0 PUNCT F
but 0 CCONJ F
was 0 VERB F
not 0 ADV F
specific 0 ADJ F
, 0 PUNCT F
and 0 CCONJ F
showed 0 VERB F
low 0 ADJ F
reproducibility 0 NOUN F
. 0 PUNCT F

Measurements 0 NOUN T
from 0 ADP F
Doppler 0 NOUN T
sonography 0 NOUN F
had 0 DET F
lower 0 PUNCT F
reproducibility 0 NOUN F
and 0 CCONJ F
sensitivity B-OTHER NOUN F
compared 0 VERB F
with 0 ADP F
the 0 DET F
other 0 ADJ F
applied 0 DET F
methods 0 NOUN F
. 0 PUNCT F

4 0 NUM F
. 0 PUNCT F

There 0 PUNCT T
was 0 VERB F
a 0 DET F
significant 0 ADJ F
sex 0 NOUN F
difference 0 NOUN F
for 0 ADP F
several 0 ADJ F
of 0 ADP F
the 0 DET F
haemodynamic 0 ADJ F
parameters 0 NOUN F
under 0 ADP F
baseline 0 NOUN F
conditions 0 NOUN F
; 0 PUNCT F
however 0 ADV F
, 0 PUNCT F
the 0 DET F
responsiveness 0 NOUN F
to 0 ADP F
the 0 DET F
drugs 0 NOUN F
under 0 ADP F
study 0 NOUN F
was 0 VERB F
not 0 ADV F
different 0 ADJ F
, 0 PUNCT F
when 0 ADP F
drug 0 NOUN F
effects 0 NOUN F
were 0 VERB F
expressed 0 VERB F
as 0 PUNCT F
% 0 ADV F
-change 0 NOUN F
from 0 ADP F
the 0 DET F
baseline 0 NOUN F
. 0 PUNCT F

5 0 NUM F
. 0 PUNCT F

Laser 0 NOUN T
interferometry 0 NOUN F
is 0 VERB F
a 0 DET F
valuable 0 ADJ F
non-invasive 0 ADJ F
, 0 PUNCT F
highly 0 ADV F
sensitive 0 ADJ F
and 0 CCONJ F
specific 0 ADJ F
approach 0 NOUN F
for 0 ADP F
the 0 DET F
detection 0 NOUN F
of 0 ADP F
pulse 0 PUNCT F
pressure 0 NOUN F
changes 0 NOUN F
. 0 PUNCT F

A 0 DET T
battery 0 NOUN F
of 0 ADP F
non-invasive 0 ADJ F
tests 0 NOUN F
appears 0 PART F
useful 0 ADJ F
for 0 ADP F
the 0 DET F
characterization 0 NOUN F
of 0 ADP F
cardiovascular 0 ADJ F
drugs 0 NOUN F
. 0 PUNCT F

Gender 0 NOUN T
differences 0 NOUN F
may 0 ADP F
not 0 NOUN F
pose 0 CCONJ F
a 0 DET F
relevant 0 ADJ F
problem 0 NOUN F
for 0 ADP F
the 0 DET F
study 0 NOUN F
of 0 ADP F
acute 0 ADJ F
haemodynamic 0 ADJ F
effects 0 NOUN F
of 0 ADP F
cardiovascular 0 ADJ F
drugs 0 NOUN F
. 0 PUNCT F

Prehydration 0 NOUN T
alone 0 ADJ F
is 0 VERB F
sufficient 0 ADJ F
to 0 PART F
prevent 0 ADJ F
contrast-induced 0 VERB F
nephropathy 0 NOUN F
after 0 ADP F
day-only 0 ADV F
angiography 0 NOUN F
procedures 0 NOUN F
-- 0 PUNCT F
a 0 DET F
randomised 0 VERB F
controlled 0 VERB F
trial 0 NOUN F
. 0 PUNCT F

BACKGROUND 0 NOUN T
Contrast 0 NOUN T
agents 0 NOUN F
used 0 VERB F
in 0 ADP F
angiography 0 NOUN F
procedures 0 NOUN F
for 0 ADP F
patients 0 NOUN F
with 0 ADP F
cardiovascular 0 ADJ F
disease 0 NOUN F
are 0 VERB F
known 0 VERB F
to 0 ADP F
cause 0 PUNCT F
contrast-induced 0 ADP F
nephropathy 0 NOUN F
( 0 PUNCT F
CIN 0 NOUN T
) 0 PUNCT F
, 0 PUNCT F
which 0 ADP F
may 0 VERB F
be 0 VERB F
partially 0 ADV F
due 0 PUNCT F
to 0 ADP F
the 0 DET F
production 0 NOUN F
of 0 ADP F
nephrotoxic 0 ADJ F
oxygen-free 0 ADP F
radicals 0 NOUN F
. 0 PUNCT F

It 0 PRON T
is 0 VERB F
uncertain 0 VERB F
whether 0 ADP F
administration 0 NOUN F
of 0 ADP F
intravenous 0 ADJ F
( 0 PUNCT F
IV 0 NUM T
) 0 PUNCT F
anti-oxidant 0 ADP F
, 0 PUNCT F
N-acetylcysteine 0 NOUN T
( 0 PUNCT F
NAC 0 NOUN T
) 0 PUNCT F
, 0 PUNCT F
can 0 VERB F
prevent 0 VERB F
reduction 0 NOUN F
in 0 ADP F
renal 0 ADJ F
function 0 NOUN F
and 0 CCONJ F
whether 0 ADP F
this 0 PUNCT F
is 0 VERB F
a 0 DET F
cost-effective 0 ADJ F
approach 0 NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
Sixty-five 0 ADP T
day-only 0 PROPN F
patients 0 NOUN F
with 0 ADP F
renal 0 ADJ F
impairment 0 NOUN F
( 0 PUNCT F
mean 0 NOUN F
serum 0 NOUN F
creatinine 0 NOUN F
concentration 0 NOUN F
0.16+/-0.03 0 PUNCT F
mmol/l 0 NOUN F
) 0 PUNCT F
due 0 ADJ F
to 0 PUNCT F
undergo 0 PUNCT F
coronary 0 ADJ F
or 0 CCONJ F
peripheral 0 ADJ F
angiography 0 NOUN F
and/or 0 CCONJ F
stenting 0 VERB F
were 0 VERB F
randomly 0 ADV F
assigned 0 VERB F
to 0 ADP F
IV 0 PUNCT T
NAC 0 NOUN T
300 0 NUM F
or 0 CCONJ F
600 0 NUM F
mg 0 NOUN F
immediately 0 ADV F
before 0 PUNCT F
and 0 CCONJ F
after 0 ADP F
the 0 DET F
procedure 0 NOUN F
or 0 CCONJ F
IV 0 NUM T
fluid 0 NOUN F
alone 0 ADJ F
. 0 PUNCT F

RESULTS 0 NOUN T
Of 0 ADP T
the 0 DET F
60 0 ADV F
patients 0 NOUN F
with 0 ADP F
complete 0 ADJ F
data 0 NOUN F
, 0 PUNCT F
none 0 NUM F
had 0 PUNCT F
acute 0 ADJ F
CIN 0 NOUN T
( 0 PUNCT F
increase 0 ADP F
in 0 ADP F
serum 0 NOUN F
creatinine 0 NOUN F
concentration 0 NOUN F
> 0 SYM F
or 0 CCONJ F
= 0 SYM F
0.044 0 NUM F
mmol/l 0 NOUN F
, 0 PUNCT F
48 0 NUM F
h 0 NOUN F
after 0 ADP F
administration 0 NOUN F
of 0 ADP F
contrast 0 NOUN F
agent 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

Eight 0 NUM T
patients 0 NOUN F
( 0 PUNCT F
13 0 NUM F
% 0 SYM F
) 0 PUNCT F
have 0 PUNCT F
demonstrated 0 VERB F
an 0 DET F
increase 0 NOUN F
in 0 ADP F
their 0 PUNCT F
serum B-PHYSICAL NOUN F
creatinine I-PHYSICAL NOUN F
concentration I-PHYSICAL NOUN F
> 0 SYM F
or 0 CCONJ F
= 0 SYM F
0.044 0 PUNCT F
mmol/l 0 NOUN F
30 0 NUM F
days 0 NOUN F
after 0 ADP F
administration 0 NOUN F
of 0 ADP F
contrast 0 NOUN F
agent 0 NOUN F
: 0 PUNCT F
2/19 0 NOUN F
( 0 PUNCT F
11 0 NUM F
% 0 SYM F
) 0 PUNCT F
in 0 ADP F
the 0 DET F
control 0 NOUN F
group 0 NOUN F
, 0 PUNCT F
2/21 0 NOUN F
( 0 PUNCT F
10 0 NUM F
% 0 SYM F
) 0 PUNCT F
in 0 ADP F
the 0 DET F
600 0 NUM F
mg 0 NOUN F
NAC 0 NOUN T
group 0 NOUN F
and 0 CCONJ F
4/20 0 NOUN F
( 0 PUNCT F
20 0 NUM F
% 0 SYM F
) 0 PUNCT F
the 0 DET F
300 0 NUM F
mg 0 NOUN F
NAC 0 NOUN T
group 0 NOUN F
( 0 PUNCT F
p 0 NOUN F
= 0 SYM F
0.66 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
mean 0 NOUN F
volumes B-OTHER NOUN F
of I-OTHER ADP F
contrast 0 NOUN F
agent B-OTHER NOUN F
used 0 ADP F
and 0 CCONJ F
prehydration 0 ADJ F
given 0 ADJ F
for 0 ADP F
each 0 PUNCT F
of 0 ADP F
the 0 DET F
three 0 NUM F
groups 0 NOUN F
did 0 ADP F
not 0 ADV F
differ 0 VERB F
significantly 0 ADV F
( 0 PUNCT F
p 0 NOUN F
> 0 SYM F
0.83 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

There 0 PUNCT T
was 0 VERB F
significant 0 ADJ F
improvement 0 NOUN F
in 0 PUNCT F
creatinine B-PHYSICAL PUNCT F

Incidence 0 NOUN T
of 0 ADP F
puberty B-PHYSICAL NOUN F
in 0 ADP F
beef 0 NOUN F
heifers 0 PUNCT F
fed 0 ADJ F
high- 0 NOUN F
or 0 CCONJ F
low-starch 0 NOUN F
diets 0 NOUN F
for 0 ADP F
different 0 ADJ F
periods 0 NOUN F
before 0 ADP F
breeding 0 VERB F
. 0 PUNCT F

Spring-born 0 PUNCT T
Hereford 0 NOUN T
x 0 ADJ F
Angus 0 NOUN T
heifers 0 PUNCT F
( 0 PUNCT F
n 0 NOUN F
= 0 SYM F
206 0 NUM F
) 0 PUNCT F
were 0 VERB F
used 0 VERB F
to 0 PART F
determine 0 ADP F
effects 0 NOUN F
of 0 ADP F
energy 0 NOUN F
supplementation 0 NOUN F
programs 0 NOUN F
and 0 CCONJ F
amount 0 NOUN F
of 0 ADP F
starch 0 NOUN F
in 0 ADP F
the 0 DET F
diet 0 NOUN F
on 0 ADP F
incidence 0 NOUN F
of 0 ADP F
puberty B-OTHER NOUN F
. 0 PUNCT F

In 0 ADP T
Exp 0 NOUN T
. 0 PUNCT F

1 0 NUM F
, 0 PUNCT F
heifers 0 ADJ F
( 0 PUNCT F
205 0 NUM F
+/- 0 SYM F
5 0 NUM F
kg 0 NOUN F
; 0 PUNCT F
n 0 NOUN F
= 0 SYM F
68 0 NUM F
) 0 PUNCT F
grazing 0 CCONJ F
dormant 0 PUNCT F
native 0 ADJ F
pasture 0 NOUN F
were 0 VERB F
fed 0 VERB F
0.9 0 NUM F
kg/d 0 NOUN F
( 0 PUNCT F
as-fed 0 PUNCT F
basis 0 NOUN F
) 0 PUNCT F
of 0 ADP F
a 0 DET F
42 0 NUM F
% 0 SYM F
CP 0 NOUN T
supplement 0 NOUN F
from 0 ADP F
November 0 NOUN T
until 0 ADP F
February 0 PUNCT T
14 0 NUM F
. 0 PUNCT F

Heifers 0 VERB T
were 0 VERB F
stratified 0 VERB F
by 0 ADP F
weaning 0 VERB F
weight 0 NOUN F
and 0 CCONJ F
allotted 0 ADP F
randomly 0 ADV F
to 0 ADP F
treatment 0 NOUN F
before 0 ADP F
breeding 0 VERB F
( 0 PUNCT F
May 0 NOUN T
to 0 ADP F
July 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

Treatments 0 NOUN T
were 0 VERB F
1 0 NUM F
) 0 PUNCT F
0.9 0 NUM F
kg 0 NOUN F
( 0 PUNCT F
as-fed 0 PUNCT F
basis 0 NOUN F
) 0 PUNCT F
of 0 ADP F
a 0 DET F
42 0 NUM F
% 0 SYM F
CP 0 NOUN T
supplement/d 0 NOUN F
and 0 CCONJ F
pasture 0 NOUN F
( 0 PUNCT F
control 0 NOUN F
) 0 PUNCT F
; 0 PUNCT F
2 0 NUM F
) 0 PUNCT F
a 0 DET F
high-starch 0 NOUN F
( 0 PUNCT F
HS 0 NOUN T
) 0 PUNCT F
diet 0 NOUN F
( 0 PUNCT F
73 0 NUM F
% 0 SYM F
corn 0 NOUN F
; 0 PUNCT F
53 0 NUM F
% 0 SYM F
starch 0 NOUN F
) 0 PUNCT F
fed 0 VERB F
in 0 ADP F
a 0 DET F
drylot 0 NOUN F
for 0 ADP F
60 0 NUM F
d 0 NOUN F
( 0 PUNCT F
HS-60 0 NOUN T
) 0 PUNCT F
; 0 PUNCT F
3 0 NUM F
) 0 PUNCT F
a 0 DET F
HS 0 NOUN T
diet 0 NOUN F
fed 0 VERB F
in 0 ADP F
drylot 0 NOUN F
for 0 ADP F
30 0 NUM F
d 0 NOUN F
( 0 PUNCT F
HS-30 0 NOUN T
) 0 PUNCT F
; 0 PUNCT F
or 0 CCONJ F
4 0 NUM F
) 0 PUNCT F
a 0 DET F
low-starch 0 NOUN F
( 0 PUNCT F
LS 0 NOUN T
) 0 PUNCT F
diet 0 NOUN F
( 0 PUNCT F
49 0 NUM F
% 0 SYM F
corn 0 NOUN F
; 0 PUNCT F
37 0 NUM F
% 0 SYM F
starch 0 NOUN F
) 0 PUNCT F
self-fed 0 VERB F
on 0 ADP F
pasture 0 NOUN F
for 0 ADP F
30 0 NUM F
d 0 NOUN F
( 0 PUNCT F
LS-30 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
HS-60 0 NOUN T
and 0 CCONJ F
HS-30 0 NOUN T
heifers 0 ADV F
were 0 ADV F
limited-fed 0 PUNCT F
to 0 PUNCT F
gain 0 NOUN F
0.9 0 NUM F
kg/d 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
the 0 DET F
LS-30 0 NOUN T
heifers 0 VERB F
had 0 PUNCT F
ad 0 PUNCT F
libitum 0 PUNCT F
access 0 NOUN F
to 0 ADP F
the 0 DET F
diet 0 NOUN F
. 0 PUNCT F

High-starch-60 0 NOUN T
and 0 CCONJ F
LS-30 0 NOUN T
heifers 0 PUNCT F
were 0 VERB F
heavier B-PHYSICAL NOUN F
( 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.05 0 NUM F
) 0 PUNCT F
than 0 PUNCT F
control 0 NOUN F
and 0 CCONJ F
HS-30 0 NOUN T
heifers 0 VERB F
at 0 ADP F
the 0 DET F
beginning 0 PUNCT F
of 0 ADP F
the 0 DET F
breeding 0 ADJ F
season 0 ADJ F
. 0 PUNCT F

Thirty-one 0 NUM T
, 0 PUNCT F
25 0 NUM F
, 0 PUNCT F
and 0 CCONJ F
26 0 NUM F
% 0 ADJ F
more 0 DET F
HS-60 0 NOUN T
heifers 0 DET F
were 0 PUNCT F
pubertal 0 ADJ F
( 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.05 0 NUM F
) 0 PUNCT F
on 0 ADP F
May 0 NOUN T
1 0 NUM F
compared 0 VERB F
with 0 ADP F
LS-30 0 NOUN T
, 0 PUNCT F
HS-30 0 NOUN T
, 0 PUNCT F
and 0 CCONJ F
control 0 NOUN F
heifers 0 PUNCT F
, 0 PUNCT F
respectively 0 ADV F
. 0 PUNCT F

At 0 ADP T
puberty 0 NOUN F
, 0 PUNCT F
HS-60 0 NOUN T
heifers 0 NUM F
were 0 VERB F
24 0 NUM F
and 0 CCONJ F
22 0 NUM F
d 0 NOUN F
younger 0 PUNCT F
( 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.05 0 NUM F
) 0 PUNCT F
than 0 ADP F
LS-30 0 NOUN T
and 0 CCONJ F
control 0 NOUN F
heifers 0 PUNCT F
, 0 PUNCT F
and 0 CCONJ F
31 0 NUM F
kg 0 NOUN F
lighter 0 VERB F
( 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.01 0 NUM F
) 0 PUNCT F
than 0 ADP F
LS-30 0 NOUN T
heifers 0 VERB F
. 0 PUNCT F

In 0 ADP T
Exp 0 NOUN T
. 0 PUNCT F

2 0 NUM F
, 0 PUNCT F
heifers 0 PUNCT F
grazed 0 ADP F
dormant 0 ADJ F
pasture 0 NOUN F
and 0 CCONJ F
were 0 VERB F
fed 0 VERB F
0.9 0 NUM F
kg 0 NOUN F
( 0 PUNCT F
as-fed 0 PUNCT F
basis 0 NOUN F
) 0 PUNCT F
of 0 ADP F
a 0 DET F
42 0 NUM F
% 0 SYM F
CP 0 NOUN T
supplement/d 0 NOUN F
from 0 ADP F
weaning 0 VERB F
in 0 ADP F
October 0 NOUN T
to 0 ADP F
late 0 ADJ F
February 0 ADJ T
; 0 PUNCT F
then 0 ADV F
heifers 0 PUNCT F
were 0 VERB F
assigned 0 VERB F
randomly 0 ADV F
to 0 PUNCT F
treatments 0 ADV F
for 0 ADP F
60 0 NUM F
d 0 NOUN F
before 0 ADP F
the 0 DET F
breeding 0 ADJ F
season 0 ADJ F
. 0 PUNCT F

In 0 ADP T
two 0 NUM F
years 0 NOUN F
, 0 PUNCT F
control 0 PUNCT F
heifers 0 PUNCT F
( 0 PUNCT F
n 0 NOUN F
= 0 SYM F
46 0 NUM F
) 0 PUNCT F
grazed 0 VERB F
pasture 0 NOUN F
and 0 CCONJ F
received 0 VERB F
0.9 0 NUM F
kg 0 NOUN F
of 0 ADP F
SBM 0 NOUN T
supplement/d 0 NOUN F
; 0 PUNCT F
LS 0 NOUN T
( 0 PUNCT F
n 0 NOUN F
= 0 SYM F
46 0 NUM F
) 0 PUNCT F
heifers 0 PUNCT F
were 0 ADP F
self-fed 0 VERB F
a 0 DET F
distiller 0 NOUN F
's 0 PUNCT F
grain 0 NOUN F
and 0 CCONJ F
soybean 0 NOUN F
hull-based 0 NOUN F
diet 0 NOUN F
in 0 ADP F
drylot 0 NOUN F
; 0 PUNCT F
and 0 CCONJ F
HS 0 NOUN T
heifers 0 PUNCT F
( 0 PUNCT F
n 0 NOUN F
= 0 SYM F
46 0 NUM F
) 0 PUNCT F
were 0 ADV F
limited-fed 0 PUNCT F
a 0 DET F
corn-based 0 ADJ F
diet 0 NOUN F
in 0 ADP F
drylot 0 NOUN F
. 0 PUNCT F

During 0 ADP T
treatment 0 NOUN F
, 0 PUNCT F
HS 0 NOUN T
and 0 CCONJ F
LS 0 NOUN T
heifers 0 PROPN F
had 0 ADP F
greater 0 PUNCT F
weight 0 NOUN F
gains B-PHYSICAL NOUN F
than 0 PUNCT F
control 0 NOUN F
heifers 0 ADJ F
. 0 PUNCT F

Pubertal B-PHYSICAL PUNCT T
BW I-PHYSICAL NOUN T
( 0 PUNCT F
313 0 NUM F
+/- 0 SYM F
6 0 NUM F
kg 0 NOUN F
) 0 PUNCT F
was 0 VERB F
not 0 ADV F
influenced 0 VERB F
by 0 ADP F
treatment 0 NOUN F
, 0 PUNCT F
but 0 CCONJ F
HS 0 NOUN T
and 0 CCONJ F
LS 0 NOUN T
heifers 0 NUM F
were 0 VERB F
younger 0 PUNCT F
( 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.03 0 NUM F
) 0 PUNCT F
than 0 PUNCT F
control 0 NOUN F
heifers 0 VERB F
at 0 ADP F
puberty 0 NOUN F
. 0 PUNCT F

During 0 ADP T
a 0 DET F
60-d 0 NOUN F
breeding 0 ADJ F
period 0 NOUN F
, 0 PUNCT F
the 0 DET F
incidence 0 NOUN F
of 0 ADP F
puberty B-PHYSICAL NOUN F
was 0 VERB F
greater 0 PUNCT F
( 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.05 0 NUM F
) 0 PUNCT F
for 0 ADP F
HS 0 NOUN T
and 0 CCONJ F
LS 0 NOUN T
heifers 0 PUNCT F
than 0 VERB F
for 0 ADP F
control 0 NOUN F
heifers 0 ADJ F
and 0 CCONJ F
was 0 VERB F
greater 0 PUNCT F
( 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.05 0 NUM F
) 0 PUNCT F
in 0 ADP F
HS 0 NOUN T
than 0 PUNCT F
in 0 ADP F
LS 0 NOUN T
heifers 0 VERB F
in 0 ADP F
Year 0 NOUN T
1 0 NUM F
. 0 PUNCT F

Feeding 0 ADP T
a 0 DET F
LS 0 NOUN T
or 0 CCONJ F
a 0 DET F
HS 0 NOUN T
diet 0 NOUN F
for 0 ADP F
30 0 NUM F
d 0 NOUN F
before 0 ADP F
breeding 0 VERB F
may 0 SYM F
be 0 VERB F
inadequate 0 ADJ F
to 0 ADP F
stimulate 0 ADJ F
puberty B-PHYSICAL NOUN F
in 0 ADP F
beef 0 NOUN F
heifers 0 PUNCT F
, 0 PUNCT F
but 0 CCONJ F
feeding 0 ADP F
a 0 DET F
diet 0 NOUN F
with 0 ADP F
a 0 DET F
greater 0 PUNCT F
amount 0 NOUN F
of 0 ADP F
starch 0 NOUN F
for 0 ADP F
60 0 NUM F
d 0 NOUN F
before 0 ADP F
breeding 0 VERB F
may 0 SYM F
increase 0 VERB F
the 0 DET F
incidence 0 NOUN F
of 0 ADP F
puberty B-PHYSICAL NOUN F
during 0 ADP F
breeding 0 VERB F
of 0 ADP F
heifers 0 CCONJ F
that 0 VERB F
have 0 PUNCT F
inadequate 0 ADJ F
yearling 0 PUNCT F
weight 0 NOUN F
. 0 PUNCT F

Conduit 0 NOUN T
artery 0 NOUN F
structure 0 NOUN F
and 0 CCONJ F
function 0 NOUN F
in 0 ADP F
lowlanders 0 NOUN F
and 0 CCONJ F
native 0 ADJ F
highlanders 0 NOUN F
: 0 PUNCT F
relationships 0 NOUN F
with 0 ADP F
oxidative 0 ADJ F
stress 0 NOUN F
and 0 CCONJ F
role 0 NOUN F
of 0 ADP F
sympathoexcitation 0 NOUN F
. 0 PUNCT F

Research 0 NOUN T
detailing 0 ADP F
the 0 DET F
normal 0 ADJ F
vascular 0 ADJ F
adaptions 0 NOUN F
to 0 ADP F
high 0 ADJ F
altitude 0 NOUN F
is 0 VERB F
minimal 0 ADJ F
and 0 CCONJ F
often 0 ADV F
confounded 0 VERB F
by 0 ADP F
pathology 0 NOUN F
( 0 PUNCT F
e.g. 0 ADP F
, 0 PUNCT F
chronic 0 ADJ F
mountain 0 NUM F
sickness 0 NOUN F
) 0 PUNCT F
and 0 CCONJ F
methodological 0 ADJ F
issues 0 NOUN F
. 0 PUNCT F

We 0 PRON T
examined 0 VERB F
vascular 0 ADJ F
function 0 NOUN F
and 0 CCONJ F
structure 0 NOUN F
in 0 ADP F
: 0 PUNCT F
( 0 PUNCT F
1 0 NUM F
) 0 PUNCT F
healthy 0 ADJ F
lowlanders 0 NOUN F
during 0 ADP F
acute 0 ADJ F
hypoxia 0 NOUN F
and 0 CCONJ F
prolonged 0 PUNCT F
( 0 PUNCT F
?2 0 PUNCT F
weeks 0 NOUN F
) 0 PUNCT F
exposure 0 NOUN F
to 0 ADP F
high 0 ADJ F
altitude 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
( 0 PUNCT F
2 0 NUM F
) 0 PUNCT F
high-altitude 0 PUNCT F
natives 0 NOUN F
at 0 ADP F
5050 0 NUM F
m 0 NOUN F
( 0 PUNCT F
highlanders 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

In 0 ADP T
12 0 NUM F
healthy 0 ADJ F
lowlanders 0 NOUN F
( 0 PUNCT F
aged 0 DET F
32 0 NUM F
? 0 PUNCT F

7 0 NUM F
years 0 NOUN F
) 0 PUNCT F
and 0 CCONJ F
12 0 NUM F
highlanders 0 NOUN F
( 0 PUNCT F
Sherpa 0 ADJ T
; 0 PUNCT F
33 0 NUM F
? 0 PUNCT F

14 0 NUM F
years 0 NOUN F
) 0 PUNCT F
we 0 PRON F
assessed 0 VERB F
brachial 0 ADJ F
endothelium-dependent 0 ADJ F
flow-mediated 0 ADP F
dilatation 0 NOUN F
( 0 PUNCT F
FMD 0 NOUN T
) 0 PUNCT F
, 0 PUNCT F
endothelium-independent 0 PUNCT F
dilatation 0 NOUN F
( 0 PUNCT F
via 0 ADP F
glyceryl 0 NOUN F
trinitrate 0 ADV F
; 0 PUNCT F
GTN 0 NOUN T
) 0 PUNCT F
, 0 PUNCT F
common 0 ADJ F
carotid 0 ADJ F
intima-media 0 ADJ F
thickness 0 NOUN F
( 0 PUNCT F
CIMT 0 NOUN T
) 0 PUNCT F
and 0 CCONJ F
diameter 0 NOUN F
( 0 PUNCT F
ultrasound 0 NOUN F
) 0 PUNCT F
, 0 PUNCT F
and 0 CCONJ F
arterial 0 ADJ F
stiffness 0 NOUN F
via 0 ADP F
pulse 0 NOUN F
wave 0 NOUN F
velocity 0 NOUN F
( 0 PUNCT F
PWV 0 NOUN T
; 0 PUNCT F
applanation 0 NOUN F
tonometry 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

Cephalic 0 ADJ T
venous 0 ADJ F
biomarkers 0 CCONJ F
of 0 ADP F
free 0 ADJ F
radical-mediated 0 DET F
lipid 0 NOUN F
peroxidation 0 NOUN F
( 0 PUNCT F
lipid 0 NOUN F
hydroperoxides 0 ADJ F
, 0 PUNCT F
LOOH 0 NOUN T
) 0 PUNCT F
, 0 PUNCT F
nitrite 0 NOUN F
( 0 PUNCT F
NO2- 0 ADP T
) 0 PUNCT F
and 0 CCONJ F
lipid 0 NOUN F
soluble 0 ADJ F
antioxidants 0 NOUN F
were 0 VERB F
also 0 ADV F
obtained 0 VERB F
at 0 ADP F
rest 0 NOUN F
. 0 PUNCT F

In 0 ADP T
lowlanders 0 NOUN F
, 0 PUNCT F
measurements 0 NOUN F
were 0 VERB F
performed 0 VERB F
at 0 ADP F
sea 0 NOUN F
level 0 NOUN F
( 0 PUNCT F
334 0 NUM F
m 0 NOUN F
) 0 PUNCT F
and 0 CCONJ F
between 0 ADP F
days 0 NOUN F
3-4 0 NUM F
( 0 PUNCT F
acute 0 ADJ F
high 0 ADJ F
altitude 0 NOUN F
) 0 PUNCT F
and 0 CCONJ F
12-14 0 NUM F
( 0 PUNCT F
chronic 0 ADJ F
high 0 ADJ F
altitude 0 NOUN F
) 0 PUNCT F
following 0 VERB F
arrival 0 NOUN F
to 0 ADP F
5050 0 NUM F
m. 0 NOUN F
Highlanders 0 NOUN T
were 0 VERB F
assessed 0 VERB F
once 0 PUNCT F
at 0 ADP F
5050 0 NUM F
m. 0 ADV F
Compared 0 ADV T
with 0 ADP F
sea 0 NOUN F
level 0 NOUN F
, 0 PUNCT F
acute 0 ADJ F
high 0 ADJ F
altitude 0 NOUN F
reduced 0 DET F
lowlanders 0 NOUN F
' 0 PUNCT F
FMD 0 NOUN T
( 0 PUNCT F
7.9 0 NUM F
? 0 PUNCT F

0.4 0 NUM F
vs. 0 CCONJ F
6.8 0 NUM F
? 0 PUNCT F

0.4 0 NUM F
% 0 SYM F
; 0 PUNCT F
P 0 NOUN T
= 0 SYM F
0.004 0 NUM F
) 0 PUNCT F
and 0 CCONJ F
GTN-induced 0 VERB T
dilatation 0 NOUN F
( 0 PUNCT F
16.6 0 NUM F
? 0 PUNCT F

0.9 0 NUM F
vs. 0 CCONJ F
14.5 0 NUM F
? 0 PUNCT F

0.8 0 NUM F
% 0 SYM F
; 0 PUNCT F
P 0 NOUN T
= 0 SYM F
0.006 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
and 0 CCONJ F
raised 0 VERB F
central 0 ADJ F
PWV 0 NOUN T
( 0 PUNCT F
6.0 0 NUM F
? 0 PUNCT F

0.2 0 NUM F
vs. 0 CCONJ F
6.6 0 NUM F
? 0 PUNCT F

0.3 0 NUM F
m 0 NOUN F
s 0 NOUN F
( 0 PUNCT F
-1 0 NUM F
) 0 PUNCT F
; 0 PUNCT F
P 0 NOUN T
= 0 SYM F
0.001 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

These 0 DET T
changes 0 NOUN F
persisted 0 VERB F
at 0 ADP F
days 0 NOUN F
12-14 0 ADJ F
, 0 PUNCT F
and 0 CCONJ F
after 0 ADP F
allometrically 0 ADJ F
scaling 0 PUNCT F
FMD 0 NOUN T
to 0 PUNCT F
adjust 0 PUNCT F
for 0 ADP F
altered 0 VERB F
baseline 0 NOUN F
diameter 0 NOUN F
. 0 PUNCT F

Compared 0 VERB T
to 0 ADP F
lowlanders 0 CCONJ F
at 0 ADP F
sea 0 NOUN F
level 0 NOUN F
and 0 CCONJ F
high 0 ADJ F
altitude 0 NOUN F
, 0 PUNCT F
highlanders 0 NOUN F
had 0 ADP F
a 0 DET F
lower 0 PUNCT F
carotid B-PHYSICAL ADJ F
wall I-PHYSICAL NOUN F
: 0 PUNCT F
lumen B-PHYSICAL NOUN F
ratio B-PHYSICAL NOUN F
( 0 PUNCT F
?19 0 PUNCT F
% 0 ADP F
, 0 PUNCT F
P 0 NOUN T
? 0 PUNCT F

0.04 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
attributable 0 ADJ F
to 0 ADP F
a 0 DET F
narrower 0 PUNCT F
CIMT 0 NOUN T
and 0 CCONJ F
wider 0 PUNCT F
lumen 0 NOUN F
. 0 PUNCT F

Although 0 ADP T
both 0 CCONJ F
LOOH B-PHYSICAL NOUN T
and 0 PUNCT F

The 0 DET T
impact 0 NOUN F
of 0 ADP F
schizophrenic 0 ADJ F
patient 0 NOUN F
functionality 0 NOUN F
on 0 ADP F
service B-OTHER NOUN F
utilization I-OTHER NOUN F
and 0 CCONJ F
cost B-OTHER NOUN F
. 0 PUNCT F

Based 0 VERB T
on 0 ADP F
a 0 DET F
presentation 0 NOUN F
by 0 ADP F
Sandra 0 CCONJ T
L. 0 ADV T
Tunis 0 NOUN T
, 0 PUNCT F
PhD 0 NOUN T
. 0 PUNCT F

With 0 ADP T
the 0 DET F
advent 0 NOUN F
of 0 ADP F
atypical 0 ADJ F
agents 0 NOUN F
in 0 ADP F
the 0 DET F
treatment 0 NOUN F
of 0 ADP F
schizophrenia 0 NOUN F
, 0 PUNCT F
physicians 0 NOUN F
and 0 CCONJ F
policy 0 NOUN F
makers 0 NOUN F
must 0 DET F
consider 0 VERB F
the 0 DET F
costs 0 NOUN F
that 0 ADP F
may 0 VERB F
accompany 0 VERB F
greater 0 PUNCT F
clinical 0 ADJ F
efficacy 0 NOUN F
. 0 PUNCT F

Analyses 0 NOUN T
reveal 0 VERB F
that 0 ADP F
olanzapine 0 NOUN F
shows 0 NOUN F
a 0 DET F
greater 0 PUNCT F
clinical B-OTHER ADJ F
cost I-OTHER NOUN F
effectiveness I-OTHER NOUN F
, 0 PUNCT F
as 0 PUNCT F
well 0 PUNCT F
as 0 CCONJ F
a 0 DET F
greater 0 PUNCT F
functional B-OTHER ADJ F
cost I-OTHER NOUN F
effectiveness I-OTHER NOUN F
, 0 PUNCT F
than 0 PUNCT F
haloperidol 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
that 0 ADP F
functional 0 ADJ F
outcomes 0 NOUN F
, 0 PUNCT F
in 0 ADP F
particular 0 NOUN F
, 0 PUNCT F
show 0 NUM F
promise 0 PUNCT F
as 0 ADP F
important 0 ADJ F
measures 0 NOUN F
of 0 ADP F
effectiveness 0 NOUN F
. 0 PUNCT F

Functional 0 ADJ T
outcomes 0 NOUN F
can 0 VERB F
help 0 ADP F
differentiate 0 PUNCT F
medications 0 NOUN F
and 0 CCONJ F
can 0 PRON F
be 0 VERB F
used 0 VERB F
to 0 PART F
help 0 PUNCT F
demonstrate 0 ADP F
the 0 DET F
cost B-OTHER NOUN F
effectiveness I-OTHER NOUN F
of 0 ADP F
atypical 0 ADJ F
agents 0 NOUN F
. 0 PUNCT F

Mental B-MENTAL ADJ T
health I-MENTAL NOUN F
and 0 CCONJ F
physical B-PHYSICAL ADJ F
health I-PHYSICAL NOUN F
functioning I-PHYSICAL VERB F
, 0 PUNCT F
as 0 CCONJ F
well 0 PUNCT F
as 0 CCONJ F
work B-MENTAL NOUN F
status I-MENTAL NOUN F
, 0 PUNCT F
are 0 VERB F
all 0 DET F
measures 0 NOUN F
of 0 ADP F
functioning 0 VERB F
that 0 VERB F
have 0 PUNCT F
been 0 PUNCT F
used 0 VERB F
to 0 PART F
evaluate 0 NOUN F
treatment 0 NOUN F
strategies 0 NOUN F
. 0 PUNCT F

When 0 ADP T
comparing 0 ADJ F
olanzapine 0 NOUN F
with 0 ADP F
haloperidol 0 NOUN F
, 0 PUNCT F
cost B-OTHER NOUN F
savings I-OTHER NOUN F
are 0 VERB F
seen 0 VERB F
throughout 0 ADP F
the 0 DET F
treatment 0 NOUN F
period 0 NOUN F
( 0 PUNCT F
1 0 NUM F
year 0 NOUN F
) 0 PUNCT F
, 0 PUNCT F
with 0 ADP F
physical B-PHYSICAL ADJ F
functioning I-PHYSICAL ADP F
most 0 ADJ F
highly 0 ADV F
affected 0 VERB F
over 0 PUNCT F
time 0 NOUN F
. 0 PUNCT F

Functional 0 ADJ T
outcomes 0 NOUN F
can 0 ADP F
therefore 0 ADV F
serve 0 VERB F
2 0 NUM F
purposes 0 NOUN F
: 0 PUNCT F
to 0 PART F
enhance 0 ADJ F
compliance 0 NOUN F
by 0 ADP F
improving 0 VERB F
health-related B-OTHER VERB F
quality I-OTHER NOUN F
of I-OTHER ADP F
life I-OTHER NOUN F
and 0 CCONJ F
to 0 PART F
assist 0 NOUN F
in 0 ADP F
making 0 VERB F
both 0 PUNCT F
treatment 0 NOUN F
and 0 CCONJ F
formulary 0 PUNCT F
decisions 0 NOUN F
. 0 PUNCT F

Efficacy 0 NOUN T
and 0 CCONJ F
safety 0 NOUN F
of 0 ADP F
10 0 NUM F
% 0 SYM F
HES 0 NOUN T
130/0.4 0 ADV F
versus 0 CCONJ F
10 0 NUM F
% 0 SYM F
HES 0 NOUN T
200/0.5 0 ADV F
for 0 ADP F
plasma 0 NOUN F
volume 0 NOUN F
expansion 0 NOUN F
in 0 ADP F
cardiac 0 ADJ F
surgery 0 NOUN F
patients 0 NOUN F
. 0 PUNCT F

AIM 0 NOUN T
Hydroxyethyl 0 NOUN T
starch 0 NOUN F
( 0 PUNCT F
HES 0 NOUN T
) 0 PUNCT F
solutions 0 NOUN F
are 0 PROPN F
frequently 0 ADV F
used 0 VERB F
for 0 ADP F
perioperative 0 ADJ F
volume 0 NOUN F
replacement 0 NOUN F
. 0 PUNCT F

Whereas 0 ADP T
older 0 PUNCT F
HES 0 NOUN T
specimen 0 NOUN F
tended 0 VERB F
to 0 PART F
accumulate 0 NOUN F
in 0 ADP F
the 0 DET F
plasma 0 NOUN F
and 0 CCONJ F
to 0 ADP F
cause 0 PROPN F
negative 0 ADJ F
effects 0 NOUN F
on 0 ADP F
hemostasis 0 NOUN F
, 0 PUNCT F
more 0 ADV F
recent 0 ADJ F
products 0 NOUN F
, 0 PUNCT F
e.g. 0 ADP F
, 0 PUNCT F
HES 0 NOUN T
130/0.4 0 ADV F
, 0 PUNCT F
are 0 VERB F
characterised 0 VERB F
by 0 ADP F
improved 0 CCONJ F
pharmacological 0 ADJ F
properties 0 NOUN F
. 0 PUNCT F

The 0 DET T
present 0 ADJ F
study 0 NOUN F
was 0 VERB F
designed 0 VERB F
to 0 PART F
compare 0 NOUN F
the 0 DET F
efficacy 0 NOUN F
and 0 CCONJ F
safety B-OTHER NOUN F
of 0 ADP F
10 0 NUM F
% 0 SYM F
HES 0 NOUN T
130/0.4 0 ADV F
and 0 CCONJ F
10 0 NUM F
% 0 SYM F
HES 0 NOUN T
200/0.5 0 ADV F
. 0 PUNCT F

METHODS 0 NOUN T
In 0 ADP T
this 0 DET F
post-hoc 0 NOUN F
analysis 0 NOUN F
of 0 ADP F
a 0 DET F
prospective 0 ADJ F
, 0 PUNCT F
randomised 0 DET F
, 0 PUNCT F
double-blind 0 ADJ F
, 0 PUNCT F
multi-center 0 NOUN F
therapeutic 0 ADJ F
equivalence 0 ADJ F
trial 0 NOUN F
, 0 PUNCT F
76 0 NUM F
patients 0 NOUN F
undergoing 0 VERB F
elective 0 ADJ F
on-pump 0 NOUN F
cardiac 0 ADJ F
surgery 0 NOUN F
received 0 ADP F
perioperative 0 ADP F
volume 0 NOUN F
replacement 0 NOUN F
using 0 ADP F
either 0 PUNCT F
10 0 NUM F
% 0 SYM F
HES 0 NOUN T
130/0.4 0 ADV F
( 0 PUNCT F
N.=37 0 ADP T
) 0 PUNCT F
or 0 CCONJ F
10 0 NUM F
% 0 SYM F
HES 0 NOUN T
200/0.5 0 ADV F
( 0 PUNCT F
N.=39 0 NOUN T
) 0 PUNCT F
up 0 PUNCT F
to 0 ADP F
a 0 DET F
maximum 0 NOUN F
dose 0 NOUN F
of 0 ADP F
20 0 NUM F
mL 0 NOUN F
kg-1 0 NOUN F
. 0 PUNCT F

RESULTS 0 ADJ T
Equivalent B-OTHER ADJ T
volumes I-OTHER NOUN F
of I-OTHER ADP F
investigational I-OTHER ADJ F
medication I-OTHER NOUN F
were 0 VERB F
infused 0 VERB F
until 0 ADP F
24 0 NUM F
hours 0 NOUN F
after 0 ADP F
the 0 DET F
first 0 ADJ F
administration 0 NOUN F
( 0 PUNCT F
1577 0 NUM F
vs. 0 CCONJ F
1540 0 NUM F
mL 0 NOUN F
; 0 PUNCT F
treatment 0 NOUN F
difference 0 NOUN F
37 0 NUM F
[ 0 PUNCT F
-150 0 ADP F
; 0 PUNCT F
223 0 NUM F
] 0 PUNCT F
mL 0 NOUN F
; 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.0001 0 NUM F
for 0 ADP F
equivalence 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

Whereas 0 ADP T
standard 0 ADJ F
laboratory 0 NOUN F
tests 0 NOUN F
of 0 ADP F
coagulation 0 NOUN F
were 0 VERB F
comparable 0 ADJ F
between 0 ADP F
groups 0 NOUN F
, 0 PUNCT F
von B-PHYSICAL ADP F
Willebrand I-PHYSICAL NOUN T
factor 0 NOUN F
activity B-PHYSICAL NOUN F
on 0 ADP F
the 0 DET F
first 0 ADJ F
postoperative 0 ADJ F
morning 0 NOUN F
tended 0 VERB F
to 0 PART F
be 0 PUNCT F
higher 0 PUNCT F
following 0 PUNCT F
treatment 0 NOUN F
with 0 ADP F
10 0 NUM F
% 0 SYM F
HES 0 NOUN T
130/0.4 0 ADV F
as 0 VERB F
compared 0 VERB F
to 0 ADP F
10 0 NUM F
% 0 SYM F
HES 0 NOUN T
200/0.5 0 ADV F
( 0 PUNCT F
P=0.025 0 NOUN T
) 0 PUNCT F
with 0 ADP F
this 0 DET F
difference 0 NOUN F
being 0 VERB F
statistically 0 ADV F
significant 0 ADJ F
only 0 ADV F
in 0 ADP F
the 0 DET F
per-protocol 0 NOUN F
analysis 0 NOUN F
( 0 PUNCT F
P=0.02 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

Treatment 0 NOUN T
groups 0 NOUN F
were 0 VERB F
comparable 0 ADJ F
concerning 0 ADJ F
other 0 ADJ F
safety B-OTHER NOUN F
parameters I-OTHER NOUN F
and 0 CCONJ F
the 0 DET F
incidence 0 NOUN F
of 0 ADP F
adverse B-ADVERSE-EFFECTS ADJ F
drug I-ADVERSE-EFFECTS NOUN F
reactions B-ADVERSE-EFFECTS NOUN F
. 0 PUNCT F

In 0 ADP T
particular 0 NOUN F
, 0 PUNCT F

Over 0 ADP T
time 0 NOUN F
relationships 0 NOUN F
between 0 ADP F
early 0 ADJ F
adolescent 0 NOUN F
and 0 CCONJ F
peer B-MENTAL NOUN F
substance I-MENTAL NOUN F
use 0 NOUN F
. 0 PUNCT F

Peer 0 NOUN T
and 0 CCONJ F
adolescent 0 NOUN F
substance 0 NOUN F
use 0 NOUN F
are 0 VERB F
highly 0 ADV F
correlated 0 VERB F
, 0 PUNCT F
but 0 CCONJ F
this 0 DET F
relationship 0 NOUN F
is 0 VERB F
not 0 ADV F
fully 0 ADV F
understood 0 VERB F
. 0 PUNCT F

In 0 ADP T
particular 0 NOUN F
, 0 PUNCT F
the 0 DET F
relative 0 ADJ F
contributions 0 NOUN F
of 0 ADP F
selection 0 NOUN F
and 0 CCONJ F
socialization 0 NOUN F
to 0 ADP F
substance 0 NOUN F
use 0 NOUN F
progression 0 NOUN F
have 0 PUNCT F
not 0 ADV F
been 0 PUNCT F
established 0 VERB F
. 0 PUNCT F

Students 0 NOUN T
( 0 PUNCT F
n=2453 0 NOUN F
) 0 PUNCT F
in 0 ADP F
the 0 DET F
seven 0 NUM F
middle 0 ADJ F
schools 0 NOUN F
in 0 ADP F
one 0 NUM F
school 0 NOUN F
district 0 NOUN F
were 0 VERB F
assessed 0 VERB F
at 0 ADP F
school 0 NOUN F
at 0 ADP F
the 0 DET F
beginning 0 PUNCT F
and 0 CCONJ F
end 0 NOUN F
of 0 ADP F
the 0 DET F
sixth 0 ADJ F
, 0 PUNCT F
seventh 0 NOUN F
, 0 PUNCT F
eighth 0 PUNCT F
grade 0 NOUN F
and 0 CCONJ F
beginning 0 ADJ F
of 0 ADP F
the 0 DET F
9th 0 PUNCT F
grade 0 NOUN F
. 0 PUNCT F

Self-reported B-MENTAL VERB T
smoking I-MENTAL VERB F
and I-MENTAL CCONJ F
drinking I-MENTAL PROPN F
and 0 CCONJ F
the 0 DET F
number 0 NOUN F
of 0 ADP F
substance 0 NOUN F
using 0 PROPN F
friends 0 NOUN F
were 0 VERB F
assessed 0 VERB F
5 0 NUM F
times 0 NOUN F
over 0 ADP F
3 0 NUM F
years 0 NOUN F
. 0 PUNCT F

The 0 DET T
relationship 0 NOUN F
between 0 ADP F
peer B-MENTAL NOUN F
and 0 CCONJ F
adolescent B-MENTAL NOUN F
substance I-MENTAL NOUN F
use I-MENTAL NOUN F
were 0 VERB F
assessed 0 VERB F
in 0 ADP F
parallel 0 ADJ F
processes 0 NOUN F
as 0 ADP F
part 0 NOUN F
of 0 ADP F
an 0 DET F
autoregressive 0 ADJ F
latent 0 ADJ F
trajectory 0 NOUN F
model 0 NOUN F
. 0 PUNCT F

Substance B-MENTAL ADJ T
use I-MENTAL NOUN F
and 0 CCONJ F
the 0 DET F
number B-MENTAL NOUN F
of I-MENTAL ADP F
substance I-MENTAL NOUN F
using 0 VERB F
friends 0 NOUN F
increased 0 VERB F
in 0 ADP F
linear 0 ADJ F
fashion 0 NOUN F
from 0 ADP F
T1 0 NOUN T
to 0 ADP F
T5 0 NOUN T
. 0 PUNCT F

Initial 0 ADJ T
substance 0 NOUN F
use 0 NOUN F
predicted 0 VERB F
an 0 DET F
increase 0 NOUN F
in 0 ADP F
the 0 DET F
number B-MENTAL NOUN F
of I-MENTAL ADP F
substance I-MENTAL NOUN F
using I-MENTAL VERB F
friends I-MENTAL DET F
over I-MENTAL PUNCT F
time I-MENTAL NOUN F
, 0 PUNCT F
indicating 0 VERB F
an 0 DET F
effect 0 NOUN F
of 0 ADP F
selection 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
the 0 DET F
initial 0 ADJ F
number 0 NOUN F
of 0 ADP F
substance 0 NOUN F
using 0 VERB F
friends 0 NOUN F
predicted 0 VERB F
substance B-MENTAL NOUN F
use I-MENTAL NOUN F
progression 0 NOUN F
, 0 PUNCT F
providing 0 CCONJ F
evidence 0 NOUN F
of 0 ADP F
socialization 0 NOUN F
. 0 PUNCT F

The 0 DET T
magnitudes 0 NOUN F
of 0 ADP F
these 0 DET F
relationships 0 NOUN F
were 0 VERB F
similar 0 ADJ F
. 0 PUNCT F

Bivariate 0 PUNCT T
, 0 PUNCT F
lagged 0 CCONJ F
autoregressive 0 ADJ F
analyses 0 NOUN F
of 0 ADP F
the 0 DET F
successive 0 ADJ F
relationships 0 NOUN F
from 0 ADP F
one 0 NUM F
assessment 0 NOUN F
to 0 ADP F
the 0 DET F
next 0 PUNCT F
showed 0 ADP F
consistent 0 ADJ F
, 0 PUNCT F
significant 0 ADJ F
associations 0 NOUN F
from 0 ADP F
peer B-MENTAL NOUN F
use I-MENTAL ADP F
to I-MENTAL ADP F
adolescent I-MENTAL NOUN F
substance I-MENTAL NOUN F
use I-MENTAL NOUN F
. 0 PUNCT F

The 0 DET T
association 0 NOUN F
from 0 ADP F
adolescent B-MENTAL NOUN F
to I-MENTAL ADP F
peer I-MENTAL NOUN F
use I-MENTAL NOUN F
was 0 VERB F
significant 0 ADJ F
only 0 ADV F
from 0 ADP F
7th 0 NOUN F
to 0 ADP F
8th 0 ADJ F
grade 0 NOUN F
. 0 PUNCT F

The 0 DET T
findings 0 NOUN F
provide 0 VERB F
evidence 0 NOUN F
of 0 ADP F
reciprocal 0 ADJ F
influences 0 NOUN F
, 0 PUNCT F
but 0 CCONJ F
socialization 0 NOUN F
was 0 VERB F
a 0 DET F
more 0 ADV F
consistent 0 ADJ F
influence 0 NOUN F
than 0 PUNCT F
selection 0 NOUN F
. 0 PUNCT F

Why 0 PUNCT T
the 0 DET F
prone 0 ADJ F
position 0 NOUN F
is 0 VERB F
a 0 DET F
risk 0 NOUN F
factor 0 NOUN F
for 0 ADP F
sudden 0 ADJ F
infant 0 NOUN F
death 0 NOUN F
syndrome 0 NOUN F
. 0 PUNCT F

INTRODUCTION 0 NOUN T
The 0 DET T
laryngeal 0 ADJ F
chemoreflex 0 VERB F
may 0 PART F
explain 0 PUNCT F
why 0 ADP F
prone 0 ADJ F
sleeping 0 ADV F
increases 0 CCONJ F
the 0 DET F
risk 0 NOUN F
of 0 ADP F
sudden 0 ADJ F
infant 0 NOUN F
death 0 NOUN F
syndrome 0 NOUN F
( 0 PUNCT F
SIDS 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

Swallowing 0 PUNCT T
and 0 CCONJ F
arousal 0 ADJ F
are 0 ADJ F
crucial 0 ADJ F
to 0 PART F
prevent 0 VERB F
laryngeal 0 ADJ F
chemoreflex 0 PUNCT F
stimulation 0 NOUN F
. 0 PUNCT F

Our 0 PUNCT T
aim 0 NOUN F
was 0 VERB F
to 0 ADV F
examine 0 NOUN F
these 0 DET F
reflexes B-PHYSICAL NOUN F
and 0 CCONJ F
breathing B-PHYSICAL PROPN F
responses I-PHYSICAL NOUN F
in 0 ADP F
healthy 0 ADJ F
neonates 0 NOUN F
after 0 ADP F
pharyngeal 0 ADJ F
infusion 0 NOUN F
of 0 ADP F
water 0 NOUN F
in 0 ADP F
the 0 DET F
supine 0 NOUN F
versus 0 CCONJ F
the 0 DET F
prone 0 ADJ F
position 0 NOUN F
, 0 PUNCT F
controlling 0 ADJ F
for 0 ADP F
sleep 0 NOUN F
state 0 NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
A 0 PUNCT T
total 0 NOUN F
of 0 ADP F
10 0 NUM F
term 0 NOUN F
infants 0 NOUN F
were 0 VERB F
recruited 0 VERB F
after 0 ADP F
parental 0 ADJ F
consent 0 NOUN F
and 0 CCONJ F
ethics 0 ADP F
approval 0 PUNCT F
. 0 PUNCT F

Polygraphic 0 ADJ T
recordings 0 NOUN F
included 0 VERB F
sleep B-PHYSICAL NOUN F
state I-PHYSICAL NOUN F
( 0 PUNCT F
active B-PHYSICAL ADJ F
and 0 CCONJ F
quiet B-PHYSICAL NOUN F
sleep I-PHYSICAL NOUN F
by I-PHYSICAL ADP F
electroencephalogram I-PHYSICAL NOUN F
, 0 PUNCT F
eye B-PHYSICAL NOUN F
movements I-PHYSICAL NOUN F
, 0 PUNCT F
breathing B-PHYSICAL DET F
, 0 PUNCT F
and 0 PUNCT F

Brief 0 PUNCT T
Report 0 NOUN T
: 0 PUNCT F
Randomized 0 VERB T
test 0 NOUN F
of 0 ADP F
the 0 DET F
efficacy 0 NOUN F
of 0 ADP F
picture 0 NOUN F
exchange 0 NOUN F
communication 0 NOUN F
system 0 NOUN F
on 0 ADP F
highly 0 ADV F
generalized B-OTHER VERB F
picture I-OTHER NOUN F
exchanges I-OTHER NOUN F
in 0 ADP F
children 0 NOUN F
with 0 ADP F
ASD 0 NOUN T
. 0 PUNCT F

A 0 DET T
randomized 0 VERB F
control 0 NOUN F
trial 0 NOUN F
comparing 0 VERB F
two 0 NUM F
social-communication 0 NOUN F
interventions 0 NOUN F
in 0 ADP F
young 0 ADJ F
children 0 NOUN F
with 0 ADP F
autism 0 NOUN F
examined 0 VERB F
far-transfer 0 NOUN F
of B-MENTAL ADP F
the 0 DET F
use B-MENTAL NOUN F
of I-MENTAL ADP F
picture I-MENTAL NOUN F
exchange I-MENTAL NOUN F
to B-MENTAL ADP F
communicate I-MENTAL PUNCT F
. 0 PUNCT F

Thirty-six 0 NUM T
children 0 NOUN F
were 0 ADJ F
randomly 0 ADV F
assigned 0 VERB F
to 0 ADP F
one 0 PUNCT F
of 0 ADP F
two 0 NUM F
treatment 0 NOUN F
conditions 0 NOUN F
, 0 PUNCT F
one 0 NUM F
of 0 ADP F
which 0 ADP F
was 0 ADV F
the 0 DET F
Picture 0 NOUN T
Exchange 0 NOUN T
Communication 0 NOUN T
System 0 NOUN T
( 0 PUNCT F
PECS 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

All 0 DET T
children 0 NOUN F
had 0 PUNCT F
access 0 NOUN F
to 0 ADP F
picture 0 NOUN F
symbols 0 ADJ F
during 0 ADP F
assessments 0 NOUN F
. 0 PUNCT F

Post-treatment 0 ADJ T
measurement 0 NOUN F
of 0 ADP F
the 0 DET F
number B-MENTAL NOUN F
of I-MENTAL ADP F
picture I-MENTAL NOUN F
exchanges I-MENTAL ADJ F
in I-MENTAL ADP F
a I-MENTAL DET F
far-transfer I-MENTAL NOUN F
, 0 PUNCT F
assessment 0 NOUN F
context 0 NOUN F
favored 0 PUNCT F
the 0 DET F
PECS 0 NOUN T
intervention 0 NOUN F
. 0 PUNCT F

These 0 DET T
findings 0 NOUN F
were 0 VERB F
interpreted 0 VERB F
as 0 PUNCT F
support 0 NOUN F
for 0 ADP F
the 0 DET F
hypothesis 0 NOUN F
that 0 ADP F
the 0 DET F
PECS 0 NOUN T
curriculum 0 NOUN F
can 0 VERB F
successfully 0 VERB F
teach 0 PUNCT F
a 0 DET F
generalized 0 VERB F
means 0 NOUN F
of 0 ADP F
showing 0 PUNCT F

Women 0 NOUN T
's 0 PUNCT F
responses 0 DET F
to 0 ADP F
information 0 NOUN F
on 0 ADP F
mammographic 0 ADJ F
breast 0 NOUN F
density 0 NOUN F
. 0 PUNCT F

The 0 DET T
objective 0 NOUN F
of 0 ADP F
this 0 DET F
study 0 NOUN F
was 0 VERB F
to 0 PART F
determine 0 NOUN F
the 0 DET F
negative 0 ADJ F
and 0 CCONJ F
positive 0 ADJ F
outcomes 0 NOUN F
of 0 ADP F
providing 0 VERB F
mammographic 0 ADJ F
breast 0 NOUN F
density 0 NOUN F
( 0 PUNCT F
MBD 0 NOUN T
) 0 PUNCT F
information 0 NOUN F
to 0 ADP F
participants 0 NOUN F
of 0 ADP F
a 0 DET F
screening 0 VERB F
program 0 NOUN F
. 0 PUNCT F

A 0 DET T
randomized 0 VERB F
experiment 0 NOUN F
was 0 VERB F
conducted 0 VERB F
with 0 ADP F
a 0 DET F
sample 0 NOUN F
of 0 ADP F
618 0 NUM F
women 0 NOUN F
50 0 NUM F
years 0 NOUN F
or 0 CCONJ F
older 0 PUNCT F
with 0 ADP F
MBD 0 NOUN T
greater 0 PUNCT F
than 0 VERB F
50 0 NUM F
% 0 SYM F
of 0 ADP F
breast 0 NOUN F
volume 0 NOUN F
. 0 PUNCT F

The 0 DET T
intervention 0 NOUN F
consisted 0 ADJ F
of 0 ADP F
reporting 0 SYM F
the 0 DET F
presence 0 NOUN F
of 0 ADP F
MBD 0 NOUN T
in 0 ADP F
the 0 DET F
screening 0 VERB F
mammography 0 NOUN F
results 0 PUNCT F
letter 0 NOUN F
that 0 PUNCT F
was 0 VERB F
sent 0 NOUN F
along 0 PUNCT F
with 0 ADP F
an 0 DET F
information 0 NOUN F
pamphlet 0 NOUN F
. 0 PUNCT F

Compared 0 VERB T
to 0 ADP F
the 0 DET F
controls 0 NOUN F
, 0 PUNCT F
more 0 DET F
women 0 NOUN F
in 0 ADP F
the 0 DET F
intervention 0 NOUN F
group 0 NOUN F
described 0 VERB F
the 0 DET F
term 0 NOUN F
breast B-PHYSICAL NOUN F
density I-PHYSICAL NOUN F
correctly 0 ADV F
and 0 CCONJ F
recognized 0 ADP F
it 0 VERB F
as 0 CCONJ F
a 0 DET F
risk 0 NOUN F
factor 0 NOUN F
for 0 ADP F
breast 0 NOUN F
cancer 0 NOUN F
. 0 PUNCT F

Although 0 ADP T
at 0 ADP F
the 0 DET F
4-week 0 NOUN F
follow-up 0 NOUN F
the 0 DET F
intervention 0 NOUN F
group 0 NOUN F
indicated 0 VERB F
that 0 ADP F
they 0 PRON F
were 0 VERB F
very 0 ADV F
likely 0 ADJ F
to 0 PART F
have 0 PUNCT F
an 0 DET F
annual 0 ADJ F
clinical 0 ADJ F
breast 0 NOUN F
examination 0 NOUN F
more 0 ADV F
frequently 0 ADV F
than 0 PUNCT F
controls 0 NOUN F
, 0 PUNCT F
no 0 DET F
differences 0 NOUN F
were 0 VERB F
detected 0 VERB F
at 0 ADP F
6 0 NUM F
months 0 NOUN F
. 0 PUNCT F

There 0 PUNCT T
were 0 VERB F
no 0 DET F
significant 0 ADJ F
differences 0 NOUN F
on 0 ADP F
other 0 ADJ F
behavioural B-MENTAL ADJ F
or I-MENTAL CCONJ F
psychological I-MENTAL ADJ F
measures I-MENTAL NOUN F
, 0 PUNCT F
although 0 ADP F
at 0 ADP F
the 0 DET F
4-week 0 NOUN F
follow-up 0 NOUN F
the 0 DET F
control 0 NOUN F
group 0 NOUN F
perceived 0 ADP F
their 0 ADP F
risk 0 NOUN F
for 0 ADP F
breast 0 NOUN F
cancer 0 NOUN F
, 0 PUNCT F
relative 0 ADJ F
to 0 ADP F
other 0 ADJ F
women 0 ADP F
their 0 ADJ F
age 0 NOUN F
, 0 PUNCT F
as 0 ADP F
a 0 DET F
lot 0 NOUN F
lower 0 PUNCT F
than 0 PUNCT F
did 0 PUNCT F
women 0 CCONJ F
in 0 ADP F
the 0 DET F
intervention 0 NOUN F
group 0 NOUN F
. 0 PUNCT F

The 0 DET T
results 0 ADV F
demonstrate 0 VERB F
a 0 DET F
feasible 0 ADJ F
and 0 CCONJ F
non-threatening 0 PUNCT F
way 0 NOUN F
to 0 ADV F
provide 0 NOUN F
women 0 NOUN F
with 0 ADP F
important 0 ADJ F
personalized 0 DET F
information 0 NOUN F
about 0 PUNCT F
breast B-PHYSICAL NOUN F
cancer I-PHYSICAL NOUN F
risk I-PHYSICAL NOUN F
. 0 PUNCT F

The 0 DET T
6 0 NUM F
minute 0 ADJ F
walk 0 NOUN F
in 0 ADP F
idiopathic 0 ADJ F
pulmonary 0 ADJ F
fibrosis 0 NOUN F
: 0 PUNCT F
longitudinal 0 ADJ F
changes 0 NOUN F
and 0 CCONJ F
minimum 0 NOUN F
important 0 ADJ F
difference 0 NOUN F
. 0 PUNCT F

RATIONALE 0 NOUN T
The 0 DET T
response 0 NOUN F
characteristics 0 NOUN F
of 0 ADP F
the 0 DET F
6 0 NUM F
minute 0 ADJ F
walk 0 NOUN F
test 0 NOUN F
( 0 PUNCT F
6MWT 0 NOUN F
) 0 PUNCT F
in 0 ADP F
studies 0 NOUN F
of 0 ADP F
idiopathic 0 ADJ F
pulmonary 0 ADJ F
fibrosis 0 NOUN F
( 0 PUNCT F
IPF 0 NOUN T
) 0 PUNCT F
are 0 VERB F
only 0 ADV F
poorly 0 ADV F
understood 0 VERB F
, 0 PUNCT F
and 0 CCONJ F
the 0 DET F
change 0 NOUN F
in 0 ADP F
walk 0 NOUN F
distance 0 NOUN F
that 0 PUNCT F
constitutes 0 NOUN F
the 0 DET F
minimum 0 NOUN F
important 0 ADJ F
difference 0 NOUN F
( 0 PUNCT F
MID 0 NOUN T
) 0 PUNCT F
over 0 PUNCT F
time 0 NOUN F
is 0 VERB F
unknown 0 VERB F
. 0 PUNCT F

OBJECTIVES 0 ADP T
To 0 PROPN T
examine 0 NOUN F
changes 0 NOUN F
over 0 PUNCT F
time B-MENTAL NOUN F
in I-MENTAL ADP F
distance 0 NOUN F
walked B-MENTAL CCONJ F
( 0 PUNCT F
ie 0 ADP F
, 0 PUNCT F
6MWD 0 NOUN F
) 0 PUNCT F
during 0 ADP F
the 0 DET F
6MWT 0 NOUN F
and 0 CCONJ F
to 0 PART F
estimate 0 NOUN F
the 0 DET F
change 0 NOUN F
in 0 ADP F
distance 0 NOUN F
that 0 PUNCT F
constitutes 0 NOUN F
the 0 DET F
MID 0 NOUN T
in 0 ADP F
patients 0 NOUN F
with 0 ADP F
IPF 0 NOUN T
. 0 PUNCT F

METHODS 0 NOUN T
Data 0 NOUN T
from 0 ADP F
a 0 DET F
recently 0 ADV F
completed 0 VERB F
trial 0 NOUN F
that 0 ADP F
included 0 PUNCT F
subjects 0 NOUN F
with 0 ADP F
IPF 0 NOUN T
who 0 ADP F
completed 0 VERB F
the 0 DET F
6MWT 0 NOUN F
, 0 PUNCT F
Saint 0 NOUN T
George 0 NOUN T
's 0 PUNCT F
Respiratory 0 ADJ T
Questionnaire 0 NOUN T
( 0 PUNCT F
SGRQ 0 NOUN T
) 0 PUNCT F
and 0 CCONJ F
forced 0 VERB F
vital 0 ADJ F
capacity 0 NOUN F
( 0 PUNCT F
FVC 0 NOUN T
) 0 PUNCT F
at 0 ADP F
6 0 NUM F
and 0 CCONJ F
12 0 NUM F
months 0 NOUN F
were 0 VERB F
used 0 VERB F
to 0 PART F
examine 0 NOUN F
longitudinal 0 ADJ F
changes 0 NOUN F
in 0 ADP F
6MWD 0 NOUN F
. 0 PUNCT F

Both 0 CCONJ T
anchor- 0 NOUN F
and 0 CCONJ F
distribution-based 0 VERB F
approaches 0 NOUN F
as 0 PUNCT F
well 0 PUNCT F
as 0 CCONJ F
linear 0 ADJ F
regression 0 NOUN F
analyses 0 NOUN F
were 0 VERB F
used 0 VERB F
to 0 PART F
determine 0 NOUN F
the 0 DET F
MID 0 NOUN T
for 0 ADP F
6MWD 0 NOUN F
. 0 PUNCT F

The 0 DET T
SGRQ B-OTHER NOUN T
Total 0 ADP T
score 0 NOUN F
and 0 PUNCT F

Motion 0 NOUN T
aftereffects 0 VERB F
with 0 ADP F
horizontally 0 ADJ F
moving 0 DET F
sound 0 ADJ F
sources 0 NOUN F
in 0 ADP F
the 0 DET F
free 0 ADJ F
field 0 NOUN F
. 0 PUNCT F

A 0 PUNCT T
horizontally 0 ADJ F
moving 0 VERB F
sound 0 ADJ F
was 0 VERB F
presented 0 VERB F
to 0 ADP F
an 0 DET F
observer 0 NOUN F
seated 0 VERB F
in 0 ADP F
the 0 DET F
center 0 NOUN F
of 0 ADP F
an 0 DET F
anechoic 0 PUNCT F
chamber 0 NOUN F
. 0 PUNCT F

The 0 DET T
sound 0 ADJ F
, 0 PUNCT F
either 0 PUNCT F
a 0 DET F
500-Hz 0 PUNCT F
low-pass 0 NOUN F
noise 0 NOUN F
or 0 CCONJ F
a 0 PUNCT F
6300-Hz 0 ADP F
high-pass 0 NOUN F
noise 0 NOUN F
, 0 PUNCT F
repeatedly 0 ADV F
traversed 0 PUNCT F
a 0 DET F
semicircular 0 ADJ F
arc 0 PUNCT F
in 0 ADP F
the 0 DET F
observer 0 NOUN F
's 0 PUNCT F
front 0 NOUN F
hemifield 0 PUNCT F
at 0 ADP F
ear 0 NOUN F
level 0 NOUN F
( 0 PUNCT F
distance 0 NOUN F
: 0 PUNCT F
1.5 0 NUM F
m 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

At 0 ADP T
10-sec 0 ADJ F
intervals 0 NOUN F
this 0 PUNCT F
adaptor 0 NOUN F
was 0 VERB F
interrupted 0 VERB F
, 0 PUNCT F
and 0 CCONJ F
a 0 DET F
750-msec 0 NOUN F
moving 0 VERB F
probe 0 NOUN F
( 0 PUNCT F
a 0 DET F
500-Hz 0 PUNCT F
low-pass 0 NOUN F
noise 0 NOUN F
) 0 PUNCT F
was 0 VERB F
presented 0 VERB F
from 0 ADP F
a 0 DET F
horizontal 0 ADJ F
arc 0 PUNCT F
1.6 0 NUM F
m 0 NOUN F
in 0 ADP F
front 0 NOUN F
of 0 ADP F
the 0 DET F
observer 0 NOUN F
. 0 PUNCT F

During 0 ADP T
a 0 DET F
run 0 PUNCT F
, 0 PUNCT F
the 0 DET F
adaptor 0 NOUN F
was 0 VERB F
presented 0 VERB F
at 0 ADP F
a 0 DET F
constant 0 ADJ F
velocity 0 NOUN F
( 0 PUNCT F
-200 0 ADP F
degrees 0 NOUN F
to 0 PUNCT F
+200 0 PUNCT F
degrees/sec 0 NOUN F
) 0 PUNCT F
, 0 PUNCT F
while 0 ADP F
probes 0 NOUN F
with 0 ADP F
velocities 0 NOUN F
varying 0 PUNCT F
from 0 ADP F
-10 0 NUM F
degrees 0 NOUN F
to 0 ADP F
+10 0 NUM F
degrees/sec 0 PUNCT F
were 0 VERB F
presented 0 VERB F
in 0 ADP F
a 0 DET F
random 0 ADJ F
order 0 NOUN F
. 0 PUNCT F

Observers 0 CCONJ T
judged 0 ADP F
the 0 DET F
direction 0 NOUN F
of 0 ADP F
motion 0 NOUN F
( 0 PUNCT F
left 0 PUNCT F
or 0 CCONJ F
right 0 ADJ F
) 0 PUNCT F
of 0 ADP F
each 0 DET F
probe 0 NOUN F
. 0 PUNCT F

As 0 PUNCT T
in 0 ADP F
the 0 DET F
case 0 NOUN F
of 0 ADP F
stimuli 0 NOUN F
presented 0 VERB F
over 0 ADP F
headphones 0 NOUN F
( 0 PUNCT F
Grantham 0 PUNCT T
& 0 CCONJ F
Wightman 0 NOUN T
, 0 PUNCT F
1979 0 PUNCT F
) 0 PUNCT F
, 0 PUNCT F
an 0 DET F
auditory B-PHYSICAL ADJ F
motion I-PHYSICAL NOUN F
aftereffect I-PHYSICAL NOUN F
( I-PHYSICAL PUNCT F
MAE I-PHYSICAL NOUN T
) I-PHYSICAL PUNCT F
occurred 0 VERB F
: 0 PUNCT F
subjects 0 NOUN F
responded 0 VERB F
left 0 PUNCT F
to 0 PUNCT F
probes 0 ADJ F
more 0 ADV F
often 0 ADV F
when 0 ADP F
the 0 DET F
adaptor 0 ADJ F
moved 0 PART F
right 0 ADJ F
than 0 ADP F
when 0 CCONJ F
it 0 NOUN F
moved 0 ADV F
left 0 ADV F
. 0 PUNCT F

When 0 ADP T
the 0 DET F
adaptor 0 ADJ F
and 0 CCONJ F
probe 0 NOUN F
were 0 VERB F
spectrally 0 ADV F
the 0 DET F
same 0 ADJ F
, 0 PUNCT F
the 0 DET F
MAE B-PHYSICAL NOUN T
was 0 VERB F
greater 0 PUNCT F
than 0 PUNCT F
when 0 CCONJ F
they 0 PRON F
were 0 SYM F
from 0 ADP F
different 0 ADJ F
spectral 0 ADJ F
regions 0 NOUN F
; 0 PUNCT F
the 0 DET F
magnitude 0 NOUN F
of 0 ADP F
this 0 DET F
difference 0 NOUN F
depended 0 VERB F
on 0 ADP F
adaptor 0 PUNCT F
speed 0 NOUN F
and 0 CCONJ F
was 0 ADV F
subject-dependent 0 PUNCT F
. 0 PUNCT F

It 0 PRON T
is 0 VERB F
proposed 0 VERB F
that 0 ADP F
there 0 PUNCT F
are 0 VERB F
two 0 NUM F
components 0 NOUN F
underlying 0 ADV F
the 0 DET F
auditory 0 ADJ F
MAE B-PHYSICAL NOUN T
: 0 PUNCT F
( 0 PUNCT F
1 0 NUM F
) 0 PUNCT F
a 0 DET F
generalized 0 VERB F
bias 0 NOUN F
to 0 PART F
respond 0 PUNCT F
that 0 ADP F
probes 0 NOUN F
move 0 PUNCT F
in 0 ADP F
the 0 DET F
direction 0 ADJ F
opposite 0 CCONJ F
to 0 ADP F
that 0 PUNCT F
of 0 ADP F
the 0 DET F
adaptor 0 ADJ F
, 0 PUNCT F
independent 0 ADJ F
of 0 ADP F
their 0 DET F
spectra 0 NOUN F
; 0 PUNCT F
and 0 CCONJ F
( 0 PUNCT F
2 0 NUM F
) 0 PUNCT F
a 0 DET F
loss 0 NOUN F
of 0 ADP F
sensitivity 0 NOUN F
to 0 ADP F
the 0 DET F
velocity 0 NOUN F
of 0 ADP F
moving 0 PROPN F
sounds 0 NOUN F
after 0 ADP F
prolonged 0 VERB F
exposure 0 NOUN F
to 0 PUNCT F
moving 0 PUNCT F
sounds 0 NOUN F
having 0 ADJ F
the 0 DET F
same 0 ADJ F
spectral 0 ADJ F
content 0 NOUN F
. 0 PUNCT F

Dietary 0 ADJ T
sodium 0 NOUN F
intake 0 NOUN F
modulates 0 NOUN F
myocardial B-PHYSICAL ADJ F
relaxation I-PHYSICAL NOUN F
responsiveness I-PHYSICAL NOUN F
to 0 ADP F
angiotensin 0 NOUN F
II 0 NUM T
. 0 PUNCT F

Dietary 0 ADJ T
sodium 0 NOUN F
alters 0 VERB F
renovascular 0 ADJ F
responsiveness 0 NOUN F
to 0 ADP F
angiotensin 0 NOUN F
II 0 NUM T
( 0 PUNCT F
Ang 0 NOUN T
II 0 NUM T
) 0 PUNCT F
in 0 ADP F
normal 0 ADJ F
subjects 0 NOUN F
. 0 PUNCT F

Evidence 0 NOUN T
supports 0 NOUN F
a 0 DET F
connection 0 NOUN F
among 0 ADP F
dietary 0 ADJ F
sodium 0 NOUN F
, 0 PUNCT F
the 0 DET F
rennin-angiotensin 0 NOUN F
system 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
myocardial 0 ADJ F
function 0 NOUN F
. 0 PUNCT F

The 0 DET T
authors 0 NOUN F
hypothesized 0 VERB F
that 0 ADP F
a 0 DET F
similar 0 ADJ F
relationship 0 NOUN F
would 0 VERB F
exist 0 VERB F
in 0 ADP F
the 0 DET F
heart 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
that 0 ADP F
the 0 DET F
pattern 0 NOUN F
of 0 ADP F
responses 0 NOUN F
would 0 VERB F
be 0 VERB F
qualitatively 0 ADV F
similar 0 ADJ F
to 0 ADP F
the 0 DET F
renal 0 ADJ F
vasculature 0 NOUN F
. 0 PUNCT F

Thirteen 0 PUNCT T
healthy 0 ADJ F
volunteers 0 NOUN F
( 0 PUNCT F
aged 0 DET F
38.6 0 NUM F
+/- 0 SYM F
4 0 NUM F
years 0 NOUN F
) 0 PUNCT F
entered 0 VERB F
a 0 DET F
2 0 NUM F
week 0 NOUN F
crossover 0 NOUN F
design 0 NOUN F
study 0 NOUN F
( 0 PUNCT F
week 0 NOUN F
1 0 NUM F
, 0 PUNCT F
high 0 ADJ F
sodium 0 NOUN F
diet 0 NOUN F
[ 0 PUNCT F
HS 0 NOUN T
] 0 PUNCT F
> 0 SYM F
200 0 NUM F
mmol 0 NOUN F
Na/day 0 NOUN T
; 0 PUNCT F
week 0 NOUN F
2 0 NUM F
, 0 PUNCT F
low 0 ADJ F
sodium 0 NOUN F
diet 0 NOUN F
[ 0 PUNCT F
LS 0 NOUN T
] 0 PUNCT F
, 0 PUNCT F
< 0 ADP F
10 0 NUM F
mmol 0 NOUN F
Na/day 0 NOUN T
) 0 PUNCT F
to 0 PART F
investigate 0 NOUN F
the 0 DET F
influence 0 NOUN F
of 0 ADP F
dietary 0 ADJ F
sodium 0 NOUN F
and 0 CCONJ F
Ang 0 NOUN T
II 0 NUM T
on 0 ADP F
myocardial 0 ADJ F
relaxation 0 NOUN F
and 0 CCONJ F
renal B-PHYSICAL ADJ F
blood I-PHYSICAL NOUN F
flow I-PHYSICAL NOUN F
( I-PHYSICAL PUNCT F
RBF I-PHYSICAL NOUN T
) I-PHYSICAL PUNCT F
. 0 PUNCT F

At 0 ADP T
the 0 DET F
end 0 NOUN F
of 0 ADP F
each 0 DET F
study 0 NOUN F
week 0 NOUN F
, 0 PUNCT F
the 0 DET F
authors 0 NOUN F
assessed 0 VERB F
diastolic B-PHYSICAL ADJ F
function I-PHYSICAL NOUN F
( 0 PUNCT F
myocardial B-PHYSICAL ADJ F
relaxation I-PHYSICAL NOUN F
velocities I-PHYSICAL NOUN F
[ 0 PUNCT F
E 0 NOUN T
' 0 PUNCT F
] 0 PUNCT F
using 0 VERB F
tissue 0 NOUN F
Doppler 0 NOUN T
imaging 0 VERB F
) 0 PUNCT F
and 0 CCONJ F
RBF B-PHYSICAL NOUN T
( 0 PUNCT F
para-aminohippurate 0 NOUN F
clearance 0 NOUN F
) 0 PUNCT F
at 0 ADP F
baseline 0 NOUN F
and 0 CCONJ F
after 0 ADP F
infusion 0 NOUN F
of 0 ADP F
Ang 0 NOUN T
II 0 NUM T
( 0 PUNCT F
3 0 NUM F
ng/kg/min 0 NOUN F
x 0 SYM F
45 0 NUM F
min 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

On 0 ADP T
HS 0 NOUN T
diet 0 NOUN F
, 0 PUNCT F
E 0 NOUN T
' 0 PUNCT F
and 0 CCONJ F
RBF B-PHYSICAL NOUN T
were 0 VERB F
higher 0 PUNCT F
than 0 PUNCT F
on 0 ADP F
LS 0 NOUN T
diet 0 NOUN F
( 0 PUNCT F
E 0 NOUN T
' 0 PUNCT F
14.0 0 NUM F
+/- 0 SYM F
1.2 0 NUM F
vs 0 CCONJ F
12.6 0 NUM F
+/- 0 SYM F
1.0 0 NUM F
cm/s 0 NOUN F
, 0 PUNCT F
P 0 NOUN T
= 0 SYM F
0.02 0 NUM F
; 0 PUNCT F
RBF 0 NOUN T
596 0 NUM F
+/- 0 SYM F
24 0 NUM F
vs 0 CCONJ F
563 0 NUM F
+/- 0 SYM F
26 0 NUM F
mL/min 0 NOUN F
, 0 PUNCT F
P 0 NOUN T
= 0 SYM F
0.02 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Dietary 0 ADJ T
sodium 0 NOUN F
significantly 0 ADV F
modulated 0 PUNCT F
E B-PHYSICAL NOUN T
' 0 PUNCT F
and 0 CCONJ F
RBF B-PHYSICAL NOUN T
responsiveness I-PHYSICAL NOUN F
to 0 ADP F
Ang 0 NOUN T
II 0 NUM T
infusion 0 NOUN F
in 0 ADP F
like 0 ADP F
manner 0 NOUN F
. 0 PUNCT F

HS 0 NOUN T
was 0 VERB F
associated 0 VERB F
with 0 ADP F
increased 0 VERB F
responsiveness 0 NOUN F
compared 0 VERB F
with 0 ADP F
a 0 DET F
blunted 0 VERB F
LS B-PHYSICAL NOUN T
response I-PHYSICAL NOUN F
( 0 PUNCT F
HS 0 NOUN T
DeltaE 0 NOUN T
' 0 PUNCT F
-1.4 0 NUM F
+/- 0 SYM F
0.4 0 NUM F
cm/s 0 NOUN F
vs 0 CCONJ F
LS 0 NOUN T
DeltaE 0 NOUN T
' 0 PUNCT F
-0.1 0 NUM F
+/- 0 SYM F
0.3 0 NUM F
cm/s 0 NOUN F
, 0 PUNCT F
P 0 NOUN T
= 0 SYM F
0.02 0 NUM F
; 0 PUNCT F
HS 0 NOUN T
DeltaRBF 0 VERB T
-135.2 0 NUM F
+/- 0 SYM F
13.2 0 NUM F
vs 0 CCONJ F
LS 0 NOUN T
DeltaRBF 0 NOUN T
-62.5 0 NUM F
+/- 0 SYM F
10.1 0 NUM F
mL/min 0 NOUN F
, 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.01 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
authors 0 NOUN F
describe 0 VERB F
for 0 ADP F
the 0 DET F
first 0 ADJ F
time 0 NOUN F
that 0 ADP F
dietary 0 ADJ F
sodium 0 NOUN F
modulates 0 NOUN F
myocardial B-PHYSICAL ADJ F
relaxation I-PHYSICAL NOUN F
and I-PHYSICAL CCONJ F
responsiveness I-PHYSICAL NOUN F
to 0 ADP F
Ang 0 NOUN T
II 0 NUM T
. 0 PUNCT F

It 0 PRON T
is 0 VERB F
important 0 ADJ F
to 0 PART F
consider 0 NOUN F
dietary 0 ADJ F
sodium 0 NOUN F
intake 0 NOUN F
when 0 ADP F
assessing 0 VERB F
diastolic B-PHYSICAL ADJ F
function I-PHYSICAL NOUN F
. 0 PUNCT F

Ang 0 NOUN T
II 0 NUM T
may 0 NOUN F
play 0 VERB F
a 0 DET F
role 0 NOUN F
in 0 ADP F
the 0 DET F
interaction 0 NOUN F
between 0 ADP F
dietary 0 ADJ F
sodium 0 NOUN F
and 0 CCONJ F
myocardial B-PHYSICAL ADJ F
relaxation I-PHYSICAL NOUN F
. 0 PUNCT F

Future 0 ADJ T
research 0 NOUN F
will 0 VERB F
investigate 0 PUNCT F
whether 0 ADP F
abnormalities 0 NOUN F
in 0 ADP F
these 0 DET F
mechanisms 0 NOUN F
play 0 VERB F
a 0 DET F
role 0 NOUN F
in 0 ADP F
disorders 0 NOUN F
of 0 ADP F
diastolic 0 ADJ F
function 0 NOUN F
. 0 PUNCT F

The 0 DET T
effect 0 NOUN F
of 0 ADP F
HCG 0 NOUN T
supplementation 0 NOUN F
after 0 ADP F
combined 0 VERB F
GnRH 0 NOUN T
agonist/HMG 0 NOUN F
treatment 0 NOUN F
in 0 ADP F
an 0 DET F
IVF 0 NOUN T
programme 0 NOUN F
. 0 PUNCT F

The 0 DET T
necessity 0 NOUN F
of 0 ADP F
luteal-phase 0 NOUN F
supplementation 0 NOUN F
in 0 ADP F
an 0 DET F
IVF 0 NOUN T
programme 0 NOUN F
is 0 ADJ F
of 0 ADP F
continuing 0 VERB F
interest 0 NOUN F
. 0 PUNCT F

After 0 ADP T
ovarian 0 ADJ F
stimulation 0 NOUN F
with 0 ADP F
clomiphene 0 NOUN F
and 0 CCONJ F
human 0 NOUN F
menopausal 0 ADJ F
gonadotrophin 0 NOUN F
( 0 PUNCT F
HMG 0 NOUN T
) 0 PUNCT F
, 0 PUNCT F
the 0 DET F
beneficial 0 ADJ F
effect 0 NOUN F
of 0 ADP F
supporting 0 PUNCT F
the 0 DET F
luteal 0 ADJ F
phase 0 NOUN F
has 0 VERB F
never 0 ADV F
been 0 PUNCT F
scientifically 0 ADV F
demonstrated 0 VERB F
. 0 PUNCT F

After 0 ADP T
ovarian 0 ADJ F
stimulation 0 NOUN F
with 0 ADP F
GnRH 0 NOUN T
agonist/HMG 0 NOUN F
, 0 PUNCT F
the 0 DET F
luteal 0 ADJ F
phase 0 NOUN F
seems 0 NOUN F
to 0 PART F
be 0 PUNCT F
inadequate 0 ADJ F
, 0 PUNCT F
but 0 CCONJ F
in 0 ADP F
a 0 DET F
previous 0 ADJ F
study 0 NOUN F
we 0 PROPN F
did 0 CCONJ F
not 0 ADV F
find 0 VERB F
evidence 0 NOUN F
to 0 PART F
support 0 NOUN F
the 0 DET F
need 0 NOUN F
for 0 ADP F
oral 0 ADJ F
progesterone 0 NOUN F
supplementation 0 NOUN F
. 0 PUNCT F

To 0 PART T
evaluate 0 NOUN F
the 0 DET F
beneficial 0 ADJ F
effect 0 NOUN F
of 0 ADP F
human 0 NOUN F
chorionic 0 ADJ F
gonadotrophin 0 NOUN F
( 0 PUNCT F
HCG 0 NOUN T
) 0 PUNCT F
supplementation 0 NOUN F
, 0 PUNCT F
we 0 PRON F
performed 0 VERB F
a 0 DET F
multicentre 0 NOUN F
, 0 PUNCT F
double-blind 0 ADJ F
, 0 PUNCT F
randomized 0 ADP F
study 0 NOUN F
with 0 ADP F
HCG 0 NOUN T
( 0 PUNCT F
193 0 NUM F
transfers 0 NOUN F
) 0 PUNCT F
against 0 ADP F
placebo 0 NOUN F
( 0 PUNCT F
194 0 NUM F
transfers 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
ongoing B-PHYSICAL VERB F
pregnancy I-PHYSICAL NOUN F
rate I-PHYSICAL NOUN F
per I-PHYSICAL ADP F
transfer I-PHYSICAL NOUN F
cycle I-PHYSICAL NOUN F
was 0 VERB F
significantly 0 ADV F
better 0 PUNCT F
with 0 ADP F
HCG 0 NOUN T
( 0 PUNCT F
18.7 0 NUM F
versus 0 CCONJ F
9.3 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

This 0 DET T
is 0 VERB F
the 0 DET F
first 0 ADJ F
truly 0 ADV F
objective 0 PUNCT F
( 0 PUNCT F
randomized 0 PUNCT F
) 0 PUNCT F
study 0 NOUN F
demonstrating 0 VERB F
the 0 DET F
beneficial 0 ADJ F
effect 0 NOUN F
of 0 ADP F
supporting 0 PUNCT F
the 0 DET F
luteal 0 ADJ F
phase 0 NOUN F
in 0 ADP F
an 0 DET F
IVF 0 NOUN T
programme 0 NOUN F
. 0 PUNCT F

Corticosteroid-induced 0 VERB T
osteopenia B-PHYSICAL NOUN F
and 0 CCONJ F
vitamin B-PHYSICAL NOUN F
D I-PHYSICAL NOUN T
metabolism I-PHYSICAL NOUN F
. 0 PUNCT F

Effect 0 NOUN T
of 0 ADP F
vitamin 0 NOUN F
D2 0 NOUN T
, 0 PUNCT F
calcium 0 NOUN F
phosphate 0 NOUN F
and 0 CCONJ F
sodium 0 NOUN F
fluoride 0 NOUN F
administration 0 NOUN F
. 0 PUNCT F

Thirty-one 0 NUM T
patients 0 NOUN F
scheduled 0 DET F
for 0 ADP F
long-term 0 NOUN F
( 0 PUNCT F
24 0 NUM F
weeks 0 NOUN F
) 0 PUNCT F
treatment 0 NOUN F
with 0 ADP F
prednisone 0 NOUN F
in 0 ADP F
comparatively 0 ADV F
high 0 ADJ F
doses 0 NOUN F
were 0 VERB F
randomly 0 ADV F
allocated 0 VERB F
to 0 ADP F
two 0 NUM F
further 0 ADJ F
treatment 0 NOUN F
groups 0 NOUN F
. 0 PUNCT F

Group 0 NOUN T
A 0 NOUN T
received 0 ADP F
prednisone 0 NOUN F
plus 0 CCONJ F
'triple-treatment 0 PUNCT F
' 0 PUNCT F
( 0 PUNCT F
vitamin 0 NOUN F
D2 0 NOUN T
45000 0 NUM F
iu 0 PUNCT F
twice 0 ADV F
weekly 0 ADV F
, 0 PUNCT F
sodium 0 NOUN F
fluoride 0 NOUN F
50 0 NUM F
mg 0 NOUN F
and 0 CCONJ F
calcium 0 NOUN F
phosphate 0 NOUN F
4.5 0 NUM F
g 0 ADP F
daily 0 CCONJ F
) 0 PUNCT F
, 0 PUNCT F
group 0 NOUN F
B 0 NOUN T
received 0 VERB F
only 0 ADV F
prednisone 0 NOUN F
. 0 PUNCT F

The 0 DET T
study 0 NOUN F
was 0 VERB F
undertaken 0 VERB F
in 0 ADP F
order 0 NOUN F
to 0 PART F
evaluate 0 NOUN F
the 0 DET F
effect 0 NOUN F
of 0 ADP F
prednisone- 0 NOUN F
and 0 CCONJ F
triple-treatment 0 PUNCT F
upon 0 ADP F
bone B-PHYSICAL NOUN F
mineral I-PHYSICAL NOUN F
content I-PHYSICAL NOUN F
( I-PHYSICAL PUNCT F
BMC I-PHYSICAL NOUN T
) I-PHYSICAL PUNCT F
and 0 CCONJ F
vitamin B-PHYSICAL NOUN F
D I-PHYSICAL NOUN T
metabolism I-PHYSICAL NOUN F
. 0 PUNCT F

The 0 DET T
groups 0 NOUN F
were 0 VERB F
comparable 0 ADJ F
with 0 ADP F
regard 0 NOUN F
to 0 ADP F
age 0 NOUN F
, 0 PUNCT F
sex 0 NOUN F
and 0 CCONJ F
prednisone 0 NOUN F
dose 0 NOUN F
. 0 PUNCT F

BMC B-PHYSICAL NOUN T
fell 0 ADP F
rapidly 0 ADV F
and 0 CCONJ F
similarly 0 ADV F
in 0 ADP F
both 0 CCONJ F
groups 0 NOUN F
, 0 PUNCT F
demonstrating 0 VERB F
that 0 PUNCT F
the 0 DET F
triple-treatment 0 PUNCT F
has 0 PUNCT F
no 0 DET F
preventive 0 ADJ F
effect 0 NOUN F
on 0 ADP F
corticosteroid 0 NOUN F
induced 0 VERB F
osteopenia 0 NOUN F
. 0 PUNCT F

Serum B-PHYSICAL NOUN T
concentrations I-PHYSICAL NOUN F
of I-PHYSICAL ADP F
25OHD2 I-PHYSICAL NOUN F
, I-PHYSICAL PUNCT F
25OHD3 I-PHYSICAL NOUN F
and I-PHYSICAL CCONJ F
1,25 I-PHYSICAL ADP F
( I-PHYSICAL PUNCT F
OH I-PHYSICAL NOUN T
) I-PHYSICAL PUNCT F
2D I-PHYSICAL NOUN F
were 0 VERB F
unchanged 0 VERB F
in 0 ADP F
group 0 NOUN F
B 0 NOUN T
( 0 PUNCT F
without 0 ADP F
triple-treatment 0 PUNCT F
) 0 PUNCT F
, 0 PUNCT F
whereas 0 ADP F
in 0 ADP F
group 0 NOUN F
A 0 NOUN T
25OHD2 B-PHYSICAL NOUN F
increased 0 VERB F
enormously 0 ADV F
, 0 PUNCT F
25OHD3 B-PHYSICAL NOUN F
was 0 VERB F
suppressed 0 ADJ F
possibly 0 ADV F
by 0 ADP F
substrate 0 NOUN F
competition 0 NOUN F
for 0 ADP F
hydroxylation 0 NOUN F
in 0 ADP F
the 0 DET F
liver 0 NOUN F
and 0 CCONJ F
1,25 0 ADP F
( B-PHYSICAL PUNCT F
OH I-PHYSICAL NOUN T
) I-PHYSICAL PUNCT F
2D I-PHYSICAL NOUN F
was 0 VERB F
halved 0 ADV F
. 0 PUNCT F

The 0 DET T
suppression 0 NOUN F
of 0 ADP F
1,25 0 NOUN F
( B-PHYSICAL PUNCT F
OH I-PHYSICAL NOUN T
) I-PHYSICAL PUNCT F
2D I-PHYSICAL NOUN F
may 0 VERB F
be 0 VERB F
an 0 DET F
effect 0 NOUN F
of 0 ADP F
raised 0 VERB F
25OHD2 0 NOUN F
alone 0 ADJ F
, 0 PUNCT F
or 0 CCONJ F
in 0 ADP F
combination 0 NOUN F
with 0 ADP F
corticosteroid 0 NOUN F
excess 0 NOUN F
. 0 PUNCT F

Citalopram 0 NOUN T
for 0 ADP F
post-stroke 0 NOUN F
pathological 0 ADJ F
crying 0 NOUN F
. 0 PUNCT F

Post-stroke 0 NOUN T
pathological 0 ADJ F
crying 0 PUNCT F
is 0 NOUN F
a 0 DET F
distressing 0 VERB F
condition 0 NOUN F
in 0 ADP F
which 0 PUNCT F
episodes 0 PUNCT F
occur 0 VERB F
in 0 ADP F
response 0 NOUN F
to 0 ADP F
minor 0 ADJ F
stimuli 0 NOUN F
without 0 ADP F
associated 0 ADP F
mood 0 PUNCT F
changes 0 NOUN F
. 0 PUNCT F

There 0 PUNCT T
is 0 VERB F
preliminary 0 ADJ F
evidence 0 NOUN F
of 0 ADP F
disturbed 0 PUNCT F
serotoninergic 0 ADJ F
neurotransmission 0 NOUN F
in 0 ADP F
such 0 DET F
cases 0 NOUN F
. 0 PUNCT F

We 0 PRON T
investigated 0 VERB F
the 0 DET F
effect 0 NOUN F
of 0 ADP F
the 0 DET F
selective B-PHYSICAL ADJ F
serotonin I-PHYSICAL NOUN F
reuptake I-PHYSICAL NOUN F
inhibitor I-PHYSICAL NOUN F
citalopram I-PHYSICAL NOUN F
on 0 ADP F
uncontrolled B-MENTAL PUNCT F
crying I-MENTAL NUM F
in 0 ADP F
stroke 0 NOUN F
patients 0 NOUN F
in 0 ADP F
a 0 DET F
double-blind 0 ADJ F
placebo-controlled 0 DET F
crossover 0 NOUN F
study 0 NOUN F
. 0 PUNCT F

16 0 NUM F
consecutive 0 ADJ F
patients 0 NOUN F
( 0 PUNCT F
median 0 ADJ F
age 0 NOUN F
58.5 0 NUM F
years 0 NOUN F
, 0 PUNCT F
range 0 NOUN F
40-83 0 PUNCT F
) 0 PUNCT F
entered 0 VERB F
the 0 DET F
9-week 0 NOUN F
study 0 PUNCT F
a 0 DET F
median 0 ADJ F
of 0 ADP F
168 0 NUM F
days 0 NOUN F
( 0 PUNCT F
range 0 NOUN F
6-913 0 ADV F
) 0 PUNCT F
post 0 PUNCT F
stroke 0 NOUN F
and 0 CCONJ F
were 0 VERB F
treated 0 VERB F
with 0 ADP F
citalopram 0 NOUN F
10-20 0 NUM F
mg 0 NOUN F
daily 0 ADJ F
for 0 ADP F
3 0 NUM F
weeks 0 NOUN F
. 0 PUNCT F

Crying B-MENTAL ADV T
history I-MENTAL NOUN F
was 0 VERB F
determined 0 VERB F
from 0 ADP F
semistructured 0 DET F
interviews 0 NOUN F
and 0 CCONJ F
from 0 ADP F
diaries 0 NOUN F
kept 0 PUNCT F
by 0 ADP F
the 0 DET F
patients 0 NOUN F
. 0 PUNCT F

Psychiatric B-MENTAL ADJ T
assessment I-MENTAL NOUN F
was 0 VERB F
made 0 VERB F
with 0 ADP F
the 0 DET F
Hamilton B-MENTAL PUNCT T
depression I-MENTAL NOUN F
scale I-MENTAL NOUN F
( 0 PUNCT F
HDS 0 NOUN T
) 0 PUNCT F
, 0 PUNCT F
and 0 CCONJ F
unwanted B-ADVERSE-EFFECTS VERB F
effects I-ADVERSE-EFFECTS NOUN F
were 0 VERB F
measured 0 VERB F
with 0 ADP F
the 0 DET F
UKU B-ADVERSE-EFFECTS NOUN T
side-effect I-ADVERSE-EFFECTS NOUN F
scale I-ADVERSE-EFFECTS NOUN F
. 0 PUNCT F

In 0 ADP T
13 0 NUM F
patients 0 NOUN F
in 0 ADP F
whom 0 ADP F
frequency 0 NOUN F
of 0 ADP F
crying B-MENTAL NOUN F
could 0 PUNCT F
be 0 VERB F
assessed 0 VERB F
, 0 PUNCT F
the 0 DET F
number 0 NOUN F
of 0 ADP F
daily B-MENTAL PUNCT F
crying I-MENTAL PUNCT F
episodes I-MENTAL NOUN F
decreased 0 VERB F
by 0 ADP F
at 0 ADP F
least 0 ADV F
50 0 NUM F
% 0 SYM F
in 0 ADP F
all 0 DET F
cases 0 NOUN F
during 0 ADP F
citalopram 0 NOUN F
treatment 0 NOUN F
vs 0 CCONJ F
2 0 NUM F
patients 0 NOUN F
during 0 ADP F
placebo 0 NOUN F
treatment 0 NOUN F
( 0 PUNCT F
p 0 NOUN F
< 0 SYM F
0.005 0 NUM F
, 0 PUNCT F
McNemar 0 NOUN T
's 0 PUNCT F
test 0 NOUN F
) 0 PUNCT F
, 0 PUNCT F
the 0 DET F
effect 0 NOUN F
being 0 ADP F
rapid 0 ADJ F
( 0 PUNCT F
1-3 0 PUNCT F
days 0 NOUN F
) 0 PUNCT F
and 0 CCONJ F
pronounced 0 VERB F
in 0 ADP F
11 0 NUM F
( 0 PUNCT F
73 0 NUM F
% 0 SYM F
) 0 PUNCT F
. 0 PUNCT F

There 0 PUNCT T
was 0 VERB F
a 0 DET F
concomitant 0 ADJ F
significant 0 ADJ F
decrease 0 NOUN F
in 0 ADP F
depression B-MENTAL NOUN F
rating I-MENTAL PUNCT F
from 0 ADP F
HDS 0 NOUN T
8.9 0 NUM F
to 0 ADP F
5.3 0 PUNCT F
( 0 PUNCT F
p 0 NOUN F
< 0 SYM F
0.005 0 NUM F
, 0 PUNCT F
Wilcoxon 0 NOUN T
's 0 PUNCT F
test 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

Citalopram 0 NOUN T
was 0 VERB F
well 0 VERB F
tolerated 0 ADP F
, 0 PUNCT F
the 0 DET F
few 0 ADJ F
side-effects 0 NOUN F
being 0 VERB F
mild 0 ADJ F
and 0 CCONJ F
transient 0 ADJ F
. 0 PUNCT F

We 0 PRON T
conclude 0 VERB F
that 0 ADP F
serotoninergic 0 ADJ F
neurotransmission 0 NOUN F
plays 0 NOUN F
an 0 DET F
important 0 ADJ F
part 0 NOUN F
in 0 ADP F
post-stroke 0 NOUN F
pathological 0 ADJ F
crying 0 PROPN F
and 0 CCONJ F
that 0 ADP F
citalopram 0 NOUN F
is 0 VERB F
an 0 DET F
effective 0 ADJ F
and 0 CCONJ F
well-tolerated 0 VERB F
treatment 0 NOUN F
. 0 PUNCT F

Acute 0 ADJ T
prolactin 0 NOUN F
and 0 CCONJ F
oxytocin 0 NOUN F
responses 0 NOUN F
and 0 CCONJ F
milk B-PHYSICAL NOUN F
yield I-PHYSICAL NOUN F
to 0 ADP F
infant 0 NOUN F
suckling 0 PUNCT F
and 0 CCONJ F
artificial B-OTHER ADJ F
methods I-OTHER NOUN F
of I-OTHER ADP F
expression I-OTHER NOUN F
in 0 ADP F
lactating 0 DET F
women 0 NOUN F
. 0 PUNCT F

Breast-feeding 0 ADJ T
is 0 VERB F
today 0 NOUN F
the 0 DET F
major 0 ADJ F
form 0 NOUN F
of 0 ADP F
infant 0 NOUN F
nutrition 0 NOUN F
in 0 ADP F
the 0 DET F
immediate 0 ADJ F
postpartum 0 NOUN F
period 0 NOUN F
. 0 PUNCT F

Despite 0 ADP T
this 0 PUNCT F
, 0 PUNCT F
recent 0 ADJ F
trends 0 NOUN F
in 0 ADP F
modern 0 ADJ F
life-styles 0 NOUN F
have 0 PUNCT F
raised 0 VERB F
obstacles 0 ADJ F
to 0 ADP F
successful 0 ADJ F
lactation 0 NOUN F
. 0 PUNCT F

These 0 CCONJ T
include 0 VERB F
infant 0 NOUN F
illness 0 NOUN F
and 0 CCONJ F
maternal 0 ADJ F
responsibilities 0 NOUN F
outside 0 ADP F
the 0 DET F
home 0 NOUN F
, 0 PUNCT F
both 0 PUNCT F
requiring 0 ADJ F
separation 0 NOUN F
from 0 ADP F
the 0 DET F
mother 0 NOUN F
. 0 PUNCT F

While 0 ADP T
the 0 DET F
hormonal 0 ADJ F
dynamics 0 NOUN F
of 0 ADP F
infant 0 NOUN F
suckling 0 PUNCT F
are 0 VERB F
understood 0 VERB F
, 0 PUNCT F
little 0 PUNCT F
is 0 VERB F
known 0 VERB F
about 0 ADP F
the 0 DET F
effects 0 NOUN F
of 0 ADP F
artificial 0 ADJ F
methods 0 NOUN F
of 0 ADP F
milk B-OTHER NOUN F
expression I-OTHER NOUN F
. 0 PUNCT F

A 0 DET T
variety 0 NOUN F
of 0 ADP F
breast 0 NOUN F
pumps 0 NOUN F
exist 0 VERB F
in 0 ADP F
the 0 DET F
current 0 ADJ F
US 0 PUNCT T
market 0 NOUN F
which 0 ADP F
vary 0 VERB F
considerably 0 ADV F
in 0 ADP F
price 0 NOUN F
and 0 CCONJ F
effectiveness 0 NOUN F
. 0 PUNCT F

To 0 ADJ T
understand 0 ADJ F
better 0 ADP F
the 0 DET F
ability 0 NOUN F
of 0 ADP F
these 0 DET F
pumps 0 NOUN F
to 0 PART F
assist 0 ADJ F
women 0 NOUN F
in 0 ADP F
the 0 DET F
maintenance 0 NOUN F
of 0 ADP F
lactation 0 NOUN F
, 0 PUNCT F
the 0 DET F
current 0 ADJ F
study 0 NOUN F
was 0 VERB F
undertaken 0 VERB F
to 0 ADJ F
evaluate 0 NOUN F
their 0 ADP F
effects 0 NOUN F
on 0 ADP F
milk 0 NOUN F
yield 0 NOUN F
and 0 CCONJ F
prolactin 0 NOUN F
and 0 CCONJ F
oxytocin B-OTHER NOUN F
release I-OTHER NOUN F
when 0 ADP F
compared 0 VERB F
to 0 ADP F
natural 0 ADJ F
infant 0 NOUN F
suckling 0 PUNCT F
. 0 PUNCT F

Twenty-three 0 DET T
women 0 NOUN F
who 0 ADP F
were 0 VERB F
exclusively 0 ADV F
breast-feeding 0 ADP F
their 0 ADP F
infants 0 NOUN F
were 0 VERB F
randomly 0 ADV F
assigned 0 VERB F
to 0 ADP F
serially 0 ADV F
use 0 PUNCT F
several 0 ADJ F
pumping 0 PUNCT F
methods 0 NOUN F
, 0 PUNCT F
as 0 CCONJ F
well 0 PUNCT F
as 0 PUNCT F
infant 0 NOUN F
suckling 0 ADJ F
, 0 PUNCT F
with 0 ADP F
blood 0 NOUN F
being 0 ADV F
taken 0 VERB F
at 0 ADP F
10-minute 0 PUNCT F
intervals 0 NOUN F
to 0 PART F
determine 0 NOUN F
the 0 DET F
hormonal 0 ADJ F
responses 0 NOUN F
. 0 PUNCT F

The 0 DET T
results 0 NOUN F
reveal 0 VERB F
variability 0 NOUN F
in 0 ADP F
the 0 DET F
prolactin B-OTHER NOUN F
responses I-OTHER NOUN F
to 0 ADP F
the 0 DET F
artificial 0 ADJ F
pumping 0 PUNCT F
methods 0 NOUN F
, 0 PUNCT F
with 0 ADP F
the 0 DET F
greatest 0 PUNCT F
responses 0 NOUN F
found 0 VERB F
with 0 ADP F
an 0 DET F
electric 0 ADJ F
pulsatile 0 ADJ F
pump 0 NOUN F
; 0 PUNCT F
these 0 DET F
responses 0 NOUN F
compare 0 NUM F
favorably 0 ADV F
with 0 ADP F
those 0 PUNCT F
of 0 ADP F
natural 0 ADJ F
infant 0 NOUN F
suckling 0 PUNCT F
. 0 PUNCT F

Other 0 ADJ T
methods 0 NOUN F
were 0 VERB F
less 0 ADV F
successful 0 ADJ F
in 0 ADP F
causing 0 VERB F
prolactin B-OTHER NOUN F
elevations I-OTHER NOUN F
. 0 PUNCT F

No 0 DET T
differences 0 NOUN F
were 0 VERB F
seen 0 VERB F
among 0 ADP F
the 0 DET F
methods 0 NOUN F
in 0 ADP F
the 0 DET F
oxytocin B-OTHER NOUN F
response I-OTHER NOUN F
. 0 PUNCT F

The 0 DET T
results 0 NOUN F
of 0 ADP F
this 0 DET F
study 0 NOUN F
demonstrate 0 PART F
striking 0 VERB F
differences 0 NOUN F
in 0 ADP F
the 0 DET F
ability 0 NOUN F
of 0 ADP F
breast-pumping 0 VERB F
methods 0 NOUN F
to 0 PART F
produce 0 NOUN F
an 0 DET F
acute B-OTHER ADJ F
and I-OTHER CCONJ F
sustained I-OTHER VERB F
prolactin I-OTHER NOUN F
rise I-OTHER NOUN F
in 0 ADP F
breast-feeding 0 PUNCT F
mothers 0 NOUN F
. 0 PUNCT F

The 0 DET T
large 0 ADJ F
discrepancies 0 NOUN F
found 0 VERB F
suggest 0 VERB F
the 0 DET F
need 0 NOUN F
for 0 ADP F
further 0 PUNCT F
studies 0 NOUN F
in 0 ADP F
to 0 PUNCT F
enable 0 NOUN F
women 0 NOUN F
and 0 CCONJ F
health 0 NOUN F
care 0 NOUN F
providers 0 NOUN F
to 0 ADP F
choose 0 NOUN F
the 0 DET F
most 0 PUNCT F
appropriate 0 ADJ F
method 0 NOUN F
for 0 ADP F
milk 0 NOUN F
expression 0 NOUN F
. 0 PUNCT F
( 0 PUNCT F

ABSTRACT 0 ADP T
TRUNCATED 0 PUNCT T
AT 0 ADP T
250 0 NUM F
WORDS 0 NOUN T
) 0 PUNCT F

Yoga 0 NOUN T
effects 0 NOUN F
on 0 ADP F
mood B-MENTAL ADP F
and 0 CCONJ F
quality 0 NOUN F
of 0 ADP F
life 0 NOUN F
in 0 ADP F
Chinese 0 NOUN T
women 0 NOUN F
undergoing 0 VERB F
heroin 0 ADJ F
detoxification 0 NOUN F
: 0 PUNCT F
a 0 DET F
randomized 0 VERB F
controlled 0 VERB F
trial 0 NOUN F
. 0 PUNCT F

BACKGROUND 0 NOUN T
Yoga 0 NOUN T
, 0 PUNCT F
as 0 ADP F
a 0 DET F
mind-body 0 NOUN F
therapy 0 NOUN F
, 0 PUNCT F
is 0 VERB F
effective 0 ADJ F
in 0 ADP F
improving 0 VERB F
quality 0 NOUN F
of 0 ADP F
life 0 NOUN F
for 0 ADP F
patients 0 NOUN F
with 0 ADP F
chronic 0 ADJ F
diseases 0 NOUN F
, 0 PUNCT F
yet 0 ADV F
little 0 PUNCT F
is 0 VERB F
known 0 VERB F
about 0 ADP F
its 0 PUNCT F
effectiveness 0 NOUN F
in 0 ADP F
female 0 NOUN F
heroin 0 NOUN F
addicts 0 NOUN F
. 0 PUNCT F

OBJECTIVES 0 NOUN T
The 0 DET T
aim 0 NOUN F
of 0 ADP F
this 0 DET F
study 0 NOUN F
was 0 VERB F
to 0 PART F
evaluate 0 NOUN F
the 0 DET F
effects 0 NOUN F
of 0 ADP F
yoga 0 NOUN F
on 0 ADP F
mood 0 PUNCT F
status 0 NOUN F
and 0 CCONJ F
quality 0 NOUN F
of 0 ADP F
life 0 NOUN F
among 0 ADP F
women 0 NOUN F
undergoing 0 VERB F
detoxification 0 NOUN F
for 0 ADP F
heroin 0 ADJ F
dependence 0 NOUN F
in 0 ADP F
China 0 NOUN T
. 0 PUNCT F

METHOD 0 NOUN T
This 0 DET T
study 0 NOUN F
was 0 VERB F
a 0 DET F
randomized 0 VERB F
controlled 0 VERB F
trial 0 NOUN F
. 0 PUNCT F

Seventy-five 0 ADJ T
women 0 NOUN F
aged 0 ADP F
20-37 0 NUM F
years 0 NOUN F
undergoing 0 VERB F
detoxification 0 NOUN F
for 0 ADP F
heroin 0 ADJ F
dependence 0 NOUN F
at 0 ADP F
AnKang 0 NOUN T
Hospital 0 NOUN T
were 0 VERB F
allocated 0 VERB F
randomly 0 ADV F
into 0 ADP F
an 0 DET F
intervention 0 NOUN F
or 0 CCONJ F
a 0 DET F
control 0 NOUN F
group 0 NOUN F
. 0 PUNCT F

Women 0 NOUN T
in 0 ADP F
the 0 DET F
intervention 0 NOUN F
group 0 NOUN F
received 0 VERB F
a 0 DET F
6-month 0 NOUN F
yoga 0 NOUN F
intervention 0 NOUN F
in 0 ADP F
addition 0 NOUN F
to 0 ADP F
hospital 0 NOUN F
routine 0 ADJ F
care 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
women 0 NOUN F
in 0 ADP F
the 0 DET F
control 0 NOUN F
group 0 NOUN F
received 0 VERB F
hospital 0 NOUN F
routine 0 ADJ F
care 0 NOUN F
only 0 ADV F
. 0 PUNCT F

Mood 0 DET T
status 0 NOUN F
and 0 CCONJ F
quality 0 NOUN F
of 0 ADP F
life 0 NOUN F
were 0 VERB F
assessed 0 VERB F
using 0 VERB F
the 0 DET F
Profile B-MENTAL NOUN T
of I-MENTAL ADP F
Mood I-MENTAL PUNCT T
States I-MENTAL NOUN T
and 0 CCONJ F
Medical B-MENTAL ADJ T
Outcomes I-MENTAL NOUN T
Study I-MENTAL ADP T
36-item I-MENTAL NOUN F
Short-Form I-MENTAL NOUN T
Health I-MENTAL NOUN T
Survey I-MENTAL NOUN T
at 0 ADP F
baseline 0 NOUN F
and 0 CCONJ F
following 0 VERB F
3 0 NUM F
and 0 CCONJ F
6 0 NUM F
months 0 NOUN F
of 0 ADP F
treatment 0 NOUN F
. 0 PUNCT F

Repeated-measures 0 VERB T
analysis 0 NOUN F
of 0 ADP F
variance 0 NOUN F
was 0 VERB F
used 0 VERB F
to 0 PART F
evaluate 0 NOUN F
treatment 0 NOUN F
and 0 CCONJ F
time 0 NOUN F
effects 0 NOUN F
on 0 ADP F
mood 0 ADP F
and 0 CCONJ F
quality 0 NOUN F
of 0 ADP F
life 0 NOUN F
. 0 PUNCT F

RESULTS 0 PUNCT T
Most 0 PUNCT T
female 0 NOUN F
heroin 0 NOUN F
addicts 0 NOUN F
were 0 VERB F
young 0 ADP F
and 0 CCONJ F
single 0 ADJ F
, 0 PUNCT F
with 0 ADP F
a 0 DET F
low 0 ADJ F
education 0 NOUN F
level 0 NOUN F
. 0 PUNCT F

Most 0 ADV T
had 0 PUNCT F
used 0 ADP F
heroin 0 CCONJ F
by 0 ADP F
injection 0 NOUN F
. 0 PUNCT F

Mood 0 PUNCT T
state 0 NOUN F
and 0 CCONJ F
quality 0 NOUN F
of 0 ADP F
life 0 NOUN F
of 0 ADP F
female 0 NOUN F
heroin 0 NOUN F
addicts 0 NOUN F
were 0 VERB F
poor 0 ADJ F
. 0 PUNCT F

The 0 DET T
intervention 0 NOUN F
group 0 NOUN F
showed 0 VERB F
a 0 DET F
significant 0 ADJ F
improvement 0 NOUN F
in 0 ADP F
mood 0 PUNCT F
status 0 NOUN F
and 0 CCONJ F
quality 0 NOUN F
of 0 ADP F
life 0 NOUN F
over 0 PUNCT F
time 0 NOUN F
compared 0 PRON F
with 0 ADP F
their 0 ADP F
counterparts 0 NOUN F
in 0 ADP F
the 0 DET F
control 0 NOUN F
group 0 NOUN F
. 0 PUNCT F

CONCLUSION 0 NOUN T
Yoga 0 NOUN T
may 0 PART F
improve 0 ADJ F
mood 0 PUNCT F
status 0 NOUN F
and 0 CCONJ F
quality 0 NOUN F
of 0 ADP F
life 0 NOUN F
for 0 ADP F
women 0 NOUN F
undergoing 0 VERB F
detoxification 0 NOUN F
for 0 ADP F
heroin 0 ADJ F
dependence 0 NOUN F
. 0 PUNCT F

Yoga 0 NOUN T
can 0 VERB F
be 0 VERB F
used 0 VERB F
as 0 ADP F
an 0 DET F
auxiliary 0 ADJ F
treatment 0 NOUN F
with 0 ADP F
traditional 0 ADJ F
hospital 0 NOUN F
routine 0 ADJ F
care 0 NOUN F
for 0 ADP F
these 0 DET F
women 0 NOUN F
. 0 PUNCT F

Assessing 0 ADP T
drug 0 NOUN F
use 0 NOUN F
prevalence 0 NOUN F
in 0 ADP F
the 0 DET F
workplace 0 PUNCT F
: 0 PUNCT F
a 0 DET F
comparison 0 NOUN F
of 0 ADP F
self-report 0 ADJ F
methods 0 NOUN F
and 0 CCONJ F
urinalysis 0 NOUN F
. 0 PUNCT F

A 0 DET T
random 0 ADJ F
sample 0 NOUN F
of 0 ADP F
800 0 NUM F
employees 0 NOUN F
of 0 ADP F
a 0 DET F
steel 0 NOUN F
manufacturing 0 ADP F
company 0 NOUN F
were 0 VERB F
randomly 0 ADV F
assigned 0 VERB F
to 0 ADP F
one 0 PUNCT F
of 0 ADP F
four 0 NUM F
self-report 0 ADJ F
methods 0 NOUN F
of 0 ADP F
assessing 0 VERB F
illicit 0 NOUN F
drug 0 NOUN F
use 0 NOUN F
: 0 PUNCT F
1 0 NUM F
) 0 PUNCT F
Individual 0 ADJ T
interview 0 NOUN F
in 0 ADP F
the 0 DET F
workplace 0 CCONJ F
, 0 PUNCT F
2 0 NUM F
) 0 PUNCT F
group-administered 0 VERB F
questionnaire 0 NOUN F
in 0 ADP F
the 0 DET F
workplace 0 CCONJ F
, 0 PUNCT F
3 0 NUM F
) 0 PUNCT F
telephone 0 NOUN F
interview 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
4 0 NUM F
) 0 PUNCT F
individual 0 ADJ F
interview 0 NOUN F
off 0 ADP F
the 0 DET F
worksite 0 NOUN F
. 0 PUNCT F

All 0 DET T
621 0 NUM F
subjects 0 NOUN F
participating 0 VERB F
in 0 ADP F
the 0 DET F
research 0 NOUN F
were 0 VERB F
also 0 ADV F
tested 0 VERB F
by 0 ADP F
urinalysis 0 NOUN F
. 0 PUNCT F

Rates 0 NOUN T
of 0 ADP F
drug B-MENTAL NOUN F
use I-MENTAL ADV F
self-report I-MENTAL ADJ F
were 0 ADV F
highest 0 PUNCT F
in 0 ADP F
the 0 DET F
workplace 0 CCONJ F
interview 0 NOUN F
condition 0 NOUN F
and 0 CCONJ F
lowest 0 PUNCT F
in 0 ADP F
the 0 DET F
overall 0 ADJ F
group 0 NOUN F
questionnaire 0 NOUN F
condition 0 NOUN F
. 0 PUNCT F

Although 0 ADP T
the 0 DET F
overall B-OTHER ADJ F
prevalence 0 NOUN F
rates B-OTHER NOUN F
produced 0 VERB F
by 0 ADP F
self-reports 0 NOUN F
and 0 CCONJ F
urinalysis 0 NOUN F
were 0 VERB F
similar 0 ADJ F
, 0 PUNCT F
there 0 PUNCT F
was 0 VERB F
little 0 DET F
concordance 0 NOUN F
between 0 ADP F
urinalysis B-OTHER NOUN F
positives 0 NOUN F
and 0 CCONJ F
self-report B-MENTAL DET F
positives 0 NOUN F
. 0 PUNCT F

The 0 DET T
results 0 NOUN F
indicated 0 VERB F
that 0 ADP F
self-reports 0 VERB F
and 0 CCONJ F
urinalysis 0 NOUN F
are 0 VERB F
complementary 0 ADJ F
methods 0 NOUN F
of 0 PUNCT F

Hemolytic 0 ADJ T
streptococcus 0 NOUN F
preparation 0 NOUN F
OK-432 0 NOUN T
; 0 PUNCT F
beneficial 0 ADJ F
adjuvant 0 NOUN F
therapy 0 NOUN F
in 0 ADP F
recurrent 0 ADJ F
gastric 0 ADJ F
carcinoma 0 NOUN F
. 0 PUNCT F

The 0 DET T
administration 0 NOUN F
of 0 ADP F
a 0 DET F
hemolytic 0 ADJ F
streptococcus 0 NOUN F
preparation 0 NOUN F
, 0 PUNCT F
OK-432 0 NOUN T
, 0 PUNCT F
is 0 VERB F
thought 0 VERB F
to 0 PART F
be 0 PUNCT F
of 0 ADP F
therapeutic 0 ADJ F
value 0 NOUN F
in 0 ADP F
the 0 DET F
treatment 0 NOUN F
of 0 ADP F
cancer 0 NOUN F
patients 0 NOUN F
through 0 ADP F
a 0 DET F
stimulatory 0 ADJ F
effect 0 NOUN F
on 0 ADP F
the 0 DET F
immune 0 ADJ F
system 0 NOUN F
. 0 PUNCT F

In 0 ADP T
order 0 NOUN F
to 0 PART F
evaluate 0 NOUN F
any 0 DET F
beneficial 0 ADJ F
effect 0 NOUN F
of 0 ADP F
such 0 CCONJ F
an 0 ADP F
administration 0 NOUN F
, 0 PUNCT F
a 0 DET F
group 0 NOUN F
of 0 ADP F
patients 0 NOUN F
with 0 ADP F
recurrent 0 ADJ F
gastric 0 ADJ F
cancer 0 NOUN F
was 0 VERB F
studied 0 VERB F
. 0 PUNCT F

This 0 DET T
group 0 NOUN F
was 0 VERB F
randomly 0 ADV F
subdivided 0 VERB F
into 0 ADP F
3 0 NUM F
groups 0 NOUN F
: 0 PUNCT F
1 0 NUM F
) 0 PUNCT F
Intradermal 0 PUNCT T
group 0 NOUN F
( 0 PUNCT F
ID 0 NOUN T
Group 0 NOUN T
) 0 PUNCT F
, 0 PUNCT F
42 0 NUM F
patients 0 NOUN F
given 0 VERB F
an 0 DET F
intradermal 0 VERB F
injections 0 NOUN F
of 0 ADP F
OK-432 0 NOUN T
. 0 PUNCT F

2 0 NUM F
) 0 PUNCT F
Intramuscular 0 ADJ T
group 0 NOUN F
( 0 PUNCT F
IM 0 NOUN T
Group 0 NOUN T
) 0 PUNCT F
, 0 PUNCT F
40 0 NUM F
patients 0 NOUN F
given 0 VERB F
an 0 DET F
intramuscular 0 ADJ F
injections 0 NOUN F
of 0 ADP F
OK-432 0 NOUN T
. 0 PUNCT F

3 0 NUM F
) 0 PUNCT F
Control 0 NOUN T
group 0 NOUN F
( 0 PUNCT F
C 0 NOUN T
Group 0 NOUN T
) 0 PUNCT F
, 0 PUNCT F
39 0 NUM F
patients 0 NOUN F
not 0 ADV F
given 0 PUNCT F
injections 0 NOUN F
. 0 PUNCT F

Each 0 DET T
group 0 NOUN F
was 0 VERB F
studied 0 VERB F
in 0 ADP F
regards 0 ADP F
to 0 ADP F
the 0 DET F
length B-MORTALITY NOUN F
of I-MORTALITY ADP F
survival I-MORTALITY NOUN F
, 0 PUNCT F
the 0 DET F
host B-PHYSICAL NOUN F
immune I-PHYSICAL ADJ F
response I-PHYSICAL NOUN F
and 0 CCONJ F
the 0 DET F
incidence 0 NOUN F
of 0 ADP F
side B-ADVERSE-EFFECTS NOUN F
effects I-ADVERSE-EFFECTS NOUN F
. 0 PUNCT F

When 0 ADP T
compared 0 VERB F
to 0 ADP F
the 0 DET F
IM 0 NOUN T
and 0 CCONJ F
C 0 NOUN T
Groups 0 NOUN T
, 0 PUNCT F
the 0 DET F
ID 0 NOUN T
Group 0 NOUN T
showed 0 VERB F
improved 0 VERB F
survival B-MORTALITY NOUN F
. 0 PUNCT F

Accompanying 0 PUNCT T
this 0 ADP F
improved 0 PUNCT F
survival 0 NOUN F
, 0 PUNCT F
the 0 DET F
ID 0 NOUN T
Group 0 NOUN T
also 0 ADV F
had 0 PUNCT F
greater 0 PUNCT F
white B-PHYSICAL ADJ F
cell I-PHYSICAL NOUN F
and I-PHYSICAL CCONJ F
lymphocyte I-PHYSICAL NOUN F
counts I-PHYSICAL NOUN F
, 0 PUNCT F
a 0 DET F
greater 0 PUNCT F
number 0 NOUN F
of 0 ADP F
T 0 NOUN T
cells B-PHYSICAL NOUN F
, 0 PUNCT F
and 0 CCONJ F
a 0 DET F
more 0 DET F
dramatic B-PHYSICAL ADJ F
skin I-PHYSICAL NOUN F
reaction I-PHYSICAL NOUN F
to 0 ADP F
the 0 DET F
extracted 0 ADP F
cell 0 NOUN F
wall 0 NOUN F
polysaccharide 0 ADP F
of 0 ADP F
hemolytic 0 ADJ F
streptococcus 0 NOUN F
Su-strain 0 NOUN T
( 0 PUNCT F
Su-PS 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
ID 0 NOUN T
Group 0 NOUN T
, 0 PUNCT F
following 0 CCONJ F
OK-432 0 NOUN T
injection 0 NOUN F
, 0 PUNCT F
had 0 VERB F
a 0 DET F
4.8 0 NUM F
% 0 SYM F
incidence 0 NOUN F
of 0 ADP F
fever B-PHYSICAL NOUN F
and 0 CCONJ F
a 0 DET F
52.4 0 NUM F
% 0 SYM F
incidence 0 NOUN F
of 0 ADP F
local B-PHYSICAL ADJ F
abscess I-PHYSICAL NOUN F
formation I-PHYSICAL NOUN F
at 0 ADP F
the 0 DET F
injection 0 NOUN F
site 0 NOUN F
. 0 PUNCT F

90 0 NUM F
% 0 SYM F
of 0 ADP F
the 0 DET F
IM 0 NOUN T
Group 0 NOUN T
developed 0 VERB F
fever B-PHYSICAL NOUN F
but 0 CCONJ F
abscess B-PHYSICAL ADJ F
formation I-PHYSICAL NOUN F
was 0 VERB F
absent 0 ADJ F
in 0 ADP F
all 0 DET F
patients 0 NOUN F
. 0 PUNCT F

From 0 ADP T
these 0 DET F
results 0 NOUN F
, 0 PUNCT F
it 0 PRON F
was 0 VERB F
concluded 0 VERB F
that 0 ADP F
in 0 ADP F
the 0 DET F
patients 0 NOUN F
tested 0 VERB F
, 0 PUNCT F
intradermal 0 VERB F
injection 0 NOUN F
of 0 ADP F
OK-432 0 NOUN T
appears 0 NOUN F
to 0 PART F
be 0 PUNCT F
clinically 0 ADV F
superior 0 ADJ F
to 0 ADP F
intramuscular 0 ADJ F
injection 0 NOUN F
. 0 PUNCT F

Is 0 PUNCT T
the 0 DET F
effect 0 NOUN F
of 0 ADP F
mobile 0 ADJ F
phone 0 NOUN F
radiofrequency 0 NOUN F
waves 0 PUNCT F
on 0 ADP F
human 0 NOUN F
skin 0 NOUN F
perfusion 0 NOUN F
non-thermal 0 ADJ F
? 0 PUNCT F

OBJECTIVE 0 NOUN T
To 0 PROPN T
establish 0 ADJ F
whether 0 ADP F
SkBF B-PHYSICAL NOUN T
can 0 VERB F
be 0 VERB F
modified 0 VERB F
by 0 ADP F
exposure 0 NOUN F
to 0 ADP F
the 0 DET F
radiofrequency 0 NOUN F
waves 0 PUNCT F
emitted 0 PRON F
by 0 ADP F
a 0 DET F
mobile 0 ADJ F
phone 0 NOUN F
when 0 ADP F
the 0 DET F
latter 0 NOUN F
is 0 VERB F
held 0 NOUN F
against 0 ADP F
the 0 DET F
jaw 0 NOUN F
and 0 CCONJ F
ear 0 NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
Variations B-PHYSICAL NOUN T
in I-PHYSICAL ADP F
SkBF I-PHYSICAL NOUN T
and 0 CCONJ F
Tsk 0 NOUN T
in 0 ADP F
adult 0 NOUN F
volunteers 0 NOUN F
were 0 VERB F
simultaneously 0 ADV F
recorded 0 VERB F
with 0 ADP F
a 0 DET F
thermostatic 0 ADJ F
laser 0 NOUN F
Doppler 0 NOUN T
system 0 NOUN F
during 0 ADP F
a 0 DET F
20-minute 0 NOUN F
radiofrequency 0 NOUN F
exposure 0 NOUN F
session 0 NOUN F
and 0 CCONJ F
a 0 DET F
20-minute 0 NOUN F
sham 0 ADJ F
session 0 NOUN F
. 0 PUNCT F

The 0 DET T
skin 0 NOUN F
microvessels 0 NOUN F
' 0 PUNCT F
vasodilatory 0 ADJ F
reserve 0 NOUN F
was 0 VERB F
assessed 0 VERB F
with 0 ADP F
a 0 DET F
heat 0 NOUN F
challenge 0 NOUN F
at 0 ADP F
the 0 DET F
end 0 NOUN F
of 0 ADP F
the 0 DET F
protocol 0 NOUN F
. 0 PUNCT F

RESULTS 0 NOUN T
During 0 ADP T
the 0 DET F
radiofrequency 0 NOUN F
exposure 0 NOUN F
session 0 NOUN F
, 0 PUNCT F
SkBF B-PHYSICAL NOUN T
increased 0 VERB F
( 0 PUNCT F
vs. 0 CCONJ F
baseline 0 NOUN F
) 0 PUNCT F
more 0 ADV F
than 0 PUNCT F
during 0 ADP F
the 0 DET F
sham 0 ADJ F
exposure 0 NOUN F
session 0 NOUN F
. 0 PUNCT F

The 0 DET T
sessions 0 NOUN F
did 0 PUNCT F
not 0 ADV F
differ 0 VERB F
significant 0 ADJ F
in 0 ADP F
terms 0 NOUN F
of 0 ADP F
the 0 DET F
Tsk B-OTHER PUNCT T
time-course I-OTHER PUNCT F
response I-OTHER NOUN F
. 0 PUNCT F

The 0 DET T
skin B-PHYSICAL NOUN F
microvessels I-PHYSICAL NOUN F
' 0 PUNCT F
vasodilatory B-PHYSICAL ADJ F
ability B-PHYSICAL NOUN F
was 0 VERB F
found 0 VERB F
to 0 PART F
be 0 PUNCT F
greater 0 PUNCT F
during 0 ADP F
radiofrequency 0 NOUN F
exposure 0 NOUN F
than 0 PUNCT F
during 0 ADP F
sham 0 ADJ F
exposure 0 NOUN F
. 0 PUNCT F

CONCLUSIONS 0 ADP T
Our 0 PUNCT T
results 0 NOUN F
reveal 0 VERB F
the 0 DET F
existence 0 NOUN F
of 0 ADP F
a 0 DET F
specific 0 PUNCT F

Vitamin 0 NOUN T
A 0 DET T
supplementation 0 NOUN F
for 0 ADP F
extremely-low-birth-weight 0 ADJ F
infants 0 NOUN F
. 0 PUNCT F

National 0 ADJ T
Institute 0 NOUN T
of 0 ADP F
Child 0 NOUN T
Health 0 NOUN T
and 0 CCONJ F
Human 0 NOUN T
Development 0 NOUN T
Neonatal 0 ADJ T
Research 0 NOUN T
Network 0 NOUN T
. 0 PUNCT F

BACKGROUND 0 NOUN T
Vitamin 0 NOUN T
A 0 DET T
supplementation 0 NOUN F
may 0 VERB F
reduce 0 VERB F
the 0 DET F
risk 0 NOUN F
of 0 ADP F
chronic 0 ADJ F
lung 0 NOUN F
disease 0 NOUN F
and 0 CCONJ F
sepsis 0 NOUN F
in 0 ADP F
extremely-low-birth-weight 0 ADJ F
infants 0 NOUN F
. 0 PUNCT F

The 0 DET T
results 0 NOUN F
of 0 ADP F
our 0 VERB F
pilot 0 NOUN F
study 0 NOUN F
suggested 0 VERB F
that 0 ADP F
a 0 DET F
dose 0 NOUN F
of 0 ADP F
5000 0 NUM F
IU 0 NOUN T
administered 0 PUNCT F
intramuscularly 0 ADV F
three 0 NUM F
times 0 NOUN F
per 0 ADP F
week 0 NOUN F
for 0 ADP F
four 0 NUM F
weeks 0 NOUN F
was 0 VERB F
more 0 ADV F
effective 0 ADJ F
than 0 CCONJ F
the 0 DET F
lower 0 PUNCT F
doses 0 NOUN F
given 0 VERB F
in 0 ADP F
past 0 ADJ F
trials 0 NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
We 0 PRON T
performed 0 VERB F
a 0 DET F
multicenter 0 NOUN F
, 0 PUNCT F
blinded 0 ADP F
, 0 PUNCT F
randomized 0 VERB F
trial 0 NOUN F
to 0 PART F
assess 0 NOUN F
the 0 DET F
effectiveness 0 NOUN F
and 0 CCONJ F
safety B-OTHER NOUN F
of 0 ADP F
this 0 DET F
regimen 0 NOUN F
as 0 ADP F
compared 0 VERB F
with 0 ADP F
sham 0 ADJ F
treatment 0 NOUN F
in 0 ADP F
807 0 NUM F
infants 0 NOUN F
in 0 ADP F
need 0 NOUN F
of 0 ADP F
respiratory 0 ADJ F
support 0 ADP F
24 0 NUM F
hours 0 NOUN F
after 0 ADP F
birth 0 NOUN F
. 0 PUNCT F

The 0 DET T
mean 0 NOUN F
birth B-PHYSICAL NOUN F
weight I-PHYSICAL NOUN F
was 0 VERB F
770 0 NUM F
g 0 NOUN F
in 0 ADP F
the 0 DET F
vitamin 0 NOUN F
A 0 DET T
group 0 NOUN F
and 0 CCONJ F
769 0 NUM F
g 0 NOUN F
in 0 ADP F
the 0 DET F
control 0 NOUN F
group 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
the 0 DET F
respective 0 ADJ F
gestational 0 ADJ F
ages 0 NOUN F
were 0 VERB F
26.8 0 NUM F
and 0 CCONJ F
26.7 0 NUM F
weeks 0 NOUN F
. 0 PUNCT F

RESULTS 0 NOUN T
By 0 ADP T
36 0 NUM F
weeks 0 NOUN F
' 0 PUNCT F
postmenstrual 0 ADJ F
age 0 NOUN F
, 0 PUNCT F
59 0 NUM F
of 0 ADP F
the 0 DET F
405 0 NUM F
infants 0 NOUN F
( 0 PUNCT F
15 0 NUM F
percent 0 NOUN F
) 0 PUNCT F
in 0 ADP F
the 0 DET F
vitamin 0 NOUN F
A 0 DET T
group 0 NOUN F
and 0 CCONJ F
55 0 NUM F
of 0 ADP F
the 0 DET F
402 0 NUM F
infants 0 NOUN F
( 0 PUNCT F
14 0 NUM F
percent 0 NOUN F
) 0 PUNCT F
in 0 ADP F
the 0 DET F
control 0 NOUN F
group 0 NOUN F
had 0 PUNCT F
died 0 VERB F
. 0 PUNCT F

The 0 DET T
primary 0 ADJ F
outcome 0 NOUN F
- 0 PUNCT F
death B-MORTALITY NOUN F
or I-MORTALITY CCONJ F
chronic I-MORTALITY ADJ F
lung I-MORTALITY NOUN F
disease I-MORTALITY NOUN F
at 0 ADP F
36 0 NUM F
weeks 0 NOUN F
' 0 PUNCT F
postmenstrual 0 ADJ F
age 0 NOUN F
- 0 PUNCT F
occurred 0 PUNCT F
in 0 ADP F
significantly 0 ADV F
fewer 0 PUNCT F
infants 0 NOUN F
in 0 ADP F
the 0 DET F
vitamin 0 NOUN F
A 0 DET T
group 0 NOUN F
than 0 PUNCT F
in 0 ADP F
the 0 DET F
control 0 NOUN F
group 0 NOUN F
( 0 PUNCT F
55 0 NUM F
percent 0 NOUN F
vs. 0 CCONJ F
62 0 NUM F
percent 0 NOUN F
; 0 PUNCT F
relative 0 ADJ F
risk 0 NOUN F
, 0 PUNCT F
0.89 0 NUM F
; 0 PUNCT F
95 0 NUM F
percent 0 NOUN F
confidence 0 NOUN F
interval 0 NOUN F
, 0 PUNCT F
0.80 0 NUM F
to 0 ADP F
0.99 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Overall 0 ADJ T
, 0 PUNCT F
1 0 NUM F
additional 0 ADJ F
infant 0 NOUN F
survived 0 PUNCT F
without 0 ADP F
chronic B-MORTALITY ADJ F
lung I-MORTALITY NOUN F
disease I-MORTALITY NOUN F
for 0 ADP F
every 0 DET F
14 0 NUM F
to 0 ADP F
15 0 NUM F
infants 0 NOUN F
who 0 ADP F
received 0 VERB F
vitamin 0 NOUN F
A 0 DET T
supplements 0 NOUN F
. 0 PUNCT F

The 0 DET T
proportions 0 NOUN F
of 0 ADP F
infants 0 NOUN F
in 0 ADP F
the 0 DET F
vitamin 0 NOUN F
A 0 DET T
group 0 NOUN F
and 0 CCONJ F
the 0 DET F
control 0 NOUN F
group 0 NOUN F
who 0 ADP F
had 0 DET F
signs 0 NOUN F
of 0 ADP F
potential B-PHYSICAL ADJ F
vitamin I-PHYSICAL NOUN F
A I-PHYSICAL DET T
toxicity I-PHYSICAL NOUN F
were 0 VERB F
similar 0 ADJ F
. 0 PUNCT F

The 0 DET T
proportion B-PHYSICAL NOUN F
of I-PHYSICAL ADP F
infants I-PHYSICAL NOUN F
with I-PHYSICAL ADP F
serum 0 NOUN F
retinol 0 NOUN F
values 0 NOUN F
below 0 ADP F
20 0 NUM F
microg 0 NOUN F
per 0 ADP F
deciliter 0 VERB F
( 0 PUNCT F
0.70 0 NUM F
micromol 0 NOUN F
per 0 ADP F
liter 0 ADJ F
) 0 PUNCT F
was 0 VERB F
lower 0 PUNCT F
in 0 ADP F
the 0 DET F
vitamin 0 NOUN F
A 0 DET T
group 0 NOUN F
than 0 PUNCT F
in 0 ADP F
the 0 DET F
control 0 NOUN F
group 0 NOUN F
( 0 PUNCT F
25 0 NUM F
percent 0 NOUN F
vs. 0 CCONJ F
54 0 NUM F
percent 0 NOUN F
, 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.001 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

CONCLUSIONS 0 NOUN T
Intramuscular 0 ADJ T
administration 0 NOUN F
of 0 ADP F
5000 0 NUM F
IU 0 NOUN T
of 0 ADP F
vitamin 0 NOUN F
A 0 CCONJ T
three 0 NUM F
times 0 NOUN F
per 0 ADP F
week 0 NOUN F
for 0 ADP F
four 0 NUM F
weeks 0 NOUN F
reduced 0 ADV F
biochemical 0 ADJ F
evidence 0 NOUN F
of 0 ADP F
vitamin 0 NOUN F
A 0 DET T
deficiency 0 NOUN F
and 0 CCONJ F
slightly 0 ADV F
decreased 0 ADP F
the 0 DET F
risk 0 NOUN F
of 0 ADP F
chronic B-MORTALITY ADJ F
lung I-MORTALITY NOUN F
disease I-MORTALITY NOUN F
in 0 ADP F
extremely-low-birth-weight 0 ADJ F
infants 0 NOUN F
. 0 PUNCT F

Uncomplicated 0 DET T
moderate 0 ADJ F
coronary 0 ADJ F
artery 0 NOUN F
dissections 0 NOUN F
after 0 ADP F
balloon 0 NOUN F
angioplasty 0 NOUN F
: 0 PUNCT F
good 0 ADJ F
outcome 0 NOUN F
without 0 ADP F
stenting 0 VERB F
. 0 PUNCT F

OBJECTIVE 0 NOUN T
To 0 PART T
study 0 NOUN F
the 0 DET F
relation 0 NOUN F
between 0 ADP F
moderate 0 ADJ F
coronary 0 ADJ F
dissections 0 NOUN F
, 0 PUNCT F
coronary 0 ADJ F
flow 0 NOUN F
velocity 0 NOUN F
reserve 0 NOUN F
( 0 PUNCT F
CFVR 0 NOUN T
) 0 PUNCT F
, 0 PUNCT F
and 0 CCONJ F
long 0 ADJ F
term 0 NOUN F
outcome 0 NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
523 0 NUM F
patients 0 NOUN F
undergoing 0 PRON F
balloon 0 NOUN F
angioplasty 0 NOUN F
and 0 CCONJ F
sequential 0 ADJ F
intracoronary 0 ADJ F
Doppler 0 NOUN T
measurements 0 NOUN F
were 0 VERB F
examined 0 VERB F
as 0 ADP F
part 0 NOUN F
of 0 ADP F
the 0 DET F
DEBATE 0 NOUN T
II 0 NUM T
trial 0 NOUN F
( 0 PUNCT F
Doppler 0 NOUN T
endpoints 0 NOUN F
balloon 0 NOUN F
angioplasty 0 NOUN F
trial 0 NOUN F
Europe 0 PUNCT T
) 0 PUNCT F
. 0 PUNCT F

After 0 ADP T
successful 0 ADJ F
balloon 0 NOUN F
angioplasty 0 NOUN F
, 0 PUNCT F
patients 0 NOUN F
were 0 VERB F
randomised 0 VERB F
to 0 ADP F
stenting 0 VERB F
or 0 CCONJ F
no 0 DET F
further 0 ADJ F
treatment 0 NOUN F
. 0 PUNCT F

Dissections 0 NOUN T
were 0 VERB F
graded 0 VERB F
at 0 ADP F
the 0 DET F
core 0 NOUN F
laboratory 0 NOUN F
by 0 ADP F
two 0 NUM F
observers 0 ADJ F
and 0 CCONJ F
divided 0 VERB F
into 0 ADP F
four 0 NUM F
categories 0 NOUN F
: 0 PUNCT F
none 0 NUM F
, 0 PUNCT F
mild 0 ADJ F
( 0 PUNCT F
type 0 NOUN F
A-B 0 NOUN T
) 0 PUNCT F
, 0 PUNCT F
moderate 0 ADJ F
( 0 PUNCT F
type 0 NOUN F
C 0 NUM T
) 0 PUNCT F
, 0 PUNCT F
severe 0 ADJ F
( 0 PUNCT F
types 0 NOUN F
D 0 NOUN T
to 0 ADP F
F 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

Patients 0 NOUN T
with 0 ADP F
severe 0 ADJ F
dissections 0 NOUN F
( 0 PUNCT F
n 0 NOUN F
= 0 SYM F
128 0 NUM F
) 0 PUNCT F
or 0 CCONJ F
without 0 ADP F
available 0 ADJ F
reference 0 NOUN F
vessel 0 NOUN F
CFVR 0 NOUN T
( 0 PUNCT F
n 0 NOUN F
= 0 SYM F
139 0 NUM F
) 0 PUNCT F
were 0 VERB F
excluded 0 VERB F
. 0 PUNCT F

The 0 DET T
remaining 0 VERB F
256 0 NUM F
patients 0 NOUN F
were 0 VERB F
divided 0 VERB F
into 0 ADP F
two 0 NUM F
groups 0 NOUN F
according 0 CCONJ F
to 0 ADP F
the 0 DET F
presence 0 NOUN F
( 0 PUNCT F
group 0 NOUN F
A 0 NOUN T
, 0 PUNCT F
n 0 NOUN F
= 0 SYM F
45 0 NUM F
) 0 PUNCT F
or 0 CCONJ F
absence 0 NOUN F
( 0 PUNCT F
group 0 NOUN F
B 0 NOUN T
, 0 PUNCT F
n 0 NOUN F
= 0 SYM F
211 0 NUM F
) 0 PUNCT F
of 0 ADP F
moderate 0 ADJ F
dissection 0 NOUN F
. 0 PUNCT F

RESULTS 0 NOUN T
Following 0 VERB T
balloon 0 NOUN F
angioplasty 0 NOUN F
, 0 PUNCT F
there 0 PUNCT F
was 0 VERB F
no 0 DET F
difference 0 NOUN F
in 0 ADP F
CFVR B-PHYSICAL NOUN T
between 0 ADP F
the 0 DET F
two 0 NUM F
groups 0 NOUN F
. 0 PUNCT F

At 0 ADP T
12 0 NUM F
months 0 NOUN F
follow 0 VERB F
up 0 ADP F
, 0 PUNCT F
a 0 DET F
higher 0 PUNCT F
rate 0 NOUN F
of 0 ADP F
major B-ADVERSE-EFFECTS ADJ F
adverse I-ADVERSE-EFFECTS ADJ F
cardiac I-ADVERSE-EFFECTS ADJ F
events I-ADVERSE-EFFECTS NOUN F
was 0 VERB F
observed 0 NUM F
overall 0 PUNCT F
in 0 ADP F
group 0 NOUN F
A 0 ADJ T
than 0 PUNCT F
in 0 ADP F
group 0 NOUN F
B 0 NOUN T
( 0 PUNCT F
10 0 NUM F
( 0 PUNCT F
22 0 NUM F
% 0 SYM F
) 0 PUNCT F
v 0 NUM F
23 0 NUM F
( 0 PUNCT F
11 0 NUM F
% 0 SYM F
) 0 PUNCT F
, 0 PUNCT F
p 0 NOUN F
= 0 SYM F
0.041 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

However 0 ADV T
, 0 PUNCT F
the 0 DET F
risk 0 NOUN F
of 0 ADP F
major B-ADVERSE-EFFECTS ADJ F
adverse I-ADVERSE-EFFECTS ADJ F
events I-ADVERSE-EFFECTS NOUN F
was 0 VERB F
similar 0 ADJ F
in 0 ADP F
the 0 DET F
subgroups 0 NOUN F
receiving 0 VERB F
balloon 0 NOUN F
angioplasty 0 NOUN F
( 0 PUNCT F
group 0 NOUN F
A 0 NOUN T
, 0 PUNCT F
6 0 NUM F
( 0 PUNCT F
19 0 NUM F
% 0 SYM F
) 0 PUNCT F
v 0 DET F
group 0 NOUN F
B 0 NOUN T
, 0 PUNCT F
16 0 NUM F
( 0 PUNCT F
16 0 NUM F
% 0 SYM F
) 0 PUNCT F
, 0 PUNCT F
NS 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

Among 0 ADP T
group 0 NOUN F
A 0 DET T
patients 0 NOUN F
, 0 PUNCT F
the 0 DET F
adverse B-ADVERSE-EFFECTS ADJ F
events I-ADVERSE-EFFECTS NOUN F
risk I-ADVERSE-EFFECTS NOUN F
was 0 VERB F
greater 0 PUNCT F
in 0 ADP F
those 0 ADP F
randomised 0 NOUN F
to 0 ADP F
stenting 0 PUNCT F
( 0 PUNCT F
odds 0 NOUN F
ratios 0 NOUN F
6.603 0 NUM F
v 0 NUM F
1.197 0 PUNCT F
, 0 PUNCT F
p 0 NOUN F
= 0 SYM F
0.046 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
whereas 0 CCONJ F
there 0 PUNCT F
was 0 VERB F
no 0 DET F
difference 0 NOUN F
in 0 ADP F
risk 0 NOUN F
if 0 ADP F
the 0 DET F
group 0 NOUN F
was 0 VERB F
analysed 0 VERB F
according 0 PUNCT F
to 0 ADP F
whether 0 PUNCT F
the 0 DET F
CFVR 0 NOUN T
was 0 VERB F
< 0 ADV F
2.5 0 NUM F
or 0 CCONJ F
> 0 NOUN F
/= 0 ADP F
2.5 0 NUM F
after 0 ADP F
balloon 0 NOUN F
angioplasty 0 NOUN F
. 0 PUNCT F

CONCLUSIONS 0 NOUN T
Moderate 0 ADJ T
dissections 0 NOUN F
left 0 PUNCT F
untreated 0 VERB F
result 0 ADJ F
in 0 ADP F
no 0 DET F
increased 0 ADV F
risk 0 NOUN F
of 0 ADP F
major B-ADVERSE-EFFECTS ADJ F
adverse I-ADVERSE-EFFECTS ADJ F
cardiac I-ADVERSE-EFFECTS ADJ F
events I-ADVERSE-EFFECTS NOUN F
. 0 PUNCT F

Additional 0 ADJ T
stenting 0 ADP F
does 0 PUNCT F
not 0 ADV F
improve 0 VERB F
the 0 DET F
long 0 ADJ F
term 0 NOUN F
outcome 0 NOUN F
. 0 PUNCT F

Pharmacokinetics B-OTHER NOUN T
and I-OTHER CCONJ F
relative I-OTHER ADJ F
bioavailability I-OTHER NOUN F
of 0 ADP F
prajmalium 0 NOUN F
bitartrate 0 ADP F
after 0 ADP F
single 0 ADJ F
oral 0 ADJ F
dosing 0 VERB F
. 0 PUNCT F

Pharmacokinetics B-PHYSICAL NOUN T
and 0 CCONJ F
relative B-PHYSICAL ADJ F
bioavailability I-PHYSICAL NOUN F
of 0 ADP F
the 0 DET F
marketed 0 VERB F
prajmalium 0 NOUN F
bitartrate 0 ADP F
tablet 0 NOUN F
( 0 PUNCT F
Neo-Gilurytmal 0 PUNCT T
, 0 PUNCT F
CAS 0 NOUN T
2589-47-1 0 NUM F
) 0 PUNCT F
compared 0 VERB F
to 0 ADP F
an 0 DET F
oral 0 ADJ F
solution 0 NOUN F
were 0 VERB F
investigated 0 VERB F
in 0 ADP F
an 0 DET F
open 0 ADJ F
, 0 PUNCT F
randomized 0 VERB F
, 0 PUNCT F
single-dose 0 NOUN F
two-fold 0 NOUN F
crossover 0 NOUN F
study 0 NOUN F
in 0 ADP F
20 0 NUM F
healthy 0 ADJ F
male 0 NOUN F
volunteers 0 NOUN F
. 0 PUNCT F

One 0 NUM T
subject 0 NOUN F
was 0 VERB F
identified 0 VERB F
to 0 PUNCT F
be 0 PUNCT F
a 0 DET F
poor B-OTHER ADJ F
metabolizer I-OTHER NOUN F
. 0 PUNCT F

In 0 ADP T
the 0 DET F
study 0 ADV F
population 0 NOUN F
with 0 ADP F
normal 0 ADJ F
metabolic 0 ADJ F
status 0 NOUN F
the 0 DET F
two 0 NUM F
oral 0 ADJ F
formulations 0 NOUN F
proved 0 VERB F
to 0 PART F
be 0 PUNCT F
bioequivalent 0 ADJ F
with 0 ADP F
regard 0 NOUN F
to 0 ADP F
the 0 DET F
pharmacokinetic B-PHYSICAL ADJ F
parameters I-PHYSICAL ADJ F
Cmax I-PHYSICAL NOUN T
, 0 PUNCT F
AUC B-PHYSICAL NOUN T
( I-PHYSICAL PUNCT F
0-Tlast I-PHYSICAL NUM F
) I-PHYSICAL PUNCT F
, 0 PUNCT F
AUC B-PHYSICAL NOUN T
( I-PHYSICAL PUNCT F
0-infinity I-PHYSICAL NUM F
) I-PHYSICAL PUNCT F
and 0 CCONJ F
Ae B-PHYSICAL NOUN T
( I-PHYSICAL PUNCT F
24h I-PHYSICAL NOUN F
) I-PHYSICAL PUNCT F
. 0 PUNCT F

tmax B-PHYSICAL ADJ F
was 0 VERB F
prolonged 0 VERB F
after 0 ADP F
administration 0 NOUN F
of 0 ADP F
the 0 DET F
tablets 0 ADV F
. 0 PUNCT F

The 0 DET T
relative B-PHYSICAL ADJ F
bioavailability I-PHYSICAL NOUN F
of 0 ADP F
prajmalium 0 NOUN F
bitartrate 0 ADP F
from 0 ADP F
the 0 DET F
tablet 0 NOUN F
amounted 0 VERB F
to 0 ADP F
112 0 NUM F
% 0 SYM F
. 0 PUNCT F

The 0 DET T
poor 0 ADJ F
metabolizer 0 NOUN F
demonstrated 0 VERB F
in 0 ADP F
both 0 CCONJ F
oral 0 ADJ F
formulations 0 NOUN F
high B-PHYSICAL ADJ F
plasma I-PHYSICAL NOUN F
concentrations I-PHYSICAL NOUN F
, 0 PUNCT F
increased B-PHYSICAL VERB F
AUCs I-PHYSICAL NOUN T
and I-PHYSICAL CCONJ F
prolonged I-PHYSICAL VERB F
terminal I-PHYSICAL ADJ F
half-lives I-PHYSICAL PUNCT F
as I-PHYSICAL PUNCT F
well I-PHYSICAL VERB F
as I-PHYSICAL CCONJ F
increased I-PHYSICAL VERB F
renal I-PHYSICAL ADJ F
excretion I-PHYSICAL NOUN F
of I-PHYSICAL ADP F
prajmalium I-PHYSICAL PUNCT F

Evaluation 0 NOUN T
of 0 ADP F
the 0 DET F
effect 0 NOUN F
of 0 ADP F
acetazolamide 0 NOUN F
on 0 ADP F
cystoid 0 NOUN F
macular 0 ADJ F
oedema 0 NOUN F
in 0 ADP F
patients 0 NOUN F
with 0 ADP F
Behcet 0 PUNCT T
's 0 PUNCT F
disease 0 NOUN F
. 0 PUNCT F

AIM 0 NOUN T
To 0 NOUN T
study 0 NOUN F
the 0 DET F
effect 0 NOUN F
of 0 ADP F
acetazolamide 0 NOUN F
on 0 ADP F
cystoid 0 NOUN F
macular 0 ADJ F
oedema 0 NOUN F
( 0 PUNCT F
CMO 0 NOUN T
) 0 PUNCT F
in 0 ADP F
patients 0 NOUN F
with 0 ADP F
Behcet 0 PUNCT T
's 0 PUNCT F
disease 0 NOUN F
. 0 PUNCT F

PATIENTS 0 NOUN T
AND 0 CCONJ T
METHODS 0 NOUN T
A 0 PUNCT T
total 0 NOUN F
of 0 ADP F
67 0 NUM F
eyes 0 NOUN F
of 0 ADP F
35 0 NUM F
Behcet 0 PUNCT T
's 0 PUNCT F
patients 0 NOUN F
with 0 ADP F
chronic 0 ADJ F
, 0 PUNCT F
but 0 CCONJ F
well-controlled 0 ADJ F
uveitis 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
CMO 0 NOUN T
were 0 VERB F
randomised 0 VERB F
into 0 ADP F
a 0 DET F
double-masked 0 NOUN F
, 0 PUNCT F
crossover 0 ADP F
trial 0 NOUN F
comparing 0 VERB F
the 0 DET F
effect 0 NOUN F
of 0 ADP F
acetazolamide 0 NOUN F
vs 0 CCONJ F
placebo 0 NOUN F
. 0 PUNCT F

The 0 DET T
patients 0 NOUN F
received 0 VERB F
an 0 DET F
initial 0 ADJ F
4-week 0 NOUN F
course 0 NOUN F
of 0 ADP F
either 0 CCONJ F
250 0 NUM F
mg 0 NOUN F
acetazolamide 0 NOUN F
twice 0 ADV F
daily 0 ADJ F
( 0 PUNCT F
b.i.d 0 ADP F
. 0 PUNCT F
) 0 PUNCT F

or 0 CCONJ F
placebo 0 NOUN F
, 0 PUNCT F
followed 0 VERB F
by 0 ADP F
a 0 DET F
4-week 0 NOUN F
washout 0 PUNCT F
period 0 NOUN F
. 0 PUNCT F

They 0 PRON T
then 0 ADV F
received 0 VERB F
a 0 DET F
4-week 0 NOUN F
course 0 NOUN F
of 0 ADP F
the 0 DET F
reverse 0 ADJ F
study 0 NOUN F
medication 0 NOUN F
. 0 PUNCT F

An 0 DET T
improvement 0 NOUN F
in 0 ADP F
visual B-PHYSICAL ADJ F
acuity I-PHYSICAL NOUN F
and 0 CCONJ F
fundus B-PHYSICAL NOUN F
fluorescein I-PHYSICAL NOUN F
angiographic I-PHYSICAL ADJ F
findings I-PHYSICAL NOUN F
was 0 VERB F
assessed 0 VERB F
. 0 PUNCT F

RESULTS 0 NOUN T
In 0 ADP T
total 0 NOUN F
, 0 PUNCT F
29 0 NUM F
patients 0 NOUN F
( 0 PUNCT F
55 0 NUM F
eyes 0 NOUN F
) 0 PUNCT F
completed 0 VERB F
the 0 DET F
trial 0 NOUN F
and 0 CCONJ F
were 0 VERB F
available 0 ADJ F
for 0 ADP F
analysis 0 NOUN F
. 0 PUNCT F

Of 0 ADP T
the 0 DET F
29 0 NUM F
, 0 PUNCT F
16 0 NUM F
men 0 NOUN F
and 0 CCONJ F
13 0 NUM F
were 0 DET F
women 0 NOUN F
. 0 PUNCT F

The 0 DET T
age 0 NOUN F
range 0 NOUN F
was 0 ADV F
13-50 0 NUM F
years 0 NOUN F
( 0 PUNCT F
mean 0 NOUN F
33.6 0 NUM F
years 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

Patients 0 NOUN T
on 0 ADP F
acetazolamide 0 NOUN F
showed 0 VERB F
a 0 DET F
slightly 0 ADV F
better 0 PUNCT F
improvement 0 NOUN F
of 0 ADP F
angiographic B-PHYSICAL ADJ F
signs I-PHYSICAL NOUN F
( 0 PUNCT F
at 0 DET F
least 0 ADV F
by 0 ADP F
one 0 NUM F
grade 0 NOUN F
improvement 0 NOUN F
) 0 PUNCT F
over 0 ADP F
that 0 PUNCT F
of 0 ADP F
placebo 0 NOUN F
( 0 PUNCT F
12 0 NUM F
vs 0 CCONJ F
five 0 NUM F
eyes 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

They 0 PRON T
also 0 ADV F
had 0 PUNCT F
less 0 DET F
deterioration 0 NOUN F
of 0 ADP F
angiographic B-PHYSICAL ADJ F
signs I-PHYSICAL NOUN F
over 0 ADP F
that 0 PUNCT F
of 0 ADP F
placebo 0 NOUN F
( 0 PUNCT F
three 0 NUM F
vs 0 CCONJ F
seven 0 NUM F
eyes 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

However 0 ADV T
, 0 PUNCT F
these 0 DET F
findings 0 NOUN F
were 0 VERB F
not 0 ADV F
statistically 0 ADV F
significant 0 ADJ F
( 0 PUNCT F
P=0.99 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

Acetazolamide 0 NOUN T
had 0 PUNCT F
no 0 DET F
statistically 0 ADV F
significant 0 ADJ F
effect 0 NOUN F
( 0 PUNCT F
P=0.53 0 NOUN T
) 0 PUNCT F
on 0 ADP F
the 0 DET F
improvement 0 NOUN F
of 0 ADP F
visual B-PHYSICAL ADJ F
acuity I-PHYSICAL NOUN F
of 0 ADP F
patients 0 NOUN F
over 0 ADP F
that 0 PUNCT F
of 0 ADP F
placebo 0 NOUN F
( 0 PUNCT F
13 0 NUM F
vs 0 CCONJ F
eight 0 NUM F
eyes 0 NOUN F
) 0 PUNCT F
, 0 PUNCT F
nor 0 CCONJ F
on 0 ADP F
the 0 DET F
deterioration 0 NOUN F
of 0 ADP F
visual B-PHYSICAL ADJ F
acuity I-PHYSICAL NOUN F
( 0 PUNCT F
three 0 NUM F
vs 0 CCONJ F
11 0 NUM F
eyes 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

CONCLUSION 0 NOUN T
Despite 0 ADP T
seemingly 0 ADV F
favourable 0 ADJ F
results 0 NOUN F
, 0 PUNCT F
the 0 DET F
4-week 0 NOUN F
course 0 NOUN F
of 0 ADP F
acetazolamide 0 NOUN F
( 0 PUNCT F
250 0 NUM F
mg 0 NOUN F
b.i.d 0 PUNCT F
. 0 PUNCT F
) 0 PUNCT F

has 0 VERB F
no 0 DET F
statistically 0 ADV F
significant 0 ADJ F
effect 0 NOUN F
on 0 ADP F
the 0 DET F
improvement 0 NOUN F
of 0 ADP F
the 0 DET F
visual B-PHYSICAL ADJ F
acuity I-PHYSICAL NOUN F
and 0 CCONJ F
the 0 DET F
fluorescein B-PHYSICAL NOUN F
angiographic I-PHYSICAL ADJ F
findings I-PHYSICAL NOUN F
in 0 ADP F
Behcet 0 PUNCT T
's 0 PUNCT F
patients 0 NOUN F
with 0 ADP F
CMO 0 NOUN T
. 0 PUNCT F

CDP571 0 NOUN T
, 0 PUNCT F
a 0 DET F
humanized 0 VERB F
monoclonal 0 ADJ F
antibody 0 NOUN F
to 0 ADP F
tumour 0 NOUN F
necrosis 0 NOUN F
factor-alpha 0 NOUN F
, 0 PUNCT F
for 0 ADP F
steroid-dependent 0 ADJ F
Crohn 0 NOUN T
's 0 PUNCT F
disease 0 NOUN F
: 0 PUNCT F
a 0 DET F
randomized 0 VERB F
, 0 PUNCT F
double-blind 0 ADJ F
, 0 PUNCT F
placebo-controlled 0 VERB F
trial 0 NOUN F
. 0 PUNCT F

BACKGROUND 0 NOUN T
More 0 PUNCT T
than 0 PUNCT F
50 0 NUM F
% 0 SYM F
of 0 ADP F
patients 0 NOUN F
with 0 ADP F
Crohn 0 NOUN T
's 0 PUNCT F
disease 0 NOUN F
become 0 ADP F
either 0 PUNCT F
steroid 0 NOUN F
resistant 0 ADJ F
or 0 CCONJ F
dependent 0 ADJ F
. 0 PUNCT F

Accordingly 0 ADV T
, 0 PUNCT F
development 0 NOUN F
of 0 ADP F
new 0 ADJ F
treatments 0 NOUN F
for 0 ADP F
steroid-dependent 0 ADJ F
Crohn 0 NOUN T
's 0 PUNCT F
disease 0 NOUN F
is 0 VERB F
a 0 DET F
research 0 NOUN F
priority 0 NOUN F
. 0 PUNCT F

AIM 0 NOUN T
To 0 ADV T
evaluate 0 NOUN F
CDP571 0 NOUN T
, 0 PUNCT F
a 0 DET F
humanized 0 VERB F
antibody 0 NOUN F
to 0 ADP F
tumour 0 NOUN F
necrosis 0 NOUN F
factor-alpha 0 NOUN F
, 0 PUNCT F
for 0 ADP F
the 0 DET F
treatment 0 NOUN F
of 0 ADP F
steroid-dependent 0 ADJ F
Crohn 0 NOUN T
's 0 PUNCT F
disease 0 NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
Patients 0 NOUN T
with 0 ADP F
steroid-dependent 0 ADJ F
Crohn 0 NOUN T
's 0 PUNCT F
disease 0 NOUN F
( 0 PUNCT F
n 0 NOUN F
= 0 SYM F
271 0 NUM F
) 0 PUNCT F
were 0 VERB F
enrolled 0 VERB F
in 0 ADP F
a 0 DET F
36-week 0 NOUN F
, 0 PUNCT F
double-blind 0 ADJ F
, 0 PUNCT F
placebo-controlled 0 VERB F
trial 0 NOUN F
. 0 PUNCT F

Steroid 0 NOUN T
dependence 0 NOUN F
was 0 VERB F
defined 0 VERB F
as 0 ADP F
use 0 NOUN F
of 0 ADP F
prednisolone 0 NOUN F
or 0 CCONJ F
prednisone 0 NOUN F
( 0 PUNCT F
15-40 0 NUM F
mg/day 0 NOUN F
) 0 PUNCT F
or 0 CCONJ F
budesonide 0 NOUN F
( 0 PUNCT F
9 0 NUM F
mg/day 0 NOUN F
) 0 PUNCT F
for 0 ADP F
> 0 ADJ F
or 0 CCONJ F
=8 0 NUM F
weeks 0 NOUN F
, 0 PUNCT F
a 0 DET F
previous 0 ADJ F
failed 0 VERB F
attempt 0 PUNCT F
to 0 ADP F
decrease 0 ADP F
or 0 CCONJ F
discontinue 0 NOUN F
steroids 0 NOUN F
within 0 ADP F
8 0 NUM F
weeks 0 NOUN F
of 0 ADP F
screening 0 PUNCT F
, 0 PUNCT F
and 0 CCONJ F
a 0 DET F
Crohn 0 NOUN T
's 0 PUNCT F
Disease 0 NOUN T
Activity 0 NOUN T
Index 0 NOUN T
score 0 NOUN F
of 0 ADP F
< 0 SYM F
or 0 CCONJ F
=150 0 PUNCT F
points 0 NOUN F
. 0 PUNCT F

Patients 0 NOUN T
were 0 VERB F
randomized 0 VERB F
to 0 PART F
receive 0 NOUN F
intravenous 0 ADJ F
CDP571 0 NOUN T
10 0 NUM F
mg/kg 0 NOUN F
or 0 CCONJ F
placebo 0 NOUN F
8-weekly 0 ADJ F
through 0 ADP F
to 0 PUNCT F
week 0 NOUN F
32 0 NUM F
. 0 PUNCT F

Steroids 0 NOUN T
were 0 ADJ F
then 0 ADV F
tapered 0 VERB F
using 0 VERB F
a 0 DET F
defined 0 VERB F
schedule 0 NOUN F
. 0 PUNCT F

The 0 DET T
primary 0 ADJ F
efficacy 0 NOUN F
endpoint 0 NOUN F
was 0 VERB F
the 0 DET F
percentage 0 NOUN F
of 0 ADP F
patients B-PHYSICAL NOUN F
with I-PHYSICAL ADP F
steroid I-PHYSICAL NOUN F
sparing I-PHYSICAL PROPN F
, 0 PUNCT F
defined 0 VERB F
as 0 ADP F
discontinuation 0 NOUN F
of 0 ADP F
steroid 0 NOUN F
therapy 0 NOUN F
without 0 ADP F
a 0 DET F
disease 0 NOUN F
flare 0 NOUN F
( 0 PUNCT F
Crohn 0 NOUN T
's 0 PUNCT F
Disease 0 NOUN T
Activity 0 NOUN T
Index 0 NOUN T
score 0 NOUN F
> 0 SYM F
or 0 CCONJ F
=220 0 ADJ F
points 0 ADP F
) 0 PUNCT F
at 0 ADP F
week 0 NOUN F
36 0 NUM F
. 0 PUNCT F

RESULTS 0 NOUN T
Steroid B-PHYSICAL NOUN T
sparing I-PHYSICAL PUNCT F
occurred 0 VERB F
in 0 ADP F
53 0 NUM F
of 0 ADP F
181 0 NUM F
( 0 PUNCT F
29.3 0 NUM F
% 0 SYM F
) 0 PUNCT F
CDP571 0 NOUN T
patients 0 NOUN F
and 0 CCONJ F
33 0 NUM F
of 0 ADP F
90 0 NUM F
( 0 PUNCT F
36.7 0 NUM F
% 0 SYM F
) 0 PUNCT F
placebo 0 NOUN F
patients 0 NOUN F
( 0 PUNCT F
P 0 NOUN T
= 0 SYM F
0.24 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Adverse B-ADVERSE-EFFECTS ADJ T
events I-ADVERSE-EFFECTS NOUN F
occurred 0 VERB F
at 0 ADP F
similar 0 ADJ F
frequencies 0 NOUN F
in 0 ADP F
both 0 CCONJ F
treatment 0 NOUN F
groups 0 NOUN F
. 0 PUNCT F

CONCLUSIONS 0 NOUN T
CDP571 0 NOUN T
was 0 VERB F
ineffective 0 ADJ F
for 0 ADP F
sparing B-ADVERSE-EFFECTS PROPN F
steroids I-ADVERSE-EFFECTS NOUN F
in 0 ADP F
patients 0 NOUN F
with 0 ADP F
steroid-dependent 0 ADJ F
Crohn 0 NOUN T
's 0 PUNCT F
disease 0 NOUN F
. 0 PUNCT F

CDP571 0 NOUN T
was 0 VERB F
well 0 VERB F
tolerated 0 ADP F
. 0 PUNCT F

Letrozole 0 NOUN T
in 0 ADP F
the 0 DET F
neoadjuvant 0 ADJ F
setting 0 VERB F
: 0 PUNCT F
the 0 DET F
P024 0 NOUN T
trial 0 NOUN F
. 0 PUNCT F

Neoadjuvant 0 ADV T
chemotherapy 0 NOUN F
trials 0 NOUN F
have 0 ADP F
consistently 0 ADV F
reported 0 ADP F
lower 0 PUNCT F
response 0 NOUN F
rates B-OTHER NOUN F
in 0 ADP F
hormone 0 NOUN F
receptor-positive 0 ADJ F
( 0 PUNCT F
HR+ 0 NOUN T
) 0 PUNCT F
breast 0 NOUN F
cancer 0 NOUN F
when 0 ADP F
compared 0 VERB F
with 0 ADP F
HR- 0 NOUN T
cases 0 NOUN F
. 0 PUNCT F

Preoperative 0 ADJ T
endocrine 0 ADJ F
therapy 0 NOUN F
has 0 PUNCT F
therefore 0 ADV F
become 0 VERB F
a 0 DET F
logical 0 ADJ F
alternative 0 ADJ F
and 0 CCONJ F
has 0 PUNCT F
gained 0 VERB F
considerable 0 ADJ F
momentum 0 NOUN F
from 0 ADP F
the 0 DET F
finding 0 VERB F
that 0 ADP F
aromatase 0 NOUN F
inhibitors 0 NOUN F
( 0 PUNCT F
AIs 0 PROPN T
) 0 PUNCT F
are 0 VERB F
more 0 ADV F
effective 0 ADJ F
than 0 PUNCT F
tamoxifen 0 NOUN F
for 0 ADP F
HR+ 0 NOUN T
breast 0 NOUN F
cancer 0 NOUN F
in 0 ADP F
both 0 CCONJ F
the 0 DET F
neoadjuvant 0 ADJ F
and 0 CCONJ F
adjuvant 0 NOUN F
settings 0 NOUN F
. 0 PUNCT F

The 0 DET T
most 0 PUNCT F
convincing 0 VERB F
neoadjuvant 0 PUNCT F
trial 0 NOUN F
to 0 PART F
demonstrate 0 ADJ F
the 0 DET F
superiority 0 NOUN F
of 0 ADP F
an 0 DET F
AI 0 NOUN T
versus 0 CCONJ F
tamoxifen 0 NOUN F
was 0 VERB F
the 0 DET F
P024 0 NOUN T
study 0 NOUN F
, 0 PUNCT F
a 0 DET F
large 0 ADJ F
multinational 0 ADJ F
double-blind 0 ADJ F
trial 0 NOUN F
in 0 ADP F
postmenopausal 0 ADJ F
women 0 NOUN F
with 0 ADP F
HR+ 0 NOUN T
breast 0 NOUN F
cancer 0 NOUN F
ineligible 0 ADJ F
for 0 ADP F
breast-conserving 0 PUNCT F
surgery 0 NOUN F
. 0 PUNCT F

The 0 DET T
overall B-OTHER ADJ F
response 0 NOUN F
rate B-OTHER NOUN F
( I-OTHER PUNCT F
ORR I-OTHER NOUN T
) B-OTHER PUNCT F
was 0 VERB F
55 0 NUM F
% 0 SYM F
for 0 ADP F
letrozole 0 NOUN F
and 0 CCONJ F
36 0 NUM F
% 0 SYM F
for 0 ADP F
tamoxifen 0 NOUN F
( 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.001 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Significantly 0 ADV T
more 0 DET F
letrozole-treated 0 ADJ F
patients 0 NOUN F
underwent B-OTHER VERB F
breast-conserving B-OTHER PUNCT F
surgery I-OTHER NOUN F
( 0 PUNCT F
45 0 NUM F
vs. 0 CCONJ F
35 0 NUM F
% 0 SYM F
, 0 PUNCT F
respectively 0 ADV F
; 0 PUNCT F
P=0.022 0 ADP T
) 0 PUNCT F
. 0 PUNCT F

In 0 ADP T
addition 0 NOUN F
, 0 PUNCT F
ORR B-OTHER NOUN T
was 0 VERB F
significantly 0 ADV F
higher 0 PUNCT F
with 0 ADP F
letrozole 0 NOUN F
than 0 PUNCT F
tamoxifen 0 NOUN F
in 0 ADP F
the 0 DET F
human 0 NOUN F
epidermal 0 ADJ F
growth 0 NOUN F
factor 0 NOUN F
receptor 0 NOUN F
HER1/HER2+ 0 NOUN T
subgroup 0 NOUN F
( 0 PUNCT F
P=0.0004 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
clinical B-OTHER ADJ F
efficacy I-OTHER NOUN F
of 0 ADP F
letrozole 0 NOUN F
in 0 ADP F
HER2+ 0 NOUN T
breast 0 NOUN F
cancer 0 NOUN F
was 0 VERB F
confirmed 0 VERB F
by 0 ADP F
fluorescent 0 ADJ F
in 0 PUNCT F
situ 0 ADJ F
hybridization 0 NOUN F
analysis 0 NOUN F
and 0 CCONJ F
was 0 VERB F
found 0 VERB F
to 0 PART F
be 0 PUNCT F
comparable 0 ADJ F
to 0 ADP F
that 0 ADP F
of 0 ADP F
HER2- 0 NOUN T
cases 0 NOUN F
( 0 PUNCT F
ORR 0 NOUN T
71 0 NUM F
% 0 SYM F
in 0 ADP F
both 0 CCONJ F
subsets 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

Biomarker B-OTHER NOUN T
studies I-OTHER NOUN F
confirmed 0 VERB F
the 0 DET F
superiority 0 NOUN F
of 0 ADP F
letrozole 0 NOUN F
in 0 ADP F
centrally 0 ADJ F
assessed 0 ADP F
estrogen 0 NOUN F
receptor-positive 0 ADJ F
( 0 PUNCT F
ER+ 0 NOUN T
) 0 PUNCT F
tumors 0 NOUN F
and 0 CCONJ F
found 0 PROPN F
a 0 DET F
strong 0 ADJ F
relationship 0 NOUN F
with 0 ADP F
the 0 DET F
degree B-OTHER NOUN F
of I-OTHER PUNCT F

Effects 0 NOUN T
of 0 ADP F
a 0 DET F
low-salt 0 NOUN F
diet 0 NOUN F
and 0 CCONJ F
of 0 ADP F
acute 0 ADJ F
salt 0 NOUN F
loading 0 VERB F
on 0 ADP F
blood B-PHYSICAL NOUN F
pressure I-PHYSICAL NOUN F
and 0 CCONJ F
intralymphocytic B-PHYSICAL ADJ F
sodium I-PHYSICAL NOUN F
concentration I-PHYSICAL NOUN F
in 0 ADP F
young 0 ADJ F
subjects 0 NOUN F
with 0 ADP F
borderline 0 NOUN F
hypertension 0 NOUN F
. 0 PUNCT F

1 0 NUM F
. 0 PUNCT F

Three 0 DET T
groups 0 NOUN F
of 0 ADP F
young 0 ADJ F
patients 0 NOUN F
with 0 ADP F
borderline 0 NOUN F
hypertension 0 NOUN F
were 0 VERB F
studied 0 VERB F
for 0 ADP F
a 0 DET F
12 0 NUM F
months 0 NOUN F
period 0 NOUN F
. 0 PUNCT F

The 0 DET T
first 0 PUNCT F
was 0 NOUN F
on 0 ADP F
a 0 DET F
free 0 ADJ F
sodium 0 NOUN F
diet 0 NOUN F
while 0 ADP F
the 0 DET F
second 0 ADJ F
was 0 VERB F
on 0 ADP F
a 0 DET F
low-salt 0 NOUN F
diet 0 NOUN F
. 0 PUNCT F

The 0 DET T
third 0 ADJ F
group 0 NOUN F
of 0 ADP F
patients 0 NOUN F
underwent 0 VERB F
acute 0 ADJ F
salt 0 NOUN F
loading 0 VERB F
. 0 PUNCT F

2 0 NUM F
. 0 PUNCT F

After 0 ADP T
12 0 NUM F
months 0 NOUN F
the 0 DET F
group 0 NOUN F
on 0 ADP F
free 0 ADJ F
diet 0 NOUN F
showed 0 VERB F
a 0 DET F
significant 0 ADJ F
increase 0 NOUN F
of 0 ADP F
intralymphocytic B-PHYSICAL ADJ F
sodium I-PHYSICAL NOUN F
but 0 CCONJ F
no 0 DET F
change 0 NOUN F
in 0 ADP F
blood B-PHYSICAL NOUN F
pressure I-PHYSICAL NOUN F
was 0 VERB F
noted 0 VERB F
. 0 PUNCT F

Five 0 NUM T
patients 0 NOUN F
who 0 ADP F
were 0 VERB F
re-checked 0 VERB F
after 0 ADP F
24 0 NUM F
months 0 NOUN F
also 0 ADV F
had 0 PUNCT F
a 0 DET F
significant 0 ADJ F
increase 0 NOUN F
in 0 ADP F
blood B-PHYSICAL NOUN F
pressure I-PHYSICAL NOUN F
. 0 PUNCT F

3 0 NUM F
. 0 PUNCT F

Patients 0 NOUN T
treated 0 VERB F
with 0 ADP F
a 0 DET F
low-salt 0 NOUN F
diet 0 NOUN F
showed 0 VERB F
a 0 DET F
significant 0 ADJ F
decrease 0 NOUN F
of 0 ADP F
both 0 PUNCT F
intralymphocytic B-PHYSICAL ADJ F
sodium I-PHYSICAL NOUN F
concentration I-PHYSICAL NOUN F
and 0 CCONJ F
blood B-PHYSICAL NOUN F
pressure I-PHYSICAL NOUN F
. 0 PUNCT F

4 0 NUM F
. 0 PUNCT F

After 0 ADP T
acute 0 ADJ F
salt 0 NOUN F
loading 0 VERB F
, 0 PUNCT F
borderline 0 NOUN F
subjects 0 NOUN F
with 0 ADP F
high 0 ADJ F
intralymphocytic 0 ADJ F
sodium 0 NOUN F
showed 0 VERB F
a 0 DET F
significant 0 ADJ F
greater 0 PUNCT F
natriuresis B-PHYSICAL NOUN F
whereas 0 ADP F
intralymphocytic B-PHYSICAL ADJ F
sodium I-PHYSICAL NOUN F
increased 0 VERB F
only 0 ADV F
in 0 ADP F
those 0 PUNCT F
subjects 0 NOUN F
in 0 ADP F
whom 0 ADP F
it 0 PRON F
was 0 VERB F
initially 0 ADV F
normal 0 ADJ F
. 0 PUNCT F

Marginal 0 ADJ T
zone 0 NOUN F
B 0 NOUN T
cell 0 NOUN F
lymphoma 0 NOUN F
of 0 ADP F
the 0 DET F
parotid 0 NOUN F
glands 0 NOUN F
: 0 PUNCT F
results 0 CCONJ F
of 0 ADP F
a 0 DET F
randomised 0 VERB F
trial 0 NOUN F
comparing 0 PUNCT F
radiotherapy 0 NOUN F
to 0 ADP F
combined 0 VERB F
therapy 0 NOUN F
. 0 PUNCT F

39 0 NUM F
patients 0 NOUN F
with 0 ADP F
marginal 0 ADJ F
zone 0 NOUN F
B 0 NOUN T
cell 0 NOUN F
lymphoma 0 NOUN F
( 0 PUNCT F
MZBCL 0 NOUN T
) 0 PUNCT F
of 0 ADP F
the 0 DET F
parotid 0 NOUN F
glands 0 NOUN F
( 0 PUNCT F
stages 0 NOUN F
I 0 NUM T
or 0 CCONJ F
II 0 ADP T
) 0 PUNCT F
were 0 VERB F
studied 0 VERB F
. 0 PUNCT F

They 0 PRON T
were 0 VERB F
randomized 0 VERB F
to 0 PART F
be 0 PUNCT F
treated 0 VERB F
with 0 ADP F
either 0 CCONJ F
radiotherapy 0 NOUN F
alone 0 ADJ F
( 0 PUNCT F
extended 0 ADJ F
fields 0 NOUN F
, 0 PUNCT F
4500 0 NUM F
cGy 0 NOUN F
) 0 PUNCT F
or 0 CCONJ F
radiotherapy 0 NOUN F
( 0 PUNCT F
the 0 DET F
same 0 ADJ F
schedule 0 NOUN F
) 0 PUNCT F
plus 0 CCONJ F
adjuvant 0 NOUN F
chemotherapy 0 NOUN F
( 0 PUNCT F
cyclophosphamide 0 NOUN F
, 0 PUNCT F
vincristine 0 NOUN F
and 0 CCONJ F
prednisone 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
end B-PHYSICAL NOUN F
points I-PHYSICAL NOUN F
were 0 VERB F
survival 0 NOUN F
and 0 CCONJ F
time 0 NOUN F
to 0 ADP F
treatment 0 NOUN F
failure 0 NOUN F
( 0 PUNCT F
TTF 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

Patients 0 NOUN T
who 0 PROPN F
received 0 CCONJ F
radiotherapy 0 NOUN F
alone 0 ADJ F
had 0 PUNCT F
a 0 DET F
complete B-PHYSICAL ADJ F
remission I-PHYSICAL NOUN F
rate I-PHYSICAL NOUN F
of 0 ADP F
100 0 NUM F
% 0 SYM F
, 0 PUNCT F
the 0 DET F
TTF B-OTHER NOUN T
was 0 VERB F
90 0 NUM F
% 0 SYM F
at 0 ADP F
5 0 NUM F
years 0 NOUN F
and 0 CCONJ F
overall B-MORTALITY ADJ F
survival I-MORTALITY NOUN F
at 0 ADP F
5 0 NUM F
years 0 NOUN F
was 0 VERB F
90 0 NUM F
% 0 SYM F
with 0 ADP F
no 0 DET F
statistical 0 ADJ F
difference 0 NOUN F
when 0 ADP F
compared 0 VERB F
with 0 ADP F
patients 0 NOUN F
who 0 ADP F
received 0 VERB F
combined 0 VERB F
therapy 0 NOUN F
[ 0 PUNCT F
100 0 NUM F
, 0 PUNCT F
80 0 NUM F
and 0 CCONJ F
95 0 NUM F
% 0 SYM F
, 0 PUNCT F
respectively 0 ADV F
( 0 PUNCT F
P 0 NOUN T
= 0 SYM F
0.5 0 NUM F
) 0 PUNCT F
] 0 PUNCT F
. 0 PUNCT F

Although 0 ADP T
adjuvant 0 NOUN F
chemotherapy 0 NOUN F
was 0 VERB F
well 0 VERB F
tolerated B-OTHER ADP F
, 0 PUNCT F
the 0 DET F
use 0 NOUN F
of 0 ADP F
this 0 DET F
therapeutic 0 ADJ F
approach 0 NOUN F
in 0 ADP F
patients 0 NOUN F
with 0 ADP F
early 0 ADJ F
stage 0 NOUN F
MZBCL 0 NOUN T
did 0 PUNCT F
not 0 ADV F
offer 0 VERB F
any 0 DET F
advantage 0 NOUN F
over 0 ADP F
radiotherapy 0 NOUN F
alone 0 ADJ F
as 0 ADP F
the 0 DET F
initial 0 ADJ F
treatment 0 NOUN F
. 0 PUNCT F

Until 0 ADP T
now 0 ADV F
, 0 PUNCT F
radiotherapy 0 NOUN F
was 0 VERB F
considered 0 VERB F
the 0 DET F
treatment 0 NOUN F
of 0 ADP F
choice 0 NOUN F
in 0 ADP F
this 0 DET F
clinical 0 ADJ F
setting 0 VERB F
of 0 ADP F
patients 0 NOUN F
. 0 PUNCT F

A 0 DET T
placebo-controlled 0 VERB F
, 0 PUNCT F
fixed-dose 0 NOUN F
study 0 NOUN F
of 0 ADP F
aripiprazole 0 NOUN F
in 0 ADP F
children 0 NOUN F
and 0 CCONJ F
adolescents 0 NOUN F
with 0 ADP F
irritability 0 NOUN F
associated 0 VERB F
with 0 ADP F
autistic 0 ADJ F
disorder 0 NOUN F
. 0 PUNCT F

OBJECTIVE 0 NOUN T
To 0 PROPN T
evaluate 0 NOUN F
the 0 DET F
short-term 0 NOUN F
efficacy 0 NOUN F
and 0 CCONJ F
safety B-OTHER NOUN F
of 0 ADP F
aripiprazole 0 NOUN F
in 0 ADP F
the 0 DET F
treatment 0 NOUN F
of 0 ADP F
irritability 0 NOUN F
in 0 ADP F
children 0 NOUN F
and 0 CCONJ F
adolescents 0 NOUN F
with 0 ADP F
autistic 0 ADJ F
disorder 0 NOUN F
. 0 PUNCT F

METHOD 0 NOUN T
Two 0 NUM T
hundred 0 PUNCT F
eighteen 0 NUM F
children 0 NOUN F
and 0 CCONJ F
adolescents 0 NOUN F
( 0 PUNCT F
aged 0 PROPN F
6-17 0 NUM F
years 0 NOUN F
) 0 PUNCT F
with 0 ADP F
a 0 DET F
diagnosis 0 NOUN F
of 0 ADP F
autistic 0 ADJ F
disorder 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
with 0 ADP F
behaviors 0 NOUN F
such 0 ADP F
as 0 ADP F
tantrums 0 ADP F
, 0 PUNCT F
aggression 0 NOUN F
, 0 PUNCT F
self-injurious 0 ADJ F
behavior 0 NOUN F
, 0 PUNCT F
or 0 CCONJ F
a 0 DET F
combination 0 NOUN F
of 0 ADP F
these 0 PUNCT F
symptoms 0 NOUN F
, 0 PUNCT F
were 0 VERB F
randomized 0 VERB F
1:1:1:1 0 PUNCT F
to 0 ADP F
aripiprazole 0 NOUN F
( 0 PUNCT F
5 0 NUM F
, 0 PUNCT F
10 0 NUM F
, 0 PUNCT F
or 0 CCONJ F
15 0 NUM F
mg/day 0 NOUN F
) 0 PUNCT F
or 0 CCONJ F
placebo 0 NOUN F
in 0 ADP F
this 0 DET F
8-week 0 NOUN F
double-blind 0 ADJ F
, 0 PUNCT F
randomized 0 VERB F
, 0 PUNCT F
placebo-controlled 0 VERB F
, 0 PUNCT F
parallel-group 0 NOUN F
study 0 NOUN F
. 0 PUNCT F

Efficacy 0 NOUN T
was 0 VERB F
evaluated 0 VERB F
using 0 VERB F
the 0 DET F
caregiver-rated 0 VERB F
Aberrant B-MENTAL ADJ T
Behavior I-MENTAL NOUN T
Checklist I-MENTAL NOUN T
Irritability I-MENTAL NOUN T
subscale I-MENTAL NOUN F
( I-MENTAL PUNCT F
primary I-MENTAL ADJ F
efficacy 0 NOUN F
measure B-MENTAL NOUN F
) B-MENTAL PUNCT F
and 0 CCONJ F
the 0 DET F
clinician-rated B-MENTAL VERB F
Clinical B-MENTAL ADJ T
Global B-MENTAL PUNCT T
Impressions-Improvement B-MENTAL PUNCT T
score 0 NOUN F
. 0 PUNCT F

Safety B-OTHER NOUN T
and 0 CCONJ F
tolerability B-OTHER NOUN F
were 0 VERB F
also 0 ADV F
assessed 0 VERB F
. 0 PUNCT F

RESULTS 0 NOUN T
At 0 ADP T
week 0 NOUN F
8 0 NUM F
, 0 PUNCT F
all 0 DET F
aripiprazole 0 NOUN F
doses 0 NOUN F
produced 0 VERB F
significantly 0 ADV F
greater 0 PUNCT F
improvement B-OTHER NOUN F
than 0 PUNCT F
placebo 0 NOUN F
in 0 ADP F
mean 0 NOUN F
Aberrant B-MENTAL ADJ T
Behavior I-MENTAL NOUN T
Checklist B-MENTAL NOUN T
Irritability I-MENTAL NOUN T
subscale B-MENTAL NOUN F
scores 0 NOUN F
( 0 PUNCT F
5 0 NUM F
mg/day 0 NOUN F
, 0 PUNCT F
-12.4 0 NUM F
; 0 PUNCT F
10 0 NUM F
mg/day 0 NOUN F
, 0 PUNCT F
-13.2 0 ADJ F
; 0 PUNCT F
15 0 NUM F
mg/day 0 NOUN F
, 0 PUNCT F
-14.4 0 NUM F
; 0 PUNCT F
versus 0 CCONJ F
placebo 0 NOUN F
, 0 PUNCT F
-8.4 0 ADJ F
; 0 PUNCT F
all 0 DET F
p 0 NOUN F
< 0 SYM F
.05 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

All 0 DET T
aripiprazole 0 NOUN F
doses 0 NOUN F
demonstrated 0 VERB F
significantly 0 ADP F
greater 0 PUNCT F
improvements B-MENTAL NOUN F
in B-MENTAL ADP F
mean 0 NOUN F
Clinical B-MENTAL ADJ T
Global B-MENTAL PUNCT T
Impressions-Improvement B-MENTAL ADJ T
score 0 ADJ F
than 0 PUNCT F
placebo 0 NOUN F
at 0 ADP F
week 0 NOUN F
8 0 NUM F
. 0 PUNCT F

Discontinuation 0 NOUN T
rates 0 NOUN F
due 0 CCONJ F
to 0 ADP F
adverse B-ADVERSE-EFFECTS ADJ F
events I-ADVERSE-EFFECTS NOUN F
were 0 NUM F
as 0 ADP F
follows 0 PUNCT F
: 0 PUNCT F
placebo 0 NOUN F
7.7 0 NUM F
% 0 SYM F
, 0 PUNCT F
aripiprazole 0 NOUN F
5 0 NUM F
mg/day 0 NOUN F
9.4 0 NUM F
% 0 SYM F
, 0 PUNCT F
10 0 NUM F
mg/day 0 NOUN F
13.6 0 NUM F
% 0 SYM F
, 0 PUNCT F
and 0 CCONJ F
15 0 NUM F
mg/day 0 NOUN F
7.4 0 NUM F
% 0 SYM F
. 0 PUNCT F

The 0 DET T
most 0 PUNCT F
common 0 PUNCT F

Haemodynamic 0 ADJ T
profile 0 NOUN F
of 0 ADP F
angiotensin 0 NOUN F
II 0 NUM T
antagonism 0 NOUN F
in 0 ADP F
essential 0 ADJ F
hypertensive 0 ADJ F
patients 0 NOUN F
. 0 PUNCT F

1 0 NUM F
. 0 PUNCT F

The 0 DET T
haemodynamic 0 ADJ F
response 0 NOUN F
to 0 ADP F
antagonistic 0 ADJ F
( 0 PUNCT F
10 0 NUM F
microgram 0 NOUN F
min-1 0 NOUN F
kg-1 0 NOUN F
) 0 PUNCT F
and 0 CCONJ F
agonistic 0 ADJ F
( 0 PUNCT F
40 0 NUM F
microgram 0 NOUN F
min-1 0 NOUN F
kg-1 0 NOUN F
) 0 PUNCT F
doses 0 NOUN F
of 0 ADP F
saralasin 0 NOUN F
was 0 VERB F
studied 0 VERB F
in 0 ADP F
young 0 ADJ F
essential 0 ADJ F
hypertensive 0 ADJ F
patients 0 NOUN F
. 0 PUNCT F

Blood B-PHYSICAL NOUN T
pressure I-PHYSICAL NOUN F
behaviour I-PHYSICAL NOUN F
alone 0 ADJ F
was 0 ADV F
thought 0 VERB F
to 0 PART F
be 0 PUNCT F
inadequate 0 ADJ F
to 0 ADP F
describe 0 ADJ F
the 0 DET F
response 0 NOUN F
pattern 0 NOUN F
. 0 PUNCT F

2 0 NUM F
. 0 PUNCT F

Pre-saralasin 0 NOUN T
setting 0 VERB F
of 0 ADP F
the 0 DET F
renin-angiotensin 0 NOUN F
axis 0 NOUN F
was 0 VERB F
varied 0 VERB F
with 0 ADP F
salt 0 NOUN F
intake 0 NOUN F
( 0 PUNCT F
15 0 NUM F
and 0 CCONJ F
290 0 NUM F
mmol 0 NOUN F
of 0 ADP F
Na+/day 0 PUNCT T
) 0 PUNCT F
each 0 PUNCT F
for 0 ADP F
10 0 NUM F
days 0 NOUN F
. 0 PUNCT F

This 0 DET T
failed 0 VERB F
to 0 PART F
influence 0 ADJ F
blood B-PHYSICAL NOUN F
pressure I-PHYSICAL NOUN F
or 0 CCONJ F
plasma B-PHYSICAL NOUN F
volume I-PHYSICAL NOUN F
. 0 PUNCT F

3 0 NUM F
. 0 PUNCT F

Antagonist 0 NOUN T
blockade 0 NOUN F
after 0 ADP F
low 0 ADJ F
salt 0 NOUN F
lowered 0 PUNCT F
blood B-PHYSICAL NOUN F
pressure I-PHYSICAL NOUN F
in 0 ADP F
three 0 NUM F
patients 0 NOUN F
with 0 ADP F
the 0 DET F
highest 0 PUNCT F
plasma 0 NOUN F
renin 0 NOUN F
values 0 NOUN F
. 0 PUNCT F

Cardiac B-PHYSICAL ADJ T
output I-PHYSICAL NOUN F
rose 0 CCONJ F
in 0 ADP F
two 0 NUM F
of 0 ADP F
these 0 PUNCT F
, 0 PUNCT F
but 0 CCONJ F
it 0 NOUN F
dropped 0 VERB F
in 0 ADP F
all 0 DET F
others 0 NOUN F
. 0 PUNCT F

4 0 NUM F
. 0 PUNCT F

Decreases 0 CCONJ T
in 0 ADP F
cardiac B-PHYSICAL ADJ F
output I-PHYSICAL NOUN F
occurred 0 VERB F
with 0 ADP F
both 0 PUNCT F
doses 0 NOUN F
of 0 ADP F
saralasin 0 NOUN F
and 0 CCONJ F
even 0 ADV F
with 0 ADP F
suppression 0 NOUN F
of 0 ADP F
the 0 DET F
renin-angiotensin 0 NOUN F
axis 0 NOUN F
. 0 PUNCT F

This 0 DET T
response 0 NOUN F
is 0 VERB F
therefore 0 ADV F
unlikely 0 ADV F
to 0 PART F
be 0 PUNCT F
due 0 CCONJ F
to 0 ADP F
removal 0 NOUN F
of 0 ADP F
myocardial B-PHYSICAL ADJ F
or I-PHYSICAL CCONJ F
venous I-PHYSICAL ADJ F
angiotensin I-PHYSICAL NOUN F
effects I-PHYSICAL NOUN F
. 0 PUNCT F

5 0 NUM F
. 0 PUNCT F

The 0 DET T
renin-angiotensin 0 NOUN F
system 0 NOUN F
played 0 VERB F
a 0 DET F
part 0 NOUN F
in 0 ADP F
maintenance 0 NOUN F
of 0 ADP F
blood B-PHYSICAL NOUN F
pressure I-PHYSICAL NOUN F
only 0 ADV F
with 0 ADP F
severe 0 ADJ F
salt 0 NOUN F
restriction 0 NOUN F
and 0 CCONJ F
in 0 ADP F
a 0 DET F
small 0 ADJ F
proportion 0 NOUN F
of 0 ADP F
cases 0 NOUN F
. 0 PUNCT F

6 0 NUM F
. 0 PUNCT F

No 0 DET T
heart B-PHYSICAL NOUN F
rate I-PHYSICAL NOUN F
effect 0 NOUN F
was 0 VERB F
seen 0 VERB F
with 0 ADP F
sarcalasin 0 NOUN F
. 0 PUNCT F

7 0 NUM F
. 0 PUNCT F

Blood B-PHYSICAL NOUN T
pressure I-PHYSICAL NOUN F
and I-PHYSICAL CCONJ F
total 0 ADJ F
peripheral B-PHYSICAL ADJ F
resistance I-PHYSICAL NOUN F
responses B-PHYSICAL NOUN F
were 0 VERB F
dependent 0 ADJ F
on 0 ADP F
pre- 0 ADJ F
( 0 PUNCT F
antagonist/agonist 0 NOUN F
) 0 PUNCT F
setting 0 VERB F
, 0 PUNCT F
but 0 CCONJ F
heart B-PHYSICAL NOUN F
rate I-PHYSICAL NOUN F
and 0 PUNCT F

A 0 DET T
randomized 0 VERB F
trial 0 NOUN F
of 0 ADP F
a 0 DET F
health 0 NOUN F
care 0 NOUN F
program 0 NOUN F
for 0 ADP F
first-time 0 NOUN F
adolescent 0 NOUN F
mothers 0 NOUN F
and 0 CCONJ F
their 0 ADJ F
infants 0 NOUN F
. 0 PUNCT F

To 0 PART T
test 0 VERB F
the 0 DET F
effectiveness 0 NOUN F
of 0 ADP F
a 0 DET F
special 0 ADJ F
health 0 NOUN F
care 0 NOUN F
program 0 NOUN F
for 0 ADP F
adolescent 0 NOUN F
mothers 0 NOUN F
( 0 PUNCT F
17 0 NUM F
years 0 NOUN F
old 0 ADJ F
or 0 CCONJ F
younger 0 PUNCT F
) 0 PUNCT F
and 0 CCONJ F
their 0 ADJ F
infants 0 NOUN F
, 0 PUNCT F
243 0 NUM F
mother-infant 0 NOUN F
pairs 0 NOUN F
were 0 VERB F
randomly 0 ADV F
assigned 0 VERB F
to 0 ADP F
one 0 PUNCT F
of 0 ADP F
two 0 NUM F
groups 0 NOUN F
. 0 PUNCT F

All 0 PUNCT T
of 0 ADP F
the 0 DET F
mothers 0 NOUN F
were 0 VERB F
unwed 0 ADP F
, 0 PUNCT F
on 0 ADP F
Medicaid 0 NOUN T
, 0 PUNCT F
and 0 CCONJ F
black 0 NOUN F
. 0 PUNCT F

The 0 DET T
control 0 NOUN F
group 0 NOUN F
received 0 VERB F
routine 0 ADJ F
well-baby 0 NOUN F
care 0 NOUN F
. 0 PUNCT F

The 0 DET T
experimental 0 ADJ F
group 0 NOUN F
received 0 VERB F
routine 0 ADJ F
care 0 NOUN F
and 0 CCONJ F
services 0 NOUN F
that 0 DET F
included 0 VERB F
rigorous 0 ADJ F
follow-up 0 NOUN F
, 0 PUNCT F
discussions 0 NOUN F
with 0 ADP F
the 0 DET F
mother 0 NOUN F
about 0 ADP F
her 0 ADP F
plans 0 NOUN F
for 0 ADP F
return 0 ADP F
to 0 ADP F
school 0 NOUN F
and 0 CCONJ F
use 0 NOUN F
of 0 ADP F
family 0 NOUN F
planning 0 ADJ F
methods 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
extra 0 ADJ F
health 0 NOUN F
teaching 0 PUNCT F
. 0 PUNCT F

The 0 DET T
dropout 0 ADP F
rate 0 NOUN F
in 0 ADP F
the 0 DET F
experimental 0 ADJ F
group 0 NOUN F
( 0 PUNCT F
60 0 NUM F
% 0 SYM F
) 0 PUNCT F
was 0 VERB F
significantly 0 ADV F
less 0 ADV F
after 0 ADP F
18 0 NUM F
months 0 NOUN F
than 0 VERB F
the 0 DET F
control 0 NOUN F
group 0 NOUN F
( 0 PUNCT F
82 0 NUM F
% 0 SYM F
) 0 PUNCT F
. 0 PUNCT F

In 0 ADP T
spite 0 NOUN F
of 0 ADP F
the 0 DET F
high 0 ADJ F
dropout 0 ADP F
rate 0 NOUN F
, 0 PUNCT F
91 0 NUM F
% 0 SYM F
of 0 ADP F
the 0 DET F
mothers 0 NOUN F
were 0 VERB F
located 0 VERB F
for 0 ADP F
the 0 DET F
18 0 NUM F
month 0 NOUN F
follow-up 0 NOUN F
interview 0 NOUN F
. 0 PUNCT F

The 0 DET T
repeat B-PHYSICAL NOUN F
pregnancy I-PHYSICAL NOUN F
rate I-PHYSICAL NOUN F
in 0 ADP F
the 0 DET F
experimental 0 ADJ F
group 0 NOUN F
was 0 VERB F
12 0 NUM F
% 0 SYM F
after 0 ADP F
18 0 NUM F
months 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
28 0 NUM F
% 0 SYM F
in 0 ADP F
the 0 DET F
control 0 NOUN F
group 0 NOUN F
. 0 PUNCT F

There 0 PUNCT T
was 0 VERB F
no 0 DET F
significant 0 ADJ F
difference 0 NOUN F
in 0 ADP F
the 0 DET F
percentage B-MENTAL NOUN F
returning I-MENTAL ADJ F
to I-MENTAL ADP F
school I-MENTAL NOUN F
. 0 PUNCT F

After 0 ADP T
12 0 NUM F
months 0 NOUN F
, 0 PUNCT F
the 0 DET F
infants 0 NOUN F
in 0 ADP F
the 0 DET F
experimental 0 ADJ F
group 0 NOUN F
were 0 VERB F
more 0 ADV F
likely 0 ADJ F
to 0 PART F
be 0 PUNCT F
fully B-PHYSICAL ADV F
immunized I-PHYSICAL PROPN F
( 0 PUNCT F
33 0 NUM F
% 0 SYM F
) 0 PUNCT F
than 0 PUNCT F
the 0 DET F
infants 0 NOUN F
in 0 ADP F
the 0 DET F
control 0 NOUN F
group 0 NOUN F
( 0 PUNCT F
18 0 NUM F
% 0 SYM F
) 0 PUNCT F
. 0 PUNCT F

Mothers 0 NOUN T
in 0 ADP F
the 0 DET F
special 0 ADJ F
care 0 NOUN F
program 0 NOUN F
who 0 ADP F
continued 0 VERB F
to 0 ADP F
attend 0 PUNCT F
clinic 0 NOUN F
used 0 VERB F
the B-OTHER DET F
emergency I-OTHER NOUN F
room I-OTHER NOUN F
less 0 ADV F
than 0 PUNCT F
the 0 DET F
mothers 0 NOUN F
who 0 ADP F
continued 0 VERB F
to 0 ADP F
attend 0 PUNCT F
in 0 ADP F
the 0 DET F
control 0 NOUN F
group 0 NOUN F
. 0 PUNCT F

These 0 DET T
results 0 CCONJ F
suggest 0 VERB F
that 0 ADP F
a 0 DET F
comprehensive 0 ADJ F
health 0 NOUN F
care 0 NOUN F
program 0 NOUN F
is 0 VERB F
one 0 NUM F
way 0 NOUN F
to 0 ADP F
bring 0 PUNCT F
about 0 PUNCT F
better 0 PUNCT F
outcomes 0 NOUN F
for 0 ADP F
both 0 CCONJ F
adolescent 0 NOUN F
mothers 0 NOUN F
and 0 CCONJ F
their 0 ADJ F
infants 0 NOUN F
. 0 PUNCT F

Hypotensive 0 ADJ T
effects 0 NOUN F
and 0 CCONJ F
influence 0 NOUN F
on 0 ADP F
serum B-PHYSICAL NOUN F
lipids I-PHYSICAL NOUN F
of 0 ADP F
SQ29,852 0 NOUN T
, 0 PUNCT F
a 0 DET F
new 0 ADJ F
angiotensin 0 NOUN F
converting 0 VERB F
enzyme 0 NOUN F
inhibitor 0 NOUN F
, 0 PUNCT F
in 0 ADP F
patients 0 NOUN F
with 0 ADP F
essential 0 ADJ F
hypertension 0 NOUN F
: 0 PUNCT F
a 0 DET F
comparison 0 NOUN F
with 0 ADP F
atenolol 0 NOUN F
. 0 PUNCT F

The 0 DET T
effects 0 NOUN F
of 0 ADP F
SQ29,852 0 NOUN T
( 0 PUNCT F
n 0 NOUN F
= 0 SYM F
24 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
a 0 DET F
new 0 ADJ F
angiotensin 0 NOUN F
converting 0 VERB F
enzyme 0 NOUN F
inhibitor 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
atenolol 0 NOUN F
( 0 PUNCT F
n 0 NOUN F
= 0 SYM F
22 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
monotherapies 0 ADJ F
were 0 VERB F
compared 0 VERB F
in 0 ADP F
46 0 NUM F
patients 0 NOUN F
with 0 ADP F
mild 0 ADJ F
to 0 ADP F
moderate 0 ADJ F
essential 0 ADJ F
hypertension 0 NOUN F
. 0 PUNCT F

Both 0 CCONJ T
SQ29,852 0 NOUN T
( 0 PUNCT F
mean 0 ADP F
dose 0 NOUN F
15.0 0 NUM F
+/- 0 SYM F
5.1 0 NUM F
mg/day 0 NOUN F
) 0 PUNCT F
and 0 CCONJ F
atenolol 0 NOUN F
( 0 PUNCT F
mean 0 ADP F
dose 0 NOUN F
37.5 0 NUM F
+/- 0 SYM F
18.5 0 NUM F
mg/day 0 NOUN F
) 0 PUNCT F
significantly 0 ADV F
decreased 0 VERB F
both 0 CCONJ F
systolic B-PHYSICAL ADJ F
and I-PHYSICAL CCONJ F
diastolic I-PHYSICAL ADJ F
blood I-PHYSICAL NOUN F
pressures I-PHYSICAL NOUN F
. 0 PUNCT F

There 0 PUNCT T
were 0 VERB F
no 0 DET F
significant 0 ADJ F
changes 0 NOUN F
in 0 ADP F
serum B-PHYSICAL NOUN F
lipids I-PHYSICAL NOUN F
, 0 PUNCT F
apolipoproteins B-PHYSICAL NOUN F
, 0 PUNCT F
lipoproteins B-PHYSICAL NOUN F
or 0 CCONJ F
atherosclerotic B-PHYSICAL ADJ F
indices I-PHYSICAL NOUN F
after 0 ADP F
both 0 CCONJ F
SQ29,852 0 NUM T
and 0 CCONJ F
atenolol 0 NOUN F
. 0 PUNCT F

There 0 PUNCT T
were 0 VERB F
also 0 ADV F
no 0 DET F
significant B-OTHER ADJ F
inter-group I-OTHER NOUN F
differences I-OTHER NOUN F
. 0 PUNCT F

There 0 PUNCT T
were 0 VERB F
no 0 DET F
serious B-ADVERSE-EFFECTS ADJ F
side I-ADVERSE-EFFECTS NOUN F
effects I-ADVERSE-EFFECTS NOUN F
or I-ADVERSE-EFFECTS CCONJ F
abnormal I-ADVERSE-EFFECTS ADJ F
laboratory I-ADVERSE-EFFECTS NOUN F
tests I-ADVERSE-EFFECTS NOUN F
in 0 ADP F
both 0 CCONJ F
treatment 0 NOUN F
groups 0 NOUN F
. 0 PUNCT F

It 0 PRON T
is 0 VERB F
concluded 0 VERB F
that 0 ADP F
SQ29,852 0 NOUN T
is 0 VERB F
an 0 DET F
effective 0 ADJ F
antihypertensive 0 ADJ F
drug 0 NOUN F
without 0 ADP F
adverse B-ADVERSE-EFFECTS ADJ F
effect 0 NOUN F
on 0 ADP F
lipid 0 NOUN F
metabolism 0 NOUN F
. 0 PUNCT F

Prediction 0 NOUN T
of 0 ADP F
metabolic 0 ADJ F
and 0 CCONJ F
cardiopulmonary 0 ADJ F
responses 0 NOUN F
to 0 ADP F
maximum 0 NOUN F
cycle 0 NOUN F
ergometry 0 NOUN F
: 0 PUNCT F
a 0 DET F
randomised 0 VERB F
study 0 NOUN F
. 0 PUNCT F

All 0 PUNCT T
of 0 ADP F
the 0 DET F
most 0 PUNCT F
widely-cited 0 VERB F
studies 0 NOUN F
for 0 ADP F
the 0 DET F
prediction 0 NOUN F
of 0 ADP F
maximum B-PHYSICAL NOUN F
exercise I-PHYSICAL NOUN F
responses I-PHYSICAL NOUN F
have 0 PUNCT F
utilized 0 VERB F
either 0 PUNCT F
volunteers 0 NUM F
or 0 CCONJ F
referred 0 ADJ F
subjects 0 NOUN F
. 0 PUNCT F

Therefore 0 ADV T
, 0 PUNCT F
selection 0 NOUN F
bias 0 NOUN F
, 0 PUNCT F
with 0 ADP F
overestimation 0 NOUN F
of 0 ADP F
the 0 DET F
reference 0 NOUN F
values 0 NOUN F
, 0 PUNCT F
is 0 VERB F
a 0 DET F
likely 0 ADJ F
consequence 0 NOUN F
. 0 PUNCT F

In 0 ADP T
order 0 NOUN F
to 0 PART F
establish 0 NOUN F
a 0 DET F
set 0 NOUN F
of 0 ADP F
predictive 0 ADJ F
equations 0 NOUN F
for 0 ADP F
the 0 DET F
gas B-PHYSICAL NOUN F
exchange I-PHYSICAL NOUN F
, 0 PUNCT F
ventilatory B-PHYSICAL ADJ F
and 0 CCONJ F
cardiovascular B-PHYSICAL ADJ F
responses I-PHYSICAL NOUN F
to 0 ADP F
maximum 0 NOUN F
ramp-incremental 0 ADJ F
cycle 0 NOUN F
ergometry 0 NOUN F
, 0 PUNCT F
this 0 DET F
study 0 NOUN F
prospectively 0 ADV F
evaluated 0 ADP F
120 0 NUM F
sedentary 0 ADJ F
individuals 0 NOUN F
( 0 PUNCT F
60 0 ADP F
males 0 PROPN F
, 0 PUNCT F
60 0 NUM F
females 0 NOUN F
, 0 PUNCT F
aged 0 PUNCT F
20-80 0 ADP F
) 0 PUNCT F
, 0 PUNCT F
randomly-selected 0 PUNCT F
from 0 ADP F
> 0 ADP F
8,000 0 NUM F
subjects 0 NOUN F
. 0 PUNCT F

Regular 0 ADJ T
physical B-PHYSICAL ADJ F
activity I-PHYSICAL NOUN F
pattern I-PHYSICAL NOUN F
by I-PHYSICAL ADP F
questionnaire 0 NOUN F
, 0 PUNCT F
body B-PHYSICAL NOUN F
composition I-PHYSICAL NOUN F
by I-PHYSICAL ADP F
anthropometry I-PHYSICAL NOUN F
and I-PHYSICAL CCONJ F
dual I-PHYSICAL ADJ F
energy I-PHYSICAL NOUN F
X-ray I-PHYSICAL NOUN T
absorptiometry I-PHYSICAL NOUN F
( 0 PUNCT F
n B-PHYSICAL NOUN F
= I-PHYSICAL SYM F
75 I-PHYSICAL NUM F
) 0 PUNCT F
and B-PHYSICAL CCONJ F
knee I-PHYSICAL NOUN F
strength I-PHYSICAL NOUN F
by I-PHYSICAL ADP F
isokinetic I-PHYSICAL ADJ F
dynamometry B-PHYSICAL NOUN F
were 0 VERB F
also 0 ADV F
assessed 0 VERB F
. 0 PUNCT F

Previously 0 ADV T
reported 0 VERB F
equations 0 ADP F
typically 0 ADV F
overestimated 0 PUNCT F
the 0 DET F
subjects 0 NOUN F
' 0 PUNCT F
peak 0 ADJ F
oxygen B-PHYSICAL NOUN F
uptake I-PHYSICAL NOUN F
( 0 PUNCT F
p 0 NOUN F
< 0 SYM F
0.05 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Prediction 0 NOUN T
linear 0 ADJ F
equations 0 NOUN F
for 0 ADP F
the 0 DET F
main 0 ADJ F
variables 0 NOUN F
of 0 ADP F
clinical 0 ADJ F
interest 0 NOUN F
were 0 VERB F
established 0 VERB F
by 0 ADP F
backward 0 NOUN F
stepwise 0 ADJ F
regression 0 NOUN F
analysis 0 NOUN F
including 0 ADV F
: 0 PUNCT F
sex 0 NOUN F
, 0 PUNCT F
age 0 NOUN F
, 0 PUNCT F
knee 0 NOUN F
extensor 0 NOUN F
peak 0 ADJ F
torque 0 NOUN F
, 0 PUNCT F
bone-free 0 ADP F
lean 0 ADJ F
leg 0 NOUN F
mass 0 NOUN F
, 0 PUNCT F
total 0 ADJ F
and 0 CCONJ F
lean 0 ADJ F
body 0 NOUN F
mass 0 NOUN F
, 0 PUNCT F
height 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
physical 0 ADJ F
activity 0 NOUN F
scores 0 NOUN F
. 0 PUNCT F

Reference B-PHYSICAL NOUN T
intervals I-PHYSICAL NOUN F
( 0 PUNCT F
95 0 NUM F
% 0 SYM F
confidence 0 ADP F
limits 0 NOUN F
) 0 PUNCT F
were 0 VERB F
calculated 0 VERB F
: 0 PUNCT F
some 0 PUNCT F
of 0 ADP F
these 0 DET F
values 0 NOUN F
differed 0 VERB F
markedly 0 ADV F
from 0 ADP F
those 0 PUNCT F
formerly 0 ADV F
recommended 0 VERB F
. 0 PUNCT F

The 0 DET T
results 0 ADP F
therefore 0 ADV F
might 0 CCONJ F
provide 0 VERB F
a 0 DET F
more 0 ADV F
appropriate 0 ADJ F
frame 0 NOUN F
of 0 ADP F
reference 0 NOUN F
for 0 ADP F
interpretation 0 NOUN F
of 0 ADP F
the 0 PUNCT F

Comparison 0 NOUN T
of 0 ADP F
alfentanil 0 NOUN F
, 0 PUNCT F
fentanyl 0 NOUN F
and 0 CCONJ F
sufentanil 0 NOUN F
for 0 ADP F
total 0 ADJ F
intravenous 0 ADJ F
anaesthesia 0 NOUN F
with 0 ADP F
propofol 0 NOUN F
in 0 ADP F
patients 0 NOUN F
undergoing 0 VERB F
coronary 0 ADJ F
artery 0 NOUN F
bypass 0 NOUN F
surgery 0 NOUN F
. 0 PUNCT F

We 0 PRON T
have 0 VERB F
studied 0 VERB F
the 0 DET F
pharmacokinetics B-PHYSICAL NOUN F
and 0 CCONJ F
pharmacodynamics B-PHYSICAL NOUN F
of 0 ADP F
alfentanil 0 NOUN F
, 0 PUNCT F
fentanyl 0 NOUN F
and 0 CCONJ F
sufentanil 0 NOUN F
together 0 ADV F
with 0 ADP F
propofol 0 NOUN F
in 0 ADP F
patients 0 NOUN F
undergoing 0 VERB F
coronary 0 ADJ F
artery 0 NOUN F
bypass 0 NOUN F
graft 0 NOUN F
surgery 0 NOUN F
( 0 PUNCT F
CABG 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

Sixty 0 NUM T
patients 0 NOUN F
( 0 PUNCT F
age 0 NOUN F
40-73 0 PUNCT F
yr 0 NOUN F
, 0 PUNCT F
56 0 NUM F
male 0 NOUN F
) 0 PUNCT F
were 0 VERB F
assigned 0 VERB F
randomly 0 ADV F
to 0 PART F
receive 0 NOUN F
alfentanil 0 NOUN F
, 0 PUNCT F
fentanyl 0 NOUN F
or 0 CCONJ F
sufentanil 0 NOUN F
and 0 CCONJ F
propofol 0 NOUN F
. 0 PUNCT F

Plasma B-PHYSICAL NOUN T
concentrations I-PHYSICAL NOUN F
of 0 ADP F
these 0 DET F
drugs 0 NOUN F
and 0 CCONJ F
times B-OTHER NOUN F
for I-OTHER ADP F
the I-OTHER DET F
plasma I-OTHER NOUN F
concentration 0 NOUN F
to B-OTHER ADP F
decrease 0 VERB F
by B-OTHER ADP F
50 B-OTHER NUM F
% B-OTHER SYM F
( 0 PUNCT F
t50 0 NOUN F
) 0 PUNCT F
and 0 CCONJ F
80 0 NUM F
% 0 SYM F
( 0 PUNCT F
t80 0 NOUN F
) 0 PUNCT F
after 0 ADP F
cessation 0 NOUN F
of 0 ADP F
the 0 DET F
infusion 0 NOUN F
were 0 VERB F
determined 0 VERB F
. 0 PUNCT F

Times 0 NOUN T
were 0 VERB F
recorded 0 VERB F
to 0 ADP F
awakening 0 VERB F
and 0 CCONJ F
tracheal 0 ADJ F
extubation 0 NOUN F
. 0 PUNCT F

Total 0 ADJ T
dose B-PHYSICAL NOUN F
and 0 CCONJ F
plasma B-PHYSICAL NOUN F
concentrations I-PHYSICAL NOUN F
of 0 ADP F
propofol 0 NOUN F
were 0 VERB F
similar 0 ADJ F
in 0 ADP F
all 0 DET F
groups 0 NOUN F
. 0 PUNCT F

Mean 0 DET T
total 0 ADJ F
doses B-OTHER NOUN F
of 0 ADP F
alfentanil 0 NOUN F
, 0 PUNCT F
fentanyl 0 NOUN F
and 0 CCONJ F
sufentanil 0 NOUN F
were 0 VERB F
443 0 PUNCT F
, 0 PUNCT F
45 0 NUM F
and 0 CCONJ F
4.4 0 NUM F
micrograms 0 NOUN F
kg-1 0 NOUN F
, 0 PUNCT F
respectively 0 ADV F
. 0 PUNCT F

Time B-PHYSICAL NOUN T
to B-PHYSICAL ADP F
awakening B-PHYSICAL PROPN F
did 0 PUNCT F
not 0 ADV F
differ 0 VERB F
significantly 0 ADV F
. 0 PUNCT F

In 0 ADP T
patients 0 NOUN F
receiving 0 VERB F
fentanyl 0 NOUN F
, 0 PUNCT F
the 0 DET F
trachea B-PHYSICAL NOUN F
was 0 VERB F
extubated B-PHYSICAL VERB F
on 0 ADP F
average 0 VERB F
2 0 NUM F
h 0 NOUN F
later 0 ADV F
than 0 PUNCT F
in 0 ADP F
those 0 PUNCT F
receiving 0 SYM F
sufentanil 0 NOUN F
and 0 CCONJ F
3 0 NUM F
h 0 NOUN F
later 0 ADV F
than 0 PUNCT F
in 0 ADP F
those 0 PUNCT F
receiving 0 VERB F
alfentanil 0 NOUN F
( 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.05 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
t80 B-PHYSICAL NOUN F
of 0 ADP F
fentanyl 0 NOUN F
was 0 VERB F
longer 0 PUNCT F
( 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.05 0 NUM F
) 0 PUNCT F
than 0 PUNCT F
that 0 PUNCT F
of 0 ADP F
alfentanil 0 NOUN F
or 0 CCONJ F
sufentanil 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
there 0 PUNCT F
was 0 VERB F
a 0 DET F
linear 0 ADJ F
correlation 0 NOUN F
between 0 ADP F
the 0 DET F
t80 B-PHYSICAL NOUN F
of 0 ADP F
the 0 DET F
opioid 0 NOUN F
and 0 CCONJ F
the 0 DET F
time B-OTHER NOUN F
to I-OTHER ADP F
tracheal I-OTHER ADJ F
extubation B-OTHER NOUN F
( 0 PUNCT F
r 0 NOUN F
= 0 SYM F
0.51 0 NUM F
; 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.01 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

However 0 ADV T
, 0 PUNCT F
the 0 PUNCT F

Famotidine 0 NOUN T
treatment 0 NOUN F
of 0 ADP F
children 0 NOUN F
with 0 ADP F
autistic 0 ADJ F
spectrum 0 NOUN F
disorders 0 NOUN F
: 0 PUNCT F
pilot 0 NOUN F
research 0 NOUN F
using 0 SYM F
single 0 PUNCT F
subject 0 ADJ F
research 0 NOUN F
design 0 NOUN F
. 0 PUNCT F

Using 0 VERB T
single 0 ADJ F
subject 0 ADJ F
research 0 NOUN F
design 0 NOUN F
, 0 PUNCT F
we 0 NOUN F
performed 0 PART F
pilot 0 NOUN F
research 0 NOUN F
to 0 ADJ F
evaluate 0 NOUN F
the 0 DET F
safety 0 NOUN F
and 0 CCONJ F
efficacy 0 NOUN F
of 0 ADP F
famotidine 0 NOUN F
for 0 ADP F
the 0 DET F
treatment 0 NOUN F
of 0 ADP F
children 0 NOUN F
with 0 ADP F
autistic 0 ADJ F
spectrum 0 NOUN F
disorders 0 NOUN F
. 0 PUNCT F

We 0 PRON T
studied 0 VERB F
9 0 NUM F
Caucasian 0 ADJ T
boys 0 NOUN F
, 0 PUNCT F
3.8-8.1 0 NUM F
years 0 NOUN F
old 0 ADJ F
, 0 PUNCT F
with 0 ADP F
a 0 DET F
DSM-IV 0 NOUN T
diagnosis 0 NOUN F
of 0 ADP F
a 0 DET F
pervasive 0 ADJ F
developmental 0 ADJ F
disorder 0 NOUN F
, 0 PUNCT F
living 0 CCONJ F
with 0 ADP F
their 0 ADP F
families 0 NOUN F
, 0 PUNCT F
receiving 0 VERB F
no 0 DET F
chronic 0 ADJ F
medications 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
without 0 ADP F
significant 0 ADJ F
gastrointestinal 0 ADJ F
symptoms 0 NOUN F
. 0 PUNCT F

The 0 DET T
dose 0 NOUN F
of 0 ADP F
oral 0 ADJ F
famotidine 0 NOUN F
was 0 VERB F
2 0 NUM F
mg/kg/day 0 NOUN F
( 0 PUNCT F
given 0 ADP F
in 0 ADP F
two 0 NUM F
divided 0 VERB F
doses 0 NOUN F
) 0 PUNCT F
; 0 PUNCT F
the 0 DET F
maximum 0 NOUN F
total 0 ADJ F
daily 0 ADJ F
dose 0 NOUN F
was 0 VERB F
100 0 PUNCT F
mg 0 NOUN F
. 0 PUNCT F

Using 0 VERB T
single-subject 0 NOUN F
research 0 NOUN F
analysis 0 NOUN F
and 0 CCONJ F
medication 0 NOUN F
given 0 VERB F
in 0 ADP F
a 0 DET F
randomized 0 VERB F
, 0 PUNCT F
double-blind 0 ADJ F
, 0 PUNCT F
placebo-controlled 0 VERB F
, 0 PUNCT F
cross-over 0 NOUN F
design 0 NOUN F
, 0 PUNCT F
4 0 NUM F
of 0 ADP F
9 0 NUM F
children 0 NOUN F
randomized 0 DET F
( 0 PUNCT F
44 0 NUM F
% 0 SYM F
) 0 PUNCT F
had 0 PUNCT F
evidence 0 NOUN F
of 0 ADP F
behavioral B-MENTAL ADJ F
improvement I-MENTAL NOUN F
. 0 PUNCT F

Primary 0 ADJ T
efficacy 0 NOUN F
was 0 VERB F
based 0 VERB F
on 0 ADP F
data 0 NOUN F
kept 0 PUNCT F
by 0 ADP F
primary 0 ADJ F
caregivers 0 NOUN F
, 0 PUNCT F
including 0 VERB F
a 0 DET F
daily 0 ADJ F
diary 0 PUNCT F
; 0 PUNCT F
daily 0 ADJ F
visual 0 ADJ F
analogue 0 NOUN F
scales 0 NOUN F
of 0 ADP F
affection 0 NOUN F
, 0 PUNCT F
reciting 0 PUNCT F
, 0 PUNCT F
or 0 CCONJ F
aspects 0 NOUN F
of 0 ADP F
social 0 ADJ F
interaction 0 NOUN F
; 0 PUNCT F
Aberrant B-PHYSICAL ADJ T
Behavior I-PHYSICAL NOUN T
Checklists I-PHYSICAL NOUN T
( 0 PUNCT F
ABC B-PHYSICAL NOUN T
, 0 PUNCT F
Aman B-PHYSICAL NOUN T
) 0 PUNCT F
; 0 PUNCT F
and 0 PUNCT F

Five-year 0 PUNCT T
outcome 0 NOUN F
of 0 ADP F
surgical 0 ADJ F
treatment 0 NOUN F
of 0 ADP F
migraine B-PAIN NOUN F
headaches I-PAIN PUNCT F
. 0 PUNCT F

BACKGROUND 0 NOUN T
This 0 DET T
study 0 NOUN F
was 0 VERB F
designed 0 VERB F
to 0 PART F
assess 0 NOUN F
the 0 DET F
long-term 0 NOUN F
efficacy 0 NOUN F
of 0 ADP F
surgical 0 ADJ F
deactivation 0 NOUN F
of 0 ADP F
migraine B-PHYSICAL NOUN F
headache I-PHYSICAL PUNCT F
trigger 0 VERB F
sites 0 NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
One 0 NUM T
hundred 0 NUM F
twenty-five 0 PUNCT F
volunteers 0 NOUN F
were 0 VERB F
randomly 0 ADV F
assigned 0 VERB F
to 0 ADP F
the 0 DET F
treatment 0 NOUN F
( 0 PUNCT F
n 0 NOUN F
= 0 SYM F
100 0 NUM F
) 0 PUNCT F
or 0 CCONJ F
control 0 NOUN F
group 0 NOUN F
( 0 PUNCT F
n 0 NOUN F
= 0 SYM F
25 0 NUM F
) 0 PUNCT F
after 0 ADP F
examination 0 NOUN F
by 0 ADP F
the 0 DET F
team 0 ADJ F
neurologist 0 NOUN F
to 0 PART F
ensure 0 NOUN F
a 0 DET F
diagnosis 0 NOUN F
of 0 ADP F
migraine B-PAIN NOUN F
headache I-PAIN NOUN F
. 0 PUNCT F

Patients 0 NOUN T
were 0 VERB F
asked 0 ADV F
to 0 PUNCT F
complete 0 PUNCT F
the 0 DET F
Medical B-PHYSICAL ADJ T
Outcomes I-PHYSICAL NOUN T
Study I-PHYSICAL ADP T
36-Item I-PHYSICAL NOUN F
Short I-PHYSICAL ADJ T
Form I-PHYSICAL NOUN T
Health I-PHYSICAL NOUN T
Survey I-PHYSICAL NOUN T
, 0 PUNCT F
Migraine-Specific B-OTHER ADJ T
Quality I-OTHER NOUN T
of I-OTHER ADP F
Life I-OTHER NOUN T
, 0 PUNCT F
and 0 CCONJ F
Migraine B-PHYSICAL NOUN T
Disability I-PHYSICAL NOUN T
Assessment I-PHYSICAL NOUN T
questionnaires I-PHYSICAL NOUN F
before 0 ADP F
treatment 0 NOUN F
and 0 CCONJ F
at 0 ADP F
12- 0 NUM F
and 0 CCONJ F
60-month 0 NOUN F
postoperative 0 ADJ F
follow-up 0 NOUN F
. 0 PUNCT F

The 0 DET T
treatment 0 NOUN F
group 0 NOUN F
received 0 ADV F
botulinum 0 NOUN F
toxin 0 NOUN F
to 0 PUNCT F
confirm 0 ADJ F
the 0 DET F
trigger 0 VERB F
sites 0 NOUN F
; 0 PUNCT F
controls 0 NOUN F
received 0 ADP F
saline 0 ADJ F
injections 0 NOUN F
. 0 PUNCT F

Treated 0 ADJ T
patients 0 NOUN F
underwent 0 VERB F
surgical 0 ADJ F
deactivation 0 NOUN F
of 0 ADP F
trigger 0 PUNCT F
site 0 NOUN F
( 0 PUNCT F
s 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

Results 0 NOUN T
were 0 VERB F
analyzed 0 VERB F
at 0 ADP F
1 0 NUM F
year 0 NOUN F
( 0 PUNCT F
previously 0 ADJ F
published 0 VERB F
) 0 PUNCT F
and 0 CCONJ F
5 0 NUM F
years 0 NOUN F
postoperatively 0 ADV F
( 0 PUNCT F
the 0 DET F
subject 0 NOUN F
of 0 ADP F
this 0 PUNCT F
report 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

RESULTS 0 ADP T
Eighty-nine 0 NUM T
of 0 ADP F
100 0 NUM F
patients 0 NOUN F
in 0 ADP F
the 0 DET F
treatment 0 NOUN F
group 0 NOUN F
underwent 0 VERB F
surgery 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
79 0 NUM F
were 0 VERB F
followed 0 VERB F
for 0 ADP F
5 0 NUM F
years 0 NOUN F
. 0 PUNCT F

Ten 0 DET T
patients 0 NOUN F
underwent 0 VERB F
deactivation 0 NOUN F
of 0 ADP F
additional 0 ADJ F
( 0 PUNCT F
different 0 ADJ F
) 0 PUNCT F
trigger 0 DET F
sites 0 NOUN F
during 0 ADP F
the 0 DET F
follow-up 0 NOUN F
period 0 NOUN F
and 0 CCONJ F
were 0 VERB F
not 0 ADV F
included 0 VERB F
in 0 ADP F
the 0 DET F
data 0 ADJ F
analysis 0 NOUN F
. 0 PUNCT F

The 0 DET T
final 0 ADJ F
outcome 0 NOUN F
with 0 ADP F
or 0 CCONJ F
without 0 ADP F
inclusion 0 NOUN F
of 0 ADP F
these 0 DET F
10 0 NUM F
patients 0 NOUN F
was 0 VERB F
not 0 ADV F
statistically 0 ADV F
different 0 ADJ F
. 0 PUNCT F

Sixty-one 0 NUM T
( 0 PUNCT F
88 0 NUM F
percent 0 NOUN F
) 0 PUNCT F
of 0 ADP F
69 0 NUM F
patients 0 NOUN F
have 0 CCONJ F
experienced 0 VERB F
a 0 DET F
positive 0 ADJ F
response B-PHYSICAL NOUN F
to 0 ADP F
the 0 DET F
surgery 0 NOUN F
after 0 ADP F
5 0 NUM F
years 0 NOUN F
. 0 PUNCT F

Twenty 0 PUNCT T
( 0 PUNCT F
29 0 NUM F
percent 0 NOUN F
) 0 PUNCT F
reported 0 ADP F
complete B-OTHER ADJ F
elimination 0 NOUN F
of B-OTHER ADP F
migraine I-OTHER NOUN F
headache B-OTHER NOUN F
, 0 PUNCT F
41 0 NUM F
( 0 PUNCT F
59 0 NUM F
percent 0 NOUN F
) 0 PUNCT F
noticed 0 VERB F
a 0 DET F
significant 0 ADJ F
decrease 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
eight 0 NUM F
( 0 PUNCT F
12 0 NUM F
percent 0 NOUN F
) 0 PUNCT F
experienced 0 VERB F
no 0 DET F
significant 0 ADJ F
change 0 NOUN F
. 0 PUNCT F

When 0 ADP T
compared 0 VERB F
with 0 ADP F
the 0 DET F
baseline 0 NOUN F
values 0 NOUN F
, 0 PUNCT F
all 0 DET F
measured 0 PUNCT F
variables 0 NOUN F
at 0 ADP F
60 0 NUM F
months 0 NOUN F
improved 0 VERB F
significantly 0 ADV F
( 0 PUNCT F
p 0 NOUN F
< 0 SYM F
0.0001 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

CONCLUSION 0 NOUN T
Based 0 PUNCT T
on 0 ADP F
the 0 DET F
5-year 0 ADJ F
follow-up 0 NOUN F
data 0 NOUN F
, 0 PUNCT F
there 0 PUNCT F
is 0 VERB F
strong 0 ADJ F
evidence 0 NOUN F
that 0 ADP F
surgical 0 ADJ F
manipulation 0 NOUN F
of 0 ADP F
one 0 NUM F
or 0 CCONJ F
more 0 DET F
migraine 0 NOUN F
trigger 0 VERB F
sites 0 NOUN F
can 0 PRON F
successfully 0 ADV F
eliminate B-OTHER VERB F
or B-OTHER PUNCT F
reduce I-OTHER PUNCT F

Neridronate 0 VERB T
prevents 0 VERB F
bone B-PHYSICAL NOUN F
loss I-PHYSICAL NOUN F
in 0 ADP F
patients 0 NOUN F
receiving 0 VERB F
androgen 0 NOUN F
deprivation 0 NOUN F
therapy 0 NOUN F
for 0 ADP F
prostate 0 NOUN F
cancer 0 NOUN F
. 0 PUNCT F

UNLABELLED 0 NOUN T
Today 0 NOUN T
, 0 PUNCT F
androgen 0 NOUN F
deprivation 0 NOUN F
therapy 0 NOUN F
is 0 VERB F
a 0 DET F
cornerstone 0 NOUN F
of 0 ADP F
treatment 0 NOUN F
for 0 ADP F
advanced 0 VERB F
prostate 0 NOUN F
cancer 0 NOUN F
, 0 PUNCT F
although 0 ADP F
it 0 PRON F
presents 0 NOUN F
important 0 ADJ F
complications 0 NOUN F
such 0 CCONJ F
as 0 ADP F
osteoporosis B-PHYSICAL NOUN F
. 0 PUNCT F

Neridronate 0 ADV T
, 0 PUNCT F
a 0 DET F
relatively 0 ADV F
new 0 ADJ F
bisphosphonate 0 NOUN F
, 0 PUNCT F
is 0 VERB F
able 0 ADJ F
to 0 PART F
prevent 0 NOUN F
bone B-PHYSICAL NOUN F
loss I-PHYSICAL NOUN F
in 0 ADP F
patients 0 NOUN F
with 0 ADP F
prostate 0 NOUN F
cancer 0 NOUN F
during 0 ADP F
androgen 0 NOUN F
ablation 0 NOUN F
. 0 PUNCT F

INTRODUCTION 0 NOUN T
Androgen-deprivation 0 NOUN T
therapy 0 NOUN F
( 0 PUNCT F
ADT 0 NOUN T
) 0 PUNCT F
is 0 VERB F
a 0 DET F
cornerstone 0 NOUN F
of 0 ADP F
treatment 0 NOUN F
for 0 ADP F
advanced 0 VERB F
prostate 0 NOUN F
cancer 0 NOUN F
. 0 PUNCT F

This 0 DET T
therapy 0 NOUN F
has 0 ADP F
iatrogenic 0 ADJ F
complications 0 NOUN F
, 0 PUNCT F
such 0 CCONJ F
as 0 ADP F
osteoporosis 0 NOUN F
. 0 PUNCT F

The 0 DET T
aim 0 NOUN F
of 0 ADP F
our 0 PUNCT F
study 0 NOUN F
was 0 VERB F
to 0 PART F
evaluate 0 NOUN F
the 0 DET F
efficacy 0 NOUN F
of 0 ADP F
neridronate 0 PUNCT F
, 0 PUNCT F
a 0 DET F
relatively 0 ADV F
new 0 ADJ F
bisphosphonate 0 NOUN F
, 0 PUNCT F
to 0 PART F
prevent 0 NOUN F
bone 0 NOUN F
loss 0 NOUN F
during 0 ADP F
androgen 0 NOUN F
ablation 0 NOUN F
. 0 PUNCT F

MATERIALS 0 NOUN T
AND 0 CCONJ T
METHODS 0 NOUN T
Forty-eight 0 PUNCT T
osteoporotic 0 ADJ F
patients 0 NOUN F
with 0 ADP F
prostate 0 NOUN F
cancer 0 NOUN F
, 0 PUNCT F
treated 0 VERB F
with 0 ADP F
3-month 0 NOUN F
depot 0 NOUN F
triptorelina 0 ADJ F
, 0 PUNCT F
were 0 VERB F
enrolled 0 VERB F
and 0 CCONJ F
randomly 0 ADV F
assigned 0 VERB F
to 0 ADP F
two 0 NUM F
different 0 ADJ F
treatment 0 NOUN F
groups 0 NOUN F
: 0 PUNCT F
group 0 NOUN F
A 0 NOUN T
( 0 PUNCT F
n 0 NOUN F
= 0 SYM F
24 0 NUM F
) 0 PUNCT F
was 0 VERB F
treated 0 VERB F
with 0 ADP F
a 0 DET F
daily 0 ADJ F
calcium 0 NOUN F
and 0 CCONJ F
cholecalciferol 0 NOUN F
supplement 0 NOUN F
( 0 PUNCT F
500 0 NUM F
mg 0 NOUN F
of 0 ADP F
elemental 0 ADJ F
calcium 0 NOUN F
and 0 CCONJ F
400 0 NUM F
IU 0 NOUN T
cholecalciferol 0 NOUN F
) 0 PUNCT F
, 0 PUNCT F
and 0 CCONJ F
group 0 NOUN F
B 0 NOUN T
( 0 PUNCT F
n 0 NOUN F
= 0 SYM F
24 0 NUM F
) 0 PUNCT F
received 0 VERB F
in 0 ADP F
addition 0 NOUN F
to 0 ADP F
the 0 DET F
same 0 ADJ F
daily 0 ADJ F
calcium 0 NOUN F
and 0 CCONJ F
cholecalciferol 0 NOUN F
supplement 0 NOUN F
, 0 PUNCT F
25 0 NUM F
mg 0 NOUN F
of 0 ADP F
neridronate 0 VERB F
given 0 VERB F
intramuscularly 0 ADV F
every 0 DET F
month 0 NOUN F
. 0 PUNCT F

All 0 DET T
patients 0 NOUN F
also 0 ADV F
received 0 ADP F
bicalutamide 0 NOUN F
for 0 ADP F
4 0 NUM F
weeks 0 NOUN F
. 0 PUNCT F

Lumbar B-PHYSICAL ADJ T
and I-PHYSICAL CCONJ F
femoral I-PHYSICAL ADJ F
BMD I-PHYSICAL NOUN T
was 0 VERB F
evaluated 0 VERB F
by 0 ADP F
DXA 0 NOUN T
at 0 ADP F
baseline 0 NOUN F
and 0 CCONJ F
after 0 ADP F
1 0 NUM F
year 0 NOUN F
of 0 ADP F
therapy 0 NOUN F
; 0 PUNCT F
moreover 0 ADV F
, 0 PUNCT F
deoxypyridinoline 0 NOUN F
( 0 PUNCT F
DPD 0 NOUN T
) 0 PUNCT F
and 0 CCONJ F
bone 0 NOUN F
alkaline 0 ADJ F
phosphatase 0 NOUN F
( 0 PUNCT F
BALP 0 NOUN T
) 0 PUNCT F
were 0 VERB F
determined 0 VERB F
at 0 ADP F
the 0 DET F
beginning 0 PUNCT F
, 0 PUNCT F
midway 0 NOUN F
through 0 CCONJ F
, 0 PUNCT F
and 0 CCONJ F
at 0 ADP F
the 0 DET F
end 0 NOUN F
of 0 ADP F
the 0 DET F
study 0 NOUN F
. 0 PUNCT F

RESULTS 0 NOUN T
After 0 ADP T
6 0 NUM F
and 0 CCONJ F
12 0 NUM F
months 0 NOUN F
, 0 PUNCT F
whereas 0 ADP F
patients 0 NOUN F
treated 0 PUNCT F
only 0 ADV F
with 0 ADP F
calcium 0 NOUN F
and 0 CCONJ F
cholecalciferol 0 NOUN F
( 0 PUNCT F
group 0 NOUN F
A 0 NOUN T
) 0 PUNCT F
showed 0 VERB F
a 0 DET F
marked B-PHYSICAL VERB F
bone I-PHYSICAL NOUN F
loss I-PHYSICAL NOUN F
, 0 PUNCT F
with 0 ADP F
increased 0 VERB F
levels B-PHYSICAL NOUN F
of I-PHYSICAL ADP F
DPD I-PHYSICAL NOUN T
and I-PHYSICAL CCONJ F
BALP I-PHYSICAL NOUN T
compared 0 VERB F
with 0 ADP F
baseline 0 NOUN F
values 0 NOUN F
, 0 PUNCT F
patients 0 NOUN F
treated 0 VERB F
also 0 ADV F
with 0 ADP F
neridronate 0 VERB F
( 0 PUNCT F
group 0 NOUN F
B 0 NOUN T
) 0 PUNCT F
had 0 PUNCT F
substantially 0 ADV F
unchanged 0 VERB F
levels 0 NOUN F
of 0 ADP F
these 0 DET F
markers 0 NOUN F
. 0 PUNCT F

After 0 ADP T
1 0 NUM F
year 0 NOUN F
of 0 ADP F
treatment 0 NOUN F
, 0 PUNCT F
lumbar B-PHYSICAL ADJ F
and 0 CCONJ F
total 0 ADJ F
hip B-PHYSICAL NOUN F
BMD I-PHYSICAL NOUN T
decreased I-PHYSICAL VERB F
significantly 0 ADV F
in 0 ADP F
patients 0 NOUN F
treated 0 PUNCT F
only 0 ADV F
with 0 ADP F
calcium 0 NOUN F
and 0 CCONJ F
cholecalciferol 0 NOUN F
( 0 PUNCT F
group 0 NOUN F
A 0 NOUN T
) 0 PUNCT F
, 0 PUNCT F
whereas 0 ADP F
it 0 DET F
did 0 VERB F
not 0 ADV F
change B-OTHER VERB F
significantly I-OTHER ADV F
at 0 ADP F
any 0 DET F
skeletal 0 ADJ F
site 0 NOUN F
in 0 ADP F
patients 0 NOUN F
treated 0 VERB F
also 0 ADV F
with 0 ADP F
neridronate 0 VERB F
( 0 PUNCT F
group 0 NOUN F
B 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

No 0 DET T
relevant B-ADVERSE-EFFECTS ADJ F
side I-ADVERSE-EFFECTS NOUN F
effects I-ADVERSE-EFFECTS NOUN F
were 0 VERB F
recorded 0 VERB F
during 0 ADP F
our 0 PUNCT F
study 0 NOUN F
. 0 PUNCT F

CONCLUSIONS 0 NOUN T
Neridronate 0 ADV T
is 0 VERB F
an 0 DET F
effective 0 ADJ F
treatment 0 NOUN F
in 0 ADP F
preventing 0 VERB F
bone B-PHYSICAL NOUN F
loss I-PHYSICAL NOUN F
in 0 ADP F
the 0 DET F
hip 0 NOUN F
and 0 CCONJ F
lumbar 0 ADJ F
spine 0 NOUN F
in 0 ADP F
men 0 NOUN F
receiving 0 VERB F
ADT 0 NOUN T
for 0 ADP F
prostate 0 NOUN F
cancer 0 NOUN F
. 0 PUNCT F

[ 0 PUNCT F
The 0 DET T
effect 0 NOUN F
of 0 ADP F
indobufen 0 NOUN F
on 0 ADP F
aortocoronary 0 ADJ F
bypass 0 NOUN F
patency 0 NOUN F
after 0 ADP F
1 0 NUM F
week 0 NOUN F
and 0 CCONJ F
after 0 ADP F
1 0 NUM F
year 0 NOUN F
] 0 PUNCT F
. 0 PUNCT F

A 0 DET T
randomized 0 VERB F
clinical 0 ADJ F
study 0 NOUN F
was 0 VERB F
conducted 0 VERB F
to 0 PART F
compare 0 NOUN F
the 0 DET F
effect 0 NOUN F
of 0 ADP F
conventional 0 ADJ F
antiaggregation 0 NOUN F
therapy 0 NOUN F
( 0 PUNCT F
ASA 0 NOUN T
plus 0 CCONJ F
dipyridamole 0 NOUN F
) 0 PUNCT F
versus 0 CCONJ F
indobufen 0 NOUN F
in 0 ADP F
patients 0 NOUN F
after 0 ADP F
aortocoronary 0 ADJ F
bypass 0 NOUN F
( 0 PUNCT F
ACB 0 NOUN T
) 0 PUNCT F
surgery 0 NOUN F
. 0 PUNCT F

The 0 DET T
patency 0 NOUN F
of 0 ADP F
venous 0 ADJ F
ACB 0 NOUN T
using 0 SYM F
coronary 0 ADJ F
DSA 0 NOUN T
one 0 NUM F
week 0 NOUN F
and 0 CCONJ F
one 0 NUM F
year 0 NOUN F
after 0 ADP F
surgery 0 NOUN F
was 0 VERB F
evaluated 0 VERB F
in 0 ADP F
52 0 NUM F
patients 0 NOUN F
divided 0 VERB F
into 0 ADP F
two 0 NUM F
groups 0 NOUN F
. 0 PUNCT F

The 0 DET T
study 0 NOUN F
included 0 VERB F
only 0 ADV F
ACB 0 NOUN T
's 0 PUNCT F
with 0 ADP F
intraoperative 0 ADJ F
blood 0 NOUN F
flow 0 NOUN F
rates 0 NOUN F
< 0 SYM F
or 0 CCONJ F
= 0 SYM F
40 0 NUM F
ml/min 0 NOUN F
as 0 ADP F
it 0 PRON F
is 0 VERB F
just 0 ADV F
these 0 DET F
ACB 0 NOUN T
's 0 PUNCT F
which 0 ADP F
are 0 VERB F
at 0 ADP F
the 0 DET F
highest 0 ADV F
risk 0 NOUN F
of 0 ADP F
early 0 PUNCT F
and 0 CCONJ F
late 0 ADJ F
occlusions 0 NOUN F
. 0 PUNCT F

While 0 ADP T
, 0 PUNCT F
in 0 ADP F
the 0 DET F
ASA 0 NOUN T
plus 0 CCONJ F
dipyridamole-treated 0 VERB F
group 0 NOUN F
, 0 PUNCT F
occlusions B-PHYSICAL NOUN F
were 0 VERB F
found 0 VERB F
in 0 ADP F
11 0 NUM F
of 0 ADP F
the 0 DET F
39 0 NUM F
reconstructions 0 NOUN F
( 0 PUNCT F
28.2 0 NUM F
% 0 SYM F
) 0 PUNCT F
, 0 PUNCT F
the 0 DET F
proportion 0 NOUN F
was 0 VERB F
nine 0 NUM F
out 0 PUNCT F
of 0 ADP F
37 0 NUM F
procedures 0 NOUN F
( 0 PUNCT F
24.3 0 NUM F
% 0 SYM F
) 0 PUNCT F
in 0 ADP F
the 0 DET F
indobufen 0 NOUN F
group 0 NOUN F
. 0 PUNCT F

One 0 NUM T
year 0 NOUN F
after 0 ADP F
surgery 0 NOUN F
, 0 PUNCT F
occlusion B-PHYSICAL NOUN F
was 0 VERB F
found 0 VERB F
in 0 ADP F
14 0 NUM F
out 0 PUNCT F
of 0 ADP F
32 0 NUM F
ACB 0 NOUN T
's 0 PUNCT F
( 0 PUNCT F
43.7 0 NUM F
% 0 SYM F
) 0 PUNCT F
in 0 ADP F
the 0 DET F
ASA 0 NOUN T
plus 0 CCONJ F
dipyridamole 0 NOUN F
group 0 NOUN F
compared 0 VERB F
to 0 ADP F
14 0 NUM F
occlusions 0 NOUN F
in 0 ADP F
31 0 NUM F
ACB 0 NOUN T
's 0 PUNCT F
( 0 PUNCT F
45.2 0 NUM F
% 0 SYM F
) 0 PUNCT F
in 0 ADP F
the 0 DET F
indobufen 0 NOUN F
group 0 NOUN F
. 0 PUNCT F

The 0 DET T
difference 0 NOUN F
in 0 ADP F
the 0 DET F
number B-PHYSICAL NOUN F
of I-PHYSICAL ADP F
occlusions I-PHYSICAL NOUN F
between 0 ADP F
the 0 DET F
two 0 NUM F
groups 0 NOUN F
was 0 VERB F
not 0 ADV F
statistically 0 ADV F
significant 0 ADJ F
. 0 PUNCT F

Because 0 PUNCT T
of 0 ADP F
some 0 DET F
benefits 0 NOUN F
of 0 ADP F
indobufen 0 NOUN F
compared 0 VERB F
to 0 ADP F
ASA 0 NOUN T
( 0 PUNCT F
shorter 0 VERB F
time 0 NOUN F
of 0 ADP F
effect 0 NOUN F
, 0 PUNCT F
superior 0 ADJ F
tolerance 0 NOUN F
in 0 ADP F
patients 0 NOUN F
with 0 ADP F
ulceration 0 NOUN F
) 0 PUNCT F
, 0 PUNCT F
the 0 DET F
former 0 ADJ F
drug 0 NOUN F
can 0 VERB F
be 0 VERB F
recommended 0 VERB F
for 0 ADP F
use 0 NOUN F
in 0 ADP F
some 0 DET F
indicated 0 VERB F
cases 0 NOUN F
. 0 PUNCT F

Local B-MENTAL ADJ T
contextual I-MENTAL ADJ F
processing I-MENTAL VERB F
in 0 ADP F
major 0 ADJ F
depressive 0 ADJ F
disorder 0 NOUN F
. 0 PUNCT F

OBJECTIVE 0 NOUN T
The 0 DET T
study 0 NOUN F
investigated 0 DET F
local B-MENTAL ADJ F
contextual I-MENTAL ADJ F
processing I-MENTAL VERB F
in 0 ADP F
patients 0 NOUN F
with 0 ADP F
major 0 ADJ F
depressive 0 ADJ F
disorder 0 NOUN F
( 0 PUNCT F
MDD 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

This 0 DET T
was 0 VERB F
defined 0 VERB F
as 0 ADP F
the 0 DET F
ability 0 NOUN F
to 0 PART F
utilize 0 NOUN F
predictive 0 ADJ F
contextual 0 ADJ F
information 0 NOUN F
to 0 PART F
facilitate 0 NOUN F
detection 0 NOUN F
of 0 ADP F
predictable 0 ADJ F
versus 0 CCONJ F
random 0 ADJ F
targets 0 NOUN F
. 0 PUNCT F

METHOD 0 NOUN T
We 0 PRON T
recorded 0 PROPN F
EEG 0 NOUN T
in 0 ADP F
15 0 NUM F
MDD 0 NOUN T
patients 0 NOUN F
and 0 CCONJ F
14 0 NUM F
age-matched 0 VERB F
controls 0 NOUN F
. 0 PUNCT F

Recording 0 PUNCT T
blocks 0 CCONJ F
consisted 0 DET F
of 0 ADP F
targets 0 NOUN F
preceded 0 VERB F
by 0 ADP F
randomized 0 VERB F
sequences 0 NOUN F
of 0 ADP F
standards 0 NOUN F
and 0 CCONJ F
by 0 ADP F
sequences 0 NOUN F
of 0 ADP F
standards 0 NOUN F
that 0 ADP F
included 0 VERB F
a 0 DET F
predictive 0 ADJ F
sequence 0 NOUN F
signaling 0 VERB F
the 0 DET F
occurrence 0 NOUN F
of 0 ADP F
a 0 DET F
subsequent 0 ADJ F
target 0 NOUN F
event 0 NOUN F
. 0 PUNCT F

RESULTS 0 NOUN T
Both 0 PUNCT T
MDD 0 NOUN T
patients 0 NOUN F
and 0 CCONJ F
age-matched 0 VERB F
controls 0 NOUN F
demonstrated 0 VERB F
a 0 DET F
significant B-PHYSICAL ADJ F
reaction 0 NOUN F
time 0 NOUN F
( 0 PUNCT F
RT 0 NOUN T
) 0 PUNCT F
and 0 CCONJ F
P3b B-MENTAL NOUN T
latency I-MENTAL NOUN F
differences B-PHYSICAL NOUN F
between 0 ADP F
predicted 0 ADP F
and 0 CCONJ F
random 0 ADJ F
targets 0 NOUN F
. 0 PUNCT F

However 0 ADV T
, 0 PUNCT F
patients 0 NOUN F
demonstrated 0 VERB F
a 0 DET F
specific B-PHYSICAL ADJ F
prolongation B-MENTAL NOUN F
of 0 ADP F
these 0 DET F
measures 0 NOUN F
during 0 ADP F
processing 0 VERB F
of 0 ADP F
predicted 0 VERB F
targets 0 NOUN F
, 0 PUNCT F
as 0 PUNCT F
well 0 PUNCT F
as 0 CCONJ F
an 0 DET F
attenuation 0 NOUN F
of 0 ADP F
P3b B-MENTAL NOUN T
amplitudes I-MENTAL NOUN F
for 0 ADP F
the 0 DET F
predictive 0 ADJ F
sequence 0 NOUN F
. 0 PUNCT F

In 0 ADP T
addition 0 NOUN F
, 0 PUNCT F
patients 0 NOUN F
target 0 NOUN F
N1 B-MENTAL NOUN T
amplitudes I-MENTAL NOUN F
were 0 VERB F
attenuated B-PHYSICAL VERB F
compared 0 VERB F
with 0 ADP F
controls 0 NOUN F
. 0 PUNCT F

CONCLUSION 0 NOUN T
MDD 0 NOUN T
patients 0 NOUN F
were 0 VERB F
able 0 ADJ F
to 0 PART F
utilize B-MENTAL NOUN F
predictive I-MENTAL ADJ F
context I-MENTAL NOUN F
in 0 ADP F
order 0 NOUN F
to 0 PART F
facilitate 0 NOUN F
processing 0 VERB F
of 0 ADP F
deterministic 0 ADJ F
targets 0 NOUN F
, 0 PUNCT F
however 0 ADV F
, 0 PUNCT F
this 0 DET F
ability B-PHYSICAL NOUN F
was 0 VERB F
limited B-ADVERSE-EFFECTS ADP F
compared 0 VERB F
to 0 ADP F
controls 0 NOUN F
, 0 PUNCT F
as 0 PUNCT F
demonstrated 0 VERB F
by 0 ADP F
context-dependent 0 PUNCT F
P3b 0 NOUN T
deficits 0 NOUN F
. 0 PUNCT F

SIGNIFICANCE 0 NOUN T
These 0 DET T
findings 0 NOUN F
suggest 0 VERB F
that 0 ADP F
patients 0 NOUN F
with 0 ADP F
major 0 ADJ F
depression 0 NOUN F
have 0 CCONJ F
altered B-MENTAL VERB F
processing I-MENTAL VERB F
of I-MENTAL ADP F
local I-MENTAL ADJ F
contextual I-MENTAL ADJ F
processing I-MENTAL VERB F
. 0 PUNCT F

Low 0 ADJ T
intensity 0 NOUN F
physical 0 ADJ F
training 0 VERB F
in 0 ADP F
older 0 PUNCT F
subjects 0 NOUN F
. 0 PUNCT F

BACKGROUND 0 NOUN T
This 0 DET T
study 0 NOUN F
was 0 VERB F
designed 0 VERB F
to 0 PART F
evaluate 0 NOUN F
the 0 DET F
effects 0 NOUN F
of 0 ADP F
a 0 DET F
low 0 ADJ F
intensity 0 NOUN F
general 0 ADJ F
training 0 ADJ F
program 0 NOUN F
( 0 PUNCT F
< 0 PROPN F
50 0 NUM F
% 0 SYM F
of 0 ADP F
heart 0 NOUN F
rate 0 NOUN F
reserve 0 NOUN F
) 0 PUNCT F
on 0 ADP F
physical 0 ADJ F
fitness 0 NOUN F
of 0 ADP F
healthy 0 ADJ F
older 0 PUNCT F
subjects 0 NOUN F
, 0 PUNCT F
by 0 ADP F
comparing 0 DET F
maximal 0 ADJ F
and 0 CCONJ F
submaximal 0 ADJ F
indices 0 NOUN F
of 0 ADP F
training 0 NUM F
response 0 NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
Twenty-two 0 NUM T
volunteers 0 NOUN F
over 0 ADP F
60 0 NUM F
years 0 NOUN F
of 0 ADP F
age 0 NOUN F
participated 0 PUNCT F
in 0 ADP F
the 0 DET F
present 0 ADJ F
study 0 NOUN F
. 0 PUNCT F

The 0 DET T
sample 0 NOUN F
was 0 VERB F
randomly 0 ADV F
divided 0 VERB F
in 0 ADP F
an 0 DET F
experimental 0 ADJ F
group 0 NOUN F
of 0 ADP F
13 0 NUM F
older 0 PUNCT F
subjects 0 NOUN F
( 0 PUNCT F
3 0 NUM F
men 0 NOUN F
and 0 CCONJ F
10 0 NUM F
women 0 NOUN F
, 0 PUNCT F
mean 0 NOUN F
age 0 NOUN F
63.5 0 NUM F
+/- 0 SYM F
3 0 NUM F
years 0 NOUN F
) 0 PUNCT F
while 0 ADP F
the 0 DET F
remaining 0 VERB F
9 0 NUM F
subjects 0 NOUN F
( 0 PUNCT F
3 0 NUM F
men 0 NOUN F
and 0 CCONJ F
6 0 NUM F
women 0 NOUN F
, 0 PUNCT F
mean 0 NOUN F
age 0 NOUN F
64.2 0 NUM F
+/- 0 SYM F
4 0 NUM F
years 0 NOUN F
) 0 PUNCT F
served 0 VERB F
as 0 ADP F
inactive 0 ADJ F
control 0 NOUN F
group 0 NOUN F
. 0 PUNCT F

After 0 ADP T
medical 0 ADJ F
screening 0 PUNCT F
all 0 DET F
participants 0 NOUN F
were 0 VERB F
evaluated 0 VERB F
before 0 ADP F
and 0 CCONJ F
after 0 ADP F
12 0 NUM F
weeks 0 NOUN F
in 0 ADP F
which 0 ADP F
the 0 DET F
experimental 0 ADJ F
subjects 0 NOUN F
underwent 0 VERB F
a 0 DET F
low 0 ADJ F
intensity 0 NOUN F
training 0 VERB F
. 0 PUNCT F

Each 0 DET T
subjects-either 0 PUNCT F
inactive 0 ADJ F
or 0 CCONJ F
active-performed 0 NOUN F
two 0 NUM F
treadmill 0 NOUN F
tests 0 CCONJ F
at 0 ADP F
two-days 0 NOUN F
interval 0 NOUN F
, 0 PUNCT F
to 0 PART F
measure 0 VERB F
maximal 0 ADJ F
and 0 CCONJ F
submaximal 0 ADJ F
responses 0 NOUN F
to 0 ADP F
exercise 0 NOUN F
, 0 PUNCT F
respectively 0 ADV F
. 0 PUNCT F

Heart 0 NOUN T
rate 0 NOUN F
( 0 PUNCT F
HR 0 NOUN T
) 0 PUNCT F
, 0 PUNCT F
oxygen B-PHYSICAL NOUN F
uptake I-PHYSICAL NOUN F
( I-PHYSICAL PUNCT F
VO2 I-PHYSICAL NOUN T
) I-PHYSICAL PUNCT F
and 0 CCONJ F
pulmonary B-PHYSICAL ADJ F
ventilation I-PHYSICAL NOUN F
( I-PHYSICAL PUNCT F
VE I-PHYSICAL NOUN T
) I-PHYSICAL PUNCT F
were 0 VERB F
measured 0 VERB F
using 0 VERB F
a 0 DET F
telemetric 0 ADJ F
apparatus 0 NOUN F
. 0 PUNCT F

RESULTS 0 PUNCT T
The 0 DET T
major 0 ADJ F
finding 0 NOUN F
of 0 ADP F
the 0 DET F
study 0 NOUN F
was 0 ADV F
the 0 DET F
significant 0 ADJ F
improvement 0 NOUN F
in 0 ADP F
submaximal B-PHYSICAL ADJ F
response 0 NOUN F
to B-PHYSICAL ADP F
exercise I-PHYSICAL NOUN F
of I-PHYSICAL ADP F
experimental I-PHYSICAL ADJ F
subjects B-PHYSICAL NOUN F
, 0 PUNCT F
expressed 0 VERB F
by 0 ADP F
the 0 DET F
reduction 0 NOUN F
in 0 ADP F
HR B-PHYSICAL NOUN T
, 0 PUNCT F
VO2 B-PHYSICAL NOUN T
VE 0 NOUN T
while 0 ADP F
VO2 B-PHYSICAL ADP T
max 0 NOUN F
did 0 VERB F
not 0 ADV F
change 0 NUM F
. 0 PUNCT F

CONCLUSIONS 0 NOUN T
Thus 0 ADV T
, 0 PUNCT F
it 0 PRON F
appears 0 NOUN F
that 0 ADP F
a 0 DET F
low 0 ADJ F
intensity 0 NOUN F
general 0 ADJ F
training 0 SYM F
similar 0 ADJ F
to 0 ADP F
that 0 ADP F
followed 0 VERB F
in 0 ADP F
the 0 DET F
present 0 ADJ F
study 0 NOUN F
may 0 VERB F
represent 0 VERB F
a 0 DET F
good 0 ADJ F
means 0 NOUN F
to 0 PART F
improve 0 PUNCT F
physical B-PHYSICAL ADJ F
fitness I-PHYSICAL PUNCT F
in 0 ADP F
healthy 0 ADJ F
elderly 0 ADJ F
people 0 NOUN F
. 0 PUNCT F

Similarly 0 ADV T
, 0 PUNCT F
this 0 DET F
study 0 NOUN F
supports 0 NOUN F
the 0 DET F
effectiveness 0 NOUN F
of 0 ADP F
evaluation 0 NOUN F
tests 0 NOUN F
based 0 VERB F
on 0 PUNCT F

Virtual 0 ADJ T
patients 0 NOUN F
design 0 NOUN F
and 0 CCONJ F
its 0 PUNCT F
effect 0 NOUN F
on 0 ADP F
clinical B-MENTAL ADJ F
reasoning I-MENTAL VERB F
and 0 CCONJ F
student B-OTHER VERB F
experience I-OTHER NOUN F
: 0 PUNCT F
a 0 DET F
protocol 0 NOUN F
for 0 ADP F
a 0 DET F
randomised 0 VERB F
factorial 0 ADP F
multi-centre 0 NOUN F
study 0 NOUN F
. 0 PUNCT F

BACKGROUND 0 NOUN T
Virtual 0 ADJ T
Patients 0 NOUN T
( 0 PUNCT F
VPs 0 NOUN T
) 0 PUNCT F
are 0 VERB F
web-based 0 VERB F
representations 0 NOUN F
of 0 ADP F
realistic 0 ADJ F
clinical 0 ADJ F
cases 0 NOUN F
. 0 PUNCT F

They 0 PRON T
are 0 VERB F
proposed 0 VERB F
as 0 VERB F
being 0 ADV F
an 0 DET F
optimal 0 ADJ F
method 0 NOUN F
for 0 ADP F
teaching 0 PUNCT F
clinical 0 ADJ F
reasoning 0 ADJ F
skills 0 NOUN F
. 0 PUNCT F

International 0 ADJ T
standards 0 NOUN F
exist 0 ADP F
which 0 ADP F
define 0 VERB F
precisely 0 NOUN F
what 0 PUNCT F
constitutes 0 VERB F
a 0 DET F
VP 0 NOUN T
. 0 PUNCT F

There 0 PUNCT T
are 0 VERB F
multiple 0 ADJ F
design 0 NOUN F
possibilities 0 ADJ F
for 0 ADP F
VPs 0 NOUN T
, 0 PUNCT F
however 0 ADV F
there 0 PUNCT F
is 0 VERB F
little 0 DET F
formal 0 ADJ F
evidence 0 NOUN F
to 0 PART F
support 0 ADJ F
individual 0 PUNCT F
design 0 NOUN F
features 0 NOUN F
. 0 PUNCT F

The 0 DET T
purpose 0 NOUN F
of 0 ADP F
this 0 DET F
trial 0 NOUN F
is 0 VERB F
to 0 PART F
explore 0 VERB F
the 0 DET F
effect 0 NOUN F
of 0 ADP F
two 0 NUM F
different 0 ADJ F
potentially 0 ADV F
important 0 ADJ F
design 0 NOUN F
features 0 NOUN F
on 0 ADP F
clinical B-MENTAL ADJ F
reasoning I-MENTAL ADJ F
skills I-MENTAL NOUN F
and 0 CCONJ F
the 0 DET F
student B-OTHER ADJ F
experience I-OTHER NOUN F
. 0 PUNCT F

These 0 PUNCT T
are 0 ADJ F
the 0 DET F
branching 0 VERB F
case 0 NOUN F
pathways 0 NOUN F
( 0 PUNCT F
present 0 ADJ F
or 0 CCONJ F
absent 0 ADJ F
) 0 PUNCT F
and 0 CCONJ F
structured 0 VERB F
clinical 0 ADJ F
reasoning 0 ADJ F
feedback 0 NOUN F
( 0 PUNCT F
present 0 ADJ F
or 0 CCONJ F
absent 0 ADJ F
) 0 PUNCT F
. 0 PUNCT F

METHODS/DESIGN 0 PUNCT T
This 0 PUNCT T
is 0 VERB F
a 0 DET F
multi-centre 0 NOUN F
randomised 0 VERB F
2 0 NUM F
x 0 SYM F
2 0 NUM F
factorial 0 ADJ F
design 0 NOUN F
study 0 NOUN F
evaluating 0 ADP F
two 0 NUM F
independent 0 ADJ F
variables 0 NOUN F
of 0 ADP F
VP 0 NOUN T
design 0 NOUN F
, 0 PUNCT F
branching 0 ADP F
( 0 PUNCT F
present 0 ADJ F
or 0 CCONJ F
absent 0 ADJ F
) 0 PUNCT F
, 0 PUNCT F
and 0 CCONJ F
structured 0 VERB F
clinical 0 ADJ F
reasoning 0 ADJ F
feedback 0 NOUN F
( 0 PUNCT F
present 0 ADJ F
or 0 CCONJ F
absent 0 ADJ F
) 0 PUNCT F
.The 0 PUNCT F
study 0 NOUN F
will 0 VERB F
be 0 DET F
carried 0 VERB F
out 0 ADP F
in 0 ADP F
medical 0 ADJ F
student 0 ADJ F
volunteers 0 NOUN F
in 0 ADP F
one 0 NUM F
year 0 NOUN F
group 0 NOUN F
from 0 ADP F
three 0 NUM F
university 0 NOUN F
medical 0 ADJ F
schools 0 NOUN F
in 0 ADP F
the 0 DET F
United 0 VERB T
Kingdom 0 NOUN T
, 0 PUNCT F
Warwick 0 NOUN T
, 0 PUNCT F
Keele 0 ADP T
and 0 CCONJ F
Birmingham 0 PUNCT T
. 0 PUNCT F

There 0 PUNCT T
are 0 VERB F
four 0 NUM F
core 0 NOUN F
musculoskeletal 0 ADJ F
topics 0 NOUN F
. 0 PUNCT F

Each 0 DET T
case 0 NOUN F
can 0 VERB F
be 0 VERB F
designed 0 VERB F
in 0 ADP F
four 0 NUM F
different 0 ADJ F
ways 0 NOUN F
, 0 PUNCT F
equating 0 CCONJ F
to 0 ADP F
16 0 NUM F
VPs 0 PUNCT T
required 0 VERB F
for 0 ADP F
the 0 DET F
research 0 NOUN F
. 0 PUNCT F

Students 0 NOUN T
will 0 ADP F
be 0 VERB F
randomised 0 VERB F
to 0 ADP F
four 0 NUM F
groups 0 NOUN F
, 0 PUNCT F
completing 0 ADV F
the 0 DET F
four 0 ADV F
VP 0 NOUN T
topics 0 NOUN F
in 0 ADP F
the 0 DET F
same 0 ADJ F
order 0 NOUN F
, 0 PUNCT F
but 0 CCONJ F
with 0 ADP F
each 0 DET F
group 0 NOUN F
exposed 0 VERB F
to 0 ADP F
a 0 DET F
different 0 ADJ F
VP 0 NOUN T
design 0 NOUN F
sequentially 0 ADV F
. 0 PUNCT F

All 0 DET T
students 0 NOUN F
will 0 VERB F
be 0 VERB F
exposed 0 VERB F
to 0 ADP F
the 0 DET F
four 0 NUM F
designs 0 NOUN F
. 0 PUNCT F

Primary 0 ADJ T
outcomes 0 NOUN F
are 0 NOUN F
performance 0 NOUN F
for 0 ADP F
each 0 DET F
case B-MENTAL NOUN F
design I-MENTAL NOUN F
in I-MENTAL ADP F
a I-MENTAL DET F
standardized I-MENTAL VERB F
fifteen I-MENTAL PUNCT F
item I-MENTAL NOUN F
clinical I-MENTAL ADJ F
reasoning I-MENTAL ADJ F
assessment I-MENTAL NOUN F
, 0 PUNCT F
integrated 0 VERB F
into 0 ADP F
each 0 PUNCT F
VP 0 NOUN T
, 0 PUNCT F
which 0 ADP F
is 0 VERB F
identical 0 ADJ F
for 0 ADP F
each 0 DET F
topic 0 NOUN F
. 0 PUNCT F

Additionally 0 ADV T
a 0 DET F
15-item B-OTHER NOUN F
self-reported I-OTHER VERB F
evaluation I-OTHER NOUN F
is 0 VERB F
completed 0 VERB F
for 0 ADP F
each 0 DET F
VP 0 NOUN T
, 0 PUNCT F
based 0 VERB F
on 0 ADP F
a 0 DET F
widely 0 ADV F
used 0 PUNCT F
EViP 0 NOUN T
tool 0 NOUN F
. 0 PUNCT F

Student 0 ADJ T
patterns 0 NOUN F
of 0 ADP F
use 0 NOUN F
of 0 ADP F
the 0 DET F
VPs 0 NOUN T
will 0 NOUN F
be 0 VERB F
recorded.In 0 ADP F
one 0 NUM F
centre 0 NOUN F
, 0 PUNCT F
formative 0 ADJ F
clinical 0 ADJ F
and 0 CCONJ F
examination 0 NOUN F
performance 0 NOUN F
will 0 VERB F
be 0 VERB F
recorded 0 VERB F
, 0 PUNCT F
along 0 PUNCT F
with 0 ADP F
a 0 ADP F
self 0 PUNCT F
reported 0 VERB F
pre 0 NOUN F
and 0 CCONJ F
post-intervention 0 NOUN F
reasoning 0 PUNCT F
score 0 NOUN F
, 0 PUNCT F
the 0 DET F
DTI 0 NOUN T
. 0 PUNCT F

Our 0 ADJ T
power 0 NOUN F
calculations 0 NOUN F
indicate 0 VERB F
a 0 DET F
sample 0 NOUN F
size 0 NOUN F
of 0 ADP F
112 0 NUM F
is 0 VERB F
required 0 VERB F
for 0 ADP F
both 0 CCONJ F
primary 0 ADJ F
outcomes 0 NOUN F
. 0 PUNCT F

DISCUSSION 0 NOUN T
This 0 DET T
trial 0 NOUN F
will 0 NOUN F
provide 0 VERB F
robust 0 ADJ F
evidence 0 NOUN F
to 0 PART F
support 0 NOUN F
the 0 DET F
effectiveness 0 NOUN F
of 0 ADP F
different 0 ADJ F
designs 0 NOUN F
of 0 ADP F
virtual 0 ADJ F
patients 0 NOUN F
, 0 PUNCT F
based 0 VERB F
on 0 ADP F
student B-MENTAL ADJ F
performance I-MENTAL NOUN F
and 0 CCONJ F
evaluation B-OTHER NOUN F
. 0 PUNCT F

The 0 DET T
cases 0 NOUN F
and 0 CCONJ F
all 0 DET F
learning 0 VERB F
materials 0 NOUN F
will 0 VERB F
be 0 PUNCT F
open 0 ADJ F
access 0 NOUN F
and 0 CCONJ F
available 0 ADJ F
on 0 ADP F
a 0 DET F
Creative 0 ADJ T
Commons 0 NOUN T
Attribution-Share-Alike 0 VERB T
license 0 NOUN F
. 0 PUNCT F

Chronic 0 ADJ T
fatigue 0 NOUN F
syndrome 0 NOUN F
versus 0 CCONJ F
neuroendocrineimmune 0 ADJ F
dysfunction 0 NOUN F
syndrome 0 NOUN F
: 0 PUNCT F
differential 0 ADJ F
attributions 0 NOUN F
. 0 PUNCT F

Since 0 ADP T
1988 0 NUM F
, 0 PUNCT F
when 0 ADP F
the 0 DET F
term 0 NOUN F
chronic 0 ADJ F
fatigue 0 NOUN F
syndrome 0 NOUN F
( 0 PUNCT F
CFS 0 NOUN T
) 0 PUNCT F
was 0 VERB F
coined 0 VERB F
, 0 PUNCT F
considerable 0 ADJ F
discussion 0 NOUN F
has 0 PUNCT F
occurred 0 VERB F
about 0 PUNCT F
stigma 0 NOUN F
associated 0 VERB F
with 0 ADP F
this 0 DET F
diagnostic 0 ADJ F
term 0 NOUN F
. 0 PUNCT F

In 0 ADP T
particular 0 NOUN F
, 0 PUNCT F
patients 0 NOUN F
with 0 ADP F
CFS 0 NOUN T
have 0 PUNCT F
felt 0 PUNCT F
that 0 ADP F
this 0 DET F
term 0 NOUN F
trivializes 0 NOUN F
the 0 DET F
serious 0 ADJ F
nature 0 NOUN F
of 0 ADP F
this 0 PUNCT F
disorder 0 NOUN F
. 0 PUNCT F

A 0 DET T
Name 0 PUNCT T
Change 0 NOUN T
Work 0 NOUN T
group 0 NOUN F
, 0 PUNCT F
appointed 0 VERB F
by 0 ADP F
the 0 DET F
CFS 0 NOUN T
Coordinating 0 VERB T
Committee 0 NOUN T
, 0 PUNCT F
developed 0 VERB F
an 0 DET F
umbrella 0 CCONJ F
term 0 NOUN F
: 0 PUNCT F
chronic 0 ADJ F
neuroendocrineimmune 0 CCONJ F
dysfunction 0 NOUN F
syndrome 0 NOUN F
( 0 PUNCT F
CNDS 0 NOUN T
) 0 PUNCT F
, 0 PUNCT F
and 0 CCONJ F
proposed 0 VERB F
that 0 ADP F
there 0 PUNCT F
would 0 VERB F
be 0 ADP F
sub-types 0 DET F
under 0 ADP F
this 0 PUNCT F
term 0 NOUN F
, 0 PUNCT F
one 0 NUM F
being 0 PART F
CFS 0 NOUN T
. 0 PUNCT F

The 0 DET T
present 0 ADJ F
study 0 NOUN F
examined 0 VERB F
attributions B-OTHER NOUN F
of 0 ADP F
this 0 DET F
new 0 ADJ F
umbrella 0 NOUN F
term 0 NOUN F
when 0 ADP F
compared 0 VERB F
with 0 ADP F
CFS 0 NOUN T
. 0 PUNCT F

Nurses 0 NOUN T
and 0 CCONJ F
physician 0 NOUN F
assistants 0 NOUN F
( 0 PUNCT F
PAs 0 PUNCT T
) 0 PUNCT F
were 0 VERB F
presented 0 VERB F
a 0 DET F
case 0 NOUN F
study 0 NOUN F
of 0 ADP F
a 0 DET F
patient 0 NOUN F
with 0 ADP F
symptoms 0 NOUN F
of 0 ADP F
CFS 0 NOUN T
. 0 PUNCT F

They 0 PRON T
were 0 VERB F
told 0 ADJ F
that 0 PUNCT F
the 0 DET F
patient 0 NOUN F
had 0 PUNCT F
either 0 CCONJ F
chronic 0 ADJ F
fatigue 0 NOUN F
syndrome 0 NOUN F
, 0 PUNCT F
chronic 0 ADJ F
neuroendocrineimmune 0 CCONJ F
dysfunction 0 NOUN F
syndrome 0 NOUN F
, 0 PUNCT F
or 0 CCONJ F
chronic 0 ADJ F
neuroendocrineimmune 0 CCONJ F
dysfunction 0 NOUN F
syndrome 0 NOUN F
, 0 PUNCT F
which 0 ADP F
had 0 PUNCT F
formerly 0 ADV F
been 0 PUNCT F
called 0 VERB F
chronic 0 ADJ F
fatigue 0 NOUN F
syndrome 0 NOUN F
. 0 PUNCT F

The 0 DET T
different 0 ADJ F
terms 0 NOUN F
led 0 VERB F
to 0 ADP F
different 0 ADJ F
attributions 0 NOUN F
, 0 PUNCT F
with 0 ADP F
PA 0 NOUN T
respondents 0 ADJ F
rating 0 VERB F
the 0 DET F
CNDS 0 NOUN T
label 0 NOUN F
as 0 PUNCT F
more 0 VERB F
severe 0 ADJ F
. 0 PUNCT F

Results 0 CCONJ T
suggest 0 VERB F
that 0 ADP F
a 0 DET F
more 0 PUNCT F
medical B-OTHER ADJ F
sounding I-OTHER ADJ F
term I-OTHER NOUN F
( 0 PUNCT F
CNDS 0 NOUN T
) 0 PUNCT F
may 0 VERB F
lead 0 VERB F
to 0 ADP F
attributions B-OTHER NOUN F
that 0 ADP F
this 0 DET F
syndrome 0 NOUN F
is 0 VERB F
a 0 DET F
more 0 ADV F
serious 0 ADJ F
, 0 PUNCT F
disabling 0 ADP F
illness 0 NOUN F
. 0 PUNCT F

The 0 DET T
policy 0 NOUN F
implications 0 NOUN F
of 0 ADP F
these 0 DET F
findings 0 NOUN F
are 0 VERB F
discussed 0 VERB F
. 0 PUNCT F

Detection 0 NOUN T
of 0 ADP F
traumatic 0 ADJ F
arthrotomy 0 NOUN F
of 0 ADP F
the 0 DET F
knee 0 NOUN F
using 0 VERB F
the 0 DET F
saline 0 ADJ F
solution 0 NOUN F
load 0 ADP F
test 0 NOUN F
. 0 PUNCT F

BACKGROUND 0 NOUN T
The 0 DET T
saline 0 ADJ F
solution 0 NOUN F
load 0 ADP F
test 0 ADV F
helps 0 PUNCT F
to 0 CCONJ F
determine 0 VERB F
if 0 PUNCT F
a 0 DET F
wound 0 NOUN F
extends 0 NOUN F
into 0 ADP F
the 0 DET F
knee 0 NOUN F
joint 0 NOUN F
. 0 PUNCT F

Little 0 PUNCT T
is 0 VERB F
known 0 VERB F
about 0 ADP F
the 0 DET F
volume 0 NOUN F
of 0 ADP F
injected 0 PUNCT F
intra-articular 0 ADJ F
saline 0 ADJ F
solution 0 NOUN F
that 0 ADP F
is 0 VERB F
needed 0 VERB F
to 0 ADP F
effectively 0 ADJ F
rule 0 NOUN F
in 0 ADP F
or 0 CCONJ F
rule 0 NOUN F
out 0 ADP F
a 0 DET F
traumatic 0 ADJ F
arthrotomy 0 NOUN F
of 0 ADP F
the 0 DET F
knee 0 NOUN F
. 0 PUNCT F

The 0 DET T
purpose 0 NOUN F
of 0 ADP F
the 0 DET F
present 0 ADJ F
study 0 NOUN F
was 0 VERB F
to 0 PART F
determine 0 NOUN F
the 0 DET F
appropriate B-OTHER PUNCT F
volume I-OTHER NOUN F
and 0 CCONJ F
needle B-OTHER NOUN F
location I-OTHER NOUN F
for 0 ADP F
the 0 DET F
diagnosis 0 NOUN F
of 0 ADP F
a 0 DET F
traumatic 0 ADJ F
knee 0 NOUN F
arthrotomy 0 NOUN F
and 0 CCONJ F
to 0 PART F
assess 0 NOUN F
the 0 DET F
effect 0 NOUN F
of 0 ADP F
associated 0 VERB F
variables 0 NOUN F
, 0 PUNCT F
including 0 CCONJ F
knee 0 NOUN F
circumference 0 NOUN F
, 0 PUNCT F
body 0 NOUN F
mass 0 NOUN F
index 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
sex 0 NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
Fifty-six 0 ADJ T
consecutive 0 ADJ F
patients 0 NOUN F
scheduled 0 VERB F
for 0 ADP F
knee 0 NOUN F
arthroscopy 0 NOUN F
were 0 VERB F
enrolled 0 VERB F
. 0 PUNCT F

A 0 DET T
standard 0 ADJ F
inferolateral 0 ADJ F
arthroscopic 0 ADJ F
portal 0 NOUN F
was 0 VERB F
made 0 VERB F
with 0 ADP F
a 0 DET F
single 0 ADJ F
stab 0 NOUN F
incision 0 NOUN F
with 0 ADP F
use 0 NOUN F
of 0 ADP F
a 0 DET F
number-11 0 NOUN F
blade 0 NOUN F
. 0 PUNCT F

Injection 0 NOUN T
sites 0 NOUN F
were 0 VERB F
randomized 0 VERB F
to 0 ADP F
either 0 CCONJ F
a 0 DET F
superomedial 0 ADJ F
or 0 CCONJ F
inferomedial 0 ADJ F
location 0 NOUN F
. 0 PUNCT F

The 0 DET T
injection 0 NOUN F
of 0 ADP F
normal 0 ADJ F
saline 0 ADJ F
solution 0 NOUN F
at 0 ADP F
a 0 DET F
rate 0 NOUN F
of 0 ADP F
5 0 NUM F
mL/sec 0 NOUN F
through 0 ADP F
an 0 DET F
18-gauge 0 NOUN F
needle 0 NOUN F
was 0 VERB F
continued 0 PUNCT F
while 0 ADP F
the 0 DET F
knee 0 NOUN F
was 0 VERB F
moved 0 VERB F
through 0 ADP F
a 0 DET F
range 0 NOUN F
of 0 ADP F
motion 0 NOUN F
until 0 ADP F
fluid 0 NOUN F
extravasated 0 VERB F
from 0 ADP F
the 0 DET F
iatrogenic 0 ADJ F
laceration 0 NOUN F
. 0 PUNCT F

The 0 DET T
volume 0 NOUN F
of 0 ADP F
injected 0 ADJ F
fluid 0 NOUN F
was 0 VERB F
recorded 0 VERB F
. 0 PUNCT F

RESULTS 0 PUNCT T
The 0 DET T
study 0 ADJ F
group 0 NOUN F
included 0 VERB F
thirty-one 0 NUM F
female 0 NOUN F
patients 0 NOUN F
and 0 CCONJ F
twenty-five 0 ADJ F
male 0 NOUN F
patients 0 NOUN F
with 0 ADP F
a 0 DET F
combined 0 VERB F
average 0 ADP F
age 0 NOUN F
of 0 ADP F
fifty 0 NUM F
years 0 NOUN F
and 0 CCONJ F
an 0 DET F
average 0 PUNCT F
body B-PHYSICAL NOUN F
mass I-PHYSICAL NOUN F
index I-PHYSICAL NOUN F
of 0 ADP F
30.9 0 NUM F
. 0 PUNCT F

In 0 ADP T
order 0 NOUN F
to 0 ADP F
effectively 0 ADV F
diagnose B-OTHER PUNCT F
50 I-OTHER NUM F
% I-OTHER SYM F
of I-OTHER ADP F
the I-OTHER DET F
arthrotomies I-OTHER NOUN F
, 0 PUNCT F
75 0 NUM F
mL 0 NOUN F
of 0 ADP F
injected 0 VERB F
fluid 0 NOUN F
was 0 VERB F
needed 0 VERB F
; 0 PUNCT F
the 0 DET F
volumes 0 NOUN F
that 0 DET F
were B-OTHER VERB F
needed I-OTHER VERB F
in I-OTHER ADP F
order I-OTHER NOUN F
to I-OTHER ADP F
effectively I-OTHER ADV F
diagnose I-OTHER PUNCT F
75 0 NUM F
% 0 SYM F
, 0 PUNCT F
90 0 NUM F
% 0 SYM F
, 0 PUNCT F
95 0 NUM F
% 0 SYM F
, 0 PUNCT F
and 0 CCONJ F
99 0 NUM F
% 0 SYM F
of 0 ADP F
the 0 DET F
arthrotomies 0 NOUN F
were 0 VERB F
110 0 PUNCT F
, 0 PUNCT F
145 0 NUM F
, 0 PUNCT F
155 0 NUM F
, 0 PUNCT F
and 0 CCONJ F
175 0 NUM F
mL 0 NOUN F
, 0 PUNCT F
respectively 0 ADV F
. 0 PUNCT F

The 0 DET T
mean 0 NOUN F
volumes B-PHYSICAL NOUN F
of I-PHYSICAL ADP F
injected I-PHYSICAL VERB F
fluid I-PHYSICAL NOUN F
needed I-PHYSICAL VERB F
for I-PHYSICAL ADP F
a I-PHYSICAL DET F
positive 0 ADJ F
result B-PHYSICAL CCONJ F
at I-PHYSICAL ADP F
the I-PHYSICAL DET F
inferomedial I-PHYSICAL ADJ F
and I-PHYSICAL CCONJ F
superomedial I-PHYSICAL ADJ F
needle I-PHYSICAL NOUN F
locations B-PHYSICAL NOUN F
were 0 VERB F
64.0 0 NUM F
and 0 CCONJ F
95.2 0 NUM F
mL 0 NOUN F
, 0 PUNCT F
respectively 0 ADV F
; 0 PUNCT F
this 0 DET F
difference 0 NOUN F
was 0 VERB F
significant 0 ADJ F
( 0 PUNCT F
p 0 NOUN F
= 0 SYM F
0.01 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

There 0 PUNCT T
was 0 VERB F
no 0 DET F
correlation 0 NOUN F
between 0 ADP F
necessary 0 ADJ F
injection 0 NOUN F
volume 0 NOUN F
and 0 CCONJ F
sex 0 NOUN F
, 0 PUNCT F
body 0 NOUN F
mass 0 NOUN F
index 0 NOUN F
, 0 PUNCT F
or 0 CCONJ F
knee 0 NOUN F
circumference 0 NOUN F
. 0 PUNCT F

CONCLUSIONS 0 NOUN T
In 0 ADP T
order 0 NOUN F
to 0 PART F
detect 0 NOUN F
95 0 NUM F
% 0 SYM F
of 0 ADP F
1-cm 0 PUNCT F
inferolateral 0 ADJ F
arthrotomies 0 NOUN F
of 0 ADP F
the 0 DET F
knee 0 NOUN F
with 0 ADP F
use 0 NOUN F
of 0 ADP F
the 0 DET F
saline 0 ADJ F
solution 0 NOUN F
load 0 ADP F
test 0 NOUN F
, 0 PUNCT F
155 0 NUM F
mL 0 NOUN F
must 0 VERB F
be 0 VERB F
injected 0 VERB F
. 0 PUNCT F

An 0 DET T
inferomedial 0 ADJ F
injection 0 NOUN F
location 0 NOUN F
requires 0 PUNCT F

Bright 0 PUNCT T
light 0 VERB F
therapy 0 NOUN F
in 0 ADP F
Parkinson 0 NOUN T
's 0 PUNCT F
disease 0 NOUN F
: 0 PUNCT F
a 0 DET F
pilot 0 NOUN F
study 0 NOUN F
. 0 PUNCT F

Several 0 ADJ T
observations 0 CCONJ F
suggest 0 VERB F
a 0 DET F
beneficial 0 ADJ F
effect 0 NOUN F
of 0 ADP F
melatonin 0 NOUN F
antagonism 0 NOUN F
for 0 ADP F
Parkinson 0 NOUN T
's 0 PUNCT F
disease 0 NOUN F
( 0 PUNCT F
PD 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

Although 0 ADP T
bright 0 PUNCT F
light 0 VERB F
therapy 0 NOUN F
( 0 PUNCT F
BLT 0 NOUN T
) 0 PUNCT F
suppresses 0 VERB F
melatonin 0 NOUN F
release 0 NOUN F
and 0 CCONJ F
is 0 VERB F
an 0 DET F
established 0 VERB F
treatment 0 NOUN F
for 0 ADP F
depression 0 NOUN F
and 0 CCONJ F
sleep 0 NOUN F
disturbances 0 NOUN F
, 0 PUNCT F
it 0 PRON F
has 0 PUNCT F
not 0 ADV F
been 0 PUNCT F
evaluated 0 VERB F
in 0 ADP F
PD 0 NOUN T
. 0 PUNCT F

We 0 PRON T
examined 0 VERB F
effects 0 NOUN F
of 0 ADP F
BLT 0 NOUN T
on 0 ADP F
motor B-MENTAL NOUN F
symptoms I-MENTAL NOUN F
, 0 PUNCT F
depression B-MENTAL NOUN F
, 0 PUNCT F
and 0 CCONJ F
sleep B-MENTAL NOUN F
in 0 ADP F
PD 0 NOUN T
in 0 ADP F
a 0 DET F
randomized 0 VERB F
placebo-controlled 0 VERB F
double-blind 0 ADJ F
study 0 NOUN F
in 0 ADP F
36 0 NUM F
PD 0 NOUN T
patients 0 NOUN F
, 0 PUNCT F
using 0 VERB F
Parkinson 0 NOUN T
's 0 PUNCT F
Disease 0 NOUN T
Rating 0 PUNCT T
Scale 0 NOUN T
( 0 PUNCT F
UPDRS 0 NOUN T
) 0 PUNCT F
I-IV 0 NOUN T
, 0 PUNCT F
Beck 0 NOUN T
's 0 PUNCT F
Depression 0 NOUN T
Inventory 0 ADJ T
, 0 PUNCT F
and 0 CCONJ F
Epworth B-MENTAL ADP T
Sleepiness I-MENTAL NOUN T
Scale I-MENTAL NOUN T
. 0 PUNCT F

All 0 DET T
patients 0 NOUN F
received 0 VERB F
BLT 0 NOUN T
for 0 ADP F
15 0 NUM F
days 0 NOUN F
in 0 ADP F
the 0 DET F
morning 0 NOUN F
, 0 PUNCT F
30 0 NUM F
min 0 NOUN F
daily 0 ADJ F
. 0 PUNCT F

Illuminance B-MENTAL NOUN T
was 0 VERB F
7.500 0 NUM F
lux 0 NOUN F
in 0 ADP F
the 0 DET F
active 0 ADJ F
treatment 0 NOUN F
group 0 NOUN F
and 0 CCONJ F
950 0 NUM F
lux 0 NOUN F
in 0 ADP F
the 0 DET F
placebo 0 NOUN F
group 0 NOUN F
. 0 PUNCT F

Although 0 ADP T
group 0 NOUN F
differences 0 NOUN F
were 0 VERB F
small 0 ADJ F
, 0 PUNCT F
BLT 0 NOUN T
led 0 VERB F
to 0 ADP F
significant 0 ADJ F
improvement 0 NOUN F
of 0 ADP F
tremor B-MENTAL NOUN F
, 0 PUNCT F
UPDRS B-MENTAL NOUN T
I I-MENTAL NUM T
, 0 PUNCT F
II B-MENTAL NUM T
, 0 PUNCT F
and 0 PUNCT F

Effect 0 NOUN T
of 0 ADP F
dietary 0 ADJ F
supplementation 0 NOUN F
with 0 ADP F
n-3 0 NOUN F
fatty 0 ADJ F
acids 0 NOUN F
on 0 ADP F
coronary 0 ADJ F
artery 0 NOUN F
bypass 0 NOUN F
graft 0 NOUN F
patency 0 NOUN F
. 0 PUNCT F

Epidemiologic 0 ADJ T
and 0 CCONJ F
experimental 0 ADJ F
data 0 NOUN F
suggest 0 VERB F
that 0 ADP F
a 0 DET F
high 0 ADJ F
dietary 0 ADJ F
intake 0 NOUN F
of 0 ADP F
long-chain 0 NOUN F
polyunsaturated 0 DET F
n-3 0 NOUN F
fatty 0 ADJ F
acids 0 NOUN F
may 0 VERB F
reduce 0 VERB F
the 0 DET F
risk 0 NOUN F
of 0 ADP F
atherothrombotic 0 ADJ F
disease 0 NOUN F
. 0 PUNCT F

In 0 ADP T
a 0 DET F
randomized 0 VERB F
, 0 PUNCT F
controlled 0 ADP F
study 0 NOUN F
, 0 PUNCT F
610 0 NUM F
patients 0 NOUN F
undergoing 0 VERB F
coronary 0 ADJ F
artery 0 NOUN F
bypass 0 NOUN F
grafting 0 VERB F
were 0 VERB F
assigned 0 NUM F
either 0 PUNCT F
to 0 ADP F
a 0 DET F
fish 0 NOUN F
oil 0 NOUN F
group 0 NOUN F
, 0 PUNCT F
receiving 0 VERB F
4 0 NUM F
g/day 0 PUNCT F
of 0 ADP F
fish 0 NOUN F
oil 0 NOUN F
concentrate 0 NOUN F
, 0 PUNCT F
or 0 CCONJ F
to 0 ADP F
a 0 DET F
control 0 NOUN F
group 0 NOUN F
. 0 PUNCT F

All 0 DET T
patients 0 NOUN F
received 0 VERB F
antithrombotic 0 ADJ F
treatment 0 NOUN F
, 0 PUNCT F
either 0 CCONJ F
aspirin 0 NOUN F
or 0 CCONJ F
warfarin 0 NOUN F
. 0 PUNCT F

Their 0 NOUN T
diet 0 NOUN F
and 0 CCONJ F
serum 0 NOUN F
phospholipid 0 NOUN F
fatty 0 ADJ F
acid 0 NOUN F
profiles 0 NOUN F
were 0 VERB F
monitored 0 VERB F
. 0 PUNCT F

The 0 DET T
primary 0 ADJ F
end 0 NOUN F
point 0 NOUN F
was 0 VERB F
1-year 0 ADJ F
graft B-PHYSICAL NOUN F
patency I-PHYSICAL NOUN F
, 0 PUNCT F
which 0 ADP F
was 0 VERB F
assessed 0 VERB F
by 0 ADP F
angiography 0 NOUN F
in 0 ADP F
95 0 NUM F
% 0 SYM F
of 0 ADP F
patients 0 NOUN F
. 0 PUNCT F

Vein B-PHYSICAL NOUN T
graft I-PHYSICAL NOUN F
occlusion I-PHYSICAL NOUN F
rates I-PHYSICAL NOUN F
per I-PHYSICAL ADP F
distal I-PHYSICAL ADJ F
anastomoses I-PHYSICAL NOUN F
were 0 VERB F
27 0 NUM F
% 0 SYM F
in 0 ADP F
the 0 DET F
fish 0 NOUN F
oil 0 NOUN F
group 0 NOUN F
and 0 CCONJ F
33 0 NUM F
% 0 SYM F
in 0 ADP F
the 0 DET F
control 0 NOUN F
group 0 NOUN F
( 0 PUNCT F
odds 0 NOUN F
ratio 0 NOUN F
0.77 0 NUM F
, 0 PUNCT F
95 0 NUM F
% 0 SYM F
confidence 0 NOUN F
interval 0 NOUN F
, 0 PUNCT F
0.60 0 NUM F
to 0 ADP F
0.99 0 NUM F
, 0 PUNCT F
p 0 NOUN F
= 0 SYM F
0.034 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

In 0 ADP T
the 0 DET F
fish 0 NOUN F
oil 0 NOUN F
group 0 NOUN F
, 0 PUNCT F
43 0 NUM F
% 0 SYM F
of 0 ADP F
the 0 DET F
patients 0 NOUN F
had 0 PUNCT F
> 0 SYM F
or 0 PUNCT F

Safety 0 NOUN T
of 0 ADP F
intravitreous 0 PUNCT F
fomivirsen 0 PUNCT F
for 0 ADP F
treatment 0 NOUN F
of 0 ADP F
cytomegalovirus 0 NOUN F
retinitis 0 NOUN F
in 0 ADP F
patients 0 NOUN F
with 0 ADP F
AIDS 0 NOUN T
. 0 PUNCT F

PURPOSE 0 NOUN T
To 0 ADP T
report 0 NOUN F
data 0 NOUN F
regarding 0 VERB F
the 0 DET F
safety 0 NOUN F
of 0 ADP F
intravitreous 0 PUNCT F
fomivirsen 0 PUNCT F
for 0 ADP F
treatment 0 NOUN F
of 0 ADP F
cytomegalovirus 0 NOUN F
( 0 PUNCT F
CMV 0 NOUN T
) 0 PUNCT F
retinitis 0 NOUN F
in 0 ADP F
patients 0 NOUN F
with 0 ADP F
acquired 0 VERB F
immunodeficiency 0 NOUN F
syndrome 0 NOUN F
( 0 PUNCT F
AIDS 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

DESIGN 0 NOUN T
Critical 0 ADJ T
review 0 NOUN F
of 0 ADP F
safety 0 NOUN F
data 0 NOUN F
from 0 ADP F
three 0 NUM F
randomized 0 VERB F
controlled 0 VERB F
clinical 0 ADJ F
trials 0 NOUN F
with 0 ADP F
supplemental 0 ADJ F
information 0 NOUN F
from 0 ADP F
an 0 DET F
expanded 0 VERB F
drug 0 NOUN F
access 0 NOUN F
program 0 NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
Adverse 0 ADJ T
ocular 0 ADJ F
events 0 NOUN F
reported 0 VERB F
by 0 ADP F
clinician 0 NOUN F
investigators 0 NOUN F
were 0 VERB F
listed 0 VERB F
using 0 PUNCT F
terms 0 NOUN F
modified 0 VERB F
from 0 ADP F
the 0 DET F
COSTART 0 NOUN T
dictionary 0 VERB F
. 0 PUNCT F

Data 0 NOUN T
for 0 ADP F
two 0 NUM F
doses 0 NOUN F
( 0 PUNCT F
165-microg/injection 0 NOUN F
[ 0 PUNCT F
35 0 PUNCT F
eyes 0 NOUN F
, 0 PUNCT F
30 0 NUM F
patients 0 NOUN F
] 0 PUNCT F
and 0 CCONJ F
330-microg/injection 0 NOUN F
[ 0 PUNCT F
153 0 PUNCT F
eyes 0 NOUN F
, 0 PUNCT F
120 0 NUM F
patients 0 NOUN F
] 0 PUNCT F
) 0 PUNCT F
and 0 CCONJ F
two 0 NUM F
330-microg/injection 0 NOUN F
dose 0 NOUN F
schedules 0 NOUN F
of 0 ADP F
different 0 ADJ F
intensity 0 NOUN F
were 0 VERB F
pooled 0 VERB F
to 0 PART F
calculate 0 NOUN F
incidence 0 NOUN F
rates 0 NOUN F
for 0 ADP F
each 0 DET F
event 0 NOUN F
. 0 PUNCT F

Rates 0 NOUN T
were 0 VERB F
calculated 0 VERB F
as 0 PUNCT F
events/patient-year 0 PUNCT F
( 0 PUNCT F
based 0 ADP F
on 0 ADP F
total 0 ADJ F
cumulative 0 ADJ F
reported 0 VERB F
events 0 NOUN F
and 0 CCONJ F
duration 0 NOUN F
of 0 ADP F
treatment 0 NOUN F
) 0 PUNCT F
for 0 ADP F
events 0 NOUN F
that 0 NUM F
could 0 VERB F
recur 0 ADP F
during 0 ADP F
treatment 0 NOUN F
. 0 PUNCT F

Rates 0 NOUN T
were 0 VERB F
calculated 0 VERB F
as 0 ADP F
patients 0 NOUN F
with 0 ADP F
events/person-year 0 ADJ F
for 0 ADP F
the 0 DET F
following 0 ADJ F
events 0 NOUN F
: 0 PUNCT F
retinal 0 ADJ F
detachment 0 NOUN F
, 0 PUNCT F
cataract 0 NOUN F
, 0 PUNCT F
visual 0 ADJ F
field 0 NOUN F
disturbance 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
retinal 0 ADJ F
pigment 0 NOUN F
epitheliopathy 0 NOUN F
. 0 PUNCT F

To 0 PART T
assess 0 NOUN F
the 0 DET F
ability 0 NOUN F
to 0 PART F
manage 0 ADJ F
events 0 NOUN F
, 0 PUNCT F
we 0 PRON F
reviewed 0 VERB F
treatments 0 NOUN F
given 0 ADJ F
for 0 ADP F
two 0 NUM F
events 0 NOUN F
( 0 PUNCT F
anterior 0 ADJ F
chamber 0 NOUN F
inflammation 0 NOUN F
, 0 PUNCT F
increased 0 VERB F
intraocular 0 ADJ F
pressure 0 NOUN F
) 0 PUNCT F
in 0 ADP F
one 0 NUM F
trial 0 NOUN F
. 0 PUNCT F

We 0 PRON T
also 0 ADV F
report 0 VERB F
an 0 DET F
analysis 0 NOUN F
comparing 0 VERB F
the 0 DET F
proportion 0 NOUN F
of 0 ADP F
eyes 0 NOUN F
that 0 ADP F
developed 0 VERB F
one 0 NUM F
or 0 CCONJ F
more 0 DET F
key 0 ADJ F
events 0 NOUN F
to 0 ADP F
the 0 DET F
cumulative 0 ADJ F
number 0 NOUN F
of 0 ADP F
injections 0 NOUN F
. 0 PUNCT F

RESULTS 0 NOUN T
Incidence 0 NOUN T
rates 0 NOUN F
were 0 DET F
dose 0 NOUN F
and 0 CCONJ F
schedule 0 NOUN F
dependent 0 ADJ F
( 0 PUNCT F
165 0 NUM F
microg/injection 0 NOUN F
, 0 PUNCT F
4.06 0 NUM F
events/patient-year 0 PUNCT F
; 0 PUNCT F
330 0 NUM F
microg/injection 0 NOUN F
, 0 PUNCT F
6.58 0 NUM F
events/patient-year 0 PUNCT F
[ 0 PUNCT F
less 0 ADV F
intense 0 ADJ F
regimen 0 NOUN F
] 0 PUNCT F
and 0 CCONJ F
8.35 0 NUM F
events/patient-year 0 PUNCT F
[ 0 PUNCT F
more 0 ADV F
intense 0 ADJ F
regimen 0 NOUN F
] 0 PUNCT F
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
most 0 PUNCT F
frequently 0 ADV F
reported 0 VERB F
events 0 NOUN F
were 0 VERB F
anterior B-ADVERSE-EFFECTS ADJ F
chamber I-ADVERSE-EFFECTS NOUN F
inflammation I-ADVERSE-EFFECTS NOUN F
and 0 CCONJ F
increased 0 ADV F
intraocular B-ADVERSE-EFFECTS ADJ F
pressure I-ADVERSE-EFFECTS NOUN F
. 0 PUNCT F

We 0 PRON T
found 0 VERB F
no 0 DET F
evidence 0 NOUN F
that 0 ADP F
the 0 DET F
proportion 0 NOUN F
of 0 ADP F
patients B-OTHER NOUN F
with I-OTHER ADP F
events I-OTHER NOUN F
increased 0 NUM F
as 0 ADP F
the 0 DET F
number B-OTHER NOUN F
of I-OTHER ADP F
injections I-OTHER NOUN F
increased 0 VERB F
. 0 PUNCT F

CONCLUSIONS 0 NOUN T
Intravitreous 0 PUNCT T
fomivirsen 0 PUNCT F
is 0 VERB F
well B-OTHER ADP F
tolerated I-OTHER VERB F
with I-OTHER ADP F
an I-OTHER DET F
acceptable I-OTHER ADJ F
safety I-OTHER NOUN F
profile I-OTHER NOUN F
. 0 PUNCT F

Adverse B-ADVERSE-EFFECTS ADJ T
ocular I-ADVERSE-EFFECTS ADJ F
events I-ADVERSE-EFFECTS NOUN F
associated 0 VERB F
with 0 ADP F
doses 0 NOUN F
and 0 CCONJ F
schedules 0 NOUN F
used 0 VERB F
clinically 0 ADV F
can 0 ADP F
be 0 VERB F
managed 0 PROPN F
successfully 0 ADV F
with 0 ADP F
medical 0 ADJ F
therapy 0 NOUN F
. 0 PUNCT F

Clinical B-PHYSICAL ADJ T
pharmacology I-PHYSICAL NOUN F
of 0 ADP F
methadone 0 NOUN F
in 0 ADP F
dogs 0 NOUN F
. 0 PUNCT F

OBJECTIVE 0 NOUN T
To 0 PROPN T
investigate 0 NOUN F
the 0 DET F
pharmacokinetics B-PHYSICAL NOUN F
and 0 CCONJ F
effects 0 NOUN F
of 0 ADP F
methadone 0 NOUN F
on 0 ADP F
behaviour B-MENTAL NOUN F
and 0 CCONJ F
plasma B-PHYSICAL NOUN F
concentrations I-PHYSICAL NOUN F
of I-PHYSICAL ADP F
cortisol I-PHYSICAL NOUN F
and I-PHYSICAL CCONJ F
vasopressin I-PHYSICAL NOUN F
in 0 ADP F
healthy 0 ADJ F
dogs 0 NOUN F
. 0 PUNCT F

STUDY 0 NOUN T
DESIGN 0 NOUN T
Randomized 0 PROPN T
, 0 PUNCT F
cross-over 0 NOUN F
, 0 PUNCT F
experimental 0 ADJ F
trial 0 NOUN F
. 0 PUNCT F

ANIMALS 0 NOUN T
Nine 0 NUM T
adult 0 NOUN F
dogs 0 NOUN F
( 0 PUNCT F
beagle 0 NOUN F
and 0 CCONJ F
beagle 0 NOUN F
cross 0 NOUN F
breeds 0 PUNCT F
) 0 PUNCT F
, 0 PUNCT F
four 0 NUM F
males 0 PROPN F
and 0 CCONJ F
five 0 NUM F
females 0 NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
Methadone 0 NOUN T
hydrochloride 0 NOUN F
, 0 PUNCT F
0.4 0 NUM F
mg 0 NOUN F
kg 0 NOUN F
( 0 PUNCT F
-1 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
was 0 VERB F
administered 0 VERB F
intravenously 0 ADV F
( 0 PUNCT F
IV 0 NUM T
) 0 PUNCT F
and 0 CCONJ F
subcutaneously 0 ADV F
( 0 PUNCT F
SC 0 NOUN T
) 0 PUNCT F
with 0 ADP F
a 0 DET F
crossover 0 NOUN F
design 0 NOUN F
. 0 PUNCT F

Drug 0 NOUN T
and 0 CCONJ F
hormone 0 NOUN F
analyses B-PHYSICAL NOUN F
in I-PHYSICAL ADP F
plasma I-PHYSICAL NOUN F
were 0 VERB F
performed 0 VERB F
using 0 SYM F
Liquid 0 ADJ T
Chromatography-Electrospray 0 NOUN T
Ionization-Tandem 0 NOUN T
Mass 0 NOUN T
Spectrometry 0 NOUN T
and 0 CCONJ F
radioimmunoassay 0 NOUN F
respectively 0 ADV F
. 0 PUNCT F

Behavioural B-MENTAL ADJ T
data I-MENTAL NOUN F
were 0 VERB F
collected 0 VERB F
using 0 PROPN F
a 0 DET F
standardized 0 VERB F
protocol 0 NOUN F
. 0 PUNCT F

RESULTS 0 NOUN T
After 0 ADP T
IV 0 NUM T
administration 0 NOUN F
, 0 PUNCT F
the 0 DET F
plasma B-PHYSICAL NOUN F
concentration 0 NOUN F
of B-PHYSICAL ADP F
methadone B-PHYSICAL NOUN F
at 0 ADP F
10 0 NUM F
minutes 0 NOUN F
was 0 VERB F
82.1 0 NUM F
+/- 0 SYM F
9.2 0 NUM F
ng 0 NOUN F
mL 0 NOUN F
( 0 PUNCT F
-1 0 NUM F
) 0 PUNCT F
( 0 PUNCT F
mean 0 NOUN F
+/- 0 SYM F
SD 0 NOUN T
) 0 PUNCT F
, 0 PUNCT F
the 0 DET F
terminal 0 ADJ F
half-life 0 NOUN F
was 0 VERB F
3.9 0 NUM F
+/- 0 SYM F
1.0 0 NUM F
hours 0 NOUN F
, 0 PUNCT F
the 0 DET F
volume 0 NOUN F
of 0 ADP F
distribution 0 NOUN F
9.2 0 NUM F
+/- 0 SYM F
3.3 0 NUM F
L 0 NOUN T
kg 0 NOUN F
( 0 PUNCT F
-1 0 NUM F
) 0 PUNCT F
and 0 CCONJ F
plasma 0 NOUN F
clearance 0 NOUN F
27.9 0 NUM F
+/- 0 SYM F
7.6 0 NUM F
mL 0 NOUN F
minute 0 PUNCT F
( 0 PUNCT F
-1 0 NUM F
) 0 PUNCT F
kg 0 NOUN F
( 0 PUNCT F
-1 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

After 0 ADP T
SC 0 NOUN T
administration 0 NOUN F
, 0 PUNCT F
time 0 NOUN F
to 0 ADP F
maximal 0 ADJ F
plasma 0 NOUN F
concentration 0 NOUN F
was 0 VERB F
1.26 0 NUM F
+/- 0 SYM F
1.04 0 NUM F
hours 0 NOUN F
and 0 CCONJ F
maximal B-PHYSICAL ADJ F
plasma B-PHYSICAL NOUN F
concentration 0 NOUN F
of B-PHYSICAL ADP F
methadone B-PHYSICAL NOUN F
was 0 VERB F
23.9 0 NUM F
+/- 0 SYM F
14.4 0 NUM F
ng 0 NOUN F
mL 0 NOUN F
( 0 PUNCT F
-1 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
the 0 DET F
terminal 0 ADJ F
half-life 0 NOUN F
was 0 VERB F
10.7 0 NUM F
+/- 0 SYM F
4.3 0 NUM F
hours 0 NOUN F
and 0 CCONJ F
bioavailability B-PHYSICAL NOUN F
was 0 VERB F
79 0 NUM F
+/- 0 SYM F
22 0 NUM F
% 0 SYM F
. 0 PUNCT F

Concentrations 0 NOUN T
of 0 ADP F
both 0 CCONJ F
cortisol B-PHYSICAL NOUN F
and 0 CCONJ F
vasopressin B-PHYSICAL NOUN F
were 0 VERB F
increased 0 VERB F
for 0 ADP F
an 0 DET F
hour 0 NOUN F
following 0 ADP F
IV 0 NUM T
methadone 0 NOUN F
. 0 PUNCT F

The 0 DET T
observed 0 VERB F
behavioural 0 ADJ F
effects 0 NOUN F
of 0 ADP F
methadone 0 NOUN F
were 0 VERB F
decreased 0 PUNCT F
licking B-MENTAL PROPN F
and 0 CCONJ F
swallowing B-MENTAL VERB F
and 0 CCONJ F
an 0 DET F
increase 0 NOUN F
in 0 ADP F
whining B-MENTAL ADP F
after 0 PUNCT F
SC 0 NOUN T
administration 0 NOUN F
. 0 PUNCT F

The 0 DET T
latter 0 ADJ F
finding 0 NOUN F
is 0 VERB F
notable 0 ADJ F
as 0 PUNCT F
it 0 DET F
can 0 VERB F
be 0 VERB F
misinterpreted 0 VERB F
as 0 ADP F
pain B-PAIN NOUN F
when 0 ADP F
methadone 0 NOUN F
is 0 VERB F
used 0 VERB F
as 0 PUNCT F
an 0 DET F
analgesic 0 ADJ F
. 0 PUNCT F

CONCLUSION 0 NOUN T
AND 0 CCONJ T
CLINICAL 0 ADJ T
RELEVANCE 0 NOUN T
When 0 ADP T
methadone 0 NOUN F
was 0 VERB F
administered 0 VERB F
by 0 ADP F
the 0 DET F
SC 0 NOUN T
route 0 PUNCT F
, 0 PUNCT F
the 0 DET F
half-life 0 NOUN F
was 0 VERB F
longer 0 PUNCT F
, 0 PUNCT F
but 0 CCONJ F
the 0 DET F
individual 0 ADJ F
variation 0 NOUN F
in 0 PUNCT F

Physician-pharmacist 0 PUNCT T
cooperation 0 NOUN F
program 0 NOUN F
for 0 ADP F
blood 0 NOUN F
pressure 0 NOUN F
control 0 NOUN F
in 0 ADP F
patients 0 NOUN F
with 0 ADP F
hypertension 0 NOUN F
: 0 PUNCT F
a 0 DET F
randomized-controlled 0 VERB F
trial 0 NOUN F
. 0 PUNCT F

BACKGROUND 0 NOUN T
The 0 DET T
aim 0 NOUN F
of 0 ADP F
the 0 DET F
trial 0 NOUN F
was 0 VERB F
to 0 PART F
evaluate 0 NOUN F
the 0 DET F
effectiveness 0 NOUN F
of 0 ADP F
a 0 DET F
program 0 NOUN F
of 0 ADP F
cooperation 0 NOUN F
between 0 ADP F
physician 0 NOUN F
and 0 CCONJ F
pharmacist 0 NOUN F
to 0 PART F
reduce 0 NOUN F
cardiovascular 0 ADJ F
risk 0 NOUN F
factors 0 NOUN F
in 0 ADP F
patients 0 NOUN F
with 0 ADP F
mild 0 ADJ F
to 0 ADP F
moderate 0 ADJ F
hypertension 0 NOUN F
by 0 ADP F
promoting 0 VERB F
better 0 PUNCT F
blood 0 NOUN F
pressure 0 NOUN F
( 0 PUNCT F
BP 0 NOUN T
) 0 PUNCT F
control 0 NOUN F
, 0 PUNCT F
appropriate 0 ADJ F
changes 0 NOUN F
in 0 ADP F
antihypertensive 0 ADJ F
medications 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
beneficial 0 ADJ F
changes 0 NOUN F
in 0 ADP F
lifestyle 0 NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
The 0 DET T
132 0 ADJ F
subjects 0 NOUN F
in 0 ADP F
this 0 DET F
randomized 0 VERB F
, 0 PUNCT F
controlled 0 VERB F
trial 0 NOUN F
were 0 VERB F
in 0 ADP F
the 0 DET F
age 0 NOUN F
range 0 NOUN F
of 0 ADP F
40-79 0 NUM F
years 0 NOUN F
. 0 PUNCT F

The 0 DET T
inclusion 0 NOUN F
criteria 0 NOUN F
were 0 ADV F
: 0 PUNCT F
systolic B-PHYSICAL ADJ F
BP I-PHYSICAL NOUN T
( I-PHYSICAL PUNCT F
SBP I-PHYSICAL NOUN T
) I-PHYSICAL PUNCT F
ranging 0 CCONJ F
from 0 ADP F
140-179 0 NUM F
mm 0 NOUN F
Hg 0 NOUN T
and/or 0 CCONJ F
diastolic B-PHYSICAL ADJ F
BP I-PHYSICAL NOUN T
( I-PHYSICAL PUNCT F
DBP I-PHYSICAL NOUN T
) I-PHYSICAL PUNCT F
ranging 0 CCONJ F
from 0 ADP F
90-99 0 NUM F
mm 0 NOUN F
Hg 0 NOUN T
and 0 CCONJ F
treatment-naive 0 ADJ F
( 0 PUNCT F
untreated 0 PROPN F
for 0 ADP F
hypertension 0 NOUN F
) 0 PUNCT F
; 0 PUNCT F
or 0 CCONJ F
on 0 ADP F
a 0 DET F
regimen 0 NOUN F
of 0 ADP F
medication 0 NOUN F
for 0 ADP F
hypertension 0 NOUN F
. 0 PUNCT F

Of 0 ADP T
these 0 DET F
132 0 NUM F
subjects 0 NOUN F
, 0 PUNCT F
124 0 NUM F
( 0 PUNCT F
94 0 NUM F
% 0 SYM F
) 0 PUNCT F
were 0 VERB F
already 0 ADV F
receiving 0 ADP F
treatment 0 NOUN F
with 0 ADP F
antihypertensive 0 ADJ F
medications 0 NOUN F
. 0 PUNCT F

Equal 0 ADJ T
numbers 0 NOUN F
of 0 ADP F
subjects 0 NOUN F
were 0 VERB F
randomly 0 ADV F
assigned 0 VERB F
to 0 ADP F
one 0 PUNCT F
of 0 ADP F
two 0 NUM F
groups 0 NOUN F
: 0 PUNCT F
a 0 DET F
physician-pharmacist 0 NOUN F
intervention 0 NOUN F
group 0 NOUN F
( 0 PUNCT F
n 0 NOUN F
= 0 SYM F
66 0 NUM F
) 0 PUNCT F
and 0 CCONJ F
a 0 DET F
control 0 NOUN F
group 0 NOUN F
( 0 PUNCT F
n 0 NOUN F
= 0 SYM F
66 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

RESULTS 0 PUNCT T
The 0 DET T
6-month 0 NOUN F
follow-up 0 NOUN F
rate 0 NOUN F
was 0 VERB F
97 0 NUM F
% 0 SYM F
in 0 ADP F
both 0 CCONJ F
groups 0 NOUN F
. 0 PUNCT F

At 0 ADP T
6 0 NUM F
months 0 NOUN F
, 0 PUNCT F
the 0 DET F
mean 0 NOUN F
decrease 0 NOUN F
in 0 ADP F
SBP/DBP B-PHYSICAL ADP T
, 0 PUNCT F
as 0 PUNCT F
measured 0 VERB F
at 0 ADP F
home 0 NOUN F
in 0 ADP F
the 0 DET F
morning 0 NOUN F
, 0 PUNCT F
was 0 VERB F
2.9/3.3 0 PUNCT F
mm 0 NOUN F
Hg 0 NOUN T
in 0 ADP F
the 0 DET F
intervention 0 NOUN F
group 0 NOUN F
relative 0 ADJ F
to 0 ADP F
baseline 0 NOUN F
( 0 PUNCT F
P 0 NOUN T
= 0 SYM F
0.02 0 NUM F
and 0 CCONJ F
P 0 NOUN T
< 0 SYM F
0.0001 0 NUM F
for 0 ADP F
SBP 0 NOUN T
and 0 CCONJ F
DBP 0 NOUN T
, 0 PUNCT F
respectively 0 ADV F
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
mean 0 NOUN F
decrease 0 NOUN F
in 0 ADP F
home B-PHYSICAL NOUN F
morning I-PHYSICAL NOUN F
SBP I-PHYSICAL NOUN T
in 0 ADP F
the 0 DET F
intervention 0 NOUN F
group 0 NOUN F
was 0 VERB F
not 0 ADV F
significantly 0 ADV F
greater 0 PUNCT F
than 0 CCONJ F
in 0 ADP F
the 0 DET F
control 0 NOUN F
group 0 NOUN F
. 0 PUNCT F

However 0 ADV T
, 0 PUNCT F
the 0 DET F
DBP B-PHYSICAL NOUN T
decline 0 NOUN F
was 0 VERB F
significantly 0 ADV F
greater 0 PUNCT F
in 0 ADP F
the 0 DET F
intervention 0 NOUN F
than 0 PUNCT F
control 0 NOUN F
groups 0 NOUN F
, 0 PUNCT F
which 0 ADP F
showed 0 VERB F
a 0 DET F
mean 0 NOUN F
decrease 0 NOUN F
of 0 ADP F
2.8 0 NUM F
mm 0 NOUN F
Hg 0 NOUN T
( 0 PUNCT F
confidence 0 NOUN F
interval 0 NOUN F
: 0 PUNCT F
-5.5 0 ADJ F
to 0 ADP F
-0.1 0 ADV F
; 0 PUNCT F
P 0 NOUN T
= 0 SYM F
0.04 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
percentage 0 NOUN F
of 0 ADP F
patients 0 NOUN F
in 0 ADP F
whom 0 ADP F
control 0 NOUN F
of 0 ADP F
home B-PHYSICAL NOUN F
morning I-PHYSICAL NOUN F
BP I-PHYSICAL NOUN T
was 0 VERB F
achieved 0 VERB F
was 0 VERB F
53 0 NUM F
% 0 SYM F
in 0 ADP F
the 0 DET F
intervention 0 NOUN F
group 0 NOUN F
and 0 CCONJ F
47 0 NUM F
% 0 SYM F
in 0 ADP F
the 0 DET F
control 0 NOUN F
group 0 NOUN F
( 0 PUNCT F
P 0 NOUN T
= 0 SYM F
0.40 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

A 0 DET T
higher 0 PUNCT F
percentage 0 NOUN F
of 0 ADP F
patients 0 NOUN F
in 0 ADP F
the 0 DET F
intervention 0 NOUN F
group 0 NOUN F
, 0 PUNCT F
relative 0 ADJ F
to 0 ADP F
the 0 DET F
control 0 NOUN F
group 0 NOUN F
, 0 PUNCT F
were 0 VERB F
able 0 ADJ F
to 0 PART F
reduce 0 NOUN F
the 0 DET F
use 0 NOUN F
of 0 ADP F
antihypertensive B-OTHER ADJ F
medications I-OTHER NOUN F
( 0 PUNCT F
31 0 NUM F
vs. 0 CCONJ F
8 0 NUM F
% 0 SYM F
, 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.0001 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
and 0 CCONJ F
fewer 0 PUNCT F
patients 0 NOUN F
in 0 ADP F
this 0 DET F
group 0 NOUN F
required 0 VERB F
additional B-PHYSICAL ADJ F
medications I-PHYSICAL NOUN F
or 0 CCONJ F
increases 0 NOUN F
in 0 ADP F
dosage 0 NOUN F
relative 0 ADJ F
to 0 ADP F
the 0 DET F
controls 0 NOUN F
( 0 PUNCT F
11 0 NUM F
vs. 0 CCONJ F
28 0 NUM F
% 0 SYM F
, 0 PUNCT F
P 0 NOUN T
= 0 SYM F
0.03 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Patients 0 NOUN T
of 0 ADP F
the 0 DET F
intervention 0 NOUN F
group 0 NOUN F
were 0 VERB F
more 0 ADV F
likely 0 ADJ F
to 0 PART F
show 0 NOUN F
reduction 0 NOUN F
in 0 ADP F
body 0 NOUN F
mass 0 NOUN F
index 0 NOUN F
and 0 CCONJ F
sodium B-MENTAL NOUN F
intake I-MENTAL NOUN F
and 0 CCONJ F
to 0 PART F
stop B-MENTAL NOUN F
smoking I-MENTAL VERB F
, 0 PUNCT F
as 0 PUNCT F
compared 0 VERB F
with 0 ADP F
the 0 DET F
control 0 NOUN F
group 0 NOUN F
. 0 PUNCT F

CONCLUSIONS 0 NOUN T
A 0 DET T
program 0 NOUN F
of 0 ADP F
cooperation 0 NOUN F
between 0 ADP F
physician 0 NOUN F
and 0 CCONJ F
pharmacist 0 NOUN F
was 0 VERB F
successful 0 ADJ F
in 0 ADP F
reducing 0 VERB F
cardiovascular 0 ADJ F
risk 0 NOUN F
factors 0 NOUN F
in 0 ADP F
patients 0 NOUN F
with 0 ADP F
mild 0 ADJ F
to 0 ADP F
moderate 0 ADJ F
hypertension 0 NOUN F
by 0 ADP F
promoting 0 VERB F
better 0 PUNCT F
blood 0 NOUN F
pressure 0 NOUN F
( 0 PUNCT F
BP 0 NOUN T
) 0 PUNCT F
control 0 NOUN F
, 0 PUNCT F
appropriate 0 ADJ F
changes 0 NOUN F
in 0 ADP F
antihypertensive 0 ADJ F
medications 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
beneficial 0 ADJ F
changes 0 NOUN F
in 0 ADP F
lifestyle 0 NOUN F
. 0 PUNCT F

The 0 DET T
instruction 0 NOUN F
to 0 PUNCT F
refrain 0 ADJ F
from 0 ADP F
blinking 0 ADV F
affects 0 PART F
auditory B-PHYSICAL ADJ F
P3 I-PHYSICAL NOUN T
and 0 CCONJ F
N1 B-PHYSICAL NOUN T
amplitudes I-PHYSICAL NOUN F
. 0 PUNCT F

Often 0 DET T
subjects 0 NOUN F
have 0 NOUN F
been 0 PUNCT F
instructed 0 VERB F
to 0 PUNCT F
refrain 0 ADJ F
from 0 ADP F
blinking 0 ADP F
lest 0 ADP F
their 0 PUNCT F
evoked 0 VERB F
EEG 0 NOUN T
potentials 0 NOUN F
should 0 VERB F
be 0 VERB F
distorted 0 VERB F
. 0 PUNCT F

We 0 PRON T
studied 0 VERB F
whether 0 CCONJ F
these 0 DET F
very 0 DET F
instructions 0 NOUN F
have 0 PUNCT F
any 0 DET F
impact 0 NOUN F
on 0 ADP F
P3 B-PHYSICAL NOUN T
amplitude 0 NOUN F
. 0 PUNCT F

Two 0 NUM T
tones 0 NOUN F
were 0 VERB F
presented 0 VERB F
in 0 ADP F
random 0 ADJ F
order 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
subjects 0 NOUN F
had 0 PUNCT F
to 0 PUNCT F
count 0 PUNCT F
the 0 DET F
high-pitched 0 PUNCT F
tones 0 NOUN F
. 0 PUNCT F

Half 0 PUNCT T
the 0 DET F
subjects 0 NOUN F
were 0 VERB F
instructed 0 VERB F
not 0 ADV F
to 0 DET F
blink 0 PUNCT F
, 0 PUNCT F
whereas 0 CCONJ F
this 0 DET F
instruction 0 NOUN F
was 0 VERB F
omitted 0 VERB F
for 0 ADP F
the 0 DET F
other 0 ADJ F
subjects 0 NOUN F
. 0 PUNCT F

Target 0 NOUN T
tones 0 NOUN F
evoked 0 ADV F
larger 0 PUNCT F
P3s B-PHYSICAL NOUN T
than 0 CCONJ F
non-targets 0 PUNCT F
in 0 ADP F
the 0 DET F
latter 0 ADJ F
group 0 NOUN F
but 0 CCONJ F
not 0 ADV F
in 0 ADP F
the 0 DET F
former 0 NOUN F
, 0 PUNCT F
in 0 ADP F
particular 0 ADJ F
not 0 ADV F
in 0 ADP F
those 0 PUNCT F
subjects 0 NOUN F
that 0 ADP F
actually 0 ADV F
blinked 0 ADP F
rarely 0 ADV F
. 0 PUNCT F

The 0 DET T
groups 0 NOUN F
also 0 ADV F
differed 0 VERB F
in 0 ADP F
their 0 ADJ F
N1 B-PHYSICAL NOUN T
amplitudes I-PHYSICAL NOUN F
. 0 PUNCT F

These 0 DET T
findings 0 NOUN F
might 0 VERB F
be 0 VERB F
relevant 0 ADJ F
to 0 ADP F
P3 0 NOUN T
studies 0 ADP F
working 0 CCONJ F
with 0 ADP F
patients 0 NOUN F
and 0 CCONJ F
controls 0 NOUN F
: 0 PUNCT F
the 0 DET F
harder 0 ADJ F
some 0 CCONJ F
frequently 0 ADV F
blinking 0 ADP F
subjects 0 NOUN F
try 0 NOUN F
to 0 PUNCT F
refrain 0 NOUN F
from 0 ADP F
blinking 0 DET F
, 0 PUNCT F
the 0 DET F
smaller 0 PUNCT F
might 0 PUNCT F
become 0 VERB F
their 0 ADP F
P3 B-PHYSICAL NOUN T
amplitudes I-PHYSICAL NOUN F
. 0 PUNCT F

Omitting 0 VERB T
the 0 DET F
instruction 0 NOUN F
and 0 CCONJ F
using 0 VERB F
off-line 0 NOUN F
blink 0 PUNCT F
subtraction 0 NOUN F
procedures 0 NOUN F
seems 0 NOUN F
a 0 DET F
viable 0 ADJ F
alternative 0 NOUN F
. 0 PUNCT F

This 0 DET T
study 0 NOUN F
was 0 VERB F
actually 0 ADV F
motivated 0 VERB F
by 0 ADP F
discrepant 0 NOUN F
findings 0 NOUN F
on 0 ADP F
the 0 DET F
effects 0 NOUN F
of 0 ADP F
the 0 DET F
preceding 0 ADJ F
tone 0 NOUN F
sequence 0 NOUN F
on 0 ADP F
P3 0 NOUN T
. 0 PUNCT F

These 0 DET T
discrepancies 0 NOUN F
could 0 VERB F
be 0 VERB F
largely 0 ADV F
resolved 0 VERB F
by 0 ADP F
the 0 DET F
instructional 0 ADJ F
variable 0 NOUN F
, 0 PUNCT F
in 0 ADP F
conjunction 0 NOUN F
with 0 ADP F
different 0 ADJ F
tone B-PHYSICAL NOUN F
intensities I-PHYSICAL NOUN F
. 0 PUNCT F

It 0 PRON T
is 0 VERB F
suggested 0 VERB F
that 0 ADP F
subjects 0 NOUN F
who 0 ADP F
are 0 VERB F
discouraged 0 PRON F
from 0 ADP F
blinking 0 ADP F
try 0 NOUN F
to 0 PART F
protect 0 ADP F
themselves 0 PUNCT F
against 0 ADP F
the 0 DET F
arousing 0 VERB F
effects 0 NOUN F
of 0 ADP F
stimuli 0 NOUN F
. 0 PUNCT F

Cirrhosis 0 NOUN T
and 0 CCONJ F
bleeding 0 VERB F
: 0 PUNCT F
the 0 DET F
need 0 NOUN F
for 0 ADP F
very 0 ADV F
early 0 ADJ F
management 0 NOUN F
. 0 PUNCT F

BACKGROUND/AIMS 0 ADJ T
Retrospective 0 ADJ T
studies 0 NOUN F
suggest 0 VERB F
that 0 ADP F
the 0 DET F
prognosis 0 NOUN F
of 0 ADP F
patients 0 NOUN F
with 0 ADP F
cirrhosis 0 NOUN F
and 0 CCONJ F
variceal 0 ADP F
hemorrhage 0 NOUN F
has 0 PUNCT F
improved 0 VERB F
in 0 ADP F
more 0 DET F
recent 0 ADJ F
decades 0 NOUN F
. 0 PUNCT F

In 0 ADP T
a 0 DET F
prospective 0 ADJ F
cohort 0 NOUN F
study 0 NOUN F
in 0 ADP F
which 0 ADP F
the 0 DET F
choice 0 NOUN F
of 0 ADP F
prophylactic 0 ADJ F
therapy 0 NOUN F
was 0 VERB F
left 0 CCONJ F
to 0 ADP F
each 0 DET F
practitioner 0 NOUN F
, 0 PUNCT F
we 0 PRON F
followed 0 VERB F
cirrhotic 0 ADJ F
patients 0 NOUN F
with 0 ADP F
medium/large 0 NOUN F
varices 0 NOUN F
to 0 DET F
determine 0 NOUN F
factors 0 NOUN F
predictive 0 ADJ F
of 0 ADP F
bleeding 0 VERB F
and 0 CCONJ F
death 0 NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
Three 0 NUM T
hundred 0 NUM F
fourteen 0 ADP F
patients 0 NOUN F
with 0 ADP F
grades 0 NOUN F
2 0 NUM F
or 0 CCONJ F
3 0 NUM F
esophageal 0 ADJ F
varices 0 NOUN F
( 0 PUNCT F
Child 0 NOUN T
A 0 NOUN T
and 0 CCONJ F
B/C 0 NUM T
: 0 PUNCT F
218 0 NUM F
and 0 CCONJ F
96 0 NUM F
) 0 PUNCT F
were 0 VERB F
enrolled 0 VERB F
. 0 PUNCT F

One 0 NUM T
hundred 0 NUM F
seventy-three 0 ADJ F
patients 0 NOUN F
had 0 VERB F
no 0 DET F
previous 0 ADJ F
history 0 NOUN F
of 0 ADP F
variceal 0 PUNCT F
bleeding 0 VERB F
. 0 PUNCT F

Only 0 ADV T
245 0 NUM F
patients 0 NOUN F
( 0 PUNCT F
100 0 NUM F
% 0 SYM F
of 0 ADP F
patients 0 NOUN F
with 0 ADP F
prior 0 DET F
variceal 0 PUNCT F
hemorrhage 0 NOUN F
, 0 PUNCT F
61 0 NUM F
% 0 SYM F
of 0 ADP F
patients 0 NOUN F
without 0 ADP F
prior 0 CCONJ F
hemorrhage 0 NOUN F
) 0 PUNCT F
were 0 VERB F
receiving 0 ADJ F
some 0 DET F
form 0 NOUN F
of 0 ADP F
prophylactic 0 ADJ F
therapy 0 NOUN F
. 0 PUNCT F

The 0 DET T
median 0 ADJ F
follow-up 0 NOUN F
was 0 VERB F
18 0 NUM F
months 0 NOUN F
. 0 PUNCT F

RESULTS 0 NOUN T
There 0 CCONJ T
were 0 VERB F
76 0 NUM F
bleeding B-PHYSICAL VERB F
events I-PHYSICAL NOUN F
and 0 CCONJ F
14 0 NUM F
related B-MORTALITY ADJ F
deaths I-MORTALITY ADV F
( 0 PUNCT F
18 0 NUM F
% 0 SYM F
) 0 PUNCT F
; 0 PUNCT F
nine 0 NUM F
of 0 ADP F
these 0 DET F
deaths 0 NOUN F
occurred 0 VERB F
within 0 ADP F
24 0 NUM F
h 0 NOUN F
of 0 ADP F
bleeding B-PHYSICAL PUNCT F
onset 0 NOUN F
( 0 PUNCT F
two 0 NUM F
at 0 ADP F
home 0 NOUN F
, 0 PUNCT F
two 0 NUM F
during 0 ADP F
hospital 0 NOUN F
transfer 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
five 0 NUM F
in 0 ADP F
hospital 0 NOUN F
, 0 PUNCT F
a 0 DET F
mean 0 NOUN F
of 0 ADP F
2.5 0 NUM F
h 0 NOUN F
after 0 ADP F
onset 0 NOUN F
; 0 PUNCT F
six 0 NUM F
involved 0 VERB F
Child 0 NOUN T
C 0 NOUN T
patients 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

Twenty-five 0 PUNCT T
deaths B-MORTALITY NOUN F
were 0 VERB F
not 0 ADV F
due 0 PUNCT F
to 0 ADP F
bleeding 0 DET F
but 0 CCONJ F
were 0 VERB F
closely 0 ADV F
related 0 VERB F
to 0 ADP F
cirrhosis 0 NOUN F
. 0 PUNCT F

In 0 ADP T
a 0 DET F
Cox 0 NOUN T
model 0 NOUN F
, 0 PUNCT F
the 0 DET F
presence 0 NOUN F
of 0 ADP F
tense 0 NOUN F
ascites 0 CCONJ F
( 0 PUNCT F
relative 0 ADJ F
risk 0 NOUN F
3.4 0 NUM F
, 0 PUNCT F
95 0 NUM F
% 0 SYM F
confidence 0 NOUN F
interval 0 NOUN F
, 0 PUNCT F
CI 0 NOUN T
2.5-5.9 0 NUM F
) 0 PUNCT F
and 0 CCONJ F
a 0 DET F
prior 0 ADJ F
history 0 NOUN F
of 0 ADP F
hemorrhage 0 NOUN F
( 0 PUNCT F
relative 0 ADJ F
risk 0 NOUN F
4.4 0 NUM F
, 0 PUNCT F
95 0 NUM F
% 0 SYM F
CI 0 NOUN T
2.6-7.5 0 NUM F
) 0 PUNCT F
were 0 VERB F
independent 0 ADJ F
predictors 0 NOUN F
of 0 ADP F
variceal B-PHYSICAL PUNCT F
hemorrhage I-PHYSICAL NOUN F
. 0 PUNCT F

In 0 ADP T
patients 0 NOUN F
without 0 ADP F
a 0 DET F
prior 0 ADJ F
history 0 NOUN F
of 0 ADP F
bleeding 0 VERB F
, 0 PUNCT F
bleeding 0 ADP F
risk 0 NOUN F
was 0 VERB F
higher 0 PUNCT F
with 0 ADP F
more 0 DET F
prolonged 0 VERB F
prothrombin 0 NOUN F
time 0 NOUN F
and 0 CCONJ F
lower 0 PUNCT F
when 0 ADP F
patients 0 NOUN F
were 0 VERB F
receiving 0 VERB F
propranolol 0 NOUN F
. 0 PUNCT F

CONCLUSIONS 0 NOUN T
Despite 0 ADP T
the 0 DET F
advent 0 NOUN F
of 0 ADP F
effective 0 ADJ F
drugs 0 NOUN F
and 0 CCONJ F
endoscopic 0 ADJ F
therapy 0 NOUN F
for 0 ADP F
variceal 0 ADJ F
bleeding 0 VERB F
, 0 PUNCT F
about 0 PUNCT F
a 0 DET F
quarter 0 NOUN F
of 0 ADP F
deaths B-MORTALITY NOUN F
occur 0 VERB F
very 0 ADV F
early 0 ADJ F
after 0 ADP F
bleeding 0 NUM F
onset 0 NOUN F
, 0 PUNCT F
confirming 0 CCONJ F
the 0 DET F
need 0 NOUN F
for 0 ADP F
rapid 0 ADJ F
specific 0 ADJ F
management 0 NOUN F
. 0 PUNCT F

Effect 0 NOUN T
of 0 ADP F
supplementary 0 ADJ F
antioxidant 0 NOUN F
vitamin 0 NOUN F
intake 0 NOUN F
on 0 ADP F
carotid B-PHYSICAL ADJ F
arterial I-PHYSICAL ADJ F
wall I-PHYSICAL NOUN F
intima-media I-PHYSICAL NOUN F
thickness I-PHYSICAL NOUN F
in 0 ADP F
a 0 DET F
controlled 0 VERB F
clinical 0 ADJ F
trial 0 NOUN F
of 0 ADP F
cholesterol 0 NOUN F
lowering 0 VERB F
. 0 PUNCT F

BACKGROUND 0 NOUN T
There 0 PUNCT T
is 0 VERB F
accumulating 0 ADP F
experimental 0 ADJ F
, 0 PUNCT F
epidemiological 0 ADJ F
, 0 PUNCT F
and 0 CCONJ F
clinical 0 ADJ F
evidence 0 NOUN F
of 0 ADP F
an 0 DET F
association 0 NOUN F
between 0 ADP F
anti-oxidant 0 ADJ F
vitamin 0 NOUN F
intake 0 NOUN F
and 0 CCONJ F
reduced 0 ADV F
risk 0 NOUN F
of 0 ADP F
coronary 0 ADJ F
heart 0 NOUN F
disease 0 NOUN F
. 0 PUNCT F

Using 0 VERB T
data 0 NOUN F
from 0 ADP F
the 0 DET F
Cholesterol 0 NOUN T
Lowering 0 PUNCT T
Atherosclerosis 0 NOUN T
Study 0 NOUN T
( 0 PUNCT F
CLAS 0 NOUN T
) 0 PUNCT F
, 0 PUNCT F
we 0 PRON F
explored 0 PUNCT F
the 0 DET F
association 0 NOUN F
of 0 ADP F
self-selected 0 VERB F
supplementary 0 ADJ F
antioxidant 0 NOUN F
vitamin 0 NOUN F
intake 0 NOUN F
on 0 ADP F
the 0 DET F
rate 0 NOUN F
of 0 ADP F
progression 0 NOUN F
of 0 ADP F
early 0 ADJ F
preintrusive 0 ADJ F
atherosclerosis 0 NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
AND 0 CCONJ T
RESULTS 0 NOUN T
CLAS 0 NOUN T
was 0 VERB F
an 0 DET F
arterial 0 ADJ F
imaging 0 VERB F
trial 0 NOUN F
in 0 ADP F
which 0 ADP F
nonsmoking 0 PUNCT F
40- 0 ADV F
to 0 ADP F
59-year-old 0 PUNCT F
men 0 NOUN F
with 0 ADP F
previous 0 ADJ F
coronary 0 ADJ F
artery 0 NOUN F
bypass 0 NOUN F
graft 0 NOUN F
surgery 0 NOUN F
were 0 VERB F
randomized 0 VERB F
to 0 ADP F
colestipol/niacin 0 NOUN F
plus 0 CCONJ F
diet 0 NOUN F
or 0 CCONJ F
placebo 0 NOUN F
plus 0 CCONJ F
diet 0 NOUN F
. 0 PUNCT F

The 0 DET T
rate 0 NOUN F
of 0 ADP F
progression 0 NOUN F
of 0 ADP F
early 0 ADJ F
preintrusive 0 ADJ F
atherosclerosis B-PHYSICAL NOUN F
was 0 VERB F
determined 0 VERB F
in 0 ADP F
146 0 NUM F
subjects 0 NOUN F
using 0 VERB F
high-resolution 0 NOUN F
B-mode 0 NOUN T
ultrasound 0 NOUN F
quantification 0 NOUN F
of 0 ADP F
the 0 DET F
distal 0 ADJ F
common 0 ADJ F
carotid 0 ADJ F
artery 0 NOUN F
far 0 ADV F
wall 0 NOUN F
intima-media 0 NOUN F
thickness 0 NOUN F
( 0 PUNCT F
IMT 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

From 0 ADP T
the 0 DET F
nutritional 0 ADJ F
supplement 0 NOUN F
database 0 NOUN F
, 0 PUNCT F
22 0 NUM F
subjects 0 NOUN F
had 0 VERB F
an 0 DET F
on-trial 0 ADJ F
average 0 ADJ F
supplementary 0 ADJ F
vitamin 0 NOUN F
E 0 NOUN T
intake 0 NOUN F
of 0 ADP F
> 0 PROPN F
or 0 CCONJ F
= 0 SYM F
100 0 NUM F
IU 0 NOUN T
per 0 ADP F
day 0 NOUN F
( 0 PUNCT F
high 0 ADJ F
users 0 NOUN F
) 0 PUNCT F
and 0 CCONJ F
29 0 NUM F
subjects 0 NOUN F
had 0 ADP F
an 0 DET F
average 0 ADJ F
on-trial 0 ADJ F
supplementary 0 ADJ F
vitamin 0 NOUN F
C 0 NOUN T
intake 0 NOUN F
of 0 ADP F
> 0 PROPN F
or 0 CCONJ F
= 0 SYM F
250 0 NUM F
mg 0 NOUN F
per 0 ADP F
day 0 NOUN F
( 0 PUNCT F
high 0 ADJ F
users 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

Within 0 ADP T
the 0 DET F
placebo 0 NOUN F
group 0 NOUN F
, 0 PUNCT F
less 0 ADV F
carotid B-PHYSICAL ADJ F
IMT I-PHYSICAL NOUN T
progression I-PHYSICAL NOUN F
was 0 VERB F
found 0 VERB F
for 0 ADP F
high 0 ADJ F
supplementary 0 ADJ F
vitamin 0 NOUN F
E 0 NOUN T
users 0 NOUN F
when 0 ADP F
compared 0 VERB F
with 0 ADP F
low 0 ADJ F
vitamin 0 NOUN F
E 0 NOUN T
users 0 NOUN F
( 0 PUNCT F
0.008 0 ADP F
versus 0 CCONJ F
0.023 0 NUM F
mm/y 0 NOUN F
, 0 PUNCT F
P 0 NOUN T
= 0 SYM F
.03 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

No 0 DET T
effect 0 NOUN F
of 0 ADP F
vitamin B-PHYSICAL NOUN F
E 0 NOUN T
within 0 ADP F
the 0 DET F
drug 0 NOUN F
group 0 NOUN F
was 0 VERB F
found 0 VERB F
. 0 PUNCT F

No 0 DET T
effect 0 NOUN F
of 0 ADP F
vitamin 0 NOUN F
C 0 NOUN T
within 0 ADP F
the 0 DET F
drug 0 NOUN F
or 0 CCONJ F
placebo 0 NOUN F
group 0 NOUN F
was 0 VERB F
found 0 VERB F
. 0 PUNCT F

CONCLUSIONS 0 NOUN T
Supplementary 0 ADJ T
vitamin 0 NOUN F
E 0 NOUN T
intake 0 NOUN F
appears 0 NOUN F
to 0 PART F
be 0 PUNCT F
effective 0 ADJ F
in 0 ADP F
reducing 0 VERB F
the 0 DET F
progression B-PHYSICAL NOUN F
of I-PHYSICAL ADP F
atherosclerosis I-PHYSICAL NOUN F
in 0 ADP F
subjects 0 NOUN F
not 0 ADV F
treated 0 PUNCT F
with 0 ADP F
lipid-lowering 0 VERB F
drugs 0 NOUN F
while 0 ADP F
the 0 DET F
process 0 NOUN F
is 0 VERB F
still 0 ADV F
confined 0 VERB F
to 0 ADP F
the 0 DET F
arterial 0 ADJ F
wall 0 NOUN F
( 0 PUNCT F
early 0 ADJ F
preintrusive 0 ADJ F
atherosclerosis 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

Noradrenergic B-PHYSICAL ADJ T
response I-PHYSICAL NOUN F
to 0 ADP F
intravenous 0 ADJ F
yohimbine 0 NOUN F
in 0 ADP F
patients 0 NOUN F
with 0 ADP F
depression 0 NOUN F
and 0 CCONJ F
comorbidity 0 NOUN F
of 0 ADP F
depression 0 NOUN F
and 0 CCONJ F
panic 0 ADJ F
. 0 PUNCT F

Adrenergic B-PHYSICAL ADJ T
response I-PHYSICAL NOUN F
following 0 VERB F
infusions 0 NOUN F
of 0 ADP F
yohimbine 0 NOUN F
or 0 CCONJ F
normal 0 ADJ F
saline 0 NOUN F
was 0 VERB F
evaluated 0 VERB F
in 0 ADP F
9 0 NUM F
control 0 NOUN F
subjects 0 NOUN F
, 0 PUNCT F
8 0 NUM F
patients 0 NOUN F
suffering 0 VERB F
from 0 ADP F
a 0 DET F
major 0 ADJ F
depressive 0 ADJ F
episode 0 NOUN F
( 0 PUNCT F
MDE 0 NOUN T
) 0 PUNCT F
, 0 PUNCT F
and 0 CCONJ F
12 0 NUM F
patients 0 NOUN F
suffering 0 VERB F
from 0 ADP F
concurrent 0 ADJ F
MDE 0 NOUN T
and 0 CCONJ F
panic 0 ADJ F
disorder 0 NOUN F
( 0 PUNCT F
MDE 0 NOUN T
+ 0 SYM F
P 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

Blood 0 NOUN T
was 0 VERB F
drawn 0 VERB F
at 0 ADP F
-20 0 NUM F
, 0 PUNCT F
0 0 NUM F
, 0 PUNCT F
5 0 NUM F
, 0 PUNCT F
10 0 NUM F
, 0 PUNCT F
20 0 NUM F
, 0 PUNCT F
45 0 NUM F
, 0 PUNCT F
and 0 CCONJ F
90 0 NUM F
min 0 NOUN F
following 0 VERB F
the 0 DET F
infusions 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
assayed 0 ADJ F
for 0 ADP F
norepinephrine 0 NOUN F
( 0 PUNCT F
NE 0 NOUN T
) 0 PUNCT F
and 0 CCONJ F
3-methoxy-4-hydroxy-phenyl 0 NUM F
glycol 0 NOUN F
( 0 PUNCT F
MHPG 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

Although 0 ADP T
the 0 DET F
patient 0 NOUN F
groups 0 NOUN F
exhibited 0 VERB F
higher 0 PUNCT F
baseline 0 NOUN F
NE B-PHYSICAL NOUN T
concentrations I-PHYSICAL NOUN F
, 0 PUNCT F
and 0 CCONJ F
a 0 DET F
greater 0 PUNCT F
NE B-PHYSICAL NOUN T
area 0 NOUN F
under B-PHYSICAL ADP F
the I-PHYSICAL DET F
plasma I-PHYSICAL NOUN F
concentration 0 NOUN F
versus B-PHYSICAL CCONJ F
time B-PHYSICAL NOUN F
curve 0 NOUN F
( 0 PUNCT F
AUC0-90 0 NOUN T
) 0 PUNCT F
during 0 ADP F
the 0 DET F
yohimbine 0 NOUN F
infusion 0 NOUN F
, 0 PUNCT F
the 0 DET F
differences 0 NOUN F
were 0 VERB F
not 0 ADV F
statistically 0 ADV F
significant 0 ADJ F
. 0 PUNCT F

Baseline 0 PUNCT T

Clomipramine 0 NOUN T
versus 0 CCONJ F
haloperidol 0 NOUN F
in 0 ADP F
the 0 DET F
treatment 0 NOUN F
of 0 ADP F
autistic 0 ADJ F
disorder 0 NOUN F
: 0 PUNCT F
a 0 DET F
double-blind 0 ADJ F
, 0 PUNCT F
placebo-controlled 0 VERB F
, 0 PUNCT F
crossover 0 ADP F
study 0 NOUN F
. 0 PUNCT F

Clomipramine 0 NOUN T
, 0 PUNCT F
haloperidol 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
placebo 0 NOUN F
were 0 VERB F
compared 0 VERB F
with 0 ADP F
baseline 0 NOUN F
in 0 ADP F
the 0 DET F
treatment 0 NOUN F
of 0 ADP F
autism 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
overall B-MENTAL ADJ F
outcome I-MENTAL NOUN F
, 0 PUNCT F
specific B-MENTAL ADJ F
symptoms I-MENTAL NOUN F
, 0 PUNCT F
and 0 CCONJ F
side 0 NOUN F
effects 0 NOUN F
were 0 VERB F
examined 0 VERB F
. 0 PUNCT F

It 0 PRON T
was 0 VERB F
hypothesized 0 VERB F
that 0 ADP F
clomipramine 0 NOUN F
would 0 VERB F
be 0 ADP F
better 0 PUNCT F
tolerated 0 ADP F
than 0 PUNCT F
haloperidol 0 NOUN F
and 0 CCONJ F
prove 0 ADP F
superior 0 ADJ F
on 0 ADP F
a 0 DET F
measure 0 NOUN F
of 0 ADP F
stereotypy 0 ADJ F
. 0 PUNCT F

Individuals 0 NOUN T
with 0 ADP F
a 0 DET F
DSM-IV 0 NOUN T
diagnosis 0 NOUN F
of 0 ADP F
autistic 0 ADJ F
disorder 0 NOUN F
( 0 PUNCT F
mean 0 NOUN F
age 0 NOUN F
, 0 PUNCT F
16.3 0 NUM F
years 0 NOUN F
; 0 PUNCT F
range 0 NOUN F
, 0 PUNCT F
10-36 0 NUM F
years 0 NOUN F
) 0 PUNCT F
were 0 VERB F
randomly 0 ADV F
assigned 0 VERB F
, 0 PUNCT F
by 0 ADP F
using 0 VERB F
a 0 DET F
Latin 0 NOUN T
square 0 NOUN F
design 0 NOUN F
, 0 PUNCT F
to 0 ADP F
the 0 DET F
following 0 ADP F
7-week 0 NOUN F
trials 0 NOUN F
: 0 PUNCT F
placebo 0 NOUN F
, 0 PUNCT F
clomipramine 0 NOUN F
( 0 PUNCT F
mean 0 NOUN F
daily 0 ADJ F
dose 0 NOUN F
, 0 PUNCT F
128.4 0 NUM F
mg 0 NOUN F
; 0 PUNCT F
range 0 NOUN F
, 0 PUNCT F
100-150 0 NUM F
mg 0 NOUN F
) 0 PUNCT F
, 0 PUNCT F
or 0 CCONJ F
haloperidol 0 NOUN F
( 0 PUNCT F
mean 0 NOUN F
daily 0 ADJ F
dose 0 NOUN F
, 0 PUNCT F
1.3 0 NUM F
mg 0 NOUN F
; 0 PUNCT F
range 0 NOUN F
, 0 PUNCT F
1-1.5 0 NUM F
mg 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

Data 0 NOUN T
on 0 ADP F
36 0 NUM F
subjects 0 NOUN F
were 0 VERB F
analyzed 0 VERB F
and 0 CCONJ F
taken 0 VERB F
together 0 ADV F
; 0 PUNCT F
the 0 DET F
results 0 ADP F
favored 0 VERB F
haloperidol 0 NOUN F
. 0 PUNCT F

In 0 ADP T
those 0 ADP F
patients 0 NOUN F
who 0 PROPN F
were 0 VERB F
able 0 ADJ F
to 0 ADP F
complete 0 ADJ F
a 0 DET F
full 0 ADJ F
therapeutic 0 ADJ F
trial 0 NOUN F
, 0 PUNCT F
clomipramine 0 NOUN F
proved 0 VERB F
comparable 0 ADJ F
to 0 ADP F
haloperidol 0 NOUN F
in 0 ADP F
terms 0 NOUN F
of 0 ADP F
improvement B-PHYSICAL NOUN F
compared 0 VERB F
with 0 ADP F
baseline 0 NOUN F
. 0 PUNCT F

However 0 ADV T
, 0 PUNCT F
significantly 0 ADV F
fewer 0 PUNCT F
individuals 0 NOUN F
receiving 0 DET F
clomipramine 0 NOUN F
versus 0 CCONJ F
haloperidol 0 NOUN F
were 0 VERB F
able 0 ADJ F
to 0 ADP F
complete 0 ADP F
the 0 DET F
trial 0 NOUN F
( 0 PUNCT F
37.5 0 NUM F
% 0 SYM F
vs. 0 CCONJ F
69.7 0 NUM F
% 0 SYM F
, 0 PUNCT F
respectively 0 ADV F
) 0 PUNCT F
for 0 ADP F
reasons 0 NOUN F
related 0 VERB F
to 0 ADP F
both 0 CCONJ F
side 0 NOUN F
effects 0 NOUN F
and 0 CCONJ F
efficacy 0 NOUN F
or 0 CCONJ F
behavior B-MENTAL NOUN F
problems I-MENTAL NOUN F
. 0 PUNCT F

In 0 ADP T
the 0 DET F
intent-to-treat 0 NOUN F
sample 0 NOUN F
, 0 PUNCT F
which 0 ADP F
is 0 VERB F
perhaps 0 ADV F
more 0 DET F
clinically 0 ADV F
relevant 0 ADJ F
, 0 PUNCT F
only 0 ADV F
haloperidol 0 NOUN F
proved 0 ADP F
superior 0 ADJ F
to 0 ADP F
baseline 0 NOUN F
on 0 ADP F
a 0 DET F
global 0 ADJ F
measure 0 NOUN F
of 0 ADP F
autistic B-MENTAL ADJ F
symptom I-MENTAL NOUN F
severity I-MENTAL NOUN F
, 0 PUNCT F
as 0 CCONJ F
well 0 PUNCT F
as 0 CCONJ F
specific 0 ADJ F
measures 0 NOUN F
for 0 ADP F
irritability B-MENTAL NOUN F
and 0 CCONJ F
hyperactivity B-MENTAL NOUN F
. 0 PUNCT F

Clomipramine 0 NOUN T
did 0 PUNCT F
not 0 ADV F
seem 0 VERB F
more 0 ADV F
effective 0 ADJ F
on 0 ADP F
a 0 DET F
measure 0 NOUN F
of 0 ADP F
stereotypy 0 ADP F
, 0 PUNCT F
nor 0 CCONJ F
was 0 VERB F
it 0 PRON F
better 0 PUNCT F
tolerated 0 ADP F
. 0 PUNCT F

Anxiety 0 NOUN T
disorders 0 NOUN F
in 0 ADP F
typically 0 ADV F
developing 0 ADV F
youth 0 NOUN F
: 0 PUNCT F
autism 0 NOUN F
spectrum 0 NOUN F
symptoms 0 ADJ F
as 0 ADP F
a 0 DET F
predictor 0 NOUN F
of 0 ADP F
cognitive-behavioral 0 ADJ F
treatment 0 NOUN F
. 0 PUNCT F

Symptoms 0 NOUN T
of 0 ADP F
autism 0 NOUN F
spectrum 0 NOUN F
disorder 0 NOUN F
( 0 PUNCT F
ASD 0 NOUN T
) 0 PUNCT F
were 0 VERB F
assessed 0 VERB F
( 0 PUNCT F
Social 0 ADJ T
Responsiveness 0 NOUN T
Scale-Parent 0 ADJ T
( 0 PUNCT F
SRS-P 0 NOUN T
) 0 PUNCT F
; 0 PUNCT F
coded 0 VERB F
in-session 0 NOUN F
behavior 0 NOUN F
) 0 PUNCT F
in 0 ADP F
typically-developing 0 PUNCT F
, 0 PUNCT F
anxiety-disordered 0 VERB F
children 0 NOUN F
( 0 PUNCT F
N 0 NOUN T
= 0 SYM F
50 0 NUM F
) 0 PUNCT F
treated 0 VERB F
with 0 ADP F
cognitive-behavioral 0 ADJ F
therapy 0 NOUN F
( 0 PUNCT F
CBT 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

Study 0 ADJ T
1 0 NUM F
: 0 PUNCT F
children 0 NOUN F
with 0 ADP F
moderate 0 ADJ F
autistic 0 ADJ F
symptomology 0 NOUN F
( 0 PUNCT F
per 0 ADP F
SRS-P 0 NOUN T
) 0 PUNCT F
were 0 VERB F
significantly 0 ADV F
more 0 ADV F
likely 0 ADJ F
to 0 PART F
improve 0 VERB F
from 0 ADP F
family 0 NOUN F
CBT 0 NOUN T
( 0 PUNCT F
FCBT 0 NOUN T
) 0 PUNCT F
than 0 ADP F
individual 0 ADJ F
CBT 0 NOUN T
( 0 PUNCT F
ICBT 0 NOUN T
; 0 PUNCT F
OR 0 NOUN T
= 0 SYM F
8.67 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Coded 0 VERB T
behavior 0 NOUN F
did 0 PUNCT F
not 0 ADV F
predict 0 VERB F
outcome 0 NOUN F
. 0 PUNCT F

Study 0 ADV T
2 0 NUM F
: 0 PUNCT F
CBT 0 NOUN T
components 0 NOUN F
were 0 VERB F
compared 0 VERB F
by 0 ADP F
treatment 0 NOUN F
and 0 CCONJ F
ASD 0 NOUN T
symptom 0 NOUN F
status 0 NOUN F
. 0 PUNCT F

At-home 0 PUNCT T
exposure 0 NOUN F
completion 0 NOUN F
was 0 VERB F
greater 0 PUNCT F
in 0 ADP F
FCBT 0 PUNCT T
and 0 CCONJ F
there 0 PUNCT F
was 0 VERB F
an 0 DET F
interaction 0 NOUN F
in 0 ADP F
child 0 NOUN F
involvement 0 NOUN F
for 0 ADP F
treatment 0 NOUN F
and 0 CCONJ F
ASD 0 NOUN T
status 0 NOUN F
. 0 PUNCT F

Though 0 ADP T
both 0 CCONJ F
treatments 0 NOUN F
reduced 0 VERB F
anxiety B-MENTAL NOUN F
, 0 PUNCT F
FCBT 0 NOUN T
outperformed 0 PUNCT F
ICBT 0 NOUN T
for 0 ADP F
children 0 NOUN F
with 0 ADP F
moderate 0 ADJ F
ASD 0 NOUN T
symptoms 0 NOUN F
, 0 PUNCT F
a 0 DET F
benefit 0 NOUN F
potentially 0 ADV F
linked 0 ADP F
to 0 ADP F
more 0 PUNCT F
at-home 0 NOUN F
exposures 0 NOUN F
and 0 CCONJ F
greater 0 PUNCT F
child 0 NOUN F
involvement 0 NOUN F
in 0 ADP F
FCBT 0 NOUN T
. 0 PUNCT F

Enhancing 0 ADP T
antiepileptic 0 ADJ F
drug 0 NOUN F
adherence 0 NOUN F
: 0 PUNCT F
a 0 DET F
randomized 0 VERB F
controlled 0 VERB F
trial 0 NOUN F
. 0 PUNCT F

Suboptimal 0 ADJ T
adherence 0 NOUN F
to 0 ADP F
antiepileptic 0 ADJ F
drug 0 NOUN F
( 0 PUNCT F
AED 0 NOUN T
) 0 PUNCT F
treatment 0 NOUN F
is 0 VERB F
commonplace 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
increases 0 PUNCT F
the 0 DET F
risk 0 NOUN F
of 0 ADP F
status 0 NOUN F
epilepticus 0 NOUN F
and 0 CCONJ F
sudden 0 PUNCT F
unexplained 0 VERB F
death 0 NOUN F
in 0 ADP F
epilepsy 0 NOUN F
. 0 PUNCT F

This 0 DET T
randomized 0 VERB F
controlled 0 VERB F
trial 0 NOUN F
was 0 VERB F
designed 0 VERB F
to 0 PART F
demonstrate 0 NOUN F
whether 0 ADP F
an 0 DET F
implementation 0 NOUN F
intention 0 NOUN F
intervention 0 NOUN F
involving 0 VERB F
the 0 DET F
completion 0 NOUN F
of 0 ADP F
a 0 DET F
simple 0 ADJ F
self-administered 0 ADJ F
questionnaire 0 NOUN F
linking 0 ADJ F
the 0 DET F
intention 0 NOUN F
of 0 ADP F
taking 0 ADP F
medication 0 NOUN F
with 0 ADP F
a 0 DET F
particular 0 ADJ F
time 0 NOUN F
, 0 PUNCT F
place 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
other 0 ADJ F
activity 0 NOUN F
can 0 VERB F
improve 0 VERB F
AED 0 NOUN T
treatment 0 NOUN F
schedule 0 NOUN F
adherence 0 NOUN F
. 0 PUNCT F

Of 0 ADP T
the 0 DET F
81 0 NUM F
patients 0 NOUN F
with 0 ADP F
epilepsy 0 NOUN F
who 0 ADP F
were 0 VERB F
randomized 0 PROPN F
, 0 PUNCT F
69 0 NUM F
completed 0 DET F
a 0 DET F
1-month 0 NOUN F
monitoring 0 VERB F
period 0 NOUN F
with 0 ADP F
an 0 DET F
objective 0 ADJ F
measure 0 NOUN F
of 0 ADP F
tablet 0 NOUN F
taking 0 PUNCT F
( 0 PUNCT F
electronic 0 ADJ F
registration 0 NOUN F
of 0 ADP F
pill 0 ADJ F
bottle 0 NOUN F
openings 0 NOUN F
, 0 PUNCT F
Medication 0 NOUN T
Event 0 NOUN T
Monitoring 0 PUNCT T
System 0 NOUN T
[ 0 PUNCT F
MEMS 0 NOUN T
] 0 PUNCT F
) 0 PUNCT F
. 0 PUNCT F

Intervention 0 NOUN T
participants 0 NOUN F
showed 0 VERB F
improved B-MENTAL VERB F
adherence I-MENTAL NOUN F
relative I-MENTAL ADJ F
to I-MENTAL ADP F
controls I-MENTAL CCONJ F
on 0 ADP F
all 0 DET F
three 0 NUM F
outcomes 0 NOUN F
: 0 PUNCT F
doses B-OTHER NOUN F
taken I-OTHER VERB F
in I-OTHER ADP F
total 0 ADJ F
( 0 PUNCT F
93.4 0 NUM F
% 0 SYM F
vs. 0 CCONJ F
79.1 0 NUM F
% 0 SYM F
) 0 PUNCT F
, 0 PUNCT F
days 0 NOUN F
on 0 ADP F
which 0 CCONJ F
correct B-OTHER ADJ F
dose I-OTHER NOUN F
was I-OTHER VERB F
taken I-OTHER VERB F
( 0 PUNCT F
88.7 0 NUM F
% 0 SYM F
vs. 0 CCONJ F
65.3 0 NUM F
% 0 SYM F
) 0 PUNCT F
, 0 PUNCT F
and 0 CCONJ F
doses B-OTHER NOUN F
taken I-OTHER VERB F
on I-OTHER ADP F
schedule I-OTHER NOUN F
( 0 PUNCT F
78.8 0 NUM F
% 0 SYM F
vs. 0 CCONJ F
55.3 0 NUM F
% 0 SYM F
) 0 PUNCT F
( 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.01 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
implementation 0 NOUN F
intention 0 NOUN F
intervention 0 NOUN F
may 0 VERB F
be 0 ADJ F
an 0 DET F
easy-to-administer 0 ADJ F
and 0 CCONJ F
effective 0 ADJ F
means 0 NOUN F
of 0 ADP F
promoting 0 VERB F
AED 0 NOUN T
adherence 0 NOUN F
. 0 PUNCT F

RAB-plate 0 ADJ T
versus 0 CCONJ F
sliding 0 ADJ F
hip 0 NOUN F
screw 0 PUNCT F
for 0 ADP F
unstable 0 ADJ F
trochanteric 0 NOUN F
hip 0 NOUN F
fractures 0 NOUN F
: 0 PUNCT F
stability 0 NOUN F
of 0 ADP F
the 0 DET F
fixation 0 NOUN F
and 0 CCONJ F
modes 0 NOUN F
of 0 ADP F
failure 0 NOUN F
-- 0 PUNCT F
radiographic 0 ADJ F
analysis 0 NOUN F
of 0 ADP F
218 0 NUM F
fractures 0 NOUN F
. 0 PUNCT F

BACKGROUND 0 NOUN T
The 0 DET T
sliding 0 ADJ F
hip 0 NOUN F
screw 0 PUNCT F
has 0 PUNCT F
gained 0 VERB F
considerable 0 ADJ F
acceptance 0 NOUN F
in 0 ADP F
the 0 DET F
treatment 0 NOUN F
of 0 ADP F
unstable 0 ADJ F
trochanteric 0 NOUN F
fractures 0 NOUN F
. 0 PUNCT F

However 0 ADV T
, 0 PUNCT F
the 0 DET F
new 0 ADJ F
type 0 NOUN F
of 0 ADP F
120 0 NUM F
degrees 0 NOUN F
fixed 0 VERB F
angle 0 NOUN F
blade-plate 0 ADJ F
with 0 ADP F
a 0 DET F
buttress 0 PUNCT F
rod 0 NOUN F
( 0 PUNCT F
RAB-plate 0 NOUN T
) 0 PUNCT F
showed 0 VERB F
encouraging 0 ADP F
clinical 0 ADJ F
results 0 NOUN F
. 0 PUNCT F

The 0 DET T
purpose 0 NOUN F
of 0 ADP F
this 0 DET F
study 0 NOUN F
was 0 VERB F
to 0 ADV F
assess 0 NOUN F
stability 0 NOUN F
of 0 ADP F
fixation 0 NOUN F
and 0 CCONJ F
analyze 0 ADP F
modes 0 NOUN F
of 0 ADP F
failure 0 NOUN F
in 0 ADP F
unstable 0 ADJ F
trochanteric 0 NOUN F
hip 0 NOUN F
fractures 0 NOUN F
treated 0 VERB F
with 0 ADP F
these 0 DET F
devices 0 NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
A 0 PUNCT T
retrospective 0 ADJ F
radiographic 0 ADJ F
review 0 NOUN F
of 0 ADP F
218 0 NUM F
unstable 0 ADJ F
fractures 0 NOUN F
was 0 VERB F
performed 0 VERB F
. 0 PUNCT F

Linear 0 ADJ T
and 0 CCONJ F
angular 0 ADJ F
displacements 0 NOUN F
of 0 ADP F
the 0 DET F
major 0 ADJ F
fragments 0 NOUN F
and 0 CCONJ F
implant B-PHYSICAL NOUN F
migration I-PHYSICAL NOUN F
into I-PHYSICAL ADP F
the I-PHYSICAL DET F
femoral I-PHYSICAL ADJ F
head I-PHYSICAL NOUN F
during 0 ADP F
healing 0 ADP F
were 0 VERB F
assessed 0 VERB F
. 0 PUNCT F

Additionally 0 ADV T
, 0 PUNCT F
adequacy 0 NOUN F
of 0 ADP F
the 0 DET F
reduction 0 NOUN F
and 0 CCONJ F
the 0 DET F
location 0 NOUN F
of 0 ADP F
the 0 DET F
implant 0 NOUN F
within 0 ADP F
the 0 DET F
femoral 0 ADJ F
head 0 NOUN F
as 0 ADP F
predictors 0 NOUN F
of 0 ADP F
fixation 0 NOUN F
failure 0 NOUN F
were 0 VERB F
evaluated 0 VERB F
. 0 PUNCT F

RESULTS 0 PUNCT T
The 0 DET T
postreduction 0 NOUN F
neck-shaft 0 NOUN F
angle 0 NOUN F
was 0 VERB F
maintained 0 VERB F
in 0 ADP F
the 0 DET F
majority 0 NOUN F
of 0 ADP F
the 0 DET F
fractures 0 NOUN F
in 0 ADP F
both 0 CCONJ F
groups 0 NOUN F
. 0 PUNCT F

However 0 ADV T
, 0 PUNCT F
there 0 PUNCT F
was 0 VERB F
a 0 DET F
significantly 0 ADV F
higher 0 PUNCT F
incidence 0 NOUN F
of 0 ADP F
varus 0 NOUN F
angulation 0 NOUN F
by 0 ADP F
10 0 NUM F
degrees 0 NOUN F
or 0 CCONJ F
more 0 DET F
by 0 ADP F
the 0 DET F
completion 0 NOUN F
of 0 ADP F
healing 0 VERB F
among 0 ADP F
fractures 0 NOUN F
treated 0 VERB F
with 0 ADP F
the 0 DET F
sliding 0 ADJ F
hip 0 NOUN F
screw 0 PUNCT F
( 0 PUNCT F
p 0 NOUN F
= 0 SYM F
0.04 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

There 0 PUNCT T
was 0 VERB F
no 0 DET F
statistically 0 ADV F
significant 0 ADJ F
difference 0 NOUN F
in 0 ADP F
vertical B-PHYSICAL ADJ F
migration I-PHYSICAL NOUN F
of I-PHYSICAL ADP F
the I-PHYSICAL DET F
device I-PHYSICAL NOUN F
into I-PHYSICAL ADP F
the I-PHYSICAL DET F
femoral I-PHYSICAL ADJ F
head I-PHYSICAL NOUN F
between 0 ADP F
the 0 DET F
implants 0 NOUN F
used 0 ADJ F
( 0 PUNCT F
p 0 NOUN F
= 0 SYM F
0.3 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

There 0 PUNCT T
was 0 VERB F
a 0 DET F
significant 0 ADJ F
relationship 0 NOUN F
between 0 ADP F
failure 0 NOUN F
of 0 ADP F
the 0 DET F
fixation 0 NOUN F
and 0 CCONJ F
varus 0 NOUN F
reduction 0 NOUN F
( 0 PUNCT F
p 0 NOUN F
= 0 SYM F
0.04 0 NUM F
) 0 PUNCT F
as 0 PUNCT F
well 0 PUNCT F
as 0 CCONJ F
screw/neck 0 NOUN F
angle 0 NOUN F
deviation 0 NOUN F
more 0 ADV F
than 0 PUNCT F
20 0 NUM F
degrees 0 NOUN F
in 0 ADP F
the 0 DET F
lateral 0 ADJ F
projection 0 NOUN F
( 0 PUNCT F
p 0 NOUN F
= 0 SYM F
0.005 0 NUM F
) 0 PUNCT F
or 0 CCONJ F
if 0 PUNCT F
the 0 DET F
implant 0 NOUN F
was 0 VERB F
in 0 ADP F
a 0 DET F
superior 0 ADJ F
or 0 CCONJ F
posterior 0 ADJ F
position 0 NOUN F
( 0 PUNCT F
p 0 NOUN F
= 0 SYM F
0.02 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

CONCLUSION 0 NOUN T
The 0 DET T
RAB-plate 0 ADJ T
provided 0 VERB F
a 0 DET F
more 0 ADV F
stable 0 ADJ F
fixation 0 NOUN F
, 0 PUNCT F
especially 0 ADV F
with 0 ADP F
regard 0 NOUN F
to 0 ADP F
maintained 0 PUNCT F
postoperative 0 ADJ F
alignment 0 NOUN F
. 0 PUNCT F

However 0 ADV T
, 0 PUNCT F
positive 0 ADJ F
predictors 0 NOUN F
for 0 ADP F
fixation B-PHYSICAL NOUN F
failure I-PHYSICAL NOUN F
were 0 VERB F
identical 0 ADJ F
for 0 ADP F
both 0 PUNCT F
devices 0 NOUN F
. 0 PUNCT F

Here 0 ADV T
, 0 PUNCT F
the 0 DET F
screw/neck 0 NOUN F
angle 0 NOUN F
deviation 0 NOUN F
has 0 PUNCT F
had 0 PUNCT F
the 0 DET F
strongest 0 PUNCT F
significance 0 NOUN F
for 0 ADP F
prediction 0 NOUN F
of 0 ADP F
fixation 0 NOUN F
failure 0 NOUN F
. 0 PUNCT F

Randomized 0 VERB T
clinical 0 ADJ F
trial 0 NOUN F
of 0 ADP F
balance-based 0 VERB F
torso 0 ADP F
weighting 0 CCONJ F
for 0 ADP F
improving 0 ADP F
upright B-PHYSICAL PUNCT F
mobility I-PHYSICAL NOUN F
in 0 ADP F
people 0 NOUN F
with 0 ADP F
multiple 0 ADJ F
sclerosis 0 NOUN F
. 0 PUNCT F

BACKGROUND 0 NOUN T
Torso 0 NOUN T
weighting 0 ADP F
has 0 PUNCT F
sometimes 0 NOUN F
been 0 PUNCT F
effective 0 ADJ F
for 0 ADP F
improving 0 ADP F
upright B-PHYSICAL PUNCT F
mobility I-PHYSICAL NOUN F
in 0 ADP F
people 0 NOUN F
with 0 ADP F
multiple 0 ADJ F
sclerosis 0 NOUN F
, 0 PUNCT F
but 0 CCONJ F
parameters B-PHYSICAL NOUN F
for I-PHYSICAL ADP F
weighting I-PHYSICAL PROPN F
have 0 DET F
been 0 PUNCT F
inconsistent 0 ADJ F
. 0 PUNCT F

OBJECTIVE 0 NOUN T
To 0 PROPN T
determine 0 NOUN F
whether 0 ADP F
balance-based 0 VERB F
torso 0 ADP F
weighting 0 PROPN F
( 0 PUNCT F
BBTW 0 PUNCT T
) 0 PUNCT F
has 0 PUNCT F
immediate 0 ADJ F
effects 0 NOUN F
on 0 ADP F
upright 0 PUNCT F
mobility 0 NOUN F
in 0 ADP F
people 0 NOUN F
with 0 ADP F
multiple 0 ADJ F
sclerosis 0 NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
This 0 PUNCT T
was 0 VERB F
a 0 DET F
2-phase 0 NOUN F
randomized 0 VERB F
clinical 0 ADJ F
trial 0 NOUN F
. 0 PUNCT F

In 0 ADP T
phase 0 NOUN F
1 0 NUM F
, 0 PUNCT F
36 0 NUM F
participants 0 NOUN F
were 0 VERB F
randomly 0 ADV F
assigned 0 VERB F
to 0 ADP F
experimental 0 ADJ F
and 0 CCONJ F
control 0 NOUN F
groups 0 NOUN F
. 0 PUNCT F

In 0 ADP T
phase 0 NOUN F
2 0 NUM F
, 0 PUNCT F
the 0 DET F
control 0 NOUN F
group 0 NOUN F
was 0 VERB F
subsequently 0 ADV F
randomized 0 PUNCT F
into 0 ADP F
2 0 NUM F
groups 0 NOUN F
with 0 ADP F
alternate 0 NOUN F
weight-placement 0 ADJ F
. 0 PUNCT F

Tests 0 NOUN T
of 0 ADP F
upright B-PHYSICAL PUNCT F
mobility I-PHYSICAL NOUN F
included 0 VERB F
: 0 PUNCT F
timed B-PHYSICAL PUNCT F
up I-PHYSICAL PUNCT F
and I-PHYSICAL CCONJ F
go I-PHYSICAL NOUN F
( I-PHYSICAL PUNCT F
TUG I-PHYSICAL NOUN T
) I-PHYSICAL PUNCT F
, 0 PUNCT F
sharpened B-PHYSICAL ADP F
Romberg I-PHYSICAL NOUN T
, 0 PUNCT F
360-degree B-PHYSICAL ADP F
turns I-PHYSICAL NOUN F
, 0 PUNCT F
25-foot B-PHYSICAL NOUN F
walk I-PHYSICAL NOUN F
, 0 PUNCT F
and 0 CCONJ F
computerized B-PHYSICAL VERB F
platform I-PHYSICAL NOUN F
posturography I-PHYSICAL NOUN F
. 0 PUNCT F

Participants 0 NOUN T
were 0 VERB F
tested 0 VERB F
at 0 ADP F
baseline 0 NOUN F
and 0 CCONJ F
again 0 ADV F
with 0 ADP F
weights 0 PUNCT F
placed 0 VERB F
according 0 ADP F
to 0 ADP F
group 0 NOUN F
membership 0 NOUN F
. 0 PUNCT F

In 0 ADP T
both 0 PUNCT F
phases 0 NOUN F
, 0 PUNCT F
a 0 DET F
physical 0 ADJ F
therapist 0 NOUN F
assessed 0 VERB F
balance 0 NOUN F
for 0 ADP F
the 0 DET F
BBTW 0 ADJ T
group 0 NOUN F
and 0 CCONJ F
then 0 ADV F
placed 0 VERB F
weights 0 NOUN F
to 0 VERB F
decrease 0 NOUN F
balance B-PHYSICAL NOUN F
loss I-PHYSICAL NOUN F
. 0 PUNCT F

In 0 ADP T
phase 0 NOUN F
1 0 NUM F
, 0 PUNCT F
the 0 DET F
control 0 ADV F
group 0 NOUN F
had 0 PUNCT F
no 0 DET F
weights 0 NOUN F
placed 0 VERB F
. 0 PUNCT F

In 0 ADP T
phase 0 NOUN F
2 0 NUM F
, 0 PUNCT F
the 0 DET F
alternate 0 NOUN F
treatment 0 NOUN F
group 0 NOUN F
received 0 VERB F
standard 0 ADJ F
weight 0 NOUN F
placement 0 NOUN F
of 0 ADP F
1.5 0 NUM F
% 0 SYM F
body 0 NOUN F
weight 0 NOUN F
. 0 PUNCT F

RESULTS 0 DET T
People 0 NUM T
with 0 ADP F
BBTW 0 NOUN T
showed 0 VERB F
a 0 DET F
significant 0 ADJ F
improvement 0 NOUN F
in 0 ADP F
the 0 DET F
25-foot B-PHYSICAL NOUN F
walk I-PHYSICAL NOUN F
( 0 PUNCT F
P 0 NOUN T
= 0 SYM F
.01 0 NUM F
) 0 PUNCT F
over 0 ADP F
those 0 PUNCT F
with 0 ADP F
no 0 DET F
weight 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
the 0 DET F
TUG B-PHYSICAL NOUN T
( 0 PUNCT F
P 0 NOUN T
= 0 SYM F
.01 0 NUM F
) 0 PUNCT F
over 0 ADP F
those 0 PUNCT F
with 0 ADP F
standard 0 ADJ F
weight 0 NOUN F
placement 0 NOUN F
. 0 PUNCT F

BBTW 0 PUNCT T
participants 0 NOUN F
received 0 VERB F
an 0 DET F
average 0 NOUN F
of 0 ADP F
0.5 0 NUM F
kg 0 NOUN F
, 0 PUNCT F
less 0 ADV F
than 0 ADP F
1.5 0 NUM F
% 0 SYM F
of 0 ADP F
any 0 DET F
participant 0 NOUN F
's 0 PUNCT F
body 0 NOUN F
weight 0 NOUN F
. 0 PUNCT F

CONCLUSION 0 NOUN T
BBTW 0 CCONJ T
can 0 VERB F
have 0 PUNCT F
immediate 0 ADJ F
advantages 0 NOUN F
over 0 ADP F
a 0 DET F
nonweighted 0 ADJ F
condition 0 NOUN F
for 0 ADP F
gait B-PHYSICAL NOUN F
velocity I-PHYSICAL NOUN F
and 0 CCONJ F
over 0 ADP F
a 0 DET F
standardized 0 VERB F
weighted 0 VERB F
condition 0 NOUN F
for 0 ADP F
a 0 DET F
functional B-PHYSICAL ADJ F
activity I-PHYSICAL NOUN F
in 0 ADP F
people 0 NOUN F
with 0 ADP F
multiple 0 ADJ F
sclerosis 0 NOUN F
( 0 PUNCT F
MS 0 NOUN T
) 0 PUNCT F
who 0 DET F
are 0 VERB F
ambulatory 0 ADJ F
but 0 CCONJ F
have 0 PUNCT F
balance 0 NOUN F
and 0 CCONJ F
mobility 0 NOUN F
abnormalities 0 NOUN F
. 0 PUNCT F

Peritoneovenous 0 ADJ T
shunting 0 PUNCT F
as 0 PUNCT F
compared 0 VERB F
with 0 ADP F
medical 0 ADJ F
treatment 0 NOUN F
in 0 ADP F
patients 0 NOUN F
with 0 ADP F
alcoholic 0 ADJ F
cirrhosis 0 NOUN F
and 0 CCONJ F
massive 0 ADJ F
ascites 0 VERB F
. 0 PUNCT F

Veterans 0 PUNCT T
Administration 0 NOUN T
Cooperative 0 VERB T
Study 0 NOUN T
on 0 ADP F
Treatment 0 NOUN T
of 0 ADP F
Alcoholic 0 ADJ T
Cirrhosis 0 NOUN T
with 0 ADP F
Ascites 0 NOUN T
. 0 PUNCT F

The 0 DET T
optimal 0 ADJ F
management 0 NOUN F
of 0 ADP F
severe 0 ADJ F
ascites 0 CCONJ F
in 0 ADP F
patients 0 NOUN F
with 0 ADP F
alcoholic 0 ADJ F
cirrhosis 0 NOUN F
has 0 VERB F
not 0 ADV F
been 0 PUNCT F
defined 0 VERB F
. 0 PUNCT F

in 0 ADP F
a 0 DET F
5 0 NUM F
1/2-year 0 ADJ F
study 0 NOUN F
, 0 PUNCT F
we 0 PRON F
randomly 0 PUNCT F
assigned 0 PUNCT F
299 0 NUM F
men 0 NOUN F
with 0 ADP F
alcoholic 0 ADJ F
cirrhosis 0 NOUN F
, 0 PUNCT F
who 0 ADP F
had 0 ADP F
persistent 0 ADJ F
or 0 CCONJ F
recurrent 0 ADJ F
severe 0 ADJ F
ascites 0 CCONJ F
despite 0 ADP F
a 0 DET F
standard 0 ADJ F
medical 0 ADJ F
regimen 0 NOUN F
, 0 PUNCT F
to 0 PART F
receive 0 NOUN F
either 0 PUNCT F
intensive 0 ADJ F
medical 0 ADJ F
treatment 0 NOUN F
or 0 CCONJ F
peritoneovenous 0 ADJ F
( 0 PUNCT F
LeVeen 0 NUM T
) 0 PUNCT F
shunting 0 PUNCT F
. 0 PUNCT F

We 0 PRON T
identified 0 VERB F
three 0 NUM F
risk 0 NOUN F
groups 0 NOUN F
: 0 PUNCT F
Group 0 NOUN T
1 0 NUM F
had 0 PUNCT F
normal 0 ADJ F
or 0 CCONJ F
mildly 0 ADV F
abnormal 0 ADJ F
results 0 CCONJ F
on 0 ADP F
liver-function 0 NOUN F
tests 0 NOUN F
, 0 PUNCT F
Group 0 NOUN T
2 0 NUM F
had 0 PUNCT F
more 0 ADV F
severe 0 ADJ F
liver 0 NOUN F
dysfunction 0 NOUN F
or 0 CCONJ F
previous 0 ADJ F
complications 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
Group 0 NOUN T
3 0 NUM F
had 0 PUNCT F
severe 0 ADJ F
prerenal 0 ADJ F
azotemia 0 NOUN F
without 0 ADP F
kidney 0 NOUN F
disease 0 NOUN F
. 0 PUNCT F

For 0 ADP T
the 0 DET F
patients 0 NOUN F
who 0 ADP F
received 0 VERB F
the 0 DET F
medical 0 ADJ F
treatment 0 NOUN F
and 0 CCONJ F
those 0 ADP F
who 0 ADP F
received 0 VERB F
the 0 DET F
surgical 0 ADJ F
treatment 0 NOUN F
combined 0 PROPN F
, 0 PUNCT F
the 0 DET F
median 0 ADJ F
survival 0 NOUN F
times 0 NOUN F
were 0 VERB F
1093 0 NUM F
days 0 NOUN F
in 0 ADP F
Group 0 NOUN T
1 0 NUM F
, 0 PUNCT F
222 0 NUM F
days 0 NOUN F
in 0 ADP F
Group 0 NOUN T
2 0 NUM F
, 0 PUNCT F
and 0 CCONJ F
37 0 NUM F
days 0 NOUN F
in 0 ADP F
Group 0 NOUN T
3 0 NUM F
( 0 PUNCT F
P 0 NOUN T
less 0 ADV F
than 0 PUNCT F
or 0 CCONJ F
equal 0 ADJ F
to 0 ADP F
0.01 0 NUM F
) 0 PUNCT F
for 0 ADP F
all 0 DET F
comparisons 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

For 0 ADP T
all 0 DET F
the 0 DET F
groups 0 NOUN F
combined 0 PROPN F
, 0 PUNCT F
the 0 DET F
median 0 ADJ F
time 0 NOUN F
to 0 ADP F
the 0 DET F
resolution 0 NOUN F
of 0 ADP F
ascites 0 NOUN F
was 0 VERB F
5.4 0 NUM F
weeks 0 NOUN F
for 0 ADP F
medical 0 ADJ F
patients 0 NOUN F
and 0 CCONJ F
3.0 0 NUM F
weeks 0 NOUN F
for 0 ADP F
surgical 0 ADJ F
patients 0 NOUN F
( 0 PUNCT F
P 0 NOUN T
less 0 ADV F
than 0 PUNCT F
0.01 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Within 0 ADP T
each 0 DET F
risk 0 NOUN F
group 0 NOUN F
, 0 PUNCT F
mortality B-MORTALITY NOUN F
during 0 ADP F
the 0 DET F
initial 0 ADJ F
hospitalization 0 NOUN F
and 0 CCONJ F
median 0 ADJ F
long-term B-MORTALITY NOUN F
survival I-MORTALITY NOUN F
were 0 VERB F
similar 0 ADJ F
among 0 ADP F
patients 0 NOUN F
receiving 0 VERB F
either 0 PUNCT F
treatment 0 NOUN F
. 0 PUNCT F

However 0 ADV T
, 0 PUNCT F
the 0 DET F
median 0 ADJ F
time 0 NOUN F
to 0 ADP F
the 0 DET F
recurrence B-PHYSICAL NOUN F
of I-PHYSICAL ADP F
ascites I-PHYSICAL CCONJ F
in 0 ADP F
Group 0 NOUN T
1 0 NUM F
was 0 VERB F
4 0 NUM F
months 0 NOUN F
in 0 ADP F
medical 0 ADJ F
patients 0 NOUN F
, 0 PUNCT F
as 0 PUNCT F
compared 0 VERB F
with 0 ADP F
18 0 NUM F
months 0 NOUN F
in 0 ADP F
surgical 0 ADJ F
patients 0 NOUN F
( 0 PUNCT F
P 0 NOUN T
= 0 SYM F
0.01 0 NUM F
) 0 PUNCT F
; 0 PUNCT F
in 0 ADP F
Group 0 NOUN T
2 0 NUM F
it 0 PUNCT F
was 0 VERB F
3 0 NUM F
months 0 NOUN F
in 0 ADP F
medical 0 ADJ F
patients 0 NOUN F
as 0 PUNCT F
compared 0 VERB F
with 0 ADP F
12 0 NUM F
months 0 NOUN F
in 0 ADP F
surgical 0 ADJ F
patients 0 NOUN F
( 0 PUNCT F
P 0 NOUN T
= 0 SYM F
0.04 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
median 0 ADJ F
duration B-OTHER NOUN F
of I-OTHER ADP F
hospitalization I-OTHER NOUN F
was 0 VERB F
longer 0 PUNCT F
in 0 ADP F
medical 0 ADJ F
patients 0 NOUN F
than 0 PUNCT F
in 0 ADP F
surgical 0 ADJ F
patients 0 NOUN F
( 0 PUNCT F
6.1 0 ADJ F
vs. 0 CCONJ F
2.4 0 NUM F
weeks 0 NOUN F
in 0 ADP F
Group 0 NOUN T
1 0 NUM F
[ 0 PUNCT F
P 0 NOUN T
less 0 ADV F
than 0 ADP F
0.001 0 NUM F
] 0 PUNCT F
and 0 CCONJ F
5.0 0 NUM F
vs. 0 CCONJ F
3.1 0 NUM F
weeks 0 NOUN F
in 0 ADP F
Group 0 NOUN T
2 0 NUM F
[ 0 PUNCT F
P 0 NOUN T
less 0 ADV F
than 0 ADP F
0.01 0 NUM F
] 0 PUNCT F
) 0 PUNCT F
. 0 PUNCT F

Group 0 NOUN T
3 0 NUM F
was 0 VERB F
too 0 ADV F
small 0 ADJ F
to 0 PART F
permit 0 PUNCT F
a 0 DET F
meaningful 0 ADJ F
comparison 0 NOUN F
. 0 PUNCT F

During 0 ADP T
the 0 DET F
initial 0 ADJ F
hospitalization 0 NOUN F
, 0 PUNCT F
the 0 DET F
incidence 0 NOUN F
of 0 ADP F
infections B-ADVERSE-EFFECTS NOUN F
, 0 PUNCT F
gastrointestinal B-ADVERSE-EFFECTS ADJ F
bleeding I-ADVERSE-EFFECTS VERB F
, 0 PUNCT F
and 0 PUNCT F

Effect 0 NOUN T
of 0 ADP F
ischaemic 0 ADJ F
preconditioning 0 VERB F
, 0 PUNCT F
cardiopulmonary 0 ADJ F
bypass 0 NOUN F
and 0 CCONJ F
myocardial 0 ADJ F
ischaemic/reperfusion 0 NOUN F
on 0 ADP F
free B-PHYSICAL ADJ F
radical I-PHYSICAL NOUN F
generation I-PHYSICAL NOUN F
in 0 ADP F
CABG 0 NOUN T
patients 0 NOUN F
. 0 PUNCT F

OBJECTIVE 0 NOUN T
To 0 PROPN T
investigate 0 NOUN F
the 0 DET F
free 0 ADJ F
radicals 0 NOUN F
( 0 PUNCT F
FR 0 NOUN T
) 0 PUNCT F
generation 0 NOUN F
after 0 ADP F
ischaemic 0 ADJ F
preconditioning 0 VERB F
and 0 CCONJ F
cardiopulmonary 0 ADJ F
bypass 0 NOUN F
and 0 CCONJ F
during 0 ADP F
reperfusion 0 NOUN F
in 0 ADP F
CABG 0 NOUN T
patients 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
the 0 DET F
role 0 NOUN F
of 0 ADP F
ischaemic 0 ADJ F
preconditioning 0 VERB F
. 0 PUNCT F

METHODS 0 NOUN T
Forty-three 0 ADP T
CABG 0 NOUN T
patients 0 NOUN F
were 0 VERB F
randomised 0 VERB F
into 0 ADP F
an 0 DET F
ischaemic 0 ADJ F
preconditioning 0 VERB F
and 0 CCONJ F
a 0 DET F
control 0 NOUN F
group 0 NOUN F
. 0 PUNCT F

The 0 DET T
protocol 0 NOUN F
for 0 ADP F
ischaemic 0 ADJ F
preconditioning 0 VERB F
was 0 VERB F
two 0 NUM F
cycles 0 NOUN F
of 0 ADP F
2-min 0 NOUN F
ischaemia 0 NOUN F
followed 0 VERB F
by 0 ADP F
3-min 0 NOUN F
reperfusion 0 NOUN F
. 0 PUNCT F

Free B-PHYSICAL ADJ T
radicals I-PHYSICAL NOUN F
were 0 VERB F
measured 0 VERB F
using 0 VERB F
electron 0 NOUN F
spin 0 NOUN F
resonance 0 NOUN F
spectroscopy 0 NOUN F
. 0 PUNCT F

Global B-PHYSICAL VERB T
and I-PHYSICAL CCONJ F
right I-PHYSICAL VERB F
heart I-PHYSICAL NOUN F
functions I-PHYSICAL CCONJ F
were 0 VERB F
collected 0 VERB F
. 0 PUNCT F

RESULTS 0 PUNCT T
The 0 DET T
free B-PHYSICAL ADJ F
radicals I-PHYSICAL NOUN F
generation I-PHYSICAL NOUN F
in I-PHYSICAL ADP F
coronary I-PHYSICAL ADJ F
sinus I-PHYSICAL NOUN F
blood I-PHYSICAL NOUN F
in 0 ADP F
the 0 DET F
ischaemic 0 ADJ F
preconditioning 0 PUNCT F
group 0 NOUN F
was 0 VERB F
9.7 0 NUM F
and 0 CCONJ F
16.6 0 NUM F
% 0 SYM F
after 0 ADP F
the 0 DET F
ischaemic 0 ADJ F
preconditioning 0 VERB F
protocol 0 NOUN F
and 0 CCONJ F
10 0 NUM F
min 0 NOUN F
after 0 ADP F
declamping 0 ADP F
, 0 PUNCT F
6.8 0 NUM F
and 0 CCONJ F
13.3 0 NUM F
% 0 SYM F
in 0 ADP F
the 0 DET F
controls 0 NOUN F
. 0 PUNCT F

The 0 DET T
free B-PHYSICAL ADJ F
radicals I-PHYSICAL NOUN F
in I-PHYSICAL ADP F
arterial I-PHYSICAL ADJ F
samples I-PHYSICAL NOUN F
were 0 VERB F
, 0 PUNCT F
respectively 0 ADV F
, 0 PUNCT F
21 0 NUM F
, 0 PUNCT F
14 0 NUM F
, 0 PUNCT F
10 0 NUM F
and 0 CCONJ F
9 0 NUM F
% 0 SYM F
at 0 ADP F
10 0 NUM F
min 0 NOUN F
, 0 PUNCT F
1 0 NUM F
, 0 PUNCT F
2 0 NUM F
and 0 CCONJ F
24 0 NUM F
h 0 NOUN F
after 0 ADP F
reperfusion 0 NOUN F
. 0 PUNCT F

Cardiac B-PHYSICAL ADJ T
index 0 NOUN F
( B-PHYSICAL PUNCT F
CI I-PHYSICAL NOUN T
) B-PHYSICAL PUNCT F
and 0 CCONJ F
right B-PHYSICAL ADJ F
ventricular I-PHYSICAL ADJ F
ejection I-PHYSICAL NOUN F
fraction I-PHYSICAL NOUN F
( I-PHYSICAL PUNCT F
RVEF B-PHYSICAL PUNCT T
) I-PHYSICAL PUNCT F
were 0 VERB F
improved 0 VERB F
by 0 ADP F
ischaemic 0 ADJ F
preconditioning 0 VERB F
. 0 PUNCT F

CONCLUSION 0 NOUN T
Both 0 CCONJ T
ischaemic 0 ADJ F
preconditioning 0 VERB F
and 0 CCONJ F
cardiopulmonary 0 ADJ F
bypass 0 NOUN F
induced 0 VERB F
free B-PHYSICAL ADJ F
radicals I-PHYSICAL NOUN F
generation I-PHYSICAL NOUN F
. 0 PUNCT F

Although 0 ADP T
ischaemic 0 ADJ F
preconditioning 0 VERB F
had 0 PUNCT F
no 0 DET F
effect 0 NOUN F
on 0 PUNCT F

A 0 DET T
comparison 0 NOUN F
of 0 ADP F
the 0 DET F
effect 0 NOUN F
of 0 ADP F
short-term 0 NOUN F
aromatase 0 NOUN F
inhibitor 0 NOUN F
( 0 PUNCT F
letrozole 0 NOUN F
) 0 PUNCT F
and 0 CCONJ F
GnRH 0 NOUN T
agonist 0 NOUN F
( 0 PUNCT F
triptorelin 0 NOUN F
) 0 PUNCT F
versus 0 CCONJ F
case 0 NOUN F
control 0 NOUN F
on 0 ADP F
pregnancy B-PHYSICAL NOUN F
rate I-PHYSICAL NOUN F
and 0 CCONJ F
symptom B-PHYSICAL NOUN F
and 0 CCONJ F
sign B-PHYSICAL ADP F
recurrence I-PHYSICAL NOUN F
after 0 ADP F
laparoscopic 0 ADJ F
treatment 0 NOUN F
of 0 ADP F
endometriosis 0 NOUN F
. 0 PUNCT F

PURPOSE 0 NOUN T
To 0 ADJ T
compare 0 NOUN F
the 0 DET F
role 0 NOUN F
of 0 ADP F
an 0 DET F
aromatase 0 NOUN F
inhibitor 0 NOUN F
( 0 PUNCT F
letrozole 0 NOUN F
) 0 PUNCT F
with 0 ADP F
a 0 DET F
GnRH 0 NOUN T
agonist 0 NOUN F
( 0 PUNCT F
triptorelin 0 NOUN F
) 0 PUNCT F
versus 0 CCONJ F
case 0 NOUN F
control 0 NOUN F
on 0 ADP F
the 0 DET F
pregnancy B-PHYSICAL NOUN F
rate I-PHYSICAL NOUN F
and 0 CCONJ F
recurrence 0 NOUN F
of 0 ADP F
symptoms B-PHYSICAL NOUN F
and 0 CCONJ F
signs B-PHYSICAL NOUN F
in 0 ADP F
patients 0 NOUN F
with 0 ADP F
endometriosis 0 NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
In 0 ADP T
a 0 DET F
prospective 0 ADJ F
randomized 0 VERB F
clinical 0 ADJ F
trial 0 NOUN F
, 0 PUNCT F
after 0 ADP F
treatment 0 NOUN F
of 0 ADP F
144 0 NUM F
infertile 0 ADP F
women 0 NOUN F
in 0 ADP F
their 0 PUNCT F
reproductive 0 ADJ F
age 0 NOUN F
by 0 ADP F
laparoscopy 0 NOUN F
( 0 PUNCT F
whose 0 ADP F
endometriosis 0 NOUN F
was 0 VERB F
confirmed 0 VERB F
by 0 PUNCT F
prior 0 PUNCT F
laparoscopy 0 NOUN F
) 0 PUNCT F
, 0 PUNCT F
they 0 PUNCT F
were 0 VERB F
divided 0 VERB F
into 0 ADP F
3 0 NUM F
groups 0 NOUN F
: 0 PUNCT F
group 0 NOUN F
1 0 NUM F
( 0 PUNCT F
47 0 NUM F
cases 0 NOUN F
) 0 PUNCT F
who 0 ADP F
received 0 VERB F
letrozole 0 NOUN F
for 0 ADP F
2 0 NUM F
months 0 NOUN F
, 0 PUNCT F
group 0 NOUN F
2 0 NUM F
( 0 PUNCT F
40 0 NUM F
patients 0 NOUN F
) 0 PUNCT F
who 0 ADP F
were 0 VERB F
prescribed 0 VERB F
triptorelin 0 NOUN F
for 0 ADP F
2 0 NUM F
months 0 NOUN F
and 0 CCONJ F
group 0 NOUN F
3 0 NUM F
who 0 ADP F
were 0 VERB F
57 0 NUM F
patients 0 NOUN F
in 0 ADP F
the 0 DET F
control 0 NOUN F
group 0 NOUN F
and 0 CCONJ F
did 0 DET F
not 0 ADV F
receive 0 VERB F
any 0 DET F
medication 0 NOUN F
. 0 PUNCT F

We 0 PRON T
followed 0 VERB F
up 0 PUNCT F
each 0 DET F
group 0 NOUN F
at 0 DET F
least 0 DET F
for 0 ADP F
12 0 NUM F
months 0 NOUN F
after 0 ADP F
their 0 PUNCT F
restoration 0 NOUN F
of 0 ADP F
regular 0 ADJ F
cycle 0 NOUN F
. 0 PUNCT F

RESULTS 0 NOUN T
Pregnancy B-PHYSICAL NOUN T
rate I-PHYSICAL NOUN F
was 0 VERB F
23.4 0 NUM F
% 0 SYM F
in 0 ADP F
group 0 NOUN F
1 0 NUM F
, 0 PUNCT F
27.5 0 NUM F
% 0 SYM F
in 0 ADP F
group 0 NOUN F
2 0 NUM F
, 0 PUNCT F
and 0 CCONJ F
28.1 0 NUM F
% 0 SYM F
in 0 ADP F
group 0 NOUN F
3 0 NUM F
. 0 PUNCT F

The 0 DET T
results 0 NOUN F
did 0 PUNCT F
not B-OTHER ADV F
show I-OTHER VERB F
significant I-OTHER ADJ F
differences I-OTHER NOUN F
among 0 ADP F
the 0 DET F
3 0 NUM F
groups 0 NOUN F
. 0 PUNCT F

Recurrence B-PHYSICAL NOUN T
rate I-PHYSICAL NOUN F
of I-PHYSICAL ADP F
endometriosis I-PHYSICAL NOUN F
was 0 VERB F
6.4 0 NUM F
% 0 SYM F
in 0 ADP F
group 0 NOUN F
1 0 NUM F
, 0 PUNCT F
5 0 NUM F
% 0 ADV F
group 0 NOUN F
2 0 NUM F
and 0 CCONJ F
5.3 0 NUM F
% 0 SYM F
in 0 ADP F
group 0 NOUN F
3 0 NUM F
, 0 PUNCT F
which 0 ADP F
was 0 VERB F
not 0 ADV F
statistically B-OTHER ADJ F
significantly I-OTHER ADV F
different I-OTHER ADJ F
as 0 CCONJ F
well 0 PUNCT F
. 0 PUNCT F

CONCLUSION 0 NOUN T
Pregnancy B-PHYSICAL NOUN T
rate I-PHYSICAL NOUN F
and 0 CCONJ F
endometriosis B-PHYSICAL NOUN F
recurrence I-PHYSICAL NOUN F
rate I-PHYSICAL NOUN F
are 0 VERB F
comparable 0 ADJ F
among 0 ADP F
the 0 DET F
3 0 NUM F
groups 0 NOUN F
. 0 PUNCT F

Standardized 0 VERB T
preoperative 0 ADJ F
corticosteroid 0 NOUN F
treatment 0 NOUN F
in 0 ADP F
neonates 0 NOUN F
undergoing 0 VERB F
cardiac 0 ADJ F
surgery 0 NOUN F
: 0 PUNCT F
results 0 CCONJ F
from 0 ADP F
a 0 DET F
randomized 0 VERB F
trial 0 NOUN F
. 0 PUNCT F

OBJECTIVE 0 NOUN T
A 0 ADV T
heightened 0 VERB F
inflammatory 0 ADJ F
response 0 NOUN F
occurs 0 NOUN F
after 0 ADP F
cardiac 0 ADJ F
surgery 0 NOUN F
. 0 PUNCT F

The 0 DET T
perioperative 0 ADJ F
use 0 NOUN F
of 0 ADP F
glucocorticoids 0 NOUN F
has 0 PUNCT F
been 0 PUNCT F
advocated 0 VERB F
as 0 ADP F
a 0 DET F
method 0 NOUN F
to 0 PART F
improve 0 PUNCT F
postoperative 0 ADJ F
outcomes 0 NOUN F
. 0 PUNCT F

Randomized 0 VERB T
prospective 0 ADJ F
studies 0 NOUN F
to 0 PART F
quantify 0 NOUN F
the 0 DET F
effect 0 NOUN F
of 0 ADP F
methylprednisolone 0 NUM F
on 0 ADP F
perioperative 0 ADP F
outcomes 0 NOUN F
in 0 ADP F
neonatal 0 ADJ F
cardiac 0 ADJ F
surgery 0 NOUN F
have 0 PUNCT F
not 0 ADV F
been 0 PUNCT F
performed 0 VERB F
. 0 PUNCT F

We 0 PRON T
sought 0 PROPN F
to 0 PART F
determine 0 NOUN F
whether 0 ADP F
preoperative 0 ADJ F
methylprednisolone 0 NOUN F
would 0 VERB F
improve 0 VERB F
postoperative 0 ADJ F
recovery 0 NOUN F
in 0 ADP F
neonates 0 NOUN F
requiring 0 VERB F
cardiac 0 ADJ F
surgery 0 NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
Neonates 0 PROPN T
scheduled 0 VERB F
for 0 ADP F
cardiac 0 ADJ F
surgery 0 NOUN F
were 0 VERB F
randomly 0 ADV F
assigned 0 VERB F
to 0 PART F
receive 0 NOUN F
either 0 PUNCT F
2-dose 0 NOUN F
( 0 PUNCT F
8 0 NUM F
hours 0 NOUN F
preoperatively 0 ADV F
and 0 CCONJ F
operatively 0 ADV F
, 0 PUNCT F
n 0 NOUN F
= 0 SYM F
39 0 NUM F
) 0 PUNCT F
or 0 CCONJ F
single-dose 0 NOUN F
( 0 PUNCT F
operatively 0 PROPN F
, 0 PUNCT F
n 0 NOUN F
= 0 SYM F
37 0 NUM F
) 0 PUNCT F
methylprednisolone 0 NOUN F
( 0 PUNCT F
30 0 NUM F
mg/kg 0 NOUN F
per 0 ADP F
dose 0 NOUN F
) 0 PUNCT F
in 0 ADP F
a 0 DET F
prospective 0 ADJ F
double-blind 0 ADJ F
trial 0 NOUN F
. 0 PUNCT F

The 0 DET T
primary 0 ADJ F
outcome 0 NOUN F
was 0 VERB F
the 0 DET F
incidence 0 NOUN F
of 0 ADP F
low 0 ADJ F
cardiac 0 ADJ F
output 0 NOUN F
syndrome 0 NOUN F
( 0 PUNCT F
standardized 0 VERB F
score 0 NOUN F
) 0 PUNCT F
or 0 CCONJ F
death 0 NOUN F
36 0 NUM F
hours 0 NOUN F
postoperatively 0 NUM F
. 0 PUNCT F

Secondary 0 ADJ T
outcomes 0 NOUN F
were 0 VERB F
death 0 NOUN F
at 0 ADP F
30 0 NUM F
days 0 NOUN F
, 0 PUNCT F
interleukin-6 0 NOUN F
levels 0 NOUN F
, 0 PUNCT F
inotropic 0 ADJ F
score 0 NOUN F
, 0 PUNCT F
fluid 0 NOUN F
balance 0 NOUN F
, 0 PUNCT F
serum 0 NOUN F
creatinine 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
intensive 0 ADJ F
care 0 NOUN F
unit 0 NOUN F
and 0 CCONJ F
hospital 0 NOUN F
stay 0 NOUN F
. 0 PUNCT F

RESULTS 0 NOUN T
Preoperative 0 ADJ T
plasma 0 NOUN F
levels 0 NOUN F
of 0 ADP F
the 0 DET F
inflammatory 0 ADJ F
cytokine 0 NOUN F
interleukin-6 0 NOUN F
were 0 VERB F
reduced 0 VERB F
by 0 ADP F
2-fold 0 NOUN F
( 0 PUNCT F
P 0 NOUN T
< 0 SYM F
.001 0 NUM F
) 0 PUNCT F
in 0 ADP F
the 0 DET F
2-dose 0 NOUN F
methylprednisolone 0 NUM F
group 0 NOUN F
, 0 PUNCT F
consistent 0 ADJ F
with 0 ADP F
the 0 DET F
anti-inflammatory 0 ADJ F
effects 0 NOUN F
of 0 ADP F
methylprednisolone 0 NOUN F
. 0 PUNCT F

However 0 ADV T
, 0 PUNCT F
the 0 DET F
incidence 0 NOUN F
of 0 ADP F
low 0 ADJ F
cardiac 0 ADJ F
output 0 NOUN F
syndrome 0 NOUN F
was 0 VERB F
46 0 NUM F
% 0 SYM F
( 0 PUNCT F
17/37 0 PUNCT F
) 0 PUNCT F
in 0 ADP F
the 0 DET F
single-dose 0 NOUN F
and 0 CCONJ F
38 0 NUM F
% 0 SYM F
( 0 PUNCT F
15/39 0 PUNCT F
) 0 PUNCT F
in 0 ADP F
the 0 DET F
2-dose 0 NOUN F
methylprednisolone 0 NUM F
groups 0 NOUN F
( 0 PUNCT F
P 0 NOUN T
= 0 SYM F
.51 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Two-dose 0 ADJ T
methylprednisolone 0 NOUN F
was 0 VERB F
associated 0 VERB F
with 0 ADP F
a 0 DET F
higher 0 PUNCT F
serum B-PHYSICAL NOUN F
creatinine I-PHYSICAL NOUN F
( 0 PUNCT F
0.61 0 NUM F
? 0 PUNCT F

0.18 0 NUM F
mg/dL 0 NOUN F
vs 0 CCONJ F
0.53 0 NUM F
? 0 PUNCT F

0.12 0 NUM F
mg/dL 0 NOUN F
, 0 PUNCT F
P 0 NOUN T
= 0 SYM F
.03 0 NUM F
) 0 PUNCT F
and 0 CCONJ F
poorer 0 PUNCT F
postoperative 0 ADJ F
diuresis 0 NOUN F
( 0 PUNCT F
-96 0 ADJ F
? 0 PUNCT F

49 0 NUM F
mL 0 NOUN F
, 0 PUNCT F
P 0 NOUN T
= 0 SYM F
.05 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Inotropic 0 ADJ T
requirement 0 NOUN F
, 0 PUNCT F
duration 0 NOUN F
of 0 ADP F
mechanical 0 ADJ F
ventilation 0 NOUN F
, 0 PUNCT F
intensive 0 ADJ F
care 0 NOUN F
unit 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
hospital 0 NOUN F
stay 0 NOUN F
did 0 PUNCT F
not 0 ADV F
differ 0 VERB F
between 0 ADP F
the 0 DET F
2 0 NUM F
groups 0 NOUN F
. 0 PUNCT F

CONCLUSIONS 0 NOUN T
Combined 0 PROPN T
preoperative 0 ADJ F
and 0 CCONJ F
intraoperative 0 ADJ F
use 0 NOUN F
of 0 ADP F
glucocorticoids 0 NOUN F
in 0 ADP F
neonatal 0 ADJ F
cardiac 0 ADJ F
surgery 0 NOUN F
does 0 PUNCT F
not 0 ADV F
favorably 0 ADV F
affect 0 ADV F
early 0 ADJ F
clinical 0 ADJ F
outcomes 0 NOUN F
and 0 CCONJ F
may 0 ADJ F
exacerbate 0 CCONJ F
perioperative 0 ADJ F
renal 0 ADJ F
dysfunction 0 NOUN F
. 0 PUNCT F

Temporal 0 ADJ T
expectation 0 NOUN F
in 0 ADP F
focal 0 ADJ F
hand 0 NOUN F
dystonia 0 NOUN F
. 0 PUNCT F

Patients 0 NOUN T
with 0 ADP F
writer 0 ADJ F
's 0 PUNCT F
cramp 0 NOUN F
present 0 VERB F
sensory 0 ADJ F
and 0 CCONJ F
representational 0 ADJ F
abnormalities 0 NOUN F
relevant 0 ADJ F
to 0 ADP F
motor 0 NOUN F
control 0 NOUN F
, 0 PUNCT F
such 0 PUNCT F
as 0 VERB F
impairment 0 NOUN F
in 0 ADP F
the 0 DET F
temporal 0 ADJ F
discrimination 0 NOUN F
between 0 ADP F
tactile 0 NOUN F
stimuli 0 NOUN F
and 0 CCONJ F
in 0 ADP F
pure 0 ADJ F
motor 0 NOUN F
imagery 0 PUNCT F
tasks 0 NOUN F
, 0 PUNCT F
like 0 ADP F
the 0 DET F
mental 0 ADJ F
rotation 0 NOUN F
of 0 ADP F
corporeal 0 ADJ F
and 0 CCONJ F
inanimate 0 PUNCT F
objects 0 NOUN F
. 0 PUNCT F

However 0 ADV T
, 0 PUNCT F
only 0 ADV F
limited 0 VERB F
information 0 NOUN F
is 0 VERB F
available 0 ADJ F
on 0 ADP F
the 0 DET F
ability 0 NOUN F
of 0 ADP F
patients 0 NOUN F
with 0 ADP F
dystonia 0 NOUN F
to 0 ADP F
process 0 NOUN F
the 0 DET F
time-dependent 0 ADJ F
features 0 NOUN F
( 0 PUNCT F
e.g 0 NUM F
. 0 PUNCT F

speed 0 NOUN F
) 0 PUNCT F
of 0 ADP F
movement 0 NOUN F
in 0 ADP F
real 0 ADJ F
time 0 NOUN F
. 0 PUNCT F

The 0 DET T
processing 0 VERB F
of 0 ADP F
time-dependent 0 ADJ F
features 0 NOUN F
of 0 ADP F
movement 0 NOUN F
has 0 VERB F
a 0 DET F
crucial 0 ADJ F
role 0 NOUN F
in 0 ADP F
predicting 0 VERB F
whether 0 ADP F
the 0 DET F
outcome 0 NOUN F
of 0 ADP F
a 0 DET F
complex 0 ADJ F
motor 0 NOUN F
sequence 0 NOUN F
, 0 PUNCT F
such 0 PUNCT F
as 0 ADP F
handwriting 0 VERB F
or 0 CCONJ F
playing 0 VERB F
a 0 DET F
musical 0 ADJ F
passage 0 NOUN F
, 0 PUNCT F
will 0 VERB F
be 0 VERB F
consistent 0 ADJ F
with 0 ADP F
its 0 PUNCT F
ultimate 0 ADJ F
goal 0 NOUN F
, 0 PUNCT F
or 0 CCONJ F
results 0 ADJ F
instead 0 PUNCT F
in 0 ADP F
an 0 DET F
execution 0 NOUN F
error 0 NOUN F
. 0 PUNCT F

In 0 ADP T
this 0 DET F
study 0 NOUN F
, 0 PUNCT F
we 0 PRON F
sought 0 PROPN F
to 0 PART F
evaluate 0 NOUN F
the 0 DET F
implicit 0 NOUN F
ability 0 NOUN F
to 0 ADP F
perceive 0 CCONJ F
the 0 DET F
temporal 0 ADJ F
outcome 0 NOUN F
of 0 ADP F
different 0 ADJ F
movements 0 NOUN F
in 0 ADP F
a 0 DET F
group 0 NOUN F
of 0 ADP F
patients 0 NOUN F
with 0 ADP F
writer 0 ADJ F
's 0 PUNCT F
cramp 0 NOUN F
. 0 PUNCT F

Fourteen 0 NUM T
patients 0 NOUN F
affected 0 VERB F
by 0 ADP F
writer 0 ADJ F
's 0 PUNCT F
cramp 0 NOUN F
in 0 ADP F
the 0 DET F
right 0 ADJ F
hand 0 NOUN F
and 0 CCONJ F
17 0 NUM F
age- 0 NOUN F
and 0 CCONJ F
gender-matched 0 NOUN F
healthy 0 ADJ F
subjects 0 NOUN F
were 0 VERB F
recruited 0 VERB F
for 0 ADP F
the 0 DET F
study 0 NOUN F
. 0 PUNCT F

Subjects 0 NOUN T
were 0 VERB F
asked 0 VERB F
to 0 PART F
perform 0 NOUN F
a 0 DET F
temporal 0 ADJ F
expectation 0 NOUN F
task 0 NOUN F
by 0 ADP F
predicting 0 VERB F
the 0 DET F
end 0 NOUN F
of 0 ADP F
visually 0 ADV F
perceived 0 VERB F
human 0 NOUN F
body 0 NOUN F
motion 0 NOUN F
( 0 PUNCT F
handwriting 0 NUM F
, 0 PUNCT F
i.e 0 PUNCT F
. 0 PUNCT F

the 0 DET F
action 0 NOUN F
performed 0 VERB F
by 0 ADP F
the 0 DET F
human 0 NOUN F
body 0 NOUN F
segment 0 PUNCT F
specifically 0 ADV F
affected 0 VERB F
by 0 ADP F
writer 0 ADJ F
's 0 PUNCT F
cramp 0 NOUN F
) 0 PUNCT F
or 0 CCONJ F
inanimate 0 ADJ F
object 0 NOUN F
motion 0 NOUN F
( 0 PUNCT F
a 0 ADP F
moving 0 ADJ F
circle 0 NOUN F
reaching 0 VERB F
a 0 DET F
spatial 0 ADJ F
target 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

Videos 0 PUNCT T
representing 0 ADP F
movements 0 NOUN F
were 0 VERB F
shown 0 VERB F
in 0 ADP F
full 0 ADJ F
before 0 ADP F
experimental 0 ADJ F
trials 0 NOUN F
; 0 PUNCT F
the 0 DET F
actual 0 ADJ F
tasks 0 NOUN F
consisted 0 DET F
of 0 ADP F
watching 0 NUM F
the 0 DET F
same 0 ADJ F
videos 0 PUNCT F
, 0 PUNCT F
but 0 CCONJ F
interrupted 0 VERB F
after 0 ADP F
a 0 DET F
variable 0 ADJ F
interval 0 NOUN F
( 0 PUNCT F
'pre-dark 0 PUNCT F
' 0 PUNCT F
) 0 PUNCT F
from 0 ADP F
its 0 PUNCT F
onset 0 NOUN F
by 0 ADP F
a 0 DET F
dark 0 ADJ F
interval 0 NOUN F
of 0 ADP F
variable 0 ADJ F
duration 0 NOUN F
. 0 PUNCT F

During 0 ADP T
the 0 DET F
'dark 0 PUNCT F
' 0 PUNCT F
interval 0 NOUN F
, 0 PUNCT F
subjects 0 NOUN F
were 0 VERB F
asked 0 VERB F
to 0 ADP F
indicate 0 ADJ F
when 0 ADP F
the 0 DET F
movement 0 NOUN F
represented 0 ADJ F
in 0 ADP F
the 0 DET F
video 0 ADJ F
reached 0 VERB F
its 0 PUNCT F
end 0 NOUN F
by 0 ADP F
clicking 0 ADJ F
on 0 ADP F
the 0 DET F
space 0 NOUN F
bar 0 PUNCT F
of 0 ADP F
the 0 DET F
keyboard 0 NOUN F
. 0 PUNCT F

We 0 PRON T
also 0 ADV F
included 0 VERB F
a 0 DET F
visual B-MENTAL ADJ F
working I-MENTAL ADP F
memory I-MENTAL NOUN F
task I-MENTAL NOUN F
. 0 PUNCT F

Performance 0 NOUN T
on 0 ADP F
the 0 DET F
timing 0 PUNCT F
task 0 NOUN F
was 0 VERB F
analysed 0 VERB F
measuring 0 ADP F
the 0 DET F
absolute 0 ADJ F
value 0 NOUN F
of 0 ADP F
timing 0 VERB F
error 0 NOUN F
, 0 PUNCT F
the 0 DET F
coefficient 0 NOUN F
of 0 ADP F
variability 0 NOUN F
and 0 CCONJ F
the 0 DET F
percentage 0 NOUN F
of 0 ADP F
anticipation 0 NOUN F
responses 0 NOUN F
. 0 PUNCT F

Patients 0 NOUN T
with 0 ADP F
writer 0 ADJ F
's 0 PUNCT F
cramp 0 NOUN F
exhibited 0 VERB F
greater 0 PUNCT F
absolute 0 ADJ F
timing 0 ADP F
error 0 NOUN F
compared 0 VERB F
with 0 ADP F
control 0 NOUN F
subjects 0 NOUN F
in 0 ADP F
the 0 DET F
human 0 NOUN F
body 0 NOUN F
motion 0 NOUN F
task 0 NOUN F
( 0 PUNCT F
whereas 0 ADP F
no 0 DET F
difference 0 NOUN F
was 0 VERB F
observed 0 VERB F
in 0 ADP F
the 0 DET F
inanimate 0 ADJ F
object 0 NOUN F
motion 0 NOUN F
task 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

No 0 DET T
effect 0 NOUN F
of 0 ADP F
group 0 NOUN F
was 0 VERB F
documented 0 VERB F
on 0 ADP F
the 0 DET F
visual 0 ADJ F
working 0 ADP F
memory 0 NOUN F
tasks 0 NOUN F
. 0 PUNCT F

Absolute B-MENTAL ADJ T
timing I-MENTAL PART F
error I-MENTAL NOUN F
on 0 ADP F
the 0 DET F
human 0 NOUN F
body 0 NOUN F
motion 0 NOUN F
task 0 NOUN F
did 0 VERB F
not 0 ADV F
significantly 0 ADV F
correlate 0 VERB F
with 0 ADP F
symptom 0 NOUN F
severity 0 NOUN F
, 0 PUNCT F
disease 0 NOUN F
duration 0 NOUN F
or 0 CCONJ F
writing 0 DET F
speed 0 NOUN F
. 0 PUNCT F

Our 0 DET T
findings 0 NOUN F
suggest 0 VERB F
an 0 DET F
alteration 0 NOUN F
of 0 ADP F
the 0 DET F
writing 0 ADJ F
movement 0 NOUN F
representation 0 NOUN F
at 0 ADP F
a 0 DET F
central 0 ADJ F
level 0 NOUN F
and 0 CCONJ F
are 0 NOUN F
consistent 0 ADJ F
with 0 ADP F
the 0 DET F
view 0 NOUN F
that 0 PUNCT F
dystonia 0 NOUN F
is 0 VERB F
not 0 ADV F
a 0 DET F
purely 0 ADV F
motor 0 NOUN F
disorder 0 NOUN F
, 0 PUNCT F
but 0 CCONJ F
it 0 PRON F
also 0 ADP F
involves 0 NOUN F
non-motor 0 NOUN F
( 0 PUNCT F
sensory 0 ADJ F
, 0 PUNCT F
cognitive 0 ADJ F
) 0 PUNCT F
aspects 0 NOUN F
related 0 VERB F
to 0 ADP F
movement 0 NOUN F
processing 0 VERB F
and 0 CCONJ F
planning 0 VERB F
. 0 PUNCT F

Stepwise 0 PUNCT T
hook 0 PUNCT F
extension 0 NOUN F
technique 0 NOUN F
for 0 ADP F
radiofrequency 0 NOUN F
ablation 0 NOUN F
therapy 0 NOUN F
of 0 ADP F
hepatocellular 0 ADJ F
carcinoma 0 NOUN F
. 0 PUNCT F

OBJECTIVE 0 NOUN T
Our 0 PUNCT T
study 0 NOUN F
was 0 VERB F
designed 0 VERB F
to 0 PART F
examine 0 NOUN F
the 0 DET F
efficacy 0 NOUN F
of 0 ADP F
stepwise 0 PUNCT F
hook 0 PUNCT F
extension 0 NOUN F
technique 0 NOUN F
for 0 ADP F
radiofrequency 0 NOUN F
ablation 0 NOUN F
( 0 PUNCT F
RFA 0 NOUN T
) 0 PUNCT F
therapy 0 NOUN F
of 0 ADP F
hepatocellular 0 ADJ F
carcinoma 0 NOUN F
in 0 ADP F
a 0 DET F
randomized 0 VERB F
controlled 0 DET F
study 0 NOUN F
. 0 PUNCT F

METHOD 0 NOUN T
Twenty 0 NUM T
patients 0 NOUN F
with 0 ADP F
hepatocellular 0 ADJ F
carcinoma 0 NOUN F
measuring 0 VERB F
< 0 ADP F
25 0 NUM F
mm 0 NOUN F
were 0 VERB F
divided 0 VERB F
randomly 0 ADV F
into 0 ADP F
two 0 NUM F
equal 0 ADJ F
groups 0 NOUN F
. 0 PUNCT F

RFA 0 NOUN T
was 0 VERB F
applied 0 VERB F
using 0 VERB F
our 0 PUNCT F
new 0 ADJ F
stepwise 0 PUNCT F
hook 0 PUNCT F
extension 0 NOUN F
technique 0 NOUN F
in 0 ADP F
patients 0 NOUN F
of 0 ADP F
group 0 NOUN F
1 0 NUM F
, 0 PUNCT F
and 0 CCONJ F
the 0 DET F
full 0 ADJ F
extension 0 NOUN F
method 0 NOUN F
in 0 ADP F
group 0 NOUN F
2 0 NUM F
. 0 PUNCT F

The 0 DET T
10-hook 0 PUNCT F
electrode 0 NOUN F
of 0 ADP F
LeVeen 0 NUM T
needle 0 NOUN F
was 0 VERB F
deployed 0 VERB F
in 0 ADP F
four 0 NUM F
steps 0 NOUN F
to 0 ADP F
full 0 ADJ F
extension 0 NOUN F
during 0 ADP F
ablation 0 NOUN F
in 0 ADP F
group 0 NOUN F
1 0 NUM F
, 0 PUNCT F
and 0 CCONJ F
full 0 ADJ F
extension 0 NOUN F
at 0 ADP F
start 0 NOUN F
of 0 ADP F
treatment 0 NOUN F
in 0 ADP F
group 0 NOUN F
2 0 NUM F
. 0 PUNCT F

RESULTS 0 DET T
Roll-off B-PHYSICAL PUNCT T
was 0 VERB F
achieved 0 VERB F
in 0 ADP F
all 0 DET F
10 0 NUM F
patients 0 NOUN F
of 0 ADP F
group 0 NOUN F
1 0 NUM F
, 0 PUNCT F
indicative 0 ADJ F
of 0 ADP F
sufficient 0 ADJ F
tumor 0 NOUN F
coagulation 0 NOUN F
, 0 PUNCT F
but 0 CCONJ F
only 0 ADV F
in 0 ADP F
3 0 NUM F
of 0 ADP F
10 0 NUM F
patients 0 NOUN F
of 0 ADP F
group 0 NOUN F
2 0 NUM F
. 0 PUNCT F

The 0 DET T
median 0 ADJ F
time B-OTHER NOUN F
to I-OTHER ADP F
completion I-OTHER NOUN F
of I-OTHER ADP F
treatment I-OTHER NOUN F
was 0 VERB F
6 0 NUM F
min 0 NOUN F
and 0 CCONJ F
55 0 NUM F
s 0 NOUN F
( 0 PUNCT F
range 0 NOUN F
3 0 NUM F
min 0 NOUN F
to 0 ADP F
14 0 NUM F
min 0 NOUN F
and 0 CCONJ F
3 0 NUM F
s 0 NOUN F
) 0 PUNCT F
and 0 CCONJ F
15 0 NUM F
min 0 NOUN F
( 0 PUNCT F
6-15 0 ADP F
min 0 NOUN F
) 0 PUNCT F
, 0 PUNCT F
respectively 0 ADV F
. 0 PUNCT F

The 0 DET T
total 0 ADJ F
power 0 NOUN F
output B-OTHER NOUN F
used 0 VERB F
for 0 ADP F
RF 0 NOUN T
was 0 VERB F
lower 0 PUNCT F
in 0 ADP F
group 0 NOUN F
1 0 NUM F
than 0 PUNCT F
in 0 ADP F
group 0 NOUN F
2 0 NUM F
( 0 PUNCT F
median 0 ADJ F
271 0 NUM F
vs. 0 CCONJ F
1,045 0 NUM F
W.m 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
diameters 0 NOUN F
of 0 ADP F
RFA-induced B-PHYSICAL VERB T
lesions I-PHYSICAL NOUN F
were 0 VERB F
not 0 ADV F
significantly 0 ADV F
different 0 ADJ F
between 0 ADP F
the 0 DET F
groups 0 NOUN F
( 0 PUNCT F
group 0 NOUN F
1 0 NUM F
: 0 PUNCT F
27 0 NUM F
, 0 PUNCT F
range 0 NOUN F
23-37 0 NUM F
mm 0 NOUN F
; 0 PUNCT F
group 0 NOUN F
2 0 NUM F
: 0 PUNCT F
23 0 NUM F
, 0 PUNCT F
0-42 0 NUM F
mm 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

CONCLUSIONS 0 NOUN T
Application 0 NOUN T
of 0 ADP F
RFA 0 NOUN T
using 0 VERB F
stepwise 0 PUNCT F
hook 0 PUNCT F
extension 0 NOUN F
technique 0 NOUN F
is 0 VERB F
superior 0 ADJ F
to 0 ADP F
the 0 DET F
full 0 ADJ F
extension 0 NOUN F
method 0 NOUN F
since 0 ADP F
it 0 DET F
produces 0 NOUN F
the 0 DET F
same 0 ADJ F
therapeutic B-OTHER ADJ F
effects I-OTHER NOUN F
within 0 ADP F
a 0 DET F
short 0 ADJ F
period 0 NOUN F
using 0 ADJ F
a 0 DET F
lower 0 PUNCT F
energy 0 NOUN F
. 0 PUNCT F

Active 0 ADJ T
warming 0 DET F
, 0 PUNCT F
not 0 ADV F
passive 0 ADJ F
heat 0 NOUN F
retention 0 NOUN F
, 0 PUNCT F
maintains 0 NOUN F
normothermia B-PHYSICAL NOUN F
during 0 ADP F
combined 0 VERB F
epidural-general 0 ADJ F
anesthesia 0 NOUN F
for 0 ADP F
hip 0 NOUN F
and 0 CCONJ F
knee 0 NOUN F
arthroplasty 0 NOUN F
. 0 PUNCT F

STUDY 0 NOUN T
OBJECTIVE 0 NOUN T
to 0 PART F
compare 0 NOUN F
passive 0 ADJ F
heat 0 NOUN F
retention 0 NOUN F
by 0 ADP F
low-flow 0 PUNCT F
anesthesia 0 NOUN F
, 0 PUNCT F
alone 0 ADJ F
and 0 CCONJ F
with 0 ADP F
additional 0 ADJ F
thermal 0 ADJ F
insulation 0 NOUN F
by 0 ADP F
reflective 0 ADJ F
blankets 0 NOUN F
, 0 PUNCT F
with 0 ADP F
forced-air 0 NOUN F
warming 0 PUNCT F
preventing 0 VERB F
intraoperative 0 ADJ F
hypothermia 0 NOUN F
during 0 ADP F
combined 0 VERB F
epidural-general 0 ADJ F
anesthesia 0 NOUN F
. 0 PUNCT F

DESIGN 0 NOUN T
Randomized 0 PROPN T
, 0 PUNCT F
controlled 0 ADP F
study 0 NOUN F
. 0 PUNCT F

SETTING 0 NUM T
Inpatient 0 NOUN T
anesthesia 0 NOUN F
at 0 ADP F
a 0 DET F
university 0 NOUN F
department 0 NOUN F
of 0 ADP F
orthopedic 0 ADJ F
surgery 0 NOUN F
. 0 PUNCT F

PATIENTS 0 NOUN T
30 0 NUM F
ASA 0 NOUN T
physical 0 ADJ F
status 0 NOUN F
I 0 NUM T
and 0 CCONJ F
II 0 NUM T
patients 0 NOUN F
, 0 PUNCT F
who 0 ADP F
were 0 VERB F
scheduled 0 VERB F
for 0 ADP F
elective 0 ADJ F
hip 0 NOUN F
or 0 CCONJ F
knee 0 NOUN F
arthroplasty 0 ADJ F
and 0 CCONJ F
were 0 VERB F
free 0 ADJ F
from 0 ADP F
systemic 0 ADJ F
disease 0 NOUN F
. 0 PUNCT F

INTERVENTIONS 0 NOUN T
Patients 0 NOUN T
received 0 VERB F
epidural 0 ADJ F
block 0 NOUN F
up 0 PUNCT F
to 0 ADP F
T10 0 PUNCT T
by 0 ADP F
alkalinized 0 VERB F
lidocaine 0 NOUN F
2 0 NUM F
% 0 SYM F
, 0 PUNCT F
and 0 CCONJ F
then 0 ADV F
were 0 ADV F
administered 0 NUM F
standard 0 PUNCT F
general 0 ADJ F
anesthesia 0 NOUN F
by 0 ADP F
means 0 NOUN F
of 0 ADP F
low-flow 0 ADJ F
rebreathing 0 VERB F
system 0 NOUN F
( 0 PUNCT F
fresh 0 ADJ F
gas 0 NOUN F
flow 0 NOUN F
= 0 SYM F
1 0 NUM F
L/min 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

All 0 DET T
procedures 0 NOUN F
started 0 VERB F
between 0 ADP F
8 0 NUM F
and 0 CCONJ F
10 0 NUM F
AM 0 NOUN T
, 0 PUNCT F
and 0 CCONJ F
operating 0 PRON F
room 0 NOUN F
( 0 PUNCT F
OR 0 CCONJ T
) 0 PUNCT F
temperature 0 NOUN F
was 0 VERB F
maintained 0 VERB F
between 0 ADP F
21 0 NUM F
degrees 0 NOUN F
and 0 CCONJ F
23 0 NUM F
degrees 0 NOUN F
C 0 NOUN T
, 0 PUNCT F
with 0 ADP F
relative 0 ADJ F
humidity 0 NOUN F
ranging 0 ADJ F
between 0 ADP F
40 0 NUM F
% 0 SYM F
and 0 CCONJ F
45 0 NUM F
% 0 SYM F
. 0 PUNCT F

For 0 ADP T
heat 0 NOUN F
retention 0 NOUN F
or 0 CCONJ F
warming 0 PROPN F
therapy 0 NOUN F
, 0 PUNCT F
patients 0 NOUN F
received 0 VERB F
either 0 PUNCT F
low-flow 0 PUNCT F
anesthesia 0 NOUN F
only 0 ADV F
( 0 PUNCT F
control 0 NOUN F
, 0 PUNCT F
n 0 NOUN F
= 0 SYM F
10 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
low-flow 0 PUNCT F
anesthesia 0 NOUN F
with 0 ADP F
additional 0 ADJ F
reflective 0 ADJ F
blankets 0 NOUN F
( 0 PUNCT F
blanket 0 NOUN F
, 0 PUNCT F
n 0 NOUN F
= 0 SYM F
10 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
or 0 CCONJ F
low-flow 0 ADJ F
anesthesia 0 NOUN F
with 0 ADP F
active 0 ADJ F
forced-air 0 NOUN F
warming 0 PROPN F
( 0 PUNCT F
forced-air 0 NOUN F
, 0 PUNCT F
n 0 NOUN F
= 0 SYM F
10 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Tympanic B-PHYSICAL ADJ T
temperature I-PHYSICAL NOUN F
was 0 VERB F
measured 0 VERB F
at 0 ADP F
OR 0 NOUN T
arrival 0 NOUN F
( 0 PUNCT F
baseline 0 NOUN F
) 0 PUNCT F
; 0 PUNCT F
immediately 0 ADV F
following 0 CCONJ F
general 0 ADJ F
anesthesia 0 NOUN F
induction 0 NOUN F
; 0 PUNCT F
30 0 NUM F
, 0 PUNCT F
60 0 NUM F
, 0 PUNCT F
90 0 NUM F
, 0 PUNCT F
and 0 CCONJ F
120 0 NUM F
minutes 0 NOUN F
from 0 ADP F
general 0 ADJ F
anesthesia 0 NOUN F
induction 0 NOUN F
; 0 PUNCT F
and 0 CCONJ F
at 0 ADP F
the 0 DET F
end 0 NOUN F
of 0 ADP F
surgery 0 NOUN F
. 0 PUNCT F

MEASUREMENTS 0 ADP T
AND 0 CCONJ T
MAIN 0 ADJ T
RESULTS 0 NOUN T
Duration B-PHYSICAL NOUN T
of I-PHYSICAL ADP F
anesthesia I-PHYSICAL NOUN F
, 0 PUNCT F
invasiveness B-PHYSICAL NOUN F
of I-PHYSICAL ADP F
surgery I-PHYSICAL NOUN F
, 0 PUNCT F
and 0 PUNCT F
baseline 0 PUNCT F

A 0 DET T
double-blind 0 ADJ F
, 0 PUNCT F
randomized 0 VERB F
, 0 PUNCT F
controlled 0 PUNCT F
, 0 PUNCT F
multicenter 0 NOUN F
study 0 NOUN F
to 0 PRON F
assess 0 NOUN F
the 0 DET F
safety B-OTHER NOUN F
and 0 CCONJ F
cardiovascular B-ADVERSE-EFFECTS ADJ F
effects I-ADVERSE-EFFECTS NOUN F
of 0 ADP F
skeletal 0 ADJ F
myoblast 0 NOUN F
implantation 0 NOUN F
by 0 ADP F
catheter 0 NOUN F
delivery 0 NOUN F
in 0 ADP F
patients 0 NOUN F
with 0 ADP F
chronic 0 ADJ F
heart 0 NOUN F
failure 0 NOUN F
after 0 ADP F
myocardial 0 ADJ F
infarction 0 NOUN F
. 0 PUNCT F

BACKGROUND 0 NOUN T
We 0 PRON T
sought 0 PROPN F
to 0 PART F
determine 0 NOUN F
the 0 DET F
safety B-OTHER NOUN F
and 0 CCONJ F
preliminary 0 ADJ F
efficacy 0 NOUN F
of 0 ADP F
transcatheter 0 CCONJ F
intramyocardial 0 ADJ F
administration 0 NOUN F
of 0 ADP F
myoblasts 0 NOUN F
in 0 ADP F
patients 0 NOUN F
with 0 ADP F
heart 0 NOUN F
failure 0 NOUN F
( 0 PUNCT F
HF 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

METHODS 0 NOUN T
MARVEL 0 NOUN T
is 0 VERB F
a 0 DET F
randomized 0 VERB F
placebo-controlled 0 VERB F
trial 0 NOUN F
of 0 ADP F
image-guided 0 ADJ F
, 0 PUNCT F
catheter-based 0 VERB F
intramyocardial 0 ADJ F
injection 0 NOUN F
of 0 ADP F
placebo 0 NOUN F
or 0 CCONJ F
myoblasts 0 NOUN F
( 0 PUNCT F
400 0 NUM F
or 0 CCONJ F
800 0 NUM F
million 0 NUM F
) 0 PUNCT F
in 0 ADP F
patients 0 NOUN F
with 0 ADP F
class 0 NOUN F
II 0 NUM T
to 0 ADP F
IV 0 NUM T
HF 0 NOUN T
and 0 CCONJ F
ejection 0 NOUN F
fraction 0 NOUN F
< 0 SYM F
35 0 NUM F
% 0 SYM F
. 0 PUNCT F

Primary 0 ADJ T
end 0 NOUN F
points 0 NOUN F
were 0 VERB F
frequency 0 NOUN F
of 0 ADP F
serious B-ADVERSE-EFFECTS ADJ F
adverse I-ADVERSE-EFFECTS ADJ F
events I-ADVERSE-EFFECTS NOUN F
( 0 PUNCT F
safety B-PHYSICAL NOUN F
) 0 PUNCT F
and 0 CCONJ F
changes B-PHYSICAL NOUN F
in I-PHYSICAL ADP F
6-minute I-PHYSICAL ADJ F
walk I-PHYSICAL NOUN F
test I-PHYSICAL NOUN F
and 0 CCONJ F
Minnesota B-OTHER NOUN T
Living I-OTHER PUNCT T
With I-OTHER ADP T
HF I-OTHER NOUN T
score 0 NOUN F
( 0 PUNCT F
efficacy 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

Of 0 ADP T
330 0 NUM F
patients 0 NOUN F
intended 0 VERB F
for 0 ADP F
enrollment 0 NOUN F
, 0 PUNCT F
23 0 NUM F
were 0 VERB F
randomized 0 PROPN F
( 0 PUNCT F
MARVEL-1 0 NOUN T
) 0 PUNCT F
before 0 ADP F
stopping 0 ADP F
the 0 DET F
study 0 NOUN F
for 0 ADP F
financial 0 ADJ F
reasons 0 NOUN F
. 0 PUNCT F

RESULTS 0 NOUN T
At 0 ADP T
6 0 NUM F
months 0 NOUN F
, 0 PUNCT F
similar 0 ADJ F
numbers 0 NOUN F
of 0 ADP F
events 0 NOUN F
occurred 0 VERB F
in 0 ADP F
each 0 DET F
group 0 NOUN F
: 0 PUNCT F
8 0 NUM F
( 0 PUNCT F
placebo 0 NOUN F
) 0 PUNCT F
, 0 PUNCT F
7 0 NUM F
( 0 PUNCT F
low 0 ADJ F
dose 0 NOUN F
) 0 PUNCT F
, 0 PUNCT F
and 0 CCONJ F
8 0 NUM F
( 0 PUNCT F
high 0 ADJ F
dose 0 NOUN F
) 0 PUNCT F
, 0 PUNCT F
without 0 ADP F
deaths 0 NOUN F
. 0 PUNCT F

Ventricular B-PHYSICAL ADJ T
tachycardia I-PHYSICAL NOUN F
responsive I-PHYSICAL ADJ F
to I-PHYSICAL ADP F
amiodarone I-PHYSICAL NOUN F
was 0 VERB F
more 0 ADV F
frequent 0 ADP F
in 0 ADP F
myoblast-treated 0 VERB F
patients 0 NOUN F
: 0 PUNCT F
1 0 NUM F
( 0 PUNCT F
placebo 0 NOUN F
) 0 PUNCT F
, 0 PUNCT F
3 0 NUM F
( 0 PUNCT F
low 0 ADJ F
dose 0 NOUN F
) 0 PUNCT F
, 0 PUNCT F
and 0 CCONJ F
4 0 NUM F
( 0 PUNCT F
high 0 ADJ F
dose 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

A 0 DET T
trend 0 NOUN F
toward 0 ADP F
improvement 0 NOUN F
in 0 ADP F
functional B-MENTAL ADJ F
capacity I-MENTAL NOUN F
was 0 VERB F
noted 0 VERB F
in 0 ADP F
myoblast-treated 0 ADJ F
groups 0 NOUN F
( 0 PUNCT F
?6-minute 0 PUNCT F
walk 0 NOUN F
test 0 NOUN F
of 0 ADP F
-3.6 0 NUM F
vs 0 CCONJ F
+95.6 0 PUNCT F
vs 0 CCONJ F
+85.5 0 PUNCT F
m 0 NOUN F
[ 0 PUNCT F
placebo 0 NOUN F
vs 0 CCONJ F
low 0 ADJ F
dose 0 NOUN F
vs 0 CCONJ F
high 0 ADJ F
dose 0 NOUN F
; 0 PUNCT F
P 0 NOUN T
= 0 SYM F
.50 0 PUNCT F
] 0 PUNCT F
) 0 PUNCT F
without 0 ADP F
significant 0 ADJ F
changes 0 NOUN F
in 0 ADP F
Minnesota 0 NOUN T
Living 0 PUNCT T
With 0 ADP T
HF 0 NOUN T
scores 0 NOUN F
. 0 PUNCT F

CONCLUSIONS 0 NOUN T
In 0 ADP T
HF 0 NOUN T
patients 0 NOUN F
with 0 ADP F
chronic 0 ADJ F
postinfarction 0 NOUN F
cardiomyopathy 0 NOUN F
, 0 PUNCT F
transcatheter 0 CCONJ F
administration 0 NOUN F
of 0 ADP F
myoblasts 0 NOUN F
in 0 ADP F
doses 0 NOUN F
of 0 ADP F
400 0 NUM F
to 0 ADP F
800 0 NUM F
million 0 NUM F
cells 0 NOUN F
is 0 VERB F
feasible 0 ADJ F
and 0 CCONJ F
may 0 VERB F
lead 0 VERB F
to 0 ADP F
important 0 ADJ F
clinical 0 ADJ F
benefits 0 NOUN F
. 0 PUNCT F

Ventricular 0 ADJ T
tachycardia 0 NOUN F
may 0 VERB F
be 0 VERB F
provoked 0 PROPN F
by 0 ADP F
myoblast 0 NOUN F
injection 0 NOUN F
but 0 CCONJ F
appears 0 NOUN F
to 0 PART F
be 0 PUNCT F
a 0 DET F
transient 0 ADJ F
and 0 CCONJ F
treatable 0 ADJ F
problem 0 NOUN F
. 0 PUNCT F

A 0 DET T
large-scale 0 NOUN F
outcome 0 NOUN F
trial 0 NOUN F
of 0 ADP F
myoblast 0 NOUN F
administration 0 NOUN F
in 0 ADP F
HF 0 NOUN T
patients 0 NOUN F
with 0 ADP F
postinfarction 0 NOUN F
cardiomyopathy 0 NOUN F
is 0 VERB F
feasible 0 ADJ F
and 0 CCONJ F
warranted 0 VERB F
. 0 PUNCT F

Oral B-PHYSICAL ADJ T
estrogen I-PHYSICAL NOUN F
antagonizes I-PHYSICAL VERB F
the I-PHYSICAL DET F
metabolic I-PHYSICAL ADJ F
actions I-PHYSICAL NOUN F
of I-PHYSICAL ADP F
growth I-PHYSICAL NOUN F
hormone I-PHYSICAL NOUN F
in I-PHYSICAL ADP F
growth I-PHYSICAL NOUN F
hormone-deficient I-PHYSICAL ADP F
women I-PHYSICAL NOUN F
. 0 PUNCT F

We 0 PRON T
have 0 ADP F
determined 0 VERB F
whether 0 ADP F
oral 0 ADJ F
estrogen 0 NOUN F
reduces 0 NOUN F
the 0 DET F
biological 0 ADJ F
effects 0 NOUN F
of 0 ADP F
growth 0 NOUN F
hormone 0 NOUN F
( 0 PUNCT F
GH 0 NOUN T
) 0 PUNCT F
in 0 ADP F
GH-deficient 0 ADJ T
( 0 PUNCT F
GHD 0 NOUN T
) 0 PUNCT F
women 0 NOUN F
compared 0 VERB F
with 0 ADP F
transdermal 0 ADJ F
estrogen 0 NOUN F
treatment 0 NOUN F
. 0 PUNCT F

In 0 ADP T
two 0 NUM F
separate 0 ADJ F
studies 0 NOUN F
, 0 PUNCT F
eight 0 NUM F
GHD 0 NOUN T
women 0 NOUN F
randomly 0 ADV F
received 0 PUNCT F
either 0 CCONJ F
oral 0 ADJ F
or 0 CCONJ F
transdermal 0 ADJ F
estrogen 0 NOUN F
for 0 ADP F
8 0 NUM F
wk 0 NOUN F
before 0 PUNCT F
crossing 0 ADJ F
over 0 PUNCT F
to 0 PUNCT F
the 0 DET F
alternate 0 NOUN F
route 0 NOUN F
of 0 ADP F
administration 0 NOUN F
. 0 PUNCT F

The 0 DET T
first 0 ADJ F
study 0 NOUN F
assessed 0 VERB F
the 0 DET F
effects 0 NOUN F
of 0 ADP F
incremental 0 ADJ F
doses 0 NOUN F
of 0 ADP F
GH 0 NOUN T
( 0 PUNCT F
0.5 0 NUM F
, 0 PUNCT F
1.0 0 NUM F
, 0 PUNCT F
2.0 0 NUM F
IU/day 0 NOUN T
for 0 ADP F
1 0 NUM F
wk 0 NOUN F
each 0 ADP F
) 0 PUNCT F
on 0 ADP F
insulin-like 0 ADJ F
growth 0 NOUN F
factor 0 NOUN F
I 0 NUM T
( 0 PUNCT F
IGF-I 0 NOUN T
) 0 PUNCT F
levels 0 NOUN F
during 0 ADP F
each 0 DET F
estrogen 0 NOUN F
treatment 0 NOUN F
phase 0 NOUN F
. 0 PUNCT F

The 0 DET T
second 0 ADJ F
study 0 NOUN F
assessed 0 VERB F
the 0 DET F
effects 0 NOUN F
of 0 ADP F
GH 0 NOUN T
( 0 PUNCT F
2 0 NUM F
IU/day 0 NOUN T
) 0 PUNCT F
on 0 ADP F
lipid 0 NOUN F
oxidation 0 NOUN F
and 0 CCONJ F
on 0 ADP F
protein 0 NOUN F
metabolism 0 NOUN F
using 0 VERB F
the 0 DET F
whole 0 ADJ F
body 0 NOUN F
leucine 0 NOUN F
turnover 0 NOUN F
technique 0 NOUN F
. 0 PUNCT F

Mean 0 NOUN T
IGF-I 0 NOUN T
level 0 NOUN F
was 0 VERB F
significantly 0 ADV F
lower 0 PUNCT F
during 0 ADP F
oral 0 ADJ F
estrogen 0 NOUN F
treatment 0 NOUN F
( 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.05 0 NUM F
) 0 PUNCT F
and 0 CCONJ F
rose B-PHYSICAL PUNCT F
dose I-PHYSICAL NOUN F
dependently I-PHYSICAL ADV F
during I-PHYSICAL ADP F
GH I-PHYSICAL NOUN T
administration I-PHYSICAL NOUN F
by 0 ADP F
a 0 DET F
lesser 0 PUNCT F
magnitude 0 NOUN F
( 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.05 0 NUM F
) 0 PUNCT F
compared 0 VERB F
with 0 ADP F
transdermal 0 ADJ F
treatment 0 NOUN F
. 0 PUNCT F

Postprandial B-PHYSICAL ADJ T
lipid I-PHYSICAL NOUN F
oxidation I-PHYSICAL NOUN F
was I-PHYSICAL VERB F
significantly I-PHYSICAL ADV F
lower 0 PUNCT F
with B-PHYSICAL ADP F
oral I-PHYSICAL ADJ F
estrogen B-PHYSICAL NOUN F
treatment 0 NOUN F
, 0 PUNCT F
both 0 PUNCT F
before 0 PUNCT F
( 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.05 0 NUM F
) 0 PUNCT F
and 0 CCONJ F
during 0 ADP F
( 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.05 0 NUM F
) 0 PUNCT F
GH 0 NOUN T
administration 0 NOUN F
, 0 PUNCT F
compared 0 VERB F
with 0 ADP F
transdermal 0 ADJ F
treatment 0 NOUN F
. 0 PUNCT F

Protein B-PHYSICAL NOUN T
synthesis I-PHYSICAL NOUN F
was 0 VERB F
lower 0 PUNCT F
during 0 ADP F
oral 0 ADJ F
estrogen 0 NOUN F
both 0 PUNCT F
before 0 ADP F
and 0 CCONJ F
during 0 ADP F
GH 0 NOUN T
administration 0 NOUN F
( 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.05 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Oral 0 ADJ T
estrogen 0 NOUN F
antagonizes B-PHYSICAL VERB F
several I-PHYSICAL ADJ F
of I-PHYSICAL ADP F
the B-PHYSICAL DET F
metabolic I-PHYSICAL ADJ F
actions I-PHYSICAL NOUN F
of I-PHYSICAL ADP F
GH I-PHYSICAL NOUN T
. 0 PUNCT F

It 0 PRON T
may 0 PUNCT F
aggravate 0 PUNCT F

Safety 0 NOUN T
and 0 CCONJ F
efficacy 0 NOUN F
of 0 ADP F
sitaxsentan 0 NOUN F
50 0 NUM F
and 0 CCONJ F
100 0 NUM F
mg 0 NOUN F
in 0 ADP F
patients 0 NOUN F
with 0 ADP F
pulmonary 0 ADJ F
arterial 0 ADJ F
hypertension 0 NOUN F
. 0 PUNCT F

OBJECTIVE 0 NOUN T
To 0 PROPN T
assess 0 NOUN F
safety 0 NOUN F
and 0 CCONJ F
efficacy 0 NOUN F
of 0 ADP F
sitaxsentan 0 NOUN F
50 0 NUM F
and 0 CCONJ F
100 0 NUM F
mg 0 NOUN F
in 0 ADP F
patients 0 NOUN F
with 0 ADP F
pulmonary 0 ADJ F
arterial 0 ADJ F
hypertension 0 NOUN F
( 0 PUNCT F
PAH 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

BACKGROUND 0 NOUN T
Sitaxsentan 0 NOUN T
is 0 VERB F
a 0 DET F
highly 0 ADV F
selective 0 ADJ F
endothelin-A 0 NOUN F
receptor 0 NOUN F
antagonist 0 NOUN F
that 0 ADP F
was 0 VERB F
recently 0 ADV F
withdrawn 0 PUNCT F
by 0 ADP F
the 0 DET F
manufacturer 0 NOUN F
because 0 PUNCT F
of 0 ADP F
a 0 DET F
pattern 0 NOUN F
of 0 ADP F
idiosyncratic 0 ADJ F
liver 0 NOUN F
injury 0 NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
Before 0 PUNCT T
sitaxsentan 0 NOUN F
withdrawal 0 NOUN F
, 0 PUNCT F
this 0 DET F
18-week 0 NOUN F
double-blind 0 ADJ F
, 0 PUNCT F
placebo-controlled 0 VERB F
study 0 NOUN F
randomized 0 VERB F
patients 0 NOUN F
with 0 ADP F
PAH 0 NOUN T
to 0 PROPN F
receive 0 NOUN F
placebo 0 NOUN F
or 0 CCONJ F
sitaxsentan 0 NOUN F
50 0 NUM F
or 0 CCONJ F
100 0 NUM F
mg 0 NOUN F
once 0 PUNCT F
daily 0 ADJ F
. 0 PUNCT F

The 0 DET T
primary 0 ADJ F
efficacy 0 NOUN F
endpoint 0 NOUN F
was 0 VERB F
change 0 NUM F
from 0 ADP F
baseline 0 NOUN F
in 0 ADP F
6-min 0 NOUN F
walk 0 NOUN F
distance 0 NOUN F
( 0 PUNCT F
6MWD 0 NUM F
) 0 PUNCT F
at 0 ADP F
week 0 NOUN F
18 0 NUM F
. 0 PUNCT F

Changes 0 NOUN T
in 0 ADP F
World 0 NOUN T
Health 0 NOUN T
Organization 0 NOUN T
( 0 PUNCT F
WHO 0 NOUN T
) 0 PUNCT F
functional 0 ADJ F
class 0 NOUN F
and 0 CCONJ F
time 0 NOUN F
to 0 ADP F
clinical 0 ADJ F
worsening 0 ADP F
( 0 PUNCT F
TTCW 0 NOUN T
) 0 PUNCT F
were 0 VERB F
secondary 0 ADJ F
endpoints 0 NOUN F
. 0 PUNCT F

The 0 DET T
primary 0 ADJ F
efficacy 0 NOUN F
analysis 0 NOUN F
was 0 VERB F
powered 0 VERB F
for 0 ADP F
sitaxsentan 0 NOUN F
100 0 NUM F
mg 0 NOUN F
versus 0 CCONJ F
placebo 0 NOUN F
. 0 PUNCT F

RESULTS 0 NOUN T
Of 0 ADP T
98 0 NUM F
randomized 0 VERB F
patients 0 NOUN F
, 0 PUNCT F
61 0 NUM F
% 0 SYM F
were 0 VERB F
WHO 0 NOUN T
functional 0 ADJ F
class 0 NOUN F
II 0 NUM T
at 0 ADP F
baseline 0 NOUN F
. 0 PUNCT F

Improvement 0 NOUN T
from 0 ADP F
baseline 0 NOUN F
to 0 PUNCT F
week 0 ADJ F
18 0 NUM F
in 0 ADP F
6MWD 0 NOUN F
occurred 0 VERB F
with 0 ADP F
sitaxsentan 0 NOUN F
100 0 NUM F
but 0 CCONJ F
not 0 ADV F
50 0 NUM F
mg 0 NOUN F
; 0 PUNCT F
a 0 DET F
strong 0 ADJ F
placebo 0 NOUN F
effect 0 NOUN F
was 0 VERB F
observed 0 VERB F
. 0 PUNCT F

At 0 ADP T
week 0 NOUN F
18 0 NUM F
, 0 PUNCT F
WHO 0 NOUN T
functional 0 ADJ F
class 0 NOUN F
was 0 VERB F
improved 0 ADP F
or 0 CCONJ F
maintained 0 VERB F
in 0 ADP F
more 0 DET F
patients 0 NOUN F
receiving 0 VERB F
sitaxsentan 0 NOUN F
100 0 NUM F
mg 0 NOUN F
than 0 PUNCT F
placebo 0 NOUN F
( 0 PUNCT F
P 0 NOUN T
= 0 SYM F
0.038 0 NUM F
) 0 PUNCT F
; 0 PUNCT F
0 0 NUM F
% 0 SYM F
versus 0 CCONJ F
12 0 NUM F
% 0 SYM F
of 0 ADP F
patients 0 NOUN F
deteriorated 0 VERB F
, 0 PUNCT F
respectively 0 ADV F
. 0 PUNCT F

TTCW B-PHYSICAL NOUN T
was 0 VERB F
not 0 ADV F
significantly 0 ADV F
different 0 ADJ F
for 0 ADP F
100-mg 0 NOUN F
sitaxsentan 0 NOUN F
patients 0 NOUN F
than 0 ADP F
placebo 0 NOUN F
( 0 PUNCT F
P 0 NOUN T
= 0 SYM F
0.090 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Adverse 0 ADJ T
events 0 NOUN F
( 0 PUNCT F
AEs 0 ADP T
) 0 PUNCT F
occurring 0 ADP F
more 0 ADV F
frequently 0 ADV F
with 0 ADP F
sitaxsentan 0 NOUN F
( 0 PUNCT F
50 0 NUM F
or 0 CCONJ F
100 0 NUM F
mg 0 NOUN F
) 0 PUNCT F
included 0 VERB F
headache B-ADVERSE-EFFECTS NOUN F
, 0 PUNCT F
peripheral B-ADVERSE-EFFECTS ADJ F
edema I-ADVERSE-EFFECTS NOUN F
, 0 PUNCT F
dizziness B-ADVERSE-EFFECTS NOUN F
, 0 PUNCT F
nausea B-ADVERSE-EFFECTS NOUN F
, 0 PUNCT F
extremity B-ADVERSE-EFFECTS NOUN F
pain I-ADVERSE-EFFECTS NOUN F
, 0 PUNCT F
and 0 PUNCT F

Dual-task-related 0 ADP T
gait 0 NOUN F
changes 0 NOUN F
in 0 ADP F
transitionally 0 ADV F
frail 0 ADP F
older 0 CCONJ F
adults 0 NOUN F
: 0 PUNCT F
the 0 DET F
type 0 NOUN F
of 0 ADP F
the 0 DET F
walking-associated 0 ADV F
cognitive 0 ADJ F
task 0 NOUN F
matters 0 NOUN F
. 0 PUNCT F

BACKGROUND 0 NOUN T
Changes 0 PROPN T
in 0 ADP F
gait 0 NOUN F
patterns 0 NOUN F
due 0 CCONJ F
to 0 ADP F
a 0 DET F
simultaneously 0 ADV F
performed 0 PUNCT F
cognitive 0 ADJ F
task 0 NOUN F
have 0 ADP F
been 0 PUNCT F
reported 0 VERB F
previously 0 ADV F
and 0 CCONJ F
associated 0 VERB F
with 0 ADP F
an 0 DET F
increased 0 VERB F
falling 0 VERB F
risk 0 NOUN F
among 0 ADP F
older 0 PUNCT F
adults 0 NOUN F
. 0 PUNCT F

Little 0 PUNCT T
is 0 VERB F
known 0 NOUN F
whether 0 ADP F
the 0 DET F
type 0 NOUN F
of 0 ADP F
cognitive 0 ADJ F
task 0 NOUN F
performed 0 VERB F
while 0 VERB F
walking 0 VERB F
is 0 ADV F
important 0 ADJ F
concerning 0 ADJ F
possible 0 ADJ F
gait 0 NOUN F
interference 0 NOUN F
in 0 ADP F
older 0 PUNCT F
fall-prone 0 NOUN F
individuals 0 NOUN F
. 0 PUNCT F

OBJECTIVE 0 NOUN T
To 0 PROPN T
quantify 0 NOUN F
and 0 CCONJ F
compare 0 ADJ F
the 0 DET F
effects 0 NOUN F
of 0 ADP F
two 0 NUM F
different 0 ADJ F
cognitive 0 ADJ F
tasks 0 NOUN F
on 0 ADP F
gait 0 NOUN F
in 0 ADP F
transitionally 0 ADV F
frail 0 ADP F
older 0 CCONJ F
adults 0 NOUN F
. 0 PUNCT F

MEASUREMENTS 0 ADP T
Gait 0 NOUN T
was 0 VERB F
tested 0 VERB F
in 0 ADP F
30 0 NUM F
transitionally 0 ADV F
frail 0 ADJ F
older 0 CCONJ F
adults 0 NOUN F
( 0 PUNCT F
mean 0 NOUN F
age 0 NOUN F
82.6 0 NUM F
+/- 0 SYM F
7.1 0 NUM F
years 0 NOUN F
, 0 PUNCT F
90 0 NUM F
% 0 SYM F
female 0 NOUN F
) 0 PUNCT F
while 0 ADP F
either 0 CCONJ F
walking B-MENTAL PUNCT F
alone I-MENTAL ADJ F
, 0 PUNCT F
performing B-MENTAL PUNCT F
a I-MENTAL DET F
simple I-MENTAL ADJ F
arithmetic I-MENTAL ADJ F
task I-MENTAL NOUN F
, 0 PUNCT F
or 0 CCONJ F
performing 0 PUNCT F
a 0 DET F
task 0 NOUN F
of 0 ADP F
verbal 0 ADJ F
fluency 0 NOUN F
. 0 PUNCT F

Walking 0 DET T
time 0 NOUN F
in 0 ADP F
seconds 0 NOUN F
, 0 PUNCT F
number B-MENTAL NOUN F
of I-MENTAL ADP F
steps I-MENTAL NOUN F
, 0 PUNCT F
frequency 0 NOUN F
of 0 ADP F
lateral B-MENTAL ADJ F
line I-MENTAL NOUN F
stepping-over I-MENTAL NOUN F
, 0 PUNCT F
and 0 PUNCT F

The 0 DET T
effects 0 NOUN F
of 0 ADP F
delay 0 NOUN F
in 0 ADP F
standard 0 ADJ F
treatment 0 NOUN F
due 0 VERB F
to 0 ADP F
induction 0 NOUN F
chemotherapy 0 NOUN F
in 0 ADP F
two 0 NUM F
randomized 0 VERB F
prospective 0 ADJ F
studies 0 NOUN F
. 0 PUNCT F

It 0 PRON T
is 0 VERB F
often 0 ADV F
suggested 0 VERB F
that 0 ADP F
tumors 0 NOUN F
will 0 VERB F
respond 0 VERB F
to 0 ADP F
induction 0 NOUN F
chemotherapy 0 NOUN F
and 0 CCONJ F
result 0 NOUN F
in 0 ADP F
improved 0 VERB F
survival B-MORTALITY NOUN F
for 0 ADP F
patients 0 NOUN F
with 0 ADP F
squamous 0 ADJ F
cell 0 NOUN F
carcinoma 0 NOUN F
of 0 ADP F
the 0 DET F
head 0 NOUN F
and 0 CCONJ F
neck 0 NOUN F
. 0 PUNCT F

Two 0 NUM T
regimens 0 NOUN F
of 0 ADP F
induction 0 NOUN F
chemotherapy 0 NOUN F
were 0 VERB F
studied 0 VERB F
in 0 ADP F
separate 0 PUNCT F
randomized 0 VERB F
, 0 PUNCT F
prospective 0 ADJ F
trials 0 NOUN F
over 0 ADP F
the 0 DET F
last 0 ADJ F
6 0 NUM F
years 0 NOUN F
. 0 PUNCT F

Eighty-three 0 VERB T
patients 0 NOUN F
with 0 ADP F
advanced 0 VERB F
disease 0 NOUN F
were 0 VERB F
entered 0 VERB F
into 0 ADP F
the 0 DET F
first 0 ADJ F
study 0 NOUN F
( 0 PUNCT F
43/chemotherapy 0 NOUN F
; 0 PUNCT F
40/control 0 NOUN F
) 0 PUNCT F
, 0 PUNCT F
and 0 CCONJ F
60 0 NUM F
into 0 ADP F
the 0 DET F
second 0 ADJ F
( 0 PUNCT F
27/chemotherapy 0 NOUN F
; 0 PUNCT F
33/control 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

Patient 0 NOUN T
randomization 0 NOUN F
was 0 VERB F
stratified 0 VERB F
by 0 ADP F
stage 0 NOUN F
( 0 PUNCT F
III/IV 0 NOUN T
) 0 PUNCT F
and 0 CCONJ F
site 0 NOUN F
( 0 PUNCT F
oral 0 ADJ F
cavity 0 NOUN F
, 0 PUNCT F
oropharynx 0 ADP F
, 0 PUNCT F
nasopharynx 0 NOUN F
, 0 PUNCT F
hypopharynx 0 NOUN F
, 0 PUNCT F
larynx 0 NOUN F
, 0 PUNCT F
paranasal 0 ADJ F
sinuses 0 ADP F
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
first 0 ADJ F
study 0 NOUN F
utilized 0 PUNCT F
bleomycin 0 NOUN F
, 0 PUNCT F
Cytoxan 0 PUNCT T
, 0 PUNCT F
methotrexate 0 ADJ F
and 0 CCONJ F
5-fluorouracil 0 NOUN F
in 0 ADP F
two 0 NUM F
cycles 0 NOUN F
( 0 PUNCT F
one 0 NUM F
cycle 0 NOUN F
if 0 PUNCT F
no 0 DET F
tumor 0 NOUN F
response 0 NOUN F
) 0 PUNCT F
, 0 PUNCT F
followed 0 VERB F
by 0 ADP F
standard 0 ADJ F
treatment 0 NOUN F
which 0 ADP F
consisted 0 VERB F
of 0 ADP F
combined 0 VERB F
irradiation 0 NOUN F
and 0 CCONJ F
surgery 0 NOUN F
or 0 CCONJ F
, 0 PUNCT F
in 0 ADP F
some 0 DET F
instances 0 NOUN F
, 0 PUNCT F
primary 0 ADJ F
irradiation 0 NOUN F
alone 0 ADJ F
. 0 PUNCT F

The 0 DET T
second 0 ADJ F
study 0 NOUN F
utilized 0 PUNCT F
cisplatin 0 NOUN F
and 0 CCONJ F
5-fluorouracil 0 NOUN F
in 0 ADP F
three 0 NUM F
cycles 0 NOUN F
prior 0 PUNCT F
to 0 ADP F
standard 0 CCONJ F
treatment 0 NOUN F
. 0 PUNCT F

An 0 DET T
objective B-OTHER ADJ F
tumor I-OTHER NOUN F
response I-OTHER NOUN F
to 0 ADP F
chemotherapy 0 NOUN F
was 0 VERB F
observed 0 VERB F
in 0 ADP F
68 0 NUM F
% 0 SYM F
in 0 ADP F
the 0 DET F
first 0 ADJ F
study 0 NOUN F
and 0 CCONJ F
85 0 NUM F
% 0 SYM F
in 0 ADP F
the 0 DET F
second 0 ADJ F
. 0 PUNCT F

The 0 DET T
patient B-MORTALITY NOUN F
survival I-MORTALITY NOUN F
in 0 ADP F
both 0 PUNCT F
studies 0 NOUN F
( 0 PUNCT F
at 0 ADP F
24 0 NUM F
months 0 NOUN F
in 0 ADP F
the 0 DET F
first 0 ADP F
; 0 PUNCT F
at 0 ADP F
19 0 NUM F
in 0 ADP F
the 0 DET F
second 0 ADJ F
) 0 PUNCT F
was 0 VERB F
better 0 PUNCT F
in 0 ADP F
the 0 DET F
control 0 NOUN F
than 0 PUNCT F
that 0 PUNCT F
in 0 ADP F
the 0 DET F
experimental 0 ADJ F
groups 0 NOUN F
( 0 PUNCT F
43 0 NUM F
% 0 SYM F
to 0 ADP F
31 0 NUM F
% 0 SYM F
; 0 PUNCT F
69 0 NUM F
% 0 SYM F
to 0 ADP F
46 0 NUM F
% 0 SYM F
) 0 PUNCT F
. 0 PUNCT F

In 0 ADP T
the 0 DET F
second 0 ADJ F
study 0 NOUN F
, 0 PUNCT F
the 0 DET F
average 0 ADJ F
length 0 NOUN F
of B-OTHER ADP F
delay I-OTHER NOUN F
of I-OTHER ADP F
standard I-OTHER ADJ F
treatment B-OTHER NOUN F
was 0 VERB F
longer 0 PUNCT F
than 0 PUNCT F
in 0 ADP F
the 0 DET F
first 0 ADJ F
study 0 NOUN F
( 0 PUNCT F
95 0 NUM F
days 0 NOUN F
vs. 0 CCONJ F
66 0 NUM F
days 0 NOUN F
; 0 PUNCT F
P 0 NOUN T
less 0 ADV F
than 0 CCONJ F
.02 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Results 0 NOUN T
combining 0 ADP F
the 0 DET F
P-values 0 NOUN T
of 0 ADP F
both 0 PUNCT F
studies 0 NOUN F
indicate 0 VERB F
that 0 ADP F
the 0 DET F
relative 0 ADJ F
risk 0 NOUN F
of 0 ADP F
having 0 VERB F
persistent 0 ADJ F
disease 0 NOUN F
was 0 VERB F
2.9 0 NUM F
times 0 NOUN F
greater 0 PUNCT F
for 0 ADP F
patients 0 NOUN F
who 0 ADP F
received 0 VERB F
chemotherapy 0 NOUN F
. 0 PUNCT F

While 0 PUNCT T

MRI 0 NOUN T
signal 0 NOUN F
hyperintensities 0 CCONJ F
in 0 ADP F
geriatric 0 ADJ F
depression 0 NOUN F
. 0 PUNCT F

OBJECTIVE 0 NOUN T
The 0 DET T
authors 0 NOUN F
rated 0 ADP F
periventricular 0 PUNCT F
and 0 CCONJ F
subcortical 0 ADJ F
signal 0 NOUN F
hyperintensities 0 CCONJ F
on 0 ADP F
magnetic 0 ADJ F
resonance 0 NOUN F
imaging 0 VERB F
( 0 PUNCT F
MRI 0 NOUN T
) 0 PUNCT F
scans 0 PUNCT F
in 0 ADP F
elderly 0 ADJ F
patients 0 NOUN F
with 0 ADP F
depression 0 NOUN F
and 0 CCONJ F
in 0 ADP F
normal 0 ADJ F
subjects 0 NOUN F
with 0 ADP F
similar 0 ADJ F
demographic 0 ADJ F
features 0 NOUN F
to 0 PART F
examine 0 NOUN F
whether 0 ADP F
such 0 ADJ F
changes 0 DET F
discriminate 0 ADP F
patients 0 NOUN F
with 0 ADP F
depression 0 NOUN F
from 0 ADP F
normal 0 ADJ F
subjects 0 NOUN F
and 0 CCONJ F
whether 0 ADP F
they 0 PRON F
are 0 VERB F
associated 0 VERB F
with 0 ADP F
any 0 DET F
clinical 0 ADJ F
variables 0 NOUN F
. 0 PUNCT F

METHOD 0 NOUN T
Two 0 NUM T
established 0 VERB F
hyperintensity 0 NOUN F
rating 0 VERB F
systems 0 NOUN F
were 0 VERB F
used 0 VERB F
to 0 PART F
compare 0 NOUN F
the 0 DET F
MRI 0 NOUN T
brain 0 NOUN F
scans 0 ADJ F
of 0 ADP F
48 0 NUM F
elderly 0 ADJ F
patients 0 NOUN F
with 0 ADP F
depression 0 NOUN F
diagnosed 0 VERB F
according 0 CCONJ F
to 0 ADP F
DSM-III-R 0 NOUN T
with 0 ADP F
the 0 DET F
scans 0 NOUN F
of 0 ADP F
39 0 NUM F
normal 0 ADJ F
elderly 0 ADJ F
subjects 0 NOUN F
. 0 PUNCT F

RESULTS 0 DET T
Elderly 0 ADJ T
depressed 0 DET F
patients 0 NOUN F
manifested 0 ADJ F
significantly 0 ADV F
more 0 ADV F
severe 0 ADJ F
hyperintensity B-PHYSICAL NOUN F
ratings I-PHYSICAL NOUN F
in 0 ADP F
the 0 DET F
subcortical 0 ADJ F
gray 0 ADJ F
matter 0 NOUN F
than 0 PUNCT F
age-matched 0 DET F
comparison 0 NOUN F
subjects 0 NOUN F
. 0 PUNCT F

Significant 0 ADJ T
differences 0 NOUN F
were 0 VERB F
not 0 ADV F
identified 0 VERB F
between 0 ADP F
patients 0 NOUN F
with 0 ADP F
similar 0 ADJ F
current 0 ADJ F
ages 0 NOUN F
and 0 CCONJ F
cerebrovascular 0 ADJ F
disease 0 NOUN F
risk 0 NOUN F
who 0 ADP F
had 0 PUNCT F
early-onset 0 NOUN F
or 0 CCONJ F
late-onset 0 NOUN F
depression 0 NOUN F
. 0 PUNCT F

CONCLUSIONS 0 NOUN T
These 0 DET T
findings 0 NOUN F
support 0 VERB F
those 0 PUNCT F
of 0 ADP F
neuroimaging 0 PUNCT F
studies 0 NOUN F
implicating 0 VERB F
the 0 DET F
basal 0 ADJ F
ganglia 0 NOUN F
in 0 ADP F
depression 0 NOUN F
and 0 CCONJ F
geriatric 0 ADJ F
depression 0 NOUN F
. 0 PUNCT F

The 0 DET T
data 0 NOUN F
suggest 0 VERB F
that 0 ADP F
the 0 DET F
relationship 0 NOUN F
observed 0 VERB F
in 0 ADP F
some 0 DET F
reports 0 NOUN F
between 0 ADP F
late-onset 0 NOUN F
depression 0 NOUN F
and 0 CCONJ F
MRI 0 NOUN T
hyperintensities 0 CCONJ F
is 0 VERB F
most 0 PUNCT F
likely 0 PUNCT F
a 0 DET F
function 0 NOUN F
of 0 ADP F
cerebrovascular 0 ADJ F
disease 0 NOUN F
risk 0 NOUN F
and 0 CCONJ F
age 0 NOUN F
. 0 PUNCT F

A 0 DET T
pilot 0 NOUN F
randomised 0 VERB F
control 0 NOUN F
trial 0 NOUN F
of 0 ADP F
a 0 DET F
parent 0 NOUN F
training 0 NUM F
intervention 0 NOUN F
for 0 ADP F
pre-school 0 NOUN F
children 0 NOUN F
with 0 ADP F
autism 0 NOUN F
. 0 PUNCT F

Preliminary 0 ADJ T
findings 0 NOUN F
and 0 CCONJ F
methodological 0 ADJ F
challenges 0 NOUN F
. 0 PUNCT F

Few 0 ADJ T
attempts 0 PUNCT F
have 0 PUNCT F
been 0 PUNCT F
made 0 VERB F
to 0 PUNCT F
conduct 0 NOUN F
randomised 0 CCONJ F
control 0 NOUN F
trials 0 NOUN F
( 0 PUNCT F
RCTs 0 NOUN T
) 0 PUNCT F
of 0 ADP F
interventions 0 NOUN F
for 0 ADP F
pre-school 0 NOUN F
children 0 NOUN F
with 0 ADP F
autism 0 NOUN F
. 0 PUNCT F

We 0 PRON T
report 0 VERB F
findings 0 NOUN F
of 0 ADP F
a 0 DET F
pilot 0 NOUN F
RCT 0 NOUN T
for 0 ADP F
a 0 DET F
parent 0 NOUN F
training 0 NUM F
intervention 0 NOUN F
with 0 ADP F
a 0 DET F
focus 0 NOUN F
on 0 ADP F
the 0 DET F
development 0 NOUN F
of 0 ADP F
joint 0 NOUN F
attention 0 NOUN F
skills 0 NOUN F
and 0 CCONJ F
joint 0 NOUN F
action 0 NOUN F
routines 0 NOUN F
. 0 PUNCT F

Twenty-four 0 PUNCT T
children 0 NOUN F
meeting 0 PUNCT F
ICD-10 0 NOUN T
criteria 0 NOUN F
for 0 ADP F
childhood 0 NOUN F
autism 0 NOUN F
( 0 PUNCT F
mean 0 NOUN F
age 0 NOUN F
= 0 SYM F
23 0 NUM F
months 0 NOUN F
) 0 PUNCT F
were 0 VERB F
identified 0 VERB F
using 0 VERB F
the 0 DET F
CHAT 0 NOUN T
screen 0 NOUN F
and 0 CCONJ F
randomised 0 PUNCT F
to 0 ADP F
the 0 DET F
parent 0 NOUN F
training 0 ADV F
group 0 NOUN F
or 0 CCONJ F
to 0 DET F
local 0 PUNCT F
services 0 NOUN F
only 0 ADV F
. 0 PUNCT F

A 0 DET T
follow-up 0 NOUN F
was 0 VERB F
conducted 0 VERB F
12 0 NUM F
months 0 NOUN F
later 0 ADJ F
( 0 PUNCT F
mean 0 NOUN F
age 0 NOUN F
= 0 SYM F
35 0 NUM F
months 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

There 0 PUNCT T
was 0 VERB F
some 0 DET F
evidence 0 NOUN F
that 0 ADP F
the 0 DET F
parent 0 NOUN F
training 0 ADV F
group 0 NOUN F
made 0 PUNCT F
more 0 DET F
progress 0 CCONJ F
in 0 ADP F
language B-MENTAL NOUN F
development I-MENTAL NOUN F
than 0 PUNCT F
the 0 DET F
local 0 ADJ F
services 0 NOUN F
group 0 NOUN F
. 0 PUNCT F

However 0 ADV T
, 0 PUNCT F
the 0 DET F
present 0 ADJ F
pilot 0 NOUN F
study 0 NOUN F
was 0 VERB F
compromised 0 VERB F
by 0 ADP F
several 0 ADJ F
factors 0 NOUN F
: 0 PUNCT F
a 0 DET F
reliance 0 NOUN F
on 0 ADP F
parental 0 ADJ F
report 0 NOUN F
to 0 PART F
measure 0 ADJ F
language 0 NOUN F
, 0 PUNCT F
non-matching 0 PUNCT F
of 0 ADP F
the 0 DET F
groups 0 NOUN F
on 0 ADP F
initial 0 ADJ F
IQ 0 NOUN T
, 0 PUNCT F
and 0 CCONJ F
a 0 DET F
lack 0 NOUN F
of 0 ADP F
systematic 0 ADJ F
checking 0 ADP F
regarding 0 ADP F
the 0 DET F
implementation 0 NOUN F
of 0 ADP F
the 0 DET F
parent 0 NOUN F
training 0 NUM F
intervention 0 NOUN F
. 0 PUNCT F

Furthermore 0 ADV T
, 0 PUNCT F
three 0 NUM F
parents 0 NOUN F
in 0 ADP F
the 0 DET F
local 0 ADJ F
services 0 NOUN F
group 0 NOUN F
commenced 0 VERB F
intensive 0 ADJ F
, 0 PUNCT F
home-based 0 VERB F
behavioural 0 ADJ F
intervention 0 NOUN F
during 0 ADP F
the 0 DET F
course 0 NOUN F
of 0 ADP F
the 0 DET F
study 0 NOUN F
. 0 PUNCT F

The 0 DET T
difficulties 0 NOUN F
encountered 0 PUNCT F
in 0 ADP F
the 0 DET F
conduct 0 NOUN F
of 0 ADP F
RCTs 0 NOUN T
for 0 ADP F
pre-school 0 NOUN F
children 0 NOUN F
with 0 ADP F
autism 0 NOUN F
are 0 VERB F
discussed 0 VERB F
. 0 PUNCT F

Methodological 0 ADJ T
challenges 0 NOUN F
and 0 CCONJ F
strategies 0 NOUN F
for 0 ADP F
future 0 NOUN F
well-designed 0 VERB F
RCTs 0 NOUN T
for 0 ADP F
autism 0 NOUN F
interventions 0 NOUN F
are 0 PROPN F
highlighted 0 VERB F
. 0 PUNCT F

Further 0 ADJ T
evaluation 0 NOUN F
of 0 ADP F
docosahexaenoic 0 ADJ F
acid 0 NOUN F
in 0 ADP F
patients 0 NOUN F
with 0 ADP F
retinitis 0 NOUN F
pigmentosa 0 NOUN F
receiving 0 DET F
vitamin 0 NOUN F
A 0 CCONJ T
treatment 0 NOUN F
: 0 PUNCT F
subgroup 0 NOUN F
analyses 0 NOUN F
. 0 PUNCT F

OBJECTIVE 0 NOUN T
To 0 PROPN T
determine 0 NOUN F
whether 0 ADP F
docosahexaenoic 0 ADJ F
acid 0 NOUN F
will 0 PART F
slow 0 CCONJ F
the 0 DET F
course 0 NOUN F
of 0 ADP F
retinal 0 ADJ F
degeneration 0 NOUN F
in 0 ADP F
subgroups 0 NOUN F
of 0 ADP F
patients 0 NOUN F
with 0 ADP F
retinitis 0 NOUN F
pigmentosa 0 NOUN F
who 0 ADP F
are 0 VERB F
receiving 0 ADP F
vitamin 0 NOUN F
A 0 NOUN T
. 0 PUNCT F

DESIGN 0 NOUN T
A 0 DET T
cohort 0 NOUN F
of 0 ADP F
208 0 NUM F
patients 0 NOUN F
with 0 ADP F
retinitis 0 NOUN F
pigmentosa 0 NOUN F
, 0 PUNCT F
aged 0 PUNCT F
18 0 NUM F
to 0 ADP F
55 0 NUM F
years 0 NOUN F
, 0 PUNCT F
were 0 VERB F
randomly 0 ADV F
assigned 0 VERB F
to 0 ADP F
1200 0 NUM F
mg 0 NOUN F
of 0 ADP F
docosahexaenoic 0 ADJ F
acid 0 NOUN F
plus 0 CCONJ F
15 0 NUM F
000 0 NUM F
IU/d 0 NOUN T
of 0 ADP F
vitamin 0 NOUN F
A 0 NOUN T
given 0 VERB F
as 0 ADP F
retinyl 0 NOUN F
palmitate 0 NOUN F
( 0 PUNCT F
DHA 0 NOUN T
+ 0 SYM F
A 0 PUNCT T
group 0 NOUN F
) 0 PUNCT F
or 0 CCONJ F
control 0 NOUN F
fatty 0 ADJ F
acid 0 NOUN F
plus 0 CCONJ F
15 0 NUM F
000 0 NUM F
IU/d 0 NOUN T
of 0 ADP F
vitamin 0 NOUN F
A 0 NOUN T
( 0 PUNCT F
control 0 NOUN F
+ 0 ADP F
A 0 PUNCT T
group 0 NOUN F
) 0 PUNCT F
and 0 CCONJ F
followed 0 VERB F
up 0 ADP F
over 0 ADP F
4 0 NUM F
years 0 NOUN F
. 0 PUNCT F

Seventy 0 ADJ T
percent 0 NOUN F
of 0 ADP F
the 0 DET F
patients 0 NOUN F
in 0 ADP F
each 0 DET F
group 0 NOUN F
were 0 VERB F
taking 0 PUNCT F
vitamin 0 NOUN F
A 0 NOUN T
, 0 PUNCT F
15 0 NUM F
000 0 NUM F
IU/d 0 NOUN T
, 0 PUNCT F
prior 0 PUNCT F
to 0 ADP F
entry 0 NOUN F
. 0 PUNCT F

We 0 PRON T
compared 0 PUNCT F
rates 0 NOUN F
of 0 ADP F
decline 0 NOUN F
in 0 ADP F
ocular 0 ADJ F
function 0 NOUN F
in 0 ADP F
the 0 DET F
DHA 0 NOUN T
+ 0 SYM F
A 0 NOUN T
vs 0 CCONJ F
control 0 NOUN F
+ 0 SYM F
A 0 DET T
groups 0 NOUN F
among 0 ADP F
the 0 DET F
subgroups 0 NOUN F
defined 0 VERB F
by 0 ADP F
use 0 NOUN F
or 0 CCONJ F
nonuse 0 NOUN F
of 0 ADP F
vitamin 0 NOUN F
A 0 CCONJ T
prior 0 PUNCT F
to 0 ADP F
entry 0 NOUN F
. 0 PUNCT F

We 0 PRON T
also 0 ADV F
determined 0 VERB F
whether 0 ADP F
decline 0 PUNCT F
in 0 ADP F
ocular 0 ADJ F
function 0 NOUN F
was 0 VERB F
related 0 VERB F
to 0 ADP F
red 0 ADJ F
blood 0 NOUN F
cell 0 NOUN F
phosphatidylethanolamine 0 NOUN F
docosahexaenoic 0 ADJ F
acid 0 NOUN F
level 0 NOUN F
, 0 PUNCT F
dietary 0 ADJ F
omega-3 0 NOUN F
fatty 0 ADJ F
acid 0 NOUN F
intake 0 NOUN F
, 0 PUNCT F
or 0 CCONJ F
duration 0 NOUN F
of 0 ADP F
vitamin 0 NOUN F
A 0 CCONJ T
use 0 NOUN F
. 0 PUNCT F

Main 0 ADJ T
outcome 0 NOUN F
measures 0 NOUN F
were 0 PUNCT F
Humphrey B-PHYSICAL PUNCT T
Field I-PHYSICAL NOUN T
Analyzer I-PHYSICAL NOUN T
visual I-PHYSICAL ADJ F
field I-PHYSICAL NOUN F
sensitivity I-PHYSICAL NOUN F
, 0 PUNCT F
30-Hz B-OTHER NOUN F
electroretinogram I-OTHER NOUN F
amplitude I-OTHER NOUN F
, 0 PUNCT F
and 0 CCONJ F
visual B-PHYSICAL ADJ F
acuity I-PHYSICAL NOUN F
. 0 PUNCT F

RESULTS 0 NOUN T
Among 0 ADP T
patients 0 NOUN F
not 0 ADV F
taking 0 PUNCT F
vitamin 0 NOUN F
A 0 DET T
prior 0 PUNCT F
to 0 ADP F
entry 0 NOUN F
, 0 PUNCT F
those 0 PUNCT F
in 0 ADP F
the 0 DET F
DHA 0 NOUN T
+ 0 SYM F
A 0 PUNCT T
group 0 NOUN F
had 0 PUNCT F
a 0 DET F
slower 0 PUNCT F
decline 0 NOUN F
in 0 ADP F
field B-PHYSICAL NOUN F
sensitivity I-PHYSICAL NOUN F
and 0 CCONJ F
electroretinogram B-OTHER PUNCT F
amplitude I-OTHER ADJ F
than 0 PUNCT F
those 0 PUNCT F
in 0 ADP F
the 0 DET F
control 0 NOUN F
+ 0 ADV F
A 0 PUNCT T
group 0 NOUN F
over 0 ADP F
the 0 DET F
first 0 ADJ F
2 0 NUM F
years 0 NOUN F
( 0 PUNCT F
P 0 NOUN T
=.01 0 PUNCT F
and 0 CCONJ F
P 0 NOUN T
=.03 0 PUNCT F
, 0 PUNCT F
respectively 0 ADV F
) 0 PUNCT F
; 0 PUNCT F
these 0 DET F
differences 0 NOUN F
were 0 VERB F
not 0 ADV F
observed 0 VERB F
in 0 ADP F
years 0 NOUN F
3 0 NUM F
and 0 CCONJ F
4 0 NUM F
of 0 ADP F
follow-up 0 NOUN F
or 0 CCONJ F
among 0 ADP F
patients 0 NOUN F
taking 0 ADP F
vitamin 0 NOUN F
A 0 DET T
prior 0 PUNCT F
to 0 ADP F
entry 0 NOUN F
. 0 PUNCT F

In 0 ADP T
the 0 DET F
entire 0 ADJ F
cohort 0 NOUN F
, 0 PUNCT F
red 0 ADJ F
blood 0 NOUN F
cell 0 NOUN F
phosphatidylethanolamine 0 NOUN F
docosahexaenoic 0 ADJ F
acid 0 NOUN F
level 0 NOUN F
was 0 VERB F
inversely 0 ADV F
related 0 VERB F
to 0 ADP F
rate 0 NOUN F
of 0 ADP F
decline 0 NOUN F
in 0 ADP F
total 0 ADJ F
field B-PHYSICAL NOUN F
sensitivity I-PHYSICAL NOUN F
over 0 ADP F
4 0 NUM F
years 0 NOUN F
( 0 PUNCT F
test 0 NOUN F
for 0 ADP F
trend 0 NOUN F
, 0 PUNCT F
P 0 NOUN T
=.05 0 ADP F
) 0 PUNCT F
. 0 PUNCT F

This 0 DET T
was 0 VERB F
particularly 0 ADV F
evident 0 ADJ F
over 0 ADP F
the 0 DET F
first 0 ADJ F
2 0 NUM F
years 0 NOUN F
among 0 ADP F
those 0 PUNCT F
not 0 ADV F
on 0 ADP F
vitamin 0 NOUN F
A 0 DET T
prior 0 PUNCT F
to 0 ADP F
entry 0 NOUN F
( 0 PUNCT F
test 0 NOUN F
for 0 ADP F
trend 0 NOUN F
, 0 PUNCT F
P 0 NOUN T
=.003 0 ADP F
) 0 PUNCT F
. 0 PUNCT F

In 0 ADP T
the 0 DET F
entire 0 ADJ F
control 0 NOUN F
+ 0 SYM F
A 0 PUNCT T
group 0 NOUN F
, 0 PUNCT F
dietary 0 ADJ F
omega-3 0 NOUN F
fatty 0 ADJ F
acid 0 NOUN F
intake 0 NOUN F
was 0 VERB F
inversely 0 ADV F
related 0 ADP F
to 0 ADP F
loss 0 NOUN F
of 0 ADP F
total 0 ADJ F
field B-PHYSICAL NOUN F
sensitivity I-PHYSICAL NOUN F
over 0 ADP F
4 0 NUM F
years 0 NOUN F
( 0 PUNCT F
intake 0 NOUN F
, 0 PUNCT F
< 0 SYM F
0.20 0 NUM F
vs 0 CCONJ F
> 0 ADJ F
or 0 CCONJ F
=0.20 0 NUM F
g/d 0 NOUN F
; 0 PUNCT F
P 0 NOUN T
=.02 0 PUNCT F
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
duration B-PHYSICAL NOUN F
of I-PHYSICAL ADP F
vitamin I-PHYSICAL NOUN F
A I-PHYSICAL DET T
supplementation I-PHYSICAL NOUN F
prior 0 PUNCT F
to 0 ADP F
entry 0 NOUN F
was 0 VERB F
inversely 0 ADV F
related 0 VERB F
to 0 ADP F
rate 0 NOUN F
of 0 ADP F
decline 0 NOUN F
in 0 ADP F
electroretinogram 0 PUNCT F
amplitude 0 NOUN F
( 0 PUNCT F
P 0 NOUN T
=.008 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

CONCLUSIONS 0 NOUN T
For 0 ADP T
patients 0 NOUN F
with 0 ADP F
retinitis 0 NOUN F
pigmentosa 0 NOUN F
beginning 0 ADP F
vitamin 0 NOUN F
A 0 CCONJ T
therapy 0 NOUN F
, 0 PUNCT F
addition 0 NOUN F
of 0 ADP F
docosahexaenoic 0 ADJ F
acid 0 NOUN F
, 0 PUNCT F
1200 0 NUM F
mg/d 0 NOUN F
, 0 PUNCT F
slowed 0 PUNCT F
the 0 DET F
course 0 NOUN F
of 0 ADP F
disease 0 NOUN F
for 0 ADP F
2 0 NUM F
years 0 NOUN F
. 0 PUNCT F

Among 0 ADP T
patients 0 NOUN F
on 0 ADP F
vitamin 0 NOUN F
A 0 NOUN T
for 0 ADP F
at 0 ADP F
least 0 ADV F
2 0 NUM F
years 0 NOUN F
, 0 PUNCT F
a 0 DET F
diet 0 NOUN F
rich 0 VERB F
in 0 ADP F
omega-3 0 NOUN F
fatty 0 ADJ F
acids 0 NOUN F
( 0 PUNCT F
> 0 ADJ F
or 0 CCONJ F
=0.20 0 NUM F
g/d 0 NOUN F
) 0 PUNCT F
slowed 0 PUNCT F
the 0 DET F
decline 0 NOUN F
in 0 ADP F
visual 0 ADJ F
field 0 NOUN F
sensitivity 0 NOUN F
. 0 PUNCT F

A 0 DET T
comparison 0 NOUN F
of 0 ADP F
acupuncture 0 ADP F
with 0 ADP F
advice 0 NOUN F
and 0 CCONJ F
exercises 0 NOUN F
on 0 ADP F
the 0 DET F
symptomatic B-PHYSICAL ADJ F
treatment I-PHYSICAL NOUN F
of 0 ADP F
osteoarthritis 0 NOUN F
of 0 ADP F
the 0 DET F
hip 0 NOUN F
-- 0 PUNCT F
a 0 DET F
randomised 0 VERB F
controlled 0 VERB F
trial 0 NOUN F
. 0 PUNCT F

Acupuncture 0 ADP T
is 0 ADP F
becoming 0 VERB F
a 0 DET F
common 0 ADJ F
technique 0 NOUN F
within 0 ADP F
the 0 DET F
physiotherapy 0 NOUN F
profession 0 NOUN F
as 0 ADP F
a 0 DET F
treatment 0 NOUN F
modality 0 NOUN F
for 0 ADP F
pain B-PAIN NOUN F
relief I-PAIN NOUN F
; 0 PUNCT F
however 0 ADV F
, 0 PUNCT F
few 0 ADJ F
randomised 0 VERB F
controlled 0 VERB F
trials 0 NOUN F
have 0 ADP F
been 0 PUNCT F
undertaken 0 VERB F
to 0 PART F
assess 0 NOUN F
the 0 DET F
effectiveness 0 NOUN F
of 0 ADP F
acupuncture 0 ADP F
, 0 PUNCT F
particularly 0 ADV F
in 0 ADP F
the 0 DET F
treatment 0 NOUN F
of 0 ADP F
osteoarthritis 0 NOUN F
( 0 PUNCT F
OA 0 NOUN T
) 0 PUNCT F
of 0 ADP F
the 0 DET F
hip 0 NOUN F
. 0 PUNCT F

Therefore 0 ADV T
, 0 PUNCT F
a 0 DET F
randomised 0 VERB F
trial 0 NOUN F
to 0 PART F
compare 0 NOUN F
the 0 DET F
effectiveness 0 NOUN F
of 0 ADP F
acupuncture 0 ADP F
with 0 ADP F
advice 0 NOUN F
and 0 CCONJ F
exercises 0 NOUN F
on 0 ADP F
the 0 DET F
symptomatic 0 ADJ F
treatment 0 NOUN F
of 0 ADP F
OA 0 NOUN T
of 0 ADP F
the 0 DET F
hip 0 NOUN F
was 0 VERB F
carried 0 VERB F
out 0 ADP F
. 0 PUNCT F

Thirty-two 0 ADJ T
patients 0 NOUN F
awaiting 0 PUNCT F
a 0 DET F
total 0 ADJ F
hip 0 NOUN F
arthroplasty 0 NOUN F
were 0 VERB F
randomly 0 ADV F
allocated 0 VERB F
to 0 ADP F
either 0 CCONJ F
the 0 DET F
experimental 0 ADJ F
group 0 NOUN F
, 0 PUNCT F
( 0 PUNCT F
A 0 NOUN T
) 0 PUNCT F
, 0 PUNCT F
to 0 ADP F
have 0 PUNCT F
six 0 NUM F
sessions 0 NOUN F
of 0 ADP F
acupuncture 0 ADP F
each 0 ADP F
lasting 0 ADP F
up 0 CCONJ F
to 0 DET F
25 0 NUM F
minutes 0 NOUN F
, 0 PUNCT F
or 0 CCONJ F
the 0 DET F
control 0 NOUN F
group 0 NOUN F
, 0 PUNCT F
( 0 PUNCT F
B 0 NOUN T
) 0 PUNCT F
, 0 PUNCT F
to 0 PART F
be 0 PUNCT F
given 0 VERB F
advice 0 NOUN F
and 0 CCONJ F
exercises 0 NOUN F
for 0 ADP F
their 0 PUNCT F
hip 0 NOUN F
over 0 ADP F
a 0 DET F
six 0 NUM F
week 0 NOUN F
period 0 NOUN F
. 0 PUNCT F

Group 0 NOUN T
A 0 NOUN T
consisted 0 PUNCT F
of 0 ADP F
three 0 NUM F
men 0 NOUN F
and 0 CCONJ F
13 0 NUM F
women 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
group 0 NOUN F
B 0 NOUN T
consisted 0 VERB F
of 0 ADP F
four 0 NUM F
men 0 NOUN F
and 0 CCONJ F
eight 0 NUM F
women 0 NOUN F
. 0 PUNCT F

The 0 DET T
average 0 ADJ F
age 0 NOUN F
in 0 ADP F
group 0 NOUN F
A 0 NOUN T
was 0 VERB F
66 0 NUM F
years 0 NOUN F
and 0 CCONJ F
in 0 ADP F
group 0 NOUN F
B 0 NOUN T
it 0 PUNCT F
was 0 VERB F
68 0 NUM F
years 0 NOUN F
. 0 PUNCT F

Patients 0 NOUN T
were 0 VERB F
assessed 0 VERB F
for 0 ADP F
pain 0 NOUN F
and 0 CCONJ F
functional 0 ADJ F
ability 0 NOUN F
, 0 PUNCT F
using 0 VERB F
a 0 DET F
modified 0 VERB F
version 0 NOUN F
of 0 ADP F
the 0 DET F
WOMAC B-OTHER PUNCT T
questionnaire 0 NOUN F
, 0 PUNCT F
pre-treatment 0 NOUN F
, 0 PUNCT F
immediately 0 ADV F
post-treatment 0 NOUN F
and 0 CCONJ F
at 0 ADP F
eight 0 NUM F
weeks 0 NOUN F
post-treatment 0 NOUN F
. 0 PUNCT F

The 0 DET T
pre-treatment 0 NOUN F
WOMAC B-OTHER ADJ T
scores I-OTHER NOUN F
in 0 ADP F
the 0 DET F
two 0 NUM F
groups 0 NOUN F
were 0 VERB F
similar 0 ADJ F
( 0 PUNCT F
p=0.85 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

There 0 PUNCT T
was 0 VERB F
a 0 DET F
significant 0 ADJ F
improvement 0 NOUN F
in 0 ADP F
group 0 NOUN F
A 0 NOUN T
( 0 PUNCT F
decrease 0 NOUN F
in 0 ADP F
WOMAC B-OTHER PUNCT T
score I-OTHER NOUN F
) 0 PUNCT F
immediately 0 ADV F
post-treatment 0 NOUN F
( 0 PUNCT F
p=0.002 0 NOUN F
) 0 PUNCT F
and 0 CCONJ F
this 0 PUNCT F
was 0 NUM F
maintained 0 VERB F
at 0 ADP F
the 0 DET F
eight-week 0 CCONJ F
follow-up 0 NOUN F
( 0 PUNCT F
p=0.03 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

There 0 PUNCT T
were 0 VERB F
no 0 DET F
significant 0 ADJ F
changes 0 NOUN F
in 0 ADP F
group 0 NOUN F
B 0 NOUN T
. 0 PUNCT F

When 0 ADP T
the 0 DET F
changes 0 NOUN F
in 0 ADP F
WOMAC B-OTHER ADJ T
scores I-OTHER NOUN F
were 0 VERB F
compared 0 VERB F
between 0 ADP F
groups 0 NOUN F
, 0 PUNCT F
a 0 DET F
significantly 0 ADV F
greater 0 PUNCT F
improvement 0 NOUN F
was 0 VERB F
found 0 VERB F
between 0 ADP F
pre-treatment 0 NOUN F
and 0 CCONJ F
immediately 0 ADV F
post-treatment 0 NOUN F
in 0 ADP F
group 0 NOUN F
A 0 NOUN T
, 0 PUNCT F
compared 0 VERB F
with 0 ADP F
group 0 NOUN F
B 0 NOUN T
( 0 PUNCT F
p=0.02 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
changes 0 NOUN F
between 0 ADP F
pre-treatment 0 NOUN F
and 0 CCONJ F
the 0 DET F
eight-week 0 CCONJ F
follow-up 0 NOUN F
also 0 ADV F
showed 0 VERB F
a 0 DET F
significant 0 ADJ F
improvement 0 NOUN F
in 0 ADP F
group 0 NOUN F
A 0 NOUN T
compared 0 PUNCT F
with 0 ADP F
group 0 NOUN F
B 0 NOUN T
( 0 PUNCT F
p=0.03 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

In 0 ADP T
conclusion 0 NOUN F
, 0 PUNCT F
this 0 DET F
trial 0 NOUN F
supports 0 NOUN F
the 0 DET F
hypothesis 0 NOUN F
that 0 ADP F
acupuncture 0 ADP F
is 0 VERB F
more 0 ADV F
effective 0 ADJ F
than 0 PUNCT F
advice 0 NOUN F
and 0 CCONJ F
exercises 0 NOUN F
in 0 ADP F
the 0 DET F
symptomatic 0 ADJ F
treatment 0 NOUN F
of 0 ADP F
OA 0 NOUN T
of 0 ADP F
the 0 DET F
hip 0 NOUN F
. 0 PUNCT F

The 0 DET T
long-term 0 NOUN F
effect 0 NOUN F
of 0 ADP F
oxandrolone 0 ADJ F
on 0 ADP F
hepatic 0 ADJ F
acute 0 ADJ F
phase 0 NOUN F
proteins 0 NOUN F
in 0 ADP F
severely 0 ADV F
burned 0 ADP F
children 0 NOUN F
. 0 PUNCT F

BACKGROUND 0 NOUN T
Acute 0 ADJ T
phase 0 NOUN F
protein 0 NOUN F
production 0 NOUN F
is 0 VERB F
a 0 DET F
hallmark 0 NOUN F
of 0 ADP F
severe 0 ADJ F
burns 0 NOUN F
. 0 PUNCT F

We 0 PRON T
wondered 0 VERB F
whether 0 ADP F
anabolic 0 ADJ F
treatment 0 NOUN F
with 0 ADP F
oxandrolone 0 ADJ F
would 0 VERB F
affect 0 VERB F
these 0 DET F
proteins 0 NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
Thirty-five 0 PUNCT T
children 0 NOUN F
with 0 ADP F
> 0 ADJ F
or 0 CCONJ F
=40 0 NUM F
% 0 ADJ F
total 0 ADJ F
body 0 NOUN F
surface 0 NOUN F
area 0 NOUN F
burns 0 NOUN F
were 0 VERB F
randomized 0 VERB F
to 0 PART F
receive 0 NOUN F
either 0 PUNCT F
placebo 0 NOUN F
or 0 CCONJ F
oxandrolone 0 ADJ F
( 0 PUNCT F
0.1 0 NUM F
mg/kg 0 NOUN F
by 0 ADP F
mouth 0 NOUN F
twice 0 ADP F
daily 0 ADP F
) 0 PUNCT F
from 0 ADP F
postoperative 0 ADJ F
day 0 NOUN F
5 0 NUM F
to 0 ADP F
1 0 NUM F
year 0 NOUN F
postburn 0 ADP F
. 0 PUNCT F

Levels 0 NOUN T
of 0 ADP F
constitutive 0 DET F
proteins 0 NOUN F
and 0 CCONJ F
acute 0 ADJ F
phase 0 NOUN F
proteins 0 NOUN F
were 0 VERB F
measured 0 VERB F
at 0 ADP F
admission 0 NOUN F
; 0 PUNCT F
at 0 ADP F
discharge 0 NOUN F
; 0 PUNCT F
and 0 CCONJ F
at 0 ADP F
6 0 NUM F
, 0 PUNCT F
9 0 NUM F
, 0 PUNCT F
and 0 CCONJ F
12 0 NUM F
months 0 NOUN F
after 0 ADP F
burn 0 NOUN F
. 0 PUNCT F

Total 0 ADJ T
albumin B-PHYSICAL NOUN F
supplementation I-PHYSICAL NOUN F
and 0 CCONJ F
hepatic B-PHYSICAL ADJ F
transaminases I-PHYSICAL NOUN F
were 0 VERB F
also 0 ADV F
assessed 0 VERB F
. 0 PUNCT F

RESULTS 0 PUNCT T
Constitutive B-PHYSICAL ADJ T
proteins I-PHYSICAL NOUN F
such I-PHYSICAL CCONJ F
as I-PHYSICAL ADP F
albumin I-PHYSICAL NOUN F
, I-PHYSICAL PUNCT F
prealbumin I-PHYSICAL NOUN F
, I-PHYSICAL PUNCT F
and I-PHYSICAL CCONJ F
retinol-binding I-PHYSICAL ADP F
protein I-PHYSICAL NOUN F
levels I-PHYSICAL NOUN F
increased 0 VERB F
( 0 PUNCT F
p 0 NOUN F
< 0 SYM F
0.05 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
and 0 CCONJ F
acute B-PHYSICAL ADJ F
phase 0 NOUN F
proteins B-PHYSICAL NOUN F
such I-PHYSICAL CCONJ F
as I-PHYSICAL ADP F
alpha I-PHYSICAL NOUN F
1-acid I-PHYSICAL NOUN F
glycoprotein I-PHYSICAL NOUN F
, I-PHYSICAL PUNCT F
C3 I-PHYSICAL NOUN T
complement I-PHYSICAL NOUN F
, I-PHYSICAL PUNCT F
alpha I-PHYSICAL NOUN F
2-macroglobulin I-PHYSICAL NOUN F
, I-PHYSICAL PUNCT F
and I-PHYSICAL CCONJ F
fibrinogen I-PHYSICAL NOUN F
levels B-PHYSICAL NOUN F
significantly 0 ADV F
decreased 0 NUM F
in 0 ADP F
the 0 DET F
oxandrolone 0 ADJ F
group 0 NOUN F
compared 0 VERB F
with 0 ADP F
placebo 0 NOUN F
( 0 PUNCT F
p 0 NOUN F
< 0 SYM F
0.05 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Albumin B-PHYSICAL NOUN T
supplementation I-PHYSICAL NOUN F
during B-PHYSICAL ADP F
the I-PHYSICAL DET F
acute B-PHYSICAL ADJ F
hospitalization I-PHYSICAL NOUN F
was 0 VERB F
reduced 0 VERB F
in 0 ADP F
the 0 DET F
oxandrolone 0 ADJ F
group 0 NOUN F
. 0 PUNCT F

Randomised 0 VERB T
multicentre 0 NOUN F
trial 0 NOUN F
of 0 ADP F
circular 0 ADJ F
stapling 0 ADP F
devices 0 NOUN F
. 0 PUNCT F

PURPOSE 0 NOUN T
In 0 ADP T
a 0 DET F
register 0 NOUN F
study 0 NOUN F
, 0 PUNCT F
the 0 DET F
risk 0 NOUN F
of 0 ADP F
anastomotic B-PHYSICAL ADJ F
leakage I-PHYSICAL NOUN F
correlated 0 PUNCT F
to 0 ADP F
the 0 DET F
choice 0 NOUN F
of 0 ADP F
circular 0 ADJ F
stapling 0 ADP F
device 0 NOUN F
with 0 ADP F
a 0 DET F
4 0 NUM F
% 0 ADV F
difference 0 NOUN F
between 0 ADP F
the 0 DET F
two 0 NUM F
brands 0 NOUN F
used 0 VERB F
. 0 PUNCT F

Based 0 VERB T
on 0 ADP F
those 0 PUNCT F
data 0 NOUN F
, 0 PUNCT F
a 0 DET F
randomised 0 VERB F
multicentre 0 NOUN F
study 0 NOUN F
was 0 VERB F
started 0 VERB F
to 0 PART F
explore 0 VERB F
the 0 DET F
risk 0 NOUN F
of 0 ADP F
an 0 DET F
anastomotic B-PHYSICAL ADJ F
leakage I-PHYSICAL NOUN F
based 0 VERB F
upon 0 ADP F
the 0 DET F
surgical 0 ADJ F
device 0 NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
Patients 0 NOUN T
above 0 ADP F
18 0 NUM F
years 0 NOUN F
with 0 ADP F
a 0 DET F
rectal 0 ADJ F
cancer 0 NOUN F
, 0 PUNCT F
able 0 ADJ F
to 0 PART F
give 0 VERB F
informed 0 ADJ F
consent 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
scheduled 0 PUNCT F
for 0 ADP F
an 0 DET F
anterior 0 ADJ F
resection 0 NOUN F
were 0 VERB F
eligible 0 ADJ F
for 0 ADP F
the 0 DET F
study 0 NOUN F
. 0 PUNCT F

Perioperative 0 PUNCT T
randomisation 0 NOUN F
was 0 VERB F
to 0 ADP F
Ethicon? 0 PUNCT T
PROXIMATE? 0 NUM T
ILS? 0 PUNCT T
or 0 CCONJ F
Autosuture? 0 ADJ T
Premium 0 NOUN T
Plus 0 CCONJ T
CEEA? 0 NUM T
. 0 PUNCT F

Anastomotic 0 ADJ T
leakage 0 NOUN F
was 0 VERB F
defined 0 VERB F
as 0 ADP F
a 0 DET F
clinically 0 ADJ F
manifest 0 ADJ F
leak 0 NOUN F
. 0 PUNCT F

RESULTS 0 NOUN T
Five 0 NUM T
hundred 0 NUM F
twenty-nine 0 PUNCT F
patients 0 NOUN F
were 0 VERB F
randomised 0 NUM F
( 0 PUNCT F
58 0 NUM F
% 0 SYM F
male 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

A 0 DET T
leak 0 ADP F
occurred 0 VERB F
in 0 ADP F
8.3 0 NUM F
% 0 SYM F
. 0 PUNCT F

The 0 DET T
anastomoses 0 NOUN F
created 0 VERB F
by 0 ADP F
PROXIMATE? 0 NUM T
ILS? 0 PUNCT T
leaked 0 PUNCT F
in 0 ADP F
25/265 0 NOUN F
( 0 PUNCT F
9.4 0 NUM F
% 0 SYM F
) 0 PUNCT F
anastomoses 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
the 0 DET F
Premium 0 NOUN T
Plus 0 CCONJ T
CEEA? 0 NUM T
leaked 0 PUNCT F
in 0 ADP F
19/260 0 NOUN F
( 0 PUNCT F
7.3 0 NUM F
% 0 SYM F
) 0 PUNCT F
, 0 PUNCT F
p 0 NOUN F
= 0 SYM F
.419 0 NUM F
. 0 PUNCT F

CONCLUSION 0 NOUN T
No 0 DET T
difference 0 NOUN F
in 0 ADP F
the 0 DET F
leak 0 ADJ F
rate 0 NOUN F
could 0 VERB F
be 0 VERB F
revealed 0 VERB F
. 0 PUNCT F

Several 0 ADJ T
centres 0 NOUN F
replaced 0 DET F
one 0 NUM F
of 0 ADP F
the 0 DET F
staplers 0 NOUN F
by 0 ADP F
a 0 DET F
new 0 ADJ F
product 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
the 0 DET F
study 0 NOUN F
was 0 VERB F
ended 0 NOUN F
before 0 ADP F
the 0 DET F
stipulated 0 VERB F
number 0 NOUN F
of 0 ADP F
patients 0 NOUN F
was 0 VERB F
reached 0 VERB F
. 0 PUNCT F

In 0 ADP T
the 0 DET F
future 0 NOUN F
, 0 PUNCT F
surgical 0 ADJ F
devices 0 NOUN F
may 0 VERB F
have 0 PUNCT F
to 0 ADJ F
prove 0 ADJ F
superiority 0 NOUN F
in 0 ADP F
randomised 0 VERB F
trials 0 NOUN F
or 0 CCONJ F
be 0 PUNCT F
monitored 0 VERB F
in 0 ADP F
quality 0 NOUN F
registers 0 NOUN F
before 0 PUNCT F
they 0 ADP F
can 0 VERB F
be 0 VERB F
introduced 0 VERB F
into 0 ADP F
day 0 NOUN F
to 0 ADP F
day 0 NOUN F
surgical 0 ADJ F
practice 0 NOUN F
. 0 PUNCT F

The 0 DET T
study 0 NOUN F
was 0 ADV F
registered 0 PUNCT F
at 0 ADP F
ClinicalTrials.gov 0 PUNCT T
: 0 PUNCT F
NCT00399009 0 NOUN T
. 0 PUNCT F

Laser 0 NOUN T
therapy 0 NOUN F
combined 0 VERB F
with 0 ADP F
brachytherapy 0 NOUN F
for 0 ADP F
the 0 DET F
palliation 0 NOUN F
of 0 ADP F
malignant 0 ADJ F
dysphagia 0 NOUN F
. 0 PUNCT F

BACKGROUND/AIM 0 NUM T
OF 0 ADP T
STUDY 0 NOUN T
Laser 0 NOUN T
therapy 0 NOUN F
is 0 VERB F
effective 0 ADJ F
in 0 ADP F
relieving 0 ADV F
malignant B-PHYSICAL ADJ F
dysphagia I-PHYSICAL NOUN F
, 0 PUNCT F
but 0 CCONJ F
repeated 0 VERB F
treatments 0 NOUN F
at 0 ADP F
4 0 NUM F
to 0 ADP F
6 0 NUM F
week 0 NOUN F
intervals 0 NOUN F
are 0 VERB F
usually 0 ADV F
required 0 VERB F
. 0 PUNCT F

This 0 DET T
prospective 0 ADJ F
randomised 0 VERB F
trial 0 NOUN F
is 0 VERB F
designed 0 VERB F
to 0 PART F
determine 0 NOUN F
if 0 PUNCT F
addition 0 NOUN F
of 0 ADP F
brachytherapy 0 NOUN F
offers 0 NOUN F
any 0 DET F
advantages 0 NOUN F
over 0 ADP F
laser 0 NOUN F
therapy 0 NOUN F
alone 0 ADJ F
. 0 PUNCT F

METHODS 0 NOUN T
Patients 0 NOUN T
with 0 ADP F
inoperable 0 ADJ F
carcinoma 0 NOUN F
of 0 ADP F
the 0 DET F
oesophagus 0 NOUN F
were 0 VERB F
randomised 0 VERB F
to 0 PART F
receive 0 ADP F
either 0 PUNCT F
endoscopic 0 ADJ F
Nd 0 NOUN T
: 0 PUNCT F
YAG 0 NOUN T
laser 0 NOUN F
therapy 0 NOUN F
alone 0 ADJ F
, 0 PUNCT F
or 0 CCONJ F
laser 0 NOUN F
followed 0 VERB F
by 0 ADP F
brachytherapy 0 NOUN F
. 0 PUNCT F

Patients 0 NOUN T
who 0 ADP F
developed 0 VERB F
worsening 0 ADP F
dysphagia 0 NOUN F
during 0 ADP F
follow-up 0 NOUN F
were 0 VERB F
offered 0 PUNCT F
further 0 ADP F
treatment 0 NOUN F
as 0 PUNCT F
appropriate 0 ADJ F
. 0 PUNCT F

RESULTS 0 NOUN T
Fourteen 0 PUNCT T
patients 0 NOUN F
were 0 VERB F
randomised 0 VERB F
to 0 PART F
receive 0 NOUN F
laser 0 NOUN F
only 0 ADV F
, 0 PUNCT F
and 0 CCONJ F
12 0 NUM F
to 0 PUNCT F
receive 0 NOUN F
laser 0 NOUN F
followed 0 NOUN F
by 0 ADP F
brachytherapy 0 NOUN F
. 0 PUNCT F

Of 0 ADP T
these 0 DET F
12 0 NUM F
, 0 PUNCT F
one 0 NUM F
was 0 VERB F
lost 0 VERB F
to 0 ADP F
follow-up 0 NOUN F
and 0 CCONJ F
four 0 NUM F
did 0 ADP F
not 0 ADV F
receive 0 VERB F
brachytherapy 0 NOUN F
because 0 PUNCT F
they 0 ADP F
were 0 VERB F
unfit 0 ADJ F
, 0 PUNCT F
had 0 PUNCT F
extension 0 NOUN F
into 0 ADP F
the 0 DET F
cardia 0 NOUN F
or 0 CCONJ F
had 0 PUNCT F
mainly 0 ADV F
extrinsic 0 ADJ F
compression 0 NOUN F
. 0 PUNCT F

These 0 DET T
4 0 NUM F
are 0 VERB F
included 0 VERB F
on 0 ADP F
an 0 DET F
'intention-to-treat 0 PUNCT F
' 0 PUNCT F
basis 0 NOUN F
. 0 PUNCT F

The 0 DET T
mean 0 NOUN F
therapeutic B-PHYSICAL ADJ F
interval I-PHYSICAL NOUN F
for 0 ADP F
the 0 DET F
brachytherapy 0 NOUN F
group 0 NOUN F
was 0 VERB F
significantly 0 ADV F
longer 0 PUNCT F
, 0 PUNCT F
83 0 VERB F
days 0 NOUN F
compared 0 VERB F
to 0 ADP F
36 0 NUM F
days 0 NOUN F
for 0 ADP F
the 0 DET F
laser 0 NOUN F
group 0 NOUN F
( 0 PUNCT F
p 0 NOUN F
= 0 SYM F
0.026 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

There 0 PUNCT T
were 0 VERB F
no 0 DET F
differences 0 NOUN F
in 0 ADP F
the 0 DET F
degree 0 NOUN F
of 0 ADP F
dysphagia B-PHYSICAL NOUN F
relief I-PHYSICAL NOUN F
, 0 PUNCT F
number 0 NOUN F
of 0 ADP F
endoscopic B-OTHER ADJ F
procedures I-OTHER NOUN F
or 0 CCONJ F
survival B-MORTALITY NOUN F
times I-MORTALITY NOUN F
. 0 PUNCT F

CONCLUSION 0 NOUN T
The 0 DET T
preliminary 0 ADJ F
results 0 NOUN F
of 0 ADP F
this 0 DET F
trial 0 NOUN F
suggest 0 VERB F
that 0 ADP F
brachytherapy 0 NOUN F
in 0 ADP F
addition 0 NOUN F
to 0 ADP F
laser 0 NOUN F
therapy 0 NOUN F
prolongs 0 NOUN F
the 0 DET F
first 0 ADJ F
therapeutic B-PHYSICAL ADJ F
interval I-PHYSICAL NOUN F
. 0 PUNCT F

However 0 ADV T
, 0 PUNCT F
no 0 DET F
long-term 0 NOUN F
advantages 0 NOUN F
have 0 PUNCT F
been 0 PUNCT F
shown 0 VERB F
. 0 PUNCT F

JobTIPS 0 NOUN T
: 0 PUNCT F
a 0 DET F
transition 0 NOUN F
to 0 PUNCT F
employment 0 PUNCT F
program 0 NOUN F
for 0 ADP F
individuals 0 NOUN F
with 0 ADP F
autism 0 NOUN F
spectrum 0 NOUN F
disorders 0 NOUN F
. 0 PUNCT F

This 0 DET T
study 0 NOUN F
evaluated 0 VERB F
the 0 DET F
effectiveness 0 NOUN F
of 0 ADP F
an 0 DET F
internet B-OTHER NOUN F
accessed I-OTHER DET F
training I-OTHER PROPN F
program I-OTHER NOUN F
that 0 ADP F
included 0 PUNCT F
Theory 0 NOUN T
of 0 ADP F
Mind-based 0 VERB T
guidance 0 NOUN F
, 0 PUNCT F
video 0 ADJ F
models 0 NOUN F
, 0 PUNCT F
visual 0 ADJ F
supports 0 PUNCT F
, 0 PUNCT F
and 0 CCONJ F
virtual 0 ADJ F
reality 0 NOUN F
practice 0 NOUN F
sessions 0 NOUN F
in 0 ADP F
teaching 0 PUNCT F
appropriate 0 ADP F
job 0 PUNCT F
interview 0 NOUN F
skills 0 NOUN F
to 0 ADP F
individuals 0 CCONJ F
with 0 ADP F
high 0 ADJ F
functioning 0 VERB F
Autism 0 NOUN T
Spectrum 0 NOUN T
Disorders 0 NOUN T
. 0 PUNCT F

In 0 ADP T
a 0 DET F
randomized 0 VERB F
study 0 NOUN F
, 0 PUNCT F
twenty-two 0 PUNCT F
youth 0 NOUN F
, 0 PUNCT F
ages 0 NOUN F
16-19 0 ADJ F
, 0 PUNCT F
were 0 VERB F
evaluated 0 VERB F
during 0 ADP F
two 0 NUM F
employment 0 PUNCT F
interviews 0 NOUN F
. 0 PUNCT F

Half 0 ADJ T
received 0 VERB F
a 0 DET F
training 0 DET F
intervention 0 NOUN F
following 0 VERB F
the 0 DET F
initial 0 ADJ F
interview 0 NOUN F
and 0 CCONJ F
the 0 DET F
half 0 ADJ F
who 0 ADP F
served 0 VERB F
as 0 ADP F
a 0 DET F
contrast 0 NOUN F
group 0 NOUN F
did 0 VERB F
not 0 ADV F
. 0 PUNCT F

Their 0 ADJ T
performance 0 NOUN F
pre 0 ADP F
and 0 CCONJ F
post 0 PUNCT F
intervention 0 NOUN F
was 0 VERB F
assessed 0 VERB F
by 0 ADP F
four 0 NUM F
independent 0 ADJ F
raters 0 NOUN F
using 0 VERB F
a 0 DET F
scale 0 NOUN F
that 0 PUNCT F
included 0 PUNCT F
evaluation 0 NOUN F
of 0 ADP F
both 0 PUNCT F
Content B-OTHER NOUN T
and 0 CCONJ F
Delivery B-OTHER NOUN T
. 0 PUNCT F

Results 0 CCONJ T
suggest 0 VERB F
that 0 ADP F
youth 0 NOUN F
who 0 ADP F
completed 0 PROPN F
the 0 DET F
JobTIPS 0 NOUN T
employment 0 ADJ F
program 0 NOUN F
demonstrated 0 VERB F
significantly B-MENTAL ADP F
more I-MENTAL ADV F
effective I-MENTAL ADJ F
verbal I-MENTAL ADJ F
content I-MENTAL NOUN F
skills I-MENTAL NOUN F
than 0 PUNCT F
those 0 DET F
who 0 PROPN F
did 0 CCONJ F
not 0 ADV F
. 0 PUNCT F

In 0 ADJ T
vivo 0 ADJ F
effect 0 NOUN F
of 0 ADP F
clarithromycin 0 NOUN F
on 0 ADP F
multiple 0 ADJ F
cytochrome 0 NOUN F
P450s 0 NOUN T
. 0 PUNCT F

The 0 DET T
in 0 PUNCT F
vivo 0 ADJ F
effects 0 NOUN F
of 0 ADP F
oral 0 ADJ F
clarithromycin 0 NOUN F
administration 0 NOUN F
on 0 ADP F
the 0 DET F
in 0 ADP F
vivo 0 ADJ F
activity 0 NOUN F
of 0 ADP F
cytochrome 0 NOUN F
P450 0 NOUN T
1A2 0 NOUN F
, 0 PUNCT F
2C9 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
2D6 0 NOUN F
were 0 VERB F
determined 0 VERB F
. 0 PUNCT F

The 0 DET T
cytochrome 0 NOUN F
P450 0 NOUN T
probes 0 NOUN F
caffeine 0 NOUN F
( 0 PUNCT F
CYP1A2 0 NOUN T
) 0 PUNCT F
, 0 PUNCT F
tolbutamide 0 NOUN F
( 0 PUNCT F
CYP2C9 0 NOUN T
) 0 PUNCT F
, 0 PUNCT F
and 0 CCONJ F
dextromethorphan 0 PUNCT F
( 0 PUNCT F
CYP2D6 0 NOUN T
) 0 PUNCT F
were 0 VERB F
administered 0 VERB F
as 0 ADP F
an 0 DET F
oral 0 ADJ F
cocktail 0 NOUN F
prior 0 PUNCT F
to 0 ADP F
and 0 CCONJ F
7 0 NUM F
days 0 NOUN F
after 0 ADP F
oral 0 ADJ F
clarithromycin 0 NOUN F
( 0 PUNCT F
500 0 NUM F
mg 0 NOUN F
twice 0 ADV F
daily 0 ADJ F
) 0 PUNCT F
administration 0 NOUN F
to 0 ADP F
12 0 NUM F
healthy 0 ADJ F
male 0 NOUN F
subjects 0 NOUN F
. 0 PUNCT F

Blood B-PHYSICAL NOUN T
and 0 CCONJ F
urine B-PHYSICAL NOUN F
samples I-PHYSICAL NOUN F
were 0 VERB F
collected 0 ADV F
and 0 CCONJ F
assayed 0 ADJ F
for 0 ADP F
each 0 PUNCT F
of 0 ADP F
the 0 DET F
compounds 0 NOUN F
and 0 CCONJ F
their 0 ADJ F
metabolites 0 NOUN F
using 0 VERB F
high-performance 0 NOUN F
liquid 0 NOUN F
chromatography 0 NOUN F
. 0 PUNCT F

The 0 DET T
CYP1A2 B-PHYSICAL NOUN T
indices I-PHYSICAL NOUN F
, 0 PUNCT F
oral B-PHYSICAL ADJ F
caffeine I-PHYSICAL NOUN F
clearance I-PHYSICAL NOUN F
( 0 PUNCT F
6.2 0 NUM F
+/- 0 SYM F
3.3 0 NUM F
l/h 0 NOUN F
before 0 ADP F
and 0 CCONJ F
5.7 0 ADP F
+/- 0 SYM F
4.2 0 NUM F
l/h 0 NOUN F
after 0 ADP F
, 0 PUNCT F
p 0 NOUN F
> 0 SYM F
0.05 0 NUM F
) 0 PUNCT F
and 0 CCONJ F
the 0 DET F
6-h B-PHYSICAL NOUN F
paraxanthine I-PHYSICAL NOUN F
to I-PHYSICAL ADP F
caffeine I-PHYSICAL NOUN F
serum I-PHYSICAL NOUN F
concentration 0 NOUN F
ratio B-PHYSICAL NOUN F
( 0 PUNCT F
0.49 0 NUM F
+/- 0 SYM F
0.3 0 NUM F
before 0 ADP F
and 0 CCONJ F
0.44 0 NUM F
+/- 0 SYM F
0.3 0 NUM F
after 0 ADP F
, 0 PUNCT F
p 0 NOUN F
> 0 SYM F
0.05 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
were 0 VERB F
unchanged 0 VERB F
following 0 VERB F
clarithromycin 0 NOUN F
dosing 0 VERB F
. 0 PUNCT F

Neither 0 CCONJ T
the 0 DET F
tolbutamide B-PHYSICAL NOUN F
oral I-PHYSICAL ADJ F
clearance I-PHYSICAL NOUN F
( 0 PUNCT F
0.77 0 NUM F
+/- 0 SYM F
0.28 0 NUM F
l/h 0 NOUN F
before 0 ADP F
and 0 CCONJ F
0.72 0 NUM F
+/-0.24 0 PUNCT F
l/h 0 ADP F
after 0 CCONJ F
, 0 PUNCT F
p 0 NOUN F
> 0 SYM F
0.05 0 NUM F
) 0 PUNCT F
nor 0 CCONJ F
the 0 DET F
tolbutamide B-PHYSICAL NOUN F
urinary B-PHYSICAL ADJ F
metabolic I-PHYSICAL ADJ F
ratio I-PHYSICAL NOUN F
( 0 PUNCT F
779 0 NUM F
+/- 0 SYM F
294 0 NUM F
before 0 ADP F
and 0 CCONJ F
681 0 NUM F
+/- 0 SYM F
416 0 NUM F
after 0 ADP F
, 0 PUNCT F
p 0 NOUN F
> 0 SYM F
0.05 0 NUM F
) 0 PUNCT F
indices 0 NOUN F
of 0 ADP F
CYP2C9 0 NOUN T
were 0 VERB F
altered 0 VERB F
by 0 ADP F
clarithromycin 0 NOUN F
administration 0 NOUN F
. 0 PUNCT F

In 0 ADP T
the 0 DET F
case 0 NOUN F
of 0 ADP F
CYP2D6 0 NOUN T
, 0 PUNCT F
the 0 DET F
dextromethorphan B-PHYSICAL PUNCT F
to 0 PUNCT F
dextrorphan B-PHYSICAL PUNCT F
urinary I-PHYSICAL ADJ F
ratio I-PHYSICAL NOUN F
was 0 PUNCT F
not 0 PUNCT F

Simulating 0 PROPN T
a 0 DET F
memory 0 NOUN F
impairment 0 NOUN F
: 0 PUNCT F
can 0 PUNCT F
amnesics 0 PUNCT F
implicitly 0 ADV F
outperform 0 ADJ F
simulators 0 NOUN F
? 0 PUNCT F

OBJECTIVES 0 NOUN T
The 0 DET T
purpose 0 NOUN F
of 0 ADP F
this 0 DET F
study 0 NOUN F
was 0 VERB F
to 0 ADV F
examine 0 NOUN F
the 0 DET F
effectiveness 0 NOUN F
of 0 ADP F
a 0 DET F
variety 0 NOUN F
of 0 ADP F
tests 0 NOUN F
in 0 ADP F
differentiating 0 VERB F
simulating B-MENTAL PUNCT F
test I-MENTAL ADV F
performances I-MENTAL NOUN F
from 0 ADP F
genuine 0 ADJ F
memory-impaired B-MENTAL NOUN F
and 0 CCONJ F
normal 0 ADJ F
( 0 PUNCT F
control 0 NOUN F
) 0 PUNCT F
test 0 PUNCT F
performances 0 NOUN F
. 0 PUNCT F

DESIGN 0 NOUN T
A 0 PUNCT T
simulation 0 ADJ F
design 0 NOUN F
was 0 VERB F
implemented 0 VERB F
, 0 PUNCT F
based 0 VERB F
on 0 ADP F
an 0 DET F
analogue 0 NOUN F
design 0 NOUN F
in 0 ADP F
which 0 ADP F
normal 0 ADJ F
participants 0 NOUN F
were 0 VERB F
given 0 VERB F
experimental 0 ADJ F
instructions 0 NOUN F
to 0 ADP F
feign 0 CCONJ F
a 0 DET F
mental 0 ADJ F
impairment 0 NOUN F
and 0 CCONJ F
are 0 VERB F
compared 0 VERB F
to 0 ADP F
( 0 PUNCT F
a 0 NOUN F
) 0 PUNCT F
other 0 ADJ F
normal 0 ADJ F
participants 0 NOUN F
with 0 ADP F
instructions 0 NOUN F
to 0 PART F
perform 0 NOUN F
honestly 0 ADV F
, 0 PUNCT F
and 0 CCONJ F
( 0 PUNCT F
b 0 NOUN F
) 0 PUNCT F
a 0 DET F
comparison 0 NOUN F
group 0 NOUN F
, 0 PUNCT F
for 0 ADP F
example 0 NOUN F
, 0 PUNCT F
acquired 0 DET F
brain-injured 0 ADJ F
persons 0 NOUN F
, 0 PUNCT F
with 0 ADP F
similar 0 ADJ F
instructions 0 NOUN F
. 0 PUNCT F

METHOD 0 NOUN T
Forty 0 PUNCT T
individuals 0 NOUN F
comprised 0 VERB F
the 0 DET F
simulating 0 PUNCT F
and 0 CCONJ F
control 0 NOUN F
group 0 NOUN F
and 0 CCONJ F
all 0 DET F
participants 0 NOUN F
were 0 VERB F
randomly 0 ADV F
assigned 0 VERB F
to 0 ADP F
the 0 DET F
simulating 0 PUNCT F
and 0 CCONJ F
control 0 NOUN F
groups 0 NOUN F
. 0 PUNCT F

Twenty 0 VERB T
memory-impaired 0 VERB F
patients 0 NOUN F
, 0 PUNCT F
all 0 DET F
of 0 ADP F
whom 0 NOUN F
had 0 PUNCT F
been 0 ADP F
diagnosed 0 VERB F
as 0 ADP F
suffering 0 VERB F
from 0 ADP F
a 0 DET F
memory 0 NOUN F
impairment 0 NOUN F
following 0 VERB F
acquired 0 VERB F
brain 0 NOUN F
damage 0 NOUN F
, 0 PUNCT F
participated 0 NUM F
as 0 ADP F
the 0 DET F
memory-impaired 0 VERB F
control 0 NOUN F
group 0 NOUN F
. 0 PUNCT F

The 0 DET T
simulation 0 ADJ F
group 0 NOUN F
was 0 VERB F
directed 0 VERB F
to 0 ADP F
imitate 0 PUNCT F
a 0 DET F
person 0 NOUN F
with 0 ADP F
a 0 DET F
memory 0 NOUN F
impairment 0 NOUN F
. 0 PUNCT F

The 0 DET T
primary 0 ADJ F
outcome 0 NOUN F
measure 0 ADV F
involved 0 PUNCT F
identifying B-MENTAL VERB F
those I-MENTAL ADP F
tests I-MENTAL NOUN F
, I-MENTAL PUNCT F
if I-MENTAL VERB F
any I-MENTAL DET F
, I-MENTAL PUNCT F
where I-MENTAL ADP F
simulators I-MENTAL PUNCT F
were I-MENTAL VERB F
significantly I-MENTAL ADV F
different I-MENTAL ADJ F
from I-MENTAL ADP F
normal I-MENTAL ADJ F
and I-MENTAL CCONJ F
memory-impaired I-MENTAL VERB F
participants I-MENTAL NOUN F
. 0 PUNCT F

RESULTS 0 NOUN T
On 0 ADP T
5 0 NUM F
of 0 ADP F
the 0 DET F
15 0 NUM F
tasks 0 NOUN F
administered 0 ADP F
, 0 PUNCT F
simulators B-MENTAL NOUN F
performed I-MENTAL VERB F
significantly I-MENTAL ADV F
differently I-MENTAL ADV F
from I-MENTAL ADP F
normal I-MENTAL ADJ F
and I-MENTAL CCONJ F
memory-impaired I-MENTAL VERB F
participants I-MENTAL NOUN F
. 0 PUNCT F

Of 0 ADP T
these 0 DET F
5 0 NUM F
tasks 0 NOUN F
, 0 PUNCT F
the 0 DET F
coin-in-the-hand 0 CCONJ F
, 0 PUNCT F
when 0 ADP F
administered 0 VERB F
in 0 ADP F
conjunction 0 NOUN F
with 0 ADP F
the 0 DET F
autobiographical 0 ADJ F
interview 0 NOUN F
, 0 PUNCT F
identified 0 ADP F
95 0 NUM F
per 0 ADP F
cent 0 NUM F
of 0 ADP F
the 0 DET F
simulators 0 NOUN F
without 0 ADP F
misclassifying 0 NUM F
any 0 PUNCT F
of 0 ADP F
the 0 DET F
memory-impaired 0 NOUN F
or 0 CCONJ F
normal 0 ADJ F
participants 0 NOUN F
. 0 PUNCT F

CONCLUSION 0 NOUN T
It 0 PRON T
is 0 VERB F
suggested 0 VERB F
that 0 ADP F
these 0 DET F
two 0 NUM F
tests 0 NOUN F
, 0 PUNCT F
when 0 ADP F
administered 0 PUNCT F
jointly 0 ADV F
, 0 PUNCT F
might 0 PROPN F
be 0 PUNCT F
of 0 ADP F
use 0 NOUN F
in 0 ADP F
clinical 0 ADJ F
settings 0 NOUN F
to 0 PART F
assist 0 NOUN F
in 0 ADP F
the 0 DET F
detection 0 NOUN F
of 0 ADP F
malingerers 0 NOUN F
. 0 PUNCT F

The 0 DET T
cognitive B-PHYSICAL ADJ F
, 0 PUNCT F
subjective B-PHYSICAL ADJ F
, 0 PUNCT F
and 0 PUNCT F

Tramadol 0 PUNCT T
suppository 0 ADJ F
versus 0 CCONJ F
placebo 0 NOUN F
for 0 ADP F
the 0 DET F
relief 0 NOUN F
of 0 ADP F
perineal B-PAIN NOUN F
pain I-PAIN NOUN F
after 0 ADP F
perineorrhaphy 0 NOUN F
: 0 PUNCT F
a 0 DET F
randomized 0 VERB F
controlled 0 VERB F
trial 0 NOUN F
in 0 ADP F
Thailand 0 CCONJ T
. 0 PUNCT F

OBJECTIVE 0 NOUN T
This 0 PUNCT T
randomized 0 VERB F
double-blinded 0 ADV F
control 0 NOUN F
trial 0 NOUN F
was 0 VERB F
conducted 0 VERB F
to 0 PART F
compare 0 NOUN F
the 0 DET F
effectiveness 0 NOUN F
of 0 ADP F
tramodol 0 NOUN F
and 0 CCONJ F
placebo 0 NOUN F
rectal 0 ADJ F
suppository 0 ADJ F
for 0 ADP F
the 0 DET F
management 0 NOUN F
of 0 ADP F
postpartum B-PAIN NOUN F
perineal I-PAIN ADP F
pain I-PAIN NOUN F
after 0 ADP F
perineorrhaphy 0 NOUN F
. 0 PUNCT F

MATERIAL 0 NOUN T
AND 0 CCONJ T
METHOD 0 NOUN T
One 0 NUM T
hundred 0 NUM F
women 0 NOUN F
who 0 ADP F
gave 0 VERB F
birth 0 NOUN F
vaginally 0 PUNCT F
with 0 ADP F
episiotomy 0 NOUN F
and 0 CCONJ F
a 0 DET F
second- 0 ADJ F
or 0 CCONJ F
third-degree 0 ADP F
tear 0 NOUN F
, 0 PUNCT F
were 0 VERB F
randomly 0 ADV F
assign 0 PUNCT F
to 0 PART F
receive 0 NOUN F
two 0 ADJ F
tablets 0 ADV F
oftramadol 0 NOUN F
50 0 NUM F
mg 0 NOUN F
or 0 CCONJ F
two 0 NUM F
tablets 0 ADV F
ofplacebo 0 NOUN F
, 0 PUNCT F
the 0 DET F
pill 0 ADJ F
were 0 VERB F
physically 0 ADV F
similar 0 ADJ F
to 0 ADP F
the 0 DET F
real 0 ADJ F
drug 0 NOUN F
. 0 PUNCT F

Pain B-PAIN NOUN T
ratings I-PAIN NOUN F
were 0 VERB F
recorded 0 VERB F
immediately 0 ADV F
after 0 ADP F
perineorrhaphy 0 NOUN F
, 0 PUNCT F
30 0 NUM F
minutes 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
1 0 NUM F
, 0 PUNCT F
2 0 NUM F
, 0 PUNCT F
6 0 NUM F
, 0 PUNCT F
12 0 NUM F
and 0 CCONJ F
24 0 NUM F
hours 0 NOUN F
after 0 ADP F
first 0 ADJ F
dose 0 NOUN F
on 0 ADP F
a 0 DET F
10-cm 0 ADJ F
visual 0 ADJ F
analogue 0 NOUN F
scale 0 NOUN F
. 0 PUNCT F

Side B-ADVERSE-EFFECTS NOUN T
effects I-ADVERSE-EFFECTS NOUN F
and I-ADVERSE-EFFECTS CCONJ F
overall I-ADVERSE-EFFECTS ADJ F
opinion I-ADVERSE-EFFECTS NOUN F
were 0 VERB F
assessed 0 VERB F
. 0 PUNCT F

RESULTS 0 NOUN T
Tramadol 0 NOUN T
and 0 CCONJ F
placebo 0 NOUN F
had 0 PUNCT F
no 0 DET F
statistical 0 ADJ F
significances 0 PUNCT F
in 0 ADP F
analgesic B-PAIN ADP F
properties I-PAIN NOUN F
, 0 PUNCT F
assessed 0 VERB F
by 0 ADP F
the 0 DET F
means 0 NOUN F
of 0 ADP F
pain B-PAIN NOUN F
rating I-PAIN PUNCT F
at 0 ADP F
the 0 DET F
different 0 ADJ F
time 0 NOUN F
intervals 0 NOUN F
. 0 PUNCT F

There 0 PUNCT T
were 0 VERB F
no 0 DET F
serious B-ADVERSE-EFFECTS ADJ F
adverse I-ADVERSE-EFFECTS ADJ F
events I-ADVERSE-EFFECTS NOUN F
reported 0 VERB F
. 0 PUNCT F

CONCLUSION 0 NOUN T
No 0 DET T
differences 0 NOUN F
were 0 VERB F
found 0 VERB F
in 0 ADP F
between 0 ADP F
Tramadol 0 NOUN T
and 0 CCONJ F
placebo 0 NOUN F
in 0 ADP F
relief 0 NOUN F
perineal 0 NOUN F
pain 0 NOUN F
after 0 ADP F
perineorrhaphy 0 PUNCT F

Preoperative 0 ADJ T
lanreotide 0 NOUN F
treatment 0 NOUN F
in 0 ADP F
acromegalic 0 ADJ F
patients 0 NOUN F
with 0 ADP F
macroadenomas 0 PUNCT F
increases 0 PUNCT F
short-term B-PHYSICAL NOUN F
postoperative I-PHYSICAL ADJ F
cure I-PHYSICAL NOUN F
rates I-PHYSICAL NOUN F
: 0 PUNCT F
a 0 DET F
prospective 0 ADJ F
, 0 PUNCT F
randomised 0 VERB F
trial 0 NOUN F
. 0 PUNCT F

OBJECTIVE 0 NOUN T
To 0 PROPN T
investigate 0 NOUN F
whether 0 ADP F
4-month 0 NOUN F
preoperative 0 ADJ F
lanreotide 0 NOUN F
treatment 0 NOUN F
would 0 VERB F
improve 0 ADJ F
the 0 DET F
surgical B-OTHER ADJ F
cure I-OTHER NOUN F
rate I-OTHER NOUN F
of 0 ADP F
newly 0 ADJ F
diagnosed 0 VERB F
acromegalic 0 ADJ F
patients 0 NOUN F
with 0 ADP F
macroadenomas 0 NOUN F
. 0 PUNCT F

DESIGN 0 NOUN T
A 0 CCONJ T
prospective 0 ADJ F
, 0 PUNCT F
randomised 0 ADP F
study 0 NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
After 0 ADP T
a 0 DET F
baseline 0 NOUN F
evaluation 0 NOUN F
, 0 PUNCT F
patients 0 NOUN F
were 0 VERB F
randomly 0 ADV F
assigned 0 VERB F
to 0 ADP F
4-month 0 NOUN F
preoperative 0 ADJ F
treatment 0 NOUN F
with 0 ADP F
lanreotide 0 NOUN F
( 0 PUNCT F
starting 0 ADJ F
with 0 ADP F
30 0 NUM F
mg/2 0 NOUN F
weeks 0 NOUN F
i.m 0 NUM F
. 0 PUNCT F

and 0 CCONJ F
increasing 0 VERB F
to 0 ADP F
30 0 NUM F
mg/week 0 NOUN F
i.m 0 NUM F
. 0 PUNCT F

at 0 ADP F
week 0 NOUN F
8 0 NUM F
if 0 CCONJ F
mean 0 PUNCT F
GH 0 NOUN T
> 0 SYM F
2.5 0 NUM F
microg/l 0 NOUN F
on 0 ADP F
GH 0 NOUN T
day 0 NOUN F
curves 0 NOUN F
; 0 PUNCT F
pretreatment 0 NOUN F
group 0 NOUN F
, 0 PUNCT F
Group 0 NOUN T
1 0 NUM F
) 0 PUNCT F
or 0 CCONJ F
to 0 ADP F
transsphenoidal 0 ADJ F
surgery 0 NOUN F
( 0 PUNCT F
direct 0 ADJ F
surgery 0 NOUN F
group 0 NOUN F
, 0 PUNCT F
Group 0 NOUN T
2 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Cure B-OTHER NOUN T
was 0 VERB F
evaluated 0 VERB F
4 0 NUM F
months 0 NOUN F
postoperatively 0 ADJ F
primarily 0 ADV F
by 0 ADP F
fasting 0 DET F
IGF1 0 NOUN T
less 0 ADV F
than 0 PUNCT F
or 0 CCONJ F
equal 0 ADJ F
to 0 ADP F
age-adjusted 0 VERB F
upper 0 ADJ F
limit 0 NOUN F
of 0 ADP F
normal 0 ADJ F
. 0 PUNCT F

RESULTS 0 NOUN T
A 0 PUNCT T
pool 0 NOUN F
of 0 ADP F
108 0 NUM F
patients 0 NOUN F
was 0 ADJ F
randomly 0 ADV F
divided 0 VERB F
into 0 ADP F
two 0 NUM F
groups 0 NOUN F
. 0 PUNCT F

Five 0 NUM T
patients 0 NOUN F
in 0 ADP F
each 0 DET F
group 0 NOUN F
were 0 VERB F
lost 0 VERB F
to 0 ADP F
follow-up 0 NOUN F
during 0 ADP F
the 0 DET F
study 0 ADV F
period 0 NOUN F
, 0 PUNCT F
so 0 PUNCT F
49 0 ADJ F
patients 0 NOUN F
in 0 ADP F
each 0 DET F
group 0 NOUN F
were 0 VERB F
analysed 0 VERB F
. 0 PUNCT F

At 0 ADP T
baseline 0 NOUN F
, 0 PUNCT F
no 0 DET F
difference 0 NOUN F
was 0 VERB F
observed 0 VERB F
between 0 ADP F
the 0 DET F
two 0 NUM F
groups 0 NOUN F
. 0 PUNCT F

Cure B-OTHER NOUN T
was 0 VERB F
established 0 VERB F
in 0 ADP F
24 0 NUM F
of 0 ADP F
49 0 NUM F
( 0 PUNCT F
49.0 0 NUM F
% 0 SYM F
, 0 PUNCT F
95 0 NUM F
% 0 SYM F
confidence 0 NOUN F
interval 0 NOUN F
( 0 PUNCT F
CI 0 NOUN T
) 0 PUNCT F
, 0 PUNCT F
35.0-63.0 0 NUM F
% 0 SYM F
) 0 PUNCT F
pretreated 0 DET F
patients 0 NOUN F
( 0 PUNCT F
Group 0 NOUN T
1 0 NUM F
) 0 PUNCT F
versus 0 CCONJ F
9 0 NUM F
of 0 ADP F
49 0 NUM F
( 0 PUNCT F
18.4 0 NUM F
% 0 SYM F
, 0 PUNCT F
95 0 NUM F
% 0 SYM F
CI 0 NOUN T
, 0 PUNCT F
7.6-29.2 0 PUNCT F
% 0 SYM F
) 0 PUNCT F
direct 0 ADJ F
surgery 0 NOUN F
patients 0 NOUN F
( 0 PUNCT F
Group 0 NOUN T
2 0 NUM F
; 0 PUNCT F
P=0.001 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

Surgical B-PHYSICAL ADJ T
morbidity I-PHYSICAL NOUN F
was 0 VERB F
recorded 0 VERB F
in 0 ADP F
12 0 NUM F
patients 0 NOUN F
( 0 PUNCT F
12.2 0 NUM F
% 0 SYM F
) 0 PUNCT F
and 0 CCONJ F
was 0 VERB F
similar 0 ADJ F
in 0 ADP F
Group 0 NOUN T
1 0 NUM F
and 0 CCONJ F
2 0 NUM F
patients 0 NOUN F
( 0 PUNCT F
14.3 0 NUM F
and 0 CCONJ F
10.2 0 NUM F
% 0 SYM F
respectively 0 ADV F
; 0 PUNCT F
P=0.538 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
postoperative B-OTHER ADJ F
hospital I-OTHER NOUN F
stay I-OTHER NOUN F
was 0 VERB F
similar 0 ADJ F
between 0 ADP F
groups 0 NOUN F
: 0 PUNCT F
being 0 ADV F
4.5+/-1.6 0 PUNCT F
days 0 NOUN F
in 0 ADP F
Group 0 NOUN T
1 0 NUM F
vs 0 CCONJ F
4.8+/-1.9 0 PUNCT F
days 0 NOUN F
in 0 ADP F
Group 0 NOUN T
2 0 NUM F
( 0 PUNCT F
P=0.328 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

CONCLUSIONS 0 NOUN T
Pretreatment 0 NOUN T
with 0 ADP F
lanreotide 0 NOUN F
before 0 ADP F
transsphenoidal 0 ADJ F
surgery 0 NOUN F
improves 0 NOUN F
surgical B-OTHER ADJ F
cure I-OTHER NOUN F
rates I-OTHER NOUN F
in 0 ADP F
patients 0 NOUN F
with 0 ADP F
GH-secreting 0 PUNCT T
pituitary 0 NOUN F
macroadenomas 0 NOUN F
. 0 PUNCT F

Pretreatment 0 NOUN T
does 0 PUNCT F
not 0 ADV F
affect 0 VERB F
surgical B-ADVERSE-EFFECTS ADJ F
complications I-ADVERSE-EFFECTS NOUN F
or 0 CCONJ F
duration 0 NOUN F
of 0 ADP F
hospital B-OTHER NOUN F
stay I-OTHER NOUN F
( 0 PUNCT F
ClinicalTrials.gov 0 PUNCT T
number 0 NOUN F
, 0 PUNCT F
NCT00993356 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

Oral 0 ADJ T
S-adenosylmethionine 0 NOUN T
in 0 ADP F
the 0 DET F
symptomatic 0 ADJ F
treatment 0 NOUN F
of 0 ADP F
intrahepatic B-PHYSICAL ADJ F
cholestasis I-PHYSICAL NOUN F
. 0 PUNCT F

A 0 DET T
double-blind 0 ADJ F
, 0 PUNCT F
placebo-controlled 0 VERB F
study 0 NOUN F
. 0 PUNCT F

Parenteral 0 ADJ T
S-adenosylmethionine 0 NOUN T
proved 0 VERB F
to 0 PART F
be 0 VERB F
effective 0 ADJ F
in 0 ADP F
reversing 0 PUNCT F
intrahepatic B-PHYSICAL ADJ F
cholestasis I-PHYSICAL NOUN F
in 0 ADP F
pregnant 0 ADJ F
women 0 NOUN F
. 0 PUNCT F

Based 0 VERB T
on 0 ADP F
these 0 DET F
findings 0 NOUN F
, 0 PUNCT F
a 0 DET F
prospective 0 ADJ F
multicenter 0 NOUN F
, 0 PUNCT F
double-blind 0 ADJ F
, 0 PUNCT F
placebo-controlled 0 VERB F
trial 0 NOUN F
was 0 VERB F
planned 0 PROPN F
to 0 ADJ F
assess 0 NOUN F
whether 0 ADP F
oral 0 ADJ F
S-adenosylmethionine 0 NOUN T
is 0 VERB F
effective 0 ADJ F
in 0 ADP F
cholestatic B-PHYSICAL ADJ F
patients I-PHYSICAL NOUN F
with 0 ADP F
chronic 0 ADJ F
liver 0 NOUN F
disease 0 NOUN F
. 0 PUNCT F

Accordingly 0 ADV T
, 0 PUNCT F
220 0 NUM F
inpatients 0 NOUN F
( 0 PUNCT F
26 0 NUM F
% 0 SYM F
chronic 0 ADJ F
active 0 ADJ F
hepatitis 0 NOUN F
, 0 PUNCT F
68 0 NUM F
% 0 SYM F
cirrhosis 0 NOUN F
, 0 PUNCT F
6 0 NUM F
% 0 SYM F
primary 0 ADJ F
biliary 0 ADJ F
cirrhosis 0 NOUN F
) 0 PUNCT F
with 0 ADP F
stable 0 ADJ F
( 0 PUNCT F
1 0 NUM F
month 0 NOUN F
or 0 CCONJ F
more 0 DET F
) 0 PUNCT F
at 0 VERB F
least 0 ADV F
twofold 0 NOUN F
increases 0 CCONJ F
in 0 ADP F
serum B-PHYSICAL NOUN F
total 0 ADJ F
and 0 CCONJ F
conjugated B-PHYSICAL VERB F
bilirubin I-PHYSICAL NOUN F
and I-PHYSICAL CCONJ F
alkaline I-PHYSICAL ADJ F
phosphatase I-PHYSICAL NOUN F
volunteered 0 PUNCT F
for 0 ADP F
the 0 DET F
trial 0 NOUN F
. 0 PUNCT F

Serum B-PHYSICAL NOUN T
markers I-PHYSICAL NOUN F
of I-PHYSICAL ADP F
cholestasis I-PHYSICAL NOUN F
significantly 0 ADV F
( 0 PUNCT F
P 0 NOUN T
less 0 ADV F
than 0 PUNCT F
0.01 0 NUM F
) 0 PUNCT F
decreased 0 VERB F
after 0 PUNCT F
oral 0 ADJ F
S-adenosylmethionine 0 NOUN T
administration 0 NOUN F
( 0 PUNCT F
1600 0 NUM F
mg/day 0 NOUN F
) 0 PUNCT F
, 0 PUNCT F
and 0 CCONJ F
their 0 ADJ F
values 0 NOUN F
were 0 VERB F
significantly 0 ADV F
( 0 PUNCT F
P 0 NOUN T
less 0 ADV F
than 0 PUNCT F
0.01 0 NUM F
) 0 PUNCT F
lower 0 PUNCT F
than 0 PUNCT F
the 0 DET F
corresponding 0 ADJ F
values 0 NOUN F
in 0 ADP F
the 0 DET F
placebo 0 NOUN F
group 0 NOUN F
. 0 PUNCT F

S-adenosylmethionine 0 NOUN T
significantly 0 NOUN F
( 0 PUNCT F
P 0 NOUN T
less 0 ADV F
than 0 PUNCT F
0.01 0 NUM F
) 0 PUNCT F
improved 0 VERB F
subjective B-PHYSICAL ADJ F
symptoms I-PHYSICAL NOUN F
such I-PHYSICAL ADP F
as I-PHYSICAL ADP F
pruritus I-PHYSICAL NOUN F
, 0 PUNCT F
fatigue B-PHYSICAL NOUN F
, 0 PUNCT F
and 0 CCONJ F
feeling 0 DET F
of 0 PUNCT F

Effect 0 NOUN T
of 0 ADP F
entacapone 0 NOUN F
, 0 PUNCT F
a 0 DET F
peripherally 0 ADV F
acting 0 ADP F
catechol-O-methyltransferase 0 NOUN F
inhibitor 0 NOUN F
, 0 PUNCT F
on 0 ADP F
the 0 DET F
motor B-PHYSICAL NOUN F
response 0 NOUN F
to B-PHYSICAL ADP F
acute I-PHYSICAL ADJ F
treatment 0 NOUN F
with B-PHYSICAL ADP F
levodopa B-PHYSICAL NOUN F
in 0 ADP F
patients 0 NOUN F
with 0 ADP F
Parkinson 0 NOUN T
's 0 PUNCT F
disease 0 NOUN F
. 0 PUNCT F

Catechol-O-methyltransferase 0 NOUN T
( 0 PUNCT F
COMT 0 NOUN T
) 0 PUNCT F
inhibitors 0 NOUN F
may 0 ADP F
be 0 VERB F
useful 0 ADJ F
in 0 ADP F
the 0 DET F
treatment 0 NOUN F
of 0 ADP F
Parkinson 0 NOUN T
's 0 PUNCT F
disease 0 NOUN F
by 0 ADP F
improving 0 VERB F
the 0 DET F
bioavailability B-OTHER NOUN F
of 0 ADP F
levodopa 0 NOUN F
and 0 CCONJ F
by 0 ADP F
prolonging 0 VERB F
its 0 ADP F
effects 0 NOUN F
. 0 PUNCT F

Entacapone 0 NOUN T
( 0 PUNCT F
OR-611 0 NOUN T
) 0 PUNCT F
, 0 PUNCT F
a 0 DET F
novel 0 ADJ F
COMT 0 NOUN T
inhibitor 0 NOUN F
, 0 PUNCT F
which 0 DET F
does 0 PUNCT F
not 0 ADV F
cross 0 ADP F
the 0 DET F
blood 0 NOUN F
brain 0 NOUN F
barrier 0 NOUN F
, 0 PUNCT F
was 0 VERB F
assessed 0 VERB F
in 0 ADP F
12 0 NUM F
patients 0 NOUN F
with 0 ADP F
Parkinson 0 NOUN T
's 0 PUNCT F
disease 0 NOUN F
and 0 CCONJ F
motor 0 NOUN F
fluctuations 0 NOUN F
in 0 ADP F
a 0 DET F
randomised 0 VERB F
, 0 PUNCT F
double-blind 0 ADJ F
, 0 PUNCT F
cross-over 0 NOUN F
, 0 PUNCT F
single 0 ADJ F
dose 0 NOUN F
study 0 NOUN F
. 0 PUNCT F

The 0 DET T
magnitude 0 NOUN F
and 0 CCONJ F
duration 0 NOUN F
of 0 ADP F
the 0 DET F
therapeutic 0 ADJ F
response 0 NOUN F
to 0 ADP F
a 0 DET F
single 0 ADJ F
dose 0 NOUN F
of 0 ADP F
200 0 NUM F
mg 0 NOUN F
levodopa/50 0 NOUN F
mg 0 NOUN F
carbidopa 0 NOUN F
was 0 VERB F
evaluated 0 VERB F
after 0 ADP F
concomitant 0 ADJ F
placebo 0 NOUN F
, 0 PUNCT F
or 0 CCONJ F
200 0 NUM F
or 0 CCONJ F
800 0 NUM F
mg 0 NOUN F
entacapone 0 NOUN F
. 0 PUNCT F

A 0 DET T
significant 0 ADJ F
increase 0 NOUN F
in 0 ADP F
the 0 DET F
duration 0 NOUN F
of 0 ADP F
the 0 DET F
motor B-PHYSICAL NOUN F
response 0 NOUN F
to B-PHYSICAL ADP F
levodopa I-PHYSICAL NOUN F
was 0 VERB F
seen 0 VERB F
when 0 ADP F
200 0 NUM F
mg 0 NOUN F
entacapone 0 NOUN F
was 0 VERB F
given 0 VERB F
with 0 ADP F
levodopa/carbidopa 0 NOUN F
. 0 PUNCT F

Pretreatment 0 NOUN T
with 0 ADP F
thiopental 0 ADJ F
for 0 ADP F
prevention 0 NOUN F
of 0 ADP F
pain B-PAIN NOUN F
associated I-PAIN VERB F
with I-PAIN ADP F
propofol I-PAIN NOUN F
injection I-PAIN NOUN F
. 0 PUNCT F

UNLABELLED 0 NOUN T
Propofol 0 NOUN T
causes 0 PUNCT F
pain 0 NOUN F
on 0 ADP F
IV B-PAIN NUM T
injection I-PAIN NOUN F
in 0 ADP F
28 0 NUM F
% 0 SYM F
-90 0 NUM F
% 0 SYM F
of 0 ADP F
patients 0 NOUN F
. 0 PUNCT F

A 0 DET T
number 0 NOUN F
of 0 ADP F
techniques 0 NOUN F
have 0 ADP F
been 0 PUNCT F
tried 0 PRON F
to 0 PART F
minimize 0 NOUN F
propofol-induced 0 VERB F
pain 0 NOUN F
, 0 PUNCT F
with 0 ADP F
variable 0 ADJ F
results 0 NOUN F
. 0 PUNCT F

We 0 PRON T
compared 0 VERB F
the 0 DET F
efficacy 0 NOUN F
of 0 ADP F
pretreatment 0 NOUN F
with 0 ADP F
thiopental 0 ADJ F
0.25 0 NUM F
mg/kg 0 NOUN F
and 0 CCONJ F
0.5 0 NUM F
mg/kg 0 NOUN F
and 0 CCONJ F
lidocaine 0 NOUN F
40 0 NUM F
mg 0 NOUN F
after 0 ADP F
venous 0 ADJ F
occlusion 0 NOUN F
for 0 ADP F
prevention 0 NOUN F
of 0 ADP F
propofol-induced B-PAIN VERB F
pain I-PAIN NOUN F
. 0 PUNCT F

One-hundred-twenty-four 0 NOUN T
adult 0 NOUN F
patients 0 NOUN F
, 0 PUNCT F
ASA 0 NOUN T
physical 0 ADJ F
status 0 NOUN F
I-II 0 ADV T
, 0 PUNCT F
undergoing 0 CCONJ F
elective 0 ADJ F
surgery 0 NOUN F
were 0 VERB F
randomly 0 ADV F
assigned 0 VERB F
into 0 ADP F
4 0 NUM F
groups 0 NOUN F
of 0 ADP F
31 0 NUM F
each 0 ADP F
. 0 PUNCT F

Group 0 NOUN T
I 0 NUM T
received 0 VERB F
normal 0 ADJ F
saline 0 NOUN F
, 0 PUNCT F
group 0 NOUN F
II 0 NUM T
received 0 ADJ F
lidocaine 0 NOUN F
2 0 NUM F
% 0 SYM F
( 0 PUNCT F
40 0 NUM F
mg 0 NOUN F
) 0 PUNCT F
, 0 PUNCT F
and 0 CCONJ F
groups 0 NOUN F
III 0 NUM T
and 0 CCONJ F
IV 0 NUM T
received 0 PUNCT F
thiopental 0 ADJ F
0.25 0 NUM F
mg/kg 0 NOUN F
and 0 CCONJ F
0.5 0 NUM F
mg/kg 0 NOUN F
, 0 PUNCT F
respectively 0 ADV F
. 0 PUNCT F

All 0 DET T
pretreatment 0 NOUN F
drugs 0 NOUN F
were 0 VERB F
made 0 VERB F
in 0 ADP F
2 0 NUM F
mL 0 NOUN F
and 0 CCONJ F
were 0 VERB F
accompanied 0 VERB F
by 0 ADP F
manual 0 ADJ F
venous 0 ADJ F
occlusion 0 NOUN F
for 0 ADP F
1 0 NUM F
min 0 NOUN F
. 0 PUNCT F

Propofol 0 NOUN T
was 0 VERB F
administered 0 VERB F
after 0 ADP F
release 0 NOUN F
of 0 ADP F
venous 0 ADJ F
occlusion 0 NOUN F
. 0 PUNCT F

Pain B-PHYSICAL NOUN T
was 0 VERB F
assessed 0 VERB F
with 0 ADP F
a 0 DET F
four-point 0 NOUN F
scale 0 NOUN F
: 0 PUNCT F
0 0 NUM F
= 0 SYM F
no 0 DET F
pain 0 NOUN F
, 0 PUNCT F
1 0 NUM F
= 0 SYM F
mild 0 ADJ F
pain 0 NOUN F
, 0 PUNCT F
2 0 NUM F
= 0 SYM F
moderate 0 ADJ F
pain 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
3 0 NUM F
= 0 SYM F
severe 0 ADJ F
pain 0 NOUN F
at 0 ADP F
the 0 DET F
time 0 NOUN F
of 0 ADP F
propofol 0 NOUN F
injection 0 NOUN F
. 0 PUNCT F

Twenty-four 0 PUNCT T
patients 0 NOUN F
( 0 PUNCT F
77 0 NUM F
% 0 SYM F
) 0 PUNCT F
complained 0 PUNCT F
of 0 ADP F
pain B-PHYSICAL NOUN F
in 0 ADP F
the 0 DET F
group 0 NOUN F
pretreated 0 VERB F
with 0 ADP F
normal 0 ADJ F
saline 0 NOUN F
as 0 VERB F
compared 0 VERB F
with 0 ADP F
12 0 NUM F
( 0 PUNCT F
39 0 NUM F
% 0 SYM F
) 0 PUNCT F
, 0 PUNCT F
10 0 NUM F
( 0 PUNCT F
32 0 NUM F
% 0 SYM F
) 0 PUNCT F
, 0 PUNCT F
and 0 CCONJ F
1 0 NUM F
( 0 PUNCT F
3 0 NUM F
% 0 SYM F
) 0 PUNCT F
in 0 ADP F
the 0 DET F
groups 0 NOUN F
pretreated 0 VERB F
with 0 ADP F
lidocaine 0 NOUN F
40 0 NUM F
mg 0 NOUN F
, 0 PUNCT F
thiopental 0 ADJ F
0.25 0 NUM F
mg/kg 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
thiopental 0 ADJ F
0.5 0 NUM F
mg/kg 0 NOUN F
, 0 PUNCT F
respectively 0 ADV F
( 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.05 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Thiopental 0 ADJ T
0.5 0 NUM F
mg/kg 0 NOUN F
was 0 VERB F
the 0 DET F
most 0 ADJ F
effective 0 ADJ F
treatment 0 NOUN F
. 0 PUNCT F

We 0 ADP T
therefore 0 ADV F
suggest 0 VERB F
routine 0 ADJ F
pretreatment 0 NOUN F
with 0 ADP F
thiopental 0 ADJ F
0.5 0 NUM F
mg/kg 0 NOUN F
along 0 ADP F
with 0 ADP F
venous 0 ADJ F
occlusion 0 NOUN F
for 0 ADP F
1 0 NUM F
min 0 NOUN F
for 0 ADP F
prevention 0 NOUN F
of 0 ADP F
pain B-PHYSICAL NOUN F
associated 0 VERB F
with 0 ADP F
propofol 0 NOUN F
injection 0 NOUN F
. 0 PUNCT F

IMPLICATIONS 0 NOUN T
Pain B-PHYSICAL NOUN T
associated 0 VERB F
with 0 ADP F
IV 0 NUM T
injection 0 NOUN F
of 0 ADP F
propofol 0 NOUN F
is 0 VERB F
seen 0 VERB F
in 0 ADP F
28 0 NUM F
% 0 SYM F
-90 0 NUM F
% 0 SYM F
patients 0 NOUN F
. 0 PUNCT F

Pretreatment 0 NOUN T
with 0 ADP F
thiopental 0 ADJ F
0.25 0 NUM F
mg/kg 0 NOUN F
and 0 CCONJ F
0.5 0 NUM F
mg/kg 0 NOUN F
after 0 ADP F
manual 0 ADJ F
venous 0 ADJ F
occlusion 0 NOUN F
for 0 ADP F
1 0 NUM F
min 0 NOUN F
effectively 0 ADV F
attenuated 0 VERB F
pain B-PHYSICAL NOUN F
associated 0 VERB F
with 0 ADP F
propofol 0 NOUN F
injection 0 NOUN F
. 0 PUNCT F

Thiopental 0 ADJ T
0.5 0 NUM F
mg/kg 0 NOUN F
was 0 VERB F
the 0 DET F
most 0 ADJ F
effective 0 ADJ F
in 0 ADP F
prevention 0 NOUN F
of 0 ADP F
propofol B-PAIN NOUN F
pain I-PAIN NOUN F
and 0 CCONJ F
can 0 PRON F
be 0 VERB F
used 0 VERB F
routinely 0 ADV F
. 0 PUNCT F

Riluzole 0 NUM T
as 0 ADP F
an 0 DET F
adjunctive 0 ADJ F
therapy 0 NOUN F
to 0 ADP F
risperidone 0 NUM F
for 0 ADP F
the 0 DET F
treatment 0 NOUN F
of 0 ADP F
irritability B-MENTAL NOUN F
in 0 ADP F
children 0 NOUN F
with 0 ADP F
autistic 0 ADJ F
disorder 0 NOUN F
: 0 PUNCT F
a 0 DET F
double-blind 0 ADJ F
, 0 PUNCT F
placebo-controlled 0 VERB F
, 0 PUNCT F
randomized 0 VERB F
trial 0 NOUN F
. 0 PUNCT F

BACKGROUND 0 NOUN T
A 0 PUNCT T
hyperglutamatergic 0 ADJ F
state 0 NOUN F
has 0 PUNCT F
been 0 PUNCT F
shown 0 VERB F
to 0 PART F
play 0 NOUN F
a 0 DET F
possible 0 ADJ F
role 0 NOUN F
in 0 ADP F
the 0 DET F
pathophysiology 0 NOUN F
of 0 ADP F
autistic 0 ADJ F
disorders 0 NOUN F
. 0 PUNCT F

Riluzole 0 NOUN T
is 0 VERB F
a 0 DET F
glutamate-modulating 0 VERB F
agent 0 NOUN F
with 0 ADP F
neuroprotective 0 ADJ F
properties 0 NOUN F
, 0 PUNCT F
which 0 ADP F
has 0 PUNCT F
been 0 PUNCT F
shown 0 VERB F
to 0 DET F
have 0 PUNCT F
positive 0 ADJ F
effects 0 NOUN F
in 0 ADP F
many 0 DET F
neuropsychiatric B-PHYSICAL ADJ F
disorders I-PHYSICAL NOUN F
. 0 PUNCT F

OBJECTIVE 0 NOUN T
The 0 DET T
aim 0 NOUN F
of 0 ADP F
this 0 DET F
study 0 NOUN F
was 0 VERB F
to 0 ADV F
assess 0 NOUN F
the 0 DET F
efficacy 0 NOUN F
and 0 CCONJ F
tolerability B-OTHER NOUN F
of 0 ADP F
riluzole 0 ADJ F
as 0 ADP F
an 0 DET F
adjunctive 0 ADJ F
to 0 PUNCT F
risperidone 0 ADP F
in 0 ADP F
the 0 DET F
treatment 0 NOUN F
of 0 ADP F
irritability 0 NOUN F
in 0 ADP F
autistic 0 ADJ F
children 0 NOUN F
who 0 PROPN F
were 0 VERB F
not 0 ADV F
optimally 0 ADV F
responding 0 PUNCT F
to 0 ADP F
previous 0 ADJ F
medications 0 NOUN F
. 0 PUNCT F

STUDY 0 NOUN T
DESIGN 0 NOUN T
This 0 PUNCT T
was 0 VERB F
a 0 DET F
10-week 0 NOUN F
, 0 PUNCT F
randomized 0 VERB F
, 0 PUNCT F
double-blind 0 ADJ F
, 0 PUNCT F
parallel-group 0 NOUN F
, 0 PUNCT F
placebo-controlled 0 VERB F
trial 0 NOUN F
. 0 PUNCT F

PARTICIPANTS 0 ADP T
The 0 DET T
study 0 NOUN F
enrolled 0 VERB F
male 0 NOUN F
and 0 CCONJ F
female 0 NOUN F
outpatients 0 ADJ F
aged 0 NOUN F
5-12 0 NUM F
years 0 NOUN F
with 0 ADP F
a 0 DET F
diagnosis 0 NOUN F
of 0 ADP F
autistic 0 ADJ F
disorder 0 NOUN F
based 0 VERB F
on 0 ADP F
the 0 DET F
DSM-IV-TR 0 NOUN T
criteria 0 NOUN F
and 0 CCONJ F
a 0 DET F
score 0 NOUN F
of 0 ADP F
?12 0 PUNCT F
on 0 ADP F
the 0 DET F
Aberrant 0 ADJ T
Behavior 0 NOUN T
Checklist-Community 0 NOUN T
( 0 PUNCT F
ABC-C 0 NOUN T
) 0 PUNCT F
irritability 0 NOUN F
subscale 0 NOUN F
who 0 ADP F
had 0 PUNCT F
discontinued 0 DET F
other 0 ADJ F
medications 0 NOUN F
because 0 PUNCT F
of 0 ADP F
a 0 DET F
lack 0 NOUN F
of 0 ADP F
efficacy 0 NOUN F
. 0 PUNCT F

INTERVENTIONS 0 VERB T
Subjects 0 NOUN T
received 0 ADV F
riluzole 0 VERB F
( 0 PUNCT F
titrated 0 NOUN F
to 0 ADP F
50 0 NUM F
or 0 CCONJ F
100 0 NUM F
mg/day 0 NOUN F
based 0 VERB F
on 0 ADP F
bodyweight 0 NOUN F
) 0 PUNCT F
or 0 CCONJ F
placebo 0 NOUN F
in 0 ADP F
addition 0 NOUN F
to 0 ADP F
risperidone 0 NUM F
( 0 PUNCT F
titrated 0 NOUN F
up 0 ADP F
to 0 ADP F
2 0 NUM F
or 0 CCONJ F
3 0 NUM F
mg/day 0 NOUN F
based 0 VERB F
on 0 ADP F
bodyweight 0 NOUN F
) 0 PUNCT F
for 0 ADP F
10 0 NUM F
weeks 0 NOUN F
. 0 PUNCT F

OUTCOME 0 NOUN T
Patients 0 NOUN T
were 0 VERB F
assessed 0 VERB F
at 0 ADP F
baseline 0 NOUN F
, 0 PUNCT F
week 0 NOUN F
5 0 NUM F
, 0 PUNCT F
and 0 CCONJ F
week 0 NOUN F
10 0 NUM F
. 0 PUNCT F

The 0 DET T
primary 0 ADJ F
outcome 0 NOUN F
measure 0 ADV F
was 0 VERB F
the 0 DET F
difference 0 NOUN F
in 0 ADP F
the 0 DET F
change 0 NOUN F
in 0 ADP F
the 0 DET F
ABC-C 0 NOUN T
irritability 0 NOUN F
subscale 0 NOUN F
score 0 NOUN F
from 0 ADP F
baseline 0 NOUN F
to 0 PUNCT F
week 0 ADP F
10 0 NUM F
between 0 ADP F
the 0 DET F
two 0 NUM F
groups 0 NOUN F
. 0 PUNCT F

We 0 PRON T
also 0 ADV F
compared 0 PUNCT F
changes 0 NOUN F
in 0 ADP F
other 0 ADJ F
ABC-C 0 NOUN T
subscale 0 NOUN F
scores 0 NOUN F
and 0 CCONJ F
Clinical 0 ADJ T
Global 0 PUNCT T
Impressions-Improvement 0 ADJ T
( 0 PUNCT F
CGI-I 0 NOUN T
) 0 PUNCT F
scale 0 NOUN F
scores 0 NOUN F
between 0 ADP F
the 0 DET F
two 0 NUM F
groups 0 NOUN F
. 0 PUNCT F

RESULTS 0 NOUN T
Forty-nine 0 NUM T
patients 0 NOUN F
were 0 VERB F
enrolled 0 VERB F
in 0 ADP F
the 0 DET F
study 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
forty 0 NUM F
children 0 NOUN F
completed 0 VERB F
the 0 DET F
trial 0 NOUN F
( 0 PUNCT F
dropouts 0 PUNCT F
: 0 PUNCT F
placebo 0 NOUN F
= 0 SYM F
4 0 NUM F
, 0 PUNCT F
riluzole 0 NOUN F
= 0 SYM F
5 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

A 0 PUNCT T
significantly 0 ADV F
greater 0 PUNCT F
improvement 0 NOUN F
in 0 ADP F
the 0 DET F
study 0 ADV F
primary 0 ADJ F
outcome 0 NOUN F
( 0 PUNCT F
the 0 DET F
ABC-C 0 NOUN T
irritability 0 NOUN F
subscale 0 NOUN F
score 0 NOUN F
) 0 PUNCT F
was 0 VERB F
achieved 0 VERB F
by 0 ADP F
the 0 DET F
riluzole-treated 0 VERB F
children 0 NOUN F
compared 0 VERB F
with 0 ADP F
the 0 DET F
placebo 0 NOUN F
group 0 NOUN F
( 0 PUNCT F
P 0 NOUN T
= 0 SYM F
0.03 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Patients 0 NOUN T
in 0 ADP F
the 0 DET F
riluzole 0 ADJ F
group 0 NOUN F
also 0 ADV F
showed 0 VERB F
significantly 0 ADP F
greater 0 PUNCT F
improvement 0 NOUN F
on 0 ADP F
the 0 DET F
lethargy/social 0 ADJ F
withdrawal 0 NOUN F
( 0 PUNCT F
P 0 NOUN T
= 0 SYM F
0.02 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
stereotypic 0 ADJ F
behavior 0 NOUN F
( 0 PUNCT F
P 0 NOUN T
= 0 SYM F
0.03 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
and 0 CCONJ F
hyperactivity/non-compliance 0 PUNCT F
subscales 0 NOUN F
( 0 PUNCT F
P 0 NOUN T
= 0 SYM F
0.005 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
but 0 CCONJ F
not 0 ADV F
on 0 ADP F
the 0 DET F
inappropriate 0 PUNCT F
speech 0 NOUN F
subscale 0 NOUN F
( 0 PUNCT F
P 0 NOUN T
= 0 SYM F
0.20 0 NUM F
) 0 PUNCT F
than 0 ADP F
patients 0 NOUN F
in 0 ADP F
the 0 DET F
placebo 0 NOUN F
group 0 NOUN F
. 0 PUNCT F

Eleven 0 ADP T
patients 0 NOUN F
in 0 ADP F
the 0 DET F
riluzole 0 ADJ F
group 0 NOUN F
and 0 CCONJ F
five 0 NUM F
patients 0 NOUN F
in 0 ADP F
the 0 DET F
placebo 0 NOUN F
group 0 NOUN F
were 0 VERB F
classified 0 VERB F
as 0 ADP F
responders 0 NOUN F
based 0 VERB F
on 0 ADP F
their 0 PUNCT F
CGI-I 0 NOUN T
scores 0 NOUN F
[ 0 PUNCT F
? 0 PUNCT F
( 0 PUNCT F

2 0 NUM F
) 0 PUNCT F
( 0 PUNCT F
1 0 NUM F
) 0 PUNCT F
= 0 ADP F
3.750 0 DET F
, 0 PUNCT F
P 0 NOUN T
= 0 SYM F
0.05 0 NUM F
] 0 PUNCT F
. 0 PUNCT F

Children 0 NOUN T
in 0 ADP F
the 0 DET F
riluzole 0 ADJ F
group 0 NOUN F
experienced 0 ADP F
significantly 0 ADV F
more 0 DET F
increases 0 PUNCT F
in 0 ADP F
their 0 PUNCT F
appetite 0 NOUN F
and 0 CCONJ F
bodyweight 0 ADJ F
than 0 ADP F
children 0 NOUN F
in 0 ADP F
the 0 DET F
placebo 0 NOUN F
group 0 NOUN F
by 0 ADP F
the 0 DET F
end 0 NOUN F
of 0 ADP F
the 0 DET F
study 0 NOUN F
. 0 PUNCT F

CONCLUSION 0 NOUN T
Riluzole 0 ADP T
add-on 0 NOUN F
therapy 0 NOUN F
shows 0 NOUN F
several 0 ADJ F
therapeutic 0 ADJ F
outcomes 0 NOUN F
, 0 PUNCT F
particularly 0 ADV F
for 0 ADP F
improving 0 VERB F
irritability 0 NOUN F
, 0 PUNCT F
in 0 ADP F
children 0 NOUN F
with 0 ADP F
autism 0 NOUN F
. 0 PUNCT F

However 0 ADV T
, 0 PUNCT F
its 0 PUNCT F
add-on 0 NOUN F
to 0 ADP F
risperidone 0 NUM F
also 0 ADV F
results 0 VERB F
in 0 ADP F
significantly 0 ADV F
increased 0 ADJ F
appetite 0 NOUN F
and 0 CCONJ F
weight 0 NOUN F
gain 0 NOUN F
. 0 PUNCT F

The 0 DET T
evaluation 0 NOUN F
of 0 ADP F
pulmonary 0 ADJ F
hypertension 0 NOUN F
using 0 VERB F
right 0 ADJ F
ventricular 0 ADJ F
myocardial 0 ADJ F
isovolumic 0 ADJ F
relaxation 0 NOUN F
time 0 NOUN F
. 0 PUNCT F

Right 0 ADJ T
ventricular 0 ADJ F
( 0 PUNCT F
RV 0 NOUN T
) 0 PUNCT F
blood 0 NOUN F
pool-derived 0 DET F
isovolumic 0 ADJ F
relaxation 0 NOUN F
time 0 NOUN F
( 0 PUNCT F
IVRT 0 NOUN T
) 0 PUNCT F
correlates 0 VERB F
well 0 VERB F
with 0 CCONJ F
systolic 0 ADJ F
pulmonary 0 ADJ F
arterial 0 ADJ F
pressure 0 NOUN F
( 0 PUNCT F
PAP 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

However 0 ADV T
, 0 PUNCT F
because 0 PUNCT F
of 0 ADP F
complex 0 ADJ F
parameter 0 NOUN F
derivation 0 NOUN F
, 0 PUNCT F
the 0 DET F
method 0 NOUN F
is 0 VERB F
rarely 0 ADV F
used 0 VERB F
. 0 PUNCT F

The 0 DET T
aim 0 NOUN F
of 0 ADP F
this 0 DET F
study 0 NOUN F
was 0 VERB F
to 0 ADV F
validate 0 VERB F
the 0 DET F
measurement 0 NOUN F
of 0 ADP F
myocardial 0 ADJ F
velocity 0 NOUN F
imaging-derived 0 VERB F
RV 0 NOUN T
IVRT 0 NOUN T
( 0 PUNCT F
IVRT 0 NOUN T
' 0 PUNCT F
) 0 PUNCT F
against 0 ADP F
invasively 0 PUNCT F
measured 0 PUNCT F
PAP 0 NOUN T
. 0 PUNCT F

Transthoracic 0 ADJ T
echocardiography 0 NOUN F
with 0 ADP F
myocardial 0 ADJ F
velocity 0 NOUN F
imaging 0 VERB F
and 0 CCONJ F
right 0 VERB F
heart 0 NOUN F
catheterization 0 NOUN F
were 0 VERB F
performed 0 VERB F
in 0 ADP F
33 0 NUM F
patients 0 NOUN F
with 0 ADP F
pulmonary 0 ADJ F
hypertension 0 NOUN F
. 0 PUNCT F

Blood B-PHYSICAL NOUN T
pool I-PHYSICAL NOUN F
IVRT I-PHYSICAL NOUN T
and 0 CCONJ F
myocardial B-PHYSICAL ADJ F
IVRTs I-PHYSICAL NOUN T
for I-PHYSICAL ADP F
the I-PHYSICAL DET F
tricuspid I-PHYSICAL NOUN F
valve I-PHYSICAL NOUN F
annulus I-PHYSICAL NOUN F
ring I-PHYSICAL NOUN F
, 0 PUNCT F
basal B-PHYSICAL ADJ F
and 0 CCONJ F
apical B-PHYSICAL ADJ F
RV I-PHYSICAL NOUN T
free I-PHYSICAL ADJ F
wall I-PHYSICAL NOUN F
segments I-PHYSICAL NOUN F
were 0 VERB F
measured 0 VERB F
and 0 CCONJ F
compared 0 VERB F
with 0 ADP F
data 0 NOUN F
from 0 ADP F
33 0 NUM F
age- 0 NOUN F
and 0 CCONJ F
sex-matched 0 VERB F
control 0 NOUN F
subjects 0 NOUN F
. 0 PUNCT F

Measured B-PHYSICAL PUNCT T
IVRTs I-PHYSICAL NOUN T
were 0 VERB F
significantly 0 ADV F
longer 0 PUNCT F
in 0 ADP F
patients 0 NOUN F
with 0 ADP F
pulmonary 0 ADJ F
hypertension 0 NOUN F
than 0 PUNCT F
in 0 ADP F
control 0 NOUN F
subjects 0 NOUN F
. 0 PUNCT F

The 0 DET T
strongest 0 PUNCT F
correlation 0 NOUN F
( 0 PUNCT F
R 0 NOUN T
= 0 SYM F
0.74 0 NUM F
, 0 PUNCT F
P 0 NOUN T
< 0 SYM F
.0001 0 NUM F
) 0 PUNCT F
was 0 VERB F
found 0 VERB F
between 0 ADP F
systolic B-PHYSICAL ADJ F
PAP I-PHYSICAL NOUN T
and 0 CCONJ F
the B-PHYSICAL DET F
heart I-PHYSICAL NOUN F
rate-corrected I-PHYSICAL DET F
IVRT I-PHYSICAL NOUN T
' 0 PUNCT F
derived 0 VERB F
from 0 ADP F
the 0 DET F
basal 0 ADJ F
RV 0 NOUN T
free 0 ADJ F
wall 0 NOUN F
segment 0 NOUN F
. 0 PUNCT F

The 0 DET T
basal B-PHYSICAL ADJ F
segment I-PHYSICAL NOUN F
IVRT I-PHYSICAL NOUN T
' 0 PUNCT F
corrected 0 VERB F
for 0 ADP F
heart B-PHYSICAL NOUN F
rate I-PHYSICAL NOUN F
correlates 0 VERB F
well 0 VERB F
with 0 CCONJ F
the 0 DET F
invasive 0 ADJ F
PAP 0 NOUN T
measurement 0 NOUN F
and 0 CCONJ F
, 0 PUNCT F
therefore 0 ADV F
, 0 PUNCT F
can 0 PROPN F
be 0 VERB F
used 0 VERB F
to 0 PART F
predict 0 NOUN F
systolic B-PHYSICAL ADJ F
PAP I-PHYSICAL NOUN T
. 0 PUNCT F

It 0 PRON T
can 0 PUNCT F
even 0 ADV F
be 0 ADP F
considered 0 VERB F
as 0 ADP F
an 0 DET F
alternative 0 ADJ F
to 0 ADP F
tricuspid 0 NOUN F
regurgitation-derived 0 VERB F
PAP 0 NOUN T
systolic 0 ADJ F
when 0 ADP F
tricuspid 0 NOUN F
regurgitation 0 NOUN F
is 0 VERB F
nonrecordable 0 ADJ F
. 0 PUNCT F

A 0 PUNCT T
proposed 0 VERB F
method 0 NOUN F
to 0 PART F
derive 0 NOUN F
systolic 0 ADJ F
PAP 0 NOUN T
should 0 VERB F
be 0 VERB F
used 0 VERB F
while 0 ADP F
screening 0 ADP F
the 0 DET F
patients 0 NOUN F
at 0 ADP F
risk 0 NOUN F
for 0 ADP F
pulmonary 0 ADJ F
hypertension 0 NOUN F
, 0 PUNCT F
monitoring 0 VERB F
the 0 DET F
disease 0 NOUN F
progression 0 NOUN F
and 0 CCONJ F
the 0 DET F
effect 0 NOUN F
of 0 ADP F
treatment 0 NOUN F
. 0 PUNCT F

Adjvant 0 PUNCT T
treatment 0 NOUN F
of 0 ADP F
tongue 0 NOUN F
and 0 CCONJ F
floor 0 NOUN F
of 0 ADP F
the 0 DET F
mouth 0 NOUN F
cancers 0 NOUN F
. 0 PUNCT F

Since 0 ADP T
January 0 NOUN T
1974 0 NUM F
, 0 PUNCT F
95 0 NUM F
patients 0 NOUN F
with 0 ADP F
anterior 0 ADJ F
tongue 0 NOUN F
and 0 CCONJ F
floor 0 NOUN F
of 0 ADP F
the 0 DET F
mouth 0 NOUN F
cancers 0 NOUN F
were 0 VERB F
included 0 VERB F
in 0 ADP F
a 0 DET F
randomized 0 VERB F
trial 0 NOUN F
. 0 PUNCT F

After 0 ADP T
stratification 0 NOUN F
according 0 VERB F
to 0 ADP F
staging 0 DET F
and 0 CCONJ F
initial 0 ADJ F
treatment 0 NOUN F
, 0 PUNCT F
one-third 0 NOUN F
of 0 ADP F
the 0 DET F
patients 0 NOUN F
received 0 VERB F
chemotherapy 0 NOUN F
for 0 ADP F
2 0 NUM F
years 0 NOUN F
( 0 PUNCT F
methotrexate 0 PUNCT F
400 0 NUM F
mg 0 NOUN F
followed 0 VERB F
by 0 ADP F
citrovorum 0 NOUN F
factor 0 NOUN F
100 0 NUM F
mg 0 NOUN F
+ 0 ADJ F
bleomycin 0 NOUN F
60 0 NUM F
mg/week 0 NOUN F
, 0 PUNCT F
during 0 ADP F
the 0 DET F
first 0 ADJ F
15 0 NUM F
weeks 0 NOUN F
) 0 PUNCT F
, 0 PUNCT F
one-third 0 NOUN F
of 0 ADP F
the 0 DET F
patients 0 NOUN F
received 0 VERB F
immunotherapy 0 NOUN F
with 0 ADP F
weekly 0 ADV F
C. 0 ADJ T
parvum 0 VERB F
injections 0 NOUN F
during 0 ADP F
2 0 NUM F
years 0 NOUN F
, 0 PUNCT F
while 0 ADP F
the 0 DET F
remaining 0 VERB F
third 0 PUNCT F
did 0 PUNCT F
not 0 ADV F
receive 0 VERB F
any 0 DET F
treatment 0 NOUN F
. 0 PUNCT F

If 0 ADP T
adjuvant 0 NOUN F
treatment 0 NOUN F
seems 0 NOUN F
to 0 ADP F
delay B-OTHER ADJ F
recurrence I-OTHER NOUN F
it 0 PROPN F
did 0 VERB F
not 0 ADV F
significantly 0 ADV F
decrease 0 PUNCT F
the 0 DET F
recurrence B-OTHER NOUN F
rate I-OTHER NOUN F
. 0 PUNCT F

Survival B-MORTALITY NOUN T
is 0 VERB F
also 0 ADV F
not 0 ADV F
signigicantly 0 ADJ F
modified 0 VERB F
by 0 ADP F
adjuvant 0 NOUN F
treatment 0 NOUN F
and 0 CCONJ F
was 0 PROPN F
better 0 PUNCT F
for 0 ADP F
patients 0 NOUN F
with 0 ADP F
small 0 ADJ F
tumors 0 NOUN F
. 0 PUNCT F

Patients 0 NOUN T
who 0 ADP F
previously 0 PUNCT F
received 0 NOUN F
radiotherapy 0 NOUN F
did 0 PUNCT F
not 0 ADV F
benefit 0 NOUN F
from 0 ADP F
adjuvant 0 NOUN F
therapy 0 NOUN F
. 0 PUNCT F

Getting 0 ADP T
a 0 DET F
high 0 ADJ F
response 0 NOUN F
rate 0 NOUN F
of 0 ADP F
sexual 0 ADJ F
behavior 0 NOUN F
survey 0 NOUN F
among 0 ADP F
the 0 DET F
general 0 ADJ F
population 0 NOUN F
in 0 ADP F
Japan 0 PUNCT T
: 0 PUNCT F
three 0 NUM F
different 0 ADJ F
methods 0 NOUN F
of 0 ADP F
survey 0 NOUN F
on 0 ADP F
sexual 0 ADJ F
behavior 0 NOUN F
. 0 PUNCT F

The 0 DET T
purpose 0 NOUN F
of 0 ADP F
this 0 DET F
study 0 NOUN F
was 0 VERB F
to 0 ADV F
specify 0 NOUN F
the 0 DET F
most 0 PUNCT F
accurate 0 ADJ F
, 0 PUNCT F
reliable 0 ADJ F
and 0 CCONJ F
valid 0 PUNCT F
technique 0 NOUN F
for 0 ADP F
a 0 DET F
general 0 ADJ F
sexual 0 ADJ F
behavioral 0 ADJ F
survey 0 NOUN F
in 0 ADP F
Japan 0 PUNCT T
. 0 PUNCT F

This 0 DET T
pilot 0 NOUN F
study 0 NOUN F
was 0 VERB F
conducted 0 VERB F
to 0 PART F
assure 0 VERB F
a 0 DET F
high 0 ADJ F
response 0 NOUN F
rate 0 NOUN F
and 0 CCONJ F
to 0 PUNCT F
keep 0 PUNCT F
respondents 0 NOUN F
' 0 PUNCT F
privacy 0 NOUN F
confidential 0 ADJ F
by 0 ADP F
using 0 VERB F
an 0 DET F
anonymous 0 ADJ F
questionnaire 0 NOUN F
survey 0 NOUN F
technique 0 NOUN F
. 0 PUNCT F

The 0 DET T
sample 0 NOUN F
( 0 PUNCT F
360 0 NUM F
potential 0 ADJ F
respondents 0 NOUN F
) 0 PUNCT F
was 0 VERB F
selected 0 VERB F
randomly 0 ADV F
from 0 ADP F
basic 0 ADJ F
resident 0 ADJ F
registers 0 NOUN F
in 0 ADP F
two 0 NUM F
geographically 0 NOUN F
different 0 ADJ F
areas 0 NOUN F
. 0 PUNCT F

From 0 ADP T
the 0 DET F
registries 0 NOUN F
, 0 PUNCT F
90 0 NUM F
residents 0 NOUN F
, 0 PUNCT F
aged 0 ADP F
20 0 NUM F
to 0 ADP F
49 0 NUM F
years 0 NOUN F
old 0 ADJ F
, 0 PUNCT F
were 0 VERB F
randomly 0 ADV F
selected 0 VERB F
to 0 ADJ F
represent 0 PUNCT F
each 0 DET F
sex 0 NOUN F
from 0 ADP F
each 0 DET F
area 0 NOUN F
. 0 PUNCT F

The 0 DET T
subjects 0 NOUN F
were 0 VERB F
randomly 0 ADV F
assigned 0 VERB F
to 0 ADP F
three 0 NUM F
groups 0 NOUN F
each 0 CCONJ F
having 0 ADJ F
a 0 DET F
different 0 ADJ F
procedure 0 NOUN F
of 0 ADP F
requesting 0 PUNCT F
the 0 DET F
completion 0 NOUN F
of 0 ADP F
the 0 DET F
survey 0 NOUN F
and 0 CCONJ F
providing 0 VERB F
the 0 DET F
questionnaires 0 NOUN F
: 0 PUNCT F
( 0 PUNCT F
1 0 NUM F
) 0 PUNCT F
Postal 0 ADJ T
Group 0 NOUN T
, 0 PUNCT F
( 0 PUNCT F
2 0 NUM F
) 0 PUNCT F
Telephone 0 NOUN T
Group 0 NOUN T
, 0 PUNCT F
and 0 CCONJ F
( 0 PUNCT F
3 0 NUM F
) 0 PUNCT F
Face-to-face 0 NOUN T
Group 0 NOUN T
. 0 PUNCT F

The 0 DET T
survey 0 NOUN F
was 0 VERB F
carried 0 VERB F
out 0 ADP F
from 0 ADP F
October 0 NOUN T
1995 0 NUM F
to 0 ADP F
February 0 PUNCT T
1996 0 NUM F
. 0 PUNCT F

Effective B-OTHER ADJ T
response 0 NOUN F
rates B-OTHER NOUN F
for 0 ADP F
the 0 DET F
above 0 DET F
mentioned 0 ADP F
three 0 NUM F
groups 0 NOUN F
were 0 VERB F
69.2 0 NUM F
% 0 SYM F
, 0 PUNCT F
69.2 0 NUM F
% 0 SYM F
and 0 CCONJ F
55.8 0 NUM F
% 0 SYM F
, 0 PUNCT F
respectively 0 ADV F
. 0 PUNCT F

It 0 PRON T
is 0 VERB F
difficult 0 ADJ F
to 0 ADJ F
determine 0 NOUN F
the 0 DET F
best 0 PUNCT F
method 0 NOUN F
when 0 ADP F
only 0 ADV F
considering 0 PUNCT F
the 0 PUNCT F

Sequential 0 ADJ T
therapy 0 NOUN F
versus 0 CCONJ F
standard 0 ADJ F
triple-drug 0 NOUN F
therapy 0 NOUN F
for 0 ADP F
Helicobacter 0 NOUN T
pylori 0 NOUN F
eradication 0 NOUN F
: 0 PUNCT F
a 0 DET F
randomized 0 VERB F
study 0 NOUN F
. 0 PUNCT F

BACKGROUND 0 NOUN T
Antimicrobial 0 ADJ T
resistance 0 NOUN F
has 0 PUNCT F
decreased 0 PUNCT F
eradication 0 NOUN F
rates 0 NOUN F
for 0 ADP F
Helicobacter 0 NOUN T
pylori 0 NOUN F
infection 0 NOUN F
worldwide 0 ADJ F
. 0 PUNCT F

A 0 DET T
sequential 0 ADJ F
treatment 0 NOUN F
schedule 0 NOUN F
has 0 PUNCT F
been 0 PUNCT F
reported 0 VERB F
to 0 PART F
be 0 VERB F
effective 0 ADJ F
, 0 PUNCT F
but 0 CCONJ F
studies 0 NOUN F
published 0 VERB F
to 0 ADP F
date 0 NOUN F
were 0 VERB F
performed 0 VERB F
in 0 ADP F
Italy 0 PUNCT T
. 0 PUNCT F

We 0 ADP T
undertook 0 ADJ F
this 0 DET F
study 0 NOUN F
to 0 PART F
determine 0 NOUN F
whether 0 ADP F
these 0 DET F
results 0 NOUN F
could 0 VERB F
be 0 VERB F
replicated 0 VERB F
in 0 ADP F
India 0 PUNCT T
. 0 PUNCT F

METHODS 0 NOUN T
A 0 CCONJ T
randomized 0 VERB F
, 0 PUNCT F
open-labeled 0 PUNCT F
, 0 PUNCT F
prospective 0 ADJ F
controlled 0 VERB F
trial 0 NOUN F
comparing 0 ADJ F
sequential 0 ADJ F
vs. 0 CCONJ F
standard 0 ADJ F
triple-drug 0 NOUN F
therapy 0 NOUN F
was 0 VERB F
carried 0 VERB F
out 0 ADP F
at 0 ADP F
Lokmanya 0 PUNCT T
Tilak 0 NOUN T
Municipal 0 ADJ T
General 0 ADJ T
Hospital 0 NOUN T
, 0 PUNCT F
Mumbai 0 NOUN T
. 0 PUNCT F

Two 0 NUM T
hundred 0 NUM F
and 0 CCONJ F
thirty-one 0 NUM F
patients 0 NOUN F
with 0 ADP F
dyspepsia 0 NOUN F
were 0 VERB F
randomized 0 VERB F
to 0 ADP F
a 0 DET F
10-day 0 NOUN F
sequential 0 ADJ F
regimen 0 NOUN F
( 0 PUNCT F
40 0 NUM F
mg 0 NOUN F
of 0 ADP F
pantoprazole 0 NOUN F
, 0 PUNCT F
1 0 NUM F
g 0 NOUN F
of 0 ADP F
amoxicillin 0 NOUN F
, 0 PUNCT F
each 0 DET F
administered 0 VERB F
twice 0 ADV F
daily 0 ADJ F
for 0 ADP F
the 0 DET F
first 0 ADJ F
5 0 NUM F
days 0 NOUN F
, 0 PUNCT F
followed 0 VERB F
by 0 ADP F
40 0 NUM F
mg 0 NOUN F
of 0 ADP F
pantoprazole 0 NOUN F
, 0 PUNCT F
500 0 NUM F
mg 0 NOUN F
of 0 ADP F
clarithromycin 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
500 0 NUM F
mg 0 NOUN F
of 0 ADP F
tinidazole 0 NOUN F
, 0 PUNCT F
each 0 DET F
administered 0 VERB F
twice 0 ADV F
daily 0 ADJ F
for 0 ADP F
the 0 DET F
remaining 0 VERB F
5 0 NUM F
days 0 NOUN F
) 0 PUNCT F
or 0 CCONJ F
to 0 ADP F
standard 0 ADJ F
14-day 0 NOUN F
therapy 0 NOUN F
( 0 PUNCT F
40 0 NUM F
mg 0 NOUN F
of 0 ADP F
pantoprazole 0 NOUN F
, 0 PUNCT F
500 0 NUM F
mg 0 NOUN F
of 0 ADP F
clarithromycin 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
1 0 NUM F
g 0 NOUN F
of 0 ADP F
amoxicillin 0 NOUN F
, 0 PUNCT F
each 0 DET F
administered 0 VERB F
twice 0 PUNCT F
daily 0 ADP F
) 0 PUNCT F
. 0 PUNCT F

RESULTS 0 PUNCT T
The 0 DET T
eradication B-OTHER NOUN F
rate I-OTHER NOUN F
achieved 0 VERB F
with 0 ADP F
the 0 DET F
sequential 0 ADJ F
regimen 0 NOUN F
was 0 VERB F
significantly 0 ADV F
greater 0 PUNCT F
than 0 CCONJ F
that 0 PUNCT F
obtained 0 VERB F
with 0 ADP F
the 0 DET F
triple 0 ADJ F
therapy 0 NOUN F
. 0 PUNCT F

Per-protocol B-OTHER ADJ T
eradication I-OTHER NOUN F
rate I-OTHER NOUN F
of 0 ADP F
sequential 0 ADJ F
therapy 0 NOUN F
was 0 VERB F
92.4 0 NUM F
% 0 SYM F
( 0 PUNCT F
95 0 NUM F
% 0 SYM F
CI 0 NOUN T
85.8-96.1 0 ADV F
% 0 SYM F
) 0 PUNCT F
vs. 0 CCONJ F
81.8 0 NUM F
% 0 SYM F
( 0 PUNCT F
95 0 NUM F
% 0 SYM F
CI 0 NOUN T
73.9-87.8 0 NUM F
% 0 SYM F
) 0 PUNCT F
( 0 PUNCT F
p 0 NOUN F
= 0 SYM F
0.027 0 NUM F
) 0 PUNCT F
for 0 ADP F
standard 0 ADJ F
drug 0 NOUN F
therapy 0 NOUN F
. 0 PUNCT F

Intention-to-treat 0 NOUN T
eradication 0 NOUN F
rates 0 NOUN F
were 0 VERB F
88.2 0 NUM F
% 0 SYM F
( 0 PUNCT F
95 0 NUM F
% 0 SYM F
CI 0 NOUN T
80.9-93.0 0 NUM F
% 0 SYM F
) 0 PUNCT F
vs. 0 CCONJ F
79.1 0 NUM F
% 0 SYM F
( 0 PUNCT F
95 0 NUM F
% 0 SYM F
CI 0 NOUN T
71.1-85.4 0 NUM F
% 0 SYM F
) 0 PUNCT F
, 0 PUNCT F
p 0 NOUN F
= 0 SYM F
0.029 0 NUM F
, 0 PUNCT F
respectively 0 ADV F
. 0 PUNCT F

The 0 DET T
incidence 0 NOUN F
of 0 ADP F
major 0 ADJ F
and 0 CCONJ F
minor 0 ADJ F
side 0 NOUN F
effects 0 NOUN F
between 0 ADP F
therapy 0 NOUN F
groups 0 NOUN F
was 0 VERB F
not 0 ADV F
significantly 0 ADV F
different 0 ADJ F
( 0 PUNCT F
14.6 0 NUM F
% 0 SYM F
in 0 ADP F
the 0 DET F
triple 0 ADJ F
therapy 0 NOUN F
group 0 NOUN F
vs. 0 CCONJ F
23.5 0 NUM F
% 0 SYM F
in 0 ADP F
sequential 0 ADJ F
group 0 NOUN F
, 0 PUNCT F
p 0 NOUN F
= 0 SYM F
0.12 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Follow 0 PUNCT T
up 0 ADP F
was 0 ADP F
incomplete 0 PUNCT F
in 0 ADP F
3.3 0 NUM F
% 0 SYM F
and 0 CCONJ F
4.7 0 NUM F
% 0 ADV F
patients 0 NOUN F
in 0 ADP F
standard 0 ADJ F
and 0 CCONJ F
sequential 0 ADJ F
therapy 0 NOUN F
groups 0 NOUN F
, 0 PUNCT F
respectively 0 ADV F
. 0 PUNCT F

Sequential 0 ADJ T
therapy 0 NOUN F
includes 0 NOUN F
one 0 NUM F
additional 0 ADJ F
antibiotic 0 NOUN F
( 0 PUNCT F
tinidazole 0 NOUN F
) 0 PUNCT F
that 0 ADP F
is 0 VERB F
not 0 ADV F
contained 0 VERB F
in 0 ADP F
standard 0 ADJ F
therapy 0 NOUN F
. 0 PUNCT F

CONCLUSIONS 0 NOUN T
Sequential 0 ADJ T
therapy 0 NOUN F
was 0 VERB F
significantly 0 ADV F
better 0 PUNCT F
than 0 VERB F
standard 0 ADJ F
therapy 0 NOUN F
for 0 ADP F
eradicating 0 VERB F
H. 0 NOUN T
pylori 0 NOUN F
infection 0 NOUN F
. 0 PUNCT F

Moisture-vapour-permeable 0 ADJ T
film 0 NOUN F
as 0 ADP F
an 0 DET F
outpatient 0 ADJ F
burn 0 NOUN F
dressing 0 VERB F
. 0 PUNCT F

This 0 DET T
study 0 NOUN F
compares 0 PUNCT F
a 0 DET F
moisture-vapour-permeable 0 ADJ F
film 0 NOUN F
( 0 PUNCT F
MVPF 0 NOUN T
) 0 PUNCT F
with 0 ADP F
silver 0 NOUN F
sulphadiazine 0 NOUN F
in 0 ADP F
a 0 DET F
randomized 0 VERB F
prospective 0 ADJ F
manner 0 NOUN F
for 0 ADP F
the 0 DET F
treatment 0 NOUN F
of 0 ADP F
outpatient 0 ADJ F
burns 0 NOUN F
. 0 PUNCT F

The 0 DET T
two 0 NUM F
treatment 0 NOUN F
groups 0 NOUN F
were 0 VERB F
closely 0 ADV F
matched 0 PROPN F
in 0 ADP F
age 0 NOUN F
, 0 PUNCT F
sex 0 NOUN F
, 0 PUNCT F
per 0 ADP F
cent 0 NUM F
of 0 ADP F
BSA 0 NOUN T
burned 0 VERB F
, 0 PUNCT F
and 0 CCONJ F
in 0 ADP F
burn 0 NOUN F
severity 0 NOUN F
and 0 CCONJ F
locations 0 NOUN F
. 0 PUNCT F

The 0 DET T
MVPF 0 NOUN T
group 0 NOUN F
demonstrated 0 VERB F
a 0 DET F
39.0 0 NUM F
per 0 ADP F
cent 0 NUM F
greater 0 PUNCT F
reduction 0 NOUN F
in 0 ADP F
pain B-PAIN NOUN F
after 0 ADP F
application 0 NOUN F
of 0 ADP F
the 0 DET F
dressing 0 PUNCT F
over 0 ADP F
the 0 DET F
silver 0 NOUN F
sulphadiazine 0 NOUN F
group 0 NOUN F
. 0 PUNCT F

Patients 0 NOUN T
in 0 ADP F
the 0 DET F
MVPF 0 NOUN T
film 0 NOUN F
group 0 NOUN F
also 0 ADV F
reported 0 ADJ F
significantly 0 ADV F
less 0 ADV F
difficulty 0 NOUN F
in 0 ADP F
wound B-OTHER NOUN F
care I-OTHER NOUN F
and 0 CCONJ F
in 0 ADP F
dressing B-OTHER PUNCT F
interference I-OTHER NOUN F
with I-OTHER ADP F
their I-OTHER ADJ F
daily I-OTHER ADJ F
functions I-OTHER NOUN F
. 0 PUNCT F

The 0 DET T
clinical B-ADVERSE-EFFECTS ADJ F
infection I-ADVERSE-EFFECTS NOUN F
rate I-ADVERSE-EFFECTS NOUN F
and 0 CCONJ F
time B-OTHER NOUN F
to I-OTHER ADP F
healing I-OTHER VERB F
were 0 VERB F
similar 0 ADJ F
in 0 ADP F
both 0 CCONJ F
groups 0 NOUN F
. 0 PUNCT F

In 0 ADP T
the 0 DET F
management B-OTHER NOUN F
of 0 ADP F
outpatient 0 ADJ F
burns 0 NOUN F
, 0 PUNCT F
MVPF 0 NOUN T
was 0 VERB F
found 0 VERB F
to 0 PART F
be 0 PUNCT F
superior 0 ADJ F
to 0 ADP F
silver 0 NOUN F
sulphadiazine 0 NOUN F
. 0 PUNCT F

Specific 0 ADJ T
immunoglobulin 0 NOUN F
for 0 ADP F
treatment 0 NOUN F
of 0 ADP F
whooping 0 PUNCT F
cough 0 NOUN F
. 0 PUNCT F

Immunoglobulin 0 NOUN T
treatment 0 NOUN F
for 0 ADP F
whooping 0 PROPN F
cough 0 NOUN F
( 0 PUNCT F
pertussis 0 NOUN F
) 0 PUNCT F
is 0 VERB F
widely 0 ADV F
believed 0 VERB F
to 0 PART F
be 0 PUNCT F
ineffective B-OTHER ADJ F
although 0 ADP F
there 0 PUNCT F
are 0 ADJ F
sound 0 ADJ F
reasons 0 NOUN F
for 0 ADP F
regarding 0 PUNCT F
the 0 DET F
condition 0 NOUN F
as 0 ADP F
a 0 DET F
toxin-induced 0 VERB F
disease 0 NOUN F
. 0 PUNCT F

We 0 PRON T
wondered 0 VERB F
whether 0 ADP F
the 0 DET F
lack B-OTHER NOUN F
of I-OTHER ADP F
success I-OTHER NOUN F
with 0 ADP F
pertussis 0 NOUN F
immunoglobulins 0 NOUN F
might 0 VERB F
be 0 VERB F
attributable 0 ADJ F
to 0 ADP F
inadequate 0 ADJ F
dose 0 NOUN F
, 0 PUNCT F
so 0 PUNCT F
we 0 ADP F
designed 0 VERB F
a 0 DET F
randomised 0 VERB F
, 0 PUNCT F
double-blind 0 ADJ F
, 0 PUNCT F
placebo-controlled 0 VERB F
trial 0 NOUN F
of 0 ADP F
two 0 NUM F
immunoglobulin 0 NOUN F
preparations 0 NOUN F
. 0 PUNCT F

The 0 DET T
study 0 NOUN F
was 0 VERB F
conducted 0 VERB F
at 0 ADP F
three 0 NUM F
Swedish 0 PUNCT T
hospitals 0 NOUN F
. 0 PUNCT F

We 0 PRON T
enrolled 0 VERB F
73 0 NUM F
children 0 NOUN F
aged 0 PROPN F
less 0 ADV F
than 0 ADP F
36 0 NUM F
months 0 NOUN F
who 0 ADP F
were 0 VERB F
admitted 0 VERB F
with 0 ADP F
a 0 DET F
clinical 0 ADJ F
diagnosis 0 NOUN F
of 0 ADP F
whooping 0 PUNCT F
cough 0 NOUN F
. 0 PUNCT F

On 0 ADP T
admission 0 NOUN F
they 0 PUNCT F
were 0 VERB F
assigned 0 VERB F
to 0 ADP F
one 0 PUNCT F
of 0 ADP F
three 0 NUM F
groups 0 NOUN F
: 0 PUNCT F
( 0 PUNCT F
a 0 NOUN F
) 0 PUNCT F
monocomponent 0 ADJ F
pertussis 0 NOUN F
toxoid 0 NOUN F
vaccine 0 NOUN F
; 0 PUNCT F
( 0 PUNCT F
b 0 NOUN F
) 0 PUNCT F
two-component 0 ADJ F
acellular 0 ADJ F
vaccine 0 NOUN F
also 0 ADV F
containing 0 CCONJ F
filamentous 0 ADJ F
haemagglutinin 0 NOUN F
; 0 PUNCT F
or 0 CCONJ F
( 0 PUNCT F
c 0 NOUN F
) 0 PUNCT F
20 0 NUM F
% 0 SYM F
albumin 0 NOUN F
solution 0 NOUN F
( 0 PUNCT F
placebo 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
immunoglobulins 0 NOUN F
had 0 DET F
a 0 DET F
high 0 ADJ F
antitoxin 0 NOUN F
content 0 NOUN F
and 0 CCONJ F
had 0 PUNCT F
been 0 PUNCT F
raised 0 VERB F
with 0 ADP F
acellular 0 ADJ F
pertussis 0 NOUN F
vaccines 0 NOUN F
. 0 PUNCT F

Diagnosis 0 NOUN T
of 0 ADP F
pertussis 0 NOUN F
was 0 VERB F
confirmed 0 VERB F
by 0 ADP F
laboratory 0 NOUN F
tests 0 NOUN F
and 0 CCONJ F
the 0 DET F
follow-up 0 NOUN F
was 0 VERB F
completed 0 VERB F
in 0 ADP F
67 0 NUM F
children 0 NOUN F
. 0 PUNCT F

The 0 DET T
main 0 ADJ F
study 0 ADJ F
group 0 NOUN F
consisted 0 VERB F
of 0 ADP F
47 0 NUM F
children 0 NOUN F
with 0 ADP F
less 0 ADV F
than 0 PUNCT F
or 0 CCONJ F
equal 0 ADJ F
to 0 ADP F
14 0 NUM F
days 0 NOUN F
of 0 ADP F
disease 0 NOUN F
before 0 ADP F
therapy 0 NOUN F
. 0 PUNCT F

Duration 0 NOUN T
of 0 ADP F
whoops B-PHYSICAL ADJ F
post-treatment I-PHYSICAL NOUN F
was 0 VERB F
8.7 0 DET F
days 0 NOUN F
( 0 PUNCT F
95 0 NUM F
% 0 SYM F
Cl 0 NOUN T
4.8 0 NUM F
, 0 PUNCT F
12.6 0 NUM F
) 0 PUNCT F
in 0 ADP F
the 0 DET F
33 0 NUM F
children 0 NOUN F
receiving 0 DET F
immunoglobulin 0 NOUN F
vs 0 CCONJ F
20.6 0 NUM F
( 0 PUNCT F
95 0 NUM F
% 0 SYM F
Cl 0 NOUN T
11.9 0 NUM F
, 0 PUNCT F
29.3 0 NUM F
) 0 PUNCT F
in 0 ADP F
the 0 DET F
14 0 NUM F
receiving 0 VERB F
placebo 0 NOUN F
( 0 PUNCT F
p 0 NOUN F
= 0 SYM F
0.0041 0 DET F
) 0 PUNCT F
. 0 PUNCT F

Mean 0 ADJ T
number B-PHYSICAL NOUN F
of I-PHYSICAL ADP F
whoops I-PHYSICAL NOUN F
during 0 ADP F
the 0 DET F
first 0 ADJ F
week 0 NOUN F
of 0 ADP F
follow-up 0 NOUN F
was 0 VERB F
also 0 ADV F
significantly 0 ADV F
reduced 0 ADP F
( 0 PUNCT F
p 0 NOUN F
= 0 SYM F
0.0196 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

We 0 PRON T
found 0 VERB F
that 0 ADP F
early 0 ADJ F
treatment 0 NOUN F
was 0 VERB F
important 0 ADJ F
, 0 PUNCT F
since 0 ADP F
the 0 DET F
effect 0 NOUN F
on 0 ADP F
duration B-PHYSICAL NOUN F
of I-PHYSICAL ADP F
whoops I-PHYSICAL NOUN F
was 0 ADJ F
most 0 PUNCT F
pronounced 0 NOUN F
when 0 ADP F
disease 0 NOUN F
duration 0 NOUN F
before 0 ADP F
treatment 0 NOUN F
was 0 VERB F
less 0 ADV F
than 0 PUNCT F
or 0 CCONJ F
equal 0 ADJ F
to 0 ADP F
7 0 NUM F
days 0 NOUN F
. 0 PUNCT F

There 0 PUNCT T
were 0 VERB F
no 0 DET F
significant 0 ADJ F
differences B-PHYSICAL NOUN F
between 0 ADP F
the 0 DET F
two 0 NUM F
immunoglobulin 0 NOUN F
preparations 0 NOUN F
. 0 PUNCT F

High-dose 0 NOUN T
specific 0 ADJ F
pertussis 0 NOUN F
immunoglobulin 0 NOUN F
with 0 ADP F
a 0 DET F
high 0 ADJ F
antitoxin 0 NOUN F
concentration 0 NOUN F
has 0 ADP F
a 0 DET F
beneficial B-OTHER ADJ F
effect 0 NOUN F
in 0 ADP F
the 0 DET F
treatment 0 NOUN F
of 0 ADP F
whooping 0 PUNCT F
cough 0 NOUN F
. 0 PUNCT F

The 0 DET T
Finnish 0 NOUN T
Diabetes 0 NOUN T
Prevention 0 NOUN T
Study 0 NOUN T
. 0 PUNCT F

The 0 DET T
aim 0 NOUN F
of 0 ADP F
the 0 DET F
Finnish 0 NOUN T
Diabetes 0 NOUN T
Prevention 0 NOUN T
Study 0 NOUN T
is 0 VERB F
to 0 PART F
assess 0 NOUN F
the 0 DET F
efficacy 0 NOUN F
of 0 ADP F
an 0 DET F
intensive 0 ADJ F
diet-exercise 0 ADJ F
programme 0 NOUN F
in 0 ADP F
preventing 0 VERB F
or 0 CCONJ F
delaying 0 PUNCT F
type 0 NOUN F
2 0 NUM F
diabetes B-PHYSICAL PUNCT F
in 0 ADP F
individuals 0 NOUN F
with 0 ADP F
impaired 0 VERB F
glucose 0 NOUN F
tolerance 0 NOUN F
( 0 PUNCT F
IGT 0 NOUN T
) 0 PUNCT F
and 0 CCONJ F
to 0 PUNCT F
evaluate 0 NOUN F
the 0 DET F
effect 0 NOUN F
of 0 ADP F
the 0 DET F
programme 0 NOUN F
on 0 ADP F
the 0 DET F
risk 0 NOUN F
factors 0 NOUN F
of 0 ADP F
atherosclerotic 0 ADJ F
vascular 0 ADJ F
diseases 0 NOUN F
and 0 CCONJ F
the 0 DET F
incidence 0 NOUN F
of 0 ADP F
cardiovascular 0 ADJ F
events 0 NOUN F
. 0 PUNCT F

In 0 ADP T
this 0 PUNCT F
ongoing 0 ADV F
study 0 NOUN F
, 0 PUNCT F
a 0 DET F
total 0 NOUN F
of 0 ADP F
523 0 NUM F
overweight 0 PUNCT F
subjects 0 NOUN F
with 0 ADP F
IGT 0 NOUN T
based 0 VERB F
on 0 ADP F
two 0 NUM F
oral 0 ADJ F
glucose 0 NOUN F
tolerance 0 NOUN F
tests 0 NOUN F
were 0 VERB F
randomized 0 VERB F
to 0 ADP F
either 0 CCONJ F
an 0 DET F
intervention 0 NOUN F
group 0 NOUN F
or 0 CCONJ F
a 0 DET F
control 0 NOUN F
group 0 NOUN F
. 0 PUNCT F

The 0 DET T
main 0 ADJ F
measure 0 NOUN F
in 0 ADP F
the 0 DET F
intervention 0 NOUN F
group 0 NOUN F
is 0 ADJ F
individual B-OTHER ADJ F
dietary I-OTHER ADJ F
advice I-OTHER NOUN F
aimed 0 PUNCT F
at 0 ADP F
reducing 0 VERB F
weight 0 NOUN F
and 0 CCONJ F
intake 0 NOUN F
of 0 ADP F
saturated 0 VERB F
fat 0 NOUN F
and 0 CCONJ F
increasing 0 ADJ F
intake 0 NOUN F
of 0 ADP F
dietary 0 ADJ F
fibre 0 NOUN F
. 0 PUNCT F

The 0 DET T
intervention 0 NOUN F
subjects 0 NOUN F
are 0 VERB F
individually 0 ADV F
guided 0 PROPN F
to 0 PART F
increase 0 NOUN F
their 0 NOUN F
level 0 NOUN F
of 0 ADP F
physical 0 ADJ F
activity 0 NOUN F
. 0 PUNCT F

The 0 DET T
control 0 NOUN F
group 0 NOUN F
receives 0 NOUN F
general 0 ADJ F
information 0 NOUN F
about 0 PUNCT F
the 0 DET F
benefits 0 NOUN F
of 0 ADP F
weight 0 NOUN F
reduction 0 NOUN F
, 0 PUNCT F
physical 0 ADJ F
activity 0 NOUN F
and 0 CCONJ F
healthy 0 ADJ F
diet 0 NOUN F
in 0 ADP F
the 0 DET F
prevention 0 NOUN F
of 0 ADP F
diabetes 0 NOUN F
. 0 PUNCT F

A 0 DET T
pilot 0 NOUN F
study 0 VERB F
began 0 ADV F
in 0 ADP F
1993 0 NUM F
, 0 PUNCT F
and 0 CCONJ F
recruitment 0 NOUN F
ended 0 PUNCT F
in 0 ADP F
1998 0 NUM F
. 0 PUNCT F

By 0 ADP T
the 0 DET F
end 0 NOUN F
of 0 ADP F
April 0 NOUN T
1999 0 NUM F
there 0 PUNCT F
were 0 VERB F
65 0 PUNCT F
new 0 ADJ F
cases 0 NOUN F
of 0 ADP F
diabetes 0 NOUN F
, 0 PUNCT F
34 0 NUM F
drop-outs 0 NOUN F
and 0 CCONJ F
one 0 NUM F
death B-MORTALITY NOUN F
. 0 PUNCT F

The 0 DET T
weight 0 NOUN F
reduction B-PHYSICAL NOUN F
was 0 VERB F
greater 0 PUNCT F
( 0 PUNCT F
-4.6 0 NUM F
kg 0 NOUN F
) 0 PUNCT F
at 0 ADP F
1 0 NUM F
year 0 NOUN F
in 0 ADP F
the 0 DET F
intervention 0 NOUN F
group 0 NOUN F
( 0 PUNCT F
n 0 NOUN F
= 0 SYM F
152 0 NUM F
) 0 PUNCT F
than 0 PUNCT F
in 0 ADP F
the 0 DET F
control 0 NOUN F
group 0 NOUN F
( 0 PUNCT F
n 0 NOUN F
= 0 SYM F
143 0 NUM F
, 0 PUNCT F
-0.9 0 NUM F
kg 0 NOUN F
, 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.0001 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
and 0 CCONJ F
this 0 DET F
difference 0 NOUN F
was 0 VERB F
sustained 0 VERB F
in 0 ADP F
the 0 DET F
second 0 ADJ F
year 0 NOUN F
of 0 ADP F
follow-up 0 NOUN F
. 0 PUNCT F

At 0 ADP T
1 0 NUM F
year 0 NOUN F
43.4 0 NUM F
% 0 SYM F
and 0 CCONJ F
at 0 ADP F
2 0 NUM F
years 0 NOUN F
41.8 0 NUM F
% 0 SYM F
of 0 ADP F
the 0 DET F
intervention 0 NOUN F
subjects 0 NOUN F
had 0 PUNCT F
achieved 0 PUNCT F
a 0 DET F
weight 0 NOUN F
reduction B-PHYSICAL NOUN F
of 0 ADP F
at 0 ADP F
least 0 ADV F
5 0 NUM F
kg 0 NOUN F
, 0 PUNCT F
while 0 ADP F
the 0 DET F
corresponding 0 VERB F
figures 0 NOUN F
for 0 ADP F
the 0 DET F
control 0 NOUN F
subjects 0 NOUN F
were 0 VERB F
14.0 0 NUM F
and 0 CCONJ F
12.0 0 NUM F
% 0 SYM F
( 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.001 0 NUM F
between 0 ADP F
the 0 DET F
groups 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

At 0 ADP T
1 0 NUM F
year 0 PUNCT F
the 0 DET F
intervention 0 NOUN F
group 0 NOUN F
showed 0 VERB F
significantly 0 ADV F
greater 0 PUNCT F
reductions 0 NOUN F
in 0 ADP F
2 0 NUM F
h B-PHYSICAL NOUN F
glucose I-PHYSICAL NOUN F
, 0 PUNCT F
fasting B-PHYSICAL PUNCT F
and I-PHYSICAL CCONJ F
2 I-PHYSICAL NUM F
h I-PHYSICAL NOUN F
insulin I-PHYSICAL NOUN F
, 0 PUNCT F
systolic B-PHYSICAL ADJ F
and I-PHYSICAL CCONJ F
diastolic I-PHYSICAL ADJ F
blood I-PHYSICAL NOUN F
pressure I-PHYSICAL NOUN F
, 0 PUNCT F
and 0 CCONJ F
serum B-PHYSICAL NOUN F
triglycerides I-PHYSICAL NOUN F
. 0 PUNCT F

Most 0 PUNCT T
of 0 ADP F
the 0 DET F
beneficial 0 ADJ F
changes 0 NOUN F
in 0 ADP F
cardiovascular B-PHYSICAL ADJ F
risk 0 NOUN F
factors B-PHYSICAL NOUN F
were 0 VERB F
sustained 0 VERB F
for 0 ADP F
2 0 NUM F
years 0 NOUN F
. 0 PUNCT F

These 0 DET T
interim 0 ADJ F
results 0 NOUN F
of 0 ADP F
the 0 DET F
ongoing 0 ADV F
Finnish 0 ADV T
Diabetes 0 NOUN T
Prevention 0 NOUN T
Study 0 NOUN T
demonstrate 0 VERB F
the 0 DET F
efficacy 0 NOUN F
and 0 PUNCT F

A 0 DET T
study 0 NOUN F
of 0 ADP F
a 0 DET F
Self-Care 0 NOUN T
Rehabilitation 0 NOUN T
Program 0 NOUN T
in 0 ADP F
pediatric 0 ADJ F
asthma 0 NOUN F
. 0 PUNCT F

The 0 DET T
Self-Care 0 NOUN T
Rehabilitation 0 NOUN T
in 0 ADP F
Pediatric 0 ADJ T
Asthma 0 NOUN T
( 0 PUNCT F
SCRPA 0 NOUN T
) 0 PUNCT F
project 0 NOUN F
was 0 VERB F
designed 0 VERB F
to 0 PART F
ascertain 0 NOUN F
the 0 DET F
level 0 NOUN F
to 0 ADP F
which 0 PUNCT F
children 0 ADJ F
with 0 ADP F
asthma 0 NOUN F
are 0 VERB F
able 0 ADJ F
to 0 PART F
acquire 0 NOUN F
the 0 DET F
asthma 0 NOUN F
knowledge 0 NOUN F
and 0 CCONJ F
skills 0 NOUN F
presented 0 VERB F
in 0 ADP F
a 0 DET F
self-management 0 ADJ F
training 0 DET F
program 0 NOUN F
conducted 0 VERB F
by 0 ADP F
the 0 DET F
American 0 ADJ T
Lung 0 NOUN T
Association 0 NOUN T
of 0 ADP F
Utah 0 CCONJ T
and 0 CCONJ F
the 0 DET F
effect 0 NOUN F
of 0 ADP F
such 0 CCONJ F
training 0 ADJ F
on 0 ADP F
the 0 DET F
asthma 0 NOUN F
experience 0 NOUN F
. 0 PUNCT F

The 0 DET T
preschool 0 NOUN F
SCRPA 0 NOUN T
Curriculum 0 NOUN T
( 0 PUNCT F
ages 0 NOUN F
2-5 0 NUM F
) 0 PUNCT F
consisted 0 VERB F
of 0 ADP F
six 0 NUM F
1-hour 0 NOUN F
classes 0 NOUN F
scheduled 0 DET F
twice 0 CCONJ F
a 0 DET F
week 0 NOUN F
for 0 ADP F
3 0 NUM F
weeks 0 NOUN F
. 0 PUNCT F

The 0 DET T
first 0 ADJ F
and 0 CCONJ F
last 0 ADP F
classes 0 NOUN F
were 0 VERB F
for 0 ADP F
one 0 NUM F
or 0 CCONJ F
both 0 CCONJ F
parents 0 NOUN F
only 0 ADV F
, 0 PUNCT F
and 0 CCONJ F
the 0 DET F
middle 0 ADJ F
four 0 NUM F
sessions 0 NOUN F
were 0 VERB F
for 0 ADP F
the 0 DET F
child 0 NOUN F
and 0 CCONJ F
parent 0 NOUN F
( 0 PUNCT F
s 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
school-age 0 NOUN F
SCRPA 0 NOUN T
curriculum 0 NOUN F
( 0 PUNCT F
ages 0 PROPN F
6-14 0 NUM F
) 0 PUNCT F
consisted 0 VERB F
of 0 ADP F
eight 0 NUM F
90-minute 0 NOUN F
classes 0 NOUN F
for 0 ADP F
both 0 PUNCT F
child 0 NOUN F
and 0 CCONJ F
parent 0 NOUN F
( 0 PUNCT F
s 0 NOUN F
) 0 PUNCT F
scheduled 0 VERB F
twice 0 CCONJ F
a 0 DET F
week 0 NOUN F
for 0 ADP F
4 0 NUM F
weeks 0 NOUN F
. 0 PUNCT F

Private 0 ADJ T
physicians 0 NOUN F
referred 0 DET F
21 0 NUM F
preschool 0 NOUN F
children 0 NOUN F
and 0 CCONJ F
38 0 NUM F
school-age 0 NOUN F
children 0 NOUN F
into 0 ADP F
the 0 DET F
program 0 NOUN F
. 0 PUNCT F

The 0 DET T
school-age 0 NOUN F
children 0 NOUN F
were 0 VERB F
randomly 0 ADV F
assigned 0 VERB F
to 0 ADP F
a 0 DET F
study 0 NOUN F
or 0 CCONJ F
control 0 NOUN F
group 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
the 0 DET F
preschool 0 NOUN F
children 0 NOUN F
served 0 VERB F
as 0 ADP F
their 0 PUNCT F
own 0 ADJ F
controls 0 NOUN F
. 0 PUNCT F

A 0 DET T
comparison 0 NOUN F
of 0 ADP F
asthma 0 NOUN F
episodes 0 NOUN F
during 0 ADP F
the 0 DET F
3 0 NUM F
months 0 NOUN F
before 0 ADP F
and 0 CCONJ F
after 0 ADP F
training 0 VERB F
showed 0 VERB F
a 0 DET F
statistically 0 ADV F
significant 0 ADJ F
decrease 0 NOUN F
in 0 ADP F
the B-MENTAL DET F
number I-MENTAL NOUN F
of I-MENTAL ADP F
episodes I-MENTAL NOUN F
but 0 CCONJ F
no 0 DET F
change 0 NOUN F
in 0 ADP F
severity B-MENTAL NOUN F
in 0 ADP F
the 0 DET F
preschool 0 NOUN F
, 0 PUNCT F
school 0 NOUN F
study 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
school 0 NOUN F
control 0 NOUN F
groups 0 NOUN F
. 0 PUNCT F

The 0 DET T
decrease 0 NOUN F
in 0 ADP F
episodes B-MENTAL NOUN F
for 0 ADP F
the 0 DET F
control 0 NOUN F
groups 0 NOUN F
suggest 0 VERB F
that 0 ADP F
the 0 DET F
family 0 NOUN F
record 0 NOUN F
keeping 0 PUNCT F
required 0 VERB F
of 0 ADP F
all 0 DET F
subjects 0 NOUN F
may 0 VERB F
have 0 PUNCT F
a 0 DET F
beneficial 0 ADJ F
effect 0 NOUN F
, 0 PUNCT F
a 0 DET F
phenomenon 0 NOUN F
worth 0 ADP F
further 0 ADJ F
investigation 0 NOUN F
. 0 PUNCT F

Also 0 ADV T
, 0 PUNCT F
the 0 DET F
school-age 0 NOUN F
group 0 NOUN F
, 0 PUNCT F
in 0 ADP F
pre- 0 ADJ F
and 0 CCONJ F
posttesting 0 PROPN F
, 0 PUNCT F
demonstrated 0 VERB F
that 0 ADP F
the 0 DET F
SCRPA 0 NOUN T
curriculum 0 NOUN F
increased 0 VERB F
knowledge B-MENTAL NOUN F
and 0 CCONJ F
skills B-MENTAL NOUN F
in 0 ADP F
the 0 DET F
study 0 PUNCT F
group 0 NOUN F
, 0 PUNCT F
changes 0 NOUN F
not 0 ADV F
found 0 VERB F
in 0 ADP F
the 0 DET F
control 0 NOUN F
group 0 NOUN F
. 0 PUNCT F

Randomised 0 VERB T
clinical 0 ADJ F
trial 0 NOUN F
of 0 ADP F
physiotherapy 0 NOUN F
after 0 ADP F
open 0 ADJ F
abdominal 0 ADJ F
surgery 0 NOUN F
in 0 ADP F
high 0 ADJ F
risk 0 NOUN F
patients 0 NOUN F
. 0 PUNCT F

Postoperative 0 ADJ T
physiotherapy 0 NOUN F
has 0 PUNCT F
been 0 PUNCT F
shown 0 VERB F
to 0 PART F
reduce B-OTHER NOUN F
the I-OTHER DET F
incidence I-OTHER NOUN F
of 0 ADP F
postoperative 0 ADJ F
pulmonary 0 ADJ F
complications 0 NOUN F
after 0 ADP F
open 0 ADJ F
abdominal 0 ADJ F
surgery 0 NOUN F
. 0 PUNCT F

This 0 DET T
study 0 NOUN F
aimed 0 VERB F
to 0 PART F
determine 0 NOUN F
if 0 PUNCT F
the 0 DET F
addition 0 NOUN F
of 0 ADP F
deep 0 ADJ F
breathing 0 DET F
exercises 0 NOUN F
and 0 CCONJ F
secretion 0 NOUN F
clearing 0 PUNCT F
techniques 0 NOUN F
to 0 ADP F
a 0 DET F
standardised 0 VERB F
physiotherapist-directed 0 VERB F
program 0 NOUN F
of 0 ADP F
early 0 ADJ F
mobilisation 0 NOUN F
improved 0 PROPN F
clinical 0 ADJ F
outcomes 0 NOUN F
in 0 ADP F
patients 0 NOUN F
undergoing 0 CCONJ F
open 0 ADJ F
abdominal 0 ADJ F
surgery 0 NOUN F
. 0 PUNCT F

Fifty-six 0 ADJ T
patients 0 NOUN F
undergoing 0 CCONJ F
open 0 ADJ F
abdominal 0 ADJ F
surgery 0 NOUN F
, 0 PUNCT F
at 0 ADP F
high 0 ADJ F
risk 0 NOUN F
of 0 ADP F
developing 0 ADV F
postoperative 0 ADJ F
pulmonary 0 ADJ F
complications 0 NOUN F
, 0 PUNCT F
were 0 VERB F
randomised 0 VERB F
before 0 ADP F
operation 0 NOUN F
to 0 ADP F
an 0 DET F
early 0 ADJ F
mobilisation-only 0 DET F
group 0 NOUN F
or 0 CCONJ F
an 0 DET F
early 0 ADJ F
mobilisation-plus-deep 0 ADJ F
breathing 0 VERB F
and 0 CCONJ F
coughing 0 PROPN F
group 0 NOUN F
. 0 PUNCT F

Mobility B-PHYSICAL NOUN T
duration I-PHYSICAL NOUN F
, 0 PUNCT F
frequency 0 NOUN F
and 0 CCONJ F
intensity 0 NOUN F
of 0 ADP F
breathing B-PHYSICAL PROPN F
interventions I-PHYSICAL NOUN F
were 0 VERB F
quantified 0 VERB F
for 0 ADP F
both 0 CCONJ F
groups 0 NOUN F
. 0 PUNCT F

All 0 DET T
outcomes 0 NOUN F
were 0 VERB F
assessed 0 VERB F
by 0 ADP F
a 0 DET F
blinded 0 ADJ F
outcomes 0 NOUN F
researcher 0 PUNCT F
using 0 ADP F
a 0 DET F
standardised 0 VERB F
outcomes 0 NOUN F
measurement 0 NOUN F
tool 0 NOUN F
developed 0 ADP F
specifically 0 ADV F
for 0 ADP F
this 0 DET F
population 0 NOUN F
. 0 PUNCT F

Outcomes 0 NOUN T
included 0 VERB F
incidence 0 NOUN F
of 0 ADP F
clinically 0 ADV F
significant 0 ADJ F
postoperative B-PHYSICAL ADJ F
pulmonary I-PHYSICAL ADJ F
complications I-PHYSICAL NOUN F
, 0 PUNCT F
fever B-PHYSICAL NOUN F
, 0 PUNCT F
length B-OTHER NOUN F
of I-OTHER ADP F
stay I-OTHER NOUN F
, 0 PUNCT F
and 0 CCONJ F
restoration B-PHYSICAL NOUN F
of I-PHYSICAL ADP F
mobility I-PHYSICAL NOUN F
. 0 PUNCT F

There 0 PUNCT T
were 0 VERB F
no 0 DET F
significant 0 ADJ F
differences 0 NOUN F
between 0 ADP F
groups 0 NOUN F
in 0 ADP F
mean 0 NOUN F
age 0 NOUN F
, 0 PUNCT F
anaesthetic B-OTHER ADJ F
time I-OTHER NOUN F
, 0 PUNCT F
perioperative B-PHYSICAL ADJ F
morbidity I-PHYSICAL NOUN F
, 0 PUNCT F
or 0 PUNCT F

[ 0 PUNCT F
Clinical 0 ADJ T
study 0 NOUN F
of 0 ADP F
the 0 DET F
efficacy 0 NOUN F
of 0 ADP F
and 0 CCONJ F
tolerance 0 NOUN F
to 0 ADP F
nimesulide 0 PUNCT F
in 0 ADP F
suppository 0 ADJ F
formulation 0 NOUN F
in 0 ADP F
pain-inflammatory 0 ADJ F
pathologies 0 NOUN F
of 0 ADP F
the 0 DET F
ear 0 NOUN F
, 0 PUNCT F
nose 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
throat 0 NOUN F
] 0 PUNCT F
. 0 PUNCT F

The 0 DET T
efficacy 0 NOUN F
and 0 CCONJ F
tolerability B-OTHER NOUN F
of 0 ADP F
a 0 DET F
new 0 ADJ F
pharmaceutical 0 ADJ F
form 0 NOUN F
of 0 ADP F
the 0 DET F
non-steroid 0 NOUN F
anti-inflammatory 0 ADJ F
drug 0 NOUN F
. 0 PUNCT F

Nimesulide 0 PUNCT T
have 0 PUNCT F
been 0 PUNCT F
studied 0 VERB F
in 0 ADP F
a 0 DET F
double 0 ADJ F
blind 0 PUNCT F
study 0 NOUN F
compared 0 VERB F
with 0 ADP F
flurbiprofen 0 NOUN F
, 0 PUNCT F
in 0 ADP F
98 0 NUM F
patients 0 NOUN F
aged 0 VERB F
between 0 ADP F
18 0 NUM F
and 0 CCONJ F
75 0 NUM F
suffering 0 ADJ F
from 0 ADP F
pain-inflammatory 0 ADJ F
pathologies 0 NOUN F
of 0 ADP F
ENT 0 NOUN T
nature 0 NOUN F
. 0 PUNCT F

Both 0 CCONJ T
drugs 0 NOUN F
, 0 PUNCT F
administered 0 VERB F
in 0 ADP F
a 0 DET F
dose 0 NOUN F
of 0 ADP F
one 0 NUM F
suppository 0 ADJ F
twice 0 CCONJ F
a 0 DET F
day 0 NOUN F
for 0 ADP F
7 0 NUM F
days 0 NOUN F
, 0 PUNCT F
showed 0 VERB F
marked 0 VERB F
anti-inflammatory B-PHYSICAL ADJ F
, 0 PUNCT F
analgesic B-PHYSICAL PUNCT F
and 0 CCONJ F
antipyretic B-PHYSICAL ADJ F
activity I-PHYSICAL NOUN F
and 0 CCONJ F
produced 0 VERB F
a 0 DET F
significant 0 ADJ F
, 0 PUNCT F
progressive 0 ADJ F
improvement 0 NOUN F
in 0 ADP F
the 0 DET F
typical 0 ADJ F
symptoms 0 NOUN F
of 0 ADP F
the 0 DET F
inflammatory B-PHYSICAL ADJ F
state I-PHYSICAL NOUN F
up 0 PUNCT F
to 0 ADP F
their 0 PUNCT F
complete 0 ADJ F
remission 0 NOUN F
. 0 PUNCT F

Nimesulide 0 NOUN T
evidenced 0 PUNCT F
greater 0 PUNCT F
speed B-PHYSICAL NOUN F
and 0 CCONJ F
duration 0 NOUN F
of 0 ADP F
therapeutic B-PHYSICAL ADJ F
action I-PHYSICAL NOUN F
. 0 PUNCT F

Assessment 0 NOUN T
on 0 ADP F
the 0 DET F
effectiveness 0 NOUN F
and 0 CCONJ F
tolerability B-OTHER NOUN F
as 0 PUNCT F
expressed 0 VERB F
separately 0 ADV F
by 0 ADP F
the 0 DET F
physician 0 NOUN F
and 0 CCONJ F
patient 0 NOUN F
were 0 VERB F
positive 0 ADJ F
in 0 ADP F
almost 0 ADV F
all 0 DET F
cases 0 NOUN F
of 0 ADP F
both 0 PUNCT F
treatments 0 NOUN F
. 0 PUNCT F

Superior 0 ADJ T
visual 0 ADJ F
search 0 NOUN F
in 0 ADP F
adults 0 NOUN F
with 0 ADP F
autism 0 NOUN F
. 0 PUNCT F

Recent 0 ADJ T
studies 0 NOUN F
have 0 ADP F
suggested 0 VERB F
that 0 ADP F
children 0 NOUN F
with 0 ADP F
autism 0 NOUN F
perform 0 PUNCT F
better 0 ADP F
than 0 VERB F
matched 0 VERB F
controls 0 CCONJ F
on 0 ADP F
visual 0 ADJ F
search 0 NOUN F
tasks 0 NOUN F
and 0 CCONJ F
that 0 ADP F
this 0 ADP F
stems 0 PUNCT F
from 0 ADP F
a 0 DET F
superior 0 ADJ F
visual B-MENTAL ADJ F
discrimination I-MENTAL NOUN F
ability I-MENTAL NOUN F
. 0 PUNCT F

This 0 DET T
study 0 NOUN F
assessed 0 VERB F
whether 0 CCONJ F
these 0 DET F
findings 0 NOUN F
generalize 0 PUNCT F
from 0 ADP F
children 0 NOUN F
to 0 ADP F
adults 0 NOUN F
with 0 ADP F
autism 0 NOUN F
. 0 PUNCT F

Experiments 0 NOUN T
1 0 NUM F
and 0 CCONJ F
2 0 NUM F
showed 0 VERB F
that 0 ADP F
, 0 PUNCT F
like 0 ADP F
children 0 NOUN F
, 0 PUNCT F
adults 0 NOUN F
with 0 ADP F
autism 0 NOUN F
were 0 VERB F
superior 0 ADJ F
to 0 ADP F
controls 0 CCONJ F
at 0 ADP F
searching B-MENTAL VERB F
for I-MENTAL ADP F
targets I-MENTAL NOUN F
. 0 PUNCT F

Experiment 0 NOUN T
3 0 NUM F
showed 0 VERB F
that 0 ADP F
increases 0 CCONJ F
in 0 ADP F
target-distractor B-MENTAL NOUN F
similarity 0 NOUN F
slowed B-MENTAL PUNCT F
the I-MENTAL DET F
visual I-MENTAL ADJ F
search I-MENTAL NOUN F
performance B-MENTAL NOUN F
of 0 ADP F
the 0 DET F
control 0 NOUN F
group 0 NOUN F
significantly 0 ADV F
more 0 ADV F
than 0 PUNCT F
that 0 ADP F
of 0 ADP F
the 0 DET F
autism 0 NOUN F
group 0 NOUN F
, 0 PUNCT F
suggesting 0 VERB F
that 0 ADP F
the 0 DET F
adults 0 NOUN F
with 0 ADP F
autism 0 NOUN F
have 0 PUNCT F
a 0 DET F
superior B-PHYSICAL ADJ F
visual I-PHYSICAL ADJ F
discrimination I-PHYSICAL PUNCT F

Hepatorenal 0 ADJ T
syndrome 0 NOUN F
. 0 PUNCT F

Studies 0 NOUN T
of 0 ADP F
the 0 DET F
effect 0 NOUN F
of 0 ADP F
vascular 0 ADJ F
volume 0 NOUN F
and 0 CCONJ F
intraperitoneal 0 ADJ F
pressure 0 NOUN F
on 0 ADP F
renal B-PHYSICAL ADJ F
and I-PHYSICAL CCONJ F
hepatic I-PHYSICAL ADJ F
function I-PHYSICAL NOUN F
. 0 PUNCT F

Eleven 0 ADP T
patients 0 NOUN F
with 0 ADP F
well-documented 0 VERB F
hepatorenal 0 ADJ F
syndrome 0 NOUN F
were 0 VERB F
studied 0 VERB F
by 0 ADP F
measurement 0 NOUN F
of 0 ADP F
blood B-PHYSICAL NOUN F
volume I-PHYSICAL NOUN F
, 0 PUNCT F
glomerular B-PHYSICAL ADJ F
filtration I-PHYSICAL NOUN F
rate I-PHYSICAL NOUN F
, 0 PUNCT F
renal B-PHYSICAL ADJ F
plasma I-PHYSICAL NOUN F
flow I-PHYSICAL NOUN F
, 0 PUNCT F
plasma B-PHYSICAL NOUN F
aldosterone I-PHYSICAL NOUN F
concentration I-PHYSICAL NOUN F
, 0 PUNCT F
renin B-PHYSICAL NOUN F
substrate I-PHYSICAL NOUN F
concentration I-PHYSICAL NOUN F
, 0 PUNCT F
and 0 CCONJ F
plasma B-PHYSICAL NOUN F
renin I-PHYSICAL NOUN F
activity I-PHYSICAL NOUN F
. 0 PUNCT F

They 0 PRON T
were 0 VERB F
then 0 ADV F
given 0 VERB F
750 0 NUM F
ml 0 NOUN F
of 0 ADP F
stored 0 VERB F
plasma 0 NOUN F
, 0 PUNCT F
750 0 NUM F
ml 0 NOUN F
of 0 ADP F
fresh 0 ADJ F
frozen 0 VERB F
plasma 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
then 0 ADV F
an 0 DET F
infusion 0 NOUN F
of 0 ADP F
angiotensin 0 NOUN F
II 0 NUM T
, 0 PUNCT F
in 0 ADP F
random 0 ADJ F
order 0 NOUN F
on 0 ADP F
successive 0 ADJ F
days 0 NOUN F
. 0 PUNCT F

Infusion 0 NOUN T
of 0 ADP F
fresh 0 ADJ F
frozen 0 VERB F
plasma 0 NOUN F
improved 0 ADP F
function 0 ADP F
more 0 ADV F
than 0 PUNCT F
did 0 PUNCT F
stored 0 PUNCT F
plasma 0 NOUN F
and 0 CCONJ F
in 0 ADP F
addition 0 NOUN F
returned 0 VERB F
a 0 DET F
very 0 ADJ F
low 0 ADJ F
filtration 0 NOUN F
fraction 0 NOUN F
toward 0 ADP F
normal 0 ADJ F
. 0 PUNCT F

Angiotensin 0 NOUN T
II 0 NUM T
infusion 0 NOUN F
increased 0 VERB F
filtration B-PHYSICAL NOUN F
fraction I-PHYSICAL NOUN F
, 0 PUNCT F
but 0 CCONJ F
decreased 0 ADV F
glomerular B-PHYSICAL ADJ F
filtration I-PHYSICAL NOUN F
rate I-PHYSICAL NOUN F
, 0 PUNCT F
renal B-PHYSICAL ADJ F
plasma I-PHYSICAL NOUN F
flow I-PHYSICAL NOUN F
, 0 PUNCT F
and 0 CCONJ F
urine B-PHYSICAL NOUN F
flow I-PHYSICAL NOUN F
sharply 0 ADV F
. 0 PUNCT F

Patients 0 NOUN T
were 0 VERB F
then 0 ADV F
given 0 VERB F
a 0 DET F
daily 0 ADJ F
infusion 0 NOUN F
of 0 ADP F
1,000 0 NUM F
ml 0 NOUN F
of 0 ADP F
fresh 0 ADJ F
frozen 0 VERB F
plasma 0 NOUN F
for 0 ADP F
seven 0 NUM F
to 0 ADP F
18 0 NUM F
days 0 NOUN F
to 0 PUNCT F
expand 0 VERB F
the 0 DET F
blood 0 NOUN F
volume 0 NOUN F
to 0 ADP F
supranormal 0 ADJ F
levels 0 NOUN F
as 0 CCONJ F
assayed 0 VERB F
by 0 ADP F
serial 0 ADJ F
measurement 0 NOUN F
of 0 ADP F
blood 0 NOUN F
volume 0 NOUN F
. 0 PUNCT F

Plasma B-PHYSICAL NOUN T
aldosterone I-PHYSICAL NOUN F
levels I-PHYSICAL NOUN F
decreased 0 ADJ F
to 0 ADP F
a 0 DET F
normal 0 ADJ F
range 0 NOUN F
, 0 PUNCT F
glomerular B-PHYSICAL ADJ F
filtration I-PHYSICAL NOUN F
rate I-PHYSICAL NOUN F
and 0 CCONJ F
renal B-PHYSICAL ADJ F
plasma I-PHYSICAL NOUN F
flow I-PHYSICAL NOUN F
both 0 PUNCT F
increased 0 VERB F
, 0 PUNCT F
and 0 CCONJ F
urinary B-PHYSICAL ADJ F
excretion I-PHYSICAL NOUN F
of I-PHYSICAL ADP F
sodium I-PHYSICAL NOUN F
and 0 CCONJ F
potassium B-PHYSICAL NOUN F
both 0 PUNCT F
returned 0 VERB F
toward 0 ADP F
normal 0 ADJ F
. 0 PUNCT F

The 0 DET T
effect 0 NOUN F
of 0 ADP F
intraperitoneal 0 ADJ F
pressure 0 NOUN F
was 0 VERB F
then 0 ADV F
studied 0 VERB F
by 0 ADP F
measuring 0 VERB F
glomerular B-PHYSICAL ADJ F
filtration I-PHYSICAL NOUN F
rate I-PHYSICAL NOUN F
, 0 PUNCT F
renal B-PHYSICAL ADJ F
plasma I-PHYSICAL NOUN F
flow I-PHYSICAL NOUN F
, 0 PUNCT F
pressure B-PHYSICAL NOUN F
in I-PHYSICAL ADP F
the I-PHYSICAL DET F
vena I-PHYSICAL ADP F
cava I-PHYSICAL PUNCT F
, 0 PUNCT F
hepatic B-PHYSICAL ADJ F
vein I-PHYSICAL NOUN F
free I-PHYSICAL ADJ F
flow I-PHYSICAL NOUN F
, 0 PUNCT F
and 0 CCONJ F
hepatic B-PHYSICAL ADJ F
vein I-PHYSICAL NOUN F
wedged I-PHYSICAL ADV F
pressure I-PHYSICAL NOUN F
before 0 ADP F
, 0 PUNCT F
during 0 ADP F
, 0 PUNCT F
and 0 CCONJ F
after 0 ADP F
paracentesis 0 NOUN F
to 0 PART F
reduce 0 ADJ F
the 0 DET F
intraperitoneal 0 ADJ F
pressure 0 NOUN F
from 0 ADP F
30 0 NUM F
to 0 ADP F
40 0 NUM F
cm 0 NOUN F
H2O 0 NOUN T
to 0 ADP F
12 0 NUM F
to 0 ADP F
17 0 NUM F
cm 0 NOUN F
H2O 0 NOUN T
. 0 PUNCT F

Venous B-PHYSICAL ADJ T
pressures I-PHYSICAL NOUN F
moved 0 DET F
parallel 0 PUNCT F
to 0 ADP F
ascitic B-PHYSICAL ADJ F
fluid I-PHYSICAL NOUN F
pressures I-PHYSICAL NOUN F
, 0 PUNCT F
and 0 CCONJ F
glomerular B-PHYSICAL ADJ F
filtration I-PHYSICAL NOUN F
rate I-PHYSICAL NOUN F
, 0 PUNCT F
renal B-PHYSICAL ADJ F
plasma I-PHYSICAL NOUN F
flow I-PHYSICAL NOUN F
, 0 PUNCT F
and 0 CCONJ F
urine B-PHYSICAL NOUN F
flow I-PHYSICAL NOUN F
all 0 PUNCT F
improved 0 CCONJ F
sharply 0 ADV F
; 0 PUNCT F
then 0 ADV F
, 0 PUNCT F
as 0 PUNCT F
ascitic 0 ADJ F
fluid 0 NOUN F
continued 0 VERB F
to 0 PART F
form 0 ADP F
, 0 PUNCT F
reducing 0 PUNCT F
vascular B-PHYSICAL ADJ F
volume I-PHYSICAL NOUN F
, 0 PUNCT F
urine 0 NOUN F
flow 0 NOUN F
, 0 PUNCT F
glomerular 0 ADJ F
filtration 0 NOUN F
rate 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
renal B-PHYSICAL ADJ F
plasma I-PHYSICAL NOUN F
flow I-PHYSICAL NOUN F
all 0 PUNCT F
decreased 0 ADP F
slowly 0 ADV F
. 0 PUNCT F

Six 0 NUM T
patients 0 NOUN F
then 0 ADV F
underwent 0 PUNCT F
placement 0 NOUN F
of 0 ADP F
a 0 DET F
LeVeen 0 NOUN T
shunt 0 NOUN F
. 0 PUNCT F

Improvement 0 NOUN T
in 0 ADP F
glomerular B-PHYSICAL ADJ F
filtration I-PHYSICAL NOUN F
rate I-PHYSICAL NOUN F
and 0 CCONJ F
renal B-PHYSICAL ADJ F
plasma I-PHYSICAL NOUN F
flow I-PHYSICAL NOUN F
and 0 CCONJ F
clinical B-PHYSICAL ADJ F
condition I-PHYSICAL NOUN F
was 0 VERB F
dramatic 0 VERB F
. 0 PUNCT F

During 0 ADP T
postoperative 0 ADJ F
observation 0 NOUN F
of 0 ADP F
up 0 PUNCT F
to 0 ADV F
two 0 NUM F
years 0 NOUN F
, 0 PUNCT F
progressive 0 ADJ F
improvement 0 NOUN F
in 0 ADP F
hepatic B-PHYSICAL ADJ F
function I-PHYSICAL NOUN F
has 0 PUNCT F
occurred 0 VERB F
. 0 PUNCT F

Capsular 0 ADJ T
contracture 0 NOUN F
around 0 ADP F
saline-filled 0 ADV F
fine 0 ADJ F
textured 0 PUNCT F
and 0 CCONJ F
smooth 0 ADJ F
mammary 0 ADJ F
implants 0 NOUN F
: 0 PUNCT F
a 0 DET F
prospective 0 ADJ F
7.5-year 0 NOUN F
follow-up 0 NOUN F
. 0 PUNCT F

In 0 ADP T
a 0 DET F
previous 0 ADJ F
prospective 0 ADJ F
randomized 0 VERB F
clinical 0 ADJ F
study 0 NOUN F
comparing 0 VERB F
in 0 ADP F
the 0 DET F
same 0 ADJ F
patient 0 NOUN F
textured 0 PUNCT F
and 0 CCONJ F
smooth 0 ADJ F
saline-filled 0 VERB F
mammary 0 ADJ F
implants 0 NOUN F
( 0 PUNCT F
Biocell 0 CCONJ T
) 0 PUNCT F
with 0 ADP F
large 0 ADJ F
pore 0 CCONJ F
size 0 NOUN F
( 0 PUNCT F
300 0 NUM F
to 0 ADP F
600 0 ADV F
microm 0 NOUN F
) 0 PUNCT F
, 0 PUNCT F
we 0 PRON F
saw 0 ADJ F
no 0 DET F
difference 0 NOUN F
in 0 ADP F
capsular 0 ADJ F
contracture 0 NOUN F
. 0 PUNCT F

This 0 DET T
study 0 NOUN F
was 0 VERB F
undertaken 0 VERB F
in 0 ADP F
a 0 DET F
similar 0 ADJ F
way 0 NOUN F
to 0 PART F
compare 0 PART F
capsular 0 ADJ F
contracture 0 NOUN F
around 0 ADP F
smooth 0 ADJ F
and 0 CCONJ F
textured 0 ADP F
saline-filled 0 NOUN F
prostheses 0 NOUN F
with 0 ADP F
pores 0 NOUN F
of 0 ADP F
small 0 ADJ F
size 0 NOUN F
. 0 PUNCT F

During 0 ADP T
a 0 DET F
period 0 NOUN F
of 0 ADP F
7.5 0 NUM F
years 0 NOUN F
, 0 PUNCT F
the 0 DET F
breast 0 NOUN F
hardness 0 VERB F
was 0 VERB F
followed 0 VERB F
up 0 ADP F
, 0 PUNCT F
and 0 CCONJ F
at 0 ADP F
the 0 DET F
end 0 NOUN F
of 0 ADP F
the 0 DET F
study 0 ADJ F
patient 0 NOUN F
satisfaction 0 NOUN F
was 0 VERB F
evaluated 0 VERB F
. 0 PUNCT F

Twenty 0 NUM T
healthy 0 ADJ F
women 0 NOUN F
with 0 ADP F
a 0 DET F
mean 0 NOUN F
age 0 NOUN F
of 0 ADP F
30 0 NUM F
years 0 NOUN F
were 0 VERB F
operated 0 VERB F
on 0 ADP F
for 0 ADP F
breast 0 NOUN F
augmentation 0 NOUN F
. 0 PUNCT F

Two 0 NUM T
surgeons 0 NOUN F
performed 0 VERB F
all 0 DET F
operations 0 NOUN F
in 0 ADP F
a 0 DET F
standardized 0 VERB F
way 0 NOUN F
. 0 PUNCT F

Each 0 DET T
patient 0 NOUN F
received 0 VERB F
subglandularly 0 PUNCT F
a 0 DET F
Siltex 0 NOUN T
textured 0 PUNCT F
saline-filled 0 VERB F
prosthesis 0 NOUN F
with 0 ADP F
a 0 DET F
pore 0 ADJ F
size 0 NOUN F
of 0 ADP F
30 0 NUM F
to 0 ADP F
70 0 NUM F
microm 0 NOUN F
in 0 ADP F
one 0 NUM F
breast 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
a 0 DET F
smooth 0 ADJ F
saline-filled 0 VERB F
prosthesis 0 NOUN F
in 0 ADP F
the 0 DET F
other 0 PUNCT F
. 0 PUNCT F

The 0 DET T
hardness B-PHYSICAL NOUN F
of I-PHYSICAL ADP F
the I-PHYSICAL DET F
breasts I-PHYSICAL NOUN F
was 0 VERB F
evaluated 0 VERB F
after 0 ADP F
0.5 0 NUM F
, 0 PUNCT F
1 0 NUM F
, 0 PUNCT F
and 0 CCONJ F
7.5 0 NUM F
years 0 NOUN F
using 0 VERB F
Baker B-OTHER ADJ T
grading I-OTHER NUM F
and I-OTHER CCONJ F
applanation I-OTHER NOUN F
tonometry I-OTHER NOUN F
. 0 PUNCT F

Eighteen 0 NUM T
patients 0 NOUN F
completed 0 VERB F
1-year 0 NOUN F
and 0 CCONJ F
7.5-year 0 NOUN F
follow-up 0 NOUN F
. 0 PUNCT F

Two 0 NUM T
breasts 0 NOUN F
with 0 ADP F
smooth 0 ADJ F
prostheses 0 NOUN F
were 0 VERB F
contracted 0 VERB F
after 0 ADP F
6 0 NUM F
months 0 NOUN F
( 0 PUNCT F
Baker 0 NOUN T
III 0 NUM T
or 0 CCONJ F
IV 0 NUM T
) 0 PUNCT F
. 0 PUNCT F

After 0 ADP T
1 0 NUM F
year 0 NOUN F
, 0 PUNCT F
four 0 NUM F
patients 0 NOUN F
with 0 ADP F
smooth 0 ADJ F
prostheses 0 NOUN F
and 0 CCONJ F
one 0 NUM F
with 0 ADP F
a 0 DET F
textured 0 VERB F
prosthesis 0 NOUN F
had 0 PUNCT F
capsular B-PHYSICAL ADJ F
contracture I-PHYSICAL NOUN F
( 0 PUNCT F
p 0 NOUN F
= 0 SYM F
0.34 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Seven 0 NUM T
and 0 CCONJ F
one-half 0 NOUN F
years 0 NOUN F
after 0 ADP F
surgery 0 NOUN F
, 0 PUNCT F
six 0 NUM F
patents 0 NOUN F
with 0 ADP F
smooth 0 ADJ F
and 0 CCONJ F
four 0 NUM F
with 0 ADP F
textured 0 VERB F
implants 0 NOUN F
had 0 PUNCT F
contracture B-PHYSICAL NOUN F
( 0 PUNCT F
p 0 NOUN F
= 0 SYM F
0.66 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

On 0 ADP T
two 0 NUM F
patients 0 NOUN F
with 0 ADP F
smooth 0 ADJ F
prostheses 0 NOUN F
and 0 CCONJ F
one 0 NUM F
patient 0 NOUN F
with 0 ADP F
a 0 DET F
textured 0 VERB F
prosthesis 0 NOUN F
, 0 PUNCT F
the 0 DET F
capsule 0 NOUN F
around 0 ADP F
the 0 DET F
implant 0 NOUN F
hardened 0 ADP F
between 0 ADP F
6 0 NUM F
and 0 CCONJ F
12 0 NUM F
months 0 NOUN F
. 0 PUNCT F

Between 0 ADP T
1 0 NUM F
year 0 NOUN F
and 0 CCONJ F
7.5 0 NUM F
years 0 NOUN F
, 0 PUNCT F
three 0 NUM F
breasts 0 NOUN F
with 0 ADP F
smooth B-OTHER ADJ F
and 0 CCONJ F
textured B-OTHER DET F
implants I-OTHER NOUN F
contracted I-OTHER VERB F
and 0 CCONJ F
one 0 NUM F
with 0 ADP F
a 0 DET F
textured 0 CCONJ F
implant 0 ADP F
softened.The 0 PUNCT F
patients 0 NOUN F
reported 0 VERB F
on 0 ADP F
a 0 DET F
Visual 0 ADJ T
Analogue 0 NOUN T
Scale 0 NOUN T
( 0 PUNCT F
1 0 NUM F
to 0 ADP F
10 0 NUM F
) 0 PUNCT F
the 0 DET F
impact 0 NOUN F
of 0 ADP F
the 0 DET F
augmentation 0 NOUN F
on 0 ADP F
their 0 ADJ F
quality 0 NOUN F
of 0 ADP F
life 0 NOUN F
to 0 PART F
be 0 PUNCT F
9 0 NUM F
+/- 0 SYM F
1 0 NUM F
. 0 PUNCT F

Four 0 NUM T
patients 0 NOUN F
preferred 0 VERB F
the 0 DET F
breast 0 NOUN F
with 0 ADP F
the 0 DET F
smooth 0 ADJ F
prosthesis 0 NOUN F
, 0 PUNCT F
three 0 PUNCT F
preferred 0 VERB F
the 0 DET F
breast 0 NOUN F
with 0 ADP F
the 0 DET F
textured 0 VERB F
prosthesis 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
the 0 DET F
others 0 NOUN F
found 0 VERB F
both 0 PUNCT F
breasts 0 DET F
equal 0 ADJ F
. 0 PUNCT F

This 0 DET T
study 0 NOUN F
showed 0 VERB F
no 0 DET F
significant B-OTHER ADJ F
difference I-OTHER NOUN F
of 0 ADP F
contracture B-PHYSICAL NOUN F
with 0 ADP F
smooth 0 ADJ F
versus 0 CCONJ F
fine 0 ADJ F
textured 0 ADP F
implants 0 NOUN F
. 0 PUNCT F

The 0 DET T
majority 0 NOUN F
of 0 ADP F
the 0 DET F
patients 0 NOUN F
preferred 0 VERB F
the 0 DET F
smooth 0 ADJ F
implants 0 NOUN F
. 0 PUNCT F

The 0 DET T
patients 0 NOUN F
reported 0 VERB F
that 0 ADP F
the 0 DET F
breast 0 NOUN F
augmentation 0 NOUN F
had 0 PUNCT F
had 0 PUNCT F
an 0 DET F
extremely 0 ADV F
high 0 ADJ F
impact 0 NOUN F
on 0 ADP F
their 0 ADJ F
quality 0 NOUN F
of 0 ADP F
life 0 NOUN F
. 0 PUNCT F

A 0 DET T
prospective 0 ADJ F
randomized 0 VERB F
treatment 0 NOUN F
study 0 NOUN F
comparing 0 VERB F
three 0 NUM F
treatment 0 NOUN F
options 0 NOUN F
for 0 ADP F
chalazia 0 ADJ F
: 0 PUNCT F
triamcinolone 0 ADV F
acetonide 0 NOUN F
injections 0 NOUN F
, 0 PUNCT F
incision 0 NOUN F
and 0 CCONJ F
curettage 0 NOUN F
and 0 CCONJ F
treatment 0 NOUN F
with 0 ADP F
hot 0 ADJ F
compresses 0 CCONJ F
. 0 PUNCT F

BACKGROUND 0 NOUN T
Three 0 PUNCT T
methods 0 NOUN F
of 0 ADP F
treating 0 VERB F
chalazia 0 ADP F
were 0 ADP F
compared 0 VERB F
: 0 PUNCT F
intralesional 0 ADJ F
triamcinolone 0 NUM F
acetonide 0 NOUN F
injections 0 NOUN F
( 0 PUNCT F
0.2 0 NUM F
mL 0 NOUN F
of 0 ADP F
10 0 NUM F
mg/mL 0 PUNCT F
) 0 PUNCT F
, 0 PUNCT F
incision 0 NOUN F
and 0 CCONJ F
curettage 0 NOUN F
and 0 CCONJ F
advice 0 NOUN F
regarding 0 VERB F
the 0 DET F
application 0 NOUN F
of 0 ADP F
hot 0 ADJ F
compresses 0 PUNCT F
to 0 ADP F
the 0 DET F
affected 0 PUNCT F
eyelid 0 ADJ F
. 0 PUNCT F

METHODS 0 NOUN T
This 0 PUNCT T
was 0 VERB F
a 0 DET F
single 0 ADJ F
centre 0 NOUN F
randomized 0 VERB F
treatment 0 NOUN F
study 0 NOUN F
. 0 PUNCT F

Patients 0 NOUN T
with 0 ADP F
a 0 DET F
chalazion 0 NOUN F
underwent 0 PROPN F
either 0 PUNCT F
of 0 ADP F
the 0 DET F
three 0 NUM F
treatment 0 NOUN F
options 0 NOUN F
. 0 PUNCT F

Chalazion B-OTHER NOUN T
resolution I-OTHER NOUN F
, 0 PUNCT F
pain B-PAIN NOUN F
, 0 PUNCT F
satisfaction B-OTHER NOUN F
and 0 CCONJ F
inconvenience B-PAIN NOUN F
experienced I-PAIN ADJ F
because I-PAIN PUNCT F
of I-PAIN ADP F
treatments I-PAIN NOUN F
were 0 VERB F
the 0 DET F
outcomes 0 NOUN F
assessed 0 VERB F
via 0 ADP F
a 0 DET F
telephone 0 NOUN F
interview 0 NOUN F
at 0 ADP F
3 0 NUM F
weeks 0 NOUN F
. 0 PUNCT F

RESULTS 0 NOUN T
136 0 NUM F
consecutive 0 ADJ F
patients 0 NOUN F
were 0 VERB F
enrolled 0 VERB F
into 0 ADP F
the 0 DET F
study 0 NOUN F
. 0 PUNCT F

At 0 ADP T
the 0 DET F
3-week 0 NOUN F
follow 0 VERB F
up 0 ADP F
, 0 PUNCT F
the 0 DET F
resolution B-OTHER NOUN F
rates I-OTHER NOUN F
in 0 ADP F
the 0 DET F
triamcinolone 0 ADV F
acetonide 0 NOUN F
injection 0 NOUN F
and 0 CCONJ F
surgical 0 ADJ F
treatment 0 NOUN F
groups 0 NOUN F
were 0 VERB F
not 0 ADV F
significantly 0 ADV F
different 0 ADJ F
from 0 ADP F
each 0 DET F
other 0 PUNCT F
at 0 ADP F
84 0 NUM F
% 0 ADJ F
( 0 PUNCT F
47/56 0 PUNCT F
) 0 PUNCT F
and 0 CCONJ F
87 0 NUM F
% 0 SYM F
( 0 PUNCT F
39/45 0 PUNCT F
) 0 PUNCT F
, 0 PUNCT F
respectively 0 ADV F
( 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.001 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
but 0 CCONJ F
was 0 VERB F
significantly 0 ADV F
lower 0 PUNCT F
in 0 ADP F
the 0 DET F
conservative 0 ADJ F
treatment 0 NOUN F
group 0 NOUN F
at 0 ADP F
46 0 NUM F
% 0 SYM F
( 0 PUNCT F
16/35 0 PUNCT F
) 0 PUNCT F
( 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.001 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Pain B-PAIN NOUN T
scores I-PAIN NOUN F
were 0 VERB F
higher 0 PUNCT F
in 0 ADP F
the 0 DET F
surgical 0 ADJ F
treatment 0 NOUN F
group 0 NOUN F
compared 0 VERB F
with 0 ADP F
the 0 DET F
triamcinolone 0 NUM F
injection 0 NOUN F
group 0 NOUN F
( 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.003 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Inconvenience B-PHYSICAL NOUN T
experienced I-PHYSICAL VERB F
by I-PHYSICAL ADP F
patients I-PHYSICAL NOUN F
was 0 VERB F
reported 0 VERB F
as 0 PUNCT F
significantly 0 ADV F
less 0 ADV F
in 0 ADP F
the 0 DET F
triamcinolone 0 NUM F
group 0 NOUN F
compared 0 VERB F
with 0 ADP F
the 0 DET F
conservative 0 ADJ F
and 0 CCONJ F
surgical 0 ADJ F
treatment 0 NOUN F
groups 0 NOUN F
( 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.001 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Patient B-OTHER NOUN T
satisfaction I-OTHER NOUN F
scores I-OTHER NOUN F
were 0 VERB F
lower 0 PUNCT F
in 0 ADP F
the 0 DET F
conservative 0 ADJ F
treatment 0 NOUN F
group 0 NOUN F
compared 0 VERB F
with 0 ADP F
each 0 CCONJ F
of 0 ADP F
the 0 DET F
other 0 ADJ F
two 0 NUM F
groups 0 NOUN F
which 0 DET F
in 0 ADP F
turn 0 NOUN F
, 0 PUNCT F
were 0 VERB F
no 0 DET F
different 0 ADJ F
from 0 ADP F
each 0 DET F
other 0 PUNCT F
regarding 0 ADP F
this 0 DET F
outcome 0 NOUN F
( 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.001 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

CONCLUSIONS 0 NOUN T
To 0 ADP T
our 0 PUNCT F
knowledge 0 NOUN F
, 0 PUNCT F
this 0 DET F
is 0 VERB F
the 0 DET F
first 0 ADJ F
prospective 0 ADJ F
randomized 0 VERB F
study 0 NOUN F
comparing 0 VERB F
the 0 DET F
three 0 NUM F
methods 0 NOUN F
of 0 ADP F
chalazia 0 ADJ F
treatment 0 NOUN F
. 0 PUNCT F

Results 0 CCONJ T
suggest 0 VERB F
that 0 ADP F
a 0 DET F
single 0 ADJ F
triamcinolone 0 NUM F
acetonide 0 NOUN F
injection 0 NOUN F
followed 0 VERB F
by 0 ADP F
lid 0 DET F
massage 0 NOUN F
is 0 VERB F
almost 0 ADV F
as 0 PUNCT F
effective 0 ADJ F
as 0 CCONJ F
incision 0 NOUN F
and 0 CCONJ F
curettage 0 NOUN F
in 0 ADP F
the 0 DET F
treatment 0 NOUN F
of 0 ADP F
chalazia 0 ADJ F
and 0 CCONJ F
with 0 ADP F
similar 0 ADJ F
patient B-OTHER NOUN F
satisfaction I-OTHER NOUN F
and 0 CCONJ F
less 0 DET F
pain B-PAIN NOUN F
and 0 CCONJ F
patient B-ADVERSE-EFFECTS NOUN F
inconvenience I-ADVERSE-EFFECTS NOUN F
. 0 PUNCT F

[ 0 PUNCT F
Clinilal 0 NOUN T
study 0 NOUN F
of 0 ADP F
medical 0 ADJ F
ozone 0 NOUN F
therapy 0 NOUN F
in 0 ADP F
chronic 0 ADJ F
hepatitis 0 NOUN F
B 0 NOUN T
of 0 ADP F
20 0 NUM F
patients 0 NOUN F
] 0 PUNCT F
. 0 PUNCT F

OBJECTIVE 0 NOUN T
To 0 PART T
study 0 NOUN F
the 0 DET F
effect 0 NOUN F
of 0 ADP F
medical 0 ADJ F
ozone 0 NOUN F
in 0 ADP F
the 0 DET F
treatment 0 NOUN F
of 0 ADP F
chronic 0 ADJ F
hepatitis 0 NOUN F
B 0 NOUN T
. 0 PUNCT F

METHODS 0 NOUN T
42 0 NUM F
patients 0 NOUN F
with 0 ADP F
chronic 0 ADJ F
hepatitis 0 NOUN F
B 0 NOUN T
were 0 VERB F
divided 0 VERB F
randomly 0 ADV F
into 0 ADP F
two 0 NUM F
groups 0 NOUN F
. 0 PUNCT F

22 0 DET F
patients 0 NOUN F
treated 0 VERB F
with 0 ADP F
basic 0 ADJ F
therapy 0 NOUN F
were 0 VERB F
as 0 ADP F
a 0 DET F
control 0 NOUN F
group 0 NOUN F
. 0 PUNCT F

20 0 NUM F
patients 0 NOUN F
treated 0 VERB F
with 0 ADP F
basic 0 ADJ F
therapy 0 NOUN F
plus 0 CCONJ F
ozone 0 NOUN F
therapy 0 NOUN F
were 0 VERB F
taken 0 VERB F
as 0 CCONJ F
a 0 DET F
treatment 0 NOUN F
group 0 NOUN F
. 0 PUNCT F

Index 0 NOUN T
of 0 ADP F
biochemistry B-PHYSICAL NOUN F
and 0 CCONJ F
virology B-PHYSICAL NOUN F
were 0 VERB F
studied 0 VERB F
at 0 ADP F
initial 0 ADJ F
and 0 CCONJ F
post-treatment 0 NOUN F
8 0 NUM F
weeks 0 NOUN F
. 0 PUNCT F

RESULTS 0 NOUN T
After 0 ADP T
the 0 DET F
treatment 0 NOUN F
, 0 PUNCT F
liver 0 NOUN F
function 0 NOUN F
of 0 ADP F
the 0 DET F
treatment 0 NOUN F
group 0 NOUN F
and 0 CCONJ F
the 0 DET F
control 0 NOUN F
group 0 NOUN F
had 0 PUNCT F
more 0 DET F
significant 0 ADJ F
improvement 0 NOUN F
. 0 PUNCT F

The 0 DET T
treatment 0 NOUN F
group 0 NOUN F
complete B-OTHER ADJ F
effective I-OTHER ADJ F
and 0 CCONJ F
partial B-OTHER ADJ F
effective I-OTHER ADJ F
were 0 VERB F
10 0 NUM F
% 0 SYM F
and 0 CCONJ F
35 0 NUM F
% 0 ADV F
difference 0 NOUN F
. 0 PUNCT F

The 0 DET T
control 0 NOUN F
group 0 NOUN F
complete 0 ADJ F
effective 0 ADJ F
and 0 CCONJ F
partial 0 ADJ F
effective 0 ADJ F
were 0 VERB F
4.6 0 NUM F
% 0 SYM F
and 0 CCONJ F
13.6 0 NUM F
% 0 SYM F
( 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.05 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

CONCLUSION 0 NOUN T
Treatment 0 NOUN T
of 0 ADP F
medical 0 ADJ F
ozone 0 NOUN F
on 0 ADP F
patients 0 NOUN F
with 0 ADP F
chronic 0 ADJ F
hepatitis 0 NOUN F
B 0 NOUN T
is 0 ADV F
effective 0 ADJ F
. 0 PUNCT F

Late 0 ADJ T
patient-reported 0 NOUN F
toxicity 0 NOUN F
after 0 ADP F
preoperative 0 ADJ F
radiotherapy 0 NOUN F
or 0 CCONJ F
chemoradiotherapy 0 NOUN F
in 0 ADP F
nonresectable 0 ADJ F
rectal 0 ADJ F
cancer 0 NOUN F
: 0 PUNCT F
results 0 CCONJ F
from 0 ADP F
a 0 DET F
randomized 0 VERB F
Phase 0 NOUN T
III 0 NUM T
study 0 NOUN F
. 0 PUNCT F

PURPOSE 0 NOUN T
Preoperative 0 ADJ T
chemoradiotherapy 0 NOUN F
( 0 PUNCT F
CRT 0 NOUN T
) 0 PUNCT F
is 0 VERB F
superior 0 ADJ F
to 0 ADP F
radiotherapy 0 NOUN F
( 0 PUNCT F
RT 0 NOUN T
) 0 PUNCT F
in 0 ADP F
locally 0 ADV F
advanced 0 VERB F
rectal 0 ADJ F
cancer 0 NOUN F
, 0 PUNCT F
but 0 CCONJ F
the 0 DET F
survival B-MORTALITY NOUN F
gain I-MORTALITY NOUN F
is 0 VERB F
limited 0 VERB F
. 0 PUNCT F

Late 0 ADJ T
toxicity B-ADVERSE-EFFECTS NOUN F
is 0 VERB F
, 0 PUNCT F
therefore 0 ADV F
, 0 PUNCT F
important 0 ADJ F
. 0 PUNCT F

The 0 DET T
aim 0 NOUN F
was 0 VERB F
to 0 ADV F
compare 0 NOUN F
late B-PHYSICAL ADJ F
bowel I-PHYSICAL NOUN F
, I-PHYSICAL PUNCT F
urinary I-PHYSICAL ADJ F
, 0 PUNCT F
and 0 CCONJ F
sexual B-PHYSICAL ADJ F
functions I-PHYSICAL NOUN F
after 0 ADP F
CRT 0 NOUN T
or 0 CCONJ F
RT 0 NOUN T
. 0 PUNCT F

METHODS 0 NOUN T
AND 0 CCONJ T
MATERIALS 0 NOUN T
Patients 0 NOUN T
( 0 PUNCT F
N 0 NOUN T
= 0 SYM F
207 0 NUM F
) 0 PUNCT F
with 0 ADP F
nonresectable 0 ADJ F
rectal 0 ADJ F
cancer 0 NOUN F
were 0 VERB F
randomized 0 VERB F
to 0 ADP F
preoperative 0 ADJ F
CRT 0 NOUN T
or 0 CCONJ F
RT 0 NOUN T
( 0 PUNCT F
2 0 NUM F
Gy 0 NOUN T
? 0 PUNCT F

25 0 NUM F
? 0 PUNCT F

5-fluorouracil/leucovorin 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

Extended 0 VERB T
surgery 0 NOUN F
was 0 VERB F
often 0 ADV F
required 0 VERB F
. 0 PUNCT F

Self-reported 0 VERB T
late 0 ADJ F
toxicity 0 NOUN F
was 0 VERB F
scored 0 VERB F
according 0 CCONJ F
to 0 ADP F
the 0 DET F
LENT 0 NOUN T
SOMA 0 NOUN T
criteria 0 NOUN F
in 0 ADP F
a 0 DET F
structured 0 VERB F
telephone 0 NOUN F
interview 0 NOUN F
and 0 CCONJ F
with 0 ADP F
questionnaires 0 ADJ F
European 0 NOUN T
Organisation 0 NOUN T
for 0 ADP F
Research 0 NOUN T
and 0 CCONJ F
Treatment 0 NOUN T
of 0 ADP F
Cancer 0 NOUN T
( 0 PUNCT F
EORTC 0 NOUN T
) 0 PUNCT F
Quality 0 NOUN T
of 0 ADP F
Life 0 NOUN T
Questionnaire 0 NOUN T
( 0 PUNCT F
QLQ-C30 0 NOUN T
) 0 PUNCT F
, 0 PUNCT F
International 0 ADJ T
Index 0 NOUN T
of 0 ADP F
Erectile 0 ADJ T
Function 0 NOUN T
( 0 PUNCT F
IIEF 0 NOUN T
) 0 PUNCT F
, 0 PUNCT F
and 0 CCONJ F
sexual 0 ADJ F
function-vaginal 0 ADJ F
changes 0 NOUN F
questionnaire 0 NOUN F
( 0 PUNCT F
SVQ 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

RESULTS 0 NOUN T
Of 0 ADP T
the 0 DET F
105 0 NUM F
patients 0 NOUN F
alive 0 ADJ F
in 0 ADP F
Norway 0 NOUN T
and 0 CCONJ F
Sweden 0 ADP T
after 0 ADP F
4 0 NUM F
to 0 ADP F
12 0 NUM F
years 0 NOUN F
of 0 ADP F
follow-up 0 NOUN F
, 0 PUNCT F
78 0 NUM F
( 0 PUNCT F
74 0 NUM F
% 0 SYM F
) 0 PUNCT F
responded 0 VERB F
. 0 PUNCT F

More 0 DET T
patients 0 NOUN F
in 0 ADP F
the 0 DET F
CRT 0 NOUN T
group 0 NOUN F
had 0 PUNCT F
received 0 PUNCT F
a 0 DET F
stoma 0 NOUN F
( 0 PUNCT F
73 0 NUM F
% 0 SYM F
vs. 0 CCONJ F
52 0 NUM F
% 0 SYM F
, 0 PUNCT F
p 0 NOUN F
= 0 SYM F
0.09 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Most 0 DET T
patients 0 NOUN F
without 0 ADP F
a 0 DET F
stoma 0 NOUN F
( 0 PUNCT F
7 0 NUM F
of 0 ADP F
12 0 NUM F
in 0 ADP F
CRT 0 NOUN T
group 0 NOUN F
and 0 CCONJ F
9 0 NUM F
of 0 ADP F
16 0 NUM F
in 0 ADP F
RT 0 NOUN T
group 0 NOUN F
) 0 PUNCT F
had 0 PUNCT F
incontinence 0 NOUN F
for 0 ADP F
liquid 0 PUNCT F
stools 0 NOUN F
or 0 CCONJ F
gas 0 NOUN F
. 0 PUNCT F

No 0 DET T
stoma 0 NOUN F
and 0 CCONJ F
good 0 ADJ F
anal 0 ADJ F
function 0 NOUN F
were 0 VERB F
seen 0 VERB F
in 0 ADP F
5 0 NUM F
patients 0 NOUN F
( 0 PUNCT F
11 0 NUM F
% 0 SYM F
) 0 PUNCT F
in 0 ADP F
the 0 DET F
CRT 0 NOUN T
group 0 NOUN F
and 0 CCONJ F
in 0 ADP F
11 0 NUM F
( 0 PUNCT F
30 0 NUM F
% 0 SYM F
) 0 PUNCT F
in 0 ADP F
the 0 DET F
RT 0 NOUN T
group 0 NOUN F
( 0 PUNCT F
p 0 NOUN F
= 0 SYM F
0.046 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Of 0 ADP T
44 0 NUM F
patients 0 NOUN F
in 0 ADP F
the 0 DET F
CRT 0 NOUN T
group 0 NOUN F
, 0 PUNCT F
12 0 NUM F
( 0 PUNCT F
28 0 NUM F
% 0 SYM F
) 0 PUNCT F
had 0 PUNCT F
had 0 PUNCT F
bowel 0 NOUN F
obstruction 0 NOUN F
compared 0 VERB F
with 0 ADP F
5 0 NUM F
of 0 ADP F
33 0 NUM F
( 0 PUNCT F
15 0 NUM F
% 0 SYM F
) 0 PUNCT F
in 0 ADP F
the 0 DET F
RT 0 NOUN T
group 0 NOUN F
( 0 PUNCT F
p 0 NOUN F
= 0 SYM F
0.27 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

One-quarter 0 ADJ T
of 0 ADP F
the 0 DET F
patients 0 NOUN F
reported 0 ADP F
urinary 0 ADJ F
incontinence 0 NOUN F
. 0 PUNCT F

The 0 DET T
majority 0 NOUN F
of 0 ADP F
men 0 NOUN F
had 0 PUNCT F
severe 0 ADJ F
erectile 0 ADJ F
dysfunction 0 NOUN F
. 0 PUNCT F

Few 0 DET T
women 0 NOUN F
reported 0 VERB F
sexual 0 ADJ F
activity 0 NOUN F
during 0 ADP F
the 0 DET F
previous 0 ADJ F
month 0 NOUN F
. 0 PUNCT F

However 0 ADV T
, 0 PUNCT F
the 0 DET F
majority 0 NOUN F
did 0 PUNCT F
not 0 ADV F
have 0 PUNCT F
concerns 0 VERB F
about 0 CCONJ F
their 0 PUNCT F
sex 0 NOUN F
life 0 NOUN F
. 0 PUNCT F

CONCLUSIONS 0 NOUN T
Fecal 0 PUNCT T
incontinence 0 NOUN F
and 0 CCONJ F
erectile 0 ADJ F
dysfunction 0 NOUN F
are 0 VERB F
frequent 0 ADJ F
after 0 ADP F
combined 0 VERB F
treatment 0 NOUN F
for 0 ADP F
locally 0 ADV F
advanced 0 VERB F
rectal 0 ADJ F
cancer 0 NOUN F
. 0 PUNCT F

There 0 PUNCT T
was 0 VERB F
a 0 DET F
clear 0 ADJ F
tendency 0 NOUN F
for 0 ADP F
the 0 DET F
problems 0 NOUN F
to 0 PART F
be 0 PUNCT F
more 0 ADV F
common 0 ADJ F
after 0 ADP F
CRT 0 NOUN T
than 0 PUNCT F
after 0 ADP F
RT 0 NOUN T
. 0 PUNCT F

Combined 0 VERB T
delivery 0 NOUN F
approach 0 NOUN F
of 0 ADP F
bone 0 NOUN F
marrow 0 NOUN F
mononuclear 0 ADJ F
stem 0 NOUN F
cells 0 NOUN F
early 0 ADJ F
and 0 CCONJ F
late 0 ADJ F
after 0 ADP F
myocardial 0 ADJ F
infarction 0 NOUN F
: 0 PUNCT F
the 0 DET F
MYSTAR 0 NOUN T
prospective 0 ADJ F
, 0 PUNCT F
randomized 0 ADP F
study 0 NOUN F
. 0 PUNCT F

BACKGROUND 0 NOUN T
Combined 0 PUNCT T
intracoronary 0 ADJ F
and 0 CCONJ F
intramyocardial 0 ADJ F
administration 0 NOUN F
might 0 PART F
improve 0 VERB F
outcomes 0 NOUN F
for 0 ADP F
bone-marrow-derived 0 ADJ F
stem 0 NOUN F
cell 0 NOUN F
therapy 0 NOUN F
for 0 ADP F
acute 0 ADJ F
myocardial 0 ADJ F
infarction 0 NOUN F
( 0 PUNCT F
AMI 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

We 0 PRON T
compared 0 VERB F
the 0 DET F
safety B-OTHER NOUN F
and 0 CCONJ F
feasibility B-OTHER NOUN F
of 0 ADP F
early 0 PUNCT F
and 0 CCONJ F
late 0 ADJ F
delivery 0 NOUN F
of 0 ADP F
stem 0 NOUN F
cells 0 NOUN F
with 0 ADP F
combined 0 VERB F
therapy 0 NOUN F
approaches 0 NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
Patients 0 NOUN T
with 0 ADP F
left 0 ADJ F
ventricular 0 ADJ F
ejection 0 NOUN F
fraction 0 NOUN F
less 0 ADV F
than 0 PUNCT F
45 0 NUM F
% 0 SYM F
after 0 ADP F
AMI 0 NOUN T
were 0 VERB F
randomly 0 ADV F
assigned 0 PUNCT F
stem 0 NOUN F
cell 0 NOUN F
delivery 0 NOUN F
via 0 ADP F
intramyocardial 0 ADJ F
injection 0 NOUN F
and 0 CCONJ F
intracoronary 0 ADJ F
infusion 0 NOUN F
3-6 0 NUM F
weeks 0 NOUN F
or 0 CCONJ F
3-4 0 NUM F
months 0 NOUN F
after 0 ADP F
AMI 0 NOUN T
. 0 PUNCT F

Primary 0 ADJ T
end 0 NOUN F
points 0 NOUN F
were 0 VERB F
changes 0 NOUN F
in 0 ADP F
infarct B-PHYSICAL NOUN F
size I-PHYSICAL NOUN F
and 0 CCONJ F
left B-PHYSICAL ADJ F
ventricular I-PHYSICAL ADJ F
ejection I-PHYSICAL NOUN F
fraction I-PHYSICAL NOUN F
3 I-PHYSICAL NUM F
months I-PHYSICAL NOUN F
after I-PHYSICAL ADP F
therapy I-PHYSICAL NOUN F
. 0 PUNCT F

RESULTS 0 NOUN T
A 0 PUNCT T
total 0 NOUN F
of 0 ADP F
60 0 NUM F
patients 0 NOUN F
were 0 VERB F
treated 0 VERB F
. 0 PUNCT F

The 0 DET T
mean 0 NOUN F
changes 0 NOUN F
in 0 ADP F
infarct B-PHYSICAL NOUN F
size 0 NOUN F
at B-PHYSICAL ADP F
3 I-PHYSICAL NUM F
months B-PHYSICAL NOUN F
were 0 VERB F
-3.5 0 NUM F
+/- 0 SYM F
5.1 0 NUM F
% 0 SYM F
( 0 PUNCT F
95 0 NUM F
% 0 SYM F
CI 0 NOUN T
-5.5 0 ADJ F
% 0 SYM F
to 0 ADP F
-1.5 0 NUM F
% 0 SYM F
, 0 PUNCT F
P 0 NOUN T
= 0 SYM F
0.001 0 NUM F
) 0 PUNCT F
in 0 ADP F
the 0 DET F
early 0 ADJ F
group 0 NOUN F
and 0 CCONJ F
-3.9 0 NUM F
+/- 0 SYM F
5.6 0 NUM F
% 0 SYM F
( 0 PUNCT F
95 0 NUM F
% 0 SYM F
CI 0 NOUN T
-6.1 0 ADP F
% 0 SYM F
to 0 ADP F
-1.6 0 PUNCT F
% 0 SYM F
, 0 PUNCT F
P 0 NOUN T
= 0 SYM F
0.002 0 NUM F
) 0 PUNCT F
in 0 ADP F
the 0 DET F
late 0 ADJ F
group 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
changes 0 NOUN F
in 0 ADP F
ejection B-PHYSICAL NOUN F
fraction I-PHYSICAL NOUN F
were 0 VERB F
3.5 0 NUM F
+/- 0 SYM F
5.6 0 NUM F
% 0 SYM F
( 0 PUNCT F
95 0 NUM F
% 0 SYM F
CI 0 NOUN T
1.3-5.6 0 NUM F
% 0 SYM F
, 0 PUNCT F
P 0 NOUN T
= 0 SYM F
0.003 0 NUM F
) 0 PUNCT F
and 0 CCONJ F
3.4 0 ADP F
+/- 0 SYM F
7.0 0 NUM F
% 0 SYM F
( 0 PUNCT F
95 0 NUM F
% 0 SYM F
CI 0 NOUN T
0.7-6.1 0 NUM F
% 0 SYM F
, 0 PUNCT F
P 0 NOUN T
= 0 SYM F
0.017 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
respectively 0 ADV F
. 0 PUNCT F

At 0 ADP T
9-12 0 NUM F
months 0 NOUN F
after 0 ADP F
AMI 0 NOUN T
, 0 PUNCT F
ejection B-PHYSICAL NOUN F
fraction I-PHYSICAL NOUN F
remained 0 VERB F
significantly 0 ADV F
higher 0 PUNCT F
than 0 CCONJ F
at 0 ADP F
baseline 0 NOUN F
in 0 ADP F
both 0 CCONJ F
groups 0 NOUN F
. 0 PUNCT F

In 0 ADP T
the 0 DET F
early 0 ADJ F
and 0 CCONJ F
late 0 ADJ F
groups 0 NOUN F
, 0 PUNCT F
a 0 DET F
mean 0 NOUN F
of 0 ADP F
200.3 0 NUM F
+/- 0 SYM F
68.7 0 NUM F
x 0 SYM F
10 0 NUM F
( 0 PUNCT F
6 0 NUM F
) 0 PUNCT F
and 0 CCONJ F
194.8 0 NUM F
+/- 0 SYM F
60.4 0 NUM F
x 0 SYM F
10 0 NUM F
( 0 PUNCT F
6 0 NUM F
) 0 PUNCT F
stem B-PHYSICAL NOUN F
cells I-PHYSICAL NOUN F
, 0 PUNCT F
respectively 0 ADV F
, 0 PUNCT F
were 0 VERB F
delivered 0 VERB F
to 0 ADP F
the 0 DET F
myocardium 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
1.30 0 NUM F
+/- 0 SYM F
0.68 0 NUM F
x 0 SYM F
10 0 NUM F
( 0 PUNCT F
9 0 NUM F
) 0 PUNCT F
and 0 CCONJ F
1.29 0 NUM F
+/- 0 SYM F
0.41 0 NUM F
x 0 SYM F
10 0 NUM F
( 0 PUNCT F
9 0 NUM F
) 0 PUNCT F
cells 0 NOUN F
, 0 PUNCT F
respectively 0 ADV F
, 0 PUNCT F
were 0 VERB F
delivered 0 VERB F
into 0 ADP F
the 0 DET F
artery 0 NOUN F
. 0 PUNCT F

A 0 DET T
high 0 ADJ F
number B-PHYSICAL NOUN F
of I-PHYSICAL ADP F
cells I-PHYSICAL NOUN F
was 0 VERB F
required 0 VERB F
for 0 ADP F
significant 0 ADJ F
improvements 0 NOUN F
in 0 ADP F
the 0 DET F
primary 0 ADJ F
end 0 NOUN F
points 0 NOUN F
. 0 PUNCT F

CONCLUSIONS 0 NOUN T
Combined 0 PROPN T
cardiac 0 ADJ F
stem 0 NOUN F
cell 0 NOUN F
delivery 0 NOUN F
induces 0 NOUN F
a 0 DET F
moderate 0 ADJ F
but 0 CCONJ F
significant 0 ADJ F
improvement 0 NOUN F
in 0 ADP F
myocardial B-PHYSICAL ADJ F
infarct I-PHYSICAL NOUN F
size I-PHYSICAL NOUN F
and 0 PUNCT F

The 0 DET T
Low 0 ADJ T
Energy 0 NOUN T
Safety 0 NOUN T
Study 0 NOUN T
( 0 PUNCT F
LESS 0 ADP T
) 0 PUNCT F
: 0 PUNCT F
rationale 0 NOUN F
, 0 PUNCT F
design 0 NOUN F
, 0 PUNCT F
patient 0 NOUN F
characteristics 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
device 0 NOUN F
utilization 0 NOUN F
. 0 PUNCT F

BACKGROUND 0 NOUN T
A 0 DET T
10-J 0 NOUN F
energy 0 NOUN F
safety 0 NOUN F
margin 0 NOUN F
has 0 VERB F
traditionally 0 VERB F
been 0 PUNCT F
used 0 VERB F
in 0 ADP F
programming 0 ADP F
implantable 0 ADJ F
cardioverter 0 ADJ F
defibrillators 0 NOUN F
( 0 PUNCT F
ICDs 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
Low 0 ADJ T
Energy 0 NOUN T
Safety 0 NOUN T
Study 0 NOUN T
( 0 PUNCT F
LESS 0 ADP T
) 0 PUNCT F
tests 0 PUNCT F
the 0 DET F
hypothesis 0 NOUN F
that 0 ADP F
programming 0 DET F
shocks 0 PUNCT F
to 0 PUNCT F
lower 0 PUNCT F
energy 0 NOUN F
margins 0 NOUN F
is 0 VERB F
safe 0 ADJ F
and 0 CCONJ F
effective 0 ADJ F
. 0 PUNCT F

METHODS 0 NOUN T
Patients 0 NOUN T
with 0 ADP F
standard 0 ADJ F
ICD 0 NOUN T
indications 0 NOUN F
undergo 0 VERB F
defibrillation 0 NOUN F
threshold 0 NOUN F
testing 0 SYM F
( 0 PUNCT F
DFT 0 NOUN T
) 0 PUNCT F
at 0 ADP F
the 0 DET F
time 0 NOUN F
of 0 ADP F
ICD 0 NOUN T
implant 0 NOUN F
, 0 PUNCT F
with 0 ADP F
reconfirmation 0 NOUN F
of 0 ADP F
lowest 0 PUNCT F
successful 0 ADJ F
energy 0 NOUN F
twice 0 ADV F
( 0 PUNCT F
DFT++ 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

Patients 0 NOUN T
are 0 VERB F
randomized 0 VERB F
to 0 ADP F
2 0 NUM F
groups 0 NOUN F
: 0 PUNCT F
the 0 DET F
first 0 PUNCT F
has 0 PUNCT F
the 0 DET F
initial 0 ADJ F
2 0 NUM F
shocks 0 PUNCT F
for 0 ADP F
ventricular 0 ADJ F
fibrillation 0 NOUN F
conversion 0 NOUN F
programmed 0 DET F
at 0 ADP F
2 0 NUM F
energy 0 NOUN F
steps 0 NOUN F
above 0 CCONJ F
DFT++ 0 NOUN T
( 0 PUNCT F
typically 0 ADV F
4-6 0 NUM F
J 0 NOUN T
, 0 PUNCT F
maximum 0 NOUN F
10 0 NUM F
J 0 NOUN T
) 0 PUNCT F
with 0 ADP F
subsequent 0 ADJ F
shocks 0 PUNCT F
at 0 ADP F
maximum 0 NOUN F
energy 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
the 0 DET F
second 0 ADJ F
has 0 PUNCT F
all 0 PUNCT F
shocks 0 PUNCT F
programmed 0 ADP F
at 0 ADP F
maximum 0 NOUN F
energy 0 NOUN F
. 0 PUNCT F

Patients 0 NOUN T
are 0 VERB F
followed 0 VERB F
up 0 PUNCT F
every 0 DET F
3 0 NUM F
months 0 NOUN F
for 0 ADP F
2 0 NUM F
years 0 NOUN F
to 0 PART F
assess 0 NOUN F
shock B-PHYSICAL NOUN F
conversion I-PHYSICAL NOUN F
efficacy 0 NOUN F
of B-PHYSICAL ADP F
spontaneous I-PHYSICAL ADJ F
arrhythmias B-PHYSICAL NOUN F
. 0 PUNCT F

In 0 ADP T
a 0 DET F
subgroup 0 NOUN F
of 0 ADP F
patients 0 NOUN F
, 0 PUNCT F
there 0 PUNCT F
is 0 VERB F
a 0 DET F
second 0 ADJ F
randomization 0 NOUN F
to 0 ADP F
energy 0 NOUN F
levels 0 NOUN F
of 0 ADP F
0 0 NUM F
, 0 PUNCT F
1 0 NUM F
, 0 PUNCT F
2 0 NUM F
, 0 PUNCT F
3 0 NUM F
, 0 PUNCT F
or 0 CCONJ F
4 0 NUM F
steps 0 NOUN F
above 0 CCONJ F
implant 0 NOUN F
DFT++ 0 NOUN T
for 0 ADP F
conversion 0 NOUN F
testing 0 VERB F
of 0 ADP F
3 0 NUM F
induced 0 ADP F
ventricular 0 ADJ F
fibrillation 0 NOUN F
episodes 0 NOUN F
at 0 ADP F
prehospital 0 ADJ F
discharge 0 NOUN F
, 0 PUNCT F
3 0 NUM F
months 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
12 0 NUM F
months 0 NOUN F
after 0 ADP F
implant 0 NOUN F
. 0 PUNCT F

RESULTS 0 NOUN T
Enrollment 0 NOUN T
is 0 VERB F
complete 0 ADJ F
( 0 PUNCT F
702 0 NUM F
patients 0 NOUN F
) 0 PUNCT F
, 0 PUNCT F
but 0 CCONJ F
follow-up 0 NOUN F
results 0 CCONJ F
are 0 VERB F
pending 0 VERB F
. 0 PUNCT F

There 0 PUNCT T
were 0 VERB F
no 0 DET F
significant 0 ADJ F
variations 0 NOUN F
in 0 ADP F
implant B-PHYSICAL NOUN F
indications I-PHYSICAL NOUN F
and 0 CCONJ F
baseline 0 NOUN F
antiarrhythmic B-PHYSICAL ADJ F
drug I-PHYSICAL NOUN F
use I-PHYSICAL NOUN F
over 0 ADP F
the 0 DET F
3-year 0 NOUN F
enrollment 0 NOUN F
period 0 NOUN F
, 0 PUNCT F
although 0 ADP F
an 0 DET F
increase 0 NOUN F
in 0 ADP F
the 0 DET F
percentage 0 NOUN F
of 0 ADP F
dual-chamber B-PHYSICAL NOUN F
ICDs I-PHYSICAL NOUN T
implanted I-PHYSICAL VERB F
occurred 0 PROPN F
, 0 PUNCT F
with 0 ADP F
the 0 DET F
majority 0 NOUN F
( 0 PUNCT F
65 0 NUM F
% 0 SYM F
) 0 PUNCT F
of 0 ADP F
implanted 0 VERB F
ICDs 0 NOUN T
being 0 VERB F
dual-chamber 0 NOUN F
devices 0 ADP F
by 0 ADP F
the 0 DET F
end 0 NOUN F
of 0 ADP F
the 0 DET F
enrollment 0 NOUN F
period 0 NOUN F
. 0 PUNCT F

CONCLUSION 0 NOUN T
The 0 DET T
results 0 NOUN F
of 0 ADP F
LESS 0 PUNCT T
should 0 NOUN F
facilitate 0 VERB F
the 0 DET F
development 0 NOUN F
of 0 ADP F
algorithms 0 NOUN F
for 0 ADP F
programming 0 NUM F
ICD 0 PUNCT T

Using 0 VERB T
dietetic 0 ADJ F
assistants 0 ADP F
to 0 PART F
improve 0 ADJ F
the 0 DET F
outcome 0 NOUN F
of 0 ADP F
hip 0 NOUN F
fracture 0 NOUN F
: 0 PUNCT F
a 0 DET F
randomised 0 VERB F
controlled 0 VERB F
trial 0 NOUN F
of 0 ADP F
nutritional 0 ADJ F
support 0 NOUN F
in 0 ADP F
an 0 DET F
acute 0 ADJ F
trauma 0 NOUN F
ward 0 NOUN F
. 0 PUNCT F

OBJECTIVE 0 NOUN T
To 0 PROPN T
examine 0 NOUN F
how 0 ADP F
improved 0 DET F
attention 0 NOUN F
to 0 ADP F
nutritional B-PHYSICAL ADJ F
status I-PHYSICAL NOUN F
and 0 CCONJ F
dietary B-MENTAL ADJ F
intake I-MENTAL NOUN F
, 0 PUNCT F
achieved 0 VERB F
through 0 ADP F
the 0 DET F
employment 0 NOUN F
of 0 ADP F
dietetic 0 ADJ F
assistants 0 NOUN F
( 0 PUNCT F
DAs 0 NOUN T
) 0 PUNCT F
, 0 PUNCT F
will 0 VERB F
affect 0 VERB F
postoperative B-OTHER ADJ F
clinical I-OTHER ADJ F
outcome I-OTHER NOUN F
among 0 ADP F
elderly 0 ADJ F
women 0 NOUN F
with 0 ADP F
hip 0 NOUN F
fracture 0 NOUN F
. 0 PUNCT F

DESIGN 0 NOUN T
Open 0 PUNCT T
prospective 0 ADJ F
randomised 0 VERB F
controlled 0 VERB F
trial 0 NOUN F
, 0 PUNCT F
comparing 0 CCONJ F
conventional 0 ADJ F
nursing 0 ADJ F
care 0 NOUN F
with 0 ADP F
the 0 DET F
additional 0 ADJ F
nutritional 0 ADJ F
support 0 NOUN F
provided 0 VERB F
by 0 ADP F
DA 0 NOUN T
. 0 PUNCT F

SETTING 0 CCONJ T
Thirty-eight 0 PUNCT T
bedded 0 ADJ F
acute 0 ADJ F
trauma 0 NOUN F
ward 0 ADP F
in 0 ADP F
a 0 DET F
teaching 0 VERB F
hospital 0 NOUN F
. 0 PUNCT F

PARTICIPANTS 0 ADP T
All 0 PUNCT T
but 0 CCONJ F
11 0 NUM F
of 0 ADP F
344 0 NUM F
consecutive 0 ADJ F
admissions 0 NOUN F
with 0 ADP F
acute 0 ADJ F
nonpathological 0 ADJ F
hip 0 NOUN F
fracture 0 NOUN F
were 0 VERB F
approached 0 VERB F
. 0 PUNCT F

Three 0 NUM T
hundred 0 NUM F
and 0 CCONJ F
eighteen 0 ADV F
( 0 PUNCT F
93 0 NUM F
% 0 SYM F
) 0 PUNCT F
agreed 0 VERB F
to 0 ADP F
inclusion 0 NOUN F
. 0 PUNCT F

Sixteen 0 NUM T
were 0 VERB F
ineligible 0 ADJ F
as 0 PUNCT F
they 0 DET F
were 0 VERB F
immediately 0 ADV F
transferred 0 VERB F
to 0 ADP F
another 0 CCONJ F
acute 0 ADJ F
ward 0 NOUN F
, 0 PUNCT F
were 0 VERB F
managed 0 PROPN F
conservatively 0 ADV F
or 0 CCONJ F
died 0 VERB F
preoperatively 0 ADV F
. 0 PUNCT F

PRIMARY 0 ADJ T
OUTCOME 0 NOUN T
MEASURE 0 NOUN T
Postoperative B-MORTALITY ADJ T
mortality I-MORTALITY NOUN F
in 0 ADP F
the 0 DET F
acute 0 ADJ F
trauma 0 NOUN F
unit 0 NOUN F
. 0 PUNCT F

SECONDARY 0 ADJ T
OUTCOME 0 NOUN T
MEASURES 0 NOUN T
Postoperative B-MORTALITY PUNCT T
mortality I-MORTALITY NOUN F
at I-MORTALITY ADP F
4 I-MORTALITY NUM F
months I-MORTALITY NOUN F
after I-MORTALITY ADP F
fracture I-MORTALITY NOUN F
, 0 PUNCT F
length B-OTHER NOUN F
of I-OTHER ADP F
stay I-OTHER NOUN F
, 0 PUNCT F
energy B-MENTAL NOUN F
intake I-MENTAL NOUN F
and 0 CCONJ F
nutritional B-PHYSICAL ADJ F
status I-PHYSICAL NOUN F
. 0 PUNCT F

RESULTS 0 NOUN T
DA-supported 0 NOUN T
participants 0 NOUN F
were 0 VERB F
less 0 ADV F
likely B-MORTALITY ADJ F
to I-MORTALITY PART F
die I-MORTALITY ADP F
in 0 ADP F
the 0 DET F
acute 0 ADJ F
ward 0 ADJ F
( 0 PUNCT F
4.1 0 NUM F
versus 0 CCONJ F
10.1 0 NUM F
% 0 SYM F
, 0 PUNCT F
P 0 NOUN T
= 0 SYM F
0.048 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

This 0 DET T
effect 0 NOUN F
was 0 VERB F
still 0 ADV F
apparent 0 ADJ F
at 0 ADP F
4 0 NUM F
month 0 NOUN F
follow-up 0 NOUN F
( 0 PUNCT F
13.1 0 NUM F
versus 0 CCONJ F
22.9 0 NUM F
% 0 SYM F
, 0 PUNCT F
P 0 NOUN T
= 0 SYM F
0.036 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

DA-supported 0 VERB T
subjects 0 NOUN F
had 0 PUNCT F
significantly 0 ADV F
better 0 PUNCT F
mean 0 NOUN F
daily B-MENTAL ADJ F
energy I-MENTAL NOUN F
intake I-MENTAL NOUN F
( 0 PUNCT F
1,105 0 NUM F
kcal 0 ADJ F
versus 0 CCONJ F
756 0 NUM F
kcal/24 0 PUNCT F
h 0 NOUN F
, 0 PUNCT F
95 0 NUM F
% 0 SYM F
CI 0 NOUN T
259-440 0 NUM F
kcal/24 0 PUNCT F
h 0 NOUN F
, 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.001 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
significantly 0 ADV F
smaller 0 PUNCT F
reduction 0 NOUN F
in 0 ADP F
mid-arm 0 NOUN F
circumference 0 NOUN F
during 0 ADP F
their 0 PUNCT F
inpatient 0 NOUN F
stay 0 NOUN F
( 0 PUNCT F
0.39 0 ADP F
cm 0 NOUN F
, 0 PUNCT F
P 0 NOUN T
= 0 SYM F
0.002 0 NUM F
) 0 PUNCT F
and 0 CCONJ F
nonsignificantly 0 ADV F
favourable 0 ADJ F
results 0 CCONJ F
for 0 ADP F
other 0 ADJ F
anthropometric B-OTHER ADJ F
and 0 CCONJ F
laboratory B-OTHER NOUN F
measurements I-OTHER NOUN F
. 0 PUNCT F

CONCLUSION 0 NOUN T
Dietetic 0 ADJ T
or 0 CCONJ F
nutrition 0 NOUN F
assistants 0 NOUN F
are 0 VERB F
being 0 VERB F
introduced 0 VERB F
in 0 ADP F
units 0 NOUN F
across 0 ADP F
the 0 DET F
UK 0 NOUN T
. 0 PUNCT F

This 0 PUNCT T
, 0 PUNCT F
the 0 DET F
largest 0 VERB F
ever 0 PUNCT F
study 0 NOUN F
of 0 ADP F
nutritional 0 ADJ F
support 0 NOUN F
after 0 ADP F
hip 0 NOUN F
fracture 0 NOUN F
, 0 PUNCT F
shows 0 NOUN F
that 0 ADP F
their 0 PUNCT F
employment 0 ADJ F
significantly 0 ADV F
reduced 0 VERB F
patients B-MORTALITY NOUN F
' 0 PUNCT F
risk 0 PUNCT F

Zinc B-PHYSICAL NOUN T
and 0 CCONJ F
copper B-PHYSICAL NOUN F
balances I-PHYSICAL NOUN F
in 0 ADP F
preterm 0 NOUN F
infants 0 NOUN F
. 0 PUNCT F

Preterm 0 NOUN T
infants 0 NOUN F
are 0 VERB F
at 0 ADP F
risk 0 NOUN F
for 0 ADP F
copper 0 NOUN F
and 0 CCONJ F
zinc 0 NOUN F
depletion 0 NOUN F
if 0 ADP F
sufficient 0 ADJ F
quantities 0 NOUN F
of 0 ADP F
these 0 DET F
nutrients 0 NOUN F
are 0 VERB F
not 0 ADV F
provided 0 VERB F
in 0 ADP F
a 0 DET F
bioavailable 0 ADJ F
form 0 NOUN F
in 0 ADP F
postnatal 0 ADJ F
life 0 NOUN F
. 0 PUNCT F

The 0 DET T
purpose 0 NOUN F
of 0 ADP F
this 0 DET F
study 0 NOUN F
was 0 VERB F
to 0 PART F
determine 0 NOUN F
whether 0 ADP F
the 0 DET F
use 0 NOUN F
of 0 ADP F
a 0 DET F
whey-predominant 0 ADJ F
, 0 PUNCT F
50 0 NUM F
% 0 DET F
medium 0 ADJ F
chain 0 NOUN F
triglyceride 0 NOUN F
formula 0 NOUN F
with 0 ADP F
relatively 0 ADV F
high 0 ADJ F
concentrations 0 NOUN F
of 0 ADP F
zinc 0 NOUN F
and 0 CCONJ F
copper 0 NOUN F
would 0 VERB F
promote 0 VERB F
the 0 DET F
achievement 0 NOUN F
of 0 ADP F
the 0 DET F
in 0 PUNCT F
utero B-PHYSICAL NOUN F
accretion I-PHYSICAL NOUN F
rate I-PHYSICAL NOUN F
for I-PHYSICAL ADP F
zinc I-PHYSICAL NOUN F
and I-PHYSICAL CCONJ F
copper I-PHYSICAL NOUN F
in 0 ADP F
the 0 DET F
preterm 0 NOUN F
infant 0 NOUN F
. 0 PUNCT F

Two 0 NUM T
groups 0 NOUN F
of 0 ADP F
five 0 NUM F
preterm 0 NOUN F
infants 0 NOUN F
were 0 VERB F
fed 0 VERB F
a 0 DET F
diet 0 NOUN F
containing 0 VERB F
12.5 0 NUM F
mg/L 0 NOUN F
of 0 ADP F
zinc 0 NOUN F
and 0 CCONJ F
either 0 CCONJ F
0.9 0 NUM F
mg/L 0 NOUN F
or 0 CCONJ F
2.1 0 NUM F
mg/L 0 NOUN F
of 0 ADP F
copper 0 NOUN F
. 0 PUNCT F

Seventy-two-hour 0 NUM T
metabolic 0 ADJ F
balance 0 NOUN F
studies 0 NOUN F
were 0 VERB F
performed 0 VERB F
at 0 ADP F
an 0 DET F
average 0 ADJ F
postconceptual 0 ADJ F
age 0 NOUN F
of 0 ADP F
34 0 NUM F
weeks 0 NOUN F
and 0 CCONJ F
an 0 DET F
average 0 ADJ F
weight 0 NOUN F
of 0 ADP F
1,549 0 NUM F
g. 0 PUNCT F
All 0 PUNCT T
infants 0 NOUN F
were 0 VERB F
in 0 ADP F
positive 0 ADJ F
zinc B-PHYSICAL NOUN F
balance I-PHYSICAL NOUN F
and 0 CCONJ F
nine 0 NUM F
of 0 ADP F
ten 0 NUM F
achieved 0 VERB F
the 0 DET F
in 0 PUNCT F
utero B-PHYSICAL NOUN F
accretion I-PHYSICAL NOUN F
rate I-PHYSICAL NOUN F
for I-PHYSICAL ADP F
zinc I-PHYSICAL NOUN F
for 0 ADP F
a 0 DET F
34-week 0 NOUN F
gestation 0 NOUN F
fetus 0 NOUN F
( 0 PUNCT F
greater 0 PUNCT F
than 0 VERB F
or 0 CCONJ F
equal 0 ADJ F
to 0 ADP F
0.432 0 NUM F
mg/d 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

Three 0 NUM T
infants 0 NOUN F
receiving 0 DET F
the 0 DET F
high 0 ADJ F
copper 0 NOUN F
formula 0 NOUN F
and 0 CCONJ F
two 0 NUM F
receiving 0 VERB F
the 0 DET F
lower 0 PUNCT F
copper 0 NOUN F
formula 0 NOUN F
were 0 VERB F
in 0 ADP F
positive 0 ADJ F
copper B-PHYSICAL NOUN F
balance I-PHYSICAL NOUN F
. 0 PUNCT F

Two 0 NUM T
infants 0 NOUN F
from 0 ADP F
each 0 DET F
group 0 NOUN F
achieved 0 VERB F
the 0 DET F
in 0 PUNCT F
utero B-PHYSICAL NOUN F
accretion I-PHYSICAL NOUN F
rate I-PHYSICAL NOUN F
for I-PHYSICAL ADP F
copper I-PHYSICAL NOUN F
for 0 ADP F
a 0 DET F
34-week 0 NOUN F
gestation 0 NOUN F
fetus 0 NOUN F
( 0 PUNCT F
0.088 0 NUM F
mg/d 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

A 0 DET T
formula 0 NOUN F
that 0 ADP F
provides 0 NOUN F
12.5 0 NUM F
mg/L 0 NOUN F
of 0 ADP F
zinc 0 NOUN F
permits 0 ADJ F
positive 0 ADJ F
zinc B-PHYSICAL NOUN F
balance I-PHYSICAL NOUN F
and 0 CCONJ F
zinc B-PHYSICAL NOUN F
retention I-PHYSICAL NOUN F
similar 0 ADJ F
to 0 ADP F
in 0 ADP F
utero 0 ADP F
rates 0 NOUN F
. 0 PUNCT F

A 0 DET T
formula 0 NOUN F
that 0 ADP F
provides 0 NOUN F
as 0 PUNCT F
much 0 PUNCT F
as 0 PUNCT F
2.1 0 NUM F
mg/L 0 NOUN F
of 0 ADP F
copper 0 NOUN F
, 0 PUNCT F
however 0 ADV F
, 0 PUNCT F
may 0 ADP F
not 0 ADV F
always 0 ADV F
permit 0 VERB F
positive 0 ADJ F
copper B-PHYSICAL NOUN F
balance I-PHYSICAL NOUN F
. 0 PUNCT F

Oxidative 0 ADJ T
DNA 0 NOUN T
damage 0 NOUN F
measured 0 PRON F
in 0 ADP F
human 0 NOUN F
lymphocytes 0 NOUN F
: 0 PUNCT F
large 0 ADJ F
differences 0 NOUN F
between 0 DET F
sexes 0 NOUN F
and 0 CCONJ F
between 0 ADP F
countries 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
correlations 0 ADP F
with 0 ADP F
heart 0 NOUN F
disease 0 NOUN F
mortality 0 NOUN F
rates 0 NOUN F
. 0 PUNCT F

The 0 DET T
'antioxidant 0 PUNCT F
hypothesis 0 NOUN F
' 0 PUNCT F
proposes 0 PUNCT F
that 0 ADP F
vitamin 0 NOUN F
C 0 NOUN T
, 0 PUNCT F
vitamin 0 NOUN F
E 0 NOUN T
, 0 PUNCT F
carotenoids 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
other 0 ADJ F
antioxidants 0 NOUN F
occurring 0 VERB F
in 0 ADP F
fruit 0 ADJ F
and 0 CCONJ F
vegetables 0 VERB F
afford 0 NOUN F
protection 0 NOUN F
against 0 ADP F
heart 0 NOUN F
disease 0 NOUN F
and 0 CCONJ F
cancer 0 NOUN F
by 0 ADP F
preventing 0 VERB F
oxidative 0 ADJ F
damage 0 NOUN F
to 0 ADP F
lipids 0 NOUN F
and 0 CCONJ F
to 0 ADP F
DNA 0 NOUN T
, 0 PUNCT F
respectively 0 ADV F
. 0 PUNCT F

To 0 PART T
test 0 ADP F
elements 0 NOUN F
of 0 ADP F
this 0 DET F
hypothesis 0 NOUN F
, 0 PUNCT F
we 0 PRON F
have 0 VERB F
measured 0 VERB F
blood 0 NOUN F
levels 0 NOUN F
of 0 ADP F
dietary 0 ADJ F
antioxidants 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
8-oxodeoxyguanosine 0 NOUN F
( 0 PUNCT F
8-oxo-dG 0 ADV F
) 0 PUNCT F
concentrations 0 NOUN F
in 0 ADP F
lymphocyte 0 NOUN F
DNA 0 NOUN T
, 0 PUNCT F
in 0 ADP F
healthy 0 ADJ F
men 0 NOUN F
and 0 CCONJ F
women 0 NOUN F
from 0 ADP F
five 0 NUM F
European 0 NOUN T
countries 0 NOUN F
: 0 PUNCT F
France 0 NOUN T
, 0 PUNCT F
Ireland 0 PUNCT T
, 0 PUNCT F
The 0 DET T
Netherlands 0 NOUN T
, 0 PUNCT F
Spain 0 PUNCT T
, 0 PUNCT F
and 0 CCONJ F
the 0 DET F
U.K 0 NOUN T
. 0 PUNCT F

Volunteers 0 NOUN T
, 0 PUNCT F
aged 0 PUNCT F
25 0 NUM F
45 0 NUM F
, 0 PUNCT F
all 0 DET F
nonsmokers 0 NOUN F
, 0 PUNCT F
gave 0 VERB F
blood 0 NOUN F
samples 0 NOUN F
before 0 ADP F
and 0 CCONJ F
after 0 ADP F
a 0 DET F
12-wk 0 PUNCT F
carotenoid 0 NOUN F
supplementation 0 NOUN F
regime 0 NOUN F
. 0 PUNCT F

Vitamin 0 NOUN T
C 0 NOUN T
was 0 VERB F
measured 0 VERB F
in 0 ADP F
plasma 0 NOUN F
and 0 CCONJ F
vitamin 0 NOUN F
E 0 NOUN T
and 0 CCONJ F
carotenoids 0 NOUN F
were 0 VERB F
measured 0 VERB F
in 0 ADP F
serum 0 NOUN F
by 0 ADP F
high-performance 0 NOUN F
liquid 0 NOUN F
chromatography 0 NOUN F
( 0 PUNCT F
HPLC 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

8-oxo-dG 0 ADV F
was 0 ADP F
assayed 0 VERB F
by 0 ADP F
HPLC 0 NOUN T
( 0 PUNCT F
with 0 ADP F
coulometric 0 ADJ F
detection 0 NOUN F
) 0 PUNCT F
in 0 ADP F
DNA 0 NOUN T
isolated 0 VERB F
from 0 ADP F
lymphocytes 0 NOUN F
from 0 ADP F
the 0 DET F
same 0 ADJ F
blood 0 NOUN F
samples 0 NOUN F
. 0 PUNCT F

Mean 0 ADJ T
values 0 NOUN F
were 0 VERB F
calculated 0 VERB F
for 0 ADP F
groups 0 NOUN F
of 0 ADP F
volunteers 0 NOUN F
at 0 ADP F
each 0 DET F
sampling 0 VERB F
time 0 NOUN F
according 0 CCONJ F
to 0 ADP F
country 0 NOUN F
, 0 PUNCT F
sex 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
supplementation 0 NOUN F
( 0 PUNCT F
between 0 ADP F
9 0 NUM F
and 0 CCONJ F
24 0 NUM F
individual 0 ADJ F
samples 0 NOUN F
contributing 0 VERB F
to 0 ADP F
each 0 DET F
mean 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

We 0 PRON T
found 0 VERB F
that 0 ADP F
8-oxo-dG 0 ADV F
levels 0 NOUN F
in 0 ADP F
lymphocyte 0 NOUN F
DNA 0 NOUN T
vary 0 VERB F
significantly 0 ADV F
according 0 PUNCT F
to 0 ADP F
sex 0 NOUN F
and 0 CCONJ F
country 0 NOUN F
. 0 PUNCT F

A 0 DET T
low 0 ADJ F
mean 0 NOUN F
8-oxo-dG B-PHYSICAL NUM F
concentration I-PHYSICAL NOUN F
is 0 ADJ F
seen 0 VERB F
in 0 ADP F
DNA 0 NOUN T
of 0 ADP F
women 0 NOUN F
from 0 ADP F
all 0 DET F
five 0 NUM F
countries 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
of 0 ADP F
men 0 NOUN F
from 0 ADP F
France 0 NOUN T
and 0 CCONJ F
Spain 0 PUNCT T
. 0 PUNCT F

8-oxo-dG B-PHYSICAL ADV F
is 0 VERB F
significantly 0 ADV F
higher 0 PUNCT F
( 0 PUNCT F
up 0 PUNCT F
to 0 CCONJ F
about 0 PUNCT F
threefold 0 NOUN F
) 0 PUNCT F
in 0 ADP F
lymphocyte 0 NOUN F
DNA 0 NOUN T
from 0 ADP F
men 0 NOUN F
in 0 ADP F
Ireland 0 PUNCT T
and 0 CCONJ F
the 0 DET F
U.K. 0 PUNCT T
Oxidative B-PHYSICAL ADJ T
DNA I-PHYSICAL NOUN T
damage I-PHYSICAL NOUN F
is 0 VERB F
not 0 ADV F
significantly 0 ADV F
affected 0 VERB F
by 0 ADP F
carotenoid 0 NOUN F
supplementation 0 NOUN F
; 0 PUNCT F
nor 0 CCONJ F
is 0 VERB F
there 0 PUNCT F
any 0 DET F
association 0 NOUN F
with 0 ADP F
mean 0 NOUN F
baseline 0 NOUN F
levels B-PHYSICAL NOUN F
of I-PHYSICAL ADP F
antioxidants I-PHYSICAL NOUN F
, 0 PUNCT F
which 0 ADP F
are 0 VERB F
generally 0 ADV F
similar 0 ADJ F
in 0 ADP F
the 0 DET F
five 0 NUM F
countries 0 NOUN F
. 0 PUNCT F

The 0 DET T
five 0 NUM F
countries 0 NOUN F
sampled 0 VERB F
lie 0 PUNCT F
on 0 ADP F
an 0 DET F
axis 0 NOUN F
from 0 ADP F
northern 0 NOUN F
to 0 ADP F
southern 0 PUNCT F
Europe 0 PUNCT T
with 0 ADP F
a 0 DET F
steep 0 ADJ F
gradient 0 NOUN F
in 0 ADP F
terms 0 NOUN F
of 0 ADP F
premature 0 ADJ F
heart 0 NOUN F
disease 0 NOUN F
. 0 PUNCT F

There 0 PUNCT T
is 0 VERB F
a 0 DET F
strong 0 ADJ F
association 0 NOUN F
between 0 ADP F
premature B-MORTALITY ADJ F
coronary I-MORTALITY ADJ F
heart I-MORTALITY NOUN F
disease I-MORTALITY NOUN F
mortality I-MORTALITY NOUN F
in 0 ADP F
men 0 NOUN F
and 0 CCONJ F
the 0 DET F
mean 0 NOUN F
levels 0 NOUN F
of 0 ADP F
8-oxo-dG 0 ADV F
for 0 ADP F
the 0 DET F
five 0 NUM F
countries 0 NOUN F
( 0 PUNCT F
r 0 NOUN F
= 0 SYM F
0.95 0 NUM F
, 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.01 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Women 0 NOUN T
have 0 PUNCT F
low 0 ADJ F
coronary B-MORTALITY ADJ F
heart I-MORTALITY NOUN F
disease I-MORTALITY NOUN F
mortality I-MORTALITY NOUN F
rates I-MORTALITY NOUN F
, 0 PUNCT F
which 0 ADP F
do 0 PUNCT F
not 0 ADV F
correlate 0 PUNCT F
with 0 ADP F
8-oxo-dG 0 ADV F
. 0 PUNCT F

In 0 ADP T
terms 0 NOUN F
of 0 ADP F
cancer 0 NOUN F
deaths 0 NOUN F
, 0 PUNCT F
only 0 ADV F
colorectal 0 ADJ F
cancer 0 NOUN F
in 0 ADP F
men 0 NOUN F
shows 0 ADJ F
a 0 DET F
significant B-OTHER ADJ F
positive 0 ADJ F
correlation B-OTHER NOUN F
( 0 PUNCT F
r 0 NOUN F
= 0 SYM F
0.91 0 NUM F
, 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.05 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
and 0 PUNCT F

[ 0 PUNCT F
Local 0 ADJ T
application 0 NOUN F
of 0 ADP F
anti-cancer 0 NOUN F
drugs 0 NOUN F
for 0 ADP F
the 0 DET F
treatment 0 NOUN F
of 0 ADP F
malignant 0 ADJ F
pleural 0 ADP F
and 0 CCONJ F
pericardial 0 ADJ F
effusion 0 NOUN F
] 0 PUNCT F
. 0 PUNCT F

Pleural 0 ADJ T
effusion 0 NOUN F
is 0 VERB F
a 0 DET F
common 0 ADJ F
complication 0 NOUN F
in 0 ADP F
patients 0 NOUN F
with 0 ADP F
malignant 0 ADJ F
neoplasm 0 NOUN F
. 0 PUNCT F

A 0 DET T
randomized 0 VERB F
controlled 0 DET F
study 0 NOUN F
of 0 ADP F
intrapleural 0 PUNCT F
instillation 0 NOUN F
of 0 ADP F
Adriamycin 0 NOUN T
( 0 PUNCT F
control 0 NOUN F
group 0 NOUN F
, 0 PUNCT F
30 0 NUM F
patients 0 NOUN F
) 0 PUNCT F
and 0 CCONJ F
Adriamycin 0 NOUN T
Nocardia 0 PUNCT T
rubra 0 NOUN F
cell 0 NOUN F
wall 0 NOUN F
skeleton 0 NOUN F
( 0 PUNCT F
N-CWS 0 NOUN T
group 0 NOUN F
, 0 PUNCT F
26 0 NUM F
patients 0 NOUN F
) 0 PUNCT F
with 0 ADP F
tube 0 NOUN F
thoracostomy 0 NOUN F
was 0 VERB F
performed 0 VERB F
in 0 ADP F
55 0 NUM F
patients 0 NOUN F
with 0 ADP F
malignant 0 ADJ F
pleural 0 ADJ F
effusion 0 NOUN F
due 0 VERB F
to 0 ADP F
primary 0 ADJ F
lung 0 NOUN F
cancer 0 NOUN F
. 0 PUNCT F

The 0 DET T
response 0 NOUN F
rates 0 NOUN F
for 0 ADP F
control 0 NOUN F
of 0 ADP F
pleural B-PHYSICAL ADJ F
effusion I-PHYSICAL NOUN F
were 0 VERB F
73.4 0 NUM F
% 0 SYM F
in 0 ADP F
the 0 DET F
N-CWS 0 NOUN T
group 0 NOUN F
and 0 CCONJ F
46.1 0 NUM F
% 0 SYM F
in 0 ADP F
the 0 DET F
N-CWS 0 NOUN T
group 0 NOUN F
. 0 PUNCT F

These 0 DET T
results 0 CCONJ F
suggest 0 VERB F
that 0 ADP F
intrapleural 0 PUNCT F
instillation 0 NOUN F
using 0 VERB F
a 0 DET F
combination 0 NOUN F
of 0 ADP F
anti-cancer 0 NOUN F
agent 0 NOUN F
and 0 CCONJ F
immunopotentiator 0 NOUN F
is 0 VERB F
an 0 DET F
effective 0 ADJ F
treatment 0 NOUN F
for 0 ADP F
malignant 0 ADJ F
pleurisy 0 NOUN F
. 0 PUNCT F

Cardiac 0 ADJ T
tamponade 0 NOUN F
secondary 0 ADJ F
to 0 ADP F
cancer 0 NOUN F
is 0 VERB F
a 0 DET F
life-threatening 0 VERB F
complication 0 NOUN F
requiring 0 VERB F
immediate 0 ADJ F
treatment 0 NOUN F
. 0 PUNCT F

Twenty-four 0 PUNCT T
patients 0 NOUN F
with 0 ADP F
malignant 0 ADJ F
pericardial 0 ADJ F
effusion 0 NOUN F
were 0 VERB F
treated 0 VERB F
by 0 ADP F
intrapericardial 0 ADJ F
instillation 0 NOUN F
of 0 ADP F
anti-cancer 0 NOUN F
drugs 0 NOUN F
, 0 PUNCT F
such 0 PUNCT F
as 0 ADP F
Carbazilquinone 0 NOUN T
, 0 PUNCT F
Mitomycin-C 0 NOUN T
or 0 CCONJ F
ACNU 0 NOUN T
, 0 PUNCT F
with 0 ADP F
pericardial 0 ADJ F
drainage 0 NOUN F
. 0 PUNCT F

The 0 DET T
range 0 NOUN F
of 0 ADP F
survival B-MORTALITY NOUN F
time I-MORTALITY NOUN F
from 0 ADP F
the 0 DET F
instillation 0 NOUN F
of 0 ADP F
anti-cancer 0 NOUN F
drug 0 NOUN F
was 0 VERB F
3-365 0 NUM F
days 0 NOUN F
( 0 PUNCT F
average 0 ADJ F
days 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

In 0 ADP T
only 0 ADV F
4 0 NUM F
patients 0 NOUN F
, 0 PUNCT F
reaccumulation 0 NOUN F
of 0 ADP F
pericardial B-PHYSICAL ADJ F
effusion I-PHYSICAL NOUN F
was 0 VERB F
recognized 0 VERB F
. 0 PUNCT F

There 0 PUNCT T
were 0 VERB F
no 0 DET F
serious 0 ADJ F
complications 0 NOUN F
with 0 ADP F
this 0 DET F
procedure 0 NOUN F
. 0 PUNCT F

It 0 PRON T
was 0 VERB F
considered 0 VERB F
that 0 VERB F
local 0 ADJ F
instillation 0 NOUN F
of 0 ADP F
anti-cancer 0 NOUN F
agents 0 NOUN F
with 0 ADP F
pericardial 0 ADJ F
drainage 0 NOUN F
was 0 VERB F
a 0 DET F
useful 0 ADJ F
therapeutic 0 ADJ F
modality 0 NOUN F
for 0 ADP F
malignant 0 ADJ F
pericarditis 0 NOUN F
. 0 PUNCT F

Pregabalin 0 NOUN T
versus 0 CCONJ F
naltrexone 0 NUM F
in 0 ADP F
alcohol 0 NOUN F
dependence 0 NOUN F
: 0 PUNCT F
a 0 DET F
randomised 0 VERB F
, 0 PUNCT F
double-blind 0 ADJ F
, 0 PUNCT F
comparison 0 NOUN F
trial 0 NOUN F
. 0 PUNCT F

Pregabalin 0 NOUN T
( 0 PUNCT F
PRE 0 NOUN T
) 0 PUNCT F
acts 0 NOUN F
as 0 ADP F
a 0 DET F
presynaptic 0 ADJ F
inhibitor 0 NOUN F
of 0 ADP F
the 0 DET F
release 0 NOUN F
of 0 ADP F
excessive 0 ADJ F
levels 0 NOUN F
of 0 ADP F
excitatory 0 ADJ F
neurotransmitters 0 NOUN F
by 0 ADP F
selectively 0 PRON F
binding 0 VERB F
to 0 ADP F
the 0 DET F
alpha 0 NOUN F
( 0 PUNCT F
2 0 NUM F
) 0 PUNCT F
-delta 0 NOUN F
subunit 0 NOUN F
of 0 ADP F
voltage-gated 0 DET F
calcium 0 NOUN F
channels 0 NOUN F
. 0 PUNCT F

In 0 ADP T
this 0 DET F
randomised 0 VERB F
, 0 PUNCT F
double-blind 0 ADJ F
comparison 0 NOUN F
trial 0 NOUN F
with 0 ADP F
naltrexone 0 NUM F
( 0 PUNCT F
NAL 0 NOUN T
) 0 PUNCT F
, 0 PUNCT F
we 0 PROPN F
aimed 0 VERB F
to 0 PART F
investigate 0 NOUN F
the 0 DET F
efficacy 0 NOUN F
of 0 ADP F
PRE 0 NOUN T
on 0 ADP F
alcohol B-MENTAL NOUN F
drinking I-MENTAL PROPN F
indices I-MENTAL NOUN F
. 0 PUNCT F

Craving B-MENTAL PUNCT T
reduction I-MENTAL NOUN F
and 0 CCONJ F
improvement 0 NOUN F
of 0 ADP F
psychiatric B-MENTAL ADJ F
symptoms I-MENTAL NOUN F
were 0 VERB F
the 0 DET F
secondary 0 ADJ F
endpoints 0 NOUN F
. 0 PUNCT F

Seventy-one 0 NUM T
alcohol-dependent 0 ADJ F
subjects 0 NOUN F
were 0 VERB F
detoxified 0 PUNCT F
and 0 CCONJ F
subsequently 0 ADV F
randomised 0 PUNCT F
into 0 ADP F
two 0 NUM F
groups 0 NOUN F
, 0 PUNCT F
receiving 0 VERB F
50 0 NUM F
mg 0 NOUN F
of 0 ADP F
NAL 0 NOUN T
or 0 CCONJ F
150-450 0 NUM F
mg 0 NOUN F
of 0 ADP F
PRE 0 NOUN T
. 0 PUNCT F

Craving B-MENTAL PUNCT T
( I-MENTAL PUNCT F
VAS 0 NOUN T
; 0 PUNCT F
OCDS B-MENTAL NUM T
) I-MENTAL PUNCT F
, 0 PUNCT F
withdrawal B-OTHER NOUN F
( B-OTHER PUNCT F
CIWA-Ar I-OTHER NOUN T
) I-OTHER PUNCT F
and 0 CCONJ F
psychiatric B-MENTAL ADJ F
symptoms I-MENTAL NOUN F
( B-MENTAL PUNCT F
SCL-90-R I-MENTAL NOUN T
) I-MENTAL PUNCT F
rating B-MENTAL ADP F
scales 0 NOUN F
were 0 VERB F
applied 0 VERB F
. 0 PUNCT F

Alcohol B-MENTAL NOUN T
drinking B-MENTAL PROPN F
indices B-MENTAL NOUN F
and 0 CCONJ F
craving B-MENTAL ADP F
scores I-MENTAL NOUN F
were 0 VERB F
not 0 ADV F
significantly 0 ADV F
different 0 ADJ F
between 0 ADP F
groups 0 NOUN F
. 0 PUNCT F

Compared 0 VERB T
with 0 ADP F
NAL 0 NOUN T
, 0 PUNCT F
PRE 0 NOUN T
resulted 0 VERB F
in 0 ADP F
greater 0 PUNCT F
improvement 0 NOUN F
of 0 ADP F
specific 0 ADJ F
symptoms 0 NOUN F
in 0 ADP F
the 0 DET F
areas 0 NOUN F
of 0 ADP F
anxiety B-MENTAL NOUN F
, 0 PUNCT F

Ceftriaxone 0 NOUN T
versus 0 CCONJ F
ampicillin 0 NOUN F
and 0 CCONJ F
chloramphenicol 0 NOUN F
for 0 ADP F
treatment 0 NOUN F
of 0 ADP F
bacterial B-PHYSICAL ADJ F
meningitis I-PHYSICAL NOUN F
in 0 ADP F
children 0 NOUN F
. 0 PUNCT F

78 0 DET F
patients 0 NOUN F
with 0 ADP F
bacterial 0 ADJ F
meningitis 0 NOUN F
were 0 VERB F
evaluated 0 VERB F
in 0 ADP F
a 0 DET F
prospective 0 ADJ F
, 0 PUNCT F
randomised 0 ADP F
study 0 NOUN F
comparing 0 ADV F
twice-daily 0 PUNCT F
ceftriaxone 0 NOUN F
as 0 PUNCT F
single-drug 0 NOUN F
therapy 0 NOUN F
with 0 ADP F
ampicillin 0 NOUN F
and 0 CCONJ F
chloramphenicol 0 NOUN F
given 0 ADP F
every 0 ADP F
6 0 NUM F
h. 0 NOUN F
The 0 DET T
groups 0 NOUN F
were 0 VERB F
comparable 0 ADJ F
in 0 ADP F
age 0 NOUN F
, 0 PUNCT F
sex 0 NOUN F
, 0 PUNCT F
days 0 NOUN F
of 0 ADP F
illness 0 NOUN F
before 0 ADP F
admission 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
bacterial 0 ADJ F
colony 0 NOUN F
counts 0 NOUN F
in 0 ADP F
cerebrospinal 0 ADJ F
fluid 0 NOUN F
( 0 PUNCT F
CSF 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
pathogens 0 NOUN F
were 0 VERB F
Haemophilus 0 NOUN T
influenzae 0 PUNCT F
type 0 NOUN F
b 0 NOUN F
( 0 PUNCT F
54 0 NUM F
cases 0 NOUN F
) 0 PUNCT F
, 0 PUNCT F
streptococci 0 ADJ F
( 0 PUNCT F
9 0 NUM F
cases 0 NOUN F
) 0 PUNCT F
, 0 PUNCT F
meningococci 0 PUNCT F
( 0 PUNCT F
9 0 NUM F
cases 0 NOUN F
) 0 PUNCT F
, 0 PUNCT F
and 0 CCONJ F
unknown 0 VERB F
( 0 PUNCT F
6 0 NUM F
cases 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

In 0 ADP T
40 0 NUM F
CSF 0 NOUN T
specimens 0 NOUN F
obtained 0 VERB F
4-12 0 NUM F
h 0 NOUN F
after 0 ADP F
initiation 0 NOUN F
of 0 ADP F
therapy 0 NOUN F
, 0 PUNCT F
cultures B-OTHER NOUN F
were I-OTHER VERB F
negative 0 ADJ F
in 0 ADP F
57 0 NUM F
% 0 SYM F
of 0 ADP F
the 0 DET F
ceftriaxone 0 NOUN F
patients 0 NOUN F
and 0 CCONJ F
in 0 ADP F
42 0 NUM F
% 0 SYM F
of 0 ADP F
the 0 DET F
others 0 NOUN F
. 0 PUNCT F

The 0 DET T
mean 0 NOUN F
falls B-OTHER CCONJ F
in I-OTHER ADP F
the I-OTHER DET F
CSF I-OTHER NOUN T
bacterial I-OTHER ADJ F
colony I-OTHER NOUN F
counts I-OTHER NOUN F
were 0 VERB F
4.7 0 NUM F
and 0 CCONJ F
5.0 0 NUM F
log10 0 NOUN F
colony-forming 0 VERB F
units/ml 0 ADV F
, 0 PUNCT F
respectively 0 ADV F
. 0 PUNCT F

Mean 0 ADJ T
bactericidal B-PHYSICAL ADJ F
activity I-PHYSICAL NOUN F
in I-PHYSICAL ADP F
CSF I-PHYSICAL NOUN T
was 0 VERB F
significantly 0 ADV F
greater 0 PUNCT F
in 0 ADP F
the 0 DET F
ceftriaxone 0 NOUN F
than 0 PUNCT F
in 0 ADP F
the 0 DET F
conventional 0 ADJ F
treatment 0 NOUN F
group 0 NOUN F
at 0 ADP F
the 0 DET F
beginning 0 PUNCT F
and 0 CCONJ F
end 0 NOUN F
of 0 ADP F
therapy 0 NOUN F
. 0 PUNCT F

There 0 PUNCT T
were 0 VERB F
no 0 DET F
significant 0 ADJ F
differences 0 NOUN F
in 0 ADP F
clinical B-PHYSICAL ADJ F
responses I-PHYSICAL NOUN F
or 0 CCONJ F
in 0 ADP F
frequency 0 NOUN F
of 0 ADP F
complications B-ADVERSE-EFFECTS NOUN F
, 0 PUNCT F
except 0 PUNCT F
for 0 ADP F
mild B-PHYSICAL ADJ F
diarrhoea I-PHYSICAL NOUN F
, 0 PUNCT F
which 0 ADP F
occurred 0 VERB F
in 0 ADP F
16 0 NUM F
ceftriaxone 0 NOUN F
patients 0 NOUN F
and 0 CCONJ F
in 0 ADP F
8 0 NUM F
in 0 ADP F
the 0 DET F
other 0 ADJ F
group 0 NOUN F
( 0 PUNCT F
p 0 NOUN F
less 0 ADV F
than 0 PUNCT F
0.05 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Efficacy 0 NOUN T
of 0 ADP F
dose-intensified 0 VERB F
MEC 0 NOUN T
( 0 PUNCT F
methotrexate 0 NOUN F
, 0 PUNCT F
epirubicin 0 NOUN F
and 0 CCONJ F
cisplatin 0 NOUN F
) 0 PUNCT F
chemotherapy 0 NOUN F
for 0 ADP F
advanced 0 VERB F
urothelial 0 ADJ F
carcinoma 0 NOUN F
: 0 PUNCT F
a 0 DET F
prospective 0 ADJ F
randomized 0 VERB F
trial 0 NOUN F
comparing 0 VERB F
MEC 0 NOUN T
and 0 CCONJ F
M-VAC 0 NOUN T
( 0 PUNCT F
methotrexate 0 NOUN F
, 0 PUNCT F
vinblastine 0 NOUN F
, 0 PUNCT F
doxorubicin 0 NOUN F
and 0 CCONJ F
cisplatin 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

Japanese 0 ADJ T
Urothelial 0 ADJ T
Cancer 0 NOUN T
Research 0 NOUN T
Group 0 NOUN T
. 0 PUNCT F

BACKGROUND 0 NOUN T
To 0 ADV T
evaluate 0 NOUN F
the 0 DET F
antitumor B-OTHER NOUN F
activity I-OTHER NOUN F
in 0 ADP F
patients 0 NOUN F
with 0 ADP F
T3b 0 PUNCT T
, 0 PUNCT F
T4 0 NOUN T
or 0 CCONJ F
metastatic 0 ADJ F
urothelial 0 ADJ F
carcinoma 0 NOUN F
treated 0 VERB F
with 0 ADP F
MEC 0 NOUN T
or 0 CCONJ F
M-VAC 0 NOUN T
chemotherapy 0 NOUN F
, 0 PUNCT F
by 0 ADP F
performing 0 ADP F
a 0 DET F
multi-center 0 NOUN F
randomized 0 VERB F
prospective 0 ADJ F
study 0 NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
From 0 ADP T
1991 0 NUM F
to 0 ADP F
1995 0 NUM F
, 0 PUNCT F
89 0 NUM F
patients 0 NOUN F
with 0 ADP F
T3b 0 PUNCT T
, 0 PUNCT F
T4 0 NOUN T
or 0 CCONJ F
metastatic 0 ADJ F
urothelial 0 ADJ F
carcinoma 0 NOUN F
were 0 VERB F
randomly 0 ADV F
allocated 0 VERB F
to 0 ADP F
a 0 DET F
methotrexate 0 NOUN F
, 0 PUNCT F
epirubicin 0 NOUN F
and 0 CCONJ F
cisplatin 0 NOUN F
chemotherapy 0 NOUN F
group 0 NOUN F
( 0 PUNCT F
arm 0 NOUN F
1 0 NUM F
: 0 PUNCT F
S-MEC 0 NOUN T
therapy 0 NOUN F
; 0 PUNCT F
n 0 NOUN F
= 0 SYM F
29 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
a 0 DET F
dose-intensified 0 VERB F
MEC 0 NOUN T
therapy 0 NOUN F
combined 0 VERB F
with 0 ADP F
G-CSF 0 NOUN T
group 0 NOUN F
( 0 PUNCT F
arm 0 NOUN F
2 0 NUM F
: 0 PUNCT F
I-MEC 0 NOUN T
therapy 0 NOUN F
; 0 PUNCT F
n 0 NOUN F
= 0 SYM F
30 0 NUM F
) 0 PUNCT F
or 0 CCONJ F
a 0 DET F
methotrexate 0 NOUN F
, 0 PUNCT F
vinblastine 0 NOUN F
, 0 PUNCT F
doxorubicin 0 NOUN F
and 0 CCONJ F
cisplatin 0 NOUN F
chemotherapy 0 NOUN F
( 0 PUNCT F
arm 0 NOUN F
3 0 NUM F
: 0 PUNCT F
M-VAC 0 NOUN T
therapy 0 NOUN F
; 0 PUNCT F
n 0 NOUN F
= 0 SYM F
30 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

At 0 ADP T
the 0 DET F
registration 0 NOUN F
center 0 NOUN F
, 0 PUNCT F
the 0 DET F
patients 0 NOUN F
were 0 VERB F
stratified 0 VERB F
into 0 ADP F
previously 0 ADV F
untreated 0 VERB F
patients 0 NOUN F
and 0 CCONJ F
patients 0 NOUN F
with 0 ADP F
recurrence 0 NOUN F
after 0 ADP F
radical 0 ADJ F
operation 0 NOUN F
and 0 CCONJ F
then 0 ADV F
randomly 0 ADV F
allocated 0 VERB F
to 0 ADP F
the 0 DET F
treatment 0 NOUN F
groups 0 NOUN F
. 0 PUNCT F

In 0 ADP T
each 0 DET F
arm 0 NOUN F
, 0 PUNCT F
two 0 NUM F
or 0 CCONJ F
more 0 DET F
courses 0 CCONJ F
of 0 ADP F
chemotherapy 0 NOUN F
( 0 PUNCT F
4-week 0 NOUN F
cycles 0 NOUN F
) 0 PUNCT F
were 0 VERB F
performed 0 VERB F
. 0 PUNCT F

RESULTS 0 NOUN T
Of 0 ADP T
the 0 DET F
88 0 NUM F
eligible 0 ADJ F
patients 0 NOUN F
, 0 PUNCT F
four 0 NUM F
treated 0 PRON F
with 0 ADP F
S-MEC 0 NOUN T
therapy 0 NOUN F
and 0 CCONJ F
two 0 NUM F
treated 0 PRON F
with 0 ADP F
I-MEC 0 NOUN T
therapy 0 NOUN F
showed 0 VERB F
CR 0 NOUN T
. 0 PUNCT F

The 0 DET T
response 0 NOUN F
rates B-OTHER NOUN F
( 0 PUNCT F
CR 0 NOUN T
+ 0 SYM F
PR 0 NOUN T
) 0 PUNCT F
were 0 VERB F
52 0 NUM F
% 0 SYM F
( 0 PUNCT F
15/29 0 PUNCT F
) 0 PUNCT F
with 0 ADP F
S-MEC 0 NOUN T
therapy 0 NOUN F
, 0 PUNCT F
76 0 NUM F
% 0 SYM F
( 0 PUNCT F
22/29 0 PUNCT F
) 0 PUNCT F
with 0 ADP F
I-MEC 0 NOUN T
therapy 0 NOUN F
and 0 CCONJ F
47 0 NUM F
% 0 SYM F
( 0 PUNCT F
14/30 0 PUNCT F
) 0 PUNCT F
with 0 ADP F
M-VAC 0 NOUN T
therapy 0 NOUN F
. 0 PUNCT F

The 0 DET T
response 0 NOUN F
rate 0 NOUN F
with 0 ADP F
I-MEC B-OTHER NOUN T
therapy I-OTHER NOUN F
was 0 VERB F
significantly 0 ADV F
higher 0 PUNCT F
than 0 VERB F
that 0 PUNCT F
with 0 ADP F
M-VAC 0 NOUN T
therapy 0 NOUN F
( 0 PUNCT F
P 0 NOUN T
= 0 SYM F
0.02 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Although 0 ADP T
the 0 DET F
incidence 0 NOUN F
of 0 ADP F
leukopenia 0 NOUN F
was 0 VERB F
low 0 ADJ F
with 0 ADP F
I-MEC B-OTHER NOUN T
therapy I-OTHER NOUN F
, 0 PUNCT F
the 0 DET F
incidence 0 NOUN F
of 0 ADP F
thrombocytopenia B-PHYSICAL NOUN F
was 0 VERB F
high 0 ADJ F
with 0 ADP F
this 0 DET F
therapy 0 NOUN F
. 0 PUNCT F

CONCLUSION 0 NOUN T
MEC 0 NOUN T
therapy 0 NOUN F
used 0 VERB F
in 0 ADP F
this 0 DET F
study 0 NOUN F
is 0 VERB F
promising 0 PUNCT F
in 0 ADP F
terms 0 NOUN F
of 0 ADP F
the 0 DET F
antitumor B-OTHER NOUN F
effects I-OTHER NOUN F
. 0 PUNCT F

Budesonide 0 NOUN T
and 0 CCONJ F
beclomethasone 0 NOUN F
dipropionate 0 PUNCT F
in 0 ADP F
hay 0 ADP F
fever 0 NOUN F
- 0 PUNCT F
a 0 DET F
single 0 ADJ F
blind 0 ADJ F
comparison 0 NOUN F
. 0 PUNCT F

93 0 NUM F
patients 0 NOUN F
with 0 ADP F
seasonal 0 ADJ F
allergic 0 ADJ F
rhinitis 0 NOUN F
took 0 PROPN F
part 0 NOUN F
in 0 ADP F
a 0 DET F
single 0 ADJ F
blind 0 NOUN F
randomized 0 VERB F
clinical 0 ADJ F
comparison 0 NOUN F
of 0 ADP F
budesonide 0 NOUN F
and 0 CCONJ F
beclomethasone 0 NOUN F
dipropionate 0 PUNCT F
( 0 PUNCT F
Becotide 0 NOUN T
Nasal 0 ADJ T
) 0 PUNCT F
. 0 PUNCT F

All 0 DET T
patients 0 NOUN F
were 0 VERB F
sensitive 0 ADJ F
to 0 ADP F
either 0 CCONJ F
birch 0 NOUN F
or 0 CCONJ F
grass 0 NOUN F
pollen 0 ADJ F
, 0 PUNCT F
their 0 ADP F
sensitivity 0 NOUN F
being 0 VERB F
confirmed 0 VERB F
by 0 ADP F
a 0 DET F
skin 0 NOUN F
prick 0 NOUN F
test 0 NOUN F
. 0 PUNCT F

The 0 DET T
total 0 ADJ F
daily 0 ADJ F
dose 0 NOUN F
was 0 VERB F
400 0 NUM F
micrograms 0 NOUN F
for 0 ADP F
both 0 CCONJ F
drugs 0 NOUN F
. 0 PUNCT F

Budesonide 0 NOUN T
was 0 VERB F
administered 0 VERB F
twice 0 CCONJ F
a 0 DET F
day 0 NOUN F
and 0 CCONJ F
Becotide 0 NOUN T
Nasal 0 ADJ T
four 0 NUM F
times 0 NOUN F
a 0 DET F
day 0 NOUN F
. 0 PUNCT F

Symptoms 0 NOUN T
were 0 VERB F
assessed 0 VERB F
over 0 ADP F
a 0 DET F
four-week 0 NOUN F
period 0 NOUN F
starting 0 ADJ F
with 0 ADP F
a 0 DET F
run-in 0 NOUN F
period 0 NOUN F
of 0 ADP F
one 0 NUM F
week 0 NOUN F
. 0 PUNCT F

There 0 PUNCT T
was 0 VERB F
no 0 DET F
placebo 0 NOUN F
control 0 NOUN F
group 0 NOUN F
. 0 PUNCT F

Daily B-PHYSICAL ADJ T
pollen I-PHYSICAL ADJ F
counts I-PHYSICAL NOUN F
were 0 VERB F
measured 0 VERB F
throughout 0 ADP F
the 0 DET F
trial 0 NOUN F
. 0 PUNCT F

The 0 DET T
patients 0 NOUN F
' 0 PUNCT F
diary 0 PUNCT F
cards 0 VERB F
revealed 0 VERB F
that 0 PUNCT F
both 0 PUNCT F
drugs 0 NOUN F
had 0 ADP F
a 0 DET F
beneficial 0 ADJ F
therapeutic 0 ADJ F
effect 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
that 0 ADP F
budesonide 0 NOUN F
was 0 VERB F
significantly 0 ADV F
more 0 DET F
active 0 ADJ F
than 0 PUNCT F
Becotide 0 NOUN T
Nasal 0 ADJ T
. 0 PUNCT F

The 0 DET T
side 0 NOUN F
effects 0 NOUN F
of 0 ADP F
both 0 PUNCT F
drugs 0 NOUN F
were 0 VERB F
few 0 ADJ F
and 0 CCONJ F
transient 0 ADJ F
. 0 PUNCT F

The 0 DET T
immediate B-OTHER ADJ F
efficacy I-OTHER NOUN F
of 0 ADP F
adjunctive 0 ADJ F
doxycycline 0 NOUN F
in 0 ADP F
treatment 0 NOUN F
of 0 ADP F
localized 0 VERB F
juvenile 0 ADJ F
periodontitis 0 NOUN F
. 0 PUNCT F

A 0 DET T
randomized 0 VERB F
, 0 PUNCT F
double-blind 0 ADJ F
, 0 PUNCT F
placebo-controlled 0 VERB F
study 0 NOUN F
on 0 ADP F
the 0 DET F
immediate B-OTHER ADJ F
clinical I-OTHER ADJ F
and I-OTHER CCONJ F
microbiological I-OTHER ADJ F
efficacy I-OTHER NOUN F
of 0 ADP F
doxycycline 0 NOUN F
( 0 PUNCT F
100 0 NUM F
mg 0 NOUN F
for 0 ADP F
14 0 NUM F
days 0 NOUN F
) 0 PUNCT F
was 0 VERB F
carried 0 VERB F
out 0 ADP F
to 0 PART F
determine 0 NOUN F
the 0 DET F
benefit 0 NOUN F
of 0 ADP F
adjunctive 0 ADJ F
medication 0 NOUN F
in 0 ADP F
16 0 NUM F
patients 0 NOUN F
with 0 ADP F
localized 0 VERB F
juvenile 0 ADJ F
periodontitis 0 NOUN F
. 0 PUNCT F

Measurements 0 NOUN T
of 0 ADP F
gingival B-PHYSICAL ADJ F
fluid I-PHYSICAL NOUN F
flow I-PHYSICAL NOUN F
, 0 PUNCT F
probing B-PHYSICAL PROPN F
depths I-PHYSICAL NOUN F
, 0 PUNCT F
bleeding B-PHYSICAL VERB F
on I-PHYSICAL ADP F
probing I-PHYSICAL ADP F
and 0 CCONJ F
suppuration B-PHYSICAL NOUN F
were 0 VERB F
determined 0 VERB F
at 0 ADP F
2 0 NUM F
periodontal 0 ADJ F
sites 0 NOUN F
with 0 ADP F
and 0 CCONJ F
2 0 NUM F
without 0 ADP F
radiographic 0 ADJ F
attachment 0 NOUN F
loss 0 NOUN F
, 0 PUNCT F
at 0 ADP F
weeks 0 NOUN F
0 0 NUM F
, 0 PUNCT F
1 0 NUM F
, 0 PUNCT F
3 0 NUM F
and 0 CCONJ F
8 0 NUM F
. 0 PUNCT F

Subgingival B-PHYSICAL PUNCT T
bacterial I-PHYSICAL ADJ F
samples I-PHYSICAL NOUN F
were 0 VERB F
taken 0 VERB F
with 0 ADP F
curettes 0 PUNCT F
from 0 ADP F
the 0 DET F
same 0 ADJ F
sites 0 NOUN F
. 0 PUNCT F

Spirochaetes 0 PUNCT T
were 0 VERB F
searched 0 VERB F
for 0 ADP F
by 0 ADP F
dark-field 0 NOUN F
microscopy 0 NOUN F
. 0 PUNCT F

Actinobacillus 0 NOUN T
actinomycetemcomitans 0 NOUN F
, 0 PUNCT F
pigmented 0 ADP F
and 0 CCONJ F
non-pigmented 0 VERB F
Bacteroides 0 PUNCT T
spp. 0 NOUN F
, 0 PUNCT F
Capnocytophaga 0 NOUN T
, 0 PUNCT F
Fusobacterium 0 NOUN T
and 0 CCONJ F
Actinomyces 0 NOUN T
spp 0 NOUN F
. 0 PUNCT F

were 0 VERB F
cultured 0 VERB F
on 0 ADP F
various 0 ADJ F
selective 0 ADJ F
and 0 CCONJ F
non-selective 0 ADJ F
media 0 NOUN F
. 0 PUNCT F

Bacterial 0 ADJ T
species 0 NOUN F
found 0 VERB F
at 0 ADP F
least 0 ADV F
in 0 ADP F
50 0 NUM F
% 0 SYM F
of 0 ADP F
the 0 DET F
patients 0 NOUN F
and 0 CCONJ F
comprising 0 VERB F
on 0 ADP F
average 0 ADJ F
5 0 NUM F
% 0 SYM F
or 0 CCONJ F
more 0 DET F
of 0 ADP F
the 0 DET F
cultivable 0 NOUN F
flora 0 NOUN F
were 0 VERB F
included 0 VERB F
in 0 ADP F
the 0 DET F
analysis 0 NOUN F
. 0 PUNCT F

Neither 0 CCONJ T
short-term B-OTHER NOUN F
clinical I-OTHER ADJ F
nor I-OTHER CCONJ F
microbiological I-OTHER ADJ F
efficacy I-OTHER NOUN F
beyond 0 ADP F
that 0 PUNCT F
of 0 ADP F
a 0 DET F
course 0 NOUN F
of 0 ADP F
mechanical 0 ADJ F
debridement 0 NOUN F
alone 0 ADJ F
was 0 ADV F
found 0 VERB F
by 0 ADP F
using 0 VERB F
systemic 0 ADJ F
medication 0 NOUN F
with 0 ADP F
doxycycline 0 NOUN F
in 0 ADP F
patients 0 NOUN F
with 0 ADP F
localized 0 VERB F
juvenile 0 ADJ F
periodontitis 0 NOUN F
. 0 PUNCT F

Blood B-PHYSICAL NOUN T
purification I-PHYSICAL NOUN F
for 0 ADP F
critical 0 ADJ F
care 0 NOUN F
medicine 0 NOUN F
: 0 PUNCT F
endotoxin 0 NOUN F
adsorption 0 NOUN F
. 0 PUNCT F

Many 0 PUNCT T
kinds 0 NOUN F
of 0 ADP F
blood 0 NOUN F
purifying 0 ADP F
technologies 0 NOUN F
have 0 CCONJ F
been 0 PUNCT F
applied 0 VERB F
to 0 ADP F
the 0 DET F
treatment 0 NOUN F
of 0 ADP F
critically 0 ADV F
ill 0 ADJ F
patients 0 NOUN F
since 0 ADP F
1979 0 NUM F
when 0 ADP F
plasma 0 NOUN F
exchange 0 NOUN F
with 0 ADP F
hollow-fiber 0 ADJ F
membranes 0 NOUN F
was 0 VERB F
developed 0 VERB F
. 0 PUNCT F

These 0 DET T
technologies 0 NOUN F
have 0 CCONJ F
been 0 PUNCT F
applied 0 VERB F
not 0 ADV F
only 0 ADV F
to 0 ADP F
the 0 DET F
removal 0 NOUN F
of 0 ADP F
toxic 0 ADJ F
substances 0 NOUN F
, 0 PUNCT F
but 0 CCONJ F
also 0 ADV F
to 0 ADP F
the 0 DET F
treatment 0 NOUN F
of 0 ADP F
objective 0 ADJ F
diseases 0 NOUN F
and 0 CCONJ F
the 0 DET F
removal 0 NOUN F
of 0 ADP F
the 0 DET F
factors 0 NOUN F
relating 0 ADJ F
to 0 ADP F
the 0 DET F
associated 0 VERB F
inflammation 0 NOUN F
. 0 PUNCT F

This 0 DET T
article 0 NOUN F
summarizes 0 VERB F
these 0 DET F
methods 0 NOUN F
and 0 CCONJ F
their 0 ADJ F
efficacies 0 NOUN F
for 0 ADP F
critically 0 ADV F
ill 0 ADJ F
patients 0 NOUN F
, 0 PUNCT F
especially 0 ADV F
those 0 PUNCT F
with 0 ADP F
severe 0 ADJ F
sepsis 0 NOUN F
. 0 PUNCT F

Attempts 0 PUNCT T
have 0 PUNCT F
been 0 PUNCT F
made 0 VERB F
to 0 PART F
remove 0 NOUN F
endotoxin 0 NOUN F
, 0 PUNCT F
the 0 DET F
main 0 ADJ F
cause 0 NOUN F
of 0 ADP F
sepsis 0 NOUN F
, 0 PUNCT F
from 0 ADP F
the 0 DET F
circulation 0 NOUN F
using 0 VERB F
polymyxin 0 NOUN F
B 0 NOUN T
immobilized 0 VERB F
fiber 0 NOUN F
, 0 PUNCT F
charcoal 0 ADJ F
hemoperfusion 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
plasma 0 NOUN F
or 0 CCONJ F
whole 0 ADJ F
blood 0 NOUN F
exchange 0 NOUN F
. 0 PUNCT F

Attempts 0 PUNCT T
have 0 PUNCT F
also 0 ADV F
been 0 PUNCT F
made 0 VERB F
to 0 PART F
remove 0 ADJ F
proinflammatory 0 ADJ F
cytokines 0 NOUN F
, 0 PUNCT F
eicosanoides 0 CCONJ F
, 0 PUNCT F
and 0 CCONJ F
coagulative 0 ADJ F
factors 0 NOUN F
from 0 ADP F
the 0 DET F
circulation 0 NOUN F
in 0 ADP F
the 0 DET F
human 0 NOUN F
body 0 NOUN F
. 0 PUNCT F

Continuous 0 ADJ T
hemofiltration 0 NOUN F
or 0 CCONJ F
hemodiafiltration 0 NOUN F
is 0 VERB F
the 0 DET F
representative 0 ADJ F
technology 0 NOUN F
. 0 PUNCT F

The 0 DET T
efficacy 0 NOUN F
of 0 ADP F
these 0 DET F
methods 0 NOUN F
has 0 VERB F
been 0 PUNCT F
established 0 VERB F
, 0 PUNCT F
but 0 CCONJ F
several 0 ADJ F
issues 0 NOUN F
remain 0 VERB F
unresolved 0 PROPN F
. 0 PUNCT F

All 0 DET T
methods 0 NOUN F
of 0 ADP F
the 0 DET F
treatment 0 NOUN F
of 0 ADP F
severe 0 ADJ F
sepsis 0 NOUN F
are 0 VERB F
discussed 0 VERB F
with 0 ADP F
reference 0 NOUN F
to 0 ADP F
treatment 0 NOUN F
indications B-OTHER NOUN F
, 0 PUNCT F
efficacy 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
outcome 0 NOUN F
parameters 0 NOUN F
. 0 PUNCT F

In 0 ADP T
particular 0 NOUN F
, 0 PUNCT F
the 0 DET F
clinical 0 ADJ F
results 0 NOUN F
of 0 ADP F
endotoxin 0 NOUN F
removal 0 NOUN F
with 0 ADP F
polymyxin 0 NOUN F
B 0 NOUN T
immobilized 0 PUNCT F
fiber 0 NOUN F
are 0 VERB F
summarized 0 VERB F
in 0 ADP F
this 0 DET F
article 0 NOUN F
. 0 PUNCT F

In 0 ADJ T
vitro 0 ADJ F
biocompatibility 0 NOUN F
tests 0 NOUN F
of 0 ADP F
glass 0 NOUN F
ionomer 0 NOUN F
cements 0 NOUN F
impregnated 0 ADP F
with 0 ADP F
collagen 0 NOUN F
or 0 CCONJ F
bioactive 0 ADJ F
glass 0 NOUN F
to 0 ADP F
fibroblasts 0 NOUN F
. 0 PUNCT F

AIM 0 NOUN T
AND 0 CCONJ T
DESIGN 0 NOUN T
To 0 ADV T
evaluate 0 NOUN F
the 0 DET F
biocompatibility 0 NOUN F
of 0 ADP F
glass 0 NOUN F
ionomer 0 NOUN F
cement 0 NOUN F
( 0 PUNCT F
GIC 0 NOUN T
) 0 PUNCT F
impregnated 0 VERB F
with 0 ADP F
collagen 0 NOUN F
or 0 CCONJ F
bioactive 0 ADJ F
glass 0 NOUN F
to 0 ADP F
BHK-21 0 NOUN T
fibroblasts 0 NOUN F
in 0 ADP F
vitro 0 ADV F
. 0 PUNCT F

Mineral 0 NOUN T
Trioxide 0 NOUN T
Aggregate 0 NOUN T
was 0 VERB F
used 0 VERB F
as 0 ADP F
the 0 DET F
standard 0 CCONJ F
for 0 ADP F
comparison 0 NOUN F
. 0 PUNCT F

Human 0 NOUN T
maxillary 0 ADJ F
central 0 ADJ F
incisors 0 NOUN F
( 0 PUNCT F
n 0 NOUN F
= 0 SYM F
70 0 NUM F
) 0 PUNCT F
were 0 VERB F
instrumented 0 VERB F
with 0 ADP F
a 0 DET F
rotary 0 ADJ F
NiTi 0 NOUN T
system 0 NOUN F
and 0 CCONJ F
filled 0 VERB F
. 0 PUNCT F

Following 0 ADP T
resection 0 NOUN F
of 0 ADP F
the 0 DET F
apical 0 ADJ F
3mm 0 ADP F
, 0 PUNCT F
root 0 NOUN F
end 0 NOUN F
cavities 0 NOUN F
were 0 VERB F
prepared 0 VERB F
and 0 CCONJ F
restored 0 VERB F
with 0 ADP F
conventional 0 ADJ F
GIC 0 NOUN T
( 0 PUNCT F
group 0 NOUN F
1 0 NUM F
) 0 PUNCT F
or 0 CCONJ F
GIC 0 NOUN T
with 0 ADP F
0.01 0 NUM F
% 0 SYM F
, 0 PUNCT F
0.1 0 NUM F
% 0 SYM F
or 0 CCONJ F
1 0 NUM F
% 0 SYM F
collagen 0 NOUN F
( 0 PUNCT F
groups 0 NOUN F
2 0 NUM F
, 0 PUNCT F
3 0 NUM F
, 0 PUNCT F
4 0 NUM F
respectively 0 ADV F
) 0 PUNCT F
or 0 CCONJ F
, 0 PUNCT F
10 0 NUM F
% 0 SYM F
, 0 PUNCT F
30 0 NUM F
% 0 SYM F
or 0 CCONJ F
50 0 NUM F
% 0 SYM F
bioactive 0 ADJ F
glass 0 NOUN F
( 0 PUNCT F
groups 0 NOUN F
5 0 NUM F
, 0 PUNCT F
6 0 NUM F
, 0 PUNCT F
7 0 NUM F
respectively 0 ADV F
) 0 PUNCT F
, 0 PUNCT F
or 0 CCONJ F
Mineral 0 NOUN T
Trioxide 0 NOUN T
Aggregate 0 NOUN T
( 0 PUNCT F
group 0 NOUN F
8 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
root 0 NOUN F
slices 0 NOUN F
were 0 VERB F
incubated 0 VERB F
in 0 ADP F
tissue 0 NOUN F
culture 0 NOUN F
plates 0 NOUN F
with 0 ADP F
BHK-21 0 NOUN T
fibroblast 0 NOUN F
cell 0 NOUN F
line 0 NOUN F
. 0 PUNCT F

Phase 0 NOUN T
contrast 0 NOUN F
and 0 CCONJ F
scanning 0 ADJ F
electron 0 NOUN F
microscopes 0 ADP F
were 0 VERB F
used 0 VERB F
to 0 PART F
score 0 DET F
cell B-OTHER NOUN F
quantity I-OTHER NOUN F
, 0 PUNCT F
morphology B-OTHER NOUN F
and 0 CCONJ F
cell B-OTHER NOUN F
attachment I-OTHER NOUN F
. 0 PUNCT F

The 0 DET T
data 0 NOUN F
were 0 VERB F
statistically 0 ADV F
analyzed 0 VERB F
by 0 ADP F
one 0 NUM F
way 0 NOUN F
ANOVA 0 NOUN T
with 0 ADP F
Post B-OTHER PUNCT T
Hoc I-OTHER NOUN T
Tukey I-OTHER NOUN T
HSD I-OTHER NOUN T
test I-OTHER NOUN F
( 0 PUNCT F
p 0 NOUN F
= 0 SYM F
0.05 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

RESULTS 0 NOUN T
AND 0 CCONJ T
CONCLUSIONS 0 NOUN T
Group 0 NOUN T
5 0 NUM F
showed 0 VERB F
the 0 DET F
highest 0 PUNCT F
scores 0 NOUN F
which 0 ADP F
was 0 VERB F
significantly 0 ADV F
higher 0 PUNCT F
than 0 PUNCT F
all 0 DET F
other 0 ADJ F
groups 0 NOUN F
( 0 PUNCT F
p 0 NOUN F
< 0 SYM F
0.05 0 NUM F
) 0 PUNCT F
except 0 PUNCT F
group 0 NOUN F
8 0 NUM F
, 0 PUNCT F
with 0 ADP F
which 0 DET F
there 0 PUNCT F
was 0 VERB F
no 0 DET F
significant 0 ADJ F
difference 0 NOUN F
( 0 PUNCT F
p 0 NOUN F
> 0 SYM F
0.05 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Glass 0 ADJ T
ionomer 0 NOUN F
cement 0 NOUN F
with 0 ADP F
10 0 NUM F
% 0 SYM F
bioactive 0 ADJ F
glass 0 NOUN F
showed 0 VERB F
better B-OTHER PUNCT F
adhesion I-OTHER NOUN F
and 0 CCONJ F
spreading B-OTHER DET F
of I-OTHER ADP F
cells I-OTHER NOUN F
than 0 PUNCT F
glass 0 NOUN F
ionomer 0 NOUN F
cement 0 NOUN F
with 0 ADP F
0.01 0 NUM F
% 0 ADP F
collagen 0 NOUN F
. 0 PUNCT F

The 0 DET T
biocompatibility 0 NOUN F
of 0 ADP F
collagen B-OTHER NOUN F
and 0 CCONJ F
bioactive B-OTHER ADJ F
glass I-OTHER NOUN F
was 0 VERB F
concentration 0 NOUN F
dependent 0 ADJ F
. 0 PUNCT F

The 0 DET T
addition 0 NOUN F
of 0 ADP F
bioactive 0 ADJ F
glass 0 NOUN F
improved 0 VERB F
the 0 DET F
biocompatibility 0 NOUN F
of 0 ADP F
glass 0 NOUN F
ionomer 0 NOUN F
cement 0 NOUN F
to 0 ADP F
fibroblasts 0 PUNCT F
better 0 PUNCT F
than 0 PUNCT F
addition 0 NOUN F
of 0 ADP F
collagen 0 NOUN F
. 0 PUNCT F

Osteoporosis 0 NOUN T
and 0 CCONJ F
gait 0 NOUN F
and 0 CCONJ F
balance 0 NOUN F
disturbances 0 NOUN F
in 0 ADP F
older 0 PUNCT F
sarcopenic 0 ADJ F
obese 0 PUNCT F
New 0 ADJ T
Zealanders 0 NOUN T
. 0 PUNCT F

UNLABELLED 0 NOUN T
Bone 0 NOUN T
, 0 PUNCT F
muscle 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
fat 0 NOUN F
may 0 PROPN F
affect 0 VERB F
gait 0 NOUN F
and 0 CCONJ F
balance 0 NOUN F
in 0 ADP F
older 0 PUNCT F
adults 0 NOUN F
. 0 PUNCT F

Osteoporosis 0 NOUN T
was 0 VERB F
prevalent 0 ADJ F
in 0 ADP F
low 0 ADJ F
muscle 0 NOUN F
mass 0 NOUN F
participants 0 NOUN F
and 0 CCONJ F
related 0 VERB F
to 0 ADP F
gait 0 NOUN F
and 0 CCONJ F
balance 0 NOUN F
deficits 0 NOUN F
. 0 PUNCT F

Low 0 ADJ T
muscle 0 NOUN F
combined 0 VERB F
with 0 ADP F
high 0 ADJ F
fat 0 NOUN F
mass 0 NOUN F
had 0 PUNCT F
more 0 DET F
functional 0 ADJ F
deficits 0 NOUN F
and 0 CCONJ F
poorer 0 PUNCT F
bone 0 NOUN F
health 0 NOUN F
, 0 PUNCT F
which 0 ADP F
has 0 ADP F
implications 0 NOUN F
for 0 ADP F
falls 0 CCONJ F
risk 0 NOUN F
and 0 CCONJ F
fractures 0 NOUN F
. 0 PUNCT F

INTRODUCTION 0 NOUN T
Decreasing 0 ADJ T
bone 0 NOUN F
density 0 NOUN F
and 0 CCONJ F
muscle 0 NOUN F
mass 0 NOUN F
and 0 CCONJ F
increasing 0 ADJ F
fat 0 NOUN F
mass 0 NOUN F
may 0 VERB F
act 0 VERB F
synergistically 0 ADV F
to 0 PART F
affect 0 ADJ F
gait 0 NOUN F
and 0 CCONJ F
balance 0 NOUN F
in 0 ADP F
older 0 PUNCT F
adults 0 NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
One 0 NUM T
hundred 0 NUM F
eighty-three 0 ADP F
older 0 PUNCT F
adults 0 NOUN F
( 0 PUNCT F
age 0 NOUN F
72.7 0 NUM F
+/- 0 SYM F
6 0 NUM F
years 0 NOUN F
, 0 PUNCT F
range 0 NOUN F
56-93 0 NUM F
; 0 PUNCT F
body 0 NOUN F
mass 0 NOUN F
index 0 NOUN F
28.2 0 NUM F
+/- 0 SYM F
4.9 0 NUM F
, 0 PUNCT F
range 0 NOUN F
16.6-46.0 0 NUM F
) 0 PUNCT F
were 0 VERB F
recruited 0 VERB F
from 0 ADP F
a 0 DET F
New 0 ADJ T
Zealand 0 NOUN T
falls 0 PUNCT F
prevention 0 NOUN F
intervention 0 NOUN F
trial 0 NOUN F
. 0 PUNCT F

Total 0 ADJ T
and 0 CCONJ F
appendicular B-PHYSICAL ADJ F
skeletal I-PHYSICAL ADJ F
muscle I-PHYSICAL NOUN F
mass I-PHYSICAL NOUN F
( I-PHYSICAL PUNCT F
ASM I-PHYSICAL NOUN T
) I-PHYSICAL PUNCT F
, 0 PUNCT F
percent B-PHYSICAL NOUN F
fat I-PHYSICAL NOUN F
, 0 PUNCT F
and 0 CCONJ F
bone B-PHYSICAL NOUN F
mineralization I-PHYSICAL NOUN F
were 0 VERB F
assessed 0 VERB F
by 0 ADP F
dual 0 ADJ F
energy 0 NOUN F
X-ray 0 NOUN T
absorptiometry 0 NOUN F
and 0 CCONJ F
used 0 VERB F
to 0 PART F
characterize 0 NOUN F
normal 0 ADJ F
lean 0 PUNCT F
( 0 PUNCT F
NL 0 NOUN T
, 0 PUNCT F
n 0 NOUN F
= 0 SYM F
51 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
sarcopenic 0 ADJ F
( 0 PUNCT F
SS 0 NOUN T
, 0 PUNCT F
n 0 NOUN F
= 0 SYM F
18 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
sarcopenic 0 ADJ F
obese 0 ADJ F
( 0 PUNCT F
SO 0 NOUN T
, 0 PUNCT F
n 0 NOUN F
= 0 SYM F
29 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
and 0 CCONJ F
obese 0 ADP F
( 0 PUNCT F
OO 0 NOUN T
, 0 PUNCT F
n 0 NOUN F
= 0 SYM F
85 0 NUM F
) 0 PUNCT F
phenotypes 0 NOUN F
. 0 PUNCT F

Functional 0 ADJ T
performance 0 NOUN F
was 0 VERB F
assessed 0 VERB F
using 0 SYM F
timed 0 PUNCT F
up 0 PUNCT F
and 0 CCONJ F
go 0 NOUN F
, 0 PUNCT F
chair 0 PUNCT F
stand 0 CCONJ F
, 0 PUNCT F
single 0 ADJ F
leg 0 NOUN F
stand 0 CCONJ F
, 0 PUNCT F
and 0 CCONJ F
step 0 NOUN F
test 0 NOUN F
. 0 PUNCT F

Regression 0 NOUN T
models 0 NOUN F
were 0 VERB F
adjusted 0 VERB F
for 0 ADP F
age 0 NOUN F
, 0 PUNCT F
sex 0 NOUN F
, 0 PUNCT F
medications 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
physical 0 ADJ F
activity 0 NOUN F
. 0 PUNCT F

RESULTS 0 NOUN T
Femoral B-PHYSICAL ADJ T
neck I-PHYSICAL ADJ F
osteoporosis I-PHYSICAL NOUN F
was 0 VERB F
present 0 ADJ F
in 0 ADP F
22 0 NUM F
% 0 SYM F
SS 0 NOUN T
, 0 PUNCT F
17 0 NUM F
% 0 SYM F
SO 0 NOUN T
, 0 PUNCT F
12 0 NUM F
% 0 SYM F
NL 0 NOUN T
, 0 PUNCT F
and 0 CCONJ F
7 0 NUM F
% 0 SYM F
OO 0 NOUN T
. 0 PUNCT F

Femoral 0 ADJ T
neck 0 NOUN F
osteoporosis 0 NOUN F
with 0 ADP F
low 0 ADJ F
ASM B-PHYSICAL NOUN T
predicted 0 ADP F
poor 0 ADJ F
chair B-PHYSICAL PUNCT F
stand I-PHYSICAL CCONJ F
performance I-PHYSICAL NOUN F
( 0 PUNCT F
beta 0 NOUN F
-3.3 0 NUM F
, 0 PUNCT F
standard 0 ADJ F
error 0 NOUN F
1.6 0 NUM F
, 0 PUNCT F
p 0 NOUN F
= 0 SYM F
0.04 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

SO 0 NOUN T
scored 0 PUNCT F
lowest 0 PUNCT F
on 0 ADP F
the 0 DET F
chair 0 PUNCT F
stand 0 CCONJ F
( 0 PUNCT F
p 0 NOUN F
= 0 SYM F
0.03 0 NUM F
) 0 PUNCT F
and 0 CCONJ F
step 0 NOUN F
test 0 NOUN F
( 0 PUNCT F
p 0 NOUN F
= 0 SYM F
0.03 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Higher B-PHYSICAL PUNCT T
ASM I-PHYSICAL NOUN T
predicted 0 VERB F
faster 0 PUNCT F
timed 0 ADP F
up 0 PUNCT F
and 0 CCONJ F
go 0 ADP F
performance 0 NOUN F
( 0 PUNCT F
p 0 NOUN F
= 0 SYM F
0.001 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

CONCLUSIONS 0 NOUN T
Osteoporosis 0 NOUN T
was 0 VERB F
prevalent 0 ADJ F
in 0 ADP F
low 0 ADJ F
ASM 0 NOUN T
groups 0 NOUN F
( 0 PUNCT F
SS 0 NOUN T
and 0 CCONJ F
SO 0 NOUN T
) 0 PUNCT F
and 0 CCONJ F
related 0 VERB F
to 0 ADP F
gait 0 NOUN F
and 0 CCONJ F
balance 0 NOUN F
deficits 0 NOUN F
, 0 PUNCT F
particularly 0 ADV F
in 0 ADP F
the 0 DET F
SO 0 NOUN T
. 0 PUNCT F

This 0 DET T
has 0 PUNCT F
implications 0 NOUN F
for 0 ADP F
falls 0 CCONJ F
risk 0 NOUN F
, 0 PUNCT F
fractures 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
interventions 0 NOUN F
. 0 PUNCT F

[ 0 PUNCT F
Efficacy 0 NOUN T
of 0 ADP F
paliperidone 0 NOUN F
extended-release 0 NOUN F
tablets 0 NOUN F
in 0 ADP F
the 0 DET F
improvement 0 NOUN F
of 0 ADP F
social B-MENTAL ADJ F
functions I-MENTAL CCONJ F
in 0 ADP F
schizophrenics 0 NOUN F
: 0 PUNCT F
a 0 DET F
randomized 0 VERB F
and 0 CCONJ F
controlled 0 VERB F
study 0 NOUN F
] 0 PUNCT F
. 0 PUNCT F

OBJECTIVE 0 NOUN T
To 0 ADJ T
explore 0 CCONJ F
the 0 DET F
efficacy 0 NOUN F
of 0 ADP F
paliperidone 0 NOUN F
extended-release 0 NOUN F
tablets 0 NOUN F
in 0 ADP F
the 0 DET F
improvement 0 NOUN F
of 0 ADP F
social B-MENTAL ADJ F
functions I-MENTAL CCONJ F
in 0 ADP F
schizophrenics 0 NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
A 0 PUNCT T
total 0 NOUN F
of 0 ADP F
81 0 NUM F
schizophrenics 0 NOUN F
were 0 VERB F
randomly 0 ADV F
divided 0 VERB F
into 0 ADP F
study 0 NOUN F
group 0 NOUN F
with 0 ADP F
paliperidone 0 NOUN F
extended-release 0 NOUN F
tablets 0 NOUN F
and 0 CCONJ F
control 0 NOUN F
group 0 NOUN F
with 0 ADP F
risperidone 0 NUM F
for 0 ADP F
a 0 DET F
12-week 0 NOUN F
treatment 0 NOUN F
. 0 PUNCT F

They 0 PRON T
were 0 VERB F
assessed 0 VERB F
and 0 CCONJ F
analyzed 0 VERB F
by 0 ADP F
positive 0 ADJ F
and 0 CCONJ F
negative 0 ADJ F
symptoms 0 NOUN F
scales 0 NOUN F
( 0 PUNCT F
PANSS 0 NOUN T
) 0 PUNCT F
, 0 PUNCT F
social 0 ADJ F
disability 0 NOUN F
screening 0 NUM F
schedule 0 NOUN F
( 0 PUNCT F
SDSS 0 NOUN T
) 0 PUNCT F
and 0 CCONJ F
treatment 0 NOUN F
emergent 0 ADJ F
symptom 0 NOUN F
scale 0 NOUN F
( 0 PUNCT F
TESS 0 NOUN T
) 0 PUNCT F
at 0 ADP F
baseline 0 NOUN F
, 0 PUNCT F
6 0 NUM F
( 0 PUNCT F
th 0 PUNCT F
) 0 PUNCT F
weekend 0 VERB F
and 0 CCONJ F
12 0 NUM F
( 0 PUNCT F
th 0 PUNCT F
) 0 PUNCT F
weekend 0 ADJ F
. 0 PUNCT F

RESULTS 0 NOUN T
In 0 ADP T
study 0 ADV F
group 0 NOUN F
, 0 PUNCT F
the 0 DET F
factors 0 NOUN F
and 0 CCONJ F
total 0 ADJ F
scores 0 NOUN F
of 0 ADP F
PANSS 0 NOUN T
in 0 ADP F
the 0 DET F
12 0 NUM F
( 0 PUNCT F
th 0 PUNCT F
) 0 PUNCT F
weekend 0 NOUN F
of 0 ADP F
treatment 0 NOUN F
[ 0 PUNCT F
( 0 PUNCT F
12.0 0 NUM F
? 0 PUNCT F

2.8 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
( 0 PUNCT F
12.1 0 NUM F
? 0 PUNCT F

3.6 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
( 0 PUNCT F
26.2 0 NUM F
? 0 PUNCT F

5.0 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
( 0 PUNCT F
50.2 0 NUM F
? 0 PUNCT F

8.7 0 NUM F
) 0 PUNCT F
] 0 PUNCT F
were 0 VERB F
all 0 PUNCT F
significantly 0 ADV F
lower 0 PUNCT F
than 0 PUNCT F
those 0 PUNCT F
at 0 ADP F
baseline 0 NOUN F
[ 0 PUNCT F
( 0 PUNCT F
24.7 0 NUM F
? 0 PUNCT F

5.3 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
( 0 PUNCT F
23.8 0 NUM F
? 0 PUNCT F

3.6 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
( 0 PUNCT F
45.0 0 NUM F
? 0 PUNCT F

2.9 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
( 0 PUNCT F
93.5 0 NUM F
? 0 PUNCT F

6.8 0 NUM F
) 0 PUNCT F
] 0 PUNCT F
( 0 PUNCT F
t 0 NOUN F
= 0 SYM F
9.60-16.78 0 NUM F
, 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.05 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

In 0 ADP T
study 0 ADV F
group 0 NOUN F
, 0 PUNCT F
the 0 DET F
positive 0 ADJ F
factor 0 NOUN F
, 0 PUNCT F
negative 0 ADJ F
factor 0 NOUN F
and 0 CCONJ F
total 0 ADJ F
scores 0 NOUN F
of 0 ADP F
PANSS 0 NOUN T
in 0 ADP F
the 0 DET F
12 0 NUM F
( 0 PUNCT F
th 0 PUNCT F
) 0 PUNCT F
weekend 0 NOUN F
of 0 ADP F
treatment 0 NOUN F
[ 0 PUNCT F
( 0 PUNCT F
12.0 0 NUM F
? 0 PUNCT F

2.8 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
( 0 PUNCT F
12.1 0 NUM F
? 0 PUNCT F

3.6 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
( 0 PUNCT F
50.2 0 NUM F
? 0 PUNCT F

8.7 0 NUM F
) 0 PUNCT F
] 0 PUNCT F
were 0 VERB F
all 0 PUNCT F
significantly 0 ADV F
lower 0 PUNCT F
than 0 PUNCT F
those 0 PUNCT F
in 0 ADP F
the 0 DET F
6 0 NUM F
( 0 PUNCT F
th 0 PUNCT F
) 0 PUNCT F
weekend 0 NOUN F
of 0 ADP F
treatment 0 NOUN F
[ 0 PUNCT F
( 0 PUNCT F
14.2 0 NUM F
? 0 PUNCT F

1.8 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
( 0 PUNCT F
14.6 0 NUM F
? 0 PUNCT F

2.4 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
( 0 PUNCT F
56.5 0 NUM F
? 0 PUNCT F

6.4 0 NUM F
) 0 PUNCT F
] 0 PUNCT F
( 0 PUNCT F
t 0 NOUN F
= 0 SYM F
2.58-4.26 0 NUM F
, 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.05 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

In 0 ADP T
the 0 DET F
12 0 NUM F
( 0 PUNCT F
th 0 PUNCT F
) 0 PUNCT F
weekend 0 NOUN F
of 0 ADP F
treatment 0 NOUN F
, 0 PUNCT F
the 0 DET F
factors 0 NOUN F
and 0 CCONJ F
total 0 ADJ F
scores 0 NOUN F
of 0 ADP F
PANSS 0 NOUN T
in 0 ADP F
study 0 ADV F
group 0 NOUN F
[ 0 PUNCT F
( 0 PUNCT F
12.0 0 NUM F
? 0 PUNCT F

2.8 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
( 0 PUNCT F
12.1 0 NUM F
? 0 PUNCT F

3.6 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
( 0 PUNCT F
26.2 0 NUM F
? 0 PUNCT F

5.0 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
( 0 PUNCT F
50.2 0 NUM F
? 0 PUNCT F

8.7 0 NUM F
) 0 PUNCT F
] 0 PUNCT F
were 0 VERB F
all 0 PUNCT F
significantly 0 ADV F
lower 0 PUNCT F
than 0 PUNCT F
those 0 PUNCT F
in 0 ADP F
control 0 NOUN F
group 0 NOUN F
[ 0 PUNCT F
( 0 PUNCT F
16.9 0 NUM F
? 0 PUNCT F

4.9 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
( 0 PUNCT F
18.7 0 NUM F
? 0 PUNCT F

5.3 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
( 0 PUNCT F
32.5 0 NUM F
? 0 PUNCT F

5.1 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
( 0 PUNCT F
68.1 0 NUM F
? 0 PUNCT F

13.0 0 NUM F
) 0 PUNCT F
] 0 PUNCT F
( 0 PUNCT F
t 0 NOUN F
= 0 SYM F
-4.28 0 NUM F
-- 0 PUNCT F
5.67 0 NUM F
, 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.05 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

In 0 ADP T
study 0 ADV F
group 0 NOUN F
, 0 PUNCT F
the 0 DET F
total 0 ADJ F
scores 0 NOUN F
of 0 ADP F
SDSS 0 NOUN T
in 0 ADP F
the 0 DET F
12 0 NUM F
( 0 PUNCT F
th 0 PUNCT F
) 0 PUNCT F
weekend 0 NOUN F
of 0 ADP F
treatment 0 NOUN F
( 0 PUNCT F
5.93 0 NUM F
? 0 PUNCT F

2.78 0 NUM F
) 0 PUNCT F
were 0 VERB F
significantly 0 ADV F
lower 0 PUNCT F
than 0 PUNCT F
those 0 PUNCT F
at 0 ADP F
baseline 0 NOUN F
( 0 PUNCT F
13.9 0 NUM F
? 0 PUNCT F

3.4 0 NUM F
) 0 PUNCT F
( 0 PUNCT F
t 0 NOUN F
= 0 SYM F
10.83 0 NUM F
, 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.05 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

In 0 ADP T
study 0 ADV F
group 0 NOUN F
, 0 PUNCT F
the 0 DET F
total 0 ADJ F
scores 0 NOUN F
of 0 ADP F
SDSS 0 NOUN T
in 0 ADP F
the 0 DET F
12 0 NUM F
( 0 PUNCT F
th 0 PUNCT F
) 0 PUNCT F
weekend 0 NOUN F
of 0 ADP F
treatment 0 NOUN F
( 0 PUNCT F
5.9 0 NUM F
? 0 PUNCT F

2.8 0 NUM F
) 0 PUNCT F
were 0 VERB F
significantly 0 ADV F
lower 0 PUNCT F
than 0 PUNCT F
those 0 PUNCT F
in 0 ADP F
the 0 DET F
6 0 NUM F
( 0 PUNCT F
th 0 PUNCT F
) 0 PUNCT F
weekend 0 NOUN F
of 0 ADP F
treatment 0 NOUN F
( 0 PUNCT F
7.6 0 NUM F
? 0 PUNCT F

2.9 0 NUM F
) 0 PUNCT F
( 0 PUNCT F
t 0 NOUN F
= 0 SYM F
5.21 0 NUM F
, 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.05 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

But 0 CCONJ T
there 0 PUNCT F
was 0 VERB F
no 0 DET F
significant 0 ADJ F
improvement 0 NOUN F
in 0 ADP F
control 0 NOUN F
group 0 NOUN F
( 0 PUNCT F
t 0 NOUN F
= 0 SYM F
1.88 0 NUM F
, 0 PUNCT F
P 0 NOUN T
> 0 SYM F
0.05 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

In 0 ADP T
the 0 DET F
12 0 NUM F
( 0 PUNCT F
th 0 PUNCT F
) 0 PUNCT F
weekend 0 NOUN F
of 0 ADP F
treatment 0 NOUN F
, 0 PUNCT F
the 0 DET F
total 0 ADJ F
scores 0 NOUN F
of 0 ADP F
SDSS 0 NOUN T
in 0 ADP F
study 0 ADV F
group 0 NOUN F
( 0 PUNCT F
5.9 0 NUM F
? 0 PUNCT F

2.8 0 NUM F
) 0 PUNCT F
were 0 VERB F
significantly 0 ADV F
lower 0 PUNCT F
than 0 PUNCT F
those 0 PUNCT F
in 0 ADP F
control 0 NOUN F
group 0 NOUN F
( 0 PUNCT F
8.8 0 NUM F
? 0 PUNCT F

2.9 0 NUM F
) 0 PUNCT F
( 0 PUNCT F
t 0 NOUN F
= 0 SYM F
-4.49 0 NUM F
, 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.05 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

No 0 DET T
severe 0 ADJ F
adverse 0 ADJ F
effect 0 NOUN F
was 0 VERB F
reported 0 VERB F
in 0 ADP F
either 0 PUNCT F
group 0 NOUN F
. 0 PUNCT F

CONCLUSION 0 NOUN T
Paliperidone 0 NOUN T
extended-release 0 NOUN F
tablets 0 NOUN F
are 0 VERB F
effective 0 ADJ F
to 0 PART F
improve 0 VERB F
social 0 ADJ F
functions 0 NOUN F
and 0 CCONJ F
psychiatric 0 ADJ F
symptoms 0 NOUN F
of 0 ADP F
schizophrenics 0 NOUN F
. 0 PUNCT F

Ursodeoxycholic 0 ADJ T
acid 0 NOUN F
has 0 CCONJ F
no 0 DET F
influence 0 NOUN F
on 0 ADP F
function 0 NOUN F
after 0 ADP F
restorative 0 ADJ F
proctocolectomy B-PHYSICAL NOUN F
in 0 ADP F
ulcerative 0 ADJ F
colitis 0 NOUN F
. 0 PUNCT F

BACKGROUND 0 NOUN T
Poor 0 ADJ T
pouch 0 DET F
function 0 NOUN F
is 0 VERB F
associated 0 VERB F
with 0 ADP F
impaired 0 VERB F
bile 0 NOUN F
acid 0 NOUN F
absorption 0 NOUN F
and 0 CCONJ F
increased 0 VERB F
faecal 0 ADJ F
loss 0 NOUN F
of 0 ADP F
bile 0 NOUN F
acids 0 NOUN F
. 0 PUNCT F

Bile 0 NOUN T
acid 0 NOUN F
replacement 0 NOUN F
therapy 0 NOUN F
might 0 PUNCT F
therefore 0 ADV F
be 0 DET F
of 0 ADP F
clinical 0 ADJ F
benefit 0 NOUN F
, 0 PUNCT F
provided 0 CCONJ F
that 0 PUNCT F
diarrhoea 0 NOUN F
is 0 VERB F
not 0 ADV F
aggravated 0 VERB F
by 0 ADP F
therapy 0 NOUN F
. 0 PUNCT F

AIM 0 NOUN T
To 0 ADV T
investigate 0 NOUN F
the 0 DET F
role 0 NOUN F
of 0 ADP F
exogenous 0 ADJ F
bile 0 NOUN F
acid 0 NOUN F
therapy 0 NOUN F
in 0 ADP F
patients 0 NOUN F
with 0 ADP F
poor 0 ADJ F
pouch 0 DET F
function 0 NOUN F
after 0 ADP F
restorative 0 ADJ F
proctocolectomy 0 NOUN F
for 0 ADP F
ulcerative 0 ADJ F
colitis 0 NOUN F
. 0 PUNCT F

PATIENTS 0 NOUN T
AND 0 CCONJ T
METHODS 0 NOUN T
Twenty 0 NUM T
ulcerative 0 ADJ F
colitis 0 NOUN F
patients 0 NOUN F
with 0 ADP F
poor 0 ADJ F
pouch 0 DET F
function 0 NOUN F
( 0 PUNCT F
score 0 NOUN F
> 0 SYM F
4 0 NUM F
on 0 ADP F
a 0 DET F
12-point 0 NOUN F
score 0 NOUN F
) 0 PUNCT F
were 0 VERB F
recruited 0 VERB F
for 0 ADP F
inclusion 0 NOUN F
to 0 ADP F
a 0 DET F
prospective 0 ADJ F
, 0 PUNCT F
randomized 0 VERB F
, 0 PUNCT F
double-blind 0 ADJ F
crossover 0 NOUN F
, 0 PUNCT F
placebo-controlled 0 VERB F
trial 0 NOUN F
of 0 ADP F
ursodeoxycholic 0 ADJ F
acid 0 NOUN F
( 0 PUNCT F
10 0 NUM F
mg/kg 0 NOUN F
per 0 ADP F
day 0 NOUN F
in 0 ADP F
two 0 NUM F
divided 0 VERB F
doses 0 NOUN F
for 0 ADP F
1 0 NUM F
month 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

RESULTS 0 NOUN T
A 0 PUNCT T
total 0 NOUN F
of 0 ADP F
16 0 NUM F
patients 0 NOUN F
completed 0 NOUN F
the 0 DET F
study 0 NOUN F
. 0 PUNCT F

There 0 PUNCT T
was 0 VERB F
no 0 DET F
significant 0 ADJ F
difference 0 NOUN F
in 0 ADP F
the 0 DET F
functional B-PHYSICAL ADJ F
score 0 NOUN F
or B-PHYSICAL CCONJ F
bowel I-PHYSICAL NOUN F
frequency B-PHYSICAL NOUN F
following 0 VERB F
treatment 0 NOUN F
irrespective 0 ADJ F
of 0 ADP F
whether 0 ADP F
the 0 DET F
active 0 ADJ F
treatment 0 NOUN F
was 0 VERB F
given 0 VERB F
before 0 ADP F
or 0 CCONJ F
after 0 ADP F
placebo 0 NOUN F
. 0 PUNCT F

CONCLUSIONS 0 NOUN T
We 0 PRON T
conclude 0 VERB F
that 0 PUNCT F
ursodeoxycholic 0 ADJ F
acid 0 NOUN F
given 0 VERB F
over 0 ADP F
4 0 NUM F
weeks 0 NOUN F
had 0 PUNCT F
no 0 DET F
influence 0 NOUN F
on 0 ADP F
functional B-PHYSICAL ADJ F
score 0 PUNCT F

Environmental 0 ADJ T
enrichment 0 ADJ F
as 0 ADP F
an 0 DET F
effective 0 ADJ F
treatment 0 NOUN F
for 0 ADP F
autism B-PHYSICAL NOUN F
: 0 PUNCT F
a 0 DET F
randomized 0 VERB F
controlled 0 VERB F
trial 0 NOUN F
. 0 PUNCT F

Enriched 0 VERB T
sensorimotor 0 NOUN F
environments 0 NOUN F
enable 0 PUNCT F
rodents 0 NOUN F
to 0 PART F
compensate 0 VERB F
for 0 ADP F
a 0 DET F
wide 0 ADJ F
range 0 NOUN F
of 0 ADP F
neurological 0 ADJ F
challenges 0 NOUN F
, 0 PUNCT F
including 0 VERB F
those 0 PUNCT F
induced 0 VERB F
in 0 ADP F
animal 0 NOUN F
models 0 NOUN F
of 0 ADP F
autism 0 NOUN F
. 0 PUNCT F

Given 0 VERB T
the 0 DET F
sensorimotor 0 NOUN F
deficits 0 NOUN F
in 0 ADP F
most 0 DET F
children 0 NOUN F
with 0 ADP F
autism 0 NOUN F
, 0 PUNCT F
we 0 PRON F
attempted 0 VERB F
to 0 PART F
translate 0 NOUN F
that 0 ADP F
approach 0 NOUN F
to 0 ADP F
their 0 PUNCT F
treatment 0 NOUN F
. 0 PUNCT F

In 0 ADP T
a 0 DET F
randomized 0 VERB F
controlled 0 VERB F
trial 0 NOUN F
, 0 PUNCT F
3-12 0 NUM F
year-old 0 PUNCT F
children 0 NOUN F
with 0 ADP F
autism 0 NOUN F
were 0 VERB F
assigned 0 VERB F
to 0 ADP F
either 0 CCONJ F
a 0 DET F
sensorimotor 0 NOUN F
enrichment 0 ADJ F
group 0 NOUN F
, 0 PUNCT F
which 0 ADP F
received 0 VERB F
daily 0 ADJ F
olfactory/tactile 0 NOUN F
stimulation 0 NOUN F
along 0 PUNCT F
with 0 ADP F
exercises 0 NOUN F
that 0 ADP F
stimulated 0 VERB F
other 0 ADJ F
paired 0 ADP F
sensory 0 ADJ F
modalities 0 NOUN F
, 0 PUNCT F
or 0 CCONJ F
to 0 ADP F
a 0 DET F
control 0 NOUN F
group 0 NOUN F
. 0 PUNCT F

We 0 PRON T
administered 0 VERB F
tests 0 NOUN F
of 0 ADP F
cognitive 0 ADJ F
performance 0 NOUN F
and 0 CCONJ F
autism 0 NOUN F
severity 0 NOUN F
to 0 ADP F
both 0 CCONJ F
groups 0 NOUN F
at 0 ADP F
the 0 DET F
initiation 0 NOUN F
of 0 ADP F
the 0 DET F
study 0 NOUN F
and 0 CCONJ F
after 0 ADP F
6 0 NUM F
months 0 NOUN F
. 0 PUNCT F

Severity B-PHYSICAL NOUN T
of I-PHYSICAL ADP F
autism I-PHYSICAL NOUN F
, 0 PUNCT F
as 0 PUNCT F
assessed 0 VERB F
with 0 ADP F
the 0 DET F
Childhood B-OTHER NOUN T
Autism I-OTHER NOUN T
Rating I-OTHER PUNCT T
Scale 0 NOUN T
, 0 PUNCT F
improved 0 VERB F
significantly 0 ADV F
in 0 ADP F
the 0 DET F
enriched 0 VERB F
group 0 NOUN F
compared 0 VERB F
to 0 ADP F
controls 0 NOUN F
. 0 PUNCT F

Indeed 0 ADV T
, 0 PUNCT F
42 0 NUM F
% 0 SYM F
of 0 ADP F
the 0 DET F
enriched 0 VERB F
group 0 NOUN F
and 0 CCONJ F
only 0 ADV F
7 0 NUM F
% 0 SYM F
of 0 ADP F
the 0 DET F
control 0 NOUN F
group 0 NOUN F
had 0 PUNCT F
what 0 PUNCT F
we 0 ADJ F
considered 0 VERB F
to 0 PART F
be 0 PUNCT F
a 0 DET F
clinically 0 ADV F
significant 0 ADJ F
improvement 0 NOUN F
of 0 ADP F
5 0 NUM F
points 0 NOUN F
on 0 ADP F
that 0 PUNCT F
scale 0 NOUN F
. 0 PUNCT F

Sensorimotor 0 NOUN T
enrichment 0 ADJ F
also 0 ADV F
produced 0 VERB F
a 0 DET F
clear B-OTHER ADJ F
improvement I-OTHER NOUN F
in I-OTHER ADP F
cognition I-OTHER NOUN F
, 0 PUNCT F
as 0 CCONJ F
determined 0 VERB F
by 0 ADP F
their 0 ADP F
Leiter-R 0 NOUN T
Visualization 0 NOUN T
and 0 CCONJ F
Reasoning 0 PUNCT T
scores 0 NOUN F
. 0 PUNCT F

At 0 ADP T
6 0 NUM F
months 0 NOUN F
, 0 PUNCT F
the 0 DET F
change 0 NOUN F
in 0 ADP F
average 0 ADJ F
scores 0 NOUN F
for 0 ADP F
the 0 DET F
enriched 0 VERB F
group 0 NOUN F
was 0 VERB F
11.3 0 NUM F
points 0 ADP F
higher 0 PUNCT F
than 0 CCONJ F
that 0 PUNCT F
for 0 ADP F
the 0 DET F
control 0 NOUN F
group 0 NOUN F
. 0 PUNCT F

Finally 0 ADV T
, 0 PUNCT F
69 0 NUM F
% 0 SYM F
of 0 ADP F
parents 0 NOUN F
in 0 ADP F
the 0 DET F
enriched 0 VERB F
group 0 NOUN F
and 0 CCONJ F
31 0 NUM F
% 0 SYM F
of 0 ADP F
parents 0 NOUN F
in 0 ADP F
the 0 DET F
control 0 NOUN F
group 0 NOUN F
reported 0 VERB F
improvement 0 NOUN F
in 0 ADP F
their 0 PUNCT F
child 0 NOUN F
over 0 ADP F
the 0 DET F
6-month 0 NOUN F
study 0 NOUN F
. 0 PUNCT F

Environmental 0 ADJ T
enrichment 0 ADJ F
therefore 0 ADV F
appears 0 NOUN F
to 0 PART F
be 0 PUNCT F
effective 0 ADJ F
in 0 ADP F
ameliorating 0 PUNCT F
some 0 DET F
of 0 ADP F
the 0 DET F
symptoms 0 NOUN F
of 0 ADP F
autism 0 NOUN F
in 0 ADP F
children 0 NOUN F
. 0 PUNCT F

Safety 0 NOUN T
and 0 CCONJ F
efficacy 0 NOUN F
of 0 ADP F
dalcetrapib 0 ADP F
on 0 ADP F
atherosclerotic 0 ADJ F
disease 0 NOUN F
using 0 VERB F
novel 0 ADJ F
non-invasive 0 ADJ F
multimodality 0 NOUN F
imaging 0 VERB F
( 0 PUNCT F
dal-PLAQUE 0 NOUN F
) 0 PUNCT F
: 0 PUNCT F
a 0 DET F
randomised 0 VERB F
clinical 0 ADJ F
trial 0 NOUN F
. 0 PUNCT F

BACKGROUND 0 NOUN T
Dalcetrapib 0 NUM T
modulates 0 NOUN F
cholesteryl 0 NOUN F
ester 0 NOUN F
transfer 0 NOUN F
protein 0 NOUN F
( 0 PUNCT F
CETP 0 NOUN T
) 0 PUNCT F
activity 0 NOUN F
to 0 PART F
raise 0 ADJ F
high-density 0 NOUN F
lipoprotein 0 NOUN F
cholesterol 0 NOUN F
( 0 PUNCT F
HDL-C 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

After 0 ADP T
the 0 DET F
failure 0 NOUN F
of 0 ADP F
torcetrapib 0 ADJ F
it 0 PUNCT F
was 0 VERB F
unknown 0 VERB F
if 0 PUNCT F
HDL 0 NOUN T
produced 0 VERB F
by 0 ADP F
interaction 0 NOUN F
with 0 ADP F
CETP 0 NOUN T
had 0 VERB F
pro-atherogenic 0 ADJ F
or 0 CCONJ F
pro-inflammatory 0 ADJ F
properties 0 NOUN F
. 0 PUNCT F

dal-PLAQUE 0 NOUN F
is 0 VERB F
the 0 DET F
first 0 ADJ F
multicentre 0 NOUN F
study 0 NOUN F
using 0 VERB F
novel 0 ADJ F
non-invasive 0 ADJ F
multimodality 0 NOUN F
imaging 0 VERB F
to 0 ADJ F
assess 0 NOUN F
structural 0 ADJ F
and 0 CCONJ F
inflammatory 0 ADJ F
indices 0 NOUN F
of 0 ADP F
atherosclerosis 0 NOUN F
as 0 ADP F
primary 0 ADJ F
endpoints 0 NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
In 0 ADP T
this 0 DET F
phase 0 NOUN F
2b 0 NOUN F
, 0 PUNCT F
double-blind 0 ADJ F
, 0 PUNCT F
multicentre 0 NOUN F
trial 0 NOUN F
, 0 PUNCT F
patients 0 NOUN F
( 0 PUNCT F
aged 0 PROPN F
18-75 0 NUM F
years 0 NOUN F
) 0 PUNCT F
with 0 ADP F
, 0 PUNCT F
or 0 CCONJ F
with 0 ADP F
high 0 ADJ F
risk 0 NOUN F
of 0 ADP F
, 0 PUNCT F
coronary 0 ADJ F
heart 0 NOUN F
disease 0 NOUN F
were 0 VERB F
randomly 0 ADV F
assigned 0 VERB F
( 0 PUNCT F
1:1 0 NUM F
) 0 PUNCT F
to 0 ADP F
dalcetrapib 0 PUNCT F
600 0 NUM F
mg/day 0 NOUN F
or 0 CCONJ F
placebo 0 NOUN F
for 0 ADP F
24 0 NUM F
months 0 NOUN F
. 0 PUNCT F

Randomisation 0 NOUN T
was 0 VERB F
done 0 PUNCT F
with 0 ADP F
a 0 DET F
computer-generated 0 VERB F
randomisation 0 NOUN F
code 0 NOUN F
and 0 CCONJ F
was 0 VERB F
stratified 0 VERB F
by 0 ADP F
centre 0 NOUN F
. 0 PUNCT F

Patients 0 NOUN T
and 0 CCONJ F
investigators 0 NOUN F
were 0 VERB F
masked 0 VERB F
to 0 ADP F
treatment 0 NOUN F
. 0 PUNCT F

Coprimary 0 NOUN T
endpoints 0 NOUN F
were 0 VERB F
MRI-assessed B-OTHER VERB T
indices I-OTHER NOUN F
( 0 PUNCT F
total 0 ADJ F
vessel B-OTHER NOUN F
area 0 NOUN F
, 0 PUNCT F
wall B-OTHER NOUN F
area 0 NOUN F
, 0 PUNCT F
wall B-OTHER NOUN F
thickness I-OTHER NOUN F
, 0 PUNCT F
and 0 CCONJ F
normalised B-OTHER PUNCT F
wall I-OTHER NOUN F
index I-OTHER NOUN F
[ 0 PUNCT F
average 0 PUNCT F
carotid 0 ADJ F
] 0 PUNCT F
) 0 PUNCT F
after 0 ADP F
24 0 NUM F
months 0 NOUN F
and 0 CCONJ F
( 0 PUNCT F
18 0 NUM F
) 0 PUNCT F
F-fluorodeoxyglucose 0 VERB T
( 0 PUNCT F
( 0 PUNCT F
18 0 NUM F
) 0 PUNCT F
F-FDG 0 NOUN T
) 0 PUNCT F
PET/CT 0 NOUN T
assessment 0 NOUN F
of 0 ADP F
arterial 0 ADJ F
inflammation 0 NOUN F
within 0 ADP F
an 0 DET F
index 0 NOUN F
vessel 0 NOUN F
( 0 PUNCT F
right 0 PUNCT F
carotid 0 ADJ F
, 0 PUNCT F
left 0 ADJ F
carotid 0 ADJ F
, 0 PUNCT F
or 0 CCONJ F
ascending 0 ADV F
thoracic 0 ADJ F
aorta 0 NOUN F
) 0 PUNCT F
after 0 ADP F
6 0 NUM F
months 0 NOUN F
, 0 PUNCT F
with 0 ADP F
no-harm 0 NOUN F
boundaries 0 NOUN F
established 0 VERB F
before 0 ADP F
unblinding 0 PUNCT F
of 0 ADP F
the 0 DET F
trial 0 NOUN F
. 0 PUNCT F

Analysis 0 NOUN T
was 0 VERB F
by 0 ADP F
intention 0 NOUN F
to 0 PART F
treat 0 ADV F
. 0 PUNCT F

This 0 DET T
trial 0 NOUN F
is 0 VERB F
registered 0 NOUN F
at 0 ADP F
ClinicalTrials.gov 0 PUNCT T
, 0 PUNCT F
NCT00655473 0 NOUN T
. 0 PUNCT F

FINDINGS 0 NOUN T
189 0 NUM F
patients 0 NOUN F
were 0 VERB F
screened 0 NUM F
and 0 CCONJ F
130 0 NUM F
randomly 0 ADV F
assigned 0 VERB F
to 0 ADP F
placebo 0 NOUN F
( 0 PUNCT F
66 0 NUM F
patients 0 NOUN F
) 0 PUNCT F
or 0 CCONJ F
dalcetrapib 0 ADP F
( 0 PUNCT F
64 0 NUM F
patients 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

For 0 ADP T
the 0 DET F
coprimary 0 ADJ F
MRI 0 NOUN T
and 0 CCONJ F
PET/CT 0 ADP T
endpoints 0 NOUN F
, 0 PUNCT F
CIs 0 PUNCT T
were 0 VERB F
below 0 ADP F
the 0 DET F
no-harm 0 NOUN F
boundary 0 NOUN F
or 0 CCONJ F
the 0 DET F
adverse 0 ADJ F
change 0 NOUN F
was 0 VERB F
numerically 0 ADV F
lower 0 PUNCT F
in 0 ADP F
the 0 DET F
dalcetrapib 0 PUNCT F
group 0 NOUN F
than 0 PUNCT F
in 0 ADP F
the 0 DET F
placebo 0 NOUN F
group 0 NOUN F
. 0 PUNCT F

MRI-derived B-OTHER VERB T
change I-OTHER NOUN F
in I-OTHER PUNCT F
total 0 PUNCT F

Atrial 0 ADJ T
natriuretic 0 ADJ F
factor 0 NOUN F
inhibits 0 VERB F
metoclopramide 0 CCONJ F
stimulated 0 ADV F
aldosterone B-PHYSICAL NOUN F
release I-PHYSICAL NOUN F
in 0 ADP F
man 0 NOUN F
. 0 PUNCT F

1 0 NUM F
. 0 PUNCT F

Atrial 0 ADJ T
natriuretic 0 ADJ F
factor 0 NOUN F
( 0 PUNCT F
ANF 0 NOUN T
) 0 PUNCT F
has 0 VERB F
an 0 DET F
inhibitory 0 ADJ F
effect 0 NOUN F
on 0 ADP F
angiotensin B-PHYSICAL NOUN F
II I-PHYSICAL NUM T
and 0 CCONJ F
ACTH B-PHYSICAL NOUN T
stimulated I-PHYSICAL PUNCT F
aldosterone I-PHYSICAL NOUN F
secretion I-PHYSICAL NOUN F
in 0 ADP F
man 0 NOUN F
. 0 PUNCT F

The 0 DET T
selectivity 0 NOUN F
of 0 ADP F
this 0 DET F
aldosterone 0 NOUN F
suppressing 0 PUNCT F
effect 0 NOUN F
of 0 ADP F
ANF 0 NOUN T
is 0 VERB F
unclear 0 ADJ F
in 0 ADP F
man 0 NOUN F
. 0 PUNCT F

The 0 DET T
present 0 ADJ F
study 0 NOUN F
investigated 0 VERB F
the 0 DET F
effect 0 NOUN F
of 0 ADP F
ANF 0 NOUN T
on 0 ADP F
the 0 DET F
increase 0 NOUN F
in 0 ADP F
plasma B-PHYSICAL NOUN F
aldosterone I-PHYSICAL NOUN F
due 0 ADP F
to 0 ADP F
metoclopramide B-OTHER CCONJ F
in 0 ADP F
man 0 NOUN F
. 0 PUNCT F

2 0 NUM F
. 0 PUNCT F

Eight 0 NUM T
normal 0 ADJ F
male 0 NOUN F
volunteers 0 NOUN F
were 0 VERB F
studied 0 VERB F
on 0 ADP F
three 0 NUM F
occasions 0 NOUN F
. 0 PUNCT F

Metoclopramide 0 CCONJ T
( 0 PUNCT F
10 0 NUM F
mg 0 NOUN F
slow 0 ADJ F
i.v 0 NUM F
. 0 PUNCT F
) 0 PUNCT F

was 0 VERB F
given 0 VERB F
on 0 ADP F
all 0 DET F
study 0 ADJ F
days 0 NOUN F
and 0 CCONJ F
each 0 DET F
volunteer 0 ADV F
was 0 VERB F
randomised 0 VERB F
to 0 PART F
receive 0 ADV F
45 0 NUM F
min 0 NOUN F
infusion 0 NOUN F
of 0 ADP F
either 0 CCONJ F
5 0 NUM F
% 0 SYM F
D-glucose 0 NOUN T
( 0 PUNCT F
placebo 0 NOUN F
) 0 PUNCT F
or 0 CCONJ F
ANF 0 NOUN T
( 0 PUNCT F
99-126 0 NUM F
) 0 PUNCT F
3 0 NUM F
or 0 CCONJ F
15 0 NUM F
pmol 0 NOUN F
kg-1 0 NOUN F
min-1 0 NOUN F
. 0 PUNCT F

3 0 NUM F
. 0 PUNCT F

Metoclopramide 0 CCONJ T
increased 0 VERB F
plasma B-PHYSICAL NOUN F
aldosterone I-PHYSICAL NOUN F
to 0 ADP F
approximately 0 ADV F
170 0 NUM F
% 0 SYM F
of 0 ADP F
baseline 0 NOUN F
levels 0 NOUN F
( 0 PUNCT F
P 0 NOUN T
less 0 ADV F
than 0 PUNCT F
0.01 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Concomitant 0 ADJ T
infusion 0 NOUN F
of 0 ADP F
ANF 0 NOUN T
3 0 NUM F
pmol 0 NOUN F
kg-1 0 NOUN F
min-1 0 NOUN F
and 0 CCONJ F
15 0 NUM F
pmol 0 NOUN F
kg-1 0 NOUN F
min-1 0 NOUN F
significantly 0 ADV F
attenuated 0 VERB F
this 0 DET F
rise 0 NOUN F
in 0 ADP F
plasma 0 NOUN F
aldosterone 0 NOUN F
to 0 ADP F
approximately 0 ADV F
130 0 NUM F
% 0 SYM F
( 0 PUNCT F
P 0 NOUN T
less 0 ADV F
than 0 PUNCT F
0.05 0 NUM F
) 0 PUNCT F
and 0 CCONJ F
110 0 NUM F
% 0 SYM F
( 0 PUNCT F
P 0 NOUN T
less 0 ADV F
than 0 PUNCT F
0.01 0 NUM F
) 0 PUNCT F
of 0 ADP F
baseline 0 NOUN F
values 0 NOUN F
respectively 0 ADV F
. 0 PUNCT F

4 0 NUM F
. 0 PUNCT F

It 0 PRON T
is 0 VERB F
suggested 0 VERB F
, 0 PUNCT F
in 0 ADP F
the 0 DET F
light 0 NOUN F
of 0 ADP F
previous 0 ADJ F
findings 0 NOUN F
, 0 PUNCT F
that 0 ADP F
the 0 DET F
inhibitory 0 ADJ F
effect 0 NOUN F
of 0 ADP F
ANF 0 NOUN T
represents 0 NOUN F
a 0 DET F
non-selective 0 ADJ F
action 0 NOUN F
of 0 ADP F
ANF 0 NOUN T
on 0 ADP F
aldosterone B-PHYSICAL NOUN F
release I-PHYSICAL NOUN F
. 0 PUNCT F

Determination 0 NOUN T
of 0 ADP F
vital 0 ADJ F
status 0 NOUN F
at 0 ADP F
the 0 DET F
end 0 NOUN F
of 0 ADP F
the 0 DET F
DIG 0 NOUN T
trial 0 NOUN F
. 0 PUNCT F

The 0 DET T
Digitalis 0 NOUN T
Investigation 0 NOUN T
Group 0 NOUN T
( 0 PUNCT F
DIG 0 NOUN T
) 0 PUNCT F
trial 0 NOUN F
was 0 VERB F
a 0 DET F
randomized 0 VERB F
, 0 PUNCT F
double-blind 0 ADJ F
placebo-controlled 0 VERB F
trial 0 NOUN F
whose 0 ADP F
primary 0 ADJ F
objective 0 ADJ F
was 0 VERB F
to 0 PART F
determine 0 NOUN F
whether 0 VERB F
digoxin 0 NOUN F
had 0 PUNCT F
beneficial 0 ADJ F
, 0 PUNCT F
harmful 0 ADJ F
, 0 PUNCT F
or 0 CCONJ F
no 0 DET F
effect 0 NOUN F
on 0 ADP F
total 0 ADJ F
mortality 0 NOUN F
in 0 ADP F
patients 0 NOUN F
with 0 ADP F
heart 0 NOUN F
failure 0 NOUN F
who 0 ADP F
were 0 VERB F
in 0 ADP F
sinus 0 NOUN F
rhythm 0 NOUN F
and 0 CCONJ F
whose 0 ADP F
ejection 0 NOUN F
fraction 0 NOUN F
was 0 VERB F
< 0 SYM F
/=0.45 0 ADV F
. 0 PUNCT F

The 0 DET T
study 0 NOUN F
was 0 VERB F
designed 0 VERB F
as 0 ADP F
a 0 DET F
large 0 ADJ F
simple 0 ADJ F
trial 0 NOUN F
with 0 ADP F
a 0 DET F
large 0 ADJ F
number 0 NOUN F
of 0 ADP F
centers 0 NOUN F
( 0 PUNCT F
302 0 NUM F
) 0 PUNCT F
in 0 ADP F
the 0 DET F
United 0 ADV T
States 0 NOUN T
and 0 CCONJ F
Canada 0 PUNCT T
, 0 PUNCT F
many 0 DET F
of 0 ADP F
which 0 ADP F
were 0 VERB F
inexperienced 0 VERB F
in 0 ADP F
research 0 NOUN F
. 0 PUNCT F

To 0 PART T
ensure 0 NOUN F
that 0 ADP F
the 0 DET F
results 0 NOUN F
of 0 ADP F
the 0 DET F
trial 0 NOUN F
would 0 VERB F
be 0 VERB F
reported 0 VERB F
accurately 0 ADV F
without 0 ADP F
possible 0 ADJ F
bias 0 NOUN F
due 0 PUNCT F
to 0 PUNCT F
missing 0 PUNCT F
data 0 NOUN F
, 0 PUNCT F
the 0 DET F
study 0 PUNCT F
leadership 0 PUNCT F
decided 0 CCONJ F
that 0 PUNCT F
no 0 DET F
outcome 0 NOUN F
results 0 NOUN F
would 0 VERB F
be 0 VERB F
reported 0 VERB F
until 0 ADP F
the 0 DET F
vital 0 ADJ F
status 0 NOUN F
at 0 ADP F
the 0 DET F
end 0 NOUN F
of 0 ADP F
the 0 DET F
study 0 NOUN F
was 0 VERB F
known 0 VERB F
for 0 ADP F
at 0 ADP F
least 0 ADV F
97 0 NUM F
% 0 SYM F
of 0 ADP F
the 0 DET F
study 0 ADJ F
participants 0 NOUN F
. 0 PUNCT F

Planning 0 VERB T
for 0 ADP F
closeout 0 ADP F
of 0 ADP F
the 0 DET F
study 0 NOUN F
began 0 VERB F
a 0 DET F
year 0 NOUN F
prior 0 PUNCT F
to 0 ADP F
the 0 DET F
common 0 ADJ F
end 0 NOUN F
date 0 NOUN F
of 0 ADP F
December 0 NOUN T
31 0 NUM F
, 0 PUNCT F
1995 0 NUM F
and 0 CCONJ F
included 0 ADJ F
plans 0 NOUN F
for 0 ADP F
obtaining 0 DET F
vital 0 ADJ F
status 0 NOUN F
on 0 ADP F
December 0 NOUN T
31 0 NUM F
, 0 PUNCT F
1995 0 NUM F
. 0 PUNCT F

Participants 0 NOUN T
were 0 VERB F
given 0 VERB F
postcards 0 NOUN F
at 0 ADP F
their 0 PUNCT F
final 0 ADJ F
study 0 NOUN F
visit 0 NOUN F
to 0 PART F
be 0 PUNCT F
completed 0 VERB F
and 0 CCONJ F
mailed 0 VERB F
on 0 ADP F
or 0 CCONJ F
after 0 ADP F
January 0 NOUN T
1 0 NUM F
, 0 PUNCT F
1996 0 NUM F
. 0 PUNCT F

Of 0 ADP T
5602 0 NUM F
postcards 0 NOUN F
distributed 0 VERB F
, 0 PUNCT F
5070 0 NUM F
( 0 PUNCT F
90.5 0 NUM F
% 0 SYM F
) 0 PUNCT F
were 0 VERB F
completed 0 VERB F
and 0 CCONJ F
returned 0 PUNCT F
. 0 PUNCT F

A 0 PUNCT T
contract 0 PUNCT F
search 0 NOUN F
agency 0 NOUN F
was 0 VERB F
hired 0 NUM F
to 0 ADP F
locate 0 PUNCT F
the 0 DET F
remaining 0 VERB F
participants 0 NOUN F
. 0 PUNCT F

Of 0 ADP T
the 0 DET F
total 0 ADJ F
7788 0 NUM F
participants 0 NOUN F
entered 0 VERB F
into 0 ADP F
the 0 DET F
DIG 0 NOUN T
trial 0 NOUN F
, 0 PUNCT F
only 0 ADV F
97 0 NUM F
participants 0 NOUN F
( 0 PUNCT F
1.2 0 NUM F
% 0 SYM F
) 0 PUNCT F
could 0 VERB F
not 0 ADV F
have 0 VERB F
their 0 CCONJ F
vital B-PHYSICAL ADJ F
status I-PHYSICAL NOUN F
as 0 PUNCT F
of 0 ADP F
December 0 NOUN T
31 0 NUM F
, 0 PUNCT F
1995 0 NUM F
determined 0 PROPN F
. 0 PUNCT F

It 0 PRON T
is 0 VERB F
recommended 0 VERB F
that 0 ADP F
investigators 0 NOUN F
having 0 VERB F
an 0 DET F
outcome 0 NOUN F
measure 0 NOUN F
with 0 ADP F
a 0 DET F
common 0 ADJ F
end 0 NOUN F
date 0 NOUN F
include 0 ADP F
plans 0 NOUN F
in 0 ADP F
their 0 PUNCT F
protocols 0 NOUN F
for 0 ADP F
obtaining 0 DET F
their 0 PUNCT F
measures 0 NOUN F
and 0 CCONJ F
activate 0 VERB F
those 0 PUNCT F
plans 0 NOUN F
as 0 PUNCT F
early 0 ADJ F
as 0 VERB F
possible 0 ADJ F
during 0 ADP F
the 0 DET F
course 0 NOUN F
of 0 ADP F
the 0 DET F
study 0 NOUN F
. 0 PUNCT F

Effect 0 NOUN T
of 0 ADP F
CX516 0 NOUN T
, 0 PUNCT F
an 0 DET F
AMPA-modulating 0 VERB T
compound 0 ADV F
, 0 PUNCT F
on 0 ADP F
cognition B-MENTAL NOUN F
and 0 CCONJ F
behavior B-MENTAL NOUN F
in 0 ADP F
fragile 0 ADJ F
X 0 NUM T
syndrome 0 NOUN F
: 0 PUNCT F
a 0 DET F
controlled 0 VERB F
trial 0 NOUN F
. 0 PUNCT F

A 0 DET T
Phase 0 NOUN T
II 0 NUM T
, 0 PUNCT F
4-week 0 NOUN F
randomized 0 VERB F
, 0 PUNCT F
double-blind 0 ADJ F
, 0 PUNCT F
placebo-controlled 0 VERB F
clinical 0 ADJ F
trial 0 NOUN F
was 0 VERB F
conducted 0 VERB F
to 0 PART F
evaluate 0 NOUN F
the 0 DET F
safety 0 NOUN F
and 0 CCONJ F
efficacy 0 NOUN F
of 0 ADP F
the 0 DET F
Ampakine 0 NOUN T
compound 0 ADP F
CX516 0 NOUN T
as 0 ADP F
a 0 DET F
potential 0 ADJ F
treatment 0 NOUN F
for 0 ADP F
the 0 DET F
underlying 0 ADP F
disorder 0 NOUN F
in 0 ADP F
fragile 0 ADJ F
X 0 NUM T
syndrome 0 NOUN F
( 0 PUNCT F
FXS 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

After 0 ADP T
baseline 0 NOUN F
screening 0 PUNCT F
, 0 PUNCT F
subjects 0 NOUN F
with 0 ADP F
FXS 0 NOUN T
( 0 PUNCT F
n 0 NOUN F
= 0 SYM F
49 0 NUM F
) 0 PUNCT F
underwent 0 VERB F
a 0 DET F
1-week 0 NOUN F
placebo 0 NOUN F
lead-in 0 PUNCT F
and 0 CCONJ F
then 0 ADV F
were 0 VERB F
randomized 0 VERB F
to 0 ADJ F
study 0 NOUN F
drug 0 NOUN F
or 0 CCONJ F
placebo 0 NOUN F
for 0 ADP F
a 0 DET F
4-week 0 NOUN F
period 0 NOUN F
. 0 PUNCT F

Cognitive B-MENTAL ADJ T
and 0 CCONJ F
behavioral B-MENTAL ADJ F
outcome 0 NOUN F
measures 0 NOUN F
were 0 VERB F
administered 0 VERB F
prior 0 PUNCT F
to 0 ADP F
treatment 0 NOUN F
, 0 PUNCT F
at 0 ADP F
the 0 DET F
end 0 NOUN F
of 0 ADP F
treatment 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
2 0 NUM F
weeks 0 NOUN F
posttreatment 0 NOUN F
. 0 PUNCT F

There 0 PUNCT T
were 0 VERB F
minimal B-ADVERSE-EFFECTS ADJ F
side I-ADVERSE-EFFECTS NOUN F
effects I-ADVERSE-EFFECTS NOUN F
, 0 PUNCT F
no 0 DET F
significant B-OTHER ADJ F
changes I-OTHER NOUN F
in I-OTHER ADP F
safety I-OTHER NOUN F
parameters I-OTHER NOUN F
, 0 PUNCT F
and 0 CCONJ F
no 0 DET F
serious B-ADVERSE-EFFECTS ADJ F
adverse I-ADVERSE-EFFECTS ADJ F
events I-ADVERSE-EFFECTS NOUN F
. 0 PUNCT F

There 0 PUNCT T
was 0 VERB F
a 0 DET F
12.5 0 NUM F
% 0 SYM F
frequency 0 NOUN F
of 0 ADP F
allergic B-PHYSICAL ADJ F
rash I-PHYSICAL NOUN F
in 0 ADP F
the 0 DET F
CX516 0 NOUN T
group 0 NOUN F
and 0 CCONJ F
1 0 NUM F
subject 0 NOUN F
developed 0 VERB F
a 0 DET F
substantial B-ADVERSE-EFFECTS ADJ F
rash I-ADVERSE-EFFECTS NOUN F
. 0 PUNCT F

There 0 PUNCT T
was 0 VERB F
also 0 ADV F
no 0 DET F
significant B-MENTAL ADJ F
improvement I-MENTAL NOUN F
in 0 ADP F
memory B-MENTAL NOUN F
, 0 PUNCT F
the 0 DET F
primary 0 ADJ F
outcome 0 NOUN F
measure 0 NOUN F
, 0 PUNCT F
or 0 CCONJ F
in 0 ADP F
secondary 0 ADJ F
measures 0 NOUN F
of 0 ADP F
language B-MENTAL NOUN F
, I-MENTAL PUNCT F
attention/executive I-MENTAL ADJ F
function I-MENTAL NOUN F
, I-MENTAL PUNCT F
behavior I-MENTAL NOUN F
, I-MENTAL PUNCT F
and I-MENTAL CCONJ F
overall I-MENTAL ADJ F
functioning I-MENTAL VERB F
in 0 ADP F
CX516-treated 0 VERB T
subjects 0 NOUN F
compared 0 VERB F
to 0 ADP F
placebo 0 NOUN F
. 0 PUNCT F

This 0 DET T
study 0 NOUN F
did 0 PUNCT F
demonstrate 0 VERB F
that 0 ADP F
many 0 DET F
outcome 0 NOUN F
measures B-OTHER NOUN F
were 0 VERB F
reproducible 0 ADJ F
in 0 ADP F
this 0 DET F
test-retest 0 ADV F
setting 0 VERB F
for 0 ADP F
the 0 DET F
FXS 0 NOUN T
population 0 NOUN F
, 0 PUNCT F
yet 0 ADV F
some 0 PUNCT F
were 0 VERB F
too 0 ADV F
difficult 0 ADJ F
or 0 CCONJ F
variable 0 ADJ F
. 0 PUNCT F

Adult 0 ADJ T
subjects 0 NOUN F
with 0 ADP F
FXS 0 NOUN T
were 0 VERB F
able 0 ADJ F
to 0 ADP F
complete 0 ADJ F
an 0 DET F
intensive 0 ADJ F
clinical 0 ADJ F
trial 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
some 0 DET F
valid 0 ADP F
outcome 0 NOUN F
measures 0 NOUN F
were 0 VERB F
identified 0 VERB F
for 0 ADP F
future 0 ADJ F
FXS 0 NOUN T
trial 0 NOUN F
design 0 NOUN F
. 0 PUNCT F

Problems 0 NOUN T
with 0 ADP F
potency 0 NOUN F
of 0 ADP F
CX516 0 NOUN T
in 0 ADP F
other 0 ADJ F
studies 0 NOUN F
have 0 CCONJ F
suggested 0 VERB F
dosing 0 VERB F
may 0 ADJ F
have 0 PUNCT F
been 0 PUNCT F
inadequate 0 PUNCT F
for 0 ADP F
therapeutic 0 ADJ F
effect 0 NOUN F
and 0 CCONJ F
thus 0 ADV F
it 0 PRON F
remains 0 NOUN F
unclear 0 ADJ F
whether 0 ADP F
modulation 0 NOUN F
of 0 ADP F
AMPA-mediated 0 VERB T
neurotransmission 0 NOUN F
is 0 VERB F
a 0 DET F
viable B-OTHER ADJ F
therapeutic I-OTHER ADJ F
strategy I-OTHER NOUN F
for 0 ADP F
the 0 DET F
treatment 0 NOUN F
of 0 ADP F
FXS 0 NOUN T
. 0 PUNCT F

Topiramate 0 ADV T
improves 0 NOUN F
health-related B-PHYSICAL VERB F
quality I-PHYSICAL NOUN F
of I-PHYSICAL ADP F
life I-PHYSICAL NOUN F
when 0 ADP F
used 0 VERB F
to 0 PART F
prevent 0 NOUN F
migraine 0 NOUN F
. 0 PUNCT F

OBJECTIVE 0 NOUN T
To 0 PROPN T
assess 0 NOUN F
changes 0 NOUN F
in 0 ADP F
health-related B-PHYSICAL VERB F
quality 0 NOUN F
of 0 ADP F
life 0 NOUN F
( B-PHYSICAL PUNCT F
HRQoL B-PHYSICAL NOUN T
) B-PHYSICAL PUNCT F
measures I-PHYSICAL NOUN F
among 0 ADP F
patients 0 NOUN F
receiving 0 CCONJ F
topiramate 0 NOUN F
( 0 PUNCT F
TPM 0 NOUN T
) 0 PUNCT F
100 0 NUM F
mg/d 0 NOUN F
in 0 ADP F
two 0 NUM F
divided 0 VERB F
doses 0 NOUN F
for 0 ADP F
migraine 0 NOUN F
prevention 0 NOUN F
in 0 ADP F
three 0 NUM F
randomized 0 VERB F
, 0 PUNCT F
double-blind 0 ADJ F
, 0 PUNCT F
placebo-controlled 0 VERB F
, 0 PUNCT F
26-week 0 NOUN F
trials 0 NOUN F
with 0 ADP F
similar 0 ADJ F
protocols 0 NOUN F
and 0 CCONJ F
study 0 ADV F
populations 0 NOUN F
. 0 PUNCT F

BACKGROUND 0 NOUN T
Migraine 0 ADV T
substantially 0 ADV F
impairs 0 VERB F
HRQoL B-PHYSICAL NOUN T
and 0 CCONJ F
work B-OTHER ADP F
productivity I-OTHER NOUN F
before 0 ADP F
, 0 PUNCT F
during 0 ADP F
, 0 PUNCT F
and 0 CCONJ F
after 0 ADP F
attacks 0 NOUN F
. 0 PUNCT F

Approximately 0 ADV T
50 0 NUM F
% 0 SYM F
of 0 ADP F
patients 0 NOUN F
with 0 ADP F
migraine 0 NOUN F
could 0 VERB F
be 0 VERB F
recommended 0 VERB F
for 0 ADP F
preventive 0 ADJ F
therapies 0 NOUN F
, 0 PUNCT F
yet 0 ADV F
only 0 ADV F
3 0 NUM F
% 0 SYM F
to 0 ADP F
5 0 NUM F
% 0 SYM F
of 0 ADP F
patients 0 NOUN F
receive 0 VERB F
them 0 PRON F
. 0 PUNCT F

TPM 0 NOUN T
is 0 VERB F
an 0 DET F
effective B-OTHER ADJ F
and B-OTHER CCONJ F
generally B-OTHER ADV F
well-tolerated B-OTHER VERB F
migraine 0 NOUN F
prophylactic 0 PUNCT F
( 0 PUNCT F
preventive 0 ADP F
) 0 PUNCT F
therapy 0 NOUN F
for 0 ADP F
adults 0 NOUN F
, 0 PUNCT F
as 0 PUNCT F
demonstrated 0 VERB F
in 0 ADP F
several 0 ADJ F
randomized 0 VERB F
, 0 PUNCT F
double-blind 0 ADJ F
, 0 PUNCT F
placebo-controlled 0 VERB F
trials 0 NOUN F
. 0 PUNCT F

The 0 DET T
most 0 ADP F
common 0 ADJ F
adverse 0 ADJ F
events 0 NOUN F
in 0 ADP F
double-blind 0 ADJ F
, 0 PUNCT F
placebo-controlled 0 VERB F
studies 0 NOUN F
of 0 ADP F
TPM 0 NOUN T
in 0 ADP F
migraine 0 NOUN F
prevention 0 NOUN F
are 0 VERB F
paresthesia B-ADVERSE-EFFECTS NOUN F
, 0 PUNCT F
fatigue B-ADVERSE-EFFECTS NOUN F
, 0 PUNCT F
anorexia B-ADVERSE-EFFECTS PUNCT F
, 0 PUNCT F
nausea B-ADVERSE-EFFECTS NOUN F
, 0 PUNCT F
taste B-ADVERSE-EFFECTS NOUN F
alteration I-ADVERSE-EFFECTS ADP F
, 0 PUNCT F
and 0 CCONJ F
diarrhea B-ADVERSE-EFFECTS NOUN F
. 0 PUNCT F

DESIGN 0 NOUN T
AND 0 CCONJ T
METHODS 0 NOUN T
The 0 DET T
Migraine-Specific B-PHYSICAL ADJ T
Questionnaire 0 NOUN T
( B-PHYSICAL PUNCT F
MSQ B-PHYSICAL NOUN T
, 0 PUNCT F
version 0 ADJ F
2.1 0 PUNCT F
) 0 PUNCT F
was 0 VERB F
used 0 VERB F
to 0 PART F
assess 0 NOUN F
the 0 DET F
effect 0 NOUN F
of 0 ADP F
TPM 0 NOUN T
100 0 NUM F
mg/d 0 NOUN F
on 0 ADP F
the 0 DET F
functionality 0 ADJ F
and 0 CCONJ F
HRQoL 0 NOUN T
of 0 ADP F
randomized 0 VERB F
intent-to-treat 0 NOUN F
( 0 PUNCT F
ITT 0 NOUN T
) 0 PUNCT F
and 0 CCONJ F
study-completer 0 NOUN F
populations 0 NOUN F
pooled 0 VERB F
from 0 ADP F
three 0 NUM F
randomized 0 VERB F
, 0 PUNCT F
double-blind 0 ADJ F
, 0 PUNCT F
placebo-controlled 0 VERB F
trials 0 NOUN F
. 0 PUNCT F

MSQ B-PHYSICAL NOUN T
scores I-PHYSICAL NOUN F
( 0 PUNCT F
0 0 NUM F
to 0 ADP F
100 0 NUM F
, 0 PUNCT F
higher 0 PUNCT F
score 0 NOUN F
indicates 0 PART F
better 0 PUNCT F
functioning 0 SYM F
) 0 PUNCT F
were 0 VERB F
assessed 0 VERB F
for 0 ADP F
the 0 DET F
following 0 ADP F
three 0 NUM F
domains 0 NOUN F
: 0 PUNCT F
role 0 NOUN F
restriction 0 NOUN F
( 0 PUNCT F
examines 0 PROPN F
the 0 DET F
degree 0 NOUN F
to 0 ADP F
which 0 PUNCT F
performance 0 NOUN F
of 0 ADP F
daily 0 ADJ F
activities 0 NOUN F
is 0 VERB F
limited 0 VERB F
by 0 ADP F
migraine 0 NOUN F
) 0 PUNCT F
, 0 PUNCT F
role 0 NOUN F
prevention 0 NOUN F
( 0 PUNCT F
examines 0 PROPN F
the 0 DET F
degree 0 NOUN F
to 0 ADP F
which 0 PUNCT F
performance 0 NOUN F
of 0 ADP F
daily 0 ADJ F
activities 0 NOUN F
is 0 VERB F
interrupted 0 VERB F
by 0 ADP F
migraine 0 NOUN F
) 0 PUNCT F
, 0 PUNCT F
and 0 CCONJ F
emotional B-MENTAL ADJ F
function I-MENTAL NOUN F
( 0 PUNCT F
examines 0 NUM F
feelings 0 NOUN F
of 0 ADP F
frustration 0 NOUN F
and 0 CCONJ F
helplessness 0 NOUN F
due 0 CCONJ F
to 0 ADP F
migraine 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

Between-group 0 ADP T
differences 0 NOUN F
from 0 ADP F
baseline 0 NOUN F
in 0 ADP F
mean 0 NOUN F
MSQ B-PHYSICAL PUNCT T

Activator 0 NOUN T
protein-1 0 NOUN F
( 0 PUNCT F
AP-1 0 NOUN T
) 0 PUNCT F
signalling 0 VERB F
in 0 ADP F
human 0 NOUN F
atherosclerosis 0 NOUN F
: 0 PUNCT F
results 0 NOUN F
of 0 ADP F
a 0 DET F
systematic 0 ADJ F
evaluation 0 NOUN F
and 0 CCONJ F
intervention 0 NOUN F
study 0 NOUN F
. 0 PUNCT F

Animal 0 NOUN T
studies 0 NOUN F
implicate 0 VERB F
the 0 DET F
AP-1 0 NOUN T
( 0 PUNCT F
activator 0 NOUN F
protein-1 0 NOUN F
) 0 PUNCT F
pro-inflammatory 0 ADJ F
pathway 0 NOUN F
as 0 ADP F
a 0 DET F
promising 0 ADJ F
target 0 NOUN F
in 0 ADP F
the 0 DET F
treatment 0 NOUN F
of 0 ADP F
atherosclerotic 0 ADJ F
disease 0 NOUN F
. 0 PUNCT F

It 0 PRON T
is 0 VERB F
, 0 PUNCT F
however 0 ADV F
, 0 PUNCT F
unclear 0 ADJ F
whether 0 ADP F
these 0 DET F
observations 0 NOUN F
apply 0 VERB F
to 0 ADP F
human 0 NOUN F
atherosclerosis 0 NOUN F
. 0 PUNCT F

Therefore 0 ADV T
we 0 PRON F
evaluated 0 VERB F
the 0 DET F
profile 0 NOUN F
of 0 ADP F
AP-1 0 NOUN T
activation 0 NOUN F
through 0 ADP F
histological 0 ADJ F
analysis 0 NOUN F
and 0 CCONJ F
tested 0 VERB F
the 0 DET F
potential 0 ADJ F
benefit 0 NOUN F
of 0 ADP F
AP-1 0 NOUN T
inhibition 0 NOUN F
in 0 ADP F
a 0 DET F
clinical 0 ADJ F
trial 0 NOUN F
. 0 PUNCT F

AP-1 0 NOUN T
activation 0 NOUN F
was 0 VERB F
quantified 0 VERB F
by 0 ADP F
phospho-c-Jun 0 NOUN F
nuclear 0 ADJ F
translocation 0 NOUN F
( 0 PUNCT F
immunohistochemistry 0 NOUN F
) 0 PUNCT F
on 0 ADP F
a 0 DET F
biobank 0 CCONJ F
of 0 ADP F
aortic 0 ADJ F
wall 0 NOUN F
samples 0 NOUN F
from 0 ADP F
organ 0 NOUN F
donors 0 NOUN F
. 0 PUNCT F

The 0 DET T
effect 0 NOUN F
of 0 ADP F
AP-1 B-PHYSICAL NOUN T
inhibition I-PHYSICAL NOUN F
on 0 ADP F
vascular 0 ADJ F
parameters 0 NOUN F
was 0 VERB F
tested 0 VERB F
through 0 ADP F
a 0 DET F
double 0 ADJ F
blind 0 ADP F
placebo-controlled 0 VERB F
cross-over 0 NOUN F
study 0 ADJ F
of 0 ADP F
28 0 NUM F
days 0 NOUN F
doxycycline 0 NOUN F
or 0 CCONJ F
placebo 0 NOUN F
in 0 ADP F
patients 0 NOUN F
with 0 ADP F
symptomatic 0 ADJ F
peripheral 0 ADJ F
artery 0 NOUN F
disease 0 NOUN F
. 0 PUNCT F

Vascular 0 ADJ T
function 0 NOUN F
was 0 VERB F
assessed 0 VERB F
by 0 ADP F
brachial 0 ADJ F
dilation 0 NOUN F
as 0 PUNCT F
well 0 PUNCT F
as 0 CCONJ F
by 0 ADP F
plasma 0 NOUN F
samples 0 NOUN F
analysed 0 VERB F
for 0 ADP F
hs-CRP 0 NOUN F
( 0 PUNCT F
high-sensitivity 0 NOUN F
C-reactive 0 ADJ T
protein 0 NOUN F
) 0 PUNCT F
, 0 PUNCT F
IL-6 0 NOUN T
( 0 PUNCT F
interleukin-6 0 NOUN F
) 0 PUNCT F
, 0 PUNCT F
IL-8 0 NOUN T
, 0 PUNCT F
ICAM-1 0 NOUN T
( 0 PUNCT F
intercellular 0 ADJ F
adhesion 0 NOUN F
molecule-1 0 NOUN F
) 0 PUNCT F
, 0 PUNCT F
vWF 0 NOUN F
( 0 PUNCT F
von 0 PUNCT F
Willebrand 0 NOUN T
factor 0 NOUN F
) 0 PUNCT F
, 0 PUNCT F
MCP-1 0 NOUN T
( 0 PUNCT F
monocyte 0 NOUN F
chemoattractant 0 NOUN F
protein-1 0 NOUN F
) 0 PUNCT F
, 0 PUNCT F
PAI-1 0 NOUN T
( 0 PUNCT F
plasminogen 0 NOUN F
activator 0 NOUN F
inhibitor-1 0 NOUN F
) 0 PUNCT F
and 0 CCONJ F
fibrinogen 0 NOUN F
. 0 PUNCT F

Histological 0 ADJ T
evaluation 0 NOUN F
of 0 ADP F
human 0 NOUN F
atherosclerosis 0 NOUN F
showed 0 VERB F
minimal 0 ADJ F
AP-1 0 NOUN T
activation 0 NOUN F
in 0 ADP F
non-diseased 0 VERB F
arterial 0 ADJ F
wall 0 NOUN F
( 0 PUNCT F
i.e 0 ADV F
. 0 PUNCT F

vessel 0 NOUN F
wall 0 NOUN F
without 0 ADP F
any 0 DET F
signs 0 NOUN F
of 0 ADP F
atherosclerotic 0 ADJ F
disease 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

A 0 DET T
gradual 0 ADJ F
increase 0 NOUN F
of 0 ADP F
AP-1 0 NOUN T
activation 0 NOUN F
was 0 VERB F
found 0 VERB F
in 0 ADP F
non-progressive 0 ADJ F
and 0 CCONJ F
progressive 0 ADJ F
phases 0 NOUN F
of 0 ADP F
atherosclerosis 0 NOUN F
respectively 0 ADV F
( 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.044 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

No 0 DET T
significant 0 ADJ F
difference 0 NOUN F
was 0 VERB F
found 0 VERB F
between 0 ADP F
progressive 0 ADJ F
and 0 CCONJ F
vulnerable 0 ADJ F
lesions 0 NOUN F
. 0 PUNCT F

The 0 DET T
expression 0 NOUN F
of 0 ADP F
phospho-c-Jun 0 NOUN F
diminished 0 VERB F
as 0 PUNCT F
the 0 DET F
lesion 0 NOUN F
stabilized 0 VERB F
( 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.016 0 NUM F
) 0 PUNCT F
and 0 CCONJ F
does 0 PUNCT F
not 0 ADV F
significantly 0 ADV F
differ 0 VERB F
from 0 ADP F
the 0 DET F
normal 0 ADJ F
aortic 0 ADJ F
wall 0 NOUN F
( 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.33 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Evaluation 0 NOUN T
of 0 ADP F
the 0 DET F
doxycycline 0 NOUN F
intervention 0 NOUN F
only 0 ADV F
revealed 0 VERB F
a 0 DET F
borderline-significant 0 ADP F
reduction 0 NOUN F
of 0 ADP F
circulating 0 VERB F
hs-CRP 0 NOUN F
levels 0 NOUN F
( 0 PUNCT F
-0.51 0 ADP F
?g/ml 0 PUNCT F
, 0 PUNCT F
P=0.05 0 NOUN T
) 0 PUNCT F
and 0 CCONJ F
did 0 DET F
not 0 ADV F
affect 0 VERB F
any 0 PUNCT F
of 0 ADP F
the 0 DET F
other 0 ADJ F
markers 0 NOUN F
of 0 ADP F
systemic 0 ADJ F
inflammation 0 NOUN F
and 0 CCONJ F
vascular 0 ADJ F
function 0 NOUN F
. 0 PUNCT F

Our 0 ADJ T
studies 0 NOUN F
do 0 PUNCT F
not 0 ADV F
characterize 0 ADJ F
AP-1 0 NOUN T
as 0 ADP F
a 0 DET F
therapeutic 0 ADJ F
target 0 NOUN F
for 0 ADP F
progressive 0 ADJ F
human 0 NOUN F
atherosclerotic 0 ADJ F
disease 0 NOUN F
. 0 PUNCT F

Efficacy 0 NOUN T
of 0 ADP F
chlorhexidine 0 NOUN F
gluconate 0 VERB F
use 0 NUM F
in 0 ADP F
the 0 DET F
prevention 0 NOUN F
of 0 ADP F
perirectal 0 ADJ F
infections 0 NOUN F
in 0 ADP F
patients 0 NOUN F
with 0 ADP F
acute 0 ADJ F
leukemia 0 NOUN F
. 0 PUNCT F

The 0 DET T
frequency 0 NOUN F
of 0 ADP F
rectal B-PHYSICAL ADJ F
infections I-PHYSICAL NOUN F
is 0 VERB F
increased 0 VERB F
in 0 ADP F
patients 0 NOUN F
with 0 ADP F
acute 0 ADJ F
leukemia 0 NOUN F
. 0 PUNCT F

Complications 0 NOUN T
associated 0 VERB F
with 0 ADP F
rectal 0 ADJ F
lesions 0 NOUN F
may 0 VERB F
be 0 ADJ F
severe 0 ADJ F
enough 0 DET F
to 0 ADP F
cause 0 NOUN F
life-threatening 0 VERB F
septicemia 0 NOUN F
. 0 PUNCT F

Clinical 0 ADJ T
research 0 NOUN F
evaluating 0 VERB F
the 0 DET F
effects 0 NOUN F
of 0 ADP F
preventive 0 ADJ F
perirectal 0 ADJ F
skin 0 NOUN F
care 0 NOUN F
is 0 ADP F
scarce 0 NOUN F
. 0 PUNCT F

This 0 DET T
study 0 NOUN F
's 0 PUNCT F
purpose 0 NOUN F
was 0 VERB F
to 0 PART F
determine 0 NOUN F
whether 0 VERB F
using 0 PUNCT F
chlorhexidine 0 NOUN F
gluconate 0 ADJ F
( 0 PUNCT F
CHG 0 NOUN T
) 0 PUNCT F
in 0 ADP F
a 0 DET F
prophylactic 0 ADJ F
perirectal 0 ADJ F
skin-care 0 NOUN F
regimen 0 NOUN F
decreases 0 ADP F
perirectal 0 ADJ F
infections 0 NOUN F
and 0 CCONJ F
whether 0 ADP F
it 0 PRON F
produces 0 NOUN F
more 0 PUNCT F
skin 0 NOUN F
irritation 0 NOUN F
than 0 PUNCT F
a 0 DET F
nonmedicated 0 VERB F
skin 0 NOUN F
cleanser 0 ADJ F
. 0 PUNCT F

The 0 DET T
sample 0 NOUN F
consisted 0 VERB F
of 0 ADP F
40 0 NUM F
patients 0 NOUN F
, 0 PUNCT F
16 0 NUM F
of 0 ADP F
whom 0 ADP F
were 0 VERB F
randomized 0 ADP F
to 0 ADP F
use 0 PUNCT F
chlorhexidine 0 PUNCT F
and 0 CCONJ F
24 0 NUM F
of 0 ADP F
whom 0 ADP F
were 0 VERB F
randomized 0 ADP F
to 0 ADP F
use 0 PUNCT F
nonmedicated 0 PUNCT F
skin 0 NOUN F
cleanser 0 ADJ F
. 0 PUNCT F

Chi-square 0 PUNCT T
and 0 CCONJ F
t-tests 0 ADV F
were 0 VERB F
used 0 VERB F
to 0 PART F
analyze 0 NOUN F
the 0 DET F
incidence 0 NOUN F
of 0 ADP F
skin B-PHYSICAL NOUN F
breakdown I-PHYSICAL NOUN F
and 0 CCONJ F
rectal B-PHYSICAL ADJ F
infections I-PHYSICAL NOUN F
; 0 PUNCT F
the 0 DET F
correlation 0 NOUN F
between 0 ADP F
the 0 DET F
two 0 NUM F
factors 0 NOUN F
; 0 PUNCT F
a 0 DET F
positive 0 ADJ F
history 0 NOUN F
of 0 ADP F
rectal 0 ADJ F
infections 0 NOUN F
, 0 PUNCT F
fissures 0 PUNCT F
, 0 PUNCT F
or 0 CCONJ F
hemorrhoids 0 NOUN F
; 0 PUNCT F
presence 0 NOUN F
of 0 ADP F
hemorrhoids 0 NOUN F
; 0 PUNCT F
severity 0 NOUN F
of 0 ADP F
diarrhea 0 NOUN F
; 0 PUNCT F
and 0 CCONJ F
duration 0 NOUN F
and 0 CCONJ F
severity 0 NOUN F
of 0 ADP F
granulocytopenia 0 NOUN F
. 0 PUNCT F

A 0 DET T
positive 0 ADJ F
relationship 0 NOUN F
was 0 VERB F
found 0 VERB F
between 0 ADP F
the 0 DET F
severity B-PHYSICAL NOUN F
of I-PHYSICAL ADP F
granulocytopenia I-PHYSICAL NOUN F
and 0 CCONJ F
the 0 DET F
incidence 0 NOUN F
of 0 ADP F
rectal B-PHYSICAL ADJ F
infections I-PHYSICAL NOUN F
( 0 PUNCT F
p 0 NOUN F
= 0 SYM F
0.02 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

No 0 DET T
significant 0 ADJ F
difference 0 NOUN F
was 0 VERB F
seen 0 VERB F
in 0 ADP F
the 0 DET F
occurrence 0 NOUN F
of 0 ADP F
perirectal B-PHYSICAL ADJ F
infections I-PHYSICAL NOUN F
( 0 PUNCT F
p 0 NOUN F
= 0 SYM F
0.35 0 NUM F
) 0 PUNCT F
or 0 CCONJ F
skin B-PHYSICAL NOUN F
breakdown I-PHYSICAL NOUN F
( 0 PUNCT F
p 0 NOUN F
= 0 SYM F
0.18 0 NUM F
) 0 PUNCT F
between 0 ADP F
the 0 DET F
two 0 NUM F
groups 0 NOUN F
. 0 PUNCT F

The 0 DET T
data 0 NOUN F
suggest 0 VERB F
that 0 ADP F
CHG 0 NOUN T
does 0 PUNCT F
not 0 ADV F
offer 0 VERB F
increased 0 VERB F
protection 0 NOUN F
against 0 ADP F
perirectal 0 ADJ F
infections 0 NOUN F
in 0 ADP F
patients 0 NOUN F
undergoing 0 SYM F
intensive 0 ADJ F
chemotherapy 0 NOUN F
, 0 PUNCT F
nor 0 CCONJ F
is 0 VERB F
it 0 PRON F
more 0 ADJ F
irritating 0 PUNCT F
than 0 PUNCT F
a 0 DET F
nonmedicated 0 VERB F
skin 0 NOUN F
cleanser 0 ADJ F
. 0 PUNCT F

Further 0 ADJ T
studies 0 NOUN F
are 0 ADV F
needed 0 VERB F
to 0 PART F
examine 0 NOUN F
the 0 DET F
efficacy 0 NOUN F
of 0 ADP F
hygienic 0 ADJ F
measures 0 NOUN F
such 0 CCONJ F
as 0 ADP F
using 0 PUNCT F
skin 0 NOUN F
disinfectants 0 NOUN F
to 0 PART F
prevent 0 ADJ F
infections 0 NOUN F
in 0 ADP F
patients 0 NOUN F
who 0 ADP F
are 0 VERB F
immunocompromised 0 VERB F
. 0 PUNCT F

[ 0 PUNCT F
Triple 0 ADJ T
therapy 0 NOUN F
regimens 0 NOUN F
involving 0 PUNCT F
H2 0 NOUN T
blockaders 0 NOUN F
for 0 ADP F
therapy 0 NOUN F
of 0 ADP F
Helicobacter B-PHYSICAL NOUN T
pylori I-PHYSICAL NOUN F
infections I-PHYSICAL NOUN F
] I-PHYSICAL PUNCT F
. 0 PUNCT F

Comparison B-OTHER NOUN T
of 0 ADP F
ranitidine 0 NOUN F
and 0 CCONJ F
lansoprazole 0 PUNCT F
in 0 ADP F
short-term 0 NOUN F
low-dose 0 NOUN F
triple 0 ADJ F
therapy 0 NOUN F
for 0 ADP F
Helicobacter 0 NOUN T
pylori 0 NOUN F
infection 0 NOUN F
. 0 PUNCT F

To 0 PART T
evaluate 0 NOUN F
the 0 DET F
efficacy 0 NOUN F
and 0 CCONJ F
safety 0 NOUN F
of 0 ADP F
two 0 NUM F
1-week 0 NOUN F
low-dose 0 NOUN F
triple-therapy 0 NOUN F
drug 0 NOUN F
regimens 0 NOUN F
involving 0 PUNCT F
antisecretory 0 ADJ F
drugs 0 NOUN F
for 0 ADP F
Helicobacter 0 NOUN T
pylori 0 NOUN F
infection 0 NOUN F
, 0 PUNCT F
99 0 NUM F
patients 0 NOUN F
with 0 ADP F
H. 0 NOUN T
pylori 0 NOUN F
infection 0 NOUN F
were 0 VERB F
treated 0 VERB F
with 0 ADP F
either 0 CCONJ F
lansoprazole 0 PUNCT F
( 0 PUNCT F
LPZ 0 NOUN T
) 0 PUNCT F
or 0 CCONJ F
ranitidine 0 NOUN F
( 0 PUNCT F
RNT 0 NOUN T
) 0 PUNCT F
used 0 PUNCT F
together 0 ADV F
with 0 ADP F
clarithromycin 0 NOUN F
( 0 PUNCT F
CAM 0 NOUN T
) 0 PUNCT F
and 0 CCONJ F
metrinidazole 0 PUNCT F
( 0 PUNCT F
MTZ 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
drug 0 NOUN F
combination 0 NOUN F
and 0 CCONJ F
administration 0 NOUN F
periods 0 NOUN F
in 0 ADP F
the 0 DET F
PPI 0 NOUN T
group 0 NOUN F
were 0 VERB F
LPZ 0 NOUN T
30 0 PUNCT F
mg 0 NOUN F
, 0 PUNCT F
CAM 0 NOUN T
400 0 NUM F
mg 0 NOUN F
, 0 PUNCT F
MTZ 0 NOUN T
500 0 NUM F
mg 0 NOUN F
( 0 PUNCT F
LCM 0 NOUN T
group 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
ranitidine 0 NOUN F
group 0 NOUN F
received 0 VERB F
RNT 0 NOUN T
300 0 NUM F
mg 0 NOUN F
, 0 PUNCT F
CAM 0 NOUN T
400 0 NUM F
mg 0 NOUN F
, 0 PUNCT F
MTZ 0 NOUN T
500 0 NUM F
mg 0 NOUN F
( 0 PUNCT F
RCM 0 NOUN T
group 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
cure B-OTHER ADV F
rate I-OTHER NOUN F
of I-OTHER ADP F
H. 0 NOUN T
pylori B-PHYSICAL NOUN F
infection I-PHYSICAL NOUN F
was 0 VERB F
88 0 NUM F
% 0 SYM F
in 0 ADP F
the 0 DET F
LCM 0 NOUN T
group 0 NOUN F
; 0 PUNCT F
95 0 NUM F
% 0 SYM F
CI 0 NOUN T
79-97 0 NUM F
and 0 CCONJ F
92 0 NUM F
% 0 SYM F
in 0 ADP F
the 0 DET F
RCM 0 NOUN T
group 0 NOUN F
; 0 PUNCT F
95 0 NUM F
% 0 SYM F
CI 0 NOUN T
84-99 0 NUM F
. 0 PUNCT F

[ 0 PUNCT F
Intravenous 0 ADJ T
treatment 0 NOUN F
of 0 ADP F
postpartum 0 NOUN F
anemia 0 NOUN F
with 0 ADP F
trivalent 0 ADJ F
ferrum 0 NOUN F
preparation 0 NOUN F
] 0 PUNCT F
. 0 PUNCT F

AIM 0 NOUN T
OF 0 ADP T
THE 0 DET T
STUDY 0 NOUN T
To 0 PROPN T
assess 0 NOUN F
the 0 DET F
effectivity 0 NOUN F
and 0 CCONJ F
safeness B-OTHER ADP F
of 0 ADP F
intravenous 0 ADJ F
treatment 0 NOUN F
of 0 ADP F
pospartal 0 ADJ F
anemia 0 NOUN F
with 0 ADP F
trivalent 0 ADJ F
ferrum 0 NOUN F
preparation 0 NOUN F
. 0 PUNCT F

TYPE 0 NOUN T
OF 0 ADP T
THE 0 DET T
STUDY 0 NOUN T
Prospective 0 ADJ T
randomized 0 VERB F
study 0 NOUN F
. 0 PUNCT F

SETTING 0 VERB T
Department 0 NOUN T
of 0 ADP F
Obstetric 0 ADJ T
and 0 CCONJ F
Gynecology 0 NOUN T
2nd 0 ADJ F
Medical 0 ADJ T
Faculty 0 NOUN T
Charles 0 NUM T
University 0 NOUN T
and 0 CCONJ F
Teaching 0 PUNCT T
Hospital 0 NOUN T
Motol 0 NOUN T
, 0 PUNCT F
Prague 0 NOUN T
, 0 PUNCT F
and 0 CCONJ F
Department 0 NOUN T
of 0 ADP F
Obstetric 0 ADJ T
and 0 CCONJ F
Gynecology 0 NOUN T
1st 0 ADJ F
Medical 0 ADJ T
Faculty 0 NOUN T
and 0 CCONJ F
Teaching 0 PUNCT T
Hospital 0 NOUN T
Bulovka 0 NOUN T
, 0 PUNCT F
Prague 0 NOUN T
. 0 PUNCT F

METHODS 0 NOUN T
500 0 NUM F
mg 0 NOUN F
of 0 ADP F
sacharose 0 NOUN F
ferric 0 ADJ F
oxide 0 NOUN F
( 0 PUNCT F
Venofer 0 NOUN T
) 0 PUNCT F
was 0 ADV F
intravenously 0 ADV F
administered 0 VERB F
in 0 ADP F
two 0 NUM F
days 0 NOUN F
regimen 0 NOUN F
to 0 ADP F
50 0 NUM F
women 0 NOUN F
with 0 ADP F
clinical 0 ADJ F
and 0 CCONJ F
lab 0 NOUN F
signs 0 NOUN F
of 0 ADP F
postpartal 0 ADJ F
anemia 0 NOUN F
. 0 PUNCT F

The 0 DET T
effect 0 NOUN F
of 0 ADP F
administered 0 VERB F
drug 0 NOUN F
was 0 VERB F
determined 0 VERB F
by 0 ADP F
comparsion 0 NOUN F
of 0 ADP F
values 0 NOUN F
of 0 ADP F
red 0 ADJ F
blood 0 NOUN F
count 0 NOUN F
recovered 0 VERB F
before 0 ADP F
the 0 DET F
treatment 0 NOUN F
, 0 PUNCT F
2nd 0 ADJ F
or 0 CCONJ F
3rd 0 ADJ F
day 0 NOUN F
post 0 PUNCT F
administration 0 NOUN F
and 0 CCONJ F
two 0 NUM F
weeks 0 NOUN F
later 0 ADJ F
. 0 PUNCT F

The 0 DET T
serum 0 NOUN F
values 0 NOUN F
of 0 ADP F
soluble 0 ADJ F
transferrin 0 NOUN F
receptors 0 NOUN F
and 0 CCONJ F
ferritin 0 NOUN F
were 0 VERB F
observed 0 NUM F
as 0 ADP F
markers 0 NOUN F
of 0 ADP F
iron B-PHYSICAL NOUN F
cell I-PHYSICAL NOUN F
saturation I-PHYSICAL NOUN F
and 0 CCONJ F
body B-PHYSICAL NOUN F
iron I-PHYSICAL NOUN F
reserves I-PHYSICAL PUNCT F
, 0 PUNCT F
too 0 ADV F
. 0 PUNCT F

Integral 0 ADJ T
part 0 NOUN F
of 0 ADP F
the 0 DET F
study 0 NOUN F
was 0 VERB F
the 0 DET F
monitoring 0 VERB F
of 0 ADP F
adverse B-ADVERSE-EFFECTS ADJ F
events I-ADVERSE-EFFECTS NOUN F
during 0 ADP F
the 0 DET F
treatment 0 NOUN F
. 0 PUNCT F

RESULTS 0 DET T
Venofer 0 VERB T
came 0 VERB F
in 0 ADP F
sight 0 PUNCT F
as 0 CCONJ F
effective 0 ADJ F
drug 0 NOUN F
in 0 ADP F
the 0 DET F
treatment 0 NOUN F
of 0 ADP F
pospartal B-PHYSICAL ADJ F
anemia I-PHYSICAL NOUN F
and 0 CCONJ F
could 0 VERB F
become 0 VERB F
as 0 ADP F
the 0 DET F
alternative 0 ADJ F
to 0 ADP F
blood 0 NOUN F
transfusion 0 NOUN F
in 0 ADP F
mid-severe 0 NOUN F
cases 0 NOUN F
. 0 PUNCT F

It 0 PRON T
should 0 VERB F
be 0 VERB F
emphasized 0 PUNCT F
that 0 PUNCT F
we 0 PRON F
have 0 PUNCT F
not 0 ADV F
encountered 0 PUNCT F
any 0 DET F
serious B-ADVERSE-EFFECTS ADJ F
adverse I-ADVERSE-EFFECTS ADJ F
event I-ADVERSE-EFFECTS NOUN F
with 0 ADP F
intravenous 0 ADJ F
trivalent 0 ADJ F
saccharose 0 NOUN F
ferric 0 ADJ F
oxide 0 NOUN F
treatment 0 NOUN F
. 0 PUNCT F

The 0 DET T
role 0 NOUN F
of 0 ADP F
somatostatin 0 NOUN F
( 0 PUNCT F
octreotide 0 NOUN F
) 0 PUNCT F
in 0 ADP F
the 0 DET F
regulation 0 NOUN F
of 0 ADP F
melatonin B-PHYSICAL NOUN F
secretion I-PHYSICAL NOUN F
in 0 ADP F
healthy 0 ADJ F
volunteers 0 NOUN F
and 0 CCONJ F
in 0 ADP F
patients 0 NOUN F
with 0 ADP F
primary 0 ADJ F
hypothyroidism 0 NOUN F
. 0 PUNCT F

Somatostatin 0 NOUN T
has 0 PUNCT F
been 0 PUNCT F
found 0 VERB F
in 0 ADP F
the 0 DET F
pineal 0 ADJ F
gland 0 NOUN F
of 0 ADP F
several 0 ADJ F
animal 0 NOUN F
species 0 NOUN F
, 0 PUNCT F
which 0 ADP F
suggests 0 NOUN F
that 0 ADP F
it 0 PRON F
may 0 VERB F
be 0 VERB F
involved 0 VERB F
in 0 ADP F
the 0 DET F
regulation 0 NOUN F
of 0 ADP F
melatonin B-PHYSICAL NOUN F
secretion I-PHYSICAL NOUN F
. 0 PUNCT F

Whether 0 ADP T
somatostatin 0 NOUN F
has 0 PUNCT F
regulatory 0 ADJ F
influence 0 NOUN F
on 0 ADP F
melatonin B-PHYSICAL NOUN F
secretion I-PHYSICAL NOUN F
in 0 ADP F
man 0 NOUN F
has 0 PUNCT F
never 0 ADV F
been 0 PUNCT F
unequivocally 0 ADV F
shown 0 ADP F
. 0 PUNCT F

We 0 PRON T
studied 0 VERB F
the 0 DET F
nocturnal B-PHYSICAL ADJ F
melatonin I-PHYSICAL NOUN F
secretion I-PHYSICAL NOUN F
in 0 ADP F
8 0 NUM F
healthy 0 ADJ F
volunteers 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
6 0 NUM F
women 0 NOUN F
with 0 ADP F
untreated 0 VERB F
primary 0 ADJ F
hypothyroidism 0 NOUN F
, 0 PUNCT F
a 0 DET F
disease 0 NOUN F
state 0 NOUN F
that 0 ADP F
is 0 VERB F
associated 0 VERB F
with 0 ADP F
increased 0 CCONJ F
nocturnal 0 ADJ F
secretion 0 NOUN F
of 0 ADP F
melatonin 0 NOUN F
. 0 PUNCT F

The 0 DET T
participants 0 NOUN F
were 0 VERB F
given 0 VERB F
subcutaneous 0 ADJ F
injections 0 NOUN F
at 0 ADP F
18:00 0 NOUN F
h 0 NOUN F
and 0 CCONJ F
23:00 0 PUNCT F
h 0 NOUN F
of 0 ADP F
either 0 CCONJ F
saline 0 ADJ F
or 0 CCONJ F
octreotide 0 ADJ F
( 0 PUNCT F
Sandostatin 0 NOUN T
; 0 PUNCT F
each 0 DET F
injection 0 NOUN F
50 0 NUM F
microg 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

During 0 ADP T
the 0 DET F
nights 0 NOUN F
when 0 ADP F
the 0 DET F
healthy 0 ADJ F
volunteers 0 NOUN F
were 0 VERB F
given 0 VERB F
octreotide 0 NOUN F
, 0 PUNCT F
melatonin B-PHYSICAL NOUN F
secretion I-PHYSICAL NOUN F
was 0 VERB F
similar 0 ADJ F
to 0 ADP F
that 0 PUNCT F
recorded 0 VERB F
during 0 ADP F
administration 0 NOUN F
of 0 ADP F
saline 0 NOUN F
. 0 PUNCT F

Also 0 PUNCT T
the 0 DET F
urinary B-PHYSICAL ADJ F
excretion I-PHYSICAL NOUN F
of I-PHYSICAL ADP F
melatonin I-PHYSICAL NOUN F
was 0 NUM F
of 0 ADP F
similar 0 ADJ F
magnitude 0 NOUN F
at 0 ADP F
these 0 DET F
two 0 NUM F
occasions 0 NOUN F
. 0 PUNCT F

By 0 ADP T
contrast 0 NOUN F
, 0 PUNCT F
the 0 DET F
GH B-PHYSICAL NOUN T
secretion I-PHYSICAL NOUN F
was 0 VERB F
significantly 0 ADV F
lower 0 PUNCT F
the 0 ADP F
nights 0 ADP F
the 0 DET F
healthy 0 ADJ F
controls 0 NOUN F
were 0 VERB F
given 0 VERB F
octreotide 0 NOUN F
( 0 PUNCT F
GH 0 NOUN T
AUC 0 NOUN T
22.6+/-5.4 0 NOUN F
mU/l 0 PUNCT F
x 0 SYM F
h 0 NOUN F
during 0 ADP F
octreotide 0 ADJ F
and 0 CCONJ F
126.6+/-21.9 0 NUM F
mU/l 0 PUNCT F
x 0 SYM F
h 0 NOUN F
during 0 ADP F
saline 0 NOUN F
; 0 PUNCT F
p 0 NOUN F
< 0 SYM F
0.01 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
patients 0 NOUN F
with 0 ADP F
hypothyroidism 0 NOUN F
also 0 ADV F
showed 0 VERB F
similar 0 ADJ F
nocturnal B-PHYSICAL ADJ F
melatonin I-PHYSICAL NOUN F
secretion I-PHYSICAL NOUN F
during 0 ADP F
octreotide 0 ADJ F
and 0 CCONJ F
saline 0 NOUN F
. 0 PUNCT F

Urinary B-PHYSICAL ADJ T
excretion I-PHYSICAL NOUN F
of I-PHYSICAL ADP F
melatonin I-PHYSICAL NOUN F
also 0 ADV F
remained 0 VERB F
unchanged 0 PROPN F
, 0 PUNCT F
as 0 PUNCT F
did 0 PUNCT F
GH B-PHYSICAL NOUN T
secretion I-PHYSICAL NOUN F
. 0 PUNCT F

The 0 DET T
total 0 ADJ F
nocturnal B-PHYSICAL ADJ F
secretion I-PHYSICAL NOUN F
of I-PHYSICAL ADP F
TSH I-PHYSICAL NOUN T
was 0 VERB F
, 0 PUNCT F
however 0 ADV F
, 0 PUNCT F
significantly 0 ADV F
reduced 0 VERB F
by 0 ADP F
octreotide 0 NOUN F
( 0 PUNCT F
TSH 0 NOUN T
AUC 0 NOUN T
562+/-136 0 PUNCT F
mU/l 0 PUNCT F
x 0 SYM F
h 0 NOUN F
during 0 ADP F
octreotide 0 ADJ F
and 0 CCONJ F
851+/-185 0 PUNCT F
mU/l 0 PUNCT F
x 0 SYM F
h 0 NOUN F
during 0 ADP F
saline 0 NOUN F
; 0 PUNCT F
p 0 NOUN F
< 0 SYM F
0.05 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
thus 0 ADV F
suggesting 0 VERB F
that 0 ADP F
100 0 NUM F
microg 0 NOUN F
of 0 ADP F
octreotide 0 PUNCT F
should 0 VERB F
be 0 VERB F
sufficient 0 ADJ F
to 0 PART F
inhibit 0 NOUN F
also 0 ADV F
the 0 DET F
pinealocytes 0 ADJ F
if 0 PUNCT F
their 0 VERB F
function 0 NOUN F
were 0 VERB F
regulated 0 VERB F
by 0 ADP F
somatostatin 0 NOUN F
. 0 PUNCT F

Since 0 ADP T
exogenous 0 ADJ F
somatostatin 0 NOUN F
-- 0 PUNCT F
in 0 ADP F
the 0 DET F
form 0 NOUN F
of 0 ADP F
octreotide 0 ADJ F
-- 0 PUNCT F
fails 0 NOUN F
to 0 PART F
influence 0 ADJ F
nocturnal B-PHYSICAL ADJ F
secretion I-PHYSICAL NOUN F
and 0 CCONJ F
urinary B-PHYSICAL ADJ F
excretion I-PHYSICAL NOUN F
of I-PHYSICAL ADP F
melatonin I-PHYSICAL NOUN F
in 0 ADP F
normal 0 ADJ F
subjects 0 NOUN F
and 0 CCONJ F
in 0 ADP F
patients 0 NOUN F
with 0 ADP F
primary 0 ADJ F
hypothyroidism 0 NOUN F
, 0 PUNCT F
it 0 PRON F
is 0 VERB F
reasonable 0 ADJ F
to 0 PART F
assume 0 PUNCT F
that 0 ADP F
endogenous 0 ADJ F
somatostatin 0 NOUN F
may 0 VERB F
not 0 ADV F
be 0 VERB F
an 0 DET F
important 0 ADJ F
regulator 0 NOUN F
of 0 ADP F
melatonin 0 NOUN F
secretion 0 NOUN F
in 0 ADP F
man 0 NOUN F
. 0 PUNCT F

Is 0 PUNCT T
anti-Pseudomonas 0 NOUN F
therapy 0 NOUN F
warranted 0 ADJ F
in 0 ADP F
acute 0 ADJ F
respiratory B-PHYSICAL ADJ F
exacerbations I-PHYSICAL NOUN F
in 0 ADP F
children 0 NOUN F
with 0 ADP F
cystic 0 ADJ F
fibrosis 0 NOUN F
? 0 PUNCT F

A 0 DET T
controlled 0 VERB F
study 0 NOUN F
was 0 VERB F
designed 0 VERB F
to 0 PART F
clarify 0 NOUN F
the 0 DET F
indications 0 NOUN F
for 0 ADP F
antibiotic 0 ADJ F
therapy 0 NOUN F
in 0 ADP F
children 0 NOUN F
with 0 ADP F
advanced 0 VERB F
cystic 0 ADJ F
fibrosis 0 NOUN F
hospitalized 0 VERB F
with 0 ADP F
respiratory 0 ADJ F
exacerbations 0 NOUN F
. 0 PUNCT F

Twenty-two 0 NUM T
children 0 NOUN F
with 0 ADP F
severe 0 ADJ F
CF 0 NOUN T
and 0 CCONJ F
signs 0 NOUN F
of 0 ADP F
acute 0 ADJ F
lower 0 PUNCT F
respiratory 0 ADJ F
infection 0 NOUN F
were 0 VERB F
randomly 0 ADV F
assigned 0 VERB F
to 0 PART F
receive 0 NOUN F
either 0 PUNCT F
cloxacillin 0 NOUN F
or 0 CCONJ F
carbenicillin 0 NOUN F
plus 0 CCONJ F
gentamicin 0 NOUN F
administered 0 ADP F
intravenously 0 ADV F
for 0 ADP F
ten 0 NUM F
days 0 NOUN F
. 0 PUNCT F

Other 0 ADJ T
aspects 0 NOUN F
of 0 ADP F
therapy 0 NOUN F
were 0 VERB F
constant 0 ADP F
. 0 PUNCT F

The 0 DET T
groups 0 NOUN F
were 0 VERB F
comparable 0 ADJ F
in 0 ADP F
all 0 DET F
respects 0 ADP F
and 0 CCONJ F
Pseudomonas 0 NOUN T
aeruginosa 0 NOUN F
was 0 VERB F
the 0 DET F
predominant 0 ADJ F
sputum 0 NOUN F
pathogen 0 NOUN F
in 0 ADP F
most 0 DET F
patients 0 NOUN F
. 0 PUNCT F

Clinical B-PHYSICAL ADJ T
improvement I-PHYSICAL NOUN F
, 0 PUNCT F
chest B-PHYSICAL NOUN F
radiograph I-PHYSICAL NOUN F
changes I-PHYSICAL NOUN F
, 0 PUNCT F
evidence B-PHYSICAL NOUN F
of I-PHYSICAL ADP F
airway I-PHYSICAL NOUN F
obstruction I-PHYSICAL NOUN F
, 0 PUNCT F
and 0 PUNCT F

Placebo-controlled 0 DET T
acute 0 ADJ F
dosage 0 NOUN F
naltrexone 0 NUM F
study 0 NOUN F
in 0 ADP F
young 0 ADJ F
autistic 0 ADJ F
children 0 NOUN F
. 0 PUNCT F

In 0 ADP T
a 0 DET F
double-blind 0 ADJ F
, 0 PUNCT F
placebo-controlled 0 VERB F
crossover 0 NOUN F
trial 0 NOUN F
23 0 NUM F
autistic 0 ADJ F
children 0 NOUN F
were 0 VERB F
treated 0 VERB F
with 0 ADP F
a 0 DET F
single 0 ADJ F
40-mg 0 NOUN F
dose 0 NOUN F
of 0 ADP F
the 0 DET F
opiate 0 ADJ F
antagonist 0 NOUN F
naltrexone 0 NUM F
. 0 PUNCT F

Drug 0 NOUN T
effects 0 NOUN F
were 0 VERB F
monitored 0 VERB F
by 0 ADP F
detailed 0 ADV F
playroom 0 NOUN F
observations 0 NOUN F
, 0 PUNCT F
actometers 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
parents 0 NOUN F
' 0 PUNCT F
checklist 0 NOUN F
ratings 0 NOUN F
( 0 PUNCT F

Infliximab 0 NOUN T
in 0 ADP F
ankylosing 0 ADP F
spondylitis 0 ADJ F
: 0 PUNCT F
alone 0 ADJ F
or 0 CCONJ F
in 0 ADP F
combination 0 NOUN F
with 0 ADP F
methotrexate 0 NOUN F
? 0 PUNCT F

A 0 DET T
pharmacokinetic 0 ADJ F
comparative 0 ADJ F
study 0 NOUN F
. 0 PUNCT F

INTRODUCTION 0 NOUN T
Methotrexate 0 NOUN T
( 0 PUNCT F
MTX 0 NOUN T
) 0 PUNCT F
has 0 PUNCT F
been 0 PUNCT F
shown 0 VERB F
to 0 PART F
modify 0 PUNCT F
infliximab 0 NOUN F
pharmacokinetics 0 NOUN F
in 0 ADP F
rheumatoid 0 ADJ F
arthritis 0 NOUN F
. 0 PUNCT F

However 0 ADV T
, 0 PUNCT F
its 0 PUNCT F
combination 0 NOUN F
with 0 ADP F
infliximab 0 NOUN F
in 0 ADP F
the 0 DET F
treatment 0 NOUN F
of 0 ADP F
ankylosing 0 ADP F
spondylitis 0 ADJ F
( 0 PUNCT F
AS 0 ADP T
) 0 PUNCT F
is 0 VERB F
not 0 ADV F
recommended 0 VERB F
. 0 PUNCT F

The 0 DET T
objective 0 NOUN F
of 0 ADP F
this 0 DET F
study 0 NOUN F
was 0 VERB F
to 0 ADV F
examine 0 NOUN F
the 0 DET F
influence 0 NOUN F
of 0 ADP F
MTX 0 NOUN T
on 0 ADP F
infliximab 0 NOUN F
exposure 0 NOUN F
in 0 ADP F
patients 0 NOUN F
with 0 ADP F
AS 0 CCONJ T
. 0 PUNCT F

METHODS 0 NOUN T
Patients 0 NOUN T
with 0 ADP F
AS 0 ADP T
patients 0 NOUN F
who 0 ADP F
had 0 PUNCT F
predominantly 0 ADV F
axial 0 ADJ F
symptoms 0 NOUN F
were 0 VERB F
randomised 0 VERB F
to 0 PART F
receive 0 NOUN F
infliximab 0 NOUN F
alone 0 ADJ F
( 0 PUNCT F
infusions 0 NOUN F
of 0 ADP F
5 0 NUM F
mg/kg 0 NOUN F
at 0 ADP F
weeks 0 NOUN F
0 0 NUM F
, 0 PUNCT F
2 0 NUM F
, 0 PUNCT F
6 0 NUM F
, 0 PUNCT F
12 0 NUM F
and 0 CCONJ F
18 0 NUM F
) 0 PUNCT F
or 0 CCONJ F
infliximab 0 NOUN F
combined 0 PROPN F
with 0 ADP F
MTX 0 NOUN T
( 0 PUNCT F
10 0 NUM F
mg/week 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

Infliximab B-PHYSICAL NOUN T
concentrations I-PHYSICAL NOUN F
were 0 VERB F
measured 0 VERB F
before 0 ADP F
and 0 CCONJ F
2 0 NUM F
hours 0 NOUN F
after 0 ADP F
each 0 DET F
infusion 0 NOUN F
and 0 CCONJ F
at 0 ADP F
1 0 NUM F
, 0 PUNCT F
3 0 NUM F
, 0 PUNCT F
4 0 NUM F
, 0 PUNCT F
5 0 NUM F
, 0 PUNCT F
8 0 NUM F
, 0 PUNCT F
10 0 NUM F
, 0 PUNCT F
14 0 NUM F
and 0 CCONJ F
18 0 NUM F
weeks 0 NOUN F
. 0 PUNCT F

We 0 PRON T
estimated 0 PUNCT F
individual 0 VERB F
cumulative 0 ADJ F
area 0 NOUN F
under 0 ADP F
the 0 DET F
concentration 0 NOUN F
versus 0 CCONJ F
time 0 NOUN F
curves 0 NOUN F
( 0 PUNCT F
AUC 0 NOUN T
) 0 PUNCT F
for 0 ADP F
infliximab B-PHYSICAL NOUN F
concentration I-PHYSICAL NOUN F
between 0 ADP F
baseline 0 NOUN F
and 0 CCONJ F
week 0 NOUN F
18 0 NUM F
( 0 PUNCT F
AUC 0 NOUN T
( 0 PUNCT F
0-18 0 NUM F
) 0 PUNCT F
) 0 PUNCT F
. 0 PUNCT F

Clinical 0 ADJ T
and 0 CCONJ F
laboratory 0 NOUN F
evaluations 0 NOUN F
were 0 VERB F
performed 0 VERB F
at 0 ADP F
each 0 DET F
visit 0 NOUN F
. 0 PUNCT F

The 0 DET T
Bath B-OTHER NOUN T
Ankylosing I-OTHER VERB T
Spondylitis I-OTHER ADP T
Disease I-OTHER NOUN T
Activity I-OTHER NOUN T
Index 0 NOUN T
( B-OTHER PUNCT F
BASDAI I-OTHER NOUN T
) B-OTHER PUNCT F
score 0 NOUN F
was 0 VERB F
the 0 DET F
primary 0 ADJ F
end 0 NOUN F
point 0 NOUN F
for 0 ADP F
clinical 0 ADJ F
response 0 NOUN F
. 0 PUNCT F

RESULTS 0 NOUN T
Twenty-six 0 NUM T
patients 0 NOUN F
were 0 VERB F
included 0 VERB F
( 0 PUNCT F
infliximab 0 NOUN F
group 0 NOUN F
: 0 PUNCT F
n 0 NOUN F
= 0 SYM F
12 0 NUM F
, 0 PUNCT F
infliximab 0 NOUN F
+ 0 DET F
MTX 0 NOUN T
group 0 NOUN F
: 0 PUNCT F
n 0 NOUN F
= 0 SYM F
14 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
and 0 CCONJ F
507 0 NUM F
serum 0 NOUN F
samples 0 NOUN F
were 0 VERB F
available 0 ADJ F
for 0 ADP F
measurement 0 NOUN F
of 0 ADP F
infliximab B-PHYSICAL NOUN F
concentration B-PHYSICAL NOUN F
. 0 PUNCT F

The 0 DET T
two 0 NUM F
groups 0 NOUN F
did 0 ADP F
not 0 ADV F
differ 0 VERB F
with 0 ADP F
regard 0 NOUN F
to 0 ADP F
AUC B-OTHER NOUN T
( B-PHYSICAL PUNCT F

Comparative B-PHYSICAL ADJ T
bioavailability I-PHYSICAL NOUN F
of 0 ADP F
two 0 NUM F
formulations 0 NOUN F
of 0 ADP F
terbinafine 0 NOUN F
. 0 PUNCT F

Data 0 NOUN T
from 0 ADP F
a 0 DET F
cross-over 0 NOUN F
, 0 PUNCT F
randomised 0 ADP F
, 0 PUNCT F
open-label 0 NOUN F
bioequivalence 0 NOUN F
study 0 NOUN F
in 0 ADP F
healthy 0 ADJ F
volunteers 0 NOUN F
. 0 PUNCT F

An 0 DET T
open-label 0 NOUN F
, 0 PUNCT F
randomised 0 VERB F
, 0 PUNCT F
cross-over 0 ADP F
single 0 ADJ F
dose 0 NOUN F
study 0 NOUN F
, 0 PUNCT F
using 0 VERB F
2 0 NUM F
periods 0 NOUN F
x 0 SYM F
2 0 NUM F
sequences 0 NOUN F
, 0 PUNCT F
with 0 ADP F
a 0 DET F
minimum 0 NOUN F
washout 0 PUNCT F
period 0 NOUN F
of 0 ADP F
21 0 NUM F
days 0 NOUN F
, 0 PUNCT F
was 0 VERB F
conducted 0 VERB F
in 0 ADP F
order 0 NOUN F
to 0 PART F
assess 0 NOUN F
the 0 DET F
comparative B-PHYSICAL ADJ F
bioavailability I-PHYSICAL NOUN F
of 0 ADP F
two 0 NUM F
formulations 0 NOUN F
of 0 ADP F
terbinafine 0 NOUN F
( 0 PUNCT F
CAS 0 NOUN T
78628-80-5 0 PUNCT F
) 0 PUNCT F
250 0 NUM F
mg 0 NOUN F
tablets 0 ADV F
. 0 PUNCT F

Plasma B-PHYSICAL NOUN T
samples I-PHYSICAL NOUN F
were 0 VERB F
obtained 0 VERB F
at 0 ADP F
baseline 0 NOUN F
, 0 PUNCT F
+0.333 0 ADJ F
; 0 PUNCT F
0.667 0 NUM F
; 0 PUNCT F
1.00 0 ADV F
; 0 PUNCT F
1.33 0 NUM F
; 0 PUNCT F
1.67 0 NUM F
; 0 PUNCT F
2.00 0 NUM F
; 0 PUNCT F
2.33 0 ADV F
; 0 PUNCT F
2.67 0 NUM F
; 0 PUNCT F
3.00 0 ADV F
; 0 PUNCT F
3.50 0 ADV F
; 0 PUNCT F
4.00 0 ADV F
; 0 PUNCT F
6.00 0 ADV F
; 0 PUNCT F
8.00 0 ADV F
; 0 PUNCT F
12.0 0 NUM F
; 0 PUNCT F
24.0 0 NUM F
; 0 PUNCT F
36.0 0 NUM F
; 0 PUNCT F
48.0 0 NUM F
and 0 CCONJ F
72.0 0 NUM F
h 0 NOUN F
post-administration 0 NOUN F
. 0 PUNCT F

Terbinafine B-PHYSICAL NOUN T
levels I-PHYSICAL NOUN F
were 0 VERB F
determined 0 VERB F
by 0 ADP F
high B-PHYSICAL ADJ F
pressure I-PHYSICAL NOUN F
liquid I-PHYSICAL NOUN F
chromatography I-PHYSICAL NOUN F
with 0 ADP F
tandem 0 NOUN F
mass 0 NOUN F
detection 0 NOUN F
( 0 PUNCT F
HPLC-MS/MS 0 NOUN T
) 0 PUNCT F
and 0 CCONJ F
the 0 DET F
lower 0 PUNCT F
limit 0 NOUN F
of 0 ADP F
quantification 0 NOUN F
was 0 VERB F
set 0 ADP F
at 0 ADP F
9.99 0 NUM F
ng/mL 0 NOUN F
. 0 PUNCT F

The 0 DET T
pharmacokinetic B-OTHER ADJ F
parameters I-OTHER NOUN F
used 0 VERB F
for 0 ADP F
the 0 DET F
bioequivalence B-MENTAL NOUN F
assessment I-MENTAL NOUN F
( 0 PUNCT F
AUClast B-MENTAL NOUN T
, 0 PUNCT F
AUCinf B-MENTAL PUNCT T
and 0 CCONJ F
Cmax B-MENTAL NOUN T
) 0 PUNCT F
were 0 VERB F
determined 0 VERB F
from 0 ADP F
the 0 DET F
terbinafine 0 NOUN F
concentration 0 NOUN F
data 0 NOUN F
using 0 PRON F
non-compartmental 0 ADJ F
analysis 0 NOUN F
. 0 PUNCT F

Bilateral 0 ADJ T
transversus 0 PUNCT F
abdominis 0 NOUN F
plane 0 NOUN F
block 0 NOUN F
does 0 PUNCT F
not 0 ADV F
decrease 0 NUM F
postoperative 0 ADJ F
pain 0 NOUN F
after 0 ADP F
laparoscopic 0 ADJ F
cholecystectomy 0 NOUN F
when 0 ADP F
compared 0 VERB F
with 0 ADP F
local 0 ADJ F
anesthetic 0 ADJ F
infiltration 0 NOUN F
of 0 ADP F
trocar 0 PUNCT F
insertion 0 NOUN F
sites 0 NOUN F
. 0 PUNCT F

BACKGROUND 0 NOUN T
AND 0 CCONJ T
OBJECTIVES 0 NOUN T
Transversus 0 PUNCT T
abdominis 0 NOUN F
plane 0 NOUN F
( 0 PUNCT F
TAP 0 NOUN T
) 0 PUNCT F
block 0 NOUN F
has 0 PUNCT F
been 0 PUNCT F
shown 0 VERB F
to 0 PART F
reduce 0 NOUN F
pain 0 NOUN F
and 0 CCONJ F
analgesic 0 ADP F
requirements 0 NOUN F
after 0 ADP F
abdominal 0 ADJ F
surgery 0 NOUN F
. 0 PUNCT F

Our 0 VERB T
hypothesis 0 NOUN F
was 0 VERB F
that 0 ADP F
bilateral 0 PUNCT F
TAP 0 NOUN T
blocks 0 NOUN F
decrease 0 NOUN F
pain 0 NOUN F
after 0 ADP F
laparoscopic 0 ADJ F
cholecystectomy 0 NOUN F
when 0 ADP F
compared 0 VERB F
with 0 ADP F
local 0 ADJ F
anesthetic 0 ADJ F
infiltration 0 NOUN F
of 0 ADP F
trocar 0 PUNCT F
insertion 0 NOUN F
sites 0 NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
Eighty 0 PUNCT T
patients 0 NOUN F
undergoing 0 SYM F
laparoscopic 0 PUNCT F
cholecystectomy 0 NOUN F
were 0 VERB F
randomized 0 VERB F
to 0 PART F
receive 0 ADP F
either 0 PUNCT F
bilateral 0 PUNCT F
TAP 0 NOUN T
blocks 0 DET F
or 0 CCONJ F
local 0 ADJ F
anesthetic 0 ADJ F
infiltration 0 NOUN F
of 0 ADP F
trocar 0 PUNCT F
insertion 0 NOUN F
sites 0 NOUN F
with 0 ADP F
ropivacaine 0 NOUN F
0.5 0 NUM F
% 0 SYM F
. 0 PUNCT F

Postoperative B-PAIN ADJ T
pain I-PAIN NOUN F
scores 0 NOUN F
and 0 CCONJ F
analgesic 0 PUNCT F
use 0 NOUN F
for 0 ADP F
the 0 DET F
first 0 ADJ F
24 0 NUM F
hrs 0 NOUN F
were 0 VERB F
recorded 0 VERB F
. 0 PUNCT F

RESULTS 0 NOUN T
Eighty 0 PUNCT T
patients 0 NOUN F
were 0 VERB F
enrolled 0 VERB F
in 0 ADP F
the 0 DET F
study 0 NOUN F
. 0 PUNCT F

After 0 ADP T
exclusions 0 NOUN F
, 0 PUNCT F
data 0 NOUN F
were 0 VERB F
analyzed 0 VERB F
on 0 ADP F
39 0 NUM F
patients 0 NOUN F
in 0 ADP F
group 0 NOUN F
T 0 NOUN T
( 0 PUNCT F
bilateral 0 ADJ F
TAP 0 NOUN T
block 0 NOUN F
) 0 PUNCT F
and 0 CCONJ F
35 0 NUM F
patients 0 NOUN F
in 0 ADP F
group 0 NOUN F
I 0 NUM T
( 0 PUNCT F
infiltration 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

There 0 PUNCT T
was 0 VERB F
no 0 DET F
statistically 0 ADV F
significant 0 ADJ F
difference B-PHYSICAL NOUN F
in 0 ADP F
pain B-PAIN NOUN F
scores I-PAIN NOUN F
on I-PAIN ADP F
the I-PAIN DET F
numeric I-PAIN ADJ F
analog I-PAIN NOUN F
scale 0 NOUN F
( 0 PUNCT F
0-10 0 NUM F
) 0 PUNCT F
between 0 ADP F
the 0 DET F
groups 0 NOUN F
at 0 ADP F
4 0 NUM F
hrs 0 NOUN F
after 0 ADP F
surgery 0 NOUN F
( 0 PUNCT F
P 0 NOUN T
= 0 SYM F
0.18 0 NUM F
) 0 PUNCT F
or 0 CCONJ F
during 0 ADP F
the 0 DET F
24 0 NUM F
hrs 0 NOUN F
after 0 ADP F
surgery 0 NOUN F
( 0 PUNCT F
P 0 NOUN T
= 0 SYM F
0.23 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
time B-OTHER NOUN F
interval I-OTHER NOUN F
from I-OTHER ADP F
anesthesia I-OTHER NOUN F
start I-OTHER ADJ F
to I-OTHER ADP F
surgery I-OTHER NOUN F
start I-OTHER NOUN F
was 0 VERB F
greater 0 PUNCT F
in 0 ADP F
group 0 NOUN F
T 0 NOUN T
than 0 ADP F
group 0 NOUN F
I 0 NUM T
( 0 PUNCT F
48 0 NUM F
vs 0 CCONJ F
35 0 NUM F
mins 0 NOUN F
, 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.001 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

There 0 PUNCT T
was 0 VERB F
no 0 DET F
significant B-PHYSICAL ADJ F
difference I-PHYSICAL NOUN F
found 0 VERB F
in 0 ADP F
analgesic B-OTHER CCONJ F
use I-OTHER NOUN F
during 0 ADP F
the 0 DET F
first 0 ADJ F
24 0 NUM F
hrs 0 NOUN F
after 0 ADP F
surgery 0 NOUN F
. 0 PUNCT F

CONCLUSIONS 0 NOUN T
Bilateral 0 ADJ T
ultrasound-guided 0 VERB F
TAP 0 NOUN T
block 0 NOUN F
is 0 VERB F
equivalent 0 ADJ F
to 0 ADP F
local 0 PUNCT F
anesthetic 0 ADJ F
infiltration 0 NOUN F
of 0 ADP F
trocar 0 PUNCT F
insertion 0 NOUN F
sites 0 NOUN F
for 0 ADP F
overall 0 PUNCT F
postoperative B-PAIN ADJ F
pain I-PAIN NOUN F
in 0 ADP F
a 0 DET F
heterogeneous 0 ADJ F
group 0 NOUN F
of 0 ADP F
patients 0 NOUN F
undergoing 0 SYM F
laparoscopic 0 PUNCT F
cholecystectomy 0 NOUN F
. 0 PUNCT F

Oral 0 ADJ T
ganciclovir 0 NOUN F
dosing 0 NUM F
in 0 ADP F
transplant 0 ADJ F
recipients 0 NOUN F
and 0 CCONJ F
dialysis 0 NOUN F
patients 0 NOUN F
based 0 VERB F
on 0 ADP F
renal 0 ADJ F
function 0 NOUN F
. 0 PUNCT F

BACKGROUND 0 NOUN T
An 0 DET T
oral 0 ADJ F
formulation 0 NOUN F
of 0 ADP F
ganciclovir 0 NOUN F
( 0 PUNCT F
GCV 0 NOUN T
) 0 PUNCT F
was 0 VERB F
recently 0 ADV F
approved 0 VERB F
for 0 ADP F
the 0 DET F
prevention 0 NOUN F
of 0 ADP F
cytomegalovirus 0 NOUN F
disease 0 NOUN F
in 0 ADP F
solid 0 ADJ F
organ 0 NOUN F
transplant 0 NOUN F
recipients 0 NOUN F
. 0 PUNCT F

This 0 DET T
study 0 NOUN F
was 0 VERB F
designed 0 VERB F
to 0 PART F
determine 0 NOUN F
the 0 DET F
bioavailability 0 NOUN F
of 0 ADP F
GCV 0 NOUN T
and 0 CCONJ F
to 0 PART F
test 0 NOUN F
a 0 DET F
dosing 0 VERB F
algorithm 0 NOUN F
in 0 ADP F
transplant 0 NOUN F
and 0 CCONJ F
dialysis 0 NOUN F
patients 0 NOUN F
with 0 ADP F
different 0 ADJ F
levels 0 NOUN F
of 0 ADP F
renal 0 ADJ F
function 0 NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
Pharmacokinetic 0 ADJ T
studies 0 NOUN F
were 0 VERB F
carried 0 VERB F
out 0 ADP F
in 0 ADP F
23 0 NUM F
patients 0 NOUN F
who 0 ADP F
were 0 VERB F
either 0 PUNCT F
a 0 DET F
recipient 0 NOUN F
of 0 ADP F
an 0 DET F
organ 0 NOUN F
transplant 0 NOUN F
or 0 CCONJ F
on 0 ADP F
hemodialysis 0 NOUN F
. 0 PUNCT F

Drug 0 NOUN T
dosing 0 VERB F
was 0 VERB F
established 0 VERB F
by 0 ADP F
the 0 DET F
following 0 VERB F
algorithm 0 NOUN F
based 0 VERB F
on 0 ADP F
calculated 0 VERB F
creatinine 0 NOUN F
clearance 0 NOUN F
( 0 PUNCT F
CrCl 0 ADJ T
) 0 PUNCT F
: 0 PUNCT F
CrCl 0 ADJ T
= 0 ADJ F
[ 0 PUNCT F
( 0 PUNCT F
140-age 0 NOUN F
) 0 PUNCT F
x 0 SYM F
body 0 NOUN F
weight 0 NOUN F
] 0 PUNCT F
/ 0 SYM F
( 0 PUNCT F
72 0 NUM F
x 0 PUNCT F
Cr 0 NOUN T
) 0 PUNCT F
x 0 SYM F
0.85 0 NUM F
for 0 ADP F
women 0 NOUN F
that 0 PUNCT F
is 0 VERB F
, 0 PUNCT F
CrCl 0 ADJ T
> 0 SYM F
50 0 NUM F
ml/min 0 NOUN F
, 0 PUNCT F
1000 0 NUM F
mg 0 NOUN F
every 0 DET F
8 0 NUM F
hr 0 NOUN F
; 0 PUNCT F
CrCl 0 NOUN T
of 0 ADP F
25-50 0 NUM F
ml/min 0 NOUN F
, 0 PUNCT F
1000 0 NUM F
mg 0 NOUN F
every 0 DET F
24 0 NUM F
hr 0 NOUN F
; 0 PUNCT F
CrCl 0 NOUN T
of 0 ADP F
10-24 0 NUM F
ml/ 0 NOUN F
min 0 NOUN F
, 0 PUNCT F
500 0 NUM F
mg 0 NOUN F
every 0 DET F
day 0 NOUN F
; 0 PUNCT F
CrCl 0 ADJ T
< 0 SYM F
10 0 NUM F
ml/min 0 NOUN F
( 0 PUNCT F
or 0 CCONJ F
on 0 ADP F
dialysis 0 NOUN F
) 0 PUNCT F
, 0 PUNCT F
500 0 NUM F
mg 0 NOUN F
every 0 DET F
other 0 ADJ F
day 0 NOUN F
after 0 ADP F
dialysis 0 NOUN F
. 0 PUNCT F

GCV 0 NOUN T
was 0 VERB F
taken 0 VERB F
within 0 ADP F
30 0 NUM F
min 0 NOUN F
after 0 ADP F
a 0 DET F
meal 0 NOUN F
. 0 PUNCT F

The 0 DET T
patients 0 NOUN F
received 0 ADP F
oral 0 ADJ F
GCV 0 NOUN T
for 0 ADP F
between 0 ADP F
12 0 NUM F
days 0 NOUN F
and 0 CCONJ F
14 0 NUM F
weeks 0 NOUN F
. 0 PUNCT F

Serum 0 NOUN T
specimens 0 NOUN F
( 0 PUNCT F
or 0 CCONJ F
plasma 0 NOUN F
from 0 ADP F
patients 0 NOUN F
on 0 ADP F
hemodialysis 0 NOUN F
) 0 PUNCT F
obtained 0 VERB F
at 0 ADP F
steady 0 ADJ F
state 0 NOUN F
were 0 VERB F
analyzed 0 VERB F
for 0 ADP F
GCV 0 NOUN T
concentrations 0 NOUN F
by 0 ADP F
high-performance 0 NOUN F
liquid 0 NOUN F
chromatography 0 NOUN F
. 0 PUNCT F

In 0 ADP T
nine 0 NUM F
of 0 ADP F
the 0 DET F
transplant 0 ADJ F
recipients 0 NOUN F
, 0 PUNCT F
absolute B-PHYSICAL ADJ F
bioavailability I-PHYSICAL NOUN F
was 0 VERB F
determined 0 VERB F
by 0 ADP F
comparing 0 PUNCT F
GCV B-PHYSICAL NOUN T
levels I-PHYSICAL NOUN F
after 0 ADP F
single 0 ADJ F
oral 0 ADJ F
and 0 CCONJ F
intravenous 0 ADJ F
doses 0 NOUN F
of 0 ADP F
GCV 0 NOUN T
. 0 PUNCT F

RESULTS 0 PUNCT T
The 0 DET T
following 0 ADJ F
GCV B-PHYSICAL NOUN T
concentrations I-PHYSICAL NOUN F
( 0 PUNCT F
mean 0 NOUN F
+/-SD 0 PUNCT F
) 0 PUNCT F
were 0 VERB F
determined 0 VERB F
: 0 PUNCT F
with 0 ADP F
CrCl 0 NOUN T
of 0 ADP F
> 0 PROPN F
or 0 CCONJ F
=70 0 NUM F
ml/min 0 NOUN F
, 0 PUNCT F
the 0 DET F
minimum 0 NOUN F
steady-state 0 NOUN F
concentration 0 NOUN F
( 0 PUNCT F
Cmin 0 NOUN T
) 0 PUNCT F
and 0 CCONJ F
maximum 0 NOUN F
concentration 0 NOUN F
( 0 PUNCT F
Cmax 0 NOUN T
) 0 PUNCT F
were 0 VERB F
0.78+/-0.46 0 PUNCT F
microg/ml 0 NOUN F
and 0 CCONJ F
1.42+/-0.37 0 ADV F
microg/ml 0 NOUN F
, 0 PUNCT F
respectively 0 ADV F
, 0 PUNCT F
with 0 ADP F
a 0 DET F
24-hr 0 NOUN F
area 0 NOUN F
under 0 ADP F
the 0 DET F
concentration 0 NOUN F
time 0 NOUN F
curve 0 NOUN F
( 0 PUNCT F
AUC0-24 0 NOUN T
) 0 PUNCT F
of 0 ADP F
24.7+/-7.8 0 NUM F
microg 0 NOUN F
x 0 SYM F
hr/ml 0 NOUN F
; 0 PUNCT F
with 0 ADP F
CrCl 0 NOUN T
of 0 ADP F
50-69 0 NUM F
ml/min 0 NOUN F
, 0 PUNCT F
the 0 DET F
Cmin 0 NOUN T
and 0 CCONJ F
Cmax 0 NOUN T
were 0 VERB F
1.93+/-0.48 0 ADV F
and 0 CCONJ F
2.57+/-0.39 0 NOUN F
microg/ml 0 NOUN F
, 0 PUNCT F
respectively 0 ADV F
, 0 PUNCT F
with 0 ADP F
an 0 DET F
AUC0-24 0 NOUN T
of 0 ADP F
52.1+/-10.1 0 NUM F
microg 0 NOUN F
x 0 SYM F
hr/ml 0 NOUN F
; 0 PUNCT F
with 0 ADP F
CrCl 0 NOUN T
of 0 ADP F
25-50 0 NUM F
ml/min 0 NOUN F
, 0 PUNCT F
the 0 DET F
Cmin 0 NOUN T
and 0 CCONJ F
Cmax 0 NOUN T
were 0 VERB F
0.41+/-0.27 0 ADV F
and 0 CCONJ F
1.17+/-0.32 0 NOUN F
microg/ml 0 NOUN F
, 0 PUNCT F
respectively 0 ADV F
, 0 PUNCT F
with 0 ADP F
an 0 DET F
AUC0-24 0 NOUN T
of 0 ADP F
14.6+/-7.4 0 NOUN F
microg 0 NOUN F
x 0 SYM F
hr/ml 0 NOUN F
. 0 PUNCT F

For 0 ADP T
one 0 NUM F
patient 0 NOUN F
with 0 ADP F
a 0 DET F
CrCl 0 NOUN T
of 0 ADP F
23.8 0 NUM F
ml/min 0 NOUN F
, 0 PUNCT F
the 0 DET F
Cmin 0 NOUN T
and 0 CCONJ F
Cmax 0 NOUN T
were 0 VERB F
0.32 0 NUM F
and 0 CCONJ F
0.7 0 NUM F
microg/ml 0 NOUN F
, 0 PUNCT F
respectively 0 ADV F
, 0 PUNCT F
with 0 ADP F
an 0 DET F
AUC0-24 0 NOUN T
of 0 ADP F
10.7 0 NUM F
microg 0 NOUN F
x 0 SYM F
hr/ml 0 NOUN F
. 0 PUNCT F

With 0 ADP T
CrCl 0 NOUN T
of 0 ADP F
< 0 SYM F
10 0 NUM F
ml/min 0 NOUN F
, 0 PUNCT F
the 0 DET F
mean 0 NOUN F
Cmin 0 NOUN T
and 0 CCONJ F
Cmax 0 NOUN T
were 0 VERB F
0.75+/-0.42 0 PUNCT F
and 0 CCONJ F
1.59+/-0.55 0 ADV F
microg/ml 0 NOUN F
, 0 PUNCT F
respectively 0 ADV F
, 0 PUNCT F
with 0 ADP F
a 0 DET F
mean 0 NOUN F
AUC0-24 0 NOUN T
of 0 ADP F
64.6+/-18.8 0 PUNCT F
microg 0 NOUN F
x 0 SYM F
hr/ml 0 NOUN F
. 0 PUNCT F

Absolute B-PHYSICAL ADJ T
bioavailability I-PHYSICAL NOUN F
, 0 PUNCT F
for 0 ADP F
the 0 DET F
nine 0 NUM F
patients 0 NOUN F
so 0 ADP F
analyzed 0 ADP F
, 0 PUNCT F
was 0 VERB F
7.2+/-2.4 0 PUNCT F
% 0 PUNCT F
. 0 PUNCT F

For 0 ADP T
those 0 ADP F
patients 0 NOUN F
with 0 ADP F
end-stage 0 NOUN F
renal 0 ADJ F
failure 0 NOUN F
, 0 PUNCT F
GCV B-PHYSICAL NOUN T
concentrations I-PHYSICAL NOUN F
fell 0 VERB F
during 0 ADP F
dialysis 0 NOUN F
from 0 ADP F
a 0 DET F
mean 0 NOUN F
of 0 ADP F
1.47+/-0.48 0 PUNCT F
microg/ml 0 NOUN F
before 0 ADP F
dialysis 0 NOUN F
to 0 VERB F
0.69+/-0.38 0 PUNCT F
microg/ml 0 NOUN F
after 0 ADP F
dialysis 0 NOUN F
. 0 PUNCT F

CONCLUSIONS 0 NOUN T
The 0 DET T
bioavailability 0 NOUN F
of 0 ADP F
oral 0 ADJ F
GCV 0 NOUN T
in 0 ADP F
transplant 0 ADJ F
patients 0 NOUN F
was 0 VERB F
similar 0 ADJ F
to 0 ADP F
that 0 PUNCT F
observed 0 VERB F
in 0 ADP F
human 0 NOUN F
immunodeficiency 0 NOUN F
virus-infected 0 VERB F
patients 0 NOUN F
. 0 PUNCT F

However 0 ADV T
, 0 PUNCT F
levels 0 NOUN F
between 0 ADP F
0.5 0 NUM F
and 0 CCONJ F
1 0 NUM F
microg/ml 0 NOUN F
( 0 PUNCT F
within 0 ADP F
the 0 DET F
IC50 0 NOUN T
of 0 ADP F
most 0 CCONJ F
cytomegalovirus 0 NOUN F
isolates 0 NOUN F
) 0 PUNCT F
could 0 VERB F
be 0 VERB F
achieved 0 VERB F
with 0 ADP F
tolerable 0 ADJ F
oral 0 ADJ F
doses 0 NOUN F
. 0 PUNCT F

The 0 DET T
proposed 0 VERB F
dosing 0 VERB F
algorithm 0 NOUN F
resulted 0 VERB F
in 0 ADP F
adequate 0 ADJ F
levels 0 NOUN F
for 0 ADP F
patients 0 NOUN F
with 0 ADP F
CrCl 0 ADJ T
greater 0 PUNCT F
than 0 VERB F
50 0 NUM F
ml/min 0 NOUN F
and 0 CCONJ F
for 0 ADP F
patients 0 NOUN F
on 0 ADP F
dialysis 0 NOUN F
. 0 PUNCT F

For 0 ADP T
patients 0 NOUN F
with 0 ADP F
CrCl 0 ADJ T
between 0 ADP F
10 0 NUM F
and 0 CCONJ F
50 0 NUM F
ml/min 0 NOUN F
, 0 PUNCT F
the 0 DET F
levels 0 NOUN F
achieved 0 VERB F
were 0 VERB F
low 0 ADJ F
and 0 CCONJ F
these 0 DET F
patients 0 NOUN F
would 0 ADP F
likely 0 PUNCT F
benefit 0 NOUN F
from 0 ADP F
increased 0 VERB F
doses 0 NOUN F
. 0 PUNCT F

The 0 DET T
effect 0 NOUN F
of 0 ADP F
aging 0 VERB F
on 0 ADP F
circulating 0 VERB F
levels 0 NOUN F
of 0 ADP F
proinflammatory 0 ADJ F
cytokines 0 NOUN F
during 0 ADP F
septic 0 ADJ F
shock 0 NOUN F
. 0 PUNCT F

Norasept 0 PUNCT T
II 0 NUM T
Study 0 NOUN T
Investigators 0 NOUN T
. 0 PUNCT F

BACKGROUND 0 NOUN T
As 0 ADP T
the 0 DET F
proportion 0 NOUN F
of 0 ADP F
the 0 DET F
population 0 NOUN F
that 0 ADP F
is 0 VERB F
older 0 PUNCT F
continues 0 VERB F
to 0 PUNCT F
rise 0 NOUN F
, 0 PUNCT F
infection 0 NOUN F
in 0 ADP F
older 0 PUNCT F
people 0 NOUN F
has 0 PUNCT F
become 0 VERB F
an 0 DET F
important 0 ADJ F
healthcare 0 NOUN F
problem 0 NOUN F
. 0 PUNCT F

Although 0 ADP T
aging 0 ADP F
is 0 VERB F
associated 0 VERB F
with 0 ADP F
multiple 0 ADJ F
abnormalities 0 NOUN F
in 0 ADP F
immune 0 ADJ F
function 0 NOUN F
, 0 PUNCT F
the 0 DET F
effect 0 NOUN F
of 0 ADP F
aging 0 VERB F
on 0 ADP F
the 0 DET F
production 0 NOUN F
of 0 ADP F
proinflammatory B-PHYSICAL ADJ F
cytokines 0 NOUN F
has 0 VERB F
not 0 ADV F
been 0 PUNCT F
well 0 PUNCT F
studied 0 CCONJ F
under 0 ADP F
conditions 0 NOUN F
of 0 ADP F
clinical 0 ADJ F
stress 0 NOUN F
. 0 PUNCT F

OBJECTIVES 0 NOUN T
The 0 DET T
aim 0 NOUN F
of 0 ADP F
this 0 DET F
study 0 NOUN F
was 0 VERB F
to 0 ADV F
examine 0 NOUN F
the 0 DET F
effect 0 NOUN F
of 0 ADP F
aging 0 VERB F
on 0 ADP F
circulating 0 VERB F
levels 0 NOUN F
of 0 ADP F
the 0 DET F
proinflammatory 0 ADJ F
cytokines 0 NOUN F
in 0 ADP F
a 0 DET F
large 0 ADJ F
cohort 0 NOUN F
of 0 ADP F
septic 0 ADJ F
shock 0 NOUN F
patients 0 NOUN F
. 0 PUNCT F

We 0 PRON T
hypothesized 0 VERB F
that 0 ADP F
aging 0 ADV F
would 0 VERB F
be 0 VERB F
associated 0 VERB F
with 0 ADP F
a 0 DET F
diminished 0 VERB F
proinflammatory 0 ADJ F
cytokine 0 NOUN F
response 0 NOUN F
to 0 ADP F
sepsis 0 NOUN F
. 0 PUNCT F

DESIGN 0 NOUN T
Patients 0 NOUN T
with 0 ADP F
septic 0 ADJ F
shock 0 NOUN F
who 0 ADP F
were 0 VERB F
enrolled 0 VERB F
in 0 ADP F
the 0 DET F
placebo 0 NOUN F
limb 0 NOUN F
of 0 ADP F
the 0 DET F
North 0 NOUN T
American 0 ADJ T
Sepsis 0 NOUN T
Trial 0 NOUN T
( 0 PUNCT F
NORASEPT 0 NOUN T
II 0 NUM T
) 0 PUNCT F
study 0 NOUN F
were 0 VERB F
analyzed 0 VERB F
. 0 PUNCT F

SETTING 0 VERB T
The 0 DET T
intensive 0 ADJ F
care 0 NOUN F
units 0 NOUN F
of 0 ADP F
105 0 NUM F
hospitals 0 PROPN F
in 0 ADP F
the 0 DET F
United 0 ADV T
States 0 NOUN T
and 0 CCONJ F
Canada 0 PUNCT T
. 0 PUNCT F

PARTICIPANTS 0 ADP T
Nine 0 NUM T
hundred 0 NUM F
and 0 CCONJ F
thirty 0 NUM F
patients 0 NOUN F
presenting 0 ADJ F
to 0 ADP F
hospital 0 NOUN F
within 0 ADP F
12 0 NUM F
hours 0 NOUN F
of 0 ADP F
the 0 DET F
onset 0 NOUN F
of 0 ADP F
septic 0 ADJ F
shock 0 NOUN F
. 0 PUNCT F

MEASUREMENTS 0 ADP T
Interleukin-6 B-PHYSICAL NOUN T
( I-PHYSICAL PUNCT F
IL-6 I-PHYSICAL NOUN T
) I-PHYSICAL PUNCT F
, 0 PUNCT F
tumor B-PHYSICAL NOUN F
necrosis I-PHYSICAL NOUN F
factor-alpha I-PHYSICAL NOUN F
( I-PHYSICAL PUNCT F
TNF-alpha I-PHYSICAL NOUN T
) I-PHYSICAL PUNCT F
, 0 PUNCT F
soluble B-PHYSICAL ADJ F
tumor I-PHYSICAL NOUN F
necrosis I-PHYSICAL NOUN F
factor-receptor-55 I-PHYSICAL NOUN F
( I-PHYSICAL PUNCT F
sTNF-R55 I-PHYSICAL NOUN F
) I-PHYSICAL PUNCT F
, 0 PUNCT F
and 0 CCONJ F
soluble B-PHYSICAL ADJ F
tumor I-PHYSICAL NOUN F
necrosis I-PHYSICAL NOUN F
factor-receptor-75 I-PHYSICAL NOUN F
( I-PHYSICAL PUNCT F
sTNF-R75 I-PHYSICAL NOUN F
) I-PHYSICAL PUNCT F
concentrations I-PHYSICAL NOUN F
were 0 VERB F
measured 0 VERB F
at 0 ADP F
enrollment 0 NOUN F
. 0 PUNCT F

The 0 DET T
study 0 ADV F
population 0 NOUN F
was 0 ADP F
broken 0 NUM F
down 0 ADJ F
into 0 ADP F
five 0 NUM F
age 0 NOUN F
groups 0 NOUN F
as 0 ADP F
follows 0 VERB F
: 0 PUNCT F
less 0 ADV F
than 0 ADP F
50 0 NUM F
years 0 NOUN F
( 0 PUNCT F
group 0 NOUN F
one 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
50 0 NUM F
to 0 ADP F
64 0 NUM F
years 0 NOUN F
( 0 PUNCT F
group 0 NOUN F
two 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
65 0 NUM F
to 0 ADP F
74 0 NUM F
years 0 NOUN F
( 0 PUNCT F
group 0 NOUN F
three 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
75 0 NUM F
to 0 ADP F
84 0 NUM F
years 0 NOUN F
( 0 PUNCT F
group 0 NOUN F
four 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
and 0 CCONJ F
85 0 NUM F
or 0 CCONJ F
older 0 PUNCT F
( 0 PUNCT F
group 0 NOUN F
five 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Clinical B-OTHER ADJ T
, 0 PUNCT F
demographic B-OTHER ADJ F
, 0 PUNCT F
and 0 PUNCT F

Perceptual B-MENTAL ADJ T
learning I-MENTAL PUNCT F
of I-MENTAL ADP F
speech I-MENTAL NOUN F
under 0 ADP F
optimal 0 ADJ F
and 0 CCONJ F
adverse 0 ADJ F
conditions 0 NOUN F
. 0 PUNCT F

Humans 0 NOUN T
have 0 CCONJ F
a 0 DET F
remarkable 0 ADJ F
ability 0 NOUN F
to 0 PART F
understand 0 CCONJ F
spoken 0 PUNCT F
language 0 NOUN F
despite 0 ADP F
the 0 DET F
large 0 ADJ F
amount 0 NOUN F
of 0 ADP F
variability 0 NOUN F
in 0 ADP F
speech 0 NOUN F
. 0 PUNCT F

Previous 0 ADJ T
research 0 NOUN F
has 0 PUNCT F
shown 0 VERB F
that 0 ADP F
listeners 0 NOUN F
can 0 VERB F
use 0 ADV F
lexical 0 ADJ F
information 0 NOUN F
to 0 PART F
guide 0 NOUN F
their 0 ADP F
interpretation 0 NOUN F
of 0 ADP F
atypical 0 ADJ F
sounds 0 NOUN F
in 0 ADP F
speech 0 NOUN F
( 0 PUNCT F
Norris 0 NOUN T
, 0 PUNCT F
McQueen 0 PUNCT T
, 0 PUNCT F
& 0 CCONJ F
Cutler 0 PUNCT T
, 0 PUNCT F
2003 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

This 0 DET T
kind 0 ADV F
of 0 ADP F
lexically 0 ADV F
induced 0 ADJ F
perceptual B-MENTAL ADJ F
learning I-MENTAL ADV F
enables 0 NUM F
people 0 NOUN F
to 0 PUNCT F
adjust 0 PUNCT F
to 0 ADP F
the 0 DET F
variations 0 NOUN F
in 0 ADP F
utterances 0 NOUN F
due 0 CCONJ F
to 0 ADP F
talker-specific 0 ADJ F
characteristics 0 NOUN F
, 0 PUNCT F
such 0 PUNCT F
as 0 ADP F
individual 0 ADJ F
identity 0 NOUN F
and 0 CCONJ F
dialect 0 ADP F
. 0 PUNCT F

The 0 DET T
current 0 ADJ F
study 0 NOUN F
investigated 0 ADP F
perceptual B-MENTAL ADJ F
learning I-MENTAL PROPN F
in 0 ADP F
two 0 NUM F
optimal 0 ADJ F
conditions 0 NOUN F
: 0 PUNCT F
conversational 0 ADJ F
speech 0 NOUN F
( 0 PUNCT F
Experiment 0 NOUN T
1 0 NUM F
) 0 PUNCT F
versus 0 CCONJ F
clear 0 ADJ F
speech 0 NOUN F
( 0 PUNCT F
Experiment 0 NOUN T
2 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
and 0 CCONJ F
three 0 NUM F
adverse 0 ADJ F
conditions 0 NOUN F
: 0 PUNCT F
noise 0 NOUN F
( 0 PUNCT F
Experiment 0 NOUN T
3a 0 NOUN F
) 0 PUNCT F
versus 0 CCONJ F
two 0 NUM F
cognitive 0 ADJ F
loads 0 NOUN F
( 0 PUNCT F
Experiments 0 PROPN T
4a 0 NOUN F
and 0 CCONJ F
4b 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Perceptual B-MENTAL ADJ T
learning I-MENTAL PUNCT F
occurred 0 VERB F
in 0 ADP F
the 0 DET F
two 0 NUM F
optimal 0 ADJ F
conditions 0 NOUN F
and 0 CCONJ F
in 0 ADP F
the 0 DET F
two 0 NUM F
cognitive 0 ADJ F
load 0 ADP F
conditions 0 NOUN F
, 0 PUNCT F
but 0 CCONJ F
not 0 ADV F
in 0 ADP F
the 0 DET F
noise 0 ADJ F
condition 0 NOUN F
. 0 PUNCT F

Furthermore 0 ADV T
, 0 PUNCT F
perceptual B-MENTAL ADJ F
learning I-MENTAL PUNCT F
occurred 0 VERB F
only 0 ADV F
in 0 ADP F
the 0 DET F
first 0 ADJ F
of 0 ADP F
two 0 NUM F
sessions 0 NOUN F
for 0 ADP F
each 0 DET F
participant 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
only 0 ADV F
for 0 ADP F
atypical 0 ADJ F
/s/ 0 PUNCT F
sounds 0 NOUN F
and 0 CCONJ F
not 0 ADV F
for 0 ADP F
atypical 0 ADJ F
/f/ 0 PUNCT F
sounds 0 NOUN F
. 0 PUNCT F

This 0 DET T
pattern 0 NOUN F
of 0 ADP F
learning 0 ADV F
and 0 CCONJ F
nonlearning 0 PUNCT F
reflects 0 PUNCT F
a 0 DET F
balance 0 NOUN F
between 0 ADP F
flexibility 0 NOUN F
and 0 CCONJ F
stability 0 NOUN F
that 0 ADP F
the 0 DET F
speech 0 NOUN F
system 0 NOUN F
must 0 VERB F
have 0 PUNCT F
to 0 PART F
deal 0 ADV F
with 0 ADP F
speech 0 NOUN F
variability 0 NOUN F
in 0 ADP F
the 0 DET F
diverse 0 ADJ F
conditions 0 NOUN F
that 0 PUNCT F
speech 0 NOUN F
is 0 VERB F
encountered 0 VERB F
. 0 PUNCT F

Oesophageal 0 ADJ T
intubation 0 NOUN F
can 0 VERB F
be 0 VERB F
undetected 0 VERB F
by 0 ADP F
auscultation 0 NOUN F
of 0 ADP F
the 0 DET F
chest 0 NOUN F
. 0 PUNCT F

Prompt 0 NOUN T
detection 0 NOUN F
of 0 ADP F
oesophageal 0 ADJ F
intubation 0 NOUN F
is 0 VERB F
a 0 DET F
primary 0 ADJ F
concern 0 NOUN F
in 0 ADP F
anaesthetic 0 ADJ F
practice 0 NOUN F
. 0 PUNCT F

This 0 DET T
blind 0 NOUN F
, 0 PUNCT F
randomised 0 ADP F
study 0 NOUN F
evaluates 0 VERB F
three 0 NUM F
widely 0 ADV F
used 0 NUM F
tests 0 NOUN F
of 0 ADP F
intubation 0 NOUN F
. 0 PUNCT F

Forty 0 CCONJ T
patients 0 NOUN F
had 0 ADP F
both 0 CCONJ F
their 0 PUNCT F
trachea 0 NOUN F
and 0 CCONJ F
oesophagus 0 NOUN F
intubated 0 PUNCT F
, 0 PUNCT F
each 0 DET F
patient 0 NOUN F
was 0 VERB F
studied 0 VERB F
twice 0 ADV F
. 0 PUNCT F

Auscultation B-OTHER NOUN T
of I-OTHER ADP F
the I-OTHER DET F
epigastrium I-OTHER NOUN F
, 0 PUNCT F
right 0 ADP F
and 0 CCONJ F
left 0 ADJ F
axilla 0 NOUN F
is 0 VERB F
more 0 ADV F
reliable 0 ADJ F
than 0 PUNCT F
auscultation 0 NOUN F
of 0 ADP F
the 0 DET F
chest 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
the 0 DET F
anaesthetist 0 NOUN F
's 0 PUNCT F
feeling 0 ADP F
when 0 ADP F
he 0 NOUN F
squeezes 0 ADP F
the 0 DET F
bag 0 NOUN F
. 0 PUNCT F

P 0 NOUN T
= 0 SYM F
0.001 0 NUM F
and 0 CCONJ F
P 0 NOUN T
= 0 SYM F
0.048 0 NUM F
, 0 PUNCT F
respectively 0 ADV F
. 0 PUNCT F

The 0 DET T
tests 0 NOUN F
were 0 VERB F
carried 0 VERB F
out 0 ADP F
after 0 ADP F
gastric 0 ADJ F
distension 0 NOUN F
with 0 ADP F
gas 0 NOUN F
had 0 PUNCT F
occurred 0 VERB F
. 0 PUNCT F

We 0 PRON T
conclude 0 VERB F
that 0 ADP F
auscultation 0 NOUN F
of 0 ADP F
epigastrium 0 NOUN F
, 0 PUNCT F
right 0 ADP F
and 0 CCONJ F
left 0 ADJ F
axilla 0 NOUN F
, 0 PUNCT F
are 0 VERB F
recommended 0 VERB F
. 0 PUNCT F

The 0 DET T
use 0 NOUN F
of 0 ADP F
adrenocorticotrophic 0 ADJ F
hormone 0 NOUN F
( 0 PUNCT F
4-9 0 PUNCT F
) 0 PUNCT F
analog 0 NOUN F
ORG 0 NOUN T
2766 0 NUM F
in 0 ADP F
autistic 0 ADJ F
children 0 NOUN F
: 0 PUNCT F
effects 0 NOUN F
on 0 ADP F
the 0 DET F
organization 0 NOUN F
of 0 ADP F
behavior 0 NOUN F
. 0 PUNCT F

In 0 ADP T
a 0 DET F
double-blind 0 ADJ F
placebo-controlled 0 VERB F
crossover 0 NOUN F
trial 0 NOUN F
, 0 PUNCT F
14 0 NUM F
autistic 0 ADJ F
children 0 NOUN F
were 0 VERB F
treated 0 VERB F
with 0 ADP F
the 0 DET F
neuropeptide 0 NOUN F
ORG 0 NOUN T
2766 0 NUM F
, 0 PUNCT F
a 0 DET F
synthetic 0 ADJ F
analog 0 NOUN F
of 0 ADP F
adrenocorticotrophic 0 ADJ F
hormone 0 NOUN F
( 0 PUNCT F
ACTH 0 NOUN T
) 0 PUNCT F
( 0 PUNCT F
4-9 0 PUNCT F
) 0 PUNCT F
. 0 PUNCT F

ORG 0 NOUN T
2766 0 NUM F
treatment 0 NOUN F
( 0 PUNCT F
20 0 NUM F
mg 0 NOUN F
per 0 ADP F
day 0 NOUN F
during 0 ADP F
4 0 NUM F
weeks 0 NOUN F
) 0 PUNCT F
was 0 VERB F
associated 0 VERB F
with 0 ADP F
an 0 DET F
increased 0 VERB F
amount 0 NOUN F
and 0 CCONJ F
an 0 DET F
improved 0 VERB F
quality 0 NOUN F
of 0 ADP F
the 0 DET F
social 0 ADJ F
interaction 0 NOUN F
of 0 ADP F
the 0 DET F
autistic 0 ADJ F
children 0 NOUN F
with 0 ADP F
a 0 DET F
familiar 0 PUNCT F
experimenter 0 NOUN F
. 0 PUNCT F

These 0 DET T
changes 0 NOUN F
in 0 ADP F
interaction 0 NOUN F
were 0 VERB F
clinically 0 ADV F
relevant 0 ADJ F
. 0 PUNCT F

Following 0 VERB T
treatment 0 NOUN F
with 0 ADP F
ORG 0 NOUN T
2766 0 NUM F
gaze 0 NOUN F
and 0 PUNCT F

Randomized 0 VERB T
study 0 NOUN F
of 0 ADP F
chlorambucil 0 NOUN F
( 0 PUNCT F
CB 0 NOUN T
) 0 PUNCT F
compared 0 VERB F
to 0 ADP F
interferon 0 NOUN F
( 0 PUNCT F
alfa-2b 0 NOUN F
) 0 PUNCT F
combined 0 VERB F
with 0 ADP F
CB 0 NOUN T
in 0 ADP F
low-grade 0 NOUN F
non-Hodgkin 0 NOUN F
's 0 PUNCT F
lymphoma 0 NOUN F
: 0 PUNCT F
an 0 DET F
interim 0 ADJ F
report 0 NOUN F
of 0 ADP F
a 0 DET F
randomized 0 VERB F
study 0 NOUN F
. 0 PUNCT F

Non-Hodgkin 0 NOUN T
's 0 PUNCT F
Lymphoma 0 NOUN T
Cooperative 0 ADJ T
Study 0 NOUN T
Group 0 NOUN T
. 0 PUNCT F

Alpha 0 NOUN T
interferon 0 NOUN F
has 0 PUNCT F
shown 0 VERB F
initial 0 PUNCT F
promise 0 CCONJ F
in 0 ADP F
the 0 DET F
treatment 0 NOUN F
of 0 ADP F
low-grade 0 NOUN F
non-Hodgkin 0 NOUN F
's 0 PUNCT F
lymphoma 0 NOUN F
( 0 PUNCT F
NHL 0 NOUN T
) 0 PUNCT F
, 0 PUNCT F
especially 0 ADV F
with 0 ADP F
the 0 DET F
nodular 0 ADJ F
form 0 NOUN F
of 0 ADP F
the 0 DET F
disease 0 NOUN F
. 0 PUNCT F

The 0 DET T
present 0 ADJ F
study 0 NOUN F
enrolled 0 ADP F
70 0 NUM F
NHL 0 NOUN T
patients 0 NOUN F
who 0 PROPN F
received 0 VERB F
either 0 PUNCT F
chlorambucil 0 NOUN F
( 0 PUNCT F
CB 0 NOUN T
; 0 PUNCT F
10 0 NUM F
mg/day 0 NOUN F
) 0 PUNCT F
or 0 CCONJ F
CB 0 NOUN T
plus 0 CCONJ F
interferon 0 NOUN F
alfa-2b 0 NOUN F
( 0 PUNCT F
5 0 NUM F
million 0 NUM F
units 0 NOUN F
( 0 PUNCT F
MU 0 NOUN T
) 0 PUNCT F
/m2 0 ADV F
subcutaneously 0 ADV F
three 0 NUM F
times 0 NOUN F
a 0 DET F
week 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

Among 0 ADP T
63 0 NUM F
evaluable 0 ADJ F
patients 0 NOUN F
, 0 PUNCT F
similar 0 ADJ F
response 0 NOUN F
rates 0 NOUN F
( 0 PUNCT F
62.1 0 NUM F
% 0 SYM F
and 0 CCONJ F
64.7 0 NUM F
% 0 SYM F
respectively 0 ADV F
) 0 PUNCT F
were 0 VERB F
recorded 0 VERB F
for 0 ADP F
the 0 DET F
treatment 0 NOUN F
arms 0 NOUN F
. 0 PUNCT F

In 0 ADP T
patients 0 NOUN F
receiving 0 VERB F
no 0 DET F
maintenance 0 NOUN F
therapy 0 NOUN F
, 0 PUNCT F
those 0 ADP F
who 0 ADP F
received 0 VERB F
interferon 0 NOUN F
alfa-2b 0 NOUN F
during 0 ADP F
the 0 DET F
induction 0 NOUN F
phase 0 NOUN F
showed 0 VERB F
a 0 DET F
favourable 0 ADJ F
trend 0 NOUN F
in 0 ADP F
terms 0 NOUN F
of 0 ADP F
incidence 0 NOUN F
of 0 ADP F
relapse B-PHYSICAL NOUN F
compared 0 VERB F
to 0 ADP F
those 0 PUNCT F
who 0 ADP F
had 0 PUNCT F
received 0 PUNCT F
chlorambucil 0 NOUN F
alone 0 ADJ F
. 0 PUNCT F

During 0 ADP T
maintenance 0 NOUN F
therapy 0 NOUN F
with 0 ADP F
interferon 0 NOUN F
alfa-2b 0 NOUN F
, 0 PUNCT F
no 0 DET F
significant 0 ADJ F
differences 0 NOUN F
in 0 ADP F
the 0 DET F
occurrence B-PHYSICAL NOUN F
of I-PHYSICAL ADP F
relapse I-PHYSICAL NOUN F
have 0 CCONJ F
yet 0 ADV F
been 0 PUNCT F
seen 0 VERB F
compared 0 VERB F
to 0 ADP F
patients 0 NOUN F
on 0 ADP F
no 0 DET F
maintenance 0 NOUN F
therapy 0 NOUN F
. 0 PUNCT F

A 0 PUNCT T
longer 0 PUNCT F
observation 0 NOUN F
period 0 NOUN F
is 0 VERB F
needed 0 VERB F
to 0 PART F
make 0 NOUN F
a 0 DET F
definitive 0 ADJ F
conclusion 0 NOUN F
about 0 ADP F
the 0 DET F
usefulness 0 NOUN F
of 0 ADP F
interferon 0 NOUN F
maintenance 0 NOUN F
therapy 0 NOUN F
and 0 CCONJ F
to 0 PUNCT F
evaluate 0 NOUN F
further 0 ADP F
the 0 DET F
effects 0 NOUN F
of 0 ADP F
the 0 DET F
combined 0 VERB F
schedule 0 NOUN F
of 0 ADP F
chlorambucil 0 NOUN F
and 0 CCONJ F
interferon 0 NOUN F
induction 0 NOUN F
on 0 ADP F
the 0 DET F
duration 0 NOUN F
of 0 ADP F
remission 0 NOUN F
. 0 PUNCT F

Local 0 ADJ T
injection 0 NOUN F
of 0 ADP F
bupivacaine 0 NOUN F
after 0 ADP F
rubber 0 NOUN F
band 0 NOUN F
ligation 0 NOUN F
of 0 ADP F
hemorrhoids 0 NOUN F
: 0 PUNCT F
prospective 0 ADJ F
, 0 PUNCT F
randomized 0 ADP F
study 0 NOUN F
. 0 PUNCT F

PURPOSE 0 NOUN T
The 0 DET T
aim 0 NOUN F
of 0 ADP F
this 0 DET F
study 0 NOUN F
was 0 VERB F
to 0 PART F
determine 0 VERB F
if 0 PUNCT F
local 0 ADJ F
injection 0 NOUN F
of 0 ADP F
bupivacaine 0 NOUN F
after 0 ADP F
hemorrhoidal 0 ADP F
banding 0 ADP F
causes 0 VERB F
a 0 DET F
decrease 0 NOUN F
in B-PAIN ADP F
pain I-PAIN NOUN F
and I-PAIN CCONJ F
in I-PAIN ADP F
the I-PAIN DET F
incidence 0 NOUN F
of B-PAIN ADP F
associated B-PAIN PUNCT F
symptoms B-PAIN NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
After 0 ADP T
hemorrhoidal 0 ADP F
banding 0 ADP F
, 0 PUNCT F
patients 0 NOUN F
were 0 VERB F
randomly 0 ADV F
assigned 0 VERB F
to 0 PART F
receive 0 NOUN F
a 0 DET F
local 0 ADJ F
injection 0 NOUN F
of 0 ADP F
bupivacaine 0 NOUN F
with 0 ADP F
1:200,000 0 CCONJ F
epinephrine 0 NOUN F
, 0 PUNCT F
an 0 DET F
injection 0 NOUN F
of 0 ADP F
normal 0 ADJ F
saline 0 NOUN F
, 0 PUNCT F
or 0 CCONJ F
no 0 DET F
injection 0 NOUN F
, 0 PUNCT F
just 0 ADP F
superior 0 ADJ F
to 0 ADP F
each 0 DET F
band 0 NOUN F
. 0 PUNCT F

Pain B-PAIN NOUN T
was 0 VERB F
graded 0 VERB F
by 0 ADP F
the 0 DET F
patient 0 NOUN F
and 0 CCONJ F
by 0 ADP F
the 0 DET F
study 0 NOUN F
nurse 0 ADJ F
within 0 ADP F
30 0 NUM F
minutes 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
any 0 DET F
associated B-PHYSICAL PUNCT F
symptoms I-PHYSICAL NOUN F
were 0 VERB F
recorded 0 VERB F
. 0 PUNCT F

At 0 ADP T
intervals 0 NOUN F
6 0 NUM F
, 0 PUNCT F
24 0 NUM F
, 0 PUNCT F
and 0 CCONJ F
48 0 NUM F
hours 0 NOUN F
postbanding 0 PUNCT F
, 0 PUNCT F
the 0 DET F
patient 0 NOUN F
recorded 0 PUNCT F

[ 0 PUNCT F
Rilmenidine 0 PUNCT T
sympatholytic 0 ADJ F
activity 0 NOUN F
preserves 0 PUNCT F
mental B-MENTAL ADJ F
and I-MENTAL CCONJ F
orthostatic I-MENTAL ADJ F
sympathetic I-MENTAL ADJ F
response I-MENTAL NOUN F
and 0 CCONJ F
epinephrine B-PHYSICAL NOUN F
secretion I-PHYSICAL NOUN F
] I-PHYSICAL PUNCT F
. 0 PUNCT F

BACKGROUND 0 NOUN T
Heightened 0 PROPN T
central 0 ADJ F
sympathetic 0 ADJ F
nervous 0 ADJ F
outflow 0 PUNCT F
is 0 PUNCT F
common 0 ADJ F
in 0 ADP F
essential 0 ADJ F
hypertension 0 NOUN F
, 0 PUNCT F
contributing 0 VERB F
to 0 ADV F
hypertension 0 NOUN F
development 0 NOUN F
and 0 CCONJ F
perhaps 0 ADV F
also 0 ADV F
to 0 PUNCT F
complications 0 NOUN F
. 0 PUNCT F

Acute 0 ADJ T
sympathetic 0 ADJ F
nervous 0 ADJ F
activation 0 NOUN F
is 0 VERB F
a 0 DET F
proven 0 VERB F
trigger 0 ADP F
for 0 ADP F
adverse B-ADVERSE-EFFECTS ADJ F
cardiovascular I-ADVERSE-EFFECTS ADJ F
events I-ADVERSE-EFFECTS NOUN F
. 0 PUNCT F

Accordingly 0 ADV T
, 0 PUNCT F
antihypertensive 0 ADJ F
drugs 0 NOUN F
inhibiting 0 ADV F
sympathetic 0 ADJ F
outflow 0 ADP F
represent 0 ADP F
a 0 DET F
theoretically 0 ADV F
attractive 0 ADJ F
therapeutic 0 ADJ F
option 0 NOUN F
. 0 PUNCT F

OBJECTIVES 0 NOUN T
To 0 ADP T
study 0 NOUN F
the 0 DET F
sympatholytic 0 ADJ F
and 0 CCONJ F
blood B-PHYSICAL NOUN F
pressure I-PHYSICAL NOUN F
lowering I-PHYSICAL PUNCT F
activity I-PHYSICAL NOUN F
of 0 ADP F
the 0 DET F
imidazoline 0 ADJ F
binding 0 DET F
agent 0 NOUN F
rilmenidine 0 PUNCT F
at 0 ADP F
rest 0 NOUN F
and 0 CCONJ F
during 0 ADP F
reflex 0 NOUN F
sympathetic 0 ADJ F
activation 0 NOUN F
. 0 PUNCT F

DESIGN 0 NOUN T
AND 0 CCONJ T
METHODS 0 NOUN T
The 0 DET T
HERA 0 NOUN T
study 0 NOUN F
( 0 PUNCT F
Hyperium 0 NOUN T
Effect 0 NOUN T
on 0 ADP F
the 0 DET F
sympathetic 0 ADJ F
Reflex 0 NOUN T
activation 0 NOUN F
and 0 CCONJ F
Adrenaline 0 NOUN T
) 0 PUNCT F
is 0 VERB F
a 0 DET F
randomised 0 VERB F
, 0 PUNCT F
double-blind 0 ADJ F
, 0 PUNCT F
6-week 0 NOUN F
cross-over 0 NOUN F
trial 0 NOUN F
, 0 PUNCT F
with 0 ADP F
a 0 DET F
1-week 0 NOUN F
placebo 0 NOUN F
run-in 0 NOUN F
period 0 NOUN F
, 0 PUNCT F
two 0 NUM F
2-week 0 NOUN F
active 0 ADJ F
treatment 0 NOUN F
intervals 0 NOUN F
( 0 PUNCT F
rilmenidine 0 PUNCT F
1 0 NUM F
mg 0 NOUN F
bid 0 PUNCT F
, 0 PUNCT F
placebo 0 NOUN F
) 0 PUNCT F
and 0 CCONJ F
intervening 0 PUNCT F
one 0 NUM F
week 0 NOUN F
placebo 0 NOUN F
wash-out 0 PUNCT F
. 0 PUNCT F

In 0 ADP T
15 0 NUM F
hypertensive 0 ADJ F
patients 0 NOUN F
, 0 PUNCT F
noradrenaline B-PHYSICAL NOUN F
and I-PHYSICAL CCONJ F
adrenaline I-PHYSICAL PUNCT F
plasma I-PHYSICAL NOUN F
kinetics I-PHYSICAL NOUN F
and I-PHYSICAL CCONJ F
intra-arterial I-PHYSICAL ADJ F
blood I-PHYSICAL NOUN F
pressure I-PHYSICAL NOUN F
measurements I-PHYSICAL NOUN F
were 0 VERB F
performed 0 VERB F
at 0 ADP F
rest 0 NOUN F
, 0 PUNCT F
after 0 ADP F
mental 0 ADJ F
stress 0 NOUN F
( 0 PUNCT F
difficult 0 ADJ F
mental 0 ADJ F
arithmetic 0 ADJ F
) 0 PUNCT F
and 0 CCONJ F
during 0 ADP F
head-up 0 ADJ F
tilting 0 PUNCT F
, 0 PUNCT F
at 0 ADP F
the 0 DET F
end 0 NOUN F
of 0 ADP F
the 0 DET F
2-week 0 NOUN F
dosing 0 PUNCT F
periods 0 NOUN F
. 0 PUNCT F

RESULTS 0 PUNCT T
The 0 DET T
noradrenaline 0 NOUN F
spillover 0 NOUN F
rate 0 NOUN F
, 0 PUNCT F
indicative 0 ADJ F
of 0 ADP F
whole 0 ADJ F
body 0 NOUN F
sympathetic 0 ADJ F
activity 0 NOUN F
, 0 PUNCT F
was 0 VERB F
reduced 0 VERB F
35 0 NUM F
% 0 SYM F
by 0 ADP F
rilmenidine 0 PUNCT F
at 0 ADP F
rest 0 NOUN F
( 0 PUNCT F
p 0 NOUN F
< 0 SYM F
0.01 0 NUM F
) 0 PUNCT F
and 0 CCONJ F
remained 0 VERB F
significantly 0 ADV F
lower 0 PUNCT F
during 0 ADP F
mental 0 ADJ F
stress 0 NOUN F
and 0 CCONJ F
tilting 0 PUNCT F
, 0 PUNCT F
although 0 CCONJ F
the 0 DET F
increases 0 CCONJ F
in 0 ADP F
noradrenaline B-PHYSICAL NOUN F
spillover I-PHYSICAL NOUN F
with 0 ADP F
both 0 PUNCT F
stimuli 0 NOUN F
were 0 VERB F
preserved 0 VERB F
. 0 PUNCT F

The 0 DET T
effects 0 NOUN F
on 0 ADP F
intraarterial B-PHYSICAL ADJ F
blood I-PHYSICAL NOUN F
pressure I-PHYSICAL NOUN F
ran 0 NOUN F
in 0 ADP F
parallel 0 NOUN F
, 0 PUNCT F
a 0 DET F
fall 0 NOUN F
in 0 ADP F
supine 0 NOUN F
resting 0 VERB F
pressure 0 NOUN F
, 0 PUNCT F
but 0 CCONJ F
no 0 DET F
reduction 0 NOUN F
in 0 ADP F
BP B-PHYSICAL NOUN T
rise I-PHYSICAL NOUN F
during 0 ADP F
mental 0 ADJ F
stress 0 NOUN F
and 0 CCONJ F
a 0 DET F
lack 0 NOUN F
of 0 ADP F
fall 0 NOUN F
in 0 ADP F
BP B-PHYSICAL NOUN T
with 0 ADP F
tilting 0 ADP F
. 0 PUNCT F

On 0 ADP T
placebo 0 NOUN F
, 0 PUNCT F
adrenaline B-PHYSICAL PUNCT F
secretion I-PHYSICAL NOUN F
was 0 VERB F
162 0 NUM F
+/- 0 SYM F
27 0 NUM F
ng/min 0 NOUN F
( 0 PUNCT F
mean 0 NOUN F
, 0 PUNCT F
SE 0 NOUN T
) 0 PUNCT F
at 0 ADP F
rest 0 NOUN F
, 0 PUNCT F
increased 0 PUNCT F
by 0 ADP F
77 0 NUM F
+/- 0 SYM F
42 0 NUM F
ng/min 0 PUNCT F
with 0 ADP F
mental 0 ADJ F
stress 0 NOUN F
( 0 PUNCT F
p=0.019 0 NOUN F
) 0 PUNCT F
and 0 CCONJ F
was 0 VERB F
unchanged 0 VERB F
with 0 ADP F
tilting 0 ADP F
. 0 PUNCT F

Rilmenidine 0 ADJ T
left 0 ADJ F
adrenaline B-PHYSICAL ADJ F
secretion I-PHYSICAL NOUN F
untouched 0 VERB F
under 0 ADP F
all 0 DET F
conditions 0 NOUN F
. 0 PUNCT F

CONCLUSIONS 0 NOUN T
This 0 DET T
study 0 NOUN F
confirms 0 NOUN F
a 0 DET F
sympatholytic 0 ADJ F
effect 0 NOUN F
of 0 ADP F
rilmenidine 0 PUNCT F
during 0 ADP F
supine 0 NOUN F
rest 0 NOUN F
but 0 CCONJ F
demonstrates 0 NOUN F
that 0 ADP F
sympathetic B-PHYSICAL ADJ F
responses I-PHYSICAL NOUN F
during 0 ADP F
mental 0 ADJ F
stress 0 NOUN F
and 0 CCONJ F
tilting 0 PUNCT F
are 0 VERB F
preserved 0 ADP F
, 0 PUNCT F
the 0 DET F
latter 0 ADJ F
underlying 0 SYM F
a 0 DET F
perhaps 0 PUNCT F
surprising 0 VERB F
absence 0 NOUN F
of 0 ADP F
postural 0 ADJ F
hypotension 0 NOUN F
on 0 ADP F
the 0 DET F
drug 0 NOUN F
. 0 PUNCT F

The 0 DET T
absence 0 NOUN F
of 0 ADP F
suppression 0 NOUN F
of 0 ADP F
reflexive 0 ADJ F
sympathetic 0 ADJ F
responses 0 NOUN F
contrasts 0 PUNCT F
with 0 ADP F
the 0 DET F
effects 0 NOUN F
of 0 ADP F
rilmenidine 0 PUNCT F
in 0 ADP F
experimental 0 ADJ F
animals 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
emphasises 0 PUNCT F
the 0 DET F
previously 0 ADV F
demonstrated 0 PUNCT F
unique 0 ADJ F
importance 0 NOUN F
in 0 ADP F
humans 0 NOUN F
of 0 ADP F
suprabulbar 0 ADJ F
noradrenergic 0 ADJ F
neuronal 0 ADJ F
projections 0 NOUN F
from 0 ADP F
the 0 DET F
brainstem 0 NOUN F
, 0 PUNCT F
which 0 ADP F
are 0 VERB F
inhibited 0 VERB F
by 0 ADP F
imidazoline 0 ADJ F
binding 0 VERB F
agents 0 NOUN F
, 0 PUNCT F
in 0 ADP F
regulating 0 VERB F
tonic B-PHYSICAL ADJ F
sympathetic I-PHYSICAL ADJ F
activity I-PHYSICAL NOUN F
in 0 ADP F
essential 0 ADJ F
hypertension 0 NOUN F
. 0 PUNCT F

Sympathetic 0 ADJ T
nervous 0 ADJ F
inhibition 0 NOUN F
with 0 ADP F
rilmenidine 0 PUNCT F
contrasted 0 PROPN F
with 0 ADP F
an 0 DET F
absence 0 NOUN F
of 0 ADP F
suppression 0 NOUN F
of 0 ADP F
the 0 DET F
secretion 0 NOUN F
of 0 ADP F
adrenaline 0 ADJ F
affirming 0 PUNCT F
that 0 PUNCT F
here 0 ADV F
, 0 PUNCT F
as 0 VERB F
elsewhere 0 VERB F
, 0 PUNCT F
sympathetic B-MENTAL ADJ F
nervous I-MENTAL ADJ F
and 0 CCONJ F
adrenal B-PHYSICAL ADJ F
medullary I-PHYSICAL ADJ F
function I-PHYSICAL NOUN F
can 0 VERB F
be 0 VERB F
disconnected 0 VERB F
. 0 PUNCT F

A 0 DET T
randomized 0 VERB F
effectiveness 0 NOUN F
trial 0 NOUN F
of 0 ADP F
collaborative 0 ADJ F
care 0 NOUN F
for 0 ADP F
patients 0 NOUN F
with 0 ADP F
panic 0 ADJ F
disorder 0 NOUN F
in 0 ADP F
primary 0 ADJ F
care 0 NOUN F
. 0 PUNCT F

BACKGROUND 0 NOUN T
Effectiveness 0 NOUN T
studies 0 NOUN F
have 0 PUNCT F
tested 0 VERB F
interventions 0 NOUN F
to 0 PROPN F
improve 0 ADP F
quality B-OTHER NOUN F
of I-OTHER ADP F
care I-OTHER NOUN F
for 0 ADP F
depression 0 NOUN F
in 0 ADP F
primary 0 ADJ F
care 0 NOUN F
, 0 PUNCT F
but 0 CCONJ F
none 0 NUM F
, 0 PUNCT F
to 0 ADP F
our 0 PUNCT F
knowledge 0 NOUN F
, 0 PUNCT F
have 0 ADP F
been 0 PUNCT F
completed 0 VERB F
for 0 ADP F
panic 0 ADJ F
disorder 0 NOUN F
( 0 PUNCT F
PD 0 NOUN T
) 0 PUNCT F
in 0 ADP F
this 0 PUNCT F
setting 0 VERB F
. 0 PUNCT F

This 0 DET T
study 0 NOUN F
sought 0 ADP F
to 0 ADJ F
test 0 NOUN F
the 0 DET F
clinical B-OTHER ADJ F
effectiveness I-OTHER NOUN F
of 0 ADP F
PD 0 NOUN T
pharmacotherapy 0 NOUN F
embedded 0 ADP F
in 0 ADP F
a 0 DET F
disease 0 NOUN F
management 0 NOUN F
framework 0 NOUN F
of 0 ADP F
collaborative 0 ADJ F
care 0 NOUN F
( 0 PUNCT F
CC 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

METHODS 0 NOUN T
One 0 NUM T
hundred 0 NUM F
fifteen 0 ADP F
patients 0 NOUN F
with 0 ADP F
PD 0 NOUN T
from 0 ADP F
3 0 NUM F
primary 0 ADJ F
care 0 NOUN F
clinics 0 ADV F
were 0 VERB F
randomized 0 VERB F
to 0 ADP F
CC 0 NOUN T
or 0 CCONJ F
usual 0 ADJ F
care 0 NOUN F
( 0 PUNCT F
UC 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

Patients 0 NOUN T
in 0 ADP F
CC 0 NOUN T
( 0 PUNCT F
n 0 NOUN F
= 0 SYM F
57 0 NUM F
) 0 PUNCT F
received 0 VERB F
educational 0 ADJ F
videotapes 0 NOUN F
and 0 CCONJ F
pamphlets 0 ADJ F
; 0 PUNCT F
pharmacotherapy 0 NOUN F
with 0 ADP F
the 0 DET F
selective 0 ADJ F
serotonin 0 NOUN F
reuptake 0 NOUN F
inhibitor 0 NOUN F
paroxetine 0 NOUN F
; 0 PUNCT F
2 0 NUM F
psychiatrist 0 NOUN F
visits 0 NOUN F
and 0 CCONJ F
2 0 NUM F
telephone 0 NOUN F
calls 0 ADP F
in 0 ADP F
the 0 DET F
first 0 ADJ F
8 0 NUM F
weeks 0 NOUN F
; 0 PUNCT F
and 0 CCONJ F
up 0 PUNCT F
to 0 ADP F
5 0 NUM F
telephone 0 NOUN F
calls 0 NOUN F
between 0 ADP F
3 0 NUM F
and 0 CCONJ F
12 0 NUM F
months 0 NOUN F
' 0 PUNCT F
follow-up 0 NOUN F
. 0 PUNCT F

Usual 0 ADJ T
care 0 NOUN F
patients 0 NOUN F
( 0 PUNCT F
n 0 NOUN F
= 0 SYM F
58 0 NUM F
) 0 PUNCT F
were 0 VERB F
treated 0 VERB F
by 0 ADP F
their 0 PUNCT F
primary 0 ADJ F
care 0 NOUN F
physician 0 NOUN F
. 0 PUNCT F

Telephone 0 NOUN T
assessments 0 NOUN F
of 0 ADP F
panic B-MENTAL ADJ F
, 0 PUNCT F
anxiety B-MENTAL NOUN F
sensitivity I-MENTAL NOUN F
, 0 PUNCT F
depression B-MENTAL NOUN F
, 0 PUNCT F
and 0 CCONJ F
disability B-MENTAL NOUN F
variables I-MENTAL NOUN F
were 0 VERB F
performed 0 VERB F
at 0 ADP F
3 0 NUM F
, 0 PUNCT F
6 0 NUM F
, 0 PUNCT F
9 0 NUM F
, 0 PUNCT F
and 0 CCONJ F
12 0 NUM F
months 0 NOUN F
' 0 PUNCT F
follow-up 0 NOUN F
. 0 PUNCT F

Adequacy B-OTHER NOUN T
of I-OTHER ADP F
pharmacotherapy I-OTHER NOUN F
was 0 VERB F
assessed 0 VERB F
with 0 ADP F
an 0 DET F
algorithm 0 NOUN F
based 0 VERB F
on 0 ADP F
a 0 DET F
review 0 NOUN F
of 0 ADP F
efficacy 0 NOUN F
studies 0 NOUN F
. 0 PUNCT F

RESULTS 0 DET T
Patients 0 NOUN T
in 0 ADP F
CC 0 NOUN T
were 0 VERB F
more 0 ADV F
likely 0 ADJ F
to 0 PART F
receive 0 NOUN F
adequate B-OTHER ADJ F
( 0 PUNCT F
type 0 NOUN F
, 0 PUNCT F

Safety 0 NOUN T
of 0 ADP F
injectable 0 ADJ F
opioid 0 NOUN F
maintenance 0 NOUN F
treatment 0 NOUN F
for 0 ADP F
heroin 0 ADJ F
dependence 0 NOUN F
. 0 PUNCT F

BACKGROUND 0 NOUN T
There 0 PUNCT T
is 0 VERB F
a 0 DET F
growing 0 VERB F
debate 0 NOUN F
about 0 ADP F
injectable 0 ADJ F
opioid 0 NOUN F
treatment 0 NOUN F
programs 0 NOUN F
in 0 ADP F
many 0 DET F
Western 0 NOUN T
countries 0 NOUN F
. 0 PUNCT F

This 0 DET T
is 0 VERB F
the 0 DET F
first 0 ADJ F
placebo-controlled 0 VERB F
study 0 NOUN F
of 0 ADP F
the 0 DET F
safety 0 NOUN F
of 0 ADP F
injectable 0 ADJ F
opioids 0 NOUN F
in 0 ADP F
a 0 DET F
controlled 0 VERB F
treatment 0 NOUN F
setting 0 VERB F
. 0 PUNCT F

METHODS 0 NOUN T
Twenty-five 0 PUNCT T
opioid-dependent 0 ADJ F
patients 0 NOUN F
on 0 ADP F
intravenous 0 ADJ F
( 0 PUNCT F
IV 0 NUM T
) 0 PUNCT F
heroin 0 ADJ F
or 0 CCONJ F
IV 0 NUM T
methadone 0 NOUN F
maintenance 0 NOUN F
treatment 0 NOUN F
were 0 VERB F
randomly 0 ADV F
assigned 0 VERB F
to 0 ADP F
either 0 CCONJ F
their 0 ADP F
individual 0 ADJ F
prescribed 0 PUNCT F
IV 0 NUM T
maintenance 0 NOUN F
dose 0 NOUN F
or 0 CCONJ F
placebo 0 NOUN F
. 0 PUNCT F

Acute B-OTHER ADJ T
drug I-OTHER NOUN F
effects I-OTHER NOUN F
were 0 VERB F
recorded 0 VERB F
, 0 PUNCT F
focusing 0 VERB F
on 0 ADP F
electrocardiography B-OTHER NOUN F
, 0 PUNCT F
respiratory B-PHYSICAL ADJ F
movements I-PHYSICAL NOUN F
, 0 PUNCT F
arterial B-PHYSICAL ADJ F
blood I-PHYSICAL NOUN F
oxygen I-PHYSICAL NOUN F
saturation I-PHYSICAL NOUN F
, 0 PUNCT F
and 0 CCONJ F
electroencephalography B-PHYSICAL NOUN F
( I-PHYSICAL PUNCT F
EEG I-PHYSICAL NOUN T
) I-PHYSICAL PUNCT F
. 0 PUNCT F

RESULTS 0 NOUN T
After 0 ADP T
heroin 0 ADJ F
injection 0 NOUN F
, 0 PUNCT F
marked 0 VERB F
respiratory B-PHYSICAL ADJ F
depression I-PHYSICAL NOUN F
progressing 0 CCONJ F
to 0 ADP F
a 0 DET F
Cheyne-Stokes B-PHYSICAL PUNCT T
pattern I-PHYSICAL NOUN F
occurred 0 VERB F
. 0 PUNCT F

Peripheral B-PHYSICAL ADJ T
arterial I-PHYSICAL ADJ F
blood I-PHYSICAL NOUN F
oxygenation I-PHYSICAL NOUN F
decreased 0 VERB F
to 0 ADP F
78.9 0 NUM F
+/- 0 SYM F
8.7 0 NUM F
% 0 SYM F
( 0 PUNCT F
mean 0 NOUN F
+/- 0 SYM F
SD 0 NOUN T
) 0 PUNCT F
ranging 0 CCONJ F
from 0 ADP F
52 0 NUM F
% 0 SYM F
-90 0 NUM F
% 0 SYM F
. 0 PUNCT F

During 0 ADP T
hypoxia B-PHYSICAL NOUN F
, 0 PUNCT F
7 0 NUM F
of 0 ADP F
the 0 DET F
16 0 ADJ F
subjects 0 NOUN F
experienced 0 PUNCT F
intermittent 0 ADJ F
and 0 CCONJ F
somewhat 0 ADV F
severe 0 ADJ F
bradycardia B-PHYSICAL NUM F
. 0 PUNCT F

Five 0 NUM T
subjects 0 NOUN F
exhibited 0 ADP F
paroxysmal B-PHYSICAL ADJ F
EEG I-PHYSICAL NOUN T
patterns I-PHYSICAL NOUN F
. 0 PUNCT F

After 0 ADP T
methadone 0 NOUN F
injection 0 NOUN F
, 0 PUNCT F
respiratory B-PHYSICAL ADJ F
depression I-PHYSICAL NOUN F
was 0 VERB F
less 0 ADV F
pronounced 0 ADP F
than 0 PUNCT F
after 0 PUNCT F
heroin 0 NOUN F
injection 0 NOUN F
. 0 PUNCT F

No 0 DET T
relevant 0 ADJ F
bradycardia B-PHYSICAL NOUN F
was 0 VERB F
noted 0 VERB F
. 0 PUNCT F

CONCLUSIONS 0 NOUN T
Opioid 0 NOUN T
doses 0 NOUN F
commonly 0 ADV F
prescribed 0 VERB F
in 0 ADP F
IV 0 NUM T
opioid 0 NOUN F
treatment 0 NOUN F
induce 0 VERB F
marked 0 VERB F
respiratory B-PHYSICAL ADJ F
and I-PHYSICAL CCONJ F
circulatory I-PHYSICAL ADJ F
depression I-PHYSICAL NOUN F
, 0 PUNCT F
as 0 PUNCT F
well 0 PUNCT F
as 0 CCONJ F
occasionally 0 VERB F
irregular B-PHYSICAL ADJ F
paroxysmal I-PHYSICAL ADJ F
EEG I-PHYSICAL NOUN T
activity I-PHYSICAL NOUN F
. 0 PUNCT F

Further 0 ADJ T
studies 0 NOUN F
are 0 ADV F
needed 0 VERB F
to 0 PART F
optimize 0 NOUN F
the 0 DET F
clinical 0 ADJ F
practice 0 NOUN F
of 0 ADP F
IV 0 NUM T
opioid 0 NOUN F
treatment 0 NOUN F
to 0 PART F
prevent 0 ADJ F
serious 0 ADJ F
complications 0 NOUN F
. 0 PUNCT F

Moreover 0 ADV T
, 0 PUNCT F
the 0 DET F
extent 0 NOUN F
of 0 ADP F
the 0 PUNCT F
observed 0 VERB F
effects 0 NOUN F
raises 0 PUNCT F
questions 0 NOUN F
about 0 ADP F
the 0 DET F
appropriateness 0 NOUN F
of 0 ADP F
IV 0 NUM T
opioid 0 NOUN F
treatment 0 NOUN F
in 0 ADP F
the 0 DET F
present 0 ADJ F
form 0 NOUN F
. 0 PUNCT F

Phosphate 0 NOUN T
binder 0 ADJ F
impact 0 NOUN F
on 0 ADP F
bone B-PHYSICAL NOUN F
remodeling I-PHYSICAL VERB F
and 0 CCONJ F
coronary B-PHYSICAL ADJ F
calcification I-PHYSICAL NOUN F
-- 0 PUNCT F
results 0 ADJ F
from 0 ADP F
the 0 DET F
BRiC 0 NOUN T
study 0 NOUN F
. 0 PUNCT F

BACKGROUND 0 NOUN T
AND 0 CCONJ T
AIMS 0 NOUN T
Calcium-containing 0 PROPN T
phosphate 0 NOUN F
binders 0 NOUN F
have 0 ADP F
been 0 PUNCT F
shown 0 VERB F
to 0 PART F
increase 0 NOUN F
the 0 DET F
progression 0 NOUN F
of 0 ADP F
vascular B-PHYSICAL ADJ F
calcification I-PHYSICAL NOUN F
in 0 ADP F
hemodialysis 0 NOUN F
patients 0 NOUN F
. 0 PUNCT F

This 0 DET T
is 0 VERB F
a 0 DET F
prospective 0 ADJ F
study 0 NOUN F
that 0 PUNCT F
compares 0 ADP F
the 0 DET F
effects 0 NOUN F
of 0 ADP F
calcium 0 NOUN F
acetate 0 NOUN F
and 0 CCONJ F
sevelamer 0 NOUN F
on 0 ADP F
coronary B-PHYSICAL ADJ F
calcification I-PHYSICAL NOUN F
( 0 PUNCT F
CAC 0 NOUN T
) 0 PUNCT F
and 0 CCONJ F
bone B-PHYSICAL NOUN F
histology I-PHYSICAL NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
101 0 NUM F
hemodialysis 0 NOUN F
patients 0 NOUN F
were 0 VERB F
randomized 0 VERB F
for 0 ADP F
each 0 DET F
phosphate 0 NOUN F
binder 0 ADJ F
and 0 CCONJ F
submitted 0 VERB F
to 0 PUNCT F
multislice 0 PUNCT F
coronary 0 ADJ F
tomographies 0 NOUN F
and 0 CCONJ F
bone 0 NOUN F
biopsies 0 NOUN F
at 0 ADP F
entry 0 NOUN F
and 0 CCONJ F
12 0 NUM F
months 0 NOUN F
. 0 PUNCT F

RESULTS 0 PUNCT T
The 0 DET T
71 0 NUM F
patients 0 NOUN F
who 0 ADP F
concluded 0 VERB F
the 0 DET F
study 0 NOUN F
had 0 PUNCT F
similar 0 ADJ F
baseline 0 NOUN F
characteristics 0 NOUN F
. 0 PUNCT F

On 0 ADP T
follow-up 0 NOUN F
, 0 PUNCT F
the 0 DET F
sevelamer 0 NOUN F
group 0 NOUN F
had 0 PUNCT F
higher 0 CCONJ F
levels 0 NOUN F
of 0 ADP F
intact B-PHYSICAL ADJ F
parathyroid I-PHYSICAL NOUN F
hormone I-PHYSICAL NOUN F
( 0 PUNCT F
498 0 NUM F
+/- 0 SYM F
352 0 NUM F
vs. 0 CCONJ F
326 0 ADP F
+/- 0 SYM F
236 0 NUM F
pg/ml 0 NOUN F
, 0 PUNCT F
p 0 NOUN F
= 0 SYM F
0.017 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
bone B-PHYSICAL NOUN F
alkaline I-PHYSICAL ADJ F
phosphatase I-PHYSICAL NOUN F
( 0 PUNCT F
38 0 NUM F
+/- 0 SYM F
24 0 NUM F
vs. 0 CCONJ F
28 0 NUM F
+/- 0 SYM F
15 0 NUM F
U/l 0 NOUN T
, 0 PUNCT F
p 0 NOUN F
= 0 SYM F
0.03 0 NUM F
) 0 PUNCT F
and 0 CCONJ F
deoxypyridinoline B-PHYSICAL NOUN F
( 0 PUNCT F
135 0 NUM F
+/- 0 SYM F
107 0 NUM F
vs. 0 CCONJ F
89 0 NUM F
+/- 0 SYM F
71 0 NUM F
nmol/l 0 NOUN F
, 0 PUNCT F
p 0 NOUN F
= 0 SYM F
0.03 0 NUM F
) 0 PUNCT F
and 0 CCONJ F
lower B-PHYSICAL PUNCT F
LDL I-PHYSICAL NOUN T
cholesterol I-PHYSICAL NOUN F
( 0 PUNCT F
74 0 NUM F
+/- 0 SYM F
21 0 NUM F
vs. 0 CCONJ F
91 0 NUM F
+/- 0 SYM F
28 0 NUM F
mg/dl 0 NOUN F
, 0 PUNCT F
p 0 NOUN F
= 0 SYM F
0.015 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Phosphorus B-PHYSICAL NOUN T
( 0 PUNCT F
5.8 0 NUM F
+/- 0 SYM F
1.0 0 NUM F
vs. 0 CCONJ F
6 0 NUM F
+/- 0 SYM F
1.0 0 NUM F
mg/dl 0 NOUN F
, 0 PUNCT F
p 0 NOUN F
= 0 SYM F
0.47 0 NUM F
) 0 PUNCT F
and 0 CCONJ F
calcium B-PHYSICAL NOUN F
( 0 PUNCT F
1.27 0 NUM F
+/- 0 SYM F
0.07 0 NUM F
vs. 0 CCONJ F
1.23 0 NUM F
+/- 0 SYM F
0.08 0 NUM F
mmol/l 0 NOUN F
, 0 PUNCT F
p 0 NOUN F
= 0 SYM F
0.68 0 NUM F
) 0 PUNCT F
levels 0 NOUN F
did 0 ADP F
not 0 ADV F
differ 0 VERB F
between 0 ADP F
groups 0 NOUN F
. 0 PUNCT F

CAC B-PHYSICAL NOUN T
progression I-PHYSICAL NOUN F
( 0 PUNCT F
35 0 NUM F
vs. 0 CCONJ F
24 0 NUM F
% 0 SYM F
, 0 PUNCT F
p 0 NOUN F
= 0 SYM F
0.94 0 NUM F
) 0 PUNCT F
and 0 CCONJ F
bone B-PHYSICAL NOUN F
histological I-PHYSICAL ADJ F
diagnosis I-PHYSICAL NOUN F
at 0 ADP F
baseline 0 NOUN F
and 0 CCONJ F
12 0 NUM F
months 0 NOUN F
were 0 VERB F
similar 0 ADJ F
in 0 ADP F
both 0 CCONJ F
groups 0 NOUN F
. 0 PUNCT F

Patients 0 NOUN T
of 0 ADP F
the 0 DET F
sevelamer 0 NOUN F
group 0 NOUN F
with 0 ADP F
a 0 DET F
high 0 ADJ F
turnover 0 NOUN F
at 0 ADP F
baseline 0 NOUN F
had 0 PUNCT F
an 0 DET F
increase 0 NOUN F
in 0 ADP F
bone B-PHYSICAL NOUN F
resorption I-PHYSICAL NOUN F
( 0 PUNCT F
eroded 0 PUNCT F
surface 0 NOUN F
, 0 PUNCT F
ES/BS 0 CCONJ T
= 0 ADP F
9.0 0 NUM F
+/- 0 SYM F
5.9 0 NUM F
vs. 0 CCONJ F
13.1 0 NUM F
+/- 0 SYM F
9.5 0 NUM F
% 0 SYM F
, 0 PUNCT F
p 0 NOUN F
= 0 SYM F
0.05 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
whereas 0 ADP F
patients 0 NOUN F
of 0 ADP F
both 0 CCONJ F
groups 0 NOUN F
with 0 ADP F
low 0 ADJ F
turnover 0 NOUN F
at 0 ADP F
baseline 0 NOUN F
had 0 PUNCT F
an 0 DET F
improvement 0 NOUN F
in 0 ADP F
bone B-PHYSICAL NOUN F
formation I-PHYSICAL NOUN F
rate I-PHYSICAL NOUN F
( 0 PUNCT F
BFR/BS 0 NOUN T
= 0 SYM F
0.015 0 NUM F
+/- 0 SYM F
0.016 0 NUM F
vs. 0 CCONJ F
0.062 0 NUM F
+/- 0 SYM F
0.078 0 NUM F
, 0 PUNCT F
p 0 NOUN F
= 0 SYM F
0.003 0 NUM F
for 0 ADP F
calcium 0 NOUN F
and 0 CCONJ F
0.017 0 NUM F
+/- 0 SYM F
0.016 0 NUM F
vs. 0 CCONJ F
0.071 0 ADP F
+/- 0 SYM F
0.084 0 NUM F
microm 0 NOUN F
( 0 PUNCT F
3 0 NUM F
) 0 PUNCT F
/microm 0 PUNCT F
( 0 PUNCT F
2 0 NUM F
) 0 PUNCT F
/day 0 NOUN F
, 0 PUNCT F
p 0 NOUN F
= 0 SYM F
0.010 0 NUM F
for 0 ADP F
sevelamer 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

CONCLUSIONS 0 NOUN T
There 0 PUNCT T
was 0 VERB F
no 0 DET F
difference 0 NOUN F
in 0 ADP F
CAC B-PHYSICAL NOUN T
progression I-PHYSICAL NOUN F
or 0 CCONJ F
changes 0 NOUN F
in 0 ADP F
bone B-PHYSICAL NOUN F
remodeling I-PHYSICAL VERB F
between 0 ADP F
the 0 DET F
calcium 0 NOUN F
and 0 CCONJ F
the 0 DET F
sevelamer 0 NOUN F
groups 0 NOUN F
. 0 PUNCT F

An 0 DET T
analysis 0 NOUN F
of 0 ADP F
the 0 DET F
radiation 0 NOUN F
related 0 VERB F
morbidity B-MENTAL NOUN F
observed 0 VERB F
in 0 ADP F
a 0 DET F
randomized 0 VERB F
trial 0 NOUN F
of 0 ADP F
neutron 0 NOUN F
therapy 0 NOUN F
for 0 ADP F
bladder 0 NOUN F
cancer 0 NOUN F
. 0 PUNCT F

This 0 DET T
report 0 NOUN F
is 0 VERB F
an 0 DET F
analysis 0 NOUN F
of 0 ADP F
the 0 DET F
morbidity B-PHYSICAL NOUN F
in 0 ADP F
the 0 DET F
bladder 0 NOUN F
and 0 CCONJ F
bowel 0 NOUN F
observed 0 VERB F
in 0 ADP F
a 0 DET F
randomized 0 VERB F
trial 0 NOUN F
of 0 ADP F
d 0 NOUN F
( 0 PUNCT F
15 0 NUM F
) 0 PUNCT F
+Be 0 ADP F
neutrons 0 NOUN F
versus 0 CCONJ F
megavoltage 0 NOUN F
photons 0 NOUN F
in 0 ADP F
the 0 DET F
treatment 0 NOUN F
of 0 ADP F
bladder 0 NOUN F
cancer 0 NOUN F
. 0 PUNCT F

Acute B-PHYSICAL ADJ T
reactions I-PHYSICAL NOUN F
in 0 ADP F
the 0 DET F
bladder 0 NOUN F
and 0 CCONJ F
bowel 0 NOUN F
were 0 VERB F
significantly 0 ADV F
worse 0 ADJ F
after 0 ADP F
photon 0 PUNCT F
therapy 0 NOUN F
. 0 PUNCT F

Of 0 ADP T
the 0 DET F
patients 0 NOUN F
treated 0 VERB F
with 0 ADP F
photons 0 NOUN F
45.7 0 NUM F
% 0 SYM F
had 0 PUNCT F
severe 0 ADJ F
reactions B-PHYSICAL NOUN F
in I-PHYSICAL ADP F
the I-PHYSICAL DET F
bladder I-PHYSICAL NOUN F
compared 0 VERB F
with 0 ADP F
10.6 0 NUM F
% 0 SYM F
after 0 ADP F
neutron 0 NOUN F
therapy 0 NOUN F
( 0 PUNCT F
p 0 NOUN F
less 0 ADV F
than 0 PUNCT F
0.001 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Severe B-PHYSICAL ADJ T
acute I-PHYSICAL ADJ F
bowel I-PHYSICAL NOUN F
reactions I-PHYSICAL NOUN F
were 0 VERB F
observed 0 VERB F
in 0 ADP F
8.5 0 NUM F
% 0 DET F
of 0 ADP F
the 0 DET F
patients 0 NOUN F
after 0 ADP F
photon 0 PUNCT F
therapy 0 NOUN F
compared 0 VERB F
with 0 ADP F
3.8 0 NUM F
% 0 SYM F
after 0 ADP F
neutron 0 NOUN F
therapy 0 NOUN F
( 0 PUNCT F
p 0 NOUN F
less 0 ADV F
than 0 PUNCT F
0.05 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Late B-PHYSICAL ADJ T
reactions I-PHYSICAL NOUN F
were 0 VERB F
significantly 0 ADV F
worse 0 ADJ F
after 0 ADP F
neutrons 0 NOUN F
. 0 PUNCT F

Severe B-PHYSICAL ADJ T
late I-PHYSICAL ADJ F
reactions I-PHYSICAL NOUN F
in I-PHYSICAL ADP F
the I-PHYSICAL DET F
bladder I-PHYSICAL NOUN F
were 0 VERB F
seen 0 VERB F
in 0 ADP F
58.5 0 NUM F
% 0 SYM F
of 0 ADP F
patients 0 NOUN F
after 0 ADP F
neutron 0 NOUN F
therapy 0 NOUN F
and 0 CCONJ F
in 0 ADP F
40.5 0 NUM F
% 0 SYM F
after 0 ADP F
photon 0 CCONJ F
therapy 0 NOUN F
( 0 PUNCT F
p 0 NOUN F
less 0 ADV F
than 0 PUNCT F
0.05 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

In 0 ADP T
the 0 DET F
bowel 0 NOUN F
they 0 PUNCT F
were 0 VERB F
observed 0 VERB F
in 0 ADP F
53.3 0 NUM F
% 0 SYM F
of 0 ADP F
patients 0 NOUN F
after 0 ADP F
neutron 0 NOUN F
therapy 0 NOUN F
compared 0 VERB F
with 0 ADP F
8 0 NUM F
% 0 SYM F
after 0 ADP F
photon 0 CCONJ F
therapy 0 NOUN F
( 0 PUNCT F
p 0 NOUN F
less 0 ADV F
than 0 PUNCT F
0.0001 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
disparity 0 NOUN F
in 0 ADP F
the B-MENTAL DET F
degree I-MENTAL NOUN F
of I-MENTAL ADP F
early I-MENTAL PUNCT F
and I-MENTAL CCONJ F
late I-MENTAL ADJ F
complications I-MENTAL NOUN F
makes 0 NOUN F
assessment 0 NOUN F
of 0 ADP F
RBE B-MORTALITY NOUN T
values I-MORTALITY NOUN F
difficult 0 ADJ F
. 0 PUNCT F

It 0 PRON T
is 0 VERB F
estimated 0 VERB F
that 0 ADP F
for 0 ADP F
bladder B-PHYSICAL NOUN F
morbidity I-PHYSICAL NOUN F
the 0 DET F
RBE B-PHYSICAL NOUN T
value I-PHYSICAL NOUN F
, 0 PUNCT F
for 0 ADP F
photon 0 PUNCT F
dose 0 NOUN F
fractions 0 NOUN F
of 0 ADP F
2.75 0 NUM F
Gy 0 NOUN T
, 0 PUNCT F
is 0 VERB F
less 0 ADV F
than 0 ADP F
3.3 0 NUM F
for 0 ADP F
early 0 ADJ F
reactions 0 NOUN F
and 0 CCONJ F
equal 0 ADJ F
to 0 ADP F
3.4 0 NUM F
for 0 ADP F
late 0 ADJ F
effects 0 NOUN F
. 0 PUNCT F

The 0 DET T
respective 0 ADJ F
RBE B-PHYSICAL NOUN T
values I-PHYSICAL NOUN F
for 0 ADP F
early 0 PUNCT F
and 0 CCONJ F
late 0 ADJ F
effects 0 NOUN F
in 0 ADP F
the 0 DET F
bowel 0 NOUN F
are 0 VERB F
less 0 ADV F
than 0 PUNCT F
3.4 0 NUM F
and 0 CCONJ F
3.8 0 NUM F
. 0 PUNCT F

The 0 DET T
response 0 NOUN F
of 0 ADP F
neuropathic B-PAIN ADJ F
pain I-PAIN NOUN F
and 0 CCONJ F
pain B-PAIN NOUN F
in 0 ADP F
complex B-PAIN PUNCT F
regional I-PAIN ADJ F
pain B-PAIN NOUN F
syndrome I-PAIN NOUN F
I 0 NUM T
to 0 ADP F
carbamazepine 0 NOUN F
and 0 CCONJ F
sustained-release 0 NOUN F
morphine 0 NOUN F
in 0 ADP F
patients 0 NOUN F
pretreated 0 VERB F
with 0 ADP F
spinal 0 ADJ F
cord 0 NOUN F
stimulation 0 NOUN F
: 0 PUNCT F
a 0 DET F
double-blinded 0 ADV F
randomized 0 DET F
study 0 NOUN F
. 0 PUNCT F

Forty-three 0 ADP T
patients 0 NOUN F
with 0 ADP F
peripheral 0 ADJ F
neuropathic 0 ADJ F
pain 0 NOUN F
, 0 PUNCT F
exclusively 0 ADV F
pain 0 NOUN F
reduced 0 VERB F
by 0 ADP F
spinal 0 ADJ F
cord 0 NOUN F
stimulation 0 NOUN F
( 0 PUNCT F
SCS 0 NOUN T
) 0 PUNCT F
, 0 PUNCT F
were 0 VERB F
switched 0 VERB F
into 0 ADP F
a 0 DET F
painful 0 ADJ F
state 0 NOUN F
after 0 ADP F
SCS 0 NOUN T
inactivation 0 NOUN F
. 0 PUNCT F

This 0 DET T
mode 0 NOUN F
was 0 VERB F
used 0 VERB F
to 0 PART F
assess 0 NOUN F
the 0 DET F
pain-relieving 0 VERB F
effect 0 NOUN F
of 0 ADP F
carbamazepine 0 NOUN F
( 0 PUNCT F
CMZ 0 NOUN T
) 0 PUNCT F
and 0 CCONJ F
opioids 0 NOUN F
in 0 ADP F
a 0 DET F
double-blinded 0 ADV F
, 0 PUNCT F
placebo-controlled 0 VERB F
trial 0 NOUN F
. 0 PUNCT F

In 0 ADP T
Phase 0 NOUN T
1 0 NUM F
, 0 PUNCT F
the 0 DET F
patients 0 NOUN F
were 0 VERB F
randomly 0 ADV F
allocated 0 VERB F
to 0 PART F
receive 0 NOUN F
either 0 PUNCT F
CMZ 0 NOUN T
( 0 PUNCT F
600 0 ADP F
mg/d 0 NOUN F
) 0 PUNCT F
or 0 CCONJ F
placebo 0 NOUN F
during 0 ADP F
an 0 DET F
SCS-free 0 ADJ T
period 0 NOUN F
of 0 ADP F
8 0 NUM F
days 0 NOUN F
. 0 PUNCT F

In 0 ADP T
Phase 0 NOUN T
2 0 NUM F
, 0 PUNCT F
after 0 ADP F
a 0 DET F
CMZ 0 NOUN T
elimination 0 NOUN F
interval 0 NOUN F
of 0 ADP F
7 0 NUM F
days 0 NOUN F
, 0 PUNCT F
38 0 NUM F
patients 0 NOUN F
received 0 VERB F
either 0 CCONJ F
sustained-release 0 NOUN F
morphine 0 NOUN F
( 0 PUNCT F
90 0 NUM F
mg/d 0 NOUN F
) 0 PUNCT F
or 0 CCONJ F
placebo 0 NOUN F
for 0 ADP F
8 0 NUM F
days 0 NOUN F
. 0 PUNCT F

In 0 ADP T
cases 0 NOUN F
of 0 ADP F
intolerable B-PAIN ADJ F
pain I-PAIN NOUN F
, 0 PUNCT F
the 0 DET F
patients 0 NOUN F
were 0 VERB F
authorized 0 VERB F
to 0 PUNCT F
reactivate 0 ADV F
their 0 NOUN F
SCS 0 NOUN T
. 0 PUNCT F

The 0 DET T
pain B-PAIN NOUN F
intensity I-PAIN NOUN F
was 0 VERB F
rated 0 VERB F
on 0 ADP F
a 0 DET F
numeric B-OTHER ADJ F
analog I-OTHER NOUN F
scale I-OTHER NOUN F
. 0 PUNCT F

In 0 ADP T
38 0 NUM F
patients 0 NOUN F
who 0 ADP F
completed 0 PUNCT F
Phase 0 NOUN T
1 0 NUM F
, 0 PUNCT F
significant 0 ADJ F
delay B-PAIN NOUN F
in I-PAIN ADP F
pain I-PAIN NOUN F
increase 0 NOUN F
was 0 VERB F
observed 0 VERB F
in 0 ADP F
the 0 DET F
CMZ 0 NOUN T
group 0 NOUN F
as 0 PUNCT F
compared 0 VERB F
with 0 ADP F
placebo 0 NOUN F
( 0 PUNCT F
P 0 NOUN T
= 0 SYM F
0.038 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

In 0 ADP T
Phase 0 NOUN T
2 0 NUM F
, 0 PUNCT F
the 0 DET F
trend 0 NOUN F
observed 0 VERB F
with 0 ADP F
morphine 0 NOUN F
was 0 VERB F
insignificant 0 PUNCT F
( 0 PUNCT F
P 0 NOUN T
= 0 SYM F
0.41 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Two 0 NUM T
CMZ 0 NOUN T
patients 0 NOUN F
and 0 CCONJ F
one 0 NUM F
morphine 0 NOUN F
patient 0 NOUN F
showed 0 VERB F
complete B-PAIN ADJ F
pain I-PAIN PUNCT F

Fadrozole 0 PUNCT T
HCL 0 NOUN T
( 0 PUNCT F
CGS-16949A 0 NOUN T
) 0 PUNCT F
versus 0 CCONJ F
megestrol 0 NOUN F
acetate 0 NOUN F
treatment 0 NOUN F
of 0 ADP F
postmenopausal 0 ADJ F
patients 0 NOUN F
with 0 ADP F
metastatic 0 ADJ F
breast 0 NOUN F
carcinoma 0 NOUN F
: 0 PUNCT F
results 0 NOUN F
of 0 ADP F
two 0 NUM F
randomized 0 VERB F
double 0 VERB F
blind 0 ADP F
controlled 0 VERB F
multiinstitutional 0 ADJ F
trials 0 NOUN F
. 0 PUNCT F

BACKGROUND 0 NOUN T
Breast 0 NOUN T
cancer 0 NOUN F
patients 0 NOUN F
with 0 ADP F
prior 0 PUNCT F
response 0 NOUN F
to 0 ADP F
endocrine 0 ADJ F
therapy 0 NOUN F
achieve 0 PUNCT F
subsequent 0 ADJ F
benefit 0 NOUN F
from 0 ADP F
additional 0 ADJ F
endocrine 0 ADJ F
therapies 0 NOUN F
. 0 PUNCT F

The 0 DET T
efficacy 0 NOUN F
and 0 CCONJ F
safety 0 NOUN F
of 0 ADP F
an 0 DET F
aromatase 0 NOUN F
inhibitor 0 NOUN F
, 0 PUNCT F
fadrozole 0 PUNCT F
HCL 0 NOUN T
, 0 PUNCT F
were 0 VERB F
compared 0 VERB F
with 0 ADP F
megestrol 0 NOUN F
acetate 0 NOUN F
in 0 ADP F
post 0 PUNCT F
menopausal 0 ADJ F
patients 0 NOUN F
who 0 ADP F
had 0 PUNCT F
disease 0 NOUN F
progression 0 NOUN F
after 0 ADP F
receiving 0 ADP F
antiestrogen 0 NOUN F
therapy 0 NOUN F
either 0 CCONJ F
for 0 ADP F
metastatic 0 ADJ F
disease 0 NOUN F
or 0 CCONJ F
as 0 PUNCT F
adjuvant 0 NOUN F
therapy 0 NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
In 0 ADP T
2 0 NUM F
multiinstitutional 0 ADJ F
prospective 0 ADJ F
trials 0 NOUN F
, 0 PUNCT F
683 0 NUM F
postmenopausal 0 ADJ F
patients 0 NOUN F
were 0 VERB F
randomized 0 VERB F
to 0 PART F
receive 0 ADP F
either 0 PUNCT F
fadrozole 0 PUNCT F
HCL 0 NOUN T
, 0 PUNCT F
1 0 NUM F
mg 0 NOUN F
twice 0 ADV F
daily 0 PUNCT F
, 0 PUNCT F
or 0 CCONJ F
megestrol 0 NOUN F
acetate 0 NOUN F
, 0 PUNCT F
40 0 NUM F
mg 0 NOUN F
4 0 NUM F
times 0 NOUN F
daily 0 ADJ F
, 0 PUNCT F
in 0 ADP F
a 0 DET F
double 0 ADJ F
blind 0 ADJ F
fashion 0 NOUN F
after 0 ADP F
progression 0 NOUN F
on 0 ADP F
first-line 0 NOUN F
hormonal 0 ADJ F
therapy 0 NOUN F
. 0 PUNCT F

Objective B-PHYSICAL ADJ T
response 0 NOUN F
rates B-PHYSICAL NOUN F
, 0 PUNCT F
time B-PHYSICAL NOUN F
to B-PHYSICAL ADP F
progression B-PHYSICAL NOUN F
, 0 PUNCT F
survival B-MORTALITY NOUN F
and 0 CCONJ F
safety B-OTHER NOUN F
of 0 ADP F
the 0 DET F
two 0 NUM F
regimens 0 NOUN F
were 0 VERB F
compared 0 VERB F
. 0 PUNCT F

RESULTS 0 DET T
Results 0 PUNCT T
of 0 ADP F
intent-to-treat 0 NOUN F
analyses 0 NOUN F
are 0 VERB F
presented 0 VERB F
in 0 ADP F
this 0 DET F
study 0 NOUN F
. 0 PUNCT F

No 0 DET T
significant 0 ADJ F
differences 0 NOUN F
were 0 VERB F
detected 0 VERB F
between 0 ADP F
the 0 DET F
two 0 NUM F
treatment 0 NOUN F
groups 0 NOUN F
in 0 ADP F
time B-PHYSICAL NOUN F
to I-PHYSICAL ADP F
progression B-PHYSICAL NOUN F
, 0 PUNCT F
objective B-PHYSICAL ADJ F
response 0 NOUN F
rates B-PHYSICAL NOUN F
, 0 PUNCT F
duration B-PHYSICAL NOUN F
of I-PHYSICAL ADP F
response B-PHYSICAL NOUN F
, 0 PUNCT F
and 0 CCONJ F
survival B-MORTALITY NOUN F
in 0 ADP F
either 0 PUNCT F
trial 0 NOUN F
. 0 PUNCT F

There 0 PUNCT T
were 0 VERB F
no 0 DET F
clinically 0 ADV F
meaningful 0 ADJ F
differences 0 NOUN F
between 0 ADP F
the 0 DET F
treatment 0 NOUN F
groups 0 NOUN F
in 0 ADP F
the 0 DET F
incidence 0 NOUN F
and 0 CCONJ F
severity 0 NOUN F
of 0 ADP F
adverse B-ADVERSE-EFFECTS ADJ F
experiences B-ADVERSE-EFFECTS ADJ F
, 0 PUNCT F
except 0 PUNCT F
that 0 PUNCT F
weight 0 NOUN F
gain B-ADVERSE-EFFECTS NOUN F
, 0 PUNCT F
fluid B-ADVERSE-EFFECTS NOUN F
retention B-ADVERSE-EFFECTS NOUN F
, 0 PUNCT F
and 0 CCONJ F
dyspnea B-ADVERSE-EFFECTS NOUN F
were 0 VERB F
observed 0 VERB F
in 0 ADP F
more 0 DET F
patients 0 NOUN F
in 0 ADP F
the 0 DET F
megestrol 0 NOUN F
acetate 0 NOUN F
group 0 NOUN F
compared 0 VERB F
with 0 ADP F
those 0 PUNCT F
receiving 0 PUNCT F
fadrozole 0 PUNCT F
HCL 0 NOUN T
, 0 PUNCT F
whereas 0 CCONJ F
nausea B-ADVERSE-EFFECTS NOUN F
and 0 CCONJ F
vomiting B-ADVERSE-EFFECTS VERB F
were 0 VERB F
observed 0 VERB F
in 0 ADP F
more 0 DET F
patients 0 NOUN F
in 0 ADP F
the 0 DET F
fadrozole 0 PUNCT F
HCL 0 NOUN T
group 0 NOUN F
compared 0 VERB F
with 0 ADP F
those 0 PUNCT F
receiving 0 VERB F
megestrol 0 NOUN F
acetate 0 NOUN F
. 0 PUNCT F

CONCLUSIONS 0 NOUN T
Fadrozole 0 PUNCT T
HCL 0 NOUN T
was 0 VERB F
as 0 PUNCT F
efficacious B-PHYSICAL ADJ F
as 0 VERB F
megestrol 0 NOUN F
acetate 0 NOUN F
in 0 ADP F
postmenopausal 0 ADJ F
patients 0 NOUN F
with 0 ADP F
metastatic 0 ADJ F
breast 0 NOUN F
carcinoma 0 NOUN F
after 0 ADP F
one 0 NUM F
hormonal 0 ADJ F
therapy 0 NOUN F
. 0 PUNCT F

Adverse 0 ADJ T
experiences 0 NOUN F
were 0 VERB F
mild 0 ADJ F
with 0 ADP F
both 0 PUNCT F
therapies 0 NOUN F
, 0 PUNCT F
but 0 CCONJ F
megestrol 0 NOUN F
acetate 0 NOUN F
was 0 VERB F
associated 0 VERB F
wiht 0 ADP F
a 0 DET F
higher 0 PUNCT F
frequency 0 NOUN F
of 0 ADP F
weight 0 PUNCT F

Microbial 0 ADJ T
protein 0 NOUN F
synthesis 0 NOUN F
, 0 PUNCT F
nitrogen 0 NOUN F
capture 0 NOUN F
efficiency 0 NOUN F
and 0 CCONJ F
nutrient 0 NOUN F
utilisation 0 NOUN F
in 0 ADP F
sheep 0 NOUN F
fed 0 VERB F
on 0 ADP F
finger 0 NOUN F
millet 0 NOUN F
straw 0 NOUN F
( 0 PUNCT F
Eleucine 0 NOUN T
coracana 0 ADP F
) 0 PUNCT F
-based 0 ADP F
diet 0 NOUN F
with 0 ADP F
different 0 ADJ F
rumen-degradable 0 ADJ F
nitrogen 0 NOUN F
levels 0 NOUN F
. 0 PUNCT F

BACKGROUND 0 NOUN T
Microbial 0 ADJ T
protein 0 NOUN F
synthesised 0 VERB F
in 0 ADP F
the 0 DET F
rumen 0 VERB F
is 0 VERB F
a 0 DET F
very 0 ADJ F
important 0 ADJ F
protein 0 NOUN F
source 0 NOUN F
for 0 ADP F
ruminants 0 NOUN F
. 0 PUNCT F

It 0 PRON T
is 0 VERB F
essential 0 ADJ F
to 0 PART F
provide 0 NOUN F
an 0 DET F
adequate 0 ADJ F
amount 0 NOUN F
of 0 ADP F
rumen-degradable 0 ADJ F
nitrogen 0 NOUN F
( 0 PUNCT F
RDN 0 NOUN T
) 0 PUNCT F
for 0 ADP F
optimum 0 NOUN F
microbial 0 ADJ F
protein 0 NOUN F
synthesis 0 NOUN F
in 0 ADP F
the 0 DET F
rumen 0 CCONJ F
on 0 ADP F
straw-based 0 VERB F
diets 0 NOUN F
. 0 PUNCT F

The 0 DET T
objective 0 NOUN F
of 0 ADP F
this 0 DET F
study 0 NOUN F
was 0 VERB F
to 0 PART F
determine 0 NOUN F
the 0 DET F
RDN 0 NOUN T
requirement 0 NOUN F
for 0 ADP F
optimum 0 NOUN F
microbial 0 ADJ F
protein 0 NOUN F
synthesis 0 NOUN F
( 0 PUNCT F
MPS 0 NOUN T
) 0 PUNCT F
, 0 PUNCT F
nitrogen 0 NOUN F
capture 0 NOUN F
efficiency 0 NOUN F
( 0 PUNCT F
NCE 0 NOUN T
) 0 PUNCT F
and 0 CCONJ F
nutrient 0 NOUN F
utilisation 0 NOUN F
in 0 ADP F
Nellore 0 ADP T
rams 0 CCONJ F
fed 0 VERB F
on 0 ADP F
a 0 DET F
finger 0 NOUN F
millet 0 NOUN F
straw 0 NOUN F
( 0 PUNCT F
FMS 0 NOUN T
) 0 PUNCT F
-based 0 ADP F
diet 0 NOUN F
. 0 PUNCT F

RESULTS 0 NOUN T
Thirty-six 0 NUM T
Nellore 0 PUNCT T
sheep 0 NOUN F
were 0 VERB F
randomly 0 ADV F
divided 0 VERB F
into 0 ADP F
four 0 NUM F
groups 0 NOUN F
of 0 ADP F
nine 0 NUM F
animals 0 NOUN F
each 0 DET F
using 0 ADJ F
a 0 DET F
balanced 0 VERB F
, 0 PUNCT F
completely 0 ADV F
randomised 0 VERB F
design 0 NOUN F
. 0 PUNCT F

The 0 DET T
animals 0 NOUN F
in 0 ADP F
group 0 NOUN F
1 0 NUM F
( 0 PUNCT F
RDN0 0 NOUN T
) 0 PUNCT F
were 0 VERB F
fed 0 VERB F
with 0 ADP F
ad 0 PUNCT F
libitum 0 PUNCT F
FMS 0 NOUN T
. 0 PUNCT F

Those 0 PUNCT T
in 0 ADP F
groups 0 NOUN F
2 0 NUM F
, 0 PUNCT F
3 0 NUM F
and 0 CCONJ F
4 0 NUM F
( 0 PUNCT F
RDN1 0 NOUN T
, 0 PUNCT F
RDN2 0 NOUN T
and 0 CCONJ F
RDN3 0 NOUN T
) 0 PUNCT F
were 0 VERB F
supplemented 0 VERB F
with 0 ADP F
groundnut 0 NOUN F
cake 0 VERB F
to 0 PART F
provide 0 NOUN F
RDN B-PHYSICAL NOUN T
levels I-PHYSICAL NOUN F
of 0 ADP F
14 0 NUM F
, 0 PUNCT F
18 0 NUM F
and 0 CCONJ F
23 0 NUM F
g 0 ADP F
RDN 0 NOUN T
kg?? 0 NOUN F
digestible 0 ADJ F
organic 0 ADJ F
matter 0 NOUN F
intake 0 NOUN F
( 0 PUNCT F
DOMI 0 NOUN T
) 0 PUNCT F
or 0 CCONJ F
21 0 NUM F
, 0 PUNCT F
27 0 NUM F
and 0 CCONJ F
35 0 NUM F
g 0 ADP F
RDN 0 NOUN T
kg?? 0 NOUN F
digestible 0 ADJ F
organic 0 ADJ F
matter 0 NOUN F
apparently 0 ADV F
digested 0 VERB F
in 0 ADP F
the 0 DET F
rumen 0 NOUN F
( 0 PUNCT F
DOMR 0 NOUN T
) 0 PUNCT F
respectively 0 ADV F
along 0 PUNCT F
with 0 ADP F
FMS 0 NOUN T
. 0 PUNCT F

The 0 DET T
digestibility 0 NOUN F
coefficients 0 PUNCT F
of 0 ADP F
all 0 DET F
nutrients 0 NOUN F
and 0 CCONJ F
MPS 0 NOUN T
increased 0 NOUN F
( 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.05 0 NUM F
) 0 PUNCT F
quadratically 0 ADV F
with 0 ADP F
increasing 0 ADJ F
level 0 NOUN F
of 0 ADP F
RDN 0 NOUN T
supplementation 0 NOUN F
. 0 PUNCT F

NCE 0 NOUN T
decreased 0 VERB F
linearly 0 ADV F
( 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.05 0 NUM F
) 0 PUNCT F
as 0 ADP F
the 0 DET F
level 0 NOUN F
of 0 ADP F
RDN 0 NOUN T
increased 0 PUNCT F
. 0 PUNCT F

CONCLUSION 0 NOUN T
The 0 DET T
results 0 CCONJ F
suggest 0 VERB F
that 0 ADP F
12 0 NUM F
g 0 ADP F
RDN 0 NOUN T
kg?? 0 NOUN F
DOMI 0 ADP T
or 0 CCONJ F
19 0 NUM F
g 0 ADP F
RDN 0 NOUN T
kg?? 0 NOUN F
DOMR 0 NOUN T
may 0 VERB F
be 0 VERB F
adequate 0 ADJ F
for 0 ADP F
optimum 0 NOUN F
MPS 0 NOUN T
, 0 PUNCT F
NCE 0 NOUN T
and 0 CCONJ F
digestibility 0 NOUN F
of 0 ADP F
nutrients 0 NOUN F
in 0 ADP F
sheep 0 NOUN F
fed 0 VERB F
on 0 ADP F
an 0 DET F
FMS-based 0 NOUN T
diet 0 NOUN F
. 0 PUNCT F

Sustained 0 VERB T
oral B-PHYSICAL ADJ F
health I-PHYSICAL NOUN F
improvement I-PHYSICAL NOUN F
and 0 CCONJ F
use 0 NOUN F
of 0 ADP F
toothbrushes 0 DET F
and 0 CCONJ F
dentifrice 0 NOUN F
by 0 ADP F
previous 0 ADJ F
users 0 NOUN F
of 0 ADP F
traditional 0 ADJ F
materials 0 NOUN F
in 0 ADP F
a 0 DET F
rural 0 ADJ F
population 0 NOUN F
in 0 ADP F
Andhra 0 NOUN T
Pradesh 0 NOUN T
, 0 PUNCT F
India 0 PUNCT T
. 0 PUNCT F

AIM 0 NOUN T
To 0 ADP T
follow-up 0 NOUN F
, 0 PUNCT F
one 0 NUM F
year 0 NOUN F
later 0 ADJ F
, 0 PUNCT F
a 0 DET F
double-blind 0 ADJ F
, 0 PUNCT F
randomised 0 ADP F
study 0 NOUN F
, 0 PUNCT F
which 0 ADP F
investigated 0 VERB F
the 0 DET F
effect 0 NOUN F
of 0 ADP F
regular 0 ADJ F
brushing 0 PUNCT F
with 0 ADP F
dentifrices 0 NOUN F
on 0 ADP F
the 0 DET F
oral 0 ADJ F
health 0 NOUN F
of 0 ADP F
an 0 DET F
economically 0 ADV F
disadvantaged 0 VERB F
rural 0 ADJ F
population 0 NOUN F
in 0 ADP F
Andhra 0 NOUN T
Pradesh 0 NOUN T
, 0 PUNCT F
India 0 PUNCT T
who 0 ADP F
were 0 VERB F
primarily 0 ADJ F
users 0 NOUN F
of 0 ADP F
traditional 0 ADJ F
materials 0 NOUN F
. 0 PUNCT F

SUBJECTS 0 NOUN T
150 0 NUM F
of 0 ADP F
the 0 DET F
original 0 ADJ F
study 0 NOUN F
population 0 NOUN F
. 0 PUNCT F

METHOD 0 NOUN T
Examination 0 NOUN T
to 0 PART F
determine 0 NOUN F
whether 0 ADP F
the 0 DET F
improvements 0 NOUN F
in 0 ADP F
oral B-PHYSICAL ADJ F
health I-PHYSICAL NOUN F
status I-PHYSICAL NOUN F
and 0 CCONJ F
oral B-PHYSICAL ADJ F
health I-PHYSICAL NOUN F
behaviour I-PHYSICAL NOUN F
( 0 PUNCT F
use 0 NOUN F
of 0 ADP F
toothbrush 0 NOUN F
and 0 CCONJ F
dentifrice 0 NOUN F
) 0 PUNCT F
, 0 PUNCT F
being 0 VERB F
unsupported 0 PUNCT F
, 0 PUNCT F
had 0 PUNCT F
been 0 ADP F
sustained 0 VERB F
since 0 ADP F
completion 0 NOUN F
of 0 ADP F
the 0 DET F
original 0 ADJ F
study 0 NOUN F
. 0 PUNCT F

RESULTS 0 DET T
Data 0 ADP T
analysis 0 NOUN F
showed 0 VERB F
sustained 0 DET F
, 0 PUNCT F
statistically 0 ADV F
significant 0 ADJ F
improvements 0 NOUN F
in 0 ADP F
gingival B-PHYSICAL ADJ F
health I-PHYSICAL NOUN F
as I-PHYSICAL VERB F
measured I-PHYSICAL VERB F
by I-PHYSICAL ADP F
gingival I-PHYSICAL ADJ F
bleeding I-PHYSICAL VERB F
and I-PHYSICAL CCONJ F
plaque I-PHYSICAL NOUN F
indices I-PHYSICAL NOUN F
( 0 PUNCT F
GBI B-PHYSICAL NOUN T
and I-PHYSICAL CCONJ F
PI I-PHYSICAL NOUN T
) 0 PUNCT F
comparing 0 ADP F
users 0 NOUN F
and 0 CCONJ F
non-users 0 PROPN F
of 0 ADP F
toothbrushes 0 DET F
and 0 CCONJ F
dentifrice 0 NOUN F
in 0 ADP F
the 0 DET F
original 0 ADJ F
study 0 NOUN F
( 0 PUNCT F
PI 0 NOUN T
: 0 PUNCT F
p 0 NOUN F
= 0 SYM F
0.04 0 NUM F
; 0 PUNCT F
GBI 0 NOUN T
: 0 PUNCT F
p 0 NOUN F
= 0 SYM F
0.03 0 NUM F
) 0 PUNCT F
and 0 CCONJ F
sustained B-OTHER VERB F
use I-OTHER NOUN F
of I-OTHER ADP F
toothbrushes I-OTHER DET F
and 0 CCONJ F
dentifrice B-OTHER NOUN F
by 0 ADP F
60 0 NUM F
% 0 SYM F
of 0 ADP F
the 0 DET F
subjects 0 NOUN F
at 0 ADP F
follow-up 0 NOUN F
one 0 NUM F
year 0 NOUN F
later 0 ADJ F
. 0 PUNCT F

CONCLUSIONS 0 NOUN T
This 0 DET T
study 0 NOUN F
shows 0 NOUN F
a 0 DET F
beneficial B-PHYSICAL ADJ F
effect 0 NOUN F
on B-PHYSICAL ADP F
oral I-PHYSICAL PUNCT F

Investigation 0 NOUN T
of 0 ADP F
erosion B-PHYSICAL NOUN F
and 0 CCONJ F
abrasion B-PHYSICAL NOUN F
on 0 ADP F
enamel B-PHYSICAL NOUN F
and 0 CCONJ F
dentine B-PHYSICAL NOUN F
: 0 PUNCT F
a 0 DET F
model 0 NOUN F
in 0 ADP F
situ 0 ADJ F
using 0 PUNCT F
toothpastes 0 NOUN F
of 0 ADP F
different 0 ADJ F
abrasivity 0 NOUN F
. 0 PUNCT F

BACKGROUND 0 NOUN T
Studies 0 NOUN T
in 0 ADP F
vitro 0 ADJ F
suggest 0 VERB F
that 0 ADP F
abrasion B-PHYSICAL NOUN F
and 0 CCONJ F
erosion B-PHYSICAL NOUN F
may 0 VERB F
act 0 VERB F
synergistically 0 ADV F
to 0 PART F
produce 0 CCONJ F
wear 0 PUNCT F
of 0 ADP F
enamel B-PHYSICAL NOUN F
and 0 CCONJ F
dentine B-PHYSICAL NOUN F
. 0 PUNCT F

Methods 0 NOUN T
in 0 ADP F
situ 0 PUNCT F
are 0 ADJ F
recently 0 ADV F
available 0 ADP F
to 0 PART F
study 0 ADP F
separately 0 ADV F
erosion B-PHYSICAL NOUN F
and 0 CCONJ F
abrasion B-PHYSICAL NOUN F
of 0 ADP F
dental B-PHYSICAL ADJ F
tissues I-PHYSICAL NOUN F
. 0 PUNCT F

The 0 DET T
aim 0 NOUN F
of 0 ADP F
this 0 DET F
study 0 NOUN F
was 0 VERB F
to 0 PROPN F
combine 0 NOUN F
two 0 NUM F
in 0 PUNCT F
situ 0 ADJ F
protocols 0 NOUN F
to 0 ADJ F
study 0 NOUN F
the 0 DET F
interplay 0 NOUN F
between 0 ADP F
erosion B-PHYSICAL NOUN F
and 0 CCONJ F
abrasion B-PHYSICAL NOUN F
of 0 ADP F
enamel B-PHYSICAL NOUN F
and 0 CCONJ F
dentine B-PHYSICAL NOUN F
. 0 PUNCT F

METHOD 0 NOUN T
The 0 DET T
study 0 NOUN F
was 0 ADV F
a 0 DET F
single-blind 0 NOUN F
, 0 PUNCT F
randomised 0 VERB F
, 0 PUNCT F
five-treatment 0 PUNCT F
cross-over 0 NOUN F
design 0 NOUN F
involving 0 VERB F
15 0 NUM F
healthy 0 ADJ F
volunteers 0 NOUN F
. 0 PUNCT F

During 0 ADP T
each 0 DET F
10-day 0 NOUN F
study 0 NUM F
period 0 NOUN F
, 0 PUNCT F
subjects 0 NOUN F
wore 0 ADP F
from 0 ADP F
0900 0 NUM F
to 0 ADP F
1700 0 NUM F
h 0 NOUN F
an 0 DET F
upper 0 ADJ F
removable 0 ADJ F
acrylic 0 ADJ F
appliance 0 PUNCT F
holding 0 ADJ F
one 0 NUM F
polished 0 ADP F
enamel 0 NOUN F
and 0 CCONJ F
one 0 NUM F
polished 0 ADP F
dentine 0 NOUN F
specimen 0 NOUN F
. 0 PUNCT F

The 0 DET T
specimen 0 NOUN F
treatment 0 NOUN F
regimens 0 NOUN F
were 0 ADJ F
: 0 PUNCT F
1 0 NUM F
. 0 PUNCT F

Drinking 0 VERB T
water 0 NOUN F
and 0 CCONJ F
brushing 0 PUNCT F
with 0 ADP F
toothpaste 0 NOUN F
A 0 NOUN T
. 0 PUNCT F

2 0 NUM F
. 0 PUNCT F

Drinking 0 VERB T
water 0 NOUN F
and 0 CCONJ F
brushing 0 PUNCT F
with 0 ADP F
toothpaste 0 PUNCT F
B 0 NOUN T
. 0 PUNCT F

3 0 NUM F
. 0 PUNCT F

Drinking 0 PROPN T
orange 0 NOUN F
juice 0 NOUN F
. 0 PUNCT F

4 0 NUM F
. 0 PUNCT F

Drinking 0 PROPN T
orange 0 NOUN F
juice 0 ADP F
and 0 CCONJ F
brushing 0 PUNCT F
with 0 ADP F
toothpaste 0 NOUN F
A 0 NOUN T
. 0 PUNCT F

5 0 NUM F
. 0 PUNCT F

Drinking 0 PROPN T
orange 0 NOUN F
juice 0 ADP F
and 0 CCONJ F
brushing 0 PUNCT F
with 0 ADP F
toothpaste 0 PUNCT F
B 0 NOUN T
. 0 PUNCT F

Drinking 0 PROPN T
and 0 CCONJ F
brushing 0 PUNCT F
times 0 NOUN F
were 0 VERB F
around 0 ADP F
0900 0 NUM F
, 0 PUNCT F
1100 0 NUM F
, 0 PUNCT F
1300 0 NUM F
and 0 CCONJ F
1500 0 NUM F
h. 0 NOUN F
Drinks 0 PUNCT T
were 0 VERB F
consumed 0 VERB F
as 0 ADP F
250 0 NUM F
ml 0 NOUN F
over 0 ADP F
10 0 NUM F
min 0 NOUN F
and 0 CCONJ F
brushing 0 PUNCT F
ex 0 ADP F
vivo 0 NUM F
for 0 ADP F
1 0 NUM F
min 0 NOUN F
to 0 ADP F
each 0 CCONJ F
specimen 0 NOUN F
. 0 PUNCT F

Measurement 0 NOUN T
of 0 ADP F
tissue B-PHYSICAL NOUN F
loss I-PHYSICAL NOUN F
was 0 VERB F
made 0 VERB F
on 0 ADP F
days 0 NOUN F
5 0 NUM F
and 0 CCONJ F
10 0 NUM F
of 0 ADP F
each 0 DET F
period 0 NOUN F
using 0 VERB F
a 0 DET F
profilometer 0 ADJ F
. 0 PUNCT F

RESULTS 0 PUNCT T
All 0 PUNCT T
treatments 0 NOUN F
produced 0 VERB F
increasing 0 ADP F
tissue B-PHYSICAL NOUN F
loss I-PHYSICAL NOUN F
over I-PHYSICAL ADP F
time I-PHYSICAL NOUN F
, 0 PUNCT F
which 0 ADP F
was 0 VERB F
considerably 0 ADV F
greater 0 PUNCT F
for 0 ADP F
dentine 0 NOUN F
than 0 PUNCT F
enamel 0 NOUN F
. 0 PUNCT F

For 0 ADP T
enamel 0 NOUN F
, 0 PUNCT F
the 0 DET F
data 0 NOUN F
at 0 ADP F
days 0 NOUN F
5 0 NUM F
and 0 CCONJ F
10 0 NUM F
showed 0 VERB F
a 0 DET F
significant 0 ADJ F
effect 0 NOUN F
for 0 ADP F
erosion B-PHYSICAL NOUN F
( 0 PUNCT F
i.e 0 ADV F
. 0 PUNCT F

orange 0 ADV F
juice 0 ADV F
was 0 VERB F
significantly 0 ADV F
more 0 DET F
erosive 0 ADJ F
than 0 PUNCT F
water 0 NOUN F
) 0 PUNCT F
, 0 PUNCT F
but 0 CCONJ F
no 0 DET F
significant 0 ADJ F
effect 0 NOUN F
for 0 ADP F
abrasion B-PHYSICAL NOUN F
( 0 PUNCT F
i.e 0 ADV F
. 0 PUNCT F

no 0 DET F
significant 0 ADJ F
difference 0 NOUN F
between 0 ADP F
the 0 DET F
two 0 NUM F
toothpaste 0 NOUN F
treatments 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
combined 0 VERB F
orange 0 NOUN F
juice 0 ADP F
and 0 CCONJ F
toothpaste 0 NOUN F
effects 0 NOUN F
were 0 VERB F
directional 0 ADJ F
for 0 ADP F
synergy 0 NOUN F
but 0 CCONJ F
did 0 PUNCT F
not 0 ADV F
reach 0 ADJ F
significance 0 NOUN F
. 0 PUNCT F

For 0 ADP T
dentine 0 NOUN F
at 0 ADP F
day 0 NOUN F
10 0 NUM F
, 0 PUNCT F
many 0 DET F
specimens 0 NOUN F
exceeded 0 ADP F
the 0 DET F
50 0 NUM F
microm 0 NOUN F
set 0 ADV F
limit 0 VERB F
of 0 ADP F
the 0 DET F
profilometer 0 ADP F
and 0 CCONJ F
only 0 ADJ F
day 0 NOUN F
5 0 NUM F
data 0 NOUN F
were 0 VERB F
considered 0 VERB F
. 0 PUNCT F

There 0 PUNCT T
were 0 VERB F
significant 0 ADJ F
effects 0 NOUN F
for 0 ADP F
erosion B-PHYSICAL NOUN F
( 0 PUNCT F
orange 0 ADV F
juice 0 NOUN F
produced 0 ADV F
significantly 0 ADV F
more 0 DET F
erosion 0 NOUN F
than 0 PUNCT F
water 0 NOUN F
) 0 PUNCT F
and 0 CCONJ F
for 0 ADP F
abrasion B-PHYSICAL NOUN F
( 0 PUNCT F
paste 0 NOUN F
A 0 NOUN T
was 0 VERB F
significantly 0 ADV F
more 0 DET F
abrasive 0 VERB F
to 0 ADP F
dentine 0 NOUN F
than 0 PUNCT F
paste 0 NOUN F
B 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
synergy 0 NOUN F
effect 0 NOUN F
could 0 SYM F
not 0 ADV F
be 0 VERB F
examined 0 VERB F
for 0 ADP F
dentine 0 NOUN F
due 0 PUNCT F
to 0 ADP F
the 0 DET F
truncation 0 NOUN F
effect 0 NOUN F
as 0 ADP F
the 0 DET F
set 0 ADJ F
limit 0 VERB F
of 0 ADP F
the 0 DET F
profilometer 0 VERB F
was 0 VERB F
exceeded 0 ADP F
. 0 PUNCT F

CONCLUSIONS 0 NOUN T
Erosion 0 NOUN T
increases 0 NOUN F
the 0 DET F
susceptibility B-PHYSICAL NOUN F
of I-PHYSICAL ADP F
enamel I-PHYSICAL NOUN F
to 0 ADP F
toothpaste B-PHYSICAL PUNCT F
abrasion I-PHYSICAL NOUN F
. 0 PUNCT F

Dentine 0 PUNCT T
is 0 VERB F
considerably 0 ADV F
more 0 ADV F
susceptible 0 ADJ F
than 0 PUNCT F
enamel 0 NOUN F
to 0 VERB F
erosion B-PHYSICAL NOUN F
and 0 CCONJ F
abrasion B-PHYSICAL NOUN F
alone 0 ADJ F
or 0 CCONJ F
combined 0 PUNCT F
. 0 PUNCT F

Dentine B-PHYSICAL NOUN T
loss I-PHYSICAL NOUN F
appears 0 NOUN F
to 0 PUNCT F
correlate 0 NOUN F
with 0 ADP F
toothpaste 0 NOUN F
abrasivity 0 NOUN F
( 0 PUNCT F
RDA 0 NOUN T
value 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

Analysis 0 NOUN T
of 0 ADP F
prevention 0 NOUN F
program 0 NOUN F
effectiveness 0 NOUN F
with 0 ADP F
clustered 0 ADP F
data 0 NOUN F
using 0 VERB F
generalized 0 VERB F
estimating 0 ADV F
equations 0 NOUN F
. 0 PUNCT F

Experimental 0 ADJ T
studies 0 NOUN F
of 0 ADP F
prevention 0 NOUN F
programs 0 NOUN F
often 0 ADV F
randomize 0 ADJ F
clusters 0 NOUN F
of 0 ADP F
individuals 0 NOUN F
rather 0 PUNCT F
than 0 ADP F
individuals 0 NOUN F
to 0 ADP F
treatment 0 NOUN F
conditions 0 NOUN F
. 0 PUNCT F

When 0 ADP T
the 0 DET F
correlation 0 NOUN F
among 0 ADP F
individuals 0 NOUN F
within 0 ADP F
clusters 0 NOUN F
is 0 VERB F
not 0 ADV F
accounted 0 VERB F
for 0 ADP F
in 0 PUNCT F
statistical 0 ADJ F
analysis 0 NOUN F
, 0 PUNCT F
the 0 DET F
standard 0 ADJ F
errors 0 NOUN F
are 0 VERB F
biased 0 PROPN F
, 0 PUNCT F
potentially 0 ADV F
resulting 0 VERB F
in 0 ADP F
misleading 0 ADP F
conclusions 0 NOUN F
about 0 PUNCT F
the 0 DET F
significance 0 NOUN F
of 0 ADP F
treatment 0 NOUN F
effects 0 NOUN F
. 0 PUNCT F

This 0 DET T
study 0 NOUN F
demonstrates 0 NOUN F
the 0 DET F
generalized 0 VERB F
estimating 0 ADV F
equations 0 NOUN F
( 0 PUNCT F
GEE 0 NOUN T
) 0 PUNCT F
method 0 NOUN F
, 0 PUNCT F
focusing 0 VERB F
specifically 0 ADV F
on 0 ADP F
the 0 DET F
GEE-independent 0 ADJ T
method 0 NOUN F
, 0 PUNCT F
to 0 ADP F
control 0 NOUN F
for 0 ADP F
within-cluster 0 ADJ F
correlation 0 NOUN F
in 0 ADP F
regression 0 NOUN F
models 0 NOUN F
with 0 ADP F
either 0 CCONJ F
continuous B-OTHER ADJ F
or 0 CCONJ F
binary B-OTHER ADJ F
outcomes I-OTHER NOUN F
. 0 PUNCT F

The 0 DET T
GEE-independent 0 ADJ T
method 0 NOUN F
yields 0 NOUN F
consistent B-OTHER ADJ F
and 0 CCONJ F
robust B-OTHER ADJ F
variance 0 PUNCT F

Timing B-MORTALITY DET T
of I-MORTALITY ADP F
death I-MORTALITY NOUN F
and 0 CCONJ F
myocardial B-PHYSICAL ADJ F
infarction I-PHYSICAL NOUN F
in 0 ADP F
patients 0 NOUN F
with 0 ADP F
non-ST 0 NOUN F
elevation 0 NOUN F
acute 0 ADJ F
coronary 0 ADJ F
syndromes 0 NOUN F
: 0 PUNCT F
insights 0 NOUN F
from 0 ADP F
randomized 0 VERB F
clinical 0 ADJ F
trials 0 NOUN F
. 0 PUNCT F

BACKGROUND 0 NOUN T
Adverse 0 ADJ T
events 0 NOUN F
occur 0 VERB F
following 0 ADJ F
non-ST 0 NOUN F
elevation 0 NOUN F
acute 0 ADJ F
coronary 0 ADJ F
syndromes 0 NOUN F
( 0 PUNCT F
NSTE 0 NOUN T
ACS 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

However 0 ADV T
, 0 PUNCT F
the 0 DET F
timing 0 VERB F
of 0 ADP F
these 0 DET F
events 0 NOUN F
in 0 ADP F
relation 0 NOUN F
to 0 ADP F
index 0 NOUN F
event 0 NOUN F
is 0 VERB F
less 0 DET F
clear 0 ADJ F
. 0 PUNCT F

METHODS 0 NOUN T
Accordingly 0 ADV T
, 0 PUNCT F
we 0 PRON F
evaluated 0 VERB F
26,466 0 NUM F
NSTE 0 NOUN T
ACS 0 NOUN T
patients 0 NOUN F
from 0 ADP F
the 0 DET F
Global 0 ADJ T
Use 0 NOUN T
of 0 ADP F
Strategies 0 NOUN T
to 0 VERB F
Open 0 ADJ T
Occluded 0 ADJ T
Arteries 0 NOUN T
in 0 ADP F
Acute 0 ADJ T
Coronary 0 ADJ T
Syndromes 0 NOUN T
( 0 PUNCT F
GUSTO-IIb 0 NOUN T
) 0 PUNCT F
, 0 PUNCT F
Platelet 0 NOUN T
Glycoprotein 0 NOUN T
IIb/IIIa 0 NOUN T
in 0 ADP F
Unstable 0 ADJ T
Angina 0 NOUN T
: 0 PUNCT F
Receptor 0 NOUN T
Suppression 0 NOUN T
Using 0 PROPN T
Integrilin 0 NOUN T
Therapy 0 NOUN T
( 0 PUNCT F
PURSUIT 0 NOUN T
) 0 PUNCT F
, 0 PUNCT F
and 0 CCONJ F
Platelet 0 NOUN T
IIb/IIIa 0 NOUN T
Antagonism 0 NOUN T
for 0 ADP F
the 0 DET F
Reduction 0 NOUN T
of 0 ADP F
Acute 0 ADJ T
Coronary 0 ADJ T
Syndrome 0 NOUN T
Events 0 NOUN T
in 0 ADP F
a 0 DET F
Global 0 ADJ T
Organization 0 NOUN T
Network 0 NOUN T
( 0 PUNCT F
PARAGON 0 NOUN T
) 0 PUNCT F
A 0 DET T
and 0 CCONJ F
B 0 NOUN T
trials 0 NOUN F
to 0 PART F
ascertain 0 NOUN F
the 0 DET F
timing 0 VERB F
of 0 ADP F
adverse 0 ADJ F
events 0 NOUN F
. 0 PUNCT F

Outcomes 0 NOUN T
of 0 ADP F
interest 0 NOUN F
were 0 VERB F
death B-MORTALITY NOUN F
, 0 PUNCT F
myocardial B-PHYSICAL ADJ F
infarction I-PHYSICAL NOUN F
( I-PHYSICAL PUNCT F
MI I-PHYSICAL NOUN T
) I-PHYSICAL PUNCT F
, 0 PUNCT F
and 0 CCONJ F
death B-MORTALITY NOUN F
or 0 CCONJ F
MI 0 NOUN T
at 0 ADP F
180 B-PHYSICAL NUM F
days I-PHYSICAL NOUN F
. 0 PUNCT F

Logistic 0 ADJ T
regression 0 NOUN F
modeling 0 ADJ F
for 0 ADP F
death 0 NOUN F
was 0 VERB F
used 0 VERB F
to 0 PART F
categorize 0 ADJ F
patients 0 NOUN F
into 0 ADP F
low- 0 ADP F
, 0 PUNCT F
medium- 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
high-risk 0 NOUN F
groups 0 NOUN F
. 0 PUNCT F

RESULTS 0 NOUN T
At 0 ADP T
6 0 NUM F
months 0 NOUN F
, 0 PUNCT F
6.2 0 NUM F
% 0 SYM F
of 0 ADP F
patients 0 NOUN F
died B-MORTALITY VERB F
, 0 PUNCT F
12.1 0 NUM F
% 0 SYM F
had 0 PUNCT F
MI B-PHYSICAL NOUN T
, 0 PUNCT F
and 0 CCONJ F
15.7 0 NUM F
% 0 SYM F
suffered 0 VERB F
death B-MORTALITY NOUN F
or 0 PUNCT F
MI B-PHYSICAL NOUN T
. 0 PUNCT F

From 0 ADP T
15 0 NUM F
% 0 SYM F
to 0 ADP F
40 0 NUM F
% 0 SYM F
of 0 ADP F
these 0 DET F
events 0 NOUN F
occurred 0 VERB F
beyond 0 ADP F
30 0 NUM F
days 0 NOUN F
. 0 PUNCT F

At 0 ADP T
6 0 NUM F
months 0 NOUN F
, 0 PUNCT F
3 0 NUM F
% 0 SYM F
, 0 PUNCT F
4 0 NUM F
% 0 SYM F
, 0 PUNCT F
and 0 CCONJ F
13 0 NUM F
% 0 SYM F
of 0 ADP F
patients 0 NOUN F
died 0 VERB F
in 0 ADP F
low- 0 ADJ F
, 0 PUNCT F
medium- 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
high-risk 0 NOUN F
groups 0 NOUN F
, 0 PUNCT F
respectively 0 ADV F
. 0 PUNCT F

However 0 ADV T
, 0 PUNCT F
the 0 DET F
proportion 0 NOUN F
of 0 ADP F
patients B-MORTALITY NOUN F
dying I-MORTALITY CCONJ F
beyond 0 ADP F
30 0 NUM F
days 0 NOUN F
was 0 VERB F
similar 0 ADJ F
in 0 ADP F
the 0 DET F
three 0 NUM F
groups 0 NOUN F
( 0 PUNCT F
44 0 NUM F
% 0 SYM F
, 0 PUNCT F
43 0 NUM F
% 0 SYM F
, 0 PUNCT F
and 0 CCONJ F
41 0 NUM F
% 0 SYM F
of 0 ADP F
death 0 NOUN F
, 0 PUNCT F
respectively 0 ADV F
) 0 PUNCT F
. 0 PUNCT F

Similarly 0 ADV T
, 0 PUNCT F
whereas 0 ADP F
death B-MORTALITY NOUN F
or 0 CCONJ F
MI B-MORTALITY NOUN T
increased 0 VERB F
with 0 ADP F
higher 0 PUNCT F
risk 0 NOUN F
( 0 PUNCT F
11 0 NUM F
% 0 SYM F
, 0 PUNCT F
14 0 NUM F
% 0 SYM F
, 0 PUNCT F
and 0 CCONJ F
23 0 NUM F
% 0 SYM F
, 0 PUNCT F
respectively 0 ADV F
) 0 PUNCT F
, 0 PUNCT F
the 0 DET F
proportion B-PHYSICAL NOUN F
of I-PHYSICAL ADP F
patients I-PHYSICAL NOUN F
with 0 ADP F
this 0 DET F
event 0 NOUN F
beyond 0 ADP F
30 0 NUM F
days 0 NOUN F
did 0 ADP F
not 0 ADV F
differ 0 VERB F
in 0 ADP F
the 0 DET F
three 0 NUM F
strata 0 NOUN F
( 0 PUNCT F
22 0 NUM F
% 0 SYM F
, 0 PUNCT F
20 0 NUM F
% 0 SYM F
, 0 PUNCT F
and 0 CCONJ F
25 0 NUM F
% 0 SYM F
, 0 PUNCT F
respectively 0 ADV F
) 0 PUNCT F
. 0 PUNCT F

CONCLUSIONS 0 ADP T
Our 0 PUNCT T
study 0 NOUN F
provides 0 NOUN F
important 0 ADJ F
insights 0 NOUN F
into 0 ADP F
the 0 DET F
timing 0 VERB F
of 0 ADP F
adverse 0 ADJ F
events 0 NOUN F
and 0 CCONJ F
suggests 0 NOUN F
that 0 ADP F
the 0 DET F
substantial 0 ADJ F
proportion 0 NOUN F
of 0 ADP F
patients 0 NOUN F
suffer 0 ADP F
subsequent 0 ADJ F
adverse 0 ADJ F
events 0 NOUN F
after 0 ADP F
their 0 PUNCT F
index 0 NOUN F
NSTE 0 NOUN T
ACS 0 NOUN T
. 0 PUNCT F

Thus 0 ADV T
, 0 PUNCT F
these 0 DET F
data 0 NOUN F
call 0 PUNCT F
for 0 ADP F
continuous 0 ADJ F
surveillance 0 NOUN F
for 0 ADP F
these 0 DET F
events 0 NOUN F
and 0 CCONJ F
efforts 0 NOUN F
beyond 0 ADP F
the 0 DET F
acute 0 ADJ F
phase 0 NOUN F
at 0 ADP F
increasing 0 ADV F
adherence 0 NOUN F
to 0 ADP F
evidence-based 0 ADJ F
therapies 0 NOUN F
to 0 PART F
improve 0 ADJ F
the 0 DET F
outcomes 0 NOUN F
of 0 ADP F
these 0 DET F
patients 0 NOUN F
. 0 PUNCT F

A 0 DET T
randomised 0 VERB F
comparison 0 NOUN F
of 0 ADP F
UK 0 ADP T
genetic 0 ADJ F
risk 0 NOUN F
counselling 0 ADJ F
services 0 NOUN F
for 0 ADP F
familial 0 ADJ F
cancer 0 NOUN F
: 0 PUNCT F
psychosocial B-MENTAL ADJ F
outcomes I-MENTAL NOUN F
. 0 PUNCT F

The 0 DET T
aim 0 NOUN F
of 0 ADP F
the 0 DET F
study 0 NOUN F
was 0 VERB F
to 0 ADV F
compare 0 NOUN F
psychosocial B-MENTAL ADJ F
outcomes I-MENTAL NOUN F
for 0 ADP F
50 0 NUM F
new 0 ADJ F
clinic 0 ADJ F
attendees 0 NOUN F
, 0 PUNCT F
referred 0 VERB F
for 0 ADP F
cancer 0 NOUN F
genetic 0 ADJ F
counselling 0 VERB F
to 0 ADP F
five 0 ADV F
UK 0 ADV T
centres 0 NOUN F
. 0 PUNCT F

The 0 DET T
centres 0 NOUN F
represented 0 VERB F
England 0 PUNCT T
, 0 PUNCT F
Scotland 0 PUNCT T
and 0 CCONJ F
Wales 0 ADP T
, 0 PUNCT F
and 0 CCONJ F
were 0 VERB F
randomly 0 ADV F
selected 0 VERB F
from 0 ADP F
groups 0 NOUN F
ranked 0 VERB F
by 0 ADP F
different 0 ADJ F
levels 0 NOUN F
of 0 ADP F
clinical 0 ADJ F
activity 0 NOUN F
in 0 ADP F
cancer 0 NOUN F
genetics 0 ADJ F
practice 0 NOUN F
. 0 PUNCT F

Questionnaires 0 NOUN T
assessed 0 VERB F
demographic B-OTHER ADJ F
data I-OTHER NOUN F
, 0 PUNCT F
risk 0 NOUN F
perception 0 NOUN F
, 0 PUNCT F
mental 0 ADJ F
health 0 NOUN F
and 0 CCONJ F
use 0 NOUN F
of 0 ADP F
health B-OTHER NOUN F
services I-OTHER NOUN F
pre-consultation I-OTHER NOUN F
and 0 CCONJ F
at 0 ADP F
1 0 NUM F
and 0 CCONJ F
12 0 NUM F
months 0 NOUN F
follow-up 0 NOUN F
. 0 PUNCT F

Satisfaction B-OTHER NOUN T
was 0 VERB F
measured 0 VERB F
for 0 ADP F
attendees 0 NOUN F
and 0 CCONJ F
referring 0 PUNCT F
doctors 0 NOUN F
at 0 ADP F
follow-up 0 NOUN F
. 0 PUNCT F

A 0 DET T
total 0 NOUN F
of 0 ADP F
256 0 NUM F
unaffected 0 VERB F
adults 0 NOUN F
fulfilled 0 PUNCT F
the 0 DET F
study 0 ADV F
criteria 0 NOUN F
. 0 PUNCT F

The 0 DET T
five 0 NUM F
centres 0 NOUN F
varied 0 VERB F
widely 0 ADV F
with 0 ADP F
respect 0 NOUN F
to 0 ADP F
service 0 NOUN F
organisation 0 NOUN F
and 0 CCONJ F
activity 0 NOUN F
, 0 PUNCT F
but 0 CCONJ F
all 0 DET F
had 0 PUNCT F
a 0 DET F
greater 0 PUNCT F
proportion 0 NOUN F
of 0 ADP F
unaffected 0 VERB F
attendees 0 NOUN F
with 0 ADP F
a 0 DET F
breast 0 NOUN F
cancer 0 NOUN F
risk 0 NOUN F
( 0 PUNCT F
61-91 0 NUM F
% 0 SYM F
) 0 PUNCT F
than 0 ADP F
either 0 PUNCT F
a 0 DET F
bowel 0 NOUN F
cancer 0 NOUN F
risk 0 NOUN F
( 0 PUNCT F
0-33 0 NUM F
% 0 SYM F
) 0 PUNCT F
or 0 CCONJ F
ovarian 0 ADJ F
cancer 0 NOUN F
risk 0 NOUN F
( 0 PUNCT F
3-25 0 NUM F
% 0 SYM F
) 0 PUNCT F
. 0 PUNCT F

There 0 PUNCT T
were 0 VERB F
no 0 DET F
significant 0 ADJ F
differences 0 NOUN F
in 0 ADP F
the 0 DET F
psychosocial B-MENTAL ADJ F
data I-MENTAL NOUN F
between 0 ADP F
centres 0 NOUN F
pre-counselling 0 CCONJ F
. 0 PUNCT F

No 0 DET T
significant 0 ADJ F
change 0 NOUN F
over 0 PUNCT F
time 0 NOUN F
occurred 0 VERB F
for 0 ADP F
any 0 PUNCT F
of 0 ADP F
the 0 DET F
centres 0 NOUN F
for 0 ADP F
risk 0 NOUN F
perception B-OTHER NOUN F
or 0 CCONJ F
general B-MENTAL ADJ F
psychological I-MENTAL ADJ F
distress I-MENTAL NOUN F
. 0 PUNCT F

There 0 PUNCT T
were 0 VERB F
significant 0 ADJ F
differences 0 NOUN F
between 0 ADP F
centres 0 NOUN F
in 0 ADP F
reduction 0 NOUN F
of 0 ADP F
cancer B-PHYSICAL NOUN F
worry 0 PUNCT F
from 0 ADP F
baseline 0 NOUN F
to 0 ADP F
12 0 NUM F
months 0 NOUN F
and 0 CCONJ F
with 0 ADP F
the 0 DET F
number 0 NOUN F
of 0 ADP F
women 0 NOUN F
who 0 ADP F
were 0 VERB F
recommended 0 VERB F
to 0 PUNCT F
have 0 PUNCT F
mammographic 0 ADJ F
surveillance 0 NOUN F
who 0 ADP F
had 0 ADJ F
not 0 ADV F
received 0 PUNCT F
this 0 PUNCT F
. 0 PUNCT F

Overall 0 ADJ T
, 0 PUNCT F
one-third 0 NOUN F
of 0 ADP F
women 0 NOUN F
for 0 ADP F
whom 0 ADP F
mammography 0 NOUN F
had 0 PUNCT F
been 0 PUNCT F
recommended 0 VERB F
had 0 PUNCT F
not 0 ADV F
been 0 PUNCT F
screened 0 VERB F
within 0 ADP F
1 0 NUM F
year 0 NOUN F
of 0 ADP F
follow-up 0 NOUN F
. 0 PUNCT F

Subsequent 0 ADJ T
attendance 0 NOUN F
at 0 ADP F
the 0 DET F
GP 0 NOUN T
, 0 PUNCT F
but 0 CCONJ F
not 0 ADV F
at 0 ADP F
a 0 DET F
hospital 0 NOUN F
, 0 PUNCT F
was 0 VERB F
associated 0 VERB F
with 0 ADP F
risk 0 NOUN F
level 0 NOUN F
, 0 PUNCT F
but 0 CCONJ F
differences 0 NOUN F
between 0 ADP F
centres 0 NOUN F
could 0 VERB F
not 0 ADV F
be 0 ADP F
analysed 0 VERB F
. 0 PUNCT F

Satisfaction B-OTHER NOUN T
differed 0 VERB F
significantly 0 ADV F
between 0 ADP F
centres 0 NOUN F
for 0 ADP F
4 0 NUM F
: 0 PUNCT F
14 0 NUM F
aspects 0 NOUN F
of 0 ADP F
service 0 NOUN F
provision 0 NOUN F
and 0 CCONJ F
with 0 ADP F
3 0 NUM F
: 0 PUNCT F
17 0 NUM F
items 0 ADJ F
concerning 0 SYM F
communication 0 NOUN F
; 0 PUNCT F
satisfaction 0 NOUN F
was 0 VERB F
high 0 ADJ F
overall 0 ADV F
. 0 PUNCT F

Over 0 ADV T
90 0 NUM F
% 0 SYM F
of 0 ADP F
referring 0 VERB F
doctors 0 NOUN F
were 0 VERB F
moderately/very 0 PUNCT F
satisfied 0 VERB F
with 0 ADP F
the 0 DET F
service 0 NOUN F
, 0 PUNCT F
but 0 CCONJ F
23 0 NUM F
% 0 SYM F
were 0 VERB F
dissatisfied 0 VERB F
with 0 ADP F
waiting 0 PUNCT F
times 0 NOUN F
and 0 CCONJ F
19 0 NUM F
% 0 SYM F
with 0 ADP F
access 0 NOUN F
to 0 ADP F
preventive 0 ADJ F
treatment 0 NOUN F
. 0 PUNCT F

Results 0 NOUN T
differed 0 VERB F
significantly 0 ADV F
between 0 ADP F
centres 0 NOUN F
for 0 ADP F
doctor 0 NOUN F
's 0 PUNCT F
satisfaction 0 NOUN F
with 0 ADP F
the 0 DET F
provision 0 NOUN F
of 0 ADP F
referral 0 ADJ F
criteria 0 NOUN F
and 0 CCONJ F
prescribing 0 VERB F
information 0 NOUN F
. 0 PUNCT F

In 0 ADP T
conclusion 0 NOUN F
, 0 PUNCT F
there 0 PUNCT F
were 0 VERB F
relatively 0 ADV F
few 0 ADJ F
significant 0 ADJ F
differences 0 NOUN F
in 0 ADP F
psychosocial B-MENTAL ADJ F
outcomes I-MENTAL NOUN F
between 0 ADP F
centres 0 NOUN F
, 0 PUNCT F
considering 0 ADP F
the 0 DET F
wide 0 ADJ F
variation 0 NOUN F
in 0 ADP F
service 0 NOUN F
organisation 0 NOUN F
and 0 CCONJ F
activity 0 NOUN F
. 0 PUNCT F

These 0 DET T
significant 0 ADJ F
differences 0 NOUN F
were 0 VERB F
not 0 ADV F
consistent 0 ADJ F
across 0 ADP F
the 0 DET F
centres 0 NOUN F
, 0 PUNCT F
therefore 0 ADV F
, 0 PUNCT F
differences 0 NOUN F
could 0 ADP F
not 0 ADV F
be 0 VERB F
linked 0 VERB F
to 0 ADP F
specific 0 ADJ F
aspects 0 NOUN F
of 0 ADP F
service 0 NOUN F
provision 0 NOUN F
. 0 PUNCT F

Dronabinol 0 NOUN T
versus 0 CCONJ F
megestrol 0 NOUN F
acetate 0 NOUN F
versus 0 CCONJ F
combination 0 NOUN F
therapy 0 NOUN F
for 0 ADP F
cancer-associated 0 VERB F
anorexia 0 NOUN F
: 0 PUNCT F
a 0 DET F
North 0 NOUN T
Central 0 ADJ T
Cancer 0 NOUN T
Treatment 0 NOUN T
Group 0 NOUN T
study 0 NOUN F
. 0 PUNCT F

PURPOSE 0 NOUN T
To 0 ADJ T
determine 0 NOUN F
whether 0 ADP F
dronabinol 0 NOUN F
administered 0 VERB F
alone 0 ADJ F
or 0 CCONJ F
with 0 ADP F
megestrol 0 NOUN F
acetate 0 NOUN F
was 0 VERB F
more 0 DET F
, 0 PUNCT F
less 0 DET F
, 0 PUNCT F
or 0 CCONJ F
equal 0 ADJ F
in 0 ADP F
efficacy 0 NOUN F
to 0 ADP F
single-agent 0 PUNCT F
megestrol 0 NOUN F
acetate 0 NOUN F
for 0 ADP F
palliating 0 VERB F
cancer-associated 0 VERB F
anorexia 0 NOUN F
. 0 PUNCT F

PATIENTS 0 NOUN T
AND 0 CCONJ T
METHODS 0 NOUN T
Four 0 NUM T
hundred 0 NUM F
sixty-nine 0 NOUN F
assessable 0 ADJ F
advanced 0 VERB F
cancer 0 NOUN F
patients 0 NOUN F
were 0 VERB F
randomized 0 ADP F
to 0 ADP F
( 0 PUNCT F
1 0 NUM F
) 0 PUNCT F
oral 0 ADJ F
megestrol 0 NOUN F
acetate 0 NOUN F
800 0 NUM F
mg/d 0 NOUN F
liquid 0 NOUN F
suspension 0 NOUN F
plus 0 CCONJ F
placebo 0 NOUN F
, 0 PUNCT F
( 0 PUNCT F
2 0 NUM F
) 0 PUNCT F
oral 0 ADJ F
dronabinol 0 NOUN F
2.5 0 NUM F
mg 0 NOUN F
twice 0 ADV F
a 0 DET F
day 0 NOUN F
plus 0 CCONJ F
placebo 0 NOUN F
, 0 PUNCT F
or 0 CCONJ F
( 0 PUNCT F
3 0 NUM F
) 0 PUNCT F
both 0 PUNCT F
agents 0 NOUN F
. 0 PUNCT F

Eligible 0 ADJ T
patients 0 NOUN F
acknowledged 0 VERB F
that 0 ADP F
loss 0 NOUN F
of 0 ADP F
appetite 0 NOUN F
or 0 CCONJ F
weight 0 NOUN F
was 0 VERB F
a 0 DET F
problem 0 NOUN F
and 0 CCONJ F
reported 0 VERB F
the 0 DET F
loss 0 NOUN F
of 0 ADP F
5 0 NUM F
pounds 0 NOUN F
or 0 CCONJ F
more 0 DET F
during 0 ADP F
2 0 NUM F
months 0 NOUN F
and/or 0 CCONJ F
a 0 DET F
daily 0 ADJ F
intake 0 NOUN F
of 0 ADP F
less 0 ADV F
than 0 CCONJ F
20 0 NUM F
calories/kg 0 NOUN F
of 0 ADP F
body 0 NOUN F
weight 0 NOUN F
. 0 PUNCT F

RESULTS 0 DET T
Groups 0 PUNCT T
were 0 VERB F
comparable 0 ADJ F
at 0 ADP F
baseline 0 NOUN F
in 0 ADP F
age 0 NOUN F
, 0 PUNCT F
sex 0 NOUN F
, 0 PUNCT F
tumor 0 NOUN F
type 0 NOUN F
, 0 PUNCT F
weight 0 NOUN F
loss 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
performance 0 NOUN F
status 0 NOUN F
. 0 PUNCT F

A 0 DET T
greater 0 PUNCT F
percentage 0 NOUN F
of 0 ADP F
megestrol 0 NOUN F
acetate-treated 0 VERB F
patients 0 NOUN F
reported 0 ADV F
appetite B-PHYSICAL NOUN F
improvement I-PHYSICAL NOUN F
and 0 CCONJ F
weight 0 NOUN F
gain B-PHYSICAL NOUN F
compared 0 VERB F
with 0 ADP F
dronabinol-treated 0 VERB F
patients 0 NOUN F
: 0 PUNCT F
75 0 NUM F
% 0 SYM F
versus 0 CCONJ F
49 0 NUM F
% 0 SYM F
( 0 PUNCT F
P 0 NOUN T
=.0001 0 ADP F
) 0 PUNCT F
for 0 ADP F
appetite 0 NOUN F
and 0 CCONJ F
11 0 NUM F
% 0 SYM F
versus 0 CCONJ F
3 0 NUM F
% 0 SYM F
( 0 PUNCT F
P 0 NOUN T
=.02 0 PUNCT F
) 0 PUNCT F
for 0 ADP F
> 0 ADJ F
or 0 CCONJ F
= 0 SYM F
10 0 NUM F
% 0 SYM F
baseline 0 NOUN F
weight 0 NOUN F
gain 0 NOUN F
. 0 PUNCT F

Combination 0 NOUN T
treatment 0 NOUN F
resulted 0 VERB F
in 0 ADP F
no 0 DET F
significant 0 ADJ F
differences 0 NOUN F
in 0 ADP F
appetite B-PHYSICAL NOUN F
or 0 CCONJ F
weight B-PHYSICAL NOUN F
compared 0 VERB F
with 0 ADP F
megestrol 0 NOUN F
acetate 0 NOUN F
alone 0 ADJ F
. 0 PUNCT F

The 0 DET T
Functional 0 ADJ T
Assessment 0 NOUN T
of 0 ADP F
Anorexia/Cachexia 0 NOUN T
Therapy 0 NOUN T
questionnaire 0 NOUN F
, 0 PUNCT F
which 0 ADP F
emphasizes 0 NOUN F
anorexia-related 0 ADJ F
questions 0 NOUN F
, 0 PUNCT F
demonstrated 0 VERB F
an 0 DET F
improvement 0 NOUN F
in 0 ADP F
quality 0 NOUN F
of 0 ADP F
life 0 NOUN F
( B-OTHER PUNCT F
QOL I-OTHER NOUN T
) I-OTHER PUNCT F
among 0 ADP F
megestrol 0 NOUN F
acetate-treated 0 VERB F
and 0 CCONJ F
combination-treated 0 VERB F
patients 0 NOUN F
. 0 PUNCT F

The 0 DET T
single-item 0 NOUN F
Uniscale 0 NOUN T
, 0 PUNCT F
a 0 DET F
global 0 ADJ F
QOL B-OTHER NOUN T
instrument 0 NOUN F
, 0 PUNCT F
found 0 VERB F
comparable 0 ADJ F
scores 0 NOUN F
. 0 PUNCT F

Toxicity B-ADVERSE-EFFECTS NOUN T
was 0 VERB F
also 0 ADV F
comparable 0 ADJ F
, 0 PUNCT F
with 0 ADP F
the 0 DET F
exception 0 NOUN F
of 0 ADP F
an 0 DET F
increased 0 VERB F
incidence 0 NOUN F
of 0 ADP F
impotence B-PHYSICAL NOUN F
among 0 ADP F
men 0 NOUN F
who 0 ADP F
received 0 VERB F
megestrol 0 NOUN F
acetate 0 NOUN F
. 0 PUNCT F

CONCLUSION 0 NOUN T
In 0 ADP T
the 0 DET F
doses 0 NOUN F
and 0 CCONJ F
schedules 0 NOUN F
we 0 ADJ F
studied 0 VERB F
, 0 PUNCT F
megestrol 0 NUM F
acetate 0 NOUN F
provided 0 ADP F
superior 0 ADJ F
anorexia 0 NOUN F
palliation 0 NOUN F
among 0 ADP F
advanced 0 VERB F
cancer 0 NOUN F
patients 0 NOUN F
compared 0 VERB F
with 0 ADP F
dronabinol 0 NOUN F
alone 0 ADJ F
. 0 PUNCT F

Combination 0 NOUN T
therapy 0 NOUN F
did 0 PUNCT F
not 0 ADV F
appear 0 VERB F
to 0 PART F
confer 0 ADJ F
additional 0 ADJ F
benefit 0 NOUN F
. 0 PUNCT F

Bevacizumab 0 PUNCT T
compared 0 VERB F
with 0 ADP F
macular 0 ADJ F
laser 0 NOUN F
grid 0 NOUN F
photocoagulation 0 NOUN F
for 0 ADP F
cystoid 0 NOUN F
macular 0 ADJ F
edema 0 NOUN F
in 0 ADP F
branch 0 NOUN F
retinal 0 ADJ F
vein 0 NOUN F
occlusion 0 NOUN F
. 0 PUNCT F

INTRODUCTION 0 NOUN T
To 0 ADV T
evaluate 0 NOUN F
the 0 DET F
outcome 0 NOUN F
of 0 ADP F
cystoid 0 NOUN F
macular 0 ADJ F
edema 0 NOUN F
treated 0 VERB F
with 0 ADP F
intravitreal 0 ADJ F
injections 0 NOUN F
of 0 ADP F
bevacizumab 0 PUNCT F
and 0 CCONJ F
macular 0 ADJ F
grid 0 NOUN F
laser 0 NOUN F
photocoagulation 0 NOUN F
( 0 PUNCT F
GLP 0 NOUN T
) 0 PUNCT F
, 0 PUNCT F
in 0 ADP F
patients 0 NOUN F
with 0 ADP F
perfused 0 VERB F
branch 0 NOUN F
retinal 0 ADJ F
vein 0 NOUN F
occlusion 0 NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
Thirty 0 NUM T
eyes 0 NOUN F
of 0 ADP F
30 0 NUM F
consecutive 0 ADJ F
patients 0 NOUN F
with 0 ADP F
cystoid 0 NOUN F
macular 0 ADJ F
edema 0 NOUN F
secondary 0 ADJ F
to 0 ADP F
nonischemic 0 ADJ F
branch 0 NOUN F
retinal 0 ADJ F
vein 0 NOUN F
occlusion 0 NOUN F
were 0 VERB F
assigned 0 VERB F
to 0 ADP F
either 0 CCONJ F
GLP 0 NOUN T
group 0 NOUN F
or 0 CCONJ F
to 0 ADP F
intravitreal 0 ADJ F
bevacizumab 0 PUNCT F
( 0 PUNCT F
IB 0 NOUN T
) 0 PUNCT F
group 0 NOUN F
. 0 PUNCT F

Complete B-PHYSICAL ADJ T
ophthalmologic I-PHYSICAL ADJ F
examinations I-PHYSICAL NOUN F
were 0 VERB F
performed 0 VERB F
just 0 ADV F
before 0 PUNCT F
GLP 0 NOUN T
and 0 CCONJ F
IB 0 NOUN T
injection 0 NOUN F
at 0 ADP F
1 0 NUM F
, 0 PUNCT F
3 0 NUM F
, 0 PUNCT F
6 0 NUM F
, 0 PUNCT F
and 0 CCONJ F
12 0 NUM F
months 0 NOUN F
after 0 ADP F
treatment 0 NOUN F
. 0 PUNCT F

Changes 0 NOUN T
in 0 ADP F
logarithm 0 NOUN F
of B-PHYSICAL ADP F
minimum I-PHYSICAL NOUN F
angle I-PHYSICAL NOUN F
of I-PHYSICAL ADP F
resolution I-PHYSICAL NOUN F
( I-PHYSICAL PUNCT F
logMAR I-PHYSICAL NUM F
) I-PHYSICAL PUNCT F
best-corrected I-PHYSICAL VERB F
visual I-PHYSICAL ADJ F
acuity I-PHYSICAL NOUN F
( I-PHYSICAL PUNCT F
BCVA I-PHYSICAL NOUN T
) B-PHYSICAL PUNCT F
, 0 PUNCT F
central B-PHYSICAL ADJ F
macular I-PHYSICAL ADJ F
thickness I-PHYSICAL NOUN F
( I-PHYSICAL PUNCT F
CMT I-PHYSICAL NOUN T
) I-PHYSICAL PUNCT F
shown I-PHYSICAL VERB F
by I-PHYSICAL ADP F
optical B-PHYSICAL ADJ F
coherence 0 NOUN F
tomography-3 B-PHYSICAL NOUN F
were 0 VERB F
evaluated 0 VERB F
. 0 PUNCT F

RESULTS 0 NOUN T
Baseline 0 NOUN T
BCVA 0 NOUN T
( 0 PUNCT F
logMAR 0 NUM F
) 0 PUNCT F
and 0 CCONJ F
CMT 0 NOUN T
were 0 VERB F
, 0 PUNCT F
respectively 0 ADV F
, 0 PUNCT F
0.89 0 NUM F
+/- 0 SYM F
0.13 0 NUM F
and 0 CCONJ F
650 0 NUM F
+/- 0 SYM F
140 0 NUM F
microm 0 NOUN F
for 0 ADP F
the 0 DET F
GLP 0 NOUN T
group 0 NOUN F
, 0 PUNCT F
0.87 0 NUM F
+/- 0 SYM F
0.16 0 NUM F
and 0 CCONJ F
690 0 NUM F
+/- 0 SYM F
120 0 NUM F
microm 0 NOUN F
for 0 ADP F
the 0 DET F
IB 0 NOUN T
group 0 NOUN F
. 0 PUNCT F

After 0 ADP T
the 0 DET F
treatment 0 NOUN F
, 0 PUNCT F
at 0 ADP F
1 0 NUM F
, 0 PUNCT F
3 0 NUM F
, 0 PUNCT F
6 0 NUM F
, 0 PUNCT F
and 0 CCONJ F
12 0 NUM F
months 0 NOUN F
in 0 ADP F
the 0 DET F
GLP 0 NOUN T
group 0 NOUN F
, 0 PUNCT F
BCVA B-PHYSICAL NOUN T
had 0 PUNCT F
improved 0 VERB F
by 0 ADP F
0.19 0 NUM F
, 0 PUNCT F
0.22 0 NUM F
, 0 PUNCT F
0.21 0 NUM F
, 0 PUNCT F
and 0 CCONJ F
0.20 0 NUM F
logMAR 0 NUM F
, 0 PUNCT F
CMT B-PHYSICAL NOUN T
had 0 PUNCT F
decreased 0 VERB F
by 0 ADP F
40 0 NUM F
% 0 SYM F
, 0 PUNCT F
41.3 0 NUM F
% 0 SYM F
, 0 PUNCT F
40.5 0 NUM F
% 0 SYM F
, 0 PUNCT F
and 0 CCONJ F
42 0 NUM F
% 0 SYM F
. 0 PUNCT F

In 0 ADP T
the 0 DET F
IB 0 NOUN T
group 0 NOUN F
, 0 PUNCT F
BCVA B-PHYSICAL NOUN T
had 0 PUNCT F
improved 0 VERB F
by 0 ADP F
0.31 0 NUM F
, 0 PUNCT F
0.32 0 NUM F
, 0 PUNCT F
0.30 0 NUM F
, 0 PUNCT F
and 0 CCONJ F
0.31 0 NUM F
logMAR B-PHYSICAL NUM F
and 0 CCONJ F
CMT B-PHYSICAL NOUN T
had 0 PUNCT F
decreased 0 VERB F
by 0 ADP F
59.5 0 NUM F
% 0 SYM F
, 0 PUNCT F
59 0 NUM F
% 0 SYM F
, 0 PUNCT F
60 0 NUM F
% 0 SYM F
, 0 PUNCT F
and 0 CCONJ F
60.3 0 NUM F
% 0 SYM F
. 0 PUNCT F

The 0 DET T
group 0 NOUN F
receiving 0 CCONJ F
bevacizumab 0 ADJ F
had 0 PUNCT F
better 0 PUNCT F
BCVA B-PHYSICAL NOUN T
and 0 CCONJ F
lower 0 PUNCT F
CMT B-PHYSICAL NOUN T
values 0 NOUN F
at 0 ADP F
all 0 DET F
time 0 NOUN F
points 0 NOUN F
( 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.05 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

CONCLUSION 0 NOUN T
Intravitreal 0 PUNCT T
bevacizumab 0 PUNCT F
injection 0 NOUN F
improves 0 PUNCT F

Effects 0 NOUN T
of 0 ADP F
a 0 DET F
caregiver 0 NOUN F
intervention 0 NOUN F
on 0 ADP F
negative 0 ADJ F
caregiver 0 NOUN F
appraisals 0 NOUN F
of 0 ADP F
behavior 0 ADJ F
problems 0 NOUN F
in 0 ADP F
patients 0 NOUN F
with 0 ADP F
Alzheimer 0 PUNCT T
's 0 PUNCT F
disease 0 NOUN F
: 0 PUNCT F
results 0 NOUN F
of 0 ADP F
a 0 DET F
randomized 0 VERB F
trial 0 NOUN F
. 0 PUNCT F

Behavioral 0 ADJ T
problems 0 NOUN F
are 0 VERB F
among 0 ADP F
the 0 DET F
most 0 VERB F
challenging 0 VERB F
aspects 0 NOUN F
of 0 ADP F
caring 0 ADJ F
for 0 ADP F
a 0 DET F
person 0 NOUN F
with 0 ADP F
Alzheimer 0 PUNCT T
's 0 PUNCT F
disease 0 NOUN F
. 0 PUNCT F

A 0 DET T
sample 0 NOUN F
of 0 ADP F
406 0 NUM F
spouses-caregivers 0 NOUN F
of 0 ADP F
patients 0 NOUN F
with 0 ADP F
Alzheimer 0 PUNCT T
's 0 PUNCT F
disease 0 NOUN F
was 0 VERB F
randomized 0 VERB F
to 0 ADP F
an 0 DET F
active 0 ADJ F
multicomponent 0 PUNCT F
counseling 0 PUNCT F
and 0 CCONJ F
support 0 ADP F
intervention 0 NOUN F
condition 0 NOUN F
or 0 CCONJ F
to 0 ADP F
a 0 DET F
usual 0 ADJ F
care 0 NOUN F
condition 0 NOUN F
. 0 PUNCT F

Caregivers 0 NOUN T
reported 0 VERB F
on 0 ADP F
the 0 DET F
frequency 0 NOUN F
of 0 ADP F
troublesome B-MENTAL PUNCT F
patient I-MENTAL NOUN F
behaviors I-MENTAL NOUN F
and I-MENTAL CCONJ F
their I-MENTAL ADJ F
reactions I-MENTAL NOUN F
to I-MENTAL ADP F
them 0 PUNCT F
at 0 ADP F
baseline 0 NOUN F
and 0 CCONJ F
at 0 ADP F
regular 0 ADJ F
follow-up 0 NOUN F
interviews 0 NOUN F
. 0 PUNCT F

Random-effects 0 VERB T
regression 0 NOUN F
models 0 NOUN F
over 0 ADP F
the 0 DET F
first 0 ADJ F
4 0 NUM F
years 0 NOUN F
after 0 ADP F
randomization 0 NOUN F
revealed 0 VERB F
that 0 ADP F
, 0 PUNCT F
although 0 ADP F
the 0 DET F
intervention 0 NOUN F
did 0 DET F
not 0 ADV F
affect 0 VERB F
the 0 DET F
frequency 0 NOUN F
of 0 ADP F
patient 0 NOUN F
behavioral 0 ADJ F
problems 0 NOUN F
, 0 PUNCT F
it 0 PROPN F
did 0 PUNCT F
significantly 0 ADV F
reduce 0 VERB F
caregivers B-MENTAL NOUN F
' 0 PUNCT F
reaction B-MENTAL PUNCT F

Etanercept 0 PUNCT T
treatment 0 NOUN F
in 0 ADP F
adults 0 NOUN F
with 0 ADP F
established 0 ADP F
rheumatoid 0 ADJ F
arthritis 0 NOUN F
: 0 PUNCT F
7 0 NUM F
years 0 NOUN F
of 0 ADP F
clinical 0 ADJ F
experience 0 NOUN F
. 0 PUNCT F

OBJECTIVE 0 NOUN T
To 0 PROPN T
evaluate 0 NOUN F
safety B-OTHER NOUN F
and 0 CCONJ F
efficacy 0 NOUN F
of 0 ADP F
longterm 0 NOUN F
etanercept 0 PUNCT F
treatment 0 NOUN F
in 0 ADP F
patients 0 NOUN F
with 0 ADP F
disease 0 NOUN F
modifying 0 NUM F
antirheumatic 0 ADJ F
drug 0 NOUN F
( 0 PUNCT F
DMARD 0 NOUN T
) 0 PUNCT F
refractory 0 ADJ F
rheumatoid 0 ADJ F
arthritis 0 NOUN F
( 0 PUNCT F
RA 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

METHODS 0 NOUN T
Safety 0 NOUN T
results 0 NOUN F
are 0 VERB F
reported 0 VERB F
for 0 ADP F
714 0 NUM F
patients 0 NOUN F
who 0 PROPN F
received 0 VERB F
etanercept 0 PUNCT F
in 0 ADP F
one 0 NUM F
of 0 ADP F
7 0 NUM F
initial 0 ADJ F
trials 0 NOUN F
or 0 CCONJ F
a 0 DET F
longterm 0 NOUN F
extension 0 NOUN F
. 0 PUNCT F

Efficacy 0 NOUN T
results 0 CCONJ F
are 0 VERB F
reported 0 VERB F
for 0 ADP F
581 0 NUM F
patients 0 NOUN F
who 0 PROPN F
enrolled 0 PUNCT F
in 0 ADP F
the 0 DET F
extension 0 NOUN F
. 0 PUNCT F

RESULTS 0 NOUN T
Of 0 ADP T
the 0 DET F
714 0 NUM F
patients 0 NOUN F
enrolled 0 VERB F
in 0 ADP F
the 0 DET F
initial 0 ADJ F
trials 0 NOUN F
, 0 PUNCT F
581 0 NUM F
( 0 PUNCT F
81 0 NUM F
% 0 SYM F
) 0 PUNCT F
enrolled 0 ADV F
in 0 ADP F
the 0 DET F
extension 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
388 0 NUM F
( 0 PUNCT F
54 0 NUM F
% 0 SYM F
) 0 PUNCT F
patients 0 NOUN F
are 0 VERB F
continuing 0 PUNCT F
to 0 DET F
receive 0 ADP F
etanercept 0 PUNCT F
therapy 0 NOUN F
. 0 PUNCT F

The 0 DET T
longest 0 PUNCT F
individual 0 ADJ F
treatment 0 NOUN F
was 0 VERB F
8.2 0 NUM F
years 0 NOUN F
, 0 PUNCT F
with 0 ADP F
3139 0 NUM F
total 0 ADJ F
patient-years 0 NOUN F
of 0 ADP F
etanercept 0 PUNCT F
exposure 0 NOUN F
. 0 PUNCT F

Rates 0 NOUN T
of 0 ADP F
serious B-ADVERSE-EFFECTS ADJ F
adverse I-ADVERSE-EFFECTS ADJ F
events I-ADVERSE-EFFECTS NOUN F
( 0 PUNCT F
overall 0 PUNCT F
rate=14.8 0 PUNCT F
events/100 0 PUNCT F
patient-yrs 0 PUNCT F
) 0 PUNCT F
, 0 PUNCT F
serious B-ADVERSE-EFFECTS ADJ F
infections I-ADVERSE-EFFECTS NOUN F
( 0 PUNCT F
overall 0 ADJ F
rate=4.2 0 NOUN F
events/100 0 PUNCT F
patient-yrs 0 PUNCT F
) 0 PUNCT F
, 0 PUNCT F
cancer B-PHYSICAL NOUN F
( 0 PUNCT F
overall 0 PUNCT F
rate=1.0 0 ADP F
events/100 0 PUNCT F
patient-yrs 0 PUNCT F
) 0 PUNCT F
, 0 PUNCT F
and 0 CCONJ F
deaths B-MORTALITY NOUN F
( 0 PUNCT F
overall 0 PUNCT F
rate=0.7 0 PUNCT F
events/100 0 PUNCT F
patient-yrs 0 PUNCT F
) 0 PUNCT F
were 0 VERB F
stable 0 ADJ F
each 0 DET F
year 0 NOUN F
, 0 PUNCT F
through 0 ADP F
8 0 NUM F
years 0 NOUN F
of 0 ADP F
etanercept 0 PUNCT F
exposure 0 NOUN F
. 0 PUNCT F

For 0 ADP T
356 0 NUM F
patients 0 NOUN F
who 0 ADP F
completed 0 PROPN F
6 0 NUM F
years 0 NOUN F
of 0 ADP F
etanercept 0 PUNCT F
treatment 0 NOUN F
, 0 PUNCT F
response 0 NOUN F
rates B-OTHER NOUN F
were 0 VERB F
ACR20=73 0 ADP T
% 0 SYM F
, 0 PUNCT F
ACR50=52 0 ADJ T
% 0 SYM F
, 0 PUNCT F
ACR70=27 0 NOUN T
% 0 SYM F
, 0 PUNCT F
DAS28 0 NOUN T
CRP 0 NOUN T
good 0 ADJ F
response=52 0 NOUN F
% 0 SYM F
, 0 PUNCT F
and 0 CCONJ F
DAS28 0 NOUN T
CRP 0 NOUN T
remission=37 0 NOUN F
% 0 SYM F
of 0 ADP F
patients 0 NOUN F
. 0 PUNCT F

Similar 0 ADJ T
responses 0 NOUN F
occurred 0 VERB F
in 0 ADP F
167 0 NUM F
patients 0 NOUN F
who 0 ADP F
completed 0 CCONJ F
Year 0 NOUN T
7 0 NUM F
. 0 PUNCT F

Doses B-OTHER NOUN T
of 0 ADP F
concomitant 0 ADJ F
methotrexate 0 NOUN F
or 0 CCONJ F
corticosteroids 0 NOUN F
were 0 VERB F
reduced 0 VERB F
in 0 ADP F
many 0 DET F
patients 0 NOUN F
who 0 PROPN F
maintained 0 VERB F
clinical 0 ADJ F
responses 0 NOUN F
. 0 PUNCT F

CONCLUSION 0 NOUN T
The 0 DET T
safety B-OTHER NOUN F
profile I-OTHER NOUN F
of 0 ADP F
etanercept 0 PUNCT F
was 0 VERB F
consistent 0 ADJ F
over 0 PUNCT F
time 0 NOUN F
, 0 PUNCT F
with 0 ADP F
rates 0 NOUN F
of 0 ADP F
adverse B-ADVERSE-EFFECTS ADJ F
events I-ADVERSE-EFFECTS NOUN F
similar 0 ADJ F
to 0 ADP F
those 0 DET F
reported 0 VERB F
for 0 ADP F
patients 0 NOUN F
with 0 ADP F
RA 0 NOUN T
in 0 ADP F
general 0 NOUN F
. 0 PUNCT F

Durable 0 ADJ T
clinical 0 ADJ F
responses 0 NOUN F
were 0 VERB F
observed 0 VERB F
in 0 ADP F
some 0 DET F
patients 0 NOUN F
for 0 ADP F
7 0 NUM F
years 0 NOUN F
or 0 CCONJ F
more 0 DET F
. 0 PUNCT F

The 0 DET T
benefit-to-risk 0 NOUN F
ratio 0 NOUN F
for 0 ADP F
longterm 0 NOUN F
etanercept 0 PUNCT F
treatment 0 NOUN F
remains 0 NOUN F
highly 0 ADV F
favorable 0 ADJ F
. 0 PUNCT F

Hypoxic 0 ADJ T
exercise 0 NOUN F
training 0 ADV F
reduces 0 SYM F
senescent B-PHYSICAL ADJ F
T-lymphocyte I-PHYSICAL NOUN T
subsets I-PHYSICAL NOUN F
in I-PHYSICAL ADP F
blood I-PHYSICAL NOUN F
. 0 PUNCT F

The 0 DET T
integration 0 NOUN F
and 0 CCONJ F
control 0 NOUN F
of 0 ADP F
systemic 0 ADJ F
immune 0 ADJ F
responses 0 NOUN F
depends 0 NOUN F
on 0 ADP F
the 0 DET F
regulated 0 ADP F
trafficking 0 ADJ F
of 0 ADP F
T-lymphocytes 0 NOUN T
. 0 PUNCT F

This 0 DET T
study 0 NOUN F
elucidates 0 ADV F
how 0 ADP F
various 0 ADJ F
exercises 0 DET F
regimens 0 CCONJ F
with/without 0 PUNCT F
hypoxia 0 NOUN F
affect 0 VERB F
phenotypic B-PHYSICAL ADJ F
characteristics I-PHYSICAL NOUN F
of I-PHYSICAL ADP F
T-lymphocyte I-PHYSICAL NOUN T
subsets I-PHYSICAL NOUN F
in I-PHYSICAL ADP F
blood I-PHYSICAL NOUN F
. 0 PUNCT F

Fifty 0 NUM T
sedentary 0 ADJ F
males 0 NOUN F
were 0 VERB F
randomly 0 ADV F
divided 0 VERB F
into 0 ADP F
five 0 NUM F
groups 0 NOUN F
. 0 PUNCT F

Each 0 DET T
group 0 NOUN F
( 0 PUNCT F
n=10 0 NUM F
) 0 PUNCT F
received 0 VERB F
one 0 NUM F
of 0 ADP F
five 0 NUM F
interventions 0 NOUN F
: 0 PUNCT F
normoxic 0 ADJ F
( 0 PUNCT F
21 0 NUM F
% 0 SYM F
O? 0 NOUN T
) 0 PUNCT F
resting 0 PUNCT F
( 0 PUNCT F
N-C 0 NOUN T
) 0 PUNCT F
, 0 PUNCT F
hypoxic 0 ADJ F
( 0 PUNCT F
15 0 NUM F
% 0 SYM F
O? 0 NOUN T
) 0 PUNCT F
resting 0 PUNCT F
( 0 PUNCT F
H-C 0 NOUN T
) 0 PUNCT F
, 0 PUNCT F
normoxic 0 ADJ F
exercise 0 NOUN F
( 0 PUNCT F
50 0 NUM F
% 0 SYM F
W 0 NOUN T
( 0 PUNCT F
max 0 NOUN F
) 0 PUNCT F
under 0 ADP F
21 0 NUM F
% 0 SYM F
O? 0 NOUN T
, 0 PUNCT F
N-T 0 NOUN T
) 0 PUNCT F
, 0 PUNCT F
hypoxic-relative 0 ADJ F
exercise 0 NOUN F
( 0 PUNCT F
50 0 NUM F
% 0 SYM F
maximal 0 ADJ F
heart 0 NOUN F
rate 0 NOUN F
reserve 0 NOUN F
under 0 ADP F
15 0 NUM F
% 0 SYM F
O? 0 NOUN T
, 0 PUNCT F
H-RT 0 NOUN T
) 0 PUNCT F
, 0 PUNCT F
or 0 CCONJ F
hypoxic-absolute 0 NOUN F
exercise 0 NOUN F
( 0 PUNCT F
50 0 NUM F
% 0 SYM F
W 0 NOUN T
( 0 PUNCT F
max 0 NOUN F
) 0 PUNCT F
under 0 ADP F
15 0 NUM F
% 0 SYM F
O? 0 NOUN T
, 0 PUNCT F
H-AT 0 NOUN T
) 0 PUNCT F
for 0 ADP F
30 0 NUM F
min/day 0 PUNCT F
, 0 PUNCT F
5 0 NUM F
days/week 0 NOUN F
for 0 ADP F
4 0 NUM F
weeks 0 NOUN F
. 0 PUNCT F

Before 0 ADP T
the 0 DET F
intervention 0 NOUN F
, 0 PUNCT F
strenuous 0 ADJ F
exercise 0 NOUN F
up 0 PUNCT F
to 0 ADP F
exhaustion 0 NOUN F
increased 0 PUNCT F
the 0 DET F
mobilization 0 NOUN F
of 0 ADP F
CD3 0 NOUN T
, 0 PUNCT F
CD4 0 NOUN T
, 0 PUNCT F
CD8 0 NOUN T
, 0 PUNCT F
or 0 CCONJ F
CD8 0 NOUN T
( 0 PUNCT F
bright 0 ADJ F
) 0 PUNCT F
lymphocytes 0 NOUN F
expressing 0 PROPN F
activated 0 NOUN F
( 0 PUNCT F
CD11a 0 NOUN T
) 0 PUNCT F
or 0 CCONJ F
senescent 0 ADJ F
( 0 PUNCT F
KLRG1 0 NOUN T
) 0 PUNCT F
molecules 0 NOUN F
into 0 ADP F
the 0 DET F
peripheral 0 ADJ F
blood 0 NOUN F
compartment 0 NOUN F
. 0 PUNCT F

The 0 DET T
H-AT 0 NOUN T
for 0 ADP F
4 0 NUM F
weeks 0 NOUN F
up-regulated 0 ADP F
co-stimulatory 0 PUNCT F
molecule 0 NOUN F
CD28 0 NOUN T
expression 0 NOUN F
and 0 CCONJ F
was 0 VERB F
accompanied 0 VERB F
by 0 ADP F
depressed 0 VERB F
KLRG1 0 NOUN T
level 0 NOUN F
on 0 ADP F
CD3 0 NOUN T
, 0 PUNCT F
CD4 0 NOUN T
, 0 PUNCT F
CD8 0 NOUN T
, 0 PUNCT F
or 0 CCONJ F
CD8 0 NOUN T
( 0 PUNCT F
bright 0 ADJ F
) 0 PUNCT F
lymphocytes 0 NOUN F
at 0 ADP F
rest 0 NOUN F
or 0 CCONJ F
following 0 PUNCT F
exercise 0 NOUN F
. 0 PUNCT F

Simultaneously 0 ADV T
, 0 PUNCT F
this 0 DET F
intervention 0 NOUN F
increased 0 VERB F
interferon-? 0 PUNCT F
( 0 PUNCT F
IFN-? 0 NOUN T
) 0 PUNCT F
level 0 NOUN F
and 0 CCONJ F
unchanged 0 VERB F
interleukin-4 0 NOUN F
level 0 NOUN F
, 0 PUNCT F
as 0 PUNCT F
well 0 PUNCT F
as 0 CCONJ F
, 0 PUNCT F
decreased 0 VERB F
myeloperoxidase 0 NOUN F
( 0 PUNCT F
MPO 0 NOUN T
) 0 PUNCT F
and 0 CCONJ F
interleukin-6 0 NOUN F
levels 0 NOUN F
in 0 ADP F
plasma 0 NOUN F
. 0 PUNCT F

However 0 ADV T
, 0 PUNCT F
no 0 DET F
significant 0 ADJ F
changes 0 NOUN F
in 0 ADP F
resting 0 VERB F
and 0 CCONJ F
exercise-induced 0 VERB F
mobilizations 0 NOUN F
of 0 ADP F
various 0 ADJ F
T-lymphocyte 0 NOUN T
subsets 0 NOUN F
and 0 CCONJ F
productions 0 NOUN F
of 0 ADP F
cytokines 0 NOUN F
and 0 CCONJ F
MPO 0 NOUN T
occurred 0 VERB F
following 0 VERB F
the 0 DET F
N-C 0 NOUN T
, 0 PUNCT F
H-C 0 NOUN T
, 0 PUNCT F
N-T 0 NOUN T
, 0 PUNCT F
and 0 CCONJ F
H-RT 0 NOUN T
interventions 0 NOUN F
. 0 PUNCT F

Therefore 0 ADV T
, 0 PUNCT F
we 0 PRON F
conclude 0 VERB F
that 0 ADP F
4-week 0 NOUN F
H-AT 0 NOUN T
intervention 0 NOUN F
reduced 0 CCONJ F
senescent 0 ADJ F
T-lymphocyte 0 NOUN T
subsets 0 NOUN F
with 0 ADP F
increasing 0 ADJ F
IFN-? 0 NOUN T
level 0 NOUN F
in 0 ADP F
blood 0 NOUN F
, 0 PUNCT F
which 0 DET F
responses 0 NOUN F
are 0 VERB F
accompanied 0 VERB F
by 0 ADP F
depressed 0 VERB F
oxidative 0 ADJ F
stress 0 NOUN F
and 0 CCONJ F
pro-inflammatory 0 ADJ F
cytokine 0 NOUN F
production 0 NOUN F
. 0 PUNCT F

These 0 DET T
findings 0 NOUN F
can 0 PROPN F
help 0 VERB F
to 0 ADJ F
determine 0 ADV F
an 0 DET F
effective 0 ADJ F
hypoxic 0 ADJ F
exercise 0 NOUN F
regimen 0 NOUN F
to 0 PART F
minimize 0 NOUN F
immune 0 ADJ F
dysfunction 0 NOUN F
by 0 ADP F
retarding 0 PUNCT F
T-lymphocyte 0 NOUN T
senescence 0 ADP F
. 0 PUNCT F

Should 0 CCONJ T
insertion 0 NOUN F
of 0 ADP F
intramedullary 0 ADJ F
nails 0 NOUN F
for 0 ADP F
tibial 0 ADJ F
fractures 0 NOUN F
be 0 CCONJ F
with 0 ADP F
or 0 CCONJ F
without 0 ADP F
reaming 0 ADP F
? 0 PUNCT F

A 0 DET T
prospective 0 ADJ F
, 0 PUNCT F
randomized 0 ADP F
study 0 NOUN F
with 0 ADP F
3.8 0 NUM F
years 0 NOUN F
' 0 PUNCT F
follow-up 0 NOUN F
. 0 PUNCT F

OBJECTIVE 0 NOUN T
To 0 PROPN T
determine 0 NOUN F
if 0 PUNCT F
any 0 DET F
differences 0 NOUN F
exist 0 VERB F
in 0 ADP F
healing B-PHYSICAL VERB F
and 0 CCONJ F
complications 0 NOUN F
between 0 ADP F
reamed 0 VERB F
and 0 CCONJ F
unreamed 0 VERB F
nailing 0 VERB F
in 0 ADP F
patients 0 NOUN F
with 0 ADP F
tibial 0 ADJ F
shaft 0 ADJ F
fractures 0 NOUN F
. 0 PUNCT F

DESIGN 0 NOUN T
Prospective 0 ADJ T
, 0 PUNCT F
randomized 0 VERB F
. 0 PUNCT F

SETTING 0 NUM T
Level 0 NOUN T
1 0 NUM F
trauma 0 NOUN F
center 0 NOUN F
. 0 PUNCT F

PATIENTS 0 NOUN T
Forty-five 0 PUNCT T
patients 0 NOUN F
with 0 ADP F
displaced 0 VERB F
closed 0 VERB F
and 0 CCONJ F
open 0 ADJ F
Gustilo 0 NOUN T
type 0 NOUN F
I-IIIA 0 ADJ T
fractures 0 NOUN F
of 0 ADP F
the 0 DET F
central 0 ADJ F
two 0 NUM F
thirds 0 NOUN F
of 0 ADP F
the 0 DET F
tibia 0 NOUN F
. 0 PUNCT F

INTERVENTION 0 NOUN T
Stabilization 0 NOUN T
of 0 ADP F
tibial 0 ADJ F
fractures 0 NOUN F
either 0 CCONJ F
with 0 ADP F
a 0 DET F
slotted 0 VERB F
, 0 PUNCT F
stainless 0 NOUN F
steel 0 NOUN F
reamed 0 VERB F
nail 0 NOUN F
or 0 CCONJ F
a 0 DET F
solid 0 ADP F
, 0 PUNCT F
titanium 0 NOUN F
unreamed 0 NOUN F
nail 0 NOUN F
. 0 PUNCT F

MAIN 0 ADJ T
OUTCOME 0 NOUN T
MEASUREMENTS 0 NOUN T
Nonunions B-PHYSICAL NOUN T
, 0 PUNCT F
time B-OTHER NOUN F
to I-OTHER ADP F
fracture I-OTHER NOUN F
healing I-OTHER VERB F
, I-OTHER PUNCT F
and I-OTHER CCONJ F
rate I-OTHER NOUN F
of I-OTHER ADP F
malunions I-OTHER NOUN F
. 0 PUNCT F

RESULTS 0 PUNCT T
The 0 DET T
average 0 ADJ F
time B-OTHER NOUN F
to I-OTHER ADP F
fracture I-OTHER NOUN F
healing I-OTHER VERB F
was 0 VERB F
16.7 0 NUM F
weeks 0 NOUN F
in 0 ADP F
the 0 DET F
reamed 0 VERB F
group 0 NOUN F
and 0 CCONJ F
25.7 0 NUM F
weeks 0 NOUN F
in 0 ADP F
the 0 DET F
unreamed 0 VERB F
group 0 NOUN F
. 0 PUNCT F

The 0 DET T
difference 0 NOUN F
was 0 VERB F
statistically 0 ADV F
significant 0 ADJ F
( 0 PUNCT F
P 0 NOUN T
= 0 SYM F
0.004 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

There 0 PUNCT T
were 0 VERB F
three 0 NUM F
nonunions B-PHYSICAL NOUN F
, 0 PUNCT F
all 0 CCONJ F
in 0 ADP F
the 0 DET F
unreamed 0 VERB F
nail 0 NOUN F
group 0 NOUN F
. 0 PUNCT F

Two 0 NUM T
of 0 ADP F
these 0 DET F
fractures 0 NOUN F
healed 0 VERB F
after 0 ADP F
dynamization B-PHYSICAL NOUN F
by I-PHYSICAL ADP F
removing I-PHYSICAL VERB F
static I-PHYSICAL ADJ F
interlocking I-PHYSICAL ADP F
screws I-PHYSICAL NOUN F
. 0 PUNCT F

The 0 DET T
third 0 ADJ F
nonunion 0 NOUN F
did 0 VERB F
not 0 ADV F
heal B-PHYSICAL PUNCT F
despite 0 ADP F
exchange 0 NOUN F
reamed 0 DET F
nailing 0 VERB F
2 0 NUM F
years 0 NOUN F
after 0 ADP F
the 0 DET F
primary 0 ADJ F
surgery 0 NOUN F
and 0 CCONJ F
dynamization 0 NOUN F
with 0 ADP F
a 0 DET F
fibular 0 ADJ F
osteotomy 0 NOUN F
after 0 ADP F
an 0 DET F
additional 0 ADJ F
1 0 NUM F
year 0 NOUN F
. 0 PUNCT F

There 0 PUNCT T
were 0 VERB F
two 0 NUM F
malunions B-PHYSICAL NOUN F
in 0 ADP F
the 0 DET F
reamed 0 VERB F
group 0 NOUN F
and 0 CCONJ F
four 0 NUM F
malunions B-PHYSICAL NOUN F
in 0 ADP F
the 0 DET F
unreamed 0 VERB F
group 0 NOUN F
. 0 PUNCT F

There 0 PUNCT T
were 0 VERB F
no 0 DET F
differences 0 NOUN F
for 0 ADP F
all 0 DET F
other 0 ADJ F
outcome 0 NOUN F
measurements 0 NOUN F
. 0 PUNCT F

CONCLUSION 0 NOUN T
Unreamed 0 PUNCT T
nailing 0 VERB F
in 0 ADP F
patients 0 NOUN F
with 0 ADP F
tibial 0 ADJ F
shaft 0 ADJ F
fractures 0 NOUN F
may 0 VERB F
be 0 VERB F
associated 0 VERB F
with 0 ADP F
higher 0 PUNCT F
rates 0 NOUN F
of 0 ADP F
secondary B-OTHER ADJ F
operations I-OTHER NOUN F
and 0 CCONJ F
malunions B-OTHER NOUN F
compared 0 VERB F
with 0 ADP F
reamed 0 VERB F
nailing 0 VERB F
. 0 PUNCT F

The 0 DET T
time B-OTHER NOUN F
to I-OTHER ADP F
fracture I-OTHER NOUN F
healing I-OTHER VERB F
was 0 VERB F
significantly 0 ADV F
longer 0 PUNCT F
with 0 ADP F
unreamed 0 NOUN F
nails 0 VERB F
. 0 PUNCT F

Dofequidar 0 NOUN T
fumarate 0 NOUN F
( 0 PUNCT F
MS-209 0 NOUN T
) 0 PUNCT F
in 0 ADP F
combination 0 NOUN F
with 0 ADP F
cyclophosphamide 0 NOUN F
, 0 PUNCT F
doxorubicin 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
fluorouracil 0 NOUN F
for 0 ADP F
patients 0 NOUN F
with 0 ADP F
advanced 0 VERB F
or 0 CCONJ F
recurrent 0 ADJ F
breast 0 NOUN F
cancer 0 NOUN F
. 0 PUNCT F

PURPOSE 0 NOUN T
To 0 ADJ T
evaluate 0 NOUN F
the 0 DET F
efficacy 0 NOUN F
and 0 CCONJ F
tolerability B-OTHER NOUN F
of 0 ADP F
dofequidar 0 NOUN F
plus 0 CCONJ F
cyclophosphamide 0 NOUN F
, 0 PUNCT F
doxorubicin 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
fluorouracil 0 NOUN F
( 0 PUNCT F
CAF 0 NOUN T
) 0 PUNCT F
therapy 0 NOUN F
in 0 ADP F
comparison 0 NOUN F
with 0 ADP F
CAF 0 NOUN T
alone 0 ADJ F
, 0 PUNCT F
in 0 ADP F
patients 0 NOUN F
with 0 ADP F
advanced 0 VERB F
or 0 CCONJ F
recurrent 0 ADJ F
breast 0 NOUN F
cancer 0 NOUN F
. 0 PUNCT F

Dofequidar 0 NOUN T
is 0 VERB F
a 0 DET F
novel 0 ADJ F
, 0 PUNCT F
orally 0 ADV F
active 0 ADJ F
quinoline 0 NUM F
derivative 0 NOUN F
that 0 ADP F
reverses 0 PUNCT F
multidrug 0 NOUN F
resistance 0 NOUN F
. 0 PUNCT F

PATIENTS 0 NOUN T
AND 0 CCONJ T
METHODS 0 NOUN T
In 0 ADP T
this 0 DET F
randomized 0 VERB F
, 0 PUNCT F
double-blind 0 ADJ F
, 0 PUNCT F
placebo-controlled 0 VERB F
trial 0 NOUN F
, 0 PUNCT F
patients 0 NOUN F
were 0 VERB F
treated 0 VERB F
with 0 ADP F
six 0 NUM F
cycles 0 NOUN F
of 0 ADP F
CAF 0 NOUN T
therapy 0 NOUN F
: 0 PUNCT F
28 0 NUM F
days/cycle 0 NOUN F
, 0 PUNCT F
with 0 ADP F
doxorubicin 0 NOUN F
( 0 PUNCT F
25 0 ADP F
mg/m2 0 ADV F
) 0 PUNCT F
and 0 CCONJ F
fluorouracil 0 NOUN F
( 0 PUNCT F
500 0 NUM F
mg/m2 0 ADV F
) 0 PUNCT F
administered 0 VERB F
on 0 ADP F
days 0 NOUN F
1 0 NUM F
and 0 CCONJ F
8 0 NUM F
and 0 CCONJ F
cyclophosphamide 0 NOUN F
( 0 PUNCT F
100 0 NUM F
mg 0 NOUN F
orally 0 ADV F
[ 0 PUNCT F
PO 0 NOUN T
] 0 PUNCT F
) 0 PUNCT F
administered 0 VERB F
on 0 ADP F
day 0 NOUN F
1 0 NUM F
through 0 ADP F
14 0 NUM F
. 0 PUNCT F

Patients 0 NOUN T
received 0 VERB F
dofequidar 0 NOUN F
( 0 PUNCT F
900 0 NUM F
mg 0 NOUN F
PO 0 NOUN T
) 0 PUNCT F
30 0 NUM F
minutes 0 NOUN F
before 0 CCONJ F
each 0 DET F
dose 0 NOUN F
of 0 ADP F
doxorubicin 0 NOUN F
. 0 PUNCT F

Primary 0 ADJ T
end 0 NOUN F
point 0 NOUN F
was 0 VERB F
overall B-PHYSICAL ADJ F
response 0 NOUN F
rate B-PHYSICAL NOUN F
( I-PHYSICAL PUNCT F
ORR I-PHYSICAL NOUN T
; 0 PUNCT F
partial B-PHYSICAL ADJ F
or I-PHYSICAL CCONJ F
complete B-PHYSICAL ADJ F
response 0 NOUN F
) B-PHYSICAL PUNCT F
. 0 PUNCT F

In 0 ADP T
total 0 NOUN F
, 0 PUNCT F
221 0 NUM F
patients 0 NOUN F
were 0 VERB F
assessable 0 ADJ F
. 0 PUNCT F

RESULTS 0 NOUN T
ORR B-PHYSICAL NOUN T
was 0 VERB F
42.6 0 NUM F
% 0 SYM F
for 0 ADP F
CAF 0 NOUN T
compared 0 VERB F
with 0 ADP F
53.1 0 NUM F
% 0 SYM F
for 0 ADP F
dofequidar 0 NOUN F
+ 0 SYM F
CAF 0 NOUN T
, 0 PUNCT F
a 0 DET F
24.6 0 NUM F
% 0 ADJ F
relative 0 ADJ F
improvement 0 NOUN F
and 0 CCONJ F
10.5 0 NUM F
% 0 SYM F
absolute 0 ADJ F
increase 0 NOUN F
( 0 PUNCT F
P 0 NOUN T
= 0 SYM F
.077 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

There 0 PUNCT T
was 0 VERB F
a 0 DET F
trend 0 NOUN F
for 0 ADP F
prolonged B-ADVERSE-EFFECTS VERB F
progression-free B-ADVERSE-EFFECTS NOUN F
survival B-ADVERSE-EFFECTS NOUN F
( I-ADVERSE-EFFECTS PUNCT F
PFS I-ADVERSE-EFFECTS NOUN T
; 0 PUNCT F
median 0 ADJ F
241 0 NUM F
days 0 NOUN F
for 0 ADP F
CAF 0 NOUN T
v 0 CCONJ F
366 0 NUM F
days 0 NOUN F
for 0 ADP F
dofequidar 0 NOUN F
+ 0 SYM F
CAF 0 NOUN T
; 0 PUNCT F
P 0 NOUN T
= 0 SYM F
.145 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

In 0 ADP T
retrospectively 0 ADV F
defined 0 VERB F
subgroups 0 NOUN F
, 0 PUNCT F
significant 0 ADJ F
improvement 0 NOUN F
in 0 PUNCT F

A 0 DET T
controlled 0 VERB F
trial 0 NOUN F
of 0 ADP F
cisapride 0 NOUN F
in 0 ADP F
anorexia 0 PUNCT F
nervosa 0 NOUN F
. 0 PUNCT F

To 0 PART T
determine 0 NOUN F
the 0 DET F
efficacy 0 NOUN F
of 0 ADP F
cisapride 0 NOUN F
, 0 PUNCT F
10 0 NUM F
mg 0 NOUN F
three 0 NUM F
times 0 NOUN F
daily 0 ADJ F
, 0 PUNCT F
in 0 ADP F
improving 0 VERB F
gastric B-PHYSICAL ADJ F
emptying I-PHYSICAL ADJ F
, 0 PUNCT F
reducing 0 VERB F
distress B-MENTAL NOUN F
during I-MENTAL ADP F
meals I-MENTAL NOUN F
, 0 PUNCT F
and 0 CCONJ F
facilitating 0 PUNCT F
weight 0 NOUN F
gain B-MENTAL NOUN F
in 0 ADP F
anorexia 0 PUNCT F
nervosa 0 NOUN F
, 0 PUNCT F
we 0 PRON F
conducted 0 VERB F
an 0 DET F
8-week 0 NOUN F
, 0 PUNCT F
randomized 0 VERB F
, 0 PUNCT F
double-blind 0 ADJ F
, 0 PUNCT F
placebo-controlled 0 VERB F
trial 0 NOUN F
on 0 ADP F
29 0 NUM F
inpatients 0 NOUN F
. 0 PUNCT F

Measures 0 NOUN T
included 0 VERB F
scintigraphic 0 ADJ F
gastric 0 ADJ F
emptying 0 PUNCT F
studies 0 NOUN F
at 0 ADP F
0 0 NUM F
, 0 PUNCT F
2 0 NUM F
, 0 PUNCT F
4 0 NUM F
, 0 PUNCT F
and 0 CCONJ F
8 0 NUM F
weeks 0 NOUN F
; 0 PUNCT F
subjective B-MENTAL ADJ F
distress I-MENTAL NOUN F
during I-MENTAL ADP F
meals I-MENTAL NOUN F
measured 0 VERB F
by 0 ADP F
visual B-OTHER ADJ F
analogue I-OTHER NOUN F
scales I-OTHER NOUN F
; 0 PUNCT F
self-rating B-OTHER CCONJ F
of I-OTHER ADP F
degree I-OTHER NOUN F
of I-OTHER ADP F
global I-OTHER ADJ F
improvement I-OTHER NOUN F
in I-OTHER ADP F
symptoms I-OTHER NOUN F
associated 0 VERB F
with B-OTHER ADP F
eating B-OTHER ADP F
at 0 ADP F
end 0 NOUN F
of 0 ADP F
study 0 NOUN F
; 0 PUNCT F
and 0 CCONJ F
weight 0 NOUN F
measured 0 ADP F
weekly 0 ADV F
. 0 PUNCT F

Gastric B-PHYSICAL ADJ T
emptying B-PHYSICAL ADJ F
improved 0 VERB F
significantly 0 ADV F
but 0 CCONJ F
equally 0 ADV F
in 0 ADP F
both 0 CCONJ F
groups 0 NOUN F
over 0 ADP F
the 0 DET F
study 0 ADV F
period 0 NOUN F
. 0 PUNCT F

Yet 0 ADV T
subjective 0 ADJ F
measures 0 NOUN F
were 0 VERB F
better 0 PUNCT F
in 0 ADP F
the 0 DET F
cisapride 0 NOUN F
group 0 NOUN F
; 0 PUNCT F
they 0 ADV F
rated 0 PUNCT F
themselves 0 PUNCT F
as 0 PUNCT F
more 0 CCONJ F
hungry B-MENTAL NOUN F
( 0 PUNCT F
p 0 NOUN F
= 0 SYM F
.02 0 NUM F
) 0 PUNCT F
and 0 CCONJ F
more 0 DET F
improved 0 VERB F
on 0 ADP F
the 0 DET F
global 0 ADJ F
measure 0 NOUN F
of 0 ADP F
change B-OTHER NOUN F
in B-OTHER ADP F
symptoms I-OTHER NOUN F
( 0 PUNCT F
p 0 NOUN F
= 0 SYM F
.02 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Even 0 ADV T
so 0 ADP F
, 0 PUNCT F
the 0 DET F
cisapride 0 NOUN F
group 0 NOUN F
did 0 VERB F
not 0 ADV F
gain 0 VERB F
more 0 DET F
weight 0 NOUN F
. 0 PUNCT F

The 0 DET T
correlation 0 NOUN F
between 0 PUNCT F

TEN 0 NUM T
versus 0 CCONJ F
TPN 0 NOUN T
following 0 VERB F
major 0 ADJ F
abdominal 0 ADJ F
trauma 0 NOUN F
-- 0 PUNCT F
reduced 0 VERB F
septic 0 ADJ F
morbidity 0 NOUN F
. 0 PUNCT F

Recent 0 ADJ T
animal 0 NOUN F
models 0 NOUN F
suggest 0 VERB F
that 0 ADP F
enteral 0 ADJ F
feeding 0 ADJ F
( 0 PUNCT F
TEN 0 NUM T
) 0 PUNCT F
compared 0 VERB F
to 0 ADP F
parenteral 0 ADJ F
nutrition 0 NOUN F
( 0 PUNCT F
TPN 0 NOUN T
) 0 PUNCT F
improves 0 NOUN F
resistance 0 NOUN F
to 0 ADP F
infection 0 NOUN F
. 0 PUNCT F

This 0 DET T
prospective 0 ADJ F
clinical 0 ADJ F
trial 0 NOUN F
examined 0 VERB F
the 0 DET F
impact 0 NOUN F
of 0 ADP F
early 0 ADJ F
TEN 0 NUM T
vs. 0 CCONJ F
TPN 0 NOUN T
in 0 ADP F
the 0 DET F
critically 0 ADV F
injured 0 NUM F
. 0 PUNCT F

Seventy-five 0 ADJ T
patients 0 NOUN F
with 0 ADP F
an 0 DET F
abdominal 0 ADJ F
trauma 0 NOUN F
index 0 NOUN F
( 0 PUNCT F
ATI 0 NOUN T
) 0 PUNCT F
greater 0 PUNCT F
than 0 PUNCT F
15 0 NUM F
and 0 CCONJ F
less 0 ADV F
than 0 ADP F
40 0 NUM F
were 0 VERB F
randomized 0 VERB F
at 0 ADP F
initial 0 ADJ F
laparotomy 0 NOUN F
to 0 PART F
receive 0 NOUN F
either 0 PUNCT F
TEN 0 NUM T
( 0 PUNCT F
Vivonex 0 PUNCT T
TEN 0 NUM T
) 0 PUNCT F
or 0 CCONJ F
TPN 0 NOUN T
( 0 PUNCT F
Freamine 0 NUM T
HBC 0 NOUN T
6.9 0 NUM F
% 0 SYM F
and 0 CCONJ F
Trophamine 0 NUM T
6 0 NUM F
% 0 SYM F
) 0 PUNCT F
; 0 PUNCT F
both 0 CCONJ F
regimens 0 NOUN F
contained 0 VERB F
2.5 0 NUM F
% 0 SYM F
fat 0 NOUN F
, 0 PUNCT F
33 0 NUM F
% 0 SYM F
branched 0 VERB F
chain 0 NOUN F
amino 0 ADJ F
acids 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
had 0 PUNCT F
a 0 DET F
calorie 0 NOUN F
to 0 ADP F
nitrogen 0 NOUN F
ratio 0 NOUN F
of 0 ADP F
150:1 0 NOUN F
. 0 PUNCT F

TEN 0 NUM T
was 0 VERB F
delivered 0 VERB F
via 0 ADP F
a 0 DET F
needle 0 NOUN F
catheter 0 NOUN F
jejunostomy 0 NOUN F
. 0 PUNCT F

Nutritional 0 ADJ T
support 0 NOUN F
was 0 VERB F
initiated 0 VERB F
within 0 ADP F
12 0 NUM F
hours 0 NOUN F
postoperatively 0 NUM F
in 0 ADP F
both 0 CCONJ F
groups 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
infused 0 VERB F
at 0 ADP F
a 0 DET F
rate 0 NOUN F
sufficient 0 ADJ F
to 0 ADP F
render 0 NOUN F
the 0 DET F
patients 0 NOUN F
in 0 ADP F
positive 0 ADJ F
nitrogen 0 NOUN F
balance 0 NOUN F
. 0 PUNCT F

The 0 DET T
study 0 ADV F
groups 0 NOUN F
( 0 PUNCT F
TEN 0 NUM T
= 0 SYM F
29 0 NUM F
vs 0 CCONJ F
TPN 0 NOUN T
= 0 SYM F
30 0 NUM F
) 0 PUNCT F
were 0 VERB F
comparable 0 ADJ F
in 0 ADP F
age 0 NOUN F
, 0 PUNCT F
injury 0 NOUN F
severity 0 NOUN F
and 0 CCONJ F
initial 0 ADJ F
metabolic 0 ADJ F
stress 0 NOUN F
. 0 PUNCT F

Jejunal 0 PUNCT T
feeding 0 ADP F
was 0 VERB F
tolerated B-OTHER VERB F
unconditionally 0 NOUN F
in 0 ADP F
25 0 NUM F
( 0 PUNCT F
86 0 NUM F
% 0 SYM F
) 0 PUNCT F
of 0 ADP F
the 0 DET F
TEN 0 NUM T
group 0 NOUN F
. 0 PUNCT F

Nitrogen B-PHYSICAL NOUN T
balance I-PHYSICAL NOUN F
remained 0 VERB F
equivalent 0 ADJ F
throughout 0 ADP F
the 0 DET F
study 0 ADV F
period 0 NOUN F
, 0 PUNCT F
at 0 ADP F
day 0 NOUN F
5 0 NUM F
TEN 0 NUM T
= 0 SYM F
-0.3 0 NUM F
+/- 0 SYM F
1.0 0 NUM F
vs. 0 CCONJ F
TPN 0 NOUN T
0.1 0 NUM F
+/- 0 SYM F
0.8 0 NUM F
gm/day 0 NOUN F
. 0 PUNCT F

Traditional 0 ADJ T
nutritional B-PHYSICAL ADJ F
protein I-PHYSICAL NOUN F
markers I-PHYSICAL NOUN F
( 0 PUNCT F
albumin B-PHYSICAL NOUN F
, 0 PUNCT F
transferrin B-PHYSICAL NOUN F
, 0 PUNCT F
and 0 PUNCT F

Evaluation 0 NOUN T
of 0 ADP F
prostaglandin 0 NOUN F
E1 0 NOUN T
for 0 ADP F
prevention 0 NOUN F
of 0 ADP F
respiratory 0 ADJ F
failure 0 NOUN F
in 0 ADP F
high 0 ADJ F
risk 0 NOUN F
trauma 0 NOUN F
patients 0 NOUN F
: 0 PUNCT F
a 0 DET F
prospective 0 ADJ F
clinical 0 ADJ F
trial 0 NOUN F
and 0 CCONJ F
correlation 0 NOUN F
with 0 ADP F
plasma 0 NOUN F
suppressive 0 ADJ F
factors 0 NOUN F
for 0 ADP F
neutrophil 0 NOUN F
activation 0 NOUN F
. 0 PUNCT F

A 0 DET T
group 0 NOUN F
of 0 ADP F
48 0 NUM F
critically 0 ADV F
injured 0 VERB F
patients 0 NOUN F
were 0 VERB F
entered 0 VERB F
into 0 ADP F
a 0 DET F
prospective 0 ADJ F
, 0 PUNCT F
double-blind 0 ADJ F
, 0 PUNCT F
placebo-controlled 0 VERB F
trial 0 NOUN F
to 0 PART F
evaluate 0 NOUN F
the 0 DET F
efficacy 0 NOUN F
of 0 ADP F
early 0 ADJ F
infusion 0 NOUN F
of 0 ADP F
PGE1 0 NOUN T
for 0 ADP F
reducing 0 VERB F
the 0 DET F
incidence 0 NOUN F
of 0 ADP F
severe B-PHYSICAL ADJ F
respiratory I-PHYSICAL ADJ F
failure I-PHYSICAL NOUN F
and 0 CCONJ F
mortality B-MORTALITY NOUN F
. 0 PUNCT F

Secondary 0 ADJ T
assessments 0 NOUN F
examined 0 VERB F
the 0 DET F
effects 0 NOUN F
of 0 ADP F
the 0 DET F
PGE1 0 NOUN T
infusion 0 NOUN F
on 0 ADP F
plasma 0 NOUN F
mediated 0 ADP F
suppression 0 NOUN F
of 0 ADP F
PMN 0 NOUN T
superoxide 0 NOUN F
production 0 NOUN F
and 0 CCONJ F
loss 0 NOUN F
of 0 ADP F
PMN 0 NOUN T
granule 0 NOUN F
enzyme 0 NOUN F
content 0 NOUN F
. 0 PUNCT F

The 0 DET T
incidence 0 NOUN F
of 0 ADP F
severe B-PHYSICAL ADJ F
respiratory I-PHYSICAL ADJ F
failure I-PHYSICAL NOUN F
was 0 VERB F
lower 0 PUNCT F
in 0 ADP F
the 0 DET F
PGE1 0 NOUN T
group 0 NOUN F
-- 0 PUNCT F
13 0 NUM F
% 0 SYM F
versus 0 CCONJ F
32 0 NUM F
% 0 SYM F
, 0 PUNCT F
but 0 CCONJ F
this 0 PUNCT F
did 0 PUNCT F
not 0 ADV F
reach 0 ADJ F
significance 0 NOUN F
. 0 PUNCT F

The 0 DET T
overall 0 ADJ F
morality 0 NOUN F
was 0 VERB F
equivalent 0 ADJ F
between 0 ADP F
the 0 DET F
two 0 NUM F
groups 0 NOUN F
-- 0 PUNCT F
26 0 NUM F
% 0 SYM F
( 0 PUNCT F
PGE1 0 NOUN T
) 0 PUNCT F
versus 0 CCONJ F
28 0 NUM F
% 0 SYM F
( 0 PUNCT F
placebo 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
suppressive 0 ADJ F
activity 0 NOUN F
of 0 ADP F
the 0 DET F
patient 0 NOUN F
plasma 0 NOUN F
was 0 VERB F
assayed 0 VERB F
by 0 ADP F
measurement 0 NOUN F
of 0 ADP F
normal 0 ADJ F
PMN 0 NOUN T
superoxide 0 NOUN F
production 0 NOUN F
relative 0 ADJ F
to 0 ADP F
normal 0 ADJ F
control 0 NOUN F
plasma 0 NOUN F
( 0 PUNCT F
ratio 0 NOUN F
P 0 NOUN T
: 0 PUNCT F
C 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
baseline 0 NOUN F
ratio 0 NOUN F
P 0 NOUN T
: 0 PUNCT F
C 0 NOUN T
was 0 VERB F
62 0 NUM F
+/- 0 SYM F
5 0 NUM F
% 0 SYM F
in 0 ADP F
the 0 DET F
PGE1 0 NOUN T
group 0 NOUN F
versus 0 CCONJ F
60 0 NUM F
+/- 0 SYM F
5 0 NUM F
% 0 SYM F
in 0 ADP F
the 0 DET F
placebo 0 NOUN F
group 0 NOUN F
. 0 PUNCT F

The 0 DET T
day 0 NOUN F
1 0 NUM F
plasma 0 NOUN F
samples 0 NOUN F
showed 0 VERB F
significant 0 ADJ F
reversal 0 NOUN F
of 0 ADP F
plasma B-PHYSICAL NOUN F
suppressive I-PHYSICAL ADJ F
activity I-PHYSICAL NOUN F
in 0 ADP F
the 0 DET F
PGE1 0 NOUN T
group 0 NOUN F
-- 0 PUNCT F
ratio 0 NOUN F
P 0 NOUN T
: 0 PUNCT F
C 0 NOUN T
88 0 NUM F
+/- 0 SYM F
5 0 NUM F
% 0 SYM F
versus 0 CCONJ F
67 0 NUM F
+/- 0 SYM F
5 0 NUM F
% 0 SYM F
in 0 ADP F
the 0 DET F
placebo 0 NOUN F
group 0 NOUN F
( 0 PUNCT F
P 0 NOUN T
less 0 ADV F
than 0 CCONJ F
0.02 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

In 0 ADP T
patients 0 NOUN F
who 0 ADP F
received 0 VERB F
the 0 DET F
full 0 ADJ F
7 0 NUM F
days 0 NOUN F
of 0 ADP F
infusion 0 NOUN F
, 0 PUNCT F
the 0 DET F
plasma B-PHYSICAL NOUN F
suppressive I-PHYSICAL ADJ F
activity I-PHYSICAL NOUN F
remained 0 VERB F
significantly 0 ADV F
diminished 0 ADP F
in 0 ADP F
the 0 DET F
PGE1 0 NOUN T
group 0 NOUN F
-- 0 PUNCT F
ratio 0 NOUN F
P 0 NOUN T
: 0 PUNCT F
C 0 NOUN T
77 0 NUM F
+/- 0 SYM F
4 0 NUM F
% 0 SYM F
versus 0 CCONJ F
61 0 NUM F
+/- 0 SYM F
5 0 NUM F
% 0 SYM F
( 0 PUNCT F
P 0 NOUN T
less 0 ADV F
than 0 PUNCT F
0.04 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
baseline 0 NOUN F
lysozyme 0 NOUN F
content 0 NOUN F
of 0 ADP F
patient 0 NOUN F
PMN 0 NOUN T
's 0 PUNCT F
relative 0 ADJ F
to 0 ADP F
that 0 PUNCT F
of 0 ADP F
normal 0 ADJ F
control 0 NOUN F
PMNs 0 NOUN T
( 0 PUNCT F
ratio 0 NOUN F
P 0 NOUN T
: 0 PUNCT F
C 0 NOUN T
) 0 PUNCT F
was 0 VERB F
119 0 NUM F
+/- 0 SYM F
14 0 NUM F
% 0 SYM F
in 0 ADP F
the 0 DET F
PGE1 0 NOUN T
group 0 NOUN F
. 0 PUNCT F

A 0 DET T
significant 0 ADJ F
loss 0 NOUN F
of 0 ADP F
lysozyme 0 NOUN F
content 0 NOUN F
was 0 VERB F
observed 0 VERB F
in 0 ADP F
the 0 DET F
PGE1 0 NOUN T
group 0 NOUN F
on 0 ADP F
day 0 NOUN F
1 0 PUNCT F
of 0 ADP F
the 0 DET F
infusion 0 NOUN F
-- 0 PUNCT F
ratio 0 NOUN F
P 0 NOUN T
: 0 PUNCT F
C 0 NOUN T
79 0 NUM F
+/- 0 SYM F
8 0 NUM F
% 0 SYM F
( 0 PUNCT F
P 0 NOUN T
less 0 ADV F
than 0 PUNCT F
0.03 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
and 0 CCONJ F
was 0 VERB F
associated 0 VERB F
with 0 ADP F
a 0 DET F
reduction 0 NOUN F
in 0 ADP F
the 0 DET F
plasma 0 NOUN F
suppressive 0 ADJ F
activity 0 NOUN F
. 0 PUNCT F
( 0 PUNCT F

ABSTRACT 0 ADP T
TRUNCATED 0 PUNCT T
AT 0 ADP T
250 0 NUM F
WORDS 0 NOUN T
) 0 PUNCT F

Does 0 PUNCT T
surface 0 NOUN F
preparation 0 NOUN F
alter 0 PART F
ALA B-OTHER NOUN T
uptake I-OTHER NOUN F
in 0 ADP F
superficial 0 ADJ F
non-melanoma 0 NOUN F
skin 0 NOUN F
cancer 0 NOUN F
in 0 ADP F
vivo 0 ADV F
? 0 PUNCT F

BACKGROUND/PURPOSE 0 PUNCT T
Photodynamic 0 PUNCT T
therapy 0 NOUN F
( 0 PUNCT F
PDT 0 NOUN T
) 0 PUNCT F
using 0 SYM F
aminolaevulinic 0 ADJ F
acid 0 NOUN F
( 0 PUNCT F
ALA 0 NOUN T
) 0 PUNCT F
is 0 VERB F
widely 0 ADV F
used 0 VERB F
in 0 ADP F
the 0 DET F
treatment 0 NOUN F
of 0 ADP F
non-melanoma 0 NOUN F
skin 0 NOUN F
cancer 0 NOUN F
. 0 PUNCT F

Surface 0 NOUN T
preparation 0 NOUN F
of 0 ADP F
the 0 DET F
lesion 0 NOUN F
is 0 VERB F
commonly 0 ADV F
performed 0 VERB F
before 0 ADP F
application 0 NOUN F
of 0 ADP F
ALA 0 NOUN T
but 0 CCONJ F
the 0 DET F
extent 0 NOUN F
of 0 ADP F
the 0 DET F
preparation 0 NOUN F
varies 0 NOUN F
from 0 ADP F
centre 0 NOUN F
to 0 PUNCT F
centre 0 NOUN F
and 0 CCONJ F
there 0 PUNCT F
has 0 DET F
been 0 ADP F
no 0 ADP F
study 0 NOUN F
of 0 ADP F
its 0 DET F
effects 0 NOUN F
. 0 PUNCT F

The 0 DET T
purpose 0 NOUN F
of 0 ADP F
this 0 DET F
study 0 NOUN F
was 0 VERB F
to 0 ADV F
examine 0 NOUN F
the 0 DET F
effects 0 NOUN F
of 0 ADP F
surface 0 NOUN F
preparation 0 NOUN F
on 0 ADP F
the 0 DET F
local 0 ADJ F
uptake B-OTHER NOUN F
of I-OTHER ADP F
ALA I-OTHER NOUN T
by 0 ADP F
recording 0 PUNCT F
fluorescence 0 NOUN F
from 0 ADP F
accumulated 0 VERB F
protoporphyrin 0 NOUN F
IX 0 NUM T
( 0 PUNCT F
PPIX 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

METHODS 0 NOUN T
The 0 DET T
study 0 NOUN F
was 0 VERB F
performed 0 VERB F
on 0 ADP F
16 0 NUM F
lesions 0 NOUN F
, 0 PUNCT F
either 0 PUNCT F
superficial 0 ADJ F
basal 0 ADJ F
cell 0 NOUN F
carcinoma 0 NOUN F
( 0 PUNCT F
BCC 0 NOUN T
) 0 PUNCT F
or 0 CCONJ F
Bowen 0 NOUN T
's 0 PUNCT F
disease 0 NOUN F
( 0 PUNCT F
BD 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

Each 0 DET T
half 0 NOUN F
of 0 ADP F
the 0 DET F
lesion 0 NOUN F
was 0 ADJ F
randomly 0 ADV F
assigned 0 VERB F
to 0 ADP F
( 0 PUNCT F
a 0 NOUN F
) 0 PUNCT F
no 0 DET F
surface 0 NOUN F
preparation 0 NOUN F
or 0 CCONJ F
( 0 PUNCT F
b 0 NOUN F
) 0 PUNCT F
surface 0 NOUN F
preparation 0 NOUN F
( 0 PUNCT F
randomly 0 ADV F
allocated 0 VERB F
to 0 PUNCT F
gentle 0 PUNCT F
curettage 0 NOUN F
or 0 CCONJ F
abrasion 0 NOUN F
with 0 ADP F
a 0 DET F
spatula 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

ALA 0 NOUN T
was 0 VERB F
left 0 VERB F
for 0 ADP F
4 0 NUM F
h 0 NOUN F
( 0 PUNCT F
BCC 0 NOUN T
) 0 PUNCT F
or 0 CCONJ F
6 0 NUM F
h 0 NOUN F
( 0 PUNCT F
BD 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

PPIX B-OTHER NOUN T
fluorescence I-OTHER NOUN F
was 0 VERB F
measured 0 VERB F
using 0 VERB F
an 0 DET F
excitation 0 NOUN F
wavelength 0 NOUN F
of 0 ADP F
405+/-5 0 NOUN F
nm 0 NOUN F
and 0 CCONJ F
emission 0 NOUN F
spectrum 0 NOUN F
recorded 0 PROPN F
using 0 VERB F
a 0 DET F
photodiode 0 NOUN F
array 0 NOUN F
. 0 PUNCT F

Spectra 0 PROPN T
were 0 VERB F
measured 0 VERB F
( 0 PUNCT F
a 0 NOUN F
) 0 PUNCT F
before 0 ADP F
and 0 CCONJ F
( 0 PUNCT F
b 0 NOUN F
) 0 PUNCT F
after 0 ADP F
surface 0 NOUN F
preparation 0 NOUN F
, 0 PUNCT F
( 0 PUNCT F
c 0 NOUN F
) 0 PUNCT F
immediately 0 ADV F
before 0 PUNCT F
and 0 CCONJ F
( 0 PUNCT F
d 0 NOUN F
) 0 PUNCT F
after 0 ADP F
laser 0 NOUN F
irradiation 0 NOUN F
at 0 ADP F
630 0 NUM F
nm 0 NOUN F
. 0 PUNCT F

RESULTS 0 PUNCT T
The 0 DET T
ratio 0 NOUN F
of 0 ADP F
fluorescence B-OTHER NOUN F
after I-OTHER ADP F
incubation I-OTHER NOUN F
to 0 VERB F
that 0 PUNCT F
before 0 ADP F
incubation 0 NOUN F
was 0 DET F
6.1+/-1.2 0 PUNCT F
in 0 ADP F
the 0 DET F
non-prepared 0 DET F
section 0 NOUN F
. 0 PUNCT F

This 0 DET T
increased 0 VERB F
slightly 0 ADV F
but 0 CCONJ F
not 0 ADV F
significantly 0 ADV F
to 0 ADP F
6.8 0 NUM F
+/-1.8 0 PUNCT F
in 0 ADP F
the 0 DET F
prepared 0 VERB F
section 0 NOUN F
( 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.1 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

There 0 PUNCT T
was 0 VERB F
no 0 DET F
significant 0 ADJ F
difference 0 NOUN F
between 0 ADP F
curettage B-OTHER NOUN F
and 0 CCONJ F
abrasion B-OTHER NOUN F
. 0 PUNCT F

There 0 PUNCT T
was 0 VERB F
also 0 ADV F
no 0 DET F
significant 0 ADJ F
difference 0 NOUN F
in 0 ADP F
outcome 0 NOUN F
after 0 ADP F
PDT 0 NOUN T
. 0 PUNCT F

CONCLUSIONS 0 NOUN T
The 0 DET T
clinical 0 ADJ F
assessment 0 NOUN F
agrees 0 NOUN F
with 0 ADP F
the 0 DET F
fluorescence 0 NOUN F
data 0 NOUN F
as 0 ADP F
no 0 DET F
significant 0 ADJ F
difference 0 NOUN F
was 0 VERB F
seen 0 VERB F
between 0 ADP F
prepared 0 VERB F
and 0 CCONJ F
unprepared 0 PUNCT F
halves 0 NOUN F
of 0 ADP F
the 0 DET F
lesion 0 NOUN F
12 0 NUM F
months 0 NOUN F
after 0 ADP F
PDT 0 NOUN T
. 0 PUNCT F

Overall 0 ADJ T
our 0 ADJ F
data 0 NOUN F
seem 0 VERB F
to 0 ADP F
suggest 0 NOUN F
that 0 PUNCT F
for 0 ADP F
most 0 CCONJ F
BCC 0 NOUN T
and 0 CCONJ F
BD 0 NOUN T
lesions 0 NOUN F
, 0 PUNCT F
surface 0 NOUN F
preparation 0 NOUN F
did 0 PUNCT F
not 0 ADV F
increase 0 VERB F
ALA B-OTHER NOUN T
uptake I-OTHER NOUN F
. 0 PUNCT F

A 0 DET T
comparison 0 NOUN F
of 0 ADP F
live 0 ADJ F
and 0 CCONJ F
videotape 0 NOUN F
ratings 0 NOUN F
: 0 PUNCT F
clomipramine 0 NOUN F
and 0 CCONJ F
haloperidol 0 NOUN F
in 0 ADP F
autism 0 NOUN F
. 0 PUNCT F

This 0 DET T
study 0 NOUN F
compared 0 DET F
live 0 ADJ F
ratings 0 NOUN F
with 0 ADP F
ratings 0 NOUN F
of 0 ADP F
videotapes 0 PUNCT F
and 0 CCONJ F
compared 0 PUNCT F
response 0 NOUN F
to 0 ADP F
clomipramine 0 NOUN F
with 0 ADP F
response 0 NOUN F
to 0 ADP F
haloperidol 0 NOUN F
in 0 ADP F
8 0 NUM F
subjects 0 NOUN F
, 0 PUNCT F
mean 0 NOUN F
age 0 NOUN F
5.62 0 NUM F
years 0 NOUN F
, 0 PUNCT F
who 0 ADP F
met 0 VERB F
criteria 0 NOUN F
for 0 ADP F
autism 0 NOUN F
. 0 PUNCT F

They 0 PRON T
were 0 VERB F
consecutive 0 ADJ F
admissions 0 NOUN F
to 0 ADP F
a 0 DET F
pilot 0 NOUN F
study 0 NOUN F
of 0 ADP F
clomipramine 0 NOUN F
( 0 PUNCT F
n 0 NOUN F
= 0 SYM F
4 0 NUM F
) 0 PUNCT F
or 0 CCONJ F
a 0 DET F
double-blind 0 ADJ F
, 0 PUNCT F
placebo 0 NOUN F
controlled 0 VERB F
study 0 NOUN F
of 0 ADP F
haloperidol 0 NOUN F
( 0 PUNCT F
n 0 NOUN F
= 0 SYM F
4 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Live 0 ADJ T
ratings 0 NOUN F
were 0 VERB F
performed 0 VERB F
by 0 ADP F
two 0 NUM F
raters 0 NOUN F
at 0 ADP F
the 0 DET F
end 0 NOUN F
of 0 ADP F
the 0 DET F
pre-treatment 0 NOUN F
placebo 0 NOUN F
baseline 0 NOUN F
period 0 NOUN F
and 0 CCONJ F
at 0 ADP F
the 0 DET F
end 0 NOUN F
of 0 ADP F
the 0 DET F
drug 0 NOUN F
treatment 0 NOUN F
period 0 NOUN F
on 0 ADP F
the 0 DET F
CPRS 0 NOUN T
and 0 CCONJ F
the 0 DET F
CGI 0 NOUN T
and 0 CCONJ F
were 0 VERB F
videotaped 0 NUM F
. 0 PUNCT F

Employing 0 ADP T
the 0 DET F
same 0 ADJ F
instruments 0 NOUN F
, 0 PUNCT F
these 0 DET F
videotapes 0 NOUN F
were 0 VERB F
rated 0 VERB F
by 0 ADP F
two 0 NUM F
raters 0 NOUN F
who 0 DET F
did 0 CCONJ F
not 0 ADV F
know 0 VERB F
the 0 DET F
subjects 0 NOUN F
and 0 CCONJ F
were 0 VERB F
blind 0 VERB F
to 0 ADP F
study 0 PUNCT F
design 0 NOUN F
, 0 PUNCT F
treatment 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
study 0 ADV F
phase 0 NOUN F
. 0 PUNCT F

Ratings B-OTHER PROPN T
of I-OTHER ADP F
videotapes I-OTHER PUNCT F
significantly 0 ADV F
differed 0 CCONJ F
from 0 ADP F
live B-OTHER ADJ F
ratings I-OTHER NOUN F
. 0 PUNCT F

A 0 DET T
treatment 0 NOUN F
effect 0 NOUN F
for 0 ADP F
haloperidol 0 NOUN F
was 0 VERB F
detected 0 ADJ F
only 0 ADV F
on 0 ADP F
live B-OTHER ADJ F
ratings I-OTHER NOUN F
and 0 CCONJ F
not 0 ADV F
on 0 ADP F
ratings B-OTHER NOUN F
of I-OTHER ADP F
videotapes I-OTHER NOUN F
. 0 PUNCT F

No 0 DET T
treatment 0 NOUN F
effect 0 NOUN F
was 0 VERB F
detected 0 VERB F
for 0 ADP F
clomipramine 0 NOUN F
in 0 ADP F
either 0 CCONJ F
live B-OTHER ADJ F
or 0 CCONJ F
videotape B-OTHER NOUN F
ratings I-OTHER NOUN F
. 0 PUNCT F

Rapid 0 ADJ T
injection 0 NOUN F
of 0 ADP F
propofol 0 NOUN F
reduces 0 NOUN F
vascular 0 ADJ F
pain 0 NOUN F
and 0 CCONJ F
facilitates 0 SYM F
Laryngeal 0 ADJ T
Mask 0 NOUN T
Airway 0 NOUN T
insertion 0 NOUN F
. 0 PUNCT F

STUDY 0 NOUN T
OBJECTIVE 0 NOUN T
To 0 PROPN T
compare 0 NOUN F
the 0 DET F
clinical 0 ADJ F
efficacy 0 NOUN F
of 0 ADP F
a 0 DET F
rapid 0 ADJ F
injection 0 NOUN F
of 0 ADP F
propofol 0 NOUN F
in 0 ADP F
regard 0 NOUN F
to 0 ADP F
pain 0 NOUN F
and 0 CCONJ F
ability 0 NOUN F
to 0 PART F
facilitate 0 SYM F
Laryngeal 0 ADJ T
Mask 0 NOUN T
Airway 0 NOUN T
( 0 PUNCT F
LMA 0 NOUN T
) 0 PUNCT F
insertion 0 NOUN F
. 0 PUNCT F

DESIGN 0 NOUN T
Randomized 0 PROPN T
, 0 PUNCT F
single-blinded 0 SYM F
, 0 PUNCT F
placebo-controlled 0 VERB F
study 0 NOUN F
. 0 PUNCT F

SETTING 0 ADJ T
University 0 NOUN T
hospital 0 NOUN F
. 0 PUNCT F

PATIENTS 0 NOUN T
120 0 NUM F
ASA 0 NOUN T
physical 0 ADJ F
status 0 NOUN F
1 0 NUM F
and 0 CCONJ F
2 0 NUM F
patients 0 NOUN F
undergoing 0 VERB F
elective 0 ADJ F
orthopedic 0 ADJ F
surgeries 0 NOUN F
. 0 PUNCT F

INTERVENTIONS 0 NOUN T
Patients 0 NOUN T
were 0 VERB F
randomly 0 ADV F
allocated 0 VERB F
to 0 ADP F
one 0 PUNCT F
of 0 ADP F
4 0 NUM F
groups 0 NOUN F
. 0 PUNCT F

Group 0 NOUN T
A 0 DET T
patients 0 NOUN F
were 0 VERB F
pretreated 0 VERB F
with 0 ADP F
normal 0 ADJ F
saline 0 NOUN F
followed 0 VERB F
by 0 ADP F
propofol 0 NOUN F
2.0 0 NUM F
mg/kg 0 NOUN F
at 0 ADP F
3.3 0 NUM F
mg/sec 0 ADJ F
. 0 PUNCT F

Group 0 NOUN T
B 0 NOUN T
patients 0 NOUN F
were 0 VERB F
pretreated 0 VERB F
with 0 ADP F
lidocaine 0 NOUN F
0.5 0 NUM F
mg/kg 0 NOUN F
followed 0 VERB F
by 0 ADP F
propofol 0 NOUN F
2.0 0 NUM F
mg/kg 0 NOUN F
at 0 ADP F
3.3 0 NUM F
mg/sec 0 ADJ F
. 0 PUNCT F

In 0 ADP T
Group 0 NOUN T
C 0 NOUN T
, 0 PUNCT F
patients 0 NOUN F
were 0 VERB F
pretreated 0 VERB F
with 0 ADP F
lidocaine 0 NOUN F
1.0 0 NUM F
mg/kg 0 NOUN F
followed 0 VERB F
by 0 ADP F
propofol 0 NOUN F
2.0 0 NUM F
mg/kg 0 NOUN F
at 0 ADP F
3.3 0 NUM F
mg/sec 0 ADJ F
. 0 PUNCT F

In 0 ADP T
Group 0 NOUN T
D 0 NOUN T
, 0 PUNCT F
patients 0 NOUN F
were 0 VERB F
pretreated 0 VERB F
with 0 ADP F
normal 0 ADJ F
saline 0 NOUN F
followed 0 VERB F
by 0 ADP F
propofol 0 NOUN F
2.0 0 NUM F
mg/kg 0 NOUN F
at 0 ADP F
50 0 NUM F
mg/sec 0 ADJ F
. 0 PUNCT F

MEASUREMENTS 0 ADP T
Pain 0 NOUN T
on 0 ADP F
injection 0 NOUN F
was 0 VERB F
measured 0 VERB F
using 0 VERB F
a 0 DET F
4-point 0 NOUN F
scale 0 NOUN F
. 0 PUNCT F

Scale 0 NOUN T
and 0 CCONJ F
success 0 NOUN F
rate 0 NOUN F
of 0 ADP F
smooth 0 ADJ F
LMA 0 NOUN T
insertion 0 NOUN F
also 0 ADV F
were 0 VERB F
recorded 0 VERB F
. 0 PUNCT F

MAIN 0 ADJ T
RESULTS 0 NOUN T
Rapid 0 ADJ T
injection 0 NOUN F
was 0 VERB F
less 0 ADV F
painful B-PAIN ADJ F
than 0 PUNCT F
after 0 ADP F
pretreatment 0 NOUN F
with 0 ADP F
lidocaine 0 NOUN F
0.5 0 NUM F
mg/kg 0 NOUN F
, 0 PUNCT F
but 0 CCONJ F
was 0 VERB F
similar 0 ADJ F
to 0 ADP F
slow 0 ADJ F
injection 0 NOUN F
after 0 ADP F
pretreatment 0 NOUN F
with 0 ADP F
lidocaine 0 NOUN F
1.0 0 NUM F
mg/kg 0 NOUN F
. 0 PUNCT F

Rapid 0 ADJ T
injection 0 NOUN F
facilitated 0 PUNCT F
LMA B-OTHER NOUN T
insertion I-OTHER NOUN F
, 0 PUNCT F
unlike 0 ADP F
slow 0 ADJ F
injection 0 NOUN F
with 0 ADP F
lidocaine 0 NOUN F
0.5 0 NUM F
mg/kg 0 NOUN F
pretreatment 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
was 0 VERB F
similarly 0 ADV F
successful 0 ADJ F
to 0 ADP F
slow 0 ADJ F
injection 0 NOUN F
after 0 ADP F
pretreatment 0 NOUN F
with 0 ADP F
lidocaine 0 NOUN F
1.0 0 NUM F
mg/kg 0 NOUN F
. 0 PUNCT F

CONCLUSIONS 0 NOUN T
The 0 DET T
rapid 0 ADJ F
administration 0 NOUN F
of 0 ADP F
propofol 0 NOUN F
reduces 0 NOUN F
pain 0 NOUN F
and 0 CCONJ F
facilitates 0 NOUN F
LMA 0 NOUN T
insertion 0 NOUN F
versus 0 CCONJ F
slow 0 ADJ F
administration 0 NOUN F
of 0 ADP F
propofol 0 NOUN F
. 0 PUNCT F

Evaluation 0 NOUN T
of 0 ADP F
the 0 DET F
effects 0 NOUN F
of 0 ADP F
human 0 NOUN F
leukocyte 0 NOUN F
IFN-alpha 0 NOUN T
on 0 ADP F
the 0 DET F
immune B-PHYSICAL ADJ F
response 0 NOUN F
to B-PHYSICAL ADP F
the I-PHYSICAL DET F
HBV I-PHYSICAL NOUN T
vaccine B-PHYSICAL NOUN F
in 0 ADP F
healthy 0 ADJ F
unvaccinated 0 VERB F
individuals 0 NOUN F
. 0 PUNCT F

HBV 0 NOUN T
vaccine 0 NOUN F
needs 0 NOUN F
3 0 NUM F
injections 0 NOUN F
over 0 ADP F
6 0 NUM F
months 0 NOUN F
to 0 PART F
induce 0 ADJ F
immunity 0 NOUN F
. 0 PUNCT F

Thus 0 ADV T
, 0 PUNCT F
the 0 DET F
use 0 NOUN F
of 0 ADP F
adjuvants 0 NOUN F
capable 0 ADJ F
of 0 ADP F
inducing 0 VERB F
earlier 0 PUNCT F
immune 0 ADJ F
protection 0 NOUN F
would 0 VERB F
be 0 VERB F
highly 0 ADV F
desirable 0 ADJ F
. 0 PUNCT F

Most 0 DET T
adjuvants 0 NOUN F
may 0 VERB F
act 0 NUM F
by 0 ADP F
inducing 0 PUNCT F
cytokines 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
among 0 ADP F
them 0 NUM F
, 0 PUNCT F
type 0 NOUN F
I 0 NUM T
interferons 0 NOUN F
( 0 PUNCT F
IFNs 0 NOUN T
) 0 PUNCT F
, 0 PUNCT F
deserve 0 ADP F
a 0 DET F
special 0 ADJ F
attention 0 NOUN F
in 0 ADP F
view 0 NOUN F
of 0 ADP F
the 0 DET F
potent 0 ADJ F
immunomostimulatory 0 ADJ F
activity 0 NOUN F
observed 0 VERB F
in 0 ADP F
mouse 0 NOUN F
models 0 NOUN F
and 0 CCONJ F
on 0 ADP F
dendritic 0 ADJ F
cell 0 NOUN F
functions 0 NOUN F
. 0 PUNCT F

The 0 DET T
aim 0 NOUN F
of 0 ADP F
the 0 DET F
present 0 ADJ F
trial 0 NOUN F
was 0 VERB F
to 0 PART F
evaluate 0 NOUN F
the 0 DET F
effects 0 NOUN F
of 0 ADP F
IFN-alpha 0 NOUN T
administered 0 DET F
as 0 ADP F
an 0 DET F
adjuvant 0 ADJ F
of 0 ADP F
HBV 0 NOUN T
vaccine 0 NOUN F
in 0 ADP F
healthy 0 ADJ F
unvaccinated 0 VERB F
individuals 0 NOUN F
. 0 PUNCT F

No 0 DET T
significant 0 ADJ F
enhancing 0 ADP F
effect 0 NOUN F
on 0 ADP F
the 0 DET F
antibody B-PHYSICAL NOUN F
response I-PHYSICAL NOUN F
was 0 VERB F
observed 0 VERB F
, 0 PUNCT F
in 0 ADP F
spite 0 NOUN F
of 0 ADP F
an 0 DET F
early 0 ADJ F
and 0 CCONJ F
transient 0 ADJ F
upregulation 0 NOUN F
of 0 ADP F
costimulatory 0 ADJ F
molecule 0 NOUN F
expression 0 NOUN F
on 0 PUNCT F

Take 0 ADV T
a 0 DET F
walk 0 NOUN F
in 0 ADP F
the 0 DET F
park 0 PUNCT F
? 0 PUNCT F

A 0 CCONJ T
cross-over 0 NOUN F
pilot 0 NOUN F
trial 0 NOUN F
comparing 0 ADJ F
brisk 0 PUNCT F
walking 0 NUM F
in 0 ADP F
two 0 NUM F
different 0 ADJ F
environments 0 NOUN F
: 0 PUNCT F
park 0 VERB F
and 0 CCONJ F
urban 0 ADJ F
. 0 PUNCT F

OBJECTIVE 0 NOUN T
The 0 DET T
objective 0 NOUN F
of 0 ADP F
the 0 DET F
present 0 ADJ F
study 0 NOUN F
is 0 VERB F
to 0 PART F
investigate 0 NOUN F
whether 0 ADP F
differences 0 NOUN F
exist 0 VERB F
between 0 ADP F
a 0 DET F
30 0 NUM F
minute 0 ADJ F
brisk 0 PUNCT F
walk 0 NOUN F
taken 0 VERB F
in 0 ADP F
two 0 NUM F
different 0 ADJ F
environments 0 NOUN F
in 0 ADP F
order 0 NOUN F
to 0 PART F
determine 0 VERB F
which 0 PUNCT F
environment 0 NOUN F
best 0 ADV F
facilitates 0 PUNCT F
current 0 ADJ F
physical 0 ADJ F
activity 0 NOUN F
guidelines 0 NOUN F
: 0 PUNCT F
park 0 ADP F
or 0 CCONJ F
urban 0 ADJ F
. 0 PUNCT F

METHODS 0 NOUN T
In 0 ADP T
this 0 DET F
randomised 0 VERB F
cross-over 0 NOUN F
pilot 0 NOUN F
study 0 NOUN F
, 0 PUNCT F
participants 0 NOUN F
performed 0 VERB F
a 0 DET F
self-timed 0 ADV F
30 0 NUM F
minute 0 ADJ F
brisk 0 PUNCT F
walk 0 NOUN F
in 0 ADP F
two 0 NUM F
different 0 ADJ F
environments 0 NOUN F
, 0 PUNCT F
park 0 PUNCT F
and 0 CCONJ F
urban 0 PUNCT F
, 0 PUNCT F
in 0 ADP F
Glasgow 0 PUNCT T
, 0 PUNCT F
Scotland 0 PUNCT T
( 0 PUNCT F
October 0 NOUN T
2009 0 NUM F
to 0 ADP F
January 0 NOUN T
2010 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Cadence B-PHYSICAL NOUN T
, 0 PUNCT F
recorded 0 PROPN F
using 0 VERB F
the 0 DET F
activPAL? 0 NOUN F
activity 0 NOUN F
monitor 0 NOUN F
, 0 PUNCT F
was 0 VERB F
used 0 VERB F
to 0 PART F
measure 0 NOUN F
intensity 0 NOUN F
. 0 PUNCT F

Outcome 0 NOUN T
measures 0 NOUN F
were 0 ADV F
: 0 PUNCT F
mean 0 NOUN F
cadence 0 NOUN F
; 0 PUNCT F
moderate-to-vigorous 0 ADJ F
physical 0 ADJ F
activity 0 NOUN F
time 0 NOUN F
accumulated 0 VERB F
in 0 ADP F
bouts 0 NOUN F
lasting 0 PUNCT F
? 0 PUNCT F

10 0 NUM F
min 0 NOUN F
; 0 PUNCT F
number 0 NOUN F
of 0 ADP F
walking 0 VERB F
breaks 0 NOUN F
; 0 PUNCT F
and 0 CCONJ F
duration 0 NOUN F
. 0 PUNCT F

RESULTS 0 VERB T
A 0 PUNCT T
convenience 0 NOUN F
sample 0 NOUN F
of 0 ADP F
40 0 NUM F
healthy 0 ADJ F
adults 0 NOUN F
was 0 VERB F
recruited 0 VERB F
: 0 PUNCT F
16 0 NUM F
males 0 PROPN F
, 0 PUNCT F
24 0 NUM F
females 0 NOUN F
, 0 PUNCT F
mean 0 NOUN F
age 0 NOUN F
22.9 0 NUM F
( 0 PUNCT F
5.5 0 NUM F
) 0 PUNCT F
years 0 NOUN F
. 0 PUNCT F

The 0 DET T
mean 0 NOUN F
cadence 0 NOUN F
for 0 ADP F
the 0 DET F
whole 0 ADJ F
walk 0 NOUN F
was 0 ADJ F
higher 0 PUNCT F
in 0 ADP F
the 0 DET F
park 0 CCONJ F
: 0 PUNCT F
119.3 0 NUM F
( 0 PUNCT F
8.3 0 NUM F
) 0 PUNCT F
vs. 0 CCONJ F
110.9 0 NUM F
( 0 PUNCT F
8.9 0 NUM F
) 0 PUNCT F
steps/min 0 NOUN F
. 0 PUNCT F

Participants 0 NOUN T
accumulated 0 VERB F
more 0 DET F
moderate-to-vigorous 0 ADJ F
physical 0 ADJ F
activity 0 NOUN F
in 0 ADP F
? 0 PUNCT F

10 0 NUM F
minute 0 ADJ F
bouts 0 PUNCT F
during 0 ADP F
park 0 CCONJ F
walks 0 PUNCT F
: 0 PUNCT F
25.5 0 NUM F
( 0 PUNCT F
9.6 0 NUM F
) 0 PUNCT F
[ 0 PUNCT F
median 0 ADJ F
( 0 PUNCT F
interquartile 0 NOUN F
range 0 NOUN F
) 0 PUNCT F
] 0 PUNCT F
vs. 0 CCONJ F
14.0 0 NUM F
( 0 PUNCT F
20.3 0 NUM F
) 0 PUNCT F
min 0 NOUN F
. 0 PUNCT F

There 0 PUNCT T
was 0 VERB F
no 0 DET F
difference 0 NOUN F
in 0 ADP F
self-timed 0 VERB F
duration 0 NOUN F
between 0 ADP F
locations 0 NOUN F
. 0 PUNCT F

CONCLUSION 0 NOUN T
Participants 0 NOUN T
accumulated 0 VERB F
more 0 DET F
moderate-to-vigorous 0 ADJ F
physical 0 ADJ F
activity 0 NOUN F
in 0 ADP F
bouts 0 NOUN F
? 0 PUNCT F

10 0 NUM F
min 0 NOUN F
in 0 ADP F
duration 0 NOUN F
on 0 PUNCT F
park 0 CCONJ F
walks 0 PUNCT F
due 0 PUNCT F
to 0 ADP F
the 0 DET F
lack 0 NOUN F
of 0 ADP F
interruptions 0 NOUN F
in 0 ADP F
walking 0 ADP F
. 0 PUNCT F

Hence 0 ADV T
the 0 DET F
park 0 ADJ F
environment 0 NOUN F
better 0 PUNCT F
facilitated 0 ADP F
the 0 DET F
achievement 0 NOUN F
of 0 ADP F
current 0 ADJ F
physical 0 ADJ F
activity 0 NOUN F
guidelines 0 NOUN F
. 0 PUNCT F

Further 0 ADJ T
research 0 NOUN F
involving 0 VERB F
a 0 DET F
larger 0 PUNCT F
, 0 PUNCT F
more 0 DET F
heterogeneous 0 ADJ F
sample 0 NOUN F
is 0 VERB F
recommended 0 VERB F
. 0 PUNCT F

Profound 0 ADJ T
luteinizing 0 VERB F
hormone 0 NOUN F
suppression 0 NOUN F
after 0 ADP F
stopping 0 PUNCT F
the 0 DET F
gonadotropin-releasing 0 VERB F
hormone-agonist 0 NOUN F
leuprolide 0 NOUN F
acetate 0 NOUN F
. 0 PUNCT F

OBJECTIVE 0 NOUN T
To 0 PROPN T
compare 0 NOUN F
levels 0 NOUN F
of 0 ADP F
serum 0 NOUN F
LH 0 NOUN T
during 0 ADP F
continued 0 VERB F
use 0 NOUN F
of 0 ADP F
leuprolide 0 NOUN F
acetate 0 NOUN F
( 0 PUNCT F
LA 0 NOUN T
) 0 PUNCT F
with 0 ADP F
levels 0 NOUN F
during 0 ADP F
the 0 DET F
first 0 ADJ F
week 0 NOUN F
after 0 ADP F
discontinuing 0 PUNCT F
LA 0 NOUN T
. 0 PUNCT F

DESIGN 0 NOUN T
Prospective 0 ADJ T
controlled 0 VERB F
study 0 NOUN F
. 0 PUNCT F

SETTING 0 NUM T
Clinical 0 ADJ T
assisted 0 VERB F
conception 0 NOUN F
program 0 NOUN F
. 0 PUNCT F

PATIENTS 0 ADP T
Women 0 NOUN T
undergoing 0 VERB F
controlled 0 VERB F
ovarian 0 ADJ F
stimulation 0 NOUN F
for 0 ADP F
assisted 0 VERB F
conception 0 NOUN F
were 0 VERB F
randomized 0 VERB F
to 0 PART F
receive 0 NOUN F
LA 0 NOUN T
according 0 CCONJ F
to 0 ADP F
short 0 ADJ F
or 0 CCONJ F
ultrashort 0 PUNCT F
protocols 0 NOUN F
. 0 PUNCT F

The 0 DET T
alternative 0 ADJ F
protocol 0 NOUN F
was 0 VERB F
used 0 VERB F
then 0 ADV F
in 0 ADP F
a 0 DET F
second 0 ADJ F
cycle 0 NOUN F
. 0 PUNCT F

Each 0 DET T
patient 0 NOUN F
was 0 VERB F
thus 0 ADP F
her 0 PUNCT F
own 0 ADJ F
control 0 NOUN F
. 0 PUNCT F

MAIN 0 ADJ T
OUTCOME 0 NOUN T
MEASURES 0 NOUN T
Serum B-PHYSICAL NOUN T
LH I-PHYSICAL NOUN T
over I-PHYSICAL PUNCT F
time I-PHYSICAL NOUN F
. 0 PUNCT F

RESULTS 0 NOUN T
When 0 ADP T
LA 0 NOUN T
was 0 VERB F
stopped 0 PUNCT F
after 0 ADP F
5 0 NUM F
days 0 NOUN F
of 0 ADP F
administration 0 NOUN F
, 0 PUNCT F
LH B-PHYSICAL NOUN T
levels I-PHYSICAL NOUN F
fell 0 VERB F
profoundly 0 ADV F
when 0 ADP F
compared 0 VERB F
with 0 ADP F
levels 0 NOUN F
when 0 ADP F
LA 0 NOUN T
was 0 VERB F
continued 0 PUNCT F
. 0 PUNCT F

CONCLUSION 0 NOUN T
Loss 0 NOUN T
of 0 ADP F
LH B-MENTAL NOUN T
after 0 ADP F
stopping 0 VERB F
LA 0 NOUN T
is 0 VERB F
likely 0 ADJ F
to 0 PART F
be 0 PUNCT F
clinically 0 ADV F
important 0 ADJ F
in 0 ADP F
ovarian 0 ADJ F
stimulation 0 NOUN F
regimens 0 CCONJ F
that 0 ADP F
use 0 PUNCT F
pure 0 ADJ F
FSH 0 NOUN T
with 0 ADP F
LA 0 NOUN T
in 0 ADP F
ultrashort 0 PUNCT F
protocols 0 NOUN F
. 0 PUNCT F

The 0 DET T
fall 0 NOUN F
in 0 ADP F
LH B-PHYSICAL NOUN T
lasts 0 VERB F
at 0 ADP F
least 0 ADV F
1 0 NUM F
week 0 NOUN F
and 0 CCONJ F
may 0 VERB F
be 0 VERB F
explainable 0 ADJ F
by 0 ADP F
persistent 0 ADJ F
suppression 0 NOUN F
of 0 ADP F
endogenous 0 ADJ F
GnRH 0 NOUN T
by 0 ADP F
LA 0 NOUN T
during 0 ADP F
this 0 DET F
time 0 NOUN F
. 0 PUNCT F

Hitting 0 VERB T
the 0 DET F
target 0 NOUN F
: 0 PUNCT F
relatively 0 ADV F
easy 0 PUNCT F
, 0 PUNCT F
yet 0 ADV F
absolutely 0 ADV F
difficult 0 ADJ F
. 0 PUNCT F

It 0 PRON T
is 0 VERB F
generally 0 ADP F
agreed 0 PROPN F
that 0 ADP F
absolute-direction 0 NOUN F
judgments 0 NOUN F
require 0 VERB F
information 0 NOUN F
about 0 PUNCT F
eye 0 NOUN F
position 0 NOUN F
, 0 PUNCT F
whereas 0 ADP F
relative-direction 0 NOUN F
judgments 0 NOUN F
do 0 PUNCT F
not 0 ADV F
. 0 PUNCT F

The 0 DET T
source 0 NOUN F
of 0 ADP F
this 0 ADP F
eye-position 0 NOUN F
information 0 NOUN F
, 0 PUNCT F
particularly 0 ADV F
during 0 ADP F
monocular 0 ADJ F
viewing 0 VERB F
, 0 PUNCT F
is 0 VERB F
a 0 DET F
matter 0 NOUN F
of 0 ADP F
debate 0 NOUN F
. 0 PUNCT F

It 0 PRON T
may 0 VERB F
be 0 PUNCT F
either 0 CCONJ F
binocular 0 ADJ F
eye 0 NOUN F
position 0 NOUN F
, 0 PUNCT F
or 0 CCONJ F
the 0 DET F
position 0 NOUN F
of 0 ADP F
the 0 DET F
viewing-eye 0 NOUN F
only 0 ADV F
, 0 PUNCT F
that 0 ADP F
is 0 VERB F
crucial 0 ADJ F
. 0 PUNCT F

Using 0 PRON T
more 0 ADV F
ecologically 0 ADV F
valid 0 PUNCT F
stimulus 0 NOUN F
situations 0 ADJ F
than 0 PUNCT F
the 0 DET F
traditional 0 ADJ F
LED 0 NOUN T
in 0 ADP F
the 0 DET F
dark 0 ADJ F
, 0 PUNCT F
we 0 PRON F
performed 0 VERB F
two 0 NUM F
experiments 0 NOUN F
. 0 PUNCT F

In 0 ADP T
experiment 0 NOUN F
1 0 NUM F
, 0 PUNCT F
observers 0 PUNCT F
threw 0 PUNCT F
darts 0 NOUN F
at 0 ADP F
targets 0 NOUN F
that 0 PUNCT F
were 0 VERB F
fixated 0 ADP F
either 0 CCONJ F
monocularly 0 ADV F
or 0 CCONJ F
binocularly 0 ADV F
. 0 PUNCT F

In 0 ADP T
experiment 0 NOUN F
2 0 NUM F
, 0 PUNCT F
observers 0 PUNCT F
aimed 0 VERB F
a 0 DET F
laser 0 NOUN F
gun 0 NOUN F
at 0 ADP F
targets 0 NOUN F
while 0 ADP F
fixating 0 PUNCT F
either 0 PUNCT F
the 0 DET F
rear 0 ADJ F
or 0 CCONJ F
the 0 DET F
front 0 NOUN F
gunsight 0 NOUN F
monocularly 0 ADV F
, 0 PUNCT F
or 0 CCONJ F
the 0 DET F
target 0 NOUN F
either 0 PUNCT F
monocularly 0 ADV F
or 0 CCONJ F
binocularly 0 ADV F
. 0 PUNCT F

We 0 PRON T
measured 0 VERB F
the 0 DET F
accuracy 0 NOUN F
and 0 CCONJ F
precision 0 NOUN F
of 0 ADP F
the 0 DET F
observers 0 ADJ F
' 0 PUNCT F
absolute- 0 NOUN F
and 0 CCONJ F
relative-direction 0 NOUN F
judgments 0 NOUN F
. 0 PUNCT F

We 0 PRON T
found 0 VERB F
that 0 ADP F
( 0 PUNCT F
a 0 NOUN F
) 0 PUNCT F
relative-direction 0 NOUN F
judgments 0 NOUN F
were 0 VERB F
precise 0 ADJ F
and 0 CCONJ F
independent 0 ADJ F
of 0 ADP F
phoria 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
( 0 PUNCT F
b 0 NOUN F
) 0 PUNCT F
monocular 0 ADJ F
absolute-direction 0 NOUN F
judgments 0 NOUN F
were 0 VERB F
inaccurate B-OTHER VERB F
, 0 PUNCT F
and 0 CCONJ F
the 0 DET F
magnitude 0 NOUN F
of 0 ADP F
the 0 DET F
inaccuracy B-MENTAL NOUN F
was 0 VERB F
predictable 0 ADJ F
from 0 ADP F
the 0 DET F
magnitude 0 NOUN F
of 0 ADP F
phoria 0 NOUN F
. 0 PUNCT F

These 0 DET T
results 0 NOUN F
confirm 0 VERB F
that 0 ADP F
relative-direction 0 NOUN F
judgments 0 NOUN F
do 0 PUNCT F
not 0 ADV F
require 0 VERB F
information 0 NOUN F
about 0 PUNCT F
eye 0 NOUN F
position 0 NOUN F
. 0 PUNCT F

Moreover 0 ADV T
, 0 PUNCT F
they 0 PRON F
show 0 VERB F
that 0 ADP F
binocular 0 ADJ F
eye-position 0 NOUN F
information 0 NOUN F
is 0 VERB F
crucial 0 ADJ F
when 0 ADP F
judging 0 PUNCT F
the 0 DET F
absolute 0 ADJ F
direction 0 NOUN F
of 0 ADP F
both 0 CCONJ F
monocular 0 ADJ F
and 0 CCONJ F
binocular 0 ADJ F
targets 0 NOUN F
. 0 PUNCT F

The 0 DET T
effects 0 NOUN F
of 0 ADP F
strength 0 NOUN F
training 0 VERB F
on 0 ADP F
central B-PHYSICAL ADJ F
arterial I-PHYSICAL ADJ F
compliance I-PHYSICAL NOUN F
in 0 ADP F
middle-aged 0 NOUN F
and 0 CCONJ F
older 0 PUNCT F
adults 0 NOUN F
. 0 PUNCT F

BACKGROUND 0 NOUN T
Contrary 0 PUNCT T
to 0 ADP F
aerobic 0 ADJ F
exercise 0 NOUN F
, 0 PUNCT F
strength 0 NOUN F
training 0 VERB F
( 0 PUNCT F
ST 0 NOUN T
) 0 PUNCT F
is 0 VERB F
associated 0 VERB F
with 0 ADP F
decreased 0 VERB F
central B-PHYSICAL ADJ F
arterial I-PHYSICAL ADJ F
compliance I-PHYSICAL NOUN F
in 0 ADP F
young 0 ADJ F
men 0 NOUN F
. 0 PUNCT F

It 0 PRON T
is 0 VERB F
unknown 0 VERB F
whether 0 ADP F
ST 0 NOUN T
, 0 PUNCT F
with 0 ADP F
or 0 CCONJ F
without 0 ADP F
concurrent 0 ADJ F
endurance 0 NOUN F
training 0 VERB F
, 0 PUNCT F
would 0 PUNCT F
have 0 CCONJ F
a 0 DET F
similar 0 ADJ F
effect 0 NOUN F
in 0 ADP F
older 0 PUNCT F
adults 0 NOUN F
with 0 ADP F
reduced 0 VERB F
baseline 0 NOUN F
arterial B-PHYSICAL ADJ F
compliance I-PHYSICAL NOUN F
. 0 PUNCT F

OBJECTIVE 0 NOUN T
The 0 DET T
primary 0 ADJ F
aim 0 NOUN F
of 0 ADP F
this 0 DET F
study 0 NOUN F
was 0 VERB F
to 0 PART F
determine 0 NOUN F
the 0 DET F
effect 0 NOUN F
of 0 ADP F
a 0 DET F
ST 0 NOUN T
program 0 NOUN F
on 0 ADP F
central B-PHYSICAL ADJ F
arterial I-PHYSICAL ADJ F
compliance I-PHYSICAL NOUN F
in 0 ADP F
middle-aged 0 NOUN F
and 0 CCONJ F
older 0 PUNCT F
adults 0 NOUN F
. 0 PUNCT F

DESIGN 0 NOUN T
Randomized 0 PROPN T
, 0 PUNCT F
controlled 0 VERB F
intervention 0 NOUN F
study 0 NOUN F
in 0 ADP F
which 0 DET F
37 0 NUM F
healthy 0 ADJ F
, 0 PUNCT F
sedentary 0 ADJ F
men 0 NOUN F
and 0 CCONJ F
women 0 NOUN F
( 0 PUNCT F
52+/-2 0 NOUN F
years 0 NOUN F
) 0 PUNCT F
performed 0 DET F
13 0 NUM F
weeks 0 NOUN F
of 0 ADP F
ST 0 NOUN T
( 0 PUNCT F
n=13 0 NOUN F
) 0 PUNCT F
, 0 PUNCT F
ST+aerobic 0 ADJ T
exercise 0 NOUN F
( 0 PUNCT F
n=12 0 NOUN F
) 0 PUNCT F
or 0 CCONJ F
stretching 0 VERB F
exercises 0 NOUN F
as 0 ADP F
a 0 DET F
control 0 NOUN F
group 0 NOUN F
( 0 PUNCT F
n=12 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

METHODS 0 NOUN T
Participants 0 PUNCT T
were 0 VERB F
rigorously 0 ADV F
screened 0 VERB F
for 0 ADP F
cardiovascular 0 ADJ F
disease 0 NOUN F
and 0 CCONJ F
underwent 0 VERB F
pre-post 0 CCONJ F
testing 0 VERB F
for 0 ADP F
carotid B-PHYSICAL ADJ F
arterial I-PHYSICAL ADJ F
compliance I-PHYSICAL NOUN F
( 0 PUNCT F
via 0 ADP F
simultaneous 0 ADJ F
ultrasound 0 NOUN F
and 0 CCONJ F
applanation 0 NOUN F
tonometry 0 NOUN F
) 0 PUNCT F
, 0 PUNCT F
carotid-femoral 0 ADJ F
pulse 0 NOUN F
wave 0 NOUN F
velocity 0 NOUN F
, 0 PUNCT F
plasma 0 NOUN F
endothelin-1 0 NOUN F
and 0 CCONJ F
angiotensin B-PHYSICAL NOUN F
II I-PHYSICAL NUM T
concentrations I-PHYSICAL NOUN F
and 0 CCONJ F
carotid B-PHYSICAL ADJ F
artery I-PHYSICAL NOUN F
vasoreactivity I-PHYSICAL NOUN F
( 0 PUNCT F
cold 0 NOUN F
pressor 0 NOUN F
test 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

RESULTS 0 NOUN T
ST 0 NOUN T
performed 0 VERB F
alone 0 ADJ F
, 0 PUNCT F
or 0 CCONJ F
in 0 ADP F
conjunction 0 NOUN F
with 0 ADP F
aerobic 0 ADJ F
exercise 0 NOUN F
, 0 PUNCT F
improved 0 DET F
maximal B-PHYSICAL ADJ F
muscle I-PHYSICAL NOUN F
strength I-PHYSICAL NOUN F
and I-PHYSICAL CCONJ F
increased 0 ADV F
total 0 ADJ F
lean B-PHYSICAL ADJ F
body B-PHYSICAL NOUN F
mass I-PHYSICAL NOUN F
( 0 PUNCT F
both 0 CCONJ F
P 0 NOUN T
< 0 SYM F
0.01 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

No 0 DET T
significant 0 ADJ F
changes 0 NOUN F
were 0 VERB F
observed 0 VERB F
in 0 ADP F
carotid B-OTHER ADJ F
artery I-OTHER NOUN F
compliance I-OTHER NOUN F
or 0 CCONJ F
carotid-femoral B-PHYSICAL ADJ F
pulse I-PHYSICAL NOUN F
wave I-PHYSICAL NOUN F
velocity I-PHYSICAL NOUN F
following 0 ADJ F
ST B-OTHER NOUN T
or I-OTHER CCONJ F
ST+aerobic I-OTHER ADJ T
exercise B-OTHER NOUN F
. 0 PUNCT F

Carotid B-PHYSICAL ADJ T
artery B-PHYSICAL NOUN F
compliance I-PHYSICAL NOUN F
increased 0 VERB F
significantly 0 ADV F
( 0 PUNCT F
23 0 NUM F
% 0 SYM F
) 0 PUNCT F
following 0 VERB F
stretching 0 VERB F
which 0 ADP F
may 0 VERB F
be 0 VERB F
attributed 0 VERB F
to 0 ADP F
a 0 DET F
reduction 0 NOUN F
in 0 ADP F
carotid 0 ADJ F
pulse 0 NOUN F
pressure 0 NOUN F
. 0 PUNCT F

No 0 DET T
significant 0 ADJ F
changes 0 NOUN F
were 0 VERB F
observed 0 VERB F
in 0 ADP F
plasma B-PHYSICAL NOUN F
vasoconstrictor I-PHYSICAL NOUN F
hormones I-PHYSICAL DET F
or 0 PUNCT F

[ 0 PUNCT F
Plasma 0 NOUN T
separation 0 NOUN F
combined 0 VERB F
with 0 ADP F
CVVHF 0 NOUN T
in 0 ADP F
septic 0 ADJ F
and 0 CCONJ F
SIRS 0 NOUN T
patients 0 NOUN F
] 0 PUNCT F
. 0 PUNCT F

In 0 ADP T
a 0 DET F
prospective 0 ADJ F
non-randomized 0 VERB F
trial 0 NOUN F
, 0 PUNCT F
59 0 NUM F
patients 0 NOUN F
with 0 ADP F
sepsis 0 NOUN F
( 0 PUNCT F
n 0 NOUN F
= 0 SYM F
43 0 NUM F
) 0 PUNCT F
and 0 CCONJ F
SIRS 0 NOUN T
( 0 PUNCT F
n 0 NOUN F
= 0 SYM F
16 0 NUM F
) 0 PUNCT F
were 0 VERB F
treated 0 VERB F
on 0 ADP F
a 0 DET F
surgical 0 ADJ F
intensive 0 ADJ F
care 0 NOUN F
unit 0 NOUN F
. 0 PUNCT F

In 0 ADP T
22 0 NUM F
patients 0 NOUN F
plasmapheresis 0 NOUN F
in 0 ADP F
combination 0 NOUN F
with 0 ADP F
continuous 0 ADJ F
venovenous 0 ADJ F
hemofiltration 0 NOUN F
( 0 PUNCT F
CVVHF 0 NOUN T
) 0 PUNCT F
was 0 VERB F
administered 0 VERB F
. 0 PUNCT F

Lethality B-ADVERSE-EFFECTS NOUN T
was 0 VERB F
56 0 NUM F
% 0 SYM F
in 0 ADP F
the 0 DET F
sepsis B-PHYSICAL NOUN F
group I-PHYSICAL NOUN F
; 0 PUNCT F
in 0 ADP F
the 0 DET F
therapy B-MENTAL NOUN F
group I-MENTAL NOUN F
lethality B-MORTALITY NOUN F
was 0 VERB F
significantly B-MENTAL ADV F
lower 0 PUNCT F
in B-MENTAL ADP F
patients I-MENTAL NOUN F
with I-MENTAL ADP F
plasmapheresis B-MENTAL NOUN F
, 0 PUNCT F
even 0 ADV F
though 0 CCONJ F
in 0 ADP F
this 0 DET F
population 0 NOUN F
the 0 DET F
organic 0 ADJ F
failure 0 NOUN F
rate 0 NOUN F
was 0 VERB F
higher 0 PUNCT F
. 0 PUNCT F

Finally 0 ADV T
the 0 DET F
dependency 0 NOUN F
of 0 ADP F
lethality B-MENTAL NOUN F
and B-MENTAL CCONJ F
age 0 NOUN F
was B-MENTAL VERB F
similar I-MENTAL ADJ F
in I-MENTAL ADP F
both I-MENTAL CCONJ F
groups I-MENTAL NOUN F
. 0 PUNCT F

Intranasal 0 ADJ T
recombinant 0 ADJ F
alfa-2b 0 NOUN F
interferon 0 NOUN F
treatment 0 NOUN F
of 0 ADP F
naturally B-PHYSICAL ADV F
occurring I-PHYSICAL PUNCT F
common I-PHYSICAL ADJ F
colds I-PHYSICAL NOUN F
. 0 PUNCT F

In 0 ADP T
a 0 DET F
double-blind 0 ADJ F
, 0 PUNCT F
placebo-controlled 0 VERB F
study 0 NOUN F
, 0 PUNCT F
patients 0 NOUN F
with 0 ADP F
naturally 0 ADV F
occurring 0 PUNCT F
common 0 ADJ F
colds 0 NOUN F
of 0 ADP F
less 0 ADV F
than 0 PUNCT F
or 0 CCONJ F
equal 0 ADJ F
to 0 ADP F
48 0 NUM F
h 0 NOUN F
duration 0 NOUN F
were 0 VERB F
randomly 0 ADV F
assigned 0 VERB F
to 0 PART F
receive 0 NOUN F
nasal 0 ADJ F
sprays 0 NOUN F
of 0 ADP F
recombinant 0 ADJ F
alfa-2b 0 NOUN F
interferon 0 NOUN F
at 0 ADP F
10 0 NUM F
or 0 CCONJ F
20 0 NUM F
MU/day 0 NOUN T
or 0 CCONJ F
placebo 0 NOUN F
four 0 NUM F
times 0 NOUN F
per 0 ADP F
day 0 NOUN F
for 0 ADP F
5 0 NUM F
days 0 NOUN F
. 0 PUNCT F

The 0 DET T
10-MU 0 ADP F
( 0 PUNCT F
n 0 NOUN F
= 0 SYM F
74 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
20-MU 0 PUNCT F
( 0 PUNCT F
n 0 NOUN F
= 0 SYM F
74 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
and 0 CCONJ F
placebo 0 NOUN F
( 0 PUNCT F
n 0 NOUN F
= 0 SYM F
72 0 NUM F
) 0 PUNCT F
groups 0 NOUN F
had 0 DET F
comparable 0 ADJ F
frequencies 0 NOUN F
of 0 ADP F
documented 0 VERB F
rhinovirus 0 NOUN F
colds 0 NOUN F
( 0 PUNCT F
50 0 NUM F
to 0 ADP F
65 0 NUM F
% 0 SYM F
) 0 PUNCT F
and 0 CCONJ F
mean 0 NOUN F
durations 0 NOUN F
of 0 ADP F
pretreatment B-PHYSICAL NOUN F
symptoms I-PHYSICAL NOUN F
( 0 PUNCT F
26 0 NUM F
to 0 ADP F
27 0 NUM F
h 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
median 0 ADJ F
duration B-PHYSICAL NOUN F
of I-PHYSICAL ADP F
colds I-PHYSICAL NOUN F
tended 0 VERB F
to 0 PART F
be 0 PUNCT F
longer 0 PUNCT F
in 0 ADP F
the 0 DET F
20-MU 0 PUNCT F
group 0 NOUN F
( 0 PUNCT F
10 0 NUM F
days 0 NOUN F
) 0 PUNCT F
than 0 PUNCT F
the 0 DET F
10-MU 0 PUNCT F
group 0 NOUN F
( 0 PUNCT F
8 0 NUM F
days 0 NOUN F
) 0 PUNCT F
or 0 CCONJ F
placebo 0 NOUN F
group 0 NOUN F
( 0 PUNCT F
8 0 NUM F
days 0 NOUN F
) 0 PUNCT F
( 0 PUNCT F
P 0 NOUN T
= 0 SYM F
0.06 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

In 0 ADP T
those 0 PUNCT F
with 0 ADP F
proven 0 VERB F
rhinovirus 0 NOUN F
colds 0 NOUN F
treated 0 VERB F
within 0 ADP F
24 0 NUM F
h 0 NOUN F
, 0 PUNCT F
the 0 DET F
median 0 ADJ F
duration B-PHYSICAL NOUN F
was 0 VERB F
significantly 0 ADV F
longer 0 PUNCT F
in 0 ADP F
the 0 DET F
20-MU 0 PUNCT F
group 0 NOUN F
( 0 PUNCT F
9 0 NUM F
days 0 NOUN F
) 0 PUNCT F
than 0 PUNCT F
in 0 ADP F
the 0 DET F
placebo 0 NOUN F
group 0 NOUN F
( 0 PUNCT F
6 0 NUM F
days 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

No 0 DET T
differences 0 NOUN F
favoring 0 ADV F
interferon 0 NOUN F
treatment 0 NOUN F
were 0 VERB F
found 0 VERB F
in 0 ADP F
respiratory 0 ADJ F
symptom 0 NOUN F
scores 0 NOUN F
or 0 CCONJ F
resolution 0 NOUN F
of 0 ADP F
specific 0 ADJ F
symptoms 0 NOUN F
. 0 PUNCT F

On 0 ADP T
days 0 NOUN F
5 0 NUM F
and 0 CCONJ F
7 0 NUM F
, 0 PUNCT F
nasal 0 ADJ F
washings 0 DET F
from 0 ADP F
compliant 0 NOUN F
subjects 0 NOUN F
with 0 ADP F
proven 0 VERB F
rhinovirus 0 NOUN F
colds 0 NOUN F
yielded 0 VERB F
rhinoviruses 0 NOUN F
more 0 ADV F
often 0 ADV F
in 0 ADP F
placebo 0 NOUN F
( 0 PUNCT F
47 0 NUM F
and 0 CCONJ F
48 0 NUM F
% 0 SYM F
, 0 PUNCT F
respectively 0 ADV F
) 0 PUNCT F
than 0 PUNCT F
in 0 ADP F
interferon 0 NOUN F
( 0 PUNCT F
15 0 NUM F
and 0 CCONJ F
16 0 NUM F
% 0 SYM F
, 0 PUNCT F
respectively 0 ADV F
) 0 PUNCT F
recipients 0 NOUN F
( 0 PUNCT F
P 0 NOUN T
less 0 ADV F
than 0 CCONJ F
0.02 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
but 0 CCONJ F
no 0 DET F
differences 0 NOUN F
in 0 ADP F
new 0 ADJ F
respiratory B-PHYSICAL ADJ F
illness I-PHYSICAL NOUN F
occurrence I-PHYSICAL NOUN F
were 0 VERB F
observed 0 VERB F
in 0 ADP F
household 0 PUNCT F
contacts 0 NOUN F
. 0 PUNCT F

Interferon 0 NOUN T
recipients 0 NOUN F
had 0 PUNCT F
significantly 0 ADV F
higher 0 PUNCT F
frequencies 0 NOUN F
of 0 ADP F
blood 0 NOUN F
in 0 ADP F
nasal B-ADVERSE-EFFECTS ADJ F
mucus I-ADVERSE-EFFECTS NOUN F
( 0 PUNCT F
16 0 NUM F
to 0 ADP F
18 0 NUM F
% 0 SYM F
) 0 PUNCT F
than 0 PUNCT F
did 0 PUNCT F
placebo 0 NOUN F
recipients 0 NOUN F
( 0 PUNCT F
4 0 NUM F
% 0 SYM F
) 0 PUNCT F
during 0 ADP F
treatment 0 NOUN F
. 0 PUNCT F

Antibiotics B-PHYSICAL NOUN T
for 0 ADP F
presumed 0 ADP F
secondary 0 ADJ F
infections 0 NOUN F
were 0 VERB F
given 0 VERB F
more 0 ADV F
often 0 ADV F
in 0 ADP F
the 0 DET F
20-MU 0 PUNCT F
group 0 NOUN F
( 0 PUNCT F
11 0 NUM F
% 0 SYM F
) 0 PUNCT F
than 0 PUNCT F
in 0 ADP F
the 0 DET F
placebo 0 NOUN F
group 0 NOUN F
( 0 PUNCT F
0 0 NUM F
% 0 SYM F
) 0 PUNCT F
( 0 PUNCT F
P 0 NOUN T
less 0 ADV F
than 0 PUNCT F
0.01 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Nasal 0 ADJ T
sprays 0 NOUN F
of 0 ADP F
recombinant 0 ADJ F
alfa-2b 0 NOUN F
interferon 0 NOUN F
were 0 VERB F
not 0 ADV F
an 0 DET F
effective B-PHYSICAL ADJ F
treatment 0 NOUN F
for B-PHYSICAL ADP F
natural I-PHYSICAL ADJ F
colds B-PHYSICAL NOUN F
and 0 CCONJ F
were 0 VERB F
associated 0 VERB F
with 0 PUNCT F

Age 0 NOUN T
and 0 CCONJ F
autonomic 0 ADJ F
effects 0 NOUN F
on 0 ADP F
interrelationships 0 PUNCT F
between 0 ADP F
lung 0 NOUN F
volume 0 NOUN F
and 0 CCONJ F
heart 0 NOUN F
rate 0 NOUN F
. 0 PUNCT F

To 0 PART T
determine 0 DET F
effects 0 NOUN F
of 0 ADP F
aging 0 VERB F
and 0 CCONJ F
autonomic 0 ADJ F
input 0 NOUN F
on 0 ADP F
interrelationships 0 PUNCT F
between 0 ADP F
respiratory 0 ADJ F
and 0 CCONJ F
heart 0 NOUN F
rate 0 NOUN F
variability 0 NOUN F
, 0 PUNCT F
we 0 PRON F
collected 0 PROPN F
5 0 NUM F
min 0 NOUN F
of 0 ADP F
lung 0 NOUN F
volume 0 NOUN F
of 0 ADP F
R-R 0 NOUN T
interval 0 NOUN F
data 0 NOUN F
from 0 ADP F
7 0 NUM F
young 0 ADJ F
[ 0 PUNCT F
27 0 NUM F
+/- 0 SYM F
3 0 NUM F
( 0 PUNCT F
SD 0 NOUN T
) 0 PUNCT F
yr 0 NOUN F
] 0 PUNCT F
and 0 CCONJ F
10 0 NUM F
older 0 PUNCT F
( 0 PUNCT F
69 0 NUM F
+/- 0 SYM F
6 0 NUM F
yr 0 NOUN F
) 0 PUNCT F
healthy 0 ADJ F
supine 0 NOUN F
humans 0 NOUN F
before 0 ADP F
and 0 CCONJ F
after 0 ADP F
double 0 PUNCT F
pharmacological 0 ADJ F
autonomic 0 ADJ F
blockade 0 NOUN F
with 0 ADP F
propranolol 0 NOUN F
( 0 PUNCT F
0.2 0 NUM F
mg/kg 0 NOUN F
iv 0 PUNCT F
) 0 PUNCT F
and 0 CCONJ F
atropine 0 NOUN F
( 0 PUNCT F
0.04 0 NUM F
mg/kg 0 NOUN F
iv 0 PUNCT F
) 0 PUNCT F
. 0 PUNCT F

Estimates 0 NOUN T
of 0 ADP F
respiratory 0 ADJ F
and 0 CCONJ F
heart 0 NOUN F
rate 0 NOUN F
power 0 NOUN F
spectra 0 NOUN F
and 0 CCONJ F
linear 0 ADJ F
transfer 0 NOUN F
functions 0 DET F
between 0 ADP F
the 0 DET F
two 0 NUM F
groups 0 NOUN F
were 0 VERB F
generated 0 VERB F
by 0 ADP F
Fourier 0 NOUN T
analysis 0 NOUN F
. 0 PUNCT F

Age 0 NOUN T
, 0 PUNCT F
double 0 PUNCT F
blockade 0 NOUN F
effects 0 NOUN F
, 0 PUNCT F
the 0 DET F
age-drug 0 NOUN F
interactions 0 NOUN F
were 0 VERB F
determined 0 VERB F
by 0 ADP F
analysis 0 NOUN F
of 0 ADP F
variance 0 NOUN F
for 0 ADP F
repeated 0 VERB F
measures 0 NOUN F
. 0 PUNCT F

Basal 0 ADJ T
R-R 0 NOUN T
intervals 0 NOUN F
were 0 VERB F
unaffected 0 VERB F
by 0 ADP F
age 0 NOUN F
. 0 PUNCT F

Double 0 DET T
blockade 0 NOUN F
decreased 0 ADV F
R-R B-PHYSICAL NOUN T
intervals I-PHYSICAL NOUN F
and 0 CCONJ F
variability 0 NOUN F
in 0 ADP F
both 0 PUNCT F
age 0 NOUN F
groups 0 NOUN F
( 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.0001 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
but 0 CCONJ F
R-R 0 NOUN T
intervals 0 NOUN F
decreased 0 VERB F
less 0 ADV F
in 0 ADP F
older 0 PUNCT F
than 0 CCONJ F
in 0 ADP F
young 0 ADJ F
subjects 0 NOUN F
( 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.0001 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

In 0 ADP T
contrast 0 NOUN F
, 0 PUNCT F
basal B-PHYSICAL ADJ F
respiratory I-PHYSICAL ADJ F
intervals I-PHYSICAL NOUN F
and 0 CCONJ F
standard 0 ADJ F
deviation 0 NOUN F
were 0 VERB F
greater 0 PUNCT F
in 0 ADP F
older 0 PUNCT F
subjects 0 NOUN F
( 0 PUNCT F
P 0 NOUN T
= 0 SYM F
0.05 0 NUM F
) 0 PUNCT F
and 0 CCONJ F
were 0 VERB F
unaffected 0 VERB F
by 0 ADP F
double 0 PUNCT F
blockade 0 NOUN F
in 0 ADP F
young 0 ADJ F
and 0 CCONJ F
older 0 PUNCT F
subjects 0 NOUN F
. 0 PUNCT F

Lung B-PHYSICAL NOUN T
volume-to-heart I-PHYSICAL NOUN F
rate I-PHYSICAL NOUN F
spectral I-PHYSICAL ADJ F
coherence I-PHYSICAL NOUN F
was 0 ADV F
highest 0 PUNCT F
at 0 ADP F
frequencies 0 NOUN F
associated 0 VERB F
with 0 ADP F
respiration 0 NOUN F
and 0 CCONJ F
greater 0 PUNCT F
in 0 ADP F
young 0 PUNCT F
than 0 PUNCT F
in 0 ADP F
older 0 PUNCT F
subjects 0 NOUN F
( 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.07 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Double 0 DET T
blockade 0 NOUN F
decreased 0 VERB F
lung B-PHYSICAL NOUN F
volume-to-heart I-PHYSICAL NOUN F
rate I-PHYSICAL NOUN F
variability 0 NOUN F
transfer 0 NOUN F
function 0 NUM F
magnitude B-PHYSICAL NOUN F
( 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.007 0 NUM F
) 0 PUNCT F
and 0 CCONJ F
increased 0 VERB F
phase 0 NOUN F
angle B-PHYSICAL NOUN F
( 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.02 0 NUM F
) 0 PUNCT F
without 0 ADP F
age 0 NOUN F
effects 0 NOUN F
or 0 CCONJ F
age-drug 0 NOUN F
interactions 0 NOUN F
. 0 PUNCT F

In 0 ADP T
conclusion 0 NOUN F
, 0 PUNCT F
heart B-PHYSICAL NOUN F
rate B-PHYSICAL NOUN F
, 0 PUNCT F
respiration B-PHYSICAL NOUN F
, 0 PUNCT F
and 0 PUNCT F

Prognosis 0 NOUN T
of 0 ADP F
advanced 0 VERB F
hepatocellular 0 ADJ F
carcinoma 0 NOUN F
: 0 PUNCT F
comparison 0 NOUN F
of 0 ADP F
three 0 NUM F
staging 0 VERB F
systems 0 NOUN F
in 0 ADP F
two 0 NUM F
French 0 ADJ T
clinical 0 ADJ F
trials 0 NOUN F
. 0 PUNCT F

OBJECTIVE 0 NOUN T
The 0 DET T
objective 0 NOUN F
of 0 ADP F
this 0 DET F
study 0 NOUN F
was 0 VERB F
to 0 ADV F
assess 0 NOUN F
the 0 DET F
performance 0 NOUN F
of 0 ADP F
three 0 NUM F
staging 0 VERB F
systems 0 NOUN F
[ 0 PUNCT F
Okuda 0 NOUN T
, 0 PUNCT F
Cancer 0 NOUN T
of 0 ADP F
the 0 DET F
Liver 0 NOUN T
Italian 0 ADJ T
Program 0 NOUN T
( 0 PUNCT F
CLIP 0 NOUN T
) 0 PUNCT F
and 0 CCONJ F
Barcelona 0 NOUN T
Clinic 0 PUNCT T
Liver 0 NOUN T
Cancer 0 NOUN T
group 0 NOUN F
( 0 PUNCT F
BCLC 0 NOUN T
) 0 PUNCT F
] 0 PUNCT F
, 0 PUNCT F
for 0 ADP F
predicting 0 VERB F
survival B-MORTALITY NOUN F
in 0 ADP F
patients 0 NOUN F
with 0 ADP F
hepatocellular 0 ADJ F
carcinoma 0 NOUN F
( 0 PUNCT F
HCC 0 NOUN T
) 0 PUNCT F
and 0 CCONJ F
to 0 PUNCT F
explore 0 NOUN F
how 0 ADP F
to 0 PUNCT F
improve 0 ADJ F
prognostic 0 ADJ F
classification 0 NOUN F
among 0 ADP F
French 0 PUNCT T
patients 0 NOUN F
with 0 ADP F
HCC 0 NOUN T
whose 0 ADP F
main 0 ADJ F
etiology 0 NOUN F
is 0 VERB F
alcoholic 0 ADJ F
cirrhosis 0 NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
We 0 PRON T
have 0 PUNCT F
pooled 0 VERB F
two 0 NUM F
randomized 0 VERB F
clinical 0 ADJ F
trials 0 NOUN F
in 0 ADP F
palliative 0 ADJ F
condition 0 NOUN F
from 0 ADP F
the 0 DET F
F?d?ration 0 NOUN T
Francophone 0 NOUN T
de 0 ADP F
Cancerologie 0 ADJ T
Digestive 0 ADJ T
. 0 PUNCT F

They 0 PRON T
had 0 PUNCT F
included 0 PUNCT F
416 0 NUM F
and 0 CCONJ F
122 0 NUM F
patients 0 NOUN F
. 0 PUNCT F

Performances 0 NOUN T
of 0 ADP F
Okuda 0 NOUN T
, 0 PUNCT F
CLIP 0 NOUN T
and 0 CCONJ F
BCLC 0 NOUN T
scores 0 NOUN F
have 0 ADP F
been 0 PUNCT F
compared 0 VERB F
using 0 PROPN F
Akaike 0 ADJ T
information 0 NOUN F
criterion 0 NOUN F
, 0 PUNCT F
discriminatory 0 ADJ F
ability 0 NOUN F
( 0 PUNCT F
Harrell 0 NOUN T
's 0 PUNCT F
C 0 NOUN T
and 0 CCONJ F
the 0 DET F
Royston 0 NOUN T
's 0 PUNCT F
D 0 NOUN T
statistics 0 NOUN F
) 0 PUNCT F
, 0 PUNCT F
monotonicity 0 NOUN F
of 0 ADP F
gradients 0 NOUN F
and 0 CCONJ F
predictive 0 ADJ F
accuracy 0 NOUN F
( 0 PUNCT F
Schemper 0 PUNCT T
statistics 0 NOUN F
Vs 0 PUNCT T
) 0 PUNCT F
. 0 PUNCT F

To 0 PART T
explore 0 VERB F
how 0 ADP F
to 0 PUNCT F
improve 0 ADJ F
classifications 0 NOUN F
, 0 PUNCT F
univariate 0 ADJ F
and 0 CCONJ F
multivariate 0 ADJ F
Cox 0 NOUN T
model 0 NOUN F
analyses 0 NOUN F
were 0 VERB F
carried 0 VERB F
out 0 ADP F
. 0 PUNCT F

RESULTS 0 PUNCT T
The 0 DET T
pooled 0 VERB F
database 0 NOUN F
included 0 VERB F
538 0 NUM F
patients 0 NOUN F
. 0 PUNCT F

The 0 DET T
median 0 ADJ F
survival 0 NOUN F
was 0 ADV F
5.3 0 NUM F
months 0 NOUN F
( 0 PUNCT F
95 0 NUM F
% 0 SYM F
confidence 0 NOUN F
interval 0 NOUN F
4.6-6.2 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

For 0 ADP T
all 0 DET F
statistics 0 NOUN F
CLIP 0 NOUN T
staging 0 VERB F
system 0 NOUN F
had 0 PUNCT F
a 0 DET F
better 0 PUNCT F
prognostic 0 ADJ F
ability 0 NOUN F
. 0 PUNCT F

Performances 0 NOUN T
of 0 ADP F
all 0 DET F
staging 0 VERB F
systems 0 NOUN F
were 0 NUM F
rather 0 ADP F
disappointing 0 PUNCT F
. 0 PUNCT F

World 0 NOUN T
Health 0 NOUN T
Organization 0 NOUN T
performance 0 NOUN F
status 0 NOUN F
( 0 PUNCT F
WHO 0 NOUN T
PS 0 NOUN T
) 0 PUNCT F
for 0 ADP F
CLIP 0 NOUN T
or 0 CCONJ F
alpha-fetoprotein 0 NOUN F
for 0 ADP F
BCLC 0 NOUN T
allowed 0 VERB F
a 0 DET F
significant 0 ADJ F
improvement 0 NOUN F
of 0 ADP F
prognostic 0 ADJ F
information 0 NOUN F
. 0 PUNCT F

CONCLUSION 0 NOUN T
Our 0 PUNCT T
results 0 NOUN F
indicate 0 VERB F
that 0 ADP F
CLIP 0 NOUN T
staging 0 ADV F
seems 0 SYM F
to 0 DET F
be 0 PUNCT F
most 0 PUNCT F
adapted 0 VERB F
to 0 ADP F
palliative 0 ADJ F
setting 0 ADP F
and 0 CCONJ F
that 0 ADP F
it 0 PRON F
could 0 VERB F
be 0 ADP F
better 0 PUNCT F
by 0 ADP F
associating 0 PUNCT F
WHO 0 NOUN T
PS 0 NOUN T
. 0 PUNCT F

Parenteral 0 ADJ T
nutrition 0 NOUN F
and 0 CCONJ F
protein 0 NOUN F
sparing 0 PUNCT F
after 0 ADP F
surgery 0 NOUN F
: 0 PUNCT F
do 0 PUNCT F
we 0 PRON F
need 0 VERB F
glucose 0 NOUN F
? 0 PUNCT F

Although 0 ADP T
capable 0 ADJ F
of 0 ADP F
inducing 0 VERB F
an 0 DET F
anabolic 0 ADJ F
state 0 NOUN F
after 0 ADP F
surgery 0 NOUN F
, 0 PUNCT F
parenteral 0 ADJ F
nutrition 0 NOUN F
, 0 PUNCT F
including 0 CCONJ F
glucose 0 NOUN F
, 0 PUNCT F
leads 0 NOUN F
to 0 ADP F
hyperglycemia 0 NOUN F
. 0 PUNCT F

Even 0 ADV T
moderate 0 ADJ F
increases 0 CCONJ F
in 0 ADP F
blood 0 NOUN F
glucose 0 NOUN F
are 0 VERB F
associated 0 VERB F
with 0 ADP F
poor 0 ADJ F
surgical 0 ADJ F
outcome 0 NOUN F
. 0 PUNCT F

We 0 PRON T
examined 0 VERB F
the 0 DET F
hypothesis 0 NOUN F
that 0 ADP F
amino 0 ADJ F
acids 0 NOUN F
, 0 PUNCT F
in 0 ADP F
the 0 DET F
absence 0 NOUN F
of 0 ADP F
glucose 0 NOUN F
supply 0 NOUN F
, 0 PUNCT F
spare 0 NOUN F
protein 0 NOUN F
while 0 ADP F
preventing 0 PUNCT F
hyperglycemia 0 NOUN F
. 0 PUNCT F

In 0 ADP T
this 0 DET F
prospective 0 ADJ F
study 0 NOUN F
, 0 PUNCT F
14 0 NUM F
patients 0 NOUN F
with 0 ADP F
colonic 0 ADJ F
cancer 0 NOUN F
were 0 VERB F
randomly 0 ADV F
assigned 0 VERB F
to 0 ADJ F
undergo 0 VERB F
a 0 DET F
6-hour 0 NOUN F
stable 0 ADJ F
isotope 0 NOUN F
infusion 0 NOUN F
study 0 NOUN F
( 0 PUNCT F
3 0 NUM F
hours 0 NOUN F
of 0 ADP F
fasting 0 PUNCT F
followed 0 VERB F
by 0 ADP F
3-hour 0 NOUN F
infusions 0 NOUN F
of 0 ADP F
amino 0 ADJ F
acids 0 NOUN F
, 0 PUNCT F
Travasol 0 NOUN T
[ 0 PUNCT F
Baxter 0 NOUN T
, 0 PUNCT F
Montreal 0 PUNCT T
, 0 PUNCT F
Canada 0 PUNCT T
] 0 PUNCT F
10 0 NUM F
% 0 SYM F
at 0 ADP F
0.02 0 NUM F
mL.kg 0 NOUN F
( 0 PUNCT F
-1 0 NUM F
) 0 PUNCT F
.min 0 PUNCT F
( 0 PUNCT F
-1 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
with 0 ADP F
or 0 CCONJ F
without 0 ADP F
glucose 0 NOUN F
at 0 ADP F
4 0 NUM F
mg.kg 0 NOUN F
( 0 PUNCT F
-1 0 NUM F
) 0 PUNCT F
.min 0 PUNCT F
( 0 PUNCT F
-1 0 NUM F
) 0 PUNCT F
) 0 PUNCT F
on 0 ADP F
the 0 DET F
second 0 ADJ F
day 0 NOUN F
after 0 PUNCT F
colorectal 0 ADJ F
surgery 0 NOUN F
. 0 PUNCT F

Protein B-PHYSICAL NOUN T
breakdown I-PHYSICAL NOUN F
, 0 PUNCT F
protein B-PHYSICAL NOUN F
oxidation I-PHYSICAL NOUN F
, 0 PUNCT F
protein B-PHYSICAL NOUN F
balance I-PHYSICAL NOUN F
, 0 PUNCT F
and 0 CCONJ F
glucose B-PHYSICAL NOUN F
production I-PHYSICAL NOUN F
were 0 VERB F
assessed 0 VERB F
by 0 ADP F
stable 0 ADJ F
isotope 0 NOUN F
tracer 0 NOUN F
kinetics 0 NOUN F
using 0 ADJ F
l- 0 PUNCT F
[ 0 PUNCT F
1- 0 NUM F
( 0 PUNCT F
13 0 NUM F
) 0 PUNCT F
C 0 NOUN T
] 0 PUNCT F
leucine 0 NOUN F
and 0 CCONJ F
[ 0 PUNCT F
6,6- 0 NUM F
( 0 PUNCT F
2 0 NUM F
) 0 PUNCT F
H2 0 NOUN T
] 0 PUNCT F
glucose 0 NOUN F
. 0 PUNCT F

Circulating B-PHYSICAL VERB T
concentrations I-PHYSICAL NOUN F
of I-PHYSICAL ADP F
glucose I-PHYSICAL NOUN F
, 0 PUNCT F
cortisol B-PHYSICAL NOUN F
, 0 PUNCT F
insulin B-PHYSICAL NOUN F
, 0 PUNCT F
and 0 CCONJ F
glucagon B-PHYSICAL NOUN F
were 0 VERB F
determined 0 VERB F
. 0 PUNCT F

The 0 DET T
administration 0 NOUN F
of 0 ADP F
amino 0 ADJ F
acids 0 NOUN F
increased 0 ADV F
protein B-PHYSICAL NOUN F
balance I-PHYSICAL NOUN F
from 0 ADP F
-16+/-4 0 NOUN F
micromol.kg 0 NOUN F
( 0 PUNCT F
-1 0 NUM F
) 0 PUNCT F
.h 0 PUNCT F
( 0 PUNCT F
-1 0 NUM F
) 0 PUNCT F
in 0 ADP F
the 0 DET F
fasted 0 VERB F
state 0 NOUN F
to 0 ADP F
16+/-3 0 NOUN F
micromol.kg 0 NOUN F
( 0 PUNCT F
-1 0 NUM F
) 0 PUNCT F
.h 0 PUNCT F
( 0 PUNCT F
-1 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Combined 0 VERB T
infusion 0 NOUN F
of 0 ADP F
amino 0 ADJ F
acids 0 NOUN F
and 0 CCONJ F
glucose 0 NOUN F
increased 0 ADV F
protein B-PHYSICAL NOUN F
balance I-PHYSICAL NOUN F
from 0 ADP F
-17+/-7 0 VERB F
to 0 ADP F
7+/-5 0 CCONJ F
micromol.kg 0 NOUN F
( 0 PUNCT F
-1 0 NUM F
) 0 PUNCT F
.h 0 PUNCT F
( 0 PUNCT F
-1 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
increase 0 NOUN F
in 0 ADP F
protein B-PHYSICAL NOUN F
balance I-PHYSICAL NOUN F
during 0 ADP F
nutrition 0 NOUN F
was 0 VERB F
comparable 0 ADJ F
in 0 ADP F
the 0 DET F
2 0 NUM F
groups 0 NOUN F
( 0 PUNCT F
P=.07 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

Combined 0 VERB T
administration 0 NOUN F
of 0 ADP F
amino 0 ADJ F
acids 0 NOUN F
and 0 CCONJ F
glucose 0 NOUN F
decreased 0 VERB F
endogenous B-PHYSICAL ADJ F
glucose I-PHYSICAL NOUN F
production I-PHYSICAL NOUN F
( 0 PUNCT F
P=.001 0 NOUN T
) 0 PUNCT F
and 0 CCONJ F
stimulated 0 VERB F
insulin B-PHYSICAL NOUN F
secretion I-PHYSICAL NOUN F
( 0 PUNCT F
P=.001 0 NOUN T
) 0 PUNCT F
to 0 ADP F
a 0 DET F
greater 0 PUNCT F
extent 0 NOUN F
than 0 PUNCT F
the 0 DET F
administration 0 NOUN F
of 0 ADP F
amino 0 ADJ F
acids 0 NOUN F
alone 0 ADJ F
. 0 PUNCT F

Hyperglycemia B-PHYSICAL NOUN T
( 0 PUNCT F
blood 0 NOUN F
glucose 0 NOUN F
, 0 PUNCT F
10.1+/-1.9 0 NOUN F
micromol/L 0 NOUN F
) 0 PUNCT F
occurred 0 VERB F
only 0 ADV F
in 0 ADP F
the 0 DET F
presence 0 NOUN F
of 0 ADP F
glucose 0 NOUN F
infusion 0 NOUN F
. 0 PUNCT F

In 0 ADP T
summary 0 NOUN F
, 0 PUNCT F
excluding 0 CCONJ F
glucose 0 NOUN F
from 0 ADP F
a 0 DET F
short-term 0 NOUN F
feeding 0 ADP F
protocol 0 NOUN F
does 0 PUNCT F
not 0 ADV F
diminish 0 VERB F
the 0 DET F
protein-sparing B-PHYSICAL ADV F
effect 0 NOUN F
of 0 ADP F
amino 0 ADJ F
acids 0 NOUN F
and 0 CCONJ F
avoids 0 NOUN F
hyperglycemia B-PHYSICAL NOUN F
. 0 PUNCT F

Variations 0 NOUN T
in 0 ADP F
EEG B-PHYSICAL NOUN T
discharges I-PHYSICAL ADJ F
predict 0 ADJ F
ADHD 0 NOUN T
severity 0 NOUN F
within 0 ADP F
individual 0 ADJ F
Smith-Lemli-Opitz 0 PUNCT T
patients 0 NOUN F
. 0 PUNCT F

OBJECTIVE 0 NOUN T
We 0 PRON T
sought 0 PROPN F
to 0 PART F
examine 0 NOUN F
the 0 DET F
prevalence 0 NOUN F
of 0 ADP F
EEG 0 NOUN T
abnormalities 0 NOUN F
in 0 ADP F
Smith-Lemli-Opitz 0 PUNCT T
syndrome 0 NOUN F
( 0 PUNCT F
SLOS 0 NOUN T
) 0 PUNCT F
as 0 CCONJ F
well 0 PUNCT F
as 0 CCONJ F
the 0 DET F
relationship 0 NOUN F
between 0 ADP F
interictal 0 ADJ F
epileptiform 0 NUM F
discharges 0 ADJ F
( 0 PUNCT F
IEDs 0 NOUN T
) 0 PUNCT F
and 0 CCONJ F
within-subject 0 ADP F
variations 0 NOUN F
in 0 ADP F
attentional 0 ADJ F
symptom 0 NOUN F
severity 0 NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
In 0 ADP T
the 0 DET F
context 0 NOUN F
of 0 ADP F
a 0 DET F
clinical 0 ADJ F
trial 0 NOUN F
for 0 ADP F
SLOS 0 NOUN T
, 0 PUNCT F
we 0 PRON F
performed 0 VERB F
cross-sectional 0 ADJ F
and 0 CCONJ F
repeated-measure 0 NOUN F
observational 0 ADJ F
studies 0 NOUN F
of 0 ADP F
the 0 DET F
relationship 0 NOUN F
between 0 ADP F
EEG 0 NOUN T
findings 0 NOUN F
and 0 CCONJ F
cognitive/behavioral 0 ADJ F
factors 0 NOUN F
on 0 ADP F
23 0 NUM F
children 0 NOUN F
( 0 PUNCT F
aged 0 PROPN F
4-17 0 NUM F
years 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

EEGs 0 NOUN T
were 0 VERB F
reviewed 0 VERB F
for 0 ADP F
clinical 0 ADJ F
abnormalities 0 NOUN F
, 0 PUNCT F
including 0 VERB F
IEDs 0 NOUN T
, 0 PUNCT F
by 0 ADP F
readers 0 NOUN F
blinded 0 VERB F
to 0 ADP F
participants 0 NOUN F
' 0 PUNCT F
behavioral 0 ADJ F
symptoms 0 NOUN F
. 0 PUNCT F

Between-group 0 ADP T
differences 0 NOUN F
in 0 ADP F
baseline 0 NOUN F
characteristics 0 NOUN F
of 0 ADP F
participants 0 NOUN F
with 0 ADP F
and 0 CCONJ F
without 0 ADP F
IEDs 0 NOUN T
were 0 VERB F
analyzed 0 VERB F
. 0 PUNCT F

Within-subject 0 PUNCT T
analyses 0 NOUN F
examined 0 VERB F
the 0 DET F
association 0 NOUN F
between 0 ADP F
the 0 DET F
presence 0 NOUN F
of 0 ADP F
IEDs 0 NOUN T
and 0 CCONJ F
changes 0 NOUN F
in 0 ADP F
attention-deficit/hyperactivity B-PHYSICAL NOUN F
disorder I-PHYSICAL NOUN F
( I-PHYSICAL PUNCT F
ADHD I-PHYSICAL NOUN T
) I-PHYSICAL PUNCT F
symptoms I-PHYSICAL NOUN F
. 0 PUNCT F

RESULTS 0 NOUN T
Of 0 ADP T
85 0 NUM F
EEGs 0 PUNCT T
, 0 PUNCT F
43 0 NUM F
( 0 PUNCT F
51 0 NUM F
% 0 SYM F
) 0 PUNCT F
were 0 VERB F
abnormal B-PHYSICAL ADJ F
, 0 PUNCT F
predominantly 0 ADP F
because 0 PUNCT F
of 0 ADP F
IEDs 0 NOUN T
. 0 PUNCT F

Only 0 ADV T
one 0 NUM F
subject 0 NOUN F
had 0 PUNCT F
documented 0 VERB F
clinical B-ADVERSE-EFFECTS ADJ F
seizures I-ADVERSE-EFFECTS NOUN F
. 0 PUNCT F

IEDs 0 NOUN T
clustered 0 VERB F
in 0 ADP F
13 0 NUM F
subjects 0 NOUN F
( 0 PUNCT F
57 0 NUM F
% 0 SYM F
) 0 PUNCT F
, 0 PUNCT F
whereas 0 ADP F
9 0 NUM F
subjects 0 NOUN F
( 0 PUNCT F
39 0 NUM F
% 0 SYM F
) 0 PUNCT F
had 0 PUNCT F
EEGs 0 NOUN T
consistently 0 ADV F
free 0 ADJ F
of 0 ADP F
IEDs 0 NOUN T
. 0 PUNCT F

While 0 ADP T
there 0 PUNCT F
were 0 VERB F
no 0 DET F
significant 0 ADJ F
group 0 NOUN F
differences 0 NOUN F
in 0 ADP F
sex 0 NOUN F
, 0 PUNCT F
age 0 NOUN F
, 0 PUNCT F
intellectual 0 ADJ F
disability 0 NOUN F
, 0 PUNCT F
language 0 NOUN F
level 0 NOUN F
, 0 PUNCT F
or 0 CCONJ F
baseline 0 NOUN F
ADHD 0 NOUN T
symptoms 0 NOUN F
, 0 PUNCT F
autistic 0 ADJ F
symptoms 0 NOUN F
tended 0 VERB F
to 0 PART F
be 0 PUNCT F
more 0 ADV F
prevalent 0 ADJ F
in 0 ADP F
the 0 DET F
IED 0 NOUN T
group 0 NOUN F
( 0 PUNCT F
according 0 PUNCT F
to 0 ADP F
Autism B-MENTAL NOUN T
Diagnostic I-MENTAL ADJ T
Observation I-MENTAL NOUN T
Schedule-2 I-MENTAL NOUN T
criteria I-MENTAL NOUN F
) I-MENTAL PUNCT F
. 0 PUNCT F

Within 0 ADP T
individuals 0 NOUN F
, 0 PUNCT F
the 0 DET F
presence 0 NOUN F
of 0 ADP F
IEDs 0 NOUN T
on 0 ADP F
a 0 DET F
particular 0 ADJ F
EEG 0 NOUN T
predicted 0 PUNCT F
, 0 PUNCT F
on 0 ADP F
average 0 NOUN F
, 0 PUNCT F
a 0 DET F
27 0 NUM F
% 0 SYM F
increase 0 NOUN F
in 0 ADP F
ADHD B-MENTAL NOUN T
symptom I-MENTAL NOUN F
severity I-MENTAL NOUN F
. 0 PUNCT F

CONCLUSIONS 0 NOUN T
Epileptiform 0 PUNCT T
discharges 0 ADJ F
are 0 CCONJ F
common 0 ADJ F
in 0 ADP F
SLOS 0 NOUN T
, 0 PUNCT F
despite 0 ADP F
a 0 DET F
relatively 0 ADV F
low 0 ADJ F
prevalence 0 NOUN F
of 0 ADP F
epilepsy 0 NOUN F
. 0 PUNCT F

Fluctuations 0 NOUN T
in 0 ADP F
the 0 DET F
presence 0 NOUN F
of 0 ADP F
epileptiform 0 VERB F
discharges 0 ADJ F
within 0 ADP F
individual 0 ADJ F
children 0 NOUN F
with 0 ADP F
a 0 DET F
developmental 0 ADJ F
disability 0 NOUN F
syndrome 0 NOUN F
may 0 VERB F
be 0 VERB F
associated 0 VERB F
with 0 ADP F
fluctuations 0 NOUN F
in 0 ADP F
ADHD 0 NOUN T
symptomatology 0 NOUN F
, 0 PUNCT F
even 0 ADV F
in 0 ADP F
the 0 DET F
absence 0 NOUN F
of 0 ADP F
clinical 0 ADJ F
seizures 0 NOUN F
. 0 PUNCT F

Cyclosporin 0 NOUN T
A 0 DET T
increases 0 ADP F
somatomedin B-ADVERSE-EFFECTS NOUN F
C I-ADVERSE-EFFECTS NOUN T
insulin-like I-ADVERSE-EFFECTS ADJ F
growth I-ADVERSE-EFFECTS NOUN F
factor 0 NOUN F
I B-ADVERSE-EFFECTS NUM T
levels B-ADVERSE-EFFECTS NOUN F
in 0 ADP F
chronic 0 ADJ F
rheumatic 0 ADJ F
diseases 0 NOUN F
. 0 PUNCT F

OBJECTIVE 0 NOUN T
To 0 PROPN T
determine 0 NOUN F
whether 0 ADP F
anabolic 0 ADJ F
hormones 0 NOUN F
that 0 ADP F
affect 0 VERB F
the 0 DET F
musculoskeletal 0 ADJ F
system 0 NOUN F
and 0 CCONJ F
active 0 ADJ F
on 0 ADP F
the 0 DET F
immune 0 ADJ F
cells 0 NOUN F
changed 0 VERB F
during 0 ADP F
cyclosporin 0 NOUN F
A 0 NOUN T
( 0 PUNCT F
CysA 0 NOUN T
) 0 PUNCT F
therapy 0 NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
We 0 ADJ T
carried 0 PUNCT F
out 0 ADP F
a 0 DET F
randomized 0 VERB F
study 0 NOUN F
of 0 ADP F
patients 0 NOUN F
with 0 ADP F
rheumatic 0 ADJ F
disease 0 NOUN F
attending 0 VERB F
the 0 DET F
outpatient 0 ADJ F
clinic 0 NOUN F
for 0 ADP F
rheumatic 0 ADJ F
diseases 0 NOUN F
. 0 PUNCT F

Twenty-four 0 PUNCT T
patients 0 NOUN F
with 0 ADP F
chronic 0 ADJ F
arthritis 0 NOUN F
[ 0 PUNCT F
20 0 NUM F
with 0 ADP F
rheumatoid 0 ADJ F
arthritis 0 NOUN F
( 0 PUNCT F
RA 0 NOUN T
) 0 PUNCT F
and 0 CCONJ F
4 0 NUM F
with 0 ADP F
psoriatic 0 ADJ F
arthritis 0 NOUN F
( 0 PUNCT F
PsA 0 NOUN T
) 0 PUNCT F
] 0 PUNCT F
were 0 VERB F
divided 0 VERB F
into 0 ADP F
2 0 NUM F
groups 0 NOUN F
( 0 PUNCT F
10 0 NUM F
RA 0 NOUN T
, 0 PUNCT F
2 0 NUM F
PsA 0 NOUN T
) 0 PUNCT F
and 0 CCONJ F
randomly 0 ADV F
given 0 VERB F
CysA 0 NOUN T
5 0 NUM F
mg/kg 0 NOUN F
daily 0 ADP F
or 0 CCONJ F
hydroxychloroquine 0 NOUN F
( 0 PUNCT F
OH-Chlor 0 NOUN T
) 0 PUNCT F
6 0 NUM F
mg/kg 0 NOUN F
daily 0 ADP F
in 0 ADP F
divided 0 VERB F
doses 0 NOUN F
. 0 PUNCT F

RESULTS 0 NOUN T
A 0 PUNCT T
significant 0 ADJ F
increase 0 NOUN F
of 0 ADP F
insulin-like B-PHYSICAL ADJ F
growth I-PHYSICAL NOUN F
factor 0 NOUN F
I 0 NUM T
( 0 PUNCT F
IGF-I 0 NOUN T
) 0 PUNCT F
( 0 PUNCT F
somatomedin 0 NOUN F
C 0 NOUN T
) 0 PUNCT F
levels 0 NOUN F
and 0 CCONJ F
of 0 PUNCT F

Effectiveness 0 NOUN T
of 0 ADP F
a 0 DET F
clinical 0 ADJ F
intervention 0 NOUN F
in 0 ADP F
improving 0 VERB F
pain 0 NOUN F
control 0 NOUN F
in 0 ADP F
outpatients 0 ADJ F
with 0 ADP F
cancer 0 NOUN F
treated 0 VERB F
by 0 ADP F
radiation 0 NOUN F
therapy 0 NOUN F
. 0 PUNCT F

PURPOSE 0 NOUN T
To 0 PROPN T
determine 0 NOUN F
the 0 DET F
effectiveness 0 NOUN F
of 0 ADP F
a 0 DET F
multicomponent 0 ADJ F
clinical 0 ADJ F
intervention 0 NOUN F
to 0 PART F
reduce 0 NOUN F
pain 0 NOUN F
in 0 ADP F
outpatients 0 ADJ F
with 0 ADP F
cancer 0 NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
AND 0 CCONJ T
MATERIALS 0 CCONJ T
Sixty-four 0 PUNCT T
patients 0 NOUN F
were 0 VERB F
randomly 0 ADV F
assigned 0 VERB F
to 0 PART F
receive 0 NOUN F
either 0 PUNCT F
a 0 DET F
clinical 0 ADJ F
intervention 0 NOUN F
including 0 ADJ F
an 0 DET F
information 0 NOUN F
session 0 NOUN F
, 0 PUNCT F
the 0 DET F
use 0 NOUN F
of 0 ADP F
a 0 DET F
pain 0 NOUN F
diary 0 PUNCT F
, 0 PUNCT F
and 0 CCONJ F
the 0 DET F
possibility 0 NOUN F
to 0 ADV F
contact 0 NOUN F
a 0 DET F
physician 0 NOUN F
to 0 PUNCT F
adjust 0 PUNCT F
the 0 DET F
pain 0 NOUN F
medication 0 NOUN F
, 0 PUNCT F
or 0 CCONJ F
the 0 DET F
usual 0 ADJ F
treatment 0 NOUN F
of 0 ADP F
pain 0 NOUN F
by 0 ADP F
the 0 DET F
staff 0 NOUN F
radiation 0 NOUN F
oncologist 0 NOUN F
. 0 PUNCT F

All 0 DET T
patients 0 NOUN F
reported 0 VERB F
their 0 PUNCT F
average 0 ADJ F
and 0 CCONJ F
worst 0 PUNCT F
pain B-PAIN NOUN F
levels I-PAIN NOUN F
at 0 ADP F
baseline 0 NOUN F
and 0 CCONJ F
2 0 NUM F
and 0 CCONJ F
3 0 NUM F
weeks 0 NOUN F
after 0 ADP F
the 0 DET F
start 0 NOUN F
of 0 ADP F
the 0 DET F
intervention 0 NOUN F
. 0 PUNCT F

RESULTS 0 PUNCT T
The 0 DET T
study 0 ADV F
groups 0 NOUN F
were 0 VERB F
similar 0 ADJ F
with 0 ADP F
respect 0 NOUN F
to 0 ADP F
their 0 PUNCT F
baseline 0 NOUN F
characteristics 0 NOUN F
and 0 CCONJ F
pain 0 NOUN F
levels 0 NOUN F
at 0 ADP F
randomization 0 NOUN F
. 0 PUNCT F

After 0 ADP T
3 0 NUM F
weeks 0 NOUN F
, 0 PUNCT F
the 0 DET F
average 0 ADJ F
and 0 CCONJ F
worst 0 PUNCT F
pain 0 NOUN F
experienced 0 VERB F
by 0 ADP F
patients 0 NOUN F
randomized 0 VERB F
to 0 ADP F
the 0 DET F
clinical 0 ADJ F
intervention 0 NOUN F
group 0 NOUN F
was 0 VERB F
significantly 0 ADV F
inferior 0 ADJ F
to 0 ADP F
the 0 DET F
average 0 ADJ F
pain 0 NOUN F
experienced 0 VERB F
by 0 ADP F
patients 0 NOUN F
in 0 ADP F
the 0 DET F
control 0 NOUN F
group 0 NOUN F
( 0 PUNCT F
2.9/10 0 NUM F
vs. 0 CCONJ F
4.4/10 0 NOUN F
and 0 CCONJ F
4.2/10 0 NOUN F
vs. 0 CCONJ F
5.5/10 0 ADV F
, 0 PUNCT F
respectively 0 ADV F
) 0 PUNCT F
. 0 PUNCT F

Results 0 NOUN T
showed 0 VERB F
that 0 ADP F
the 0 DET F
experimental 0 ADJ F
group 0 NOUN F
patients 0 NOUN F
decreased 0 VERB F
their 0 ADP F
pain 0 NOUN F
levels 0 NOUN F
more 0 ADV F
than 0 PUNCT F
the 0 DET F
control 0 NOUN F
group 0 NOUN F
patients 0 NOUN F
did 0 PUNCT F
over 0 PUNCT F
time 0 NOUN F
. 0 PUNCT F

CONCLUSION 0 NOUN T
An 0 DET T
intervention 0 NOUN F
including 0 DET F
patient 0 NOUN F
education 0 NOUN F
, 0 PUNCT F
a 0 DET F
pain B-PAIN NOUN F
diary I-PAIN PUNCT F
, 0 PUNCT F
and 0 CCONJ F
defining 0 VERB F
a 0 DET F
procedure 0 NOUN F
for 0 ADP F
therapeutic 0 ADJ F
adjustments 0 NOUN F
can 0 VERB F
be 0 NOUN F
effective 0 ADJ F
to 0 PART F
improve B-PAIN ADJ F
pain I-PAIN NOUN F
relief I-PAIN NOUN F
in 0 ADP F
outpatients B-PHYSICAL ADJ F
with I-PHYSICAL ADP F
cancer I-PHYSICAL NOUN F
. 0 PUNCT F

A 0 DET T
randomised 0 VERB F
, 0 PUNCT F
controlled 0 ADP F
study 0 NOUN F
of 0 ADP F
dietary 0 ADJ F
intervention 0 NOUN F
in 0 ADP F
autistic 0 ADJ F
syndromes 0 NOUN F
. 0 PUNCT F

Impaired 0 VERB T
social 0 ADJ F
interaction 0 NOUN F
, 0 PUNCT F
communication 0 NOUN F
and 0 CCONJ F
imaginative 0 ADJ F
skills 0 NOUN F
characterize 0 VERB F
autistic 0 ADJ F
syndromes 0 NOUN F
. 0 PUNCT F

In 0 ADP T
these 0 DET F
syndromes 0 NOUN F
urinary 0 ADJ F
peptide 0 NOUN F
abnormalities 0 NOUN F
, 0 PUNCT F
derived 0 VERB F
from 0 ADP F
gluten 0 PUNCT F
, 0 PUNCT F
gliadin 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
casein 0 NOUN F
, 0 PUNCT F
are 0 VERB F
reported 0 VERB F
. 0 PUNCT F

They 0 PRON T
reflect 0 ADP F
processes 0 NOUN F
with 0 ADP F
opioid 0 NOUN F
effect 0 NOUN F
. 0 PUNCT F

The 0 DET T
aim 0 NOUN F
of 0 ADP F
this 0 DET F
single 0 ADJ F
blind 0 ADJ F
study 0 NOUN F
was 0 VERB F
to 0 PART F
evaluate 0 NOUN F
effect 0 NOUN F
of 0 ADP F
gluten 0 ADJ F
and 0 CCONJ F
casein-free 0 ADJ F
diet 0 NOUN F
for 0 ADP F
children 0 NOUN F
with 0 ADP F
autistic 0 ADJ F
syndromes 0 NOUN F
and 0 CCONJ F
urinary 0 ADJ F
peptide 0 NOUN F
abnormalities 0 NOUN F
. 0 PUNCT F

A 0 DET T
randomly 0 ADV F
selected 0 VERB F
diet 0 NOUN F
and 0 CCONJ F
control 0 NOUN F
group 0 NOUN F
with 0 ADP F
10 0 NUM F
children 0 NOUN F
in 0 ADP F
each 0 DET F
group 0 NOUN F
participated 0 ADJ F
. 0 PUNCT F

Observations B-OTHER NOUN T
and 0 CCONJ F
tests B-OTHER NOUN F
were 0 VERB F
done 0 PUNCT F
before 0 PUNCT F
and 0 CCONJ F
after 0 ADP F
a 0 DET F
period 0 NOUN F
of 0 ADP F
1 0 NUM F
year 0 NOUN F
. 0 PUNCT F

The 0 DET T
development B-OTHER NOUN F
for 0 ADP F
the 0 DET F
group 0 NOUN F
of 0 ADP F
children 0 NOUN F
on 0 ADP F
diet 0 NOUN F
was 0 VERB F
significantly 0 ADV F
better 0 PUNCT F
than 0 PUNCT F
for 0 ADP F
the 0 DET F
controls 0 NOUN F
. 0 PUNCT F

A 0 DET T
comparison 0 NOUN F
of 0 ADP F
urinary B-PHYSICAL ADJ F
and I-PHYSICAL CCONJ F
sexual I-PHYSICAL ADJ F
outcomes I-PHYSICAL NOUN F
in 0 ADP F
women 0 NOUN F
experiencing 0 ADJ F
vaginal 0 ADJ F
and 0 CCONJ F
Caesarean 0 NOUN T
births 0 NOUN F
. 0 PUNCT F

OBJECTIVE 0 NOUN T
To 0 PROPN T
evaluate 0 NOUN F
the 0 DET F
urinary B-PHYSICAL ADJ F
and I-PHYSICAL CCONJ F
sexual I-PHYSICAL ADJ F
consequences I-PHYSICAL NOUN F
of 0 ADP F
vaginal 0 ADJ F
delivery 0 NOUN F
compared 0 VERB F
with 0 ADP F
Caesarean 0 NOUN T
section 0 NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
We 0 PRON T
performed 0 VERB F
a 0 DET F
cohort 0 NOUN F
analysis 0 NOUN F
of 0 ADP F
data 0 NOUN F
from 0 ADP F
a 0 DET F
randomized 0 VERB F
controlled 0 VERB F
trial 0 NOUN F
of 0 ADP F
episiotomy 0 NOUN F
conducted 0 VERB F
in 0 ADP F
3 0 NUM F
Montreal 0 ADJ T
hospitals 0 PROPN F
in 0 ADP F
1990-1991 0 NUM F
. 0 PUNCT F

Of 0 ADP T
the 0 DET F
999 0 NUM F
trial 0 NOUN F
participants 0 NOUN F
for 0 ADP F
whom 0 ADP F
follow-up 0 NOUN F
data 0 NOUN F
were 0 VERB F
available 0 ADJ F
, 0 PUNCT F
135 0 NUM F
delivered 0 VERB F
by 0 ADP F
Caesarean 0 NOUN T
section 0 NOUN F
( 0 PUNCT F
CS 0 NOUN T
) 0 PUNCT F
, 0 PUNCT F
and 0 CCONJ F
864 0 NUM F
had 0 PUNCT F
a 0 DET F
vaginal 0 ADJ F
birth 0 NOUN F
( 0 PUNCT F
VB 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

After 0 ADP T
stratifying 0 ADP F
for 0 ADP F
parity 0 NOUN F
, 0 PUNCT F
we 0 NOUN F
compared 0 PUNCT F
rates 0 NOUN F
of 0 ADP F
urinary B-PHYSICAL ADJ F
incontinence I-PHYSICAL NOUN F
( I-PHYSICAL PUNCT F
UI I-PHYSICAL NOUN T
) I-PHYSICAL PUNCT F
and 0 CCONJ F
sexual B-PHYSICAL ADJ F
functioning I-PHYSICAL ADP F
at 0 ADP F
3 0 NUM F
months 0 NOUN F
postpartum 0 NOUN F
in 0 ADP F
women 0 NOUN F
who 0 ADP F
had 0 ADP F
a 0 DET F
VB 0 NOUN T
with 0 ADP F
the 0 DET F
rates 0 NOUN F
in 0 ADP F
women 0 NOUN F
who 0 ADP F
had 0 ADP F
a 0 DET F
CS 0 NOUN T
. 0 PUNCT F

RESULTS 0 NOUN T
Primiparous 0 ADJ T
women 0 NOUN F
reported 0 ADP F
unspecified 0 VERB F
UI B-PHYSICAL NOUN T
at 0 ADP F
3 0 NUM F
months 0 NOUN F
postpartum 0 PUNCT F
more 0 ADV F
often 0 ADV F
( 0 PUNCT F
17.9 0 NUM F
% 0 SYM F
) 0 PUNCT F
in 0 ADP F
the 0 DET F
VB 0 NOUN T
group 0 NOUN F
than 0 PUNCT F
in 0 ADP F
the 0 DET F
CS 0 NOUN T
group 0 NOUN F
( 0 PUNCT F
6.4 0 NUM F
% 0 SYM F
) 0 PUNCT F
. 0 PUNCT F

This 0 DET T
difference 0 NOUN F
remained 0 VERB F
significant 0 ADJ F
whether 0 ADP F
or 0 CCONJ F
not 0 ADP F
there 0 PUNCT F
was 0 VERB F
a 0 DET F
prior 0 ADP F
history 0 NOUN F
of 0 ADP F
UI 0 NOUN T
. 0 PUNCT F

Multiparous 0 ADJ T
women 0 NOUN F
showed 0 VERB F
no 0 DET F
difference 0 NOUN F
in 0 ADP F
rates B-PHYSICAL NOUN F
of 0 ADP F
UI 0 NOUN T
( 0 PUNCT F
VB 0 NOUN T
17.1 0 NUM F
% 0 SYM F
vs. 0 CCONJ F
CS 0 NOUN T
16.0 0 NUM F
% 0 SYM F
) 0 PUNCT F
, 0 PUNCT F
whether 0 ADP F
there 0 PUNCT F
was 0 VERB F
a 0 DET F
prior 0 ADP F
history 0 NOUN F
of 0 ADP F
UI 0 NOUN T
or 0 CCONJ F
not 0 ADV F
. 0 PUNCT F

Stress 0 NOUN T
incontinence B-PHYSICAL NOUN F
was 0 VERB F
greater 0 PUNCT F
among 0 ADP F
primiparous 0 ADJ F
women 0 NOUN F
in 0 ADP F
the 0 DET F
VB 0 NOUN T
group 0 NOUN F
( 0 PUNCT F
VB 0 NOUN T
34.5 0 NUM F
% 0 SYM F
vs. 0 CCONJ F
CS 0 NOUN T
12.8 0 NUM F
% 0 SYM F
) 0 PUNCT F
regardless 0 PUNCT F
of 0 PUNCT F
prior 0 PUNCT F
UI 0 NOUN T
history 0 NOUN F
, 0 PUNCT F
but 0 CCONJ F
the 0 DET F
proportion 0 NOUN F
of 0 ADP F
women 0 NOUN F
whose 0 ADJ F
UI B-PHYSICAL NOUN T
was 0 VERB F
severe 0 ADJ F
enough 0 NOUN F
to 0 ADP F
wear 0 CCONJ F
a 0 DET F
pad 0 NOUN F
was 0 VERB F
similar 0 ADJ F
in 0 ADP F
primiparous 0 ADJ F
women 0 NOUN F
( 0 PUNCT F
VB 0 NOUN T
16.0 0 NUM F
% 0 SYM F
, 0 PUNCT F
CS 0 NOUN T
15.4 0 NUM F
% 0 SYM F
) 0 PUNCT F
and 0 CCONJ F
multiparous 0 ADJ F
women 0 NOUN F
( 0 PUNCT F
VB 0 NOUN T
23.8 0 NUM F
% 0 SYM F
, 0 PUNCT F
CS 0 NOUN T
25.0 0 NUM F
% 0 SYM F
) 0 PUNCT F
. 0 PUNCT F

Women B-MENTAL NOUN T
's 0 PUNCT F
sexual B-MENTAL ADJ F
dissatisfaction I-MENTAL NOUN F
was 0 VERB F
greater 0 PUNCT F
among 0 ADP F
primiparous 0 ADJ F
women 0 NOUN F
who 0 ADP F
had 0 ADJ F
a 0 DET F
vaginal 0 ADJ F
birth 0 NOUN F
( 0 PUNCT F
VB 0 NOUN T
70.1 0 NUM F
% 0 SYM F
, 0 PUNCT F
CS 0 NOUN T
54.5 0 NUM F
% 0 SYM F
) 0 PUNCT F
, 0 PUNCT F
but 0 CCONJ F
in 0 ADP F
multiparous 0 ADJ F
women 0 NOUN F
, 0 PUNCT F
the 0 DET F
rates 0 NOUN F
of 0 ADP F
sexual B-PHYSICAL ADJ F
dissatisfaction I-PHYSICAL NOUN F
were 0 VERB F
similar 0 ADJ F
( 0 PUNCT F
VB 0 NOUN T
64.2 0 NUM F
% 0 SYM F
, 0 PUNCT F
CS 0 NOUN T
71.4 0 NUM F
% 0 SYM F
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
frequency 0 NOUN F
of 0 ADP F
dyspareunia B-PHYSICAL DET F
for 0 ADP F
each 0 DET F
mode 0 NOUN F
of 0 ADP F
delivery 0 NOUN F
was 0 VERB F
similar 0 ADJ F
in 0 ADP F
primiparous 0 ADJ F
women 0 NOUN F
( 0 PUNCT F
VB 0 NOUN T
30.7 0 NUM F
% 0 SYM F
, 0 PUNCT F
CS 0 NOUN T
31.6 0 NUM F
% 0 SYM F
) 0 PUNCT F
. 0 PUNCT F

Overall 0 ADJ T
, 0 PUNCT F
both 0 CCONJ F
primiparous 0 ADJ F
and 0 CCONJ F
multiparous 0 ADJ F
women 0 NOUN F
who 0 ADP F
had 0 ADP F
intact 0 ADJ F
perineums 0 ADP F
after 0 ADP F
VB 0 NOUN T
had 0 PUNCT F
less 0 DET F
dyspareunia B-PHYSICAL PUNCT F
than 0 PUNCT F
those 0 PUNCT F
undergoing 0 VERB F
CS 0 NOUN T
( 0 PUNCT F
VB 0 NOUN T
26.2 0 NUM F
, 0 PUNCT F
CS 0 NOUN T
40.7 0 NUM F
% 0 SYM F
) 0 PUNCT F
. 0 PUNCT F

However 0 ADV T
, 0 PUNCT F
the 0 DET F
proportion 0 NOUN F
of 0 ADP F
women 0 NOUN F
experiencing 0 CCONJ F
dyspareunia B-PHYSICAL ADV F
was 0 ADV F
greatest 0 PUNCT F
among 0 ADP F
those 0 ADP F
who 0 ADP F
had 0 ADP F
an 0 DET F
episiotomy 0 NOUN F
with 0 ADP F
or 0 CCONJ F
without 0 ADP F
forceps 0 NOUN F
. 0 PUNCT F

Music 0 ADJ T
or 0 CCONJ F
guided 0 ADJ F
imagery 0 NOUN F
for 0 ADP F
women 0 NOUN F
undergoing 0 VERB F
colposcopy 0 NOUN F
: 0 PUNCT F
a 0 DET F
randomized 0 VERB F
controlled 0 DET F
study 0 NOUN F
of 0 ADP F
effects 0 NOUN F
on 0 ADP F
anxiety B-PAIN NOUN F
, 0 PUNCT F
perceived B-PAIN DET F
pain I-PAIN NOUN F
, 0 PUNCT F
and 0 CCONJ F
patient B-OTHER NOUN F
satisfaction I-OTHER NOUN F
. 0 PUNCT F

OBJECTIVE 0 NOUN T
It 0 PRON T
was 0 VERB F
hypothesized 0 VERB F
that 0 PUNCT F
music 0 ADJ F
or 0 CCONJ F
guided 0 ADJ F
imagery 0 NOUN F
versus 0 CCONJ F
usual 0 ADJ F
care 0 NOUN F
would 0 VERB F
result 0 VERB F
in 0 ADP F
less 0 DET F
anxiety B-MENTAL NOUN F
and 0 CCONJ F
perceived B-PAIN ADJ F
pain I-PAIN NOUN F
for 0 ADP F
colposcopy 0 NOUN F
patients 0 NOUN F
. 0 PUNCT F

MATERIALS 0 NOUN T
AND 0 CCONJ T
METHODS 0 NOUN T
Patients 0 NOUN T
were 0 VERB F
randomized 0 VERB F
to 0 ADP F
music 0 ADP F
, 0 PUNCT F
guided 0 DET F
imagery 0 NOUN F
, 0 PUNCT F
or 0 CCONJ F
usual 0 ADJ F
care 0 NOUN F
after 0 ADP F
completing 0 ADJ F
a 0 DET F
baseline 0 NOUN F
questionnaire 0 NOUN F
. 0 PUNCT F

All 0 DET T
patients 0 NOUN F
completed 0 VERB F
a 0 DET F
postprocedure 0 NOUN F
questionnaire 0 NOUN F
. 0 PUNCT F

RESULTS 0 DET T
Study 0 ADP T
participants 0 NOUN F
( 0 PUNCT F
N=170 0 NOUN T
) 0 PUNCT F
had 0 ADP F
a 0 DET F
mean 0 NOUN F
age 0 NOUN F
of 0 ADP F
28.4 0 NUM F
years 0 NOUN F
( 0 PUNCT F
SD=9.6 0 NOUN T
; 0 PUNCT F
range 0 NOUN F
18-60 0 PUNCT F
) 0 PUNCT F
and 0 CCONJ F
formed 0 VERB F
a 0 DET F
racially 0 PUNCT F
diverse 0 ADJ F
group 0 NOUN F
. 0 PUNCT F

Education/income 0 NOUN T
levels 0 NOUN F
were 0 VERB F
low 0 ADJ F
. 0 PUNCT F

No 0 DET T
between-group 0 ADP F
differences 0 NOUN F
were 0 VERB F
found 0 VERB F
for 0 ADP F
postprocedure B-PAIN NOUN F
anxiety I-PAIN NOUN F
or 0 CCONJ F
pain B-PAIN NOUN F
rating I-PAIN ADP F
. 0 PUNCT F

CONCLUSIONS 0 NOUN T
Mind-body 0 NOUN T
interventions 0 NOUN F
had 0 CCONJ F
no 0 DET F
statistically 0 ADV F
significant 0 ADJ F
impact 0 NOUN F
on 0 ADP F
reported 0 PUNCT F
anxiety B-MENTAL NOUN F
, 0 PUNCT F
perceived B-PAIN DET F
pain I-PAIN NOUN F
, 0 PUNCT F
or 0 CCONJ F
satisfaction B-OTHER NOUN F
with I-OTHER ADP F
care I-OTHER NOUN F
, 0 PUNCT F
even 0 ADV F
for 0 ADP F
those 0 ADJ F
who 0 ADP F
anticipated 0 PUNCT F
the 0 DET F
most 0 PUNCT F
pain 0 NOUN F
or 0 CCONJ F
started 0 VERB F
with 0 ADP F
high 0 ADJ F
anxiety 0 NOUN F
. 0 PUNCT F

Cone 0 NOUN T
biopsy 0 NOUN F
: 0 PUNCT F
has 0 PUNCT F
endocervical 0 ADJ F
sampling 0 ADP F
a 0 DET F
role 0 NOUN F
? 0 PUNCT F

OBJECTIVE 0 NOUN T
To 0 PROPN T
investigate 0 NOUN F
the 0 DET F
sensitivity 0 NOUN F
, 0 PUNCT F
specificity 0 NOUN F
and 0 CCONJ F
predictive 0 ADJ F
value 0 NOUN F
of 0 ADP F
endocervical 0 ADJ F
sampling 0 PART F
in 0 ADP F
women 0 NOUN F
with 0 ADP F
abnormal 0 ADJ F
cervical 0 ADJ F
smears 0 NOUN F
. 0 PUNCT F

DESIGN 0 NOUN T
A 0 NOUN T
randomized 0 VERB F
study 0 NOUN F
of 0 ADP F
two 0 NUM F
methods 0 NOUN F
of 0 ADP F
endocervical 0 ADJ F
sampling 0 VERB F
. 0 PUNCT F

SETTING 0 NUM T
Colposcopy 0 NOUN T
clinic 0 NOUN F
at 0 ADP F
Aberdeen 0 ADV T
Royal 0 ADJ T
Infirmary 0 NOUN T
. 0 PUNCT F

SUBJECTS 0 NOUN T
100 0 NUM F
women 0 NOUN F
with 0 ADP F
abnormal 0 ADJ F
cervical 0 ADJ F
smears 0 NOUN F
selected 0 VERB F
for 0 ADP F
cone 0 NOUN F
biopsy 0 NOUN F
according 0 PUNCT F
to 0 ADP F
current 0 ADJ F
colposcopy 0 NOUN F
criteria 0 NOUN F
. 0 PUNCT F

INTERVENTIONS 0 NOUN T
53 0 NUM F
women 0 NOUN F
were 0 VERB F
randomized 0 VERB F
to 0 PUNCT F
have 0 PUNCT F
endocervical 0 ADJ F
sampling 0 VERB F
with 0 ADP F
the 0 DET F
Kevorkian 0 ADJ T
curette 0 NOUN F
and 0 CCONJ F
47 0 NUM F
to 0 ADP F
have 0 PUNCT F
sampling 0 VERB F
with 0 ADP F
the 0 DET F
Medscand 0 PUNCT T
endocervical 0 ADJ F
brush 0 NOUN F
. 0 PUNCT F

MAIN 0 ADJ T
OUTCOME 0 NOUN T
MEASURES 0 NOUN T
Cytology B-OTHER NOUN T
and 0 CCONJ F
histology B-OTHER NOUN F
results I-OTHER NOUN F
from I-OTHER ADP F
endocervical I-OTHER ADJ F
sampling I-OTHER PUNCT F
compared 0 VERB F
with 0 ADP F
cone B-OTHER NOUN F
biopsy I-OTHER NOUN F
histology I-OTHER NOUN F
. 0 PUNCT F

RESULTS 0 PUNCT T
The 0 DET T
overall 0 ADJ F
sensitivity 0 NOUN F
of 0 ADP F
endocervical B-OTHER ADJ F
sampling I-OTHER VERB F
was 0 VERB F
56 0 NUM F
% 0 SYM F
, 0 PUNCT F
with 0 ADP F
a 0 DET F
false 0 ADJ F
negative 0 ADJ F
rate B-OTHER NOUN F
of 0 ADP F
44 0 NUM F
% 0 SYM F
and 0 CCONJ F
a 0 DET F
negative 0 ADJ F
predictive B-OTHER ADJ F
value I-OTHER NOUN F
of 0 ADP F
26 0 NUM F
% 0 SYM F
. 0 PUNCT F

CONCLUSIONS 0 NOUN T
Endocervical 0 ADJ T
sampling 0 ADV F
should 0 SYM F
not 0 ADV F
influence 0 VERB F
management 0 NOUN F
when 0 ADP F
colposcopy 0 NOUN F
is 0 VERB F
unsatisfactory 0 ADJ F
. 0 PUNCT F

Ciprofloxacin/dexamethasone 0 NOUN T
drops 0 PUNCT F
decrease 0 ADP F
the 0 DET F
incidence 0 NOUN F
of 0 ADP F
physician 0 NOUN F
and 0 CCONJ F
patient 0 NOUN F
outcomes 0 NOUN F
of 0 ADP F
otorrhea B-PHYSICAL NOUN F
after 0 ADP F
tube 0 NOUN F
placement 0 NOUN F
. 0 PUNCT F

OBJECTIVE 0 NOUN T
To 0 PROPN T
evaluate 0 NOUN F
ciprofloxacin 0 NOUN F
0.3 0 NUM F
% 0 SYM F
/dexamethasone 0 NOUN F
0.1 0 NUM F
% 0 SYM F
( 0 PUNCT F
CIPRODEX 0 NOUN T
, 0 PUNCT F
Alcon 0 NOUN T
, 0 PUNCT F
Ft. 0 NOUN T
Worth 0 PUNCT T
, 0 PUNCT F
TX 0 NOUN T
) 0 PUNCT F
for 0 ADP F
the 0 DET F
prevention 0 NOUN F
of 0 ADP F
early 0 ADJ F
post-operative 0 ADJ F
otorrhea 0 NOUN F
following 0 ADJ F
TT 0 NOUN T
placement 0 NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
This 0 PUNCT T
was 0 VERB F
a 0 DET F
single-center 0 NOUN F
, 0 PUNCT F
randomized 0 VERB F
, 0 PUNCT F
evaluator-blinded 0 PUNCT F
, 0 PUNCT F
parallel-group 0 NOUN F
study 0 NOUN F
. 0 PUNCT F

Two 0 NUM T
hundred 0 NUM F
children 0 NOUN F
undergoing 0 SYM F
bilateral 0 PUNCT F
TT 0 NOUN T
placement 0 NOUN F
were 0 VERB F
categorized 0 VERB F
as 0 ADP F
having 0 VERB F
unilateral 0 ADJ F
( 0 PUNCT F
wet/dry 0 PUNCT F
) 0 PUNCT F
, 0 PUNCT F
bilateral 0 ADJ F
( 0 PUNCT F
wet/wet 0 PUNCT F
) 0 PUNCT F
, 0 PUNCT F
or 0 CCONJ F
no 0 DET F
( 0 PUNCT F
dry/dry 0 PUNCT F
) 0 PUNCT F
effusion 0 NOUN F
at 0 ADP F
the 0 DET F
time 0 NOUN F
of 0 ADP F
surgery 0 NOUN F
. 0 PUNCT F

All 0 DET T
patients 0 NOUN F
received 0 VERB F
Ciprodex 0 NOUN T
or 0 CCONJ F
no 0 DET F
treatment 0 NOUN F
for 0 ADP F
5 0 NUM F
days 0 NOUN F
post-operatively 0 ADV F
and 0 CCONJ F
returned 0 VERB F
at 0 ADP F
2 0 NUM F
weeks 0 NOUN F
. 0 PUNCT F

RESULTS 0 NOUN T
Physician-observed B-PHYSICAL PUNCT T
otorrhea I-PHYSICAL NOUN F
was 0 VERB F
reported 0 VERB F
in 0 ADP F
5 0 NUM F
( 0 PUNCT F
4.95 0 NUM F
% 0 SYM F
) 0 PUNCT F
patients 0 NOUN F
receiving 0 VERB F
Ciprodex 0 NOUN T
and 0 CCONJ F
39 0 NUM F
( 0 PUNCT F
39.39 0 NUM F
% 0 SYM F
) 0 PUNCT F
patients 0 NOUN F
receiving 0 VERB F
no 0 DET F
treatment 0 NOUN F
( 0 PUNCT F
p 0 NOUN F
< 0 SYM F
0.0001 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Treatment 0 NOUN T
decreased 0 VERB F
otorrhea B-PHYSICAL NOUN F
in 0 ADP F
all 0 DET F
groups 0 NOUN F
, 0 PUNCT F
while 0 ADP F
the 0 DET F
greatest 0 PUNCT F
benefit 0 NOUN F
was 0 VERB F
observed 0 VERB F
in 0 ADP F
patients 0 NOUN F
with 0 ADP F
bilateral 0 ADJ F
effusion 0 NOUN F
( 0 PUNCT F
93 0 NUM F
% 0 SYM F
reduction 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

Ciprodex 0 ADJ T
treatment 0 NOUN F
also 0 ADV F
decreased 0 VERB F
the 0 DET F
rate 0 NOUN F
of 0 ADP F
clinically B-PHYSICAL ADV F
diagnosed I-PHYSICAL ADJ F
otitis I-PHYSICAL ADJ F
media I-PHYSICAL NOUN F
( I-PHYSICAL PUNCT F
OM I-PHYSICAL NOUN T
) I-PHYSICAL PUNCT F
and 0 CCONJ F
effusion B-PHYSICAL NOUN F
following 0 VERB F
TT 0 NOUN T
placement 0 NOUN F
( 0 PUNCT F
p 0 NOUN F
< 0 SYM F
or 0 CCONJ F
=0.0006 0 PUNCT F
) 0 PUNCT F
. 0 PUNCT F

CONCLUSION 0 NOUN T
Ciprodex 0 NOUN T
reduced 0 VERB F
early B-PHYSICAL ADJ F
post-operative I-PHYSICAL ADJ F
otorrhea I-PHYSICAL NOUN F
, 0 PUNCT F
clinically B-PHYSICAL ADV F
diagnosed I-PHYSICAL VERB F
OM I-PHYSICAL NOUN T
and 0 CCONJ F
effusion B-PHYSICAL NOUN F
following 0 VERB F
TT 0 NOUN T
insertion 0 NOUN F
. 0 PUNCT F

The 0 DET T
greatest 0 ADP F
reduction 0 NOUN F
in 0 ADP F
otorrhea B-PHYSICAL NOUN F
was 0 VERB F
observed 0 VERB F
in 0 ADP F
patients 0 NOUN F
with 0 ADP F
bilateral 0 ADJ F
effusion 0 NOUN F
at 0 ADP F
the 0 DET F
time 0 NOUN F
of 0 ADP F
surgery 0 NOUN F
. 0 PUNCT F

Bronchial B-PHYSICAL ADJ T
matrix I-PHYSICAL NOUN F
and I-PHYSICAL CCONJ F
inflammation I-PHYSICAL NOUN F
respond 0 VERB F
to 0 ADP F
inhaled 0 PUNCT F
steroids 0 NOUN F
despite 0 ADP F
ongoing 0 ADP F
allergen 0 NOUN F
exposure 0 NOUN F
in 0 ADP F
asthma 0 NOUN F
. 0 PUNCT F

BACKGROUND 0 NOUN T
Inflammatory B-PHYSICAL ADJ T
and 0 CCONJ F
structural 0 ADJ F
changes 0 NOUN F
of B-PHYSICAL ADP F
the I-PHYSICAL DET F
airway I-PHYSICAL NOUN F
mucosa I-PHYSICAL NOUN F
are 0 VERB F
chronic 0 ADJ F
features 0 NOUN F
of 0 ADP F
asthma 0 NOUN F
. 0 PUNCT F

The 0 DET T
mechanisms 0 NOUN F
underlying 0 VERB F
these 0 DET F
changes 0 NOUN F
and 0 CCONJ F
their 0 ADP F
modulation 0 NOUN F
by 0 ADP F
steroid 0 NOUN F
prophylaxis 0 NOUN F
have 0 PUNCT F
not 0 ADV F
been 0 PUNCT F
clarified 0 VERB F
. 0 PUNCT F

OBJECTIVE 0 NOUN T
We 0 PRON T
postulated 0 VERB F
that 0 ADP F
asymptomatic 0 ADJ F
ongoing 0 VERB F
allergen 0 NOUN F
exposure 0 NOUN F
could 0 VERB F
drive 0 VERB F
airway 0 NOUN F
inflammation 0 NOUN F
as 0 VERB F
well 0 PUNCT F
as 0 CCONJ F
changes 0 VERB F
in 0 ADP F
the 0 DET F
extracellular 0 ADJ F
matrix 0 NOUN F
( 0 PUNCT F
ECM 0 NOUN T
) 0 PUNCT F
, 0 PUNCT F
and 0 CCONJ F
that 0 ADP F
inhaled 0 PUNCT F
steroids 0 NOUN F
could 0 ADV F
prevent 0 VERB F
this 0 PUNCT F
. 0 PUNCT F

METHODS 0 NOUN T
Therefore 0 ADV T
, 0 PUNCT F
we 0 PRON F
exposed 0 VERB F
patients 0 NOUN F
with 0 ADP F
mild 0 ADJ F
asthma 0 NOUN F
to 0 ADP F
2 0 NUM F
weeks 0 NOUN F
of 0 ADP F
repeated 0 VERB F
low-dose 0 NOUN F
allergen 0 NOUN F
, 0 PUNCT F
with 0 ADP F
concomitant 0 ADJ F
inhaled 0 VERB F
steroid 0 NOUN F
or 0 CCONJ F
placebo 0 NOUN F
treatment 0 NOUN F
. 0 PUNCT F

Bronchial 0 ADJ T
biopsies 0 NOUN F
, 0 PUNCT F
which 0 ADP F
were 0 VERB F
taken 0 VERB F
before 0 ADP F
and 0 CCONJ F
after 0 ADP F
this 0 DET F
exposure 0 NOUN F
, 0 PUNCT F
were 0 VERB F
stained 0 VERB F
and 0 CCONJ F
digitally 0 ADV F
analysed 0 VERB F
. 0 PUNCT F

The 0 DET T
ECM 0 NOUN T
proteins 0 NOUN F
in 0 ADP F
asthmatics 0 NOUN F
were 0 VERB F
also 0 ADV F
compared 0 VERB F
with 0 ADP F
a 0 DET F
normal 0 ADJ F
control 0 NOUN F
group 0 NOUN F
. 0 PUNCT F

RESULTS 0 ADJ T
Low-dose 0 ADJ T
allergen 0 NOUN F
exposure 0 NOUN F
alone 0 ADJ F
resulted 0 ADP F
in 0 ADP F
a 0 DET F
significant 0 ADJ F
increase 0 NOUN F
of 0 ADP F
bronchial B-PHYSICAL ADJ F
epithelial I-PHYSICAL ADJ F
macrophages I-PHYSICAL NOUN F
. 0 PUNCT F

Despite 0 ADP T
ongoing 0 DET F
allergen 0 NOUN F
exposure 0 NOUN F
, 0 PUNCT F
inhaled 0 VERB F
steroids 0 NOUN F
reduced 0 ADP F
the 0 DET F
numbers B-PHYSICAL NOUN F
of I-PHYSICAL ADP F
mucosal I-PHYSICAL ADJ F
eosinophils I-PHYSICAL NOUN F
, 0 PUNCT F
neutrophils B-PHYSICAL NOUN F
and 0 CCONJ F
T B-PHYSICAL NOUN T
lymphocytes I-PHYSICAL NOUN F
. 0 PUNCT F

At 0 ADP T
baseline 0 NOUN F
, 0 PUNCT F
the 0 DET F
mean 0 NOUN F
density 0 NOUN F
of 0 ADP F
the 0 DET F
proteoglycans B-PHYSICAL NOUN F
( 0 PUNCT F
PGS B-PHYSICAL NOUN T
) 0 PUNCT F
biglycan B-PHYSICAL PUNCT F
and 0 CCONJ F
decorin B-PHYSICAL NOUN F
were 0 VERB F
, 0 PUNCT F
respectively 0 ADV F
, 0 PUNCT F
higher 0 PUNCT F
and 0 CCONJ F
lower 0 PUNCT F
in 0 ADP F
the 0 DET F
bronchial 0 ADJ F
mucosa 0 NOUN F
of 0 ADP F
asthmatics 0 NOUN F
as 0 CCONJ F
compared 0 VERB F
with 0 ADP F
normal 0 ADJ F
controls 0 NOUN F
. 0 PUNCT F

Steroid 0 NOUN T
treatment 0 NOUN F
, 0 PUNCT F
during 0 ADP F
allergen 0 NOUN F
exposure 0 NOUN F
, 0 PUNCT F
increased 0 VERB F
the 0 DET F
mean 0 NOUN F
density 0 NOUN F
of 0 ADP F
the 0 DET F
PGS B-PHYSICAL NOUN T
biglycan I-PHYSICAL PUNCT F
and 0 CCONJ F
versican B-PHYSICAL ADP F
. 0 PUNCT F

CONCLUSION 0 NOUN T
We 0 PRON T
conclude 0 VERB F
that 0 ADP F
chronic 0 ADJ F
allergen 0 NOUN F
exposure 0 NOUN F
induces 0 NOUN F
inflammatory 0 ADJ F
changes 0 NOUN F
in 0 ADP F
the 0 DET F
bronchial 0 ADJ F
mucosa 0 NOUN F
. 0 PUNCT F

Despite 0 ADP T
ongoing 0 DET F
allergen 0 NOUN F
exposure 0 NOUN F
, 0 PUNCT F
steroid 0 NOUN F
treatment 0 NOUN F
decreases 0 VERB F
mucosal B-PHYSICAL ADJ F
inflammatory I-PHYSICAL ADJ F
cells I-PHYSICAL NOUN F
while 0 ADP F
altering 0 VERB F
PG 0 NOUN T
density 0 NOUN F
. 0 PUNCT F

The 0 DET T
latter 0 ADJ F
observation 0 NOUN F
highlights 0 PUNCT F
the 0 DET F
need 0 ADP F
to 0 PART F
examine 0 NOUN F
steroid-induced B-OTHER VERB F
changes I-OTHER NOUN F
closely 0 ADV F
in 0 ADP F
the 0 DET F
airway 0 NOUN F
structure 0 NOUN F
in 0 ADP F
patients 0 NOUN F
with 0 ADP F
asthma 0 NOUN F
. 0 PUNCT F

Failure 0 NOUN T
of 0 ADP F
lithium 0 NOUN F
to 0 PART F
reduce 0 NOUN F
period 0 NOUN F
of 0 ADP F
neutropenia 0 NOUN F
during 0 ADP F
induction 0 NOUN F
therapy 0 NOUN F
of 0 ADP F
acute 0 ADJ F
myeloid 0 NOUN F
leukemia 0 NOUN F
. 0 PUNCT F

Fifty-four 0 PUNCT T
patients 0 NOUN F
treated 0 VERB F
with 0 ADP F
daunorubicin 0 NOUN F
, 0 PUNCT F
cytosine 0 NOUN F
arabinoside 0 NOUN F
and 0 CCONJ F
thioquanine 0 ADP F
for 0 ADP F
acute 0 ADJ F
myeloid 0 NOUN F
leukemia 0 NOUN F
were 0 VERB F
randomly 0 ADV F
assigned 0 VERB F
to 0 PART F
receive 0 NOUN F
oral 0 ADJ F
lithium 0 NOUN F
carbonate 0 NOUN F
1200 0 NUM F
mg 0 NOUN F
daily 0 ADJ F
or 0 CCONJ F
no 0 DET F
lithium 0 NOUN F
. 0 PUNCT F

The 0 DET T
duration B-PHYSICAL NOUN F
of I-PHYSICAL ADP F
neutropenia I-PHYSICAL NOUN F
( 0 PUNCT F
less 0 ADV F
than 0 ADP F
0.5 0 NUM F
x 0 SYM F
10 0 NUM F
( 0 PUNCT F
9 0 NUM F
) 0 PUNCT F
/L 0 PUNCT F
) 0 PUNCT F
was 0 VERB F
similar 0 ADJ F
between 0 ADP F
controls 0 NOUN F
( 0 PUNCT F
median 0 ADJ F
22.5 0 NUM F
days 0 NOUN F
) 0 PUNCT F
and 0 CCONJ F
patients 0 NOUN F
treated 0 VERB F
with 0 ADP F
lithium 0 NOUN F
( 0 PUNCT F
median 0 ADJ F
24 0 NUM F
days 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
number B-PHYSICAL NOUN F
of I-PHYSICAL ADP F
remissions I-PHYSICAL NOUN F
, 0 PUNCT F
relapse-free B-MORTALITY PUNCT F
survival I-MORTALITY NOUN F
and 0 CCONJ F
survival B-MORTALITY NOUN F
were 0 VERB F
similar 0 ADJ F
for 0 ADP F
the 0 DET F
lithium 0 NOUN F
treated 0 VERB F
and 0 CCONJ F
control 0 NOUN F
groups 0 NOUN F
of 0 ADP F
patients 0 NOUN F
. 0 PUNCT F

There 0 PUNCT T
was 0 VERB F
no 0 DET F
apparent 0 ADJ F
clinical B-OTHER ADJ F
efficacy I-OTHER NOUN F
in 0 ADP F
the 0 DET F
use 0 NOUN F
of 0 ADP F
lithium 0 NOUN F
to 0 PART F
reduce 0 ADJ F
the 0 DET F
period 0 NOUN F
of 0 ADP F
neutropenia 0 NOUN F
in 0 ADP F
patients 0 NOUN F
undergoing 0 VERB F
remission 0 NOUN F
induction 0 NOUN F
therapy 0 NOUN F
for 0 ADP F
acute 0 ADJ F
myeloid 0 NOUN F
leukemia 0 NOUN F
. 0 PUNCT F

Low-dose 0 ADJ T
angiotensin 0 NOUN F
II 0 NUM T
receptor 0 NOUN F
antagonists 0 NOUN F
and 0 CCONJ F
angiotensin 0 NOUN F
II-converting 0 PUNCT T
enzyme 0 NOUN F
inhibitors 0 NOUN F
alone 0 ADJ F
or 0 CCONJ F
in 0 ADP F
combination 0 NOUN F
for 0 ADP F
treatment 0 NOUN F
of 0 ADP F
primary 0 ADJ F
glomerulonephritis 0 NOUN F
. 0 PUNCT F

OBJECTIVE 0 NOUN T
The 0 DET T
renin-angiotensin 0 NOUN F
system 0 NOUN F
is 0 VERB F
thought 0 VERB F
to 0 PART F
be 0 PUNCT F
involved 0 VERB F
in 0 ADP F
the 0 DET F
progression 0 NOUN F
of 0 ADP F
chronic 0 ADJ F
renal 0 ADJ F
diseases 0 NOUN F
of 0 ADP F
both 0 CCONJ F
diabetic 0 ADJ F
and 0 CCONJ F
non-diabetic 0 ADJ F
origin 0 NOUN F
. 0 PUNCT F

It 0 PRON T
has 0 ADP F
been 0 PUNCT F
confirmed 0 VERB F
that 0 ADP F
angiotensin-converting 0 VERB F
enzyme 0 NOUN F
inhibitors 0 NOUN F
( 0 PUNCT F
ACEIs 0 NOUN T
) 0 PUNCT F
and 0 CCONJ F
angiotensin 0 NOUN F
II 0 NUM T
receptor 0 NOUN F
blockers 0 NOUN F
( 0 PUNCT F
ARBs 0 NOUN T
) 0 PUNCT F
reduce 0 VERB F
urinary 0 ADJ F
protein 0 NOUN F
excretion 0 NOUN F
and 0 CCONJ F
attenuate 0 VERB F
the 0 DET F
development 0 NOUN F
of 0 ADP F
renal 0 ADJ F
injury 0 NOUN F
. 0 PUNCT F

Clinical 0 ADJ T
data 0 NOUN F
comparing 0 VERB F
the 0 DET F
renal 0 ADJ F
effects 0 NOUN F
of 0 ADP F
ACEIs 0 PUNCT T
and 0 CCONJ F
ARBs 0 NOUN T
, 0 PUNCT F
either 0 PUNCT F
singly 0 ADV F
or 0 CCONJ F
in 0 ADP F
combination 0 NOUN F
, 0 PUNCT F
are 0 VERB F
scarce 0 NOUN F
and 0 CCONJ F
usually 0 ADV F
concern 0 PUNCT F
the 0 DET F
use 0 NOUN F
of 0 ADP F
standard 0 ADJ F
or 0 CCONJ F
high 0 ADJ F
doses 0 NOUN F
. 0 PUNCT F

MATERIAL 0 NOUN T
AND 0 CCONJ T
METHODS 0 NOUN T
This 0 PUNCT T
was 0 VERB F
a 0 DET F
prospective 0 ADJ F
, 0 PUNCT F
randomized 0 VERB F
, 0 PUNCT F
9-month 0 NOUN F
study 0 NOUN F
of 0 ADP F
the 0 DET F
effects 0 NOUN F
of 0 ADP F
low 0 ADJ F
doses 0 NOUN F
of 0 ADP F
losartan 0 NOUN F
( 0 PUNCT F
25 0 NUM F
mg 0 NOUN F
; 0 PUNCT F
n 0 NOUN F
= 0 SYM F
18 0 NUM F
) 0 PUNCT F
versus 0 CCONJ F
enalapril 0 NOUN F
( 0 PUNCT F
10 0 NUM F
mg 0 NOUN F
; 0 PUNCT F
n 0 NOUN F
= 0 SYM F
18 0 NUM F
) 0 PUNCT F
versus 0 CCONJ F
the 0 DET F
combination 0 NOUN F
of 0 ADP F
losartan 0 NOUN F
( 0 PUNCT F
25 0 NUM F
mg 0 NOUN F
) 0 PUNCT F
and 0 CCONJ F
enalapril 0 NOUN F
( 0 PUNCT F
10 0 NUM F
mg 0 NOUN F
) 0 PUNCT F
( 0 PUNCT F
n 0 NOUN F
= 0 SYM F
16 0 NUM F
) 0 PUNCT F
on 0 ADP F
proteinuria B-PHYSICAL NOUN F
, 0 PUNCT F
kidney B-PHYSICAL NOUN F
function I-PHYSICAL NOUN F
and 0 CCONJ F
metabolic B-PHYSICAL ADJ F
profile I-PHYSICAL NOUN F
in 0 ADP F
54 0 NUM F
patients 0 NOUN F
with 0 ADP F
biopsy-proven 0 PUNCT F
chronic 0 ADJ F
glomerulonephritis 0 NOUN F
, 0 PUNCT F
hypertension 0 NOUN F
and 0 CCONJ F
normal 0 ADJ F
or 0 CCONJ F
slightly 0 ADV F
impaired 0 VERB F
kidney 0 NOUN F
function 0 NOUN F
. 0 PUNCT F

The 0 DET T
clinical B-PHYSICAL ADJ F
evaluation I-PHYSICAL NOUN F
and I-PHYSICAL CCONJ F
laboratory I-PHYSICAL NOUN F
tests I-PHYSICAL NOUN F
were 0 VERB F
performed 0 VERB F
before 0 ADP F
treatment 0 NOUN F
( 0 PUNCT F
baseline 0 NOUN F
) 0 PUNCT F
and 0 CCONJ F
after 0 ADP F
3 0 NUM F
and 0 CCONJ F
9 0 NUM F
months 0 NOUN F
of 0 ADP F
therapy 0 NOUN F
. 0 PUNCT F

RESULTS 0 NOUN T
After 0 ADP T
3 0 NUM F
months 0 NOUN F
, 0 PUNCT F
significant 0 ADJ F
decreases 0 DET F
in 0 ADP F
proteinuria B-PHYSICAL NOUN F
were 0 VERB F
observed 0 VERB F
in 0 ADP F
all 0 DET F
groups 0 NOUN F
: 0 PUNCT F
losartan 0 NOUN F
, 0 PUNCT F
22.6 0 NUM F
% 0 SYM F
( 0 PUNCT F
p 0 NOUN F
= 0 SYM F
0.02 0 NUM F
) 0 PUNCT F
; 0 PUNCT F
enalapril 0 NOUN F
, 0 PUNCT F
43 0 NUM F
% 0 SYM F
( 0 PUNCT F
p 0 NOUN F
= 0 SYM F
0.012 0 NUM F
) 0 PUNCT F
; 0 PUNCT F
and 0 CCONJ F
combined 0 VERB F
therapy 0 NOUN F
, 0 PUNCT F
63 0 NUM F
% 0 SYM F
( 0 PUNCT F
p 0 NOUN F
= 0 SYM F
0.001 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

This 0 DET T
anti-proteinuric B-PHYSICAL ADJ F
effect 0 NOUN F
was 0 VERB F
even 0 ADV F
greater 0 PUNCT F
after 0 ADP F
9 0 NUM F
months 0 NOUN F
of 0 ADP F
therapy 0 NOUN F
: 0 PUNCT F
losartan 0 NOUN F
, 0 PUNCT F
44.2 0 NUM F
% 0 SYM F
( 0 PUNCT F
p 0 NOUN F
= 0 SYM F
0.02 0 NUM F
) 0 PUNCT F
; 0 PUNCT F
enalapril 0 NOUN F
, 0 PUNCT F
49.6 0 NUM F
% 0 SYM F
( 0 PUNCT F
p 0 NOUN F
= 0 SYM F
0.02 0 NUM F
) 0 PUNCT F
; 0 PUNCT F
and 0 CCONJ F
combined 0 VERB F
therapy 0 NOUN F
, 0 PUNCT F
51 0 NUM F
% 0 SYM F
( 0 PUNCT F
p 0 NOUN F
= 0 SYM F
0.003 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

There 0 PUNCT T
was 0 VERB F
no 0 DET F
significant 0 ADJ F
difference 0 NOUN F
between 0 ADP F
losartan 0 NOUN F
and 0 CCONJ F
enalapril 0 NOUN F
with 0 ADP F
respect 0 NOUN F
to 0 ADP F
their 0 PUNCT F
impact 0 NOUN F
on 0 ADP F
proteinuria B-PHYSICAL NOUN F
level 0 NOUN F
. 0 PUNCT F

Proteinuria B-PHYSICAL NOUN T
reduction I-PHYSICAL NOUN F
was 0 VERB F
significantly 0 ADV F
greater 0 PUNCT F
in 0 ADP F
patients 0 NOUN F
receiving 0 VERB F
combined 0 VERB F
therapy 0 NOUN F
in 0 ADP F
comparison 0 NOUN F
with 0 ADP F
losartan 0 NOUN F
treatment 0 NOUN F
after 0 ADP F
3 0 NUM F
months 0 NOUN F
of 0 ADP F
therapy 0 NOUN F
( 0 PUNCT F
p 0 NOUN F
= 0 SYM F
0.02 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Creatinine B-PHYSICAL NOUN T
clearance I-PHYSICAL NOUN F
and 0 CCONJ F
serum B-PHYSICAL NOUN F
creatinine I-PHYSICAL NOUN F
were 0 VERB F
stable 0 ADJ F
during 0 ADP F
the 0 DET F
entire 0 ADJ F
study 0 NOUN F
period 0 NOUN F
in 0 ADP F
all 0 DET F
patients 0 NOUN F
. 0 PUNCT F

No 0 DET T
significant 0 ADJ F
changes 0 NOUN F
in 0 ADP F
lipids B-PHYSICAL NOUN F
, I-PHYSICAL PUNCT F
serum I-PHYSICAL NOUN F
uric I-PHYSICAL ADJ F
acid I-PHYSICAL NOUN F
or I-PHYSICAL CCONJ F
protein I-PHYSICAL NOUN F
levels I-PHYSICAL NOUN F
were 0 VERB F
observed 0 VERB F
. 0 PUNCT F

CONCLUSIONS 0 NOUN T
These 0 PUNCT T
results 0 NOUN F
indicate 0 VERB F
that 0 ADP F
proteinuria 0 NOUN F
is 0 VERB F
reduced 0 VERB F
by 0 ADP F
low 0 ADJ F
doses 0 NOUN F
of 0 ADP F
losartan 0 NOUN F
or 0 CCONJ F
enalapril 0 NOUN F
. 0 PUNCT F

The 0 DET T
combination 0 NOUN F
of 0 ADP F
these 0 DET F
drugs 0 NOUN F
seems 0 NOUN F
to 0 PART F
be 0 PUNCT F
beneficial 0 ADJ F
and 0 CCONJ F
may 0 VERB F
offer 0 VERB F
an 0 DET F
additional 0 ADJ F
renoprotective 0 ADJ F
effect 0 NOUN F
. 0 PUNCT F

This 0 DET T
needs 0 CCONJ F
to 0 PART F
be 0 PUNCT F
confirmed 0 VERB F
in 0 ADP F
a 0 DET F
study 0 NOUN F
with 0 ADP F
a 0 DET F
larger 0 PUNCT F
sample 0 NOUN F
size 0 NOUN F
. 0 PUNCT F

[ 0 PUNCT F
The 0 DET T
comparison 0 NOUN F
of 0 ADP F
the 0 DET F
effect 0 NOUN F
of 0 ADP F
enalapril 0 NOUN F
and 0 CCONJ F
indapamide 0 NOUN F
on 0 ADP F
the 0 DET F
peripheral B-PHYSICAL ADJ F
blood I-PHYSICAL NOUN F
pressure I-PHYSICAL NOUN F
and 0 CCONJ F
central B-PHYSICAL ADJ F
blood I-PHYSICAL NOUN F
pressure I-PHYSICAL NOUN F
through 0 ADP F
pulse 0 NOUN F
wave 0 NOUN F
analysis 0 NOUN F
] 0 PUNCT F
. 0 PUNCT F

OBJECTIVES 0 NOUN T
The 0 DET T
purpose 0 NOUN F
of 0 ADP F
this 0 DET F
study 0 NOUN F
was 0 VERB F
to 0 PART F
evaluate 0 NOUN F
the 0 DET F
effects 0 NOUN F
of 0 ADP F
the 0 DET F
angiotensin-converting 0 VERB F
enzyme 0 NOUN F
( 0 PUNCT F
ACE 0 NOUN T
) 0 PUNCT F
inhibitor 0 NOUN F
enalapril 0 NOUN F
and 0 CCONJ F
diuretic 0 NOUN F
indapamide 0 NOUN F
on 0 ADP F
the 0 DET F
peripheral B-PHYSICAL ADJ F
blood I-PHYSICAL NOUN F
pressure I-PHYSICAL NOUN F
and 0 CCONJ F
the B-PHYSICAL DET F
central I-PHYSICAL ADJ F
blood I-PHYSICAL NOUN F
pressure I-PHYSICAL NOUN F
in 0 ADP F
Chinese 0 NOUN T
patients 0 NOUN F
with 0 ADP F
essential 0 ADJ F
hypertension 0 NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
This 0 PUNCT T
study 0 NOUN F
was 0 ADV F
a 0 DET F
double 0 ADJ F
blind 0 ADP F
, 0 PUNCT F
randomized 0 ADP F
study 0 NOUN F
. 0 PUNCT F

Informed 0 VERB T
consent 0 NOUN F
were 0 VERB F
given 0 VERB F
by 0 ADP F
all 0 DET F
patients 0 NOUN F
. 0 PUNCT F

After 0 ADP T
2 0 NUM F
weeks 0 NOUN F
of 0 ADP F
placebo 0 NOUN F
run-in 0 NOUN F
period 0 NOUN F
, 0 PUNCT F
105 0 NUM F
patients 0 NOUN F
with 0 ADP F
mild 0 ADJ F
or 0 CCONJ F
moderate 0 ADJ F
essential 0 ADJ F
hypertension 0 NOUN F
were 0 VERB F
randomized 0 VERB F
to 0 PART F
receive 0 NOUN F
either 0 PUNCT F
enalapril 0 NOUN F
( 0 PUNCT F
10 0 NUM F
mg 0 NOUN F
per 0 ADP F
day 0 NOUN F
) 0 PUNCT F
or 0 CCONJ F
indapamide 0 NOUN F
( 0 PUNCT F
2.5 0 NUM F
mg 0 NOUN F
per 0 ADP F
day 0 NOUN F
) 0 PUNCT F
for 0 ADP F
8 0 NUM F
weeks 0 NOUN F
. 0 PUNCT F

Radial 0 ADJ T
pulse 0 NOUN F
wave 0 NOUN F
recordings 0 CCONJ F
were 0 VERB F
performed 0 VERB F
in 0 ADP F
all 0 DET F
the 0 DET F
patients 0 NOUN F
before 0 ADP F
the 0 DET F
active 0 ADJ F
treatments 0 NOUN F
were 0 VERB F
given 0 VERB F
and 0 CCONJ F
at 0 ADP F
the 0 DET F
end 0 NOUN F
of 0 ADP F
the 0 DET F
study 0 NOUN F
. 0 PUNCT F

Only 0 ADV T
those 0 PUNCT F
patients 0 NOUN F
who 0 ADP F
have 0 PUNCT F
finished 0 VERB F
8 0 NUM F
weeks 0 NOUN F
of 0 ADP F
active 0 ADJ F
treatment 0 NOUN F
in 0 ADP F
both 0 CCONJ F
groups 0 NOUN F
were 0 VERB F
included 0 VERB F
into 0 ADP F
the 0 DET F
final 0 ADJ F
analysis 0 NOUN F
. 0 PUNCT F

RESULTS 0 NOUN T
One 0 NUM T
hundred 0 NUM F
one 0 NUM F
patients 0 NOUN F
( 0 PUNCT F
51 0 NUM F
in 0 ADP F
enalapril 0 NOUN F
group 0 NOUN F
and 0 CCONJ F
50 0 NUM F
in 0 ADP F
indapamide 0 NOUN F
group 0 NOUN F
) 0 PUNCT F
completed 0 VERB F
the 0 DET F
study 0 NOUN F
. 0 PUNCT F

No 0 DET T
significant 0 ADJ F
difference 0 NOUN F
( 0 PUNCT F
all 0 DET F
P 0 NOUN T
values 0 NOUN F
> 0 SYM F
0.05 0 NUM F
) 0 PUNCT F
was 0 VERB F
found 0 VERB F
in 0 ADP F
baseline 0 NOUN F
data 0 NOUN F
between 0 ADP F
the 0 DET F
two 0 NUM F
groups 0 NOUN F
. 0 PUNCT F

After 0 ADP T
8 0 NUM F
weeks 0 NOUN F
of 0 ADP F
treatment 0 NOUN F
, 0 PUNCT F
all 0 ADJ F
the 0 DET F
parameters 0 NOUN F
of 0 ADP F
pulse B-PHYSICAL NOUN F
wave I-PHYSICAL NOUN F
( 0 PUNCT F
except 0 VERB F
heart 0 NOUN F
rates 0 NOUN F
in 0 ADP F
both 0 CCONJ F
groups 0 NOUN F
and 0 CCONJ F
augmentation 0 NOUN F
index 0 NOUN F
in 0 ADP F
indapamide 0 NOUN F
group 0 NOUN F
) 0 PUNCT F
decreased 0 VERB F
significantly 0 ADV F
. 0 PUNCT F

Comparison 0 NOUN T
of 0 ADP F
the 0 DET F
2 0 NUM F
groups 0 NOUN F
showed 0 VERB F
that 0 ADP F
there 0 PUNCT F
were 0 VERB F
no 0 DET F
significant 0 ADJ F
differences 0 NOUN F
( 0 PUNCT F
all 0 DET F
P 0 NOUN T
values 0 NOUN F
> 0 SYM F
0.05 0 NUM F
) 0 PUNCT F
in 0 ADP F
all 0 DET F
the 0 DET F
parameters 0 NOUN F
of 0 ADP F
pulse 0 NOUN F
wave 0 NOUN F
except 0 VERB F
that 0 CCONJ F
the 0 DET F
central B-PHYSICAL ADJ F
systolic I-PHYSICAL ADJ F
blood I-PHYSICAL NOUN F
pressure I-PHYSICAL NOUN F
, 0 PUNCT F
augmentation B-PHYSICAL NOUN F
and 0 CCONJ F
augmentation B-PHYSICAL NOUN F
index I-PHYSICAL NOUN F
were 0 VERB F
significantly 0 ADV F
lower 0 PUNCT F
in 0 ADP F
enalapril 0 NOUN F
group 0 NOUN F
than 0 PUNCT F
in 0 ADP F
indapamide 0 NOUN F
group 0 NOUN F
. 0 PUNCT F

In 0 ADP T
enalapril 0 NOUN F
group 0 NOUN F
, 0 PUNCT F
the 0 DET F
reduced 0 ADJ F
values 0 NOUN F
of 0 ADP F
systolic B-PHYSICAL ADJ F
blood I-PHYSICAL NOUN F
pressure I-PHYSICAL NOUN F
and 0 CCONJ F
pulse B-PHYSICAL NOUN F
pressure I-PHYSICAL NOUN F
in I-PHYSICAL ADP F
central I-PHYSICAL ADJ F
aorta I-PHYSICAL NOUN F
were 0 VERB F
significantly 0 ADV F
larger 0 PUNCT F
than 0 PUNCT F
those 0 PUNCT F
in 0 ADP F
brachial 0 ADJ F
artery 0 NOUN F
. 0 PUNCT F

However 0 ADV T
, 0 PUNCT F
the 0 DET F
difference B-PHYSICAL NOUN F
was 0 VERB F
not 0 ADV F
observed 0 VERB F
in 0 ADP F
indapamide 0 NOUN F
group 0 NOUN F
. 0 PUNCT F

CONCLUSIONS 0 NOUN T
Enalapril 0 NOUN T
and 0 CCONJ F
indapamide 0 NOUN F
are 0 ADP F
both 0 CCONJ F
similarly 0 ADV F
effective 0 ADJ F
in 0 ADP F
reducing 0 VERB F
peripheral B-PHYSICAL ADJ F
arterial I-PHYSICAL ADJ F
blood I-PHYSICAL NOUN F
pressure I-PHYSICAL NOUN F
. 0 PUNCT F

Moreover 0 ADV T
, 0 PUNCT F
enalapril 0 NOUN F
is 0 VERB F
more 0 ADV F
effective 0 ADJ F
in 0 ADP F
reducing 0 VERB F
central B-PHYSICAL ADJ F
systolic I-PHYSICAL ADJ F
pressure I-PHYSICAL NOUN F
and I-PHYSICAL CCONJ F
augmentation I-PHYSICAL NOUN F
index I-PHYSICAL NOUN F
than 0 ADP F
indapamide 0 NOUN F
. 0 PUNCT F

The 0 DET T
difference 0 NOUN F
is 0 VERB F
probably 0 ADV F
due 0 PUNCT F
to 0 ADP F
the 0 DET F
reduction 0 NOUN F
of 0 ADP F
wave B-PHYSICAL NOUN F
reflection I-PHYSICAL NOUN F
caused 0 VERB F
by 0 ADP F
enalapril 0 NOUN F
. 0 PUNCT F

Sustained 0 VERB T
ventricular 0 ADJ F
arrhythmias 0 NOUN F
and 0 CCONJ F
mortality 0 NOUN F
among 0 ADP F
patients 0 NOUN F
with 0 ADP F
acute 0 ADJ F
myocardial 0 ADJ F
infarction 0 NOUN F
: 0 PUNCT F
results 0 ADJ F
from 0 ADP F
the 0 DET F
GUSTO-III 0 PUNCT T
trial 0 NOUN F
. 0 PUNCT F

BACKGROUND 0 NOUN T
In 0 ADP T
many 0 DET F
patients 0 NOUN F
, 0 PUNCT F
ventricular 0 ADJ F
arrhythmias 0 NOUN F
will 0 VERB F
develop 0 ADV F
early 0 DET F
after 0 ADP F
acute 0 ADJ F
myocardial 0 ADJ F
infarction 0 NOUN F
. 0 PUNCT F

We 0 PRON T
studied 0 VERB F
the 0 DET F
incidence 0 NOUN F
, 0 PUNCT F
timing 0 VERB F
, 0 PUNCT F
and 0 CCONJ F
outcomes 0 NOUN F
of 0 ADP F
such 0 ADP F
arrhythmias 0 NOUN F
in 0 ADP F
the 0 DET F
international 0 ADJ F
Global 0 ADJ T
Utilization 0 NOUN T
of 0 ADP F
Streptokinase 0 NOUN T
and 0 CCONJ F
TPA 0 NOUN T
( 0 PUNCT F
alteplase 0 NOUN F
) 0 PUNCT F
for 0 ADP F
Occluded 0 PROPN T
Coronary 0 ADJ T
Arteries 0 NOUN T
( 0 PUNCT F
GUSTO 0 NOUN T
) 0 PUNCT F
-III 0 VERB F
trial 0 NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
We 0 PRON T
identified 0 VERB F
independent 0 ADJ F
predictors 0 NOUN F
of 0 ADP F
inhospital 0 ADJ F
ventricular 0 ADJ F
fibrillation 0 NOUN F
( 0 PUNCT F
VF 0 NOUN T
) 0 PUNCT F
and 0 CCONJ F
ventricular 0 ADJ F
tachycardia 0 NOUN F
( 0 PUNCT F
VT 0 NOUN T
) 0 PUNCT F
and 0 CCONJ F
compared 0 PUNCT F
30-day 0 NOUN F
and 0 CCONJ F
1-year 0 NOUN F
mortality 0 NOUN F
rates 0 NOUN F
of 0 ADP F
patients 0 NOUN F
who 0 PROPN F
did 0 PUNCT F
( 0 PUNCT F
n 0 NOUN F
= 0 SYM F
1121 0 NUM F
) 0 PUNCT F
and 0 CCONJ F
did 0 DET F
not 0 ADV F
( 0 PUNCT F
n 0 NOUN F
= 0 SYM F
13,921 0 NUM F
) 0 PUNCT F
have 0 PUNCT F
these 0 DET F
arrhythmias 0 NOUN F
during 0 ADP F
the 0 DET F
index 0 NOUN F
hospitalization 0 NOUN F
. 0 PUNCT F

RESULTS 0 NOUN T
Significant 0 ADJ T
independent 0 ADJ F
predictors 0 NOUN F
of 0 ADP F
inhospital 0 ADJ F
VF 0 NOUN T
were 0 VERB F
higher 0 PUNCT F
Killip B-PHYSICAL NOUN T
class I-PHYSICAL NOUN F
, 0 PUNCT F
lower B-PHYSICAL PUNCT F
baseline 0 NOUN F
systolic B-PHYSICAL ADJ F
pressure B-PHYSICAL NOUN F
, 0 PUNCT F
intravenous B-OTHER ADJ F
preenrollment I-OTHER ADJ F
lidocaine B-OTHER NOUN F
use B-OTHER NOUN F
, 0 PUNCT F
shorter 0 PUNCT F
time 0 NOUN F
to 0 ADP F
thrombolysis B-PHYSICAL NOUN F
, 0 PUNCT F
and 0 CCONJ F
beta-blocker 0 NOUN F
use 0 NOUN F
< 0 SYM F
2 0 NUM F
weeks 0 NOUN F
before 0 ADP F
enrollment 0 NOUN F
; 0 PUNCT F
independent 0 ADJ F
predictors 0 NOUN F
of 0 ADP F
inhospital 0 ADJ F
VT 0 NOUN T
were 0 VERB F
lower 0 VERB F
baseline 0 NOUN F
systolic B-PHYSICAL ADJ F
pressure I-PHYSICAL NOUN F
, 0 PUNCT F
intravenous B-PHYSICAL ADJ F
lidocaine I-PHYSICAL NOUN F
use 0 NOUN F
before 0 ADP F
enrollment 0 NOUN F
, 0 PUNCT F
higher 0 PUNCT F
Killip 0 NOUN T
class 0 NOUN F
, 0 PUNCT F
faster 0 PUNCT F
baseline 0 NOUN F
heart B-PHYSICAL NOUN F
rate I-PHYSICAL NOUN F
, 0 PUNCT F
and 0 CCONJ F
advanced 0 VERB F
age 0 NOUN F
. 0 PUNCT F

The 0 DET T
30-day B-MORTALITY NOUN F
mortality I-MORTALITY NOUN F
rate I-MORTALITY NOUN F
was 0 VERB F
31 0 NUM F
% 0 SYM F
in 0 ADP F
patients 0 NOUN F
with 0 ADP F
VF 0 NOUN T
, 0 PUNCT F
24 0 NUM F
% 0 SYM F
in 0 ADP F
those 0 PUNCT F
with 0 ADP F
VT 0 NOUN T
, 0 PUNCT F
44 0 NUM F
% 0 SYM F
in 0 ADP F
those 0 PUNCT F
with 0 ADP F
both 0 CCONJ F
, 0 PUNCT F
and 0 CCONJ F
6 0 NUM F
% 0 SYM F
in 0 ADP F
those 0 PUNCT F
with 0 ADP F
neither 0 CCONJ F
( 0 PUNCT F
P 0 NOUN T
=.001 0 PUNCT F
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
corresponding 0 VERB F
1-year B-MORTALITY NOUN F
mortality I-MORTALITY PUNCT F

Clinical 0 ADJ T
description 0 NOUN F
of 0 ADP F
encephalopathic 0 ADJ F
syndromes 0 NOUN F
and 0 CCONJ F
risk 0 NOUN F
factors 0 NOUN F
for 0 ADP F
their 0 PUNCT F
occurrence 0 NOUN F
and 0 CCONJ F
outcome 0 NOUN F
during 0 ADP F
melarsoprol 0 NOUN F
treatment 0 NOUN F
of 0 ADP F
human 0 NOUN F
African 0 ADJ T
trypanosomiasis 0 NOUN F
. 0 PUNCT F

Encephalopathies 0 NUM T
are 0 VERB F
the 0 DET F
most 0 PUNCT F
feared 0 VERB F
complications 0 NOUN F
of 0 ADP F
sleeping 0 VERB F
sickness 0 NOUN F
treatment 0 NOUN F
with 0 ADP F
melarsoprol 0 NOUN F
. 0 PUNCT F

To 0 PART T
investigate 0 NOUN F
the 0 DET F
existence 0 NOUN F
of 0 ADP F
risk 0 NOUN F
factors 0 NOUN F
, 0 PUNCT F
the 0 DET F
incidence 0 NOUN F
of 0 ADP F
encephalopathic 0 ADJ F
syndromes 0 NOUN F
and 0 CCONJ F
the 0 DET F
relationship 0 NOUN F
between 0 ADP F
the 0 DET F
development 0 NOUN F
of 0 ADP F
different 0 ADJ F
types 0 NOUN F
of 0 ADP F
encephalopathies 0 NOUN F
and 0 CCONJ F
the 0 DET F
clinical 0 ADJ F
outcome 0 NOUN F
was 0 VERB F
studied 0 VERB F
in 0 ADP F
a 0 DET F
clinical 0 ADJ F
trial 0 NOUN F
with 0 ADP F
588 0 NUM F
patients 0 NOUN F
under 0 ADP F
treatment 0 NOUN F
with 0 ADP F
melarsoprol 0 NOUN F
. 0 PUNCT F

The 0 DET T
38 0 NUM F
encephalopathy 0 NOUN F
cases 0 NOUN F
were 0 VERB F
classified 0 VERB F
into 0 ADP F
three 0 NUM F
types 0 NOUN F
according 0 CCONJ F
to 0 ADP F
the 0 DET F
leading 0 ADJ F
clinical 0 ADJ F
picture 0 NOUN F
: 0 PUNCT F
coma 0 NOUN F
type 0 NOUN F
, 0 PUNCT F
convulsion 0 NOUN F
type 0 NOUN F
and 0 CCONJ F
psychotic 0 ADJ F
reactions 0 NOUN F
. 0 PUNCT F

Nine 0 NUM T
patients 0 NOUN F
were 0 VERB F
attributed 0 VERB F
to 0 ADP F
the 0 DET F
convulsion 0 NOUN F
type 0 NOUN F
, 0 PUNCT F
defined 0 VERB F
as 0 ADP F
a 0 DET F
transient 0 ADJ F
event 0 NOUN F
of 0 ADP F
short 0 ADJ F
duration 0 NOUN F
with 0 ADP F
convulsions 0 NOUN F
followed 0 VERB F
by 0 ADP F
a 0 DET F
post-ictal 0 ADJ F
phase 0 NOUN F
, 0 PUNCT F
without 0 ADP F
signs 0 NOUN F
of 0 ADP F
a 0 DET F
generalized 0 VERB F
disease 0 NOUN F
. 0 PUNCT F

None 0 NUM T
of 0 ADP F
these 0 DET F
patients 0 NOUN F
died 0 VERB F
from 0 ADP F
the 0 DET F
reaction 0 NOUN F
. 0 PUNCT F

Febrile B-PHYSICAL ADJ T
reactions I-PHYSICAL NOUN F
in 0 ADP F
the 0 DET F
48 0 NUM F
h 0 NOUN F
preceding 0 VERB F
the 0 DET F
reaction 0 NOUN F
were 0 VERB F
generally 0 ADV F
not 0 ADV F
observed 0 VERB F
in 0 ADP F
this 0 DET F
group 0 NOUN F
. 0 PUNCT F

Twenty-five 0 PUNCT T
patients 0 NOUN F
were 0 VERB F
attributed 0 VERB F
to 0 ADP F
the 0 DET F
coma 0 NOUN F
type 0 NOUN F
, 0 PUNCT F
which 0 ADP F
is 0 VERB F
a 0 DET F
progredient 0 ADJ F
coma 0 NOUN F
lasting 0 PUNCT F
several 0 ADJ F
days 0 NOUN F
. 0 PUNCT F

Those 0 ADP T
patients 0 NOUN F
often 0 ADV F
had 0 PUNCT F
signs 0 NOUN F
of 0 ADP F
a 0 DET F
generalized 0 VERB F
disease 0 NOUN F
such 0 PUNCT F
as 0 ADP F
fever B-PHYSICAL NOUN F
( 0 PUNCT F
84 0 NUM F
% 0 SYM F
) 0 PUNCT F
, 0 PUNCT F
headache B-PHYSICAL ADJ F
( 0 PUNCT F
72 0 NUM F
% 0 SYM F
) 0 PUNCT F
or 0 CCONJ F
bullous 0 ADJ F
skin 0 NOUN F
( 0 PUNCT F
8 0 NUM F
% 0 SYM F
) 0 PUNCT F
reactions 0 NOUN F
. 0 PUNCT F

The 0 DET T
risk 0 NOUN F
of 0 ADP F
mortality B-MORTALITY NOUN F
was 0 VERB F
high 0 ADJ F
in 0 ADP F
this 0 DET F
group 0 NOUN F
( 0 PUNCT F
52 0 NUM F
% 0 SYM F
) 0 PUNCT F
. 0 PUNCT F

About 0 PUNCT T
14/16 0 PUNCT F
patients 0 NOUN F
with 0 ADP F
encephalopathic 0 ADJ F
syndrome 0 NOUN F
of 0 ADP F
the 0 DET F
coma 0 NOUN F
type 0 NOUN F
were 0 VERB F
infected 0 VERB F
with 0 ADP F
malaria 0 NOUN F
. 0 PUNCT F

Patients 0 NOUN T
with 0 ADP F
psychotic 0 ADJ F
reactions 0 NOUN F
or 0 CCONJ F
abnormal 0 ADJ F
psychiatric 0 ADJ F
behaviour 0 NOUN F
( 0 PUNCT F
3/38 0 NOUN F
) 0 PUNCT F
and 0 CCONJ F
one 0 NUM F
patient 0 NOUN F
who 0 ADP F
died B-MORTALITY VERB F
after 0 ADP F
alcohol 0 NOUN F
intake 0 NOUN F
were 0 VERB F
excluded 0 VERB F
from 0 ADP F
the 0 DET F
analysis 0 NOUN F
. 0 PUNCT F

The 0 DET T
overall B-PHYSICAL ADJ F
rate I-PHYSICAL NOUN F
of I-PHYSICAL ADP F
encephalopathic I-PHYSICAL ADJ F
syndromes I-PHYSICAL NOUN F
in 0 ADP F
the 0 DET F
cases 0 NOUN F
analysed 0 VERB F
( 0 PUNCT F
n=34 0 NOUN F
) 0 PUNCT F
was 0 VERB F
5.8 0 NUM F
% 0 SYM F
, 0 PUNCT F
of 0 ADP F
which 0 ADP F
38.2 0 NUM F
% 0 SYM F
died 0 VERB F
. 0 PUNCT F

We 0 PRON T
did 0 CCONJ F
not 0 ADV F
find 0 VERB F
any 0 DET F
parameters 0 NOUN F
of 0 ADP F
predictive 0 ADJ F
value 0 NOUN F
for 0 ADP F
the 0 DET F
risk 0 NOUN F
of 0 ADP F
developing B-PHYSICAL PUNCT F
an I-PHYSICAL DET F
encephalopathic I-PHYSICAL ADJ F
syndrome I-PHYSICAL NOUN F
based 0 VERB F
on 0 ADP F
the 0 DET F
symptoms 0 NOUN F
and 0 CCONJ F
signs 0 NOUN F
before 0 ADP F
treatment 0 NOUN F
initiation 0 NOUN F
. 0 PUNCT F

The 0 DET T
appearance 0 NOUN F
during 0 ADP F
treatment 0 NOUN F
of 0 ADP F
febrile B-PHYSICAL ADJ F
reactions I-PHYSICAL NOUN F
( 0 PUNCT F
RR 0 NOUN T
11.5 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
headache B-PHYSICAL NOUN F
( 0 PUNCT F
RR 0 NOUN T
2.5 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
bullous B-PHYSICAL ADJ F
eruptions I-PHYSICAL NOUN F
( 0 PUNCT F
RR 0 NOUN T
4.5 0 NUM F
) 0 PUNCT F
and 0 CCONJ F
systolic B-PHYSICAL ADJ F
hypotension I-PHYSICAL NOUN F
( 0 PUNCT F
RR 0 NOUN T
2.6 0 NUM F
) 0 PUNCT F
were 0 VERB F
associated 0 VERB F
with 0 ADP F
an 0 DET F
increased 0 VERB F
risk 0 NOUN F
for 0 ADP F
the 0 DET F
occurrence 0 NOUN F
of 0 ADP F
encephalopathic 0 ADJ F
syndromes 0 NOUN F
especially 0 DET F
of 0 ADP F
the 0 DET F
coma 0 NOUN F
type 0 NOUN F
. 0 PUNCT F

Oral 0 ADJ T
6-mercaptopurine 0 NOUN F
versus 0 CCONJ F
oral 0 ADJ F
6-thioguanine 0 NOUN F
and 0 CCONJ F
veno-occlusive 0 ADJ F
disease 0 NOUN F
in 0 ADP F
children 0 NOUN F
with 0 ADP F
standard-risk 0 NOUN F
acute 0 ADJ F
lymphoblastic 0 ADJ F
leukemia 0 NOUN F
: 0 PUNCT F
report 0 NOUN F
of 0 ADP F
the 0 DET F
Children 0 NOUN T
's 0 PUNCT F
Oncology 0 NOUN T
Group 0 NOUN T
CCG-1952 0 NOUN T
clinical 0 ADJ F
trial 0 NOUN F
. 0 PUNCT F

The 0 DET T
Children 0 NOUN T
's 0 PUNCT F
Cancer 0 NOUN T
Group 0 NOUN T
1952 0 NUM F
( 0 PUNCT F
CCG-1952 0 NOUN T
) 0 PUNCT F
clinical 0 ADJ F
trial 0 NOUN F
studied 0 VERB F
the 0 DET F
substitution 0 NOUN F
of 0 ADP F
oral 0 ADJ F
6-thioguanine 0 NOUN F
( 0 PUNCT F
TG 0 NOUN T
) 0 PUNCT F
for 0 ADP F
6-mercaptopurine 0 NOUN F
( 0 PUNCT F
MP 0 NOUN T
) 0 PUNCT F
and 0 CCONJ F
triple 0 ADJ F
intrathecal 0 ADJ F
therapy 0 NOUN F
( 0 PUNCT F
ITT 0 NOUN T
) 0 PUNCT F
for 0 ADP F
intrathecal 0 ADJ F
methotrexate 0 NOUN F
( 0 PUNCT F
IT-MTX 0 NOUN T
) 0 PUNCT F
in 0 ADP F
the 0 DET F
treatment 0 NOUN F
of 0 ADP F
standard-risk 0 NOUN F
acute 0 ADJ F
lymphoblastic 0 ADJ F
leukemia 0 NOUN F
. 0 PUNCT F

After 0 ADP T
remission 0 NOUN F
induction 0 NOUN F
, 0 PUNCT F
2027 0 NUM F
patients 0 NOUN F
were 0 VERB F
randomized 0 VERB F
to 0 PART F
receive 0 NOUN F
MP 0 NOUN T
( 0 PUNCT F
n 0 NOUN F
= 0 SYM F
1010 0 NUM F
) 0 PUNCT F
or 0 CCONJ F
TG 0 NOUN T
( 0 PUNCT F
n 0 NOUN F
= 0 SYM F
1017 0 NUM F
) 0 PUNCT F
and 0 CCONJ F
IT-MTX 0 NOUN T
( 0 PUNCT F
n 0 NOUN F
= 0 SYM F
1018 0 NUM F
) 0 PUNCT F
or 0 CCONJ F
ITT 0 NOUN T
( 0 PUNCT F
n 0 NOUN F
= 0 SYM F
1009 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
results 0 NOUN F
of 0 ADP F
the 0 DET F
thiopurine 0 NOUN F
comparison 0 NOUN F
are 0 ADP F
as 0 PUNCT F
follows 0 PUNCT F
. 0 PUNCT F

The 0 DET T
estimated 0 VERB F
7-year 0 NOUN F
event-free B-MORTALITY CCONJ F
survival I-MORTALITY NOUN F
( I-MORTALITY PUNCT F
EFS I-MORTALITY NOUN T
) I-MORTALITY PUNCT F
for 0 ADP F
subjects 0 NOUN F
randomized 0 VERB F
to 0 ADP F
TG 0 NOUN T
was 0 VERB F
84.1 0 NUM F
% 0 ADJ F
( 0 PUNCT F
+/- 0 PROPN F
1.8 0 NUM F
% 0 SYM F
) 0 PUNCT F
and 0 CCONJ F
to 0 ADP F
MP 0 NOUN T
was 0 VERB F
79.0 0 NUM F
% 0 SYM F
( 0 PUNCT F
+/- 0 PROPN F
2.1 0 NUM F
% 0 SYM F
; 0 PUNCT F
P 0 NOUN T
= 0 SYM F
.004 0 NUM F
log 0 NOUN F
rank 0 NOUN F
) 0 PUNCT F
, 0 PUNCT F
although 0 ADP F
overall B-MORTALITY ADJ F
survival I-MORTALITY NOUN F
was 0 VERB F
91.9 0 NUM F
% 0 SYM F
( 0 PUNCT F
+/- 0 PROPN F
1.4 0 NUM F
% 0 SYM F
) 0 PUNCT F
and 0 CCONJ F
91.2 0 NUM F
% 0 SYM F
( 0 PUNCT F
+/- 0 PROPN F
1.5 0 NUM F
% 0 SYM F
) 0 PUNCT F
, 0 PUNCT F
respectively 0 ADV F
( 0 PUNCT F
P 0 NOUN T
= 0 SYM F
.6 0 PUNCT F
log 0 NOUN F
rank 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
TG 0 NOUN T
starting 0 PUNCT F
dose 0 NOUN F
was 0 VERB F
reduced 0 VERB F
from 0 ADP F
60 0 NUM F
to 0 ADP F
50 0 NUM F
mg/m 0 NOUN F
( 0 PUNCT F
2 0 NUM F
) 0 PUNCT F
per 0 ADP F
day 0 NOUN F
after 0 PUNCT F
recognition 0 NOUN F
of 0 ADP F
hepatic B-PHYSICAL ADJ F
veno-occlusive I-PHYSICAL ADJ F
disease I-PHYSICAL NOUN F
( I-PHYSICAL PUNCT F
VOD I-PHYSICAL NOUN T
) I-PHYSICAL PUNCT F
. 0 PUNCT F

A 0 DET T
total 0 NOUN F
of 0 ADP F
257 0 NUM F
patients 0 NOUN F
on 0 ADP F
TG 0 NOUN T
( 0 PUNCT F
25 0 NUM F
% 0 SYM F
) 0 PUNCT F
developed 0 VERB F
VOD B-PHYSICAL NOUN T
or 0 CCONJ F
disproportionate B-PHYSICAL ADJ F
thrombocytopenia I-PHYSICAL NOUN F
and 0 CCONJ F
switched 0 VERB F
to 0 ADP F
MP 0 NOUN T
. 0 PUNCT F

Once 0 PUNCT T
portal B-PHYSICAL NOUN F
hypertension I-PHYSICAL NOUN F
occurred 0 VERB F
, 0 PUNCT F
all 0 DET F
subjects 0 NOUN F
on 0 ADP F
TG 0 NOUN T
were 0 VERB F
changed 0 NUM F
to 0 ADP F
MP 0 NOUN T
. 0 PUNCT F

The 0 DET T
benefit 0 NOUN F
of 0 ADP F
randomization 0 NOUN F
to 0 ADP F
TG 0 NOUN T
over 0 ADP F
MP 0 NOUN T
, 0 PUNCT F
as 0 PUNCT F
measured 0 VERB F
by 0 ADP F
EFS 0 NOUN T
, 0 PUNCT F
was 0 VERB F
evident 0 ADJ F
primarily 0 ADV F
in 0 ADP F
boys 0 NOUN F
who 0 ADP F
began 0 ADV F
TG 0 NOUN T
at 0 ADP F
60 0 NUM F
mg/m 0 NOUN F
( 0 PUNCT F
2 0 NUM F
) 0 PUNCT F
( 0 PUNCT F
relative 0 ADJ F
hazard 0 NOUN F
rate 0 NOUN F
[ 0 PUNCT F
RHR 0 NOUN T
] 0 PUNCT F
0.65 0 NUM F
, 0 PUNCT F
P 0 NOUN T
= 0 SYM F
.002 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
toxicities 0 NOUN F
of 0 ADP F
TG 0 NOUN T
preclude 0 PUNCT F
its 0 ADP F
protracted 0 VERB F
use 0 NOUN F
as 0 PUNCT F
given 0 VERB F
in 0 ADP F
this 0 DET F
study 0 NOUN F
. 0 PUNCT F

This 0 DET T
study 0 NOUN F
is 0 VERB F
registered 0 NOUN F
at 0 ADP F
http 0 PUNCT F
: 0 PUNCT F
//clinicaltrials.gov 0 PUNCT F
as 0 PUNCT F
NCT00002744 0 NOUN T
. 0 PUNCT F

Effects 0 NOUN T
of 0 ADP F
two 0 NUM F
types 0 NOUN F
of 0 ADP F
social 0 ADJ F
support 0 NOUN F
and 0 CCONJ F
education 0 NOUN F
on 0 ADP F
adaptation 0 NOUN F
to 0 ADP F
early-stage 0 NOUN F
breast 0 NOUN F
cancer 0 NOUN F
. 0 PUNCT F

A 0 DET T
Roy 0 NOUN T
adaptation 0 NOUN F
model-based 0 VERB F
support 0 NOUN F
and 0 CCONJ F
education 0 NOUN F
intervention 0 NOUN F
for 0 ADP F
women 0 NOUN F
with 0 ADP F
early-stage 0 NOUN F
breast 0 NOUN F
cancer 0 NOUN F
was 0 VERB F
tested 0 VERB F
in 0 ADP F
a 0 DET F
three-group 0 NOUN F
, 0 PUNCT F
three-phase 0 NOUN F
randomized 0 VERB F
clinical 0 ADJ F
trial 0 NOUN F
of 0 ADP F
a 0 DET F
sample 0 NOUN F
of 0 ADP F
125 0 NUM F
women 0 NOUN F
. 0 PUNCT F

The 0 DET T
experimental 0 ADJ F
group 0 NOUN F
received 0 VERB F
13 0 NUM F
months 0 NOUN F
of 0 ADP F
combined 0 VERB F
individual 0 ADP F
telephone 0 NOUN F
and 0 CCONJ F
in-person 0 NOUN F
group 0 NOUN F
support 0 NOUN F
and 0 CCONJ F
education 0 NOUN F
, 0 PUNCT F
Control 0 NOUN T
Group 0 NOUN T
1 0 NUM F
received 0 PUNCT F
13 0 NUM F
months 0 NOUN F
of 0 ADP F
telephone-only 0 PUNCT F
individual 0 ADJ F
support 0 NOUN F
and 0 CCONJ F
education 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
Control 0 NOUN T
Group 0 NOUN T
2 0 NUM F
received 0 VERB F
one-time 0 ADJ F
mailed 0 PUNCT F
educational 0 ADJ F
information 0 NOUN F
. 0 PUNCT F

The 0 DET T
experimental 0 ADJ F
group 0 NOUN F
and 0 CCONJ F
Control 0 NOUN T
Group 0 NOUN T
1 0 NUM F
reported 0 PUNCT F
less 0 ADV F
mood B-MENTAL PUNCT F
disturbance I-MENTAL NOUN F
at 0 ADP F
the 0 DET F
end 0 NOUN F
of 0 ADP F
all 0 DET F
three 0 NUM F
phases 0 NOUN F
, 0 PUNCT F
less B-MENTAL DET F
loneliness I-MENTAL NOUN F
at 0 ADP F
the 0 DET F
end 0 NOUN F
of 0 ADP F
Phases 0 NOUN T
II 0 NUM T
and 0 CCONJ F
III 0 NUM T
, 0 PUNCT F
and 0 CCONJ F
a 0 DET F
higher-quality B-MENTAL NOUN F
relationship I-MENTAL NOUN F
with I-MENTAL ADP F
a I-MENTAL DET F
significant I-MENTAL ADJ F
other 0 PUNCT F
at 0 ADP F
the 0 DET F
end 0 NOUN F
of 0 ADP F
Phase 0 NOUN T
II 0 NUM T
than 0 PUNCT F
did 0 PUNCT F
Control 0 NOUN T
Group 0 NOUN T
2 0 NUM F
. 0 PUNCT F

No 0 DET T
group 0 NOUN F
differences 0 NOUN F
were 0 VERB F
found 0 VERB F
for 0 ADP F
cancer-related B-PHYSICAL VERB F
worry I-PHYSICAL NOUN F
or I-PHYSICAL CCONJ F
well-being I-PHYSICAL PUNCT F
. 0 PUNCT F

The 0 DET T
findings 0 NOUN F
suggest 0 VERB F
that 0 ADP F
individual 0 ADJ F
telephone 0 NOUN F
support 0 NOUN F
may 0 VERB F
provide 0 VERB F
an 0 DET F
effective 0 ADJ F
alternative 0 ADJ F
to 0 ADP F
in-person 0 NOUN F
support 0 ADV F
groups 0 NOUN F
. 0 PUNCT F

Further 0 ADJ T
study 0 NOUN F
of 0 ADP F
telephone 0 NOUN F
interventions 0 NOUN F
is 0 VERB F
recommended 0 VERB F
using 0 VERB F
ethnically 0 NUM F
and 0 CCONJ F
economically 0 ADV F
heterogeneous 0 ADJ F
samples 0 NOUN F
. 0 PUNCT F

Efficiency 0 NOUN T
of 0 ADP F
slush 0 NOUN F
nitrogen 0 NOUN F
vitrification 0 NOUN F
of 0 ADP F
human 0 NOUN F
oocytes 0 NOUN F
vitrified 0 ADP F
with 0 ADP F
or 0 CCONJ F
without 0 ADP F
cumulus 0 ADJ F
cells 0 NOUN F
in 0 ADP F
relation 0 NOUN F
to 0 ADP F
survival B-MORTALITY NOUN F
rate I-MORTALITY NOUN F
and 0 CCONJ F
meiotic B-PHYSICAL ADJ F
spindle I-PHYSICAL NOUN F
competence I-PHYSICAL NOUN F
. 0 PUNCT F

OBJECTIVE 0 NOUN T
To 0 PROPN T
evaluate 0 NOUN F
the 0 DET F
efficiency 0 NOUN F
of 0 ADP F
slush 0 NOUN F
nitrogen 0 NOUN F
vitrification 0 NOUN F
of 0 ADP F
human 0 NOUN F
oocytes 0 NOUN F
with 0 ADP F
or 0 CCONJ F
without 0 ADP F
cumulus 0 ADJ F
cells 0 NOUN F
in 0 ADP F
terms 0 NOUN F
of 0 ADP F
survival B-MORTALITY NOUN F
rate I-MORTALITY NOUN F
and 0 CCONJ F
maintenance 0 NOUN F
of 0 ADP F
meiotic B-PHYSICAL ADJ F
spindle I-PHYSICAL NOUN F
. 0 PUNCT F

DESIGN 0 NOUN T
Randomized 0 PROPN T
, 0 PUNCT F
comparative 0 ADJ F
study 0 NOUN F
. 0 PUNCT F

SETTING 0 NUM T
Medical 0 ADJ T
center 0 NOUN F
. 0 PUNCT F

PATIENT 0 NOUN T
( 0 PUNCT F
S 0 NOUN T
) 0 PUNCT F
A 0 DET T
total 0 NOUN F
of 0 ADP F
274 0 NUM F
oocytes 0 NOUN F
obtained 0 VERB F
from 0 ADP F
46 0 NUM F
couples 0 ADJ F
undergoing 0 CCONJ F
infertility 0 NOUN F
treatment 0 NOUN F
. 0 PUNCT F

INTERVENTION 0 NOUN T
( 0 PUNCT F
S 0 NOUN T
) 0 PUNCT F
Metaphase 0 NOUN T
II 0 NUM T
oocytes 0 NOUN F
were 0 VERB F
divided 0 VERB F
into 0 ADP F
groups 0 NOUN F
A 0 DET T
and 0 CCONJ F
B 0 NOUN T
, 0 PUNCT F
vitrified 0 PUNCT F
with 0 ADP F
and 0 CCONJ F
without 0 ADP F
cumulus 0 NOUN F
cells 0 NOUN F
, 0 PUNCT F
respectively 0 ADV F
. 0 PUNCT F

MAIN 0 ADJ T
OUTCOMES 0 NOUN T
MEASURE 0 PUNCT T
( 0 PUNCT F
S 0 NOUN T
) 0 PUNCT F
Survival B-MORTALITY NOUN T
rates I-MORTALITY NOUN F
and 0 CCONJ F
maintenance 0 NOUN F
of 0 ADP F
meiotic B-OTHER ADJ F
spindle I-OTHER NOUN F
observed I-OTHER DET F
immediately I-OTHER ADV F
after I-OTHER ADP F
warming I-OTHER VERB F
and I-OTHER CCONJ F
3 I-OTHER NUM F
hours I-OTHER NOUN F
after I-OTHER ADP F
incubation I-OTHER NOUN F
. 0 PUNCT F

RESULT 0 NOUN T
( 0 PUNCT F
S 0 NOUN T
) 0 PUNCT F
No 0 DET T
statistically 0 ADV F
significant 0 ADJ F
difference 0 NOUN F
was 0 VERB F
detected 0 VERB F
between 0 ADP F
the 0 DET F
two 0 NUM F
groups 0 NOUN F
in 0 ADP F
terms 0 NOUN F
of 0 ADP F
survival B-MORTALITY NOUN F
rate I-MORTALITY NOUN F
, 0 PUNCT F
but 0 CCONJ F
a 0 DET F
significantly 0 ADV F
higher 0 PUNCT F
percentage 0 NOUN F
of 0 ADP F
detectable B-PHYSICAL ADJ F
spindle I-PHYSICAL NOUN F
was 0 VERB F
observed 0 VERB F
in 0 ADP F
group 0 NOUN F
B 0 NOUN T
( 0 PUNCT F
completely 0 ADV F
denuded 0 VERB F
oocytes 0 NOUN F
) 0 PUNCT F
, 0 PUNCT F
either 0 PUNCT F
immediately 0 ADV F
after 0 ADP F
warming 0 VERB F
or 0 CCONJ F
3 0 NUM F
hours 0 NOUN F
after 0 ADP F
incubation 0 NOUN F
. 0 PUNCT F

CONCLUSION 0 NOUN T
( 0 PUNCT F
S 0 NOUN T
) 0 PUNCT F
Complete 0 ADJ T
denudation 0 NOUN F
of 0 ADP F
oocytes 0 NOUN F
before 0 ADP F
slush 0 NOUN F
nitrogen 0 NOUN F
vitrification 0 NOUN F
does 0 PUNCT F
not 0 ADV F
influence 0 ADV F
survival B-MORTALITY NOUN F
rates I-MORTALITY NOUN F
but 0 CCONJ F
positively 0 ADV F
affects 0 NOUN F
oocyte 0 NOUN F
meiotic B-PHYSICAL ADJ F
spindle I-PHYSICAL NOUN F
competence I-PHYSICAL NOUN F
. 0 PUNCT F

These 0 DET T
data 0 NOUN F
support 0 VERB F
the 0 DET F
hypothesis 0 NOUN F
that 0 ADP F
cumulus 0 NOUN F
cells 0 NOUN F
during 0 ADP F
vitrification 0 NOUN F
represent 0 VERB F
an 0 DET F
obstacle 0 ADJ F
to 0 VERB F
cryoprotectant 0 PUNCT F
penetration 0 NOUN F
more 0 ADV F
than 0 PUNCT F
having 0 DET F
a 0 DET F
protective 0 ADJ F
role 0 NOUN F
for 0 ADP F
the 0 DET F
oocyte 0 NOUN F
. 0 PUNCT F

Beneficial 0 ADJ T
effects 0 NOUN F
of 0 ADP F
a 0 DET F
soy-based 0 ADV F
dietary 0 ADJ F
supplement 0 NOUN F
on 0 ADP F
lipid B-PHYSICAL NOUN F
levels I-PHYSICAL NOUN F
and 0 CCONJ F
cardiovascular B-PHYSICAL ADJ F
risk 0 NOUN F
markers B-PHYSICAL NOUN F
in 0 ADP F
type 0 NOUN F
2 0 NUM F
diabetic 0 ADJ F
subjects 0 NOUN F
. 0 PUNCT F

OBJECTIVE 0 NOUN T
Consumption 0 NOUN T
of 0 ADP F
soy 0 NOUN F
protein 0 NOUN F
has 0 ADP F
recently 0 ADV F
been 0 PUNCT F
shown 0 VERB F
to 0 PART F
improve 0 ADJ F
the 0 DET F
blood B-PHYSICAL NOUN F
lipid I-PHYSICAL NOUN F
levels B-PHYSICAL NOUN F
in 0 ADP F
nondiabetic 0 ADJ F
subjects 0 NOUN F
. 0 PUNCT F

The 0 DET T
purpose 0 NOUN F
of 0 ADP F
this 0 DET F
study 0 NOUN F
was 0 VERB F
to 0 PART F
evaluate 0 NOUN F
if 0 PUNCT F
a 0 DET F
dietary 0 ADJ F
supplement 0 NOUN F
of 0 ADP F
soy 0 NOUN F
protein 0 NOUN F
, 0 PUNCT F
isoflavones 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
cotyledon 0 NOUN F
fiber 0 NOUN F
( 0 PUNCT F
Abalon 0 NOUN T
) 0 PUNCT F
affects 0 NOUN F
cardiovascular B-PHYSICAL ADJ F
risk 0 NOUN F
markers B-PHYSICAL NOUN F
, 0 PUNCT F
blood B-PHYSICAL NOUN F
glucose I-PHYSICAL NOUN F
, 0 PUNCT F
and 0 CCONJ F
insulin B-PHYSICAL NOUN F
levels B-PHYSICAL NOUN F
in 0 ADP F
type 0 NOUN F
2 0 NUM F
diabetic 0 ADJ F
subjects 0 NOUN F
. 0 PUNCT F

RESEARCH 0 NOUN T
DESIGN 0 NOUN T
AND 0 CCONJ T
METHODS 0 NOUN T
Twenty 0 PUNCT T
type 0 NOUN F
2 0 NUM F
diabetic 0 ADJ F
subjects 0 NOUN F
participated 0 VERB F
in 0 ADP F
a 0 DET F
crossover 0 ADP F
trial 0 NOUN F
. 0 PUNCT F

They 0 PRON T
were 0 VERB F
randomized 0 ADP F
to 0 ADP F
double-blind 0 ADJ F
supplementation 0 NOUN F
for 0 ADP F
6 0 NUM F
weeks 0 NOUN F
with 0 ADP F
Abalon 0 NOUN T
( 0 PUNCT F
soy 0 NOUN F
protein 0 NOUN F
[ 0 PUNCT F
50 0 ADP F
g/day 0 PUNCT F
] 0 PUNCT F
with 0 ADP F
high 0 ADJ F
levels 0 NOUN F
of 0 ADP F
isoflavones 0 NOUN F
[ 0 PUNCT F
minimum 0 NOUN F
165 0 PUNCT F
mg/day 0 NOUN F
] 0 PUNCT F
and 0 CCONJ F
cotyledon 0 NOUN F
fiber 0 NOUN F
[ 0 PUNCT F
20 0 ADP F
g/day 0 PUNCT F
] 0 PUNCT F
) 0 PUNCT F
or 0 CCONJ F
placebo 0 NOUN F
( 0 PUNCT F
casein 0 NOUN F
[ 0 PUNCT F
50 0 ADP F
g/day 0 PUNCT F
] 0 PUNCT F
and 0 CCONJ F
cellulose 0 ADJ F
[ 0 PUNCT F
20 0 ADP F
g/day 0 PUNCT F
] 0 PUNCT F
) 0 PUNCT F
, 0 PUNCT F
separated 0 VERB F
by 0 ADP F
a 0 DET F
3-week 0 NOUN F
wash-out 0 PUNCT F
period 0 NOUN F
. 0 PUNCT F

RESULTS 0 PUNCT T
The 0 DET T
results 0 NOUN F
are 0 VERB F
expressed 0 VERB F
as 0 ADP F
means 0 NOUN F
+/- 0 SYM F
SD 0 NOUN T
. 0 PUNCT F

The 0 DET T
percentage 0 NOUN F
mean 0 NOUN F
treatment 0 NOUN F
difference 0 NOUN F
between 0 ADP F
Abalon 0 NOUN T
and 0 CCONJ F
placebo 0 NOUN F
demonstrated 0 PUNCT F
significantly 0 ADV F
lower 0 PUNCT F
mean 0 NOUN F
values 0 NOUN F
after 0 ADP F
Abalon 0 NOUN T
for 0 ADP F
LDL B-PHYSICAL NOUN T
cholesterol B-PHYSICAL NOUN F
( 0 PUNCT F
10 0 NUM F
+/- 0 SYM F
15 0 NUM F
% 0 SYM F
, 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.05 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
LDL/UHDL B-PHYSICAL PUNCT T
ratio I-PHYSICAL NOUN F
( 0 PUNCT F
12 0 NUM F
+/- 0 SYM F
18 0 NUM F
% 0 SYM F
, 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.05 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
apolipoprotein B-PHYSICAL NOUN F
( 0 PUNCT F
apo 0 NOUN F
) 0 PUNCT F
B100 0 NOUN T
( 0 PUNCT F
30 0 NUM F
+/- 0 SYM F
38 0 NUM F
% 0 SYM F
, 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.01 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
triglycerides B-PHYSICAL NOUN F
( 0 PUNCT F
22 0 NUM F
+/- 0 SYM F
10 0 NUM F
% 0 SYM F
, 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.05 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
and 0 CCONJ F
homocysteine B-PHYSICAL PUNCT F
( 0 PUNCT F
14 0 NUM F
+/- 0 SYM F
21 0 NUM F
% 0 SYM F
, 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.01 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
whereas 0 ADP F
the 0 DET F
total 0 ADJ F
cholesterol B-PHYSICAL NOUN F
value I-PHYSICAL NOUN F
tended 0 VERB F
to 0 PART F
be 0 PUNCT F
less 0 ADV F
significant 0 ADJ F
but 0 CCONJ F
still 0 PUNCT F
lower 0 PUNCT F
( 0 PUNCT F
8 0 NUM F
+/- 0 SYM F
15 0 NUM F
% 0 SYM F
, 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.08 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

No 0 DET T
change 0 NOUN F
occurred 0 VERB F
in 0 ADP F
HDL B-PHYSICAL NOUN T
cholesterol B-PHYSICAL NOUN F
, 0 PUNCT F
apo B-PHYSICAL NOUN F
B100/apo B-PHYSICAL VERB T
A1 B-PHYSICAL NOUN T
ratio B-PHYSICAL NOUN F
, 0 PUNCT F
plasminogen B-PHYSICAL NOUN F
activator B-PHYSICAL NOUN F
inhibitor I-PHYSICAL PUNCT F

Theta 0 NOUN T
burst 0 NOUN F
stimulation 0 NOUN F
in 0 ADP F
the 0 DET F
rehabilitation 0 NOUN F
of 0 ADP F
the 0 DET F
upper 0 ADJ F
limb 0 NOUN F
: 0 PUNCT F
a 0 DET F
semirandomized 0 VERB F
, 0 PUNCT F
placebo-controlled 0 VERB F
trial 0 NOUN F
in 0 ADP F
chronic 0 ADJ F
stroke 0 NOUN F
patients 0 NOUN F
. 0 PUNCT F

BACKGROUND 0 NOUN T
Noninvasive 0 ADJ T
cortical 0 ADJ F
stimulation 0 NOUN F
could 0 VERB F
represent 0 VERB F
an 0 DET F
add-on 0 NOUN F
treatment 0 NOUN F
to 0 PART F
enhance 0 ADJ F
motor B-PHYSICAL NOUN F
recovery I-PHYSICAL NOUN F
after 0 ADP F
stroke 0 NOUN F
. 0 PUNCT F

However 0 ADV T
, 0 PUNCT F
its 0 VERB F
clinical 0 ADJ F
value 0 NOUN F
, 0 PUNCT F
including 0 VERB F
anticipated 0 VERB F
size 0 NOUN F
and 0 CCONJ F
duration 0 NOUN F
of 0 ADP F
the 0 DET F
treatment 0 NOUN F
effects 0 NOUN F
, 0 PUNCT F
remains 0 NOUN F
largely 0 ADV F
unknown 0 VERB F
. 0 PUNCT F

OBJECTIVE 0 NOUN T
The 0 DET T
authors 0 NOUN F
designed 0 VERB F
a 0 DET F
small 0 ADJ F
semi-randomized 0 VERB F
clinical 0 ADJ F
trial 0 NOUN F
to 0 PART F
explore 0 NOUN F
whether 0 PUNCT F
long-lasting 0 ADJ F
clinically 0 ADV F
important 0 ADJ F
gains 0 NOUN F
can 0 VERB F
be 0 VERB F
achieved 0 VERB F
by 0 ADP F
adding 0 VERB F
theta 0 NOUN F
burst 0 NOUN F
stimulation 0 NOUN F
( 0 PUNCT F
TBS 0 NOUN T
) 0 PUNCT F
, 0 PUNCT F
a 0 DET F
form 0 NOUN F
of 0 ADP F
repetitive 0 ADJ F
transcranial 0 ADJ F
magnetic 0 ADJ F
stimulation 0 NOUN F
( 0 PUNCT F
TMS 0 NOUN T
) 0 PUNCT F
, 0 PUNCT F
to 0 ADP F
a 0 DET F
rehabilitation 0 NOUN F
program 0 NOUN F
for 0 ADP F
the 0 DET F
hand 0 NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
A 0 PUNCT T
total 0 NOUN F
of 0 ADP F
41 0 NUM F
chronic 0 ADJ F
stroke 0 NOUN F
patients 0 NOUN F
received 0 VERB F
excitatory 0 ADJ F
TBS 0 NOUN T
to 0 ADP F
the 0 DET F
ipsilesional 0 ADJ F
hemisphere 0 VERB F
or 0 CCONJ F
inhibitory 0 ADJ F
TBS 0 NOUN T
to 0 ADP F
the 0 DET F
contralesional 0 ADJ F
hemisphere 0 VERB F
in 0 ADP F
2 0 NUM F
centers 0 NOUN F
; 0 PUNCT F
each 0 DET F
active 0 ADJ F
group 0 NOUN F
was 0 VERB F
compared 0 VERB F
with 0 ADP F
a 0 DET F
group 0 NOUN F
receiving 0 SYM F
sham 0 ADJ F
TBS 0 NOUN T
. 0 PUNCT F

TBS 0 NOUN T
was 0 VERB F
followed 0 VERB F
by 0 ADP F
physical 0 ADJ F
therapy 0 NOUN F
for 0 ADP F
10 0 NUM F
working 0 VERB F
days 0 NOUN F
. 0 PUNCT F

Patients 0 NOUN T
and 0 CCONJ F
therapists 0 NOUN F
were 0 VERB F
blinded 0 ADP F
to 0 ADP F
the 0 DET F
type 0 NOUN F
of 0 ADP F
TBS 0 NOUN T
. 0 PUNCT F

Primary 0 ADJ T
outcome 0 NOUN F
measures 0 NOUN F
( 0 PUNCT F
9-hole 0 NOUN F
Peg 0 NOUN T
Test 0 NOUN T
[ 0 PUNCT F
9HPT 0 NUM F
] 0 PUNCT F
, 0 PUNCT F
Jebsen 0 PUNCT T
Taylor 0 NOUN T
Test 0 NOUN T
[ 0 PUNCT F
JTT 0 NOUN T
] 0 PUNCT F
, 0 PUNCT F
and 0 CCONJ F
grip 0 NOUN F
and 0 CCONJ F
pinch-grip 0 NOUN F
dynamometry 0 NOUN F
) 0 PUNCT F
were 0 VERB F
assessed 0 VERB F
4 0 NUM F
, 0 PUNCT F
30 0 NUM F
, 0 PUNCT F
and 0 CCONJ F
90 0 NUM F
days 0 NOUN F
post 0 PUNCT F
treatment 0 NOUN F
. 0 PUNCT F

The 0 DET T
clinically 0 ADV F
important 0 ADJ F
difference 0 NOUN F
was 0 VERB F
defined 0 VERB F
as 0 ADP F
10 0 NUM F
% 0 DET F
of 0 ADP F
the 0 DET F
maximum 0 NOUN F
score 0 NOUN F
. 0 PUNCT F

RESULTS 0 NOUN T
There 0 CCONJ T
were 0 VERB F
no 0 DET F
differences 0 NOUN F
between 0 ADP F
the 0 DET F
active 0 ADJ F
treatment 0 NOUN F
and 0 CCONJ F
sham 0 ADJ F
groups 0 NOUN F
in 0 ADP F
any 0 PUNCT F
of 0 ADP F
the 0 DET F
outcome 0 NOUN F
measures 0 NOUN F
. 0 PUNCT F

All 0 DET T
patients 0 NOUN F
achieved 0 VERB F
small 0 ADJ F
sustainable 0 ADJ F
improvements B-PHYSICAL NOUN F
-- I-PHYSICAL PUNCT F
9HPT I-PHYSICAL NUM F
, 0 PUNCT F
5 B-PHYSICAL NUM F
% I-PHYSICAL SYM F
of I-PHYSICAL ADP F
maximum I-PHYSICAL NOUN F
( 0 PUNCT F
confidence 0 NOUN F
interval 0 NOUN F
[ 0 PUNCT F
CI 0 NOUN T
] 0 PUNCT F
= 0 ADP F
3 0 NUM F
% 0 SYM F
-7 0 NUM F
% 0 SYM F
) 0 PUNCT F
; 0 PUNCT F
JTT B-PHYSICAL NOUN T
, 0 PUNCT F
5.7 0 NUM F
% 0 SYM F
( 0 PUNCT F
CI 0 NOUN T
= 0 SYM F
3 0 NUM F
% 0 SYM F
-8 0 NUM F
% 0 SYM F
) 0 PUNCT F
; 0 PUNCT F
and 0 CCONJ F
grip B-PHYSICAL NOUN F
strength I-PHYSICAL NOUN F
, 0 PUNCT F
6 0 NUM F
% 0 SYM F
( 0 PUNCT F
CI 0 NOUN T
= 0 SYM F
2 0 NUM F
% 0 SYM F
-10 0 NUM F
% 0 SYM F
) 0 PUNCT F
-- 0 PUNCT F
all 0 PUNCT F
below 0 ADP F
the 0 DET F
defined 0 ADP F
clinically 0 ADV F
important 0 ADJ F
level 0 NOUN F
. 0 PUNCT F

CONCLUSIONS 0 NOUN T
Cortical 0 ADJ T
stimulation 0 NOUN F
did 0 PUNCT F
not 0 ADV F
augment 0 VERB F
the 0 DET F
gains 0 NOUN F
from 0 ADP F
a 0 DET F
late 0 ADJ F
rehabilitation 0 NOUN F
program 0 NOUN F
. 0 PUNCT F

The 0 DET T
effect 0 NOUN F
size 0 NOUN F
anticipated 0 PROPN F
by 0 ADP F
the 0 DET F
authors 0 NOUN F
was 0 VERB F
overestimated 0 VERB F
. 0 PUNCT F

These 0 DET T
results 0 NOUN F
can 0 VERB F
improve 0 VERB F
the 0 DET F
design 0 NOUN F
of 0 ADP F
future 0 ADJ F
work 0 NOUN F
on 0 ADP F
therapeutic 0 ADJ F
uses 0 NOUN F
of 0 ADP F
TMS 0 NOUN T
. 0 PUNCT F

Promoting 0 VERB T
social 0 ADJ F
skill 0 ADJ F
development 0 NOUN F
in 0 ADP F
children 0 NOUN F
with 0 ADP F
pervasive 0 ADJ F
developmental 0 ADJ F
disorders 0 NOUN F
: 0 PUNCT F
a 0 DET F
feasibility 0 NOUN F
and 0 CCONJ F
efficacy 0 NOUN F
study 0 NOUN F
. 0 PUNCT F

A 0 DET T
randomized 0 VERB F
controlled 0 VERB F
design 0 NOUN F
was 0 VERB F
employed 0 VERB F
to 0 PART F
evaluate 0 NOUN F
a 0 DET F
social 0 ADJ F
skills 0 NOUN F
intervention 0 NOUN F
for 0 ADP F
children 0 NOUN F
with 0 ADP F
pervasive 0 ADJ F
developmental 0 ADJ F
disorders 0 NOUN F
. 0 PUNCT F

Aims 0 NOUN T
included 0 DET F
evaluating 0 SYM F
the 0 DET F
acceptability 0 NOUN F
of 0 ADP F
the 0 DET F
program 0 NOUN F
and 0 CCONJ F
gathering 0 PUNCT F
preliminary 0 ADJ F
evidence 0 NOUN F
on 0 ADP F
efficacy 0 NOUN F
. 0 PUNCT F

Forty-four 0 ADP T
children 0 NOUN F
, 0 PUNCT F
ages 0 NOUN F
8-11 0 NUM F
years 0 NOUN F
, 0 PUNCT F
were 0 VERB F
randomly 0 ADV F
assigned 0 VERB F
to 0 ADP F
treatment 0 NOUN F
or 0 CCONJ F
wait 0 NOUN F
list 0 NOUN F
. 0 PUNCT F

Treatment 0 NOUN T
consisted 0 VERB F
of 0 ADP F
a 0 DET F
16-week 0 NOUN F
group 0 NOUN F
intervention 0 NOUN F
designed 0 VERB F
to 0 VERB F
teach 0 PUNCT F
appropriate 0 PUNCT F
social 0 ADJ F
behavior 0 NOUN F
. 0 PUNCT F

Between 0 ADP T
group 0 NOUN F
comparisons 0 NOUN F
showed 0 VERB F
that 0 ADP F
children 0 NOUN F
in 0 ADP F
treatment 0 NOUN F
were 0 VERB F
rated 0 VERB F
as 0 PUNCT F
improved 0 NOUN F
on 0 ADP F
the 0 DET F
primary 0 ADJ F
outcome 0 NOUN F
measure 0 NOUN F
, 0 PUNCT F
( 0 PUNCT F
unblinded B-MENTAL VERB F
parent I-MENTAL NOUN F
report I-MENTAL NOUN F
) 0 PUNCT F
, 0 PUNCT F
but 0 CCONJ F
not 0 ADV F
on 0 ADP F
the 0 DET F
secondary 0 ADJ F
outcome 0 NOUN F
measure 0 NOUN F
, 0 PUNCT F
a 0 DET F
parent B-MENTAL NOUN F
questionnaire 0 NOUN F
. 0 PUNCT F

Parents 0 NOUN T
reported 0 VERB F
a 0 DET F
high 0 ADJ F
level B-OTHER NOUN F
of I-OTHER ADP F
satisfaction I-OTHER NOUN F
with 0 ADP F
the 0 DET F
intervention 0 NOUN F
. 0 PUNCT F

The 0 DET T
study 0 NOUN F
supports 0 NOUN F
the 0 DET F
feasibility 0 NOUN F
of 0 ADP F
this 0 DET F
intervention 0 NOUN F
to 0 ADP F
families 0 NOUN F
and 0 CCONJ F
highlights 0 PUNCT F
challenges 0 NOUN F
for 0 ADP F
future 0 ADJ F
research 0 NOUN F
in 0 ADP F
social 0 ADJ F
skills 0 NOUN F
intervention 0 NOUN F
. 0 PUNCT F

Pilot 0 NOUN T
study 0 NOUN F
of 0 ADP F
a 0 DET F
moderate 0 ADJ F
dose 0 NOUN F
multivitamin/mineral 0 ADJ F
supplement 0 NOUN F
for 0 ADP F
children 0 NOUN F
with 0 ADP F
autistic 0 ADJ F
spectrum 0 NOUN F
disorder 0 NOUN F
. 0 PUNCT F

OBJECTIVE 0 NOUN T
Determine 0 PUNCT T
the 0 DET F
effect 0 NOUN F
of 0 ADP F
a 0 DET F
moderate 0 ADJ F
dose 0 NOUN F
multivitamin/mineral 0 ADJ F
supplement 0 NOUN F
on 0 ADP F
children 0 NOUN F
with 0 ADP F
autistic 0 ADJ F
spectrum 0 NOUN F
disorder 0 NOUN F
. 0 PUNCT F

DESIGN 0 NOUN T
Randomized 0 PROPN T
, 0 PUNCT F
double-blind 0 ADJ F
, 0 PUNCT F
placebo-controlled 0 VERB F
3-month 0 NOUN F
study 0 NOUN F
. 0 PUNCT F

SUBJECTS 0 NOUN T
Twenty 0 PUNCT T
( 0 PUNCT F
20 0 NUM F
) 0 PUNCT F
children 0 NOUN F
with 0 ADP F
autistic 0 ADJ F
spectrum 0 NOUN F
disorder 0 NOUN F
, 0 PUNCT F
ages 0 NOUN F
3-8 0 NUM F
years 0 NOUN F
. 0 PUNCT F

RESULTS 0 DET T
A 0 DET T
Global 0 ADJ T
Impressions 0 NOUN T
parental 0 ADJ F
questionnaire 0 NOUN F
found 0 ADP F
that 0 ADP F
the 0 DET F
supplement 0 ADJ F
group 0 NOUN F
reported 0 VERB F
statistically 0 ADV F
significant 0 ADJ F
improvements B-OTHER NOUN F
in 0 ADP F
sleep B-PHYSICAL NOUN F
and I-PHYSICAL CCONJ F
gastrointestinal I-PHYSICAL ADJ F
problems I-PHYSICAL NOUN F
compared 0 VERB F
to 0 ADP F
the 0 DET F
placebo 0 NOUN F
group 0 NOUN F
. 0 PUNCT F

An 0 DET T
evaluation 0 NOUN F
of 0 ADP F
vitamin B-PHYSICAL NOUN F
B I-PHYSICAL NOUN T
( I-PHYSICAL PUNCT F
6 I-PHYSICAL NUM F
) I-PHYSICAL PUNCT F
levels I-PHYSICAL NOUN F
prior 0 PUNCT F
to 0 ADP F
the 0 DET F
study 0 NOUN F
found 0 VERB F
that 0 ADP F
the 0 DET F
autistic 0 ADJ F
children 0 NOUN F
had 0 PUNCT F
substantially 0 ADV F
elevated 0 VERB F
levels 0 NOUN F
of 0 ADP F
B6 0 PUNCT T
compared 0 VERB F
to 0 ADP F
a 0 DET F
control 0 NOUN F
group 0 NOUN F
of 0 ADP F
typical 0 ADJ F
children 0 NOUN F
( 0 PUNCT F
75 0 NUM F
% 0 SYM F
higher 0 PUNCT F
, 0 PUNCT F
p 0 NOUN F
< 0 SYM F
0.0000001 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Vitamin B-PHYSICAL NOUN T
C I-PHYSICAL NOUN T
levels I-PHYSICAL NOUN F
were 0 VERB F
measured 0 VERB F
at 0 ADP F
the 0 DET F
end 0 NOUN F
of 0 ADP F
the 0 DET F
study 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
the 0 DET F
placebo 0 NOUN F
group 0 NOUN F
had 0 VERB F
levels 0 NOUN F
that 0 ADP F
were 0 VERB F
significantly 0 ADV F
below 0 ADP F
average 0 CCONJ F
for 0 ADP F
typical 0 ADJ F
children 0 NOUN F
, 0 PUNCT F
whereas 0 ADP F
the 0 DET F
supplement 0 ADJ F
group 0 NOUN F
had 0 PUNCT F
near-average 0 NOUN F
levels 0 NOUN F
. 0 PUNCT F

DISCUSSION 0 NOUN T
The 0 DET T
finding 0 VERB F
of 0 ADP F
high B-PHYSICAL ADJ F
vitamin I-PHYSICAL NOUN F
B I-PHYSICAL NOUN T
( I-PHYSICAL PUNCT F
6 I-PHYSICAL NUM F
) I-PHYSICAL PUNCT F
levels I-PHYSICAL NOUN F
is 0 ADV F
consistent 0 ADJ F
with 0 ADP F
recent 0 ADJ F
reports 0 NOUN F
of 0 ADP F
low 0 ADJ F
levels B-PHYSICAL NOUN F
of I-PHYSICAL ADP F
pyridoxal-5-phosphate I-PHYSICAL NOUN F
and 0 CCONJ F
low 0 ADJ F
activity 0 NOUN F
of 0 ADP F
pyridoxal B-PHYSICAL ADJ F
kinase I-PHYSICAL NOUN F
( 0 PUNCT F
i.e. 0 CCONJ F
, 0 PUNCT F
pyridoxal 0 CCONJ F
is 0 VERB F
only 0 ADV F
poorly 0 ADV F
converted 0 VERB F
to 0 ADP F
pyridoxal-5-phosphate 0 NOUN F
, 0 PUNCT F
the 0 DET F
enzymatically 0 ADJ F
active 0 ADJ F
form 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

This 0 PUNCT T
may 0 VERB F
explain 0 VERB F
the 0 DET F
functional 0 ADJ F
need 0 NOUN F
for 0 ADP F
high-dose 0 NOUN F
vitamin 0 NOUN F
B 0 NOUN T
( 0 PUNCT F
6 0 NUM F
) 0 PUNCT F
supplementation 0 NOUN F
in 0 ADP F
many 0 DET F
children 0 NOUN F
and 0 CCONJ F
adults 0 NOUN F
with 0 ADP F
autism 0 NOUN F
. 0 PUNCT F

Maternal B-PHYSICAL ADJ T
erythropoietin I-PHYSICAL NOUN F
in 0 ADP F
singleton 0 NOUN F
pregnancies 0 NOUN F
: 0 PUNCT F
a 0 DET F
randomized 0 VERB F
trial 0 NOUN F
on 0 ADP F
the 0 DET F
effect 0 NOUN F
of 0 ADP F
oral 0 ADJ F
hematinic 0 ADJ F
supplementation 0 NOUN F
. 0 PUNCT F

OBJECTIVE 0 NOUN T
Our 0 PUNCT T
purpose 0 NOUN F
was 0 VERB F
to 0 ADV F
study 0 NOUN F
the 0 DET F
effect 0 NOUN F
of 0 ADP F
hematinic 0 ADJ F
supplementation 0 NOUN F
on 0 ADP F
the 0 DET F
maternal B-PHYSICAL ADJ F
erythropoietin I-PHYSICAL NOUN F
response I-PHYSICAL NOUN F
during 0 ADP F
singleton 0 NOUN F
pregnancy 0 NOUN F
. 0 PUNCT F

STUDY 0 NOUN T
DESIGN 0 NOUN T
In 0 ADP T
a 0 DET F
randomized 0 VERB F
, 0 PUNCT F
double-blind 0 ADJ F
trial 0 NOUN F
97 0 NUM F
patients 0 NOUN F
with 0 ADP F
a 0 DET F
first-trimester 0 NOUN F
hemoglobin 0 NOUN F
level 0 NOUN F
> 0 SYM F
or 0 CCONJ F
= 0 SYM F
14.0 0 NUM F
gm/dl 0 NOUN F
received 0 VERB F
either 0 CCONJ F
iron 0 NOUN F
and 0 CCONJ F
folic 0 ADJ F
acid 0 NOUN F
( 0 PUNCT F
hematinic 0 ADJ F
group 0 NOUN F
, 0 PUNCT F
n 0 NOUN F
= 0 SYM F
53 0 NUM F
) 0 PUNCT F
or 0 CCONJ F
a 0 DET F
placebo 0 NOUN F
( 0 PUNCT F
n 0 NOUN F
= 0 SYM F
44 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Serial B-PHYSICAL ADJ T
hemoglobin I-PHYSICAL NOUN F
, 0 PUNCT F
hematocrit B-PHYSICAL NOUN F
, 0 PUNCT F
and 0 CCONJ F
serum B-PHYSICAL NOUN F
erythropoietin I-PHYSICAL NOUN F
were 0 VERB F
recorded 0 VERB F
from 0 ADP F
maternal 0 ADJ F
blood 0 NOUN F
and 0 CCONJ F
from 0 ADP F
cord 0 NOUN F
blood 0 NOUN F
on 0 ADP F
delivery 0 NOUN F
. 0 PUNCT F

Serum B-PHYSICAL NOUN T
ferritin I-PHYSICAL NOUN F
was 0 VERB F
measured 0 VERB F
in 0 ADP F
the 0 DET F
first 0 ADJ F
trimester 0 NOUN F
, 0 PUNCT F
at 0 ADP F
36 0 NUM F
weeks 0 NOUN F
' 0 PUNCT F
gestation 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
in 0 ADP F
cord 0 NOUN F
blood 0 NOUN F
. 0 PUNCT F

RESULTS 0 NOUN T
In 0 ADP T
both 0 CCONJ F
groups 0 NOUN F
( 0 PUNCT F
1 0 NUM F
) 0 PUNCT F
the 0 DET F
mean 0 NOUN F
hemoglobin B-PHYSICAL NOUN F
was 0 VERB F
lower 0 PUNCT F
( 0 PUNCT F
p 0 NOUN F
< 0 SYM F
0.01 0 NUM F
) 0 PUNCT F
at 0 ADP F
40 0 NUM F
weeks 0 NOUN F
' 0 PUNCT F
gestation 0 NOUN F
than 0 PUNCT F
when 0 PUNCT F
first 0 PUNCT F
examined 0 ADP F
and 0 CCONJ F
( 0 PUNCT F
2 0 NUM F
) 0 PUNCT F
the 0 DET F
mean 0 NOUN F
serum 0 NOUN F
erythropoietin 0 NOUN F
was 0 VERB F
higher 0 PUNCT F
( 0 PUNCT F
p 0 NOUN F
< 0 SYM F
0.01 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
mean 0 NOUN F
serum B-PHYSICAL NOUN F
ferritin I-PHYSICAL NOUN F
was 0 VERB F
lower 0 PUNCT F
( 0 PUNCT F
p 0 NOUN F
< 0 SYM F
0.001 0 NUM F
) 0 PUNCT F
in 0 ADP F
both 0 CCONJ F
groups 0 NOUN F
at 0 ADP F
36 0 NUM F
weeks 0 NOUN F
' 0 PUNCT F
gestation 0 NOUN F
than 0 PUNCT F
at 0 ADP F
presentation 0 NOUN F
but 0 CCONJ F
higher 0 PUNCT F
( 0 PUNCT F
p 0 NOUN F
= 0 SYM F
0.04 0 NUM F
) 0 PUNCT F
in 0 ADP F
the 0 DET F
hematinic 0 ADJ F
group 0 NOUN F
than 0 PUNCT F
in 0 ADP F
the 0 DET F
placebo 0 NOUN F
group 0 NOUN F
. 0 PUNCT F

The 0 DET T
mean 0 NOUN F
hemoglobin B-PHYSICAL NOUN F
and 0 CCONJ F
hematocrit B-PHYSICAL NOUN F
were 0 VERB F
similar 0 ADJ F
in 0 ADP F
the 0 DET F
two 0 NUM F
groups 0 NOUN F
until 0 ADP F
the 0 DET F
third 0 ADJ F
trimester 0 NOUN F
but 0 CCONJ F
thereafter 0 ADV F
were 0 VERB F
higher 0 PUNCT F
( 0 PUNCT F
p 0 NOUN F
< 0 SYM F
0.05 0 NUM F
) 0 PUNCT F
in 0 ADP F
the 0 DET F
hematinic 0 ADJ F
group 0 NOUN F
. 0 PUNCT F

The 0 DET T
mean 0 NOUN F
maternal B-PHYSICAL ADJ F
serum I-PHYSICAL NOUN F
erythropoietin I-PHYSICAL NOUN F
was 0 VERB F
higher 0 PUNCT F
( 0 PUNCT F
p 0 NOUN F
< 0 SYM F
0.05 0 NUM F
) 0 PUNCT F
in 0 ADP F
the 0 DET F
placebo 0 NOUN F
group 0 NOUN F
than 0 PUNCT F
in 0 ADP F
the 0 DET F
hematinic 0 ADJ F
group 0 NOUN F
after 0 ADP F
24 0 NUM F
weeks 0 NOUN F
' 0 PUNCT F
gestation 0 NOUN F
. 0 PUNCT F

The 0 DET T
mean 0 NOUN F
cord B-PHYSICAL NOUN F
blood 0 NOUN F
hematologic 0 ADJ F
values 0 NOUN F
were 0 VERB F
similar 0 ADJ F
in 0 ADP F
the 0 DET F
two 0 NUM F
groups 0 NOUN F
. 0 PUNCT F

CONCLUSION 0 NOUN T
Maternal B-PHYSICAL ADJ T
serum I-PHYSICAL NOUN F
erythropoietin I-PHYSICAL NOUN F
increased 0 VERB F
during 0 ADP F
pregnancy 0 NOUN F
, 0 PUNCT F
but 0 CCONJ F
this 0 DET F
response 0 NOUN F
was 0 VERB F
reduced 0 VERB F
in 0 ADP F
the 0 DET F
third 0 ADJ F
trimester 0 NOUN F
in 0 ADP F
the 0 DET F
hematinic-supplemented 0 VERB F
group 0 NOUN F
. 0 PUNCT F

Activation 0 NOUN T
and 0 CCONJ F
intermuscular 0 ADJ F
coherence 0 NOUN F
of 0 ADP F
distal 0 ADJ F
arm 0 NOUN F
muscles 0 NOUN F
during 0 ADP F
proximal 0 ADJ F
muscle 0 NOUN F
contraction 0 NOUN F
. 0 PUNCT F

In 0 ADP T
the 0 DET F
human 0 NOUN F
upper 0 ADJ F
extremity 0 NOUN F
( 0 PUNCT F
UE 0 NOUN T
) 0 PUNCT F
, 0 PUNCT F
unintended 0 VERB F
effects 0 NOUN F
of 0 ADP F
proximal 0 ADJ F
muscle 0 NOUN F
activation 0 NOUN F
on 0 ADP F
muscles 0 NOUN F
controlling 0 VERB F
the 0 DET F
hand 0 NOUN F
could 0 VERB F
be 0 ADJ F
an 0 DET F
important 0 ADJ F
aspect 0 NOUN F
of 0 ADP F
motor 0 NOUN F
control 0 NOUN F
due 0 CCONJ F
to 0 ADP F
the 0 DET F
necessary 0 ADJ F
coordination 0 NOUN F
of 0 ADP F
distal 0 ADJ F
and 0 CCONJ F
proximal 0 ADJ F
segments 0 NOUN F
during 0 ADP F
functional 0 ADJ F
activities 0 NOUN F
. 0 PUNCT F

This 0 DET T
study 0 NOUN F
aimed 0 VERB F
to 0 PART F
elucidate 0 NOUN F
the 0 DET F
effects 0 NOUN F
of 0 ADP F
concurrent 0 ADJ F
activation 0 NOUN F
of 0 ADP F
elbow 0 NOUN F
muscles 0 NOUN F
on 0 ADP F
the 0 DET F
coordination 0 NOUN F
between 0 ADP F
hand 0 NOUN F
muscles 0 NOUN F
performing 0 PUNCT F
a 0 DET F
grip 0 NOUN F
task 0 NOUN F
. 0 PUNCT F

Eleven 0 ADJ T
healthy 0 ADJ F
subjects 0 NOUN F
performed 0 PUNCT F
precision 0 NOUN F
grip 0 NOUN F
tasks 0 NOUN F
while 0 ADP F
a 0 DET F
constant 0 ADJ F
extension 0 NOUN F
or 0 CCONJ F
flexion 0 NOUN F
moment 0 ADJ F
was 0 VERB F
applied 0 VERB F
to 0 ADP F
their 0 PUNCT F
elbow 0 NOUN F
joints 0 NOUN F
, 0 PUNCT F
inducing 0 PUNCT F
a 0 DET F
sustained 0 VERB F
submaximal 0 ADJ F
contraction 0 NOUN F
of 0 ADP F
elbow 0 NOUN F
muscles 0 NOUN F
to 0 ADP F
counter 0 ADJ F
the 0 DET F
applied 0 ADP F
torque 0 NOUN F
. 0 PUNCT F

Activation 0 NOUN T
of 0 ADP F
four 0 NUM F
hand 0 NOUN F
muscles 0 NOUN F
was 0 VERB F
measured 0 VERB F
during 0 ADP F
each 0 DET F
task 0 NOUN F
condition 0 NOUN F
using 0 VERB F
surface 0 NOUN F
electromyography 0 NOUN F
( 0 PUNCT F
EMG 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

When 0 PUNCT T
concurrent 0 ADJ F
activation 0 NOUN F
of 0 ADP F
elbow 0 NOUN F
muscles 0 NOUN F
was 0 VERB F
induced 0 VERB F
, 0 PUNCT F
significant 0 ADJ F
changes 0 NOUN F
in 0 ADP F
the 0 DET F
activation 0 NOUN F
levels 0 NOUN F
of 0 ADP F
the 0 DET F
hand 0 NOUN F
muscles 0 NOUN F
were 0 VERB F
observed 0 VERB F
, 0 PUNCT F
with 0 ADP F
greater 0 PUNCT F
effects 0 NOUN F
on 0 ADP F
the 0 DET F
extrinsic 0 ADJ F
finger 0 NOUN F
extensor 0 NOUN F
( 0 PUNCT F
23.2 0 NUM F
% 0 ADV F
increase 0 NOUN F
under 0 ADP F
30 0 NUM F
% 0 SYM F
elbow 0 NOUN F
extensor 0 NOUN F
activation 0 NOUN F
; 0 PUNCT F
p 0 NOUN F
= 0 SYM F
0.003 0 NUM F
) 0 PUNCT F
than 0 ADP F
extrinsic 0 ADJ F
finger 0 NOUN F
flexor 0 NOUN F
( 0 PUNCT F
14.2 0 NUM F
% 0 ADV F
increase 0 NOUN F
under 0 ADP F
30 0 NUM F
% 0 SYM F
elbow 0 NOUN F
flexor 0 NOUN F
activation 0 NOUN F
; 0 PUNCT F
p 0 NOUN F
= 0 SYM F
0.130 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Elbow B-PHYSICAL NOUN T
muscle I-PHYSICAL NOUN F
activation I-PHYSICAL NOUN F
also 0 ADV F
induced 0 ADJ F
involuntary 0 ADJ F
changes 0 NOUN F
in 0 ADP F
the 0 DET F
intrinsic B-PHYSICAL ADJ F
thumb I-PHYSICAL NOUN F
flexor I-PHYSICAL NOUN F
activation I-PHYSICAL NOUN F
( 0 PUNCT F
44.6 0 NUM F
% 0 ADV F
increase 0 NOUN F
under 0 ADP F
30 0 NUM F
% 0 SYM F
elbow 0 NOUN F
extensor 0 NOUN F
activation 0 NOUN F
; 0 PUNCT F
p 0 NOUN F
= 0 SYM F
0.005 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

EMG-EMG 0 PUNCT T
coherence 0 NOUN F
analyses 0 NOUN F
revealed 0 VERB F
that 0 ADP F
elbow B-PHYSICAL NOUN F
muscle I-PHYSICAL NOUN F
activation I-PHYSICAL NOUN F
significantly 0 ADV F
reduced 0 VERB F
intermuscular B-PHYSICAL ADJ F
coherence 0 NOUN F
between B-PHYSICAL ADP F
distal I-PHYSICAL ADJ F
muscle I-PHYSICAL PUNCT F

Stepping 0 VERB T
Stones 0 VERB T
Triple 0 ADJ T
P 0 NOUN T
: 0 PUNCT F
an 0 DET F
RCT 0 NOUN T
of 0 ADP F
a 0 DET F
parenting 0 ADP F
program 0 NOUN F
with 0 ADP F
parents 0 NOUN F
of 0 ADP F
a 0 DET F
child 0 NOUN F
diagnosed 0 VERB F
with 0 ADP F
an 0 DET F
autism 0 NOUN F
spectrum 0 NOUN F
disorder 0 NOUN F
. 0 PUNCT F

Whilst 0 PUNCT T
the 0 DET F
Triple 0 ADJ T
P 0 NOUN T
Positive 0 ADJ T
Parenting 0 PUNCT T
Program 0 NOUN T
has 0 ADP F
a 0 DET F
large 0 ADJ F
evidence 0 NOUN F
base 0 NOUN F
( 0 PUNCT F
Sanders 0 PUNCT T
, 0 PUNCT F
Clinical 0 ADJ T
Child 0 NOUN T
and 0 CCONJ F
Family 0 NOUN T
Psychology 0 NOUN T
Review 0 NOUN T
2:71-90 0 NOUN F
, 0 PUNCT F
1999 0 NUM F
; 0 PUNCT F
Sanders 0 PROPN T
, 0 PUNCT F
Journal 0 CCONJ T
of 0 ADP F
Consulting 0 ADP T
and 0 CCONJ F
Clinical 0 ADJ T
Psychology 0 NOUN T
68:624-640 0 PUNCT F
, 0 PUNCT F
2000 0 PUNCT F
) 0 PUNCT F
and 0 CCONJ F
preliminary 0 ADJ F
evidence 0 NOUN F
indicates 0 VERB F
that 0 ADP F
Stepping 0 PUNCT T
Stones 0 NOUN T
Triple 0 ADJ T
P 0 NOUN T
is 0 VERB F
also 0 ADV F
efficacious 0 ADJ F
( 0 PUNCT F
Roberts 0 NOUN T
, 0 PUNCT F
Journal 0 CCONJ T
of 0 ADP F
Clinical 0 ADJ T
Child 0 NOUN T
and 0 CCONJ F
Adolescent 0 NOUN T
Psychology 0 NOUN T
, 0 PUNCT F
35 0 NUM F
( 0 PUNCT F
2 0 NUM F
) 0 PUNCT F
:180-193 0 NOUN F
, 0 PUNCT F
2006 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
to 0 ADP F
date 0 NOUN F
Stepping 0 PUNCT T
Stones 0 NOUN T
has 0 PUNCT F
not 0 ADV F
been 0 PUNCT F
evaluated 0 VERB F
with 0 ADP F
the 0 DET F
ASD 0 NOUN T
population 0 NOUN F
. 0 PUNCT F

Fifty-nine 0 DET T
families 0 NOUN F
with 0 ADP F
a 0 DET F
child 0 NOUN F
with 0 ADP F
ASD 0 NOUN T
aged 0 PUNCT F
between 0 ADP F
2 0 NUM F
and 0 CCONJ F
9 0 NUM F
participated 0 PUNCT F
in 0 ADP F
this 0 DET F
randomized 0 VERB F
controlled 0 VERB F
trial 0 NOUN F
. 0 PUNCT F

The 0 DET T
results 0 ADV F
demonstrate 0 VERB F
significant 0 ADJ F
improvements 0 NOUN F
in 0 ADP F
parental B-MENTAL ADJ F
reports I-MENTAL NOUN F
of I-MENTAL ADP F
child I-MENTAL NOUN F
behaviour I-MENTAL NOUN F
and 0 CCONJ F
parenting B-MENTAL PUNCT F
styles I-MENTAL NOUN F
with I-MENTAL ADP F
the I-MENTAL DET F
treatment 0 NOUN F
effects B-MENTAL NOUN F
for I-MENTAL ADP F
child I-MENTAL NOUN F
behaviour B-MENTAL NOUN F
, 0 PUNCT F
parental B-MENTAL ADJ F
over B-MENTAL ADP F
reactivity I-MENTAL NOUN F
and 0 CCONJ F
parental B-MENTAL ADJ F
verbosity I-MENTAL NOUN F
being 0 VERB F
maintained 0 VERB F
at 0 ADP F
follow-up 0 NOUN F
6 0 NUM F
months 0 NOUN F
later 0 ADJ F
. 0 PUNCT F

Further 0 ADV T
, 0 PUNCT F
the 0 DET F
results 0 CCONJ F
suggest 0 VERB F
significant 0 ADJ F
improvements 0 NOUN F
in 0 ADP F
parental B-MENTAL ADJ F
satisfaction I-MENTAL NOUN F
and 0 CCONJ F
conflict B-MENTAL PUNCT F
about I-MENTAL PUNCT F

Growth 0 NOUN T
hormone 0 NOUN F
effects 0 NOUN F
on 0 ADP F
cortical B-PHYSICAL ADJ F
bone I-PHYSICAL NOUN F
dimensions I-PHYSICAL NOUN F
in 0 ADP F
young 0 ADJ F
adults 0 NOUN F
with 0 ADP F
childhood-onset 0 NOUN F
growth 0 NOUN F
hormone 0 NOUN F
deficiency 0 NOUN F
. 0 PUNCT F

UNLABELLED 0 NOUN T
Growth 0 NOUN T
hormone 0 NOUN F
( 0 PUNCT F
GH 0 NOUN T
) 0 PUNCT F
treatment 0 NOUN F
in 0 ADP F
young 0 ADJ F
adults 0 NOUN F
with 0 ADP F
childhood-onset 0 NOUN F
GH 0 NOUN T
deficiency 0 NOUN F
has 0 ADP F
beneficial 0 ADJ F
effects 0 NOUN F
on 0 ADP F
bone B-PHYSICAL NOUN F
mass I-PHYSICAL NOUN F
. 0 PUNCT F

The 0 DET T
present 0 ADJ F
study 0 NOUN F
shows 0 NOUN F
that 0 ADP F
cortical 0 ADJ F
bone 0 NOUN F
dimensions 0 NOUN F
also 0 ADV F
benefit 0 PUNCT F
from 0 ADP F
GH 0 NOUN T
treatment 0 NOUN F
, 0 PUNCT F
with 0 ADP F
endosteal 0 ADJ F
expansion 0 NOUN F
and 0 CCONJ F
increased 0 PART F
cortical 0 ADJ F
thickness 0 NOUN F
leading 0 ADJ F
to 0 ADP F
improved B-PHYSICAL VERB F
bone I-PHYSICAL NOUN F
strength I-PHYSICAL NOUN F
. 0 PUNCT F

INTRODUCTION 0 NOUN T
In 0 ADP T
young 0 ADJ F
adults 0 NOUN F
with 0 ADP F
childhood-onset 0 NOUN F
growth 0 NOUN F
hormone 0 NOUN F
deficiency 0 NOUN F
( 0 PUNCT F
CO 0 NOUN T
GHD 0 NOUN T
) 0 PUNCT F
, 0 PUNCT F
GH 0 NOUN T
treatment 0 NOUN F
after 0 ADP F
final 0 ADJ F
height 0 NOUN F
is 0 VERB F
reached 0 NOUN F
has 0 PUNCT F
been 0 PUNCT F
shown 0 VERB F
to 0 DET F
have 0 PUNCT F
beneficial 0 ADJ F
effects 0 NOUN F
on 0 ADP F
spine 0 NOUN F
and 0 CCONJ F
hip 0 NOUN F
bone 0 NOUN F
mineral 0 NOUN F
density 0 NOUN F
. 0 PUNCT F

The 0 DET T
objective 0 NOUN F
of 0 ADP F
the 0 DET F
study 0 NOUN F
was 0 VERB F
to 0 PART F
evaluate 0 NOUN F
the 0 DET F
influence 0 NOUN F
of 0 ADP F
GH B-PHYSICAL NOUN T
on 0 ADP F
cortical B-PHYSICAL ADJ F
bone I-PHYSICAL NOUN F
dimensions I-PHYSICAL NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
Patients 0 NOUN T
( 0 PUNCT F
n 0 NOUN F
= 0 SYM F
160 0 NUM F
; 0 PUNCT F
mean 0 NOUN F
age 0 NOUN F
, 0 PUNCT F
21.2 0 NUM F
years 0 NOUN F
; 0 PUNCT F
63 0 NUM F
% 0 SYM F
males 0 NOUN F
) 0 PUNCT F
with 0 ADP F
CO 0 NOUN T
GHD 0 NOUN T
were 0 VERB F
randomised 0 VERB F
2:1 0 NOUN F
to 0 ADP F
GH 0 NOUN T
or 0 CCONJ F
no 0 DET F
treatment 0 NOUN F
for 0 ADP F
24 0 NUM F
months 0 NOUN F
. 0 PUNCT F

Cortical 0 ADJ T
bone 0 NOUN F
dimensions 0 NOUN F
were 0 VERB F
evaluated 0 VERB F
by 0 ADP F
digital 0 ADJ F
x-ray 0 NOUN F
radiogrammetry 0 NOUN F
of 0 ADP F
the 0 DET F
metacarpal 0 ADJ F
bones 0 PUNCT F
every 0 DET F
6 0 NUM F
months 0 NOUN F
. 0 PUNCT F

RESULTS 0 NOUN T
After 0 ADP T
24 0 NUM F
months 0 NOUN F
, 0 PUNCT F
cortical 0 ADJ F
thickness 0 NOUN F
was 0 VERB F
increased 0 PUNCT F
compared 0 VERB F
with 0 ADP F
the 0 DET F
controls 0 NOUN F
( 0 PUNCT F
6.43 0 NUM F
% 0 SYM F
, 0 PUNCT F
CI 0 NOUN T
3.34 0 NUM F
to 0 ADP F
9.61 0 NUM F
% 0 SYM F
; 0 PUNCT F
p 0 NOUN F
= 0 SYM F
0.0001 0 NUM F
) 0 PUNCT F
and 0 CCONJ F
metacarpal 0 ADJ F
index 0 NOUN F
( 0 PUNCT F
MCI 0 NOUN T
) 0 PUNCT F
( 0 PUNCT F
6.14 0 NUM F
% 0 SYM F
, 0 PUNCT F
CI 0 NOUN T
3.95 0 NUM F
to 0 ADP F
8.38 0 NUM F
% 0 SYM F
; 0 PUNCT F
p 0 NOUN F
< 0 SYM F
0.0001 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
while 0 ADP F
the 0 DET F
endosteal 0 ADJ F
diameter 0 NOUN F
decreased 0 NOUN F
( 0 PUNCT F
-4.64 0 NUM F
% 0 SYM F
, 0 PUNCT F
CI 0 NOUN T
-7.15 0 NUM F
to 0 ADP F
-2.05 0 PUNCT F
; 0 PUNCT F
p 0 NOUN F
< 0 SYM F
0.001 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Total 0 ADJ T
bone 0 NOUN F
width 0 NOUN F
did 0 PUNCT F
not 0 ADV F
change 0 VERB F
significantly 0 ADV F
( 0 PUNCT F
0.68 0 NUM F
% 0 SYM F
, 0 PUNCT F
CI 0 NOUN T
-1.17 0 NUM F
to 0 ADP F
2.57 0 NUM F
% 0 SYM F
; 0 PUNCT F
not 0 ADV F
significant 0 ADJ F
( 0 PUNCT F
NS 0 NOUN T
) 0 PUNCT F
) 0 PUNCT F
. 0 PUNCT F

A 0 DET T
gender 0 NOUN F
effect 0 NOUN F
was 0 VERB F
seen 0 VERB F
on 0 ADP F
bone 0 NOUN F
width 0 NOUN F
( 0 PUNCT F
p 0 NOUN F
< 0 SYM F
0.0001 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
endosteal 0 ADJ F
diameter 0 NOUN F
( 0 PUNCT F
p 0 NOUN F
< 0 SYM F
0.01 0 NUM F
) 0 PUNCT F
and 0 CCONJ F
cortical 0 ADJ F
thickness 0 NOUN F
( 0 PUNCT F
p 0 NOUN F
< 0 SYM F
0.01 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
but 0 CCONJ F
not 0 ADV F
with 0 ADP F
MCI 0 NOUN T
( 0 PUNCT F
NS 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

CONCLUSIONS 0 NOUN T
Cortical 0 ADJ T
bone 0 NOUN F
reacts 0 NOUN F
promptly 0 ADV F
to 0 ADP F
reinstitution 0 NOUN F
of 0 ADP F
GH 0 NOUN T
beyond 0 ADP F
the 0 DET F
attainment 0 NOUN F
of 0 ADP F
final 0 ADJ F
height 0 NOUN F
by 0 ADP F
increasing 0 VERB F
the 0 DET F
cortical 0 ADJ F
thickness 0 NOUN F
through 0 ADP F
endosteal 0 ADJ F
bone 0 NOUN F
growth 0 NOUN F
. 0 PUNCT F

This 0 DET T
leads 0 NOUN F
to 0 ADP F
a 0 DET F
higher 0 PUNCT F
peak 0 ADJ F
bone 0 NOUN F
mass 0 NOUN F
and 0 CCONJ F
may 0 VERB F
reduce 0 VERB F
the 0 DET F
risk 0 NOUN F
of 0 ADP F
cortical 0 ADJ F
bone 0 NOUN F
fragility 0 NOUN F
later 0 ADJ F
in 0 ADP F
life 0 NOUN F
. 0 PUNCT F

Effects 0 NOUN T
of 0 ADP F
oral 0 ADJ F
Lactobacillus 0 NOUN T
GG 0 NOUN T
on 0 ADP F
enteric B-PHYSICAL ADJ F
microflora I-PHYSICAL NOUN F
in 0 ADP F
low-birth-weight 0 ADJ F
neonates 0 NOUN F
. 0 PUNCT F

BACKGROUND 0 NOUN T
Colonization 0 NOUN T
patterns 0 NOUN F
, 0 PUNCT F
especially 0 ADV F
by 0 ADP F
anaerobic 0 ADJ F
flora 0 NOUN F
, 0 PUNCT F
may 0 VERB F
play 0 VERB F
an 0 DET F
important 0 ADJ F
role 0 NOUN F
in 0 ADP F
neonatal 0 ADJ F
gut 0 NOUN F
function 0 NOUN F
. 0 PUNCT F

Probiotics 0 NOUN T
could 0 ADV F
affect 0 VERB F
disease B-PHYSICAL NOUN F
risk I-PHYSICAL NOUN F
either 0 CCONJ F
directly 0 ADV F
through 0 ADP F
colonization 0 NOUN F
or 0 CCONJ F
indirectly 0 ADV F
by 0 ADP F
promoting 0 PROPN F
changes 0 NOUN F
in 0 ADP F
gut 0 NOUN F
microbial 0 ADJ F
ecology 0 NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
To 0 ADJ T
study 0 NOUN F
the 0 DET F
ability 0 NOUN F
of 0 ADP F
Lactobacillus 0 NOUN T
GG 0 NOUN T
( 0 PUNCT F
LGG 0 NOUN T
) 0 PUNCT F
to 0 VERB F
colonize 0 PUNCT F
the 0 DET F
neonatal B-PHYSICAL ADJ F
gut I-PHYSICAL NOUN F
and I-PHYSICAL CCONJ F
modify I-PHYSICAL VERB F
its I-PHYSICAL VERB F
microbial I-PHYSICAL ADJ F
ecology I-PHYSICAL NOUN F
, 0 PUNCT F
a 0 DET F
prospective 0 ADJ F
, 0 PUNCT F
randomized 0 ADP F
study 0 NOUN F
was 0 VERB F
performed 0 VERB F
in 0 ADP F
71 0 NUM F
preterm 0 NOUN F
infants 0 NOUN F
of 0 ADP F
less 0 ADV F
than 0 ADP F
2000 0 NUM F
g 0 NOUN F
birth 0 NOUN F
weight 0 NOUN F
. 0 PUNCT F

Infants 0 NOUN T
less 0 ADV F
than 0 CCONJ F
1500 0 NUM F
g 0 NOUN F
( 0 PUNCT F
24 0 NUM F
treated 0 PUNCT F
, 0 PUNCT F
15 0 NUM F
control 0 NOUN F
) 0 PUNCT F
received 0 VERB F
10 0 NUM F
( 0 PUNCT F
9 0 NUM F
) 0 PUNCT F
LGG 0 NOUN T
orally 0 ADV F
twice 0 PUNCT F
daily 0 ADJ F
for 0 ADP F
21 0 NUM F
days 0 NOUN F
. 0 PUNCT F

Those 0 PUNCT T
infants 0 NOUN F
weighing 0 CCONJ F
1500 0 NUM F
to 0 ADP F
1999 0 NUM F
g 0 NOUN F
( 0 PUNCT F
23 0 NUM F
treated 0 PUNCT F
, 0 PUNCT F
9 0 NUM F
control 0 NOUN F
) 0 PUNCT F
were 0 VERB F
treated 0 VERB F
for 0 ADP F
8 0 NUM F
days 0 NOUN F
. 0 PUNCT F

Stools 0 NOUN T
were 0 VERB F
collected 0 VERB F
before 0 ADP F
treatment 0 NOUN F
and 0 CCONJ F
on 0 ADP F
day 0 NOUN F
7 0 NUM F
to 0 ADP F
8 0 PUNCT F
( 0 PUNCT F
and 0 CCONJ F
day 0 NOUN F
14 0 NUM F
and 0 CCONJ F
21 0 NUM F
, 0 PUNCT F
in 0 ADP F
the 0 DET F
infants 0 NOUN F
weighing 0 CCONJ F
less 0 NOUN F
than 0 PUNCT F
1500 0 NUM F
g 0 NOUN F
) 0 PUNCT F
for 0 ADP F
quantitative B-PHYSICAL ADJ F
aerobic I-PHYSICAL ADJ F
and I-PHYSICAL CCONJ F
anaerobic I-PHYSICAL ADJ F
cultures I-PHYSICAL NOUN F
. 0 PUNCT F

RESULTS 0 ADJ T
Colonization 0 NOUN T
with 0 ADP F
LGG B-PHYSICAL NOUN T
occurred I-PHYSICAL VERB F
in 0 ADP F
5 0 NUM F
of 0 ADP F
24 0 NUM F
( 0 PUNCT F
21 0 NUM F
% 0 SYM F
) 0 PUNCT F
infants 0 NOUN F
who 0 PROPN F
weighed 0 PROPN F
less 0 ADV F
than 0 ADP F
1500 0 NUM F
g 0 NOUN F
versus 0 CCONJ F
11 0 NUM F
of 0 ADP F
23 0 NUM F
( 0 PUNCT F
47 0 NUM F
% 0 SYM F
) 0 PUNCT F
in 0 ADP F
larger 0 PUNCT F
infants 0 NOUN F
. 0 PUNCT F

Colonization B-PHYSICAL NOUN T
was 0 VERB F
limited 0 VERB F
to 0 ADP F
infants 0 NOUN F
who 0 ADP F
were 0 VERB F
not 0 ADV F
on 0 ADP F
antibiotics 0 NOUN F
within 0 ADP F
7 0 NUM F
days 0 NOUN F
of 0 ADP F
treatment 0 NOUN F
with 0 ADP F
LGG 0 NOUN T
. 0 PUNCT F

There 0 PUNCT T
was 0 VERB F
a 0 DET F
paucity 0 NOUN F
of 0 ADP F
bacterial 0 ADJ F
species 0 NOUN F
at 0 ADP F
baseline 0 NOUN F
, 0 PUNCT F
although 0 CCONJ F
larger 0 PUNCT F
infants 0 NOUN F
had 0 PUNCT F
more 0 DET F
bacterial B-PHYSICAL ADJ F
species I-PHYSICAL NOUN F
( 0 PUNCT F
1.59 0 NUM F
+/- 0 SYM F
0.13 0 NUM F
( 0 PUNCT F
SEM 0 NOUN T
) 0 PUNCT F
vs 0 CCONJ F
1.11 0 NUM F
+/- 0 SYM F
0.12 0 NUM F
; 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.03 0 NUM F
) 0 PUNCT F
and 0 CCONJ F
higher 0 PUNCT F
mean 0 NOUN F
log B-PHYSICAL NOUN F
colony I-PHYSICAL NOUN F
forming I-PHYSICAL VERB F
units I-PHYSICAL NOUN F
( 0 PUNCT F
CFU B-PHYSICAL NOUN T
) 0 PUNCT F
( 0 PUNCT F
8.79 0 NUM F
+/- 0 SYM F
0.43 0 NUM F
vs 0 CCONJ F
7.22 0 NUM F
+/- 0 SYM F
0.63 0 NUM F
; 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.05 0 NUM F
) 0 PUNCT F
compared 0 VERB F
with 0 ADP F
infants 0 NOUN F
weighing 0 CCONJ F
less 0 NOUN F
than 0 PUNCT F
1500 0 NUM F
g 0 ADP F
LGG 0 NOUN T
. 0 PUNCT F

Treatment 0 NOUN T
in 0 ADP F
infants 0 NOUN F
weighing 0 CCONJ F
less 0 NOUN F
than 0 PUNCT F
1500 0 NUM F
g 0 NOUN F
resulted 0 VERB F
in 0 ADP F
a 0 DET F
significant 0 ADJ F
increase 0 NOUN F
in 0 ADP F
species B-PHYSICAL NOUN F
number I-PHYSICAL NOUN F
by I-PHYSICAL ADP F
day I-PHYSICAL NOUN F
7 I-PHYSICAL NUM F
, I-PHYSICAL PUNCT F
with I-PHYSICAL ADP F
further I-PHYSICAL ADJ F
increases I-PHYSICAL CCONJ F
by I-PHYSICAL ADP F
day I-PHYSICAL NOUN F
21 I-PHYSICAL NUM F
. 0 PUNCT F

This 0 DET T
increase 0 NOUN F
was 0 VERB F
mainly 0 ADV F
the 0 DET F
result 0 NOUN F
of 0 ADP F
increased 0 CCONJ F
Gram 0 NOUN T
( 0 PUNCT F
+ 0 SYM F
) 0 PUNCT F
and 0 CCONJ F
anaerobic 0 ADJ F
species 0 NOUN F
. 0 PUNCT F

No 0 DET T
difference 0 NOUN F
in 0 ADP F
species B-PHYSICAL NOUN F
number I-PHYSICAL NOUN F
was 0 VERB F
noted 0 VERB F
in 0 ADP F
controls 0 NOUN F
. 0 PUNCT F

Mean 0 ADJ T
log B-PHYSICAL NOUN F
CFU I-PHYSICAL ADJ T
of I-PHYSICAL ADP F
Gram I-PHYSICAL NOUN T
( I-PHYSICAL PUNCT F
- I-PHYSICAL SYM F
) I-PHYSICAL PUNCT F
bacteria I-PHYSICAL NOUN F
did 0 PUNCT F
not 0 ADV F
change 0 NUM F
in 0 ADP F
treated 0 VERB F
infants 0 NOUN F
weighing 0 CCONJ F
less 0 NOUN F
than 0 PUNCT F
1500 0 NUM F
g. 0 PUNCT F
However 0 PROPN T
, 0 PUNCT F
Gram B-PHYSICAL NOUN T
( I-PHYSICAL PUNCT F
+ I-PHYSICAL SYM F
) I-PHYSICAL PUNCT F
mean 0 NOUN F
log B-PHYSICAL NOUN F
CFU B-PHYSICAL NOUN T
showed 0 VERB F
a 0 DET F
significant 0 ADJ F
increase 0 NOUN F
on 0 ADP F
day 0 NOUN F
21 0 NUM F
( 0 PUNCT F
6.1 0 NUM F
+/- 0 SYM F
0.9 0 NUM F
) 0 PUNCT F
compared 0 VERB F
with 0 ADP F
day 0 NOUN F
0 0 NUM F
( 0 PUNCT F
3.5 0 NUM F
+/- 0 SYM F
0.9 0 NUM F
) 0 PUNCT F
( 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.05 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

No 0 DET T
significant 0 ADJ F
changes 0 NOUN F
in 0 ADP F
species B-PHYSICAL NOUN F
number I-PHYSICAL ADJ F
or I-PHYSICAL CCONJ F
quantitative I-PHYSICAL ADJ F
counts B-PHYSICAL NOUN F
were 0 VERB F
noted 0 NUM F
after 0 ADP F
LGG 0 NOUN T
treatment 0 NOUN F
in 0 ADP F
the 0 DET F
infants 0 NOUN F
weighing 0 CCONJ F
1500 0 NUM F
to 0 ADP F
1999 0 NUM F
g 0 ADP F
LGG B-OTHER NOUN T
was I-OTHER VERB F
well I-OTHER VERB F
tolerated I-OTHER ADP F
in 0 ADP F
all 0 DET F
infants 0 NOUN F
. 0 PUNCT F

CONCLUSION 0 NOUN T
The 0 PUNCT T

Short-term 0 NOUN T
metabolic 0 ADJ F
effects 0 NOUN F
of 0 ADP F
prednisone 0 NOUN F
administration 0 NOUN F
in 0 ADP F
healthy 0 ADJ F
subjects 0 NOUN F
. 0 PUNCT F

AIMS 0 NOUN T
Supraphysiologic 0 ADJ T
glucocorticoid 0 NOUN F
activity 0 NOUN F
is 0 VERB F
well 0 ADV F
established 0 ADP F
to 0 ADP F
cause 0 PUNCT F
impaired 0 VERB F
glucose B-PHYSICAL NOUN F
tolerance 0 NOUN F
and 0 CCONJ F
insulin B-PHYSICAL NOUN F
resistance I-PHYSICAL NOUN F
, 0 PUNCT F
yet 0 ADV F
no 0 DET F
study 0 NOUN F
has 0 PUNCT F
evaluated 0 VERB F
dose-dependent 0 ADJ F
effects 0 NOUN F
of 0 ADP F
low-dose 0 NOUN F
prednisone 0 NOUN F
during 0 ADP F
short-term 0 NOUN F
oral 0 ADJ F
administration 0 NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
The 0 DET T
objective 0 NOUN F
of 0 ADP F
this 0 DET F
study 0 NOUN F
was 0 VERB F
to 0 PART F
quantify 0 NOUN F
the 0 DET F
effects 0 NOUN F
of 0 ADP F
daily 0 PUNCT F
10 0 NUM F
or 0 CCONJ F
25 0 NUM F
mg 0 NOUN F
prednisone 0 NOUN F
administration 0 NOUN F
for 0 ADP F
one 0 NUM F
week 0 NOUN F
on 0 ADP F
insulin 0 NOUN F
sensitivity 0 NOUN F
by 0 ADP F
employing 0 VERB F
a 0 DET F
two-step 0 NOUN F
hyperinsulinemic 0 ADJ F
euglycemic 0 ADJ F
glucose 0 NOUN F
clamp 0 NOUN F
( 0 PUNCT F
Step 0 NOUN T
1 0 NUM F
: 0 PUNCT F
insulin 0 NOUN F
infusion 0 NOUN F
= 0 SYM F
20 0 NUM F
mU/m?/min 0 NOUN F
; 0 PUNCT F
Step 0 NOUN T
2 0 NUM F
: 0 PUNCT F
insulin 0 NOUN F
infusion 0 NOUN F
= 0 SYM F
80 0 NUM F
mU/m?/min 0 PUNCT F
) 0 PUNCT F
in 0 ADP F
healthy 0 ADJ F
, 0 PUNCT F
lean 0 ADJ F
males 0 NOUN F
. 0 PUNCT F

The 0 DET T
amount 0 NOUN F
of 0 ADP F
glucose 0 NOUN F
infused 0 VERB F
at 0 ADP F
steady-state 0 NOUN F
to 0 ADJ F
maintain 0 ADV F
stable 0 ADJ F
blood 0 NOUN F
glucose 0 NOUN F
[ 0 PUNCT F
90 0 NUM F
mg/dl 0 NOUN F
( 0 PUNCT F
4.95 0 NUM F
mmol/l 0 NOUN F
) 0 PUNCT F
] 0 PUNCT F
was 0 VERB F
used 0 VERB F
to 0 PART F
calculate 0 NOUN F
several 0 ADJ F
indices 0 NOUN F
of 0 ADP F
insulin 0 NOUN F
sensitivity 0 NOUN F
. 0 PUNCT F

RESULTS 0 NOUN T
During 0 ADP T
Step 0 NOUN T
1 0 NUM F
of 0 ADP F
the 0 DET F
clamp 0 NOUN F
, 0 PUNCT F
whole 0 ADJ F
body 0 NOUN F
glucose 0 NOUN F
disposal 0 ADJ F
( 0 PUNCT F
M 0 NOUN T
) 0 PUNCT F
was 0 VERB F
reduced 0 VERB F
by 0 ADP F
35 0 NUM F
% 0 SYM F
( 0 PUNCT F
p 0 NOUN F
= 0 SYM F
0.003 0 NUM F
) 0 PUNCT F
and 0 CCONJ F
M/I 0 NOUN T
was 0 VERB F
reduced 0 VERB F
by 0 ADP F
29 0 NUM F
% 0 SYM F
( 0 PUNCT F
p 0 NOUN F
= 0 SYM F
0.025 0 NUM F
) 0 PUNCT F
for 0 ADP F
25 0 NUM F
mg 0 NOUN F
prednisone 0 NOUN F
compared 0 VERB F
to 0 ADP F
placebo 0 NOUN F
. 0 PUNCT F

No 0 DET T
appreciable 0 ADJ F
effect 0 NOUN F
of 0 ADP F
10 0 NUM F
mg 0 NOUN F
prednisone 0 NOUN F
was 0 VERB F
observed 0 VERB F
. 0 PUNCT F

During 0 ADP T
Step 0 NOUN T
2 0 NUM F
, 0 PUNCT F
M 0 NOUN T
was 0 VERB F
reduced 0 VERB F
by 0 ADP F
33 0 NUM F
% 0 SYM F
( 0 PUNCT F
p 0 NOUN F
= 0 SYM F
0.001 0 NUM F
) 0 PUNCT F
and 0 CCONJ F
15 0 NUM F
% 0 SYM F
( 0 PUNCT F
p 0 NOUN F
= 0 SYM F
0.006 0 NUM F
) 0 PUNCT F
for 0 ADP F
25 0 NUM F
and 0 CCONJ F
10 0 NUM F
mg 0 NOUN F
prednisone 0 NOUN F
compared 0 VERB F
to 0 ADP F
placebo 0 NOUN F
; 0 PUNCT F
and 0 CCONJ F
M/I 0 NOUN T
ratio 0 NOUN F
was 0 VERB F
reduced 0 VERB F
by 0 ADP F
31 0 NUM F
% 0 SYM F
( 0 PUNCT F
p 0 NOUN F
< 0 SYM F
0.001 0 NUM F
) 0 PUNCT F
and 0 CCONJ F
13 0 NUM F
% 0 SYM F
( 0 PUNCT F
p 0 NOUN F
= 0 SYM F
0.026 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
respectively 0 ADV F
. 0 PUNCT F

The 0 DET T
insulin 0 NOUN F
sensitivity 0 NOUN F
index 0 NOUN F
, 0 PUNCT F
Si 0 NOUN T
, 0 PUNCT F
calculated 0 VERB F
as 0 ADP F
the 0 DET F
quotient 0 NOUN F
of 0 ADP F
augmentation 0 NOUN F
of 0 ADP F
M/I 0 NOUN T
between 0 ADP F
Step 0 NOUN T
1 0 NUM F
and 0 CCONJ F
2 0 NUM F
, 0 PUNCT F
was 0 VERB F
reduced 0 VERB F
by 0 ADP F
35.3 0 NUM F
% 0 SYM F
( 0 PUNCT F
p 0 NOUN F
< 0 SYM F
0.01 0 NUM F
) 0 PUNCT F
and 0 CCONJ F
23.5 0 NUM F
% 0 SYM F
( 0 PUNCT F
p 0 NOUN F
< 0 SYM F
0.05 0 NUM F
) 0 PUNCT F
for 0 ADP F
25 0 NUM F
and 0 CCONJ F
10 0 NUM F
mg 0 NOUN F
prednisone 0 NOUN F
, 0 PUNCT F
respectively 0 ADV F
. 0 PUNCT F

CONCLUSION 0 NOUN T
Administration 0 NOUN T
of 0 ADP F
relatively 0 ADV F
low 0 ADJ F
pharmacological 0 ADJ F
doses 0 NOUN F
of 0 ADP F
prednisone 0 NOUN F
for 0 ADP F
one 0 NUM F
week 0 NOUN F
impaired 0 VERB F
insulin 0 NOUN F
sensitivity 0 NOUN F
in 0 ADP F
a 0 DET F
dose-dependent 0 ADJ F
manner 0 NOUN F
in 0 ADP F
healthy 0 ADJ F
males 0 NOUN F
. 0 PUNCT F

These 0 DET T
observed 0 PUNCT F
changes 0 NOUN F
in 0 ADP F
insulin 0 NOUN F
sensitivity 0 NOUN F
are 0 VERB F
likely 0 ADV F
to 0 PART F
be 0 PUNCT F
clinically 0 ADV F
relevant 0 ADJ F
, 0 PUNCT F
especially 0 ADV F
in 0 ADP F
individuals 0 NOUN F
predisposed 0 VERB F
to 0 ADJ F
develop 0 NOUN F
glucose 0 NOUN F
intolerance 0 NOUN F
. 0 PUNCT F

The 0 DET T
limit 0 NOUN F
to 0 ADP F
exercise 0 NOUN F
tolerance 0 NOUN F
in 0 ADP F
humans 0 NOUN F
: 0 PUNCT F
mind 0 NOUN F
over 0 ADP F
muscle 0 NOUN F
? 0 PUNCT F

In 0 ADP T
exercise 0 NOUN F
physiology 0 NOUN F
, 0 PUNCT F
it 0 PRON F
has 0 PUNCT F
been 0 PUNCT F
traditionally 0 ADV F
assumed 0 VERB F
that 0 ADP F
high-intensity 0 NOUN F
aerobic 0 ADJ F
exercise 0 NOUN F
stops 0 PUNCT F
at 0 ADP F
the 0 DET F
point 0 NOUN F
commonly 0 ADV F
called 0 VERB F
exhaustion 0 NOUN F
because 0 PUNCT F
fatigued 0 DET F
subjects 0 NOUN F
are 0 VERB F
no 0 DET F
longer 0 PUNCT F
able 0 ADJ F
to 0 PART F
generate 0 NOUN F
the 0 DET F
power 0 NOUN F
output 0 NOUN F
required 0 VERB F
by 0 ADP F
the 0 DET F
task 0 NOUN F
despite 0 ADP F
their 0 PUNCT F
maximal 0 ADJ F
voluntary 0 PUNCT F
effort 0 NOUN F
. 0 PUNCT F

We 0 PRON T
tested 0 VERB F
the 0 DET F
validity 0 NOUN F
of 0 ADP F
this 0 DET F
assumption 0 NOUN F
by 0 ADP F
measuring 0 VERB F
maximal B-PHYSICAL ADJ F
voluntary I-PHYSICAL PUNCT F
cycling I-PHYSICAL ADJ F
power I-PHYSICAL NOUN F
before 0 ADP F
( 0 PUNCT F
mean 0 NOUN F
+/- 0 SYM F
SD 0 NOUN T
, 0 PUNCT F
1,075 0 NUM F
+/- 0 SYM F
214 0 NUM F
W 0 NOUN T
) 0 PUNCT F
and 0 CCONJ F
immediately 0 ADV F
after 0 PUNCT F
( 0 PUNCT F
731 0 NUM F
+/- 0 SYM F
206 0 NUM F
W 0 NOUN T
) 0 PUNCT F
( 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.001 0 NUM F
) 0 PUNCT F
exhaustive 0 ADJ F
cycling 0 ADJ F
exercise 0 NOUN F
at 0 ADP F
242 0 NUM F
+/- 0 SYM F
24 0 NUM F
W 0 NOUN T
( 0 PUNCT F
80 0 NUM F
% 0 SYM F
of 0 ADP F
peak 0 ADJ F
aerobic 0 ADJ F
power 0 NOUN F
measured 0 VERB F
during 0 ADP F
a 0 DET F
preliminary 0 ADJ F
incremental 0 ADJ F
exercise 0 NOUN F
test 0 NOUN F
) 0 PUNCT F
in 0 ADP F
ten 0 NUM F
fit 0 PUNCT F
male 0 NOUN F
human 0 NOUN F
subjects 0 NOUN F
. 0 PUNCT F

Perceived B-PHYSICAL VERB T
exertion I-PHYSICAL NOUN F
during 0 ADP F
exhaustive 0 ADJ F
cycling 0 ADJ F
exercise 0 NOUN F
was 0 ADJ F
strongly 0 ADV F
correlated 0 VERB F
( 0 PUNCT F
r 0 NOUN F
= 0 SYM F
-0.82 0 NUM F
, 0 PUNCT F
P 0 NOUN T
= 0 SYM F
0.003 0 NUM F
) 0 PUNCT F
with 0 ADP F
time B-PHYSICAL NOUN F
to I-PHYSICAL ADP F
exhaustion I-PHYSICAL NOUN F
( 0 PUNCT F
10.5 0 NUM F
+/- 0 SYM F
2.1 0 NUM F
min 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

These 0 DET T
results 0 DET F
challenge 0 ADP F
the 0 DET F
long-standing 0 VERB F
assumption 0 NOUN F
that 0 ADP F
muscle 0 NOUN F
fatigue 0 NOUN F
causes 0 NOUN F
exhaustion 0 NOUN F
during 0 ADP F
high-intensity 0 NOUN F
aerobic 0 ADJ F
exercise 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
suggest 0 VERB F
that 0 ADP F
exercise 0 NOUN F
tolerance 0 NOUN F
in 0 ADP F
highly 0 ADV F
motivated 0 DET F
subjects 0 NOUN F
is 0 VERB F
ultimately 0 ADV F
limited 0 VERB F
by 0 ADP F
perception 0 NOUN F
of 0 ADP F
effort 0 NOUN F
. 0 PUNCT F

Ropivacaine-clonidine 0 ADJ T
combination 0 NOUN F
for 0 ADP F
caudal 0 ADJ F
blockade 0 NOUN F
in 0 ADP F
children 0 NOUN F
. 0 PUNCT F

BACKGROUND 0 NOUN T
Adding 0 PUNCT T
clonidine 0 NOUN F
to 0 ADP F
weak 0 ADJ F
ropivacaine 0 NOUN F
solutions 0 NOUN F
( 0 PUNCT F
< 0 PROPN F
0.2 0 NUM F
% 0 SYM F
) 0 PUNCT F
could 0 VERB F
potentially 0 ADV F
enhance B-OTHER ADJ F
analgesia I-OTHER NOUN F
as 0 PUNCT F
well 0 PUNCT F
as 0 CCONJ F
further 0 VERB F
reduce 0 VERB F
the 0 DET F
risk 0 NOUN F
for B-PHYSICAL ADP F
unwanted I-PHYSICAL VERB F
motor I-PHYSICAL NOUN F
blockade I-PHYSICAL NOUN F
. 0 PUNCT F

The 0 DET T
aim 0 NOUN F
of 0 ADP F
the 0 DET F
present 0 ADJ F
study 0 NOUN F
was 0 VERB F
to 0 ADV F
compare 0 NOUN F
the 0 DET F
postoperative 0 ADJ F
pain-relieving B-PAIN PUNCT F
quality I-PAIN NOUN F
of 0 ADP F
a 0 DET F
ropivacaine 0 NOUN F
0.1 0 NUM F
% 0 SYM F
-clonidine 0 ADJ F
mixture 0 NOUN F
to 0 ADP F
that 0 PUNCT F
of 0 ADP F
plain 0 ADJ F
ropivacaine 0 NOUN F
0.2 0 NUM F
% 0 SYM F
following 0 ADV F
caudal 0 ADJ F
administration 0 NOUN F
in 0 ADP F
children 0 NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
In 0 ADP T
a 0 DET F
prospective 0 ADJ F
, 0 PUNCT F
observer-blinded 0 VERB F
fashion 0 NOUN F
, 0 PUNCT F
40 0 NUM F
ASA 0 NOUN T
1 0 NUM F
paediatric 0 ADJ F
patients 0 NOUN F
undergoing 0 VERB F
subumbilical 0 ADJ F
surgery 0 NOUN F
were 0 VERB F
randomly 0 ADV F
allocated 0 VERB F
to 0 PART F
receive 0 NOUN F
a 0 DET F
caudal 0 ADJ F
injection 0 NOUN F
of 0 ADP F
either 0 CCONJ F
plain 0 ADJ F
ropivacaine 0 NOUN F
0.2 0 NUM F
% 0 SYM F
( 0 PUNCT F
1 0 NUM F
ml/kg 0 NUM F
) 0 PUNCT F
( 0 PUNCT F
R0.2 0 NOUN T
) 0 PUNCT F
or 0 CCONJ F
a 0 DET F
mixture 0 NOUN F
of 0 ADP F
ropivacaine 0 NOUN F
0.1 0 NUM F
% 0 SYM F
with 0 ADP F
clonidine 0 NOUN F
2 0 NUM F
microg/kg 0 NOUN F
( 0 PUNCT F
1 0 NUM F
ml/kg 0 NUM F
) 0 PUNCT F
( 0 PUNCT F
R0.1C 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

Objective 0 ADJ T
pain 0 NOUN F
scale 0 NOUN F
score 0 NOUN F
and 0 CCONJ F
need 0 ADP F
for 0 ADP F
supplemental 0 ADJ F
analgesia 0 NOUN F
were 0 VERB F
used 0 VERB F
to 0 PART F
evaluate 0 NOUN F
analgesia 0 NOUN F
during 0 ADP F
the 0 DET F
first 0 ADJ F
24 0 NUM F
h 0 NOUN F
postoperatively 0 NOUN F
. 0 PUNCT F

Residual 0 ADJ T
postoperative B-PHYSICAL ADJ F
sedation I-PHYSICAL NOUN F
was 0 VERB F
also 0 ADV F
assessed 0 VERB F
. 0 PUNCT F

RESULTS 0 NOUN T
A 0 PUNCT T
significantly 0 ADV F
higher 0 PUNCT F
number 0 NOUN F
of 0 ADP F
patients 0 NOUN F
in 0 ADP F
the 0 DET F
R0.1C 0 NOUN T
group 0 NOUN F
( 0 PUNCT F
18/20 0 PUNCT F
) 0 PUNCT F
could 0 VERB F
be 0 VERB F
managed 0 PROPN F
without 0 ADP F
supplemental B-PHYSICAL ADJ F
analgesia I-PHYSICAL NOUN F
during 0 ADP F
the 0 DET F
first 0 ADJ F
24 0 NUM F
h 0 NOUN F
postoperatively 0 ADV F
compared 0 VERB F
to 0 ADP F
the 0 DET F
R0.2 0 ADJ T
group 0 NOUN F
( 0 PUNCT F
11/20 0 PUNCT F
) 0 PUNCT F
( 0 PUNCT F
P=0.034 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

Both 0 CCONJ T
the 0 DET F
degree B-PHYSICAL NOUN F
and 0 CCONJ F
the B-PHYSICAL DET F
duration I-PHYSICAL NOUN F
of I-PHYSICAL ADP F
postoperative I-PHYSICAL ADJ F
sedation I-PHYSICAL NOUN F
was 0 VERB F
similar 0 ADJ F
in 0 ADP F
both 0 CCONJ F
groups 0 NOUN F
. 0 PUNCT F

No 0 DET T
signs 0 NOUN F
of 0 ADP F
postoperative B-PHYSICAL ADJ F
motor I-PHYSICAL NOUN F
blockade I-PHYSICAL NOUN F
were 0 VERB F
observed 0 VERB F
. 0 PUNCT F

CONCLUSIONS 0 NOUN T
The 0 DET T
combination 0 NOUN F
of 0 ADP F
clonidine 0 NOUN F
( 0 PUNCT F
2 0 NUM F
microg/kg 0 NOUN F
) 0 PUNCT F
and 0 CCONJ F
ropivacaine 0 NOUN F
0.1 0 NUM F
% 0 PUNCT F
is 0 ADV F
associated 0 VERB F
with 0 ADP F
an 0 DET F
improved 0 VERB F
quality B-OTHER NOUN F
of I-OTHER ADP F
postoperative I-OTHER ADJ F
analgesia I-OTHER NOUN F
compared 0 VERB F
to 0 ADP F
plain 0 ADJ F
0.2 0 NUM F
% 0 SYM F
ropivacaine 0 NOUN F
. 0 PUNCT F

The 0 DET T
improved B-OTHER VERB F
analgesic I-OTHER PUNCT F
quality I-OTHER NOUN F
of 0 ADP F
the 0 DET F
clonidine-ropivacaine 0 NOUN F
mixture 0 NOUN F
is 0 VERB F
achieved 0 VERB F
without 0 ADP F
causing 0 DET F
any 0 DET F
significant 0 ADJ F
degree 0 NOUN F
of 0 ADP F
postoperative 0 ADJ F
sedation 0 NOUN F
. 0 PUNCT F

Randomized 0 VERB T
controlled 0 VERB F
trial 0 NOUN F
of 0 ADP F
entecavir 0 NOUN F
prophylaxis 0 NOUN F
for 0 ADP F
rituximab-associated 0 VERB F
hepatitis 0 NOUN F
B 0 NOUN T
virus 0 NOUN F
reactivation 0 NOUN F
in 0 ADP F
patients 0 NOUN F
with 0 ADP F
lymphoma 0 NOUN F
and 0 CCONJ F
resolved 0 PUNCT F
hepatitis 0 NOUN F
B 0 NOUN T
. 0 PUNCT F

PURPOSE 0 NOUN T
The 0 DET T
role 0 NOUN F
of 0 ADP F
antiviral 0 ADJ F
prophylaxis 0 NOUN F
in 0 ADP F
preventing 0 VERB F
hepatitis 0 NOUN F
B 0 NOUN T
virus 0 NOUN F
( 0 PUNCT F
HBV 0 NOUN T
) 0 PUNCT F
reactivation 0 NOUN F
before 0 PUNCT F
rituximab-based 0 VERB F
chemotherapy 0 NOUN F
in 0 ADP F
patients 0 NOUN F
with 0 ADP F
lymphoma 0 NOUN F
and 0 CCONJ F
resolved 0 PUNCT F
hepatitis 0 NOUN F
B 0 NOUN T
is 0 VERB F
unclear 0 ADJ F
. 0 PUNCT F

PATIENTS 0 NOUN T
AND 0 CCONJ T
METHODS 0 NOUN T
Eighty 0 PUNCT T
patients 0 NOUN F
with 0 ADP F
CD20 0 NOUN T
( 0 PUNCT F
+ 0 SYM F
) 0 PUNCT F
lymphoma 0 NOUN F
and 0 CCONJ F
resolved 0 PUNCT F
hepatitis 0 NOUN F
B 0 NOUN T
were 0 VERB F
randomly 0 ADV F
assigned 0 VERB F
to 0 PART F
receive 0 NOUN F
either 0 PUNCT F
prophylactic 0 ADP F
entecavir 0 NOUN F
( 0 PUNCT F
ETV 0 NOUN T
) 0 PUNCT F
before 0 ADP F
chemotherapy 0 NOUN F
to 0 ADP F
3 0 NUM F
months 0 NOUN F
after 0 ADP F
completing 0 ADJ F
chemotherapy 0 NOUN F
( 0 PUNCT F
ETV 0 NOUN T
prophylactic 0 ADJ F
group 0 NOUN F
, 0 PUNCT F
n 0 NOUN F
= 0 SYM F
41 0 NUM F
) 0 PUNCT F
or 0 CCONJ F
to 0 PART F
receive 0 NOUN F
therapeutic 0 ADJ F
ETV 0 NOUN T
at 0 ADP F
the 0 DET F
time 0 NOUN F
of 0 ADP F
HBV 0 NOUN T
reactivation 0 NOUN F
and 0 CCONJ F
hepatitis 0 NOUN F
B 0 NOUN T
surface 0 NOUN F
antigen 0 NOUN F
( 0 PUNCT F
HBsAg 0 NOUN T
) 0 PUNCT F
reverse 0 ADJ F
seroconversion 0 NOUN F
since 0 ADP F
chemotherapy 0 NOUN F
( 0 PUNCT F
control 0 NOUN F
group 0 NOUN F
, 0 PUNCT F
n 0 NOUN F
= 0 SYM F
39 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

RESULTS 0 NOUN T
Fifty-eight 0 PUNCT T
patients 0 NOUN F
( 0 PUNCT F
72.5 0 NUM F
% 0 SYM F
) 0 PUNCT F
were 0 VERB F
positive 0 ADJ F
for 0 ADP F
hepatitis 0 NOUN F
B 0 NOUN T
surface 0 NOUN F
antibody 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
HBV 0 NOUN T
DNA 0 NOUN T
was 0 VERB F
undetectable 0 ADJ F
in 0 ADP F
50 0 NUM F
patients 0 NOUN F
( 0 PUNCT F
62.5 0 NUM F
% 0 SYM F
) 0 PUNCT F
. 0 PUNCT F

During 0 ADP T
a 0 DET F
mean 0 NOUN F
18-month 0 NOUN F
follow-up 0 NOUN F
period 0 NOUN F
, 0 PUNCT F
one 0 NUM F
patient 0 NOUN F
( 0 PUNCT F
2.4 0 NUM F
% 0 SYM F
) 0 PUNCT F
in 0 ADP F
the 0 DET F
ETV 0 NOUN T
prophylactic 0 ADJ F
group 0 NOUN F
and 0 CCONJ F
seven 0 NUM F
patients 0 NOUN F
( 0 PUNCT F
17.9 0 NUM F
% 0 SYM F
) 0 PUNCT F
in 0 ADP F
the 0 DET F
control 0 NOUN F
group 0 NOUN F
developed 0 VERB F
HBV 0 NOUN T
reactivation 0 NOUN F
( 0 PUNCT F
P 0 NOUN T
= 0 SYM F
.027 0 PUNCT F
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
cumulative B-PHYSICAL ADJ F
HBV I-PHYSICAL NOUN T
reactivation I-PHYSICAL NOUN F
rates I-PHYSICAL NOUN F
at 0 ADP F
months 0 NOUN F
6 0 NUM F
, 0 PUNCT F
12 0 NUM F
, 0 PUNCT F
and 0 CCONJ F
18 0 NUM F
after 0 ADP F
chemotherapy 0 NOUN F
were 0 VERB F
8 0 NUM F
% 0 SYM F
, 0 PUNCT F
11.2 0 NUM F
% 0 SYM F
, 0 PUNCT F
and 0 CCONJ F
25.9 0 NUM F
% 0 SYM F
, 0 PUNCT F
respectively 0 ADV F
, 0 PUNCT F
in 0 ADP F
the 0 DET F
control 0 NOUN F
group 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
0 0 NUM F
% 0 SYM F
, 0 PUNCT F
0 0 NUM F
% 0 SYM F
, 0 PUNCT F
and 0 CCONJ F
4.3 0 NUM F
% 0 SYM F
in 0 ADP F
the 0 DET F
ETV 0 NOUN T
prophylactic 0 ADJ F
group 0 NOUN F
( 0 PUNCT F
P 0 NOUN T
= 0 SYM F
.019 0 PUNCT F
) 0 PUNCT F
. 0 PUNCT F

Four 0 NUM T
patients 0 NOUN F
( 0 PUNCT F
50 0 NUM F
% 0 SYM F
) 0 PUNCT F
in 0 ADP F
the 0 DET F
control 0 NOUN F
group 0 NOUN F
had 0 PUNCT F
HBsAg B-PHYSICAL NOUN T
reverse I-PHYSICAL ADJ F
seroconversion I-PHYSICAL NOUN F
after 0 ADP F
HBV 0 NOUN T
reactivation 0 NOUN F
. 0 PUNCT F

The 0 DET T
cumulative B-PHYSICAL ADJ F
HBsAg I-PHYSICAL NOUN T
reverse I-PHYSICAL ADJ F
seroconversion I-PHYSICAL NOUN F
rates I-PHYSICAL NOUN F
at 0 ADP F
months 0 NOUN F
6 0 NUM F
, 0 PUNCT F
12 0 NUM F
, 0 PUNCT F
and 0 CCONJ F
18 0 NUM F
since 0 ADP F
chemotherapy 0 NOUN F
were 0 VERB F
0 0 NUM F
% 0 SYM F
, 0 PUNCT F
6.4 0 NUM F
% 0 SYM F
, 0 PUNCT F
and 0 CCONJ F
16.3 0 NUM F
% 0 SYM F
in 0 ADP F
the 0 DET F
control 0 NOUN F
group 0 NOUN F
, 0 PUNCT F
respectively 0 ADV F
, 0 PUNCT F
which 0 ADP F
were 0 VERB F
significantly 0 ADV F
higher 0 PUNCT F
than 0 CCONJ F
those 0 PUNCT F
in 0 ADP F
the 0 DET F
ETV 0 NOUN T
prophylactic 0 ADJ F
group 0 NOUN F
( 0 PUNCT F
P 0 NOUN T
= 0 SYM F
.032 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Patients 0 NOUN T
with 0 ADP F
detectable 0 ADJ F
or 0 CCONJ F
undetectable 0 ADJ F
viral 0 ADJ F
load 0 NOUN F
could 0 VERB F
develop 0 VERB F
HBV B-PHYSICAL NOUN T
reactivation I-PHYSICAL NOUN F
and 0 CCONJ F
HBsAg B-PHYSICAL NOUN T
reverse I-PHYSICAL ADJ F
seroconversion I-PHYSICAL NOUN F
. 0 PUNCT F

CONCLUSION 0 NOUN T
Undetectable 0 ADJ T
HBV 0 NOUN T
viral 0 ADJ F
load 0 NOUN F
before 0 ADP F
chemotherapy 0 NOUN F
did 0 PUNCT F
not 0 ADV F
confer 0 VERB F
reactivation-free 0 ADJ F
status 0 NOUN F
. 0 PUNCT F

Antiviral 0 ADJ T
prophylaxis 0 NOUN F
can 0 PRON F
potentially 0 ADV F
prevent 0 VERB F
rituximab-associated 0 VERB F
HBV 0 NOUN T
reactivation 0 NOUN F
in 0 ADP F
patients 0 NOUN F
with 0 ADP F
lymphoma 0 NOUN F
and 0 CCONJ F
resolved 0 PUNCT F
hepatitis 0 NOUN F
B 0 NOUN T
. 0 PUNCT F

Single 0 ADJ T
nucleotide 0 NOUN F
polymorphism 0 NOUN F
in 0 ADP F
the 0 DET F
hypoxia-inducible 0 ADJ F
factor-1alpha 0 NOUN F
gene 0 NOUN F
in 0 ADP F
colorectal 0 ADJ F
carcinoma 0 NOUN F
. 0 PUNCT F

Colorectal 0 ADJ T
carcinoma 0 NOUN F
is 0 VERB F
one 0 NUM F
of 0 ADP F
the 0 DET F
most 0 VERB F
common 0 ADJ F
malignancies 0 NOUN F
in 0 ADP F
the 0 DET F
world 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
its 0 PUNCT F
incidence 0 NOUN F
has 0 PUNCT F
increased 0 PUNCT F
in 0 ADP F
recent 0 ADJ F
years 0 NOUN F
. 0 PUNCT F

We 0 PRON T
have 0 PUNCT F
reported 0 VERB F
that 0 ADP F
expression 0 NOUN F
of 0 ADP F
hypoxia-inducible 0 ADJ F
factor 0 NOUN F
( 0 PUNCT F
HIF 0 NOUN T
) 0 PUNCT F
-1alpha 0 NOUN F
correlates 0 NOUN F
with 0 ADP F
expression 0 NOUN F
of 0 ADP F
vascular 0 ADJ F
endothelial 0 ADJ F
growth 0 NOUN F
factor 0 NOUN F
( 0 PUNCT F
VEGF 0 NOUN T
) 0 PUNCT F
, 0 PUNCT F
tumor 0 NOUN F
stage 0 NOUN F
, 0 PUNCT F
lymphatic 0 ADJ F
invasion 0 NOUN F
, 0 PUNCT F
venous 0 ADJ F
invasion 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
liver 0 NOUN F
metastasis 0 NOUN F
. 0 PUNCT F

It 0 PRON T
has 0 ADV F
also 0 ADV F
been 0 PUNCT F
reported 0 VERB F
that 0 ADP F
a 0 DET F
single 0 ADJ F
nucleotide 0 NOUN F
polymorphism 0 NOUN F
( 0 PUNCT F
SNP 0 NOUN T
) 0 PUNCT F
in 0 ADP F
exon 0 NOUN F
12 0 NUM F
of 0 ADP F
HIF-1alpha 0 NOUN T
gene 0 NOUN F
is 0 VERB F
present 0 ADJ F
in 0 ADP F
renal 0 ADJ F
cell 0 NOUN F
carcinoma 0 NOUN F
and 0 CCONJ F
head 0 NOUN F
and 0 CCONJ F
neck 0 ADJ F
squamous 0 ADJ F
cell 0 NOUN F
carcinoma 0 NOUN F
patients 0 NOUN F
. 0 PUNCT F

We 0 PRON T
investigated 0 VERB F
the 0 DET F
C1772T 0 NOUN T
polymorphism 0 NOUN F
in 0 ADP F
colorectal 0 ADJ F
cancer 0 NOUN F
patients 0 NOUN F
and 0 CCONJ F
healthy 0 ADJ F
control 0 NOUN F
subjects 0 NOUN F
to 0 PART F
clarify 0 NOUN F
the 0 DET F
mechanism 0 NOUN F
of 0 ADP F
HIF-1alpha 0 NOUN T
activation 0 NOUN F
in 0 ADP F
colorectal 0 ADJ F
carcinoma 0 NOUN F
. 0 PUNCT F

The 0 DET T
exon 0 NOUN F
12 0 NUM F
genotype 0 NOUN F
was 0 VERB F
not 0 ADV F
associated 0 VERB F
with 0 ADP F
sex 0 NOUN F
or 0 CCONJ F
age 0 NOUN F
. 0 PUNCT F

The 0 DET T
distribution 0 NOUN F
of 0 ADP F
HIF-1alpha B-PHYSICAL NOUN T
genotypes I-PHYSICAL VERB F
in 0 ADP F
controls 0 NOUN F
was 0 VERB F
89 0 NUM F
C/C 0 NOUN T
( 0 PUNCT F
89 0 NUM F
% 0 SYM F
) 0 PUNCT F
, 0 PUNCT F
11 0 NUM F
C/T 0 ADV T
( 0 PUNCT F
11 0 NUM F
% 0 SYM F
) 0 PUNCT F
, 0 PUNCT F
and 0 CCONJ F
0 0 NUM F
T/T 0 PUNCT T
( 0 PUNCT F
0 0 NUM F
% 0 SYM F
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
distribution 0 NOUN F
of 0 ADP F
HIF-1alpha B-PHYSICAL NOUN T
genotypes I-PHYSICAL VERB F
in 0 ADP F
colorectal 0 ADJ F
cancer 0 NOUN F
patients 0 NOUN F
was 0 VERB F
100 0 NUM F
C/C 0 ADJ T
( 0 PUNCT F
100 0 NUM F
% 0 SYM F
) 0 PUNCT F
, 0 PUNCT F
0 0 NUM F
C/T 0 NUM T
( 0 PUNCT F
0 0 NUM F
% 0 SYM F
) 0 PUNCT F
, 0 PUNCT F
and 0 CCONJ F
0 0 NUM F
T/T 0 PUNCT T
( 0 PUNCT F
0 0 NUM F
% 0 SYM F
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
difference 0 NOUN F
in 0 ADP F
genotype 0 NOUN F
distribution 0 NOUN F
between 0 ADP F
patients 0 NOUN F
and 0 CCONJ F
control 0 NOUN F
subjects 0 NOUN F
was 0 VERB F
significant 0 ADJ F
( 0 PUNCT F
p 0 NOUN F
< 0 SYM F
0.0005 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

These 0 DET T
results 0 CCONJ F
suggest 0 VERB F
that 0 ADP F
the 0 DET F
C1772T B-PHYSICAL NOUN T
polymorphism I-PHYSICAL NOUN F
in 0 ADP F
HIF-1alpha 0 NOUN T
is 0 VERB F
not 0 ADV F
involved 0 VERB F
in 0 ADP F
progression 0 NOUN F
or 0 CCONJ F
metastasis 0 NOUN F
of 0 ADP F
colorectal 0 ADJ F
carcinoma 0 NOUN F
. 0 PUNCT F

Is 0 PUNCT T
a 0 DET F
2-week 0 NOUN F
duration 0 NOUN F
sufficient 0 ADJ F
for 0 ADP F
stenting 0 VERB F
in 0 ADP F
endopyelotomy 0 NOUN F
? 0 PUNCT F

PURPOSE 0 NOUN T
Internal 0 ADJ T
stenting 0 VERB F
is 0 VERB F
an 0 DET F
integral 0 ADJ F
part 0 NOUN F
of 0 ADP F
endopyelotomy 0 NOUN F
. 0 PUNCT F

Studies 0 NOUN T
in 0 ADP F
animals 0 NOUN F
show 0 VERB F
good 0 ADJ F
healing 0 VERB F
after 0 ADP F
1 0 NUM F
to 0 ADP F
2 0 NUM F
weeks 0 NOUN F
of 0 ADP F
ureterotomy 0 NOUN F
. 0 PUNCT F

Inherent 0 ADJ T
stent 0 NOUN F
related 0 VERB F
problems 0 NOUN F
warrant 0 VERB F
a 0 DET F
minimum 0 NOUN F
possible 0 ADJ F
duration 0 NOUN F
of 0 ADP F
stenting 0 VERB F
without 0 ADP F
compromising 0 PUNCT F
the 0 DET F
results 0 CCONJ F
of 0 ADP F
endopyelotomy 0 NOUN F
. 0 PUNCT F

We 0 PRON T
performed 0 VERB F
a 0 DET F
prospective 0 ADJ F
randomized 0 VERB F
trial 0 NOUN F
to 0 PART F
evaluate 0 NOUN F
the 0 DET F
optimum B-OTHER NOUN F
duration I-OTHER NOUN F
of I-OTHER ADP F
stenting I-OTHER VERB F
after 0 ADP F
endopyelotomy 0 NOUN F
. 0 PUNCT F

MATERIALS 0 NOUN T
AND 0 CCONJ T
METHODS 0 NOUN T
A 0 PUNCT T
total 0 NOUN F
of 0 ADP F
57 0 NUM F
consecutive 0 ADJ F
patients 0 NOUN F
with 0 ADP F
primary 0 ADJ F
ureteropelvic 0 ADJ F
junction 0 NOUN F
obstruction 0 NOUN F
were 0 VERB F
randomized 0 VERB F
to 0 PUNCT F
undergo 0 PUNCT F
7/14Fr 0 PUNCT F
internal 0 ADJ F
endopyelotomy 0 NOUN F
stent 0 NOUN F
placement 0 NOUN F
for 0 ADP F
2 0 NUM F
( 0 PUNCT F
group 0 NOUN F
1 0 NUM F
) 0 PUNCT F
and 0 CCONJ F
4 0 NUM F
( 0 PUNCT F
group 0 NOUN F
2 0 NUM F
) 0 PUNCT F
weeks 0 NOUN F
. 0 PUNCT F

A 0 DET T
symptom 0 NOUN F
based 0 VERB F
questionnaire 0 NOUN F
was 0 VERB F
administered 0 VERB F
to 0 ADP F
all 0 DET F
patients 0 NOUN F
at 0 ADP F
stent 0 NOUN F
removal 0 NOUN F
. 0 PUNCT F

Followup 0 NOUN T
was 0 VERB F
done 0 PUNCT F
with 0 ADP F
diuretic 0 NOUN F
scanning 0 VERB F
at 0 ADP F
3 0 NUM F
, 0 PUNCT F
6 0 NUM F
, 0 PUNCT F
9 0 NUM F
and 0 CCONJ F
12 0 NUM F
months 0 NOUN F
and 0 CCONJ F
then 0 ADV F
yearly 0 PUNCT F
, 0 PUNCT F
and 0 CCONJ F
thereafter 0 ADV F
with 0 ADP F
diuretic 0 NOUN F
renography 0 NOUN F
. 0 PUNCT F

RESULTS 0 NOUN T
In 0 ADP T
each 0 DET F
group 0 NOUN F
26 0 NUM F
patients 0 NOUN F
were 0 VERB F
available 0 ADJ F
for 0 ADP F
evaluation 0 NOUN F
. 0 PUNCT F

The 0 DET T
2 0 NUM F
groups 0 NOUN F
were 0 VERB F
comparable 0 ADJ F
in 0 ADP F
terms 0 NOUN F
of 0 ADP F
age 0 NOUN F
, 0 PUNCT F
sex 0 NOUN F
, 0 PUNCT F
symptoms B-PHYSICAL NOUN F
and 0 CCONJ F
ipsilateral B-PHYSICAL ADJ F
glomerular I-PHYSICAL ADJ F
filtration I-PHYSICAL NOUN F
rate I-PHYSICAL NOUN F
. 0 PUNCT F

Mean 0 DET T
followup 0 NOUN F
was 0 VERB F
22.3 0 NUM F
( 0 PUNCT F
range 0 NOUN F
12 0 NUM F
to 0 ADP F
36 0 NUM F
) 0 PUNCT F
and 0 CCONJ F
21.3 0 NUM F
months 0 NOUN F
( 0 PUNCT F
range 0 NOUN F
12 0 NUM F
to 0 ADP F
35 0 NUM F
) 0 PUNCT F
in 0 ADP F
groups 0 NOUN F
1 0 NUM F
and 0 CCONJ F
2 0 NUM F
, 0 PUNCT F
respectively 0 ADV F
. 0 PUNCT F

At 0 ADP T
the 0 DET F
end 0 NOUN F
of 0 ADP F
1 0 NUM F
year 0 NOUN F
24 0 NUM F
group 0 NOUN F
1 0 NUM F
( 0 PUNCT F
92.3 0 NUM F
% 0 SYM F
) 0 PUNCT F
and 0 CCONJ F
23 0 NUM F
group 0 NOUN F
2 0 NUM F
( 0 PUNCT F
90.3 0 NUM F
% 0 SYM F
) 0 PUNCT F
patients 0 NOUN F
had 0 VERB F
an 0 DET F
improved 0 VERB F
drainage B-OTHER NOUN F
pattern I-OTHER NOUN F
. 0 PUNCT F

This 0 DET T
difference 0 NOUN F
was 0 VERB F
not 0 ADV F
significant 0 ADJ F
. 0 PUNCT F

Stent B-PHYSICAL NOUN T
related I-PHYSICAL VERB F
symptoms I-PHYSICAL NOUN F
were 0 VERB F
present 0 ADJ F
in 0 ADP F
a 0 DET F
good 0 ADJ F
proportion 0 NOUN F
of 0 ADP F
patients 0 NOUN F
in 0 ADP F
groups 0 NOUN F
1 0 NUM F
and 0 CCONJ F
2 0 NUM F
but 0 CCONJ F
there 0 PUNCT F
was 0 VERB F
a 0 DET F
significant 0 ADJ F
difference 0 NOUN F
in 0 ADP F
the 0 DET F
incidence 0 NOUN F
of 0 ADP F
urinary B-ADVERSE-EFFECTS ADJ F
tract I-ADVERSE-EFFECTS NOUN F
infections I-ADVERSE-EFFECTS NOUN F
( 0 PUNCT F
11.5 0 NUM F
% 0 SYM F
versus 0 CCONJ F
38.1 0 NUM F
% 0 SYM F
, 0 PUNCT F
p 0 NOUN F
= 0 SYM F
0.04 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Of 0 ADP T
the 0 DET F
group 0 NOUN F
2 0 NUM F
patients 0 NOUN F
64 0 NUM F
% 0 SYM F
preferred 0 ADP F
2 0 NUM F
weeks B-OTHER NOUN F
of I-OTHER ADP F
stenting I-OTHER ADV F
. 0 PUNCT F

CONCLUSIONS 0 NOUN T
Two 0 NUM T
weeks 0 NOUN F
seems 0 NOUN F
to 0 DET F
be 0 PUNCT F
a 0 DET F
sufficient 0 ADJ F
duration 0 NOUN F
to 0 PART F
allow 0 NOUN F
functional 0 ADJ F
restoration 0 NOUN F
across 0 ADP F
the 0 DET F
ureteropelvic 0 ADJ F
junction 0 NOUN F
after 0 ADP F
endopyelotomy 0 NOUN F
and 0 CCONJ F
decrease 0 ADP F
stent B-ADVERSE-EFFECTS NOUN F
related I-ADVERSE-EFFECTS VERB F
complications I-ADVERSE-EFFECTS NOUN F
. 0 PUNCT F

Short-term 0 NOUN T
aerobic 0 ADJ F
exercise 0 NOUN F
training 0 VERB F
in 0 ADP F
obese 0 DET F
humans 0 NOUN F
with 0 ADP F
type 0 NOUN F
2 0 NUM F
diabetes 0 NOUN F
mellitus 0 NOUN F
improves 0 NOUN F
whole-body 0 NOUN F
insulin 0 NOUN F
sensitivity 0 NOUN F
through 0 ADP F
gains 0 NOUN F
in 0 ADP F
peripheral 0 ADJ F
, 0 PUNCT F
not 0 ADV F
hepatic 0 ADJ F
insulin 0 NOUN F
sensitivity 0 NOUN F
. 0 PUNCT F

CONTEXT 0 NOUN T
Short-term 0 NOUN T
aerobic 0 ADJ F
exercise 0 NOUN F
training 0 VERB F
can 0 VERB F
improve 0 VERB F
whole-body B-PHYSICAL NOUN F
insulin I-PHYSICAL NOUN F
sensitivity I-PHYSICAL NOUN F
in 0 ADP F
humans 0 NOUN F
with 0 ADP F
type 0 NOUN F
2 0 NUM F
diabetes 0 NOUN F
mellitus 0 NOUN F
; 0 PUNCT F
however 0 ADV F
, 0 PUNCT F
the 0 DET F
contributions 0 NOUN F
of 0 ADP F
peripheral 0 ADJ F
and 0 CCONJ F
hepatic 0 ADJ F
tissues 0 NOUN F
to 0 ADP F
these 0 DET F
improvements 0 NOUN F
are 0 PROPN F
not 0 ADV F
known 0 VERB F
. 0 PUNCT F

OBJECTIVE 0 NOUN T
Our 0 PUNCT T
objective 0 ADJ F
was 0 VERB F
to 0 PART F
determine 0 NOUN F
the 0 DET F
effect 0 NOUN F
of 0 ADP F
7-d 0 NOUN F
aerobic 0 ADJ F
exercise 0 NOUN F
training 0 VERB F
on 0 ADP F
peripheral 0 ADJ F
and 0 CCONJ F
hepatic 0 ADJ F
insulin 0 NOUN F
sensitivity 0 NOUN F
during 0 ADP F
isoglycemic/hyperinsulinemic 0 ADJ F
clamp 0 NOUN F
conditions 0 NOUN F
. 0 PUNCT F

DESIGN 0 NOUN T
Subjects 0 NOUN T
were 0 VERB F
randomly 0 ADV F
assigned 0 VERB F
to 0 ADP F
one 0 PUNCT F
of 0 ADP F
two 0 NUM F
groups 0 NOUN F
. 0 PUNCT F

The 0 DET T
energy 0 NOUN F
balance 0 NOUN F
group 0 NOUN F
consumed 0 PUNCT F
an 0 DET F
isocaloric 0 ADJ F
diet 0 NOUN F
consisting 0 VERB F
of 0 ADP F
50 0 NUM F
% 0 SYM F
carbohydrate 0 NOUN F
, 0 PUNCT F
30 0 NUM F
% 0 SYM F
fat 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
20 0 NUM F
% 0 ADV F
protein 0 NOUN F
for 0 ADP F
15 0 NUM F
d. 0 NOUN F
The 0 DET T
energy 0 NOUN F
balance 0 NOUN F
plus 0 CCONJ F
exercise 0 NOUN F
group 0 NOUN F
consumed 0 PUNCT F
a 0 DET F
similar 0 ADJ F
diet 0 NOUN F
over 0 ADP F
the 0 DET F
15 0 NUM F
d 0 NOUN F
and 0 CCONJ F
performed 0 PART F
50-min 0 NOUN F
of 0 ADP F
treadmill 0 NOUN F
walking 0 PUNCT F
at 0 ADP F
70 0 NUM F
% 0 SYM F
of 0 ADP F
maximum 0 NOUN F
oxygen 0 NOUN F
consumption 0 NOUN F
maximum 0 NOUN F
during 0 ADP F
the 0 DET F
second 0 ADJ F
7 0 NUM F
d 0 NOUN F
of 0 ADP F
the 0 DET F
15-d 0 NOUN F
study 0 NOUN F
period 0 NOUN F
. 0 PUNCT F

Each 0 DET T
subject 0 NOUN F
underwent 0 VERB F
an 0 DET F
initial 0 ADJ F
isoglycemic/hyperinsulinemic 0 ADJ F
clamp 0 NOUN F
after 0 ADP F
1-wk 0 PUNCT F
dietary 0 ADJ F
control 0 NOUN F
and 0 CCONJ F
a 0 DET F
second 0 ADJ F
clamp 0 NOUN F
after 0 ADP F
completing 0 VERB F
the 0 DET F
study 0 NOUN F
. 0 PUNCT F

SETTING 0 VERB T
The 0 DET T
study 0 NOUN F
was 0 VERB F
performed 0 VERB F
at 0 ADP F
Ohio 0 PUNCT T
State 0 NOUN T
University 0 NOUN T
's 0 PUNCT F
General 0 ADJ T
Clinical 0 ADJ T
Research 0 NOUN T
Center 0 NOUN T
. 0 PUNCT F

PARTICIPANTS 0 ADP T
There 0 PUNCT T
were 0 VERB F
18 0 NUM F
obese 0 PUNCT F
, 0 PUNCT F
mildly 0 ADV F
diabetic 0 ADJ F
humans 0 NOUN F
included 0 VERB F
in 0 ADP F
the 0 DET F
study 0 NOUN F
. 0 PUNCT F

INTERVENTION 0 NOUN T
Aerobic 0 ADJ T
exercise 0 NOUN F
training 0 VERB F
was 0 VERB F
performed 0 VERB F
for 0 ADP F
7 0 NUM F
d. 0 NOUN F
MAIN 0 ADJ T
OUTCOME 0 NOUN T
MEASURES 0 NOUN T
Whole-body B-PHYSICAL NOUN T
, 0 PUNCT F
peripheral B-PHYSICAL ADJ F
, 0 PUNCT F
and 0 PUNCT F

In 0 ADP T
high 0 ADJ F
risk 0 NOUN F
hypertensive 0 ADJ F
subjects 0 NOUN F
with 0 ADP F
incidental 0 DET F
and 0 CCONJ F
unilateral 0 ADJ F
renal 0 ADJ F
artery 0 NOUN F
stenosis 0 NOUN F
percutaneous 0 ADJ F
revascularization 0 NOUN F
with 0 ADP F
stent 0 NOUN F
improves 0 NOUN F
blood B-PHYSICAL NOUN F
pressure I-PHYSICAL NOUN F
control I-PHYSICAL NOUN F
but 0 CCONJ F
not 0 ADV F
glomerular B-PHYSICAL ADJ F
filtration I-PHYSICAL NOUN F
rate I-PHYSICAL NOUN F
. 0 PUNCT F

AIM 0 NOUN T
In 0 ADP T
high-risk 0 NOUN F
hypertensive 0 ADJ F
subjects 0 NOUN F
( 0 PUNCT F
HTs 0 NOUN T
) 0 PUNCT F
with 0 ADP F
incidental 0 DET F
unilateral 0 ADJ F
renal 0 ADJ F
artery 0 NOUN F
stenosis 0 NOUN F
( 0 PUNCT F
RAS 0 NOUN T
) 0 PUNCT F
, 0 PUNCT F
the 0 DET F
effectiveness 0 NOUN F
of 0 ADP F
percutaneous 0 ADJ F
revascularization 0 NOUN F
with 0 ADP F
stent 0 NOUN F
( 0 PUNCT F
PR-STENT 0 NOUN T
) 0 PUNCT F
on 0 ADP F
blood B-PHYSICAL NOUN F
pressure I-PHYSICAL NOUN F
( 0 PUNCT F
BP 0 NOUN T
) 0 PUNCT F
and 0 CCONJ F
glomerular B-PHYSICAL ADJ F
filtration I-PHYSICAL NOUN F
rate I-PHYSICAL NOUN F
( I-PHYSICAL PUNCT F
GFR I-PHYSICAL NOUN T
) I-PHYSICAL PUNCT F
is 0 VERB F
not 0 ADV F
established 0 VERB F
. 0 PUNCT F

METHODS 0 NOUN T
Eighteen 0 PUNCT T
HTs 0 ADP T
aged 0 ADP F
65.7 0 NUM F
? 0 PUNCT F

9.2 0 NUM F
years 0 NOUN F
with 0 ADP F
angiographically 0 ADJ F
diagnosed 0 ADP F
unilateral 0 ADJ F
RAS 0 NOUN T
( 0 PUNCT F
? 0 PUNCT F

60 0 NUM F
% 0 SYM F
) 0 PUNCT F
were 0 VERB F
randomized 0 VERB F
to 0 PART F
receive 0 NOUN F
PR-STENT 0 NOUN T
( 0 PUNCT F
N=9 0 NOUN T
) 0 PUNCT F
or 0 CCONJ F
to 0 ADP F
NO-STENT 0 NOUN T
( 0 PUNCT F
N=9 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

BP 0 NOUN T
( 0 PUNCT F
mercury 0 NOUN F
sphygmomanometer 0 NOUN F
) 0 PUNCT F
and 0 CCONJ F
GFR 0 NOUN T
( 0 PUNCT F
99mTc-DTPA 0 PUNCT F
clearances 0 CCONJ F
during 0 ADP F
renal 0 ADJ F
scintigraphy 0 NOUN F
) 0 PUNCT F
were 0 VERB F
evaluated 0 ADP F
yearly 0 PUNCT F
for 0 ADP F
three 0 NUM F
years 0 NOUN F
. 0 PUNCT F

Echo-Doppler 0 NOUN T
of 0 ADP F
renal 0 ADJ F
arteries 0 NOUN F
was 0 VERB F
performed 0 VERB F
to 0 ADP F
verify 0 NOUN F
the 0 DET F
anatomic 0 ADJ F
patency 0 NOUN F
and 0 CCONJ F
flow 0 NOUN F
velocities 0 NOUN F
of 0 ADP F
the 0 DET F
reperfused 0 ADJ F
artery 0 NOUN F
. 0 PUNCT F

Analysis 0 NOUN T
of 0 ADP F
variance 0 NOUN F
compared 0 VERB F
BP 0 NOUN T
and 0 CCONJ F
GFR 0 NOUN T
values 0 NOUN F
changes 0 NOUN F
from 0 ADP F
baseline 0 NOUN F
to 0 ADP F
the 0 DET F
follow-up 0 NOUN F
; 0 PUNCT F
differences 0 NOUN F
for 0 ADP F
continuous 0 ADJ F
variables 0 NOUN F
were 0 VERB F
evaluated 0 VERB F
between 0 ADP F
groups 0 NOUN F
with 0 ADP F
the 0 DET F
Tukey 0 NOUN T
's 0 PUNCT F
post 0 PUNCT F
hoc 0 CCONJ F
test 0 NOUN F
after 0 ADP F
adjustment 0 NOUN F
for 0 ADP F
age 0 NOUN F
, 0 PUNCT F
change 0 NOUN F
of 0 ADP F
BP 0 NOUN T
between 0 ADP F
baseline 0 NOUN F
and 0 CCONJ F
at 0 ADP F
the 0 DET F
follow-up 0 NOUN F
, 0 PUNCT F
GFR 0 NOUN T
and 0 CCONJ F
body 0 NOUN F
mass 0 NOUN F
index 0 NOUN F
( 0 PUNCT F
BMI 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

RESULTS 0 NOUN T
Baseline 0 NOUN T
systolic 0 ADJ F
BP 0 NOUN T
and 0 CCONJ F
GFR 0 NOUN T
values 0 NOUN F
were 0 VERB F
not 0 ADV F
different 0 ADJ F
between 0 ADP F
groups 0 NOUN F
. 0 PUNCT F

The 0 DET T
significantly 0 ADV F
greater 0 PUNCT F
GFR 0 NOUN T
increase 0 NOUN F
observed 0 PRON F
in 0 ADP F
PR-STENT 0 NOUN T
than 0 PUNCT F
in 0 ADP F
NO-STENT 0 NOUN T
at 0 ADP F
univariate 0 ADJ F
analysis 0 NOUN F
at 0 ADP F
the 0 DET F
end 0 NOUN F
of 0 ADP F
follow-up 0 NOUN F
( 0 PUNCT F
62.5 0 NUM F
? 0 PUNCT F

19.2 0 NUM F
vs. 0 CCONJ F
42.24 0 NUM F
? 0 PUNCT F

17.6 0 NUM F
, 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.02 0 NUM F
) 0 PUNCT F
disappeared 0 ADP F
after 0 ADP F
adjustment 0 NOUN F
for 0 ADP F
confounding 0 VERB F
factors 0 NOUN F
. 0 PUNCT F

However 0 ADV T
, 0 PUNCT F
systolic 0 ADJ F
BP 0 NOUN T
remained 0 VERB F
significantly 0 ADV F
lower 0 PUNCT F
in 0 ADP F
PR-STENT 0 NOUN T
than 0 PUNCT F
in 0 ADP F
NO-STENT 0 NOUN T
( 0 PUNCT F
140.1 0 NUM F
? 0 PUNCT F

4.6 0 NUM F
vs. 0 CCONJ F
170.0 0 NUM F
? 0 PUNCT F

8.3 0 NUM F
, 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.0001 0 NUM F
) 0 PUNCT F
also 0 ADV F
after 0 ADP F
adjustment 0 NOUN F
for 0 ADP F
age 0 NOUN F
, 0 PUNCT F
GFR 0 NOUN T
and 0 CCONJ F
BMI 0 NOUN T
. 0 PUNCT F

CONCLUSION 0 NOUN T
PR-STENT 0 NOUN T
reduces 0 NOUN F
systolic 0 ADJ F
BP 0 NOUN T
without 0 ADP F
improving 0 VERB F
GFR 0 NOUN T
. 0 PUNCT F

Due 0 PUNCT T
to 0 ADP F
the 0 DET F
strong 0 ADJ F
association 0 NOUN F
between 0 ADP F
high 0 ADJ F
BP 0 NOUN T
and 0 CCONJ F
renal 0 ADJ F
damage 0 NOUN F
, 0 PUNCT F
this 0 DET F
study 0 NOUN F
raises 0 PUNCT F
the 0 DET F
question 0 NOUN F
on 0 ADP F
whether 0 PUNCT F
PR-STENT 0 NOUN T
should 0 VERB F
be 0 VERB F
performed 0 VERB F
in 0 ADP F
all 0 DET F
HTs 0 NOUN T
with 0 ADP F
unilateral 0 ADJ F
and 0 CCONJ F
incidental 0 DET F
RAS 0 NOUN T
. 0 PUNCT F

Perceptual B-OTHER ADJ T
wind-up I-OTHER NOUN F
in 0 ADP F
the 0 DET F
human 0 NOUN F
oesophagus 0 NOUN F
is 0 VERB F
enhanced 0 VERB F
by 0 ADP F
central 0 ADJ F
sensitisation 0 NOUN F
. 0 PUNCT F

BACKGROUND 0 NOUN T
Oesophageal 0 PUNCT T
acid 0 NOUN F
infusion 0 NOUN F
induces 0 NOUN F
enhanced 0 VERB F
pain 0 NOUN F
hypersensitivity 0 NOUN F
in 0 ADP F
non-acid 0 NOUN F
exposed 0 VERB F
upper 0 ADJ F
oesophagus 0 NOUN F
( 0 PUNCT F
secondary 0 ADJ F
hyperalgesia 0 CCONJ F
) 0 PUNCT F
in 0 ADP F
patients 0 NOUN F
with 0 ADP F
non-cardiac 0 PUNCT F
chest 0 NOUN F
pain 0 NOUN F
, 0 PUNCT F
thus 0 ADV F
suggesting 0 VERB F
central 0 ADJ F
sensitisation 0 NOUN F
contributes 0 NOUN F
to 0 ADP F
visceral 0 ADJ F
pain 0 NOUN F
hypersensitivity 0 NOUN F
in 0 ADP F
functional 0 ADJ F
gut 0 NOUN F
disorders 0 NOUN F
( 0 PUNCT F
FGD 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

Perceptual 0 ADJ T
wind-up 0 PUNCT F
( 0 PUNCT F
increased 0 VERB F
pain 0 NOUN F
perception 0 NOUN F
to 0 ADP F
constant 0 ADJ F
intensity 0 NOUN F
sensory 0 ADJ F
stimuli 0 NOUN F
at 0 ADP F
frequencies 0 NOUN F
> 0 SYM F
or=0.3 0 NOUN F
Hz 0 NOUN T
) 0 PUNCT F
is 0 VERB F
used 0 VERB F
as 0 ADP F
a 0 DET F
proxy 0 NOUN F
for 0 ADP F
central 0 ADJ F
sensitisation 0 NOUN F
to 0 PART F
investigate 0 ADJ F
pain 0 NOUN F
syndromes 0 NOUN F
where 0 ADP F
pain 0 NOUN F
hypersensitivity 0 NOUN F
is 0 VERB F
important 0 ADJ F
( 0 PUNCT F
for 0 ADP F
example 0 NOUN F
, 0 PUNCT F
fibromyalgia 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

AIMS 0 ADP T
Wind-up 0 PUNCT T
in 0 ADP F
central 0 ADJ F
sensitisation 0 NOUN F
induced 0 VERB F
human 0 NOUN F
visceral 0 ADJ F
pain 0 NOUN F
hypersensitivity 0 NOUN F
has 0 PUNCT F
not 0 ADV F
been 0 PUNCT F
explored 0 VERB F
. 0 PUNCT F

We 0 PRON T
hypothesised 0 VERB F
that 0 ADP F
if 0 VERB F
wind-up 0 PUNCT F
is 0 ADP F
a 0 DET F
proxy 0 NOUN F
for 0 ADP F
central 0 ADJ F
sensitisation 0 NOUN F
induced 0 VERB F
human 0 NOUN F
visceral 0 ADJ F
pain 0 NOUN F
hypersensitivity 0 NOUN F
, 0 PUNCT F
then 0 ADV F
oesophageal 0 ADJ F
wind-up 0 NOUN F
should 0 ADP F
be 0 VERB F
enhanced 0 VERB F
by 0 ADP F
secondary 0 ADJ F
hyperalgesia 0 CCONJ F
. 0 PUNCT F

METHODS 0 NOUN T
In 0 ADP T
eight 0 NUM F
healthy 0 ADJ F
volunteers 0 NOUN F
( 0 PUNCT F
seven 0 NUM F
males 0 NOUN F
; 0 PUNCT F
mean 0 NOUN F
age 0 NOUN F
32 0 NUM F
years 0 NOUN F
) 0 PUNCT F
, 0 PUNCT F
perception 0 NOUN F
at 0 ADP F
pain 0 NOUN F
threshold 0 NOUN F
to 0 ADP F
a 0 DET F
train 0 NOUN F
of 0 ADP F
20 0 NUM F
electrical 0 ADJ F
stimuli 0 NOUN F
applied 0 VERB F
to 0 ADP F
the 0 DET F
hand 0 NOUN F
and 0 CCONJ F
upper 0 ADJ F
oesophagus 0 NOUN F
( 0 PUNCT F
UO 0 NOUN T
) 0 PUNCT F
at 0 ADP F
either 0 CCONJ F
0.1 0 ADP F
Hz 0 NOUN T
( 0 PUNCT F
control 0 NOUN F
) 0 PUNCT F
or 0 CCONJ F
2 0 NUM F
Hz 0 NOUN T
was 0 VERB F
determined 0 VERB F
before 0 ADP F
and 0 CCONJ F
one 0 NUM F
hour 0 NOUN F
after 0 ADP F
a 0 DET F
30 0 NUM F
minute 0 ADJ F
lower 0 PUNCT F
oesophageal 0 ADJ F
acid 0 NOUN F
infusion 0 NOUN F
. 0 PUNCT F

RESULTS 0 ADP T
Wind-up B-OTHER PUNCT T
occurred 0 VERB F
only 0 ADV F
with 0 ADP F
the 0 DET F
2 0 NUM F
Hz 0 NOUN T
train 0 PUNCT F
in 0 ADP F
the 0 DET F
UO 0 NOUN T
and 0 CCONJ F
hand 0 NOUN F
( 0 PUNCT F
both 0 CCONJ F
p=0.01 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

Following 0 ADP T
acid 0 NOUN F
infusion 0 NOUN F
, 0 PUNCT F
pain B-PAIN NOUN F
threshold I-PAIN NOUN F
decreased 0 VERB F
( 0 PUNCT F
17 0 NUM F
( 0 PUNCT F
4 0 NUM F
) 0 PUNCT F
% 0 SYM F
; 0 PUNCT F
p=0.01 0 NOUN F
) 0 PUNCT F
in 0 ADP F
the 0 DET F
UO 0 NOUN T
, 0 PUNCT F
suggesting 0 VERB F
the 0 DET F
presence 0 NOUN F
of 0 ADP F
secondary 0 ADJ F
hyperalgesia 0 ADV F
. 0 PUNCT F

Wind-up B-OTHER PUNCT T
to I-OTHER ADP F
the I-OTHER DET F
2 I-OTHER NUM F
Hz I-OTHER NOUN T
train I-OTHER PUNCT F
increased 0 VERB F
in 0 ADP F
the 0 DET F
UO B-PHYSICAL NOUN T
( 0 PUNCT F
wind-up 0 PUNCT F
ratio 0 NOUN F
1.4 0 NUM F
( 0 PUNCT F
0.1 0 NUM F
) 0 PUNCT F
to 0 ADP F
1.6 0 NUM F
( 0 PUNCT F
0.1 0 NUM F
) 0 PUNCT F
; 0 PUNCT F
p=0.03 0 NOUN F
) 0 PUNCT F
but 0 CCONJ F
not 0 ADV F
in 0 ADP F
the 0 DET F
hand 0 NOUN F
( 0 PUNCT F
wind-up 0 PUNCT F
ratio 0 NOUN F
1.3 0 NUM F
( 0 PUNCT F
0.1 0 PUNCT F
) 0 PUNCT F
and 0 CCONJ F
1.3 0 NUM F
( 0 PUNCT F
0.1 0 NUM F
) 0 PUNCT F
; 0 PUNCT F
p=0.3 0 NOUN F
) 0 PUNCT F
CONCLUSION 0 NOUN T
Enhanced 0 ADV T
wind-up 0 PUNCT F
after 0 ADP F
secondary 0 ADJ F
oesophageal 0 ADJ F
hyperalgesia 0 NOUN F
suggests 0 ADJ F
that 0 ADP F
visceral 0 ADJ F
pain 0 NOUN F
hypersensitivity 0 NOUN F
induced 0 VERB F
by 0 ADP F
central 0 ADJ F
sensitisation 0 NOUN F
results 0 PROPN F
from 0 ADP F
increased 0 VERB F
central 0 ADJ F
neuronal 0 ADJ F
excitability 0 NOUN F
. 0 PUNCT F

Wind-up 0 PUNCT T
may 0 CCONJ F
offer 0 VERB F
new 0 ADJ F
opportunities 0 NOUN F
to 0 PART F
investigate 0 NOUN F
the 0 DET F
contribution 0 NOUN F
of 0 ADP F
central 0 ADJ F
neuronal 0 ADJ F
changes 0 NOUN F
to 0 PUNCT F
symptoms 0 PUNCT F
in 0 ADP F
FGD 0 NOUN T
. 0 PUNCT F

Treatment 0 NOUN T
outcome 0 NOUN F
of 0 ADP F
appliance 0 PUNCT F
therapy 0 NOUN F
in 0 ADP F
temporomandibular 0 ADJ F
disorder 0 NOUN F
patients 0 NOUN F
with 0 ADP F
myofascial B-PAIN ADJ F
pain I-PAIN NOUN F
after 0 ADP F
6 0 NUM F
and 0 CCONJ F
12 0 NUM F
months 0 NOUN F
. 0 PUNCT F

AIM 0 NOUN T
To 0 ADV T
compare 0 NOUN F
the 0 DET F
long-term 0 NOUN F
effect 0 NOUN F
of 0 ADP F
treatment 0 NOUN F
with 0 ADP F
a 0 DET F
stabilization 0 NOUN F
appliance 0 ADP F
( 0 PUNCT F
group 0 NOUN F
T 0 NOUN T
) 0 PUNCT F
and 0 CCONJ F
treatment 0 NOUN F
with 0 ADP F
a 0 DET F
control 0 NOUN F
appliance 0 ADP F
( 0 PUNCT F
group 0 NOUN F
C 0 NOUN T
) 0 PUNCT F
in 0 ADP F
temporomandibular 0 ADJ F
disorder 0 NOUN F
( 0 PUNCT F
TMD 0 NOUN T
) 0 PUNCT F
patients 0 NOUN F
with 0 ADP F
myofascial 0 ADJ F
pain 0 NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
In 0 ADP T
this 0 DET F
controlled 0 VERB F
trial 0 NOUN F
, 0 PUNCT F
60 0 NUM F
patients 0 NOUN F
( 0 PUNCT F
mean 0 NOUN F
age 0 NOUN F
29 0 NUM F
years 0 NOUN F
) 0 PUNCT F
with 0 ADP F
myofascial 0 ADJ F
pain 0 NOUN F
were 0 VERB F
evaluated 0 VERB F
after 0 ADP F
10 0 NUM F
weeks 0 NOUN F
of 0 ADP F
treatment 0 NOUN F
with 0 ADP F
either 0 CCONJ F
a 0 DET F
stabilization 0 NOUN F
appliance 0 ADP F
or 0 CCONJ F
a 0 DET F
control 0 ADP F
appliance 0 ADP F
. 0 PUNCT F

All 0 DET T
60 0 NUM F
patients 0 NOUN F
were 0 VERB F
then 0 ADV F
assigned 0 VERB F
to 0 ADP F
1 0 PUNCT F
of 0 ADP F
3 0 NUM F
groups 0 NOUN F
according 0 CCONJ F
to 0 ADP F
demand 0 NOUN F
for 0 ADP F
treatment 0 NOUN F
. 0 PUNCT F

Seventeen 0 PUNCT T
patients 0 NOUN F
from 0 ADP F
group 0 NOUN F
C 0 NOUN T
requested 0 VERB F
another 0 PUNCT F
appliance 0 ADP F
and 0 CCONJ F
were 0 VERB F
given 0 VERB F
a 0 DET F
stabilization 0 NOUN F
appliance 0 ADP F
, 0 PUNCT F
thus 0 ADV F
creating 0 PUNCT F
a 0 DET F
mixed 0 VERB F
group 0 NOUN F
( 0 PUNCT F
group 0 NOUN F
M 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

RESULTS 0 NOUN T
A 0 PUNCT T
significant 0 ADJ F
difference 0 NOUN F
in 0 ADP F
improvement 0 NOUN F
of 0 ADP F
overall B-PHYSICAL ADJ F
subjective I-PHYSICAL ADJ F
symptoms I-PHYSICAL NOUN F
in 0 ADP F
an 0 DET F
intent-to-treat 0 NOUN F
analysis 0 NOUN F
between 0 ADP F
groups 0 NOUN F
T 0 NOUN T
and 0 CCONJ F
C 0 NOUN T
was 0 VERB F
found 0 VERB F
at 0 ADP F
the 0 DET F
follow-ups 0 PUNCT F
. 0 PUNCT F

In 0 ADP T
a 0 DET F
survival 0 NOUN F
analysis 0 NOUN F
of 0 ADP F
treatment 0 NOUN F
compliance 0 NOUN F
, 0 PUNCT F
a 0 DET F
significant 0 ADJ F
difference 0 NOUN F
was 0 VERB F
found 0 VERB F
between 0 ADP F
groups 0 NOUN F
T 0 NOUN T
and 0 CCONJ F
C. 0 NOUN T
At 0 ADP T
the 0 DET F
6- 0 NUM F
and 0 CCONJ F
12-month 0 NOUN F
follow-ups 0 PUNCT F
, 0 PUNCT F
a 0 DET F
significant 0 ADJ F
reduction 0 NOUN F
in 0 ADP F
myofascial B-PAIN ADJ F
pain 0 NOUN F
, 0 PUNCT F
as 0 PUNCT F
measured 0 VERB F
on 0 ADP F
a 0 DET F
visual 0 ADJ F
analog 0 NOUN F
scale 0 NOUN F
, 0 PUNCT F
was 0 VERB F
found 0 VERB F
in 0 ADP F
all 0 DET F
three 0 NUM F
groups 0 NOUN F
. 0 PUNCT F

A 0 DET T
significant 0 ADJ F
decrease 0 NOUN F
in 0 ADP F
frequency 0 NOUN F
and 0 CCONJ F
intensity 0 NOUN F
of 0 ADP F
myofascial B-PAIN ADJ F
pain I-PAIN NOUN F
was 0 VERB F
found 0 VERB F
in 0 ADP F
group 0 NOUN F
T 0 NOUN T
at 0 ADP F
the 0 DET F
follow-ups 0 PUNCT F
. 0 PUNCT F

A 0 DET T
significant 0 ADJ F
decrease 0 NOUN F
in 0 ADP F
number 0 NOUN F
of 0 ADP F
tender B-PHYSICAL NOUN F
sites I-PHYSICAL NOUN F
on I-PHYSICAL ADP F
the I-PHYSICAL DET F
masticatory I-PHYSICAL ADJ F
muscles I-PHYSICAL NOUN F
was 0 VERB F
found 0 VERB F
in 0 ADP F
group 0 NOUN F
T 0 NOUN T
at 0 ADP F
the 0 DET F
follow-ups 0 PUNCT F
. 0 PUNCT F

CONCLUSION 0 NOUN T
The 0 DET T
results 0 NOUN F
support 0 VERB F
the 0 DET F
conclusion 0 NOUN F
that 0 ADP F
the 0 DET F
positive 0 ADJ F
treatment 0 NOUN F
outcome 0 NOUN F
obtained 0 VERB F
by 0 ADP F
use 0 NOUN F
of 0 ADP F
a 0 DET F
stabilization 0 NOUN F
appliance 0 CCONJ F
to 0 ADP F
alleviate 0 CCONJ F
the 0 DET F
signs 0 NOUN F
and 0 CCONJ F
symptoms 0 NOUN F
in 0 ADP F
patients 0 NOUN F
with 0 ADP F
myofascial 0 ADJ F
pain 0 NOUN F
persisted 0 VERB F
after 0 ADP F
6 0 NUM F
and 0 CCONJ F
12 0 NUM F
months 0 NOUN F
. 0 PUNCT F

Most 0 DET T
patients 0 NOUN F
in 0 ADP F
groups 0 NOUN F
T 0 NOUN T
and 0 CCONJ F
M 0 NOUN T
reported 0 ADP F
positive 0 ADJ F
changes 0 NOUN F
in 0 ADP F
overall B-PHYSICAL PUNCT F
subjective I-PHYSICAL ADJ F
symptoms I-PHYSICAL NOUN F
in 0 ADP F
this 0 DET F
trial 0 NOUN F
. 0 PUNCT F

We 0 PRON T
therefore 0 ADV F
recommend 0 VERB F
use 0 NOUN F
of 0 ADP F
the 0 DET F
stabilization 0 NOUN F
appliance 0 CCONJ F
in 0 ADP F
the 0 DET F
treatment 0 NOUN F
of 0 ADP F
TMD 0 NOUN T
patients 0 NOUN F
with 0 ADP F
myofascial B-PAIN ADJ F
pain I-PAIN NOUN F
. 0 PUNCT F

Local 0 ADJ T
warming 0 PROPN F
and 0 CCONJ F
insertion 0 NOUN F
of 0 ADP F
peripheral 0 ADJ F
venous 0 ADJ F
cannulas 0 ADJ F
: 0 PUNCT F
single 0 ADJ F
blinded 0 VERB F
prospective 0 ADJ F
randomised 0 VERB F
controlled 0 VERB F
trial 0 NOUN F
and 0 CCONJ F
single 0 ADJ F
blinded 0 VERB F
randomised 0 VERB F
crossover 0 NOUN F
trial 0 NOUN F
. 0 PUNCT F

OBJECTIVE 0 NOUN T
To 0 PROPN T
determine 0 NOUN F
whether 0 VERB F
local 0 ADJ F
warming 0 DET F
of 0 ADP F
the 0 DET F
lower 0 PUNCT F
arm 0 NOUN F
and 0 CCONJ F
hand 0 NOUN F
facilitates 0 PUNCT F
peripheral B-PHYSICAL ADJ F
venous I-PHYSICAL ADJ F
cannulation I-PHYSICAL NOUN F
. 0 PUNCT F

DESIGN 0 NOUN T
Single 0 PUNCT T
blinded 0 VERB F
prospective 0 ADJ F
randomised 0 VERB F
controlled 0 VERB F
trial 0 NOUN F
and 0 CCONJ F
single 0 ADJ F
blinded 0 VERB F
randomised 0 VERB F
crossover 0 NOUN F
trial 0 NOUN F
. 0 PUNCT F

SETTING 0 NUM T
Neurosurgical 0 ADJ T
unit 0 NOUN F
and 0 CCONJ F
haematology 0 NOUN F
ward 0 NOUN F
of 0 ADP F
university 0 NOUN F
hospital 0 NOUN F
. 0 PUNCT F

PARTICIPANTS 0 ADP T
100 0 NUM F
neurosurgical 0 ADJ F
patients 0 NOUN F
and 0 CCONJ F
40 0 NUM F
patients 0 NOUN F
with 0 ADP F
leukaemia 0 NOUN F
who 0 ADP F
required 0 VERB F
chemotherapy 0 NOUN F
. 0 PUNCT F

INTERVENTIONS 0 NOUN T
Neurosurgical 0 ADJ T
patients 0 NOUN F
' 0 PUNCT F
hands 0 NOUN F
and 0 CCONJ F
forearms 0 ADP F
were 0 ADV F
covered 0 VERB F
for 0 ADP F
15 0 NUM F
minutes 0 NOUN F
with 0 ADP F
a 0 DET F
carbon 0 NOUN F
fibre 0 NOUN F
heating 0 ADJ F
mitt 0 NOUN F
. 0 PUNCT F

Patients 0 NOUN T
were 0 VERB F
assigned 0 VERB F
randomly 0 ADV F
to 0 PUNCT F
active 0 ADJ F
warming 0 PUNCT F
at 0 ADP F
52 0 NUM F
degrees 0 NOUN F
C 0 NUM T
or 0 CCONJ F
passive 0 ADJ F
insulation 0 NOUN F
( 0 PUNCT F
heater 0 NOUN F
not 0 ADV F
activated 0 VERB F
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
same 0 ADJ F
warming 0 VERB F
system 0 NOUN F
was 0 VERB F
used 0 VERB F
for 0 ADP F
10 0 NUM F
minutes 0 NOUN F
in 0 ADP F
patients 0 NOUN F
with 0 ADP F
leukaemia 0 NOUN F
. 0 PUNCT F

They 0 PRON T
were 0 VERB F
assigned 0 VERB F
randomly 0 ADV F
to 0 PUNCT F
active 0 ADJ F
warming 0 ADP F
or 0 CCONJ F
passive 0 ADJ F
insulation 0 NOUN F
on 0 ADP F
day 0 NOUN F
1 0 NUM F
and 0 CCONJ F
given 0 VERB F
alternative 0 ADJ F
treatment 0 NOUN F
during 0 ADP F
the 0 DET F
subsequent 0 ADJ F
visit 0 NOUN F
. 0 PUNCT F

MAIN 0 ADJ T
OUTCOME 0 NOUN T
MEASURES 0 NOUN T
PRIMARY 0 ADP T
: 0 PUNCT F
success B-OTHER NOUN F
rate I-OTHER NOUN F
for I-OTHER ADP F
insertion I-OTHER NOUN F
of I-OTHER ADP F
18 I-OTHER NUM F
gauge I-OTHER ADJ F
cannula I-OTHER NOUN F
into I-OTHER ADP F
vein I-OTHER NOUN F
on I-OTHER ADP F
back I-OTHER ADP F
of I-OTHER ADP F
hand I-OTHER NOUN F
. 0 PUNCT F

SECONDARY 0 ADJ T
: 0 PUNCT F
time B-OTHER NOUN F
required I-OTHER ADJ F
for I-OTHER ADP F
successful I-OTHER ADJ F
cannulation I-OTHER NOUN F
. 0 PUNCT F

RESULTS 0 NOUN T
In 0 ADP T
neurosurgical 0 ADJ F
patients 0 NOUN F
, 0 PUNCT F
it 0 ADP F
took 0 PROPN F
36 0 NUM F
seconds 0 NOUN F
( 0 PUNCT F
95 0 NUM F
% 0 SYM F
confidence 0 NOUN F
interval 0 NOUN F
31 0 NUM F
to 0 ADP F
40 0 NUM F
seconds 0 NOUN F
) 0 PUNCT F
to 0 VERB F
insert B-OTHER PUNCT F
a I-OTHER DET F
cannula I-OTHER NOUN F
in 0 ADP F
the 0 DET F
active 0 ADJ F
warming 0 DET F
group 0 NOUN F
and 0 CCONJ F
62 0 NUM F
( 0 PUNCT F
50 0 NUM F
to 0 ADP F
74 0 PUNCT F
) 0 PUNCT F
seconds 0 NOUN F
in 0 ADP F
the 0 DET F
passive 0 ADJ F
insulation 0 NOUN F
group 0 NOUN F
( 0 PUNCT F
P=0.002 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

Three 0 NUM T
( 0 PUNCT F
6 0 NUM F
% 0 SYM F
) 0 PUNCT F
first 0 VERB F
attempts 0 PUNCT F
failed B-OTHER PUNCT F
in 0 ADP F
the 0 DET F
active 0 ADJ F
warming 0 DET F
group 0 NOUN F
compared 0 VERB F
with 0 ADP F
14 0 NUM F
( 0 PUNCT F
28 0 NUM F
% 0 SYM F
) 0 PUNCT F
in 0 ADP F
the 0 DET F
passive 0 ADJ F
insulation 0 NOUN F
group 0 NOUN F
( 0 PUNCT F
P=0.008 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
crossover 0 NOUN F
study 0 NOUN F
in 0 ADP F
patients 0 NOUN F
with 0 ADP F
leukaemia 0 NOUN F
showed 0 VERB F
that 0 ADP F
insertion B-OTHER NOUN F
time I-OTHER NOUN F
was 0 VERB F
reduced 0 VERB F
by 0 ADP F
20 0 NUM F
seconds 0 NOUN F
( 0 PUNCT F
8 0 NUM F
to 0 ADP F
32 0 NUM F
, 0 PUNCT F
P=0.013 0 NOUN T
) 0 PUNCT F
with 0 ADP F
active 0 ADJ F
warming 0 PROPN F
and 0 CCONJ F
that 0 ADP F
failure B-OTHER NOUN F
rates I-OTHER NOUN F
at I-OTHER ADP F
first I-OTHER VERB F
attempt I-OTHER NOUN F
were 0 VERB F
6 0 NUM F
% 0 SYM F
with 0 ADP F
warming 0 PROPN F
and 0 CCONJ F
30 0 NUM F
% 0 SYM F
with 0 ADP F
passive 0 ADJ F
insulation 0 NOUN F
( 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.001 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

CONCLUSIONS 0 NOUN T
Local 0 ADJ T
warming 0 ADP F
facilitates 0 DET F
the 0 DET F
insertion 0 NOUN F
of 0 ADP F
peripheral B-OTHER ADJ F
venous I-OTHER ADJ F
cannulas I-OTHER ADP F
, 0 PUNCT F
reducing 0 ADP F
both 0 PUNCT F
time B-OTHER NOUN F
and I-OTHER CCONJ F
number I-OTHER NOUN F
of I-OTHER ADP F
attempts I-OTHER CCONJ F
required I-OTHER VERB F
. 0 PUNCT F

This 0 PUNCT T
may 0 CCONJ F
decrease 0 VERB F
the 0 DET F
time 0 NOUN F
staff 0 NOUN F
spend 0 NOUN F
inserting B-OTHER PUNCT F
cannulas I-OTHER ADP F
, 0 PUNCT F
reduce 0 PART F
supply B-OTHER NOUN F
costs I-OTHER NOUN F
, 0 PUNCT F
and 0 CCONJ F
improve 0 VERB F
patient 0 NOUN F
satisfaction 0 NOUN F
. 0 PUNCT F

[ 0 PUNCT F
Opiate 0 ADJ T
hypothesis 0 NOUN F
in 0 ADP F
infantile 0 ADJ F
autism 0 NOUN F
? 0 PUNCT F

Therapeutic 0 ADJ T
trials 0 NOUN F
with 0 ADP F
naltrexone 0 NUM F
] 0 PUNCT F
. 0 PUNCT F

The 0 DET T
opioid 0 NOUN F
hypothesis 0 NOUN F
suggests 0 NOUN F
that 0 ADP F
childhood 0 NOUN F
autism 0 NOUN F
may 0 VERB F
result 0 VERB F
from 0 ADP F
excessive 0 ADJ F
brain 0 NOUN F
opioid 0 NOUN F
activity 0 NOUN F
during 0 ADP F
neonatal 0 ADJ F
period 0 NOUN F
which 0 ADP F
may 0 VERB F
constitutionally 0 ADV F
inhibit 0 VERB F
social 0 ADJ F
motivation 0 NOUN F
, 0 PUNCT F
yielding 0 PUNCT F
autistic 0 ADJ F
isolation 0 NOUN F
and 0 CCONJ F
aloofness 0 NOUN F
( 0 PUNCT F
Panksepp 0 PUNCT T
, 0 PUNCT F
1979 0 PUNCT F
) 0 PUNCT F
. 0 PUNCT F

This 0 DET T
hypothesis 0 NOUN F
has 0 PUNCT F
now 0 ADV F
received 0 VERB F
strong 0 ADJ F
support 0 NOUN F
and 0 CCONJ F
is 0 VERB F
currently 0 ADV F
based 0 VERB F
on 0 ADP F
three 0 NUM F
types 0 NOUN F
of 0 ADP F
arguments 0 NOUN F
: 0 PUNCT F
( 0 PUNCT F
1 0 NUM F
) 0 PUNCT F
similarity 0 NOUN F
between 0 ADP F
autistic 0 ADJ F
symptomatology 0 NOUN F
and 0 CCONJ F
abnormal 0 ADJ F
behaviors 0 NOUN F
induced 0 VERB F
in 0 ADP F
young 0 ADJ F
animals 0 NOUN F
by 0 ADP F
injections 0 NOUN F
of 0 ADP F
exogenous 0 ADJ F
opioids 0 NOUN F
, 0 PUNCT F
such 0 PUNCT F
as 0 ADP F
increasing 0 VERB F
social 0 ADJ F
aloofness 0 NOUN F
and 0 CCONJ F
decreasing 0 ADJ F
social 0 ADJ F
vocalization 0 ADJ F
; 0 PUNCT F
( 0 PUNCT F
2 0 NUM F
) 0 PUNCT F
direct 0 ADJ F
biochemical 0 ADJ F
evidence 0 NOUN F
of 0 ADP F
abnormalities 0 NOUN F
of 0 ADP F
peripheral 0 ADJ F
endogenous 0 ADJ F
opioids 0 NOUN F
being 0 DET F
reported 0 VERB F
in 0 ADP F
autism 0 NOUN F
and 0 CCONJ F
( 0 PUNCT F
3 0 NUM F
) 0 PUNCT F
therapeutic 0 ADJ F
effects 0 NOUN F
of 0 ADP F
the 0 DET F
long 0 ADJ F
lasting 0 ADP F
opioid 0 NOUN F
receptor 0 NOUN F
blocking 0 DET F
agent 0 NOUN F
naltrexone 0 NUM F
in 0 ADP F
autism 0 NOUN F
. 0 PUNCT F

In 0 ADP T
this 0 DET F
article 0 NOUN F
, 0 PUNCT F
we 0 PRON F
give 0 VERB F
description 0 NOUN F
of 0 ADP F
open 0 ADJ F
and 0 CCONJ F
double-blind 0 ADJ F
studies 0 NOUN F
of 0 ADP F
naltrexone 0 NUM F
in 0 ADP F
autism 0 NOUN F
. 0 PUNCT F

Naltrexone 0 NUM T
has 0 PUNCT F
been 0 PUNCT F
tested 0 VERB F
in 0 ADP F
several 0 ADJ F
open 0 ADJ F
studies 0 NOUN F
. 0 PUNCT F

We 0 PRON T
performed 0 VERB F
an 0 DET F
open 0 ADJ F
trial 0 NOUN F
with 0 ADP F
naltrexone 0 NUM F
in 0 ADP F
2 0 NUM F
autistic 0 ADJ F
girls 0 NOUN F
, 0 PUNCT F
displaying 0 ADP F
serious 0 ADJ F
self-injurious 0 ADJ F
behavior 0 NOUN F
, 0 PUNCT F
reduced 0 ADJ F
crying 0 PROPN F
and 0 CCONJ F
a 0 DET F
marked 0 VERB F
preference 0 NOUN F
for 0 ADP F
salty 0 NOUN F
and 0 CCONJ F
spicy 0 NUM F
foods 0 NOUN F
, 0 PUNCT F
symptoms 0 NOUN F
that 0 ADP F
could 0 ADJ F
be 0 VERB F
related 0 VERB F
to 0 ADP F
a 0 DET F
dysfunction 0 NOUN F
of 0 ADP F
the 0 DET F
opioid 0 NOUN F
system 0 NOUN F
. 0 PUNCT F

With 0 ADP T
dosages 0 NOUN F
of 0 ADP F
1 0 NUM F
mg/kg/day 0 PUNCT F
, 0 PUNCT F
we 0 NOUN F
observed 0 VERB F
an 0 DET F
immediate 0 ADJ F
reduction 0 NOUN F
of 0 ADP F
hyperactivity B-MENTAL NOUN F
, 0 PUNCT F
self-injurious B-MENTAL ADJ F
behavior I-MENTAL NOUN F
and 0 CCONJ F
aggressiveness B-MENTAL ADP F
, 0 PUNCT F
while B-MENTAL ADP F
attention I-MENTAL NOUN F
improved 0 VERB F
. 0 PUNCT F

In 0 ADP T
addition 0 NOUN F
, 0 PUNCT F
social B-MENTAL ADJ F
behaviors I-MENTAL NOUN F
, 0 PUNCT F
smiling B-MENTAL PUNCT F
, 0 PUNCT F
social B-MENTAL ADJ F
seeking I-MENTAL PUNCT F
behaviors I-MENTAL NOUN F
and 0 CCONJ F
play B-MENTAL ADJ F
interactions I-MENTAL NOUN F
increased 0 VERB F
( 0 PUNCT F
Leboyer 0 NOUN T
, 0 PUNCT F
Bouvard 0 PUNCT T
et 0 CCONJ F
Dugas 0 NOUN T
, 0 PUNCT F
1988 0 PUNCT F
) 0 PUNCT F
. 0 PUNCT F

Campbell 0 PUNCT T
et 0 CCONJ F
al 0 NOUN F
. 0 PUNCT F
( 0 PUNCT F

1988 0 NUM F
) 0 PUNCT F
has 0 PUNCT F
also 0 ADV F
reported 0 VERB F
a 0 DET F
tranquilizing B-MENTAL VERB F
and I-MENTAL CCONJ F
a I-MENTAL DET F
stimulating I-MENTAL ADJ F
effect 0 NOUN F
in 0 ADP F
6 0 NUM F
out 0 PUNCT F
of 0 ADP F
8 0 NUM F
children 0 NOUN F
with 0 ADP F
autism 0 NOUN F
. 0 PUNCT F

We 0 PRON T
did 0 CCONJ F
confirm 0 VERB F
these 0 DET F
preliminary 0 ADJ F
results 0 DET F
in 0 ADP F
a 0 DET F
double-blind 0 ADJ F
study 0 NOUN F
performed 0 VERB F
on 0 ADP F
4 0 NUM F
children 0 NOUN F
with 0 ADP F
autism 0 NOUN F
. 0 PUNCT F

In 0 ADP T
a 0 DET F
cross-over 0 NOUN F
double-blind 0 ADJ F
study 0 NOUN F
, 0 PUNCT F
three 0 NUM F
dosages 0 NOUN F
of 0 ADP F
naltrexone 0 NUM F
( 0 PUNCT F
0.5 0 NUM F
, 0 PUNCT F
1 0 NUM F
and 0 CCONJ F
2 0 NUM F
mg/kg/day 0 NOUN F
) 0 PUNCT F
and 0 CCONJ F
placebo 0 NOUN F
were 0 VERB F
compared 0 VERB F
. 0 PUNCT F
( 0 PUNCT F

ABSTRACT 0 ADP T
TRUNCATED 0 PUNCT T
AT 0 ADP T
250 0 NUM F
WORDS 0 NOUN T
) 0 PUNCT F

Effects 0 NOUN T
of 0 ADP F
mecamylamine 0 PUNCT F
on 0 ADP F
human 0 NOUN F
cigarette 0 NOUN F
smoking 0 VERB F
and 0 CCONJ F
subjective 0 ADJ F
ratings 0 NOUN F
. 0 PUNCT F

Multiple 0 ADJ T
measures 0 NOUN F
of 0 ADP F
cigarette 0 NOUN F
smoking 0 VERB F
, 0 PUNCT F
subjective 0 ADJ F
effect 0 NOUN F
and 0 CCONJ F
physiological 0 ADJ F
effect 0 NOUN F
were 0 VERB F
collected 0 VERB F
during 0 ADP F
90-min 0 NOUN F
test 0 NUM F
sessions 0 NOUN F
in 0 ADP F
normal 0 ADJ F
volunteers 0 NOUN F
. 0 PUNCT F

Before 0 ADP T
sessions 0 PUNCT F
subjects 0 NOUN F
received 0 VERB F
oral 0 ADJ F
doses 0 NOUN F
of 0 ADP F
mecamylamine 0 NOUN F
( 0 PUNCT F
2.5 0 NUM F
, 0 PUNCT F
5.0 0 NUM F
, 0 PUNCT F
10 0 NUM F
, 0 PUNCT F
20 0 NUM F
mg 0 NOUN F
) 0 PUNCT F
or 0 CCONJ F
placebo 0 NOUN F
. 0 PUNCT F

Each 0 DET T
dose 0 NOUN F
and 0 CCONJ F
placebo 0 NOUN F
was 0 VERB F
given 0 VERB F
three 0 NUM F
times 0 NOUN F
in 0 ADP F
a 0 DET F
randomized 0 VERB F
block 0 NOUN F
sequence 0 NOUN F
. 0 PUNCT F

Mecamylamine 0 NOUN T
increased 0 CCONJ F
several 0 ADJ F
measures 0 NOUN F
of 0 ADP F
cigarette 0 NOUN F
smoking 0 VERB F
, 0 PUNCT F
including 0 CCONJ F
number B-PHYSICAL NOUN F
of I-PHYSICAL ADP F
cigarettes I-PHYSICAL NOUN F
, 0 PUNCT F
number 0 NOUN F
of 0 ADP F
puffs B-PHYSICAL PUNCT F
per I-PHYSICAL ADP F
cigarette I-PHYSICAL NOUN F
, 0 PUNCT F
and 0 CCONJ F
expired B-PHYSICAL ADP F
air I-PHYSICAL NOUN F
carbon I-PHYSICAL NOUN F
monoxide I-PHYSICAL NOUN F
level I-PHYSICAL NOUN F
. 0 PUNCT F

Mecamylamine 0 ADV T
also 0 ADV F
produced 0 ADP F
modest 0 ADJ F
, 0 PUNCT F
dose-related 0 VERB F
decreases 0 CCONJ F
in 0 ADP F
standing 0 NUM F
blood B-PHYSICAL NOUN F
pressure I-PHYSICAL NOUN F
and 0 CCONJ F
increases 0 NOUN F
in 0 ADP F
standing B-PHYSICAL NUM F
heart I-PHYSICAL NOUN F
rate I-PHYSICAL NOUN F
. 0 PUNCT F

The 0 DET T
subjective 0 ADJ F
effects 0 NOUN F
produced 0 VERB F
by 0 ADP F
mecamylamine 0 PUNCT F
were 0 VERB F
not 0 ADV F
characteristic 0 ADJ F
of 0 ADP F
those 0 PUNCT F
of 0 ADP F
psychoactive 0 ADJ F
drugs 0 NOUN F
. 0 PUNCT F

Mecamylamine 0 ADV T
appears 0 PART F
to 0 PUNCT F
have 0 PUNCT F
increased 0 DET F
cigarette 0 NOUN F
smoking 0 VERB F
by 0 ADP F
decreasing 0 VERB F
the 0 DET F
effective 0 ADJ F
dose 0 NOUN F
level 0 NOUN F
of 0 ADP F
nicotine 0 NOUN F
available 0 ADJ F
from 0 ADP F
cigarette 0 NOUN F
smoking 0 VERB F
. 0 PUNCT F

Monitoring 0 ADV T
acute 0 ADJ F
effects 0 NOUN F
on 0 ADP F
athletic 0 ADJ F
performance 0 NOUN F
with 0 ADP F
mixed 0 VERB F
linear 0 ADJ F
modeling 0 PUNCT F
. 0 PUNCT F

UNLABELLED 0 NOUN T
There 0 PUNCT T
is 0 VERB F
a 0 DET F
need 0 NOUN F
for 0 ADP F
a 0 DET F
sophisticated 0 PUNCT F
approach 0 NOUN F
to 0 PART F
track 0 CCONJ F
athletic 0 ADJ F
performance 0 NOUN F
and 0 CCONJ F
to 0 PUNCT F
quantify 0 NOUN F
factors 0 NOUN F
affecting 0 VERB F
it 0 NUM F
in 0 ADP F
practical 0 ADJ F
settings 0 NOUN F
. 0 PUNCT F

PURPOSE 0 NOUN T
To 0 ADJ T
demonstrate 0 ADJ F
the 0 DET F
application 0 NOUN F
of 0 ADP F
mixed 0 VERB F
linear 0 ADJ F
modeling 0 PUNCT F
for 0 ADP F
monitoring 0 VERB F
athletic 0 ADJ F
performance 0 NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
Elite 0 ADJ T
sprint 0 NOUN F
and 0 CCONJ F
middle-distance 0 ADP F
swimmers 0 NOUN F
( 0 PUNCT F
three 0 NUM F
females 0 NOUN F
and 0 CCONJ F
six 0 NUM F
males 0 NOUN F
; 0 PUNCT F
aged 0 PUNCT F
21-26 0 NUM F
yr 0 NOUN F
) 0 PUNCT F
performed 0 DET F
6-13 0 DET F
time 0 NOUN F
trials 0 NOUN F
in 0 ADP F
training 0 VERB F
and 0 CCONJ F
competition 0 NOUN F
in 0 ADP F
the 0 DET F
9 0 NUM F
wk 0 NOUN F
before 0 ADP F
and 0 CCONJ F
including 0 PUNCT F
Olympic-qualifying 0 ADJ T
trials 0 NOUN F
, 0 PUNCT F
all 0 CCONJ F
in 0 ADP F
their 0 PUNCT F
specialty 0 NOUN F
event 0 NOUN F
. 0 PUNCT F

We 0 PRON T
included 0 VERB F
a 0 DET F
double-blind 0 ADJ F
, 0 PUNCT F
randomized 0 VERB F
, 0 PUNCT F
diet-controlled 0 PUNCT F
crossover 0 NOUN F
intervention 0 NOUN F
, 0 PUNCT F
in 0 ADP F
which 0 ADP F
the 0 DET F
swimmers 0 NOUN F
consumed 0 PUNCT F
caffeine 0 NOUN F
( 0 PUNCT F
5 0 NUM F
mg 0 NOUN F
x 0 SYM F
kg 0 NOUN F
( 0 PUNCT F
-1 0 NUM F
) 0 PUNCT F
body 0 NOUN F
mass 0 NOUN F
) 0 PUNCT F
or 0 CCONJ F
placebo 0 NOUN F
. 0 PUNCT F

The 0 DET T
swimmers 0 NOUN F
also 0 ADV F
knowingly 0 ADV F
consumed 0 PUNCT F
varying 0 VERB F
doses 0 NOUN F
of 0 ADP F
caffeine 0 NOUN F
in 0 ADP F
some 0 DET F
time 0 NOUN F
trials 0 NOUN F
. 0 PUNCT F

We 0 PRON T
used 0 DET F
mixed 0 NOUN F
linear 0 ADJ F
modeling 0 VERB F
of 0 ADP F
log-transformed 0 PUNCT F
swim 0 PUNCT F
time 0 NOUN F
to 0 PART F
quantify 0 NOUN F
effects B-OTHER NOUN F
on I-OTHER ADP F
performance I-OTHER NOUN F
in 0 ADP F
training 0 VERB F
versus 0 CCONJ F
competition 0 NOUN F
, 0 PUNCT F
in 0 ADP F
morning 0 NOUN F
versus 0 CCONJ F
evening 0 NOUN F
swims 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
with 0 ADP F
use 0 NOUN F
of 0 ADP F
caffeine 0 NOUN F
. 0 PUNCT F

Predictor 0 NOUN T
variables 0 NOUN F
were 0 VERB F
coded 0 VERB F
as 0 ADP F
0 0 NUM F
or 0 CCONJ F
1 0 NUM F
to 0 PUNCT F
represent 0 ADJ F
absence 0 NOUN F
or 0 CCONJ F
presence 0 NOUN F
, 0 PUNCT F
respectively 0 ADV F
, 0 PUNCT F
of 0 ADP F
each 0 DET F
condition 0 NOUN F
and 0 CCONJ F
were 0 VERB F
included 0 VERB F
as 0 PUNCT F
fixed 0 ADJ F
effects 0 NOUN F
. 0 PUNCT F

The 0 DET T
date 0 NOUN F
of 0 ADP F
each 0 DET F
performance 0 NOUN F
test 0 NOUN F
was 0 VERB F
included 0 VERB F
as 0 ADP F
a 0 DET F
continuous 0 ADJ F
linear 0 ADJ F
fixed 0 VERB F
effect 0 NOUN F
and 0 CCONJ F
interacted 0 DET F
with 0 ADP F
the 0 DET F
random 0 ADJ F
effect 0 NOUN F
for 0 ADP F
the 0 DET F
athlete 0 NOUN F
to 0 ADP F
represent 0 ADJ F
individual 0 ADJ F
differences 0 NOUN F
in 0 ADP F
linear 0 ADJ F
trends 0 NOUN F
in 0 ADP F
performance 0 NOUN F
. 0 PUNCT F

RESULTS 0 PUNCT T
Most 0 PUNCT T
effects 0 NOUN F
were 0 VERB F
clear 0 ADJ F
, 0 PUNCT F
owing 0 PUNCT F
to 0 ADP F
the 0 DET F
high 0 ADJ F
reliability 0 NOUN F
of 0 ADP F
performance 0 NOUN F
times 0 NOUN F
in 0 ADP F
training 0 VERB F
and 0 CCONJ F
competition 0 NOUN F
( 0 PUNCT F
typical 0 ADJ F
errors 0 NOUN F
of 0 ADP F
0.9 0 NUM F
% 0 SYM F
and 0 CCONJ F
0.8 0 NUM F
% 0 SYM F
, 0 PUNCT F
respectively 0 ADV F
) 0 PUNCT F
. 0 PUNCT F

Performance B-OTHER NOUN T
time I-OTHER NOUN F
improved 0 VERB F
linearly 0 ADV F
by 0 ADP F
0.8 0 NUM F
% 0 SYM F
per 0 ADP F
4 0 NUM F
wk 0 NOUN F
. 0 PUNCT F

The 0 DET T
swimmers 0 NOUN F
performed B-OTHER ADJ F
substantially I-OTHER ADV F
better I-OTHER PUNCT F
in 0 ADP F
evenings 0 NOUN F
versus 0 CCONJ F
mornings 0 NOUN F
and 0 CCONJ F
in 0 ADP F
competition 0 NOUN F
versus 0 CCONJ F
training 0 VERB F
. 0 PUNCT F

A 0 DET T
100-mg 0 NOUN F
dose 0 NOUN F
of 0 ADP F
caffeine 0 NOUN F
enhanced 0 ADJ F
performance 0 NOUN F
in 0 ADP F
training B-OTHER VERB F
and 0 CCONJ F
competition B-OTHER NOUN F
by 0 ADP F
approximately 0 ADV F
1.3 0 NUM F
% 0 SYM F
. 0 PUNCT F

There 0 PUNCT T
were 0 VERB F
substantial 0 ADJ F
but 0 CCONJ F
unclear 0 ADJ F
individual 0 ADJ F
responses 0 NOUN F
to 0 ADP F
training 0 ADV F
and 0 CCONJ F
caffeine 0 NOUN F
( 0 PUNCT F
SD 0 NOUN T
of 0 ADP F
0.3 0 NUM F
% 0 SYM F
and 0 CCONJ F
0.8 0 NUM F
% 0 SYM F
, 0 PUNCT F
respectively 0 ADV F
) 0 PUNCT F
. 0 PUNCT F

CONCLUSIONS 0 NOUN T
Mixed 0 NOUN T
linear 0 ADJ F
modeling 0 VERB F
can 0 VERB F
be 0 VERB F
applied 0 VERB F
successfully 0 ADV F
to 0 ADP F
monitor 0 NOUN F
factors 0 NOUN F
affecting 0 VERB F
performance 0 NOUN F
in 0 ADP F
a 0 DET F
squad 0 NOUN F
of 0 ADP F
elite 0 ADJ F
athletes 0 NOUN F
. 0 PUNCT F

Bradykinin-induced 0 VERB T
cough 0 NOUN F
reflex 0 NOUN F
markedly 0 ADV F
increases 0 PUNCT F
in 0 ADP F
patients 0 NOUN F
with 0 ADP F
cough 0 NOUN F
associated 0 VERB F
with 0 ADP F
captopril 0 NOUN F
and 0 CCONJ F
enalapril 0 NOUN F
. 0 PUNCT F

We 0 PRON T
studied 0 VERB F
the 0 DET F
effects 0 NOUN F
of 0 ADP F
angiotensin 0 NOUN F
converting 0 VERB F
enzyme 0 NOUN F
( 0 PUNCT F
ACE 0 NOUN T
) 0 PUNCT F
inhibitors 0 NOUN F
on 0 ADP F
cough B-ADVERSE-EFFECTS NOUN F
responses I-ADVERSE-EFFECTS NOUN F
to 0 ADP F
bradykinin 0 NOUN F
( 0 PUNCT F
BK 0 NOUN T
) 0 PUNCT F
, 0 PUNCT F
substance 0 NOUN F
P 0 NOUN T
( 0 PUNCT F
SP 0 NOUN T
) 0 PUNCT F
and 0 CCONJ F
citric 0 ADJ F
acid 0 NOUN F
in 0 ADP F
a 0 DET F
double 0 ADJ F
blind 0 NOUN F
, 0 PUNCT F
random 0 ADJ F
study 0 NOUN F
on 0 ADP F
10 0 NUM F
hypertensive 0 ADJ F
patients 0 NOUN F
receiving 0 DET F
ACE 0 NOUN T
inhibitors 0 NOUN F
. 0 PUNCT F

Of 0 ADP T
these 0 DET F
patients 0 NOUN F
, 0 PUNCT F
five 0 NUM F
had 0 PUNCT F
reported 0 PUNCT F
cough 0 NOUN F
with 0 ADP F
ACE 0 NOUN T
inhibitors 0 NOUN F
. 0 PUNCT F

Cough 0 NOUN T
responses 0 NOUN F
to 0 ADP F
citric 0 ADJ F
acid 0 NOUN F
were 0 VERB F
similar 0 ADJ F
between 0 ADP F
patients 0 NOUN F
with 0 ADP F
and 0 CCONJ F
without 0 ADP F
cough 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
SP 0 NOUN T
up 0 PUNCT F
to 0 ADP F
10 0 NUM F
( 0 PUNCT F
-5 0 NUM F
) 0 PUNCT F
M 0 NOUN T
did 0 PUNCT F
not 0 ADV F
cause 0 ADP F
cough 0 NOUN F
in 0 ADP F
any 0 PUNCT F
of 0 ADP F
the 0 DET F
subjects 0 NOUN F
. 0 PUNCT F

BK 0 NOUN T
caused 0 PUNCT F
cough B-ADVERSE-EFFECTS NOUN F
at 0 ADP F
13.4 0 NUM F
+/- 0 SYM F
1.2 0 NUM F
( 0 PUNCT F
-log 0 NOUN F
M 0 NOUN T
) 0 PUNCT F
in 0 ADP F
5 0 NUM F
patients 0 NOUN F
with 0 ADP F
cough 0 NOUN F
associated 0 VERB F
with 0 ADP F
ACE 0 NOUN T
inhibitors 0 NOUN F
, 0 PUNCT F
but 0 CCONJ F
it 0 PRON F
did 0 VERB F
not 0 ADV F
cause 0 ADP F
cough B-ADVERSE-EFFECTS NOUN F
at 0 ADP F
concentrations 0 NOUN F
up 0 PUNCT F
to 0 ADP F
10 0 NUM F
( 0 PUNCT F
-5 0 NUM F
) 0 PUNCT F
M 0 NOUN T
in 0 ADP F
other 0 ADJ F
5 0 NUM F
patients 0 NOUN F
. 0 PUNCT F

One 0 NUM T
month 0 NOUN F
after 0 ADP F
the 0 DET F
withdrawal 0 NOUN F
of 0 ADP F
ACE 0 NOUN T
inhibitors 0 NOUN F
, 0 PUNCT F
5 0 NUM F
patients 0 NOUN F
were 0 VERB F
free 0 ADJ F
from 0 ADP F
cough B-PHYSICAL NOUN F
symptoms I-PHYSICAL NOUN F
, 0 PUNCT F
and 0 CCONJ F
BK 0 NOUN T
did 0 PUNCT F
not 0 ADV F
cause 0 ADP F
cough B-PHYSICAL NOUN F
up 0 PUNCT F
to 0 ADP F
10 0 NUM F
( 0 PUNCT F
-5 0 NUM F
) 0 PUNCT F
M 0 NOUN T
in 0 ADP F
these 0 DET F
patients 0 NOUN F
, 0 PUNCT F
except 0 PUNCT F
for 0 ADP F
one 0 NUM F
who 0 ADP F
coughed 0 CCONJ F
at 0 ADP F
10 0 NUM F
( 0 PUNCT F
-9 0 NUM F
) 0 PUNCT F
M 0 NOUN T
, 0 PUNCT F
without 0 ADP F
changes 0 NOUN F
in 0 ADP F
responses 0 NOUN F
to 0 ADP F
citric 0 ADJ F
acid 0 NOUN F
. 0 PUNCT F

BK 0 NOUN T
caused 0 PUNCT F
cough B-PHYSICAL NOUN F
at 0 ADP F
14.3 0 NUM F
+/- 0 SYM F
0.7 0 NUM F
( 0 PUNCT F
-log 0 NOUN F
M 0 NOUN T
) 0 PUNCT F
although 0 ADP F
BK1-7 0 NUM T
, 0 PUNCT F
a 0 DET F
major 0 ADJ F
metabolite 0 NOUN F
of 0 ADP F
BK 0 NOUN T
by 0 ADP F
ACE 0 NOUN T
, 0 PUNCT F
caused 0 VERB F
cough B-PHYSICAL NOUN F
at 0 ADP F
5.7 0 NUM F
+/- 0 SYM F
0.7 0 NUM F
( 0 PUNCT F
-log 0 NOUN F
M 0 NOUN T
) 0 PUNCT F
in 0 ADP F
another 0 DET F
3 0 NUM F
patients 0 NOUN F
with 0 ADP F
cough 0 NOUN F
associated 0 VERB F
with 0 ADP F
ACE 0 NOUN T
inhibitor 0 NOUN F
. 0 PUNCT F

These 0 DET T
results 0 CCONJ F
suggest 0 VERB F
that 0 ADP F
impaired 0 VERB F
metabolism 0 NOUN F
of 0 ADP F
BK 0 NOUN T
induced 0 VERB F
by 0 ADP F
ACE 0 NOUN T
inhibitors 0 NOUN F
may 0 VERB F
relate 0 PUNCT F
to 0 ADP F
the 0 DET F
manifestation 0 NOUN F
of 0 ADP F
cough 0 NOUN F
in 0 ADP F
hypertensive 0 ADJ F
patients 0 NOUN F
receiving 0 DET F
ACE 0 NOUN T
inhibitors 0 NOUN F
. 0 PUNCT F

Marimastat 0 NOUN T
as 0 ADP F
maintenance 0 NOUN F
therapy 0 NOUN F
for 0 ADP F
patients 0 NOUN F
with 0 ADP F
advanced 0 VERB F
gastric 0 ADJ F
cancer 0 NOUN F
: 0 PUNCT F
a 0 DET F
randomised 0 VERB F
trial 0 NOUN F
. 0 PUNCT F

This 0 DET T
randomised 0 VERB F
, 0 PUNCT F
double-blind 0 ADJ F
, 0 PUNCT F
placebo-controlled 0 VERB F
study 0 NOUN F
was 0 VERB F
designed 0 VERB F
to 0 PART F
evaluate 0 NOUN F
the 0 DET F
ability 0 NOUN F
of 0 ADP F
the 0 DET F
orally 0 ADV F
administered 0 VERB F
matrix 0 NOUN F
metalloproteinase 0 NOUN F
inhibitor 0 NOUN F
, 0 PUNCT F
marimastat 0 NOUN F
, 0 PUNCT F
to 0 PART F
prolong 0 NOUN F
survival B-MORTALITY NOUN F
in 0 ADP F
patients 0 NOUN F
with 0 ADP F
non-resectable 0 ADJ F
gastric 0 ADJ F
and 0 CCONJ F
gastro-oesophageal 0 ADJ F
adenocarcinoma 0 NOUN F
. 0 PUNCT F

Three 0 NUM T
hundred 0 NUM F
and 0 CCONJ F
sixty-nine 0 NOUN F
patients 0 NOUN F
with 0 ADP F
histological 0 ADJ F
proof 0 NOUN F
of 0 ADP F
adenocarcinoma 0 NOUN F
, 0 PUNCT F
who 0 ADP F
had 0 PUNCT F
received 0 PUNCT F
no 0 DET F
more 0 ADV F
than 0 PUNCT F
a 0 DET F
single 0 ADJ F
regimen 0 NOUN F
of 0 ADP F
5-fluorouracil-based 0 VERB F
chemotherapy 0 NOUN F
, 0 PUNCT F
were 0 VERB F
randomised 0 VERB F
to 0 PART F
receive 0 ADP F
either 0 PUNCT F
marimastat 0 NOUN F
( 0 PUNCT F
10 0 NUM F
mg 0 NOUN F
b.d 0 NOUN F
. 0 PUNCT F
) 0 PUNCT F

or 0 CCONJ F
placebo 0 NOUN F
. 0 PUNCT F

Patients 0 NOUN T
were 0 VERB F
treated 0 VERB F
for 0 ADP F
as 0 VERB F
long 0 VERB F
as 0 PUNCT F
was 0 NOUN F
tolerable 0 ADJ F
. 0 PUNCT F

The 0 DET T
primary 0 ADJ F
endpoint 0 NOUN F
was 0 VERB F
overall B-MORTALITY ADJ F
survival I-MORTALITY NOUN F
with 0 ADP F
secondary 0 ADJ F
endpoints 0 NOUN F
of 0 ADP F
time 0 NOUN F
to 0 ADP F
disease B-PHYSICAL NOUN F
progression I-PHYSICAL NOUN F
and 0 CCONJ F
quality 0 NOUN F
of 0 ADP F
life 0 NOUN F
. 0 PUNCT F

At 0 ADP T
the 0 DET F
point 0 NOUN F
of 0 ADP F
protocol-defined 0 ADJ F
study 0 NOUN F
completion 0 NOUN F
( 0 PUNCT F
85 0 NUM F
% 0 SYM F
mortality 0 NOUN F
in 0 ADP F
the 0 DET F
placebo 0 NOUN F
arm 0 NOUN F
) 0 PUNCT F
there 0 PUNCT F
was 0 VERB F
a 0 DET F
modest 0 ADJ F
difference 0 NOUN F
in 0 ADP F
survival 0 NOUN F
in 0 ADP F
the 0 DET F
intention-to-treat 0 NOUN F
population 0 NOUN F
in 0 ADP F
favour 0 NOUN F
of 0 ADP F
marimastat 0 NOUN F
( 0 PUNCT F
P=0.07 0 NOUN T
log-rank 0 NOUN F
test 0 NOUN F
, 0 PUNCT F
hazard 0 NOUN F
ratio=1.23 0 NOUN F
( 0 PUNCT F
95 0 NUM F
% 0 SYM F
confidence 0 NOUN F
interval 0 NOUN F
0.98-1.55 0 NUM F
) 0 PUNCT F
) 0 PUNCT F
. 0 PUNCT F

This 0 DET T
survival B-MORTALITY NOUN F
benefit I-MORTALITY NOUN F
was 0 VERB F
maintained 0 VERB F
over 0 ADP F
a 0 DET F
further 0 ADJ F
2 0 NUM F
years 0 NOUN F
of 0 ADP F
follow-up 0 NOUN F
( 0 PUNCT F
P=0.024 0 NOUN T
, 0 PUNCT F
hazard 0 NOUN F
ratio=1.27 0 NOUN F
( 0 PUNCT F
1.03-1.57 0 NUM F
) 0 PUNCT F
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
median 0 ADJ F
survival B-MORTALITY NOUN F
was 0 ADV F
138 0 NUM F
days 0 NOUN F
for 0 ADP F
placebo 0 NOUN F
and 0 CCONJ F
160 0 NUM F
days 0 NOUN F
for 0 ADP F
marimastat 0 NOUN F
, 0 PUNCT F
with 0 ADP F
2-year 0 NOUN F
survival 0 NOUN F
of 0 ADP F
3 0 NUM F
% 0 SYM F
and 0 CCONJ F
9 0 NUM F
% 0 SYM F
respectively 0 ADV F
. 0 PUNCT F

A 0 DET T
significant B-MORTALITY ADJ F
survival I-MORTALITY NOUN F
benefit I-MORTALITY NOUN F
was 0 VERB F
identified 0 VERB F
at 0 ADP F
study 0 NOUN F
completion 0 NOUN F
in 0 ADP F
the 0 DET F
pre-defined 0 VERB F
sub-group 0 NOUN F
of 0 ADP F
123 0 NUM F
patients 0 NOUN F
who 0 PROPN F
had 0 PUNCT F
received 0 VERB F
prior 0 PUNCT F
chemotherapy 0 NOUN F
( 0 PUNCT F
P=0.045 0 NOUN T
, 0 PUNCT F
hazard 0 NOUN F
ratio=1.53 0 NOUN F
( 0 PUNCT F
1.00-2.34 0 NUM F
) 0 PUNCT F
) 0 PUNCT F
. 0 PUNCT F

This 0 DET T
benefit 0 NOUN F
increased 0 PUNCT F
with 0 ADP F
2 0 NUM F
years 0 NOUN F
additional 0 ADJ F
follow-up 0 NOUN F
( 0 PUNCT F
P=0.006 0 NOUN T
, 0 PUNCT F
hazard 0 NOUN F
ratio=1.68 0 NOUN F
( 0 PUNCT F
1.16-2.44 0 NUM F
) 0 PUNCT F
) 0 PUNCT F
, 0 PUNCT F
with 0 ADP F
2-year B-MORTALITY NOUN F
survival I-MORTALITY NOUN F
of 0 ADP F
5 0 NUM F
% 0 SYM F
and 0 CCONJ F
18 0 NUM F
% 0 SYM F
respectively 0 ADV F
. 0 PUNCT F

Progression-free B-MORTALITY ADJ T
survival I-MORTALITY NOUN F
was 0 VERB F
also 0 ADV F
significantly 0 ADV F
longer 0 PUNCT F
for 0 ADP F
patients 0 NOUN F
receiving 0 VERB F
marimastat 0 NOUN F
compared 0 VERB F
to 0 ADP F
placebo 0 NOUN F
( 0 PUNCT F
P=0.009 0 NOUN T
, 0 PUNCT F
hazard 0 NOUN F
ratio=1.32 0 NOUN F
( 0 PUNCT F
1.07-1.63 0 NUM F
) 0 PUNCT F
) 0 PUNCT F
. 0 PUNCT F

Marimastat 0 NOUN T
treatment 0 NOUN F
was 0 VERB F
associated 0 VERB F
with 0 ADP F
the 0 DET F
development 0 NOUN F
of 0 ADP F
musculoskeletal B-PAIN ADJ F
pain I-PAIN NOUN F
and I-PAIN CCONJ F
inflammation I-PAIN NOUN F
. 0 PUNCT F

Events B-PHYSICAL NOUN T
of I-PHYSICAL ADP F
anaemia I-PHYSICAL NOUN F
, 0 PUNCT F
abdominal B-PHYSICAL ADJ F
pain I-PHYSICAL NOUN F
, 0 PUNCT F
jaundice B-PHYSICAL PUNCT F
and 0 CCONJ F
weight 0 NOUN F
loss B-PHYSICAL NOUN F
were 0 VERB F
more 0 ADV F
common 0 ADJ F
in 0 ADP F
the 0 DET F
placebo 0 NOUN F
arm 0 NOUN F
. 0 PUNCT F

This 0 DET T
is 0 VERB F
one 0 NUM F
of 0 ADP F
the 0 DET F
first 0 ADJ F
demonstrations 0 NOUN F
of 0 ADP F
a 0 DET F
therapeutic 0 ADJ F
benefit 0 NOUN F
for 0 ADP F
a 0 DET F
matrix 0 NOUN F
metalloproteinase 0 NOUN F
inhibitor 0 NOUN F
in 0 ADP F
cancer 0 NOUN F
patients 0 NOUN F
. 0 PUNCT F

The 0 DET T
greatest 0 VERB F
benefit 0 NOUN F
was 0 VERB F
observed 0 VERB F
in 0 ADP F
patients 0 NOUN F
who 0 ADP F
had 0 PUNCT F
previously 0 ADV F
received 0 PUNCT F
chemotherapy 0 NOUN F
. 0 PUNCT F

A 0 DET T
further 0 ADJ F
randomised 0 DET F
study 0 NOUN F
of 0 ADP F
marimastat 0 NOUN F
in 0 ADP F
these 0 DET F
patients 0 NOUN F
is 0 VERB F
warranted 0 VERB F
. 0 PUNCT F

Aerobic 0 ADJ T
and 0 CCONJ F
strength 0 NOUN F
training 0 ADV F
reduces 0 NOUN F
adiposity B-PHYSICAL NOUN F
in 0 ADP F
overweight 0 DET F
Latina 0 PUNCT T
adolescents 0 NOUN F
. 0 PUNCT F

PURPOSE 0 NOUN T
To 0 ADP T
date 0 NOUN F
, 0 PUNCT F
no 0 DET F
study 0 NOUN F
has 0 PUNCT F
examined 0 VERB F
the 0 DET F
synergistic 0 ADJ F
effects 0 NOUN F
of 0 ADP F
a 0 DET F
nutrition 0 NOUN F
and 0 CCONJ F
combination 0 NOUN F
of 0 ADP F
aerobic 0 ADJ F
and 0 CCONJ F
strength 0 NOUN F
training 0 VERB F
( 0 PUNCT F
CAST 0 NOUN T
) 0 PUNCT F
on 0 ADP F
both 0 PUNCT F
adiposity B-PHYSICAL NOUN F
and 0 CCONJ F
metabolic B-PHYSICAL ADJ F
parameters I-PHYSICAL NOUN F
in 0 ADP F
overweight 0 DET F
Latina 0 PUNCT T
adolescent 0 NOUN F
females 0 NOUN F
. 0 PUNCT F

The 0 DET T
goal 0 NOUN F
was 0 VERB F
to 0 PART F
assess 0 NOUN F
if 0 PUNCT F
a 0 DET F
16-wk 0 NOUN F
nutrition 0 NOUN F
plus 0 CCONJ F
CAST 0 NOUN T
pilot 0 NOUN F
study 0 NOUN F
had 0 CCONJ F
stronger 0 PUNCT F
effects 0 NOUN F
on 0 ADP F
reducing 0 NUM F
adiposity B-PHYSICAL NOUN F
and 0 CCONJ F
on 0 ADP F
improving 0 VERB F
glucose/insulin B-PHYSICAL NOUN F
indices I-PHYSICAL NOUN F
compared 0 VERB F
with 0 ADP F
control 0 NOUN F
( 0 PUNCT F
C 0 NOUN T
) 0 PUNCT F
, 0 PUNCT F
nutrition 0 NOUN F
only 0 ADV F
( 0 PUNCT F
N 0 NOUN T
) 0 PUNCT F
, 0 PUNCT F
and 0 CCONJ F
a 0 DET F
nutrition 0 NOUN F
plus 0 CCONJ F
strength 0 NOUN F
training 0 VERB F
( 0 PUNCT F
N 0 NOUN T
+ 0 SYM F
ST 0 NOUN T
) 0 PUNCT F
groups 0 NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
In 0 ADP T
a 0 DET F
16-wk 0 NOUN F
randomized 0 VERB F
trial 0 NOUN F
, 0 PUNCT F
41 0 NUM F
overweight 0 VERB F
Latina 0 PUNCT T
girls 0 NOUN F
( 0 PUNCT F
15.2 0 NUM F
+/- 0 SYM F
1.1 0 NUM F
yr 0 NOUN F
) 0 PUNCT F
were 0 VERB F
randomly 0 ADV F
assigned 0 VERB F
to 0 ADP F
C 0 NOUN T
( 0 PUNCT F
n 0 NOUN F
= 0 SYM F
7 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
N 0 NOUN T
( 0 PUNCT F
n 0 NOUN F
= 0 SYM F
10 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
N 0 NOUN T
+ 0 SYM F
ST 0 NOUN T
( 0 PUNCT F
n 0 NOUN F
= 0 SYM F
9 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
or 0 CCONJ F
N 0 NOUN T
+ 0 SYM F
CAST 0 NOUN T
( 0 PUNCT F
n 0 NOUN F
= 0 SYM F
15 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

All 0 DET T
intervention 0 NOUN F
groups 0 NOUN F
received 0 DET F
modified 0 VERB F
carbohydrate 0 NOUN F
nutrition 0 NOUN F
classes 0 NOUN F
( 0 PUNCT F
once 0 PUNCT F
a 0 DET F
week 0 NOUN F
) 0 PUNCT F
, 0 PUNCT F
whereas 0 ADP F
the 0 DET F
N 0 NOUN T
+ 0 SYM F
ST 0 NOUN T
also 0 ADV F
received 0 CCONJ F
strength 0 NOUN F
training 0 VERB F
( 0 PUNCT F
twice 0 CCONJ F
a 0 DET F
week 0 NOUN F
) 0 PUNCT F
and 0 CCONJ F
the 0 DET F
N 0 NOUN T
+ 0 SYM F
CAST 0 NOUN T
received 0 VERB F
a 0 DET F
combination 0 NOUN F
of 0 ADP F
strength 0 NOUN F
and 0 CCONJ F
aerobic 0 ADJ F
training 0 SYM F
( 0 PUNCT F
twice 0 CCONJ F
a 0 DET F
week 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
following 0 ADP F
were 0 VERB F
measured 0 VERB F
before 0 ADP F
and 0 CCONJ F
after 0 ADP F
intervention 0 NOUN F
: 0 PUNCT F
strength B-PHYSICAL NOUN F
by 0 ADP F
one 0 NUM F
repetition 0 NOUN F
maximum 0 NOUN F
, 0 PUNCT F
physical B-MENTAL ADJ F
activity I-MENTAL NOUN F
by I-MENTAL ADP F
the I-MENTAL DET F
7-d I-MENTAL NOUN F
accelerometry I-MENTAL NOUN F
and 0 CCONJ F
the 0 DET F
3-d B-MENTAL NOUN F
physical I-MENTAL ADJ F
activity I-MENTAL NOUN F
recall I-MENTAL VERB F
, 0 PUNCT F
dietary B-MENTAL ADJ F
intake I-MENTAL NOUN F
by 0 ADP F
3-d 0 NOUN F
records 0 NOUN F
, 0 PUNCT F
body B-PHYSICAL NOUN F
composition I-PHYSICAL NOUN F
by 0 ADP F
dual-energy 0 NOUN F
x-ray 0 NOUN F
absorptiometry 0 NOUN F
( 0 PUNCT F
DEXA 0 NOUN T
) 0 PUNCT F
, 0 PUNCT F
glucose/insulin B-PHYSICAL NOUN F
indices I-PHYSICAL NOUN F
by 0 ADP F
oral 0 ADJ F
glucose 0 NOUN F
tolerance 0 NOUN F
test 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
intravenous 0 ADJ F
glucose 0 NOUN F
tolerance 0 NOUN F
test 0 NOUN F
with 0 ADP F
minimal 0 ADJ F
modeling 0 VERB F
. 0 PUNCT F

Across 0 ADP T
intervention 0 NOUN F
group 0 NOUN F
, 0 PUNCT F
effects 0 NOUN F
were 0 VERB F
tested 0 VERB F
using 0 VERB F
ANCOVA 0 NOUN T
with 0 ADP F
post 0 PUNCT F
hoc 0 PUNCT F
pairwise 0 PUNCT F
comparisons 0 NOUN F
. 0 PUNCT F

RESULTS 0 NOUN T
There 0 CCONJ T
were 0 VERB F
significant 0 ADJ F
overall 0 ADJ F
intervention 0 NOUN F
effects 0 NOUN F
for 0 ADP F
all 0 DET F
adiposity B-PHYSICAL NOUN F
measures 0 NOUN F
( 0 PUNCT F
weight 0 NOUN F
, 0 PUNCT F
body 0 NOUN F
mass 0 NOUN F
index 0 NOUN F
[ 0 PUNCT F
BMI 0 NOUN T
] 0 PUNCT F
, 0 PUNCT F
BMI 0 NOUN T
z-scores B-PHYSICAL NOUN F
, 0 PUNCT F
and 0 CCONJ F
DEXA B-PHYSICAL NOUN T
total 0 ADJ F
body B-PHYSICAL NOUN F
fat B-PHYSICAL NOUN F
) 0 PUNCT F
, 0 PUNCT F
with 0 ADP F
a 0 DET F
decrease 0 NOUN F
of 0 ADP F
3 0 NUM F
% 0 SYM F
in 0 ADP F
the 0 DET F
N 0 NOUN T
+ 0 DET F
CAST 0 NOUN T
group 0 NOUN F
compared 0 VERB F
with 0 ADP F
a 0 DET F
3 0 NUM F
% 0 SYM F
increase 0 NOUN F
in 0 ADP F
the 0 DET F
N 0 NOUN T
+ 0 SYM F
ST 0 NOUN T
group 0 NOUN F
( 0 PUNCT F
P 0 NOUN T
< 0 SYM F
or 0 CCONJ F
= 0 SYM F
0.05 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

There 0 PUNCT T
was 0 VERB F
also 0 ADV F
an 0 DET F
intervention 0 NOUN F
effect 0 NOUN F
for 0 ADP F
fasting B-PHYSICAL ADV F
glucose I-PHYSICAL NOUN F
with 0 ADP F
the 0 DET F
N 0 NOUN T
group 0 NOUN F
increasing 0 VERB F
by 0 ADP F
3 0 NUM F
% 0 SYM F
and 0 CCONJ F
the 0 DET F
N 0 NOUN T
+ 0 DET F
CAST 0 NOUN T
group 0 NOUN F
decreasing 0 NUM F
by 0 ADP F
4 0 NUM F
% 0 SYM F
( 0 PUNCT F
P 0 NOUN T
< 0 SYM F
or 0 CCONJ F
= 0 SYM F
0.05 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

CONCLUSION 0 NOUN T
The 0 DET T
CAST 0 NOUN T
was 0 VERB F
more 0 ADV F
effective 0 ADJ F
than 0 PUNCT F
nutrition 0 NOUN F
alone 0 ADJ F
or 0 CCONJ F
nutrition 0 NOUN F
plus 0 CCONJ F
strength 0 NOUN F
training 0 VERB F
for 0 ADP F
reducing 0 VERB F
multiple B-PHYSICAL ADJ F
adiposity I-PHYSICAL NOUN F
outcomes B-PHYSICAL NOUN F
and 0 CCONJ F
fasting B-PHYSICAL VERB F
glucose I-PHYSICAL NOUN F
in 0 ADP F
overweight 0 ADP F
Latina 0 PUNCT T
girls 0 ADP F
. 0 PUNCT F

However 0 ADV T
, 0 PUNCT F
further 0 ADJ F
research 0 NOUN F
investigating 0 VERB F
and 0 CCONJ F
identifying 0 PUNCT F
intervention 0 NOUN F
approaches 0 NOUN F
that 0 ADP F
improve 0 VERB F
both 0 PUNCT F

Lack 0 NOUN T
of 0 ADP F
effect 0 NOUN F
of 0 ADP F
warfarin 0 NOUN F
on 0 ADP F
the 0 DET F
restenosis B-PHYSICAL NOUN F
rate I-PHYSICAL NOUN F
or 0 CCONJ F
on 0 ADP F
clinical 0 ADJ F
outcome 0 NOUN F
after 0 ADP F
balloon 0 NOUN F
coronary 0 ADJ F
angioplasty 0 NOUN F
. 0 PUNCT F

Between 0 ADP T
September 0 NOUN T
1985 0 NUM F
and 0 CCONJ F
April 0 NOUN T
1987 0 NUM F
, 0 PUNCT F
110 0 NUM F
consecutive 0 ADJ F
patients 0 NOUN F
who 0 ADP F
had 0 CCONJ F
successful 0 ADJ F
coronary 0 ADJ F
angioplasty 0 NOUN F
were 0 VERB F
included 0 VERB F
in 0 ADP F
a 0 DET F
randomised 0 VERB F
prospective 0 ADJ F
controlled 0 VERB F
evaluation 0 NOUN F
of 0 ADP F
the 0 DET F
effects 0 NOUN F
of 0 ADP F
warfarin 0 NOUN F
on 0 ADP F
restenosis 0 NOUN F
. 0 PUNCT F

The 0 DET T
warfarin 0 NOUN F
( 0 PUNCT F
n 0 NOUN F
= 0 SYM F
56 0 NUM F
) 0 PUNCT F
and 0 CCONJ F
the 0 DET F
control 0 NOUN F
( 0 PUNCT F
n 0 NOUN F
= 0 SYM F
54 0 NUM F
) 0 PUNCT F
groups 0 NOUN F
were 0 VERB F
not 0 ADV F
different 0 ADJ F
in 0 ADP F
terms 0 NOUN F
of 0 ADP F
age 0 NOUN F
, 0 PUNCT F
sex 0 NOUN F
, 0 PUNCT F
previous 0 ADJ F
coronary 0 ADJ F
bypass 0 NOUN F
surgery 0 NOUN F
or 0 CCONJ F
coronary 0 ADJ F
balloon 0 NOUN F
angioplasty 0 NOUN F
, 0 PUNCT F
severity 0 NOUN F
of 0 ADP F
symptoms 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
frequency 0 NOUN F
of 0 ADP F
multivessel 0 NOUN F
disease 0 NOUN F
or 0 CCONJ F
of 0 ADP F
total 0 ADJ F
coronary 0 ADJ F
occlusions 0 NOUN F
. 0 PUNCT F

Warfarin 0 NOUN T
was 0 VERB F
started 0 VERB F
on 0 ADP F
the 0 DET F
day 0 NOUN F
of 0 ADP F
the 0 DET F
procedure 0 NOUN F
and 0 CCONJ F
the 0 DET F
dosage 0 NOUN F
was 0 VERB F
adjusted 0 VERB F
to 0 ADJ F
maintain 0 ADV F
the 0 DET F
thromboplastin 0 NOUN F
international 0 ADJ F
normalised 0 VERB F
ratio 0 NOUN F
greater 0 PUNCT F
than 0 VERB F
or 0 CCONJ F
equal 0 ADJ F
to 0 ADP F
2.5 0 NUM F
. 0 PUNCT F

One 0 NUM T
hundred 0 NUM F
and 0 CCONJ F
five 0 NUM F
( 0 PUNCT F
96 0 NUM F
% 0 SYM F
) 0 PUNCT F
of 0 ADP F
the 0 DET F
patients 0 NOUN F
were 0 VERB F
given 0 VERB F
verapamil 0 NOUN F
and 0 CCONJ F
other 0 ADJ F
antianginal 0 ADJ F
drugs 0 NOUN F
were 0 VERB F
prescribed 0 PROPN F
as 0 PUNCT F
needed 0 NOUN F
. 0 PUNCT F

Low 0 ADJ T
molecular 0 ADJ F
weight 0 NOUN F
dextran 0 NOUN F
and 0 CCONJ F
heparin 0 NOUN F
were 0 VERB F
given 0 VERB F
during 0 ADP F
the 0 DET F
procedure 0 NOUN F
and 0 CCONJ F
heparin 0 NOUN F
was 0 VERB F
continued 0 VERB F
for 0 ADP F
24 0 NUM F
hours 0 NOUN F
in 0 ADP F
all 0 DET F
patients 0 NOUN F
. 0 PUNCT F

One 0 NUM T
hundred 0 NUM F
and 0 CCONJ F
eight 0 NUM F
( 0 PUNCT F
98 0 NUM F
% 0 SYM F
) 0 PUNCT F
of 0 ADP F
patients 0 NOUN F
were 0 VERB F
followed 0 VERB F
up 0 PUNCT F
clinically 0 ADV F
after 0 ADP F
a 0 DET F
median 0 ADJ F
of 0 ADP F
five 0 NUM F
months 0 NOUN F
( 0 PUNCT F
range 0 NOUN F
1-20 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Eighty 0 PUNCT T
five 0 NUM F
( 0 PUNCT F
77 0 NUM F
% 0 SYM F
) 0 PUNCT F
had 0 PUNCT F
follow 0 CCONJ F
up 0 PUNCT F
angiography 0 NOUN F
at 0 ADP F
five 0 NUM F
months 0 NOUN F
. 0 PUNCT F

In 0 ADP T
the 0 DET F
warfarin 0 NOUN F
group 0 NOUN F
symptoms B-PHYSICAL NOUN F
improved B-OTHER VERB F
in 0 ADP F
46 0 NUM F
( 0 PUNCT F
85 0 NUM F
% 0 SYM F
) 0 PUNCT F
patients 0 NOUN F
by 0 ADP F
at 0 ADP F
least 0 ADV F
1 0 NUM F
angina 0 NOUN F
class 0 NOUN F
and 0 CCONJ F
31 0 NUM F
( 0 PUNCT F
57 0 NUM F
% 0 SYM F
) 0 PUNCT F
were 0 VERB F
symptom B-OTHER NOUN F
free I-OTHER ADJ F
; 0 PUNCT F
the 0 DET F
exercise 0 NOUN F
test 0 NOUN F
remained 0 ADP F
positive 0 ADJ F
in 0 ADP F
20 0 NUM F
( 0 PUNCT F
36 0 NUM F
% 0 SYM F
) 0 PUNCT F
patients 0 NOUN F
and 0 CCONJ F
the 0 DET F
angiographic B-PHYSICAL ADJ F
restenosis I-PHYSICAL NOUN F
rate I-PHYSICAL NOUN F
was 0 VERB F
25 0 NUM F
% 0 SYM F
per 0 ADP F
lesion 0 NOUN F
and 0 CCONJ F
29 0 NUM F
% 0 SYM F
per 0 ADP F
patient 0 NOUN F
. 0 PUNCT F

There 0 PUNCT T
were 0 VERB F
no 0 DET F
major B-ADVERSE-EFFECTS ADJ F
bleeding I-ADVERSE-EFFECTS VERB F
complications I-ADVERSE-EFFECTS NOUN F
. 0 PUNCT F

In 0 ADP T
the 0 DET F
control 0 NOUN F
group 0 NOUN F
46 0 NUM F
( 0 PUNCT F
85 0 NUM F
% 0 SYM F
) 0 PUNCT F
patients 0 NOUN F
were 0 VERB F
improved 0 VERB F
by 0 ADP F
at 0 ADP F
least 0 ADV F
1 0 NUM F
angina 0 NOUN F
class 0 NOUN F
and 0 CCONJ F
31 0 NUM F
( 0 PUNCT F
57 0 NUM F
% 0 SYM F
) 0 PUNCT F
were 0 VERB F
symptom 0 NOUN F
free 0 ADJ F
; 0 PUNCT F
the 0 DET F
exercise B-OTHER NOUN F
test I-OTHER NOUN F
was 0 VERB F
positive 0 ADJ F
in 0 ADP F
11 0 NUM F
( 0 PUNCT F
21 0 NUM F
% 0 SYM F
) 0 PUNCT F
patients 0 NOUN F
and 0 CCONJ F
the 0 DET F
angiographic B-PHYSICAL ADJ F
restenosis I-PHYSICAL NOUN F
rate I-PHYSICAL NOUN F
was 0 VERB F
33 0 NUM F
% 0 SYM F
per 0 ADP F
lesion 0 NOUN F
and 0 CCONJ F
37 0 NUM F
% 0 SYM F
per 0 ADP F
patient 0 NOUN F
. 0 PUNCT F

Although 0 ADP T
the 0 DET F
incidence 0 NOUN F
of 0 ADP F
angiographic 0 ADJ F
restenosis 0 NOUN F
tended 0 VERB F
to 0 PART F
be 0 PUNCT F
lower 0 PUNCT F
with 0 ADP F
warfarin 0 NOUN F
, 0 PUNCT F
none 0 NUM F
of 0 ADP F
these 0 DET F
differences 0 NOUN F
was 0 VERB F
significant 0 ADJ F
. 0 PUNCT F

These 0 DET T
data 0 NOUN F
suggest 0 VERB F
that 0 ADP F
the 0 DET F
combination 0 NOUN F
of 0 ADP F
verapamil 0 NOUN F
and 0 CCONJ F
warfarin 0 NOUN F
, 0 PUNCT F
in 0 ADP F
the 0 DET F
absence 0 NOUN F
of 0 ADP F
aspirin 0 NOUN F
, 0 PUNCT F
is 0 VERB F
not 0 ADV F
significantly 0 ADV F
better 0 PUNCT F
than 0 VERB F
verapamil 0 NOUN F
alone 0 ADJ F
in 0 ADP F
preventing 0 VERB F
symptom 0 NOUN F
recurrence 0 NOUN F
or 0 CCONJ F
angiographic B-PHYSICAL ADJ F
restenosis I-PHYSICAL NOUN F
after 0 ADP F
coronary 0 ADJ F
angioplasty 0 NOUN F
. 0 PUNCT F

Rational-emotive 0 ADJ T
therapy 0 NOUN F
and 0 CCONJ F
the 0 DET F
reduction 0 NOUN F
of 0 ADP F
interpersonal B-MENTAL PUNCT F
anxiety I-MENTAL NOUN F
in 0 ADP F
junior 0 PUNCT F
high 0 ADJ F
school 0 NOUN F
students 0 NOUN F
. 0 PUNCT F

This 0 DET T
study 0 NOUN F
evaluated 0 VERB F
the 0 DET F
effectiveness 0 NOUN F
of 0 ADP F
rational-emotive 0 ADJ F
therapy 0 NOUN F
and 0 CCONJ F
rational-emotive 0 ADJ F
imagery 0 NOUN F
. 0 PUNCT F

Fifty-nine 0 DET T
junior 0 PUNCT F
high 0 ADJ F
school 0 NOUN F
students 0 NOUN F
who 0 PROPN F
volunteered 0 PUNCT F
to 0 ADJ F
participate 0 ADP F
in 0 ADP F
treatment 0 NOUN F
for 0 ADP F
interpersonal B-MENTAL PUNCT F
anxiety I-MENTAL NOUN F
were 0 VERB F
randomly 0 ADV F
assigned 0 VERB F
to 0 ADP F
rational-emotive 0 ADJ F
therapy 0 NOUN F
without 0 ADP F
imagery 0 ADJ F
( 0 PUNCT F
RET 0 NOUN T
) 0 PUNCT F
, 0 PUNCT F
rational-emotive 0 ADJ F
therapy 0 NOUN F
with 0 ADP F
imagery 0 NOUN F
( 0 PUNCT F
REI 0 NOUN T
) 0 PUNCT F
, 0 PUNCT F
relationship-oriented 0 VERB F
counseling 0 VERB F
( 0 PUNCT F
ROC 0 NOUN T
) 0 PUNCT F
, 0 PUNCT F
and 0 CCONJ F
waiting-list 0 NOUN F
control 0 NOUN F
( 0 PUNCT F
WLC 0 NOUN T
) 0 PUNCT F
groups 0 NOUN F
. 0 PUNCT F

Groups 0 NOUN T
met 0 ADJ F
for 0 ADP F
seven 0 NUM F
50-minute 0 NOUN F
treatment 0 NOUN F
sessions 0 NOUN F
during 0 ADP F
a 0 DET F
three-week 0 ADJ F
period 0 NOUN F
. 0 PUNCT F

Assessments 0 NOUN T
were 0 VERB F
conducted 0 VERB F
at 0 ADP F
pretreatment 0 NOUN F
, 0 PUNCT F
posttreatment 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
three-week 0 ADJ F
follow-up 0 NOUN F
. 0 PUNCT F

Both 0 CCONJ T
self-report B-OTHER ADJ F
and I-OTHER CCONJ F
sociometric I-OTHER ADJ F
measures I-OTHER NOUN F
were 0 VERB F
used 0 VERB F
to 0 PART F
evaluate 0 NOUN F
treatment 0 NOUN F
outcome 0 NOUN F
. 0 PUNCT F

At 0 ADP T
postassessment 0 NOUN F
, 0 PUNCT F
both 0 PUNCT F
the 0 DET F
RET 0 NOUN T
and 0 CCONJ F
REI 0 ADJ T
groups 0 NOUN F
were 0 VERB F
rated 0 VERB F
on 0 ADP F
sociometric B-MENTAL ADJ F
measures I-MENTAL NOUN F
as 0 ADP F
significantly 0 VERB F
less 0 ADV F
interpersonally 0 NOUN F
anxious B-OTHER ADJ F
than 0 PUNCT F
the 0 DET F
WLC 0 NOUN T
group 0 NOUN F
. 0 PUNCT F

Mean 0 ADJ T
scores 0 NOUN F
favored 0 VERB F
the 0 DET F
RET 0 NOUN T
and 0 CCONJ F
REI 0 ADJ T
groups 0 NOUN F
, 0 PUNCT F
but 0 CCONJ F
no 0 DET F
significant 0 ADJ F
differences 0 NOUN F
between 0 ADP F
these 0 DET F
groups 0 NOUN F
and 0 CCONJ F
the 0 DET F
ROC 0 NOUN T
group 0 NOUN F
were 0 VERB F
obtained 0 VERB F
. 0 PUNCT F

The 0 DET T
self-report B-OTHER ADJ F
measure I-OTHER ADV F
did 0 CCONJ F
not 0 ADV F
significantly 0 ADV F
differentiate 0 PUNCT F
between 0 ADP F
groups 0 NOUN F
, 0 PUNCT F
but 0 CCONJ F
the 0 DET F
REI 0 ADJ T
group 0 NOUN F
demonstrated 0 VERB F
significant 0 ADJ F
pre- 0 ADJ F
to 0 ADP F
follow-up 0 NOUN F
changes 0 NOUN F
. 0 PUNCT F

Both 0 CCONJ T
the 0 DET F
RET 0 NOUN T
and 0 CCONJ F
REI 0 ADJ T
groups 0 NOUN F
yielded 0 VERB F
greater 0 PUNCT F
reductions 0 NOUN F
in 0 ADP F
irrational B-MENTAL ADJ F
thinking I-MENTAL PUNCT F
than 0 PUNCT F
did 0 PUNCT F
the 0 DET F
ROC 0 NOUN T
and 0 CCONJ F
WLC 0 NOUN T
groups 0 NOUN F
. 0 PUNCT F

In 0 ADP T
addition 0 NOUN F
, 0 PUNCT F
the 0 DET F
pattern 0 NOUN F
of 0 ADP F
the 0 DET F
results 0 NOUN F
supported 0 VERB F
the 0 DET F
use 0 NOUN F
of 0 ADP F
rational-emotive 0 ADJ F
imagery 0 VERB F
as 0 PUNCT F
a 0 DET F
component 0 NOUN F
of 0 ADP F
rational-emotive 0 ADJ F
therapy 0 NOUN F
. 0 PUNCT F

The 0 DET T
practical 0 ADJ F
implications 0 NOUN F
of 0 ADP F
these 0 DET F
findings 0 NOUN F
are 0 VERB F
discussed 0 VERB F
. 0 PUNCT F

A 0 DET T
randomized 0 VERB F
clinical 0 ADJ F
trial 0 NOUN F
of 0 ADP F
treatment 0 NOUN F
of 0 ADP F
clomiphene 0 NOUN F
citrate-resistant 0 PUNCT F
anovulation 0 NOUN F
with 0 ADP F
the 0 DET F
use 0 NOUN F
of 0 ADP F
oral 0 ADJ F
contraceptive 0 ADJ F
pill 0 ADJ F
suppression 0 NOUN F
and 0 CCONJ F
repeat 0 NOUN F
clomiphene 0 NOUN F
citrate 0 NOUN F
treatment 0 NOUN F
. 0 PUNCT F

OBJECTIVE 0 NOUN T
The 0 DET T
purpose 0 NOUN F
of 0 ADP F
this 0 DET F
study 0 NOUN F
was 0 VERB F
to 0 PART F
evaluate 0 NOUN F
the 0 DET F
effectiveness 0 NOUN F
and 0 CCONJ F
endocrine B-PHYSICAL ADJ F
response I-PHYSICAL NOUN F
of 0 ADP F
oral 0 ADJ F
contraceptive 0 ADJ F
ovarian 0 ADJ F
suppression 0 NOUN F
followed 0 VERB F
by 0 ADP F
clomiphene 0 NOUN F
citrate 0 NOUN F
in 0 ADP F
patients 0 NOUN F
who 0 PROPN F
previously 0 ADP F
were 0 VERB F
clomiphene 0 NOUN F
citrate 0 NOUN F
resistant 0 ADJ F
. 0 PUNCT F

STUDY 0 NOUN T
DESIGN 0 NOUN T
Forty-eight 0 PUNCT T
patients 0 NOUN F
from 0 ADP F
a 0 DET F
private 0 ADJ F
tertiary 0 ADJ F
infertility 0 ADJ F
clinic 0 NOUN F
were 0 VERB F
assigned 0 VERB F
randomly 0 ADV F
prospectively 0 ADV F
to 0 ADP F
either 0 PUNCT F
group 0 NOUN F
1 0 NUM F
( 0 PUNCT F
oral 0 ADJ F
contraceptive/clomiphene 0 NOUN F
citrate 0 NOUN F
) 0 PUNCT F
, 0 PUNCT F
which 0 ADP F
received 0 VERB F
continuous 0 ADJ F
oral 0 ADJ F
contraceptives 0 NOUN F
followed 0 VERB F
by 0 ADP F
clomiphene 0 NOUN F
citrate 0 NOUN F
, 0 PUNCT F
or 0 CCONJ F
to 0 PUNCT F
group 0 NOUN F
2 0 NUM F
( 0 PUNCT F
control 0 NOUN F
) 0 PUNCT F
received 0 VERB F
no 0 DET F
treatment 0 NOUN F
in 0 ADP F
the 0 DET F
cycle 0 NOUN F
before 0 ADP F
clomiphene 0 NOUN F
citrate 0 NOUN F
treatment 0 NOUN F
. 0 PUNCT F

On 0 ADP T
day 0 NOUN F
3 0 NUM F
, 0 PUNCT F
17 0 NUM F
beta-estradiol B-OTHER NOUN F
, 0 PUNCT F
follicle-stimulating B-OTHER VERB F
hormone I-OTHER NOUN F
, 0 PUNCT F
luteinizing B-OTHER ADP F
hormone I-OTHER NOUN F
, 0 PUNCT F
and 0 PUNCT F

[ 0 PUNCT F
The 0 DET T
application 0 NOUN F
of 0 ADP F
naphcon 0 NOUN F
eye 0 NOUN F
drops 0 PUNCT F
during 0 ADP F
Lasik 0 PUNCT T
surgery 0 NOUN F
] 0 PUNCT F
. 0 PUNCT F

PURPOSE 0 NOUN T
To 0 ADJ T
evaluate 0 NOUN F
the 0 DET F
effects 0 NOUN F
of 0 ADP F
Naphcon 0 NOUN T
eye 0 NOUN F
drops 0 PUNCT F
for 0 ADP F
preventing 0 VERB F
conjunctival 0 ADJ F
bleeding 0 VERB F
during 0 ADP F
Lasik 0 PUNCT T
surgery 0 NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
One 0 NUM T
hundred 0 NUM F
cases 0 NOUN F
( 0 PUNCT F
200 0 NUM F
eyes 0 NOUN F
) 0 PUNCT F
were 0 VERB F
divided 0 VERB F
into 0 ADP F
treating 0 VERB F
group 0 NOUN F
and 0 CCONJ F
control 0 NOUN F
group 0 NOUN F
randomly 0 ADV F
according 0 PUNCT F
to 0 PUNCT F
using 0 ADP F
and 0 CCONJ F
not 0 ADV F
using 0 PUNCT F
Naphcon 0 NOUN T
eye 0 NOUN F
drops 0 PUNCT F
before 0 ADP F
Lasik 0 PUNCT T
surgery 0 NOUN F
. 0 PUNCT F

Treating 0 ADJ T
group 0 NOUN F
patients 0 NOUN F
received 0 VERB F
three 0 NUM F
times 0 NOUN F
Naphcon 0 NOUN T
eye 0 NOUN F
drops 0 PUNCT F
during 0 ADP F
15 0 NUM F
minutes 0 NOUN F
before 0 ADP F
surgery 0 NOUN F
. 0 PUNCT F

RESULTS 0 PUNCT T
The 0 DET T
incidence 0 NOUN F
of 0 ADP F
conjunctival B-PHYSICAL ADJ F
bleeding I-PHYSICAL VERB F
from 0 ADP F
treating 0 VERB F
and 0 CCONJ F
control 0 NOUN F
group 0 NOUN F
were 0 VERB F
8 0 NUM F
% 0 SYM F
and 0 CCONJ F
15 0 NUM F
% 0 SYM F
respectively 0 ADV F
. 0 PUNCT F

There 0 PUNCT T
was 0 VERB F
significant 0 ADJ F
statistical 0 ADJ F
difference 0 NOUN F
between 0 ADP F
them 0 PRON F
. 0 PUNCT F

CONCLUSION 0 NOUN T
Naphcon 0 NOUN T
eye 0 NOUN F
drop 0 VERB F
is 0 VERB F
an 0 DET F
effective 0 ADJ F
agent 0 NOUN F
to 0 PART F
prevent 0 ADJ F
conjunctival 0 ADJ F
bleeding 0 VERB F
. 0 PUNCT F

Enhanced 0 VERB T
inotropic 0 ADJ F
state 0 NOUN F
of 0 ADP F
the 0 DET F
failing 0 VERB F
left 0 ADJ F
ventricle 0 NOUN F
by 0 ADP F
cardiac 0 ADJ F
contractility 0 NOUN F
modulation 0 NOUN F
electrical 0 ADJ F
signals 0 NOUN F
is 0 VERB F
not 0 ADV F
associated 0 VERB F
with 0 ADP F
increased 0 VERB F
myocardial B-PHYSICAL ADJ F
oxygen I-PHYSICAL NOUN F
consumption I-PHYSICAL NOUN F
. 0 PUNCT F

BACKGROUND 0 NOUN T
Previous 0 ADJ T
studies 0 NOUN F
in 0 ADP F
patients 0 NOUN F
and 0 CCONJ F
in 0 ADP F
dogs 0 NOUN F
with 0 ADP F
experimentally 0 ADV F
induced 0 PUNCT F
heart 0 NOUN F
failure 0 NOUN F
( 0 PUNCT F
HF 0 NOUN T
) 0 PUNCT F
showed 0 VERB F
that 0 ADP F
electrical 0 ADJ F
signals 0 NOUN F
applied 0 VERB F
to 0 ADP F
the 0 DET F
failing 0 VERB F
myocardium 0 NOUN F
during 0 ADP F
the 0 DET F
absolute 0 ADJ F
refractory 0 ADJ F
period 0 NOUN F
improved 0 VERB F
left B-PHYSICAL ADJ F
ventricular I-PHYSICAL ADJ F
( I-PHYSICAL PUNCT F
LV I-PHYSICAL NOUN T
) I-PHYSICAL PUNCT F
function I-PHYSICAL NOUN F
. 0 PUNCT F

We 0 PRON T
examined 0 VERB F
the 0 DET F
effects 0 NOUN F
these 0 DET F
same 0 ADJ F
cardiac 0 ADJ F
contractility 0 NOUN F
modulating 0 SYM F
( 0 PUNCT F
CCM 0 NOUN T
) 0 PUNCT F
electrical 0 ADJ F
signals 0 NOUN F
on 0 ADP F
myocardial B-PHYSICAL ADJ F
oxygen I-PHYSICAL NOUN F
consumption I-PHYSICAL NOUN F
( 0 PUNCT F
MVO B-PHYSICAL NOUN T
( 0 PUNCT F
2 B-PHYSICAL NUM F
) 0 PUNCT F
) 0 PUNCT F
in 0 ADP F
both 0 CCONJ F
patients 0 NOUN F
and 0 CCONJ F
dogs 0 NOUN F
with 0 ADP F
chronic 0 ADJ F
HF 0 NOUN T
. 0 PUNCT F

METHODS 0 NOUN T
AND 0 CCONJ T
RESULTS 0 NOUN T
Six 0 NUM T
dogs 0 NOUN F
with 0 ADP F
microembolizations-induced 0 VERB F
HF 0 NOUN T
and 0 CCONJ F
9 0 NUM F
HF 0 NOUN T
patients 0 NOUN F
underwent 0 VERB F
CCM 0 NOUN T
leads 0 NOUN F
and 0 CCONJ F
generator 0 NOUN F
( 0 PUNCT F
OPTIMIZER 0 NOUN T
II 0 NUM T
) 0 PUNCT F
implantation 0 NOUN F
. 0 PUNCT F

After 0 ADP T
baseline 0 NOUN F
measurements 0 NOUN F
, 0 PUNCT F
CCM 0 NOUN T
signals 0 NOUN F
were 0 VERB F
delivered 0 VERB F
continuously 0 ADV F
for 0 ADP F
2 0 NUM F
hours 0 NOUN F
in 0 ADP F
dogs 0 NOUN F
and 0 CCONJ F
for 0 ADP F
30 0 NUM F
minutes 0 NOUN F
in 0 ADP F
patients 0 NOUN F
. 0 PUNCT F

MVO B-PHYSICAL NOUN T
( 0 PUNCT F
2 B-PHYSICAL NUM F
) 0 PUNCT F
was 0 VERB F
measured 0 VERB F
before 0 ADP F
and 0 CCONJ F
after 0 ADP F
CCM 0 NOUN T
therapy 0 NOUN F
. 0 PUNCT F

In 0 ADP T
dogs 0 NOUN F
, 0 PUNCT F
CCM 0 NOUN T
therapy 0 NOUN F
increased 0 VERB F
LV B-PHYSICAL NOUN T
ejection I-PHYSICAL NOUN F
fraction I-PHYSICAL NOUN F
at 0 ADP F
2 0 NUM F
hours 0 NOUN F
( 0 PUNCT F
26 0 NUM F
+/- 0 SYM F
1 0 NUM F
versus 0 CCONJ F
31 0 NUM F
+/- 0 SYM F
2 0 NUM F
% 0 SYM F
, 0 PUNCT F
P 0 NOUN T
= 0 SYM F
.001 0 NUM F
) 0 PUNCT F
without 0 ADP F
increasing 0 VERB F
MVO B-PHYSICAL NOUN T
( 0 PUNCT F
2 B-PHYSICAL NUM F
) 0 PUNCT F
( 0 PUNCT F
257 0 NUM F
+/- 0 SYM F
41 0 NUM F
versus 0 CCONJ F
180 0 NUM F
+/- 0 SYM F
34 0 NUM F
micromol/min 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

In 0 ADP T
patients 0 NOUN F
, 0 PUNCT F
CCM 0 NOUN T
therapy 0 NOUN F
increased 0 VERB F
LV B-PHYSICAL NOUN T
peak 0 NOUN F
+dP/dt B-PHYSICAL ADV F
by 0 ADP F
10.1 0 NUM F
+/- 0 SYM F
1.5 0 NUM F
% 0 SYM F
. 0 PUNCT F

As 0 PUNCT T
with 0 ADP F
dogs 0 NOUN F
, 0 PUNCT F
the 0 DET F
increase 0 NOUN F
in 0 ADP F
LV B-PHYSICAL NOUN T
function I-PHYSICAL NOUN F
after 0 ADP F
30 0 NUM F
minutes 0 NOUN F
of 0 ADP F
CCM 0 NOUN T
therapy 0 NOUN F
was 0 VERB F
not 0 ADV F
associated 0 VERB F
with 0 ADP F
increased 0 NOUN F
MVO B-PHYSICAL NOUN T
( 0 PUNCT F

Randomised 0 VERB T
trial 0 NOUN F
of 0 ADP F
efficacy 0 NOUN F
and 0 CCONJ F
safety 0 NOUN F
of 0 ADP F
oral 0 ADJ F
ganciclovir 0 NOUN F
in 0 ADP F
the 0 DET F
prevention 0 NOUN F
of 0 ADP F
cytomegalovirus 0 NOUN F
disease 0 NOUN F
in 0 ADP F
liver-transplant 0 ADJ F
recipients 0 NOUN F
. 0 PUNCT F

The 0 DET T
Oral 0 ADJ T
Ganciclovir 0 NOUN T
International 0 ADJ T
Transplantation 0 NOUN T
Study 0 NOUN T
Group 0 NOUN T
[ 0 PUNCT F
corrected 0 PUNCT F
] 0 PUNCT F
. 0 PUNCT F

BACKGROUND 0 NOUN T
Cytomegalovirus 0 NOUN T
( 0 PUNCT F
CMV 0 NOUN T
) 0 PUNCT F
disease 0 NOUN F
is 0 VERB F
a 0 DET F
frequent 0 ADJ F
cause 0 ADJ F
of 0 ADP F
serious 0 ADJ F
morbidity 0 NOUN F
after 0 ADP F
solid-organ 0 NOUN F
transplantation 0 NOUN F
. 0 PUNCT F

The 0 DET T
prophylactic 0 ADP F
regimens 0 NOUN F
used 0 VERB F
to 0 PART F
prevent 0 ADJ F
CMV 0 NOUN T
infection 0 NOUN F
and 0 CCONJ F
disease 0 NOUN F
have 0 PUNCT F
shown 0 VERB F
limited 0 VERB F
benefit 0 NOUN F
in 0 ADP F
seronegative 0 ADJ F
recipients 0 NOUN F
. 0 PUNCT F

We 0 PRON T
studied 0 VERB F
the 0 DET F
safety 0 NOUN F
and 0 CCONJ F
efficacy 0 NOUN F
of 0 ADP F
oral 0 ADJ F
ganciclovir 0 NOUN F
in 0 ADP F
the 0 DET F
prevention 0 NOUN F
of 0 ADP F
CMV 0 NOUN T
disease 0 NOUN F
following 0 VERB F
orthotopic 0 ADJ F
liver 0 NOUN F
transplantation 0 NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
Between 0 ADP T
December 0 NOUN T
, 0 PUNCT F
1993 0 NUM F
, 0 PUNCT F
and 0 CCONJ F
April 0 NOUN T
, 0 PUNCT F
1995 0 NUM F
, 0 PUNCT F
304 0 NUM F
liver-transplant 0 ADJ F
recipients 0 NOUN F
were 0 VERB F
randomised 0 VERB F
to 0 PART F
receive 0 NOUN F
oral 0 ADJ F
ganciclovir 0 NOUN F
1000 0 NUM F
mg 0 NOUN F
or 0 CCONJ F
matching 0 VERB F
placebo 0 NOUN F
three 0 NUM F
times 0 NOUN F
a 0 DET F
day 0 NOUN F
. 0 PUNCT F

Seronegative 0 ADJ T
recipients 0 NOUN F
of 0 ADP F
seronegative 0 ADJ F
livers 0 NOUN F
were 0 VERB F
excluded 0 VERB F
. 0 PUNCT F

Study 0 ADJ T
drug 0 NOUN F
was 0 VERB F
administered 0 NUM F
as 0 PUNCT F
soon 0 VERB F
as 0 CCONJ F
the 0 DET F
patient 0 NOUN F
was 0 VERB F
able 0 ADJ F
to 0 PART F
take 0 ADJ F
medication 0 NOUN F
by 0 ADP F
mouth 0 NOUN F
( 0 PUNCT F
no 0 ADP F
later 0 PUNCT F
than 0 ADP F
day 0 NOUN F
10 0 NUM F
) 0 PUNCT F
until 0 ADP F
the 0 DET F
98th 0 ADJ F
day 0 NOUN F
after 0 ADP F
transplantation 0 NOUN F
. 0 PUNCT F

Patients 0 NOUN T
were 0 VERB F
assessed 0 VERB F
at 0 ADP F
specified 0 VERB F
times 0 NOUN F
throughout 0 ADP F
the 0 DET F
first 0 ADJ F
6 0 NUM F
months 0 NOUN F
after 0 ADP F
surgery 0 NOUN F
for 0 ADP F
evidence 0 NOUN F
of 0 ADP F
CMV B-OTHER NOUN T
infection I-OTHER NOUN F
, 0 PUNCT F
CMV B-OTHER NOUN T
disease I-OTHER NOUN F
, 0 PUNCT F
rejection B-OTHER NOUN F
, 0 PUNCT F
opportunistic B-OTHER ADJ F
infections I-OTHER NOUN F
, 0 PUNCT F
and 0 PUNCT F

Alternative 0 ADJ T
voice 0 NOUN F
after 0 ADP F
laryngectomy 0 NOUN F
using 0 VERB F
a 0 DET F
sound-producing 0 PUNCT F
voice 0 NOUN F
prosthesis 0 NOUN F
. 0 PUNCT F

OBJECTIVE 0 NOUN T
To 0 PROPN T
improve 0 ADJ F
the 0 DET F
voice 0 NOUN F
quality 0 NOUN F
of 0 ADP F
female 0 NOUN F
laryngectomees 0 NOUN F
and/or 0 CCONJ F
laryngectomees 0 NOUN F
with 0 ADP F
a 0 DET F
hypotonic 0 ADJ F
pharyngoesophageal 0 ADJ F
( 0 PUNCT F
PE 0 NOUN T
) 0 PUNCT F
segment 0 NOUN F
by 0 ADP F
means 0 NOUN F
of 0 ADP F
a 0 DET F
pneumatic B-PHYSICAL ADJ F
artificial I-PHYSICAL ADJ F
source I-PHYSICAL NOUN F
of I-PHYSICAL ADP F
voice I-PHYSICAL NOUN F
incorporated I-PHYSICAL ADP F
in I-PHYSICAL ADP F
a I-PHYSICAL DET F
regular I-PHYSICAL ADJ F
tracheoesophageal I-PHYSICAL DET F
( 0 PUNCT F
TE B-PHYSICAL NOUN T
) 0 PUNCT F
shunt B-PHYSICAL NOUN F
valve B-PHYSICAL NOUN F
. 0 PUNCT F

STUDY 0 NOUN T
DESIGN 0 NOUN T
Experimental 0 ADJ T
, 0 PUNCT F
randomized 0 VERB F
, 0 PUNCT F
crossover 0 ADP F
trial 0 NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
The 0 DET T
new 0 ADJ F
sound 0 ADJ F
source 0 NOUN F
consists 0 NOUN F
of 0 ADP F
a 0 DET F
single 0 ADJ F
silicone 0 NUM F
lip 0 NOUN F
, 0 PUNCT F
which 0 ADP F
performs 0 NOUN F
an 0 DET F
oscillatory 0 ADJ F
movement 0 NOUN F
driven 0 VERB F
by 0 ADP F
expired 0 PUNCT F
pulmonary 0 ADJ F
air 0 NOUN F
flowing 0 NUM F
along 0 ADP F
the 0 DET F
outward-striking 0 VERB F
lip 0 NOUN F
through 0 ADP F
the 0 DET F
TE 0 NOUN T
shunt 0 NOUN F
valve 0 NOUN F
. 0 PUNCT F

A 0 DET T
prototype 0 NOUN F
of 0 ADP F
this 0 DET F
pneumatic 0 ADJ F
sound 0 ADJ F
source 0 NOUN F
is 0 VERB F
evaluated 0 VERB F
in 0 ADP F
vitro 0 ADJ F
and 0 CCONJ F
in 0 ADP F
six 0 NUM F
laryngectomees 0 NOUN F
. 0 PUNCT F

In 0 ADJ T
vivo 0 ADJ F
evaluation 0 NOUN F
includes 0 ADP F
speech 0 NOUN F
rate 0 NOUN F
, 0 PUNCT F
maximal 0 ADJ F
phonation 0 NOUN F
time 0 NOUN F
, 0 PUNCT F
perceptual 0 ADJ F
voice 0 NOUN F
evaluation 0 NOUN F
of 0 ADP F
read-aloud 0 NOUN F
prose 0 ADP F
by 0 ADP F
an 0 DET F
expert 0 NOUN F
listener 0 PUNCT F
, 0 PUNCT F
speech 0 NOUN F
intelligibility 0 NOUN F
measurements 0 NOUN F
with 0 ADP F
12 0 NUM F
listeners 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
self-assessment 0 VERB F
by 0 ADP F
the 0 DET F
patients 0 NOUN F
. 0 PUNCT F

Moreover 0 ADV T
, 0 PUNCT F
extensive B-OTHER ADJ F
acoustical I-OTHER ADJ F
and 0 CCONJ F
aerodynamic B-PHYSICAL ADJ F
in B-PHYSICAL ADJ F
vivo I-PHYSICAL ADJ F
registrations I-PHYSICAL ADJ F
are 0 VERB F
performed 0 VERB F
using 0 VERB F
a 0 DET F
newly B-OTHER ADV F
developed I-OTHER VERB F
data 0 NOUN F
acquisition B-OTHER NOUN F
system I-OTHER NOUN F
. 0 PUNCT F

RESULTS 0 PUNCT T
The 0 DET T
current 0 ADJ F
prototype 0 NOUN F
seems 0 NOUN F
beneficial 0 ADJ F
in 0 ADP F
female 0 NOUN F
laryngectomees 0 NOUN F
with 0 ADP F
a 0 DET F
hypotonic 0 ADJ F
PE 0 NOUN T
segment 0 NOUN F
only 0 ADV F
. 0 PUNCT F

For 0 ADP T
them 0 PUNCT F
the 0 DET F
sound-producing 0 PUNCT F
voice 0 NOUN F
prosthesis 0 NOUN F
improves B-PHYSICAL NOUN F
voice I-PHYSICAL NOUN F
quality I-PHYSICAL NOUN F
and I-PHYSICAL CCONJ F
increases 0 PUNCT F
the B-PHYSICAL DET F
average 0 ADJ F
pitch B-PHYSICAL NOUN F
of I-PHYSICAL ADP F
voice I-PHYSICAL NOUN F
, 0 PUNCT F
without B-PHYSICAL ADP F
decreasing I-PHYSICAL ADP F
intelligibility 0 NOUN F
or B-PHYSICAL CCONJ F
necessitating I-PHYSICAL PUNCT F
other B-PHYSICAL PUNCT F

[ 0 PUNCT F
Supplementary 0 ADJ T
treatment 0 NOUN F
with 0 ADP F
Esberitox 0 PUNCT T
of 0 ADP F
female 0 NOUN F
patients 0 NOUN F
undergoing 0 VERB F
curative 0 ADJ F
adjuvant 0 NOUN F
irradiation 0 NOUN F
following 0 VERB F
breast 0 NOUN F
cancer 0 NOUN F
] 0 PUNCT F
. 0 PUNCT F

1 0 NUM F
. 0 PUNCT F

The 0 DET T
study 0 NOUN F
was 0 VERB F
supposed 0 VERB F
to 0 PART F
investigate 0 NOUN F
a 0 DET F
possible 0 ADJ F
prevention B-PHYSICAL NOUN F
or 0 CCONJ F
reduction B-PHYSICAL NOUN F
of I-PHYSICAL ADP F
the I-PHYSICAL DET F
toxicity I-PHYSICAL NOUN F
of 0 ADP F
radiotherapy 0 NOUN F
by 0 ADP F
an 0 DET F
additional 0 ADJ F
treatment 0 NOUN F
with 0 ADP F
Esberitox 0 ADV T
. 0 PUNCT F

This 0 DET T
question 0 NOUN F
arose 0 VERB F
when 0 ADP F
performing 0 PUNCT F
an 0 DET F
investigation 0 NOUN F
about 0 PUNCT F
the 0 DET F
effect 0 NOUN F
of 0 ADP F
Esberitox 0 DET T
in 0 ADP F
a 0 DET F
combined 0 VERB F
chemo-radiotherapy 0 NOUN F
. 0 PUNCT F

Whereas 0 ADP T
the 0 DET F
latter 0 ADJ F
induces 0 NOUN F
above 0 ADP F
all 0 PUNCT F
a 0 DET F
systemic 0 ADJ F
damage 0 NOUN F
to 0 ADP F
the 0 DET F
hemopoietic 0 ADJ F
system 0 NOUN F
, 0 PUNCT F
radiotherapy 0 NOUN F
is 0 VERB F
a 0 DET F
regional 0 ADJ F
noxa 0 PUNCT F
. 0 PUNCT F

2 0 NUM F
. 0 PUNCT F

The 0 DET T
present 0 ADJ F
prospective 0 ADJ F
, 0 PUNCT F
randomized 0 ADP F
study 0 NOUN F
was 0 VERB F
conducted 0 VERB F
with 0 ADP F
50 0 NUM F
patients 0 NOUN F
submitted 0 VERB F
to 0 ADP F
curative 0 ADJ F
adjuvant 0 NOUN F
irradiation 0 NOUN F
following 0 VERB F
surgery 0 NOUN F
for 0 ADP F
mammary 0 ADJ F
carcinoma 0 NOUN F
. 0 PUNCT F

The 0 DET T
radiotherapy 0 NOUN F
was 0 VERB F
performed 0 VERB F
in 0 ADP F
the 0 DET F
same 0 ADJ F
way 0 NOUN F
in 0 ADP F
all 0 DET F
patients 0 NOUN F
with 0 ADP F
irradiations 0 NOUN F
of 0 ADP F
the 0 DET F
thoracic 0 ADJ F
wall 0 NOUN F
and 0 CCONJ F
the 0 DET F
regional 0 ADJ F
lymph 0 NOUN F
nodes 0 NOUN F
. 0 PUNCT F

Two 0 NUM T
groups 0 NOUN F
were 0 VERB F
built 0 PUNCT F
by 0 ADP F
randomization 0 NOUN F
. 0 PUNCT F

The 0 DET T
study 0 ADJ F
group 0 NOUN F
received 0 VERB F
an 0 DET F
additional 0 ADJ F
treatment 0 NOUN F
with 0 ADP F
Esberitox 0 DET T
, 0 PUNCT F
the 0 DET F
control 0 NOUN F
group 0 NOUN F
did 0 VERB F
not 0 ADV F
receive 0 VERB F
an 0 DET F
additional 0 ADJ F
treatment 0 NOUN F
. 0 PUNCT F

3 0 NUM F
. 0 PUNCT F

As 0 ADP T
a 0 DET F
result 0 NOUN F
, 0 PUNCT F
no 0 DET F
protective 0 ADJ F
influence 0 NOUN F
of 0 ADP F
Esberitox 0 ADV T
could 0 VERB F
be 0 VERB F
demonstrated 0 VERB F
. 0 PUNCT F

The 0 DET T
parameters 0 NOUN F
investigated 0 VERB F
were 0 VERB F
the 0 DET F
peripheral B-PHYSICAL ADJ F
blood I-PHYSICAL NOUN F
count I-PHYSICAL NOUN F
( 0 PUNCT F
leucocytes B-PHYSICAL PROPN F
, 0 PUNCT F
granulocytes B-PHYSICAL NOUN F
, 0 PUNCT F
lymphocytes B-PHYSICAL NOUN F
, 0 PUNCT F
monocytes B-PHYSICAL NOUN F
, 0 PUNCT F
thrombocytes B-PHYSICAL PUNCT F
, 0 PUNCT F
hemoglobin B-PHYSICAL NOUN F
, 0 PUNCT F
hematocrit B-PHYSICAL NOUN F
) 0 PUNCT F
and B-PHYSICAL CCONJ F
the I-PHYSICAL DET F
incidence 0 PUNCT F

[ 0 PUNCT F
Dexmedetomidine 0 NOUN T
use 0 NOUN F
for 0 ADP F
postoperative B-PHYSICAL ADJ F
adrenergic I-PHYSICAL ADJ F
analgesia I-PHYSICAL NOUN F
and I-PHYSICAL CCONJ F
sedation I-PHYSICAL NOUN F
in 0 ADP F
abdominal 0 ADJ F
surgery 0 NOUN F
] 0 PUNCT F
. 0 PUNCT F

Comparative 0 ADJ T
study 0 NOUN F
of 0 ADP F
postoperative 0 ADJ F
analgesia 0 NOUN F
and 0 CCONJ F
sedation 0 NOUN F
with 0 ADP F
trimeperidine 0 ADJ F
and 0 CCONJ F
dexmedetomidine 0 PUNCT F
and 0 CCONJ F
their 0 ADP F
effects 0 NOUN F
on 0 ADP F
haemodynamics 0 NOUN F
and 0 CCONJ F
vegetative 0 ADJ F
nervous 0 ADJ F
system 0 NOUN F
was 0 VERB F
performed 0 VERB F
. 0 PUNCT F

Assessment 0 NOUN T
of 0 ADP F
analgesia 0 NOUN F
and 0 CCONJ F
sedation 0 NOUN F
during 0 ADP F
vagotonia 0 NOUN F
( 0 PUNCT F
first 0 ADP F
part 0 NOUN F
of 0 ADP F
the 0 DET F
study 0 NOUN F
) 0 PUNCT F
and 0 CCONJ F
hypokinetic 0 ADJ F
type 0 NOUN F
of 0 ADP F
haemodynamics 0 NOUN F
( 0 PUNCT F
second 0 ADP F
part 0 NOUN F
of 0 ADP F
the 0 DET F
study 0 NOUN F
) 0 PUNCT F
was 0 VERB F
carried 0 VERB F
out 0 ADP F
with 0 ADP F
visual 0 ADJ F
analogue 0 NOUN F
scale 0 NOUN F
( 0 PUNCT F
VAS 0 NOUN T
) 0 PUNCT F
and 0 CCONJ F
Richmond B-PHYSICAL NOUN T
scale I-PHYSICAL NOUN F
. 0 PUNCT F

Results 0 NOUN T
of 0 ADP F
the 0 DET F
study 0 NOUN F
showed 0 VERB F
that 0 ADP F
dexmedetomidine 0 PUNCT F
is 0 VERB F
more 0 ADV F
effective B-OTHER ADJ F
and 0 CCONJ F
safer B-OTHER PUNCT F
than 0 PUNCT F
trimeperidine 0 ADP F
for 0 ADP F
analgesia B-PHYSICAL NOUN F
and 0 CCONJ F
sedation B-PHYSICAL NOUN F
in 0 ADP F
patients 0 NOUN F
with 0 ADP F
spontaneous 0 ADJ F
breathing 0 VERB F
after 0 ADP F
abdominal 0 ADJ F
surgery 0 NOUN F
. 0 PUNCT F

Dexmedetomidine 0 PUNCT T
use 0 NOUN F
allows 0 NOUN F
keeping 0 VERB F
optimal 0 ADJ F
type 0 NOUN F
of 0 ADP F
haemodynamics 0 NOUN F
and 0 CCONJ F
vegetative 0 ADJ F
nervous 0 ADJ F
system 0 NOUN F
parameters 0 NOUN F
on 0 ADP F
first 0 ADJ F
day 0 NOUN F
of 0 ADP F
postoperative 0 ADJ F
period 0 NOUN F
. 0 PUNCT F

Daclizumab 0 NOUN T
high-yield 0 NOUN F
process 0 NOUN F
in 0 ADP F
relapsing-remitting B-PHYSICAL PUNCT F
multiple I-PHYSICAL ADJ F
sclerosis I-PHYSICAL NOUN F
( 0 PUNCT F
SELECT 0 NOUN T
) 0 PUNCT F
: 0 PUNCT F
a 0 DET F
randomised 0 VERB F
, 0 PUNCT F
double-blind 0 ADJ F
, 0 PUNCT F
placebo-controlled 0 VERB F
trial 0 NOUN F
. 0 PUNCT F

BACKGROUND 0 NOUN T
Daclizumab 0 NOUN T
, 0 PUNCT F
a 0 DET F
humanised 0 VERB F
monoclonal 0 ADJ F
antibody 0 NOUN F
, 0 PUNCT F
modulates 0 NOUN F
interleukin-2 0 NOUN F
signalling 0 VERB F
by 0 ADP F
blocking 0 VERB F
the 0 DET F
? 0 PUNCT F

subunit 0 NOUN F
( 0 PUNCT F
CD25 0 NOUN T
) 0 PUNCT F
of 0 ADP F
the 0 DET F
interleukin-2 0 NOUN F
receptor 0 NOUN F
. 0 PUNCT F

We 0 PRON T
assessed 0 VERB F
whether 0 ADP F
daclizumab 0 NOUN F
high-yield 0 NOUN F
process 0 NOUN F
( 0 PUNCT F
HYP 0 NOUN T
) 0 PUNCT F
would 0 VERB F
be 0 NOUN F
effective 0 ADJ F
when 0 ADP F
given 0 VERB F
as 0 ADP F
monotherapy 0 NOUN F
for 0 ADP F
a 0 DET F
1 0 NUM F
year 0 NOUN F
treatment 0 NOUN F
period 0 NOUN F
in 0 ADP F
patients 0 NOUN F
with 0 ADP F
relapsing-remitting 0 PUNCT F
multiple 0 ADJ F
sclerosis 0 NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
We 0 ADJ T
did 0 CCONJ F
a 0 DET F
randomised 0 VERB F
, 0 PUNCT F
double-blind 0 ADJ F
, 0 PUNCT F
placebo-controlled 0 VERB F
trial 0 NOUN F
at 0 ADP F
76 0 NUM F
centres 0 NOUN F
in 0 ADP F
the 0 DET F
Czech 0 NOUN T
Republic 0 ADJ T
, 0 PUNCT F
Germany 0 PUNCT T
, 0 PUNCT F
Hungary 0 PUNCT T
, 0 PUNCT F
India 0 PUNCT T
, 0 PUNCT F
Poland 0 PUNCT T
, 0 PUNCT F
Russia 0 NOUN T
, 0 PUNCT F
Ukraine 0 NOUN T
, 0 PUNCT F
Turkey 0 ADJ T
, 0 PUNCT F
and 0 CCONJ F
the 0 DET F
UK 0 NOUN T
between 0 ADP F
Feb 0 NOUN T
15 0 NUM F
, 0 PUNCT F
2008 0 NUM F
, 0 PUNCT F
and 0 CCONJ F
May 0 NOUN T
14 0 NUM F
, 0 PUNCT F
2010 0 NUM F
. 0 PUNCT F

Patients 0 NOUN T
aged 0 DET F
18-55 0 NUM F
years 0 NOUN F
with 0 ADP F
relapsing-remitting 0 PUNCT F
multiple 0 ADJ F
sclerosis 0 NOUN F
were 0 VERB F
randomly 0 ADV F
assigned 0 VERB F
( 0 PUNCT F
1:1:1 0 NOUN F
) 0 PUNCT F
, 0 PUNCT F
via 0 ADP F
a 0 DET F
central 0 ADJ F
interactive 0 ADJ F
voice 0 NOUN F
response 0 NOUN F
system 0 NOUN F
, 0 PUNCT F
to 0 ADP F
subcutaneous 0 ADJ F
injections 0 NOUN F
of 0 ADP F
daclizumab 0 NOUN F
HYP 0 NOUN T
150 0 NUM F
mg 0 NOUN F
or 0 CCONJ F
300 0 NUM F
mg 0 NOUN F
, 0 PUNCT F
or 0 CCONJ F
placebo 0 NOUN F
, 0 PUNCT F
every 0 DET F
4 0 NUM F
weeks 0 NOUN F
for 0 ADP F
52 0 NUM F
weeks 0 NOUN F
. 0 PUNCT F

Patients 0 NOUN T
and 0 CCONJ F
study 0 ADV F
personnel 0 NOUN F
were 0 VERB F
masked 0 VERB F
to 0 ADP F
treatment 0 NOUN F
assignment 0 NOUN F
, 0 PUNCT F
except 0 PUNCT F
for 0 ADP F
the 0 DET F
site 0 NOUN F
pharmacist 0 NOUN F
who 0 ADP F
prepared 0 VERB F
the 0 DET F
study 0 ADP F
drug 0 NOUN F
for 0 ADP F
injection 0 NOUN F
, 0 PUNCT F
but 0 CCONJ F
had 0 VERB F
no 0 DET F
interaction 0 NOUN F
with 0 ADP F
the 0 DET F
patient 0 NOUN F
. 0 PUNCT F

The 0 DET T
primary 0 ADJ F
endpoint 0 NOUN F
was 0 VERB F
annualised 0 VERB F
relapse 0 NOUN F
rate 0 NOUN F
. 0 PUNCT F

Analysis 0 NOUN T
was 0 VERB F
by 0 ADP F
intention 0 NOUN F
to 0 PART F
treat 0 ADV F
. 0 PUNCT F

The 0 DET T
trial 0 NOUN F
is 0 VERB F
registered 0 PUNCT F
with 0 ADP F
ClinicalTrials.gov 0 PUNCT T
, 0 PUNCT F
number 0 NOUN F
NCT00390221 0 NOUN T
. 0 PUNCT F

FINDINGS 0 NOUN T
204 0 NUM F
patients 0 NOUN F
were 0 VERB F
assigned 0 VERB F
to 0 PART F
receive 0 NOUN F
placebo 0 NOUN F
, 0 PUNCT F
208 0 NUM F
to 0 ADP F
daclizumab 0 NOUN F
HYP 0 NOUN T
150 0 NUM F
mg 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
209 0 NUM F
to 0 ADP F
daclizumab 0 NOUN F
HYP 0 NOUN T
300 0 NUM F
mg 0 NOUN F
, 0 PUNCT F
of 0 ADP F
whom 0 ADP F
188 0 NUM F
( 0 PUNCT F
92 0 NUM F
% 0 SYM F
) 0 PUNCT F
, 0 PUNCT F
192 0 NUM F
( 0 PUNCT F
92 0 NUM F
% 0 SYM F
) 0 PUNCT F
, 0 PUNCT F
and 0 CCONJ F
197 0 NUM F
( 0 PUNCT F
94 0 NUM F
% 0 SYM F
) 0 PUNCT F
, 0 PUNCT F
respectively 0 ADV F
, 0 PUNCT F
completed 0 VERB F
follow-up 0 NOUN F
to 0 ADP F
week 0 NOUN F
52 0 NUM F
. 0 PUNCT F

The 0 DET T
annualised 0 VERB F
relapse 0 NOUN F
rate 0 NOUN F
was 0 VERB F
lower 0 PUNCT F
for 0 ADP F
patients 0 NOUN F
given 0 VERB F
daclizumab 0 NOUN F
HYP 0 NOUN T
150 0 NUM F
mg 0 NOUN F
( 0 PUNCT F
0?21 0 ADJ F
, 0 PUNCT F
95 0 NUM F
% 0 SYM F
CI 0 NOUN T
0?16-0?29 0 ADV F
; 0 PUNCT F
54 0 NUM F
% 0 SYM F
reduction 0 NOUN F
, 0 PUNCT F
95 0 NUM F
% 0 SYM F
CI 0 NOUN T
33-68 0 NUM F
% 0 SYM F
; 0 PUNCT F
p 0 NOUN F
< 0 SYM F
0?0001 0 NUM F
) 0 PUNCT F
or 0 CCONJ F
300 0 NUM F
mg 0 NOUN F
( 0 PUNCT F
0?23 0 ADP F
, 0 PUNCT F
0?17-0?31 0 ADV F
, 0 PUNCT F
50 0 NUM F
% 0 SYM F
reduction 0 NOUN F
, 0 PUNCT F
28-65 0 NUM F
% 0 SYM F
; 0 PUNCT F
p=0?00015 0 NOUN F
) 0 PUNCT F
than 0 PUNCT F
for 0 ADP F
those 0 ADJ F
given 0 VERB F
placebo 0 NOUN F
( 0 PUNCT F
0?46 0 NUM F
, 0 PUNCT F
0?37-0?57 0 PUNCT F
) 0 PUNCT F
. 0 PUNCT F

More 0 DET T
patients 0 NOUN F
were 0 VERB F
relapse 0 NOUN F
free 0 ADJ F
in 0 ADP F
the 0 DET F
daclizumab 0 NOUN F
HYP 0 NOUN T
150 0 NUM F
mg 0 NOUN F
( 0 PUNCT F
81 0 NUM F
% 0 SYM F
) 0 PUNCT F
and 0 CCONJ F
300 0 NUM F
mg 0 NOUN F
( 0 PUNCT F
80 0 NUM F
% 0 SYM F
) 0 PUNCT F
groups 0 NOUN F
than 0 CCONJ F
in 0 ADP F
the 0 DET F
placebo 0 NOUN F
group 0 NOUN F
( 0 PUNCT F
64 0 NUM F
% 0 SYM F
; 0 PUNCT F
p 0 NOUN F
< 0 SYM F
0?0001 0 DET F
in 0 ADP F
the 0 DET F
150 0 NUM F
mg 0 NOUN F
group 0 NOUN F
and 0 CCONJ F
p=0?0003 0 NUM F
in 0 ADP F
the 0 DET F
300 0 NUM F
mg 0 NOUN F
group 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

12 0 NUM F
( 0 PUNCT F
6 0 NUM F
% 0 SYM F
) 0 PUNCT F
patients 0 NOUN F
in 0 ADP F
the 0 DET F
placebo 0 NOUN F
group 0 NOUN F
, 0 PUNCT F
15 0 NUM F
( 0 PUNCT F
7 0 NUM F
% 0 SYM F
) 0 PUNCT F
of 0 ADP F
those 0 PUNCT F
in 0 ADP F
the 0 DET F
daclizumab 0 NOUN F
150 0 NUM F
mg 0 NOUN F
group 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
19 0 NUM F
( 0 PUNCT F
9 0 NUM F
% 0 SYM F
) 0 PUNCT F
in 0 ADP F
the 0 DET F
300 0 NUM F
mg 0 NOUN F
group 0 NOUN F
had 0 PUNCT F
serious 0 ADJ F
adverse 0 ADJ F
events 0 NOUN F
excluding 0 ADJ F
multiple 0 ADJ F
sclerosis 0 NOUN F
relapse 0 NOUN F
. 0 PUNCT F

One 0 NUM T
patient 0 NOUN F
given 0 VERB F
daclizumab 0 NOUN F
HYP 0 NOUN T
150 0 NUM F
mg 0 NOUN F
who 0 ADP F
was 0 VERB F
recovering 0 ADV F
from 0 ADP F
a 0 DET F
serious 0 ADJ F
rash 0 NOUN F
died 0 VERB F
because 0 PUNCT F
of 0 ADP F
local 0 ADJ F
complication 0 NOUN F
of 0 ADP F
a 0 DET F
psoas 0 NOUN F
abscess 0 NOUN F
. 0 PUNCT F

INTERPRETATION 0 NOUN T
Subcutaneous 0 ADJ T
daclizumab 0 NOUN F
HYP 0 NOUN T
administered 0 VERB F
every 0 DET F
4 0 NUM F
weeks 0 NOUN F
led 0 VERB F
to 0 ADP F
clinically 0 ADV F
important 0 ADJ F
effects 0 NOUN F
on 0 ADP F
multiple 0 ADJ F
sclerosis 0 NOUN F
disease 0 NOUN F
activity 0 NOUN F
during 0 ADP F
1 0 NUM F
year 0 NOUN F
of 0 ADP F
treatment 0 NOUN F
. 0 PUNCT F

Our 0 DET T
findings 0 NOUN F
support 0 VERB F
the 0 DET F
potential 0 ADJ F
for 0 ADP F
daclizumab 0 NOUN F
HYP 0 NOUN T
to 0 PROPN F
offer 0 ADJ F
an 0 DET F
additional 0 ADJ F
treatment 0 NOUN F
option 0 NOUN F
for 0 ADP F
relapsing-remitting 0 ADV F
disease 0 NOUN F
. 0 PUNCT F

FUNDING 0 PUNCT T
Biogen 0 NOUN T
Idec 0 ADJ T
and 0 CCONJ F
AbbVie 0 PUNCT T
Biotherapeutics 0 PROPN T
Inc 0 NOUN T
. 0 PUNCT F

Efficacy 0 NOUN T
and 0 CCONJ F
safety 0 NOUN F
of 0 ADP F
mizolastine 0 PUNCT F
10 0 NUM F
mg 0 NOUN F
in 0 ADP F
a 0 DET F
placebo-controlled 0 ADV F
comparison 0 NOUN F
with 0 ADP F
loratadine 0 NOUN F
in 0 ADP F
chronic 0 ADJ F
idiopathic 0 ADJ F
urticaria 0 NOUN F
: 0 PUNCT F
results 0 CCONJ F
of 0 ADP F
the 0 DET F
MILOR 0 NOUN T
Study 0 NOUN T
. 0 PUNCT F

BACKGROUND 0 NOUN T
Mizolastine 0 ADV T
is 0 VERB F
a 0 DET F
novel 0 ADJ F
histamine 0 NOUN F
H1-antagonist 0 NOUN T
registered 0 NOUN F
in 0 ADP F
Europe 0 PUNCT T
for 0 ADP F
the 0 DET F
management 0 NOUN F
of 0 ADP F
allergic 0 ADJ F
rhinitis 0 NOUN F
and 0 CCONJ F
urticaria 0 NOUN F
. 0 PUNCT F

OBJECTIVES 0 ADP T
To 0 PROPN T
compare 0 NOUN F
the 0 DET F
clinical 0 ADJ F
efficacy 0 NOUN F
and 0 CCONJ F
safety 0 NOUN F
of 0 ADP F
mizolastine 0 ADV F
with 0 ADP F
loratadine 0 NOUN F
and 0 CCONJ F
placebo 0 NOUN F
in 0 ADP F
patients 0 NOUN F
with 0 ADP F
chronic 0 ADJ F
idiopathic 0 ADJ F
urticaria 0 NOUN F
( 0 PUNCT F
CIU 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

METHODS 0 NOUN T
A 0 PUNCT T
multicentre 0 NOUN F
, 0 PUNCT F
double-blind 0 ADJ F
, 0 PUNCT F
parallel 0 ADJ F
group 0 NOUN F
study 0 NOUN F
was 0 VERB F
designed 0 VERB F
in 0 ADP F
which 0 ADP F
247 0 NUM F
patients 0 NOUN F
with 0 ADP F
CIU 0 NOUN T
were 0 VERB F
randomised 0 NUM F
after 0 ADP F
a 0 DET F
1-week 0 NOUN F
placebo 0 NOUN F
run-in 0 NOUN F
period 0 NOUN F
to 0 ADP F
10 0 NUM F
mg 0 NOUN F
daily 0 ADJ F
mizolastine 0 NOUN F
( 0 PUNCT F
n 0 NOUN F
= 0 SYM F
88 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
10 0 NUM F
mg 0 NOUN F
daily 0 PUNCT F
loratadine 0 NOUN F
( 0 PUNCT F
n 0 NOUN F
= 0 SYM F
79 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
or 0 CCONJ F
placebo 0 NOUN F
( 0 PUNCT F
n 0 NOUN F
= 0 SYM F
80 0 NUM F
) 0 PUNCT F
for 0 ADP F
a 0 DET F
4-week 0 NOUN F
treatment 0 NOUN F
period 0 NOUN F
. 0 PUNCT F

RESULTS 0 DET T
Mizolastine 0 PUNCT T
and 0 CCONJ F
loratadine 0 NOUN F
both 0 CCONJ F
relieved B-PHYSICAL PUNCT F
symptoms I-PHYSICAL NOUN F
of I-PHYSICAL ADP F
CIU I-PHYSICAL NOUN T
. 0 PUNCT F

After 0 ADP T
2 0 NUM F
weeks 0 NOUN F
' 0 PUNCT F
treatment 0 NOUN F
, 0 PUNCT F
the 0 DET F
severity 0 NOUN F
of 0 ADP F
pruritus B-PHYSICAL NOUN F
( I-PHYSICAL PUNCT F
visual I-PHYSICAL ADJ F
analogue I-PHYSICAL NOUN F
score 0 NOUN F
( B-PHYSICAL PUNCT F
VAS 0 NOUN T
) B-PHYSICAL PUNCT F
assessed I-PHYSICAL VERB F
by I-PHYSICAL ADP F
patients B-PHYSICAL NOUN F
) I-PHYSICAL PUNCT F
decreased 0 VERB F
significantly 0 ADV F
in 0 ADP F
both 0 CCONJ F
the 0 DET F
mizolastine 0 ADP F
and 0 CCONJ F
loratadine 0 NOUN F
groups 0 NOUN F
compared 0 VERB F
with 0 ADP F
placebo 0 NOUN F
( 0 PUNCT F
mizolastine 0 ADV F
: 0 PUNCT F
-36.7 0 PUNCT F
mm 0 NOUN F
, 0 PUNCT F
P 0 NOUN T
= 0 SYM F
0.0001 0 NUM F
; 0 PUNCT F
loratadine 0 NOUN F
: 0 PUNCT F
-29.8 0 PUNCT F
, 0 PUNCT F
P 0 NOUN T
= 0 SYM F
0.0071 0 ADV F
; 0 PUNCT F
placebo 0 NOUN F
: 0 PUNCT F
-16.3 0 PUNCT F
) 0 PUNCT F
; 0 PUNCT F
this 0 DET F
improvement 0 NOUN F
with 0 ADP F
both 0 CCONJ F
active 0 ADJ F
treatments 0 NOUN F
was 0 VERB F
maintained 0 VERB F
throughout 0 ADP F
the 0 DET F
treatment 0 NOUN F
period 0 NOUN F
, 0 PUNCT F
the 0 DET F
difference 0 NOUN F
being 0 VERB F
significant 0 ADJ F
only 0 ADV F
for 0 ADP F
the 0 DET F
mizolastine 0 ADJ F
group 0 NOUN F
( 0 PUNCT F
P 0 NOUN T
= 0 SYM F
0.0090 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Both 0 CCONJ T
active 0 ADJ F
treatments 0 NOUN F
were 0 VERB F
also 0 ADV F
associated 0 VERB F
with 0 ADP F
reduced 0 ADP F
weekly 0 ADV F
episodes B-PHYSICAL PUNCT F
of B-PHYSICAL ADP F
urticaria I-PHYSICAL NOUN F
compared 0 VERB F
with 0 ADP F
placebo 0 NOUN F
, 0 PUNCT F
which 0 ADP F
was 0 VERB F
significant 0 ADJ F
after 0 ADP F
2 0 NUM F
weeks 0 NOUN F
' 0 PUNCT F
treatment 0 NOUN F
( 0 PUNCT F
mizolastine 0 ADV F
: 0 PUNCT F
7.9 0 NUM F
episodes 0 NOUN F
, 0 PUNCT F
P 0 NOUN T
= 0 SYM F
0.0061 0 NUM F
; 0 PUNCT F
loratadine 0 NOUN F
: 0 PUNCT F
8.3 0 NUM F
, 0 PUNCT F
P 0 NOUN T
= 0 SYM F
0.0221 0 NUM F
; 0 PUNCT F
placebo 0 NOUN F
: 0 PUNCT F
13.3 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Angioedema B-PHYSICAL NOUN T
was 0 VERB F
improved 0 VERB F
to 0 ADP F
a 0 DET F
clinically 0 ADV F
significant 0 ADJ F
extent 0 NOUN F
with 0 ADP F
mizolastine 0 ADV F
, 0 PUNCT F
and 0 CCONJ F
loratadine 0 NOUN F
compared 0 VERB F
with 0 ADP F
placebo 0 NOUN F
in 0 ADP F
those 0 ADP F
patients 0 NOUN F
who 0 ADP F
had 0 PUNCT F
this 0 DET F
symptom 0 NOUN F
before 0 ADP F
treatment 0 NOUN F
. 0 PUNCT F

Overall B-OTHER ADJ T
tolerability I-OTHER NOUN F
of 0 ADP F
both 0 PUNCT F
treatments 0 NOUN F
was 0 VERB F
similar 0 ADJ F
to 0 ADP F
placebo 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
there 0 PUNCT F
were 0 VERB F
no 0 DET F
clinically 0 ADV F
relevant 0 ADJ F
effects 0 NOUN F
on 0 ADP F
cardiac B-PHYSICAL ADJ F
repolarisation I-PHYSICAL NOUN F
with 0 ADP F
either 0 PUNCT F
mizolastine 0 ADP F
or 0 CCONJ F
loratadine 0 NOUN F
. 0 PUNCT F

CONCLUSION 0 NOUN T
Mizolastine 0 NOUN T
( 0 PUNCT F
10 0 NUM F
mg 0 NOUN F
daily 0 ADJ F
) 0 PUNCT F
is 0 VERB F
confirmed 0 VERB F
as 0 PUNCT F
an 0 PUNCT F

An 0 DET T
assessment 0 NOUN F
of 0 ADP F
beta-adrenoceptor 0 NOUN F
blockade 0 NOUN F
in 0 ADP F
man 0 NOUN F
by 0 ADP F
prizidilol 0 NOUN F
hydrochloride 0 NOUN F
. 0 PUNCT F

1 0 NUM F
Prizidilol 0 NOUN T
hydrochloride 0 NOUN F
( 0 PUNCT F
SK 0 NOUN T
& 0 CCONJ F
F 0 NOUN T
92657 0 NUM F
) 0 PUNCT F
is 0 VERB F
a 0 DET F
new 0 ADJ F
compound 0 NOUN F
which 0 ADP F
causes 0 ADP F
both 0 PUNCT F
arteriolar 0 ADJ F
dilatation 0 NOUN F
and 0 CCONJ F
beta-adrenoceptor B-PHYSICAL NOUN F
blockade I-PHYSICAL NOUN F
. 0 PUNCT F

The 0 DET T
effect 0 NOUN F
of 0 ADP F
a 0 DET F
single 0 ADJ F
oral 0 ADJ F
dose 0 NOUN F
on 0 ADP F
the 0 DET F
responses 0 NOUN F
of 0 ADP F
heart 0 NOUN F
rate 0 NOUN F
and 0 CCONJ F
blood 0 NOUN F
pressure 0 NOUN F
to 0 ADP F
isoprenaline 0 PUNCT F
infusion 0 NOUN F
has 0 PUNCT F
been 0 PUNCT F
studied 0 VERB F
in 0 ADP F
healthy 0 ADJ F
volunteers 0 NOUN F
. 0 PUNCT F

2 0 NUM F
Isoprenaline 0 ADP T
heart B-PHYSICAL NOUN F
rate I-PHYSICAL NOUN F
dose-response I-PHYSICAL NOUN F
curves I-PHYSICAL NOUN F
showed 0 VERB F
parallel 0 ADJ F
shifts 0 DET F
to 0 ADP F
the 0 DET F
right 0 ADJ F
after 0 ADP F
oral 0 ADJ F
prizidilol 0 NOUN F
, 0 PUNCT F
indicating 0 ADP F
antagonism 0 NOUN F
by 0 ADP F
this 0 DET F
compound 0 CCONJ F
at 0 ADP F
beta-adrenoceptors 0 NOUN F
in 0 ADP F
the 0 DET F
heart 0 NOUN F
. 0 PUNCT F

3 0 NUM F
Isoprenaline 0 PUNCT T
dose-response 0 NOUN F
curves 0 NOUN F
for 0 ADP F
decreases 0 CCONJ F
in 0 ADP F
diastolic B-PHYSICAL ADJ F
blood I-PHYSICAL NOUN F
pressure I-PHYSICAL NOUN F
also 0 ADV F
showed 0 VERB F
shifts 0 NOUN F
to 0 ADP F
the 0 DET F
right 0 ADJ F
after 0 ADP F
oral 0 ADJ F
prizidilol 0 NOUN F
, 0 PUNCT F
providing 0 CCONJ F
evidence 0 NOUN F
of 0 ADP F
beta-adrenoceptor 0 NOUN F
antagonism 0 NOUN F
by 0 ADP F
this 0 PUNCT F
drug 0 NOUN F
in 0 ADP F
peripheral 0 ADJ F
resistance 0 NOUN F
vessels 0 NOUN F
. 0 PUNCT F

4 0 NUM F
The 0 DET T
peak 0 ADJ F
effect 0 NOUN F
of 0 ADP F
a 0 DET F
40 0 NUM F
mg 0 NOUN F
dose 0 NOUN F
of 0 ADP F
propranolol 0 NOUN F
was 0 VERB F
greater 0 PUNCT F
than 0 CCONJ F
that 0 PUNCT F
of 0 ADP F
a 0 DET F
200 0 NUM F
mg 0 NOUN F
dose 0 NOUN F
of 0 ADP F
prizidilol 0 NOUN F
but 0 CCONJ F
both 0 PUNCT F
drugs 0 NOUN F
caused 0 VERB F
persistent 0 ADJ F
beta-adrenoceptor B-PHYSICAL NOUN F
blockade I-PHYSICAL NOUN F
for 0 ADP F
at 0 ADP F
least 0 ADV F
7 0 NUM F
h 0 NOUN F
after 0 ADP F
ingestion 0 NOUN F
. 0 PUNCT F

Evaluation 0 NOUN T
of 0 ADP F
postural B-OTHER ADJ F
stability I-OTHER NOUN F
by 0 ADP F
computerised 0 VERB F
posturography 0 NOUN F
following 0 VERB F
outpatient 0 ADJ F
paediatric 0 ADJ F
anaesthesia 0 NOUN F
. 0 PUNCT F

Comparison 0 NOUN T
of 0 ADP F
propofol/alfentanil/N2O 0 NOUN F
anaesthesia 0 NOUN F
with 0 ADP F
thiopentone/halothane/N2O 0 PUNCT F
anaesthesia 0 NOUN F
. 0 PUNCT F

Simple 0 ADJ T
clinical 0 ADJ F
tests 0 NOUN F
, 0 PUNCT F
like 0 ADP F
Romberg 0 NOUN T
's 0 PUNCT F
test 0 NOUN F
or 0 CCONJ F
a 0 DET F
walking 0 VERB F
test 0 ADP F
, 0 PUNCT F
have 0 CCONJ F
proved 0 VERB F
to 0 PART F
be 0 PUNCT F
inadequate 0 ADJ F
guidelines 0 NOUN F
for 0 ADP F
safe B-OTHER ADJ F
discharge I-OTHER NOUN F
after 0 ADP F
outpatient 0 ADJ F
anaesthesia 0 NOUN F
. 0 PUNCT F

A 0 DET T
randomised 0 VERB F
study 0 NOUN F
was 0 VERB F
therefore 0 ADV F
planned 0 ADP F
to 0 PART F
compare 0 NOUN F
postural 0 ADJ F
stability 0 NOUN F
measured 0 VERB F
by 0 ADP F
computerised 0 VERB F
posturography 0 NOUN F
in 0 ADP F
31 0 NUM F
oral 0 ADJ F
midazolam-atropine 0 ADJ F
premedicated 0 PRON F
children 0 NOUN F
aged 0 PROPN F
6.9 0 NUM F
( 0 PUNCT F
s.e 0 PUNCT F
. 0 PUNCT F

0.4 0 NUM F
) 0 PUNCT F
years 0 NOUN F
who 0 ADP F
had 0 PUNCT F
been 0 ADP F
anaesthetised 0 VERB F
with 0 ADP F
either 0 CCONJ F
propofol/alfentanil/N2O 0 NOUN F
or 0 CCONJ F
thiopentone/halothane/N2O 0 PUNCT F
. 0 PUNCT F

The 0 DET T
sway B-MENTAL NOUN F
velocity I-MENTAL NOUN F
of 0 ADP F
the 0 DET F
children 0 NOUN F
was 0 VERB F
measured 0 VERB F
before 0 ADP F
premedication 0 NOUN F
and 0 CCONJ F
1 0 NUM F
, 0 PUNCT F
2 0 NUM F
and 0 CCONJ F
3 0 NUM F
h 0 NOUN F
after 0 ADP F
the 0 DET F
end 0 NOUN F
of 0 ADP F
anaesthesia 0 NOUN F
. 0 PUNCT F

Results 0 NOUN T
show 0 VERB F
that 0 ADP F
sway B-MENTAL NOUN F
velocity I-MENTAL NOUN F
had 0 PUNCT F
returned 0 VERB F
to 0 ADP F
baseline 0 NOUN F
values 0 NOUN F
3 0 NUM F
h 0 NOUN F
after 0 ADP F
the 0 DET F
end 0 NOUN F
of 0 ADP F
anaesthesia 0 NOUN F
in 0 ADP F
all 0 DET F
children 0 NOUN F
who 0 PROPN F
had 0 PUNCT F
received 0 CCONJ F
propofol/alfentanil/N2O 0 NOUN F
and 0 CCONJ F
in 0 ADP F
12 0 NUM F
of 0 ADP F
the 0 DET F
15 0 NUM F
children 0 NOUN F
who 0 PROPN F
had 0 PUNCT F
received 0 PUNCT F
thiopentone/halothane/N2O 0 PUNCT F
. 0 PUNCT F

The 0 DET T
quantified 0 VERB F
version 0 NOUN F
of 0 ADP F
the 0 DET F
Romberg B-OTHER ADV T
test I-OTHER NOUN F
performed 0 VERB F
with 0 ADP F
eyes 0 NOUN F
open 0 PUNCT F
or 0 CCONJ F
closed 0 PUNCT F
was 0 PROPN F
not 0 ADV F
impaired 0 VERB F
after 0 ADP F
anaesthesia 0 NOUN F
, 0 PUNCT F
compared 0 VERB F
with 0 ADP F
the 0 DET F
control 0 NOUN F
values 0 NOUN F
, 0 PUNCT F
indicating 0 VERB F
that 0 ADP F
in 0 ADP F
children 0 ADJ F
poor 0 ADJ F
equilibrium 0 NOUN F
is 0 VERB F
not 0 ADV F
compensated 0 ADV F
by 0 ADP F
vision 0 NOUN F
. 0 PUNCT F

The 0 DET T
clinical 0 ADJ F
recovery 0 NOUN F
with 0 ADP F
respect 0 NOUN F
to 0 ADP F
the 0 DET F
times 0 NOUN F
to 0 ADP F
eye B-PHYSICAL NOUN F
opening I-PHYSICAL ADJ F
, 0 PUNCT F
to 0 PUNCT F
responding 0 PUNCT F
to 0 ADP F
command 0 NOUN F
or 0 CCONJ F
to 0 PUNCT F
being 0 ADV F
fully 0 ADV F
awake 0 NOUN F
did 0 PUNCT F
not 0 ADV F
differ 0 VERB F
between 0 ADP F
the 0 DET F
two 0 NUM F
anaesthesia 0 NOUN F
methods 0 NOUN F
. 0 PUNCT F

On 0 ADP T
the 0 DET F
basis 0 NOUN F
of 0 ADP F
recovery 0 NOUN F
assessed 0 VERB F
by 0 ADP F
postural 0 ADJ F
stability 0 NOUN F
, 0 PUNCT F
propofol/alfentanil/N2O 0 NOUN F
anaesthesia 0 NOUN F
was 0 VERB F
not 0 ADV F
preferable 0 ADJ F
to 0 ADP F
thiopentone/halothane/N2O 0 PUNCT F
anaesthesia 0 NOUN F
after 0 ADP F
minor 0 ADJ F
paediatric 0 ADJ F
otolaryngological 0 ADP F
surgery 0 NOUN F
. 0 PUNCT F

Insular 0 ADJ T
and 0 CCONJ F
anterior 0 ADJ F
cingulate 0 ADJ F
circuits 0 PUNCT F
in 0 ADP F
smokers 0 NOUN F
with 0 ADP F
schizophrenia 0 NOUN F
. 0 PUNCT F

Schizophrenia 0 NOUN T
( 0 PUNCT F
SZ 0 NOUN T
) 0 PUNCT F
is 0 VERB F
associated 0 VERB F
with 0 ADP F
high 0 ADJ F
rates 0 NOUN F
of 0 ADP F
smoking 0 VERB F
. 0 PUNCT F

We 0 PRON T
previously 0 ADV F
found 0 PUNCT F
that 0 ADP F
resting 0 ADJ F
state 0 NOUN F
functional 0 ADJ F
connectivity 0 NOUN F
( 0 PUNCT F
rsFC 0 NOUN F
) 0 PUNCT F
between 0 ADP F
the 0 DET F
dorsal 0 ADJ F
anterior 0 ADJ F
cingulate 0 NOUN F
( 0 PUNCT F
dACC 0 NOUN F
) 0 PUNCT F
and 0 CCONJ F
striatum 0 NOUN F
is 0 VERB F
independently 0 ADV F
associated 0 VERB F
with 0 ADP F
nicotine 0 NOUN F
addiction 0 NOUN F
and 0 CCONJ F
psychiatric 0 ADJ F
illness 0 NOUN F
. 0 PUNCT F

Since 0 ADP T
the 0 DET F
insula 0 NOUN F
is 0 VERB F
implicated 0 VERB F
in 0 ADP F
nicotine 0 NOUN F
dependence 0 NOUN F
, 0 PUNCT F
we 0 PRON F
hypothesized 0 VERB F
that 0 ADP F
SZ 0 NOUN T
smokers 0 NOUN F
will 0 VERB F
have 0 CCONJ F
greater 0 PUNCT F
dysfunction 0 NOUN F
in 0 ADP F
smoking-related 0 VERB F
insular 0 ADJ F
and 0 CCONJ F
dACC 0 NOUN F
circuits 0 PUNCT F
than 0 PUNCT F
normal 0 ADJ F
control 0 NOUN F
smokers 0 NOUN F
( 0 PUNCT F
NC 0 NOUN T
) 0 PUNCT F
independent 0 ADJ F
of 0 ADP F
smoking 0 NUM F
severity 0 NOUN F
, 0 PUNCT F
consistent 0 ADJ F
with 0 ADP F
an 0 DET F
inherent 0 ADJ F
disease-related 0 VERB F
weakening 0 ADJ F
of 0 ADP F
smoking-related 0 ADJ F
circuits 0 NOUN F
. 0 PUNCT F

Nicotine 0 NOUN T
challenge 0 NOUN F
was 0 VERB F
used 0 VERB F
to 0 PART F
demonstrate 0 NOUN F
that 0 ADP F
decreased 0 VERB F
rsFC 0 NOUN F
in 0 ADP F
identified 0 ADV F
circuits 0 PUNCT F
reflects 0 ADP F
addiction 0 NOUN F
trait 0 NOUN F
and 0 CCONJ F
is 0 VERB F
not 0 ADV F
affected 0 VERB F
by 0 ADP F
pharmacological 0 ADJ F
state 0 NOUN F
. 0 PUNCT F

Twenty-four 0 PUNCT T
NC 0 NOUN T
smokers 0 NOUN F
and 0 CCONJ F
20 0 NUM F
smokers 0 ADJ F
with 0 ADP F
SZ 0 NOUN T
matched 0 PROPN F
on 0 ADP F
nicotine 0 NOUN F
addiction 0 NOUN F
severity 0 NOUN F
participated 0 DET F
in 0 ADP F
a 0 DET F
resting 0 VERB F
state 0 NOUN F
fMRI 0 NOUN F
study 0 NOUN F
and 0 CCONJ F
were 0 VERB F
scanned 0 VERB F
during 0 ADP F
two 0 NUM F
separate 0 ADJ F
sessions 0 NOUN F
while 0 ADP F
receiving 0 VERB F
a 0 DET F
placebo 0 NOUN F
or 0 CCONJ F
nicotine 0 NOUN F
patch 0 NOUN F
, 0 PUNCT F
in 0 ADP F
a 0 DET F
randomized 0 VERB F
, 0 PUNCT F
cross-over 0 NOUN F
design 0 NOUN F
. 0 PUNCT F

Using 0 PROPN T
individualized 0 PRON F
, 0 PUNCT F
anatomically 0 ADV F
defined 0 ADP F
anterior 0 ADJ F
and 0 CCONJ F
posterior 0 ADJ F
insula 0 NOUN F
and 0 CCONJ F
dACC 0 NOUN F
as 0 ADP F
regions 0 VERB F
of 0 ADP F
interest 0 NOUN F
( 0 PUNCT F
ROI 0 NOUN T
) 0 PUNCT F
, 0 PUNCT F
whole 0 ADJ F
brain 0 NOUN F
rsFC 0 NOUN F
was 0 VERB F
performed 0 VERB F
using 0 SYM F
each 0 DET F
ROI 0 NOUN T
as 0 ADP F
a 0 DET F
seed 0 NOUN F
. 0 PUNCT F

Significant 0 ADJ T
negative 0 ADJ F
correlations 0 NOUN F
between 0 ADP F
smoking B-MENTAL ADJ F
severity I-MENTAL NOUN F
and 0 CCONJ F
rsFC B-PHYSICAL NOUN F
between I-PHYSICAL ADP F
insula I-PHYSICAL NOUN F
, 0 PUNCT F
dACC 0 NOUN F
and 0 CCONJ F
striatum 0 NOUN F
were 0 VERB F
found 0 VERB F
for 0 ADP F
both 0 CCONJ F
groups 0 NOUN F
. 0 PUNCT F

Furthermore 0 ADV T
, 0 PUNCT F
smokers 0 ADJ F
with 0 ADP F
SZ 0 NOUN T
demonstrated 0 VERB F
additive 0 ADJ F
reductions 0 NOUN F
in 0 ADP F
circuit 0 NOUN F
strength 0 NOUN F
between 0 ADP F
the 0 DET F
dACC 0 NOUN F
and 0 CCONJ F
insula 0 ADJ F
compared 0 VERB F
to 0 ADP F
NC 0 NOUN T
smokers 0 ADJ F
independent 0 ADJ F
of 0 ADP F
smoking 0 VERB F
severity 0 NOUN F
. 0 PUNCT F

Nicotine B-OTHER NOUN T
challenge I-OTHER NOUN F
did 0 VERB F
not 0 ADV F
significantly 0 ADV F
alter B-PHYSICAL VERB F
rsFC I-PHYSICAL NOUN F
in I-PHYSICAL ADP F
insula-dACC-striatal I-PHYSICAL ADJ F
circuits I-PHYSICAL ADV F
. 0 PUNCT F

Reduced 0 VERB T
rsFC B-PHYSICAL NOUN F
strength I-PHYSICAL NOUN F
between 0 ADP F
the 0 DET F
insula 0 NOUN F
, 0 PUNCT F
dACC 0 NOUN F
and 0 CCONJ F
striatum 0 NOUN F
is 0 VERB F
associated 0 VERB F
with 0 ADP F
nicotine 0 NOUN F
addiction 0 NOUN F
severity 0 NOUN F
in 0 ADP F
both 0 CCONJ F
non-psychiatrically 0 NOUN F
ill 0 ADJ F
and 0 CCONJ F
in 0 ADP F
SZ 0 NOUN T
smokers 0 NOUN F
. 0 PUNCT F

Decreased 0 VERB T
insula-dACC 0 NOUN F
rsFC 0 NOUN F
may 0 PUNCT F
index 0 NOUN F
overlapping 0 VERB F
circuitry 0 NOUN F
associated 0 VERB F
with 0 ADP F
smoking 0 PUNCT F
and 0 CCONJ F
SZ 0 NOUN T
. 0 PUNCT F

Pharmacokinetics 0 NOUN T
and 0 CCONJ F
pharmacodynamics 0 NOUN F
of 0 ADP F
six 0 NUM F
epoetin 0 NOUN F
alfa 0 NOUN F
dosing 0 ADP F
regimens 0 NOUN F
in 0 ADP F
anemic 0 PUNCT F
critically 0 ADV F
ill 0 ADJ F
patients 0 NOUN F
without 0 ADP F
acute 0 ADJ F
blood 0 NOUN F
loss 0 NOUN F
. 0 PUNCT F

OBJECTIVE 0 NOUN T
To 0 ADJ T
describe 0 PROPN F
the 0 DET F
pharmacokinetic 0 ADJ F
profiles 0 NOUN F
of 0 ADP F
six 0 NUM F
different 0 ADJ F
dosing 0 ADP F
regimens 0 NOUN F
for 0 ADP F
epoetin 0 NOUN F
alfa 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
whether 0 ADP F
more 0 DET F
rapid 0 ADJ F
and 0 CCONJ F
robust 0 ADJ F
reticulocytosis 0 NOUN F
can 0 VERB F
be 0 VERB F
elicited 0 VERB F
with 0 ADP F
more 0 ADV F
frequent 0 ADP F
administration 0 NOUN F
of 0 ADP F
epoetin 0 NOUN F
alfa 0 NOUN F
in 0 ADP F
anemic 0 PUNCT F
critically 0 ADV F
ill 0 ADJ F
patients 0 NOUN F
. 0 PUNCT F

DESIGN 0 NOUN T
Randomized 0 PROPN T
, 0 PUNCT F
open-label 0 NOUN F
, 0 PUNCT F
multicenter 0 NOUN F
, 0 PUNCT F
28-day 0 NOUN F
clinical 0 ADJ F
trial 0 NOUN F
. 0 PUNCT F

SETTING 0 VERB T
Ten 0 NUM T
centers 0 NOUN F
in 0 ADP F
the 0 DET F
United 0 ADV T
States 0 NOUN T
. 0 PUNCT F

PATIENTS 0 NOUN T
Adult 0 NOUN T
( 0 PUNCT F
age 0 NOUN F
> 0 SYM F
or=18 0 NOUN F
years 0 NOUN F
) 0 PUNCT F
critically 0 ADV F
ill 0 ADJ F
patients 0 NOUN F
with 0 ADP F
hemoglobin 0 NOUN F
< 0 SYM F
or=12 0 NOUN F
g/dL 0 ADV F
, 0 PUNCT F
expected 0 PUNCT F
hospitalization 0 NOUN F
of 0 ADP F
> 0 SYM F
or=7 0 CCONJ F
days 0 NOUN F
, 0 PUNCT F
with 0 ADP F
no 0 DET F
ongoing 0 VERB F
acute 0 ADJ F
blood 0 NOUN F
loss 0 NOUN F
. 0 PUNCT F

INTERVENTIONS 0 NOUN T
One 0 PUNCT T
of 0 ADP F
six 0 NUM F
dosing 0 VERB F
epoetin 0 NOUN F
alfa 0 NOUN F
regimens 0 NOUN F
for 0 ADP F
15 0 NUM F
days 0 NOUN F
, 0 PUNCT F
as 0 ADP F
follows 0 VERB F
: 0 PUNCT F
40,000 0 NUM F
IU 0 NOUN T
once 0 PUNCT F
weekly 0 ADV F
, 0 PUNCT F
subcutaneously 0 ADV F
( 0 PUNCT F
group 0 NOUN F
A 0 NOUN T
) 0 PUNCT F
or 0 CCONJ F
intravenously 0 DET F
( 0 PUNCT F
IV 0 NUM T
) 0 PUNCT F
( 0 PUNCT F
group 0 NOUN F
B 0 NOUN T
) 0 PUNCT F
; 0 PUNCT F
15,000 0 NUM F
IU 0 NOUN T
every 0 DET F
other 0 ADJ F
day 0 NOUN F
, 0 PUNCT F
subcutaneously 0 ADV F
( 0 PUNCT F
group 0 NOUN F
C 0 NOUN T
) 0 PUNCT F
or 0 CCONJ F
IV 0 NUM T
( 0 PUNCT F
group 0 NOUN F
D 0 NOUN T
) 0 PUNCT F
; 0 PUNCT F
or 0 CCONJ F
40,000 0 NUM F
IU 0 NOUN T
day 0 NOUN F
1 0 NUM F
and 0 CCONJ F
3 0 NUM F
, 0 PUNCT F
subcutaneously 0 ADV F
( 0 PUNCT F
group 0 NOUN F
E 0 NOUN T
) 0 PUNCT F
or 0 CCONJ F
IV 0 NUM T
( 0 PUNCT F
group 0 NOUN F
F 0 NOUN T
) 0 PUNCT F
, 0 PUNCT F
followed 0 VERB F
by 0 ADP F
15,000 0 NUM F
IU 0 NOUN T
once 0 PUNCT F
every 0 DET F
other 0 ADJ F
day 0 NOUN F
on 0 ADP F
[ 0 PUNCT F
corrected 0 PUNCT F
] 0 PUNCT F
days 0 NOUN F
5-15 0 NUM F
[ 0 PUNCT F
corrected 0 NOUN F
] 0 PUNCT F
MEASUREMENTS 0 NOUN T
Serum B-PHYSICAL NOUN T
erythropoietin I-PHYSICAL NOUN F
concentration I-PHYSICAL NOUN F
, 0 PUNCT F
absolute B-PHYSICAL ADJ F
reticulocyte I-PHYSICAL NOUN F
count I-PHYSICAL NOUN F
, 0 PUNCT F
and 0 CCONJ F
adverse B-ADVERSE-EFFECTS ADJ F
events I-ADVERSE-EFFECTS NOUN F
. 0 PUNCT F

MAIN 0 ADJ T
RESULTS 0 NOUN T
Of 0 ADP T
the 0 DET F
60 0 ADV F
patients 0 NOUN F
who 0 PROPN F
were 0 VERB F
enrolled 0 VERB F
( 0 PUNCT F
60 0 NUM F
% 0 ADV F
men 0 NOUN F
, 0 PUNCT F
mean 0 NOUN F
age 0 NOUN F
53 0 NUM F
years 0 NOUN F
, 0 PUNCT F
mean 0 NOUN F
Acute 0 ADJ T
Physiology 0 NOUN T
and 0 CCONJ F
Chronic 0 ADJ T
Health 0 NOUN T
Evaluation 0 NOUN T
II 0 NUM T
score 0 NOUN F
, 0 PUNCT F
19.5 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
30 0 NUM F
were 0 VERB F
evaluable 0 ADJ F
for 0 ADP F
both 0 CCONJ F
pharmacokinetics 0 NOUN F
and 0 CCONJ F
pharmacodynamics 0 NOUN F
( 0 PUNCT F
50 0 NUM F
% 0 SYM F
) 0 PUNCT F
. 0 PUNCT F

Erythropoietin B-PHYSICAL NOUN T
exposure I-PHYSICAL NOUN F
was 0 ADP F
approximately 0 ADV F
ten 0 NUM F
times 0 NOUN F
greater 0 PUNCT F
for 0 ADP F
IV 0 NUM T
dosing 0 VERB F
than 0 PUNCT F
for 0 ADP F
subcutaneous 0 ADJ F
dosing 0 VERB F
. 0 PUNCT F

Mean 0 ADJ T
absolute B-PHYSICAL ADJ F
reticulocyte I-PHYSICAL NOUN F
count I-PHYSICAL NOUN F
peaked 0 VERB F
at 0 ADP F
day 0 NOUN F
11 0 NUM F
or 0 CCONJ F
15 0 NUM F
in 0 ADP F
each 0 DET F
group 0 NOUN F
and 0 CCONJ F
appeared 0 VERB F
to 0 PART F
be 0 PUNCT F
greater 0 PUNCT F
for 0 ADP F
subcutaneous 0 ADJ F
dosing 0 VERB F
( 0 PUNCT F
mean 0 NOUN F
peak 0 ADJ F
response 0 NOUN F
149-169 0 NUM F
x 0 SYM F
10 0 NUM F
( 0 PUNCT F
9 0 NUM F
) 0 PUNCT F
/L 0 PUNCT F
) 0 PUNCT F
compared 0 VERB F
with 0 ADP F
IV 0 NUM T
dosing 0 VERB F
( 0 PUNCT F
mean 0 NOUN F
peak 0 ADJ F
response 0 NOUN F
138-147 0 NUM F
x 0 SYM F
10 0 NUM F
( 0 PUNCT F
9 0 NUM F
) 0 PUNCT F
/L 0 PUNCT F
) 0 PUNCT F
at 0 ADP F
most 0 DET F
visits 0 NOUN F
. 0 PUNCT F

The 0 DET T
most 0 PUNCT F
frequently 0 ADV F
reported 0 ADP F
adverse B-ADVERSE-EFFECTS ADJ F
events I-ADVERSE-EFFECTS NOUN F
were 0 VERB F
pyrexia B-ADVERSE-EFFECTS NOUN F
( 0 PUNCT F
18 0 NUM F
% 0 SYM F
) 0 PUNCT F
, 0 PUNCT F
hypokalemia B-ADVERSE-EFFECTS NOUN F
( 0 PUNCT F
15 0 NUM F
% 0 SYM F
) 0 PUNCT F
, 0 PUNCT F
and 0 CCONJ F
hypophosphatemia B-ADVERSE-EFFECTS NOUN F
( 0 PUNCT F
15 0 NUM F
% 0 SYM F
) 0 PUNCT F
. 0 PUNCT F

CONCLUSIONS 0 NOUN T
In 0 ADP T
this 0 DET F
study 0 NOUN F
of 0 ADP F
anemic 0 PUNCT F
critically 0 ADV F
ill 0 ADJ F
patients 0 NOUN F
treated 0 VERB F
with 0 ADP F
epoetin 0 NOUN F
alfa 0 NOUN F
, 0 PUNCT F
all 0 DET F
dosing 0 ADP F
regimens 0 ADV F
were 0 VERB F
well 0 VERB F
tolerated B-OTHER PUNCT F
and 0 CCONJ F
appeared 0 VERB F
to 0 ADV F
effect 0 ADP F
reticulocytosis B-PHYSICAL NOUN F
, 0 PUNCT F
with 0 ADP F
a 0 DET F
peak 0 ADJ F
at 0 ADP F
day 0 NOUN F
11 0 NUM F
or 0 CCONJ F
15 0 NUM F
in 0 ADP F
most 0 DET F
patients 0 NOUN F
. 0 PUNCT F

The 0 DET T
pharmacokinetics 0 NOUN F
of 0 ADP F
epoetin 0 NOUN F
alfa 0 NOUN F
did 0 VERB F
not 0 ADV F
predict 0 VERB F
pharmacodynamic B-PHYSICAL ADJ F
response I-PHYSICAL NOUN F
in 0 ADP F
anemic 0 PUNCT F
critically 0 ADV F
ill 0 ADJ F
patients 0 NOUN F
. 0 PUNCT F

Combination 0 NOUN T
therapy 0 NOUN F
with 0 ADP F
methotrexate 0 ADJ F
and 0 CCONJ F
hydroxychloroquine 0 NOUN F
for 0 ADP F
rheumatoid 0 ADJ F
arthritis 0 NOUN F
increases 0 NOUN F
exposure 0 NOUN F
to 0 ADP F
methotrexate 0 NOUN F
. 0 PUNCT F

OBJECTIVE 0 NOUN T
To 0 PROPN T
examine 0 NOUN F
the 0 DET F
bioavailability 0 NOUN F
of 0 ADP F
methotrexate 0 NOUN F
( 0 PUNCT F
MTX 0 NOUN T
) 0 PUNCT F
in 0 ADP F
the 0 DET F
presence 0 NOUN F
of 0 ADP F
hydroxychloroquine 0 NOUN F
( 0 PUNCT F
HCQ 0 NOUN T
) 0 PUNCT F
, 0 PUNCT F
and 0 CCONJ F
vice 0 PUNCT F
versa 0 ADV F
, 0 PUNCT F
to 0 PART F
determine 0 NOUN F
a 0 DET F
possible 0 ADJ F
pharmacokinetic 0 ADJ F
explanation 0 NOUN F
for 0 ADP F
the 0 DET F
observation 0 NOUN F
that 0 VERB F
combination 0 NOUN F
treatment 0 NOUN F
of 0 ADP F
rheumatoid 0 ADJ F
arthritis 0 NOUN F
with 0 ADP F
MTX 0 NOUN T
and 0 CCONJ F
HCQ 0 NOUN T
has 0 PUNCT F
been 0 PUNCT F
shown 0 VERB F
, 0 PUNCT F
clinically 0 ADV F
, 0 PUNCT F
to 0 PART F
be 0 PUNCT F
more 0 ADV F
potent 0 ADJ F
than 0 PUNCT F
MTX 0 NOUN T
used 0 VERB F
alone 0 ADJ F
. 0 PUNCT F

METHODS 0 NOUN T
In 0 ADP T
a 0 DET F
randomized 0 VERB F
crossover 0 NOUN F
study 0 NOUN F
, 0 PUNCT F
10 0 NUM F
healthy 0 ADJ F
subjects 0 NOUN F
received 0 VERB F
, 0 PUNCT F
on 0 ADP F
each 0 PUNCT F
of 0 ADP F
5 0 NUM F
dosing 0 PUNCT F
occasions 0 NOUN F
, 0 PUNCT F
MTX 0 NOUN T
alone 0 ADJ F
as 0 ADP F
tablets 0 VERB F
or 0 CCONJ F
intravenous 0 ADJ F
solution 0 NOUN F
, 0 PUNCT F
HCQ 0 NOUN T
alone 0 ADJ F
as 0 ADP F
a 0 DET F
tablet 0 NOUN F
or 0 CCONJ F
oral 0 ADJ F
solution 0 NOUN F
, 0 PUNCT F
or 0 CCONJ F
a 0 DET F
coadministered 0 VERB F
dose 0 NOUN F
of 0 ADP F
MTX 0 NOUN T
tablets 0 NOUN F
with 0 ADP F
an 0 DET F
HCQ 0 NOUN T
tablet 0 NOUN F
. 0 PUNCT F

The 0 DET T
area 0 NOUN F
under 0 ADP F
the 0 DET F
concentration-time B-OTHER NOUN F
curve 0 NOUN F
( B-OTHER PUNCT F
AUC I-OTHER NOUN T
) B-OTHER PUNCT F
was 0 VERB F
determined 0 VERB F
for 0 ADP F
each 0 DET F
subject 0 NOUN F
, 0 PUNCT F
on 0 ADP F
each 0 DET F
dosing 0 ADJ F
occasion 0 NOUN F
, 0 PUNCT F
for 0 ADP F
each 0 DET F
compound 0 CCONJ F
. 0 PUNCT F

RESULTS 0 PUNCT T
The 0 DET T
mean 0 NOUN F
AUC B-OTHER NOUN T
for I-OTHER ADP F
MTX I-OTHER NOUN T
was 0 VERB F
increased 0 VERB F
( 0 PUNCT F
p 0 NOUN F
= 0 SYM F
0.005 0 NUM F
) 0 PUNCT F
and 0 CCONJ F
the 0 DET F
maximum B-OTHER NOUN F
MTX I-OTHER NOUN T
concentration 0 NOUN F
( B-OTHER PUNCT F
Cmax I-OTHER NOUN T
) I-OTHER PUNCT F
decreased 0 VERB F
( 0 PUNCT F
p 0 NOUN F
= 0 SYM F
0.025 0 NUM F
) 0 PUNCT F
when 0 ADP F
MTX 0 NOUN T
was 0 VERB F
coadministered 0 VERB F
with 0 ADP F
HCQ 0 NOUN T
, 0 PUNCT F
compared 0 VERB F
to 0 ADP F
MTX 0 NOUN T
administered 0 VERB F
alone 0 ADJ F
. 0 PUNCT F

The 0 PUNCT T

Comparing 0 VERB T
microvascular B-PHYSICAL ADJ F
alterations I-PHYSICAL NOUN F
during 0 ADP F
minimal 0 ADJ F
extracorporeal 0 ADJ F
circulation 0 NOUN F
and 0 CCONJ F
conventional 0 ADJ F
cardiopulmonary 0 ADJ F
bypass 0 NOUN F
in 0 ADP F
coronary 0 ADJ F
artery 0 NOUN F
bypass 0 NOUN F
graft 0 NOUN F
surgery 0 NOUN F
: 0 PUNCT F
a 0 DET F
prospective 0 ADJ F
, 0 PUNCT F
randomized 0 ADP F
study 0 NOUN F
. 0 PUNCT F

OBJECTIVES 0 NOUN T
Minimal 0 ADJ T
extracorporeal 0 ADJ F
circulation 0 NOUN F
( 0 PUNCT F
MECC 0 NOUN T
) 0 PUNCT F
has 0 PUNCT F
been 0 PUNCT F
introduced 0 VERB F
in 0 ADP F
coronary 0 ADJ F
artery 0 NOUN F
bypass 0 NOUN F
graft 0 NOUN F
( 0 PUNCT F
CABG 0 NOUN T
) 0 PUNCT F
surgery 0 NOUN F
, 0 PUNCT F
offering 0 PUNCT F
clinical 0 ADJ F
benefits 0 NOUN F
owing 0 PUNCT F
to 0 ADP F
reduced 0 PUNCT F
hemodilution 0 NOUN F
and 0 CCONJ F
no 0 DET F
blood-air 0 ADJ F
interface 0 NOUN F
. 0 PUNCT F

Yet 0 ADV T
, 0 PUNCT F
the 0 DET F
effects 0 NOUN F
of 0 ADP F
MECC 0 NOUN T
on 0 ADP F
the 0 DET F
intraoperative 0 ADJ F
microvascular 0 ADJ F
perfusion 0 NOUN F
in 0 ADP F
comparison 0 NOUN F
with 0 ADP F
conventional 0 ADJ F
extracorporeal 0 ADJ F
circulation 0 NOUN F
( 0 PUNCT F
CECC 0 NOUN T
) 0 PUNCT F
have 0 PUNCT F
not 0 ADV F
been 0 PUNCT F
studied 0 VERB F
so 0 PUNCT F
far 0 ADP F
. 0 PUNCT F

METHODS 0 NOUN T
The 0 DET T
current 0 ADJ F
study 0 NOUN F
aimed 0 VERB F
to 0 PART F
analyze 0 NOUN F
alterations 0 NOUN F
in 0 ADP F
microvascular B-PHYSICAL ADJ F
perfusion I-PHYSICAL NOUN F
at 0 ADP F
4 0 NUM F
predefined 0 DET F
time 0 NOUN F
points 0 NOUN F
( 0 PUNCT F
T1-T4 0 NOUN T
) 0 PUNCT F
during 0 ADP F
on-pump 0 NOUN F
CABG 0 NOUN T
using 0 SYM F
orthogonal 0 ADJ F
polarization 0 NOUN F
spectral 0 ADJ F
imaging 0 PROPN F
. 0 PUNCT F

Forty 0 CCONJ T
patients 0 NOUN F
were 0 VERB F
randomized 0 VERB F
for 0 ADP F
being 0 VERB F
operated 0 VERB F
on 0 ADP F
with 0 ADP F
either 0 CCONJ F
MECC 0 NOUN T
or 0 CCONJ F
CECC 0 NOUN T
. 0 PUNCT F

Changes 0 NOUN T
in 0 ADP F
functional B-PHYSICAL ADJ F
capillary I-PHYSICAL NOUN F
density I-PHYSICAL NOUN F
( I-PHYSICAL PUNCT F
FCD I-PHYSICAL NOUN T
) I-PHYSICAL PUNCT F
, 0 PUNCT F
blood B-PHYSICAL NOUN F
flow I-PHYSICAL NOUN F
velocity I-PHYSICAL NOUN F
, 0 PUNCT F
and 0 CCONJ F
vessel B-PHYSICAL NOUN F
diameter I-PHYSICAL NOUN F
were 0 VERB F
analyzed 0 VERB F
by 0 ADP F
a 0 DET F
blinded 0 VERB F
investigator 0 NOUN F
. 0 PUNCT F

RESULTS 0 NOUN T
After 0 PUNCT T
start 0 NOUN F
of 0 ADP F
extracorporeal 0 ADJ F
circulation 0 NOUN F
( 0 PUNCT F
ECC 0 NOUN T
) 0 PUNCT F
and 0 CCONJ F
aortic 0 ADJ F
crossclamping 0 PUNCT F
( 0 PUNCT F
T2 0 NOUN T
) 0 PUNCT F
, 0 PUNCT F
both 0 CCONJ F
groups 0 NOUN F
showed 0 VERB F
a 0 DET F
significant 0 ADJ F
drop 0 NOUN F
of 0 ADP F
FCD B-PHYSICAL NOUN T
, 0 PUNCT F
with 0 ADP F
a 0 DET F
significantly 0 ADV F
higher 0 PUNCT F
FCD B-PHYSICAL NOUN T
in 0 ADP F
the 0 DET F
MECC 0 ADJ T
group 0 NOUN F
( 0 PUNCT F
206.8 0 ADP F
? 0 PUNCT F

33.6 0 NUM F
cm/cm? 0 NOUN F
in 0 ADP F
CECC 0 NOUN T
group 0 NOUN F
versus 0 CCONJ F
217.8 0 NUM F
? 0 PUNCT F

35.3 0 NUM F
cm/cm? 0 NOUN F
in 0 ADP F
MECC 0 NOUN T
group 0 NOUN F
; 0 PUNCT F
P 0 NOUN T
= 0 SYM F
.034 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

In 0 ADP T
the 0 DET F
late 0 ADJ F
phase 0 NOUN F
of 0 ADP F
the 0 DET F
ECC 0 NOUN T
( 0 PUNCT F
T3 0 NOUN T
) 0 PUNCT F
, 0 PUNCT F
FCD 0 NOUN T
in 0 ADP F
the 0 DET F
MECC 0 ADJ T
group 0 NOUN F
was 0 VERB F
already 0 ADV F
recovered 0 PUNCT F
, 0 PUNCT F
whereas 0 ADP F
FCD 0 NOUN T
in 0 ADP F
the 0 DET F
CECC 0 NOUN T
group 0 NOUN F
was 0 VERB F
still 0 ADV F
significantly 0 ADV F
depressed 0 VERB F
( 0 PUNCT F
223.1 0 ADP F
? 0 PUNCT F

35.6 0 NUM F
cm/cm? 0 NOUN F
in 0 ADP F
MECC 0 NOUN T
group 0 NOUN F
; 0 PUNCT F
P 0 NOUN T
= 0 SYM F
.100 0 NUM F
vs 0 CCONJ F
T1 0 NOUN T
; 0 PUNCT F
211.1 0 NUM F
? 0 PUNCT F

36.9 0 NUM F
cm/cm? 0 NOUN F
in 0 ADP F
CECC 0 NOUN T
group 0 NOUN F
; 0 PUNCT F
P 0 NOUN T
= 0 SYM F
.017 0 NUM F
vs 0 CCONJ F
T1 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

After 0 ADP T
termination 0 NOUN F
of 0 ADP F
ECC 0 NOUN T
( 0 PUNCT F
T4 0 NOUN T
) 0 PUNCT F
, 0 PUNCT F
FCD 0 NOUN T
recovered 0 PUNCT F
in 0 ADP F
both 0 CCONJ F
groups 0 NOUN F
to 0 ADP F
baseline 0 NOUN F
. 0 PUNCT F

Blood 0 NOUN T
flow 0 NOUN F
velocity 0 NOUN F
tended 0 VERB F
to 0 PART F
be 0 PUNCT F
higher 0 PUNCT F
in 0 ADP F
the 0 DET F
MECC 0 ADJ T
group 0 NOUN F
, 0 PUNCT F
with 0 ADP F
a 0 DET F
significant 0 ADJ F
intergroup 0 NOUN F
difference 0 NOUN F
after 0 ADP F
aortic 0 ADJ F
crossclamping 0 PUNCT F
( 0 PUNCT F
T2 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

CONCLUSIONS 0 NOUN T
Orthogonal 0 ADJ T
polarization 0 NOUN F
spectral 0 ADJ F
imaging 0 DET F
data 0 NOUN F
reveal 0 VERB F
an 0 DET F
impairment 0 NOUN F
of 0 ADP F
microvascular 0 ADJ F
perfusion 0 NOUN F
during 0 ADP F
on-pump 0 NOUN F
CABG 0 NOUN T
. 0 PUNCT F

Changes 0 NOUN T
in 0 ADP F
FCD 0 NOUN T
indicate 0 VERB F
a 0 DET F
faster 0 PUNCT F
recovery 0 NOUN F
of 0 ADP F
the 0 DET F
microvascular 0 ADJ F
perfusion 0 NOUN F
in 0 ADP F
MECC 0 NOUN T
during 0 ADP F
the 0 DET F
reperfusion 0 NOUN F
period 0 NOUN F
. 0 PUNCT F

Beneficial 0 ADJ T
recovery 0 NOUN F
of 0 ADP F
microvascular 0 ADJ F
organ 0 NOUN F
perfusion 0 NOUN F
could 0 PUNCT F
partly 0 ADV F
explain 0 VERB F
the 0 DET F
perioperative 0 ADJ F
advantages 0 NOUN F
reported 0 VERB F
for 0 ADP F
MECC 0 NOUN T
. 0 PUNCT F

Chlorthalidone 0 NOUN T
does 0 PUNCT F
not 0 ADV F
increase 0 VERB F
the 0 DET F
hypotensive B-PHYSICAL ADJ F
effect 0 NOUN F
of 0 ADP F
nifedipine 0 NOUN F
in 0 ADP F
essential 0 ADJ F
hypertensives 0 NOUN F
: 0 PUNCT F
a 0 DET F
crossover 0 NOUN F
multicentre 0 NOUN F
study 0 NOUN F
. 0 PUNCT F

To 0 PART T
determine 0 NOUN F
whether 0 ADP F
the 0 DET F
combination 0 NOUN F
of 0 ADP F
nifedipine 0 NOUN F
+ 0 DET F
chlorthalidone 0 NOUN F
exerts 0 NOUN F
an 0 DET F
additive B-PHYSICAL ADJ F
antihypertensive I-PHYSICAL ADJ F
effect 0 NOUN F
when 0 ADP F
compared 0 VERB F
with 0 ADP F
single-drug 0 NOUN F
treatment 0 NOUN F
, 0 PUNCT F
we 0 PRON F
studied 0 VERB F
66 0 NUM F
uncomplicated 0 VERB F
essential 0 ADJ F
hypertensives 0 NOUN F
, 0 PUNCT F
with 0 ADP F
diastolic 0 ADJ F
blood 0 NOUN F
pressure 0 NOUN F
of 0 ADP F
greater 0 PUNCT F
than 0 PUNCT F
100 0 NUM F
and 0 CCONJ F
less 0 ADV F
than 0 CCONJ F
115 0 NUM F
mmHg 0 NOUN F
. 0 PUNCT F

At 0 ADP T
the 0 DET F
end 0 NOUN F
of 0 ADP F
a 0 DET F
1-month 0 NOUN F
washout 0 PUNCT F
placebo 0 NOUN F
period 0 NOUN F
, 0 PUNCT F
using 0 VERB F
a 0 DET F
double-blind 0 ADJ F
crossover 0 NOUN F
design 0 NOUN F
, 0 PUNCT F
the 0 DET F
patients 0 NOUN F
were 0 VERB F
randomly 0 ADV F
allocated 0 VERB F
to 0 ADP F
nifedipine 0 NOUN F
( 0 PUNCT F
20 0 NUM F
mg 0 NOUN F
twice 0 ADV F
a 0 DET F
day 0 NOUN F
) 0 PUNCT F
, 0 PUNCT F
chlorthalidone 0 NOUN F
( 0 PUNCT F
25 0 NUM F
mg 0 NOUN F
once 0 PUNCT F
a 0 DET F
day 0 NOUN F
) 0 PUNCT F
, 0 PUNCT F
the 0 DET F
two 0 NUM F
drugs 0 NOUN F
combined 0 PUNCT F
at 0 ADP F
the 0 DET F
same 0 ADJ F
doses 0 NOUN F
and 0 CCONJ F
the 0 DET F
corresponding 0 VERB F
placebo 0 NOUN F
. 0 PUNCT F

Compared 0 VERB T
with 0 ADP F
the 0 DET F
randomly 0 ADV F
allocated 0 VERB F
placebo 0 NOUN F
, 0 PUNCT F
the 0 DET F
three 0 NUM F
active 0 ADJ F
treatments 0 NOUN F
significantly 0 ADV F
reduced 0 PUNCT F
blood B-PHYSICAL NOUN F
pressure I-PHYSICAL NOUN F
without 0 ADP F
changing 0 VERB F
the 0 DET F
heart B-PHYSICAL NOUN F
rate I-PHYSICAL NOUN F
or 0 CCONJ F
body B-PHYSICAL NOUN F
weight 0 NOUN F
. 0 PUNCT F

Both 0 CCONJ T
the 0 DET F
absolute 0 ADJ F
and 0 CCONJ F
percentage 0 NOUN F
decreases 0 VERB F
in 0 ADP F
mean 0 NOUN F
blood B-PHYSICAL NOUN F
pressure I-PHYSICAL NOUN F
induced 0 VERB F
by 0 ADP F
nifedipine 0 NOUN F
and 0 CCONJ F
the 0 DET F
combination 0 NOUN F
compared 0 VERB F
with 0 ADP F
placebo 0 NOUN F
were 0 VERB F
similar 0 ADJ F
and 0 CCONJ F
significantly 0 ADV F
greater 0 PUNCT F
than 0 PUNCT F
those 0 ADP F
induced 0 VERB F
by 0 ADP F
chlorthalidone 0 NOUN F
. 0 PUNCT F

Taken 0 VERB T
together 0 ADV F
, 0 PUNCT F
these 0 DET F
data 0 NOUN F
show 0 VERB F
that 0 ADP F
the 0 DET F
combination 0 NOUN F
of 0 ADP F
nifedipine 0 NOUN F
+ 0 SYM F
chlorthalidone 0 NOUN F
does 0 PUNCT F
not 0 ADV F
exert 0 VERB F
any 0 DET F
additive B-PHYSICAL ADJ F
antihypertensive I-PHYSICAL ADJ F
effect 0 NOUN F
compared 0 VERB F
with 0 ADP F
nifedipine 0 NOUN F
alone 0 ADJ F
. 0 PUNCT F

This 0 PUNCT T
finding 0 VERB F
indicates 0 NOUN F
that 0 ADP F
the 0 DET F
combination 0 NOUN F
of 0 ADP F
a 0 DET F
dihydropyridine 0 NOUN F
calcium 0 NOUN F
antagonist 0 NOUN F
+ 0 DET F
a 0 DET F
thiazide 0 NOUN F
diuretic 0 NOUN F
is 0 VERB F
probably 0 ADV F
devoid 0 PUNCT F
of 0 ADP F
any 0 DET F
particular 0 ADJ F
clinical B-PHYSICAL ADJ F
significance I-PHYSICAL NOUN F
in 0 ADP F
the 0 DET F
treatment 0 NOUN F
of 0 ADP F
uncomplicated 0 VERB F
essential 0 ADJ F
hypertensives 0 NOUN F
. 0 PUNCT F

A 0 DET T
drug 0 NOUN F
interaction 0 NOUN F
study 0 NOUN F
between 0 ADP F
ticlopidine 0 NOUN F
and 0 CCONJ F
cyclosporin 0 NOUN F
in 0 ADP F
heart 0 NOUN F
transplant 0 NOUN F
recipients 0 NOUN F
. 0 PUNCT F

OBJECTIVES 0 NOUN T
Previous 0 ADJ T
uncontrolled 0 VERB F
studies 0 NOUN F
have 0 ADP F
suggested 0 VERB F
an 0 DET F
interaction 0 NOUN F
between 0 ADP F
ticlopidine 0 NOUN F
, 0 PUNCT F
a 0 DET F
major 0 ADJ F
antiplatelet 0 NOUN F
agent 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
cyclosporin 0 NOUN F
in 0 ADP F
heart- 0 NOUN F
and 0 CCONJ F
kidney-transplant 0 ADJ F
recipients 0 NOUN F
. 0 PUNCT F

The 0 DET T
aims 0 NOUN F
of 0 ADP F
this 0 DET F
study 0 NOUN F
were 0 VERB F
to 0 PART F
examine 0 NOUN F
in 0 ADP F
a 0 DET F
randomised 0 VERB F
, 0 PUNCT F
double-blind 0 ADJ F
fashion 0 NOUN F
, 0 PUNCT F
the 0 DET F
possible 0 ADJ F
interaction 0 NOUN F
between 0 ADP F
cyclosporin 0 NOUN F
A 0 NOUN T
and 0 CCONJ F
ticlopidine 0 NOUN F
( 0 PUNCT F
250 0 NUM F
mg 0 NOUN F
per 0 ADP F
day 0 NOUN F
) 0 PUNCT F
and 0 CCONJ F
the 0 DET F
tolerability 0 NOUN F
of 0 ADP F
this 0 PUNCT F
combination 0 NOUN F
in 0 ADP F
heart-transplant 0 ADJ F
recipients 0 NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
Twenty 0 NUM T
heart-transplant 0 ADJ F
recipients 0 NOUN F
were 0 VERB F
randomised 0 VERB F
into 0 ADP F
either 0 CCONJ F
a 0 DET F
treated 0 PUNCT F
or 0 CCONJ F
a 0 DET F
placebo 0 NOUN F
group 0 NOUN F
. 0 PUNCT F

Blood 0 NOUN T
samples 0 NOUN F
were 0 VERB F
drawn 0 VERB F
for 0 ADP F
time-course 0 PUNCT F
evaluation 0 NOUN F
of 0 ADP F
cyclosporin 0 NOUN F
blood 0 NOUN F
levels 0 NOUN F
over 0 ADP F
a 0 DET F
period 0 NOUN F
of 0 ADP F
12 0 NUM F
h 0 NOUN F
, 0 PUNCT F
following 0 VERB F
the 0 DET F
morning 0 NOUN F
intake 0 NOUN F
of 0 ADP F
cyclosporin 0 NOUN F
and 0 CCONJ F
, 0 PUNCT F
for 0 ADP F
platelet 0 NOUN F
aggregation 0 NOUN F
studies 0 NOUN F
, 0 PUNCT F
before 0 ADP F
and 0 CCONJ F
after 0 ADP F
14 0 NUM F
days 0 NOUN F
of 0 ADP F
ticlopidine 0 NOUN F
administration 0 NOUN F
. 0 PUNCT F

Twenty 0 VERB T
four-hour 0 NOUN F
urine 0 NOUN F
samples 0 NOUN F
were 0 VERB F
collected 0 VERB F
for 0 ADP F
6-beta-hydroxycortisol 0 NOUN F
measurements 0 NOUN F
, 0 PUNCT F
before 0 ADP F
and 0 CCONJ F
after 0 ADP F
14 0 NUM F
days 0 NOUN F
of 0 ADP F
ticlopidine 0 NOUN F
. 0 PUNCT F

RESULTS 0 NOUN T
Although 0 ADP T
given 0 VERB F
at 0 ADP F
half 0 ADP F
the 0 DET F
recommended 0 VERB F
daily 0 ADJ F
dosage 0 NOUN F
, 0 PUNCT F
ticlopidine 0 NOUN F
significantly 0 ADV F
reduced 0 CCONJ F
platelet B-PHYSICAL NOUN F
aggregation 0 NOUN F
. 0 PUNCT F

Pharmacokinetic 0 ADJ T
parameters 0 NOUN F
indicate 0 VERB F
that 0 ADP F
the 0 DET F
bioavailability B-OTHER NOUN F
of I-OTHER ADP F
cyclosporin I-OTHER NOUN F
A 0 NOUN T
was 0 NUM F
not 0 ADV F
significantly 0 ADV F
modified 0 VERB F
by 0 ADP F
ticlopidine 0 NOUN F
. 0 PUNCT F

However 0 ADV T
, 0 PUNCT F
one 0 NUM F
patient 0 NOUN F
in 0 ADP F
the 0 DET F
ticlopidine 0 NOUN F
group 0 NOUN F
was 0 VERB F
withdrawn 0 PUNCT F
because 0 PUNCT F
of 0 ADP F
a 0 DET F
major 0 ADJ F
fall B-OTHER NOUN F
in I-OTHER ADP F
cyclosporin I-OTHER NOUN F
blood I-OTHER NOUN F
level I-OTHER NOUN F
within 0 ADP F
3 0 NUM F
days 0 NOUN F
of 0 ADP F
treatment 0 NOUN F
. 0 PUNCT F

Urinary B-PHYSICAL ADJ T
excretion I-PHYSICAL NOUN F
of I-PHYSICAL ADP F
6-beta-hydroxycortisol I-PHYSICAL NOUN F
was 0 VERB F
augmented 0 VERB F
after 0 ADP F
treatment 0 NOUN F
in 0 ADP F
the 0 DET F
ticlopidine 0 NOUN F
group 0 NOUN F
compared 0 VERB F
with 0 ADP F
the 0 DET F
placebo 0 NOUN F
group 0 NOUN F
, 0 PUNCT F
suggesting 0 VERB F
that 0 ADP F
induction 0 NOUN F
of 0 ADP F
drug 0 NOUN F
metabolism 0 NOUN F
might 0 VERB F
have 0 PUNCT F
occurred 0 VERB F
. 0 PUNCT F

Data 0 NOUN T
also 0 ADV F
show 0 VERB F
quite 0 ADP F
a 0 DET F
large 0 ADJ F
intra-individual 0 ADJ F
variability 0 NOUN F
in 0 ADP F
cyclosporin B-PHYSICAL NOUN F
bioavailability I-PHYSICAL NOUN F
in 0 ADP F
the 0 DET F
placebo 0 NOUN F
group 0 NOUN F
, 0 PUNCT F
suggesting 0 VERB F
that 0 ADP F
poor 0 ADJ F
absorption 0 NOUN F
of 0 ADP F
the 0 DET F
drug 0 NOUN F
formulation 0 NOUN F
and/or 0 CCONJ F
poor 0 ADJ F
compliance 0 NOUN F
might 0 PUNCT F
have 0 PUNCT F
contributed 0 VERB F
to 0 ADP F
the 0 DET F
decreased 0 VERB F
cyclosporin B-PHYSICAL NOUN F
blood I-PHYSICAL NOUN F
levels I-PHYSICAL NOUN F
in 0 ADP F
the 0 DET F
patient 0 NOUN F
withdrawn 0 PUNCT F
from 0 ADP F
this 0 DET F
study 0 NOUN F
and 0 CCONJ F
in 0 ADP F
previous 0 ADJ F
uncontrolled 0 VERB F
studies 0 NOUN F
. 0 PUNCT F

CONCLUSION 0 NOUN T
Cyclosporin 0 NOUN T
bioavailability 0 NOUN F
was 0 VERB F
not 0 ADV F
clearly 0 ADV F
modified 0 PUNCT F
by 0 ADP F
a 0 DET F
half 0 PUNCT F
dosage 0 NOUN F
of 0 ADP F
ticlopidine 0 NOUN F
in 0 ADP F
this 0 DET F
study 0 NOUN F
. 0 PUNCT F

We 0 PRON T
, 0 PUNCT F
however 0 ADV F
, 0 PUNCT F
recommend 0 VERB F
closely 0 ADV F
monitoring 0 VERB F
cyclosporin 0 NOUN F
blood 0 NOUN F
levels 0 NOUN F
when 0 ADP F
prescribing 0 ADP F
ticlopidine 0 NOUN F
. 0 PUNCT F

Further 0 ADJ T
studies 0 NOUN F
will 0 VERB F
be 0 VERB F
needed 0 VERB F
with 0 ADP F
new 0 ADJ F
formulations 0 NOUN F
of 0 ADP F
cyclosporin 0 NOUN F
or 0 CCONJ F
when 0 ADP F
using 0 VERB F
the 0 DET F
full 0 ADJ F
dosage 0 NOUN F
of 0 ADP F
ticlopidine 0 NOUN F
. 0 PUNCT F

Improving 0 VERB T
the 0 DET F
immunogenicity B-PHYSICAL NOUN F
of 0 ADP F
pneumococcal 0 ADJ F
conjugate 0 PUNCT F
vaccine 0 NOUN F
in 0 ADP F
HIV-infected 0 VERB T
adults 0 NOUN F
with 0 ADP F
a 0 DET F
toll-like 0 ADJ F
receptor 0 NOUN F
9 0 NUM F
agonist 0 NOUN F
adjuvant 0 NOUN F
: 0 PUNCT F
a 0 DET F
randomized 0 VERB F
, 0 PUNCT F
controlled 0 VERB F
trial 0 NOUN F
. 0 PUNCT F

BACKGROUND 0 NOUN T
Persons 0 NOUN T
infected 0 VERB F
with 0 ADP F
human 0 NOUN F
immunodeficiency 0 NOUN F
virus 0 NOUN F
( 0 PUNCT F
HIV 0 NOUN T
) 0 PUNCT F
are 0 VERB F
often 0 ADV F
hyporesponsive 0 ADJ F
to 0 ADP F
immunization 0 NOUN F
, 0 PUNCT F
including 0 VERB F
pneumococcal 0 ADJ F
vaccines 0 NOUN F
. 0 PUNCT F

We 0 PRON T
hypothesized 0 VERB F
that 0 ADP F
adding 0 VERB F
CPG 0 NOUN T
7909 0 NUM F
, 0 PUNCT F
a 0 DET F
toll-like 0 ADJ F
receptor 0 NOUN F
9 0 NUM F
( 0 PUNCT F
TLR9 0 NOUN T
) 0 PUNCT F
agonist 0 NOUN F
and 0 CCONJ F
vaccine 0 NOUN F
adjuvant 0 ADJ F
, 0 PUNCT F
to 0 PUNCT F
7-valent 0 ADJ F
pneumococcal 0 ADJ F
conjugate 0 PUNCT F
vaccine 0 NOUN F
( 0 PUNCT F
7vPnC 0 NOUN F
) 0 PUNCT F
would 0 ADJ F
increase 0 VERB F
its 0 ADP F
immunogenicity 0 NOUN F
in 0 ADP F
HIV-infected 0 VERB T
adults 0 NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
We 0 PRON T
performed 0 VERB F
a 0 DET F
double-blind 0 ADJ F
, 0 PUNCT F
placebo-controlled 0 VERB F
, 0 PUNCT F
phase 0 NOUN F
1b/2a 0 NOUN F
trial 0 NOUN F
randomizing 0 PUNCT F
HIV-positive 0 ADJ T
patients 0 NOUN F
to 0 PART F
receive 0 NOUN F
double 0 ADJ F
doses 0 NOUN F
of 0 ADP F
7vPnC 0 ADJ F
( 0 PUNCT F
Prevnar 0 NOUN T
) 0 PUNCT F
at 0 ADP F
0 0 NUM F
and 0 CCONJ F
3 0 NUM F
months 0 NOUN F
and 0 CCONJ F
1 0 NUM F
dose 0 NOUN F
of 0 ADP F
23-valent 0 ADJ F
pneumococcal 0 ADJ F
polysaccharide 0 ADP F
vaccine 0 NOUN F
( 0 PUNCT F
PPV-23 0 NOUN T
; 0 PUNCT F
Pneumo 0 NOUN T
Novum 0 NOUN T
) 0 PUNCT F
at 0 ADP F
9 0 NUM F
months 0 NOUN F
, 0 PUNCT F
with 0 ADP F
experimental 0 ADJ F
patients 0 NOUN F
receiving 0 VERB F
1 0 NUM F
mg 0 NOUN F
of 0 ADP F
CPG 0 NOUN T
7909 0 NUM F
added 0 VERB F
to 0 ADP F
each 0 PUNCT F
of 0 ADP F
their 0 ADP F
3 0 NUM F
vaccine 0 NOUN F
doses 0 NOUN F
; 0 PUNCT F
control 0 NOUN F
patients 0 NOUN F
had 0 PUNCT F
phosphate-buffered 0 ADP F
saline 0 NOUN F
added 0 VERB F
instead 0 PUNCT F
. 0 PUNCT F

Immunogenicity B-PHYSICAL NOUN T
and 0 CCONJ F
safety B-PHYSICAL NOUN F
were 0 VERB F
evaluated 0 VERB F
for 0 ADP F
up 0 PUNCT F
to 0 ADP F
10 0 NUM F
months 0 NOUN F
. 0 PUNCT F

The 0 DET T
primary 0 ADJ F
end 0 NOUN F
point 0 NOUN F
was 0 VERB F
the 0 DET F
proportion 0 NOUN F
of 0 ADP F
vaccine B-PHYSICAL NOUN F
high I-PHYSICAL ADJ F
responders I-PHYSICAL NOUN F
at I-PHYSICAL ADP F
9 I-PHYSICAL NUM F
months I-PHYSICAL NOUN F
, 0 PUNCT F
defined 0 VERB F
as 0 ADP F
a 0 DET F
2-fold 0 ADP F
increase 0 NOUN F
in 0 ADP F
IgG 0 NOUN T
levels 0 NOUN F
to 0 ADP F
> 0 ADP F
or 0 CCONJ F
= 0 SYM F
1 0 NUM F
microg/mL 0 NOUN F
for 0 ADP F
at 0 ADP F
least 0 ADV F
5 0 NUM F
of 0 ADP F
7 0 NUM F
of 0 ADP F
the 0 DET F
7vPnC 0 ADJ F
serotypes 0 NOUN F
. 0 PUNCT F

RESULTS 0 DET T
Ninety-seven 0 PUNCT T
participants 0 NOUN F
were 0 VERB F
included 0 VERB F
in 0 ADP F
the 0 DET F
study 0 NOUN F
. 0 PUNCT F

The 0 DET T
proportion 0 NOUN F
of 0 ADP F
vaccine B-PHYSICAL NOUN F
high I-PHYSICAL ADJ F
responders I-PHYSICAL NOUN F
was 0 VERB F
higher 0 PUNCT F
in 0 ADP F
the 0 DET F
experimental 0 ADJ F
group 0 NOUN F
( 0 PUNCT F
n 0 NOUN F
= 0 SYM F
48 0 NUM F
) 0 PUNCT F
than 0 PUNCT F
among 0 ADP F
controls 0 NOUN F
( 0 PUNCT F
n 0 NOUN F
= 0 SYM F
49 0 NUM F
; 0 PUNCT F
48.8 0 NUM F
% 0 SYM F
vs 0 CCONJ F
25.0 0 NUM F
% 0 SYM F
; 0 PUNCT F
P 0 NOUN T
= 0 SYM F
.02 0 NUM F
) 0 PUNCT F
at 0 ADP F
9 0 NUM F
months 0 NOUN F
. 0 PUNCT F

Greater 0 PUNCT T
proportions 0 NOUN F
of 0 ADP F
high B-PHYSICAL ADJ F
responders I-PHYSICAL NOUN F
were 0 VERB F
also 0 ADV F
observed 0 VERB F
at 0 ADP F
3 0 NUM F
( 0 PUNCT F
51.1 0 NUM F
% 0 SYM F
vs 0 CCONJ F
39.6 0 NUM F
% 0 SYM F
; 0 PUNCT F
P 0 NOUN T
= 0 SYM F
.26 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
4 0 NUM F
( 0 PUNCT F
77.3 0 NUM F
% 0 SYM F
vs 0 CCONJ F
56.3 0 NUM F
% 0 SYM F
; 0 PUNCT F
P 0 NOUN T
= 0 SYM F
.03 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
and 0 CCONJ F
10 0 NUM F
months 0 NOUN F
( 0 PUNCT F
87.8 0 NUM F
% 0 SYM F
vs 0 CCONJ F
51.1 0 NUM F
% 0 SYM F
; 0 PUNCT F
P 0 NOUN T
< 0 SYM F
.001 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Mild B-PHYSICAL ADJ T
systemic I-PHYSICAL ADJ F
and I-PHYSICAL CCONJ F
injection I-PHYSICAL NOUN F
site I-PHYSICAL NOUN F
reactions I-PHYSICAL NOUN F
to 0 ADP F
7vPnC 0 ADJ F
were 0 VERB F
more 0 ADV F
common 0 ADJ F
in 0 ADP F
the 0 DET F
experimental 0 ADJ F
group 0 NOUN F
than 0 PUNCT F
the 0 DET F
control 0 NOUN F
group 0 NOUN F
( 0 PUNCT F
100 0 NUM F
% 0 SYM F
vs 0 CCONJ F
81.3 0 NUM F
% 0 SYM F
; 0 PUNCT F
P 0 NOUN T
= 0 SYM F
.002 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

CPG 0 NOUN T
7909 0 NUM F
did 0 PUNCT F
not 0 ADV F
increase 0 NOUN F
non-7vPnC B-PHYSICAL NOUN F
IgG I-PHYSICAL NOUN T
levels I-PHYSICAL NOUN F
after 0 ADP F
PPV-23 0 NOUN T
immunization 0 NOUN F
. 0 PUNCT F

No 0 DET T
adverse 0 ADJ F
effects 0 NOUN F
on 0 ADP F
CD4 B-PHYSICAL NOUN T
( I-PHYSICAL PUNCT F
+ I-PHYSICAL SYM F
) I-PHYSICAL PUNCT F
cell I-PHYSICAL NOUN F
count I-PHYSICAL NOUN F
or 0 CCONJ F
organ B-PHYSICAL NOUN F
functions I-PHYSICAL ADJ F
occurred 0 VERB F
in 0 ADP F
either 0 PUNCT F
group 0 NOUN F
. 0 PUNCT F

CONCLUSIONS 0 NOUN T
The 0 DET T
addition 0 NOUN F
of 0 ADP F
a 0 DET F
TLR9 0 NOUN T
agonist 0 NOUN F
to 0 ADP F
7vPnC 0 ADJ F
significantly 0 PRON F
enhanced 0 PROPN F
the 0 DET F
proportion 0 NOUN F
of 0 ADP F
vaccine B-PHYSICAL NOUN F
high I-PHYSICAL ADJ F
responders I-PHYSICAL NOUN F
. 0 PUNCT F

TRIAL 0 NOUN T
REGISTRATION 0 NOUN T
ClinicalTrials.gov 0 PUNCT T
identifier 0 NOUN F
: 0 PUNCT F
NCT00562939 0 PUNCT T
. 0 PUNCT F

Intravenous 0 ADP T
aflibercept 0 PUNCT F
administered 0 PUNCT F
in 0 ADP F
combination 0 NOUN F
with 0 ADP F
irinotecan 0 PUNCT F
, 0 PUNCT F
5-fluorouracil 0 NOUN F
and 0 CCONJ F
leucovorin 0 NOUN F
in 0 ADP F
patients 0 NOUN F
with 0 ADP F
advanced 0 ADP F
solid 0 ADJ F
tumours 0 NOUN F
: 0 PUNCT F
results 0 DET F
from 0 ADP F
the 0 DET F
expansion 0 NOUN F
cohort 0 NOUN F
of 0 ADP F
a 0 DET F
phase 0 NOUN F
I 0 NUM T
study 0 NOUN F
. 0 PUNCT F

BACKGROUND 0 NOUN T
Following 0 VERB T
the 0 DET F
dose-escalation 0 ADJ F
stage 0 NOUN F
, 0 PUNCT F
this 0 DET F
double-blind 0 ADJ F
expansion 0 NOUN F
stage 0 NOUN F
of 0 ADP F
the 0 DET F
phase 0 NOUN F
I 0 NUM T
study 0 NOUN F
evaluated 0 VERB F
the 0 DET F
safety 0 NOUN F
, 0 PUNCT F
pharmacodynamics 0 NOUN F
, 0 PUNCT F
pharmacokinetics 0 NOUN F
, 0 PUNCT F
anti-vascular 0 ADJ F
effects 0 NOUN F
and 0 CCONJ F
antitumour 0 ADP F
activity 0 NOUN F
of 0 ADP F
aflibercept 0 CCONJ F
4 0 NUM F
mg/kg 0 NOUN F
with 0 ADP F
irinotecan 0 PUNCT F
, 0 PUNCT F
5-fluorouracil 0 NOUN F
and 0 CCONJ F
leucovorin 0 NOUN F
( 0 PUNCT F
LV5FU2 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

PATIENTS 0 NOUN T
AND 0 CCONJ T
METHODS 0 NOUN T
Patients 0 NOUN T
with 0 ADP F
advanced 0 ADP F
solid 0 ADJ F
tumours 0 NOUN F
were 0 VERB F
randomised 0 VERB F
at 0 ADP F
cycle-1 0 NOUN F
to 0 ADP F
placebo 0 NOUN F
or 0 CCONJ F
aflibercept 0 ADP F
( 0 PUNCT F
4 0 NUM F
mg/kg 0 NOUN F
) 0 PUNCT F
on 0 ADP F
day 0 NOUN F
1 0 NUM F
then 0 ADV F
irinotecan-LV5FU2 0 PUNCT F
on 0 ADP F
days 0 NOUN F
1 0 NUM F
and 0 CCONJ F
2 0 NUM F
. 0 PUNCT F

Subsequently 0 ADV T
, 0 PUNCT F
all 0 DET F
patients 0 NOUN F
received 0 DET F
aflibercept 0 PUNCT F
with 0 ADP F
irinotecan-LV5FU2 0 ADP F
every 0 DET F
2 0 NUM F
weeks 0 NOUN F
. 0 PUNCT F

Anti-vascular 0 ADJ T
effects 0 NOUN F
were 0 VERB F
assessed 0 VERB F
using 0 SYM F
dynamic 0 ADJ F
contrast-enhanced 0 VERB F
magnetic 0 ADJ F
resonance 0 NOUN F
imaging 0 VERB F
( 0 PUNCT F
DCE-MRI 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

RESULTS 0 NOUN T
Twenty-seven 0 PUNCT T
patients 0 NOUN F
were 0 VERB F
treated 0 VERB F
; 0 PUNCT F
14 0 NUM F
received 0 DET F
placebo 0 NOUN F
in 0 ADP F
cycle-1 0 NOUN F
followed 0 VERB F
by 0 ADP F
aflibercept 0 CCONJ F
in 0 ADP F
later 0 PUNCT F
cycles 0 NOUN F
and 0 CCONJ F
13 0 NUM F
received 0 PUNCT F
aflibercept 0 PUNCT F
4 0 NUM F
mg/kg 0 ADP F
upfront 0 NOUN F
. 0 PUNCT F

The 0 DET T
median 0 ADJ F
number 0 NOUN F
of 0 ADP F
aflibercept B-PHYSICAL VERB F
cycles I-PHYSICAL NOUN F
was 0 VERB F
16 0 NUM F
( 0 PUNCT F
range 0 NOUN F
1-44 0 PUNCT F
) 0 PUNCT F
, 0 PUNCT F
12 0 NUM F
patients 0 NOUN F
received 0 PUNCT F
?20 0 PUNCT F
cycles 0 NOUN F
. 0 PUNCT F

Most 0 PUNCT T
frequent 0 ADJ F
grade 0 NOUN F
3/4 0 NUM F
adverse 0 ADJ F
events 0 NOUN F
were 0 ADP F
neutropenia 0 NOUN F
( 0 PUNCT F
37 0 NUM F
% 0 SYM F
) 0 PUNCT F
, 0 PUNCT F
fatigue 0 NOUN F
( 0 PUNCT F
33 0 NUM F
% 0 SYM F
) 0 PUNCT F
and 0 CCONJ F
hypertension 0 NOUN F
( 0 PUNCT F
30 0 NUM F
% 0 SYM F
) 0 PUNCT F
. 0 PUNCT F

No 0 DET T
anti-aflibercept 0 NOUN F
antibodies 0 NOUN F
were 0 VERB F
detected 0 VERB F
. 0 PUNCT F

Four 0 NUM T
patients 0 NOUN F
achieved 0 VERB F
partial 0 ADJ F
responses 0 NOUN F
and 0 CCONJ F
17 0 NUM F
had 0 PUNCT F
stable 0 ADJ F
disease 0 NOUN F
, 0 PUNCT F
lasting 0 PUNCT F
> 0 SYM F
3 0 NUM F
months 0 NOUN F
in 0 ADP F
14 0 NUM F
patients 0 NOUN F
. 0 PUNCT F

Plasma 0 NOUN T
levels 0 NOUN F
of 0 ADP F
free 0 ADJ F
over 0 ADP F
vascular 0 ADJ F
endothelial 0 ADJ F
growth 0 NOUN F
factor-bound 0 ADP F
aflibercept 0 PUNCT F
were 0 ADP F
adequate 0 ADJ F
, 0 PUNCT F
with 0 ADP F
steady-state 0 NOUN F
achieved 0 VERB F
from 0 ADP F
cycle-3 0 NOUN F
. 0 PUNCT F

Exploratory 0 ADJ T
DCE-MRI 0 NOUN T
showed 0 VERB F
no 0 DET F
significant 0 ADJ F
perfusion 0 NOUN F
changes 0 NOUN F
with 0 ADP F
aflibercept 0 ADV F
. 0 PUNCT F

CONCLUSION 0 NOUN T
Aflibercept 0 PUNCT T
4 0 NUM F
mg/kg 0 NOUN F
plus 0 CCONJ F
irinotecan-LV5FU2 0 PUNCT F
every 0 DET F
2 0 NUM F
weeks 0 NOUN F
had 0 PUNCT F
acceptable 0 ADJ F
toxicity 0 NOUN F
and 0 CCONJ F
pharmacokinetics 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
showed 0 VERB F
promising 0 PUNCT F
antitumour 0 ADP F
activity 0 NOUN F
. 0 PUNCT F

Effects 0 NOUN T
of 0 ADP F
maternal 0 ADJ F
glucose 0 NOUN F
infusion 0 NOUN F
on 0 ADP F
fetal 0 ADJ F
acid-base 0 NOUN F
status 0 NOUN F
in 0 ADP F
human 0 NOUN F
pregnancy 0 NOUN F
. 0 PUNCT F

The 0 DET T
maternal 0 ADJ F
and 0 CCONJ F
fetal 0 ADJ F
metabolic 0 ADJ F
effects 0 NOUN F
of 0 ADP F
three 0 NUM F
commonly 0 ADV F
used 0 VERB F
intravenous 0 ADJ F
fluids 0 NOUN F
administered 0 VERB F
before 0 ADP F
regional 0 ADJ F
anesthesia 0 NOUN F
were 0 VERB F
studied 0 VERB F
in 0 ADP F
32 0 NUM F
gravid 0 NOUN F
women 0 NOUN F
undergoing 0 VERB F
elective 0 ADJ F
cesarean 0 NOUN F
section 0 NOUN F
at 0 ADP F
term 0 NOUN F
. 0 PUNCT F

Patients 0 NOUN T
were 0 VERB F
randomized 0 VERB F
into 0 ADP F
one 0 NUM F
of 0 ADP F
three 0 NUM F
groups 0 NOUN F
to 0 PART F
receive 0 NOUN F
1 0 NUM F
L 0 NOUN T
of 0 ADP F
either 0 CCONJ F
5 0 NUM F
% 0 SYM F
dextrose 0 NOUN F
( 0 PUNCT F
50 0 NUM F
gm 0 NOUN F
of 0 ADP F
glucose 0 NOUN F
) 0 PUNCT F
or 0 CCONJ F
Ringer 0 ADV T
's 0 PUNCT F
lactate 0 NOUN F
or 0 CCONJ F
isotonic 0 ADJ F
saline 0 ADJ F
solution 0 NOUN F
before 0 ADP F
epidural 0 ADJ F
anesthesia 0 NOUN F
. 0 PUNCT F

Acute B-PHYSICAL ADJ T
glucose I-PHYSICAL NOUN F
infusion I-PHYSICAL NOUN F
resulted 0 VERB F
in 0 ADP F
maternal B-ADVERSE-EFFECTS ADJ F
hyperglycemia I-ADVERSE-EFFECTS NOUN F
, 0 PUNCT F
hyperinsulinemia B-PHYSICAL NOUN F
, 0 PUNCT F
and 0 CCONJ F
an 0 DET F
increase 0 NOUN F
in 0 ADP F
the B-PHYSICAL DET F
blood I-PHYSICAL NOUN F
lactate I-PHYSICAL NOUN F
level I-PHYSICAL NOUN F
. 0 PUNCT F

Cord 0 NOUN T
blood 0 NOUN F
glucose 0 NOUN F
, 0 PUNCT F
insulin 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
lactate 0 NOUN F
levels 0 NOUN F
were 0 VERB F
also 0 ADV F
increased 0 VERB F
in 0 ADP F
this 0 DET F
group 0 NOUN F
. 0 PUNCT F

The 0 DET T
key 0 ADJ F
finding 0 DET F
of 0 ADP F
this 0 DET F
study 0 NOUN F
was 0 VERB F
the 0 DET F
significant B-PHYSICAL ADJ F
lowering I-PHYSICAL DET F
of I-PHYSICAL ADP F
pH I-PHYSICAL NOUN F
in I-PHYSICAL ADP F
the I-PHYSICAL DET F
umbilical I-PHYSICAL ADJ F
cord I-PHYSICAL NOUN F
vein I-PHYSICAL NOUN F
( 0 PUNCT F
7.31 0 NUM F
+/- 0 SYM F
0.04 0 NUM F
) 0 PUNCT F
and 0 CCONJ F
artery B-PHYSICAL NOUN F
( 0 PUNCT F
7.21 0 NUM F
+/- 0 SYM F
0.06 0 NUM F
) 0 PUNCT F
in 0 ADP F
the 0 DET F
glucose-infused 0 VERB F
group 0 NOUN F
when 0 ADP F
compared 0 VERB F
with 0 ADP F
the 0 DET F
non-glucose B-PHYSICAL ADJ F
infusion I-PHYSICAL NOUN F
groups 0 NOUN F
( 0 PUNCT F
p 0 NOUN F
less 0 ADV F
than 0 PUNCT F
0.05 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Confounding 0 ADJ T
perinatal 0 ADJ F
factors 0 NOUN F
such 0 CCONJ F
as 0 ADP F
maternal B-PHYSICAL ADJ F
position 0 NOUN F
, 0 PUNCT F
maternal B-PHYSICAL ADJ F
hypotension I-PHYSICAL NOUN F
, 0 PUNCT F
and 0 CCONJ F
prolonged 0 DET F
time 0 NOUN F
of 0 ADP F
surgery 0 NOUN F
did 0 PUNCT F
not 0 ADV F
influence 0 VERB F
the 0 DET F
fetal 0 ADJ F
acid-base 0 NOUN F
status 0 NOUN F
. 0 PUNCT F

Thus 0 ADV T
acute 0 ADJ F
maternal B-PHYSICAL ADJ F
glucose I-PHYSICAL NOUN F
infusion I-PHYSICAL NOUN F
in 0 ADP F
normal 0 ADJ F
patients 0 NOUN F
can 0 ADJ F
cause 0 ADP F
fetal B-PHYSICAL ADJ F
hyperglycemia I-PHYSICAL NOUN F
, 0 PUNCT F
metabolic B-PHYSICAL ADJ F
acidosis I-PHYSICAL NOUN F
, 0 PUNCT F
and 0 CCONJ F
neonatal B-PHYSICAL ADJ F
hypoglycemia I-PHYSICAL NOUN F
. 0 PUNCT F

These 0 DET T
findings 0 NOUN F
may 0 VERB F
be 0 PUNCT F
of 0 ADP F
particular 0 ADJ F
clinical 0 ADJ F
importance 0 NOUN F
when 0 ADP F
fetal B-PHYSICAL ADJ F
distress I-PHYSICAL NOUN F
or 0 CCONJ F
fetal B-PHYSICAL ADJ F
hypoxemia I-PHYSICAL NOUN F
is 0 VERB F
due 0 CCONJ F
to 0 ADP F
other 0 CCONJ F
perinatal 0 ADJ F
events 0 NOUN F
. 0 PUNCT F

Under 0 ADP T
these 0 DET F
circumstances 0 NOUN F
, 0 PUNCT F
acute B-PHYSICAL ADJ F
maternal I-PHYSICAL ADJ F
glucose I-PHYSICAL NOUN F
infusion I-PHYSICAL NOUN F
may 0 SYM F
further 0 ADV F
contribute 0 VERB F
to 0 ADP F
fetal B-PHYSICAL ADJ F
metabolic I-PHYSICAL ADJ F
acidosis I-PHYSICAL NOUN F
. 0 PUNCT F

Rosiglitazone 0 NOUN T
and 0 CCONJ F
cognitive 0 ADJ F
function 0 NOUN F
in 0 ADP F
clozapine-treated 0 VERB F
patients 0 NOUN F
with 0 ADP F
schizophrenia 0 NOUN F
: 0 PUNCT F
a 0 DET F
pilot 0 NOUN F
study 0 NOUN F
. 0 PUNCT F

Studies 0 NOUN T
have 0 ADP F
shown 0 VERB F
that 0 VERB F
insulin 0 NOUN F
resistance 0 NOUN F
is 0 VERB F
associated 0 VERB F
with 0 ADP F
cognitive 0 ADJ F
impairment 0 NOUN F
. 0 PUNCT F

Peroxisome 0 NOUN T
proliferator-activated 0 VERB F
receptor-? 0 NOUN F
( 0 PUNCT F
PPAR-? 0 NUM T
) 0 PUNCT F
agonists 0 NOUN F
improve 0 VERB F
insulin 0 NOUN F
sensitivity 0 NOUN F
. 0 PUNCT F

The 0 DET T
purpose 0 NOUN F
of 0 ADP F
this 0 DET F
study 0 NOUN F
was 0 VERB F
to 0 PART F
evaluate 0 NOUN F
the 0 DET F
effect 0 NOUN F
of 0 ADP F
rosiglitazone 0 NOUN F
, 0 PUNCT F
a 0 DET F
PPAR-? 0 ADJ T
agonist 0 NOUN F
, 0 PUNCT F
on 0 ADP F
cognition 0 NOUN F
in 0 ADP F
clozapine-treated 0 VERB F
patients 0 NOUN F
with 0 ADP F
schizophrenia 0 NOUN F
. 0 PUNCT F

In 0 ADP T
an 0 DET F
eight-week 0 NOUN F
double-blind 0 ADJ F
, 0 PUNCT F
placebo-controlled 0 PUNCT F
pilot 0 NOUN F
trial 0 NOUN F
, 0 PUNCT F
clozapine-treated 0 VERB F
patients 0 NOUN F
with 0 ADP F
schizophrenia 0 NOUN F
were 0 VERB F
randomized 0 VERB F
to 0 PART F
receive 0 ADJ F
rosiglitazone 0 NOUN F
( 0 PUNCT F
4mg/day 0 NOUN F
) 0 PUNCT F
or 0 CCONJ F
placebo 0 NOUN F
. 0 PUNCT F

A 0 DET T
neuropsychological 0 ADJ F
battery 0 NOUN F
including 0 VERB F
the 0 DET F
Digit 0 NOUN T
Span 0 NOUN T
subtest 0 NOUN F
from 0 ADP F
the 0 DET F
Wechsler 0 PUNCT T
Adult 0 NOUN T
Intelligence 0 NOUN T
Scale-III 0 ADV T
( 0 PUNCT F
WAIS-III 0 PUNCT T
) 0 PUNCT F
, 0 PUNCT F
the 0 DET F
verbal 0 ADJ F
fluency 0 NOUN F
test 0 NOUN F
, 0 PUNCT F
the 0 DET F
Hopkins 0 ADV T
Verbal 0 ADJ T
Learning 0 PUNCT T
Test 0 NOUN T
( 0 PUNCT F
HVLT 0 NOUN T
) 0 PUNCT F
, 0 PUNCT F
the 0 DET F
Trail-Making 0 PUNCT T
Test 0 NOUN T
( 0 PUNCT F
TMT 0 NOUN T
) 0 PUNCT F
and 0 CCONJ F
the 0 DET F
Wisconsin 0 NOUN T
Card 0 NOUN T
Sorting 0 PUNCT T
Test 0 NOUN T
( 0 PUNCT F
WCST 0 ADV T
) 0 PUNCT F
was 0 VERB F
administered 0 VERB F
at 0 ADP F
baseline 0 NOUN F
and 0 CCONJ F
week 0 NOUN F
eight 0 NUM F
. 0 PUNCT F

Nineteen 0 NUM T
patients 0 NOUN F
completed 0 NOUN F
the 0 DET F
study 0 NOUN F
. 0 PUNCT F

There 0 PUNCT T
were 0 VERB F
no 0 DET F
significant 0 ADJ F
differences 0 NOUN F
on 0 ADP F
any 0 DET F
demographic 0 ADJ F
or 0 CCONJ F
general 0 ADJ F
clinical 0 ADJ F
variables 0 NOUN F
between 0 ADP F
the 0 DET F
rosiglitazone 0 NOUN F
group 0 NOUN F
( 0 PUNCT F
n=9 0 NOUN F
) 0 PUNCT F
and 0 CCONJ F
the 0 DET F
placebo 0 NOUN F
group 0 NOUN F
( 0 PUNCT F
n=10 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

When 0 ADP T
baseline 0 NOUN F
scores 0 NOUN F
were 0 VERB F
controlled 0 VERB F
, 0 PUNCT F
there 0 PUNCT F
were 0 VERB F
no 0 DET F
significant 0 ADJ F
differences 0 NOUN F
in 0 ADP F
change 0 ADV F
scores 0 NOUN F
of 0 ADP F
cognitive B-MENTAL ADJ F
performance I-MENTAL NOUN F
over 0 ADP F
eight 0 NUM F
weeks 0 NOUN F
between 0 ADP F
the 0 DET F
two 0 NUM F
groups 0 NOUN F
. 0 PUNCT F

In 0 ADP T
this 0 PUNCT F
pilot 0 NOUN F
study 0 NOUN F
, 0 PUNCT F
rosiglitazone 0 NOUN F
had 0 PUNCT F
no 0 DET F
cognitive B-MENTAL ADJ F
benefit I-MENTAL NOUN F
in 0 ADP F
clozapine-treated 0 VERB F
patients 0 NOUN F
with 0 ADP F
schizophrenia 0 NOUN F
. 0 PUNCT F

Future 0 ADJ T
studies 0 NOUN F
with 0 ADP F
longer 0 PUNCT F
treatment 0 NOUN F
duration 0 NOUN F
and 0 CCONJ F
larger 0 PUNCT F
sample 0 NOUN F
size 0 NOUN F
are 0 VERB F
needed 0 VERB F
to 0 ADP F
further 0 ADJ F
explore 0 PUNCT F
the 0 DET F
potential 0 ADJ F
role 0 NOUN F
of 0 ADP F
rosiglitazone 0 NOUN F
in 0 ADP F
improving 0 VERB F
cognitive 0 ADJ F
function 0 NOUN F
in 0 ADP F
patients 0 NOUN F
with 0 ADP F
schizophrenia 0 NOUN F
. 0 PUNCT F

Mecamylamine 0 ADV T
reduces 0 NOUN F
some 0 DET F
EEG B-PHYSICAL NOUN T
effects I-PHYSICAL NOUN F
of 0 ADP F
nicotine 0 NOUN F
chewing 0 VERB F
gum 0 NOUN F
in 0 ADP F
humans 0 NOUN F
. 0 PUNCT F

Spontaneous B-PHYSICAL ADJ T
EEG I-PHYSICAL NOUN T
was 0 VERB F
recorded 0 VERB F
in 0 ADP F
nine 0 DET F
cigarette 0 NOUN F
smokers 0 NOUN F
who 0 PROPN F
had 0 PUNCT F
been 0 PUNCT F
abstinent 0 ADP F
from 0 ADP F
tobacco 0 NOUN F
for 0 ADP F
12 0 NUM F
hr 0 NOUN F
. 0 PUNCT F

Subjects 0 NOUN T
were 0 VERB F
treated 0 VERB F
with 0 ADP F
a 0 DET F
capsule 0 NOUN F
containing 0 VERB F
either 0 PUNCT F
centrally 0 ADV F
acting 0 PUNCT F
nicotine 0 NOUN F
blocker 0 NOUN F
, 0 PUNCT F
mecamylamine 0 PUNCT F
( 0 PUNCT F
10 0 NUM F
mg 0 NOUN F
) 0 PUNCT F
, 0 PUNCT F
or 0 CCONJ F
placebo 0 NOUN F
. 0 PUNCT F

At 0 ADP T
each 0 PUNCT F
of 0 ADP F
three 0 NUM F
60-min 0 NOUN F
intervals 0 NOUN F
after 0 ADP F
the 0 DET F
capsule 0 NOUN F
was 0 VERB F
ingested 0 VERB F
, 0 PUNCT F
the 0 DET F
subjects 0 NOUN F
chewed 0 ADV F
two 0 NUM F
pieces 0 NOUN F
of 0 ADP F
gum 0 NOUN F
containing 0 VERB F
a 0 DET F
total 0 NOUN F
of 0 ADP F
0 0 NUM F
, 0 PUNCT F
4 0 NUM F
or 0 CCONJ F
8 0 NUM F
mg 0 NOUN F
of 0 ADP F
nicotine 0 NOUN F
. 0 PUNCT F

Nicotine 0 NOUN T
and 0 CCONJ F
mecamylamine 0 PUNCT F
dose 0 NOUN F
combinations 0 NOUN F
were 0 VERB F
randomized 0 PUNCT F
across 0 ADP F
subjects 0 NOUN F
. 0 PUNCT F

Two 0 NUM T
three-minute 0 ADJ F
periods 0 NOUN F
of 0 ADP F
spontaneous B-PHYSICAL ADJ F
EEG I-PHYSICAL NOUN T
were 0 VERB F
recorded 0 VERB F
before 0 ADP F
the 0 DET F
capsule 0 NOUN F
and 0 CCONJ F
before 0 ADP F
and 0 CCONJ F
after 0 ADP F
gum 0 NOUN F
chewing 0 VERB F
from 0 ADP F
bipolar 0 ADJ F
electrode 0 NOUN F
montages 0 NOUN F
at 0 ADP F
the 0 DET F
following 0 PUNCT F
positions 0 NOUN F
: 0 PUNCT F
Cz-T5 0 NOUN T
, 0 PUNCT F
Cz-T6 0 NOUN T
, 0 PUNCT F
Cz-F7 0 NOUN T
and 0 CCONJ F
Cz-F8 0 NUM T
. 0 PUNCT F

During 0 ADP T
one 0 NUM F
period 0 NOUN F
the 0 DET F
subjects 0 NOUN F
relaxed 0 NUM F
with 0 ADP F
eyes 0 NOUN F
closed 0 PUNCT F
, 0 PUNCT F
in 0 ADP F
the 0 DET F
other 0 ADJ F
period 0 NOUN F
they 0 PRON F
performed 0 VERB F
a 0 DET F
math 0 ADP F
task 0 NOUN F
with 0 ADP F
eyes 0 NOUN F
open 0 PUNCT F
. 0 PUNCT F

When 0 ADP T
the 0 DET F
drugs 0 NOUN F
were 0 VERB F
given 0 VERB F
individually 0 ADV F
, 0 PUNCT F
mecamylamine 0 PUNCT F
decreased 0 VERB F
beta B-PHYSICAL NOUN F
power I-PHYSICAL NOUN F
and 0 CCONJ F
nicotine 0 NOUN F
gum 0 NOUN F
( 0 PUNCT F
4 0 NUM F
and 0 CCONJ F
8 0 NUM F
mg 0 NOUN F
) 0 PUNCT F
increased 0 VERB F
alpha B-PHYSICAL NOUN F
frequency 0 NOUN F
. 0 PUNCT F

Mecamylamine 0 ADJ T
pretreatment 0 NOUN F
prevented 0 VERB F
the 0 DET F
increase 0 NOUN F
in 0 ADP F
alpha B-PHYSICAL NOUN F
frequency I-PHYSICAL NOUN F
caused 0 VERB F
by 0 ADP F
the 0 DET F
4 0 NUM F
mg 0 NOUN F
gum 0 NOUN F
dose 0 NOUN F
but 0 CCONJ F
not 0 ADV F
the 0 DET F
8 0 NUM F
mg 0 NOUN F
dose 0 NOUN F
. 0 PUNCT F

Alpha B-OTHER NOUN T
power I-OTHER NOUN F
was 0 VERB F
increased 0 VERB F
by 0 ADP F
the 0 DET F
8 0 NUM F
mg 0 NOUN F
gum 0 NOUN F
dose 0 NOUN F
and 0 CCONJ F
that 0 ADP F
increase 0 VERB F
was 0 VERB F
prevented 0 VERB F
by 0 ADP F
mecamylamine 0 PUNCT F
. 0 PUNCT F

Self-reported 0 PUNCT T
ratings 0 NOUN F
of 0 ADP F
the 0 DET F
strength B-PHYSICAL NOUN F
of 0 ADP F
the 0 DET F
gum 0 NOUN F
were 0 VERB F
significantly 0 ADV F
diminished 0 VERB F
by 0 ADP F
mecamylamine 0 PUNCT F
pretreatment 0 NOUN F
. 0 PUNCT F

The 0 DET T
data 0 NOUN F
are 0 VERB F
consistent 0 ADJ F
with 0 ADP F
the 0 DET F
results 0 NOUN F
of 0 ADP F
earlier 0 PUNCT F
studies 0 NOUN F
which 0 ADP F
indicate 0 VERB F
that 0 ADP F
the 0 DET F
effects 0 NOUN F
of 0 ADP F
tobacco 0 NOUN F
administration 0 NOUN F
and 0 CCONJ F
withdrawal 0 NOUN F
are 0 VERB F
mediated 0 VERB F
by 0 ADP F
central 0 ADJ F
actions 0 NOUN F
of 0 ADP F
nicotine 0 NOUN F
. 0 PUNCT F

Racial 0 ADJ T
differences 0 NOUN F
in 0 ADP F
primary 0 ADJ F
and 0 CCONJ F
repeat 0 NOUN F
lower 0 PUNCT F
extremity 0 NOUN F
amputation 0 NOUN F
: 0 PUNCT F
results 0 ADJ F
from 0 ADP F
a 0 DET F
multihospital 0 ADJ F
study 0 NOUN F
. 0 PUNCT F

OBJECTIVE 0 ADP T
African 0 ADJ T
Americans 0 PUNCT T
have 0 PUNCT F
a 0 DET F
much 0 ADJ F
higher 0 PUNCT F
risk 0 NOUN F
of 0 ADP F
major B-PHYSICAL ADJ F
( 0 PUNCT F
above- B-PHYSICAL NOUN F
or 0 CCONJ F
below-knee 0 NOUN F
) 0 PUNCT F
lower 0 CCONJ F
extremity 0 NOUN F
amputation 0 NOUN F
and 0 CCONJ F
a 0 DET F
lower 0 PUNCT F
rate 0 NOUN F
of 0 ADP F
limb-preserving B-PHYSICAL PROPN F
vascular I-PHYSICAL ADJ F
surgery I-PHYSICAL NOUN F
or 0 CCONJ F
angioplasty 0 NOUN F
than 0 VERB F
white 0 ADJ F
patients 0 NOUN F
. 0 PUNCT F

This 0 DET T
article 0 NOUN F
analyzes 0 PUNCT F
two 0 NUM F
potential 0 ADJ F
pathways 0 NOUN F
for 0 ADP F
racial 0 ADJ F
disparities 0 NOUN F
: 0 PUNCT F
primary 0 ADJ F
amputation 0 NOUN F
, 0 PUNCT F
defined 0 VERB F
as 0 ADP F
a 0 DET F
major 0 ADJ F
amputation 0 NOUN F
performed 0 VERB F
without 0 ADP F
any 0 DET F
prior 0 PUNCT F
attempt 0 ADJ F
at 0 ADP F
revascularization 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
repeat 0 NOUN F
amputation 0 NOUN F
, 0 PUNCT F
defined 0 VERB F
as 0 ADP F
a 0 DET F
major 0 ADJ F
amputation 0 NOUN F
subsequent 0 PUNCT F
to 0 ADP F
a 0 DET F
previous 0 ADJ F
through-foot 0 NOUN F
or 0 CCONJ F
major 0 ADJ F
amputation 0 NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
Randomly 0 ADV T
selected 0 VERB F
medical 0 ADJ F
records 0 NOUN F
were 0 VERB F
reviewed 0 VERB F
for 0 ADP F
248 0 ADJ F
African 0 ADJ T
American 0 ADJ T
, 0 PUNCT F
30 0 NUM F
Hispanic 0 ADJ T
, 0 PUNCT F
and 0 CCONJ F
235 0 NUM F
white 0 ADJ F
or 0 CCONJ F
other-race 0 ADJ F
patients 0 NOUN F
undergoing 0 PRON F
above- 0 NOUN F
or 0 CCONJ F
below-knee 0 NOUN F
amputation 0 NOUN F
between 0 ADP F
1995 0 NUM F
and 0 CCONJ F
2003 0 NUM F
at 0 ADP F
three 0 NUM F
Chicago 0 PUNCT T
teaching 0 VERB F
hospitals 0 NOUN F
. 0 PUNCT F

Chronic 0 ADJ T
disease 0 NOUN F
prevalence 0 NOUN F
and 0 CCONJ F
severity 0 NOUN F
, 0 PUNCT F
preadmission 0 NOUN F
functional 0 ADJ F
status 0 NOUN F
, 0 PUNCT F
clinical 0 ADJ F
presentation 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
vascular 0 ADJ F
history 0 NOUN F
were 0 VERB F
used 0 VERB F
to 0 PART F
test 0 NOUN F
the 0 DET F
risk-adjusted 0 VERB F
effect 0 NOUN F
of 0 ADP F
race 0 NOUN F
and 0 CCONJ F
ethnicity 0 NOUN F
on 0 ADP F
rates 0 NOUN F
of 0 ADP F
primary B-PHYSICAL ADJ F
and 0 CCONJ F
repeat B-PHYSICAL NOUN F
amputation I-PHYSICAL NOUN F
. 0 PUNCT F

RESULTS 0 NOUN T
Controlling 0 ADJ T
for 0 ADP F
demographic 0 ADJ F
, 0 PUNCT F
functional 0 ADJ F
, 0 PUNCT F
chronic 0 ADJ F
disease 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
clinical 0 ADJ F
characteristics 0 NOUN F
, 0 PUNCT F
African 0 ADJ T
American 0 ADJ T
patients 0 NOUN F
were 0 VERB F
1.7 0 PUNCT F
times 0 ADP F
more 0 ADV F
likely 0 ADJ F
to 0 PART F
have 0 PUNCT F
undergone 0 ADP F
both 0 PUNCT F
primary 0 ADJ F
( 0 PUNCT F
P 0 NOUN T
= 0 SYM F
.01 0 NUM F
) 0 PUNCT F
and 0 CCONJ F
repeat 0 NOUN F
( 0 PUNCT F
P 0 NOUN T
= 0 SYM F
.03 0 NUM F
) 0 PUNCT F
amputation 0 NOUN F
than 0 PUNCT F
white 0 PUNCT F
or 0 CCONJ F
other-race 0 ADJ F
amputees 0 ADV F
. 0 PUNCT F

Race 0 NOUN T
remained 0 VERB F
a 0 DET F
significant 0 ADJ F
independent 0 ADJ F
risk 0 NOUN F
factor 0 NOUN F
even 0 ADV F
after 0 PUNCT F
controlling 0 ADJ F
for 0 ADP F
the 0 DET F
higher 0 PUNCT F
severity 0 NOUN F
of 0 ADP F
illness 0 NOUN F
, 0 PUNCT F
greater 0 PUNCT F
disability 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
more 0 DET F
complex 0 ADJ F
presentation 0 NOUN F
of 0 ADP F
African 0 ADJ T
American 0 ADJ T
amputees 0 ADJ F
. 0 PUNCT F

CONCLUSIONS 0 NOUN T
Higher 0 PUNCT T
rates 0 NOUN F
of 0 ADP F
primary B-PHYSICAL ADJ F
and I-PHYSICAL CCONJ F
repeat I-PHYSICAL NOUN F
amputation I-PHYSICAL NOUN F
for 0 ADP F
African 0 ADJ T
American 0 ADJ T
patients 0 NOUN F
at 0 ADP F
study 0 PUNCT F
hospitals 0 PROPN F
, 0 PUNCT F
which 0 ADP F
all 0 DET F
have 0 CCONJ F
significant 0 ADJ F
vascular 0 ADJ F
surgery 0 NOUN F
capacity 0 NOUN F
and 0 CCONJ F
an 0 DET F
aggressive 0 ADJ F
policy 0 NOUN F
of 0 ADP F
limb 0 NOUN F
salvage 0 NOUN F
, 0 PUNCT F
suggest 0 VERB F
that 0 ADP F
these 0 DET F
rates 0 NOUN F
may 0 VERB F
be 0 VERB F
even 0 ADV F
higher 0 PUNCT F
at 0 ADP F
less 0 VERB F
well 0 VERB F
equipped 0 DET F
institutions 0 NOUN F
. 0 PUNCT F

Improving 0 ADV T
access 0 NOUN F
to 0 ADP F
primary 0 ADJ F
and 0 CCONJ F
preventive 0 ADJ F
care 0 NOUN F
for 0 ADP F
lower-income 0 NOUN F
patients 0 NOUN F
could 0 VERB F
reduce 0 VERB F
amputation B-PHYSICAL NOUN F
rates I-PHYSICAL NOUN F
among 0 ADP F
African 0 ADJ T
Americans 0 PUNCT T
. 0 PUNCT F

Tegaserod 0 NOUN T
, 0 PUNCT F
a 0 DET F
5-hydroxytryptamine 0 NOUN F
type 0 NOUN F
4 0 NUM F
receptor 0 NOUN F
partial 0 ADJ F
agonist 0 NOUN F
, 0 PUNCT F
is 0 VERB F
devoid 0 CCONJ F
of 0 ADP F
electrocardiographic B-PHYSICAL ADJ F
effects I-PHYSICAL NOUN F
. 0 PUNCT F

OBJECTIVES 0 NOUN T
Certain 0 ADJ T
GI 0 NOUN T
prokinetic 0 ADJ F
agents 0 NOUN F
have 0 ADP F
been 0 PUNCT F
shown 0 VERB F
to 0 PART F
affect 0 ADJ F
cardiac 0 ADJ F
repolarization 0 NOUN F
, 0 PUNCT F
which 0 ADP F
may 0 VERB F
be 0 VERB F
associated 0 VERB F
with 0 ADP F
life-threatening 0 VERB F
arrhythmias 0 NOUN F
. 0 PUNCT F

The 0 DET T
selective 0 ADJ F
5-hydroxytryptamine 0 NOUN F
type 0 NOUN F
4 0 NUM F
receptor 0 NOUN F
partial 0 ADJ F
agonist 0 NOUN F
tegaserod 0 NOUN F
is 0 VERB F
a 0 DET F
novel 0 ADJ F
promotile 0 ADP F
agent 0 NOUN F
developed 0 VERB F
for 0 ADP F
the 0 DET F
treatment 0 NOUN F
of 0 ADP F
functional 0 ADJ F
motility 0 NOUN F
disorders 0 NOUN F
such 0 CCONJ F
as 0 ADP F
irritable 0 ADJ F
bowel 0 NOUN F
syndrome 0 NOUN F
( 0 PUNCT F
IBS 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
aim 0 NOUN F
of 0 ADP F
the 0 DET F
study 0 NOUN F
was 0 VERB F
to 0 PART F
investigate 0 NOUN F
the 0 DET F
cardiac B-OTHER ADJ F
safety I-OTHER NOUN F
profile I-OTHER NOUN F
of 0 ADP F
tegaserod 0 NOUN F
through 0 ADP F
analysis 0 NOUN F
of 0 ADP F
electrocardiographic 0 ADJ F
data 0 NOUN F
from 0 ADP F
clinical 0 ADJ F
studies 0 NOUN F
conducted 0 VERB F
in 0 ADP F
patients 0 NOUN F
with 0 ADP F
IBS 0 NOUN T
and 0 CCONJ F
a 0 DET F
study 0 NOUN F
conducted 0 VERB F
in 0 ADP F
healthy 0 ADJ F
male 0 NOUN F
subjects 0 NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
In 0 ADP T
three 0 NUM F
randomized 0 VERB F
, 0 PUNCT F
double 0 ADJ F
blind 0 ADJ F
, 0 PUNCT F
placebo-controlled 0 VERB F
, 0 PUNCT F
parallel 0 ADJ F
group 0 NOUN F
clinical 0 ADJ F
studies 0 NOUN F
, 0 PUNCT F
2516 0 NUM F
IBS 0 NOUN T
patients 0 NOUN F
with 0 ADP F
symptoms 0 NOUN F
of 0 ADP F
abdominal 0 ADJ F
pain 0 NOUN F
and 0 CCONJ F
constipation 0 NOUN F
received 0 ADP F
tegaserod 0 NOUN F
2 0 NUM F
or 0 CCONJ F
6 0 NUM F
mg 0 NOUN F
b.i.d 0 PUNCT F
. 0 PUNCT F
( 0 PUNCT F

n 0 NOUN F
= 0 SYM F
1679 0 NUM F
) 0 PUNCT F
or 0 CCONJ F
placebo 0 NOUN F
( 0 PUNCT F
n 0 NOUN F
= 0 SYM F
837 0 NUM F
) 0 PUNCT F
for 0 ADP F
12 0 NUM F
wk 0 NOUN F
. 0 PUNCT F

In 0 ADP T
an 0 DET F
additional 0 ADJ F
study 0 NOUN F
, 0 PUNCT F
36 0 NUM F
healthy 0 ADJ F
male 0 NOUN F
subjects 0 NOUN F
received 0 VERB F
iv 0 PUNCT F
. 0 PUNCT F

single 0 ADJ F
doses 0 NOUN F
of 0 ADP F
tegaserod 0 NOUN F
( 0 PUNCT F
0.8 0 NUM F
mg 0 NOUN F
to 0 ADP F
20 0 NUM F
mg 0 NOUN F
) 0 PUNCT F
or 0 CCONJ F
placebo 0 NOUN F
. 0 PUNCT F

Standard 0 ADJ T
12-lead 0 NOUN F
electrocardiograms 0 NOUN F
were 0 VERB F
recorded 0 VERB F
at 0 ADP F
baseline 0 NOUN F
and 0 CCONJ F
during 0 ADP F
treatment 0 NOUN F
. 0 PUNCT F

Baseline 0 NOUN T
values 0 NOUN F
were 0 VERB F
compared 0 VERB F
with 0 ADP F
data 0 NOUN F
collected 0 VERB F
during 0 ADP F
the 0 DET F
treatment 0 NOUN F
period 0 NOUN F
. 0 PUNCT F

RESULTS 0 PUNCT T
The 0 DET T
proportion 0 NOUN F
of 0 ADP F
patients 0 NOUN F
with 0 ADP F
prolongation B-PHYSICAL NOUN F
of I-PHYSICAL ADP F
the I-PHYSICAL DET F
QTc I-PHYSICAL PUNCT T
interval I-PHYSICAL NOUN F
was 0 VERB F
the 0 DET F
same 0 ADP F
for 0 ADP F
placebo 0 NOUN F
and 0 CCONJ F
tegaserod 0 NOUN F
, 0 PUNCT F
as 0 PUNCT F
was 0 VERB F
the 0 DET F
frequency 0 NOUN F
of 0 ADP F
overall B-PHYSICAL ADJ F
electrocardiographic I-PHYSICAL ADJ F
abnormalities I-PHYSICAL NOUN F
. 0 PUNCT F

No 0 DET T
ventricular B-PHYSICAL ADJ F
or I-PHYSICAL CCONJ F
supraventricular I-PHYSICAL ADJ F
tachycardia I-PHYSICAL NOUN F
was 0 VERB F
observed 0 VERB F
. 0 PUNCT F

Comparable 0 ADJ T
electrocardiographic B-PHYSICAL ADJ F
results I-PHYSICAL NOUN F
were 0 VERB F
obtained 0 VERB F
during 0 ADP F
placebo 0 NOUN F
and 0 CCONJ F
tegaserod 0 NOUN F
treatment 0 NOUN F
. 0 PUNCT F

In 0 ADP T
healthy 0 ADJ F
volunteers 0 NOUN F
, 0 PUNCT F
tegaserod 0 NOUN F
at 0 ADP F
i.v 0 NUM F
. 0 PUNCT F

doses 0 NOUN F
resulting 0 VERB F
in 0 ADP F
plasma B-PHYSICAL NOUN F
concentrations I-PHYSICAL NOUN F
up 0 PUNCT F
to 0 ADP F
100 0 NUM F
times 0 NOUN F
those 0 VERB F
measured 0 VERB F
after 0 ADP F
therapeutic 0 ADJ F
doses 0 NOUN F
( 0 PUNCT F
6 0 NUM F
mg 0 NOUN F
b.i.d 0 PUNCT F
. 0 PUNCT F
) 0 PUNCT F

did 0 PUNCT F
not 0 ADV F
influence 0 NUM F
electrocardiographic 0 ADJ F
parameters 0 NOUN F
. 0 PUNCT F

CONCLUSIONS 0 NOUN T
Tegaserod 0 NOUN T
is 0 VERB F
devoid 0 CCONJ F
of 0 ADP F
electrocardiographic B-PHYSICAL ADJ F
effects I-PHYSICAL NOUN F
and 0 CCONJ F
is 0 VERB F
not 0 ADV F
expected 0 VERB F
to 0 ADP F
adversely 0 PUNCT F
influence 0 VERB F
cardiac B-PHYSICAL ADJ F
function I-PHYSICAL NOUN F
. 0 PUNCT F

These 0 DET T
data 0 NOUN F
confirm 0 DET F
preclinical 0 ADJ F
findings 0 NOUN F
. 0 PUNCT F

Oral 0 ADJ T
magnesium 0 NOUN F
supplementation 0 NOUN F
improves 0 NOUN F
the 0 DET F
metabolic B-PHYSICAL ADJ F
profile I-PHYSICAL NOUN F
of 0 ADP F
metabolically 0 ADV F
obese 0 ADP F
, 0 PUNCT F
normal-weight 0 ADJ F
individuals 0 NOUN F
: 0 PUNCT F
a 0 DET F
randomized 0 VERB F
double-blind 0 ADJ F
placebo-controlled 0 VERB F
trial 0 NOUN F
. 0 PUNCT F

BACKGROUND 0 NOUN T
AND 0 CCONJ T
AIMS 0 ADP T
We 0 ADJ T
undertook 0 ADJ F
this 0 DET F
study 0 NOUN F
to 0 DET F
determine 0 NOUN F
the 0 DET F
efficacy 0 NOUN F
of 0 ADP F
oral 0 ADJ F
magnesium 0 NOUN F
supplementation 0 NOUN F
in 0 ADP F
the 0 DET F
improvement 0 NOUN F
of 0 ADP F
the 0 DET F
metabolic B-OTHER ADJ F
profile I-OTHER ADJ F
and 0 CCONJ F
blood B-OTHER NOUN F
pressure I-OTHER NOUN F
in 0 ADP F
metabolically 0 ADV F
obese 0 ADP F
, 0 PUNCT F
normal-weight 0 NOUN F
( 0 PUNCT F
MONW 0 NOUN T
) 0 PUNCT F
individuals 0 NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
A 0 PUNCT T
total 0 NOUN F
of 0 ADP F
47 0 NUM F
MONW 0 NOUN T
individuals 0 NOUN F
with 0 ADP F
hypomagnesemia 0 NOUN F
were 0 VERB F
enrolled 0 VERB F
in 0 ADP F
clinical 0 CCONJ F
a 0 DET F
randomized 0 VERB F
double-blind 0 ADJ F
placebo-controlled 0 VERB F
trial 0 NOUN F
. 0 PUNCT F

Individuals 0 NOUN T
in 0 ADP F
the 0 DET F
intervention 0 NOUN F
group 0 NOUN F
received 0 VERB F
30 0 NUM F
mL 0 NOUN F
of 0 ADP F
MgCl2 0 NOUN T
5 0 NUM F
% 0 SYM F
solution 0 NOUN F
( 0 PUNCT F
equivalent 0 PUNCT F
to 0 ADP F
382 0 NUM F
mg 0 NOUN F
of 0 ADP F
magnesium 0 NOUN F
) 0 PUNCT F
and 0 CCONJ F
individuals 0 NOUN F
in 0 ADP F
the 0 DET F
control 0 NOUN F
group 0 NOUN F
30 0 PUNCT F
mL 0 NOUN F
of 0 ADP F
placebo 0 NOUN F
solution 0 NOUN F
, 0 PUNCT F
once 0 PUNCT F
daily 0 ADJ F
during 0 ADP F
4 0 NUM F
months 0 NOUN F
. 0 PUNCT F

In 0 ADP T
the 0 DET F
absence 0 NOUN F
of 0 ADP F
obesity 0 NOUN F
or 0 CCONJ F
overweight 0 ADV F
, 0 PUNCT F
the 0 DET F
presence 0 NOUN F
of 0 ADP F
fasting B-PHYSICAL VERB F
glucose I-PHYSICAL NOUN F
levels I-PHYSICAL NOUN F
?100 0 PUNCT F
mg/dL 0 NOUN F
, 0 PUNCT F
HOMA-IR 0 NOUN T
index 0 NOUN F
?3 0 PUNCT F
, 0 PUNCT F
triglyceride 0 NOUN F
levels 0 NOUN F
?150 0 PUNCT F
mg/dL 0 NOUN F
and/or 0 CCONJ F
systolic 0 ADJ F
and 0 CCONJ F
diastolic 0 ADJ F
blood 0 NOUN F
pressure 0 NOUN F
?140 0 PUNCT F
and 0 CCONJ F
90 0 NUM F
mmHg 0 NOUN F
defined 0 ADP F
the 0 DET F
presence 0 NOUN F
of 0 ADP F
the 0 DET F
MONW 0 NOUN T
phenotype 0 NOUN F
. 0 PUNCT F

Hypomagnesemia 0 NOUN T
was 0 VERB F
defined 0 VERB F
by 0 ADP F
serum 0 NOUN F
magnesium 0 NOUN F
concentration 0 NOUN F
?1.8 0 PUNCT F
mg/dL 0 NOUN F
. 0 PUNCT F

RESULTS 0 NOUN T
At 0 ADP T
basal 0 ADJ F
conditions 0 NOUN F
there 0 VERB F
were 0 VERB F
no 0 DET F
significant 0 ADJ F
differences 0 NOUN F
between 0 ADP F
groups 0 NOUN F
. 0 PUNCT F

At 0 ADP T
the 0 DET F
end 0 NOUN F
of 0 ADP F
follow-up 0 NOUN F
, 0 PUNCT F
changes 0 NOUN F
in 0 ADP F
the 0 DET F
mean 0 NOUN F
of 0 ADP F
systolic 0 ADJ F
( 0 PUNCT F
-2.1 0 NUM F
vs. 0 CCONJ F
3.9 0 NUM F
% 0 SYM F
mmHg 0 NOUN F
, 0 PUNCT F
p 0 NOUN F
< 0 SYM F
0.05 0 NUM F
) 0 PUNCT F
and 0 CCONJ F
diastolic 0 ADJ F
( 0 PUNCT F
-3.8 0 ADP F
vs. 0 CCONJ F
7.5 0 NUM F
% 0 SYM F
mmHg 0 NOUN F
, 0 PUNCT F
p 0 NOUN F
< 0 SYM F
0.05 0 NUM F
) 0 PUNCT F
blood 0 NOUN F
pressures 0 NOUN F
, 0 PUNCT F
HOMA-IR 0 NOUN T
index 0 NOUN F
( 0 PUNCT F
-46.5 0 NUM F
vs. 0 CCONJ F
-5.4 0 NUM F
% 0 SYM F
, 0 PUNCT F
p 0 NOUN F
< 0 SYM F
0.0001 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
fasting 0 ADP F
glucose 0 NOUN F
( 0 PUNCT F
-12.3 0 PUNCT F
vs. 0 CCONJ F
-1.8 0 ADP F
% 0 ADV F
mg/dL 0 NOUN F
, 0 PUNCT F
p 0 NOUN F
< 0 SYM F
0.05 0 NUM F
) 0 PUNCT F
and 0 CCONJ F
triglyceride 0 NOUN F
levels 0 NOUN F
( 0 PUNCT F
-47.4 0 NUM F
% 0 SYM F
vs. 0 CCONJ F
10.1 0 NUM F
% 0 SYM F
mg/dL 0 NOUN F
, 0 PUNCT F
p 0 NOUN F
< 0 SYM F
0.0001 0 NUM F
) 0 PUNCT F
were 0 VERB F
significantly 0 ADV F
lower 0 PUNCT F
in 0 ADP F
the 0 DET F
subjects 0 NOUN F
who 0 ADP F
received 0 VERB F
MgCl2 0 NOUN T
compared 0 VERB F
with 0 ADP F
individuals 0 NOUN F
in 0 ADP F
the 0 DET F
control 0 NOUN F
group 0 NOUN F
. 0 PUNCT F

CONCLUSIONS 0 NOUN T
Oral 0 ADJ T
magnesium 0 NOUN F
supplementation 0 NOUN F
improves 0 NOUN F
the 0 DET F
metabolic 0 ADJ F
profile 0 ADJ F
and 0 CCONJ F
blood 0 NOUN F
pressure 0 NOUN F
of 0 ADP F
MONW 0 NOUN T
individuals 0 NOUN F
. 0 PUNCT F

Efficacy 0 NOUN T
of 0 ADP F
nebulized 0 VERB F
flunisolide 0 NOUN F
combined 0 VERB F
with 0 ADP F
salbutamol 0 NOUN F
and 0 CCONJ F
ipratropium 0 NOUN F
bromide 0 NOUN F
in 0 ADP F
stable 0 ADJ F
patients 0 NOUN F
with 0 ADP F
moderate-to-severe 0 NOUN F
chronic 0 ADJ F
obstructive 0 ADJ F
pulmonary 0 ADJ F
disease 0 NOUN F
. 0 PUNCT F

BACKGROUND 0 NOUN T
The 0 DET T
efficacy 0 NOUN F
of 0 ADP F
nebulized 0 ADJ F
corticosteroids 0 NOUN F
in 0 ADP F
the 0 DET F
prevention 0 NOUN F
of 0 ADP F
exacerbation 0 NOUN F
of 0 ADP F
chronic 0 ADJ F
obstructive 0 ADJ F
pulmonary 0 ADJ F
disease 0 NOUN F
( 0 PUNCT F
COPD 0 NOUN T
) 0 PUNCT F
has 0 PUNCT F
been 0 PUNCT F
poorly 0 ADV F
studied 0 VERB F
. 0 PUNCT F

OBJECTIVE 0 NOUN T
To 0 PROPN T
evaluate 0 NOUN F
the 0 DET F
efficacy 0 NOUN F
and 0 CCONJ F
tolerability B-OTHER NOUN F
of 0 ADP F
nebulized 0 VERB F
flunisolide 0 NOUN F
( 0 PUNCT F
1 0 NUM F
mg 0 NOUN F
) 0 PUNCT F
+ 0 SYM F
salbutamol/ipratropium 0 NOUN F
bromide 0 NOUN F
( 0 PUNCT F
1,875/375 0 NOUN F
microg 0 NOUN F
) 0 PUNCT F
b.i.d 0 ADP F
. 0 PUNCT F

in 0 ADP F
comparison 0 NOUN F
with 0 ADP F
placebo 0 NOUN F
+ 0 SYM F
salbutamol/ipratropium 0 NOUN F
bromide 0 NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
This 0 PUNCT T
was 0 VERB F
a 0 DET F
randomized 0 VERB F
, 0 PUNCT F
parallel-group 0 NOUN F
, 0 PUNCT F
double-blind 0 ADJ F
study 0 NOUN F
on 0 ADP F
114 0 NUM F
patients 0 NOUN F
with 0 ADP F
COPD 0 NOUN T
of 0 ADP F
moderate-to-severe 0 NOUN F
degree 0 NOUN F
. 0 PUNCT F

The 0 DET T
main 0 ADJ F
outcome 0 NOUN F
was 0 VERB F
the 0 DET F
frequency 0 NOUN F
of 0 ADP F
severe B-PHYSICAL ADJ F
exacerbations I-PHYSICAL NOUN F
over 0 ADP F
a 0 DET F
6-month 0 NOUN F
period 0 NOUN F
. 0 PUNCT F

Before 0 ADP T
and 0 CCONJ F
after 0 ADP F
treatment 0 NOUN F
, 0 PUNCT F
respiratory B-PHYSICAL ADJ F
symptoms I-PHYSICAL NOUN F
, I-PHYSICAL PUNCT F
forced I-PHYSICAL VERB F
expiratory I-PHYSICAL ADJ F
volume I-PHYSICAL NOUN F
in I-PHYSICAL ADP F
1 I-PHYSICAL NUM F
s I-PHYSICAL NOUN F
( I-PHYSICAL PUNCT F
FEV I-PHYSICAL NOUN T
( I-PHYSICAL PUNCT F
1 I-PHYSICAL NUM F
) I-PHYSICAL PUNCT F
) I-PHYSICAL PUNCT F
, I-PHYSICAL PUNCT F
shuttle I-PHYSICAL PART F
walking I-PHYSICAL PUNCT F
test I-PHYSICAL NOUN F
distance 0 NOUN F
and B-PHYSICAL CCONJ F
St. 0 NOUN T
George B-PHYSICAL NOUN T
's 0 PUNCT F
Respiratory B-PHYSICAL ADJ T
Questionnaire 0 NOUN T
scores 0 NOUN F
were 0 VERB F
evaluated 0 VERB F
. 0 PUNCT F

RESULTS 0 PUNCT T
The 0 DET T
total 0 ADJ F
number B-PHYSICAL NOUN F
of I-PHYSICAL ADP F
exacerbations I-PHYSICAL NOUN F
was 0 ADJ F
slightly 0 ADV F
lower 0 PUNCT F
in 0 ADP F
the 0 DET F
flunisolide 0 NOUN F
group 0 NOUN F
compared 0 VERB F
to 0 ADP F
the 0 DET F
placebo 0 NOUN F
group 0 NOUN F
( 0 PUNCT F
19 0 NUM F
vs. 0 CCONJ F
34 0 NUM F
, 0 PUNCT F
p 0 NOUN F
= 0 SYM F
0.054 0 NUM F
) 0 PUNCT F
; 0 PUNCT F
the 0 DET F
number 0 NOUN F
of 0 ADP F
patients B-PHYSICAL NOUN F
experiencing I-PHYSICAL PRON F
at I-PHYSICAL ADP F
least B-PHYSICAL ADV F
one B-PHYSICAL NUM F
exacerbation B-PHYSICAL NOUN F
during I-PHYSICAL ADP F
the B-PHYSICAL DET F
study B-PHYSICAL NOUN F
was 0 VERB F
also 0 ADV F
decreased 0 VERB F
( 0 PUNCT F
16 0 NUM F
vs. 0 CCONJ F
26 0 NUM F
, 0 PUNCT F
p 0 NOUN F
= 0 SYM F
0.059 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

In 0 ADP T
particular 0 NOUN F
, 0 PUNCT F
type 0 NOUN F
3 0 NUM F
Anthonisens B-PHYSICAL NOUN T
's 0 PUNCT F
exacerbations B-PHYSICAL NOUN F
were 0 VERB F
significantly 0 ADV F
reduced 0 VERB F
by 0 ADP F
flunisolide 0 NOUN F
( 0 PUNCT F
p 0 NOUN F
= 0 SYM F
0.044 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

In 0 ADP T
the 0 DET F
placebo 0 NOUN F
group 0 NOUN F
, 0 PUNCT F
scores 0 NOUN F
were 0 VERB F
higher 0 PUNCT F
than 0 PUNCT F
in 0 ADP F
the 0 DET F
flunisolide 0 NOUN F
group 0 NOUN F
but 0 CCONJ F
nonsignificant 0 ADJ F
for 0 PUNCT F

Comparison 0 NOUN T
of 0 ADP F
intravenous 0 ADJ F
and 0 CCONJ F
intra-arterial 0 ADJ F
urokinase 0 NOUN F
thrombolysis 0 NOUN F
for 0 ADP F
acute 0 ADJ F
ischaemic 0 ADJ F
stroke 0 NOUN F
. 0 PUNCT F

Intravenous 0 ADJ T
fibrinolysis 0 NOUN F
( 0 PUNCT F
IVF 0 NOUN T
) 0 PUNCT F
with 0 ADP F
rt-PA 0 NOUN F
( 0 PUNCT F
alteplase 0 NOUN F
) 0 PUNCT F
provides 0 NOUN F
significant 0 ADJ F
benefits 0 NOUN F
in 0 ADP F
acute 0 ADJ F
ischaemic 0 ADJ F
stroke 0 NOUN F
when 0 ADP F
it 0 PRON F
is 0 VERB F
given 0 VERB F
within 0 ADP F
the 0 DET F
first 0 ADJ F
three 0 NUM F
hours 0 NOUN F
following 0 VERB F
stroke 0 NOUN F
onset 0 NOUN F
. 0 PUNCT F

Intra-arterial 0 ADJ T
fibrinolysis 0 NOUN F
( 0 PUNCT F
IAF 0 NOUN T
) 0 PUNCT F
with 0 ADP F
pro-urokinase 0 NOUN F
in 0 ADP F
PROACT 0 NOUN T
II 0 NUM T
study 0 NOUN F
provides 0 NOUN F
quite 0 ADV F
the 0 DET F
same 0 ADJ F
benefit 0 NOUN F
in 0 ADP F
the 0 DET F
first 0 ADJ F
6 0 NUM F
hours 0 NOUN F
. 0 PUNCT F

IVF 0 NOUN T
and 0 CCONJ F
IAF 0 NOUN T
have 0 PUNCT F
never 0 ADV F
been 0 PUNCT F
compared 0 VERB F
. 0 PUNCT F

To 0 PART T
compare 0 NOUN F
the 0 DET F
efficacy 0 NOUN F
and 0 CCONJ F
safety 0 NOUN F
of 0 ADP F
IVF 0 NOUN T
and 0 CCONJ F
IAF 0 NOUN T
with 0 ADP F
urokinase 0 NOUN F
given 0 VERB F
within 0 ADP F
the 0 DET F
first 0 ADJ F
6 0 NUM F
hours 0 NOUN F
of 0 ADP F
acute 0 ADJ F
ischaemic 0 ADJ F
stroke 0 NOUN F
. 0 PUNCT F

Patients 0 NOUN T
fulfilling 0 VERB F
the 0 DET F
selection 0 NOUN F
criteria 0 NOUN F
were 0 VERB F
randomly 0 ADV F
assigned 0 VERB F
to 0 PART F
receive 0 NOUN F
urokinase 0 NOUN F
900,000 0 NUM F
units 0 NOUN F
via 0 ADP F
intravenous 0 ADJ F
or 0 CCONJ F
intra-arterial 0 ADJ F
routes 0 NOUN F
. 0 PUNCT F

This 0 DET T
randomised 0 VERB F
monocentre 0 NOUN F
study 0 NOUN F
was 0 VERB F
done 0 PUNCT F
between 0 ADP F
December 0 NOUN T
1995 0 NUM F
and 0 CCONJ F
August 0 NOUN T
1997 0 NUM F
. 0 PUNCT F

The 0 DET T
primary 0 ADJ F
outcome 0 NOUN F
was 0 VERB F
defined 0 VERB F
as 0 ADP F
the 0 DET F
number 0 NOUN F
of B-OTHER ADP F
patients I-OTHER NOUN F
with I-OTHER ADP F
a I-OTHER DET F
modified 0 VERB F
Rankin B-OTHER PUNCT T
score 0 PUNCT F

Evidence 0 NOUN T
for 0 ADP F
poorer 0 PUNCT F
outcome 0 NOUN F
in 0 ADP F
patients 0 NOUN F
with 0 ADP F
severe 0 ADJ F
negative 0 ADJ F
trauma-related 0 VERB F
cognitions 0 NOUN F
receiving 0 VERB F
prolonged 0 VERB F
exposure 0 NOUN F
plus 0 CCONJ F
cognitive 0 ADJ F
restructuring 0 ADP F
: 0 PUNCT F
implications 0 NOUN F
for 0 ADP F
treatment 0 NOUN F
matching 0 PUNCT F
in 0 ADP F
posttraumatic 0 ADJ F
stress 0 NOUN F
disorder 0 NOUN F
. 0 PUNCT F

In 0 ADP T
the 0 DET F
current 0 ADJ F
article 0 NOUN F
, 0 PUNCT F
we 0 PRON F
address 0 VERB F
the 0 DET F
existing 0 VERB F
assumption 0 NOUN F
in 0 ADP F
the 0 DET F
literature 0 NOUN F
on 0 ADP F
cognitive 0 ADJ F
behavioral 0 ADJ F
treatment 0 NOUN F
of 0 ADP F
PTSD 0 NOUN T
that 0 PUNCT F
patients 0 NOUN F
with 0 ADP F
severe 0 ADJ F
negative 0 ADJ F
trauma-related 0 VERB F
cognitions 0 NOUN F
would 0 VERB F
benefit 0 VERB F
more 0 ADV F
from 0 ADP F
a 0 DET F
treatment 0 NOUN F
package 0 NOUN F
that 0 DET F
includes 0 ADP F
exposure 0 NOUN F
and 0 CCONJ F
cognitive 0 ADJ F
techniques 0 NOUN F
compared 0 VERB F
with 0 ADP F
a 0 DET F
treatment 0 NOUN F
that 0 ADP F
includes 0 ADP F
exposure 0 NOUN F
only 0 ADV F
. 0 PUNCT F

To 0 PART T
test 0 ADP F
this 0 DET F
assumption 0 NOUN F
, 0 PUNCT F
54 0 NUM F
PTSD 0 NOUN T
patients 0 NOUN F
were 0 VERB F
randomized 0 ADP F
to 0 ADP F
prolonged 0 ADJ F
exposure 0 NOUN F
therapy 0 NOUN F
or 0 CCONJ F
prolonged 0 VERB F
exposure 0 NOUN F
therapy 0 NOUN F
plus 0 CCONJ F
cognitive 0 ADJ F
restructuring 0 ADP F
. 0 PUNCT F

Contrary 0 PUNCT T
to 0 ADP F
expectations 0 PROPN F
, 0 PUNCT F
findings 0 NOUN F
revealed 0 VERB F
that 0 ADP F
patients 0 NOUN F
characterized 0 VERB F
by 0 ADP F
more 0 ADV F
severe 0 ADJ F
pretreatment 0 NOUN F
trauma-related 0 DET F
cognitions 0 NOUN F
( 0 PUNCT F
and 0 CCONJ F
more 0 ADV F
severe 0 ADJ F
pretreatment 0 NOUN F
PTSD 0 NOUN T
symptoms 0 NOUN F
) 0 PUNCT F
fared 0 VERB F
slightly 0 ADV F
worse 0 ADJ F
in 0 ADP F
treatment 0 NOUN F
combining 0 PUNCT F
exposure 0 NOUN F
and 0 CCONJ F
cognitive 0 ADJ F
restructuring 0 ADP F
. 0 PUNCT F

However 0 ADV T
, 0 PUNCT F
there 0 PUNCT F
was 0 VERB F
no 0 DET F
relationship 0 NOUN F
between 0 ADP F
pre- 0 ADJ F
and 0 CCONJ F
post-treatment B-MENTAL NOUN F
measures I-MENTAL NOUN F
of I-MENTAL ADP F
negative 0 ADJ F
cognitions B-MENTAL NOUN F
and 0 PUNCT F

Effect 0 NOUN T
of 0 ADP F
total 0 ADJ F
androgen 0 NOUN F
ablation 0 NOUN F
on 0 ADP F
pathologic B-PHYSICAL ADJ F
stage I-PHYSICAL NOUN F
and 0 CCONJ F
resection B-PHYSICAL NOUN F
limit I-PHYSICAL ADV F
status I-PHYSICAL NOUN F
of I-PHYSICAL ADP F
prostate I-PHYSICAL NOUN F
cancer I-PHYSICAL NOUN F
. 0 PUNCT F

Initial 0 ADJ T
results 0 NOUN F
of 0 ADP F
the 0 DET F
Italian 0 ADJ T
PROSIT 0 NOUN T
study 0 NOUN F
. 0 PUNCT F

The 0 DET T
likelihood 0 NOUN F
of 0 ADP F
finding 0 VERB F
organ-confined 0 VERB F
untreated 0 VERB F
prostate 0 NOUN F
cancer 0 NOUN F
( 0 PUNCT F
PCa 0 NOUN T
) 0 PUNCT F
by 0 ADP F
pathological 0 ADJ F
examination 0 NOUN F
at 0 ADP F
the 0 DET F
time 0 NOUN F
of 0 ADP F
radical 0 ADJ F
prostatectomy 0 NOUN F
( 0 PUNCT F
RP 0 NOUN T
) 0 PUNCT F
is 0 VERB F
only 0 ADV F
50 0 NUM F
% 0 SYM F
in 0 ADP F
patients 0 NOUN F
with 0 ADP F
clinically 0 ADV F
organ-confined 0 ADJ F
disease 0 NOUN F
. 0 PUNCT F

In 0 ADP T
addition 0 NOUN F
, 0 PUNCT F
tumour 0 NOUN F
is 0 VERB F
present 0 ADJ F
at 0 ADP F
the 0 DET F
resection 0 NOUN F
margin 0 NOUN F
in 0 ADP F
approximately 0 ADV F
30 0 NUM F
% 0 SYM F
of 0 ADP F
clinical 0 ADJ F
T2 0 NOUN T
( 0 PUNCT F
clinical 0 ADJ F
stage 0 NOUN F
B 0 NOUN T
) 0 PUNCT F
cases 0 NOUN F
. 0 PUNCT F

The 0 DET T
issue 0 NOUN F
of 0 ADP F
clinical 0 ADJ F
understaging 0 PUNCT F
and 0 CCONJ F
of 0 DET F
resection 0 NOUN F
limit 0 ADV F
positivity 0 NOUN F
have 0 CCONJ F
led 0 VERB F
to 0 ADP F
the 0 DET F
development 0 NOUN F
of 0 ADP F
novel 0 ADJ F
management 0 NOUN F
practices 0 PROPN F
, 0 PUNCT F
including 0 CCONJ F
neoadjuvant 0 PUNCT F
hormonal 0 ADJ F
therapy 0 NOUN F
( 0 PUNCT F
NHT 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
optimal 0 ADJ F
duration 0 NOUN F
of 0 ADP F
NHT 0 NOUN T
is 0 VERB F
unknown 0 VERB F
. 0 PUNCT F

We 0 ADP T
undertook 0 ADJ F
the 0 DET F
present 0 ADJ F
analysis 0 NOUN F
to 0 PART F
evaluate 0 NOUN F
the 0 DET F
effect 0 NOUN F
of B-PHYSICAL ADP F
NHT 0 NOUN T
on 0 ADP F
pathologic B-PHYSICAL ADJ F
stage B-PHYSICAL NOUN F
of I-PHYSICAL ADP F
PCa I-PHYSICAL NOUN T
and 0 CCONJ F
resection B-PHYSICAL NOUN F
limit I-PHYSICAL ADV F
status I-PHYSICAL NOUN F
in 0 ADP F
patients 0 NOUN F
with 0 ADP F
prostate 0 NOUN F
cancer 0 NOUN F
and 0 CCONJ F
treated 0 VERB F
with 0 ADP F
total 0 ADJ F
androgen 0 NOUN F
ablation 0 NOUN F
either 0 CCONJ F
for 0 ADP F
three 0 NUM F
or 0 CCONJ F
six 0 NUM F
months 0 NOUN F
before 0 ADP F
RP 0 NOUN T
. 0 PUNCT F

Between 0 ADP T
January 0 NOUN T
1996 0 NUM F
and 0 CCONJ F
February 0 PUNCT T
1998 0 NUM F
, 0 PUNCT F
259 0 DET F
men 0 NOUN F
with 0 ADP F
prostate 0 NOUN F
cancer 0 NOUN F
underwent 0 VERB F
radical 0 ADJ F
retropubic 0 ADJ F
prostatectomy 0 NOUN F
and 0 CCONJ F
bilateral 0 ADJ F
pelvic 0 ADJ F
node 0 NOUN F
dissection 0 NOUN F
in 0 ADP F
the 0 DET F
26 0 NUM F
centres 0 NOUN F
participating 0 VERB F
in 0 ADP F
the 0 DET F
Italian 0 ADJ T
randomised 0 VERB F
prospective 0 ADJ F
PROSIT 0 NOUN T
study 0 NOUN F
. 0 PUNCT F

Whole 0 ADJ T
mount 0 NOUN F
sectioning 0 ADJ F
of 0 ADP F
the 0 DET F
complete 0 ADJ F
RP 0 NOUN T
specimens 0 NOUN F
was 0 VERB F
adopted 0 VERB F
in 0 ADP F
each 0 DET F
centre 0 NOUN F
for 0 ADP F
accurately 0 ADV F
evaluating 0 ADP F
the 0 DET F
pathologic B-PHYSICAL ADJ F
stage I-PHYSICAL NOUN F
and I-PHYSICAL CCONJ F
resection B-PHYSICAL NOUN F
limit I-PHYSICAL ADV F
status I-PHYSICAL NOUN F
. 0 PUNCT F

By 0 ADP T
February 0 PUNCT T
1998 0 NUM F
, 0 PUNCT F
haematoxylin 0 NOUN F
and 0 CCONJ F
eosin 0 NOUN F
stained 0 VERB F
sections 0 NOUN F
from 0 ADP F
155 0 NUM F
RP 0 NOUN T
specimens 0 NOUN F
had 0 VERB F
been 0 PUNCT F
received 0 VERB F
and 0 CCONJ F
evaluated 0 VERB F
by 0 ADP F
the 0 DET F
reviewing 0 ADJ F
pathologist 0 NOUN F
( 0 PUNCT F
RM 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

64 0 NUM F
cases 0 NOUN F
had 0 ADP F
not 0 ADV F
been 0 PUNCT F
treated 0 VERB F
with 0 ADP F
total 0 ADJ F
androgen 0 NOUN F
ablation 0 NOUN F
( 0 PUNCT F
e.g 0 NUM F
. 0 PUNCT F

NHT 0 NOUN T
) 0 PUNCT F
before 0 ADP F
RP 0 NOUN T
was 0 VERB F
performed 0 VERB F
, 0 PUNCT F
whereas 0 ADP F
58 0 ADP F
and 0 CCONJ F
33 0 NUM F
had 0 PUNCT F
been 0 ADV F
treated 0 VERB F
for 0 ADP F
three 0 NUM F
and 0 CCONJ F
six 0 NUM F
months 0 NOUN F
, 0 PUNCT F
respectively 0 ADV F
. 0 PUNCT F

114 0 DET F
patients 0 NOUN F
were 0 VERB F
clinical 0 ADJ F
stage 0 NOUN F
B 0 NOUN T
whereas 0 ADP F
41 0 NUM F
were 0 PUNCT F
clinical 0 ADJ F
stage 0 NOUN F
C. 0 NOUN T
After 0 ADP T
three 0 NUM F
months 0 NOUN F
of 0 ADP F
total 0 ADJ F
androgen 0 NOUN F
ablation 0 NOUN F
, 0 PUNCT F
pathological B-PHYSICAL ADJ F
stage I-PHYSICAL NOUN F
B I-PHYSICAL NOUN T
was 0 VERB F
more 0 ADV F
prevalent 0 ADJ F
among 0 ADP F
patients 0 NOUN F
with 0 ADP F
clinical 0 ADJ F
B 0 NOUN T
tumours 0 NOUN F
, 0 PUNCT F
compared 0 VERB F
with 0 ADP F
untreated 0 VERB F
patients 0 NOUN F
( 0 PUNCT F
57 0 NUM F
% 0 SYM F
in 0 ADP F
treated 0 VERB F
patients 0 NOUN F
vs. 0 CCONJ F
36 0 NUM F
% 0 SYM F
in 0 ADP F
untreated 0 VERB F
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
percentage 0 NOUN F
of 0 ADP F
cancers B-PHYSICAL NOUN F
with B-PHYSICAL ADP F
negative 0 ADJ F
margins B-PHYSICAL NOUN F
was 0 VERB F
statistically 0 ADV F
significantly 0 ADV F
greater 0 PUNCT F
in 0 ADP F
patients 0 NOUN F
treated 0 VERB F
with 0 ADP F
neoadjuvant 0 PUNCT F
therapy 0 NOUN F
than 0 CCONJ F
those 0 PUNCT F
treated 0 VERB F
with 0 ADP F
immediate 0 ADJ F
surgery 0 NOUN F
alone 0 ADJ F
( 0 PUNCT F
69 0 NUM F
% 0 SYM F
vs. 0 CCONJ F
42 0 NUM F
% 0 SYM F
, 0 PUNCT F
respectively 0 ADV F
) 0 PUNCT F
. 0 PUNCT F

After 0 ADP T
six 0 NUM F
months 0 NOUN F
of 0 ADP F
NHT 0 NOUN T
therapy 0 NOUN F
the 0 DET F
proportion 0 NOUN F
of 0 ADP F
patients B-PHYSICAL NOUN F
with I-PHYSICAL ADP F
pathological B-PHYSICAL ADJ F
stage I-PHYSICAL NOUN F
B I-PHYSICAL NOUN T
( 0 PUNCT F
67 0 NUM F
% 0 SYM F
vs. 0 CCONJ F
36 0 NUM F
% 0 SYM F
, 0 PUNCT F
respectively 0 ADV F
) 0 PUNCT F
and 0 CCONJ F
negative 0 ADJ F
margins B-PHYSICAL NOUN F
was 0 VERB F
greater 0 PUNCT F
than 0 PUNCT F
after 0 ADP F
3 0 NUM F
months 0 NOUN F
( 0 PUNCT F
92 0 NUM F
% 0 SYM F
vs. 0 CCONJ F
42 0 NUM F
% 0 SYM F
, 0 PUNCT F
respectively 0 ADV F
) 0 PUNCT F
. 0 PUNCT F

For 0 ADP T
clinical 0 ADJ F
C 0 NOUN T
tumours 0 NOUN F
, 0 PUNCT F
the 0 DET F
prevalence 0 NOUN F
of 0 PUNCT F

Bupropion 0 NOUN T
SR 0 NOUN T
and 0 CCONJ F
counseling 0 VERB F
for 0 ADP F
smoking 0 VERB F
cessation 0 NOUN F
in 0 ADP F
actual 0 ADJ F
practice 0 NOUN F
: 0 PUNCT F
predictors 0 NOUN F
of 0 ADP F
outcome 0 NOUN F
. 0 PUNCT F

To 0 ADP T
date 0 NOUN F
, 0 PUNCT F
only 0 ADV F
one 0 ADP F
study 0 NOUN F
has 0 PUNCT F
been 0 PUNCT F
published 0 VERB F
on 0 ADP F
individual 0 ADJ F
characteristics 0 NOUN F
associated 0 VERB F
with 0 ADP F
outcome 0 NOUN F
following 0 VERB F
standard 0 ADJ F
treatment 0 NOUN F
with 0 ADP F
bupropion 0 NOUN F
SR 0 NOUN T
for 0 ADP F
smoking 0 VERB F
cessation 0 NOUN F
. 0 PUNCT F

To 0 PART T
investigate 0 NOUN F
treatment 0 NOUN F
outcome 0 NOUN F
beyond 0 ADP F
the 0 DET F
6-week 0 NOUN F
end-of-treatment 0 PUNCT F
point 0 NOUN F
, 0 PUNCT F
the 0 DET F
present 0 ADJ F
study 0 NOUN F
examined 0 VERB F
characteristics 0 NOUN F
associated 0 VERB F
with 0 ADP F
more 0 DET F
clinically 0 ADV F
relevant 0 ADJ F
smoking 0 VERB F
endpoints 0 NOUN F
following 0 VERB F
treatment 0 NOUN F
with 0 ADP F
bupropion 0 NOUN F
SR 0 NOUN T
in 0 ADP F
a 0 DET F
large 0 ADJ F
health 0 NOUN F
care 0 NOUN F
system 0 NOUN F
. 0 PUNCT F

A 0 DET T
total 0 NOUN F
of 0 ADP F
1,524 0 NUM F
smokers 0 NOUN F
( 0 PUNCT F
649 0 NUM F
men 0 NOUN F
and 0 CCONJ F
875 0 NUM F
women 0 NOUN F
) 0 PUNCT F
of 0 ADP F
average 0 ADJ F
age 0 NOUN F
45.1 0 NUM F
years 0 NOUN F
were 0 VERB F
randomized 0 VERB F
to 0 PART F
receive 0 NOUN F
one 0 NUM F
of 0 ADP F
four 0 NUM F
combinations 0 NOUN F
of 0 ADP F
bupropion 0 NOUN F
SR 0 NOUN T
( 0 PUNCT F
150 0 ADP F
or 0 CCONJ F
300 0 NUM F
mg 0 NOUN F
) 0 PUNCT F
and 0 CCONJ F
behavioral 0 ADJ F
counseling 0 SYM F
( 0 PUNCT F
tailored 0 PUNCT F
mailings 0 PUNCT F
or 0 CCONJ F
proactive 0 ADJ F
telephone 0 NOUN F
counseling 0 VERB F
) 0 PUNCT F
and 0 CCONJ F
assessed 0 VERB F
for 0 ADP F
point-prevalent 0 ADJ F
smoking 0 DET F
status 0 NOUN F
at 0 ADP F
3 0 NUM F
and 0 CCONJ F
12 0 NUM F
months 0 NOUN F
. 0 PUNCT F

Multiple 0 ADJ T
logistic 0 ADJ F
regression 0 NOUN F
analyses 0 NOUN F
of 0 ADP F
potential 0 ADJ F
risk 0 NOUN F
factors 0 NOUN F
for 0 ADP F
12-month 0 NOUN F
point-prevalent 0 ADJ F
smoking 0 PROPN F
and 0 CCONJ F
for 0 ADP F
persistent 0 ADJ F
smoking 0 ADP F
( 0 PUNCT F
point-prevalent 0 ADJ F
smoking 0 VERB F
at 0 ADP F
both 0 PUNCT F
follow-ups 0 PUNCT F
) 0 PUNCT F
following 0 VERB F
treatment 0 NOUN F
were 0 VERB F
conducted 0 VERB F
for 0 ADP F
men 0 NOUN F
and 0 CCONJ F
women 0 NOUN F
combined 0 ADP F
and 0 CCONJ F
separately 0 ADV F
. 0 PUNCT F

Risk 0 NOUN T
factors 0 NOUN F
for 0 ADP F
smoking 0 VERB F
at 0 ADP F
both 0 CCONJ F
endpoints 0 NOUN F
in 0 ADP F
the 0 DET F
combined 0 VERB F
sample 0 NOUN F
included 0 VERB F
treatment 0 NOUN F
with 0 ADP F
tailored 0 VERB F
mailings 0 DET F
, 0 PUNCT F
female 0 NOUN F
gender 0 NOUN F
, 0 PUNCT F
younger 0 PUNCT F
age 0 NOUN F
, 0 PUNCT F
higher 0 PUNCT F
levels 0 NOUN F
of 0 ADP F
tobacco 0 NOUN F
dependence 0 NOUN F
, 0 PUNCT F
shorter 0 PUNCT F
previous 0 ADJ F
quit 0 NOUN F
attempts 0 PUNCT F
, 0 PUNCT F
previous 0 ADJ F
use 0 NOUN F
of 0 ADP F
nicotine 0 NOUN F
replacement 0 NOUN F
therapy 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
report 0 NOUN F
of 0 ADP F
current 0 ADJ F
depressive 0 ADJ F
symptoms 0 NOUN F
or 0 CCONJ F
lifetime 0 NOUN F
depression 0 NOUN F
. 0 PUNCT F

Risk 0 NOUN T
factors 0 NOUN F
for 0 ADP F
smoking 0 VERB F
following 0 ADP F
treatment 0 NOUN F
identified 0 VERB F
in 0 ADP F
women 0 NOUN F
only 0 ADV F
included 0 VERB F
treatment 0 NOUN F
with 0 ADP F
the 0 DET F
lower 0 PUNCT F
dose 0 NOUN F
of 0 ADP F
bupropion 0 NOUN F
SR 0 NOUN T
, 0 PUNCT F
younger 0 PUNCT F
age 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
higher 0 PUNCT F
perceived 0 DET F
stress 0 NOUN F
, 0 PUNCT F
whereas 0 ADP F
those 0 ADP F
that 0 ADV F
were 0 VERB F
unique 0 ADJ F
to 0 ADP F
men 0 NOUN F
included 0 VERB F
the 0 DET F
presence 0 NOUN F
of 0 ADP F
lifetime 0 NOUN F
depression 0 NOUN F
. 0 PUNCT F

The 0 DET T
results 0 NOUN F
are 0 VERB F
discussed 0 VERB F
in 0 ADP F
terms 0 NOUN F
of 0 ADP F
their 0 ADJ F
implications 0 NOUN F
for 0 ADP F
the 0 DET F
need 0 NOUN F
for 0 ADP F
more B-OTHER ADV F
effective I-OTHER ADJ F
treatments I-OTHER NOUN F
in 0 ADP F
general 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
the 0 DET F
role 0 NOUN F
of 0 ADP F
individual 0 ADJ F
differences 0 NOUN F
in 0 ADP F
the 0 DET F
likelihood 0 NOUN F
of 0 ADP F
returning B-MENTAL ADJ F
to I-MENTAL ADP F
smoking I-MENTAL ADP F
following I-MENTAL PUNCT F
treatment I-MENTAL NOUN F
for 0 ADP F
quitting 0 PROPN F
. 0 PUNCT F

Social 0 ADJ T
stories 0 NOUN F
: 0 PUNCT F
mechanisms 0 NOUN F
of 0 ADP F
effectiveness 0 NOUN F
in 0 ADP F
increasing 0 ADP F
game 0 NOUN F
play 0 NOUN F
skills 0 NOUN F
in 0 ADP F
children 0 NOUN F
diagnosed 0 VERB F
with 0 ADP F
autism 0 NOUN F
spectrum 0 NOUN F
disorder 0 NOUN F
using 0 VERB F
a 0 DET F
pretest 0 ADV F
posttest 0 ADV F
repeated 0 VERB F
measures 0 NOUN F
randomized 0 VERB F
control 0 NOUN F
group 0 NOUN F
design 0 NOUN F
. 0 PUNCT F

An 0 DET T
increasing 0 ADJ F
body 0 NOUN F
of 0 ADP F
literature 0 NOUN F
has 0 PUNCT F
indicated 0 VERB F
that 0 ADP F
social 0 ADJ F
stories 0 NOUN F
are 0 VERB F
an 0 DET F
effective 0 ADJ F
way 0 NOUN F
to 0 VERB F
teach 0 PUNCT F
individuals 0 PUNCT F
diagnosed 0 VERB F
with 0 ADP F
autism 0 NOUN F
appropriate 0 ADJ F
social 0 ADJ F
behavior 0 NOUN F
. 0 PUNCT F

This 0 DET T
study 0 NOUN F
compared 0 VERB F
two 0 NUM F
formats 0 NOUN F
of 0 ADP F
a 0 DET F
social 0 ADJ F
story 0 ADJ F
targeting 0 ADP F
the 0 DET F
improvement 0 NOUN F
of 0 ADP F
social B-MENTAL ADJ F
skills I-MENTAL NOUN F
during 0 ADP F
game 0 NOUN F
play 0 NUM F
using 0 SYM F
a 0 DET F
pretest 0 ADV F
posttest 0 ADV F
repeated 0 VERB F
measures 0 NOUN F
randomized 0 VERB F
control 0 NOUN F
group 0 NOUN F
design 0 NOUN F
. 0 PUNCT F

A 0 DET T
total 0 NOUN F
of 0 ADP F
45 0 NUM F
children 0 NOUN F
diagnosed 0 VERB F
with 0 ADP F
Autism 0 NOUN T
Spectrum 0 NOUN T
Disorder 0 NOUN T
( 0 PUNCT F
ASD 0 NOUN T
) 0 PUNCT F
ages 0 NOUN F
7-14 0 PUNCT F
were 0 ADJ F
randomly 0 ADV F
assigned 0 VERB F
to 0 ADP F
standard 0 PUNCT F
, 0 PUNCT F
directive 0 ADJ F
, 0 PUNCT F
or 0 CCONJ F
control 0 NOUN F
story 0 ADJ F
conditions 0 NOUN F
. 0 PUNCT F

Results 0 NOUN T
demonstrated 0 VERB F
that 0 ADP F
the 0 DET F
standard 0 ADJ F
and 0 CCONJ F
directive 0 ADJ F
story 0 ADJ F
formats 0 NOUN F
were 0 VERB F
equally 0 ADV F
as 0 PUNCT F
effective 0 ADJ F
in 0 ADP F
eliciting B-OTHER VERB F
, 0 PUNCT F
generalizing B-OTHER PUNCT F
and 0 CCONJ F
maintaining B-MENTAL ADP F
the I-MENTAL DET F
targeted I-MENTAL VERB F
social I-MENTAL ADJ F
skills I-MENTAL NOUN F
in 0 ADP F
participants 0 NOUN F
who 0 ADP F
had 0 PUNCT F
prior 0 VERB F
game 0 NOUN F
play 0 PUNCT F
experience 0 ADJ F
and 0 CCONJ F
Verbal B-MENTAL ADJ T
Comprehension I-MENTAL NOUN T
Index 0 NOUN T
( B-MENTAL PUNCT F
VCI I-MENTAL NOUN T
) I-MENTAL PUNCT F
scores I-MENTAL NOUN F
from I-MENTAL ADP F
the I-MENTAL DET F
WISC-IV I-MENTAL NOUN T
intelligence I-MENTAL PUNCT F

A 0 DET T
randomized 0 VERB F
comparison 0 NOUN F
of 0 ADP F
the 0 DET F
effect 0 NOUN F
of 0 ADP F
two 0 NUM F
prelinguistic 0 ADJ F
communication 0 NOUN F
interventions 0 NOUN F
on 0 ADP F
the 0 DET F
acquisition 0 NOUN F
of 0 ADP F
spoken 0 PUNCT F
communication 0 NOUN F
in 0 ADP F
preschoolers 0 NOUN F
with 0 ADP F
ASD 0 NOUN T
. 0 PUNCT F

PURPOSE 0 NOUN T
This 0 PUNCT T
randomized 0 VERB F
group 0 NOUN F
experiment 0 NOUN F
compared 0 VERB F
the 0 DET F
efficacy 0 NOUN F
of 0 ADP F
2 0 NUM F
communication 0 NOUN F
interventions 0 NOUN F
( 0 PUNCT F
Responsive 0 ADJ T
Education 0 NOUN T
and 0 CCONJ F
Prelinguistic 0 PUNCT T
Milieu 0 NOUN T
Teaching 0 PUNCT T
[ 0 PUNCT F
RPMT 0 NOUN T
] 0 PUNCT F
and 0 CCONJ F
the 0 DET F
Picture 0 NOUN T
Exchange 0 NOUN T
Communication 0 NOUN T
System 0 NOUN T
[ 0 PUNCT F
PECS 0 NOUN T
] 0 PUNCT F
) 0 PUNCT F
on 0 ADP F
spoken 0 PUNCT F
communication 0 NOUN F
in 0 ADP F
36 0 NUM F
preschoolers 0 NOUN F
with 0 ADP F
autism 0 NOUN F
spectrum 0 NOUN F
disorders 0 NOUN F
( 0 PUNCT F
ASD 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

METHOD 0 NOUN T
Each 0 PUNCT T
treatment 0 NOUN F
was 0 VERB F
delivered 0 VERB F
to 0 ADP F
children 0 NOUN F
for 0 ADP F
a 0 DET F
maximum 0 NOUN F
total 0 NOUN F
of 0 ADP F
24 0 NUM F
hr 0 NOUN F
over 0 ADP F
a 0 DET F
6-month 0 NOUN F
period 0 NOUN F
. 0 PUNCT F

Spoken 0 PUNCT T
communication 0 NOUN F
was 0 VERB F
assessed 0 VERB F
in 0 ADP F
a 0 DET F
rigorous 0 ADJ F
test 0 NOUN F
of 0 ADP F
generalization 0 NOUN F
at 0 ADP F
pretreatment 0 NOUN F
, 0 PUNCT F
posttreatment 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
6-month 0 NOUN F
follow-up 0 NOUN F
periods 0 NOUN F
. 0 PUNCT F

RESULTS 0 NOUN T
PECS B-PHYSICAL NOUN T
was I-PHYSICAL VERB F
more I-PHYSICAL ADV F
successful I-PHYSICAL ADJ F
than I-PHYSICAL PUNCT F
RPMT I-PHYSICAL ADJ T
in I-PHYSICAL ADP F
increasing 0 VERB F
the 0 DET F
number 0 NOUN F
of 0 ADP F
nonimitative B-MENTAL ADJ F
spoken I-MENTAL PUNCT F
communication I-MENTAL NOUN F
acts I-MENTAL VERB F
and 0 CCONJ F
the B-PHYSICAL DET F
number I-PHYSICAL NOUN F
of I-PHYSICAL ADP F
different I-PHYSICAL ADJ F
nonimitative I-PHYSICAL ADJ F
words I-PHYSICAL NOUN F
used I-PHYSICAL VERB F
at I-PHYSICAL ADP F
the I-PHYSICAL DET F
posttreatment I-PHYSICAL ADJ F
period 0 NOUN F
. 0 PUNCT F

Considering 0 PUNCT T
growth 0 NOUN F
over 0 ADP F
all 0 DET F
3 0 NUM F
measurement 0 NOUN F
periods 0 NOUN F
, 0 PUNCT F
an 0 DET F
exploratory 0 ADJ F
analysis 0 NOUN F
showed 0 VERB F
that 0 ADP F
growth B-MENTAL NOUN F
rate I-MENTAL NOUN F
of I-MENTAL ADP F
the I-MENTAL DET F
number I-MENTAL NOUN F
of I-MENTAL ADP F
different I-MENTAL ADJ F
nonimitative I-MENTAL ADJ F
words I-MENTAL NOUN F
was 0 ADV F
faster B-PHYSICAL PUNCT F
in I-PHYSICAL ADP F
the I-PHYSICAL DET F
PECS I-PHYSICAL NOUN T
group 0 NOUN F
than 0 PUNCT F
in 0 ADP F
the 0 DET F
RPMT 0 ADJ T
group 0 NOUN F
for 0 ADP F
children 0 NOUN F
who 0 ADP F
began 0 ADV F
treatment 0 NOUN F
with 0 ADP F
relatively 0 ADV F
high 0 ADJ F
object 0 NOUN F
exploration 0 NOUN F
. 0 PUNCT F

In 0 ADP T
contrast 0 NOUN F
, 0 PUNCT F
analogous B-MENTAL ADJ F
slopes I-MENTAL ADP F
were 0 VERB F
steeper 0 PUNCT F
in 0 ADP F
the 0 DET F
RPMT 0 ADJ T
group 0 NOUN F
than 0 PUNCT F
in 0 ADP F
the 0 DET F
PECS 0 NOUN T
group 0 NOUN F
for 0 ADP F
children 0 NOUN F
who 0 ADP F
began 0 ADV F
treatment 0 NOUN F
with 0 ADP F
relatively 0 ADV F
low 0 ADJ F
object 0 NOUN F
exploration 0 NOUN F
. 0 PUNCT F

Rationale 0 NOUN T
and 0 CCONJ F
design 0 NOUN F
of 0 ADP F
a 0 DET F
randomized 0 VERB F
trial 0 NOUN F
to 0 PART F
evaluate 0 NOUN F
an 0 DET F
evidence-based 0 VERB F
prescription 0 NOUN F
drug 0 NOUN F
label 0 NOUN F
on 0 ADP F
actual 0 ADJ F
medication 0 NOUN F
use 0 NOUN F
. 0 PUNCT F

BACKGROUND 0 NOUN T
Medication 0 NOUN T
errors 0 NOUN F
are 0 NOUN F
an 0 DET F
important 0 ADJ F
public 0 ADJ F
health 0 NOUN F
concern 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
poor 0 ADJ F
understanding 0 VERB F
of 0 ADP F
medication 0 NOUN F
labels 0 ADP F
are 0 VERB F
a 0 DET F
root 0 NOUN F
cause 0 NUM F
. 0 PUNCT F

Research 0 NOUN T
shows 0 VERB F
that 0 ADP F
labels 0 ADJ F
are 0 VERB F
variable 0 ADJ F
, 0 PUNCT F
of 0 ADP F
poor 0 ADJ F
quality 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
not 0 ADV F
patient-centered 0 NUM F
. 0 PUNCT F

No 0 DET T
real-world 0 NOUN F
trials 0 NOUN F
have 0 ADJ F
evaluated 0 VERB F
whether 0 ADP F
improved 0 VERB F
medication 0 NOUN F
labels 0 NOUN F
can 0 VERB F
affect 0 VERB F
appropriate 0 ADJ F
medication 0 NOUN F
use 0 NOUN F
, 0 PUNCT F
adherence 0 NOUN F
or 0 CCONJ F
health 0 NOUN F
outcomes 0 NOUN F
. 0 PUNCT F

TRIAL 0 NOUN T
DESIGN 0 NOUN T
We 0 PRON T
developed 0 VERB F
an 0 DET F
evidence-based 0 VERB F
prescription 0 NOUN F
label 0 NOUN F
that 0 ADP F
addresses 0 PART F
both 0 PUNCT F
content 0 NOUN F
and 0 CCONJ F
format 0 NOUN F
. 0 PUNCT F

The 0 DET T
enhanced 0 VERB F
label 0 NOUN F
includes 0 NOUN F
a 0 DET F
universal 0 ADJ F
medication 0 NOUN F
schedule 0 NOUN F
( 0 PUNCT F
UMS 0 NOUN T
) 0 PUNCT F
that 0 PUNCT F
standardizes 0 ADP F
the 0 DET F
directions 0 NOUN F
for 0 ADP F
use 0 NOUN F
incorporating 0 PROPN F
1 0 NUM F
) 0 PUNCT F
standard 0 DET F
time 0 NOUN F
periods 0 NOUN F
for 0 ADP F
administration 0 NOUN F
( 0 PUNCT F
morning 0 NOUN F
, 0 PUNCT F
noon 0 NOUN F
, 0 PUNCT F
evening 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
bedtime 0 NOUN F
) 0 PUNCT F
, 0 PUNCT F
2 0 NUM F
) 0 PUNCT F
numeric 0 ADJ F
vs. 0 CCONJ F
alpha 0 NOUN F
characters 0 NOUN F
, 0 PUNCT F
3 0 NUM F
) 0 PUNCT F
'carriage 0 PUNCT F
returns 0 ADP F
' 0 PUNCT F
to 0 PUNCT F
separate 0 ADJ F
daily 0 ADJ F
dose 0 NOUN F
and 0 CCONJ F
4 0 NUM F
) 0 PUNCT F
a 0 DET F
graphic 0 ADJ F
aid 0 ADP F
to 0 ADP F
visually 0 CCONJ F
depict 0 PUNCT F
dose 0 NOUN F
and 0 CCONJ F
frequency 0 NOUN F
. 0 PUNCT F

We 0 PRON T
will 0 VERB F
evaluate 0 ADP F
the 0 DET F
effect 0 NOUN F
of 0 ADP F
providing 0 PUNCT F
this 0 DET F
label 0 NOUN F
to 0 ADP F
randomly 0 ADV F
sampled 0 DET F
patients 0 NOUN F
who 0 NUM F
receive 0 PUNCT F
their 0 ADP F
care 0 NOUN F
from 0 ADP F
free 0 ADJ F
clinics 0 ADP F
, 0 PUNCT F
mobile 0 ADJ F
vans 0 ADP F
and 0 CCONJ F
federally 0 ADV F
qualified 0 VERB F
health 0 NOUN F
centers 0 NOUN F
( 0 PUNCT F
FQHCs 0 PUNCT T
) 0 PUNCT F
in 0 ADP F
Northern 0 NOUN T
Virginia 0 NOUN T
. 0 PUNCT F

We 0 PRON T
will 0 ADV F
recruit 0 PUNCT F
patients 0 NOUN F
with 0 ADP F
diabetes 0 NOUN F
or 0 CCONJ F
hypertension 0 NOUN F
; 0 PUNCT F
these 0 DET F
patients 0 NOUN F
will 0 ADP F
be 0 VERB F
randomly 0 ADV F
assigned 0 VERB F
to 0 PART F
receive 0 NOUN F
all 0 PUNCT F
of 0 ADP F
their 0 ADP F
medications 0 NOUN F
with 0 ADP F
improved 0 NOUN F
labels 0 NOUN F
or 0 CCONJ F
to 0 PART F
receive 0 PART F
prescriptions 0 ADJ F
with 0 ADP F
standard 0 ADJ F
labels 0 NOUN F
. 0 PUNCT F

The 0 DET T
primary 0 ADJ F
outcome 0 NOUN F
will 0 PUNCT F
be 0 VERB F
the 0 DET F
patient B-MENTAL NOUN F
's 0 PUNCT F
ability B-MENTAL NOUN F
to I-MENTAL PUNCT F
correctly I-MENTAL DET F
demonstrate I-MENTAL VERB F
dosing I-MENTAL ADJ F
instructions I-MENTAL NOUN F
. 0 PUNCT F

Other 0 ADJ T
outcomes 0 NOUN F
include 0 VERB F
adherence B-MENTAL NOUN F
, 0 PUNCT F
error 0 ADJ F
rates B-OTHER NOUN F
and 0 CCONJ F
health B-PHYSICAL NOUN F
outcomes I-PHYSICAL NOUN F
. 0 PUNCT F

CONCLUSION 0 NOUN T
To 0 ADP T
our 0 PUNCT F
knowledge 0 NOUN F
, 0 PUNCT F
this 0 DET F
trial 0 NOUN F
is 0 VERB F
the 0 DET F
first 0 ADJ F
to 0 PART F
evaluate 0 NOUN F
the 0 DET F
effect 0 NOUN F
of 0 ADP F
prescription 0 NOUN F
label 0 NOUN F
improvement 0 NOUN F
on 0 ADP F
understanding B-MENTAL VERB F
, 0 PUNCT F
medication B-MENTAL NOUN F
use I-MENTAL NOUN F
and 0 CCONJ F
outcomes 0 NOUN F
in 0 ADP F
a 0 DET F
clinical 0 ADJ F
setting 0 VERB F
. 0 PUNCT F

If 0 ADP T
successful 0 ADJ F
, 0 PUNCT F
these 0 DET F
findings 0 NOUN F
could 0 VERB F
be 0 VERB F
implemented 0 PROPN F
broadly 0 ADP F
to 0 PART F
promote 0 PUNCT F
safe 0 ADJ F
and 0 CCONJ F
appropriate 0 ADJ F
medication 0 NOUN F
use 0 NOUN F
and 0 CCONJ F
to 0 PART F
support 0 NOUN F
evidence-based 0 VERB F
standards 0 NOUN F
in 0 ADP F
the 0 DET F
development 0 NOUN F
of 0 ADP F
labels 0 NOUN F
. 0 PUNCT F

Effects 0 NOUN T
of 0 ADP F
a 0 DET F
Chinese 0 NOUN T
medical 0 ADJ F
herbs 0 NOUN F
complex 0 NOUN F
on 0 ADP F
cellular 0 ADJ F
immunity 0 NOUN F
and 0 CCONJ F
toxicity-related 0 VERB F
conditions 0 NOUN F
of 0 ADP F
breast 0 NOUN F
cancer 0 NOUN F
patients 0 NOUN F
. 0 PUNCT F

Rose 0 NOUN T
geranium 0 NOUN F
( 0 PUNCT F
Pelargonium 0 NOUN T
graveolens 0 NOUN F
, 0 PUNCT F
Geraniaceae 0 NOUN T
) 0 PUNCT F
has 0 ADP F
anti-cancer 0 NOUN F
and 0 CCONJ F
anti-inflammatory 0 ADJ F
properties 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
promotes 0 VERB F
wound 0 NOUN F
healing 0 VERB F
. 0 PUNCT F

Similarly 0 ADV T
, 0 PUNCT F
Ganoderma 0 NOUN T
tsugae 0 NOUN F
( 0 PUNCT F
Ganodermataceae 0 NOUN T
) 0 PUNCT F
, 0 PUNCT F
Codonopsis 0 NOUN T
pilosula 0 NOUN F
( 0 PUNCT F
Campanulaceae 0 NOUN T
) 0 PUNCT F
and 0 CCONJ F
Angelica 0 NOUN T
sinensis 0 NOUN F
( 0 PUNCT F
Apiaceae 0 NOUN T
) 0 PUNCT F
are 0 VERB F
traditional 0 ADJ F
Chinese 0 NOUN T
herbs 0 NOUN F
associated 0 VERB F
with 0 ADP F
immunomodulatory 0 ADJ F
functions 0 NOUN F
. 0 PUNCT F

In 0 ADP T
the 0 DET F
present 0 ADJ F
study 0 NOUN F
, 0 PUNCT F
a 0 DET F
randomised 0 VERB F
, 0 PUNCT F
double-blind 0 ADJ F
, 0 PUNCT F
placebo-controlled 0 VERB F
study 0 NOUN F
was 0 VERB F
conducted 0 VERB F
to 0 PART F
examine 0 NOUN F
whether 0 ADP F
the 0 DET F
Chinese 0 NOUN T
medicinal 0 ADJ F
herb 0 ADJ F
complex 0 NOUN F
, 0 PUNCT F
RG-CMH 0 NOUN T
, 0 PUNCT F
which 0 DET F
represents 0 NOUN F
a 0 DET F
mixture 0 NOUN F
of 0 ADP F
rose 0 ADP F
geranium 0 NOUN F
and 0 CCONJ F
extracts 0 NOUN F
of 0 ADP F
G. 0 PUNCT T
tsugae 0 ADP F
, 0 PUNCT F
C. 0 NOUN T
pilosula 0 NOUN F
and 0 CCONJ F
A. 0 NOUN T
sinensis 0 NOUN F
, 0 PUNCT F
can 0 VERB F
improve 0 VERB F
the 0 DET F
immune 0 ADJ F
cell 0 NOUN F
count 0 NOUN F
of 0 ADP F
cancer 0 NOUN F
patients 0 NOUN F
receiving 0 VERB F
chemotherapy 0 NOUN F
and/or 0 CCONJ F
radiotherapy 0 NOUN F
to 0 PROPN F
prevent 0 ADJ F
leucopenia 0 NOUN F
and 0 CCONJ F
immune 0 ADJ F
impairment 0 NOUN F
that 0 ADP F
usually 0 ADV F
occurs 0 NOUN F
during 0 ADP F
cancer 0 NOUN F
therapy 0 NOUN F
. 0 PUNCT F

A 0 DET T
total 0 NOUN F
of 0 ADP F
fifty-eight 0 PUNCT F
breast 0 NOUN F
cancer 0 NOUN F
patients 0 NOUN F
who 0 ADP F
received 0 VERB F
chemotherapy 0 NOUN F
or 0 CCONJ F
radiotherapy 0 NOUN F
were 0 VERB F
enrolled 0 VERB F
. 0 PUNCT F

Immune 0 ADJ T
cell 0 NOUN F
levels 0 NOUN F
in 0 ADP F
patient 0 NOUN F
serum 0 NOUN F
were 0 VERB F
determined 0 VERB F
before 0 CCONJ F
, 0 PUNCT F
and 0 CCONJ F
following 0 DET F
, 0 PUNCT F
6 0 NUM F
weeks 0 NOUN F
of 0 ADP F
cancer 0 NOUN F
treatment 0 NOUN F
for 0 ADP F
patients 0 NOUN F
receiving 0 VERB F
either 0 PUNCT F
an 0 DET F
RG-CMH 0 NOUN T
or 0 CCONJ F
a 0 DET F
placebo 0 NOUN F
. 0 PUNCT F

Administration 0 NOUN T
of 0 ADP F
RG-CMH 0 NOUN T
was 0 VERB F
associated 0 VERB F
with 0 ADP F
a 0 DET F
significant 0 ADJ F
reduction 0 NOUN F
in 0 ADP F
levels B-PHYSICAL NOUN F
of I-PHYSICAL ADP F
leucocytes I-PHYSICAL NOUN F
from 0 ADP F
31?5 0 NOUN F
% 0 SYM F
for 0 ADP F
the 0 DET F
placebo 0 NOUN F
group 0 NOUN F
to 0 ADP F
13?4 0 ADP F
% 0 SYM F
for 0 ADP F
the 0 DET F
RG-CMH 0 NOUN T
group 0 NOUN F
. 0 PUNCT F

Similarly 0 ADV T
, 0 PUNCT F
levels 0 NOUN F
of 0 ADP F
neutrophils 0 NOUN F
significantly 0 ADV F
decreased 0 VERB F
from 0 ADP F
35?6 0 NOUN F
% 0 SYM F
for 0 ADP F
the 0 DET F
placebo 0 NOUN F
group 0 NOUN F
to 0 VERB F
11?0 0 NOUN F
% 0 SYM F
for 0 ADP F
the 0 DET F
RG-CMH 0 NOUN T
group 0 NOUN F
. 0 PUNCT F

RG-CMH 0 NOUN T
intervention 0 NOUN F
was 0 VERB F
also 0 ADV F
associated 0 VERB F
with 0 ADP F
a 0 DET F
decrease 0 NOUN F
in 0 ADP F
levels 0 NOUN F
of 0 ADP F
T 0 NOUN T
cells 0 NOUN F
, 0 PUNCT F
helper 0 NOUN F
T 0 NOUN T
cells 0 NOUN F
, 0 PUNCT F
cytotoxic 0 ADJ F
T 0 NOUN T
cells 0 NOUN F
and 0 CCONJ F
natural 0 ADJ F
killer 0 NOUN F
cells 0 NOUN F
compared 0 VERB F
with 0 ADP F
the 0 DET F
placebo 0 NOUN F
group 0 NOUN F
. 0 PUNCT F

However 0 ADV T
, 0 PUNCT F
these 0 DET F
differences 0 NOUN F
between 0 ADP F
the 0 DET F
two 0 NUM F
groups 0 NOUN F
were 0 VERB F
not 0 ADV F
statistically 0 ADV F
significant 0 ADJ F
. 0 PUNCT F

In 0 ADP T
conclusion 0 NOUN F
, 0 PUNCT F
administration 0 NOUN F
of 0 ADP F
RG-CMH 0 NOUN T
to 0 ADP F
patients 0 NOUN F
receiving 0 VERB F
chemotherapy/radiotherapy 0 NOUN F
may 0 PUNCT F
have 0 PUNCT F
the 0 DET F
capacity 0 NOUN F
to 0 ADP F
delay 0 PUNCT F
, 0 PUNCT F
or 0 CCONJ F
ease 0 NOUN F
, 0 PUNCT F
the 0 DET F
reduction 0 NOUN F
in 0 ADP F
levels 0 NOUN F
of 0 ADP F
leucocytes 0 NOUN F
and 0 CCONJ F
neutrophils 0 NOUN F
that 0 ADP F
are 0 VERB F
experienced 0 VERB F
by 0 ADP F
patients 0 NOUN F
during 0 ADP F
cancer 0 NOUN F
treatment 0 NOUN F
. 0 PUNCT F

Immunoenhanced 0 DET T
enteral 0 ADJ F
nutrition 0 NOUN F
formulas 0 PUNCT F
in 0 ADP F
head 0 NOUN F
and 0 CCONJ F
neck 0 ADJ F
cancer 0 NOUN F
surgery 0 NOUN F
: 0 PUNCT F
a 0 DET F
prospective 0 ADJ F
, 0 PUNCT F
randomized 0 VERB F
clinical 0 ADJ F
trial 0 NOUN F
. 0 PUNCT F

INTRODUCTION 0 NOUN T
Significant 0 ADJ T
malnutrition 0 NOUN F
exists 0 NOUN F
in 0 ADP F
a 0 DET F
high 0 ADJ F
percentage 0 NOUN F
of 0 ADP F
patients 0 NOUN F
with 0 ADP F
head 0 NOUN F
and 0 CCONJ F
neck 0 ADJ F
cancer 0 NOUN F
. 0 PUNCT F

Malnutrition 0 NOUN T
is 0 VERB F
associated 0 VERB F
with 0 ADP F
defects 0 NOUN F
in 0 ADP F
immune 0 ADJ F
function 0 NOUN F
that 0 ADP F
may 0 VERB F
impair 0 VERB F
the 0 DET F
host 0 NOUN F
response 0 NOUN F
to 0 ADP F
malignancy 0 NOUN F
. 0 PUNCT F

Malnutrition 0 NOUN T
and 0 CCONJ F
immunosupression 0 NOUN F
make 0 VERB F
patients 0 NOUN F
highly 0 ADV F
susceptible 0 ADJ F
to 0 ADP F
postoperative 0 ADJ F
infections 0 NOUN F
and 0 CCONJ F
complications 0 NOUN F
. 0 PUNCT F

OBJECTIVES 0 NOUN T
Compare 0 ADV T
two 0 NUM F
immunoenhanced 0 VERB F
enteral 0 ADJ F
nutritions 0 NOUN F
with 0 ADP F
a 0 DET F
control 0 NOUN F
diet 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
evaluate 0 ADJ F
the 0 DET F
effect 0 NOUN F
in 0 ADP F
postoperative B-PHYSICAL ADJ F
infections I-PHYSICAL NOUN F
, 0 PUNCT F
length B-PHYSICAL NOUN F
of I-PHYSICAL ADP F
stay I-PHYSICAL NOUN F
and 0 CCONJ F
inflammatory B-PHYSICAL ADJ F
markers I-PHYSICAL NOUN F
. 0 PUNCT F

PATIENTS 0 NOUN T
A 0 PUNCT T
population 0 NOUN F
of 0 ADP F
44 0 NUM F
patients 0 NOUN F
with 0 ADP F
oral 0 ADJ F
and 0 CCONJ F
laryngeal 0 ADJ F
cancer 0 NOUN F
was 0 VERB F
enrolled 0 VERB F
in 0 ADP F
a 0 DET F
randomized 0 VERB F
trial 0 NOUN F
. 0 PUNCT F

At 0 ADP T
surgery 0 NOUN F
, 0 PUNCT F
patients 0 NOUN F
were 0 VERB F
randomly 0 ADV F
allocated 0 VERB F
to 0 ADP F
three 0 DET F
groups 0 NOUN F
: 0 PUNCT F
( 0 PUNCT F
group 0 NOUN F
I 0 NUM T
) 0 PUNCT F
; 0 PUNCT F
patients 0 NOUN F
receiving 0 VERB F
an 0 DET F
arginine-enhanced 0 VERB F
formula 0 NOUN F
( 0 PUNCT F
group 0 NOUN F
II 0 NUM T
) 0 PUNCT F
; 0 PUNCT F
patients 0 NOUN F
receiving 0 VERB F
a 0 DET F
standard 0 ADJ F
polymeric 0 ADJ F
formula 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
( 0 PUNCT F
group 0 NOUN F
III 0 NUM T
) 0 PUNCT F
patients 0 NOUN F
receiving 0 VERB F
an 0 DET F
arginine 0 NOUN F
, 0 PUNCT F
RNA 0 NOUN T
and 0 CCONJ F
omega-3 0 NOUN F
fatty 0 ADJ F
acids 0 NOUN F
enhanced 0 PUNCT F
formula 0 NOUN F
, 0 PUNCT F
in 0 ADP F
an 0 DET F
isonitrogenous 0 ADJ F
way 0 NOUN F
. 0 PUNCT F

RESULTS 0 PUNCT T
The 0 DET T
duration 0 NOUN F
of 0 ADP F
enteral B-PHYSICAL ADJ F
nutrition I-PHYSICAL NOUN F
in 0 ADP F
the 0 DET F
three 0 NUM F
groups 0 NOUN F
was 0 VERB F
similar 0 ADJ F
with 0 ADP F
an 0 DET F
average 0 ADJ F
duration 0 NOUN F
of 0 ADP F
14,5 0 NOUN F
+/- 0 SYM F
8 0 NUM F
days 0 NOUN F
. 0 PUNCT F

The 0 DET T
length 0 NOUN F
of 0 ADP F
postoperative B-PHYSICAL ADJ F
stay I-PHYSICAL NOUN F
was 0 VERB F
similar 0 ADJ F
, 0 PUNCT F
with 0 ADP F
an 0 DET F
average 0 NOUN F
of 0 ADP F
19,8 0 NOUN F
+/- 0 SYM F
8,5 0 NOUN F
days 0 NOUN F
. 0 PUNCT F

Wound B-PHYSICAL NOUN T
infections I-PHYSICAL NOUN F
and 0 CCONJ F
general B-PHYSICAL ADJ F
infections I-PHYSICAL NOUN F
were 0 VERB F
more 0 ADV F
frequent 0 ADP F
in 0 ADP F
the 0 DET F
control 0 NOUN F
group 0 NOUN F
. 0 PUNCT F

Fistula 0 NOUN T
rates 0 NOUN F
were 0 VERB F
not 0 ADV F
improved 0 VERB F
in 0 ADP F
the 0 DET F
enhanced 0 VERB F
diet 0 NOUN F
groups 0 NOUN F
. 0 PUNCT F

No 0 DET T
significant 0 ADJ F
intergroup 0 NOUN F
differences 0 NOUN F
in 0 ADP F
the 0 DET F
trend 0 NOUN F
of 0 ADP F
the 0 DET F
two 0 NUM F
plasma 0 NOUN F
proteins 0 NOUN F
( 0 PUNCT F
albumin 0 NOUN F
, 0 PUNCT F
transferrin 0 NOUN F
) 0 PUNCT F
, 0 PUNCT F
lymphocytes 0 NOUN F
, 0 PUNCT F
weight 0 NOUN F
, 0 PUNCT F
IL-6 0 NOUN T
, 0 PUNCT F
CPR 0 NOUN T
and 0 CCONJ F
TNFalpha 0 NOUN T
were 0 VERB F
detected 0 VERB F
. 0 PUNCT F

The 0 DET T
control 0 NOUN F
group 0 NOUN F
showed 0 VERB F
the 0 DET F
highest 0 PUNCT F
levels 0 NOUN F
of 0 ADP F
TNFalpha B-OTHER NOUN T
at 0 ADP F
the 0 DET F
fourteenth 0 NOUN F
postoperative 0 ADJ F
day 0 NOUN F
. 0 PUNCT F

Gastrointestinal 0 ADJ T
tolerance 0 NOUN F
and 0 CCONJ F
diarrhoea 0 NOUN F
rate 0 NOUN F
were 0 VERB F
similar 0 ADJ F
in 0 ADP F
all 0 DET F
the 0 DET F
patients 0 NOUN F
. 0 PUNCT F

CONCLUSIONS 0 NOUN T
Immunoenhanced 0 PROPN T
enteral 0 ADJ F
nutrition 0 NOUN F
formulas 0 PUNCT F
improved 0 VERB F
the 0 DET F
infection 0 NOUN F
rate 0 NOUN F
in 0 ADP F
the 0 DET F
postoperative 0 ADJ F
of 0 ADP F
head 0 NOUN F
and 0 CCONJ F
neck 0 ADJ F
cancer 0 NOUN F
patients 0 NOUN F
. 0 PUNCT F

In 0 ADP T
the 0 DET F
fistula 0 NOUN F
rates 0 NOUN F
, 0 PUNCT F
we 0 PRON F
observed 0 VERB F
that 0 ADP F
technical 0 ADJ F
problems 0 NOUN F
and 0 CCONJ F
nutritional 0 ADJ F
status 0 NOUN F
might 0 VERB F
have 0 PUNCT F
played 0 VERB F
an 0 DET F
equally 0 ADV F
important 0 ADJ F
role 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
therefore 0 ADV F
the 0 DET F
positive 0 ADJ F
effect 0 NOUN F
of 0 ADP F
immunonutrition 0 NOUN F
in 0 ADP F
this 0 DET F
parameter 0 NOUN F
might 0 PUNCT F
have 0 PUNCT F
been 0 PUNCT F
overestimated 0 VERB F
. 0 PUNCT F

Randomized 0 VERB T
placebo 0 NOUN F
controlled 0 VERB F
human 0 NOUN F
volunteer 0 NOUN F
trial 0 NOUN F
of 0 ADP F
a 0 DET F
live 0 ADJ F
oral 0 ADJ F
cholera 0 NOUN F
vaccine 0 NOUN F
VA1.3 0 NUM T
for 0 ADP F
safety B-OTHER NOUN F
and 0 CCONJ F
immune 0 ADJ F
response 0 NOUN F
. 0 PUNCT F

A 0 DET T
live 0 ADJ F
oral 0 ADJ F
cholera 0 NOUN F
vaccine 0 NOUN F
developed 0 VERB F
from 0 ADP F
a 0 DET F
non-toxigenic 0 ADJ F
Vibrio 0 NOUN T
cholerae 0 NOUN F
O1 0 NOUN T
El 0 NOUN T
Tor 0 PUNCT T
strain 0 NOUN F
VA1.3 0 NUM T
was 0 VERB F
tested 0 VERB F
in 0 ADP F
a 0 DET F
double-blind 0 ADJ F
randomized 0 VERB F
placebo 0 NOUN F
controlled 0 VERB F
study 0 NOUN F
for 0 ADP F
safety 0 NOUN F
and 0 CCONJ F
immunogenicity 0 NOUN F
in 0 ADP F
304 0 NUM F
men 0 NOUN F
aged 0 VERB F
between 0 ADP F
16 0 NUM F
and 0 CCONJ F
50 0 NUM F
years 0 NOUN F
from 0 ADP F
Kolkata 0 NOUN T
, 0 PUNCT F
India 0 PUNCT T
. 0 PUNCT F

A 0 DET T
dose 0 NOUN F
of 0 ADP F
5 0 NUM F
x 0 SYM F
10 0 NUM F
( 0 PUNCT F
9 0 NUM F
) 0 PUNCT F
CFU 0 NOUN T
( 0 PUNCT F
n=186 0 NOUN F
) 0 PUNCT F
or 0 CCONJ F
a 0 DET F
placebo 0 NOUN F
( 0 PUNCT F
n=116 0 NOUN F
) 0 PUNCT F
containing 0 VERB F
the 0 DET F
diluent 0 ADJ F
buffer 0 NOUN F
was 0 VERB F
administered 0 VERB F
. 0 PUNCT F

The 0 DET T
vaccine 0 NOUN F
did 0 PUNCT F
not 0 ADV F
elicit 0 VERB F
adverse B-ADVERSE-EFFECTS ADJ F
events I-ADVERSE-EFFECTS NOUN F
except 0 PUNCT F
in 0 ADP F
two 0 NUM F
vaccine 0 NOUN F
recipients 0 NOUN F
with 0 ADP F
mild B-ADVERSE-EFFECTS ADJ F
diarrhoea I-ADVERSE-EFFECTS NOUN F
and 0 CCONJ F
vomiting B-ADVERSE-EFFECTS PUNCT F
. 0 PUNCT F

None 0 NUM T
excreted 0 PUNCT F
the 0 DET F
vaccine 0 NOUN F
strain 0 NOUN F
. 0 PUNCT F

Vibriocidal B-PHYSICAL ADJ T
antibody I-PHYSICAL NOUN F
response I-PHYSICAL NOUN F
developed 0 PUNCT F
in 0 ADP F
105/186 0 ADV F
( 0 PUNCT F
57 0 NUM F
% 0 SYM F
) 0 PUNCT F
and 0 CCONJ F
5/116 0 NOUN F
( 0 PUNCT F
4 0 NUM F
% 0 SYM F
) 0 PUNCT F
in 0 ADP F
vaccine 0 NOUN F
and 0 CCONJ F
placebo 0 NOUN F
recipients 0 NOUN F
, 0 PUNCT F
respectively 0 ADV F
. 0 PUNCT F

In 0 ADP T
a 0 DET F
subgroup 0 NOUN F
, 0 PUNCT F
anti-CT B-PHYSICAL NOUN F
antibody I-PHYSICAL NOUN F
rose I-PHYSICAL NOUN F
( 0 PUNCT F
> 0 PROPN F
or 0 CCONJ F
=2-folds 0 PUNCT F
) 0 PUNCT F
in 0 ADP F
23/30 0 PUNCT F
( 0 PUNCT F
77 0 NUM F
% 0 SYM F
) 0 PUNCT F
and 0 CCONJ F
6/19 0 NOUN F
( 0 PUNCT F
32 0 NUM F
% 0 SYM F
) 0 PUNCT F
in 0 ADP F
vaccine 0 NOUN F
and 0 CCONJ F
placebo 0 NOUN F
recipients 0 NOUN F
, 0 PUNCT F
respectively 0 ADV F
. 0 PUNCT F

These 0 DET T
studies 0 NOUN F
demonstrate 0 VERB F
that 0 ADP F
VA1.3 0 NUM T
at 0 ADP F
a 0 DET F
dose 0 NOUN F
of 0 ADP F
5 0 NUM F
x 0 SYM F
10 0 NUM F
( 0 PUNCT F
9 0 NUM F
) 0 PUNCT F
is 0 VERB F
safe B-OTHER ADJ F
and 0 CCONJ F
immunogenic B-OTHER ADJ F
in 0 ADP F
adults 0 NOUN F
from 0 ADP F
a 0 DET F
cholera 0 NOUN F
endemic 0 ADJ F
region 0 NOUN F
. 0 PUNCT F

A 0 DET T
stable 0 ADJ F
prostacyclin 0 NOUN F
analogue 0 NOUN F
( 0 PUNCT F
iloprost 0 PUNCT F
) 0 PUNCT F
in 0 ADP F
the 0 DET F
treatment 0 NOUN F
of 0 ADP F
ischaemic 0 ADJ F
ulcers 0 NOUN F
of 0 ADP F
the 0 DET F
lower 0 PUNCT F
limb 0 NOUN F
. 0 PUNCT F

A 0 DET T
Scandinavian-Polish 0 NOUN T
placebo 0 NOUN F
controlled 0 PUNCT F
, 0 PUNCT F
randomised 0 VERB F
multicenter 0 NOUN F
study 0 NOUN F
. 0 PUNCT F

The 0 DET T
clinical B-OTHER ADJ F
efficacy I-OTHER NOUN F
of 0 ADP F
the 0 DET F
prostacyclin 0 NOUN F
analogue 0 NOUN F
iloprost 0 PUNCT F
was 0 VERB F
studied 0 VERB F
during 0 ADP F
a 0 DET F
2 0 NUM F
week 0 NOUN F
treatment 0 NOUN F
and 0 CCONJ F
6 0 NUM F
month 0 NOUN F
follow-up 0 NOUN F
period 0 NOUN F
in 0 ADP F
103 0 NUM F
patients 0 NOUN F
with 0 ADP F
ischaemic 0 ADJ F
ulcers 0 NOUN F
who 0 ADP F
were 0 VERB F
randomised 0 VERB F
to 0 PART F
receive 0 NOUN F
active 0 ADJ F
treatment 0 NOUN F
or 0 CCONJ F
placebo 0 NOUN F
. 0 PUNCT F

Responders 0 NOUN T
were 0 VERB F
defined 0 VERB F
as 0 ADP F
those 0 PUNCT F
patients 0 NOUN F
who 0 PROPN F
achieved 0 PUNCT F
healing 0 VERB F
of 0 ADP F
at 0 ADJ F
least 0 ADV F
one 0 NUM F
third 0 ADJ F
of 0 ADP F
the 0 DET F
ulcer 0 NOUN F
area 0 NOUN F
during 0 ADP F
the 0 DET F
study 0 ADV F
period 0 NOUN F
. 0 PUNCT F

The 0 DET T
overall 0 ADJ F
responder B-PHYSICAL NOUN F
rate I-PHYSICAL NOUN F
was 0 VERB F
41.3 0 NUM F
% 0 SYM F
, 0 PUNCT F
compared 0 VERB F
with 0 ADP F
25 0 NUM F
% 0 SYM F
for 0 ADP F
the 0 DET F
control 0 NOUN F
group 0 NOUN F
( 0 PUNCT F
P 0 NOUN T
= 0 SYM F
0.086 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Side 0 NOUN T
effects 0 NOUN F
including 0 VERB F
flushing B-ADVERSE-EFFECTS VERB F
and 0 CCONJ F
headache B-ADVERSE-EFFECTS NOUN F
, 0 PUNCT F
were 0 VERB F
common 0 ADJ F
. 0 PUNCT F

The 0 DET T
study 0 ADV F
population 0 NOUN F
had 0 PUNCT F
a 0 DET F
mortality B-MORTALITY NOUN F
of 0 ADP F
23 0 NUM F
% 0 SYM F
during 0 ADP F
the 0 DET F
6 0 NUM F
month 0 NOUN F
period 0 NOUN F
, 0 PUNCT F
the 0 DET F
amputation B-PHYSICAL NOUN F
rate I-PHYSICAL NOUN F
was 0 VERB F
43.5 0 NUM F
% 0 SYM F
for 0 ADP F
iloprost 0 PUNCT F
and 0 CCONJ F
50 0 NUM F
% 0 SYM F
for 0 ADP F
placebo 0 NOUN F
treated 0 VERB F
patients 0 NOUN F
. 0 PUNCT F

In 0 ADP T
this 0 PUNCT F
severely 0 PRON F
diseased 0 VERB F
population 0 NOUN F
of 0 ADP F
patients 0 NOUN F
a 0 DET F
treatment 0 NOUN F
period 0 NOUN F
limited 0 VERB F
to 0 ADP F
2 0 NUM F
weeks 0 NOUN F
did 0 VERB F
not 0 ADV F
sufficiently 0 ADV F
improve 0 VERB F
ulcer B-PHYSICAL NOUN F
healing I-PHYSICAL VERB F
. 0 PUNCT F

Cardiovascular 0 ADJ T
effects 0 NOUN F
of 0 ADP F
non-depolarizing 0 VERB F
neuromuscular 0 ADJ F
blockers 0 NOUN F
in 0 ADP F
patients 0 NOUN F
with 0 ADP F
aortic 0 ADJ F
valve 0 NOUN F
disease 0 NOUN F
. 0 PUNCT F

To 0 PART T
compare 0 NOUN F
haemodynamic 0 ADJ F
responses 0 NOUN F
associated 0 VERB F
with 0 ADP F
equipotent 0 ADP F
doses 0 NOUN F
of 0 ADP F
neuromuscular 0 ADJ F
blockers 0 NOUN F
and 0 CCONJ F
high-dose 0 NOUN F
fentanyl 0 NOUN F
( 0 PUNCT F
50 0 NUM F
micrograms.kg-1 0 NOUN F
) 0 PUNCT F
, 0 PUNCT F
40 0 NUM F
patients 0 NOUN F
with 0 ADP F
aortic 0 ADJ F
valve 0 NOUN F
stenosis 0 NOUN F
( 0 PUNCT F
AS 0 ADP T
) 0 PUNCT F
and 0 CCONJ F
20 0 NUM F
patients 0 NOUN F
with 0 ADP F
aortic 0 ADJ F
insufficiency 0 NOUN F
( 0 PUNCT F
AI 0 NOUN T
) 0 PUNCT F
were 0 VERB F
randomized 0 VERB F
to 0 ADP F
four 0 NUM F
study 0 ADV F
groups 0 NOUN F
to 0 PART F
receive 0 NOUN F
the 0 DET F
following 0 PUNCT F
: 0 PUNCT F
( 0 PUNCT F
1 0 NUM F
) 0 PUNCT F
pancuronium 0 NOUN F
0.12 0 NUM F
mg.kg-1 0 NOUN F
, 0 PUNCT F
( 0 PUNCT F
2 0 NUM F
) 0 PUNCT F
vecuronium 0 NOUN F
0.12 0 NUM F
mg.kg-1 0 NOUN F
, 0 PUNCT F
( 0 PUNCT F
3 0 NUM F
) 0 PUNCT F
atracurium 0 NOUN F
0.4 0 NUM F
mg.kg-1 0 NOUN F
, 0 PUNCT F
or 0 CCONJ F
( 0 PUNCT F
4 0 NUM F
) 0 PUNCT F
pancuronium-metocurine 0 NOUN F
mixture 0 NOUN F
( 0 PUNCT F
0.4 0 NUM F
mg 0 NOUN F
+ 0 SYM F
1.6 0 NUM F
mg/ml 0 NOUN F
) 0 PUNCT F
: 0 PUNCT F
1 0 NUM F
ml/10 0 NOUN F
kg 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

Neuromuscular 0 ADJ T
blockers 0 NOUN F
were 0 VERB F
injected 0 VERB F
at 0 ADP F
the 0 DET F
same 0 ADJ F
time 0 NOUN F
with 0 ADP F
the 0 DET F
fentanyl 0 NOUN F
; 0 PUNCT F
haemodynamics 0 NOUN F
were 0 VERB F
recorded 0 VERB F
with 0 ADP F
the 0 DET F
patients 0 NOUN F
awake 0 ADJ F
( 0 PUNCT F
baseline 0 NOUN F
) 0 PUNCT F
, 0 PUNCT F
at 0 ADP F
two 0 NUM F
minutes 0 NOUN F
post-induction 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
at 0 ADP F
two 0 NUM F
and 0 CCONJ F
five 0 NUM F
minutes 0 NOUN F
after 0 ADP F
intubation 0 NOUN F
. 0 PUNCT F

In 0 ADP T
patients 0 NOUN F
with 0 ADP F
AS 0 ADP T
, 0 PUNCT F
pancuronium 0 NOUN F
increased 0 VERB F
heart B-PHYSICAL NOUN F
rate I-PHYSICAL NOUN F
more 0 ADV F
than 0 PUNCT F
vecuronium 0 NOUN F
or 0 CCONJ F
atracurium 0 NOUN F
; 0 PUNCT F
heart B-PHYSICAL NOUN F
rates I-PHYSICAL NOUN F
were 0 VERB F
also 0 ADV F
higher 0 PUNCT F
with 0 ADP F
the 0 DET F
pancuronium-metocurine 0 NOUN F
mixture 0 NOUN F
than 0 PUNCT F
with 0 ADP F
vecuronium 0 NOUN F
. 0 PUNCT F

Although 0 ADP T
there 0 PUNCT F
were 0 VERB F
no 0 DET F
ECG B-PHYSICAL NOUN T
signs I-PHYSICAL NOUN F
of I-PHYSICAL ADP F
ischaemia I-PHYSICAL NOUN F
, 0 PUNCT F
one 0 NUM F
patient 0 NOUN F
given 0 ADJ F
pancuronium 0 NOUN F
developed 0 VERB F
severe B-PHYSICAL ADJ F
hypotension I-PHYSICAL NOUN F
associated 0 VERB F
with B-PHYSICAL ADP F
tachycardia B-PHYSICAL NOUN F
. 0 PUNCT F

Reductions 0 NOUN T
in 0 ADP F
SVR B-PHYSICAL NOUN T
after 0 ADP F
atracurium 0 NOUN F
allowed 0 VERB F
small 0 ADJ F
but 0 CCONJ F
significant 0 ADJ F
( 0 PUNCT F
p 0 NOUN F
less 0 ADV F
than 0 PUNCT F
0.01 0 NUM F
) 0 PUNCT F
decreases 0 PROPN F
in 0 ADP F
MAP B-PHYSICAL NOUN T
which 0 ADP F
were 0 VERB F
well B-OTHER VERB F
tolerated I-OTHER ADP F
; 0 PUNCT F
one 0 NUM F
patient 0 NOUN F
, 0 PUNCT F
however 0 ADV F
, 0 PUNCT F
did 0 PUNCT F
develop 0 VERB F
severe B-PHYSICAL ADJ F
hypotension B-PHYSICAL NOUN F
. 0 PUNCT F

Intubation 0 NOUN T
resulted 0 VERB F
in 0 ADP F
significant 0 ADJ F
( 0 PUNCT F
p 0 NOUN F
less 0 ADV F
than 0 PUNCT F
0.01 0 NUM F
) 0 PUNCT F
increases 0 NOUN F
in 0 ADP F
MAP B-PHYSICAL NOUN T
in 0 ADP F
the 0 DET F
pancuronium-metocurine 0 NOUN F
mixture 0 NOUN F
group 0 NOUN F
. 0 PUNCT F

Vecuronium 0 NOUN T
permitted 0 VERB F
the 0 DET F
most 0 ADP F
stable 0 ADJ F
overall B-PHYSICAL ADJ F
haemodynamic B-PHYSICAL ADJ F
course B-PHYSICAL NOUN F
at 0 ADP F
all 0 DET F
measurement 0 NOUN F
times 0 NOUN F
. 0 PUNCT F

In 0 ADP T
contrast 0 NOUN F
, 0 PUNCT F
patients 0 NOUN F
with 0 ADP F
AI 0 NOUN T
showed 0 VERB F
stable B-PHYSICAL ADJ F
haemodynamics B-PHYSICAL NOUN F
after 0 ADP F
vecuronium 0 NOUN F
, 0 PUNCT F
pancuronium 0 NOUN F
and 0 CCONJ F
the 0 DET F
pancuronium-metocurine 0 NOUN F
mixture 0 NOUN F
; 0 PUNCT F
one 0 NUM F
patient 0 NOUN F
became 0 ADP F
tachycardic B-PHYSICAL NOUN F
following 0 PUNCT F
vecuronium 0 NOUN F
. 0 PUNCT F

Atracurium 0 NOUN T
caused 0 VERB F
unexplained 0 VERB F
elevations 0 NOUN F
in 0 PUNCT F

[ 0 PUNCT F
Clinical 0 ADJ T
study 0 NOUN F
on 0 ADP F
retarding B-PHYSICAL VERB F
aging I-PHYSICAL ADJ F
effect 0 NOUN F
of 0 ADP F
tongbu 0 NOUN F
recipe 0 NOUN F
to 0 ADP F
traditional 0 ADJ F
Chinese 0 NOUN T
medicine 0 NOUN F
] 0 PUNCT F
. 0 PUNCT F

OBJECTIVE 0 NOUN T
To 0 PART T
study 0 NOUN F
the 0 DET F
mechanism 0 NOUN F
of 0 ADP F
Tongbu 0 NOUN T
No 0 ADP T
. 0 PUNCT F

1 0 NUM F
( 0 PUNCT F
TB1 0 NOUN T
, 0 PUNCT F
a 0 DET F
prescription 0 NOUN F
for 0 ADP F
reinforcing 0 ADJ F
Kidney 0 NOUN T
and 0 CCONJ F
Spleen 0 NOUN T
, 0 PUNCT F
clearing 0 PUNCT F
up 0 PUNCT F
the 0 DET F
bowel 0 NOUN F
viscera 0 PUNCT F
to 0 PUNCT F
send 0 CCONJ F
Turbid 0 NOUN T
downward 0 ADJ F
and 0 CCONJ F
regulating 0 ADP F
Qi 0 NOUN T
and 0 CCONJ F
blood 0 NOUN F
) 0 PUNCT F
in 0 ADP F
retarding B-PHYSICAL VERB F
aging I-PHYSICAL VERB F
. 0 PUNCT F

METHODS 0 NOUN T
A 0 PUNCT T
controlled 0 VERB F
, 0 PUNCT F
multiple 0 ADJ F
indexes 0 PUNCT F
study 0 NOUN F
was 0 VERB F
conducted 0 VERB F
in 0 ADP F
56 0 NUM F
old 0 ADJ F
subjects 0 NOUN F
randomized 0 PUNCT F
into 0 ADP F
3 0 NUM F
groups 0 NOUN F
. 0 PUNCT F

RESULTS 0 NOUN T
TB1 0 NOUN T
( 0 PUNCT F
containing 0 ADP F
ginseng 0 PUNCT F
leaf 0 PUNCT F
, 0 PUNCT F
cistanche 0 NOUN F
, 0 PUNCT F
fleeceflower 0 PUNCT F
root 0 NOUN F
, 0 PUNCT F
immature 0 ADJ F
bitter 0 ADJ F
orange 0 NOUN F
, 0 PUNCT F
rhubarb 0 NOUN F
, 0 PUNCT F
etc 0 NOUN F
) 0 PUNCT F
could 0 VERB F
improve 0 VERB F
various 0 ADJ F
symptoms B-PHYSICAL NOUN F
of I-PHYSICAL ADP F
aging I-PHYSICAL VERB F
, 0 PUNCT F
and 0 CCONJ F
had 0 PUNCT F
the 0 DET F
effect 0 NOUN F
in 0 ADP F
regulating B-PHYSICAL VERB F
immune I-PHYSICAL ADJ F
and 0 CCONJ F
endocrinal B-PHYSICAL ADJ F
function I-PHYSICAL NOUN F
, 0 PUNCT F
scavenging B-PHYSICAL ADP F
free I-PHYSICAL ADJ F
radicals I-PHYSICAL NOUN F
and 0 CCONJ F
adjusting B-PHYSICAL SYM F
coli I-PHYSICAL NOUN F
flora I-PHYSICAL ADJ F
. 0 PUNCT F

The 0 DET T
effects 0 NOUN F
of 0 ADP F
TB1 0 NOUN T
and 0 CCONJ F
TB2 0 NOUN T
( 0 PUNCT F
containing 0 ADP F
ginseng 0 PUNCT F
leaf 0 PUNCT F
, 0 PUNCT F
cistanche 0 NOUN F
and 0 CCONJ F
fleeceflower 0 PUNCT F
root 0 NOUN F
) 0 PUNCT F
were 0 VERB F
different 0 ADJ F
significantly 0 ADV F
( 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.05 0 NUM F
, 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.01 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

CONCLUSION 0 NOUN T
TB1 0 NOUN T
has 0 ADP F
a 0 DET F
good 0 ADJ F
comprehensive 0 ADJ F
effect 0 NOUN F
in 0 ADP F
retarding B-PHYSICAL VERB F
aging I-PHYSICAL VERB F
. 0 PUNCT F

Effect 0 NOUN T
of 0 ADP F
age 0 NOUN F
and 0 CCONJ F
radiation 0 NOUN F
dose 0 NOUN F
on 0 ADP F
local B-PHYSICAL ADJ F
control I-PHYSICAL NOUN F
after 0 ADP F
breast 0 NOUN F
conserving 0 PROPN F
treatment 0 NOUN F
: 0 PUNCT F
EORTC 0 NOUN T
trial 0 NOUN F
22881-10882 0 NUM F
. 0 PUNCT F

PURPOSE 0 NOUN T
To 0 ADJ T
determine 0 NOUN F
whether 0 ADP F
the 0 DET F
effect 0 NOUN F
of 0 ADP F
an 0 DET F
additional 0 ADJ F
boost 0 CCONJ F
radiation 0 NOUN F
after 0 ADP F
breast 0 NOUN F
conservative 0 ADJ F
therapy 0 NOUN F
( 0 PUNCT F
BCT 0 NOUN T
) 0 PUNCT F
on 0 ADP F
local 0 ADJ F
control 0 NOUN F
depends 0 NOUN F
on 0 ADP F
age 0 NOUN F
and 0 CCONJ F
evaluate 0 ADJ F
the 0 DET F
impact 0 NOUN F
of 0 ADP F
a 0 DET F
treatment 0 NOUN F
policy 0 NOUN F
with 0 ADP F
a 0 DET F
threshold 0 NOUN F
for 0 ADP F
age 0 NOUN F
. 0 PUNCT F

PATIENTS 0 NOUN T
AND 0 CCONJ T
METHODS 0 NOUN T
We 0 ADJ T
used 0 VERB F
data 0 NOUN F
from 0 ADP F
EORTC 0 NOUN T
22881-10882 0 NUM F
trial 0 NOUN F
, 0 PUNCT F
with 0 ADP F
median 0 ADJ F
follow-up 0 NOUN F
of 0 ADP F
77.4 0 NUM F
months 0 NOUN F
. 0 PUNCT F

Patients 0 NOUN T
receiving 0 VERB F
BCT 0 NOUN T
and 0 CCONJ F
50Gy 0 PUNCT F
whole 0 ADJ F
breast 0 NOUN F
irradiation 0 NOUN F
were 0 VERB F
randomized 0 VERB F
to 0 ADP F
no 0 CCONJ F
boost 0 ADV F
and 0 CCONJ F
16Gy 0 PUNCT F
boost 0 PUNCT F
( 0 PUNCT F
N=5318 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

RESULTS 0 NOUN T
In 0 ADP T
univariate 0 ADJ F
analysis 0 NOUN F
, 0 PUNCT F
a 0 DET F
boost 0 ADP F
reduced 0 DET F
local B-PHYSICAL ADJ F
failure I-PHYSICAL NOUN F
by 0 ADP F
a 0 DET F
factor 0 NOUN F
of 0 ADP F
2 0 NUM F
( 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.0001 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Multivariate 0 ADJ T
analysis 0 NOUN F
showed 0 VERB F
local B-PHYSICAL ADJ F
control I-PHYSICAL NOUN F
increased 0 VERB F
with 0 ADP F
age 0 NOUN F
( 0 PUNCT F
P=0.0003 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

There 0 PUNCT T
was 0 VERB F
no 0 DET F
evidence 0 NOUN F
that 0 ADP F
the 0 DET F
relative 0 ADJ F
effect 0 NOUN F
of 0 ADP F
a 0 DET F
boost 0 ADV F
on 0 ADP F
local B-PHYSICAL ADJ F
control I-PHYSICAL NOUN F
depends 0 NOUN F
on 0 ADP F
age 0 NOUN F
( 0 PUNCT F
P=0.97 0 NOUN T
) 0 PUNCT F
However 0 ADV T
in 0 ADP F
younger 0 PUNCT F
patients 0 NOUN F
the 0 DET F
5-year 0 ADJ F
local B-PHYSICAL ADJ F
failure I-PHYSICAL NOUN F
was 0 VERB F
higher 0 PUNCT F
, 0 PUNCT F
therefore 0 ADV F
the 0 DET F
absolute 0 ADJ F
reduction 0 NOUN F
was 0 VERB F
greater 0 PUNCT F
. 0 PUNCT F

If 0 PUNCT T
the 0 DET F
threshold-age 0 NOUN F
for 0 ADP F
boost 0 PUNCT F
treatment 0 NOUN F
were 0 VERB F
set 0 ADP F
at 0 ADP F
40 0 NUM F
years 0 NOUN F
, 0 PUNCT F
8.4 0 NUM F
% 0 SYM F
of 0 ADP F
the 0 DET F
study 0 ADV F
population 0 NOUN F
would 0 VERB F
receive 0 VERB F
a 0 DET F
boost 0 ADV F
, 0 PUNCT F
resulting 0 VERB F
in 0 ADP F
a 0 DET F
5-year 0 ADJ F
local B-PHYSICAL ADJ F
failure I-PHYSICAL NOUN F
of 0 ADP F
6.1 0 NUM F
% 0 SYM F
in 0 ADP F
the 0 DET F
study 0 ADV F
population 0 NOUN F
. 0 PUNCT F

Changing 0 PROPN T
the 0 DET F
threshold-age 0 NOUN F
to 0 ADP F
60 0 NUM F
years 0 NOUN F
, 0 PUNCT F
67 0 NUM F
% 0 SYM F
of 0 ADP F
the 0 DET F
study 0 ADV F
population 0 NOUN F
would 0 VERB F
receive 0 VERB F
a 0 DET F
boost 0 ADV F
and 0 CCONJ F
the 0 DET F
5-year 0 ADJ F
local B-PHYSICAL ADJ F
failure I-PHYSICAL NOUN F
would 0 VERB F
be 0 VERB F
reduced 0 VERB F
to 0 ADP F
4.4 0 NUM F
% 0 SYM F
. 0 PUNCT F

CONCLUSIONS 0 NOUN T
In 0 ADP T
younger 0 PUNCT F
patients 0 NOUN F
a 0 DET F
boost 0 PUNCT F
dose 0 NOUN F
resulted 0 VERB F
in 0 ADP F
a 0 DET F
greater 0 PUNCT F
absolute 0 ADJ F
reduction 0 NOUN F
of 0 ADP F
local B-PHYSICAL ADJ F
failure I-PHYSICAL NOUN F
. 0 PUNCT F

The 0 DET T
relative 0 ADJ F
risk 0 NOUN F
reduction B-OTHER NOUN F
was 0 ADJ F
however 0 ADV F
similar 0 ADJ F
for 0 ADP F
all 0 DET F
ages 0 NOUN F
. 0 PUNCT F

Applying 0 VERB T
a 0 DET F
treatment 0 NOUN F
policy 0 NOUN F
with 0 ADP F
a 0 DET F
threshold-age 0 NOUN F
of 0 ADP F
60 0 PUNCT F
would 0 ADJ F
result 0 PRON F
in 0 ADP F
0.6 0 NUM F
% 0 ADV F
increase 0 NOUN F
in 0 ADP F
local B-PHYSICAL ADJ F
failure I-PHYSICAL NOUN F
in 0 ADP F
the 0 DET F
total 0 ADJ F
study 0 NOUN F
population 0 NOUN F
, 0 PUNCT F
while 0 ADP F
sparing 0 PUNCT F
the 0 PUNCT F
boost 0 CCONJ F
to 0 ADP F
1/3 0 NOUN F
of 0 ADP F
the 0 DET F
patients 0 NOUN F
. 0 PUNCT F

Two-year 0 ADJ T
prospective 0 ADJ F
clinical 0 ADJ F
comparison 0 NOUN F
of 0 ADP F
immediate 0 ADJ F
replacement 0 NOUN F
vs. 0 CCONJ F
immediate 0 ADJ F
restoration 0 NOUN F
of 0 ADP F
single 0 ADJ F
tooth 0 NOUN F
in 0 ADP F
the 0 DET F
esthetic 0 ADJ F
zone 0 NOUN F
. 0 PUNCT F

AIM 0 NOUN T
To 0 ADV T
compare 0 NOUN F
the 0 DET F
immediate 0 ADJ F
restoration 0 NOUN F
of 0 ADP F
single 0 ADJ F
implants 0 NOUN F
in 0 ADP F
the 0 DET F
esthetic 0 ADJ F
zones 0 NOUN F
performed 0 VERB F
on 0 ADP F
implants 0 NOUN F
placed 0 PUNCT F
immediately 0 ADV F
after 0 ADP F
tooth 0 NOUN F
extraction 0 NOUN F
or 0 CCONJ F
8 0 NUM F
weeks 0 NOUN F
later 0 ADJ F
( 0 PUNCT F
immediate 0 ADJ F
replacement 0 NOUN F
vs. 0 CCONJ F
immediate 0 ADJ F
restoration 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

METHODS 0 NOUN T
Sixteen 0 NUM T
patients 0 NOUN F
( 0 PUNCT F
10 0 NUM F
women 0 NOUN F
and 0 CCONJ F
6 0 NUM F
men 0 NOUN F
) 0 PUNCT F
with 0 ADP F
a 0 DET F
mean 0 NOUN F
age 0 NOUN F
of 0 ADP F
35 0 NUM F
years 0 NOUN F
( 0 PUNCT F
ranging 0 PUNCT F
from 0 ADP F
21 0 NUM F
to 0 ADP F
49 0 NUM F
years 0 NOUN F
old 0 ADJ F
) 0 PUNCT F
were 0 VERB F
treated 0 VERB F
from 0 ADP F
2004 0 NUM F
to 0 ADP F
2005 0 NUM F
for 0 ADP F
single-tooth 0 PUNCT F
replacement 0 NOUN F
in 0 ADP F
the 0 DET F
upper 0 ADJ F
arch 0 NOUN F
. 0 PUNCT F

The 0 DET T
patients 0 NOUN F
were 0 VERB F
randomly 0 ADV F
divided 0 VERB F
into 0 ADP F
two 0 NUM F
groups 0 NOUN F
: 0 PUNCT F
in 0 ADP F
the 0 DET F
test 0 ADV F
group 0 NOUN F
patients 0 NOUN F
received 0 DET F
implants 0 NOUN F
placed 0 ADP F
and 0 CCONJ F
restored 0 ADJ F
( 0 PUNCT F
non-occlusal 0 ADJ F
loading 0 VERB F
) 0 PUNCT F
at 0 ADP F
the 0 DET F
time 0 NOUN F
of 0 ADP F
tooth 0 NOUN F
extraction 0 NOUN F
; 0 PUNCT F
in 0 ADP F
the 0 DET F
control 0 NOUN F
group 0 NOUN F
implants 0 NOUN F
were 0 VERB F
placed 0 VERB F
8 0 NUM F
weeks 0 NOUN F
after 0 ADP F
tooth 0 NOUN F
extraction 0 NOUN F
and 0 CCONJ F
immediately 0 ADV F
restored 0 VERB F
. 0 PUNCT F

All 0 DET T
the 0 DET F
patients 0 NOUN F
received 0 DET F
tapered 0 PUNCT F
effect 0 NOUN F
( 0 PUNCT F
TE 0 NOUN T
) 0 PUNCT F
implants 0 NOUN F
from 0 ADP F
the 0 DET F
Straumann 0 NOUN T
Dental 0 ADJ T
Implant 0 NOUN T
System 0 NOUN T
. 0 PUNCT F

The 0 DET T
following 0 ADJ F
parameters 0 NOUN F
were 0 VERB F
evaluated 0 VERB F
at 0 ADP F
the 0 DET F
moment 0 ADJ F
of 0 ADP F
provisional 0 ADJ F
restoration 0 NOUN F
( 0 PUNCT F
within 0 ADP F
48 0 NUM F
h 0 NOUN F
after 0 ADP F
implant 0 NOUN F
placement 0 NOUN F
) 0 PUNCT F
and 0 CCONJ F
at 0 ADP F
the 0 DET F
2 0 NUM F
years 0 NOUN F
follow-up 0 NOUN F
visit 0 NOUN F
: 0 PUNCT F
marginal B-PHYSICAL ADJ F
bone I-PHYSICAL NOUN F
resorption I-PHYSICAL NOUN F
, 0 PUNCT F
papilla B-PHYSICAL NOUN F
index 0 NOUN F
, 0 PUNCT F
position 0 NOUN F
of B-PHYSICAL ADP F
the I-PHYSICAL DET F
mucosal I-PHYSICAL ADJ F
margin I-PHYSICAL NOUN F
. 0 PUNCT F

The 0 DET T
implant B-PHYSICAL NOUN F
stability I-PHYSICAL NOUN F
quotient I-PHYSICAL NOUN F
was 0 VERB F
measured 0 VERB F
at 0 ADP F
the 0 DET F
moment 0 ADJ F
of 0 ADP F
implant 0 NOUN F
placement 0 NOUN F
and 0 CCONJ F
at 0 ADP F
the 0 DET F
moment 0 ADJ F
of 0 ADP F
the 0 DET F
delivery 0 NOUN F
of 0 ADP F
the 0 DET F
definitive 0 ADJ F
restoration 0 NOUN F
. 0 PUNCT F

RESULTS 0 PUNCT T
No 0 DET T
statistically 0 ADV F
significant 0 ADJ F
differences 0 NOUN F
were 0 VERB F
found 0 VERB F
in 0 ADP F
any 0 PUNCT F
of 0 ADP F
the 0 DET F
studied 0 DET F
parameters 0 NOUN F
between 0 ADP F
the 0 DET F
test 0 NOUN F
and 0 CCONJ F
the 0 DET F
control 0 NOUN F
groups 0 NOUN F
( 0 PUNCT F
P 0 NOUN T
> 0 SYM F
0.05 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
implant B-PHYSICAL NOUN F
stability 0 NOUN F
quotient 0 NOUN F
values 0 NOUN F
between 0 ADP F
the 0 DET F
test 0 NOUN F
and 0 CCONJ F
control 0 NOUN F
groups 0 NOUN F
were 0 VERB F
significant 0 ADJ F
( 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.05 0 NUM F
) 0 PUNCT F
at 0 ADP F
the 0 DET F
moment 0 ADJ F
of 0 ADP F
implant 0 NOUN F
placement 0 NOUN F
but 0 CCONJ F
were 0 VERB F
no 0 DET F
more 0 DET F
significant 0 ADJ F
at 0 ADP F
the 0 DET F
loading 0 VERB F
of 0 ADP F
the 0 DET F
definitive 0 ADJ F
restoration 0 NOUN F
( 0 PUNCT F
P 0 NOUN T
> 0 SYM F
0.05 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

CONCLUSION 0 NOUN T
The 0 DET T
results 0 NOUN F
of 0 ADP F
the 0 DET F
present 0 ADJ F
study 0 NOUN F
suggest 0 VERB F
that 0 ADP F
immediate 0 ADJ F
replacement 0 NOUN F
without 0 ADP F
functional 0 ADJ F
loading 0 VERB F
may 0 VERB F
be 0 VERB F
considered 0 VERB F
a 0 DET F
valuable 0 ADJ F
therapeutic 0 ADJ F
option 0 NOUN F
for 0 ADP F
selected 0 VERB F
cases 0 NOUN F
of 0 ADP F
single-tooth 0 PUNCT F
replacement 0 NOUN F
in 0 ADP F
the 0 DET F
esthetic 0 ADJ F
area 0 NOUN F
when 0 ADP F
TE 0 NOUN T
implants 0 NOUN F
are 0 VERB F
used 0 VERB F
. 0 PUNCT F

Implant B-PHYSICAL NOUN T
stability I-PHYSICAL NOUN F
at 0 ADP F
the 0 DET F
moment 0 ADJ F
of 0 ADP F
implant 0 NOUN F
placement 0 NOUN F
is 0 VERB F
slightly 0 ADV F
inferior 0 ADJ F
in 0 ADP F
the 0 DET F
immediate 0 ADJ F
replacement 0 NOUN F
group 0 NOUN F
, 0 PUNCT F
but 0 CCONJ F
it 0 PRON F
does 0 PUNCT F
not 0 ADV F
affect 0 VERB F
the 0 DET F
treatment 0 NOUN F
result 0 NOUN F
. 0 PUNCT F

Postoperative B-PAIN ADJ T
pain I-PAIN NOUN F
control I-PAIN NOUN F
for 0 ADP F
outpatient 0 ADJ F
oral 0 ADJ F
surgery 0 NOUN F
. 0 PUNCT F

16 0 NUM F
healthy 0 ADJ F
patients 0 NOUN F
requiring 0 DET F
removal 0 NOUN F
of 0 ADP F
bilateral 0 ADJ F
symmetrically-impacted 0 ADJ F
mandibular 0 ADJ F
third 0 ADJ F
molars 0 NOUN F
participated 0 DET F
in 0 ADP F
a 0 DET F
double-blind 0 ADJ F
randomised 0 VERB F
crossover 0 NOUN F
trial 0 NOUN F
to 0 ADP F
test 0 NOUN F
the 0 DET F
effectiveness 0 NOUN F
of 0 ADP F
postoperative B-PAIN ADJ F
pain I-PAIN NOUN F
control I-PAIN NOUN F
using 0 VERB F
a 0 DET F
long-acting 0 VERB F
anti-inflammatory 0 ADJ F
agent 0 NOUN F
( 0 PUNCT F
diflunisal 0 ADP F
) 0 PUNCT F
in 0 ADP F
combination 0 NOUN F
with 0 ADP F
a 0 DET F
long-acting 0 VERB F
local 0 ADJ F
anaesthetic 0 ADJ F
agent 0 NOUN F
( 0 PUNCT F
bupivacaine 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

Results 0 NOUN T
were 0 VERB F
compared 0 VERB F
to 0 ADP F
the 0 DET F
more 0 DET F
traditional 0 ADJ F
method 0 NOUN F
of 0 ADP F
using 0 PUNCT F
an 0 DET F
oral 0 ADJ F
analgesic 0 CCONJ F
with 0 ADP F
shorter 0 PUNCT F
duration 0 NOUN F
of 0 ADP F
action 0 NOUN F
( 0 PUNCT F
paracetamol 0 NOUN F
with 0 ADP F
codeine 0 NOUN F
) 0 PUNCT F
with 0 ADP F
lignocaine 0 ADP F
as 0 ADP F
the 0 DET F
local 0 ADJ F
anaesthetic 0 ADJ F
. 0 PUNCT F

Using 0 ADJ T
a 0 DET F
visual B-PAIN ADJ F
analogue I-PAIN NOUN F
pain I-PAIN NOUN F
scale 0 NOUN F
, 0 PUNCT F
patients 0 NOUN F
reported 0 VERB F
that 0 ADP F
significantly 0 ADV F
reduced 0 ADV F
pain B-PAIN NOUN F
was 0 VERB F
experienced 0 VERB F
over 0 ADP F
the 0 DET F
first 0 ADJ F
4 0 NUM F
days 0 NOUN F
postoperatively 0 ADV F
with 0 ADP F
the 0 DET F
diflunisal/bupivacaine 0 NOUN F
treatment 0 NOUN F
and 0 CCONJ F
patient B-PAIN NOUN F
preference I-PAIN NOUN F
for 0 ADP F
this 0 DET F
treatment 0 NOUN F
was 0 VERB F
highly 0 ADV F
significant 0 ADJ F
. 0 PUNCT F

This 0 DET T
report 0 NOUN F
represents 0 NOUN F
the 0 DET F
first 0 CCONJ F
such 0 DET F
study 0 NOUN F
of 0 ADP F
diflunisal 0 ADJ F
used 0 PUNCT F
for 0 ADP F
an 0 DET F
extended 0 VERB F
course 0 NOUN F
in 0 ADP F
oral 0 ADJ F
surgery 0 NOUN F
with 0 ADP F
pain B-PAIN NOUN F
assessment 0 NOUN F
over 0 ADP F
the 0 DET F
same 0 ADJ F
period 0 NOUN F
. 0 PUNCT F

No 0 DET T
significant 0 ADJ F
side-effects B-ADVERSE-EFFECTS NOUN F
or I-ADVERSE-EFFECTS CCONJ F
adverse I-ADVERSE-EFFECTS ADJ F
reactions I-ADVERSE-EFFECTS NOUN F
were 0 VERB F
encountered 0 VERB F
. 0 PUNCT F

The 0 DET T
immunogenicity B-PHYSICAL NOUN F
of 0 ADP F
three 0 NUM F
Haemophilus 0 NOUN T
influenzae 0 PUNCT F
type 0 NOUN F
B 0 NOUN T
conjugate 0 PUNCT F
vaccines 0 NOUN F
after 0 ADP F
a 0 DET F
primary 0 ADJ F
vaccination 0 NOUN F
series 0 NOUN F
in 0 ADP F
Philippine 0 PUNCT T
infants 0 NOUN F
. 0 PUNCT F

Serum B-PHYSICAL NOUN T
antibody I-PHYSICAL NOUN F
responses I-PHYSICAL NOUN F
to 0 ADP F
three 0 NUM F
Haemophilus 0 NOUN T
influenzae 0 PUNCT F
type 0 NOUN F
b 0 NOUN F
( 0 PUNCT F
Hib 0 NOUN T
) 0 PUNCT F
capsular 0 ADJ F
polysaccharide-protein 0 NOUN F
conjugate 0 ADJ F
vaccine 0 NOUN F
( 0 PUNCT F
PRP-OMP 0 NOUN T
, 0 PUNCT F
PRP-T 0 NOUN T
, 0 PUNCT F
and 0 CCONJ F
HbOC 0 NOUN T
) 0 PUNCT F
were 0 VERB F
evaluated 0 VERB F
in 0 ADP F
174 0 NUM F
Philippine 0 PUNCT T
infants 0 NOUN F
after 0 ADP F
a 0 DET F
primary 0 ADJ F
vaccination 0 NOUN F
series 0 NOUN F
. 0 PUNCT F

Children 0 NOUN T
were 0 VERB F
randomized 0 VERB F
to 0 PART F
receive 0 NOUN F
one 0 NUM F
of 0 ADP F
the 0 DET F
Hib 0 NOUN T
vaccines 0 NOUN F
( 0 PUNCT F
Hib 0 NOUN T
groups 0 NOUN F
) 0 PUNCT F
or 0 CCONJ F
into 0 ADP F
a 0 DET F
control 0 NOUN F
group 0 NOUN F
. 0 PUNCT F

Vaccination 0 NOUN T
was 0 VERB F
carried 0 VERB F
out 0 ADP F
at 0 ADP F
six 0 NUM F
, 0 PUNCT F
10 0 NUM F
and 0 CCONJ F
14 0 NUM F
weeks 0 NOUN F
of 0 ADP F
age 0 NOUN F
based 0 VERB F
on 0 ADP F
the 0 DET F
local 0 ADJ F
Expanded 0 ADP T
Program 0 NOUN T
of 0 ADP F
Immunization 0 NOUN T
schedule 0 NOUN F
. 0 PUNCT F

Sera 0 NOUN T
were 0 VERB F
collected 0 VERB F
at 0 ADP F
six 0 NUM F
weeks 0 NOUN F
of 0 ADP F
age 0 NOUN F
for 0 ADP F
the 0 DET F
Hib 0 NOUN T
groups 0 NOUN F
and 0 CCONJ F
one 0 NUM F
month 0 NOUN F
after 0 ADP F
the 0 DET F
third 0 ADJ F
dose 0 NOUN F
for 0 ADP F
all 0 DET F
subjects 0 NOUN F
. 0 PUNCT F

Anti-Hib B-PHYSICAL NOUN T
concentrations I-PHYSICAL NOUN F
were 0 VERB F
determined 0 VERB F
by 0 ADP F
the 0 DET F
Farr-type 0 NOUN T
radioimmunoassay 0 NOUN F
. 0 PUNCT F

There 0 PUNCT T
were 0 VERB F
no 0 DET F
significant 0 ADJ F
differences 0 NOUN F
( 0 PUNCT F
P 0 NOUN T
= 0 SYM F
0.3626 0 NUM F
) 0 PUNCT F
in 0 ADP F
the 0 DET F
prevaccination B-PHYSICAL NOUN F
anti-Hib I-PHYSICAL NOUN F
geometric 0 ADJ F
mean 0 NOUN F
concentration 0 NOUN F
( B-PHYSICAL PUNCT F
GMC B-PHYSICAL NOUN T
) B-PHYSICAL PUNCT F
among 0 ADP F
the 0 DET F
three 0 NUM F
Hib 0 NOUN T
groups 0 NOUN F
. 0 PUNCT F

Differences 0 NOUN T
in 0 ADP F
the 0 PUNCT F

Virtual 0 ADJ T
reality 0 NOUN F
for 0 ADP F
acute 0 ADJ F
pain 0 NOUN F
reduction 0 NOUN F
in 0 ADP F
adolescents 0 NOUN F
undergoing 0 VERB F
burn 0 NOUN F
wound 0 NOUN F
care 0 NOUN F
: 0 PUNCT F
a 0 DET F
prospective 0 ADJ F
randomized 0 VERB F
controlled 0 VERB F
trial 0 NOUN F
. 0 PUNCT F

BACKGROUND 0 NOUN T
Effective 0 ADJ T
pain 0 NOUN F
management 0 NOUN F
remains 0 NOUN F
a 0 DET F
challenge 0 NOUN F
for 0 ADP F
adolescents 0 NOUN F
during 0 ADP F
conscious 0 ADJ F
burn 0 NOUN F
wound 0 NOUN F
care 0 NOUN F
procedures 0 NOUN F
. 0 PUNCT F

Virtual 0 ADJ T
reality 0 NOUN F
( 0 PUNCT F
VR 0 NOUN T
) 0 PUNCT F
shows 0 VERB F
promise 0 PUNCT F
as 0 ADP F
a 0 DET F
non-pharmacological 0 ADJ F
adjunct 0 NOUN F
in 0 ADP F
reducing 0 PROPN F
pain 0 NOUN F
. 0 PUNCT F

AIMS 0 PUNCT T
This 0 DET T
study 0 NOUN F
assessed 0 VERB F
off-the-shelf 0 PUNCT F
VR 0 NOUN T
for 0 ADP F
( 0 PUNCT F
1 0 NUM F
) 0 PUNCT F
its 0 PUNCT F
effect 0 NOUN F
on 0 ADP F
reducing 0 SYM F
acute 0 ADJ F
pain 0 NOUN F
intensity 0 NOUN F
during 0 ADP F
adolescent 0 NOUN F
burn 0 ADJ F
wound 0 NOUN F
care 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
( 0 PUNCT F
2 0 NUM F
) 0 PUNCT F
its 0 ADP F
clinical 0 ADJ F
utility 0 NOUN F
in 0 ADP F
a 0 DET F
busy 0 NOUN F
hospital 0 NOUN F
setting 0 VERB F
. 0 PUNCT F

METHODS 0 NOUN T
Forty-one 0 NUM T
adolescents 0 NOUN F
( 0 PUNCT F
11-17 0 PUNCT F
years 0 NOUN F
) 0 PUNCT F
participated 0 PUNCT F
in 0 ADP F
this 0 DET F
prospective 0 ADJ F
randomized 0 VERB F
controlled 0 VERB F
trial 0 NOUN F
. 0 PUNCT F

Acute 0 ADJ T
pain 0 NOUN F
outcomes 0 NOUN F
including 0 VERB F
adolescent 0 NOUN F
self-report 0 ADJ F
, 0 PUNCT F
nursing 0 ADP F
staff 0 NOUN F
behavioral 0 ADJ F
observation 0 NOUN F
, 0 PUNCT F
caregiver 0 NOUN F
observation 0 NOUN F
and 0 CCONJ F
physiological 0 ADJ F
measures 0 NOUN F
were 0 VERB F
collected 0 VERB F
. 0 PUNCT F

Length 0 NOUN T
of 0 ADP F
procedure 0 NOUN F
times 0 NOUN F
and 0 CCONJ F
adolescent 0 NOUN F
reactions 0 NOUN F
were 0 VERB F
also 0 ADV F
recorded 0 VERB F
to 0 PART F
inform 0 VERB F
clinical 0 ADJ F
utility 0 NOUN F
. 0 PUNCT F

RESULTS 0 ADJ T
Nursing 0 PUNCT T
staff 0 NOUN F
reported 0 VERB F
a 0 DET F
statistically 0 ADV F
significant 0 ADJ F
reduction 0 NOUN F
in 0 ADP F
pain B-PHYSICAL NOUN F
scores I-PHYSICAL NOUN F
during 0 ADP F
dressing 0 PUNCT F
removal 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
significantly 0 ADV F
less 0 DET F
rescue B-PHYSICAL PUNCT F
doses I-PHYSICAL NOUN F
of I-PHYSICAL ADP F
Entonox I-PHYSICAL NOUN T
given 0 ADJ F
to 0 ADP F
those 0 PUNCT F
receiving 0 VERB F
VR 0 NOUN T
, 0 PUNCT F
compared 0 VERB F
to 0 ADP F
those 0 PUNCT F
receiving 0 VERB F
standard 0 ADJ F
distraction 0 NOUN F
. 0 PUNCT F

For 0 ADP T
all 0 DET F
other 0 ADJ F
pain 0 NOUN F
outcomes 0 NOUN F
and 0 CCONJ F
length 0 NOUN F
of 0 ADP F
treatment 0 NOUN F
, 0 PUNCT F
there 0 PUNCT F
was 0 VERB F
a 0 DET F
trend 0 NOUN F
for 0 ADP F
lower 0 PUNCT F
pain B-OTHER NOUN F
scores I-OTHER NOUN F
and I-OTHER PUNCT F
treatment 0 PUNCT F

Levobunolol 0 NOUN T
compared 0 VERB F
with 0 ADP F
timolol 0 NOUN F
: 0 PUNCT F
a 0 DET F
four-year 0 ADJ F
study 0 NOUN F
. 0 PUNCT F

Fifty-one 0 NUM T
patients 0 NOUN F
with 0 ADP F
raised 0 VERB F
intraocular 0 ADJ F
pressure 0 NOUN F
( 0 PUNCT F
IOP 0 NOUN T
) 0 PUNCT F
were 0 VERB F
treated 0 VERB F
for 0 ADP F
up 0 PUNCT F
to 0 ADV F
four 0 NUM F
years 0 NOUN F
with 0 ADP F
one 0 NUM F
of 0 ADP F
three 0 NUM F
ophthalmic 0 ADJ F
solutions 0 NOUN F
: 0 PUNCT F
0.5 0 NUM F
% 0 SYM F
levobunolol 0 NOUN F
, 0 PUNCT F
1 0 NUM F
% 0 SYM F
levobunolol 0 NOUN F
, 0 PUNCT F
or 0 CCONJ F
0.5 0 NUM F
% 0 SYM F
timolol 0 NOUN F
. 0 PUNCT F

The 0 DET T
study 0 NOUN F
was 0 VERB F
conducted 0 VERB F
as 0 ADP F
a 0 DET F
double-masked 0 NOUN F
, 0 PUNCT F
randomised 0 VERB F
trial 0 NOUN F
in 0 ADP F
which 0 DET F
medications 0 NOUN F
were 0 VERB F
administered 0 VERB F
twice 0 ADV F
daily 0 ADJ F
to 0 ADP F
both 0 PUNCT F
eyes 0 NOUN F
. 0 PUNCT F

Levobunolol 0 NOUN T
and 0 CCONJ F
timolol 0 NOUN F
were 0 VERB F
equally 0 ADV F
effective 0 ADJ F
in 0 ADP F
reducing 0 VERB F
overall B-PHYSICAL ADJ F
mean 0 NOUN F
IOP B-PHYSICAL NOUN T
; 0 PUNCT F
reductions 0 NOUN F
were 0 VERB F
greater 0 PUNCT F
than 0 PUNCT F
8.8 0 NUM F
mmHg 0 NOUN F
in 0 ADP F
all 0 DET F
three 0 NUM F
treatment 0 NOUN F
groups 0 NOUN F
. 0 PUNCT F

The 0 DET T
study 0 NOUN F
showed 0 VERB F
levobunolol 0 NOUN F
to 0 PART F
be 0 PUNCT F
as 0 PUNCT F
safe 0 ADJ F
and 0 CCONJ F
effective 0 ADJ F
as 0 PUNCT F
timolol 0 ADJ F
in 0 ADP F
the 0 DET F
long-term 0 NOUN F
control 0 NOUN F
of 0 PUNCT F
raised 0 PUNCT F

Behavioral B-MENTAL ADJ T
changes I-MENTAL NOUN F
in 0 ADP F
autistic 0 ADJ F
individuals 0 NOUN F
as 0 ADP F
a 0 DET F
result 0 NOUN F
of 0 ADP F
wearing 0 PUNCT F
ambient 0 ADJ F
transitional 0 ADJ F
prism 0 NOUN F
lenses 0 NOUN F
. 0 PUNCT F

A 0 DET T
double-blind 0 ADJ F
crossover 0 NOUN F
design 0 NOUN F
was 0 VERB F
used 0 VERB F
to 0 PART F
assess 0 NOUN F
the 0 DET F
efficacy 0 NOUN F
of 0 ADP F
wearing 0 DET F
ambient 0 ADJ F
lenses 0 ADP F
to 0 PUNCT F
reduce 0 NOUN F
the 0 DET F
behavioral 0 ADJ F
symptoms 0 NOUN F
of 0 ADP F
autism 0 NOUN F
. 0 PUNCT F

Eighteen 0 PUNCT T
autistic 0 ADJ F
individuals 0 NOUN F
, 0 PUNCT F
ranging 0 VERB F
in 0 ADP F
age 0 NOUN F
from 0 ADP F
7 0 NUM F
to 0 ADP F
18 0 NUM F
years 0 NOUN F
, 0 PUNCT F
participated 0 DET F
in 0 ADP F
the 0 DET F
study 0 NOUN F
. 0 PUNCT F

Behavior B-MENTAL NOUN T
, 0 PUNCT F
attention B-MENTAL NOUN F
, 0 PUNCT F
and 0 CCONJ F
orientation B-MENTAL NOUN F
were 0 VERB F
evaluated 0 VERB F
at 0 ADP F
1 0 NUM F
1/2 0 NOUN F
months 0 NOUN F
, 0 PUNCT F
2 0 NUM F
months 0 NOUN F
, 0 PUNCT F
3 0 NUM F
months 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
4 0 NUM F
months 0 NOUN F
. 0 PUNCT F

Compared 0 VERB T
to 0 ADP F
the 0 DET F
placebo 0 NOUN F
condition 0 NOUN F
, 0 PUNCT F
the 0 DET F
results 0 NOUN F
showed 0 VERB F
a 0 DET F
decrease 0 NOUN F
in 0 ADP F
behavior B-MENTAL NOUN F
problems I-MENTAL NOUN F
at 0 ADP F
the 0 DET F
1 0 NUM F
1/2 0 NOUN F
and 0 CCONJ F
2 0 NUM F
month 0 NOUN F
assessment 0 NOUN F
periods 0 NOUN F
and 0 CCONJ F
a 0 DET F
slight 0 ADJ F
loss 0 NOUN F
of 0 ADP F
these 0 DET F
benefits 0 NOUN F
at 0 ADP F
the 0 DET F
3 0 NUM F
and 0 CCONJ F
4 0 NUM F
month 0 NOUN F
assessment 0 NOUN F
periods 0 NOUN F
. 0 PUNCT F

These 0 DET T
findings 0 NOUN F
support 0 VERB F
the 0 DET F
prediction 0 NOUN F
that 0 ADP F
ambient 0 ADJ F
lenses 0 NOUN F
, 0 PUNCT F
worn 0 PUNCT F
without 0 ADP F
engaging 0 PUNCT F
in 0 ADP F
visual-motor 0 NOUN F
exercises 0 NOUN F
, 0 PUNCT F
have 0 CCONJ F
positive 0 ADJ F
effects 0 NOUN F
on 0 ADP F
autistic 0 ADJ F
individuals 0 NOUN F
. 0 PUNCT F

Low-dose 0 NOUN T
mifepristone 0 NOUN F
for 0 ADP F
uterine 0 ADJ F
leiomyomata 0 NOUN F
. 0 PUNCT F

OBJECTIVE 0 NOUN T
To 0 PROPN T
compare 0 NOUN F
the 0 DET F
effect 0 NOUN F
of 0 ADP F
5 0 NUM F
and 0 CCONJ F
10 0 NUM F
mg 0 NOUN F
of 0 ADP F
mifepristone 0 NOUN F
on 0 ADP F
uterine B-PHYSICAL ADJ F
leiomyoma I-PHYSICAL NOUN F
size 0 NOUN F
and 0 CCONJ F
symptoms B-PHYSICAL NOUN F
, 0 PUNCT F
and 0 CCONJ F
to 0 PART F
measure 0 ADJ F
side 0 NOUN F
effects 0 NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
Forty 0 CCONJ T
premenopausal 0 ADJ F
women 0 NOUN F
with 0 ADP F
large 0 ADJ F
, 0 PUNCT F
symptomatic 0 ADJ F
leiomyomata 0 NOUN F
were 0 VERB F
randomized 0 VERB F
to 0 PART F
receive 0 NOUN F
either 0 PUNCT F
5 0 NUM F
or 0 CCONJ F
10 0 NUM F
mg 0 NOUN F
of 0 ADP F
mifepristone 0 NOUN F
daily 0 ADJ F
for 0 ADP F
6 0 NUM F
months 0 NOUN F
in 0 ADP F
an 0 DET F
open-label 0 NOUN F
study 0 NOUN F
. 0 PUNCT F

Uterine 0 ADJ T
volume 0 NOUN F
was 0 VERB F
measured 0 VERB F
at 0 ADP F
bimonthly 0 PUNCT F
intervals 0 NOUN F
by 0 ADP F
sonography 0 NOUN F
. 0 PUNCT F

Serum 0 NOUN T
concentrations 0 NOUN F
of 0 ADP F
hemoglobin 0 NOUN F
levels 0 NOUN F
, 0 PUNCT F
follicle-stimulating 0 VERB F
hormone 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
liver 0 NOUN F
enzymes 0 NOUN F
were 0 VERB F
obtained 0 VERB F
, 0 PUNCT F
and 0 CCONJ F
endometrial 0 ADJ F
samples 0 NOUN F
, 0 PUNCT F
symptoms 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
menstrual 0 ADJ F
bleeding 0 VERB F
were 0 VERB F
also 0 ADV F
assessed 0 VERB F
. 0 PUNCT F

RESULTS 0 NOUN T
Nineteen 0 PUNCT T
of 0 ADP F
20 0 NUM F
subjects 0 NOUN F
taking 0 ADP F
5 0 NUM F
mg 0 NOUN F
and 0 CCONJ F
all 0 DET F
20 0 NUM F
subjects 0 NOUN F
taking 0 ADP F
10 0 NUM F
mg 0 NOUN F
completed 0 ADV F
all 0 PUNCT F
6 0 NUM F
months 0 NOUN F
of 0 ADP F
the 0 DET F
study 0 NOUN F
. 0 PUNCT F

Mean 0 ADJ T
uterine B-PHYSICAL ADJ F
volume I-PHYSICAL NOUN F
shrank I-PHYSICAL NOUN F
by 0 ADP F
48 0 NUM F
% 0 SYM F
( 0 PUNCT F
P 0 NOUN T
< 0 SYM F
.001 0 NUM F
) 0 PUNCT F
in 0 ADP F
the 0 DET F
5-mg 0 PUNCT F
group 0 NOUN F
and 0 CCONJ F
49 0 NUM F
% 0 SYM F
( 0 PUNCT F
P 0 NOUN T
< 0 SYM F
.001 0 NUM F
) 0 PUNCT F
in 0 ADP F
the 0 DET F
10-mg 0 PUNCT F
group 0 NOUN F
, 0 PUNCT F
a 0 DET F
nonsignificant 0 ADJ F
difference 0 NOUN F
. 0 PUNCT F

Leiomyoma-related B-PHYSICAL VERB T
symptoms I-PHYSICAL NOUN F
were 0 VERB F
comparably 0 ADV F
reduced 0 VERB F
in 0 ADP F
both 0 CCONJ F
groups 0 NOUN F
. 0 PUNCT F

Amenorrhea B-PHYSICAL NOUN T
occurred 0 VERB F
in 0 ADP F
60-65 0 NUM F
% 0 SYM F
of 0 ADP F
both 0 CCONJ F
groups 0 NOUN F
. 0 PUNCT F

Hemoglobin B-PHYSICAL NOUN T
levels I-PHYSICAL NOUN F
increased 0 PRON F
by 0 ADP F
2.5 0 NUM F
g/dL 0 ADV F
in 0 ADP F
anemic 0 ADJ F
subjects 0 NOUN F
. 0 PUNCT F

The 0 DET T
incidence 0 NOUN F
of 0 ADP F
hot B-PHYSICAL ADJ F
flashes I-PHYSICAL NOUN F
increased 0 VERB F
significantly 0 ADV F
over 0 ADP F
baseline 0 NOUN F
in 0 ADP F
the 0 DET F
10-mg 0 PUNCT F
group 0 NOUN F
but 0 CCONJ F
not 0 ADV F
in 0 ADP F
the 0 DET F
5-mg 0 PUNCT F
group 0 NOUN F
. 0 PUNCT F

Simple B-PHYSICAL ADJ T
endometrial I-PHYSICAL ADJ F
hyperplasia I-PHYSICAL NOUN F
occurred 0 VERB F
in 0 ADP F
28 0 NUM F
% 0 SYM F
of 0 ADP F
all 0 DET F
subjects 0 NOUN F
, 0 PUNCT F
with 0 ADP F
no 0 DET F
difference 0 NOUN F
between 0 ADP F
groups 0 NOUN F
. 0 PUNCT F

No 0 DET T
atypical B-PHYSICAL ADJ F
hyperplasia I-PHYSICAL NOUN F
was 0 VERB F
noted 0 VERB F
. 0 PUNCT F

CONCLUSION 0 NOUN T
Mifepristone 0 NOUN T
in 0 ADP F
doses 0 NOUN F
of 0 ADP F
5 0 NUM F
mg 0 NOUN F
or 0 CCONJ F
10 0 NUM F
mg 0 NOUN F
results 0 NOUN F
in 0 ADP F
comparable 0 ADJ F
leiomyoma B-PHYSICAL NOUN F
regression I-PHYSICAL NOUN F
, 0 PUNCT F
improvement B-OTHER NOUN F
in I-OTHER ADP F
symptoms I-OTHER NOUN F
, 0 PUNCT F
and 0 CCONJ F
few 0 ADJ F
side B-ADVERSE-EFFECTS NOUN F
effects I-ADVERSE-EFFECTS NOUN F
. 0 PUNCT F

Further 0 DET T
study 0 NOUN F
is 0 VERB F
needed 0 VERB F
to 0 PART F
assess 0 NOUN F
the 0 DET F
long-term 0 NOUN F
safety 0 NOUN F
and 0 CCONJ F
efficacy 0 NOUN F
of 0 ADP F
low-dose 0 NOUN F
mifepristone 0 NOUN F
. 0 PUNCT F

Prevalence 0 NOUN T
and 0 CCONJ F
treatment 0 NOUN F
outcome 0 NOUN F
of 0 ADP F
cervicitis B-PHYSICAL NOUN F
of 0 ADP F
unknown 0 VERB F
etiology 0 NOUN F
. 0 PUNCT F

BACKGROUND 0 NOUN T
Mucopurulent 0 ADJ T
cervicitis 0 NOUN F
( 0 PUNCT F
MPC 0 NOUN T
) 0 PUNCT F
is 0 VERB F
a 0 DET F
clinical 0 ADJ F
syndrome 0 NOUN F
characterized 0 VERB F
by 0 ADP F
mucopurulent 0 ADJ F
discharge 0 NOUN F
from 0 ADP F
the 0 DET F
cervix 0 NOUN F
and 0 CCONJ F
other 0 ADJ F
signs 0 NOUN F
of 0 ADP F
inflammation 0 NOUN F
. 0 PUNCT F

This 0 DET T
was 0 VERB F
a 0 DET F
phase 0 NOUN F
III 0 NUM T
, 0 PUNCT F
multicenter 0 NOUN F
study 0 NOUN F
designed 0 VERB F
to 0 PART F
evaluate 0 NOUN F
the 0 DET F
effectiveness 0 NOUN F
of 0 ADP F
placebo 0 NOUN F
versus 0 CCONJ F
empiric 0 ADJ F
antibiotic 0 ADJ F
treatment 0 NOUN F
for 0 ADP F
clinical 0 ADJ F
cure 0 NOUN F
of 0 ADP F
MPC B-PHYSICAL NOUN T
of 0 ADP F
unknown 0 VERB F
etiology 0 NOUN F
at 0 ADP F
2-month 0 NOUN F
follow-up 0 NOUN F
. 0 PUNCT F

Unfortunately 0 ADV T
, 0 PUNCT F
enrollment 0 NOUN F
was 0 VERB F
terminated 0 VERB F
because 0 PUNCT F
of 0 ADP F
low 0 ADJ F
accrual 0 ADJ F
of 0 ADP F
women 0 NOUN F
with 0 ADP F
cervicitis 0 NOUN F
of 0 ADP F
unknown 0 VERB F
etiology 0 NOUN F
, 0 PUNCT F
but 0 CCONJ F
important 0 ADJ F
prevalence 0 NOUN F
and 0 CCONJ F
outcome 0 NOUN F
data 0 NOUN F
were 0 VERB F
obtained 0 VERB F
. 0 PUNCT F

METHODS 0 NOUN T
Five 0 NUM T
hundred 0 NUM F
seventy-seven 0 PUNCT F
women 0 NOUN F
were 0 VERB F
screened 0 VERB F
for 0 ADP F
MPC 0 NOUN T
. 0 PUNCT F

Women 0 NOUN T
with 0 ADP F
MPC 0 NOUN T
were 0 VERB F
randomized 0 VERB F
to 0 ADP F
the 0 DET F
treatment 0 NOUN F
or 0 CCONJ F
placebo 0 NOUN F
arm 0 NOUN F
of 0 ADP F
the 0 DET F
study 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
the 0 DET F
2 0 NUM F
arms 0 NOUN F
were 0 VERB F
evaluated 0 VERB F
based 0 VERB F
on 0 ADP F
the 0 DET F
etiology 0 NOUN F
, 0 PUNCT F
clinical B-OTHER ADJ F
cure I-OTHER NOUN F
rates I-OTHER NOUN F
, 0 PUNCT F
adverse B-PHYSICAL ADJ F
events I-PHYSICAL NOUN F
( I-PHYSICAL PUNCT F
AEs I-PHYSICAL ADP T
) I-PHYSICAL PUNCT F
, 0 PUNCT F
and 0 CCONJ F
rates 0 NOUN F
of 0 ADP F
pelvic B-PHYSICAL ADJ F
inflammatory I-PHYSICAL ADJ F
disease I-PHYSICAL NOUN F
. 0 PUNCT F

RESULTS 0 NOUN T
One 0 NUM T
hundred 0 NUM F
thirty-one 0 NOUN F
( 0 PUNCT F
23 0 NUM F
% 0 SYM F
[ 0 PUNCT F
131/577 0 NOUN F
] 0 PUNCT F
) 0 PUNCT F
screened 0 VERB F
women 0 NOUN F
were 0 VERB F
found 0 VERB F
to 0 DET F
have 0 PUNCT F
MPC 0 NOUN T
. 0 PUNCT F

Eighty-seven 0 PUNCT T
were 0 VERB F
enrolled 0 VERB F
and 0 CCONJ F
randomized 0 NUM F
. 0 PUNCT F

After 0 ADP T
excluding 0 ADJ F
women 0 NOUN F
with 0 ADP F
sexually 0 ADV F
transmitted 0 VERB F
infections 0 NOUN F
and 0 CCONJ F
other 0 ADJ F
exclusions 0 NOUN F
, 0 PUNCT F
61 0 NUM F
% 0 SYM F
( 0 PUNCT F
53/87 0 PUNCT F
) 0 PUNCT F
had 0 PUNCT F
cervicitis B-PHYSICAL NOUN F
of 0 ADP F
unknown 0 VERB F
etiology 0 NOUN F
. 0 PUNCT F

The 0 DET T
overall B-OTHER ADJ F
clinical I-OTHER ADJ F
failure I-OTHER NOUN F
rate I-OTHER NOUN F
was 0 VERB F
30 0 NUM F
% 0 SYM F
( 0 PUNCT F
10/33 0 PUNCT F
) 0 PUNCT F
, 0 PUNCT F
and 0 CCONJ F
the 0 DET F
clinical B-OTHER ADJ F
cure I-OTHER NOUN F
rate I-OTHER NOUN F
was 0 VERB F
only 0 ADV F
24 0 NUM F
% 0 SYM F
( 0 PUNCT F
8/33 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

Rates 0 NOUN T
were 0 VERB F
not 0 ADV F
significantly 0 ADV F
different 0 ADJ F
between 0 ADP F
the 0 DET F
arms 0 NOUN F
. 0 PUNCT F

There 0 PUNCT T
were 0 VERB F
24 0 NUM F
gastrointestinal B-PHYSICAL ADJ F
AEs I-PHYSICAL ADP T
in 0 ADP F
the 0 DET F
treatment 0 NOUN F
arm 0 NOUN F
compared 0 VERB F
with 0 ADP F
1 0 NUM F
AE 0 NOUN T
in 0 ADP F
the 0 DET F
placebo 0 NOUN F
arm 0 NOUN F
. 0 PUNCT F

CONCLUSIONS 0 NOUN T
More 0 PUNCT T
than 0 ADP F
half 0 NOUN F
of 0 ADP F
the 0 DET F
cases 0 NOUN F
of 0 ADP F
MPC 0 NOUN T
were 0 ADV F
of 0 ADP F
unknown 0 VERB F
etiology 0 NOUN F
. 0 PUNCT F

Clinical B-OTHER ADJ T
cure I-OTHER NOUN F
rates I-OTHER NOUN F
for 0 ADP F
the 0 DET F
placebo 0 NOUN F
and 0 CCONJ F
treatment 0 NOUN F
arms 0 NOUN F
were 0 VERB F
extremely 0 ADV F
low 0 ADJ F
, 0 PUNCT F
with 0 ADP F
most 0 DET F
women 0 NOUN F
concluding 0 PUNCT F
the 0 DET F
study 0 NOUN F
with 0 ADP F
a 0 DET F
partial 0 ADJ F
response 0 NOUN F
. 0 PUNCT F

Gastrointestinal B-PHYSICAL ADJ T
AEs I-PHYSICAL ADP T
were 0 VERB F
higher 0 PUNCT F
in 0 ADP F
the 0 DET F
treatment 0 NOUN F
arm 0 ADP F
. 0 PUNCT F

Effects 0 NOUN T
of 0 ADP F
two 0 NUM F
combined 0 VERB F
oral 0 ADJ F
contraceptives 0 NOUN F
containing 0 VERB F
ethinyl 0 NOUN F
estradiol 0 NOUN F
20 0 NUM F
microg 0 NOUN F
combined 0 VERB F
with 0 ADP F
either 0 CCONJ F
drospirenone 0 NOUN F
or 0 CCONJ F
desogestrel 0 NOUN F
on 0 ADP F
lipids 0 NOUN F
, 0 PUNCT F
hemostatic 0 ADJ F
parameters 0 NOUN F
and 0 CCONJ F
carbohydrate 0 NOUN F
metabolism 0 NOUN F
. 0 PUNCT F

OBJECTIVE 0 NOUN T
To 0 PROPN T
compare 0 NOUN F
the 0 DET F
effect 0 NOUN F
of 0 ADP F
ethinyl 0 NOUN F
estradiol 0 NOUN F
20 0 NUM F
microg/drospirenone 0 NOUN F
3 0 NUM F
mg 0 NOUN F
( 0 PUNCT F
EE 0 NOUN T
20 0 NUM F
microg/DRSP 0 NOUN F
3 0 NUM F
mg 0 NOUN F
) 0 PUNCT F
administered 0 VERB F
according 0 CCONJ F
to 0 ADP F
a 0 DET F
24/4 0 NOUN F
regimen 0 NOUN F
with 0 ADP F
ethinyl 0 NOUN F
estradiol 0 NOUN F
20 0 NUM F
microg/desogestrel 0 NOUN F
150 0 NUM F
microg 0 NOUN F
( 0 PUNCT F
EE 0 NOUN T
20 0 NUM F
microg/DSG 0 NUM F
150 0 NUM F
microg 0 NOUN F
) 0 PUNCT F
administered 0 VERB F
according 0 CCONJ F
to 0 ADP F
the 0 DET F
conventional 0 ADJ F
21/7 0 PUNCT F
regimen 0 NOUN F
on 0 ADP F
lipid 0 NOUN F
, 0 PUNCT F
carbohydrate 0 NOUN F
and 0 CCONJ F
hemostatic 0 ADJ F
parameters 0 NOUN F
. 0 PUNCT F

STUDY 0 NOUN T
DESIGN 0 NOUN T
In 0 ADP T
this 0 DET F
open-label 0 NOUN F
study 0 NOUN F
, 0 PUNCT F
healthy 0 ADJ F
women 0 NOUN F
were 0 VERB F
randomized 0 VERB F
to 0 ADP F
EE 0 NOUN T
20 0 NUM F
microg/DRSP 0 NOUN F
3 0 NUM F
mg 0 NOUN F
or 0 CCONJ F
EE 0 NOUN T
20 0 NUM F
microg/DSG 0 NUM F
150 0 NUM F
microg 0 NOUN F
for 0 ADP F
seven 0 NUM F
cycles 0 NOUN F
. 0 PUNCT F

Mean 0 PUNCT T
differences 0 NOUN F
in 0 ADP F
high-density B-PHYSICAL NOUN F
lipoprotein I-PHYSICAL NOUN F
( I-PHYSICAL PUNCT F
HDL I-PHYSICAL NOUN T
) I-PHYSICAL PUNCT F
- 0 PUNCT F
and 0 CCONJ F
low-density B-PHYSICAL NOUN F
lipoprotein I-PHYSICAL NOUN F
( I-PHYSICAL PUNCT F
LDL I-PHYSICAL NOUN T
) I-PHYSICAL PUNCT F
-cholesterol I-PHYSICAL NOUN F
levels I-PHYSICAL NOUN F
at 0 ADP F
cycle 0 NOUN F
7 0 NUM F
compared 0 VERB F
to 0 ADP F
baseline 0 NOUN F
were 0 VERB F
assessed 0 VERB F
. 0 PUNCT F

Secondary 0 ADJ T
variables 0 NOUN F
included 0 VERB F
changes 0 NOUN F
in 0 ADP F
other 0 ADJ F
lipid B-PHYSICAL NOUN F
, 0 PUNCT F
hemostatic B-PHYSICAL ADJ F
and 0 CCONJ F
carbohydrate B-PHYSICAL NOUN F
parameters I-PHYSICAL NOUN F
. 0 PUNCT F

RESULTS 0 NOUN T
Both 0 PUNCT T
treatments 0 ADJ F
increased 0 VERB F
HDL-cholesterol B-PHYSICAL NOUN T
, 0 PUNCT F
but 0 CCONJ F
decreased 0 VERB F
LDL-cholesterol B-PHYSICAL NOUN T
by 0 ADP F
a 0 DET F
comparable 0 ADJ F
extent 0 NOUN F
. 0 PUNCT F

Although 0 ADP T
slightly 0 ADV F
elevated 0 VERB F
in 0 ADP F
both 0 CCONJ F
groups 0 NOUN F
, 0 PUNCT F
blood B-PHYSICAL NOUN F
glucose I-PHYSICAL NOUN F
and I-PHYSICAL CCONJ F
C-peptide I-PHYSICAL NOUN T
levels I-PHYSICAL NOUN F
measured 0 VERB F
during 0 ADP F
oral 0 ADJ F
glucose 0 NOUN F
tolerance 0 NOUN F
tests 0 NOUN F
were 0 VERB F
within 0 ADP F
normal 0 ADJ F
reference 0 NOUN F
ranges 0 ADJ F
at 0 ADP F
cycle 0 NOUN F
7 0 NUM F
. 0 PUNCT F

Overall 0 ADJ T
, 0 PUNCT F
the 0 DET F
differences 0 NOUN F
in 0 ADP F
lipid B-PHYSICAL NOUN F
, 0 PUNCT F
hemostatic B-PHYSICAL ADJ F
or I-PHYSICAL CCONJ F
carbohydrate I-PHYSICAL NOUN F
parameters I-PHYSICAL NOUN F
were 0 VERB F
not 0 ADV F
significant 0 ADJ F
between 0 ADP F
the 0 DET F
two 0 ADJ F
treatments 0 NOUN F
. 0 PUNCT F

CONCLUSION 0 NOUN T
EE 0 NOUN T
20 0 NUM F
microg/DRSP 0 NOUN F
3 0 NUM F
mg 0 NOUN F
has 0 CCONJ F
a 0 DET F
good 0 ADJ F
safety 0 NOUN F
profile 0 ADJ F
comparable 0 ADJ F
with 0 ADP F
EE 0 NOUN T
20 0 NUM F
microg/DSG 0 NUM F
150 0 NUM F
microg 0 NOUN F
. 0 PUNCT F

Effect 0 NOUN T
of 0 ADP F
ozone 0 NOUN F
application 0 NOUN F
on 0 ADP F
the 0 DET F
resin-dentin B-OTHER NOUN F
microtensile I-OTHER ADJ F
bond I-OTHER NOUN F
strength I-OTHER NOUN F
. 0 PUNCT F

When 0 ADP T
ozone 0 NOUN F
is 0 VERB F
used 0 VERB F
during 0 ADP F
caries 0 NOUN F
treatment 0 NOUN F
, 0 PUNCT F
bond 0 NOUN F
strength 0 NOUN F
can 0 VERB F
be 0 VERB F
compromised 0 VERB F
by 0 ADP F
the 0 DET F
release 0 NOUN F
of 0 ADP F
oxygen 0 NOUN F
. 0 PUNCT F

The 0 DET T
use 0 NOUN F
of 0 ADP F
antioxidant 0 NOUN F
agents 0 NOUN F
neutralizes 0 NOUN F
the 0 DET F
free 0 ADJ F
oxygen 0 NOUN F
. 0 PUNCT F

The 0 DET T
aim 0 NOUN F
of 0 ADP F
this 0 DET F
study 0 NOUN F
was 0 VERB F
to 0 PART F
evaluate 0 NOUN F
the 0 DET F
effects 0 NOUN F
of 0 ADP F
ozone 0 NOUN F
and 0 CCONJ F
sodium 0 NOUN F
ascorbate 0 NOUN F
on 0 ADP F
resin-dentin 0 NOUN F
microtensile 0 ADJ F
bond 0 NOUN F
strength 0 NOUN F
( 0 PUNCT F
?TBS 0 PUNCT F
) 0 PUNCT F
. 0 PUNCT F

Forty 0 CCONJ T
human 0 NOUN F
third 0 ADJ F
molars 0 NOUN F
were 0 VERB F
divided 0 VERB F
into 0 ADP F
four 0 NUM F
groups 0 NOUN F
: 0 PUNCT F
Group 0 NOUN T
1 0 NUM F
, 0 PUNCT F
not 0 ADV F
treated 0 PUNCT F
with 0 ADP F
ozone 0 NOUN F
; 0 PUNCT F
Group 0 NOUN T
2 0 NUM F
, 0 PUNCT F
ozone 0 NOUN F
application 0 NOUN F
followed 0 VERB F
by 0 ADP F
acid 0 NOUN F
etching 0 VERB F
; 0 PUNCT F
Group 0 NOUN T
3 0 NUM F
, 0 PUNCT F
acid 0 NOUN F
etching 0 PUNCT F
followed 0 VERB F
by 0 ADP F
ozone 0 NOUN F
application 0 NOUN F
; 0 PUNCT F
and 0 CCONJ F
Group 0 NOUN T
4 0 NUM F
, 0 PUNCT F
ozone 0 NOUN F
and 0 CCONJ F
application 0 NOUN F
of 0 ADP F
sodium 0 NOUN F
ascorbate 0 NOUN F
. 0 PUNCT F

Bonded 0 PUNCT T
beams 0 NOUN F
( 0 PUNCT F
1.0 0 NUM F
mm 0 NOUN F
( 0 PUNCT F
2 0 NUM F
) 0 PUNCT F
) 0 PUNCT F
were 0 VERB F
tested 0 VERB F
under 0 ADP F
tension 0 NOUN F
( 0 PUNCT F
0.5 0 NUM F
mm 0 NOUN F
min 0 NOUN F
( 0 PUNCT F
-1 0 NUM F
) 0 PUNCT F
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
?TBS 0 PUNCT F
values 0 NOUN F
were 0 VERB F
analyzed 0 VERB F
using 0 VERB F
one-way 0 NOUN F
analysis 0 NOUN F
of 0 ADP F
variance 0 NOUN F
( 0 PUNCT F
ANOVA 0 NOUN T
) 0 PUNCT F
and 0 CCONJ F
the 0 DET F
Tukey 0 ADJ T
test 0 NOUN F
( 0 PUNCT F
p=0.05 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

All 0 DET T
beams 0 NOUN F
that 0 PUNCT F
fractured 0 ADP F
were 0 VERB F
analyzed 0 VERB F
under 0 ADP F
stereomicroscopy 0 NOUN F
( 0 PUNCT F
40? 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

Group 0 NOUN T
1 0 NUM F
had 0 PUNCT F
significantly 0 ADV F
higher 0 PUNCT F
?TBS 0 PUNCT F
values 0 NOUN F
than 0 PUNCT F
Group 0 NOUN T
2 0 NUM F
or 0 CCONJ F
3 0 NUM F
. 0 PUNCT F

The 0 DET T
?TBS 0 PUNCT F
values 0 NOUN F
of 0 ADP F
Groups 0 NOUN T
1 0 NUM F
and 0 CCONJ F
4 0 NUM F
were 0 VERB F
similar 0 ADJ F
and 0 CCONJ F
higher 0 PUNCT F
than 0 PUNCT F
those 0 ADP F
of 0 ADP F
Group 0 NOUN T
2 0 NUM F
. 0 PUNCT F

The 0 DET T
use 0 NOUN F
of 0 ADP F
ozone 0 NOUN F
in 0 ADP F
Group 0 NOUN T
2 0 NUM F
resulted 0 VERB F
in 0 ADP F
lower 0 PUNCT F
values 0 NOUN F
of 0 ADP F
?TBS 0 PUNCT F
in 0 ADP F
all 0 DET F
conditions 0 NOUN F
evaluated 0 VERB F
. 0 PUNCT F

The 0 DET T
predominant 0 ADJ F
failure 0 NOUN F
mode 0 NOUN F
was 0 VERB F
adhesive 0 ADJ F
. 0 PUNCT F

The 0 DET T
application 0 NOUN F
of 0 ADP F
ozone 0 NOUN F
decreased 0 VERB F
the 0 DET F
?TBS 0 PUNCT F
of 0 ADP F
the 0 DET F
dentin-composite 0 NOUN F
resin 0 NOUN F
interface 0 NOUN F
. 0 PUNCT F

These 0 DET T
values 0 NOUN F
were 0 VERB F
reversed 0 VERB F
when 0 ADP F
compared 0 VERB F
with 0 ADP F
Groups 0 NOUN T
1 0 NUM F
and 0 CCONJ F
2 0 NUM F
when 0 ADP F
sodium 0 NOUN F
ascorbate 0 NOUN F
was 0 VERB F
used 0 VERB F
. 0 PUNCT F

Differences 0 NOUN T
in 0 ADP F
reach B-OTHER NOUN F
and 0 CCONJ F
attrition 0 NOUN F
between B-OTHER ADP F
Web-based I-OTHER PUNCT T
and 0 CCONJ F
print-delivered B-OTHER VERB F
tailored I-OTHER VERB F
interventions I-OTHER NOUN F
among 0 ADP F
adults 0 NOUN F
over 0 ADP F
50 0 NUM F
years 0 NOUN F
of 0 ADP F
age 0 NOUN F
: 0 PUNCT F
clustered 0 VERB F
randomized 0 VERB F
trial 0 NOUN F
. 0 PUNCT F

BACKGROUND 0 NOUN T
The 0 DET T
Internet 0 NOUN T
has 0 PUNCT F
the 0 DET F
potential 0 ADJ F
to 0 PART F
provide 0 NOUN F
large 0 ADJ F
populations 0 NOUN F
with 0 ADP F
individual 0 ADJ F
health 0 NOUN F
promotion 0 NOUN F
advice 0 NOUN F
at 0 ADP F
a 0 DET F
relatively 0 ADV F
low 0 ADJ F
cost 0 NOUN F
. 0 PUNCT F

Despite 0 ADP T
the 0 DET F
high 0 ADJ F
rates 0 NOUN F
of 0 ADP F
Internet 0 NOUN T
access 0 NOUN F
, 0 PUNCT F
actual 0 ADJ F
reach 0 NOUN F
by 0 ADP F
Web-based 0 VERB T
interventions 0 NOUN F
is 0 VERB F
often 0 ADV F
disappointingly 0 PRON F
low 0 ADJ F
, 0 PUNCT F
and 0 CCONJ F
differences 0 NOUN F
in 0 ADP F
use 0 NOUN F
between 0 ADP F
demographic 0 ADJ F
subgroups 0 NOUN F
are 0 PROPN F
present 0 ADJ F
. 0 PUNCT F

Furthermore 0 ADV T
, 0 PUNCT F
Web-based 0 VERB T
interventions 0 NOUN F
often 0 ADV F
have 0 PUNCT F
to 0 PART F
deal 0 ADV F
with 0 ADP F
high 0 ADJ F
rates 0 NOUN F
of 0 ADP F
attrition 0 NOUN F
. 0 PUNCT F

OBJECTIVE 0 NOUN T
This 0 DET T
study 0 NOUN F
aims 0 ADP F
to 0 PART F
assess 0 CCONJ F
user B-OTHER VERB F
characteristics I-OTHER NOUN F
related I-OTHER VERB F
to I-OTHER ADP F
participation I-OTHER NOUN F
and I-OTHER CCONJ F
attrition I-OTHER NOUN F
when 0 ADP F
comparing 0 PUNCT F
Web-based 0 VERB T
and 0 CCONJ F
print-delivered 0 VERB F
tailored 0 VERB F
interventions 0 NOUN F
containing 0 VERB F
similar 0 ADJ F
content 0 NOUN F
and 0 CCONJ F
thereby 0 ADV F
to 0 PART F
provide 0 NOUN F
recommendations 0 NOUN F
in 0 ADP F
choosing 0 VERB F
the 0 DET F
appropriate 0 ADJ F
delivery 0 NOUN F
mode 0 NOUN F
for 0 ADP F
a 0 DET F
particular 0 ADJ F
target 0 NOUN F
audience 0 NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
We 0 PRON T
studied 0 VERB F
the 0 DET F
distribution 0 NOUN F
of 0 ADP F
a 0 DET F
Web-based 0 VERB T
and 0 CCONJ F
a 0 DET F
print-delivered 0 VERB F
version 0 NOUN F
of 0 ADP F
the 0 DET F
Active 0 ADJ T
Plus 0 CCONJ T
intervention 0 NOUN F
in 0 ADP F
a 0 DET F
clustered 0 ADJ F
randomized 0 VERB F
controlled 0 VERB F
trial 0 NOUN F
( 0 PUNCT F
RCT 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

Participants 0 NOUN T
were 0 VERB F
recruited 0 VERB F
via 0 ADP F
direct 0 ADJ F
mailing 0 PUNCT F
within 0 ADP F
the 0 DET F
participating 0 PUNCT F
Municipal 0 ADJ T
Health 0 NOUN T
Council 0 NOUN T
regions 0 NOUN F
and 0 CCONJ F
randomized 0 PUNCT F
to 0 ADP F
the 0 DET F
printed 0 VERB F
or 0 CCONJ F
Web-based 0 VERB T
intervention 0 NOUN F
by 0 ADP F
their 0 PUNCT F
region 0 NOUN F
. 0 PUNCT F

Based 0 VERB T
on 0 ADP F
the 0 DET F
answers 0 NOUN F
given 0 VERB F
in 0 ADP F
a 0 DET F
prior 0 ADJ F
assessment 0 NOUN F
, 0 PUNCT F
participants 0 NOUN F
received 0 PUNCT F
tailored 0 VERB F
advice 0 NOUN F
on 0 ADP F
3 0 NUM F
occasions 0 NOUN F
: 0 PUNCT F
( 0 PUNCT F
1 0 NUM F
) 0 PUNCT F
within 0 ADP F
2 0 NUM F
weeks 0 NOUN F
after 0 ADP F
the 0 DET F
baseline 0 NOUN F
, 0 PUNCT F
( 0 PUNCT F
2 0 NUM F
) 0 PUNCT F
2 0 NUM F
months 0 NOUN F
after 0 ADP F
the 0 DET F
baseline 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
( 0 PUNCT F
3 0 NUM F
) 0 PUNCT F
within 0 ADP F
4 0 NUM F
months 0 NOUN F
after 0 ADP F
the 0 DET F
baseline 0 NOUN F
( 0 PUNCT F
based 0 ADP F
on 0 ADP F
a 0 DET F
second 0 ADJ F
assessment 0 NOUN F
at 0 ADP F
3 0 NUM F
months 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
baseline 0 NOUN F
( 0 PUNCT F
printed 0 DET F
or 0 CCONJ F
Web-based 0 VERB T
) 0 PUNCT F
results 0 PUNCT F
were 0 VERB F
analyzed 0 VERB F
using 0 VERB F
ANOVA 0 NOUN T
and 0 CCONJ F
chi-square 0 NOUN F
tests 0 NOUN F
to 0 PUNCT F
establish 0 ADJ F
the 0 DET F
differences 0 NOUN F
in 0 ADP F
user 0 VERB F
characteristics 0 NOUN F
between 0 ADP F
both 0 PUNCT F
intervention 0 NOUN F
groups 0 NOUN F
. 0 PUNCT F

We 0 PRON T
used 0 VERB F
logistic 0 ADJ F
regression 0 NOUN F
analyses 0 NOUN F
to 0 PUNCT F
study 0 VERB F
the 0 DET F
interaction 0 NOUN F
between 0 ADP F
the 0 DET F
user B-MENTAL VERB F
characteristics I-MENTAL NOUN F
and 0 CCONJ F
the 0 DET F
delivery 0 NOUN F
mode 0 NOUN F
in 0 ADP F
the 0 DET F
prediction 0 NOUN F
of 0 ADP F
dropout 0 NOUN F
rate B-OTHER NOUN F
within 0 ADP F
the 0 DET F
intervention 0 NOUN F
period 0 NOUN F
. 0 PUNCT F

RESULTS 0 PUNCT T
The 0 DET T
printed 0 VERB F
intervention 0 NOUN F
resulted 0 VERB F
in 0 ADP F
a 0 DET F
higher B-MENTAL PUNCT F
participation I-MENTAL NOUN F
rate I-MENTAL NOUN F
( 0 PUNCT F
19 0 NUM F
% 0 SYM F
) 0 PUNCT F
than 0 PUNCT F
the 0 DET F
Web-based 0 VERB T
intervention 0 NOUN F
( 0 PUNCT F
12 0 NUM F
% 0 SYM F
) 0 PUNCT F
. 0 PUNCT F

Participants 0 NOUN T
of 0 ADP F
the 0 DET F
Web-based 0 VERB T
intervention 0 NOUN F
were 0 VERB F
significantly 0 ADV F
younger 0 PUNCT F
( 0 PUNCT F
P 0 NOUN T
< 0 SYM F
.001 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
more 0 ADV F
often 0 ADP F
men 0 NOUN F
( 0 PUNCT F
P=.01 0 NOUN T
) 0 PUNCT F
, 0 PUNCT F
had 0 VERB F
a 0 DET F
higher 0 PUNCT F
body 0 NOUN F
mass 0 NOUN F
index 0 NOUN F
( 0 PUNCT F
BMI 0 NOUN T
) 0 PUNCT F
( 0 PUNCT F
P=.001 0 NOUN T
) 0 PUNCT F
and 0 CCONJ F
a 0 DET F
lower 0 PUNCT F
intention 0 NOUN F
to 0 PART F
be 0 PUNCT F
physically 0 ADV F
active 0 ADJ F
( 0 PUNCT F
P=.03 0 NOUN T
) 0 PUNCT F
than 0 ADP F
participants 0 NOUN F
of 0 ADP F
the 0 DET F
printed 0 VERB F
intervention 0 NOUN F
. 0 PUNCT F

The 0 DET T
dropout 0 ADP F
rate B-OTHER NOUN F
was 0 VERB F
significantly 0 ADV F
higher 0 PUNCT F
in 0 ADP F
the 0 DET F
Web-based 0 ADJ T
intervention 0 NOUN F
group 0 NOUN F
( 0 PUNCT F
53 0 NUM F
% 0 SYM F
) 0 PUNCT F
compared 0 VERB F
to 0 ADP F
the 0 DET F
print-delivered 0 VERB F
intervention 0 NOUN F
( 0 PUNCT F
39 0 NUM F
% 0 SYM F
, 0 PUNCT F
P 0 NOUN T
< 0 SYM F
.001 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

A 0 DET T
low 0 ADJ F
intention B-MENTAL NOUN F
to I-MENTAL PART F
be I-MENTAL PUNCT F
physically I-MENTAL ADV F
active I-MENTAL ADJ F
was 0 VERB F
a 0 DET F
strong 0 ADJ F
predictor 0 NOUN F
for 0 ADP F
dropout 0 NOUN F
within 0 ADP F
both 0 CCONJ F
delivery 0 NOUN F
modes 0 NOUN F
( 0 PUNCT F
P 0 NOUN T
< 0 SYM F
.001 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
difference 0 NOUN F
in 0 ADP F
dropout 0 NOUN F
rate 0 NOUN F
between 0 ADP F
the 0 DET F
Web-based 0 VERB T
and 0 CCONJ F
the 0 DET F
printed 0 VERB F
intervention 0 NOUN F
was 0 VERB F
not 0 ADV F
explained 0 VERB F
by 0 ADP F
user 0 PUNCT F
characteristics 0 NOUN F
. 0 PUNCT F

CONCLUSIONS 0 NOUN T
The 0 DET T
reach 0 NOUN F
of 0 ADP F
the 0 DET F
same 0 ADJ F
tailored B-MENTAL DET F
physical I-MENTAL ADJ F
activity I-MENTAL NOUN F
( 0 PUNCT F
PA B-MENTAL NOUN T
) 0 PUNCT F
intervention 0 NOUN F
in 0 ADP F
a 0 DET F
printed 0 VERB F
or 0 CCONJ F
Web-based 0 VERB T
delivery 0 NOUN F
mode 0 NOUN F
differed 0 VERB F
between 0 ADP F
sociodemographic 0 ADJ F
subgroups 0 NOUN F
of 0 ADP F
participants 0 NOUN F
over 0 ADP F
50 0 NUM F
years 0 NOUN F
of 0 ADP F
age 0 NOUN F
. 0 PUNCT F

Although 0 ADP T
the 0 DET F
reach 0 NOUN F
of 0 ADP F
the 0 DET F
Web-based 0 ADJ T
intervention 0 NOUN F
is 0 VERB F
lower 0 PUNCT F
, 0 PUNCT F
Web-based 0 VERB T
interventions 0 NOUN F
can 0 ADP F
be 0 ADJ F
a 0 DET F
good 0 ADJ F
channel 0 NOUN F
to 0 ADP F
reach 0 NOUN F
high-risk 0 NOUN F
populations 0 NOUN F
( 0 PUNCT F
lower 0 CCONJ F
PA 0 NOUN T
intention 0 NOUN F
and 0 CCONJ F
higher 0 PUNCT F
BMI 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

While 0 ADP T
the 0 DET F
dropout 0 ADP F
rate B-OTHER NOUN F
was 0 VERB F
significantly 0 ADV F
higher 0 PUNCT F
in 0 ADP F
the 0 DET F
Web-based 0 ADJ T
intervention 0 NOUN F
group 0 NOUN F
, 0 PUNCT F
no 0 DET F
specific 0 ADJ F
user 0 VERB F
characteristics 0 NOUN F
explained 0 VERB F
the 0 DET F
difference 0 NOUN F
in 0 ADP F
dropout 0 ADP F
rates B-OTHER NOUN F
between 0 ADP F
the 0 DET F
delivery 0 NOUN F
modes 0 NOUN F
. 0 PUNCT F

More 0 DET T
research 0 NOUN F
is 0 VERB F
needed 0 VERB F
to 0 PART F
determine 0 NOUN F
what 0 PUNCT F
caused 0 VERB F
the 0 DET F
high 0 ADJ F
rate B-OTHER NOUN F
of I-OTHER ADP F
dropout I-OTHER NOUN F
in 0 ADP F
the 0 DET F
Web-based 0 ADJ T
intervention 0 NOUN F
. 0 PUNCT F

TRIAL 0 NOUN T
REGISTRATION 0 NOUN T
Dutch 0 NOUN T
Trial 0 NOUN T
Register 0 NOUN T
( 0 PUNCT F
NTR 0 NOUN T
) 0 PUNCT F
: 0 PUNCT F
2297 0 NUM F
: 0 PUNCT F
http 0 PUNCT F
: 0 PUNCT F
//www.trialregister.nl/trialreg/admin/rctview.asp 0 ADV F
? 0 PUNCT F

TC=2297 0 PUNCT T
( 0 PUNCT F
Archived 0 PUNCT T
by 0 ADP F
WebCite 0 NOUN T
at 0 ADP F
http 0 PUNCT F
: 0 PUNCT F
//www.webcitation.org/65TkwoESp 0 PUNCT F
) 0 PUNCT F
. 0 PUNCT F

Human 0 NOUN T
motor 0 NOUN F
responses 0 NOUN F
to 0 ADP F
simultaneous 0 ADJ F
aversive 0 ADJ F
stimulation 0 NOUN F
and 0 CCONJ F
failure 0 NOUN F
on 0 ADP F
a 0 DET F
valued 0 PUNCT F
task 0 NOUN F
. 0 PUNCT F

The 0 DET T
effects 0 NOUN F
of 0 ADP F
presentation 0 NOUN F
of 0 ADP F
an 0 DET F
aversive 0 ADJ F
stimulus 0 NOUN F
and 0 CCONJ F
simultaneous 0 ADJ F
failure 0 NOUN F
on 0 ADP F
a 0 DET F
bogus 0 NOUN F
intelligence 0 NOUN F
test 0 NOUN F
upon 0 ADP F
a 0 DET F
subject 0 NOUN F
's 0 PUNCT F
aggressive B-MENTAL ADJ F
reactions I-MENTAL NOUN F
were 0 VERB F
studied 0 VERB F
. 0 PUNCT F

The 0 DET T
subject 0 NOUN F
's 0 PUNCT F
fist B-MENTAL NOUN F
clenching I-MENTAL PUNCT F
was 0 VERB F
used 0 VERB F
as 0 ADP F
an 0 DET F
indicator B-MENTAL NOUN F
of I-MENTAL ADP F
aggression I-MENTAL NOUN F
. 0 PUNCT F

Four 0 NUM T
conditions 0 NOUN F
, 0 PUNCT F
generated 0 VERB F
by 0 ADP F
the 0 DET F
combinations 0 NOUN F
of 0 ADP F
two 0 NUM F
kinds 0 NOUN F
of 0 ADP F
stimulus 0 NOUN F
delivered 0 VERB F
to 0 ADP F
the 0 DET F
subjects 0 NOUN F
( 0 PUNCT F
aversive 0 ADJ F
or 0 CCONJ F
nonaversive 0 ADJ F
) 0 PUNCT F
and 0 CCONJ F
two 0 NUM F
outcomes 0 NOUN F
of 0 ADP F
the 0 DET F
task 0 NOUN F
( 0 PUNCT F
failure 0 NOUN F
or 0 CCONJ F
success 0 NOUN F
) 0 PUNCT F
, 0 PUNCT F
were 0 VERB F
investigated 0 VERB F
. 0 PUNCT F

20 0 NUM F
female 0 NOUN F
and 0 CCONJ F
20 0 NUM F
male 0 NOUN F
students 0 NOUN F
( 0 PUNCT F
ages 0 NOUN F
: 0 PUNCT F
17-34 0 NUM F
years 0 NOUN F
) 0 PUNCT F
were 0 VERB F
instructed 0 VERB F
, 0 PUNCT F
upon 0 ADP F
the 0 DET F
reception 0 NOUN F
of 0 ADP F
an 0 DET F
aversive 0 ADJ F
or 0 CCONJ F
nonaversive 0 ADJ F
acoustic 0 ADJ F
signal 0 NOUN F
, 0 PUNCT F
to 0 PUNCT F
press 0 CCONJ F
with 0 ADP F
the 0 DET F
right 0 ADJ F
hand 0 NOUN F
a 0 DET F
device 0 NOUN F
that 0 PUNCT F
displayed 0 VERB F
a 0 DET F
slide 0 NOUN F
. 0 PUNCT F

Each 0 DET T
slide 0 NOUN F
presented 0 ADP F
an 0 DET F
item 0 NOUN F
from 0 ADP F
an 0 DET F
intelligence 0 NOUN F
test 0 NOUN F
, 0 PUNCT F
to 0 CCONJ F
which 0 PUNCT F
the 0 DET F
subjects 0 NOUN F
were 0 PUNCT F
either 0 PUNCT F
allowed 0 NUM F
to 0 ADJ F
answer 0 ADP F
successfully 0 ADP F
( 0 PUNCT F
success 0 NOUN F
) 0 PUNCT F
or 0 CCONJ F
not 0 ADV F
( 0 PUNCT F
failure 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

Failure 0 NOUN T
increased 0 VERB F
the 0 DET F
subject 0 NOUN F
's 0 PUNCT F
autonomic B-MENTAL ADJ F
arousal I-MENTAL ADJ F
, 0 PUNCT F
as 0 PUNCT F
measured 0 VERB F
by 0 ADP F
photoplethysmographic 0 ADJ F
sensors 0 NOUN F
, 0 PUNCT F
in 0 ADP F
all 0 DET F
stimulation 0 NOUN F
conditions 0 NOUN F
, 0 PUNCT F
but 0 CCONJ F
only 0 ADV F
the 0 DET F
condition 0 NOUN F
with 0 ADP F
aversive 0 ADJ F
stimulation 0 NOUN F
increased 0 VERB F
the 0 DET F
speed B-MENTAL NOUN F
of I-MENTAL ADP F
clenching I-MENTAL PROPN F
. 0 PUNCT F

This 0 DET T
was 0 VERB F
interpreted 0 VERB F
as 0 PUNCT F
indicating 0 PUNCT F
subject 0 NOUN F
's 0 PUNCT F
tendencies B-MENTAL DET F
to I-MENTAL ADP F
aggression I-MENTAL NOUN F
. 0 PUNCT F

These 0 DET T
results 0 NOUN F
are 0 VERB F
discussed 0 VERB F
in 0 ADP F
relation 0 NOUN F
to 0 ADP F
the 0 DET F
effects 0 NOUN F
of 0 ADP F
frustration 0 NOUN F
. 0 PUNCT F

Pre-bent 0 ADJ T
instruments 0 NOUN F
used 0 VERB F
in 0 ADP F
single-port 0 NOUN F
laparoscopic 0 ADJ F
surgery 0 NOUN F
versus 0 CCONJ F
conventional 0 ADJ F
laparoscopic 0 ADJ F
surgery 0 NOUN F
: 0 PUNCT F
comparative 0 ADJ F
study 0 NOUN F
of 0 ADP F
performance 0 NOUN F
in 0 ADP F
a 0 DET F
dry 0 ADJ F
lab 0 NOUN F
. 0 PUNCT F

BACKGROUND 0 NOUN T
Different 0 ADJ T
types 0 NOUN F
of 0 ADP F
single-incision 0 NOUN F
laparoscopic 0 ADJ F
surgery 0 NOUN F
( 0 PUNCT F
SILS 0 NOUN T
) 0 PUNCT F
have 0 CCONJ F
become 0 VERB F
increasingly 0 ADV F
popular 0 ADJ F
. 0 PUNCT F

Although 0 ADP T
SILS 0 NOUN T
is 0 VERB F
technically 0 ADV F
even 0 ADV F
more 0 DET F
challenging 0 PUNCT F
than 0 PUNCT F
conventional 0 ADJ F
laparoscopy 0 NOUN F
, 0 PUNCT F
published 0 DET F
data 0 NOUN F
of 0 ADP F
first 0 ADJ F
clinical 0 ADJ F
series 0 NOUN F
seem 0 VERB F
to 0 PART F
demonstrate 0 NOUN F
the 0 DET F
feasibility 0 NOUN F
of 0 ADP F
these 0 DET F
approaches 0 NOUN F
. 0 PUNCT F

Various 0 ADJ T
attempts 0 PUNCT F
have 0 PUNCT F
been 0 PUNCT F
made 0 VERB F
to 0 PART F
overcome 0 NOUN F
restrictions 0 NOUN F
due 0 CCONJ F
to 0 ADP F
loss 0 NOUN F
of 0 ADP F
triangulation 0 NOUN F
in 0 ADP F
SILS 0 NOUN T
by 0 ADP F
specially 0 ADJ F
designed 0 DET F
SILS-specific 0 ADJ T
instruments 0 NOUN F
. 0 PUNCT F

This 0 DET T
study 0 NOUN F
involving 0 PUNCT F
novices 0 NOUN F
in 0 ADP F
a 0 DET F
dry 0 ADJ F
lab 0 NOUN F
compared 0 ADP F
task B-MENTAL NOUN F
performances I-MENTAL NOUN F
between 0 ADP F
conventional 0 ADJ F
laparoscopic 0 ADJ F
surgery 0 NOUN F
( 0 PUNCT F
CLS 0 NOUN T
) 0 PUNCT F
and 0 CCONJ F
single-port 0 NOUN F
laparoscopic 0 ADJ F
surgery 0 NOUN F
( 0 PUNCT F
SPLS 0 NOUN T
) 0 PUNCT F
using 0 VERB F
newly 0 ADV F
designed 0 PUNCT F
pre-bent 0 ADJ F
instruments 0 NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
In 0 ADP T
this 0 DET F
study 0 NOUN F
, 0 PUNCT F
90 0 NUM F
medical 0 ADJ F
students 0 NOUN F
without 0 ADP F
previous 0 ADJ F
experience 0 NOUN F
in 0 ADP F
laparoscopic 0 ADJ F
techniques 0 NOUN F
were 0 VERB F
randomly 0 ADV F
assigned 0 VERB F
to 0 ADJ F
undergo 0 VERB F
one 0 NUM F
of 0 ADP F
three 0 NUM F
procedures 0 NOUN F
: 0 PUNCT F
CLS 0 NOUN T
, 0 PUNCT F
SPLS 0 NOUN T
using 0 VERB F
two 0 NUM F
pre-bent 0 ADJ F
instruments 0 NOUN F
( 0 PUNCT F
SPLS-pp 0 PUNCT T
) 0 PUNCT F
, 0 PUNCT F
or 0 CCONJ F
SPLS 0 NOUN T
using 0 VERB F
one 0 NUM F
pre-bent 0 ADJ F
and 0 CCONJ F
one 0 NUM F
straight 0 NOUN F
laparoscopic 0 ADJ F
instrument 0 NOUN F
( 0 PUNCT F
SPLS-ps 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

In 0 ADP T
the 0 DET F
dry 0 ADJ F
lab 0 NOUN F
, 0 PUNCT F
the 0 DET F
participants 0 NOUN F
performed 0 DET F
four 0 NUM F
typical 0 ADJ F
laparoscopic 0 ADJ F
tasks 0 NOUN F
of 0 ADP F
increasing 0 VERB F
difficulty 0 NOUN F
. 0 PUNCT F

Evaluation 0 NOUN T
included 0 VERB F
performance B-MENTAL NOUN F
times I-MENTAL NOUN F
or 0 CCONJ F
number 0 NOUN F
of 0 ADP F
completed 0 VERB F
tasks 0 NOUN F
within 0 ADP F
a 0 DET F
given 0 PUNCT F
time 0 NOUN F
frame 0 NOUN F
. 0 PUNCT F

All 0 DET T
performances B-MENTAL NOUN F
were 0 VERB F
videotaped 0 ADJ F
and 0 CCONJ F
evaluated 0 VERB F
for 0 ADP F
unsuccessful B-MENTAL ADJ F
attempts I-MENTAL PUNCT F
and 0 CCONJ F
unwanted B-MENTAL VERB F
interactions I-MENTAL NOUN F
of I-MENTAL ADP F
instruments I-MENTAL NOUN F
. 0 PUNCT F

Using 0 PRON T
subjective B-OTHER ADJ F
questionnaires I-OTHER NOUN F
, 0 PUNCT F
the 0 DET F
participants 0 NOUN F
rated B-MENTAL ADP F
difficulties I-MENTAL NOUN F
with I-MENTAL ADP F
two-dimensional I-MENTAL ADJ F
vision I-MENTAL NOUN F
and 0 CCONJ F
coordination B-MENTAL NOUN F
of I-MENTAL ADP F
instruments I-MENTAL NOUN F
. 0 PUNCT F

RESULTS 0 NOUN T
Task B-MENTAL NOUN T
performances I-MENTAL NOUN F
were 0 VERB F
significantly 0 ADV F
better 0 PUNCT F
in 0 ADP F
the 0 DET F
CLS 0 NOUN T
group 0 NOUN F
than 0 PUNCT F
in 0 ADP F
either 0 CCONJ F
SPLS 0 NOUN T
group 0 NOUN F
. 0 PUNCT F

The 0 DET T
SPLS-ps 0 NOUN T
group 0 NOUN F
showed 0 VERB F
a 0 DET F
tendency 0 NOUN F
toward 0 ADP F
better 0 PUNCT F
performances B-OTHER NOUN F
than 0 PUNCT F
the 0 DET F
SPLS-pp 0 PUNCT T
group 0 NOUN F
, 0 PUNCT F
but 0 CCONJ F
the 0 DET F
difference 0 NOUN F
was 0 VERB F
not 0 ADV F
significant 0 ADJ F
. 0 PUNCT F

Video 0 PUNCT T
sequences 0 NOUN F
and 0 CCONJ F
participants` 0 PUNCT F
questionnaires 0 NOUN F
showed 0 VERB F
instrument B-MENTAL ADJ F
interaction I-MENTAL NOUN F
as 0 VERB F
the 0 DET F
major B-ADVERSE-EFFECTS ADJ F
problem I-ADVERSE-EFFECTS NOUN F
in 0 ADP F
the 0 DET F
single-incision 0 NOUN F
surgery 0 NOUN F
groups 0 NOUN F
. 0 PUNCT F

CONCLUSIONS 0 NOUN T
Although 0 ADP T
SILS 0 NOUN T
is 0 VERB F
feasible 0 ADJ F
, 0 PUNCT F
as 0 CCONJ F
shown 0 VERB F
in 0 ADP F
clinical 0 ADJ F
series 0 NOUN F
published 0 VERB F
by 0 ADP F
laparoscopically 0 ADV F
experienced 0 VERB F
experts 0 NOUN F
, 0 PUNCT F
SILS 0 ADJ T
techniques 0 NOUN F
are 0 PROPN F
demanding 0 ADP F
due 0 PUNCT F
to 0 ADP F
restrictions 0 NOUN F
that 0 ADP F
come 0 VERB F
with 0 ADP F
the 0 DET F
loss 0 NOUN F
of 0 ADP F
triangulation 0 NOUN F
. 0 PUNCT F

These 0 PUNCT T
can 0 VERB F
be 0 PART F
compensated 0 PUNCT F
only 0 ADV F
partially 0 ADV F
by 0 ADP F
currently 0 ADV F
available 0 ADJ F
SILS-designed 0 VERB T
instruments 0 NOUN F
. 0 PUNCT F

The 0 DET T
future 0 NOUN F
of 0 ADP F
SILS 0 ADJ T
depends 0 NOUN F
on 0 ADP F
further 0 ADJ F
improvements 0 NOUN F
in 0 ADP F
the 0 DET F
available 0 ADJ F
equipment 0 ADJ F
or 0 CCONJ F
the 0 DET F
development 0 NOUN F
of 0 ADP F
new 0 ADJ F
approaches 0 NOUN F
such 0 CCONJ F
as 0 PUNCT F
needlescopically 0 VERB F
assisted 0 ADJ F
or 0 CCONJ F
robotically 0 ADV F
assisted 0 VERB F
procedures 0 NOUN F
. 0 PUNCT F

Markers 0 NOUN T
of 0 ADP F
systemic B-PHYSICAL ADJ F
inflammation I-PHYSICAL NOUN F
predict 0 ADJ F
survival 0 NOUN F
in 0 ADP F
patients 0 NOUN F
with 0 ADP F
advanced 0 VERB F
renal 0 ADJ F
cell 0 NOUN F
cancer 0 NOUN F
. 0 PUNCT F

BACKGROUND 0 NOUN T
The 0 DET T
host 0 NOUN F
inflammatory 0 ADJ F
response 0 NOUN F
has 0 VERB F
a 0 DET F
vital 0 ADJ F
role 0 NOUN F
in 0 ADP F
carcinogenesis 0 NOUN F
and 0 CCONJ F
tumour 0 NOUN F
progression 0 NOUN F
. 0 PUNCT F

We 0 PRON T
examined 0 VERB F
the 0 DET F
prognostic 0 ADJ F
value 0 NOUN F
of 0 ADP F
inflammatory 0 ADJ F
markers 0 NOUN F
( 0 PUNCT F
albumin 0 NOUN F
, 0 PUNCT F
white-cell 0 VERB F
count 0 NOUN F
and 0 CCONJ F
its 0 DET F
components 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
platelets 0 NOUN F
) 0 PUNCT F
in 0 ADP F
pre-treated 0 VERB F
patients 0 NOUN F
with 0 ADP F
advanced 0 VERB F
renal 0 ADJ F
cell 0 NOUN F
carcinoma 0 NOUN F
( 0 PUNCT F
RCC 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

METHODS 0 NOUN T
Using 0 ADJ T
data 0 NOUN F
from 0 ADP F
a 0 DET F
randomised 0 VERB F
trial 0 NOUN F
, 0 PUNCT F
multivariable 0 ADJ F
proportional 0 ADJ F
hazards 0 NOUN F
models 0 NOUN F
were 0 VERB F
generated 0 VERB F
to 0 PART F
examine 0 NOUN F
the 0 DET F
impact 0 NOUN F
of 0 ADP F
inflammatory B-PHYSICAL ADJ F
markers I-PHYSICAL NOUN F
and 0 CCONJ F
established 0 ADP F
prognostic B-PHYSICAL ADJ F
factors I-PHYSICAL NOUN F
( 0 PUNCT F
performance 0 NOUN F
status 0 NOUN F
, 0 PUNCT F
calcium 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
haemoglobin 0 NOUN F
) 0 PUNCT F
on 0 ADP F
overall B-MORTALITY ADJ F
survival I-MORTALITY NOUN F
( 0 PUNCT F
OS 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

We 0 PRON T
evaluated 0 VERB F
a 0 DET F
new 0 ADJ F
prognostic 0 ADJ F
classification 0 NOUN F
incorporating 0 SYM F
additional 0 ADJ F
information 0 NOUN F
from 0 ADP F
inflammatory 0 ADJ F
markers 0 NOUN F
. 0 PUNCT F

RESULTS 0 NOUN T
Of 0 ADP T
the 0 DET F
416 0 ADJ F
patients 0 NOUN F
, 0 PUNCT F
362 0 NUM F
were 0 VERB F
included 0 VERB F
in 0 ADP F
the 0 DET F
analysis 0 NOUN F
. 0 PUNCT F

Elevated B-PHYSICAL VERB T
neutrophil I-PHYSICAL NOUN F
counts I-PHYSICAL NOUN F
, 0 PUNCT F
elevated B-PHYSICAL ADP F
platelet I-PHYSICAL NOUN F
counts I-PHYSICAL NOUN F
, 0 PUNCT F
and 0 CCONJ F
a B-PHYSICAL DET F
high I-PHYSICAL ADJ F
neutrophil-lymphocyte I-PHYSICAL NOUN F
ratio I-PHYSICAL NOUN F
were 0 VERB F
significant 0 ADJ F
independent 0 ADJ F
predictors 0 NOUN F
for 0 ADP F
shorter 0 PUNCT F
OS 0 PUNCT T
in 0 ADP F
a 0 DET F
model 0 NOUN F
with 0 ADP F
established 0 ADP F
prognostic 0 ADJ F
factors 0 NOUN F
. 0 PUNCT F

The 0 DET T
addition 0 NOUN F
of 0 ADP F
inflammatory 0 ADJ F
markers 0 NOUN F
improves 0 NOUN F
the 0 DET F
discriminatory 0 ADJ F
value 0 NOUN F
of 0 ADP F
the 0 DET F
prognostic 0 ADJ F
classification 0 NOUN F
as 0 CCONJ F
compared 0 VERB F
with 0 ADP F
established 0 VERB F
factors 0 NOUN F
alone 0 ADJ F
( 0 PUNCT F
C-statistic 0 ADJ T
0.673 0 NUM F
vs 0 CCONJ F
0.654 0 PUNCT F
, 0 PUNCT F
P=0.002 0 NOUN T
for 0 ADP F
the 0 DET F
difference 0 NOUN F
) 0 PUNCT F
, 0 PUNCT F
with 0 ADP F
25.8 0 NUM F
% 0 SYM F
( 0 PUNCT F
P=0.004 0 NOUN T
) 0 PUNCT F
of 0 ADP F
patients 0 NOUN F
more 0 ADV F
appropriately 0 ADV F
classified 0 VERB F
using 0 VERB F
the 0 DET F
new 0 ADJ F
classification 0 NOUN F
. 0 PUNCT F

CONCLUSION 0 NOUN T
Markers 0 PROPN T
of 0 ADP F
systemic 0 ADJ F
inflammation 0 NOUN F
contribute 0 VERB F
significantly 0 ADV F
to 0 ADP F
prognostic 0 ADJ F
classification 0 NOUN F
in 0 ADP F
addition 0 NOUN F
to 0 ADP F
established 0 VERB F
factors 0 NOUN F
for 0 ADP F
pre-treated 0 VERB F
patients 0 NOUN F
with 0 ADP F
advanced 0 VERB F
RCC 0 NOUN T
. 0 PUNCT F

Upon 0 ADP T
validation 0 NOUN F
of 0 ADP F
these 0 DET F
data 0 NOUN F
in 0 ADP F
independent 0 ADJ F
studies 0 NOUN F
, 0 PUNCT F
stratification 0 NOUN F
of 0 ADP F
patients 0 NOUN F
using 0 VERB F
these 0 DET F
markers 0 NOUN F
in 0 ADP F
future 0 ADJ F
clinical 0 ADJ F
trials 0 NOUN F
is 0 VERB F
recommended 0 VERB F
. 0 PUNCT F

Evaluating 0 ADP T
online 0 ADV F
continuing 0 VERB F
medical 0 ADJ F
education 0 NOUN F
seminars 0 NOUN F
: 0 PUNCT F
evidence 0 NOUN F
for 0 ADP F
improving 0 VERB F
clinical 0 ADJ F
practices 0 NOUN F
. 0 PUNCT F

The 0 DET T
purpose 0 NOUN F
of 0 ADP F
this 0 DET F
study 0 NOUN F
was 0 VERB F
to 0 PART F
evaluate 0 NOUN F
the 0 DET F
potential 0 ADJ F
for 0 ADP F
online 0 ADV F
continuing 0 VERB F
medical 0 ADJ F
education 0 NOUN F
( 0 PUNCT F
CME 0 NOUN T
) 0 PUNCT F
seminars 0 PROPN F
to 0 PROPN F
improve B-OTHER ADP F
quality I-OTHER NOUN F
of I-OTHER ADP F
care I-OTHER NOUN F
. 0 PUNCT F

Primary 0 ADJ T
care 0 NOUN F
physicians 0 NOUN F
( 0 PUNCT F
113 0 NUM F
) 0 PUNCT F
participated 0 PUNCT F
in 0 ADP F
a 0 DET F
randomized 0 VERB F
controlled 0 VERB F
trial 0 NOUN F
to 0 PART F
evaluate 0 NOUN F
an 0 DET F
online 0 ADV F
CME 0 NOUN T
series 0 NOUN F
. 0 PUNCT F

Physicians 0 NOUN T
were 0 VERB F
randomized 0 VERB F
to 0 ADP F
view 0 ADJ F
either 0 CCONJ F
a 0 DET F
seminar 0 CCONJ F
about 0 ADP F
type 0 NOUN F
2 0 NUM F
diabetes 0 NOUN F
or 0 CCONJ F
a 0 DET F
seminar 0 ADJ F
about 0 ADP F
systolic 0 ADJ F
heart 0 NOUN F
failure 0 NOUN F
. 0 PUNCT F

Following 0 VERB T
the 0 DET F
seminar 0 ADJ F
, 0 PUNCT F
physicians 0 NOUN F
were 0 VERB F
presented 0 VERB F
with 0 ADP F
4 0 NUM F
clinical 0 ADJ F
vignettes 0 NOUN F
and 0 CCONJ F
asked 0 PROPN F
to 0 PART F
describe 0 ADP F
what 0 DET F
tests 0 NOUN F
, 0 PUNCT F
treatments 0 ADJ F
, 0 PUNCT F
counseling 0 DET F
, 0 PUNCT F
or 0 CCONJ F
referrals 0 PUNCT F
they 0 PRON F
would 0 ADJ F
recommend 0 VERB F
. 0 PUNCT F

Physicians 0 NOUN T
who 0 PROPN F
viewed 0 VERB F
the 0 DET F
seminars 0 ADV F
were 0 VERB F
significantly 0 ADV F
more 0 ADV F
likely 0 ADJ F
to 0 PART F
recommend B-MENTAL VERB F
guideline-consistent I-MENTAL ADJ F
care I-MENTAL NOUN F
to 0 ADP F
patients 0 NOUN F
in 0 ADP F
the 0 DET F
vignettes 0 NOUN F
. 0 PUNCT F

For 0 ADP T
example 0 NOUN F
, 0 PUNCT F
physicians 0 NOUN F
who 0 PROPN F
viewed 0 VERB F
the 0 DET F
diabetes 0 NOUN F
seminar 0 ADJ F
were 0 VERB F
significantly 0 ADV F
more 0 ADV F
likely 0 ADJ F
to 0 PUNCT F
order B-MENTAL ADP F
an I-MENTAL DET F
eye I-MENTAL NOUN F
exam I-MENTAL NOUN F
for I-MENTAL ADP F
diabetes I-MENTAL NOUN F
patients I-MENTAL NOUN F
( 0 PUNCT F
63 0 NUM F
% 0 SYM F
) 0 PUNCT F
compared 0 VERB F
with 0 ADP F
physicians 0 NOUN F
in 0 ADP F
the 0 DET F
control 0 NOUN F
group 0 NOUN F
( 0 PUNCT F
27 0 NUM F
% 0 SYM F
) 0 PUNCT F
. 0 PUNCT F

For 0 ADP T
some 0 DET F
guidelines 0 NOUN F
there 0 VERB F
were 0 VERB F
no 0 DET F
group 0 NOUN F
differences 0 NOUN F
. 0 PUNCT F

These 0 DET T
results 0 NOUN F
provide 0 VERB F
early 0 ADJ F
evidence 0 NOUN F
of 0 ADP F
the 0 DET F
effectiveness 0 NOUN F
of 0 ADP F
online 0 ADV F
CME 0 NOUN T
programs 0 NOUN F
to 0 PROPN F
improve 0 ADP F
physician B-OTHER NOUN F
clinical I-OTHER ADJ F
practice I-OTHER NOUN F
. 0 PUNCT F

Randomized 0 VERB T
controlled 0 DET F
study 0 NOUN F
of 0 ADP F
customized 0 VERB F
preventive 0 ADJ F
medicine 0 NOUN F
reminder 0 ADP F
letters 0 CCONJ F
in 0 ADP F
a 0 DET F
community 0 NOUN F
practice 0 NOUN F
. 0 PUNCT F

OBJECTIVE 0 NOUN T
To 0 PROPN T
test 0 NOUN F
the 0 DET F
effectiveness 0 NOUN F
of 0 ADP F
customized 0 DET F
, 0 PUNCT F
family-oriented 0 ADP F
reminder 0 ADP F
letters 0 CCONJ F
in 0 ADP F
activating 0 ADJ F
patients 0 NOUN F
to 0 ADP F
seek 0 PROPN F
appropriate 0 ADJ F
preventive 0 ADJ F
services 0 NOUN F
. 0 PUNCT F

DESIGN 0 NOUN T
Randomized 0 PROPN T
clinical 0 ADJ F
trial 0 NOUN F
. 0 PUNCT F

One 0 NUM T
group 0 NOUN F
received 0 VERB F
computer-generated 0 VERB F
, 0 PUNCT F
customized 0 PUNCT F
letters 0 NOUN F
explaining 0 PUNCT F
recommended 0 PUNCT F
preventive 0 ADJ F
procedures 0 NOUN F
for 0 ADP F
each 0 DET F
family 0 NOUN F
member 0 NOUN F
. 0 PUNCT F

A 0 DET T
second 0 ADJ F
group 0 NOUN F
received 0 VERB F
a 0 DET F
form 0 ADV F
letter 0 NOUN F
listing 0 SYM F
recommendations 0 NOUN F
for 0 ADP F
all 0 DET F
preventive 0 ADJ F
procedures 0 NOUN F
for 0 ADP F
all 0 DET F
age 0 NOUN F
and 0 CCONJ F
sex 0 NOUN F
groups 0 NOUN F
. 0 PUNCT F

A 0 DET T
third 0 ADJ F
group 0 NOUN F
( 0 PUNCT F
control 0 NOUN F
group 0 NOUN F
) 0 PUNCT F
received 0 VERB F
no 0 DET F
letters 0 NOUN F
. 0 PUNCT F

SETTING 0 NUM T
A 0 PUNCT T
private 0 ADJ F
medical 0 ADJ F
centre 0 NOUN F
, 0 PUNCT F
without 0 ADP F
university 0 NOUN F
affiliation 0 NOUN F
, 0 PUNCT F
in 0 ADP F
rural 0 ADJ F
Quebec 0 ADP T
. 0 PUNCT F

PARTICIPANTS 0 ADP T
From 0 ADP T
8770 0 NUM F
patients 0 NOUN F
who 0 PROPN F
met 0 VERB F
study 0 ADV F
criteria 0 NOUN F
, 0 PUNCT F
719 0 NUM F
families 0 NOUN F
were 0 VERB F
randomly 0 ADV F
selected 0 VERB F
. 0 PUNCT F

Data 0 NOUN T
were 0 VERB F
available 0 ADJ F
for 0 ADP F
1971 0 NUM F
of 0 ADP F
1998 0 NUM F
patients 0 NOUN F
in 0 ADP F
these 0 DET F
families 0 NOUN F
. 0 PUNCT F

MAIN 0 ADJ T
OUTCOME 0 NOUN T
MEASURES 0 NOUN T
The 0 DET T
Family B-PHYSICAL NOUN T
Received I-PHYSICAL PUNCT T
Index I-PHYSICAL NOUN T
is 0 VERB F
the 0 DET F
proportion 0 NOUN F
of 0 ADP F
all 0 DET F
procedures 0 NOUN F
for 0 ADP F
which 0 ADP F
a 0 DET F
family 0 NOUN F
was 0 VERB F
overdue 0 PUNCT F
that 0 PUNCT F
they 0 PRON F
received 0 ADJ F
. 0 PUNCT F

The 0 DET T
Family B-PHYSICAL NOUN T
End-of-study I-PHYSICAL NOUN T
Up-to-date I-PHYSICAL PUNCT T
Index I-PHYSICAL NOUN T
is 0 VERB F
the 0 DET F
proportion 0 NOUN F
of 0 ADP F
procedures 0 NOUN F
for 0 ADP F
which 0 ADP F
the 0 DET F
family 0 NOUN F
was 0 VERB F
eligible 0 ADJ F
and 0 CCONJ F
for 0 ADP F
which 0 ADP F
they 0 PUNCT F
were 0 VERB F
up-to-date 0 PUNCT F
at 0 ADP F
the 0 DET F
end 0 NOUN F
of 0 ADP F
the 0 DET F
study 0 NOUN F
. 0 PUNCT F

RESULTS 0 PUNCT T
The 0 DET T
Family B-PHYSICAL NOUN T
Received I-PHYSICAL PUNCT T
Index I-PHYSICAL NOUN T
for 0 ADP F
families 0 NOUN F
mailed 0 PUNCT F
customized 0 PUNCT F
letters 0 NOUN F
was 0 VERB F
more 0 ADV F
than 0 PUNCT F
double 0 PUNCT F
the 0 DET F
index 0 NOUN F
for 0 ADP F
patients 0 NOUN F
not 0 ADV F
mailed 0 PUNCT F
letters 0 PROPN F
( 0 PUNCT F
Kruskal-Wallis 0 NOUN T
P 0 NOUN T
= 0 SYM F
.0139 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Comparison 0 NOUN T
of 0 ADP F
the 0 DET F
Family B-PHYSICAL NOUN T
End-of-study I-PHYSICAL NOUN T
Up-to-date I-PHYSICAL PUNCT T
indices I-PHYSICAL ADJ F
also 0 ADV F
demonstrated 0 VERB F
that 0 ADP F
families 0 NOUN F
of 0 ADP F
patients 0 NOUN F
sent 0 NOUN F
customized 0 VERB F
letters 0 NOUN F
were 0 VERB F
more 0 ADV F
likely 0 ADJ F
to 0 PART F
be 0 PUNCT F
up-to-date 0 PUNCT F
than 0 ADP F
families 0 NOUN F
not 0 ADV F
sent 0 PUNCT F
letters 0 ADJ F
( 0 PUNCT F
Kruskal-Wallis 0 NOUN T
P 0 NOUN T
= 0 SYM F
.0054 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

No 0 DET T
statistically 0 ADV F
significant 0 ADJ F
difference 0 NOUN F
appeared 0 VERB F
between 0 ADP F
the 0 DET F
number 0 NOUN F
of 0 ADP F
preventive 0 ADJ F
measures 0 NOUN F
received 0 VERB F
by 0 ADP F
the 0 DET F
control 0 NOUN F
group 0 NOUN F
and 0 CCONJ F
the 0 DET F
form-letter 0 ADJ F
group 0 NOUN F
. 0 PUNCT F

CONCLUSIONS 0 NOUN T
This 0 DET T
study 0 NOUN F
demonstrates 0 VERB F
a 0 DET F
clinically 0 ADV F
small 0 ADJ F
but 0 CCONJ F
statistically 0 ADV F
significant 0 ADJ F
value 0 NOUN F
to 0 ADP F
customizing 0 CCONJ F
reminder 0 ADP F
letters 0 NOUN F
. 0 PUNCT F

Incidence 0 NOUN T
and 0 CCONJ F
clinical 0 ADJ F
significance 0 NOUN F
of 0 ADP F
false-negative 0 ADJ F
sextant 0 ADJ F
prostate 0 NOUN F
biopsies 0 NOUN F
. 0 PUNCT F

PURPOSE 0 NOUN T
Since 0 ADP T
most 0 DET F
patients 0 NOUN F
do 0 PUNCT F
not 0 ADV F
undergo 0 ADV F
repeat 0 NOUN F
sextant 0 ADJ F
prostate 0 NOUN F
biopsies 0 NOUN F
after 0 ADP F
a 0 DET F
biopsy 0 NOUN F
is 0 VERB F
positive 0 ADJ F
for 0 ADP F
prostate 0 NOUN F
cancer 0 NOUN F
, 0 PUNCT F
the 0 DET F
true 0 ADJ F
incidence 0 NOUN F
of 0 ADP F
false-negative 0 ADJ F
biopsies 0 NOUN F
is 0 VERB F
not 0 ADV F
well 0 VERB F
defined 0 CCONJ F
. 0 PUNCT F

We 0 PRON T
assess 0 VERB F
the 0 DET F
incidence 0 NOUN F
and 0 CCONJ F
clinical 0 ADJ F
significance 0 NOUN F
of 0 ADP F
false-negative 0 ADJ F
sextant 0 ADJ F
prostate 0 NOUN F
biopsies 0 NOUN F
in 0 ADP F
patients 0 NOUN F
undergoing 0 VERB F
radical 0 ADJ F
prostatectomy 0 NOUN F
. 0 PUNCT F

MATERIALS 0 NOUN T
AND 0 CCONJ T
METHODS 0 NOUN T
A 0 PUNCT T
total 0 NOUN F
of 0 ADP F
118 0 NUM F
patients 0 NOUN F
with 0 ADP F
biopsy 0 NOUN F
proved 0 CCONJ F
prostate 0 NOUN F
cancer 0 NOUN F
underwent 0 VERB F
repeat 0 NOUN F
sextant 0 ADJ F
prostate 0 NOUN F
biopsy 0 NOUN F
before 0 ADP F
enrollment 0 NOUN F
in 0 ADP F
a 0 DET F
prospective 0 ADJ F
randomized 0 VERB F
trial 0 NOUN F
of 0 ADP F
radical 0 ADJ F
prostatectomy 0 NOUN F
with 0 ADP F
or 0 CCONJ F
without 0 ADP F
neoadjuvant 0 PUNCT F
hormonal 0 ADJ F
therapy 0 NOUN F
. 0 PUNCT F

Clinical 0 ADJ T
parameters 0 NOUN F
were 0 VERB F
assessed 0 VERB F
to 0 PART F
determine 0 ADJ F
potential 0 ADJ F
sources 0 NOUN F
of 0 ADP F
bias 0 NOUN F
. 0 PUNCT F

Pathological 0 ADJ T
parameters 0 NOUN F
and 0 CCONJ F
prostate B-ADVERSE-EFFECTS NOUN F
specific I-ADVERSE-EFFECTS ADJ F
antigen I-ADVERSE-EFFECTS NOUN F
relapse-free I-ADVERSE-EFFECTS PUNCT F
survival I-ADVERSE-EFFECTS NOUN F
rates I-ADVERSE-EFFECTS NOUN F
were 0 VERB F
compared 0 VERB F
to 0 PART F
determine 0 NOUN F
the 0 DET F
clinical 0 ADJ F
significance 0 NOUN F
of 0 ADP F
false-negative 0 ADJ F
biopsies 0 NOUN F
. 0 PUNCT F

RESULTS 0 NOUN T
Of 0 ADP T
the 0 DET F
118 0 ADJ F
patients 0 NOUN F
27 0 NUM F
( 0 PUNCT F
23 0 NUM F
% 0 SYM F
) 0 PUNCT F
had 0 PUNCT F
a 0 DET F
negative 0 ADJ F
repeat 0 NOUN F
sextant 0 ADJ F
biopsy 0 NOUN F
. 0 PUNCT F

Except 0 PUNCT T
for 0 ADP F
initial 0 ADJ F
clinical 0 ADJ F
stage 0 NOUN F
, 0 PUNCT F
no 0 DET F
differences 0 NOUN F
were 0 VERB F
noted 0 VERB F
in 0 ADP F
the 0 DET F
clinical B-PHYSICAL ADJ F
or I-PHYSICAL CCONJ F
pathological I-PHYSICAL ADJ F
parameters I-PHYSICAL NOUN F
, 0 PUNCT F
or 0 CCONJ F
prostate B-PHYSICAL NOUN F
specific I-PHYSICAL ADJ F
antigen I-PHYSICAL NOUN F
relapse I-PHYSICAL NOUN F
rates I-PHYSICAL NOUN F
in 0 ADP F
patients 0 NOUN F
with 0 ADP F
negative 0 ADJ F
versus 0 CCONJ F
positive 0 ADJ F
repeat 0 NOUN F
biopsies 0 NOUN F
. 0 PUNCT F

CONCLUSIONS 0 ADP T
Our 0 PUNCT T
findings 0 NOUN F
suggest 0 VERB F
that 0 ADP F
this 0 DET F
23 0 NUM F
% 0 SYM F
incidence 0 NOUN F
of 0 ADP F
false-negative 0 ADJ F
biopsies 0 NOUN F
represents 0 NOUN F
significant 0 ADJ F
cancer 0 NOUN F
. 0 PUNCT F

This 0 PUNCT T
relatively 0 ADV F
high 0 ADJ F
incidence 0 NOUN F
is 0 VERB F
important 0 ADJ F
to 0 PART F
consider 0 NOUN F
in 0 ADP F
treatment 0 NOUN F
modalities 0 NOUN F
in 0 ADP F
which 0 ADP F
prostate 0 NOUN F
biopsy 0 NOUN F
may 0 VERB F
be 0 NOUN F
performed 0 VERB F
to 0 PART F
determine 0 NOUN F
response 0 NOUN F
to 0 ADP F
therapy 0 NOUN F
. 0 PUNCT F

Comparison 0 NOUN T
of 0 ADP F
split-course 0 PUNCT F
radiation 0 NOUN F
therapy 0 NOUN F
and 0 CCONJ F
continuous 0 ADJ F
radiation 0 NOUN F
therapy 0 NOUN F
for 0 ADP F
unresectable 0 ADJ F
bronchogenic 0 ADJ F
carcinoma 0 NOUN F
: 0 PUNCT F
5 0 NUM F
year 0 NOUN F
results 0 NOUN F
. 0 PUNCT F

One 0 NUM T
hundred 0 NUM F
and 0 CCONJ F
eighty-eight 0 PUNCT F
patients 0 NOUN F
with 0 ADP F
inoperable 0 ADJ F
or 0 CCONJ F
unresectable 0 ADJ F
bronchogenic 0 ADJ F
carcinoma 0 NOUN F
were 0 VERB F
stratified 0 VERB F
by 0 ADP F
cell 0 NOUN F
type 0 NOUN F
, 0 PUNCT F
TNM 0 NOUN T
staging 0 VERB F
, 0 PUNCT F
and 0 CCONJ F
prior 0 VERB F
surgery 0 NOUN F
and 0 CCONJ F
then 0 ADV F
randomized 0 PUNCT F
into 0 ADP F
two 0 NUM F
treatment 0 NOUN F
groups 0 NOUN F
: 0 PUNCT F
continuous 0 ADJ F
radiation 0 NOUN F
therapy 0 NOUN F
and 0 CCONJ F
split-course 0 PUNCT F
radiation 0 NOUN F
therapy 0 NOUN F
. 0 PUNCT F

There 0 PUNCT T
was 0 VERB F
no 0 DET F
difference 0 NOUN F
in 0 ADP F
clinical 0 ADJ F
or 0 CCONJ F
objective 0 ADJ F
improvement 0 NOUN F
in 0 ADP F
the 0 DET F
two 0 NUM F
groups 0 NOUN F
. 0 PUNCT F

Survival B-MORTALITY NOUN T
rates I-MORTALITY NOUN F
for 0 ADP F
cases 0 NOUN F
of 0 ADP F
squamous 0 ADJ F
cell 0 NOUN F
carcinoma 0 NOUN F
, 0 PUNCT F
small 0 ADJ F
cell 0 NOUN F
carcinoma 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
adrenocarcinoma 0 NOUN F
were 0 VERB F
the 0 DET F
same 0 ADP F
after 0 ADP F
both 0 CCONJ F
regimens 0 NOUN F
of 0 ADP F
therapy 0 NOUN F
. 0 PUNCT F

Split-course B-OTHER ADJ T
therapy I-OTHER NOUN F
resulted 0 VERB F
in 0 ADP F
a 0 DET F
significantly 0 ADV F
better 0 PUNCT F
survival 0 NOUN F
rate 0 NOUN F
in 0 ADP F
cases 0 NOUN F
of 0 ADP F
large 0 ADJ F
cell 0 NOUN F
carcinoma 0 NOUN F
but 0 CCONJ F
the 0 DET F
number 0 NOUN F
of 0 ADP F
cases 0 NOUN F
was 0 VERB F
small 0 ADJ F
. 0 PUNCT F

We 0 PRON T
doubt 0 ADP F
that 0 CCONJ F
the 0 DET F
difference 0 NOUN F
is 0 VERB F
clinically 0 ADV F
significant 0 ADJ F
. 0 PUNCT F

Objective B-PHYSICAL ADJ T
roentgenographic I-PHYSICAL ADJ F
response I-PHYSICAL NOUN F
was 0 VERB F
accompanied 0 VERB F
by 0 ADP F
improved B-MORTALITY VERB F
survival I-MORTALITY NOUN F
in 0 ADP F
squamous 0 ADJ F
cell 0 NOUN F
carcinoma 0 NOUN F
, 0 PUNCT F
but 0 CCONJ F
not 0 ADV F
in 0 ADP F
the 0 DET F
other 0 ADJ F
three 0 NUM F
cell 0 NOUN F
types 0 NOUN F
. 0 PUNCT F

Split-course 0 ADJ T
radiation 0 NOUN F
therapy 0 NOUN F
is 0 VERB F
superior 0 ADJ F
to 0 ADP F
continuous 0 ADJ F
radiation 0 NOUN F
therapy 0 NOUN F
because 0 PUNCT F
it 0 PRON F
is 0 VERB F
better B-OTHER PUNCT F
tolerated I-OTHER ADP F
by 0 ADP F
the 0 DET F
patient 0 NOUN F
and 0 CCONJ F
because 0 PUNCT F
re-examination 0 NOUN F
of 0 ADP F
the 0 DET F
patient 0 NOUN F
prior 0 PUNCT F
to 0 ADP F
the 0 DET F
second 0 ADJ F
half 0 NOUN F
of 0 ADP F
split-course 0 PUNCT F
therapy 0 NOUN F
permits 0 NOUN F
the 0 DET F
detection 0 NOUN F
of 0 ADP F
new 0 ADJ F
metastatic 0 ADJ F
disease 0 NOUN F
that 0 ADP F
has 0 PUNCT F
become 0 NUM F
manifest 0 ADV F
during 0 ADP F
the 0 DET F
rest 0 NOUN F
period 0 NOUN F
and 0 CCONJ F
spares 0 NOUN F
the 0 DET F
patient 0 NOUN F
the 0 DET F
futile 0 ADJ F
second 0 ADJ F
half 0 NOUN F
of 0 ADP F
radiation 0 NOUN F
therapy 0 NOUN F
. 0 PUNCT F

Sustained 0 VERB T
benefit 0 NOUN F
of 0 ADP F
continuous 0 ADJ F
glucose 0 NOUN F
monitoring 0 VERB F
on 0 ADP F
A1C 0 NOUN T
, 0 PUNCT F
glucose 0 NOUN F
profiles 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
hypoglycemia 0 NOUN F
in 0 ADP F
adults 0 NOUN F
with 0 ADP F
type 0 NOUN F
1 0 NUM F
diabetes 0 NOUN F
. 0 PUNCT F

OBJECTIVE 0 NOUN T
To 0 PROPN T
evaluate 0 NOUN F
long-term 0 NOUN F
effects 0 NOUN F
of 0 ADP F
continuous 0 ADJ F
glucose 0 NOUN F
monitoring 0 VERB F
( 0 PUNCT F
CGM 0 NOUN T
) 0 PUNCT F
in 0 ADP F
intensively 0 ADV F
treated 0 VERB F
adults 0 NOUN F
with 0 ADP F
type 0 NOUN F
1 0 NUM F
diabetes 0 NOUN F
. 0 PUNCT F

RESEARCH 0 NOUN T
DESIGN 0 NOUN T
AND 0 CCONJ T
METHODS 0 NOUN T
We 0 PRON T
studied 0 VERB F
83 0 NUM F
of 0 ADP F
86 0 NUM F
individuals 0 NOUN F
> 0 SYM F
or=25 0 ADJ F
years 0 NOUN F
of 0 ADP F
age 0 NOUN F
with 0 ADP F
type 0 NOUN F
1 0 NUM F
diabetes 0 NOUN F
who 0 ADP F
used 0 VERB F
CGM 0 NOUN T
as 0 ADP F
part 0 NOUN F
of 0 ADP F
a 0 DET F
6-month 0 NOUN F
randomized 0 VERB F
clinical 0 ADJ F
trial 0 NOUN F
in 0 ADP F
a 0 DET F
subsequent 0 ADJ F
6-month 0 NOUN F
extension 0 NOUN F
study 0 NOUN F
. 0 PUNCT F

RESULTS 0 NOUN T
After 0 ADP T
12 0 NUM F
months 0 NOUN F
, 0 PUNCT F
median 0 ADJ F
CGM 0 NOUN T
use 0 NOUN F
was 0 VERB F
6.8 0 NUM F
days 0 NOUN F
per 0 ADP F
week 0 NOUN F
. 0 PUNCT F

Mean 0 PUNCT T
change B-PHYSICAL NOUN F
in I-PHYSICAL ADP F
A1C I-PHYSICAL NOUN T
level I-PHYSICAL NOUN F
from 0 ADP F
baseline 0 NOUN F
to 0 ADP F
12 0 NUM F
months 0 NOUN F
was 0 VERB F
-0.4 0 NUM F
+/- 0 SYM F
0.6 0 NUM F
% 0 SYM F
( 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.001 0 NUM F
) 0 PUNCT F
in 0 ADP F
subjects 0 NOUN F
with 0 ADP F
baseline 0 NOUN F
A1C 0 NOUN T
> 0 SYM F
or=7.0 0 NOUN F
% 0 SYM F
. 0 PUNCT F

A1C B-PHYSICAL NOUN T
remained 0 VERB F
stable 0 ADJ F
at 0 ADP F
6.4 0 NUM F
% 0 SYM F
in 0 ADP F
those 0 PUNCT F
with 0 ADP F
baseline 0 NOUN F
A1C 0 NOUN T
< 0 SYM F
7.0 0 NUM F
% 0 SYM F
. 0 PUNCT F

The 0 DET T
incidence 0 NOUN F
rate 0 NOUN F
of 0 ADP F
severe B-PHYSICAL ADJ F
hypoglycemia I-PHYSICAL NOUN F
was 0 VERB F
21.8 0 NUM F
and 0 CCONJ F
7.1 0 NUM F
events 0 NOUN F
per 0 ADP F
100 0 NUM F
person-years 0 PROPN F
in 0 ADP F
the 0 DET F
first 0 ADJ F
and 0 CCONJ F
last 0 PUNCT F
6 0 NUM F
months 0 NOUN F
, 0 PUNCT F
respectively 0 ADV F
. 0 PUNCT F

Time B-PHYSICAL NOUN T
per I-PHYSICAL ADP F
day I-PHYSICAL NOUN F
with I-PHYSICAL ADP F
glucose I-PHYSICAL NOUN F
levels I-PHYSICAL NOUN F
in 0 ADP F
the 0 DET F
range 0 NOUN F
of 0 ADP F
71-180 0 NUM F
mg/dl 0 NOUN F
increased 0 VERB F
significantly 0 ADV F
( 0 PUNCT F
P 0 NOUN T
= 0 SYM F
0.02 0 NUM F
) 0 PUNCT F
from 0 ADP F
baseline 0 NOUN F
to 0 ADP F
12 0 NUM F
months 0 NOUN F
. 0 PUNCT F

CONCLUSIONS 0 NOUN T
In 0 ADP T
intensively 0 ADV F
treated 0 VERB F
adults 0 NOUN F
with 0 ADP F
type 0 NOUN F
1 0 NUM F
diabetes 0 NOUN F
, 0 PUNCT F
CGM 0 CCONJ T
use 0 NOUN F
and 0 CCONJ F
benefit 0 NOUN F
can 0 VERB F
be 0 VERB F
sustained 0 VERB F
for 0 ADP F
12 0 NUM F
months 0 NOUN F
. 0 PUNCT F

Growth B-PHYSICAL NOUN T
hormone I-PHYSICAL NOUN F
( I-PHYSICAL PUNCT F
GH I-PHYSICAL NOUN T
) I-PHYSICAL PUNCT F
responses I-PHYSICAL NOUN F
to 0 ADP F
GH-releasing 0 VERB T
hormone 0 NOUN F
alone 0 ADJ F
or 0 CCONJ F
combined 0 VERB F
with 0 ADP F
arginine 0 NOUN F
in 0 ADP F
patients 0 NOUN F
with 0 ADP F
adrenal 0 ADJ F
incidentaloma 0 NOUN F
: 0 PUNCT F
evidence 0 NOUN F
for 0 ADP F
enhanced 0 NOUN F
somatostatinergic 0 ADJ F
tone 0 NOUN F
. 0 PUNCT F

Spontaneous 0 ADJ T
and 0 CCONJ F
stimulated 0 PUNCT F
GH 0 NOUN T
secretion 0 NOUN F
is 0 VERB F
blunted 0 VERB F
in 0 ADP F
hypercortisolemic 0 ADJ F
states 0 NOUN F
due 0 CCONJ F
to 0 ADP F
increased 0 PUNCT F
hypothalamic 0 ADJ F
somatostatinergic 0 ADJ F
tone 0 NOUN F
. 0 PUNCT F

However 0 ADV T
, 0 PUNCT F
no 0 DET F
data 0 NOUN F
are 0 VERB F
available 0 ADJ F
on 0 ADP F
the 0 DET F
characteristics 0 NOUN F
of 0 ADP F
GH 0 NOUN T
secretion 0 NOUN F
in 0 ADP F
patients 0 NOUN F
with 0 ADP F
incidentally 0 ADV F
discovered 0 PUNCT F
adrenal 0 ADJ F
adenomas 0 NOUN F
. 0 PUNCT F

They 0 PRON T
represent 0 VERB F
an 0 DET F
interesting 0 VERB F
model 0 NOUN F
for 0 ADP F
studying 0 VERB F
GH 0 NOUN T
secretion 0 NOUN F
, 0 PUNCT F
as 0 ADP F
a 0 DET F
slight 0 ADJ F
degree 0 NOUN F
of 0 ADP F
cortisol 0 NOUN F
excess 0 ADJ F
may 0 ADP F
frequently 0 ADV F
be 0 PUNCT F
observed 0 VERB F
in 0 ADP F
such 0 DET F
patients 0 NOUN F
who 0 ADP F
do 0 PUNCT F
not 0 ADV F
present 0 PUNCT F
with 0 ADP F
any 0 DET F
clear 0 ADJ F
Cushingoid 0 NOUN T
sign 0 NOUN F
. 0 PUNCT F

In 0 ADP T
the 0 DET F
present 0 ADJ F
study 0 NOUN F
, 0 PUNCT F
10 0 NUM F
patients 0 NOUN F
( 0 PUNCT F
3 0 NUM F
men 0 NOUN F
and 0 CCONJ F
7 0 NUM F
women 0 NOUN F
, 0 PUNCT F
aged 0 PUNCT F
48-63 0 NUM F
yr 0 NOUN F
) 0 PUNCT F
with 0 ADP F
an 0 DET F
adrenal 0 ADJ F
mass 0 NOUN F
discovered 0 ADP F
serendipitously 0 ADV F
underwent 0 ADP F
, 0 PUNCT F
on 0 ADP F
separate 0 ADJ F
occasions 0 NOUN F
, 0 PUNCT F
a 0 DET F
GHRH 0 NOUN T
injection 0 NOUN F
alone 0 ADJ F
or 0 CCONJ F
combined 0 VERB F
with 0 ADP F
an 0 DET F
infusion 0 NOUN F
of 0 ADP F
the 0 DET F
functional 0 ADJ F
somatostatin 0 NOUN F
antagonist 0 NOUN F
, 0 PUNCT F
arginine 0 NOUN F
. 0 PUNCT F

Thirteen 0 ADP T
age-matched 0 DET F
healthy 0 ADJ F
volunteers 0 NOUN F
served 0 VERB F
as 0 ADP F
controls 0 VERB F
. 0 PUNCT F

Briefly 0 ADP T
, 0 PUNCT F
arginine 0 NOUN F
( 0 PUNCT F
30 0 NUM F
g 0 NOUN F
) 0 PUNCT F
was 0 VERB F
infused 0 VERB F
from 0 ADP F
-30 0 PUNCT F
to 0 ADP F
0 0 NUM F
min 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
GHRH 0 NOUN T
( 0 PUNCT F
100 0 NUM F
microg 0 NOUN F
) 0 PUNCT F
was 0 VERB F
injected 0 VERB F
as 0 ADP F
a 0 DET F
bolus 0 NOUN F
at 0 ADP F
0 0 NUM F
min 0 NOUN F
, 0 PUNCT F
with 0 ADP F
measurement 0 NOUN F
of 0 ADP F
serum 0 NOUN F
GH 0 NOUN T
[ 0 PUNCT F
immunoradiometric 0 ADJ F
assay 0 NOUN F
( 0 PUNCT F
IRMA 0 NOUN T
) 0 PUNCT F
] 0 PUNCT F
every 0 DET F
15 0 NUM F
min 0 NOUN F
for 0 ADP F
150 0 NUM F
min 0 NOUN F
. 0 PUNCT F

Plasma 0 NOUN T
IGF-I 0 NOUN T
( 0 PUNCT F
RIA 0 NOUN T
after 0 ADP F
acid-ethanol 0 NOUN F
extraction 0 NOUN F
) 0 PUNCT F
was 0 VERB F
measured 0 VERB F
in 0 ADP F
a 0 DET F
morning 0 NOUN F
sample 0 NOUN F
. 0 PUNCT F

The 0 DET T
diagnosis 0 NOUN F
of 0 ADP F
cortical 0 ADJ F
adenoma 0 NOUN F
was 0 VERB F
based 0 VERB F
on 0 ADP F
computed 0 PUNCT F
tomography 0 NOUN F
features 0 NOUN F
and 0 CCONJ F
pattern 0 NOUN F
of 0 ADP F
uptake 0 NOUN F
on 0 ADP F
adrenal 0 ADJ F
scintigraphy 0 NOUN F
. 0 PUNCT F

Patients 0 NOUN T
with 0 ADP F
obesity 0 NOUN F
and/or 0 CCONJ F
diabetes 0 NOUN F
were 0 VERB F
excluded 0 VERB F
. 0 PUNCT F

The 0 DET T
study 0 NOUN F
design 0 NOUN F
included 0 VERB F
also 0 ADV F
an 0 DET F
endocrine 0 ADJ F
work-up 0 ADJ F
aimed 0 ADJ F
to 0 ADV F
study 0 NOUN F
the 0 DET F
hypothalamic-pituitary-adrenal B-PHYSICAL ADJ F
axis I-PHYSICAL NOUN F
[ I-PHYSICAL PUNCT F
urinary I-PHYSICAL ADJ F
free I-PHYSICAL ADJ F
cortisol I-PHYSICAL NOUN F
( I-PHYSICAL PUNCT F
UFC I-PHYSICAL NOUN T
) I-PHYSICAL PUNCT F
excretion I-PHYSICAL NOUN F
, 0 PUNCT F
serum B-PHYSICAL NOUN F
cortisol I-PHYSICAL NOUN F
at I-PHYSICAL ADP F
0800 I-PHYSICAL NUM F
h I-PHYSICAL NOUN F
, 0 PUNCT F
plasma B-PHYSICAL NOUN F
ACTH I-PHYSICAL NOUN T
at I-PHYSICAL ADP F
0800 I-PHYSICAL NUM F
h I-PHYSICAL NOUN F
, 0 PUNCT F
morning B-PHYSICAL NOUN F
cortisol I-PHYSICAL NOUN F
after I-PHYSICAL ADP F
overnight I-PHYSICAL CCONJ F
1 I-PHYSICAL NUM F
mg I-PHYSICAL NOUN F
dexamethasone I-PHYSICAL NOUN F
] 0 PUNCT F
. 0 PUNCT F

Five 0 NUM T
of 0 ADP F
10 0 NUM F
patients 0 NOUN F
showed 0 VERB F
abnormalities 0 NOUN F
of 0 ADP F
the 0 DET F
hypothalamic-pituitary-adrenal B-PHYSICAL ADJ F
axis I-PHYSICAL NOUN F
, 0 PUNCT F
including 0 CCONJ F
borderline B-PHYSICAL NOUN F
or 0 CCONJ F
increased 0 VERB F
UFC B-PHYSICAL NOUN T
excretion I-PHYSICAL NOUN F
in 0 ADP F
4 0 NUM F
of 0 ADP F
them 0 PRON F
accompanied 0 VERB F
by 0 ADP F
blunted 0 VERB F
ACTH 0 NOUN T
in 0 ADP F
2 0 NUM F
cases 0 NOUN F
and 0 CCONJ F
failure 0 NOUN F
of 0 ADP F
cortisol 0 NOUN F
to 0 ADP F
suppress 0 ADP F
after 0 ADP F
dexamethasone 0 NOUN F
in 0 ADP F
1 0 NUM F
; 0 PUNCT F
the 0 DET F
fifth 0 ADJ F
patient 0 NOUN F
displayed 0 VERB F
low 0 ADJ F
ACTH 0 NOUN T
and 0 CCONJ F
resistance 0 NOUN F
to 0 ADP F
dexamethasone 0 NOUN F
suppression 0 NOUN F
. 0 PUNCT F

However 0 ADV T
, 0 PUNCT F
all 0 DET F
patients 0 NOUN F
had 0 ADP F
a 0 DET F
unilateral 0 ADJ F
uptake 0 NOUN F
of 0 ADP F
the 0 DET F
tracer 0 NOUN F
on 0 ADP F
the 0 DET F
side 0 NOUN F
of 0 ADP F
the 0 DET F
mass 0 NOUN F
with 0 ADP F
suppression 0 NOUN F
of 0 ADP F
the 0 DET F
contralateral 0 ADJ F
normal 0 ADJ F
adrenal 0 ADJ F
gland 0 NOUN F
. 0 PUNCT F

As 0 ADP T
a 0 DET F
group 0 NOUN F
, 0 PUNCT F
the 0 DET F
patients 0 NOUN F
displayed 0 VERB F
greater 0 PUNCT F
UFC B-PHYSICAL NOUN T
excretion I-PHYSICAL NOUN F
and 0 CCONJ F
lower B-PHYSICAL PUNCT F
ACTH I-PHYSICAL NOUN T
concentrations I-PHYSICAL ADJ F
than 0 PUNCT F
the 0 DET F
controls 0 NOUN F
. 0 PUNCT F

GH B-PHYSICAL NOUN T
release I-PHYSICAL NOUN F
after I-PHYSICAL ADP F
GHRH I-PHYSICAL NOUN T
treatment I-PHYSICAL NOUN F
was 0 VERB F
blunted 0 VERB F
in 0 ADP F
patients 0 NOUN F
bearing 0 SYM F
adrenal 0 ADJ F
incidentaloma 0 NOUN F
compared 0 VERB F
with 0 ADP F
controls 0 NOUN F
( 0 PUNCT F
GH 0 NOUN T
peak 0 NOUN F
, 0 PUNCT F
5.7 0 NUM F
+/- 0 SYM F
5.2 0 NUM F
vs. 0 CCONJ F
18.0 0 NUM F
+/- 0 SYM F
7.0 0 NUM F
microg/L 0 NOUN F
; 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.0001 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
whereas 0 ADP F
GHRH 0 ADP T
plus 0 CCONJ F
arginine 0 NOUN F
was 0 VERB F
able 0 ADJ F
to 0 PART F
elicit 0 NOUN F
a 0 DET F
comparable 0 ADJ F
response 0 NOUN F
in 0 ADP F
the 0 DET F
2 0 NUM F
groups 0 NOUN F
( 0 PUNCT F
GH 0 NOUN T
peak 0 NOUN F
, 0 PUNCT F
33.5 0 NUM F
+/- 0 SYM F
20.3 0 NUM F
vs. 0 CCONJ F
33.7 0 NUM F
+/- 0 SYM F
17.5 0 NUM F
microg/L 0 NOUN F
; 0 PUNCT F
P 0 NOUN T
= 0 SYM F
NS 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
ratio 0 NOUN F
between 0 ADP F
GH B-PHYSICAL NOUN T
peaks I-PHYSICAL CCONJ F
after I-PHYSICAL ADP F
GHRH I-PHYSICAL ADP T
plus I-PHYSICAL CCONJ F
arginine I-PHYSICAL NOUN F
and 0 CCONJ F
after 0 ADP F
GHRH B-PHYSICAL ADP T
plus 0 CCONJ F
saline B-PHYSICAL NOUN F
was 0 VERB F
significantly 0 ADV F
greater 0 PUNCT F
in 0 ADP F
patients 0 NOUN F
than 0 PUNCT F
in 0 ADP F
controls 0 NOUN F
( 0 PUNCT F
751 0 NUM F
+/- 0 SYM F
531 0 NUM F
% 0 SYM F
vs. 0 CCONJ F
81 0 NUM F
+/- 0 SYM F
45 0 NUM F
% 0 ADJ F
; 0 PUNCT F
P 0 NOUN T
= 0 SYM F
0.0001 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Similar 0 ADJ T
data 0 NOUN F
were 0 VERB F
obtained 0 VERB F
when 0 ADP F
comparing 0 VERB F
GH 0 NOUN T
area 0 NOUN F
under 0 ADP F
the 0 DET F
curve 0 NOUN F
after 0 ADP F
GHRH 0 ADP T
plus 0 CCONJ F
saline 0 ADJ F
or 0 CCONJ F
GHRH 0 ADP T
plus 0 CCONJ F
arginine 0 NOUN F
between 0 ADP F
the 0 DET F
2 0 NUM F
groups 0 NOUN F
. 0 PUNCT F

In 0 ADP T
summary 0 NOUN F
, 0 PUNCT F
the 0 DET F
present 0 ADJ F
data 0 NOUN F
suggest 0 VERB F
that 0 ADP F
in 0 ADP F
patients 0 NOUN F
with 0 ADP F
incidental 0 DET F
adrenal 0 ADJ F
adenomas 0 NOUN F
the 0 DET F
GH B-PHYSICAL NOUN T
response I-PHYSICAL NOUN F
to 0 ADP F
GHRH 0 NOUN T
is 0 VERB F
blunted 0 VERB F
due 0 CCONJ F
to 0 ADP F
increased 0 VERB F
somatostatinergic B-PHYSICAL ADJ F
tone I-PHYSICAL NOUN F
, 0 PUNCT F
as 0 PUNCT F
it 0 DET F
can 0 VERB F
be 0 VERB F
restored 0 VERB F
to 0 ADP F
normal 0 ADJ F
by 0 ADP F
pretreatment 0 NOUN F
with 0 ADP F
the 0 DET F
functional 0 ADJ F
somatostatin 0 NOUN F
antagonist 0 NOUN F
arginine 0 NOUN F
. 0 PUNCT F

The 0 DET T
blunted 0 VERB F
GH 0 NOUN T
release 0 NOUN F
to 0 ADP F
GHRH 0 NOUN T
may 0 VERB F
be 0 ADJ F
an 0 DET F
early 0 ADJ F
and 0 CCONJ F
long 0 VERB F
lasting 0 NOUN F
sign 0 NOUN F
of 0 ADP F
autonomous 0 ADJ F
cortisol 0 NOUN F
secretion 0 NOUN F
by 0 ADP F
the 0 DET F
adrenal 0 ADJ F
adenoma 0 NOUN F
. 0 PUNCT F

Impact B-OTHER NOUN T
of 0 ADP F
a 0 DET F
fixed 0 VERB F
combination 0 NOUN F
of 0 ADP F
clindamycin 0 NOUN F
phosphate 0 NOUN F
1.2 0 NUM F
% 0 ADP F
-benzoyl 0 DET F
peroxide 0 NOUN F
2.5 0 NUM F
% 0 SYM F
aqueous 0 ADJ F
gel 0 NOUN F
on 0 ADP F
health-related 0 VERB F
quality 0 NOUN F
of 0 ADP F
life 0 NOUN F
in 0 ADP F
moderate 0 ADJ F
to 0 ADP F
severe 0 ADJ F
acne 0 NOUN F
vulgaris 0 NOUN F
. 0 PUNCT F

The 0 DET T
acne-specific 0 ADJ F
quality 0 NOUN F
of 0 ADP F
life 0 NOUN F
( 0 PUNCT F
Acne-QoL 0 NOUN T
) 0 PUNCT F
questionnaire 0 NOUN F
was 0 VERB F
developed 0 VERB F
to 0 PART F
measure B-PHYSICAL VERB F
the I-PHYSICAL DET F
impact I-PHYSICAL NOUN F
of I-PHYSICAL ADP F
facial I-PHYSICAL ADJ F
acne I-PHYSICAL NOUN F
across 0 ADP F
4 0 NUM F
domains 0 NOUN F
( 0 PUNCT F
acne 0 NOUN F
symptoms 0 NOUN F
, 0 PUNCT F
role-emotional 0 ADJ F
, 0 PUNCT F
self-perception 0 NOUN F
, 0 PUNCT F
role-social 0 ADJ F
) 0 PUNCT F
of 0 ADP F
health-related B-PHYSICAL VERB F
quality 0 NOUN F
of 0 ADP F
life 0 NOUN F
( B-PHYSICAL PUNCT F
HRQL B-PHYSICAL NOUN T
) B-PHYSICAL PUNCT F
. 0 PUNCT F

This 0 DET T
analysis 0 NOUN F
assessed 0 VERB F
the 0 DET F
impact 0 NOUN F
of 0 ADP F
clindamycin 0 NOUN F
phosphate 0 NOUN F
1.2 0 NUM F
% 0 ADP F
-benzoyl 0 DET F
peroxide 0 NOUN F
2.5 0 NUM F
% 0 SYM F
( 0 PUNCT F
clindamycin-BPO 0 NOUN F
2.5 0 NUM F
% 0 SYM F
) 0 PUNCT F
gel 0 NOUN F
on 0 ADP F
HRQL 0 NOUN T
in 0 ADP F
a 0 DET F
combined 0 ADP F
study 0 NOUN F
population 0 NOUN F
( 0 PUNCT F
N 0 NOUN T
= 0 SYM F
2813 0 NUM F
) 0 PUNCT F
of 0 ADP F
participants 0 NOUN F
with 0 ADP F
moderate 0 ADJ F
to 0 ADP F
severe 0 ADJ F
acne 0 NOUN F
vulgaris 0 NOUN F
. 0 PUNCT F

Although 0 ADP T
the 0 DET F
results 0 NOUN F
presented 0 VERB F
within 0 ADP F
do 0 PUNCT F
not 0 ADV F
include 0 VERB F
factors 0 NOUN F
of 0 ADP F
study 0 NOUN F
and 0 CCONJ F
study-by-treatment 0 PUNCT F
interaction 0 NOUN F
, 0 PUNCT F
analyses 0 NOUN F
were 0 VERB F
performed 0 VERB F
to 0 ADP F
confirm 0 ADJ F
that 0 ADP F
the 0 DET F
results 0 NOUN F
were 0 VERB F
consistent 0 ADJ F
across 0 ADP F
the 0 DET F
2 0 NUM F
identical 0 ADJ F
, 0 PUNCT F
double-blind 0 ADJ F
, 0 PUNCT F
randomized 0 VERB F
studies 0 NOUN F
and 0 CCONJ F
within 0 ADP F
each 0 DET F
treatment 0 NOUN F
group 0 NOUN F
across 0 ADP F
studies 0 NOUN F
to 0 ADP F
justify 0 VERB F
pooling 0 PUNCT F
the 0 DET F
data 0 NOUN F
from 0 ADP F
both 0 CCONJ F
studies 0 NOUN F
. 0 PUNCT F

The 0 DET T
Acne-QoL B-PHYSICAL NOUN T
questionnaire 0 NOUN F
was 0 VERB F
administered 0 VERB F
at 0 ADP F
baseline 0 NOUN F
and 0 CCONJ F
at 0 ADP F
the 0 DET F
end 0 NOUN F
of 0 ADP F
treatment 0 NOUN F
( 0 PUNCT F
week 0 NOUN F
12 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Treatment 0 NOUN T
with 0 ADP F
clindamycin-BPO 0 NOUN F
2.5 0 NUM F
% 0 SYM F
gel 0 NOUN F
significantly 0 ADV F
improved 0 VERB F
participant-reported 0 PUNCT F

The 0 DET T
impact 0 NOUN F
of 0 ADP F
patient 0 NOUN F
and 0 CCONJ F
physician 0 NOUN F
computer 0 NOUN F
mediated 0 ADP F
communication 0 NOUN F
skill 0 ADP F
training 0 SYM F
on 0 ADP F
reported 0 VERB F
communication 0 NOUN F
and 0 CCONJ F
patient 0 NOUN F
satisfaction 0 NOUN F
. 0 PUNCT F

OBJECTIVE 0 NOUN T
The 0 DET T
objective 0 ADJ F
was 0 VERB F
to 0 PART F
evaluate 0 NOUN F
parallel B-MENTAL DET F
patient I-MENTAL NOUN F
and I-MENTAL CCONJ F
physician I-MENTAL NOUN F
computer-mediated I-MENTAL VERB F
communication I-MENTAL NOUN F
skill I-MENTAL PUNCT F
training I-MENTAL SYM F
on 0 ADP F
participants 0 NOUN F
' 0 PUNCT F
report 0 NOUN F
of 0 ADP F
skill 0 DET F
use 0 ADP F
and 0 CCONJ F
patient 0 NOUN F
satisfaction 0 NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
Separate 0 ADJ T
patient 0 NOUN F
and 0 CCONJ F
clinician 0 NOUN F
web-tools 0 PROPN F
comprised 0 ADP F
of 0 ADP F
over 0 PUNCT F
500 0 NUM F
, 0 PUNCT F
10-s 0 ADP F
video 0 ADJ F
clips 0 NOUN F
demonstrating 0 VERB F
patient-centered B-MENTAL VERB F
skills I-MENTAL NOUN F
in 0 ADP F
various 0 ADJ F
ways 0 NOUN F
. 0 PUNCT F

Four 0 NUM T
clinician 0 NOUN F
members 0 NOUN F
of 0 ADP F
the 0 DET F
American 0 ADJ T
Academy 0 PUNCT T
of 0 ADP F
Family 0 NOUN T
Physicians 0 PROPN T
National 0 ADJ T
Research 0 NOUN T
Network 0 NOUN T
participated 0 VERB F
by 0 ADP F
enrolling 0 ADP F
194 0 NUM F
patients 0 NOUN F
into 0 ADP F
a 0 DET F
randomized 0 VERB F
patient 0 NOUN F
trial 0 NOUN F
and 0 CCONJ F
29 0 NUM F
physicians 0 NOUN F
into 0 ADP F
a 0 DET F
non-randomized 0 ADJ F
clinician 0 NOUN F
trial 0 NOUN F
of 0 ADP F
respective 0 ADJ F
interventions 0 NOUN F
. 0 PUNCT F

All 0 DET T
participants 0 NOUN F
completed 0 ADV F
baseline 0 NOUN F
and 0 CCONJ F
follow-up 0 NOUN F
self-report 0 ADJ F
measures 0 NOUN F
of 0 ADP F
visit 0 NOUN F
communication B-OTHER NOUN F
and 0 CCONJ F
satisfaction B-OTHER NOUN F
. 0 PUNCT F

RESULTS 0 CCONJ T
Intervention 0 NOUN T
patients 0 NOUN F
reported 0 VERB F
using 0 SYM F
more 0 ADP F
skills B-MENTAL NOUN F
than 0 CCONJ F
controls 0 CCONJ F
in 0 ADP F
five 0 NUM F
of 0 ADP F
six 0 NUM F
skill 0 PUNCT F
areas 0 NOUN F
, 0 PUNCT F
including 0 CCONJ F
identification 0 NOUN F
of 0 ADP F
problems/concerns B-MENTAL PUNCT F
, 0 PUNCT F
information 0 NOUN F
exchange B-MENTAL NOUN F
, 0 PUNCT F
treatment 0 NOUN F
adherence B-MENTAL NOUN F
, 0 PUNCT F
shared 0 VERB F
decision-making B-MENTAL PROPN F
and 0 CCONJ F
interpersonal B-MENTAL PUNCT F
rapport I-MENTAL NOUN F
( 0 PUNCT F
all 0 DET F
p 0 NOUN F
< 0 SYM F
.05 0 NUM F
) 0 PUNCT F
; 0 PUNCT F
post 0 PUNCT F
intervention 0 NOUN F
, 0 PUNCT F
physicians 0 NOUN F
reported 0 VERB F
using 0 SYM F
more 0 ADP F
skills 0 NOUN F
in 0 ADP F
the 0 DET F
same 0 ADJ F
5 0 NUM F
areas 0 NOUN F
( 0 PUNCT F
all 0 DET F
p 0 NOUN F
< 0 SYM F
.01 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Intervention 0 NOUN T
group 0 NOUN F
patients 0 NOUN F
reported 0 VERB F
higher 0 PUNCT F
levels 0 NOUN F
of 0 ADP F
satisfaction 0 NOUN F
than 0 PUNCT F
controls 0 CCONJ F
in 0 ADP F
five 0 NUM F
of 0 ADP F
six 0 NUM F
domains 0 NOUN F
( 0 PUNCT F
all 0 DET F
p 0 NOUN F
< 0 SYM F
.05 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

CONCLUSION 0 NOUN T
Communication 0 NOUN T
skill 0 ADJ F
training 0 SYM F
delivered 0 VERB F
in 0 ADP F
a 0 DET F
computer 0 NOUN F
mediated 0 PUNCT F
format 0 NOUN F
had 0 PUNCT F
a 0 DET F
positive 0 ADJ F
and 0 CCONJ F
parallel B-OTHER ADP F
impact I-OTHER NOUN F
on 0 ADP F
both 0 PUNCT F
patient 0 NOUN F
and 0 CCONJ F
clinician 0 NOUN F
reported 0 ADP F
use 0 NOUN F
of 0 ADP F
patient-centered B-MENTAL VERB F
communication I-MENTAL NOUN F
and 0 CCONJ F
in 0 ADP F
patient B-OTHER NOUN F
satisfaction I-OTHER NOUN F
. 0 PUNCT F

PRACTICE 0 NOUN T
IMPLICATIONS 0 NOUN T
Computer-mediated 0 VERB T
interventions 0 NOUN F
are 0 VERB F
cost 0 NOUN F
and 0 CCONJ F
time 0 NOUN F
effective 0 ADJ F
thereby 0 PUNCT F
increasing 0 ADP F
patient 0 NOUN F
and 0 CCONJ F
clinician 0 NOUN F
willingness 0 ADP F
to 0 ADP F
undertake 0 NOUN F
training 0 ADV F
. 0 PUNCT F

Left 0 ADJ T
thoracoabdominal 0 ADJ F
approach 0 NOUN F
versus 0 CCONJ F
abdominal-transhiatal 0 ADJ F
approach 0 NOUN F
for 0 ADP F
gastric 0 ADJ F
cancer 0 NOUN F
of 0 ADP F
the 0 DET F
cardia 0 NOUN F
or 0 CCONJ F
subcardia 0 NOUN F
: 0 PUNCT F
a 0 DET F
randomised 0 VERB F
controlled 0 VERB F
trial 0 NOUN F
. 0 PUNCT F

BACKGROUND 0 NOUN T
Because 0 PUNCT T
of 0 ADP F
the 0 DET F
inaccessibility 0 ADJ F
of 0 ADP F
mediastinal 0 ADJ F
nodal 0 ADJ F
metastases 0 NOUN F
, 0 PUNCT F
the 0 DET F
left 0 ADJ F
thoracoabdominal 0 ADJ F
approach 0 NOUN F
( 0 PUNCT F
LTA 0 PUNCT T
) 0 PUNCT F
has 0 PUNCT F
often 0 ADV F
been 0 PUNCT F
used 0 VERB F
to 0 PART F
treat 0 NOUN F
gastric 0 DET F
cancer 0 NOUN F
of 0 ADP F
the 0 DET F
cardia 0 NOUN F
or 0 CCONJ F
subcardia 0 NOUN F
. 0 PUNCT F

In 0 ADP T
a 0 DET F
randomised 0 VERB F
phase 0 NOUN F
III 0 NUM T
study 0 NOUN F
, 0 PUNCT F
we 0 PROPN F
aimed 0 VERB F
to 0 PART F
compare B-OTHER ADP F
LTA 0 NOUN T
with 0 ADP F
the 0 DET F
abdominal-transhiatal 0 ADJ F
approach 0 NOUN F
( 0 PUNCT F
TH 0 NOUN T
) 0 PUNCT F
in 0 ADP F
the 0 DET F
treatment 0 NOUN F
of 0 ADP F
these 0 DET F
tumours 0 NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
Between 0 ADP T
July 0 NOUN T
, 0 PUNCT F
1995 0 NUM F
, 0 PUNCT F
and 0 CCONJ F
December 0 NOUN T
, 0 PUNCT F
2003 0 NUM F
, 0 PUNCT F
167 0 NUM F
patients 0 NOUN F
were 0 VERB F
enrolled 0 VERB F
from 0 ADP F
27 0 NUM F
Japanese 0 ADJ T
hospitals 0 NOUN F
and 0 CCONJ F
randomly 0 ADV F
assigned 0 VERB F
to 0 ADP F
TH 0 NOUN T
( 0 PUNCT F
n=82 0 NOUN F
) 0 PUNCT F
or 0 PUNCT F
LTA 0 NOUN T
( 0 PUNCT F
n=85 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
primary 0 ADJ F
endpoint 0 NOUN F
was 0 VERB F
overall B-MORTALITY ADJ F
survival I-MORTALITY NOUN F
, 0 PUNCT F
and 0 CCONJ F
secondary 0 ADJ F
endpoints 0 NOUN F
were 0 VERB F
disease-free B-PHYSICAL ADJ F
survival I-PHYSICAL NOUN F
, 0 PUNCT F
postoperative B-PHYSICAL ADJ F
morbidity I-PHYSICAL NOUN F
and 0 CCONJ F
hospital B-MORTALITY NOUN F
mortality I-MORTALITY NOUN F
, 0 PUNCT F
and 0 CCONJ F
postoperative B-PHYSICAL ADJ F
symptoms I-PHYSICAL NOUN F
and 0 CCONJ F
change 0 NOUN F
of 0 ADP F
respiratory B-PHYSICAL ADJ F
function I-PHYSICAL NOUN F
. 0 PUNCT F

The 0 DET T
projected 0 VERB F
sample 0 NOUN F
size 0 NOUN F
was 0 VERB F
302 0 NUM F
. 0 PUNCT F

After 0 ADP T
the 0 DET F
first 0 ADJ F
interim 0 ADJ F
analysis 0 NOUN F
, 0 PUNCT F
the 0 DET F
predicted 0 VERB F
probability 0 NOUN F
of 0 ADP F
LTA 0 NOUN T
having 0 VERB F
a 0 DET F
significantly 0 ADV F
better 0 PUNCT F
overall 0 ADP F
survival 0 NOUN F
than 0 PUNCT F
TH 0 NOUN T
at 0 ADP F
the 0 DET F
final 0 ADJ F
analysis 0 NOUN F
was 0 VERB F
only 0 ADV F
3.65 0 NUM F
% 0 SYM F
, 0 PUNCT F
and 0 CCONJ F
the 0 DET F
trial 0 NOUN F
was 0 VERB F
closed 0 VERB F
immediately 0 ADV F
. 0 PUNCT F

Analysis 0 NOUN T
was 0 VERB F
by 0 ADP F
intention 0 NOUN F
to 0 PART F
treat 0 ADV F
. 0 PUNCT F

This 0 DET T
study 0 NOUN F
is 0 VERB F
registered 0 PUNCT F
with 0 ADP F
, 0 PUNCT F
number 0 NOUN F
NCT00149266 0 NOUN T
. 0 PUNCT F

FINDINGS 0 NOUN T
5-year B-MORTALITY NOUN F
overall I-MORTALITY ADJ F
survival I-MORTALITY NOUN F
was 0 VERB F
52.3 0 NUM F
% 0 SYM F
( 0 PUNCT F
95 0 NUM F
% 0 SYM F
CI 0 NOUN T
40.4-64.1 0 NUM F
) 0 PUNCT F
in 0 ADP F
the 0 DET F
TH 0 NOUN T
group 0 NOUN F
and 0 CCONJ F
37.9 0 NUM F
% 0 SYM F
( 0 PUNCT F
26.1-49.6 0 ADP F
) 0 PUNCT F
in 0 ADP F
the 0 DET F
LTA 0 PUNCT T
group 0 NOUN F
. 0 PUNCT F

The 0 DET T
hazard 0 NOUN F
ratio 0 NOUN F
of 0 ADP F
death B-MORTALITY NOUN F
for 0 ADP F
LTA B-PHYSICAL NOUN T
compared 0 VERB F
with 0 ADP F
TH 0 NOUN T
was 0 VERB F
1.36 0 NUM F
( 0 PUNCT F
0.89-2.08 0 NUM F
, 0 PUNCT F
p=0.92 0 PUNCT F
) 0 PUNCT F
. 0 PUNCT F

Three 0 NUM T
patients 0 NOUN F
died B-MORTALITY VERB F
in 0 ADP F
hospital 0 NOUN F
after 0 PUNCT F
LTA 0 NOUN T
but 0 CCONJ F
none 0 NUM F
after 0 ADP F
TH 0 NOUN T
. 0 PUNCT F

Morbidity B-PHYSICAL NOUN T
was 0 VERB F
worse 0 ADJ F
after 0 PUNCT F
LTA 0 CCONJ T
than 0 PUNCT F
after 0 ADP F
TH 0 NOUN T
. 0 PUNCT F

INTERPRETATION 0 NOUN T
Because 0 PUNCT T
LTA 0 NOUN T
does 0 PUNCT F
not 0 ADV F
improve 0 PUNCT F
survival 0 NOUN F
after 0 ADP F
TH 0 NOUN T
and 0 CCONJ F
leads 0 NOUN F
to 0 ADP F
increased 0 VERB F
morbidity 0 NOUN F
in 0 ADP F
patients 0 NOUN F
with 0 ADP F
cancer 0 NOUN F
of 0 ADP F
the 0 DET F
cardia 0 NOUN F
or 0 CCONJ F
subcardia 0 NOUN F
, 0 PUNCT F
LTA 0 NOUN T
can 0 ADP F
not 0 ADV F
be 0 VERB F
justified 0 VERB F
to 0 PART F
treat 0 NOUN F
these 0 DET F
tumours 0 NOUN F
. 0 PUNCT F

Prevention 0 NOUN T
of 0 ADP F
bone 0 NOUN F
loss 0 NOUN F
in 0 ADP F
survivors 0 NOUN F
of 0 ADP F
breast 0 NOUN F
cancer 0 NOUN F
: 0 PUNCT F
A 0 PUNCT T
randomized 0 VERB F
, 0 PUNCT F
double-blind 0 ADJ F
, 0 PUNCT F
placebo-controlled 0 VERB F
clinical 0 ADJ F
trial 0 NOUN F
. 0 PUNCT F

BACKGROUND 0 NOUN T
Few 0 ADJ T
data 0 NOUN F
are 0 VERB F
available 0 ADJ F
on 0 ADP F
the 0 DET F
safety 0 NOUN F
and 0 CCONJ F
efficacy 0 NOUN F
of 0 ADP F
once-weekly 0 PUNCT F
oral 0 ADJ F
bisphosphonate 0 NOUN F
therapy 0 NOUN F
in 0 ADP F
breast 0 NOUN F
cancer 0 NOUN F
survivors 0 NOUN F
. 0 PUNCT F

OBJECTIVE 0 NOUN T
Our 0 PUNCT T
objective 0 ADJ F
was 0 VERB F
to 0 PART F
determine 0 NOUN F
whether 0 ADP F
risedronate 0 NOUN F
, 0 PUNCT F
35 0 NUM F
mg 0 NOUN F
weekly 0 ADV F
, 0 PUNCT F
is 0 VERB F
efficacious 0 ADJ F
and 0 CCONJ F
safe 0 ADJ F
in 0 ADP F
preventing 0 VERB F
bone 0 NOUN F
loss 0 NOUN F
associated 0 VERB F
with 0 ADP F
chemotherapy-induced 0 VERB F
menopause 0 NOUN F
. 0 PUNCT F

DESIGN 0 NOUN T
The 0 DET T
study 0 NOUN F
was 0 ADV F
a 0 DET F
randomized 0 VERB F
, 0 PUNCT F
double-blind 0 ADJ F
, 0 PUNCT F
placebo-controlled 0 VERB F
clinical 0 ADJ F
trial 0 NOUN F
over 0 ADP F
12 0 NUM F
months 0 NOUN F
. 0 PUNCT F

SETTING 0 VERB T
AND 0 CCONJ T
PARTICIPANTS 0 ADP T
Participants 0 NOUN T
included 0 VERB F
87 0 NUM F
newly 0 ADV F
postmenopausal 0 ADJ F
women 0 NOUN F
with 0 ADP F
status 0 NOUN F
post 0 PUNCT F
chemotherapy 0 NOUN F
, 0 PUNCT F
recruited 0 VERB F
from 0 ADP F
a 0 DET F
breast 0 NOUN F
cancer 0 NOUN F
clinic 0 NOUN F
in 0 ADP F
an 0 DET F
academic 0 ADJ F
medical 0 ADJ F
center 0 NOUN F
. 0 PUNCT F

INTERVENTION 0 NOUN T
Participants 0 PUNCT T
were 0 VERB F
randomly 0 ADV F
assigned 0 VERB F
to 0 PART F
receive 0 NOUN F
risedronate 0 NOUN F
35 0 NUM F
mg/wk 0 NOUN F
or 0 CCONJ F
placebo 0 NOUN F
. 0 PUNCT F

MAIN 0 ADJ T
OUTCOME 0 NOUN T
MEASURES 0 NOUN T
The 0 DET T
primary 0 ADJ F
outcomes 0 NOUN F
were 0 VERB F
the 0 DET F
12-month B-PHYSICAL NOUN F
changes I-PHYSICAL NOUN F
in I-PHYSICAL ADP F
spine I-PHYSICAL NOUN F
and 0 CCONJ F
hip B-PHYSICAL NOUN F
bone I-PHYSICAL NOUN F
mineral I-PHYSICAL NOUN F
density I-PHYSICAL NOUN F
. 0 PUNCT F

Secondary 0 ADJ T
outcomes 0 NOUN F
included 0 VERB F
changes 0 NOUN F
in 0 ADP F
markers B-PHYSICAL NOUN F
of I-PHYSICAL ADP F
bone I-PHYSICAL NOUN F
resorption I-PHYSICAL NOUN F
( I-PHYSICAL PUNCT F
urine I-PHYSICAL NOUN F
N-telopeptide I-PHYSICAL NOUN T
cross-linked I-PHYSICAL VERB F
collagen I-PHYSICAL NOUN F
type 0 NOUN F
I B-PHYSICAL NUM T
) B-PHYSICAL PUNCT F
and 0 CCONJ F
formation B-PHYSICAL NOUN F
( B-PHYSICAL PUNCT F
osteocalcin I-PHYSICAL NOUN F
, 0 PUNCT F
N-terminal B-PHYSICAL ADJ T
propeptide I-PHYSICAL PUNCT F

Photodynamic 0 ADJ T
therapy 0 NOUN F
with 0 ADP F
5-aminolaevulinic 0 ADJ F
acid 0 NOUN F
or 0 CCONJ F
placebo 0 NOUN F
for 0 ADP F
recalcitrant 0 VERB F
foot B-PHYSICAL NOUN F
and 0 CCONJ F
hand B-PHYSICAL NOUN F
warts I-PHYSICAL NOUN F
: 0 PUNCT F
randomised 0 DET F
double-blind 0 ADJ F
trial 0 NOUN F
. 0 PUNCT F

BACKGROUND 0 NOUN T
Photodynamic 0 PUNCT T
therapy 0 NOUN F
( 0 PUNCT F
PDT 0 NOUN T
) 0 PUNCT F
with 0 ADP F
topical 0 ADJ F
5-aminolaevulinic 0 ADJ F
acid 0 NOUN F
( 0 PUNCT F
ALA 0 NOUN T
) 0 PUNCT F
followed 0 VERB F
by 0 ADP F
irradiation 0 NOUN F
with 0 ADP F
incoherent 0 ADJ F
light 0 ADJ F
( 0 PUNCT F
ALA-PDT 0 NOUN T
) 0 PUNCT F
for 0 ADP F
recalcitrant 0 VERB F
warts 0 NOUN F
have 0 PUNCT F
had 0 PUNCT F
beneficial 0 ADJ F
results 0 NOUN F
. 0 PUNCT F

Therefore 0 ADV T
, 0 PUNCT F
we 0 ADP F
undertook 0 ADJ F
a 0 DET F
randomised 0 VERB F
, 0 PUNCT F
parallel 0 PUNCT F
, 0 PUNCT F
double-blind 0 ADJ F
clinical 0 ADJ F
trial 0 NOUN F
of 0 ADP F
ALA-PDT 0 NOUN T
versus 0 CCONJ F
placeboPDT 0 NOUN F
for 0 ADP F
recalcitrant 0 VERB F
foot 0 NOUN F
and 0 CCONJ F
hand 0 NOUN F
warts 0 NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
Recalcitrant 0 PUNCT T
foot 0 NOUN F
and 0 CCONJ F
hand 0 NOUN F
warts 0 ADV F
were 0 ADJ F
randomly 0 ADV F
assigned 0 VERB F
to 0 ADP F
six 0 PUNCT F
repetitive 0 ADJ F
ALA-PDT 0 NOUN T
or 0 CCONJ F
placebo-PDT 0 NOUN F
interventions 0 NOUN F
combined 0 VERB F
with 0 ADP F
standard 0 ADJ F
treatment 0 NOUN F
encompassing 0 PUNCT F
paring 0 VERB F
followed 0 VERB F
by 0 ADP F
a 0 DET F
keratolytic 0 ADJ F
( 0 PUNCT F
Verucid 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

Standardised 0 ADP T
photographs 0 PUNCT F
of 0 ADP F
each 0 DET F
wart 0 ADJ F
were 0 VERB F
taken 0 VERB F
before 0 ADP F
, 0 PUNCT F
during 0 ADP F
( 0 PUNCT F
week 0 NOUN F
7 0 NUM F
) 0 PUNCT F
and 0 CCONJ F
after 0 ADP F
treatment 0 NOUN F
( 0 PUNCT F
weeks 0 NOUN F
14 0 NUM F
and 0 CCONJ F
18 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
area 0 NOUN F
of 0 ADP F
each 0 DET F
wart 0 ADJ F
compared 0 VERB F
with 0 ADP F
entry 0 NOUN F
area 0 NOUN F
was 0 VERB F
the 0 DET F
primary 0 ADJ F
outcome 0 NOUN F
variable 0 NOUN F
, 0 PUNCT F
measured 0 VERB F
from 0 ADP F
photographs 0 PUNCT F
by 0 ADP F
an 0 DET F
evaluator 0 NOUN F
unaware 0 PUNCT F
of 0 ADP F
treatment 0 NOUN F
allocation 0 NOUN F
for 0 ADP F
intervention 0 NOUN F
. 0 PUNCT F

Pain B-PAIN NOUN T
intensity I-PAIN NOUN F
immediately 0 ADV F
and 0 CCONJ F
24 0 NUM F
h 0 NOUN F
after 0 ADP F
each 0 DET F
intervention 0 NOUN F
was 0 VERB F
assessed 0 VERB F
by 0 ADP F
a 0 DET F
five-point 0 NOUN F
scale 0 NOUN F
. 0 PUNCT F

FINDINGS 0 NOUN T
A 0 DET T
total 0 NOUN F
of 0 ADP F
232 0 NUM F
foot 0 NOUN F
and 0 CCONJ F
hand 0 NOUN F
warts 0 NOUN F
in 0 ADP F
45 0 NUM F
patients 0 NOUN F
were 0 VERB F
entered 0 VERB F
into 0 ADP F
the 0 DET F
trial 0 NOUN F
: 0 PUNCT F
117 0 NUM F
warts 0 NOUN F
were 0 VERB F
allocated 0 NUM F
to 0 ADP F
ALA-PDT 0 NOUN T
and 0 CCONJ F
115 0 NUM F
warts 0 NOUN F
to 0 ADP F
placebo-PDT 0 NOUN F
. 0 PUNCT F

In 0 ADP T
week 0 NOUN F
14 0 NUM F
, 0 PUNCT F
the 0 DET F
median 0 ADJ F
relative B-PHYSICAL ADJ F
reduction I-PHYSICAL NOUN F
in I-PHYSICAL ADP F
wart I-PHYSICAL NOUN F
area 0 NOUN F
was 0 VERB F
98 0 NUM F
% 0 SYM F
in 0 ADP F
the 0 DET F
ALA-PDT 0 NOUN T
group 0 NOUN F
( 0 PUNCT F
interquartile 0 NOUN F
range 0 NOUN F
100 0 NUM F
% 0 SYM F
, 0 PUNCT F
55 0 NUM F
% 0 SYM F
) 0 PUNCT F
versus 0 CCONJ F
52 0 NUM F
% 0 SYM F
( 0 PUNCT F
100 0 NUM F
% 0 SYM F
, 0 PUNCT F
0 0 NUM F
) 0 PUNCT F
in 0 ADP F
the 0 DET F
placebo 0 NOUN F
group 0 NOUN F
( 0 PUNCT F
p=0.0006 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

In 0 ADP T
week 0 NOUN F
18 0 NUM F
, 0 PUNCT F
the 0 DET F
median 0 ADJ F
relative B-PHYSICAL ADJ F
reduction I-PHYSICAL NOUN F
in I-PHYSICAL ADP F
wart I-PHYSICAL NOUN F
area 0 NOUN F
was 0 VERB F
100 0 NUM F
% 0 SYM F
in 0 ADP F
the 0 DET F
ALA-PDT 0 NOUN T
group 0 NOUN F
( 0 PUNCT F
100 0 NUM F
% 0 SYM F
, 0 PUNCT F
57 0 NUM F
% 0 SYM F
) 0 PUNCT F
versus 0 CCONJ F
71 0 NUM F
% 0 SYM F
( 0 PUNCT F
100 0 NUM F
% 0 SYM F
, 0 PUNCT F
0 0 NUM F
) 0 PUNCT F
in 0 ADP F
the 0 DET F
placebo-PDT 0 NOUN F
arm 0 NOUN F
( 0 PUNCT F
p=0.008 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

Both 0 CCONJ T
the 0 DET F
number 0 NOUN F
of 0 ADP F
vanishing B-OTHER NUM F
warts I-OTHER NOUN F
and 0 CCONJ F
the 0 DET F
difference 0 NOUN F
in 0 ADP F
relative B-OTHER ADJ F
wart I-OTHER NOUN F
area 0 NOUN F
of B-OTHER ADP F
persisting I-OTHER ADV F
warts B-OTHER NOUN F
at 0 ADP F
week 0 NOUN F
14 0 NUM F
and 0 CCONJ F
18 0 NUM F
were 0 VERB F
significant 0 ADJ F
( 0 PUNCT F
p 0 NOUN F
< 0 SYM F
0.05 0 NUM F
) 0 PUNCT F
in 0 ADP F
favour 0 NOUN F
of 0 ADP F
ALA-PDT 0 NOUN T
. 0 PUNCT F

Significantly 0 ADV T
more 0 DET F
ALA-PDT 0 NOUN T
warts 0 NOUN F
were 0 VERB F
graded 0 VERB F
at 0 ADP F
a 0 DET F
higher B-PAIN PUNCT F
pain I-PAIN PUNCT F

Can 0 PUNCT T
patient 0 NOUN F
coaching 0 VERB F
reduce 0 VERB F
racial/ethnic 0 ADJ F
disparities 0 NOUN F
in 0 ADP F
cancer 0 NOUN F
pain 0 NOUN F
control 0 NOUN F
? 0 PUNCT F

Secondary 0 ADJ T
analysis 0 NOUN F
of 0 ADP F
a 0 DET F
randomized 0 VERB F
controlled 0 VERB F
trial 0 NOUN F
. 0 PUNCT F

PURPOSE 0 NOUN T
Minority 0 NOUN T
patients 0 NOUN F
with 0 ADP F
cancer 0 NOUN F
experience 0 NOUN F
worse 0 ADJ F
control 0 NOUN F
of 0 ADP F
their 0 PUNCT F
pain 0 NOUN F
than 0 PUNCT F
do 0 PUNCT F
their 0 PUNCT F
white 0 ADJ F
counterparts 0 NOUN F
. 0 PUNCT F

This 0 DET T
disparity 0 NOUN F
may 0 ADP F
, 0 PUNCT F
in 0 ADP F
part 0 NOUN F
, 0 PUNCT F
reflect 0 VERB F
more 0 DET F
miscommunication 0 NOUN F
between 0 ADP F
minority 0 NOUN F
patients 0 NOUN F
and 0 CCONJ F
their 0 ADJ F
physicians 0 NOUN F
. 0 PUNCT F

Therefore 0 ADV T
, 0 PUNCT F
we 0 PRON F
examined 0 VERB F
whether 0 ADP F
patient 0 NOUN F
coaching 0 CCONJ F
could 0 PUNCT F
reduce 0 VERB F
disparities 0 DET F
in 0 ADP F
pain B-PAIN NOUN F
control I-PAIN NOUN F
in 0 ADP F
a 0 DET F
secondary 0 ADJ F
analysis 0 NOUN F
of 0 ADP F
a 0 DET F
randomized 0 VERB F
controlled 0 VERB F
trial 0 NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
Sixty-seven 0 PUNCT T
English-speaking 0 ADJ T
adult 0 NOUN F
cancer 0 NOUN F
outpatients 0 ADJ F
, 0 PUNCT F
including 0 VERB F
15 0 NUM F
minorities 0 NOUN F
, 0 PUNCT F
with 0 ADP F
moderate 0 ADJ F
pain 0 NOUN F
over 0 ADP F
the 0 DET F
prior 0 ADP F
2 0 NUM F
weeks 0 NOUN F
were 0 VERB F
randomly 0 ADV F
assigned 0 VERB F
to 0 ADP F
the 0 DET F
experimental 0 ADJ F
( 0 PUNCT F
N 0 NOUN T
= 0 SYM F
34 0 NUM F
) 0 PUNCT F
or 0 CCONJ F
control 0 NOUN F
group 0 NOUN F
( 0 PUNCT F
N 0 NOUN T
= 0 SYM F
33 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Experimental 0 ADJ T
patients 0 NOUN F
received 0 VERB F
a 0 DET F
20-minute 0 NOUN F
individualized 0 VERB F
education 0 NOUN F
and 0 CCONJ F
coaching 0 NUM F
session 0 NOUN F
to 0 PART F
increase 0 NOUN F
knowledge 0 NOUN F
of 0 ADP F
pain 0 NOUN F
self-management 0 ADJ F
, 0 PUNCT F
to 0 PART F
redress 0 ADP F
personal 0 ADJ F
misconceptions 0 NOUN F
about 0 PUNCT F
pain 0 NOUN F
treatment 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
to 0 PUNCT F
rehearse 0 PUNCT F
an 0 DET F
individually 0 ADV F
scripted 0 VERB F
patient-physician 0 ADJ F
dialog 0 NOUN F
about 0 ADP F
pain B-PAIN NOUN F
control I-PAIN NOUN F
. 0 PUNCT F

The 0 DET T
control 0 NOUN F
group 0 NOUN F
received 0 VERB F
standardized 0 VERB F
information 0 NOUN F
on 0 ADP F
controlling 0 PUNCT F
pain 0 NOUN F
. 0 PUNCT F

Data 0 NOUN T
on 0 ADP F
average 0 ADJ F
pain B-PAIN NOUN F
( 0 PUNCT F
0-10 0 NUM F
scale 0 NOUN F
) 0 PUNCT F
were 0 VERB F
collected 0 VERB F
at 0 ADP F
enrollment 0 NOUN F
and 0 CCONJ F
2-week 0 NOUN F
follow-up 0 NOUN F
. 0 PUNCT F

RESULTS 0 NOUN T
At 0 ADP T
enrollment 0 NOUN F
, 0 PUNCT F
minority 0 NOUN F
patients 0 NOUN F
had 0 PUNCT F
significantly 0 ADV F
more 0 DET F
pain B-PAIN NOUN F
than 0 ADP F
their 0 PUNCT F
white 0 ADJ F
counterparts 0 NOUN F
( 0 PUNCT F
6.0 0 NUM F
vs 0 CCONJ F
5.0 0 NUM F
, 0 PUNCT F
P 0 NOUN T
= 0 SYM F
0.05 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

At 0 ADP T
follow-up 0 NOUN F
, 0 PUNCT F
minorities 0 CCONJ F
in 0 ADP F
the 0 DET F
control 0 NOUN F
group 0 NOUN F
continued 0 VERB F
to 0 ADP F
have 0 PUNCT F
more 0 DET F
pain B-PAIN NOUN F
( 0 PUNCT F
6.4 0 NUM F
vs 0 CCONJ F
4.7 0 NUM F
, 0 PUNCT F
P 0 NOUN T
= 0 SYM F
0.01 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
whereas 0 ADP F
in 0 ADP F
the 0 DET F
experimental 0 ADJ F
group 0 NOUN F
, 0 PUNCT F
disparities 0 NOUN F
were 0 VERB F
eliminated 0 NOUN F
( 0 PUNCT F
4.0 0 NUM F
vs 0 CCONJ F
4.3 0 NUM F
, 0 PUNCT F
P 0 NOUN T
= 0 SYM F
0.71 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
effect 0 NOUN F
of 0 ADP F
the 0 DET F
intervention 0 NOUN F
on 0 ADP F
reducing 0 PROPN F
disparities 0 NOUN F
was 0 VERB F
significant 0 ADJ F
( 0 PUNCT F
P 0 NOUN T
= 0 SYM F
0.04 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

CONCLUSIONS 0 DET T
Patient 0 NOUN T
coaching 0 VERB F
offers 0 PUNCT F
promise 0 PUNCT F
as 0 ADP F
a 0 DET F
means 0 NOUN F
of 0 ADP F
reducing 0 VERB F
racial/ethnic B-PAIN ADJ F
disparities I-PAIN NOUN F
in I-PAIN ADP F
pain I-PAIN NOUN F
control I-PAIN NOUN F
. 0 PUNCT F

Larger 0 PUNCT T
studies 0 NOUN F
are 0 VERB F
needed 0 VERB F
to 0 ADP F
validate 0 VERB F
these 0 DET F
findings 0 NOUN F
and 0 CCONJ F
to 0 PUNCT F
explore 0 NOUN F
possible 0 ADJ F
mechanisms 0 NOUN F
. 0 PUNCT F

Methodological 0 ADJ T
issues 0 NOUN F
in 0 ADP F
designing 0 ADP F
a 0 DET F
multisite 0 PUNCT F
trial 0 NOUN F
of 0 ADP F
risperidone 0 NUM F
in 0 ADP F
children 0 NOUN F
and 0 CCONJ F
adolescents 0 NOUN F
with 0 ADP F
autism 0 NOUN F
. 0 PUNCT F

OBJECTIVE 0 NOUN T
To 0 ADJ T
describe 0 PROPN F
the 0 DET F
methodological 0 ADJ F
challenges 0 NOUN F
and 0 CCONJ F
decisions 0 NOUN F
made 0 VERB F
in 0 ADP F
developing 0 VERB F
a 0 DET F
multisite 0 NOUN F
, 0 PUNCT F
controlled 0 ADP F
study 0 NOUN F
of 0 ADP F
risperidone 0 NUM F
in 0 ADP F
children 0 NOUN F
and 0 CCONJ F
adolescents 0 NOUN F
with 0 ADP F
autism 0 NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
Review 0 PUNCT T
the 0 DET F
design 0 NOUN F
considerations 0 NOUN F
for 0 ADP F
clinical 0 ADJ F
trials 0 NOUN F
in 0 ADP F
children 0 NOUN F
with 0 ADP F
autistic 0 ADJ F
disorder 0 NOUN F
accompanied 0 VERB F
by 0 ADP F
severe 0 ADJ F
tantrums 0 ADP F
, 0 PUNCT F
aggressive 0 ADJ F
and/or 0 CCONJ F
self-injurious 0 ADJ F
behaviors 0 NOUN F
. 0 PUNCT F

These 0 DET T
design 0 NOUN F
considerations 0 NOUN F
include 0 VERB F
the 0 DET F
definition 0 NOUN F
of 0 ADP F
inclusion 0 NOUN F
criteria 0 NOUN F
that 0 DET F
are 0 VERB F
relevant 0 ADJ F
to 0 ADP F
clinical 0 ADJ F
practice 0 NOUN F
and 0 CCONJ F
matching 0 ADV F
study 0 NOUN F
design 0 NOUN F
to 0 ADP F
the 0 DET F
goal 0 NOUN F
of 0 ADP F
evaluating 0 ADJ F
short- 0 ADJ F
and 0 CCONJ F
long-term 0 NOUN F
effects 0 NOUN F
. 0 PUNCT F

Additional 0 ADJ T
ethical 0 ADJ F
and 0 CCONJ F
scientific 0 ADJ F
issues 0 NOUN F
concern 0 ADJ F
the 0 DET F
length 0 NOUN F
of 0 ADP F
trial 0 NOUN F
and 0 CCONJ F
sample 0 NOUN F
size 0 NOUN F
. 0 PUNCT F

RESULTS 0 NOUN T
We 0 ADP T
undertook 0 ADJ F
a 0 DET F
short-term 0 NOUN F
, 0 PUNCT F
placebo-controlled 0 VERB F
study 0 NOUN F
to 0 PART F
evaluate 0 NOUN F
the 0 DET F
efficacy 0 NOUN F
and 0 CCONJ F
safety B-OTHER NOUN F
of 0 ADP F
risperidone 0 NUM F
in 0 ADP F
children 0 NOUN F
and 0 CCONJ F
adolescents 0 NOUN F
with 0 ADP F
autistic 0 ADJ F
disorder 0 NOUN F
. 0 PUNCT F

This 0 DET T
trial 0 NOUN F
design 0 NOUN F
was 0 VERB F
followed 0 VERB F
by 0 ADP F
an 0 DET F
extended 0 VERB F
open-label 0 NOUN F
maintenance 0 NOUN F
on 0 ADP F
risperidone 0 NUM F
to 0 ADP F
confirm 0 ADP F
durability B-OTHER NOUN F
of 0 ADP F
treatment 0 NOUN F
effects 0 NOUN F
and 0 CCONJ F
to 0 ADP F
monitor 0 NOUN F
safety B-OTHER NOUN F
. 0 PUNCT F

Finally 0 ADV T
, 0 PUNCT F
a 0 DET F
placebo-controlled 0 ADV F
discontinuation 0 NOUN F
study 0 NOUN F
tested 0 VERB F
the 0 DET F
need 0 NOUN F
for 0 ADP F
continuous 0 ADJ F
treatment 0 NOUN F
. 0 PUNCT F

CONCLUSIONS 0 NOUN T
In 0 ADP T
the 0 DET F
absence 0 NOUN F
of 0 ADP F
standard 0 ADJ F
pharmacological 0 ADJ F
treatment 0 NOUN F
for 0 ADP F
children 0 NOUN F
with 0 ADP F
autistic 0 ADJ F
disorder 0 NOUN F
, 0 PUNCT F
a 0 DET F
placebo-controlled 0 VERB F
study 0 NOUN F
remains 0 NOUN F
the 0 DET F
most 0 PUNCT F
appropriate 0 ADJ F
method 0 NOUN F
of 0 ADP F
testing 0 NUM F
efficacy 0 NOUN F
and 0 CCONJ F
safety 0 NOUN F
. 0 PUNCT F

The 0 DET T
clinical 0 ADJ F
relevance 0 NOUN F
of 0 ADP F
this 0 DET F
study 0 NOUN F
is 0 VERB F
enhanced 0 VERB F
by 0 ADP F
the 0 DET F
addition 0 NOUN F
of 0 ADP F
an 0 DET F
extended 0 VERB F
maintenance 0 NOUN F
phase 0 NOUN F
followed 0 VERB F
by 0 ADP F
a 0 DET F
placebo 0 NOUN F
discontinuation 0 NOUN F
. 0 PUNCT F

A 0 DET T
randomized 0 VERB F
study 0 NOUN F
comparing 0 VERB F
the 0 DET F
use 0 NOUN F
of 0 ADP F
the 0 DET F
Ligaclip 0 ADV T
with 0 ADP F
bipolar 0 ADJ F
energy 0 NOUN F
to 0 PART F
prevent 0 NOUN F
lymphocele 0 NOUN F
during 0 ADP F
laparoscopic 0 ADJ F
pelvic 0 ADJ F
lymphadenectomy 0 NOUN F
for 0 ADP F
gynecologic 0 ADJ F
cancer 0 NOUN F
. 0 PUNCT F

OBJECTIVE 0 NOUN T
This 0 PUNCT T
prospective 0 ADJ F
randomized 0 VERB F
pilot 0 NOUN F
study 0 NOUN F
compared 0 VERB F
the 0 DET F
use 0 NOUN F
of 0 ADP F
the 0 DET F
Ligaclip 0 ADV T
( 0 PUNCT F
Ethicon 0 NOUN T
Endo-Surgery 0 NOUN T
, 0 PUNCT F
Cincinnati 0 NOUN T
, 0 PUNCT F
OH 0 NOUN T
) 0 PUNCT F
with 0 ADP F
bipolar 0 ADJ F
coagulation 0 NOUN F
in 0 ADP F
preventing 0 VERB F
lymphoceles 0 PUNCT F
after 0 ADP F
laparoscopic 0 ADJ F
pelvic 0 ADJ F
lymphadenectomy 0 NOUN F
for 0 ADP F
gynecologic 0 ADJ F
cancer 0 NOUN F
. 0 PUNCT F

STUDY 0 NOUN T
DESIGN 0 NOUN T
Thirty 0 NUM T
patients 0 NOUN F
with 0 ADP F
gynecologic 0 ADJ F
malignancy 0 NOUN F
, 0 PUNCT F
who 0 ADP F
had 0 CCONJ F
laparoscopic 0 ADJ F
pelvic 0 ADJ F
lymphadenectomy 0 NOUN F
were 0 VERB F
randomly 0 ADV F
assigned 0 VERB F
for 0 ADP F
lymphadenectomy 0 NOUN F
in 0 ADP F
1 0 NUM F
side 0 NOUN F
of 0 ADP F
the 0 DET F
pelvis 0 NOUN F
using 0 VERB F
the 0 DET F
Ligaclip 0 NOUN T
, 0 PUNCT F
whereas 0 ADP F
, 0 PUNCT F
in 0 ADP F
the 0 DET F
other 0 ADJ F
side 0 NOUN F
, 0 PUNCT F
the 0 DET F
bipolar 0 ADJ F
coagulation 0 NOUN F
to 0 ADP F
seal 0 ADJ F
lymphatic 0 ADJ F
vessels 0 NOUN F
was 0 VERB F
used 0 VERB F
. 0 PUNCT F

RESULTS 0 NOUN T
At 0 ADP T
ultrasound 0 NOUN F
examination 0 NOUN F
, 0 PUNCT F
we 0 NOUN F
detected 0 VERB F
lymphocele B-PHYSICAL NOUN F
in 0 ADP F
10 0 NUM F
patients 0 NOUN F
( 0 PUNCT F
33 0 NUM F
% 0 SYM F
) 0 PUNCT F
. 0 PUNCT F

Lymphocele B-PHYSICAL NOUN T
developed 0 PUNCT F
in 0 ADP F
9 0 NUM F
( 0 PUNCT F
30 0 NUM F
% 0 SYM F
) 0 PUNCT F
patients 0 NOUN F
on 0 ADP F
the 0 DET F
side 0 NOUN F
where 0 ADP F
laparoscopic 0 ADJ F
pelvic 0 ADJ F
lymphadenectomy 0 NOUN F
was 0 VERB F
perfomed 0 NOUN F
using 0 VERB F
bipolar 0 PUNCT F
coagulation 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
in 0 ADP F
1 0 NUM F
( 0 PUNCT F
3.3 0 NUM F
% 0 SYM F
) 0 PUNCT F
patient 0 NOUN F
on 0 ADP F
the 0 DET F
side 0 NOUN F
where 0 ADP F
laparoscopic 0 ADJ F
pelvic 0 ADJ F
lymphadenectomy 0 NOUN F
was 0 VERB F
performed 0 VERB F
using 0 VERB F
the 0 DET F
Ligaclip 0 NOUN T
. 0 PUNCT F

Univariate 0 ADJ T
analysis 0 NOUN F
revealed 0 VERB F
that 0 ADP F
the 0 DET F
Ligaclip 0 NOUN T
's 0 PUNCT F
use 0 NOUN F
compared 0 VERB F
with 0 ADP F
electrocoagulation 0 NOUN F
in 0 ADP F
the 0 DET F
laparoscopic 0 ADJ F
pelvic 0 ADJ F
lymphadenectomy 0 NOUN F
is 0 VERB F
an 0 DET F
independent 0 ADJ F
predictive 0 ADJ F
factor 0 NOUN F
for 0 ADP F
development B-PHYSICAL NOUN F
of I-PHYSICAL ADP F
lymphocele I-PHYSICAL NOUN F
( 0 PUNCT F
P 0 NOUN T
= 0 SYM F
.006 0 PUNCT F
) 0 PUNCT F
. 0 PUNCT F

CONCLUSION 0 NOUN T
This 0 DET T
study 0 NOUN F
demonstrates 0 NOUN F
that 0 ADP F
the 0 DET F
use 0 NOUN F
of 0 ADP F
the 0 PUNCT F
Ligaclip 0 ADV T
to 0 ADP F
close 0 ADJ F
lymphatic 0 ADJ F
vessels 0 NOUN F
may 0 VERB F
reduce 0 VERB F
the 0 DET F
incidence 0 NOUN F
of 0 ADP F
lymphoceles B-PHYSICAL PUNCT F
in 0 ADP F
patients 0 NOUN F
undergoing 0 SYM F
laparoscopic 0 PUNCT F
pelvic 0 ADJ F
lymphadenectomy 0 NOUN F
. 0 PUNCT F

Role 0 NOUN T
of 0 ADP F
oxidized 0 VERB F
regenerated 0 CCONJ F
cellulose 0 NOUN F
in 0 ADP F
preventing 0 VERB F
infections 0 NOUN F
at 0 ADP F
the 0 DET F
surgical 0 ADJ F
site 0 NOUN F
: 0 PUNCT F
prospective 0 ADJ F
, 0 PUNCT F
randomized 0 ADP F
study 0 NOUN F
in 0 ADP F
98 0 NUM F
patients 0 NOUN F
affected 0 VERB F
by 0 ADP F
a 0 DET F
dirty 0 CCONJ F
wound 0 NOUN F
. 0 PUNCT F

AIM 0 NOUN T
The 0 DET T
aim 0 NOUN F
of 0 ADP F
this 0 DET F
study 0 NOUN F
was 0 VERB F
to 0 PART F
evaluate 0 NOUN F
whether 0 ADP F
oxidized B-PHYSICAL VERB F
regenerated I-PHYSICAL CCONJ F
cellulose I-PHYSICAL NOUN F
( 0 PUNCT F
ORC B-PHYSICAL NOUN T
) 0 PUNCT F
, 0 PUNCT F
applied 0 VERB F
to 0 PUNCT F
dirty 0 PUNCT F
surgical 0 ADJ F
wounds 0 NOUN F
, 0 PUNCT F
is 0 VERB F
able 0 ADJ F
to 0 PART F
reduce 0 NOUN F
the 0 DET F
microbial 0 ADJ F
load 0 NOUN F
and 0 CCONJ F
, 0 PUNCT F
consequently 0 ADV F
, 0 PUNCT F
the 0 DET F
infection B-PHYSICAL NOUN F
rate I-PHYSICAL NOUN F
as 0 PUNCT F
compared 0 VERB F
to 0 ADP F
conventional 0 ADJ F
local 0 ADJ F
wound 0 NOUN F
treatment 0 NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
The 0 DET T
study 0 NOUN F
included 0 VERB F
98 0 NUM F
patients 0 NOUN F
who 0 ADP F
underwent 0 VERB F
intestinal 0 ADJ F
recanalization 0 NOUN F
procedures 0 NOUN F
between 0 ADP F
December 0 NOUN T
2003 0 NUM F
and 0 CCONJ F
December 0 NOUN T
2008 0 NUM F
, 0 PUNCT F
with 0 ADP F
the 0 DET F
stoma 0 NOUN F
as 0 ADP F
the 0 DET F
surgical 0 ADJ F
site 0 NOUN F
. 0 PUNCT F

Authors 0 NOUN T
considered 0 VERB F
several 0 ADJ F
risk 0 NOUN F
factors 0 NOUN F
for 0 ADP F
SSI 0 NOUN T
. 0 PUNCT F

The 0 DET T
patients 0 NOUN F
were 0 VERB F
divided 0 VERB F
into 0 ADP F
two 0 NUM F
groups 0 NOUN F
. 0 PUNCT F

In 0 ADP T
group 0 NOUN F
A 0 NOUN T
( 0 PUNCT F
50 0 NUM F
patients 0 NOUN F
) 0 PUNCT F
, 0 PUNCT F
the 0 DET F
surgical B-PHYSICAL ADJ F
wound I-PHYSICAL NOUN F
, 0 PUNCT F
previous 0 ADJ F
site 0 NOUN F
of 0 ADP F
the 0 DET F
stoma 0 NOUN F
, 0 PUNCT F
was 0 VERB F
packed 0 VERB F
with 0 ADP F
ORC 0 NOUN T
, 0 PUNCT F
whereas 0 ADP F
in 0 ADP F
group 0 NOUN F
B 0 NOUN T
( 0 PUNCT F
48 0 NUM F
patients 0 NOUN F
) 0 PUNCT F
gauze 0 PUNCT F
soaked 0 VERB F
in 0 ADP F
iodine 0 NOUN F
was 0 VERB F
used 0 VERB F
. 0 PUNCT F

Microbial B-PHYSICAL ADJ T
contamination I-PHYSICAL NOUN F
was 0 VERB F
evaluated 0 VERB F
with 0 ADP F
three 0 NUM F
swabs 0 NOUN F
( 0 PUNCT F
in 0 ADP F
subcutaneous 0 ADJ F
tissue 0 NOUN F
and 0 CCONJ F
the 0 DET F
dermis 0 NOUN F
) 0 PUNCT F
, 0 PUNCT F
in 0 ADP F
the 0 DET F
operating 0 VERB F
room 0 NOUN F
before 0 PUNCT F
wound 0 NOUN F
packing 0 VERB F
and 0 CCONJ F
on 0 ADP F
the 0 DET F
2nd 0 ADJ F
and 0 CCONJ F
3rd 0 ADJ F
postoperative 0 ADJ F
day 0 NOUN F
( 0 PUNCT F
before 0 ADP F
suturing 0 PUNCT F
the 0 DET F
skin 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

RESULTS 0 NOUN T
There 0 CCONJ T
were 0 VERB F
no 0 DET F
cases 0 NOUN F
of 0 ADP F
wound B-PHYSICAL NOUN F
dehiscence I-PHYSICAL NOUN F
and 0 CCONJ F
no 0 DET F
clinically B-PHYSICAL ADV F
evident I-PHYSICAL ADJ F
superficial I-PHYSICAL ADJ F
or I-PHYSICAL CCONJ F
deep I-PHYSICAL ADJ F
surgical I-PHYSICAL ADJ F
site I-PHYSICAL NOUN F
infections I-PHYSICAL NOUN F
in 0 ADP F
either 0 PUNCT F
group 0 NOUN F
. 0 PUNCT F

Analysis 0 NOUN T
of 0 ADP F
all 0 DET F
data 0 NOUN F
revealed 0 VERB F
that 0 ADP F
there 0 PUNCT F
was 0 VERB F
no 0 DET F
or 0 CCONJ F
reduced B-PHYSICAL VERB F
bacterial I-PHYSICAL ADJ F
contamination I-PHYSICAL NOUN F
in 0 ADP F
the 0 DET F
second 0 ADJ F
and 0 CCONJ F
third 0 ADJ F
swab 0 NOUN F
in 0 ADP F
33 0 NUM F
patients 0 NOUN F
( 0 PUNCT F
66 0 NUM F
% 0 SYM F
) 0 PUNCT F
of 0 ADP F
Group 0 NOUN T
A 0 NOUN T
versus 0 CCONJ F
12 0 NUM F
patients 0 NOUN F
( 0 PUNCT F
25 0 NUM F
% 0 SYM F
) 0 PUNCT F
of 0 ADP F
Group 0 NOUN T
B 0 NOUN T
. 0 PUNCT F

CONCLUSION 0 NOUN T
Although 0 ADP T
it 0 PRON F
is 0 VERB F
necessary 0 ADJ F
to 0 PART F
consider 0 NOUN F
all 0 DET F
factors 0 NOUN F
which 0 ADP F
can 0 VERB F
have 0 PUNCT F
an 0 DET F
influence 0 NOUN F
on 0 ADP F
SSI 0 NOUN T
and 0 CCONJ F
use 0 ADP F
all 0 DET F
the 0 DET F
means 0 NOUN F
shown 0 VERB F
to 0 PART F
be 0 PUNCT F
effective 0 ADJ F
to 0 PART F
reduce 0 NOUN F
the 0 DET F
risk 0 NOUN F
of 0 ADP F
SSI 0 NOUN T
, 0 PUNCT F
there 0 PUNCT F
is 0 VERB F
a 0 DET F
rationale 0 NOUN F
for 0 ADP F
using 0 NOUN F
ORC 0 NOUN T
to 0 ADJ F
prevent 0 NOUN F
this 0 DET F
kind 0 ADV F
of 0 ADP F
infection 0 NOUN F
, 0 PUNCT F
especially 0 ADV F
in 0 ADP F
patients 0 NOUN F
who 0 ADP F
undergo 0 VERB F
dirty 0 CCONJ F
surgery 0 NOUN F
. 0 PUNCT F

A 0 DET T
comparison 0 NOUN F
of 0 ADP F
three 0 NUM F
highly 0 ADV F
active 0 ADJ F
antiretroviral 0 ADP F
treatment 0 NOUN F
strategies 0 NOUN F
consisting 0 DET F
of 0 ADP F
non-nucleoside 0 NOUN F
reverse 0 ADJ F
transcriptase 0 NOUN F
inhibitors 0 NOUN F
, 0 PUNCT F
protease 0 NOUN F
inhibitors 0 NOUN F
, 0 PUNCT F
or 0 CCONJ F
both 0 PUNCT F
in 0 ADP F
the 0 DET F
presence 0 NOUN F
of 0 ADP F
nucleoside 0 NOUN F
reverse 0 ADJ F
transcriptase 0 NOUN F
inhibitors 0 NOUN F
as 0 ADP F
initial 0 ADJ F
therapy 0 NOUN F
( 0 PUNCT F
CPCRA 0 NOUN T
058 0 NUM F
FIRST 0 PUNCT T
Study 0 NOUN T
) 0 PUNCT F
: 0 PUNCT F
a 0 DET F
long-term 0 NOUN F
randomised 0 VERB F
trial 0 NOUN F
. 0 PUNCT F

BACKGROUND 0 NOUN T
Long-term 0 NOUN T
data 0 NOUN F
from 0 ADP F
randomised 0 VERB F
trials 0 NOUN F
on 0 ADP F
the 0 DET F
consequences 0 NOUN F
of 0 ADP F
treatment 0 NOUN F
with 0 ADP F
a 0 DET F
protease 0 NOUN F
inhibitor 0 NOUN F
( 0 PUNCT F
PI 0 NOUN T
) 0 PUNCT F
, 0 PUNCT F
non-nucleoside 0 NOUN F
reverse 0 ADJ F
transcriptase 0 NOUN F
inhibitor 0 NOUN F
( 0 PUNCT F
NNRTI 0 NOUN T
) 0 PUNCT F
, 0 PUNCT F
or 0 CCONJ F
both 0 PUNCT F
are 0 VERB F
lacking 0 ADJ F
. 0 PUNCT F

Here 0 ADV T
, 0 PUNCT F
we 0 PUNCT F
report 0 VERB F
results 0 PUNCT F
from 0 ADP F
the 0 DET F
FIRST 0 PUNCT T
trial 0 NOUN F
, 0 PUNCT F
which 0 ADP F
compared 0 VERB F
initial 0 ADJ F
treatment 0 NOUN F
strategies 0 NOUN F
for 0 ADP F
clinical 0 ADJ F
, 0 PUNCT F
immunological 0 ADJ F
, 0 PUNCT F
and 0 CCONJ F
virological 0 ADJ F
outcomes 0 NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
Between 0 ADP T
1999 0 NUM F
and 0 CCONJ F
2002 0 NUM F
, 0 PUNCT F
1397 0 NUM F
antiretroviral-treatment-naive 0 ADJ F
patients 0 NOUN F
, 0 PUNCT F
presenting 0 PUNCT F
at 0 ADP F
18 0 NUM F
clinical 0 ADJ F
trial 0 NOUN F
units 0 NOUN F
with 0 ADP F
80 0 NUM F
research 0 NOUN F
sites 0 NOUN F
in 0 ADP F
the 0 DET F
USA 0 PUNCT T
, 0 PUNCT F
were 0 VERB F
randomly 0 ADV F
assigned 0 VERB F
in 0 ADP F
a 0 DET F
ratio 0 NOUN F
of 0 ADP F
1:1:1 0 NOUN F
to 0 ADP F
a 0 DET F
protease 0 NOUN F
inhibitor 0 NOUN F
( 0 PUNCT F
PI 0 NOUN T
) 0 PUNCT F
strategy 0 NOUN F
( 0 PUNCT F
PI 0 NOUN T
plus 0 CCONJ F
nucleoside 0 NOUN F
reverse 0 ADJ F
transcriptase 0 NOUN F
inhibitor 0 NOUN F
[ 0 PUNCT F
NRTI 0 NOUN T
] 0 PUNCT F
; 0 PUNCT F
n=470 0 NOUN F
) 0 PUNCT F
, 0 PUNCT F
a 0 DET F
non-nucleoside 0 NOUN F
reverse 0 ADJ F
transcriptase 0 NOUN F
inhibitor 0 NOUN F
( 0 PUNCT F
NNRTI 0 NOUN T
) 0 PUNCT F
strategy 0 NOUN F
( 0 PUNCT F
NNRTI 0 NOUN T
plus 0 CCONJ F
NRTI 0 NOUN T
; 0 PUNCT F
n=463 0 NOUN F
) 0 PUNCT F
, 0 PUNCT F
or 0 CCONJ F
a 0 DET F
three-class 0 NOUN F
strategy 0 NOUN F
( 0 PUNCT F
PI 0 NOUN T
plus 0 CCONJ F
NNRTI 0 NOUN T
plus 0 CCONJ F
NRTI 0 NOUN T
; 0 PUNCT F
n=464 0 ADV F
) 0 PUNCT F
. 0 PUNCT F

Primary 0 ADJ T
endpoints 0 NOUN F
were 0 VERB F
a 0 DET F
composite 0 NOUN F
of 0 ADP F
an 0 DET F
AIDS-defining B-PHYSICAL ADP T
event I-PHYSICAL NOUN F
, 0 PUNCT F
death B-MORTALITY NOUN F
, 0 PUNCT F
or 0 CCONJ F
CD4 B-PHYSICAL NOUN T
cell I-PHYSICAL NOUN F
count I-PHYSICAL NOUN F
decline I-PHYSICAL DET F
to 0 ADP F
less 0 DET F
than 0 PUNCT F
200 0 NUM F
cells 0 NOUN F
per 0 ADP F
mm3 0 NOUN F
for 0 ADP F
the 0 DET F
PI 0 NOUN T
versus 0 CCONJ F
NNRTI 0 NOUN T
comparison 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
average 0 PUNCT F
change 0 NOUN F
in 0 ADP F
CD4 B-PHYSICAL NOUN T
cell I-PHYSICAL NOUN F
count I-PHYSICAL NOUN F
at 0 ADP F
or 0 CCONJ F
after 0 ADP F
32 0 NUM F
months 0 NOUN F
for 0 ADP F
the 0 DET F
three-class 0 NOUN F
versus 0 CCONJ F
combined 0 VERB F
two-class 0 NOUN F
comparison 0 NOUN F
. 0 PUNCT F

Analyses 0 NOUN T
were 0 VERB F
by 0 ADP F
intention-to-treat 0 NOUN F
. 0 PUNCT F

This 0 DET T
study 0 NOUN F
is 0 VERB F
registered 0 PUNCT F
ClinicalTrials.gov 0 PUNCT T
, 0 PUNCT F
number 0 NOUN F
NCT00000922 0 NOUN T
. 0 PUNCT F

FINDINGS 0 NOUN T
1397 0 NUM F
patients 0 NOUN F
were 0 VERB F
assessed 0 VERB F
for 0 ADP F
the 0 DET F
composite 0 PUNCT F
endpoint 0 NOUN F
. 0 PUNCT F

A 0 DET T
total 0 NOUN F
of 0 ADP F
388 0 NUM F
participants 0 NOUN F
developed 0 VERB F
the 0 DET F
composite B-OTHER PUNCT F
endpoint I-OTHER NOUN F
, 0 PUNCT F
302 0 NUM F
developed 0 VERB F
AIDS 0 NOUN T
or 0 CCONJ F
died 0 PROPN F
, 0 PUNCT F
and 0 CCONJ F
188 0 NUM F
died 0 PROPN F
. 0 PUNCT F

NNRTI 0 NOUN T
versus 0 CCONJ F
PI 0 NOUN T
hazard 0 NOUN F
ratios B-OTHER NOUN F
( 0 PUNCT F
HRs 0 PUNCT T
) 0 PUNCT F
for 0 ADP F
the 0 DET F
composite 0 PUNCT F
endpoint 0 NOUN F
, 0 PUNCT F
for 0 ADP F
AIDS B-MORTALITY NOUN T
or 0 CCONJ F
death B-MORTALITY NOUN F
, 0 PUNCT F
for 0 ADP F
death B-MORTALITY NOUN F
, 0 PUNCT F
and 0 CCONJ F
for 0 ADP F
virological B-PHYSICAL ADJ F
failure I-PHYSICAL NOUN F
were 0 VERB F
1.02 0 PUNCT F
( 0 PUNCT F
95 0 NUM F
% 0 SYM F
CI 0 NOUN T
0.79-1.31 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
1.07 0 NUM F
( 0 PUNCT F
0.80-1.41 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
0.95 0 NUM F
( 0 PUNCT F
0.66-1.37 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
and 0 CCONJ F
0.66 0 NUM F
( 0 PUNCT F
0.56-0.78 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
respectively 0 ADV F
. 0 PUNCT F

1196 0 DET F
patients 0 NOUN F
were 0 VERB F
assessed 0 VERB F
for 0 ADP F
the 0 DET F
three-class 0 NOUN F
versus 0 CCONJ F
combined 0 VERB F
two-class 0 NOUN F
primary 0 ADJ F
endpoint 0 NOUN F
. 0 PUNCT F

Mean 0 PUNCT T
change 0 NOUN F
in 0 ADP F
CD4 B-PHYSICAL NOUN T
cell I-PHYSICAL NOUN F
count I-PHYSICAL NOUN F
at 0 ADP F
or 0 CCONJ F
after 0 ADP F
32 0 NUM F
months 0 NOUN F
was 0 VERB F
+234 0 PUNCT F
cells 0 NOUN F
per 0 ADP F
mm3 0 NOUN F
and 0 CCONJ F
+227 0 ADV F
cells 0 NOUN F
per 0 ADP F
mm3 0 NOUN F
for 0 ADP F
the 0 DET F
three-class 0 NOUN F
and 0 CCONJ F
the 0 DET F
combined 0 VERB F
two-class 0 NOUN F
strategies 0 NOUN F
( 0 PUNCT F
p=0.62 0 NOUN F
) 0 PUNCT F
, 0 PUNCT F
respectively 0 ADV F
. 0 PUNCT F

HRs B-OTHER ADV T
( 0 PUNCT F
three-class 0 NOUN F
vs 0 CCONJ F
combined 0 VERB F
two-class 0 NOUN F
) 0 PUNCT F
for 0 ADP F
AIDS B-MORTALITY NOUN T
or 0 CCONJ F
death B-MORTALITY NOUN F
and 0 CCONJ F
virological B-PHYSICAL ADJ F
failure I-PHYSICAL NOUN F
were 0 VERB F
1.15 0 NUM F
( 0 PUNCT F
0.91-1.45 0 NUM F
) 0 PUNCT F
and 0 CCONJ F
0.87 0 NUM F
( 0 PUNCT F
0.75-1.00 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
respectively 0 ADV F
. 0 PUNCT F

HRs B-OTHER ADV T
( 0 PUNCT F
three-class 0 NOUN F
vs 0 CCONJ F
combined 0 VERB F
two-class 0 NOUN F
) 0 PUNCT F
for 0 ADP F
AIDS B-MORTALITY NOUN T
or 0 CCONJ F
death B-MORTALITY NOUN F
were 0 VERB F
similar 0 ADJ F
for 0 ADP F
participants 0 NOUN F
with 0 ADP F
baseline 0 NOUN F
CD4 0 NOUN T
cell 0 NOUN F
counts 0 NOUN F
of 0 ADP F
200 0 NUM F
cells 0 NOUN F
per 0 ADP F
mm3 0 NOUN F
or 0 CCONJ F
less 0 DET F
and 0 CCONJ F
of 0 ADP F
more 0 ADV F
than 0 PUNCT F
200 0 NUM F
cells 0 NOUN F
per 0 ADP F
mm3 0 NOUN F
( 0 PUNCT F
p=0.38 0 NOUN F
for 0 ADP F
interaction 0 NOUN F
) 0 PUNCT F
, 0 PUNCT F
and 0 CCONJ F
for 0 ADP F
participants 0 NOUN F
with 0 ADP F
baseline 0 NOUN F
HIV 0 NOUN T
RNA 0 NOUN T
concentrations 0 NOUN F
less 0 ADV F
than 0 CCONJ F
100 0 NUM F
000 0 NUM F
copies 0 NOUN F
per 0 ADP F
mL 0 NOUN F
and 0 CCONJ F
100,000 0 NUM F
copies 0 NOUN F
per 0 ADP F
mL 0 NOUN F
or 0 CCONJ F
more 0 DET F
( 0 PUNCT F
p=0.26 0 NOUN F
for 0 ADP F
interaction 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

Participants 0 NOUN T
assigned 0 VERB F
the 0 DET F
three-class 0 NOUN F
strategy 0 NOUN F
were 0 VERB F
significantly 0 ADV F
more 0 ADV F
likely 0 ADJ F
to 0 ADP F
discontinue B-OTHER ADP F
treatment I-OTHER NOUN F
because 0 PUNCT F
of 0 ADP F
toxic B-ADVERSE-EFFECTS ADJ F
effects I-ADVERSE-EFFECTS NOUN F
than 0 PUNCT F
were 0 VERB F
those 0 PUNCT F
assigned 0 VERB F
to 0 ADP F
the 0 DET F
two-class 0 NOUN F
strategies 0 NOUN F
( 0 PUNCT F
HR 0 NOUN T
1.58 0 NUM F
; 0 PUNCT F
p 0 NOUN F
< 0 SYM F
0.0001 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

INTERPRETATION 0 NOUN T
Initial 0 ADJ T
treatment 0 NOUN F
with 0 ADP F
either 0 CCONJ F
an 0 DET F
NNRTI-based 0 VERB T
regimen 0 NOUN F
or 0 CCONJ F
a 0 DET F
PI-based 0 VERB T
regimen 0 NOUN F
, 0 PUNCT F
but 0 CCONJ F
not 0 ADV F
both 0 CCONJ F
together 0 ADV F
, 0 PUNCT F
is 0 VERB F
a 0 DET F
good 0 ADJ F
strategy 0 NOUN F
for 0 ADP F
long-term 0 NOUN F
antiretroviral 0 ADJ F
management 0 NOUN F
in 0 ADP F
treatment-naive 0 ADJ F
patients 0 NOUN F
with 0 ADP F
HIV 0 NOUN T
. 0 PUNCT F

The 0 DET T
overt 0 ADJ F
aggression 0 NOUN F
scale 0 NOUN F
for 0 ADP F
rating 0 VERB F
aggression 0 NOUN F
in 0 ADP F
outpatient 0 ADJ F
youth 0 NOUN F
with 0 ADP F
autistic 0 ADJ F
disorder 0 NOUN F
: 0 PUNCT F
preliminary 0 ADJ F
findings 0 NOUN F
. 0 PUNCT F

Aggression 0 NOUN T
is 0 VERB F
a 0 DET F
common 0 ADJ F
and 0 CCONJ F
costly 0 PUNCT F
problem 0 NOUN F
in 0 ADP F
youth 0 NOUN F
with 0 ADP F
developmental 0 ADJ F
disabilities 0 NOUN F
. 0 PUNCT F

Rating 0 ADJ T
scales 0 NOUN F
that 0 PUNCT F
accurately 0 PUNCT F
capture 0 NOUN F
and 0 CCONJ F
measure 0 PUNCT F
subtypes 0 NOUN F
of 0 ADP F
aggression 0 NOUN F
phenomenology 0 NOUN F
, 0 PUNCT F
frequency 0 NOUN F
and 0 CCONJ F
severity 0 NOUN F
are 0 VERB F
urgently 0 ADV F
needed 0 PROPN F
, 0 PUNCT F
in 0 ADP F
both 0 CCONJ F
clinical 0 ADJ F
practice 0 NOUN F
and 0 CCONJ F
research 0 NOUN F
. 0 PUNCT F

The 0 DET T
authors 0 NOUN F
studied 0 VERB F
the 0 DET F
Overt 0 ADJ T
Aggression 0 NOUN T
Scale 0 NOUN T
( 0 PUNCT F
OAS 0 NOUN T
) 0 PUNCT F
in 0 ADP F
a 0 DET F
preliminary 0 ADJ F
sample 0 NOUN F
of 0 ADP F
eight 0 NUM F
outpatients 0 NOUN F
who 0 PROPN F
participated 0 VERB F
in 0 ADP F
an 0 DET F
ongoing 0 ADJ F
placebo-controlled 0 VERB F
study 0 NOUN F
of 0 ADP F
valproate 0 NOUN F
for 0 ADP F
aggression 0 NOUN F
in 0 ADP F
autism 0 NOUN F
. 0 PUNCT F

Subjects 0 NOUN T
' 0 PUNCT F
OAS B-MENTAL NOUN T
aggression I-MENTAL NOUN F
scores I-MENTAL NOUN F
showed 0 VERB F
significant 0 ADJ F
correlation 0 NOUN F
with 0 ADP F
the 0 DET F
already 0 ADV F
validated 0 ADP F
retrospectively 0 ADV F
rated 0 VERB F
Aberrant 0 ADJ T
Behavior 0 NOUN T
Checklist 0 NOUN T
Community 0 NOUN T
Scale 0 NOUN T
irritability 0 NOUN F
subscale 0 NOUN F
. 0 PUNCT F

Further 0 ADJ T
study 0 NOUN F
of 0 ADP F
the 0 DET F
OAS B-MENTAL NOUN T
in 0 ADP F
outpatients 0 ADJ F
with 0 ADP F
aggression 0 NOUN F
and 0 CCONJ F
developmental 0 ADJ F
disabilities 0 PUNCT F
is 0 VERB F
warranted 0 VERB F
. 0 PUNCT F

MRI B-PHYSICAL NOUN T
signal I-PHYSICAL NOUN F
hyperintensities I-PHYSICAL DET F
and 0 CCONJ F
failure B-PHYSICAL NOUN F
to I-PHYSICAL ADJ F
remit I-PHYSICAL PUNCT F
following 0 ADP F
antidepressant 0 NOUN F
treatment 0 NOUN F
. 0 PUNCT F

BACKGROUND 0 NOUN T
MRI 0 NOUN T
signal 0 NOUN F
hyperintensities 0 CCONJ F
predict 0 VERB F
poor 0 ADJ F
remission B-PHYSICAL NOUN F
to 0 ADP F
antidepressant 0 NOUN F
treatment 0 NOUN F
. 0 PUNCT F

Previous 0 ADJ T
studies 0 NOUN F
using 0 VERB F
volumetrics 0 NOUN F
in 0 ADP F
outpatient 0 ADJ F
samples 0 NOUN F
have 0 ADP F
relied 0 VERB F
on 0 ADP F
total 0 ADJ F
lesion B-PHYSICAL NOUN F
volume I-PHYSICAL NOUN F
. 0 PUNCT F

The 0 DET T
purpose 0 NOUN F
of 0 ADP F
this 0 DET F
study 0 NOUN F
was 0 VERB F
to 0 ADV F
test 0 VERB F
whether 0 PUNCT F
remission 0 NOUN F
from 0 ADP F
geriatric 0 ADJ F
depression 0 NOUN F
depends 0 NOUN F
on 0 ADP F
lesion B-PHYSICAL NOUN F
volume I-PHYSICAL NOUN F
by I-PHYSICAL ADP F
region I-PHYSICAL NOUN F
of I-PHYSICAL ADP F
interest I-PHYSICAL NOUN F
( I-PHYSICAL PUNCT F
ROI I-PHYSICAL NOUN T
) I-PHYSICAL PUNCT F
. 0 PUNCT F

METHOD 0 NOUN T
Thirty-eight 0 PUNCT T
patients 0 NOUN F
received 0 VERB F
baseline 0 NOUN F
MRIs 0 NOUN T
as 0 ADP F
part 0 NOUN F
of 0 ADP F
a 0 DET F
larger 0 PUNCT F
12-week 0 NOUN F
, 0 PUNCT F
randomized 0 VERB F
clinical 0 ADJ F
trial 0 NOUN F
comparing 0 VERB F
sertraline 0 NOUN F
and 0 CCONJ F
nortriptyline 0 NOUN F
in 0 ADP F
the 0 DET F
treatment 0 NOUN F
of 0 ADP F
late-life 0 NOUN F
depression 0 NOUN F
. 0 PUNCT F

MRIcro 0 NOUN T
was 0 VERB F
used 0 VERB F
to 0 PART F
quantify 0 NOUN F
MRI-hyperintensity 0 NOUN T
volume 0 NOUN F
into 0 ADP F
total 0 ADJ F
hyperintensity 0 NOUN F
, 0 PUNCT F
deep 0 ADJ F
white 0 ADJ F
matter 0 NOUN F
hyperintensity 0 NOUN F
( 0 PUNCT F
DWMH 0 NOUN T
) 0 PUNCT F
, 0 PUNCT F
and 0 CCONJ F
periventricular 0 ADJ F
hyperintensity 0 NOUN F
( 0 PUNCT F
PVH 0 NOUN T
) 0 PUNCT F
volumes 0 NOUN F
. 0 PUNCT F

High 0 ADJ T
versus 0 CCONJ F
low 0 ADJ F
total 0 NOUN F
, 0 PUNCT F
DWMH B-PHYSICAL NOUN T
, 0 PUNCT F
and 0 CCONJ F
PVH B-PHYSICAL NOUN T
volumes I-PHYSICAL NOUN F
were 0 VERB F
defined 0 VERB F
based 0 VERB F
on 0 ADP F
the 0 DET F
highest 0 PUNCT F
quartile 0 NOUN F
of 0 ADP F
their 0 PUNCT F
respective 0 ADJ F
distributions 0 NOUN F
. 0 PUNCT F

Remission B-MENTAL NOUN T
from I-MENTAL ADP F
depression I-MENTAL NOUN F
was 0 VERB F
defined 0 VERB F
as 0 ADP F
a 0 DET F
24-item 0 NOUN F
Hamilton B-MENTAL PUNCT T
Rating I-MENTAL PUNCT T
Scale I-MENTAL NOUN T
for I-MENTAL ADP F
Depression I-MENTAL NOUN T
score 0 NOUN F
? 0 PUNCT F

7 0 NUM F
for 0 ADP F
two 0 NUM F
consecutive 0 ADJ F
weeks 0 NOUN F
. 0 PUNCT F

RESULTS 0 DET T
Patients 0 NOUN T
classified 0 PUNCT F
as 0 ADP F
having 0 VERB F
high 0 ADJ F
DWMH 0 NOUN T
were 0 VERB F
7.14 0 NUM F
times 0 NOUN F
more 0 ADV F
likely 0 ADJ F
not 0 ADV F
to 0 ADP F
remit 0 PUNCT F
following 0 ADP F
antidepressant 0 NOUN F
treatment 0 NOUN F
compared 0 VERB F
to 0 ADP F
patients 0 NOUN F
classified 0 PUNCT F
as 0 ADP F
having 0 VERB F
low 0 ADJ F
DWMH 0 NOUN T
( 0 PUNCT F
p=0.02 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

Similar 0 ADJ T
odds 0 NOUN F
ratios 0 NOUN F
were 0 VERB F
obtained 0 VERB F
for 0 ADP F
PVH 0 NOUN T
( 0 PUNCT F
OR=4.17 0 NOUN T
, 0 PUNCT F
p=0.16 0 NOUN F
) 0 PUNCT F
and 0 CCONJ F
total 0 ADJ F
volumes 0 NOUN F
( 0 PUNCT F
OR=5.00 0 PUNCT T
, 0 PUNCT F
p=0.05 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

Importantly 0 ADV T
, 0 PUNCT F
adjusting 0 ADJ F
for 0 ADP F
age 0 NOUN F
did 0 PUNCT F
not 0 ADV F
change 0 VERB F
the 0 DET F
magnitude 0 NOUN F
of 0 ADP F
these 0 DET F
effects 0 NOUN F
. 0 PUNCT F

LIMITATIONS 0 NOUN T
A 0 DET T
small 0 ADJ F
and 0 CCONJ F
predominantly 0 ADV F
White 0 PUNCT T
sample 0 NOUN F
. 0 PUNCT F

CONCLUSIONS 0 NOUN T
This 0 PUNCT T
is 0 VERB F
the 0 DET F
first 0 ADJ F
study 0 NOUN F
to 0 ADP F
test 0 VERB F
whether 0 PUNCT F
remission 0 NOUN F
from 0 ADP F
geriatric 0 ADJ F
depression 0 NOUN F
depends 0 NOUN F
on 0 ADP F
lesion 0 NOUN F
volume 0 NOUN F
by 0 ADP F
ROI 0 NOUN T
in 0 ADP F
an 0 DET F
outpatient 0 ADJ F
sample 0 NOUN F
. 0 PUNCT F

The 0 DET T
pattern 0 NOUN F
of 0 ADP F
remission 0 NOUN F
rates 0 NOUN F
and 0 CCONJ F
odds 0 NOUN F
ratios 0 NOUN F
was 0 VERB F
similar 0 ADJ F
when 0 ADP F
patients 0 NOUN F
were 0 VERB F
classified 0 VERB F
as 0 ADP F
having 0 VERB F
high 0 ADJ F
DWMH 0 NOUN T
, 0 PUNCT F
PVH 0 NOUN T
or 0 CCONJ F
total 0 ADJ F
volume 0 NOUN F
suggesting 0 VERB F
that 0 ADP F
lesion 0 NOUN F
location 0 NOUN F
may 0 VERB F
not 0 ADV F
be 0 VERB F
critical 0 ADJ F
. 0 PUNCT F

Using 0 PROPN T
personalized 0 VERB F
feedback 0 NOUN F
to 0 PART F
reduce 0 NOUN F
alcohol 0 NOUN F
use 0 NOUN F
among 0 ADP F
hazardous 0 ADJ F
drinking 0 VERB F
college 0 NOUN F
students 0 NOUN F
: 0 PUNCT F
the 0 DET F
moderating 0 VERB F
effect 0 NOUN F
of 0 ADP F
alcohol-related 0 VERB F
negative 0 ADJ F
consequences 0 NOUN F
. 0 PUNCT F

UNLABELLED 0 NOUN T
Web-based 0 ADP T
screening 0 VERB F
and 0 CCONJ F
brief 0 ADJ F
interventions 0 NOUN F
that 0 CCONJ F
include 0 DET F
personalized 0 PUNCT F
feedback 0 NOUN F
about 0 ADP F
their 0 PUNCT F
alcohol 0 NOUN F
use 0 NOUN F
have 0 ADP F
proven 0 VERB F
to 0 PART F
be 0 PUNCT F
particularly 0 ADV F
promising 0 PUNCT F
for 0 ADP F
reducing 0 SYM F
hazardous 0 ADJ F
drinking 0 PROPN F
among 0 ADP F
university 0 NOUN F
students 0 NOUN F
. 0 PUNCT F

Despite 0 ADP T
the 0 DET F
increasing 0 ADJ F
use 0 NOUN F
of 0 ADP F
these 0 DET F
approaches 0 NOUN F
, 0 PUNCT F
there 0 PUNCT F
is 0 ADV F
still 0 ADV F
relatively 0 ADV F
little 0 DET F
known 0 VERB F
about 0 PUNCT F
how 0 PUNCT F
the 0 DET F
content 0 NOUN F
of 0 ADP F
these 0 DET F
interventions 0 NOUN F
may 0 VERB F
influence 0 VERB F
outcomes 0 NOUN F
and 0 CCONJ F
who 0 ADP F
may 0 VERB F
benefit 0 VERB F
most 0 PUNCT F
from 0 ADP F
these 0 DET F
approaches 0 NOUN F
. 0 PUNCT F

The 0 DET T
current 0 ADJ F
study 0 NOUN F
sought 0 ADP F
to 0 PART F
address 0 NOUN F
these 0 DET F
issues 0 NOUN F
by 0 ADP F
examining 0 ADV F
how 0 ADP F
individual 0 ADJ F
differences 0 NOUN F
in 0 ADP F
alcohol 0 NOUN F
consequences 0 NOUN F
influence 0 PUNCT F
outcomes 0 NOUN F
of 0 ADP F
a 0 DET F
laboratory-based 0 VERB F
computerized 0 VERB F
intervention 0 NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
One-hundred 0 ADP T
and 0 CCONJ F
nineteen 0 NUM F
introductory 0 ADJ F
psychology 0 NOUN F
students 0 NOUN F
who 0 DET F
either 0 PUNCT F
had 0 PUNCT F
two 0 NUM F
episodes 0 NOUN F
of 0 ADP F
heavy 0 ADJ F
episodic 0 ADJ F
drinking 0 ADV F
in 0 ADP F
the 0 DET F
past 0 ADJ F
month 0 NOUN F
or 0 CCONJ F
scored 0 VERB F
?8 0 PUNCT F
on 0 ADP F
the 0 DET F
AUDIT 0 NOUN T
participated 0 PUNCT F
in 0 ADP F
this 0 DET F
randomized 0 VERB F
controlled 0 VERB F
trial 0 NOUN F
for 0 ADP F
course 0 NOUN F
credit 0 NOUN F
. 0 PUNCT F

Participants 0 NOUN T
were 0 VERB F
assigned 0 VERB F
to 0 ADP F
1 0 PUNCT F
of 0 ADP F
4 0 NUM F
conditions 0 NOUN F
in 0 ADP F
this 0 DET F
2 0 NUM F
Intervention 0 NOUN T
( 0 PUNCT F
Alcohol 0 NOUN T
Feedback 0 NOUN T
vs. 0 CCONJ F
Control 0 NOUN T
) 0 PUNCT F
?2 0 PUNCT F
Assessment 0 NOUN T
( 0 PUNCT F
Motivational 0 ADJ T
Assessment 0 NOUN T
vs. 0 CCONJ F
No 0 DET T
Motivational 0 ADJ T
Assessment 0 NOUN T
) 0 PUNCT F
between-subjects 0 PUNCT F
design 0 NOUN F
. 0 PUNCT F

Quantity 0 NOUN T
of 0 ADP F
alcohol 0 NOUN F
consumed 0 PUNCT F
per 0 CCONJ F
week 0 NOUN F
and 0 CCONJ F
heavy B-MENTAL ADJ F
episodic I-MENTAL ADJ F
drinking I-MENTAL ADV F
one I-MENTAL NUM F
month I-MENTAL NOUN F
later I-MENTAL PUNCT F
were 0 VERB F
the 0 DET F
primary 0 ADJ F
dependent 0 ADJ F
variables 0 NOUN F
. 0 PUNCT F

RESULTS 0 NOUN T
Controlling 0 ADJ T
for 0 ADP F
corresponding 0 PUNCT F
baseline 0 NOUN F
alcohol 0 NOUN F
measures 0 NOUN F
, 0 PUNCT F
hierarchical 0 ADJ F
linear 0 ADJ F
regression 0 NOUN F
analyses 0 NOUN F
showed 0 VERB F
a 0 DET F
significant 0 ADJ F
interaction 0 NOUN F
between 0 ADP F
intervention 0 NOUN F
condition 0 NOUN F
and 0 CCONJ F
baseline 0 NOUN F
alcohol-related 0 VERB F
consequences 0 NOUN F
. 0 PUNCT F

For 0 ADP T
those 0 ADJ F
who 0 ADP F
reported 0 VERB F
more 0 ADP F
alcohol 0 NOUN F
consequences 0 NOUN F
at 0 ADP F
baseline 0 NOUN F
, 0 PUNCT F
the 0 DET F
alcohol 0 NOUN F
intervention 0 NOUN F
resulted 0 VERB F
in 0 ADP F
significantly 0 ADV F
less 0 DET F
alcohol 0 NOUN F
use 0 NOUN F
and 0 CCONJ F
fewer 0 PUNCT F
heavy B-MENTAL ADJ F
drinking I-MENTAL VERB F
episodes I-MENTAL NOUN F
at 0 ADP F
follow-up 0 NOUN F
, 0 PUNCT F
while 0 ADP F
no 0 DET F
difference 0 NOUN F
was 0 VERB F
observed 0 VERB F
between 0 ADP F
intervention 0 NOUN F
conditions 0 NOUN F
for 0 ADP F
those 0 PUNCT F
with 0 ADP F
few 0 ADJ F
baseline 0 NOUN F
consequences 0 NOUN F
. 0 PUNCT F

Assessment 0 NOUN T
did 0 PUNCT F
not 0 ADV F
moderate 0 ADJ F
intervention 0 NOUN F
effects 0 NOUN F
. 0 PUNCT F

DISCUSSION 0 NOUN T
These 0 DET T
findings 0 NOUN F
suggest 0 VERB F
that 0 ADP F
a 0 DET F
feedback-based 0 VERB F
computerized 0 VERB F
intervention 0 NOUN F
that 0 ADP F
includes 0 VERB F
normative 0 ADJ F
information 0 NOUN F
about 0 PUNCT F
alcohol 0 NOUN F
use 0 NOUN F
and 0 CCONJ F
consequences 0 NOUN F
may 0 VERB F
be 0 VERB F
more 0 ADV F
effective 0 ADJ F
for 0 ADP F
hazardous 0 ADJ F
drinking 0 VERB F
students 0 NOUN F
who 0 DET F
are 0 VERB F
experiencing 0 ADV F
higher 0 VERB F
levels 0 NOUN F
of 0 ADP F
alcohol-related 0 VERB F
consequences 0 NOUN F
. 0 PUNCT F

[ 0 PUNCT F
Comparison 0 NOUN T
of 0 ADP F
three 0 NUM F
analgesic 0 ADJ F
methods 0 NOUN F
for 0 ADP F
postoperative 0 ADJ F
pain 0 NOUN F
relief 0 NOUN F
and 0 CCONJ F
their 0 ADP F
effects 0 NOUN F
on 0 ADP F
plasma B-PHYSICAL NOUN F
interleukin-6 I-PHYSICAL NOUN F
concentration I-PHYSICAL NOUN F
following 0 VERB F
radical 0 ADJ F
surgery 0 NOUN F
for 0 ADP F
gastric 0 ADJ F
carcinoma 0 NOUN F
] 0 PUNCT F
. 0 PUNCT F

OBJECTIVE 0 NOUN T
To 0 PROPN T
compare 0 NOUN F
the 0 DET F
efficacy 0 NOUN F
of 0 ADP F
preemptive 0 ADJ F
epidural 0 ADJ F
analgesia 0 NOUN F
combined 0 VERB F
with 0 ADP F
postoperative 0 ADJ F
epidural 0 ADJ F
analgesia 0 NOUN F
, 0 PUNCT F
postoperative 0 ADJ F
epidural 0 ADJ F
analgesia 0 NOUN F
alone 0 ADJ F
and 0 CCONJ F
intravenous 0 ADJ F
analgesia 0 NOUN F
for 0 ADP F
postoperative B-PAIN ADJ F
pain I-PAIN NOUN F
relief I-PAIN NOUN F
and 0 CCONJ F
their 0 ADP F
effects 0 NOUN F
on 0 ADP F
plasma B-PHYSICAL NOUN F
interleukin-6 I-PHYSICAL NOUN F
( I-PHYSICAL PUNCT F
IL-6 I-PHYSICAL NOUN T
) I-PHYSICAL PUNCT F
concentration I-PHYSICAL NOUN F
following 0 VERB F
radical 0 ADJ F
surgery 0 NOUN F
for 0 ADP F
gastric 0 ADJ F
carcinoma 0 NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
Sixty-six 0 ADJ T
patients 0 NOUN F
with 0 ADP F
gastric 0 ADJ F
carcinoma 0 NOUN F
scheduled 0 VERB F
for 0 ADP F
gastrectomy 0 NOUN F
were 0 VERB F
randomly 0 ADV F
divided 0 VERB F
into 0 ADP F
3 0 NUM F
groups 0 NOUN F
, 0 PUNCT F
namely 0 DET F
group 0 NOUN F
P 0 NOUN T
( 0 PUNCT F
n=22 0 NOUN F
) 0 PUNCT F
, 0 PUNCT F
group 0 NOUN F
E 0 NOUN T
( 0 PUNCT F
n=22 0 NOUN F
) 0 PUNCT F
and 0 CCONJ F
group 0 NOUN F
V 0 NUM T
( 0 PUNCT F
n=22 0 NOUN F
) 0 PUNCT F
, 0 PUNCT F
to 0 PUNCT F
receive 0 NOUN F
preemptive 0 ADJ F
epidural 0 ADJ F
analgesia 0 NOUN F
combined 0 VERB F
with 0 ADP F
postoperative 0 ADJ F
epidural 0 ADJ F
analgesia 0 NOUN F
, 0 PUNCT F
exclusive 0 ADJ F
postoperative 0 ADJ F
epidural 0 ADJ F
analgesia 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
exclusive 0 ADJ F
postoperative 0 ADJ F
intravenous 0 ADJ F
analgesia 0 NOUN F
, 0 PUNCT F
respectively 0 ADV F
. 0 PUNCT F

Hemodynamic B-PHYSICAL ADJ T
data I-PHYSICAL NOUN F
were 0 VERB F
recorded 0 VERB F
for 0 ADP F
all 0 CCONJ F
the 0 DET F
patients 0 NOUN F
during 0 ADP F
the 0 DET F
operation 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
visual 0 ADJ F
analogue 0 NOUN F
scale 0 NOUN F
( 0 PUNCT F
VAS 0 NOUN T
) 0 PUNCT F
was 0 VERB F
used 0 VERB F
to 0 PART F
assess 0 NOUN F
the 0 DET F
pain B-PAIN NOUN F
intensity I-PAIN NOUN F
at 0 ADP F
4 0 NUM F
, 0 PUNCT F
8 0 NUM F
, 0 PUNCT F
16 0 NUM F
, 0 PUNCT F
24 0 NUM F
, 0 PUNCT F
48 0 NUM F
and 0 CCONJ F
72 0 NUM F
h 0 NOUN F
after 0 ADP F
surgery 0 NOUN F
. 0 PUNCT F

Plasma B-PHYSICAL NOUN T
IL-6 I-PHYSICAL NOUN T
concentration I-PHYSICAL NOUN F
was 0 VERB F
determined 0 VERB F
before 0 ADP F
surgery 0 NOUN F
and 0 CCONJ F
at 0 ADP F
24 0 NUM F
, 0 PUNCT F
48 0 NUM F
, 0 PUNCT F
72 0 NUM F
h 0 NOUN F
after 0 ADP F
surgery 0 NOUN F
. 0 PUNCT F

RESULTS 0 PUNCT T
No 0 DET T
significant 0 ADJ F
changes 0 NOUN F
occurred 0 VERB F
in 0 ADP F
the 0 DET F
hemodynamics 0 NOUN F
during 0 ADP F
the 0 DET F
preoperative 0 ADJ F
periods 0 NOUN F
. 0 PUNCT F

VAS 0 NOUN T
and 0 CCONJ F
IL-6 B-PHYSICAL NOUN T
were 0 VERB F
lower 0 PUNCT F
in 0 ADP F
group 0 NOUN F
P 0 NOUN T
than 0 PUNCT F
in 0 ADP F
group 0 NOUN F
E 0 NOUN T
and 0 CCONJ F
V 0 NUM T
, 0 PUNCT F
and 0 CCONJ F
group 0 NOUN F
E 0 NOUN T
had 0 PUNCT F
lower 0 PUNCT F
measurement 0 NOUN F
than 0 PUNCT F
group 0 NOUN F
V 0 NUM T
( 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.05 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

CONCLUSION 0 NOUN T
Preemptive 0 ADJ T
epidural 0 ADJ F
analgesia 0 NOUN F
combined 0 VERB F
with 0 ADP F
postoperative 0 ADJ F
epidural 0 ADJ F
analgesia 0 NOUN F
provides 0 NOUN F
more 0 DET F
satisfactory 0 ADJ F
pain B-PAIN NOUN F
relief I-PAIN NOUN F
and 0 CCONJ F
more 0 DET F
effectively 0 ADV F
prevents 0 NOUN F
IL-6 B-PHYSICAL NOUN T
increment I-PHYSICAL NOUN F
than 0 PUNCT F
exclusive 0 ADJ F
epidural 0 ADJ F
analgesia 0 NOUN F
or 0 CCONJ F
intravenous 0 ADJ F
analgesia 0 NOUN F
after 0 ADP F
gastrectomy 0 NOUN F
for 0 ADP F
gastric 0 ADJ F
carcinoma 0 NOUN F
. 0 PUNCT F

Nephrotoxicity 0 NOUN T
of 0 ADP F
cyclosporin 0 NOUN F
A 0 NOUN T
in 0 ADP F
patients 0 NOUN F
with 0 ADP F
newly 0 ADJ F
diagnosed 0 VERB F
type 0 NOUN F
1 0 NUM F
diabetes 0 NOUN F
mellitus 0 NOUN F
. 0 PUNCT F

Renal 0 ADJ T
function 0 NOUN F
was 0 VERB F
studied 0 VERB F
in 0 ADP F
18 0 NUM F
patients 0 NOUN F
with 0 ADP F
Type 0 NOUN T
1 0 NUM F
diabetes 0 NOUN F
mellitus 0 NOUN F
. 0 PUNCT F

All 0 PUNCT T
were 0 ADJ F
participating 0 VERB F
in 0 ADP F
the 0 DET F
Canadian-European 0 ADV T
randomized 0 VERB F
placebo-controlled 0 VERB F
cyclosporin 0 NOUN F
trial 0 NOUN F
in 0 ADP F
newly 0 ADV F
diagnosed 0 VERB F
Type 0 NOUN T
1 0 NUM F
diabetic 0 ADJ F
patients 0 NOUN F
, 0 PUNCT F
nine 0 NUM F
being 0 VERB F
randomized 0 VERB F
to 0 ADP F
placebo 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
nine 0 NUM F
to 0 ADP F
cyclosporin 0 NOUN F
A 0 NOUN T
. 0 PUNCT F

During 0 ADP T
treatment 0 NOUN F
for 0 ADP F
12 0 NUM F
to 0 ADP F
18 0 NUM F
months 0 NOUN F
, 0 PUNCT F
cyclosporin 0 NOUN F
A 0 NOUN T
caused 0 ADP F
significant 0 ADJ F
reductions 0 NOUN F
in 0 ADP F
the 0 DET F
glomerular B-ADVERSE-EFFECTS ADJ F
filtration I-ADVERSE-EFFECTS NOUN F
rate I-ADVERSE-EFFECTS NOUN F
( 0 PUNCT F
before 0 ADP F
drug 0 NOUN F
withdrawal 0 NOUN F
, 0 PUNCT F
cyclosporin 0 NOUN F
97 0 NUM F
+/- 0 SYM F
18 0 NUM F
vs 0 CCONJ F
placebo 0 NOUN F
125 0 NUM F
+/- 0 SYM F
16 0 NUM F
ml 0 NOUN F
min-1 0 NOUN F
1.73-m-2 0 PUNCT F
, 0 PUNCT F
p 0 NOUN F
less 0 ADV F
than 0 PUNCT F
0.05 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
renal B-ADVERSE-EFFECTS ADJ F
plasma I-ADVERSE-EFFECTS NOUN F
flow I-ADVERSE-EFFECTS NOUN F
( 0 PUNCT F
454 0 NUM F
+/- 0 SYM F
83 0 NUM F
vs 0 CCONJ F
536 0 NUM F
+/- 0 SYM F
70 0 NUM F
ml 0 NOUN F
min-1 0 NOUN F
1.73-m-2 0 PUNCT F
, 0 PUNCT F
p 0 NOUN F
less 0 ADV F
than 0 PUNCT F
0.05 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
and 0 CCONJ F
lithium B-PHYSICAL NOUN F
clearance I-PHYSICAL NOUN F
( 0 PUNCT F
17 0 NUM F
+/- 0 SYM F
3 0 NUM F
vs 0 CCONJ F
28 0 NUM F
+/- 0 SYM F
5 0 NUM F
ml 0 NOUN F
min-1 0 NOUN F
1.73-m-2 0 PUNCT F
, 0 PUNCT F
p 0 NOUN F
less 0 ADV F
than 0 PUNCT F
0.05 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
fractional B-PHYSICAL ADJ F
proximal I-PHYSICAL ADJ F
reabsorption I-PHYSICAL NOUN F
was 0 VERB F
increased 0 VERB F
( 0 PUNCT F
0.82 0 NUM F
+/- 0 SYM F
0.03 0 NUM F
vs 0 CCONJ F
0.78 0 NUM F
+/- 0 SYM F
0.03 0 NUM F
, 0 PUNCT F
p 0 NOUN F
less 0 ADV F
than 0 PUNCT F
0.05 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
and 0 CCONJ F
the 0 DET F
fractional B-PHYSICAL ADJ F
distal I-PHYSICAL ADJ F
sodium I-PHYSICAL NOUN F
reabsorption I-PHYSICAL NOUN F
reduced 0 NOUN F
( 0 PUNCT F
0.88 0 NUM F
+/- 0 SYM F
0.03 0 NUM F
vs 0 CCONJ F
0.94 0 NUM F
+/- 0 SYM F
0.02 0 NUM F
, 0 PUNCT F
p 0 NOUN F
less 0 ADV F
than 0 PUNCT F
0.05 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

These 0 DET T
results 0 NOUN F
are 0 VERB F
in 0 ADP F
accordance 0 NOUN F
with 0 ADP F
the 0 DET F
hypothesis 0 NOUN F
that 0 ADP F
the 0 DET F
nephrotoxic 0 ADJ F
effect 0 NOUN F
of 0 ADP F
cyclosporin 0 NOUN F
A 0 DET T
results 0 ADV F
from 0 ADP F
a 0 DET F
preferential 0 ADJ F
constriction 0 NOUN F
of 0 ADP F
afferent 0 NOUN F
glomerular 0 ADJ F
vessels 0 NOUN F
. 0 PUNCT F

One 0 NUM T
year 0 NOUN F
after 0 ADP F
withdrawal 0 NOUN F
of 0 ADP F
the 0 DET F
drug 0 NOUN F
, 0 PUNCT F
all 0 DET F
variables 0 NOUN F
were 0 VERB F
similar 0 ADJ F
in 0 ADP F
the 0 DET F
two 0 NUM F
groups 0 NOUN F
, 0 PUNCT F
except 0 PUNCT F
for 0 ADP F
blood B-PHYSICAL NOUN F
glucose I-PHYSICAL NOUN F
control I-PHYSICAL NOUN F
which 0 ADP F
was 0 VERB F
worse 0 ADJ F
in 0 ADP F
the 0 DET F
cyclosporin 0 NOUN F
A 0 DET T
treated 0 VERB F
group 0 NOUN F
. 0 PUNCT F

When 0 ADP T
corrected 0 VERB F
for 0 ADP F
differences 0 NOUN F
in 0 ADP F
blood 0 NOUN F
glucose 0 NOUN F
control 0 NOUN F
it 0 PROPN F
appeared 0 VERB F
that 0 ADP F
in 0 ADP F
three 0 NUM F
out 0 PUNCT F
of 0 ADP F
nine 0 NUM F
patients 0 NOUN F
glomerular B-PHYSICAL ADJ F
filtration I-PHYSICAL NOUN F
rate I-PHYSICAL NOUN F
had 0 PUNCT F
not 0 ADV F
completely 0 ADV F
returned 0 VERB F
to 0 ADP F
the 0 DET F
reference 0 NOUN F
range 0 NOUN F
of 0 ADP F
the 0 DET F
placebo 0 NOUN F
group 0 NOUN F
. 0 PUNCT F

We 0 PRON T
conclude 0 VERB F
that 0 ADP F
the 0 DET F
nephrotoxic 0 ADJ F
side-effects 0 NOUN F
of 0 ADP F
cyclosporin 0 NOUN F
A 0 PUNCT T
treatment 0 NOUN F
for 0 ADP F
1 0 NUM F
year 0 NOUN F
are 0 VERB F
reversible 0 ADJ F
. 0 PUNCT F

There 0 PUNCT T
are 0 PROPN F
, 0 PUNCT F
however 0 ADV F
, 0 PUNCT F
signs 0 NOUN F
of 0 ADP F
minor 0 ADJ F
and 0 CCONJ F
perhaps 0 ADV F
chronic 0 ADJ F
renal 0 ADJ F
injury 0 NOUN F
. 0 PUNCT F

Sivelestat 0 NOUN T
sodium 0 NOUN F
hydrate 0 NOUN F
improves 0 VERB F
septic 0 ADJ F
acute 0 ADJ F
lung 0 NOUN F
injury 0 NOUN F
by 0 ADP F
reducing 0 VERB F
alveolar 0 ADJ F
dysfunction 0 NOUN F
. 0 PUNCT F

Sivelestat 0 NOUN T
sodium 0 NOUN F
hydrate 0 NOUN F
( 0 PUNCT F
sivelestat 0 NOUN F
) 0 PUNCT F
is 0 VERB F
a 0 DET F
selective 0 ADJ F
inhibitor 0 NOUN F
of 0 ADP F
polymorphonuclear 0 ADJ F
leukocyte 0 NOUN F
elastase 0 NOUN F
( 0 PUNCT F
PMN-E 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

We 0 PRON T
administered 0 VERB F
sivelestat 0 NOUN F
to 0 ADP F
patients 0 NOUN F
with 0 ADP F
septic 0 ADJ F
acute 0 ADJ F
lung 0 NOUN F
injury 0 NOUN F
( 0 PUNCT F
ALI 0 NOUN T
) 0 PUNCT F
to 0 PART F
examine 0 NOUN F
its 0 PUNCT F
usefulness 0 NOUN F
. 0 PUNCT F

The 0 DET T
primary 0 ADJ F
endpoints 0 NOUN F
in 0 ADP F
the 0 DET F
study 0 NOUN F
were 0 VERB F
the 0 DET F
duration 0 NOUN F
of 0 ADP F
artificial B-OTHER ADJ F
ventilation I-OTHER NOUN F
and 0 CCONJ F
pulmonary B-PHYSICAL ADJ F
oxygenation I-PHYSICAL NOUN F
ability I-PHYSICAL NOUN F
, 0 PUNCT F
and 0 CCONJ F
the 0 DET F
secondary 0 ADJ F
endpoints 0 NOUN F
were 0 VERB F
mortality B-MORTALITY NOUN F
and 0 CCONJ F
the 0 DET F
concentrations 0 NOUN F
of 0 ADP F
PMN-E 0 NOUN T
, B-MORTALITY PUNCT F
SP-D 0 NOUN T
, B-MORTALITY PUNCT F
TNF-alpha I-MORTALITY NOUN T
and I-MORTALITY CCONJ F
IL-8 I-MORTALITY NOUN T
in B-MORTALITY ADP F
blood I-MORTALITY NOUN F
. 0 PUNCT F

In 0 ADP T
the 0 DET F
sivelestat 0 NOUN F
group 0 NOUN F
, 0 PUNCT F
the 0 DET F
duration 0 NOUN F
of 0 ADP F
artificial B-OTHER ADJ F
ventilation I-OTHER NOUN F
, 0 PUNCT F
pulmonary 0 ADJ F
oxygenation 0 NOUN F
ability 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
the 0 DET F
blood B-PHYSICAL NOUN F
PMN-E B-PHYSICAL NOUN T
, 0 PUNCT F
SP-D B-PHYSICAL NOUN T
, 0 PUNCT F
TNF-alpha B-PHYSICAL NOUN T
and 0 CCONJ F
IL-8 B-PHYSICAL NOUN T
concentrations I-PHYSICAL NOUN F
decreased 0 VERB F
significantly 0 ADV F
. 0 PUNCT F

Administration 0 NOUN T
of 0 ADP F
sivelestat 0 NOUN F
was 0 VERB F
found 0 VERB F
to 0 PUNCT F
reduce 0 PUNCT F

Preservative-free 0 ADJ T
ocular 0 ADJ F
hydrating 0 PUNCT F
agents 0 NOUN F
in 0 ADP F
symptomatic 0 ADJ F
contact 0 NOUN F
lens 0 NOUN F
wearers 0 NOUN F
: 0 PUNCT F
saline 0 ADP F
versus 0 CCONJ F
PVP 0 NOUN T
solution 0 NOUN F
. 0 PUNCT F

PURPOSE 0 NOUN T
To 0 ADJ T
compare 0 ADV F
two 0 NUM F
preservative-free 0 ADJ F
hydrating 0 ADP F
agents 0 NOUN F
, 0 PUNCT F
in 0 ADP F
multidose 0 NOUN F
( 0 PUNCT F
ABAK 0 NOUN T
) 0 PUNCT F
bottles 0 NOUN F
, 0 PUNCT F
in 0 ADP F
contact 0 NOUN F
lens 0 NOUN F
wearers 0 NOUN F
experiencing 0 PUNCT F
symptoms 0 NOUN F
of 0 ADP F
ocular B-PHYSICAL ADJ F
dryness I-PHYSICAL NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
The 0 DET T
endpoint 0 NOUN F
of 0 ADP F
this 0 DET F
4-week 0 NOUN F
multicenter 0 NOUN F
, 0 PUNCT F
randomized 0 VERB F
, 0 PUNCT F
double-blind 0 ADJ F
, 0 PUNCT F
parallel-group 0 NOUN F
study 0 NOUN F
comparing 0 VERB F
a 0 DET F
2 0 NUM F
% 0 SYM F
polyvinylpyrrolidone 0 NOUN F
( 0 PUNCT F
PVP 0 NOUN T
) 0 PUNCT F
solution 0 NOUN F
with 0 ADP F
a 0 DET F
0.9 0 NUM F
% 0 ADP F
NaCl 0 NOUN T
solution 0 NOUN F
was 0 VERB F
to 0 PART F
assess 0 NOUN F
ocular 0 ADJ F
discomfort 0 NOUN F
using 0 VERB F
a 0 DET F
visual 0 ADJ F
analog 0 NOUN F
scale 0 NOUN F
. 0 PUNCT F

A 0 DET T
biomicroscopic 0 ADJ F
examination 0 NOUN F
and 0 CCONJ F
a 0 DET F
test 0 NOUN F
of 0 ADP F
tolerability 0 NOUN F
on 0 ADP F
instillation 0 NOUN F
were 0 VERB F
also 0 ADV F
performed 0 VERB F
, 0 PUNCT F
and 0 CCONJ F
adverse 0 ADJ F
events 0 NOUN F
were 0 VERB F
recorded 0 VERB F
. 0 PUNCT F

RESULTS 0 NOUN T
Thirty-nine 0 NUM T
subjects 0 NOUN F
were 0 VERB F
enrolled 0 NOUN F
( 0 PUNCT F
23 0 NUM F
PVP 0 NOUN T
; 0 PUNCT F
16 0 NUM F
NaCl 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
average 0 ADJ F
age 0 NOUN F
was 0 VERB F
30 0 NUM F
; 0 PUNCT F
subjects 0 NOUN F
were 0 VERB F
predominantly 0 ADV F
female 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
mostly 0 ADV F
wore 0 PUNCT F
frequent-replacement 0 ADP F
contact 0 NOUN F
lenses 0 NOUN F
. 0 PUNCT F

They 0 PRON T
were 0 VERB F
all 0 CCONJ F
exposed 0 ADV F
to 0 ADP F
environmental 0 ADJ F
factors 0 NOUN F
such 0 ADP F
as 0 ADP F
routine 0 ADJ F
use 0 NOUN F
of 0 ADP F
video 0 ADJ F
monitors 0 NOUN F
or 0 CCONJ F
air 0 NOUN F
conditioning 0 NOUN F
. 0 PUNCT F

The 0 DET T
two 0 NUM F
groups 0 NOUN F
were 0 VERB F
similar 0 ADJ F
at 0 ADP F
baseline 0 NOUN F
( 0 PUNCT F
D0 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

Both 0 CCONJ T
PVP 0 NOUN T
and 0 CCONJ F
NaCl 0 NOUN T
improved 0 VERB F
the 0 DET F
comfort 0 NOUN F
of 0 ADP F
contact B-OTHER NOUN F
lens I-OTHER NOUN F
wear I-OTHER VERB F
( 0 PUNCT F
P 0 NOUN T
= 0 SYM F
0.0003 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
with 0 ADP F
no 0 DET F
difference 0 NOUN F
between 0 ADP F
them 0 NUM F
( 0 PUNCT F
P 0 NOUN T
= 0 SYM F
0.25 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
mean 0 NOUN F
daily 0 ADJ F
duration 0 NOUN F
of 0 ADP F
lens 0 NOUN F
wear 0 ADJ F
and 0 CCONJ F
the 0 DET F
daily 0 ADJ F
number 0 NOUN F
of 0 ADP F
instillations 0 NOUN F
to 0 PUNCT F
relieve 0 PUNCT F
discomfort 0 NOUN F
( 0 PUNCT F
4.2 0 NUM F
+/- 0 SYM F
2.0 0 NUM F
for 0 ADP F
PVP 0 NOUN T
ABAK 0 NOUN T
; 0 PUNCT F
4.6 0 NUM F
+/- 0 SYM F
1.9 0 NUM F
for 0 ADP F
NaCl 0 NOUN T
ABAK 0 NOUN T
) 0 PUNCT F
were 0 VERB F
comparable 0 ADJ F
. 0 PUNCT F

However 0 ADV T
, 0 PUNCT F
PVP 0 NOUN T
use 0 NUM F
led 0 VERB F
to 0 ADP F
more 0 CCONJ F
favorable 0 ADJ F
evolution 0 NOUN F
of 0 ADP F
fluorescein-staining B-OTHER VERB F
corneal I-OTHER ADJ F
punctuations I-OTHER NOUN F
( 0 PUNCT F
P 0 NOUN T
= 0 SYM F
0.028 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Safety B-OTHER NOUN T
was 0 VERB F
good 0 ADJ F
, 0 PUNCT F
with 0 ADP F
minimal 0 ADJ F
adverse B-ADVERSE-EFFECTS ADJ F
events I-ADVERSE-EFFECTS NOUN F
considered 0 DET F
unrelated 0 VERB F
to 0 ADP F
the 0 DET F
products 0 NOUN F
. 0 PUNCT F

Lens B-OTHER NOUN T
wettability I-OTHER NOUN F
was 0 ADP F
excellent 0 ADJ F
, 0 PUNCT F
and 0 CCONJ F
there 0 PUNCT F
were 0 VERB F
no 0 DET F
clinically 0 ADV F
relevant 0 ADJ F
deposits 0 NOUN F
. 0 PUNCT F

Most 0 DET T
subjects 0 NOUN F
also 0 ADV F
found 0 PROPN F
the 0 DET F
ABAK 0 NOUN T
bottles 0 NOUN F
convenient 0 ADJ F
. 0 PUNCT F

CONCLUSIONS 0 NOUN T
Ocular 0 PUNCT T
hydration 0 NOUN F
improves 0 VERB F
comfort B-OTHER ADP F
in 0 ADP F
contact 0 NOUN F
lens 0 NOUN F
wearers 0 NOUN F
. 0 PUNCT F

NaCl 0 NOUN T
is 0 VERB F
an 0 DET F
appropriate 0 ADJ F
first-line 0 NOUN F
treatment 0 NOUN F
, 0 PUNCT F
but 0 CCONJ F
for 0 ADP F
subjects 0 NOUN F
with 0 ADP F
fluorescein-staining 0 VERB F
punctuations 0 NOUN F
, 0 PUNCT F
lubrication 0 NOUN F
with 0 ADP F
PVP 0 NOUN T
is 0 VERB F
preferable 0 ADJ F
. 0 PUNCT F

Predictors 0 NOUN T
of 0 ADP F
recruited 0 VERB F
melanoma 0 NOUN F
families 0 NOUN F
into 0 ADP F
a 0 DET F
behavioral 0 ADJ F
intervention 0 NOUN F
project 0 NOUN F
. 0 PUNCT F

BACKGROUND 0 NOUN T
Examination 0 NOUN T
of 0 ADP F
families 0 NOUN F
represents 0 NOUN F
an 0 DET F
important 0 ADJ F
priority 0 NOUN F
in 0 ADP F
health 0 NOUN F
research 0 NOUN F
. 0 PUNCT F

In 0 ADP T
this 0 DET F
paper 0 NOUN F
we 0 PRON F
report B-OTHER NOUN F
on 0 ADP F
individual B-MENTAL ADJ F
and I-MENTAL CCONJ F
family-level I-MENTAL VERB F
factors I-MENTAL NOUN F
associated 0 VERB F
with 0 ADP F
enrollment 0 NOUN F
in 0 ADP F
a 0 DET F
cancer 0 NOUN F
prevention 0 NOUN F
research 0 NOUN F
project 0 NOUN F
. 0 PUNCT F

We 0 PRON T
approached 0 VERB F
families 0 NOUN F
affected 0 VERB F
by 0 ADP F
melanoma 0 NOUN F
for 0 ADP F
possible 0 ADJ F
participation 0 NOUN F
in 0 ADP F
a 0 DET F
randomized 0 VERB F
controlled 0 VERB F
trial 0 NOUN F
of 0 ADP F
a 0 DET F
web-based 0 VERB F
communication 0 NOUN F
and 0 CCONJ F
support 0 VERB F
intervention 0 NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
We 0 PRON T
recruited 0 VERB F
three 0 NUM F
family 0 NOUN F
members 0 NOUN F
per 0 ADP F
family 0 NOUN F
for 0 ADP F
assessment 0 NOUN F
- 0 PUNCT F
the 0 DET F
melanoma 0 NOUN F
case 0 NOUN F
, 0 PUNCT F
a 0 DET F
first-degree 0 ADJ F
relative 0 ADJ F
( 0 PUNCT F
FDR 0 NOUN T
) 0 PUNCT F
, 0 PUNCT F
and 0 CCONJ F
a 0 DET F
relative 0 ADJ F
who 0 CCONJ F
is 0 VERB F
a 0 DET F
parent 0 NOUN F
of 0 ADP F
a 0 DET F
child 0 NOUN F
age 0 NOUN F
18 0 NUM F
or 0 CCONJ F
younger 0 PUNCT F
. 0 PUNCT F

Recruitment 0 NOUN T
involved 0 ADP F
three 0 NUM F
steps 0 NOUN F
: 0 PUNCT F
requesting 0 PUNCT F
the 0 DET F
physician 0 NOUN F
's 0 PUNCT F
consent 0 NOUN F
to 0 ADP F
approach 0 NOUN F
the 0 DET F
melanoma 0 NOUN F
case 0 NOUN F
, 0 PUNCT F
approaching 0 PUNCT F
the 0 DET F
case 0 NOUN F
to 0 ADP F
request 0 PUNCT F
their 0 ADP F
participation 0 NOUN F
and 0 CCONJ F
family 0 NOUN F
contact 0 NOUN F
information 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
they 0 PUNCT F
approaching 0 CCONJ F
the 0 DET F
FDRs 0 NOUN T
and 0 CCONJ F
parents 0 NOUN F
. 0 PUNCT F

RESULTS 0 NOUN T
Of 0 ADP T
the 0 DET F
1380 0 NUM F
families 0 NOUN F
approached 0 DET F
, 0 PUNCT F
313 0 NUM F
were 0 VERB F
enrolled 0 VERB F
, 0 PUNCT F
263 0 PUNCT F
were 0 VERB F
excluded 0 VERB F
because 0 ADP F
we 0 PRON F
could 0 ADP F
not 0 ADV F
find 0 VERB F
or 0 PUNCT F
contact 0 NOUN F
a 0 DET F
family 0 NOUN F
member 0 NOUN F
( 0 PUNCT F
FDR 0 NOUN T
or 0 CCONJ F
parent 0 NOUN F
) 0 PUNCT F
, 0 PUNCT F
331 0 NUM F
did 0 PUNCT F
not 0 ADV F
have 0 PUNCT F
eligible 0 ADJ F
family 0 NOUN F
members 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
473 0 NUM F
refused 0 PROPN F
. 0 PUNCT F

The 0 DET T
most 0 PUNCT F
frequently 0 ADV F
noted 0 PUNCT F
reason 0 NOUN F
for 0 ADP F
refusal B-OTHER ADJ F
was 0 PUNCT F
being 0 SYM F
too 0 ADV F
busy 0 NOUN F
or 0 CCONJ F
having 0 VERB F
no 0 DET F
time 0 NOUN F
. 0 PUNCT F

The 0 DET T
primary 0 ADJ F
predictors 0 NOUN F
of 0 ADP F
participation 0 NOUN F
for 0 ADP F
cases 0 NOUN F
( 0 PUNCT F
OR=1.6 0 NOUN T
; 0 PUNCT F
CI=1.01-2.51 0 NOUN T
) 0 PUNCT F
and 0 CCONJ F
FDRs 0 PUNCT T
( 0 PUNCT F
OR=2.15 0 NOUN T
; 0 PUNCT F
CI=1.11-4.13 0 NOUN T
) 0 PUNCT F
included 0 VERB F
higher B-MENTAL PUNCT F
educational I-MENTAL ADJ F
attainment I-MENTAL NOUN F
. 0 PUNCT F

FDRs 0 PUNCT T
were 0 VERB F
more 0 ADV F
likely 0 ADJ F
to 0 ADP F
enroll 0 PUNCT F
if 0 PUNCT F
they 0 ADV F
were 0 PUNCT F
female 0 NOUN F
( 0 PUNCT F
OR=1.77 0 PUNCT T
; 0 PUNCT F
CI=1.1-.85 0 PUNCT T
) 0 PUNCT F
and 0 CCONJ F
parents 0 NOUN F
were 0 VERB F
more 0 ADV F
likely 0 ADJ F
to 0 ADP F
enroll 0 PUNCT F
if 0 PUNCT F
the 0 DET F
case 0 NOUN F
had 0 PUNCT F
been 0 PUNCT F
diagnosed B-PHYSICAL VERB F
more I-PHYSICAL ADV F
recently I-PHYSICAL ADV F
( 0 PUNCT F
OR=3.3 0 ADP T
; 0 PUNCT F
CI=1.9-5.93 0 NOUN T
) 0 PUNCT F
, 0 PUNCT F
if 0 PUNCT F
the 0 DET F
parent B-OTHER NOUN F
was I-OTHER VERB F
partnered I-OTHER VERB F
( 0 PUNCT F
OR=4.37 0 NOUN T
; 0 PUNCT F
CI=1.86-10.26 0 NOUN T
) 0 PUNCT F
, 0 PUNCT F
and 0 CCONJ F
if 0 PUNCT F
the 0 DET F
parent B-MENTAL NOUN F
lived I-MENTAL VERB F
in I-MENTAL ADP F
the I-MENTAL DET F
same I-MENTAL ADJ F
city I-MENTAL NOUN F
as I-MENTAL ADP F
the I-MENTAL DET F
case I-MENTAL NOUN F
( 0 PUNCT F
OR=2.88 0 PUNCT T
; 0 PUNCT F
CI=1.08-7.68 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

CONCLUSIONS 0 NOUN T
The 0 DET T
results 0 NOUN F
can 0 VERB F
provide 0 VERB F
information 0 NOUN F
on 0 ADP F
potential 0 ADJ F
directions 0 NOUN F
for 0 ADP F
future 0 PUNCT F
family 0 NOUN F
recruitment 0 NOUN F
. 0 PUNCT F

Olanzapine 0 NOUN T
versus 0 CCONJ F
haloperidol 0 NOUN F
in 0 ADP F
children 0 NOUN F
with 0 ADP F
autistic B-PHYSICAL ADJ F
disorder I-PHYSICAL NOUN F
: 0 PUNCT F
an 0 DET F
open 0 ADJ F
pilot 0 NOUN F
study 0 NOUN F
. 0 PUNCT F

OBJECTIVES 0 NOUN T
Conventional 0 ADJ T
neuroleptics 0 NOUN F
ameliorate 0 NOUN F
symptoms 0 NOUN F
in 0 ADP F
children 0 NOUN F
with 0 ADP F
autistic 0 ADJ F
disorder 0 NOUN F
; 0 PUNCT F
however 0 ADV F
, 0 PUNCT F
they 0 PUNCT F
are 0 VERB F
known 0 VERB F
to 0 ADP F
cause 0 PROPN F
dyskinesias 0 NOUN F
. 0 PUNCT F

Atypical 0 ADJ T
neuroleptics 0 NOUN F
, 0 PUNCT F
including 0 SYM F
olanzapine 0 NOUN F
, 0 PUNCT F
may 0 VERB F
have 0 PUNCT F
less 0 DET F
risk 0 NOUN F
for 0 ADP F
dyskinesia 0 NOUN F
, 0 PUNCT F
but 0 CCONJ F
their 0 VERB F
efficacy 0 NOUN F
in 0 ADP F
autistic 0 ADJ F
disorder 0 NOUN F
is 0 VERB F
not 0 ADV F
established 0 VERB F
. 0 PUNCT F

This 0 DET T
study 0 NOUN F
was 0 VERB F
designed 0 VERB F
to 0 PART F
investigate 0 NOUN F
the 0 DET F
safety 0 NOUN F
and 0 CCONJ F
effectiveness 0 NOUN F
of 0 ADP F
open-label 0 NOUN F
olanzapine 0 NOUN F
as 0 ADP F
a 0 DET F
treatment 0 NOUN F
for 0 ADP F
children 0 NOUN F
with 0 ADP F
autistic 0 ADJ F
disorder 0 NOUN F
by 0 ADP F
using 0 PART F
haloperidol 0 NOUN F
as 0 ADP F
a 0 DET F
standard 0 ADJ F
comparator 0 NOUN F
treatment 0 NOUN F
. 0 PUNCT F

METHOD 0 NOUN T
In 0 ADP T
a 0 DET F
parallel 0 ADJ F
groups 0 NOUN F
design 0 NOUN F
, 0 PUNCT F
12 0 NUM F
children 0 NOUN F
with 0 ADP F
DSM-IV 0 NOUN T
autistic 0 ADJ F
disorder 0 NOUN F
( 0 PUNCT F
mean 0 NOUN F
age 0 NOUN F
7.8+/-2.1 0 NOUN F
years 0 NOUN F
) 0 PUNCT F
were 0 VERB F
randomized 0 VERB F
to 0 ADP F
6 0 NUM F
weeks 0 NOUN F
of 0 ADP F
open 0 ADJ F
treatment 0 NOUN F
with 0 ADP F
olanzapine 0 NOUN F
or 0 CCONJ F
haloperidol 0 NOUN F
. 0 PUNCT F

Mean 0 ADJ T
final 0 ADJ F
dosages 0 NOUN F
were 0 VERB F
7.9+/-2.5 0 CCONJ F
mg/day 0 NOUN F
for 0 ADP F
olanzapine 0 NOUN F
and 0 CCONJ F
1.4+/-0.7 0 NUM F
mg/day 0 NOUN F
for 0 ADP F
haloperidol 0 NOUN F
. 0 PUNCT F

Outcome 0 NOUN T
measures 0 NOUN F
included 0 VERB F
the 0 DET F
Clinical B-MENTAL ADJ T
Global I-MENTAL PUNCT T
Impressions I-MENTAL NOUN T
( I-MENTAL PUNCT F
CGI I-MENTAL NOUN T
) I-MENTAL PUNCT F
and 0 CCONJ F
the 0 DET F
Children 0 NOUN T
's 0 PUNCT F
Psychiatric 0 ADJ T
Rating 0 PUNCT T
Scale 0 NOUN T
( 0 PUNCT F
CPRS 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

RESULTS 0 NOUN T
Both 0 PUNCT T
groups 0 NOUN F
had 0 PUNCT F
symptom B-MENTAL NOUN F
reduction I-MENTAL NOUN F
. 0 PUNCT F

Five 0 NUM T
of 0 ADP F
six 0 NUM F
in 0 ADP F
the 0 DET F
olanzapine 0 PUNCT F
group 0 NOUN F
and 0 CCONJ F
three 0 NUM F
of 0 ADP F
six 0 NUM F
in 0 ADP F
the 0 DET F
haloperidol 0 NOUN F
group 0 NOUN F
were 0 VERB F
rated 0 VERB F
as 0 ADP F
responders 0 NOUN F
according 0 CCONJ F
to 0 ADP F
the 0 DET F
CGI B-MENTAL NOUN T
Improvement 0 NOUN T
item 0 NOUN F
. 0 PUNCT F

Subjects 0 NOUN T
showed 0 VERB F
improvement 0 NOUN F
on 0 ADP F
the 0 DET F
CPRS B-MENTAL NOUN T
Autism I-MENTAL NOUN T
Factor I-MENTAL NOUN T
( 0 PUNCT F
F1,9 0 NOUN T
= 0 SYM F
24.4 0 NUM F
, 0 PUNCT F
p 0 NOUN F
= 0 SYM F
.0008 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Side 0 NOUN T
effects 0 NOUN F
included 0 ADP F
drowsiness B-ADVERSE-EFFECTS PUNCT F
and 0 CCONJ F
weight 0 NOUN F
gain B-ADVERSE-EFFECTS NOUN F
. 0 PUNCT F

CONCLUSIONS 0 NOUN T
The 0 DET T
findings 0 NOUN F
suggest 0 VERB F
that 0 ADP F
olanzapine 0 NOUN F
is 0 VERB F
a 0 DET F
promising 0 VERB F
treatment 0 NOUN F
for 0 ADP F
children 0 NOUN F
with 0 ADP F
autistic 0 ADJ F
disorder 0 NOUN F
. 0 PUNCT F

Further 0 PUNCT T
placebo-controlled 0 VERB F
and 0 CCONJ F
long-term 0 NOUN F
studies 0 NOUN F
of 0 ADP F
olanzapine 0 NOUN F
in 0 ADP F
autistic 0 ADJ F
disorder 0 NOUN F
are 0 VERB F
required 0 VERB F
. 0 PUNCT F

Long-term 0 NOUN T
follow-up 0 NOUN F
of 0 ADP F
cytostatic 0 ADJ F
intravesical 0 ADJ F
instillation 0 NOUN F
in 0 ADP F
patients 0 NOUN F
with 0 ADP F
superficial 0 ADJ F
bladder 0 NOUN F
carcinoma 0 NOUN F
. 0 PUNCT F

Is 0 PUNCT T
short-term 0 NOUN F
, 0 PUNCT F
intensive 0 ADJ F
instillation 0 NOUN F
better 0 PUNCT F
than 0 ADP F
maintenance 0 NOUN F
therapy 0 NOUN F
? 0 PUNCT F

OBJECTIVES 0 ADP T
Comparisons 0 NOUN T
of 0 ADP F
two 0 NUM F
3-year 0 NOUN F
protocols 0 NOUN F
, 0 PUNCT F
one 0 NUM F
20-week 0 NOUN F
protocol 0 NOUN F
of 0 ADP F
mitomycin 0 NUM F
C 0 NOUN T
instillation 0 NOUN F
and 0 CCONJ F
one 0 NUM F
3-year 0 NOUN F
protocol 0 NOUN F
of 0 ADP F
doxorubicin 0 NOUN F
instillation 0 NOUN F
for 0 ADP F
the 0 DET F
prevention 0 NOUN F
of 0 ADP F
recurrent B-PHYSICAL ADJ F
tumors I-PHYSICAL NOUN F
and 0 CCONJ F
progression B-PHYSICAL NOUN F
in 0 ADP F
patients 0 NOUN F
whose 0 ADP F
superficial 0 VERB F
bladder 0 NOUN F
tumors 0 NOUN F
had 0 VERB F
been 0 ADP F
removed 0 VERB F
by 0 ADP F
transurethral 0 ADJ F
resection 0 NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
A 0 PUNCT T
prospective 0 ADJ F
, 0 PUNCT F
randomized 0 VERB F
parallel 0 ADJ F
group 0 NOUN F
multicenter 0 NOUN F
trial 0 NOUN F
was 0 VERB F
conducted 0 VERB F
. 0 PUNCT F

419 0 DET F
patients 0 NOUN F
were 0 VERB F
evaluated 0 VERB F
after 0 ADP F
a 0 DET F
median 0 ADJ F
follow-up 0 NOUN F
of 0 ADP F
57 0 NUM F
months 0 NOUN F
. 0 PUNCT F

Cox 0 NOUN T
proportional 0 ADJ F
hazards 0 NOUN F
analysis 0 NOUN F
was 0 VERB F
performed 0 VERB F
. 0 PUNCT F

RESULTS 0 PUNCT T
An 0 DET T
overall B-PHYSICAL ADJ F
recurrence I-PHYSICAL NOUN F
rate I-PHYSICAL NOUN F
of 0 ADP F
22.7 0 NUM F
% 0 SYM F
and 0 CCONJ F
an 0 DET F
overall B-PHYSICAL ADJ F
progression I-PHYSICAL NOUN F
rate I-PHYSICAL NOUN F
of 0 ADP F
9.8 0 NUM F
% 0 SYM F
was 0 VERB F
found 0 VERB F
. 0 PUNCT F

For 0 ADP T
time 0 NOUN F
to 0 ADP F
progression 0 NOUN F
a 0 DET F
significant 0 ADJ F
overall B-OTHER ADJ F
treatment I-OTHER NOUN F
effect 0 NOUN F
was 0 VERB F
detected 0 VERB F
dependent 0 ADJ F
on 0 ADP F
the 0 DET F
recurrence 0 NOUN F
status 0 NOUN F
before 0 ADP F
entry 0 NOUN F
into 0 ADP F
the 0 DET F
study 0 NOUN F
( 0 PUNCT F
p 0 NOUN F
= 0 SYM F
0.0059 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Pairwise 0 PUNCT T
comparisons 0 NOUN F
showed 0 VERB F
the 0 DET F
mitomycin 0 NOUN F
protocol 0 NOUN F
with 0 ADP F
short-term 0 NOUN F
intensive 0 ADJ F
( 0 PUNCT F
weekly 0 ADV F
) 0 PUNCT F
combined 0 VERB F
with 0 ADP F
long-term 0 NOUN F
maintenance 0 NOUN F
instillation 0 NOUN F
to 0 ADP F
have 0 PUNCT F
a 0 DET F
highly 0 ADV F
beneficial B-OTHER ADJ F
effect 0 NOUN F
compared 0 VERB F
to 0 ADP F
long-term 0 NOUN F
maintenance 0 NOUN F
instillation 0 NOUN F
only 0 ADV F
especially 0 ADV F
for 0 ADP F
patients 0 NOUN F
entering 0 CCONJ F
the 0 DET F
study 0 NOUN F
with 0 ADP F
recurrent 0 ADJ F
tumors 0 NOUN F
( 0 PUNCT F
RR 0 NOUN T
= 0 SYM F
0.06 0 NUM F
, 0 PUNCT F
95 0 NUM F
% 0 SYM F
CI 0 NOUN T
: 0 PUNCT F
[ 0 PUNCT F
0.008 0 NUM F
, 0 PUNCT F
0.506 0 PUNCT F
] 0 PUNCT F
. 0 PUNCT F

CONCLUSION 0 NOUN T
These 0 DET T
results 0 NOUN F
show 0 VERB F
that 0 ADP F
intensive B-PHYSICAL ADJ F
therapeutic I-PHYSICAL ADJ F
instillation I-PHYSICAL NOUN F
may 0 VERB F
have 0 CCONJ F
an 0 DET F
advantage 0 NOUN F
over 0 ADP F
less 0 DET F
intensive 0 ADJ F
, 0 PUNCT F
prophylactic 0 ADP F
regimens 0 NOUN F
. 0 PUNCT F

A 0 DET T
double-blind 0 ADJ F
crossover 0 NOUN F
comparison 0 NOUN F
of 0 ADP F
pindolol 0 NOUN F
, 0 PUNCT F
metoprolol 0 NOUN F
, 0 PUNCT F
atenolol 0 NOUN F
and 0 CCONJ F
labetalol 0 NOUN F
in 0 ADP F
mild 0 ADJ F
to 0 ADP F
moderate 0 ADJ F
hypertension 0 NOUN F
. 0 PUNCT F

1 0 NUM F
This 0 DET T
study 0 NOUN F
was 0 VERB F
designed 0 VERB F
to 0 PART F
compare 0 NOUN F
in 0 ADP F
a 0 DET F
double-blind 0 ADJ F
randomized 0 VERB F
crossover 0 NOUN F
trial 0 NOUN F
, 0 PUNCT F
atenolol 0 NOUN F
, 0 PUNCT F
labetalol 0 NOUN F
, 0 PUNCT F
metoprolol 0 NOUN F
and 0 CCONJ F
pindolol 0 NOUN F
. 0 PUNCT F

Considerable 0 ADJ T
differences 0 NOUN F
in 0 ADP F
dose B-OTHER NOUN F
( 0 PUNCT F
atenolol 0 NOUN F
138 0 NUM F
+/- 0 SYM F
13 0 NUM F
mg 0 NOUN F
daily 0 ADJ F
; 0 PUNCT F
labetalol 0 NOUN F
308 0 NUM F
+/- 0 SYM F
34 0 NUM F
mg 0 NOUN F
daily 0 ADJ F
; 0 PUNCT F
metoprolol 0 NOUN F
234 0 NUM F
+/- 0 SYM F
22 0 NUM F
mg 0 NOUN F
daily 0 ADJ F
; 0 PUNCT F
and 0 CCONJ F
pindolol 0 NOUN F
24 0 NUM F
+/-2 0 ADJ F
mg 0 NOUN F
daily 0 ADJ F
were 0 VERB F
required 0 VERB F
to 0 PART F
produce 0 ADV F
similar 0 ADJ F
antihypertensive B-PHYSICAL ADJ F
effects I-PHYSICAL NOUN F
. 0 PUNCT F

3 0 NUM F
The 0 DET T
overall 0 ADJ F
incidence 0 NOUN F
of 0 ADP F
side-effects B-ADVERSE-EFFECTS NOUN F
was 0 VERB F
similar 0 ADJ F
with 0 ADP F
atenolol 0 NOUN F
, 0 PUNCT F
metoprolol 0 NOUN F
and 0 CCONJ F
pindolol 0 NOUN F
but 0 CCONJ F
was 0 VERB F
slightly 0 ADV F
less 0 DET F
with 0 ADP F
labetalol 0 NOUN F
. 0 PUNCT F

Sleep B-MENTAL NOUN T
disturbances I-MENTAL NOUN F
and 0 CCONJ F
abnormal B-MENTAL ADJ F
dreaming I-MENTAL ADJ F
patterns I-MENTAL NOUN F
were 0 VERB F
most 0 PUNCT F
frequent 0 CCONJ F
with 0 ADP F
pindolol 0 NOUN F
. 0 PUNCT F

4 0 NUM F
There 0 PUNCT T
was 0 VERB F
a 0 DET F
significantly B-PHYSICAL ADV F
greater 0 PUNCT F
fall B-PHYSICAL NOUN F
in I-PHYSICAL ADP F
pulse I-PHYSICAL PUNCT F

Effects 0 NOUN T
of 0 ADP F
cuff 0 ADJ F
inflation 0 NOUN F
on 0 ADP F
self-recorded B-PHYSICAL VERB F
blood I-PHYSICAL NOUN F
pressure I-PHYSICAL NOUN F
. 0 PUNCT F

Changes 0 NOUN T
in 0 ADP F
continuously 0 ADV F
recorded 0 PUNCT F
'Finapres 0 PUNCT F
' 0 PUNCT F
finger B-PHYSICAL NOUN F
blood I-PHYSICAL NOUN F
pressure I-PHYSICAL NOUN F
in 0 ADP F
ten 0 NUM F
normotensive 0 ADJ F
and 0 CCONJ F
seven 0 NUM F
hypertensive 0 ADJ F
subjects 0 NOUN F
induced 0 VERB F
by 0 ADP F
self-inflation 0 NOUN F
of 0 ADP F
the 0 DET F
cuff 0 ADJ F
or 0 CCONJ F
just 0 ADV F
wearing 0 CCONJ F
the 0 DET F
inflated 0 PUNCT F
cuff 0 ADJ F
were 0 VERB F
studied 0 VERB F
. 0 PUNCT F

Inflating 0 PUNCT T
the 0 DET F
cuff 0 ADJ F
caused 0 VERB F
an 0 DET F
instantaneous 0 ADJ F
rise 0 NOUN F
in 0 ADP F
systolic B-PHYSICAL ADJ F
blood I-PHYSICAL NOUN F
pressure I-PHYSICAL NOUN F
of 0 ADP F
13 0 NUM F
and 0 CCONJ F
12 0 NUM F
mm 0 NOUN F
Hg 0 NOUN T
( 0 PUNCT F
hypertensive 0 ADJ F
and 0 CCONJ F
normotensive 0 ADJ F
subjects 0 NOUN F
, 0 PUNCT F
respectively 0 ADV F
) 0 PUNCT F
. 0 PUNCT F

Wearing 0 PUNCT T
the 0 DET F
inflated 0 PUNCT F
cuff 0 ADJ F
did 0 PUNCT F
not 0 ADV F
change 0 NUM F
blood B-PHYSICAL NOUN F
pressure I-PHYSICAL NOUN F
. 0 PUNCT F

Thus 0 PUNCT T
the 0 DET F
rise 0 NOUN F
in 0 ADP F
pressure B-PHYSICAL NOUN F
was 0 VERB F
related 0 VERB F
to 0 ADP F
the 0 DET F
muscular 0 ADJ F
activity 0 NOUN F
required 0 VERB F
for 0 ADP F
cuff 0 ADJ F
inflation 0 NOUN F
. 0 PUNCT F

Systolic B-PHYSICAL ADJ T
blood I-PHYSICAL NOUN F
pressure I-PHYSICAL NOUN F
took 0 PRON F
on 0 ADP F
average 0 ADJ F
7 0 NUM F
s 0 NOUN F
and 0 CCONJ F
at 0 ADP F
most 0 CCONJ F
21 0 NUM F
s 0 ADP F
to 0 PUNCT F
return 0 CCONJ F
to 0 ADP F
baseline 0 NOUN F
level 0 NOUN F
after 0 ADP F
stopping 0 ADP F
cuff 0 ADJ F
inflation 0 NOUN F
. 0 PUNCT F

Since 0 ADP T
first 0 ADJ F
Korotkoff 0 NOUN T
sounds 0 NOUN F
may 0 VERB F
already 0 ADV F
be 0 PUNCT F
heard 0 NOUN F
after 0 ADP F
10-15 0 NUM F
s 0 NOUN F
when 0 ADP F
following 0 PUNCT F
recommended 0 VERB F
procedures 0 NOUN F
, 0 PUNCT F
self-recorded B-PHYSICAL VERB F
systolic I-PHYSICAL ADJ F
blood I-PHYSICAL NOUN F
pressure I-PHYSICAL NOUN F
may 0 VERB F
be 0 VERB F
recorded 0 VERB F
as 0 PUNCT F
too 0 ADV F
high 0 ADJ F
when 0 PUNCT F
subjects 0 NOUN F
inflate 0 ADP F
their 0 PUNCT F
cuff 0 ADJ F
at 0 ADP F
too 0 ADV F
low 0 PUNCT F
a 0 DET F
pressure 0 NOUN F
or 0 CCONJ F
deflate 0 PUNCT F
it 0 ADP F
too 0 ADV F
fast 0 ADJ F
. 0 PUNCT F

Clinical 0 ADJ T
trial 0 NOUN F
: 0 PUNCT F
exposure 0 NOUN F
to 0 ADP F
ribavirin 0 NOUN F
predicts 0 PROPN F
EVR 0 NOUN T
and 0 CCONJ F
SVR 0 NOUN T
in 0 ADP F
patients 0 NOUN F
with 0 ADP F
HCV 0 NOUN T
genotype 0 NOUN F
1 0 NUM F
infection 0 NOUN F
treated 0 VERB F
with 0 ADP F
peginterferon 0 ADJ F
alpha-2a 0 NOUN F
plus 0 CCONJ F
ribavirin 0 NOUN F
. 0 PUNCT F

BACKGROUND 0 NOUN T
The 0 DET T
impact 0 NOUN F
of 0 ADP F
reduced 0 VERB F
drug 0 NOUN F
exposure 0 NOUN F
on 0 ADP F
outcomes 0 NOUN F
in 0 ADP F
patients 0 NOUN F
with 0 ADP F
chronic 0 ADJ F
hepatitis 0 NOUN F
C 0 NOUN T
has 0 VERB F
not 0 ADV F
been 0 PUNCT F
determined 0 VERB F
in 0 ADP F
routine 0 ADJ F
clinical 0 ADJ F
practice 0 NOUN F
. 0 PUNCT F

AIM 0 NOUN T
To 0 ADV T
examine 0 NOUN F
the 0 DET F
impact 0 NOUN F
of 0 ADP F
exposure 0 NOUN F
to 0 ADP F
peginterferon 0 PUNCT F
alpha-2a 0 NOUN F
and 0 CCONJ F
ribavirin 0 NOUN F
on 0 ADP F
early 0 ADJ F
virological 0 ADJ F
response 0 NOUN F
( 0 PUNCT F
EVR 0 NOUN T
) 0 PUNCT F
and 0 CCONJ F
sustained 0 VERB F
virological 0 ADJ F
response 0 NOUN F
( 0 PUNCT F
SVR 0 NOUN T
) 0 PUNCT F
in 0 ADP F
treatment-naive 0 ADJ F
patients 0 NOUN F
with 0 ADP F
HCV 0 NOUN T
genotype 0 NOUN F
1 0 NUM F
infection 0 NOUN F
enrolled 0 ADJ F
in 0 ADP F
a 0 DET F
large 0 ADJ F
expanded 0 PUNCT F
access 0 NOUN F
programme 0 NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
Eight 0 NUM T
hundred 0 NUM F
and 0 CCONJ F
ninety-one 0 PUNCT F
patients 0 NOUN F
treated 0 VERB F
for 0 ADP F
48 0 NUM F
weeks 0 NOUN F
with 0 ADP F
an 0 DET F
initial 0 ADJ F
ribavirin 0 NOUN F
dose 0 NOUN F
of 0 ADP F
800 0 NUM F
or 0 CCONJ F
1000/1200 0 NOUN F
mg/day 0 NOUN F
were 0 VERB F
evaluated 0 VERB F
. 0 PUNCT F

Ribavirin 0 NOUN T
1000 0 NUM F
mg/day 0 NOUN F
( 0 PUNCT F
< 0 SYM F
75 0 NUM F
kg 0 NOUN F
) 0 PUNCT F
or 0 CCONJ F
1200 0 NUM F
mg/day 0 NOUN F
( 0 PUNCT F
> 0 PROPN F
or=75 0 PUNCT F
kg 0 NOUN F
) 0 PUNCT F
and 0 CCONJ F
peginterferon 0 ADP F
alpha-2a 0 NOUN F
180 0 NUM F
microg/week 0 NOUN F
were 0 VERB F
considered 0 VERB F
optimal 0 ADJ F
. 0 PUNCT F

The 0 DET T
impact 0 NOUN F
of 0 ADP F
reduced B-PHYSICAL VERB F
drug I-PHYSICAL NOUN F
exposure I-PHYSICAL NOUN F
( 0 PUNCT F
expressed 0 VERB F
as 0 ADP F
a 0 DET F
percentage 0 NOUN F
of 0 ADP F
optimal 0 ADJ F
) 0 PUNCT F
on 0 ADP F
EVR B-PHYSICAL NOUN T
and 0 CCONJ F
SVR B-PHYSICAL NOUN T
was 0 VERB F
evaluated 0 VERB F
. 0 PUNCT F

RESULTS 0 NOUN T
Mean 0 VERB T
ribavirin B-OTHER NOUN F
exposure I-OTHER NOUN F
in 0 ADP F
week 0 NOUN F
0-12 0 NUM F
was 0 VERB F
70 0 NUM F
% 0 SYM F
and 0 CCONJ F
96 0 NUM F
% 0 SYM F
in 0 ADP F
patients 0 NOUN F
assigned 0 VERB F
to 0 ADP F
ribavirin 0 NOUN F
800 0 NUM F
and 0 CCONJ F
1000/1200 0 NOUN F
mg/day 0 NOUN F
, 0 PUNCT F
respectively 0 ADV F
. 0 PUNCT F

EVR B-PHYSICAL NOUN T
and 0 CCONJ F
SVR B-PHYSICAL NOUN T
rates I-PHYSICAL NOUN F
were 0 VERB F
lower 0 PUNCT F
in 0 ADP F
patients 0 NOUN F
assigned 0 VERB F
to 0 ADP F
ribavirin 0 NOUN F
800 0 ADJ F
than 0 PUNCT F
1000/1200 0 NOUN F
mg/day 0 NOUN F
( 0 PUNCT F
EVR 0 NOUN T
, 0 PUNCT F
75 0 NUM F
% 0 SYM F
vs. 0 CCONJ F
84 0 NUM F
% 0 SYM F
, 0 PUNCT F
respectively 0 ADV F
, 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.001 0 NUM F
; 0 PUNCT F
SVR 0 NOUN T
, 0 PUNCT F
45 0 NUM F
% 0 SYM F
vs. 0 CCONJ F
54 0 NUM F
% 0 SYM F
, 0 PUNCT F
respectively 0 ADV F
, 0 PUNCT F
P 0 NOUN T
= 0 SYM F
0.011 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Furthermore 0 ADV T
, 0 PUNCT F
there 0 PUNCT F
was 0 VERB F
a 0 DET F
strong 0 ADJ F
correlation 0 NOUN F
between 0 ADP F
achievement 0 NOUN F
of 0 ADP F
EVR B-PHYSICAL NOUN T
and 0 CCONJ F
SVR B-PHYSICAL NOUN T
and 0 CCONJ F
ribavirin 0 NOUN F
dose 0 NOUN F
over 0 ADP F
the 0 DET F
first 0 ADJ F
12 0 NUM F
weeks 0 NOUN F
expressed 0 VERB F
either 0 PUNCT F
as 0 PUNCT F
absolute 0 ADJ F
dose 0 NOUN F
or 0 CCONJ F
proportion 0 NOUN F
of 0 ADP F
optimal 0 ADJ F
dose 0 NOUN F
received 0 VERB F
( 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.001 0 NUM F
for 0 ADP F
both 0 PUNCT F
) 0 PUNCT F
. 0 PUNCT F

CONCLUSIONS 0 NOUN T
Ribavirin 0 NOUN T
exposure 0 NOUN F
to 0 ADP F
week 0 ADJ F
12 0 NUM F
is 0 VERB F
significantly 0 ADV F
associated 0 VERB F
with 0 ADP F
EVR 0 NOUN T
and 0 CCONJ F
SVR 0 NOUN T
in 0 ADP F
genotype 0 NOUN F
1 0 NUM F
patients 0 NOUN F
. 0 PUNCT F

Maintenance 0 NOUN T
of 0 ADP F
an 0 DET F
optimal 0 ADJ F
ribavirin 0 NOUN F
dose 0 NOUN F
is 0 VERB F
the 0 DET F
most 0 VERB F
important 0 ADJ F
modifiable 0 ADJ F
factor 0 NOUN F
during 0 ADP F
combination 0 NOUN F
therapy 0 NOUN F
for 0 ADP F
chronic 0 ADJ F
hepatitis 0 NOUN F
C 0 NOUN T
. 0 PUNCT F

A 0 DET T
randomized 0 VERB F
, 0 PUNCT F
phase 0 NOUN F
II 0 NUM T
trial 0 NOUN F
of 0 ADP F
two 0 NUM F
dose 0 NOUN F
schedules 0 NOUN F
of 0 ADP F
carboplatin/paclitaxel/cetuximab 0 NOUN F
in 0 ADP F
stage 0 NOUN F
IIIB/IV 0 NOUN T
non-small-cell 0 NOUN F
lung 0 NOUN F
cancer 0 NOUN F
( 0 PUNCT F
NSCLC 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

BACKGROUND 0 NOUN T
This 0 DET T
trial 0 NOUN F
investigated 0 VERB F
the 0 DET F
efficacy 0 NOUN F
and 0 CCONJ F
safety 0 NOUN F
of 0 ADP F
weekly 0 ADV F
cetuximab 0 NOUN F
combined 0 VERB F
with 0 ADP F
two 0 NUM F
different 0 ADJ F
schedules 0 NOUN F
of 0 ADP F
paclitaxel/carboplatin 0 NOUN F
for 0 ADP F
stage 0 NOUN F
IIIB/IV 0 NOUN T
non-small-cell 0 NOUN F
lung 0 NOUN F
cancer 0 NOUN F
( 0 PUNCT F
NSCLC 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

METHODS 0 NOUN T
A 0 PUNCT T
total 0 NOUN F
of 0 ADP F
168 0 NUM F
patients 0 NOUN F
with 0 ADP F
previously 0 ADV F
untreated 0 VERB F
stage 0 NOUN F
IIIB/IV 0 NOUN T
NSCLC 0 NOUN T
were 0 VERB F
randomized 0 VERB F
to 0 ADP F
arm 0 NOUN F
A 0 NOUN T
, 0 PUNCT F
cetuximab 0 NOUN F
( 0 PUNCT F
400 0 NUM F
mg/m 0 NOUN F
( 0 PUNCT F
2 0 NUM F
) 0 PUNCT F
day 0 NOUN F
1 0 NUM F
followed 0 VERB F
by 0 ADP F
weekly 0 ADV F
250 0 NUM F
mg/m 0 NOUN F
( 0 PUNCT F
2 0 NUM F
) 0 PUNCT F
) 0 PUNCT F
+ 0 SYM F
paclitaxel 0 NOUN F
( 0 PUNCT F
Taxol 0 ADV T
) 0 PUNCT F
( 0 PUNCT F
225 0 NUM F
mg/m 0 NOUN F
( 0 PUNCT F
2 0 NUM F
) 0 PUNCT F
) 0 PUNCT F
/carboplatin 0 NOUN F
( 0 PUNCT F
AUC6 0 NOUN T
) 0 PUNCT F
day 0 NOUN F
1 0 NUM F
every 0 DET F
3 0 NUM F
weeks 0 NOUN F
or 0 CCONJ F
arm 0 NOUN F
B 0 NOUN T
, 0 PUNCT F
same 0 ADJ F
cetuximab 0 NOUN F
regimen 0 NOUN F
plus 0 CCONJ F
paclitaxel 0 NOUN F
( 0 PUNCT F
100 0 NUM F
mg/m 0 NOUN F
( 0 PUNCT F
2 0 NUM F
) 0 PUNCT F
) 0 PUNCT F
days 0 NOUN F
1 0 NUM F
, 0 PUNCT F
8 0 NUM F
, 0 PUNCT F
and 0 CCONJ F
15 0 NUM F
every 0 DET F
3 0 NUM F
weeks 0 NOUN F
and 0 CCONJ F
carboplatin 0 NOUN F
( 0 PUNCT F
AUC6 0 NOUN T
) 0 PUNCT F
day 0 NOUN F
1 0 NUM F
every 0 DET F
4 0 NUM F
weeks 0 NOUN F
. 0 PUNCT F

Treatment 0 NOUN T
continued 0 VERB F
for 0 ADP F
a 0 DET F
four-cycle 0 NOUN F
maximum 0 NOUN F
. 0 PUNCT F

Patients 0 NOUN T
with 0 ADP F
a 0 DET F
complete 0 ADJ F
response 0 NOUN F
, 0 PUNCT F
partial 0 ADJ F
response 0 NOUN F
, 0 PUNCT F
or 0 CCONJ F
stable 0 ADJ F
disease 0 NOUN F
after 0 ADP F
four 0 NUM F
cycles 0 NOUN F
could 0 VERB F
receive 0 VERB F
cetuximab 0 NOUN F
250 0 NUM F
mg/m 0 NOUN F
( 0 PUNCT F
2 0 NUM F
) 0 PUNCT F
/week 0 NOUN F
until 0 ADP F
disease B-PHYSICAL NOUN F
progression I-PHYSICAL NOUN F
or I-PHYSICAL CCONJ F
unacceptable I-PHYSICAL ADJ F
toxicity I-PHYSICAL NOUN F
. 0 PUNCT F

The 0 DET T
primary 0 ADJ F
end 0 NOUN F
point 0 NOUN F
was 0 VERB F
to 0 PART F
evaluate 0 PUNCT F
progression-free B-MORTALITY ADJ F
survival I-MORTALITY NOUN F
( I-MORTALITY PUNCT F
PFS I-MORTALITY NOUN T
) I-MORTALITY PUNCT F
. 0 PUNCT F

RESULTS 0 ADJ T
Median 0 ADJ T
PFS B-PHYSICAL NOUN T
was 0 VERB F
4.7 0 NUM F
and 0 CCONJ F
4.3 0 NUM F
months 0 NOUN F
for 0 ADP F
arms 0 NOUN F
A 0 DET T
and 0 CCONJ F
B 0 NOUN T
, 0 PUNCT F
respectively 0 ADV F
( 0 PUNCT F
6-month 0 NOUN F
PFS 0 NOUN T
, 0 PUNCT F
27.3 0 NUM F
% 0 SYM F
versus 0 CCONJ F
30.9 0 NUM F
% 0 SYM F
) 0 PUNCT F
. 0 PUNCT F

Median 0 ADJ T
overall B-MORTALITY ADJ F
survival I-MORTALITY NOUN F
was 0 VERB F
11.4 0 NUM F
versus 0 CCONJ F
9.8 0 NUM F
months 0 NOUN F
for 0 ADP F
arms 0 NOUN F
A 0 DET T
and 0 CCONJ F
B 0 NOUN T
, 0 PUNCT F
respectively 0 ADV F
; 0 PUNCT F
estimated 0 DET F
1-year 0 ADJ F
survival 0 NOUN F
, 0 PUNCT F
47.7 0 NUM F
% 0 SYM F
versus 0 CCONJ F
39.3 0 NUM F
% 0 SYM F
; 0 PUNCT F
and 0 CCONJ F
objective 0 ADJ F
response 0 NOUN F
rate 0 NOUN F
, 0 PUNCT F
29.6 0 NUM F
% 0 SYM F
versus 0 CCONJ F
25 0 NUM F
% 0 SYM F
. 0 PUNCT F

The 0 DET T
regimen 0 NOUN F
was 0 VERB F
well 0 VERB F
tolerated B-OTHER VERB F
with 0 ADP F
rash B-PHYSICAL NOUN F
and I-PHYSICAL CCONJ F
hematologic I-PHYSICAL ADJ F
toxicity I-PHYSICAL NOUN F
being 0 VERB F
most 0 CCONJ F
common 0 ADJ F
. 0 PUNCT F

CONCLUSIONS 0 NOUN T
This 0 DET T
study 0 NOUN F
did 0 PUNCT F
not 0 ADV F
meet 0 VERB F
the 0 DET F
prespecified 0 ADJ F
benchmark 0 ADJ F
of 0 ADP F
35 0 NUM F
% 0 SYM F
6-month 0 NOUN F
PFS 0 NOUN T
rate 0 NOUN F
; 0 PUNCT F
both 0 PUNCT F
combination 0 NOUN F
schedules 0 NOUN F
of 0 ADP F
cetuximab 0 NOUN F
plus 0 CCONJ F
paclitaxel/carboplatin 0 NOUN F
were 0 VERB F
feasible 0 ADJ F
and 0 CCONJ F
equivalent 0 ADJ F
for 0 ADP F
treating 0 VERB F
advanced 0 NOUN F
NSCLC 0 NOUN T
. 0 PUNCT F

A 0 DET T
randomized 0 VERB F
trial 0 NOUN F
of 0 ADP F
external 0 ADJ F
beam 0 VERB F
radiotherapy 0 NOUN F
versus 0 CCONJ F
cryoablation 0 NOUN F
in 0 ADP F
patients 0 NOUN F
with 0 ADP F
localized 0 VERB F
prostate 0 NOUN F
cancer 0 NOUN F
: 0 PUNCT F
quality 0 NOUN F
of 0 ADP F
life 0 NOUN F
outcomes 0 NOUN F
. 0 PUNCT F

BACKGROUND 0 NOUN T
A 0 PUNCT T
recent 0 ADJ F
randomized 0 VERB F
trial 0 NOUN F
to 0 PART F
compare 0 NOUN F
external 0 ADJ F
beam 0 PUNCT F
radiation 0 NOUN F
therapy 0 NOUN F
( 0 PUNCT F
EBRT 0 PUNCT T
) 0 PUNCT F
to 0 ADP F
cryoablation 0 NOUN F
for 0 ADP F
localized 0 VERB F
disease 0 NOUN F
showed 0 VERB F
cryoablation 0 NOUN F
to 0 PART F
be 0 PUNCT F
noninferior 0 ADJ F
to 0 PUNCT F
external 0 ADJ F
beam 0 PUNCT F
EBRT 0 NOUN T
in 0 ADP F
disease 0 NOUN F
progression 0 NOUN F
and 0 CCONJ F
overall 0 ADJ F
and 0 CCONJ F
disease-specific 0 ADJ F
survival 0 NOUN F
. 0 PUNCT F

We 0 PRON T
report 0 VERB F
on 0 ADP F
the 0 DET F
quality 0 NOUN F
of 0 ADP F
life 0 NOUN F
( B-OTHER PUNCT F
QOL I-OTHER NOUN T
) I-OTHER PUNCT F
outcomes 0 NOUN F
for 0 ADP F
this 0 DET F
trial 0 NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
From 0 ADP T
December 0 NOUN T
1997 0 NUM F
through 0 ADP F
February 0 PUNCT T
2003 0 NUM F
, 0 PUNCT F
244 0 NUM F
men 0 NOUN F
with 0 ADP F
newly 0 ADJ F
diagnosed 0 DET F
localized 0 PUNCT F
prostate 0 NOUN F
cancer 0 NOUN F
were 0 VERB F
randomly 0 ADV F
assigned 0 VERB F
to 0 ADP F
cryoablation 0 NOUN F
or 0 CCONJ F
EBRT 0 NOUN T
( 0 PUNCT F
median 0 ADJ F
dose 0 NOUN F
68 0 NUM F
Gy 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

All 0 DET T
patients 0 NOUN F
received 0 CCONJ F
neoadjuvant 0 PUNCT F
antiandrogen 0 NOUN F
therapy 0 NOUN F
. 0 PUNCT F

Patients 0 NOUN T
completed 0 VERB F
the 0 DET F
EORTC 0 NOUN T
QLQ 0 NOUN T
C30 0 NOUN T
and 0 CCONJ F
the 0 DET F
Prostate 0 NOUN T
Cancer 0 NOUN T
Index 0 NOUN T
( 0 PUNCT F
PCI 0 NOUN T
) 0 PUNCT F
before 0 ADP F
treatment 0 NOUN F
and 0 CCONJ F
at 0 ADP F
1.5 0 NUM F
, 0 PUNCT F
3 0 NUM F
, 0 PUNCT F
6 0 NUM F
, 0 PUNCT F
12 0 NUM F
, 0 PUNCT F
18 0 NUM F
, 0 PUNCT F
24 0 NUM F
, 0 PUNCT F
and 0 CCONJ F
36 0 NUM F
months 0 NOUN F
post-treatment 0 PUNCT F
. 0 PUNCT F

RESULTS 0 DET T
Regardless 0 PUNCT T
of 0 ADP F
treatment 0 NOUN F
arm 0 ADP F
, 0 PUNCT F
participants 0 NOUN F
reported 0 ADP F
high 0 ADJ F
levels 0 NOUN F
of 0 ADP F
QOL B-OTHER NOUN T
with 0 ADP F
few 0 ADJ F
exceptions 0 NOUN F
. 0 PUNCT F

cryoablation 0 NOUN F
was 0 VERB F
associated 0 VERB F
with 0 ADP F
more 0 DET F
acute B-PHYSICAL ADJ F
urinary I-PHYSICAL ADJ F
dysfunction I-PHYSICAL NOUN F
( 0 PUNCT F
mean 0 NOUN F
PCI 0 NOUN T
urinary 0 ADJ F
function 0 NOUN F
cryoablation=69.4 0 NOUN F
; 0 PUNCT F
mean 0 NOUN F
EBRT=90.7 0 NOUN T
; 0 PUNCT F
P 0 NOUN T
< 0 SYM F
.001 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
which 0 ADP F
resolved 0 VERB F
over 0 PUNCT F
time 0 NOUN F
. 0 PUNCT F

No 0 DET T
late B-OTHER ADJ F
arising I-OTHER ADJ F
QOL I-OTHER NOUN T
issues I-OTHER NOUN F
were 0 VERB F
observed 0 VERB F
. 0 PUNCT F

Both 0 CCONJ T
EBRT 0 ADP T
and 0 CCONJ F
cryoablation 0 NOUN F
participants 0 NOUN F
reported 0 ADV F
decreases 0 DET F
in 0 ADP F
sexual B-PHYSICAL ADJ F
function I-PHYSICAL NOUN F
at 0 ADP F
3 0 NUM F
months 0 NOUN F
with 0 ADP F
the 0 DET F
cryoablation 0 NOUN F
patients 0 NOUN F
reporting 0 PUNCT F
poorer 0 PUNCT F
functioning 0 NOUN F
( 0 PUNCT F
mean 0 NOUN F
cryoablation=7.2 0 NOUN F
: 0 PUNCT F
mean 0 NOUN F
EBRT=32.9 0 NUM T
; 0 PUNCT F
P 0 NOUN T
< 0 SYM F
.001 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Mean 0 ADJ T
sexual B-PHYSICAL ADJ F
function I-PHYSICAL ADV F
score I-PHYSICAL NOUN F
was 0 VERB F
15 0 NUM F
points 0 ADP F
lower 0 PUNCT F
at 0 ADP F
3 0 NUM F
years 0 NOUN F
for 0 ADP F
the 0 DET F
cryoablation 0 NOUN F
group 0 NOUN F
and 0 CCONJ F
13 0 NUM F
% 0 ADP F
more 0 DET F
of 0 ADP F
the 0 DET F
cryoablation 0 NOUN F
men 0 NOUN F
said 0 PUNCT F
that 0 ADP F
sexuality 0 NOUN F
was 0 VERB F
a 0 DET F
moderate 0 ADJ F
or 0 CCONJ F
big 0 NOUN F
problem 0 NOUN F
. 0 PUNCT F

CONCLUSIONS 0 NOUN T
In 0 ADP T
this 0 DET F
randomized 0 VERB F
trial 0 NOUN F
, 0 PUNCT F
no 0 DET F
long-term 0 NOUN F
QOL B-OTHER NOUN T
advantage 0 PUNCT F
for 0 ADP F
either 0 CCONJ F
treatment 0 NOUN F
was 0 VERB F
apparent 0 ADJ F
with 0 ADP F
the 0 DET F
exception 0 NOUN F
of 0 ADP F
poorer 0 PUNCT F
sexual B-MENTAL ADJ F
function I-MENTAL NOUN F
reported 0 VERB F
by 0 ADP F
those 0 ADP F
treated 0 VERB F
with 0 ADP F
cryoablation 0 NOUN F
. 0 PUNCT F

Men 0 NOUN T
who 0 ADP F
wish 0 NOUN F
to 0 PART F
increase 0 NOUN F
their 0 ADP F
odds 0 NOUN F
of 0 ADP F
retaining 0 NUM F
sexual B-MENTAL ADJ F
function I-MENTAL NOUN F
might 0 VERB F
be 0 VERB F
counseled 0 VERB F
to 0 ADP F
choose 0 NOUN F
EBRT 0 NOUN T
over 0 ADP F
cryoablation 0 NOUN F
. 0 PUNCT F

In-season 0 NOUN T
effect 0 NOUN F
of 0 ADP F
short-term 0 NOUN F
sprint 0 NOUN F
and 0 CCONJ F
power 0 NOUN F
training 0 VERB F
programs 0 NOUN F
on 0 ADP F
elite 0 ADJ F
junior 0 PUNCT F
soccer 0 NOUN F
players 0 ADJ F
. 0 PUNCT F

The 0 DET T
aim 0 NOUN F
of 0 ADP F
this 0 DET F
study 0 NOUN F
was 0 VERB F
to 0 ADV F
examine 0 NOUN F
the 0 DET F
effects 0 NOUN F
of 0 ADP F
2 0 NUM F
in-season 0 NOUN F
short-term 0 NOUN F
sprint 0 NOUN F
and 0 CCONJ F
power 0 NOUN F
training 0 NUM F
protocols 0 NOUN F
on 0 ADP F
vertical 0 ADJ F
countermovement 0 ADJ F
jump 0 NOUN F
height 0 NOUN F
( 0 PUNCT F
with 0 ADP F
or 0 CCONJ F
without 0 ADP F
arms 0 NOUN F
) 0 PUNCT F
, 0 PUNCT F
sprint 0 NOUN F
( 0 PUNCT F
Sprint-15m 0 NOUN T
) 0 PUNCT F
speed 0 ADP F
, 0 PUNCT F
and 0 CCONJ F
agility 0 NOUN F
( 0 PUNCT F
Agility-15m 0 NOUN T
) 0 PUNCT F
speed 0 DET F
in 0 ADP F
male 0 NOUN F
elite 0 ADJ F
junior 0 PUNCT F
soccer 0 NOUN F
players 0 ADJ F
. 0 PUNCT F

Twenty 0 NUM T
highly 0 ADV F
trained 0 VERB F
soccer 0 NOUN F
players 0 ADJ F
( 0 PUNCT F
age 0 NOUN F
18.3 0 NUM F
+/- 0 SYM F
0.6 0 NUM F
years 0 NOUN F
, 0 PUNCT F
height 0 PUNCT F
177 0 NUM F
+/- 0 SYM F
4 0 NUM F
cm 0 NOUN F
, 0 PUNCT F
body 0 NOUN F
mass 0 NOUN F
71.4 0 NUM F
+/- 0 SYM F
6.9 0 NUM F
kg 0 NOUN F
, 0 PUNCT F
sum 0 NOUN F
skinfolds 0 CCONJ F
48.1 0 NUM F
+/- 0 SYM F
11.4 0 NUM F
mm 0 NOUN F
) 0 PUNCT F
, 0 PUNCT F
members 0 NOUN F
of 0 ADP F
a 0 DET F
professional 0 ADJ F
soccer 0 NOUN F
academy 0 PUNCT F
, 0 PUNCT F
were 0 VERB F
randomly 0 ADV F
allocated 0 VERB F
to 0 ADP F
either 0 CCONJ F
a 0 DET F
CONTRAST 0 NOUN T
( 0 PUNCT F
n 0 NOUN F
= 0 SYM F
10 0 NUM F
) 0 PUNCT F
or 0 CCONJ F
SPRINT 0 NOUN T
( 0 PUNCT F
n 0 NOUN F
= 0 SYM F
10 0 NUM F
) 0 PUNCT F
group 0 NOUN F
. 0 PUNCT F

The 0 DET T
training 0 VERB F
intervention 0 NOUN F
consisted 0 ADJ F
of 0 ADP F
6 0 NUM F
supervised 0 PUNCT F
training 0 ADJ F
sessions 0 NOUN F
over 0 ADP F
7 0 NUM F
weeks 0 NOUN F
, 0 PUNCT F
targeting 0 ADP F
the 0 DET F
improvement 0 NOUN F
of 0 ADP F
the 0 DET F
players 0 ADJ F
' 0 PUNCT F
speed B-MENTAL NOUN F
and 0 CCONJ F
power B-MENTAL NOUN F
. 0 PUNCT F

CONTRAST 0 NOUN T
protocol 0 NOUN F
consisted 0 VERB F
of 0 ADP F
alternating 0 PUNCT F
heavy-light 0 ADJ F
resistance 0 NOUN F
( 0 PUNCT F
15-50 0 NUM F
% 0 SYM F
body 0 NOUN F
mass 0 NOUN F
) 0 PUNCT F
with 0 ADP F
soccer-specific 0 ADJ F
drills 0 NOUN F
( 0 PUNCT F
small-sided 0 PROPN F
games 0 NOUN F
or 0 CCONJ F
technical 0 ADJ F
skills 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

SPRINT 0 NOUN T
training 0 ADJ F
protocol 0 NOUN F
used 0 PUNCT F
line 0 NOUN F
30-m 0 NOUN F
sprints 0 NOUN F
( 0 PUNCT F
2-4 0 NUM F
sets 0 NOUN F
of 0 ADP F
4 0 NUM F
x 0 SYM F
30 0 NUM F
m 0 NOUN F
with 0 ADP F
180 0 NUM F
and 0 CCONJ F
90 0 NUM F
seconds 0 NOUN F
of 0 ADP F
recovery 0 NOUN F
, 0 PUNCT F
respectively 0 ADV F
) 0 PUNCT F
. 0 PUNCT F

At 0 ADP T
baseline 0 NOUN F
no 0 DET F
difference 0 NOUN F
between 0 ADP F
physical B-PHYSICAL ADJ F
test I-PHYSICAL ADV F
performance I-PHYSICAL NOUN F
was 0 VERB F
evident 0 ADJ F
between 0 ADP F
the 0 DET F
2 0 NUM F
groups 0 NOUN F
( 0 PUNCT F
p 0 NOUN F
> 0 SYM F
0.05 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

No 0 DET T
time 0 NOUN F
x 0 SYM F
training 0 ADV F
group 0 NOUN F
effect 0 NOUN F
was 0 VERB F
found 0 VERB F
for 0 ADP F
any 0 PUNCT F
of 0 ADP F
the 0 DET F
vertical B-OTHER ADJ F
jump I-OTHER NOUN F
and I-OTHER CCONJ F
Agility-15m I-OTHER NOUN T
variables I-OTHER NOUN F
( 0 PUNCT F
p B-PHYSICAL NOUN F
> 0 SYM F
0.05 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

A 0 DET T
time 0 NOUN F
x 0 SYM F
training 0 ADV F
group 0 NOUN F
effect 0 NOUN F
was 0 VERB F
found 0 VERB F
for 0 ADP F
Sprint-15m 0 NOUN T
performance 0 NOUN F
with 0 ADP F
the 0 DET F
CONTRAST 0 NOUN T
group 0 NOUN F
showing 0 VERB F
significantly 0 ADV F
better 0 PUNCT F
scores 0 NOUN F
than 0 PUNCT F
the 0 DET F
SPRINT 0 NOUN T
group 0 NOUN F
( 0 PUNCT F
7.23 0 NUM F
+/- 0 SYM F
0.18 0 NUM F
vs. 0 CCONJ F
7.09 0 NUM F
+/- 0 SYM F
0.20 0 DET F
m.s 0 ADV F
, 0 PUNCT F
p 0 NOUN F
< 0 SYM F
0.01 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

In 0 ADP T
light 0 NOUN F
of 0 ADP F
these 0 DET F
findings 0 NOUN F
CONTRAST 0 NOUN T
training 0 VERB F
should 0 VERB F
be 0 VERB F
preferred 0 VERB F
to 0 ADP F
line 0 NOUN F
sprint 0 NOUN F
training 0 VERB F
in 0 ADP F
the 0 DET F
short 0 ADJ F
term 0 NOUN F
in 0 ADP F
young 0 ADJ F
elite 0 ADJ F
soccer 0 NOUN F
players 0 ADJ F
when 0 ADP F
the 0 DET F
aim 0 NOUN F
is 0 VERB F
to 0 PART F
improve 0 PUNCT F
soccer-specific B-MENTAL ADJ F
sprint I-MENTAL NOUN F
performance I-MENTAL NOUN F
( 0 PUNCT F
15 B-PHYSICAL NUM F
m I-PHYSICAL NOUN F
) 0 PUNCT F
during 0 ADP F
the 0 DET F
competitive 0 ADJ F
season 0 ADJ F
. 0 PUNCT F

Long-term 0 NOUN T
decrease 0 NOUN F
in 0 ADP F
bladder B-PHYSICAL NOUN F
cancer I-PHYSICAL NOUN F
recurrence I-PHYSICAL NOUN F
with 0 ADP F
hexaminolevulinate 0 PUNCT F
enabled 0 VERB F
fluorescence 0 NOUN F
cystoscopy 0 NOUN F
. 0 PUNCT F

PURPOSE 0 NOUN T
We 0 PRON T
assessed 0 VERB F
the 0 DET F
impact 0 NOUN F
of 0 ADP F
hexaminolevulinate 0 PUNCT F
fluorescence 0 NOUN F
cystoscopic 0 ADJ F
detection 0 NOUN F
of 0 ADP F
papillary 0 ADJ F
, 0 PUNCT F
nonmuscle 0 NOUN F
invasive 0 ADJ F
bladder 0 NOUN F
cancer 0 NOUN F
on 0 ADP F
the 0 DET F
long-term B-PHYSICAL NOUN F
recurrence I-PHYSICAL NOUN F
rate I-PHYSICAL NOUN F
. 0 PUNCT F

MATERIALS 0 NOUN T
AND 0 CCONJ T
METHODS 0 NOUN T
Long-term 0 NOUN T
followup 0 NOUN F
was 0 VERB F
assessed 0 VERB F
in 0 ADP F
551 0 NUM F
participants 0 NOUN F
enrolled 0 VERB F
in 0 ADP F
a 0 DET F
prospective 0 ADJ F
, 0 PUNCT F
randomized 0 ADP F
study 0 NOUN F
of 0 ADP F
fluorescence 0 NOUN F
cystoscopy 0 NOUN F
for 0 ADP F
Ta 0 NOUN T
or 0 CCONJ F
T1 0 NOUN T
urothelial 0 ADJ F
bladder 0 NOUN F
cancer 0 NOUN F
. 0 PUNCT F

In 0 ADP T
the 0 DET F
original 0 ADJ F
study 0 NOUN F
280 0 NUM F
patients 0 NOUN F
in 0 ADP F
the 0 DET F
white 0 ADJ F
light 0 ADJ F
cystoscopy 0 NOUN F
group 0 NOUN F
and 0 CCONJ F
271 0 NUM F
in 0 ADP F
the 0 DET F
fluorescence 0 NOUN F
cystoscopy 0 NOUN F
group 0 NOUN F
were 0 VERB F
followed 0 VERB F
with 0 ADP F
cystoscopy 0 NOUN F
for 0 ADP F
3 0 NUM F
, 0 PUNCT F
6 0 NUM F
and 0 CCONJ F
9 0 NUM F
months 0 NOUN F
after 0 ADP F
initial 0 ADJ F
resection 0 NOUN F
or 0 CCONJ F
until 0 ADP F
recurrence 0 NOUN F
. 0 PUNCT F

A 0 DET T
study 0 NOUN F
extension 0 NOUN F
protocol 0 NOUN F
was 0 ADJ F
done 0 PUNCT F
for 0 ADP F
long-term 0 NOUN F
followup 0 NOUN F
of 0 ADP F
these 0 DET F
patients 0 NOUN F
. 0 PUNCT F

RESULTS 0 DET T
Followup 0 NOUN T
information 0 NOUN F
was 0 VERB F
obtained 0 VERB F
for 0 ADP F
261 0 ADJ F
of 0 ADP F
the 0 DET F
280 0 NUM F
patients 0 NOUN F
( 0 PUNCT F
93 0 NUM F
% 0 SYM F
) 0 PUNCT F
in 0 ADP F
the 0 DET F
white 0 ADJ F
light 0 ADJ F
group 0 NOUN F
and 0 CCONJ F
255 0 NUM F
of 0 ADP F
the 0 DET F
271 0 NUM F
( 0 PUNCT F
94 0 NUM F
% 0 SYM F
) 0 PUNCT F
in 0 ADP F
the 0 DET F
fluorescence 0 NOUN F
group 0 NOUN F
. 0 PUNCT F

Median 0 ADJ T
followup 0 NOUN F
in 0 ADP F
the 0 DET F
white 0 ADJ F
light 0 ADJ F
and 0 CCONJ F
fluorescence 0 NOUN F
groups 0 NOUN F
was 0 VERB F
53.0 0 NUM F
and 0 CCONJ F
55.1 0 NUM F
months 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
83 0 NUM F
( 0 PUNCT F
31.8 0 NUM F
% 0 SYM F
) 0 PUNCT F
and 0 CCONJ F
97 0 NUM F
patients 0 NOUN F
( 0 PUNCT F
38 0 NUM F
% 0 SYM F
) 0 PUNCT F
remained 0 VERB F
tumor 0 NOUN F
free 0 ADJ F
, 0 PUNCT F
respectively 0 ADV F
. 0 PUNCT F

Median 0 ADJ T
time B-PHYSICAL NOUN F
to I-PHYSICAL ADP F
recurrence I-PHYSICAL NOUN F
was 0 VERB F
9.4 0 NUM F
months 0 NOUN F
in 0 ADP F
the 0 DET F
white 0 ADJ F
light 0 ADJ F
group 0 NOUN F
and 0 CCONJ F
16.4 0 NUM F
months 0 NOUN F
in 0 ADP F
the 0 DET F
fluorescence 0 NOUN F
group 0 NOUN F
( 0 PUNCT F
p 0 NOUN F
= 0 SYM F
0.04 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
intravesical B-OTHER ADJ F
therapy I-OTHER NOUN F
rate I-OTHER NOUN F
was 0 VERB F
similar 0 ADJ F
in 0 ADP F
the 0 DET F
2 0 NUM F
groups 0 NOUN F
( 0 PUNCT F
46 0 NUM F
% 0 SYM F
and 0 CCONJ F
45 0 NUM F
% 0 SYM F
, 0 PUNCT F
respectively 0 ADV F
) 0 PUNCT F
. 0 PUNCT F

Cystectomy 0 NOUN T
was 0 VERB F
done 0 PUNCT F
in 0 ADP F
22 0 NUM F
of 0 ADP F
280 0 NUM F
cases 0 NOUN F
( 0 PUNCT F
7.9 0 NUM F
% 0 SYM F
) 0 PUNCT F
in 0 ADP F
the 0 DET F
white 0 ADJ F
light 0 ADJ F
group 0 NOUN F
and 0 CCONJ F
in 0 ADP F
13 0 NUM F
of 0 ADP F
the 0 DET F
271 0 NUM F
( 0 PUNCT F
4.8 0 NUM F
% 0 SYM F
) 0 PUNCT F
in 0 ADP F
the 0 DET F
fluorescence 0 NOUN F
group 0 NOUN F
( 0 PUNCT F
p 0 NOUN F
= 0 SYM F
0.16 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

CONCLUSIONS 0 NOUN T
Hexaminolevulinate 0 ADV T
fluorescence 0 NOUN F
cystoscopy 0 NOUN F
significantly 0 ADV F
improves 0 NOUN F
long-term 0 NOUN F
bladder 0 NOUN F
cancer 0 NOUN F
time 0 NOUN F
to 0 ADP F
recurrence 0 NOUN F
with 0 ADP F
a 0 DET F
trend 0 NOUN F
toward 0 ADP F
improved 0 VERB F
bladder 0 NOUN F
preservation 0 NOUN F
. 0 PUNCT F

Cognitive 0 ADJ T
effects 0 NOUN F
of 0 ADP F
lithium 0 NOUN F
carbonate 0 NOUN F
and 0 CCONJ F
haloperidol 0 NOUN F
in 0 ADP F
treatment-resistant 0 ADJ F
aggressive 0 ADJ F
children 0 NOUN F
. 0 PUNCT F

The 0 DET T
effects 0 NOUN F
of 0 ADP F
lithium 0 NOUN F
carbonate 0 NOUN F
and 0 CCONJ F
haloperidol 0 NOUN F
on 0 ADP F
cognition 0 NOUN F
were 0 VERB F
examined 0 VERB F
in 0 ADP F
a 0 DET F
placebo-controlled 0 VERB F
, 0 PUNCT F
double-blind 0 ADJ F
study 0 NOUN F
of 0 ADP F
61 0 NUM F
treatment-resistant 0 ADJ F
, 0 PUNCT F
hospitalized 0 DET F
school-aged 0 ADJ F
children 0 NOUN F
. 0 PUNCT F

They 0 ADP T
all 0 ADV F
had 0 PUNCT F
a 0 DET F
DSM-III 0 NUM T
diagnosis 0 NOUN F
of 0 ADP F
conduct 0 NOUN F
disorder 0 NOUN F
-- 0 PUNCT F
undersocialized 0 ADP F
, 0 PUNCT F
aggressive 0 ADJ F
, 0 PUNCT F
with 0 ADP F
a 0 DET F
profile 0 NOUN F
of 0 ADP F
highly 0 ADV F
explosive 0 ADJ F
and 0 CCONJ F
aggressive 0 ADJ F
behavior 0 NOUN F
. 0 PUNCT F

Children 0 NOUN T
were 0 VERB F
assessed 0 VERB F
at 0 ADP F
the 0 DET F
end 0 NOUN F
of 0 ADP F
a 0 DET F
two-week 0 NOUN F
placebo-baseline 0 NOUN F
period 0 NOUN F
and 0 CCONJ F
again 0 ADV F
after 0 ADP F
four 0 NUM F
weeks 0 NOUN F
of 0 ADP F
treatment 0 NOUN F
. 0 PUNCT F

Drug 0 NOUN T
effects 0 NOUN F
on 0 ADP F
cognition 0 NOUN F
were 0 VERB F
mild 0 ADJ F
. 0 PUNCT F

Haloperidol 0 NOUN T
( 0 PUNCT F
mean 0 ADP F
dose 0 NOUN F
, 0 PUNCT F
2.95 0 NUM F
mg/day 0 NOUN F
) 0 PUNCT F
caused 0 VERB F
significant 0 ADJ F
decreases 0 NOUN F
in 0 ADP F
Porteus B-MENTAL NOUN T
Maze I-MENTAL NOUN T
test I-MENTAL NOUN F
quotient I-MENTAL NOUN F
scores 0 NOUN F
and 0 CCONJ F
a 0 DET F
slowing 0 VERB F
of 0 DET F
reaction 0 NOUN F
time 0 NOUN F
( 0 PUNCT F
RT 0 NOUN T
) 0 PUNCT F
on 0 ADP F
a 0 DET F
simple 0 ADJ F
RT 0 NOUN T
task 0 NOUN F
. 0 PUNCT F

Lithium 0 NOUN T
carbonate 0 NOUN F
( 0 PUNCT F
mean 0 ADP F
dose 0 NOUN F
, 0 PUNCT F
1,166 0 NUM F
mg/day 0 NOUN F
) 0 PUNCT F
adversely 0 ADV F
affected 0 VERB F
qualitative B-MENTAL ADJ F
scores I-MENTAL NOUN F
on I-MENTAL ADP F
the I-MENTAL DET F
Porteus I-MENTAL ADJ T
Maze I-MENTAL NOUN T
test I-MENTAL NOUN F
. 0 PUNCT F

No 0 DET T
significant 0 ADJ F
treatment 0 NOUN F
effects 0 NOUN F
were 0 VERB F
found 0 VERB F
for 0 ADP F
the 0 DET F
Matching 0 PUNCT T
Familiar 0 NOUN T
Figures 0 NOUN T
Test 0 NOUN T
, 0 PUNCT F
short-term 0 NOUN F
recognition 0 NOUN F
memory 0 NOUN F
and 0 CCONJ F
concept B-MENTAL NOUN F
attainment I-MENTAL NOUN F
tasks I-MENTAL NOUN F
, 0 PUNCT F
or 0 CCONJ F
the 0 DET F
Stroop 0 NOUN T
Test 0 NOUN T
. 0 PUNCT F

Just-in-time 0 NOUN T
evidence-based 0 VERB F
e-mail 0 NOUN F
reminders 0 NOUN F
in 0 ADP F
home 0 NOUN F
health 0 NOUN F
care 0 NOUN F
: 0 PUNCT F
impact 0 NOUN F
on 0 ADP F
nurse 0 ADJ F
practices 0 NOUN F
. 0 PUNCT F

OBJECTIVE 0 NOUN T
To 0 PROPN T
test 0 NOUN F
the 0 DET F
effectiveness 0 NOUN F
of 0 ADP F
two 0 NUM F
interventions 0 NOUN F
designed 0 VERB F
to 0 PART F
improve 0 ADJ F
the 0 DET F
adoption 0 NOUN F
of 0 ADP F
evidence-based 0 VERB F
practices 0 NOUN F
by 0 ADP F
home 0 NOUN F
health 0 NOUN F
nurses 0 NOUN F
caring 0 ADJ F
for 0 ADP F
heart 0 NOUN F
failure 0 NOUN F
( 0 PUNCT F
HF 0 NOUN T
) 0 PUNCT F
patients 0 NOUN F
. 0 PUNCT F

DATA 0 NOUN T
SOURCES/STUDY 0 CCONJ T
SETTING 0 DET T
Information 0 NOUN T
on 0 ADP F
nurse 0 ADJ F
practices 0 NOUN F
was 0 VERB F
abstracted 0 VERB F
from 0 ADP F
the 0 DET F
clinical 0 ADJ F
records 0 NOUN F
of 0 ADP F
patients 0 NOUN F
admitted 0 VERB F
between 0 ADP F
June 0 NOUN T
2000 0 NUM F
and 0 CCONJ F
November 0 NOUN T
2001 0 NUM F
to 0 ADP F
the 0 DET F
care 0 NOUN F
of 0 ADP F
354 0 NUM F
study 0 ADV F
nurses 0 NOUN F
at 0 ADP F
a 0 DET F
large 0 ADJ F
, 0 PUNCT F
urban 0 ADJ F
, 0 PUNCT F
nonprofit 0 PUNCT F
home 0 NOUN F
care 0 NOUN F
agency 0 NOUN F
. 0 PUNCT F

STUDY 0 NOUN T
DESIGN 0 NOUN T
The 0 DET T
study 0 NOUN F
employed 0 VERB F
a 0 DET F
randomized 0 VERB F
design 0 NOUN F
with 0 ADP F
nurses 0 NOUN F
assigned 0 NUM F
to 0 ADP F
usual 0 ADJ F
care 0 NOUN F
or 0 CCONJ F
one 0 NUM F
of 0 ADP F
two 0 NUM F
intervention 0 NOUN F
groups 0 NOUN F
upon 0 ADP F
identification 0 NOUN F
of 0 ADP F
an 0 DET F
eligible 0 ADJ F
patient 0 NOUN F
. 0 PUNCT F

The 0 DET T
basic 0 ADJ F
intervention 0 NOUN F
was 0 VERB F
a 0 DET F
one-time 0 ADJ F
e-mail 0 NOUN F
reminder 0 ADP F
highlighting 0 SYM F
six 0 NUM F
HF-specific 0 ADJ T
clinical 0 ADJ F
recommendations 0 NOUN F
. 0 PUNCT F

The 0 DET T
augmented 0 VERB F
intervention 0 NOUN F
consisted 0 ADJ F
of 0 ADP F
the 0 DET F
initial 0 ADJ F
e-mail 0 NOUN F
reminder 0 ADJ F
supplemented 0 VERB F
by 0 ADP F
provider 0 NOUN F
prompts 0 NOUN F
, 0 PUNCT F
patient 0 NOUN F
education 0 NOUN F
material 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
clinical 0 ADJ F
nurse 0 ADJ F
specialist 0 NOUN F
outreach 0 ADJ F
. 0 PUNCT F

DATA 0 NOUN T
COLLECTION 0 NOUN T
At 0 ADP T
each 0 DET F
home 0 NOUN F
health 0 NOUN F
visit 0 NOUN F
provided 0 VERB F
by 0 ADP F
a 0 DET F
study 0 NOUN F
nurse 0 PUNCT F
to 0 ADP F
an 0 DET F
eligible 0 ADJ F
HF 0 NOUN T
patient 0 NOUN F
during 0 ADP F
the 0 DET F
45-day 0 NOUN F
follow-up 0 NOUN F
period 0 NOUN F
, 0 PUNCT F
a 0 DET F
structured 0 VERB F
chart 0 NOUN F
abstraction 0 NOUN F
tool 0 NOUN F
was 0 VERB F
used 0 VERB F
to 0 PART F
collect 0 PUNCT F
information 0 NOUN F
on 0 ADP F
whether 0 ADP F
the 0 DET F
nurse 0 ADJ F
provided 0 VERB F
the 0 DET F
care 0 NOUN F
practices 0 PROPN F
highlighted 0 VERB F
in 0 ADP F
the 0 DET F
e-mail 0 NOUN F
reminder 0 ADP F
. 0 PUNCT F

PRINCIPAL 0 NOUN T
FINDINGS 0 NOUN T
Both 0 CCONJ T
the 0 DET F
basic 0 ADJ F
and 0 CCONJ F
the 0 DET F
augmented 0 DET F
interventions 0 NOUN F
greatly 0 ADV F
increased 0 VERB F
the 0 DET F
practice 0 NOUN F
of 0 ADP F
evidence-based B-OTHER VERB F
care I-OTHER NOUN F
, 0 PUNCT F
according 0 CCONJ F
to 0 ADP F
patient 0 NOUN F
records 0 NOUN F
, 0 PUNCT F
in 0 ADP F
the 0 DET F
areas 0 NOUN F
of 0 ADP F
patient 0 NOUN F
assessment 0 NOUN F
and 0 CCONJ F
instructions 0 NOUN F
about 0 PUNCT F
HF 0 NOUN T
disease 0 NOUN F
management 0 NOUN F
. 0 PUNCT F

While 0 ADP T
not 0 ADP F
all 0 DET F
results 0 ADP F
were 0 VERB F
statistically 0 ADV F
significant 0 ADJ F
at 0 ADP F
conventional 0 ADJ F
levels 0 NOUN F
, 0 PUNCT F
intervention B-OTHER NOUN F
effects I-OTHER NOUN F
were 0 VERB F
positive 0 ADJ F
in 0 ADP F
virtually 0 ADV F
all 0 DET F
cases 0 NOUN F
and 0 CCONJ F
effect 0 NOUN F
magnitudes B-OTHER NOUN F
frequently I-OTHER ADV F
were 0 VERB F
large 0 ADJ F
. 0 PUNCT F

CONCLUSIONS 0 NOUN T
The 0 DET T
results 0 NOUN F
of 0 ADP F
this 0 DET F
randomized 0 VERB F
trial 0 NOUN F
strongly 0 ADV F
support 0 VERB F
the 0 DET F
efficacy 0 NOUN F
of 0 ADP F
just-in-time B-OTHER NOUN F
evidence-based I-OTHER VERB F
reminders I-OTHER NOUN F
as 0 ADP F
a 0 DET F
means 0 NOUN F
of 0 ADP F
changing 0 PROPN F
clinical 0 ADJ F
practice 0 NOUN F
among 0 ADP F
home 0 NOUN F
health 0 NOUN F
nurses 0 NOUN F
who 0 ADP F
are 0 VERB F
geographically 0 ADV F
dispersed 0 PROPN F
and 0 CCONJ F
spend 0 PUNCT F
much 0 ADV F
of 0 ADP F
their 0 PUNCT F
time 0 NOUN F
in 0 ADP F
the 0 DET F
field 0 NOUN F
. 0 PUNCT F

Physical 0 ADJ T
activity 0 NOUN F
for 0 ADP F
patients 0 NOUN F
undergoing 0 VERB F
an 0 DET F
allogeneic 0 ADJ F
hematopoietic 0 ADJ F
stem 0 NOUN F
cell 0 NOUN F
transplantation 0 NOUN F
: 0 PUNCT F
benefits 0 NOUN F
of 0 ADP F
a 0 DET F
moderate 0 ADJ F
exercise 0 NOUN F
intervention 0 NOUN F
. 0 PUNCT F

UNLABELLED 0 PUNCT T
An 0 DET T
allogeneic 0 ADJ F
hematopoietic 0 ADJ F
stem 0 NOUN F
cell 0 NOUN F
transplantation 0 NOUN F
( 0 PUNCT F
HSCT 0 NOUN T
) 0 PUNCT F
can 0 VERB F
have 0 PUNCT F
profound 0 ADJ F
and 0 CCONJ F
lasting 0 ADJ F
adverse 0 ADJ F
effects 0 NOUN F
on 0 ADP F
a 0 DET F
patient 0 NOUN F
's 0 PUNCT F
physical 0 ADJ F
and 0 CCONJ F
psychological 0 ADJ F
well-being 0 PUNCT F
. 0 PUNCT F

So 0 ADP T
far 0 ADV F
, 0 PUNCT F
only 0 ADV F
few 0 ADJ F
studies 0 NOUN F
have 0 ADP F
investigated 0 VERB F
the 0 DET F
effectiveness 0 NOUN F
of 0 ADP F
physical 0 ADJ F
activity 0 NOUN F
over 0 ADP F
the 0 DET F
entire 0 ADJ F
inpatient 0 NOUN F
phase 0 NOUN F
of 0 ADP F
an 0 DET F
allogeneic 0 ADJ F
HSCT 0 NOUN T
. 0 PUNCT F

PURPOSE 0 NOUN T
We 0 PRON T
performed 0 VERB F
a 0 DET F
randomized 0 VERB F
controlled 0 DET F
study 0 NOUN F
to 0 PART F
examine 0 NOUN F
the 0 DET F
influence 0 NOUN F
of 0 ADP F
a 0 DET F
controlled 0 VERB F
moderate 0 ADJ F
exercise 0 NOUN F
program 0 NOUN F
starting 0 ADJ F
parallel 0 ADJ F
to 0 ADP F
chemotherapeutic 0 ADJ F
conditioning 0 VERB F
and 0 CCONJ F
total 0 ADJ F
body 0 NOUN F
irradiation 0 NOUN F
on 0 ADP F
the 0 DET F
patient 0 NOUN F
's 0 PUNCT F
physical 0 ADJ F
and 0 CCONJ F
psychological 0 ADJ F
constitution 0 NOUN F
. 0 PUNCT F

PATIENTS 0 NOUN T
AND 0 CCONJ T
METHODS 0 NOUN T
Forty-seven 0 NUM T
patients 0 NOUN F
undergoing 0 VERB F
an 0 DET F
allogeneic 0 ADJ F
HSCT 0 NOUN T
were 0 VERB F
randomly 0 ADV F
assigned 0 VERB F
to 0 ADP F
an 0 DET F
exercise 0 NOUN F
group 0 NOUN F
( 0 PUNCT F
EG 0 NOUN T
) 0 PUNCT F
or 0 CCONJ F
a 0 DET F
control 0 NOUN F
group 0 NOUN F
( 0 PUNCT F
CG 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

While 0 ADP T
the 0 DET F
EG 0 NOUN T
took 0 PROPN F
part 0 NOUN F
in 0 ADP F
an 0 DET F
endurance 0 NOUN F
and 0 CCONJ F
activity 0 NOUN F
of 0 ADP F
daily 0 PUNCT F
living-training 0 PUNCT F
twice 0 CCONJ F
a 0 DET F
day 0 NOUN F
, 0 PUNCT F
the 0 DET F
CG 0 NOUN T
received 0 VERB F
the 0 DET F
clinic 0 NOUN F
's 0 PUNCT F
standard 0 ADJ F
physiotherapy 0 NOUN F
program 0 NOUN F
once 0 PUNCT F
a 0 DET F
day 0 NOUN F
. 0 PUNCT F

RESULTS 0 NOUN T
Significant 0 ADJ T
differences 0 NOUN F
and/or 0 CCONJ F
trends 0 NOUN F
in 0 ADP F
favor 0 NOUN F
of 0 ADP F
the 0 DET F
EG 0 NOUN T
were 0 VERB F
observed 0 VERB F
regarding 0 VERB F
the 0 DET F
primary 0 ADJ F
endpoint 0 NOUN F
endurance B-PHYSICAL NOUN F
performance I-PHYSICAL NOUN F
( 0 PUNCT F
P=0.002 0 NOUN T
) 0 PUNCT F
, 0 PUNCT F
muscular B-PHYSICAL ADJ F
strength I-PHYSICAL NOUN F
( 0 PUNCT F
P=0.022 0 NOUN T
) 0 PUNCT F
, 0 PUNCT F
fatigue B-PHYSICAL NOUN F
( 0 PUNCT F
P=0.046 0 NOUN T
) 0 PUNCT F
, 0 PUNCT F
and 0 CCONJ F
emotional B-PHYSICAL ADJ F
state I-PHYSICAL NOUN F
( 0 PUNCT F
P=0.028 0 NOUN T
) 0 PUNCT F
without 0 ADP F
posing 0 SYM F
an 0 DET F
additional 0 ADJ F
risk 0 NOUN F
for 0 ADP F
the 0 DET F
individual 0 ADJ F
. 0 PUNCT F

CONCLUSION 0 NOUN T
The 0 DET T
results 0 ADV F
show 0 VERB F
that 0 ADP F
the 0 DET F
training 0 DET F
program 0 NOUN F
is 0 VERB F
feasible 0 ADJ F
and 0 CCONJ F
seems 0 NOUN F
to 0 PART F
have 0 PUNCT F
positive 0 ADJ F
influences 0 NOUN F
on 0 ADP F
physical B-PHYSICAL ADJ F
performance I-PHYSICAL NOUN F
and 0 CCONJ F
quality B-PHYSICAL NOUN F
of I-PHYSICAL ADP F
life I-PHYSICAL NOUN F
in 0 ADP F
patients 0 NOUN F
undergoing 0 VERB F
an 0 DET F
allogeneic 0 ADJ F
HSCT 0 NOUN T
. 0 PUNCT F

However 0 ADV T
, 0 PUNCT F
further 0 ADJ F
studies 0 NOUN F
are 0 VERB F
necessary 0 ADJ F
to 0 PART F
confirm 0 NOUN F
these 0 DET F
results 0 NOUN F
. 0 PUNCT F

Tomato 0 NOUN T
paste 0 NOUN F
rich 0 ADJ F
in 0 ADP F
lycopene 0 NOUN F
protects 0 PUNCT F
against 0 ADP F
cutaneous B-PHYSICAL ADJ F
photodamage I-PHYSICAL NOUN F
in 0 ADP F
humans 0 NOUN F
in 0 DET F
vivo 0 ADJ F
: 0 PUNCT F
a 0 DET F
randomized 0 VERB F
controlled 0 VERB F
trial 0 NOUN F
. 0 PUNCT F

BACKGROUND 0 NOUN T
Previous 0 ADJ T
epidemiological 0 ADJ F
, 0 PUNCT F
animal 0 NOUN F
and 0 CCONJ F
human 0 NOUN F
data 0 NOUN F
report 0 NOUN F
that 0 ADP F
lycopene 0 NOUN F
has 0 PUNCT F
a 0 DET F
protective 0 ADJ F
effect 0 NOUN F
against 0 ADP F
ultraviolet B-PHYSICAL ADJ F
radiation I-PHYSICAL NOUN F
( 0 PUNCT F
UVR B-PHYSICAL NOUN T
) 0 PUNCT F
-induced B-PHYSICAL VERB F
erythema B-PHYSICAL NOUN F
. 0 PUNCT F

OBJECTIVES 0 NOUN T
We 0 PRON T
examined 0 VERB F
whether 0 ADP F
tomato 0 NOUN F
paste 0 NOUN F
-- 0 PUNCT F
rich 0 ADJ F
in 0 ADP F
lycopene 0 NOUN F
, 0 PUNCT F
a 0 DET F
powerful 0 ADJ F
antioxidant 0 NOUN F
-- 0 PUNCT F
can 0 VERB F
protect 0 VERB F
human 0 NOUN F
skin 0 NOUN F
against 0 ADP F
UVR-induced 0 VERB T
effects 0 NOUN F
partially 0 ADV F
mediated 0 VERB F
by 0 ADP F
oxidative 0 ADJ F
stress 0 NOUN F
, 0 PUNCT F
i.e 0 PUNCT F
. 0 PUNCT F

erythema 0 NOUN F
, 0 PUNCT F
matrix 0 NOUN F
changes 0 NOUN F
and 0 CCONJ F
mitochondrial 0 ADJ F
DNA 0 NOUN T
( 0 PUNCT F
mtDNA 0 NOUN F
) 0 PUNCT F
damage 0 NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
In 0 ADP T
a 0 DET F
randomized 0 VERB F
controlled 0 DET F
study 0 NOUN F
, 0 PUNCT F
20 0 NUM F
healthy 0 ADJ F
women 0 NOUN F
( 0 PUNCT F
median 0 ADJ F
age 0 NOUN F
33 0 NUM F
years 0 NOUN F
, 0 PUNCT F
range 0 NOUN F
21-47 0 NUM F
; 0 PUNCT F
phototype 0 NOUN F
I/II 0 NOUN T
) 0 PUNCT F
ingested 0 ADP F
55 0 NUM F
g 0 ADP F
tomato 0 NOUN F
paste 0 NOUN F
( 0 PUNCT F
16 0 NUM F
mg 0 NOUN F
lycopene 0 NOUN F
) 0 PUNCT F
in 0 ADP F
olive 0 NOUN F
oil 0 NOUN F
, 0 PUNCT F
or 0 CCONJ F
olive 0 VERB F
oil 0 NOUN F
alone 0 ADJ F
, 0 PUNCT F
daily 0 ADJ F
for 0 ADP F
12 0 NUM F
weeks 0 NOUN F
. 0 PUNCT F

Pre- 0 PUNCT T
and 0 CCONJ F
postsupplementation 0 NOUN F
, 0 PUNCT F
UVR 0 PUNCT T

Double-blind 0 ADJ T
, 0 PUNCT F
randomized 0 VERB F
, 0 PUNCT F
placebo-controlled 0 VERB F
clinical 0 ADJ F
trial 0 NOUN F
on 0 ADP F
the 0 DET F
efficacy 0 NOUN F
and 0 CCONJ F
tolerability B-OTHER NOUN F
of I-OTHER ADP F
a I-OTHER DET F
physostigmine I-OTHER ADJ F
patch I-OTHER NOUN F
in 0 ADP F
patients 0 NOUN F
with 0 ADP F
senile 0 ADJ F
dementia 0 NOUN F
of 0 ADP F
the 0 DET F
Alzheimer 0 PUNCT T
type 0 NOUN F
. 0 PUNCT F

Owing 0 PUNCT T
to 0 ADP F
the 0 DET F
pharmacokinetic 0 ADJ F
properties 0 NOUN F
of 0 ADP F
physostigmine 0 ADJ F
when 0 PUNCT F
administered 0 VERB F
by 0 ADP F
conventional 0 ADJ F
routes 0 NOUN F
, 0 PUNCT F
long-term 0 NOUN F
cholinergic 0 ADJ F
treatment 0 NOUN F
of 0 ADP F
Alzheimer 0 PUNCT T
's 0 PUNCT F
disease 0 NOUN F
is 0 VERB F
difficult 0 ADJ F
to 0 ADJ F
manage 0 ADV F
. 0 PUNCT F

In 0 ADP T
order 0 NOUN F
to 0 PART F
overcome 0 NOUN F
the 0 DET F
problems 0 NOUN F
associated 0 VERB F
with 0 ADP F
the 0 DET F
oral 0 ADJ F
and 0 CCONJ F
intravenous 0 ADJ F
application 0 NOUN F
of 0 ADP F
physostigmine 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
to 0 PART F
improve 0 ADJ F
patients B-MENTAL NOUN F
' 0 PUNCT F
compliance B-MENTAL NOUN F
, 0 PUNCT F
a 0 DET F
transdermal 0 ADJ F
therapeutic 0 ADJ F
system 0 NOUN F
was 0 VERB F
developed 0 VERB F
. 0 PUNCT F

The 0 DET T
efficacy 0 NOUN F
and 0 CCONJ F
tolerability B-OTHER NOUN F
of 0 ADP F
this 0 DET F
system 0 NOUN F
were 0 VERB F
evaluated 0 VERB F
in 0 ADP F
a 0 DET F
double-blind 0 ADJ F
, 0 PUNCT F
randomized 0 VERB F
, 0 PUNCT F
multicenter 0 NOUN F
study 0 NOUN F
comparing 0 PUNCT F
patches 0 NOUN F
containing 0 VERB F
30 0 NUM F
mg 0 NOUN F
and 0 CCONJ F
60 0 NUM F
mg 0 NOUN F
physostigmine 0 NOUN F
with 0 ADP F
a 0 DET F
placebo 0 NOUN F
patch 0 NOUN F
. 0 PUNCT F

The 0 DET T
clinical 0 ADJ F
trial 0 NOUN F
followed 0 VERB F
the 0 DET F
basic 0 ADJ F
principles 0 NOUN F
of 0 ADP F
the 0 DET F
various 0 ADJ F
guidelines 0 NOUN F
on 0 ADP F
the 0 DET F
evaluation 0 NOUN F
of 0 ADP F
anti-dementia 0 NOUN F
drugs 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
included 0 VERB F
patients 0 NOUN F
with 0 ADP F
mild 0 ADJ F
to 0 ADP F
moderate 0 ADJ F
probable 0 ADJ F
Alzheimer 0 PUNCT T
's 0 PUNCT F
disease 0 NOUN F
. 0 PUNCT F

A 0 DET T
total 0 NOUN F
of 0 ADP F
204 0 NUM F
patients 0 NOUN F
with 0 ADP F
probable 0 ADJ F
Alzheimer 0 PUNCT T
's 0 PUNCT F
disease 0 NOUN F
were 0 VERB F
included 0 VERB F
in 0 ADP F
the 0 DET F
study 0 NOUN F
. 0 PUNCT F

Of 0 ADP T
these 0 PUNCT F
, 0 PUNCT F
136 0 NUM F
patients 0 NOUN F
were 0 VERB F
eligible 0 ADJ F
for 0 ADP F
the 0 DET F
according-to-protocol 0 ADJ F
analysis 0 NOUN F
of 0 ADP F
efficacy 0 NOUN F
, 0 PUNCT F
167 0 NUM F
subjects 0 NOUN F
for 0 ADP F
the 0 DET F
intention-to-treat 0 NOUN F
analysis 0 NOUN F
of 0 ADP F
efficacy 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
181 0 NUM F
patients 0 NOUN F
were 0 VERB F
included 0 VERB F
in 0 ADP F
the 0 DET F
safety 0 NOUN F
analysis 0 NOUN F
. 0 PUNCT F

In 0 ADP T
contrast 0 NOUN F
to 0 ADP F
the 0 DET F
hypothesis 0 NOUN F
to 0 PART F
be 0 PUNCT F
tested 0 VERB F
, 0 PUNCT F
the 0 DET F
efficacy 0 NOUN F
of 0 ADP F
physostigmine 0 NOUN F
was 0 VERB F
not 0 ADV F
superior 0 ADJ F
to 0 ADP F
that 0 PUNCT F
of 0 ADP F
placebo 0 NOUN F
after 0 ADP F
a 0 DET F
treatment 0 NOUN F
period 0 NOUN F
of 0 ADP F
24 0 NUM F
weeks 0 NOUN F
. 0 PUNCT F

On 0 ADP T
the 0 DET F
contrary 0 PUNCT F
, 0 PUNCT F
there 0 PUNCT F
was 0 VERB F
even 0 ADV F
a 0 DET F
slight 0 ADJ F
, 0 PUNCT F
but 0 CCONJ F
not 0 ADV F
statistically 0 ADV F
significant 0 ADJ F
, 0 PUNCT F
trend 0 NOUN F
toward 0 ADP F
a 0 DET F
better 0 PUNCT F
outcome 0 NOUN F
in 0 ADP F
the 0 DET F
placebo 0 NOUN F
group 0 NOUN F
. 0 PUNCT F

Median 0 ADJ T
physostigmine B-PHYSICAL ADJ F
plasma I-PHYSICAL NOUN F
concentrations I-PHYSICAL NOUN F
of 0 ADP F
approximately 0 ADV F
100 0 NUM F
pg/ml 0 NOUN F
were 0 VERB F
measured 0 VERB F
, 0 PUNCT F
showing 0 VERB F
a 0 DET F
high 0 ADJ F
degree 0 NOUN F
of 0 ADP F
interindividual 0 ADJ F
variability 0 NOUN F
and 0 CCONJ F
no 0 DET F
linear 0 ADJ F
dose 0 NOUN F
relationship 0 NOUN F
between 0 ADP F
the 0 DET F
30 0 NUM F
mg 0 NOUN F
and 0 CCONJ F
60 0 NUM F
mg 0 NOUN F
dosages 0 NOUN F
. 0 PUNCT F

Plasma B-PHYSICAL NOUN T
cholinesterase I-PHYSICAL NOUN F
activity I-PHYSICAL NOUN F
was 0 VERB F
not 0 ADV F
significantly 0 ADV F
affected 0 VERB F
by 0 ADP F
physostigmine 0 NOUN F
. 0 PUNCT F

The 0 DET T
physostigmine 0 ADJ F
patch 0 NOUN F
application 0 NOUN F
in 0 ADP F
doses 0 NOUN F
of 0 ADP F
30 0 NUM F
mg 0 NOUN F
and 0 CCONJ F
60 0 NUM F
mg 0 NOUN F
apparently 0 ADV F
did 0 PUNCT F
not 0 ADV F
lead 0 VERB F
to 0 ADP F
physostigmine B-PHYSICAL PUNCT F
plasma I-PHYSICAL NOUN F
concentrations B-PHYSICAL NOUN F
that 0 DET F
were 0 VERB F
sufficient 0 ADJ F
to 0 PART F
compensate 0 VERB F
for 0 ADP F
cholinergic 0 ADJ F
deficiencies 0 NOUN F
in 0 ADP F
affected 0 VERB F
brain 0 NOUN F
areas 0 NOUN F
and 0 CCONJ F
produce 0 NOUN F
clinical 0 ADJ F
benefits 0 NOUN F
. 0 PUNCT F

Both 0 CCONJ T
the 0 DET F
drug 0 NOUN F
and 0 CCONJ F
the 0 DET F
transdermal 0 ADJ F
system 0 NOUN F
were 0 VERB F
generally 0 VERB F
well B-OTHER VERB F
tolerated I-OTHER ADP F
under 0 ADP F
the 0 DET F
study 0 ADJ F
conditions 0 NOUN F
. 0 PUNCT F

Modifications 0 NOUN T
of 0 ADP F
the 0 DET F
patch 0 NOUN F
system 0 NOUN F
may 0 ADP F
perhaps 0 NOUN F
make 0 VERB F
it 0 ADV F
possible 0 ADJ F
to 0 PART F
achieve 0 VERB F
higher 0 PUNCT F

[ 0 PUNCT F
4 0 NUM F
years 0 NOUN F
' 0 PUNCT F
experience 0 NOUN F
with 0 ADP F
a 0 DET F
balloon-expandable 0 ADJ F
endoprosthesis 0 NOUN F
. 0 PUNCT F

Experimental 0 ADJ T
and 0 CCONJ F
clinical 0 ADJ F
application 0 NOUN F
] 0 PUNCT F
. 0 PUNCT F

During 0 ADP T
a 0 DET F
4-year 0 NOUN F
period 0 NOUN F
of 0 ADP F
clinical 0 ADJ F
application 0 NOUN F
of 0 ADP F
the 0 DET F
balloon-expandable 0 ADJ F
Palmaz 0 NOUN T
stent 0 NOUN F
, 0 PUNCT F
a 0 DET F
randomized 0 VERB F
trial 0 NOUN F
comparing 0 VERB F
stent 0 NOUN F
implantation 0 NOUN F
and 0 CCONJ F
traditional 0 ADJ F
balloon 0 NOUN F
angioplasty 0 NOUN F
of 0 ADP F
iliac 0 PUNCT F
arteries 0 NOUN F
in 0 ADP F
arterial 0 ADJ F
occlusive 0 ADJ F
disease 0 NOUN F
was 0 VERB F
started 0 VERB F
. 0 PUNCT F

The 0 DET T
first 0 ADJ F
long-term 0 NOUN F
results 0 NOUN F
, 0 PUNCT F
recorded 0 PROPN F
after 0 ADP F
2 0 NUM F
years 0 NOUN F
, 0 PUNCT F
indicate 0 VERB F
statistically 0 ADV F
significant 0 ADJ F
differences 0 NOUN F
in 0 ADP F
the 0 DET F
complication B-ADVERSE-EFFECTS NOUN F
rate I-ADVERSE-EFFECTS NOUN F
( 0 PUNCT F
after 0 ADP F
stenting 0 NUM F
2/62 0 NOUN F
and 0 CCONJ F
after 0 ADP F
angioplasty 0 NOUN F
5/69 0 NOUN F
) 0 PUNCT F
and 0 CCONJ F
patency B-OTHER NOUN F
( 0 PUNCT F
greater 0 PUNCT F
than 0 VERB F
or 0 CCONJ F
equal 0 ADJ F
to 0 ADP F
70 0 NUM F
% 0 SYM F
of 0 ADP F
original 0 ADJ F
lumen 0 NOUN F
size 0 NOUN F
upon 0 ADP F
stent 0 NOUN F
implantation 0 NOUN F
or 0 CCONJ F
balloon 0 NOUN F
inflation 0 NOUN F
: 0 PUNCT F
95 0 NUM F
% 0 SYM F
after 0 ADP F
stenting 0 NUM F
and 0 CCONJ F
72 0 NUM F
% 0 SYM F
after 0 ADP F
angioplasty 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

Clinical B-OTHER ADJ T
improvement I-OTHER NOUN F
after 0 ADP F
2 0 NUM F
years B-PHYSICAL NOUN F
was 0 VERB F
89 0 NUM F
% 0 SYM F
after 0 ADP F
stenting 0 NUM F
and 0 CCONJ F
70 0 NUM F
% 0 SYM F
after 0 ADP F
angioplasty 0 NOUN F
. 0 PUNCT F

Parallel 0 ADJ T
to 0 ADP F
the 0 DET F
clinical 0 ADJ F
trials 0 NOUN F
, 0 PUNCT F
experimental 0 ADJ F
canine 0 ADJ F
artery 0 NOUN F
stenting 0 PUNCT F
was 0 VERB F
performed 0 VERB F
to 0 PART F
evaluate 0 NOUN F
differences 0 NOUN F
in 0 ADP F
the 0 DET F
long-term 0 NOUN F
patency 0 NOUN F
of 0 ADP F
stents 0 ADJ F
exposed 0 VERB F
to 0 ADP F
restricted 0 PUNCT F
flow 0 NOUN F
. 0 PUNCT F

Significant 0 ADJ T
differences 0 NOUN F
in 0 ADP F
neointimal B-PHYSICAL ADJ F
healing I-PHYSICAL VERB F
were 0 VERB F
found 0 VERB F
between 0 ADP F
normally 0 ADV F
perfused 0 PUNCT F
stents 0 NOUN F
and 0 CCONJ F
stents 0 ADJ F
with 0 ADP F
artificially 0 ADJ F
reduced 0 VERB F
flow 0 NOUN F
: 0 PUNCT F
during 0 ADP F
the 0 DET F
total 0 ADJ F
observation 0 NOUN F
period 0 NOUN F
of 0 ADP F
6 0 NUM F
months 0 NOUN F
the 0 DET F
neointimal B-PHYSICAL ADJ F
height I-PHYSICAL NOUN F
was 0 VERB F
up 0 PUNCT F
to 0 PUNCT F
200 0 NUM F
% 0 SYM F
higher 0 PUNCT F
in 0 ADP F
flow-restricted 0 VERB F
stents 0 NOUN F
, 0 PUNCT F
while 0 ADP F
the 0 DET F
histological B-PHYSICAL ADJ F
composition I-PHYSICAL NOUN F
of I-PHYSICAL ADP F
the I-PHYSICAL DET F
neointima I-PHYSICAL NOUN F
was 0 VERB F
the 0 DET F
same 0 ADJ F
as 0 PUNCT F
with 0 ADP F
normally 0 ADV F
perfused 0 PUNCT F
stents 0 NOUN F
. 0 PUNCT F

[ 0 PUNCT F
Comparative 0 ADJ T
effects 0 NOUN F
of 0 ADP F
nebivolol 0 NOUN F
and 0 CCONJ F
valsartan 0 NOUN F
on 0 ADP F
atrial 0 ADJ F
electromechanical B-PHYSICAL ADJ F
coupling I-PHYSICAL VERB F
in 0 ADP F
newly 0 ADV F
diagnosed 0 ADJ F
stage 0 NOUN F
1 0 NUM F
hypertensive 0 ADJ F
patients 0 NOUN F
] 0 PUNCT F
. 0 PUNCT F

OBJECTIVES 0 ADJ T
Hypertension 0 NOUN T
is 0 VERB F
an 0 DET F
important 0 ADJ F
cardiovascular 0 ADJ F
risk 0 NOUN F
factor 0 NOUN F
for 0 ADP F
the 0 DET F
development 0 NOUN F
of 0 ADP F
atrial 0 ADJ F
fibrillation B-PHYSICAL NOUN F
( I-PHYSICAL PUNCT F
AF I-PHYSICAL NOUN T
) I-PHYSICAL PUNCT F
. 0 PUNCT F

Increased 0 ADP T
atrial 0 ADJ F
electromechanical 0 ADJ F
coupling 0 VERB F
time 0 NOUN F
interval 0 NOUN F
measured 0 VERB F
by 0 ADP F
tissue 0 NOUN F
Doppler 0 NOUN T
is 0 VERB F
accepted 0 VERB F
as 0 ADP F
an 0 DET F
important 0 ADJ F
factor 0 NOUN F
for 0 ADP F
prediction 0 NOUN F
of 0 ADP F
AF B-PHYSICAL NOUN T
development I-PHYSICAL NOUN F
in 0 ADP F
hypertensive 0 ADJ F
patients 0 NOUN F
. 0 PUNCT F

The 0 DET T
aim 0 NOUN F
of 0 ADP F
this 0 DET F
study 0 NOUN F
was 0 VERB F
to 0 ADV F
compare 0 NOUN F
the 0 DET F
effects 0 NOUN F
of 0 ADP F
valsartan 0 NOUN F
, 0 PUNCT F
an 0 DET F
angiotensin 0 NOUN F
receptor 0 NOUN F
blocker 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
nebivolol 0 NOUN F
, 0 PUNCT F
a 0 DET F
beta-blocker 0 NOUN F
, 0 PUNCT F
on 0 ADP F
atrial 0 ADJ F
electromechanical 0 ADJ F
coupling 0 VERB F
in 0 ADP F
newly 0 ADV F
diagnosed 0 ADJ F
stage 0 NOUN F
1 0 NUM F
hypertensive 0 ADJ F
patients 0 NOUN F
. 0 PUNCT F

STUDY 0 NOUN T
DESIGN 0 NOUN T
The 0 DET T
study 0 NOUN F
included 0 VERB F
60 0 NUM F
newly 0 ADV F
diagnosed 0 VERB F
stage 0 NOUN F
1 0 NUM F
hypertensive 0 ADJ F
patients 0 NOUN F
with 0 ADP F
no 0 DET F
other 0 ADJ F
systemic 0 ADJ F
disease 0 NOUN F
. 0 PUNCT F

The 0 DET T
patients 0 NOUN F
were 0 VERB F
randomized 0 VERB F
to 0 PART F
receive 0 NOUN F
nebivolol 0 NOUN F
5 0 NUM F
mg 0 NOUN F
( 0 PUNCT F
30 0 NUM F
patients 0 NOUN F
; 0 PUNCT F
21 0 NUM F
women 0 NOUN F
, 0 PUNCT F
9 0 NUM F
men 0 NOUN F
; 0 PUNCT F
mean 0 NOUN F
age 0 NOUN F
48.4 0 NUM F
? 0 PUNCT F

11.4 0 NUM F
years 0 NOUN F
) 0 PUNCT F
and 0 CCONJ F
valsartan 0 NOUN F
160 0 NUM F
mg 0 NOUN F
( 0 PUNCT F
30 0 NUM F
patients 0 NOUN F
; 0 PUNCT F
21 0 NUM F
women 0 NOUN F
, 0 PUNCT F
9 0 NUM F
men 0 NOUN F
; 0 PUNCT F
mean 0 NOUN F
age 0 NOUN F
49.8 0 NUM F
? 0 PUNCT F

11.3 0 NUM F
years 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

All 0 DET T
the 0 DET F
patients 0 NOUN F
underwent 0 VERB F
tissue 0 NOUN F
Doppler 0 NOUN T
echocardiographic 0 ADJ F
examination 0 NOUN F
before 0 ADP F
and 0 CCONJ F
three 0 NUM F
months 0 NOUN F
after 0 ADP F
treatment 0 NOUN F
to 0 PART F
compare 0 NOUN F
the 0 DET F
effects 0 NOUN F
of 0 ADP F
the 0 DET F
two 0 NUM F
drugs 0 NOUN F
on 0 ADP F
atrial 0 ADJ F
electromechanical 0 ADJ F
coupling 0 VERB F
. 0 PUNCT F

RESULTS 0 NOUN T
Baseline 0 NOUN T
blood 0 NOUN F
pressures 0 NOUN F
, 0 PUNCT F
electrocardiographic 0 ADJ F
and 0 CCONJ F
echocardiographic 0 ADJ F
findings 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
atrial 0 ADJ F
electromechanical 0 ADJ F
coupling 0 VERB F
were 0 VERB F
similar 0 ADJ F
in 0 ADP F
both 0 CCONJ F
groups 0 NOUN F
( 0 PUNCT F
p 0 NOUN F
> 0 SYM F
0.05 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Both 0 CCONJ T
drugs 0 NOUN F
significantly 0 ADV F
reduced 0 PUNCT F
blood 0 NOUN F
pressure 0 NOUN F
after 0 ADP F
treatment 0 NOUN F
, 0 PUNCT F
with 0 ADP F
similar 0 ADJ F
efficacy 0 NOUN F
( 0 PUNCT F
p 0 NOUN F
> 0 SYM F
0.05 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Atrial 0 ADJ T
electromechanical 0 ADJ F
coupling 0 ADJ F
time 0 NOUN F
intervals 0 NOUN F
showed 0 VERB F
significant 0 ADJ F
decreases 0 NOUN F
in 0 ADP F
both 0 CCONJ F
groups 0 NOUN F
. 0 PUNCT F

CONCLUSION 0 NOUN T
Prolonged 0 PROPN T
interatrial 0 ADJ F
electromechanical 0 ADJ F
time 0 NOUN F
intervals 0 NOUN F
in 0 ADP F
hypertensives 0 NOUN F
are 0 VERB F
improved 0 VERB F
with 0 ADP F
antihypertensive 0 ADJ F
treatment 0 NOUN F
. 0 PUNCT F

Amphotericin 0 NOUN T
versus 0 CCONJ F
pentamidine 0 NOUN F
in 0 ADP F
antimony-unresponsive 0 ADJ F
kala-azar 0 NOUN F
. 0 PUNCT F

We 0 PRON T
compared 0 VERB F
the 0 DET F
efficacy 0 NOUN F
of 0 ADP F
amphotericin 0 NOUN F
B 0 NOUN T
and 0 CCONJ F
pentamidine 0 NOUN F
isethionate 0 VERB F
in 0 ADP F
a 0 DET F
prospective 0 ADJ F
randomised 0 VERB F
trial 0 NOUN F
in 0 ADP F
120 0 NUM F
uncomplicated 0 VERB F
and 0 CCONJ F
parasitologically 0 ADV F
confirmed 0 VERB F
cases 0 NOUN F
of 0 ADP F
antimony-unresponsive 0 ADJ F
kala-azar 0 NOUN F
. 0 PUNCT F

Doses 0 NOUN T
were 0 VERB F
twenty 0 NUM F
intramuscular 0 ADJ F
injections 0 NOUN F
of 0 ADP F
pentamidine 0 NOUN F
4 0 NUM F
mg/kg 0 NOUN F
on 0 ADP F
alternate 0 NOUN F
days 0 NOUN F
or 0 CCONJ F
fourteen 0 NUM F
definitive 0 ADJ F
doses 0 NOUN F
of 0 ADP F
amphotericin 0 NOUN F
0.5 0 NUM F
mg/kg 0 NOUN F
infused 0 VERB F
in 0 ADP F
5 0 NUM F
% 0 SYM F
dextrose 0 NOUN F
on 0 ADP F
alternate 0 NOUN F
days 0 NOUN F
. 0 PUNCT F

48 0 NUM F
( 0 PUNCT F
80 0 NUM F
% 0 SYM F
) 0 PUNCT F
patients 0 NOUN F
given 0 PUNCT F
pentamidine 0 ADP F
showed 0 VERB F
initial B-OTHER ADJ F
cure I-OTHER NOUN F
and 0 CCONJ F
46 0 NUM F
( 0 PUNCT F
77 0 NUM F
% 0 SYM F
) 0 PUNCT F
showed 0 VERB F
definitive B-OTHER ADJ F
cure I-OTHER NOUN F
compared 0 VERB F
with 0 ADP F
60 0 NUM F
( 0 PUNCT F
100 0 NUM F
% 0 SYM F
) 0 PUNCT F
and 0 CCONJ F
59 0 NUM F
( 0 PUNCT F
98 0 NUM F
% 0 SYM F
) 0 PUNCT F
cases 0 NOUN F
, 0 PUNCT F
respectively 0 ADV F
, 0 PUNCT F
on 0 ADP F
amphotericin 0 NOUN F
( 0 PUNCT F
p 0 NOUN F
< 0 SYM F
0.001 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Amphotericin 0 NOUN T
also 0 ADV F
brought 0 PUNCT F
about 0 ADP F
quicker 0 PUNCT F
abatement B-PHYSICAL ADJ F
of I-PHYSICAL ADP F
fever I-PHYSICAL NOUN F
and 0 CCONJ F
more 0 DET F
complete B-ADVERSE-EFFECTS ADJ F
spleen I-ADVERSE-EFFECTS NOUN F
regression I-ADVERSE-EFFECTS NOUN F
. 0 PUNCT F

Effects 0 NOUN T
of 0 ADP F
intranasal 0 ADJ F
oxytocin 0 NOUN F
on 0 ADP F
the 0 DET F
neural 0 ADJ F
basis 0 NOUN F
of 0 ADP F
face 0 PUNCT F
processing 0 VERB F
in 0 ADP F
autism 0 NOUN F
spectrum 0 NOUN F
disorder 0 NOUN F
. 0 PUNCT F

BACKGROUND 0 NOUN T
Autism 0 NOUN T
spectrum 0 NOUN F
disorder 0 NOUN F
( 0 PUNCT F
ASD 0 NOUN T
) 0 PUNCT F
is 0 VERB F
associated 0 VERB F
with 0 ADP F
altered 0 CCONJ F
face 0 ADP F
processing 0 ADP F
and 0 CCONJ F
decreased 0 VERB F
activity 0 NOUN F
in 0 ADP F
brain 0 NOUN F
regions 0 NOUN F
involved 0 VERB F
in 0 ADP F
face 0 PUNCT F
processing 0 VERB F
. 0 PUNCT F

The 0 DET T
neuropeptide 0 NOUN F
oxytocin 0 NOUN F
has 0 VERB F
been 0 PUNCT F
shown 0 VERB F
to 0 PART F
promote 0 CCONJ F
face 0 PUNCT F
processing 0 PUNCT F
and 0 CCONJ F
modulate 0 NOUN F
brain 0 NOUN F
activity 0 NOUN F
in 0 ADP F
healthy 0 ADJ F
adults 0 NOUN F
. 0 PUNCT F

The 0 DET T
present 0 ADJ F
study 0 NOUN F
examined 0 VERB F
the 0 DET F
effects 0 NOUN F
of 0 ADP F
oxytocin 0 NOUN F
on 0 ADP F
the 0 DET F
neural 0 ADJ F
basis 0 NOUN F
of 0 ADP F
face 0 PUNCT F
processing 0 VERB F
in 0 ADP F
adults 0 NOUN F
with 0 ADP F
Asperger 0 ADJ T
syndrome 0 NOUN F
( 0 PUNCT F
AS 0 ADP T
) 0 PUNCT F
. 0 PUNCT F

METHODS 0 NOUN T
A 0 PUNCT T
group 0 NOUN F
of 0 ADP F
14 0 NUM F
individuals 0 NOUN F
with 0 ADP F
AS 0 ADP T
and 0 CCONJ F
a 0 DET F
group 0 NOUN F
of 0 ADP F
14 0 NUM F
neurotypical 0 ADJ F
control 0 NOUN F
participants 0 NOUN F
performed 0 VERB F
a 0 DET F
face-matching 0 PROPN F
and 0 CCONJ F
a 0 DET F
house-matching 0 ADV F
task 0 NOUN F
during 0 ADP F
functional 0 ADJ F
magnetic 0 ADJ F
resonance 0 NOUN F
imaging 0 VERB F
. 0 PUNCT F

The 0 DET T
effects 0 NOUN F
of 0 ADP F
a 0 DET F
single 0 ADJ F
dose 0 NOUN F
of 0 ADP F
24 0 NUM F
IU 0 NOUN T
intranasally 0 ADV F
administered 0 ADP F
oxytocin 0 NOUN F
were 0 VERB F
tested 0 VERB F
in 0 ADP F
a 0 DET F
randomized 0 VERB F
, 0 PUNCT F
placebo-controlled 0 VERB F
, 0 PUNCT F
within-subject 0 PUNCT F
, 0 PUNCT F
cross-over 0 NOUN F
design 0 NOUN F
. 0 PUNCT F

RESULTS 0 NOUN T
Under 0 ADP T
placebo 0 NOUN F
, 0 PUNCT F
the 0 DET F
AS 0 PUNCT T
group 0 NOUN F
showed 0 VERB F
decreased 0 ADV F
activity 0 NOUN F
in 0 ADP F
the B-PHYSICAL DET F
right I-PHYSICAL ADJ F
amygdala I-PHYSICAL NOUN F
, I-PHYSICAL PUNCT F
fusiform I-PHYSICAL NOUN F
gyrus I-PHYSICAL NOUN F
, I-PHYSICAL PUNCT F
and I-PHYSICAL CCONJ F
inferior I-PHYSICAL ADJ F
occipital I-PHYSICAL ADJ F
gyrus I-PHYSICAL NOUN F
compared 0 VERB F
with 0 ADP F
the 0 DET F
control 0 NOUN F
group 0 NOUN F
during 0 ADP F
face 0 PUNCT F
processing 0 VERB F
. 0 PUNCT F

After 0 ADP T
oxytocin 0 NOUN F
treatment 0 NOUN F
, 0 PUNCT F
right B-PHYSICAL VERB F
amygdala I-PHYSICAL NOUN F
activity I-PHYSICAL NOUN F
to I-PHYSICAL ADP F
facial I-PHYSICAL ADJ F
stimuli I-PHYSICAL NOUN F
increased 0 VERB F
in 0 ADP F
the 0 DET F
AS 0 PUNCT T
group 0 NOUN F
. 0 PUNCT F

CONCLUSIONS 0 NOUN T
These 0 DET T
findings 0 NOUN F
indicate 0 VERB F
that 0 ADP F
oxytocin 0 NOUN F
increases 0 NOUN F
the 0 DET F
saliency 0 NOUN F
of 0 ADP F
social 0 ADJ F
stimuli 0 NOUN F
and 0 CCONJ F
in 0 ADP F
ASD 0 NOUN T
and 0 CCONJ F
suggest 0 VERB F
that 0 ADP F
oxytocin 0 NOUN F
might 0 PART F
promote 0 ADJ F
face 0 PUNCT F
processing 0 PUNCT F
and 0 CCONJ F
eye 0 NOUN F
contact 0 NOUN F
in 0 ADP F
individuals 0 NOUN F
with 0 ADP F
ASD 0 NOUN T
as 0 VERB F
prerequisites 0 VERB F
for 0 ADP F
neurotypical 0 ADJ F
social 0 ADJ F
interaction 0 NOUN F
. 0 PUNCT F

TENS 0 NOUN T
for 0 ADP F
the 0 DET F
treatment 0 NOUN F
of 0 ADP F
writer 0 ADJ F
's 0 PUNCT F
cramp 0 NOUN F
dystonia 0 NOUN F
: 0 PUNCT F
a 0 DET F
randomized 0 VERB F
, 0 PUNCT F
placebo-controlled 0 VERB F
study 0 NOUN F
. 0 PUNCT F

Manipulation 0 NOUN T
of 0 ADP F
afferent 0 NOUN F
inputs 0 ADP F
may 0 ADP F
temporarily 0 PUNCT F
modulate 0 ADV F
dystonic 0 ADJ F
spasms 0 NOUN F
. 0 PUNCT F

Ten 0 NUM T
patients 0 NOUN F
with 0 ADP F
writer 0 ADJ F
's 0 PUNCT F
cramp 0 NOUN F
were 0 VERB F
enrolled 0 VERB F
in 0 ADP F
a 0 DET F
double-blind 0 ADJ F
, 0 PUNCT F
randomized 0 VERB F
, 0 PUNCT F
crossover 0 ADP F
study 0 NOUN F
in 0 ADP F
which 0 ADP F
the 0 DET F
effects 0 NOUN F
of 0 ADP F
transcutaneous 0 ADJ F
electrical 0 ADJ F
stimulation 0 NOUN F
( 0 PUNCT F
TENS 0 NOUN T
) 0 PUNCT F
and 0 CCONJ F
placebo 0 NOUN F
treatment 0 NOUN F
were 0 VERB F
compared 0 VERB F
. 0 PUNCT F

Patients 0 NOUN T
were 0 VERB F
evaluated 0 VERB F
using 0 VERB F
four 0 NUM F
measures 0 NOUN F
of 0 ADP F
dystonic B-PHYSICAL ADJ F
impairment I-PHYSICAL NOUN F
. 0 PUNCT F

The 0 DET T
TENS 0 NOUN T
group 0 NOUN F
showed 0 VERB F
a 0 DET F
significant B-OTHER ADJ F
improvement I-OTHER NOUN F
that 0 ADP F
persisted 0 VERB F
for 0 ADP F
3 0 NUM F
weeks 0 NOUN F
in 0 ADP F
three 0 NUM F
of 0 ADP F
the 0 DET F
four 0 NUM F
measures 0 NOUN F
. 0 PUNCT F

Predictive 0 ADJ T
validity 0 NOUN F
of 0 ADP F
a 0 DET F
medication 0 NOUN F
adherence 0 NOUN F
measure 0 NOUN F
in 0 ADP F
an 0 DET F
outpatient 0 ADJ F
setting 0 VERB F
. 0 PUNCT F

This 0 DET T
study 0 NOUN F
examines 0 NOUN F
the 0 DET F
psychometric 0 ADJ F
properties 0 NOUN F
and 0 CCONJ F
tests 0 ADJ F
the 0 DET F
concurrent 0 ADJ F
and 0 CCONJ F
predictive 0 ADJ F
validity 0 NOUN F
of 0 ADP F
a 0 DET F
structured 0 VERB F
, 0 PUNCT F
self-reported 0 VERB F
medication 0 NOUN F
adherence 0 NOUN F
measure 0 NOUN F
in 0 ADP F
patients 0 NOUN F
with 0 ADP F
hypertension 0 NOUN F
. 0 PUNCT F

The 0 DET T
authors 0 NOUN F
also 0 ADV F
assessed 0 ADP F
various 0 ADJ F
psychosocial B-MENTAL ADJ F
determinants I-MENTAL NOUN F
of I-MENTAL ADP F
adherence I-MENTAL NOUN F
, 0 PUNCT F
such 0 PUNCT F
as 0 ADP F
knowledge B-MENTAL NOUN F
, 0 PUNCT F
social B-MENTAL ADJ F
support I-MENTAL NOUN F
, 0 PUNCT F
satisfaction B-OTHER NOUN F
with I-OTHER ADP F
care I-OTHER NOUN F
, 0 PUNCT F
and 0 CCONJ F
complexity 0 NOUN F
of 0 ADP F
the 0 DET F
medical B-OTHER ADJ F
regimen I-OTHER NOUN F
. 0 PUNCT F

A 0 DET T
total 0 NOUN F
of 0 ADP F
1367 0 NUM F
patients 0 NOUN F
participated 0 VERB F
in 0 ADP F
the 0 DET F
study 0 NOUN F
; 0 PUNCT F
mean 0 NOUN F
age 0 NOUN F
was 0 VERB F
52.5 0 NUM F
years 0 NOUN F
, 0 PUNCT F
40.8 0 NUM F
% 0 SYM F
were 0 ADP F
male 0 NOUN F
, 0 PUNCT F
76.5 0 NUM F
% 0 SYM F
were 0 VERB F
black 0 NOUN F
, 0 PUNCT F
50.8 0 NUM F
% 0 SYM F
graduated 0 PUNCT F
from 0 ADP F
high 0 ADJ F
school 0 NOUN F
, 0 PUNCT F
26 0 NUM F
% 0 SYM F
were 0 VERB F
married 0 VERB F
, 0 PUNCT F
and 0 CCONJ F
54.1 0 NUM F
% 0 SYM F
had 0 PUNCT F
income 0 NOUN F
< 0 SYM F
$ 0 SYM F
5,000 0 NUM F
. 0 PUNCT F

The 0 DET T
8-item 0 NOUN F
medication 0 NOUN F
adherence 0 NOUN F
scale 0 NOUN F
was 0 VERB F
reliable 0 ADJ F
( 0 PUNCT F
alpha=.83 0 NOUN F
) 0 PUNCT F
and 0 CCONJ F
significantly 0 ADV F
associated 0 VERB F
with 0 ADP F
blood B-PHYSICAL NOUN F
pressure I-PHYSICAL NOUN F
control I-PHYSICAL NOUN F
( 0 PUNCT F
P 0 NOUN T
< 0 SYM F
.05 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Using 0 ADJ T
a 0 DET F
cutpoint 0 NOUN F
of 0 ADP F
< 0 SYM F
6 0 NUM F
, 0 PUNCT F
the 0 DET F
sensitivity 0 NOUN F
of 0 ADP F
the 0 DET F
measure 0 ADP F
to 0 PART F
identify 0 NOUN F
patients 0 NOUN F
with 0 ADP F
poor 0 ADJ F
blood B-PHYSICAL NOUN F
pressure I-PHYSICAL NOUN F
control I-PHYSICAL NOUN F
was 0 VERB F
estimated 0 VERB F
to 0 PART F
be 0 PUNCT F
93 0 NUM F
% 0 SYM F
, 0 PUNCT F
and 0 CCONJ F
the 0 DET F
specificity 0 NOUN F
was 0 VERB F
53 0 NUM F
% 0 SYM F
. 0 PUNCT F

The 0 DET T
medication 0 NOUN F
adherence 0 NOUN F
measure 0 NOUN F
proved 0 ADV F
to 0 PART F
be 0 PUNCT F
reliable 0 ADJ F
, 0 PUNCT F
with 0 ADP F
good 0 ADJ F
concurrent 0 ADJ F
and 0 CCONJ F
predictive 0 ADJ F
validity 0 NOUN F
in 0 ADP F
primarily 0 ADV F
low-income 0 NOUN F
, 0 PUNCT F
minority 0 NOUN F
patients 0 NOUN F
with 0 ADP F
hypertension 0 NOUN F
and 0 CCONJ F
might 0 CCONJ F
function 0 VERB F
as 0 ADP F
a 0 DET F
screening 0 VERB F
tool 0 NOUN F
in 0 ADP F
outpatient 0 ADJ F
settings 0 NOUN F
with 0 ADP F
other 0 ADJ F
patient 0 NOUN F
groups 0 NOUN F
. 0 PUNCT F

Histopathologic B-PHYSICAL ADJ T
changes I-PHYSICAL NOUN F
of I-PHYSICAL ADP F
the I-PHYSICAL DET F
eyelid I-PHYSICAL ADJ F
skin I-PHYSICAL NOUN F
following 0 PUNCT F
trichloroacetic 0 ADJ F
acid 0 NOUN F
chemical 0 ADJ F
peel 0 NOUN F
. 0 PUNCT F

The 0 DET T
use 0 NOUN F
of 0 ADP F
trichloroacetic 0 ADJ F
acid 0 NOUN F
( 0 PUNCT F
TCA 0 NOUN T
) 0 PUNCT F
as 0 ADP F
a 0 DET F
periorbital 0 ADJ F
and 0 CCONJ F
eyelid 0 PUNCT F
peel 0 PUNCT F
for 0 ADP F
skin 0 NOUN F
rejuvenation 0 NOUN F
is 0 VERB F
gaining 0 PUNCT F
significant 0 ADJ F
acceptance 0 NOUN F
among 0 ADP F
oculoplastic 0 ADJ F
surgeons 0 NOUN F
, 0 PUNCT F
dermatologists 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
other 0 ADJ F
surgery 0 NOUN F
groups 0 NOUN F
. 0 PUNCT F

In 0 ADP T
spite 0 NOUN F
of 0 ADP F
the 0 DET F
current 0 ADJ F
enthusiasm 0 NOUN F
, 0 PUNCT F
there 0 PUNCT F
remain 0 VERB F
potentially 0 ADV F
serious 0 ADJ F
complications 0 NOUN F
resulting 0 VERB F
from 0 ADP F
any 0 DET F
periorbital 0 ADJ F
peel 0 NOUN F
. 0 PUNCT F

Cases 0 NOUN T
of 0 ADP F
cicatricial 0 ADJ F
ectropion 0 NUM F
have 0 PUNCT F
been 0 PUNCT F
reported 0 VERB F
in 0 ADP F
phenol-peeled 0 VERB F
patients 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
lower 0 ADP F
eyelid 0 ADJ F
ectropion 0 NUM F
has 0 PUNCT F
reportedly 0 ADV F
occurred 0 PUNCT F
in 0 ADP F
patients 0 NOUN F
undergoing 0 VERB F
deep 0 ADJ F
eyelid 0 ADJ F
peel 0 PUNCT F
in 0 ADP F
conjunction 0 NOUN F
with 0 ADP F
a 0 DET F
blepharoplasty 0 NOUN F
( 0 PUNCT F
1,2 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

To 0 DET T
avoid 0 ADP F
this 0 DET F
complication 0 NOUN F
, 0 PUNCT F
it 0 PRON F
is 0 VERB F
necessary 0 ADJ F
to 0 ADJ F
better 0 PUNCT F
understand 0 PUNCT F
the 0 DET F
depth 0 NOUN F
of 0 ADP F
the 0 DET F
wound 0 NOUN F
produced 0 VERB F
by 0 ADP F
different 0 ADJ F
strengths 0 PUNCT F
and 0 CCONJ F
combinations 0 NOUN F
of 0 ADP F
peeling 0 PROPN F
agents 0 NOUN F
applied 0 VERB F
to 0 ADP F
living 0 PUNCT F
eyelid 0 PUNCT F
tissue 0 NOUN F
and 0 CCONJ F
, 0 PUNCT F
more 0 DET F
important 0 ADJ F
, 0 PUNCT F
to 0 PART F
determine 0 NOUN F
the 0 DET F
concentrations 0 NOUN F
of 0 ADP F
TCA 0 NOUN T
that 0 ADP F
are 0 VERB F
likely 0 ADV F
to 0 PART F
lead 0 PUNCT F
to 0 ADP F
cicatricial 0 ADJ F
ectropion 0 NUM F
when 0 ADP F
applied 0 VERB F
in 0 ADP F
a 0 DET F
consistent 0 ADJ F
fashion 0 NOUN F
. 0 PUNCT F

We 0 ADJ T
chose 0 PUNCT F
upper-eyelid 0 ADP F
skin 0 NOUN F
because 0 ADP F
it 0 PRON F
is 0 VERB F
easier 0 ADJ F
to 0 PUNCT F
obtain 0 ADV F
for 0 ADP F
histopathologic 0 ADJ F
study 0 NOUN F
than 0 PUNCT F
lower-eyelid 0 PUNCT F
skin 0 NOUN F
and 0 CCONJ F
, 0 PUNCT F
in 0 ADP F
our 0 PUNCT F
experience 0 NOUN F
, 0 PUNCT F
is 0 VERB F
more 0 ADV F
sensitive 0 ADJ F
to 0 ADP F
hypertrophic 0 ADJ F
changes 0 NOUN F
after 0 ADP F
chemical 0 ADJ F
peeling 0 ADP F
or 0 CCONJ F
carbon 0 NOUN F
dioxide 0 PUNCT F
laser 0 NOUN F
resurfacing 0 PUNCT F
. 0 PUNCT F

We 0 PRON T
applied 0 VERB F
TCA 0 NOUN T
to 0 ADP F
the 0 DET F
preseptal 0 ADJ F
skin 0 NOUN F
of 0 ADP F
10 0 NUM F
patients 0 NOUN F
48 0 NUM F
h 0 NOUN F
before 0 ADP F
standard 0 ADJ F
upper-eyelid 0 ADJ F
blepharoplasty 0 NOUN F
. 0 PUNCT F

The 0 DET T
acid 0 NOUN F
was 0 VERB F
applied 0 VERB F
to 0 ADJ F
produce 0 NOUN F
a 0 DET F
frost 0 ADV F
, 0 PUNCT F
using 0 VERB F
varying 0 VERB F
concentrations 0 NOUN F
of 0 ADP F
acid 0 NOUN F
, 0 PUNCT F
ranging 0 CCONJ F
from 0 ADP F
20 0 NUM F
to 0 ADP F
50 0 NUM F
% 0 SYM F
. 0 PUNCT F

The 0 DET T
treated 0 VERB F
skin 0 NOUN F
removed 0 VERB F
at 0 ADP F
the 0 DET F
time 0 NOUN F
of 0 ADP F
blepharoplasty 0 NOUN F
was 0 VERB F
reviewed 0 VERB F
in 0 ADP F
a 0 DET F
masked 0 ADJ F
fashion 0 NOUN F
by 0 ADP F
a 0 DET F
dermatopathologist 0 NOUN F
to 0 PART F
determine 0 NOUN F
the 0 DET F
depth 0 NOUN F
of 0 ADP F
necrosis 0 NOUN F
. 0 PUNCT F

We 0 PRON T
found 0 VERB F
that 0 ADP F
superficial B-PHYSICAL ADJ F
peels I-PHYSICAL NOUN F
with I-PHYSICAL ADP F
necrosis I-PHYSICAL NOUN F
involving 0 VERB F
30 0 NUM F
% 0 SYM F
of 0 ADP F
the 0 DET F
epidermis 0 NOUN F
were 0 VERB F
produced 0 VERB F
by 0 ADP F
the 0 DET F
lowest-concentration 0 NOUN F
combination 0 NOUN F
of 0 ADP F
TCA 0 NOUN T
applied B-OTHER VERB F
( 0 PUNCT F
20 0 NUM F
% 0 SYM F
followed 0 VERB F
by 0 ADP F
0 0 NUM F
% 0 SYM F
) 0 PUNCT F
. 0 PUNCT F

As 0 ADP T
the 0 DET F
strength B-OTHER NOUN F
increased 0 ADP F
, 0 PUNCT F
so 0 PUNCT F
did 0 PUNCT F
the 0 DET F
depth 0 NOUN F
of 0 ADP F
peel 0 PUNCT F
. 0 PUNCT F

The 0 DET T
combination 0 NOUN F
of 0 ADP F
50 0 NUM F
% 0 SYM F
followed 0 VERB F
by 0 ADP F
a 0 DET F
second 0 ADJ F
application 0 NOUN F
of 0 ADP F
50 0 NUM F
% 0 SYM F
produced 0 VERB F
the 0 DET F
deepest B-PHYSICAL ADV F
peel I-PHYSICAL NOUN F
, 0 PUNCT F
with 0 ADP F
necrosis 0 NOUN F
into 0 ADP F
the 0 DET F
papillary 0 ADJ F
dermis 0 NOUN F
. 0 PUNCT F

This 0 DET T
finding 0 VERB F
would 0 ADJ F
indicate 0 VERB F
that 0 ADP F
the 0 DET F
chance 0 NOUN F
of 0 ADP F
developing 0 VERB F
cicatricial 0 ADJ F
ectropion 0 NUM F
with 0 ADP F
any 0 PUNCT F
of 0 ADP F
the 0 DET F
tested 0 VERB F
combinations 0 NOUN F
of 0 ADP F
TCA 0 NOUN T
should 0 VERB F
be 0 VERB F
very 0 PUNCT F
remote 0 NOUN F
. 0 PUNCT F

Custom 0 ADJ T
tray 0 NOUN F
application 0 NOUN F
of 0 ADP F
peroxide 0 NOUN F
gel 0 NOUN F
as 0 ADP F
an 0 DET F
adjunct 0 NOUN F
to 0 ADP F
scaling 0 ADP F
and 0 CCONJ F
root 0 NOUN F
planing 0 PUNCT F
in 0 ADP F
the 0 DET F
treatment 0 NOUN F
of 0 ADP F
periodontitis 0 NOUN F
: 0 PUNCT F
results 0 NOUN F
of 0 ADP F
a 0 DET F
randomized 0 VERB F
controlled 0 VERB F
trial 0 NOUN F
after 0 ADP F
six 0 NUM F
months 0 NOUN F
. 0 PUNCT F

OBJECTIVE 0 NOUN T
Scaling 0 PUNCT T
and 0 CCONJ F
root 0 NOUN F
planing 0 PUNCT F
( 0 PUNCT F
SRP 0 NOUN T
) 0 PUNCT F
is 0 VERB F
the 0 DET F
primary 0 ADJ F
non-surgical 0 ADJ F
treatment 0 NOUN F
for 0 ADP F
periodontitis 0 NOUN F
, 0 PUNCT F
but 0 CCONJ F
its 0 PUNCT F
effectiveness 0 NOUN F
is 0 VERB F
limited 0 VERB F
. 0 PUNCT F

Consequently 0 ADV T
, 0 PUNCT F
various 0 ADJ F
adjunctive 0 ADJ F
therapies 0 NOUN F
have 0 NOUN F
been 0 PUNCT F
investigated 0 VERB F
to 0 PART F
improve 0 ADJ F
clinical 0 ADJ F
outcome 0 NOUN F
. 0 PUNCT F

This 0 DET T
study 0 NOUN F
evaluated 0 VERB F
the 0 DET F
clinical 0 ADJ F
effects 0 NOUN F
of 0 ADP F
one 0 NUM F
SRP 0 NOUN T
procedure 0 NOUN F
alone 0 ADJ F
or 0 CCONJ F
combined 0 PUNCT F
with 0 ADP F
local 0 ADJ F
administration 0 NOUN F
of 0 ADP F
hydrogen 0 NOUN F
peroxide 0 NOUN F
gel 0 NOUN F
using 0 VERB F
customized 0 VERB F
trays 0 ADP F
for 0 ADP F
the 0 DET F
treatment 0 NOUN F
of 0 ADP F
subjects 0 NOUN F
with 0 ADP F
chronic 0 ADJ F
periodontitis 0 NOUN F
over 0 ADP F
a 0 DET F
period 0 NOUN F
of 0 ADP F
six 0 NUM F
months 0 NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
An 0 DET T
examiner-blind 0 ADJ F
clinical 0 ADJ F
trial 0 NOUN F
was 0 VERB F
conducted 0 VERB F
among 0 ADP F
30 0 NUM F
subjects 0 NOUN F
with 0 ADP F
moderate 0 ADJ F
to 0 ADP F
advanced 0 VERB F
periodontitis 0 NOUN F
who 0 ADP F
were 0 VERB F
randomized 0 VERB F
to 0 ADP F
SRP 0 NOUN T
alone 0 ADJ F
or 0 CCONJ F
SRP 0 NOUN T
combined 0 VERB F
with 0 ADP F
prescription 0 NOUN F
custom-tray 0 NOUN F
application 0 NOUN F
( 0 PUNCT F
Perio 0 NOUN T
Tray 0 NOUN T
) 0 PUNCT F
of 0 ADP F
1.7 0 NUM F
% 0 SYM F
hydrogen 0 NOUN F
peroxide 0 NOUN F
gel 0 NOUN F
( 0 PUNCT F
Perio 0 NOUN T
Gel 0 NOUN T
) 0 PUNCT F
for 0 ADP F
a 0 DET F
period 0 NOUN F
of 0 ADP F
three 0 NUM F
months 0 NOUN F
, 0 PUNCT F
then 0 ADV F
extended 0 VERB F
to 0 ADP F
six 0 NUM F
months 0 NOUN F
. 0 PUNCT F

Following 0 PUNCT T
impressions 0 NOUN F
for 0 ADP F
the 0 DET F
test 0 PUNCT F
group 0 NOUN F
, 0 PUNCT F
all 0 DET F
subjects 0 NOUN F
brushed 0 PUNCT F
twice 0 ADV F
daily 0 ADJ F
with 0 ADP F
a 0 DET F
regular 0 ADJ F
dentifrice 0 NOUN F
and 0 CCONJ F
toothbrush 0 NOUN F
for 0 ADP F
a 0 DET F
four-week 0 NOUN F
acclimation 0 NOUN F
phase 0 NOUN F
to 0 PART F
standardize 0 DET F
oral 0 ADJ F
conditions 0 NOUN F
( 0 PUNCT F
while 0 PUNCT F
trays 0 NOUN F
were 0 VERB F
fabricated 0 ADJ F
) 0 PUNCT F
prior 0 PUNCT F
to 0 ADP F
initiating 0 ADP F
the 0 DET F
treatment 0 NOUN F
phase 0 NOUN F
. 0 PUNCT F

SRP 0 NOUN T
was 0 VERB F
performed 0 VERB F
three 0 NUM F
weeks 0 NOUN F
after 0 ADP F
baseline 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
clinical 0 ADJ F
assessments 0 NOUN F
, 0 PUNCT F
i.e. 0 CCONJ F
, 0 PUNCT F
pocket B-PHYSICAL NOUN F
probing I-PHYSICAL VERB F
depth I-PHYSICAL NOUN F
( 0 PUNCT F
PPD B-PHYSICAL NOUN T
) 0 PUNCT F
and B-PHYSICAL CCONJ F
bleeding I-PHYSICAL ADJ F
index 0 NOUN F
( 0 PUNCT F
BI B-PHYSICAL NOUN T
) 0 PUNCT F
, 0 PUNCT F
were 0 VERB F
conducted 0 VERB F
at 0 ADP F
baseline 0 NOUN F
and 0 CCONJ F
after 0 ADP F
two 0 NUM F
, 0 PUNCT F
five 0 NUM F
, 0 PUNCT F
13 0 NUM F
, 0 PUNCT F
and 0 CCONJ F
26 0 NUM F
weeks 0 NOUN F
of 0 ADP F
peroxide 0 NOUN F
gel 0 NOUN F
applications 0 NOUN F
. 0 PUNCT F

Clinical 0 ADJ T
variables 0 NOUN F
were 0 VERB F
compared 0 VERB F
by 0 ADP F
ANCOVA 0 NOUN T
and 0 CCONJ F
paired 0 VERB F
t-tests 0 NOUN F
after 0 ADP F
each 0 DET F
treatment 0 NOUN F
interval 0 NOUN F
. 0 PUNCT F

RESULTS 0 NOUN T
A 0 PUNCT T
total 0 NOUN F
of 0 ADP F
13 0 NUM F
test 0 NOUN F
and 0 CCONJ F
15 0 NUM F
control 0 NOUN F
subjects 0 NOUN F
completed 0 DET F
the 0 DET F
original 0 ADJ F
three-month 0 NOUN F
trial 0 NOUN F
, 0 PUNCT F
of 0 ADP F
whom 0 ADP F
10 0 NUM F
test 0 NOUN F
and 0 CCONJ F
13 0 NUM F
control 0 NOUN F
subjects 0 NOUN F
finished 0 ADV F
the 0 DET F
three-month 0 NOUN F
extension 0 NOUN F
. 0 PUNCT F

After 0 ADP T
two 0 NUM F
weeks 0 NOUN F
of 0 ADP F
peroxide 0 NOUN F
gel 0 NOUN F
use 0 ADP F
prior 0 PUNCT F
to 0 ADP F
SRP 0 NOUN T
, 0 PUNCT F
mean 0 NOUN F
PPD B-PHYSICAL NOUN T
for 0 ADP F
the 0 DET F
test 0 ADJ F
group 0 NOUN F
significantly 0 ADV F
decreased 0 VERB F
from 0 ADP F
baseline 0 NOUN F
by 0 ADP F
0.21 0 NUM F
mm 0 NOUN F
and 0 CCONJ F
mean 0 NOUN F
BI B-PHYSICAL NOUN T
significantly 0 ADV F
dropped 0 VERB F
by 0 ADP F
0.14 0 NUM F
; 0 PUNCT F
clinical 0 ADJ F
parameters 0 NOUN F
for 0 ADP F
the 0 DET F
control 0 NOUN F
group 0 NOUN F
were 0 VERB F
unchanged 0 VERB F
. 0 PUNCT F

Two 0 NUM T
weeks 0 NOUN F
following 0 VERB F
SRP 0 NOUN T
, 0 PUNCT F
mean 0 NOUN F
PPD B-PHYSICAL NOUN T
significantly 0 ADV F
decreased 0 VERB F
from 0 ADP F
baseline 0 NOUN F
by 0 ADP F
0.65 0 NUM F
mm 0 NOUN F
for 0 ADP F
the 0 DET F
test 0 ADJ F
group 0 NOUN F
and 0 CCONJ F
0.17 0 NUM F
mm 0 NOUN F
for 0 ADP F
the 0 DET F
control 0 NOUN F
; 0 PUNCT F
mean 0 NOUN F
BI 0 NOUN T
significantly 0 ADV F
dropped 0 VERB F
by 0 ADP F
0.17 0 NUM F
for 0 ADP F
the 0 DET F
test 0 ADJ F
group 0 NOUN F
and 0 CCONJ F
0.05 0 NUM F
for 0 ADP F
the 0 DET F
control 0 NOUN F
. 0 PUNCT F

Ten 0 NUM T
weeks 0 NOUN F
following 0 VERB F
SRP 0 NOUN T
, 0 PUNCT F
mean 0 NOUN F
PPD B-PHYSICAL NOUN T
decreases 0 CCONJ F
were 0 VERB F
0.77 0 NUM F
mm 0 NOUN F
for 0 ADP F
the 0 DET F
test 0 ADJ F
group 0 NOUN F
and 0 CCONJ F
0.13 0 NUM F
mm 0 NOUN F
for 0 ADP F
the 0 DET F
control 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
mean 0 NOUN F
BI B-PHYSICAL NOUN T
reductions 0 NOUN F
were 0 VERB F
0.14 0 PUNCT F
for 0 ADP F
the 0 DET F
test 0 ADJ F
group 0 NOUN F
and 0 CCONJ F
0.00 0 NUM F
for 0 ADP F
the 0 DET F
control 0 NOUN F
. 0 PUNCT F

For 0 ADP T
subjects 0 NOUN F
who 0 ADP F
completed 0 PROPN F
the 0 DET F
three-month 0 NOUN F
extension 0 NOUN F
( 0 PUNCT F
i.e. 0 CCONJ F
, 0 PUNCT F
23 0 NUM F
weeks 0 NOUN F
post-SRP 0 NOUN F
) 0 PUNCT F
, 0 PUNCT F
mean 0 NOUN F
PPD B-PHYSICAL NOUN T
decreases 0 CCONJ F
were 0 VERB F
0.72 0 NUM F
mm 0 NOUN F
for 0 ADP F
the 0 DET F
test 0 ADJ F
group 0 NOUN F
and 0 CCONJ F
0.13 0 NUM F
mm 0 NOUN F
for 0 ADP F
the 0 DET F
control 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
mean 0 NOUN F
BI B-PHYSICAL NOUN T
reductions 0 NOUN F
were 0 VERB F
0.05 0 PUNCT F
for 0 ADP F
the 0 DET F
test 0 ADJ F
group 0 NOUN F
and 0 CCONJ F
0.01 0 NUM F
for 0 ADP F
the 0 DET F
control 0 NOUN F
. 0 PUNCT F

Analysis 0 NOUN T
of 0 ADP F
deeper 0 PUNCT F
pockets 0 NOUN F
( 0 PUNCT F
i.e. 0 CCONJ F
, 0 PUNCT F
> 0 SYM F
5 0 NUM F
mm 0 NOUN F
at 0 ADP F
baseline 0 NOUN F
) 0 PUNCT F
showed 0 VERB F
the 0 DET F
same 0 ADJ F
relationship 0 NOUN F
for 0 ADP F
PPD 0 NOUN T
, 0 PUNCT F
but 0 CCONJ F
with 0 ADP F
larger 0 PUNCT F
differences 0 NOUN F
between 0 ADP F
groups 0 NOUN F
. 0 PUNCT F

For 0 ADP T
example 0 NOUN F
, 0 PUNCT F
after 0 ADP F
two 0 NUM F
weeks 0 NOUN F
of 0 ADP F
peroxide 0 NOUN F
gel 0 NOUN F
use 0 ADP F
prior 0 PUNCT F
to 0 ADP F
SRP 0 NOUN T
, 0 PUNCT F
mean 0 NOUN F
PPD B-PHYSICAL NOUN T
decreased 0 VERB F
by 0 ADP F
0.48 0 NUM F
mm 0 NOUN F
for 0 ADP F
the 0 DET F
test 0 ADJ F
group 0 NOUN F
compared 0 VERB F
to 0 ADP F
0.04 0 NUM F
mm 0 NOUN F
for 0 ADP F
the 0 DET F
control 0 NOUN F
. 0 PUNCT F

Two 0 NUM T
weeks 0 NOUN F
after 0 ADP F
SRP 0 NOUN T
, 0 PUNCT F
mean 0 NOUN F
PPD B-PHYSICAL NOUN T
decreased 0 ADP F
from 0 ADP F
baseline 0 NOUN F
by 0 ADP F
1.40 0 NUM F
mm 0 NOUN F
for 0 ADP F
the 0 DET F
test 0 ADJ F
group 0 NOUN F
and 0 CCONJ F
0.60 0 NUM F
mm 0 NOUN F
for 0 ADP F
the 0 DET F
control 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
10 0 NUM F
weeks 0 NOUN F
after 0 ADP F
SRP 0 NOUN T
by 0 ADP F
1.57 0 NUM F
mm 0 NOUN F
for 0 ADP F
the 0 DET F
test 0 ADJ F
group 0 NOUN F
and 0 CCONJ F
0.58 0 NUM F
mm 0 NOUN F
for 0 ADP F
the 0 DET F
control 0 NOUN F
. 0 PUNCT F

After 0 ADP T
the 0 DET F
extension 0 NOUN F
( 0 PUNCT F
i.e. 0 CCONJ F
, 0 PUNCT F
23 0 NUM F
weeks 0 NOUN F
post-SRP 0 NOUN F
) 0 PUNCT F
, 0 PUNCT F
mean 0 PUNCT F

A 0 DET T
comparison 0 NOUN F
of 0 ADP F
sclerotherapy 0 NOUN F
with 0 ADP F
staple 0 PUNCT F
transection 0 NOUN F
of 0 ADP F
the 0 DET F
esophagus 0 NOUN F
for 0 ADP F
the 0 DET F
emergency 0 NOUN F
control 0 NOUN F
of 0 ADP F
bleeding B-PHYSICAL VERB F
from 0 ADP F
esophageal 0 ADJ F
varices 0 NOUN F
. 0 PUNCT F

We 0 PRON T
compared 0 VERB F
two 0 ADP F
procedures 0 NOUN F
for 0 ADP F
the 0 DET F
emergency 0 NOUN F
treatment 0 NOUN F
of 0 ADP F
bleeding B-PHYSICAL PUNCT F
esophageal 0 ADJ F
varices 0 NOUN F
in 0 ADP F
patients 0 NOUN F
who 0 DET F
did 0 ADP F
not 0 ADV F
respond 0 VERB F
to 0 ADP F
blood 0 NOUN F
transfusion 0 NOUN F
and 0 CCONJ F
vasoactive 0 ADJ F
drugs 0 NOUN F
. 0 PUNCT F

We 0 PRON T
randomly 0 PUNCT F
assigned 0 PUNCT F
101 0 NUM F
patients 0 NOUN F
with 0 ADP F
cirrhosis 0 NOUN F
of 0 ADP F
the 0 DET F
liver 0 NOUN F
and 0 CCONJ F
bleeding 0 PART F
esophageal 0 ADJ F
varices 0 NOUN F
to 0 ADP F
undergo 0 VERB F
either 0 PUNCT F
emergency 0 NOUN F
sclerotherapy 0 NOUN F
( 0 PUNCT F
n 0 NOUN F
= 0 SYM F
50 0 NUM F
) 0 PUNCT F
or 0 CCONJ F
staple 0 PUNCT F
transection 0 NOUN F
of 0 ADP F
the 0 DET F
esophagus 0 NOUN F
( 0 PUNCT F
n 0 NOUN F
= 0 SYM F
51 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Four 0 NUM T
patients 0 NOUN F
assigned 0 VERB F
to 0 PUNCT F
sclerotherapy 0 NOUN F
and 0 CCONJ F
12 0 NUM F
assigned 0 VERB F
to 0 ADP F
staple 0 PUNCT F
transection 0 NOUN F
did 0 PUNCT F
not 0 ADV F
actually 0 ADV F
undergo 0 VERB F
those 0 ADP F
procedures 0 NOUN F
, 0 PUNCT F
but 0 CCONJ F
all 0 DET F
analyses 0 NOUN F
were 0 VERB F
made 0 VERB F
on 0 ADP F
an 0 DET F
intention-to-treat 0 NOUN F
basis 0 NOUN F
. 0 PUNCT F

Total 0 ADJ T
mortality B-MORTALITY NOUN F
did 0 PUNCT F
not 0 ADV F
differ 0 VERB F
significantly 0 ADV F
between 0 ADP F
the 0 DET F
two 0 NUM F
groups 0 NOUN F
; 0 PUNCT F
the 0 DET F
relative 0 ADJ F
risk 0 NOUN F
of 0 ADP F
death B-MORTALITY NOUN F
for 0 ADP F
staple 0 PUNCT F
transection 0 NOUN F
as 0 VERB F
compared 0 VERB F
with 0 ADP F
sclerotherapy 0 NOUN F
was 0 VERB F
0.88 0 NUM F
( 0 PUNCT F
95 0 NUM F
percent 0 NOUN F
confidence 0 NOUN F
interval 0 NOUN F
, 0 PUNCT F
0.51 0 NUM F
to 0 ADP F
1.54 0 PUNCT F
) 0 PUNCT F
. 0 PUNCT F

Mortality B-MORTALITY NOUN T
at 0 ADP F
six 0 NUM F
weeks 0 NOUN F
was 0 VERB F
44 0 NUM F
percent 0 NOUN F
among 0 ADP F
those 0 DET F
assigned 0 VERB F
to 0 PUNCT F
sclerotherapy 0 NOUN F
and 0 CCONJ F
35 0 NUM F
percent 0 NOUN F
among 0 ADP F
those 0 DET F
assigned 0 VERB F
to 0 ADP F
staple 0 PUNCT F
transection 0 NOUN F
. 0 PUNCT F

Complication B-PHYSICAL NOUN T
rates I-PHYSICAL NOUN F
were 0 VERB F
similar 0 ADJ F
for 0 ADP F
the 0 DET F
two 0 NUM F
groups 0 NOUN F
. 0 PUNCT F

An 0 DET T
interval 0 NOUN F
of 0 ADP F
five B-PHYSICAL NUM F
days I-PHYSICAL NOUN F
without I-PHYSICAL ADP F
bleeding I-PHYSICAL VERB F
was 0 VERB F
achieved 0 VERB F
in 0 ADP F
88 0 NUM F
percent 0 NOUN F
of 0 ADP F
those 0 ADJ F
assigned 0 VERB F
to 0 ADP F
staple 0 PUNCT F
transection 0 NOUN F
and 0 CCONJ F
in 0 ADP F
62 0 NUM F
percent 0 NOUN F
of 0 ADP F
those 0 ADJ F
assigned 0 VERB F
to 0 PUNCT F
sclerotherapy 0 NOUN F
after 0 ADP F
a 0 DET F
single 0 ADJ F
injection 0 NOUN F
( 0 PUNCT F
P 0 NOUN T
less 0 ADV F
than 0 PUNCT F
0.01 0 NUM F
) 0 PUNCT F
and 0 CCONJ F
82 0 NUM F
percent 0 NOUN F
after 0 ADP F
three 0 NUM F
injections 0 NOUN F
. 0 PUNCT F

In 0 ADP T
only 0 ADV F
2 0 NUM F
of 0 ADP F
the 0 DET F
11 0 NUM F
patients 0 NOUN F
who 0 ADP F
received 0 VERB F
a 0 DET F
third 0 ADJ F
sclerotherapy 0 NOUN F
injection 0 NOUN F
was 0 PUNCT F
bleeding B-PHYSICAL PUNCT F
controlled I-PHYSICAL VERB F
for 0 ADP F
more 0 ADV F
than 0 ADP F
five 0 DET F
days 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
9 0 NUM F
died 0 VERB F
. 0 PUNCT F

We 0 PRON T
conclude 0 VERB F
that 0 ADP F
staple 0 PUNCT F
transection 0 NOUN F
of 0 ADP F
the 0 DET F
esophagus 0 NOUN F
is 0 PUNCT F
as 0 PUNCT F
safe B-OTHER ADJ F
as I-OTHER VERB F
sclerotherapy I-OTHER NOUN F
for 0 ADP F
the 0 DET F
emergency B-PHYSICAL NOUN F
treatment 0 NOUN F
of B-PHYSICAL PUNCT F

Serotonergic 0 ADJ T
control 0 NOUN F
of 0 ADP F
TSH B-PHYSICAL NOUN T
and 0 CCONJ F
PRL B-PHYSICAL NOUN T
secretion I-PHYSICAL NOUN F
in 0 ADP F
obese 0 PUNCT F
men 0 NOUN F
. 0 PUNCT F

To 0 PART T
evaluate 0 NOUN F
whether 0 ADP F
the 0 DET F
inhibitory 0 ADJ F
control 0 NOUN F
of 0 ADP F
TSH B-PHYSICAL NOUN T
and 0 CCONJ F
the 0 DET F
stimulatory B-PHYSICAL ADJ F
control 0 NOUN F
of B-PHYSICAL ADP F
prolactin I-PHYSICAL NOUN F
( I-PHYSICAL PUNCT F
PRL I-PHYSICAL NOUN T
) I-PHYSICAL PUNCT F
secretion B-PHYSICAL NOUN F
exerted 0 VERB F
by 0 ADP F
endogenous 0 ADJ F
serotonin 0 NOUN F
was 0 VERB F
altered 0 VERB F
in 0 ADP F
obesity 0 NOUN F
, 0 PUNCT F
22 0 NUM F
obese 0 PUNCT F
men 0 NOUN F
and 0 CCONJ F
10 0 NUM F
normal 0 ADJ F
controls 0 NOUN F
were 0 VERB F
tested 0 VERB F
with 0 ADP F
TRH 0 NOUN T
( 0 PUNCT F
200 0 NUM F
micrograms 0 NOUN F
IV 0 NUM T
bolus 0 NOUN F
) 0 PUNCT F
in 0 ADP F
the 0 DET F
presence 0 NOUN F
( 0 PUNCT F
experimental 0 ADJ F
test 0 NOUN F
) 0 PUNCT F
and 0 CCONJ F
absence 0 NOUN F
( 0 PUNCT F
control 0 NOUN F
test 0 NOUN F
) 0 PUNCT F
of 0 ADP F
the 0 DET F
serotonergic 0 ADJ F
agonist 0 NOUN F
fenfluramine 0 NOUN F
( 0 PUNCT F
60 0 NUM F
mg 0 NOUN F
PO 0 NOUN T
90 0 NUM F
min 0 NOUN F
before 0 ADP F
TRH 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

Control 0 NOUN T
and 0 CCONJ F
experimental 0 ADJ F
tests 0 NOUN F
were 0 VERB F
also 0 ADV F
performed 0 VERB F
in 0 ADP F
seven 0 NUM F
male 0 NOUN F
patients 0 NOUN F
with 0 ADP F
subclinical 0 ADJ F
hypothyroidism 0 NOUN F
and 0 CCONJ F
were 0 VERB F
repeated 0 VERB F
in 0 ADP F
the 0 DET F
same 0 ADJ F
obese 0 ADP F
subjects 0 NOUN F
after 0 ADP F
substantial 0 ADJ F
weight 0 NOUN F
loss 0 NOUN F
. 0 PUNCT F

Basal B-PHYSICAL ADJ T
TSH I-PHYSICAL NOUN T
levels I-PHYSICAL NOUN F
were 0 VERB F
similar 0 ADJ F
in 0 ADP F
control 0 NOUN F
and 0 CCONJ F
obese 0 PUNCT F
men 0 NOUN F
. 0 PUNCT F

Normal B-PHYSICAL ADJ T
TSH I-PHYSICAL NOUN T
responses I-PHYSICAL NOUN F
to B-PHYSICAL ADP F
TRH I-PHYSICAL NOUN T
( 0 PUNCT F
peak 0 NOUN F
less 0 ADV F
than 0 PUNCT F
or 0 CCONJ F
equal 0 ADJ F
to 0 ADP F
14 0 NUM F
mU/L 0 NOUN F
) 0 PUNCT F
were 0 VERB F
observed 0 VERB F
in 0 ADP F
all 0 DET F
normal 0 ADJ F
controls 0 NOUN F
( 0 PUNCT F
mean 0 NOUN F
peak 0 ADJ F
+/- 0 SYM F
SE 0 PUNCT T
9.8 0 NUM F
+/- 0 SYM F
0.6 0 NUM F
mU/L 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

In 0 ADP T
contrast 0 NOUN F
, 0 PUNCT F
obese 0 PUNCT F
men 0 NOUN F
were 0 VERB F
divided 0 VERB F
into 0 ADP F
two 0 NUM F
groups 0 NOUN F
: 0 PUNCT F
nine 0 NUM F
in 0 ADP F
whom 0 ADP F
the 0 DET F
TRH-induced B-PHYSICAL VERB T
TSH I-PHYSICAL NOUN T
rise I-PHYSICAL NOUN F
was 0 VERB F
higher 0 PUNCT F
than 0 CCONJ F
normal 0 ADJ F
( 0 PUNCT F
group 0 NOUN F
I 0 NUM T
: 0 PUNCT F
mean 0 NOUN F
peak 0 ADJ F
= 0 SYM F
16.5 0 NUM F
+/- 0 SYM F
0.5 0 NUM F
mU/L 0 NOUN F
) 0 PUNCT F
and 0 CCONJ F
13 0 NUM F
in 0 ADP F
whom 0 ADP F
it 0 PRON F
was 0 VERB F
normal 0 ADJ F
( 0 PUNCT F
group 0 NOUN F
II 0 NUM T
: 0 PUNCT F
mean 0 NOUN F
peak 0 ADJ F
= 0 SYM F
10.6 0 NUM F
+/- 0 SYM F
0.7 0 NUM F
mU/L 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
hypothyroid 0 PUNCT F
men 0 ADP F
all 0 DET F
had 0 PUNCT F
elevated 0 PUNCT F

Low 0 ADJ T
protein 0 NOUN F
provision 0 NOUN F
during 0 ADP F
the 0 DET F
first 0 ADJ F
year 0 NOUN F
of 0 ADP F
life 0 NOUN F
, 0 PUNCT F
but 0 CCONJ F
not 0 ADV F
during 0 ADP F
foetal 0 ADJ F
life 0 NOUN F
, 0 PUNCT F
affects 0 NOUN F
metabolic B-PHYSICAL ADJ F
traits I-PHYSICAL NOUN F
, 0 PUNCT F
organ B-PHYSICAL NOUN F
mass I-PHYSICAL NOUN F
development I-PHYSICAL NOUN F
and 0 CCONJ F
growth B-PHYSICAL NOUN F
in 0 ADP F
male 0 NOUN F
mink 0 PUNCT F
( 0 PUNCT F
Neovison 0 NOUN T
vison 0 PUNCT F
) 0 PUNCT F
. 0 PUNCT F

Low 0 ADJ T
protein 0 NOUN F
provision 0 NOUN F
in 0 ADP F
utero 0 NOUN F
and 0 CCONJ F
post-partum 0 NOUN F
may 0 VERB F
induce 0 VERB F
metabolic B-PHYSICAL ADJ F
disorders I-PHYSICAL NOUN F
in 0 ADP F
adulthood 0 NOUN F
. 0 PUNCT F

Studies 0 NOUN T
in 0 ADP F
mink 0 PUNCT F
have 0 PUNCT F
mainly 0 ADV F
focused 0 VERB F
on 0 ADP F
short-term 0 NOUN F
consequences 0 NOUN F
of 0 ADP F
low 0 ADJ F
protein 0 NOUN F
provision 0 NOUN F
in 0 ADP F
utero 0 NOUN F
whereas 0 ADP F
the 0 DET F
long-term 0 NOUN F
responses 0 NOUN F
to 0 ADP F
low 0 ADJ F
protein 0 NOUN F
( 0 PUNCT F
LP 0 NOUN T
) 0 PUNCT F
provision 0 NOUN F
in 0 ADP F
metabolically 0 ADV F
programmed 0 ADJ F
mink 0 ADV F
are 0 VERB F
unknown 0 VERB F
. 0 PUNCT F

We 0 PRON T
investigated 0 VERB F
whether 0 ADP F
low 0 ADJ F
protein 0 NOUN F
provision 0 NOUN F
in 0 ADP F
utero 0 NOUN F
affects 0 NOUN F
the 0 DET F
long-term 0 NOUN F
response 0 NOUN F
to 0 ADP F
adequate 0 ADJ F
( 0 PUNCT F
AP 0 NOUN T
) 0 PUNCT F
or 0 CCONJ F
LP 0 NOUN T
provision 0 NOUN F
after 0 ADP F
weaning 0 NUM F
in 0 ADP F
male 0 NOUN F
mink 0 PUNCT F
. 0 PUNCT F

Eighty-six 0 NUM T
male 0 NOUN F
mink 0 PUNCT F
were 0 VERB F
exposed 0 VERB F
to 0 ADP F
low 0 ADJ F
( 0 PUNCT F
19 0 NUM F
% 0 SYM F
of 0 ADP F
ME 0 NOUN T
from 0 ADP F
CP 0 NOUN T
; 0 PUNCT F
crude 0 ADJ F
protein 0 NOUN F
) 0 PUNCT F
or 0 CCONJ F
adequate 0 ADJ F
( 0 PUNCT F
31 0 NUM F
% 0 SYM F
of 0 ADP F
ME 0 NOUN T
from 0 ADP F
CP 0 NOUN T
) 0 PUNCT F
protein 0 NOUN F
provision 0 NOUN F
in 0 ADP F
utero 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
to 0 ADP F
LP 0 NOUN T
( 0 PUNCT F
~20 0 NOUN F
% 0 NOUN F
of 0 ADP F
ME 0 NOUN T
from 0 ADP F
CP 0 NOUN T
) 0 PUNCT F
or 0 CCONJ F
AP 0 NOUN T
( 0 PUNCT F
30-42 0 NUM F
% 0 SYM F
of 0 ADP F
ME 0 NOUN T
from 0 ADP F
CP 0 NOUN T
) 0 PUNCT F
provision 0 NOUN F
post-weaning 0 VERB F
. 0 PUNCT F

Being 0 ADV T
metabolically 0 ADV F
programmed 0 PUNCT F
by 0 ADP F
low 0 ADJ F
protein 0 NOUN F
provision 0 NOUN F
in 0 ADP F
utero 0 NOUN F
did 0 DET F
not 0 ADV F
affect 0 VERB F
the 0 DET F
response 0 NOUN F
to 0 ADP F
post-weaning B-PHYSICAL DET F
diets I-PHYSICAL NOUN F
. 0 PUNCT F

Dietary B-PHYSICAL ADJ T
protein I-PHYSICAL NOUN F
content I-PHYSICAL NOUN F
in 0 ADP F
the 0 DET F
LP 0 NOUN T
feed 0 NUM F
after 0 ADP F
weaning 0 VERB F
was 0 VERB F
below 0 ADP F
requirements 0 NOUN F
; 0 PUNCT F
evidenced 0 VERB F
by 0 ADP F
lower 0 PUNCT F
nitrogen 0 NOUN F
retention 0 NOUN F
( 0 PUNCT F
p 0 NOUN F
< 0 SYM F
0.001 0 NUM F
) 0 PUNCT F
preventing 0 VERB F
LP 0 NOUN T
mink 0 PUNCT F
from 0 ADP F
attaining 0 VERB F
their 0 ADJ F
growth 0 NOUN F
potential 0 ADJ F
( 0 PUNCT F
p 0 NOUN F
< 0 SYM F
0.02 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

LP 0 NOUN T
mink 0 VERB F
had 0 PUNCT F
a 0 DET F
lower 0 PUNCT F
liver B-PHYSICAL NOUN F
, 0 PUNCT F
pancreas B-PHYSICAL NOUN F
and 0 CCONJ F
kidney B-PHYSICAL NOUN F
weight I-PHYSICAL NOUN F
( 0 PUNCT F
p 0 NOUN F
< 0 SYM F
0.05 0 NUM F
) 0 PUNCT F
as 0 PUNCT F
well 0 PUNCT F
as 0 CCONJ F
lower 0 PUNCT F
plasma B-PHYSICAL NOUN F
IGF-1 I-PHYSICAL NOUN T
concentrations I-PHYSICAL NOUN F
at 0 ADP F
8 0 NUM F
and 0 CCONJ F
25 0 NUM F
( 0 PUNCT F
p 0 NOUN F
< 0 SYM F
0.05 0 NUM F
) 0 PUNCT F
weeks 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
a 0 DET F
higher 0 PUNCT F
incidence 0 NOUN F
of 0 ADP F
hepatic B-PHYSICAL ADJ F
lipidosis I-PHYSICAL NOUN F
at 0 ADP F
25 0 NUM F
weeks 0 NOUN F
( 0 PUNCT F
p 0 NOUN F
< 0 SYM F
0.05 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Furthermore 0 ADV T
, 0 PUNCT F
LP 0 NOUN T
mink 0 VERB F
had 0 PUNCT F
a 0 DET F
higher B-PHYSICAL PUNCT F
body I-PHYSICAL NOUN F
fat I-PHYSICAL NOUN F
( 0 PUNCT F
p 0 NOUN F
< 0 SYM F
0.05 0 NUM F
) 0 PUNCT F
and 0 CCONJ F
lower 0 PUNCT F
body B-PHYSICAL NOUN F
CP I-PHYSICAL NOUN T
content I-PHYSICAL NOUN F
( 0 PUNCT F
p 0 NOUN F
< 0 SYM F
0.05 0 NUM F
) 0 PUNCT F
at 0 ADP F
50 0 NUM F
weeks 0 NOUN F
of 0 ADP F
age 0 NOUN F
. 0 PUNCT F

It 0 PRON T
is 0 VERB F
concluded 0 VERB F
that 0 ADP F
some 0 DET F
effects 0 NOUN F
of 0 ADP F
low B-PHYSICAL ADJ F
protein I-PHYSICAL NOUN F
provision I-PHYSICAL NOUN F
in 0 ADP F
utero 0 NOUN F
can 0 ADV F
be 0 VERB F
alleviated 0 VERB F
by 0 ADP F
an 0 DET F
adequate 0 ADJ F
nutrient B-PHYSICAL NOUN F
supply I-PHYSICAL NOUN F
post-partum I-PHYSICAL NOUN F
. 0 PUNCT F

However 0 ADV T
, 0 PUNCT F
long-term 0 NOUN F
exposure 0 NOUN F
to 0 ADP F
low 0 ADJ F
protein 0 NOUN F
provision 0 NOUN F
in 0 ADP F
mink 0 PUNCT F
reduces 0 NOUN F
their 0 ADP F
growth B-PHYSICAL NOUN F
potential I-PHYSICAL ADJ F
and 0 CCONJ F
induces B-PHYSICAL NOUN F
transient I-PHYSICAL ADJ F
hepatic I-PHYSICAL ADJ F
lipidosis I-PHYSICAL NOUN F
and 0 CCONJ F
modified B-PHYSICAL VERB F
body I-PHYSICAL NOUN F
composition I-PHYSICAL NOUN F
. 0 PUNCT F

Pulse 0 ADJ T
oximeter 0 NOUN F
perfusion 0 NOUN F
index 0 NOUN F
as 0 ADP F
an 0 DET F
early 0 ADJ F
indicator 0 NOUN F
of 0 ADP F
sympathectomy 0 NOUN F
after 0 ADP F
epidural 0 ADJ F
anesthesia 0 NOUN F
. 0 PUNCT F

BACKGROUND 0 NOUN T
The 0 DET T
pulse 0 NOUN F
oximeter 0 NOUN F
perfusion 0 NOUN F
index 0 NOUN F
( 0 PUNCT F
PI 0 NOUN T
) 0 PUNCT F
has 0 PUNCT F
been 0 PUNCT F
used 0 VERB F
to 0 PART F
indicate 0 NOUN F
sympathectomy-induced 0 VERB F
vasodilatation 0 NOUN F
. 0 PUNCT F

We 0 PRON T
hypothesized 0 VERB F
that 0 ADP F
pulse 0 NOUN F
oximeter 0 NOUN F
PI 0 NOUN T
provides 0 NOUN F
an 0 DET F
earlier 0 PUNCT F
and 0 CCONJ F
clearer 0 NOUN F
indication 0 NOUN F
of 0 ADP F
sympathectomy 0 NOUN F
following 0 VERB F
epidural 0 ADJ F
anesthesia 0 NOUN F
than 0 ADP F
skin 0 NOUN F
temperature 0 NOUN F
and 0 CCONJ F
arterial 0 ADJ F
pressure 0 NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
Forty 0 PUNCT T
patients 0 NOUN F
received 0 ADP F
lumbar 0 ADJ F
epidural 0 ADJ F
catheters 0 NOUN F
. 0 PUNCT F

Patients 0 NOUN T
were 0 VERB F
randomized 0 VERB F
to 0 PART F
receive 0 NOUN F
either 0 PUNCT F
10 0 NUM F
ml 0 NOUN F
0.5 0 NUM F
% 0 SYM F
bupivacaine 0 NOUN F
or 0 CCONJ F
10 0 NUM F
ml 0 NOUN F
0.25 0 NUM F
% 0 SYM F
bupivacaine 0 NOUN F
. 0 PUNCT F

PI 0 NOUN T
in 0 ADP F
the 0 DET F
toe B-PHYSICAL NOUN F
, 0 PUNCT F
mean 0 NOUN F
arterial B-PHYSICAL ADJ F
pressure I-PHYSICAL NOUN F
( 0 PUNCT F
MAP B-PHYSICAL NOUN T
) 0 PUNCT F
and 0 CCONJ F
toe B-PHYSICAL NOUN F
temperature I-PHYSICAL NOUN F
were 0 VERB F
all 0 PUNCT F
assessed 0 VERB F
at 0 ADP F
baseline 0 NOUN F
and 0 CCONJ F
at 0 ADP F
5 0 NUM F
, 0 PUNCT F
10 0 NUM F
and 0 CCONJ F
20 0 NUM F
min 0 NOUN F
following 0 VERB F
epidural 0 ADJ F
anesthesia 0 NOUN F
. 0 PUNCT F

The 0 DET T
effect 0 NOUN F
of 0 ADP F
epidural 0 ADJ F
anesthesia 0 NOUN F
over 0 PUNCT F
time 0 NOUN F
was 0 VERB F
assessed 0 VERB F
by 0 ADP F
repeated 0 VERB F
measures B-OTHER NOUN F
analysis I-OTHER NOUN F
of I-OTHER ADP F
variance I-OTHER NOUN F
. 0 PUNCT F

Additionally 0 ADV T
, 0 PUNCT F
we 0 NOUN F
defined 0 VERB F
clinically B-PHYSICAL ADV F
evident I-PHYSICAL ADJ F
sympathectomy I-PHYSICAL NOUN F
criteria I-PHYSICAL NOUN F
( I-PHYSICAL PUNCT F
a I-PHYSICAL DET F
100 I-PHYSICAL NUM F
% I-PHYSICAL SYM F
increase I-PHYSICAL NOUN F
in I-PHYSICAL ADP F
the I-PHYSICAL DET F
PI I-PHYSICAL NOUN T
, I-PHYSICAL PUNCT F
a I-PHYSICAL DET F
15 I-PHYSICAL NUM F
% I-PHYSICAL SYM F
decrease I-PHYSICAL NOUN F
in I-PHYSICAL ADP F
MAP I-PHYSICAL NOUN T
and I-PHYSICAL CCONJ F
a I-PHYSICAL DET F
1 I-PHYSICAL NUM F
degrees I-PHYSICAL NOUN F
C I-PHYSICAL NUM T
increase I-PHYSICAL NOUN F
in I-PHYSICAL ADP F
toe I-PHYSICAL NOUN F
temperature B-PHYSICAL NOUN F
) B-PHYSICAL PUNCT F
. 0 PUNCT F

The 0 DET T
numbers 0 NOUN F
of 0 ADP F
patients 0 NOUN F
demonstrating 0 VERB F
these 0 DET F
changes B-PHYSICAL NOUN F
for 0 ADP F
each 0 DET F
test 0 NOUN F
were 0 VERB F
compared 0 VERB F
using 0 VERB F
the 0 DET F
McNemar B-OTHER NOUN T
test B-OTHER NOUN F
for 0 ADP F
each 0 DET F
time 0 NOUN F
point 0 NOUN F
. 0 PUNCT F

RESULTS 0 NOUN T
Twenty-nine 0 NUM T
subjects 0 NOUN F
had 0 PUNCT F
photoplethysmography B-PHYSICAL NOUN F
signals I-PHYSICAL NOUN F
that 0 PUNCT F
met 0 VERB F
a 0 DET F
priori 0 ADJ F
signal 0 NOUN F
quality 0 NOUN F
criteria 0 NOUN F
for 0 ADP F
analysis 0 NOUN F
. 0 PUNCT F

By 0 ADP T
20 0 NUM F
min 0 NOUN F
, 0 PUNCT F
PI B-PHYSICAL NOUN T
increased 0 VERB F
by 0 ADP F
326 0 NUM F
% 0 SYM F
, 0 PUNCT F
compared 0 VERB F
with 0 ADP F
a 0 DET F
10 0 NUM F
% 0 SYM F
decrease 0 NOUN F
and 0 CCONJ F
a 0 DET F
3 0 NUM F
% 0 SYM F
increase 0 NOUN F
in 0 ADP F
MAP B-PHYSICAL NOUN T
and 0 CCONJ F
toe B-PHYSICAL NOUN F
temperature I-PHYSICAL NOUN F
, 0 PUNCT F
respectively 0 ADV F
. 0 PUNCT F

For 0 ADP T
PI 0 NOUN T
15/29 0 PUNCT F
, 0 PUNCT F
26/29 0 PUNCT F
and 0 CCONJ F
29/29 0 PUNCT F
of 0 ADP F
the 0 DET F
subjects 0 NOUN F
met 0 VERB F
the 0 DET F
sympathectomy B-PHYSICAL NOUN F
criteria I-PHYSICAL NOUN F
at 0 ADP F
5 0 NUM F
, 0 PUNCT F
10 0 NUM F
and 0 CCONJ F
20 0 NUM F
min 0 NOUN F
, 0 PUNCT F
respectively 0 ADV F
, 0 PUNCT F
compared 0 VERB F
with 0 ADP F
4/29 0 NOUN F
, 0 PUNCT F
6/29 0 CCONJ F
and 0 CCONJ F
18/29 0 PUNCT F
for 0 ADP F
MAP B-PHYSICAL NOUN T
changes 0 NOUN F
and 0 CCONJ F
3/29 0 PUNCT F
, 0 PUNCT F
8/29 0 NUM F
and 0 CCONJ F
14/29 0 PUNCT F
for 0 ADP F
toe 0 PUNCT F

Ascorbic 0 ADJ T
acid 0 NOUN F
and 0 CCONJ F
performance B-PHYSICAL NOUN F
in 0 ADP F
man 0 NOUN F
. 0 PUNCT F

Effects 0 NOUN T
on 0 ADP F
performance B-PHYSICAL NOUN F
of 0 ADP F
1 0 NUM F
, 0 PUNCT F
2 0 NUM F
and 0 CCONJ F
4 0 NUM F
g 0 NOUN F
ascorbic 0 ADJ F
acid 0 NOUN F
were 0 VERB F
studied 0 VERB F
from 0 ADP F
0.5-5.5 0 NUM F
h 0 NOUN F
after 0 ADP F
ingestion 0 NOUN F
in 0 ADP F
six 0 NUM F
healthy 0 ADJ F
females 0 NOUN F
. 0 PUNCT F

Diazepam 0 NOUN T
( 0 PUNCT F
5 0 NUM F
mg 0 NOUN F
) 0 PUNCT F
was 0 VERB F
included 0 VERB F
as 0 ADP F
an 0 DET F
active 0 ADJ F
control 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
it 0 NOUN F
impaired 0 ADV F
digit B-PHYSICAL NOUN F
symbol I-PHYSICAL NOUN F
substitution 0 NOUN F
, B-PHYSICAL PUNCT F
visuomotor I-PHYSICAL NOUN F
coordination I-PHYSICAL NOUN F
and I-PHYSICAL CCONJ F
complex I-PHYSICAL PUNCT F
reaction I-PHYSICAL NOUN F
time B-PHYSICAL NOUN F
. 0 PUNCT F

There 0 PUNCT T
were 0 VERB F
no 0 DET F
effects 0 NOUN F
of 0 ADP F
any 0 DET F
dose 0 NOUN F
of 0 ADP F
ascorbic 0 ADJ F
acid 0 NOUN F
on 0 PUNCT F

Neurophysiological 0 ADJ T
double-blind 0 ADJ F
trial 0 NOUN F
of 0 ADP F
a 0 DET F
botulinum 0 NOUN F
neurotoxin 0 NOUN F
type 0 NOUN F
a 0 DET F
free 0 ADJ F
of 0 ADP F
complexing 0 PUNCT F
proteins 0 NOUN F
. 0 PUNCT F

OBJECTIVE 0 NOUN T
Safety B-OTHER NOUN T
and 0 CCONJ F
efficacy 0 NOUN F
of 0 ADP F
botulinum 0 NOUN F
neurotoxin 0 NOUN F
type 0 NOUN F
A 0 PUNCT T
preparation 0 NOUN F
NT 0 NOUN T
201 0 NUM F
( 0 PUNCT F
Xeomin 0 NOUN T
, 0 PUNCT F
Merz 0 NOUN T
Pharmaceuticals 0 NOUN T
GmbH 0 NOUN T
, 0 PUNCT F
Frankfurt 0 PUNCT T
am 0 PUNCT F
Main 0 PUNCT T
, 0 PUNCT F
Germany 0 PUNCT T
) 0 PUNCT F
were 0 VERB F
investigated 0 VERB F
over 0 ADP F
52 0 NUM F
weeks 0 NOUN F
in 0 ADP F
a 0 DET F
double-blind 0 ADJ F
, 0 PUNCT F
randomized 0 VERB F
trial 0 NOUN F
with 0 ADP F
32 0 NUM F
male 0 NOUN F
volunteers 0 NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
Electroneurographic B-OTHER ADJ T
assessments B-PHYSICAL NOUN F
with 0 ADP F
surface 0 NOUN F
electrodes 0 NOUN F
were 0 VERB F
performed 0 VERB F
after 0 ADP F
single 0 ADJ F
injections 0 NOUN F
of 0 ADP F
NT 0 NOUN T
201 0 NUM F
( 0 PUNCT F
2 0 NUM F
, 0 PUNCT F
4 0 NUM F
, 0 PUNCT F
16 0 NUM F
, 0 PUNCT F
or 0 CCONJ F
32 0 NUM F
units 0 NOUN F
) 0 PUNCT F
into 0 ADP F
the 0 DET F
extensor 0 NOUN F
digitorum 0 NOUN F
brevis 0 ADP F
( 0 PUNCT F
EDB 0 NOUN T
) 0 PUNCT F
muscle 0 NOUN F
and 0 CCONJ F
the 0 DET F
same 0 ADJ F
dose 0 NOUN F
( 0 PUNCT F
Botox 0 NOUN T
; 0 PUNCT F
Allergan 0 PUNCT T
Pharmaceuticals 0 NOUN T
( 0 PUNCT F
Ireland 0 PUNCT T
) 0 PUNCT F
Ltd. 0 NOUN T
Westport 0 NOUN T
, 0 PUNCT F
Ireland 0 PUNCT T
) 0 PUNCT F
into 0 ADP F
the 0 DET F
contralateral 0 ADJ F
EDB 0 NOUN T
. 0 PUNCT F

RESULTS 0 NOUN T
All 0 PUNCT T
NT 0 NOUN T
201 0 NUM F
and 0 CCONJ F
BTXCo 0 PUNCT T
doses 0 NOUN F
achieved 0 VERB F
a 0 DET F
statistically 0 ADV F
significant 0 ADJ F
reduction B-PHYSICAL NOUN F
of I-PHYSICAL ADP F
the I-PHYSICAL DET F
compound I-PHYSICAL ADJ F
muscle I-PHYSICAL NOUN F
action I-PHYSICAL NOUN F
potential I-PHYSICAL ADJ F
M-wave I-PHYSICAL NOUN T
amplitude I-PHYSICAL NOUN F
in 0 ADP F
the 0 DET F
EDB 0 NOUN T
muscle 0 NOUN F
. 0 PUNCT F

At 0 ADP T
week 0 NOUN F
4 0 NUM F
, 0 PUNCT F
the 0 DET F
highest 0 PUNCT F
dose 0 NOUN F
was 0 VERB F
statistically 0 ADV F
significantly 0 ADV F
more 0 ADV F
effective 0 ADJ F
than 0 CCONJ F
the 0 DET F
lowest 0 PUNCT F
dose 0 NOUN F
( 0 PUNCT F
NT 0 NOUN T
201 0 NUM F
, 0 PUNCT F
P 0 NOUN T
= 0 SYM F
0.019 0 NUM F
; 0 PUNCT F
95 0 NUM F
% 0 SYM F
confidence 0 NOUN F
interval 0 NOUN F
, 0 PUNCT F
0.195-1.370 0 ADV F
; 0 PUNCT F
and 0 CCONJ F
BTXCo 0 NOUN T
, 0 PUNCT F
P 0 NOUN T
= 0 SYM F
0.002 0 NUM F
; 0 PUNCT F
95 0 NUM F
% 0 SYM F
confidence 0 NOUN F
interval 0 NOUN F
, 0 PUNCT F
0.309-1.167 0 CCONJ F
) 0 PUNCT F
. 0 PUNCT F

Duration B-OTHER NOUN T
of 0 ADP F
effect 0 NOUN F
was 0 DET F
dose 0 NOUN F
dependent 0 ADJ F
. 0 PUNCT F

The 0 DET T
mean 0 NOUN F
values 0 NOUN F
of 0 ADP F
compound B-PHYSICAL ADJ F
muscle I-PHYSICAL NOUN F
action I-PHYSICAL NOUN F
potential I-PHYSICAL ADJ F
M-wave I-PHYSICAL NOUN T
amplitudes I-PHYSICAL VERB F
in I-PHYSICAL ADP F
the I-PHYSICAL DET F
adjacent I-PHYSICAL ADJ F
muscles I-PHYSICAL NOUN F
( 0 PUNCT F
abductor 0 NOUN F
digiti 0 PUNCT F
quinti 0 PUNCT F
and 0 CCONJ F
abductor 0 NOUN F
hallucis 0 NOUN F
) 0 PUNCT F
were 0 VERB F
above 0 ADP F
the 0 DET F
predefined 0 VERB F
threshold 0 NOUN F
of 0 ADP F
effect 0 NOUN F
, 0 PUNCT F
indicating 0 VERB F
that 0 ADP F
there 0 PUNCT F
was 0 VERB F
no 0 DET F
relevant 0 ADJ F
diffusion-induced 0 VERB F
reduction 0 NOUN F
of 0 ADP F
muscle B-PHYSICAL NOUN F
activity I-PHYSICAL NOUN F
. 0 PUNCT F

NT 0 NOUN T
201 0 NUM F
and 0 CCONJ F
BTXCo 0 NOUN T
were 0 VERB F
well 0 VERB F
tolerated B-OTHER ADP F
. 0 PUNCT F

CONCLUSIONS 0 NOUN T
NT 0 NOUN T
201 0 NUM F
is 0 VERB F
effective 0 ADJ F
and 0 CCONJ F
safe 0 ADJ F
in 0 ADP F
inducing 0 VERB F
the 0 DET F
desired 0 VERB F
paretic 0 ADJ F
effect 0 NOUN F
. 0 PUNCT F

Residual 0 ADJ T
platelet 0 NOUN F
reactivity 0 NOUN F
, 0 PUNCT F
bleedings 0 ADJ F
, 0 PUNCT F
and 0 CCONJ F
adherence 0 NOUN F
to 0 ADP F
treatment 0 NOUN F
in 0 ADP F
patients 0 NOUN F
having 0 ADJ F
coronary 0 ADJ F
stent 0 NOUN F
implantation 0 NOUN F
treated 0 VERB F
with 0 ADP F
prasugrel 0 NOUN F
. 0 PUNCT F

Recent 0 ADJ T
guidelines 0 NOUN F
have 0 PUNCT F
recommended 0 VERB F
the 0 DET F
use 0 NOUN F
of 0 ADP F
aspirin 0 NOUN F
and 0 CCONJ F
prasugrel 0 NOUN F
in 0 ADP F
patients 0 NOUN F
with 0 ADP F
acute 0 ADJ F
coronary 0 ADJ F
syndromes 0 NOUN F
undergoing 0 VERB F
percutaneous 0 ADJ F
coronary 0 ADJ F
intervention 0 NOUN F
. 0 PUNCT F

However 0 ADV T
, 0 PUNCT F
prasugrel 0 NOUN F
use 0 NOUN F
has 0 VERB F
been 0 PUNCT F
evaluated 0 VERB F
only 0 ADV F
in 0 ADP F
randomized 0 VERB F
trials 0 NOUN F
. 0 PUNCT F

This 0 DET T
study 0 NOUN F
sought 0 ADP F
to 0 PART F
evaluate 0 NOUN F
bleeding B-PHYSICAL DET F
rates I-PHYSICAL NOUN F
and 0 CCONJ F
adherence 0 NOUN F
to 0 ADP F
treatment 0 NOUN F
in 0 ADP F
real-world 0 NOUN F
patients 0 NOUN F
treated 0 VERB F
with 0 ADP F
prasugrel 0 NOUN F
. 0 PUNCT F

In 0 ADP T
total 0 ADJ F
298 0 NUM F
consecutive 0 ADJ F
patients 0 NOUN F
68 0 NUM F
? 0 PUNCT F

10 0 NUM F
years 0 NOUN F
old 0 ADJ F
( 0 PUNCT F
31 0 NUM F
% 0 SYM F
> 0 SYM F
75 0 NUM F
years 0 NOUN F
old 0 ADJ F
) 0 PUNCT F
underwent 0 VERB F
stent 0 NOUN F
implantation 0 NOUN F
and 0 CCONJ F
received 0 ADJ F
prasugrel 0 NOUN F
therapy 0 NOUN F
. 0 PUNCT F

Indications 0 ADJ T
to 0 ADP F
prasugrel 0 NOUN F
therapy 0 NOUN F
were 0 VERB F
( 0 PUNCT F
1 0 NUM F
) 0 PUNCT F
ST-elevation 0 NOUN T
acute 0 ADJ F
myocardial 0 ADJ F
infarction 0 NOUN F
( 0 PUNCT F
41 0 NUM F
% 0 SYM F
) 0 PUNCT F
, 0 PUNCT F
( 0 PUNCT F
2 0 NUM F
) 0 PUNCT F
drug-eluting 0 ADJ F
stent 0 NOUN F
implantation 0 NOUN F
in 0 ADP F
diabetics 0 NOUN F
( 0 PUNCT F
24 0 NUM F
% 0 SYM F
) 0 PUNCT F
, 0 PUNCT F
( 0 PUNCT F
3 0 NUM F
) 0 PUNCT F
stent 0 NOUN F
thrombosis 0 NOUN F
( 0 PUNCT F
3 0 NUM F
% 0 SYM F
) 0 PUNCT F
, 0 PUNCT F
( 0 PUNCT F
4 0 NUM F
) 0 PUNCT F
left 0 ADJ F
main 0 ADJ F
coronary 0 ADJ F
artery 0 NOUN F
drug-eluting 0 ADP F
stent 0 NOUN F
implantation 0 NOUN F
( 0 PUNCT F
6 0 NUM F
% 0 SYM F
) 0 PUNCT F
, 0 PUNCT F
and 0 CCONJ F
( 0 PUNCT F
5 0 NUM F
) 0 PUNCT F
percutaneous 0 ADJ F
coronary 0 ADJ F
intervention 0 NOUN F
in 0 ADP F
patients 0 NOUN F
with 0 ADP F
high 0 ADJ F
residual 0 ADJ F
platelet 0 NOUN F
reactivity 0 NOUN F
on 0 ADP F
clopidogrel 0 NOUN F
therapy 0 NOUN F
( 0 PUNCT F
26 0 NUM F
% 0 SYM F
) 0 PUNCT F
. 0 PUNCT F

All 0 DET T
patients 0 NOUN F
received 0 VERB F
a 0 DET F
loading 0 VERB F
of 0 ADP F
prasugrel 0 NOUN F
60 0 NUM F
mg 0 NOUN F
. 0 PUNCT F

Patients 0 ADP T
?75 0 PUNCT F
years 0 NOUN F
old 0 ADJ F
and 0 CCONJ F
with 0 ADP F
body 0 NOUN F
weight 0 NOUN F
?60 0 NOUN F
kg 0 NOUN F
received 0 VERB F
a 0 DET F
maintenance 0 NOUN F
dose 0 NOUN F
of 0 ADP F
5 0 NUM F
mg/day 0 NOUN F
( 0 PUNCT F
10 0 NUM F
mg/day 0 NOUN F
for 0 ADP F
all 0 CCONJ F
the 0 DET F
other 0 ADJ F
patients 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

Follow-up 0 NOUN T
data 0 NOUN F
including 0 VERB F
adherence 0 NOUN F
to 0 ADP F
prasugrel 0 NOUN F
therapy 0 NOUN F
were 0 VERB F
collected 0 VERB F
by 0 ADP F
telephone 0 NOUN F
interviews 0 NOUN F
or 0 CCONJ F
outpatient 0 ADJ F
visits 0 NOUN F
. 0 PUNCT F

Minimal 0 ADJ T
follow-up 0 NOUN F
length 0 NOUN F
was 0 VERB F
6 0 NUM F
months 0 NOUN F
( 0 PUNCT F
mean 0 NOUN F
9 0 NUM F
? 0 PUNCT F

3 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Major 0 ADJ T
, 0 PUNCT F
minor 0 ADJ F
, 0 PUNCT F
and 0 CCONJ F
minimal 0 ADJ F
bleedings 0 NOUN F
( 0 PUNCT F
Thrombolysis 0 NOUN T
In 0 ADP T
Myocardial 0 ADJ T
Infarction 0 NOUN T
criteria 0 NOUN F
) 0 PUNCT F
occurred 0 VERB F
in 0 ADP F
2.7 0 NUM F
% 0 SYM F
, 0 PUNCT F
4.7 0 NUM F
% 0 SYM F
, 0 PUNCT F
and 0 CCONJ F
15.1 0 NUM F
% 0 DET F
of 0 ADP F
enrolled 0 ADP F
patients 0 NOUN F
. 0 PUNCT F

Low 0 ADJ T
residual 0 ADJ F
platelet 0 NOUN F
reactivity 0 NOUN F
( 0 PUNCT F
p 0 NOUN F
= 0 SYM F
0.001 0 NUM F
) 0 PUNCT F
and 0 CCONJ F
female 0 NOUN F
gender 0 NOUN F
( 0 PUNCT F
p 0 NOUN F
= 0 SYM F
0.29 0 NUM F
) 0 PUNCT F
were 0 VERB F
independent 0 ADJ F
predictors 0 NOUN F
of 0 ADP F
bleeding 0 VERB F
events 0 NOUN F
. 0 PUNCT F

The 0 DET T
most 0 PUNCT F
frequent 0 ADJ F
minimal 0 ADJ F
bleeding 0 VERB F
event 0 NOUN F
was 0 VERB F
epistaxis 0 NOUN F
. 0 PUNCT F

Only 0 ADV T
8 0 NUM F
patients 0 NOUN F
( 0 PUNCT F
2.7 0 NUM F
% 0 SYM F
) 0 PUNCT F
permanently 0 ADV F
discontinued 0 PUNCT F
prasugrel 0 NOUN F
therapy 0 NOUN F
because 0 PUNCT F
of 0 ADP F
bleeding 0 VERB F
events 0 NOUN F
( 0 PUNCT F
n 0 NOUN F
= 0 SYM F
4 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
possible 0 ADJ F
side 0 NOUN F
effects 0 NOUN F
( 0 PUNCT F
n 0 NOUN F
= 0 SYM F
2 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
or 0 CCONJ F
medical 0 ADJ F
decisions 0 NOUN F
not 0 ADV F
associated 0 VERB F
with 0 ADP F
bleeding 0 PUNCT F
or 0 CCONJ F
side 0 NOUN F
effects 0 NOUN F
( 0 PUNCT F
n 0 NOUN F
= 0 SYM F
2 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Fourteen 0 NUM T
patients 0 NOUN F
( 0 PUNCT F
4.7 0 NUM F
% 0 SYM F
) 0 PUNCT F
temporarily 0 PUNCT F
discontinued 0 ADP F
prasugrel 0 NOUN F
( 0 PUNCT F
average 0 NOUN F
6.5 0 NUM F
days 0 NOUN F
) 0 PUNCT F
mainly 0 ADV F
because 0 PUNCT F
of 0 ADP F
surgical 0 ADJ F
procedures 0 NOUN F
. 0 PUNCT F

No 0 DET T
definite 0 ADJ F
or 0 CCONJ F
probable 0 PUNCT F
stent 0 NOUN F
thrombosis 0 NOUN F
occurred 0 VERB F
, 0 PUNCT F
although 0 ADP F
3 0 NUM F
patients 0 NOUN F
develop 0 VERB F
de 0 PUNCT F
novo 0 ADJ F
myocardial 0 ADJ F
infarction 0 NOUN F
and 0 CCONJ F
1 0 NUM F
an 0 DET F
ischemic 0 ADJ F
stroke 0 NOUN F
. 0 PUNCT F

There 0 PUNCT T
were 0 VERB F
11 0 PUNCT F
deaths 0 NOUN F
because 0 PUNCT F
of 0 ADP F
heart 0 NOUN F
failure 0 NOUN F
or 0 CCONJ F
refractory 0 ADJ F
cardiogenic 0 ADJ F
shock 0 NOUN F
in 0 ADP F
9 0 NUM F
, 0 PUNCT F
pulmonary 0 ADJ F
embolism 0 NOUN F
in 0 ADP F
1 0 NUM F
, 0 PUNCT F
and 0 CCONJ F
cancer 0 NOUN F
in 0 ADP F
1 0 NUM F
. 0 PUNCT F

In 0 ADP T
conclusion 0 NOUN F
, 0 PUNCT F
in 0 ADP F
clinical 0 ADJ F
practice 0 NOUN F
, 0 PUNCT F
major 0 ADJ F
and 0 CCONJ F
minor 0 ADJ F
bleeding 0 VERB F
event 0 NOUN F
rates 0 NOUN F
associated 0 VERB F
with 0 ADP F
prasugrel 0 NOUN F
therapy 0 NOUN F
are 0 VERB F
comparable 0 ADJ F
to 0 ADP F
those 0 DET F
reported 0 VERB F
in 0 ADP F
controlled 0 VERB F
randomized 0 VERB F
trials 0 NOUN F
. 0 PUNCT F

The 0 DET T
minimal 0 ADJ F
bleeding 0 VERB F
event 0 NOUN F
rate 0 NOUN F
is 0 VERB F
higher 0 PUNCT F
than 0 PUNCT F
reported 0 DET F
but 0 CCONJ F
does 0 PUNCT F
not 0 ADV F
seem 0 VERB F
to 0 PART F
affect 0 NOUN F
adherence 0 NOUN F
to 0 ADP F
treatment 0 NOUN F
. 0 PUNCT F

Evaluation 0 NOUN T
of 0 ADP F
mood 0 PUNCT F
profiles 0 NOUN F
during 0 ADP F
malaria 0 NOUN F
chemoprophylaxis 0 NOUN F
: 0 PUNCT F
a 0 DET F
randomized 0 VERB F
, 0 PUNCT F
double-blind 0 ADJ F
, 0 PUNCT F
four-arm 0 NOUN F
study 0 NOUN F
. 0 PUNCT F

BACKGROUND 0 NOUN T
To 0 ADP T
objectively 0 DET F
compare 0 ADP F
the 0 DET F
mood 0 PUNCT F
profiles 0 NOUN F
of 0 ADP F
users 0 NOUN F
of 0 ADP F
malaria 0 NOUN F
chemoprophylaxis 0 NOUN F
regimens 0 NOUN F
( 0 PUNCT F
atovaquone-proguanil 0 PUNCT F
, 0 PUNCT F
chloroquine-proguanil 0 VERB F
, 0 PUNCT F
doxycycline 0 NOUN F
, 0 PUNCT F
or 0 CCONJ F
mefloquine 0 NOUN F
) 0 PUNCT F
in 0 ADP F
a 0 DET F
group 0 NOUN F
of 0 ADP F
nonimmune 0 ADP F
tourists 0 DET F
to 0 ADP F
sub-Saharan 0 NOUN F
Africa 0 PUNCT T
. 0 PUNCT F

METHODS 0 NOUN T
In 0 ADP T
a 0 DET F
randomized 0 VERB F
, 0 PUNCT F
double-blind 0 ADJ F
, 0 PUNCT F
four-arm 0 NOUN F
study 0 NOUN F
with 0 ADP F
placebo 0 NOUN F
run-in 0 NOUN F
phase 0 NOUN F
conducted 0 VERB F
at 0 ADP F
travel 0 NOUN F
clinics 0 ADP F
in 0 ADP F
Switzerland 0 ADV T
, 0 PUNCT F
Germany 0 PUNCT T
, 0 PUNCT F
and 0 CCONJ F
Israel 0 PUNCT T
, 0 PUNCT F
we 0 NOUN F
compared 0 PUNCT F
moods 0 NOUN F
and 0 CCONJ F
feelings 0 NOUN F
in 0 ADP F
chemoprophylaxis 0 NOUN F
users 0 NOUN F
( 0 PUNCT F
n= 0 NUM F
547 0 NUM F
) 0 PUNCT F
by 0 ADP F
administering 0 NOUN F
the 0 DET F
standardized 0 VERB F
Profile 0 NOUN T
of 0 ADP F
Mood 0 PUNCT T
States 0 NOUN T
( 0 PUNCT F
POMS 0 NOUN T
) 0 PUNCT F
questionnaire 0 NOUN F
. 0 PUNCT F

This 0 PUNCT T
is 0 VERB F
designed 0 VERB F
to 0 PART F
provide 0 NOUN F
data 0 NOUN F
on 0 ADP F
six 0 NUM F
categories 0 NOUN F
of 0 ADP F
feelings 0 NOUN F
: 0 PUNCT F
tension 0 NOUN F
, 0 PUNCT F
depression 0 NOUN F
, 0 PUNCT F
anger 0 NOUN F
, 0 PUNCT F
vigor 0 NOUN F
, 0 PUNCT F
fatigue 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
confusion 0 NOUN F
. 0 PUNCT F

The 0 DET T
questionnaire 0 NOUN F
was 0 VERB F
administered 0 VERB F
at 0 ADP F
four 0 NUM F
time 0 NOUN F
points 0 NOUN F
: 0 PUNCT F
recruitment 0 NOUN F
( 0 PUNCT F
T1 0 NOUN T
) 0 PUNCT F
, 0 PUNCT F
13 0 NUM F
to 0 ADP F
11 0 NUM F
days 0 NOUN F
before 0 ADP F
departure 0 NOUN F
( 0 PUNCT F
T2 0 NOUN T
) 0 PUNCT F
, 0 PUNCT F
6 0 NUM F
to 0 ADP F
4 0 NUM F
days 0 NOUN F
before 0 ADP F
departure 0 NOUN F
( 0 PUNCT F
T3 0 NOUN T
) 0 PUNCT F
, 0 PUNCT F
and 0 CCONJ F
7 0 NUM F
to 0 ADP F
14 0 NUM F
days 0 NOUN F
after 0 ADP F
return 0 NOUN F
from 0 ADP F
Africa 0 ADV T
( 0 PUNCT F
T4 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

RESULTS 0 NOUN T
There 0 CCONJ T
were 0 VERB F
no 0 DET F
significant 0 ADJ F
differences 0 NOUN F
with 0 ADP F
respect 0 NOUN F
to 0 ADP F
overall 0 PUNCT F
mood B-MENTAL PUNCT F
impact 0 NOUN F
between 0 ADP F
the 0 DET F
medication 0 NOUN F
arms 0 NOUN F
. 0 PUNCT F

All 0 DET T
scores 0 NOUN F
were 0 VERB F
in 0 ADP F
the 0 DET F
normal 0 ADJ F
range 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
no 0 DET F
means 0 NOUN F
were 0 VERB F
more 0 ADV F
than 0 PUNCT F
1 0 NUM F
SD 0 NOUN T
from 0 ADP F
the 0 DET F
norm 0 NOUN F
. 0 PUNCT F

The 0 DET T
POMS 0 NOUN T
data 0 NOUN F
were 0 VERB F
reanalyzed 0 VERB F
with 0 ADP F
respect 0 NOUN F
to 0 ADP F
sex 0 NOUN F
, 0 PUNCT F
age 0 NOUN F
, 0 PUNCT F
medication 0 NOUN F
group 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
control 0 NUM F
time 0 NOUN F
points 0 NOUN F
( 0 PUNCT F
T1-T4 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

There 0 PUNCT T
were 0 VERB F
significant 0 ADJ F
interaction 0 NOUN F
effects 0 NOUN F
between 0 ADP F
sex 0 NOUN F
and 0 CCONJ F
medication 0 NOUN F
group 0 NOUN F
-- 0 PUNCT F
women 0 NOUN F
in 0 ADP F
the 0 DET F
mefloquine 0 NOUN F
group 0 NOUN F
showed 0 VERB F
more 0 DET F
fatigue B-MENTAL NOUN F
( 0 PUNCT F
p= 0 NOUN F
.011 0 NUM F
) 0 PUNCT F
and 0 CCONJ F
confusion B-MENTAL NOUN F
( 0 PUNCT F
p= 0 NOUN F
.011 0 NUM F
) 0 PUNCT F
than 0 PUNCT F
men 0 NOUN F
. 0 PUNCT F

Significant 0 ADJ T
effects 0 NOUN F
of 0 ADP F
age 0 NOUN F
group 0 NOUN F
( 0 PUNCT F
below 0 ADP F
median 0 ADJ F
age 0 NOUN F
34 0 NUM F
y 0 NOUN F
vs 0 CCONJ F
median 0 ADJ F
age 0 NOUN F
and 0 CCONJ F
above 0 ADP F
) 0 PUNCT F
were 0 VERB F
noted 0 VERB F
on 0 ADP F
the 0 DET F
tension B-MENTAL NOUN F
and 0 CCONJ F
fatigue B-MENTAL NOUN F
scales 0 NOUN F
in 0 ADP F
that 0 CCONJ F
less 0 DET F
tension B-MENTAL NOUN F
( 0 PUNCT F
p= 0 NOUN F
.045 0 PUNCT F
) 0 PUNCT F
and 0 CCONJ F
less 0 DET F
fatigue B-MENTAL NOUN F
( 0 PUNCT F
p= 0 NOUN F
.000 0 NUM F
) 0 PUNCT F
were 0 VERB F
noted 0 VERB F
in 0 ADP F
those 0 PUNCT F
aged 0 PUNCT F
34 0 NUM F
years 0 NOUN F
and 0 CCONJ F
older 0 PUNCT F
. 0 PUNCT F

Younger 0 PUNCT T
participants 0 NOUN F
, 0 PUNCT F
aged 0 PUNCT F
< 0 ADP F
34 0 NUM F
years 0 NOUN F
, 0 PUNCT F
reported 0 VERB F
more 0 DET F
confusion B-MENTAL NOUN F
( 0 PUNCT F
p= 0 NOUN F
.013 0 NUM F
) 0 PUNCT F
at 0 ADP F
T2 0 NOUN T
than 0 PUNCT F
at 0 ADP F
T1 0 NOUN T
and 0 CCONJ F
T4 0 NOUN T
. 0 PUNCT F

CONCLUSIONS 0 NOUN T
Although 0 ADP T
the 0 DET F
overall 0 ADJ F
mood 0 PUNCT F
profiles 0 NOUN F
were 0 VERB F
similar 0 ADJ F
for 0 ADP F
the 0 DET F
users 0 NOUN F
of 0 ADP F
any 0 PUNCT F
of 0 ADP F
the 0 DET F
standard 0 ADJ F
malaria 0 NOUN F
chemoprophylaxis 0 NOUN F
regimens 0 NOUN F
, 0 PUNCT F
we 0 PRON F
found 0 VERB F
that 0 ADP F
women 0 NOUN F
using 0 VERB F
mefloquine 0 NOUN F
showed 0 VERB F
more 0 DET F
fatigue 0 NOUN F
and 0 CCONJ F
confusion 0 NOUN F
than 0 ADP F
men 0 NOUN F
and 0 CCONJ F
that 0 PUNCT F
younger 0 PUNCT F
persons 0 NOUN F
aged 0 ADV F
less 0 ADV F
than 0 ADP F
34 0 NUM F
years 0 NOUN F
, 0 PUNCT F
regardless 0 CCONJ F
of 0 ADP F
chemoprophylaxis 0 NOUN F
used 0 VERB F
, 0 PUNCT F
reported 0 VERB F
more 0 DET F
tension 0 NOUN F
and 0 CCONJ F
fatigue 0 NOUN F
than 0 ADP F
their 0 PUNCT F
older 0 PUNCT F
counterparts 0 NOUN F
. 0 PUNCT F

Gabapentin 0 NOUN T
for 0 ADP F
the 0 DET F
prevention 0 NOUN F
of 0 ADP F
postoperative B-PAIN ADJ F
pain I-PAIN NOUN F
after 0 ADP F
vaginal 0 ADJ F
hysterectomy 0 NOUN F
. 0 PUNCT F

Gabapentin 0 NOUN T
alleviates 0 NOUN F
and/or 0 CCONJ F
prevents 0 NOUN F
acute B-PAIN ADJ F
nociceptive I-PAIN ADJ F
and I-PAIN CCONJ F
inflammatory I-PAIN ADJ F
pain I-PAIN NOUN F
both 0 PUNCT F
in 0 ADP F
animals 0 NOUN F
and 0 CCONJ F
volunteers 0 NOUN F
, 0 PUNCT F
especially 0 ADV F
when 0 ADP F
given 0 VERB F
before 0 ADP F
trauma 0 NOUN F
. 0 PUNCT F

Gabapentin 0 NOUN T
might 0 VERB F
also 0 ADV F
reduce 0 VERB F
postoperative B-PAIN ADJ F
pain I-PAIN NOUN F
. 0 PUNCT F

To 0 PART T
test 0 VERB F
the 0 DET F
hypothesis 0 NOUN F
that 0 ADP F
gabapentin 0 NOUN F
reduces 0 NOUN F
the 0 DET F
postoperative B-PHYSICAL ADJ F
need I-PHYSICAL NOUN F
for I-PHYSICAL ADP F
additional I-PHYSICAL ADJ F
pain I-PHYSICAL NOUN F
treatment I-PHYSICAL NOUN F
( 0 PUNCT F
postoperative 0 ADJ F
opioid 0 NOUN F
sparing 0 PUNCT F
effect 0 NOUN F
of 0 ADP F
gabapentin 0 NOUN F
in 0 ADP F
humans 0 NOUN F
) 0 PUNCT F
, 0 PUNCT F
we 0 PRON F
gave 0 PROPN F
1200 0 NUM F
mg 0 NOUN F
of 0 ADP F
gabapentin 0 NOUN F
or 0 CCONJ F
15 0 NUM F
mg 0 NOUN F
of 0 ADP F
oxazepam 0 NOUN F
( 0 PUNCT F
active 0 ADJ F
placebo 0 NOUN F
) 0 PUNCT F
2.5 0 NUM F
h 0 NOUN F
prior 0 PUNCT F
to 0 ADP F
induction 0 NOUN F
of 0 ADP F
anaesthesia 0 NOUN F
to 0 ADP F
patients 0 NOUN F
undergoing 0 SYM F
elective 0 ADJ F
vaginal 0 ADJ F
hysterectomy 0 NOUN F
in 0 ADP F
an 0 DET F
active 0 ADJ F
placebo-controlled 0 VERB F
, 0 PUNCT F
double 0 ADJ F
blind 0 ADJ F
, 0 PUNCT F
randomised 0 ADP F
study 0 NOUN F
. 0 PUNCT F

Gabapentin 0 NOUN T
reduced 0 VERB F
the 0 DET F
need 0 NOUN F
for 0 ADP F
additional 0 ADJ F
postoperative B-PAIN ADJ F
pain I-PAIN NOUN F
treatment I-PAIN NOUN F
( 0 PUNCT F
PCA 0 NOUN T
boluses 0 NOUN F
of 0 ADP F
50 0 NUM F
microg 0 NOUN F
of 0 ADP F
fentanyl 0 NOUN F
) 0 PUNCT F
by 0 ADP F
40 0 NUM F
% 0 SYM F
during 0 ADP F
the 0 DET F
first 0 ADJ F
20 0 NUM F
postoperative 0 ADJ F
hours 0 NOUN F
. 0 PUNCT F

During 0 ADP T
the 0 DET F
first 0 ADJ F
2 0 NUM F
postoperative 0 ADJ F
hours 0 NOUN F
pain 0 NOUN F
scores 0 NOUN F
at 0 ADP F
rest 0 NOUN F
and 0 CCONJ F
worst B-PAIN PUNCT F
pain I-PAIN NOUN F
score I-PAIN NOUN F
( 0 PUNCT F
VAS 0 NOUN T
0-100 0 NUM F
mm 0 NOUN F
) 0 PUNCT F
were 0 VERB F
significantly 0 ADV F
higher 0 PUNCT F
in 0 ADP F
the 0 DET F
active 0 ADJ F
placebo 0 NOUN F
group 0 NOUN F
compared 0 VERB F
to 0 ADP F
the 0 DET F
gabapentin-treated 0 VERB F
patients 0 NOUN F
. 0 PUNCT F

Additionally 0 ADV T
, 0 PUNCT F
pretreatment 0 NOUN F
with 0 ADP F
gabapentin 0 NOUN F
reduced 0 VERB F
the 0 DET F
degree B-PHYSICAL NOUN F
of I-PHYSICAL ADP F
postoperative I-PHYSICAL ADJ F
nausea B-ADVERSE-EFFECTS NOUN F
and 0 CCONJ F
incidence 0 NOUN F
of B-ADVERSE-EFFECTS ADP F
vomiting/retching I-ADVERSE-EFFECTS PUNCT F
possibly 0 ADV F
either 0 PUNCT F
due 0 ADP F
to 0 ADP F
the 0 DET F
diminished 0 VERB F
need 0 NOUN F
for 0 ADP F
postoperative B-PAIN ADJ F
pain I-PAIN NOUN F
treatment 0 NOUN F
with 0 ADP F
opioids 0 NOUN F
or 0 CCONJ F
because 0 PUNCT F
of 0 ADP F
an 0 DET F
anti-emetic 0 ADJ F
effect 0 NOUN F
of 0 ADP F
gabapentin 0 NOUN F
itself 0 ADV F
. 0 PUNCT F

No 0 DET T
preoperative 0 ADJ F
differences 0 NOUN F
between 0 ADP F
the 0 DET F
two 0 NUM F
groups 0 NOUN F
were 0 VERB F
encountered 0 VERB F
with 0 ADP F
respect 0 NOUN F
to 0 ADP F
the 0 DET F
side 0 NOUN F
effects 0 NOUN F
of 0 ADP F
the 0 DET F
premedication 0 NOUN F
. 0 PUNCT F

However 0 ADV T
, 0 PUNCT F
15 0 NUM F
mg 0 NOUN F
oxazepam 0 NOUN F
was 0 VERB F
more 0 ADV F
effective 0 ADP F
in 0 ADP F
relieving 0 NUM F
preoperative B-PHYSICAL ADJ F
anxiety I-PHYSICAL NOUN F
than 0 PUNCT F
1200 0 NUM F
mg 0 NOUN F
gabapentin 0 NOUN F
. 0 PUNCT F

Influenza 0 NOUN T
and 0 CCONJ F
pneumococcal 0 ADJ F
vaccination 0 NOUN F
as 0 ADP F
a 0 DET F
model 0 NOUN F
to 0 PART F
assess 0 NOUN F
C-reactive 0 ADJ T
protein 0 NOUN F
response 0 NOUN F
to 0 ADP F
mild 0 ADJ F
inflammation 0 NOUN F
. 0 PUNCT F

This 0 DET T
study 0 NOUN F
was 0 ADP F
set 0 ADP F
up 0 ADJ F
to 0 ADP F
examine 0 NOUN F
whether 0 ADP F
an 0 DET F
influenza 0 NOUN F
vaccine 0 NOUN F
or 0 CCONJ F
an 0 DET F
influenza 0 NOUN F
vaccine 0 NOUN F
in 0 ADP F
combination 0 NOUN F
with 0 ADP F
pneumococcal 0 ADJ F
vaccine 0 NOUN F
can 0 VERB F
be 0 VERB F
used 0 VERB F
as 0 ADP F
a 0 DET F
model 0 NOUN F
to 0 ADJ F
study 0 NOUN F
responses 0 NOUN F
to 0 ADP F
mild 0 ADJ F
stimulation 0 NOUN F
of 0 ADP F
the 0 DET F
inflammatory 0 ADJ F
system 0 NOUN F
. 0 PUNCT F

In 0 ADP T
this 0 DET F
study 0 NOUN F
, 0 PUNCT F
19 0 NUM F
subjects 0 NOUN F
received 0 VERB F
the 0 DET F
influenza 0 NOUN F
vaccine 0 NOUN F
, 0 PUNCT F
20 0 NUM F
subjects 0 NOUN F
the 0 DET F
combination 0 NOUN F
of 0 ADP F
influenza 0 NOUN F
and 0 CCONJ F
pneumococcal 0 ADJ F
vaccine 0 NOUN F
. 0 PUNCT F

CRP B-PHYSICAL NOUN T
and 0 CCONJ F
prothrombin B-PHYSICAL NOUN F
fragment I-PHYSICAL NOUN F
1 I-PHYSICAL NUM F
and I-PHYSICAL CCONJ F
2 I-PHYSICAL NUM F
( 0 PUNCT F
F1+2 B-PHYSICAL NOUN T
) 0 PUNCT F
were 0 VERB F
measured 0 VERB F
at 0 ADP F
baseline 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
two 0 NUM F
times 0 NOUN F
after 0 ADP F
vaccination 0 NOUN F
. 0 PUNCT F

Influenza 0 NOUN T
vaccination 0 NOUN F
increased 0 VERB F
CRP B-PHYSICAL NOUN T
by 0 ADP F
0.20 0 NUM F
mg/L 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
influenza 0 NOUN F
in 0 ADP F
combination 0 NOUN F
with 0 ADP F
pneumococcal 0 ADJ F
vaccine 0 NOUN F
increased 0 PUNCT F
CRP B-PHYSICAL NOUN T
by 0 ADP F
0.60 0 NUM F
mg/L 0 NOUN F
. 0 PUNCT F

F1+2 B-PHYSICAL NOUN T
increased 0 VERB F
0.15 0 NUM F
nmol/L 0 ADP F
after 0 ADP F
the 0 DET F
combined 0 VERB F
vaccination 0 NOUN F
; 0 PUNCT F
an 0 DET F
increase 0 NOUN F
in 0 ADP F
response 0 NOUN F
to 0 ADP F
the 0 DET F
influenza B-PHYSICAL NOUN F
vaccination I-PHYSICAL NOUN F
was 0 VERB F
not 0 ADV F
statistically 0 ADV F
significant 0 ADJ F
. 0 PUNCT F

Our 0 DET T
findings 0 NOUN F
show 0 VERB F
that 0 ADP F
the 0 DET F
influenza 0 NOUN F
vaccine 0 NOUN F
alone 0 ADJ F
as 0 PUNCT F
well 0 PUNCT F
as 0 CCONJ F
the 0 DET F
combination 0 NOUN F
of 0 ADP F
the 0 DET F
influenza 0 NOUN F
and 0 CCONJ F
pneumococcal 0 ADJ F
vaccine 0 NOUN F
increases 0 PUNCT F
CRP-levels B-PHYSICAL CCONJ T
with 0 ADP F
a 0 DET F
peak 0 ADJ F
2 0 NUM F
days 0 NOUN F
after 0 ADP F
vaccination 0 NOUN F
. 0 PUNCT F

Superior 0 ADJ T
efficacy 0 NOUN F
of 0 ADP F
clopidogrel 0 NOUN F
plus 0 CCONJ F
acetylsalicylic 0 ADJ F
acid 0 NOUN F
compared 0 VERB F
with 0 ADP F
extended-release 0 NOUN F
dipyridamole 0 NOUN F
plus 0 CCONJ F
acetylsalicylic 0 ADJ F
acid 0 NOUN F
in 0 ADP F
preventing 0 VERB F
arterial 0 ADJ F
thrombogenesis 0 NOUN F
in 0 ADP F
healthy 0 ADJ F
volunteers 0 NOUN F
. 0 PUNCT F

INTRODUCTION 0 NOUN T
Recent 0 ADJ T
ex 0 ADP F
vivo 0 ADP F
platelet 0 NOUN F
aggregometry 0 NOUN F
data 0 NOUN F
indicate 0 VERB F
that 0 ADP F
clopidogrel 0 NOUN F
75 0 NUM F
mg/day 0 NOUN F
plus 0 CCONJ F
acetylsalicylic 0 ADJ F
acid 0 NOUN F
( 0 PUNCT F
ASA 0 NOUN T
) 0 PUNCT F
75 0 NUM F
mg/day 0 NOUN F
is 0 VERB F
a 0 DET F
more 0 ADV F
potent 0 ADJ F
antiplatelet 0 NOUN F
regimen 0 NOUN F
than 0 PUNCT F
the 0 DET F
marketed 0 VERB F
combination 0 NOUN F
of 0 ADP F
dipyridamole+ASA 0 NOUN F
. 0 PUNCT F

The 0 DET T
present 0 ADJ F
study 0 NOUN F
was 0 VERB F
designed 0 VERB F
to 0 PART F
assess 0 NOUN F
the 0 DET F
antithrombotic 0 ADJ F
effect 0 NOUN F
of 0 ADP F
both 0 CCONJ F
dual 0 ADJ F
antiplatelet 0 NOUN F
regimens 0 NOUN F
using 0 VERB F
a 0 DET F
human 0 NOUN F
ex 0 ADP F
vivo 0 ADJ F
model 0 NOUN F
of 0 ADP F
arterial 0 ADJ F
thrombosis 0 NOUN F
. 0 PUNCT F

MATERIALS 0 NOUN T
AND 0 CCONJ T
METHODS 0 NOUN T
This 0 PUNCT T
was 0 VERB F
a 0 DET F
randomized 0 VERB F
, 0 PUNCT F
double-blind 0 ADJ F
, 0 PUNCT F
placebo-controlled 0 VERB F
, 0 PUNCT F
crossover 0 ADP F
study 0 NOUN F
. 0 PUNCT F

During 0 ADP T
two 0 NUM F
10-day 0 NOUN F
treatment 0 NOUN F
periods 0 NOUN F
separated 0 VERB F
by 0 ADP F
a 0 DET F
14-day 0 NOUN F
washout 0 PUNCT F
period 0 NOUN F
, 0 PUNCT F
23 0 NUM F
healthy 0 ADJ F
male 0 NOUN F
volunteers 0 NOUN F
received 0 VERB F
once-daily 0 NOUN F
clopidogrel 0 NOUN F
75 0 NUM F
mg 0 NOUN F
plus 0 CCONJ F
acetylsalicylic 0 ADJ F
acid 0 NOUN F
75 0 NUM F
mg 0 NOUN F
, 0 PUNCT F
or 0 CCONJ F
twice-daily 0 PUNCT F
extended-release 0 NOUN F
dipyridamole 0 NOUN F
200 0 PUNCT F
mg 0 NOUN F
plus 0 CCONJ F
acetylsalicylic 0 ADJ F
acid 0 NOUN F
25 0 NUM F
mg 0 NOUN F
. 0 PUNCT F

Assessments 0 NOUN T
were 0 VERB F
made 0 VERB F
at 0 ADP F
baseline 0 NOUN F
and 0 CCONJ F
on 0 ADP F
Day 0 NOUN T
10 0 NUM F
of 0 ADP F
each 0 DET F
period 0 NOUN F
. 0 PUNCT F

Arterial 0 ADJ T
thrombus 0 NOUN F
formation 0 NOUN F
was 0 VERB F
induced 0 PUNCT F
ex 0 CCONJ F
vivo 0 ADJ F
by 0 ADP F
exposing 0 VERB F
a 0 DET F
collagen-coated 0 VERB F
surface 0 NOUN F
in 0 ADP F
a 0 DET F
parallel-plate 0 CCONJ F
perfusion 0 NOUN F
chamber 0 NOUN F
to 0 ADP F
native 0 ADJ F
blood 0 NOUN F
for 0 ADP F
3 0 NUM F
min 0 NOUN F
( 0 PUNCT F
arterial 0 ADJ F
wall 0 NOUN F
shear 0 NOUN F
rate 0 NOUN F
2600 0 NUM F
s 0 NOUN F
( 0 PUNCT F
-1 0 NUM F
) 0 PUNCT F
) 0 PUNCT F
. 0 PUNCT F

Total 0 ADJ T
platelet B-PHYSICAL NOUN F
and 0 CCONJ F
fibrin B-PHYSICAL NOUN F
deposition I-PHYSICAL NOUN F
was 0 VERB F
determined 0 VERB F
by 0 ADP F
immunoenzymatic 0 ADJ F
methods 0 NOUN F
. 0 PUNCT F

RESULTS 0 NOUN T
Compared 0 VERB T
with 0 ADP F
baseline 0 NOUN F
values 0 NOUN F
, 0 PUNCT F
the 0 DET F
mean 0 NOUN F
inhibition 0 NOUN F
of 0 ADP F
total 0 ADJ F
platelet B-PHYSICAL NOUN F
deposition I-PHYSICAL NOUN F
was 0 VERB F
63.9+/-5.9 0 NOUN F
% 0 ADP F
with 0 ADP F
clopidogrel 0 NOUN F
plus 0 CCONJ F
acetylsalicylic 0 ADJ F
acid 0 NOUN F
, 0 PUNCT F
compared 0 VERB F
with 0 ADP F
18.4+/-5.6 0 NOUN F
% 0 SYM F
for 0 ADP F
extended-release 0 NOUN F
dipyridamole 0 NOUN F
plus 0 CCONJ F
acetylsalicylic 0 ADJ F
acid 0 NOUN F
( 0 PUNCT F
67 0 NUM F
% 0 SYM F
reduction 0 NOUN F
; 0 PUNCT F
95 0 NUM F
% 0 SYM F
CI 0 NOUN T
, 0 PUNCT F
49-79 0 NUM F
% 0 SYM F
; 0 PUNCT F
p 0 NOUN F
< 0 SYM F
0.0001 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Corresponding 0 VERB T
figures 0 NOUN F
for 0 ADP F
fibrin B-PHYSICAL NOUN F
deposition I-PHYSICAL NOUN F
were 0 VERB F
64.9+/-4.8 0 NOUN F
% 0 SYM F
and 0 CCONJ F
18.3+/-9.7 0 NOUN F
% 0 SYM F
, 0 PUNCT F
respectively 0 ADV F
( 0 PUNCT F
58 0 NUM F
% 0 SYM F
reduction 0 NOUN F
; 0 PUNCT F
95 0 NUM F
% 0 SYM F
CI 0 NOUN T
, 0 PUNCT F
45-67 0 NUM F
% 0 ADV F
; 0 PUNCT F
p 0 NOUN F
< 0 SYM F
0.0001 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Both 0 CCONJ T
treatments 0 NOUN F
were 0 VERB F
well 0 VERB F
tolerated B-OTHER ADP F
. 0 PUNCT F

CONCLUSIONS 0 NOUN T
Clopidogrel 0 NOUN T
plus 0 CCONJ F
acetylsalicylic 0 ADJ F
acid 0 NOUN F
showed 0 VERB F
significantly 0 ADV F
superior 0 ADJ F
antithrombotic 0 ADJ F
efficacy 0 NOUN F
compared 0 VERB F
with 0 ADP F
extended-release 0 NOUN F
dipyridamole 0 NOUN F
plus 0 CCONJ F
acetylsalicylic 0 ADJ F
acid 0 NOUN F
in 0 ADP F
preventing 0 VERB F
arterial 0 ADJ F
thrombogenesis 0 NOUN F
in 0 ADP F
humans 0 NOUN F
. 0 PUNCT F

West 0 ADV T
Midlands 0 PROPN T
Oncology 0 NOUN T
Association 0 NOUN T
trials 0 NOUN F
of 0 ADP F
adjuvant 0 NOUN F
chemotherapy 0 NOUN F
in 0 ADP F
operable 0 ADJ F
breast 0 NOUN F
cancer 0 NOUN F
: 0 PUNCT F
results 0 DET F
after 0 ADP F
a 0 DET F
median 0 ADJ F
follow-up 0 NOUN F
of 0 ADP F
7 0 NUM F
years 0 NOUN F
. 0 PUNCT F

I 0 NUM T
. 0 PUNCT F

Patients 0 NOUN T
with 0 ADP F
involved 0 PUNCT F
axillary 0 ADJ F
lymph 0 NOUN F
nodes 0 NOUN F
. 0 PUNCT F

The 0 DET T
aim 0 NOUN F
of 0 ADP F
this 0 DET F
study 0 NOUN F
was 0 VERB F
to 0 ADV F
test 0 VERB F
the 0 DET F
effectiveness 0 NOUN F
of 0 ADP F
a 0 DET F
regimen 0 NOUN F
of 0 ADP F
combination 0 NOUN F
chemotherapy 0 NOUN F
known 0 VERB F
to 0 PART F
be 0 PUNCT F
active 0 ADJ F
in 0 ADP F
advanced 0 VERB F
breast 0 NOUN F
cancer 0 NOUN F
when 0 ADP F
given 0 VERB F
as 0 ADP F
an 0 DET F
adjuvant 0 NOUN F
treatment 0 NOUN F
after 0 ADP F
mastectomy 0 NOUN F
. 0 PUNCT F

A 0 DET T
total 0 NOUN F
of 0 ADP F
569 0 NUM F
patients 0 NOUN F
with 0 ADP F
cancer 0 NOUN F
of 0 ADP F
the 0 DET F
breast 0 NOUN F
and 0 CCONJ F
involvement 0 NOUN F
of 0 ADP F
axillary 0 ADJ F
lymph 0 NOUN F
nodes 0 NOUN F
were 0 VERB F
randomised 0 NUM F
, 0 PUNCT F
after 0 ADP F
simple 0 ADJ F
mastectomy 0 NOUN F
with 0 ADP F
axillary 0 ADJ F
sampling 0 VERB F
, 0 PUNCT F
to 0 PART F
receive 0 NOUN F
either 0 PUNCT F
no 0 DET F
adjuvant 0 NOUN F
treatment 0 NOUN F
or 0 CCONJ F
intravenous 0 ADJ F
adriamycin 0 NOUN F
50 0 NUM F
mg 0 NOUN F
, 0 PUNCT F
vincristine 0 NOUN F
1 0 NUM F
mg 0 NOUN F
, 0 PUNCT F
cyclophosphamide 0 NOUN F
250 0 NUM F
mg 0 NOUN F
, 0 PUNCT F
methotrexate 0 PUNCT F
150 0 NUM F
mg 0 NOUN F
and 0 CCONJ F
fluorouracil 0 NOUN F
250 0 NUM F
mg 0 NOUN F
( 0 PUNCT F
AVCMF 0 NOUN T
) 0 PUNCT F
every 0 DET F
21 0 NUM F
days 0 NOUN F
for 0 ADP F
eight 0 NUM F
cycles 0 NOUN F
. 0 PUNCT F

Randomisation 0 NOUN T
was 0 VERB F
stratified 0 VERB F
according 0 ADP F
to 0 ADP F
menopausal 0 ADJ F
status 0 NOUN F
and 0 CCONJ F
tumour 0 NOUN F
size 0 NOUN F
. 0 PUNCT F

Treatment 0 NOUN T
was 0 VERB F
started 0 VERB F
within 0 ADP F
14 0 NUM F
days 0 NOUN F
of 0 ADP F
surgery 0 NOUN F
in 0 ADP F
94 0 NUM F
% 0 SYM F
of 0 ADP F
patients 0 NOUN F
. 0 PUNCT F

Eighty-eight 0 PUNCT T
per 0 ADP F
cent 0 NUM F
of 0 ADP F
patients 0 NOUN F
received 0 VERB F
at 0 ADP F
least 0 ADV F
seven 0 NUM F
cycles 0 NOUN F
of 0 ADP F
chemotherapy 0 NOUN F
with 0 ADP F
no 0 DET F
dose 0 NOUN F
reduction 0 NOUN F
. 0 PUNCT F

The 0 DET T
median 0 ADJ F
relapse-free B-MORTALITY PUNCT F
survival I-MORTALITY NOUN F
was 0 VERB F
prolonged 0 VERB F
by 0 ADP F
14 0 NUM F
months 0 NOUN F
in 0 ADP F
patients 0 NOUN F
treated 0 VERB F
with 0 ADP F
AVCMF 0 NOUN T
( 0 PUNCT F
chi2 0 NOUN F
1 0 NUM F
= 0 SYM F
11.7 0 NUM F
; 0 PUNCT F
P 0 NOUN T
= 0 SYM F
0.0006 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

In 0 ADP T
the 0 DET F
premenopausal 0 ADJ F
group 0 NOUN F
this 0 PUNCT F
period 0 NOUN F
was 0 VERB F
17 0 NUM F
months 0 NOUN F
( 0 PUNCT F
chi2 0 NOUN F
1 0 NUM F
= 0 SYM F
8.8 0 NUM F
; 0 PUNCT F
P 0 NOUN T
= 0 SYM F
0.003 0 NUM F
) 0 PUNCT F
compared 0 VERB F
with 0 ADP F
8 0 NUM F
months 0 NOUN F
in 0 ADP F
the 0 DET F
post-menopausal 0 ADJ F
group 0 NOUN F
( 0 PUNCT F
chi2 0 NOUN F
1 0 NUM F
= 0 SYM F
3.3 0 NUM F
; 0 PUNCT F
P 0 NOUN T
= 0 SYM F
0.07 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Neither 0 CCONJ T
overall B-MORTALITY ADJ F
survival I-MORTALITY NOUN F
nor I-MORTALITY CCONJ F
survival I-MORTALITY NOUN F
in 0 ADP F
these 0 DET F
subgroups 0 NOUN F
was 0 NUM F
significantly 0 ADV F
influenced 0 VERB F
by 0 ADP F
treatment 0 NOUN F
. 0 PUNCT F

[ 0 PUNCT F
Study 0 NOUN T
on 0 ADP F
classification 0 NOUN F
and 0 CCONJ F
treatment 0 NOUN F
of 0 ADP F
vulvovaginal 0 ADJ F
candidiasis 0 NOUN F
] 0 PUNCT F
. 0 PUNCT F

OBJECTIVE 0 NOUN T
To 0 PROPN T
determine 0 NOUN F
the 0 DET F
clinical 0 ADJ F
manifestations 0 NOUN F
of 0 ADP F
vulvovaginal 0 ADJ F
candidiasis 0 NOUN F
( 0 PUNCT F
VVC 0 NOUN T
) 0 PUNCT F
and 0 CCONJ F
to 0 PART F
study 0 NOUN F
the 0 DET F
mycologic B-PHYSICAL ADJ F
eradication I-PHYSICAL NOUN F
rate I-PHYSICAL NOUN F
of 0 ADP F
different 0 ADJ F
miconazole 0 NOUN F
treatment 0 NOUN F
courses 0 ADP F
for 0 ADP F
VVC 0 NOUN T
. 0 PUNCT F

METHODS 0 NOUN T
Three 0 NUM T
hundred 0 NUM F
cases 0 NOUN F
of 0 ADP F
VVC 0 NOUN T
were 0 VERB F
recruited 0 VERB F
. 0 PUNCT F

The 0 DET T
Candidas 0 NOUN T
were 0 VERB F
cultured 0 VERB F
. 0 PUNCT F

A 0 DET T
prospective 0 ADJ F
and 0 CCONJ F
randomized 0 VERB F
study 0 NOUN F
was 0 VERB F
performed 0 VERB F
to 0 PART F
compare 0 NOUN F
the 0 DET F
treatment 0 NOUN F
effect 0 NOUN F
of 0 ADP F
3 0 NUM F
day 0 NOUN F
miconazole 0 NOUN F
( 0 PUNCT F
400 0 NUM F
mg/d 0 NOUN F
) 0 PUNCT F
, 0 PUNCT F
6 0 NUM F
day 0 NOUN F
miconazole 0 NOUN F
( 0 PUNCT F
400 0 NUM F
mg/d 0 NOUN F
) 0 PUNCT F
, 0 PUNCT F
and 0 CCONJ F
7 0 NUM F
day 0 NOUN F
miconazole 0 NOUN F
( 0 PUNCT F
200 0 NUM F
mg/d 0 NOUN F
) 0 PUNCT F
for 0 ADP F
uncomplicated 0 VERB F
and 0 CCONJ F
complicated 0 PUNCT F
VVC 0 NOUN T
. 0 PUNCT F

RESULTS 0 NOUN T
Among 0 ADP T
300 0 NUM F
cases 0 NOUN F
of 0 ADP F
VVC 0 NOUN T
, 0 PUNCT F
uncomplicated 0 VERB F
, 0 PUNCT F
complicated 0 ADP F
and 0 CCONJ F
recurrent 0 ADJ F
VVC 0 NOUN T
were 0 VERB F
56.0 0 NUM F
% 0 SYM F
, 0 PUNCT F
44.0 0 NUM F
% 0 SYM F
and 0 CCONJ F
9.7 0 NUM F
% 0 SYM F
( 0 PUNCT F
29/300 0 NOUN F
) 0 PUNCT F
respectively 0 ADV F
. 0 PUNCT F

C. 0 NOUN T
albicans 0 NOUN F
was 0 VERB F
isolated 0 VERB F
most 0 PUNCT F
frequently 0 ADV F
90.3 0 NUM F
% 0 SYM F
( 0 PUNCT F
271/300 0 NOUN F
) 0 PUNCT F
, 0 PUNCT F
followed 0 VERB F
by 0 ADP F
C. 0 NOUN T
glabrata 0 ADJ F
( 0 PUNCT F
7.3 0 NUM F
% 0 SYM F
) 0 PUNCT F
, 0 PUNCT F
C. 0 NOUN T
tropicalis 0 NOUN F
( 0 PUNCT F
1.3 0 NUM F
% 0 SYM F
) 0 PUNCT F
, 0 PUNCT F
C. 0 NOUN T
krusei 0 NOUN F
( 0 PUNCT F
0.7 0 NUM F
% 0 SYM F
) 0 PUNCT F
, 0 PUNCT F
and 0 CCONJ F
C. 0 NOUN T
parapsilosis 0 NOUN F
( 0 PUNCT F
0.3 0 NUM F
% 0 SYM F
) 0 PUNCT F
. 0 PUNCT F

Mycologic B-PHYSICAL ADJ T
eradication I-PHYSICAL NOUN F
rate I-PHYSICAL NOUN F
of 0 ADP F
3 0 NUM F
day 0 NOUN F
, 0 PUNCT F
6 0 NUM F
day 0 NOUN F
and 0 CCONJ F
7 0 NUM F
day 0 NOUN F
miconazole 0 NOUN F
courses 0 DET F
for 0 ADP F
uncomplicated 0 VERB F
VVC 0 NOUN T
at 0 ADP F
day 0 NOUN F
14 0 NUM F
was 0 VERB F
96.0 0 NUM F
% 0 SYM F
, 0 PUNCT F
93.5 0 NUM F
% 0 SYM F
and 0 CCONJ F
98.0 0 NUM F
% 0 SYM F
, 0 PUNCT F
respectively 0 ADV F
( 0 PUNCT F
P 0 NOUN T
> 0 SYM F
0.05 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Eradication B-PHYSICAL NOUN T
rate I-PHYSICAL NOUN F
of 0 ADP F
3 0 NUM F
day 0 NOUN F
, 0 PUNCT F
6 0 NUM F
day 0 NOUN F
and 0 CCONJ F
7 0 NUM F
day 0 NOUN F
miconazole 0 NOUN F
courses 0 DET F
for 0 ADP F
complicated 0 PUNCT F
VVC 0 NOUN T
at 0 ADP F
day 0 NOUN F
14 0 NUM F
was 0 VERB F
86.7 0 NUM F
% 0 SYM F
, 0 PUNCT F
92.5 0 NUM F
% 0 SYM F
, 0 PUNCT F
and 0 CCONJ F
86.4 0 NUM F
% 0 SYM F
, 0 PUNCT F
respectively 0 ADV F
( 0 PUNCT F
P 0 NOUN T
> 0 SYM F
0.05 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Eradication B-PHYSICAL NOUN T
rate I-PHYSICAL NOUN F
of 0 ADP F
3 0 NUM F
day 0 NOUN F
, 0 PUNCT F
6 0 NUM F
day 0 NOUN F
and 0 CCONJ F
7 0 NUM F
day 0 NOUN F
miconazole 0 NOUN F
courses 0 DET F
for 0 ADP F
uncomplicated 0 VERB F
VVC 0 NOUN T
at 0 ADP F
day 0 NOUN F
35 0 NUM F
was 0 VERB F
93.8 0 NUM F
% 0 SYM F
, 0 PUNCT F
95.3 0 NUM F
% 0 SYM F
, 0 PUNCT F
and 0 CCONJ F
89.8 0 NUM F
% 0 SYM F
, 0 PUNCT F
respectively 0 ADV F
( 0 PUNCT F
P 0 NOUN T
> 0 SYM F
0.05 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Eradication B-PHYSICAL NOUN T
rate I-PHYSICAL NOUN F
of 0 ADP F
3 0 NUM F
day 0 NOUN F
, 0 PUNCT F
6 0 NUM F
day 0 NOUN F
and 0 CCONJ F
7 0 NUM F
day 0 NOUN F
miconazole 0 NOUN F
courses 0 DET F
for 0 ADP F
complicated 0 PUNCT F
VVC 0 NOUN T
at 0 ADP F
day 0 NOUN F
35 0 NUM F
was 0 VERB F
89.7 0 NUM F
% 0 SYM F
, 0 PUNCT F
97.3 0 NUM F
% 0 SYM F
and 0 CCONJ F
86.8 0 NUM F
% 0 SYM F
, 0 PUNCT F
respectively 0 ADV F
( 0 PUNCT F
P 0 NOUN T
> 0 SYM F
0.05 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

CONCLUSION 0 NOUN T
Treatment 0 NOUN T
of 0 ADP F
VVC 0 NOUN T
should 0 VERB F
be 0 VERB F
individualized 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
women 0 NOUN F
with 0 ADP F
complicated 0 VERB F
VVC 0 NOUN T
achieve 0 PUNCT F
superior 0 ADJ F
mycologic B-PHYSICAL ADJ F
eradication I-PHYSICAL NOUN F
by 0 ADP F
a 0 DET F
6 0 NUM F
day 0 NOUN F
miconazole 0 NOUN F
course 0 NOUN F
. 0 PUNCT F

Visual 0 ADJ T
and 0 CCONJ F
kinesthetic 0 ADJ F
locomotor 0 NOUN F
imagery 0 NOUN F
training 0 SYM F
integrated 0 VERB F
with 0 ADP F
auditory 0 ADJ F
step 0 NOUN F
rhythm 0 NOUN F
for 0 ADP F
walking 0 VERB F
performance 0 NOUN F
of 0 ADP F
patients 0 NOUN F
with 0 ADP F
chronic 0 ADJ F
stroke 0 NOUN F
. 0 PUNCT F

OBJECTIVE 0 NOUN T
To 0 PROPN T
compare 0 NOUN F
the 0 DET F
effect 0 NOUN F
of 0 ADP F
visual 0 ADJ F
and 0 CCONJ F
kinesthetic 0 ADJ F
locomotor 0 NOUN F
imagery 0 NOUN F
training 0 SYM F
on 0 ADP F
walking B-MENTAL VERB F
performance I-MENTAL NOUN F
and 0 CCONJ F
to 0 PART F
determine 0 NOUN F
the 0 DET F
clinical B-OTHER ADJ F
feasibility I-OTHER NOUN F
of 0 ADP F
incorporating 0 VERB F
auditory 0 ADJ F
step 0 NOUN F
rhythm 0 NOUN F
into 0 ADP F
the 0 DET F
training 0 VERB F
. 0 PUNCT F

DESIGN 0 NOUN T
Randomized 0 PROPN T
crossover 0 NOUN F
trial 0 NOUN F
. 0 PUNCT F

SETTING 0 NUM T
Laboratory 0 NOUN T
of 0 ADP F
a 0 DET F
Department 0 NOUN T
of 0 ADP F
Physical 0 PUNCT T
Therapy 0 NOUN T
. 0 PUNCT F

SUBJECTS 0 NOUN T
Fifteen 0 PUNCT T
subjects 0 NOUN F
with 0 ADP F
post-stroke 0 NOUN F
hemiparesis 0 NOUN F
. 0 PUNCT F

INTERVENTION 0 NOUN T
Four 0 CCONJ T
locomotor 0 NOUN F
imagery 0 PUNCT F
trainings 0 NOUN F
on 0 ADP F
walking 0 VERB F
performance 0 NOUN F
: 0 PUNCT F
visual 0 ADJ F
locomotor 0 NOUN F
imagery 0 NOUN F
training 0 VERB F
, 0 PUNCT F
kinesthetic 0 ADJ F
locomotor 0 NOUN F
imagery 0 NOUN F
training 0 VERB F
, 0 PUNCT F
visual 0 ADJ F
locomotor 0 NOUN F
imagery 0 NOUN F
training 0 SYM F
with 0 ADP F
auditory 0 ADJ F
step 0 NOUN F
rhythm 0 NOUN F
and 0 CCONJ F
kinesthetic 0 ADJ F
locomotor 0 NOUN F
imagery 0 NOUN F
training 0 SYM F
with 0 ADP F
auditory 0 ADJ F
step 0 NOUN F
rhythm 0 NOUN F
. 0 PUNCT F

MAIN 0 ADJ T
OUTCOME 0 NOUN T
MEASURES 0 NOUN T
The 0 DET T
timed B-OTHER PUNCT F
up-and-go I-OTHER NOUN F
test I-OTHER NOUN F
and 0 CCONJ F
electromyographic B-OTHER ADJ F
and 0 CCONJ F
kinematic B-OTHER ADJ F
analyses I-OTHER NOUN F
of I-OTHER ADP F
the I-OTHER DET F
affected 0 ADP F
lower 0 PUNCT F
limb B-OTHER NOUN F
during 0 ADP F
one 0 NUM F
gait B-PHYSICAL NOUN F
cycle I-PHYSICAL NOUN F
. 0 PUNCT F

RESULTS 0 NOUN T
After 0 ADP T
the 0 DET F
interventions 0 NOUN F
, 0 PUNCT F
significant 0 ADJ F
differences 0 NOUN F
were 0 VERB F
found 0 VERB F
in 0 ADP F
the 0 PUNCT F

Predicting 0 VERB T
the 0 DET F
effect 0 NOUN F
of 0 ADP F
anthelmintic 0 ADJ F
treatment 0 NOUN F
on 0 ADP F
milk B-PHYSICAL NOUN F
production I-PHYSICAL NOUN F
of I-PHYSICAL ADP F
dairy I-PHYSICAL NOUN F
cattle I-PHYSICAL NOUN F
in 0 ADP F
Canada 0 PUNCT T
using 0 VERB F
an 0 DET F
Ostertagia 0 ADJ T
ostertagi 0 NOUN F
ELISA 0 NOUN T
from 0 ADP F
individual 0 ADJ F
milk 0 NOUN F
samples 0 NOUN F
. 0 PUNCT F

Gastrointestinal 0 ADJ T
nematodes 0 NOUN F
, 0 PUNCT F
such 0 PUNCT F
as 0 ADP F
Ostertagia 0 VERB T
ostertagi 0 NOUN F
and 0 CCONJ F
several 0 ADJ F
species 0 PUNCT F
of 0 ADP F
Cooperia 0 NOUN T
, 0 PUNCT F
are 0 VERB F
ubiquitous 0 ADJ F
in 0 ADP F
temperate 0 NOUN F
climates 0 PUNCT F
and 0 CCONJ F
have 0 PUNCT F
been 0 PUNCT F
shown 0 VERB F
to 0 DET F
have 0 PUNCT F
detrimental 0 ADJ F
effects 0 NOUN F
on 0 ADP F
production 0 NOUN F
in 0 ADP F
adult 0 NOUN F
dairy 0 NOUN F
cattle 0 NOUN F
. 0 PUNCT F

A 0 DET T
published 0 VERB F
meta-analysis 0 NOUN F
demonstrated 0 VERB F
that 0 ADP F
overall 0 ADJ F
, 0 PUNCT F
producers 0 ADJ F
lose 0 VERB F
approximately 0 ADV F
0.35 0 NUM F
kg 0 NOUN F
of 0 ADP F
milk 0 NOUN F
per 0 ADP F
parasitized 0 PUNCT F
cow 0 ADV F
per 0 CCONJ F
day 0 NOUN F
. 0 PUNCT F

Enzyme-linked 0 VERB T
immunosorbent 0 ADJ F
assays 0 NOUN F
( 0 PUNCT F
ELISAs 0 PUNCT T
) 0 PUNCT F
have 0 CCONJ F
the 0 DET F
ability 0 NOUN F
to 0 PART F
quantify 0 NOUN F
nematode 0 NOUN F
infections 0 NOUN F
in 0 ADP F
cattle 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
thus 0 ADV F
, 0 PUNCT F
could 0 VERB F
be 0 VERB F
used 0 VERB F
to 0 PART F
estimate 0 NOUN F
the 0 DET F
amount 0 NOUN F
of 0 ADP F
milk 0 NOUN F
production 0 NOUN F
loss 0 NOUN F
due 0 PUNCT F
to 0 ADP F
differing 0 PROPN F
levels 0 NOUN F
of 0 ADP F
parasitism 0 NOUN F
at 0 ADP F
the 0 DET F
individual 0 ADJ F
cow 0 NOUN F
level 0 NOUN F
. 0 PUNCT F

ELISA 0 NOUN T
results 0 ADJ F
from 0 ADP F
individual 0 ADJ F
cow 0 NOUN F
milk 0 NOUN F
samples 0 NOUN F
were 0 VERB F
used 0 VERB F
to 0 PART F
predict 0 NOUN F
milk 0 NOUN F
production 0 NOUN F
response 0 NOUN F
following 0 VERB F
a 0 DET F
randomized 0 VERB F
anthelmintic 0 ADJ F
treatment 0 NOUN F
in 0 ADP F
a 0 DET F
large 0 ADJ F
field 0 NOUN F
trial 0 NOUN F
. 0 PUNCT F

To 0 PART T
increase 0 NOUN F
statistical 0 ADJ F
power 0 NOUN F
, 0 PUNCT F
the 0 DET F
data 0 NOUN F
collected 0 VERB F
from 0 ADP F
this 0 DET F
field 0 NOUN F
trial 0 NOUN F
was 0 VERB F
pooled 0 VERB F
with 0 ADP F
data 0 NOUN F
from 0 ADP F
two 0 NUM F
other 0 ADJ F
published 0 ADP F
field 0 NOUN F
trials 0 NOUN F
to 0 PUNCT F
form 0 NOUN F
an 0 DET F
individual 0 ADJ F
patient 0 NOUN F
data 0 NOUN F
meta-analysis 0 NOUN F
( 0 PUNCT F
IPDMA 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
ability 0 NOUN F
to 0 PART F
predict 0 NOUN F
the 0 DET F
effect 0 NOUN F
of 0 ADP F
anthelmintic 0 ADJ F
treatment 0 NOUN F
on 0 ADP F
milk 0 NOUN F
production 0 NOUN F
depends 0 NOUN F
on 0 ADP F
the 0 DET F
level 0 NOUN F
of 0 ADP F
parasitism 0 NOUN F
quantified 0 VERB F
by 0 ADP F
an 0 DET F
ELISA 0 NOUN T
measuring 0 VERB F
milk B-PHYSICAL NOUN F
antibodies I-PHYSICAL NOUN F
against 0 ADP F
O. 0 NOUN T
ostertagi 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
reported 0 PUNCT F
as 0 ADP F
optical B-OTHER ADJ F
density I-OTHER NOUN F
ratios I-OTHER NOUN F
( I-OTHER PUNCT F
ODRs I-OTHER NOUN T
) I-OTHER PUNCT F
. 0 PUNCT F

Therefore 0 ADV T
, 0 PUNCT F
the 0 DET F
estimates 0 NOUN F
from 0 ADP F
the 0 DET F
interaction 0 NOUN F
between 0 ADP F
ODR 0 NOUN T
and 0 CCONJ F
treatment 0 NOUN F
on 0 ADP F
milk 0 NOUN F
production 0 NOUN F
were 0 VERB F
used 0 VERB F
to 0 PART F
determine 0 NOUN F
how 0 PUNCT F
well 0 PUNCT F
the 0 PUNCT F
ODR 0 NOUN T
predicted 0 VERB F
the 0 DET F
response 0 NOUN F
of 0 ADP F
the 0 DET F
treatment 0 NOUN F
. 0 PUNCT F

It 0 PRON T
was 0 VERB F
anticipated 0 NUM F
that 0 PUNCT F
the 0 DET F
relationship 0 NOUN F
between 0 ADP F
milk B-PHYSICAL NOUN F
production I-PHYSICAL NOUN F
and 0 CCONJ F
ODR B-OTHER NOUN T
was 0 VERB F
unlikely 0 ADV F
to 0 PART F
be 0 PUNCT F
linear 0 ADJ F
, 0 PUNCT F
so 0 PUNCT F
fractional 0 ADP F
polynomials 0 VERB F
were 0 VERB F
applied 0 VERB F
to 0 ADP F
the 0 DET F
continuous 0 ADJ F
ODR B-PHYSICAL NOUN T
values I-PHYSICAL NOUN F
. 0 PUNCT F

The 0 DET T
interaction 0 NOUN F
in 0 ADP F
the 0 DET F
field 0 NOUN F
trial 0 NOUN F
showed 0 VERB F
a 0 DET F
trend 0 NOUN F
( 0 PUNCT F
p=0.138 0 NOUN F
) 0 PUNCT F
toward 0 ADP F
a 0 DET F
beneficial 0 ADJ F
treatment 0 NOUN F
effect 0 NOUN F
when 0 ADP F
the 0 DET F
individual 0 ADJ F
ODR B-OTHER NOUN T
values I-OTHER NOUN F
, 0 PUNCT F
measured 0 VERB F
in 0 ADP F
late 0 ADJ F
lactation 0 NOUN F
and 0 CCONJ F
using 0 VERB F
Svanovir 0 NOUN T
( 0 PUNCT F
? 0 PUNCT F
) 0 PUNCT F
, 0 PUNCT F

were 0 VERB F
greater 0 PUNCT F
than 0 PUNCT F
0.12 0 NUM F
. 0 PUNCT F

When 0 ADP T
individual 0 ADJ F
data 0 NOUN F
from 0 ADP F
two 0 NUM F
other 0 ADJ F
similar 0 ADJ F
studies 0 NOUN F
were 0 VERB F
included 0 VERB F
in 0 ADP F
an 0 DET F
IPDMA 0 NOUN T
, 0 PUNCT F
the 0 DET F
interaction 0 NOUN F
terms 0 NOUN F
became 0 VERB F
statistically 0 ADV F
significant 0 ADJ F
( 0 PUNCT F
p=0.009 0 NOUN F
) 0 PUNCT F
indicating 0 ADP F
that 0 ADP F
there 0 PUNCT F
is 0 VERB F
a 0 DET F
beneficial 0 ADJ F
treatment 0 NOUN F
effect 0 NOUN F
when 0 ADP F
ODR 0 NOUN T
values 0 NOUN F
are 0 VERB F
slightly 0 ADV F
elevated 0 VERB F
. 0 PUNCT F

A 0 DET T
graph 0 NOUN F
was 0 VERB F
used 0 VERB F
to 0 PART F
demonstrate 0 ADJ F
the 0 DET F
treatment 0 NOUN F
effect 0 NOUN F
( 0 PUNCT F
the 0 DET F
estimated 0 VERB F
difference 0 NOUN F
of 0 ADP F
kg/cow/day 0 NUM F
of 0 ADP F
milk 0 NOUN F
yield 0 NOUN F
between 0 ADP F
the 0 DET F
treated 0 VERB F
and 0 CCONJ F
placebo 0 NOUN F
cows 0 NOUN F
) 0 PUNCT F
, 0 PUNCT F
with 0 ADP F
95 0 NUM F
% 0 SYM F
confidence 0 NOUN F
intervals 0 NOUN F
, 0 PUNCT F
as 0 ADP F
the 0 DET F
ODR 0 NOUN T
values 0 NOUN F
increase 0 ADP F
. 0 PUNCT F

It 0 PRON T
is 0 VERB F
important 0 ADJ F
to 0 PUNCT F
note 0 PUNCT F
that 0 PUNCT F
the 0 DET F
methods 0 NOUN F
of 0 ADP F
quantifying 0 VERB F
the 0 DET F
ODR 0 NOUN T
values 0 NOUN F
differed 0 VERB F
between 0 ADP F
the 0 DET F
three 0 NUM F
studies 0 NOUN F
in 0 ADP F
the 0 DET F
IPDMA 0 NOUN T
, 0 PUNCT F
therefore 0 ADV F
some 0 DET F
caution 0 NOUN F
should 0 ADP F
be 0 VERB F
used 0 VERB F
when 0 ADP F
using 0 VERB F
these 0 DET F
final 0 ADJ F
estimated 0 VERB F
values 0 NOUN F
. 0 PUNCT F

However 0 ADV T
, 0 PUNCT F
the 0 DET F
shape 0 NOUN F
and 0 CCONJ F
magnitude 0 NOUN F
of 0 ADP F
the 0 DET F
treatment 0 NOUN F
effects 0 NOUN F
, 0 PUNCT F
as 0 PUNCT F
well 0 PUNCT F
as 0 CCONJ F
the 0 DET F
other 0 ADJ F
fixed 0 VERB F
model 0 NOUN F
estimates 0 NOUN F
, 0 PUNCT F
were 0 VERB F
very 0 ADV F
similar 0 ADJ F
between 0 ADP F
the 0 DET F
field 0 NOUN F
trial 0 NOUN F
and 0 CCONJ F
the 0 DET F
IPDMA 0 NOUN T
suggesting 0 PROPN F
that 0 ADP F
any 0 DET F
bias 0 NOUN F
would 0 PUNCT F
likely 0 ADJ F
be 0 ADP F
minimal 0 ADJ F
. 0 PUNCT F

Thromboprophylaxis 0 NOUN T
by 0 ADP F
low-molecular-weight 0 NOUN F
heparin 0 NOUN F
in 0 ADP F
elective 0 ADJ F
hip 0 NOUN F
surgery 0 NOUN F
. 0 PUNCT F

A 0 DET T
placebo 0 NOUN F
controlled 0 VERB F
study 0 NOUN F
. 0 PUNCT F

In 0 ADP T
a 0 DET F
double-blind 0 ADJ F
, 0 PUNCT F
randomised 0 ADP F
study 0 NOUN F
of 0 ADP F
thromboprophylaxis 0 NOUN F
in 0 ADP F
patients 0 NOUN F
undergoing 0 VERB F
total 0 ADJ F
hip 0 NOUN F
replacement 0 NOUN F
, 0 PUNCT F
we 0 PRON F
compared 0 VERB F
a 0 DET F
low-molecular-weight 0 NOUN F
heparin 0 NOUN F
with 0 ADP F
a 0 DET F
placebo 0 NOUN F
. 0 PUNCT F

Of 0 ADP T
the 0 DET F
120 0 NUM F
patients 0 NOUN F
enrolled 0 VERB F
, 0 PUNCT F
112 0 NUM F
completed 0 PUNCT F
the 0 DET F
trial 0 NOUN F
; 0 PUNCT F
58 0 NUM F
in 0 ADP F
the 0 DET F
treatment 0 NOUN F
group 0 NOUN F
and 0 CCONJ F
54 0 NUM F
in 0 ADP F
the 0 DET F
placebo 0 NOUN F
group 0 NOUN F
. 0 PUNCT F

Nine 0 NUM T
( 0 PUNCT F
16 0 NUM F
% 0 SYM F
) 0 PUNCT F
patients 0 NOUN F
in 0 ADP F
the 0 DET F
treatment 0 NOUN F
group 0 NOUN F
and 0 CCONJ F
19 0 NUM F
( 0 PUNCT F
35 0 NUM F
% 0 SYM F
) 0 PUNCT F
in 0 ADP F
the 0 DET F
placebo 0 NOUN F
group 0 NOUN F
developed 0 VERB F
deep B-PHYSICAL ADJ F
venous I-PHYSICAL ADJ F
thrombosis I-PHYSICAL NOUN F
, 0 PUNCT F
diagnosed 0 VERB F
by 0 ADP F
the 0 DET F
125I-fibrinogen 0 NOUN F
uptake 0 NOUN F
test 0 NOUN F
( 0 PUNCT F
p 0 NOUN F
< 0 SYM F
0.02 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Verification 0 NOUN T
was 0 VERB F
obtained 0 VERB F
by 0 ADP F
phlebography 0 NOUN F
in 0 ADP F
86 0 NUM F
% 0 SYM F
of 0 ADP F
the 0 DET F
patients 0 NOUN F
. 0 PUNCT F

Prolonged 0 VERB T
surgery 0 NOUN F
increased 0 VERB F
the 0 DET F
risk 0 NOUN F
of 0 ADP F
thrombosis B-PHYSICAL NOUN F
in 0 ADP F
the 0 DET F
placebo 0 NOUN F
group 0 NOUN F
but 0 CCONJ F
not 0 ADV F
in 0 ADP F
the 0 DET F
treatment 0 NOUN F
group 0 NOUN F
( 0 PUNCT F
p 0 NOUN F
< 0 SYM F
0.05 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

There 0 PUNCT T
were 0 VERB F
significantly 0 ADV F
more 0 DET F
cases 0 NOUN F
of 0 ADP F
deep B-PHYSICAL ADJ F
venous I-PHYSICAL ADJ F
thrombosis I-PHYSICAL NOUN F
in 0 ADP F
the 0 DET F
placebo 0 NOUN F
group 0 NOUN F
during 0 ADP F
the 0 DET F
first 0 ADJ F
four 0 NUM F
postoperative 0 ADJ F
days 0 NOUN F
( 0 PUNCT F
p 0 NOUN F
< 0 SYM F
0.02 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
groups 0 NOUN F
did 0 ADP F
not 0 ADV F
differ 0 VERB F
with 0 ADP F
respect 0 NOUN F
to 0 ADP F
peroperative 0 ADJ F
and 0 CCONJ F
postoperative B-PHYSICAL ADJ F
bleeding I-PHYSICAL VERB F
. 0 PUNCT F

Low-molecular-weight 0 ADJ T
heparin 0 NOUN F
offers 0 NOUN F
safe 0 ADJ F
and 0 CCONJ F
easily 0 ADV F
administered 0 PUNCT F
thromboprophylaxis 0 NOUN F
in 0 ADP F
total 0 ADJ F
hip 0 NOUN F
replacement 0 NOUN F
. 0 PUNCT F

Predictors 0 NOUN T
of 0 ADP F
stable 0 ADJ F
return-to-work 0 NOUN F
in 0 ADP F
non-acute 0 NOUN F
, 0 PUNCT F
non-specific 0 ADJ F
spinal 0 ADJ F
pain 0 NOUN F
: 0 PUNCT F
low 0 ADJ F
total 0 ADJ F
prior 0 PUNCT F
sick-listing 0 PUNCT F
, 0 PUNCT F
high 0 ADJ F
self 0 PUNCT F
prediction 0 NOUN F
and 0 CCONJ F
young 0 ADJ F
age 0 NOUN F
. 0 PUNCT F

A 0 DET T
two-year 0 ADJ F
prospective 0 ADJ F
cohort 0 NOUN F
study 0 NOUN F
. 0 PUNCT F

BACKGROUND 0 NOUN T
Non-specific 0 ADJ T
spinal 0 ADJ F
pain 0 NOUN F
( 0 PUNCT F
NSP 0 NOUN T
) 0 PUNCT F
, 0 PUNCT F
comprising 0 CCONJ F
back 0 ADP F
and/or 0 CCONJ F
neck 0 ADJ F
pain 0 NOUN F
, 0 PUNCT F
is 0 VERB F
one 0 NUM F
of 0 ADP F
the 0 DET F
leading 0 ADJ F
disorders 0 NOUN F
in 0 ADP F
long-term 0 NOUN F
sick-listing 0 PUNCT F
. 0 PUNCT F

During 0 ADP T
2000-2004 0 NUM F
, 0 PUNCT F
125 0 PUNCT F
Swedish 0 VERB T
primary-care 0 NOUN F
patients 0 NOUN F
with 0 ADP F
non-acute 0 NOUN F
NSP 0 NOUN T
, 0 PUNCT F
full-time 0 NOUN F
sick-listed 0 VERB F
6 0 NUM F
weeks-2 0 NOUN F
years 0 NOUN F
, 0 PUNCT F
were 0 VERB F
included 0 VERB F
in 0 ADP F
a 0 DET F
randomized 0 VERB F
controlled 0 VERB F
trial 0 NOUN F
to 0 PART F
compare 0 NOUN F
a 0 DET F
cognitive-behavioural 0 ADJ F
programme 0 NOUN F
with 0 ADP F
traditional 0 ADJ F
primary 0 ADJ F
care 0 NOUN F
. 0 PUNCT F

This 0 DET T
prospective 0 ADJ F
cohort 0 NOUN F
study 0 NOUN F
is 0 VERB F
a 0 DET F
re-assessment 0 NOUN F
of 0 ADP F
the 0 DET F
data 0 NOUN F
from 0 ADP F
the 0 DET F
randomized 0 VERB F
trial 0 NOUN F
with 0 ADP F
the 0 DET F
2 0 NUM F
treatment 0 NOUN F
groups 0 NOUN F
considered 0 VERB F
as 0 ADP F
a 0 DET F
single 0 ADJ F
cohort 0 NOUN F
. 0 PUNCT F

The 0 DET T
aim 0 NOUN F
was 0 VERB F
to 0 PART F
investigate 0 DET F
which 0 ADP F
baseline 0 NOUN F
variables 0 NOUN F
predict 0 VERB F
a 0 DET F
stable 0 ADJ F
return-to-work 0 NOUN F
during 0 ADP F
a 0 DET F
2-year 0 NOUN F
period 0 NOUN F
after 0 ADP F
baseline 0 NOUN F
: 0 PUNCT F
objective 0 ADJ F
variables 0 NOUN F
from 0 ADP F
function 0 PUNCT F
tests 0 NOUN F
, 0 PUNCT F
socioeconomic 0 ADJ F
, 0 PUNCT F
subjective 0 ADJ F
and/or 0 CCONJ F
treatment 0 NOUN F
variables 0 NOUN F
. 0 PUNCT F

Stable 0 ADJ T
return-to-work 0 NOUN F
was 0 VERB F
a 0 DET F
return-to-work 0 NOUN F
lasting 0 ADJ F
for 0 ADP F
at 0 VERB F
least 0 ADV F
1 0 NUM F
month 0 NOUN F
from 0 ADP F
the 0 DET F
start 0 NOUN F
of 0 ADP F
follow-up 0 NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
Stable 0 ADJ T
return-to-work 0 NOUN F
was 0 VERB F
the 0 DET F
outcome 0 NOUN F
variable 0 NOUN F
, 0 PUNCT F
the 0 DET F
above-mentioned 0 VERB F
factors 0 NOUN F
were 0 VERB F
the 0 DET F
predictive 0 ADJ F
variables 0 NOUN F
in 0 ADP F
multiple-logistic 0 ADJ F
regression 0 NOUN F
models 0 NOUN F
, 0 PUNCT F
one 0 NUM F
per 0 ADP F
follow-up 0 NOUN F
at 0 ADP F
6 0 NUM F
, 0 PUNCT F
12 0 NUM F
, 0 PUNCT F
18 0 NUM F
and 0 CCONJ F
24 0 NUM F
months 0 NOUN F
after 0 ADP F
baseline 0 NOUN F
. 0 PUNCT F

The 0 DET T
factors 0 NOUN F
from 0 ADP F
univariate 0 ADJ F
analyzes 0 DET F
with 0 ADP F
a 0 DET F
p-value 0 NOUN F
of 0 ADP F
at 0 ADP F
most 0 CCONJ F
.10 0 PUNCT F
were 0 VERB F
included 0 VERB F
. 0 PUNCT F

The 0 DET T
non-significant 0 ADJ F
variables 0 NOUN F
were 0 VERB F
excluded 0 VERB F
stepwise 0 ADJ F
to 0 PART F
yield 0 VERB F
models 0 NOUN F
comprising 0 CCONJ F
only 0 ADJ F
significant 0 ADJ F
factors 0 NOUN F
( 0 PUNCT F
p 0 NOUN F
< 0 SYM F
.05 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

As 0 ADP T
the 0 DET F
comparatively 0 NOUN F
few 0 ADJ F
cases 0 NOUN F
made 0 PUNCT F
it 0 PUNCT F
risky 0 PUNCT F
to 0 PART F
associate 0 NOUN F
certain 0 ADJ F
predictors 0 NOUN F
with 0 ADP F
certain 0 ADJ F
time-points 0 NOUN F
, 0 PUNCT F
we 0 PRON F
finally 0 ADV F
considered 0 PUNCT F
the 0 DET F
predictors 0 NOUN F
which 0 ADP F
were 0 VERB F
represented 0 VERB F
in 0 ADP F
at 0 DET F
least 0 ADV F
3 0 NUM F
follow-ups 0 NOUN F
. 0 PUNCT F

They 0 PRON T
are 0 VERB F
presented 0 VERB F
with 0 ADP F
odds 0 NOUN F
ratios 0 NOUN F
( 0 PUNCT F
OR 0 CCONJ T
) 0 PUNCT F
and 0 CCONJ F
95 0 NUM F
% 0 SYM F
confidence 0 NOUN F
intervals 0 NOUN F
. 0 PUNCT F

RESULTS 0 DET T
Three 0 NUM T
variables 0 NOUN F
qualified 0 VERB F
, 0 PUNCT F
all 0 DET F
of 0 ADP F
them 0 PRON F
represented 0 VERB F
in 0 ADP F
3 0 NUM F
follow-ups 0 ADP F
: 0 PUNCT F
Low B-OTHER ADJ T
total 0 ADJ F
prior B-OTHER PUNCT F
sick-listing I-OTHER PUNCT F
( I-OTHER PUNCT F
including I-OTHER PROPN F
all I-OTHER DET F
diagnoses I-OTHER NOUN F
) B-OTHER PUNCT F
was 0 VERB F
the 0 DET F
strongest B-OTHER PUNCT F
predictor I-OTHER NOUN F
in 0 ADP F
2 0 NUM F
follow-ups 0 PROPN F
, 0 PUNCT F
18 0 NUM F
and 0 CCONJ F
24 0 NUM F
months 0 NOUN F
, 0 PUNCT F
OR 0 ADV T
4.8 0 NUM F
[ 0 PUNCT F
1.9-12.3 0 PUNCT F
] 0 PUNCT F
and 0 CCONJ F
3.8 0 NUM F
[ 0 PUNCT F
1.6-8.7 0 ADP F
] 0 PUNCT F
respectively 0 ADV F
, 0 PUNCT F
High B-OTHER PUNCT T

Secondary 0 ADJ T
prevention 0 NOUN F
of 0 ADP F
macrovascular B-PHYSICAL ADJ F
events I-PHYSICAL NOUN F
in 0 ADP F
patients 0 NOUN F
with 0 ADP F
type 0 NOUN F
2 0 NUM F
diabetes 0 PUNCT F
in 0 ADP F
the 0 DET F
PROactive 0 ADJ T
Study 0 NOUN T
( 0 PUNCT F
PROspective 0 ADJ T
pioglitAzone 0 NOUN F
Clinical 0 ADJ T
Trial 0 NOUN T
In 0 ADP T
macroVascular 0 ADJ F
Events 0 NOUN T
) 0 PUNCT F
: 0 PUNCT F
a 0 DET F
randomised 0 VERB F
controlled 0 VERB F
trial 0 NOUN F
. 0 PUNCT F

BACKGROUND 0 NOUN T
Patients 0 NOUN T
with 0 ADP F
type 0 NOUN F
2 0 NUM F
diabetes 0 NOUN F
are 0 VERB F
at 0 ADP F
high 0 ADJ F
risk 0 NOUN F
of 0 ADP F
fatal 0 ADJ F
and 0 CCONJ F
non-fatal 0 ADJ F
myocardial B-PHYSICAL ADJ F
infarction I-PHYSICAL NOUN F
and 0 CCONJ F
stroke B-PHYSICAL NOUN F
. 0 PUNCT F

There 0 PUNCT T
is 0 VERB F
indirect 0 ADJ F
evidence 0 NOUN F
that 0 ADP F
agonists 0 NOUN F
of 0 ADP F
peroxisome 0 NOUN F
proliferator-activated 0 VERB F
receptor 0 NOUN F
gamma 0 NOUN F
( 0 PUNCT F
PPAR 0 NOUN T
gamma 0 NOUN F
) 0 PUNCT F
could 0 VERB F
reduce 0 VERB F
macrovascular B-PHYSICAL ADJ F
complications I-PHYSICAL NOUN F
. 0 PUNCT F

Our 0 PUNCT T
aim 0 NOUN F
, 0 PUNCT F
therefore 0 ADV F
, 0 PUNCT F
was 0 VERB F
to 0 ADV F
ascertain 0 NOUN F
whether 0 PUNCT F
pioglitazone 0 ADJ F
reduces 0 NOUN F
macrovascular B-PHYSICAL ADJ F
morbidity I-PHYSICAL NOUN F
and 0 CCONJ F
mortality B-MORTALITY NOUN F
in 0 ADP F
high-risk 0 NOUN F
patients 0 NOUN F
with 0 ADP F
type 0 NOUN F
2 0 NUM F
diabetes 0 NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
We 0 ADJ T
did 0 CCONJ F
a 0 DET F
prospective 0 ADJ F
, 0 PUNCT F
randomised 0 VERB F
controlled 0 VERB F
trial 0 NOUN F
in 0 ADP F
5238 0 NUM F
patients 0 NOUN F
with 0 ADP F
type 0 NOUN F
2 0 NUM F
diabetes 0 NOUN F
who 0 ADP F
had 0 PUNCT F
evidence 0 NOUN F
of 0 ADP F
macrovascular B-PHYSICAL ADJ F
disease I-PHYSICAL NOUN F
. 0 PUNCT F

We 0 PRON T
recruited 0 VERB F
patients 0 NOUN F
from 0 ADP F
primary-care 0 ADJ F
practices 0 NOUN F
and 0 CCONJ F
hospitals 0 NOUN F
. 0 PUNCT F

We 0 PRON T
assigned 0 VERB F
patients 0 NOUN F
to 0 ADP F
oral 0 ADJ F
pioglitazone 0 NOUN F
titrated 0 PUNCT F
from 0 ADP F
15 0 NUM F
mg 0 NOUN F
to 0 ADP F
45 0 NUM F
mg 0 NOUN F
( 0 PUNCT F
n=2605 0 NOUN F
) 0 PUNCT F
or 0 CCONJ F
matching 0 VERB F
placebo 0 NOUN F
( 0 PUNCT F
n=2633 0 NOUN F
) 0 PUNCT F
, 0 PUNCT F
to 0 PART F
be 0 PUNCT F
taken 0 VERB F
in 0 ADP F
addition 0 NOUN F
to 0 ADP F
their 0 PUNCT F
glucose-lowering 0 VERB F
drugs 0 NOUN F
and 0 CCONJ F
other 0 ADJ F
medications 0 NOUN F
. 0 PUNCT F

Our 0 ADJ T
primary 0 ADJ F
endpoint 0 NOUN F
was 0 VERB F
the 0 DET F
composite B-MORTALITY NOUN F
of I-MORTALITY ADP F
all-cause I-MORTALITY NOUN F
mortality I-MORTALITY NOUN F
, 0 PUNCT F
non B-PHYSICAL ADJ F
fatal I-PHYSICAL ADJ F
myocardial I-PHYSICAL ADJ F
infarction I-PHYSICAL NOUN F
( 0 PUNCT F
including 0 PROPN F
silent B-PHYSICAL ADJ F
myocardial I-PHYSICAL ADJ F
infarction I-PHYSICAL NOUN F
) 0 PUNCT F
, 0 PUNCT F
stroke B-PHYSICAL NOUN F
, 0 PUNCT F
acute B-PHYSICAL ADJ F
coronary I-PHYSICAL ADJ F
syndrome I-PHYSICAL NOUN F
, 0 PUNCT F
endovascular B-PHYSICAL ADJ F
or 0 CCONJ F
surgical B-PHYSICAL ADJ F
intervention I-PHYSICAL NOUN F
in I-PHYSICAL ADP F
the I-PHYSICAL DET F
coronary I-PHYSICAL ADJ F
or 0 CCONJ F
leg B-PHYSICAL NOUN F
arteries I-PHYSICAL NOUN F
, 0 PUNCT F
and 0 CCONJ F
amputation B-PHYSICAL NOUN F
above I-PHYSICAL ADP F
the I-PHYSICAL DET F
ankle I-PHYSICAL NOUN F
. 0 PUNCT F

Analysis 0 NOUN T
was 0 VERB F
by 0 ADP F
intention 0 NOUN F
to 0 PART F
treat 0 ADV F
. 0 PUNCT F

This 0 DET T
study 0 NOUN F
is 0 VERB F
registered 0 VERB F
as 0 PUNCT F
an 0 DET F
International 0 ADJ T
Standard 0 NOUN T
Randomised 0 PROPN T
Controlled 0 VERB T
Trial 0 NOUN T
, 0 PUNCT F
number 0 NOUN F
ISRCTN 0 NOUN T
NCT00174993 0 NOUN T
. 0 PUNCT F

FINDINGS 0 NOUN T
Two 0 NUM T
patients 0 NOUN F
were 0 VERB F
lost 0 VERB F
to 0 ADP F
follow-up 0 NOUN F
, 0 PUNCT F
but 0 CCONJ F
were 0 VERB F
included 0 VERB F
in 0 ADP F
analyses 0 NOUN F
. 0 PUNCT F

The 0 DET T
average 0 ADJ F
time 0 NOUN F
of 0 ADP F
observation 0 NOUN F
was 0 ADV F
34.5 0 NUM F
months 0 NOUN F
. 0 PUNCT F

514 0 NUM F
of 0 ADP F
2605 0 NUM F
patients 0 NOUN F
in 0 ADP F
the 0 DET F
pioglitazone 0 ADJ F
group 0 NOUN F
and 0 CCONJ F
572 0 NUM F
of 0 ADP F
2633 0 NUM F
patients 0 NOUN F
in 0 ADP F
the 0 DET F
placebo 0 NOUN F
group 0 NOUN F
had 0 PUNCT F
at 0 VERB F
least 0 ADV F
one 0 NUM F
event 0 NOUN F
in 0 ADP F
the 0 DET F
primary B-PHYSICAL ADJ F
composite I-PHYSICAL ADJ F
endpoint I-PHYSICAL NOUN F
( 0 PUNCT F
HR 0 NOUN T
0.90 0 NUM F
, 0 PUNCT F
95 0 NUM F
% 0 SYM F
CI 0 NOUN T
0.80-1.02 0 NUM F
, 0 PUNCT F
p=0.095 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
main 0 ADJ F
secondary 0 ADJ F
endpoint 0 NOUN F
was 0 VERB F
the 0 DET F
composite B-MORTALITY NOUN F
of I-MORTALITY ADP F
all-cause I-MORTALITY NOUN F
mortality I-MORTALITY NOUN F
, 0 PUNCT F
non-fatal B-PHYSICAL ADJ F
myocardial I-PHYSICAL ADJ F
infarction I-PHYSICAL NOUN F
, 0 PUNCT F
and 0 PUNCT F

Learning 0 VERB T
curve 0 NOUN F
in 0 ADP F
multidetector 0 NOUN F
CT 0 NOUN T
coronary 0 ADJ F
angiography 0 NOUN F
( 0 PUNCT F
MDCT-CA 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

PURPOSE 0 NOUN T
Coronary 0 ADJ T
angiography 0 NOUN F
using 0 VERB F
multidetector 0 NOUN F
computed 0 VERB F
tomography 0 NOUN F
( 0 PUNCT F
MDCT-CA 0 NOUN T
) 0 PUNCT F
is 0 VERB F
a 0 DET F
recent 0 ADJ F
technique 0 NOUN F
for 0 ADP F
the 0 DET F
nonivasive 0 ADJ F
study 0 NOUN F
of 0 ADP F
coronary 0 ADJ F
arteries 0 NOUN F
. 0 PUNCT F

This 0 DET T
study 0 NOUN F
assessed 0 VERB F
the 0 DET F
diagnostic B-OTHER ADJ F
accuracy 0 NOUN F
of B-OTHER ADP F
coronary I-OTHER ADJ F
artery I-OTHER NOUN F
stenosis I-OTHER NOUN F
evaluation B-OTHER NOUN F
obtained 0 VERB F
by 0 ADP F
three 0 NUM F
readers 0 NOUN F
at 0 ADP F
different 0 ADJ F
levels 0 NOUN F
of 0 ADP F
training 0 VERB F
or 0 CCONJ F
at 0 ADP F
different 0 ADJ F
points 0 NOUN F
of 0 ADP F
the 0 DET F
learning 0 VERB F
curve 0 NOUN F
proposed 0 VERB F
by 0 ADP F
the 0 DET F
international 0 ADJ F
guidelines 0 NOUN F
. 0 PUNCT F

MATERIALS 0 NOUN T
AND 0 CCONJ T
METHODS 0 NOUN T
Three 0 NUM T
radiologists 0 NOUN F
in 0 ADP F
training 0 VERB F
with 0 ADP F
different 0 ADJ F
levels 0 NOUN F
of 0 ADP F
experience 0 NOUN F
in 0 ADP F
MDCT-CA 0 NOUN T
scored 0 PUNCT F
50 0 NUM F
cases 0 NOUN F
at 0 ADP F
various 0 ADJ F
time 0 NOUN F
points 0 NOUN F
of 0 ADP F
the 0 DET F
learning 0 VERB F
curve 0 NOUN F
: 0 PUNCT F
baseline 0 NOUN F
, 0 PUNCT F
4 0 NUM F
weeks 0 NOUN F
, 0 PUNCT F
8 0 NUM F
weeks 0 NOUN F
and 0 CCONJ F
6 0 NUM F
months 0 NOUN F
. 0 PUNCT F

The 0 DET T
trainee 0 NOUN F
radiologists 0 NOUN F
evaluated 0 VERB F
the 0 DET F
degree 0 NOUN F
of 0 ADP F
stenosis B-OTHER NOUN F
on I-OTHER ADP F
each B-OTHER ADP F
coronary I-OTHER ADJ F
segment I-OTHER NOUN F
, 0 PUNCT F
and 0 CCONJ F
overall B-OTHER ADJ F
accuracy B-OTHER NOUN F
was 0 VERB F
calculated 0 VERB F
on 0 ADP F
a 0 DET F
per-segment 0 NOUN F
, 0 PUNCT F
pervessel 0 NOUN F
and 0 CCONJ F
per-patient 0 PUNCT F
basis 0 NOUN F
. 0 PUNCT F

RESULTS 0 PUNCT T
All 0 PUNCT T
readers 0 NOUN F
improved B-OTHER ADJ F
analysis I-OTHER NOUN F
accuracy 0 PUNCT F

Comparative 0 ADJ T
trial 0 NOUN F
of 0 ADP F
carbenicillin 0 NOUN F
and 0 CCONJ F
ampicillin 0 NOUN F
therapy 0 NOUN F
for 0 ADP F
purulent 0 VERB F
meningitis 0 NOUN F
. 0 PUNCT F

A 0 DET T
randomized 0 VERB F
therapeutic 0 ADJ F
trial 0 NOUN F
of 0 ADP F
carbenicillin 0 NOUN F
( 0 PUNCT F
CB 0 NOUN T
) 0 PUNCT F
or 0 CCONJ F
ampicillin 0 NOUN F
( 0 PUNCT F
AMP 0 NOUN T
) 0 PUNCT F
in 0 ADP F
purulent 0 VERB F
meningitis 0 NOUN F
was 0 VERB F
performed 0 VERB F
in 0 ADP F
86 0 NUM F
pediatric 0 ADJ F
and 0 CCONJ F
adult 0 ADJ F
patients 0 NOUN F
( 0 PUNCT F
41 0 NUM F
Haemophilus 0 NOUN T
influenzae 0 ADV F
, 0 PUNCT F
22 0 NUM F
Streptococcus 0 NOUN T
pneumoniae 0 NOUN F
, 0 PUNCT F
13 0 NUM F
Neisseria 0 NOUN T
meningitidis 0 PUNCT F
, 0 PUNCT F
and 0 CCONJ F
10 0 NUM F
of 0 ADP F
unknown 0 VERB F
etiology 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

All 0 DET T
isolates 0 NOUN F
, 0 PUNCT F
incuding 0 PUNCT F
H. 0 NOUN T
influenzae 0 ADV F
, 0 PUNCT F
were 0 VERB F
susceptible 0 ADJ F
to 0 ADP F
CB 0 NOUN T
and 0 CCONJ F
AMP 0 NOUN T
. 0 PUNCT F

Median 0 ADJ T
cerebrospinal B-PHYSICAL ADJ F
fluid I-PHYSICAL NOUN F
( I-PHYSICAL PUNCT F
CSF I-PHYSICAL NOUN T
) I-PHYSICAL PUNCT F
antibiotic I-PHYSICAL ADJ F
concentrations I-PHYSICAL NOUN F
were 0 VERB F
0.85 0 NUM F
and 0 CCONJ F
1.60 0 NUM F
mug/ml 0 NOUN F
for 0 ADP F
CB 0 NOUN T
and 0 CCONJ F
AMP 0 NOUN T
, 0 PUNCT F
respectively 0 ADV F
, 0 PUNCT F
during 0 ADP F
administration 0 NOUN F
of 0 ADP F
daily 0 PUNCT F
doses 0 NOUN F
of 0 ADP F
400 0 NUM F
mg/kg 0 NOUN F
and 0 CCONJ F
0.65 0 NUM F
and 0 CCONJ F
0.45 0 NUM F
mug/ml 0 NOUN F
, 0 PUNCT F
respectively 0 ADV F
, 0 PUNCT F
on 0 ADP F
daily 0 ADJ F
doses 0 NOUN F
of 0 ADP F
200 0 NUM F
mg/kg 0 NOUN F
. 0 PUNCT F

Higher B-PHYSICAL PUNCT T
CSF I-PHYSICAL NOUN T
concentrations I-PHYSICAL NOUN F
, 0 PUNCT F
up 0 PUNCT F
to 0 ADP F
a 0 DET F
median 0 ADJ F
concentration 0 NOUN F
of 0 ADP F
4.5 0 NUM F
mug/ml 0 NOUN F
, 0 PUNCT F
were 0 VERB F
observed 0 VERB F
in 0 ADP F
patients 0 NOUN F
with 0 ADP F
CSF 0 NOUN T
protein 0 NOUN F
concentrations 0 NOUN F
> 0 SYM F
/=75 0 PUNCT F
mg/100 0 PUNCT F
ml 0 NOUN F
. 0 PUNCT F

Clinical B-PHYSICAL ADJ T
responses I-PHYSICAL NOUN F
were 0 VERB F
equivalent 0 ADJ F
on 0 ADP F
either 0 CCONJ F
antibiotic 0 ADJ F
regimen 0 NOUN F
. 0 PUNCT F

Among 0 ADP T
AMP 0 NOUN T
patients 0 NOUN F
( 0 PUNCT F
45 0 ADP F
) 0 PUNCT F
, 0 PUNCT F
8 0 NUM F
had 0 PUNCT F
significant B-ADVERSE-EFFECTS ADJ F
residua I-ADVERSE-EFFECTS PUNCT F
and 0 CCONJ F
3 0 NUM F
died B-MORTALITY ADV F
; 0 PUNCT F
among 0 ADP F
CB 0 NOUN T
patients 0 NOUN F
( 0 PUNCT F
41 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
5 0 NUM F
had 0 PUNCT F
residua 0 PUNCT F
and 0 CCONJ F
none 0 NUM F
died 0 VERB F
. 0 PUNCT F

However 0 ADV T
, 0 PUNCT F
38 0 NUM F
% 0 SYM F
of 0 ADP F
H. 0 NOUN T
influenzae 0 PUNCT F
patients 0 NOUN F
treated 0 VERB F
with 0 ADP F
CB 0 NOUN T
had 0 VERB F
positive 0 ADJ F
CSF B-PHYSICAL NOUN T
cultures I-PHYSICAL NOUN F
on 0 ADP F
day 0 NOUN F
1 0 NUM F
follow-up 0 NOUN F
lumbar 0 ADJ F
punctures 0 NOUN F
, 0 PUNCT F
compared 0 VERB F
with 0 ADP F
only 0 ADV F
5.8 0 NUM F
% 0 SYM F
of 0 ADP F
AMP 0 NOUN T
patients 0 NOUN F
with 0 ADP F
H. 0 NOUN T
influenzae 0 PUNCT F
. 0 PUNCT F

The 0 DET T
significance 0 NOUN F
of 0 ADP F
a 0 DET F
delay 0 NOUN F
of 0 ADP F
CSF B-PHYSICAL NOUN T
sterilization I-PHYSICAL NOUN F
among 0 ADP F
CB-treated 0 VERB T
patients 0 NOUN F
is 0 VERB F
unknown 0 VERB F
, 0 PUNCT F
since 0 ADP F
there 0 PUNCT F
was 0 VERB F
no 0 DET F
correlation 0 NOUN F
between 0 ADP F
persistence 0 NOUN F
of 0 ADP F
hemophilus 0 NOUN F
organisms 0 NOUN F
and 0 CCONJ F
the 0 DET F
frequency 0 NOUN F
of 0 ADP F
adverse 0 ADJ F
outcome 0 NOUN F
. 0 PUNCT F

AMP 0 NOUN T
and 0 CCONJ F
CB 0 NOUN T
are 0 VERB F
equivalent 0 ADJ F
for 0 ADP F
the 0 DET F
treatment 0 NOUN F
of 0 ADP F
bacterial 0 ADJ F
meningitis 0 NOUN F
due 0 PUNCT F
to 0 ADP F
susceptible 0 ADJ F
organisms 0 NOUN F
. 0 PUNCT F

Pentoxifylline 0 NOUN T
therapy 0 NOUN F
in 0 ADP F
HIV 0 NOUN T
seropositive 0 ADJ F
subjects 0 NOUN F
with 0 ADP F
elevated 0 VERB F
TNF 0 NOUN T
. 0 PUNCT F

Tumor 0 NOUN T
necrosis 0 NOUN F
factor-alpha 0 NOUN F
( 0 PUNCT F
TNF-alpha 0 NOUN T
) 0 PUNCT F
is 0 VERB F
thought 0 VERB F
to 0 PART F
induce 0 NOUN F
cachexia 0 NOUN F
in 0 ADP F
subjects 0 NOUN F
infected 0 VERB F
with 0 ADP F
human 0 NOUN F
immunodeficiency 0 NOUN F
virus 0 NOUN F
( 0 PUNCT F
HIV 0 NOUN T
) 0 PUNCT F
, 0 PUNCT F
and 0 CCONJ F
it 0 NOUN F
has 0 PUNCT F
been 0 PUNCT F
suggested 0 VERB F
that 0 ADP F
HIV-seropositive 0 ADJ T
patients 0 NOUN F
would 0 VERB F
benefit 0 VERB F
from 0 ADP F
treatment 0 NOUN F
with 0 ADP F
pentoxifylline 0 NOUN F
, 0 PUNCT F
a 0 DET F
known 0 VERB F
suppressor 0 NOUN F
of 0 ADP F
TNF-alpha 0 NOUN T
production 0 NOUN F
. 0 PUNCT F

The 0 DET T
purpose 0 NOUN F
of 0 ADP F
the 0 DET F
present 0 ADJ F
study 0 NOUN F
was 0 VERB F
to 0 ADV F
examine 0 NOUN F
how 0 ADP F
pentoxifylline 0 NOUN F
at 0 ADP F
a 0 DET F
dose 0 NOUN F
of 0 ADP F
800 0 NUM F
mg 0 NOUN F
thrice 0 ADP F
daily 0 ADJ F
would 0 ADP F
influence 0 VERB F
the 0 DET F
cellular B-PHYSICAL ADJ F
immune I-PHYSICAL ADJ F
system I-PHYSICAL NOUN F
in 0 ADP F
HIV-seropositive 0 ADJ T
persons 0 NOUN F
with 0 ADP F
elevated 0 VERB F
TNF-alpha 0 NOUN T
. 0 PUNCT F

Six 0 NUM T
HIV-seropositive 0 ADJ T
subjects 0 NOUN F
with 0 ADP F
elevated 0 VERB F
amounts 0 NOUN F
of 0 ADP F
TNF-alpha 0 NOUN T
in 0 ADP F
plasma 0 NOUN F
at 0 VERB F
least 0 ADV F
at 0 ADP F
two 0 NUM F
occasions 0 NOUN F
were 0 VERB F
included 0 VERB F
in 0 ADP F
an 0 DET F
open 0 ADJ F
, 0 PUNCT F
controlled 0 DET F
, 0 PUNCT F
randomized 0 VERB F
, 0 PUNCT F
cross-over 0 ADP F
study 0 NOUN F
consisting 0 DET F
of 0 ADP F
a 0 DET F
6 0 NUM F
week 0 NOUN F
treatment 0 NOUN F
period 0 NOUN F
and 0 CCONJ F
a 0 DET F
6 0 NUM F
week 0 NOUN F
control 0 NOUN F
period 0 NOUN F
. 0 PUNCT F

Blood 0 NOUN T
samples 0 NOUN F
were 0 VERB F
collected 0 VERB F
before 0 ADP F
and 0 CCONJ F
at 0 ADP F
the 0 DET F
end 0 NOUN F
of 0 ADP F
each 0 DET F
period 0 NOUN F
. 0 PUNCT F

Pentoxifylline 0 NOUN T
treatment 0 NOUN F
did 0 VERB F
not 0 ADV F
influence 0 VERB F
the 0 DET F
concentration 0 NOUN F
of B-PHYSICAL ADP F
plasma-TNF-alpha B-PHYSICAL NOUN F
, 0 PUNCT F
subpopulations B-PHYSICAL NOUN F
of I-PHYSICAL ADP F
blood I-PHYSICAL NOUN F
mononuclear B-PHYSICAL ADJ F
cells I-PHYSICAL NOUN F
, 0 PUNCT F
the B-PHYSICAL DET F
proliferative I-PHYSICAL ADJ F
responses I-PHYSICAL NOUN F
nor I-PHYSICAL CCONJ F
the I-PHYSICAL DET F
natural I-PHYSICAL ADJ F
killer B-PHYSICAL NOUN F
( 0 PUNCT F
NK B-PHYSICAL NOUN T
) 0 PUNCT F
, 0 PUNCT F
and 0 CCONJ F
lymphokine B-PHYSICAL PUNCT F
activated B-PHYSICAL VERB F
killer I-PHYSICAL NOUN F
( 0 PUNCT F
LAK B-PHYSICAL NOUN T
) 0 PUNCT F
cell B-PHYSICAL NOUN F
activities I-PHYSICAL NOUN F
. 0 PUNCT F

Furthermore 0 ADV T
, 0 PUNCT F
pentoxifylline 0 NOUN F
treatment 0 NOUN F
did 0 VERB F
not 0 ADV F
influence 0 VERB F
the 0 DET F
weight 0 NOUN F
, B-PHYSICAL PUNCT F
temperature I-PHYSICAL NOUN F
, I-PHYSICAL PUNCT F
well B-PHYSICAL VERB F
being I-PHYSICAL PUNCT F
, I-PHYSICAL PUNCT F
or I-PHYSICAL CCONJ F
tiredness I-PHYSICAL NOUN F
of I-PHYSICAL ADP F
the I-PHYSICAL DET F
subjects I-PHYSICAL NOUN F
. 0 PUNCT F

However 0 ADV T
, 0 PUNCT F
the 0 DET F
patients 0 NOUN F
frequently 0 ADV F
reported 0 ADP F
gastrointestinal B-ADVERSE-EFFECTS ADJ F
side B-ADVERSE-EFFECTS NOUN F
effects I-ADVERSE-EFFECTS NOUN F
. 0 PUNCT F

In 0 PUNCT T
vitro 0 ADJ F
, 0 PUNCT F
however 0 ADV F
, 0 PUNCT F
pentoxifylline 0 NOUN F
at 0 ADP F
suprapharmacological 0 ADJ F
concentrations 0 NOUN F
inhibited 0 VERB F
the 0 PUNCT F

[ 0 PUNCT F
Clinical 0 ADJ T
observation 0 NOUN F
on 0 ADP F
effect 0 NOUN F
of 0 ADP F
fuzheng 0 VERB F
yiliu 0 PUNCT F
granule 0 NOUN F
on 0 ADP F
cell 0 NOUN F
cycle 0 NOUN F
and 0 CCONJ F
nuclear 0 ADJ F
transcription 0 NOUN F
factor-kappa 0 NOUN F
B 0 NOUN T
in 0 ADP F
tissue 0 NOUN F
of 0 ADP F
esophageal-gastric 0 ADJ F
carcinoma 0 NOUN F
] 0 PUNCT F
. 0 PUNCT F

OBJECTIVE 0 NOUN T
To 0 PROPN T
observe 0 NOUN F
the 0 DET F
effect 0 NOUN F
of 0 ADP F
Fuzheng 0 NOUN T
Yiliu 0 PUNCT T
Granule 0 NOUN T
( 0 PUNCT F
FZYLG 0 NOUN T
) 0 PUNCT F
on 0 ADP F
cell 0 NOUN F
cycle 0 NOUN F
and 0 CCONJ F
nuclear 0 ADJ F
transcription 0 NOUN F
factor-kappa 0 NOUN F
B 0 NOUN T
( 0 PUNCT F
NF-kappa 0 NOUN T
B 0 NOUN T
) 0 PUNCT F
in 0 ADP F
tissue 0 NOUN F
of 0 ADP F
esophageal-gastric 0 ADJ F
carcinoma 0 NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
Seventy-six 0 NUM T
patients 0 NOUN F
with 0 ADP F
esophageal 0 ADJ F
gastric 0 ADJ F
carcinoma 0 NOUN F
were 0 VERB F
randomly 0 ADV F
divided 0 VERB F
into 0 ADP F
two 0 NUM F
groups 0 NOUN F
, 0 PUNCT F
the 0 DET F
FZYLG 0 NOUN T
group 0 NOUN F
and 0 CCONJ F
the 0 DET F
control 0 NOUN F
group 0 NOUN F
. 0 PUNCT F

FZYLG 0 NOUN T
was 0 VERB F
given 0 VERB F
to 0 ADP F
the 0 DET F
former 0 NOUN F
for 0 ADP F
15 0 NUM F
days 0 NOUN F
. 0 PUNCT F

The 0 DET T
tumor 0 NOUN F
tissue 0 NOUN F
in 0 ADP F
both 0 CCONJ F
groups 0 NOUN F
was 0 VERB F
resected 0 VERB F
and 0 CCONJ F
cell B-PHYSICAL NOUN F
cycle I-PHYSICAL NOUN F
and 0 CCONJ F
apoptosis B-PHYSICAL NOUN F
rate I-PHYSICAL NOUN F
as 0 PUNCT F
well 0 PUNCT F
as 0 CCONJ F
NF-kappa 0 NOUN T
B 0 NOUN T
were 0 VERB F
determined 0 VERB F
by 0 ADP F
flowcytometry 0 NOUN F
. 0 PUNCT F

RESULTS 0 NOUN T
Level B-PHYSICAL NOUN T
of I-PHYSICAL ADP F
NF-kappa I-PHYSICAL NOUN T
B I-PHYSICAL NOUN T
in 0 ADP F
the 0 DET F
treated 0 ADJ F
group 0 NOUN F
was 0 VERB F
significantly 0 ADV F
higher 0 PUNCT F
than 0 VERB F
that 0 CCONJ F
in 0 ADP F
the 0 DET F
control 0 NOUN F
group 0 NOUN F
( 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.05 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

In 0 ADP T
the 0 DET F
treated 0 ADJ F
group 0 NOUN F
, 0 PUNCT F
the 0 DET F
percentage 0 NOUN F
of 0 ADP F
G0/G1 B-PHYSICAL NOUN T
stage I-PHYSICAL NOUN F
cells I-PHYSICAL NOUN F
were 0 VERB F
significantly 0 ADV F
increased 0 ADP F
and 0 CCONJ F
that 0 PUNCT F
of 0 ADP F
S 0 NOUN T
stage B-PHYSICAL ADP F
significantly 0 ADV F
decreased 0 VERB F
( 0 PUNCT F
both 0 CCONJ F
P 0 NOUN T
< 0 SYM F
0.05 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

At 0 ADP T
the 0 DET F
same 0 ADJ F
time 0 NOUN F
, 0 PUNCT F
obvious 0 ADJ F
cell B-PHYSICAL NOUN F
apoptosis I-PHYSICAL NOUN F
was 0 VERB F
found 0 VERB F
in 0 ADP F
the 0 DET F
treated 0 ADJ F
group 0 NOUN F
, 0 PUNCT F
the 0 DET F
apoptosis B-PHYSICAL NOUN F
rate 0 NOUN F
of 0 ADP F
which 0 ADP F
was 0 VERB F
significantly 0 ADV F
higher 0 PUNCT F
than 0 VERB F
that 0 CCONJ F
in 0 ADP F
the 0 DET F
control 0 NOUN F
group 0 NOUN F
( 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.01 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

CONCLUSION 0 NOUN T
FZYLG 0 NOUN T
can 0 ADJ F
increase 0 VERB F
the 0 DET F
NF-kappa 0 NOUN T
B 0 NOUN T
expression 0 NOUN F
, 0 PUNCT F
block 0 ADP F
the 0 DET F
proliferation 0 NOUN F
to 0 PART F
promote 0 NOUN F
the 0 DET F
apoptosis B-PHYSICAL NOUN F
of 0 ADP F
tumor 0 NOUN F
cells 0 NOUN F
. 0 PUNCT F

Does 0 PUNCT T
waiting 0 ADP F
matter 0 NOUN F
? 0 PUNCT F

A 0 DET T
randomized 0 VERB F
controlled 0 VERB F
trial 0 NOUN F
of 0 ADP F
new 0 ADJ F
non-urgent 0 ADJ F
rheumatology 0 NOUN F
out-patient 0 ADP F
referrals 0 NOUN F
. 0 PUNCT F

OBJECTIVE 0 NOUN T
To 0 PROPN T
examine 0 NOUN F
the 0 DET F
effect 0 NOUN F
of 0 ADP F
waiting 0 PROPN F
times 0 NOUN F
on 0 ADP F
the 0 DET F
health 0 NOUN F
status 0 NOUN F
of 0 ADP F
patients 0 NOUN F
referred 0 VERB F
for 0 ADP F
a 0 DET F
non-urgent 0 ADJ F
rheumatology 0 NOUN F
opinion 0 NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
The 0 DET T
study 0 NOUN F
was 0 ADV F
a 0 DET F
randomized 0 VERB F
controlled 0 VERB F
clinical 0 ADJ F
study 0 NOUN F
evaluating 0 PUNCT F
a 0 DET F
'fast 0 PUNCT F
track 0 NOUN F
' 0 PUNCT F
appointment 0 NOUN F
with 0 ADP F
a 0 DET F
6-week 0 NOUN F
target 0 NOUN F
waiting 0 SYM F
time 0 NOUN F
against 0 ADP F
an 0 DET F
'ordinary 0 PUNCT F
' 0 PUNCT F
appointment 0 NOUN F
in 0 ADP F
the 0 DET F
main 0 ADJ F
city 0 NOUN F
out-patient 0 ADP F
clinic 0 NOUN F
of 0 ADP F
the 0 DET F
rheumatology 0 NOUN F
service 0 NOUN F
for 0 ADP F
the 0 DET F
Lothian 0 PUNCT T
and 0 CCONJ F
Borders 0 PUNCT T
region 0 NOUN F
( 0 PUNCT F
population 0 NOUN F
approximately 0 ADV F
1 0 NUM F
million 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Health B-PHYSICAL NOUN T
status I-PHYSICAL NOUN F
was 0 VERB F
measured 0 VERB F
using 0 SYM F
the 0 DET F
SF12 B-PHYSICAL NOUN T
physical I-PHYSICAL ADJ F
and I-PHYSICAL CCONJ F
mental I-PHYSICAL ADJ F
summary I-PHYSICAL NOUN F
component I-PHYSICAL NOUN F
T-scores I-PHYSICAL VERB T
and 0 CCONJ F
pain B-PAIN NOUN F
was 0 VERB F
measured 0 VERB F
with 0 ADP F
a 0 DET F
100 0 NUM F
mm 0 NOUN F
visual B-OTHER ADJ F
analogue I-OTHER NOUN F
pain I-OTHER NOUN F
scale 0 NOUN F
. 0 PUNCT F

Secondary 0 ADJ T
outcomes 0 NOUN F
were 0 VERB F
health B-PHYSICAL NOUN F
utility I-PHYSICAL NOUN F
and 0 CCONJ F
perceived B-PHYSICAL DET F
health I-PHYSICAL NOUN F
both 0 PUNCT F
measured 0 VERB F
with 0 ADP F
the 0 DET F
EuroQol 0 PUNCT T
instrument 0 NOUN F
, 0 PUNCT F
mental 0 ADJ F
health 0 NOUN F
measured 0 VERB F
with 0 ADP F
the 0 DET F
Hospital 0 NOUN T
Anxiety B-MENTAL NOUN T
and I-MENTAL CCONJ F
Depression I-MENTAL NOUN T
scale 0 NOUN F
, 0 PUNCT F
disability B-PHYSICAL NOUN F
with 0 ADP F
the 0 DET F
modified 0 VERB F
Health 0 NOUN T
Assessment 0 NOUN T
Questionnaire 0 NOUN T
and 0 CCONJ F
economic 0 ADJ F
costs 0 NOUN F
measured 0 VERB F
from 0 ADP F
a 0 DET F
societal 0 ADJ F
perspective 0 ADJ F
. 0 PUNCT F

RESULTS 0 NOUN T
Mean 0 NOUN T
waiting B-OTHER ADP F
times I-OTHER NOUN F
were 0 VERB F
43 0 NUM F
days 0 NOUN F
( 0 PUNCT F
sigma 0 NOUN F
= 0 SYM F
+/-16 0 ADV F
) 0 PUNCT F
and 0 CCONJ F
105 0 NUM F
days 0 NOUN F
( 0 PUNCT F
sigma 0 NOUN F
= 0 SYM F
+/-51 0 PUNCT F
) 0 PUNCT F
for 0 ADP F
'fast 0 PUNCT F
track 0 NOUN F
' 0 PUNCT F
and 0 CCONJ F
'ordinary 0 PUNCT F
' 0 PUNCT F
appointments 0 NOUN F
, 0 PUNCT F
respectively 0 ADV F
. 0 PUNCT F

Both 0 DET T
groups 0 NOUN F
showed 0 VERB F
significant 0 ADJ F
improvements 0 NOUN F
in 0 ADP F
mean 0 NOUN F
[ 0 PUNCT F
95 0 NUM F
% 0 SYM F
confidence 0 NOUN F
interval 0 NOUN F
( 0 PUNCT F
CI 0 NOUN T
) 0 PUNCT F
] 0 PUNCT F
scores 0 NOUN F
for 0 ADP F
pain B-PAIN NOUN F
: 0 PUNCT F
11 0 NUM F
( 0 PUNCT F
7 0 NUM F
, 0 PUNCT F
16 0 NUM F
) 0 PUNCT F
( 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.001 0 NUM F
) 0 PUNCT F
; 0 PUNCT F
physical B-PHYSICAL ADJ F
health I-PHYSICAL NOUN F
status I-PHYSICAL NOUN F
: 0 PUNCT F
4 0 NUM F
( 0 PUNCT F
2 0 NUM F
, 0 PUNCT F
5 0 NUM F
) 0 PUNCT F
( 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.001 0 NUM F
) 0 PUNCT F
; 0 PUNCT F
mental B-MENTAL ADJ F
health I-MENTAL NOUN F
status I-MENTAL NOUN F
: 0 PUNCT F
2 0 NUM F
( 0 PUNCT F
0.1 0 NUM F
, 0 PUNCT F
4 0 NUM F
) 0 PUNCT F
( 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.02 0 NUM F
) 0 PUNCT F
; 0 PUNCT F
and 0 CCONJ F
health B-PHYSICAL NOUN F
utility I-PHYSICAL NOUN F
: 0 PUNCT F
0.11 0 NUM F
( 0 PUNCT F
0.07 0 NUM F
, 0 PUNCT F
0.16 0 NUM F
) 0 PUNCT F
( 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.001 0 NUM F
) 0 PUNCT F
by 0 ADP F
the 0 DET F
end 0 NOUN F
of 0 ADP F
the 0 DET F
15-month 0 NOUN F
period 0 NOUN F
of 0 ADP F
the 0 DET F
study 0 NOUN F
, 0 PUNCT F
but 0 CCONJ F
there 0 PUNCT F
was 0 VERB F
no 0 DET F
significant 0 ADJ F
difference 0 NOUN F
between 0 ADP F
either 0 CCONJ F
arm 0 NOUN F
of 0 ADP F
the 0 DET F
study 0 NOUN F
. 0 PUNCT F

CONCLUSIONS 0 NOUN T
Rationing 0 PUNCT T
by 0 ADP F
delay 0 PUNCT F
was 0 ADV F
not 0 ADV F
detrimental 0 ADJ F
to 0 ADP F
either 0 CCONJ F
mental 0 ADJ F
or 0 CCONJ F
physical 0 ADJ F
health 0 NOUN F
and 0 CCONJ F
patients 0 NOUN F
in 0 ADP F
both 0 PUNCT F
arms 0 NOUN F
of 0 ADP F
the 0 DET F
study 0 NOUN F
showed 0 VERB F
significant 0 ADJ F
and 0 CCONJ F
similar 0 ADJ F
improvement 0 NOUN F
in 0 ADP F
health 0 NOUN F
by 0 ADP F
15 0 NUM F
months 0 NOUN F
. 0 PUNCT F

Expenditure 0 NOUN T
of 0 ADP F
resources 0 NOUN F
on 0 ADP F
waiting 0 PROPN F
times 0 NOUN F
without 0 ADP F
regard 0 NOUN F
to 0 ADP F
clinical 0 ADJ F
outcomes 0 NOUN F
is 0 VERB F
likely 0 ADJ F
to 0 PART F
be 0 PUNCT F
wasteful 0 ADJ F
and 0 CCONJ F
additional 0 ADJ F
resources 0 NOUN F
should 0 VERB F
be 0 VERB F
directed 0 VERB F
at 0 ADP F
achieving 0 VERB F
the 0 DET F
greatest 0 PUNCT F
clinical 0 ADJ F
benefit 0 NOUN F
. 0 PUNCT F

More 0 DET T
research 0 NOUN F
into 0 ADP F
effective 0 ADJ F
methods 0 NOUN F
of 0 ADP F
controlling 0 VERB F
demand 0 NOUN F
and 0 CCONJ F
better 0 PUNCT F
identification 0 NOUN F
of 0 ADP F
those 0 ADP F
who 0 ADP F
would 0 VERB F
benefit 0 VERB F
from 0 ADP F
access 0 NOUN F
to 0 ADP F
specialist 0 NOUN F
care 0 NOUN F
is 0 PUNCT F
needed 0 VERB F
. 0 PUNCT F

Heart 0 NOUN T
rate 0 NOUN F
variability 0 NOUN F
characteristics 0 NOUN F
in 0 ADP F
sedentary 0 ADJ F
postmenopausal 0 ADJ F
women 0 NOUN F
following 0 VERB F
six 0 NUM F
months 0 NOUN F
of 0 ADP F
exercise 0 NOUN F
training 0 VERB F
: 0 PUNCT F
the 0 DET F
DREW 0 NOUN T
study 0 NOUN F
. 0 PUNCT F

BACKGROUND 0 NOUN T
Decreased 0 PUNCT T
heart 0 NOUN F
rate 0 NOUN F
variability 0 NOUN F
( 0 PUNCT F
HRV 0 NOUN T
) 0 PUNCT F
is 0 VERB F
associated 0 VERB F
with 0 ADP F
a 0 DET F
higher 0 PUNCT F
risk 0 NOUN F
of 0 ADP F
mortality 0 NOUN F
. 0 PUNCT F

Overall 0 ADV T
, 0 PUNCT F
postmenopausal 0 ADJ F
women 0 NOUN F
have 0 CCONJ F
lower 0 PUNCT F
levels 0 NOUN F
of 0 ADP F
HRV 0 NOUN T
than 0 PUNCT F
premenopausal 0 ADJ F
women 0 NOUN F
, 0 PUNCT F
which 0 ADP F
may 0 VERB F
be 0 VERB F
additionally 0 ADV F
complicated 0 VERB F
by 0 ADP F
lifestyle 0 NOUN F
related 0 VERB F
behaviors 0 NOUN F
such 0 ADP F
as 0 ADP F
physical 0 ADJ F
inactivity 0 NOUN F
and 0 CCONJ F
obesity 0 NOUN F
. 0 PUNCT F

Though 0 ADP T
cardiorespiratory 0 ADJ F
exercise 0 NOUN F
training 0 PUNCT F
increases 0 CCONJ F
HRV 0 NOUN T
, 0 PUNCT F
little 0 PUNCT F
is 0 VERB F
known 0 VERB F
regarding 0 VERB F
the 0 DET F
exercise 0 NOUN F
dose 0 NOUN F
necessary 0 ADJ F
to 0 PART F
promote 0 NOUN F
this 0 DET F
improvement 0 NOUN F
. 0 PUNCT F

METHODOLOGY/PRINCIPAL 0 ADV T
FINDINGS 0 NOUN T
Our 0 ADJ T
primary 0 ADJ F
aim 0 NOUN F
was 0 VERB F
to 0 ADV F
measure 0 VERB F
HRV 0 NOUN T
in 0 ADP F
post-menopausal 0 ADJ F
women 0 NOUN F
following 0 VERB F
6-months 0 NOUN F
of 0 ADP F
exercise 0 NOUN F
training 0 VERB F
. 0 PUNCT F

We 0 PRON T
examined 0 VERB F
supine 0 NOUN F
resting 0 VERB F
HRV 0 NOUN T
in 0 ADP F
373 0 NUM F
post-menopausal 0 ADJ F
women 0 NOUN F
( 0 PUNCT F
45-75 0 PUNCT F
y 0 NOUN F
) 0 PUNCT F
after 0 ADP F
6-months 0 NOUN F
of 0 ADP F
randomly 0 ADV F
assigned 0 VERB F
and 0 CCONJ F
double-blinded 0 PUNCT F
administered 0 DET F
exercise 0 NOUN F
training 0 VERB F
exercise 0 NOUN F
training 0 VERB F
at 0 ADP F
50 0 NUM F
% 0 SYM F
, 0 PUNCT F
100 0 NUM F
% 0 SYM F
and 0 CCONJ F
150 0 NUM F
% 0 DET F
of 0 ADP F
the 0 DET F
NIH 0 NOUN T
Consensus 0 NOUN T
Development 0 NOUN T
Panel 0 NOUN T
's 0 PUNCT F
recommended 0 DET F
minimal 0 ADJ F
physical 0 ADJ F
activity 0 NOUN F
level 0 NOUN F
. 0 PUNCT F

This 0 PUNCT T
corresponded 0 CCONJ F
to 0 ADP F
4 0 PUNCT F
, 0 PUNCT F
8 0 NUM F
, 0 PUNCT F
or 0 CCONJ F
12 0 NUM F
kcal/kg 0 NOUN F
per 0 ADP F
week 0 NOUN F
( 0 PUNCT F
KKW 0 NOUN T
) 0 PUNCT F
of 0 ADP F
energy 0 NOUN F
expenditure 0 NOUN F
. 0 PUNCT F

At 0 ADP T
baseline 0 NOUN F
, 0 PUNCT F
we 0 PUNCT F
observed 0 VERB F
no 0 DET F
significant 0 ADJ F
differences 0 NOUN F
in 0 ADP F
HRV B-PHYSICAL NOUN T
or 0 CCONJ F
hormone B-PHYSICAL NOUN F
replacement 0 NOUN F
use 0 PUNCT F
between 0 ADP F
treatment 0 NOUN F
groups 0 NOUN F
. 0 PUNCT F

However 0 ADV T
, 0 PUNCT F
we 0 PROPN F
did 0 CCONJ F
observe 0 PUNCT F
that 0 ADP F
Caucasian 0 ADJ T
women 0 NOUN F
and 0 CCONJ F
those 0 PUNCT F
taking 0 PUNCT F
antidepressant 0 NOUN F
medications 0 NOUN F
had 0 ADP F
lower 0 ADP F
levels 0 NOUN F
of 0 ADP F
baseline 0 NOUN F
HRV B-PHYSICAL NOUN T
. 0 PUNCT F

After 0 ADP T
6-months 0 NOUN F
of 0 ADP F
exercise 0 NOUN F
intervention 0 NOUN F
, 0 PUNCT F
we 0 PRON F
observed 0 VERB F
a 0 DET F
dose 0 NOUN F
dependent 0 ADJ F
increase 0 NOUN F
in 0 ADP F
all 0 PUNCT F
parasympathetically 0 ADJ F
derived 0 VERB F
time B-PHYSICAL NOUN F
and I-PHYSICAL CCONJ F
frequency 0 NOUN F
domain B-PHYSICAL NOUN F
measurements B-PHYSICAL NOUN F
across 0 ADP F
exercise 0 NOUN F
groups 0 NOUN F
after 0 ADP F
adjustment 0 NOUN F
for 0 ADP F
age 0 NOUN F
, 0 PUNCT F
ethnicity 0 NOUN F
, 0 PUNCT F
antidepressants B-PHYSICAL NOUN F
, 0 PUNCT F
and 0 CCONJ F
baseline 0 NOUN F
rMSSD 0 NOUN F
( 0 PUNCT F
all 0 ADP F
, 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.001 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

For 0 ADP T
example 0 NOUN F
, 0 PUNCT F
the 0 PUNCT F

Milk 0 NOUN T
protein 0 NOUN F
quantity 0 NOUN F
and 0 CCONJ F
quality 0 NOUN F
in 0 ADP F
low-birth-weight 0 ADJ F
infants 0 NOUN F
. 0 PUNCT F

IV 0 NUM T
. 0 PUNCT F

Effects 0 NOUN T
on 0 ADP F
tyrosine B-PHYSICAL NOUN F
and 0 CCONJ F
phenylalanine B-PHYSICAL NOUN F
in 0 ADP F
plasma 0 NOUN F
and 0 CCONJ F
urine 0 NOUN F
. 0 PUNCT F

Well 0 VERB T
, 0 PUNCT F
appropriate-for-gestational 0 ADJ F
age 0 NOUN F
, 0 PUNCT F
low-birth-weight 0 ADJ F
infants 0 NOUN F
were 0 VERB F
divided 0 VERB F
into 0 ADP F
three 0 NUM F
gestational 0 ADJ F
age 0 NOUN F
groups 0 NOUN F
and 0 CCONJ F
assigned 0 PUNCT F
randomly 0 ADV F
within 0 ADP F
each 0 DET F
age 0 NOUN F
group 0 NOUN F
to 0 ADP F
one 0 PUNCT F
of 0 ADP F
five 0 NUM F
feeding 0 ADP F
regimens 0 NOUN F
: 0 PUNCT F
pooled 0 DET F
human 0 NOUN F
milk 0 NOUN F
( 0 PUNCT F
BM 0 NOUN T
) 0 PUNCT F
; 0 PUNCT F
formula 0 NOUN F
1 0 NUM F
( 0 PUNCT F
F1 0 NOUN T
) 0 PUNCT F
= 0 ADP F
1.5 0 NUM F
gm/dl 0 NOUN F
protein 0 NOUN F
, 0 PUNCT F
60 0 NUM F
parts 0 NOUN F
bovine 0 ADJ F
whey 0 PUNCT F
proteins 0 NOUN F
: 0 PUNCT F
40 0 NUM F
parts 0 NOUN F
bovine 0 ADJ F
caseins 0 NOUN F
; 0 PUNCT F
F2 0 NOUN T
= 0 SYM F
3.0 0 NUM F
gm/dl 0 NOUN F
, 0 PUNCT F
60:40 0 NOUN F
; 0 PUNCT F
F3 0 NOUN T
= 0 DET F
1.5 0 NUM F
gm/dl 0 NOUN F
, 0 PUNCT F
18:82 0 NOUN F
; 0 PUNCT F
F4 0 NOUN T
= 0 SYM F
3.0 0 NUM F
gm/dl 0 NOUN F
, 0 PUNCT F
18:82 0 NOUN F
. 0 PUNCT F

Plasma 0 NOUN T
and 0 CCONJ F
urine 0 NOUN F
concentrations 0 NOUN F
of 0 ADP F
tyrosine B-PHYSICAL NOUN F
and 0 CCONJ F
phenylalanine B-PHYSICAL NOUN F
were 0 VERB F
far 0 ADV F
higher 0 PUNCT F
in 0 ADP F
the 0 DET F
infants 0 NOUN F
fed 0 VERB F
F1 0 NOUN T
to 0 ADP F
F4 0 NOUN T
, 0 PUNCT F
especially 0 ADV F
F2 0 NOUN T
and 0 CCONJ F
F4 0 NOUN T
, 0 PUNCT F
than 0 CCONJ F
in 0 ADP F
the 0 DET F
infants 0 NOUN F
fed 0 VERB F
BM 0 NOUN T
. 0 PUNCT F

These 0 DET T
findings 0 NOUN F
offer 0 VERB F
further 0 ADJ F
evidence 0 NOUN F
for 0 ADP F
the 0 DET F
limited 0 VERB F
capacity 0 NOUN F
of 0 ADP F
the 0 DET F
low-birth-weight 0 ADJ F
infant 0 NOUN F
to 0 ADP F
catabolize B-PHYSICAL PROPN F
tyrosine I-PHYSICAL NOUN F
. 0 PUNCT F

Infants 0 NOUN T
fed 0 VERB F
F3 0 NOUN T
had 0 PUNCT F
significantly 0 ADV F
higher 0 PUNCT F
plasma B-PHYSICAL NOUN F
tyrosine I-PHYSICAL NOUN F
concentrations I-PHYSICAL ADJ F
than 0 ADP F
infants 0 NOUN F
fed 0 VERB F
F1 0 NOUN T
, 0 PUNCT F
and 0 CCONJ F
those 0 PUNCT F
fed 0 VERB F
F4 0 NOUN T
had 0 PUNCT F
higher 0 PUNCT F
concentrations 0 NOUN F
than 0 PUNCT F
those 0 PUNCT F
fed 0 VERB F
F2 0 NOUN T
. 0 PUNCT F

Thus 0 ADV T
, 0 PUNCT F
increased 0 VERB F
plasma B-PHYSICAL NOUN F
tyrosine I-PHYSICAL NOUN F
concentrations I-PHYSICAL NOUN F
in 0 ADP F
low-birth-weight 0 ADJ F
infants 0 NOUN F
are 0 VERB F
related 0 VERB F
directly 0 ADP F
both 0 PUNCT F
to 0 ADP F
the 0 DET F
quantity 0 NOUN F
and 0 CCONJ F
to 0 ADP F
the 0 DET F
quality 0 NOUN F
of 0 ADP F
the 0 DET F
protein 0 NOUN F
in 0 ADP F
their 0 DET F
diets 0 NOUN F
. 0 PUNCT F

Effect 0 NOUN T
of 0 ADP F
acebutolol 0 NOUN F
on 0 ADP F
left 0 ADJ F
ventricular 0 ADJ F
performance 0 NOUN F
. 0 PUNCT F

The 0 DET T
effect 0 NOUN F
of 0 ADP F
acebutolol 0 NOUN F
on 0 ADP F
left 0 ADJ F
ventricular 0 ADJ F
performance 0 NOUN F
was 0 VERB F
examined 0 VERB F
by 0 ADP F
various 0 ADJ F
noninvasive 0 ADJ F
means 0 NOUN F
in 0 ADP F
three 0 NUM F
studies 0 NOUN F
. 0 PUNCT F

M-mode 0 ADJ T
echocardiographic 0 ADJ F
measurements 0 NOUN F
were 0 VERB F
made 0 VERB F
in 0 ADP F
21 0 NUM F
patients 0 NOUN F
with 0 ADP F
coronary 0 ADJ F
artery 0 NOUN F
disease 0 NOUN F
who 0 ADP F
were 0 VERB F
receiving 0 ADP F
placebo 0 NOUN F
, 0 PUNCT F
acebutolol 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
propranolol 0 NOUN F
in 0 ADP F
a 0 DET F
double-blind 0 ADJ F
, 0 PUNCT F
randomized 0 VERB F
, 0 PUNCT F
crossover 0 ADP F
study 0 NOUN F
. 0 PUNCT F

In 0 ADP T
these 0 DET F
patients 0 NOUN F
with 0 ADP F
normal 0 ADJ F
or 0 CCONJ F
near-normal 0 ADJ F
resting 0 PUNCT F
left 0 ADJ F
ventricular 0 ADJ F
function 0 NOUN F
, 0 PUNCT F
neither 0 CCONJ F
drug 0 NOUN F
induced 0 VERB F
depression 0 NOUN F
of 0 ADP F
left 0 ADJ F
ventricular 0 ADJ F
function 0 NOUN F
. 0 PUNCT F

In 0 ADP T
26 0 NUM F
patients 0 NOUN F
with 0 ADP F
chronic 0 ADJ F
angina 0 NOUN F
pectoris 0 NOUN F
receiving 0 VERB F
acebutolol 0 NOUN F
under 0 ADP F
double-blind 0 ADJ F
, 0 PUNCT F
placebo-controlled 0 VERB F
conditions 0 NOUN F
, 0 PUNCT F
gated 0 VERB F
( 0 PUNCT F
equilibrium 0 NOUN F
) 0 PUNCT F
myocardial 0 ADJ F
blood 0 NOUN F
pool 0 NOUN F
imaging 0 ADJ F
using 0 ADV F
red 0 ADJ F
blood 0 NOUN F
cells 0 NOUN F
labeled 0 VERB F
with 0 ADP F
technetium 0 NOUN F
99m 0 NOUN F
showed 0 CCONJ F
acebutolol 0 NOUN F
to 0 ADP F
have 0 PUNCT F
no 0 DET F
clinically 0 ADV F
significant 0 ADJ F
negative 0 ADJ F
effect 0 NOUN F
on 0 ADP F
left 0 ADJ F
ventricular 0 ADJ F
performance 0 NOUN F
at 0 ADP F
rest 0 NOUN F
or 0 CCONJ F
during 0 ADP F
supine 0 NOUN F
bicycle 0 NOUN F
exercise 0 NOUN F
. 0 PUNCT F

Acebutolol 0 NOUN T
at 0 ADP F
effective 0 ADJ F
antianginal 0 ADJ F
doses 0 NOUN F
modestly 0 ADV F
improved 0 VERB F
resting B-PHYSICAL VERB F
global I-PHYSICAL ADJ F
and 0 CCONJ F
regional B-PHYSICAL ADJ F
myocardial I-PHYSICAL ADJ F
function I-PHYSICAL NOUN F
. 0 PUNCT F

In 0 ADP T
13 0 NUM F
patients 0 NOUN F
with 0 ADP F
stable 0 ADJ F
angina 0 NOUN F
pectoris 0 NOUN F
, 0 PUNCT F
single-pass 0 ADJ F
studies 0 NOUN F
of 0 ADP F
left 0 ADJ F
ventricular 0 ADJ F
function 0 NOUN F
with 0 ADP F
indium 0 NOUN F
113 0 NUM F
under 0 ADP F
double-blind 0 ADJ F
, 0 PUNCT F
placebo-controlled 0 VERB F
conditions 0 NOUN F
similarly 0 ADV F
showed 0 ADV F
acebutolol 0 NOUN F
to 0 ADP F
have 0 PUNCT F
no 0 DET F
clinically 0 ADV F
significant 0 ADJ F
negative 0 ADJ F
inotropic 0 ADJ F
effects 0 NOUN F
. 0 PUNCT F

In 0 ADP T
conclusion 0 NOUN F
, 0 PUNCT F
acebutolol 0 NOUN F
is 0 VERB F
safe 0 ADJ F
for 0 ADP F
use 0 NOUN F
in 0 ADP F
patients 0 NOUN F
with 0 ADP F
coronary 0 ADJ F
disease 0 NOUN F
and 0 CCONJ F
a 0 DET F
wide 0 ADJ F
range 0 NOUN F
of 0 ADP F
ejection 0 NOUN F
fractions 0 NOUN F
but 0 CCONJ F
, 0 PUNCT F
as 0 CCONJ F
with 0 ADP F
all 0 DET F
beta 0 NOUN F
blockers 0 NOUN F
, 0 PUNCT F
should 0 ADP F
be 0 VERB F
used 0 VERB F
cautiously 0 ADJ F
in 0 ADP F
patients 0 NOUN F
with 0 ADP F
markedly 0 ADV F
reduced 0 PUNCT F
resting 0 VERB F
left 0 ADJ F
ventricular 0 ADJ F
function 0 NOUN F
. 0 PUNCT F

Risperidone 0 NUM T
in 0 ADP F
children 0 NOUN F
with 0 ADP F
autism 0 NOUN F
and 0 CCONJ F
serious 0 ADJ F
behavioral 0 ADJ F
problems 0 NOUN F
. 0 PUNCT F

BACKGROUND 0 NOUN T
Atypical 0 ADJ T
antipsychotic 0 ADJ F
agents 0 NOUN F
, 0 PUNCT F
which 0 PUNCT F
block 0 VERB F
postsynaptic 0 ADJ F
dopamine 0 NOUN F
and 0 CCONJ F
serotonin 0 NOUN F
receptors 0 NOUN F
, 0 PUNCT F
have 0 VERB F
advantages 0 NOUN F
over 0 ADP F
traditional 0 ADJ F
antipsychotic 0 ADJ F
medications 0 NOUN F
in 0 ADP F
the 0 DET F
treatment 0 NOUN F
of 0 ADP F
adults 0 NOUN F
with 0 ADP F
schizophrenia 0 NOUN F
and 0 CCONJ F
may 0 VERB F
be 0 VERB F
beneficial 0 ADJ F
in 0 ADP F
children 0 NOUN F
with 0 ADP F
autistic 0 ADJ F
disorder 0 NOUN F
who 0 CCONJ F
have 0 PUNCT F
serious 0 ADJ F
behavioral 0 ADJ F
disturbances 0 NOUN F
. 0 PUNCT F

However 0 ADV T
, 0 PUNCT F
data 0 NOUN F
on 0 ADP F
the 0 DET F
safety 0 NOUN F
and 0 CCONJ F
efficacy 0 NOUN F
of 0 ADP F
atypical 0 ADJ F
antipsychotic 0 ADJ F
agents 0 NOUN F
in 0 ADP F
children 0 NOUN F
are 0 VERB F
limited 0 VERB F
. 0 PUNCT F

METHODS 0 NOUN T
We 0 PRON T
conducted 0 VERB F
a 0 DET F
multisite 0 NOUN F
, 0 PUNCT F
randomized 0 VERB F
, 0 PUNCT F
double-blind 0 ADJ F
trial 0 NOUN F
of 0 ADP F
risperidone 0 NUM F
as 0 PUNCT F
compared 0 VERB F
with 0 ADP F
placebo 0 NOUN F
for 0 ADP F
the 0 DET F
treatment 0 NOUN F
of 0 ADP F
autistic 0 ADJ F
disorder 0 NOUN F
accompanied 0 VERB F
by 0 ADP F
severe 0 ADJ F
tantrums 0 ADP F
, 0 PUNCT F
aggression 0 NOUN F
, 0 PUNCT F
or 0 CCONJ F
self-injurious 0 ADJ F
behavior 0 NOUN F
in 0 ADP F
children 0 NOUN F
5 0 NUM F
to 0 ADP F
17 0 NUM F
years 0 NOUN F
old 0 ADJ F
. 0 PUNCT F

The 0 DET T
primary 0 ADJ F
outcome 0 NOUN F
measures 0 NOUN F
were 0 VERB F
the 0 DET F
score 0 NOUN F
on 0 ADP F
the 0 DET F
Irritability 0 NOUN T
subscale 0 NOUN F
of 0 ADP F
the 0 DET F
Aberrant 0 ADJ T
Behavior 0 NOUN T
Checklist 0 NOUN T
and 0 CCONJ F
the 0 DET F
rating 0 VERB F
on 0 ADP F
the 0 DET F
Clinical 0 ADJ T
Global 0 PUNCT T
Impressions 0 NOUN T
- 0 PUNCT F
Improvement 0 NOUN T
( 0 PUNCT F
CGI-I 0 NOUN T
) 0 PUNCT F
scale 0 NOUN F
at 0 ADP F
eight 0 NUM F
weeks 0 NOUN F
. 0 PUNCT F

RESULTS 0 NOUN T
A 0 PUNCT T
total 0 NOUN F
of 0 ADP F
101 0 NUM F
children 0 NOUN F
( 0 PUNCT F
82 0 NUM F
boys 0 NOUN F
and 0 CCONJ F
19 0 NUM F
girls 0 NOUN F
; 0 PUNCT F
mean 0 NOUN F
[ 0 PUNCT F
+/-SD 0 PUNCT F
] 0 PUNCT F
age 0 NOUN F
, 0 PUNCT F
8.8+/-2.7 0 NOUN F
years 0 NOUN F
) 0 PUNCT F
were 0 VERB F
randomly 0 ADV F
assigned 0 VERB F
to 0 PART F
receive 0 NOUN F
risperidone 0 NUM F
( 0 PUNCT F
49 0 NUM F
children 0 NOUN F
) 0 PUNCT F
or 0 CCONJ F
placebo 0 NOUN F
( 0 PUNCT F
52 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Treatment 0 NOUN T
with 0 ADP F
risperidone 0 NUM F
for 0 ADP F
eight 0 NUM F
weeks 0 NOUN F
( 0 PUNCT F
dose 0 NOUN F
range 0 NOUN F
, 0 PUNCT F
0.5 0 NUM F
to 0 ADP F
3.5 0 NUM F
mg 0 NOUN F
per 0 ADP F
day 0 NOUN F
) 0 PUNCT F
resulted 0 VERB F
in 0 ADP F
a 0 DET F
56.9 0 NUM F
percent 0 NOUN F
reduction 0 NOUN F
in 0 ADP F
the 0 DET F
Irritability B-MENTAL NOUN T
score I-MENTAL NOUN F
, 0 PUNCT F
as 0 PUNCT F
compared 0 VERB F
with 0 ADP F
a 0 DET F
14.1 0 NUM F
percent 0 NOUN F
decrease 0 NOUN F
in 0 ADP F
the 0 DET F
placebo 0 NOUN F
group 0 NOUN F
( 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.001 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
rate 0 NOUN F
of 0 ADP F
a 0 DET F
positive 0 ADJ F
response 0 NOUN F
, 0 PUNCT F
defined 0 VERB F
as 0 ADP F
at 0 VERB F
least 0 DET F
a 0 DET F
25 0 NUM F
percent 0 NOUN F
decrease 0 NOUN F
in 0 ADP F
the 0 DET F
Irritability B-MENTAL NOUN T
score I-MENTAL NOUN F
and 0 CCONJ F
a 0 DET F
rating 0 PUNCT F
of 0 ADP F
much 0 DET F
improved 0 ADP F
or 0 CCONJ F
very 0 ADV F
much 0 DET F
improved 0 VERB F
on 0 ADP F
the 0 DET F
CGI-I B-MENTAL NOUN T
scale I-MENTAL NOUN F
, 0 PUNCT F
was 0 VERB F
69 0 NUM F
percent 0 NOUN F
in 0 ADP F
the 0 DET F
risperidone 0 NOUN F
group 0 NOUN F
( 0 PUNCT F
34 0 NUM F
of 0 ADP F
49 0 NUM F
children 0 NOUN F
had 0 ADP F
a 0 DET F
positive 0 ADJ F
response 0 NOUN F
) 0 PUNCT F
and 0 CCONJ F
12 0 NUM F
percent 0 NOUN F
in 0 ADP F
the 0 DET F
placebo 0 NOUN F
group 0 NOUN F
( 0 PUNCT F
6 0 NUM F
of 0 ADP F
52 0 NUM F
, 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.001 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Risperidone 0 NUM T
therapy 0 NOUN F
was 0 VERB F
associated 0 VERB F
with 0 ADP F
an 0 DET F
average 0 ADJ F
weight 0 NOUN F
gain B-PHYSICAL NOUN F
of 0 ADP F
2.7+/-2.9 0 NOUN F
kg 0 NOUN F
, 0 PUNCT F
as 0 PUNCT F
compared 0 VERB F
with 0 ADP F
0.8+/-2.2 0 PUNCT F
kg 0 NOUN F
with 0 ADP F
placebo 0 NOUN F
( 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.001 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Increased 0 VERB T
appetite B-PHYSICAL NOUN F
, 0 PUNCT F
fatigue B-ADVERSE-EFFECTS NOUN F
, 0 PUNCT F
drowsiness B-ADVERSE-EFFECTS PUNCT F
, 0 PUNCT F
dizziness B-ADVERSE-EFFECTS NOUN F
, 0 PUNCT F
and 0 CCONJ F
drooling B-ADVERSE-EFFECTS PUNCT F
were 0 VERB F
more 0 ADV F
common 0 ADJ F
in 0 ADP F
the 0 DET F
risperidone 0 NOUN F
group 0 NOUN F
than 0 PUNCT F
in 0 ADP F
the 0 DET F
placebo 0 NOUN F
group 0 NOUN F
( 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.05 0 NUM F
for 0 ADP F
each 0 DET F
comparison 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

In 0 ADP T
two 0 NUM F
thirds 0 NOUN F
of 0 ADP F
the 0 DET F
children 0 NOUN F
with 0 ADP F
a 0 DET F
positive 0 ADJ F
response 0 NOUN F
to 0 ADP F
risperidone 0 NUM F
at 0 ADP F
eight 0 NUM F
weeks 0 NOUN F
( 0 PUNCT F
23 0 NUM F
of 0 ADP F
34 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
the 0 DET F
benefit 0 NOUN F
was 0 VERB F
maintained 0 VERB F
at 0 ADP F
six 0 NUM F
months 0 NOUN F
. 0 PUNCT F

CONCLUSIONS 0 NOUN T
Risperidone 0 NUM T
was 0 VERB F
effective 0 ADJ F
and 0 CCONJ F
well 0 VERB F
tolerated 0 ADP F
for 0 ADP F
the 0 DET F
treatment 0 NOUN F
of 0 ADP F
tantrums 0 ADV F
, 0 PUNCT F
aggression 0 NOUN F
, 0 PUNCT F
or 0 CCONJ F
self-injurious 0 ADJ F
behavior 0 NOUN F
in 0 ADP F
children 0 NOUN F
with 0 ADP F
autistic 0 ADJ F
disorder 0 NOUN F
. 0 PUNCT F

The 0 DET T
short 0 ADJ F
period 0 NOUN F
of 0 ADP F
this 0 DET F
trial 0 NOUN F
limits 0 NOUN F
inferences 0 PUNCT F
about 0 PUNCT F
adverse 0 ADJ F
effects 0 NOUN F
such 0 CCONJ F
as 0 ADP F
tardive 0 ADJ F
dyskinesia 0 NOUN F
. 0 PUNCT F

Efficacy 0 NOUN T
of 0 ADP F
outpatient 0 ADJ F
induction 0 NOUN F
with 0 ADP F
low-dose 0 NOUN F
intravaginal 0 ADJ F
prostaglandin 0 NOUN F
E2 0 NOUN T
: 0 PUNCT F
a 0 DET F
randomized 0 VERB F
, 0 PUNCT F
double-blind 0 ADJ F
, 0 PUNCT F
placebo-controlled 0 VERB F
trial 0 NOUN F
. 0 PUNCT F

OBJECTIVE 0 NOUN T
Our 0 PUNCT T
purpose 0 NOUN F
was 0 VERB F
to 0 PART F
determine 0 NOUN F
whether 0 ADP F
a 0 DET F
protocol 0 NOUN F
for 0 ADP F
outpatient 0 ADJ F
induction 0 NOUN F
is 0 VERB F
safe B-PHYSICAL ADJ F
and 0 CCONJ F
effective 0 ADJ F
for 0 ADP F
initiating 0 VERB F
labor 0 NOUN F
. 0 PUNCT F

STUDY 0 NOUN T
DESIGN 0 NOUN T
A 0 NOUN T
randomized 0 VERB F
, 0 PUNCT F
double-blind 0 ADJ F
, 0 PUNCT F
placebo-controlled 0 VERB F
trial 0 NOUN F
was 0 VERB F
performed 0 VERB F
with 0 ADP F
100 0 NUM F
low-risk 0 NOUN F
patients 0 NOUN F
having 0 ADJ F
well-dated 0 VERB F
pregnancies 0 NOUN F
. 0 PUNCT F

Women 0 NOUN T
with 0 ADP F
a 0 DET F
Bishop 0 ADJ T
score 0 NOUN F
< 0 SYM F
or 0 CCONJ F
= 0 SYM F
6 0 NUM F
at 0 ADP F
38 0 NUM F
to 0 ADP F
40 0 NUM F
weeks 0 NOUN F
' 0 PUNCT F
gestation 0 NOUN F
were 0 VERB F
administered 0 ADP F
either 0 CCONJ F
2 0 NUM F
mg 0 NOUN F
of 0 ADP F
intravaginal 0 ADJ F
prostaglandin 0 NOUN F
E2 0 NOUN T
gel 0 NOUN F
or 0 CCONJ F
placebo 0 NOUN F
for 0 ADP F
5 0 NUM F
consecutive 0 ADJ F
days 0 NOUN F
as 0 ADP F
outpatients 0 VERB F
while 0 ADP F
undergoing 0 ADP F
fetal 0 ADJ F
monitoring 0 VERB F
. 0 PUNCT F

RESULTS 0 PUNCT T
The 0 DET T
median 0 ADJ F
interval 0 NOUN F
from 0 ADP F
randomization 0 NOUN F
to B-PHYSICAL ADP F
delivery I-PHYSICAL NOUN F
was 0 VERB F
4 0 NUM F
days 0 NOUN F
in 0 ADP F
the 0 DET F
prostaglandin 0 NOUN F
E2 0 NOUN T
group 0 NOUN F
( 0 PUNCT F
range 0 NOUN F
0 0 NUM F
to 0 ADP F
28 0 NUM F
days 0 NOUN F
) 0 PUNCT F
versus 0 CCONJ F
10 0 NUM F
days 0 NOUN F
in 0 ADP F
the 0 DET F
placebo 0 NOUN F
group 0 NOUN F
( 0 PUNCT F
range 0 NOUN F
0 0 NUM F
to 0 ADP F
26 0 NUM F
days 0 NOUN F
, 0 PUNCT F
p 0 NOUN F
= 0 SYM F
0.002 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Twenty-seven 0 PUNCT T
of 0 ADP F
50 0 NUM F
patients 0 NOUN F
( 0 PUNCT F
54 0 NUM F
% 0 SYM F
) 0 PUNCT F
in 0 ADP F
the 0 DET F
prostaglandin 0 NOUN F
E2 0 NOUN T
group 0 NOUN F
were 0 VERB F
admitted 0 VERB F
for 0 ADP F
labor 0 NOUN F
during 0 ADP F
the 0 DET F
dosing 0 ADJ F
interval 0 NOUN F
compared 0 VERB F
with 0 ADP F
10 0 NUM F
placebo-treated 0 VERB F
patients 0 NOUN F
( 0 PUNCT F
20 0 NUM F
% 0 SYM F
, 0 PUNCT F
p 0 NOUN F
= 0 SYM F
0.001 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
mean 0 NOUN F
gestational B-PHYSICAL ADJ F
age 0 NOUN F
at B-PHYSICAL ADP F
delivery B-PHYSICAL NOUN F
was 0 VERB F
significantly 0 ADV F
reduced 0 VERB F
in 0 ADP F
the 0 DET F
treatment 0 NOUN F
group 0 NOUN F
( 0 PUNCT F
39.9 0 NUM F
+/- 0 SYM F
1.0 0 NUM F
weeks 0 NOUN F
vs 0 CCONJ F
40.5 0 NUM F
+/- 0 SYM F
0.99 0 NUM F
weeks 0 NOUN F
, 0 PUNCT F
p 0 NOUN F
= 0 SYM F
0.003 0 NUM F
) 0 PUNCT F
as 0 CCONJ F
was 0 VERB F
the 0 DET F
incidence 0 NOUN F
of 0 ADP F
postdates B-MENTAL PUNCT F

Walking 0 VERB T
trials 0 NOUN F
in 0 ADP F
postmenopausal 0 ADJ F
women 0 NOUN F
: 0 PUNCT F
effect 0 NOUN F
of 0 ADP F
one 0 NUM F
vs 0 CCONJ F
two 0 NUM F
daily 0 ADJ F
bouts 0 NOUN F
on 0 ADP F
aerobic B-PHYSICAL ADJ F
fitness I-PHYSICAL PUNCT F
. 0 PUNCT F

We 0 PRON T
compared 0 VERB F
the 0 DET F
effects 0 NOUN F
of 0 ADP F
one 0 NUM F
vs 0 CCONJ F
two 0 NUM F
daily 0 ADJ F
bouts 0 NOUN F
of 0 ADP F
walking 0 NUM F
on 0 ADP F
aerobic B-PHYSICAL ADJ F
fitness I-PHYSICAL PUNCT F
and 0 CCONJ F
body B-PHYSICAL NOUN F
composition I-PHYSICAL NOUN F
in 0 ADP F
postmenopausal 0 ADJ F
women 0 NOUN F
. 0 PUNCT F

One 0 NUM T
hundred 0 NUM F
and 0 CCONJ F
thirty-four 0 NOUN F
subjects 0 NOUN F
were 0 VERB F
randomized 0 VERB F
into 0 ADP F
exercise 0 NOUN F
groups 0 NOUN F
or 0 CCONJ F
a 0 DET F
control 0 NOUN F
group 0 NOUN F
and 0 CCONJ F
130 0 NUM F
completed 0 PUNCT F
the 0 DET F
study 0 NOUN F
. 0 PUNCT F

The 0 DET T
subjects 0 NOUN F
walked 0 PUNCT F
5 0 NUM F
d/week 0 NOUN F
for 0 ADP F
15 0 NUM F
weeks 0 NOUN F
at 0 ADP F
65 0 NUM F
% 0 SYM F
of 0 ADP F
their 0 PUNCT F
maximal 0 ADJ F
aerobic 0 ADJ F
power 0 NOUN F
expending 0 CCONJ F
300 0 NUM F
kcal 0 NOUN F
( 0 PUNCT F
1255 0 ADP F
kJ 0 NOUN F
) 0 PUNCT F
in 0 ADP F
exercise 0 NOUN F
in 0 ADP F
one 0 NUM F
( 0 PUNCT F
Group 0 NOUN T
S1 0 NOUN T
) 0 PUNCT F
or 0 CCONJ F
two 0 NUM F
daily 0 ADJ F
sessions 0 NOUN F
( 0 PUNCT F
Group 0 NOUN T
S2 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

VO B-PHYSICAL NOUN T
( I-PHYSICAL PUNCT F
2max I-PHYSICAL NOUN F
) I-PHYSICAL PUNCT F
was 0 VERB F
measured 0 VERB F
in 0 ADP F
a 0 DET F
direct 0 ADJ F
maximal 0 ADJ F
treadmill 0 ADP F
test 0 NOUN F
. 0 PUNCT F

Body 0 NOUN T
mass 0 NOUN F
index 0 NOUN F
( 0 PUNCT F
BMI 0 NOUN T
) 0 PUNCT F
was 0 VERB F
calculated 0 VERB F
and 0 CCONJ F
the 0 DET F
percentage 0 NOUN F
of 0 ADP F
body 0 NOUN F
fat 0 NOUN F
( 0 PUNCT F
fat 0 NOUN F
% 0 ADV F
) 0 PUNCT F
estimated 0 VERB F
using 0 CCONJ F
skinfold 0 PUNCT F
measurements 0 NOUN F
. 0 PUNCT F

The 0 DET T
net 0 ADJ F
change 0 NOUN F
in 0 ADP F
the 0 DET F
VO B-PHYSICAL NOUN T
( I-PHYSICAL PUNCT F
2max I-PHYSICAL NOUN F
) I-PHYSICAL PUNCT F
was 0 VERB F
2.5 0 NUM F
mL 0 NOUN F
min/kg 0 PUNCT F
( 0 PUNCT F
95 0 NUM F
% 0 SYM F
CI 0 NOUN T
1.5 0 NUM F
, 0 PUNCT F
3.5 0 NUM F
) 0 PUNCT F
( 0 PUNCT F
8.7 0 NUM F
% 0 SYM F
) 0 PUNCT F
in 0 ADP F
Group 0 NOUN T
S1 0 NOUN T
and 0 CCONJ F
2.5 0 NUM F
mL 0 NOUN F
min/kg 0 PUNCT F
( 0 PUNCT F
95 0 NUM F
% 0 SYM F
CI 0 NOUN T
1.5 0 NUM F
, 0 PUNCT F
3.5 0 NUM F
) 0 PUNCT F
( 0 PUNCT F
8.8 0 NUM F
% 0 SYM F
) 0 PUNCT F
in 0 ADP F
Group 0 NOUN T
S2 0 NOUN T
. 0 PUNCT F

The 0 DET T
net B-PHYSICAL ADJ F
change I-PHYSICAL NOUN F
in I-PHYSICAL ADP F
body I-PHYSICAL NOUN F
mass I-PHYSICAL NOUN F
was 0 VERB F
-1.2 0 NUM F
kg 0 NOUN F
( 0 PUNCT F
95 0 NUM F
% 0 SYM F
CI-1.9 0 NOUN T
, 0 PUNCT F
-0.5 0 PUNCT F
) 0 PUNCT F
in 0 ADP F
Group 0 NOUN T
S1 0 NOUN T
and 0 CCONJ F
-1.1 0 NUM F
kg 0 NOUN F
( 0 PUNCT F
95 0 NUM F
% 0 SYM F
CI 0 NOUN T
-1.8 0 NUM F
, 0 PUNCT F
-0.4 0 PUNCT F
) 0 PUNCT F
in 0 ADP F
Group 0 NOUN T
S2 0 NOUN T
. 0 PUNCT F

The 0 DET T
net B-PHYSICAL ADJ F
fat I-PHYSICAL NOUN F
% I-PHYSICAL DET F
change I-PHYSICAL NOUN F
was 0 VERB F
-2.1 0 ADV F
% 0 SYM F
( 0 PUNCT F
95 0 NUM F
% 0 SYM F
CI-2.7 0 NOUN T
, 0 PUNCT F
-1.4 0 NUM F
) 0 PUNCT F
in 0 ADP F
Group 0 NOUN T
S1 0 NOUN T
and 0 CCONJ F
-1.7 0 NUM F
% 0 SYM F
( 0 PUNCT F
95 0 NUM F
% 0 SYM F
CI-2.3 0 NOUN T
, 0 PUNCT F
-1.0 0 NUM F
) 0 PUNCT F
in 0 ADP F
Group 0 NOUN T
S2 0 NOUN T
. 0 PUNCT F

Exercise 0 NOUN T
improved 0 VERB F
the 0 DET F
maximal 0 ADJ F
aerobic 0 ADJ F
power 0 NOUN F
and 0 CCONJ F
body 0 NOUN F
composition 0 NOUN F
equally 0 ADV F
when 0 ADP F
walking 0 ADP F
was 0 VERB F
performed 0 VERB F
in 0 ADP F
one 0 NUM F
or 0 CCONJ F
two 0 NUM F
daily 0 ADJ F
bouts 0 NOUN F
. 0 PUNCT F

Epileptogenic 0 ADJ T
activity 0 NOUN F
of 0 ADP F
folic 0 ADJ F
acid 0 NOUN F
after 0 ADP F
drug 0 NOUN F
induces 0 NOUN F
SLE 0 NOUN T
( 0 PUNCT F
folic 0 ADJ F
acid 0 NOUN F
and 0 CCONJ F
epilepsy 0 NOUN F
) 0 PUNCT F
OBJECTIVE 0 NOUN T
To 0 PART T
study 0 NOUN F
the 0 DET F
effect 0 NOUN F
of 0 ADP F
folic 0 ADJ F
acid-containing 0 PROPN F
multivitamin 0 NOUN F
supplementation 0 NOUN F
in 0 ADP F
epileptic 0 ADJ F
women 0 NOUN F
before 0 ADP F
and 0 CCONJ F
during 0 ADP F
pregnancy 0 NOUN F
in 0 ADP F
order 0 NOUN F
to 0 PART F
determine 0 NOUN F
the 0 DET F
rate 0 NOUN F
of 0 ADP F
structural 0 ADJ F
birth 0 NOUN F
defects 0 NOUN F
and 0 CCONJ F
epilepsy-related 0 VERB F
side 0 NOUN F
effects 0 NOUN F
. 0 PUNCT F

STUDY 0 NOUN T
DESIGN 0 NOUN T
First 0 ADJ T
a 0 DET F
randomised 0 VERB F
trial 0 NOUN F
, 0 PUNCT F
later 0 PUNCT F
periconception 0 NOUN F
care 0 NOUN F
including 0 ADJ F
in 0 ADP F
total 0 ADJ F
12225 0 NUM F
females 0 NOUN F
. 0 PUNCT F

RESULTS 0 NOUN T
Of 0 ADP T
60 0 NUM F
epileptic 0 ADJ F
women 0 NOUN F
with 0 ADP F
periconceptional 0 ADJ F
folic 0 ADJ F
acid 0 NOUN F
( 0 PUNCT F
0.8 0 NUM F
mg 0 NOUN F
) 0 PUNCT F
-containing 0 ADP F
multivitamin 0 NOUN F
supplementation 0 NOUN F
, 0 PUNCT F
no 0 DET F
one 0 NUM F
developed 0 VERB F
epilepsy-related 0 VERB F
side 0 NOUN F
effects 0 NOUN F
during 0 ADP F
the 0 DET F
periconception 0 NOUN F
period 0 NOUN F
. 0 PUNCT F

One 0 NUM T
epileptic 0 ADJ F
woman 0 NOUN F
delivered 0 ADV F
a 0 DET F
newborn 0 NOUN F
with 0 ADP F
cleft 0 NOUN F
lip 0 NOUN F
and 0 CCONJ F
palate 0 NOUN F
. 0 PUNCT F

Another 0 DET T
patient 0 NOUN F
exhibited 0 VERB F
with 0 ADP F
a 0 DET F
cluster 0 NOUN F
of 0 ADP F
seizures B-ADVERSE-EFFECTS NOUN F
after 0 ADP F
the 0 DET F
periconception 0 NOUN F
period 0 NOUN F
using 0 VERB F
another 0 DET F
multivitamin 0 NOUN F
. 0 PUNCT F

This 0 DET T
22-year-old 0 PUNCT F
epileptic 0 ADJ F
woman 0 NOUN F
was 0 VERB F
treated 0 VERB F
continuously 0 ADV F
by 0 ADP F
carbamazepine 0 NOUN F
and 0 CCONJ F
a 0 DET F
folic 0 ADJ F
acid 0 NOUN F
( 0 PUNCT F
1 0 NUM F
mg 0 NOUN F
) 0 PUNCT F
-containing 0 ADP F
multivitamin 0 NOUN F
from 0 ADP F
the 0 DET F
20th 0 ADJ F
week 0 NOUN F
of 0 ADP F
gestation 0 NOUN F
. 0 PUNCT F

She 0 NOUN T
developed 0 VERB F
status B-ADVERSE-EFFECTS NOUN F
epilepticus I-ADVERSE-EFFECTS NOUN F
and 0 CCONJ F
later 0 PUNCT F
symptoms 0 NOUN F
of 0 ADP F
systemic B-ADVERSE-EFFECTS ADJ F
lupus I-ADVERSE-EFFECTS NOUN F
erythematodes I-ADVERSE-EFFECTS VERB F
. 0 PUNCT F

Her 0 PUNCT T
pregnancy 0 NOUN F
ended 0 PUNCT F
with 0 ADP F
stillbirth B-MORTALITY PUNCT F
. 0 PUNCT F

CONCLUSIONS 0 NOUN T
The 0 DET T
epileptic 0 ADJ F
pregnant 0 ADJ F
patient 0 NOUN F
's 0 PUNCT F
autoimmune 0 ADJ F
disease 0 NOUN F
( 0 PUNCT F
probably 0 ADV F
drug-induced 0 VERB F
lupus 0 NOUN F
) 0 PUNCT F
could 0 VERB F
damage 0 VERB F
the 0 DET F
blood-brain 0 ADJ F
barrier 0 NOUN F
, 0 PUNCT F
therefore 0 ADV F
the 0 DET F
therapeutic 0 ADJ F
dose 0 NOUN F
( 0 PUNCT F
> 0 ADJ F
or 0 CCONJ F
=1 0 NUM F
mg 0 NOUN F
) 0 PUNCT F
of 0 ADP F
folic 0 ADJ F
acid 0 NOUN F
triggered 0 VERB F
a 0 DET F
cluster 0 NOUN F
of 0 ADP F
seizures B-ADVERSE-EFFECTS NOUN F
. 0 PUNCT F

Physiological 0 ADJ T
dose 0 NOUN F
( 0 PUNCT F
< 0 PROPN F
1 0 NUM F
mg 0 NOUN F
) 0 PUNCT F
of 0 ADP F
folic 0 ADJ F
acid 0 NOUN F
both 0 PUNCT F
in 0 ADP F
healthy 0 ADJ F
and 0 CCONJ F
60 0 NUM F
epileptic 0 ADJ F
women 0 NOUN F
, 0 PUNCT F
all 0 CCONJ F
without 0 ADP F
any 0 DET F
autoimmune 0 ADJ F
disease 0 NOUN F
, 0 PUNCT F
did 0 CCONJ F
not 0 ADV F
increase 0 VERB F
the 0 DET F
risk 0 NOUN F
for 0 ADP F
epileptic B-PHYSICAL ADJ F
seizures I-PHYSICAL NOUN F
. 0 PUNCT F

Impact 0 NOUN T
of 0 ADP F
an 0 DET F
Asha 0 ADJ T
intervention 0 NOUN F
on 0 ADP F
depressive B-PHYSICAL ADJ F
symptoms I-PHYSICAL NOUN F
among 0 ADP F
rural 0 ADJ F
women 0 NOUN F
living 0 CCONJ F
with 0 ADP F
AIDS 0 NOUN T
in 0 ADP F
India 0 PUNCT T
: 0 PUNCT F
comparison 0 NOUN F
of 0 ADP F
the 0 DET F
Asha-Life 0 NOUN T
and 0 CCONJ F
Usual 0 ADJ T
Care 0 NOUN T
program 0 NOUN F
. 0 PUNCT F

The 0 DET T
purpose 0 NOUN F
of 0 ADP F
this 0 DET F
randomized 0 VERB F
pilot 0 NOUN F
study 0 NOUN F
is 0 VERB F
to 0 PUNCT F
conduct 0 ADP F
an 0 DET F
intervention 0 NOUN F
with 0 ADP F
68 0 NUM F
rural 0 ADJ F
women 0 NOUN F
living 0 CCONJ F
with 0 ADP F
AIDS 0 NOUN T
to 0 PART F
compare 0 NOUN F
the 0 DET F
effectiveness 0 NOUN F
of 0 ADP F
two 0 NUM F
different 0 ADJ F
programs 0 NOUN F
on 0 ADP F
depressive 0 ADJ F
symptoms 0 NOUN F
. 0 PUNCT F

The 0 DET T
trial 0 NOUN F
was 0 VERB F
designed 0 VERB F
to 0 PART F
assess 0 NOUN F
the 0 DET F
impact 0 NOUN F
of 0 ADP F
the 0 DET F
Asha-Life 0 PUNCT T
intervention 0 NOUN F
engaging 0 PUNCT F
with 0 ADP F
an 0 DET F
HIV-trained 0 ADJ T
village 0 PUNCT F
woman 0 NOUN F
, 0 PUNCT F
Asha 0 NOUN T
( 0 PUNCT F
Accredited 0 NOUN T
Social 0 ADJ T
Health 0 NOUN T
Activist 0 NOUN T
) 0 PUNCT F
, 0 PUNCT F
to 0 PART F
participate 0 NOUN F
in 0 ADP F
the 0 DET F
care 0 NOUN F
of 0 ADP F
women 0 NOUN F
living 0 CCONJ F
with 0 ADP F
AIDS 0 NOUN T
( 0 PUNCT F
WLA 0 NOUN T
) 0 PUNCT F
, 0 PUNCT F
along 0 PUNCT F
with 0 ADP F
other 0 ADJ F
health 0 NOUN F
care 0 NOUN F
providers 0 ADV F
compared 0 VERB F
to 0 ADP F
a 0 DET F
Usual 0 ADJ T
Care 0 NOUN T
group 0 NOUN F
. 0 PUNCT F

Two 0 NUM T
high 0 ADJ F
prevalence 0 NOUN F
HIV/AIDS 0 NOUN T
villages 0 ADJ F
in 0 ADP F
rural 0 ADJ F
Andhra 0 NOUN T
Pradesh 0 NOUN T
, 0 PUNCT F
which 0 ADP F
were 0 VERB F
demographically 0 ADV F
alike 0 PUNCT F
and 0 CCONJ F
served 0 ADP F
by 0 ADP F
distinct 0 ADJ F
Public 0 ADJ T
Health 0 NOUN T
Centers 0 NOUN T
, 0 PUNCT F
were 0 VERB F
selected 0 VERB F
randomly 0 ADV F
from 0 ADP F
a 0 DET F
total 0 NOUN F
of 0 ADP F
16 0 NUM F
villages 0 NOUN F
. 0 PUNCT F

The 0 DET T
findings 0 NOUN F
of 0 ADP F
this 0 DET F
study 0 NOUN F
demonstrated 0 VERB F
that 0 ADP F
the 0 DET F
Asha-Life 0 NOUN T
participants 0 NOUN F
significantly B-PHYSICAL ADV F
reduced I-PHYSICAL VERB F
their 0 ADJ F
depressive B-PHYSICAL ADJ F
symptom I-PHYSICAL NOUN F
scores I-PHYSICAL NOUN F
compared 0 VERB F
to 0 ADP F
the 0 DET F
Usual 0 ADJ T
Care 0 NOUN T
participants 0 NOUN F
. 0 PUNCT F

Moreover 0 ADV T
, 0 PUNCT F
women 0 NOUN F
living 0 CCONJ F
with 0 ADP F
AIDS 0 NOUN T
who 0 ADP F
demonstrated 0 VERB F
higher 0 PUNCT F
depressive B-PHYSICAL ADJ F
symptom I-PHYSICAL NOUN F
scores I-PHYSICAL NOUN F
at 0 ADP F
baseline 0 NOUN F
had 0 PUNCT F
greater 0 PUNCT F
reduction 0 NOUN F
in 0 ADP F
their 0 PUNCT F
depressive B-PHYSICAL ADJ F
symptoms I-PHYSICAL NOUN F
than 0 ADP F
women 0 NOUN F
with 0 ADP F
lower 0 PUNCT F
scores 0 NOUN F
. 0 PUNCT F

Prophylactic B-PHYSICAL ADJ T
effect 0 NOUN F
of 0 ADP F
phenytoin 0 NOUN F
in 0 ADP F
bipolar 0 ADJ F
disorder 0 NOUN F
: 0 PUNCT F
a 0 DET F
controlled 0 VERB F
study 0 NOUN F
. 0 PUNCT F

OBJECTIVE 0 ADJ T
Phenytoin 0 NOUN T
is 0 VERB F
an 0 DET F
effective 0 ADJ F
anticonvulsant 0 ADJ F
that 0 PUNCT F
has 0 VERB F
not 0 ADV F
previously 0 ADV F
been 0 PUNCT F
studied 0 VERB F
prophylactically 0 ADV F
in 0 ADP F
bipolar 0 ADJ F
( 0 PUNCT F
BP 0 NOUN T
) 0 PUNCT F
patients 0 NOUN F
. 0 PUNCT F

Thus 0 ADV T
a 0 DET F
study 0 NOUN F
of 0 ADP F
phenytoin 0 PUNCT F
prophylaxis 0 NOUN F
was 0 VERB F
undertaken 0 VERB F
and 0 CCONJ F
is 0 VERB F
herein 0 ADV F
reported 0 VERB F
. 0 PUNCT F

METHOD 0 NOUN T
Bipolar 0 ADJ T
patients 0 NOUN F
were 0 VERB F
studied 0 VERB F
who 0 ADP F
had 0 PUNCT F
at 0 VERB F
least 0 ADV F
one 0 NUM F
episode 0 NOUN F
per 0 ADP F
year 0 NOUN F
in 0 ADP F
the 0 DET F
previous 0 ADJ F
2 0 NUM F
years 0 NOUN F
despite 0 ADP F
ongoing 0 ADP F
prophylaxis 0 NOUN F
. 0 PUNCT F

Patients 0 NOUN T
were 0 VERB F
stable 0 ADJ F
for 0 ADP F
a 0 DET F
mean 0 NOUN F
of 0 ADP F
4 0 NUM F
months 0 NOUN F
( 0 PUNCT F
range 0 NOUN F
1-13 0 NUM F
) 0 PUNCT F
before 0 ADP F
entering 0 CCONJ F
the 0 DET F
study 0 NOUN F
. 0 PUNCT F

Phenytoin 0 NOUN T
or 0 CCONJ F
placebo 0 NOUN F
was 0 VERB F
added 0 VERB F
to 0 ADP F
their 0 PUNCT F
current 0 ADJ F
therapy 0 NOUN F
in 0 ADP F
a 0 DET F
double-blind 0 ADJ F
cross-over 0 NOUN F
design 0 NOUN F
for 0 ADP F
6 0 NUM F
months 0 NOUN F
in 0 ADP F
each 0 DET F
phase 0 NOUN F
. 0 PUNCT F

Thirty 0 NUM T
observation 0 NOUN F
periods 0 NOUN F
of 0 ADP F
6 0 NUM F
months 0 NOUN F
each 0 PUNCT F
were 0 VERB F
studied 0 VERB F
for 0 ADP F
23 0 NUM F
patients 0 NOUN F
. 0 PUNCT F

RESULTS 0 NOUN T
Three 0 NUM T
patients 0 NOUN F
had 0 PUNCT F
relapse B-PHYSICAL NOUN F
on 0 ADP F
phenytoin 0 NOUN F
and 0 CCONJ F
nine 0 NUM F
had 0 PUNCT F
relapse 0 NOUN F
on 0 ADP F
placebo 0 NOUN F
. 0 PUNCT F

There 0 PUNCT T
was 0 VERB F
a 0 DET F
significant 0 ADJ F
prophylactic B-PHYSICAL ADJ F
effect 0 NOUN F
of 0 ADP F
phenytoin 0 NOUN F
in 0 ADP F
BP 0 NOUN T
disorder 0 NOUN F
[ 0 PUNCT F
Cox B-PHYSICAL NOUN T
's 0 PUNCT F
F-test B-PHYSICAL ADP T
for 0 ADP F
comparing 0 PUNCT F
survival B-MORTALITY NOUN F
in 0 ADP F
two 0 NUM F
groups 0 NOUN F
: 0 PUNCT F
F 0 NOUN T
( 0 PUNCT F
6 0 NUM F
, 0 PUNCT F
18 0 NUM F
) 0 PUNCT F
= 0 SYM F
3.44 0 NUM F
, 0 PUNCT F
p 0 NOUN F
= 0 SYM F
0.02 0 NUM F
] 0 PUNCT F
. 0 PUNCT F

CONCLUSIONS 0 NOUN T
This 0 DET T
study 0 NOUN F
suggests 0 NOUN F
prophylactic B-PHYSICAL ADP F
effects I-PHYSICAL NOUN F
of 0 ADP F
add-on 0 NOUN F
phenytoin 0 NOUN F
in 0 ADP F
BP 0 NOUN T
illness 0 NOUN F
. 0 PUNCT F

However 0 ADV T
, 0 PUNCT F
the 0 DET F
number 0 NOUN F
of 0 ADP F
patients 0 NOUN F
was 0 VERB F
small 0 ADJ F
and 0 CCONJ F
confirmation 0 NOUN F
is 0 VERB F
necessary 0 ADJ F
. 0 PUNCT F

Laparoscopic 0 ADJ T
vs 0 CCONJ F
open 0 ADJ F
appendectomy 0 NOUN F
in 0 ADP F
overweight 0 PUNCT F
patients 0 NOUN F
. 0 PUNCT F

BACKGROUND 0 NOUN T
Laparoscopic 0 ADJ T
appendectomy 0 NOUN F
( 0 PUNCT F
LA 0 NOUN T
) 0 PUNCT F
has 0 PUNCT F
been 0 PUNCT F
associated 0 VERB F
with 0 ADP F
a 0 DET F
faster 0 PUNCT F
recovery 0 NOUN F
and 0 CCONJ F
less 0 ADV F
postoperative 0 ADJ F
pain 0 NOUN F
than 0 VERB F
the 0 DET F
open 0 ADJ F
technique 0 NOUN F
. 0 PUNCT F

However 0 ADV T
, 0 PUNCT F
few 0 ADJ F
data 0 NOUN F
are 0 VERB F
available 0 ADJ F
on 0 ADP F
the 0 DET F
clinical 0 ADJ F
outcome 0 NOUN F
of 0 ADP F
LA 0 NOUN T
in 0 ADP F
overweight 0 PUNCT F
patients 0 NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
A 0 PUNCT T
group 0 NOUN F
of 0 ADP F
106 0 NUM F
patients 0 NOUN F
with 0 ADP F
a 0 DET F
body 0 NOUN F
mass 0 NOUN F
index 0 NOUN F
( 0 PUNCT F
BMI 0 NOUN T
) 0 PUNCT F
> 0 SYM F
26.4 0 NUM F
, 0 PUNCT F
representing 0 VERB F
the 0 DET F
upper 0 ADJ F
quintile 0 ADJ F
of 0 ADP F
500 0 NUM F
prospectively 0 ADV F
randomized 0 VERB F
patients 0 NOUN F
, 0 PUNCT F
were 0 VERB F
included 0 VERB F
in 0 ADP F
the 0 DET F
study 0 NOUN F
. 0 PUNCT F

They 0 PRON T
were 0 VERB F
randomized 0 VERB F
to 0 PUNCT F
undergo 0 ADP F
either 0 PUNCT F
laparoscopic 0 ADJ F
or 0 CCONJ F
open 0 ADJ F
appendectomy 0 NOUN F
( 0 PUNCT F
OA 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

Operating B-OTHER ADP T
and I-OTHER CCONJ F
anesthesia I-OTHER NOUN F
times I-OTHER NOUN F
, 0 PUNCT F
postoperative B-PAIN ADJ F
pain I-PAIN NOUN F
, 0 PUNCT F
complications B-ADVERSE-EFFECTS NOUN F
, 0 PUNCT F
hospital B-OTHER NOUN F
stay I-OTHER NOUN F
, 0 PUNCT F
functional B-PHYSICAL ADJ F
index I-PHYSICAL NOUN F
( 0 PUNCT F
1 0 NUM F
week 0 NOUN F
postoperatively 0 NOUN F
) 0 PUNCT F
, 0 PUNCT F
sick B-OTHER NOUN F
leave I-OTHER PUNCT F
, 0 PUNCT F
and 0 CCONJ F
time B-OTHER NOUN F
to I-OTHER ADP F
full I-OTHER ADJ F
recovery I-OTHER NOUN F
were 0 VERB F
documented 0 VERB F
. 0 PUNCT F

RESULTS 0 NOUN T
In 0 ADP T
OA 0 NOUN T
, 0 PUNCT F
the 0 DET F
operating B-OTHER VERB F
time I-OTHER NOUN F
for 0 ADP F
overweight 0 PUNCT F
patients 0 NOUN F
was 0 VERB F
significantly 0 ADV F
longer 0 PUNCT F
than 0 PUNCT F
that 0 ADP F
for 0 ADP F
patients 0 NOUN F
in 0 ADP F
the 0 DET F
normal 0 ADJ F
weight 0 NOUN F
range 0 NOUN F
( 0 PUNCT F
40 0 NUM F
vs 0 CCONJ F
35 0 NUM F
min 0 NOUN F
, 0 PUNCT F
p 0 NOUN F
< 0 SYM F
0.05 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

In 0 ADP T
LA 0 NOUN T
, 0 PUNCT F
there 0 PUNCT F
was 0 VERB F
no 0 DET F
difference 0 NOUN F
in 0 ADP F
operating B-OTHER DET F
time I-OTHER NOUN F
between 0 ADP F
the 0 DET F
normal 0 ADJ F
and 0 CCONJ F
overweight 0 PUNCT F
patients 0 NOUN F
. 0 PUNCT F

Overweight 0 PUNCT T
patients 0 NOUN F
who 0 PROPN F
underwent 0 VERB F
LA 0 NOUN T
had 0 PUNCT F
longer 0 PUNCT F
operating B-OTHER PUNCT F
and I-OTHER CCONJ F
anesthesia I-OTHER NOUN F
times I-OTHER NOUN F
than 0 CCONJ F
their 0 CCONJ F
OA 0 NOUN T
counterparts 0 NOUN F
( 0 PUNCT F
55 0 NUM F
vs 0 CCONJ F
40 0 NUM F
min 0 NOUN F
, 0 PUNCT F
p 0 NOUN F
< 0 SYM F
0.001 0 NUM F
; 0 PUNCT F
and 0 CCONJ F
125 0 NUM F
vs 0 CCONJ F
100 0 NUM F
min 0 NOUN F
, 0 PUNCT F
p 0 NOUN F
< 0 SYM F
0.001 0 NUM F
, 0 PUNCT F
respectively 0 ADV F
) 0 PUNCT F
. 0 PUNCT F

Postoperative B-PAIN ADJ T
pain I-PAIN NOUN F
was 0 VERB F
significantly 0 ADV F
greater 0 PUNCT F
in 0 ADP F
overweight 0 PUNCT F
patients 0 NOUN F
who 0 PROPN F
underwent 0 VERB F
OA 0 NOUN T
than 0 PUNCT F
in 0 ADP F
those 0 ADP F
treated 0 VERB F
with 0 ADP F
the 0 DET F
laparoscopic 0 ADJ F
technique 0 NOUN F
. 0 PUNCT F

Postoperative B-PAIN ADJ T
pain I-PAIN NOUN F
was 0 VERB F
also 0 ADV F
significantly 0 ADV F
greater 0 PUNCT F
in 0 ADP F
overweight 0 PUNCT F
patients 0 NOUN F
subjected 0 VERB F
to 0 ADP F
OA 0 NOUN T
than 0 PUNCT F
in 0 ADP F
patients 0 NOUN F
of 0 ADP F
normal 0 ADJ F
weight 0 NOUN F
after 0 ADP F
4 0 NUM F
weeks 0 NOUN F
; 0 PUNCT F
the 0 DET F
clinical 0 ADJ F
significance 0 NOUN F
may 0 PUNCT F
, 0 PUNCT F
however 0 ADV F
, 0 PUNCT F
be 0 PUNCT F
of 0 ADP F
less 0 PUNCT F
importance 0 NOUN F
since 0 ADP F
the 0 DET F
values 0 NOUN F
are 0 VERB F
low 0 ADJ F
( 0 PUNCT F
0.26 0 NUM F
vs 0 CCONJ F
0.09 0 NUM F
, 0 PUNCT F
p 0 NOUN F
< 0 SYM F
0.05 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

There 0 PUNCT T
were 0 VERB F
no 0 DET F
significant 0 ADJ F
differences 0 NOUN F
between 0 ADP F
the 0 DET F
two 0 ADV F
operating 0 ADJ F
techniques 0 NOUN F
in 0 ADP F
terms 0 NOUN F
of 0 ADP F
complications 0 NOUN F
. 0 PUNCT F

Hospital B-OTHER NOUN T
stay I-OTHER NOUN F
was 0 VERB F
longer 0 PUNCT F
for 0 ADP F
overweight 0 PUNCT F
patients 0 ADJ F
than 0 PUNCT F
for 0 ADP F
normal-weight 0 NOUN F
patients 0 NOUN F
undergoing 0 VERB F
OA 0 NOUN T
( 0 PUNCT F
3.0 0 NUM F
vs 0 CCONJ F
2.0 0 NUM F
, 0 PUNCT F
p 0 NOUN F
< 0 SYM F
0.01 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
functional 0 ADJ F
index 0 NOUN F
did 0 PUNCT F
not 0 ADV F
differ 0 VERB F
between 0 ADP F
any 0 DET F
group 0 NOUN F
of 0 ADP F
patients 0 NOUN F
. 0 PUNCT F

Sick B-OTHER NOUN T
leave I-OTHER PUNCT F
was 0 ADP F
longer 0 PUNCT F
for 0 ADP F
overweight 0 PUNCT F
patients 0 NOUN F
who 0 PROPN F
underwent 0 VERB F
OA 0 NOUN T
than 0 PUNCT F
for 0 ADP F
normal-weight 0 NOUN F
patients 0 NOUN F
treated 0 VERB F
with 0 ADP F
the 0 DET F
same 0 ADJ F
technique 0 NOUN F
( 0 PUNCT F
17 0 NUM F
vs 0 CCONJ F
13 0 NUM F
days 0 NOUN F
, 0 PUNCT F
p 0 NOUN F
< 0 SYM F
0.01 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

In 0 ADP T
the 0 DET F
laparoscopic 0 ADJ F
group 0 NOUN F
, 0 PUNCT F
however 0 ADV F
, 0 PUNCT F
there 0 PUNCT F
were 0 VERB F
no 0 DET F
differences 0 NOUN F
between 0 ADP F
the 0 DET F
overweight 0 ADJ F
and 0 CCONJ F
normal-weight 0 ADJ F
patients 0 NOUN F
. 0 PUNCT F

Time B-OTHER NOUN T
to I-OTHER ADP F
full I-OTHER ADJ F
recovery I-OTHER NOUN F
was 0 VERB F
greater 0 PUNCT F
in 0 ADP F
overweight 0 PUNCT F
patients 0 NOUN F
subjected 0 VERB F
to 0 ADP F
OA 0 NOUN T
than 0 PUNCT F
in 0 ADP F
the 0 DET F
overweight 0 PUNCT F
patients 0 NOUN F
in 0 ADP F
the 0 DET F
LA 0 NOUN T
group 0 NOUN F
( 0 PUNCT F
22 0 NUM F
vs 0 CCONJ F
15 0 NUM F
days 0 NOUN F
, 0 PUNCT F
p 0 NOUN F
< 0 SYM F
0.001 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

CONCLUSION 0 NOUN T
In 0 ADP T
this 0 DET F
study 0 NOUN F
, 0 PUNCT F
overweight 0 PUNCT F
patients 0 NOUN F
who 0 PROPN F
were 0 VERB F
submitted 0 VERB F
to 0 ADP F
LA 0 NOUN T
had 0 PUNCT F
less 0 ADV F
postoperative B-PAIN ADJ F
pain I-PAIN NOUN F
and 0 CCONJ F
a 0 DET F
faster 0 PUNCT F
postoperative B-OTHER ADJ F
recovery I-OTHER NOUN F
than 0 PUNCT F
overweight 0 PUNCT F
patients 0 NOUN F
who 0 PROPN F
had 0 PUNCT F
OA 0 NOUN T
. 0 PUNCT F

LA 0 NOUN T
also 0 ADV F
abolished 0 ADJ F
some 0 PUNCT F
of 0 ADP F
the 0 DET F
negative 0 ADJ F
effects 0 NOUN F
that 0 PUNCT F
overweight 0 ADV F
had 0 PUNCT F
on 0 ADP F
operating B-OTHER PUNCT F
time I-OTHER NOUN F
, 0 PUNCT F
hospital B-OTHER NOUN F
stay I-OTHER NOUN F
, 0 PUNCT F
and 0 CCONJ F
sick B-OTHER NOUN F
leave I-OTHER PUNCT F
with 0 ADP F
the 0 DET F
open 0 ADJ F
technique 0 NOUN F
. 0 PUNCT F

However 0 ADV T
, 0 PUNCT F
anesthesia 0 NOUN F
and 0 CCONJ F
operating 0 PUNCT F
times 0 NOUN F
were 0 VERB F
significantly 0 ADV F
longer 0 PUNCT F
in 0 ADP F
LA 0 NOUN T
for 0 ADP F
both 0 CCONJ F
overweight 0 PUNCT F
patients 0 NOUN F
and 0 CCONJ F
those 0 PUNCT F
with 0 ADP F
a 0 DET F
normal 0 ADJ F
BMI 0 NOUN T
. 0 PUNCT F

Do 0 PUNCT T
colonic 0 ADJ F
short-chain 0 NOUN F
fatty 0 ADJ F
acids 0 NOUN F
contribute 0 VERB F
to 0 ADP F
the 0 DET F
long-term B-PHYSICAL NOUN F
adaptation I-PHYSICAL NOUN F
of I-PHYSICAL ADP F
blood I-PHYSICAL NOUN F
lipids I-PHYSICAL NOUN F
in 0 ADP F
subjects 0 NOUN F
with 0 ADP F
type 0 NOUN F
2 0 NUM F
diabetes 0 PUNCT F
consuming 0 PUNCT F
a 0 DET F
high-fiber 0 NOUN F
diet 0 NOUN F
? 0 PUNCT F

BACKGROUND 0 NOUN T
We 0 ADP T
recently 0 ADV F
obtained 0 PUNCT F
evidence 0 NOUN F
of 0 ADP F
long-term B-PHYSICAL NOUN F
adaptation I-PHYSICAL NOUN F
of I-PHYSICAL ADP F
blood I-PHYSICAL NOUN F
lipids I-PHYSICAL NOUN F
to 0 ADP F
changes 0 NOUN F
in 0 ADP F
intakes 0 NOUN F
of 0 ADP F
carbohydrate 0 NOUN F
and 0 CCONJ F
fiber 0 NOUN F
in 0 ADP F
subjects 0 NOUN F
with 0 ADP F
type 0 NOUN F
2 0 NUM F
diabetes 0 NOUN F
. 0 PUNCT F

OBJECTIVE 0 NOUN T
We 0 PRON T
determined 0 VERB F
the 0 DET F
effect 0 NOUN F
of 0 ADP F
increased 0 VERB F
carbohydrate 0 NOUN F
and 0 CCONJ F
fiber 0 NOUN F
intakes 0 CCONJ F
on 0 ADP F
serum B-PHYSICAL NOUN F
short-chain I-PHYSICAL NOUN F
fatty I-PHYSICAL ADJ F
acids I-PHYSICAL NOUN F
( I-PHYSICAL PUNCT F
SCFAs I-PHYSICAL NOUN T
) I-PHYSICAL PUNCT F
and 0 CCONJ F
the 0 DET F
relation 0 NOUN F
between 0 ADP F
changes B-PHYSICAL NOUN F
in I-PHYSICAL ADP F
serum I-PHYSICAL NOUN F
acetate I-PHYSICAL NOUN F
and 0 CCONJ F
changes B-PHYSICAL NOUN F
in I-PHYSICAL ADP F
blood I-PHYSICAL NOUN F
lipids I-PHYSICAL NOUN F
. 0 PUNCT F

DESIGN 0 NOUN T
Subjects 0 NOUN T
with 0 ADP F
type 0 NOUN F
2 0 NUM F
diabetes 0 NOUN F
( 0 PUNCT F
n 0 NOUN F
= 0 SYM F
62 0 NUM F
) 0 PUNCT F
were 0 VERB F
randomly 0 ADV F
assigned 0 VERB F
to 0 PART F
receive 0 ADP F
approximately 0 ADV F
10 0 NUM F
% 0 SYM F
of 0 ADP F
energy 0 NOUN F
from 0 ADP F
low-fiber 0 NOUN F
breakfast 0 NOUN F
cereal 0 ADJ F
( 0 PUNCT F
LF 0 NOUN T
diet 0 NOUN F
) 0 PUNCT F
, 0 PUNCT F
high-fiber 0 NOUN F
breakfast 0 NOUN F
cereal 0 ADJ F
( 0 PUNCT F
HF 0 NOUN T
diet 0 NOUN F
) 0 PUNCT F
, 0 PUNCT F
or 0 CCONJ F
monounsaturated 0 VERB F
fatty 0 ADJ F
acids 0 NOUN F
( 0 PUNCT F
MUFA 0 NOUN T
diet 0 NOUN F
) 0 PUNCT F
for 0 ADP F
6 0 NUM F
mo 0 NOUN F
. 0 PUNCT F

RESULTS 0 NOUN T
Carbohydrate B-PHYSICAL NOUN T
intakes I-PHYSICAL NOUN F
were 0 VERB F
higher 0 PUNCT F
in 0 ADP F
the 0 DET F
LF 0 NOUN T
and 0 CCONJ F
HF 0 NOUN T
groups 0 NOUN F
than 0 CCONJ F
in 0 ADP F
the 0 DET F
MUFA 0 NOUN T
group 0 NOUN F
( 0 PUNCT F
54 0 NUM F
% 0 SYM F
compared 0 VERB F
with 0 ADP F
43 0 NUM F
% 0 SYM F
) 0 PUNCT F
, 0 PUNCT F
and 0 CCONJ F
more 0 DET F
fiber 0 NOUN F
was 0 VERB F
consumed 0 VERB F
by 0 ADP F
the 0 DET F
HF 0 NOUN T
group 0 NOUN F
( 0 PUNCT F
approximately 0 ADV F
50 0 NUM F
g/d 0 NOUN F
) 0 PUNCT F
than 0 PUNCT F
by 0 ADP F
the 0 DET F
LF 0 NOUN T
or 0 CCONJ F
MUFA 0 NOUN T
group 0 NOUN F
( 0 PUNCT F
approximately 0 ADV F
23 0 NUM F
g/d 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

Fasting B-PHYSICAL PUNCT T
serum I-PHYSICAL NOUN F
SCFAs I-PHYSICAL NOUN T
did 0 ADP F
not 0 ADV F
change 0 VERB F
significantly 0 ADV F
over 0 ADP F
the 0 DET F
first 0 ADJ F
3 0 NUM F
mo 0 NOUN F
. 0 PUNCT F

Between 0 ADP T
3 0 NUM F
and 0 CCONJ F
6 0 NUM F
mo 0 NOUN F
, 0 PUNCT F
serum B-PHYSICAL NOUN F
acetate I-PHYSICAL NOUN F
tended 0 VERB F
( 0 PUNCT F
NS 0 NOUN T
) 0 PUNCT F
to 0 ADP F
decrease 0 NOUN F
in 0 ADP F
the 0 DET F
LF 0 NOUN T
group 0 NOUN F
( 0 PUNCT F
from 0 ADP F
69 0 NUM F
+/- 0 SYM F
4 0 NUM F
to 0 ADP F
59 0 NUM F
+/- 0 SYM F
5 0 NUM F
micromol/L 0 NOUN F
) 0 PUNCT F
and 0 CCONJ F
increase 0 PUNCT F
in 0 ADP F
the 0 DET F
HF 0 NOUN T
group 0 NOUN F
( 0 PUNCT F
from 0 ADP F
100 0 NUM F
+/- 0 SYM F
18 0 NUM F
to 0 ADP F
107 0 NUM F
+/- 0 SYM F
17 0 NUM F
micromol/L 0 NOUN F
) 0 PUNCT F
, 0 PUNCT F
with 0 ADP F
no 0 DET F
significant 0 ADJ F
change 0 NOUN F
in 0 ADP F
the 0 DET F
MUFA 0 NOUN T
group 0 NOUN F
. 0 PUNCT F

Serum B-PHYSICAL NOUN T
butyrate I-PHYSICAL NOUN F
did 0 PUNCT F
not 0 ADV F
change 0 VERB F
significantly 0 ADV F
in 0 ADP F
the 0 DET F
LF 0 NOUN T
or 0 CCONJ F
MUFA 0 NOUN T
group 0 NOUN F
but 0 CCONJ F
increased 0 VERB F
in 0 ADP F
the 0 DET F
HF 0 NOUN T
group 0 NOUN F
( 0 PUNCT F
from 0 ADP F
2.5 0 NUM F
+/- 0 SYM F
0.5 0 NUM F
to 0 ADP F
3.1 0 NUM F
+/- 0 SYM F
0.6 0 NUM F
micromol/L 0 NOUN F
; 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.001 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Changes 0 NOUN T
in 0 ADP F
serum B-PHYSICAL NOUN F
acetate I-PHYSICAL NOUN F
from 0 ADP F
0 0 NUM F
to 0 ADP F
3 0 NUM F
mo 0 NOUN F
were 0 VERB F
not 0 ADV F
related 0 PUNCT F
to 0 ADP F
changes B-PHYSICAL NOUN F
in I-PHYSICAL ADP F
lipids I-PHYSICAL NOUN F
. 0 PUNCT F

However 0 ADV T
, 0 PUNCT F
changes 0 NOUN F
in 0 ADP F
serum B-PHYSICAL NOUN F
acetate I-PHYSICAL NOUN F
from 0 ADP F
3 0 NUM F
to 0 ADP F
6 0 NUM F
mo 0 NOUN F
were 0 VERB F
positively 0 ADV F
related 0 ADP F
to 0 ADP F
changes 0 NOUN F
in 0 ADP F
the 0 DET F
ratio 0 NOUN F
of B-PHYSICAL ADP F
total 0 CCONJ F
to B-PHYSICAL ADP F
HDL I-PHYSICAL NOUN T
cholesterol B-PHYSICAL NOUN F
( 0 PUNCT F
P 0 NOUN T
= 0 SYM F
0.041 0 NUM F
) 0 PUNCT F
and 0 CCONJ F
in 0 ADP F
fasting 0 PUNCT F
( 0 PUNCT F
P 0 NOUN T
= 0 SYM F
0.013 0 NUM F
) 0 PUNCT F
and 0 CCONJ F
postprandial B-PHYSICAL ADJ F
( 0 PUNCT F
P B-PHYSICAL NOUN T
= B-PHYSICAL SYM F
0.016 0 NUM F
) 0 PUNCT F
triacylglycerols B-PHYSICAL NOUN F
. 0 PUNCT F

CONCLUSIONS 0 NOUN T
In 0 ADP T
subjects 0 NOUN F
with 0 ADP F
type 0 NOUN F
2 0 NUM F
diabetes 0 PUNCT F
, 0 PUNCT F
changes 0 NOUN F
in 0 ADP F
serum B-PHYSICAL NOUN F
SCFAs I-PHYSICAL NOUN T
in 0 ADP F
response 0 NOUN F
to 0 ADP F
changes 0 NOUN F
in 0 PUNCT F

Effects 0 NOUN T
of 0 ADP F
misoprostol B-PHYSICAL NOUN F
on 0 ADP F
human 0 NOUN F
circulation 0 NOUN F
. 0 PUNCT F

Prostaglandins 0 NOUN T
( 0 PUNCT F
PGs 0 NOUN T
) 0 PUNCT F
of 0 ADP F
the 0 DET F
E-type 0 NOUN T
are 0 VERB F
potent 0 ADJ F
vasodilators 0 NOUN F
in 0 ADP F
most 0 DET F
species 0 NOUN F
and 0 CCONJ F
in 0 ADP F
most 0 DET F
vascular 0 ADJ F
beds 0 NOUN F
. 0 PUNCT F

However 0 ADV T
, 0 PUNCT F
vasoconstrictor 0 NOUN F
effects 0 NOUN F
of 0 ADP F
PGEs 0 NOUN T
have 0 PUNCT F
also 0 ADV F
been 0 PUNCT F
noted 0 VERB F
at 0 ADP F
selected 0 VERB F
sites 0 NOUN F
. 0 PUNCT F

This 0 DET T
study 0 NOUN F
examined 0 VERB F
the 0 DET F
effects 0 NOUN F
of 0 ADP F
misoprostol B-PHYSICAL NOUN F
, 0 PUNCT F
a 0 DET F
PGE1 0 NOUN T
analog 0 NOUN F
with 0 ADP F
antiulcer 0 NOUN F
activity 0 NOUN F
, 0 PUNCT F
on 0 ADP F
the 0 DET F
human 0 NOUN F
cardiovascular 0 ADJ F
system 0 NOUN F
. 0 PUNCT F

Twenty 0 NUM T
healthy 0 ADJ F
subjects 0 NOUN F
participated 0 VERB F
in 0 ADP F
this 0 DET F
double-blind 0 ADJ F
, 0 PUNCT F
placebo-controlled 0 VERB F
, 0 PUNCT F
parallel 0 ADJ F
group 0 NOUN F
study 0 NOUN F
. 0 PUNCT F

Following 0 VERB T
a 0 DET F
12 0 NUM F
hour 0 NOUN F
fast 0 ADJ F
, 0 PUNCT F
heart 0 NOUN F
rate 0 NOUN F
, 0 PUNCT F
arterial 0 ADJ F
blood 0 NOUN F
pressure 0 NOUN F
, 0 PUNCT F
light 0 PUNCT F
reflex 0 NOUN F
plethysmography 0 NOUN F
of 0 ADP F
the 0 DET F
finger 0 NOUN F
, 0 PUNCT F
resting 0 ADP F
blood 0 NOUN F
flow 0 NOUN F
volume 0 NOUN F
in 0 ADP F
the 0 DET F
lower 0 PUNCT F
arm 0 ADP F
and 0 CCONJ F
leg 0 NOUN F
and 0 CCONJ F
peripheral B-PHYSICAL ADJ F
vascular I-PHYSICAL ADJ F
resistance I-PHYSICAL NOUN F
were 0 VERB F
measured 0 VERB F
at 0 ADP F
10 0 NUM F
min 0 NOUN F
. 0 PUNCT F

intervals 0 NOUN F
for 0 ADP F
1 0 NUM F
hour 0 NOUN F
prior 0 PUNCT F
to 0 ADP F
drug 0 NOUN F
administration 0 NOUN F
, 0 PUNCT F
to 0 PART F
permit 0 PUNCT F
calculating 0 PUNCT F
baseline 0 NOUN F
values 0 NOUN F
. 0 PUNCT F

Misoprostol 0 NOUN T
( 0 PUNCT F
400 0 NUM F
mcg 0 NOUN F
) 0 PUNCT F
or 0 CCONJ F
its 0 PUNCT F
matching 0 VERB F
placebo 0 NOUN F
were 0 VERB F
administered 0 VERB F
orally 0 ADV F
, 0 PUNCT F
and 0 CCONJ F
the 0 DET F
measurements 0 NOUN F
were 0 VERB F
repeated 0 VERB F
at 0 ADP F
10 0 NUM F
min 0 NOUN F
. 0 PUNCT F

intervals 0 NOUN F
over 0 ADP F
the 0 DET F
next 0 ADJ F
2 0 NUM F
hours 0 NOUN F
. 0 PUNCT F

A 0 DET T
decrease 0 NOUN F
in 0 ADP F
leg B-PHYSICAL NOUN F
blood I-PHYSICAL NOUN F
flow I-PHYSICAL NOUN F
volume I-PHYSICAL NOUN F
and 0 CCONJ F
a 0 DET F
corresponding 0 VERB F
increase 0 NOUN F
in 0 ADP F
leg B-PHYSICAL NOUN F
peripheral I-PHYSICAL ADJ F
vascular I-PHYSICAL ADJ F
resistance I-PHYSICAL NOUN F
were 0 VERB F
noted 0 VERB F
in 0 ADP F
the 0 DET F
misoprostol 0 NOUN F
group 0 NOUN F
. 0 PUNCT F

A 0 DET T
statistically 0 ADV F
significant 0 ADJ F
decrease 0 NOUN F
in 0 ADP F
heart B-PHYSICAL NOUN F
rate I-PHYSICAL NOUN F
between 0 ADP F
the 0 DET F
two 0 NUM F
treatment 0 NOUN F
groups 0 NOUN F
was 0 VERB F
also 0 ADV F
noted 0 VERB F
. 0 PUNCT F

These 0 DET T
small 0 ADJ F
changes 0 NOUN F
were 0 VERB F
not 0 ADV F
considered 0 VERB F
to 0 PART F
be 0 PUNCT F
of 0 ADP F
clinical 0 ADJ F
importance 0 NOUN F
. 0 PUNCT F

No 0 DET T
adverse B-PHYSICAL ADJ F
experiences I-PHYSICAL NOUN F
were 0 VERB F
reported 0 VERB F
. 0 PUNCT F

In 0 ADP T
conclusion 0 NOUN F
, 0 PUNCT F
a 0 DET F
single 0 ADJ F
dose 0 NOUN F
of 0 ADP F
misoprostol 0 NOUN F
( 0 PUNCT F
400 0 NUM F
mcg 0 NOUN F
) 0 PUNCT F
has 0 CCONJ F
no 0 DET F
clinically 0 ADV F
significant 0 ADJ F
vasoconstrictive B-PHYSICAL ADJ F
or 0 CCONJ F
vasodilative B-PHYSICAL ADJ F
properties 0 NOUN F
in 0 ADP F
man 0 NOUN F
. 0 PUNCT F

Secondary 0 ADJ T
caries 0 NOUN F
formation 0 NOUN F
in 0 VERB F
vitro 0 ADJ F
around 0 ADP F
glass 0 NOUN F
ionomer-lined 0 VERB F
amalgam 0 NOUN F
and 0 CCONJ F
composite 0 ADJ F
restorations 0 NOUN F
. 0 PUNCT F

The 0 DET T
aim 0 NOUN F
of 0 ADP F
this 0 PUNCT F
in 0 DET F
vitro 0 ADJ F
secondary 0 ADJ F
caries 0 NOUN F
study 0 NOUN F
was 0 VERB F
to 0 ADV F
examine 0 NOUN F
the 0 DET F
glass-ionomer 0 NOUN F
liner 0 PUNCT F
's 0 PUNCT F
effect 0 NOUN F
on 0 ADP F
wall-lesion 0 NOUN F
inhibition 0 NOUN F
when 0 ADP F
a 0 DET F
conventional 0 ADJ F
and 0 CCONJ F
a 0 DET F
light-cured 0 PUNCT F
glass 0 NOUN F
ionomer 0 NOUN F
liner 0 PUNCT F
was 0 VERB F
placed 0 VERB F
under 0 ADP F
amalgam 0 NOUN F
and 0 CCONJ F
composite 0 PUNCT F
resin 0 NOUN F
restorations 0 NOUN F
. 0 PUNCT F

Class 0 NOUN T
V 0 NUM T
preparations 0 NOUN F
in 0 ADP F
extracted 0 ADP F
upper 0 ADJ F
premolars 0 NOUN F
were 0 VERB F
used 0 VERB F
and 0 CCONJ F
ten 0 NUM F
restorations 0 NOUN F
were 0 VERB F
used 0 VERB F
for 0 ADP F
each 0 PUNCT F
of 0 ADP F
the 0 DET F
following 0 DET F
groups 0 NOUN F
: 0 PUNCT F
( 0 PUNCT F
i 0 NUM F
) 0 PUNCT F
two 0 NUM F
layers 0 NOUN F
of 0 ADP F
copal 0 ADJ F
varnish 0 ADJ F
and 0 CCONJ F
amalgam 0 NOUN F
; 0 PUNCT F
( 0 PUNCT F
ii 0 NUM F
) 0 PUNCT F
conventional 0 ADJ F
glass-ionomer 0 NOUN F
and 0 CCONJ F
amalgam 0 NOUN F
; 0 PUNCT F
( 0 PUNCT F
iii 0 ADP F
) 0 PUNCT F
light-cured 0 NOUN F
glass-ionomer 0 NOUN F
and 0 CCONJ F
amalgam 0 NOUN F
; 0 PUNCT F
( 0 PUNCT F
iv 0 PUNCT F
) 0 PUNCT F
bonding 0 DET F
agent 0 NOUN F
and 0 CCONJ F
light-cured 0 PUNCT F
composite 0 ADJ F
resin 0 NOUN F
; 0 PUNCT F
( 0 PUNCT F
v 0 NUM F
) 0 PUNCT F
conventional 0 ADJ F
glass-ionomer 0 NOUN F
, 0 PUNCT F
bonding 0 ADP F
agent 0 NOUN F
and 0 CCONJ F
light-cured 0 PUNCT F
composite 0 ADJ F
resin 0 NOUN F
; 0 PUNCT F
( 0 PUNCT F
vi 0 CCONJ F
) 0 PUNCT F
light-cured 0 NOUN F
glass-ionomer 0 NOUN F
, 0 PUNCT F
extended 0 PUNCT F
0.3 0 NUM F
mm 0 NOUN F
short 0 ADJ F
of 0 ADP F
the 0 DET F
enamel 0 NOUN F
margin 0 NOUN F
bonding 0 VERB F
agent 0 NOUN F
and 0 CCONJ F
light-cured 0 PUNCT F
composite 0 ADJ F
resin 0 NOUN F
; 0 PUNCT F
and 0 CCONJ F
( 0 PUNCT F
vii 0 ADP F
) 0 PUNCT F
light-cured 0 NOUN F
glass-ionomer 0 NOUN F
, 0 PUNCT F
extended 0 PUNCT F
1 0 NUM F
mm 0 NOUN F
short 0 ADJ F
of 0 ADP F
the 0 DET F
enamel 0 NOUN F
margin 0 NOUN F
, 0 PUNCT F
bonding 0 ADP F
agent 0 NOUN F
and 0 CCONJ F
light-cured 0 PUNCT F
composite 0 ADJ F
resin 0 NOUN F
. 0 PUNCT F

The 0 DET T
teeth 0 NOUN F
were 0 VERB F
thermocycled 0 NUM F
and 0 CCONJ F
artificial 0 ADJ F
caries 0 NOUN F
were 0 VERB F
created 0 VERB F
using 0 VERB F
an 0 DET F
acid-gel 0 NOUN F
. 0 PUNCT F

The 0 DET T
results 0 NOUN F
of 0 ADP F
this 0 DET F
study 0 NOUN F
showed 0 VERB F
that 0 ADP F
artificial B-PHYSICAL ADJ F
recurrent I-PHYSICAL ADJ F
caries I-PHYSICAL NOUN F
can 0 VERB F
be 0 VERB F
reduced 0 VERB F
significantly 0 ADV F
( 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.05 0 NUM F
) 0 PUNCT F
with 0 ADP F
a 0 DET F
glass-ionomer 0 NOUN F
liner 0 PUNCT F
under 0 ADP F
amalgam 0 NOUN F
restorations 0 NOUN F
. 0 PUNCT F

The 0 DET T
results 0 NOUN F
also 0 ADV F
showed 0 VERB F
that 0 ADP F
when 0 ADP F
the 0 DET F
light-cured 0 PUNCT F
glass-ionomer 0 NOUN F
liner 0 PUNCT F
was 0 VERB F
placed 0 VERB F
0.3 0 NUM F
mm 0 NOUN F
from 0 ADP F
the 0 DET F
cavosurface 0 ADJ F
margin 0 NOUN F
under 0 ADP F
composite 0 ADJ F
resin 0 NOUN F
restoration 0 NOUN F
, 0 PUNCT F
the 0 DET F
artificial B-PHYSICAL ADJ F
recurrent I-PHYSICAL ADJ F
caries I-PHYSICAL NOUN F
reduced I-PHYSICAL ADP F
significantly 0 ADV F
( 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.05 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

A 0 PUNCT T
workplace 0 CCONJ F
intervention 0 NOUN F
for 0 ADP F
increasing 0 VERB F
outdoor 0 PUNCT F
workers 0 NOUN F
' 0 PUNCT F
use 0 NOUN F
of 0 ADP F
solar 0 ADJ F
protection 0 NOUN F
. 0 PUNCT F

OBJECTIVES 0 NOUN T
Outdoor 0 ADP T
workers 0 NOUN F
are 0 ADP F
at 0 ADP F
high 0 ADJ F
risk 0 NOUN F
of 0 ADP F
developing 0 PUNCT F
skin 0 NOUN F
cancer 0 NOUN F
. 0 PUNCT F

Primary 0 ADJ T
prevention 0 NOUN F
in 0 ADP F
this 0 DET F
group 0 NOUN F
can 0 PRON F
potentially 0 ADV F
reduce 0 VERB F
the 0 DET F
incidence 0 NOUN F
of 0 ADP F
skin 0 NOUN F
cancer 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
also 0 ADV F
potentiates 0 ADJ F
the 0 DET F
spontaneous 0 ADJ F
remission 0 NOUN F
of 0 ADP F
existing 0 VERB F
solar 0 ADJ F
keratoses 0 NOUN F
. 0 PUNCT F

A 0 DET T
randomized 0 VERB F
controlled 0 VERB F
trial 0 NOUN F
was 0 VERB F
conducted 0 VERB F
to 0 PART F
evaluate 0 NOUN F
a 0 DET F
solar 0 PUNCT F
protection 0 NOUN F
intervention 0 NOUN F
targeting 0 PUNCT F
outdoor 0 PUNCT F
workers 0 NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
Outdoor 0 NUM T
workers 0 NOUN F
were 0 ADJ F
randomly 0 ADV F
allocated 0 VERB F
to 0 ADP F
an 0 DET F
intervention 0 NOUN F
( 0 PUNCT F
n 0 NOUN F
= 0 SYM F
65 0 NUM F
) 0 PUNCT F
or 0 CCONJ F
control 0 NOUN F
group 0 NOUN F
( 0 PUNCT F
n 0 NOUN F
= 0 SYM F
77 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
intervention 0 NOUN F
group 0 NOUN F
received 0 VERB F
individual 0 ADJ F
skin 0 NOUN F
screening 0 ADP F
by 0 ADP F
a 0 DET F
dermatologist 0 NOUN F
and 0 CCONJ F
participated 0 PUNCT F
in 0 ADP F
an 0 DET F
education 0 NOUN F
session 0 NOUN F
. 0 PUNCT F

Pre- 0 PUNCT T
and 0 CCONJ F
posttest 0 ADV F
outcome 0 NOUN F
measures 0 NOUN F
included 0 VERB F
solar B-MENTAL PUNCT F
protection I-MENTAL NOUN F
behavior I-MENTAL NOUN F
( 0 PUNCT F
assessed 0 PROPN F
using 0 VERB F
a 0 DET F
validated 0 VERB F
diary 0 PUNCT F
) 0 PUNCT F
, 0 PUNCT F
knowledge B-MENTAL NOUN F
, 0 PUNCT F
and 0 CCONJ F
attitudes B-MENTAL NOUN F
. 0 PUNCT F

RESULTS 0 NOUN T
There 0 CCONJ T
was 0 VERB F
a 0 DET F
significant B-OTHER ADJ F
increase 0 NOUN F
( 0 PUNCT F
16 0 NUM F
% 0 SYM F
) 0 PUNCT F
in 0 ADP F
the 0 DET F
percentage 0 NOUN F
of 0 ADP F
outdoor 0 PUNCT F
workers 0 NOUN F
who 0 ADP F
were 0 VERB F
using 0 SYM F
a 0 DET F
high 0 ADJ F
level 0 NOUN F
of 0 ADP F
solar 0 ADJ F
protection 0 NOUN F
at 0 ADP F
posttest 0 NOUN F
compared 0 VERB F
to 0 ADP F
pretest 0 PUNCT F
in 0 ADP F
the 0 DET F
intervention 0 NOUN F
group 0 NOUN F
, 0 PUNCT F
but 0 CCONJ F
there 0 PUNCT F
was 0 VERB F
no 0 DET F
change B-OTHER NOUN F
in 0 ADP F
the 0 DET F
control 0 NOUN F
group 0 NOUN F
. 0 PUNCT F

Although 0 ADP T
both 0 CCONJ F
groups 0 NOUN F
improved B-OTHER VERB F
in 0 ADP F
their 0 PUNCT F
knowledge B-MENTAL NOUN F
score I-MENTAL NOUN F
, 0 PUNCT F
the 0 DET F
intervention B-OTHER NOUN F
group 0 NOUN F
showed B-OTHER VERB F
a I-OTHER DET F
significantly I-OTHER ADV F
greater 0 PUNCT F
improvement B-OTHER NOUN F
at 0 ADP F
posttest 0 NOUN F
. 0 PUNCT F

No 0 DET T
changes B-OTHER NOUN F
in I-OTHER PUNCT F

Anatomical 0 ADJ T
benefit 0 NOUN F
from 0 ADP F
ranibizumab 0 PUNCT F
treatment 0 NOUN F
of 0 ADP F
predominantly 0 ADV F
classic 0 ADJ F
neovascular 0 ADJ F
age-related 0 VERB F
macular 0 ADJ F
degeneration 0 NOUN F
in 0 ADP F
the 0 DET F
2-year 0 NOUN F
anchor 0 ADV F
study 0 NOUN F
. 0 PUNCT F

PURPOSE 0 NOUN T
To 0 ADJ T
compare 0 NOUN F
lesion 0 NOUN F
anatomical 0 ADJ F
responses 0 NOUN F
to 0 ADP F
ranibizumab 0 ADJ F
versus 0 PUNCT F
verteporfin 0 NOUN F
photodynamic 0 ADJ F
therapy 0 NOUN F
( 0 PUNCT F
PDT 0 NOUN T
) 0 PUNCT F
in 0 ADP F
the 0 DET F
ANCHOR 0 NOUN T
( 0 PUNCT F
Anti-VEGF 0 NOUN T
Antibody 0 NOUN T
for 0 ADP F
the 0 DET F
Treatment 0 NOUN T
of 0 ADP F
Predominantly 0 ADV T
Classic 0 ADJ T
Choroidal 0 ADJ T
Neovascularization 0 NOUN T
[ 0 PUNCT F
CNV 0 NOUN T
] 0 PUNCT F
in 0 ADP F
Age-Related 0 VERB T
Macular 0 ADJ T
Degeneration 0 NOUN T
) 0 PUNCT F
study 0 NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
In 0 ADP T
this 0 DET F
2-year 0 NOUN F
, 0 PUNCT F
Phase 0 NOUN T
III 0 NUM T
, 0 PUNCT F
randomized 0 VERB F
, 0 PUNCT F
multicenter 0 NOUN F
, 0 PUNCT F
double-masked 0 VERB F
trial 0 NOUN F
, 0 PUNCT F
423 0 NUM F
patients 0 NOUN F
received 0 ADJ F
ranibizumab 0 ADP F
( 0 PUNCT F
0.3 0 ADP F
or 0 CCONJ F
0.5 0 NUM F
mg 0 NOUN F
) 0 PUNCT F
monthly 0 ADV F
+ 0 VERB F
sham 0 ADJ F
PDT 0 NOUN T
or 0 CCONJ F
PDT 0 NOUN T
+ 0 SYM F
monthly 0 ADV F
sham 0 ADJ F
injection 0 NOUN F
. 0 PUNCT F

Photodynamic 0 ADJ T
therapy 0 NOUN F
( 0 PUNCT F
or 0 CCONJ F
sham 0 ADJ F
PDT 0 NOUN T
) 0 PUNCT F
was 0 VERB F
administered 0 VERB F
at 0 ADP F
Day 0 NOUN T
0 0 NUM F
and 0 CCONJ F
then 0 ADV F
quarterly 0 ADJ F
as 0 VERB F
needed 0 PUNCT F
. 0 PUNCT F

A 0 DET T
central 0 ADJ F
reading 0 VERB F
center 0 NOUN F
assessed 0 ADJ F
fundus 0 ADV F
photography 0 NOUN F
and 0 CCONJ F
fluorescein 0 NOUN F
angiography 0 NOUN F
images 0 NOUN F
. 0 PUNCT F

A 0 DET T
subset 0 NOUN F
( 0 PUNCT F
n 0 NOUN F
= 0 SYM F
61 0 NUM F
) 0 PUNCT F
had 0 ADP F
optical 0 ADJ F
coherence 0 NOUN F
tomography 0 NOUN F
assessments 0 NOUN F
. 0 PUNCT F

Main 0 ADJ T
outcome 0 NOUN F
measures 0 NOUN F
included 0 VERB F
mean 0 NOUN F
change 0 NOUN F
from 0 ADP F
baseline 0 NOUN F
at 0 ADP F
Months 0 NOUN T
12 0 NUM F
and 0 CCONJ F
24 0 NUM F
for 0 ADP F
area 0 NOUN F
of 0 ADP F
classic 0 ADJ F
CNV 0 NOUN T
and 0 CCONJ F
total 0 ADJ F
area 0 NOUN F
of 0 ADP F
leakage 0 NOUN F
from 0 ADP F
CNV 0 NOUN T
. 0 PUNCT F

RESULTS 0 NOUN T
At 0 ADP T
Months 0 NOUN T
12 0 NUM F
and 0 CCONJ F
24 0 NUM F
, 0 PUNCT F
ranibizumab 0 VERB F
was 0 VERB F
superior 0 ADJ F
to 0 ADP F
PDT 0 NOUN T
( 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.0001 0 NUM F
) 0 PUNCT F
for 0 ADP F
mean 0 NOUN F
changes 0 NOUN F
from 0 ADP F
baseline 0 NOUN F
in 0 ADP F
total B-PHYSICAL ADJ F
area 0 NOUN F
of 0 ADP F
lesion B-PHYSICAL NOUN F
, 0 PUNCT F
CNV B-PHYSICAL NOUN T
area 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
total B-PHYSICAL ADJ F
area 0 NOUN F
CNV B-PHYSICAL PUNCT T

Effect 0 NOUN T
of 0 ADP F
mild 0 ADJ F
endurance 0 NOUN F
exercise 0 NOUN F
training 0 VERB F
and 0 CCONJ F
pravastatin 0 NOUN F
on 0 ADP F
peripheral 0 ADJ F
vasodilatation 0 NOUN F
of 0 ADP F
forearm 0 NOUN F
resistance 0 NOUN F
vessels 0 CCONJ F
in 0 ADP F
patients 0 NOUN F
with 0 ADP F
coronary 0 ADJ F
artery 0 NOUN F
disease 0 NOUN F
. 0 PUNCT F

BACKGROUND 0 NOUN T
Improved 0 NOUN T
endothelial 0 ADJ F
function 0 NOUN F
may 0 PART F
contribute 0 PUNCT F
to 0 ADP F
the 0 DET F
beneficial 0 ADJ F
effects 0 NOUN F
of 0 ADP F
cholesterol 0 NOUN F
lowering 0 ADP F
therapy 0 NOUN F
in 0 ADP F
patients 0 NOUN F
with 0 ADP F
coronary 0 ADJ F
artery 0 NOUN F
disease 0 NOUN F
( 0 PUNCT F
CAD 0 NOUN T
) 0 PUNCT F
, 0 PUNCT F
but 0 CCONJ F
results 0 NOUN F
of 0 ADP F
the 0 DET F
effect 0 NOUN F
of 0 ADP F
statin 0 NOUN F
therapy 0 NOUN F
on 0 ADP F
endothelial 0 ADJ F
function 0 NOUN F
are 0 VERB F
disparate 0 ADJ F
in 0 ADP F
these 0 DET F
patients 0 NOUN F
. 0 PUNCT F

Exercise 0 NOUN T
training 0 VERB F
has 0 PUNCT F
been 0 PUNCT F
reported 0 VERB F
to 0 PART F
improve 0 ADP F
endothelial 0 ADJ F
function 0 NOUN F
of 0 ADP F
patients 0 NOUN F
at 0 ADP F
risk 0 NOUN F
of 0 ADP F
or 0 CCONJ F
with 0 ADP F
established 0 CCONJ F
CAD 0 NOUN T
. 0 PUNCT F

The 0 DET T
goal 0 NOUN F
of 0 ADP F
the 0 DET F
study 0 NOUN F
was 0 VERB F
to 0 ADV F
compare 0 NOUN F
the 0 DET F
effect 0 NOUN F
of 0 ADP F
mild 0 ADJ F
exercise 0 NOUN F
training 0 VERB F
or 0 CCONJ F
statin 0 NOUN F
therapy 0 NOUN F
on 0 ADP F
forearm 0 NOUN F
endothelial 0 ADJ F
function 0 NOUN F
in 0 ADP F
CAD 0 NOUN T
patients 0 NOUN F
with 0 ADP F
average 0 ADJ F
cholesterol 0 NOUN F
levels 0 NOUN F
. 0 PUNCT F

DESIGN 0 NOUN T
AND 0 CCONJ T
METHODS 0 NOUN T
Twenty-eight 0 PUNCT T
sedentary 0 ADJ F
male 0 NOUN F
patients 0 NOUN F
with 0 ADP F
angiographically 0 ADV F
documented 0 VERB F
CAD 0 NOUN T
and 0 CCONJ F
average 0 ADJ F
pretreatment 0 NOUN F
total 0 ADJ F
plasma 0 NOUN F
cholesterol 0 NOUN F
levels 0 NOUN F
( 0 PUNCT F
5.1+/-0.9 0 DET F
mmol/l 0 NOUN F
) 0 PUNCT F
aged 0 PUNCT F
42-75 0 NUM F
years 0 NOUN F
were 0 VERB F
included 0 VERB F
. 0 PUNCT F

They 0 PRON T
were 0 VERB F
randomly 0 ADV F
assigned 0 VERB F
in 0 ADP F
a 0 DET F
2 0 NUM F
: 0 PUNCT F
1 0 NUM F
order 0 NOUN F
to 0 ADP F
either 0 CCONJ F
statin 0 NOUN F
therapy 0 NOUN F
( 0 PUNCT F
pravastatin 0 NOUN F
, 0 PUNCT F
40 0 NUM F
mg 0 NOUN F
daily 0 ADJ F
) 0 PUNCT F
or 0 CCONJ F
exercise 0 NOUN F
training 0 ADJ F
therapy 0 NOUN F
( 0 PUNCT F
mild 0 ADJ F
endurance 0 NOUN F
exercise 0 NOUN F
three 0 NUM F
or 0 CCONJ F
more 0 DET F
times 0 CCONJ F
a 0 DET F
week 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
effects 0 NOUN F
of 0 ADP F
10 0 NUM F
weeks 0 NOUN F
of 0 ADP F
either 0 CCONJ F
treatment 0 NOUN F
on 0 ADP F
endothelium-dependent 0 ADJ F
and 0 CCONJ F
independent 0 ADJ F
vasodilation 0 NOUN F
of 0 ADP F
forearm 0 NOUN F
resistance 0 NOUN F
vessels 0 NOUN F
was 0 VERB F
assessed 0 VERB F
by 0 ADP F
plethysmography 0 NOUN F
. 0 PUNCT F

Cardiopulmonary 0 ADJ T
exercise 0 NOUN F
testing 0 VERB F
was 0 VERB F
performed 0 VERB F
at 0 ADP F
baseline 0 NOUN F
and 0 CCONJ F
after 0 ADP F
10 0 NUM F
weeks 0 NOUN F
. 0 PUNCT F

RESULTS 0 NOUN T
Ten 0 NUM T
weeks 0 NOUN F
of 0 ADP F
pravastatin 0 NOUN F
therapy 0 NOUN F
significantly 0 ADV F
reduced 0 PUNCT F
low-density B-PHYSICAL NOUN F
lipoprotein I-PHYSICAL NOUN F
cholesterol I-PHYSICAL NOUN F
( 0 PUNCT F
from 0 ADP F
3.8+/-0.6 0 PUNCT F
to 0 PUNCT F
3.1+/-0.6 0 PUNCT F
mmol/l 0 NOUN F
at 0 ADP F
study 0 NOUN F
end 0 NOUN F
, 0 PUNCT F
P=0.04 0 PUNCT T
) 0 PUNCT F
and 0 CCONJ F
the 0 DET F
ratio 0 NOUN F
of 0 ADP F
total 0 ADJ F
to 0 PUNCT F
high-density B-PHYSICAL NOUN F
lipoprotein I-PHYSICAL NOUN F
cholesterol I-PHYSICAL NOUN F
( 0 PUNCT F
from 0 ADP F
4.9+/-0.8 0 ADJ F
to 0 ADP F
3.7+/-0.7 0 NOUN F
mmol/l 0 NOUN F
, 0 PUNCT F
P=0.002 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

Exercise 0 NOUN T
training 0 VERB F
did 0 PUNCT F
not 0 ADV F
significantly 0 ADV F
modify 0 VERB F
the 0 DET F
lipid B-PHYSICAL NOUN F
profile I-PHYSICAL NOUN F
. 0 PUNCT F

Peak 0 ADJ T
oxygen B-PHYSICAL NOUN F
consumption I-PHYSICAL NOUN F
, 0 PUNCT F
maximal B-PHYSICAL ADJ F
achieved 0 CCONJ F
workload B-PHYSICAL ADJ F
and 0 CCONJ F
exercise B-MENTAL NOUN F
duration B-MENTAL NOUN F
tended 0 VERB F
to 0 PART F
improve 0 VERB F
in 0 ADP F
the 0 DET F
exercise 0 NOUN F
training 0 DET F
group 0 NOUN F
but 0 CCONJ F
remained 0 VERB F
unchanged 0 VERB F
in 0 ADP F
the 0 DET F
pravastatin-treated 0 ADJ F
group 0 NOUN F
. 0 PUNCT F

Neither 0 CCONJ T
10 0 NUM F
weeks 0 NOUN F
of 0 ADP F
pravastatin 0 NOUN F
nor 0 CCONJ F
mild 0 ADJ F
endurance 0 NOUN F
exercise 0 NOUN F
training 0 PUNCT F
improved 0 PUNCT F

Are 0 VERB T
back 0 ADP F
supports 0 PUNCT F
plus 0 CCONJ F
education 0 NOUN F
more 0 ADV F
effective 0 ADJ F
than 0 ADP F
education 0 NOUN F
alone 0 ADJ F
in 0 ADP F
promoting 0 VERB F
recovery 0 NOUN F
from 0 ADP F
low 0 ADJ F
back 0 ADP F
pain 0 NOUN F
? 0 PUNCT F
: 0 PUNCT F

Results 0 DET T
from 0 ADP F
a 0 DET F
randomized 0 VERB F
clinical 0 ADJ F
trial 0 NOUN F
. 0 PUNCT F

STUDY 0 NOUN T
DESIGN 0 NOUN T
Randomized 0 PROPN T
clinical 0 ADJ F
trial 0 NOUN F
. 0 PUNCT F

OBJECTIVES 0 ADP T
To 0 PROPN T
evaluate 0 NOUN F
the 0 DET F
effectiveness 0 NOUN F
of 0 ADP F
a 0 DET F
back 0 ADP F
support 0 NOUN F
plus 0 CCONJ F
education 0 NOUN F
versus 0 CCONJ F
education 0 NOUN F
alone 0 ADJ F
in 0 ADP F
promoting 0 VERB F
recovery 0 NOUN F
from 0 ADP F
a 0 DET F
work-related 0 VERB F
low 0 ADJ F
back 0 ADP F
disorder 0 NOUN F
( 0 PUNCT F
WR-LBD 0 NOUN T
) 0 PUNCT F
while 0 ADP F
simultaneously 0 ADV F
considering 0 PUNCT F
personal 0 ADJ F
, 0 PUNCT F
health 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
occupational 0 ADJ F
factors 0 NOUN F
and 0 CCONJ F
the 0 DET F
impact 0 NOUN F
of 0 ADP F
occupational 0 ADJ F
factors 0 NOUN F
on 0 ADP F
recovery 0 NOUN F
. 0 PUNCT F

SUMMARY 0 NOUN T
OF 0 ADP T
BACKGROUND 0 NOUN T
DATA 0 NOUN T
No 0 DET T
randomized 0 ADV F
studies 0 NOUN F
of 0 ADP F
active 0 ADJ F
industrial 0 ADJ F
workers 0 NOUN F
with 0 ADP F
low 0 ADJ F
back 0 ADP F
disorders 0 NOUN F
exist 0 VERB F
regarding 0 SYM F
the 0 DET F
effectiveness 0 NOUN F
of 0 ADP F
back 0 ADP F
supports 0 NOUN F
plus 0 CCONJ F
education 0 NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
A 0 PUNCT T
total 0 NOUN F
of 0 ADP F
433 0 NUM F
actively 0 ADV F
employed 0 VERB F
hourly 0 PUNCT F
union 0 NOUN F
workers 0 NOUN F
who 0 ADP F
had 0 ADP F
a 0 DET F
recent 0 ADJ F
diagnosis 0 NOUN F
of 0 ADP F
a 0 DET F
WR-LBD 0 NOUN T
: 0 PUNCT F
1 0 NUM F
) 0 PUNCT F
those 0 PUNCT F
who 0 PROPN F
wore 0 PUNCT F
a 0 PUNCT F
specially 0 ADJ F
designed 0 VERB F
back 0 NOUN F
support 0 NOUN F
plus 0 CCONJ F
received 0 PUNCT F
education 0 NOUN F
on 0 ADP F
back 0 ADP F
health 0 NOUN F
; 0 PUNCT F
and 0 CCONJ F
2 0 NUM F
) 0 PUNCT F
those 0 PUNCT F
who 0 ADP F
received 0 VERB F
education 0 NOUN F
on 0 ADP F
back 0 ADP F
health 0 NOUN F
only 0 ADV F
. 0 PUNCT F

Demographic 0 ADJ T
, 0 PUNCT F
health 0 NOUN F
, 0 PUNCT F
medical 0 ADJ F
, 0 PUNCT F
and 0 CCONJ F
occupational 0 ADJ F
factors 0 NOUN F
were 0 VERB F
obtained 0 VERB F
through 0 ADP F
interview 0 NOUN F
or 0 CCONJ F
abstraction 0 NOUN F
of 0 ADP F
computer 0 NOUN F
files 0 NOUN F
; 0 PUNCT F
individual 0 ADJ F
ergonomic 0 ADJ F
exposures 0 NOUN F
were 0 VERB F
measured 0 VERB F
with 0 ADP F
a 0 DET F
lumbar 0 ADJ F
motion 0 NOUN F
monitor 0 NOUN F
. 0 PUNCT F

Outcomes 0 NOUN T
evaluated 0 VERB F
over 0 ADP F
a 0 DET F
12-month 0 NOUN F
period 0 NOUN F
included 0 ADJ F
: 0 PUNCT F
self-reported B-PAIN VERB F
measures I-PAIN NOUN F
of I-PAIN ADP F
back I-PAIN ADP F
pain I-PAIN NOUN F
, 0 PUNCT F
back 0 ADP F
pain 0 NOUN F
disability 0 NOUN F
level 0 NOUN F
, 0 PUNCT F
physical 0 ADJ F
health 0 NOUN F
, 0 PUNCT F
mental B-MENTAL ADJ F
health I-MENTAL NOUN F
, 0 PUNCT F
and 0 CCONJ F
administrative 0 ADJ F
measures 0 NOUN F
of 0 ADP F
recurrence 0 NOUN F
, 0 PUNCT F
lost 0 CCONJ F
work 0 NUM F
time 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
medical 0 ADJ F
care 0 NOUN F
utilization 0 NOUN F
. 0 PUNCT F

RESULTS 0 NOUN T
There 0 CCONJ T
was 0 VERB F
no 0 DET F
difference 0 NOUN F
between 0 ADP F
the 0 DET F
study 0 ADJ F
groups 0 NOUN F
with 0 ADP F
respect 0 NOUN F
to 0 ADP F
mental 0 ADJ F
or 0 CCONJ F
physical 0 ADJ F
health 0 NOUN F
, 0 PUNCT F
low B-PAIN ADJ F
back I-PAIN ADP F
pain I-PAIN NOUN F
, 0 PUNCT F
back 0 ADP F
pain 0 NOUN F
disability 0 NOUN F
, 0 PUNCT F
neurogenic B-MENTAL ADJ F
symptoms I-MENTAL NOUN F
, 0 PUNCT F
lost 0 PUNCT F
work 0 NUM F
time 0 NOUN F
, 0 PUNCT F
likelihood 0 NOUN F
of B-PHYSICAL ADP F
recurrence 0 NOUN F
of B-PHYSICAL ADP F
an I-PHYSICAL DET F
episode I-PHYSICAL NOUN F
of I-PHYSICAL ADP F
a B-PHYSICAL DET F
back I-PHYSICAL PUNCT F

Double 0 ADP T
hearing 0 DET F
protection 0 NOUN F
and 0 CCONJ F
speech 0 NOUN F
intelligibility-room 0 PUNCT F
for 0 ADP F
improvement 0 NOUN F
. 0 PUNCT F

INTRODUCTION 0 NOUN T
Double 0 VERB T
hearing 0 DET F
protection 0 NOUN F
is 0 VERB F
used 0 VERB F
in 0 ADP F
many 0 DET F
air 0 NOUN F
forces 0 NOUN F
around 0 ADP F
the 0 DET F
world 0 NOUN F
for 0 ADP F
protection 0 NOUN F
in 0 ADP F
noisy 0 ADJ F
aircraft 0 NOUN F
environments 0 NOUN F
, 0 PUNCT F
particularly 0 ADV F
in 0 ADP F
helicopters 0 NOUN F
. 0 PUNCT F

The 0 DET T
usual 0 ADJ F
combination 0 NOUN F
is 0 VERB F
foam 0 ADP F
ear 0 NOUN F
plugs 0 NOUN F
under 0 ADP F
headset 0 NOUN F
or 0 CCONJ F
helmet 0 NOUN F
muffs 0 NOUN F
. 0 PUNCT F

Much 0 PUNCT T
of 0 ADP F
the 0 DET F
research 0 NOUN F
that 0 ADP F
spurred 0 ADJ F
the 0 DET F
introduction 0 NOUN F
of 0 ADP F
foam 0 NOUN F
earplugs 0 CCONJ F
indicated 0 DET F
little 0 DET F
change 0 NOUN F
in 0 ADP F
speech 0 NOUN F
intelligibility 0 NOUN F
in 0 ADP F
persons 0 NOUN F
with 0 ADP F
normal 0 ADJ F
hearing 0 ADP F
. 0 PUNCT F

However 0 ADV T
, 0 PUNCT F
aircrew 0 ADJ F
often 0 ADP F
complain 0 PUNCT F
about 0 PUNCT F
having 0 SYM F
to 0 PART F
maximize 0 NOUN F
intercom 0 NOUN F
volume 0 NOUN F
for 0 ADP F
speech 0 NOUN F
understanding 0 VERB F
, 0 PUNCT F
causing 0 SYM F
a 0 DET F
situation 0 NOUN F
with 0 ADP F
no 0 DET F
reserve 0 PUNCT F
volume 0 NOUN F
and 0 CCONJ F
bad 0 ADJ F
sound 0 ADJ F
quality 0 NOUN F
. 0 PUNCT F

In 0 ADP T
recent 0 ADJ F
years 0 NOUN F
, 0 PUNCT F
further 0 ADJ F
developments 0 NOUN F
have 0 PUNCT F
included 0 VERB F
so-called 0 PUNCT F
hi-fi 0 ADP F
plugs 0 NOUN F
and 0 CCONJ F
custom 0 NOUN F
made 0 VERB F
ear 0 NOUN F
plugs 0 NOUN F
which 0 ADP F
are 0 VERB F
claimed 0 VERB F
to 0 PART F
improve 0 PUNCT F
speech 0 NOUN F
communication 0 NOUN F
. 0 PUNCT F

The 0 DET T
aim 0 NOUN F
of 0 ADP F
the 0 DET F
present 0 ADJ F
project 0 NOUN F
was 0 VERB F
to 0 PART F
investigate 0 NOUN F
different 0 ADJ F
types 0 NOUN F
of 0 ADP F
ear 0 NOUN F
plugs 0 NOUN F
and 0 CCONJ F
their 0 ADP F
effect 0 NOUN F
on 0 ADP F
speech 0 NOUN F
intelligibility 0 NOUN F
in 0 ADP F
helicopter 0 ADJ F
noise 0 NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
Each 0 ADP T
of 0 ADP F
nine 0 NUM F
normal-hearing 0 VERB F
pilot 0 ADP F
subjects 0 NOUN F
were 0 VERB F
placed 0 VERB F
in 0 ADP F
an 0 DET F
environment 0 NOUN F
of 0 ADP F
recorded 0 VERB F
helicopter 0 ADJ F
noise 0 NOUN F
from 0 ADP F
a 0 DET F
BO-105 0 NOUN T
helicopter 0 NOUN F
. 0 PUNCT F

Speech 0 NOUN T
audiometry 0 NOUN F
was 0 VERB F
performed 0 VERB F
under 0 ADP F
four 0 NUM F
different 0 ADJ F
conditions 0 NOUN F
: 0 PUNCT F
headset 0 NOUN F
only 0 ADV F
, 0 PUNCT F
and 0 CCONJ F
three 0 NUM F
different 0 ADJ F
ear 0 NOUN F
plugs 0 NOUN F
worn 0 PUNCT F
under 0 ADP F
the 0 DET F
headset 0 NOUN F
. 0 PUNCT F

Fitting 0 ADJ T
of 0 ADP F
the 0 DET F
ear 0 NOUN F
plugs 0 ADV F
was 0 VERB F
performed 0 VERB F
by 0 ADP F
an 0 DET F
ear 0 NOUN F
, 0 PUNCT F
nose 0 NOUN F
and 0 CCONJ F
throat 0 NOUN F
specialist 0 NOUN F
to 0 PART F
ensure 0 NOUN F
similar 0 ADJ F
conditions 0 NOUN F
. 0 PUNCT F

The 0 DET T
sequence 0 NOUN F
of 0 ADP F
test 0 ADV F
conditions 0 NOUN F
was 0 VERB F
randomized 0 DET F
and 0 CCONJ F
double-blind 0 ADJ F
. 0 PUNCT F

In 0 ADP T
addition 0 NOUN F
, 0 PUNCT F
a 0 DET F
subjective B-OTHER ADJ F
rating I-OTHER ADP F
scale I-OTHER NOUN F
was 0 VERB F
used 0 VERB F
. 0 PUNCT F

RESULTS 0 NOUN T
Wearing 0 PUNCT T
foam 0 ADV F
ear 0 NOUN F
plugs 0 NOUN F
under 0 ADP F
the 0 DET F
headset 0 NOUN F
decreased 0 ADP F
speech B-MENTAL NOUN F
intelligibility I-MENTAL NOUN F
dramatically 0 ADV F
. 0 PUNCT F

The 0 DET T
hi-fi 0 ADP F
plug 0 NOUN F
was 0 VERB F
somewhat 0 ADV F
better 0 PUNCT F
than 0 CCONJ F
foam 0 NOUN F
plugs 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
the 0 DET F
custom 0 ADJ F
made 0 PRON F
ear 0 NOUN F
plug 0 NOUN F
provided 0 PROPN F
a 0 DET F
speech B-MENTAL NOUN F
intelligibility I-MENTAL NOUN F
close 0 ADJ F
to 0 ADP F
the 0 DET F
headset-only 0 ADP F
situation 0 NOUN F
. 0 PUNCT F

Subjective B-OTHER ADJ T
rating I-OTHER ADJ F
scores I-OTHER NOUN F
coincided 0 VERB F
with 0 ADP F
these 0 DET F
findings 0 NOUN F
. 0 PUNCT F

DISCUSSION 0 NOUN T
In 0 ADP T
helicopter 0 ADJ F
noise 0 NOUN F
, 0 PUNCT F
custom 0 PUNCT F
made 0 ADP F
ear 0 NOUN F
plugs 0 NOUN F
may 0 VERB F
provide 0 VERB F
a 0 DET F
much 0 ADP F
improved 0 ADP F
speech B-MENTAL NOUN F
intelligibility I-MENTAL NOUN F
over 0 PUNCT F
conventional 0 ADJ F
plugs 0 NOUN F
when 0 ADP F
worn 0 PUNCT F
under 0 ADP F
a 0 DET F
headset 0 NOUN F
, 0 PUNCT F
while 0 ADP F
maintaining 0 PUNCT F
improved 0 ADJ F
noise 0 ADJ F
protection B-MENTAL NOUN F
over 0 ADP F
the 0 DET F
headset-alone 0 NOUN F
situation 0 NOUN F
. 0 PUNCT F

Custom 0 NOUN T
made 0 VERB F
ear 0 NOUN F
plugs 0 NOUN F
might 0 PRON F
therefore 0 ADV F
be 0 VERB F
a 0 DET F
good 0 ADJ F
alternative 0 ADJ F
to 0 ADP F
other 0 ADJ F
forms 0 NOUN F
of 0 ADP F
enhanced B-OTHER VERB F
noise 0 PUNCT F

Does 0 PUNCT T
tetanus 0 NOUN F
immune 0 ADJ F
globulin 0 NOUN F
interfere 0 NOUN F
with 0 ADP F
the 0 DET F
immune B-PHYSICAL ADJ F
response I-PHYSICAL NOUN F
to 0 ADP F
simultaneous 0 ADJ F
administration 0 NOUN F
of 0 ADP F
tetanus-diphtheria 0 NOUN F
vaccine 0 NOUN F
? 0 PUNCT F

A 0 DET T
comparative 0 ADJ F
clinical 0 ADJ F
trial 0 NOUN F
in 0 ADP F
adults 0 NOUN F
. 0 PUNCT F

In 0 ADP T
the 0 DET F
management 0 NOUN F
of 0 ADP F
wounds 0 NOUN F
, 0 PUNCT F
sometimes 0 NOUN F
it 0 PROPN F
is 0 VERB F
recommended 0 VERB F
to 0 PART F
give 0 PUNCT F
an 0 DET F
adult-type 0 NOUN F
tetanus-diphtheria 0 NOUN F
( 0 PUNCT F
Td 0 NOUN T
) 0 PUNCT F
vaccine 0 NOUN F
dose 0 NOUN F
plus 0 CCONJ F
tetanus 0 NOUN F
immune 0 ADJ F
globulin 0 NOUN F
( 0 PUNCT F
TIG 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

Sixty 0 NUM T
and 0 CCONJ F
59 0 NUM F
healthy 0 ADJ F
young 0 ADJ F
adults 0 NOUN F
previously 0 ADV F
immunized 0 ADP F
against 0 ADP F
tetanus 0 NOUN F
( 0 PUNCT F
T 0 NOUN T
) 0 PUNCT F
and 0 CCONJ F
diphtheria 0 NOUN F
( 0 PUNCT F
D 0 NOUN T
) 0 PUNCT F
were 0 VERB F
randomized 0 VERB F
to 0 PART F
receive 0 NOUN F
intramuscularly 0 ADV F
either 0 PUNCT F
Td 0 NOUN T
vaccine 0 NOUN F
alone 0 ADJ F
( 0 PUNCT F
group 0 NOUN F
1 0 NUM F
) 0 PUNCT F
or 0 CCONJ F
Td 0 NOUN T
vaccine 0 NOUN F
plus 0 CCONJ F
500 0 NUM F
IU 0 NOUN T
of 0 ADP F
TIG 0 NOUN T
( 0 PUNCT F
group 0 NOUN F
2 0 NUM F
) 0 PUNCT F
simultaneously 0 ADV F
. 0 PUNCT F

Antitoxin B-PHYSICAL NOUN T
response I-PHYSICAL NOUN F
was 0 VERB F
assessed 0 VERB F
after 0 ADP F
4 0 NUM F
weeks 0 NOUN F
and 0 CCONJ F
4 0 NUM F
months 0 NOUN F
. 0 PUNCT F

Circulating B-PHYSICAL VERB T
antibodies I-PHYSICAL NOUN F
were I-PHYSICAL VERB F
measured I-PHYSICAL VERB F
by I-PHYSICAL ADP F
enzyme-linked I-PHYSICAL VERB F
immunosorbent I-PHYSICAL ADJ F
assay 0 NOUN F
( 0 PUNCT F
ELISA B-PHYSICAL NOUN T
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
cutoff 0 NOUN F
of 0 ADP F
these 0 DET F
tests 0 NOUN F
was 0 VERB F
0.1 0 NUM F
IU/mL 0 NOUN T
. 0 PUNCT F

Titers 0 NOUN T
of 0 ADP F
0.1 0 NUM F
IU/mL 0 NOUN T
or 0 CCONJ F
greater 0 PUNCT F
were 0 NUM F
considered 0 VERB F
protective 0 ADJ F
. 0 PUNCT F

For 0 ADP T
geometric 0 ADJ F
mean 0 NOUN F
titers 0 NOUN F
( 0 PUNCT F
GMT 0 NOUN T
) 0 PUNCT F
, 0 PUNCT F
antibody B-PHYSICAL NOUN F
titers I-PHYSICAL NOUN F
below 0 ADP F
the 0 DET F
cutoff 0 NOUN F
of 0 ADP F
the 0 DET F
assay 0 NOUN F
were 0 VERB F
given 0 VERB F
, 0 PUNCT F
arbitrarily 0 ADV F
, 0 PUNCT F
0.05 0 NUM F
IU/mL 0 NOUN T
. 0 PUNCT F

At 0 ADP T
4 0 NUM F
weeks 0 NOUN F
, 0 PUNCT F
98 0 NUM F
% 0 SYM F
or 0 CCONJ F
more 0 DET F
of 0 ADP F
the 0 DET F
subjects 0 NOUN F
in 0 ADP F
group 0 NOUN F
1 0 NUM F
had 0 PUNCT F
circulating B-PHYSICAL NUM F
T I-PHYSICAL NOUN T
and B-PHYSICAL CCONJ F
D I-PHYSICAL PUNCT T

Pre-treatment 0 ADJ T
proliferation 0 NOUN F
and 0 CCONJ F
the 0 DET F
outcome 0 NOUN F
of 0 ADP F
conventional 0 ADJ F
and 0 CCONJ F
accelerated 0 VERB F
radiotherapy 0 NOUN F
. 0 PUNCT F

This 0 DET T
study 0 NOUN F
investigated 0 VERB F
the 0 DET F
influence 0 NOUN F
of 0 ADP F
pre-treatment 0 NOUN F
proliferation 0 NOUN F
characteristics 0 NOUN F
, 0 PUNCT F
assessed 0 VERB F
by 0 ADP F
Ki-67 0 NOUN T
staining 0 VERB F
, 0 PUNCT F
in 0 ADP F
patients 0 NOUN F
treated 0 VERB F
in 0 ADP F
the 0 DET F
CHART 0 NOUN T
trial 0 NOUN F
of 0 ADP F
accelerated 0 VERB F
radiotherapy 0 NOUN F
in 0 ADP F
head 0 NOUN F
and 0 CCONJ F
neck 0 ADJ F
cancer 0 NOUN F
. 0 PUNCT F

Histological 0 ADJ T
material 0 NOUN F
from 0 ADP F
402 0 NUM F
patients 0 NOUN F
was 0 VERB F
collected 0 ADV F
and 0 CCONJ F
stained 0 VERB F
for 0 ADP F
the 0 DET F
presence 0 NOUN F
and 0 CCONJ F
pattern 0 NOUN F
of 0 ADP F
Ki-67 0 NOUN T
staining 0 VERB F
. 0 PUNCT F

Locoregional B-PHYSICAL ADJ T
control I-PHYSICAL NOUN F
and 0 CCONJ F
overall 0 ADJ F
survival 0 NOUN F
were 0 VERB F
the 0 DET F
main 0 ADJ F
clinical 0 ADJ F
endpoints 0 NOUN F
. 0 PUNCT F

Increasing 0 ADP T
Ki-67 0 NOUN T
positivity 0 NOUN F
was 0 VERB F
associated 0 VERB F
with 0 ADP F
decreasing 0 PUNCT F
differentiation 0 NOUN F
( 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.001 0 NUM F
) 0 PUNCT F
and 0 CCONJ F
increasing 0 PUNCT F
N-stage 0 ADP T
( 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.004 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Increasing 0 ADP T
N-stage 0 NOUN T
was 0 VERB F
also 0 ADV F
associated 0 VERB F
with 0 ADP F
the 0 DET F
progression 0 NOUN F
of 0 ADP F
proliferation 0 NOUN F
pattern 0 NOUN F
from 0 ADP F
marginal 0 ADJ F
to 0 ADP F
random 0 ADJ F
( 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.001 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Using 0 ADJ T
a 0 DET F
multivariate 0 ADJ F
model 0 NOUN F
, 0 PUNCT F
a 0 DET F
trend 0 NOUN F
was 0 VERB F
seen 0 VERB F
towards 0 ADP F
a 0 DET F
greater 0 PUNCT F
benefit 0 NOUN F
from 0 ADP F
CHART 0 NOUN T
in 0 ADP F
the 0 DET F
lower 0 PUNCT F
Ki-67 0 NOUN T
tumours 0 NOUN F
( 0 PUNCT F
P 0 NOUN T
= 0 SYM F
0.08 0 NUM F
) 0 PUNCT F
; 0 PUNCT F
this 0 PUNCT F
became 0 CCONJ F
significant 0 CCONJ F
by 0 ADP F
pooling 0 ADJ F
the 0 DET F
low 0 ADJ F
and 0 CCONJ F
intermediate 0 ADJ F
Ki-67 0 NOUN T
groups 0 NOUN F
in 0 ADP F
comparison 0 NOUN F
with 0 ADP F
the 0 DET F
high 0 ADJ F
Ki-67 0 NOUN T
group 0 NOUN F
( 0 PUNCT F
P 0 NOUN T
= 0 SYM F
0.032 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Tumours 0 NOUN T
with 0 ADP F
marginal 0 ADJ F
proliferation 0 NOUN F
pattern 0 NOUN F
showed 0 VERB F
a 0 DET F
lower 0 PUNCT F
hazard 0 NOUN F
ratio 0 NOUN F
with 0 ADP F
CHART 0 NOUN T
versus 0 CCONJ F
conventional 0 ADJ F
for 0 ADP F
locoregional 0 ADJ F
control 0 NOUN F
( 0 PUNCT F
P 0 NOUN T
= 0 SYM F
0.005 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
data 0 NOUN F
presented 0 VERB F
in 0 ADP F
this 0 DET F
study 0 NOUN F
do 0 PUNCT F
not 0 ADV F
support 0 VERB F
that 0 ADP F
a 0 DET F
high 0 ADJ F
pre-treatment 0 NOUN F
Ki-67 0 NOUN T
is 0 VERB F
associated 0 VERB F
with 0 ADP F
a 0 DET F
therapeutic B-OTHER ADJ F
benefit I-OTHER NOUN F
from 0 ADP F
accelerated 0 VERB F
radiotherapy 0 NOUN F
. 0 PUNCT F

Comparison 0 NOUN T
of 0 ADP F
sedative 0 ADJ F
drugs 0 NOUN F
under 0 ADP F
peribulbar 0 ADJ F
or 0 CCONJ F
topical 0 ADJ F
anesthesia 0 NOUN F
during 0 ADP F
phacoemulsification 0 NOUN F
. 0 PUNCT F

BACKGROUND 0 NOUN T
AND 0 CCONJ T
OBJECTIVE 0 NOUN T
To 0 PROPN T
compare 0 NOUN F
dexmedetomidine 0 PUNCT F
and 0 CCONJ F
midazolam+fentanyl 0 NOUN F
sedation 0 NOUN F
primarily 0 ADV F
based 0 VERB F
on 0 ADP F
patient 0 NOUN F
satisfaction 0 NOUN F
during 0 ADP F
phacoemulsification 0 NOUN F
under 0 ADP F
topical 0 ADJ F
and 0 CCONJ F
peribulbar 0 ADJ F
anesthesia 0 NOUN F
. 0 PUNCT F

PATIENTS 0 NOUN T
AND 0 CCONJ T
METHODS 0 NOUN T
Prospective 0 ADJ T
, 0 PUNCT F
randomized 0 VERB F
, 0 PUNCT F
and 0 CCONJ F
double-blind 0 ADJ F
study 0 NOUN F
of 0 ADP F
80 0 NUM F
American 0 ADJ T
Society 0 NOUN T
of 0 ADP F
Anesthesiology 0 NOUN T
grade 0 NOUN F
I-II 0 NUM T
patients 0 NOUN F
who 0 ADP F
underwent 0 VERB F
phacoemulsification 0 NOUN F
with 0 ADP F
local 0 ADJ F
anesthesia 0 NOUN F
under 0 ADP F
sedation 0 NOUN F
. 0 PUNCT F

Patients 0 NOUN T
were 0 VERB F
divided 0 VERB F
into 0 ADP F
four 0 NUM F
groups 0 NOUN F
( 0 PUNCT F
20 0 NUM F
patients 0 NOUN F
for 0 ADP F
each 0 PUNCT F
) 0 PUNCT F
: 0 PUNCT F
dexmedetomidine 0 PUNCT F
and 0 CCONJ F
topical 0 ADJ F
anesthesia 0 NOUN F
, 0 PUNCT F
dexmedetomidine 0 PUNCT F
and 0 CCONJ F
peribulbar 0 ADJ F
anesthesia 0 NOUN F
, 0 PUNCT F
midazolam+fentanyl 0 NOUN F
and 0 CCONJ F
topical 0 ADJ F
anesthesia 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
midazolam+fentanyl 0 NOUN F
and 0 CCONJ F
peribulbar 0 ADJ F
anesthesia 0 NOUN F
. 0 PUNCT F

Patient 0 NOUN T
and 0 CCONJ F
surgeon 0 NOUN F
satisfaction 0 NOUN F
were 0 VERB F
determined 0 VERB F
on 0 ADP F
a 0 DET F
5-point 0 NOUN F
scale 0 NOUN F
. 0 PUNCT F

The 0 DET T
pain 0 NOUN F
was 0 VERB F
determined 0 VERB F
by 0 ADP F
verbal 0 ADJ F
pain 0 NOUN F
scale 0 NOUN F
intraoperatively 0 ADV F
and 0 CCONJ F
postoperatively 0 NUM F
. 0 PUNCT F

Drugs 0 NOUN T
were 0 VERB F
given 0 VERB F
to 0 ADP F
a 0 DET F
Ramsay 0 NOUN T
sedation 0 NOUN F
scale 0 NOUN F
of 0 ADP F
3 0 NUM F
. 0 PUNCT F

Topical 0 ADJ T
and 0 CCONJ F
peribulbar 0 ADJ F
anesthesia 0 NOUN F
were 0 VERB F
performed 0 VERB F
by 0 ADP F
an 0 DET F
ophthalmologist 0 NOUN F
. 0 PUNCT F

Hemodynamic 0 ADJ T
, 0 PUNCT F
respiratory 0 ADJ F
, 0 PUNCT F
and 0 CCONJ F
intraocular 0 ADJ F
pressure 0 NOUN F
monitoring 0 VERB F
was 0 VERB F
done 0 PUNCT F
. 0 PUNCT F

Operative 0 ADJ T
and 0 CCONJ F
recovery 0 NOUN F
times 0 NOUN F
were 0 VERB F
recorded 0 VERB F
. 0 PUNCT F

RESULTS 0 NOUN T
In 0 ADP T
the 0 DET F
midazolam+fentanyl 0 NOUN F
groups 0 NOUN F
, 0 PUNCT F
better 0 PUNCT F
patient B-OTHER NOUN F
and I-OTHER CCONJ F
surgeon I-OTHER NOUN F
satisfaction I-OTHER NOUN F
scores 0 NOUN F
were 0 VERB F
obtained 0 VERB F
( 0 PUNCT F
P 0 NOUN T
< 0 SYM F
.005 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
verbal B-PAIN ADJ F
pain I-PAIN NOUN F
scale I-PAIN NOUN F
scores 0 NOUN F
were 0 VERB F
significantly 0 ADV F
lower 0 PUNCT F
( 0 PUNCT F
P 0 NOUN T
< 0 SYM F
.001 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
and 0 CCONJ F
patients 0 NOUN F
needed 0 PUNCT F
less 0 ADV F
postoperative B-OTHER ADJ F
analgesia I-OTHER NOUN F
. 0 PUNCT F

Ramsay B-OTHER NOUN T
sedation I-OTHER NOUN F
scale I-OTHER NOUN F
scores 0 NOUN F
were 0 VERB F
between 0 ADP F
3 0 NUM F
and 0 CCONJ F
4 0 NUM F
in 0 ADP F
all 0 DET F
patients 0 NOUN F
and 0 CCONJ F
there 0 PUNCT F
were 0 VERB F
no 0 DET F
significant 0 ADJ F
differences 0 NOUN F
. 0 PUNCT F

Intraocular B-PHYSICAL ADJ T
pressure I-PHYSICAL NOUN F
alterations I-PHYSICAL NOUN F
were 0 VERB F
similar 0 ADJ F
between 0 ADP F
groups 0 NOUN F
. 0 PUNCT F

Recovery B-OTHER DET T
time I-OTHER NOUN F
was 0 VERB F
longer 0 PUNCT F
in 0 ADP F
the 0 DET F
dexmedetomidine 0 ADJ F
groups 0 NOUN F
( 0 PUNCT F
P 0 NOUN T
< 0 SYM F
.05 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

CONCLUSION 0 NOUN T
The 0 DET T
study 0 NOUN F
demonstrated 0 VERB F
that 0 ADP F
the 0 DET F
midazolam+fentanyl 0 NOUN F
combination 0 NOUN F
provided 0 VERB F
high-level 0 NOUN F
patient B-OTHER NOUN F
satisfaction I-OTHER NOUN F
scores I-OTHER NOUN F
, 0 PUNCT F
low-level 0 NOUN F
pain B-PAIN NOUN F
scores I-PAIN NOUN F
, 0 PUNCT F
and 0 CCONJ F
shorter 0 PUNCT F
recovery B-OTHER NOUN F
time I-OTHER NOUN F
. 0 PUNCT F

Also 0 ADV T
, 0 PUNCT F
both 0 PUNCT F
of 0 ADP F
the 0 DET F
peribulbar 0 ADJ F
and 0 CCONJ F
topical 0 ADJ F
anesthesia 0 NOUN F
procedures 0 NOUN F
showed 0 VERB F
similar 0 ADJ F
efficiency 0 NOUN F
. 0 PUNCT F

[ 0 PUNCT F
Administration 0 NOUN T
of 0 ADP F
tobramycin 0 NOUN F
aerosols 0 ADP F
in 0 ADP F
patients 0 NOUN F
with 0 ADP F
nosocomial 0 ADJ F
pneumonia 0 NOUN F
: 0 PUNCT F
a 0 DET F
preliminary 0 ADJ F
study 0 NOUN F
] 0 PUNCT F
. 0 PUNCT F

OBJECTIVE 0 NOUN T
The 0 DET T
aim 0 NOUN F
of 0 ADP F
this 0 DET F
study 0 NOUN F
was 0 VERB F
to 0 ADV F
assess 0 NOUN F
renal B-PHYSICAL ADJ F
and I-PHYSICAL CCONJ F
respiratory I-PHYSICAL ADJ F
tolerance I-PHYSICAL NOUN F
of 0 ADP F
aerosolized 0 PUNCT F
tobramycin 0 NOUN F
in 0 ADP F
intubated 0 VERB F
and 0 CCONJ F
mechanically 0 ADV F
ventilated 0 DET F
patients 0 NOUN F
with 0 ADP F
nosocomial 0 ADJ F
pneumonia 0 NOUN F
. 0 PUNCT F

PATIENTS 0 NOUN T
AND 0 CCONJ T
METHODS 0 NOUN T
This 0 PUNCT T
was 0 VERB F
a 0 DET F
multicenter 0 NOUN F
, 0 PUNCT F
randomized 0 VERB F
, 0 PUNCT F
double-blind 0 ADJ F
, 0 PUNCT F
placebo 0 NOUN F
controlled 0 VERB F
study 0 NOUN F
. 0 PUNCT F

Thirty-eight 0 PUNCT T
mechanically 0 ADV F
ventilated 0 DET F
patients 0 NOUN F
with 0 ADP F
documented 0 VERB F
nosocomial 0 ADJ F
pneumonia 0 NOUN F
were 0 VERB F
included 0 VERB F
. 0 PUNCT F

Patients 0 NOUN T
treated 0 VERB F
with 0 ADP F
intravenous 0 ADJ F
betalactam 0 NOUN F
and 0 CCONJ F
tobramycin 0 NOUN F
were 0 VERB F
randomly 0 ADV F
allocated 0 VERB F
to 0 PART F
receive 0 NOUN F
aerosolized 0 PUNCT F
tobramycin 0 NOUN F
( 0 PUNCT F
6 0 ADP F
mg/kg/day 0 PUNCT F
, 0 PUNCT F
n 0 NOUN F
= 0 SYM F
21 0 NUM F
) 0 PUNCT F
or 0 CCONJ F
placebo 0 NOUN F
( 0 PUNCT F
n 0 NOUN F
= 0 SYM F
17 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
aerosol 0 NOUN F
was 0 VERB F
administered 0 VERB F
via 0 ADP F
a 0 DET F
pneumatic 0 ADJ F
nebulizer 0 NOUN F
once 0 PUNCT F
a 0 DET F
day 0 NOUN F
for 0 ADP F
5 0 NUM F
days 0 NOUN F
. 0 PUNCT F

RESULTS 0 NOUN T
Respiratory B-PHYSICAL ADJ T
tolerance I-PHYSICAL NOUN F
was 0 VERB F
good 0 ADJ F
in 0 ADP F
all 0 ADP F
but 0 CCONJ F
two 0 NUM F
patients 0 NOUN F
. 0 PUNCT F

No 0 DET T
acute B-PHYSICAL ADJ F
renal I-PHYSICAL ADJ F
failure I-PHYSICAL NOUN F
occurred 0 VERB F
. 0 PUNCT F

By 0 ADP T
day 0 NOUN F
10 0 NUM F
, 0 PUNCT F
7 0 NUM F
patients 0 NOUN F
in 0 ADP F
the 0 DET F
tobramycin 0 NOUN F
group 0 NOUN F
( 0 PUNCT F
35 0 NUM F
% 0 SYM F
) 0 PUNCT F
had 0 PUNCT F
been 0 PUNCT F
extubated B-PHYSICAL VERB F
versus 0 CCONJ F
3 0 NUM F
in 0 ADP F
the 0 DET F
placebo 0 NOUN F
group 0 NOUN F
( 0 PUNCT F
18.5 0 NUM F
% 0 SYM F
, 0 PUNCT F
p 0 NOUN F
= 0 SYM F
0.18 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

By 0 ADP T
day 0 NOUN F
28 0 NUM F
, 0 PUNCT F
6 0 NUM F
patients 0 NOUN F
had 0 PUNCT F
died B-MORTALITY ADP F
( 0 PUNCT F
2 0 NUM F
in 0 ADP F
the 0 DET F
tobramycin 0 NOUN F
group 0 NOUN F
and 0 CCONJ F
4 0 NUM F
in 0 ADP F
the 0 DET F
placebo 0 NOUN F
group 0 NOUN F
, 0 PUNCT F
p 0 NOUN F
= 0 SYM F
0.23 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

CONCLUSION 0 NOUN T
Aerosolized 0 PUNCT T
tobramycin 0 NOUN F
was 0 PUNCT F
well 0 VERB F
tolerated 0 ADP F
in 0 ADP F
ventilated 0 VERB F
patients 0 NOUN F
with 0 ADP F
documented 0 VERB F
nosocomial 0 ADJ F
pneumonia 0 NOUN F
. 0 PUNCT F

[ 0 PUNCT F
Cardiac 0 ADJ T
protection 0 NOUN F
is 0 VERB F
a 0 DET F
clinical 0 ADJ F
evidence 0 NOUN F
] 0 PUNCT F
. 0 PUNCT F

AIM 0 NOUN T
Anaesthetics 0 PROPN T
may 0 VERB F
have 0 CCONJ F
protective 0 ADJ F
effect 0 NOUN F
against 0 ADP F
myocardial 0 ADJ F
ischemia 0 NOUN F
. 0 PUNCT F

We 0 PRON T
aimed 0 VERB F
to 0 PART F
investigate 0 ADP F
if 0 PUNCT F
sevoflurane 0 VERB F
administration 0 NOUN F
could 0 PUNCT F
exert 0 VERB F
myocardial B-PHYSICAL ADJ F
protection I-PHYSICAL NOUN F
during 0 ADP F
following 0 ADP F
coronary 0 ADJ F
occlusion 0 NOUN F
in 0 ADP F
patients 0 NOUN F
with 0 ADP F
coronary 0 ADJ F
artery 0 NOUN F
disease 0 NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
a 0 CCONJ F
) 0 PUNCT F
. 0 PUNCT F

EXPERIMENTAL 0 ADJ T
DESIGN 0 NOUN T
prospective 0 ADJ F
, 0 PUNCT F
randomized 0 ADP F
study 0 NOUN F
. 0 PUNCT F

b 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

SETTING 0 ADJ T
University 0 NOUN T
Hospital 0 NOUN T
, 0 PUNCT F
cardiac 0 ADJ F
surgical 0 ADJ F
operative 0 ADJ F
theatre 0 NOUN F
. 0 PUNCT F

c 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

PATIENTS 0 NOUN T
42 0 NUM F
patients 0 NOUN F
with 0 ADP F
coronary 0 ADJ F
artery 0 NOUN F
disease 0 NOUN F
, 0 PUNCT F
scheduled 0 VERB F
to 0 PART F
undergo 0 PUNCT F
coronary 0 ADJ F
surgery 0 NOUN F
. 0 PUNCT F

INCLUSION 0 NOUN T
CRITERIA 0 NOUN T
severe 0 ADJ F
coronary 0 ADJ F
stenosis 0 NOUN F
of 0 ADP F
anterior 0 ADJ F
descending 0 ADP F
coronary 0 ADJ F
artery 0 NOUN F
; 0 PUNCT F
no 0 DET F
collateral 0 ADJ F
flow 0 NOUN F
on 0 ADP F
angiography 0 NOUN F
; 0 PUNCT F
at 0 ADP F
least 0 ADV F
two 0 NUM F
normokinetic 0 ADJ F
segments 0 NOUN F
in 0 ADP F
the 0 DET F
myocardial 0 ADJ F
region 0 NOUN F
supplied 0 VERB F
by 0 ADP F
the 0 DET F
vessel 0 NOUN F
being 0 VERB F
bypassed 0 VERB F
. 0 PUNCT F

PATIENTS 0 NOUN T
were 0 VERB F
randomized 0 VERB F
to 0 PART F
receive 0 NOUN F
( 0 PUNCT F
group 0 NOUN F
S 0 NOUN T
) 0 PUNCT F
or 0 CCONJ F
not 0 ADV F
( 0 PUNCT F
group 0 NOUN F
C 0 NOUN T
) 0 PUNCT F
sevoflurane 0 NOUN F
administration 0 NOUN F
for 0 ADP F
15 0 NUM F
min 0 NOUN F
just 0 ADV F
before 0 PUNCT F
coronary 0 ADJ F
occlusion 0 NOUN F
. 0 PUNCT F

d 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

INTERVENTIONS 0 NOUN T
Transoesophageal 0 PUNCT T
Tissue 0 NOUN T
Doppler 0 NOUN T
echocardiographic 0 ADJ F
examination 0 NOUN F
of 0 ADP F
myocardial 0 ADJ F
systolic 0 ADJ F
and 0 CCONJ F
early 0 ADJ F
diastolic 0 ADJ F
velocities 0 NOUN F
in 0 ADP F
both 0 CCONJ F
groups 0 NOUN F
basally 0 ADV F
and 0 CCONJ F
60 0 NUM F
s 0 NOUN F
after 0 ADP F
coronary 0 ADJ F
occlusion 0 NOUN F
by 0 ADP F
the 0 DET F
surgeon 0 NOUN F
. 0 PUNCT F

e 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

MEASURES 0 NOUN T
systolic B-PHYSICAL ADJ F
and I-PHYSICAL CCONJ F
early I-PHYSICAL ADJ F
diastolic I-PHYSICAL ADJ F
velocities I-PHYSICAL NOUN F
were 0 VERB F
registered 0 PUNCT F
by 0 ADP F
Tissue 0 NOUN T
Doppler 0 NOUN T
from 0 ADP F
a 0 DET F
long-axis 0 NOUN F
view 0 NOUN F
of 0 ADP F
the 0 DET F
interventricular 0 ADJ F
septum 0 NOUN F
or 0 CCONJ F
the 0 DET F
anterior 0 ADJ F
wall 0 NOUN F
of 0 ADP F
the 0 DET F
left 0 ADJ F
ventricle 0 NOUN F
. 0 PUNCT F

RESULTS 0 NOUN T
In 0 ADP T
group 0 NOUN F
C 0 NOUN T
a 0 DET F
significant 0 ADJ F
reduction 0 NOUN F
of 0 ADP F
systolic B-PHYSICAL ADJ F
and I-PHYSICAL CCONJ F
diastolic I-PHYSICAL ADJ F
intramyocardial I-PHYSICAL ADJ F
velocities I-PHYSICAL NOUN F
was 0 VERB F
found 0 VERB F
during 0 ADP F
myocardial 0 ADJ F
ischemia 0 NOUN F
due 0 VERB F
to 0 ADP F
coronary 0 ADJ F
occlusion 0 NOUN F
. 0 PUNCT F

CONCLUSION 0 NOUN T
Treatment 0 NOUN T
with 0 ADP F
sevoflurane 0 NOUN F
before 0 ADP F
coronary 0 ADJ F
occlusion 0 NOUN F
seem 0 VERB F
effective 0 ADJ F
in 0 ADP F
reducing 0 VERB F
functional B-PHYSICAL ADJ F
myocardial I-PHYSICAL ADJ F
impairment I-PHYSICAL NOUN F
due 0 CCONJ F
to 0 ADP F
ischemia 0 NOUN F
. 0 PUNCT F

Modified 0 VERB T
constraint-induced 0 VERB F
movement 0 NOUN F
therapy 0 NOUN F
improved 0 ADP F
upper 0 ADJ F
limb 0 NOUN F
function 0 NOUN F
in 0 ADP F
subacute 0 ADJ F
poststroke 0 NOUN F
patients 0 NOUN F
: 0 PUNCT F
a 0 DET F
small-scale 0 NOUN F
clinical 0 ADJ F
trial 0 NOUN F
. 0 PUNCT F

BACKGROUND 0 NOUN T
Constraint-induced 0 VERB T
movement 0 NOUN F
therapy 0 NOUN F
( 0 PUNCT F
CIMT 0 NOUN T
) 0 PUNCT F
has 0 PUNCT F
been 0 PUNCT F
advocated 0 VERB F
as 0 ADP F
a 0 DET F
means 0 NOUN F
of 0 ADP F
facilitating 0 PUNCT F
motor 0 NOUN F
function 0 NOUN F
in 0 ADP F
poststroke 0 NOUN F
patients 0 NOUN F
; 0 PUNCT F
however 0 ADV F
, 0 PUNCT F
the 0 DET F
evidence 0 NOUN F
for 0 ADP F
its 0 PUNCT F
efficacy 0 NOUN F
is 0 VERB F
controversial 0 ADJ F
. 0 PUNCT F

OBJECTIVE 0 NOUN T
To 0 PROPN T
evaluate 0 NOUN F
the 0 DET F
effect 0 NOUN F
of 0 ADP F
modified 0 VERB F
CIMT 0 NOUN T
on 0 ADP F
improving 0 VERB F
paretic 0 ADJ F
arm 0 NOUN F
function 0 NOUN F
in 0 ADP F
poststroke 0 NOUN F
patients 0 NOUN F
during 0 ADP F
a 0 DET F
subacute 0 ADJ F
rehabilitation 0 NOUN F
period 0 NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
A 0 NOUN T
single-blinded 0 VERB F
randomized 0 VERB F
controlled 0 VERB F
trial 0 NOUN F
was 0 VERB F
conducted 0 VERB F
at 0 ADP F
the 0 DET F
Loewenstein 0 NOUN T
Rehabilitation 0 NOUN T
Hospital 0 NOUN T
, 0 PUNCT F
Israel 0 PUNCT T
. 0 PUNCT F

Twenty-eight 0 PUNCT T
subacute 0 ADJ F
stroke 0 NOUN F
patients 0 NOUN F
with 0 ADP F
arm 0 NOUN F
paresis 0 NOUN F
after 0 ADP F
a 0 DET F
first 0 ADJ F
ischemic 0 ADJ F
stroke 0 NOUN F
in 0 ADP F
the 0 DET F
middle 0 ADJ F
cerebral 0 ADJ F
artery 0 NOUN F
area 0 NOUN F
were 0 VERB F
randomized 0 VERB F
into 0 ADP F
a 0 DET F
modified 0 VERB F
CIMT 0 NOUN T
or 0 CCONJ F
control 0 NOUN F
group 0 NOUN F
by 0 ADP F
a 0 DET F
1:2 0 NUM F
ratio 0 NOUN F
. 0 PUNCT F

The 0 DET T
modified 0 VERB F
CIMT 0 NOUN T
group 0 NOUN F
received 0 VERB F
1-hour 0 NOUN F
daily 0 ADJ F
physical 0 ADJ F
rehabilitation 0 NOUN F
sessions 0 NOUN F
for 0 ADP F
2 0 NUM F
weeks 0 NOUN F
. 0 PUNCT F

The 0 DET T
unaffected 0 VERB F
arm 0 NOUN F
was 0 VERB F
restrained 0 VERB F
during 0 ADP F
the 0 DET F
sessions 0 NOUN F
. 0 PUNCT F

Subjects 0 NOUN T
were 0 VERB F
encouraged 0 VERB F
to 0 ADP F
wear 0 CCONJ F
a 0 DET F
restrictive 0 ADJ F
mitten 0 ADP F
up 0 PUNCT F
to 0 ADP F
4 0 NUM F
hours 0 NOUN F
a 0 DET F
day 0 NOUN F
. 0 PUNCT F

The 0 DET T
control 0 NOUN F
group 0 NOUN F
received 0 ADP F
similar 0 ADJ F
intensive 0 ADJ F
regular 0 ADJ F
rehabilitation 0 NOUN F
. 0 PUNCT F

Three 0 NUM T
upper 0 ADJ F
limb 0 NOUN F
function 0 NOUN F
tests 0 NOUN F
, 0 PUNCT F
developed 0 VERB F
for 0 ADP F
this 0 DET F
study 0 NOUN F
, 0 PUNCT F
were 0 VERB F
used 0 VERB F
as 0 DET F
outcome 0 NOUN F
measures 0 NOUN F
. 0 PUNCT F

The 0 DET T
subjects 0 NOUN F
were 0 VERB F
asked 0 VERB F
to 0 PART F
perform 0 NOUN F
the 0 DET F
following 0 PUNCT F
tasks 0 NOUN F
, 0 PUNCT F
with 0 ADP F
the 0 DET F
affected 0 ADP F
hand 0 NOUN F
for 0 ADP F
30 0 NUM F
seconds 0 NOUN F
: 0 PUNCT F
( 0 PUNCT F
1 0 NUM F
) 0 PUNCT F
transfer 0 NOUN F
pegs 0 PUNCT F
from 0 ADP F
a 0 DET F
saucer 0 NOUN F
to 0 ADP F
a 0 DET F
pegboard 0 ADJ F
; 0 PUNCT F
( 0 PUNCT F
2 0 NUM F
) 0 PUNCT F
grasp 0 ADP F
, 0 PUNCT F
carry 0 VERB F
, 0 PUNCT F
and 0 CCONJ F
release 0 NOUN F
a 0 DET F
hard 0 PUNCT F
rubber 0 NOUN F
ball 0 NOUN F
; 0 PUNCT F
and 0 CCONJ F
( 0 PUNCT F
3 0 NUM F
) 0 PUNCT F
eating 0 ADP F
, 0 PUNCT F
using 0 VERB F
a 0 DET F
spoon 0 ADV F
to 0 PART F
remove 0 NOUN F
the 0 DET F
jelly 0 ADV F
from 0 ADP F
the 0 DET F
plate 0 NOUN F
, 0 PUNCT F
bring 0 PUNCT F
it 0 PUNCT F
towards 0 ADP F
the 0 DET F
mouth 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
then 0 ADV F
place 0 ADJ F
it 0 NUM F
on 0 ADP F
another 0 DET F
plate 0 NOUN F
. 0 PUNCT F

The 0 DET T
number B-OTHER NOUN F
of I-OTHER ADP F
repetitions I-OTHER CCONJ F
in I-OTHER ADP F
each I-OTHER DET F
test I-OTHER NOUN F
was 0 VERB F
recorded 0 VERB F
as 0 ADP F
an 0 DET F
outcome 0 NOUN F
. 0 PUNCT F

RESULTS 0 PUNCT T
The 0 DET T
modified 0 VERB F
CIMT 0 NOUN T
group 0 NOUN F
showed 0 VERB F
significantly 0 ADP F
higher 0 PUNCT F
changes 0 NOUN F
in 0 ADP F
all 0 DET F
3 0 NUM F
tests 0 NOUN F
compared 0 VERB F
to 0 ADP F
the 0 DET F
standard 0 ADJ F
rehabilitation 0 NOUN F
group 0 NOUN F
. 0 PUNCT F

CONCLUSION 0 NOUN T
Our 0 PUNCT T
study 0 NOUN F
provides 0 NOUN F
additional 0 ADJ F
support 0 NOUN F
for 0 ADP F
the 0 DET F
use 0 NOUN F
of 0 ADP F
modified 0 VERB F
CIMT 0 NOUN T
during 0 ADP F
a 0 DET F
subacute 0 ADJ F
rehabilitation 0 NOUN F
period 0 NOUN F
of 0 ADP F
poststroke 0 NOUN F
patients 0 NOUN F
. 0 PUNCT F

CIMT 0 NOUN T
may 0 VERB F
facilitate 0 VERB F
functional 0 ADJ F
improvement 0 NOUN F
of 0 ADP F
a 0 DET F
plegic 0 ADJ F
hand 0 NOUN F
. 0 PUNCT F

[ 0 PUNCT F
A 0 DET T
multicenter 0 NOUN F
, 0 PUNCT F
randomized 0 VERB F
clinical 0 ADJ F
trial 0 NOUN F
of 0 ADP F
intravenous 0 ADJ F
diltiazem 0 NOUN F
in 0 ADP F
treatment 0 NOUN F
of 0 ADP F
unstable 0 ADJ F
angina 0 NOUN F
] 0 PUNCT F
. 0 PUNCT F

OBJECTIVE 0 NOUN T
To 0 PROPN T
investigate 0 NOUN F
the 0 DET F
clinical 0 ADJ F
efficacy 0 NOUN F
and 0 CCONJ F
safety 0 NOUN F
of 0 ADP F
intravenous 0 ADJ F
diltiazem 0 NOUN F
compared 0 VERB F
with 0 ADP F
nitroglycerin 0 NOUN F
in 0 ADP F
the 0 DET F
patients 0 NOUN F
with 0 ADP F
unstable 0 ADJ F
angina 0 NOUN F
pectoris 0 NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
A 0 PUNCT T
multicenter 0 NOUN F
, 0 PUNCT F
randomized 0 VERB F
, 0 PUNCT F
open-label 0 NOUN F
, 0 PUNCT F
parallel 0 ADJ F
group 0 NOUN F
trial 0 NOUN F
was 0 VERB F
conducted 0 VERB F
. 0 PUNCT F

A 0 DET T
total 0 NOUN F
of 0 ADP F
213 0 NUM F
eligible 0 ADJ F
patients 0 NOUN F
were 0 VERB F
enrolled 0 VERB F
. 0 PUNCT F

They 0 PRON T
were 0 VERB F
randomized 0 NUM F
either 0 PUNCT F
to 0 ADP F
diltiazem 0 NOUN F
or 0 CCONJ F
nitroglycerin 0 NOUN F
treatment 0 NOUN F
. 0 PUNCT F

The 0 DET T
diltiazem 0 NOUN F
was 0 VERB F
administered 0 VERB F
from 0 ADP F
100 0 NUM F
microg/min 0 NOUN F
at 0 ADP F
the 0 DET F
initiation 0 NOUN F
of 0 ADP F
treatment 0 NOUN F
, 0 PUNCT F
the 0 DET F
largest 0 PUNCT F
dosage 0 NOUN F
was 0 VERB F
200 0 PUNCT F
- 0 PUNCT F
300 0 NUM F
microg/min 0 NOUN F
; 0 PUNCT F
the 0 DET F
nitroglycerin 0 NOUN F
was 0 VERB F
administered 0 VERB F
from 0 ADP F
20 0 NUM F
microg/min 0 NOUN F
at 0 ADP F
the 0 DET F
initiation 0 NOUN F
of 0 ADP F
treatment 0 NOUN F
. 0 PUNCT F

The 0 DET T
largest 0 PUNCT F
dosage 0 NOUN F
was 0 VERB F
80 0 PUNCT F
- 0 PUNCT F
100 0 NUM F
microg/min 0 NOUN F
. 0 PUNCT F

Intravenous 0 ADJ T
infusion 0 NOUN F
was 0 VERB F
kept 0 PUNCT F
over 0 ADP F
48 0 NUM F
hours 0 NOUN F
. 0 PUNCT F

The 0 DET T
endpoints 0 NOUN F
included 0 ADJ F
refractory B-PHYSICAL ADJ F
angina I-PHYSICAL NOUN F
pectoris I-PHYSICAL NOUN F
, 0 PUNCT F
acute B-PHYSICAL ADJ F
myocardial I-PHYSICAL ADJ F
infarction I-PHYSICAL NOUN F
, 0 PUNCT F
death B-MORTALITY NOUN F
, 0 PUNCT F
emergency B-PHYSICAL NOUN F
PTCA I-PHYSICAL NOUN T
and 0 CCONJ F
CABG B-PHYSICAL NOUN T
. 0 PUNCT F

RESULTS 0 NOUN T
( 0 PUNCT F
1 0 NUM F
) 0 PUNCT F
Intravenous 0 ADJ T
diltiazem 0 NOUN F
was 0 VERB F
effective 0 ADJ F
on 0 ADP F
the 0 DET F
improvement 0 NOUN F
of 0 ADP F
symptom B-PHYSICAL NOUN F
and 0 CCONJ F
electrocardiogram B-PHYSICAL NOUN F
, 0 PUNCT F
and 0 CCONJ F
its 0 DET F
effects 0 NOUN F
were 0 VERB F
similar 0 ADJ F
to 0 ADP F
intravenous 0 ADJ F
nitroglycerin 0 NOUN F
. 0 PUNCT F
( 0 PUNCT F

2 0 NUM F
) 0 PUNCT F
Compared 0 VERB T
with 0 ADP F
nitroglycerin 0 NOUN F
, 0 PUNCT F
intravenous 0 ADJ F
diltiazem 0 NOUN F
lowered B-PHYSICAL VERB F
heart I-PHYSICAL NOUN F
rate I-PHYSICAL NOUN F
and 0 CCONJ F
myocardial B-OTHER ADJ F
oxygen I-OTHER NOUN F
consumption I-OTHER NOUN F
index I-OTHER NOUN F
( 0 PUNCT F
systolic 0 ADJ F
pressure 0 NOUN F
x 0 SYM F
heart 0 NOUN F
rate 0 NOUN F
) 0 PUNCT F
to 0 ADP F
more 0 DET F
extent 0 NOUN F
significantly 0 ADV F
. 0 PUNCT F
( 0 PUNCT F

3 0 NUM F
) 0 PUNCT F
After 0 ADP T
treatment 0 NOUN F
, 0 PUNCT F
the 0 DET F
onsets 0 NOUN F
of 0 ADP F
refractory B-PHYSICAL ADJ F
angina I-PHYSICAL NOUN F
pectoris I-PHYSICAL NOUN F
were 0 VERB F
reduced B-OTHER VERB F
more I-OTHER ADV F
significantly I-OTHER ADV F
in 0 ADP F
the 0 DET F
diltiazem 0 NOUN F
group 0 NOUN F
than 0 PUNCT F
in 0 ADP F
nitroglycerin 0 NOUN F
group 0 NOUN F
[ 0 PUNCT F
4 0 NUM F
( 0 PUNCT F
3.8 0 NUM F
% 0 SYM F
) 0 PUNCT F
vs 0 CCONJ F
13 0 NUM F
( 0 PUNCT F
11.9 0 NUM F
% 0 SYM F
) 0 PUNCT F
, 0 PUNCT F
RR 0 NOUN T
0.32 0 NUM F
( 0 PUNCT F
95 0 NUM F
% 0 SYM F
CI 0 NOUN T
0.11 0 NUM F
- 0 PUNCT F
0.96 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.05 0 NUM F
] 0 PUNCT F
. 0 PUNCT F
( 0 PUNCT F

4 0 NUM F
) 0 PUNCT F
The 0 DET T
patients 0 NOUN F
whose 0 ADJ F
heart B-PHYSICAL NOUN F
rate I-PHYSICAL NOUN F
were 0 VERB F
reduced B-OTHER VERB F
significantly I-OTHER ADV F
( 0 PUNCT F
< 0 ADP F
or= 0 NOUN F
50 0 NUM F
beats 0 NOUN F
per 0 ADP F
minute 0 PUNCT F
) 0 PUNCT F
in 0 ADP F
the 0 DET F
diltiazem 0 NOUN F
group 0 NOUN F
were 0 VERB F
more 0 ADV F
than 0 PUNCT F
in 0 ADP F
the 0 DET F
nitroglycerin 0 NOUN F
group 0 NOUN F
[ 0 PUNCT F
8 0 NUM F
( 0 PUNCT F
7.7 0 NUM F
% 0 SYM F
) 0 PUNCT F
vs 0 CCONJ F
0 0 NUM F
( 0 PUNCT F
0 0 NUM F
% 0 SYM F
) 0 PUNCT F
, 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.01 0 NUM F
] 0 PUNCT F
. 0 PUNCT F

But 0 CCONJ T
these 0 DET F
patients 0 NOUN F
could 0 PUNCT F
tolerate 0 NOUN F
the 0 DET F
lower 0 PUNCT F
heart B-PHYSICAL NOUN F
rate I-PHYSICAL NOUN F
very 0 VERB F
well 0 VERB F
in 0 PUNCT F
the 0 DET F
diltiazem 0 NOUN F
group 0 NOUN F
. 0 PUNCT F
( 0 PUNCT F

5 0 NUM F
) 0 PUNCT F
The 0 DET T
needs 0 NOUN F
of 0 ADP F
beta 0 NOUN F
receptor 0 NOUN F
blocker 0 NOUN F
or 0 CCONJ F
calcium 0 NOUN F
antagonists 0 NOUN F
were 0 VERB F
reduced 0 VERB F
more 0 ADV F
significantly 0 ADV F
in 0 ADP F
the 0 DET F
diltiazem 0 NOUN F
group 0 NOUN F
compared 0 VERB F
with 0 ADP F
those 0 PUNCT F
in 0 ADP F
the 0 DET F
nitroglycerin 0 NOUN F
group 0 NOUN F
[ 0 PUNCT F
2 0 NUM F
( 0 PUNCT F
1.9 0 NUM F
% 0 SYM F
) 0 PUNCT F
vs 0 CCONJ F
13 0 NUM F
( 0 PUNCT F
11.9 0 NUM F
% 0 SYM F
) 0 PUNCT F
, 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.01 0 NUM F
] 0 PUNCT F
. 0 PUNCT F

CONCLUSION 0 NOUN T
Intravenous 0 ADJ T
diltiazem 0 NOUN F
therapy 0 NOUN F
is 0 VERB F
effective 0 ADJ F
and 0 CCONJ F
safe 0 ADJ F
for 0 ADP F
patients 0 NOUN F
with 0 ADP F
unstable 0 ADJ F
angina 0 NOUN F
pectoris 0 NOUN F
. 0 PUNCT F

It 0 PRON T
may 0 ADP F
significantly 0 ADV F
lower 0 CCONJ F
the 0 DET F
risk 0 NOUN F
of 0 ADP F
refractory 0 ADJ F
angina 0 NOUN F
pectoris 0 NOUN F
compared 0 VERB F
with 0 ADP F
intravenous 0 ADJ F
nitroglycerin 0 NOUN F
. 0 PUNCT F

Is 0 PUNCT T
psychotherapy 0 NOUN F
more 0 ADV F
effective 0 ADJ F
when 0 ADP F
therapists 0 DET F
disclose 0 ADJ F
information 0 NOUN F
about 0 PUNCT F
themselves 0 PUNCT F
? 0 PUNCT F

Theorists 0 NOUN T
have 0 PUNCT F
long 0 PUNCT F
debated 0 PUNCT F
the 0 DET F
wisdom 0 PUNCT F
of 0 ADP F
therapists 0 ADJ F
disclosing B-OTHER PUNCT F
personal I-OTHER ADJ F
information I-OTHER NOUN F
during 0 ADP F
psychotherapy 0 NOUN F
. 0 PUNCT F

Some 0 DET T
observers 0 ADP F
have 0 PUNCT F
argued 0 PUNCT F
that 0 PUNCT F
such 0 DET F
therapist 0 NOUN F
self-disclosure 0 ADJ F
impedes 0 PUNCT F
treatment 0 NOUN F
, 0 PUNCT F
whereas 0 ADP F
others 0 NOUN F
have 0 CCONJ F
suggested 0 VERB F
that 0 ADP F
it 0 PRON F
enhances 0 NOUN F
the 0 DET F
effectiveness 0 NOUN F
of 0 ADP F
therapy B-OTHER NOUN F
. 0 PUNCT F

To 0 PART T
test 0 NOUN F
these 0 DET F
competing 0 ADJ F
positions 0 NOUN F
, 0 PUNCT F
therapists 0 ADJ F
at 0 ADP F
a 0 DET F
university 0 NOUN F
counseling 0 DET F
center 0 NOUN F
were 0 VERB F
instructed 0 VERB F
to 0 PART F
increase 0 NOUN F
the 0 DET F
number 0 NOUN F
of 0 ADP F
self-disclosures 0 NOUN F
they 0 ADV F
made 0 SYM F
during 0 ADP F
treatment 0 NOUN F
of 0 ADP F
one 0 NUM F
client 0 ADP F
and 0 CCONJ F
refrain 0 NOUN F
from 0 ADP F
making 0 VERB F
self-disclosures 0 NOUN F
during 0 ADP F
treatment 0 NOUN F
of 0 ADP F
another 0 ADP F
client 0 ADP F
. 0 PUNCT F

Analyses 0 NOUN T
revealed 0 VERB F
that 0 ADP F
clients 0 NOUN F
receiving 0 DET F
psychotherapy 0 NOUN F
under 0 ADP F
conditions 0 NOUN F
of 0 ADP F
heightened 0 ADJ F
therapist 0 NOUN F
disclosure 0 NOUN F
not 0 ADV F
only 0 ADJ F
reported 0 PUNCT F
lower 0 VERB F
levels 0 NOUN F
of 0 ADP F
symptom 0 NOUN F
distress 0 NOUN F
but 0 CCONJ F
also 0 ADV F
liked B-OTHER PUNCT F
their I-OTHER ADJ F
therapist I-OTHER NOUN F
more 0 DET F
. 0 PUNCT F

Such 0 DET T
findings 0 NOUN F
suggest 0 VERB F
that 0 ADP F
self-disclosure 0 NOUN F
by 0 ADP F
the 0 DET F
therapist 0 NOUN F
may 0 NOUN F
improve 0 VERB F
both 0 PUNCT F
the 0 DET F
quality 0 NOUN F
of 0 ADP F
the 0 DET F
therapeutic B-OTHER ADJ F
relationship I-OTHER NOUN F
and 0 CCONJ F
the 0 DET F
outcome 0 NOUN F
of 0 ADP F
treatment B-MENTAL NOUN F
. 0 PUNCT F

Treatment 0 NOUN T
of 0 ADP F
acute 0 ADJ F
asthma 0 NOUN F
. 0 PUNCT F

Lack 0 NOUN T
of 0 ADP F
therapeutic B-PHYSICAL ADJ F
benefit I-PHYSICAL NOUN F
and 0 CCONJ F
increase 0 NOUN F
of 0 ADP F
the 0 DET F
toxicity B-ADVERSE-EFFECTS NOUN F
from 0 ADP F
aminophylline 0 NOUN F
given 0 VERB F
in 0 ADP F
addition 0 NOUN F
to 0 ADP F
high 0 ADJ F
doses 0 NOUN F
of 0 ADP F
salbutamol 0 NOUN F
delivered 0 VERB F
by 0 ADP F
metered-dose 0 NOUN F
inhaler 0 ADJ F
with 0 ADP F
a 0 DET F
spacer 0 NOUN F
. 0 PUNCT F

We 0 PRON T
conducted 0 VERB F
a 0 DET F
randomized 0 VERB F
, 0 PUNCT F
double-blind 0 ADJ F
, 0 PUNCT F
placebo-controlled 0 VERB F
study 0 NOUN F
to 0 PART F
determine 0 VERB F
if 0 PUNCT F
intravenous 0 ADJ F
aminophylline 0 ADJ F
adds 0 VERB F
any 0 PUNCT F
benefit 0 NOUN F
to 0 ADP F
high 0 ADJ F
doses 0 NOUN F
of 0 ADP F
inhaled 0 VERB F
salbutamol 0 NOUN F
in 0 ADP F
patients 0 NOUN F
who 0 PROPN F
presented 0 VERB F
for 0 ADP F
treatment 0 NOUN F
of 0 ADP F
acute 0 ADJ F
asthma 0 NOUN F
. 0 PUNCT F

We 0 PRON T
studied 0 VERB F
94 0 NUM F
patients 0 NOUN F
( 0 PUNCT F
mean 0 NOUN F
age 0 NOUN F
, 0 PUNCT F
35.6 0 NUM F
+/- 0 SYM F
11.2 0 NUM F
years 0 NOUN F
) 0 PUNCT F
with 0 ADP F
moderate 0 ADJ F
to 0 ADP F
severe 0 ADJ F
acute 0 ADJ F
asthma 0 NOUN F
. 0 PUNCT F

All 0 DET T
patients 0 NOUN F
received 0 VERB F
therapy 0 NOUN F
with 0 ADP F
salbutamol 0 NOUN F
delivered 0 VERB F
with 0 ADP F
metered-dose 0 NOUN F
inhaler 0 ADJ F
( 0 PUNCT F
MDI 0 NOUN T
) 0 PUNCT F
into 0 ADP F
a 0 DET F
spacer 0 NOUN F
device 0 NOUN F
( 0 PUNCT F
Volumatic 0 ADJ T
) 0 PUNCT F
in 0 ADP F
four 0 NUM F
puffs 0 VERB F
( 0 PUNCT F
400 0 NUM F
micrograms 0 NOUN F
) 0 PUNCT F
at 0 ADP F
10-min 0 NOUN F
interval 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
intravenous 0 ADJ F
hydrocortisone 0 NOUN F
( 0 PUNCT F
500 0 NUM F
mg 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

Patients 0 NOUN T
were 0 VERB F
randomly 0 ADV F
assigned 0 VERB F
to 0 PART F
receive 0 NOUN F
either 0 PUNCT F
a 0 DET F
loading 0 VERB F
dose 0 NOUN F
of 0 ADP F
intravenous 0 ADJ F
aminophylline 0 NOUN F
followed 0 VERB F
by 0 ADP F
a 0 DET F
routine 0 ADJ F
infusion 0 NOUN F
( 0 PUNCT F
n 0 NOUN F
= 0 SYM F
45 0 NUM F
) 0 PUNCT F
or 0 CCONJ F
an 0 DET F
equal 0 ADJ F
volume 0 NOUN F
of 0 ADP F
placebo 0 NOUN F
as 0 ADP F
a 0 DET F
loading 0 VERB F
dose 0 NOUN F
and 0 CCONJ F
infusion 0 NOUN F
( 0 PUNCT F
n 0 NOUN F
= 0 SYM F
49 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
two 0 NUM F
groups 0 NOUN F
showed 0 VERB F
no 0 DET F
differences 0 NOUN F
in 0 ADP F
measurements 0 NOUN F
of 0 ADP F
peak 0 ADJ F
expiratory B-PHYSICAL ADJ F
flow I-PHYSICAL NOUN F
, 0 PUNCT F
FEV1 B-PHYSICAL NOUN T
, 0 PUNCT F
and 0 CCONJ F
FVC B-PHYSICAL NOUN T
at 0 ADP F
baseline 0 NOUN F
and 0 CCONJ F
at 0 ADP F
the 0 DET F
end 0 NOUN F
of 0 ADP F
treatment 0 NOUN F
. 0 PUNCT F

However 0 ADV T
, 0 PUNCT F
the 0 DET F
patients 0 NOUN F
treated 0 VERB F
with 0 ADP F
aminophylline 0 NOUN F
had 0 PUNCT F
significantly 0 ADV F
more 0 DET F
adverse B-ADVERSE-EFFECTS ADJ F
effects I-ADVERSE-EFFECTS NOUN F
( 0 PUNCT F
p 0 NOUN F
< 0 SYM F
0.05 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

There 0 PUNCT T
were 0 VERB F
no 0 DET F
differences 0 NOUN F
in 0 ADP F
the 0 DET F
final 0 ADJ F
mean 0 NOUN F
dose 0 NOUN F
of 0 ADP F
salbutamol 0 NOUN F
( 0 PUNCT F
6.3 0 NUM F
+/- 0 SYM F
44.5 0 NUM F
mg 0 NOUN F
for 0 ADP F
the 0 DET F
placebo 0 NOUN F
group 0 NOUN F
and 0 CCONJ F
5.8 0 NUM F
+/- 0 SYM F
4.2 0 NUM F
mg 0 NOUN F
for 0 ADP F
the 0 DET F
aminophylline 0 ADJ F
group 0 NOUN F
) 0 PUNCT F
, 0 PUNCT F
hospital 0 NOUN F
admission 0 NOUN F
rate 0 NOUN F
( 0 PUNCT F
10.2 0 NUM F
percent 0 NOUN F
for 0 ADP F
the 0 DET F
placebo 0 NOUN F
group 0 NOUN F
and 0 CCONJ F
9.0 0 NUM F
percent 0 NOUN F
for 0 ADP F
the 0 DET F
aminophylline 0 ADJ F
group 0 NOUN F
) 0 PUNCT F
, 0 PUNCT F
and 0 CCONJ F
mean 0 NOUN F
duration 0 NOUN F
of 0 ADP F
Emergency 0 NOUN T
Department 0 NOUN T
treatment 0 NOUN F
( 0 PUNCT F
2.5 0 NUM F
+/- 0 SYM F
1.83 0 NUM F
h 0 NOUN F
for 0 ADP F
the 0 DET F
placebo 0 NOUN F
group 0 NOUN F
and 0 CCONJ F
2.37 0 NUM F
+/- 0 SYM F
1.75 0 NUM F
h 0 NOUN F
for 0 ADP F
the 0 DET F
aminophylline 0 ADJ F
group 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
results 0 ADV F
were 0 VERB F
similar 0 ADJ F
when 0 ADP F
the 0 DET F
patients 0 NOUN F
were 0 VERB F
divided 0 VERB F
in 0 ADP F
accord 0 NOUN F
with 0 ADP F
the 0 DET F
degree 0 NOUN F
of 0 ADP F
respiratory B-PHYSICAL ADJ F
obstruction I-PHYSICAL NOUN F
( 0 PUNCT F
baseline 0 NOUN F
FEV1 0 NOUN T
< 0 SYM F
30 0 NUM F
percent 0 NOUN F
of 0 ADP F
predicted 0 PUNCT F
) 0 PUNCT F
and 0 CCONJ F
theophylline B-PHYSICAL NOUN F
level I-PHYSICAL NOUN F
at 0 ADP F
30 0 NUM F
min 0 NOUN F
of 0 ADP F
treatment 0 NOUN F
( 0 PUNCT F
placebo 0 NOUN F
group 0 NOUN F
patients 0 NOUN F
with 0 ADP F
theophylline 0 NOUN F
level 0 NOUN F
< 0 SYM F
10 0 NUM F
mg/L 0 NOUN F
vs 0 CCONJ F
aminophylline 0 ADJ F
group 0 NOUN F
patients 0 NOUN F
with 0 ADP F
theophylline 0 NOUN F
level 0 NOUN F
> 0 SYM F
or 0 CCONJ F
= 0 SYM F
10 0 NUM F
mg/L 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

We 0 PRON T
conclude 0 VERB F
that 0 ADP F
intravenous 0 ADJ F
aminophylline 0 ADJ F
adds 0 PUNCT F
to 0 ADP F
the 0 DET F
toxicity B-ADVERSE-EFFECTS NOUN F
but 0 CCONJ F
not 0 ADV F
the 0 DET F
efficacy 0 NOUN F
of 0 ADP F
inhaled 0 VERB F
salbutamol 0 NOUN F
in 0 ADP F
the 0 DET F
treatment 0 NOUN F
of 0 ADP F
acute 0 ADJ F
exacerbations 0 NOUN F
of 0 ADP F
asthma 0 NOUN F
. 0 PUNCT F

There 0 PUNCT T
are 0 VERB F
some 0 DET F
benefits 0 NOUN F
for 0 ADP F
eradicating 0 NUM F
Helicobacter 0 NOUN T
pylori 0 NOUN F
in 0 ADP F
patients 0 NOUN F
with 0 ADP F
non-ulcer 0 NOUN F
dyspepsia 0 NOUN F
. 0 PUNCT F

BACKGROUND 0 NOUN T
The 0 DET T
relationship 0 NOUN F
between 0 ADP F
Helicobacter 0 NOUN T
pylori 0 NOUN F
infection 0 NOUN F
and 0 CCONJ F
non-ulcer 0 NOUN F
dyspepsia 0 NOUN F
is 0 VERB F
not 0 ADV F
established 0 VERB F
. 0 PUNCT F

AIM 0 NOUN T
To 0 PROPN T
determine 0 NOUN F
whether 0 ADP F
eradication 0 NOUN F
of 0 ADP F
H. 0 NOUN T
pylori 0 NOUN F
might 0 ADP F
be 0 PUNCT F
of 0 ADP F
benefit 0 NOUN F
in 0 ADP F
non-ulcer 0 NOUN F
dyspepsia 0 NOUN F
patients 0 NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
We 0 PRON T
randomly 0 PUNCT F
assigned 0 PUNCT F
129 0 NUM F
H. 0 NOUN T
pylori 0 NOUN F
infected 0 VERB F
patients 0 NOUN F
with 0 ADP F
severe 0 ADJ F
epigastric 0 ADJ F
pain 0 NOUN F
, 0 PUNCT F
without 0 ADP F
gastro-oesophageal 0 ADJ F
reflux 0 NOUN F
symptoms 0 NOUN F
, 0 PUNCT F
to 0 PART F
receive 0 NOUN F
twice 0 PUNCT F
daily 0 PUNCT F
treatment 0 NOUN F
with 0 ADP F
300 0 NUM F
mg 0 NOUN F
of 0 ADP F
ranitidine 0 NOUN F
, 0 PUNCT F
1000 0 NUM F
mg 0 NOUN F
of 0 ADP F
amoxicillin 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
500 0 NUM F
mg 0 NOUN F
of 0 ADP F
clarithromycin 0 NOUN F
for 0 ADP F
7 0 NUM F
days 0 NOUN F
and 0 CCONJ F
124 0 NUM F
such 0 DET F
patients 0 NOUN F
to 0 PART F
receive 0 PART F
identical-appearing 0 ADJ F
placebos 0 PUNCT F
. 0 PUNCT F

RESULTS 0 DET T
Treatment 0 NOUN T
was 0 VERB F
successful 0 ADJ F
( 0 PUNCT F
decrease 0 NOUN F
of 0 ADP F
symptoms 0 NOUN F
at 0 ADP F
12 0 NUM F
months 0 NOUN F
) 0 PUNCT F
in 0 ADP F
62 0 NUM F
% 0 SYM F
of 0 ADP F
patients 0 NOUN F
in 0 ADP F
the 0 DET F
active-treatment 0 PUNCT F
group 0 NOUN F
and 0 CCONJ F
in 0 ADP F
60 0 NUM F
% 0 SYM F
of 0 ADP F
the 0 DET F
placebo 0 NOUN F
group 0 NOUN F
( 0 PUNCT F
N.S. 0 PUNCT T
) 0 PUNCT F
. 0 PUNCT F

At 0 ADP T
12 0 NUM F
months 0 NOUN F
, 0 PUNCT F
the 0 DET F
rate 0 NOUN F
of B-PHYSICAL ADP F
eradication I-PHYSICAL NOUN F
of I-PHYSICAL ADP F
H. 0 NOUN T
pylori B-PHYSICAL NOUN F
was 0 VERB F
69 0 NUM F
% 0 SYM F
in 0 ADP F
the 0 DET F
active-treatment 0 PUNCT F
group 0 NOUN F
and 0 CCONJ F
18 0 NUM F
% 0 SYM F
in 0 ADP F
the 0 DET F
placebo 0 NOUN F
group 0 NOUN F
( 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.001 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Complete B-OTHER ADJ T
relief I-OTHER PUNCT F

A 0 DET T
comparison 0 NOUN F
of 0 ADP F
a 0 DET F
short 0 ADJ F
nurse-based 0 VERB F
and 0 CCONJ F
a 0 DET F
long 0 ADJ F
multidisciplinary 0 ADJ F
version 0 NOUN F
of 0 ADP F
structured 0 VERB F
patient 0 NOUN F
education 0 NOUN F
in 0 ADP F
irritable 0 ADJ F
bowel 0 NOUN F
syndrome 0 NOUN F
. 0 PUNCT F

OBJECTIVE 0 NOUN T
Structured 0 PUNCT T
multidisciplinary 0 ADJ F
patient 0 NOUN F
group 0 NOUN F
education 0 NOUN F
has 0 VERB F
positive 0 ADJ F
effects 0 NOUN F
on 0 ADP F
symptoms 0 NOUN F
, 0 PUNCT F
health-related 0 VERB F
quality 0 NOUN F
of 0 ADP F
life 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
disease-related 0 VERB F
knowledge 0 NOUN F
in 0 ADP F
patients 0 NOUN F
with 0 ADP F
irritable 0 ADJ F
bowel 0 NOUN F
syndrome 0 NOUN F
( 0 PUNCT F
IBS 0 NOUN T
) 0 PUNCT F
, 0 PUNCT F
but 0 CCONJ F
few 0 ADJ F
studies 0 NOUN F
comparing 0 DET F
different 0 ADJ F
forms 0 NOUN F
of 0 ADP F
educational 0 ADJ F
interventions 0 NOUN F
are 0 PROPN F
available 0 ADJ F
. 0 PUNCT F

Our 0 PUNCT T
aim 0 NOUN F
was 0 VERB F
to 0 ADV F
compare 0 NOUN F
the 0 DET F
effects 0 NOUN F
of 0 ADP F
long 0 ADJ F
multidisciplinary 0 ADJ F
group 0 NOUN F
education 0 NOUN F
with 0 ADP F
a 0 DET F
short 0 ADJ F
nurse-based 0 VERB F
group 0 NOUN F
education 0 NOUN F
with 0 ADP F
regard 0 NOUN F
to 0 ADP F
symptoms 0 NOUN F
, 0 PUNCT F
knowledge 0 NOUN F
, 0 PUNCT F
quality 0 NOUN F
of 0 ADP F
life 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
satisfaction 0 NOUN F
with 0 ADP F
the 0 DET F
intervention 0 NOUN F
in 0 ADP F
IBS 0 NOUN T
patients 0 NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
Patients 0 NOUN T
with 0 ADP F
IBS 0 NOUN T
according 0 VERB F
to 0 ADP F
the 0 DET F
Rome 0 NOUN T
II 0 NUM T
criteria 0 NOUN F
were 0 VERB F
randomized 0 VERB F
to 0 ADP F
either 0 CCONJ F
short 0 ADJ F
nurse-based 0 VERB F
or 0 CCONJ F
a 0 DET F
long 0 ADJ F
multidisciplinary-based 0 ADJ F
education 0 NOUN F
. 0 PUNCT F

The 0 DET T
effects 0 NOUN F
were 0 VERB F
evaluated 0 VERB F
by 0 ADP F
self-administered 0 ADJ F
questionnaires 0 NOUN F
at 0 ADP F
3 0 NUM F
, 0 PUNCT F
6 0 NUM F
, 0 PUNCT F
and 0 CCONJ F
12 0 NUM F
months 0 NOUN F
after 0 ADP F
baseline 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
compared 0 VERB F
between 0 ADP F
the 0 DET F
groups 0 NOUN F
. 0 PUNCT F

RESULTS 0 PUNCT T
No 0 DET T
differences 0 NOUN F
in 0 ADP F
effects 0 NOUN F
were 0 VERB F
detected 0 VERB F
in 0 ADP F
the 0 DET F
between-group 0 NOUN F
comparisons 0 NOUN F
at 0 ADP F
any 0 CCONJ F
of 0 ADP F
the 0 DET F
follow-up 0 NOUN F
assessments 0 NOUN F
. 0 PUNCT F

However 0 ADV T
, 0 PUNCT F
positive 0 ADJ F
effects 0 NOUN F
on 0 ADP F
symptoms B-PHYSICAL NOUN F
, 0 PUNCT F
knowledge B-MENTAL NOUN F
, 0 PUNCT F
quality 0 NOUN F
of 0 ADP F
life 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
satisfaction B-OTHER NOUN F
with 0 ADP F
the 0 DET F
intervention 0 NOUN F
were 0 VERB F
found 0 VERB F
in 0 ADP F
both 0 CCONJ F
the 0 DET F
short 0 ADJ F
and 0 CCONJ F
the 0 DET F
long 0 ADJ F
version 0 NOUN F
. 0 PUNCT F

CONCLUSION 0 NOUN T
A 0 CCONJ T
short 0 ADJ F
, 0 PUNCT F
nurse-based 0 PUNCT F
educational 0 ADJ F
intervention 0 NOUN F
seems 0 NOUN F
to 0 DET F
be 0 PUNCT F
as 0 CCONJ F
efficacious 0 ADJ F
as 0 ADP F
a 0 DET F
longer 0 PUNCT F
multidisciplinary 0 ADJ F
version 0 NOUN F
. 0 PUNCT F

In 0 ADP T
both 0 CCONJ F
groups 0 NOUN F
, 0 PUNCT F
positive 0 ADJ F
effects 0 NOUN F
on 0 ADP F
patients 0 NOUN F
' 0 PUNCT F
well-being 0 PUNCT F
were 0 ADP F
found 0 VERB F
to 0 ADP F
a 0 DET F
similar 0 ADJ F
extent 0 NOUN F
. 0 PUNCT F

This 0 DET T
is 0 VERB F
an 0 DET F
important 0 ADJ F
finding 0 PART F
that 0 ADP F
, 0 PUNCT F
from 0 ADP F
a 0 DET F
cost-effective 0 ADJ F
perspective 0 ADJ F
, 0 PUNCT F
could 0 VERB F
contribute 0 VERB F
toward 0 ADP F
an 0 DET F
optimized 0 VERB F
management 0 NOUN F
of 0 ADP F
patients 0 NOUN F
with 0 ADP F
IBS 0 NOUN T
. 0 PUNCT F

Effect 0 NOUN T
of 0 ADP F
motivational 0 ADJ F
music 0 ADJ F
on 0 ADP F
lactate B-PHYSICAL NOUN F
levels I-PHYSICAL NOUN F
during 0 ADP F
recovery 0 NOUN F
from 0 ADP F
intense 0 ADJ F
exercise 0 NOUN F
. 0 PUNCT F

The 0 DET T
effects 0 NOUN F
of 0 ADP F
music 0 ADJ F
played 0 VERB F
during 0 ADP F
an 0 DET F
exercise 0 NOUN F
task 0 NOUN F
on 0 ADP F
athletic 0 ADJ F
performance 0 NOUN F
have 0 PUNCT F
been 0 PUNCT F
previously 0 ADV F
studied 0 VERB F
. 0 PUNCT F

Yet 0 ADV T
, 0 PUNCT F
these 0 DET F
results 0 NOUN F
are 0 VERB F
not 0 ADV F
applicable 0 ADJ F
for 0 ADP F
competitive 0 ADJ F
athletes 0 NOUN F
, 0 PUNCT F
who 0 DET F
can 0 CCONJ F
use 0 VERB F
music 0 ADJ F
only 0 ADV F
during 0 ADP F
warm-up 0 NOUN F
or 0 CCONJ F
recovery 0 NOUN F
from 0 ADP F
exercise 0 NOUN F
. 0 PUNCT F

Therefore 0 ADV T
, 0 PUNCT F
the 0 DET F
aim 0 NOUN F
of 0 ADP F
this 0 DET F
study 0 NOUN F
was 0 VERB F
to 0 PART F
determine 0 NOUN F
the 0 DET F
effect 0 NOUN F
of 0 ADP F
motivational 0 ADJ F
music 0 ADJ F
( 0 PUNCT F
music 0 ADJ F
that 0 ADP F
stimulates 0 NOUN F
or 0 CCONJ F
inspires 0 ADJ F
physical 0 ADJ F
activity 0 NOUN F
) 0 PUNCT F
during 0 ADP F
recovery 0 NOUN F
from 0 ADP F
intense B-PHYSICAL ADJ F
exercise I-PHYSICAL NOUN F
, 0 PUNCT F
on 0 ADP F
activity B-PHYSICAL NOUN F
pattern I-PHYSICAL NOUN F
, 0 PUNCT F
rate 0 NOUN F
of 0 ADP F
perceived B-PHYSICAL DET F
exertion I-PHYSICAL NOUN F
( 0 PUNCT F
RPE B-PHYSICAL NOUN T
) 0 PUNCT F
, 0 PUNCT F
and 0 CCONJ F
blood B-PHYSICAL NOUN F
lactate I-PHYSICAL NOUN F
concentration 0 NOUN F
. 0 PUNCT F

Twenty 0 NUM T
young 0 ADJ F
, 0 PUNCT F
active 0 ADJ F
men 0 NOUN F
( 0 PUNCT F
mean 0 NOUN F
age 0 NOUN F
26.2 0 NUM F
? 0 PUNCT F

2.1 0 NUM F
years 0 NOUN F
) 0 PUNCT F
performed 0 VERB F
a 0 DET F
6-minute 0 PUNCT F
run 0 PUNCT F
at 0 ADP F
peak 0 ADJ F
oxygen 0 NOUN F
consumption 0 NOUN F
speed 0 NOUN F
( 0 PUNCT F
predetermined 0 NOUN F
from 0 ADP F
the 0 DET F
VO 0 NOUN T
( 0 PUNCT F
2 0 NUM F
) 0 PUNCT F
max 0 NOUN F
test 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
mean 0 NOUN F
heart 0 NOUN F
rate 0 NOUN F
( 0 PUNCT F
HR 0 NOUN T
) 0 PUNCT F
, 0 PUNCT F
RPE 0 NOUN T
, 0 PUNCT F
number 0 NOUN F
of 0 ADP F
steps 0 NOUN F
( 0 PUNCT F
determined 0 PROPN F
by 0 ADP F
step 0 NOUN F
counter 0 ADJ F
) 0 PUNCT F
, 0 PUNCT F
and 0 CCONJ F
blood 0 NOUN F
lactate 0 NOUN F
concentrations 0 NOUN F
were 0 VERB F
determined 0 VERB F
at 0 ADP F
3 0 NUM F
, 0 PUNCT F
6 0 NUM F
, 0 PUNCT F
9 0 NUM F
, 0 PUNCT F
12 0 NUM F
, 0 PUNCT F
and 0 CCONJ F
15 0 NUM F
minutes 0 NOUN F
during 0 ADP F
the 0 DET F
recovery 0 NOUN F
from 0 ADP F
the 0 DET F
exercise 0 NOUN F
, 0 PUNCT F
with 0 ADP F
and 0 CCONJ F
without 0 ADP F
motivational 0 ADJ F
music 0 ADJ F
( 0 PUNCT F
2 0 NUM F
separate 0 ADJ F
sessions 0 NOUN F
, 0 PUNCT F
at 0 ADP F
random 0 ADJ F
order 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

There 0 PUNCT T
was 0 VERB F
no 0 DET F
difference 0 NOUN F
in 0 ADP F
the 0 DET F
mean 0 NOUN F
HR 0 NOUN T
during 0 ADP F
the 0 DET F
recovery 0 NOUN F
with 0 ADP F
and 0 CCONJ F
without 0 ADP F
music 0 ADP F
. 0 PUNCT F

Listening 0 ADJ T
to 0 ADP F
motivational 0 ADJ F
music 0 ADJ F
during 0 ADP F
the 0 DET F
recovery 0 NOUN F
was 0 VERB F
associated 0 VERB F
with 0 ADP F
increased 0 PUNCT F
voluntary 0 PUNCT F
activity 0 NOUN F
of 0 ADP F
the 0 DET F
participants 0 NOUN F
, 0 PUNCT F
determined 0 VERB F
by 0 ADP F
increased 0 DET F
number 0 NOUN F
of 0 ADP F
steps 0 NOUN F
( 0 PUNCT F
499.4 0 ADP F
? 0 PUNCT F

220.1 0 ADJ F
vs. 0 CCONJ F
413.2 0 NUM F
? 0 PUNCT F

150.6 0 NUM F
steps 0 NOUN F
, 0 PUNCT F
with 0 ADP F
and 0 CCONJ F
without 0 ADP F
music 0 ADP F
, 0 PUNCT F
respectively 0 ADV F
; 0 PUNCT F
p 0 NOUN F
? 0 PUNCT F

0.05 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
increased 0 VERB F
number 0 NOUN F
of 0 ADP F
steps 0 NOUN F
during 0 ADP F
the 0 DET F
recovery 0 NOUN F
was 0 VERB F
accompanied 0 VERB F
by 0 ADP F
a 0 DET F
significantly 0 ADV F
greater 0 PUNCT F
decrease 0 NOUN F
in 0 ADP F
blood 0 NOUN F
lactate 0 NOUN F
concentration 0 NOUN F
percentage 0 NOUN F
( 0 PUNCT F
28.1 0 NUM F
? 0 PUNCT F

12.2 0 NUM F
vs. 0 CCONJ F
22.8 0 NUM F
? 0 PUNCT F

10.9 0 NUM F
% 0 SYM F
, 0 PUNCT F
with 0 ADP F
and 0 CCONJ F
without 0 ADP F
music 0 ADP F
, 0 PUNCT F
respectively 0 ADV F
, 0 PUNCT F
p 0 NOUN F
? 0 PUNCT F

0.05 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

This 0 DET T
was 0 VERB F
associated 0 VERB F
with 0 ADP F
a 0 DET F
greater 0 PUNCT F
decrease 0 NOUN F
in 0 ADP F
RPE 0 NOUN T
( 0 PUNCT F
77.7 0 NUM F
? 0 PUNCT F

14.4 0 NUM F
vs. 0 CCONJ F
73.1 0 NUM F
? 0 PUNCT F

14.7 0 NUM F
% 0 SYM F
with 0 ADP F
and 0 CCONJ F
without 0 ADP F
music 0 ADP F
, 0 PUNCT F
respectively 0 ADV F
; 0 PUNCT F
p 0 NOUN F
? 0 PUNCT F

0.05 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Our 0 ADJ T
results 0 NOUN F
suggest 0 VERB F
that 0 ADP F
listening 0 ADJ F
to 0 ADP F
motivational 0 ADJ F
music 0 ADJ F
during 0 ADP F
nonstructured 0 ADV F
recovery 0 NOUN F
from 0 ADP F
intense 0 ADJ F
exercise 0 NOUN F
leads 0 NOUN F
to 0 ADP F
increased 0 VERB F
activity 0 NOUN F
, 0 PUNCT F
faster 0 PUNCT F
lactate 0 NOUN F
clearance 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
reduced 0 VERB F
RPE 0 NOUN T
and 0 CCONJ F
therefore 0 ADV F
may 0 VERB F
be 0 VERB F
used 0 VERB F
by 0 ADP F
athletes 0 NOUN F
in 0 ADP F
their 0 PUNCT F
effort 0 NOUN F
to 0 PART F
enhance 0 NOUN F
recovery 0 NOUN F
. 0 PUNCT F

An 0 DET T
open-label 0 NOUN F
extension 0 NOUN F
study 0 NOUN F
of 0 ADP F
the 0 DET F
safety 0 NOUN F
and 0 CCONJ F
efficacy 0 NOUN F
of 0 ADP F
risperidone 0 NUM F
in 0 ADP F
children 0 NOUN F
and 0 CCONJ F
adolescents 0 NOUN F
with 0 ADP F
autistic 0 ADJ F
disorder 0 NOUN F
. 0 PUNCT F

OBJECTIVE 0 NOUN T
The 0 DET T
purpose 0 NOUN F
of 0 ADP F
this 0 DET F
study 0 NOUN F
was 0 VERB F
to 0 PART F
evaluate 0 NOUN F
the 0 DET F
long-term 0 NOUN F
safety 0 NOUN F
and 0 CCONJ F
efficacy 0 NOUN F
of 0 ADP F
risperidone 0 NUM F
in 0 ADP F
treating 0 PUNCT F
irritability B-PHYSICAL NOUN F
and 0 CCONJ F
related 0 VERB F
behaviors 0 NOUN F
in 0 ADP F
children 0 NOUN F
and 0 CCONJ F
adolescents 0 NOUN F
with 0 ADP F
autistic 0 ADJ F
disorders 0 NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
In 0 ADP T
this 0 DET F
6 0 NUM F
month 0 NOUN F
( 0 PUNCT F
26 0 NUM F
week 0 NOUN F
) 0 PUNCT F
open-label 0 NOUN F
extension 0 NOUN F
( 0 PUNCT F
OLE 0 NOUN T
) 0 PUNCT F
study 0 NOUN F
, 0 PUNCT F
patients 0 NOUN F
( 0 PUNCT F
5-17 0 NUM F
years 0 NOUN F
of 0 ADP F
age 0 NOUN F
, 0 PUNCT F
who 0 PROPN F
completed 0 PROPN F
the 0 DET F
previous 0 ADJ F
fixed-dose 0 NOUN F
, 0 PUNCT F
6 0 NUM F
week 0 NOUN F
, 0 PUNCT F
double-blind 0 ADJ F
[ 0 PUNCT F
DB 0 NOUN T
] 0 PUNCT F
phase 0 NOUN F
) 0 PUNCT F
were 0 VERB F
flexibly 0 ADV F
dosed 0 VERB F
with 0 ADP F
risperidone 0 NUM F
based 0 VERB F
on 0 ADP F
body 0 NOUN F
weight 0 NOUN F
. 0 PUNCT F

The 0 DET T
maximum 0 NOUN F
allowed 0 ADV F
dose 0 NOUN F
was 0 VERB F
1.25 0 NUM F
mg/day 0 NOUN F
for 0 ADP F
those 0 PUNCT F
weighing 0 CCONJ F
20 0 NUM F
to 0 PUNCT F
< 0 ADP F
45 0 NUM F
kg 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
1.75 0 NUM F
mg/day 0 NOUN F
for 0 ADP F
those 0 PUNCT F
weighing 0 CCONJ F
? 0 PUNCT F

45 0 NUM F
kg 0 NOUN F
. 0 PUNCT F

The 0 DET T
study 0 NOUN F
primarily 0 ADV F
assessed 0 ADP F
risperidone 0 ADP F
's 0 PUNCT F
safety 0 NOUN F
; 0 PUNCT F
efficacy 0 NOUN F
was 0 VERB F
assessed 0 VERB F
as 0 ADP F
a 0 DET F
secondary 0 ADJ F
end-point 0 NOUN F
. 0 PUNCT F

RESULTS 0 NOUN T
Fifty-six 0 ADJ T
( 0 PUNCT F
71 0 NUM F
% 0 SYM F
) 0 PUNCT F
out 0 PUNCT F
of 0 ADP F
79 0 NUM F
enrolled 0 VERB F
patients 0 NOUN F
completed 0 NOUN F
the 0 DET F
OLE 0 NOUN T
; 0 PUNCT F
the 0 DET F
most 0 VERB F
common 0 ADJ F
discontinuations 0 NOUN F
were 0 VERB F
for 0 ADP F
insufficient 0 ADJ F
response 0 NOUN F
( 0 PUNCT F
7 0 NUM F
[ 0 PUNCT F
9 0 NUM F
% 0 SYM F
] 0 PUNCT F
) 0 PUNCT F
or 0 CCONJ F
adverse 0 ADJ F
events 0 NOUN F
( 0 PUNCT F
AE 0 NOUN T
) 0 PUNCT F
( 0 PUNCT F
5 0 NUM F
[ 0 PUNCT F
6 0 NUM F
% 0 SYM F
] 0 PUNCT F
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
most 0 PUNCT F
common 0 ADJ F
( 0 PUNCT F
? 0 PUNCT F

5 0 NUM F
% 0 SYM F
frequency 0 NOUN F
in 0 ADP F
the 0 DET F
total 0 ADJ F
group 0 NOUN F
) 0 PUNCT F
AEs 0 ADP T
were 0 VERB F
increased 0 PUNCT F
appetite 0 NOUN F
( 0 PUNCT F
11 0 NUM F
% 0 ADJ F
[ 0 PUNCT F
n=9 0 NOUN F
] 0 PUNCT F
) 0 PUNCT F
; 0 PUNCT F
increased 0 DET F
weight 0 NOUN F
and 0 CCONJ F
vomiting 0 PROPN F
( 0 PUNCT F
9 0 NUM F
% 0 SYM F
[ 0 PUNCT F
n=7 0 NOUN F
] 0 PUNCT F
each 0 ADP F
) 0 PUNCT F
; 0 PUNCT F
sedation 0 NOUN F
, 0 PUNCT F
pyrexia 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
upper 0 ADJ F
respiratory 0 ADJ F
tract 0 NOUN F
infection 0 NOUN F
( 0 PUNCT F
8 0 NUM F
% 0 SYM F
[ 0 PUNCT F
n=6 0 NOUN F
] 0 PUNCT F
each 0 ADP F
) 0 PUNCT F
; 0 PUNCT F
nasopharyngitis 0 NOUN F
( 0 PUNCT F
6 0 NUM F
% 0 ADJ F
[ 0 PUNCT F
n=5 0 NOUN F
] 0 PUNCT F
) 0 PUNCT F
; 0 PUNCT F
and 0 CCONJ F
somnolence 0 NOUN F
and 0 CCONJ F
fatigue 0 NOUN F
( 0 PUNCT F
5 0 NUM F
% 0 SYM F
[ 0 PUNCT F
n=4 0 NOUN F
] 0 PUNCT F
each 0 ADP F
) 0 PUNCT F
. 0 PUNCT F

Extrapyramidal 0 ADJ T
AEs 0 ADP T
were 0 VERB F
reported 0 VERB F
in 0 ADP F
6 0 NUM F
( 0 PUNCT F
8 0 NUM F
% 0 SYM F
) 0 PUNCT F
patients 0 NOUN F
. 0 PUNCT F

Increase 0 NOUN T
in 0 ADP F
mean 0 NOUN F
weight 0 NOUN F
( 0 PUNCT F
11-15 0 NUM F
% 0 SYM F
) 0 PUNCT F
and 0 CCONJ F
body 0 NOUN F
mass 0 NOUN F
index 0 NOUN F
( 0 PUNCT F
5-10 0 NUM F
% 0 SYM F
) 0 PUNCT F
occurred 0 VERB F
; 0 PUNCT F
one 0 NUM F
patient 0 NOUN F
discontinued 0 PROPN F
because 0 PUNCT F
of 0 ADP F
weight 0 NOUN F
increase 0 NOUN F
. 0 PUNCT F

One 0 NUM T
potentially 0 ADV F
prolactin-related 0 VERB F
AE 0 NOUN T
( 0 PUNCT F
irregular 0 ADJ F
menstruation 0 NOUN F
) 0 PUNCT F
was 0 VERB F
reported 0 VERB F
. 0 PUNCT F

The 0 DET T
risperidone 0 NUM F
high-dose 0 NOUN F
group 0 NOUN F
had 0 PUNCT F
the 0 DET F
greatest 0 PUNCT F
mean 0 NOUN F
improvement 0 NOUN F
in 0 ADP F
sleep 0 NOUN F
visual 0 ADJ F
analog 0 NOUN F
scale 0 NOUN F
( 0 PUNCT F
24.6 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

All 0 DET T
groups 0 NOUN F
showed 0 VERB F
additional 0 ADJ F
improvement 0 NOUN F
in 0 ADP F
efficacy 0 NOUN F
scale 0 NOUN F
scores 0 NOUN F
during 0 ADP F
the 0 DET F
OLE 0 NOUN T
. 0 PUNCT F

CONCLUSIONS 0 NOUN T
During 0 ADP T
this 0 DET F
OLE 0 NOUN T
, 0 PUNCT F
safety 0 NOUN F
findings 0 NOUN F
with 0 ADP F
risperidone 0 NUM F
treatment 0 NOUN F
( 0 PUNCT F
maximum 0 NOUN F
weight-based 0 VERB F
dose 0 NOUN F
of 0 ADP F
1.25 0 NUM F
mg/day 0 NOUN F
or 0 CCONJ F
1.75 0 NUM F
mg/day 0 NOUN F
) 0 PUNCT F
were 0 VERB F
consistent 0 ADJ F
with 0 ADP F
those 0 ADJ F
observed 0 VERB F
in 0 ADP F
the 0 DET F
DB 0 NOUN T
phase 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
with 0 ADP F
the 0 DET F
current 0 ADJ F
safety 0 NOUN F
information 0 NOUN F
for 0 ADP F
risperidone 0 NUM F
in 0 ADP F
autistic 0 ADJ F
, 0 PUNCT F
psychiatric 0 ADJ F
, 0 PUNCT F
and 0 CCONJ F
behavioral 0 ADJ F
disorders 0 NOUN F
. 0 PUNCT F

Patients 0 NOUN T
experienced 0 VERB F
some 0 DET F
additional 0 ADJ F
improvement 0 NOUN F
in 0 ADP F
irritability 0 NOUN F
and 0 CCONJ F
related 0 VERB F
behaviors 0 NOUN F
. 0 PUNCT F

CLINICAL 0 ADJ T
TRIALS 0 NOUN T
REGISTRY 0 NOUN T
This 0 DET T
phase-4 0 NOUN F
study 0 NOUN F
is 0 VERB F
registered 0 NOUN F
at 0 ADP F
ClinicalTrials.gov 0 PUNCT T
( 0 PUNCT F
NCT00576732 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
effects 0 NOUN F
of 0 ADP F
encoding 0 ADP F
in 0 ADP F
hypnosis 0 NOUN F
and 0 CCONJ F
post-hypnotic 0 ADJ F
suggestion 0 NOUN F
on 0 ADP F
academic 0 ADJ F
performance 0 NOUN F
. 0 PUNCT F

This 0 DET T
study 0 NOUN F
examined 0 VERB F
the 0 DET F
relationship 0 NOUN F
between 0 ADP F
proactive 0 CCONJ F
learning 0 ADJ F
in 0 ADP F
hypnosis 0 NOUN F
, 0 PUNCT F
post-hypnotic 0 ADJ F
suggestion 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
academic 0 ADJ F
performance 0 NOUN F
. 0 PUNCT F

Participants 0 NOUN T
( 0 PUNCT F
N 0 NOUN T
= 0 SYM F
56 0 NUM F
) 0 PUNCT F
were 0 VERB F
randomly 0 ADV F
assigned 0 VERB F
to 0 ADP F
a 0 DET F
control 0 NOUN F
group 0 NOUN F
or 0 CCONJ F
a 0 DET F
treatment 0 NOUN F
group 0 NOUN F
. 0 PUNCT F

The 0 DET T
treatment 0 NOUN F
group 0 NOUN F
was 0 VERB F
hypnotized 0 VERB F
and 0 CCONJ F
read 0 ADP F
a 0 DET F
passage 0 NOUN F
while 0 ADP F
in 0 ADP F
hypnosis 0 NOUN F
. 0 PUNCT F

Concurrently 0 ADV T
, 0 PUNCT F
they 0 PUNCT F
were 0 VERB F
given 0 VERB F
a 0 DET F
post-hypnotic 0 ADJ F
suggestion 0 NOUN F
, 0 PUNCT F
which 0 ADP F
attempted 0 VERB F
to 0 ADP F
aid 0 PUNCT F
recognition 0 NOUN F
and 0 CCONJ F
performance 0 NOUN F
on 0 ADP F
a 0 DET F
test 0 NOUN F
immediately 0 ADV F
following 0 VERB F
the 0 DET F
hypnosis 0 NOUN F
session 0 NOUN F
. 0 PUNCT F

Both 0 DET T
groups 0 NOUN F
completed 0 ADV F
a 0 DET F
multiple-choice 0 NOUN F
test 0 NOUN F
based 0 VERB F
on 0 ADP F
the 0 DET F
aforementioned 0 PUNCT F
passage 0 NOUN F
. 0 PUNCT F

An 0 DET T
analysis 0 NOUN F
of 0 ADP F
covariance 0 NOUN F
discerned 0 PUNCT F
the 0 DET F
effect 0 NOUN F
of 0 ADP F
proactive B-MENTAL CCONJ F
learning I-MENTAL PROPN F
and 0 CCONJ F
post-hypnotic B-MENTAL ADJ F
suggestion I-MENTAL NOUN F
on 0 ADP F
test B-MENTAL PUNCT F
performance I-MENTAL NOUN F
, 0 PUNCT F
while 0 ADP F
controlling 0 ADJ F
for 0 ADP F
the 0 DET F
variance 0 NOUN F
introduced 0 PUNCT F
by 0 ADP F
scholastic B-OTHER ADJ F
aptitude I-OTHER ADJ F
as 0 PUNCT F
measured 0 VERB F
by 0 ADP F
the 0 DET F
ACT 0 NOUN T
. 0 PUNCT F

Results 0 NOUN T
indicated 0 VERB F
that 0 ADP F
the 0 DET F
hypnosis 0 NOUN F
sessions 0 NOUN F
predicted 0 VERB F
significantly 0 ADV F
impaired B-MENTAL ADP F
test I-MENTAL ADV F
performance I-MENTAL NOUN F
. 0 PUNCT F

Albumin-glutaraldehyde 0 NOUN T
bioadhesive 0 ADJ F
( 0 PUNCT F
Bioglue 0 NOUN T
) 0 PUNCT F
for 0 ADP F
prevention 0 NOUN F
of 0 ADP F
postoperative B-ADVERSE-EFFECTS ADJ F
complications I-ADVERSE-EFFECTS NOUN F
after 0 ADP F
stapled 0 VERB F
hemorrhoidopexy 0 NOUN F
: 0 PUNCT F
A 0 DET T
randomized 0 VERB F
controlled 0 VERB F
trial 0 NOUN F
. 0 PUNCT F

BACKGROUND 0 NOUN T
Hemorrhoidopexy 0 NOUN T
using 0 VERB F
the 0 DET F
circumferential 0 ADJ F
stapler 0 PUNCT F
is 0 VERB F
an 0 DET F
established 0 VERB F
method 0 NOUN F
for 0 ADP F
surgical 0 ADJ F
treatment 0 NOUN F
of 0 ADP F
patients 0 NOUN F
with 0 ADP F
prolapsing 0 ADJ F
hemorrhoids 0 NOUN F
. 0 PUNCT F

Despite 0 ADP T
its 0 PUNCT F
advantages 0 NOUN F
, 0 PUNCT F
complications 0 ADJ F
such 0 CCONJ F
as 0 ADP F
anal 0 ADJ F
canal 0 NOUN F
stenosis 0 NOUN F
, 0 PUNCT F
hemorrhage 0 NOUN F
and 0 CCONJ F
anastomosis 0 NOUN F
leak 0 ADJ F
with 0 ADP F
eventual 0 ADJ F
intrapelvic 0 NOUN F
sepsis 0 NOUN F
can 0 PART F
cause 0 ADP F
serious 0 ADJ F
postoperative 0 ADJ F
problems 0 NOUN F
. 0 PUNCT F

The 0 DET T
aim 0 NOUN F
of 0 ADP F
this 0 DET F
study 0 NOUN F
was 0 VERB F
to 0 PART F
evaluate 0 NOUN F
the 0 DET F
utility 0 NOUN F
of 0 ADP F
a 0 DET F
surgical 0 ADJ F
adhesive 0 ADJ F
, 0 PUNCT F
the 0 DET F
biological 0 ADJ F
albumin-glutaraldehyde 0 NOUN F
glue 0 NOUN F
Bioglue 0 NOUN T
, 0 PUNCT F
in 0 ADP F
reduction 0 NOUN F
of 0 ADP F
these 0 DET F
postoperative 0 ADJ F
complications 0 NOUN F
. 0 PUNCT F

PATIENTS 0 NOUN T
AND 0 CCONJ T
METHODS 0 NOUN T
Between 0 ADP T
January 0 NOUN T
2002 0 NUM F
and 0 CCONJ F
November 0 NOUN T
2004 0 NUM F
, 0 PUNCT F
200 0 NUM F
patients 0 NOUN F
undergoing 0 VERB F
stapled 0 ADP F
hemorrhoidopexy 0 NOUN F
were 0 VERB F
enrolled 0 VERB F
in 0 ADP F
a 0 DET F
prospective 0 ADJ F
, 0 PUNCT F
randomized 0 VERB F
clinical 0 ADJ F
trial 0 NOUN F
. 0 PUNCT F

One 0 NUM T
hundred 0 NUM F
patients 0 NOUN F
were 0 VERB F
randomly 0 ADV F
assigned 0 VERB F
to 0 ADP F
the 0 DET F
control 0 NOUN F
group 0 NOUN F
; 0 PUNCT F
the 0 DET F
study 0 ADJ F
group 0 NOUN F
consisted 0 VERB F
of 0 ADP F
100 0 NUM F
patients 0 NOUN F
who 0 PROPN F
received 0 VERB F
Bioglue 0 NOUN T
in 0 ADP F
the 0 DET F
mucosa 0 NOUN F
anastomosis 0 NOUN F
area 0 NOUN F
. 0 PUNCT F

All 0 DET T
patients 0 NOUN F
received 0 VERB F
standardized 0 VERB F
postoperative 0 ADJ F
analgesic 0 ADJ F
, 0 PUNCT F
laxative 0 ADJ F
and 0 CCONJ F
antibiotic 0 ADJ F
treatment 0 NOUN F
. 0 PUNCT F

We 0 PRON T
then 0 ADV F
evaluated 0 PUNCT F
the 0 DET F
two 0 NUM F
groups 0 NOUN F
for 0 ADP F
postoperative B-ADVERSE-EFFECTS ADJ F
complications I-ADVERSE-EFFECTS NOUN F
( 0 PUNCT F
after 0 ADP F
surgery 0 NOUN F
and 0 CCONJ F
6 0 NUM F
months 0 NOUN F
postoperatively 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

RESULTS 0 NOUN T
From 0 ADP T
the 0 DET F
control 0 NOUN F
group 0 NOUN F
( 0 PUNCT F
no 0 ADP F
Bioglue 0 NOUN T
application 0 NOUN F
) 0 PUNCT F
, 0 PUNCT F
two 0 NUM F
patients 0 NOUN F
presented 0 VERB F
with 0 ADP F
anal B-ADVERSE-EFFECTS ADJ F
stenosis I-ADVERSE-EFFECTS NOUN F
, 0 PUNCT F
two 0 NUM F
with 0 ADP F
hemorrhage B-ADVERSE-EFFECTS NOUN F
, 0 PUNCT F
three 0 NUM F
had 0 PUNCT F
anastomosis B-ADVERSE-EFFECTS NOUN F
leak I-ADVERSE-EFFECTS ADP F
and 0 CCONJ F
one 0 NUM F
had 0 PUNCT F
thrombosis B-ADVERSE-EFFECTS NOUN F
, 0 PUNCT F
whereas 0 ADP F
none 0 NUM F
of 0 ADP F
the 0 DET F
patients 0 NOUN F
from 0 ADP F
the 0 DET F
Bioglue 0 NOUN T
group 0 NOUN F
had 0 PUNCT F
any 0 PUNCT F
of 0 ADP F
these 0 DET F
complications B-ADVERSE-EFFECTS NOUN F
. 0 PUNCT F

Both 0 DET T
groups 0 NOUN F
had 0 ADP F
patients 0 NOUN F
with 0 ADP F
severe B-ADVERSE-EFFECTS ADJ F
postoperative I-ADVERSE-EFFECTS ADJ F
pain I-ADVERSE-EFFECTS NOUN F
( 0 PUNCT F
3 0 NUM F
each 0 PUNCT F
) 0 PUNCT F
and 0 CCONJ F
fecal B-ADVERSE-EFFECTS ADJ F
incontinence I-ADVERSE-EFFECTS NOUN F
( 0 PUNCT F
1 0 NUM F
patient 0 NOUN F
each 0 PUNCT F
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
overall B-OTHER ADJ F
difference I-OTHER NOUN F
in 0 ADP F
the 0 DET F
number B-ADVERSE-EFFECTS NOUN F
of I-ADVERSE-EFFECTS ADP F
complications I-ADVERSE-EFFECTS NOUN F
in 0 ADP F
the 0 DET F
two 0 NUM F
groups 0 NOUN F
was 0 VERB F
statistically 0 ADV F
significant 0 ADJ F
( 0 PUNCT F
p 0 NOUN F
< 0 SYM F
0.05 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

CONCLUSION 0 NOUN T
In 0 ADP T
this 0 DET F
first 0 ADJ F
study 0 NOUN F
using 0 VERB F
Bioglue 0 NOUN T
in 0 ADP F
patients 0 NOUN F
undergoing 0 VERB F
circumferential 0 ADJ F
stapled 0 ADP F
hemorrhoidopexy 0 NOUN F
we 0 PRON F
have 0 PUNCT F
shown 0 VERB F
that 0 ADP F
application 0 NOUN F
of 0 ADP F
the 0 DET F
glue 0 NOUN F
is 0 VERB F
effective 0 ADJ F
in 0 ADP F
reducing B-ADVERSE-EFFECTS VERB F
postoperative I-ADVERSE-EFFECTS ADJ F
complications I-ADVERSE-EFFECTS NOUN F
. 0 PUNCT F

Hemostasis 0 NOUN T
by 0 ADP F
bipolar 0 ADJ F
coagulation 0 NOUN F
versus 0 CCONJ F
suture 0 NOUN F
after 0 ADP F
surgical 0 ADJ F
stripping 0 ADJ F
of 0 ADP F
bilateral 0 ADJ F
ovarian 0 ADJ F
endometriomas 0 NOUN F
: 0 PUNCT F
a 0 DET F
randomized 0 VERB F
controlled 0 VERB F
trial 0 NOUN F
. 0 PUNCT F

STUDY 0 NOUN T
OBJECTIVE 0 NOUN T
To 0 PROPN T
estimate 0 NOUN F
whether 0 ADP F
the 0 DET F
suture 0 NOUN F
of 0 ADP F
the 0 DET F
ovary 0 NOUN F
is 0 ADV F
superior 0 ADJ F
to 0 ADP F
bipolar 0 ADJ F
coagulation 0 NOUN F
in 0 ADP F
preserving 0 VERB F
ovarian 0 ADJ F
reserve 0 NOUN F
in 0 ADP F
infertile 0 ADJ F
women 0 NOUN F
undergoing 0 VERB F
laparoscopic 0 ADJ F
stripping 0 ADJ F
of 0 ADP F
bilateral 0 ADJ F
endometriomas 0 NOUN F
. 0 PUNCT F

DESIGN 0 NOUN T
Randomized 0 PROPN T
controlled 0 VERB F
trial 0 NOUN F
( 0 PUNCT F
Canadian 0 ADJ T
Task 0 NOUN T
Force 0 NOUN T
classification 0 NOUN F
I 0 NUM T
) 0 PUNCT F
. 0 PUNCT F

SETTING 0 ADJ T
University 0 NOUN T
teaching 0 VERB F
hospital 0 NOUN F
. 0 PUNCT F

PATIENTS 0 NOUN T
100 0 NUM F
patients 0 NOUN F
with 0 ADP F
bilateral 0 ADJ F
endometriomas 0 NOUN F
. 0 PUNCT F

INTERVENTIONS 0 NOUN T
Patients 0 NOUN T
underwent 0 VERB F
stripping 0 ADJ F
of 0 ADP F
bilateral 0 ADJ F
endometriomas 0 NOUN F
and 0 CCONJ F
were 0 VERB F
randomized 0 VERB F
to 0 PUNCT F
undergo 0 VERB F
hemostasis 0 NOUN F
by 0 ADP F
use 0 NOUN F
of 0 ADP F
either 0 CCONJ F
laparoscopic 0 ADJ F
suturing 0 PUNCT F
( 0 PUNCT F
LS 0 NOUN T
group 0 NOUN F
) 0 PUNCT F
or 0 CCONJ F
bipolar 0 ADJ F
coagulation 0 NOUN F
( 0 PUNCT F
BC 0 NOUN T
group 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

Changes 0 NOUN T
in 0 ADP F
ovarian B-PHYSICAL ADJ F
reserve I-PHYSICAL NOUN F
were 0 VERB F
investigated 0 VERB F
by 0 ADP F
measuring 0 VERB F
the 0 DET F
levels 0 NOUN F
of 0 ADP F
anti-Mullerian B-PHYSICAL ADJ F
hormone I-PHYSICAL NOUN F
( I-PHYSICAL PUNCT F
AMH I-PHYSICAL NOUN T
) I-PHYSICAL PUNCT F
and 0 CCONJ F
basal B-PHYSICAL ADJ F
follicle-stimulating I-PHYSICAL VERB F
hormone I-PHYSICAL NOUN F
( I-PHYSICAL PUNCT F
FSH I-PHYSICAL NOUN T
) I-PHYSICAL PUNCT F
before 0 ADP F
surgery 0 NOUN F
and 0 CCONJ F
at 0 ADP F
3 0 NUM F
, 0 PUNCT F
6 0 NUM F
and 0 CCONJ F
12 0 NUM F
months 0 NOUN F
from 0 ADP F
surgery 0 NOUN F
. 0 PUNCT F

MEASUREMENTS 0 ADP T
AND 0 CCONJ T
MAIN 0 ADJ T
RESULTS 0 NOUN T
At 0 ADP T
3-month 0 NOUN F
, 0 PUNCT F
6-month 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
12-month 0 NOUN F
follow-up 0 NOUN F
, 0 PUNCT F
in 0 ADP F
both 0 CCONJ F
study 0 ADP F
groups 0 NOUN F
, 0 PUNCT F
postsurgical B-PHYSICAL ADJ F
AMH I-PHYSICAL NOUN T
levels I-PHYSICAL NOUN F
were 0 VERB F
significantly 0 ADV F
lower 0 PUNCT F
and 0 CCONJ F
basal B-PHYSICAL ADJ F
FSH I-PHYSICAL NOUN T
levels I-PHYSICAL NOUN F
were 0 VERB F
significantly 0 ADV F
higher 0 PUNCT F
than 0 PUNCT F
before 0 CCONJ F
surgery 0 NOUN F
. 0 PUNCT F

There 0 PUNCT T
was 0 VERB F
no 0 DET F
significant 0 ADJ F
difference 0 NOUN F
in 0 ADP F
the 0 DET F
mean 0 NOUN F
percentage 0 NOUN F
decrease 0 NOUN F
of 0 ADP F
AMH B-PHYSICAL NOUN T
levels I-PHYSICAL NOUN F
in 0 ADP F
the 0 DET F
BC 0 NOUN T
group 0 NOUN F
and 0 CCONJ F
LS 0 NOUN T
group 0 NOUN F
at 0 ADP F
3- 0 NUM F
, 0 PUNCT F
6- 0 NUM F
, 0 PUNCT F
and 0 CCONJ F
12-month 0 NOUN F
follow-up 0 NOUN F
. 0 PUNCT F

The 0 DET T
mean 0 NOUN F
percentage 0 NOUN F
increase 0 NOUN F
in 0 ADP F
basal B-PHYSICAL ADJ F
FSH I-PHYSICAL NOUN T
was 0 VERB F
higher 0 PUNCT F
in 0 ADP F
the 0 DET F
BC 0 NOUN T
group 0 NOUN F
than 0 PUNCT F
in 0 ADP F
the 0 DET F
LS 0 NOUN T
group 0 NOUN F
at 0 ADP F
both 0 CCONJ F
3-month 0 NOUN F
( 0 PUNCT F
p 0 NOUN F
= 0 SYM F
.023 0 NUM F
) 0 PUNCT F
and 0 CCONJ F
6-month 0 NOUN F
follow-up 0 NOUN F
( 0 PUNCT F
p 0 NOUN F
= 0 SYM F
.029 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
but 0 CCONJ F
not 0 ADV F
at 0 ADP F
12-month 0 NOUN F
follow-up 0 NOUN F
. 0 PUNCT F

Pregnancy 0 NOUN T
rate 0 NOUN F
, 0 PUNCT F
time 0 NOUN F
to 0 ADP F
conception 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
rate 0 NOUN F
of 0 ADP F
endometrioma 0 NOUN F
recurrence 0 NOUN F
was 0 VERB F
similar 0 ADJ F
in 0 ADP F
the 0 DET F
2 0 NUM F
study 0 ADV F
groups 0 NOUN F
. 0 PUNCT F

CONCLUSION 0 NOUN T
Laparoscopic 0 ADJ T
stripping 0 ADJ F
of 0 ADP F
ovarian 0 ADJ F
endometriotic 0 ADJ F
cyst 0 NOUN F
significantly 0 ADV F
decreases 0 PUNCT F
serum B-PHYSICAL NOUN F
AMH I-PHYSICAL NOUN T
levels I-PHYSICAL NOUN F
and 0 CCONJ F
increases 0 ADV F
basal B-PHYSICAL ADJ F
FSH I-PHYSICAL NOUN T
levels I-PHYSICAL NOUN F
independent 0 ADJ F
from 0 ADP F
the 0 DET F
method 0 NOUN F
used 0 VERB F
to 0 PART F
obtain 0 NOUN F
hemostasis 0 NOUN F
on 0 ADP F
the 0 DET F
ovarian 0 ADJ F
tissue 0 NOUN F
. 0 PUNCT F

Effects 0 NOUN T
of 0 ADP F
nutritional 0 ADJ F
supplementation 0 NOUN F
on 0 ADP F
IQ B-MENTAL NOUN T
and 0 CCONJ F
certain 0 ADJ F
other 0 ADJ F
variables 0 NOUN F
associated 0 VERB F
with 0 ADP F
Down 0 ADJ T
syndrome 0 NOUN F
. 0 PUNCT F

In 0 ADP T
a 0 DET F
double-blind 0 ADJ F
study 0 NOUN F
, 0 PUNCT F
24 0 NUM F
Down 0 ADJ T
syndrome 0 NOUN F
children 0 NOUN F
, 0 PUNCT F
ages 0 NOUN F
6 0 NUM F
to 0 ADP F
17 0 NUM F
years 0 NOUN F
living 0 VERB F
at 0 ADP F
home 0 NOUN F
, 0 PUNCT F
were 0 VERB F
given 0 VERB F
a 0 DET F
megadose 0 NOUN F
multi-vitamin/mineral 0 ADJ F
supplement 0 NOUN F
for 0 ADP F
4 0 NUM F
months 0 NOUN F
. 0 PUNCT F

A 0 DET T
matched 0 VERB F
group 0 NOUN F
of 0 ADP F
23 0 NUM F
children 0 NOUN F
received 0 VERB F
a 0 DET F
placebo 0 NOUN F
in 0 ADP F
identical 0 ADJ F
form 0 NOUN F
. 0 PUNCT F

The 0 DET T
children B-MENTAL NOUN F
's 0 PUNCT F
IQ B-MENTAL NOUN T
, 0 PUNCT F

The 0 DET T
effect 0 NOUN F
of 0 ADP F
levetiracetam 0 NOUN F
on 0 ADP F
essential B-PHYSICAL ADJ F
tremor I-PHYSICAL NOUN F
. 0 PUNCT F

The 0 DET T
effect 0 NOUN F
of 0 ADP F
a 0 DET F
single 0 ADJ F
dose 0 NOUN F
of 0 ADP F
1,000 0 NUM F
mg 0 NOUN F
of 0 ADP F
levetiracetam 0 NOUN F
on 0 ADP F
essential 0 ADJ F
tremor 0 NOUN F
was 0 VERB F
investigated 0 VERB F
in 0 ADP F
24 0 NUM F
patients 0 NOUN F
in 0 ADP F
a 0 DET F
double-blind 0 ADJ F
, 0 PUNCT F
placebo-controlled 0 VERB F
trial 0 NOUN F
. 0 PUNCT F

There 0 PUNCT T
was 0 VERB F
a 0 DET F
significant 0 ADJ F
reduction 0 NOUN F
of 0 ADP F
hand B-PHYSICAL NOUN F
tremor I-PHYSICAL NOUN F
for 0 ADP F
at 0 ADP F
least 0 ADV F
2 0 NUM F
hours 0 NOUN F
as 0 CCONJ F
measured 0 VERB F
by 0 ADP F
accelerometry 0 NOUN F
and 0 CCONJ F
functional 0 ADJ F
tests 0 NOUN F
. 0 PUNCT F

Children 0 NOUN T
with 0 ADP F
autism 0 NOUN F
's 0 PUNCT F
response 0 NOUN F
to 0 ADP F
novel B-PHYSICAL ADJ F
stimuli I-PHYSICAL NOUN F
while 0 ADP F
participating 0 ADP F
in 0 ADP F
interventions 0 NOUN F
targeting 0 VERB F
joint 0 NOUN F
attention 0 NOUN F
or 0 CCONJ F
symbolic 0 ADJ F
play 0 PUNCT F
skills 0 NOUN F
. 0 PUNCT F

Thirty-five 0 PUNCT T
children 0 NOUN F
diagnosed 0 VERB F
with 0 ADP F
autism 0 NOUN F
were 0 VERB F
randomly 0 ADV F
assigned 0 VERB F
to 0 ADP F
either 0 CCONJ F
a 0 DET F
joint 0 NOUN F
attention 0 NOUN F
or 0 CCONJ F
a 0 DET F
symbolic 0 ADJ F
play 0 VERB F
intervention 0 NOUN F
. 0 PUNCT F

During 0 ADP T
the 0 DET F
5-8 0 NUM F
week 0 NOUN F
treatment 0 NOUN F
, 0 PUNCT F
three 0 NUM F
novel 0 ADJ F
probes 0 NOUN F
were 0 VERB F
administered 0 VERB F
to 0 PART F
determine 0 NOUN F
mastery 0 NOUN F
of 0 ADP F
joint B-MENTAL NOUN F
attention I-MENTAL NOUN F
skills I-MENTAL NOUN F
. 0 PUNCT F

The 0 DET T
probes 0 NOUN F
consisted 0 DET F
of 0 ADP F
auditory 0 ADJ F
and 0 CCONJ F
visual 0 ADJ F
stimuli 0 NOUN F
, 0 PUNCT F
such 0 PUNCT F
as 0 ADP F
a 0 DET F
loud 0 ADJ F
spider 0 NOUN F
crawling 0 PUNCT F
or 0 CCONJ F
a 0 DET F
musical 0 ADP F
ball 0 NOUN F
bouncing 0 PUNCT F
. 0 PUNCT F

The 0 DET T
current 0 ADJ F
study 0 NOUN F
examined 0 CCONJ F
affect 0 NOUN F
, 0 PUNCT F
gaze 0 NOUN F
, 0 PUNCT F
joint 0 NOUN F
attention 0 NOUN F
behaviors 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
verbalizations B-MENTAL NOUN F
at 0 ADP F
three 0 NUM F
different 0 ADJ F
time 0 NOUN F
points 0 NOUN F
of 0 ADP F
intervention 0 NOUN F
. 0 PUNCT F

Results 0 NOUN T
revealed 0 VERB F
that 0 ADP F
children 0 NOUN F
randomized 0 VERB F
to 0 ADP F
the 0 DET F
joint 0 NOUN F
attention 0 NOUN F
group 0 NOUN F
were 0 VERB F
more 0 ADV F
likely 0 ADJ F
to 0 ADP F
acknowledge 0 ADP F
the 0 DET F
probe B-MENTAL ADJ F
and I-MENTAL CCONJ F
engage I-MENTAL NUM F
in I-MENTAL ADP F
shared I-MENTAL VERB F
interactions I-MENTAL NOUN F
between 0 ADP F
intervener 0 NOUN F
and 0 CCONJ F
probe 0 PUNCT F
upon 0 ADP F
termination 0 NOUN F
of 0 ADP F
intervention 0 NOUN F
. 0 PUNCT F

Additionally 0 ADV T
, 0 PUNCT F
the 0 DET F
joint 0 NOUN F
attention 0 NOUN F
group 0 NOUN F
improved 0 VERB F
in 0 ADP F
the 0 DET F
proportion 0 NOUN F
of 0 ADP F
time 0 NOUN F
spent 0 ADP F
sharing 0 PUNCT F
coordinated 0 VERB F
joint 0 NOUN F
looks 0 PUNCT F
between 0 ADP F
intervener 0 NOUN F
and 0 CCONJ F
probe 0 NOUN F
. 0 PUNCT F

These 0 DET T
results 0 CCONJ F
suggest 0 VERB F
that 0 ADP F
generalization 0 NOUN F
of 0 ADP F
joint 0 NOUN F
attention 0 NOUN F
skills 0 NOUN F
to 0 ADP F
a 0 DET F
novel 0 ADJ F
probe 0 NOUN F
did 0 PUNCT F
occur 0 ADP F
for 0 ADP F
the 0 DET F
group 0 NOUN F
targeting 0 VERB F
joint 0 NOUN F
attention 0 NOUN F
and 0 CCONJ F
provides 0 NOUN F
further 0 ADJ F
evidence 0 NOUN F
of 0 ADP F
the 0 DET F
effectiveness 0 NOUN F
of 0 ADP F
the 0 DET F
joint 0 NOUN F
attention 0 NOUN F
intervention 0 NOUN F
. 0 PUNCT F

Interactions 0 NOUN T
of 0 ADP F
morphine 0 NOUN F
and 0 CCONJ F
methotrimeprazine 0 NOUN F
in 0 ADP F
mouse 0 NOUN F
and 0 CCONJ F
man 0 NOUN F
with 0 ADP F
respect 0 NOUN F
to 0 ADP F
analgesia B-PHYSICAL NOUN F
, 0 PUNCT F
respiration B-PHYSICAL NOUN F
and 0 CCONJ F
sedation B-PHYSICAL NOUN F
. 0 PUNCT F

Interactions 0 NOUN T
between 0 ADP F
morphine 0 NOUN F
and 0 CCONJ F
methotrimeprazine 0 NOUN F
have 0 PUNCT F
been 0 PUNCT F
studied 0 VERB F
in 0 ADP F
mice 0 NOUN F
and 0 CCONJ F
man 0 NOUN F
with 0 ADP F
respect 0 NOUN F
to 0 ADP F
analgesia B-PHYSICAL NOUN F
or I-PHYSICAL CCONJ F
antinociceptive I-PHYSICAL ADJ F
activity I-PHYSICAL NOUN F
, 0 PUNCT F
respiratory B-PHYSICAL ADJ F
effects I-PHYSICAL NOUN F
and 0 CCONJ F
sedation B-PHYSICAL NOUN F
. 0 PUNCT F

The 0 DET T
volunteer 0 NOUN F
study 0 NOUN F
was 0 VERB F
a 0 DET F
double-blind 0 ADJ F
cross-over 0 NOUN F
trial 0 NOUN F
with 0 ADP F
10 0 NUM F
volunteers 0 NOUN F
. 0 PUNCT F

In 0 ADP T
mice 0 NOUN F
, 0 PUNCT F
methotrimeprazine 0 NOUN F
only 0 ADV F
possessed 0 VERB F
antinociceptive B-PHYSICAL ADJ F
activity I-PHYSICAL NOUN F
in 0 ADP F
doses 0 NOUN F
which 0 ADP F
caused 0 VERB F
marked B-PHYSICAL VERB F
sedation I-PHYSICAL NOUN F
. 0 PUNCT F

However 0 ADV T
, 0 PUNCT F
small 0 ADJ F
non-sedative 0 ADJ F
doses 0 NOUN F
of 0 ADP F
methotrimeprazine 0 NOUN F
potentiated 0 VERB F
the 0 DET F
analgesic B-PAIN ADP F
action I-PAIN NOUN F
of I-PAIN ADP F
morphine I-PAIN NOUN F
. 0 PUNCT F

The 0 DET T
volunteer 0 NOUN F
study 0 NOUN F
did 0 PUNCT F
not 0 ADV F
confirm 0 VERB F
this 0 DET F
finding 0 VERB F
in 0 ADP F
man 0 NOUN F
. 0 PUNCT F

Methotrimeprazine 0 NOUN T
7.5 0 NUM F
mg 0 NOUN F
i.m 0 NUM F
. 0 PUNCT F

caused 0 ADP F
significant B-PHYSICAL ADJ F
sedation I-PHYSICAL NOUN F
, 0 PUNCT F
but 0 CCONJ F
did 0 PUNCT F
not 0 ADV F
alter 0 VERB F
the 0 DET F
effects 0 NOUN F
of 0 ADP F
morphine 0 NOUN F
5 0 NUM F
mg 0 NOUN F
on 0 ADP F
pain B-PAIN NOUN F
threshold I-PAIN NOUN F
or 0 CCONJ F
ventilatory B-PHYSICAL ADJ F
response I-PHYSICAL NOUN F
to 0 ADP F
carbon 0 NOUN F
dioxide 0 NOUN F
. 0 PUNCT F

Effect 0 NOUN T
of 0 ADP F
postural 0 PUNCT F
supports 0 VERB F
on 0 ADP F
neuromotor B-PHYSICAL NOUN F
function I-PHYSICAL CCONJ F
in 0 ADP F
very 0 PUNCT F
preterm 0 NOUN F
infants 0 NOUN F
to 0 ADP F
term 0 NOUN F
equivalent 0 ADJ F
age 0 NOUN F
. 0 PUNCT F

OBJECTIVE 0 NOUN T
To 0 PROPN T
determine 0 NOUN F
the 0 DET F
effect 0 NOUN F
of 0 ADP F
a 0 DET F
postural 0 ADJ F
support 0 NOUN F
nappy 0 PUNCT F
and/or 0 CCONJ F
a 0 DET F
postural 0 ADJ F
support 0 NOUN F
roll 0 ADP F
on 0 ADP F
neuromotor B-PHYSICAL NOUN F
function I-PHYSICAL CCONJ F
in 0 ADP F
very 0 PUNCT F
preterm 0 NOUN F
infants 0 NOUN F
when 0 ADP F
nursed 0 VERB F
prone 0 ADJ F
to 0 ADP F
term 0 NOUN F
equivalent 0 ADJ F
age 0 NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
A 0 CCONJ T
randomized 0 VERB F
observer 0 ADP F
blind 0 PUNCT F
controlled 0 VERB F
trial 0 NOUN F
of 0 ADP F
123 0 NUM F
very 0 ADJ F
preterm 0 NOUN F
infants 0 NOUN F
was 0 VERB F
conducted 0 VERB F
in 0 ADP F
the 0 DET F
neonatal 0 ADJ F
intensive 0 ADJ F
care 0 NOUN F
unit 0 NOUN F
of 0 ADP F
the 0 DET F
sole 0 ADJ F
tertiary 0 ADJ F
referral 0 ADJ F
centre 0 NOUN F
in 0 ADP F
Western 0 NOUN T
Australia 0 PUNCT T
. 0 PUNCT F

Infants 0 NOUN T
were 0 VERB F
stratified 0 VERB F
by 0 ADP F
gestational 0 ADJ F
age 0 NOUN F
( 0 PUNCT F
< 0 PROPN F
29 0 NUM F
weeks 0 NOUN F
or 0 CCONJ F
29-30 0 NUM F
weeks 0 NOUN F
) 0 PUNCT F
, 0 PUNCT F
then 0 ADV F
randomized 0 PUNCT F
into 0 ADP F
one 0 NUM F
of 0 ADP F
three 0 NUM F
intervention 0 NOUN F
groups 0 NOUN F
: 0 PUNCT F
postural 0 ADJ F
support 0 NOUN F
nappy 0 PUNCT F
, 0 PUNCT F
postural 0 ADJ F
support 0 NOUN F
nappy 0 PUNCT F
and 0 CCONJ F
postural 0 ADJ F
support 0 NOUN F
roll 0 ADV F
, 0 PUNCT F
or 0 CCONJ F
disposable 0 ADJ F
nappy 0 ADJ F
and 0 CCONJ F
postural 0 ADJ F
support 0 NOUN F
roll 0 NOUN F
. 0 PUNCT F

Interventions 0 NOUN T
started 0 VERB F
when 0 ADP F
infants 0 NOUN F
were 0 VERB F
stable 0 ADJ F
and 0 CCONJ F
ceased 0 VERB F
when 0 PUNCT F
routine 0 ADJ F
side-lying 0 PUNCT F
commenced 0 PROPN F
. 0 PUNCT F

Measurements 0 NOUN T
of 0 ADP F
shoulder B-PHYSICAL NOUN F
and 0 CCONJ F
hip B-PHYSICAL NOUN F
posture I-PHYSICAL NOUN F
were 0 VERB F
performed 0 VERB F
pre-intervention 0 NOUN F
, 0 PUNCT F
5 0 NUM F
weeks 0 NOUN F
post-intervention 0 NOUN F
and 0 CCONJ F
term 0 NOUN F
postmenstrual 0 ADJ F
age 0 NOUN F
. 0 PUNCT F

RESULTS 0 DET T
Infants 0 NOUN T
nursed 0 VERB F
with 0 ADP F
a 0 DET F
postural 0 ADJ F
support 0 NOUN F
roll 0 ADP F
and 0 CCONJ F
a 0 DET F
postural 0 ADJ F
support 0 NOUN F
nappy 0 PUNCT F
demonstrated 0 VERB F
improved 0 ADP F
hip B-PHYSICAL NOUN F
posture I-PHYSICAL NOUN F
to 0 ADP F
term 0 NOUN F
equivalent 0 ADJ F
age 0 NOUN F
compared 0 VERB F
with 0 ADP F
infants 0 NOUN F
nursed 0 VERB F
with 0 ADP F
either 0 CCONJ F
a 0 DET F
postural 0 ADJ F
support 0 NOUN F
roll 0 VERB F
only 0 ADV F
, 0 PUNCT F
or 0 CCONJ F
a 0 DET F
postural 0 ADJ F
support 0 NOUN F
nappy 0 PUNCT F
only 0 ADV F
. 0 PUNCT F

Infants 0 NOUN T
nursed 0 VERB F
with 0 ADP F
a 0 DET F
postural 0 ADJ F
support 0 NOUN F
roll 0 VERB F
either 0 PUNCT F
with 0 ADP F
or 0 CCONJ F
without 0 ADP F
a 0 DET F
postural 0 ADJ F
support 0 NOUN F
nappy 0 PUNCT F
demonstrated 0 VERB F
improved 0 VERB F
shoulder B-PHYSICAL NOUN F
posture I-PHYSICAL NOUN F
to 0 ADP F
term 0 NOUN F
equivalent 0 ADJ F
age 0 NOUN F
. 0 PUNCT F

CONCLUSIONS 0 NOUN T
Combined 0 PROPN T
use 0 NOUN F
of 0 ADP F
a 0 DET F
postural 0 ADJ F
support 0 NOUN F
roll 0 ADP F
and 0 CCONJ F
a 0 DET F
postural 0 ADJ F
support 0 NOUN F
nappy 0 PUNCT F
while 0 PUNCT F
very 0 DET F
preterm 0 NOUN F
infants 0 NOUN F
are 0 VERB F
nursed 0 PUNCT F
prone 0 ADP F
improves 0 NOUN F
hip B-PHYSICAL NOUN F
posture I-PHYSICAL NUM F
up 0 CCONJ F
to 0 ADP F
term 0 NOUN F
postmenstrual 0 ADJ F
age 0 NOUN F
. 0 PUNCT F

Use 0 NOUN T
of 0 ADP F
a 0 DET F
postural 0 ADJ F
support 0 NOUN F
roll 0 VERB F
improves 0 ADV F
shoulder B-PHYSICAL NOUN F
posture I-PHYSICAL NUM F
up 0 PUNCT F
to 0 ADP F
term 0 NOUN F
equivalent 0 ADJ F
age 0 NOUN F
. 0 PUNCT F

Sialyl 0 NOUN T
Lewisa 0 VERB T
expression 0 NOUN F
as 0 ADP F
a 0 DET F
predictor 0 NOUN F
of 0 ADP F
the 0 DET F
prognosis 0 NOUN F
of 0 ADP F
colon 0 NOUN F
carcinoma 0 NOUN F
patients 0 NOUN F
in 0 ADP F
a 0 DET F
prospective 0 ADJ F
randomized 0 VERB F
clinical 0 ADJ F
trial 0 NOUN F
. 0 PUNCT F

BACKGROUND 0 NOUN T
The 0 DET T
metastatic 0 ADJ F
potential 0 NOUN F
of 0 ADP F
tumors 0 NOUN F
is 0 VERB F
dependent 0 ADJ F
on 0 ADP F
the 0 DET F
cell 0 NOUN F
to 0 ADP F
cell 0 NOUN F
adhesion 0 NOUN F
by 0 ADP F
cell 0 NOUN F
surface 0 NOUN F
carbohydrate 0 NOUN F
antigens 0 NOUN F
. 0 PUNCT F

Thus 0 ADV T
, 0 PUNCT F
expression 0 NOUN F
of 0 ADP F
sialyl 0 NOUN F
Lewis 0 NOUN T
( 0 PUNCT F
a 0 NOUN F
) 0 PUNCT F
, 0 PUNCT F
which 0 ADP F
is 0 VERB F
one 0 NUM F
of 0 ADP F
the 0 DET F
important 0 ADJ F
molecules 0 NOUN F
of 0 ADP F
cell 0 NOUN F
surface 0 NOUN F
carbohydrates 0 CCONJ F
, 0 PUNCT F
may 0 VERB F
serve 0 VERB F
as 0 ADP F
a 0 DET F
prognostic 0 ADJ F
marker 0 NOUN F
of 0 ADP F
aggressive 0 ADJ F
and 0 CCONJ F
metastasizing 0 VERB F
tumor 0 NOUN F
growth 0 NOUN F
. 0 PUNCT F

However 0 ADV T
, 0 PUNCT F
the 0 DET F
prognostic 0 ADJ F
value 0 NOUN F
of 0 ADP F
sialyl 0 NOUN F
Lewis 0 NOUN T
( 0 PUNCT F
a 0 NOUN F
) 0 PUNCT F
expression 0 NOUN F
in 0 ADP F
colon 0 NOUN F
cancer 0 NOUN F
is 0 VERB F
still 0 ADV F
controversial 0 ADJ F
. 0 PUNCT F

METHODS 0 NOUN T
In 0 ADP T
this 0 DET F
study 0 NOUN F
, 0 PUNCT F
we 0 PRON F
investigated 0 VERB F
the 0 DET F
expression 0 NOUN F
of 0 ADP F
sialyl 0 NOUN F
Lewis 0 NOUN T
( 0 PUNCT F
a 0 NOUN F
) 0 PUNCT F
antigen 0 NOUN F
in 0 ADP F
233 0 NUM F
colon 0 NOUN F
cancer 0 NOUN F
specimens 0 NOUN F
from 0 ADP F
patients 0 NOUN F
who 0 ADP F
were 0 ADV F
registered 0 PUNCT F
in 0 ADP F
a 0 DET F
prospective 0 ADJ F
adjuvant 0 NOUN F
immunochemotherapy 0 NOUN F
clinical 0 ADJ F
trial 0 NOUN F
. 0 PUNCT F

The 0 DET T
clinical 0 ADJ F
course 0 NOUN F
and 0 CCONJ F
the 0 DET F
prognosis 0 NOUN F
of 0 ADP F
the 0 DET F
patients 0 NOUN F
were 0 VERB F
evaluated 0 VERB F
after 0 ADP F
all 0 PUNCT F
the 0 DET F
immunohistochemical 0 ADJ F
analyses 0 NOUN F
had 0 VERB F
been 0 PUNCT F
performed 0 VERB F
. 0 PUNCT F

RESULTS 0 NOUN T
Sialyl 0 NOUN T
Lewis 0 NOUN T
( 0 PUNCT F
a 0 NOUN F
) 0 PUNCT F
expression 0 NOUN F
levels 0 NOUN F
were 0 VERB F
correlated 0 VERB F
with 0 ADP F
both 0 CCONJ F
overall B-MORTALITY ADJ F
survival I-MORTALITY NOUN F
( 0 PUNCT F
P 0 NOUN T
= 0 SYM F
0.0006 0 NUM F
) 0 PUNCT F
and 0 CCONJ F
disease-free B-MORTALITY ADJ F
survival I-MORTALITY NOUN F
( 0 PUNCT F
P 0 NOUN T
= 0 SYM F
0.004 0 NUM F
) 0 PUNCT F
in 0 ADP F
all 0 DET F
patients 0 NOUN F
with 0 ADP F
the 0 DET F
log-rank 0 NOUN F
test 0 NOUN F
. 0 PUNCT F

This 0 DET T
result 0 NOUN F
could 0 VERB F
be 0 VERB F
assumed 0 VERB F
to 0 PART F
have 0 PUNCT F
been 0 PUNCT F
influenced 0 VERB F
by 0 ADP F
the 0 DET F
difference 0 NOUN F
in 0 ADP F
the 0 DET F
metastatic 0 ADJ F
preponderance 0 NOUN F
in 0 ADP F
a 0 DET F
high 0 ADJ F
versus 0 CCONJ F
low 0 ADJ F
sialyl 0 NOUN F
Lewis 0 NOUN T
( 0 PUNCT F
a 0 NOUN F
) 0 PUNCT F
expression 0 NOUN F
in 0 ADP F
the 0 DET F
tumor 0 NOUN F
cells 0 NOUN F
. 0 PUNCT F

CONCLUSION 0 NOUN T
This 0 DET T
prospective 0 ADJ F
study 0 NOUN F
in 0 ADP F
a 0 DET F
randomized 0 VERB F
controlled 0 VERB F
trial 0 NOUN F
suggests 0 NOUN F
that 0 ADP F
sialyl 0 NOUN F
Lewis 0 NOUN T
( 0 PUNCT F
a 0 NOUN F
) 0 PUNCT F
expression 0 NOUN F
levels 0 NOUN F
may 0 VERB F
serve 0 VERB F
as 0 ADP F
an 0 DET F
indicator 0 NOUN F
of 0 ADP F
the 0 DET F
metastatic 0 ADJ F
potential 0 NOUN F
of 0 ADP F
colon 0 NOUN F
cancer 0 NOUN F
cells 0 NOUN F
, 0 PUNCT F
which 0 ADP F
would 0 VERB F
strongly 0 ADV F
predict 0 VERB F
the 0 DET F
prognosis 0 NOUN F
. 0 PUNCT F

Diet 0 NOUN T
and 0 CCONJ F
vitamin 0 NOUN F
D 0 NOUN T
status 0 NOUN F
among 0 ADP F
pregnant 0 ADJ F
Pakistani 0 NOUN T
women 0 NOUN F
in 0 ADP F
Oslo 0 NOUN T
. 0 PUNCT F

OBJECTIVES 0 NOUN T
In 0 ADP T
the 0 DET F
present 0 ADJ F
study 0 NOUN F
the 0 DET F
diet 0 NOUN F
and 0 CCONJ F
the 0 DET F
nutritional 0 ADJ F
status 0 NOUN F
of 0 ADP F
pregnant 0 ADJ F
Pakistani 0 NOUN T
immigrant 0 NOUN F
women 0 NOUN F
have 0 CCONJ F
been 0 PUNCT F
compared 0 VERB F
with 0 ADP F
a 0 DET F
group 0 NOUN F
of 0 ADP F
Norwegian 0 PUNCT T
women 0 NOUN F
. 0 PUNCT F

DESIGN 0 NOUN T
A 0 PUNCT T
cross-sectional 0 ADJ F
survey 0 NOUN F
of 0 ADP F
women 0 NOUN F
in 0 ADP F
the 0 DET F
18th 0 ADJ F
week 0 NOUN F
of 0 ADP F
pregnancy 0 NOUN F
. 0 PUNCT F

SETTING 0 NUM T
Women 0 NOUN T
referred 0 VERB F
to 0 ADP F
routine 0 PUNCT F
ultrasound 0 NOUN F
examination 0 NOUN F
at 0 ADP F
Aker 0 NOUN T
and 0 CCONJ F
Ullev?l 0 PUNCT T
Hospitals 0 PROPN T
in 0 ADP F
Norway 0 NOUN T
. 0 PUNCT F

SUBJECTS 0 NOUN T
All 0 PUNCT T
( 0 PUNCT F
58 0 NUM F
) 0 PUNCT F
healthy 0 ADJ F
women 0 NOUN F
of 0 ADP F
Pakistani 0 NOUN T
origin 0 NOUN F
referred 0 VERB F
from 0 ADP F
October 0 NOUN T
of 0 ADP F
1991 0 NUM F
to 0 ADP F
January 0 NOUN T
of 0 ADP F
1992 0 NUM F
were 0 VERB F
included 0 VERB F
, 0 PUNCT F
of 0 ADP F
whom 0 ADP F
38 0 NUM F
( 0 PUNCT F
66 0 NUM F
% 0 SYM F
) 0 PUNCT F
participated 0 VERB F
. 0 PUNCT F

Forty-five 0 ADJ T
Norwegian 0 NOUN T
women 0 NOUN F
were 0 VERB F
randomly 0 ADV F
included 0 VERB F
in 0 ADP F
the 0 DET F
same 0 ADJ F
period 0 NOUN F
and 0 CCONJ F
38 0 NUM F
( 0 PUNCT F
84 0 NUM F
% 0 SYM F
) 0 PUNCT F
of 0 ADP F
these 0 DET F
women 0 NOUN F
participated 0 VERB F
. 0 PUNCT F

RESULTS 0 PUNCT T
The 0 DET T
serum 0 NOUN F
levels 0 NOUN F
of 0 ADP F
25-hydroxyvitamin 0 NOUN F
D3 0 NOUN T
were 0 VERB F
significantly 0 ADV F
lower 0 PUNCT F
in 0 ADP F
the 0 DET F
Pakistanis 0 NOUN T
compared 0 VERB F
with 0 ADP F
the 0 DET F
Norwegians 0 NOUN T
( 0 PUNCT F
median 0 ADJ F
19 0 NUM F
nmol/l 0 NOUN F
vs 0 CCONJ F
55 0 NUM F
nmol/l 0 NOUN F
, 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.001 0 NUM F
) 0 PUNCT F
and 0 CCONJ F
83 0 NUM F
% 0 ADJ F
of 0 ADP F
the 0 DET F
Pakistani 0 PUNCT T
women 0 NOUN F
had 0 PUNCT F
25-hydroxyvitamin B-PHYSICAL NOUN F
D3 I-PHYSICAL NOUN T
levels I-PHYSICAL NOUN F
below 0 ADP F
the 0 DET F
reference 0 NOUN F
value 0 NOUN F
( 0 PUNCT F
< 0 PROPN F
30 0 NUM F
nmol/l 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
Pakistanis 0 NOUN T
had 0 PUNCT F
higher 0 CCONJ F
levels 0 NOUN F
of 0 ADP F
serum B-PHYSICAL NOUN F
parathyroid I-PHYSICAL PUNCT F
hormone I-PHYSICAL NOUN F
( 0 PUNCT F
median 0 ADJ F
2.6 0 NUM F
vs 0 CCONJ F
1.6 0 NUM F
pmol/l 0 NOUN F
, 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.001 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
Pakistanis 0 NOUN T
also 0 ADV F
had 0 PUNCT F
a 0 DET F
lower 0 PUNCT F
dietary B-PHYSICAL ADJ F
intake I-PHYSICAL NOUN F
of I-PHYSICAL ADP F
vitamin I-PHYSICAL NOUN F
D 0 NOUN T
than 0 PUNCT F
that 0 PUNCT F
of 0 ADP F
the 0 DET F
Norwegians 0 NOUN T
( 0 PUNCT F
median 0 ADJ F
2.2 0 NUM F
vs 0 CCONJ F
3.3 0 NUM F
micrograms/day 0 NOUN F
, 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.05 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
and 0 CCONJ F
a 0 DET F
lower 0 PUNCT F
total 0 ADJ F
intake 0 NOUN F
, 0 PUNCT F
including 0 PUNCT F
supplements 0 NOUN F
( 0 PUNCT F
median 0 ADJ F
2.9 0 NUM F
vs 0 CCONJ F
7.0 0 NUM F
micrograms/day 0 NOUN F
, 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.001 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Among 0 ADP T
the 0 DET F
Pakistanis 0 NOUN T
a 0 DET F
correlation 0 NOUN F
was 0 VERB F
found 0 VERB F
between 0 ADP F
the 0 DET F
dietary 0 ADJ F
intake 0 NOUN F
of 0 ADP F
margarine 0 ADP F
, 0 PUNCT F
the 0 DET F
main 0 ADJ F
source 0 NOUN F
of 0 ADP F
vitamin 0 NOUN F
D 0 NOUN T
in 0 ADP F
the 0 DET F
diet 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
the 0 DET F
concentration 0 NOUN F
of 0 ADP F
25-hydroxyvitamin 0 NOUN F
D3 0 NOUN T
in 0 ADP F
serum 0 NOUN F
, 0 PUNCT F
r 0 NOUN F
= 0 SYM F
0.48 0 NUM F
( 0 PUNCT F
P 0 NOUN T
= 0 SYM F
0.01 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

In 0 ADP T
general 0 NOUN F
, 0 PUNCT F
the 0 DET F
Pakistanis 0 NOUN T
avoided 0 PUNCT F
any 0 DET F
direct 0 ADJ F
sunshine 0 NOUN F
exposure 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
no 0 DET F
relation 0 NOUN F
between 0 ADP F
outdoor 0 PUNCT F
activity 0 NOUN F
and 0 CCONJ F
serum 0 NOUN F
level 0 NOUN F
of 0 ADP F
25-hydroxyvitamin 0 NOUN F
D3 0 NOUN T
was 0 VERB F
found 0 VERB F
. 0 PUNCT F

The 0 DET T
Pakistani 0 PUNCT T
women 0 NOUN F
had 0 DET F
a 0 DET F
lower 0 PUNCT F
intake 0 NOUN F
of 0 ADP F
calcium 0 NOUN F
than 0 PUNCT F
the 0 DET F
Norwegians 0 NOUN T
( 0 PUNCT F
median 0 ADJ F
793 0 NUM F
vs 0 CCONJ F
1134 0 NUM F
mg/day 0 NOUN F
, 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.001 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

CONCLUSION 0 NOUN T
This 0 DET T
study 0 NOUN F
has 0 PUNCT F
shown 0 VERB F
that 0 ADP F
Pakistani 0 PUNCT T
women 0 NOUN F
living 0 VERB F
in 0 ADP F
Oslo 0 NOUN T
are 0 VERB F
at 0 ADP F
great 0 ADJ F
risk 0 NOUN F
of 0 ADP F
developing 0 PUNCT F
vitamin 0 NOUN F
D 0 NOUN T
deficiency 0 NOUN F
during 0 ADP F
pregnancy 0 NOUN F
. 0 PUNCT F

The 0 DET T
main 0 ADJ F
reasons 0 NOUN F
for 0 ADP F
this 0 PUNCT F
are 0 PUNCT F
avoidance 0 NOUN F
of 0 ADP F
sun 0 DET F
exposure 0 NOUN F
, 0 PUNCT F
a 0 DET F
low 0 ADJ F
dietary 0 ADJ F
intake 0 NOUN F
of 0 ADP F
vitamin 0 NOUN F
D 0 NOUN T
, 0 PUNCT F
and 0 CCONJ F
no 0 DET F
or 0 CCONJ F
little 0 DET F
use 0 NOUN F
of 0 ADP F
supplementation 0 NOUN F
. 0 PUNCT F

A 0 DET T
randomised 0 VERB F
trial 0 NOUN F
comparing 0 VERB F
holmium 0 NOUN F
laser 0 NOUN F
enucleation 0 NOUN F
versus 0 CCONJ F
transurethral 0 ADJ F
resection 0 NOUN F
in 0 ADP F
the 0 DET F
treatment 0 NOUN F
of 0 ADP F
prostates 0 NOUN F
larger 0 PUNCT F
than 0 PUNCT F
40 0 NUM F
grams 0 NOUN F
: 0 PUNCT F
results 0 CCONJ F
at 0 ADP F
2 0 NUM F
years 0 NOUN F
. 0 PUNCT F

OBJECTIVE 0 NOUN T
To 0 PROPN T
compare 0 NOUN F
holmium 0 NOUN F
laser 0 NOUN F
enucleation 0 NOUN F
of 0 ADP F
the 0 DET F
prostate 0 NOUN F
( 0 PUNCT F
HoLEP 0 NOUN T
) 0 PUNCT F
with 0 ADP F
transurethral 0 ADJ F
resection 0 NOUN F
of 0 ADP F
the 0 DET F
prostate 0 NOUN F
( 0 PUNCT F
TURP 0 NOUN T
) 0 PUNCT F
for 0 ADP F
treatment 0 NOUN F
of 0 ADP F
men 0 NOUN F
with 0 ADP F
bladder 0 NOUN F
outflow 0 PUNCT F
obstruction 0 NOUN F
( 0 PUNCT F
BOO 0 NOUN T
) 0 PUNCT F
secondary 0 ADJ F
to 0 ADP F
benign 0 ADJ F
prostatic 0 ADJ F
hyperplasia 0 NOUN F
with 0 ADP F
a 0 DET F
minimum 0 NOUN F
of 0 ADP F
24-month 0 NOUN F
follow-up 0 NOUN F
. 0 PUNCT F

PATIENTS 0 NOUN T
AND 0 CCONJ T
METHODS 0 NOUN T
Sixty-one 0 ADJ T
patients 0 NOUN F
were 0 VERB F
randomised 0 VERB F
to 0 ADP F
either 0 CCONJ F
HoLEP 0 NOUN T
or 0 CCONJ F
TURP 0 NOUN T
. 0 PUNCT F

All 0 DET T
patients 0 NOUN F
had 0 PUNCT F
BOO 0 NOUN T
proven 0 VERB F
on 0 ADP F
urodynamic 0 VERB F
studies 0 NOUN F
pre-operatively 0 ADJ F
( 0 PUNCT F
prostate 0 NOUN F
size 0 NOUN F
40-200 0 NUM F
g 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

One 0 NUM T
patient 0 NOUN F
died 0 VERB F
before 0 ADP F
treatment 0 NOUN F
, 0 PUNCT F
which 0 ADP F
left 0 PUNCT F
30 0 NUM F
patients 0 NOUN F
in 0 ADP F
each 0 DET F
group 0 NOUN F
. 0 PUNCT F

Perioperative 0 ADJ T
data 0 NOUN F
, 0 PUNCT F
as 0 PUNCT F
well 0 PUNCT F
as 0 CCONJ F
symptom 0 NOUN F
scores 0 NOUN F
, 0 PUNCT F
Quality 0 NOUN T
of 0 ADP F
Life 0 NOUN T
( 0 PUNCT F
QoL 0 NOUN T
) 0 PUNCT F
scores 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
maximum 0 NOUN F
urinary 0 ADJ F
flow 0 NOUN F
rates 0 NOUN F
( 0 PUNCT F
Qmax 0 NOUN T
) 0 PUNCT F
were 0 VERB F
obtained 0 VERB F
at 0 ADP F
one 0 NUM F
, 0 PUNCT F
three 0 NUM F
, 0 PUNCT F
six,12 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
24 0 NUM F
months 0 NOUN F
. 0 PUNCT F

Post-void B-PHYSICAL NOUN T
residual 0 ADJ F
volumes B-PHYSICAL NOUN F
, 0 PUNCT F
transrectal B-PHYSICAL ADJ F
ultrasound B-PHYSICAL NOUN F
( 0 PUNCT F

Outpatient 0 ADP T
management 0 NOUN F
of 0 ADP F
asthma 0 NOUN F
with 0 ADP F
regular 0 ADJ F
nebulized 0 ADJ F
beta 0 NOUN F
agonists 0 NOUN F
: 0 PUNCT F
comparison 0 NOUN F
of 0 ADP F
bitolterol 0 NOUN F
mesylate 0 NOUN F
and 0 CCONJ F
isoproterenol 0 NOUN F
. 0 PUNCT F

Nebulized 0 VERB T
bitolterol 0 NOUN F
solution 0 NOUN F
and 0 CCONJ F
isoproterenol 0 NOUN F
solution 0 NOUN F
were 0 VERB F
compared 0 VERB F
when 0 ADP F
used 0 VERB F
on 0 ADP F
a 0 DET F
regular 0 ADJ F
basis 0 NOUN F
, 0 PUNCT F
2.5 0 NUM F
mg 0 NOUN F
three 0 NUM F
times 0 NOUN F
a 0 DET F
day 0 NOUN F
for 0 ADP F
1 0 NUM F
month 0 NOUN F
by 0 ADP F
patients 0 NOUN F
with 0 ADP F
chronic 0 ADJ F
asthma 0 NOUN F
. 0 PUNCT F

In 0 ADP T
this 0 DET F
multicenter 0 NOUN F
, 0 PUNCT F
double-blind 0 ADJ F
trial 0 NOUN F
; 0 PUNCT F
130 0 NUM F
nonsteroid-dependent 0 ADP F
patients 0 NOUN F
were 0 VERB F
randomized 0 VERB F
to 0 PART F
receive 0 NOUN F
one 0 NUM F
of 0 ADP F
the 0 DET F
two 0 ADJ F
treatments 0 NOUN F
concomitantly 0 ADV F
with 0 ADP F
their 0 PUNCT F
regular 0 ADJ F
asthma 0 NOUN F
medications 0 NOUN F
. 0 PUNCT F

On 0 ADP T
study 0 ADJ F
days 0 NOUN F
, 0 PUNCT F
at 0 ADP F
the 0 DET F
beginning 0 PUNCT F
of 0 ADP F
the 0 DET F
study 0 NOUN F
and 0 CCONJ F
after 0 ADP F
2 0 NUM F
and 0 CCONJ F
4 0 NUM F
weeks 0 NOUN F
, 0 PUNCT F
treatments 0 NOUN F
were 0 VERB F
given 0 VERB F
in 0 ADP F
the 0 DET F
office 0 NOUN F
or 0 CCONJ F
laboratory 0 NOUN F
and 0 CCONJ F
patients 0 NOUN F
were 0 VERB F
monitored 0 VERB F
with 0 ADP F
pulmonary B-OTHER ADJ F
function I-OTHER NOUN F
tests I-OTHER NOUN F
for 0 ADP F
eight 0 NUM F
hours 0 NOUN F
. 0 PUNCT F

Both 0 CCONJ T
medications 0 NOUN F
induced 0 VERB F
rapid B-PHYSICAL ADJ F
bronchodilation I-PHYSICAL NOUN F
that 0 ADP F
had 0 ADP F
a 0 DET F
longer 0 PUNCT F
duration B-OTHER NOUN F
after 0 ADP F
bitolterol 0 NOUN F
. 0 PUNCT F

The 0 DET T
incidence 0 NOUN F
of 0 ADP F
tremor B-PHYSICAL NOUN F
was 0 VERB F
similar 0 ADJ F
with 0 ADP F
the 0 DET F
two 0 NUM F
medications 0 NOUN F
. 0 PUNCT F

Tachycardia B-PHYSICAL PUNCT T
and 0 CCONJ F
palpitations B-PHYSICAL NOUN F
were 0 VERB F
more 0 ADV F
frequent 0 ADP F
following 0 ADJ F
isoproterenol 0 NOUN F
. 0 PUNCT F

Bitolterol 0 NOUN T
has 0 CCONJ F
a 0 DET F
much 0 ADJ F
longer 0 PUNCT F
duration B-OTHER NOUN F
of I-OTHER ADP F
action I-OTHER NOUN F
and 0 CCONJ F
should 0 VERB F
be 0 VERB F
considered 0 VERB F
as 0 ADP F
a 0 DET F
suitable 0 ADJ F
bronchodilator 0 NOUN F
for 0 ADP F
regular 0 ADJ F
nebulizer 0 NOUN F
treatment 0 NOUN F
of 0 ADP F
chronic 0 ADJ F
asthma 0 NOUN F
. 0 PUNCT F

Randomized 0 VERB T
controlled 0 VERB F
trial 0 NOUN F
of 0 ADP F
education 0 NOUN F
and 0 CCONJ F
feedback 0 NOUN F
for 0 ADP F
implementation 0 NOUN F
of 0 ADP F
guidelines 0 NOUN F
for 0 ADP F
acute 0 ADJ F
low 0 ADJ F
back 0 ADP F
pain 0 NOUN F
. 0 PUNCT F

OBJECTIVE 0 NOUN T
The 0 DET T
effect 0 NOUN F
of 0 ADP F
clinical 0 ADJ F
guidelines 0 NOUN F
on 0 ADP F
resource 0 NOUN F
utilization 0 NOUN F
for 0 ADP F
complex 0 ADJ F
conditions 0 NOUN F
with 0 ADP F
substantial 0 ADJ F
barriers 0 NOUN F
to 0 ADP F
clinician 0 PUNCT F
behavior 0 NOUN F
change 0 NOUN F
has 0 VERB F
not 0 ADV F
been 0 PUNCT F
well 0 PUNCT F
studied 0 CCONJ F
. 0 PUNCT F

We 0 PRON T
report 0 VERB F
the 0 DET F
impact 0 NOUN F
of 0 ADP F
a 0 DET F
multifaceted 0 VERB F
guideline 0 NOUN F
implementation 0 NOUN F
intervention 0 NOUN F
on 0 ADP F
primary 0 ADJ F
care 0 NOUN F
clinician 0 NOUN F
utilization 0 NOUN F
of 0 ADP F
radiologic 0 ADJ F
and 0 CCONJ F
specialty 0 NOUN F
services 0 NOUN F
for 0 ADP F
the 0 DET F
care 0 NOUN F
of 0 ADP F
acute 0 ADJ F
low 0 ADJ F
back 0 ADP F
pain 0 NOUN F
. 0 PUNCT F

DESIGN 0 NOUN T
Physician 0 NOUN T
groups 0 NOUN F
were 0 VERB F
randomized 0 VERB F
to 0 PART F
receive 0 NOUN F
guideline 0 NOUN F
education 0 NOUN F
and 0 CCONJ F
individual 0 ADJ F
feedback 0 NOUN F
, 0 PUNCT F
supporting 0 ADP F
patient 0 NOUN F
education 0 NOUN F
materials 0 ADP F
, 0 PUNCT F
both 0 PUNCT F
, 0 PUNCT F
or 0 CCONJ F
neither 0 CCONJ F
. 0 PUNCT F

The 0 DET T
impact 0 NOUN F
on 0 ADP F
guideline 0 NOUN F
adherence 0 NOUN F
and 0 CCONJ F
resource 0 NOUN F
utilization 0 NOUN F
was 0 VERB F
evaluated 0 VERB F
during 0 ADP F
the 0 DET F
12-month 0 NOUN F
period 0 NOUN F
before 0 ADP F
and 0 CCONJ F
after 0 ADP F
implementation 0 NOUN F
. 0 PUNCT F

PARTICIPANTS 0 ADP T
Fourteen 0 PUNCT T
physician 0 NOUN F
groups 0 NOUN F
with 0 ADP F
120 0 NUM F
primary 0 ADJ F
care 0 NOUN F
physician 0 NOUN F
and 0 CCONJ F
associate 0 ADV F
practitioners 0 NOUN F
from 0 ADP F
2 0 NUM F
group 0 NOUN F
model 0 NOUN F
HMO 0 NOUN T
practices 0 PROPN F
. 0 PUNCT F

INTERVENTIONS 0 NOUN T
Guideline 0 NOUN T
implementation 0 NOUN F
utilized 0 VERB F
an 0 DET F
education/audit/feedback 0 NOUN F
model 0 NOUN F
with 0 ADP F
local 0 ADJ F
peer 0 NOUN F
opinion 0 NOUN F
leaders 0 PROPN F
. 0 PUNCT F

The 0 DET T
patient 0 NOUN F
education 0 NOUN F
component 0 NOUN F
included 0 ADP F
written 0 PUNCT F
and 0 CCONJ F
videotaped 0 ADJ F
materials 0 NOUN F
on 0 ADP F
the 0 DET F
care 0 NOUN F
of 0 ADP F
low 0 ADJ F
back 0 ADP F
pain 0 NOUN F
. 0 PUNCT F

MAIN 0 ADJ T
RESULTS 0 NOUN T
The 0 DET T
clinician 0 NOUN F
intervention 0 NOUN F
was 0 VERB F
associated 0 VERB F
with 0 ADP F
an 0 DET F
absolute 0 ADJ F
increase 0 NOUN F
in 0 ADP F
guideline-consistent B-MENTAL ADJ F
behavior I-MENTAL NOUN F
of 0 ADP F
5.4 0 NUM F
% 0 SYM F
in 0 ADP F
the 0 DET F
intervention 0 NOUN F
group 0 NOUN F
versus 0 CCONJ F
a 0 DET F
decline 0 NOUN F
of 0 ADP F
2.7 0 NUM F
% 0 SYM F
in 0 ADP F
the 0 DET F
control 0 NOUN F
group 0 NOUN F
( 0 PUNCT F
P 0 NOUN T
=.04 0 PUNCT F
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
patient 0 NOUN F
education 0 NOUN F
intervention 0 NOUN F
produced 0 VERB F
no 0 DET F
significant 0 ADJ F
change 0 NOUN F
in 0 ADP F
guideline-consistent B-PHYSICAL ADJ F
behavior I-PHYSICAL NOUN F
, 0 PUNCT F
but 0 CCONJ F
was 0 VERB F
poorly 0 ADV F
adopted 0 VERB F
. 0 PUNCT F

Patient 0 ADJ T
characteristics 0 NOUN F
including 0 VERB F
duration B-PAIN NOUN F
of I-PAIN ADP F
pain I-PAIN NOUN F
, 0 PUNCT F
prior B-PAIN ADP F
history I-PAIN NOUN F
of I-PAIN ADP F
low I-PAIN ADJ F
back I-PAIN ADP F
pain I-PAIN NOUN F
, 0 PUNCT F
and 0 CCONJ F
number B-PAIN NOUN F
of I-PAIN ADP F
visits I-PAIN NOUN F
during 0 ADP F
the 0 DET F
illness 0 NOUN F
episode 0 NOUN F
were 0 VERB F
strong 0 ADJ F
predictors 0 NOUN F
of 0 ADP F
service 0 NOUN F
utilization 0 NOUN F
and 0 CCONJ F
guideline-consistent 0 ADJ F
behavior 0 NOUN F
. 0 PUNCT F

CONCLUSIONS 0 NOUN T
Implementation 0 NOUN T
of 0 ADP F
an 0 DET F
education 0 NOUN F
and 0 CCONJ F
feedback-supported 0 VERB F
acute 0 ADJ F
low 0 ADJ F
back 0 ADP F
pain 0 NOUN F
care 0 NOUN F
guideline 0 NOUN F
for 0 ADP F
primary 0 ADJ F
care 0 NOUN F
clinicians 0 NOUN F
was 0 VERB F
associated 0 VERB F
with 0 ADP F
an 0 DET F
increase 0 NOUN F
in 0 ADP F
guideline-consistent 0 ADJ F
behavior 0 NOUN F
. 0 PUNCT F

Patient 0 NOUN T
education 0 NOUN F
materials 0 NOUN F
did 0 CCONJ F
not 0 ADV F
enhance 0 ADJ F
guideline 0 NOUN F
effectiveness 0 NOUN F
. 0 PUNCT F

Implementation 0 NOUN T
barriers 0 NOUN F
could 0 ADJ F
limit 0 VERB F
the 0 DET F
utility 0 NOUN F
of 0 ADP F
this 0 DET F
approach 0 NOUN F
in 0 ADP F
usual 0 ADJ F
care 0 NOUN F
settings 0 NOUN F
. 0 PUNCT F

Effects 0 NOUN T
of 0 ADP F
alcohol 0 NOUN F
on 0 ADP F
the 0 DET F
pharmacokinetics B-OTHER NOUN F
of 0 ADP F
morphine 0 NOUN F
sulfate 0 NOUN F
and 0 CCONJ F
naltrexone 0 NUM F
hydrochloride 0 NOUN F
extended 0 VERB F
release 0 NOUN F
capsules 0 NOUN F
. 0 PUNCT F

Although 0 ADP T
contraindicated 0 VERB F
, 0 PUNCT F
coingestion 0 NOUN F
of 0 ADP F
alcohol 0 NOUN F
and 0 CCONJ F
opioids 0 NOUN F
by 0 ADP F
patients 0 NOUN F
or 0 CCONJ F
drug 0 NOUN F
abusers 0 NOUN F
is 0 VERB F
a 0 DET F
major 0 ADJ F
health 0 NOUN F
concern 0 NOUN F
because 0 PUNCT F
of 0 ADP F
dangerous 0 ADJ F
additive 0 ADJ F
and 0 CCONJ F
potentially 0 ADV F
life-threatening 0 VERB F
sedative 0 NOUN F
and 0 CCONJ F
respiratory 0 ADJ F
effects 0 NOUN F
. 0 PUNCT F

In 0 ADP T
addition 0 NOUN F
, 0 PUNCT F
alcohol 0 NOUN F
has 0 PUNCT F
been 0 PUNCT F
shown 0 VERB F
to 0 PART F
disrupt 0 NOUN F
the 0 DET F
extended-release 0 NOUN F
characteristics 0 NOUN F
of 0 ADP F
certain 0 ADJ F
extended-release 0 NOUN F
opioid 0 NOUN F
formulations 0 NOUN F
, 0 PUNCT F
releasing 0 VERB F
a 0 DET F
hazardous 0 ADJ F
amount 0 NOUN F
of 0 ADP F
opioid 0 NOUN F
over 0 ADP F
a 0 DET F
short 0 ADJ F
time 0 NOUN F
period 0 NOUN F
. 0 PUNCT F

Morphine 0 NOUN T
sulfate 0 NOUN F
and 0 CCONJ F
naltrexone 0 NUM F
hydrochloride 0 NOUN F
extended 0 VERB F
release 0 NOUN F
capsules 0 NOUN F
( 0 PUNCT F
MS-sNT 0 ADJ T
) 0 PUNCT F
, 0 PUNCT F
which 0 ADP F
contain 0 PART F
naltrexone 0 NUM F
sequestered 0 NOUN F
in 0 ADP F
each 0 DET F
pellet 0 NOUN F
core 0 NOUN F
, 0 PUNCT F
are 0 VERB F
indicated 0 VERB F
for 0 ADP F
management 0 NOUN F
of 0 ADP F
chronic 0 ADJ F
, 0 PUNCT F
moderate 0 ADJ F
to 0 ADP F
severe 0 ADJ F
pain 0 NOUN F
. 0 PUNCT F

Sequestered 0 VERB T
naltrexone 0 NUM F
is 0 VERB F
designed 0 VERB F
for 0 ADP F
release 0 NOUN F
upon 0 ADP F
product 0 NOUN F
tampering 0 PUNCT F
( 0 PUNCT F
crushing 0 PUNCT F
) 0 PUNCT F
to 0 ADP F
potentially 0 ADV F
mitigate 0 ADJ F
morphine-induced 0 DET F
subjective 0 ADJ F
effects 0 NOUN F
. 0 PUNCT F

This 0 DET T
open-label 0 NOUN F
, 0 PUNCT F
single-dose 0 NOUN F
, 0 PUNCT F
4-way 0 DET F
crossover 0 NOUN F
, 0 PUNCT F
pharmacokinetic 0 ADJ F
drug 0 NOUN F
interaction 0 NOUN F
study 0 NOUN F
compared 0 VERB F
the 0 DET F
relative B-OTHER ADJ F
bioavailability I-OTHER NOUN F
of 0 ADP F
morphine B-PHYSICAL NOUN F
and 0 CCONJ F
naltrexone B-PHYSICAL NUM F
when 0 ADP F
MS-sNT 0 ADJ T
is 0 NOUN F
administered 0 VERB F
( 0 PUNCT F
under 0 ADP F
fasting 0 VERB F
conditions 0 NOUN F
) 0 PUNCT F
with 0 ADP F
increasing 0 ADJ F
doses B-PHYSICAL NOUN F
of I-PHYSICAL ADP F
alcohol I-PHYSICAL NOUN F
. 0 PUNCT F

Thirty-two 0 NUM T
healthy 0 ADJ F
, 0 PUNCT F
opioid-naive 0 ADJ F
adults 0 NOUN F
were 0 VERB F
randomized 0 ADP F
to 0 PUNCT F
MS-sNT 0 ADJ T
administered 0 ADP F
with 0 ADP F
240 0 NUM F
mL 0 NOUN F
of 0 ADP F
4 0 NUM F
% 0 SYM F
, 0 PUNCT F
20 0 NUM F
% 0 SYM F
, 0 PUNCT F
or 0 CCONJ F
40 0 NUM F
% 0 SYM F
alcohol 0 NOUN F
or 0 CCONJ F
water 0 NOUN F
. 0 PUNCT F

No 0 DET T
drug B-PHYSICAL NOUN F
interaction I-PHYSICAL NOUN F
was 0 VERB F
found 0 VERB F
between 0 ADP F
morphine 0 NOUN F
in 0 ADP F
MS-sNT 0 ADJ T
and 0 CCONJ F
4 0 NUM F
% 0 SYM F
or 0 CCONJ F
20 0 NUM F
% 0 SYM F
alcohol 0 NOUN F
. 0 PUNCT F

Administration 0 NOUN T
with 0 ADP F
40 0 NUM F
% 0 SYM F
alcohol 0 NOUN F
did 0 VERB F
not 0 ADV F
affect 0 VERB F
overall B-OTHER ADJ F
morphine I-OTHER NOUN F
exposure I-OTHER NOUN F
but 0 CCONJ F
was 0 VERB F
associated 0 VERB F
with 0 ADP F
a 0 DET F
2-fold 0 NOUN F
increase 0 NOUN F
in 0 ADP F
C B-OTHER NOUN T
( I-OTHER PUNCT F
max I-OTHER NOUN F
) I-OTHER PUNCT F
and 0 CCONJ F
reduction 0 NOUN F
of 0 ADP F
t 0 NOUN F
( B-OTHER PUNCT F
max I-OTHER NOUN F
) I-OTHER PUNCT F
from 0 ADP F
9 0 NUM F
to 0 ADP F
4 0 NUM F
hours 0 NOUN F
versus 0 CCONJ F
MS-sNT 0 ADJ T
taken 0 ADJ F
with 0 ADP F
water 0 NOUN F
. 0 PUNCT F

Naltrexone B-OTHER NUM T
sequestering I-OTHER VERB F
was I-OTHER VERB F
successful I-OTHER ADJ F
in 0 ADP F
all 0 DET F
treatment 0 NOUN F
arms 0 NOUN F
and 0 CCONJ F
not 0 ADV F
affected 0 VERB F
by 0 ADP F
coadministration 0 NOUN F
with 0 ADP F
alcohol 0 NOUN F
over 0 ADP F
the 0 DET F
dose 0 NOUN F
range 0 NOUN F
tested 0 VERB F
. 0 PUNCT F

RCT 0 NOUN T
of 0 ADP F
a 0 DET F
manualized 0 VERB F
social 0 ADJ F
treatment 0 NOUN F
for 0 ADP F
high-functioning 0 PUNCT F
autism 0 NOUN F
spectrum 0 NOUN F
disorders 0 NOUN F
. 0 PUNCT F

This 0 DET T
RCT 0 NOUN T
examined 0 VERB F
the 0 DET F
efficacy 0 NOUN F
of 0 ADP F
a 0 DET F
manualized 0 VERB F
social 0 ADJ F
intervention 0 NOUN F
for 0 ADP F
children 0 NOUN F
with 0 ADP F
HFASDs 0 NOUN T
. 0 PUNCT F

Participants 0 NOUN T
were 0 VERB F
randomly 0 ADV F
assigned 0 VERB F
to 0 ADP F
treatment 0 NOUN F
or 0 CCONJ F
wait-list 0 NOUN F
conditions 0 NOUN F
. 0 PUNCT F

Treatment 0 NOUN T
included 0 VERB F
instruction 0 NOUN F
and 0 CCONJ F
therapeutic 0 ADJ F
activities 0 NOUN F
targeting 0 VERB F
social 0 ADJ F
skills 0 NOUN F
, 0 PUNCT F
face-emotion 0 NOUN F
recognition 0 NOUN F
, 0 PUNCT F
interest 0 NOUN F
expansion 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
interpretation 0 NOUN F
of 0 ADP F
non-literal 0 ADJ F
language 0 NOUN F
. 0 PUNCT F

A 0 DET T
response-cost 0 NOUN F
program 0 NOUN F
was 0 VERB F
applied 0 VERB F
to 0 PART F
reduce 0 NOUN F
problem 0 NOUN F
behaviors 0 NOUN F
and 0 CCONJ F
foster 0 NOUN F
skills 0 NOUN F
acquisition 0 NOUN F
. 0 PUNCT F

Significant 0 ADJ T
treatment 0 NOUN F
effects 0 NOUN F
were 0 VERB F
found 0 VERB F
for 0 ADP F
five 0 NUM F
of 0 ADP F
seven 0 NUM F
primary 0 ADJ F
outcome 0 NOUN F
measures 0 NOUN F
( 0 PUNCT F
parent B-MENTAL NOUN F
ratings I-MENTAL NOUN F
and 0 CCONJ F
direct 0 ADJ F
child 0 NOUN F
measures 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

Secondary 0 ADJ T
measures 0 NOUN F
based 0 VERB F
on 0 ADP F
staff B-OTHER NOUN F
ratings I-OTHER NOUN F
( 0 PUNCT F
treatment 0 NOUN F
group 0 NOUN F
only 0 ADV F
) 0 PUNCT F
corroborated 0 VERB F
gains 0 NOUN F
reported 0 VERB F
by 0 ADP F
parents 0 NOUN F
. 0 PUNCT F

High 0 ADJ T
levels 0 NOUN F
of 0 ADP F
parent B-OTHER NOUN F
, 0 PUNCT F
child B-OTHER NOUN F
and 0 CCONJ F
staff B-OTHER NOUN F
satisfaction I-OTHER NOUN F
were 0 VERB F
reported 0 VERB F
, 0 PUNCT F
along 0 PUNCT F
with 0 ADP F
high 0 ADJ F
levels 0 NOUN F
of 0 ADP F
treatment 0 NOUN F
fidelity B-MENTAL NOUN F
. 0 PUNCT F

Standardized 0 VERB T
effect 0 NOUN F
size 0 NOUN F
estimates 0 NOUN F
were 0 VERB F
primarily 0 ADV F
in 0 ADP F
the 0 DET F
medium 0 ADJ F
and 0 CCONJ F
large 0 ADJ F
ranges 0 PUNCT F
and 0 CCONJ F
favored 0 VERB F
the 0 DET F
treatment 0 NOUN F
group 0 NOUN F
. 0 PUNCT F

Primary 0 ADJ T
capsulectomy 0 NOUN F
, 0 PUNCT F
anterior 0 ADJ F
vitrectomy 0 NOUN F
, 0 PUNCT F
lensectomy 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
posterior 0 ADJ F
chamber 0 NOUN F
lens 0 NOUN F
implantation 0 NOUN F
in 0 ADP F
children 0 NOUN F
: 0 PUNCT F
limbal 0 ADJ F
versus 0 CCONJ F
pars 0 NOUN F
plana 0 NOUN F
. 0 PUNCT F

PURPOSE 0 NOUN T
To 0 ADJ T
compare 0 NOUN F
the 0 DET F
results 0 CCONJ F
of 0 ADP F
a 0 DET F
limbal 0 ADJ F
versus 0 CCONJ F
a 0 DET F
pars 0 NOUN F
plana 0 NOUN F
approach 0 NOUN F
for 0 ADP F
primary 0 ADJ F
posterior 0 ADJ F
capsulectomy 0 NOUN F
and 0 CCONJ F
anterior 0 ADJ F
vitrectomy 0 NOUN F
in 0 ADP F
the 0 DET F
management 0 NOUN F
of 0 ADP F
childhood B-PHYSICAL NOUN F
cataract I-PHYSICAL NOUN F
. 0 PUNCT F

SETTING 0 VERB T
Department 0 NOUN T
of 0 ADP F
Ophthalmology 0 NOUN T
, 0 PUNCT F
Labbafinejad 0 NOUN T
Medical 0 ADJ T
Center 0 NOUN T
, 0 PUNCT F
Tehran 0 NOUN T
, 0 PUNCT F
Iran 0 NOUN T
. 0 PUNCT F

METHODS 0 NOUN T
A 0 CCONJ T
randomized 0 VERB F
, 0 PUNCT F
controlled 0 PUNCT F
, 0 PUNCT F
double-masked 0 PROPN F
clinical 0 ADJ F
trial 0 NOUN F
of 0 ADP F
45 0 NUM F
eyes 0 NOUN F
was 0 VERB F
conducted 0 VERB F
. 0 PUNCT F

After 0 ADP T
being 0 VERB F
matched 0 PROPN F
, 0 PUNCT F
38 0 NUM F
eyes 0 NOUN F
were 0 VERB F
included 0 VERB F
in 0 ADP F
the 0 DET F
study 0 NOUN F
and 0 CCONJ F
were 0 VERB F
divided 0 VERB F
into 0 ADP F
2 0 NUM F
equal 0 ADJ F
groups 0 NOUN F
for 0 ADP F
data 0 NOUN F
analysis 0 NOUN F
. 0 PUNCT F

All 0 DET T
eyes 0 NOUN F
had 0 PUNCT F
lensectomy 0 NOUN F
and 0 CCONJ F
posterior 0 ADJ F
chamber 0 NOUN F
intraocular 0 ADJ F
lens 0 NOUN F
( 0 PUNCT F
PC 0 NOUN T
IOL 0 NUM T
) 0 PUNCT F
implantation 0 NOUN F
. 0 PUNCT F

Primary 0 ADJ T
posterior 0 ADJ F
capsulectomy 0 NOUN F
and 0 CCONJ F
anterior 0 ADJ F
vitrectomy 0 NOUN F
were 0 VERB F
performed 0 VERB F
through 0 ADP F
the 0 DET F
limbus 0 NOUN F
in 0 ADP F
half 0 NOUN F
of 0 ADP F
the 0 DET F
eyes 0 NOUN F
and 0 CCONJ F
the 0 DET F
pars 0 NOUN F
plana 0 NOUN F
in 0 ADP F
the 0 DET F
other 0 ADJ F
half 0 NOUN F
. 0 PUNCT F

Main 0 ADJ T
outcome 0 NOUN F
measures 0 NOUN F
included 0 VERB F
visual B-PHYSICAL ADJ F
acuity I-PHYSICAL NOUN F
, 0 PUNCT F
estimated 0 ADP F
red B-PHYSICAL ADJ F
reflex I-PHYSICAL NOUN F
, 0 PUNCT F
postsurgical B-PHYSICAL ADJ F
inflammatory I-PHYSICAL ADJ F
reaction I-PHYSICAL NOUN F
, 0 PUNCT F
corneal B-PHYSICAL ADJ F
clarity I-PHYSICAL NOUN F
, 0 PUNCT F
posterior B-PHYSICAL ADJ F
synechias I-PHYSICAL NOUN F
, 0 PUNCT F
iris B-PHYSICAL NOUN F
capture I-PHYSICAL NOUN F
, 0 PUNCT F
IOL B-PHYSICAL NUM T
position 0 NOUN F
, 0 PUNCT F
capsulectomy B-PHYSICAL NOUN F
size 0 NOUN F
, 0 PUNCT F
glaucoma B-PHYSICAL NOUN F
, 0 PUNCT F
cystoid B-PHYSICAL NOUN F
macular I-PHYSICAL ADJ F
edema I-PHYSICAL NOUN F
, 0 PUNCT F
retinal B-PHYSICAL ADJ F
tear 0 NOUN F
, 0 PUNCT F
and 0 PUNCT F

Training 0 PUNCT T
referential 0 ADP F
communicative 0 ADJ F
skills 0 NOUN F
to 0 ADP F
individuals 0 NOUN F
with 0 ADP F
autism 0 NOUN F
spectrum 0 NOUN F
disorder 0 NOUN F
: 0 PUNCT F
a 0 DET F
pilot 0 NOUN F
study 0 NOUN F
. 0 PUNCT F

The 0 DET T
present 0 ADJ F
study 0 NOUN F
reports 0 PUNCT F
the 0 DET F
effects 0 NOUN F
of 0 ADP F
referential 0 ADJ F
communication 0 NOUN F
training 0 VERB F
in 0 ADP F
individuals 0 NOUN F
formally 0 ADV F
diagnosed 0 VERB F
with 0 ADP F
autism 0 NOUN F
spectrum 0 NOUN F
disorder 0 NOUN F
( 0 PUNCT F
ASD 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

Participants 0 NOUN T
were 0 VERB F
20 0 NUM F
children 0 NOUN F
with 0 ADP F
ASD 0 NOUN T
( 0 PUNCT F
M 0 NOUN T
age 0 NOUN F
= 0 SYM F
14.3 0 NUM F
yr. 0 NOUN F
, 0 PUNCT F
SD 0 NOUN T
= 0 SYM F
4.2 0 NUM F
; 0 PUNCT F
6 0 NUM F
girls 0 NOUN F
, 0 PUNCT F
14 0 NUM F
boys 0 NOUN F
) 0 PUNCT F
in 0 ADP F
the 0 DET F
role 0 NOUN F
of 0 ADP F
speakers 0 NOUN F
and 0 CCONJ F
20 0 NUM F
control 0 NOUN F
children 0 NOUN F
, 0 PUNCT F
who 0 ADP F
acted 0 VERB F
as 0 PUNCT F
listeners 0 VERB F
. 0 PUNCT F

They 0 PRON T
were 0 VERB F
all 0 PUNCT F
enrolled 0 ADV F
in 0 ADP F
mainstream 0 NOUN F
compulsory 0 ADJ F
education 0 NOUN F
. 0 PUNCT F

Inclusion/exclusion 0 NOUN T
criteria 0 NOUN F
were 0 VERB F
defined 0 VERB F
according 0 ADP F
to 0 ADP F
the 0 DET F
clinical 0 ADJ F
diagnosis 0 NOUN F
of 0 ADP F
ASD 0 NOUN T
, 0 PUNCT F
the 0 DET F
presence 0 NOUN F
or 0 CCONJ F
absence 0 NOUN F
of 0 ADP F
additional 0 ADJ F
or 0 CCONJ F
associated 0 VERB F
disability 0 NOUN F
, 0 PUNCT F
previous 0 ADJ F
training 0 VERB F
in 0 ADP F
referential 0 ADJ F
communication 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
any 0 DET F
drug 0 NOUN F
treatment 0 NOUN F
. 0 PUNCT F

Speakers 0 NOUN T
were 0 VERB F
randomly 0 ADV F
assigned 0 VERB F
to 0 ADP F
one 0 PUNCT F
of 0 ADP F
two 0 NUM F
groups 0 NOUN F
( 0 PUNCT F
trained 0 PROPN F
vs 0 CCONJ F
untrained 0 ADP F
) 0 PUNCT F
. 0 PUNCT F

Linguistic B-PHYSICAL ADJ T
age 0 NOUN F
, 0 PUNCT F
cognitive 0 ADJ F
level 0 NOUN F
and 0 CCONJ F
autistic 0 ADJ F
symptoms 0 NOUN F
were 0 VERB F
analyzed 0 VERB F
, 0 PUNCT F
respectively 0 ADV F
, 0 PUNCT F
with 0 ADP F
the 0 DET F
Peabody 0 NOUN T
Picture 0 NOUN T
Vocabulary 0 PUNCT T
Test 0 NOUN T
( 0 PUNCT F
PPVT 0 NOUN T
) 0 PUNCT F
, 0 PUNCT F
the 0 DET F
Wechsler 0 ADP T
Intelligence 0 ADP T
Scale 0 NOUN T
( 0 PUNCT F
WISC-R 0 NOUN T
or 0 CCONJ F
WAIS-III 0 PUNCT T
) 0 PUNCT F
, 0 PUNCT F
and 0 CCONJ F
the 0 DET F
Autistic 0 ADJ T
Behavior 0 NOUN T
Checklist 0 NOUN T
( 0 PUNCT F
ABC 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

Communicative 0 ADJ T
abilities 0 NOUN F
were 0 VERB F
analyzed 0 VERB F
through 0 ADP F
two 0 NUM F
indexes 0 PUNCT F
related 0 VERB F
to 0 ADP F
message 0 NOUN F
complexity 0 NOUN F
and 0 CCONJ F
self-regulation 0 NOUN F
. 0 PUNCT F

The 0 DET T
trained 0 ADJ F
group 0 NOUN F
was 0 VERB F
trained 0 VERB F
in 0 ADP F
referential 0 ADJ F
communication 0 NOUN F
tasks 0 NOUN F
( 0 PUNCT F
task 0 NOUN F
analysis 0 NOUN F
, 0 PUNCT F
role 0 NOUN F
taking 0 PROPN F
, 0 PUNCT F
and 0 CCONJ F
task 0 NOUN F
evaluation 0 NOUN F
) 0 PUNCT F
, 0 PUNCT F
while 0 ADP F
the 0 DET F
untrained 0 ADJ F
group 0 NOUN F
took 0 PROPN F
part 0 NOUN F
in 0 ADP F
a 0 DET F
communicative 0 ADJ F
game 0 NOUN F
but 0 CCONJ F
without 0 ADP F
any 0 DET F
specific 0 ADJ F
communicative 0 ADJ F
training 0 VERB F
. 0 PUNCT F

The 0 DET T
results 0 NOUN F
showed 0 VERB F
that 0 ADP F
the 0 DET F
complexity 0 NOUN F
of 0 ADP F
emitted B-PHYSICAL PUNCT F
messages I-PHYSICAL NOUN F
had 0 ADP F
improved 0 PUNCT F
statistically 0 ADJ F
significantly 0 ADV F
in 0 ADP F
the 0 DET F
trained 0 ADJ F
group 0 NOUN F
as 0 ADP F
an 0 DET F
effect 0 NOUN F
of 0 ADP F
training 0 VERB F
. 0 PUNCT F

Ecological 0 ADJ T
referential 0 ADJ F
communication 0 NOUN F
is 0 VERB F
shown 0 VERB F
to 0 DET F
be 0 PUNCT F
an 0 DET F
appropriate 0 ADJ F
paradigm 0 NOUN F
for 0 ADP F
studying 0 VERB F
the 0 DET F
communicative 0 ADJ F
process 0 NOUN F
and 0 CCONJ F
its 0 ADJ F
products 0 NOUN F
and 0 CCONJ F
could 0 VERB F
be 0 VERB F
used 0 VERB F
to 0 PART F
develop 0 NOUN F
and 0 CCONJ F
implement 0 PUNCT F
a 0 DET F
training 0 DET F
program 0 NOUN F
focused 0 VERB F
on 0 ADP F
those 0 PUNCT F
skills 0 NOUN F
in 0 ADP F
which 0 DET F
individuals 0 NOUN F
with 0 ADP F
ASD 0 NOUN T
are 0 VERB F
most 0 DET F
deficient 0 ADJ F
. 0 PUNCT F

Antioxidant 0 NOUN T
supplementation 0 NOUN F
and 0 CCONJ F
exercise-induced 0 ADP F
oxidative 0 ADJ F
stress 0 NOUN F
in 0 ADP F
the 0 DET F
60-year-old 0 PUNCT F
as 0 VERB F
measured 0 PUNCT F
by 0 ADP F
antipyrine 0 ADP F
hydroxylates 0 NOUN F
. 0 PUNCT F

The 0 DET T
effects 0 NOUN F
of 0 ADP F
12 0 NUM F
weeks 0 NOUN F
of 0 ADP F
antioxidant 0 NOUN F
supplementation 0 NOUN F
on 0 ADP F
exercise-induced 0 ADP F
oxidative 0 ADJ F
stress 0 NOUN F
were 0 VERB F
investigated 0 VERB F
in 0 ADP F
older 0 PUNCT F
adults 0 NOUN F
( 0 PUNCT F
60 0 NUM F
( 0 PUNCT F
SE 0 NOUN T
1 0 NUM F
) 0 PUNCT F
years 0 NOUN F
; 0 PUNCT F
BMI 0 NOUN T
26 0 NUM F
( 0 PUNCT F
SE 0 NOUN T
1 0 NUM F
) 0 PUNCT F
kg/m 0 NUM F
( 0 PUNCT F
2 0 NUM F
) 0 PUNCT F
) 0 PUNCT F
. 0 PUNCT F

Subjects 0 NOUN T
were 0 VERB F
randomly 0 ADV F
divided 0 VERB F
in 0 ADP F
two 0 NUM F
groups 0 NOUN F
: 0 PUNCT F
supplementation 0 NOUN F
( 0 PUNCT F
n 0 NOUN F
11 0 NUM F
) 0 PUNCT F
with 0 ADP F
100 0 NUM F
mg 0 NOUN F
dl-alpha-tocopheryl 0 NOUN F
acetate 0 NOUN F
, 0 PUNCT F
200 0 NUM F
mg 0 NOUN F
ascorbic 0 ADJ F
acid 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
2 0 NUM F
mg 0 NOUN F
beta-carotene 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
placebo 0 NOUN F
( 0 PUNCT F
n 0 NOUN F
9 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Before 0 ADP T
and 0 CCONJ F
after 0 ADP F
the 0 DET F
12 0 NUM F
week 0 NOUN F
supplementation 0 NOUN F
period 0 NOUN F
, 0 PUNCT F
subjects 0 NOUN F
cycled 0 VERB F
for 0 ADP F
45 0 NUM F
min 0 NOUN F
at 0 ADP F
submaximal 0 ADJ F
intensity 0 NOUN F
( 0 PUNCT F
50 0 NUM F
% 0 SYM F
maximal 0 ADJ F
workload 0 ADJ F
capacity 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

Antipyrine 0 ADJ T
was 0 VERB F
used 0 VERB F
as 0 ADP F
marker 0 NOUN F
for 0 ADP F
oxidative 0 ADJ F
stress 0 NOUN F
. 0 PUNCT F

Antipyrine 0 ADJ T
reacts 0 PUNCT F
quickly 0 ADJ F
with 0 ADP F
hydroxyl 0 NOUN F
radicals 0 NOUN F
to 0 PUNCT F
form 0 ADP F
para- 0 PUNCT F
and 0 CCONJ F
ortho-hydroxyantipyrine 0 NOUN F
. 0 PUNCT F

The 0 DET T
latter 0 ADJ F
metabolite 0 NOUN F
is 0 VERB F
not 0 ADV F
formed 0 VERB F
in 0 ADP F
man 0 NOUN F
through 0 ADP F
the 0 DET F
mono-oxygenase 0 NOUN F
pathway 0 NOUN F
of 0 ADP F
cytochrome 0 NOUN F
P450 0 NOUN T
. 0 PUNCT F

Daily 0 VERB T
supplementation 0 NOUN F
significantly 0 ADV F
increased 0 ADV F
plasma B-PHYSICAL NOUN F
concentrations I-PHYSICAL NOUN F
of I-PHYSICAL ADP F
alpha-tocopherol I-PHYSICAL ADJ F
and I-PHYSICAL CCONJ F
beta-carotene I-PHYSICAL NOUN F
in 0 ADP F
the 0 DET F
supplemented 0 VERB F
group 0 NOUN F
( 0 PUNCT F
Delta 0 NOUN T
14.4 0 NUM F
( 0 PUNCT F
SE 0 NOUN T
3.2 0 NUM F
) 0 PUNCT F
and 0 CCONJ F
0.4 0 NUM F
( 0 PUNCT F
se 0 PUNCT F
0.1 0 NUM F
) 0 PUNCT F
micromol/l 0 NOUN F
; 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.001 0 NUM F
and 0 CCONJ F
P 0 NOUN T
< 0 SYM F
0.01 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

No 0 DET T
significant 0 ADJ F
differences 0 NOUN F
, 0 PUNCT F
within 0 ADP F
and 0 CCONJ F
between 0 DET F
groups 0 NOUN F
, 0 PUNCT F
were 0 VERB F
observed 0 VERB F
in 0 ADP F
the 0 DET F
exercise-induced B-PHYSICAL PUNCT F
increase 0 NOUN F
in B-PHYSICAL ADP F
the I-PHYSICAL DET F
ratios I-PHYSICAL NOUN F
para- I-PHYSICAL PUNCT F
and I-PHYSICAL CCONJ F
ortho-hydroxyantipyrine I-PHYSICAL NOUN F
to I-PHYSICAL ADP F
antipyrine B-PHYSICAL ADJ F
. 0 PUNCT F

In 0 ADP T
addition 0 NOUN F
, 0 PUNCT F
supplementation 0 NOUN F
did 0 PUNCT F
not 0 ADV F
affect 0 VERB F
the 0 DET F
exercise-induced B-PHYSICAL VERB F
increase 0 NOUN F
in B-PHYSICAL ADP F
thiobarbituric I-PHYSICAL ADJ F
acid I-PHYSICAL NOUN F
reactive I-PHYSICAL ADJ F
substances I-PHYSICAL NOUN F
in B-PHYSICAL ADP F
plasma I-PHYSICAL NOUN F
. 0 PUNCT F

In 0 ADP T
conclusion 0 NOUN F
, 0 PUNCT F
in 0 ADP F
60-year-old 0 PUNCT F
subjects 0 NOUN F
antioxidant 0 NOUN F
supplementation 0 NOUN F
had 0 PUNCT F

A 0 DET T
controlled 0 VERB F
study 0 NOUN F
of 0 ADP F
the 0 DET F
effect 0 NOUN F
of 0 ADP F
indomethacin 0 NOUN F
in 0 ADP F
uremic B-PHYSICAL ADJ F
pericarditis I-PHYSICAL NOUN F
. 0 PUNCT F

To 0 PART T
determine 0 NOUN F
the 0 DET F
impact 0 NOUN F
of 0 ADP F
indomethacin 0 NOUN F
on 0 ADP F
the 0 DET F
course 0 NOUN F
of 0 ADP F
uremic 0 ADJ F
pericarditis 0 NOUN F
we 0 PRON F
performed 0 VERB F
a 0 DET F
prospective 0 ADJ F
, 0 PUNCT F
double 0 ADJ F
blind 0 ADP F
study 0 NOUN F
in 0 ADP F
which 0 ADP F
24 0 NUM F
patients 0 NOUN F
with 0 ADP F
endstage 0 NOUN F
chronic 0 ADJ F
renal 0 ADJ F
failure 0 NOUN F
and 0 CCONJ F
pericarditis 0 NOUN F
randomly 0 ADV F
received 0 PUNCT F
indomethacin 0 NOUN F
, 0 PUNCT F
25 0 NUM F
mg 0 NOUN F
four 0 NUM F
times 0 NOUN F
daily 0 ADJ F
, 0 PUNCT F
( 0 PUNCT F
11 0 NUM F
patients 0 NOUN F
) 0 PUNCT F
or 0 CCONJ F
a 0 DET F
placebo 0 NOUN F
( 0 PUNCT F
13 0 NUM F
patients 0 NOUN F
) 0 PUNCT F
for 0 ADP F
a 0 DET F
3-week 0 NOUN F
period 0 NOUN F
. 0 PUNCT F

All 0 DET T
patients 0 NOUN F
received 0 VERB F
peritoneal 0 ADJ F
or 0 CCONJ F
hemodialysis 0 NOUN F
treatment 0 NOUN F
concurrently 0 ADV F
with 0 ADP F
the 0 DET F
study 0 ADP F
drug 0 NOUN F
. 0 PUNCT F

In 0 ADP T
contrast 0 NOUN F
to 0 ADP F
the 0 DET F
placebo 0 NOUN F
, 0 PUNCT F
indomethacin 0 NOUN F
produced 0 VERB F
an 0 DET F
immediate 0 ADJ F
and 0 CCONJ F
sustained 0 VERB F
reduction B-PHYSICAL NOUN F
of I-PHYSICAL ADP F
fever I-PHYSICAL NOUN F
in 0 ADP F
all 0 ADP F
but 0 CCONJ F
one 0 NUM F
patient 0 NOUN F
. 0 PUNCT F

On 0 ADP T
the 0 DET F
other 0 ADJ F
hand 0 NOUN F
, 0 PUNCT F
indomethacin 0 NOUN F
had 0 PUNCT F
no 0 DET F
effect 0 NOUN F
on 0 ADP F
the 0 DET F
duration 0 NOUN F
of 0 ADP F
chest B-PAIN NOUN F
pain I-PAIN NOUN F
( 0 PUNCT F
mean 0 NOUN F
days 0 NOUN F
+/- 0 SYM F
SE 0 NOUN T
: 0 PUNCT F
placebo 0 NOUN F
1.4 0 NUM F
+/- 0 SYM F
0.6 0 NUM F
, 0 PUNCT F
indomethacin 0 NOUN F
5.5 0 NUM F
+/- 0 SYM F
3.3 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
duration 0 NOUN F
of 0 ADP F
pericardial B-PHYSICAL ADJ F
friction I-PHYSICAL NOUN F
rub I-PHYSICAL NOUN F
( 0 PUNCT F
placebo 0 NOUN F
10.3 0 NUM F
+/- 0 SYM F
1.7 0 NUM F
, 0 PUNCT F
indomethacin 0 NOUN F
16.0 0 NUM F
+/- 0 SYM F
3.8 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
or 0 CCONJ F
on 0 ADP F
the 0 DET F
amount 0 NOUN F
of 0 ADP F
pericardial B-PHYSICAL ADJ F
effusion I-PHYSICAL NOUN F
. 0 PUNCT F

Further 0 ADV T
, 0 PUNCT F
indomethacin 0 NOUN F
did 0 VERB F
not 0 ADV F
diminish 0 VERB F
the 0 DET F
need 0 NOUN F
for 0 ADP F
invasive B-PHYSICAL ADJ F
surgical I-PHYSICAL ADJ F
procedures I-PHYSICAL NOUN F
for 0 ADP F
relief 0 NOUN F
of 0 ADP F
tamponade B-PHYSICAL NOUN F
( 0 PUNCT F
three 0 NUM F
of 0 ADP F
13 0 NUM F
placebo 0 NOUN F
patients 0 NOUN F
, 0 PUNCT F
two 0 NUM F
of 0 ADP F
11 0 NUM F
indomethacin 0 NOUN F
patients 0 NOUN F
) 0 PUNCT F
or 0 CCONJ F
result 0 NOUN F
in 0 ADP F
decreased 0 VERB F
mortality B-MORTALITY NOUN F
rate I-MORTALITY NOUN F
. 0 PUNCT F

Death B-MORTALITY NOUN T
( 0 PUNCT F
not 0 ADV F
due 0 PUNCT F
to 0 ADP F
pericarditis 0 NOUN F
) 0 PUNCT F
occurred 0 VERB F
in 0 ADP F
two 0 NUM F
patients 0 NOUN F
treated 0 VERB F
with 0 ADP F
indomethacin 0 NOUN F
and 0 CCONJ F
one 0 NUM F
patient 0 NOUN F
who 0 ADP F
received 0 VERB F
the 0 DET F
placebo 0 NOUN F
. 0 PUNCT F

In 0 ADP T
our 0 PUNCT F
patients 0 ADJ F
pericarditis 0 NOUN F
encompassed 0 VERB F
a 0 DET F
wide 0 ADJ F
spectrum 0 NOUN F
ranging 0 ADJ F
from 0 ADP F
a 0 DET F
mild B-PHYSICAL ADJ F
illness I-PHYSICAL NOUN F
of I-PHYSICAL ADP F
several I-PHYSICAL ADJ F
days B-PHYSICAL ADJ F
duration I-PHYSICAL NOUN F
to 0 ADP F
a 0 DET F
painful 0 ADP F
and 0 PUNCT F
debilitating B-PHYSICAL PUNCT F

Clinic 0 PUNCT T
visit 0 NOUN F
and 0 CCONJ F
waiting 0 PUNCT F
: 0 PUNCT F
patient B-MENTAL NOUN F
education I-MENTAL NOUN F
and 0 CCONJ F
satisfaction B-OTHER NOUN F
. 0 PUNCT F

Patients 0 NOUN T
who 0 PROPN F
were 0 VERB F
taught 0 ADV F
about 0 ADP F
their 0 PUNCT F
health 0 NOUN F
problems 0 NOUN F
while 0 ADP F
waiting 0 VERB F
in 0 ADP F
the 0 DET F
clinic 0 NOUN F
( 0 PUNCT F
n 0 NOUN F
= 0 SYM F
104 0 NUM F
) 0 PUNCT F
were 0 VERB F
significantly 0 ADV F
more 0 ADV F
satisfied B-OTHER VERB F
with I-OTHER ADP F
the I-OTHER DET F
education I-OTHER NOUN F
received 0 PRON F
during 0 ADP F
that 0 CCONJ F
visit 0 NOUN F
than 0 PUNCT F
the 0 DET F
control 0 NOUN F
group 0 NOUN F
( 0 PUNCT F
n 0 NOUN F
= 0 SYM F
101 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
longer 0 PUNCT F
patients 0 NOUN F
waited 0 VERB F
in 0 ADP F
the 0 DET F
clinic 0 NOUN F
to 0 PART F
see 0 NOUN F
their 0 ADP F
providers 0 NOUN F
, 0 PUNCT F
the 0 DET F
less 0 DET F
satisfied B-OTHER ADP F
they 0 PUNCT F
were 0 SYM F
with 0 ADP F
the 0 DET F
clinic 0 PUNCT F
visit 0 NOUN F
. 0 PUNCT F

Longterm B-OTHER NOUN T
safety I-OTHER NOUN F
, 0 PUNCT F
efficacy 0 NOUN F
, 0 PUNCT F
and 0 PUNCT F

The 0 DET T
dud 0 PUNCT F
effect 0 NOUN F
: 0 PUNCT F
adding 0 VERB F
highly 0 NUM F
dissimilar 0 ADJ F
fillers 0 PUNCT F
increases 0 PUNCT F
confidence 0 NOUN F
in 0 ADP F
lineup 0 NOUN F
identifications 0 NOUN F
. 0 PUNCT F

Recent 0 ADJ T
research 0 NOUN F
in 0 ADP F
decision-making 0 VERB F
has 0 PUNCT F
demonstrated 0 VERB F
the 0 DET F
dud-alternative 0 PUNCT F
effect 0 NOUN F
-- 0 PUNCT F
the 0 DET F
tendency 0 NOUN F
to 0 ADP F
become 0 ADJ F
more 0 DET F
confident 0 VERB F
that 0 PUNCT F
a 0 DET F
chosen 0 ADP F
response 0 NOUN F
option 0 NOUN F
is 0 VERB F
correct 0 ADJ F
if 0 PUNCT F
it 0 PRON F
is 0 VERB F
surrounded 0 VERB F
by 0 ADP F
implausible 0 ADJ F
response 0 NOUN F
options 0 NOUN F
( 0 PUNCT F
Windschitl 0 PUNCT T
& 0 CCONJ F
Chambers 0 PROPN T
, 0 PUNCT F
J 0 NOUN T
Exp 0 NOUN T
Psychol 0 NOUN T
30:198-215 0 NOUN F
, 0 PUNCT F
2004 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

This 0 DET T
finding 0 VERB F
may 0 VERB F
be 0 NOUN F
applicable 0 ADJ F
to 0 ADP F
a 0 DET F
lineup 0 NOUN F
task 0 NOUN F
: 0 PUNCT F
The 0 DET T
presence 0 NOUN F
of 0 ADP F
duds 0 NOUN F
( 0 PUNCT F
i.e. 0 CCONJ F
, 0 PUNCT F
highly 0 ADV F
dissimilar 0 ADJ F
fillers 0 ADP F
) 0 PUNCT F
may 0 ADJ F
increase 0 VERB F
a 0 DET F
witness B-MENTAL PUNCT F
's 0 PUNCT F
confidence B-MENTAL NOUN F
that 0 CCONJ F
an 0 DET F
identified 0 PUNCT F
( 0 PUNCT F
non-dud 0 PUNCT F
) 0 PUNCT F
lineup 0 NOUN F
member 0 NOUN F
is 0 VERB F
the 0 DET F
criminal 0 ADJ F
. 0 PUNCT F

Four 0 NUM T
studies 0 NOUN F
( 0 PUNCT F
N 0 NOUN T
= 0 SYM F
665 0 NUM F
) 0 PUNCT F
demonstrate 0 VERB F
that 0 ADP F
the 0 DET F
mere 0 ADJ F
presence 0 NOUN F
of 0 ADP F
highly 0 ADV F
dissimilar 0 ADJ F
fillers 0 PUNCT F
inflates 0 DET F
witnesses B-OTHER NOUN F
' 0 PUNCT F
confidence B-OTHER NOUN F
in 0 ADP F
a 0 DET F
mistaken 0 PUNCT F
identification 0 NOUN F
( 0 PUNCT F
Studies 0 NOUN T
1-4 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
provides 0 NOUN F
evidence 0 NOUN F
that 0 ADP F
this 0 PUNCT F

Effect 0 NOUN T
of 0 ADP F
food 0 NOUN F
on 0 ADP F
the 0 DET F
antiviral B-OTHER ADJ F
activity I-OTHER NOUN F
of 0 ADP F
didanosine 0 NOUN F
enteric-coated 0 VERB F
capsules 0 NOUN F
: 0 PUNCT F
a 0 DET F
pilot 0 NOUN F
comparative 0 ADJ F
study 0 NOUN F
. 0 PUNCT F

OBJECTIVES 0 ADP T
To 0 PROPN T
determine 0 NOUN F
the 0 DET F
effect 0 NOUN F
of 0 ADP F
food 0 NOUN F
on 0 ADP F
the 0 DET F
antiviral 0 ADJ F
activity 0 NOUN F
of 0 ADP F
enteric-coated 0 VERB F
( 0 PUNCT F
EC 0 NOUN T
) 0 PUNCT F
capsules 0 NOUN F
of 0 ADP F
didanosine 0 NOUN F
( 0 PUNCT F
ddI 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

METHODS 0 NOUN T
We 0 PRON T
conducted 0 VERB F
a 0 DET F
pilot 0 NOUN F
, 0 PUNCT F
randomized 0 VERB F
, 0 PUNCT F
open-label 0 NOUN F
study 0 NOUN F
of 0 ADP F
28-day 0 NOUN F
ddI-EC 0 NOUN F
capsules 0 NOUN F
monotherapy-administered 0 PUNCT F
in 0 ADP F
a 0 DET F
fasted 0 VERB F
state 0 NOUN F
( 0 PUNCT F
group 0 NOUN F
1 0 NUM F
, 0 PUNCT F
n=11 0 NOUN F
) 0 PUNCT F
or 0 CCONJ F
with 0 ADP F
food 0 NOUN F
( 0 PUNCT F
group 0 NOUN F
2 0 NUM F
, 0 PUNCT F
n=10 0 ADV F
) 0 PUNCT F
to 0 ADP F
treatment-na?ve 0 NOUN F
chronically 0 ADV F
HIV-1-infected 0 VERB T
individuals 0 NOUN F
. 0 PUNCT F

To 0 PART T
assess 0 NOUN F
the 0 DET F
antiviral 0 ADJ F
efficacy 0 NOUN F
, 0 PUNCT F
HIV-1 0 NOUN T
RNA 0 NOUN T
was 0 VERB F
determined 0 VERB F
at 0 ADP F
baseline 0 NOUN F
, 0 PUNCT F
day 0 NOUN F
3 0 NUM F
, 0 PUNCT F
day 0 NOUN F
7 0 NUM F
and 0 CCONJ F
weekly 0 ADV F
thereafter 0 ADV F
. 0 PUNCT F

The 0 DET T
area 0 NOUN F
under 0 ADP F
the 0 DET F
HIV-1 0 NOUN T
RNA 0 NOUN T
curve 0 NOUN F
minus 0 NOUN F
baseline 0 NOUN F
weighted 0 VERB F
by 0 ADP F
time 0 NOUN F
( 0 PUNCT F
AUCMB/day 0 NOUN T
) 0 PUNCT F
was 0 VERB F
calculated 0 VERB F
. 0 PUNCT F

RESULTS 0 NOUN T
Mean 0 VERB T
baseline 0 NOUN F
HIV-1 0 NOUN T
RNA 0 NOUN T
was 0 VERB F
4.2 0 NUM F
log 0 NOUN F
( 0 PUNCT F
10 0 NUM F
) 0 PUNCT F
copies/mL 0 NOUN F
in 0 ADP F
group 0 NOUN F
1 0 NUM F
and 0 CCONJ F
3.8 0 NUM F
log 0 NOUN F
( 0 PUNCT F
10 0 NUM F
) 0 PUNCT F
copies/mL 0 NOUN F
in 0 ADP F
group 0 NOUN F
2 0 NUM F
. 0 PUNCT F

After 0 ADP T
28 0 NUM F
days 0 NOUN F
, 0 PUNCT F
the 0 DET F
mean 0 NOUN F
HIV-1 0 NOUN T
RNA 0 NOUN T
reduction 0 NOUN F
was 0 VERB F
0.99 0 NUM F
log 0 NOUN F
( 0 PUNCT F
10 0 NUM F
) 0 PUNCT F
copies/mL 0 NOUN F
[ 0 PUNCT F
95 0 NUM F
% 0 SYM F
confidence 0 NOUN F
interval 0 NOUN F
( 0 PUNCT F
CI 0 NOUN T
) 0 PUNCT F
0.45-1.53 0 NUM F
] 0 PUNCT F
for 0 ADP F
group 0 NOUN F
1 0 NUM F
and 0 CCONJ F
0.89 0 NUM F
log 0 NOUN F
( 0 PUNCT F
10 0 NUM F
) 0 PUNCT F
copies/mL 0 NOUN F
( 0 PUNCT F
95 0 NUM F
% 0 SYM F
CI 0 NOUN T
0.38-1.40 0 NUM F
) 0 PUNCT F
for 0 ADP F
group 0 NOUN F
2 0 NUM F
. 0 PUNCT F

AUCMB/day 0 NOUN T
values 0 NOUN F
were 0 VERB F
0.775 0 NUM F
log 0 NOUN F
( 0 PUNCT F
10 0 NUM F
) 0 PUNCT F
copies/mL 0 NOUN F
( 0 PUNCT F
95 0 NUM F
% 0 SYM F
CI 0 NOUN T
0.33-1.22 0 NUM F
) 0 PUNCT F
and 0 CCONJ F
0.774 0 ADP F
log 0 NOUN F
( 0 PUNCT F
10 0 NUM F
) 0 PUNCT F
copies/mL 0 NOUN F
( 0 PUNCT F
95 0 NUM F
% 0 SYM F
CI 0 NOUN T
0.48-1.07 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
respectively 0 ADV F
, 0 PUNCT F
showing 0 VERB F
no 0 DET F
difference 0 NOUN F
in 0 ADP F
the 0 DET F
rate 0 NOUN F
of 0 ADP F
decrease 0 NOUN F
of 0 ADP F
HIV-1 0 NOUN T
RNA 0 NOUN T
( 0 PUNCT F
P=0.995 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

Mean 0 ADJ T
ddI 0 NOUN F
plasma 0 NOUN F
levels 0 NOUN F
at 0 ADP F
day 0 NOUN F
28 0 NUM F
were 0 VERB F
0.0234 0 NUM F
mg/L 0 NOUN F
for 0 ADP F
group 0 NOUN F
1 0 NUM F
and 0 CCONJ F
0.0227 0 NUM F
mg/L 0 NOUN F
for 0 ADP F
group 0 NOUN F
2 0 NUM F
( 0 PUNCT F
P=0.96 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

CONCLUSIONS 0 NOUN T
In 0 ADP T
this 0 PUNCT F
pilot 0 NOUN F
study 0 NOUN F
, 0 PUNCT F
the 0 DET F
administration 0 NOUN F
of 0 ADP F
food 0 NOUN F
did 0 PUNCT F
not 0 ADV F
have 0 PUNCT F
any 0 DET F
significant 0 ADJ F
effect 0 NOUN F
on 0 ADP F
the 0 DET F
antiviral 0 ADJ F
activity 0 NOUN F
of 0 ADP F
ddI-EC 0 NOUN F
capsules 0 NOUN F
. 0 PUNCT F

Overexpression 0 NOUN T
of 0 ADP F
vascular 0 ADJ F
endothelial 0 ADJ F
growth 0 NOUN F
factor 0 NOUN F
( 0 PUNCT F
VEGF 0 NOUN T
) 0 PUNCT F
and 0 CCONJ F
its 0 ADP F
cellular 0 ADJ F
receptor 0 NOUN F
KDR 0 NOUN T
( 0 PUNCT F
VEGFR-2 0 NOUN T
) 0 PUNCT F
in 0 ADP F
the 0 DET F
bone 0 NOUN F
marrow 0 NOUN F
of 0 ADP F
patients 0 NOUN F
with 0 ADP F
acute 0 ADJ F
myeloid 0 NOUN F
leukemia 0 NOUN F
. 0 PUNCT F

Vascular 0 ADJ T
endothelial 0 ADJ F
growth 0 NOUN F
factor 0 NOUN F
( 0 PUNCT F
VEGF 0 NOUN T
) 0 PUNCT F
and 0 CCONJ F
its 0 ADP F
cellular 0 ADJ F
receptor 0 NOUN F
VEGFR-2 0 NOUN T
have 0 PUNCT F
been 0 PUNCT F
implicated 0 VERB F
as 0 ADP F
the 0 DET F
main 0 ADJ F
endothelial 0 ADJ F
pathway 0 NOUN F
required 0 VERB F
for 0 ADP F
tumor 0 NOUN F
neovascularization 0 NOUN F
. 0 PUNCT F

However 0 ADV T
, 0 PUNCT F
the 0 DET F
importance 0 NOUN F
of 0 ADP F
the 0 DET F
VEGF/VEGFR-2 0 NOUN T
system 0 NOUN F
for 0 ADP F
angiogenesis 0 NOUN F
in 0 ADP F
hematologic 0 ADJ F
malignancies 0 NOUN F
such 0 CCONJ F
as 0 ADP F
AML 0 NOUN T
remains 0 NOUN F
to 0 PART F
be 0 PUNCT F
elucidated 0 VERB F
. 0 PUNCT F

In 0 ADP T
32 0 NUM F
patients 0 NOUN F
with 0 ADP F
newly 0 ADJ F
diagnosed 0 ADV F
untreated 0 VERB F
AML 0 NOUN T
, 0 PUNCT F
we 0 PRON F
observed 0 VERB F
by 0 ADP F
immunohistochemical 0 ADJ F
analysis 0 NOUN F
of 0 ADP F
bone 0 NOUN F
marrow 0 NOUN F
biopsies 0 NOUN F
significantly 0 ADV F
higher 0 PUNCT F
levels 0 NOUN F
of 0 ADP F
VEGF 0 NOUN T
and 0 CCONJ F
VEGFR-2 0 NOUN T
expression 0 NOUN F
than 0 PUNCT F
in 0 ADP F
10 0 NUM F
control 0 NOUN F
patients 0 NOUN F
( 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.001 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

In 0 ADP T
contrast 0 NOUN F
, 0 PUNCT F
VEGFR-1 0 NOUN T
staining 0 VERB F
levels 0 NOUN F
in 0 ADP F
AML 0 NOUN T
patients 0 NOUN F
were 0 VERB F
in 0 ADP F
the 0 DET F
same 0 ADJ F
range 0 NOUN F
as 0 PUNCT F
in 0 ADP F
the 0 DET F
controls 0 NOUN F
. 0 PUNCT F

Expression 0 NOUN T
of 0 ADP F
VEGF B-PHYSICAL NOUN T
and 0 CCONJ F
VEGFR-2 B-PHYSICAL NOUN T
was 0 VERB F
significantly 0 ADV F
higher 0 PUNCT F
in 0 ADP F
patients 0 NOUN F
with 0 ADP F
a 0 DET F
high 0 ADJ F
degree 0 NOUN F
of 0 ADP F
microvessel 0 NOUN F
density 0 NOUN F
compared 0 VERB F
to 0 ADP F
those 0 PUNCT F
with 0 ADP F
a 0 DET F
low 0 ADJ F
degree 0 NOUN F
( 0 PUNCT F
VEGF 0 NOUN T
: 0 PUNCT F
P 0 NOUN T
=0.024 0 PUNCT F
; 0 PUNCT F
VEGFR-2 0 NOUN T
: 0 PUNCT F
P 0 NOUN T
=0.040 0 PUNCT F
) 0 PUNCT F
and 0 CCONJ F
correlated 0 VERB F
well 0 VERB F
with 0 CCONJ F
bone 0 NOUN F
marrow 0 NOUN F
microvessel 0 NOUN F
density 0 NOUN F
( 0 PUNCT F
r 0 NOUN F
( 0 PUNCT F
s 0 NOUN F
) 0 PUNCT F
=0.566 0 PUNCT F
and 0 CCONJ F
0.609 0 ADP F
, 0 PUNCT F
respectively 0 ADV F
; 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.001 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Furthermore 0 ADV T
, 0 PUNCT F
in 0 ADP F
patients 0 NOUN F
who 0 ADP F
achieved 0 ADJ F
a 0 DET F
complete 0 ADJ F
remission B-PHYSICAL NOUN F
following 0 VERB F
induction 0 NOUN F
chemotherapy 0 NOUN F
VEGFR-2 B-PHYSICAL NOUN T
staining I-PHYSICAL PUNCT F
levels I-PHYSICAL NOUN F
decreased 0 VERB F
into 0 ADP F
the 0 DET F
normal 0 ADJ F
range 0 NOUN F
. 0 PUNCT F

In 0 ADP T
conclusion 0 NOUN F
, 0 PUNCT F
our 0 PUNCT F
results 0 NOUN F
provide 0 VERB F
evidence 0 NOUN F
for 0 ADP F
increased 0 VERB F
expression 0 NOUN F
of 0 ADP F
VEGF/VEGFR-2 0 PUNCT T
of 0 ADP F
leukemic B-PHYSICAL ADP F
blasts I-PHYSICAL ADP F
and 0 CCONJ F
correlation 0 NOUN F
with 0 ADP F
angiogenesis 0 NOUN F
in 0 ADP F
the 0 DET F
bone 0 NOUN F
marrow 0 NOUN F
of 0 ADP F
AML 0 NOUN T
patients 0 NOUN F
. 0 PUNCT F

Thus 0 ADV T
, 0 PUNCT F
VEGF/VEGFR-2 0 NOUN T
might 0 PUNCT F
constitute 0 VERB F
promising 0 VERB F
targets 0 NOUN F
for 0 ADP F
antiangiogenic 0 ADJ F
and 0 CCONJ F
antileukemic 0 ADJ F
treatment 0 NOUN F
strategies 0 NOUN F
in 0 ADP F
AML 0 NOUN T
. 0 PUNCT F

Gene 0 NOUN T
expression 0 NOUN F
of 0 ADP F
endothelin-1 0 NOUN F
and 0 CCONJ F
its 0 ADJ F
receptors 0 NOUN F
in 0 ADP F
the 0 DET F
heart 0 NOUN F
of 0 ADP F
broiler 0 NOUN F
chickens 0 NOUN F
with 0 ADP F
T 0 NOUN T
( 0 PUNCT F
3 0 NUM F
) 0 PUNCT F
-induced 0 VERB F
pulmonary 0 ADJ F
hypertension 0 NOUN F
. 0 PUNCT F

To 0 PART T
investigate 0 NOUN F
the 0 DET F
effect 0 NOUN F
of 0 ADP F
T 0 NOUN T
( 0 PUNCT F
3 0 NUM F
) 0 PUNCT F
-induced 0 VERB F
pulmonary 0 ADJ F
hypertension 0 NOUN F
on 0 ADP F
endothelin 0 NOUN F
( 0 PUNCT F
ET 0 NOUN T
) 0 PUNCT F
production 0 NOUN F
and 0 CCONJ F
genes B-PHYSICAL NOUN F
expression I-PHYSICAL NOUN F
of I-PHYSICAL ADP F
ET-1 I-PHYSICAL NOUN T
, 0 PUNCT F
ET B-PHYSICAL NOUN T
( 0 PUNCT F
A B-PHYSICAL NOUN T
) 0 PUNCT F
and B-PHYSICAL CCONJ F
ET I-PHYSICAL NOUN T
( 0 PUNCT F
B B-PHYSICAL NOUN T
) 0 PUNCT F
receptors B-PHYSICAL NOUN F
( 0 PUNCT F
ET B-PHYSICAL NOUN T
( 0 PUNCT F
A B-PHYSICAL NOUN T
) 0 PUNCT F
R 0 NOUN T
and B-PHYSICAL CCONJ F
ET I-PHYSICAL NOUN T
( 0 PUNCT F
B B-PHYSICAL NOUN T
) 0 PUNCT F
R 0 NOUN T
) 0 PUNCT F
during 0 ADP F
rearing 0 DET F
, 0 PUNCT F
semiquantitative 0 ADJ F
RT-PCR 0 NOUN T
and 0 CCONJ F
enzyme 0 NOUN F
immunometric 0 ADJ F
assay 0 NOUN F
were 0 VERB F
performed 0 VERB F
in 0 ADP F
the 0 DET F
heart 0 NOUN F
ventricles 0 NOUN F
and 0 CCONJ F
serum 0 NOUN F
, 0 PUNCT F
respectively 0 ADV F
. 0 PUNCT F

The 0 DET T
ET-1 B-PHYSICAL NOUN T
and I-PHYSICAL CCONJ F
its I-PHYSICAL ADJ F
receptor I-PHYSICAL NOUN F
genes I-PHYSICAL NOUN F
were 0 VERB F
expressed 0 VERB F
in 0 ADP F
the 0 DET F
right 0 ADJ F
and 0 CCONJ F
left 0 ADJ F
ventricles 0 NOUN F
of 0 ADP F
control 0 NOUN F
and 0 CCONJ F
T 0 NOUN T
( 0 PUNCT F
3 0 NUM F
) 0 PUNCT F
-treated 0 DET F
broilers 0 NOUN F
at 0 ADP F
12 0 NUM F
, 0 PUNCT F
28 0 NUM F
and 0 CCONJ F
49 0 NUM F
days 0 NOUN F
of 0 ADP F
age 0 NOUN F
. 0 PUNCT F

There 0 PUNCT T
were 0 VERB F
significant 0 ADJ F
( 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.05 0 NUM F
) 0 PUNCT F
reductions 0 NOUN F
of B-PHYSICAL ADP F
the I-PHYSICAL DET F
relative I-PHYSICAL ADJ F
amounts I-PHYSICAL NOUN F
of I-PHYSICAL ADP F
ET-1 I-PHYSICAL NOUN T
( I-PHYSICAL PUNCT F
in I-PHYSICAL ADP F
both B-PHYSICAL PUNCT F
ventricles B-PHYSICAL NOUN F
) I-PHYSICAL PUNCT F
and I-PHYSICAL CCONJ F
ET I-PHYSICAL NOUN T
( I-PHYSICAL PUNCT F
A I-PHYSICAL NOUN T
) I-PHYSICAL PUNCT F
R 0 PUNCT T

[ 0 PUNCT F
Postoperative 0 PUNCT T
analgesia 0 NOUN F
: 0 PUNCT F
peridural 0 ADJ F
morphine 0 NOUN F
versus 0 CCONJ F
sublingual 0 ADJ F
buprenorphine 0 ADJ F
. 0 PUNCT F

Comparative 0 ADJ T
clinical 0 ADJ F
study 0 NOUN F
] 0 PUNCT F
. 0 PUNCT F

The 0 DET T
authors 0 NOUN F
herein 0 ADV F
present 0 ADJ F
their 0 PUNCT F
personal 0 ADJ F
series 0 NOUN F
on 0 ADP F
the 0 DET F
clinical 0 ADJ F
evaluation 0 NOUN F
of 0 ADP F
the 0 DET F
analgesic 0 ADP F
efficacy 0 NOUN F
of 0 ADP F
2 0 NUM F
opiodes 0 PUNCT F
, 0 PUNCT F
peridural 0 ADJ F
morphine 0 NOUN F
hydrochloride 0 NOUN F
( 0 PUNCT F
0.5 0 NUM F
mg/kg 0 NOUN F
) 0 PUNCT F
administered 0 VERB F
to 0 ADV F
group 0 NOUN F
A 0 DET T
patients 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
sublingual 0 ADJ F
buprenorphine 0 ADJ F
( 0 PUNCT F
0.4 0 NUM F
mg 0 NOUN F
) 0 PUNCT F
administered 0 VERB F
to 0 ADP F
group 0 NOUN F
B 0 NOUN T
patients 0 NOUN F
in 0 ADP F
the 0 DET F
management 0 NOUN F
of 0 ADP F
post-operative 0 ADJ F
pain 0 NOUN F
in 0 ADP F
major 0 ADJ F
abdominal 0 ADJ F
surgery 0 NOUN F
. 0 PUNCT F

The 0 DET T
study 0 NOUN F
was 0 VERB F
conducted 0 VERB F
on 0 ADP F
44 0 NUM F
patients 0 NOUN F
, 0 PUNCT F
both 0 CCONJ F
male 0 NOUN F
and 0 CCONJ F
female 0 NOUN F
, 0 PUNCT F
classified 0 PUNCT F
as 0 ADP F
ASA 0 NOUN T
II 0 NUM T
and 0 CCONJ F
III 0 NUM T
. 0 PUNCT F

Statistical 0 ADJ T
analysis 0 NOUN F
of 0 ADP F
cardiovascular B-PHYSICAL ADJ F
parameters I-PHYSICAL NOUN F
( I-PHYSICAL PUNCT F
BP I-PHYSICAL NOUN T
and 0 CCONJ F
cardiac B-PHYSICAL ADJ F
frequency 0 NOUN F
) B-PHYSICAL PUNCT F
, 0 PUNCT F
respiratory B-PHYSICAL ADJ F
frequency I-PHYSICAL NOUN F
and 0 CCONJ F
pain B-PAIN NOUN F
score I-PAIN NOUN F
showed 0 VERB F
an 0 DET F
overlapping 0 VERB F
progression 0 NOUN F
among 0 ADP F
the 0 DET F
two 0 NUM F
groups 0 NOUN F
. 0 PUNCT F

Triple 0 ADJ T
antiretroviral 0 ADP F
compared 0 PUNCT F
with 0 DET F
zidovudine 0 NOUN F
and 0 CCONJ F
single-dose 0 NOUN F
nevirapine 0 NOUN F
prophylaxis 0 NOUN F
during 0 ADP F
pregnancy 0 NOUN F
and 0 CCONJ F
breastfeeding 0 DET F
for 0 ADP F
prevention 0 NOUN F
of 0 ADP F
mother-to-child 0 PUNCT F
transmission 0 NOUN F
of 0 ADP F
HIV-1 0 NOUN T
( 0 PUNCT F
Kesho 0 NOUN T
Bora 0 NOUN T
study 0 NOUN F
) 0 PUNCT F
: 0 PUNCT F
a 0 DET F
randomised 0 VERB F
controlled 0 VERB F
trial 0 NOUN F
. 0 PUNCT F

BACKGROUND 0 NOUN T
Breastfeeding 0 PUNCT T
is 0 VERB F
essential 0 ADJ F
for 0 ADP F
child 0 NOUN F
health 0 NOUN F
and 0 CCONJ F
development 0 NOUN F
in 0 ADP F
low-resource 0 NOUN F
settings 0 NOUN F
but 0 CCONJ F
carries 0 DET F
a 0 DET F
significant 0 ADJ F
risk 0 NOUN F
of 0 ADP F
transmission 0 NOUN F
of 0 ADP F
HIV-1 0 NOUN T
, 0 PUNCT F
especially 0 ADV F
in 0 ADP F
late 0 ADJ F
stages 0 NOUN F
of 0 ADP F
maternal 0 ADJ F
disease 0 NOUN F
. 0 PUNCT F

We 0 PRON T
aimed 0 VERB F
to 0 PART F
assess 0 NOUN F
the 0 DET F
efficacy 0 NOUN F
and 0 CCONJ F
safety B-OTHER NOUN F
of 0 ADP F
triple 0 ADJ F
antiretroviral 0 ADP F
compared 0 PUNCT F
with 0 DET F
zidovudine 0 NOUN F
and 0 CCONJ F
single-dose 0 NOUN F
nevirapine 0 NOUN F
prophylaxis 0 NOUN F
in 0 ADP F
pregnant 0 ADJ F
women 0 NOUN F
infected 0 VERB F
with 0 ADP F
HIV 0 NOUN T
. 0 PUNCT F

METHODS 0 NOUN T
Pregnant 0 ADJ T
women 0 NOUN F
with 0 ADP F
WHO 0 NOUN T
stage 0 PUNCT F
1 0 NUM F
, 0 PUNCT F
2 0 NUM F
, 0 PUNCT F
or 0 CCONJ F
3 0 NUM F
HIV-1 0 NOUN T
infection 0 NOUN F
who 0 ADP F
had 0 PUNCT F
CD4 0 NOUN T
cell 0 NOUN F
counts 0 NOUN F
of 0 ADP F
200-500 0 NUM F
cells 0 NOUN F
per 0 PUNCT F
?L 0 PUNCT F
were 0 PUNCT F
enrolled 0 VERB F
at 0 ADP F
five 0 NUM F
study 0 ADV F
sites 0 NOUN F
in 0 ADP F
Burkina 0 NOUN T
Faso 0 NOUN T
, 0 PUNCT F
Kenya 0 PUNCT T
, 0 PUNCT F
and 0 CCONJ F
South 0 NOUN T
Africa 0 PUNCT T
to 0 ADJ F
start 0 PUNCT F
study 0 NOUN F
treatment 0 NOUN F
at 0 ADP F
28-36 0 NUM F
weeks 0 NOUN F
' 0 PUNCT F
gestation 0 NOUN F
. 0 PUNCT F

Women 0 NOUN T
were 0 VERB F
randomly 0 ADV F
assigned 0 VERB F
( 0 PUNCT F
1:1 0 NUM F
) 0 PUNCT F
by 0 ADP F
a 0 DET F
computer 0 NOUN F
generated 0 VERB F
random 0 ADJ F
sequence 0 NOUN F
to 0 ADP F
either 0 CCONJ F
triple 0 ADJ F
antiretroviral 0 ADJ F
prophylaxis 0 NOUN F
( 0 PUNCT F
a 0 DET F
combination 0 NOUN F
of 0 ADP F
300 0 NUM F
mg 0 NOUN F
zidovudine 0 NOUN F
, 0 PUNCT F
150 0 NUM F
mg 0 NOUN F
lamivudine 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
400 0 NUM F
mg 0 NOUN F
lopinavir 0 NOUN F
plus 0 CCONJ F
100 0 NUM F
mg 0 NOUN F
ritonavir 0 NOUN F
twice 0 ADV F
daily 0 ADJ F
until 0 ADP F
cessation 0 NOUN F
of 0 ADP F
breastfeeding 0 ADJ F
to 0 ADP F
a 0 DET F
maximum 0 NOUN F
of 0 ADP F
6?5 0 ADJ F
months 0 NOUN F
post 0 PUNCT F
partum 0 NOUN F
) 0 PUNCT F
or 0 CCONJ F
zidovudine 0 NOUN F
and 0 CCONJ F
single-dose 0 NOUN F
nevirapine 0 NOUN F
( 0 PUNCT F
300 0 NUM F
mg 0 NOUN F
zidovudine 0 NOUN F
twice 0 PUNCT F
daily 0 ADJ F
until 0 ADP F
delivery 0 NOUN F
and 0 CCONJ F
a 0 DET F
dose 0 NOUN F
of 0 ADP F
600 0 NUM F
mg 0 NOUN F
zidovudine 0 NOUN F
plus 0 CCONJ F
200 0 NUM F
mg 0 NOUN F
nevirapine 0 NOUN F
at 0 ADP F
the 0 DET F
onset 0 NOUN F
of 0 ADP F
labour 0 NOUN F
and 0 CCONJ F
, 0 PUNCT F
after 0 ADP F
a 0 DET F
protocol 0 NOUN F
amendment 0 ADJ F
in 0 ADP F
December 0 NOUN T
, 0 PUNCT F
2006 0 NUM F
, 0 PUNCT F
1 0 NUM F
week 0 NOUN F
post-partum 0 NOUN F
zidovudine 0 NOUN F
300 0 NUM F
mg 0 NOUN F
twice 0 ADV F
daily 0 VERB F
and 0 CCONJ F
lamivudine 0 NOUN F
150 0 NUM F
mg 0 NOUN F
twice 0 ADV F
daily 0 ADP F
) 0 PUNCT F
. 0 PUNCT F

All 0 DET T
infants 0 NOUN F
received 0 VERB F
a 0 DET F
0?6 0 PUNCT F
mL 0 NOUN F
dose 0 NOUN F
of 0 ADP F
nevirapine 0 NOUN F
at 0 ADP F
birth 0 NOUN F
and 0 CCONJ F
, 0 PUNCT F
from 0 ADP F
December 0 NOUN T
, 0 PUNCT F
2006 0 NUM F
, 0 PUNCT F
4 0 NUM F
mg/kg 0 NOUN F
twice 0 ADV F
daily 0 ADJ F
of 0 DET F
zidovudine 0 NOUN F
for 0 ADP F
1 0 NUM F
week 0 NOUN F
after 0 ADP F
birth 0 NOUN F
. 0 PUNCT F

Patients 0 NOUN T
and 0 CCONJ F
investigators 0 NOUN F
were 0 VERB F
not 0 ADV F
masked 0 VERB F
to 0 ADP F
treatment 0 NOUN F
. 0 PUNCT F

The 0 DET T
primary 0 ADJ F
endpoints 0 NOUN F
were 0 VERB F
HIV-free 0 ADJ T
infant 0 NOUN F
survival 0 NOUN F
at 0 ADP F
6 0 NUM F
weeks 0 NOUN F
and 0 CCONJ F
12 0 NUM F
months 0 NOUN F
; 0 PUNCT F
HIV-free 0 ADJ T
survival 0 NOUN F
at 0 ADP F
12 0 NUM F
months 0 NOUN F
in 0 ADP F
infants 0 NOUN F
who 0 ADP F
were 0 VERB F
ever 0 ADV F
breastfed 0 ADV F
; 0 PUNCT F
AIDS-free 0 PUNCT T
survival 0 NOUN F
in 0 ADP F
mothers 0 NOUN F
at 0 ADP F
18 0 NUM F
months 0 NOUN F
; 0 PUNCT F
and 0 CCONJ F
serious 0 ADJ F
adverse 0 ADJ F
events 0 NOUN F
in 0 ADP F
mothers 0 NOUN F
and 0 CCONJ F
babies 0 NOUN F
. 0 PUNCT F

Analysis 0 NOUN T
was 0 VERB F
by 0 ADP F
intention 0 NOUN F
to 0 PART F
treat 0 ADV F
. 0 PUNCT F

This 0 DET T
trial 0 NOUN F
is 0 VERB F
registered 0 PUNCT F
with 0 ADP F
Current 0 ADJ T
Controlled 0 VERB T
Trials 0 NOUN T
, 0 PUNCT F
ISRCTN71468401 0 NOUN T
. 0 PUNCT F

FINDINGS 0 NOUN T
From 0 ADP T
June 0 NOUN T
, 0 PUNCT F
2005 0 NUM F
, 0 PUNCT F
to 0 ADP F
August 0 NOUN T
, 0 PUNCT F
2008 0 NUM F
, 0 PUNCT F
882 0 NUM F
women 0 NOUN F
were 0 VERB F
enrolled 0 VERB F
, 0 PUNCT F
824 0 NUM F
of 0 ADP F
whom 0 ADP F
were 0 VERB F
randomised 0 NUM F
and 0 CCONJ F
gave 0 PROPN F
birth 0 NOUN F
to 0 ADP F
805 0 NUM F
singleton 0 NOUN F
or 0 CCONJ F
first 0 ADP F
, 0 PUNCT F
liveborn 0 NOUN F
infants 0 NOUN F
. 0 PUNCT F

The 0 DET T
cumulative 0 ADJ F
rate 0 NOUN F
of 0 ADP F
HIV 0 NOUN T
transmission 0 NOUN F
at 0 ADP F
6 0 NUM F
weeks 0 NOUN F
was 0 PUNCT F
3?3 0 PUNCT F
% 0 SYM F
( 0 PUNCT F
95 0 NUM F
% 0 SYM F
CI 0 NOUN T
1?9-5?6 0 NOUN F
% 0 ADV F
) 0 PUNCT F
in 0 ADP F
the 0 DET F
triple 0 ADJ F
antiretroviral 0 ADJ F
group 0 NOUN F
compared 0 VERB F
with 0 ADP F
5?0 0 NOUN F
% 0 SYM F
( 0 PUNCT F
3?3-7?7 0 NOUN F
% 0 SYM F
) 0 PUNCT F
in 0 ADP F
the 0 DET F
zidovudine 0 NOUN F
and 0 CCONJ F
single-dose 0 NOUN F
nevirapine 0 NOUN F
group 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
at 0 ADP F
12 0 NUM F
months 0 NOUN F
was 0 VERB F
5?4 0 PUNCT F
% 0 SYM F
( 0 PUNCT F
3?6-8?1 0 NOUN F
% 0 SYM F
) 0 PUNCT F
in 0 ADP F
the 0 DET F
triple 0 ADJ F
antiretroviral 0 ADJ F
group 0 NOUN F
compared 0 VERB F
with 0 PUNCT F
9?5 0 PUNCT F
% 0 SYM F
( 0 PUNCT F
7?0-12?9 0 NOUN F
% 0 SYM F
) 0 PUNCT F
in 0 ADP F
the 0 DET F
zidovudine 0 NOUN F
and 0 CCONJ F
single-dose 0 NOUN F
nevirapine 0 NOUN F
group 0 NOUN F
( 0 PUNCT F
p=0?029 0 ADV F
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
cumulative 0 ADJ F
rate 0 NOUN F
of 0 ADP F
HIV 0 NOUN T
transmission 0 NOUN F
or 0 CCONJ F
death 0 NOUN F
at 0 ADP F
12 0 NUM F
months 0 NOUN F
was 0 VERB F
10?2 0 NUM F
% 0 SYM F
( 0 PUNCT F
95 0 NUM F
% 0 SYM F
CI 0 NOUN T
7?6-13?6 0 NOUN F
% 0 SYM F
) 0 PUNCT F
in 0 ADP F
the 0 DET F
triple 0 ADJ F
antiretroviral 0 ADJ F
group 0 NOUN F
compared 0 VERB F
with 0 ADP F
16?0 0 NOUN F
% 0 VERB F
( 0 PUNCT F
12?7-20?0 0 PUNCT F
% 0 SYM F
) 0 PUNCT F
in 0 ADP F
the 0 DET F
zidovudine 0 NOUN F
and 0 CCONJ F
single-dose 0 NOUN F
nevirapine 0 NOUN F
group 0 NOUN F
( 0 PUNCT F
p=0?017 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

In 0 ADP T
infants 0 NOUN F
whose 0 DET F
mothers 0 NOUN F
declared 0 ADP F
they 0 PUNCT F
intended 0 PUNCT F
to 0 ADP F
breastfeed 0 PUNCT F
, 0 PUNCT F
the 0 DET F
cumulative 0 ADJ F
rate 0 NOUN F
of 0 ADP F
HIV 0 NOUN T
transmission 0 NOUN F
at 0 ADP F
12 0 NUM F
months 0 NOUN F
was 0 VERB F
5?6 0 PUNCT F
% 0 SYM F
( 0 PUNCT F
95 0 NUM F
% 0 SYM F
CI 0 NOUN T
3?4-8?9 0 NOUN F
% 0 SYM F
) 0 PUNCT F
in 0 ADP F
the 0 DET F
triple 0 ADJ F
antiretroviral 0 ADJ F
group 0 NOUN F
compared 0 VERB F
with 0 ADP F
10?7 0 PUNCT F
% 0 SYM F
( 0 PUNCT F
7?6-14?8 0 ADV F
% 0 SYM F
) 0 PUNCT F
in 0 ADP F
the 0 DET F
zidovudine 0 NOUN F
and 0 CCONJ F
single-dose 0 NOUN F
nevirapine 0 NOUN F
group 0 NOUN F
( 0 PUNCT F
p=0?02 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

AIDS-free 0 ADJ T
survival 0 NOUN F
in 0 ADP F
mothers 0 NOUN F
at 0 ADP F
18 0 NUM F
months 0 NOUN F
will 0 VERB F
be 0 VERB F
reported 0 VERB F
in 0 ADP F
a 0 DET F
different 0 ADJ F
publication 0 NOUN F
. 0 PUNCT F

The 0 DET T
incidence 0 NOUN F
of 0 ADP F
laboratory 0 NOUN F
and 0 CCONJ F
clinical 0 ADJ F
serious 0 ADJ F
adverse 0 ADJ F
events 0 NOUN F
in 0 ADP F
both 0 CCONJ F
mothers 0 NOUN F
and 0 CCONJ F
their 0 ADJ F
babies 0 NOUN F
was 0 VERB F
similar 0 ADJ F
between 0 ADP F
groups 0 NOUN F
. 0 PUNCT F

INTERPRETATION 0 NOUN T
Triple 0 ADJ T
antiretroviral 0 ADP F
prophylaxis 0 NOUN F
during 0 ADP F
pregnancy 0 NOUN F
and 0 CCONJ F
breastfeeding 0 PUNCT F
is 0 VERB F
safe 0 ADJ F
and 0 CCONJ F
reduces 0 NOUN F
the 0 DET F
risk 0 NOUN F
of 0 ADP F
HIV 0 NOUN T
transmission 0 NOUN F
to 0 ADP F
infants 0 NOUN F
. 0 PUNCT F

Revised 0 VERB T
WHO 0 NOUN T
guidelines 0 NOUN F
now 0 ADV F
recommend 0 VERB F
antiretroviral 0 ADP F
prophylaxis 0 NOUN F
( 0 PUNCT F
either 0 PUNCT F
to 0 ADP F
the 0 DET F
mother 0 NOUN F
or 0 CCONJ F
to 0 ADP F
the 0 DET F
baby 0 NOUN F
) 0 PUNCT F
during 0 ADP F
breastfeeding 0 PUNCT F
if 0 PUNCT F
the 0 DET F
mother 0 NOUN F
is 0 VERB F
not 0 ADV F
already 0 ADV F
receiving 0 SYM F
antiretroviral 0 PUNCT F
treatment 0 NOUN F
for 0 ADP F
her 0 PUNCT F
own 0 ADJ F
health 0 NOUN F
. 0 PUNCT F

FUNDING 0 PUNCT T
Agence 0 ADP T
nationale 0 NOUN F
de 0 ADP F
recherches 0 NOUN F
sur 0 NOUN F
le 0 ADP F
sida 0 PUNCT F
et 0 CCONJ F
les 0 DET F
h?patites 0 PUNCT F
virales 0 ADP F
, 0 PUNCT F
Department 0 NOUN T
for 0 ADP F
International 0 ADJ T
Development 0 NOUN T
, 0 PUNCT F
European 0 ADJ T
and 0 CCONJ F
Developing 0 PROPN T
Countries 0 NOUN T
Clinical 0 ADJ T
Trials 0 NOUN T
Partnership 0 NOUN T
, 0 PUNCT F
Thrasher 0 NOUN T
Research 0 NOUN T
Fund 0 NOUN T
, 0 PUNCT F
Belgian 0 PUNCT T
Directorate 0 NOUN T
General 0 NOUN T
for 0 ADP F
International 0 ADJ T
Cooperation 0 NOUN T
, 0 PUNCT F
Centers 0 NOUN T
for 0 ADP F
Disease 0 NOUN T
Control 0 NOUN T
and 0 CCONJ F
Prevention 0 NOUN T
, 0 PUNCT F
Eunice 0 NOUN T
Kennedy 0 NOUN T
Shriver 0 NOUN T
National 0 ADJ T
Institute 0 NOUN T
of 0 ADP F
Child 0 NOUN T
Health 0 NOUN T
and 0 CCONJ F
Human 0 NOUN T
Development 0 NOUN T
, 0 PUNCT F
and 0 CCONJ F
UNDP/UNFPA/World 0 NOUN T
Bank/WHO 0 NOUN T
Special 0 ADJ T
Programme 0 NOUN T
of 0 ADP F
Research 0 NOUN T
, 0 PUNCT F
Development 0 NOUN T
and 0 CCONJ F
Research 0 NOUN T
Training 0 PROPN T
in 0 ADP F
Human 0 NOUN T
Reproduction 0 NOUN T
. 0 PUNCT F

Effects 0 NOUN T
of 0 ADP F
a 0 DET F
common 0 ADJ F
variant 0 NOUN F
in 0 ADP F
the 0 DET F
CD38 0 NOUN T
gene 0 NOUN F
on 0 ADP F
social B-MENTAL ADJ F
processing I-MENTAL VERB F
in 0 ADP F
an 0 DET F
oxytocin 0 NOUN F
challenge 0 NOUN F
study 0 NOUN F
: 0 PUNCT F
possible 0 ADJ F
links 0 ADJ F
to 0 ADP F
autism 0 NOUN F
. 0 PUNCT F

The 0 DET T
intranasal 0 ADJ F
application 0 NOUN F
of 0 ADP F
oxytocin 0 NOUN F
( 0 PUNCT F
OT 0 NOUN T
) 0 PUNCT F
has 0 PUNCT F
been 0 PUNCT F
shown 0 VERB F
to 0 ADJ F
influence 0 ADJ F
behavioral B-MENTAL ADJ F
and 0 CCONJ F
neural B-MENTAL ADJ F
correlates I-MENTAL PUNCT F
of I-MENTAL ADP F
social I-MENTAL ADJ F
processing I-MENTAL VERB F
. 0 PUNCT F

These 0 DET T
effects 0 NOUN F
are 0 VERB F
probably 0 ADV F
mediated 0 VERB F
by 0 ADP F
genetic 0 ADJ F
variations 0 NOUN F
within 0 ADP F
the 0 DET F
OT 0 NOUN T
system 0 NOUN F
. 0 PUNCT F

One 0 NUM T
potential 0 ADJ F
candidate 0 NOUN F
could 0 VERB F
be 0 ADJ F
the 0 DET F
CD38 0 NOUN T
gene 0 NOUN F
, 0 PUNCT F
which 0 DET F
codes 0 DET F
for 0 ADP F
a 0 DET F
transmembrane 0 ADJ F
protein 0 NOUN F
engaged 0 VERB F
in 0 ADP F
OT 0 NOUN T
secretion 0 NOUN F
processes 0 NOUN F
. 0 PUNCT F

A 0 CCONJ T
common 0 ADJ F
variation 0 NOUN F
in 0 ADP F
this 0 DET F
gene 0 NOUN F
( 0 PUNCT F
rs3796863 0 PUNCT F
) 0 PUNCT F
was 0 ADJ F
recently 0 ADV F
found 0 VERB F
to 0 PART F
be 0 PUNCT F
associated 0 VERB F
with 0 ADP F
autism 0 NOUN F
spectrum 0 NOUN F
disorders 0 NOUN F
( 0 PUNCT F
ASD 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

Using 0 VERB T
an 0 DET F
imaging 0 VERB F
genetics 0 NOUN F
approach 0 NOUN F
, 0 PUNCT F
we 0 PRON F
studied 0 VERB F
differential 0 ADJ F
effects 0 NOUN F
of 0 ADP F
an 0 DET F
intranasal 0 ADJ F
OT 0 NOUN T
application 0 NOUN F
on 0 ADP F
neural B-MENTAL ADJ F
processing I-MENTAL VERB F
of I-MENTAL ADP F
social I-MENTAL ADJ F
stimuli I-MENTAL NOUN F
in 0 ADP F
55 0 NUM F
healthy 0 ADJ F
young 0 ADJ F
men 0 NOUN F
depending 0 VERB F
on 0 ADP F
their 0 PUNCT F
CD38 0 NOUN T
gene 0 NOUN F
variant 0 NOUN F
in 0 ADP F
a 0 DET F
double-blind 0 ADJ F
placebo-controlled 0 VERB F
crossover 0 NOUN F
design 0 NOUN F
. 0 PUNCT F

Genotype 0 NOUN T
had 0 PUNCT F
a 0 DET F
significant 0 ADJ F
influence 0 NOUN F
on 0 ADP F
both 0 CCONJ F
behavioral B-MENTAL ADJ F
and 0 CCONJ F
neuronal B-MENTAL ADJ F
measures I-MENTAL NOUN F
of I-MENTAL ADP F
social I-MENTAL ADJ F
processing I-MENTAL VERB F
. 0 PUNCT F

Homozygotic 0 ADJ T
risk 0 NOUN F
allele 0 NOUN F
carriers 0 NOUN F
showed 0 VERB F
slower 0 PUNCT F
reaction 0 NOUN F
times 0 NOUN F
( 0 PUNCT F
RT 0 NOUN T
) 0 PUNCT F
and 0 CCONJ F
higher 0 PUNCT F
activation 0 NOUN F
of 0 ADP F
left B-MENTAL ADJ F
fusiform I-MENTAL NOUN F
gyrus I-MENTAL NOUN F
during 0 ADP F
visual 0 ADJ F
processing 0 VERB F
of 0 ADP F
social B-MENTAL ADJ F
stimuli I-MENTAL NOUN F
. 0 PUNCT F

Under 0 ADP T
OT 0 NOUN T
activation B-MENTAL NOUN F
differences I-MENTAL NOUN F
between 0 ADP F
genotypes 0 NOUN F
were 0 VERB F
more 0 ADV F
evident 0 ADJ F
( 0 PUNCT F
though 0 CCONJ F
not 0 ADV F
statistically 0 ADJ F
significantly 0 ADV F
increased 0 ADP F
) 0 PUNCT F
and 0 CCONJ F
RT 0 NOUN T
were 0 VERB F
accelerated 0 VERB F
in 0 ADP F
homozygotic 0 ADJ F
risk 0 NOUN F
allele 0 NOUN F
carriers 0 NOUN F
. 0 PUNCT F

According 0 PUNCT T
to 0 ADP F
our 0 DET F
data 0 NOUN F
, 0 PUNCT F
rs3796863 B-MENTAL PUNCT F
mainly I-MENTAL PUNCT F
influences I-MENTAL PUNCT F
fusiform I-MENTAL NOUN F
gyrus I-MENTAL NOUN F
activation I-MENTAL NOUN F
, 0 PUNCT F
an 0 DET F
area 0 NOUN F
which 0 ADP F
has 0 PUNCT F
been 0 PUNCT F
widely 0 ADV F
discussed 0 VERB F
in 0 ADP F
ASD 0 NOUN T
research 0 NOUN F
. 0 PUNCT F

OT 0 NOUN T
seems 0 NOUN F
to 0 PART F
modulate 0 NOUN F
this 0 DET F
effect 0 NOUN F
by 0 ADP F
enhancing 0 ADP F
activation B-MENTAL NOUN F
differences I-MENTAL NOUN F
between 0 ADP F
allele 0 NOUN F
groups 0 NOUN F
, 0 PUNCT F
which 0 ADP F
suggests 0 VERB F
an 0 DET F
interaction 0 NOUN F
between 0 ADP F
genetic B-PHYSICAL ADJ F
makeup I-PHYSICAL NOUN F
and 0 CCONJ F
OT B-PHYSICAL NOUN T
availability I-PHYSICAL NOUN F
on 0 ADP F
fusiform B-MENTAL NOUN F
gyrus I-MENTAL NOUN F
activation I-MENTAL NOUN F
. 0 PUNCT F

These 0 DET T
results 0 NOUN F
support 0 VERB F
recent 0 ADJ F
approaches 0 NOUN F
to 0 PART F
apply 0 CCONJ F
OT 0 NOUN T
as 0 ADP F
a 0 DET F
pharmacological 0 ADJ F
treatment 0 NOUN F
of 0 ADP F
ASD 0 NOUN T
symptoms 0 NOUN F
. 0 PUNCT F

Pharmacokinetic-pharmacodynamic B-OTHER ADJ T
modelling I-OTHER ADJ F
of 0 ADP F
the 0 DET F
antihistaminic 0 ADJ F
( 0 PUNCT F
H1 0 NOUN T
) 0 PUNCT F
effect 0 NOUN F
of 0 ADP F
bilastine 0 NOUN F
. 0 PUNCT F

OBJECTIVE 0 NOUN T
To 0 PUNCT T
model 0 NOUN F
the 0 DET F
pharmacokinetic B-PHYSICAL ADJ F
and 0 CCONJ F
pharmacodynamic B-PHYSICAL ADJ F
relationship 0 NOUN F
of 0 ADP F
bilastine 0 NOUN F
, 0 PUNCT F
a 0 DET F
new 0 ADJ F
histamine 0 NOUN F
H 0 NOUN T
( 0 PUNCT F
1 0 NUM F
) 0 PUNCT F
receptor 0 NOUN F
antagonist 0 NOUN F
, 0 PUNCT F
from 0 ADP F
single- 0 CCONJ F
and 0 CCONJ F
multiple-dose 0 PUNCT F
studies 0 NOUN F
in 0 ADP F
healthy 0 ADJ F
adult 0 NOUN F
subjects 0 NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
The 0 DET T
pharmacokinetic 0 ADJ F
model 0 NOUN F
was 0 VERB F
developed 0 VERB F
from 0 ADP F
different 0 ADJ F
single-dose 0 NOUN F
and 0 CCONJ F
multiple-dose 0 PUNCT F
studies 0 NOUN F
. 0 PUNCT F

In 0 ADP T
the 0 DET F
single-dose 0 NOUN F
studies 0 NOUN F
, 0 PUNCT F
a 0 DET F
total 0 NOUN F
of 0 ADP F
183 0 NUM F
subjects 0 NOUN F
received 0 VERB F
oral 0 ADJ F
doses 0 NOUN F
of 0 ADP F
bilastine 0 ADJ F
2.5 0 NUM F
, 0 PUNCT F
5 0 NUM F
, 0 PUNCT F
10 0 NUM F
, 0 PUNCT F
20 0 NUM F
, 0 PUNCT F
50 0 NUM F
, 0 PUNCT F
100 0 NUM F
, 0 PUNCT F
120 0 NUM F
, 0 PUNCT F
160 0 NUM F
, 0 PUNCT F
200 0 NUM F
and 0 CCONJ F
220 0 NUM F
mg 0 NOUN F
. 0 PUNCT F

In 0 ADP T
the 0 DET F
multiple-dose 0 PUNCT F
studies 0 NOUN F
, 0 PUNCT F
127 0 NUM F
healthy 0 ADJ F
subjects 0 NOUN F
received 0 ADV F
bilastine 0 NOUN F
10 0 NUM F
, 0 PUNCT F
20 0 NUM F
, 0 PUNCT F
40 0 NUM F
, 0 PUNCT F
50 0 NUM F
, 0 PUNCT F
80 0 NUM F
, 0 PUNCT F
100 0 NUM F
, 0 PUNCT F
140 0 NUM F
or 0 CCONJ F
200 0 NUM F
mg/day 0 PUNCT F
as 0 ADP F
multiple 0 ADJ F
doses 0 NOUN F
during 0 ADP F
a 0 DET F
4- 0 PUNCT F
, 0 PUNCT F
7- 0 NUM F
or 0 CCONJ F
14-day 0 NOUN F
period 0 NOUN F
. 0 PUNCT F

The 0 DET T
pharmacokinetic B-OTHER ADJ F
profile I-OTHER NOUN F
of 0 ADP F
bilastine 0 NOUN F
was 0 VERB F
investigated 0 VERB F
using 0 SYM F
a 0 DET F
simultaneous 0 ADJ F
analysis 0 NOUN F
of 0 ADP F
all 0 DET F
concentration-time B-OTHER NOUN F
data I-OTHER NOUN F
by 0 ADP F
means 0 NOUN F
of 0 ADP F
nonlinear 0 ADJ F
mixed-effects 0 VERB F
modelling 0 PUNCT F
population 0 NOUN F
pharmacokinetic 0 ADJ F
software 0 NOUN F
NONMEM 0 NOUN T
version 0 NOUN F
6.1 0 NUM F
. 0 PUNCT F

Plasma B-PHYSICAL NOUN T
concentrations I-PHYSICAL NOUN F
were 0 VERB F
modelled 0 VERB F
according 0 PUNCT F
to 0 ADP F
a 0 DET F
two-compartment 0 NOUN F
open 0 VERB F
model 0 NOUN F
with 0 ADP F
first-order 0 ADJ F
absorption 0 NOUN F
and 0 CCONJ F
elimination 0 NOUN F
. 0 PUNCT F

For 0 ADP T
the 0 DET F
pharmacodynamic 0 ADJ F
analysis 0 NOUN F
, 0 PUNCT F
the 0 DET F
inhibitory 0 ADJ F
effect 0 NOUN F
of 0 ADP F
bilastine 0 ADJ F
( 0 PUNCT F
inhibition 0 NOUN F
of 0 ADP F
histamine-induced 0 ADP F
wheal 0 ADJ F
and 0 CCONJ F
flare 0 NOUN F
) 0 PUNCT F
was 0 VERB F
assessed 0 VERB F
on 0 ADP F
a 0 DET F
preselected 0 VERB F
time 0 NOUN F
schedule 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
the 0 DET F
predicted 0 VERB F
typical B-OTHER ADJ F
pharmacokinetic I-OTHER ADJ F
profile I-OTHER NOUN F
( 0 PUNCT F
based 0 VERB F
on 0 ADP F
the 0 DET F
pharmacokinetic 0 ADJ F
model 0 NOUN F
previously 0 ADV F
developed 0 VERB F
) 0 PUNCT F
was 0 VERB F
used 0 VERB F
. 0 PUNCT F

An 0 DET T
indirect 0 ADJ F
response 0 NOUN F
model 0 NOUN F
was 0 VERB F
developed 0 VERB F
to 0 PART F
describe 0 VERB F
the 0 DET F
pharmacodynamic B-OTHER ADJ F
relationships I-OTHER NOUN F
between 0 ADP F
flare 0 NOUN F
or 0 CCONJ F
wheal 0 ADP F
areas 0 NOUN F
and 0 CCONJ F
bilastine 0 ADP F
plasma 0 NOUN F
concentrations 0 NOUN F
. 0 PUNCT F

Finally 0 ADV T
, 0 PUNCT F
once 0 PUNCT F
values 0 NOUN F
of 0 ADP F
the 0 DET F
concentration 0 NOUN F
that 0 ADP F
produced B-OTHER VERB F
50 I-OTHER NUM F
% I-OTHER SYM F
inhibition I-OTHER NOUN F
( 0 PUNCT F
IC B-OTHER NOUN T
( 0 PUNCT F
50 B-OTHER NUM F
) 0 PUNCT F
) 0 PUNCT F
had 0 PUNCT F
been 0 PUNCT F
estimated 0 VERB F
for 0 ADP F
wheal 0 ADP F
and 0 CCONJ F
flare 0 NOUN F
effects 0 NOUN F
, 0 PUNCT F
simulations 0 NOUN F
were 0 VERB F
carried 0 VERB F
out 0 ADP F
to 0 ADP F
predict 0 NOUN F
plasma B-PHYSICAL NOUN F
concentrations I-PHYSICAL NOUN F
for 0 ADP F
the 0 DET F
doses 0 NOUN F
of 0 ADP F
bilastine 0 ADJ F
5 0 NUM F
, 0 PUNCT F
10 0 NUM F
and 0 CCONJ F
20 0 NUM F
mg 0 NOUN F
at 0 ADP F
steady 0 ADJ F
state 0 NOUN F
( 0 PUNCT F
72-96 0 NUM F
hours 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

RESULTS 0 NOUN T
A 0 PUNCT T
non-compartmental 0 ADJ F
analysis 0 NOUN F
resulted 0 VERB F
in 0 ADP F
linear 0 ADJ F
kinetics 0 NOUN F
of 0 ADP F
bilastine 0 ADJ F
in 0 ADP F
the 0 DET F
dose 0 NOUN F
range 0 NOUN F
studied 0 VERB F
. 0 PUNCT F

Bilastine 0 NOUN T
was 0 VERB F
characterized 0 VERB F
by 0 ADP F
two-compartmental 0 ADP F
kinetics 0 NOUN F
with 0 ADP F
a 0 DET F
rapid-absorption 0 NOUN F
phase 0 NOUN F
( 0 PUNCT F
first-order 0 NOUN F
absorption 0 NOUN F
rate 0 NOUN F
constant 0 ADJ F
= 0 SYM F
1.50 0 NUM F
h 0 NOUN F
( 0 PUNCT F
-1 0 NUM F
) 0 PUNCT F
) 0 PUNCT F
, 0 PUNCT F
plasma B-PHYSICAL NOUN F
peak 0 ADJ F
concentrations B-PHYSICAL NOUN F
were 0 VERB F
observed 0 VERB F
at 0 ADP F
1 0 NUM F
hour 0 NOUN F
following 0 VERB F
administration 0 NOUN F
and 0 CCONJ F
the 0 DET F
maximal B-OTHER ADJ F
response I-OTHER NOUN F
was 0 VERB F
observed 0 VERB F
at 0 ADP F
approximately 0 ADV F
4 0 NUM F
hours 0 NOUN F
or 0 CCONJ F
later 0 PUNCT F
. 0 PUNCT F

Concerning 0 PROPN T
the 0 DET F
selected 0 VERB F
pharmacodynamic 0 ADJ F
model 0 NOUN F
to 0 ADP F
fit 0 PROPN F
the 0 DET F
data 0 NOUN F
( 0 PUNCT F
type 0 NOUN F
I 0 NUM T
indirect 0 ADJ F
response 0 NOUN F
model 0 NOUN F
) 0 PUNCT F
, 0 PUNCT F
this 0 DET F
selection 0 NOUN F
is 0 VERB F
attributable 0 ADJ F
to 0 ADP F
the 0 DET F
presence 0 NOUN F
of 0 ADP F
inhibitory 0 ADJ F
bilastine 0 ADJ F
plasma 0 NOUN F
concentrations 0 NOUN F
that 0 ADP F
decrease 0 VERB F
the 0 DET F
input B-OTHER NOUN F
response 0 NOUN F
function B-OTHER NOUN F
, 0 PUNCT F
i.e 0 PUNCT F
. 0 PUNCT F

the 0 DET F
production 0 NOUN F
of 0 ADP F
the 0 DET F
skin 0 NOUN F
reaction 0 NOUN F
. 0 PUNCT F

This 0 DET T
model 0 NOUN F
resulted 0 VERB F
in 0 ADP F
the 0 DET F
best 0 DET F
fit 0 NOUN F
of 0 ADP F
wheal 0 ADP F
and 0 CCONJ F
flare 0 NOUN F
data 0 NOUN F
. 0 PUNCT F

The 0 DET T
estimates 0 NOUN F
( 0 PUNCT F
with 0 ADP F
relative 0 ADJ F
standard 0 ADJ F
errors 0 NOUN F
expressed 0 VERB F
in 0 ADP F
percentages 0 NOUN F
in 0 ADP F
parentheses 0 NOUN F
) 0 PUNCT F
of 0 ADP F
the 0 DET F
apparent B-PHYSICAL ADJ F
zero-order I-PHYSICAL ADJ F
rate I-PHYSICAL NOUN F
constant B-PHYSICAL NOUN F
for I-PHYSICAL ADP F
flare I-PHYSICAL NOUN F
or 0 CCONJ F
wheal B-PHYSICAL ADP F
spontaneous B-PHYSICAL ADJ F
appearance I-PHYSICAL NOUN F
( 0 PUNCT F
k 0 NOUN F
( 0 PUNCT F
in 0 PUNCT F
) 0 PUNCT F
) 0 PUNCT F
, 0 PUNCT F
the 0 DET F
first-order B-PHYSICAL ADJ F
rate I-PHYSICAL NOUN F
constant B-PHYSICAL ADJ F
for I-PHYSICAL ADP F
flare I-PHYSICAL NOUN F
or 0 CCONJ F
wheal B-PHYSICAL ADP F
disappearance I-PHYSICAL NOUN F
( 0 PUNCT F
k 0 NOUN F
( 0 PUNCT F
out 0 PUNCT F
) 0 PUNCT F
) 0 PUNCT F
and 0 PUNCT F

The 0 DET T
effect 0 NOUN F
of 0 ADP F
prophylactic 0 ADJ F
calcium 0 NOUN F
and 0 CCONJ F
magnesium 0 NOUN F
infusions 0 NOUN F
on 0 ADP F
the 0 DET F
incidence 0 NOUN F
of 0 ADP F
neurotoxicity 0 NOUN F
and 0 CCONJ F
clinical 0 ADJ F
outcome 0 NOUN F
of 0 ADP F
oxaliplatin-based 0 VERB F
systemic 0 ADJ F
treatment 0 NOUN F
in 0 ADP F
advanced 0 VERB F
colorectal 0 ADJ F
cancer 0 NOUN F
patients 0 NOUN F
. 0 PUNCT F

BACKGROUND 0 NOUN T
Peripheral 0 ADJ T
sensory 0 ADJ F
neurotoxicity 0 NOUN F
is 0 VERB F
a 0 DET F
frequent 0 ADJ F
and 0 CCONJ F
potentially 0 ADV F
debilitating 0 NUM F
side 0 NOUN F
effect 0 NOUN F
of 0 ADP F
oxaliplatin 0 NOUN F
treatment 0 NOUN F
. 0 PUNCT F

Calcium 0 NOUN T
and 0 CCONJ F
magnesium 0 NOUN F
( 0 PUNCT F
Ca/Mg 0 ADP T
) 0 PUNCT F
infusions 0 NOUN F
are 0 PROPN F
frequently 0 ADV F
used 0 VERB F
to 0 PART F
prevent 0 ADJ F
this 0 DET F
toxicity 0 NOUN F
. 0 PUNCT F

However 0 ADV T
, 0 PUNCT F
concerns 0 PUNCT F
about 0 CCONJ F
a 0 DET F
negative 0 ADJ F
impact 0 NOUN F
of 0 ADP F
Ca/Mg 0 ADP T
infusions 0 NOUN F
on 0 ADP F
outcome 0 NOUN F
have 0 PUNCT F
been 0 PUNCT F
raised 0 VERB F
. 0 PUNCT F

We 0 PRON T
retrospectively 0 ADV F
assessed 0 VERB F
the 0 DET F
effect 0 NOUN F
of 0 ADP F
Ca/Mg 0 ADP T
infusions 0 NOUN F
on 0 ADP F
the 0 DET F
incidence 0 NOUN F
of 0 ADP F
neurotoxicity B-PHYSICAL NOUN F
and 0 CCONJ F
on 0 ADP F
clinical B-PHYSICAL ADJ F
outcome I-PHYSICAL NOUN F
in 0 ADP F
advanced 0 VERB F
colorectal 0 ADJ F
cancer 0 NOUN F
( 0 PUNCT F
ACC 0 NOUN T
) 0 PUNCT F
patients 0 NOUN F
treated 0 VERB F
in 0 ADP F
the 0 DET F
phase 0 NOUN F
III 0 NUM T
CAIRO2 0 NOUN T
study 0 NOUN F
. 0 PUNCT F

MATERIALS 0 NOUN T
AND 0 CCONJ T
METHODS 0 NOUN T
Seven 0 ADJ T
hundred 0 NUM F
and 0 CCONJ F
fifty 0 NUM F
five 0 NUM F
previously 0 ADV F
untreated 0 VERB F
ACC 0 NOUN T
patients 0 NOUN F
were 0 VERB F
randomised 0 PUNCT F
between 0 ADP F
treatment 0 NOUN F
with 0 ADP F
capecitabine 0 NOUN F
, 0 PUNCT F
oxaliplatin 0 NOUN F
and 0 CCONJ F
bevacizumab 0 PUNCT F
or 0 CCONJ F
the 0 DET F
same 0 ADJ F
combination 0 NOUN F
with 0 ADP F
the 0 DET F
addition 0 NOUN F
of 0 ADP F
cetuximab 0 NOUN F
. 0 PUNCT F

Patients 0 NOUN T
were 0 VERB F
retrospectively 0 ADV F
divided 0 VERB F
into 0 ADP F
two 0 NUM F
groups 0 NOUN F
: 0 PUNCT F
patients 0 NOUN F
in 0 ADP F
the 0 DET F
Ca/Mg 0 NOUN T
( 0 PUNCT F
+ 0 SYM F
) 0 PUNCT F
group 0 NOUN F
received 0 VERB F
Ca/Mg 0 ADP T
at 0 VERB F
least 0 DET F
during 0 ADP F
their 0 PROPN F
first 0 ADJ F
treatment 0 NOUN F
cycle 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
patients 0 NOUN F
in 0 ADP F
the 0 DET F
Ca/Mg 0 NOUN T
( 0 PUNCT F
- 0 SYM F
) 0 PUNCT F
group 0 NOUN F
did 0 VERB F
not 0 ADV F
. 0 PUNCT F

RESULTS 0 NOUN T
Seven 0 PUNCT T
hundred 0 NUM F
and 0 CCONJ F
thirty 0 NUM F
two 0 NUM F
patients 0 NOUN F
were 0 VERB F
evaluable 0 ADJ F
for 0 ADP F
this 0 DET F
analysis 0 NOUN F
. 0 PUNCT F

The 0 DET T
Ca/Mg 0 NOUN T
( 0 PUNCT F
+ 0 SYM F
) 0 PUNCT F
group 0 NOUN F
consisted 0 VERB F
of 0 ADP F
551 0 NUM F
patients 0 NOUN F
, 0 PUNCT F
the 0 DET F
Ca/Mg 0 NOUN T
( 0 PUNCT F
- 0 SYM F
) 0 PUNCT F
group 0 NOUN F
consisted 0 VERB F
of 0 ADP F
181 0 NUM F
patients 0 NOUN F
. 0 PUNCT F

The 0 DET T
incidence 0 NOUN F
of 0 ADP F
all 0 DET F
grade 0 NOUN F
neurotoxicity B-PHYSICAL NOUN F
in 0 ADP F
the 0 DET F
Ca/Mg 0 NOUN T
( 0 PUNCT F
+ 0 SYM F
) 0 PUNCT F
group 0 NOUN F
and 0 CCONJ F
the 0 DET F
Ca/Mg 0 NOUN T
( 0 PUNCT F
- 0 SYM F
) 0 PUNCT F
group 0 NOUN F
was 0 VERB F
85 0 NUM F
% 0 SYM F
and 0 CCONJ F
92 0 NUM F
% 0 SYM F
, 0 PUNCT F
respectively 0 ADV F
( 0 PUNCT F
p 0 NOUN F
= 0 SYM F
0.02 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
and 0 CCONJ F
the 0 DET F
incidence 0 NOUN F
of 0 ADP F
grade 0 NOUN F
? 0 PUNCT F

2 0 NUM F
neurotoxicity 0 NOUN F
was 0 VERB F
40 0 NUM F
% 0 SYM F
and 0 CCONJ F
45 0 NUM F
% 0 SYM F
, 0 PUNCT F
respectively 0 ADV F
( 0 PUNCT F
p 0 NOUN F
= 0 SYM F
0.22 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
median 0 ADJ F
PFS 0 NOUN T
in 0 ADP F
the 0 DET F
Ca/Mg 0 NOUN T
( 0 PUNCT F
+ 0 SYM F
) 0 PUNCT F
versus 0 CCONJ F
Ca/Mg 0 ADP T
( 0 PUNCT F
- 0 SYM F
) 0 PUNCT F
group 0 NOUN F
was 0 VERB F
10.1 0 NUM F
versus 0 CCONJ F
10.7 0 NUM F
months 0 NOUN F
( 0 PUNCT F
p 0 NOUN F
= 0 SYM F
0.92 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
the 0 DET F
median 0 ADJ F
OS 0 NOUN T
was 0 VERB F
19.8 0 NUM F
versus 0 CCONJ F
20.7 0 NUM F
months 0 NOUN F
( 0 PUNCT F
p 0 NOUN F
= 0 SYM F
0.10 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
and 0 CCONJ F
the 0 DET F
response 0 NOUN F
rate 0 NOUN F
was 0 VERB F
43.1 0 NUM F
% 0 SYM F
versus 0 CCONJ F
50 0 NUM F
% 0 SYM F
( 0 PUNCT F
p 0 NOUN F
= 0 SYM F
0.11 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
respectively 0 ADV F
. 0 PUNCT F

CONCLUSIONS 0 NOUN T
In 0 ADP T
this 0 DET F
largest 0 PUNCT F
retrospective 0 ADJ F
analysis 0 NOUN F
to 0 ADP F
date 0 NOUN F
we 0 PRON F
observed 0 VERB F
that 0 ADP F
Ca/Mg 0 ADP T
infusions 0 NOUN F
significantly 0 ADV F
reduced 0 VERB F
all 0 DET F
grade 0 NOUN F
oxaliplatin-related 0 VERB F
neurotoxicity 0 NOUN F
. 0 PUNCT F

Ca/Mg 0 ADP T
infusions 0 NOUN F
did 0 DET F
not 0 ADV F
affect 0 VERB F
the 0 DET F
clinical 0 ADJ F
efficacy 0 NOUN F
of 0 ADP F
treatment 0 NOUN F
. 0 PUNCT F

The 0 DET T
effect 0 NOUN F
of 0 ADP F
splinting 0 NOUN F
of 0 ADP F
teeth 0 NOUN F
in 0 ADP F
combination 0 NOUN F
with 0 ADP F
reconstructive 0 ADJ F
periodontal 0 ADJ F
surgery 0 NOUN F
in 0 ADP F
humans 0 NOUN F
. 0 PUNCT F

The 0 DET T
purpose 0 NOUN F
of 0 ADP F
this 0 DET F
study 0 NOUN F
was 0 VERB F
to 0 PART F
evaluate 0 NOUN F
the 0 DET F
effect 0 NOUN F
of 0 ADP F
splinting 0 NOUN F
teeth 0 NOUN F
on 0 ADP F
the 0 DET F
results 0 NOUN F
of 0 ADP F
periodontal 0 ADJ F
reconstructive 0 ADJ F
surgery 0 NOUN F
using 0 ADJ F
a 0 DET F
specific 0 ADJ F
carbonate 0 NOUN F
bone 0 NOUN F
replacement 0 NOUN F
graft 0 NOUN F
( 0 PUNCT F
BRG 0 NOUN T
) 0 PUNCT F
material 0 NOUN F
. 0 PUNCT F

Forty-five 0 ADJ T
patients 0 NOUN F
were 0 VERB F
randomly 0 ADV F
treated 0 VERB F
with 0 ADP F
a 0 DET F
periodontal 0 ADJ F
surgery 0 NOUN F
approach 0 NOUN F
. 0 PUNCT F

Natural 0 ADJ T
coral 0 PUNCT F
calcium 0 NOUN F
BRG 0 NOUN T
was 0 VERB F
utilised 0 VERB F
in 0 ADP F
33 0 NUM F
patients 0 NOUN F
. 0 PUNCT F

This 0 DET T
33-patient 0 ADJ F
group 0 NOUN F
was 0 VERB F
divided 0 VERB F
into 0 ADP F
three 0 NUM F
equal 0 ADJ F
groups 0 NOUN F
. 0 PUNCT F

In 0 ADP T
the 0 DET F
presplint 0 NOUN F
group 0 NOUN F
, 0 PUNCT F
teeth 0 NOUN F
were 0 VERB F
splinted 0 VERB F
to 0 ADP F
at 0 PUNCT F
least 0 ADV F
two 0 NUM F
rigid 0 ADJ F
teeth 0 NOUN F
before 0 ADP F
surgery 0 NOUN F
, 0 PUNCT F
in 0 ADP F
the 0 DET F
postsplint 0 NOUN F
group 0 NOUN F
, 0 PUNCT F
teeth 0 NOUN F
were 0 VERB F
splinted 0 VERB F
at 0 ADP F
suture 0 NOUN F
removal 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
in 0 ADP F
the 0 DET F
nonsplint 0 NOUN F
group 0 NOUN F
, 0 PUNCT F
the 0 DET F
treated 0 VERB F
teeth 0 NOUN F
were 0 VERB F
not 0 ADV F
splinted 0 VERB F
at 0 ADP F
all 0 PUNCT F
. 0 PUNCT F

In 0 ADP T
12 0 NUM F
patients 0 NOUN F
, 0 PUNCT F
teeth 0 NOUN F
were 0 VERB F
treated 0 VERB F
with 0 ADP F
surgical 0 ADJ F
debridement 0 NOUN F
( 0 PUNCT F
DEBR 0 NOUN T
) 0 PUNCT F
alone 0 ADJ F
and 0 CCONJ F
not 0 ADV F
splinted 0 VERB F
. 0 PUNCT F

Periodontal 0 ADJ T
probing 0 VERB F
depth 0 NOUN F
( 0 PUNCT F
PPD 0 NOUN T
) 0 PUNCT F
, 0 PUNCT F
clinical 0 ADJ F
probing 0 PUNCT F
attachment 0 NOUN F
level 0 NOUN F
( 0 PUNCT F
CPAL 0 NOUN T
) 0 PUNCT F
, 0 PUNCT F
and 0 CCONJ F
tooth 0 NOUN F
mobility 0 NOUN F
were 0 VERB F
measured 0 VERB F
using 0 SYM F
desmodontometry 0 NOUN F
( 0 PUNCT F
DDM 0 NOUN T
) 0 PUNCT F
and 0 CCONJ F
periotest 0 ADV F
( 0 PUNCT F
PTV 0 NOUN T
) 0 PUNCT F
with 0 ADP F
reproducible 0 ADJ F
methods 0 NOUN F
before 0 ADP F
surgery 0 NOUN F
and 0 CCONJ F
at 0 ADP F
various 0 ADJ F
periods 0 NOUN F
up 0 PUNCT F
to 0 ADP F
1 0 NUM F
year 0 NOUN F
afterwards 0 ADP F
. 0 PUNCT F

A 0 DET T
decrease 0 NOUN F
in 0 ADP F
PPD B-OTHER NOUN T
( 0 PUNCT F
5.4 0 ADP F
mm 0 NOUN F
, 0 PUNCT F
SD 0 NOUN T
1.4 0 NUM F
mm 0 NOUN F
) 0 PUNCT F
and 0 CCONJ F
tooth B-PHYSICAL NOUN F
mobility I-PHYSICAL NOUN F
( 0 PUNCT F
DDM-horizontal 0 ADJ T
257 0 NUM F
microns 0 NOUN F
, 0 PUNCT F
SD 0 NOUN T
60 0 NUM F
microns 0 ADJ F
) 0 PUNCT F
and 0 CCONJ F
a 0 DET F
gain B-OTHER NOUN F
of I-OTHER ADP F
CPAL I-OTHER NOUN T
( 0 PUNCT F
5.1 0 NUM F
mm 0 NOUN F
, 0 PUNCT F
SD 0 NOUN T
1.4 0 NUM F
mm 0 NOUN F
) 0 PUNCT F
were 0 VERB F
seen 0 VERB F
following 0 SYM F
the 0 DET F
use 0 NOUN F
of 0 ADP F
BRG 0 NOUN T
in 0 ADP F
presplint 0 NOUN F
teeth 0 NOUN F
. 0 PUNCT F

In 0 ADP T
the 0 DET F
same 0 ADJ F
group 0 NOUN F
, 0 PUNCT F
PPD B-OTHER NOUN T
and 0 CCONJ F
tooth B-PHYSICAL NOUN F
mobility I-PHYSICAL NOUN F
were 0 VERB F
significantly 0 ADV F
reduced 0 ADP F
compared 0 VERB F
to 0 ADP F
nonsplint 0 PUNCT F
teeth 0 NOUN F
. 0 PUNCT F

DEBR 0 NOUN T
alone 0 ADJ F
showed 0 VERB F
reductions 0 NOUN F
in 0 ADP F
tooth B-PHYSICAL NOUN F
mobility I-PHYSICAL NOUN F
and 0 CCONJ F
PPD B-OTHER NOUN T
and 0 CCONJ F
a 0 DET F
significantly 0 ADV F
smaller 0 PUNCT F
gain 0 CCONJ F
in 0 ADP F
CPAL B-OTHER NOUN T
than 0 PUNCT F
in 0 ADP F
presplint 0 NOUN F
teeth 0 NOUN F
treated 0 PUNCT F
with 0 ADP F
BRG 0 NOUN T
. 0 PUNCT F

The 0 DET T
less 0 ADV F
favourable 0 ADJ F
improvement 0 NOUN F
in 0 ADP F
periodontal 0 ADJ F
function 0 NOUN F
of 0 ADP F
postsplint 0 NOUN F
or 0 CCONJ F
nonsplint 0 NOUN F
teeth 0 NOUN F
seemed 0 VERB F
to 0 PART F
be 0 PUNCT F
due 0 CCONJ F
to 0 ADP F
the 0 DET F
loss 0 NOUN F
of 0 ADP F
BRG B-PHYSICAL NOUN T
material I-PHYSICAL NOUN F
caused 0 VERB F
by 0 ADP F
tooth B-PHYSICAL NOUN F
mobility I-PHYSICAL NOUN F
. 0 PUNCT F

These 0 DET T
results 0 NOUN F
indicate 0 VERB F
that 0 ADP F
an 0 DET F
undisturbed 0 PUNCT F
wound 0 NOUN F
healing 0 ADJ F
process 0 NOUN F
using 0 VERB F
BRG 0 NOUN T
together 0 ADV F
with 0 ADP F
tooth 0 NOUN F
stability 0 NOUN F
is 0 VERB F
beneficial 0 ADJ F
to 0 ADP F
overall B-PHYSICAL ADJ F
clinical I-PHYSICAL ADJ F
success I-PHYSICAL NOUN F
. 0 PUNCT F

Stability 0 NOUN T
, 0 PUNCT F
tipping 0 ADP F
and 0 CCONJ F
relapse 0 NOUN F
of 0 ADP F
bone-borne 0 VERB F
versus 0 CCONJ F
tooth-borne 0 NOUN F
surgically 0 ADV F
assisted 0 VERB F
rapid 0 ADJ F
maxillary 0 ADJ F
expansion 0 NOUN F
; 0 PUNCT F
a 0 DET F
prospective 0 ADJ F
randomized 0 VERB F
patient 0 NOUN F
trial 0 NOUN F
. 0 PUNCT F

This 0 DET T
study 0 NOUN F
evaluated 0 VERB F
stability 0 NOUN F
, 0 PUNCT F
tipping 0 ADP F
and 0 CCONJ F
relapse 0 NOUN F
after 0 PUNCT F
surgically 0 ADV F
assisted 0 VERB F
rapid 0 ADJ F
maxillary 0 ADJ F
expansion 0 NOUN F
( 0 PUNCT F
SARME 0 NOUN T
) 0 PUNCT F
, 0 PUNCT F
comparing 0 ADP F
bone-borne 0 VERB F
and 0 CCONJ F
tooth-borne 0 NOUN F
devices 0 NOUN F
, 0 PUNCT F
in 0 ADP F
skeletally 0 ADV F
matured 0 PUNCT F
non-syndromal 0 ADJ F
patients 0 NOUN F
with 0 ADP F
transverse 0 ADJ F
maxillary 0 ADJ F
hypoplasia 0 NOUN F
. 0 PUNCT F

The 0 DET T
study 0 NOUN F
is 0 VERB F
a 0 DET F
randomized 0 VERB F
, 0 PUNCT F
open-label 0 NOUN F
, 0 PUNCT F
clinical 0 ADJ F
trial 0 NOUN F
. 0 PUNCT F

Patients 0 NOUN T
were 0 VERB F
randomized 0 VERB F
to 0 ADP F
bone-borne 0 VERB F
( 0 PUNCT F
n=25 0 NOUN F
) 0 PUNCT F
and 0 CCONJ F
tooth-borne 0 NOUN F
( 0 PUNCT F
n=21 0 NOUN F
) 0 PUNCT F
groups 0 NOUN F
. 0 PUNCT F

The 0 DET T
surgical 0 ADJ F
technique 0 NOUN F
for 0 ADP F
corticotomy 0 NOUN F
was 0 VERB F
the 0 DET F
same 0 ADP F
in 0 ADP F
both 0 CCONJ F
groups 0 NOUN F
. 0 PUNCT F

Expansion 0 NOUN T
was 0 VERB F
performed 0 VERB F
using 0 VERB F
a 0 DET F
bone-borne 0 VERB F
or 0 CCONJ F
tooth-borne 0 NOUN F
device 0 NOUN F
. 0 PUNCT F

Dental 0 ADJ T
study 0 NOUN F
casts 0 CCONJ F
, 0 PUNCT F
lateral 0 ADJ F
and 0 CCONJ F
postero-anterior 0 ADJ F
cephalograms 0 NOUN F
were 0 VERB F
taken 0 VERB F
before 0 ADP F
treatment 0 NOUN F
, 0 PUNCT F
after 0 ADP F
the 0 DET F
distraction 0 NOUN F
phase 0 NOUN F
and 0 CCONJ F
at 0 ADP F
12-month 0 NOUN F
follow 0 VERB F
up 0 ADJ F
. 0 PUNCT F

Stability B-PHYSICAL NOUN T
, 0 PUNCT F
segmental B-PHYSICAL ADJ F
maxillary I-PHYSICAL ADJ F
tipping I-PHYSICAL PUNCT F
and 0 CCONJ F
relapse B-PHYSICAL NOUN F
were 0 VERB F
studied 0 VERB F
. 0 PUNCT F

23 0 NUM F
bone-borne 0 VERB F
and 0 CCONJ F
19 0 NUM F
tooth-borne 0 NOUN F
patients 0 NOUN F
were 0 VERB F
analyzed 0 VERB F
. 0 PUNCT F

There 0 PUNCT T
were 0 VERB F
no 0 DET F
significant 0 ADJ F
differences 0 NOUN F
between 0 ADP F
the 0 DET F
two 0 NUM F
groups 0 NOUN F
. 0 PUNCT F

Widening B-PHYSICAL VERB T
was 0 VERB F
comparable 0 ADJ F
at 0 ADP F
canine 0 ADJ F
, 0 PUNCT F
premolar 0 ADJ F
and 0 CCONJ F
molar 0 PUNCT F
level 0 NOUN F
. 0 PUNCT F

Relapse B-PHYSICAL NOUN T
was 0 ADJ F
not 0 ADV F
significant 0 ADJ F
and 0 CCONJ F
at 0 ADP F
follow 0 PUNCT F
up 0 PUNCT F
the 0 DET F
significant 0 ADJ F
increase 0 NOUN F
in 0 ADP F
distance 0 NOUN F
was 0 VERB F
sustained 0 VERB F
. 0 PUNCT F

A 0 DET T
significant 0 ADJ F
increase 0 NOUN F
in 0 ADP F
palatal B-PHYSICAL ADJ F
width I-PHYSICAL NOUN F
, I-PHYSICAL PUNCT F
at I-PHYSICAL ADP F
premolar I-PHYSICAL ADJ F
and I-PHYSICAL CCONJ F
molar I-PHYSICAL PUNCT F
level I-PHYSICAL NOUN F
, 0 PUNCT F
occurred 0 VERB F
in 0 ADP F
both 0 CCONJ F
groups 0 NOUN F
. 0 PUNCT F

The 0 DET T
maxilla 0 NOUN F
moves 0 ADP F
slightly 0 ADV F
downward 0 PUNCT F
in 0 ADP F
SARME 0 NOUN T
. 0 PUNCT F

Segmental B-PHYSICAL ADJ T
maxillary I-PHYSICAL ADJ F
tipping I-PHYSICAL PUNCT F
occurred 0 VERB F
in 0 ADP F
both 0 CCONJ F
groups 0 NOUN F
and 0 CCONJ F
did 0 DET F
not 0 ADV F
affect 0 VERB F
relapse B-PHYSICAL NOUN F
. 0 PUNCT F

There 0 PUNCT T
is 0 VERB F
no 0 DET F
significant 0 ADJ F
difference 0 NOUN F
between 0 ADP F
the 0 DET F
two 0 NUM F
groups 0 NOUN F
. 0 PUNCT F

In 0 ADP T
SARME 0 NOUN T
, 0 PUNCT F
the 0 DET F
widening 0 PUNCT F
achieved 0 VERB F
at 0 ADP F
dental 0 ADJ F
level 0 NOUN F
is 0 VERB F
stable 0 ADJ F
after 0 ADP F
12 0 NUM F
months 0 NOUN F
. 0 PUNCT F

Over-correction 0 NOUN T
is 0 VERB F
not 0 ADV F
necessary 0 ADJ F
. 0 PUNCT F

Tipping 0 DET T
of 0 ADP F
the 0 DET F
maxillary 0 ADJ F
segments 0 NOUN F
and 0 CCONJ F
increases 0 NOUN F
in 0 ADP F
the 0 DET F
retention B-PHYSICAL NOUN F
period I-PHYSICAL NOUN F
are 0 VERB F
equal 0 ADJ F
in 0 ADP F
both 0 CCONJ F
groups 0 NOUN F
. 0 PUNCT F

Divalproex 0 PUNCT T
sodium 0 NOUN F
vs 0 CCONJ F
placebo 0 NOUN F
for 0 ADP F
the 0 DET F
treatment 0 NOUN F
of 0 ADP F
irritability B-MENTAL NOUN F
in 0 ADP F
children 0 NOUN F
and 0 CCONJ F
adolescents 0 NOUN F
with 0 ADP F
autism 0 NOUN F
spectrum 0 NOUN F
disorders 0 NOUN F
. 0 PUNCT F

Autism 0 NOUN T
spectrum 0 NOUN F
disorders 0 NOUN F
( 0 PUNCT F
ASDs 0 ADJ T
) 0 PUNCT F
are 0 VERB F
neurodevelopmental 0 ADJ F
disorders 0 NOUN F
characterized 0 VERB F
by 0 ADP F
social 0 ADJ F
and 0 CCONJ F
language 0 NOUN F
deficits 0 NOUN F
and 0 CCONJ F
by 0 ADP F
repetitive 0 ADJ F
behaviors 0 NOUN F
and 0 CCONJ F
interests 0 NOUN F
. 0 PUNCT F

Irritability/aggression 0 NOUN T
is 0 VERB F
a 0 DET F
significant 0 ADJ F
comorbid 0 ADJ F
symptom 0 NOUN F
in 0 ADP F
this 0 DET F
population 0 NOUN F
, 0 PUNCT F
which 0 ADP F
greatly 0 ADV F
impacts 0 PUNCT F
burden 0 NOUN F
of 0 ADP F
care 0 NOUN F
. 0 PUNCT F

This 0 DET T
study 0 NOUN F
examined 0 VERB F
the 0 DET F
effect 0 NOUN F
of 0 ADP F
divalproex 0 PUNCT F
sodium 0 NOUN F
for 0 ADP F
irritability/aggression 0 NOUN F
in 0 ADP F
children 0 NOUN F
and 0 CCONJ F
adolescents 0 NOUN F
with 0 ADP F
ASD 0 NOUN T
. 0 PUNCT F

This 0 DET T
was 0 VERB F
a 0 DET F
12-week 0 NOUN F
randomized 0 VERB F
, 0 PUNCT F
double-blind 0 ADJ F
, 0 PUNCT F
placebo-controlled 0 VERB F
trial 0 NOUN F
. 0 PUNCT F

All 0 DET T
efficacy 0 NOUN F
measures 0 NOUN F
were 0 VERB F
obtained 0 VERB F
by 0 ADP F
an 0 DET F
independent 0 ADJ F
evaluator 0 NOUN F
blinded 0 PUNCT F
to 0 ADP F
randomization 0 NOUN F
condition 0 NOUN F
and 0 CCONJ F
side 0 NOUN F
effects 0 NOUN F
. 0 PUNCT F

A 0 DET T
total 0 NOUN F
of 0 ADP F
55 0 NUM F
subjects 0 NOUN F
gavetheir 0 PUNCT F
consent 0 NOUN F
and 0 CCONJ F
27 0 NUM F
were 0 VERB F
randomized 0 VERB F
in 0 ADP F
a 0 DET F
1 0 NUM F
: 0 PUNCT F
1 0 NUM F
manner 0 NOUN F
( 0 PUNCT F
mean 0 NOUN F
age 0 NOUN F
9.46+/-2.46 0 PUNCT F
, 0 PUNCT F
mean 0 VERB F
nonverbal 0 ADJ F
IQ 0 NOUN T
63.3+/-23.9 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Two 0 NUM T
subjects 0 NOUN F
from 0 ADP F
the 0 DET F
active 0 ADJ F
group 0 NOUN F
and 0 CCONJ F
one 0 NUM F
subject 0 NOUN F
from 0 ADP F
the 0 DET F
placebo 0 NOUN F
group 0 NOUN F
discontinued 0 VERB F
the 0 DET F
study 0 NOUN F
because 0 PUNCT F
of 0 ADP F
either 0 CCONJ F
a 0 DET F
lack 0 NOUN F
of 0 ADP F
efficacy 0 NOUN F
or 0 CCONJ F
side 0 NOUN F
effects 0 NOUN F
( 0 PUNCT F
increased 0 VERB F
irritability 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

Primary 0 ADJ T
outcome 0 NOUN F
measures 0 NOUN F
were 0 VERB F
Aberrant B-MENTAL ADJ T
Behavior I-MENTAL NOUN T
Checklist-Irritability I-MENTAL NOUN T
subscale I-MENTAL NOUN F
and I-MENTAL CCONJ F
Clinical I-MENTAL ADJ T
Global I-MENTAL ADJ T
Impression-Improvement I-MENTAL NOUN T
, 0 PUNCT F
which 0 ADP F
focused 0 VERB F
on 0 ADP F
irritability 0 NOUN F
. 0 PUNCT F

Overall 0 ADJ T
, 0 PUNCT F
62.5 0 NUM F
% 0 SYM F
of 0 ADP F
divalproex 0 PUNCT F
subjects 0 NOUN F
vs 0 CCONJ F
9 0 NUM F
% 0 SYM F
of 0 ADP F
placebo 0 NOUN F
subjects 0 NOUN F
were 0 VERB F
responders B-MENTAL NOUN F
( 0 PUNCT F
CGI-irritability 0 NOUN T
OR 0 CCONJ T
: 0 PUNCT F
16.7 0 NUM F
, 0 PUNCT F
Fisher 0 NOUN T
's 0 PUNCT F
exact 0 PUNCT F
p=0.008 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

A 0 DET T
statistically 0 ADV F
significant 0 ADJ F
improvement 0 NOUN F
was 0 VERB F
also 0 ADV F
noted 0 VERB F
on 0 ADP F
the 0 DET F
ABC-Irritability B-MENTAL NOUN T
subscale I-MENTAL NOUN F
( 0 PUNCT F
p=0.048 0 PUNCT F
) 0 PUNCT F
. 0 PUNCT F

There 0 PUNCT T
was 0 VERB F
a 0 DET F
trend 0 NOUN F
for 0 ADP F
responders 0 NOUN F
to 0 PUNCT F
have 0 PUNCT F
higher 0 PUNCT F
valproate B-PHYSICAL NOUN F
blood I-PHYSICAL NOUN F
levels I-PHYSICAL NOUN F
compared 0 VERB F
with 0 ADP F
nonresponders 0 NOUN F
. 0 PUNCT F

This 0 DET T
study 0 NOUN F
suggests 0 VERB F
the 0 DET F
efficacy 0 NOUN F
of 0 ADP F
divalproex 0 PUNCT F
for 0 ADP F
the 0 DET F
treatment 0 NOUN F
of 0 ADP F
irritability B-MENTAL NOUN F
in 0 ADP F
children 0 NOUN F
and 0 CCONJ F
adolescents 0 NOUN F
with 0 ADP F
ASD 0 NOUN T
. 0 PUNCT F

Larger 0 PUNCT T
sample 0 NOUN F
follow-up 0 NOUN F
studies 0 NOUN F
are 0 VERB F
warranted 0 VERB F
. 0 PUNCT F

The 0 DET T
role 0 NOUN F
of 0 ADP F
the 0 DET F
MA-sensitive 0 ADJ T
leukocyte 0 NOUN F
chemotaxis 0 NOUN F
in 0 ADP F
rheumatoid 0 ADJ F
arthritis 0 NOUN F
. 0 PUNCT F

A 0 DET T
randomized 0 VERB F
double-blind 0 ADJ F
clinical 0 ADJ F
trial 0 NOUN F
of 0 ADP F
griseofulvin 0 NOUN F
treatment 0 NOUN F
. 0 PUNCT F

Polymorphonuclear 0 ADJ T
leukocyte 0 NOUN F
( 0 PUNCT F
PMN 0 NOUN T
) 0 PUNCT F
chemotaxis 0 NOUN F
is 0 VERB F
thought 0 VERB F
to 0 PART F
play 0 NOUN F
an 0 DET F
essential 0 ADJ F
role 0 NOUN F
in 0 ADP F
the 0 DET F
pathogenesis 0 NOUN F
of 0 ADP F
rheumatoid 0 ADJ F
arthritis 0 NOUN F
. 0 PUNCT F

PMN 0 NOUN T
chemotaxis 0 NOUN F
is 0 VERB F
in 0 ADP F
part 0 NOUN F
sensitive 0 ADJ F
to 0 ADP F
microtubule 0 NOUN F
antagonists 0 NOUN F
( 0 PUNCT F
MAs 0 NOUN T
) 0 PUNCT F
, 0 PUNCT F
e.g 0 NUM F
. 0 PUNCT F

colchicine 0 NOUN F
. 0 PUNCT F

The 0 DET T
antimycotic 0 ADJ F
antibiotic 0 ADJ F
griseofulvin 0 NOUN F
inhibits 0 NOUN F
the 0 DET F
MA-sensitive 0 ADJ T
PMN 0 NOUN T
chemotaxis 0 NOUN F
in 0 VERB F
vitro 0 ADJ F
in 0 ADP F
concentrations 0 NOUN F
far 0 ADV F
below 0 ADP F
those 0 ADJ F
obtained 0 VERB F
in 0 ADP F
serum 0 NOUN F
during 0 ADP F
antimycotic 0 VERB F
therapy 0 NOUN F
. 0 PUNCT F

The 0 DET T
role 0 NOUN F
of 0 ADP F
the 0 DET F
MA-sensitive 0 ADJ T
chemotaxis 0 NOUN F
in 0 ADP F
rheumatoid 0 ADJ F
arthritis 0 NOUN F
could 0 VERB F
thus 0 ADV F
be 0 PUNCT F
elucidated 0 VERB F
by 0 ADP F
a 0 DET F
clinical 0 ADJ F
trial 0 NOUN F
of 0 ADP F
griseofulvin 0 NOUN F
treatment 0 NOUN F
. 0 PUNCT F

Griseofulvin 0 NOUN T
( 0 PUNCT F
n 0 NOUN F
= 0 SYM F
20 0 NUM F
) 0 PUNCT F
was 0 VERB F
tested 0 VERB F
in 0 ADP F
a 0 DET F
randomized 0 VERB F
double-blind 0 ADJ F
study 0 NOUN F
versus 0 CCONJ F
placebo 0 NOUN F
( 0 PUNCT F
m 0 NOUN F
= 0 SYM F
19 0 NUM F
) 0 PUNCT F
during 0 ADP F
one 0 NUM F
year 0 NOUN F
in 0 ADP F
patients 0 NOUN F
with 0 ADP F
rheumatoid 0 ADJ F
arthritis 0 NOUN F
of 0 ADP F
mild-moderate 0 ADJ F
activity 0 NOUN F
. 0 PUNCT F

No 0 DET T
beneficial B-OTHER ADJ F
effect 0 NOUN F
of 0 ADP F
griseofulvin 0 NOUN F
treatment 0 NOUN F
was 0 VERB F
noted 0 VERB F
on 0 ADP F
clinical B-PHYSICAL ADJ F
symptoms I-PHYSICAL NOUN F
or I-PHYSICAL CCONJ F
laboratory I-PHYSICAL NOUN F
parameters I-PHYSICAL NOUN F
of 0 ADP F
rheumatoid 0 ADJ F
arthritis 0 NOUN F
. 0 PUNCT F

Moreover 0 ADV T
, 0 PUNCT F
the 0 DET F
placebo-treated 0 ADV F
patients 0 NOUN F
showed 0 VERB F
more 0 DET F
improvement B-OTHER NOUN F
than 0 ADP F
the 0 DET F
griseofulvin-treated 0 ADJ F
patients 0 NOUN F
. 0 PUNCT F

It 0 PRON T
is 0 VERB F
therefore 0 ADV F
suggested 0 ADP F
that 0 ADP F
the 0 DET F
MA-sensitive 0 ADJ T
chemotaxis 0 NOUN F
plays 0 NOUN F
a 0 DET F
reparative 0 ADJ F
role 0 NOUN F
in 0 ADP F
the 0 DET F
inflammatory 0 ADJ F
lesions 0 NOUN F
of 0 ADP F
rheumatoid 0 ADJ F
arthritis 0 NOUN F
. 0 PUNCT F

What 0 PUNCT T
is 0 VERB F
the 0 DET F
optimum 0 NOUN F
maximal 0 ADJ F
gonadotropin 0 NOUN F
dosage 0 NOUN F
used 0 VERB F
in 0 ADP F
microdose 0 NOUN F
flare-up 0 PUNCT F
cycles 0 NOUN F
in 0 ADP F
poor 0 ADJ F
responders 0 NOUN F
? 0 PUNCT F

OBJECTIVE 0 NOUN T
To 0 PROPN T
find 0 SYM F
out 0 DET F
the 0 DET F
optimum 0 NOUN F
maximal 0 ADJ F
dosage 0 NOUN F
of 0 ADP F
recombinant 0 ADJ F
follicle 0 NOUN F
stimulating 0 ADJ F
hormone 0 NOUN F
( 0 PUNCT F
rFSH 0 NOUN F
) 0 PUNCT F
in 0 ADP F
microdose 0 NOUN F
gonadotropin-releasing 0 PUNCT F
hormone 0 NOUN F
analog 0 NOUN F
( 0 PUNCT F
GnRH-a 0 NOUN T
) 0 PUNCT F
flare 0 NOUN F
cycles 0 NOUN F
in 0 ADP F
poor 0 ADJ F
responders 0 NOUN F
. 0 PUNCT F

DESIGN 0 NOUN T
Prospective 0 ADJ T
randomized 0 VERB F
study 0 NOUN F
. 0 PUNCT F

SETTING 0 NUM T
Private 0 ADJ T
infertility 0 ADJ F
clinic 0 NOUN F
. 0 PUNCT F

PATIENT 0 NOUN T
( 0 PUNCT F
S 0 NOUN T
) 0 PUNCT F
A 0 DET T
total 0 NOUN F
of 0 ADP F
119 0 NUM F
women 0 NOUN F
were 0 VERB F
taken 0 VERB F
into 0 ADP F
the 0 DET F
study 0 NOUN F
. 0 PUNCT F

INTERVENTION 0 NOUN T
( 0 PUNCT F
S 0 NOUN T
) 0 PUNCT F
The 0 DET T
study 0 ADJ F
group 0 NOUN F
underwent 0 VERB F
a 0 DET F
microdose 0 NOUN F
protocol 0 NOUN F
with 0 ADP F
a 0 DET F
GnRH-agonist 0 NOUN T
followed 0 VERB F
by 0 ADP F
rFSH 0 NOUN F
administration 0 NOUN F
. 0 PUNCT F

On 0 ADP T
the 0 DET F
third 0 ADJ F
day 0 NOUN F
of 0 ADP F
GnRH-a 0 NOUN T
administration 0 NOUN F
, 0 PUNCT F
119 0 NUM F
patients 0 NOUN F
were 0 VERB F
randomized 0 VERB F
in 0 ADP F
three 0 DET F
groups 0 NOUN F
to 0 PART F
receive 0 ADJ F
daily 0 PUNCT F
fixed 0 VERB F
doses 0 NOUN F
of 0 ADP F
300 0 NUM F
IU 0 NOUN T
of 0 ADP F
rFSH 0 NOUN F
( 0 PUNCT F
group 0 NOUN F
A 0 NOUN T
, 0 PUNCT F
n 0 NOUN F
= 0 SYM F
38 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
or 0 CCONJ F
450 0 NUM F
IU 0 NOUN T
of 0 ADP F
rFSH 0 NOUN F
( 0 PUNCT F
group 0 NOUN F
B 0 NOUN T
, 0 PUNCT F
n 0 NOUN F
= 0 SYM F
39 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
or 0 CCONJ F
600 0 NUM F
IU 0 NOUN T
of 0 ADP F
rFSH 0 NOUN F
( 0 PUNCT F
group 0 NOUN F
C 0 NOUN T
, 0 PUNCT F
n 0 NOUN F
= 0 SYM F
42 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

MAIN 0 ADJ T
OUTCOME 0 NOUN T
MEASURE 0 NOUN T
( 0 PUNCT F
S 0 NOUN T
) 0 PUNCT F
Peak 0 NOUN T
E 0 NOUN T
( 0 PUNCT F
2 0 NUM F
) 0 PUNCT F
levels 0 NOUN F
, 0 PUNCT F
days 0 NOUN F
of B-ADVERSE-EFFECTS ADP F
stimulation 0 NOUN F
with 0 ADP F
rFSH 0 NOUN F
, 0 PUNCT F
total 0 ADJ F
rFSH 0 NOUN F
dosage 0 NOUN F
, 0 PUNCT F
total 0 ADJ F
number B-ADVERSE-EFFECTS NOUN F
of I-ADVERSE-EFFECTS ADP F
oocytes I-ADVERSE-EFFECTS NOUN F
retrieved B-ADVERSE-EFFECTS VERB F
, 0 PUNCT F
M2 0 NOUN T
oocytes B-ADVERSE-EFFECTS NOUN F
retrieved I-ADVERSE-EFFECTS VERB F
, 0 PUNCT F
total 0 ADJ F
number B-ADVERSE-EFFECTS NOUN F
of I-ADVERSE-EFFECTS ADP F
embryos I-ADVERSE-EFFECTS NOUN F
, 0 PUNCT F
number B-ADVERSE-EFFECTS NOUN F
of B-ADVERSE-EFFECTS ADP F
embryos I-ADVERSE-EFFECTS NOUN F
transferred 0 VERB F
, 0 PUNCT F
number B-ADVERSE-EFFECTS NOUN F
of I-ADVERSE-EFFECTS ADP F
Grade-1 0 NOUN T
embryos B-ADVERSE-EFFECTS NOUN F
transferred 0 ADP F
, 0 PUNCT F
clinical 0 ADJ F
pregnancy 0 NOUN F
rate 0 NOUN F
( 0 PUNCT F
positive 0 ADJ F
fetal 0 ADJ F
cardiac 0 ADJ F
activity 0 NOUN F
) 0 PUNCT F
, 0 PUNCT F
and 0 CCONJ F
cancellation 0 NOUN F
rates 0 NOUN F
of B-ADVERSE-EFFECTS ADP F
stimulation 0 NOUN F
and 0 CCONJ F
embryo 0 NOUN F
transfer 0 NOUN F
. 0 PUNCT F

RESULT 0 NOUN T
( 0 PUNCT F
S 0 NOUN T
) 0 PUNCT F

Parietal B-PHYSICAL ADJ T
cell I-PHYSICAL NOUN F
density I-PHYSICAL NOUN F
in 0 ADP F
duodenal 0 ADJ F
ulcer 0 NOUN F
patients 0 NOUN F
after 0 ADP F
short-term 0 NOUN F
treatment 0 NOUN F
with 0 ADP F
cimetidine 0 NOUN F
and 0 CCONJ F
antacids 0 NOUN F
. 0 PUNCT F

In 0 ADP T
a 0 DET F
prospective 0 ADJ F
study 0 NOUN F
, 0 PUNCT F
20 0 NUM F
patients 0 NOUN F
with 0 ADP F
endoscopically 0 ADV F
proven 0 VERB F
duodenal 0 ADJ F
ulcers 0 NOUN F
were 0 VERB F
randomised 0 VERB F
to 0 PART F
be 0 PUNCT F
treated 0 VERB F
with 0 ADP F
cimetidine 0 NOUN F
1 0 NUM F
g 0 ADP F
daily 0 ADP F
or 0 CCONJ F
with 0 ADP F
antacids 0 NOUN F
350 0 NUM F
mmol 0 NOUN F
daily 0 ADJ F
. 0 PUNCT F

The 0 DET T
duration 0 NOUN F
of 0 ADP F
treatment 0 NOUN F
was 0 VERB F
30 0 NUM F
days 0 NOUN F
, 0 PUNCT F
but 0 CCONJ F
this 0 ADP F
was 0 NUM F
extended 0 VERB F
to 0 ADP F
three 0 NUM F
months 0 NOUN F
in 0 ADP F
3 0 NUM F
patients 0 NOUN F
in 0 ADP F
the 0 DET F
cimetidine 0 NOUN F
group 0 NOUN F
and 0 CCONJ F
4 0 NUM F
patients 0 NOUN F
in 0 ADP F
the 0 DET F
antacid 0 ADJ F
group 0 NOUN F
. 0 PUNCT F

A 0 DET T
morphological 0 ADJ F
study 0 NOUN F
of 0 ADP F
biopsies 0 NOUN F
taken 0 VERB F
via 0 ADP F
a 0 DET F
gastroscope 0 NOUN F
from 0 ADP F
the 0 DET F
corpus 0 ADJ F
mucosa 0 NOUN F
showed 0 VERB F
no 0 DET F
change 0 NOUN F
in 0 ADP F
mucosal B-PHYSICAL ADJ F
height I-PHYSICAL NOUN F
, 0 PUNCT F
parietal B-PHYSICAL ADJ F
cell I-PHYSICAL NOUN F
density I-PHYSICAL NOUN F
per I-PHYSICAL ADP F
unit I-PHYSICAL NOUN F
volume I-PHYSICAL NOUN F
or 0 CCONJ F
changes 0 NOUN F
in 0 ADP F
cellular B-PHYSICAL ADJ F
infiltration I-PHYSICAL NOUN F
after 0 ADP F
30 0 NUM F
and 0 CCONJ F
90 0 NUM F
days 0 NOUN F
treatment 0 NOUN F
in 0 ADP F
the 0 DET F
two 0 NUM F
groups 0 NOUN F
. 0 PUNCT F

Neither 0 CCONJ T
H-2 0 NOUN T
receptor 0 NOUN F
blockers 0 NOUN F
nor 0 CCONJ F
antacids 0 NOUN F
alter 0 VERB F
mucosal B-PHYSICAL ADJ F
height I-PHYSICAL ADJ F
or 0 CCONJ F
parietal B-PHYSICAL ADJ F
cell I-PHYSICAL NOUN F
density I-PHYSICAL NOUN F
. 0 PUNCT F

Treatment 0 NOUN T
was 0 VERB F
not 0 ADV F
found 0 VERB F
to 0 PART F
induce 0 NOUN F
gastritic B-PHYSICAL ADJ F
changes I-PHYSICAL NOUN F
in 0 ADP F
the 0 DET F
mucosa 0 NOUN F
. 0 PUNCT F

Effect 0 NOUN T
of 0 ADP F
granulocyte/colony-stimulating 0 PUNCT F
factor 0 NOUN F
on 0 ADP F
the 0 DET F
onset 0 NOUN F
of 0 ADP F
the 0 DET F
adult 0 NOUN F
respiratory 0 ADJ F
distress 0 NOUN F
syndrome 0 NOUN F
. 0 PUNCT F

To 0 PART T
evaluate 0 NOUN F
the 0 DET F
effect 0 NOUN F
of 0 ADP F
granulocyte/colony-stimulating 0 PUNCT F
factor 0 NOUN F
( 0 PUNCT F
G-CSF 0 NOUN T
) 0 PUNCT F
on 0 ADP F
the 0 DET F
onset 0 NOUN F
of 0 ADP F
the 0 DET F
adult 0 NOUN F
respiratory 0 ADJ F
distress 0 NOUN F
syndrome 0 NOUN F
( 0 PUNCT F
ARDS 0 NOUN T
) 0 PUNCT F
, 0 PUNCT F
we 0 PRON F
investigated 0 VERB F
whether 0 ADP F
the 0 DET F
incidence 0 NOUN F
of 0 ADP F
ARDS 0 NOUN T
due 0 PUNCT F
to 0 ADP F
pulmonary 0 CCONJ F
infection 0 NOUN F
differed 0 VERB F
between 0 ADP F
the 0 DET F
G-CSF 0 NOUN T
group 0 NOUN F
which 0 ADP F
received 0 VERB F
chemotherapy 0 NOUN F
with 0 ADP F
G-CSF 0 NOUN T
and 0 CCONJ F
historical 0 ADJ F
controls 0 NOUN F
without 0 ADP F
G-CSF 0 NOUN T
. 0 PUNCT F

We 0 PRON T
evaluated 0 VERB F
132 0 NUM F
patients 0 NOUN F
with 0 ADP F
hematological 0 ADJ F
malignancy 0 NOUN F
in 0 ADP F
complete 0 ADJ F
remission 0 NOUN F
without 0 ADP F
any 0 DET F
main 0 ADJ F
organ 0 NOUN F
dysfunction 0 NOUN F
who 0 PROPN F
had 0 PUNCT F
been 0 PUNCT F
treated 0 VERB F
between 0 ADP F
April 0 NOUN T
1983 0 NUM F
and 0 CCONJ F
December 0 NOUN T
1997 0 NUM F
. 0 PUNCT F

We 0 PRON T
compared 0 VERB F
the 0 DET F
incidence 0 NOUN F
of 0 ADP F
ARDS 0 NOUN T
due 0 PUNCT F
to 0 ADP F
pulmonary 0 CCONJ F
infection 0 NOUN F
between 0 ADP F
those 0 PUNCT F
who 0 ADP F
received 0 VERB F
G-CSF 0 NOUN T
and 0 CCONJ F
those 0 ADP F
who 0 PROPN F
did 0 CCONJ F
not 0 ADV F
. 0 PUNCT F

There 0 PUNCT T
was 0 VERB F
no 0 DET F
remarkable 0 ADJ F
difference 0 NOUN F
in 0 ADP F
the 0 DET F
number 0 NOUN F
of 0 ADP F
patients 0 NOUN F
, 0 PUNCT F
gender 0 NOUN F
, 0 PUNCT F
age 0 NOUN F
, 0 PUNCT F
or 0 CCONJ F
distribution 0 NOUN F
of 0 ADP F
primary 0 ADJ F
diseases 0 NOUN F
between 0 ADP F
the 0 DET F
two 0 NUM F
groups 0 NOUN F
. 0 PUNCT F

The 0 DET T
intensity 0 NOUN F
of 0 ADP F
chemotherapy B-OTHER NOUN F
was 0 VERB F
not 0 ADV F
considered 0 VERB F
to 0 PUNCT F
significantly 0 ADV F
differ 0 VERB F
between 0 ADP F
the 0 DET F
two 0 NUM F
groups 0 NOUN F
, 0 PUNCT F
though 0 CCONJ F
the 0 DET F
chemotherapy 0 NOUN F
regimens 0 NOUN F
administered 0 VERB F
differed 0 VERB F
slightly 0 ADV F
. 0 PUNCT F

In 0 ADP T
the 0 DET F
G-CSF 0 NOUN T
group 0 NOUN F
, 0 PUNCT F
the 0 DET F
duration B-PHYSICAL NOUN F
of I-PHYSICAL ADP F
neutropenia I-PHYSICAL NOUN F
was 0 VERB F
significantly 0 ADV F
shorter 0 PUNCT F
and 0 CCONJ F
the 0 DET F
frequency 0 NOUN F
of 0 ADP F
documented 0 VERB F
infection 0 NOUN F
was 0 VERB F
significantly 0 ADV F
decreased 0 NOUN F
. 0 PUNCT F

We 0 PRON T
could 0 ADP F
not 0 ADV F
find 0 VERB F
any 0 DET F
relationship 0 NOUN F
between 0 ADP F
ARDS 0 NOUN T
due 0 PUNCT F
to 0 ADP F
pulmonary B-PHYSICAL CCONJ F
infection I-PHYSICAL NOUN F
and 0 CCONJ F
any 0 DET F
anticancer 0 NOUN F
agent 0 NOUN F
or 0 CCONJ F
antibiotics 0 NOUN F
. 0 PUNCT F

There 0 PUNCT T
was 0 VERB F
no 0 DET F
relationship 0 NOUN F
between 0 ADP F
the 0 DET F
kind 0 ADV F
of 0 ADP F
G-CSF 0 NOUN T
and 0 CCONJ F
the 0 DET F
incidence 0 NOUN F
of 0 ADP F
ARDS 0 NOUN T
due 0 PUNCT F
to 0 ADP F
pulmonary B-PHYSICAL CCONJ F
infection I-PHYSICAL NOUN F
( 0 PUNCT F
per 0 ADP F
chemotherapy 0 NOUN F
session 0 NOUN F
; 0 PUNCT F
p 0 NOUN F
> 0 SYM F
0.10 0 NUM F
, 0 PUNCT F
per 0 ADP F
case 0 NOUN F
; 0 PUNCT F
p 0 NOUN F
> 0 SYM F
0.30 0 NUM F
, 0 PUNCT F
chi2 0 NOUN F
test 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
incidence 0 NOUN F
of 0 ADP F
ARDS B-PHYSICAL NOUN T
due I-PHYSICAL PUNCT F
to I-PHYSICAL ADP F
pulmonary I-PHYSICAL CCONJ F
infection I-PHYSICAL NOUN F
per I-PHYSICAL ADP F
chemotherapy I-PHYSICAL NOUN F
session I-PHYSICAL NOUN F
was 0 VERB F
4.21 0 NUM F
% 0 SYM F
, 0 PUNCT F
and 0 CCONJ F
showed 0 VERB F
a 0 DET F
higher 0 PUNCT F
tendency 0 NOUN F
in 0 ADP F
the 0 DET F
G-CSF 0 NOUN T
group 0 NOUN F
( 0 PUNCT F
p 0 NOUN F
< 0 SYM F
0.100 0 DET F
, 0 PUNCT F
chi2 0 NOUN F
test 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
incidence 0 NOUN F
of 0 ADP F
ARDS 0 NOUN T
due 0 PUNCT F
to 0 ADP F
pulmonary 0 CCONJ F
infection 0 NOUN F
per 0 ADP F
case 0 NOUN F
was 0 VERB F
25.4 0 NUM F
% 0 SYM F
and 0 CCONJ F
was 0 VERB F
significantly 0 ADV F
higher 0 PUNCT F
in 0 ADP F
the 0 DET F
G-CSF 0 NOUN T
group 0 NOUN F
( 0 PUNCT F
p 0 NOUN F
< 0 SYM F
0.025 0 NUM F
, 0 PUNCT F
chi2 0 NOUN F
test 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
incidence 0 NOUN F
of 0 ADP F
ARDS B-PHYSICAL NOUN T
due I-PHYSICAL PUNCT F
to I-PHYSICAL ADP F
pulmonary I-PHYSICAL CCONJ F
infection I-PHYSICAL NOUN F
was I-PHYSICAL VERB F
higher 0 PUNCT F
in B-PHYSICAL ADP F
the I-PHYSICAL DET F
G-CSF I-PHYSICAL PUNCT T

Twenty-four 0 PUNCT T
vs. 0 CCONJ F
forty-eight 0 PUNCT F
weeks 0 NOUN F
of 0 ADP F
re-therapy 0 NOUN F
with 0 ADP F
interferon 0 NOUN F
alpha 0 NOUN F
2b 0 NOUN F
and 0 CCONJ F
ribavirin 0 NOUN F
in 0 ADP F
interferon 0 NOUN F
alpha 0 NOUN F
monotherapy 0 NOUN F
relapsers 0 NOUN F
with 0 ADP F
chronic 0 ADJ F
hepatitis 0 NOUN F
C. 0 NOUN T
BACKGROUND/AIM 0 NUM T
Roughly 0 PUNCT T
50 0 NUM F
% 0 SYM F
of 0 ADP F
patients 0 NOUN F
with 0 ADP F
chronic 0 ADJ F
hepatitis 0 NOUN F
C 0 NOUN T
, 0 PUNCT F
who 0 ADP F
relapsed 0 VERB F
after 0 ADP F
a 0 DET F
previous 0 ADJ F
monotherapy 0 NOUN F
with 0 ADP F
interferon 0 NOUN F
alpha 0 NOUN F
, 0 PUNCT F
will 0 VERB F
respond 0 VERB F
in 0 ADP F
a 0 DET F
sustained 0 VERB F
fashion 0 NOUN F
to 0 ADP F
24 0 NUM F
weeks 0 NOUN F
of 0 ADP F
re-therapy 0 NOUN F
with 0 ADP F
the 0 DET F
combination 0 NOUN F
of 0 ADP F
interferon 0 NOUN F
alpha 0 NOUN F
plus 0 CCONJ F
ribavirin 0 NOUN F
. 0 PUNCT F

Whether 0 VERB T
prolonging 0 ADV F
treatment 0 NOUN F
duration 0 NOUN F
to 0 ADP F
48 0 NUM F
weeks 0 NOUN F
will 0 ADP F
further 0 PUNCT F
increase 0 NUM F
sustained 0 PUNCT F
response 0 NOUN F
rates 0 NOUN F
remains 0 NOUN F
ill 0 ADJ F
defined 0 VERB F
. 0 PUNCT F

In 0 ADP T
this 0 DET F
randomised 0 VERB F
controlled 0 DET F
pilot 0 NOUN F
trial 0 NOUN F
we 0 NOUN F
compared 0 VERB F
the 0 DET F
efficacy 0 NOUN F
and 0 CCONJ F
tolerability B-OTHER NOUN F
of 0 ADP F
a 0 DET F
24 0 NUM F
week 0 NOUN F
with 0 ADP F
that 0 PUNCT F
of 0 ADP F
a 0 DET F
48 0 NUM F
week 0 NOUN F
course 0 NOUN F
of 0 ADP F
combination 0 NOUN F
therapy 0 NOUN F
with 0 ADP F
interferon 0 NOUN F
alpha 0 NOUN F
and 0 CCONJ F
ribavirin 0 NOUN F
in 0 ADP F
interferon 0 NOUN F
monotherapy 0 NOUN F
relapsers 0 NOUN F
with 0 ADP F
chronic 0 ADJ F
hepatitis 0 NOUN F
C. 0 NOUN T
METHODS 0 NOUN T
Interferon 0 NOUN T
alpha 0 NOUN F
monotherapy 0 NOUN F
relapsers 0 NOUN F
with 0 ADP F
chronic 0 ADJ F
hepatitis 0 NOUN F
C 0 NOUN T
were 0 VERB F
randomised 0 VERB F
to 0 PART F
receive 0 PART F
interferon 0 NOUN F
alpha 0 NOUN F
2b 0 NOUN F
( 0 PUNCT F
3 0 NUM F
x 0 SYM F
3 0 NUM F
MIU 0 NOUN T
sc 0 PUNCT F
weekly 0 ADV F
) 0 PUNCT F
and 0 CCONJ F
oral 0 ADJ F
ribavirin 0 NOUN F
( 0 PUNCT F
1000/1200 0 NOUN F
mg 0 NOUN F
po 0 ADP F
daily 0 ADP F
) 0 PUNCT F
for 0 ADP F
either 0 CCONJ F
24 0 NUM F
weeks 0 NOUN F
or 0 CCONJ F
48 0 NUM F
weeks 0 NOUN F
. 0 PUNCT F

Virological 0 ADJ T
response 0 NOUN F
was 0 VERB F
evaluated 0 VERB F
by 0 ADP F
HCV 0 NOUN T
RNA 0 NOUN T
PCR 0 NOUN T
at 0 ADP F
week 0 NOUN F
10 0 NUM F
( 0 PUNCT F
initial 0 ADJ F
response 0 NOUN F
) 0 PUNCT F
, 0 PUNCT F
at 0 ADP F
the 0 DET F
end 0 NOUN F
of 0 ADP F
treatment 0 NOUN F
( 0 PUNCT F
end 0 NOUN F
of- 0 NOUN F
treatment 0 NOUN F
response 0 NOUN F
) 0 PUNCT F
and 0 CCONJ F
at 0 ADP F
the 0 DET F
end 0 NOUN F
of 0 ADP F
24 0 NUM F
weeks 0 NOUN F
follow-up 0 NOUN F
( 0 PUNCT F
sustained 0 PUNCT F
response 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

Only 0 DET T
patients 0 NOUN F
with 0 ADP F
negative 0 ADJ F
HCV 0 NOUN T
RNA 0 NOUN T
at 0 ADP F
week 0 NOUN F
10 0 NUM F
continued 0 VERB F
treatment 0 NOUN F
. 0 PUNCT F

Adverse B-ADVERSE-EFFECTS ADJ T
events I-ADVERSE-EFFECTS NOUN F
were 0 VERB F
recorded 0 VERB F
at 0 ADP F
regular 0 ADJ F
intervals 0 NOUN F
. 0 PUNCT F

RESULTS 0 NOUN T
Thirty-seven 0 PUNCT T
patients 0 NOUN F
were 0 VERB F
enrolled 0 VERB F
, 0 PUNCT F
19 0 NUM F
( 0 PUNCT F
6 0 NUM F
females 0 NOUN F
, 0 PUNCT F
median 0 ADJ F
age 0 NOUN F
43 0 NUM F
) 0 PUNCT F
in 0 ADP F
the 0 DET F
24 0 NUM F
week 0 NOUN F
and 0 CCONJ F
18 0 NUM F
( 0 PUNCT F
5 0 NUM F
females 0 NOUN F
, 0 PUNCT F
median 0 ADJ F
age 0 NOUN F
40 0 NUM F
) 0 PUNCT F
in 0 ADP F
the 0 DET F
48 0 NUM F
week 0 NOUN F
treatment 0 NOUN F
arm 0 ADP F
. 0 PUNCT F

Baseline 0 NOUN T
characteristics 0 NOUN F
were 0 VERB F
similar 0 ADJ F
in 0 ADP F
both 0 CCONJ F
groups 0 NOUN F
. 0 PUNCT F

At 0 ADP T
treatment 0 NOUN F
week 0 NOUN F
10 0 NUM F
, 0 PUNCT F
12/19 0 PUNCT F
( 0 PUNCT F
63 0 NUM F
% 0 SYM F
) 0 PUNCT F
in 0 ADP F
the 0 DET F
24 0 NUM F
week 0 NOUN F
group 0 NOUN F
and 0 CCONJ F
14/18 0 PUNCT F
( 0 PUNCT F
78 0 NUM F
% 0 SYM F
) 0 PUNCT F
patients 0 NOUN F
in 0 ADP F
the 0 DET F
48 0 NUM F
week 0 NOUN F
group 0 NOUN F
had 0 PUNCT F
lost B-PHYSICAL ADJ F
HCV I-PHYSICAL NOUN T
RNA I-PHYSICAL NOUN T
in I-PHYSICAL ADP F
serum I-PHYSICAL NOUN F
( 0 PUNCT F
p 0 NOUN F
= 0 SYM F
0.33 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

All 0 DET T
initial 0 ADJ F
responders 0 NOUN F
remained 0 VERB F
HCV B-PHYSICAL NOUN T
RNA I-PHYSICAL NOUN T
negative 0 ADJ F
throughout 0 ADP F
the 0 DET F
treatment 0 NOUN F
period 0 NOUN F
. 0 PUNCT F

Sustained B-OTHER VERB T
response 0 NOUN F
rates B-OTHER NOUN F
were 0 ADP F
10/19 0 PUNCT F
( 0 PUNCT F
53 0 NUM F
% 0 SYM F
) 0 PUNCT F
in 0 ADP F
the 0 DET F
24 0 NUM F
week 0 NOUN F
group 0 NOUN F
and 0 CCONJ F
13/18 0 PUNCT F
( 0 PUNCT F
72 0 NUM F
% 0 SYM F
) 0 PUNCT F
in 0 ADP F
the 0 DET F
48 0 NUM F
week 0 NOUN F
group 0 NOUN F
( 0 PUNCT F
p 0 NOUN F
= 0 SYM F
0.31 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Three 0 NUM T
patients 0 NOUN F
discontinued 0 CCONJ F
treatment 0 NOUN F
early 0 ADJ F
( 0 PUNCT F
two 0 NUM F
due 0 PUNCT F
to 0 ADP F
moderate B-ADVERSE-EFFECTS ADJ F
adverse B-ADVERSE-EFFECTS ADJ F
events B-ADVERSE-EFFECTS NOUN F
, 0 PUNCT F
one 0 NUM F
due 0 PUNCT F
to 0 ADP F
non-compliance 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

Dose 0 NOUN T
modifications 0 NOUN F
were 0 ADP F
necessary 0 ADJ F
in 0 ADP F
9 0 NUM F
patients 0 NOUN F
, 0 PUNCT F
4 0 NUM F
in 0 ADP F
the 0 DET F
24 0 NUM F
week 0 NOUN F
and 0 CCONJ F
5 0 NUM F
in 0 ADP F
the 0 DET F
48 0 NUM F
week 0 NOUN F
group 0 NOUN F
for 0 ADP F
anaemia B-PHYSICAL NOUN F
, 0 PUNCT F
neutropenia B-PHYSICAL NOUN F
, 0 PUNCT F

A 0 DET T
double-blind 0 ADJ F
placebo 0 NOUN F
controlled 0 VERB F
trial 0 NOUN F
of 0 ADP F
Ginkgo 0 NOUN T
biloba 0 NOUN F
added 0 VERB F
to 0 ADP F
risperidone 0 NUM F
in 0 ADP F
patients 0 NOUN F
with 0 ADP F
autistic 0 ADJ F
disorders 0 NOUN F
. 0 PUNCT F

Ginkgo 0 NOUN T
biloba 0 NOUN F
has 0 PUNCT F
been 0 PUNCT F
reported 0 VERB F
to 0 PART F
affect 0 VERB F
the 0 DET F
neurotransmitter 0 NOUN F
system 0 NOUN F
and 0 CCONJ F
to 0 PRON F
have 0 PUNCT F
antioxidant 0 NOUN F
properties 0 NOUN F
that 0 NUM F
could 0 ADJ F
impact 0 ADP F
the 0 DET F
pathogenesis 0 NOUN F
of 0 ADP F
Autism 0 NOUN T
Spectrum 0 NOUN T
Disorder 0 NOUN T
. 0 PUNCT F

Based 0 VERB T
on 0 ADP F
these 0 DET F
studies 0 NOUN F
, 0 PUNCT F
we 0 PRON F
decided 0 VERB F
to 0 PART F
assess 0 NOUN F
the 0 DET F
effectiveness 0 NOUN F
of 0 ADP F
Ginkgo 0 NOUN T
biloba 0 NOUN F
extract 0 NOUN F
( 0 PUNCT F
Ginko 0 NOUN T
T.D. 0 NOUN T
, 0 PUNCT F
Tolidaru 0 NOUN T
, 0 PUNCT F
Iran 0 NOUN T
) 0 PUNCT F
as 0 ADP F
an 0 DET F
adjunctive 0 ADJ F
agent 0 NOUN F
to 0 ADP F
risperidone 0 VERB F
in 0 ADP F
the 0 DET F
treatment 0 NOUN F
of 0 ADP F
autism 0 NOUN F
. 0 PUNCT F

Forty-seven 0 NUM T
outpatients 0 NOUN F
with 0 ADP F
a 0 DET F
DSM-IV-TR 0 NOUN T
diagnosis 0 NOUN F
of 0 ADP F
autism 0 NOUN F
ages 0 NOUN F
between 0 ADP F
4 0 NUM F
and 0 CCONJ F
12 0 NUM F
years 0 NOUN F
were 0 VERB F
assigned 0 VERB F
to 0 ADP F
this 0 CCONJ F
double 0 ADJ F
blinded 0 ADP F
clinical 0 ADJ F
trial 0 NOUN F
and 0 CCONJ F
were 0 VERB F
randomly 0 ADV F
divided 0 VERB F
into 0 ADP F
two 0 NUM F
groups 0 NOUN F
. 0 PUNCT F

One 0 NUM T
group 0 NOUN F
received 0 VERB F
risperidone 0 NUM F
plus 0 CCONJ F
Ginko 0 NOUN T
T.D 0 NOUN T
and 0 CCONJ F
the 0 DET F
other 0 ADJ F
received 0 ADP F
risperidone 0 ADP F
plus 0 CCONJ F
placebo 0 NOUN F
. 0 PUNCT F

The 0 DET T
dose 0 NOUN F
of 0 ADP F
risperidone 0 NUM F
was 0 VERB F
1-3 0 NUM F
mg/day 0 NOUN F
and 0 CCONJ F
the 0 DET F
dose 0 NOUN F
of 0 ADP F
Ginko 0 NOUN T
T.D 0 NOUN T
. 0 PUNCT F

was 0 VERB F
80 0 NUM F
mg/day 0 NOUN F
for 0 ADP F
patients 0 NOUN F
under 0 ADP F
30 0 NUM F
kg 0 NOUN F
and 0 CCONJ F
120 0 NUM F
mg/day 0 NOUN F
for 0 ADP F
patients 0 NOUN F
above 0 ADP F
30 0 NUM F
kg 0 NOUN F
. 0 PUNCT F

Patients 0 NOUN T
were 0 VERB F
assessed 0 VERB F
using 0 SYM F
Aberrant B-MENTAL ADJ T
Behavior I-MENTAL NOUN T
Checklist-Community I-MENTAL NOUN T
( I-MENTAL PUNCT F
ABC-C I-MENTAL NOUN T
) I-MENTAL PUNCT F
rating I-MENTAL ADP F
scale 0 NOUN F
and 0 CCONJ F
the 0 DET F
side B-MENTAL NOUN F
effect 0 NOUN F
check B-MENTAL ADV F
list B-MENTAL NOUN F
every 0 DET F
2 0 NUM F
weeks 0 NOUN F
until 0 ADP F
the 0 DET F
endpoint 0 NOUN F
. 0 PUNCT F

None 0 NUM T
of 0 ADP F
the 0 DET F
5 0 NUM F
subscales 0 NOUN F
of 0 ADP F
ABC-C B-MENTAL NOUN T
rating I-MENTAL PUNCT F

Symptomatic 0 ADJ T
and 0 CCONJ F
functional 0 ADJ F
improvement 0 NOUN F
in 0 ADP F
employed 0 PUNCT F
depressed 0 VERB F
patients 0 NOUN F
: 0 PUNCT F
a 0 DET F
double-blind 0 ADJ F
clinical 0 ADJ F
trial 0 NOUN F
of 0 ADP F
desvenlafaxine 0 NOUN F
versus 0 CCONJ F
placebo 0 NOUN F
. 0 PUNCT F

OBJECTIVE 0 NOUN T
This 0 PUNCT T
is 0 VERB F
the 0 DET F
first 0 ADJ F
study 0 NOUN F
to 0 PART F
assess 0 NOUN F
the 0 DET F
efficacy 0 NOUN F
of 0 ADP F
desvenlafaxine 0 NOUN F
( 0 PUNCT F
administered 0 ADP F
as 0 ADP F
desvenlafaxine 0 NOUN F
succinate 0 NOUN F
) 0 PUNCT F
for 0 ADP F
improving 0 VERB F
depressive B-MENTAL ADJ F
symptoms I-MENTAL NOUN F
and 0 CCONJ F
functioning B-MENTAL SYM F
exclusively 0 ADV F
in 0 ADP F
employed 0 DET F
patients 0 NOUN F
with 0 ADP F
major 0 ADJ F
depressive 0 ADJ F
disorder 0 NOUN F
( 0 PUNCT F
MDD 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

METHODS 0 NOUN T
Gainfully 0 ADP T
employed 0 VERB F
( 0 PUNCT F
?20 0 PUNCT F
h/wk 0 NOUN F
) 0 PUNCT F
male 0 NOUN F
and 0 CCONJ F
female 0 NOUN F
outpatients 0 ADJ F
with 0 ADP F
MDD 0 NOUN T
were 0 VERB F
randomly 0 ADV F
assigned 0 VERB F
( 0 PUNCT F
2:1 0 NUM F
ratio 0 NOUN F
) 0 PUNCT F
to 0 ADP F
12 0 NUM F
weeks 0 NOUN F
of 0 ADP F
double-blind 0 ADJ F
treatment 0 NOUN F
with 0 ADP F
desvenlafaxine 0 NOUN F
50 0 NUM F
mg/d 0 NOUN F
or 0 CCONJ F
placebo 0 NOUN F
. 0 PUNCT F

Analysis 0 NOUN T
of 0 ADP F
covariance 0 NOUN F
was 0 VERB F
used 0 VERB F
to 0 PART F
compare 0 NOUN F
differences 0 NOUN F
in 0 ADP F
week 0 NOUN F
12 0 NUM F
adjusted 0 VERB F
mean 0 NOUN F
changes 0 NOUN F
from 0 ADP F
baseline 0 NOUN F
on 0 ADP F
the 0 DET F
17-item 0 NOUN F
Hamilton 0 PUNCT T
Depression 0 NOUN T
Rating 0 PUNCT T
Scale 0 NOUN T
( 0 PUNCT F
HAM-D?? 0 NOUN T
) 0 PUNCT F
( 0 PUNCT F
primary 0 ADJ F
outcome 0 NOUN F
) 0 PUNCT F
and 0 CCONJ F
Sheehan 0 PUNCT T
Disability 0 NOUN T
Scale 0 NOUN T
( 0 PUNCT F
SDS 0 NOUN T
) 0 PUNCT F
( 0 PUNCT F
key 0 ADJ F
secondary 0 ADJ F
outcome 0 NOUN F
) 0 PUNCT F
in 0 ADP F
the 0 DET F
intent-to-treat 0 NOUN F
( 0 PUNCT F
ITT 0 NOUN T
) 0 PUNCT F
population 0 NOUN F
. 0 PUNCT F

A 0 PUNCT T
predefined 0 VERB F
, 0 PUNCT F
modified 0 VERB F
ITT 0 NOUN T
population 0 NOUN F
( 0 PUNCT F
ie 0 ADP F
, 0 PUNCT F
those 0 PUNCT F
in 0 ADP F
the 0 DET F
ITT 0 NOUN T
population 0 NOUN F
with 0 ADP F
baseline 0 NOUN F
HAM-D?? 0 ADV T
?20 0 PUNCT F
) 0 PUNCT F
was 0 VERB F
also 0 ADV F
analyzed 0 VERB F
. 0 PUNCT F

Tolerability 0 NOUN T
was 0 VERB F
assessed 0 VERB F
by 0 ADP F
recording 0 ADV F
adverse 0 ADJ F
events 0 NOUN F
and 0 CCONJ F
change 0 ADP F
on 0 ADP F
the 0 DET F
Arizona 0 NOUN T
Sexual 0 ADJ T
Experience 0 NOUN T
Scale 0 NOUN T
. 0 PUNCT F

RESULTS 0 NOUN T
Baseline 0 NOUN T
HAM-D?? 0 ADP T
scores 0 NOUN F
for 0 ADP F
desvenlafaxine 0 NOUN F
( 0 PUNCT F
n 0 NOUN F
= 0 SYM F
285 0 NUM F
) 0 PUNCT F
and 0 CCONJ F
placebo 0 NOUN F
( 0 PUNCT F
n 0 NOUN F
= 0 SYM F
142 0 NUM F
) 0 PUNCT F
were 0 VERB F
22.0 0 NUM F
and 0 CCONJ F
21.8 0 NUM F
, 0 PUNCT F
whereas 0 ADP F
baseline 0 NOUN F
SDS 0 NOUN T
scores 0 NOUN F
were 0 VERB F
19.8 0 NUM F
and 0 CCONJ F
20.4 0 NUM F
. 0 PUNCT F

Adjusted 0 VERB T
mean 0 NOUN F
differences 0 NOUN F
between 0 ADP F
desvenlafaxine 0 NOUN F
and 0 CCONJ F
placebo 0 NOUN F
were 0 VERB F
2.1 0 NUM F
( 0 PUNCT F
95 0 NUM F
% 0 SYM F
confidence 0 NOUN F
interval 0 NOUN F
[ 0 PUNCT F
CI 0 NOUN T
] 0 PUNCT F
, 0 PUNCT F
0.78-3.46 0 NUM F
; 0 PUNCT F
P 0 NOUN T
= 0 SYM F
0.002 0 NUM F
) 0 PUNCT F
on 0 ADP F
the 0 DET F
HAM-D?? 0 NOUN T
and 0 CCONJ F
1.3 0 NUM F
( 0 PUNCT F
95 0 NUM F
% 0 SYM F
CI 0 NOUN T
, 0 PUNCT F
-0.09 0 ADJ F
to 0 ADP F
2.76 0 ADJ F
; 0 PUNCT F
P 0 NOUN T
= 0 SYM F
0.067 0 NUM F
) 0 PUNCT F
on 0 ADP F
the 0 DET F
SDS 0 NOUN T
. 0 PUNCT F

For 0 ADP T
the 0 DET F
modified 0 VERB F
ITT 0 NOUN T
sample 0 NOUN F
, 0 PUNCT F
desvenlafaxine 0 NOUN F
( 0 PUNCT F
n 0 NOUN F
= 0 SYM F
208 0 NUM F
) 0 PUNCT F
and 0 CCONJ F
placebo 0 NOUN F
( 0 PUNCT F
n 0 NOUN F
= 0 SYM F
102 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
baseline 0 NOUN F
HAM-D?? 0 NOUN T
scores 0 NOUN F
were 0 VERB F
23.8 0 NUM F
and 0 CCONJ F
23.9 0 NUM F
; 0 PUNCT F
the 0 DET F
SDS 0 NOUN T
baseline 0 NOUN F
scores 0 NOUN F
were 0 VERB F
20.1 0 NUM F
and 0 CCONJ F
20.8 0 NUM F
. 0 PUNCT F

Mean 0 PUNCT T
differences 0 NOUN F
were 0 VERB F
2.6 0 NUM F
( 0 PUNCT F
95 0 NUM F
% 0 SYM F
CI 0 NOUN T
, 0 PUNCT F
0.93-4.22 0 NUM F
; 0 PUNCT F
P 0 NOUN T
= 0 SYM F
0.002 0 NUM F
) 0 PUNCT F
on 0 ADP F
the 0 DET F
HAM-D?? 0 NOUN T
and 0 CCONJ F
2.1 0 NUM F
( 0 PUNCT F
95 0 NUM F
% 0 SYM F
CI 0 NOUN T
, 0 PUNCT F
0.36-3.76 0 NUM F
; 0 PUNCT F
P 0 NOUN T
= 0 SYM F
0.017 0 NUM F
) 0 PUNCT F
on 0 ADP F
the 0 DET F
SDS 0 NOUN T
. 0 PUNCT F

Adverse 0 ADJ T
events 0 NOUN F
and 0 CCONJ F
Arizona 0 NOUN T
Sexual 0 ADJ T
Experience 0 NOUN T
Scale 0 NOUN T
scores 0 NOUN F
were 0 VERB F
comparable 0 ADJ F
between 0 ADP F
groups 0 NOUN F
. 0 PUNCT F

CONCLUSIONS 0 NOUN T
Desvenlafaxine 0 NOUN T
50 0 NUM F
mg/d 0 ADV F
was 0 VERB F
efficacious 0 ADJ F
for 0 ADP F
treating 0 VERB F
MDD 0 NOUN T
in 0 ADP F
gainfully 0 ADV F
employed 0 PUNCT F
adults 0 NOUN F
. 0 PUNCT F

Between-group 0 ADP T
differences 0 NOUN F
on 0 ADP F
the 0 DET F
SDS 0 NOUN T
narrowly 0 ADV F
missed 0 VERB F
statistical 0 ADJ F
significance 0 NOUN F
in 0 ADP F
the 0 DET F
ITT 0 NOUN T
population 0 NOUN F
alone 0 ADJ F
, 0 PUNCT F
but 0 CCONJ F
the 0 DET F
totality 0 NOUN F
of 0 ADP F
data 0 NOUN F
suggests 0 NOUN F
functional 0 ADJ F
improvements 0 NOUN F
with 0 ADP F
active 0 ADJ F
treatment 0 NOUN F
. 0 PUNCT F

Clonidine 0 NOUN T
premedication 0 NOUN F
improves 0 NOUN F
metabolic B-PHYSICAL ADJ F
control 0 NOUN F
in B-PHYSICAL ADP F
type 0 NOUN F
2 B-PHYSICAL NUM F
diabetic B-PHYSICAL ADJ F
patients I-PHYSICAL NOUN F
during 0 ADP F
ophthalmic 0 VERB F
surgery 0 NOUN F
. 0 PUNCT F

BACKGROUND 0 NOUN T
In 0 ADP T
stressful 0 ADJ F
conditions 0 NOUN F
, 0 PUNCT F
increasing 0 ADP F
blood 0 NOUN F
glucose 0 NOUN F
concentrations 0 NOUN F
are 0 VERB F
closely 0 ADV F
related 0 VERB F
to 0 ADP F
an 0 DET F
increase 0 NOUN F
in 0 ADP F
catecholamines 0 NOUN F
and 0 CCONJ F
cortisol 0 NOUN F
release 0 NOUN F
. 0 PUNCT F

Clonidine 0 NOUN T
, 0 PUNCT F
a 0 DET F
centrally 0 ADV F
acting 0 VERB F
alpha 0 NOUN F
( 0 PUNCT F
2 0 NUM F
) 0 PUNCT F
-adrenoceptor 0 NOUN F
agonist 0 NOUN F
, 0 PUNCT F
has 0 PUNCT F
neuroendocrine 0 NOUN F
effects 0 NOUN F
, 0 PUNCT F
including 0 VERB F
inhibition 0 NOUN F
of 0 ADP F
sympathoadrenal 0 ADJ F
activity 0 NOUN F
. 0 PUNCT F

We 0 PRON T
therefore 0 ADV F
evaluated 0 VERB F
the 0 DET F
effect 0 NOUN F
of 0 ADP F
clonidine 0 NOUN F
on 0 ADP F
blood B-PHYSICAL NOUN F
glucose I-PHYSICAL NOUN F
control B-PHYSICAL NOUN F
and 0 CCONJ F
insulin B-PHYSICAL NOUN F
requirements B-PHYSICAL NOUN F
during 0 ADP F
ophthalmic 0 VERB F
surgery 0 NOUN F
when 0 ADP F
given 0 VERB F
as 0 ADP F
premedication 0 NOUN F
in 0 ADP F
type 0 NOUN F
2 0 NUM F
diabetic 0 ADJ F
patients 0 NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
After 0 ADP T
randomization 0 NOUN F
, 0 PUNCT F
patients 0 NOUN F
were 0 VERB F
premedicated 0 VERB F
with 0 ADP F
clonidine 0 NOUN F
or 0 CCONJ F
flunitrazepam 0 NOUN F
( 0 PUNCT F
control 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

Patients 0 NOUN T
were 0 VERB F
given 0 VERB F
insulin 0 NOUN F
by 0 ADP F
continuous 0 ADJ F
i.v 0 NOUN F
. 0 PUNCT F

infusion 0 NOUN F
to 0 PART F
maintain 0 NOUN F
blood 0 NOUN F
glucose 0 NOUN F
in 0 ADP F
the 0 DET F
range 0 NOUN F
5.5-11.1 0 PUNCT F
mmol 0 NOUN F
litre 0 NOUN F
( 0 PUNCT F
-1 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Blood B-PHYSICAL NOUN T
glucose B-PHYSICAL NOUN F
concentrations I-PHYSICAL NOUN F
were 0 VERB F
measured 0 ADP F
every 0 DET F
15 0 NUM F
min 0 NOUN F
during 0 ADP F
surgery 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
hourly 0 PROPN F
for 0 ADP F
6 0 NUM F
h 0 NOUN F
after 0 ADP F
surgery 0 NOUN F
. 0 PUNCT F

Plasma B-PHYSICAL NOUN T
C-peptide I-PHYSICAL NOUN T
and I-PHYSICAL CCONJ F
counter-regulatory B-PHYSICAL ADJ F
hormones I-PHYSICAL NOUN F
were 0 VERB F
also 0 ADV F
measured 0 VERB F
. 0 PUNCT F

RESULTS 0 DET T
Glycaemia B-PHYSICAL NOUN T
was 0 VERB F
significantly 0 ADV F
lower 0 PUNCT F
in 0 ADP F
the 0 DET F
clonidine 0 NOUN F
group 0 NOUN F
( 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.01 0 NUM F
) 0 PUNCT F
and 0 CCONJ F
the 0 DET F
median 0 ADJ F
amount 0 NOUN F
of 0 PUNCT F

Levamisole 0 NOUN T
versus 0 CCONJ F
placebo 0 NOUN F
as 0 ADP F
an 0 DET F
adjunct 0 NOUN F
to 0 ADP F
primary 0 ADJ F
therapy 0 NOUN F
of 0 ADP F
laryngopharyngeal 0 PUNCT F
epidermoid 0 NOUN F
carcinoma 0 NOUN F
. 0 PUNCT F

Evaluation 0 NOUN T
of 0 ADP F
the 0 DET F
immune 0 ADJ F
status 0 NOUN F
. 0 PUNCT F

Twenty-four 0 PUNCT T
patients 0 NOUN F
, 0 PUNCT F
with 0 ADP F
a 0 DET F
biopsy-proven 0 PUNCT F
laryngeal 0 ADJ F
or 0 CCONJ F
hypopharyngeal 0 ADJ F
carcinoma 0 NOUN F
, 0 PUNCT F
received 0 ADV F
as 0 ADP F
an 0 DET F
adjunct 0 NOUN F
to 0 ADP F
their 0 PUNCT F
primary 0 ADJ F
treatment 0 NOUN F
( 0 PUNCT F
surgery 0 NOUN F
and/or 0 CCONJ F
radiotherapy 0 NOUN F
) 0 PUNCT F
, 0 PUNCT F
levamisole 0 NOUN F
( 0 PUNCT F
150 0 NUM F
mg 0 NOUN F
daily 0 ADJ F
during 0 ADP F
three 0 NUM F
consecutive 0 ADJ F
days 0 NOUN F
, 0 PUNCT F
every 0 DET F
fortnight 0 ADV F
) 0 PUNCT F
or 0 CCONJ F
placebo 0 NOUN F
, 0 PUNCT F
following 0 CCONJ F
a 0 DET F
single-blind 0 NOUN F
, 0 PUNCT F
but 0 CCONJ F
randomized 0 VERB F
method 0 NOUN F
. 0 PUNCT F

At 0 ADP T
the 0 DET F
end 0 NOUN F
of 0 ADP F
the 0 DET F
follow-up 0 NOUN F
, 0 PUNCT F
an 0 DET F
investigation 0 NOUN F
of 0 ADP F
the 0 DET F
immune B-PHYSICAL ADJ F
status 0 NOUN F
was 0 VERB F
done 0 PUNCT F
, 0 PUNCT F
and 0 CCONJ F
compared 0 VERB F
with 0 ADP F
that 0 PUNCT F
of 0 ADP F
a 0 DET F
healthy 0 ADJ F
control-group 0 NOUN F
. 0 PUNCT F

It 0 PRON T
is 0 VERB F
concluded 0 VERB F
that 0 ADP F
the 0 DET F
immunity B-PHYSICAL NOUN F
is 0 VERB F
disturbed 0 VERB F
in 0 ADP F
patients 0 NOUN F
with 0 ADP F
laryngo-pharyngeal 0 PUNCT F
cancer 0 NOUN F
, 0 PUNCT F
but 0 CCONJ F
that 0 ADP F
this 0 DET F
disturbance 0 NOUN F
does 0 PUNCT F
not 0 ADV F
clearly 0 ADV F
correlate 0 VERB F
with 0 ADP F
the 0 DET F
clinical 0 ADJ F
state 0 NOUN F
of 0 ADP F
the 0 DET F
disease 0 NOUN F
. 0 PUNCT F

Also 0 ADV T
, 0 PUNCT F
the 0 DET F
immunological 0 ADJ F
measures 0 NOUN F
did 0 PUNCT F
not 0 ADV F
appear 0 VERB F
relevant 0 ADJ F
to 0 ADP F
the 0 DET F
significantly 0 ADV F
favourable 0 ADJ F
effect 0 NOUN F
of 0 ADP F
levamisole 0 NOUN F
on 0 ADP F
the 0 DET F
prognosis 0 NOUN F
. 0 PUNCT F

Ganitumab 0 PUNCT T
with 0 ADP F
either 0 CCONJ F
exemestane 0 NOUN F
or 0 CCONJ F
fulvestrant 0 PUNCT F
for 0 ADP F
postmenopausal 0 ADJ F
women 0 NOUN F
with 0 ADP F
advanced 0 VERB F
, 0 PUNCT F
hormone-receptor-positive 0 ADJ F
breast 0 NOUN F
cancer 0 NOUN F
: 0 PUNCT F
a 0 DET F
randomised 0 VERB F
, 0 PUNCT F
controlled 0 PUNCT F
, 0 PUNCT F
double-blind 0 ADJ F
, 0 PUNCT F
phase 0 NOUN F
2 0 NUM F
trial 0 NOUN F
. 0 PUNCT F

BACKGROUND 0 NOUN T
Insulin-like 0 ADJ T
growth 0 NOUN F
factors 0 NOUN F
( 0 PUNCT F
IGF-1 0 NOUN T
and 0 CCONJ F
IGF-2 0 NOUN T
) 0 PUNCT F
bind 0 VERB F
to 0 ADP F
the 0 DET F
IGF-1 0 NOUN T
receptor 0 NOUN F
( 0 PUNCT F
IGF-1R 0 NOUN T
) 0 PUNCT F
, 0 PUNCT F
increasing 0 PUNCT F
cell B-PHYSICAL NOUN F
proliferation I-PHYSICAL NOUN F
and 0 CCONJ F
survival B-MORTALITY NOUN F
. 0 PUNCT F

Ganitumab 0 PUNCT T
is 0 VERB F
a 0 DET F
monoclonal 0 ADJ F
IgG1 0 NOUN T
antibody 0 NOUN F
that 0 ADP F
blocks 0 PUNCT F
IGF-1R 0 NOUN T
. 0 PUNCT F

We 0 PRON T
tested 0 VERB F
the 0 DET F
efficacy 0 NOUN F
and 0 CCONJ F
safety B-OTHER NOUN F
of 0 ADP F
adding 0 VERB F
ganitumab 0 PUNCT F
to 0 ADP F
endocrine 0 ADJ F
treatment 0 NOUN F
for 0 ADP F
patients 0 NOUN F
with 0 ADP F
hormone-receptor-positive 0 ADJ F
breast 0 NOUN F
cancer 0 NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
We 0 ADJ T
did 0 VERB F
this 0 DET F
phase 0 NOUN F
2 0 NUM F
trial 0 NOUN F
in 0 ADP F
outpatient 0 ADJ F
clinics 0 ADP F
and 0 CCONJ F
hospitals 0 NOUN F
. 0 PUNCT F

We 0 PRON T
enrolled 0 VERB F
postmenopausal 0 ADJ F
women 0 NOUN F
with 0 ADP F
hormone-receptor-positive 0 ADJ F
, 0 PUNCT F
locally 0 ADV F
advanced 0 VERB F
or 0 CCONJ F
metastatic 0 ADJ F
breast 0 NOUN F
cancer 0 NOUN F
previously 0 ADV F
treated 0 VERB F
with 0 ADP F
endocrine 0 ADJ F
treatment 0 NOUN F
. 0 PUNCT F

They 0 PRON T
were 0 VERB F
randomly 0 ADV F
assigned 0 VERB F
( 0 PUNCT F
2:1 0 NUM F
) 0 PUNCT F
with 0 ADP F
a 0 DET F
central 0 ADJ F
randomisation 0 NOUN F
schedule 0 NOUN F
to 0 PUNCT F
receive 0 NOUN F
intravenous 0 ADJ F
ganitumab 0 PUNCT F
12 0 NUM F
mg 0 NOUN F
per 0 ADP F
kg 0 NOUN F
bodyweight 0 ADJ F
or 0 CCONJ F
placebo 0 NOUN F
in 0 ADP F
combination 0 NOUN F
with 0 ADP F
open-label 0 NOUN F
intramuscular 0 ADJ F
fulvestrant 0 PUNCT F
( 0 PUNCT F
500 0 NUM F
mg 0 NOUN F
on 0 ADP F
day 0 NOUN F
1 0 NUM F
, 0 PUNCT F
then 0 ADV F
250 0 NUM F
mg 0 NOUN F
on 0 ADP F
days 0 NOUN F
15 0 NUM F
, 0 PUNCT F
29 0 NUM F
, 0 PUNCT F
and 0 CCONJ F
every 0 DET F
28 0 NUM F
days 0 NOUN F
) 0 PUNCT F
or 0 CCONJ F
oral 0 ADJ F
exemestane 0 NOUN F
( 0 PUNCT F
25 0 NUM F
mg 0 NOUN F
once 0 PUNCT F
daily 0 PUNCT F
) 0 PUNCT F
on 0 ADP F
a 0 DET F
28-day 0 NOUN F
cycle 0 NOUN F
. 0 PUNCT F

Patients 0 NOUN T
, 0 PUNCT F
investigators 0 NOUN F
, 0 PUNCT F
study 0 VERB F
monitors 0 ADP F
, 0 PUNCT F
and 0 CCONJ F
the 0 DET F
sponsor 0 NOUN F
staff 0 NOUN F
were 0 VERB F
masked 0 VERB F
to 0 ADP F
treatment 0 NOUN F
allocation 0 NOUN F
. 0 PUNCT F

Response 0 NOUN T
was 0 VERB F
assessed 0 ADJ F
every 0 DET F
8 0 NUM F
weeks 0 NOUN F
. 0 PUNCT F

The 0 DET T
primary 0 ADJ F
endpoint 0 NOUN F
was 0 VERB F
median 0 ADJ F
progression-free B-MORTALITY NOUN F
survival I-MORTALITY NOUN F
in 0 ADP F
the 0 DET F
intention-to-treat 0 NOUN F
population 0 NOUN F
. 0 PUNCT F

We 0 PRON T
analysed 0 VERB F
overall B-MORTALITY ADP F
survival I-MORTALITY NOUN F
as 0 ADP F
one 0 NUM F
of 0 ADP F
our 0 CCONJ F
secondary 0 ADJ F
endpoints 0 NOUN F
. 0 PUNCT F

The 0 DET T
study 0 NOUN F
is 0 VERB F
registered 0 NOUN F
at 0 ADP F
ClinicalTrials.gov 0 PUNCT T
, 0 PUNCT F
number 0 NOUN F
NCT00626106 0 NOUN T
. 0 PUNCT F

FINDINGS 0 NOUN T
We 0 NOUN T
screened 0 VERB F
189 0 DET F
patients 0 NOUN F
and 0 CCONJ F
enrolled 0 VERB F
156 0 NUM F
( 0 PUNCT F
106 0 NUM F
in 0 ADP F
the 0 DET F
ganitumab 0 PUNCT F
group 0 NOUN F
and 0 CCONJ F
50 0 NUM F
in 0 ADP F
the 0 DET F
placebo 0 NOUN F
group 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

Median 0 ADJ T
progression-free B-MORTALITY NOUN F
survival I-MORTALITY NOUN F
did 0 PUNCT F
not 0 ADV F
differ 0 VERB F
significantly 0 ADV F
between 0 ADP F
the 0 DET F
ganitumab 0 PUNCT F
and 0 CCONJ F
placebo 0 NOUN F
groups 0 NOUN F
( 0 PUNCT F
3?9 0 PUNCT F
months 0 NOUN F
, 0 PUNCT F
80 0 NUM F
% 0 SYM F
CI 0 NOUN T
3?6-5?3 0 ADJ F
vs 0 CCONJ F
5?7 0 NOUN F
months 0 NOUN F
, 0 PUNCT F
4?4-7?4 0 NOUN F
; 0 PUNCT F
hazard 0 NOUN F
ratio 0 NOUN F
[ 0 PUNCT F
HR 0 NOUN T
] 0 PUNCT F
1?17 0 PUNCT F
, 0 PUNCT F
80 0 NUM F
% 0 SYM F
CI 0 NOUN T
0?91-1?50 0 PUNCT F
; 0 PUNCT F
p=0?44 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

However 0 ADV T
, 0 PUNCT F
overall 0 ADJ F
survival 0 NOUN F
was 0 VERB F
worse 0 ADJ F
in 0 ADP F
the 0 DET F
the 0 DET F
ganitumab 0 PUNCT F
group 0 NOUN F
than 0 PUNCT F
in 0 ADP F
the 0 DET F
placebo 0 NOUN F
group 0 NOUN F
( 0 PUNCT F
HR 0 NOUN T
1?78 0 PUNCT F
, 0 PUNCT F
80 0 NUM F
% 0 SYM F
CI 0 NOUN T
1?27-2?50 0 NOUN F
; 0 PUNCT F
p=0?025 0 ADP F
) 0 PUNCT F
. 0 PUNCT F

With 0 ADP T
the 0 DET F
exception 0 NOUN F
of 0 ADP F
hyperglycaemia 0 NOUN F
, 0 PUNCT F
adverse 0 ADJ F
events 0 NOUN F
were 0 VERB F
generally 0 ADV F
similar 0 ADJ F
between 0 ADP F
groups 0 NOUN F
. 0 PUNCT F

The 0 DET T
most 0 PUNCT F
common 0 ADJ F
grade 0 NOUN F
3 0 NUM F
or 0 CCONJ F
higher 0 PUNCT F
adverse 0 ADJ F
event 0 NOUN F
was 0 VERB F
neutropenia-reported 0 VERB F
by 0 ADP F
six 0 NUM F
of 0 ADP F
106 0 NUM F
( 0 PUNCT F
6 0 NUM F
% 0 SYM F
) 0 PUNCT F
patients 0 NOUN F
in 0 ADP F
the 0 DET F
ganitumab 0 PUNCT F
group 0 NOUN F
and 0 CCONJ F
one 0 NUM F
of 0 ADP F
49 0 NUM F
( 0 PUNCT F
2 0 NUM F
% 0 SYM F
) 0 PUNCT F
in 0 ADP F
the 0 DET F
placebo 0 NOUN F
group 0 NOUN F
. 0 PUNCT F

Hyperglycaemia 0 NOUN T
was 0 VERB F
reported 0 VERB F
by 0 ADP F
12 0 NUM F
of 0 ADP F
106 0 NUM F
( 0 PUNCT F
11 0 NUM F
% 0 SYM F
) 0 PUNCT F
patients 0 NOUN F
in 0 ADP F
the 0 DET F
ganitumab 0 PUNCT F
group 0 NOUN F
( 0 PUNCT F
with 0 ADP F
six 0 NUM F
patients 0 NOUN F
having 0 VERB F
grade 0 NOUN F
3 0 NUM F
or 0 CCONJ F
4 0 NUM F
hyperglycaemia 0 NOUN F
) 0 PUNCT F
and 0 CCONJ F
none 0 NUM F
of 0 ADP F
49 0 NUM F
in 0 ADP F
the 0 DET F
placebo 0 NOUN F
group 0 NOUN F
. 0 PUNCT F

Serious 0 ADJ T
adverse 0 ADJ F
events 0 NOUN F
were 0 VERB F
reported 0 VERB F
by 0 ADP F
27 0 NUM F
of 0 ADP F
106 0 NUM F
( 0 PUNCT F
25 0 NUM F
% 0 SYM F
) 0 PUNCT F
patients 0 NOUN F
in 0 ADP F
the 0 DET F
ganitumab 0 PUNCT F
group 0 NOUN F
and 0 CCONJ F
nine 0 NUM F
of 0 ADP F
49 0 NUM F
( 0 PUNCT F
18 0 NUM F
% 0 SYM F
) 0 PUNCT F
patients 0 NOUN F
in 0 ADP F
the 0 DET F
placebo 0 NOUN F
group 0 NOUN F
. 0 PUNCT F

INTERPRETATION 0 NOUN T
Addition 0 NOUN T
of 0 ADP F
ganitumab 0 PUNCT F
to 0 ADP F
endocrine 0 ADJ F
treatment 0 NOUN F
in 0 ADP F
women 0 NOUN F
with 0 ADP F
previously 0 ADV F
treated 0 PUNCT F
hormone-receptor-positive 0 PUNCT F
locally 0 ADV F
advanced 0 VERB F
or 0 CCONJ F
metastatic 0 ADJ F
breast 0 NOUN F
cancer 0 NOUN F
did 0 PUNCT F
not 0 ADV F
improve 0 VERB F
outcomes 0 NOUN F
. 0 PUNCT F

Our 0 ADJ T
results 0 NOUN F
do 0 PUNCT F
not 0 ADV F
support 0 VERB F
further 0 DET F
study 0 NOUN F
of 0 ADP F
ganitumab 0 PUNCT F
in 0 ADP F
this 0 DET F
subgroup 0 NOUN F
of 0 ADP F
patients 0 NOUN F
. 0 PUNCT F

FUNDING 0 PUNCT T
Amgen 0 NOUN T
. 0 PUNCT F

Efficacy 0 NOUN T
and 0 CCONJ F
safety 0 NOUN F
of 0 ADP F
routine 0 ADJ F
blood B-PHYSICAL NOUN F
pressure I-PHYSICAL NOUN F
lowering I-PHYSICAL ADJ F
in 0 ADP F
older 0 PUNCT F
patients 0 NOUN F
with 0 ADP F
diabetes 0 NOUN F
: 0 PUNCT F
results 0 DET F
from 0 ADP F
the 0 DET F
ADVANCE 0 NOUN T
trial 0 NOUN F
. 0 PUNCT F

OBJECTIVE 0 NOUN T
The 0 DET T
efficacy 0 NOUN F
and 0 CCONJ F
safety 0 NOUN F
of 0 ADP F
blood B-PHYSICAL NOUN F
pressure I-PHYSICAL NOUN F
lowering I-PHYSICAL ADJ F
in 0 ADP F
elderly 0 ADJ F
patients 0 NOUN F
have 0 CCONJ F
not 0 ADV F
been 0 PUNCT F
sufficiently 0 ADV F
investigated 0 VERB F
in 0 ADP F
patients 0 NOUN F
with 0 ADP F
diabetes 0 NOUN F
. 0 PUNCT F

Using 0 VERB T
data 0 NOUN F
from 0 ADP F
the 0 DET F
Action 0 NOUN T
in 0 ADP F
Diabetes 0 NOUN T
and 0 CCONJ F
Vascular 0 ADJ T
disease 0 NOUN F
: 0 PUNCT F
preterAx 0 NOUN F
and 0 CCONJ F
diamicroN-MR 0 ADJ F
Controlled 0 VERB T
Evaluation 0 NOUN T
study 0 NOUN F
, 0 PUNCT F
we 0 PRON F
assessed 0 VERB F
the 0 DET F
efficacy 0 NOUN F
and 0 CCONJ F
safety 0 NOUN F
of 0 ADP F
routine 0 ADJ F
blood B-PHYSICAL NOUN F
pressure I-PHYSICAL NOUN F
lowering I-PHYSICAL ADJ F
to 0 PART F
prevent 0 NOUN F
major 0 ADJ F
clinical 0 ADJ F
outcomes 0 NOUN F
in 0 ADP F
elderly 0 ADJ F
patients 0 NOUN F
with 0 ADP F
type 0 NOUN F
2 0 NUM F
diabetes 0 NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
Eleven 0 ADP T
thousand 0 CCONJ F
one 0 NUM F
hundred 0 NUM F
and 0 CCONJ F
forty 0 NUM F
patients 0 NOUN F
aged 0 VERB F
at 0 DET F
least 0 ADV F
55 0 NUM F
years 0 NOUN F
with 0 ADP F
type 0 NOUN F
2 0 NUM F
diabetes 0 NOUN F
( 0 PUNCT F
mean 0 NOUN F
66+/-6 0 NOUN F
years 0 NOUN F
) 0 PUNCT F
were 0 VERB F
randomly 0 ADV F
assigned 0 VERB F
to 0 ADP F
perindopril-indapamide 0 NOUN F
or 0 CCONJ F
placebo 0 NOUN F
. 0 PUNCT F

The 0 DET T
primary 0 ADJ F
endpoint 0 NOUN F
was 0 VERB F
a 0 DET F
composite B-PHYSICAL NOUN F
of I-PHYSICAL ADP F
major I-PHYSICAL ADJ F
macrovascular I-PHYSICAL ADJ F
and 0 CCONJ F
microvascular B-PHYSICAL ADJ F
disease I-PHYSICAL NOUN F
. 0 PUNCT F

The 0 DET T
effects 0 NOUN F
of 0 ADP F
active 0 ADJ F
treatment 0 NOUN F
on 0 ADP F
outcomes 0 NOUN F
were 0 VERB F
estimated 0 VERB F
in 0 ADP F
subgroups 0 NOUN F
according 0 CCONJ F
to 0 ADP F
age 0 NOUN F
: 0 PUNCT F
below 0 ADP F
65 0 NUM F
, 0 PUNCT F
65-74 0 NUM F
and 0 CCONJ F
at 0 ADP F
least 0 ADV F
75 0 NUM F
years 0 NOUN F
. 0 PUNCT F

RESULTS 0 NOUN T
During 0 ADP T
a 0 DET F
mean 0 NOUN F
4.3-year 0 NOUN F
follow-up 0 NOUN F
, 0 PUNCT F
1799 0 NUM F
( 0 PUNCT F
16.1 0 NUM F
% 0 SYM F
) 0 PUNCT F
patients 0 NOUN F
experienced 0 VERB F
a 0 DET F
major 0 ADJ F
event 0 NOUN F
. 0 PUNCT F

Active 0 ADJ T
treatment 0 NOUN F
produced 0 ADP F
similar 0 ADJ F
relative 0 ADJ F
risk 0 NOUN F
reductions B-PHYSICAL NOUN F
for 0 ADP F
the 0 DET F
primary 0 ADJ F
outcome 0 NOUN F
, 0 PUNCT F
major B-PHYSICAL ADJ F
macrovascular I-PHYSICAL ADJ F
disease I-PHYSICAL NOUN F
, 0 PUNCT F
death B-PHYSICAL NOUN F
and 0 CCONJ F
renal B-PHYSICAL ADJ F
events I-PHYSICAL NOUN F
across 0 ADP F
age 0 NOUN F
groups 0 NOUN F
( 0 PUNCT F
all 0 DET F
P 0 NOUN T
heterogeneity 0 NOUN F
> 0 SYM F
0.3 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Over 0 ADP T
5 0 NUM F
years 0 NOUN F
, 0 PUNCT F
active 0 ADJ F
treatment 0 NOUN F
was 0 VERB F
estimated 0 VERB F
to 0 ADJ F
prevent 0 ADJ F
one 0 NUM F
primary 0 ADJ F
outcome 0 NOUN F
in 0 ADP F
every 0 DET F
21 0 NUM F
, 0 PUNCT F
71 0 NUM F
and 0 CCONJ F
118 0 NUM F
patients 0 NOUN F
of 0 ADP F
at 0 ADP F
least 0 ADV F
75 0 NUM F
, 0 PUNCT F
65-74 0 NUM F
and 0 CCONJ F
below 0 ADP F
65 0 NUM F
years 0 NOUN F
, 0 PUNCT F
respectively 0 ADV F
. 0 PUNCT F

Similar 0 ADJ T
patterns 0 NOUN F
of 0 ADP F
benefits 0 NOUN F
were 0 VERB F
observed 0 VERB F
for 0 ADP F
secondary 0 ADJ F
outcomes 0 NOUN F
. 0 PUNCT F

There 0 PUNCT T
were 0 VERB F
no 0 DET F
differences 0 NOUN F
in 0 ADP F
the 0 DET F
tolerability B-OTHER NOUN F
between 0 ADP F
randomized 0 VERB F
allocations 0 NOUN F
across 0 ADP F
age 0 NOUN F
groups 0 NOUN F
( 0 PUNCT F
all 0 DET F
P 0 NOUN T
heterogeneity 0 NOUN F
> 0 SYM F
0.6 0 NUM F
) 0 PUNCT F
CONCLUSION 0 NOUN T
Routine 0 ADJ T
administration 0 NOUN F
of 0 ADP F
perindopril-indapamide 0 NOUN F
lowers 0 NOUN F
blood B-PHYSICAL NOUN F
pressure I-PHYSICAL NOUN F
safely 0 ADV F
and 0 CCONJ F
reduces 0 NOUN F
the 0 DET F
risk 0 NOUN F
of 0 ADP F
major 0 ADJ F
clinical 0 ADJ F
outcomes 0 NOUN F
in 0 ADP F
patients 0 NOUN F
of 0 ADP F
at 0 ADP F
least 0 ADV F
75 0 NUM F
years 0 NOUN F
with 0 ADP F
type 0 NOUN F
2 0 NUM F
diabetes 0 NOUN F
. 0 PUNCT F

The 0 DET T
greater 0 PUNCT F
absolute 0 ADJ F
benefits 0 NOUN F
in 0 ADP F
older 0 PUNCT F
patients 0 NOUN F
in 0 ADP F
this 0 DET F
age 0 NOUN F
group 0 NOUN F
were 0 VERB F
not 0 ADV F
offset 0 PUNCT F
by 0 ADP F
an 0 DET F
increased 0 VERB F
risk 0 NOUN F
of 0 ADP F
side 0 NOUN F
effects 0 NOUN F
. 0 PUNCT F

Benzodiazepine 0 ADV T
and 0 CCONJ F
opioid 0 NOUN F
sedation 0 NOUN F
attenuate 0 VERB F
the 0 DET F
sympathetic 0 ADJ F
response 0 NOUN F
to 0 ADP F
fiberoptic B-OTHER ADJ F
bronchoscopy I-OTHER NOUN F
. 0 PUNCT F

Prophylactic 0 ADJ T
labetalol 0 NOUN F
gave 0 VERB F
no 0 DET F
additional 0 ADJ F
benefit 0 NOUN F
. 0 PUNCT F

Results 0 NOUN T
of 0 ADP F
a 0 DET F
randomized 0 VERB F
double-blind 0 ADJ F
placebo-controlled 0 VERB F
study 0 NOUN F
. 0 PUNCT F

BACKGROUND 0 NOUN T
Hypertension 0 NOUN T
and 0 CCONJ F
tachycardia 0 NOUN F
are 0 VERB F
common 0 ADJ F
during 0 ADP F
fiber-optic 0 ADJ F
bronchoscopy 0 NOUN F
( 0 PUNCT F
FOB 0 NOUN T
) 0 PUNCT F
, 0 PUNCT F
and 0 CCONJ F
this 0 PUNCT F
may 0 VERB F
lead 0 PUNCT F
to 0 ADP F
cardiac 0 ADJ F
ischemia 0 NOUN F
. 0 PUNCT F

The 0 DET T
prophylactic 0 ADJ F
addition 0 NOUN F
of 0 ADP F
a 0 DET F
beta-adrenergic 0 ADJ F
anatagonist 0 ADJ F
might 0 PUNCT F
mask 0 PUNCT F
this 0 DET F
response 0 NOUN F
and 0 CCONJ F
prevent 0 VERB F
the 0 DET F
deleterious 0 ADJ F
cardiovascular B-PHYSICAL ADJ F
effects I-PHYSICAL NOUN F
of I-PHYSICAL ADP F
FOB I-PHYSICAL NOUN T
. 0 PUNCT F

METHODS 0 NOUN T
We 0 PRON T
performed 0 VERB F
a 0 DET F
randomized 0 VERB F
double-blind 0 ADJ F
placebo-controlled 0 VERB F
trial 0 NOUN F
of 0 ADP F
labetalol 0 NOUN F
10mg 0 NOUN F
iv 0 PUNCT F
given 0 VERB F
with 0 ADP F
midazolam-alfentanil 0 PUNCT F
sedation 0 NOUN F
. 0 PUNCT F

We 0 PRON T
monitored 0 VERB F
heart B-PHYSICAL NOUN F
rate I-PHYSICAL NOUN F
( I-PHYSICAL PUNCT F
HR I-PHYSICAL NOUN T
) I-PHYSICAL PUNCT F
and 0 CCONJ F
systolic/diastolic B-PHYSICAL ADJ F
blood I-PHYSICAL NOUN F
pressure I-PHYSICAL NOUN F
( I-PHYSICAL PUNCT F
SBP/DBP I-PHYSICAL ADP T
) I-PHYSICAL PUNCT F
throughout 0 ADP F
the 0 DET F
bronchoscopy 0 NOUN F
and 0 CCONJ F
calculated 0 PUNCT F
the 0 DET F
rate-pressure 0 NOUN F
product 0 NOUN F
( 0 PUNCT F
RPP= 0 NOUN T
( 0 PUNCT F
HRxSBP 0 NOUN T
) 0 PUNCT F
/100 0 VERB F
) 0 PUNCT F
. 0 PUNCT F

One-hundred 0 PUNCT T
twenty 0 PUNCT F
patients 0 NOUN F
were 0 VERB F
enrolled 0 VERB F
. 0 PUNCT F

RESULTS 0 NOUN T
In 0 ADP T
the 0 DET F
placebo 0 NOUN F
group 0 NOUN F
, 0 PUNCT F
there 0 PUNCT F
was 0 VERB F
no 0 DET F
rise 0 NOUN F
in 0 ADP F
HR B-PHYSICAL NOUN T
, 0 PUNCT F
SBP B-PHYSICAL NOUN T
, 0 PUNCT F
DBP B-PHYSICAL NOUN T
or 0 CCONJ F
RPP B-PHYSICAL NOUN T
, 0 PUNCT F
and 0 CCONJ F
there 0 PUNCT F
was 0 VERB F
no 0 DET F
difference 0 NOUN F
between 0 ADP F
the 0 DET F
placebo 0 NOUN F
and 0 CCONJ F
labetalol 0 NOUN F
groups 0 NOUN F
. 0 PUNCT F

Adverse B-ADVERSE-EFFECTS ADJ T
events I-ADVERSE-EFFECTS NOUN F
during I-ADVERSE-EFFECTS ADP F
bronchoscopy I-ADVERSE-EFFECTS NOUN F
were 0 VERB F
similar 0 ADJ F
in 0 ADP F
both 0 CCONJ F
groups 0 NOUN F
. 0 PUNCT F

In 0 ADP T
a 0 DET F
subgroup 0 NOUN F
of 0 ADP F
patients 0 NOUN F
undergoing 0 ADP F
interventional 0 ADJ F
bronchoscopy 0 NOUN F
, 0 PUNCT F
there 0 PUNCT F
was 0 VERB F
a 0 DET F
trend 0 NOUN F
towards 0 ADP F
lower 0 PUNCT F
SBP B-PHYSICAL NOUN T
( 0 PUNCT F
p=0.06 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

CONCLUSIONS 0 DET T
Patients 0 NOUN T
undergoing 0 VERB F
FOB 0 NOUN T
under 0 ADP F
adequate 0 ADJ F
midazolam-alfentanil 0 ADJ F
sedation 0 NOUN F
do 0 PUNCT F
not 0 ADV F
develop 0 VERB F
excessive 0 ADJ F
sympathetic 0 ADJ F
drive 0 ADJ F
that 0 ADP F
may 0 VERB F
lead 0 PUNCT F
to 0 ADP F
cardiac 0 ADJ F
stress 0 NOUN F
. 0 PUNCT F

The 0 DET T
addition 0 NOUN F
of 0 ADP F
labetalol 0 NOUN F
did 0 PUNCT F
not 0 ADV F
confer 0 VERB F
additional 0 ADJ F
benefit 0 NOUN F
or 0 CCONJ F
risk 0 NOUN F
to 0 ADP F
the 0 DET F
patients 0 NOUN F
. 0 PUNCT F
( 0 PUNCT F

ClinicalTrials.gov 0 PUNCT T
number 0 NOUN F
, 0 PUNCT F
NCT00394537 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

Sodium-potassium 0 NOUN T
pump 0 NOUN F
activity 0 NOUN F
in 0 ADP F
white 0 ADJ F
blood 0 NOUN F
cells 0 NOUN F
from 0 ADP F
children 0 NOUN F
with 0 ADP F
an 0 DET F
increased 0 VERB F
risk 0 NOUN F
of 0 ADP F
developing 0 VERB F
hypertension 0 NOUN F
-- 0 PUNCT F
The 0 DET T
Odense 0 NOUN T
Schoolchild 0 NOUN T
Study 0 NOUN T
. 0 PUNCT F

We 0 PRON T
have 0 VERB F
measured 0 VERB F
the 0 DET F
capacity 0 NOUN F
of 0 ADP F
the 0 DET F
sodium-potassium 0 NOUN F
pump 0 NOUN F
, 0 PUNCT F
as 0 PUNCT F
assessed 0 VERB F
by 0 ADP F
86rubidium 0 ADV F
uptake 0 NOUN F
and 0 CCONJ F
the 0 DET F
number 0 NOUN F
of 0 ADP F
[ 0 PUNCT F
3H 0 NOUN F
] 0 PUNCT F
-ouabain 0 ADJ F
binding 0 VERB F
sites 0 NOUN F
on 0 ADP F
white 0 ADJ F
blood 0 NOUN F
cells 0 NOUN F
, 0 PUNCT F
in 0 ADP F
children 0 ADJ F
aged 0 PROPN F
9-11 0 NUM F
years 0 NOUN F
, 0 PUNCT F
partly 0 ADV F
cross-sectionally 0 ADV F
and 0 CCONJ F
partly 0 ADV F
longitudinally 0 ADV F
after 0 ADP F
a 0 DET F
physical 0 ADJ F
training 0 DET F
programme 0 NOUN F
. 0 PUNCT F

Children 0 NOUN T
from 0 ADP F
a 0 DET F
hypertensive 0 ADJ F
subgroup 0 NOUN F
comprising 0 SYM F
the 0 DET F
upper 0 ADJ F
5 0 NUM F
% 0 SYM F
of 0 ADP F
the 0 DET F
blood 0 NOUN F
pressure 0 NOUN F
distribution 0 NOUN F
and 0 CCONJ F
children 0 NOUN F
from 0 ADP F
a 0 DET F
randomly 0 ADV F
selected 0 ADP F
normotensive 0 ADJ F
subgroup 0 NOUN F
were 0 VERB F
eligible 0 ADJ F
for 0 ADP F
the 0 DET F
study 0 NOUN F
. 0 PUNCT F

In 0 ADP T
the 0 DET F
cross-sectional 0 ADJ F
study 0 NOUN F
40 0 NUM F
children 0 NOUN F
from 0 ADP F
the 0 DET F
hypertensive 0 ADJ F
subgroup 0 NOUN F
and 0 CCONJ F
40 0 NUM F
children 0 NOUN F
from 0 ADP F
the 0 DET F
normotensive 0 ADJ F
subgroup 0 NOUN F
were 0 VERB F
evaluated 0 VERB F
. 0 PUNCT F

A 0 DET T
significant 0 ADJ F
increase 0 NOUN F
in 0 ADP F
86rubidium B-PHYSICAL ADP F
uptake I-PHYSICAL NOUN F
was 0 VERB F
present 0 ADJ F
in 0 ADP F
boys 0 NOUN F
as 0 CCONJ F
compared 0 VERB F
to 0 ADP F
girls 0 NOUN F
. 0 PUNCT F

After 0 ADP T
adjustment 0 NOUN F
for 0 ADP F
differences 0 NOUN F
in 0 ADP F
sexual 0 ADJ F
maturation 0 NOUN F
the 0 DET F
observed 0 VERB F
significant 0 ADJ F
difference 0 NOUN F
disappeared 0 NOUN F
. 0 PUNCT F

Important 0 ADJ T
correlates 0 PUNCT F
of 0 ADP F
pump 0 NOUN F
activity 0 NOUN F
were 0 VERB F
height 0 NOUN F
, 0 PUNCT F
plasma 0 NOUN F
glucose 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
physical 0 ADJ F
fitness 0 PUNCT F
. 0 PUNCT F

In 0 ADP T
the 0 DET F
training 0 PUNCT F
study 0 NOUN F
10 0 NUM F
boys 0 NOUN F
from 0 ADP F
the 0 DET F
hypertensive 0 ADJ F
subgroup 0 NOUN F
and 0 CCONJ F
10 0 NUM F
boys 0 NOUN F
from 0 ADP F
the 0 DET F
normotensive 0 ADJ F
subgroup 0 NOUN F
were 0 VERB F
also 0 ADV F
evaluated 0 VERB F
after 0 ADP F
eight 0 NUM F
months 0 NOUN F
of 0 ADP F
physical 0 ADJ F
training 0 VERB F
. 0 PUNCT F

A 0 DET T
significant 0 ADJ F
fall 0 NOUN F
in 0 ADP F
86rubidium B-PHYSICAL ADP F
uptake I-PHYSICAL NOUN F
was 0 VERB F
observed 0 VERB F
. 0 PUNCT F

No 0 DET T
control 0 NOUN F
group 0 NOUN F
was 0 VERB F
examined 0 VERB F
and 0 CCONJ F
probably 0 ADV F
the 0 DET F
changes 0 NOUN F
reflect 0 VERB F
some 0 DET F
effects 0 NOUN F
of 0 ADP F
sexual B-PHYSICAL ADJ F
maturation I-PHYSICAL NOUN F
on I-PHYSICAL ADP F
cation I-PHYSICAL NOUN F
handling I-PHYSICAL ADJ F
of I-PHYSICAL ADP F
cells I-PHYSICAL NOUN F
. 0 PUNCT F

These 0 DET T
results 0 NOUN F
indicate 0 VERB F
a 0 DET F
significant 0 ADJ F
effect 0 NOUN F
of 0 ADP F
sexual B-PHYSICAL ADJ F
maturation I-PHYSICAL NOUN F
in I-PHYSICAL ADP F
capacity I-PHYSICAL NOUN F
of I-PHYSICAL ADP F
sodium-potassium I-PHYSICAL NOUN F
pump I-PHYSICAL NOUN F
in 0 ADP F
children 0 NOUN F
. 0 PUNCT F

Perioperative 0 PUNCT T
immunotherapy 0 NOUN F
with 0 ADP F
recombinant 0 ADJ F
interleukin 0 NOUN F
2 0 NUM F
in 0 ADP F
patients 0 NOUN F
undergoing 0 VERB F
surgery 0 NOUN F
for 0 ADP F
colorectal 0 ADJ F
cancer 0 NOUN F
. 0 PUNCT F

Major 0 ADJ T
surgery 0 NOUN F
impairs 0 VERB F
the 0 DET F
cellular 0 ADJ F
immune 0 ADJ F
response 0 NOUN F
. 0 PUNCT F

We 0 PRON T
have 0 PUNCT F
therefore 0 ADV F
studied 0 ADP F
the 0 DET F
immunological 0 ADJ F
effects 0 NOUN F
of 0 ADP F
low-dose 0 NOUN F
recombinant 0 ADJ F
interleukin 0 NOUN F
2 0 NUM F
given 0 VERB F
to 0 ADP F
patients 0 NOUN F
undergoing 0 VERB F
surgery 0 NOUN F
for 0 ADP F
colorectal 0 ADJ F
cancer 0 NOUN F
to 0 PART F
determine 0 NOUN F
whether 0 ADP F
this 0 DET F
agent 0 NOUN F
has 0 PUNCT F
potential 0 ADP F
in 0 ADP F
perioperative 0 ADJ F
adjuvant 0 NOUN F
immunotherapy 0 NOUN F
. 0 PUNCT F

Patients 0 NOUN T
were 0 VERB F
randomly 0 ADV F
allocated 0 VERB F
to 0 PUNCT F
control 0 NOUN F
( 0 PUNCT F
n 0 NOUN F
= 0 SYM F
13 0 NUM F
) 0 PUNCT F
or 0 CCONJ F
treatment 0 NOUN F
groups 0 NOUN F
( 0 PUNCT F
n 0 NOUN F
= 0 SYM F
12 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Immunological 0 ADJ T
studies 0 NOUN F
of 0 ADP F
both 0 PUNCT F
lymphocyte B-PHYSICAL NOUN F
function I-PHYSICAL NOUN F
and 0 CCONJ F
subset 0 NOUN F
number 0 NOUN F
were 0 VERB F
performed 0 VERB F
preoperatively 0 ADV F
and 0 CCONJ F
on 0 ADP F
Days 0 NOUN T
1 0 NUM F
, 0 PUNCT F
4 0 NUM F
, 0 PUNCT F
7 0 NUM F
, 0 PUNCT F
and 0 CCONJ F
10 0 NUM F
. 0 PUNCT F

Treatment 0 NOUN T
with 0 ADP F
recombinant 0 ADJ F
interleukin 0 NOUN F
2 0 NUM F
prevented 0 VERB F
the 0 DET F
postoperative 0 ADJ F
fall 0 NOUN F
in 0 ADP F
both 0 CCONJ F
natural B-PHYSICAL ADJ F
killer I-PHYSICAL NOUN F
and 0 CCONJ F
lymphokine-activated B-PHYSICAL VERB F
killer I-PHYSICAL NOUN F
cell I-PHYSICAL NOUN F
cytotoxicity I-PHYSICAL NOUN F
, 0 PUNCT F
clearly 0 ADV F
demonstrated 0 VERB F
in 0 ADP F
the 0 DET F
control 0 NOUN F
group 0 NOUN F
. 0 PUNCT F

The 0 DET T
treatment 0 NOUN F
group 0 NOUN F
also 0 ADV F
showed 0 VERB F
in 0 ADP F
vivo B-PHYSICAL ADP F
T-cell I-PHYSICAL NOUN T
activation I-PHYSICAL NOUN F
with 0 ADP F
an 0 DET F
initial 0 ADJ F
lymphopenia 0 NOUN F
followed 0 VERB F
by 0 ADP F
a 0 DET F
rebound B-PHYSICAL NOUN F
lymphocytosis I-PHYSICAL NOUN F
and 0 CCONJ F
upregulation 0 NOUN F
of 0 ADP F
the 0 DET F
subset B-PHYSICAL NOUN F
markers I-PHYSICAL NOUN F
CD25 I-PHYSICAL NOUN T
( 0 PUNCT F
interleukin B-PHYSICAL NOUN F
2 I-PHYSICAL NUM F
receptor I-PHYSICAL NOUN F
) 0 PUNCT F
and 0 CCONJ F
CD45RO B-PHYSICAL NOUN T
( I-PHYSICAL PUNCT F
T-memory I-PHYSICAL PUNCT T
cells I-PHYSICAL NOUN F
) I-PHYSICAL PUNCT F
. 0 PUNCT F

These 0 DET T
combined 0 VERB F
effects 0 NOUN F
may 0 VERB F
have 0 PUNCT F
important 0 ADJ F
consequences 0 NOUN F
in 0 ADP F
controlling 0 DET F
metastatic 0 ADJ F
dissemination 0 NOUN F
of 0 ADP F
tumor 0 NOUN F
during 0 ADP F
the 0 DET F
vulnerable 0 ADJ F
perioperative 0 ADJ F
period 0 NOUN F
. 0 PUNCT F

Atypical 0 ADJ T
recruitment 0 NOUN F
of 0 ADP F
medial 0 ADJ F
prefrontal 0 ADJ F
cortex 0 NOUN F
in 0 ADP F
autism 0 NOUN F
spectrum 0 NOUN F
disorders 0 NOUN F
: 0 PUNCT F
an 0 DET F
fMRI 0 NOUN F
study 0 NOUN F
of 0 ADP F
two 0 NUM F
executive 0 ADJ F
function 0 NOUN F
tasks 0 NOUN F
. 0 PUNCT F

Recent 0 ADJ T
studies 0 NOUN F
have 0 CCONJ F
suggested 0 VERB F
an 0 DET F
uneven 0 NUM F
profile 0 NOUN F
of 0 ADP F
executive 0 ADJ F
dysfunction 0 NOUN F
in 0 ADP F
autism 0 NOUN F
spectrum 0 NOUN F
disorders 0 NOUN F
( 0 PUNCT F
ASD 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

For 0 ADP T
example 0 NOUN F
, 0 PUNCT F
some 0 DET F
authors 0 NOUN F
have 0 ADP F
reported 0 PUNCT F
deficits 0 NOUN F
on 0 ADP F
newly 0 ADV F
developed 0 VERB F
tests 0 NOUN F
of 0 ADP F
executive 0 ADJ F
function 0 NOUN F
sensitive 0 ADJ F
to 0 ADP F
rostral 0 ADJ F
prefrontal 0 ADJ F
function 0 NOUN F
, 0 PUNCT F
despite 0 ADP F
spared 0 PUNCT F
, 0 PUNCT F
or 0 CCONJ F
even 0 ADV F
superior 0 ADJ F
, 0 PUNCT F
performance 0 NOUN F
on 0 ADP F
other 0 ADJ F
tests 0 NOUN F
. 0 PUNCT F

We 0 PRON T
investigated 0 VERB F
the 0 DET F
performance 0 NOUN F
of 0 ADP F
a 0 DET F
group 0 NOUN F
of 0 ADP F
high-functioning 0 PUNCT F
participants 0 NOUN F
with 0 ADP F
ASD 0 NOUN T
( 0 PUNCT F
N=15 0 NOUN T
) 0 PUNCT F
and 0 CCONJ F
an 0 DET F
age- 0 NOUN F
and 0 CCONJ F
IQ-matched 0 VERB T
control 0 NOUN F
group 0 NOUN F
( 0 PUNCT F
N=18 0 ADJ T
) 0 PUNCT F
on 0 ADP F
two 0 NUM F
executive 0 ADJ F
function 0 ADV F
tests 0 NOUN F
, 0 PUNCT F
whilst 0 ADP F
undergoing 0 VERB F
functional 0 ADJ F
magnetic 0 ADJ F
resonance 0 NOUN F
imaging 0 VERB F
( 0 PUNCT F
fMRI 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

Behaviourally 0 ADV T
, 0 PUNCT F
there 0 PUNCT F
were 0 VERB F
no 0 DET F
significant 0 ADJ F
differences 0 NOUN F
between 0 ADP F
the 0 DET F
two 0 NUM F
groups 0 NOUN F
. 0 PUNCT F

In 0 ADP T
a 0 DET F
classical 0 ADJ F
test 0 NOUN F
of 0 ADP F
executive 0 PUNCT F
function 0 NOUN F
( 0 PUNCT F
random 0 ADJ F
response 0 NOUN F
generation 0 NOUN F
) 0 PUNCT F
, 0 PUNCT F
BOLD B-PHYSICAL CCONJ T
signal I-PHYSICAL PUNCT F
differed 0 VERB F
between 0 ADP F
the 0 DET F
groups 0 NOUN F
in 0 ADP F
the 0 DET F
cerebellum 0 NOUN F
but 0 CCONJ F
not 0 ADV F
in 0 ADP F
the 0 DET F
frontal 0 ADJ F
lobes 0 NOUN F
. 0 PUNCT F

However 0 ADV T
, 0 PUNCT F
on 0 ADP F
a 0 DET F
new 0 ADJ F
test 0 NOUN F
of 0 ADP F
executive 0 PUNCT F
function 0 NOUN F
( 0 PUNCT F
selection 0 NOUN F
between 0 ADP F
stimulus-oriented 0 VERB F
and 0 CCONJ F
stimulus-independent 0 ADJ F
thought 0 PUNCT F
) 0 PUNCT F
, 0 PUNCT F
the 0 DET F
ASD 0 NOUN T
group 0 NOUN F
exhibited 0 VERB F
significantly 0 ADV F
greater 0 PUNCT F
signal-change 0 NOUN F
in 0 ADP F
medial B-PHYSICAL ADJ F
rostral I-PHYSICAL ADJ F
prefrontal I-PHYSICAL ADJ F
cortex I-PHYSICAL NOUN F
( I-PHYSICAL PUNCT F
especially I-PHYSICAL ADV F
Brodmann I-PHYSICAL NOUN T
Area 0 NOUN T
10 B-PHYSICAL NUM F
) B-PHYSICAL PUNCT F
in 0 ADP F
the 0 DET F
comparison 0 NOUN F
of 0 ADP F
stimulus-oriented 0 VERB F
versus 0 CCONJ F
stimulus-independent 0 ADJ F
attention 0 NOUN F
. 0 PUNCT F

In 0 ADP T
addition 0 NOUN F
, 0 PUNCT F
the 0 DET F
new 0 ADJ F
test 0 NOUN F
( 0 PUNCT F
but 0 CCONJ F
not 0 ADV F
the 0 DET F
classical 0 ADJ F
test 0 NOUN F
) 0 PUNCT F
provided 0 VERB F
evidence 0 NOUN F
for 0 PUNCT F

Effects 0 NOUN T
of 0 ADP F
losartan 0 NOUN F
and 0 CCONJ F
enalapril 0 NOUN F
on 0 ADP F
high-sensitivity 0 NOUN F
C-reactive 0 ADJ T
protein 0 NOUN F
and 0 CCONJ F
total 0 ADJ F
antioxidant 0 NOUN F
in 0 ADP F
renal 0 ADJ F
transplant 0 NOUN F
recipients 0 NOUN F
with 0 ADP F
Renin-Angiotensin 0 NOUN T
system 0 NOUN F
polymorphisms 0 NOUN F
. 0 PUNCT F

BACKGROUND 0 NOUN T
As 0 ADP T
renin-angiotensin 0 NOUN F
system 0 NOUN F
( 0 PUNCT F
RAS 0 NOUN T
) 0 PUNCT F
activity 0 NOUN F
may 0 VERB F
affect 0 VERB F
the 0 DET F
severity 0 NOUN F
of 0 ADP F
oxidative 0 ADJ F
stress 0 NOUN F
and 0 CCONJ F
inflammatory 0 ADJ F
markers 0 NOUN F
, 0 PUNCT F
we 0 PRON F
assessed 0 VERB F
the 0 DET F
effects 0 NOUN F
of 0 ADP F
enalapril 0 NOUN F
( 0 PUNCT F
E 0 NOUN T
) 0 PUNCT F
and/or 0 CCONJ F
losartan 0 NOUN F
( 0 PUNCT F
L 0 NOUN T
) 0 PUNCT F
on 0 ADP F
these 0 DET F
markers 0 NOUN F
in 0 ADP F
renal 0 ADJ F
transplant 0 NOUN F
recipients 0 NOUN F
with 0 ADP F
RAS 0 NOUN T
polymorphisms 0 NOUN F
. 0 PUNCT F

PATIENTS 0 NOUN T
AND 0 CCONJ T
METHODS 0 NOUN T
After 0 ADP T
determination 0 NOUN F
by 0 ADP F
PCR 0 NOUN T
of 0 ADP F
RAS 0 NOUN T
genotypes 0 NOUN F
, 0 PUNCT F
consisting 0 SYM F
of 0 ADP F
the 0 DET F
angiotensin-converting 0 ADJ F
enzymes 0 NOUN F
( 0 PUNCT F
ACE 0 NOUN T
I/D 0 NOUN T
) 0 PUNCT F
, 0 PUNCT F
angiotensinogens 0 ADP F
( 0 PUNCT F
AGT 0 NOUN T
M235T 0 NOUN T
) 0 PUNCT F
and 0 CCONJ F
angiotensin 0 NOUN F
II 0 NUM T
type 0 NOUN F
1 0 NUM F
receptors 0 NOUN F
( 0 PUNCT F
ATR1 0 NOUN T
A1166C 0 NOUN T
) 0 PUNCT F
, 0 PUNCT F
76 0 NUM F
recipients 0 NOUN F
were 0 VERB F
recruited 0 VERB F
randomly 0 ADV F
and 0 CCONJ F
assigned 0 PUNCT F
4 0 NUM F
groups 0 NOUN F
. 0 PUNCT F

The 0 DET T
first 0 ADJ F
( 0 PUNCT F
n 0 NOUN F
= 0 SYM F
17 0 NUM F
) 0 PUNCT F
and 0 CCONJ F
second 0 ADJ F
( 0 PUNCT F
n 0 NOUN F
= 0 SYM F
24 0 NUM F
) 0 PUNCT F
groups 0 NOUN F
were 0 VERB F
treated 0 VERB F
with 0 ADP F
E 0 NOUN T
( 0 PUNCT F
E 0 NOUN T
( 0 PUNCT F
+ 0 SYM F
) 0 PUNCT F
: 0 PUNCT F
10 0 NUM F
mg/d 0 NOUN F
) 0 PUNCT F
and 0 CCONJ F
L 0 NOUN T
( 0 PUNCT F
L 0 NOUN T
( 0 PUNCT F
+ 0 SYM F
) 0 PUNCT F
: 0 PUNCT F
50 0 NUM F
mg/d 0 NOUN F
) 0 PUNCT F
alone 0 ADJ F
, 0 PUNCT F
respectively 0 ADV F
. 0 PUNCT F

The 0 DET T
third 0 ADJ F
positive 0 ADJ F
control 0 NOUN F
group 0 NOUN F
( 0 PUNCT F
n 0 NOUN F
= 0 SYM F
17 0 NUM F
) 0 PUNCT F
received 0 VERB F
E 0 NOUN T
+ 0 SYM F
L 0 NOUN T
( 0 PUNCT F
E 0 NOUN T
( 0 PUNCT F
+ 0 SYM F
) 0 PUNCT F
L 0 NOUN T
( 0 PUNCT F
+ 0 SYM F
) 0 PUNCT F
: 0 PUNCT F
10 0 NUM F
mg/d 0 NOUN F
+ 0 SYM F
50 0 NUM F
mg/d 0 NOUN F
) 0 PUNCT F
and 0 CCONJ F
the 0 DET F
fourth 0 ADJ F
negative 0 ADJ F
control 0 NOUN F
group 0 NOUN F
( 0 PUNCT F
n 0 NOUN F
= 0 SYM F
18 0 NUM F
) 0 PUNCT F
received 0 VERB F
no 0 DET F
medication 0 NOUN F
( 0 PUNCT F
E 0 NOUN T
( 0 PUNCT F
- 0 SYM F
) 0 PUNCT F
: 0 PUNCT F
L 0 NOUN T
( 0 PUNCT F
- 0 SYM F
) 0 PUNCT F
) 0 PUNCT F
. 0 PUNCT F

High-sensitivity 0 NOUN T
C-reactive 0 ADJ T
protein 0 NOUN F
( 0 PUNCT F
hs-CRP 0 NOUN F
) 0 PUNCT F
and 0 CCONJ F
total 0 ADJ F
antioxidant 0 NOUN F
( 0 PUNCT F
TA 0 NOUN T
) 0 PUNCT F
inflammatory 0 ADJ F
and 0 CCONJ F
antioxidative 0 ADJ F
markers 0 NOUN F
were 0 VERB F
measured 0 VERB F
after 0 ADP F
2 0 NUM F
months 0 NOUN F
. 0 PUNCT F

After 0 ADP T
a 0 DET F
2-week 0 NOUN F
washout 0 PUNCT F
period 0 NOUN F
, 0 PUNCT F
the 0 DET F
E 0 NOUN T
( 0 PUNCT F
+ 0 SYM F
) 0 PUNCT F
group 0 NOUN F
was 0 VERB F
changed 0 NUM F
to 0 ADP F
L 0 NOUN T
( 0 PUNCT F
+ 0 SYM F
) 0 PUNCT F
and 0 CCONJ F
vice 0 PUNCT F
versa 0 ADV F
in 0 ADP F
a 0 DET F
crossover 0 NOUN F
design 0 NOUN F
. 0 PUNCT F

They 0 PRON T
were 0 VERB F
followed 0 VERB F
for 0 ADP F
another 0 CCONJ F
8 0 NUM F
weeks 0 NOUN F
before 0 ADP F
retesting 0 ADJ F
hs-CRP 0 NOUN F
and 0 CCONJ F
TA 0 NOUN T
. 0 PUNCT F

A 0 DET T
value 0 NOUN F
of 0 ADP F
P 0 NOUN T
< 0 SYM F
or 0 CCONJ F
= 0 SYM F
.05 0 NUM F
was 0 VERB F
considered 0 VERB F
significant 0 ADJ F
. 0 PUNCT F

RESULTS 0 NOUN T
After 0 ADP T
2 0 NUM F
and 0 CCONJ F
4 0 NUM F
months 0 NOUN F
of 0 ADP F
treatment 0 NOUN F
with 0 ADP F
the 0 DET F
drug 0 NOUN F
regimen 0 NOUN F
, 0 PUNCT F
hs-CRP B-PHYSICAL NOUN F
and I-PHYSICAL CCONJ F
TA I-PHYSICAL NOUN T
levels I-PHYSICAL NOUN F
were 0 VERB F
significantly 0 ADV F
decreased 0 VERB F
and 0 CCONJ F
consequently 0 ADV F
increased 0 VERB F
among 0 ADP F
the 0 DET F
E 0 NOUN T
( 0 PUNCT F
+ 0 SYM F
) 0 PUNCT F
L 0 NOUN T
( 0 PUNCT F
+ 0 SYM F
) 0 PUNCT F
, 0 PUNCT F
L 0 NOUN T
( 0 PUNCT F
+ 0 SYM F
) 0 PUNCT F
and 0 CCONJ F
E 0 NOUN T
( 0 PUNCT F
+ 0 SYM F
) 0 PUNCT F
groups 0 NOUN F
( 0 PUNCT F
P 0 NOUN T
< 0 SYM F
.05 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

On 0 ADP T
analyzing 0 VERB F
the 0 DET F
relationship 0 NOUN F
between 0 ADP F
RAS 0 NOUN T
polymorphisms 0 NOUN F
and 0 CCONJ F
baseline 0 NOUN F
hs-CRP 0 NOUN F
or 0 CCONJ F
TA 0 NOUN T
levels 0 NOUN F
, 0 PUNCT F
CC 0 NOUN T
genotype 0 NOUN F
of 0 ADP F
ATR1 0 NOUN T
showed 0 VERB F
lower 0 PUNCT F
hs-CRP B-PHYSICAL NOUN F
levels I-PHYSICAL NOUN F
( 0 PUNCT F
P 0 NOUN T
= 0 SYM F
.04 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

However 0 ADV T
, 0 PUNCT F
none 0 NUM F
of 0 ADP F
the 0 DET F
RAS 0 NOUN T
polymorphisms 0 NOUN F
predicted 0 VERB F
the 0 DET F
antioxidant B-PHYSICAL NOUN F
and 0 CCONJ F
anti-inflammatory B-PHYSICAL ADJ F
response 0 NOUN F
rates 0 NOUN F
to 0 ADP F
the 0 DET F
drugs 0 NOUN F
( 0 PUNCT F
P 0 NOUN T
> 0 SYM F
.05 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

CONCLUSION 0 NOUN T
Although 0 ADP T
hs-CRP B-PHYSICAL NOUN F
was 0 VERB F
lower 0 PUNCT F
in 0 ADP F
the 0 DET F
CC 0 NOUN T
genotype 0 NOUN F
patients 0 NOUN F
of 0 ADP F
ATR1 0 NOUN T
polymorphisms 0 NOUN F
E 0 NOUN T
and/or 0 CCONJ F
L 0 NOUN T
reduced 0 ADV F
hs-CRP 0 NOUN F
and 0 CCONJ F
increased 0 VERB F
TA 0 NOUN T
regardless 0 PUNCT F
of 0 ADP F
the 0 DET F
RAS 0 NOUN T
genotype 0 NOUN F
. 0 PUNCT F

Prazosin 0 NOUN T
versus 0 CCONJ F
captopril 0 NOUN F
as 0 PUNCT F
initial 0 ADJ F
therapy 0 NOUN F
. 0 PUNCT F

Effect 0 NOUN T
on 0 ADP F
hypertension B-PHYSICAL NOUN F
and I-PHYSICAL CCONJ F
lipid I-PHYSICAL NOUN F
levels I-PHYSICAL NOUN F
. 0 PUNCT F

A 0 DET T
randomized 0 VERB F
, 0 PUNCT F
parallel 0 ADJ F
group 0 NOUN F
study 0 NOUN F
evaluated 0 VERB F
the 0 DET F
safety B-OTHER NOUN F
, I-OTHER PUNCT F
efficacy 0 NOUN F
, B-OTHER PUNCT F
and 0 CCONJ F
effect 0 NOUN F
of 0 ADP F
the 0 DET F
alpha 0 NOUN F
blocking 0 DET F
agent 0 NOUN F
prazosin 0 NOUN F
and 0 CCONJ F
the 0 DET F
angiotensin 0 NOUN F
converting 0 VERB F
enzyme 0 NOUN F
inhibitor 0 NOUN F
captopril 0 NOUN F
on 0 ADP F
serum 0 NOUN F
lipid 0 NOUN F
levels 0 NOUN F
in 0 ADP F
patients 0 NOUN F
with 0 ADP F
mild 0 ADJ F
to 0 ADP F
moderate 0 ADJ F
hypertension 0 NOUN F
. 0 PUNCT F

Baseline 0 NOUN T
evaluations 0 NOUN F
were 0 VERB F
performed 0 VERB F
on 0 ADP F
31 0 NUM F
patients 0 NOUN F
after 0 ADP F
a 0 DET F
four-week 0 NOUN F
placebo 0 NOUN F
washout 0 PUNCT F
period 0 NOUN F
. 0 PUNCT F

Patients 0 NOUN T
were 0 VERB F
randomly 0 ADV F
assigned 0 VERB F
to 0 PART F
receive 0 NOUN F
either 0 PUNCT F
prazosin 0 NOUN F
( 0 PUNCT F
n 0 NOUN F
= 0 SYM F
15 0 NUM F
) 0 PUNCT F
or 0 CCONJ F
captopril 0 NOUN F
( 0 PUNCT F
n 0 NOUN F
= 0 SYM F
16 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Daily 0 DET T
doses 0 NOUN F
were 0 VERB F
titrated 0 VERB F
as 0 PUNCT F
follows 0 VERB F
: 0 PUNCT F
for 0 ADP F
prazosin 0 NOUN F
, 0 PUNCT F
1 0 NUM F
mg 0 NOUN F
two 0 NUM F
times 0 NOUN F
daily 0 ADJ F
to 0 ADP F
maximum 0 NOUN F
of 0 ADP F
20 0 NUM F
mg 0 NOUN F
per 0 ADP F
day 0 NOUN F
; 0 PUNCT F
for 0 ADP F
captopril 0 NOUN F
, 0 PUNCT F
25 0 NUM F
mg 0 NOUN F
three 0 NUM F
times 0 NOUN F
daily 0 ADJ F
to 0 ADP F
a 0 DET F
maximum 0 NOUN F
of 0 ADP F
450 0 NUM F
mg 0 NOUN F
per 0 ADP F
day 0 NOUN F
. 0 PUNCT F

If 0 ADP T
diastolic B-PHYSICAL ADJ F
blood I-PHYSICAL NOUN F
pressure I-PHYSICAL NOUN F
was 0 VERB F
not 0 ADV F
adequately 0 ADV F
controlled 0 PROPN F
( 0 PUNCT F
less 0 ADV F
than 0 PUNCT F
85 0 NUM F
mm 0 NOUN F
Hg 0 NOUN T
) 0 PUNCT F
after 0 ADP F
four 0 NUM F
weeks 0 NOUN F
of 0 ADP F
monotherapy 0 NOUN F
, 0 PUNCT F
1 0 NUM F
mg 0 NOUN F
of 0 ADP F
polythiazide 0 NOUN F
was 0 VERB F
added 0 VERB F
to 0 ADP F
the 0 DET F
daily 0 ADJ F
regimen 0 NOUN F
. 0 PUNCT F

There 0 PUNCT T
were 0 VERB F
no 0 DET F
statistically 0 ADV F
significant 0 ADJ F
differences 0 NOUN F
between 0 ADP F
the 0 DET F
drug 0 NOUN F
groups 0 NOUN F
for 0 ADP F
the 0 DET F
measured 0 VERB F
variables 0 NOUN F
in 0 ADP F
either 0 CCONJ F
the 0 DET F
parallel 0 ADJ F
or 0 CCONJ F
crossover 0 NOUN F
phase 0 NOUN F
of 0 ADP F
the 0 DET F
study 0 NOUN F
. 0 PUNCT F

Five 0 NUM T
of 0 ADP F
15 0 NUM F
prazosin-treated 0 VERB F
patients 0 NOUN F
and 0 CCONJ F
six 0 NUM F
of 0 ADP F
16 0 NUM F
captopril-treated 0 VERB F
patients 0 NOUN F
required 0 VERB F
the 0 DET F
addition 0 NOUN F
of 0 ADP F
thiazide 0 NOUN F
to 0 PUNCT F
achieve 0 PUNCT F

The 0 DET T
benefits 0 NOUN F
of 0 ADP F
including 0 PUNCT F
clinical 0 ADJ F
factors 0 NOUN F
in 0 ADP F
rectal 0 ADJ F
normal 0 ADJ F
tissue 0 NOUN F
complication 0 NOUN F
probability 0 NOUN F
modeling 0 PUNCT F
after 0 ADP F
radiotherapy 0 NOUN F
for 0 ADP F
prostate 0 NOUN F
cancer 0 NOUN F
. 0 PUNCT F

PURPOSE 0 NOUN T
To 0 ADP T
study 0 NOUN F
the 0 DET F
impact 0 NOUN F
of 0 ADP F
clinical 0 ADJ F
predisposing 0 ADJ F
factors 0 NOUN F
on 0 ADP F
rectal 0 ADJ F
normal 0 ADJ F
tissue 0 NOUN F
complication 0 NOUN F
probability 0 NOUN F
modeling 0 PROPN F
using 0 ADP F
the 0 DET F
updated 0 VERB F
results 0 NOUN F
of 0 ADP F
the 0 DET F
Dutch 0 NOUN T
prostate 0 NOUN F
dose-escalation 0 NOUN F
trial 0 NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
AND 0 CCONJ T
MATERIALS 0 NOUN T
Toxicity 0 NOUN T
data 0 NOUN F
of 0 ADP F
512 0 NUM F
patients 0 NOUN F
( 0 PUNCT F
conformally 0 ADV F
treated 0 ADP F
to 0 ADP F
68 0 NUM F
Gy 0 NOUN T
[ 0 PUNCT F
n 0 NOUN F
= 0 SYM F
284 0 NUM F
] 0 PUNCT F
and 0 CCONJ F
78 0 NUM F
Gy 0 NOUN T
[ 0 PUNCT F
n 0 NOUN F
= 0 SYM F
228 0 NUM F
] 0 PUNCT F
) 0 PUNCT F
with 0 ADP F
complete 0 ADJ F
follow-up 0 NOUN F
at 0 ADP F
3 0 NUM F
years 0 NOUN F
after 0 ADP F
radiotherapy 0 NOUN F
were 0 VERB F
studied 0 VERB F
. 0 PUNCT F

Scored 0 VERB T
end 0 NOUN F
points 0 NOUN F
were 0 VERB F
rectal 0 ADJ F
bleeding 0 VERB F
, 0 PUNCT F
high 0 ADJ F
stool 0 NOUN F
frequency 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
fecal 0 ADJ F
incontinence 0 NOUN F
. 0 PUNCT F

Two 0 NUM T
traditional 0 ADJ F
dose-based 0 VERB F
models 0 NOUN F
( 0 PUNCT F
Lyman-Kutcher-Burman 0 NOUN T
( 0 PUNCT F
LKB 0 NOUN T
) 0 PUNCT F
and 0 CCONJ F
Relative 0 ADJ T
Seriality 0 NOUN T
( 0 PUNCT F
RS 0 NOUN T
) 0 PUNCT F
and 0 CCONJ F
a 0 DET F
logistic 0 ADJ F
model 0 NOUN F
were 0 VERB F
fitted 0 VERB F
using 0 VERB F
a 0 DET F
maximum 0 NOUN F
likelihood 0 NOUN F
approach 0 NOUN F
. 0 PUNCT F

Furthermore 0 ADV T
, 0 PUNCT F
these 0 DET F
model 0 NOUN F
fits 0 PUNCT F
were 0 VERB F
improved 0 VERB F
by 0 ADP F
including 0 PUNCT F
the 0 DET F
most 0 VERB F
significant 0 ADJ F
clinical 0 ADJ F
factors 0 NOUN F
. 0 PUNCT F

The 0 DET T
area 0 NOUN F
under 0 ADP F
the 0 DET F
receiver 0 NOUN F
operating 0 VERB F
characteristic 0 ADJ F
curve 0 NOUN F
( 0 PUNCT F
AUC 0 NOUN T
) 0 PUNCT F
was 0 VERB F
used 0 VERB F
to 0 PART F
compare 0 NOUN F
the 0 DET F
discriminating 0 VERB F
ability 0 NOUN F
of 0 ADP F
all 0 DET F
fits 0 PUNCT F
. 0 PUNCT F

RESULTS 0 NOUN T
Including 0 PUNCT T
clinical 0 ADJ F
factors 0 NOUN F
significantly 0 ADV F
increased 0 VERB F
the 0 DET F
predictive 0 ADJ F
power 0 NOUN F
of 0 ADP F
the 0 DET F
models 0 NOUN F
for 0 ADP F
all 0 DET F
end 0 NOUN F
points 0 NOUN F
. 0 PUNCT F

In 0 ADP T
the 0 DET F
optimal 0 ADJ F
LKB 0 NOUN T
, 0 PUNCT F
RS 0 NOUN T
, 0 PUNCT F
and 0 CCONJ F
logistic 0 ADJ F
models 0 NOUN F
for 0 ADP F
rectal 0 ADJ F
bleeding 0 VERB F
and 0 CCONJ F
fecal 0 ADJ F
incontinence 0 NOUN F
, 0 PUNCT F
the 0 DET F
first 0 ADJ F
significant 0 ADJ F
( 0 PUNCT F
p 0 NOUN F
= 0 SYM F
0.011-0.013 0 NUM F
) 0 PUNCT F
clinical 0 ADJ F
factor 0 NOUN F
was 0 VERB F
previous 0 ADJ F
abdominal 0 ADJ F
surgery 0 NOUN F
. 0 PUNCT F

As 0 PUNCT T
second 0 ADJ F
significant 0 ADJ F
( 0 PUNCT F
p 0 NOUN F
= 0 SYM F
0.012-0.016 0 NUM F
) 0 PUNCT F
factor 0 NOUN F
, 0 PUNCT F
cardiac 0 ADJ F
history 0 NOUN F
was 0 VERB F
included 0 VERB F
in 0 ADP F
all 0 DET F
three 0 NUM F
rectal 0 ADJ F
bleeding 0 VERB F
fits 0 PUNCT F
, 0 PUNCT F
whereas 0 ADP F
including 0 PUNCT F
diabetes 0 NOUN F
was 0 VERB F
significant 0 ADJ F
( 0 PUNCT F
p 0 NOUN F
= 0 SYM F
0.039-0.048 0 NUM F
) 0 PUNCT F
in 0 ADP F
fecal 0 ADJ F
incontinence 0 NOUN F
modeling 0 PUNCT F
but 0 CCONJ F
only 0 ADV F
in 0 ADP F
the 0 DET F
LKB 0 NOUN T
and 0 CCONJ F
logistic 0 ADJ F
models 0 NOUN F
. 0 PUNCT F

High B-PHYSICAL ADJ T
stool I-PHYSICAL NOUN F
frequency I-PHYSICAL NOUN F
fits 0 PUNCT F
only 0 ADV F
benefitted 0 ADP F
significantly 0 ADV F
( 0 PUNCT F
p 0 NOUN F
= 0 SYM F
0.003-0.006 0 PUNCT F
) 0 PUNCT F
from 0 ADP F
the 0 DET F
inclusion 0 NOUN F
of 0 ADP F
the 0 DET F
baseline 0 NOUN F
toxicity 0 NOUN F
score 0 NOUN F
. 0 PUNCT F

For 0 ADP T
all 0 DET F
models 0 NOUN F
rectal 0 ADJ F
bleeding 0 VERB F
fits 0 PUNCT F
had 0 PUNCT F
the 0 DET F
highest 0 PUNCT F
AUC 0 NOUN T
( 0 PUNCT F
0.77 0 NUM F
) 0 PUNCT F
where 0 ADP F
it 0 PRON F
was 0 VERB F
0.63 0 NUM F
and 0 CCONJ F
0.68 0 NUM F
for 0 ADP F
high 0 ADJ F
stool 0 NOUN F
frequency 0 NOUN F
and 0 CCONJ F
fecal 0 ADJ F
incontinence 0 NOUN F
, 0 PUNCT F
respectively 0 ADV F
. 0 PUNCT F

LKB 0 NOUN T
and 0 CCONJ F
logistic 0 ADJ F
model 0 NOUN F
fits 0 PUNCT F
resulted 0 PUNCT F
in 0 ADP F
similar 0 ADJ F
values 0 NOUN F
for 0 ADP F
the 0 DET F
volume 0 NOUN F
parameter 0 NOUN F
. 0 PUNCT F

The 0 DET T
steepness 0 NOUN F
parameter 0 NOUN F
was 0 VERB F
somewhat 0 ADV F
higher 0 PUNCT F
in 0 ADP F
the 0 DET F
logistic 0 ADJ F
model 0 NOUN F
, 0 PUNCT F
also 0 ADV F
resulting 0 VERB F
in 0 ADP F
a 0 DET F
slightly 0 ADV F
lower 0 PUNCT F
D 0 NOUN T
( 0 PUNCT F
50 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Anal 0 ADJ T
wall 0 NOUN F
DVHs 0 NOUN T
were 0 VERB F
used 0 VERB F
for 0 ADP F
fecal 0 ADJ F
incontinence 0 NOUN F
, 0 PUNCT F
whereas 0 CCONJ F
anorectal 0 ADJ F
wall 0 NOUN F
dose 0 NOUN F
best 0 ADV F
described 0 DET F
the 0 DET F
other 0 ADJ F
two 0 NUM F
endpoints 0 NOUN F
. 0 PUNCT F

CONCLUSIONS 0 NOUN T
Comparable 0 ADJ T
prediction 0 NOUN F
models 0 NOUN F
were 0 VERB F
obtained 0 VERB F
with 0 ADP F
LKB 0 NOUN T
, 0 PUNCT F
RS 0 NOUN T
, 0 PUNCT F
and 0 CCONJ F
logistic 0 ADJ F
NTCP 0 ADJ T
models 0 NOUN F
. 0 PUNCT F

Including 0 PUNCT T
clinical 0 ADJ F
factors 0 NOUN F
improved 0 VERB F
the 0 DET F
predictive 0 ADJ F
power 0 NOUN F
of 0 ADP F
all 0 DET F
models 0 NOUN F
significantly 0 ADV F
. 0 PUNCT F

A 0 DET T
randomized 0 VERB F
multicenter 0 NOUN F
trial 0 NOUN F
comparing 0 PUNCT F
resection 0 NOUN F
and 0 CCONJ F
radiochemotherapy 0 NOUN F
for 0 ADP F
resectable 0 ADJ F
locally 0 ADV F
invasive 0 ADJ F
pancreatic 0 ADJ F
cancer 0 NOUN F
. 0 PUNCT F

BACKGROUND 0 NOUN T
Though 0 ADP T
the 0 DET F
outcome 0 NOUN F
of 0 ADP F
resection 0 NOUN F
for 0 ADP F
locally 0 ADV F
invasive 0 ADJ F
pancreatic 0 ADJ F
cancer 0 NOUN F
is 0 VERB F
still 0 ADV F
poor 0 ADJ F
, 0 PUNCT F
it 0 PUNCT F
has 0 PUNCT F
gradually 0 ADV F
improved 0 ADP F
in 0 ADP F
Japan 0 PUNCT T
, 0 PUNCT F
and 0 CCONJ F
the 0 DET F
5-year B-MORTALITY ADJ F
survival I-MORTALITY NOUN F
is 0 VERB F
now 0 ADV F
about 0 PUNCT F
10 0 NUM F
% 0 SYM F
. 0 PUNCT F

However 0 ADV T
, 0 PUNCT F
the 0 DET F
advantage 0 NOUN F
of 0 ADP F
resection 0 NOUN F
over 0 ADP F
radiochemotherapy 0 NOUN F
has 0 VERB F
not 0 ADP F
yet 0 ADV F
been 0 PUNCT F
confirmed 0 VERB F
by 0 ADP F
a 0 DET F
randomized 0 VERB F
trial 0 NOUN F
. 0 PUNCT F

We 0 PRON T
conducted 0 VERB F
this 0 DET F
study 0 NOUN F
to 0 DET F
compare 0 NOUN F
surgical 0 ADJ F
resection 0 NOUN F
alone 0 ADJ F
versus 0 CCONJ F
radiochemotherapy 0 NOUN F
without 0 ADP F
resection 0 NOUN F
for 0 ADP F
locally 0 ADV F
invasive 0 ADJ F
pancreatic 0 ADJ F
cancer 0 NOUN F
using 0 VERB F
a 0 DET F
multicenter 0 NOUN F
randomized 0 VERB F
design 0 NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
Patients 0 NOUN T
with 0 ADP F
pancreatic 0 ADJ F
cancer 0 NOUN F
who 0 ADP F
met 0 VERB F
our 0 PUNCT F
preoperative 0 ADJ F
criteria 0 NOUN F
for 0 ADP F
inclusion 0 NOUN F
( 0 PUNCT F
pancreatic 0 ADJ F
cancer 0 NOUN F
invading 0 PUNCT F
the 0 DET F
pancreatic 0 ADJ F
capsule 0 NOUN F
without 0 ADP F
involvement 0 NOUN F
of 0 ADP F
the 0 DET F
superior 0 ADJ F
mesenteric 0 ADJ F
artery 0 NOUN F
or 0 CCONJ F
the 0 DET F
common 0 ADJ F
hepatic 0 ADJ F
artery 0 NOUN F
, 0 PUNCT F
or 0 CCONJ F
without 0 ADP F
distant 0 ADJ F
metastasis 0 NOUN F
) 0 PUNCT F
underwent 0 VERB F
laparotomy 0 NOUN F
. 0 PUNCT F

Patients 0 NOUN T
with 0 ADP F
operative 0 ADJ F
findings 0 NOUN F
consistent 0 ADJ F
with 0 ADP F
our 0 PUNCT F
criteria 0 NOUN F
were 0 VERB F
randomized 0 VERB F
into 0 ADP F
a 0 DET F
radical 0 PUNCT F
resection 0 NOUN F
group 0 NOUN F
and 0 CCONJ F
a 0 DET F
radiochemotherapy 0 NOUN F
group 0 NOUN F
( 0 PUNCT F
200 0 NUM F
mg/m 0 NOUN F
( 0 PUNCT F
2 0 NUM F
) 0 PUNCT F
/day 0 NOUN F
of 0 ADP F
intravenous 0 ADJ F
5-fluorouracil 0 NOUN F
and 0 CCONJ F
5040 0 NUM F
cGy 0 NOUN F
of 0 ADP F
radiotherapy 0 NOUN F
) 0 PUNCT F
without 0 ADP F
resection 0 NOUN F
. 0 PUNCT F

The 0 DET T
2 0 NUM F
groups 0 NOUN F
were 0 VERB F
compared 0 VERB F
for 0 ADP F
mean 0 NOUN F
survival B-MORTALITY NOUN F
, 0 PUNCT F
hazard 0 NOUN F
ratio 0 NOUN F
, 0 PUNCT F
1-year B-MORTALITY ADJ F
survival I-MORTALITY NOUN F
, 0 PUNCT F
quality 0 NOUN F
of 0 ADP F
life 0 NOUN F
scores B-MORTALITY NOUN F
, 0 PUNCT F
and 0 CCONJ F
hematologic B-PHYSICAL ADJ F
and I-PHYSICAL CCONJ F
blood I-PHYSICAL NOUN F
chemical I-PHYSICAL ADJ F
data I-PHYSICAL NOUN F
. 0 PUNCT F

RESULTS 0 NOUN T
Twenty 0 PUNCT T
patients 0 NOUN F
were 0 VERB F
assigned 0 VERB F
to 0 ADP F
the 0 DET F
resection 0 NOUN F
group 0 NOUN F
and 0 CCONJ F
22 0 NUM F
to 0 ADP F
the 0 DET F
radiochemotherapy 0 NOUN F
group 0 NOUN F
. 0 PUNCT F

There 0 PUNCT T
was 0 VERB F
1 0 NUM F
operative B-MORTALITY ADJ F
death I-MORTALITY NOUN F
. 0 PUNCT F

The 0 DET T
surgical 0 ADJ F
resection 0 NOUN F
group 0 NOUN F
had 0 PUNCT F
better 0 PUNCT F
results 0 PUNCT F
than 0 VERB F
the 0 DET F
radiochemotherapy 0 NOUN F
group 0 NOUN F
as 0 PUNCT F
measured 0 VERB F
by 0 ADP F
1-year B-MORTALITY ADJ F
survival I-MORTALITY NOUN F
( 0 PUNCT F
62 0 NUM F
% 0 SYM F
vs 0 CCONJ F
32 0 NUM F
% 0 SYM F
, 0 PUNCT F
P=.05 0 NOUN T
) 0 PUNCT F
, 0 PUNCT F
mean 0 ADP F
survival B-MORTALITY NOUN F
time I-MORTALITY NOUN F
( 0 PUNCT F
> 0 PROPN F
17 0 NUM F
vs 0 CCONJ F
11 0 NUM F
months 0 NOUN F
, 0 PUNCT F
P 0 NOUN T
< 0 SYM F
.03 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
and 0 CCONJ F
hazard 0 NOUN F
ratio 0 NOUN F
( 0 PUNCT F
0.46 0 NUM F
, 0 PUNCT F
P=.04 0 ADJ T
) 0 PUNCT F
. 0 PUNCT F

There 0 PUNCT T
were 0 VERB F
no 0 DET F
differences 0 NOUN F
in 0 ADP F
the 0 DET F
quality 0 NOUN F
of 0 ADP F
life 0 NOUN F
score 0 NOUN F
or 0 CCONJ F
laboratory B-PHYSICAL NOUN F
data I-PHYSICAL NOUN F
apart 0 PUNCT F
from 0 ADP F
increased 0 NOUN F
diarrhea B-PHYSICAL NOUN F
after 0 ADP F
surgical 0 ADJ F
resection 0 NOUN F
. 0 PUNCT F

CONCLUSIONS 0 NOUN T
Locally 0 ADJ T
invasive 0 ADJ F
pancreatic 0 ADJ F
cancer 0 NOUN F
without 0 ADP F
distant 0 ADJ F
metastases 0 NOUN F
and 0 CCONJ F
major 0 ADJ F
arterial 0 ADJ F
invasion 0 NOUN F
appears 0 NOUN F
to 0 PART F
be 0 PUNCT F
best 0 PUNCT F
treated 0 PRON F
by 0 ADP F
surgical 0 ADJ F
resection 0 NOUN F
. 0 PUNCT F

A 0 DET T
double-blind 0 ADJ F
, 0 PUNCT F
placebo-controlled 0 VERB F
trial 0 NOUN F
of 0 ADP F
intravenous 0 ADJ F
immunoglobulin 0 NOUN F
therapy 0 NOUN F
in 0 ADP F
patients 0 NOUN F
with 0 ADP F
chronic 0 ADJ F
fatigue 0 NOUN F
syndrome 0 NOUN F
. 0 PUNCT F

PURPOSE 0 NOUN T
The 0 DET T
chronic 0 ADJ F
fatigue 0 NOUN F
syndrome 0 NOUN F
( 0 PUNCT F
CFS 0 NOUN T
) 0 PUNCT F
is 0 VERB F
characterized 0 VERB F
by 0 ADP F
profound 0 ADJ F
fatigue 0 NOUN F
, 0 PUNCT F
neuropsychiatric 0 ADJ F
dysfunction 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
frequent 0 ADJ F
abnormalities 0 NOUN F
in 0 ADP F
cell-mediated 0 VERB F
immunity 0 NOUN F
. 0 PUNCT F

No 0 DET T
effective 0 ADJ F
therapy 0 NOUN F
is 0 VERB F
known 0 VERB F
. 0 PUNCT F

PATIENTS 0 NOUN T
AND 0 CCONJ T
METHODS 0 NOUN T
Forty-nine 0 NUM T
patients 0 NOUN F
( 0 PUNCT F
40 0 NUM F
with 0 ADP F
abnormal 0 ADJ F
cell-mediated 0 VERB F
immunity 0 NOUN F
) 0 PUNCT F
participated 0 PUNCT F
in 0 ADP F
a 0 DET F
randomized 0 VERB F
, 0 PUNCT F
double-blind 0 ADJ F
, 0 PUNCT F
placebo-controlled 0 VERB F
trial 0 NOUN F
to 0 PART F
determine 0 NOUN F
the 0 DET F
effectiveness 0 NOUN F
of 0 ADP F
high-dose 0 NOUN F
intravenously 0 ADV F
administered 0 ADP F
immunoglobulin 0 NOUN F
G. 0 PUNCT T
The 0 DET T
patients 0 NOUN F
received 0 VERB F
three 0 NUM F
intravenous 0 ADJ F
infusions 0 NOUN F
of 0 ADP F
a 0 DET F
placebo 0 NOUN F
solution 0 NOUN F
or 0 CCONJ F
immunoglobulin 0 NOUN F
at 0 ADP F
a 0 DET F
dose 0 NOUN F
of 0 ADP F
2 0 NUM F
g/kg/month 0 NUM F
. 0 PUNCT F

Assessment 0 NOUN T
of 0 ADP F
the 0 DET F
severity 0 NOUN F
of 0 ADP F
symptoms 0 NOUN F
and 0 CCONJ F
associated 0 VERB F
disability 0 NOUN F
, 0 PUNCT F
both 0 PUNCT F
before 0 ADP F
and 0 CCONJ F
after 0 ADP F
treatment 0 NOUN F
, 0 PUNCT F
was 0 VERB F
completed 0 VERB F
at 0 ADP F
detailed 0 VERB F
interviews 0 NOUN F
by 0 ADP F
a 0 DET F
physician 0 NOUN F
and 0 CCONJ F
psychiatrist 0 NOUN F
, 0 PUNCT F
who 0 PROPN F
were 0 VERB F
unaware 0 PUNCT F
of 0 ADP F
the 0 DET F
treatment 0 NOUN F
status 0 NOUN F
. 0 PUNCT F

In 0 ADP T
addition 0 NOUN F
, 0 PUNCT F
any 0 DET F
change 0 NOUN F
in 0 ADP F
physical 0 ADJ F
symptoms 0 NOUN F
and 0 CCONJ F
functional 0 ADJ F
capacity 0 NOUN F
was 0 VERB F
recorded 0 VERB F
using 0 VERB F
visual 0 ADJ F
analogue 0 NOUN F
scales 0 NOUN F
, 0 PUNCT F
while 0 ADP F
changes 0 NOUN F
in 0 ADP F
psychologic 0 ADJ F
morbidity 0 NOUN F
were 0 VERB F
assessed 0 VERB F
using 0 SYM F
patient-rated 0 VERB F
indices 0 NOUN F
of 0 ADP F
depression 0 NOUN F
. 0 PUNCT F

Cell-mediated 0 VERB T
immunity 0 NOUN F
was 0 VERB F
evaluated 0 VERB F
by 0 ADP F
T-cell 0 NOUN T
subset 0 NOUN F
analysis 0 NOUN F
, 0 PUNCT F
delayed-type 0 NOUN F
hypersensitivity 0 NOUN F
skin 0 NOUN F
testing 0 VERB F
, 0 PUNCT F
and 0 CCONJ F
lymphocyte 0 NOUN F
transformation 0 NOUN F
with 0 ADP F
phytohemagglutinin 0 NOUN F
. 0 PUNCT F

RESULTS 0 NOUN T
At 0 ADP T
the 0 DET F
interview 0 NOUN F
conducted 0 VERB F
by 0 ADP F
the 0 DET F
physician 0 NOUN F
3 0 NUM F
months 0 NOUN F
after 0 ADP F
the 0 DET F
final 0 ADJ F
infusion 0 NOUN F
, 0 PUNCT F
10 0 NUM F
of 0 ADP F
23 0 NUM F
( 0 PUNCT F
43 0 NUM F
% 0 SYM F
) 0 PUNCT F
immunoglobulin 0 NOUN F
recipients 0 NOUN F
and 0 CCONJ F
three 0 NUM F
of 0 ADP F
the 0 DET F
26 0 NUM F
( 0 PUNCT F
12 0 NUM F
% 0 SYM F
) 0 PUNCT F
placebo 0 NOUN F
recipients 0 NOUN F
were 0 VERB F
assessed 0 VERB F
as 0 ADP F
having 0 DET F
responded 0 VERB F
with 0 ADP F
a 0 DET F
substantial B-OTHER ADJ F
reduction I-OTHER NOUN F
in I-OTHER ADP F
their I-OTHER PUNCT F
symptoms I-OTHER NOUN F
and 0 CCONJ F
recommencement B-OTHER ADJ F
of I-OTHER ADP F
work I-OTHER NOUN F
, 0 PUNCT F
leisure B-OTHER NOUN F
, 0 PUNCT F
and 0 CCONJ F
social B-MENTAL ADJ F
activities I-MENTAL NOUN F
. 0 PUNCT F

The 0 DET T
patients 0 NOUN F
designated 0 VERB F
as 0 ADP F
having 0 DET F
responded 0 VERB F
had 0 PUNCT F
improvement 0 NOUN F
in 0 ADP F
physical 0 ADJ F
, 0 PUNCT F
psychologic 0 ADJ F
, 0 PUNCT F
and 0 CCONJ F
immunologic 0 ADJ F
measures 0 NOUN F
( 0 PUNCT F
p 0 NOUN F
less 0 ADV F
than 0 ADP F
0.01 0 NUM F
for 0 ADP F
each 0 PUNCT F
) 0 PUNCT F
. 0 PUNCT F

CONCLUSION 0 NOUN T
Immunomodulatory 0 ADJ T
treatment 0 NOUN F
with 0 ADP F
immunoglobulin 0 NOUN F
is 0 VERB F
effective 0 ADJ F
in 0 ADP F
a 0 DET F
significant 0 ADJ F
number 0 NOUN F
of 0 ADP F
patients 0 NOUN F
with 0 ADP F
CFS 0 NOUN T
, 0 PUNCT F
a 0 DET F
finding 0 VERB F
that 0 DET F
supports 0 NOUN F
the 0 DET F
concept 0 NOUN F
that 0 ADP F
an 0 DET F
immunologic 0 ADJ F
disturbance 0 NOUN F
may 0 VERB F
be 0 VERB F
important 0 ADJ F
in 0 ADP F
the 0 DET F
pathogenesis 0 NOUN F
of 0 ADP F
this 0 PUNCT F
disorder 0 NOUN F
. 0 PUNCT F

[ 0 PUNCT F
Mitomycin 0 NOUN T
C 0 NOUN T
plus 0 CCONJ F
HCFU 0 NOUN T
adjuvant 0 NOUN F
chemotherapy 0 NOUN F
for 0 ADP F
noncuratively 0 PUNCT F
resected 0 PUNCT F
cases 0 NOUN F
of 0 ADP F
colorectal 0 ADJ F
carcinoma 0 NOUN F
. 0 PUNCT F
( 0 PUNCT F

Second 0 ADJ T
report 0 NOUN F
) 0 PUNCT F
: 0 PUNCT F
5-year 0 PUNCT F
survival 0 NOUN F
rate 0 NOUN F
. 0 PUNCT F

Cooperative 0 ADJ T
Study 0 NOUN T
Group 0 NOUN T
of 0 ADP F
Kyushu 0 NOUN T
and 0 CCONJ F
Chugoku 0 NOUN T
for 0 ADP F
HCFU 0 NOUN T
Adjuvant 0 NOUN T
Chemotherapy 0 NOUN T
] 0 PUNCT F
. 0 PUNCT F

In 0 ADP T
order 0 NOUN F
to 0 PART F
examine 0 NOUN F
the 0 DET F
efficacy 0 NOUN F
of 0 ADP F
adjuvant 0 NOUN F
chemotherapy 0 NOUN F
employing 0 SYM F
mitomycin 0 NUM F
C 0 NOUN T
( 0 PUNCT F
MMC 0 NOUN T
) 0 PUNCT F
and 0 CCONJ F
carmofur 0 NOUN F
( 0 PUNCT F
HCFU 0 NOUN T
) 0 PUNCT F
for 0 ADP F
patients 0 NOUN F
with 0 ADP F
noncuratively 0 PUNCT F
resected 0 PUNCT F
colorectal 0 ADJ F
carcinoma 0 NOUN F
, 0 PUNCT F
a 0 DET F
cooperative 0 ADJ F
study 0 NOUN F
was 0 VERB F
performed 0 VERB F
by 0 ADP F
54 0 NUM F
institutions 0 NOUN F
in 0 ADP F
the 0 DET F
Kyushu 0 NOUN T
and 0 CCONJ F
Chugoku 0 NOUN T
areas 0 NOUN F
of 0 ADP F
Japan 0 PUNCT T
. 0 PUNCT F

The 0 DET T
criteria 0 NOUN F
for 0 ADP F
patient 0 NOUN F
selection 0 NOUN F
were 0 VERB F
as 0 ADP F
follows 0 PUNCT F
: 0 PUNCT F
1 0 NUM F
) 0 PUNCT F
Age 0 NOUN T
of 0 ADP F
75 0 NUM F
years 0 NOUN F
or 0 CCONJ F
less 0 DET F
and 0 CCONJ F
not 0 ADV F
accompanied 0 VERB F
by 0 ADP F
any 0 DET F
serious 0 ADJ F
disease 0 NOUN F
. 0 PUNCT F

2 0 NUM F
) 0 PUNCT F
Macroscopic 0 ADJ T
diagnosis 0 NOUN F
as 0 VERB F
being 0 VERB F
noncuratively 0 ADP F
resected 0 VERB F
on 0 ADP F
completion 0 NOUN F
of 0 ADP F
the 0 DET F
surgical 0 ADJ F
procedure 0 NOUN F
. 0 PUNCT F

3 0 NUM F
) 0 PUNCT F
Definitive 0 ADJ T
diagnosis 0 NOUN F
of 0 ADP F
colorectal 0 ADJ F
carcinomas 0 NOUN F
, 0 PUNCT F
histologically 0 ADV F
. 0 PUNCT F

4 0 NUM F
) 0 PUNCT F
No 0 DET T
synchronous 0 ADJ F
or 0 CCONJ F
metachronous 0 ADJ F
double 0 ADJ F
cancer 0 NOUN F
. 0 PUNCT F

The 0 DET T
prospective 0 ADJ F
randomized 0 VERB F
controlled 0 DET F
study 0 NOUN F
consisted 0 VERB F
of 0 ADP F
two 0 NUM F
groups 0 NOUN F
. 0 PUNCT F

In 0 ADP T
Group 0 NOUN T
A 0 NOUN T
, 0 PUNCT F
the 0 DET F
MMC 0 NOUN T
group 0 NOUN F
received 0 VERB F
bolus 0 NOUN F
intravenous 0 ADJ F
injections 0 NOUN F
of 0 ADP F
20 0 NUM F
mg 0 NOUN F
MMC 0 NOUN T
on 0 ADP F
the 0 DET F
day 0 NOUN F
of 0 ADP F
operation 0 NOUN F
and 0 CCONJ F
10 0 NUM F
mg 0 NOUN F
the 0 DET F
next 0 ADJ F
day 0 NOUN F
, 0 PUNCT F
followed 0 VERB F
by 0 ADP F
10 0 NUM F
mg 0 NOUN F
every 0 DET F
4 0 NUM F
weeks 0 NOUN F
until 0 ADP F
a 0 DET F
total 0 NOUN F
of 0 ADP F
100 0 NUM F
mg 0 NOUN F
had 0 PUNCT F
been 0 PUNCT F
administered 0 VERB F
. 0 PUNCT F

In 0 ADP T
Group 0 NOUN T
B 0 NOUN T
, 0 PUNCT F
the 0 DET F
MMC 0 NOUN T
+ 0 SYM F
HCFU 0 NOUN T
group 0 NOUN F
received 0 VERB F
the 0 DET F
same 0 ADJ F
treatment 0 NOUN F
in 0 ADP F
Group 0 NOUN T
A 0 NOUN T
, 0 PUNCT F
but 0 CCONJ F
with 0 ADP F
the 0 DET F
addition 0 NOUN F
of 0 ADP F
600 0 NUM F
mg/day 0 NOUN F
of 0 ADP F
HCFU 0 NOUN T
from 0 ADP F
the 0 DET F
second 0 ADJ F
week 0 NOUN F
, 0 PUNCT F
orally 0 ADV F
for 0 ADP F
at 0 ADP F
least 0 ADV F
one 0 NUM F
year 0 NOUN F
. 0 PUNCT F

Concerning 0 PROPN T
the 0 DET F
69-month B-MORTALITY NOUN F
survival I-MORTALITY NOUN F
rate I-MORTALITY NOUN F
, 0 PUNCT F
a 0 DET F
better 0 PUNCT F
result 0 NOUN F
was 0 VERB F
observed 0 VERB F
in 0 ADP F
the 0 DET F
MMC 0 NOUN T
+ 0 SYM F
HCFU 0 NOUN T
group 0 NOUN F
than 0 PUNCT F
in 0 ADP F
the 0 DET F
MMC 0 NOUN T
only 0 DET F
group 0 NOUN F
( 0 PUNCT F
generalized 0 VERB F
Wilcoxon 0 NOUN T
test 0 NOUN F
: 0 PUNCT F
p 0 NOUN F
less 0 ADV F
than 0 PUNCT F
0.05 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Significantly 0 ADV T
better 0 PUNCT F
survival B-MORTALITY NOUN F
rates I-MORTALITY NOUN F
were 0 VERB F
obtained 0 VERB F
in 0 ADP F
those 0 PUNCT F
cases 0 NOUN F
with 0 ADP F
disseminating 0 PUNCT F
peritoneal 0 ADJ F
metastasis 0 NOUN F
, 0 PUNCT F
hepatic 0 ADJ F
metastasis 0 NOUN F
and 0 CCONJ F
stage 0 NOUN F
V 0 NUM T
cancer 0 NOUN F
in 0 ADP F
the 0 DET F
MMC 0 NOUN T
+ 0 SYM F
HCFU 0 NOUN T
group 0 NOUN F
as 0 PUNCT F
when 0 VERB F
compared 0 VERB F
with 0 ADP F
the 0 DET F
MMC 0 NOUN T
only 0 DET F
group 0 NOUN F
. 0 PUNCT F

No 0 DET T
significant B-ADVERSE-EFFECTS ADJ F
side I-ADVERSE-EFFECTS NOUN F
effects I-ADVERSE-EFFECTS NOUN F
due 0 CCONJ F
to 0 ADP F
the 0 DET F
combined 0 ADP F
administration 0 NOUN F
of 0 ADP F
HCFU 0 NOUN T
were 0 VERB F
recognized 0 VERB F
. 0 PUNCT F

The 0 DET T
combined 0 VERB F
administration 0 NOUN F
of 0 ADP F
MMC 0 NOUN T
and 0 CCONJ F
HCFU 0 NOUN T
was 0 VERB F
suggested 0 VERB F
to 0 PART F
be 0 PUNCT F
a 0 DET F
safe 0 ADJ F
and 0 CCONJ F
effective 0 ADJ F
adjuvant 0 NOUN F
chemotherapy 0 NOUN F
for 0 ADP F
noncuratively 0 PUNCT F
resected 0 PUNCT F
cases 0 NOUN F
of 0 ADP F
colorectal 0 ADJ F
carcinoma 0 NOUN F
. 0 PUNCT F

The 0 DET T
biological 0 ADJ F
factors 0 NOUN F
in 0 ADP F
the 0 DET F
etiopathogenesis 0 NOUN F
and 0 CCONJ F
management 0 NOUN F
of 0 ADP F
cervical 0 ADJ F
spondylosis 0 NOUN F
. 0 PUNCT F

Two 0 NUM T
hundred 0 NUM F
cases 0 NOUN F
of 0 ADP F
cervical 0 ADJ F
spondylosis 0 NOUN F
were 0 VERB F
studied 0 VERB F
for 0 ADP F
1 0 NUM F
to 0 ADP F
4 0 NUM F
average 0 NOUN F
( 0 PUNCT F
2 0 NUM F
1/2 0 NOUN F
) 0 PUNCT F
years 0 NOUN F
. 0 PUNCT F

No 0 DET T
co-relation 0 NOUN F
could 0 VERB F
be 0 VERB F
established 0 VERB F
between 0 ADP F
the 0 DET F
clinical 0 ADJ F
features 0 NOUN F
and 0 CCONJ F
the 0 DET F
radiological 0 ADJ F
findings 0 NOUN F
in 0 ADP F
these 0 DET F
cases 0 NOUN F
. 0 PUNCT F

It 0 PRON T
was 0 VERB F
found 0 VERB F
that 0 ADP F
parasites B-OTHER ADV F
play I-OTHER VERB F
an I-OTHER DET F
important I-OTHER ADJ F
role I-OTHER NOUN F
in I-OTHER ADP F
the I-OTHER DET F
multifactorial I-OTHER ADJ F
etiology I-OTHER NOUN F
of I-OTHER ADP F
this I-OTHER PUNCT F
condition I-OTHER NOUN F
and I-OTHER CCONJ F
their I-OTHER ADJ F
eradication I-OTHER NOUN F
by I-OTHER ADP F
deworming I-OTHER PUNCT F
drugs I-OTHER NOUN F
gives I-OTHER PART F
better I-OTHER VERB F
results I-OTHER PUNCT F
than I-OTHER VERB F
the I-OTHER DET F
traditional I-OTHER ADJ F
therapies I-OTHER NOUN F
. 0 PUNCT F

Many 0 DET T
new 0 ADJ F
hypotheses 0 NOUN F
are 0 VERB F
proposed 0 VERB F
to 0 PART F
explain 0 NOUN F
the 0 DET F
same 0 PUNCT F
. 0 PUNCT F

Safety B-OTHER NOUN T
and 0 CCONJ F
efficacy 0 NOUN F
of 0 ADP F
a 0 DET F
low 0 ADJ F
molecular 0 ADJ F
weight 0 NOUN F
heparin 0 NOUN F
( 0 PUNCT F
Logiparin 0 NOUN T
) 0 PUNCT F
versus 0 CCONJ F
dextran 0 NOUN F
as 0 PUNCT F
prophylaxis 0 NOUN F
against 0 ADP F
thrombosis 0 NOUN F
after 0 ADP F
total 0 ADJ F
hip 0 NOUN F
replacement 0 NOUN F
. 0 PUNCT F

In 0 ADP T
order 0 NOUN F
to 0 ADP F
study 0 NOUN F
the 0 DET F
plasma 0 NOUN F
levels 0 NOUN F
of 0 ADP F
factor 0 NOUN F
XaI 0 ADJ T
and 0 CCONJ F
IIaI 0 NOUN T
activity 0 NOUN F
an 0 DET F
enzymatically 0 ADV F
depolymerized 0 PART F
low 0 ADJ F
molecular 0 ADJ F
weight 0 NOUN F
heparin 0 NOUN F
( 0 PUNCT F
LMW-heparin 0 NOUN T
; 0 PUNCT F
Logiparin 0 NOUN T
) 0 PUNCT F
was 0 VERB F
given 0 VERB F
s.c. 0 NOUN F
in 0 ADP F
a 0 DET F
dose 0 NOUN F
of 0 ADP F
35 0 NUM F
XaI 0 ADJ T
mu/kg 0 NOUN F
b.w 0 NUM F
. 0 PUNCT F

once 0 PUNCT F
daily 0 ADJ F
for 0 ADP F
7 0 NUM F
days 0 NOUN F
to 0 ADP F
10 0 NUM F
patients 0 NOUN F
undergoing 0 VERB F
total 0 ADJ F
hip 0 NOUN F
replacement 0 NOUN F
( 0 PUNCT F
THR 0 NOUN T
) 0 PUNCT F
in 0 ADP F
a 0 DET F
pilot 0 NOUN F
study 0 NOUN F
. 0 PUNCT F

The 0 DET T
XaI 0 ADJ T
activity 0 NOUN F
was 0 VERB F
less 0 ADV F
than 0 PUNCT F
or 0 CCONJ F
equal 0 ADJ F
to 0 ADP F
0.24 0 NUM F
XaI 0 NOUN T
units/ml 0 ADV F
and 0 CCONJ F
the 0 DET F
IIaI 0 NOUN T
activity 0 NOUN F
less 0 ADV F
than 0 PUNCT F
or 0 CCONJ F
equal 0 ADJ F
to 0 ADP F
0.043 0 ADJ F
IIaI 0 NOUN T
mu/ml 0 NOUN F
. 0 PUNCT F

No 0 DET T
accumulation 0 NOUN F
of 0 ADP F
the 0 DET F
activities 0 NOUN F
were 0 VERB F
seen 0 VERB F
. 0 PUNCT F

No 0 DET T
phlebographically B-PHYSICAL ADV F
verified I-PHYSICAL PUNCT F
thrombi I-PHYSICAL NOUN F
or 0 CCONJ F
any 0 DET F
bleeding B-PHYSICAL VERB F
complications I-PHYSICAL NOUN F
were 0 VERB F
registered 0 PUNCT F
. 0 PUNCT F

From 0 ADP T
this 0 DET F
study 0 NOUN F
it 0 PUNCT F
was 0 VERB F
concluded 0 VERB F
that 0 ADP F
the 0 DET F
given 0 ADJ F
dose 0 NOUN F
of 0 ADP F
Logiparin 0 NOUN T
was 0 VERB F
safe 0 ADJ F
with 0 ADP F
regard 0 NOUN F
to 0 ADP F
bleeding 0 VERB F
complications 0 NOUN F
. 0 PUNCT F

Based 0 VERB T
on 0 ADP F
these 0 DET F
data 0 NOUN F
, 0 PUNCT F
an 0 DET F
open 0 ADJ F
, 0 PUNCT F
randomized 0 VERB F
controlled 0 VERB F
trial 0 NOUN F
was 0 VERB F
started 0 VERB F
. 0 PUNCT F

In 0 ADP T
this 0 DET F
main 0 ADJ F
study 0 NOUN F
the 0 DET F
thromboprophylactic B-PHYSICAL ADJ F
effect 0 NOUN F
of 0 ADP F
the 0 DET F
LMW-heparin 0 NOUN T
( 0 PUNCT F
Logiparin 0 NOUN T
) 0 PUNCT F
in 0 ADP F
a 0 DET F
dose 0 NOUN F
of 0 ADP F
35 0 NUM F
XaI 0 ADJ T
mu/kg 0 NOUN F
b.w 0 NUM F
. 0 PUNCT F

once 0 PUNCT F
daily 0 ADJ F
was 0 VERB F
compared 0 VERB F
with 0 ADP F
that 0 PUNCT F
of 0 ADP F
dextran 0 NOUN F
70 0 NUM F
in 0 ADP F
patients 0 NOUN F
undergoing 0 VERB F
THR 0 NOUN T
. 0 PUNCT F

100 0 NUM F
patients 0 NOUN F
were 0 VERB F
randomized 0 VERB F
. 0 PUNCT F

The 0 DET T
over-all B-OTHER PUNCT F
thrombosis I-OTHER NOUN F
rate I-OTHER NOUN F
was 0 VERB F
28 0 NUM F
% 0 SYM F
in 0 ADP F
patients 0 NOUN F
treated 0 VERB F
with 0 ADP F
LMW-heparin 0 NOUN T
and 0 CCONJ F
39 0 NUM F
% 0 SYM F
in 0 ADP F
those 0 DET F
given 0 VERB F
dextran 0 NOUN F
, 0 PUNCT F
a 0 DET F
non-significant 0 ADJ F
difference 0 NOUN F
. 0 PUNCT F

No 0 DET T
bleeding B-ADVERSE-EFFECTS VERB F
complications I-ADVERSE-EFFECTS NOUN F
, 0 PUNCT F
deaths B-MORTALITY NOUN F
or 0 CCONJ F
pulmonary B-PHYSICAL ADJ F
embolism I-PHYSICAL NOUN F
were 0 VERB F
recorded 0 VERB F
in 0 ADP F
either 0 PUNCT F
group 0 NOUN F
. 0 PUNCT F

Peroperative B-PHYSICAL ADJ T
blood I-PHYSICAL NOUN F
loss I-PHYSICAL NOUN F
and I-PHYSICAL CCONJ F
transfusion I-PHYSICAL NOUN F
requirements I-PHYSICAL NOUN F
were 0 VERB F
similar 0 ADJ F
in 0 ADP F
the 0 DET F
two 0 NUM F
groups 0 NOUN F
. 0 PUNCT F

In 0 ADP T
conclusion 0 NOUN F
, 0 PUNCT F
the 0 DET F
investigated 0 ADJ F
LMW-heparin 0 NOUN T
( 0 PUNCT F
Logiparin 0 NOUN T
) 0 PUNCT F
is 0 VERB F
safe 0 ADJ F
and 0 CCONJ F
effective 0 ADJ F
in 0 ADP F
preventing 0 VERB F
postoperative 0 ADJ F
thromboembolism 0 NOUN F
in 0 ADP F
patients 0 NOUN F
undergoing 0 VERB F
total 0 ADJ F
hip 0 NOUN F
replacement 0 NOUN F
, 0 PUNCT F
but 0 CCONJ F
the 0 DET F
dosage 0 NOUN F
can 0 PRON F
probably 0 ADV F
be 0 DET F
optimized 0 VERB F
. 0 PUNCT F

Losartan 0 NOUN T
vs. 0 CCONJ F
amlodipine 0 NOUN F
treatment 0 NOUN F
in 0 ADP F
elderly 0 PUNCT F
oncologic 0 ADJ F
hypertensive 0 ADJ F
patients 0 NOUN F
: 0 PUNCT F
a 0 DET F
randomized 0 VERB F
clinical 0 ADJ F
trial 0 NOUN F
. 0 PUNCT F

Elderly 0 ADJ T
neoplastic 0 ADJ F
patients 0 NOUN F
frequently 0 ADV F
may 0 VERB F
show 0 VERB F
hypertension 0 NOUN F
and 0 CCONJ F
hyperuricemia 0 ADJ F
, 0 PUNCT F
before 0 ADP F
and 0 CCONJ F
after 0 ADP F
chemotherapeutic 0 ADJ F
treatments 0 NOUN F
. 0 PUNCT F

The 0 DET T
purpose 0 NOUN F
of 0 ADP F
this 0 DET F
study 0 NOUN F
was 0 VERB F
to 0 PART F
evaluate 0 NOUN F
the 0 DET F
efficacy 0 NOUN F
of 0 ADP F
losartan 0 NOUN F
which 0 ADP F
is 0 VERB F
an 0 DET F
antihypertensive 0 ADJ F
drug 0 NOUN F
with 0 ADP F
uricosuric 0 ADJ F
properties 0 NOUN F
vs. 0 CCONJ F
amlodipine 0 NOUN F
in 0 ADP F
hypertensive 0 ADJ F
neoplastic 0 ADJ F
elderly 0 ADJ F
patients 0 NOUN F
. 0 PUNCT F

This 0 DET T
was 0 VERB F
an 0 DET F
open-labeled 0 ADP F
, 0 PUNCT F
randomized 0 VERB F
, 0 PUNCT F
comparative 0 ADJ F
trial 0 NOUN F
. 0 PUNCT F

The 0 DET T
study 0 NOUN F
was 0 VERB F
performed 0 VERB F
as 0 ADP F
a 0 DET F
30-day 0 NOUN F
study 0 NOUN F
. 0 PUNCT F

Seventy 0 PUNCT T
patients 0 NOUN F
with 0 ADP F
cancer 0 NOUN F
were 0 VERB F
randomly 0 ADV F
assigned 0 VERB F
to 0 PART F
receive 0 NOUN F
losartan 0 NOUN F
or 0 CCONJ F
amlodipine 0 NOUN F
. 0 PUNCT F

Blood 0 NOUN T
pressure 0 NOUN F
( 0 PUNCT F
BP 0 NOUN T
) 0 PUNCT F
, 0 PUNCT F
blood 0 NOUN F
urea 0 NOUN F
nitrogen 0 NOUN F
( 0 PUNCT F
BUN 0 NOUN T
) 0 PUNCT F
levels 0 NOUN F
, 0 PUNCT F
creatinine 0 NOUN F
, 0 PUNCT F
serum 0 NOUN F
and 0 CCONJ F
urinary 0 ADJ F
uric 0 ADJ F
acid 0 NOUN F
, 0 PUNCT F
creatinine 0 NOUN F
and 0 CCONJ F
uric 0 ADJ F
acid 0 NOUN F
clearance 0 NOUN F
were 0 VERB F
determined 0 VERB F
before 0 ADP F
and 0 CCONJ F
after 0 ADP F
chemotherapy 0 NOUN F
. 0 PUNCT F

One 0 NUM T
day 0 NOUN F
after 0 PUNCT F
chemotherapy 0 NOUN F
in 0 ADP F
losartan 0 NOUN F
group 0 NOUN F
vs. 0 CCONJ F
amlodipine 0 NOUN F
group 0 NOUN F
we 0 PRON F
observed 0 VERB F
a 0 DET F
significant 0 ADJ F
difference 0 NOUN F
in 0 ADP F
urinary B-PHYSICAL ADJ F
uric I-PHYSICAL ADJ F
acid I-PHYSICAL NOUN F
( 0 PUNCT F
p 0 NOUN F
< 0 SYM F
0.001 0 NUM F
) 0 PUNCT F
of 0 ADP F
18 0 NUM F
mg/24 0 NOUN F
h 0 NOUN F
vs. 0 CCONJ F
40 0 NUM F
mg/24 0 NOUN F
h. 0 NOUN F
Thirty 0 NUM T
days 0 NOUN F
after 0 ADP F
chemotherapy 0 NOUN F
we 0 PUNCT F
observed 0 VERB F
a 0 DET F
significant 0 ADJ F
difference 0 NOUN F
in 0 ADP F
azotemia B-PHYSICAL NOUN F
of 0 ADP F
0.0 0 NUM F
mg/dl 0 NOUN F
vs. 0 CCONJ F
3.8 0 NUM F
mg/dl 0 NOUN F
( 0 PUNCT F
p 0 NOUN F
< 0 SYM F
0.001 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
serum B-PHYSICAL NOUN F
uric I-PHYSICAL ADJ F
acid I-PHYSICAL NOUN F
of 0 ADP F
0.05 0 NUM F
mg/dl 0 NOUN F
vs. 0 CCONJ F
0.49 0 NUM F
mg/dl 0 NOUN F
( 0 PUNCT F
p 0 NOUN F
< 0 SYM F
0.001 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
urinary B-PHYSICAL ADJ F
uric I-PHYSICAL ADJ F
acid I-PHYSICAL NOUN F
( 0 PUNCT F
p 0 NOUN F
< 0 SYM F
0.001 0 NUM F
) 0 PUNCT F
of 0 ADP F
23 0 NUM F
mg/24 0 NOUN F
h 0 NOUN F
vs. 0 CCONJ F
0.0 0 NUM F
mg/24 0 NOUN F
h 0 NOUN F
, 0 PUNCT F
GFR 0 NOUN T
of 0 ADP F
2 0 NUM F
ml/min/1.73 0 NOUN F
m 0 NOUN F
( 0 PUNCT F
2 0 NUM F
) 0 PUNCT F
vs. 0 CCONJ F
-8 0 NUM F
ml/min/1.73 0 NOUN F
m 0 NOUN F
( 0 PUNCT F
2 0 NUM F
) 0 PUNCT F
( 0 PUNCT F
p 0 NOUN F
< 0 SYM F
0.05 0 NUM F
) 0 PUNCT F
and 0 CCONJ F
systolic B-PHYSICAL ADJ F
BP I-PHYSICAL NOUN T
( 0 PUNCT F
SBP 0 NOUN T
) 0 PUNCT F
of 0 ADP F
3.6 0 NUM F
mmHg 0 NOUN F
vs. 0 CCONJ F
0.8 0 NUM F
mmHg 0 NOUN F
( 0 PUNCT F
p 0 NOUN F
< 0 SYM F
0.05 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
findings 0 NOUN F
of 0 ADP F
the 0 DET F
present 0 ADJ F
study 0 NOUN F
support 0 NOUN F
the 0 DET F
effective 0 ADJ F
role 0 NOUN F
of 0 ADP F
losartan 0 NOUN F
compared 0 VERB F
to 0 ADP F
amlodipine 0 NOUN F
in 0 ADP F
treating 0 VERB F
hypertension 0 NOUN F
and 0 CCONJ F
hyperuricemia 0 ADV F
in 0 ADP F
elderly 0 ADJ F
patients 0 NOUN F
under 0 ADP F
chemotherapeutic 0 ADJ F
treatment 0 NOUN F
. 0 PUNCT F

Biochemical 0 ADJ T
and 0 CCONJ F
functional 0 ADJ F
effects 0 NOUN F
of 0 ADP F
creatine 0 NOUN F
phosphate 0 NOUN F
in 0 ADP F
cardioplegic 0 ADJ F
solution 0 NOUN F
during 0 ADP F
aortic 0 ADJ F
valve 0 NOUN F
surgery 0 NOUN F
-- 0 PUNCT F
a 0 DET F
clinical 0 ADJ F
study 0 NOUN F
. 0 PUNCT F

During 0 ADP T
myocardial 0 ADJ F
ischemia 0 NOUN F
there 0 PUNCT F
is 0 VERB F
a 0 PUNCT F
drop 0 PUNCT F
in 0 ADP F
high-energy B-PHYSICAL NOUN F
phosphates I-PHYSICAL NOUN F
in 0 ADP F
the 0 DET F
myocardium 0 NOUN F
. 0 PUNCT F

Cold 0 ADJ T
potassium 0 NOUN F
cardioplegia 0 NOUN F
decreases 0 PROPN F
but 0 CCONJ F
does 0 PUNCT F
not 0 ADV F
altogether 0 CCONJ F
prevent 0 VERB F
this 0 DET F
reduction 0 NOUN F
. 0 PUNCT F

Supplementation 0 NOUN T
of 0 ADP F
cardioplegic 0 ADJ F
solutions 0 NOUN F
with 0 ADP F
the 0 DET F
high-energy 0 NOUN F
compound 0 ADP F
creatine 0 NOUN F
phosphate 0 NOUN F
( 0 PUNCT F
10 0 NUM F
mmol/L 0 NOUN F
) 0 PUNCT F
compared 0 VERB F
to 0 ADP F
plain 0 ADJ F
cardioplegic 0 ADJ F
solutions 0 NOUN F
was 0 VERB F
investigated 0 VERB F
in 0 ADP F
this 0 DET F
study 0 NOUN F
. 0 PUNCT F

Thirty 0 NUM T
patients 0 NOUN F
scheduled 0 VERB F
for 0 ADP F
aortic 0 ADJ F
valve 0 NOUN F
replacement 0 NOUN F
were 0 VERB F
included 0 VERB F
. 0 PUNCT F

The 0 DET T
patients 0 NOUN F
were 0 VERB F
randomized 0 VERB F
to 0 ADP F
group 0 NOUN F
I 0 NUM T
( 0 PUNCT F
creatine 0 NOUN F
phosphate 0 NOUN F
) 0 PUNCT F
or 0 CCONJ F
group 0 NOUN F
II 0 NUM T
( 0 PUNCT F
control 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

Postoperative 0 ADJ T
hemodynamic B-PHYSICAL ADJ F
evaluation I-PHYSICAL NOUN F
revealed 0 VERB F
no 0 DET F
significant 0 ADJ F
differences 0 NOUN F
between 0 ADP F
the 0 DET F
groups 0 NOUN F
. 0 PUNCT F

However 0 ADV T
, 0 PUNCT F
group 0 NOUN F
I 0 NUM T
exhibited 0 VERB F
a 0 DET F
tendency 0 NOUN F
toward 0 ADP F
a 0 DET F
better 0 PUNCT F
stroke-work B-PHYSICAL NUM F
index I-PHYSICAL NOUN F
( 0 PUNCT F
135 0 NUM F
+/- 0 SYM F
18 0 NUM F
% 0 SYM F
vs. 0 CCONJ F
102 0 NUM F
+/- 0 SYM F
5 0 NUM F
% 0 SYM F
recovery 0 NOUN F
15 0 NUM F
minutes 0 NOUN F
after 0 ADP F
bypass 0 NOUN F
and 0 CCONJ F
145 0 NUM F
+/- 0 SYM F
16 0 NUM F
% 0 SYM F
vs. 0 CCONJ F
119 0 NUM F
+/- 0 SYM F
11 0 NUM F
% 0 SYM F
recovery 0 NOUN F
105 0 NUM F
min 0 NOUN F
after 0 ADP F
bypass 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

There 0 PUNCT T
were 0 VERB F
fewer 0 PUNCT F
patients 0 NOUN F
in 0 ADP F
group 0 NOUN F
I 0 NUM T
( 0 PUNCT F
5/15 0 NOUN F
) 0 PUNCT F
needing B-PHYSICAL VERB F
inotropic I-PHYSICAL ADJ F
support I-PHYSICAL NOUN F
compared 0 VERB F
to 0 ADP F
group 0 NOUN F
II 0 NUM T
( 0 PUNCT F
9/14 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
myocardial B-PHYSICAL ADJ F
content I-PHYSICAL NOUN F
of I-PHYSICAL ADP F
ATP I-PHYSICAL NOUN T
and 0 CCONJ F
creatine B-PHYSICAL NOUN F
phosphate I-PHYSICAL NOUN F
showed 0 VERB F
no 0 DET F
significant 0 ADJ F
differences 0 NOUN F
during 0 ADP F
ischemia 0 NOUN F
and 0 CCONJ F
reperfusion 0 NOUN F
. 0 PUNCT F

It 0 PRON T
is 0 VERB F
concluded 0 VERB F
that 0 ADP F
the 0 DET F
myocardial 0 ADJ F
protection 0 NOUN F
during 0 ADP F
ischemia 0 NOUN F
was 0 VERB F
sufficient 0 ADJ F
to 0 PART F
prevent 0 ADJ F
significant 0 ADJ F
reductions 0 NOUN F
of 0 ADP F
myocardial B-PHYSICAL ADJ F
ATP I-PHYSICAL NOUN T
and I-PHYSICAL CCONJ F
creatine I-PHYSICAL NOUN F
phosphate I-PHYSICAL NOUN F
irrespective 0 ADJ F
of 0 ADP F
supplementation 0 NOUN F
with 0 ADP F
CP 0 NOUN T
. 0 PUNCT F

Controlled 0 DET T
, 0 PUNCT F
prospective 0 ADJ F
, 0 PUNCT F
randomized 0 VERB F
, 0 PUNCT F
clinical 0 ADJ F
evaluation 0 NOUN F
of 0 ADP F
partial 0 ADJ F
ceramic 0 ADJ F
crowns 0 NOUN F
inserted 0 VERB F
with 0 ADP F
RelyX 0 NOUN T
Unicem 0 NOUN T
with 0 ADP F
or 0 CCONJ F
without 0 ADP F
selective 0 ADJ F
enamel 0 NOUN F
etching 0 CCONJ F
. 0 PUNCT F

1-year 0 ADJ F
results 0 NOUN F
. 0 PUNCT F

PURPOSE 0 NOUN T
To 0 ADJ T
compare 0 NOUN F
the 0 DET F
performance 0 NOUN F
of 0 ADP F
partial B-OTHER ADJ F
ceramic I-OTHER ADJ F
crowns I-OTHER NOUN F
( I-OTHER PUNCT F
PCCs I-OTHER NOUN T
) I-OTHER PUNCT F
inserted 0 VERB F
with 0 ADP F
RelyX 0 NOUN T
Unicem 0 NOUN T
( 0 PUNCT F
RXU 0 NOUN T
) 0 PUNCT F
either 0 CCONJ F
with 0 ADP F
( 0 PUNCT F
RXU+E 0 NOUN T
) 0 PUNCT F
or 0 CCONJ F
without 0 ADP F
( 0 PUNCT F
RXU 0 NOUN T
) 0 PUNCT F
selective 0 ADJ F
enamel 0 NOUN F
etching 0 CCONJ F
. 0 PUNCT F

METHODS 0 NOUN T
34 0 NUM F
patients 0 NOUN F
( 0 PUNCT F
15 0 NUM F
male 0 NOUN F
, 0 PUNCT F
19 0 NUM F
female 0 NOUN F
) 0 PUNCT F
participated 0 PUNCT F
in 0 ADP F
the 0 DET F
investigation 0 NOUN F
, 0 PUNCT F
with 0 ADP F
a 0 DET F
total 0 NOUN F
of 0 ADP F
68 0 NUM F
PCC 0 NOUN T
restorations 0 NOUN F
. 0 PUNCT F

In 0 ADP T
each 0 DET F
patient 0 NOUN F
, 0 PUNCT F
one 0 NUM F
PCC 0 NOUN T
was 0 ADJ F
randomly 0 ADV F
assigned 0 VERB F
to 0 ADP F
insertion 0 NOUN F
with 0 ADP F
RXU 0 NOUN T
, 0 PUNCT F
the 0 DET F
second 0 ADJ F
PCC 0 NOUN T
was 0 VERB F
assigned 0 VERB F
to 0 ADP F
insertion 0 NOUN F
with 0 ADP F
RXU+E 0 NOUN T
. 0 PUNCT F

The 0 DET T
PCCs 0 NOUN T
were 0 ADP F
CAD/CAM 0 ADP T
fabricated 0 PUNCT F
using 0 VERB F
the 0 DET F
Cerec 0 NOUN T
3 0 NUM F
system 0 NOUN F
. 0 PUNCT F

RXU 0 NOUN T
: 0 PUNCT F
25 0 NUM F
PCCs 0 NOUN T
were 0 VERB F
placed 0 VERB F
in 0 ADP F
molars 0 NOUN F
, 0 PUNCT F
nine 0 NUM F
in 0 ADP F
premolars 0 PUNCT F
. 0 PUNCT F

RXU+E 0 NOUN T
: 0 PUNCT F
26 0 DET F
PCCs 0 NOUN T
were 0 VERB F
placed 0 VERB F
in 0 ADP F
molars 0 NOUN F
, 0 PUNCT F
eight 0 NUM F
in 0 ADP F
premolars 0 NOUN F
. 0 PUNCT F

The 0 DET T
restorations 0 NOUN F
were 0 VERB F
clinically 0 ADV F
rated 0 VERB F
using 0 VERB F
modified 0 VERB F
United 0 VERB T
States 0 NOUN T
Public 0 ADJ T
Health 0 NOUN T
Service 0 NOUN T
( 0 PUNCT F
USPHS 0 NOUN T
) 0 PUNCT F
criteria 0 NOUN F
at 0 ADP F
baseline 0 NOUN F
, 0 PUNCT F
6 0 NUM F
and 0 CCONJ F
12 0 NUM F
months 0 NOUN F
after 0 ADP F
placement 0 NOUN F
. 0 PUNCT F

The 0 DET T
median 0 ADJ F
patient 0 NOUN F
age 0 NOUN F
was 0 VERB F
41 0 NUM F
years 0 NOUN F
( 0 PUNCT F
24-59 0 NUM F
years 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
median 0 ADJ F
( 0 PUNCT F
25-75 0 ADP F
% 0 SYM F
) 0 PUNCT F
PBI 0 NOUN T
was 0 VERB F
6 0 NUM F
% 0 SYM F
( 0 PUNCT F
3-9 0 NUM F
% 0 SYM F
) 0 PUNCT F
. 0 PUNCT F

RESULTS 0 PUNCT T
All 0 PUNCT T
patients 0 NOUN F
were 0 VERB F
available 0 ADJ F
for 0 ADP F
the 0 DET F
three 0 NUM F
recall 0 NOUN F
appointments 0 NOUN F
. 0 PUNCT F

One 0 NUM T
PCC 0 NOUN T
( 0 PUNCT F
RXU 0 NOUN T
) 0 PUNCT F
debonded B-PHYSICAL VERB F
after 0 PUNCT F
11 0 NUM F
months 0 NOUN F
in 0 DET F
situ 0 ADJ F
, 0 PUNCT F
one 0 NUM F
PCC 0 NOUN T
( 0 PUNCT F
RXU+E 0 NOUN T
) 0 PUNCT F
fractured B-PHYSICAL PUNCT F
after 0 PUNCT F
12 0 NUM F
months 0 NOUN F
in 0 DET F
situ 0 ADJ F
. 0 PUNCT F

Both 0 CCONJ T
restorations B-OTHER NOUN F
had 0 PUNCT F
to 0 PART F
be 0 PUNCT F
replaced B-OTHER VERB F
. 0 PUNCT F

At 0 ADP T
the 0 DET F
12 0 NUM F
months 0 NOUN F
recall 0 PUNCT F
, 0 PUNCT F
66 0 NUM F
of 0 ADP F
68 0 NUM F
controlled 0 VERB F
restorations 0 NOUN F
were 0 VERB F
functional B-OTHER ADJ F
without 0 PUNCT F
need 0 NOUN F
of 0 ADP F
replacement 0 NOUN F
. 0 PUNCT F

The 0 DET T
evaluation 0 NOUN F
using 0 SYM F
USHPS 0 NOUN T
criteria 0 NOUN F
revealed 0 VERB F
a 0 DET F
significant 0 ADJ F
decrease 0 NOUN F
of 0 ADP F
alfa 0 NOUN F
ratings B-PHYSICAL NOUN F
over I-PHYSICAL ADP F
time I-PHYSICAL NOUN F
with 0 ADP F
respect B-OTHER NOUN F
to I-OTHER ADP F
criteria I-OTHER NOUN F
marginal I-OTHER ADJ F
adaptation I-OTHER NOUN F
and I-OTHER CCONJ F
marginal I-OTHER ADJ F
discoloration I-OTHER NOUN F
. 0 PUNCT F

No 0 DET T
statistically 0 ADV F
significant 0 ADJ F
differences 0 NOUN F
between 0 ADP F
the 0 DET F
two 0 NUM F
luting 0 ADJ F
techniques 0 NOUN F
, 0 PUNCT F
RXU 0 NOUN T
and 0 CCONJ F
RXU+E 0 NOUN T
, 0 PUNCT F
we 0 ADP F
reobserved 0 ADV F
during 0 ADP F
the 0 DET F
observation 0 NOUN F
period 0 NOUN F
of 0 ADP F
1 0 NUM F
year 0 NOUN F
. 0 PUNCT F

Within 0 ADP T
the 0 DET F
limitations 0 NOUN F
of 0 ADP F
the 0 DET F
present 0 ADJ F
study 0 NOUN F
, 0 PUNCT F
adhesive 0 ADP F
luting 0 PUNCT F
with 0 ADP F
RXU 0 NOUN T
with 0 ADP F
or 0 CCONJ F
without 0 ADP F
selective 0 ADJ F
enamel 0 NOUN F
etching 0 PUNCT F
can 0 CCONJ F
be 0 VERB F
recommended 0 VERB F
. 0 PUNCT F

Efficacy 0 NOUN T
, 0 PUNCT F
tolerability B-OTHER NOUN F
and 0 CCONJ F
pharmacokinetics B-OTHER NOUN F
of 0 ADP F
two 0 NUM F
nelfinavir-based 0 VERB F
regimens 0 NOUN F
in 0 ADP F
human 0 NOUN F
immunodeficiency 0 NOUN F
virus-infected 0 DET F
children 0 NOUN F
and 0 CCONJ F
adolescents 0 NOUN F
: 0 PUNCT F
pediatric 0 ADJ F
AIDS 0 NOUN T
clinical 0 ADJ F
trials 0 NOUN F
group 0 NOUN F
protocol 0 NOUN F
403 0 ADJ F
. 0 PUNCT F

INTRODUCTION 0 NOUN T
Few 0 ADJ T
combinations 0 NOUN F
of 0 ADP F
highly 0 ADV F
active 0 ADJ F
antiretrovirals 0 NOUN F
have 0 ADP F
been 0 PUNCT F
studied 0 VERB F
in 0 ADP F
nucleoside 0 NOUN F
reverse 0 ADJ F
transcription 0 NOUN F
inhibitor 0 NOUN F
( 0 PUNCT F
NRTI 0 NOUN T
) 0 PUNCT F
-experienced 0 VERB F
, 0 PUNCT F
human 0 NOUN F
immunodeficiency 0 NOUN F
virus 0 NOUN F
( 0 PUNCT F
HIV 0 NOUN T
) 0 PUNCT F
-infected 0 DET F
children 0 NOUN F
. 0 PUNCT F

We 0 PRON T
tested 0 VERB F
the 0 DET F
efficacy 0 NOUN F
, 0 PUNCT F
tolerability 0 NOUN F
and 0 CCONJ F
pharmacokinetics 0 NOUN F
of 0 ADP F
2 0 NUM F
combination 0 NOUN F
therapies 0 NOUN F
containing 0 VERB F
an 0 DET F
NRTI 0 NOUN T
, 0 PUNCT F
protease 0 NOUN F
inhibitors 0 NOUN F
+/- 0 VERB F
a 0 DET F
nonnucleoside 0 NOUN F
reverse 0 ADJ F
transcription 0 NOUN F
inhibitor 0 NOUN F
( 0 PUNCT F
NNRTI 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

METHODS 0 NOUN T
This 0 PUNCT T
was 0 VERB F
a 0 DET F
phase 0 NOUN F
II 0 NUM T
, 0 PUNCT F
randomized 0 VERB F
, 0 PUNCT F
multicenter 0 NOUN F
study 0 NOUN F
. 0 PUNCT F

Forty-one 0 NUM T
children 0 NOUN F
and 0 CCONJ F
youths 0 NOUN F
between 0 ADP F
5 0 NUM F
months 0 NOUN F
and 0 CCONJ F
21 0 NUM F
years 0 NOUN F
with 0 ADP F
prior 0 VERB F
NRTI 0 NOUN T
and 0 CCONJ F
no 0 DET F
prior 0 ADP F
NNRTI 0 NOUN T
or 0 CCONJ F
protease 0 NOUN F
inhibitor 0 NOUN F
experience 0 NOUN F
received 0 VERB F
either 0 CCONJ F
nelfinavir 0 NOUN F
( 0 PUNCT F
NFV 0 NOUN T
) 0 PUNCT F
30 0 NUM F
mg/kg 0 NOUN F
twice 0 ADV F
daily 0 ADJ F
( 0 PUNCT F
bid 0 PUNCT F
) 0 PUNCT F
, 0 PUNCT F
ritonavir 0 NOUN F
( 0 PUNCT F
RTV 0 NOUN T
) 0 PUNCT F
400 0 NUM F
mg/m 0 ADJ F
bid 0 ADJ F
and 0 CCONJ F
buffered 0 VERB F
didanosine 0 NOUN F
( 0 PUNCT F
ddI 0 NOUN F
) 0 PUNCT F
240 0 NUM F
mg/m 0 ADP F
daily 0 ADV F
( 0 PUNCT F
arm 0 NOUN F
A 0 NOUN T
) 0 PUNCT F
or 0 CCONJ F
NFV 0 NOUN T
50-55 0 DET F
mg/kg 0 NOUN F
bid 0 ADJ F
, 0 PUNCT F
nevirapine 0 NOUN F
( 0 PUNCT F
NVP 0 NOUN T
) 0 PUNCT F
120 0 NUM F
mg/m 0 NOUN F
bid 0 ADJ F
and 0 CCONJ F
stavudine 0 PUNCT F
( 0 PUNCT F
d4T 0 NOUN F
) 0 PUNCT F
1 0 NUM F
mg/kg 0 NOUN F
bid 0 ADP F
( 0 PUNCT F
arm 0 NOUN F
B 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

Patients 0 NOUN T
were 0 VERB F
evaluated 0 VERB F
clinically 0 ADV F
for 0 ADP F
48 0 NUM F
weeks 0 NOUN F
after 0 ADP F
initiation 0 NOUN F
of 0 ADP F
therapy 0 NOUN F
. 0 PUNCT F

Intensive 0 ADJ T
pharmacokinetic 0 ADJ F
sampling 0 VERB F
occurred 0 VERB F
after 0 ADP F
4 0 NUM F
weeks 0 NOUN F
of 0 ADP F
therapy 0 NOUN F
. 0 PUNCT F

RESULTS 0 NOUN T
: 0 PUNCT F
The 0 DET T
proportion 0 NOUN F
of 0 ADP F
children 0 NOUN F
with 0 ADP F
HIV-1 0 NOUN T
RNA 0 NOUN T
< 0 SYM F
or 0 CCONJ F
=400 0 PUNCT F
copies/mL 0 NOUN F
and 0 CCONJ F
on 0 ADP F
randomized 0 VERB F
treatment 0 NOUN F
at 0 ADP F
48 0 NUM F
weeks 0 NOUN F
was 0 VERB F
65 0 NUM F
% 0 SYM F
among 0 ADP F
children 0 NOUN F
assigned 0 PUNCT F
NFV 0 NOUN T
+ 0 SYM F
RTV 0 NOUN T
+ 0 SYM F
ddI 0 NOUN F
versus 0 CCONJ F
28 0 NUM F
% 0 SYM F
among 0 ADP F
those 0 DET F
assigned 0 PUNCT F
NFV 0 NOUN T
+ 0 SYM F
NVP 0 NOUN T
+ 0 SYM F
d4T 0 NOUN F
( 0 PUNCT F
P 0 NOUN T
= 0 SYM F
0.039 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

No 0 DET T
significant 0 ADJ F
difference 0 NOUN F
in 0 ADP F
median 0 ADJ F
CD4 B-PHYSICAL NOUN T
% I-PHYSICAL ADV F
change I-PHYSICAL NOUN F
from 0 ADP F
baseline 0 NOUN F
to 0 PUNCT F
week 0 ADJ F
48 0 NUM F
was 0 VERB F
found 0 VERB F
( 0 PUNCT F
3 0 NUM F
% 0 SYM F
versus 0 CCONJ F
1 0 NUM F
% 0 SYM F
) 0 PUNCT F
. 0 PUNCT F

No 0 DET T
significant 0 ADJ F
differences 0 NOUN F
in 0 ADP F
safety B-OTHER NOUN F
or 0 CCONJ F
tolerability B-OTHER NOUN F
between 0 ADP F
children 0 NOUN F
randomized 0 VERB F
to 0 ADP F
NFV 0 NOUN T
+ 0 SYM F
RTV 0 NOUN T
+ 0 SYM F
ddI 0 NOUN F
versus 0 CCONJ F
NFV 0 NOUN T
+ 0 SYM F
NVP 0 NOUN T
+ 0 SYM F
d4T 0 ADV F
were 0 VERB F
identified 0 VERB F
. 0 PUNCT F

However 0 ADV T
, 0 PUNCT F
a 0 DET F
trend 0 NOUN F
toward 0 ADP F
a 0 DET F
higher 0 PUNCT F
rate 0 NOUN F
of 0 ADP F
permanent B-OTHER ADJ F
discontinuation I-OTHER NOUN F
of I-OTHER ADP F
study I-OTHER VERB F
treatment I-OTHER NOUN F
was 0 VERB F
noted 0 VERB F
among 0 ADP F
children 0 NOUN F
assigned 0 NUM F
to 0 ADP F
NFV 0 NOUN T
+ 0 SYM F
NVP 0 NOUN T
+ 0 SYM F
d4T 0 ADV F
compared 0 NOUN F
with 0 ADP F
NFV 0 NOUN T
+ 0 SYM F
RTV 0 NOUN T
+ 0 SYM F
ddI 0 NOUN F
[ 0 PUNCT F
7 0 NUM F
of 0 ADP F
20 0 NUM F
( 0 PUNCT F
35 0 NUM F
% 0 SYM F
) 0 PUNCT F
versus 0 CCONJ F
2 0 NUM F
of 0 ADP F
21 0 NUM F
( 0 PUNCT F
10 0 NUM F
% 0 SYM F
) 0 PUNCT F
; 0 PUNCT F
P 0 NOUN T
= 0 SYM F
0.12 0 NUM F
] 0 PUNCT F
. 0 PUNCT F

NFV 0 NOUN T
pharmacokinetic 0 ADJ F
measurements 0 NOUN F
were 0 VERB F
not 0 ADV F
statistically 0 ADV F
different 0 ADJ F
between 0 ADP F
the 0 DET F
treatment 0 NOUN F
groups 0 NOUN F
, 0 PUNCT F
yet 0 ADV F
exposure 0 NOUN F
to 0 ADP F
the 0 DET F
NFV 0 NOUN T
metabolite 0 NOUN F
, 0 PUNCT F
M8 0 NOUN T
, 0 PUNCT F
was 0 VERB F
significantly 0 ADV F
higher 0 PUNCT F
in 0 ADP F
subjects 0 NOUN F
receiving 0 DET F
RTV 0 NOUN T
. 0 PUNCT F

The 0 DET T
pharmacokinetics 0 NOUN F
for 0 ADP F
NVP 0 NOUN T
, 0 PUNCT F
RTV 0 NOUN T
and 0 CCONJ F
d4T 0 ADV F
were 0 VERB F
similar 0 ADJ F
to 0 ADP F
those 0 PUNCT F
of 0 ADP F
previously 0 ADV F
reported 0 VERB F
data 0 NOUN F
. 0 PUNCT F

CONCLUSION 0 NOUN T
: 0 PUNCT F
Combination 0 NOUN T
therapy 0 NOUN F
containing 0 VERB F
NFV 0 NOUN T
+ 0 SYM F
RTV 0 NOUN T
+ 0 SYM F
ddI 0 NOUN F
appears 0 NOUN F
more 0 ADV F
efficacious 0 ADJ F
in 0 ADP F
NRTI-experienced 0 VERB T
children 0 ADJ F
than 0 PUNCT F
a 0 DET F
regimen 0 NOUN F
containing 0 ADP F
NFV 0 NOUN T
+ 0 SYM F
NVP 0 NOUN T
+ 0 SYM F
d4T 0 NOUN F
. 0 PUNCT F

Differences 0 NOUN T
in 0 ADP F
tolerability 0 NOUN F
between 0 ADP F
the 0 DET F
2 0 NUM F
treatment 0 NOUN F
groups 0 NOUN F
were 0 VERB F
not 0 ADV F
identified 0 VERB F
. 0 PUNCT F

Systemic 0 ADJ T
exposure 0 NOUN F
of 0 ADP F
these 0 DET F
drugs 0 ADV F
was 0 VERB F
similar 0 ADJ F
to 0 ADP F
that 0 PUNCT F
reported 0 VERB F
in 0 ADP F
other 0 ADJ F
HIV-infected 0 VERB T
children 0 NOUN F
and 0 CCONJ F
adults 0 NOUN F
. 0 PUNCT F

Combination 0 NOUN T
chemotherapy 0 NOUN F
and 0 CCONJ F
ALVAC-CEA/B7.1 0 ADJ T
vaccine 0 NOUN F
in 0 ADP F
patients 0 NOUN F
with 0 ADP F
metastatic 0 ADJ F
colorectal 0 ADJ F
cancer 0 NOUN F
. 0 PUNCT F

PURPOSE 0 NOUN T
The 0 DET T
combination 0 NOUN F
of 0 ADP F
vaccines 0 NOUN F
and 0 CCONJ F
chemotherapy 0 NOUN F
holds 0 ADP F
promise 0 PUNCT F
for 0 ADP F
cancer 0 NOUN F
therapy 0 NOUN F
, 0 PUNCT F
but 0 CCONJ F
the 0 DET F
effect 0 NOUN F
of 0 ADP F
cytotoxic 0 ADJ F
chemotherapy 0 NOUN F
on 0 ADP F
vaccine-induced 0 VERB F
antitumor 0 NOUN F
immunity 0 NOUN F
is 0 VERB F
unknown 0 VERB F
. 0 PUNCT F

This 0 DET T
study 0 NOUN F
was 0 VERB F
conducted 0 VERB F
to 0 PART F
assess 0 NOUN F
the 0 DET F
effects 0 NOUN F
of 0 ADP F
systemic 0 ADJ F
chemotherapy 0 NOUN F
on 0 ADP F
ALVAC-CEA/B7.1-induced 0 NOUN T
T-cell 0 NOUN T
immunity 0 NOUN F
in 0 ADP F
patients 0 NOUN F
with 0 ADP F
metastatic 0 ADJ F
colorectal 0 ADJ F
cancer 0 NOUN F
. 0 PUNCT F

EXPERIMENTAL 0 ADJ T
DESIGN 0 NOUN T
Patients 0 NOUN T
with 0 ADP F
metastatic 0 ADJ F
colorectal 0 ADJ F
cancer 0 NOUN F
were 0 VERB F
treated 0 VERB F
with 0 ADP F
fluorouracil 0 NOUN F
, 0 PUNCT F
leucovorin 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
irinotecan 0 NOUN F
and 0 CCONJ F
were 0 VERB F
also 0 ADV F
given 0 PUNCT F
ALVAC-CEA/B7.1 0 ADJ T
vaccine 0 NOUN F
with 0 ADP F
or 0 CCONJ F
without 0 ADP F
tetanus 0 NOUN F
toxoid 0 NOUN F
adjuvant 0 NOUN F
. 0 PUNCT F

Eligible 0 ADJ T
patients 0 NOUN F
were 0 VERB F
randomized 0 VERB F
to 0 ADP F
ALVAC 0 ADJ T
followed 0 VERB F
by 0 ADP F
chemotherapy 0 NOUN F
and 0 CCONJ F
booster 0 NOUN F
vaccination 0 NOUN F
( 0 PUNCT F
group 0 NOUN F
1 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
ALVAC 0 ADJ T
and 0 CCONJ F
tetanus 0 NOUN F
toxoid 0 NOUN F
followed 0 VERB F
by 0 ADP F
chemotherapy 0 NOUN F
( 0 PUNCT F
group 0 NOUN F
2 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
or 0 CCONJ F
chemotherapy 0 NOUN F
alone 0 ADJ F
followed 0 VERB F
by 0 ADP F
ALVAC 0 ADJ T
in 0 ADP F
patients 0 NOUN F
without 0 ADP F
disease 0 NOUN F
progression 0 NOUN F
( 0 PUNCT F
group 0 NOUN F
3 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Humoral 0 ADJ T
immune 0 ADJ F
responses 0 ADV F
were 0 VERB F
measured 0 VERB F
by 0 ADP F
standard 0 ADJ F
ELISA 0 NOUN T
assay 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
carcinoembryonic 0 ADJ F
antigen 0 NOUN F
( 0 PUNCT F
CEA 0 NOUN T
) 0 PUNCT F
-specific 0 ADJ F
T-cell 0 NOUN T
responses 0 NOUN F
were 0 VERB F
measured 0 VERB F
by 0 ADP F
IFN-gamma 0 NOUN T
enzyme-linked 0 DET F
immunospot 0 ADJ F
assay 0 NOUN F
. 0 PUNCT F

RESULTS 0 NOUN T
One 0 NUM T
hundred 0 PUNCT F
eighteen 0 NUM F
patients 0 NOUN F
were 0 VERB F
randomized 0 VERB F
to 0 PART F
receive 0 ADP F
either 0 PUNCT F
ALVAC 0 ADJ T
before 0 ADP F
and 0 CCONJ F
concomitantly 0 ADV F
with 0 ADP F
chemotherapy 0 NOUN F
( 0 PUNCT F
n 0 NOUN F
= 0 SYM F
39 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
ALVAC 0 ADJ T
with 0 ADP F
tetanus 0 NOUN F
adjuvant 0 ADJ F
before 0 ADP F
and 0 CCONJ F
concomitantly 0 ADV F
with 0 ADP F
chemotherapy 0 NOUN F
( 0 PUNCT F
n 0 NOUN F
= 0 SYM F
40 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
or 0 CCONJ F
chemotherapy 0 NOUN F
followed 0 VERB F
by 0 ADP F
ALVAC 0 ADJ T
( 0 PUNCT F
n 0 NOUN F
= 0 SYM F
39 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Serious B-ADVERSE-EFFECTS ADJ T
adverse I-ADVERSE-EFFECTS ADJ F
events I-ADVERSE-EFFECTS NOUN F
were 0 VERB F
largely 0 ADV F
gastrointestinal B-ADVERSE-EFFECTS ADJ F
( 0 PUNCT F
n 0 NOUN F
= 0 SYM F
30 0 NUM F
) 0 PUNCT F
and 0 CCONJ F
hematologic B-ADVERSE-EFFECTS ADJ F
( 0 PUNCT F
n 0 NOUN F
= 0 SYM F
24 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Overall 0 ADJ T
, 0 PUNCT F
42 0 NUM F
patients 0 NOUN F
( 0 PUNCT F
40.4 0 NUM F
% 0 SYM F
) 0 PUNCT F
showed 0 VERB F
objective 0 ADJ F
clinical 0 ADJ F
responses 0 NOUN F
. 0 PUNCT F

All 0 DET T
patients 0 NOUN F
developed 0 VERB F
antibody B-PHYSICAL NOUN F
responses I-PHYSICAL NOUN F
against I-PHYSICAL ADP F
ALVAC I-PHYSICAL ADJ T
, 0 PUNCT F
but 0 CCONJ F
increased 0 VERB F
anti-CEA B-PHYSICAL NOUN F
antibody I-PHYSICAL NOUN F
titers I-PHYSICAL NOUN F
were 0 VERB F
detected 0 VERB F
in 0 ADP F
only 0 ADV F
three 0 NUM F
patients 0 NOUN F
. 0 PUNCT F

Increases 0 CCONJ T
in 0 ADP F
CEA-specific B-PHYSICAL ADJ T
T I-PHYSICAL NOUN T
cells I-PHYSICAL NOUN F
were 0 VERB F
detected 0 VERB F
in 0 ADP F
50 0 NUM F
% 0 SYM F
, 0 PUNCT F
37 0 NUM F
% 0 SYM F
, 0 PUNCT F
and 0 CCONJ F
30 0 NUM F
% 0 SYM F
of 0 ADP F
patients 0 NOUN F
in 0 ADP F
groups 0 NOUN F
1 0 NUM F
, 0 PUNCT F
2 0 NUM F
, 0 PUNCT F
and 0 CCONJ F
3 0 NUM F
, 0 PUNCT F
respectively 0 ADV F
. 0 PUNCT F

There 0 PUNCT T
were 0 VERB F
no 0 DET F
differences 0 NOUN F
in 0 ADP F
clinical 0 ADJ F
or 0 CCONJ F
immune 0 ADJ F
responses 0 NOUN F
between 0 ADP F
the 0 DET F
treatment 0 NOUN F
groups 0 NOUN F
. 0 PUNCT F

CONCLUSION 0 NOUN T
The 0 DET T
combination 0 NOUN F
of 0 ADP F
ALVAC-CEA/B7.1 0 ADJ T
vaccine 0 NOUN F
and 0 CCONJ F
systemic 0 ADJ F
chemotherapy 0 NOUN F
has 0 PUNCT F
an 0 DET F
acceptable 0 ADJ F
safety 0 NOUN F
profile 0 NOUN F
in 0 ADP F
patients 0 NOUN F
with 0 ADP F
metastatic 0 ADJ F
colorectal 0 ADJ F
cancer 0 NOUN F
. 0 PUNCT F

Systemic 0 ADJ T
chemotherapy 0 NOUN F
did 0 PUNCT F
not 0 ADV F
affect 0 VERB F
the 0 DET F
generation 0 NOUN F
of 0 ADP F
CEA-specific B-PHYSICAL ADJ T
T-cell I-PHYSICAL NOUN T
responses I-PHYSICAL NOUN F
following 0 ADP F
vaccination 0 NOUN F
. 0 PUNCT F

Comparison 0 NOUN T
of 0 ADP F
fluid 0 NOUN F
types 0 NOUN F
for 0 ADP F
resuscitation 0 NOUN F
after 0 ADP F
acute B-PHYSICAL ADJ F
blood I-PHYSICAL NOUN F
loss I-PHYSICAL NOUN F
in 0 ADP F
mallard 0 NOUN F
ducks 0 VERB F
( 0 PUNCT F
Anas 0 NOUN T
platyrhynchos 0 ADV F
) 0 PUNCT F
. 0 PUNCT F

OBJECTIVE 0 NOUN T
The 0 DET T
purpose 0 NOUN F
of 0 ADP F
this 0 DET F
study 0 NOUN F
was 0 VERB F
to 0 PART F
determine 0 NOUN F
the 0 DET F
LD 0 NOUN T
( 0 PUNCT F
50 0 NUM F
) 0 PUNCT F
for 0 ADP F
acute 0 ADJ F
blood 0 NOUN F
loss 0 NOUN F
in 0 ADP F
mallard 0 NOUN F
ducks 0 VERB F
( 0 PUNCT F
Anas 0 NOUN T
platyrhynchos 0 ADV F
) 0 PUNCT F
, 0 PUNCT F
compare 0 VERB F
the 0 DET F
mortality 0 NOUN F
rate 0 NOUN F
among 0 ADP F
3 0 NUM F
fluid 0 NOUN F
resuscitation 0 NOUN F
groups 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
determine 0 ADJ F
the 0 DET F
time 0 NOUN F
required 0 ADJ F
for 0 ADP F
a 0 DET F
regenerative 0 ADJ F
RBC 0 NOUN T
response 0 NOUN F
. 0 PUNCT F

DESIGN 0 NOUN T
Prospective 0 ADJ T
study 0 NOUN F
. 0 PUNCT F

SETTING 0 NUM T
Medical 0 ADJ T
College 0 NOUN T
of 0 ADP F
Wisconsin 0 NOUN T
Research 0 NOUN T
facility 0 NOUN F
. 0 PUNCT F

ANIMALS 0 NOUN T
Eighteen 0 NUM T
mallard 0 NOUN F
ducks 0 VERB F
were 0 VERB F
included 0 VERB F
for 0 ADP F
the 0 DET F
LD 0 NOUN T
( 0 PUNCT F
50 0 NUM F
) 0 PUNCT F
study 0 NOUN F
and 0 CCONJ F
28 0 NUM F
for 0 ADP F
the 0 DET F
fluid 0 NOUN F
resuscitation 0 NOUN F
study 0 NOUN F
. 0 PUNCT F

INTERVENTIONS 0 NOUN T
Phlebotomy 0 NOUN T
was 0 VERB F
performed 0 VERB F
during 0 ADP F
both 0 CCONJ F
the 0 DET F
LD 0 NOUN T
( 0 PUNCT F
50 0 NUM F
) 0 PUNCT F
and 0 CCONJ F
fluid 0 NOUN F
resuscitation 0 NOUN F
studies 0 NOUN F
. 0 PUNCT F

Ducks 0 DET T
in 0 ADP F
the 0 DET F
fluid 0 NOUN F
resuscitation 0 NOUN F
study 0 NOUN F
received 0 VERB F
a 0 DET F
5 0 NUM F
mL/kg 0 ADJ F
intravenous 0 ADJ F
bolus 0 NOUN F
of 0 ADP F
crystalloids 0 NOUN F
, 0 PUNCT F
hetastarch 0 NOUN F
( 0 PUNCT F
HES 0 NOUN T
) 0 PUNCT F
, 0 PUNCT F
or 0 CCONJ F
a 0 DET F
hemoglobin-based 0 VERB F
oxygen-carrying 0 ADJ F
solution 0 NOUN F
( 0 PUNCT F
HBOCS 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

MEASUREMENTS 0 ADP T
AND 0 CCONJ T
MAIN 0 ADJ T
RESULTS 0 NOUN T
The 0 DET T
LD 0 NOUN T
( 0 PUNCT F
50 0 NUM F
) 0 PUNCT F
for 0 ADP F
acute B-PHYSICAL ADJ F
blood I-PHYSICAL NOUN F
loss I-PHYSICAL NOUN F
was 0 VERB F
60 0 NUM F
% 0 SYM F
of 0 ADP F
total 0 ADJ F
blood B-PHYSICAL NOUN F
volume I-PHYSICAL NOUN F
. 0 PUNCT F

This 0 DET T
blood 0 NOUN F
volume 0 NOUN F
was 0 VERB F
removed 0 VERB F
in 0 ADP F
the 0 DET F
fluid 0 NOUN F
resuscitation 0 NOUN F
study 0 PUNCT F
to 0 PRON F
create 0 ADJ F
a 0 DET F
model 0 NOUN F
of 0 ADP F
acute 0 ADJ F
blood 0 NOUN F
loss 0 NOUN F
. 0 PUNCT F

Following 0 VERB T
fluid 0 NOUN F
administration 0 NOUN F
, 0 PUNCT F
6 0 NUM F
birds 0 ADP F
in 0 ADP F
the 0 DET F
crystalloid 0 NOUN F
group 0 NOUN F
( 0 PUNCT F
66 0 NUM F
% 0 SYM F
) 0 PUNCT F
, 0 PUNCT F
4 0 NUM F
birds 0 ADP F
in 0 ADP F
the 0 DET F
HES 0 NOUN T
group 0 NOUN F
( 0 PUNCT F
40 0 NUM F
% 0 SYM F
) 0 PUNCT F
, 0 PUNCT F
and 0 CCONJ F
2 0 NUM F
birds 0 ADP F
in 0 ADP F
the 0 DET F
HBOCS 0 NOUN T
group 0 NOUN F
( 0 PUNCT F
20 0 NUM F
% 0 SYM F
) 0 PUNCT F
died 0 VERB F
. 0 PUNCT F

No 0 DET T
statistical 0 ADJ F
difference 0 NOUN F
in 0 ADP F
mortality B-MORTALITY NOUN F
rate I-MORTALITY NOUN F
was 0 VERB F
seen 0 VERB F
among 0 ADP F
the 0 DET F
3 0 NUM F
fluid 0 NOUN F
resuscitation 0 NOUN F
groups 0 NOUN F
. 0 PUNCT F

Relative 0 ADJ T
polychromasia 0 NOUN F
evaluated 0 VERB F
post-phlebotomy 0 NOUN F
demonstrated 0 DET F
regeneration 0 NOUN F
starting 0 ADJ F
at 0 ADP F
24 0 NUM F
hours 0 NOUN F
and 0 CCONJ F
continuing 0 PUNCT F
through 0 ADP F
48 0 NUM F
hours 0 NOUN F
. 0 PUNCT F

CONCLUSIONS 0 NOUN T
The 0 DET T
LD 0 NOUN T
( 0 PUNCT F
50 0 NUM F
) 0 PUNCT F
for 0 ADP F
acute B-PHYSICAL ADJ F
blood I-PHYSICAL NOUN F
loss I-PHYSICAL NOUN F
in 0 ADP F
mallard 0 NOUN F
ducks 0 VERB F
was 0 VERB F
60 0 NUM F
% 0 SYM F
of 0 ADP F
their 0 ADP F
total 0 ADJ F
blood 0 NOUN F
volume 0 NOUN F
. 0 PUNCT F

Although 0 ADP T
no 0 DET F
statistical 0 ADJ F
difference 0 NOUN F
in 0 ADP F
mortality B-MORTALITY NOUN F
rate I-MORTALITY NOUN F
was 0 VERB F
appreciated 0 VERB F
among 0 ADP F
the 0 DET F
3 0 NUM F
fluid 0 NOUN F
resuscitation 0 NOUN F
groups 0 NOUN F
, 0 PUNCT F
a 0 DET F
trend 0 NOUN F
of 0 ADP F
decreased 0 VERB F
mortality B-MORTALITY NOUN F
rate I-MORTALITY NOUN F
was 0 VERB F
observed 0 VERB F
in 0 ADP F
the 0 DET F
HBOCS 0 NOUN T
group 0 NOUN F
. 0 PUNCT F

An 0 DET T
early 0 ADJ F
regenerative 0 ADJ F
response 0 NOUN F
was 0 VERB F
apparent 0 ADJ F
following 0 ADJ F
acute B-PHYSICAL ADJ F
blood I-PHYSICAL NOUN F
loss I-PHYSICAL NOUN F
. 0 PUNCT F

The 0 DET T
experience 0 NOUN F
of 0 ADP F
pleasure 0 NOUN F
before 0 ADP F
and 0 CCONJ F
after 0 ADP F
hearing 0 VERB F
rehabilitation 0 NOUN F
. 0 PUNCT F

Hearing 0 VERB T
loss 0 NOUN F
may 0 VERB F
lead 0 VERB F
to 0 ADP F
major 0 ADJ F
changes 0 NOUN F
in 0 ADP F
the 0 DET F
social 0 ADJ F
and 0 CCONJ F
emotional 0 ADJ F
aspects 0 NOUN F
of 0 ADP F
daily 0 PUNCT F
life 0 NOUN F
. 0 PUNCT F

This 0 DET T
follow-up 0 NOUN F
study 0 NOUN F
investigated 0 VERB F
the 0 DET F
effect 0 NOUN F
of 0 ADP F
hearing-aid 0 PUNCT F
use 0 NOUN F
on 0 ADP F
emotional 0 ADJ F
experience 0 NOUN F
in 0 ADP F
adults 0 NOUN F
with 0 ADP F
hearing 0 VERB F
impairment 0 NOUN F
. 0 PUNCT F

Thirteen 0 PUNCT T
individuals 0 NOUN F
with 0 ADP F
impaired 0 VERB F
hearing 0 PUNCT F
were 0 VERB F
tested 0 VERB F
before 0 ADP F
and 0 CCONJ F
after 0 ADP F
6 0 NUM F
months 0 NOUN F
of 0 ADP F
hearing-aid 0 PUNCT F
use 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
were 0 VERB F
compared 0 VERB F
with 0 ADP F
19 0 NUM F
individuals 0 NOUN F
who 0 PROPN F
had 0 PUNCT F
worn 0 PUNCT F
hearing 0 PUNCT F
aids 0 NOUN F
for 0 ADP F
many 0 DET F
years 0 NOUN F
. 0 PUNCT F

The 0 DET T
participants 0 NOUN F
reported 0 VERB F
their 0 ADP F
daily B-MENTAL ADJ F
emotional I-MENTAL ADJ F
experiences I-MENTAL PROPN F
, 0 PUNCT F
by 0 ADP F
completing 0 PUNCT F
questionnaires B-MENTAL NOUN F
relating I-MENTAL ADJ F
to I-MENTAL ADP F
sensory I-MENTAL ADJ F
and I-MENTAL CCONJ F
social I-MENTAL ADJ F
pleasure I-MENTAL NOUN F
. 0 PUNCT F

After 0 ADP T
6 0 NUM F
months 0 NOUN F
of 0 ADP F
hearing-aid 0 PUNCT F
use 0 NOUN F
, 0 PUNCT F
individuals 0 NOUN F
experienced 0 PUNCT F
more 0 PUNCT F
physical B-MENTAL ADJ F
and I-MENTAL CCONJ F
social I-MENTAL ADJ F
pleasure I-MENTAL NOUN F
, 0 PUNCT F
whereas 0 ADP F
individuals 0 NOUN F
using 0 VERB F
hearing 0 VERB F
aids 0 NOUN F
for 0 ADP F
long 0 ADJ F
periods 0 NOUN F
of 0 ADP F
time 0 NOUN F
reported 0 ADP F
similar 0 ADJ F
levels 0 NOUN F
of 0 ADP F
pleasure 0 NOUN F
at 0 ADP F
the 0 DET F
beginning 0 PUNCT F
and 0 CCONJ F
at 0 ADP F
the 0 DET F
end 0 NOUN F
of 0 ADP F
a 0 DET F
6-month 0 NOUN F
interval 0 NOUN F
. 0 PUNCT F

The 0 DET T
participants 0 NOUN F
also 0 ADV F
performed 0 VERB F
a 0 DET F
visual 0 ADJ F
task 0 NOUN F
, 0 PUNCT F
in 0 ADP F
which 0 ADP F
they 0 ADV F
rated 0 PROPN F
the 0 DET F
intensity 0 NOUN F
of 0 ADP F
pleasure B-MENTAL ADJ F
they I-MENTAL PUNCT F
experienced I-MENTAL ADP F
in I-MENTAL ADP F
response 0 NOUN F
to B-MENTAL ADP F
emotionally I-MENTAL DET F
positive 0 ADJ F
and B-MENTAL CCONJ F
neutral I-MENTAL ADJ F
pictures I-MENTAL NOUN F
differing I-MENTAL PUNCT F
in I-MENTAL ADP F
luminance B-MENTAL ADJ F
contrast I-MENTAL NOUN F
. 0 PUNCT F

In 0 ADP T
this 0 DET F
task 0 NOUN F
, 0 PUNCT F
pleasure 0 NOUN F
typically 0 ADV F
decreases 0 PUNCT F
with 0 ADP F
decreasing 0 DET F
contrast 0 NOUN F
of 0 ADP F
the 0 DET F
positive 0 ADJ F
images 0 NOUN F
displayed 0 VERB F
. 0 PUNCT F

Once 0 ADP T
they 0 NOUN F
had 0 PUNCT F
been 0 PUNCT F
fitted 0 VERB F
with 0 ADP F
hearing 0 VERB F
aids 0 NOUN F
, 0 PUNCT F
the 0 DET F
participants 0 NOUN F
reported 0 ADP F
lower 0 VERB F
levels B-MENTAL NOUN F
of I-MENTAL PUNCT F

Utilization 0 NOUN T
patterns 0 NOUN F
of 0 ADP F
conventional 0 ADJ F
and 0 CCONJ F
complementary/alternative 0 ADJ F
treatments 0 NOUN F
in 0 ADP F
children 0 NOUN F
with 0 ADP F
autism 0 NOUN F
spectrum 0 NOUN F
disorders 0 NOUN F
and 0 CCONJ F
developmental 0 ADJ F
disabilities 0 NOUN F
in 0 ADP F
a 0 DET F
population-based 0 VERB F
study 0 NOUN F
. 0 PUNCT F

OBJECTIVE 0 NOUN T
To 0 PROPN T
compare 0 NOUN F
the 0 DET F
utilization 0 NOUN F
of 0 ADP F
conventional 0 ADJ F
treatments 0 NOUN F
and 0 CCONJ F
utilization 0 NOUN F
of 0 ADP F
complementary 0 ADJ F
and 0 CCONJ F
alternative 0 ADJ F
medicine 0 NOUN F
in 0 ADP F
preschoolers 0 NOUN F
with 0 ADP F
autism 0 NOUN F
spectrum 0 NOUN F
disorders 0 NOUN F
( 0 PUNCT F
ASD 0 NOUN T
) 0 PUNCT F
and 0 CCONJ F
other 0 ADJ F
developmental 0 ADP F
disabilities 0 NOUN F
( 0 PUNCT F
DD 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

METHODS 0 NOUN T
Participants 0 PUNCT T
were 0 VERB F
578 0 NUM F
children 0 NOUN F
who 0 ADP F
were 0 VERB F
part 0 NOUN F
of 0 ADP F
an 0 DET F
ongoing 0 ADJ F
population-based 0 VERB F
, 0 PUNCT F
case-control 0 NOUN F
study 0 NOUN F
of 0 ADP F
2- 0 NUM F
to 0 ADP F
5-year 0 ADJ F
olds 0 CCONJ F
with 0 ADP F
ASD 0 NOUN T
, 0 PUNCT F
DD 0 NOUN T
, 0 PUNCT F
and 0 CCONJ F
the 0 DET F
general 0 ADJ F
population 0 NOUN F
. 0 PUNCT F

Parents 0 NOUN T
completed 0 ADV F
an 0 DET F
interview 0 NOUN F
on 0 ADP F
past 0 PUNCT F
and 0 CCONJ F
current 0 ADJ F
services 0 NOUN F
. 0 PUNCT F

RESULTS 0 NOUN T
Four 0 NUM T
hundred 0 NUM F
fifty-three 0 ADJ F
children 0 NOUN F
with 0 ADP F
ASD 0 NOUN T
and 0 CCONJ F
125 0 NUM F
DD 0 NOUN T
children 0 NOUN F
were 0 VERB F
included 0 VERB F
. 0 PUNCT F

ASD 0 NOUN T
families 0 NOUN F
received 0 VERB F
more 0 PUNCT F
hours 0 NOUN F
of 0 ADP F
conventional B-OTHER ADJ F
services I-OTHER NOUN F
compared 0 VERB F
with 0 ADP F
DD 0 NOUN T
families 0 NOUN F
( 0 PUNCT F
17.8 0 ADP F
vs 0 CCONJ F
11 0 NUM F
; 0 PUNCT F
p 0 NOUN F
< 0 SYM F
.001 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
use 0 NOUN F
of 0 ADP F
psychotropic 0 ADJ F
medications 0 NOUN F
was 0 VERB F
low 0 ADJ F
in 0 ADP F
both 0 CCONJ F
groups 0 NOUN F
( 0 PUNCT F
approximately 0 ADJ F
3 0 NUM F
% 0 SYM F
) 0 PUNCT F
. 0 PUNCT F

Overall 0 ADJ T
, 0 PUNCT F
complementary B-OTHER ADJ F
and 0 CCONJ F
alternative B-OTHER ADJ F
medicine I-OTHER NOUN F
( I-OTHER PUNCT F
CAM I-OTHER NOUN T
) I-OTHER PUNCT F
use 0 NOUN F
was 0 VERB F
not 0 ADV F
significantly 0 ADV F
different 0 ADJ F
in 0 ADP F
ASD 0 NOUN T
( 0 PUNCT F
39 0 NUM F
% 0 SYM F
) 0 PUNCT F
versus 0 CCONJ F
DD 0 NOUN T
( 0 PUNCT F
30 0 NUM F
% 0 SYM F
) 0 PUNCT F
. 0 PUNCT F

Hispanic 0 ADJ T
families 0 NOUN F
in 0 ADP F
both 0 CCONJ F
groups 0 NOUN F
used 0 ADV F
CAM B-OTHER NOUN T
less 0 ADV F
often 0 ADV F
than 0 PUNCT F
non-Hispanic 0 ADP F
families 0 NOUN F
. 0 PUNCT F

Variables 0 NOUN T
such 0 CCONJ F
as 0 ADP F
level B-PHYSICAL NOUN F
of I-PHYSICAL ADP F
function I-PHYSICAL NOUN F
, I-PHYSICAL PUNCT F
immunization I-PHYSICAL NOUN F
status I-PHYSICAL NOUN F
, I-PHYSICAL PUNCT F
and I-PHYSICAL CCONJ F
the I-PHYSICAL DET F
presence I-PHYSICAL NOUN F
of I-PHYSICAL ADP F
an I-PHYSICAL DET F
identified I-PHYSICAL VERB F
neurogenetic I-PHYSICAL ADJ F
disorder I-PHYSICAL NOUN F
were 0 VERB F
not 0 ADV F
predictive 0 ADJ F
of 0 ADP F
CAM 0 NOUN T
use 0 NOUN F
. 0 PUNCT F

A 0 DET T
higher 0 PUNCT F
level B-OTHER NOUN F
of I-OTHER ADP F
parental I-OTHER ADJ F
education I-OTHER NOUN F
was 0 VERB F
associated 0 VERB F
with 0 ADP F
an 0 DET F
increased 0 VERB F
CAM B-OTHER NOUN T
use 0 NOUN F
in 0 ADP F
ASD 0 NOUN T
and 0 CCONJ F
DD 0 NOUN T
. 0 PUNCT F

Families 0 NOUN T
who 0 PROPN F
used 0 VERB F
> 0 PROPN F
20 0 NUM F
hours 0 NOUN F
per 0 ADP F
week 0 NOUN F
of 0 ADP F
conventional 0 ADJ F
services 0 NOUN F
were 0 VERB F
more 0 ADV F
likely 0 ADJ F
to 0 ADP F
use 0 VERB F
CAM 0 NOUN T
, 0 PUNCT F
including 0 VERB F
potentially 0 ADV F
unsafe 0 ADJ F
or 0 CCONJ F
disproven 0 PUNCT F
CAM 0 NOUN T
. 0 PUNCT F

Underimmunized 0 ADV T
children 0 NOUN F
were 0 VERB F
marginally 0 ADV F
more 0 ADV F
likely 0 ADJ F
to 0 ADP F
use 0 NOUN F
CAM 0 NOUN T
but 0 CCONJ F
not 0 ADV F
more 0 ADJ F
likely 0 ADJ F
to 0 PART F
have 0 PUNCT F
received 0 VERB F
potentially 0 ADV F
unsafe 0 ADJ F
or 0 CCONJ F
disproven 0 PUNCT F
CAM 0 NOUN T
. 0 PUNCT F

CONCLUSION 0 NOUN T
Use 0 NOUN T
of 0 ADP F
CAM 0 NOUN T
is 0 VERB F
common 0 ADJ F
in 0 ADP F
families 0 NOUN F
of 0 ADP F
young 0 ADJ F
children 0 NOUN F
with 0 ADP F
neurodevelopmental 0 ADJ F
disorders 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
it 0 PRON F
is 0 VERB F
predicted 0 VERB F
by 0 ADP F
higher 0 PUNCT F
parental 0 ADJ F
education 0 NOUN F
and 0 CCONJ F
non-Hispanic 0 ADP F
ethnicity 0 NOUN F
but 0 CCONJ F
not 0 ADV F
developmental 0 ADJ F
characteristics 0 NOUN F
. 0 PUNCT F

Further 0 ADJ T
research 0 NOUN F
should 0 VERB F
address 0 VERB F
how 0 ADP F
health 0 NOUN F
care 0 NOUN F
providers 0 ADV F
can 0 VERB F
support 0 VERB F
families 0 NOUN F
in 0 ADP F
making 0 PUNCT F
decisions 0 NOUN F
about 0 PUNCT F
CAM 0 NOUN T
use 0 NOUN F
. 0 PUNCT F

Development 0 NOUN T
of 0 ADP F
renal 0 ADJ F
disease 0 NOUN F
in 0 ADP F
people 0 NOUN F
at 0 ADP F
high 0 ADJ F
cardiovascular 0 ADJ F
risk 0 NOUN F
: 0 PUNCT F
results 0 NOUN F
of 0 ADP F
the 0 DET F
HOPE 0 NOUN T
randomized 0 VERB F
study 0 NOUN F
. 0 PUNCT F

In 0 ADP T
people 0 NOUN F
with 0 ADP F
diabetes 0 NOUN F
, 0 PUNCT F
renal 0 ADJ F
disease 0 NOUN F
tends 0 NOUN F
to 0 ADP F
progress 0 PUNCT F
from 0 ADP F
microalbuminuria 0 NOUN F
to 0 ADP F
clinical 0 ADJ F
proteinuria 0 NOUN F
to 0 ADP F
renal 0 ADJ F
insufficiency 0 NOUN F
. 0 PUNCT F

Little 0 DET T
evidence 0 NOUN F
has 0 PUNCT F
been 0 PUNCT F
published 0 VERB F
for 0 ADP F
the 0 DET F
nondiabetic 0 ADJ F
population 0 NOUN F
. 0 PUNCT F

This 0 DET T
study 0 NOUN F
retrospectively 0 ADP F
analyzed 0 VERB F
changes 0 NOUN F
of 0 ADP F
proteinuria 0 NOUN F
over 0 ADP F
4.5 0 NUM F
yr 0 NOUN F
in 0 ADP F
the 0 DET F
HOPE 0 NOUN T
( 0 PUNCT F
Heart 0 NOUN T
Outcomes 0 NOUN T
and 0 CCONJ F
Prevention 0 NOUN T
Evaluation 0 NOUN T
) 0 PUNCT F
study 0 NOUN F
, 0 PUNCT F
which 0 ADP F
compared 0 VERB F
ramipril 0 NOUN F
's 0 PUNCT F
effects 0 NOUN F
to 0 ADP F
placebo 0 NOUN F
in 0 ADP F
9297 0 NUM F
participants 0 NOUN F
, 0 PUNCT F
including 0 VERB F
3577 0 NUM F
with 0 ADP F
diabetes 0 NOUN F
and 0 CCONJ F
1956 0 NUM F
with 0 ADP F
microalbuminuria 0 NOUN F
. 0 PUNCT F

This 0 DET T
report 0 NOUN F
is 0 VERB F
restricted 0 VERB F
to 0 ADP F
7674 0 NUM F
participants 0 NOUN F
with 0 ADP F
albuminuria 0 NOUN F
data 0 ADP F
at 0 ADP F
baseline 0 NOUN F
and 0 CCONJ F
at 0 ADP F
follow-up 0 NOUN F
. 0 PUNCT F

Inclusion 0 NOUN T
criteria 0 NOUN F
were 0 VERB F
known 0 VERB F
vascular 0 ADJ F
disease 0 NOUN F
or 0 CCONJ F
diabetes 0 NOUN F
plus 0 CCONJ F
one 0 NUM F
other 0 ADJ F
cardiovascular 0 ADJ F
risk 0 NOUN F
factor 0 NOUN F
, 0 PUNCT F
exclusion 0 NOUN F
criteria 0 NOUN F
included 0 VERB F
heart 0 NOUN F
failure 0 NOUN F
or 0 CCONJ F
known 0 ADJ F
impaired 0 VERB F
left 0 ADJ F
ventricular 0 ADJ F
function 0 NOUN F
, 0 PUNCT F
dipstick-positive 0 PUNCT F
proteinuria 0 NOUN F
( 0 PUNCT F
> 0 PROPN F
1+ 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
and 0 CCONJ F
serum 0 NOUN F
creatinine 0 NOUN F
> 0 SYM F
2.3 0 NUM F
mg/dl 0 NOUN F
( 0 PUNCT F
200 0 NUM F
microM 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

Baseline 0 NOUN T
microalbuminuria 0 NOUN F
predicted 0 VERB F
subsequent 0 ADJ F
clinical B-PHYSICAL ADJ F
proteinuria I-PHYSICAL NOUN F
for 0 ADP F
the 0 DET F
study 0 ADP F
participants 0 NOUN F
overall 0 ADJ F
( 0 PUNCT F
adjusted 0 VERB F
odds 0 NOUN F
ratio 0 NOUN F
[ 0 PUNCT F
OR 0 CCONJ T
] 0 PUNCT F
, 0 PUNCT F
17.5 0 NUM F
; 0 PUNCT F
95 0 NUM F
% 0 SYM F
confidence 0 NOUN F
interval 0 NOUN F
[ 0 PUNCT F
CI 0 NOUN T
] 0 PUNCT F
, 0 PUNCT F
12.6 0 NUM F
to 0 ADP F
24.4 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
in 0 ADP F
participants 0 NOUN F
without 0 ADP F
diabetes 0 NOUN F
( 0 PUNCT F
OR 0 NOUN T
, 0 PUNCT F
16.7 0 NUM F
; 0 PUNCT F
95 0 NUM F
% 0 SYM F
CI 0 NOUN T
, 0 PUNCT F
8.6 0 NUM F
to 0 ADP F
32.4 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
and 0 CCONJ F
in 0 ADP F
participants 0 NOUN F
with 0 ADP F
diabetes 0 NOUN F
( 0 PUNCT F
OR 0 NOUN T
, 0 PUNCT F
18.2 0 NUM F
; 0 PUNCT F
95 0 NUM F
% 0 SYM F
CI 0 NOUN T
, 0 PUNCT F
12.4 0 NUM F
to 0 ADP F
26.7 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Any 0 DET T
progression B-PHYSICAL NOUN F
of I-PHYSICAL ADP F
albuminuria I-PHYSICAL NOUN F
( 0 PUNCT F
defined 0 PROPN F
as 0 PUNCT F
new 0 ADJ F
microalbuminuria 0 NOUN F
or 0 CCONJ F
new 0 ADJ F
clinical 0 ADJ F
proteinuria 0 NOUN F
) 0 PUNCT F
occurred 0 VERB F
in 0 ADP F
1859 0 NUM F
participants 0 NOUN F
; 0 PUNCT F
1542 0 NUM F
developed 0 PUNCT F
new 0 ADJ F
microalbuminuria B-PHYSICAL NOUN F
, 0 PUNCT F
and 0 CCONJ F
317 0 NUM F
participants 0 NOUN F
developed 0 VERB F
clinical B-PHYSICAL ADJ F
proteinuria I-PHYSICAL NOUN F
. 0 PUNCT F

Ramipril 0 NOUN T
reduced 0 VERB F
the 0 DET F
risk 0 NOUN F
for 0 ADP F
any 0 DET F
progression B-PHYSICAL NOUN F
( 0 PUNCT F
OR 0 NOUN T
, 0 PUNCT F
0.87 0 NUM F
; 0 PUNCT F
95 0 NUM F
% 0 SYM F
CI 0 NOUN T
, 0 PUNCT F
0.78 0 NUM F
to 0 ADP F
0.97 0 NUM F
; 0 PUNCT F
P 0 NOUN T
= 0 SYM F
0.0146 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

People 0 NOUN T
without 0 ADP F
and 0 CCONJ F
with 0 ADP F
diabetes 0 NOUN F
who 0 DET F
are 0 VERB F
at 0 ADP F
high B-PHYSICAL ADJ F
risk 0 NOUN F
for B-PHYSICAL ADP F
cardiovascular I-PHYSICAL ADJ F
disease B-PHYSICAL NOUN F
are 0 VERB F
also 0 ADV F
at 0 ADP F
risk 0 NOUN F
for 0 ADP F
a 0 DET F
progressive 0 ADJ F
rise 0 NOUN F
in 0 ADP F
albuminuria B-PHYSICAL ADV F
. 0 PUNCT F

Microalbuminuria B-PHYSICAL NOUN T
itself 0 ADV F
predicts 0 VERB F
clinical 0 ADJ F
proteinuria 0 NOUN F
in 0 ADP F
nondiabetic 0 ADJ F
and 0 CCONJ F
in 0 ADP F
diabetic 0 ADJ F
people 0 NOUN F
. 0 PUNCT F

Ramipril 0 NOUN T
prevents 0 VERB F
or 0 CCONJ F
delays 0 PUNCT F
the 0 PUNCT F

Pars 0 NOUN T
plana 0 NOUN F
vitrectomy 0 NOUN F
for 0 ADP F
diabetic 0 ADJ F
macular 0 ADJ F
edema 0 NOUN F
. 0 PUNCT F

Internal 0 ADJ T
limiting 0 ADP F
membrane 0 NOUN F
delamination 0 NOUN F
vs 0 CCONJ F
posterior 0 ADJ F
hyaloid 0 ADJ F
removal 0 NOUN F
. 0 PUNCT F

A 0 DET T
prospective 0 ADJ F
randomized 0 VERB F
trial 0 NOUN F
. 0 PUNCT F

BACKGROUND 0 NOUN T
Diabetes 0 NOUN T
mellitus 0 NOUN F
, 0 PUNCT F
as 0 CCONJ F
well 0 PUNCT F
as 0 CCONJ F
subsequent 0 ADJ F
ocular 0 ADJ F
complications 0 NOUN F
such 0 CCONJ F
as 0 ADP F
cystoid 0 NOUN F
macular 0 ADJ F
edema 0 NOUN F
( 0 PUNCT F
CME 0 NOUN T
) 0 PUNCT F
, 0 PUNCT F
are 0 VERB F
of 0 ADP F
fundametal 0 ADJ F
socio-economic 0 ADJ F
relevance 0 NOUN F
. 0 PUNCT F

Therefore 0 ADV T
, 0 PUNCT F
we 0 PRON F
evaluated 0 VERB F
the 0 DET F
influence 0 NOUN F
of 0 ADP F
internal 0 ADJ F
limiting 0 ADP F
membrane 0 NOUN F
( 0 PUNCT F
ILM 0 NOUN T
) 0 PUNCT F
removal 0 NOUN F
on 0 ADP F
longterm 0 NOUN F
morphological 0 ADJ F
and 0 CCONJ F
functional 0 ADJ F
outcome 0 NOUN F
in 0 ADP F
patients 0 NOUN F
with 0 ADP F
diabetes 0 NOUN F
mellitus 0 NOUN F
( 0 PUNCT F
DM 0 NOUN T
) 0 PUNCT F
type 0 NOUN F
2 0 NUM F
and 0 CCONJ F
chronic 0 ADJ F
CME 0 NOUN T
without 0 ADP F
evident 0 ADJ F
vitreomacular 0 ADJ F
traction 0 NOUN F
. 0 PUNCT F

METHOD 0 NOUN T
Forty 0 CCONJ T
eyes 0 NOUN F
with 0 ADP F
attached 0 VERB F
posterior 0 ADJ F
hyaloid 0 ADJ F
were 0 VERB F
included 0 VERB F
in 0 ADP F
this 0 DET F
prospective 0 ADJ F
trial 0 NOUN F
and 0 CCONJ F
randomized 0 VERB F
intraoperatively 0 ADV F
. 0 PUNCT F

Prior 0 ADJ T
focal 0 ADJ F
( 0 PUNCT F
n 0 NOUN F
= 0 SYM F
31 0 NUM F
) 0 PUNCT F
or 0 CCONJ F
panretinal 0 ADJ F
( 0 PUNCT F
n 0 NOUN F
= 0 SYM F
25 0 NUM F
) 0 PUNCT F
laser 0 NOUN F
coagulation 0 NOUN F
was 0 VERB F
permitted 0 VERB F
. 0 PUNCT F

Group 0 NOUN T
I 0 NUM T
( 0 PUNCT F
n 0 NOUN F
= 0 SYM F
19 0 NUM F
patients 0 NOUN F
) 0 PUNCT F
underwent 0 VERB F
surgical 0 ADJ F
induction 0 NOUN F
of 0 ADP F
posterior 0 ADJ F
vitreous 0 ADJ F
detachment 0 NOUN F
( 0 PUNCT F
PVD 0 NOUN T
) 0 PUNCT F
, 0 PUNCT F
group 0 NOUN F
II 0 NUM T
( 0 PUNCT F
n 0 NOUN F
= 0 SYM F
20 0 NUM F
patients 0 NOUN F
) 0 PUNCT F
PVD 0 NOUN T
and 0 CCONJ F
removal 0 NOUN F
of 0 ADP F
the 0 DET F
ILM 0 NOUN T
. 0 PUNCT F

Eleven 0 ADP T
patients 0 NOUN F
with 0 ADP F
detached 0 PROPN F
posterior 0 ADJ F
hyaloid 0 PUNCT F
( 0 PUNCT F
group 0 NOUN F
III 0 NUM T
) 0 PUNCT F
were 0 VERB F
not 0 ADV F
randomized 0 PROPN F
, 0 PUNCT F
and 0 CCONJ F
ILM 0 NOUN T
removal 0 NOUN F
was 0 VERB F
performed 0 VERB F
. 0 PUNCT F

One 0 NUM T
eye 0 NOUN F
had 0 PUNCT F
to 0 PART F
be 0 PUNCT F
excluded 0 VERB F
from 0 ADP F
further 0 ADJ F
analysis 0 NOUN F
. 0 PUNCT F

Examinations 0 NOUN T
included 0 VERB F
ETDRS B-PHYSICAL NOUN T
best-corrected I-PHYSICAL ADP F
visual I-PHYSICAL ADJ F
acuity I-PHYSICAL NOUN F
( I-PHYSICAL PUNCT F
BCVA I-PHYSICAL NOUN T
) I-PHYSICAL PUNCT F
, 0 PUNCT F
fluorescein 0 NOUN F
angiography 0 NOUN F
( 0 PUNCT F
FLA 0 NOUN T
) 0 PUNCT F
and 0 CCONJ F
OCT 0 NOUN T
at 0 ADP F
baseline 0 NOUN F
, 0 PUNCT F
3 0 NUM F
and 0 CCONJ F
6 0 NUM F
months 0 NOUN F
postoperatively 0 ADV F
. 0 PUNCT F

Main 0 ADJ T
outcome 0 NOUN F
measure 0 ADV F
was 0 VERB F
BCVA 0 NOUN T
at 0 ADP F
6 0 NUM F
months 0 NOUN F
, 0 PUNCT F
secondary 0 ADJ F
was 0 VERB F
foveal B-PHYSICAL ADJ F
thickness I-PHYSICAL NOUN F
. 0 PUNCT F

RESULTS 0 NOUN T
Mean 0 ADP T
BCVA B-PHYSICAL NOUN T
over 0 ADP F
6 0 NUM F
months 0 NOUN F
remained 0 DET F
unchanged 0 VERB F
in 0 ADP F
85 0 NUM F
% 0 SYM F
of 0 ADP F
patients 0 NOUN F
of 0 ADP F
group 0 NOUN F
II 0 NUM T
, 0 PUNCT F
and 0 CCONJ F
decreased 0 PUNCT F
in 0 ADP F
53 0 NUM F
% 0 SYM F
of 0 ADP F
patients 0 NOUN F
of 0 ADP F
group 0 NOUN F
I 0 NUM T
. 0 PUNCT F

Results 0 NOUN T
were 0 VERB F
not 0 ADV F
statistically 0 ADV F
significant 0 ADJ F
different 0 ADJ F
[ 0 PUNCT F
group 0 NOUN F
I 0 NUM T
: 0 PUNCT F
mean 0 NOUN F
decrease 0 NOUN F
log 0 NOUN F
MAR 0 NOUN T
95 0 NUM F
% 0 SYM F
CI 0 NOUN T
( 0 PUNCT F
0.06 0 NUM F
; 0 PUNCT F
0.32 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
group 0 NOUN F
II 0 NUM T
: 0 PUNCT F
( 0 PUNCT F
-0.02 0 NUM F
; 0 PUNCT F
0.11 0 NUM F
) 0 PUNCT F
] 0 PUNCT F
. 0 PUNCT F

OCT 0 NOUN T
revealed 0 VERB F
a 0 DET F
significantly 0 ADV F
greater 0 PUNCT F
reduction 0 NOUN F
of 0 ADP F
foveal B-PHYSICAL ADJ F
thickness I-PHYSICAL NOUN F
following 0 DET F
PVD 0 NOUN T
with 0 ADP F
ILM 0 NOUN T
removal 0 NOUN F
[ 0 PUNCT F
group 0 NOUN F
I 0 NUM T
: 0 PUNCT F
mean 0 NOUN F
change 0 NOUN F
: 0 PUNCT F
95 0 NUM F
% 0 SYM F
CI 0 NOUN T
( 0 PUNCT F
-208.95 0 NOUN F
?m 0 PUNCT F
; 0 PUNCT F
-78.05 0 PUNCT F
?m 0 PUNCT F
) 0 PUNCT F
, 0 PUNCT F
group 0 NOUN F
II 0 NUM T
: 0 PUNCT F
( 0 PUNCT F
-80.90 0 PUNCT F
?m 0 PUNCT F
: 0 PUNCT F
+59.17 0 CCONJ F
?m 0 PUNCT F
) 0 PUNCT F
] 0 PUNCT F
. 0 PUNCT F

CONCLUSION 0 NOUN T
Vitrectomy 0 NOUN T
, 0 PUNCT F
PVD 0 NOUN T
with 0 ADP F
or 0 CCONJ F
without 0 ADP F
ILM 0 NOUN T
removal 0 NOUN F
does 0 PUNCT F
not 0 ADV F
improve 0 VERB F
vision 0 NOUN F
in 0 ADP F
patients 0 NOUN F
with 0 ADP F
DM 0 NOUN T
type 0 NOUN F
2 0 NUM F
and 0 CCONJ F
cystoid 0 NOUN F
diabetic 0 ADJ F
macular 0 ADJ F
edema 0 NOUN F
without 0 ADP F
evident 0 ADJ F
vitreoretinal 0 ADJ F
traction 0 NOUN F
. 0 PUNCT F

ILM 0 NOUN T
delamination 0 NOUN F
shows 0 NOUN F
improved 0 ADP F
morphological 0 ADJ F
results 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
appears 0 NOUN F
to 0 PART F
be 0 PUNCT F
beneficial 0 ADJ F
in 0 ADP F
eyes 0 NOUN F
with 0 ADP F
preexisting 0 PUNCT F
PVD 0 NOUN T
. 0 PUNCT F

Predictive 0 ADJ T
and 0 CCONJ F
prognostic 0 ADJ F
roles 0 NOUN F
of 0 ADP F
BRAF 0 NOUN T
mutation 0 NOUN F
in 0 ADP F
stage 0 NOUN F
III 0 NUM T
colon 0 NOUN F
cancer 0 NOUN F
: 0 PUNCT F
results 0 CCONJ F
from 0 ADP F
intergroup 0 NOUN F
trial 0 NOUN F
CALGB 0 NOUN T
89803 0 NUM F
. 0 PUNCT F

PURPOSE 0 NOUN T
Alterations 0 NOUN T
in 0 ADP F
the 0 DET F
RAS-RAF-MAP2K 0 NOUN T
( 0 PUNCT F
MEK 0 NOUN T
) 0 PUNCT F
-MAPK 0 NOUN F
signaling 0 VERB F
pathway 0 NOUN F
are 0 VERB F
major 0 ADJ F
drivers 0 DET F
in 0 ADP F
colorectal 0 ADJ F
carcinogenesis 0 NOUN F
. 0 PUNCT F

In 0 ADP T
colorectal 0 ADJ F
cancer 0 NOUN F
, 0 PUNCT F
BRAF 0 NOUN T
mutation 0 NOUN F
is 0 VERB F
associated 0 VERB F
with 0 ADP F
microsatellite 0 NOUN F
instability 0 NOUN F
( 0 PUNCT F
MSI 0 NOUN T
) 0 PUNCT F
, 0 PUNCT F
and 0 CCONJ F
typically 0 ADV F
predicts 0 NOUN F
inferior 0 ADJ F
prognosis 0 NOUN F
. 0 PUNCT F

We 0 PRON T
examined 0 VERB F
the 0 DET F
effect 0 NOUN F
of 0 ADP F
BRAF 0 NOUN T
mutation 0 NOUN F
on 0 ADP F
survival 0 NOUN F
and 0 CCONJ F
treatment 0 NOUN F
efficacy 0 NOUN F
in 0 ADP F
patients 0 NOUN F
with 0 ADP F
stage 0 NOUN F
III 0 NUM T
colon 0 NOUN F
cancer 0 NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
We 0 PRON T
assessed 0 VERB F
status 0 NOUN F
of 0 ADP F
BRAF 0 NOUN T
c.1799T 0 NOUN F
> 0 SYM F
A 0 DET T
( 0 PUNCT F
p.V600E 0 NOUN F
) 0 PUNCT F
mutation 0 NOUN F
and 0 CCONJ F
MSI 0 NOUN T
in 0 ADP F
506 0 NUM F
stage 0 NOUN F
III 0 NUM T
colon 0 NOUN F
cancer 0 NOUN F
patients 0 NOUN F
enrolled 0 VERB F
in 0 ADP F
a 0 DET F
randomized 0 VERB F
adjuvant 0 NOUN F
chemotherapy 0 NOUN F
trial 0 NOUN F
[ 0 PUNCT F
5-fluorouracil 0 NOUN F
and 0 CCONJ F
leucovorin 0 NOUN F
( 0 PUNCT F
FU/LV 0 NOUN T
) 0 PUNCT F
vs. 0 CCONJ F
irinotecan 0 PUNCT F
( 0 PUNCT F
CPT11 0 NOUN T
) 0 PUNCT F
, 0 PUNCT F
FU 0 NOUN T
and 0 CCONJ F
LV 0 NOUN T
( 0 PUNCT F
IFL 0 NOUN T
) 0 PUNCT F
; 0 PUNCT F
CALGB 0 NOUN T
89803 0 NUM F
] 0 PUNCT F
. 0 PUNCT F

Cox 0 NOUN T
proportional 0 ADJ F
hazards 0 NOUN F
model 0 NOUN F
was 0 VERB F
used 0 VERB F
to 0 PART F
assess 0 NOUN F
the 0 DET F
prognostic 0 ADJ F
role 0 NOUN F
of 0 ADP F
BRAF 0 NOUN T
mutation 0 NOUN F
, 0 PUNCT F
adjusting 0 ADJ F
for 0 ADP F
clinical 0 ADJ F
features 0 NOUN F
, 0 PUNCT F
adjuvant 0 NOUN F
chemotherapy 0 NOUN F
arm 0 ADP F
, 0 PUNCT F
and 0 CCONJ F
MSI 0 NOUN T
status 0 NOUN F
. 0 PUNCT F

RESULTS 0 NOUN T
Compared 0 VERB T
with 0 ADP F
431 0 NUM F
BRAF 0 NOUN T
wild-type 0 NOUN F
patients 0 NOUN F
, 0 PUNCT F
75 0 NUM F
BRAF-mutated 0 VERB T
patients 0 NOUN F
experienced 0 PUNCT F
significantly 0 ADV F
worse 0 ADJ F
overall B-MORTALITY ADJ F
survival I-MORTALITY NOUN F
[ I-MORTALITY PUNCT F
OS I-MORTALITY NOUN T
; 0 PUNCT F
log-rank 0 NOUN F
P 0 NOUN T
= 0 SYM F
0.015 0 NUM F
; 0 PUNCT F
multivariate 0 ADJ F
HR 0 NOUN T
= 0 SYM F
1.66 0 NUM F
; 0 PUNCT F
95 0 NUM F
% 0 SYM F
CI 0 NOUN T
: 0 PUNCT F
1.05-2.63 0 NUM F
] 0 PUNCT F
. 0 PUNCT F

By 0 ADP T
assessing 0 VERB F
combined 0 VERB F
status 0 NOUN F
of 0 ADP F
BRAF 0 NOUN T
and 0 CCONJ F
MSI 0 NOUN T
, 0 PUNCT F
it 0 PRON F
seemed 0 ADP F
that 0 ADP F
BRAF-mutated 0 VERB T
MSS 0 NOUN T
( 0 PUNCT F
microsatellite 0 NOUN F
stable 0 ADJ F
) 0 PUNCT F
tumor 0 NOUN F
was 0 VERB F
an 0 DET F
unfavorable 0 ADJ F
subtype 0 NOUN F
, 0 PUNCT F
whereas 0 ADP F
BRAF 0 NOUN T
wild-type 0 NOUN F
MSI-high 0 ADJ T
tumor 0 NOUN F
was 0 VERB F
a 0 DET F
favorable 0 ADJ F
subtype 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
BRAF-mutated 0 VERB T
MSI-high 0 ADJ T
tumor 0 NOUN F
and 0 CCONJ F
BRAF 0 NOUN T
wild-type 0 NOUN F
MSS 0 NOUN T
tumor 0 NOUN F
were 0 VERB F
intermediate 0 ADJ F
subtypes 0 NOUN F
. 0 PUNCT F

Among 0 ADP T
patients 0 NOUN F
with 0 ADP F
BRAF-mutated 0 VERB T
tumors 0 NOUN F
, 0 PUNCT F
a 0 DET F
nonsignificant 0 ADJ F
trend 0 NOUN F
toward 0 ADP F
improved 0 VERB F
OS B-PHYSICAL ADV T
was 0 VERB F
observed 0 VERB F
for 0 ADP F
IFL 0 ADJ T
versus 0 CCONJ F
FU/LV 0 NOUN T
arm 0 NOUN F
( 0 PUNCT F
multivariate 0 ADJ F
HR 0 NOUN T
= 0 SYM F
0.52 0 NUM F
; 0 PUNCT F
95 0 NUM F
% 0 SYM F
CI 0 NOUN T
: 0 PUNCT F
0.25-1.10 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Among 0 ADP T
patients 0 NOUN F
with 0 ADP F
BRAF 0 NOUN T
wild-type 0 NOUN F
cancer 0 NOUN F
, 0 PUNCT F
IFL 0 NOUN T
conferred 0 VERB F
no 0 DET F
suggestion 0 NOUN F
of 0 ADP F
benefit 0 NOUN F
beyond 0 ADP F
FU/LV 0 NOUN T
alone 0 ADJ F
( 0 PUNCT F
multivariate 0 ADJ F
HR 0 NOUN T
= 0 SYM F
1.02 0 NUM F
; 0 PUNCT F
95 0 NUM F
% 0 SYM F
CI 0 NOUN T
: 0 PUNCT F
0.72-1.46 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

CONCLUSIONS 0 NOUN T
BRAF 0 NOUN T
mutation 0 NOUN F
is 0 VERB F
associated 0 VERB F
with 0 ADP F
inferior 0 ADJ F
survival B-MORTALITY NOUN F
in 0 ADP F
stage 0 NOUN F
III 0 NUM T
colon 0 NOUN F
cancer 0 NOUN F
. 0 PUNCT F

Additional 0 ADJ T
studies 0 NOUN F
are 0 VERB F
necessary 0 ADJ F
to 0 PART F
assess 0 NOUN F
whether 0 ADP F
there 0 PUNCT F
is 0 VERB F
any 0 DET F
predictive 0 ADJ F
role 0 NOUN F
of 0 ADP F
BRAF 0 NOUN T
mutation 0 NOUN F
for 0 ADP F
irinotecan-based 0 VERB F
therapy 0 NOUN F
. 0 PUNCT F

Oral 0 ADJ T
sildenafil 0 NOUN F
to 0 PUNCT F
control 0 NOUN F
pulmonary B-PHYSICAL ADJ F
hypertension I-PHYSICAL NOUN F
after 0 ADP F
congenital 0 ADJ F
heart 0 NOUN F
surgery 0 NOUN F
. 0 PUNCT F

This 0 DET T
study 0 NOUN F
investigates 0 NOUN F
the 0 DET F
role 0 NOUN F
of 0 ADP F
oral 0 ADJ F
sildenafil 0 NOUN F
in 0 ADP F
decreasing 0 PUNCT F
pulmonary B-PHYSICAL ADJ F
pressure I-PHYSICAL NOUN F
after 0 ADP F
congenital 0 ADJ F
heart 0 NOUN F
surgery 0 NOUN F
. 0 PUNCT F

Between 0 ADP T
September 0 NOUN T
2002 0 NUM F
and 0 CCONJ F
September 0 NOUN T
2004 0 NUM F
, 0 PUNCT F
among 0 ADP F
a 0 DET F
group 0 NOUN F
of 0 ADP F
postoperative 0 ADJ F
children 0 NOUN F
with 0 ADP F
large 0 ADJ F
septal 0 ADJ F
defects 0 NOUN F
, 0 PUNCT F
moderate 0 ADJ F
to 0 ADP F
severe 0 ADJ F
pulmonary 0 ADJ F
hypertension 0 NOUN F
[ 0 PUNCT F
pulmonary 0 ADJ F
artery 0 NOUN F
( 0 PUNCT F
PA 0 NOUN T
) 0 PUNCT F
to 0 ADP F
aortic 0 ADJ F
( 0 PUNCT F
Ao 0 NOUN T
) 0 PUNCT F
pressure 0 NOUN F
ratio 0 NOUN F
of 0 ADP F
0.76 0 NUM F
+/- 0 SYM F
0.17 0 NUM F
] 0 PUNCT F
and 0 CCONJ F
systemic 0 ADJ F
desaturation 0 NOUN F
( 0 PUNCT F
Ao 0 NOUN T
Sat 0 NOUN T
= 0 SYM F
0.89 0 NUM F
+/- 0 SYM F
0.11 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
oral 0 ADJ F
sildenafil 0 NOUN F
( 0 PUNCT F
0.3 0 NUM F
mg 0 NOUN F
x 0 SYM F
kg 0 NOUN F
( 0 PUNCT F
-1 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
every 0 DET F
3 0 NUM F
hours 0 NOUN F
) 0 PUNCT F
was 0 VERB F
administered 0 VERB F
for 0 ADP F
a 0 DET F
period 0 NOUN F
of 0 ADP F
24-48 0 NUM F
hours 0 NOUN F
( 0 PUNCT F
sildenafil 0 NOUN F
group 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

These 0 DET T
patients 0 NOUN F
were 0 VERB F
compared 0 VERB F
to 0 ADP F
a 0 DET F
group 0 NOUN F
of 0 ADP F
22 0 NUM F
children 0 NOUN F
with 0 ADP F
similar 0 ADJ F
pathologies 0 NOUN F
who 0 DET F
did 0 CCONJ F
not 0 ADV F
receive 0 VERB F
sildenafil 0 NOUN F
( 0 PUNCT F
control 0 NOUN F
group 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

Postoperative B-PHYSICAL ADJ T
PA I-PHYSICAL NOUN T
pressure I-PHYSICAL NOUN F
( 0 PUNCT F
28.61 0 NUM F
+/- 0 SYM F
7.80 0 NUM F
vs 0 CCONJ F
39.40 0 NUM F
+/- 0 SYM F
10.80 0 NUM F
mm 0 NOUN F
Hg 0 NOUN T
) 0 PUNCT F
and 0 CCONJ F
PA/Ao B-PHYSICAL PUNCT T
pressure I-PHYSICAL NOUN F
( 0 PUNCT F
0.28 0 NUM F
+/- 0 SYM F
0.08 0 NUM F
vs 0 CCONJ F
0.41 0 NUM F
+/- 0 SYM F
0.11 0 NUM F
) 0 PUNCT F
were 0 VERB F
significantly 0 ADV F
lower 0 PUNCT F
in 0 ADP F
the 0 DET F
sildenafil 0 NOUN F
group 0 NOUN F
( 0 PUNCT F
p 0 NOUN F
= 0 SYM F
0.001 0 NUM F
and 0 CCONJ F
0.001 0 ADP F
respectively 0 ADV F
) 0 PUNCT F
. 0 PUNCT F

Pulmonary B-PHYSICAL ADJ T
hypertensive I-PHYSICAL ADJ F
crisis I-PHYSICAL NOUN F
was 0 VERB F
detected 0 VERB F
in 0 ADP F
4 0 NUM F
patients 0 NOUN F
in 0 ADP F
the 0 DET F
control 0 NOUN F
group 0 NOUN F
, 0 PUNCT F
but 0 CCONJ F
none 0 NUM F
in 0 ADP F
the 0 DET F
sildenafil 0 NOUN F
group 0 NOUN F
( 0 PUNCT F
p 0 NOUN F
= 0 SYM F
0.02 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

There 0 PUNCT T
was 0 VERB F
no 0 DET F
significant 0 ADJ F
rise 0 NOUN F
in 0 ADP F
PA 0 NOUN T
pressure 0 NOUN F
following 0 PUNCT F
discontinuation 0 NOUN F
of 0 ADP F
the 0 DET F
drug 0 NOUN F
( 0 PUNCT F
26.30 0 NUM F
+/- 0 SYM F
6.66 0 NUM F
vs 0 CCONJ F
28.49 0 NUM F
+/- 0 SYM F
10.93 0 NUM F
mm 0 NOUN F
Hg 0 NOUN T
, 0 PUNCT F
p 0 NOUN F
= 0 SYM F
0.366 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

No 0 DET T
significant 0 ADJ F
complications B-PHYSICAL NOUN F
were 0 VERB F
noticed 0 VERB F
regarding 0 VERB F
sildenafil 0 NOUN F
use 0 NOUN F
. 0 PUNCT F

Low 0 ADJ T
doses 0 NOUN F
of 0 ADP F
oral 0 ADJ F
sildenafil 0 NOUN F
appear 0 VERB F
to 0 PART F
be 0 VERB F
effective 0 ADJ F
and 0 CCONJ F
safe 0 ADJ F
to 0 PUNCT F
control 0 NOUN F
postoperative 0 ADJ F
PA 0 NOUN T
pressure 0 NOUN F
in 0 ADP F
children 0 NOUN F
. 0 PUNCT F

Absence 0 NOUN T
of 0 ADP F
rebound 0 NOUN F
pulmonary B-PHYSICAL ADJ F
hypertension I-PHYSICAL NOUN F
, 0 PUNCT F
availability 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
low 0 ADJ F
cost 0 NOUN F
of 0 ADP F
the 0 DET F
drug 0 NOUN F
are 0 VERB F
considered 0 VERB F
as 0 ADP F
its 0 PUNCT F
major 0 ADJ F
advantages 0 NOUN F
. 0 PUNCT F

Botulinum 0 NOUN T
toxin 0 NOUN F
a 0 PUNCT F
has 0 PUNCT F
antinociceptive B-PHYSICAL ADJ F
effects I-PHYSICAL NOUN F
in 0 ADP F
treating 0 VERB F
interstitial 0 ADJ F
cystitis 0 NOUN F
. 0 PUNCT F

OBJECTIVES 0 NOUN T
To 0 PUNCT T
present 0 ADJ F
clinical 0 ADJ F
evidence 0 NOUN F
with 0 ADP F
botulinum 0 NOUN F
toxin 0 NOUN F
A 0 NOUN T
( 0 PUNCT F
BTX-A 0 NOUN T
) 0 PUNCT F
suggesting 0 VERB F
an 0 DET F
antinociceptive B-PAIN ADJ F
role I-PAIN NOUN F
in 0 ADP F
patients 0 NOUN F
with 0 ADP F
interstitial 0 ADJ F
cystitis 0 NOUN F
( 0 PUNCT F
IC 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

Intriguing 0 PUNCT T
evidence 0 NOUN F
in 0 ADP F
a 0 DET F
somatic 0 ADJ F
pain 0 NOUN F
model 0 NOUN F
has 0 PUNCT F
suggested 0 VERB F
that 0 ADP F
BTX-A 0 NOUN T
injection 0 NOUN F
may 0 VERB F
have 0 PUNCT F
an 0 DET F
antinociceptive 0 ADJ F
effect 0 NOUN F
on 0 ADP F
both 0 CCONJ F
acute 0 ADJ F
and 0 CCONJ F
chronic 0 ADJ F
( 0 PUNCT F
inflammatory 0 ADJ F
) 0 PUNCT F
pain 0 NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
Thirteen 0 PUNCT T
female 0 NOUN F
patients 0 NOUN F
( 0 PUNCT F
6 0 NUM F
in 0 ADP F
the 0 DET F
United 0 ADV T
States 0 NOUN T
and 0 CCONJ F
7 0 NUM F
in 0 ADP F
Poland 0 PUNCT T
) 0 PUNCT F
with 0 ADP F
IC 0 NOUN T
according 0 ADV F
to 0 ADP F
the 0 DET F
criteria 0 NOUN F
of 0 ADP F
the 0 DET F
National 0 ADJ T
Institute 0 NOUN T
of 0 ADP F
Diabetes 0 NOUN T
, 0 PUNCT F
Digestive 0 ADJ T
and 0 CCONJ F
Kidney 0 NOUN T
Disease 0 NOUN T
were 0 VERB F
included 0 VERB F
. 0 PUNCT F

Under 0 ADP T
short 0 ADJ F
general 0 ADJ F
anesthesia 0 NOUN F
or 0 CCONJ F
sedation 0 NOUN F
, 0 PUNCT F
100 0 NUM F
to 0 ADP F
200 0 ADV F
U 0 NOUN T
of 0 ADP F
Dysport 0 NOUN T
( 0 PUNCT F
Polish 0 PUNCT T
patients 0 NOUN F
) 0 PUNCT F
or 0 CCONJ F
Botox 0 NOUN T
( 0 PUNCT F
U.S. 0 PUNCT T
patients 0 NOUN F
) 0 PUNCT F
was 0 VERB F
injected 0 VERB F
through 0 ADP F
a 0 DET F
cystoscope 0 NOUN F
into 0 ADP F
20 0 NUM F
to 0 ADP F
30 0 NUM F
sites 0 NOUN F
submucosally 0 ADV F
in 0 ADP F
the 0 DET F
trigone 0 ADV F
and 0 CCONJ F
floor 0 NOUN F
of 0 ADP F
the 0 DET F
bladder 0 NOUN F
. 0 PUNCT F

Patients 0 NOUN T
were 0 VERB F
evaluated 0 VERB F
with 0 ADP F
the 0 DET F
O'Leary-Sant 0 ADP T
validated B-PHYSICAL VERB F
IC I-PHYSICAL NOUN T
questionnaire 0 NOUN F
or 0 CCONJ F
with B-PHYSICAL ADP F
voiding I-PHYSICAL DET F
charts I-PHYSICAL VERB F
and 0 CCONJ F
a 0 DET F
visual 0 ADJ F
analog 0 NOUN F
pain 0 NOUN F
scale 0 NOUN F
1 0 NUM F
month 0 NOUN F
postoperatively 0 ADV F
and 0 CCONJ F
at 0 ADP F
subsequent 0 ADJ F
3-month 0 NOUN F
intervals 0 NOUN F
. 0 PUNCT F

The 0 DET T
Polish 0 PUNCT T
patients 0 NOUN F
also 0 ADV F
underwent 0 ADV F
pretreatment 0 NOUN F
and 0 CCONJ F
post-treatment 0 NOUN F
urodynamic B-PHYSICAL VERB F
evaluations I-PHYSICAL NOUN F
. 0 PUNCT F

RESULTS 0 NOUN T
Overall 0 ADJ T
, 0 PUNCT F
9 0 NUM F
( 0 PUNCT F
69 0 NUM F
% 0 SYM F
) 0 PUNCT F
of 0 ADP F
13 0 NUM F
patients 0 NOUN F
noted 0 VERB F
subjective B-OTHER ADP F
improvement I-OTHER NOUN F
after 0 ADP F
BTX-A 0 NOUN T
treatment 0 NOUN F
. 0 PUNCT F

The 0 DET T
Interstitial B-PHYSICAL ADJ T
Cystitis I-PHYSICAL NOUN T
Symptom I-PHYSICAL NOUN T
Index 0 NOUN T
and B-PHYSICAL CCONJ F
Interstitial I-PHYSICAL ADJ T
Cystitis I-PHYSICAL NOUN T
Problem B-PHYSICAL NOUN T
Index 0 NOUN T
mean 0 NOUN F
scores 0 NOUN F
improved 0 PRON F
by 0 ADP F
71 0 NUM F
% 0 SYM F
and 0 CCONJ F
69 0 NUM F
% 0 SYM F
, 0 PUNCT F
respectively 0 ADV F
( 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.05 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Daytime B-PAIN NOUN T
frequency 0 NOUN F
, 0 PUNCT F

An 0 DET T
exploratory 0 ADJ F
, 0 PUNCT F
pragmatic 0 ADJ F
, 0 PUNCT F
cluster 0 NOUN F
randomised 0 VERB F
trial 0 NOUN F
of 0 ADP F
practice 0 NOUN F
nurse 0 ADJ F
training 0 VERB F
in 0 ADP F
the 0 DET F
use 0 NOUN F
of 0 ADP F
asthma 0 NOUN F
action 0 NOUN F
plans 0 NOUN F
. 0 PUNCT F

INTRODUCTION 0 NOUN T
To 0 PROPN T
investigate 0 NOUN F
the 0 DET F
feasibility B-OTHER NOUN F
of 0 ADP F
improving 0 VERB F
asthma 0 NOUN F
management 0 NOUN F
- 0 PUNCT F
in 0 ADP F
particular 0 NOUN F
, 0 PUNCT F
the 0 DET F
implementation 0 NOUN F
of 0 ADP F
individualised 0 VERB F
asthma 0 NOUN F
action 0 NOUN F
plans 0 NOUN F
( 0 PUNCT F
AAPs 0 NOUN T
) 0 PUNCT F
for 0 ADP F
poorly-controlled 0 VERB F
adult 0 NOUN F
asthma 0 NOUN F
patients 0 NOUN F
- 0 PUNCT F
by 0 ADP F
providing 0 NOUN F
training 0 VERB F
in 0 ADP F
asthma-focused 0 VERB F
clinical 0 ADJ F
and 0 CCONJ F
communication 0 NOUN F
skills 0 NOUN F
for 0 ADP F
practice 0 NOUN F
nurses 0 NOUN F
who 0 NUM F
deliver 0 PUNCT F
asthma 0 NOUN F
clinics 0 PROPN F
. 0 PUNCT F

METHODS 0 NOUN T
A 0 PUNCT T
pragmatic 0 ADJ F
, 0 PUNCT F
cluster 0 NOUN F
randomised 0 VERB F
trial 0 NOUN F
with 0 ADP F
an 0 DET F
intervention 0 NOUN F
( 0 PUNCT F
an 0 DET F
interactive 0 ADJ F
seminar 0 ADJ F
) 0 PUNCT F
delivered 0 VERB F
at 0 ADP F
practice 0 NOUN F
level 0 NOUN F
( 0 PUNCT F
n=13 0 NOUN F
practices 0 PROPN F
; 0 PUNCT F
6=intervention 0 NOUN F
, 0 PUNCT F
7=control 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
impact 0 NOUN F
of 0 ADP F
the 0 DET F
intervention 0 NOUN F
was 0 VERB F
assessed 0 VERB F
against 0 ADP F
patient B-PHYSICAL NOUN F
outcomes I-PHYSICAL NOUN F
: 0 PUNCT F
routinely B-PHYSICAL ADV F
available I-PHYSICAL ADJ F
asthma I-PHYSICAL NOUN F
outcome 0 NOUN F
measures B-PHYSICAL NOUN F
( I-PHYSICAL PUNCT F
beta2-agonist B-OTHER NOUN F
prescription B-OTHER NOUN F
rate I-OTHER NOUN F
and 0 CCONJ F
number 0 NOUN F
of 0 ADP F
oral B-OTHER ADJ F
steroid I-OTHER NOUN F
courses I-OTHER DET F
) 0 PUNCT F
for 0 ADP F
asthma 0 NOUN F
patients 0 NOUN F
identified 0 ADJ F
as 0 PUNCT F
being 0 DET F
poorly-controlled 0 PUNCT F
from 0 ADP F
practice 0 NOUN F
records 0 NOUN F
; 0 PUNCT F
and 0 CCONJ F
questionnaire 0 NOUN F
data 0 NOUN F
- B-PHYSICAL PUNCT F
Mini I-PHYSICAL PUNCT T

Analgesic 0 PUNCT T
efficacy 0 NOUN F
of 0 ADP F
low-dose 0 NOUN F
diclofenac 0 NOUN F
versus 0 CCONJ F
paracetamol 0 NOUN F
and 0 CCONJ F
placebo 0 NOUN F
in 0 ADP F
postoperative 0 ADJ F
dental 0 ADJ F
pain 0 NOUN F
. 0 PUNCT F

AIMS 0 NOUN T
To 0 PROPN T
compare 0 NOUN F
the 0 DET F
efficacy 0 NOUN F
and 0 CCONJ F
safety 0 NOUN F
of 0 ADP F
diclofenac-K 0 NOUN F
( 0 PUNCT F
12.5 0 NUM F
mg 0 NOUN F
) 0 PUNCT F
vs 0 CCONJ F
paracetamol 0 NOUN F
( 0 PUNCT F
500 0 NUM F
mg 0 NOUN F
) 0 PUNCT F
and 0 CCONJ F
placebo 0 NOUN F
given 0 VERB F
in 0 ADP F
a 0 DET F
flexible 0 ADJ F
dosage 0 NOUN F
regimen 0 NOUN F
to 0 PART F
treat 0 NOUN F
pain 0 NOUN F
resulting 0 ADJ F
from 0 ADP F
extraction 0 NOUN F
of 0 ADP F
impacted 0 VERB F
third 0 ADJ F
molar 0 ADJ F
teeth 0 NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
This 0 PUNCT T
was 0 VERB F
a 0 DET F
2-day 0 NOUN F
, 0 PUNCT F
double-blind 0 ADJ F
, 0 PUNCT F
double-dummy 0 NOUN F
, 0 PUNCT F
randomized 0 VERB F
, 0 PUNCT F
parallel-group 0 NOUN F
, 0 PUNCT F
placebo-controlled 0 VERB F
study 0 NOUN F
of 0 ADP F
diclofenac-K 0 NOUN F
( 0 PUNCT F
12.5 0 NUM F
mg 0 NOUN F
) 0 PUNCT F
tablets 0 NOUN F
vs 0 CCONJ F
paracetamol 0 NOUN F
( 0 PUNCT F
500 0 NUM F
mg 0 NOUN F
) 0 PUNCT F
tablets 0 ADV F
and 0 CCONJ F
placebo 0 NOUN F
in 0 ADP F
patients 0 NOUN F
with 0 ADP F
moderate 0 ADJ F
or 0 CCONJ F
severe 0 ADJ F
pain 0 NOUN F
within 0 ADP F
8 0 NUM F
hours 0 NOUN F
of 0 ADP F
extraction 0 NOUN F
of 0 ADP F
impacted 0 VERB F
third 0 ADJ F
molars 0 NOUN F
. 0 PUNCT F

RESULTS 0 NOUN T
After 0 ADP T
the 0 DET F
first 0 ADJ F
2-tablet 0 NOUN F
dose 0 NOUN F
, 0 PUNCT F
patients 0 NOUN F
took 0 ADJ F
on 0 ADP F
average 0 ADJ F
2.5 0 NUM F
additional 0 ADJ F
tablets 0 ADV F
of 0 ADP F
diclofenac-K 0 NOUN F
or 0 CCONJ F
2.4 0 NUM F
tablets 0 ADV F
of 0 ADP F
paracetamol 0 NOUN F
, 0 PUNCT F
almost 0 ADV F
all 0 PUNCT F
as 0 ADP F
1-tablet 0 NOUN F
doses 0 NOUN F
. 0 PUNCT F

Most 0 DET T
placebo 0 NOUN F
patients 0 NOUN F
discontinued 0 VERB F
by 0 ADP F
taking 0 VERB F
rescue B-PHYSICAL ADV F
medication I-PHYSICAL NOUN F
( 0 PUNCT F
ibuprofen 0 NOUN F
200 0 NUM F
mg 0 NOUN F
) 0 PUNCT F
on 0 ADP F
the 0 DET F
first 0 ADJ F
day 0 NOUN F
. 0 PUNCT F

Pain B-PAIN NOUN T
relief I-PAIN NOUN F
after 0 ADP F
the 0 DET F
initial 0 ADJ F
dose 0 NOUN F
of 0 ADP F
diclofenac-K 0 NOUN F
( 0 PUNCT F
2 0 NUM F
x 0 SYM F
12.5 0 NUM F
mg 0 NOUN F
) 0 PUNCT F
was 0 VERB F
superior 0 ADJ F
to 0 ADP F
placebo 0 NOUN F
( 0 PUNCT F
P 0 NOUN T
< 0 SYM F
.01 0 PUNCT F
for 0 ADP F
all 0 DET F
efficacy 0 NOUN F
outcomes 0 NOUN F
) 0 PUNCT F
and 0 CCONJ F
comparable 0 ADJ F
to 0 ADP F
paracetamol 0 NOUN F
( 0 PUNCT F
2 0 NUM F
x 0 SYM F
500 0 NUM F
mg 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

About 0 PUNCT T
30 0 NUM F
% 0 SYM F
of 0 ADP F
patients 0 NOUN F
in 0 ADP F
each 0 DET F
active 0 ADJ F
treatment 0 NOUN F
group 0 NOUN F
took 0 PROPN F
rescue B-PHYSICAL NOUN F
medication I-PHYSICAL NOUN F
during 0 ADP F
the 0 DET F
study 0 NOUN F
, 0 PUNCT F
compared 0 VERB F
to 0 ADP F
78 0 NUM F
% 0 SYM F
on 0 ADP F
placebo 0 NOUN F
. 0 PUNCT F

About 0 PUNCT T
70 0 NUM F
% 0 SYM F
in 0 ADP F
each 0 DET F
active 0 ADJ F
treatment 0 NOUN F
group 0 NOUN F
considered 0 VERB F
the 0 DET F
overall B-PAIN ADJ F
pain I-PAIN NOUN F
relief I-PAIN NOUN F
to 0 PART F
be 0 PUNCT F
some 0 DET F
, 0 PUNCT F
a 0 DET F
lot 0 NOUN F
, 0 PUNCT F
or 0 CCONJ F
complete 0 ADP F
compared 0 VERB F
to 0 ADP F
only 0 ADV F
15 0 NUM F
% 0 SYM F
on 0 ADP F
placebo 0 NOUN F
. 0 PUNCT F

The 0 DET T
incidence 0 NOUN F
of 0 ADP F
adverse B-ADVERSE-EFFECTS ADJ F
events I-ADVERSE-EFFECTS NOUN F
in 0 ADP F
each 0 DET F
active 0 ADJ F
treatment 0 NOUN F
group 0 NOUN F
was 0 VERB F
low 0 ADJ F
and 0 CCONJ F
comparable 0 ADJ F
between 0 ADP F
the 0 DET F
treatments 0 NOUN F
. 0 PUNCT F

CONCLUSION 0 NOUN T
An 0 DET T
initial 0 ADJ F
double-dose 0 VERB F
of 0 ADP F
diclofenac-K 0 NOUN F
( 0 PUNCT F
2 0 NUM F
x 0 SYM F
12.5 0 NUM F
mg 0 NOUN F
) 0 PUNCT F
or 0 CCONJ F
paracetamol 0 NOUN F
( 0 PUNCT F
2 0 NUM F
x 0 SYM F
500 0 NUM F
mg 0 NOUN F
) 0 PUNCT F
adequately 0 ADV F
relieved 0 ADP F
the 0 DET F
most 0 PUNCT F
intense 0 ADJ F
postoperative B-PAIN ADJ F
pain I-PAIN NOUN F
, 0 PUNCT F
and 0 CCONJ F
the 0 DET F
flexible 0 ADJ F
multiple 0 ADJ F
dose 0 NOUN F
regimen 0 NOUN F
( 0 PUNCT F
1 0 NUM F
or 0 CCONJ F
2 0 NUM F
tablets 0 ADV F
) 0 PUNCT F
maintained 0 VERB F
adequate 0 PUNCT F
pain B-PAIN NOUN F
relief I-PAIN NOUN F
thereafter 0 ADV F
. 0 PUNCT F

Most 0 DET T
patients 0 NOUN F
needed 0 ADJ F
only 0 ADV F
1-tablet 0 NOUN F
doses 0 NOUN F
following 0 VERB F
the 0 DET F
initial 0 ADJ F
2-tablet 0 NOUN F
dose 0 ADJ F
. 0 PUNCT F

Which 0 ADP T
socio-demographic 0 ADJ F
factors 0 NOUN F
are 0 VERB F
associated 0 VERB F
with 0 ADP F
participation 0 NOUN F
in 0 ADP F
oral 0 ADJ F
cancer 0 NOUN F
screening 0 PUNCT F
in 0 ADP F
the 0 DET F
developing 0 VERB F
world 0 NOUN F
? 0 PUNCT F

Results 0 DET T
from 0 ADP F
a 0 DET F
population-based 0 VERB F
screening 0 PUNCT F
project 0 NOUN F
in 0 ADP F
India 0 PUNCT T
. 0 PUNCT F

BACKGROUND 0 NOUN T
This 0 DET T
study 0 NOUN F
examines 0 NOUN F
socio-demographic 0 ADJ F
determinants 0 NOUN F
of 0 ADP F
participation 0 NOUN F
in 0 ADP F
a 0 DET F
population-based 0 VERB F
randomized 0 VERB F
controlled 0 VERB F
trial 0 NOUN F
that 0 PUNCT F
proved 0 CCONJ F
that 0 ADP F
oral 0 ADJ F
visual 0 ADJ F
inspection 0 NOUN F
was 0 VERB F
effective 0 ADJ F
in 0 ADP F
reducing 0 VERB F
oral B-MORTALITY ADJ F
cancer I-MORTALITY NOUN F
mortality I-MORTALITY NOUN F
in 0 ADP F
high-risk 0 NOUN F
individuals 0 NOUN F
in 0 ADP F
India 0 PUNCT T
. 0 PUNCT F

METHODS 0 NOUN T
Multivariate 0 PUNCT T
logistic 0 ADJ F
regression 0 NOUN F
was 0 VERB F
used 0 VERB F
to 0 PART F
establish 0 ADJ F
socio-demographic 0 ADJ F
characteristics 0 NOUN F
of 0 ADP F
participants 0 NOUN F
versus 0 CCONJ F
non-participants 0 NOUN F
in 0 ADP F
the 0 DET F
intervention 0 NOUN F
arm 0 NOUN F
. 0 PUNCT F

Compliance B-MENTAL NOUN T
with I-MENTAL ADP F
referral I-MENTAL NOUN F
was 0 VERB F
analysed 0 VERB F
according 0 PUNCT F
to 0 ADP F
the 0 DET F
socio-demographic 0 ADJ F
characteristics 0 NOUN F
of 0 ADP F
screen-positives 0 PUNCT F
. 0 PUNCT F

RESULTS 0 NOUN T
Of 0 ADP T
96,517 0 NUM F
eligible 0 ADJ F
subjects 0 NOUN F
, 0 PUNCT F
87,655 0 NUM F
were 0 VERB F
screened 0 VERB F
, 0 PUNCT F
8688 0 NUM F
individuals 0 NOUN F
never 0 ADV F
received 0 VERB F
the 0 DET F
invitation 0 NOUN F
and 0 CCONJ F
174 0 NUM F
refused 0 VERB F
screening 0 ADP F
. 0 PUNCT F

Compared 0 VERB T
to 0 ADP F
the 0 DET F
non-screened 0 VERB F
, 0 PUNCT F
a 0 DET F
higher 0 PUNCT F
proportion 0 NOUN F
of 0 ADP F
screened B-OTHER VERB F
individuals 0 NOUN F
were 0 DET F
women 0 NOUN F
( 0 PUNCT F
OR=4.51 0 NOUN T
; 0 PUNCT F
CI 0 NOUN T
: 0 PUNCT F
4.28-4.75 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
lived 0 VERB F
in 0 ADP F
better 0 PUNCT F
housing 0 PUNCT F
( 0 PUNCT F
OR=1.35 0 NOUN T
; 0 PUNCT F
CI 0 NOUN T
: 0 PUNCT F
1.25-1.41 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
had 0 PUNCT F
television/radio 0 NOUN F
( 0 PUNCT F
OR=1.50 0 NOUN T
; 0 PUNCT F
CI 0 NOUN T
: 0 PUNCT F
1.43-1.58 0 NUM F
) 0 PUNCT F
and 0 CCONJ F
were 0 VERB F
tobacco 0 NOUN F
and 0 CCONJ F
alcohol 0 NOUN F
users 0 NOUN F
( 0 PUNCT F
OR=2.75 0 NOUN T
; 0 PUNCT F
CI 0 NOUN T
: 0 PUNCT F
2.57-2.95 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Being 0 ADV T
65 0 NUM F
and 0 CCONJ F
older 0 PUNCT F
decreased 0 ADP F
the 0 DET F
chances B-OTHER NOUN F
of I-OTHER ADP F
screening I-OTHER PUNCT F
( 0 PUNCT F
OR=0.39 0 NOUN T
; 0 PUNCT F
CI 0 NOUN T
: 0 PUNCT F
0.37-0.42 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
as 0 PUNCT F
well 0 PUNCT F
as 0 CCONJ F
living 0 PUNCT F
in 0 ADP F
high-size B-OTHER NOUN F
households I-OTHER NOUN F
( 0 PUNCT F
OR=0.73 0 NOUN T
; 0 PUNCT F
CI 0 NOUN T
: 0 PUNCT F
0.68-0.78 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Sixty-three 0 PUNCT T
percent 0 NOUN F
of 0 ADP F
5143 0 ADJ F
screen-positives 0 PUNCT F
complied 0 VERB F
with 0 ADP F
referral B-OTHER NOUN F
. 0 PUNCT F

Controlling 0 ADJ T
for 0 ADP F
all 0 DET F
other 0 ADJ F
factors 0 NOUN F
, 0 PUNCT F
individuals 0 NOUN F
older 0 PUNCT F
than 0 ADP F
44 0 NUM F
, 0 PUNCT F
and 0 CCONJ F
those 0 PUNCT F
with 0 ADP F
more 0 DET F
advanced 0 VERB F
lesions 0 NOUN F
were 0 VERB F
more 0 ADV F
likely 0 ADJ F
to 0 ADJ F
comply 0 PUNCT F
with 0 ADP F
referral B-OTHER NOUN F
( 0 PUNCT F
p 0 NOUN F
< 0 SYM F
0.001 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Individuals 0 NOUN T
living 0 ADP F
in 0 ADP F
better 0 PUNCT F
housing 0 PUNCT F
were 0 ADP F
less 0 ADV F
likely 0 ADJ F
to 0 ADJ F
comply B-OTHER PUNCT F
with I-OTHER ADP F
referral I-OTHER NOUN F
( 0 PUNCT F
OR=0.79 0 NOUN T
; 0 PUNCT F
CI 0 NOUN T
: 0 PUNCT F
0.65-0.95 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

CONCLUSIONS 0 NOUN T
In 0 ADP T
summary 0 NOUN F
, 0 PUNCT F
adequate 0 PUNCT F
coverage 0 NOUN F
can 0 VERB F
be 0 DET F
obtained 0 VERB F
in 0 ADP F
population-based 0 VERB F
oral 0 ADJ F
screening 0 NUM F
in 0 ADP F
developing 0 VERB F
countries 0 NOUN F
. 0 PUNCT F

The 0 DET T
study 0 NOUN F
underscores 0 NOUN F
the 0 DET F
important 0 ADJ F
role 0 NOUN F
of 0 ADP F
patient-provider 0 NOUN F
communication 0 NOUN F
in 0 ADP F
assuring 0 VERB F
high 0 ADJ F
compliance 0 NOUN F
with 0 ADP F
referral 0 NOUN F
. 0 PUNCT F

A 0 DET T
randomized 0 VERB F
, 0 PUNCT F
controlled 0 VERB F
trial 0 NOUN F
of 0 ADP F
a 0 DET F
home-based 0 VERB F
intervention 0 NOUN F
program 0 NOUN F
for 0 ADP F
children 0 NOUN F
with 0 ADP F
autism 0 NOUN F
and 0 CCONJ F
developmental 0 ADJ F
delay 0 NOUN F
. 0 PUNCT F

OBJECTIVE 0 NOUN T
This 0 DET T
study 0 NOUN F
aimed 0 VERB F
to 0 PUNCT F
( 0 PUNCT F
1 0 NUM F
) 0 PUNCT F
investigate 0 PUNCT F
whether 0 ADP F
provision 0 NOUN F
of 0 ADP F
a 0 DET F
home-based 0 VERB F
program 0 NOUN F
in 0 ADP F
addition 0 NOUN F
to 0 ADP F
a 0 DET F
center-based 0 VERB F
program 0 NOUN F
improves 0 NOUN F
development 0 NOUN F
in 0 ADP F
young 0 ADJ F
children 0 NOUN F
with 0 ADP F
disabilities 0 NOUN F
and 0 CCONJ F
coping 0 PUNCT F
abilities 0 NOUN F
of 0 ADP F
their 0 PUNCT F
families 0 NOUN F
and 0 CCONJ F
( 0 PUNCT F
2 0 NUM F
) 0 PUNCT F
describe 0 VERB F
the 0 DET F
characteristics 0 NOUN F
of 0 ADP F
children 0 NOUN F
and 0 CCONJ F
families 0 NOUN F
who 0 ADP F
benefit 0 VERB F
most 0 PUNCT F
from 0 ADP F
the 0 DET F
intervention 0 NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
Fifty-nine 0 PUNCT T
children 0 NOUN F
, 0 PUNCT F
aged 0 PROPN F
3-5 0 PUNCT F
years 0 NOUN F
, 0 PUNCT F
with 0 ADP F
no 0 DET F
cerebral 0 ADJ F
palsy 0 NOUN F
, 0 PUNCT F
participated 0 DET F
in 0 ADP F
the 0 DET F
study 0 NOUN F
. 0 PUNCT F

Half 0 NOUN T
of 0 ADP F
the 0 DET F
group 0 NOUN F
was 0 VERB F
randomized 0 VERB F
to 0 PART F
receive 0 NOUN F
an 0 DET F
additional 0 ADJ F
program 0 NOUN F
in 0 ADP F
their 0 DET F
homes 0 NOUN F
. 0 PUNCT F

A 0 DET T
special 0 ADJ F
education 0 NOUN F
teacher 0 NOUN F
provided 0 VERB F
40 0 NUM F
visits 0 NOUN F
over 0 ADP F
12 0 NUM F
months 0 NOUN F
working 0 CCONJ F
with 0 ADP F
the 0 DET F
families 0 NOUN F
to 0 ADP F
help 0 PART F
generalize 0 ADP F
skills 0 NOUN F
to 0 ADP F
the 0 DET F
home 0 NOUN F
environment 0 NOUN F
and 0 CCONJ F
assist 0 PUNCT F
with 0 ADP F
their 0 PUNCT F
concerns 0 NOUN F
. 0 PUNCT F

All 0 DET T
children 0 NOUN F
were 0 VERB F
assessed 0 VERB F
before 0 ADP F
and 0 CCONJ F
after 0 ADP F
the 0 DET F
intervention 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
families 0 NOUN F
completed 0 VERB F
questionnaires 0 NOUN F
assessing 0 PUNCT F
family B-MENTAL NOUN F
stress 0 NOUN F
, 0 PUNCT F
support 0 ADP F
, 0 PUNCT F
and 0 PUNCT F

Risperidone 0 NUM T
dosing 0 VERB F
in 0 ADP F
children 0 NOUN F
and 0 CCONJ F
adolescents 0 NOUN F
with 0 ADP F
autistic 0 ADJ F
disorder 0 NOUN F
: 0 PUNCT F
a 0 DET F
double-blind 0 ADJ F
, 0 PUNCT F
placebo-controlled 0 VERB F
study 0 NOUN F
. 0 PUNCT F

Efficacy 0 NOUN T
and 0 CCONJ F
safety B-OTHER NOUN F
of 0 ADP F
2 0 NUM F
risperidone 0 NUM F
doses 0 NOUN F
were 0 VERB F
evaluated 0 VERB F
in 0 ADP F
children 0 NOUN F
and 0 CCONJ F
adolescents 0 NOUN F
with 0 ADP F
autism 0 NOUN F
. 0 PUNCT F

Patients 0 NOUN T
( 0 PUNCT F
N 0 NOUN T
= 0 SYM F
96 0 NUM F
; 0 PUNCT F
5-17 0 NUM F
years 0 NOUN F
) 0 PUNCT F
, 0 PUNCT F
received 0 CCONJ F
risperidone 0 NUM F
( 0 PUNCT F
low-dose 0 NOUN F
: 0 PUNCT F
0.125 0 NUM F
mg/day 0 NOUN F
[ 0 PUNCT F
20 0 NUM F
to 0 PUNCT F
< 0 ADP F
45 0 NUM F
kg 0 NOUN F
] 0 PUNCT F
, 0 PUNCT F
0.175 0 NUM F
mg/day 0 NOUN F
[ 0 PUNCT F
> 0 PROPN F
45 0 NUM F
kg 0 NOUN F
] 0 PUNCT F
or 0 CCONJ F
high-dose 0 NOUN F
: 0 PUNCT F
1.25 0 NUM F
mg/day 0 NOUN F
[ 0 PUNCT F
20 0 NUM F
to 0 PUNCT F
< 0 ADP F
45 0 NUM F
kg 0 NOUN F
] 0 PUNCT F
, 0 PUNCT F
1.75 0 NUM F
mg/day 0 NOUN F
[ 0 PUNCT F
> 0 PROPN F
45 0 NUM F
kg 0 NOUN F
] 0 PUNCT F
) 0 PUNCT F
or 0 CCONJ F
placebo 0 NOUN F
. 0 PUNCT F

Mean 0 ADJ T
baseline 0 NOUN F
( 0 PUNCT F
range 0 NOUN F
27-29 0 NUM F
) 0 PUNCT F
to 0 ADP F
endpoint 0 PUNCT F
change 0 PUNCT F
in 0 ADP F
Aberrant 0 ADJ T
Behavior 0 NOUN T
Checklist-Irritability 0 NOUN T
( 0 PUNCT F
primary 0 ADJ F
endpoint 0 NOUN F
) 0 PUNCT F
was 0 VERB F
significantly 0 ADV F
greater 0 PUNCT F
in 0 ADP F
the 0 DET F
high-dose- 0 NOUN F
( 0 PUNCT F
-12.4 0 NUM F
[ 0 PUNCT F
6.5 0 NUM F
] 0 PUNCT F
; 0 PUNCT F
p 0 NOUN F
< 0 SYM F
0.001 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
but 0 CCONJ F
not 0 ADV F
low-dose 0 NOUN F
( 0 PUNCT F
-7.4 0 ADV F
[ 0 PUNCT F
8.1 0 NUM F
] 0 PUNCT F
; 0 PUNCT F
p 0 NOUN F
= 0 SYM F
0.164 0 PUNCT F
) 0 PUNCT F
group 0 NOUN F
, 0 PUNCT F
versus 0 CCONJ F
placebo 0 NOUN F
( 0 PUNCT F
-3.5 0 NUM F
[ 0 PUNCT F
10.7 0 ADP F
] 0 PUNCT F
) 0 PUNCT F
. 0 PUNCT F

Clinical 0 ADJ T
Global 0 PUNCT T
Impressions-Severity 0 NOUN T
and 0 CCONJ F
Children 0 ADP T
's 0 PUNCT F
Yale-Brown 0 NOUN T
Obsessive 0 ADJ T
Compulsive 0 ADJ T
Scale 0 NOUN T
scores 0 NOUN F
improved 0 VERB F
significantly 0 ADV F
only 0 ADV F
in 0 ADP F
the 0 DET F
high-dose 0 NOUN F
group 0 NOUN F
, 0 PUNCT F
consistent 0 ADJ F
with 0 ADP F
ABC-I 0 NOUN T
results 0 NOUN F
. 0 PUNCT F

Somnolence 0 NOUN T
, 0 PUNCT F
sedation 0 NOUN F
and 0 CCONJ F
increased 0 ADV F
appetite 0 NOUN F
occurred 0 VERB F
more 0 ADV F
frequently 0 ADV F
in 0 ADP F
high-versus 0 PUNCT F
low-dose 0 NOUN F
groups 0 NOUN F
. 0 PUNCT F

Overall 0 ADJ T
, 0 PUNCT F
increased 0 ADV F
appetite 0 NOUN F
occurred 0 VERB F
most 0 PUNCT F
frequently 0 ADV F
. 0 PUNCT F

Preoperative 0 ADJ T
small-dose 0 NOUN F
ketamine 0 NOUN F
has 0 PUNCT F
no 0 DET F
preemptive 0 ADJ F
analgesic 0 ADP F
effect 0 ADP F
in 0 ADP F
patients 0 NOUN F
undergoing 0 VERB F
total 0 ADJ F
mastectomy 0 NOUN F
. 0 PUNCT F

UNLABELLED 0 NOUN T
We 0 PUNCT T
evaluated 0 VERB F
the 0 DET F
preemptive 0 ADJ F
analgesic 0 ADP F
effect 0 NOUN F
of 0 ADP F
a 0 DET F
small 0 ADJ F
dose 0 NOUN F
of 0 ADP F
ketamine 0 NOUN F
given 0 VERB F
before 0 ADP F
or 0 CCONJ F
immediately 0 ADV F
after 0 ADP F
surgery 0 NOUN F
in 0 ADP F
a 0 DET F
randomized 0 VERB F
, 0 PUNCT F
double-blinded 0 VERB F
study 0 NOUN F
performed 0 VERB F
in 0 ADP F
128 0 NUM F
women 0 NOUN F
undergoing 0 VERB F
total 0 ADJ F
mastectomy 0 NOUN F
. 0 PUNCT F

Group 0 NOUN T
1 0 NUM F
patients 0 NOUN F
received 0 ADP F
ketamine 0 ADV F
0.15 0 NUM F
mg/kg 0 NOUN F
as 0 ADP F
a 0 DET F
5-mL 0 NOUN F
i.v 0 NUM F
. 0 PUNCT F

injection 0 NOUN F
5 0 NUM F
min 0 NOUN F
before 0 ADP F
surgery 0 NOUN F
and 0 CCONJ F
isotonic 0 VERB F
saline 0 NOUN F
5 0 NUM F
mL 0 NOUN F
i.v 0 NUM F
. 0 PUNCT F

at 0 ADP F
the 0 DET F
time 0 NOUN F
of 0 ADP F
skin 0 NOUN F
closure 0 NOUN F
. 0 PUNCT F

Group 0 NOUN T
2 0 NUM F
received 0 VERB F
5 0 NUM F
mL 0 NOUN F
i.v 0 NUM F
. 0 PUNCT F

of 0 ADP F
isotonic 0 ADJ F
saline 0 NOUN F
, 0 PUNCT F
then 0 ADV F
0.15 0 NUM F
mg/kg 0 NOUN F
i.v 0 NUM F
. 0 PUNCT F

ketamine 0 NOUN F
. 0 PUNCT F

A 0 DET T
standard 0 ADJ F
general 0 ADJ F
anesthesia 0 NOUN F
procedure 0 NOUN F
including 0 DET F
sufentanil 0 NOUN F
was 0 VERB F
used 0 VERB F
. 0 PUNCT F

In 0 ADP T
the 0 DET F
recovery 0 NOUN F
room 0 NOUN F
, 0 PUNCT F
patient-controlled 0 SYM F
analgesia 0 NOUN F
i.v 0 NUM F
. 0 PUNCT F

morphine 0 NOUN F
was 0 VERB F
used 0 VERB F
for 0 ADP F
postoperative 0 ADJ F
analgesia 0 NOUN F
. 0 PUNCT F

Postoperative 0 ADJ T
pain 0 NOUN F
was 0 VERB F
assessed 0 VERB F
by 0 ADP F
measuring 0 VERB F
morphine B-PAIN NOUN F
consumption I-PAIN NOUN F
and I-PAIN CCONJ F
visual 0 ADJ F
analog 0 NOUN F
scale 0 PUNCT F

Effects 0 NOUN T
of 0 ADP F
resistance 0 NOUN F
versus 0 CCONJ F
endurance 0 NOUN F
training 0 VERB F
on 0 ADP F
serum B-PHYSICAL NOUN F
adiponectin I-PHYSICAL NOUN F
and 0 CCONJ F
insulin B-PHYSICAL NOUN F
resistance I-PHYSICAL NOUN F
index 0 NOUN F
. 0 PUNCT F

PURPOSE 0 NOUN T
The 0 DET T
purpose 0 NOUN F
of 0 ADP F
the 0 DET F
present 0 ADJ F
study 0 NOUN F
was 0 VERB F
to 0 PART F
investigate 0 NOUN F
the 0 DET F
effects 0 NOUN F
of 0 ADP F
resistance 0 NOUN F
and 0 CCONJ F
endurance 0 NOUN F
training 0 VERB F
on 0 ADP F
serum 0 NOUN F
adiponectin 0 NOUN F
and 0 CCONJ F
insulin 0 NOUN F
resistance 0 NOUN F
index 0 NOUN F
( 0 PUNCT F
SI 0 NOUN T
) 0 PUNCT F
in 0 ADP F
healthy 0 ADJ F
men 0 NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
Twenty-four 0 PUNCT T
healthy 0 ADJ F
males 0 NOUN F
( 0 PUNCT F
age 0 NOUN F
, 0 PUNCT F
35-48 0 NUM F
years 0 NOUN F
) 0 PUNCT F
participated 0 PUNCT F
in 0 ADP F
the 0 DET F
study 0 NOUN F
. 0 PUNCT F

The 0 DET T
subjects 0 NOUN F
were 0 VERB F
randomly 0 ADV F
assigned 0 VERB F
to 0 ADP F
one 0 PUNCT F
of 0 ADP F
three 0 NUM F
groups 0 NOUN F
: 0 PUNCT F
endurance 0 NOUN F
training 0 ADV F
group 0 NOUN F
( 0 PUNCT F
n=8 0 NOUN F
) 0 PUNCT F
, 0 PUNCT F
resistance 0 NOUN F
training 0 DET F
group 0 NOUN F
( 0 PUNCT F
n=8 0 NOUN F
) 0 PUNCT F
and 0 CCONJ F
control 0 NOUN F
group 0 NOUN F
( 0 PUNCT F
n=8 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

Blood B-PHYSICAL NOUN T
samples I-PHYSICAL NOUN F
were 0 VERB F
taken 0 VERB F
in 0 ADP F
fasting 0 VERB F
state 0 NOUN F
from 0 ADP F
all 0 DET F
subjects 0 NOUN F
. 0 PUNCT F

The 0 DET T
experimental 0 ADJ F
groups 0 NOUN F
performed 0 ADP F
either 0 PUNCT F
endurance 0 NOUN F
or 0 CCONJ F
resistance 0 NOUN F
training 0 VERB F
3 0 NUM F
days 0 NOUN F
a 0 DET F
week 0 NOUN F
for 0 ADP F
12 0 NUM F
weeks 0 NOUN F
. 0 PUNCT F

The 0 DET T
endurance 0 NOUN F
training 0 ADV F
programme 0 NOUN F
included 0 VERB F
continuous 0 ADJ F
running 0 VERB F
at 0 ADP F
an 0 DET F
intensity 0 NOUN F
corresponding 0 CCONJ F
to 0 ADP F
75-85 0 NUM F
% 0 SYM F
of 0 ADP F
maximal 0 ADJ F
heart 0 NOUN F
rate 0 NOUN F
, 0 PUNCT F
while 0 ADP F
resistance 0 NOUN F
training 0 PUNCT F
consisted 0 ADJ F
of 0 ADP F
four 0 NUM F
sets 0 NOUN F
of 0 ADP F
circuit 0 NOUN F
weight 0 NOUN F
training 0 VERB F
for 0 ADP F
11 0 NUM F
stations 0 ADJ F
and 0 CCONJ F
at 0 ADP F
an 0 DET F
intensity 0 NOUN F
corresponding 0 CCONJ F
to 0 ADP F
50-60 0 NUM F
% 0 SYM F
of 0 ADP F
one-repetition 0 NOUN F
maximum 0 NOUN F
. 0 PUNCT F

The 0 DET T
maximum 0 NOUN F
numbers 0 NOUN F
of 0 ADP F
repetitions 0 CCONJ F
in 0 ADP F
each 0 DET F
station 0 ADP F
was 0 VERB F
12 0 NUM F
. 0 PUNCT F

RESULTS 0 NOUN T
There 0 CCONJ T
were 0 VERB F
significant 0 ADJ F
negative 0 ADJ F
correlations 0 NOUN F
between 0 ADP F
serum B-PHYSICAL NOUN F
adiponectin I-PHYSICAL NOUN F
and 0 CCONJ F
body B-PHYSICAL NOUN F
fat I-PHYSICAL NOUN F
percentage I-PHYSICAL NOUN F
, 0 PUNCT F
waist-to-hip B-PHYSICAL PUNCT F
ratio 0 NOUN F
, 0 PUNCT F
body B-PHYSICAL NOUN F
mass 0 NOUN F
index 0 NOUN F
and 0 CCONJ F
the B-PHYSICAL DET F
insulin B-PHYSICAL NOUN F
resistance B-PHYSICAL NOUN F
index 0 PUNCT F

Complementary 0 ADJ T
feeding 0 VERB F
with 0 ADP F
fortified 0 VERB F
spread 0 PUNCT F
and 0 CCONJ F
incidence 0 NOUN F
of 0 ADP F
severe B-PHYSICAL ADJ F
stunting I-PHYSICAL NUM F
in 0 ADP F
6- 0 NUM F
to 0 ADP F
18-month-old 0 ADJ F
rural 0 ADJ F
Malawians 0 NOUN T
. 0 PUNCT F

OBJECTIVE 0 NOUN T
To 0 PROPN T
compare 0 NOUN F
growth B-OTHER NOUN F
and 0 CCONJ F
incidence 0 NOUN F
of 0 ADP F
malnutrition B-PHYSICAL NOUN F
in 0 ADP F
infants 0 NOUN F
receiving 0 VERB F
long-term 0 NOUN F
dietary 0 ADJ F
supplementation 0 NOUN F
with 0 ADP F
ready-to-use 0 NOUN F
fortified 0 ADJ F
spread 0 NOUN F
( 0 PUNCT F
FS 0 NOUN T
) 0 PUNCT F
or 0 CCONJ F
micronutrient-fortified 0 VERB F
maize-soy 0 NOUN F
flour 0 NOUN F
( 0 PUNCT F
likuni 0 NOUN F
phala 0 NOUN F
[ 0 PUNCT F
LP 0 NOUN T
] 0 PUNCT F
) 0 PUNCT F
. 0 PUNCT F

DESIGN 0 NOUN T
Randomized 0 PROPN T
, 0 PUNCT F
controlled 0 PUNCT F
, 0 PUNCT F
single-blind 0 ADP F
trial 0 NOUN F
. 0 PUNCT F

SETTING 0 NUM T
Rural 0 ADJ T
Malawi 0 NOUN T
. 0 PUNCT F

PARTICIPANTS 0 ADP T
A 0 PUNCT T
total 0 NOUN F
of 0 ADP F
182 0 NUM F
six-month-old 0 ADJ F
infants 0 NOUN F
. 0 PUNCT F

INTERVENTION 0 NOUN T
Participants 0 PUNCT T
were 0 VERB F
randomized 0 VERB F
to 0 PART F
receive 0 NOUN F
1 0 NUM F
year 0 NOUN F
of 0 ADP F
daily 0 ADJ F
supplementation 0 NOUN F
with 0 ADP F
71 0 NUM F
g 0 NOUN F
of 0 ADP F
LP 0 NOUN T
( 0 PUNCT F
282 0 NUM F
kcal 0 NOUN F
) 0 PUNCT F
, 0 PUNCT F
50 0 NUM F
g 0 NOUN F
of 0 ADP F
FS 0 NOUN T
( 0 PUNCT F
FS50 0 NOUN T
) 0 PUNCT F
( 0 PUNCT F
256 0 NUM F
kcal 0 NOUN F
) 0 PUNCT F
, 0 PUNCT F
or 0 CCONJ F
25 0 NUM F
g 0 NOUN F
of 0 ADP F
FS 0 NOUN T
( 0 PUNCT F
FS25 0 NOUN T
) 0 PUNCT F
( 0 PUNCT F
130 0 NUM F
[ 0 PUNCT F
corrected 0 PUNCT F
] 0 PUNCT F
kcal 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

OUTCOME 0 NOUN T
MEASURES 0 NOUN T
Weight 0 NOUN T
and 0 CCONJ F
length B-PHYSICAL NOUN F
gains I-PHYSICAL NOUN F
and 0 CCONJ F
the 0 DET F
incidences 0 NOUN F
of 0 ADP F
severe B-PHYSICAL ADJ F
stunting I-PHYSICAL DET F
, 0 PUNCT F
underweight B-PHYSICAL PUNCT F
, 0 PUNCT F
and 0 CCONJ F
wasting B-PHYSICAL ADP F
. 0 PUNCT F

RESULTS 0 NOUN T
Mean 0 ADP T
weight 0 NOUN F
and 0 CCONJ F
length B-PHYSICAL NOUN F
gains I-PHYSICAL NOUN F
in 0 ADP F
the 0 DET F
LP 0 NOUN T
, 0 PUNCT F
FS50 0 NOUN T
, 0 PUNCT F
and 0 CCONJ F
FS25 0 NOUN T
groups 0 NOUN F
were 0 VERB F
2.37 0 NUM F
, 0 PUNCT F
2.47 0 NUM F
, 0 PUNCT F
and 0 CCONJ F
2.37 0 NUM F
kg 0 NOUN F
( 0 PUNCT F
P 0 NOUN T
= 0 SYM F
.66 0 NUM F
) 0 PUNCT F
and 0 CCONJ F
12.7 0 NUM F
, 0 PUNCT F
13.5 0 NUM F
, 0 PUNCT F
and 0 CCONJ F
13.2 0 NUM F
cm 0 NOUN F
( 0 PUNCT F
P 0 NOUN T
= 0 SYM F
.23 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
respectively 0 ADV F
. 0 PUNCT F

In 0 ADP T
the 0 DET F
same 0 ADJ F
groups 0 NOUN F
, 0 PUNCT F
the 0 DET F
cumulative 0 ADJ F
12-month 0 NOUN F
incidence 0 NOUN F
of 0 ADP F
severe B-PHYSICAL ADJ F
stunting I-PHYSICAL DET F
was 0 ADV F
13.3 0 NUM F
% 0 SYM F
, 0 PUNCT F
0.0 0 NUM F
% 0 SYM F
, 0 PUNCT F
and 0 CCONJ F
3.5 0 NUM F
% 0 SYM F
( 0 PUNCT F
P 0 NOUN T
= 0 SYM F
.01 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
of 0 ADP F
severe 0 ADJ F
underweight B-PHYSICAL NOUN F
was 0 VERB F
15.0 0 NUM F
% 0 SYM F
, 0 PUNCT F
22.5 0 NUM F
% 0 SYM F
, 0 PUNCT F
and 0 CCONJ F
16.9 0 NUM F
% 0 SYM F
( 0 PUNCT F
P 0 NOUN T
= 0 SYM F
.71 0 PUNCT F
) 0 PUNCT F
, 0 PUNCT F
and 0 CCONJ F
of 0 ADP F
severe B-PHYSICAL ADJ F
wasting I-PHYSICAL ADP F
was 0 VERB F
1.8 0 NUM F
% 0 SYM F
, 0 PUNCT F
1.9 0 NUM F
% 0 SYM F
, 0 PUNCT F
and 0 CCONJ F
1.8 0 NUM F
% 0 SYM F
( 0 PUNCT F
P 0 NOUN T
> 0 SYM F
.99 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Compared 0 VERB T
with 0 ADP F
LP-supplemented 0 ADJ T
infants 0 NOUN F
, 0 PUNCT F
those 0 PUNCT F
given 0 VERB F
FS50 0 NOUN T
gained 0 VERB F
a 0 DET F
mean 0 NOUN F
of 0 ADP F
100 0 NUM F
g 0 NOUN F
more 0 DET F
weight 0 NOUN F
and 0 CCONJ F
0.8 0 NUM F
cm 0 NOUN F
more 0 DET F
length B-PHYSICAL NOUN F
. 0 PUNCT F

There 0 PUNCT T
was 0 VERB F
a 0 DET F
significant 0 ADJ F
interaction 0 NOUN F
between 0 ADP F
baseline 0 NOUN F
length 0 NOUN F
and 0 CCONJ F
intervention 0 NOUN F
( 0 PUNCT F
P 0 NOUN T
= 0 SYM F
.04 0 NUM F
) 0 PUNCT F
; 0 PUNCT F
in 0 ADP F
children 0 NOUN F
with 0 ADP F
below-median 0 ADJ F
length 0 NOUN F
at 0 ADP F
enrollment 0 NOUN F
, 0 PUNCT F
those 0 PUNCT F
given 0 VERB F
FS50 0 NOUN T
gained 0 VERB F
a 0 DET F
mean 0 NOUN F
of 0 ADP F
1.9 0 NUM F
cm 0 NOUN F
more 0 ADV F
than 0 ADP F
individuals 0 NOUN F
receiving 0 VERB F
LP 0 NOUN T
. 0 PUNCT F

CONCLUSION 0 NOUN T
One-year-long 0 ADP T
complementary 0 ADJ F
feeding 0 ADJ F
with 0 DET F
FS 0 NOUN T
does 0 PUNCT F
not 0 ADV F
have 0 PUNCT F
a 0 DET F
significantly 0 ADV F
larger 0 PUNCT F
effect 0 NOUN F
than 0 PUNCT F
LP 0 NOUN T
on 0 ADP F
mean 0 NOUN F
weight 0 NOUN F
gain B-PHYSICAL NOUN F
in 0 ADP F
all 0 DET F
infants 0 NOUN F
, 0 PUNCT F
but 0 CCONJ F
it 0 PRON F
is 0 VERB F
likely 0 PUNCT F
to 0 ADP F
boost 0 PUNCT F
linear B-PHYSICAL ADJ F
growth I-PHYSICAL NOUN F
in 0 ADP F
the 0 DET F
most 0 PUNCT F
disadvantaged 0 VERB F
individuals 0 NOUN F
and 0 CCONJ F
, 0 PUNCT F
hence 0 ADV F
, 0 PUNCT F
decrease 0 ADP F
the 0 DET F
incidence 0 NOUN F
of 0 ADP F
severe B-PHYSICAL ADJ F
stunting I-PHYSICAL DET F
. 0 PUNCT F

Double-blind 0 ADJ T
, 0 PUNCT F
placebo-controlled 0 VERB F
trial 0 NOUN F
of 0 ADP F
risperidone 0 NUM F
plus 0 CCONJ F
topiramate 0 PUNCT F
in 0 ADP F
children 0 NOUN F
with 0 ADP F
autistic 0 ADJ F
disorder 0 NOUN F
. 0 PUNCT F

BACKGROUND 0 NOUN T
Autism 0 NOUN T
is 0 VERB F
a 0 DET F
complex 0 ADJ F
neurodevelopmental 0 ADJ F
disorder 0 NOUN F
that 0 PUNCT F
forms 0 DET F
part 0 NOUN F
of 0 ADP F
a 0 DET F
spectrum 0 NOUN F
of 0 ADP F
related 0 VERB F
disorders 0 NOUN F
referred 0 VERB F
to 0 ADP F
as 0 PUNCT F
Autism 0 NOUN T
Spectrum 0 NOUN T
Disorders 0 NOUN T
. 0 PUNCT F

The 0 DET T
present 0 ADJ F
study 0 NOUN F
assessed 0 VERB F
the 0 DET F
effects 0 NOUN F
of 0 ADP F
topiramate 0 NOUN F
plus 0 CCONJ F
risperidone 0 NUM F
in 0 ADP F
the 0 DET F
treatment 0 NOUN F
of 0 ADP F
autistic 0 ADJ F
disorder 0 NOUN F
. 0 PUNCT F

METHOD 0 NOUN T
Forty 0 PUNCT T
children 0 NOUN F
between 0 ADP F
the 0 DET F
ages 0 NOUN F
of 0 ADP F
4 0 NUM F
and 0 CCONJ F
12 0 NUM F
years 0 NOUN F
with 0 ADP F
a 0 DET F
DSM 0 NOUN T
IV 0 NUM T
clinical 0 ADJ F
diagnosis 0 NOUN F
of 0 ADP F
autism 0 NOUN F
who 0 ADP F
were 0 ADP F
outpatients 0 ADJ F
from 0 ADP F
a 0 DET F
specialty 0 NOUN F
clinic 0 NOUN F
for 0 ADP F
children 0 NOUN F
were 0 VERB F
recruited 0 VERB F
. 0 PUNCT F

The 0 DET T
children 0 NOUN F
presented 0 VERB F
with 0 ADP F
a 0 DET F
chief 0 ADJ F
complaint 0 NOUN F
of 0 ADP F
severely 0 ADV F
disruptive 0 ADJ F
symptoms 0 NOUN F
related 0 VERB F
to 0 ADP F
autistic 0 ADJ F
disorder 0 NOUN F
. 0 PUNCT F

Patients 0 NOUN T
were 0 VERB F
randomly 0 ADV F
allocated 0 VERB F
to 0 ADP F
topiramate+risperidone 0 ADP F
( 0 PUNCT F
Group 0 NOUN T
A 0 NOUN T
) 0 PUNCT F
or 0 CCONJ F
placebo+risperidone 0 NOUN F
( 0 PUNCT F
Group 0 NOUN T
B 0 NOUN T
) 0 PUNCT F
for 0 ADP F
an 0 DET F
8-week 0 NOUN F
, 0 PUNCT F
double-blind 0 ADJ F
, 0 PUNCT F
placebo-controlled 0 VERB F
study 0 NOUN F
. 0 PUNCT F

The 0 DET T
dose 0 NOUN F
of 0 ADP F
risperidone 0 NUM F
was 0 VERB F
titrated 0 VERB F
up 0 CCONJ F
to 0 ADP F
2 0 NUM F
mg/day 0 NOUN F
for 0 ADP F
children 0 NOUN F
between 0 ADP F
10 0 NUM F
and 0 CCONJ F
40 0 NUM F
kg 0 NOUN F
and 0 CCONJ F
3 0 NUM F
mg/day 0 NOUN F
for 0 ADP F
children 0 NOUN F
weighting 0 CCONJ F
above 0 ADP F
40 0 NUM F
kg 0 NOUN F
. 0 PUNCT F

The 0 DET T
dose 0 NOUN F
of 0 ADP F
topiramate 0 NOUN F
was 0 VERB F
titrated 0 VERB F
up 0 CCONJ F
to 0 PUNCT F
200 0 NUM F
mg/day 0 NOUN F
depending 0 VERB F
on 0 ADP F
weight 0 NOUN F
( 0 PUNCT F
100 0 NUM F
mg/day 0 NOUN F
for 0 ADP F
< 0 SYM F
30 0 NUM F
kg 0 NOUN F
and 0 CCONJ F
200 0 NUM F
mg/day 0 NOUN F
for 0 ADP F
> 0 SYM F
30 0 NUM F
kg 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

Patients 0 NOUN T
were 0 VERB F
assessed 0 VERB F
at 0 ADP F
baseline 0 NOUN F
and 0 CCONJ F
after 0 ADP F
2 0 NUM F
, 0 PUNCT F
4 0 NUM F
, 0 PUNCT F
6 0 NUM F
and 0 CCONJ F
8 0 NUM F
weeks 0 NOUN F
after 0 ADP F
starting 0 ADJ F
medication 0 NOUN F
. 0 PUNCT F

Measure 0 NOUN T
of 0 ADP F
outcome 0 NOUN F
was 0 VERB F
the 0 DET F
Aberrant B-OTHER ADJ T
Behavior I-OTHER NOUN T
Checklist-Community I-OTHER NOUN T
( I-OTHER PUNCT F
ABC-C I-OTHER NOUN T
) I-OTHER PUNCT F
Rating I-OTHER PUNCT T
Scale 0 NOUN T
. 0 PUNCT F

RESULTS 0 DET T
Difference 0 NOUN T
between 0 ADP F
the 0 DET F
two 0 NUM F
protocols 0 NOUN F
was 0 VERB F
significant 0 ADJ F
as 0 ADP F
the 0 DET F
group 0 NOUN F
that 0 PUNCT F
received 0 CCONJ F
topiramate 0 NOUN F
had 0 PUNCT F
a 0 DET F
greater 0 PUNCT F
reduction 0 NOUN F
in 0 ADP F
ABC-C 0 NOUN T
subscale 0 NOUN F
scores 0 NOUN F
for 0 ADP F
irritability 0 NOUN F
, 0 PUNCT F
stereotypic B-PHYSICAL ADJ F
behavior I-PHYSICAL NOUN F
and 0 CCONJ F
hyperactivity/noncompliance B-MENTAL NOUN F
. 0 PUNCT F

CONCLUSION 0 NOUN T
The 0 DET T
results 0 CCONJ F
suggest 0 VERB F
that 0 ADP F
the 0 DET F
combination 0 NOUN F
of 0 ADP F
topiramate 0 NOUN F
with 0 ADP F
risperidone 0 NUM F
may 0 VERB F
be 0 VERB F
superior 0 ADJ F
to 0 ADP F
risperidone 0 NUM F
monotherapy 0 NOUN F
for 0 ADP F
children 0 NOUN F
with 0 ADP F
autistic 0 ADJ F
disorder 0 NOUN F
. 0 PUNCT F

However 0 ADV T
the 0 DET F
results 0 ADJ F
need 0 VERB F
to 0 PART F
be 0 PUNCT F
further 0 ADV F
confirmed 0 VERB F
by 0 ADP F
a 0 DET F
larger 0 PUNCT F
randomized 0 VERB F
controlled 0 VERB F
trial 0 NOUN F
. 0 PUNCT F

Pimecrolimus 0 NOUN T
cream 0 NUM F
and 0 CCONJ F
Tacrolimus 0 NOUN T
ointment 0 NOUN F
in 0 ADP F
the 0 DET F
treatment 0 NOUN F
of 0 ADP F
atopic B-PHYSICAL ADJ F
dermatitis I-PHYSICAL NOUN F
: 0 PUNCT F
a 0 DET F
pilot 0 NOUN F
study 0 VERB F
on 0 ADP F
patient 0 NOUN F
preference 0 NOUN F
. 0 PUNCT F

BACKGROUND 0 NOUN T
Pimecrolimus 0 NOUN T
cream 0 VERB F
1 0 NUM F
% 0 SYM F
is 0 VERB F
approved 0 VERB F
for 0 ADP F
mild 0 ADJ F
to 0 ADP F
moderate 0 ADJ F
atopic 0 ADJ F
dermatitis 0 NOUN F
in 0 ADP F
children 0 NOUN F
older 0 PUNCT F
than 0 VERB F
two 0 NUM F
years 0 NOUN F
of 0 ADP F
age 0 NOUN F
and 0 CCONJ F
adults 0 NOUN F
. 0 PUNCT F

Tacrolimus 0 NOUN T
ointment 0 NOUN F
0.03 0 PUNCT F
% 0 SYM F
is 0 VERB F
approved 0 VERB F
for 0 ADP F
moderate 0 ADJ F
to 0 ADP F
severe 0 ADJ F
atopic 0 ADJ F
dermatitis 0 NOUN F
in 0 ADP F
the 0 DET F
patient 0 NOUN F
population 0 NOUN F
between 0 ADP F
two 0 NUM F
to 0 PUNCT F
seventeen 0 PUNCT F
years 0 NOUN F
of 0 ADP F
age 0 NOUN F
and 0 CCONJ F
Tacrolimus 0 NOUN T
0.1 0 NUM F
% 0 SYM F
ointment 0 NOUN F
for 0 ADP F
moderate 0 ADJ F
to 0 ADP F
severe 0 ADJ F
atopic 0 ADJ F
dermatitis 0 NOUN F
in 0 ADP F
patients 0 NOUN F
18 0 NUM F
years 0 NOUN F
of 0 ADP F
age 0 NOUN F
and 0 CCONJ F
older 0 PUNCT F
. 0 PUNCT F

However 0 ADV T
, 0 PUNCT F
beyond 0 ADP F
safety 0 NOUN F
and 0 CCONJ F
efficacy 0 NOUN F
, 0 PUNCT F
the 0 DET F
delivery 0 NOUN F
system 0 NOUN F
or 0 CCONJ F
vehicle 0 NOUN F
used 0 PRON F
in 0 ADP F
topical 0 ADJ F
treatment 0 NOUN F
formulations 0 NOUN F
is 0 VERB F
equally 0 ADV F
important 0 ADJ F
in 0 ADP F
affecting 0 PUNCT F
patient B-OTHER NOUN F
satisfaction I-OTHER NOUN F
, 0 PUNCT F
tolerability B-OTHER NOUN F
, 0 PUNCT F
and 0 PUNCT F

[ 0 PUNCT F
Evaluating 0 VERB T
an 0 DET F
interactive 0 ADJ F
, 0 PUNCT F
multi-media 0 PUNCT F
learning 0 VERB F
system 0 NOUN F
for 0 ADP F
the 0 DET F
study 0 NOUN F
of 0 ADP F
primary 0 ADJ F
open 0 ADJ F
angle 0 NOUN F
glaucoma 0 NOUN F
] 0 PUNCT F
. 0 PUNCT F

Using 0 VERB T
the 0 DET F
interactive 0 ADJ F
multimedia 0 NOUN F
learning 0 ADP F
system 0 NOUN F
for 0 ADP F
studying 0 VERB F
open-angle 0 PUNCT F
glaucoma 0 NOUN F
[ 0 PUNCT F
3 0 NUM F
] 0 PUNCT F
a 0 DET F
prospective 0 ADJ F
, 0 PUNCT F
randomized 0 VERB F
, 0 PUNCT F
case-controlled 0 ADV F
study 0 NOUN F
was 0 ADV F
carried 0 VERB F
out 0 ADP F
to 0 PART F
determine 0 NOUN F
the 0 DET F
value 0 NOUN F
of 0 ADP F
this 0 DET F
new 0 ADJ F
form 0 NOUN F
of 0 ADP F
learning 0 PUNCT F
in 0 ADP F
terms 0 NOUN F
of 0 ADP F
acceptance B-MENTAL NOUN F
and I-MENTAL CCONJ F
the I-MENTAL DET F
imparting I-MENTAL PUNCT F
of I-MENTAL ADP F
knowledge I-MENTAL NOUN F
. 0 PUNCT F

This 0 DET T
article 0 NOUN F
describes 0 NOUN F
details 0 NOUN F
of 0 ADP F
the 0 DET F
study 0 NOUN F
and 0 CCONJ F
presents 0 NOUN F
their 0 DET F
results 0 NOUN F
. 0 PUNCT F

Results 0 NOUN T
were 0 VERB F
established 0 VERB F
on 0 ADP F
the 0 DET F
basis 0 NOUN F
of 0 ADP F
targeted 0 ADJ F
questions 0 NOUN F
asked 0 ADP F
prior 0 PUNCT F
to 0 ADP F
and 0 CCONJ F
after 0 ADP F
the 0 DET F
learning 0 VERB F
phase 0 NOUN F
, 0 PUNCT F
followed 0 VERB F
by 0 ADP F
an 0 DET F
analysis 0 NOUN F
of 0 ADP F
frequencies 0 NOUN F
and 0 CCONJ F
significance 0 NOUN F
testing 0 VERB F
by 0 ADP F
the 0 DET F
Chi 0 NOUN T
squared 0 ADP F
method 0 NOUN F
. 0 PUNCT F

It 0 PRON T
was 0 VERB F
shown 0 VERB F
that 0 ADP F
the 0 DET F
imparting B-MENTAL PUNCT F
of I-MENTAL ADP F
knowledge I-MENTAL NOUN F
is 0 VERB F
significantly 0 ADV F
improved 0 VERB F
when 0 ADP F
this 0 DET F
learning 0 NOUN F
system 0 NOUN F
is 0 VERB F
employed 0 VERB F
. 0 PUNCT F

In 0 ADP T
addition 0 NOUN F
, 0 PUNCT F
after 0 ADP F
its 0 ADP F
first 0 ADJ F
use 0 NOUN F
, 0 PUNCT F
acceptance 0 NOUN F
of 0 ADP F
this 0 DET F
new B-MENTAL ADJ F
medium I-MENTAL NOUN F
rose 0 VERB F
dramatically 0 ADV F
. 0 PUNCT F

A 0 DET T
randomized 0 VERB F
controlled 0 VERB F
trial 0 NOUN F
of 0 ADP F
COMPASS 0 NOUN T
web-based 0 VERB F
and 0 CCONJ F
face-to-face 0 PUNCT F
teacher 0 NOUN F
coaching 0 PUNCT F
in 0 ADP F
autism 0 NOUN F
. 0 PUNCT F

OBJECTIVE 0 NOUN T
Most 0 PUNCT T
children 0 NOUN F
with 0 ADP F
autism 0 NOUN F
rely 0 ADV F
on 0 ADP F
schools 0 NOUN F
as 0 ADP F
their 0 PUNCT F
primary 0 ADJ F
source 0 NOUN F
of 0 ADP F
intervention 0 NOUN F
, 0 PUNCT F
yet 0 PUNCT F
research 0 NOUN F
has 0 PUNCT F
suggested 0 VERB F
that 0 ADP F
teachers 0 NOUN F
rarely 0 ADV F
use 0 PUNCT F
evidence-based 0 ADJ F
practices 0 PROPN F
. 0 PUNCT F

To 0 PART T
address 0 NOUN F
the 0 DET F
need 0 NOUN F
for 0 ADP F
improved 0 CCONJ F
educational 0 ADJ F
outcomes 0 NOUN F
, 0 PUNCT F
a 0 DET F
previously 0 ADV F
tested 0 PUNCT F
consultation 0 NOUN F
intervention 0 NOUN F
called 0 VERB F
the 0 DET F
Collaborative 0 ADJ T
Model 0 NOUN T
for 0 ADP F
Promoting 0 PUNCT T
Competence 0 NOUN T
and 0 CCONJ F
Success 0 NOUN T
( 0 PUNCT F
COMPASS 0 NOUN T
; 0 PUNCT F
Ruble 0 ADJ T
, 0 PUNCT F
Dalrymple 0 NOUN T
, 0 PUNCT F
& 0 CCONJ F
McGrew 0 NOUN T
, 0 PUNCT F
2010 0 NUM F
; 0 PUNCT F
Ruble 0 ADJ T
, 0 PUNCT F
Dalrymple 0 NOUN T
, 0 PUNCT F
& 0 CCONJ F
McGrew 0 NOUN T
, 0 PUNCT F
2012 0 NUM F
) 0 PUNCT F
was 0 VERB F
evaluated 0 VERB F
in 0 ADP F
a 0 DET F
2nd 0 ADJ F
randomized 0 VERB F
controlled 0 VERB F
trial 0 NOUN F
, 0 PUNCT F
with 0 ADP F
the 0 DET F
addition 0 NOUN F
of 0 ADP F
a 0 DET F
web-based 0 ADV F
group 0 NOUN F
. 0 PUNCT F

METHOD 0 NOUN T
Forty-nine 0 NUM T
teacher-child 0 ADJ F
dyads 0 VERB F
were 0 VERB F
randomized 0 VERB F
into 0 ADP F
1 0 NUM F
of 0 ADP F
3 0 NUM F
groups 0 NOUN F
: 0 PUNCT F
( 0 PUNCT F
1 0 NUM F
) 0 PUNCT F
a 0 DET F
placebo 0 NOUN F
control 0 NOUN F
( 0 PUNCT F
PBO 0 NOUN T
) 0 PUNCT F
group 0 NOUN F
, 0 PUNCT F
( 0 PUNCT F
2 0 NUM F
) 0 PUNCT F
COMPASS 0 NOUN T
followed 0 VERB F
by 0 ADP F
face-to-face 0 NOUN F
( 0 PUNCT F
FF 0 NOUN T
) 0 PUNCT F
coaching 0 NUM F
sessions 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
( 0 PUNCT F
3 0 NUM F
) 0 PUNCT F
COMPASS 0 NOUN T
followed 0 NOUN F
by 0 ADP F
web-based 0 PUNCT F
( 0 PUNCT F
WEB 0 NOUN T
) 0 PUNCT F
coaching 0 NUM F
sessions 0 NOUN F
. 0 PUNCT F

Three 0 NUM T
individualized 0 VERB F
goals 0 NOUN F
( 0 PUNCT F
social 0 ADJ F
, 0 PUNCT F
communication 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
independence 0 NOUN F
skills 0 NOUN F
) 0 PUNCT F
were 0 VERB F
selected 0 VERB F
for 0 ADP F
intervention 0 NOUN F
for 0 ADP F
each 0 DET F
child 0 NOUN F
. 0 PUNCT F

The 0 DET T
primary 0 ADJ F
outcome 0 NOUN F
of 0 ADP F
independent B-PHYSICAL ADJ F
ratings I-PHYSICAL NOUN F
of I-PHYSICAL ADP F
child I-PHYSICAL NOUN F
goal I-PHYSICAL NOUN F
attainment I-PHYSICAL NOUN F
and I-PHYSICAL CCONJ F
several I-PHYSICAL ADJ F
process I-PHYSICAL NOUN F
measures I-PHYSICAL NOUN F
( 0 PUNCT F
e.g. 0 ADP F
, 0 PUNCT F
consultant 0 NOUN F
and 0 CCONJ F
teacher 0 NOUN F
fidelity 0 NOUN F
) 0 PUNCT F
were 0 VERB F
evaluated 0 VERB F
. 0 PUNCT F

RESULTS 0 NOUN T
Using 0 ADJ T
an 0 DET F
intent-to-treat 0 NOUN F
approach 0 NOUN F
, 0 PUNCT F
findings 0 NOUN F
replicated 0 VERB F
earlier 0 PUNCT F
results 0 ADP F
with 0 ADP F
a 0 DET F
very 0 ADJ F
large 0 ADJ F
effect 0 NOUN F
size 0 NOUN F
( 0 PUNCT F
d 0 NOUN F
= 0 SYM F
1.41 0 NUM F
) 0 PUNCT F
for 0 ADP F
the 0 DET F
FF 0 NOUN T
group 0 NOUN F
and 0 CCONJ F
a 0 DET F
large 0 ADJ F
effect 0 NOUN F
size 0 NOUN F
( 0 PUNCT F
d 0 NOUN F
= 0 SYM F
1.12 0 NUM F
) 0 PUNCT F
for 0 ADP F
the 0 DET F
WEB 0 NOUN T
group 0 NOUN F
relative 0 ADJ F
to 0 ADP F
the 0 DET F
PBO 0 NOUN T
group 0 NOUN F
. 0 PUNCT F

There 0 PUNCT T
were 0 VERB F
no 0 DET F
differences 0 NOUN F
in 0 ADP F
overall 0 ADJ F
change 0 NOUN F
across 0 ADP F
goal 0 NOUN F
domains 0 NOUN F
between 0 ADP F
the 0 DET F
FF 0 NOUN T
and 0 CCONJ F
WEB 0 NOUN T
groups 0 NOUN F
, 0 PUNCT F
suggesting 0 VERB F
the 0 DET F
efficacy 0 NOUN F
of 0 ADP F
videoconferencing 0 VERB F
technology 0 NOUN F
. 0 PUNCT F

CONCLUSIONS 0 NOUN T
COMPASS 0 NOUN T
is 0 VERB F
effective 0 ADJ F
and 0 CCONJ F
results 0 NOUN F
in 0 ADP F
improved 0 VERB F
educational 0 ADJ F
outcomes 0 NOUN F
for 0 ADP F
young 0 ADJ F
children 0 NOUN F
with 0 ADP F
autism 0 NOUN F
. 0 PUNCT F

Videoconferencing 0 VERB T
technology 0 NOUN F
, 0 PUNCT F
as 0 ADP F
a 0 DET F
scalable 0 ADJ F
tool 0 NOUN F
, 0 PUNCT F
has 0 PUNCT F
promise 0 PUNCT F
for 0 ADP F
facilitating 0 NOUN F
access 0 NOUN F
to 0 ADP F
autism 0 NOUN F
specialists 0 NOUN F
and 0 CCONJ F
bridging 0 PUNCT F
the 0 DET F
research-to-practice 0 NOUN F
gap 0 NOUN F
. 0 PUNCT F

Marginal 0 ADJ T
benefit/disadvantage B-OTHER NOUN F
of 0 ADP F
granulocyte 0 NOUN F
colony-stimulating 0 VERB F
factor 0 NOUN F
therapy 0 NOUN F
after 0 ADP F
autologous 0 ADJ F
blood 0 NOUN F
stem 0 NOUN F
cell 0 NOUN F
transplantation 0 NOUN F
in 0 ADP F
children 0 NOUN F
: 0 PUNCT F
results 0 NOUN F
of 0 ADP F
a 0 DET F
prospective 0 ADJ F
randomized 0 VERB F
trial 0 NOUN F
. 0 PUNCT F

The 0 DET T
Japanese 0 ADJ T
Cooperative 0 ADJ T
Study 0 NOUN T
Group 0 NOUN T
of 0 ADP F
PBSCT 0 NOUN T
. 0 PUNCT F

In 0 ADP T
this 0 DET F
prospective 0 ADJ F
trial 0 NOUN F
, 0 PUNCT F
a 0 DET F
total 0 NOUN F
of 0 ADP F
74 0 NUM F
children 0 NOUN F
who 0 ADP F
were 0 VERB F
scheduled 0 VERB F
to 0 ADJ F
undergo 0 PUNCT F
high-dose 0 NOUN F
chemotherapy 0 NOUN F
followed 0 VERB F
by 0 ADP F
autologous 0 ADJ F
peripheral 0 ADJ F
blood 0 NOUN F
stem 0 NOUN F
cell 0 NOUN F
transplantation 0 NOUN F
( 0 PUNCT F
PBSCT 0 NOUN T
) 0 PUNCT F
were 0 VERB F
prospectively 0 ADV F
randomized 0 ADP F
at 0 ADP F
diagnosis 0 NOUN F
to 0 PART F
evaluate 0 NOUN F
the 0 DET F
effectiveness 0 NOUN F
of 0 ADP F
exogenous 0 ADJ F
granulocyte 0 NOUN F
colony-stimulating 0 VERB F
factor 0 NOUN F
( 0 PUNCT F
G-CSF 0 NOUN T
) 0 PUNCT F
treatment 0 NOUN F
in 0 ADP F
accelerating 0 PUNCT F
hematopoietic B-PHYSICAL ADJ F
recovery I-PHYSICAL NOUN F
after 0 ADP F
PBSCT 0 NOUN T
. 0 PUNCT F

The 0 DET T
diagnosis 0 NOUN F
included 0 VERB F
acute 0 ADJ F
lymphoblastic 0 ADJ F
leukemia 0 NOUN F
( 0 PUNCT F
ALL 0 NOUN T
) 0 PUNCT F
( 0 PUNCT F
n 0 NOUN F
= 0 SYM F
27 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
neuroblastoma 0 NOUN F
( 0 PUNCT F
n 0 NOUN F
= 0 SYM F
29 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
and 0 CCONJ F
miscellaneous 0 ADP F
solid 0 ADP F
tumors 0 NOUN F
( 0 PUNCT F
n 0 NOUN F
= 0 SYM F
18 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Eligibility 0 NOUN T
criteria 0 NOUN F
included 0 ADP F
( 0 PUNCT F
1 0 NUM F
) 0 PUNCT F
primary 0 ADJ F
PBSCT 0 NOUN T
, 0 PUNCT F
( 0 PUNCT F
2 0 NUM F
) 0 PUNCT F
chemotherapy-responsive 0 ADJ F
disease 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
( 0 PUNCT F
3 0 NUM F
) 0 PUNCT F
collected 0 VERB F
cell 0 NOUN F
number 0 NOUN F
> 0 SYM F
1 0 NUM F
x 0 SYM F
10 0 NUM F
( 0 PUNCT F
5 0 NUM F
) 0 PUNCT F
colony-forming 0 ADP F
unit-granulocyte-macrophage 0 NOUN F
( 0 PUNCT F
CFU-GM 0 NOUN T
) 0 PUNCT F
/kg 0 ADV F
and 0 CCONJ F
> 0 SYM F
1 0 NUM F
x 0 SYM F
10 0 NUM F
( 0 PUNCT F
6 0 NUM F
) 0 PUNCT F
CD34 0 NOUN T
( 0 PUNCT F
+ 0 SYM F
) 0 PUNCT F
cells/kg 0 NOUN F
patient 0 NOUN F
's 0 PUNCT F
body 0 NOUN F
weight 0 NOUN F
. 0 PUNCT F

After 0 ADP T
applying 0 VERB F
the 0 DET F
above 0 ADP F
criteria 0 NOUN F
, 0 PUNCT F
11 0 NUM F
patients 0 NOUN F
were 0 VERB F
excluded 0 VERB F
due 0 PUNCT F
to 0 ADP F
disease 0 NOUN F
progression 0 NOUN F
before 0 ADP F
PBSCT 0 NOUN T
( 0 PUNCT F
n 0 NOUN F
= 0 SYM F
6 0 NUM F
) 0 PUNCT F
or 0 CCONJ F
a 0 DET F
low 0 ADJ F
number 0 NOUN F
of 0 ADP F
harvested 0 VERB F
cells 0 NOUN F
( 0 PUNCT F
n 0 NOUN F
= 0 SYM F
5 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
leaving 0 ADP F
63 0 NUM F
patients 0 NOUN F
for 0 ADP F
analysis 0 NOUN F
; 0 PUNCT F
32 0 NUM F
patients 0 NOUN F
in 0 ADP F
the 0 DET F
treatment 0 NOUN F
group 0 NOUN F
( 0 PUNCT F
300 0 NUM F
microg/m2 0 PUNCT F
of 0 ADP F
G-CSF 0 NOUN T
intravenously 0 ADV F
over 0 ADP F
1 0 NUM F
hour 0 NOUN F
from 0 ADP F
day 0 NOUN F
1 0 PUNCT F
of 0 ADP F
PBSCT 0 NOUN T
) 0 PUNCT F
and 0 CCONJ F
31 0 NUM F
in 0 ADP F
the 0 DET F
control 0 NOUN F
group 0 NOUN F
without 0 ADP F
treatment 0 NOUN F
. 0 PUNCT F

Two 0 NUM T
distinct 0 ADJ F
disease-oriented 0 VERB F
high-dose 0 NOUN F
regimens 0 NOUN F
without 0 ADP F
total 0 ADJ F
body 0 NOUN F
irradiation 0 NOUN F
consisted 0 VERB F
of 0 ADP F
the 0 DET F
MCVAC 0 NOUN T
regimen 0 NOUN F
using 0 PROPN F
ranimustine 0 ADJ F
( 0 PUNCT F
MCNU 0 NOUN T
, 0 PUNCT F
450 0 PUNCT F
mg/m2 0 ADV F
) 0 PUNCT F
, 0 PUNCT F
cytosine 0 NOUN F
arabinoside 0 NOUN F
( 0 PUNCT F
16 0 NUM F
g/m2 0 NOUN F
) 0 PUNCT F
, 0 PUNCT F
etoposide 0 NOUN F
( 0 PUNCT F
1.6 0 NUM F
g/m2 0 NOUN F
) 0 PUNCT F
, 0 PUNCT F
and 0 CCONJ F
cyclophosphamide 0 NOUN F
( 0 PUNCT F
100 0 NUM F
mg/kg 0 NOUN F
) 0 PUNCT F
for 0 ADP F
patients 0 NOUN F
with 0 ADP F
ALL 0 NOUN T
, 0 PUNCT F
and 0 CCONJ F
the 0 DET F
Hi-MEC 0 NOUN T
regimen 0 NOUN F
using 0 PUNCT F
melphalan 0 NOUN F
( 0 PUNCT F
180 0 NUM F
mg/m2 0 ADV F
) 0 PUNCT F
, 0 PUNCT F
etoposide 0 NOUN F
( 0 PUNCT F
1.6 0 NUM F
g/m2 0 NOUN F
) 0 PUNCT F
, 0 PUNCT F
and 0 CCONJ F
carboplatinum 0 NOUN F
( 0 PUNCT F
1.6 0 NUM F
g/m2 0 NOUN F
) 0 PUNCT F
for 0 ADP F
those 0 PUNCT F
with 0 ADP F
solid 0 ADJ F
tumors 0 NOUN F
. 0 PUNCT F

Five 0 NUM T
patients 0 NOUN F
( 0 PUNCT F
two 0 NUM F
in 0 ADP F
the 0 DET F
treatment 0 NOUN F
group 0 NOUN F
and 0 CCONJ F
three 0 NUM F
in 0 ADP F
the 0 DET F
control 0 NOUN F
group 0 NOUN F
) 0 PUNCT F
were 0 VERB F
subsequently 0 ADV F
removed 0 VERB F
due 0 ADP F
to 0 ADP F
protocol 0 NOUN F
violations 0 NOUN F
. 0 PUNCT F

All 0 DET T
patients 0 NOUN F
survived B-MORTALITY PUNCT F
PBSCT 0 NOUN T
. 0 PUNCT F

The 0 DET T
median 0 ADJ F
numbers B-PHYSICAL NOUN F
of I-PHYSICAL ADP F
transfused I-PHYSICAL PUNCT F
mononuclear I-PHYSICAL ADJ F
cells I-PHYSICAL NOUN F
( I-PHYSICAL PUNCT F
MNC I-PHYSICAL NOUN T
) I-PHYSICAL PUNCT F
, I-PHYSICAL PUNCT F
CD34 I-PHYSICAL NOUN T
( I-PHYSICAL PUNCT F
+ I-PHYSICAL SYM F
) I-PHYSICAL PUNCT F
cells I-PHYSICAL NOUN F
, I-PHYSICAL PUNCT F
and I-PHYSICAL CCONJ F
CFU-GM I-PHYSICAL NOUN T
were 0 VERB F
, 0 PUNCT F
respectively 0 ADV F
, 0 PUNCT F
4.5 0 NUM F
( 0 PUNCT F
range 0 NOUN F
, 0 PUNCT F
1 0 NUM F
to 0 ADP F
19 0 NUM F
) 0 PUNCT F
x 0 SYM F
10 0 NUM F
( 0 PUNCT F
8 0 NUM F
) 0 PUNCT F
/kg 0 ADV F
, 0 PUNCT F
8.0 0 NUM F
( 0 PUNCT F
1.1 0 NUM F
to 0 ADP F
25 0 NUM F
) 0 PUNCT F
x 0 SYM F
10 0 NUM F
( 0 PUNCT F
6 0 NUM F
) 0 PUNCT F
/kg 0 ADV F
, 0 PUNCT F
and 0 CCONJ F
3.7 0 NUM F
( 0 PUNCT F
1.2 0 NUM F
to 0 ADP F
23 0 NUM F
) 0 PUNCT F
x 0 SYM F
10 0 NUM F
( 0 PUNCT F
5 0 NUM F
) 0 PUNCT F
/kg 0 ADV F
in 0 ADP F
the 0 DET F
treatment 0 NOUN F
group 0 NOUN F
( 0 PUNCT F
n 0 NOUN F
= 0 SYM F
30 0 NUM F
) 0 PUNCT F
and 0 CCONJ F
2.9 0 NUM F
( 0 PUNCT F
0.8 0 NUM F
to 0 ADP F
21 0 NUM F
) 0 PUNCT F
x 0 SYM F
10 0 NUM F
( 0 PUNCT F
8 0 NUM F
) 0 PUNCT F
/kg 0 ADV F
, 0 PUNCT F
6.3 0 NUM F
( 0 PUNCT F
1.1 0 NUM F
to 0 ADP F
34 0 NUM F
) 0 PUNCT F
x 0 SYM F
10 0 NUM F
( 0 PUNCT F
6 0 NUM F
) 0 PUNCT F
/kg 0 ADV F
, 0 PUNCT F
and 0 CCONJ F
5.5 0 NUM F
( 0 PUNCT F
1.3 0 NUM F
to 0 ADP F
37 0 NUM F
) 0 PUNCT F
x 0 SYM F
10 0 NUM F
( 0 PUNCT F
5 0 NUM F
) 0 PUNCT F
/kg 0 ADV F
, 0 PUNCT F
respectively 0 ADV F
, 0 PUNCT F
in 0 ADP F
the 0 DET F
control 0 NOUN F
group 0 NOUN F
( 0 PUNCT F
n 0 NOUN F
= 0 SYM F
28 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
with 0 ADP F
no 0 DET F
significant 0 ADJ F
difference 0 NOUN F
. 0 PUNCT F

After 0 ADP T
PBSCT 0 NOUN T
, 0 PUNCT F
the 0 DET F
time B-OTHER NOUN F
to I-OTHER PART F
achieve I-OTHER NOUN F
an I-OTHER DET F
absolute I-OTHER ADJ F
neutrophil I-OTHER NOUN F
count I-OTHER NOUN F
( I-OTHER PUNCT F
ANC I-OTHER NOUN T
) I-OTHER PUNCT F
of I-OTHER ADP F
> I-OTHER SYM F
0.5 0 NUM F
x B-OTHER SYM F
10 I-OTHER NUM F
( I-OTHER PUNCT F
9 I-OTHER NUM F
) I-OTHER PUNCT F
/L I-OTHER PUNCT F
in 0 ADP F
the 0 DET F
treatment 0 NOUN F
group 0 NOUN F
was 0 VERB F
less 0 ADV F
than 0 PUNCT F
that 0 CCONJ F
in 0 ADP F
the 0 DET F
control 0 NOUN F
group 0 NOUN F
( 0 PUNCT F
median 0 ADJ F
, 0 PUNCT F
11 0 NUM F
v 0 NUM F
12 0 NUM F
days 0 NOUN F
; 0 PUNCT F
the 0 DET F
log-rank 0 NOUN F
test 0 NOUN F
, 0 PUNCT F
P 0 NOUN T
=.046 0 ADV F
) 0 PUNCT F
, 0 PUNCT F
although 0 ADP F
the 0 DET F
last 0 ADJ F
day 0 NOUN F
of 0 ADP F
red 0 ADJ F
blood 0 NOUN F
cell 0 NOUN F
( 0 PUNCT F
RBC 0 NOUN T
) 0 PUNCT F
transfusion 0 NOUN F
( 0 PUNCT F
day 0 NOUN F
11 0 NUM F
v 0 NUM F
day 0 NOUN F
10 0 NUM F
) 0 PUNCT F
and 0 CCONJ F
the 0 DET F
duration 0 NOUN F
of 0 ADP F
febrile B-OTHER ADJ F
days I-OTHER NOUN F
( 0 PUNCT F
> 0 PROPN F
38 0 NUM F
degrees 0 NOUN F
C 0 NUM T
) 0 PUNCT F
after 0 ADP F
PBSCT 0 NOUN T
( 0 PUNCT F
4 0 NUM F
v 0 NUM F
4 0 NUM F
days 0 NOUN F
) 0 PUNCT F
were 0 VERB F
identical 0 ADJ F
in 0 ADP F
both 0 CCONJ F
groups 0 NOUN F
. 0 PUNCT F

However 0 ADV T
, 0 PUNCT F
platelet B-OTHER NOUN F
recovery I-OTHER NOUN F
to I-OTHER ADP F
> 0 ADP F
20 B-OTHER NUM F
x I-OTHER SYM F
10 B-OTHER NUM F
( 0 PUNCT F
9 B-OTHER NUM F
) 0 PUNCT F
/L 0 PUNCT F
was 0 VERB F
significantly 0 ADV F
longer 0 PUNCT F
in 0 ADP F
treatment 0 NOUN F
group 0 NOUN F
than 0 PUNCT F
control 0 NOUN F
group 0 NOUN F
( 0 PUNCT F
26 0 NUM F
v 0 NUM F
16 0 NUM F
days 0 NOUN F
; 0 PUNCT F
P 0 NOUN T
=.009 0 NUM F
) 0 PUNCT F
and 0 CCONJ F
> 0 SYM F
50 0 NUM F
x 0 SYM F
10 0 NUM F
( 0 PUNCT F
9 0 NUM F
) 0 PUNCT F
/L 0 PUNCT F
tended 0 VERB F
to 0 PART F
take 0 ADJ F
longer 0 PUNCT F
in 0 ADP F
the 0 DET F
treatment 0 NOUN F
group 0 NOUN F
( 0 PUNCT F
29 0 NUM F
v 0 NUM F
26 0 NUM F
days 0 NOUN F
; 0 PUNCT F
P 0 NOUN T
=.126 0 PUNCT F
) 0 PUNCT F
, 0 PUNCT F
with 0 ADP F
significantly 0 ADV F
more 0 DET F
platelet B-OTHER NOUN F
transfusion-dependent I-OTHER ADJ F
days B-OTHER NOUN F
( 0 PUNCT F
27 0 NUM F
v 0 NUM F
13 0 NUM F
days 0 NOUN F
; 0 PUNCT F
t-test 0 NOUN F
, 0 PUNCT F
P 0 NOUN T
=.037 0 ADV F
) 0 PUNCT F
. 0 PUNCT F

When 0 ADP T
patients 0 NOUN F
were 0 VERB F
divided 0 VERB F
into 0 ADP F
two 0 NUM F
different 0 ADJ F
disease 0 NOUN F
cohorts 0 NOUN F
, 0 PUNCT F
ALL 0 PUNCT T
patients 0 NOUN F
showed 0 VERB F
no 0 DET F
difference 0 NOUN F
in 0 ADP F
engraftment B-PHYSICAL ADJ F
kinetics I-PHYSICAL NOUN F
between 0 ADP F
the 0 DET F
G-CSF 0 NOUN T
treatment 0 NOUN F
and 0 CCONJ F
control 0 NOUN F
groups 0 NOUN F
, 0 PUNCT F
while 0 ADP F
differences 0 NOUN F
were 0 VERB F
seen 0 VERB F
in 0 ADP F
those 0 PUNCT F
with 0 ADP F
solid 0 ADJ F
tumors 0 NOUN F
. 0 PUNCT F

We 0 PRON T
concluded 0 VERB F
that 0 ADP F
the 0 DET F
marginal 0 ADJ F
clinical 0 ADJ F
benefit 0 NOUN F
of 0 ADP F
1 0 NUM F
day 0 NOUN F
earlier 0 PUNCT F

Comparative 0 ADJ T
efficacy 0 NOUN F
and 0 CCONJ F
safety 0 NOUN F
of 0 ADP F
calcium 0 NOUN F
carbasalate 0 VERB F
plus 0 CCONJ F
metoclopramide 0 CCONJ F
versus 0 CCONJ F
ergotamine 0 NOUN F
tartrate 0 NOUN F
plus 0 CCONJ F
caffeine 0 NOUN F
in 0 ADP F
the 0 DET F
treatment 0 NOUN F
of 0 ADP F
acute 0 ADJ F
migraine 0 NOUN F
attacks 0 NOUN F
. 0 PUNCT F

This 0 DET T
randomized 0 VERB F
, 0 PUNCT F
double-blind 0 ADJ F
, 0 PUNCT F
double-dummy 0 NOUN F
, 0 PUNCT F
multicenter 0 NOUN F
, 0 PUNCT F
parallel-group 0 NOUN F
study 0 NOUN F
aimed 0 PUNCT F
at 0 ADP F
comparing 0 PUNCT F
the 0 DET F
efficacy 0 NOUN F
and 0 CCONJ F
safety 0 NOUN F
of 0 ADP F
calcium 0 NOUN F
carbasalate 0 NOUN F
( 0 PUNCT F
equivalent 0 ADJ F
to 0 ADP F
900 0 NUM F
mg 0 NOUN F
aspirin 0 NOUN F
) 0 PUNCT F
plus 0 CCONJ F
metoclopramide 0 PUNCT F
10 0 NUM F
mg 0 NOUN F
( 0 PUNCT F
CM 0 NOUN T
) 0 PUNCT F
with 0 ADP F
ergotamine 0 NOUN F
tartrate 0 NOUN F
1 0 NUM F
mg 0 NOUN F
plus 0 CCONJ F
caffeine 0 NOUN F
100 0 NUM F
mg 0 NOUN F
( 0 PUNCT F
EC 0 NOUN T
) 0 PUNCT F
administered 0 VERB F
in 0 ADP F
the 0 DET F
treatment 0 NOUN F
of 0 ADP F
2 0 NUM F
acute 0 ADJ F
migraine 0 NOUN F
attacks 0 NOUN F
. 0 PUNCT F

A 0 DET T
total 0 NOUN F
of 0 ADP F
296 0 NUM F
patients 0 NOUN F
fulfilling 0 VERB F
the 0 DET F
International 0 ADJ T
Headache 0 NOUN T
Society 0 NOUN T
diagnostic 0 ADJ F
criteria 0 NOUN F
for 0 ADP F
migraine 0 NOUN F
were 0 VERB F
enrolled 0 VERB F
. 0 PUNCT F

In 0 ADP T
total 0 NOUN F
, 0 PUNCT F
one 0 NUM F
or 0 CCONJ F
two 0 NUM F
migraine 0 NOUN F
attacks 0 NOUN F
were 0 VERB F
treated 0 VERB F
in 0 ADP F
268 0 NUM F
and 0 CCONJ F
235 0 NUM F
patients 0 NOUN F
, 0 PUNCT F
respectively 0 ADV F
. 0 PUNCT F

The 0 DET T
primary 0 ADJ F
endpoint 0 NOUN F
for 0 ADP F
the 0 DET F
first 0 ADJ F
treated 0 VERB F
attack 0 NOUN F
was 0 VERB F
headache 0 ADJ F
relief 0 NOUN F
, 0 PUNCT F
with 0 ADP F
intensity 0 NOUN F
decreasing 0 CCONJ F
from 0 ADP F
moderate 0 ADJ F
or 0 CCONJ F
severe 0 ADJ F
to 0 ADP F
mild 0 ADJ F
or 0 CCONJ F
absent 0 ADJ F
2 0 NUM F
h 0 NOUN F
after 0 ADP F
drug 0 NOUN F
intake 0 NOUN F
. 0 PUNCT F

Usual 0 ADJ T
secondary 0 ADJ F
efficacy 0 NOUN F
endpoints 0 NOUN F
were 0 VERB F
assessed 0 VERB F
. 0 PUNCT F

A 0 DET T
superiority 0 NOUN F
of 0 ADP F
CM 0 NOUN T
over 0 ADP F
EC 0 NOUN T
was 0 VERB F
observed 0 VERB F
for 0 ADP F
both 0 CCONJ F
treated 0 VERB F
attacks 0 NOUN F
for 0 ADP F
the 0 DET F
main 0 ADJ F
endpoint 0 NOUN F
: 0 PUNCT F
success 0 NOUN F
in 0 ADP F
54 0 NUM F
versus 0 CCONJ F
36 0 NUM F
% 0 SYM F
, 0 PUNCT F
p 0 NOUN F
= 0 SYM F
0.003 0 NUM F
for 0 ADP F
the 0 DET F
first 0 ADJ F
attack 0 NOUN F
and 0 CCONJ F
60 0 NUM F
versus 0 CCONJ F
44 0 NUM F
% 0 SYM F
, 0 PUNCT F
p 0 NOUN F
= 0 SYM F
0.02 0 NUM F
for 0 ADP F
the 0 DET F
second 0 ADJ F
attack 0 NOUN F
. 0 PUNCT F

CM 0 NOUN T
was 0 VERB F
also 0 ADV F
significantly 0 ADV F
superior 0 ADJ F
to 0 ADP F
EC 0 NOUN T
during 0 ADP F
the 0 DET F
first 0 ADJ F
attack 0 NOUN F
for 0 ADP F
complete B-PHYSICAL ADJ F
headache I-PHYSICAL NOUN F
relief I-PHYSICAL NOUN F
( 0 PUNCT F
20 0 ADP F
vs. 0 CCONJ F
8 0 NUM F
% 0 SYM F
, 0 PUNCT F
p 0 NOUN F
= 0 SYM F
0.006 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
nausea B-ADVERSE-EFFECTS NOUN F
( 0 PUNCT F
42 0 NUM F
vs. 0 CCONJ F
63 0 NUM F
% 0 SYM F
, 0 PUNCT F
p 0 NOUN F
= 0 SYM F
0 0 NUM F
. 0 PUNCT F

007 0 NUM F
) 0 PUNCT F
and 0 CCONJ F
willingness B-MENTAL ADP F
to I-MENTAL ADP F
take I-MENTAL NOUN F
the I-MENTAL DET F
drug I-MENTAL NOUN F
again 0 ADV F
( 0 PUNCT F
90 0 NUM F
vs. 0 CCONJ F
80 0 NUM F
% 0 SYM F
, 0 PUNCT F
p 0 NOUN F
= 0 SYM F
0.043 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
global B-OTHER ADJ F
efficacy 0 NOUN F
evaluation B-OTHER NOUN F
, 0 PUNCT F
rated B-OTHER VERB F
by I-OTHER ADP F
the B-OTHER DET F
investigators I-OTHER NOUN F
, 0 PUNCT F
was 0 VERB F
significantly 0 ADV F
more 0 ADV F
favorable 0 ADJ F
to 0 ADP F
CM 0 NOUN T
for 0 ADP F
both 0 PUNCT F
attacks 0 NOUN F
( 0 PUNCT F
p 0 NOUN F
= 0 SYM F
0.001 0 NUM F
for 0 ADP F
the 0 DET F
first 0 ADJ F
attack 0 NOUN F
and 0 CCONJ F
p 0 NOUN F
= 0 SYM F
0.02 0 NUM F
for 0 ADP F
the 0 DET F
second 0 ADJ F
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
patients B-OTHER NOUN F
' 0 PUNCT F
evaluation B-OTHER NOUN F
was I-OTHER VERB F
significant B-OTHER ADJ F
for I-OTHER ADP F
the I-OTHER DET F
first B-OTHER ADJ F
attack I-OTHER NOUN F
( I-OTHER PUNCT F
p I-OTHER NOUN F
= I-OTHER SYM F
0.002 0 NUM F
) B-OTHER PUNCT F
. 0 PUNCT F

The 0 DET T
global B-ADVERSE-EFFECTS ADJ F
incidence 0 NOUN F
of B-ADVERSE-EFFECTS ADP F
adverse I-ADVERSE-EFFECTS ADJ F
events I-ADVERSE-EFFECTS NOUN F
was 0 VERB F
45 0 NUM F
% 0 SYM F
higher 0 PUNCT F
with 0 ADP F
EC 0 NOUN T
, 0 PUNCT F
though 0 CCONJ F
not 0 ADV F
significant 0 ADJ F
( 0 PUNCT F
32 0 ADP F
vs. 0 CCONJ F
22 0 NUM F
% 0 SYM F
, 0 PUNCT F
p 0 NOUN F
= 0 SYM F
0.075 0 PUNCT F
) 0 PUNCT F
. 0 PUNCT F

They 0 PUNCT T
were 0 VERB F
most 0 PUNCT F
often 0 ADV F
unspecific 0 ADJ F
and 0 CCONJ F
mild 0 ADJ F
to 0 ADP F
moderate 0 CCONJ F
in 0 ADP F
intensity 0 NOUN F
. 0 PUNCT F

The 0 DET T
Tiotropium 0 ADV T
Safety B-OTHER NOUN T
and 0 CCONJ F
Performance B-OTHER NOUN T
in 0 ADP F
Respimat 0 NOUN T
Trial 0 NOUN T
( 0 PUNCT F
TIOSPIR 0 NOUN T
) 0 PUNCT F
, 0 PUNCT F
a 0 DET F
large 0 ADJ F
scale 0 NOUN F
, 0 PUNCT F
randomized 0 VERB F
, 0 PUNCT F
controlled 0 PUNCT F
, 0 PUNCT F
parallel-group 0 NOUN F
trial-design 0 PUNCT F
and 0 CCONJ F
rationale 0 NOUN F
. 0 PUNCT F

BACKGROUND 0 NOUN T
Tiotropium 0 ADV T
bromide 0 NOUN F
is 0 VERB F
an 0 DET F
effective 0 ADJ F
therapy 0 NOUN F
for 0 ADP F
COPD 0 NOUN T
patients 0 NOUN F
. 0 PUNCT F

Comparing 0 ADJ T
across 0 ADP F
programs 0 NOUN F
tiotropium 0 PUNCT F
Respimat 0 NOUN T
Soft 0 NOUN T
Mist 0 NOUN T
inhaler 0 ADJ F
was 0 VERB F
at 0 VERB F
least 0 ADV F
as 0 PUNCT F
efficacious 0 ADJ F
as 0 PUNCT F
tiotropium 0 PUNCT F
HandiHaler 0 VERB T
, 0 PUNCT F
however 0 ADV F
, 0 PUNCT F
concerns 0 CCONJ F
have 0 PUNCT F
been 0 PUNCT F
raised 0 VERB F
about 0 PUNCT F
tiotropium 0 NOUN F
's 0 PUNCT F
safety 0 NOUN F
when 0 ADP F
given 0 VERB F
via 0 ADP F
Respimat 0 NOUN T
. 0 PUNCT F

METHODS 0 NOUN T
The 0 DET T
TIOSPIR 0 NOUN T
trial 0 NOUN F
( 0 PUNCT F
NCT01126437 0 NOUN T
) 0 PUNCT F
compares 0 ADP F
the 0 DET F
safety B-OTHER NOUN F
and 0 CCONJ F
efficacy 0 NOUN F
of 0 ADP F
tiotropium 0 ADV F
Respimat 0 NOUN T
5 0 ADP F
?g 0 PUNCT F
once 0 PUNCT F
daily 0 DET F
( 0 PUNCT F
marketed 0 PUNCT F
) 0 PUNCT F
and 0 CCONJ F
2.5 0 ADP F
?g 0 PUNCT F
once 0 PUNCT F
daily 0 DET F
( 0 PUNCT F
investigational 0 ADP F
) 0 PUNCT F
with 0 ADP F
tiotropium 0 PUNCT F
HandiHaler 0 CCONJ T
18 0 NUM F
? 0 PUNCT F

once 0 PUNCT F
daily 0 DET F
( 0 PUNCT F
marketed 0 PUNCT F
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
hypotheses 0 ADP F
to 0 PART F
be 0 PUNCT F
tested 0 VERB F
are 0 VERB F
1 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

that 0 ADP F
tiotropium 0 PUNCT F
Respimat 0 NOUN T
5 0 ADP F
?g 0 PUNCT F
once 0 PUNCT F
daily 0 ADJ F
and 0 CCONJ F
Respimat 0 NOUN T
2.5 0 NUM F
?g 0 PUNCT F
once 0 PUNCT F
daily 0 ADJ F
are 0 CCONJ F
non-inferior 0 ADJ F
to 0 ADP F
HandiHaler 0 PUNCT T
in 0 ADP F
terms 0 NOUN F
of 0 ADP F
all-cause 0 NOUN F
mortality 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
2 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

that 0 ADP F
tiotropium 0 PUNCT F
Respimat 0 NOUN T
5 0 ADP F
?g 0 PUNCT F
once 0 PUNCT F
daily 0 ADJ F
is 0 VERB F
superior 0 ADJ F
to 0 ADP F
HandiHaler 0 PUNCT T
in 0 ADP F
terms 0 NOUN F
of 0 ADP F
time 0 NOUN F
to 0 PUNCT F
first 0 ADJ F
exacerbation 0 NOUN F
. 0 PUNCT F

A 0 DET T
spirometry 0 NOUN F
substudy 0 NOUN F
evaluates 0 VERB F
the 0 DET F
bronchodilator 0 NOUN F
efficacy 0 NOUN F
. 0 PUNCT F

The 0 DET T
trial 0 NOUN F
is 0 VERB F
a 0 DET F
randomized 0 VERB F
, 0 PUNCT F
double-blind 0 ADJ F
, 0 PUNCT F
double 0 ADJ F
dummy 0 NOUN F
, 0 PUNCT F
event-driven 0 PUNCT F
, 0 PUNCT F
parallel 0 ADJ F
group 0 NOUN F
study 0 NOUN F
. 0 PUNCT F

Participants 0 NOUN T
can 0 PART F
use 0 NOUN F
any 0 DET F
background 0 NOUN F
treatment 0 NOUN F
for 0 ADP F
COPD 0 NOUN T
except 0 VERB F
inhaled 0 VERB F
anticholinergic 0 ADJ F
agents 0 NOUN F
. 0 PUNCT F

The 0 DET T
study 0 NOUN F
encompasses 0 PUNCT F
a 0 DET F
wide 0 ADJ F
range 0 NOUN F
of 0 ADP F
COPD 0 NOUN T
patients 0 NOUN F
, 0 PUNCT F
e.g 0 NUM F
. 0 PUNCT F

patients 0 NOUN F
with 0 ADP F
stable 0 ADJ F
cardiac 0 ADJ F
diseases 0 NOUN F
including 0 DET F
arrhythmia 0 NOUN F
can 0 VERB F
be 0 VERB F
included 0 VERB F
. 0 PUNCT F

Clinical 0 ADJ T
sites 0 NOUN F
are 0 VERB F
international 0 ADJ F
and 0 CCONJ F
include 0 VERB F
both 0 PUNCT F
primary 0 ADJ F
care 0 NOUN F
as 0 CCONJ F
well 0 PUNCT F
as 0 CCONJ F
specialists 0 NOUN F
. 0 PUNCT F

RESULTS 0 NOUN T
To 0 ADP T
date 0 NOUN F
, 0 PUNCT F
over 0 ADP F
17,000 0 NUM F
participants 0 NOUN F
have 0 ADP F
been 0 PUNCT F
randomized 0 VERB F
from 0 ADP F
over 0 CCONJ F
1200 0 NUM F
sites 0 NOUN F
in 0 ADP F
50 0 NUM F
countries 0 NOUN F
with 0 ADP F
an 0 DET F
anticipated 0 VERB F
treatment 0 NOUN F
duration 0 NOUN F
of 0 ADP F
2-3 0 NUM F
years 0 NOUN F
. 0 PUNCT F

CONCLUSION 0 NOUN T
TIOSPIR 0 NOUN T
will 0 VERB F
provide 0 VERB F
precise 0 ADJ F
estimates 0 NOUN F
of 0 ADP F
the 0 DET F
relative 0 ADJ F
safety 0 NOUN F
and 0 CCONJ F
efficacy 0 NOUN F
of 0 ADP F
the 0 DET F
Respimat 0 NOUN T
and 0 CCONJ F
HandiHaler 0 ADJ T
formulations 0 NOUN F
of 0 ADP F
tiotropium 0 NOUN F
, 0 PUNCT F
assess 0 NOUN F
potential 0 ADJ F
dose-dependence 0 NOUN F
of 0 ADP F
important 0 ADJ F
outcomes 0 NOUN F
and 0 CCONJ F
provide 0 VERB F
information 0 NOUN F
on 0 ADP F
the 0 DET F
clinical 0 ADJ F
epidemiology 0 NOUN F
of 0 ADP F
COPD 0 NOUN T
in 0 ADP F
a 0 DET F
large 0 ADJ F
international 0 ADJ F
patient 0 NOUN F
cohort 0 NOUN F
. 0 PUNCT F

Comparison 0 NOUN T
of 0 ADP F
dual-axis 0 NOUN F
rotational 0 ADJ F
coronary 0 ADJ F
angiography 0 NOUN F
( 0 PUNCT F
XPERSWING 0 PUNCT T
) 0 PUNCT F
versus 0 CCONJ F
conventional 0 ADJ F
technique 0 NOUN F
in 0 ADP F
routine 0 ADJ F
practice 0 NOUN F
. 0 PUNCT F

INTRODUCTION 0 NOUN T
AND 0 CCONJ T
OBJECTIVES 0 NOUN T
Coronary 0 ADJ T
angiography 0 NOUN F
is 0 VERB F
the 0 DET F
gold 0 PUNCT F
standard 0 NOUN F
for 0 ADP F
the 0 DET F
study 0 NOUN F
of 0 ADP F
coronary 0 ADJ F
artery 0 NOUN F
disease 0 NOUN F
. 0 PUNCT F

This 0 DET T
technique 0 NOUN F
requires 0 NOUN F
several 0 ADJ F
orthogonal 0 ADJ F
projections 0 NOUN F
. 0 PUNCT F

Rotational 0 ADJ T
angiography 0 NOUN F
is 0 VERB F
a 0 DET F
new 0 ADJ F
technique 0 NOUN F
which 0 ADP F
involves 0 NOUN F
pre-set 0 NOUN F
rotation 0 NOUN F
of 0 ADP F
the 0 DET F
X-ray 0 NOUN T
tube 0 NOUN F
around 0 ADP F
the 0 DET F
patient 0 NOUN F
and 0 CCONJ F
allows 0 NOUN F
visualization 0 NOUN F
of 0 ADP F
each 0 ADP F
coronary 0 ADJ F
artery 0 NOUN F
in 0 ADP F
different 0 ADJ F
views 0 CCONJ F
, 0 PUNCT F
using 0 VERB F
a 0 DET F
single 0 ADJ F
contrast 0 NOUN F
injection 0 NOUN F
. 0 PUNCT F

The 0 DET T
purpose 0 NOUN F
of 0 ADP F
this 0 DET F
study 0 NOUN F
was 0 VERB F
to 0 ADV F
compare 0 NOUN F
conventional 0 ADJ F
coronary 0 ADJ F
angiography 0 NOUN F
( 0 PUNCT F
A 0 NOUN T
) 0 PUNCT F
vs 0 CCONJ F
rotational 0 ADJ F
angiography 0 NOUN F
( 0 PUNCT F
B 0 NOUN T
) 0 PUNCT F
, 0 PUNCT F
focusing 0 VERB F
on 0 ADP F
radiation 0 NOUN F
dose 0 NOUN F
, 0 PUNCT F
amount 0 NOUN F
of 0 ADP F
contrast 0 NOUN F
administered 0 ADP F
, 0 PUNCT F
and 0 CCONJ F
total 0 ADJ F
procedure 0 NOUN F
time 0 NOUN F
for 0 ADP F
both 0 CCONJ F
diagnostic 0 ADJ F
and 0 CCONJ F
therapeutic 0 ADJ F
percutaneous 0 ADJ F
coronary 0 ADJ F
interventions 0 NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
Prospective 0 ADJ T
study 0 NOUN F
of 0 ADP F
104 0 NUM F
consecutive 0 ADJ F
patients 0 NOUN F
undergoing 0 VERB F
coronary 0 ADJ F
angiography 0 NOUN F
who 0 ADP F
were 0 VERB F
randomized 0 VERB F
to 0 ADP F
one 0 PUNCT F
of 0 ADP F
these 0 DET F
techniques 0 NOUN F
. 0 PUNCT F

RESULTS 0 NOUN T
We 0 PRON T
found 0 VERB F
a 0 DET F
significant 0 ADJ F
reduction 0 NOUN F
in 0 ADP F
the 0 DET F
amount B-OTHER NOUN F
of I-OTHER ADP F
contrast 0 NOUN F
administered B-OTHER PUNCT F
( 0 PUNCT F
A 0 NOUN T
vs 0 CCONJ F
B 0 NOUN T
, 0 PUNCT F
93.1 0 NUM F
[ 0 PUNCT F
41.7 0 PUNCT F
] 0 PUNCT F
vs 0 CCONJ F
50.9 0 ADP F
[ 0 PUNCT F
14.7 0 NUM F
] 0 PUNCT F
mL 0 NOUN F
; 0 PUNCT F
P 0 NOUN T
< 0 SYM F
.0001 0 NUM F
) 0 PUNCT F
and 0 CCONJ F
radiation B-OTHER NOUN F
exposure I-OTHER NOUN F
( 0 PUNCT F
27.6 0 NUM F
[ 0 PUNCT F
11.5 0 PUNCT F
] 0 PUNCT F
vs 0 CCONJ F
18 0 NUM F
[ 0 PUNCT F
6.4 0 NUM F
] 0 PUNCT F
mGycm 0 NOUN F
( 0 PUNCT F
2 0 NUM F
) 0 PUNCT F
; 0 PUNCT F
P 0 NOUN T
< 0 SYM F
.0001 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

A 0 DET T
significant 0 ADJ F
increase 0 NOUN F
in 0 ADP F
total 0 ADJ F
procedure B-OTHER NOUN F
time I-OTHER NOUN F
was 0 VERB F
noted 0 VERB F
in 0 ADP F
the 0 DET F
rotational 0 ADJ F
angiography 0 NOUN F
arm 0 NOUN F
. 0 PUNCT F

However 0 ADV T
, 0 PUNCT F
when 0 ADP F
only 0 ADV F
the 0 DET F
last 0 ADJ F
50 0 NUM F
patients 0 NOUN F
were 0 VERB F
analyzed 0 VERB F
, 0 PUNCT F
we 0 PRON F
found 0 VERB F
no 0 DET F
difference 0 NOUN F
in 0 ADP F
procedure B-OTHER NOUN F
time B-OTHER NOUN F
between 0 ADP F
the 0 DET F
groups 0 NOUN F
, 0 PUNCT F
probably 0 ADV F
related 0 VERB F
to 0 ADP F
the 0 DET F
learning 0 VERB F
curve 0 NOUN F
of 0 ADP F
the 0 DET F
operators 0 NOUN F
. 0 PUNCT F

Angioplasty B-PHYSICAL NOUN T
was 0 VERB F
performed 0 VERB F
in 0 ADP F
29 0 NUM F
patients 0 NOUN F
in 0 ADP F
group 0 NOUN F
A 0 NOUN T
and 0 CCONJ F
28 0 NUM F
patients 0 NOUN F
in 0 ADP F
group 0 NOUN F
B 0 NOUN T
. 0 PUNCT F

Contrast 0 NOUN T
reduction B-OTHER NOUN F
was 0 VERB F
maintained 0 VERB F
in 0 ADP F
the 0 DET F
rotational 0 ADJ F
angiography 0 NOUN F
group 0 NOUN F
compared 0 VERB F
to 0 ADP F
the 0 DET F
conventional 0 ADJ F
technique 0 NOUN F
( 0 PUNCT F
A 0 NOUN T
vs 0 CCONJ F
B 0 NOUN T
, 0 PUNCT F
335.1 0 NUM F
[ 0 PUNCT F
192.1 0 ADP F
] 0 PUNCT F
vs 0 CCONJ F
238.5 0 ADP F
[ 0 PUNCT F
114.4 0 ADP F
] 0 PUNCT F
mL 0 NOUN F
; 0 PUNCT F
P=.02 0 PUNCT T
) 0 PUNCT F
. 0 PUNCT F

CONCLUSIONS 0 NOUN T
The 0 DET T
rotational 0 ADJ F
angiography 0 NOUN F
technique 0 NOUN F
leads 0 NOUN F
to 0 ADP F
a 0 DET F
significant 0 ADJ F
decrease 0 NOUN F
in 0 PUNCT F

Depressive 0 ADJ T
mood 0 PUNCT F
symptoms 0 NOUN F
associated 0 VERB F
with 0 ADP F
ovarian 0 ADJ F
suppression 0 NOUN F
. 0 PUNCT F

OBJECTIVE 0 NOUN T
To 0 PROPN T
determine 0 NOUN F
if 0 PUNCT F
sertraline 0 NOUN F
is 0 VERB F
helpful 0 ADJ F
in 0 ADP F
the 0 DET F
management 0 NOUN F
of 0 ADP F
depressive 0 ADJ F
symptoms 0 NOUN F
associated 0 VERB F
with 0 ADP F
ovarian 0 ADJ F
suppression 0 NOUN F
during 0 ADP F
GnRH 0 NOUN T
agonist 0 NOUN F
therapy 0 NOUN F
as 0 VERB F
compared 0 VERB F
with 0 ADP F
a 0 DET F
placebo-controlled 0 VERB F
group 0 NOUN F
. 0 PUNCT F

DESIGN 0 NOUN T
Double-blind 0 ADJ T
placebo-controlled 0 DET F
prospective 0 ADJ F
study 0 NOUN F
design 0 NOUN F
. 0 PUNCT F

SETTING 0 NUM T
An 0 DET T
obstetrics/gynecological 0 ADJ F
office 0 NOUN F
specializing 0 NUM F
in 0 ADP F
infertility 0 NOUN F
in 0 ADP F
an 0 DET F
academic 0 ADJ F
environment 0 NOUN F
. 0 PUNCT F

PATIENT 0 NOUN T
( 0 PUNCT F
S 0 NOUN T
) 0 PUNCT F
Premenstrual 0 ADJ T
women 0 NOUN F
with 0 ADP F
laparoscopically 0 ADV F
diagnosed 0 VERB F
endometriosis 0 NOUN F
who 0 ADP F
required 0 VERB F
GnRH 0 NOUN T
agonist 0 NOUN F
therapy 0 NOUN F
for 0 ADP F
treatment 0 NOUN F
and 0 CCONJ F
did 0 DET F
not 0 ADV F
have 0 PUNCT F
significant 0 ADJ F
depressive 0 ADJ F
or 0 CCONJ F
premenstrual 0 ADJ F
mood 0 ADJ F
symptoms 0 NOUN F
at 0 ADP F
baseline 0 NOUN F
. 0 PUNCT F

INTERVENTION 0 NOUN T
( 0 PUNCT F
S 0 NOUN T
) 0 PUNCT F
Participants 0 PUNCT T
were 0 VERB F
randomly 0 ADV F
assigned 0 VERB F
to 0 ADP F
either 0 CCONJ F
the 0 DET F
sertraline 0 NOUN F
treatment 0 NOUN F
group 0 NOUN F
or 0 CCONJ F
to 0 ADP F
the 0 DET F
placebo 0 NOUN F
group 0 NOUN F
for 0 ADP F
the 0 DET F
3-month 0 NOUN F
duration 0 NOUN F
of 0 ADP F
the 0 DET F
GnRH 0 NOUN T
agonist 0 NOUN F
therapy 0 NOUN F
. 0 PUNCT F

MAIN 0 ADJ T
OUTCOME 0 NOUN T
MEASURE 0 NOUN T
( 0 PUNCT F
S 0 NOUN T
) 0 PUNCT F
The 0 DET T
21-item 0 NOUN F
Hamilton 0 PUNCT T
Rating 0 PUNCT T
Scale 0 NOUN T
for 0 ADP F
Depression 0 NOUN T
( 0 PUNCT F
HRSD 0 NOUN T
) 0 PUNCT F
, 0 PUNCT F
which 0 ADP F
is 0 VERB F
an 0 DET F
instrument 0 ADJ F
designed 0 PRON F
to 0 PART F
assess 0 ADJ F
depressive 0 ADJ F
symptomatology 0 NOUN F
. 0 PUNCT F

RESULT 0 NOUN T
( 0 PUNCT F
S 0 NOUN T
) 0 PUNCT F
A 0 DET T
Hotellings 0 NOUN T
T 0 NOUN T
( 0 PUNCT F
2 0 NUM F
) 0 PUNCT F
test 0 NOUN F
for 0 ADP F
repeated 0 VERB F
measure 0 ADV F
analysis 0 NOUN F
indicated 0 VERB F
a 0 DET F
statistically 0 ADV F
significant 0 ADJ F
( 0 PUNCT F
P 0 NOUN T
< 0 SYM F
.05 0 NUM F
) 0 PUNCT F
between-group 0 ADP F
difference 0 NOUN F
across 0 ADP F
time 0 NOUN F
for 0 ADP F
the 0 DET F
HRSD 0 NOUN T
( 0 PUNCT F
T 0 NOUN T
( 0 PUNCT F
2 0 NUM F
) 0 PUNCT F
= 0 ADP F
13.3 0 NUM F
; 0 PUNCT F
F 0 NOUN T
[ 0 PUNCT F
3 0 NUM F
, 0 PUNCT F
28 0 NUM F
] 0 PUNCT F
= 0 ADP F
4.1 0 NUM F
; 0 PUNCT F
P=.02 0 PUNCT T
) 0 PUNCT F
with 0 ADP F
the 0 DET F
sertraline 0 NOUN F
treatment 0 NOUN F
group 0 NOUN F
manifesting 0 VERB F
significantly 0 ADV F
fewer 0 PUNCT F
depressive B-MENTAL ADJ F
symptoms I-MENTAL NOUN F
than 0 PUNCT F
the 0 DET F
control 0 NOUN F
group 0 NOUN F
. 0 PUNCT F

CONCLUSION 0 NOUN T
( 0 PUNCT F
S 0 NOUN T
) 0 PUNCT F
The 0 DET T
results 0 ADV F
indicate 0 VERB F
that 0 ADP F
sertraline 0 NOUN F
is 0 VERB F
an 0 DET F
effective 0 ADJ F
option 0 NOUN F
in 0 ADP F
the 0 DET F
management 0 NOUN F
of 0 ADP F
depressive 0 ADJ F
mood 0 PUNCT F
symptoms 0 NOUN F
associated 0 VERB F
with 0 ADP F
ovarian 0 ADJ F
suppression 0 NOUN F
during 0 ADP F
GnRH 0 NOUN T
agonist 0 NOUN F
therapy 0 NOUN F
. 0 PUNCT F

Predictors 0 NOUN T
of 0 ADP F
smoking 0 VERB F
cessation 0 NOUN F
among 0 ADP F
cancer 0 NOUN F
patients 0 NOUN F
enrolled 0 VERB F
in 0 ADP F
a 0 DET F
smoking 0 VERB F
cessation 0 NOUN F
program 0 NOUN F
. 0 PUNCT F

UNLABELLED 0 PUNCT T
Many 0 ADP T
cancer 0 NOUN F
patients 0 NOUN F
continue 0 VERB F
to 0 ADP F
smoke 0 ADP F
postdiagnosis 0 NOUN F
, 0 PUNCT F
which 0 ADP F
is 0 VERB F
associated 0 VERB F
with 0 ADP F
poorer 0 PUNCT F
clinical 0 ADJ F
outcomes 0 NOUN F
. 0 PUNCT F

Identifying 0 PUNCT T
prospective 0 ADJ F
predictors 0 NOUN F
of 0 ADP F
smoking 0 VERB F
cessation 0 NOUN F
among 0 ADP F
patients 0 NOUN F
currently 0 ADV F
receiving 0 CCONJ F
smoking 0 VERB F
cessation 0 NOUN F
treatment 0 NOUN F
can 0 VERB F
help 0 ADP F
guide 0 PUNCT F
the 0 DET F
development 0 NOUN F
and 0 CCONJ F
implementation 0 NOUN F
of 0 ADP F
smoking 0 VERB F
cessation 0 NOUN F
programs 0 NOUN F
with 0 ADP F
this 0 DET F
population 0 NOUN F
. 0 PUNCT F

MATERIAL 0 NOUN T
AND 0 CCONJ T
METHODS 0 PUNCT T
Data 0 NOUN T
from 0 ADP F
246 0 NUM F
cancer 0 NOUN F
patients 0 NOUN F
participating 0 VERB F
in 0 ADP F
a 0 DET F
randomized 0 VERB F
placebo-controlled 0 VERB F
smoking 0 ADJ F
cessation 0 NOUN F
clinical 0 ADJ F
trial 0 NOUN F
were 0 VERB F
used 0 VERB F
to 0 PART F
examine 0 NOUN F
baseline 0 NOUN F
predictors 0 NOUN F
of 0 ADP F
end-of-treatment 0 PUNCT F
and 0 CCONJ F
six-month 0 NOUN F
postbaseline 0 NOUN F
smoking 0 ADP F
cessation 0 NOUN F
outcomes 0 NOUN F
. 0 PUNCT F

Baseline 0 NOUN T
demographic 0 ADJ F
, 0 PUNCT F
smoking-related 0 ADJ F
, 0 PUNCT F
disease-related 0 VERB F
, 0 PUNCT F
and 0 CCONJ F
psychological 0 ADJ F
variables 0 NOUN F
were 0 PROPN F
examined 0 VERB F
as 0 ADP F
predictors 0 NOUN F
of 0 ADP F
biochemically-confirmed 0 ADJ F
point-prevalence 0 NOUN F
abstinence 0 NOUN F
. 0 PUNCT F

RESULTS 0 DET T
Multivariate B-OTHER ADJ T
analysis 0 NOUN F
indicated 0 VERB F
that 0 ADP F
, 0 PUNCT F
for 0 ADP F
end-of-treatment B-MENTAL PUNCT F
abstinence I-MENTAL NOUN F
, 0 PUNCT F
patients 0 NOUN F
were 0 VERB F
significantly 0 ADV F
more 0 ADV F
likely 0 ADJ F
to 0 PART F
have 0 PUNCT F
quit B-MENTAL NOUN F
smoking I-MENTAL NUM F
if 0 PUNCT F
they 0 PRON F
were 0 PRON F
older 0 PUNCT F
( 0 PUNCT F
OR 0 NOUN T
= 0 SYM F
1.06 0 NUM F
, 0 PUNCT F
95 0 NUM F
% 0 SYM F
CI 0 NOUN T
: 0 PUNCT F
1.03-1.10 0 NUM F
, 0 PUNCT F
p 0 NOUN F
< 0 SYM F
0.05 0 NUM F
) 0 PUNCT F
and 0 CCONJ F
were 0 VERB F
diagnosed 0 VERB F
with 0 ADP F
a 0 DET F
non-tobacco 0 NOUN F
related 0 VERB F
cancer 0 NOUN F
( 0 PUNCT F
OR 0 NOUN T
= 0 ADP F
2.54 0 NUM F
, 0 PUNCT F
95 0 NUM F
% 0 SYM F
CI 0 NOUN T
: 0 PUNCT F
1.24-5.20 0 NUM F
, 0 PUNCT F
p 0 NOUN F
< 0 SYM F
0.05 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Likewise 0 ADV T
, 0 PUNCT F
for 0 ADP F
six-month B-MENTAL NOUN F
abstinence I-MENTAL NOUN F
, 0 PUNCT F
patients 0 NOUN F
were 0 VERB F
significantly 0 ADV F
more 0 ADV F
likely 0 ADJ F
to 0 PART F
have 0 PUNCT F
quit B-MENTAL NOUN F
smoking I-MENTAL NUM F
if 0 PUNCT F
they 0 PRON F
were 0 PRON F
older 0 PUNCT F
( 0 PUNCT F
OR 0 NOUN T
= 0 SYM F
1.04 0 PUNCT F
, 0 PUNCT F
95 0 NUM F
% 0 SYM F
CI 0 NOUN T
: 0 PUNCT F
1.01-1.08 0 NUM F
, 0 PUNCT F
p 0 NOUN F
< 0 SYM F
0.05 0 NUM F
) 0 PUNCT F
and 0 CCONJ F
were 0 VERB F
significantly 0 ADV F
less 0 ADV F
likely 0 ADJ F
to 0 PART F
have 0 PUNCT F
quit 0 NOUN F
smoking 0 NUM F
if 0 PUNCT F
they 0 PRON F
were 0 PUNCT F
female 0 NOUN F
( 0 PUNCT F
OR 0 NOUN T
= 0 SYM F
0.47 0 NUM F
, 0 PUNCT F
95 0 NUM F
% 0 SYM F
CI 0 NOUN T
: 0 PUNCT F
0.22-0.97 0 NUM F
, 0 PUNCT F
p 0 NOUN F
< 0 SYM F
0.05 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Patients 0 NOUN T
with 0 ADP F
tobacco-related 0 VERB F
cancers 0 NOUN F
and 0 CCONJ F
female 0 NOUN F
patients 0 NOUN F
reported 0 VERB F
significantly 0 ADV F
higher 0 PUNCT F
levels B-MENTAL NOUN F
of I-MENTAL ADP F
depression I-MENTAL NOUN F
symptoms I-MENTAL NOUN F
( 0 PUNCT F
p 0 NOUN F
< 0 SYM F
0.05 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
which 0 ADP F
proved 0 CCONJ F
predictive B-MENTAL ADJ F
of I-MENTAL ADP F
smoking I-MENTAL ADJ F
relapse I-MENTAL NOUN F
. 0 PUNCT F

CONCLUSIONS 0 DET T
Patient 0 NOUN T
age 0 NOUN F
, 0 PUNCT F
gender 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
cancer-type 0 NOUN F
may 0 VERB F
be 0 VERB F
important 0 ADJ F
factors 0 NOUN F
to 0 PART F
consider 0 NOUN F
when 0 CCONJ F
developing 0 ADP F
and 0 CCONJ F
implementing 0 PUNCT F
smoking 0 ADP F
cessation 0 NOUN F
interventions 0 NOUN F
for 0 ADP F
cancer 0 NOUN F
patients 0 NOUN F
. 0 PUNCT F

A 0 DET T
placebo-controlled 0 VERB F
, 0 PUNCT F
randomized 0 VERB F
clinical 0 ADJ F
trial 0 NOUN F
using 0 VERB F
testosterone 0 NOUN F
undecanoate 0 ADP F
with 0 ADP F
injectable 0 ADJ F
norethisterone 0 NOUN F
enanthate 0 PUNCT F
: 0 PUNCT F
effect 0 NOUN F
on 0 ADP F
anthropometric 0 ADJ F
, 0 PUNCT F
metabolic 0 ADJ F
and 0 CCONJ F
biochemical 0 ADJ F
parameters 0 NOUN F
. 0 PUNCT F

Testosterone 0 NOUN T
administered 0 ADP F
alone 0 ADJ F
or 0 CCONJ F
in 0 ADP F
combination 0 NOUN F
with 0 ADP F
progestogens 0 NOUN F
in 0 ADP F
male 0 NOUN F
contraception 0 NOUN F
induces 0 NOUN F
reversible 0 ADJ F
oligo-azoospermia 0 NOUN F
, 0 PUNCT F
but 0 CCONJ F
its 0 ADJ F
effects 0 NOUN F
on 0 ADP F
body 0 NOUN F
composition 0 NOUN F
and 0 CCONJ F
metabolism 0 NOUN F
are 0 VERB F
less 0 ADV F
known 0 NOUN F
. 0 PUNCT F

We 0 PRON T
analysed 0 VERB F
anthropometric 0 ADJ F
and 0 CCONJ F
metabolic 0 ADJ F
parameters 0 NOUN F
in 0 ADP F
five 0 DET F
groups 0 NOUN F
of 0 ADP F
10 0 NUM F
males 0 NOUN F
: 0 PUNCT F
four 0 NUM F
receiving 0 SYM F
testosterone 0 NOUN F
undecanoate 0 NOUN F
( 0 PUNCT F
TU 0 ADV T
: 0 PUNCT F
1000 0 NUM F
mg 0 NOUN F
) 0 PUNCT F
plus 0 CCONJ F
norethisterone 0 NOUN F
enanthate 0 PUNCT F
( 0 PUNCT F
NETE 0 NOUN T
: 0 PUNCT F
200 0 NUM F
mg 0 NOUN F
) 0 PUNCT F
at 0 ADP F
different 0 ADJ F
intervals 0 NOUN F
( 0 PUNCT F
every 0 ADP F
8 0 NUM F
weeks 0 NOUN F
: 0 PUNCT F
NETE-8 0 NOUN T
; 0 PUNCT F
every 0 DET F
12 0 NUM F
weeks 0 NOUN F
: 0 PUNCT F
NETE-12 0 NOUN T
; 0 PUNCT F
every 0 DET F
6 0 NUM F
weeks 0 NOUN F
for 0 ADP F
12 0 NUM F
weeks 0 NOUN F
and 0 CCONJ F
then 0 ADP F
every 0 DET F
12 0 NUM F
weeks 0 NOUN F
: 0 PUNCT F
NETE-6/12 0 NOUN T
; 0 PUNCT F
every 0 DET F
6 0 NUM F
weeks 0 NOUN F
for 0 ADP F
12 0 NUM F
weeks 0 NOUN F
and 0 CCONJ F
then 0 ADV F
TU 0 ADV T
plus 0 CCONJ F
placebo 0 NOUN F
every 0 DET F
12 0 NUM F
weeks 0 NOUN F
: 0 PUNCT F
NETE-6/12/0 0 NOUN T
) 0 PUNCT F
and 0 CCONJ F
one 0 NUM F
placebo 0 NOUN F
( 0 PUNCT F
NETE-0/0 0 PUNCT T
) 0 PUNCT F
for 0 ADP F
a 0 DET F
total 0 NOUN F
of 0 ADP F
48 0 NUM F
weeks 0 NOUN F
. 0 PUNCT F

Body 0 NOUN T
mass 0 NOUN F
index 0 NOUN F
( B-PHYSICAL PUNCT F
BMI 0 NOUN T
) B-PHYSICAL PUNCT F
and I-PHYSICAL CCONJ F
waist I-PHYSICAL NOUN F
circumference I-PHYSICAL NOUN F
did I-PHYSICAL PUNCT F
not I-PHYSICAL ADV F
change B-PHYSICAL NUM F
in 0 ADP F
any 0 DET F
groups 0 NOUN F
except 0 PUNCT F
for 0 ADP F
the 0 DET F
NETE-8 0 NOUN T
in 0 ADP F
which 0 ADP F
BMI 0 NOUN T
increased 0 VERB F
significantly B-PHYSICAL ADV F
( 0 PUNCT F
p 0 NOUN F
= 0 SYM F
0.02 0 NUM F
) 0 PUNCT F
at 0 ADP F
the 0 DET F
end 0 NOUN F
of 0 ADP F
the 0 DET F
treatment 0 NOUN F
period 0 NOUN F
. 0 PUNCT F

Lean B-PHYSICAL ADJ T
body I-PHYSICAL NOUN F
mass I-PHYSICAL NOUN F
( I-PHYSICAL PUNCT F
MAMC I-PHYSICAL NOUN T
or B-PHYSICAL CCONJ F
AMA I-PHYSICAL NOUN T
) B-PHYSICAL PUNCT F
increased 0 VERB F
significantly B-PHYSICAL ADV F
in 0 ADP F
the 0 DET F
highest 0 PUNCT F
hormonal 0 ADJ F
dose 0 NOUN F
groups 0 NOUN F
( 0 PUNCT F
p 0 NOUN F
= 0 SYM F
0.04 0 NUM F
, 0 PUNCT F
NETE-6/12 0 NOUN T
; 0 PUNCT F
p 0 NOUN F
= 0 SYM F
0.004 0 NUM F
, 0 PUNCT F
NETE-8 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

No 0 DET T
differences 0 NOUN F
were 0 VERB F
observed 0 VERB F
in 0 ADP F
glucose 0 NOUN F
levels 0 NOUN F
, 0 PUNCT F
insulin 0 NOUN F
sensitivity 0 NOUN F
index 0 NOUN F
and 0 CCONJ F
lipid 0 NOUN F
profile 0 NOUN F
as 0 PUNCT F
well 0 PUNCT F
as 0 CCONJ F
in 0 PUNCT F

Scent 0 ADJ T
and 0 CCONJ F
mood 0 PUNCT F
state 0 NOUN F
following 0 VERB F
an 0 DET F
anxiety-provoking 0 DET F
task 0 NOUN F
. 0 PUNCT F

The 0 DET T
purpose 0 NOUN F
of 0 ADP F
this 0 DET F
study 0 NOUN F
was 0 VERB F
to 0 ADV F
assess 0 NOUN F
the 0 DET F
effects 0 NOUN F
of 0 ADP F
water 0 NOUN F
, 0 PUNCT F
lavender 0 PUNCT F
, 0 PUNCT F
or 0 CCONJ F
rosemary 0 ADJ F
scent 0 ADJ F
on 0 ADP F
physiology B-MENTAL NOUN F
and 0 CCONJ F
mood B-MENTAL PUNCT F
state I-MENTAL NOUN F
following 0 VERB F
an 0 DET F
anxiety-provoking 0 DET F
task 0 NOUN F
. 0 PUNCT F

The 0 DET T
nonsmoking 0 ADJ F
participants 0 NOUN F
, 0 PUNCT F
ages 0 NOUN F
18-30 0 NUM F
years 0 NOUN F
, 0 PUNCT F
included 0 VERB F
42 0 NUM F
women 0 NOUN F
and 0 CCONJ F
31 0 NUM F
men 0 NOUN F
who 0 ADP F
reported 0 VERB F
demographic 0 ADJ F
information 0 NOUN F
and 0 CCONJ F
measures 0 NOUN F
of 0 ADP F
external 0 ADJ F
temperature 0 NOUN F
and 0 CCONJ F
heart 0 NOUN F
rate 0 NOUN F
were 0 VERB F
taken 0 VERB F
prior 0 PUNCT F
to 0 ADP F
introduction 0 NOUN F
of 0 ADP F
an 0 DET F
anxiety-eliciting 0 VERB F
task 0 NOUN F
and 0 CCONJ F
exposure 0 NOUN F
to 0 ADP F
lavender 0 PUNCT F
, 0 PUNCT F
rosemary 0 ADJ F
, 0 PUNCT F
or 0 CCONJ F
water 0 NOUN F
scents 0 NOUN F
. 0 PUNCT F

Following 0 VERB T
the 0 DET F
task 0 NOUN F
, 0 PUNCT F
participants 0 NOUN F
completed 0 ADV F
the 0 DET F
Profile 0 NOUN T
of 0 ADP F
Mood 0 PUNCT T
States 0 NOUN T
to 0 PART F
assess 0 PUNCT F
mood B-MENTAL ADP F
, 0 PUNCT F
and 0 CCONJ F
temperature B-PHYSICAL NOUN F
and 0 CCONJ F
heart B-PHYSICAL NOUN F
rate I-PHYSICAL NOUN F
were 0 VERB F
reassessed 0 PROPN F
. 0 PUNCT F

Participants 0 NOUN T
rated 0 VERB F
the 0 DET F
pleasantness 0 NOUN F
of 0 ADP F
the 0 DET F
scent 0 ADJ F
received 0 PUNCT F
. 0 PUNCT F

When 0 ADP T
pleasantness 0 ADJ F
ratings 0 NOUN F
of 0 ADP F
scent 0 ADJ F
were 0 VERB F
covaried 0 VERB F
, 0 PUNCT F
physiological B-PHYSICAL ADJ F
changes I-PHYSICAL NOUN F
in I-PHYSICAL ADP F
temperature I-PHYSICAL NOUN F
and 0 CCONJ F
heart B-PHYSICAL NOUN F
rate I-PHYSICAL NOUN F
did 0 PUNCT F
not 0 ADV F
differ 0 VERB F
based 0 VERB F
on 0 ADP F
scent 0 ADJ F
exposure 0 NOUN F
, 0 PUNCT F
but 0 CCONJ F
mood B-MENTAL PUNCT F
ratings I-MENTAL NOUN F
differed 0 VERB F
by 0 ADP F
scent 0 ADJ F
condition 0 NOUN F
. 0 PUNCT F

Participants 0 NOUN T
in 0 ADP F
the 0 DET F
rosemary 0 NOUN F
condition 0 NOUN F
scored 0 PUNCT F
higher 0 PUNCT F
on 0 ADP F
measures 0 NOUN F
of 0 ADP F
tension-anxiety B-MENTAL NOUN F
and 0 CCONJ F
confusion-bewilderment B-MENTAL PUNCT F
relative 0 ADJ F
to 0 ADP F
the 0 PUNCT F
lavender 0 PUNCT F
and 0 CCONJ F
control 0 NOUN F
conditions 0 NOUN F
. 0 PUNCT F

The 0 DET T
lavender 0 ADJ F
and 0 CCONJ F
control 0 NOUN F
conditions 0 NOUN F
showed 0 VERB F
higher 0 PUNCT F
mean 0 NOUN F
vigor-activity B-MENTAL NOUN F
ratings I-MENTAL NOUN F
relative 0 ADJ F
to 0 ADP F
the 0 DET F
rosemary 0 NOUN F
group 0 NOUN F
, 0 PUNCT F
while 0 ADP F
both 0 CCONJ F
rosemary 0 ADJ F
and 0 CCONJ F
lavender 0 PUNCT F
scents 0 NOUN F
were 0 VERB F
associated 0 VERB F
with 0 ADP F
lower 0 PUNCT F
mean 0 NOUN F
ratings B-MENTAL NOUN F
on I-MENTAL ADP F
the I-MENTAL DET F
fatigue-inertia I-MENTAL NOUN F
subscale I-MENTAL NOUN F
, 0 PUNCT F
relative 0 ADJ F
to 0 ADP F
the 0 DET F
control 0 NOUN F
group 0 NOUN F
. 0 PUNCT F

These 0 DET T
results 0 CCONJ F
suggest 0 VERB F
that 0 ADP F
, 0 PUNCT F
when 0 ADP F
individual 0 ADJ F
perception 0 NOUN F
of 0 ADP F
scent 0 ADJ F
pleasantness 0 NOUN F
is 0 VERB F
controlled 0 NOUN F
, 0 PUNCT F
scent 0 ADJ F
has 0 PUNCT F
the 0 DET F
potential 0 ADJ F
to 0 ADP F
moderate 0 ADJ F
different 0 ADJ F
aspects 0 NOUN F
of 0 ADP F
mood 0 PUNCT F
following 0 ADP F
an 0 DET F
anxiety-provoking 0 DET F
task 0 NOUN F
. 0 PUNCT F

Effect 0 NOUN T
of 0 ADP F
prophylactic 0 ADP F
amiodarone 0 NOUN F
in 0 ADP F
patients 0 NOUN F
with 0 ADP F
rheumatic 0 ADJ F
valve 0 NOUN F
disease 0 NOUN F
undergoing 0 VERB F
valve 0 NOUN F
replacement 0 NOUN F
surgery 0 NOUN F
. 0 PUNCT F

The 0 DET T
study 0 NOUN F
was 0 ADV F
carried 0 VERB F
out 0 ADP F
to 0 PART F
evaluate 0 NOUN F
the 0 DET F
effect 0 NOUN F
of 0 ADP F
prophylactic 0 ADP F
single-dose 0 NOUN F
intravenous 0 ADJ F
amiodarone 0 NOUN F
in 0 ADP F
patients 0 NOUN F
undergoing 0 VERB F
valve 0 NOUN F
replacement 0 NOUN F
surgery 0 NOUN F
. 0 PUNCT F

Maintenance 0 NOUN T
of 0 ADP F
sinus 0 NOUN F
rhythm 0 NOUN F
is 0 VERB F
better 0 PUNCT F
than 0 ADP F
maintenance 0 NOUN F
of 0 ADP F
fixed 0 VERB F
ventricular 0 ADJ F
rate 0 NOUN F
in 0 ADP F
atrial 0 ADJ F
fibrillation 0 NOUN F
( 0 PUNCT F
AF 0 NOUN T
) 0 PUNCT F
especially 0 ADV F
in 0 ADP F
the 0 DET F
presence 0 NOUN F
of 0 ADP F
irritable 0 ADJ F
left 0 ADJ F
or 0 CCONJ F
right 0 ADJ F
atrium 0 NOUN F
because 0 PUNCT F
of 0 ADP F
enlargement 0 NOUN F
. 0 PUNCT F

Fifty-six 0 ADJ T
patients 0 NOUN F
with 0 ADP F
valvular 0 ADJ F
heart 0 NOUN F
disease 0 NOUN F
with 0 ADP F
or 0 CCONJ F
without 0 ADP F
AF 0 NOUN T
were 0 VERB F
randomly 0 ADV F
divided 0 VERB F
into 0 ADP F
two 0 NUM F
groups 0 NOUN F
. 0 PUNCT F

Group 0 NOUN T
I 0 NUM T
or 0 CCONJ F
the 0 DET F
amiodarone 0 NOUN F
group 0 NOUN F
( 0 PUNCT F
n=28 0 NOUN F
) 0 PUNCT F
received 0 VERB F
amiodarone 0 NOUN F
( 0 PUNCT F
3 0 NUM F
mg/kg 0 NOUN F
in 0 ADP F
100 0 NUM F
ml 0 NOUN F
normal 0 ADJ F
saline 0 NOUN F
) 0 PUNCT F
and 0 CCONJ F
group 0 NOUN F
II 0 NUM T
or 0 CCONJ F
the 0 DET F
control 0 NOUN F
group 0 NOUN F
received 0 VERB F
same 0 ADJ F
volume 0 NOUN F
of 0 ADP F
normal 0 ADJ F
saline 0 NOUN F
. 0 PUNCT F

The 0 DET T
standardized 0 VERB F
protocol 0 NOUN F
for 0 ADP F
cardiopulmonary 0 ADJ F
bypass 0 NOUN F
was 0 VERB F
maintained 0 VERB F
for 0 ADP F
all 0 CCONJ F
the 0 DET F
patients 0 NOUN F
. 0 PUNCT F

AF B-PHYSICAL NOUN T
occurred 0 VERB F
in 0 ADP F
7.14 0 NUM F
% 0 ADJ F
patients 0 NOUN F
in 0 ADP F
group 0 NOUN F
I 0 NUM T
, 0 PUNCT F
and 0 CCONJ F
in 0 ADP F
group 0 NOUN F
II 0 NUM T
, 0 PUNCT F
28.57 0 NUM F
% 0 SYM F
( 0 PUNCT F
P=0.035 0 NOUN T
) 0 PUNCT F
; 0 PUNCT F
ventricular B-PHYSICAL ADJ F
tachycardia/fibrillation I-PHYSICAL NOUN F
was 0 VERB F
observed 0 VERB F
in 0 ADP F
21.43 0 NUM F
% 0 ADJ F
patients 0 NOUN F
in 0 ADP F
group 0 NOUN F
I 0 NUM T
and 0 CCONJ F
46.43 0 NUM F
% 0 ADV F
patients 0 NOUN F
in 0 ADP F
group 0 NOUN F
II 0 NUM T
( 0 PUNCT F
P=0.089 0 NOUN T
) 0 PUNCT F
after 0 ADP F
release 0 NOUN F
of 0 ADP F
aortic 0 ADJ F
clamp 0 NOUN F
. 0 PUNCT F

Most 0 PUNCT T
of 0 ADP F
the 0 DET F
patients 0 NOUN F
in 0 ADP F
group 0 NOUN F
I 0 NUM T
( 0 PUNCT F
92.86 0 NUM F
% 0 SYM F
) 0 PUNCT F
maintained 0 VERB F
sinus B-PHYSICAL NOUN F
rhythm I-PHYSICAL NOUN F
without I-PHYSICAL ADP F
cardioversion I-PHYSICAL NOUN F
or I-PHYSICAL CCONJ F
defibrillation I-PHYSICAL NOUN F
after 0 ADP F
release 0 NOUN F
of 0 ADP F
aortic 0 ADJ F
cross 0 NOUN F
clamp 0 NOUN F
( 0 PUNCT F
P=0.002 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

Defibrillation B-PHYSICAL NOUN T
or 0 CCONJ F
cardio B-PHYSICAL PUNCT F
version I-PHYSICAL NOUN F
was 0 VERB F
needed 0 VERB F
in 0 ADP F
7.14 0 NUM F
% 0 ADJ F
patients 0 NOUN F
in 0 ADP F
group 0 NOUN F
I 0 NUM T
and 0 CCONJ F
28.57 0 NUM F
% 0 SYM F
patients 0 NOUN F
in 0 ADP F
group 0 NOUN F
II 0 NUM T
( 0 PUNCT F
P=0.078 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

A 0 DET T
single 0 ADJ F
prophylactic 0 ADJ F
intraoperative 0 ADJ F
dose 0 NOUN F
of 0 ADP F
intravenous 0 ADJ F
amiodarone 0 NOUN F
decreased 0 PUNCT F
post B-PHYSICAL PUNCT F
bypass I-PHYSICAL PUNCT F
arrhythmia I-PHYSICAL NOUN F
in 0 ADP F
this 0 DET F
study 0 NOUN F
in 0 ADP F
comparison 0 NOUN F
to 0 ADP F
the 0 DET F
control 0 NOUN F
group 0 NOUN F
. 0 PUNCT F

Single 0 ADJ T
dose 0 NOUN F
of 0 ADP F
intraoperative 0 ADJ F
amiodarone 0 NOUN F
may 0 VERB F
be 0 VERB F
used 0 VERB F
to 0 PART F
decrease 0 PROPN F
postoperative 0 ADJ F
arrhythmia 0 NOUN F
in 0 ADP F
open 0 ADJ F
heart 0 NOUN F
surgery 0 NOUN F
. 0 PUNCT F

Evaluation 0 NOUN T
of 0 ADP F
a 0 DET F
new 0 ADJ F
wound 0 NOUN F
closure 0 NOUN F
device 0 NOUN F
for 0 ADP F
linear 0 ADJ F
surgical 0 ADJ F
incisions 0 NOUN F
: 0 PUNCT F
3M 0 NOUN F
Steri-Strip 0 NOUN T
S 0 NOUN T
Surgical 0 ADJ T
Skin 0 NOUN T
Closure 0 NOUN T
versus 0 CCONJ F
subcuticular 0 ADJ F
closure 0 NOUN F
. 0 PUNCT F

BACKGROUND 0 NOUN T
Technological 0 ADJ T
innovations 0 NOUN F
are 0 VERB F
often 0 ADV F
adopted 0 VERB F
before 0 ADP F
scientific 0 ADJ F
comparison 0 NOUN F
to 0 ADP F
an 0 DET F
accepted 0 VERB F
standard 0 NOUN F
. 0 PUNCT F

The 0 DET T
authors 0 NOUN F
' 0 PUNCT F
study 0 NOUN F
compared 0 PUNCT F
suture 0 NOUN F
with 0 ADP F
a 0 DET F
new 0 ADJ F
coaptive 0 ADJ F
film 0 NOUN F
device 0 NOUN F
, 0 PUNCT F
3M 0 NOUN F
Steri-Strip 0 NOUN T
S 0 NOUN T
Surgical 0 ADJ T
Skin 0 NOUN T
Closure 0 NOUN T
, 0 PUNCT F
on 0 ADP F
linear 0 ADJ F
incisions 0 NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
Patients 0 NOUN T
undergoing 0 VERB F
Wise-pattern 0 NOUN T
breast 0 NOUN F
reduction 0 NOUN F
or 0 CCONJ F
abdominal 0 ADJ F
procedures 0 NOUN F
had 0 PUNCT F
paired 0 PUNCT F
incisions 0 NOUN F
randomly 0 ADV F
assigned 0 VERB F
to 0 ADP F
Steri-Strip 0 NOUN T
S 0 NOUN T
or 0 CCONJ F
suture 0 NOUN F
closure 0 NOUN F
. 0 PUNCT F

Key 0 NOUN T
outcome 0 NOUN F
measures 0 NOUN F
were 0 VERB F
closure B-OTHER NOUN F
time I-OTHER NOUN F
, 0 PUNCT F
patient B-OTHER NOUN F
comfort I-OTHER PUNCT F
, 0 PUNCT F
and 0 CCONJ F
scar B-OTHER NOUN F
quality I-OTHER NOUN F
at 0 ADP F
6 0 NUM F
months 0 NOUN F
by 0 ADP F
patients 0 NOUN F
and 0 CCONJ F
surgeons 0 NOUN F
using 0 VERB F
a 0 DET F
new 0 ADJ F
scar 0 NOUN F
evaluation 0 NOUN F
tool 0 NOUN F
, 0 PUNCT F
visual 0 ADJ F
assessment 0 NOUN F
of 0 ADP F
linear 0 ADJ F
scars 0 NOUN F
. 0 PUNCT F

Statistical 0 ADJ T
differences 0 NOUN F
between 0 ADP F
the 0 DET F
two 0 NUM F
closure 0 NOUN F
techniques 0 NOUN F
were 0 VERB F
assessed 0 VERB F
by 0 ADP F
Wilcoxon 0 NOUN T
signed 0 NOUN F
rank 0 NOUN F
test 0 NOUN F
. 0 PUNCT F

RESULTS 0 NOUN T
Of 0 ADP T
59 0 NUM F
patients 0 NOUN F
, 0 PUNCT F
eight 0 NUM F
were 0 VERB F
excluded 0 VERB F
from 0 ADP F
randomization 0 NOUN F
( 0 PUNCT F
a 0 DET F
surgeon 0 NOUN F
judged 0 DET F
Steri-Strip 0 NOUN T
S 0 NOUN T
to 0 PART F
be 0 CCONJ F
a 0 DET F
nonviable 0 ADJ F
closure 0 NOUN F
technique 0 NOUN F
for 0 ADP F
mismatched 0 PUNCT F
wound 0 NOUN F
edges 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

Fifty-one 0 NUM T
patients 0 NOUN F
( 0 PUNCT F
breast 0 NOUN F
, 0 PUNCT F
n 0 NOUN F
= 0 SYM F
24 0 NUM F
; 0 PUNCT F
abdomen 0 NOUN F
, 0 PUNCT F
n 0 NOUN F
= 0 SYM F
27 0 NUM F
) 0 PUNCT F
were 0 VERB F
randomized 0 VERB F
. 0 PUNCT F

Operative B-OTHER ADJ T
time I-OTHER NOUN F
with 0 ADP F
Steri-Strip 0 NOUN T
S 0 NOUN T
for 0 ADP F
breast 0 NOUN F
was 0 VERB F
2.0 0 NUM F
minutes 0 NOUN F
( 0 PUNCT F
SD 0 NOUN T
= 0 SYM F
1.1 0 NUM F
) 0 PUNCT F
versus 0 CCONJ F
suture 0 NOUN F
closure 0 NOUN F
at 0 ADP F
4.6 0 NUM F
minutes 0 NOUN F
( 0 PUNCT F
SD 0 NOUN T
= 0 SYM F
1.5 0 NUM F
; 0 PUNCT F
p 0 NOUN F
< 0 SYM F
0.001 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Similarly 0 ADV T
, 0 PUNCT F
Steri-Strip 0 NOUN T
S 0 NOUN T
versus 0 CCONJ F
suture 0 NOUN F
for 0 ADP F
the 0 DET F
abdomen 0 NOUN F
was 0 VERB F
faster 0 PUNCT F
( 0 PUNCT F
p 0 NOUN F
< 0 SYM F
0.001 0 NUM F
; 0 PUNCT F
4.9 0 NUM F
minutes 0 NOUN F
, 0 PUNCT F
SD 0 NOUN T
= 0 SYM F
2.3 0 NUM F
versus 0 CCONJ F
10.1 0 NUM F
minutes 0 NOUN F
, 0 PUNCT F
SD 0 NOUN T
= 0 SYM F
3.4 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Comfort 0 ADJ T
scores 0 NOUN F
did 0 PUNCT F
not 0 ADV F
differ 0 VERB F
between 0 ADP F
closures 0 ADP F
[ 0 PUNCT F
5.8 0 NUM F
( 0 PUNCT F
SD 0 NOUN T
= 0 SYM F
2.7 0 NUM F
) 0 PUNCT F
versus 0 CCONJ F
6.9 0 NUM F
( 0 PUNCT F
SD 0 NOUN T
= 0 SYM F
2.0 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
respectively 0 ADV F
, 0 PUNCT F
on 0 ADP F
breast 0 NOUN F
( 0 PUNCT F
p 0 NOUN F
= 0 SYM F
0.142 0 NUM F
) 0 PUNCT F
and 0 CCONJ F
7.7 0 NUM F
( 0 PUNCT F
SD 0 NOUN T
= 0 SYM F
1.8 0 NUM F
) 0 PUNCT F
versus 0 CCONJ F
7.7 0 NUM F
( 0 PUNCT F
SD 0 NOUN T
= 0 SYM F
2.3 0 NUM F
) 0 PUNCT F
on 0 ADP F
abdomen 0 NOUN F
( 0 PUNCT F
p 0 NOUN F
= 0 SYM F
0.903 0 NUM F
) 0 PUNCT F
] 0 PUNCT F
. 0 PUNCT F

Complication B-ADVERSE-EFFECTS NOUN T
rates I-ADVERSE-EFFECTS NOUN F
did 0 PUNCT F
not 0 ADV F
differ 0 VERB F
between 0 ADP F
closure 0 NOUN F
types 0 NOUN F
. 0 PUNCT F

Patients B-OTHER NOUN T
' 0 PUNCT F
visual B-OTHER ADJ F
assessment I-OTHER NOUN F
of I-OTHER ADP F
linear I-OTHER ADJ F
scars I-OTHER NOUN F
rating I-OTHER PUNCT F
of I-OTHER ADP F
breasts B-OTHER NOUN F
was 0 VERB F
3.8 0 NUM F
( 0 PUNCT F
SD 0 NOUN T
= 0 SYM F
2.9 0 NUM F
) 0 PUNCT F
for 0 ADP F
Steri-Strip 0 NOUN T
S 0 NOUN T
and 0 CCONJ F
better 0 PUNCT F
at 0 ADP F
2.6 0 NUM F
( 0 PUNCT F
SD 0 NOUN T
= 0 SYM F
2.9 0 NUM F
) 0 PUNCT F
for 0 ADP F
suture 0 NOUN F
( 0 PUNCT F
p 0 NOUN F
= 0 SYM F
0.008 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

One 0 NUM T
surgeon 0 NOUN F
rated 0 DET F
breast 0 NOUN F
Steri-Strip 0 NOUN T
S 0 NOUN T
scars 0 NOUN F
worse 0 ADJ F
than 0 VERB F
suture 0 NOUN F
scars 0 NOUN F
( 0 PUNCT F
4.3 0 NUM F
versus 0 CCONJ F
3.7 0 NUM F
; 0 PUNCT F
p 0 NOUN F
= 0 SYM F
0.014 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

For 0 ADP T
abdominal 0 ADJ F
scars 0 NOUN F
, 0 PUNCT F
there 0 PUNCT F
was 0 VERB F
no 0 DET F
difference 0 NOUN F
in 0 ADP F
the 0 DET F
patient 0 NOUN F
or 0 CCONJ F
surgeon 0 NOUN F
ratings 0 NOUN F
. 0 PUNCT F

CONCLUSIONS 0 NOUN T
Steri-Strip 0 NOUN T
S 0 NOUN T
permits 0 VERB F
faster 0 PUNCT F
wound B-PHYSICAL NOUN F
closure B-PHYSICAL NOUN F
than 0 PUNCT F
suture 0 NOUN F
. 0 PUNCT F

On 0 ADP T
the 0 DET F
basis 0 NOUN F
of 0 ADP F
patient 0 NOUN F
reports 0 NOUN F
of 0 ADP F
comfort B-OTHER NOUN F
and 0 PUNCT F

Erythema 0 NOUN T
migrans 0 ADJ F
: 0 PUNCT F
comparison 0 NOUN F
of 0 ADP F
treatment 0 NOUN F
with 0 ADP F
azithromycin 0 NOUN F
, 0 PUNCT F
doxycycline 0 NOUN F
and 0 CCONJ F
phenoxymethylpenicillin 0 NOUN F
. 0 PUNCT F

Azithromycin 0 NOUN T
, 0 PUNCT F
doxycycline 0 NOUN F
and 0 CCONJ F
phenoxymethylpenicillin 0 NOUN F
were 0 VERB F
compared 0 VERB F
in 0 ADP F
a 0 DET F
prospective 0 ADJ F
, 0 PUNCT F
randomized 0 ADP F
study 0 NOUN F
of 0 ADP F
64 0 NUM F
patients 0 NOUN F
with 0 ADP F
typical 0 ADJ F
erythema 0 NOUN F
migrans 0 ADJ F
. 0 PUNCT F

Twenty 0 NUM T
patients 0 NOUN F
were 0 VERB F
treated 0 VERB F
with 0 ADP F
oral 0 ADJ F
azithromycin 0 NOUN F
, 0 PUNCT F
250 0 NUM F
mg 0 NOUN F
bd 0 ADP F
for 0 ADP F
two 0 NUM F
days 0 NOUN F
followed 0 VERB F
by 0 ADP F
250 0 NUM F
mg 0 NOUN F
od 0 NOUN F
for 0 ADP F
eight 0 NUM F
days 0 NOUN F
, 0 PUNCT F
21 0 NUM F
patients 0 NOUN F
were 0 VERB F
given 0 VERB F
phenoxymethylpenicillin 0 NOUN F
1 0 NUM F
million 0 NUM F
IU 0 NOUN T
tds 0 NOUN F
for 0 ADP F
14 0 NUM F
days 0 NOUN F
and 0 CCONJ F
23 0 NUM F
patients 0 NOUN F
received 0 VERB F
doxycycline 0 NOUN F
, 0 PUNCT F
100 0 NUM F
mg 0 NOUN F
bd 0 ADP F
for 0 ADP F
14 0 NUM F
days 0 NOUN F
. 0 PUNCT F

All 0 DET T
patients 0 NOUN F
were 0 VERB F
followed 0 VERB F
up 0 ADJ F
for 0 ADP F
24 0 NUM F
months 0 NOUN F
. 0 PUNCT F

There 0 PUNCT T
were 0 VERB F
no 0 DET F
significant 0 ADJ F
differences 0 NOUN F
between 0 ADP F
the 0 DET F
groups 0 NOUN F
with 0 ADP F
respect 0 NOUN F
to 0 ADP F
the 0 DET F
persistence 0 NOUN F
of 0 ADP F
cutaneous B-PHYSICAL ADJ F
lesions I-PHYSICAL NOUN F
after 0 ADP F
starting 0 ADJ F
treatment 0 NOUN F
; 0 PUNCT F
the 0 DET F
mean 0 NOUN F
durations B-OTHER NOUN F
were 0 VERB F
10.5 0 NUM F
days 0 NOUN F
in 0 ADP F
the 0 DET F
penicillin 0 NOUN F
group 0 NOUN F
, 0 PUNCT F
8.8 0 NUM F
days 0 NOUN F
in 0 ADP F
the 0 DET F
doxycycline 0 NOUN F
group 0 NOUN F
and 0 CCONJ F
8.6 0 NUM F
days 0 NOUN F
in 0 ADP F
the 0 DET F
azithromycin 0 NOUN F
group 0 NOUN F
. 0 PUNCT F

There 0 PUNCT T
were 0 VERB F
statistically 0 ADV F
significant 0 ADJ F
differences 0 NOUN F
in 0 ADP F
terms 0 NOUN F
of 0 ADP F
the 0 DET F
resolution B-PHYSICAL NOUN F
of I-PHYSICAL ADP F
associated I-PHYSICAL VERB F
local I-PHYSICAL ADJ F
and/or I-PHYSICAL CCONJ F
systemic I-PHYSICAL ADJ F
symptoms I-PHYSICAL NOUN F
. 0 PUNCT F

The 0 DET T
response 0 NOUN F
time 0 NOUN F
was 0 VERB F
shortest 0 ADJ F
in 0 ADP F
patients 0 NOUN F
treated 0 VERB F
with 0 ADP F
azithromycin 0 NOUN F
. 0 PUNCT F

Two 0 NUM T
patients 0 NOUN F
who 0 ADP F
received 0 VERB F
phenoxymethylpenicillin 0 NOUN F
and 0 CCONJ F
two 0 NUM F
given 0 VERB F
doxycycline 0 NOUN F
subsequently 0 ADV F
developed 0 ADV F
major 0 ADJ F
manifestations 0 NOUN F
of 0 ADP F
Lyme B-PHYSICAL NOUN T
borreliosis I-PHYSICAL NOUN F
; 0 PUNCT F
these 0 PUNCT F
did 0 PUNCT F
not 0 ADV F
occur 0 VERB F
in 0 ADP F
patients 0 NOUN F
receiving 0 SYM F
azithromycin 0 NOUN F
. 0 PUNCT F

Although 0 ADP T
azithromycin 0 NOUN F
has 0 VERB F
been 0 PUNCT F
shown 0 VERB F
to 0 PART F
be 0 VERB F
effective 0 ADJ F
in 0 ADP F
the 0 DET F
treatment 0 NOUN F
of 0 ADP F
erythema 0 NOUN F
migrans 0 ADJ F
, 0 PUNCT F
further 0 ADJ F
studies 0 NOUN F
will 0 VERB F
be 0 VERB F
needed 0 VERB F
to 0 PART F
determine 0 NOUN F
the 0 DET F
optimal 0 ADJ F
dosage 0 NOUN F
and 0 CCONJ F
duration 0 NOUN F
of 0 ADP F
therapy 0 NOUN F
. 0 PUNCT F

Naltrexone 0 NUM T
in 0 ADP F
young 0 ADJ F
autistic 0 ADJ F
children 0 NOUN F
: 0 PUNCT F
a 0 DET F
double-blind 0 ADJ F
, 0 PUNCT F
placebo-controlled 0 VERB F
crossover 0 NOUN F
study 0 NOUN F
. 0 PUNCT F

OBJECTIVE 0 NOUN T
This 0 DET T
study 0 NOUN F
evaluated 0 VERB F
the 0 DET F
efficacy 0 NOUN F
and 0 CCONJ F
safety 0 NOUN F
of 0 ADP F
naltrexone 0 NUM F
, 0 PUNCT F
an 0 DET F
opiate 0 ADJ F
blocker 0 NOUN F
, 0 PUNCT F
in 0 ADP F
the 0 DET F
treatment 0 NOUN F
of 0 ADP F
autism 0 NOUN F
. 0 PUNCT F

METHOD 0 NOUN T
Thirteen 0 PUNCT T
children 0 NOUN F
with 0 ADP F
autistic 0 ADJ F
disorder 0 NOUN F
, 0 PUNCT F
aged 0 ADP F
3.4 0 NUM F
to 0 ADP F
8.3 0 NUM F
years 0 NOUN F
( 0 PUNCT F
mean 0 NOUN F
5.4 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
were 0 VERB F
studied 0 VERB F
in 0 ADP F
home 0 NOUN F
, 0 PUNCT F
school 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
outpatient 0 ADJ F
laboratory 0 NOUN F
. 0 PUNCT F

Naltrexone 0 NUM T
, 0 PUNCT F
1.0 0 NUM F
mg/kg 0 NOUN F
, 0 PUNCT F
was 0 VERB F
given 0 VERB F
daily 0 ADP F
in 0 ADP F
a 0 DET F
randomized 0 VERB F
, 0 PUNCT F
double-blind 0 ADJ F
, 0 PUNCT F
placebo-controlled 0 VERB F
crossover 0 NOUN F
design 0 NOUN F
. 0 PUNCT F

Dependent 0 ADJ T
measures 0 NOUN F
included 0 DET F
parent 0 NOUN F
and 0 CCONJ F
teacher 0 NOUN F
Clinical B-MENTAL ADJ T
Global I-MENTAL PUNCT T
Impressions I-MENTAL NOUN T
( I-MENTAL PUNCT F
CGI I-MENTAL NOUN T
) I-MENTAL PUNCT F
, 0 PUNCT F
Conners B-MENTAL PUNCT T
Rating I-MENTAL PUNCT T
Scales I-MENTAL PUNCT T
, 0 PUNCT F
and 0 CCONJ F
Naltrexone B-OTHER NUM T
Side-Effects I-OTHER NOUN T
( I-OTHER PUNCT F
SE I-OTHER NOUN T
) I-OTHER PUNCT F
Rating I-OTHER PUNCT T
Scale 0 NOUN T
; 0 PUNCT F
laboratory B-MENTAL NOUN F
CGI I-MENTAL NOUN T
, 0 PUNCT F
movement B-MENTAL NOUN F
actometer I-MENTAL NOUN F
readings I-MENTAL NOUN F
, 0 PUNCT F
and 0 CCONJ F
a 0 DET F
10-second B-MENTAL NOUN F
interval I-MENTAL NOUN F
recording I-MENTAL ADJ F
system I-MENTAL NOUN F
analysis I-MENTAL NOUN F
of I-MENTAL ADP F
on-task I-MENTAL PUNCT F
, 0 PUNCT F
communication B-MENTAL NOUN F
initiations I-MENTAL NOUN F
, 0 PUNCT F
disruptive B-MENTAL ADJ F
behavior I-MENTAL NOUN F
, 0 PUNCT F
and 0 CCONJ F
self-stimulation B-MENTAL NOUN F
. 0 PUNCT F

RESULTS 0 NOUN T
Eight 0 PUNCT T
of 0 ADP F
13 0 NUM F
subjects 0 NOUN F
improved 0 VERB F
in 0 ADP F
two 0 NUM F
or 0 CCONJ F
more 0 DET F
settings 0 NOUN F
. 0 PUNCT F

Changes 0 NOUN T
in 0 ADP F
parent B-MENTAL NOUN F
measures I-MENTAL NOUN F
( I-MENTAL PUNCT F
CGI I-MENTAL NOUN T
, 0 PUNCT F
Conners B-MENTAL PROPN T
Impulsivity-Hyperactivity I-MENTAL NOUN T
Factor I-MENTAL NOUN T
, 0 PUNCT F
and 0 CCONJ F
SE-Restlessness B-MENTAL NOUN T
) 0 PUNCT F
and 0 CCONJ F
Teacher B-MENTAL NOUN T
CGI I-MENTAL NOUN T
achieved 0 VERB F
statistical 0 ADJ F
significance 0 NOUN F
. 0 PUNCT F

Teacher B-MENTAL NOUN T
SE-Restlessness I-MENTAL NOUN T
and 0 CCONJ F
initiation B-MENTAL NOUN F
of I-MENTAL ADP F
communication I-MENTAL NOUN F
in 0 ADP F
the 0 DET F
clinic 0 NOUN F
showed 0 VERB F
a 0 DET F
trend 0 NOUN F
toward 0 ADP F
improvement 0 NOUN F
. 0 PUNCT F

Actometer B-PHYSICAL ADJ T
readings I-PHYSICAL NOUN F
improved 0 VERB F
in 0 ADP F
two 0 NUM F
children 0 NOUN F
who 0 PROPN F
were 0 VERB F
very 0 ADV F
active 0 ADJ F
at 0 ADP F
baseline 0 NOUN F
. 0 PUNCT F

Adverse B-ADVERSE-EFFECTS ADJ T
side I-ADVERSE-EFFECTS NOUN F
effects I-ADVERSE-EFFECTS NOUN F
were 0 VERB F
behavioral 0 ADJ F
, 0 PUNCT F
mild 0 ADJ F
, 0 PUNCT F
and 0 CCONJ F
transient 0 ADJ F
. 0 PUNCT F

Administering 0 ADP T
the 0 DET F
bitter 0 ADJ F
tablet 0 NOUN F
was 0 VERB F
a 0 DET F
challenge 0 NOUN F
. 0 PUNCT F

CONCLUSIONS 0 NOUN T
Naltrexone 0 NUM T
offers 0 VERB F
promise 0 PUNCT F
as 0 ADP F
an 0 DET F
agent 0 NOUN F
for 0 ADP F
modest 0 ADJ F
improvement 0 NOUN F
of 0 ADP F
behavior 0 NOUN F
and 0 CCONJ F
social B-MENTAL ADJ F
communication I-MENTAL NOUN F
in 0 ADP F
young 0 ADJ F
children 0 NOUN F
with 0 ADP F
autism 0 NOUN F
. 0 PUNCT F

Parent 0 NOUN T
and 0 CCONJ F
teacher 0 NOUN F
measures 0 NOUN F
can 0 VERB F
be 0 VERB F
useful 0 ADJ F
in 0 ADP F
outpatient 0 ADJ F
trials 0 NOUN F
to 0 PART F
evaluate 0 NOUN F
change 0 NOUN F
. 0 PUNCT F

Changes 0 NOUN T
of 0 ADP F
activated 0 VERB F
circulating 0 VERB F
endothelial 0 ADJ F
cells 0 NOUN F
and 0 CCONJ F
survivin 0 NOUN F
in 0 ADP F
patients 0 NOUN F
with 0 ADP F
non-small 0 ADP F
cell 0 NOUN F
lung 0 NOUN F
cancer 0 NOUN F
after 0 ADP F
antiangiogenesis 0 NOUN F
therapy 0 NOUN F
. 0 PUNCT F

BACKGROUND 0 NOUN T
Although 0 ADP T
antiangiogenesis 0 NOUN F
therapy 0 NOUN F
plays 0 NOUN F
an 0 DET F
important 0 ADJ F
role 0 NOUN F
in 0 ADP F
anti-neoplastic 0 ADP F
treatment 0 NOUN F
with 0 ADP F
its 0 ADP F
recognized 0 ADJ F
efficacy 0 NOUN F
and 0 CCONJ F
slight 0 ADJ F
adverse 0 ADJ F
effect 0 NOUN F
, 0 PUNCT F
there 0 PUNCT F
is 0 VERB F
no 0 DET F
prospective 0 ADJ F
clinical 0 ADJ F
trial 0 NOUN F
to 0 PART F
define 0 NOUN F
ideal 0 ADJ F
markers 0 NOUN F
for 0 ADP F
predicting 0 VERB F
efficacy 0 NOUN F
of 0 ADP F
antiangiogenic 0 ADJ F
therapy 0 NOUN F
. 0 PUNCT F

This 0 DET T
study 0 NOUN F
was 0 VERB F
undertaken 0 VERB F
to 0 PART F
investigate 0 NOUN F
the 0 DET F
changes 0 NOUN F
of 0 ADP F
activated 0 VERB F
circulating 0 VERB F
endothelial 0 ADJ F
cells 0 NOUN F
( 0 PUNCT F
aCECs 0 NOUN F
) 0 PUNCT F
and 0 CCONJ F
survivin 0 NOUN F
after 0 ADP F
anti-angiogenesis 0 NOUN F
therapy 0 NOUN F
and 0 CCONJ F
their 0 NOUN F
significance 0 NOUN F
in 0 ADP F
predicting 0 VERB F
the 0 DET F
efficacy 0 NOUN F
of 0 ADP F
the 0 DET F
therapy 0 NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
Patients 0 NOUN T
of 0 ADP F
non-small 0 ADP F
cell 0 NOUN F
lung 0 NOUN F
cancer 0 NOUN F
( 0 PUNCT F
NSCLC 0 NOUN T
) 0 PUNCT F
treated 0 VERB F
with 0 ADP F
chemotherapy 0 NOUN F
with 0 ADP F
or 0 CCONJ F
without 0 ADP F
Endostar 0 NOUN T
were 0 VERB F
observed 0 VERB F
. 0 PUNCT F

The 0 DET T
amount 0 NOUN F
of 0 ADP F
activated 0 VERB F
CECs 0 NOUN T
was 0 VERB F
detected 0 VERB F
by 0 ADP F
flow 0 NOUN F
cytometry 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
the 0 DET F
expression 0 NOUN F
of 0 ADP F
survivin 0 NOUN F
mRNA 0 NOUN F
was 0 VERB F
determined 0 VERB F
by 0 ADP F
real-time 0 NOUN F
polymerase 0 NOUN F
chain 0 NOUN F
reaction 0 NOUN F
( 0 PUNCT F
PCR 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

RESULTS 0 NOUN T
After 0 ADP T
treatment 0 NOUN F
, 0 PUNCT F
the 0 DET F
amount 0 NOUN F
of 0 ADP F
activated B-PHYSICAL VERB F
CECs I-PHYSICAL NOUN T
decreased 0 VERB F
significantly 0 ADV F
in 0 ADP F
clinical 0 ADJ F
benefit 0 ADP F
cases 0 NOUN F
( 0 PUNCT F
P 0 NOUN T
= 0 SYM F
0.021 0 NUM F
in 0 ADP F
chemotherapy 0 NOUN F
alone 0 ADJ F
, 0 PUNCT F
P 0 NOUN T
= 0 SYM F
0.001 0 NUM F
in 0 ADP F
chemotherapy 0 NOUN F
plus 0 CCONJ F
Endostar 0 NOUN T
) 0 PUNCT F
, 0 PUNCT F
increased 0 VERB F
in 0 ADP F
disease B-PHYSICAL NOUN F
progressive I-PHYSICAL ADJ F
cases I-PHYSICAL NOUN F
( 0 PUNCT F
P 0 NOUN T
= 0 SYM F
0.015 0 NUM F
in 0 ADP F
chemotherapy 0 NOUN F
alone 0 ADJ F
, 0 PUNCT F
but 0 CCONJ F
P 0 NOUN T
= 0 SYM F
0.293 0 NUM F
in 0 ADP F
chemotherapy 0 NOUN F
with 0 ADP F
Endotatar 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

After 0 ADP T
therapy 0 NOUN F
, 0 PUNCT F
the 0 DET F
expression 0 NOUN F
of 0 ADP F
survivin B-PHYSICAL NOUN F
mRNA I-PHYSICAL NOUN F
decreased 0 VERB F
in 0 ADP F
clinical 0 ADJ F
benefit 0 ADP F
cases 0 NOUN F
( 0 PUNCT F
P 0 NOUN T
= 0 SYM F
0.001 0 NUM F
) 0 PUNCT F
and 0 CCONJ F
increased 0 PUNCT F
in 0 ADP F
disease B-PHYSICAL NOUN F
progressive I-PHYSICAL ADJ F
cases I-PHYSICAL NOUN F
( 0 PUNCT F
P 0 NOUN T
= 0 SYM F
0.018 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

A 0 DET T
positive 0 ADJ F
correlation 0 NOUN F
was 0 VERB F
found 0 VERB F
between 0 ADP F
activated B-PHYSICAL VERB F
CECs I-PHYSICAL NOUN T
and 0 CCONJ F
survivin 0 NOUN F
in 0 ADP F
the 0 DET F
chemotherapy 0 NOUN F
group 0 NOUN F
pre- 0 ADJ F
and 0 CCONJ F
post-therapy 0 NOUN F
( 0 PUNCT F
P 0 NOUN T
= 0 SYM F
0.001 0 NUM F
and 0 CCONJ F
0.021 0 PUNCT F
, 0 PUNCT F
respectively 0 ADV F
) 0 PUNCT F
, 0 PUNCT F
but 0 CCONJ F
only 0 ADV F
in 0 ADP F
the 0 DET F
chemotherapy 0 NOUN F
with 0 ADP F
Endostar 0 NOUN T
group 0 NOUN F
pre-therapy 0 NOUN F
( 0 PUNCT F
P 0 NOUN T
= 0 SYM F
0.030 0 PUNCT F
) 0 PUNCT F
rather 0 PUNCT F
than 0 ADP F
post-therapy 0 NOUN F
. 0 PUNCT F

A 0 DET T
positive 0 ADJ F
correlation 0 NOUN F
was 0 VERB F
found 0 VERB F
between 0 ADP F
the 0 DET F
decreased 0 VERB F
activated B-PHYSICAL VERB F
CECs I-PHYSICAL NOUN T
after 0 ADP F
therapy 0 NOUN F
and 0 CCONJ F
time B-PHYSICAL NOUN F
to I-PHYSICAL ADP F
progression I-PHYSICAL NOUN F
( I-PHYSICAL PUNCT F
TTP I-PHYSICAL VERB T
) I-PHYSICAL PUNCT F
( 0 PUNCT F
r 0 NOUN F
= 0 SYM F
0.322 0 NUM F
, 0 PUNCT F
P 0 NOUN T
= 0 SYM F
0.012 0 NUM F
) 0 PUNCT F
; 0 PUNCT F
a 0 DET F
negative 0 ADJ F
correlation 0 NOUN F
was 0 VERB F
found 0 VERB F
between 0 ADP F
the 0 DET F
amount 0 NOUN F
of 0 ADP F
survivin B-PHYSICAL NOUN F
mRNA I-PHYSICAL NOUN F
in I-PHYSICAL ADP F
serum I-PHYSICAL NOUN F
post-therapy I-PHYSICAL NOUN F
and 0 CCONJ F
TTP B-PHYSICAL VERB T
( 0 PUNCT F
r 0 NOUN F
= 0 SYM F
-0.291 0 NOUN F
, 0 PUNCT F
P 0 NOUN T
= 0 SYM F
0.048 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

CONCLUSIONS 0 NOUN T
Activated 0 VERB T
CECs 0 NOUN T
and 0 CCONJ F
survivin 0 NOUN F
may 0 VERB F
be 0 ADJ F
ideal 0 ADJ F
markers 0 NOUN F
forecasting 0 PUNCT F
efficacy 0 NOUN F
and 0 CCONJ F
prognosis 0 NOUN F
of 0 ADP F
NSCLC 0 NOUN T
. 0 PUNCT F

The 0 DET T
former 0 ADJ F
can 0 NOUN F
reflect 0 VERB F
more 0 DET F
sensitively 0 ADV F
antiangiogenic 0 ADJ F
efficacy 0 NOUN F
and 0 CCONJ F
the 0 DET F
latter 0 NOUN F
is 0 PUNCT F
more 0 ADV F
sensitive 0 ADJ F
to 0 ADP F
shrinkage 0 NOUN F
or 0 CCONJ F
swelling 0 DET F
of 0 ADP F
tumors 0 NOUN F
. 0 PUNCT F

Their 0 VERB T
combination 0 NOUN F
can 0 NOUN F
evaluate 0 VERB F
more 0 ADP F
accurately 0 PUNCT F
the 0 ADP F
efficacy 0 NOUN F
of 0 ADP F
antiangiogenic 0 ADJ F
therapy 0 NOUN F
of 0 ADP F
NSCLC 0 NOUN T
. 0 PUNCT F

Allopurinol 0 NOUN T
improves 0 ADV F
endothelial 0 ADJ F
function 0 NOUN F
and 0 CCONJ F
reduces 0 NOUN F
oxidant-inflammatory 0 ADJ F
enzyme 0 NOUN F
of 0 ADP F
myeloperoxidase 0 NOUN F
in 0 ADP F
metabolic 0 ADJ F
syndrome 0 NOUN F
. 0 PUNCT F

OBJECTIVE 0 NOUN T
In 0 ADP T
this 0 DET F
study 0 NOUN F
, 0 PUNCT F
we 0 PRON F
tested 0 VERB F
in 0 ADP F
patients 0 NOUN F
with 0 ADP F
metabolic 0 ADJ F
syndrome 0 NOUN F
whether 0 PUNCT F
allopurinol 0 NOUN F
through 0 ADP F
decreasing 0 PUNCT F
oxidative 0 ADJ F
stress 0 NOUN F
improves 0 ADV F
endothelial 0 ADJ F
function 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
ameliorates 0 NOUN F
inflammatory 0 ADJ F
state 0 NOUN F
represented 0 ADJ F
by 0 ADP F
markers 0 NOUN F
of 0 ADP F
myeloperoxidase 0 NOUN F
, 0 PUNCT F
C-reactive 0 ADJ T
protein 0 NOUN F
( 0 PUNCT F
CRP 0 NOUN T
) 0 PUNCT F
and 0 CCONJ F
fibrinogen 0 NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
In 0 ADP T
a 0 DET F
randomized 0 VERB F
, 0 PUNCT F
double-blind 0 ADJ F
fashion 0 NOUN F
; 0 PUNCT F
subjects 0 NOUN F
with 0 ADP F
metabolic 0 ADJ F
syndrome 0 NOUN F
were 0 VERB F
treated 0 VERB F
with 0 ADP F
allopurinol 0 NOUN F
( 0 PUNCT F
n 0 NOUN F
= 0 SYM F
28 0 NUM F
) 0 PUNCT F
or 0 CCONJ F
placebo 0 NOUN F
( 0 PUNCT F
n 0 NOUN F
= 0 SYM F
22 0 NUM F
) 0 PUNCT F
for 0 ADP F
one 0 NUM F
month 0 NOUN F
. 0 PUNCT F

Before 0 ADP T
and 0 CCONJ F
after 0 ADP F
treatment 0 NOUN F
, 0 PUNCT F
blood 0 NOUN F
samples 0 NOUN F
were 0 VERB F
collected 0 ADV F
and 0 CCONJ F
the 0 DET F
flow-mediated B-PHYSICAL ADV F
dilation I-PHYSICAL NOUN F
( I-PHYSICAL PUNCT F
FMD I-PHYSICAL NOUN T
) I-PHYSICAL PUNCT F
and 0 CCONJ F
isosorbide B-PHYSICAL PUNCT F
dinitrate I-PHYSICAL PUNCT F
( 0 PUNCT F
ISDN B-PHYSICAL NOUN T
) 0 PUNCT F
-mediated B-PHYSICAL VERB F
dilation B-PHYSICAL NOUN F
of 0 ADP F
the 0 DET F
brachial 0 ADJ F
artery 0 NOUN F
were 0 ADP F
performed 0 VERB F
. 0 PUNCT F

RESULTS 0 NOUN T
Baseline 0 NOUN T
clinical 0 ADJ F
characteristics 0 NOUN F
of 0 ADP F
the 0 DET F
allopurinol 0 NOUN F
and 0 CCONJ F
placebo 0 NOUN F
groups 0 NOUN F
demonstrated 0 VERB F
no 0 DET F
differences 0 NOUN F
in 0 ADP F
terms 0 NOUN F
of 0 ADP F
clinical B-OTHER ADJ F
characteristics I-OTHER NOUN F
, 0 PUNCT F
endothelial B-PHYSICAL ADJ F
function I-PHYSICAL NOUN F
and 0 CCONJ F
inflammatory B-PHYSICAL ADJ F
markers B-PHYSICAL NOUN F
. 0 PUNCT F

After 0 ADP T
the 0 DET F
treatment 0 NOUN F
with 0 ADP F
allopurinol 0 NOUN F
, 0 PUNCT F
FMD B-PHYSICAL NOUN T
was 0 VERB F
increased 0 VERB F
from 0 ADP F
8.0 0 NUM F
+/- 0 SYM F
0.5 0 NUM F
% 0 SYM F
to 0 ADP F
11.8 0 NUM F
+/- 0 SYM F
0.6 0 NUM F
% 0 SYM F
( 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.01 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
but 0 CCONJ F
there 0 PUNCT F
were 0 VERB F
no 0 DET F
change 0 NOUN F
in 0 ADP F
the 0 DET F
placebo 0 NOUN F
group 0 NOUN F
. 0 PUNCT F

In 0 ADP T
both 0 CCONJ F
groups 0 NOUN F
, 0 PUNCT F
ISDN-mediated B-PHYSICAL VERB T
dilation I-PHYSICAL NOUN F
is 0 VERB F
unaffected 0 VERB F
by 0 ADP F
the 0 DET F
treatment 0 NOUN F
. 0 PUNCT F

As 0 ADP T
a 0 DET F
marker 0 NOUN F
of 0 ADP F
oxidative 0 ADJ F
stress 0 NOUN F
, 0 PUNCT F
allopurinol 0 NOUN F
significantly 0 ADV F
reduced B-PHYSICAL ADV F
malondialdehyde I-PHYSICAL NOUN F
. 0 PUNCT F

Moreover 0 ADV T
, 0 PUNCT F
myeloperoxidase B-PHYSICAL NOUN F
levels I-PHYSICAL NOUN F
were 0 VERB F
reduced 0 VERB F
by 0 ADP F
the 0 DET F
treatment 0 NOUN F
with 0 ADP F
allopurinol 0 NOUN F
( 0 PUNCT F
56.1 0 NUM F
+/- 0 SYM F
3.4 0 NUM F
ng/ml 0 NOUN F
vs. 0 CCONJ F
44.4 0 NUM F
+/- 0 SYM F
2.4 0 NUM F
ng/ml 0 NOUN F
, 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.05 0 NUM F
) 0 PUNCT F
but 0 CCONJ F
there 0 PUNCT F
were 0 VERB F
no 0 DET F
change 0 NOUN F
in 0 ADP F
the 0 DET F
placebo 0 NOUN F
group 0 NOUN F
. 0 PUNCT F

Surprisingly 0 ADV T
, 0 PUNCT F
neither 0 PUNCT F

Topical 0 ADJ T
administration 0 NOUN F
of 0 ADP F
diclofenac 0 NOUN F
( 0 PUNCT F
1 0 NUM F
% 0 SYM F
) 0 PUNCT F
in 0 ADP F
the 0 DET F
prevention 0 NOUN F
of 0 ADP F
miosis B-PHYSICAL NOUN F
during 0 ADP F
vitrectomy 0 NOUN F
. 0 PUNCT F

PURPOSE 0 NOUN T
A 0 CCONJ T
prospective 0 ADJ F
, 0 PUNCT F
randomized 0 VERB F
clinical 0 ADJ F
trial 0 NOUN F
was 0 VERB F
conducted 0 VERB F
to 0 PART F
assess 0 NOUN F
the 0 DET F
usefulness 0 NOUN F
of 0 ADP F
preoperative 0 ADJ F
diclofenac 0 NOUN F
eye 0 NOUN F
drops 0 PUNCT F
in 0 ADP F
maintaining 0 VERB F
mydriasis B-PHYSICAL NOUN F
during 0 ADP F
vitrectomy 0 NOUN F
and 0 CCONJ F
in 0 ADP F
reducing 0 VERB F
postoperative B-PHYSICAL ADJ F
inflammation I-PHYSICAL NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
Fifty 0 ADJ T
consecutive 0 ADJ F
patients 0 NOUN F
undergoing 0 VERB F
vitrectomy 0 NOUN F
were 0 VERB F
randomly 0 ADV F
assigned 0 VERB F
to 0 ADP F
diclofenac 0 NOUN F
( 0 PUNCT F
n 0 NOUN F
= 0 SYM F
24 0 NUM F
) 0 PUNCT F
or 0 CCONJ F
control 0 NOUN F
( 0 PUNCT F
n 0 NOUN F
= 0 SYM F
26 0 NUM F
) 0 PUNCT F
groups 0 NOUN F
. 0 PUNCT F

All 0 DET T
patients 0 NOUN F
received 0 VERB F
a 0 DET F
standard 0 ADJ F
preoperative 0 ADJ F
regimen 0 NOUN F
of 0 ADP F
cyclopentolate 0 NOUN F
( 0 PUNCT F
2 0 NUM F
% 0 SYM F
) 0 PUNCT F
and 0 CCONJ F
phenylephrine 0 NOUN F
hydrochloride 0 NOUN F
( 0 PUNCT F
2.5 0 NUM F
% 0 SYM F
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
diclofenac 0 NOUN F
group 0 NOUN F
also 0 ADV F
received 0 PUNCT F
diclofenac 0 NOUN F
( 0 PUNCT F
1 0 NUM F
% 0 SYM F
) 0 PUNCT F
preoperatively 0 ADV F
. 0 PUNCT F

Pupillary B-PHYSICAL ADJ T
diameter I-PHYSICAL NOUN F
was 0 VERB F
recorded 0 VERB F
at 0 ADP F
four 0 NUM F
time 0 NOUN F
points 0 NOUN F
during 0 ADP F
surgery 0 NOUN F
. 0 PUNCT F

Inflammatory B-PHYSICAL ADJ T
indices I-PHYSICAL NOUN F
were 0 VERB F
measured 0 PUNCT F
postoperatively 0 ADV F
using 0 PUNCT F
slit-lamp 0 NOUN F
examination 0 NOUN F
. 0 PUNCT F

RESULTS 0 NOUN T
After 0 ADP T
induction 0 NOUN F
of 0 ADP F
anesthesia 0 NOUN F
, 0 PUNCT F
the 0 DET F
decrease 0 NOUN F
in 0 ADP F
pupil B-PHYSICAL NOUN F
size I-PHYSICAL NOUN F
was 0 VERB F
not 0 ADV F
significantly 0 ADV F
different 0 ADJ F
between 0 ADP F
the 0 DET F
two 0 NUM F
groups 0 NOUN F
( 0 PUNCT F
P 0 NOUN T
= 0 SYM F
0.112 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
but 0 CCONJ F
for 0 ADP F
the 0 DET F
next 0 ADJ F
two 0 NUM F
stages 0 NOUN F
, 0 PUNCT F
it 0 PUNCT F
was 0 VERB F
significantly 0 ADV F
less 0 ADV F
in 0 ADP F
the 0 DET F
diclofenac 0 NOUN F
group 0 NOUN F
( 0 PUNCT F
P 0 NOUN T
= 0 SYM F
0.012 0 NUM F
and 0 CCONJ F
P 0 NOUN T
= 0 SYM F
0.003 0 NUM F
, 0 PUNCT F
respectively 0 ADV F
) 0 PUNCT F
. 0 PUNCT F

No 0 DET T
significant 0 ADJ F
differences 0 NOUN F
were 0 VERB F
found 0 VERB F
between 0 ADP F
the 0 DET F
two 0 NUM F
groups 0 NOUN F
for 0 ADP F
anterior B-PHYSICAL ADJ F
chamber I-PHYSICAL NOUN F
cells I-PHYSICAL NOUN F
and 0 PUNCT F
redness B-PHYSICAL PUNCT F
in I-PHYSICAL ADP F
the I-PHYSICAL DET F
eye I-PHYSICAL NOUN F
postoperatively 0 NOUN F
( 0 PUNCT F
P 0 NOUN T
= 0 SYM F
0.609 0 NUM F
and 0 CCONJ F
P 0 NOUN T
= 0 SYM F
0.123 0 NUM F
, 0 PUNCT F
respectively 0 ADV F
) 0 PUNCT F
. 0 PUNCT F

However 0 ADV T
, 0 PUNCT F
anterior B-PHYSICAL ADJ F
chamber I-PHYSICAL NOUN F
flare I-PHYSICAL NOUN F
was 0 VERB F
significantly 0 ADV F
greater 0 PUNCT F
in 0 ADP F
the 0 DET F
control 0 NOUN F
group 0 NOUN F
( 0 PUNCT F
P 0 NOUN T
= 0 SYM F
0.035 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
and 0 CCONJ F
patients 0 ADP F
felt 0 PUNCT F
significantly 0 ADV F
more 0 DET F
pain B-PAIN NOUN F
in 0 ADP F
this 0 DET F
group 0 NOUN F
( 0 PUNCT F
P 0 NOUN T
= 0 SYM F
0.001 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

CONCLUSIONS 0 NOUN T
Topical 0 ADJ T
administration 0 NOUN F
of 0 ADP F
diclofenac 0 NOUN F
was 0 VERB F
effective 0 ADJ F
in 0 ADP F
maintaining B-PHYSICAL VERB F
mydriasis I-PHYSICAL NOUN F
during 0 ADP F
vitrectomy 0 NOUN F
and 0 CCONJ F
in 0 ADP F
reducing 0 VERB F
postoperative B-PAIN ADJ F
pain I-PAIN NOUN F
and 0 CCONJ F
anterior B-PHYSICAL ADJ F
chamber I-PHYSICAL NOUN F
flare I-PHYSICAL NOUN F
as 0 VERB F
determined 0 VERB F
by 0 ADP F
slit-lamp 0 NOUN F
evaluations 0 NOUN F
. 0 PUNCT F

Promoting 0 ADV T
health 0 NOUN F
in 0 ADP F
schools 0 NOUN F
through 0 ADP F
a 0 DET F
board 0 ADP F
game 0 NOUN F
. 0 PUNCT F

Primary 0 ADJ T
prevention 0 NOUN F
and 0 CCONJ F
health 0 NOUN F
promotion 0 NOUN F
have 0 PUNCT F
become 0 ADP F
salient 0 ADJ F
topics 0 NOUN F
in 0 ADP F
Canadian 0 ADJ T
society 0 NOUN F
and 0 CCONJ F
in 0 ADP F
nursing 0 VERB F
during 0 ADP F
the 0 DET F
past 0 ADJ F
two 0 NUM F
decades 0 NOUN F
. 0 PUNCT F

The 0 DET T
noncommunicable 0 ADJ F
chronic 0 ADJ F
diseases 0 NOUN F
, 0 PUNCT F
such 0 PUNCT F
as 0 ADP F
heart 0 NOUN F
disease 0 NOUN F
and 0 CCONJ F
cancer 0 NOUN F
, 0 PUNCT F
have 0 PROPN F
been 0 PUNCT F
linked 0 VERB F
to 0 ADP F
specific 0 ADJ F
lifestyle B-MENTAL NOUN F
behaviors I-MENTAL NOUN F
or 0 CCONJ F
habits 0 PUNCT F
, 0 PUNCT F
which 0 ADP F
often 0 ADV F
develop 0 ADV F
early 0 ADJ F
in 0 ADP F
life 0 NOUN F
. 0 PUNCT F

The 0 DET T
success 0 NOUN F
of 0 ADP F
public 0 ADJ F
health 0 NOUN F
efforts 0 NOUN F
to 0 PART F
improve 0 ADJ F
the 0 DET F
health 0 NOUN F
status 0 NOUN F
of 0 ADP F
all 0 DET F
Canadians 0 PUNCT T
depends 0 NOUN F
substantially 0 ADV F
on 0 ADP F
the 0 DET F
success 0 NOUN F
of 0 ADP F
educational 0 ADJ F
programs 0 NOUN F
directed 0 VERB F
toward 0 ADP F
children 0 NOUN F
. 0 PUNCT F

Effective 0 ADJ T
teaching 0 VERB F
strategies 0 NOUN F
that 0 ADP F
seek 0 ADP F
to 0 PART F
promote 0 NOUN F
health 0 NOUN F
and 0 CCONJ F
wellness 0 NOUN F
in 0 ADP F
children 0 NOUN F
need 0 NOUN F
to 0 PART F
be 0 PUNCT F
developed 0 VERB F
and 0 CCONJ F
empirically 0 ADJ F
evaluated 0 VERB F
. 0 PUNCT F

Educational 0 ADJ T
games 0 NOUN F
may 0 VERB F
provide 0 VERB F
an 0 DET F
efficient 0 ADJ F
vehicle 0 NOUN F
for 0 ADP F
carrying 0 ADJ F
out 0 PUNCT F
developmentally 0 ADV F
specific 0 ADJ F
nursing 0 VERB F
interventions 0 NOUN F
in 0 ADP F
school 0 NOUN F
settings 0 NOUN F
. 0 PUNCT F

This 0 DET T
article 0 NOUN F
begins 0 PUNCT F
with 0 ADP F
a 0 DET F
brief 0 ADJ F
overview 0 NOUN F
of 0 ADP F
the 0 DET F
historical 0 ADJ F
origins 0 NOUN F
of 0 ADP F
games 0 NOUN F
, 0 PUNCT F
along 0 PUNCT F
with 0 ADP F
their 0 PUNCT F
advantages 0 NOUN F
and 0 CCONJ F
disadvantages 0 ADJ F
as 0 ADP F
educational 0 ADJ F
strategies 0 NOUN F
. 0 PUNCT F

The 0 DET T
results 0 NOUN F
of 0 ADP F
a 0 DET F
pretest-posttest 0 ADV F
control 0 NOUN F
group 0 NOUN F
design 0 NOUN F
study 0 PUNCT F
that 0 PUNCT F
evaluated 0 VERB F
the 0 DET F
effectiveness 0 NOUN F
of 0 ADP F
a 0 DET F
board 0 ADP F
game 0 NOUN F
as 0 ADP F
a 0 DET F
primary 0 ADJ F
prevention 0 NOUN F
teaching 0 VERB F
strategy 0 NOUN F
with 0 ADP F
23 0 NUM F
sixth 0 ADJ F
grade 0 NOUN F
children 0 NOUN F
in 0 ADP F
Winnipeg 0 PUNCT T
, 0 PUNCT F
Manitoba 0 NOUN T
are 0 VERB F
presented 0 VERB F
. 0 PUNCT F

The 0 DET T
experimental 0 ADJ F
group 0 NOUN F
had 0 PUNCT F
significant 0 ADJ F
gains 0 NOUN F
in 0 ADP F
knowledge B-MENTAL NOUN F
related I-MENTAL VERB F
to I-MENTAL ADP F
anatomy I-MENTAL NOUN F
and I-MENTAL CCONJ F
physiology I-MENTAL NOUN F
, 0 PUNCT F
diet B-MENTAL NOUN F
, 0 PUNCT F
and B-MENTAL CCONJ F
lifestyle I-MENTAL NOUN F
risk 0 NOUN F
factors B-MENTAL NOUN F
associated I-MENTAL VERB F
with I-MENTAL ADP F
the I-MENTAL DET F
development I-MENTAL NOUN F
of I-MENTAL ADP F
heart I-MENTAL NOUN F
disease I-MENTAL PUNCT F

Comparative 0 ADJ T
clinical 0 ADJ F
and 0 CCONJ F
microbiological 0 ADJ F
effects 0 NOUN F
of 0 ADP F
subgingival 0 PUNCT F
metronidazole 0 NOUN F
application 0 NOUN F
in 0 ADP F
adult 0 NOUN F
periodontitis 0 NOUN F
; 0 PUNCT F
12-months 0 NOUN F
results 0 PUNCT F
. 0 PUNCT F

The 0 DET T
aim 0 NOUN F
of 0 ADP F
the 0 DET F
present 0 ADJ F
study 0 NOUN F
was 0 VERB F
to 0 PART F
evaluate 0 NOUN F
the 0 DET F
clinical 0 ADJ F
and 0 CCONJ F
microbiological 0 ADJ F
effects 0 NOUN F
of 0 ADP F
subgingival 0 PUNCT F
application 0 NOUN F
of 0 ADP F
25 0 NUM F
% 0 SYM F
metronidazole 0 NOUN F
dental 0 ADJ F
gel 0 NOUN F
as 0 ADP F
an 0 DET F
adjunct 0 NOUN F
to 0 ADP F
scaling 0 ADP F
and 0 CCONJ F
root 0 NOUN F
planing 0 PUNCT F
( 0 PUNCT F
SRP 0 NOUN T
) 0 PUNCT F
in 0 ADP F
the 0 DET F
treatment 0 NOUN F
of 0 ADP F
adult 0 NOUN F
periodontitis 0 NOUN F
. 0 PUNCT F

Eighty 0 PUNCT T
teeth 0 NOUN F
in 0 ADP F
18 0 NUM F
patients 0 NOUN F
were 0 VERB F
evaluated 0 VERB F
using 0 VERB F
a 0 DET F
split 0 ADJ F
mouth 0 NOUN F
design 0 NOUN F
. 0 PUNCT F

The 0 DET T
test 0 CCONJ F
teeth 0 NOUN F
received 0 VERB F
SRP 0 NOUN T
and 0 CCONJ F
a 0 DET F
25 0 NUM F
% 0 SYM F
metronidazole 0 NOUN F
gel 0 NOUN F
applied 0 PUNCT F
subgingivally 0 NOUN F
on 0 ADP F
days 0 NOUN F
0 0 NUM F
and 0 CCONJ F
7 0 NUM F
. 0 PUNCT F

The 0 DET T
control 0 NOUN F
teeth 0 NOUN F
received 0 VERB F
SRP 0 NOUN T
only 0 ADV F
. 0 PUNCT F

Clinical 0 ADJ T
and 0 CCONJ F
microbiological 0 ADJ F
examinations 0 NOUN F
were 0 VERB F
carried 0 VERB F
out 0 ADP F
before 0 ADP F
treatment 0 NOUN F
and 0 CCONJ F
on 0 ADP F
weeks 0 NOUN F
1 0 NUM F
, 0 PUNCT F
3 0 NUM F
, 0 PUNCT F
7 0 NUM F
, 0 PUNCT F
13 0 NUM F
, 0 PUNCT F
26 0 NUM F
, 0 PUNCT F
38 0 NUM F
and 0 CCONJ F
52 0 NUM F
of 0 ADP F
the 0 DET F
experimental 0 ADJ F
period 0 NOUN F
. 0 PUNCT F

Colony 0 NOUN T
forming 0 VERB F
units 0 NOUN F
of 0 ADP F
Porphyromonas 0 NOUN T
gingivalis 0 NOUN F
and 0 CCONJ F
Prevotella 0 NOUN T
intermedia 0 NOUN F
/ 0 SYM F
Prevotella 0 ADP T
nigrescens 0 NUM F
were 0 VERB F
determined 0 VERB F
. 0 PUNCT F

Both 0 CCONJ T
treatments 0 NOUN F
provided 0 VERB F
significant 0 ADJ F
improvements 0 NOUN F
in 0 ADP F
all 0 DET F
the 0 DET F
clinical B-PHYSICAL ADJ F
and I-PHYSICAL CCONJ F
microbiological I-PHYSICAL ADJ F
parameters I-PHYSICAL NOUN F
( 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.05 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

However 0 ADV T
, 0 PUNCT F
none 0 NUM F
of 0 ADP F
the 0 DET F
differences 0 NOUN F
between 0 ADP F
the 0 DET F
study 0 ADV F
groups 0 NOUN F
were 0 VERB F
statistically 0 ADV F
significant 0 ADJ F
( 0 PUNCT F
P 0 NOUN T
> 0 SYM F
0.05 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

As 0 ADP T
a 0 DET F
conclusion 0 NOUN F
, 0 PUNCT F
the 0 DET F
present 0 ADJ F
study 0 NOUN F
does 0 PUNCT F
not 0 ADV F
provide 0 VERB F
evidence 0 NOUN F
in 0 ADP F
favour B-OTHER NOUN F
of I-OTHER ADP F
the I-OTHER DET F
routine I-OTHER ADJ F
use I-OTHER NOUN F
of I-OTHER ADP F
adjunctive I-OTHER ADJ F
metronidazole I-OTHER NOUN F
dental I-OTHER ADJ F
gel I-OTHER NOUN F
in 0 ADP F
the 0 DET F
treatment 0 NOUN F
of 0 ADP F
adult B-PHYSICAL NOUN F
periodontitis I-PHYSICAL NOUN F
. 0 PUNCT F

The 0 DET T
effects 0 NOUN F
of 0 ADP F
prophylactic 0 ADJ F
management 0 NOUN F
and 0 CCONJ F
therapeutics 0 ADJ F
on 0 ADP F
hypertensive B-PHYSICAL ADJ F
disease I-PHYSICAL NOUN F
in 0 ADP F
pregnancy 0 NOUN F
: 0 PUNCT F
preliminary 0 ADJ F
studies 0 NOUN F
. 0 PUNCT F

A 0 DET T
controlled 0 VERB F
prospective 0 ADJ F
evaluation 0 NOUN F
of 0 ADP F
pregnancy 0 NOUN F
complicated 0 VERB F
by 0 ADP F
chronic 0 ADJ F
hypertension 0 NOUN F
is 0 VERB F
proposed 0 VERB F
and 0 CCONJ F
preliminary 0 ADJ F
data 0 NOUN F
on 0 ADP F
population 0 NOUN F
selection B-OTHER NOUN F
and 0 CCONJ F
pregnancy B-PHYSICAL NOUN F
outcome I-PHYSICAL NOUN F
are 0 ADP F
presented 0 VERB F
. 0 PUNCT F

Sixty-three 0 PUNCT T
women 0 NOUN F
with 0 ADP F
evidence 0 NOUN F
of 0 ADP F
underlying 0 ADP F
hypertensive 0 ADJ F
disease 0 NOUN F
were 0 VERB F
followed 0 VERB F
prospectively 0 ADV F
throughout 0 ADP F
pregnancy 0 NOUN F
. 0 PUNCT F

Twenty-three 0 NUM T
patients 0 NOUN F
were 0 VERB F
followed 0 VERB F
in 0 ADP F
a 0 DET F
protocol 0 NOUN F
of 0 ADP F
intensified 0 PUNCT F
prenatal 0 ADJ F
care 0 NOUN F
and 0 CCONJ F
randomized 0 VERB F
assignment 0 NOUN F
of 0 ADP F
antihypertensive 0 ADJ F
agents 0 NOUN F
: 0 PUNCT F
placebo 0 NOUN F
, 0 PUNCT F
hydralazine 0 NOUN F
, 0 PUNCT F
or 0 CCONJ F
methyldopa 0 NOUN F
. 0 PUNCT F

Forty 0 CCONJ T
patients 0 NOUN F
were 0 VERB F
followed 0 VERB F
in 0 ADP F
the 0 DET F
high-risk 0 NOUN F
pregnancy 0 NOUN F
clinics 0 ADJ F
at 0 ADP F
Duke 0 NOUN T
University 0 NOUN T
. 0 PUNCT F

The 0 DET T
incidence 0 NOUN F
of 0 ADP F
preeclampsia B-PHYSICAL NOUN F
in 0 ADP F
the 0 DET F
randomized 0 VERB F
prophylactic 0 ADP F
antihypertensive 0 ADJ F
group 0 NOUN F
was 0 VERB F
statistically 0 ADV F
lower 0 PUNCT F
than 0 ADP F
that 0 CCONJ F
in 0 ADP F
the 0 DET F
nonrandomized 0 ADJ F
group 0 NOUN F
( 0 PUNCT F
8.7 0 NUM F
versus 0 CCONJ F
32.5 0 NUM F
% 0 SYM F
; 0 PUNCT F
P 0 NOUN T
less 0 ADV F
than 0 ADP F
.01 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

There 0 PUNCT T
were 0 VERB F
no 0 DET F
other 0 ADJ F
statistically 0 ADV F
significant 0 ADJ F
differences B-OTHER NOUN F
between 0 ADP F
the 0 DET F
groups 0 NOUN F
. 0 PUNCT F

The 0 DET T
63 0 NUM F
hypertensive 0 ADJ F
women 0 NOUN F
had 0 DET F
a 0 DET F
high 0 ADJ F
incidence 0 NOUN F
of 0 ADP F
diabetes B-PHYSICAL NOUN F
mellitus I-PHYSICAL NOUN F
diagnosed 0 VERB F
during 0 ADP F
pregnancy 0 NOUN F
( 0 PUNCT F
49.2 0 NUM F
% 0 SYM F
) 0 PUNCT F
as 0 PUNCT F
compared 0 VERB F
to 0 ADP F
the 0 DET F
authors 0 NOUN F
' 0 PUNCT F
general 0 VERB F
obstetric 0 ADJ F
population 0 NOUN F
( 0 PUNCT F
8.1 0 NUM F
% 0 SYM F
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
efficacy 0 NOUN F
of 0 ADP F
audiotapes 0 NOUN F
in 0 ADP F
promoting B-MENTAL VERB F
psychological I-MENTAL ADJ F
well-being I-MENTAL PUNCT F
in 0 ADP F
cancer 0 NOUN F
patients 0 NOUN F
: 0 PUNCT F
a 0 DET F
randomised 0 VERB F
, 0 PUNCT F
controlled 0 VERB F
trial 0 NOUN F
. 0 PUNCT F

Open 0 ADJ T
or 0 CCONJ F
uncontrolled 0 VERB F
studies 0 NOUN F
have 0 ADP F
suggested 0 VERB F
that 0 ADP F
providing 0 ADP F
cancer 0 NOUN F
patients 0 NOUN F
with 0 ADP F
audiotapes 0 NOUN F
of 0 ADP F
their 0 ADP F
clinical 0 ADJ F
interviews 0 NOUN F
can 0 PROPN F
improve 0 VERB F
information 0 NOUN F
recall B-MENTAL NOUN F
and 0 CCONJ F
reduce 0 ADJ F
psychological B-MENTAL ADJ F
distress I-MENTAL NOUN F
. 0 PUNCT F

We 0 PRON T
tested 0 VERB F
these 0 DET F
hypotheses 0 NOUN F
in 0 ADP F
a 0 DET F
'clinician-blind 0 PUNCT F
' 0 PUNCT F
, 0 PUNCT F
prospective 0 ADJ F
, 0 PUNCT F
randomised 0 VERB F
controlled 0 VERB F
trial 0 NOUN F
. 0 PUNCT F

A 0 DET T
total 0 NOUN F
of 0 ADP F
117 0 NUM F
patients 0 NOUN F
newly 0 ADV F
referred 0 ADP F
to 0 ADP F
a 0 DET F
medical 0 ADJ F
oncology 0 NOUN F
clinic 0 NOUN F
who 0 ADP F
were 0 VERB F
to 0 PART F
be 0 PUNCT F
given 0 VERB F
'bad 0 PUNCT F
news 0 NOUN F
' 0 PUNCT F
had 0 PUNCT F
their 0 DET F
consultations 0 NOUN F
audiotaped 0 PUNCT F
. 0 PUNCT F

Blind 0 NOUN T
to 0 ADP F
the 0 DET F
clinician 0 NOUN F
, 0 PUNCT F
patients 0 NOUN F
were 0 VERB F
randomly 0 ADV F
allocated 0 VERB F
to 0 PART F
receive 0 NOUN F
a 0 DET F
copy 0 NOUN F
of 0 ADP F
the 0 DET F
tape 0 NOUN F
to 0 PART F
play 0 NOUN F
at 0 ADP F
home 0 NOUN F
or 0 CCONJ F
not 0 ADV F
( 0 PUNCT F
control 0 NOUN F
group 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

At 0 ADP T
6 0 NUM F
months 0 NOUN F
follow-up 0 NOUN F
, 0 PUNCT F
tape 0 NOUN F
group 0 NOUN F
patients 0 NOUN F
reported 0 ADP F
positive 0 ADJ F
attitudes B-MENTAL NOUN F
to 0 ADP F
the 0 DET F
audiotape 0 NOUN F
and 0 CCONJ F
were 0 VERB F
shown 0 VERB F
to 0 PART F
recall B-MENTAL ADV F
significantly I-MENTAL ADV F
more I-MENTAL DET F
information 0 NOUN F
about B-MENTAL ADP F
their I-MENTAL PUNCT F
illness B-MENTAL NOUN F
than 0 PUNCT F
did 0 PUNCT F
controls 0 NOUN F
. 0 PUNCT F

Overall 0 PUNCT T
improvement 0 NOUN F
in 0 ADP F
psychological B-MENTAL ADJ F
distress I-MENTAL NOUN F
at 0 ADP F
1 0 NUM F
and 0 CCONJ F
6 0 NUM F
months 0 NOUN F
follow-up 0 NOUN F
, 0 PUNCT F
as 0 PUNCT F
measured 0 VERB F
with 0 ADP F
the 0 DET F
30-item B-MENTAL NOUN F
General I-MENTAL VERB T
Health B-MENTAL NOUN T
Questionnaire 0 NOUN T
and B-MENTAL CCONJ F
the I-MENTAL PUNCT F

Efficacy 0 NOUN T
of 0 ADP F
topical 0 ADJ F
azithromycin 0 NOUN F
ophthalmic 0 VERB F
solution 0 NOUN F
1 0 NUM F
% 0 SYM F
in 0 ADP F
the 0 DET F
treatment 0 NOUN F
of 0 ADP F
posterior 0 ADJ F
blepharitis 0 NOUN F
. 0 PUNCT F

INTRODUCTION 0 NOUN T
Azithromycin 0 NOUN T
, 0 PUNCT F
a 0 DET F
broad-spectrum 0 NOUN F
antibiotic 0 CCONJ F
with 0 ADP F
potent 0 ADJ F
anti-inflammatory 0 ADJ F
activities 0 NOUN F
, 0 PUNCT F
has 0 PUNCT F
the 0 DET F
potential 0 ADJ F
to 0 PUNCT F
effectively 0 ADV F
treat 0 PUNCT F
blepharitis B-PHYSICAL NOUN F
, 0 PUNCT F
an 0 DET F
inflammatory 0 ADJ F
disease 0 NOUN F
of 0 ADP F
the 0 DET F
eyelid 0 ADJ F
with 0 ADP F
abnormal 0 ADJ F
eyelid 0 ADJ F
flora 0 PUNCT F
as 0 PUNCT F
an 0 DET F
etiologic 0 ADJ F
determinant 0 NOUN F
. 0 PUNCT F

The 0 DET T
present 0 ADJ F
study 0 NOUN F
compared 0 VERB F
the 0 DET F
efficacy 0 NOUN F
of 0 ADP F
topical 0 ADJ F
azithromycin 0 NOUN F
ophthalmic 0 VERB F
solution 0 NOUN F
1 0 NUM F
% 0 SYM F
( 0 PUNCT F
AzaSite 0 NOUN T
; 0 PUNCT F
Inspire 0 ADP T
Pharmaceuticals 0 PROPN T
, 0 PUNCT F
Inc 0 NOUN T
, 0 PUNCT F
NC 0 NOUN T
, 0 PUNCT F
USA 0 PUNCT T
) 0 PUNCT F
combined 0 VERB F
with 0 ADP F
warm 0 NUM F
compresses 0 PUNCT F
( 0 PUNCT F
azithromycin 0 NOUN F
group 0 NOUN F
) 0 PUNCT F
to 0 ADP F
warm 0 NUM F
compresses 0 PUNCT F
alone 0 ADJ F
( 0 PUNCT F
compress 0 NOUN F
group 0 NOUN F
) 0 PUNCT F
in 0 ADP F
patients 0 NOUN F
with 0 ADP F
posterior 0 ADJ F
blepharitis 0 NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
Twenty-one 0 VERB T
patients 0 NOUN F
diagnosed 0 VERB F
with 0 ADP F
posterior 0 ADJ F
blepharitis 0 NOUN F
were 0 VERB F
randomized 0 VERB F
in 0 ADP F
an 0 DET F
open-label 0 NOUN F
study 0 NOUN F
to 0 PART F
receive 0 NOUN F
either 0 PUNCT F
azithromycin 0 NOUN F
plus 0 CCONJ F
warm 0 NUM F
compresses 0 PUNCT F
( 0 PUNCT F
10 0 NUM F
patients 0 NOUN F
) 0 PUNCT F
, 0 PUNCT F
or 0 CCONJ F
compresses 0 PUNCT F
alone 0 ADJ F
( 0 PUNCT F
11 0 NUM F
patients 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

All 0 DET T
patients 0 NOUN F
were 0 VERB F
instructed 0 VERB F
to 0 PART F
apply 0 NOUN F
compresses 0 CCONJ F
to 0 ADP F
each 0 DET F
eye 0 NOUN F
for 0 ADP F
5-10 0 NUM F
minutes 0 NOUN F
twice 0 ADV F
daily 0 ADJ F
for 0 ADP F
14 0 NUM F
days 0 NOUN F
. 0 PUNCT F

Each 0 DET T
eye 0 NOUN F
in 0 ADP F
the 0 DET F
azithromycin 0 NOUN F
group 0 NOUN F
also 0 ADV F
received 0 CCONJ F
azithromycin 0 NOUN F
solution 0 NOUN F
( 0 PUNCT F
1 0 ADP F
drop 0 VERB F
) 0 PUNCT F
twice 0 ADV F
daily 0 ADJ F
for 0 ADP F
the 0 DET F
first 0 ADJ F
2 0 NUM F
days 0 NOUN F
followed 0 VERB F
by 0 ADP F
once 0 PUNCT F
daily 0 ADJ F
for 0 ADP F
the 0 DET F
next 0 ADJ F
12 0 NUM F
days 0 NOUN F
. 0 PUNCT F

Patients 0 NOUN T
were 0 VERB F
evaluated 0 VERB F
at 0 ADP F
study 0 NOUN F
initiation 0 NOUN F
( 0 PUNCT F
visit 0 NOUN F
1 0 NUM F
) 0 PUNCT F
and 0 CCONJ F
at 0 ADP F
end 0 NOUN F
of 0 ADP F
treatment 0 NOUN F
( 0 PUNCT F
visit 0 NOUN F
2 0 NUM F
) 0 PUNCT F
for 0 ADP F
the 0 DET F
severity 0 NOUN F
of 0 ADP F
five 0 NUM F
clinical 0 ADJ F
signs 0 NOUN F
: 0 PUNCT F
eyelid B-PHYSICAL ADJ F
debris I-PHYSICAL NOUN F
, 0 PUNCT F
eyelid B-PHYSICAL PUNCT F
redness I-PHYSICAL PUNCT F
, 0 PUNCT F
eyelid B-PHYSICAL PUNCT F
swelling I-PHYSICAL SYM F
, 0 PUNCT F
meibomian B-PHYSICAL ADJ F
gland I-PHYSICAL NOUN F
( 0 PUNCT F
MG B-PHYSICAL NOUN T
) 0 PUNCT F
plugging B-PHYSICAL PUNCT F
, 0 PUNCT F
and 0 CCONJ F
the 0 DET F
quality 0 NOUN F
of 0 ADP F
MG B-PHYSICAL NOUN T
secretion I-PHYSICAL NOUN F
. 0 PUNCT F

At 0 ADP T
visit 0 NOUN F
2 0 NUM F
, 0 PUNCT F
patients 0 NOUN F
also 0 ADV F
rated 0 VERB F
their 0 ADP F
degree 0 NOUN F
of 0 ADP F
overall B-OTHER ADJ F
symptomatic I-OTHER ADJ F
relief B-OTHER NOUN F
. 0 PUNCT F

RESULTS 0 NOUN T
Twenty 0 PUNCT T
patients 0 NOUN F
completed 0 NOUN F
the 0 DET F
study 0 NOUN F
. 0 PUNCT F

At 0 ADP T
visit 0 NOUN F
2 0 NUM F
, 0 PUNCT F
patients 0 NOUN F
in 0 ADP F
the 0 DET F
azithromycin 0 NOUN F
group 0 NOUN F
demonstrated 0 VERB F
significant B-MENTAL ADJ F
improvements I-MENTAL NOUN F
in 0 ADP F
MG B-PHYSICAL NOUN T
plugging I-PHYSICAL PUNCT F
, 0 PUNCT F
MG B-PHYSICAL NOUN T
secretions I-PHYSICAL NOUN F
, 0 PUNCT F
and 0 CCONJ F
eyelid B-PHYSICAL PUNCT F
redness I-PHYSICAL PUNCT F
as 0 VERB F
compared 0 VERB F
with 0 ADP F
the 0 DET F
compress 0 NOUN F
group 0 NOUN F
. 0 PUNCT F

In 0 ADP T
the 0 DET F
azithromycin 0 NOUN F
group 0 NOUN F
, 0 PUNCT F
MG B-PHYSICAL NOUN T
plugging I-PHYSICAL PUNCT F
resolved 0 PUNCT F
completely 0 ADV F
in 0 ADP F
three 0 NUM F
patients 0 NOUN F
and 0 CCONJ F
MG B-PHYSICAL NOUN T
secretion I-PHYSICAL NOUN F
returned I-PHYSICAL VERB F
to I-PHYSICAL ADP F
normal I-PHYSICAL ADJ F
in 0 ADP F
two 0 NUM F
patients 0 NOUN F
; 0 PUNCT F
no 0 DET F
such 0 DET F
results 0 NOUN F
were 0 ADV F
seen 0 VERB F
in 0 ADP F
the 0 DET F
compress 0 NOUN F
group 0 NOUN F
. 0 PUNCT F

Furthermore 0 ADV T
, 0 PUNCT F
a 0 DET F
higher 0 PUNCT F
percentage 0 NOUN F
of 0 ADP F
patients 0 NOUN F
in 0 ADP F
the 0 DET F
azithromycin 0 NOUN F
group 0 NOUN F
rated 0 VERB F
overall B-PHYSICAL ADJ F
symptomatic I-PHYSICAL ADJ F
relief I-PHYSICAL NOUN F
as 0 ADP F
excellent 0 ADJ F
or 0 CCONJ F
good 0 ADJ F
. 0 PUNCT F

Visual B-OTHER ADJ T
acuity I-OTHER NOUN F
measurements I-OTHER PUNCT F

Naltrexone 0 NUM T
in 0 ADP F
autistic 0 ADJ F
children 0 NOUN F
: 0 PUNCT F
a 0 DET F
double-blind 0 ADJ F
and 0 CCONJ F
placebo-controlled 0 VERB F
study 0 NOUN F
. 0 PUNCT F

A 0 DET T
double-blind 0 ADJ F
, 0 PUNCT F
placebo-controlled 0 VERB F
study 0 NOUN F
was 0 VERB F
designed 0 VERB F
to 0 PART F
assess 0 NOUN F
critically 0 ADP F
the 0 DET F
effects 0 NOUN F
of 0 ADP F
naltrexone 0 NUM F
on 0 ADP F
behavioral B-MENTAL ADJ F
symptoms I-MENTAL NOUN F
and 0 CCONJ F
learning B-MENTAL ADP F
in 0 ADP F
autistic 0 ADJ F
children 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
its 0 PUNCT F
safety 0 NOUN F
. 0 PUNCT F

This 0 DET T
is 0 VERB F
a 0 DET F
preliminary 0 ADJ F
report 0 NOUN F
on 0 ADP F
18 0 NUM F
children 0 NOUN F
, 0 PUNCT F
ages 0 NOUN F
3.08 0 NUM F
to 0 ADP F
7.99 0 NUM F
years 0 NOUN F
, 0 PUNCT F
who 0 PROPN F
completed 0 PUNCT F
this 0 DET F
ongoing 0 ADV F
study 0 NOUN F
. 0 PUNCT F

Subjects 0 NOUN T
were 0 VERB F
randomly 0 ADV F
assigned 0 VERB F
to 0 ADP F
naltrexone 0 NUM F
or 0 CCONJ F
placebo 0 NOUN F
and 0 CCONJ F
received 0 ADJ F
daily 0 ADJ F
doses 0 NOUN F
over 0 ADP F
a 0 DET F
period 0 NOUN F
of 0 ADP F
21 0 NUM F
days 0 NOUN F
. 0 PUNCT F

Naltrexone 0 NUM T
was 0 VERB F
superior 0 ADJ F
to 0 ADP F
placebo 0 NOUN F
according 0 CCONJ F
to 0 ADP F
blind 0 PUNCT F
Clinical B-MENTAL ADJ T
Global I-MENTAL ADJ T
Consensus I-MENTAL NOUN T
Ratings I-MENTAL NOUN T
( 0 PUNCT F
unpublished 0 VERB F
scale 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

However 0 ADV T
, 0 PUNCT F
other 0 ADJ F
behavioral 0 ADJ F
rating 0 PUNCT F
measures 0 NOUN F
did 0 PUNCT F
not 0 ADV F
confirm 0 VERB F
this 0 DET F
result 0 NOUN F
. 0 PUNCT F

There 0 PUNCT T
was 0 VERB F
only 0 ADV F
a 0 DET F
suggestion 0 NOUN F
that 0 PUNCT F
naltrexone 0 NUM F
reduced 0 VERB F
fidgety B-MENTAL ADJ F
and I-MENTAL CCONJ F
hyperactive I-MENTAL ADJ F
behavior I-MENTAL NOUN F
and 0 CCONJ F
tended 0 VERB F
to 0 ADP F
alleviate 0 ADP F
overall B-MENTAL VERB F
symptomatology I-MENTAL NOUN F
in 0 ADP F
older 0 PUNCT F
children 0 NOUN F
. 0 PUNCT F

Naltrexone 0 NUM T
did 0 PUNCT F
not 0 ADV F
appear 0 VERB F
to 0 PART F
affect 0 NOUN F
discrimination B-MENTAL NOUN F
learning I-MENTAL PUNCT F
. 0 PUNCT F

Results 0 VERB T
are 0 VERB F
preliminary 0 ADJ F
and 0 CCONJ F
, 0 PUNCT F
owing 0 PUNCT F
to 0 ADP F
the 0 DET F
small 0 ADJ F
sample 0 NOUN F
size 0 NOUN F
, 0 PUNCT F
can 0 PRON F
be 0 VERB F
considered 0 VERB F
only 0 ADV F
suggestive 0 ADJ F
until 0 ADP F
this 0 DET F
study 0 NOUN F
is 0 VERB F
completed 0 NOUN F
or 0 CCONJ F
replication 0 NOUN F
is 0 VERB F
obtained 0 VERB F
from 0 ADP F
independent 0 ADJ F
research 0 NOUN F
. 0 PUNCT F

[ 0 PUNCT F
How 0 ADP T
to 0 DET F
treat 0 CCONJ F
the 0 DET F
relapse B-PHYSICAL NOUN F
of I-PHYSICAL ADP F
NSCLC I-PHYSICAL NOUN T
after 0 ADP F
surgery 0 NOUN F
and 0 CCONJ F
chemotherapy 0 NOUN F
? 0 PUNCT F

IFTC 0 NOUN T
0702 0 NUM F
randomized 0 VERB F
phase 0 NOUN F
III 0 NUM T
study 0 NOUN F
] 0 PUNCT F
. 0 PUNCT F

BACKGROUND 0 NOUN T
As 0 ADP T
chemotherapy 0 NOUN F
gains 0 NOUN F
wider 0 PUNCT F
acceptance 0 NOUN F
for 0 ADP F
the 0 DET F
treatment 0 NOUN F
of 0 ADP F
earlier 0 PUNCT F
stages 0 NOUN F
of 0 ADP F
NSCLC 0 NOUN T
, 0 PUNCT F
particularly 0 ADV F
in 0 ADP F
the 0 DET F
adjuvant 0 NOUN F
and 0 CCONJ F
neoadjuvant 0 PUNCT F
setting 0 VERB F
, 0 PUNCT F
physicians 0 NOUN F
face 0 NUM F
a 0 DET F
growing 0 VERB F
population 0 NOUN F
of 0 ADP F
high 0 ADJ F
performance 0 NOUN F
status 0 NOUN F
patients 0 NOUN F
who 0 ADP F
have 0 PUNCT F
relapsed 0 VERB F
after 0 ADP F
their 0 PUNCT F
first-line 0 NOUN F
chemotherapy 0 NOUN F
. 0 PUNCT F

The 0 DET T
type 0 NOUN F
of 0 ADP F
second-line 0 NOUN F
chemotherapy 0 NOUN F
after 0 ADP F
initial 0 ADJ F
adjuvant 0 NOUN F
or 0 CCONJ F
neoadjuvant 0 PUNCT F
treatment 0 NOUN F
with 0 ADP F
a 0 DET F
platinum-based 0 VERB F
regimen 0 NOUN F
remains 0 NOUN F
largely 0 ADV F
undefined 0 PROPN F
. 0 PUNCT F

The 0 DET T
current 0 ADJ F
study 0 NOUN F
has 0 PUNCT F
been 0 PUNCT F
designed 0 VERB F
to 0 PART F
compare 0 NOUN F
the 0 DET F
classical 0 ADJ F
mono 0 NOUN F
chemotherapy 0 NOUN F
docetaxel 0 PUNCT F
with 0 ADP F
a 0 DET F
docetaxel 0 VERB F
cisplatin 0 NOUN F
doublet 0 NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
Patients 0 NOUN T
will 0 ADP F
be 0 VERB F
randomized 0 VERB F
in 0 ADP F
2 0 NUM F
arms 0 NOUN F
. 0 PUNCT F

Arm 0 NOUN T
: 0 PUNCT F
docetaxel 0 ADJ F
cisplatin 0 NOUN F
( 0 PUNCT F
cycles 0 NOUN F
repeated 0 VERB F
every 0 DET F
21 0 NUM F
days 0 NOUN F
) 0 PUNCT F
, 0 PUNCT F
4 0 NUM F
cycles 0 NOUN F
followed 0 VERB F
by 0 ADP F
2 0 NUM F
cycles 0 NOUN F
of 0 ADP F
docetaxel 0 PUNCT F
alone 0 ADJ F
in 0 ADP F
case 0 NOUN F
of 0 ADP F
objective B-PHYSICAL ADJ F
response I-PHYSICAL NOUN F
or 0 CCONJ F
stabilisation 0 NOUN F
. 0 PUNCT F

Arm 0 NOUN T
B 0 NOUN T
: 0 PUNCT F
docetaxel 0 PUNCT F
alone 0 ADJ F
( 0 PUNCT F
cycles 0 NOUN F
repeated 0 VERB F
every 0 DET F
21 0 NUM F
days 0 NOUN F
) 0 PUNCT F
, 0 PUNCT F
4 0 NUM F
cycles 0 NOUN F
followed 0 VERB F
by 0 ADP F
2 0 NUM F
cycles 0 NOUN F
of 0 ADP F
docetaxel 0 PUNCT F
alone 0 ADJ F
in 0 ADP F
case 0 NOUN F
of 0 ADP F
objective 0 ADJ F
response 0 NOUN F
or 0 CCONJ F
stabilisation 0 NOUN F
. 0 PUNCT F

EXPECTED 0 CCONJ T
RESULTS 0 DET T
300 0 NUM F
patients 0 NOUN F
will 0 ADP F
be 0 VERB F
randomized 0 VERB F
with 0 ADP F
a 0 DET F
statistical 0 ADJ F
hypothesis 0 NOUN F
of 0 ADP F
a 0 DET F
progression B-MORTALITY NOUN F
free I-MORTALITY ADJ F
survival I-MORTALITY NOUN F
of 0 ADP F
3 0 NUM F
months 0 NOUN F
in 0 ADP F
the 0 DET F
control 0 NOUN F
arm 0 NOUN F
and 0 CCONJ F
of 0 ADP F
4.5 0 NUM F
months 0 NOUN F
in 0 ADP F
the 0 DET F
experimental 0 ADJ F
arm 0 NOUN F
. 0 PUNCT F

National 0 ADJ T
Surgical 0 ADJ T
Adjuvant 0 NOUN T
Breast 0 NOUN T
and 0 CCONJ F
Bowel 0 NOUN T
Project 0 NOUN T
's 0 PUNCT F
Breast 0 NOUN T
Cancer 0 NOUN T
Prevention 0 NOUN T
Trial 0 NOUN T
. 0 PUNCT F

The 0 DET T
Breast 0 NOUN T
Cancer 0 NOUN T
Prevention 0 NOUN T
Trial 0 NOUN T
is 0 VERB F
the 0 DET F
largest 0 PUNCT F
breast 0 NOUN F
cancer 0 NOUN F
prevention 0 NOUN F
study 0 NOUN F
ever 0 ADV F
undertaken 0 VERB F
. 0 PUNCT F

Administered 0 VERB T
by 0 ADP F
the 0 DET F
National 0 ADJ T
Surgical 0 ADJ T
Adjuvant 0 NOUN T
Breast 0 NOUN T
and 0 CCONJ F
Bowel 0 NOUN T
Project 0 NOUN T
, 0 PUNCT F
it 0 PRON F
is 0 VERB F
the 0 DET F
first 0 ADJ F
trial 0 NOUN F
seeking 0 ADJ F
to 0 PART F
demonstrate 0 NOUN F
whether 0 ADP F
a 0 DET F
drug 0 NOUN F
, 0 PUNCT F
tamoxifen 0 NOUN F
, 0 PUNCT F
can 0 VERB F
prevent 0 VERB F
breast 0 NOUN F
cancer 0 NOUN F
in 0 ADP F
high-risk 0 NOUN F
women 0 NOUN F
. 0 PUNCT F

The 0 DET T
objectives 0 NOUN F
of 0 ADP F
this 0 DET F
trial 0 NOUN F
are 0 ADP F
to 0 PART F
determine 0 NOUN F
whether 0 ADP F
tamoxifen 0 NOUN F
is 0 VERB F
effective 0 ADJ F
in 0 ADP F
1 0 NUM F
) 0 PUNCT F
reducing B-PHYSICAL SYM F
the I-PHYSICAL DET F
incidence 0 NOUN F
of B-PHYSICAL ADP F
invasive I-PHYSICAL ADJ F
breast I-PHYSICAL NOUN F
cancer B-PHYSICAL NOUN F
, 0 PUNCT F
2 0 NUM F
) 0 PUNCT F
reducing 0 NUM F
breast B-MORTALITY NOUN F
cancer I-MORTALITY NOUN F
mortality I-MORTALITY NOUN F
, 0 PUNCT F
3 0 NUM F
) 0 PUNCT F
reducing B-MORTALITY PUNCT F
deaths I-MORTALITY NOUN F
from I-MORTALITY ADP F
cardiovascular B-MORTALITY PUNCT F

Tinidazole 0 NOUN T
and 0 CCONJ F
metronidazole 0 NOUN F
in 0 ADP F
hepatic 0 ADJ F
amoebiasis 0 NOUN F
. 0 PUNCT F

The 0 DET T
efficacy 0 NOUN F
of 0 ADP F
metronidazole 0 NOUN F
and 0 CCONJ F
tinidazole 0 VERB F
has 0 PUNCT F
been 0 PUNCT F
compared 0 VERB F
in 0 ADP F
31 0 NUM F
patients 0 NOUN F
with 0 ADP F
hepatic 0 ADJ F
amoebiasis 0 NOUN F
. 0 PUNCT F

Only 0 ADV T
those 0 PUNCT F
with 0 ADP F
unequivocal 0 ADJ F
clinical 0 ADJ F
, 0 PUNCT F
radiological 0 ADJ F
and 0 CCONJ F
laboratory 0 NOUN F
evidence 0 NOUN F
of 0 ADP F
hepatic 0 ADJ F
amoebiasis 0 NOUN F
were 0 VERB F
included 0 VERB F
; 0 PUNCT F
diagnostic 0 ADJ F
and 0 CCONJ F
therapeutic 0 ADJ F
aspiration 0 NOUN F
was 0 VERB F
performed 0 VERB F
where 0 ADP F
necessary 0 ADJ F
. 0 PUNCT F

15 0 DET F
patients 0 NOUN F
received 0 VERB F
metronidazole 0 NOUN F
and 0 CCONJ F
16 0 NUM F
tinidazole 0 NOUN F
, 0 PUNCT F
in 0 ADP F
random 0 ADJ F
order 0 NOUN F
. 0 PUNCT F

The 0 DET T
2 0 NUM F
groups 0 NOUN F
were 0 VERB F
comparable 0 ADJ F
. 0 PUNCT F

Both 0 CCONJ T
drugs 0 NOUN F
were 0 VERB F
given 0 VERB F
orally 0 ADV F
in 0 ADP F
a 0 DET F
single 0 ADJ F
daily 0 ADJ F
dose 0 NOUN F
of 0 ADP F
2g 0 NOUN F
for 0 ADP F
a 0 DET F
minimum 0 NOUN F
of 0 ADP F
3 0 NUM F
days 0 NOUN F
, 0 PUNCT F
with 0 ADP F
treatment 0 NOUN F
extended 0 CCONJ F
if 0 PUNCT F
considered 0 PUNCT F
clinically 0 ADV F
advisable 0 ADJ F
. 0 PUNCT F

12 0 NUM F
of 0 ADP F
15 0 NUM F
patients 0 NOUN F
( 0 PUNCT F
80 0 NUM F
% 0 SYM F
) 0 PUNCT F
were 0 VERB F
cured B-PHYSICAL VERB F
with 0 ADP F
metronidazole 0 NOUN F
given 0 VERB F
for 0 ADP F
an 0 DET F
average 0 PUNCT F
period 0 NOUN F
of 0 ADP F
7 0 NUM F
days 0 NOUN F
( 0 PUNCT F
range 0 NOUN F
4 0 NUM F
to 0 ADP F
14 0 NUM F
days 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

15 0 NUM F
of 0 ADP F
16 0 NUM F
patients 0 NOUN F
( 0 PUNCT F
93.8 0 NUM F
% 0 SYM F
) 0 PUNCT F
given 0 PUNCT F
tinidazole 0 VERB F
were 0 VERB F
cured B-PHYSICAL VERB F
and 0 CCONJ F
the 0 DET F
mean 0 NOUN F
duration B-OTHER NOUN F
of I-OTHER ADP F
treatment I-OTHER NOUN F
was 0 VERB F
4 0 NUM F
days 0 NOUN F
( 0 PUNCT F
range 0 NOUN F
3 0 NUM F
to 0 ADP F
6 0 NUM F
days 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

There 0 PUNCT T
were 0 VERB F
fewer B-ADVERSE-EFFECTS PUNCT F
side-effects I-ADVERSE-EFFECTS NOUN F
with 0 ADP F
tinidazole 0 NOUN F
. 0 PUNCT F

In 0 ADP T
this 0 DET F
study 0 NOUN F
of 0 ADP F
hepatic 0 ADJ F
amoebiasis 0 NOUN F
in 0 ADP F
Bangladesh 0 NOUN T
, 0 PUNCT F
tinidazole 0 VERB F
was 0 VERB F
found 0 VERB F
to 0 PART F
be 0 PUNCT F
superior 0 ADJ F
to 0 ADP F
metronidazole 0 NOUN F
in 0 ADP F
overall B-OTHER ADJ F
efficacy I-OTHER NOUN F
because 0 PUNCT F
a 0 DET F
shorter 0 PUNCT F
course 0 NOUN F
of 0 ADP F
treatment 0 NOUN F
was 0 VERB F
necessary 0 ADJ F
and 0 CCONJ F
it 0 NOUN F
caused 0 PROPN F
fewer 0 PUNCT F
side-effects B-ADVERSE-EFFECTS NOUN F
. 0 PUNCT F

Lung 0 NOUN T
function 0 NOUN F
and 0 CCONJ F
respiratory 0 ADJ F
symptoms 0 NOUN F
in 0 ADP F
a 0 DET F
1-year 0 NOUN F
randomized 0 VERB F
smoking 0 ADJ F
cessation 0 NOUN F
trial 0 NOUN F
of 0 ADP F
varenicline 0 NOUN F
in 0 ADP F
COPD 0 NOUN T
patients 0 NOUN F
. 0 PUNCT F

UNLABELLED 0 PUNCT T
There 0 PUNCT T
are 0 VERB F
few 0 ADJ F
data 0 NOUN F
concerning 0 VERB F
changes 0 NOUN F
in 0 ADP F
lung 0 NOUN F
function 0 NOUN F
and 0 CCONJ F
respiratory 0 ADJ F
symptoms 0 NOUN F
in 0 ADP F
smokers 0 NOUN F
with 0 ADP F
chronic 0 ADJ F
obstructive 0 ADJ F
pulmonary 0 ADJ F
disease 0 NOUN F
( 0 PUNCT F
COPD 0 NOUN T
) 0 PUNCT F
weeks 0 NOUN F
to 0 ADP F
months 0 PUNCT F
after 0 ADP F
quitting 0 PUNCT F
smoking 0 ADP F
. 0 PUNCT F

We 0 PRON T
examined 0 VERB F
serial 0 ADJ F
changes 0 NOUN F
in 0 ADP F
spirometry 0 NOUN F
and 0 CCONJ F
Clinical 0 ADJ T
COPD 0 NOUN T
Questionnaire 0 NOUN T
( 0 PUNCT F
CCQ 0 NOUN T
) 0 PUNCT F
scores 0 NOUN F
( 0 PUNCT F
measuring 0 VERB F
respiratory 0 ADJ F
symptoms 0 NOUN F
and 0 CCONJ F
health-related 0 VERB F
quality 0 NOUN F
of 0 ADP F
life 0 NOUN F
) 0 PUNCT F
in 0 ADP F
COPD 0 NOUN T
participants 0 NOUN F
by 0 ADP F
smoking 0 ADJ F
status 0 NOUN F
during 0 ADP F
a 0 DET F
smoking 0 VERB F
cessation 0 NOUN F
trial 0 NOUN F
. 0 PUNCT F

In 0 ADP T
this 0 DET F
randomized 0 VERB F
, 0 PUNCT F
double-blind 0 ADJ F
trial 0 NOUN F
, 0 PUNCT F
smokers 0 ADJ F
with 0 ADP F
mild-to-moderate 0 ADJ F
COPD 0 NOUN T
were 0 VERB F
treated 0 VERB F
with 0 ADP F
varenicline 0 NOUN F
1 0 NUM F
mg 0 NOUN F
b.i.d 0 ADV F
. 0 PUNCT F

or 0 CCONJ F
placebo 0 NOUN F
for 0 ADP F
12 0 NUM F
weeks 0 NOUN F
and 0 CCONJ F
followed 0 VERB F
to 0 ADP F
Week 0 NOUN T
52 0 NUM F
. 0 PUNCT F

Primary 0 ADJ T
endpoints 0 NOUN F
of 0 ADP F
abstinence B-MENTAL NOUN F
were 0 VERB F
previously 0 ADV F
reported 0 VERB F
. 0 PUNCT F

Secondary 0 ADJ T
endpoints 0 NOUN F
were 0 VERB F
mean 0 ADJ F
changes B-OTHER NOUN F
from I-OTHER ADP F
baseline I-OTHER NOUN F
in 0 ADP F
post-bronchodilator B-PHYSICAL NOUN F
forced I-PHYSICAL DET F
expired I-PHYSICAL CCONJ F
volume I-PHYSICAL NOUN F
in I-PHYSICAL ADP F
1 I-PHYSICAL NUM F
s I-PHYSICAL NOUN F
( 0 PUNCT F
FEV B-PHYSICAL NOUN T
( 0 PUNCT F
1 B-PHYSICAL NUM F
) 0 PUNCT F
) 0 PUNCT F
and 0 CCONJ F
CCQ B-PHYSICAL NOUN T
scores I-PHYSICAL NOUN F
. 0 PUNCT F

Change B-OTHER NOUN T
from I-OTHER ADP F
baseline I-OTHER NOUN F
in 0 ADP F
post-bronchodilator 0 NOUN F
FEV B-PHYSICAL NOUN T
( I-PHYSICAL PUNCT F
1 I-PHYSICAL NUM F
) 0 PUNCT F
was 0 VERB F
significantly 0 ADV F
improved 0 VERB F
in 0 ADP F
continuous 0 ADJ F
abstainers 0 NOUN F
( 0 PUNCT F
121.8 0 NUM F
mL 0 NOUN F
) 0 PUNCT F
vs. 0 CCONJ F
continuous 0 ADJ F
smokers 0 NOUN F
( 0 PUNCT F
37.9 0 NUM F
mL 0 NOUN F
) 0 PUNCT F
at 0 ADP F
Week 0 NOUN T
12 0 NUM F
( 0 PUNCT F
P 0 NOUN T
= 0 SYM F
0.0069 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
but 0 CCONJ F
not 0 ADV F
at 0 ADP F
Weeks 0 NOUN T
24 0 NUM F
or 0 CCONJ F
52 0 NUM F
. 0 PUNCT F

Mean 0 PUNCT T
change 0 ADV F
from 0 ADP F
baseline 0 NOUN F
at B-OTHER ADP F
Week I-OTHER NOUN T
12 I-OTHER NUM F
in 0 ADP F
CCQ B-PHYSICAL NOUN T
Total 0 VERB T
Score B-PHYSICAL NOUN T
was 0 VERB F
significantly 0 ADV F
better 0 PUNCT F
in 0 ADP F
continuous 0 ADJ F
abstainers 0 NOUN F
( 0 PUNCT F
-1.04 0 NUM F
) 0 PUNCT F
vs. 0 CCONJ F
continuous 0 ADJ F
smokers 0 NOUN F
( 0 PUNCT F
-0.53 0 ADP F
; 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.0001 0 NUM F
) 0 PUNCT F
: 0 PUNCT F
this 0 DET F
improvement 0 NOUN F
was 0 VERB F
sustained 0 VERB F
at 0 ADP F
Weeks 0 NOUN T
24 0 NUM F
and 0 CCONJ F
52 0 NUM F
. 0 PUNCT F

In 0 ADP T
a 0 DET F
1-year 0 ADJ F
cessation 0 NOUN F
trial 0 NOUN F
of 0 ADP F
smokers 0 NOUN F
with 0 ADP F
COPD 0 NOUN T
, 0 PUNCT F
continuous B-MENTAL ADJ F
abstinence B-MENTAL ADJ F
compared 0 VERB F
with 0 ADP F
continuous 0 ADJ F
smoking 0 PART F
significantly 0 ADV F
improved 0 PUNCT F

[ 0 PUNCT F
Prevention 0 NOUN T
of 0 ADP F
migraine B-MENTAL NOUN F
with 0 ADP F
flunarizine 0 NOUN F
and 0 CCONJ F
acetylsalicylic 0 ADJ F
acid 0 NOUN F
. 0 PUNCT F

A 0 DET T
double-blind 0 ADJ F
study 0 NOUN F
] 0 PUNCT F
. 0 PUNCT F

UNLABELLED 0 PUNCT T
30 0 PUNCT F
children 0 NOUN F
between 0 ADP F
7 0 NUM F
and 0 CCONJ F
17 0 NUM F
years 0 NOUN F
suffering 0 VERB F
from 0 ADP F
at 0 ADP F
least 0 ADV F
2 0 NUM F
attacks/month 0 NOUN F
of 0 ADP F
common 0 ADJ F
or 0 CCONJ F
classical 0 ADJ F
migraine 0 NOUN F
since 0 ADP F
more 0 ADV F
than 0 PUNCT F
1 0 NUM F
year 0 NOUN F
were 0 NOUN F
studied 0 VERB F
. 0 PUNCT F

After 0 ADP T
clinical 0 ADJ F
exclusion 0 NOUN F
of 0 ADP F
symptomatic 0 ADJ F
headache 0 NOUN F
4 0 NUM F
weeks 0 NOUN F
were 0 VERB F
documented 0 VERB F
by 0 ADP F
means 0 NOUN F
of 0 ADP F
a 0 DET F
migraine 0 NOUN F
diary 0 PUNCT F
. 0 PUNCT F

Prophylaxis 0 NOUN T
with 0 ADP F
Calcium 0 NOUN T
entry 0 NOUN F
blocker 0 NOUN F
Flunarizine 0 NOUN T
( 0 PUNCT F
Sibelium 0 NOUN T
) 0 PUNCT F
or 0 CCONJ F
Thromboxane 0 NOUN T
A 0 DET T
inhibitor 0 NOUN F
Acetylsalicylic 0 ADJ T
acid 0 NOUN F
( 0 PUNCT F
ASS 0 NOUN T
) 0 PUNCT F
was 0 VERB F
carried 0 VERB F
out 0 ADP F
in 0 ADP F
a 0 DET F
double 0 ADJ F
blind 0 ADJ F
design 0 NOUN F
for 0 ADP F
3 0 NUM F
months 0 NOUN F
. 0 PUNCT F

Medication 0 NOUN T
was 0 VERB F
given 0 VERB F
as 0 ADP F
one 0 NUM F
dosage 0 NOUN F
in 0 ADP F
the 0 DET F
evening 0 NOUN F
: 0 PUNCT F
2-5 0 NUM F
mg/kg 0 NOUN F
KG 0 NOUN T
ASS 0 NOUN T
or 0 CCONJ F
5-10 0 NUM F
mg 0 NOUN F
Flunarizine 0 NOUN T
. 0 PUNCT F

Documented 0 VERB T
attack B-PHYSICAL NOUN F
frequency 0 NOUN F
and 0 CCONJ F
duration B-PHYSICAL NOUN F
were 0 VERB F
controlled 0 VERB F
at 0 ADP F
monthly 0 ADV F
physical 0 ADJ F
examinations 0 NOUN F
. 0 PUNCT F

Final 0 ADJ T
results 0 NOUN F
showed 0 VERB F
no 0 DET F
differences 0 NOUN F
in 0 ADP F
significant 0 ADJ F
reduction 0 NOUN F
of 0 ADP F
attack B-PHYSICAL NOUN F
frequency 0 NOUN F
or 0 CCONJ F
symptoms B-PHYSICAL NOUN F
between 0 ADP F
both 0 CCONJ F
different 0 ADJ F
therapeutic 0 ADJ F
principals 0 NOUN F
. 0 PUNCT F

72.4 0 NUM F
% 0 SYM F
( 0 PUNCT F
ASS 0 NOUN T
73.3 0 NUM F
% 0 SYM F
; 0 PUNCT F
Flunarizine 0 NOUN T
71.4 0 NUM F
% 0 SYM F
) 0 PUNCT F
of 0 ADP F
patients 0 NOUN F
were 0 VERB F
attack-free 0 ADP F
or 0 CCONJ F
had 0 PUNCT F
at 0 VERB F
least 0 ADV F
a 0 DET F
50 0 NUM F
% 0 SYM F
reduction 0 NOUN F
. 0 PUNCT F

Migraine B-PHYSICAL NOUN T
frequency I-PHYSICAL NOUN F
of 0 ADP F
initially 0 ADV F
7-8 0 PUNCT F
was 0 VERB F
reduced 0 VERB F
to 0 ADP F
1-2 0 NUM F
attacks/month 0 NOUN F
. 0 PUNCT F

Duration B-PHYSICAL NOUN T
remained 0 VERB F
constant 0 ADJ F
in 0 ADP F
both 0 CCONJ F
groups 0 NOUN F
( 0 PUNCT F
1-3 0 PUNCT F
h 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

Side 0 NOUN T
effects 0 NOUN F
were 0 VERB F
slight B-ADVERSE-EFFECTS ADJ F
body I-ADVERSE-EFFECTS NOUN F
weight 0 NOUN F
gain B-ADVERSE-EFFECTS NOUN F
or 0 PUNCT F

The 0 DET T
incidence 0 NOUN F
of 0 ADP F
first-dose 0 NOUN F
hypotension 0 NOUN F
with 0 ADP F
quinapril 0 NOUN F
in 0 ADP F
patients 0 NOUN F
with 0 ADP F
mild 0 ADJ F
to 0 ADP F
moderate 0 ADJ F
hypertension 0 NOUN F
. 0 PUNCT F

A 0 DET T
total 0 NOUN F
of 0 ADP F
2242 0 NUM F
patients 0 NOUN F
with 0 ADP F
mild 0 ADJ F
to 0 ADP F
moderate 0 ADJ F
hypertension 0 NOUN F
( 0 PUNCT F
diastolic 0 ADJ F
pressure 0 NOUN F
95-120 0 NUM F
mmHg 0 NOUN F
) 0 PUNCT F
were 0 VERB F
randomised 0 PUNCT F
on 0 ADP F
a 0 DET F
double-blind 0 ADJ F
basis 0 NOUN F
to 0 PART F
receive 0 NOUN F
a 0 DET F
single 0 ADJ F
dose 0 NOUN F
of 0 ADP F
placebo 0 NOUN F
, 0 PUNCT F
5 0 NUM F
mg 0 NOUN F
quinapril 0 NOUN F
or 0 CCONJ F
10 0 NUM F
mg 0 NOUN F
quinapril 0 NOUN F
. 0 PUNCT F

Patients 0 NOUN T
were 0 VERB F
identified 0 VERB F
who 0 ADP F
: 0 PUNCT F
( 0 PUNCT F
a 0 NOUN F
) 0 PUNCT F
met 0 VERB F
the 0 DET F
blood B-PHYSICAL NOUN F
pressure I-PHYSICAL NOUN F
( 0 PUNCT F
BP 0 NOUN T
) 0 PUNCT F
criteria 0 NOUN F
for 0 ADP F
first-dose 0 ADJ F
hypotension 0 NOUN F
( 0 PUNCT F
sitting 0 PUNCT F
or 0 CCONJ F
standing 0 ADV F
systolic 0 ADJ F
BP 0 NOUN T
< 0 SYM F
100 0 NUM F
mmHg 0 NOUN F
, 0 PUNCT F
or 0 CCONJ F
a 0 DET F
fall 0 NOUN F
in 0 ADP F
systolic 0 ADJ F
BP 0 NOUN T
> 0 SYM F
or 0 CCONJ F
= 0 SYM F
20 0 NUM F
mmHg 0 NOUN F
on 0 ADP F
standing 0 VERB F
) 0 PUNCT F
; 0 PUNCT F
( 0 PUNCT F
b 0 NOUN F
) 0 PUNCT F
had 0 PUNCT F
symptoms 0 NOUN F
suggestive 0 ADJ F
of 0 ADP F
hypotension 0 NOUN F
; 0 PUNCT F
and 0 CCONJ F
( 0 PUNCT F
c 0 NOUN F
) 0 PUNCT F
met 0 VERB F
the 0 DET F
BP 0 NOUN T
criteria 0 NOUN F
and 0 CCONJ F
had 0 PUNCT F
symptoms 0 NOUN F
. 0 PUNCT F

In 0 ADP T
all 0 DET F
three 0 NUM F
classifications 0 NOUN F
there 0 VERB F
were 0 VERB F
no 0 DET F
statistically 0 ADV F
significant 0 ADJ F
differences 0 NOUN F
between 0 ADP F
the 0 DET F
incidences 0 DET F
in 0 ADP F
placebo 0 NOUN F
and 0 CCONJ F
combined 0 VERB F
active 0 ADJ F
treatment 0 NOUN F
groups 0 NOUN F
, 0 PUNCT F
or 0 CCONJ F
between 0 ADP F
those 0 CCONJ F
in 0 ADP F
the 0 DET F
two 0 NUM F
quinapril 0 NOUN F
groups 0 NOUN F
. 0 PUNCT F

No 0 DET T
associated 0 VERB F
serious B-ADVERSE-EFFECTS ADJ F
adverse I-ADVERSE-EFFECTS ADJ F
events I-ADVERSE-EFFECTS NOUN F
were 0 VERB F
reported 0 VERB F
. 0 PUNCT F

In 0 ADP T
the 0 DET F
low-risk 0 NOUN F
population 0 NOUN F
studied 0 VERB F
, 0 PUNCT F
it 0 PRON F
would 0 PART F
appear 0 VERB F
that 0 ADP F
the 0 DET F
incidence 0 NOUN F
of 0 ADP F
first-dose 0 NOUN F
hypotension 0 NOUN F
with 0 ADP F
quinapril 0 NOUN F
is 0 ADJ F
similar 0 ADJ F
to 0 ADP F
placebo 0 NOUN F
and 0 CCONJ F
is 0 VERB F
not 0 ADV F
dose-related 0 PUNCT F
. 0 PUNCT F

Rapid-sequence 0 NOUN T
intubation 0 NOUN F
of 0 ADP F
head 0 NOUN F
trauma 0 NOUN F
patients 0 NOUN F
: 0 PUNCT F
prevention 0 NOUN F
of 0 ADP F
fasciculations B-PHYSICAL NOUN F
with 0 ADP F
pancuronium 0 NOUN F
versus 0 CCONJ F
minidose 0 NOUN F
succinylcholine 0 ADJ F
. 0 PUNCT F

INTRODUCTION 0 NOUN T
Fasciculations B-PHYSICAL PROPN T
during 0 ADP F
rapid-sequence 0 NOUN F
intubation 0 NOUN F
may 0 VERB F
lead 0 VERB F
to 0 ADP F
increased 0 VERB F
intracranial 0 ADJ F
pressure 0 NOUN F
and 0 CCONJ F
emesis B-PHYSICAL NOUN F
with 0 ADP F
aspiration 0 NOUN F
. 0 PUNCT F

Standard 0 ADJ T
rapid-sequence 0 NOUN F
intubation 0 NOUN F
requires 0 NOUN F
a 0 DET F
nondepolarizing 0 SYM F
blocking 0 DET F
agent 0 NOUN F
before 0 ADP F
succinylcholine 0 PUNCT F
administration 0 NOUN F
. 0 PUNCT F

HYPOTHESIS 0 NOUN T
Prevention 0 NOUN T
of 0 ADP F
fasciculations B-PHYSICAL NOUN F
during 0 ADP F
rapid-sequence 0 NOUN F
intubation 0 NOUN F
of 0 ADP F
head 0 NOUN F
trauma 0 NOUN F
patients 0 NOUN F
can 0 VERB F
be 0 VERB F
accomplished 0 VERB F
as 0 PUNCT F
safely 0 PUNCT F
and 0 CCONJ F
effectively 0 ADV F
with 0 ADP F
minidose 0 NOUN F
succinylcholine 0 ADJ F
as 0 PUNCT F
with 0 ADP F
a 0 DET F
defasciculating 0 ADJ F
dose 0 NOUN F
of 0 ADP F
pancuronium 0 NOUN F
. 0 PUNCT F

DESIGN 0 NOUN T
A 0 CCONJ T
prospective 0 ADJ F
, 0 PUNCT F
randomized 0 VERB F
, 0 PUNCT F
double-blind 0 ADJ F
study 0 NOUN F
. 0 PUNCT F

SETTING 0 NUM T
An 0 DET T
inner-city 0 NOUN F
county 0 NOUN F
trauma 0 NOUN F
center 0 NOUN F
with 0 ADP F
70,000 0 NUM F
patient 0 NOUN F
visits 0 NOUN F
per 0 ADP F
year 0 NOUN F
. 0 PUNCT F

PARTICIPANTS 0 ADP T
Sequential 0 PUNCT T
adult 0 NOUN F
head 0 NOUN F
trauma 0 NOUN F
patients 0 NOUN F
requiring 0 VERB F
rapid-sequence 0 NOUN F
intubation 0 NOUN F
who 0 ADP F
had 0 ADJ F
no 0 DET F
contraindications 0 NOUN F
to 0 ADP F
succinylcholine 0 PUNCT F
or 0 CCONJ F
pancuronium 0 NOUN F
. 0 PUNCT F

INTERVENTIONS 0 NOUN T
Each 0 PUNCT T
head 0 NOUN F
trauma 0 NOUN F
patient 0 NOUN F
requiring 0 VERB F
rapid-sequence 0 NOUN F
intubation 0 NOUN F
who 0 ADP F
met 0 VERB F
the 0 DET F
inclusion 0 NOUN F
criteria 0 NOUN F
received 0 VERB F
standard 0 ADJ F
rapid-sequence 0 NOUN F
intubation 0 NOUN F
maneuvers 0 NOUN F
and 0 CCONJ F
lidocaine 0 NOUN F
( 0 PUNCT F
1 0 NUM F
mg/kg 0 NOUN F
) 0 PUNCT F
IV 0 NUM T
. 0 PUNCT F

Patients 0 NOUN T
were 0 VERB F
randomized 0 VERB F
to 0 PART F
receive 0 NOUN F
either 0 PUNCT F
minidose 0 NOUN F
succinylcholine 0 ADJ F
( 0 PUNCT F
0.1 0 NUM F
mg/kg 0 NOUN F
) 0 PUNCT F
or 0 CCONJ F
pancuronium 0 NOUN F
( 0 PUNCT F
0.03 0 NUM F
mg/kg 0 NOUN F
) 0 PUNCT F
IV 0 NUM T
one 0 NUM F
minute 0 ADJ F
prior 0 PUNCT F
to 0 ADP F
the 0 DET F
full 0 ADJ F
paralytic 0 ADJ F
dose 0 NOUN F
of 0 ADP F
succinylcholine 0 ADJ F
( 0 PUNCT F
1.5 0 NUM F
mg/kg 0 NOUN F
) 0 PUNCT F
IV 0 NUM T
. 0 PUNCT F

Fasciculations B-PHYSICAL NOUN T
were 0 VERB F
recorded 0 VERB F
using 0 VERB F
a 0 DET F
graded B-OTHER VERB F
visual I-OTHER ADJ F
scale I-OTHER NOUN F
. 0 PUNCT F

RESULTS 0 NOUN T
Of 0 ADP T
46 0 NUM F
patients 0 NOUN F
, 0 PUNCT F
eight 0 NUM F
of 0 ADP F
19 0 NUM F
( 0 PUNCT F
42 0 NUM F
% 0 SYM F
) 0 PUNCT F
in 0 ADP F
the 0 DET F
pancuronium 0 NOUN F
group 0 NOUN F
and 0 CCONJ F
six 0 NUM F
of 0 ADP F
27 0 NUM F
( 0 PUNCT F
22 0 NUM F
% 0 SYM F
) 0 PUNCT F
in 0 ADP F
the 0 DET F
succinylcholine 0 PUNCT F
group 0 NOUN F
experienced 0 VERB F
fasciculations B-PHYSICAL NOUN F
. 0 PUNCT F

No 0 DET T
statistically 0 ADV F
significant 0 ADJ F
difference 0 NOUN F
in 0 ADP F
fasciculations B-PHYSICAL NOUN F
was 0 ADV F
detected 0 VERB F
between 0 ADP F
the 0 DET F
two 0 NUM F
groups 0 NOUN F
using 0 PROPN F
chi 0 NOUN F
2 0 NUM F
analysis 0 NOUN F
. 0 PUNCT F

Complete B-PHYSICAL ADJ T
relaxation I-PHYSICAL NOUN F
of I-PHYSICAL ADP F
the I-PHYSICAL DET F
cords I-PHYSICAL NOUN F
was 0 VERB F
present 0 ADJ F
in 0 ADP F
all 0 ADP F
but 0 CCONJ F
two 0 NUM F
patients 0 NOUN F
, 0 PUNCT F
one 0 NUM F
in 0 ADP F
each 0 DET F
group 0 NOUN F
. 0 PUNCT F

No 0 DET T
patient 0 NOUN F
in 0 ADP F
either 0 PUNCT F
group 0 NOUN F
experienced 0 ADP F
emesis B-PHYSICAL NOUN F
or 0 CCONJ F
significant B-PHYSICAL ADJ F
dysrhythmias I-PHYSICAL NOUN F
. 0 PUNCT F

CONCLUSION 0 NOUN T
Pretreatment 0 NOUN T
with 0 ADP F
minidose 0 NOUN F
succinylcholine 0 ADJ F
causes 0 ADP F
no 0 DET F
greater 0 PUNCT F
incidence 0 NOUN F
of 0 ADP F
fasciculations B-PHYSICAL NOUN F
than 0 CCONJ F
pancuronium 0 NOUN F
in 0 ADP F
rapid-sequence 0 NOUN F
intubation 0 NOUN F
of 0 ADP F
head 0 NOUN F
trauma 0 NOUN F
patients 0 NOUN F
in 0 ADP F
an 0 DET F
ED 0 NOUN T
setting 0 VERB F
. 0 PUNCT F

Thus 0 ADV T
succinylcholine 0 ADJ F
may 0 VERB F
be 0 VERB F
used 0 VERB F
as 0 ADP F
the 0 DET F
sole 0 ADJ F
paralytic 0 ADJ F
agent 0 NOUN F
in 0 ADP F
rapid-sequence 0 NOUN F
intubation 0 NOUN F
of 0 ADP F
head 0 NOUN F
trauma 0 NOUN F
patients 0 NOUN F
. 0 PUNCT F

In 0 ADJ T
vitro 0 ADJ F
determination 0 NOUN F
of 0 ADP F
the 0 DET F
chromatic B-OTHER ADJ F
effect 0 NOUN F
of 0 ADP F
a 0 DET F
silver 0 NOUN F
nanoparticles 0 PUNCT F
solution 0 NOUN F
linked 0 VERB F
to 0 ADP F
the 0 DET F
gantrez 0 ADJ F
S-97 0 PUNCT T
copolymer 0 NOUN F
on 0 ADP F
tooth 0 NOUN F
enamel 0 NOUN F
. 0 PUNCT F

Silver 0 NOUN T
nanoparticles 0 NOUN F
( 0 PUNCT F
NNPs 0 NOUN T
) 0 PUNCT F
, 0 PUNCT F
alone 0 ADJ F
or 0 CCONJ F
in 0 ADP F
combination 0 NOUN F
with 0 ADP F
the 0 DET F
bioadhesive 0 ADJ F
Gantrez 0 NOUN T
S-97 0 NUM T
, 0 PUNCT F
have 0 CCONJ F
demonstrated 0 VERB F
their 0 PUNCT F
efficacy 0 NOUN F
against 0 ADP F
Streptococcus 0 NOUN T
mutans 0 VERB F
; 0 PUNCT F
however 0 ADV F
, 0 PUNCT F
it 0 PRON F
is 0 VERB F
not 0 ADV F
known 0 VERB F
if 0 PUNCT F
this 0 DET F
combination 0 NOUN F
changes 0 ADP F
the 0 DET F
color B-OTHER NOUN F
of I-OTHER ADP F
teeth I-OTHER NOUN F
. 0 PUNCT F

The 0 DET T
aim 0 NOUN F
of 0 ADP F
this 0 DET F
work 0 NOUN F
was 0 VERB F
to 0 ADV F
measure 0 VERB F
the 0 DET F
color B-OTHER ADJ F
changes I-OTHER NOUN F
occurring 0 VERB F
after 0 ADP F
the 0 DET F
use 0 NOUN F
of 0 ADP F
a 0 DET F
Gantrez-NNP 0 NOUN T
combination 0 NOUN F
on 0 ADP F
enamel 0 NOUN F
tooth 0 NOUN F
blocks 0 NOUN F
. 0 PUNCT F

Two 0 NUM T
study 0 ADV F
groups 0 NOUN F
were 0 VERB F
randomly 0 ADV F
formed 0 VERB F
: 0 PUNCT F
enamel 0 NOUN F
blocks 0 PUNCT F
brushed 0 PUNCT F
with 0 ADP F
( 0 PUNCT F
a 0 NOUN F
) 0 PUNCT F
the 0 DET F
Gantrez-NNP 0 NOUN T
combination 0 NOUN F
and 0 CCONJ F
( 0 PUNCT F
b 0 NOUN F
) 0 PUNCT F
conventional 0 ADJ F
toothpaste 0 NOUN F
, 0 PUNCT F
for 0 ADP F
1 0 NUM F
minute 0 VERB F
once 0 PUNCT F
daily 0 ADJ F
for 0 ADP F
4 0 NUM F
weeks 0 NOUN F
, 0 PUNCT F
then 0 ADV F
rinsed 0 NOUN F
with 0 ADP F
distilled 0 VERB F
water 0 NOUN F
and 0 CCONJ F
placed 0 VERB F
in 0 ADP F
thymol 0 NOUN F
solution 0 NOUN F
. 0 PUNCT F

Color B-OTHER NOUN T
changes I-OTHER NOUN F
in I-OTHER ADP F
the I-OTHER DET F
enamel I-OTHER NOUN F
blocks I-OTHER CCONJ F
were 0 VERB F
measured 0 VERB F
using 0 VERB F
a 0 DET F
Minolta B-OTHER NOUN T
colorimeter I-OTHER NOUN F
CR300 I-OTHER NOUN T
. 0 PUNCT F

Analysis 0 NOUN T
of 0 ADP F
mixed 0 VERB F
models 0 NOUN F
was 0 VERB F
performed 0 VERB F
with 0 ADP F
R 0 NOUN T
2.10.1 0 NOUN F
at 0 ADP F
a 0 DET F
95 0 NUM F
% 0 SYM F
confidence 0 NOUN F
level 0 NOUN F
, 0 PUNCT F
using 0 VERB F
the 0 DET F
nonlinear 0 ADJ F
mixed 0 VERB F
effects 0 NOUN F
( 0 PUNCT F
NLME 0 NOUN T
) 0 PUNCT F
package 0 NOUN F
. 0 PUNCT F

The 0 DET T
results 0 NOUN F
showed 0 VERB F
that 0 ADP F
there 0 PUNCT F
were 0 VERB F
no 0 DET F
color B-OTHER ADJ F
changes I-OTHER NOUN F
over I-OTHER PUNCT F
time I-OTHER NOUN F
, 0 PUNCT F
only 0 ADV F
a 0 DET F
high B-PHYSICAL ADJ F
luminosity I-PHYSICAL NOUN F
equal I-PHYSICAL ADJ F
in 0 ADP F
both 0 CCONJ F
groups 0 NOUN F
. 0 PUNCT F

Our 0 PUNCT T
study 0 NOUN F
showed 0 VERB F
that 0 ADP F
the 0 DET F
use 0 NOUN F
of 0 ADP F
the 0 DET F
Gantrez-NNP 0 NOUN T
combination 0 NOUN F
is 0 VERB F
safe B-OTHER ADJ F
with 0 ADP F
respect 0 NOUN F
to 0 ADP F
dental B-OTHER ADJ F
esthetics I-OTHER ADJ F
in 0 ADP F
the 0 DET F
control 0 NOUN F
of 0 ADP F
S. 0 NOUN T
mutans B-OTHER ADV F
. 0 PUNCT F

Central 0 ADJ T
nervous 0 ADJ F
system 0 NOUN F
serotonin 0 NOUN F
function 0 NOUN F
and 0 CCONJ F
cardiovascular B-PHYSICAL ADJ F
responses I-PHYSICAL NOUN F
to 0 ADP F
stress 0 NOUN F
. 0 PUNCT F

OBJECTIVE 0 NOUN T
The 0 DET T
objective 0 NOUN F
of 0 ADP F
this 0 DET F
study 0 NOUN F
was 0 VERB F
to 0 PART F
evaluate 0 NOUN F
the 0 DET F
impact 0 NOUN F
of 0 ADP F
indices 0 NOUN F
of 0 ADP F
central 0 ADJ F
nervous 0 ADJ F
system 0 NOUN F
( 0 PUNCT F
CNS 0 NOUN T
) 0 PUNCT F
serotonin 0 NOUN F
function 0 NOUN F
on 0 ADP F
cardiovascular B-PHYSICAL ADJ F
reactivity I-PHYSICAL NOUN F
to 0 ADP F
mental 0 ADJ F
stress 0 NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
Lumbar 0 ADJ T
puncture 0 NOUN F
was 0 VERB F
performed 0 VERB F
on 0 ADP F
54 0 NUM F
healthy 0 ADJ F
volunteers 0 NOUN F
to 0 PART F
obtain 0 NOUN F
cerebrospinal 0 ADJ F
fluid 0 NOUN F
( 0 PUNCT F
CSF 0 NOUN T
) 0 PUNCT F
for 0 ADP F
determination 0 NOUN F
of 0 ADP F
5-hydroxyindoleacetic 0 ADJ F
acid 0 NOUN F
( 0 PUNCT F
5HIAA 0 NOUN F
) 0 PUNCT F
levels 0 NOUN F
. 0 PUNCT F

Genotypes 0 NOUN T
were 0 VERB F
determined 0 VERB F
with 0 ADP F
respect 0 NOUN F
to 0 ADP F
a 0 DET F
functional 0 ADJ F
polymorphism 0 NOUN F
of 0 ADP F
the 0 DET F
serotonin 0 NOUN F
transporter 0 NOUN F
gene 0 NOUN F
promoter 0 NOUN F
region 0 NOUN F
( 0 PUNCT F
5HTTLPR 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

Subjects 0 NOUN T
then 0 ADV F
underwent 0 PUNCT F
mental 0 ADJ F
stress 0 NOUN F
testing 0 VERB F
. 0 PUNCT F

RESULTS 0 DET T
Persons 0 NOUN T
with 0 ADP F
one 0 NUM F
or 0 CCONJ F
two 0 NUM F
long 0 ADJ F
( 0 PUNCT F
l 0 NOUN F
) 0 PUNCT F
5HTTLPR 0 NOUN F
alleles 0 NOUN F
had 0 PUNCT F
CSF B-PHYSICAL NOUN T
levels I-PHYSICAL NOUN F
of 0 ADP F
the 0 DET F
major 0 ADJ F
serotonin 0 NOUN F
metabolite 0 NOUN F
, 0 PUNCT F
5HIAA 0 NOUN F
, 0 PUNCT F
that 0 ADP F
were 0 VERB F
50 0 NUM F
% 0 SYM F
higher 0 PUNCT F
than 0 PUNCT F
those 0 ADP F
of 0 ADP F
persons 0 NOUN F
with 0 ADP F
the 0 DET F
s/s 0 NOUN F
5HTTLPR 0 NOUN F
genotype 0 NOUN F
. 0 PUNCT F

Persons 0 NOUN T
with 0 ADP F
one 0 NUM F
or 0 CCONJ F
two 0 NUM F
l 0 NOUN F
alleles 0 NOUN F
or 0 CCONJ F
higher 0 PUNCT F
CSF B-PHYSICAL NOUN T
5HIAA I-PHYSICAL NOUN F
levels I-PHYSICAL NOUN F
also 0 ADV F
exhibited 0 VERB F
greater 0 PUNCT F
blood B-PHYSICAL NOUN F
pressure I-PHYSICAL NOUN F
and 0 CCONJ F
heart B-PHYSICAL NOUN F
rate I-PHYSICAL NOUN F
responses I-PHYSICAL NOUN F
to 0 ADP F
a 0 DET F
mental 0 ADJ F
stress 0 NOUN F
protocol 0 NOUN F
. 0 PUNCT F

CONCLUSIONS 0 NOUN T
These 0 DET T
findings 0 NOUN F
suggest 0 VERB F
the 0 DET F
5HTTLPR 0 NOUN F
polymorphism 0 NOUN F
affects 0 NOUN F
CNS 0 NOUN T
serotonin 0 NOUN F
function 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
they 0 PRON F
are 0 VERB F
consistent 0 ADJ F
with 0 ADP F
the 0 DET F
general 0 ADJ F
hypothesis 0 NOUN F
that 0 ADP F
CNS 0 NOUN T
serotonin 0 NOUN F
function 0 NOUN F
is 0 VERB F
involved 0 VERB F
in 0 ADP F
the 0 DET F
regulation 0 NOUN F
of 0 ADP F
potentially 0 ADV F
health-damaging 0 PUNCT F
biobehavioral 0 ADJ F
characteristics 0 NOUN F
. 0 PUNCT F

In 0 ADP T
particular 0 NOUN F
, 0 PUNCT F
the 0 DET F
l 0 NOUN F
allele 0 NOUN F
could 0 VERB F
contribute 0 VERB F
, 0 PUNCT F
through 0 ADP F
its 0 PUNCT F
association 0 NOUN F
with 0 ADP F
increased 0 VERB F
cardiovascular B-PHYSICAL ADJ F
reactivity I-PHYSICAL NOUN F
to 0 ADP F
stress 0 NOUN F
, 0 PUNCT F
to 0 ADP F
increased 0 NOUN F
risk 0 NOUN F
of 0 ADP F
cardiovascular 0 ADJ F
disease 0 NOUN F
. 0 PUNCT F

[ 0 PUNCT F
Mitoxantrone 0 ADP T
( 0 PUNCT F
MTX 0 NOUN T
) 0 PUNCT F
versus 0 CCONJ F
mitomycin 0 NUM F
C 0 NOUN T
( 0 PUNCT F
MMC 0 NOUN T
) 0 PUNCT F
in 0 ADP F
the 0 DET F
ablative 0 ADJ F
treatment 0 NOUN F
of 0 ADP F
Ta 0 NOUN T
, 0 PUNCT F
T1 0 NOUN T
superficial 0 ADJ F
bladder 0 NOUN F
tumors 0 NOUN F
. 0 PUNCT F

Phase 0 NOUN T
III 0 NUM T
, 0 PUNCT F
randomized 0 VERB F
prospective 0 ADJ F
study 0 NOUN F
] 0 PUNCT F
. 0 PUNCT F

A 0 DET T
prospective 0 ADJ F
randomized 0 VERB F
study 0 NOUN F
was 0 VERB F
conducted 0 VERB F
to 0 PART F
determine 0 NOUN F
the 0 DET F
ablation B-PHYSICAL NOUN F
capacity I-PHYSICAL NOUN F
of 0 ADP F
mitoxantrone 0 PUNCT F
in 0 ADP F
Ta-T1 0 PUNCT T
superficial 0 VERB F
bladder 0 NOUN F
tumors 0 NOUN F
versus 0 CCONJ F
mitomycin 0 NUM F
C 0 NOUN T
, 0 PUNCT F
a 0 DET F
drug 0 NOUN F
whose 0 ADP F
intravesical 0 ADJ F
ablation 0 NOUN F
properties 0 NOUN F
are 0 VERB F
well-known 0 VERB F
. 0 PUNCT F

Fifty-seven 0 ADJ T
patients 0 NOUN F
comprised 0 VERB F
the 0 DET F
study 0 NOUN F
. 0 PUNCT F

The 0 DET T
tumor 0 NOUN F
was 0 VERB F
not 0 ADV F
completely 0 ADV F
resected 0 PUNCT F
when 0 ADP F
the 0 DET F
patient 0 NOUN F
underwent 0 VERB F
TUR 0 NOUN T
. 0 PUNCT F

This 0 DET T
residual 0 ADJ F
tumor 0 NOUN F
was 0 VERB F
used 0 VERB F
as 0 ADP F
control 0 NOUN F
. 0 PUNCT F

The 0 DET T
patients 0 NOUN F
were 0 VERB F
treated 0 VERB F
with 0 ADP F
either 0 CCONJ F
20 0 NUM F
mg 0 NOUN F
Mitoxantrone 0 ADV T
or 0 CCONJ F
40 0 NUM F
mg 0 NOUN F
mitomycin 0 NUM F
C 0 NOUN T
weekly 0 ADV F
for 0 ADP F
8 0 NUM F
weeks 0 NOUN F
and 0 CCONJ F
two 0 NUM F
other 0 ADJ F
instillations 0 CCONJ F
every 0 DET F
15 0 NUM F
days 0 NOUN F
in 0 ADP F
50 0 NUM F
ml 0 NOUN F
saline 0 ADJ F
solution 0 NOUN F
. 0 PUNCT F

Response 0 NOUN T
to 0 ADP F
therapy B-OTHER NOUN F
was 0 VERB F
evaluated 0 VERB F
between 0 ADP F
the 0 DET F
4th 0 NOUN F
and 0 CCONJ F
8th 0 ADJ F
week 0 NOUN F
and 0 CCONJ F
classified 0 VERB F
as 0 PUNCT F
complete B-OTHER ADJ F
response 0 NOUN F
( B-OTHER PUNCT F
CR I-OTHER NOUN T
) B-OTHER PUNCT F
, 0 PUNCT F
defined 0 VERB F
as 0 ADP F
no 0 DET F
gross B-PHYSICAL ADJ F
and 0 CCONJ F
microscopic B-PHYSICAL ADJ F
evidence I-PHYSICAL NOUN F
of B-PHYSICAL ADP F
residual 0 ADJ F
tumor B-PHYSICAL NOUN F
, 0 PUNCT F
or 0 CCONJ F
no 0 DET F
response 0 NOUN F
( B-OTHER PUNCT F
NR I-OTHER PUNCT T

The 0 DET T
influence 0 NOUN F
of 0 ADP F
sequential 0 ADJ F
annual 0 ADJ F
vaccination 0 NOUN F
and 0 CCONJ F
of 0 ADP F
DHEA 0 NOUN T
administration 0 NOUN F
on 0 ADP F
the 0 DET F
efficacy 0 NOUN F
of 0 ADP F
the 0 DET F
immune 0 ADJ F
response 0 NOUN F
to 0 ADP F
influenza 0 NOUN F
vaccine 0 NOUN F
in 0 ADP F
the 0 DET F
elderly 0 NOUN F
. 0 PUNCT F

The 0 DET T
present 0 ADJ F
study 0 NOUN F
examined 0 VERB F
the 0 DET F
effect 0 NOUN F
of 0 ADP F
repeated 0 VERB F
vaccination 0 NOUN F
and 0 CCONJ F
of 0 ADP F
dehydroepiandrosterone 0 NOUN F
( 0 PUNCT F
DHEA 0 NOUN T
) 0 PUNCT F
treatment 0 NOUN F
on 0 ADP F
the 0 DET F
immune 0 ADJ F
response 0 NOUN F
to 0 ADP F
influenza 0 NOUN F
vaccine 0 NOUN F
in 0 ADP F
elderly 0 ADJ F
subjects 0 NOUN F
. 0 PUNCT F

Seventy-one 0 NUM T
elderly 0 ADJ F
volunteers 0 NOUN F
, 0 PUNCT F
aged 0 ADP F
61-89 0 NUM F
years 0 NOUN F
, 0 PUNCT F
enrolled 0 ADV F
in 0 ADP F
a 0 DET F
prospective 0 ADJ F
randomized 0 VERB F
, 0 PUNCT F
double-blind 0 ADJ F
study 0 NOUN F
to 0 PART F
receive 0 NOUN F
either 0 PUNCT F
DHEA 0 NOUN T
( 0 PUNCT F
50 0 NUM F
mg 0 NOUN F
qd 0 PUNCT F
p.o 0 NUM F
. 0 PUNCT F

for 0 ADP F
4 0 NUM F
consecutive 0 ADJ F
days 0 NOUN F
starting 0 VERB F
2 0 NUM F
days 0 NOUN F
before 0 ADP F
immunization 0 NOUN F
) 0 PUNCT F
or 0 CCONJ F
placebo 0 NOUN F
. 0 PUNCT F

Antibody 0 NOUN T
response 0 NOUN F
against 0 ADP F
the 0 DET F
three 0 NUM F
strains 0 NOUN F
of 0 ADP F
vaccine 0 NOUN F
was 0 VERB F
measured 0 VERB F
before 0 ADP F
and 0 CCONJ F
28 0 NUM F
days 0 NOUN F
after 0 ADP F
vaccination 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
compared 0 VERB F
between 0 ADP F
previously 0 ADV F
vaccinated 0 DET F
and 0 CCONJ F
non-vaccinated 0 VERB F
subjects 0 NOUN F
. 0 PUNCT F

DHEA 0 NOUN T
treatment 0 NOUN F
did 0 VERB F
not 0 ADV F
enhance 0 VERB F
established B-PHYSICAL ADV F
immunity I-PHYSICAL NOUN F
. 0 PUNCT F

A 0 DET T
significant 0 ADJ F
decrease 0 NOUN F
in 0 ADP F
attainment 0 NOUN F
of 0 ADP F
protective B-OTHER ADJ F
antibody I-OTHER NOUN F
titer I-OTHER NOUN F
( 0 PUNCT F
titer 0 NOUN F
of 0 ADP F
1:40 0 NOUN F
or 0 CCONJ F
greater 0 PUNCT F
) 0 PUNCT F
against 0 ADP F
A/Texas 0 NOUN T
in 0 ADP F
subjects 0 NOUN F
with 0 ADP F
non-protective 0 ADJ F
baseline 0 NOUN F
antibody 0 NOUN F
titer 0 NOUN F
was 0 VERB F
recorded 0 VERB F
following 0 VERB F
DHEA 0 NOUN T
treatment 0 NOUN F
compared 0 VERB F
to 0 ADP F
placebo 0 NOUN F
( 0 PUNCT F
52 0 ADP F
vs. 0 CCONJ F
84 0 NUM F
% 0 SYM F
, 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.05 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Post-immunization B-OTHER NOUN T
titers I-OTHER NOUN F
against 0 ADP F
influenza 0 NOUN F
A 0 DET T
strains 0 NOUN F
were 0 VERB F
significantly 0 ADV F
higher 0 PUNCT F
in 0 ADP F
those 0 PUNCT F
subjects 0 NOUN F
who 0 ADP F
were 0 VERB F
never 0 ADV F
immunized 0 PUNCT F
before 0 PUNCT F
. 0 PUNCT F

Additionally 0 ADV T
, 0 PUNCT F
post-vaccination B-OTHER NOUN F
protective I-OTHER ADJ F
titers I-OTHER NOUN F
against 0 ADP F
the 0 DET F
A/Johannesburg 0 NOUN T
strain 0 NOUN F
were 0 VERB F
more 0 ADV F
prevalent 0 ADJ F
in 0 ADP F
those 0 PUNCT F
subjects 0 NOUN F
who 0 ADP F
were 0 VERB F
never 0 ADV F
vaccinated 0 PUNCT F
before 0 PUNCT F
. 0 PUNCT F

The 0 DET T
results 0 ADV F
were 0 VERB F
not 0 ADV F
the 0 DET F
same 0 PUNCT F
for 0 ADP F
anti-B/Harbin 0 NOUN F
antibodies-repeated 0 VERB F
vaccination 0 NOUN F
caused 0 VERB F
a 0 DET F
non-significant 0 ADJ F
increase 0 NOUN F
in 0 ADP F
HI 0 NOUN T
titer 0 NOUN F
in 0 ADP F
previously 0 ADV F
vaccinated 0 ADP F
subjects 0 NOUN F
. 0 PUNCT F

Levosulpiride 0 NOUN T
in 0 ADP F
functional 0 ADJ F
dyspepsia 0 NOUN F
: 0 PUNCT F
a 0 DET F
multicentric 0 ADJ F
, 0 PUNCT F
double-blind 0 ADJ F
, 0 PUNCT F
controlled 0 VERB F
trial 0 NOUN F
. 0 PUNCT F

Abnormalities 0 NOUN T
in 0 ADP F
gastrointestinal 0 ADJ F
motility 0 NOUN F
have 0 PUNCT F
been 0 PUNCT F
reported 0 VERB F
in 0 ADP F
a 0 DET F
substantial 0 ADJ F
proportion 0 NOUN F
of 0 ADP F
patients 0 NOUN F
with 0 ADP F
functional 0 ADJ F
dyspepsia 0 NOUN F
, 0 PUNCT F
supporting 0 VERB F
the 0 DET F
use 0 NOUN F
of 0 ADP F
prokinetic 0 ADJ F
drugs 0 NOUN F
for 0 ADP F
treatment 0 NOUN F
of 0 ADP F
dyspeptic 0 ADJ F
symptoms 0 NOUN F
. 0 PUNCT F

To 0 PART T
evaluate 0 NOUN F
efficacy 0 NOUN F
and 0 CCONJ F
safety 0 NOUN F
of 0 ADP F
levosulpiride 0 NOUN F
in 0 ADP F
short-term 0 NOUN F
treatment 0 NOUN F
, 0 PUNCT F
1298 0 NUM F
patients 0 NOUN F
were 0 VERB F
enrolled 0 VERB F
in 0 ADP F
a 0 DET F
double-blind 0 ADJ F
multicentric 0 ADJ F
study 0 NOUN F
carried 0 SYM F
out 0 ADP F
in 0 ADP F
45 0 NUM F
Italian 0 ADJ T
Gastroenterology 0 NOUN T
Departments 0 NOUN T
. 0 PUNCT F

Patients 0 NOUN T
were 0 VERB F
randomly 0 ADV F
assigned 0 VERB F
to 0 ADP F
either 0 PUNCT F
levosulpiride 0 NOUN F
( 0 PUNCT F
25 0 NUM F
mg 0 NOUN F
tid 0 ADJ F
) 0 PUNCT F
, 0 PUNCT F
domperidone 0 NOUN F
( 0 PUNCT F
10 0 NUM F
mg 0 NOUN F
tid 0 ADJ F
) 0 PUNCT F
, 0 PUNCT F
metoclopramide 0 CCONJ F
( 0 PUNCT F
10 0 NUM F
mg 0 NOUN F
tid 0 ADJ F
) 0 PUNCT F
or 0 CCONJ F
placebo 0 NOUN F
( 0 PUNCT F
1 0 NUM F
tablet 0 NOUN F
tid 0 ADJ F
) 0 PUNCT F
for 0 ADP F
4 0 NUM F
weeks 0 NOUN F
. 0 PUNCT F

Patients 0 NOUN T
were 0 VERB F
selected 0 VERB F
on 0 ADP F
the 0 DET F
basis 0 NOUN F
of 0 ADP F
: 0 PUNCT F
a 0 ADP F
) 0 PUNCT F
occurrence 0 NOUN F
in 0 ADP F
the 0 DET F
last 0 ADJ F
4 0 NUM F
weeks 0 NOUN F
of 0 ADP F
at 0 ADJ F
least 0 ADV F
5/10 0 NOUN F
selected 0 VERB F
symptoms 0 NOUN F
( 0 PUNCT F
anorexia B-PHYSICAL NOUN F
, I-PHYSICAL PUNCT F
nausea I-PHYSICAL NOUN F
, I-PHYSICAL PUNCT F
vomiting I-PHYSICAL VERB F
, I-PHYSICAL PUNCT F
upper I-PHYSICAL ADJ F
abdominal I-PHYSICAL ADJ F
pain I-PHYSICAL NOUN F
, I-PHYSICAL PUNCT F
postprandial I-PHYSICAL ADJ F
bloating I-PHYSICAL PUNCT F
, I-PHYSICAL PUNCT F
abdominal I-PHYSICAL ADJ F
fullness I-PHYSICAL ADV F
, I-PHYSICAL PUNCT F
early I-PHYSICAL ADJ F
satiety I-PHYSICAL NOUN F
, I-PHYSICAL PUNCT F
belching I-PHYSICAL PUNCT F
, I-PHYSICAL PUNCT F
heartburn I-PHYSICAL NOUN F
, I-PHYSICAL PUNCT F
regurgitation I-PHYSICAL NOUN F
) 0 PUNCT F
, 0 PUNCT F
severity 0 NOUN F
of 0 ADP F
which 0 ADP F
should 0 VERB F
reach/exceed 0 CCONJ F
a 0 DET F
total 0 ADJ F
score 0 NOUN F
of 0 ADP F
8 0 NUM F
, 0 PUNCT F
as 0 PUNCT F
assessed 0 VERB F
by 0 ADP F
a 0 DET F
specific 0 ADJ F
scale 0 NOUN F
ranging 0 CCONJ F
from 0 ADP F
0 0 NUM F
( 0 PUNCT F
absent 0 ADJ F
) 0 PUNCT F
to 0 ADP F
3 0 PUNCT F
( 0 PUNCT F
severe 0 PUNCT F
) 0 PUNCT F
; 0 PUNCT F
b 0 NOUN F
) 0 PUNCT F
normal 0 ADJ F
results 0 NOUN F
of 0 ADP F
routine 0 ADJ F
biochemical 0 ADJ F
, 0 PUNCT F
ultrasound 0 NOUN F
and 0 CCONJ F
endoscopic 0 ADJ F
examinations 0 NOUN F
. 0 PUNCT F

In 0 ADP T
addition 0 NOUN F
, 0 PUNCT F
each 0 DET F
patient 0 NOUN F
subjectively 0 ADV F
evaluated 0 PUNCT F
efficacy 0 NOUN F
of 0 ADP F
treatment 0 NOUN F
by 0 ADP F
a 0 DET F
visual 0 ADJ F
analogue 0 NOUN F
scale 0 NOUN F
. 0 PUNCT F

Significant 0 ADJ T
improvement 0 NOUN F
was 0 VERB F
recorded 0 VERB F
for 0 ADP F
all 0 PUNCT F
symptoms 0 NOUN F
at 0 ADP F
days 0 NOUN F
10 0 NUM F
and 0 CCONJ F
28 0 NUM F
in 0 ADP F
all 0 DET F
groups 0 NOUN F
( 0 PUNCT F
p 0 NOUN F
< 0 SYM F
0.001 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
but 0 CCONJ F
levosulpiride 0 NOUN F
was 0 VERB F
significantly 0 ADV F
( 0 PUNCT F
p 0 NOUN F
< 0 SYM F
0.01 0 NUM F
) 0 PUNCT F
superior 0 ADJ F
to 0 ADP F
domperidone 0 NOUN F
, 0 PUNCT F
metoclopramide 0 CCONJ F
and 0 CCONJ F
placebo 0 NOUN F
both 0 CCONJ F
in 0 ADP F
the 0 DET F
overall 0 ADJ F
clinical 0 ADJ F
improvement 0 NOUN F
scale 0 NOUN F
as 0 PUNCT F
well 0 PUNCT F
as 0 CCONJ F
in 0 ADP F
a 0 DET F
subgroup 0 NOUN F
of 0 ADP F
symptoms 0 NOUN F
( 0 PUNCT F
postprandial B-PHYSICAL ADJ F
bloating I-PHYSICAL PUNCT F
, 0 PUNCT F
epigastric B-PAIN ADJ F
pain I-PAIN NOUN F
, 0 PUNCT F
heartburn B-PHYSICAL NOUN F
) 0 PUNCT F
. 0 PUNCT F

Active 0 ADJ T
treatments 0 NOUN F
and 0 CCONJ F
placebo 0 NOUN F
were 0 VERB F
comparable 0 ADJ F
as 0 ADP F
far 0 PUNCT F
as 0 PUNCT F
concerns 0 VERB F
occurrence 0 NOUN F
of 0 ADP F
side-effects 0 NOUN F
( 0 PUNCT F
12-20 0 NUM F
% 0 SYM F
) 0 PUNCT F
including 0 DET F
galactorrhoea B-PHYSICAL NOUN F
, 0 PUNCT F
breast B-PHYSICAL NOUN F
tenderness I-PHYSICAL NOUN F
and 0 CCONJ F
menstrual B-PHYSICAL ADJ F
changes I-PHYSICAL NOUN F
. 0 PUNCT F

Testing 0 VERB T
three 0 NUM F
different 0 ADJ F
cancer 0 NOUN F
genetics 0 NOUN F
registry 0 NOUN F
recruitment 0 NOUN F
methods 0 NOUN F
with 0 ADP F
Hispanic 0 ADJ T
cancer 0 NOUN F
patients 0 NOUN F
and 0 CCONJ F
their 0 ADJ F
family 0 NOUN F
members 0 NOUN F
previously 0 ADV F
registered 0 PUNCT F
in 0 ADP F
local 0 ADJ F
cancer 0 NOUN F
registries 0 ADJ F
in 0 ADP F
Texas 0 NOUN T
. 0 PUNCT F

OBJECTIVE 0 NOUN T
To 0 PROPN T
increase 0 VERB F
accrual 0 ADJ F
among 0 ADP F
Hispanics 0 PROPN T
to 0 ADP F
the 0 DET F
Cancer 0 NOUN T
Genetics 0 PROPN T
Network 0 ADP T
national 0 ADJ F
cancer 0 NOUN F
genetics 0 NOUN F
registry 0 NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
Drawing 0 PUNCT T
from 0 ADP F
South 0 NOUN T
Texas 0 CCONJ T
cancer 0 NOUN F
registries 0 ADJ F
, 0 PUNCT F
444 0 NUM F
Hispanic 0 ADJ T
men 0 NOUN F
and 0 CCONJ F
women 0 NOUN F
were 0 VERB F
randomly 0 ADV F
assigned 0 VERB F
to 0 ADP F
one 0 PUNCT F
of 0 ADP F
three 0 NUM F
experimental 0 ADJ F
conditions 0 NOUN F
: 0 PUNCT F
standard 0 PUNCT F
direct-mailed 0 VERB F
procedures 0 NOUN F
( 0 PUNCT F
X1 0 NOUN T
) 0 PUNCT F
, 0 PUNCT F
X1 0 NOUN T
plus 0 CCONJ F
culturally 0 ADV F
tailored 0 VERB F
materials 0 NOUN F
( 0 PUNCT F
X2 0 NOUN T
) 0 PUNCT F
, 0 PUNCT F
and 0 CCONJ F
X2 0 NOUN T
plus 0 CCONJ F
interpersonal 0 ADJ F
phone 0 NOUN F
contact 0 NOUN F
( 0 PUNCT F
X3 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

Participants 0 NOUN T
were 0 NUM F
also 0 ADV F
surveyed 0 VERB F
about 0 PUNCT F
the 0 DET F
effectiveness 0 NOUN F
of 0 ADP F
the 0 DET F
education 0 NOUN F
materials 0 NOUN F
and 0 CCONJ F
the 0 DET F
phone 0 NOUN F
contact 0 NOUN F
. 0 PUNCT F

A 0 DET T
refusal 0 ADJ F
survey 0 NOUN F
was 0 VERB F
provided 0 VERB F
for 0 ADP F
those 0 ADJ F
who 0 ADP F
declined 0 VERB F
to 0 ADP F
join 0 NOUN F
the 0 DET F
study 0 NOUN F
. 0 PUNCT F

RESULTS 0 NOUN T
A 0 PUNCT T
total 0 NOUN F
of 0 ADP F
154 0 NUM F
individuals 0 NOUN F
joined 0 VERB F
the 0 DET F
Cancer 0 NOUN T
Genetics 0 PROPN T
Network 0 NOUN T
. 0 PUNCT F

The 0 DET T
X3 B-OTHER NOUN T
condition I-OTHER NOUN F
yielded I-OTHER VERB F
the I-OTHER DET F
greatest I-OTHER PUNCT F
accrual I-OTHER ADJ F
( 0 PUNCT F
43.2 0 NUM F
% 0 SYM F
) 0 PUNCT F
compared 0 VERB F
to 0 ADP F
X1 0 NOUN T
( 0 PUNCT F
30.9 0 NUM F
% 0 SYM F
) 0 PUNCT F
and 0 CCONJ F
X2 0 NOUN T
( 0 PUNCT F
29.9 0 NUM F
% 0 SYM F
; 0 PUNCT F
p 0 NOUN F
< 0 SYM F
0.05 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Tailored 0 VERB T
materials 0 NOUN F
appeared 0 VERB F
to 0 PART F
have 0 PUNCT F
no 0 DET F
effect 0 NOUN F
but 0 CCONJ F
were 0 VERB F
highly 0 ADV F
regarded 0 VERB F
. 0 PUNCT F

The 0 DET T
main 0 ADJ F
reasons 0 NOUN F
for 0 ADP F
not 0 ADV F
participating 0 ADP F
were 0 ADP F
a 0 DET F
lack 0 NOUN F
of 0 ADP F
interest 0 NOUN F
and 0 CCONJ F
time 0 NOUN F
requirements 0 NOUN F
. 0 PUNCT F

CONCLUSION 0 NOUN T
Interpersonal 0 ADJ T
communication 0 NOUN F
can 0 VERB F
have 0 PUNCT F
a 0 DET F
powerful 0 ADJ F
effect 0 NOUN F
on 0 ADP F
recruitment 0 NOUN F
. 0 PUNCT F

However 0 ADV T
, 0 PUNCT F
more 0 DET F
research 0 NOUN F
is 0 VERB F
needed 0 VERB F
to 0 PART F
determine 0 NOUN F
the 0 ADP F
cost-efficacy 0 NOUN F
of 0 ADP F
more 0 DET F
labor-intensive 0 ADJ F
approaches 0 NOUN F
to 0 ADP F
registry 0 NOUN F
accrual 0 ADJ F
. 0 PUNCT F

Dynamic 0 ADJ T
surface B-PHYSICAL NOUN F
electromyographic I-PHYSICAL ADJ F
responses I-PHYSICAL NOUN F
in 0 ADP F
chronic 0 ADJ F
low 0 ADJ F
back 0 ADP F
pain 0 NOUN F
treated 0 VERB F
by 0 ADP F
traditional 0 ADJ F
bone 0 NOUN F
setting 0 VERB F
and 0 CCONJ F
conventional 0 ADJ F
physical 0 ADJ F
therapy 0 NOUN F
. 0 PUNCT F

OBJECTIVE 0 NOUN T
This 0 DET T
study 0 NOUN F
compared 0 VERB F
the 0 DET F
dynamic B-PHYSICAL ADJ F
surface I-PHYSICAL NOUN F
electromyographic I-PHYSICAL ADJ F
( I-PHYSICAL PUNCT F
EMG I-PHYSICAL NOUN T
) I-PHYSICAL PUNCT F
activities I-PHYSICAL NOUN F
of 0 ADP F
back 0 ADP F
muscles 0 NOUN F
and 0 CCONJ F
pain 0 NOUN F
before 0 ADP F
and 0 CCONJ F
after 0 ADP F
traditional 0 ADJ F
bone 0 NOUN F
setting 0 VERB F
and 0 CCONJ F
physical 0 ADJ F
therapy 0 NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
This 0 PUNCT T
study 0 NOUN F
was 0 VERB F
a 0 DET F
prospective 0 ADJ F
clinical 0 ADJ F
trial 0 NOUN F
that 0 PUNCT F
compared 0 VERB F
surface B-PHYSICAL NOUN F
EMG I-PHYSICAL NOUN T
dynamic I-PHYSICAL ADJ F
activities I-PHYSICAL NOUN F
after 0 ADP F
traditional 0 ADJ F
bone 0 NOUN F
setting 0 VERB F
and 0 CCONJ F
physical 0 ADJ F
therapy 0 NOUN F
. 0 PUNCT F

Sixty-one 0 ADJ T
patients 0 NOUN F
( 0 PUNCT F
mean 0 NOUN F
age 0 NOUN F
, 0 PUNCT F
41 0 NUM F
years 0 NOUN F
) 0 PUNCT F
with 0 ADP F
nonspecific 0 ADJ F
low 0 ADJ F
back 0 ADP F
pain 0 NOUN F
were 0 VERB F
randomized 0 VERB F
into 0 ADP F
two 0 NUM F
subgroups 0 NOUN F
by 0 ADP F
treatment 0 NOUN F
. 0 PUNCT F

The 0 DET T
patients 0 NOUN F
underwent 0 VERB F
a 0 DET F
dynamic B-PHYSICAL ADJ F
EMG I-PHYSICAL NOUN T
evaluation I-PHYSICAL NOUN F
for 0 ADP F
which 0 ADP F
they 0 PUNCT F
were 0 VERB F
asked 0 ADV F
to 0 ADP F
stand 0 PUNCT F
and 0 CCONJ F
then 0 ADV F
bend 0 PUNCT F
forward 0 ADV F
as 0 PUNCT F
far 0 PUNCT F
as 0 PUNCT F
possible 0 ADJ F
, 0 PUNCT F
stay 0 NOUN F
fully 0 ADV F
flexed 0 PROPN F
, 0 PUNCT F
and 0 CCONJ F
return 0 ADJ F
to 0 ADP F
standing 0 DET F
. 0 PUNCT F

A 0 DET T
flexion-relaxation B-PHYSICAL NOUN F
ratio I-PHYSICAL NOUN F
was 0 VERB F
calculated 0 VERB F
by 0 ADP F
comparing 0 DET F
maximal B-PHYSICAL ADJ F
EMG I-PHYSICAL NOUN T
activity I-PHYSICAL NOUN F
while 0 ADP F
flexing 0 DET F
with 0 ADP F
the 0 DET F
average 0 ADJ F
EMG 0 NOUN T
activity 0 NOUN F
in 0 ADP F
full 0 ADJ F
flexion 0 NOUN F
. 0 PUNCT F

Concentric 0 ADJ T
( 0 PUNCT F
maximal 0 ADJ F
EMG 0 NOUN T
activity 0 NOUN F
during 0 ADP F
extension 0 NOUN F
) 0 PUNCT F
and 0 CCONJ F
eccentric 0 ADJ F
( 0 PUNCT F
maximal 0 ADJ F
EMG 0 NOUN T
activity 0 NOUN F
during 0 ADP F
flexion 0 NOUN F
) 0 PUNCT F
ratios 0 NOUN F
were 0 VERB F
also 0 ADV F
used 0 VERB F
in 0 ADP F
the 0 DET F
analyses 0 NOUN F
. 0 PUNCT F

RESULTS 0 NOUN T
Disability B-PHYSICAL NOUN T
, 0 PUNCT F
depression B-PHYSICAL NOUN F
, 0 PUNCT F
and 0 CCONJ F
visual 0 ADJ F
analog 0 NOUN F
scale 0 NOUN F
scores 0 NOUN F
decreased 0 VERB F
significantly 0 ADV F
after 0 ADP F
both 0 PUNCT F
treatments 0 NOUN F
. 0 PUNCT F

The 0 DET T
concentric B-PHYSICAL ADJ F
ratio I-PHYSICAL NOUN F
increased 0 VERB F
statistically 0 ADV F
in 0 ADP F
both 0 CCONJ F
groups 0 NOUN F
after 0 ADP F
the 0 DET F
treatments 0 NOUN F
. 0 PUNCT F

The 0 DET T
study 0 NOUN F
failed 0 VERB F
to 0 ADP F
show 0 VERB F
a 0 DET F
significant 0 ADJ F
association 0 NOUN F
between 0 ADP F
experienced 0 ADP F
back 0 ADP F
pain 0 NOUN F
and 0 CCONJ F
EMG B-PHYSICAL NOUN T
parameters I-PHYSICAL NOUN F
. 0 PUNCT F

CONCLUSIONS 0 NOUN T
Both 0 PUNCT T
treatments 0 NOUN F
seem 0 VERB F
to 0 PART F
have 0 PUNCT F
a 0 DET F
positive 0 ADJ F
influence 0 NOUN F
on 0 ADP F
back 0 ADP F
muscle 0 NOUN F
function 0 NOUN F
by 0 ADP F
improving 0 VERB F
muscle B-PHYSICAL NOUN F
symmetry 0 NOUN F
; 0 PUNCT F
however 0 ADV F
, 0 PUNCT F
the 0 DET F
treatments 0 NOUN F
had 0 PUNCT F
no 0 DET F
effect 0 NOUN F
on 0 ADP F
the 0 DET F
flexion-relaxation B-PHYSICAL NOUN F
phenomenon I-PHYSICAL NOUN F
after 0 ADP F
1 0 NUM F
month 0 NOUN F
. 0 PUNCT F

Active 0 ADJ T
back 0 ADP F
exercise 0 NOUN F
at 0 ADP F
home 0 NOUN F
together 0 ADV F
with 0 ADP F
rehabilitation 0 NOUN F
treatments 0 NOUN F
might 0 ADJ F
be 0 NOUN F
effective 0 ADJ F
and 0 CCONJ F
improve 0 ADJ F
function 0 NOUN F
for 0 ADP F
patients 0 NOUN F
with 0 ADP F
chronic 0 ADJ F
low 0 ADJ F
back 0 ADP F
pain 0 NOUN F
. 0 PUNCT F

Use 0 NOUN T
of 0 ADP F
an 0 DET F
Internet 0 NOUN T
portal 0 NOUN F
to 0 ADV F
improve 0 NOUN F
community-based 0 VERB F
pediatric 0 ADJ F
ADHD 0 NOUN T
care 0 NOUN F
: 0 PUNCT F
a 0 DET F
cluster 0 NOUN F
randomized 0 VERB F
trial 0 NOUN F
. 0 PUNCT F

OBJECTIVE 0 NOUN T
To 0 PROPN T
determine 0 NOUN F
the 0 DET F
effectiveness 0 NOUN F
of 0 ADP F
a 0 DET F
quality 0 NOUN F
improvement 0 NOUN F
program 0 NOUN F
to 0 PART F
improve 0 NOUN F
pediatricians 0 ADP F
' 0 PUNCT F
adherence 0 NOUN F
to 0 ADP F
existing 0 ADJ F
, 0 PUNCT F
evidence-based 0 ADP F
, 0 PUNCT F
attention-deficit/hyperactivity 0 NOUN F
disorder 0 NOUN F
( 0 PUNCT F
ADHD 0 NOUN T
) 0 PUNCT F
practice 0 NOUN F
guidelines 0 NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
Forty-nine 0 NUM T
community-based 0 VERB F
pediatricians 0 PUNCT F
at 0 ADP F
8 0 NUM F
practices 0 PROPN F
participated 0 VERB F
in 0 ADP F
a 0 DET F
cluster-randomized 0 VERB F
trial 0 NOUN F
. 0 PUNCT F

Practices 0 PROPN T
were 0 VERB F
matched 0 VERB F
according 0 CCONJ F
to 0 ADP F
the 0 DET F
numbers 0 NOUN F
of 0 ADP F
pediatricians 0 ADJ F
and 0 CCONJ F
the 0 DET F
proportions 0 NOUN F
of 0 ADP F
patients 0 NOUN F
receiving 0 VERB F
Medicaid 0 NOUN T
. 0 PUNCT F

The 0 DET T
medical 0 ADJ F
charts 0 NOUN F
for 0 ADP F
a 0 DET F
random 0 ADJ F
sample 0 NOUN F
of 0 ADP F
patients 0 NOUN F
with 0 ADP F
ADHD 0 NOUN T
for 0 ADP F
each 0 PUNCT F
of 0 ADP F
the 0 DET F
participating 0 ADP F
pediatricians 0 PUNCT F
were 0 VERB F
examined 0 VERB F
at 0 ADP F
baseline 0 NOUN F
and 0 CCONJ F
6 0 NUM F
months 0 NOUN F
. 0 PUNCT F

All 0 DET T
practices 0 PROPN F
participated 0 VERB F
in 0 ADP F
4 0 NUM F
sessions 0 NOUN F
of 0 ADP F
training 0 VERB F
, 0 PUNCT F
including 0 CCONJ F
didactic 0 ADJ F
lectures 0 NOUN F
and 0 CCONJ F
office 0 NOUN F
flow 0 NOUN F
modification 0 NOUN F
workshops 0 NOUN F
. 0 PUNCT F

Practices 0 PROPN T
were 0 ADJ F
then 0 ADV F
given 0 VERB F
access 0 NOUN F
to 0 ADP F
an 0 DET F
ADHD 0 NOUN T
Internet 0 NOUN T
portal 0 NOUN F
that 0 PUNCT F
allowed 0 VERB F
parents 0 NOUN F
, 0 PUNCT F
teachers 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
pediatricians 0 PUNCT F
to 0 ADP F
input 0 NOUN F
information 0 NOUN F
( 0 PUNCT F
eg 0 ADP F
, 0 PUNCT F
rating 0 ADP F
scales 0 NOUN F
) 0 PUNCT F
about 0 PUNCT F
patients 0 NOUN F
, 0 PUNCT F
after 0 ADP F
which 0 PUNCT F
information 0 NOUN F
was 0 VERB F
scored 0 VERB F
, 0 PUNCT F
interpreted 0 VERB F
, 0 PUNCT F
and 0 CCONJ F
formatted 0 ADP F
in 0 ADP F
a 0 DET F
report 0 ADV F
style 0 NOUN F
that 0 PUNCT F
was 0 VERB F
helpful 0 ADJ F
for 0 ADP F
assessment 0 NOUN F
and 0 CCONJ F
treatment 0 NOUN F
of 0 ADP F
patients 0 NOUN F
with 0 ADP F
ADHD 0 NOUN T
. 0 PUNCT F

Physicians 0 PROPN T
evaluated 0 VERB F
their 0 PUNCT F
practice B-MENTAL NOUN F
behaviors I-MENTAL NOUN F
quarterly 0 ADJ F
and 0 CCONJ F
addressed 0 PUNCT F
underperforming B-MENTAL PUNCT F
areas I-MENTAL NOUN F
. 0 PUNCT F

RESULTS 0 DET T
Pediatricians 0 ADJ T
in 0 ADP F
the 0 DET F
intervention 0 NOUN F
group 0 NOUN F
, 0 PUNCT F
compared 0 VERB F
with 0 ADP F
those 0 PUNCT F
in 0 ADP F
the 0 DET F
control 0 NOUN F
group 0 NOUN F
, 0 PUNCT F
demonstrated 0 VERB F
significantly 0 ADV F
higher 0 PUNCT F
rates 0 NOUN F
of 0 ADP F
many 0 CCONJ F
American 0 ADJ T
Academy 0 PUNCT T
of 0 ADP F
Pediatrics-recommended 0 ADJ T
ADHD 0 NOUN T
care 0 NOUN F
practices 0 PROPN F
, 0 PUNCT F
including 0 VERB F
collection B-MENTAL NOUN F
of I-MENTAL ADP F
parent I-MENTAL NOUN F
( 0 PUNCT F
Cohen 0 NOUN T
's 0 PUNCT F
d 0 NOUN F
= 0 SYM F
0.69 0 NUM F
) 0 PUNCT F
and 0 CCONJ F
teacher B-MENTAL NOUN F
( 0 PUNCT F
d 0 NOUN F
= 0 SYM F
0.68 0 NUM F
) 0 PUNCT F
rating B-MENTAL ADP F
scales I-MENTAL NOUN F
for 0 ADP F
assessment 0 NOUN F
of 0 ADP F
children 0 NOUN F
with 0 ADP F
ADHD 0 NOUN T
, 0 PUNCT F
use 0 NOUN F
of 0 ADP F
Diagnostic 0 ADJ T
and 0 CCONJ F
Statistical B-MENTAL ADJ T
Manual I-MENTAL NOUN T
of I-MENTAL ADP F
Mental I-MENTAL ADJ T
Disorders I-MENTAL NOUN T
, 0 PUNCT F
Fourth 0 ADJ T
Edition 0 NOUN T
, 0 PUNCT F
criteria 0 NOUN F
( 0 PUNCT F
d 0 NOUN F
= 0 SYM F
0.85 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
and 0 CCONJ F
use 0 NOUN F
of 0 ADP F
teacher B-MENTAL NOUN F
rating I-MENTAL ADJ F
scales I-MENTAL NOUN F
to 0 ADJ F
monitor 0 NOUN F
treatment 0 NOUN F
responses 0 NOUN F
( 0 PUNCT F
d 0 NOUN F
= 0 SYM F
1.01 0 PUNCT F
) 0 PUNCT F
. 0 PUNCT F

CONCLUSION 0 NOUN T
A 0 DET T
quality 0 NOUN F
improvement 0 NOUN F
intervention 0 NOUN F
that 0 ADP F
can 0 VERB F
be 0 VERB F
widely 0 ADV F
disseminated 0 VERB F
by 0 ADP F
using 0 VERB F
Internet-based 0 VERB T
information 0 NOUN F
technology 0 NOUN F
significantly 0 ADV F
improved 0 VERB F
the 0 DET F
quality 0 NOUN F
of 0 ADP F
ADHD 0 NOUN T
care 0 NOUN F
in 0 ADP F
community-based 0 VERB F
pediatric 0 ADJ F
settings 0 NOUN F
. 0 PUNCT F

Transcutaneous 0 ADJ T
electrical 0 ADJ F
nerve 0 NOUN F
stimulation 0 NOUN F
in 0 ADP F
the 0 DET F
treatment 0 NOUN F
of 0 ADP F
myofascial 0 ADJ F
pain 0 NOUN F
dysfunction 0 NOUN F
. 0 PUNCT F

The 0 DET T
effect 0 NOUN F
of 0 ADP F
transcutaneous 0 ADJ F
electrical 0 ADJ F
nerve 0 NOUN F
stimulation 0 NOUN F
( 0 PUNCT F
TENS 0 NOUN T
) 0 PUNCT F
plus 0 CCONJ F
conservative 0 ADJ F
therapy 0 NOUN F
( 0 PUNCT F
ibuprofen 0 NOUN F
, 0 PUNCT F
bite 0 NOUN F
plate 0 NOUN F
, 0 PUNCT F
self-physiotherapy 0 NOUN F
) 0 PUNCT F
on 0 ADP F
myofascial 0 ADJ F
pain 0 NOUN F
dysfunction 0 NOUN F
( 0 PUNCT F
MPD 0 CCONJ T
) 0 PUNCT F
was 0 VERB F
determined 0 VERB F
. 0 PUNCT F

A 0 PUNCT T
single-blind 0 NOUN F
trial 0 NOUN F
as 0 PUNCT F
done 0 PUNCT F
in 0 ADP F
10 0 NUM F
patients 0 NOUN F
with 0 ADP F
MPD 0 CCONJ T
with 0 ADP F
subthreshold 0 VERB F
TENS 0 NOUN T
( 0 PUNCT F
frequency 0 NOUN F
35 0 NUM F
Hz 0 NOUN T
, 0 PUNCT F
pulse 0 NOUN F
width 0 NOUN F
100 0 NUM F
milliseconds 0 NOUN F
, 0 PUNCT F
modulation 0 NOUN F
50 0 NUM F
% 0 SYM F
) 0 PUNCT F
compared 0 VERB F
with 0 ADP F
sham 0 ADJ F
TENS 0 NOUN T
at 0 ADP F
8 0 NUM F
visits 0 NOUN F
over 0 ADP F
14 0 NUM F
weeks 0 NOUN F
. 0 PUNCT F

Pain B-PAIN NOUN T
was 0 VERB F
assessed 0 VERB F
on 0 ADP F
a 0 DET F
visual 0 ADJ F
analogue 0 NOUN F
scale 0 NOUN F
before 0 ADP F
and 0 CCONJ F
after 0 ADP F
TENS 0 NOUN T
at 0 ADP F
each 0 DET F
visit 0 NOUN F
and 0 CCONJ F
the 0 DET F
data 0 NOUN F
were 0 VERB F
analysed 0 VERB F
with 0 ADP F
the 0 DET F
analysis 0 NOUN F
of 0 ADP F
variance 0 NOUN F
( 0 PUNCT F
ANOVA 0 NOUN T
) 0 PUNCT F
for 0 ADP F
repeated 0 VERB F
measures 0 NOUN F
. 0 PUNCT F

A 0 DET T
highly 0 ADV F
significant 0 ADJ F
effect 0 NOUN F
was 0 VERB F
seen 0 VERB F
for 0 ADP F
time 0 NOUN F
( 0 PUNCT F
F 0 NOUN T
= 0 SYM F
4.80 0 NUM F
, 0 PUNCT F
P 0 NOUN T
= 0 SYM F
0.0003 0 NUM F
) 0 PUNCT F
but 0 CCONJ F
not 0 ADV F
for 0 ADP F
TENS 0 NOUN T
. 0 PUNCT F

Subthreshold 0 NUM T
TENS 0 NOUN T
did 0 PUNCT F
not 0 ADV F
increase 0 VERB F
the 0 DET F
symptom 0 NOUN F
relief 0 NOUN F
produced 0 VERB F
by 0 ADP F
conservative 0 ADJ F
treatment 0 NOUN F
with 0 ADP F
the 0 DET F
protocol 0 NOUN F
used 0 VERB F
. 0 PUNCT F

Adenosinergic 0 ADJ T
mechanisms 0 NOUN F
contribute 0 VERB F
to 0 ADP F
individual 0 ADJ F
differences 0 NOUN F
in 0 ADP F
sleep 0 NOUN F
deprivation-induced 0 PUNCT F
changes 0 NOUN F
in 0 ADP F
neurobehavioral 0 ADJ F
function 0 NOUN F
and 0 CCONJ F
brain 0 NOUN F
rhythmic 0 ADJ F
activity 0 NOUN F
. 0 PUNCT F

Large 0 ADJ T
individual 0 ADJ F
differences 0 NOUN F
characterize 0 VERB F
the 0 DET F
changes 0 NOUN F
induced 0 VERB F
by 0 ADP F
sleep 0 PUNCT F
deprivation 0 NOUN F
on 0 ADP F
neurobehavioral 0 ADJ F
functions 0 NOUN F
and 0 CCONJ F
rhythmic 0 ADJ F
brain 0 NOUN F
activity 0 NOUN F
. 0 PUNCT F

To 0 PART T
investigate 0 ADV F
adenosinergic 0 ADJ F
mechanisms 0 NOUN F
in 0 ADP F
these 0 DET F
differences 0 NOUN F
, 0 PUNCT F
we 0 PRON F
studied 0 VERB F
the 0 DET F
effects 0 NOUN F
of 0 ADP F
prolonged 0 VERB F
waking 0 ADP F
and 0 CCONJ F
the 0 DET F
adenosine 0 NOUN F
receptor 0 NOUN F
antagonist 0 NOUN F
caffeine 0 NOUN F
on 0 ADP F
sustained 0 VERB F
vigilant 0 ADJ F
attention 0 NOUN F
and 0 CCONJ F
regional 0 ADJ F
electroencephalogram 0 NOUN F
( 0 PUNCT F
EEG 0 NOUN T
) 0 PUNCT F
power 0 NOUN F
in 0 ADP F
the 0 DET F
ranges 0 PUNCT F
of 0 ADP F
theta 0 NOUN F
activity 0 NOUN F
( 0 PUNCT F
6.25-8.25 0 NUM F
Hz 0 NOUN T
) 0 PUNCT F
in 0 ADP F
waking 0 ADJ F
and 0 CCONJ F
the 0 DET F
slow 0 ADJ F
oscillation 0 NOUN F
( 0 PUNCT F
< 0 PROPN F
1 0 NUM F
Hz 0 NOUN T
) 0 PUNCT F
in 0 ADP F
sleep 0 NOUN F
. 0 PUNCT F

Activity 0 NOUN T
in 0 ADP F
these 0 DET F
frequencies 0 NOUN F
is 0 VERB F
functionally 0 ADV F
related 0 ADP F
to 0 PUNCT F
sleep 0 PUNCT F
deprivation 0 NOUN F
. 0 PUNCT F

In 0 ADP T
12 0 NUM F
subjectively 0 ADV F
caffeine-sensitive 0 ADJ F
and 0 CCONJ F
10 0 NUM F
-insensitive 0 PUNCT F
young 0 ADJ F
men 0 NOUN F
, 0 PUNCT F
psychomotor 0 NOUN F
vigilance 0 NOUN F
task 0 NOUN F
( 0 PUNCT F
PVT 0 NOUN T
) 0 PUNCT F
performance 0 NOUN F
and 0 CCONJ F
EEG 0 NOUN T
were 0 VERB F
assessed 0 VERB F
at 0 ADP F
3 0 NUM F
h 0 NOUN F
intervals 0 NOUN F
before 0 CCONJ F
, 0 PUNCT F
during 0 ADP F
, 0 PUNCT F
and 0 CCONJ F
after 0 ADP F
one 0 NUM F
night 0 NOUN F
without 0 ADP F
sleep 0 PUNCT F
. 0 PUNCT F

After 0 ADP T
11 0 NUM F
and 0 CCONJ F
23 0 NUM F
h 0 NOUN F
waking 0 PUNCT F
, 0 PUNCT F
subjects 0 NOUN F
received 0 ADJ F
200 0 NUM F
mg 0 NOUN F
caffeine 0 NOUN F
and 0 CCONJ F
placebo 0 NOUN F
in 0 ADP F
double-blind 0 ADJ F
, 0 PUNCT F
cross-over 0 NOUN F
manner 0 NOUN F
. 0 PUNCT F

In 0 ADP T
the 0 DET F
placebo 0 NOUN F
condition 0 NOUN F
, 0 PUNCT F
sleep 0 ADP F
deprivation 0 NOUN F
impaired 0 DET F
PVT 0 NOUN T
speed 0 VERB F
more 0 ADV F
in 0 ADP F
caffeine-sensitive 0 ADJ F
than 0 PUNCT F
in 0 ADP F
caffeine-insensitive 0 ADJ F
men 0 NOUN F
. 0 PUNCT F

This 0 DET T
difference 0 NOUN F
was 0 VERB F
counteracted 0 VERB F
by 0 ADP F
caffeine 0 NOUN F
. 0 PUNCT F

Theta B-PHYSICAL NOUN T
power 0 NOUN F
in B-PHYSICAL ADP F
waking B-PHYSICAL ADJ F
increased 0 PUNCT F
more 0 ADV F
in 0 ADP F
a 0 DET F
frontal 0 ADJ F
EEG 0 NOUN T
derivation 0 NOUN F
than 0 CCONJ F
in 0 ADP F
a 0 DET F
posterior 0 ADJ F
derivation 0 NOUN F
. 0 PUNCT F

Caffeine 0 NOUN T
attenuated 0 VERB F
this 0 DET F
power 0 NOUN F
gradient 0 NOUN F
in 0 ADP F
caffeine 0 NOUN F
sensitive 0 ADJ F
subjects 0 NOUN F
. 0 PUNCT F

Sleep B-PHYSICAL NOUN T
loss I-PHYSICAL NOUN F
also 0 ADV F
differently 0 PUNCT F
affected 0 ADP F
the 0 DET F
power 0 NOUN F
distribution 0 NOUN F
< 0 SYM F
1 0 NUM F
Hz 0 NOUN T
in 0 ADP F
non-rapid B-PHYSICAL NOUN F
eye I-PHYSICAL NOUN F
movement B-PHYSICAL NOUN F
sleep B-PHYSICAL NOUN F
between 0 ADP F
caffeine 0 NOUN F
sensitive 0 ADJ F
and 0 CCONJ F
insensitive 0 ADJ F
subjects 0 NOUN F
. 0 PUNCT F

Also 0 ADV T
, 0 PUNCT F
this 0 DET F
difference 0 NOUN F
was 0 VERB F
mirrored 0 VERB F
by 0 ADP F
the 0 DET F
action 0 NOUN F
of 0 ADP F
caffeine 0 NOUN F
. 0 PUNCT F

The 0 DET T
effects 0 NOUN F
of 0 ADP F
sleep B-PHYSICAL NOUN F
deprivation I-PHYSICAL NOUN F
and 0 CCONJ F
caffeine 0 NOUN F
on 0 ADP F
sustained 0 VERB F
attention 0 NOUN F
and 0 CCONJ F
regional 0 ADJ F
EEG 0 NOUN T
power 0 NOUN F
in 0 PUNCT F

Delayed B-PHYSICAL VERB T
alloimmunization I-PHYSICAL NOUN F
using 0 VERB F
random 0 ADJ F
single 0 ADJ F
donor 0 NOUN F
platelet 0 NOUN F
transfusions 0 NOUN F
: 0 PUNCT F
a 0 DET F
prospective 0 ADJ F
study 0 NOUN F
in 0 ADP F
thrombocytopenic 0 ADJ F
patients 0 NOUN F
with 0 ADP F
acute 0 ADJ F
leukemia 0 NOUN F
. 0 PUNCT F

A 0 DET T
randomized 0 VERB F
study 0 NOUN F
was 0 VERB F
performed 0 VERB F
in 0 ADP F
54 0 NUM F
thrombocytopenic 0 ADJ F
patients 0 NOUN F
with 0 ADP F
acute 0 ADJ F
leukemia 0 NOUN F
. 0 PUNCT F

Alloimmunization 0 NOUN T
of 0 ADP F
recipients 0 NOUN F
of 0 ADP F
random 0 ADJ F
multiple-donor 0 NOUN F
platelet 0 NOUN F
concentrates 0 NOUN F
( 0 PUNCT F
MD 0 NOUN T
group 0 NOUN F
) 0 PUNCT F
was 0 VERB F
compared 0 VERB F
to 0 ADP F
that 0 PUNCT F
of 0 ADP F
patients 0 NOUN F
receiving 0 VERB F
random 0 ADJ F
single-donor 0 NOUN F
platelets 0 NOUN F
( 0 PUNCT F
SD 0 NOUN T
group 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

In 0 ADP T
the 0 DET F
SD 0 NOUN T
patients 0 NOUN F
, 0 PUNCT F
formation 0 NOUN F
of 0 ADP F
alloantibodies B-PHYSICAL NOUN F
( I-PHYSICAL PUNCT F
mostly I-PHYSICAL ADV F
anti-HLA I-PHYSICAL NOUN F
) I-PHYSICAL PUNCT F
occurred 0 VERB F
less 0 ADV F
frequently 0 ADV F
( 0 PUNCT F
p 0 NOUN F
less 0 ADV F
than 0 ADP F
0.002 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
after 0 ADP F
a 0 DET F
longer 0 PUNCT F
time 0 NOUN F
period 0 NOUN F
( 0 PUNCT F
p 0 NOUN F
less 0 ADV F
than 0 ADP F
0.002 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
and 0 CCONJ F
after 0 ADP F
a 0 DET F
higher 0 PUNCT F
number 0 NOUN F
of 0 ADP F
transfusions 0 NOUN F
( 0 PUNCT F
p 0 NOUN F
less 0 ADV F
than 0 CCONJ F
0.005 0 NUM F
) 0 PUNCT F
as 0 PUNCT F
compared 0 VERB F
to 0 ADP F
MD 0 NOUN T
patients 0 NOUN F
. 0 PUNCT F

SD 0 NOUN T
patients 0 NOUN F
also 0 ADV F
became 0 VERB F
refractory 0 ADJ F
to 0 ADP F
random 0 ADJ F
platelets 0 NOUN F
less 0 ADJ F
frequently 0 ADV F
( 0 PUNCT F
p 0 NOUN F
less 0 ADV F
than 0 CCONJ F
0.005 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
after 0 ADP F
a 0 DET F
longer 0 PUNCT F
time 0 NOUN F
period 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
after 0 ADP F
a 0 DET F
higher 0 PUNCT F
number 0 NOUN F
of 0 ADP F
transfusions B-OTHER NOUN F
( 0 PUNCT F
p 0 NOUN F
less 0 ADV F
than 0 CCONJ F
0.02 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

In 0 ADP T
SD 0 NOUN T
patients 0 NOUN F
, 0 PUNCT F
the 0 DET F
increments B-OTHER NOUN F
after 0 ADP F
the 0 DET F
first B-PHYSICAL ADJ F
and I-PHYSICAL CCONJ F
the I-PHYSICAL DET F
last I-PHYSICAL ADJ F
transfusion I-PHYSICAL NOUN F
were 0 VERB F
in 0 ADP F
the 0 DET F
same 0 ADJ F
range 0 NOUN F
, 0 PUNCT F
whereas 0 ADP F
in 0 ADP F
MD 0 NOUN T
patients 0 NOUN F
, 0 PUNCT F
the 0 DET F
1-hr 0 PUNCT F
( 0 PUNCT F
p 0 NOUN F
less 0 ADV F
than 0 PUNCT F
0.001 0 NUM F
) 0 PUNCT F
and 0 CCONJ F
the 0 DET F
24-hr 0 NOUN F
( 0 PUNCT F
p 0 NOUN F
less 0 ADV F
than 0 PUNCT F
0.025 0 NUM F
) 0 PUNCT F
increments B-OTHER NOUN F
decreased 0 VERB F
from 0 ADP F
the 0 DET F
first 0 ADP F
to 0 ADP F
the 0 DET F
last 0 ADJ F
transfusion 0 NOUN F
. 0 PUNCT F

Thus 0 ADV T
, 0 PUNCT F
the 0 DET F
use 0 NOUN F
of 0 ADP F
random 0 ADJ F
SD 0 NOUN T
platelet 0 NOUN F
transfusions 0 NOUN F
postponed 0 VERB F
alloimmunization 0 NOUN F
. 0 PUNCT F

Linguistic B-MENTAL ADJ T
alignment I-MENTAL NOUN F
in 0 ADP F
adults 0 NOUN F
with 0 ADP F
and 0 CCONJ F
without 0 ADP F
Asperger 0 ADJ T
's 0 PUNCT F
syndrome 0 NOUN F
. 0 PUNCT F

Individuals 0 NOUN T
with 0 ADP F
Asperger 0 ADJ T
's 0 PUNCT F
syndrome 0 NOUN F
( 0 PUNCT F
AS 0 ADP T
) 0 PUNCT F
often 0 ADV F
have 0 VERB F
difficulties 0 NOUN F
with 0 ADP F
social 0 ADJ F
interactions 0 NOUN F
and 0 CCONJ F
conversations 0 NOUN F
. 0 PUNCT F

We 0 PRON T
investigated 0 VERB F
if 0 PUNCT F
these 0 DET F
difficulties 0 NOUN F
could 0 VERB F
be 0 VERB F
attributable 0 ADJ F
to 0 ADP F
a 0 DET F
deficit 0 NOUN F
in 0 ADP F
the 0 DET F
ability 0 NOUN F
to 0 ADP F
linguistically 0 ADV F
converge 0 PUNCT F
with 0 ADP F
an 0 DET F
interlocutor 0 NOUN F
, 0 PUNCT F
which 0 ADP F
is 0 VERB F
posited 0 VERB F
to 0 PART F
be 0 PUNCT F
important 0 ADJ F
for 0 ADP F
successful 0 ADJ F
communication 0 NOUN F
. 0 PUNCT F

To 0 ADP T
that 0 PUNCT F
end 0 NOUN F
, 0 PUNCT F
participants 0 ADJ F
completed 0 VERB F
two 0 NUM F
cooperative 0 ADJ F
tasks 0 NOUN F
with 0 ADP F
a 0 DET F
confederate 0 NOUN F
, 0 PUNCT F
which 0 ADP F
allowed 0 VERB F
us 0 PROPN F
to 0 PART F
measure 0 VERB F
linguistic B-MENTAL ADJ F
alignment I-MENTAL NOUN F
with I-MENTAL ADP F
the I-MENTAL DET F
confederate I-MENTAL ADJ F
in 0 ADP F
terms 0 NOUN F
of 0 ADP F
lexical B-MENTAL ADJ F
choice I-MENTAL NOUN F
, 0 PUNCT F
syntactic B-MENTAL ADJ F
structure 0 NOUN F
and 0 CCONJ F
spatial B-MENTAL ADJ F
frame 0 NOUN F
of B-MENTAL ADP F
reference B-MENTAL NOUN F
. 0 PUNCT F

There 0 PUNCT T
was 0 VERB F
no 0 DET F
difference 0 NOUN F
in 0 ADP F
the 0 DET F
performance 0 NOUN F
of 0 ADP F
individuals 0 NOUN F
with 0 ADP F
AS 0 ADP T
and 0 CCONJ F
matched 0 VERB F
controls 0 NOUN F
and 0 CCONJ F
both 0 CCONJ F
groups 0 NOUN F
showed 0 VERB F
significant 0 ADJ F
alignment 0 NOUN F
with 0 ADP F
the 0 DET F
confederate 0 ADJ F
at 0 ADP F
all 0 DET F
three 0 NUM F
levels 0 NOUN F
. 0 PUNCT F

We 0 PRON T
conclude 0 VERB F
that 0 PUNCT F

Effectiveness 0 NOUN T
and 0 CCONJ F
safety 0 NOUN F
of 0 ADP F
inhaled 0 VERB F
treprostinil 0 NOUN F
for 0 ADP F
the 0 DET F
treatment 0 NOUN F
of 0 ADP F
pulmonary 0 ADJ F
arterial 0 ADJ F
hypertension 0 NOUN F
in 0 ADP F
children 0 NOUN F
. 0 PUNCT F

The 0 DET T
introduction 0 NOUN F
of 0 ADP F
prostanoid 0 NOUN F
therapy 0 NOUN F
has 0 PUNCT F
revolutionized 0 VERB F
the 0 DET F
treatment 0 NOUN F
of 0 ADP F
pulmonary 0 ADJ F
arterial 0 ADJ F
hypertension 0 NOUN F
( 0 PUNCT F
PAH 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

However 0 ADV T
, 0 PUNCT F
continuous 0 ADJ F
intravenous 0 ADJ F
prostacyclin 0 NOUN F
infusion 0 NOUN F
poses 0 PUNCT F
significant 0 ADJ F
risks 0 NOUN F
and 0 CCONJ F
challenges 0 NOUN F
, 0 PUNCT F
particularly 0 ADV F
in 0 ADP F
children 0 NOUN F
. 0 PUNCT F

Inhaled 0 ADJ T
treprostinil 0 NOUN F
has 0 PUNCT F
been 0 PUNCT F
shown 0 VERB F
to 0 DET F
be 0 PUNCT F
safe 0 ADJ F
and 0 CCONJ F
efficacious 0 ADJ F
in 0 ADP F
adults 0 NOUN F
. 0 PUNCT F

This 0 DET T
study 0 NOUN F
describes 0 VERB F
the 0 DET F
safety 0 NOUN F
and 0 CCONJ F
efficacy 0 NOUN F
of 0 ADP F
inhaled 0 VERB F
treprostinil 0 NOUN F
in 0 ADP F
children 0 NOUN F
with 0 ADP F
PAH 0 NOUN T
. 0 PUNCT F

A 0 DET T
retrospective 0 ADJ F
analysis 0 NOUN F
of 0 ADP F
29 0 NUM F
children 0 NOUN F
treated 0 VERB F
with 0 ADP F
inhaled 0 VERB F
treprostinil 0 NOUN F
for 0 ADP F
?6 0 PUNCT F
weeks 0 NOUN F
was 0 VERB F
performed 0 VERB F
. 0 PUNCT F

Effects 0 NOUN T
of 0 ADP F
inhaled 0 VERB F
treprostinil 0 NOUN F
on 0 ADP F
exercise 0 NOUN F
capacity 0 NOUN F
, 0 PUNCT F
functional 0 ADJ F
class 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
echocardiographic 0 ADJ F
and 0 CCONJ F
hemodynamic 0 ADJ F
data 0 NOUN F
were 0 VERB F
evaluated 0 VERB F
. 0 PUNCT F

Adverse 0 ADJ T
events 0 NOUN F
were 0 VERB F
documented 0 VERB F
. 0 PUNCT F

Patients 0 NOUN T
received 0 VERB F
3 0 NUM F
to 0 ADP F
9 0 NUM F
breaths 0 NOUN F
( 0 PUNCT F
6 0 NUM F
?g/breath 0 PUNCT F
) 0 PUNCT F
of 0 ADP F
inhaled 0 VERB F
treprostinil 0 NOUN F
4 0 NUM F
times/day 0 NOUN F
. 0 PUNCT F

All 0 PUNCT T
were 0 ADJ F
receiving 0 ADP F
background 0 NOUN F
PAH 0 NOUN T
therapy 0 NOUN F
; 0 PUNCT F
12 0 NUM F
had 0 PUNCT F
previously 0 ADV F
received 0 PUNCT F
parenteral 0 ADJ F
prostanoid 0 NOUN F
. 0 PUNCT F

Inhaled 0 ADJ T
treprostinil 0 NOUN F
was 0 VERB F
discontinued 0 VERB F
in 0 ADP F
4 0 NUM F
patients 0 NOUN F
because 0 PUNCT F
of 0 ADP F
symptoms 0 NOUN F
including 0 ADP F
cough B-ADVERSE-EFFECTS NOUN F
and 0 CCONJ F
bronchospasm B-ADVERSE-EFFECTS NOUN F
( 0 PUNCT F
n 0 NOUN F
= 0 SYM F
3 0 NUM F
) 0 PUNCT F
and 0 CCONJ F
progression 0 NOUN F
of 0 ADP F
PAH 0 NOUN T
( 0 PUNCT F
n 0 NOUN F
= 0 SYM F
1 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Mild 0 ADJ T
side 0 NOUN F
effects 0 NOUN F
including 0 ADP F
cough 0 NOUN F
( 0 PUNCT F
n 0 NOUN F
= 0 SYM F
9 0 NUM F
) 0 PUNCT F
and 0 CCONJ F
sore 0 DET F
throat 0 NOUN F
( 0 PUNCT F
n 0 NOUN F
= 0 SYM F
6 0 NUM F
) 0 PUNCT F
did 0 DET F
not 0 ADV F
require 0 VERB F
discontinuation 0 NOUN F
of 0 ADP F
therapy 0 NOUN F
. 0 PUNCT F

World 0 NOUN T
Health 0 NOUN T
Organization 0 NOUN T
functional 0 ADJ F
class 0 NOUN F
improved 0 VERB F
in 0 ADP F
19 0 NUM F
and 0 CCONJ F
was 0 VERB F
unchanged 0 VERB F
in 0 ADP F
10 0 NUM F
; 0 PUNCT F
exercise B-PHYSICAL NOUN F
capacity I-PHYSICAL NOUN F
significantly 0 ADV F
improved 0 VERB F
with 0 ADP F
the 0 DET F
6-minute 0 PUNCT F
walk 0 NOUN F
distance 0 NOUN F
, 0 PUNCT F
improving 0 VERB F
on 0 ADP F
follow-up 0 NOUN F
from 0 ADP F
455.7 0 NUM F
? 0 PUNCT F

71.5 0 NUM F
to 0 ADP F
498 0 PUNCT F
? 0 PUNCT F

70 0 NUM F
m 0 NOUN F
( 0 PUNCT F
p 0 NOUN F
= 0 SYM F
0.01 0 NUM F
) 0 PUNCT F
and 0 CCONJ F
peak 0 ADJ F
oxygen B-PHYSICAL NOUN F
consumption I-PHYSICAL NOUN F
increasing 0 ADJ F
from 0 ADP F
25.5 0 NUM F
? 0 PUNCT F

10.2 0 NUM F
to 0 ADP F
27.4 0 NUM F
? 0 PUNCT F

10 0 NUM F
( 0 PUNCT F
p 0 NOUN F
= 0 SYM F
0.04 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

In 0 ADP T
conclusion 0 NOUN F
, 0 PUNCT F
inhaled 0 ADJ F
treprostinil 0 NOUN F
was 0 VERB F
associated 0 VERB F
with 0 ADP F
improvement 0 NOUN F
in 0 ADP F
exercise 0 NOUN F
capacity 0 NOUN F
and 0 CCONJ F
World 0 NOUN T
Health 0 NOUN T
Organization 0 NOUN T
functional 0 ADJ F
class 0 NOUN F
when 0 ADP F
added 0 VERB F
to 0 ADP F
background 0 NOUN F
targeted 0 VERB F
PAH 0 NOUN T
therapy 0 NOUN F
in 0 ADP F
children 0 NOUN F
and 0 CCONJ F
had 0 PUNCT F
an 0 DET F
acceptable 0 ADJ F
safety 0 NOUN F
profile 0 NOUN F
. 0 PUNCT F

Based 0 VERB T
on 0 ADP F
these 0 ADP F
early 0 ADJ F
data 0 NOUN F
, 0 PUNCT F
further 0 DET F
study 0 NOUN F
of 0 ADP F
inhaled 0 VERB F
treprostinil 0 NOUN F
appears 0 NOUN F
warranted 0 VERB F
in 0 ADP F
pediatric 0 ADJ F
patients 0 NOUN F
with 0 ADP F
PAH 0 NOUN T
. 0 PUNCT F

Why 0 VERB T
distinctive 0 ADJ F
information 0 NOUN F
reduces 0 NOUN F
false B-PHYSICAL ADJ F
memories I-PHYSICAL NOUN F
: 0 PUNCT F
evidence 0 NOUN F
for 0 ADP F
both 0 CCONJ F
impoverished 0 PUNCT F
relational-encoding 0 VERB F
and 0 CCONJ F
distinctiveness 0 NOUN F
heuristic 0 ADJ F
accounts 0 PUNCT F
. 0 PUNCT F

Two 0 NUM T
accounts 0 VERB F
explain 0 ADP F
why 0 ADP F
studying 0 DET F
pictures 0 NOUN F
reduces 0 NOUN F
false B-PHYSICAL ADJ F
memories I-PHYSICAL NOUN F
within 0 ADP F
the 0 DET F
Deese-Roediger-McDermott 0 ADJ T
paradigm 0 NOUN F
( 0 PUNCT F
J. 0 NOUN T
Deese 0 NOUN T
, 0 PUNCT F
1959 0 NUM F
; 0 PUNCT F
H. 0 ADV T
L. 0 PUNCT T
Roediger 0 ADJ T
& 0 CCONJ F
K. 0 ADV T
B. 0 NOUN T
McDermott 0 NOUN T
, 0 PUNCT F
1995 0 PUNCT F
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
impoverished 0 VERB F
relational-encoding 0 PUNCT F
account 0 VERB F
suggests 0 VERB F
that 0 ADP F
studying B-PHYSICAL DET F
pictures I-PHYSICAL NOUN F
interferes 0 NOUN F
with 0 ADP F
the 0 DET F
encoding 0 PUNCT F
of 0 ADP F
relational 0 ADJ F
information 0 NOUN F
, 0 PUNCT F
which 0 ADP F
is 0 VERB F
the 0 DET F
primary 0 ADJ F
basis 0 NOUN F
for 0 ADP F
false 0 ADJ F
memories 0 NOUN F
in 0 ADP F
this 0 DET F
paradigm 0 NOUN F
. 0 PUNCT F

Alternatively 0 ADV T
, 0 PUNCT F
the 0 DET F
distinctiveness 0 ADV F
heuristic 0 ADJ F
assumes 0 PUNCT F
that 0 ADP F
critical B-PHYSICAL ADJ F
lures I-PHYSICAL NOUN F
are 0 VERB F
actively 0 ADV F
withheld 0 ADJ F
by 0 ADP F
the 0 DET F
use 0 NOUN F
of 0 ADP F
a 0 DET F
retrieval 0 NOUN F
strategy 0 NOUN F
. 0 PUNCT F

When 0 ADP T
participants 0 NOUN F
were 0 VERB F
given 0 VERB F
inclusion 0 NOUN F
recall 0 VERB F
instructions 0 DET F
to 0 PUNCT F
report 0 PUNCT F
studied 0 NOUN F
items 0 VERB F
as 0 PUNCT F
well 0 PUNCT F
as 0 CCONJ F
related 0 PUNCT F
items 0 ADP F
, 0 PUNCT F
they 0 PRON F
still 0 ADV F
reported B-PHYSICAL PUNCT F
critical I-PHYSICAL ADJ F
lures I-PHYSICAL NOUN F
less 0 ADV F
often 0 ADV F
after 0 ADP F
picture 0 NOUN F
encoding 0 CCONJ F
than 0 PUNCT F
they 0 ADP F
did 0 PUNCT F
after 0 ADP F
word 0 NOUN F
encoding 0 ADJ F
. 0 PUNCT F

As 0 ADP T
the 0 DET F
impoverished 0 VERB F
relational-encoding 0 PUNCT F
account 0 VERB F
suggests 0 VERB F
, 0 PUNCT F
critical B-PHYSICAL ADJ F
lures I-PHYSICAL NOUN F
appear 0 VERB F
less 0 ADV F
likely 0 ADJ F
to 0 ADP F
come 0 PROPN F
to 0 PUNCT F
mind 0 CCONJ F
after 0 ADP F
picture 0 NOUN F
encoding 0 CCONJ F
than 0 PUNCT F
they 0 ADV F
do 0 PUNCT F
after 0 ADP F
word 0 NOUN F
encoding 0 ADJ F
. 0 PUNCT F

However 0 ADV T
, 0 PUNCT F
the 0 DET F
results 0 ADP F
from 0 ADP F
a 0 DET F
postrecall B-PHYSICAL ADJ F
recognition I-PHYSICAL NOUN F
test 0 PUNCT F
provide 0 PUNCT F
evidence 0 NOUN F
in 0 ADP F
favor 0 NOUN F
of 0 ADP F
the 0 DET F
distinctiveness 0 ADV F
heuristic 0 ADJ F
. 0 PUNCT F

Pharmacokinetic B-OTHER ADJ T
and 0 CCONJ F
safety B-OTHER NOUN F
assessments B-PHYSICAL NOUN F
of 0 ADP F
galantamine 0 NOUN F
and 0 CCONJ F
risperidone 0 NUM F
after 0 ADP F
the 0 DET F
two 0 NUM F
drugs 0 NOUN F
are 0 VERB F
administered 0 VERB F
alone 0 ADJ F
and 0 CCONJ F
together 0 ADV F
. 0 PUNCT F

To 0 PART T
explore 0 CCONJ F
the 0 DET F
steady-state 0 NOUN F
pharmacokinetic 0 ADJ F
profile 0 NOUN F
after 0 ADP F
coadministration 0 NOUN F
of 0 ADP F
galantamine 0 NOUN F
and 0 CCONJ F
risperidone 0 NUM F
, 0 PUNCT F
an 0 DET F
open-label 0 NOUN F
, 0 PUNCT F
randomized 0 VERB F
, 0 PUNCT F
single-center 0 NOUN F
, 0 PUNCT F
two-way 0 NOUN F
crossover 0 NOUN F
drug-drug 0 NOUN F
interaction 0 NOUN F
study 0 NOUN F
was 0 VERB F
conducted 0 VERB F
in 0 ADP F
16 0 NUM F
healthy 0 ADJ F
elderly 0 ADJ F
subjects 0 NOUN F
, 0 PUNCT F
ages 0 NOUN F
60 0 NUM F
years 0 NOUN F
and 0 CCONJ F
older 0 PUNCT F
. 0 PUNCT F

The 0 DET T
results 0 NOUN F
showed 0 VERB F
that 0 ADP F
risperidone 0 ADV F
, 0 PUNCT F
when 0 ADP F
administered 0 VERB F
with 0 ADP F
galantamine 0 NOUN F
, 0 PUNCT F
did 0 PUNCT F
not 0 ADV F
change 0 VERB F
the 0 DET F
bioavailability B-OTHER NOUN F
of 0 ADP F
galantamine 0 NOUN F
at 0 ADP F
steady 0 ADJ F
state 0 NOUN F
. 0 PUNCT F

In 0 ADP T
addition 0 NOUN F
, 0 PUNCT F
systemic 0 ADJ F
exposure 0 NOUN F
of 0 ADP F
risperidone 0 NUM F
active 0 ADJ F
moiety 0 NOUN F
( 0 PUNCT F
risperidone 0 ADP F
plus 0 CCONJ F
9-hydroxyrisperidone 0 NOUN F
) 0 PUNCT F
, 0 PUNCT F
the 0 DET F
most 0 PUNCT F
clinically 0 ADV F
relevant 0 ADJ F
component 0 NOUN F
of 0 ADP F
risperidone 0 NUM F
treatment 0 NOUN F
, 0 PUNCT F
was 0 VERB F
not 0 ADV F
affected 0 VERB F
by 0 ADP F
galantamine 0 PUNCT F
coadministration 0 NOUN F
, 0 PUNCT F
while 0 ADP F
systemic B-OTHER ADJ F
exposure I-OTHER NOUN F
was 0 VERB F
increased 0 VERB F
by 0 ADP F
approximately 0 ADV F
10 0 NUM F
% 0 SYM F
for 0 ADP F
risperidone 0 NUM F
and 0 CCONJ F
decreased 0 PUNCT F
by 0 ADP F
about 0 PUNCT F
10 0 NUM F
% 0 SYM F
for 0 ADP F
9-hydroxyrisperidone 0 NOUN F
( 0 PUNCT F
active 0 ADJ F
metabolite 0 NOUN F
of 0 ADP F
risperidone 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Galantamine 0 NOUN T
and 0 CCONJ F
risperidone 0 NUM F
were 0 VERB F
both 0 CCONJ F
safe B-OTHER ADJ F
and I-OTHER CCONJ F
well I-OTHER VERB F
tolerated I-OTHER ADP F
administered 0 PUNCT F
either 0 CCONJ F
alone 0 ADJ F
or 0 CCONJ F
together 0 ADV F
. 0 PUNCT F

Thus 0 ADV T
, 0 PUNCT F
no 0 DET F
dose 0 NOUN F
adjustment 0 NOUN F
for 0 ADP F
either 0 CCONJ F
risperidone 0 ADP F
orgalantamine 0 ADP F
is 0 ADP F
necessary 0 ADJ F
when 0 PUNCT F
these 0 DET F
two 0 NUM F
drugs 0 NOUN F
are 0 VERB F
administered 0 VERB F
together 0 ADV F
in 0 ADP F
the 0 DET F
dose 0 NOUN F
range 0 NOUN F
evaluated 0 NOUN F
. 0 PUNCT F

A 0 DET T
carbohydrate 0 NOUN F
meal 0 NOUN F
attenuates 0 ADP F
the 0 DET F
forearm 0 NOUN F
vasoconstrictor 0 NOUN F
response 0 NOUN F
to 0 ADP F
lower 0 PUNCT F
body 0 NOUN F
subatmospheric 0 ADJ F
pressure 0 NOUN F
in 0 ADP F
healthy 0 ADJ F
young 0 ADJ F
adults 0 NOUN F
. 0 PUNCT F

The 0 DET T
cardiovascular 0 ADJ F
( 0 PUNCT F
CV 0 NOUN T
) 0 PUNCT F
responses 0 NOUN F
to 0 ADP F
meal 0 PUNCT F
ingestion 0 NOUN F
and 0 CCONJ F
orthostasis 0 NOUN F
are 0 VERB F
well 0 VERB F
established 0 VERB F
. 0 PUNCT F

The 0 DET T
effect 0 NOUN F
of 0 ADP F
meal 0 NOUN F
ingestion 0 NOUN F
and 0 CCONJ F
meal 0 NOUN F
composition 0 NOUN F
on 0 ADP F
the 0 DET F
CV 0 NOUN T
responses 0 NOUN F
to 0 ADP F
orthostasis 0 NOUN F
are 0 VERB F
unknown 0 VERB F
. 0 PUNCT F

The 0 DET T
effect 0 NOUN F
of 0 ADP F
high 0 ADJ F
carbohydrate 0 NOUN F
( 0 PUNCT F
HC 0 NOUN T
) 0 PUNCT F
and 0 CCONJ F
high 0 ADJ F
fat 0 NOUN F
( 0 PUNCT F
HF 0 NOUN T
) 0 PUNCT F
meal 0 ADJ F
ingestion 0 NOUN F
on 0 ADP F
the 0 DET F
CV 0 NOUN T
responses 0 NOUN F
to 0 ADP F
simulated 0 VERB F
orthostatic 0 ADJ F
stress 0 NOUN F
( 0 PUNCT F
using 0 PUNCT F
graded 0 VERB F
lower 0 PUNCT F
body 0 NOUN F
subatmospheric 0 ADJ F
pressure 0 NOUN F
( 0 PUNCT F
LBSP 0 NOUN T
) 0 PUNCT F
) 0 PUNCT F
was 0 VERB F
assessed 0 VERB F
in 0 ADP F
nine 0 NUM F
healthy 0 ADJ F
young 0 ADJ F
volunteers 0 NOUN F
. 0 PUNCT F

Cardiac B-PHYSICAL ADJ T
output I-PHYSICAL NOUN F
( 0 PUNCT F
CO B-PHYSICAL NOUN T
) 0 PUNCT F
, 0 PUNCT F

Single-use 0 PUNCT T
plaque 0 NOUN F
removal 0 NOUN F
efficacy 0 NOUN F
of 0 ADP F
three 0 NUM F
power 0 NOUN F
toothbrushes 0 ADP F
. 0 PUNCT F

OBJECTIVES 0 ADP T
To 0 PROPN T
compare 0 NOUN F
the 0 DET F
safety B-OTHER NOUN F
and 0 CCONJ F
plaque B-OTHER NOUN F
removal I-OTHER NOUN F
efficacy I-OTHER NOUN F
of 0 ADP F
two 0 NUM F
oscillating/rotating/pulsating 0 PUNCT F
toothbrushes 0 PUNCT F
( 0 PUNCT F
Oral-B 0 PUNCT T
ProfessionalCare 0 NOUN T
7000 0 NUM F
[ 0 PUNCT F
PC 0 NOUN T
7000 0 NUM F
] 0 PUNCT F
and 0 CCONJ F
Oral-B 0 ADJ T
3D 0 NOUN F
Excel 0 PUNCT T
[ 0 PUNCT F
3DE 0 PUNCT F
] 0 PUNCT F
) 0 PUNCT F
and 0 CCONJ F
a 0 DET F
high-frequency 0 NOUN F
toothbrush 0 NOUN F
( 0 PUNCT F
Sonicare 0 NOUN T
Advance 0 NOUN T
, 0 PUNCT F
Philips 0 ADV T
Oral 0 PUNCT T
Healthcare 0 NOUN T
; 0 PUNCT F
SA 0 NOUN T
) 0 PUNCT F
in 0 ADP F
a 0 DET F
single-use 0 NOUN F
, 0 PUNCT F
examiner-blind 0 PUNCT F
, 0 PUNCT F
three 0 NUM F
period 0 NOUN F
crossover 0 NOUN F
study 0 NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
After 0 ADP T
refraining 0 ADJ F
from 0 ADP F
all 0 DET F
oral 0 ADJ F
hygiene 0 NOUN F
procedures 0 NOUN F
for 0 ADP F
23-25 0 NUM F
hours 0 NOUN F
, 0 PUNCT F
subjects 0 NOUN F
received 0 VERB F
an 0 DET F
oral 0 ADJ F
tissue 0 NOUN F
examination 0 NOUN F
and 0 CCONJ F
those 0 PUNCT F
with 0 ADP F
pre-brushing 0 PUNCT F
whole 0 ADJ F
mouth 0 NOUN F
mean 0 NOUN F
plaque 0 NOUN F
scores 0 NOUN F
> 0 SYM F
or 0 CCONJ F
= 0 SYM F
0.6 0 NUM F
based 0 VERB F
on 0 ADP F
the 0 DET F
Rustogi 0 PUNCT T
et 0 CCONJ F
al 0 NOUN F
. 0 PUNCT F

Modified 0 VERB T
Navy 0 PUNCT T
Plaque 0 NOUN T
Index 0 NOUN T
were 0 VERB F
randomly 0 ADV F
assigned 0 VERB F
to 0 ADP F
treatment 0 NOUN F
sequence 0 NOUN F
. 0 PUNCT F

After 0 ADP T
brushing 0 PUNCT F
with 0 ADP F
the 0 DET F
assigned 0 PUNCT F
toothbrush 0 NOUN F
and 0 CCONJ F
a 0 DET F
commercially 0 ADV F
available 0 ADJ F
dentifrice 0 NOUN F
for 0 ADP F
2 0 NUM F
minutes 0 NOUN F
, 0 PUNCT F
oral 0 ADJ F
tissues 0 NOUN F
were 0 VERB F
then 0 ADV F
re-examined 0 VERB F
and 0 CCONJ F
post-brushing 0 PROPN F
plaque 0 NOUN F
scores 0 NOUN F
recorded 0 PROPN F
. 0 PUNCT F

Following 0 VERB T
a 0 DET F
brief 0 ADJ F
washout 0 PUNCT F
period 0 NOUN F
between 0 ADP F
two 0 NUM F
additional 0 ADJ F
visits 0 NOUN F
, 0 PUNCT F
the 0 DET F
above 0 ADP F
procedures 0 NOUN F
were 0 VERB F
repeated 0 VERB F
with 0 ADP F
the 0 DET F
two 0 NUM F
alternate 0 PUNCT F
toothbrushes 0 VERB F
. 0 PUNCT F

One 0 NUM T
examiner 0 NOUN F
, 0 PUNCT F
blinded 0 PUNCT F
to 0 ADP F
the 0 DET F
treatment 0 NOUN F
sequence 0 NOUN F
, 0 PUNCT F
performed 0 VERB F
all 0 DET F
clinical 0 ADJ F
measurements 0 NOUN F
. 0 PUNCT F

RESULTS 0 NOUN T
A 0 PUNCT T
total 0 NOUN F
of 0 ADP F
79 0 NUM F
subjects 0 NOUN F
( 0 PUNCT F
28 0 NUM F
males 0 NOUN F
and 0 CCONJ F
51 0 NUM F
females 0 NOUN F
) 0 PUNCT F
were 0 VERB F
enrolled 0 VERB F
and 0 CCONJ F
completed 0 DET F
the 0 DET F
study 0 NOUN F
. 0 PUNCT F

Each 0 DET T
toothbrush 0 NOUN F
was 0 VERB F
found 0 VERB F
to 0 PART F
be 0 PUNCT F
safe B-OTHER ADJ F
and 0 CCONJ F
significantly 0 ADV F
reduced 0 ADJ F
plaque B-OTHER NOUN F
levels I-OTHER NOUN F
after 0 ADP F
a 0 DET F
single 0 ADJ F
brushing 0 ADJ F
. 0 PUNCT F

The 0 DET T
PC 0 NOUN T
7000 0 NUM F
and 0 CCONJ F
3DE 0 PUNCT F
were 0 VERB F
equally 0 ADV F
more 0 ADV F
effective 0 ADJ F
in 0 ADP F
plaque B-PHYSICAL NOUN F
removal I-PHYSICAL NOUN F
than 0 ADP F
the 0 DET F
SA 0 NOUN T
, 0 PUNCT F
at 0 ADP F
all 0 DET F
tooth 0 NOUN F
areas 0 NOUN F
, 0 PUNCT F
reducing 0 PUNCT F
plaque B-PHYSICAL NOUN F
by 0 ADP F
59.0 0 NUM F
% 0 SYM F
, 0 PUNCT F
59.7 0 NUM F
% 0 SYM F
and 0 CCONJ F
51.8 0 NUM F
% 0 SYM F
, 0 PUNCT F
respectively 0 ADV F
on 0 ADP F
whole 0 ADJ F
mouth 0 NOUN F
surfaces 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
by 0 ADP F
67.5 0 NUM F
% 0 SYM F
, 0 PUNCT F
67.8 0 NUM F
% 0 SYM F
and 0 CCONJ F
59.4 0 NUM F
% 0 SYM F
, 0 PUNCT F
respectively 0 ADV F
on 0 ADP F
approximal 0 ADJ F
surfaces 0 NOUN F
. 0 PUNCT F

CONCLUSIONS 0 NOUN T
The 0 DET T
action 0 NOUN F
of 0 ADP F
the 0 DET F
oscillating/rotating/pulsating 0 PUNCT F
toothbrushes 0 PUNCT F
( 0 PUNCT F
Oral-B 0 PUNCT T
ProfessionalCare 0 NOUN T
7000 0 NUM F
and 0 CCONJ F
Oral-B 0 ADJ T
3D 0 NOUN F
Excel 0 PUNCT T
) 0 PUNCT F
was 0 VERB F
more 0 ADV F
effective 0 ADJ F
in 0 ADP F
plaque 0 NOUN F
removal 0 NOUN F
than 0 PUNCT F
the 0 DET F
high-frequency 0 NOUN F
toothbrush 0 NOUN F
( 0 PUNCT F
Sonicare 0 NOUN T
Advance 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
efficacy 0 NOUN F
of 0 ADP F
melatonin 0 NOUN F
for 0 ADP F
sleep 0 ADJ F
problems 0 NOUN F
in 0 ADP F
children 0 NOUN F
with 0 ADP F
autism 0 NOUN F
, 0 PUNCT F
fragile 0 PUNCT F
X 0 NUM T
syndrome 0 NOUN F
, 0 PUNCT F
or 0 CCONJ F
autism 0 NOUN F
and 0 CCONJ F
fragile 0 PUNCT F
X 0 NUM T
syndrome 0 NOUN F
. 0 PUNCT F

STUDY 0 NOUN T
OBJECTIVE 0 NOUN T
To 0 PROPN T
determine 0 NOUN F
the 0 DET F
efficacy 0 NOUN F
of 0 ADP F
melatonin 0 NOUN F
on 0 ADP F
sleep 0 ADJ F
problems 0 NOUN F
in 0 ADP F
children 0 NOUN F
with 0 ADP F
autistic 0 ADJ F
spectrum 0 NOUN F
disorder 0 NOUN F
( 0 PUNCT F
ASD 0 NOUN T
) 0 PUNCT F
and 0 CCONJ F
fragile 0 PUNCT F
X 0 NUM T
syndrome 0 NOUN F
( 0 PUNCT F
FXS 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

METHODS 0 NOUN T
A 0 PUNCT T
4-week 0 NOUN F
, 0 PUNCT F
randomized 0 VERB F
, 0 PUNCT F
double 0 ADJ F
blind 0 ADJ F
, 0 PUNCT F
placebo-controlled 0 VERB F
, 0 PUNCT F
crossover 0 ADP F
design 0 NOUN F
was 0 VERB F
conducted 0 VERB F
following 0 ADJ F
a 0 DET F
1-week 0 NOUN F
baseline 0 NOUN F
period 0 NOUN F
. 0 PUNCT F

Either 0 CCONJ T
melatonin 0 NOUN F
, 0 PUNCT F
3 0 NUM F
mg 0 NOUN F
, 0 PUNCT F
or 0 CCONJ F
placebo 0 NOUN F
was 0 VERB F
given 0 VERB F
to 0 ADP F
participants 0 NOUN F
for 0 ADP F
2 0 NUM F
weeks 0 NOUN F
and 0 CCONJ F
then 0 ADV F
alternated 0 VERB F
for 0 ADP F
another 0 DET F
2 0 NUM F
weeks 0 NOUN F
. 0 PUNCT F

Sleep B-PHYSICAL NOUN T
variables I-PHYSICAL NOUN F
, 0 PUNCT F
including 0 CCONJ F
sleep 0 NOUN F
duration 0 NOUN F
, 0 PUNCT F
sleep-onset 0 NOUN F
time 0 NOUN F
, 0 PUNCT F
sleep-onset 0 NOUN F
latency 0 NOUN F
time 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
the 0 DET F
number 0 NOUN F
of 0 ADP F
night 0 NOUN F
awakenings 0 NOUN F
, 0 PUNCT F
were 0 VERB F
recorded 0 VERB F
using 0 VERB F
an 0 DET F
Actiwatch 0 NOUN T
and 0 CCONJ F
from 0 ADP F
sleep 0 NOUN F
diaries 0 NOUN F
completed 0 VERB F
by 0 ADP F
parents 0 NOUN F
. 0 PUNCT F

All 0 DET T
participants 0 NOUN F
had 0 PUNCT F
been 0 PUNCT F
thoroughly 0 ADV F
assessed 0 VERB F
for 0 ADP F
ASD 0 NOUN T
and 0 CCONJ F
also 0 ADV F
had 0 PUNCT F
DNA 0 NOUN T
testing 0 VERB F
for 0 ADP F
the 0 DET F
diagnosis 0 NOUN F
of 0 ADP F
FXS 0 NOUN T
. 0 PUNCT F

RESULTS 0 DET T
Data 0 NOUN T
were 0 VERB F
successfully 0 ADV F
obtained 0 VERB F
from 0 ADP F
the 0 DET F
12 0 NUM F
of 0 ADP F
18 0 NUM F
subjects 0 NOUN F
who 0 ADP F
completed 0 PROPN F
the 0 DET F
study 0 NOUN F
( 0 PUNCT F
11 0 NUM F
males 0 PROPN F
, 0 PUNCT F
age 0 NOUN F
range 0 NOUN F
2 0 NUM F
to 0 ADP F
15.25 0 NUM F
years 0 NOUN F
, 0 PUNCT F
mean 0 NOUN F
5.47 0 NUM F
, 0 PUNCT F
SD 0 NOUN T
3.6 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Five 0 NUM T
participants 0 NOUN F
met 0 VERB F
diagnostic 0 ADJ F
criteria 0 NOUN F
for 0 ADP F
ASD 0 NOUN T
, 0 PUNCT F
3 0 NUM F
for 0 ADP F
FXS 0 NOUN T
alone 0 ADJ F
, 0 PUNCT F
3 0 NUM F
for 0 ADP F
FXS 0 NOUN T
and 0 CCONJ F
ASD 0 NOUN T
, 0 PUNCT F
and 0 CCONJ F
1 0 NUM F
for 0 ADP F
fragile 0 ADJ F
X 0 ADP T
premutation 0 NUM F
. 0 PUNCT F

Eight 0 NUM T
out 0 PUNCT F
of 0 ADP F
12 0 NUM F
had 0 PUNCT F
melatonin 0 NOUN F
first 0 ADJ F
. 0 PUNCT F

The 0 DET T
conclusions 0 NOUN F
from 0 ADP F
a 0 DET F
nonparametric 0 ADJ F
repeated-measures 0 NOUN F
technique 0 NOUN F
indicate 0 VERB F
that 0 ADP F
mean 0 NOUN F
night B-OTHER NOUN F
sleep I-OTHER NOUN F
duration I-OTHER NOUN F
was 0 VERB F
longer 0 PUNCT F
on 0 ADP F
melatonin 0 NOUN F
than 0 PUNCT F
placebo 0 NOUN F
by 0 ADP F
21 0 NUM F
minutes 0 NOUN F
( 0 PUNCT F
p 0 NOUN F
= 0 SYM F
.02 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
mean 0 VERB F
sleep-onset B-OTHER NOUN F
latency I-OTHER NOUN F
was 0 VERB F
shorter 0 PUNCT F
by 0 ADP F
28 0 NUM F
minutes 0 NOUN F
( 0 PUNCT F
p 0 NOUN F
= 0 SYM F
.0001 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
and 0 CCONJ F
mean 0 NOUN F
sleep-onset B-OTHER NOUN F
time I-OTHER NOUN F
was 0 VERB F
earlier 0 PUNCT F
by 0 ADP F
42 0 NUM F
minutes 0 NOUN F
( 0 PUNCT F
p 0 NOUN F
= 0 SYM F
.02 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

CONCLUSION 0 NOUN T
The 0 DET T
results 0 NOUN F
of 0 ADP F
this 0 DET F
study 0 NOUN F
support 0 VERB F
the 0 DET F
efficacy 0 NOUN F
and 0 CCONJ F
tolerability 0 NOUN F
of 0 ADP F
melatonin 0 NOUN F
treatment 0 NOUN F
for 0 ADP F
sleep 0 ADJ F
problems 0 NOUN F
in 0 ADP F
children 0 NOUN F
with 0 ADP F
ASD 0 NOUN T
and 0 CCONJ F
FXS 0 NOUN T
. 0 PUNCT F

[ 0 PUNCT F
The 0 DET T
chemotherapy 0 NOUN F
of 0 ADP F
advanced 0 VERB F
breast 0 NOUN F
cancer 0 NOUN F
. 0 PUNCT F

A 0 DET T
report 0 NOUN F
on 0 ADP F
the 0 DET F
first 0 ADJ F
600 0 NUM F
cases 0 NOUN F
in 0 ADP F
a 0 DET F
cooperative 0 ADJ F
programme 0 NOUN F
to 0 VERB F
carry 0 PUNCT F
out 0 DET F
a 0 DET F
systematic 0 ADJ F
study 0 NOUN F
( 0 PUNCT F
1974-1977 0 NUM F
) 0 PUNCT F
( 0 PUNCT F
author 0 NOUN F
's 0 PUNCT F
transl 0 NOUN F
) 0 PUNCT F
] 0 PUNCT F
. 0 PUNCT F

The 0 DET T
authors 0 NOUN F
explain 0 VERB F
the 0 DET F
objectives 0 NOUN F
and 0 CCONJ F
the 0 DET F
structure 0 NOUN F
of 0 ADP F
a 0 DET F
programme 0 NOUN F
evolved 0 VERB F
for 0 ADP F
the 0 DET F
methodic 0 ADJ F
study 0 NOUN F
of 0 ADP F
advanced 0 VERB F
breast 0 NOUN F
cancers 0 NOUN F
which 0 ADP F
they 0 PRON F
have 0 VERB F
worked 0 VERB F
out 0 PUNCT F
and 0 CCONJ F
carried 0 ADP F
out 0 ADP F
in 0 ADP F
cooperation 0 NOUN F
with 0 ADP F
the 0 DET F
departments 0 NOUN F
of 0 ADP F
medicine 0 NOUN F
in 0 ADP F
eight 0 NUM F
French 0 ADJ T
anticancer 0 NOUN F
centres 0 NOUN F
. 0 PUNCT F

They 0 NOUN T
analyse 0 ADP F
the 0 DET F
initial 0 ADJ F
phases 0 NOUN F
, 0 PUNCT F
which 0 ADP F
correspond 0 PUNCT F
to 0 ADP F
the 0 DET F
three 0 NUM F
first 0 ADJ F
years 0 NOUN F
of 0 ADP F
work 0 NOUN F
. 0 PUNCT F

They 0 PRON T
give 0 VERB F
the 0 DET F
state 0 NOUN F
of 0 ADP F
the 0 DET F
results 0 NOUN F
that 0 ADP F
have 0 PUNCT F
been 0 PUNCT F
obtained 0 VERB F
in 0 ADP F
603 0 NUM F
patients 0 NOUN F
using 0 VERB F
three 0 NUM F
protocols 0 NOUN F
for 0 ADP F
treatment 0 NOUN F
. 0 PUNCT F

These 0 ADP T
consisted 0 DET F
of 0 ADP F
the 0 DET F
administration 0 NOUN F
in 0 ADP F
interrupted 0 VERB F
doses 0 NOUN F
of 0 ADP F
chemotherapy 0 NOUN F
which 0 ADP F
consisted 0 VERB F
of 0 ADP F
vincristine 0 NOUN F
associated 0 VERB F
for 0 ADP F
the 0 DET F
one 0 NUM F
part 0 NOUN F
with 0 ADP F
cyclophosphamide 0 NOUN F
and 0 CCONJ F
5-fluoro-uracil 0 NOUN F
and 0 CCONJ F
on 0 ADP F
the 0 DET F
other 0 ADJ F
hand 0 NOUN F
with 0 ADP F
doxorubicine 0 NOUN F
or/and 0 PUNCT F
with 0 ADP F
methotrexate 0 NOUN F
. 0 PUNCT F

From 0 ADP T
this 0 DET F
study 0 NOUN F
there 0 PUNCT F
emerged 0 PUNCT F
the 0 DET F
value 0 NOUN F
of 0 ADP F
combined 0 VERB F
therapy 0 NOUN F
using 0 VERB F
doxorubicine 0 NOUN F
as 0 PUNCT F
much 0 PUNCT F
because 0 PUNCT F
of 0 ADP F
the 0 DET F
frequency 0 NOUN F
with 0 ADP F
which B-PHYSICAL PUNCT F
results I-PHYSICAL PUNCT F
better I-PHYSICAL PUNCT F
than 0 VERB F
50 0 NUM F
% 0 SYM F
were 0 VERB F
obtained 0 VERB F
( 0 PUNCT F
in 0 ADP F
a 0 DET F
randomised 0 VERB F
trial 0 NOUN F
) 0 PUNCT F
as 0 VERB F
by 0 ADP F
their 0 PUNCT F
quality B-OTHER NOUN F
, 0 PUNCT F
which 0 ADP F
was 0 VERB F
made 0 SYM F
clear 0 ADJ F
in 0 ADP F
an 0 DET F
important 0 ADJ F
series 0 NOUN F
of 0 ADP F
240 0 NUM F
cases 0 NOUN F
. 0 PUNCT F

They 0 NUM T
point 0 PUNCT F
out 0 ADP F
the 0 DET F
conditions 0 NOUN F
required 0 VERB F
to 0 PART F
initiate 0 NOUN F
the 0 DET F
place 0 NOUN F
of 0 ADP F
such 0 CCONJ F
a 0 ADP F
scheme 0 NOUN F
in 0 ADP F
all 0 DET F
complex 0 ADJ F
therapy 0 NOUN F
which 0 ADP F
aims 0 ADP F
as 0 PUNCT F
much 0 PUNCT F
at 0 ADP F
palliation 0 NOUN F
as 0 PUNCT F
at 0 CCONJ F
cure 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
point 0 NOUN F
out 0 ADJ F
how 0 PUNCT F
important 0 ADJ F
it 0 NOUN F
is 0 VERB F
to 0 PART F
be 0 PUNCT F
methodical 0 ADP F
in 0 ADP F
the 0 DET F
application 0 NOUN F
of 0 ADP F
chemotherapy 0 NOUN F
in 0 ADP F
order 0 NOUN F
to 0 PART F
ensure 0 NOUN F
its 0 ADP F
development 0 NOUN F
as 0 ADP F
an 0 DET F
anticancer 0 NOUN F
therapy 0 NOUN F
. 0 PUNCT F

Circadian 0 ADJ T
changes 0 NOUN F
in 0 ADP F
the 0 DET F
pharmacokinetics B-PHYSICAL NOUN F
of 0 ADP F
oral 0 ADJ F
ketoprofen 0 NOUN F
. 0 PUNCT F

Several 0 ADJ T
investigations 0 NOUN F
which 0 ADP F
have 0 PUNCT F
taken 0 ADP F
treatment 0 NOUN F
time 0 NOUN F
into 0 ADP F
account 0 PUNCT F
have 0 PUNCT F
shown 0 VERB F
that 0 ADP F
the 0 DET F
pharmacokinetic 0 ADJ F
parameters 0 NOUN F
, 0 PUNCT F
the 0 DET F
therapeutic B-OTHER ADJ F
efficacy I-OTHER NOUN F
and 0 CCONJ F
even 0 ADV F
the 0 ADP F
toxicity B-PHYSICAL NOUN F
of 0 ADP F
a 0 DET F
large 0 ADJ F
number 0 NOUN F
of 0 ADP F
products 0 NOUN F
may 0 VERB F
vary 0 VERB F
according 0 CCONJ F
to 0 ADP F
the 0 DET F
administration 0 NOUN F
schedule 0 NOUN F
. 0 PUNCT F

The 0 DET T
present 0 ADJ F
study 0 NOUN F
was 0 VERB F
carried 0 VERB F
out 0 ADP F
in 0 ADP F
order 0 NOUN F
to 0 PART F
evaluate 0 NOUN F
any 0 DET F
circadian 0 ADJ F
changes 0 NOUN F
in 0 ADP F
pharmacokinetic 0 ADJ F
parameters 0 NOUN F
of 0 ADP F
ketoprofen 0 NOUN F
, 0 PUNCT F
a 0 DET F
new 0 ADJ F
non-steroidal 0 ADJ F
anti-inflammatory 0 ADJ F
drug 0 NOUN F
( 0 PUNCT F
NSAID 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

This 0 DET T
randomised 0 VERB F
crossover 0 NOUN F
study 0 NOUN F
consisted 0 VERB F
of 0 ADP F
a 0 DET F
single 0 ADJ F
oral 0 ADJ F
dose 0 NOUN F
of 0 ADP F
ketoprofen 0 NOUN F
100mg 0 NOUN F
administered 0 VERB F
to 0 ADP F
8 0 NUM F
healthy 0 ADJ F
male 0 NOUN F
volunteers 0 NOUN F
, 0 PUNCT F
mean 0 NOUN F
age 0 NOUN F
27.2 0 NUM F
years 0 NOUN F
, 0 PUNCT F
at 0 ADP F
07.00 0 NUM F
hours 0 NOUN F
, 0 PUNCT F
13.00 0 NUM F
hours 0 NOUN F
, 0 PUNCT F
19.00 0 NUM F
hours 0 NOUN F
or 0 CCONJ F
01.00 0 NUM F
hours 0 NOUN F
in 0 ADP F
4 0 NUM F
study 0 ADV F
periods 0 NOUN F
during 0 ADP F
the 0 DET F
first 0 ADJ F
3 0 NUM F
months 0 NOUN F
of 0 ADP F
the 0 DET F
year 0 NOUN F
. 0 PUNCT F

The 0 DET T
order 0 NOUN F
of 0 ADP F
administration 0 NOUN F
was 0 VERB F
randomised 0 NUM F
, 0 PUNCT F
with 0 ADP F
each 0 DET F
subject 0 NOUN F
acting 0 VERB F
as 0 PUNCT F
his 0 PUNCT F
own 0 ADJ F
control 0 NOUN F
. 0 PUNCT F

A 0 DET T
total 0 NOUN F
of 0 ADP F
14 0 NUM F
blood 0 NOUN F
and 0 CCONJ F
4 0 NUM F
urine 0 NOUN F
samples 0 NOUN F
were 0 VERB F
taken 0 VERB F
over 0 ADP F
a 0 DET F
12-hour 0 NOUN F
period 0 NOUN F
. 0 PUNCT F

The 0 DET T
peak 0 ADJ F
plasma B-PHYSICAL NOUN F
concentration I-PHYSICAL NOUN F
was 0 VERB F
twice 0 ADV F
as 0 VERB F
high 0 ADJ F
after 0 ADP F
drug 0 NOUN F
administration 0 NOUN F
at 0 ADP F
07.00 0 NUM F
hours 0 NOUN F
( 0 PUNCT F
13.4 0 NUM F
+/- 0 SYM F
1 0 NUM F
mg/L 0 NOUN F
) 0 PUNCT F
than 0 PUNCT F
after 0 ADP F
other 0 ADJ F
administration 0 NOUN F
times 0 NOUN F
( 0 PUNCT F
13.00 0 NUM F
hours 0 NOUN F
: 0 PUNCT F
6.9 0 NUM F
+/- 0 SYM F
1 0 NUM F
; 0 PUNCT F
19.00 0 NUM F
hours 0 NOUN F
: 0 PUNCT F
7.2 0 NUM F
+/- 0 SYM F
0.7 0 NUM F
; 0 PUNCT F
01.00 0 NUM F
hours 0 NOUN F
: 0 PUNCT F
6.3 0 NUM F
+/- 0 SYM F
0.5 0 NUM F
mg/L 0 NOUN F
) 0 PUNCT F
[ 0 PUNCT F
p 0 NOUN F
less 0 ADV F
than 0 ADP F
0.001 0 NUM F
] 0 PUNCT F
. 0 PUNCT F

The 0 DET T
time B-PHYSICAL NOUN F
to I-PHYSICAL ADP F
reach I-PHYSICAL NOUN F
peak 0 ADJ F
concentration B-PHYSICAL NOUN F
was 0 VERB F
much 0 ADV F
longer 0 PUNCT F
after 0 ADP F
drug 0 NOUN F
administration 0 NOUN F
at 0 ADP F
01.00 0 NUM F
hours 0 NOUN F
( 0 PUNCT F
135 0 NUM F
+/- 0 SYM F
16.7 0 NUM F
min 0 NOUN F
) 0 PUNCT F
than 0 PUNCT F
at 0 ADP F
07.00 0 NUM F
( 0 PUNCT F
73.1 0 NUM F
+/- 0 SYM F
14.1 0 NUM F
min 0 NOUN F
) 0 PUNCT F
, 0 PUNCT F
13.00 0 NUM F
( 0 PUNCT F
75 0 NUM F
+/- 0 SYM F
16.5 0 NUM F
min 0 NOUN F
) 0 PUNCT F
or 0 CCONJ F
19.00 0 NUM F
hours 0 NOUN F
( 0 PUNCT F
82.5 0 NUM F
+/- 0 SYM F
12.7 0 NUM F
min 0 NOUN F
) 0 PUNCT F
[ 0 PUNCT F
p 0 NOUN F
less 0 ADV F
than 0 ADP F
0.05 0 NUM F
] 0 PUNCT F
. 0 PUNCT F

The 0 DET T
lag 0 NOUN F
time 0 NOUN F
was 0 VERB F
significantly 0 ADV F
longer 0 PUNCT F
at 0 ADP F
01.00 0 NUM F
hours 0 NOUN F
than 0 CCONJ F
at 0 ADP F
13.00 0 NUM F
hours 0 NOUN F
( 0 PUNCT F
p 0 NOUN F
less 0 ADV F
than 0 PUNCT F
0.01 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
absorption B-PHYSICAL NOUN F
rate I-PHYSICAL NOUN F
constant 0 ADJ F
after 0 ADP F
treatment 0 NOUN F
at 0 ADP F
01.00 0 NUM F
hours 0 NOUN F
was 0 NUM F
less 0 ADV F
than 0 PUNCT F
at 0 ADP F
the 0 DET F
other 0 ADJ F
times 0 NOUN F
of 0 ADP F
administration 0 NOUN F
( 0 PUNCT F
p 0 NOUN F
less 0 ADV F
than 0 PUNCT F
0.05 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
bodyweight-corrected B-PHYSICAL VERB F
area 0 NOUN F
under B-PHYSICAL ADP F
the B-PHYSICAL DET F
curve 0 NOUN F
( 0 PUNCT F

Does 0 PUNCT T
aerobic 0 ADP F
training 0 VERB F
lead 0 NOUN F
to 0 ADP F
a 0 DET F
more 0 DET F
active B-MENTAL ADJ F
lifestyle I-MENTAL NOUN F
and 0 CCONJ F
improved B-OTHER VERB F
quality I-OTHER NOUN F
of I-OTHER ADP F
life I-OTHER NOUN F
in 0 ADP F
patients 0 NOUN F
with 0 ADP F
chronic 0 ADJ F
heart 0 NOUN F
failure 0 NOUN F
? 0 PUNCT F

BACKGROUND 0 NOUN T
Due 0 PUNCT T
to 0 ADP F
dyspnea 0 NOUN F
and 0 CCONJ F
fatigue 0 NOUN F
, 0 PUNCT F
patients 0 NOUN F
with 0 ADP F
chronic 0 ADJ F
heart 0 NOUN F
failure 0 NOUN F
( 0 PUNCT F
CHF 0 NOUN T
) 0 PUNCT F
are 0 VERB F
often 0 ADV F
restricted 0 VERB F
in 0 ADP F
the 0 DET F
performance 0 NOUN F
of 0 ADP F
everyday 0 NOUN F
activities 0 NOUN F
, 0 PUNCT F
which 0 ADP F
gradually 0 ADV F
may 0 VERB F
lead 0 PUNCT F
to 0 ADP F
hypoactivity 0 NOUN F
. 0 PUNCT F

AIMS 0 NOUN T
To 0 PROPN T
assess 0 NOUN F
whether 0 PUNCT F
aerobic 0 ADJ F
training 0 ADV F
leads 0 SYM F
to 0 ADP F
a 0 DET F
more 0 DET F
active B-MENTAL ADJ F
lifestyle I-MENTAL NOUN F
and 0 CCONJ F
improved 0 VERB F
quality 0 NOUN F
of 0 ADP F
life 0 NOUN F
( B-PHYSICAL PUNCT F
QoL I-PHYSICAL NOUN T
) I-PHYSICAL PUNCT F
in 0 ADP F
patients 0 NOUN F
with 0 ADP F
CHF 0 NOUN T
. 0 PUNCT F

METHODS 0 NOUN T
Patients 0 NOUN T
with 0 ADP F
stable 0 ADJ F
CHF 0 NOUN T
( 0 PUNCT F
NYHA 0 NOUN T
II/III 0 PUNCT T
; 0 PUNCT F
59 0 NUM F
( 0 PUNCT F
11 0 NUM F
) 0 PUNCT F
years 0 NOUN F
) 0 PUNCT F
were 0 VERB F
randomly 0 ADV F
assigned 0 VERB F
to 0 ADP F
a 0 DET F
training 0 VERB F
group 0 NOUN F
( 0 PUNCT F
n=18 0 NOUN F
; 0 PUNCT F
3-month 0 NOUN F
aerobic 0 ADJ F
program 0 NOUN F
above 0 ADP F
standard 0 ADJ F
treatment 0 NOUN F
) 0 PUNCT F
or 0 CCONJ F
control 0 NOUN F
group 0 NOUN F
( 0 PUNCT F
n=16 0 NOUN F
; 0 PUNCT F
standard 0 ADJ F
treatment 0 NOUN F
without 0 ADP F
special 0 ADJ F
advice 0 NOUN F
for 0 ADP F
exercise 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

Measurements 0 NOUN T
were 0 VERB F
performed 0 VERB F
on 0 ADP F
level 0 NOUN F
of 0 ADP F
everyday B-MENTAL NOUN F
physical I-MENTAL ADJ F
activity I-MENTAL NOUN F
( 0 PUNCT F
PA B-MENTAL NOUN T
, 0 PUNCT F
novel B-MENTAL ADJ F
accelerometry-based I-MENTAL VERB F
activity I-MENTAL NOUN F
monitor I-MENTAL NOUN F
) 0 PUNCT F
and 0 PUNCT F

Human 0 NOUN T
achaete-scute 0 ADP F
homologue 0 NOUN F
( 0 PUNCT F
hASH1 0 NOUN F
) 0 PUNCT F
mRNA 0 NOUN F
level 0 NOUN F
as 0 ADP F
a 0 DET F
diagnostic 0 ADJ F
marker 0 NOUN F
to 0 ADJ F
distinguish 0 ADJ F
esthesioneuroblastoma 0 NOUN F
from 0 ADP F
poorly 0 ADV F
differentiated 0 VERB F
tumors 0 NOUN F
arising 0 VERB F
in 0 ADP F
the 0 DET F
sinonasal 0 ADJ F
tract 0 NOUN F
. 0 PUNCT F

Distinction 0 NOUN T
of 0 ADP F
high-grade 0 NOUN F
esthesioneuroblastomas 0 NOUN F
from 0 ADP F
other 0 VERB F
poorly 0 ADV F
differentiated 0 VERB F
tumors 0 NOUN F
arising 0 VERB F
in 0 ADP F
the 0 DET F
nasal 0 ADJ F
cavity 0 NOUN F
is 0 VERB F
an 0 DET F
important 0 ADJ F
diagnostic 0 ADJ F
challenge 0 NOUN F
because 0 ADP F
it 0 ADP F
determines 0 NOUN F
patient 0 NOUN F
management 0 NOUN F
and 0 CCONJ F
prognosis 0 NOUN F
. 0 PUNCT F

The 0 DET T
human 0 NOUN F
achaete-scute 0 ADP F
homologue 0 NOUN F
( 0 PUNCT F
hASH1 0 NOUN F
) 0 PUNCT F
gene 0 NOUN F
is 0 VERB F
critical 0 ADJ F
in 0 PUNCT F
olfactory 0 NOUN F
neuronal 0 ADJ F
differentiation 0 NOUN F
and 0 CCONJ F
is 0 PROPN F
expressed 0 VERB F
in 0 ADP F
immature 0 ADJ F
olfactory 0 NOUN F
cells 0 NOUN F
; 0 PUNCT F
therefore 0 ADV F
, 0 PUNCT F
it 0 PRON F
could 0 VERB F
have 0 PUNCT F
potential 0 ADJ F
use 0 NOUN F
as 0 ADP F
a 0 DET F
diagnostic 0 ADJ F
marker 0 NOUN F
The 0 DET T
aim 0 NOUN F
of 0 ADP F
the 0 DET F
present 0 ADJ F
study 0 NOUN F
was 0 VERB F
to 0 PART F
determine 0 NOUN F
the 0 DET F
value 0 NOUN F
of 0 ADP F
hASH1 0 NOUN F
messenger 0 NOUN F
RNA 0 NOUN T
( 0 PUNCT F
mRNA 0 NOUN F
) 0 PUNCT F
levels 0 NOUN F
in 0 ADP F
differentiating 0 ADJ F
esthesioneuroblastoma 0 NOUN F
from 0 ADP F
other 0 VERB F
poorly 0 ADV F
differentiated 0 VERB F
tumors 0 NOUN F
. 0 PUNCT F

A 0 DET T
real-time 0 NOUN F
polymerase 0 NOUN F
chain 0 NOUN F
reaction 0 NOUN F
assay 0 NOUN F
was 0 VERB F
developed 0 VERB F
, 0 PUNCT F
permitting 0 VERB F
the 0 DET F
comparative 0 ADJ F
determination 0 NOUN F
of 0 ADP F
hASH1 B-PHYSICAL NOUN F
mRNA I-PHYSICAL NOUN F
levels I-PHYSICAL NOUN F
in 0 ADP F
triplicate 0 NOUN F
in 0 ADP F
a 0 DET F
double-blind 0 ADJ F
pilot 0 NOUN F
study 0 NOUN F
including 0 ADP F
24 0 NUM F
frozen 0 VERB F
cases 0 NOUN F
of 0 ADP F
esthesioneuroblastoma 0 NOUN F
and 0 CCONJ F
poorly 0 ADV F
differentiated 0 VERB F
tumors 0 NOUN F
. 0 PUNCT F

All 0 DET T
4 0 NUM F
positive 0 ADJ F
cases 0 NOUN F
were 0 DET F
esthesioneuroblastomas B-PHYSICAL NOUN F
, 0 PUNCT F
and 0 CCONJ F
all 0 DET F
19 0 NUM F
poorly 0 ADV F
differentiated 0 VERB F
tumors 0 NOUN F
were 0 VERB F
negative 0 ADJ F
. 0 PUNCT F

In 0 ADP T
addition 0 NOUN F
, 0 PUNCT F
there 0 PUNCT F
was 0 VERB F
an 0 DET F
inverse 0 ADJ F
association 0 NOUN F
between 0 ADP F
the 0 DET F
grade 0 NOUN F
of 0 ADP F
esthesioneuroblastomas B-PHYSICAL NOUN F
and 0 CCONJ F
hASH1 0 NOUN F
mRNA 0 NOUN F
levels 0 NOUN F
. 0 PUNCT F

The 0 DET T
hASH1 0 NOUN F
mRNA 0 NOUN F
level 0 NOUN F
might 0 VERB F
represent 0 VERB F
a 0 DET F
useful 0 ADJ F
tool 0 NOUN F
for 0 ADP F
distinguishing 0 VERB F
esthesioneuroblastoma 0 NOUN F
from 0 ADP F
poorly 0 ADV F
differentiated 0 VERB F
tumors 0 NOUN F
of 0 ADP F
the 0 DET F
sinonasal 0 ADJ F
region 0 NOUN F
. 0 PUNCT F

Lack 0 NOUN T
of 0 ADP F
benefit 0 PUNCT F
of 0 ADP F
an 0 DET F
active 0 ADJ F
pectoral 0 ADJ F
pulse 0 NOUN F
generator 0 NOUN F
on 0 ADP F
atrial 0 ADJ F
defibrillation 0 NOUN F
thresholds 0 NOUN F
. 0 PUNCT F

INTRODUCTION 0 NOUN T
Atrial 0 ADJ T
defibrillation 0 NOUN F
can 0 PROPN F
be 0 VERB F
achieved 0 VERB F
with 0 ADP F
standard 0 ADJ F
implantable 0 ADJ F
cardioverter 0 ADJ F
defibrillator 0 NOUN F
leads 0 NOUN F
, 0 PUNCT F
which 0 ADP F
has 0 PUNCT F
led 0 VERB F
to 0 ADP F
the 0 DET F
development 0 NOUN F
of 0 ADP F
combined 0 VERB F
atrial 0 ADJ F
and 0 CCONJ F
ventricular 0 ADJ F
devices 0 NOUN F
. 0 PUNCT F

For 0 ADP T
ventricular 0 ADJ F
defibrillation 0 NOUN F
, 0 PUNCT F
use 0 NOUN F
of 0 ADP F
an 0 DET F
active 0 ADJ F
pectoral 0 ADJ F
electrode 0 NOUN F
( 0 PUNCT F
active 0 ADJ F
can 0 PUNCT F
) 0 PUNCT F
in 0 ADP F
the 0 DET F
shocking 0 ADJ F
pathway 0 NOUN F
markedly 0 ADV F
reduces 0 NOUN F
defibrillation 0 NOUN F
thresholds 0 NOUN F
( 0 PUNCT F
DFTs 0 ADJ T
) 0 PUNCT F
. 0 PUNCT F

However 0 ADV T
, 0 PUNCT F
the 0 DET F
effect 0 NOUN F
of 0 ADP F
an 0 DET F
active 0 ADJ F
pectoral 0 ADJ F
can 0 PUNCT F
on 0 ADP F
atrial 0 ADJ F
defibrillation 0 NOUN F
is 0 VERB F
unknown 0 VERB F
. 0 PUNCT F

METHODS 0 NOUN T
AND 0 CCONJ T
RESULTS 0 PUNCT T
This 0 PUNCT T
study 0 NOUN F
was 0 VERB F
a 0 DET F
prospective 0 ADJ F
, 0 PUNCT F
randomized 0 VERB F
, 0 PUNCT F
paired 0 ADP F
comparison 0 NOUN F
of 0 ADP F
two 0 NUM F
shock 0 NOUN F
configurations 0 NOUN F
on 0 ADP F
atrial 0 ADJ F
DFTs 0 NOUN T
in 0 ADP F
33 0 NUM F
patients 0 NOUN F
. 0 PUNCT F

The 0 DET T
lead 0 ADV F
system 0 NOUN F
evaluated 0 VERB F
was 0 VERB F
a 0 DET F
dual-coil 0 NOUN F
transvenous 0 ADJ F
defibrillation 0 NOUN F
lead 0 DET F
with 0 ADP F
a 0 DET F
left 0 ADJ F
pectoral 0 ADJ F
pulse 0 NOUN F
generator 0 NOUN F
emulator 0 NOUN F
. 0 PUNCT F

Shocks 0 PUNCT T
were 0 ADJ F
delivered 0 ADP F
either 0 PUNCT F
between 0 ADP F
the 0 DET F
right 0 ADJ F
ventricular 0 ADJ F
coil 0 NOUN F
and 0 CCONJ F
proximal 0 ADJ F
atrial 0 ADJ F
coil 0 NOUN F
( 0 PUNCT F
lead 0 PUNCT F
) 0 PUNCT F
or 0 CCONJ F
between 0 ADP F
the 0 DET F
right 0 ADJ F
ventricular 0 ADJ F
coil 0 NOUN F
and 0 CCONJ F
an 0 DET F
active 0 ADJ F
can 0 ADP F
in 0 ADP F
common 0 ADJ F
with 0 ADP F
the 0 DET F
atrial 0 ADJ F
coil 0 NOUN F
( 0 PUNCT F
active 0 ADJ F
can 0 PUNCT F
) 0 PUNCT F
. 0 PUNCT F

Delivered B-PHYSICAL VERB T
energy I-PHYSICAL NOUN F
at I-PHYSICAL ADP F
DFT I-PHYSICAL NOUN T
was 0 VERB F
4.2 0 NUM F
+/- 0 SYM F
4.1 0 NUM F
J 0 NOUN T
in 0 ADP F
the 0 DET F
lead 0 ADV F
configuration 0 NOUN F
and 0 CCONJ F
5.0 0 NUM F
+/- 0 SYM F
3.7 0 NUM F
J 0 NOUN T
in 0 ADP F
the 0 DET F
active 0 ADJ F
can 0 PUNCT F
configuration 0 NOUN F
( 0 PUNCT F
P 0 NOUN T
= 0 SYM F
NS 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

Peak 0 ADJ T
current B-PHYSICAL ADJ F
was 0 VERB F
32 0 NUM F
% 0 SYM F
higher 0 PUNCT F
with 0 ADP F
an 0 DET F
active 0 ADJ F
can 0 PUNCT F
( 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.01 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
whereas 0 CCONJ F
shock B-PHYSICAL NOUN F
impedance I-PHYSICAL NOUN F
was 0 VERB F
18 0 NUM F
% 0 SYM F
lower 0 PUNCT F
( 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.001 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Moreover 0 ADV T
, 0 PUNCT F
a 0 DET F
low B-PHYSICAL ADJ F
threshold I-PHYSICAL NOUN F
( 0 PUNCT F
< 0 PROPN F
or 0 CCONJ F
= 0 SYM F
3 0 NUM F
J 0 NOUN T
) 0 PUNCT F
was 0 VERB F
observed 0 VERB F
in 0 ADP F
61 0 NUM F
% 0 SYM F
of 0 ADP F
subjects 0 NOUN F
in 0 ADP F
the 0 DET F
lead 0 ADV F
configuration 0 NOUN F
but 0 CCONJ F
in 0 ADP F
only 0 ADV F
36 0 NUM F
% 0 SYM F
in 0 ADP F
the 0 DET F
active 0 ADJ F
can 0 PUNCT F
configuration 0 NOUN F
( 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.05 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

There 0 PUNCT T
were 0 VERB F
no 0 DET F
clinical B-PHYSICAL ADJ F
predictors I-PHYSICAL NOUN F
of 0 ADP F
the 0 DET F
atrial 0 ADJ F
DFT 0 NOUN T
. 0 PUNCT F

CONCLUSION 0 NOUN T
These 0 DET T
results 0 NOUN F
indicate 0 VERB F
that 0 ADP F
low 0 ADJ F
atrial 0 ADJ F
DFTs 0 NOUN T
can 0 VERB F
be 0 VERB F
achieved 0 VERB F
using 0 VERB F
a 0 DET F
transvenous 0 ADJ F
ventricular 0 ADJ F
defibrillation 0 NOUN F
lead 0 ADV F
. 0 PUNCT F

Because 0 PUNCT T
no 0 DET F
benefit 0 NOUN F
was 0 VERB F
observed 0 VERB F
with 0 ADP F
the 0 DET F
use 0 NOUN F
of 0 ADP F
an 0 DET F
active 0 ADJ F
pectoral 0 ADJ F
electrode 0 NOUN F
for 0 ADP F
atrial 0 ADJ F
defibrillation 0 NOUN F
, 0 PUNCT F
programmable 0 ADJ F
shock 0 NOUN F
vectors 0 NOUN F
may 0 VERB F
be 0 VERB F
useful 0 ADJ F
for 0 ADP F
dual-chamber 0 NOUN F
implantable 0 ADJ F
cardioverter 0 ADJ F
defibrillators 0 NOUN F
. 0 PUNCT F

Testosterone 0 NOUN T
and 0 CCONJ F
gonadotropins 0 NOUN F
but 0 CCONJ F
not 0 ADV F
estrogen 0 NOUN F
associated 0 VERB F
with 0 ADP F
spatial B-MENTAL ADJ F
ability I-MENTAL NOUN F
in 0 ADP F
women 0 NOUN F
suffering 0 VERB F
from 0 ADP F
schizophrenia 0 NOUN F
: 0 PUNCT F
a 0 DET F
double-blind 0 ADJ F
, 0 PUNCT F
placebo-controlled 0 VERB F
study 0 NOUN F
. 0 PUNCT F

The 0 DET T
aim 0 NOUN F
of 0 ADP F
this 0 DET F
study 0 NOUN F
was 0 VERB F
to 0 PART F
investigate 0 NOUN F
the 0 DET F
association 0 NOUN F
between 0 ADP F
estrogen B-PHYSICAL NOUN F
and 0 CCONJ F
spatial B-MENTAL ADJ F
ability I-MENTAL NOUN F
tasks 0 NOUN F
in 0 ADP F
women 0 NOUN F
suffering 0 VERB F
from 0 ADP F
schizophrenia 0 NOUN F
. 0 PUNCT F

For 0 ADP T
this 0 DET F
purpose 0 NOUN F
, 0 PUNCT F
a 0 DET F
placebo-controlled 0 VERB F
, 0 PUNCT F
double-blind 0 ADJ F
, 0 PUNCT F
three-time 0 NOUN F
cross-over 0 NOUN F
study 0 NOUN F
using 0 VERB F
17beta-estradiol 0 NOUN F
combined 0 PUNCT F
with 0 ADP F
norethisterone 0 NOUN F
acetate 0 NOUN F
for 0 ADP F
replacement 0 NOUN F
therapy 0 NOUN F
and 0 CCONJ F
as 0 VERB F
an 0 DET F
adjunct 0 NOUN F
to 0 ADP F
a 0 DET F
naturalistic 0 ADJ F
maintenance 0 NOUN F
antipsychotic 0 ADJ F
treatment 0 NOUN F
was 0 VERB F
carried 0 VERB F
out 0 ADP F
over 0 ADP F
a 0 DET F
period 0 NOUN F
of 0 ADP F
8 0 NUM F
months 0 NOUN F
. 0 PUNCT F

Nineteen 0 NUM T
women 0 NOUN F
( 0 PUNCT F
mean 0 NOUN F
age=38.0 0 PUNCT F
years 0 NOUN F
, 0 PUNCT F
SD=9.9 0 PUNCT T
years 0 NOUN F
) 0 PUNCT F
with 0 ADP F
schizophrenia 0 NOUN F
hospitalized 0 VERB F
for 0 ADP F
the 0 DET F
first 0 ADJ F
time 0 NOUN F
or 0 CCONJ F
repeatedly 0 DET F
were 0 VERB F
included 0 VERB F
in 0 ADP F
the 0 DET F
study 0 NOUN F
. 0 PUNCT F

Sex B-PHYSICAL NOUN T
hormones I-PHYSICAL NOUN F
- I-PHYSICAL PUNCT F
17beta-estradiol I-PHYSICAL NOUN F
, 0 PUNCT F
luteinizing B-PHYSICAL ADP F
hormone I-PHYSICAL NOUN F
( 0 PUNCT F
LH B-PHYSICAL NOUN T
) 0 PUNCT F
, 0 PUNCT F
follicle-stimulating B-PHYSICAL VERB F
hormone I-PHYSICAL NOUN F
( 0 PUNCT F
FSH B-PHYSICAL NOUN T
) 0 PUNCT F
, 0 PUNCT F
prolactin B-PHYSICAL NOUN F
, 0 PUNCT F
testosterone B-PHYSICAL NOUN F
, 0 PUNCT F
and 0 CCONJ F
dehydroepiandrosterone B-PHYSICAL NOUN F
sulfate I-PHYSICAL NOUN F
- 0 PUNCT F
were 0 VERB F
measured 0 VERB F
and 0 CCONJ F
the 0 DET F
patients 0 NOUN F
completed 0 ADV F
a 0 DET F
neuropsychological 0 ADJ F
test 0 NOUN F
in 0 ADP F
the 0 DET F
last 0 ADJ F
two 0 NUM F
active 0 ADJ F
drug 0 NOUN F
and/or 0 CCONJ F
placebo 0 NOUN F
phases 0 NOUN F
. 0 PUNCT F

Three 0 NUM T
different 0 ADJ F
spatial 0 ADJ F
ability 0 NOUN F
tasks 0 NOUN F
- 0 PUNCT F
spatial B-MENTAL ADJ F
orientation I-MENTAL NOUN F
, 0 PUNCT F
spatial B-MENTAL ADJ F
visualization I-MENTAL NOUN F
, 0 PUNCT F
and 0 CCONJ F
flexibility B-MENTAL NOUN F
of I-MENTAL ADP F
closure I-MENTAL NOUN F
- 0 PUNCT F
were 0 VERB F
measured 0 VERB F
by 0 ADP F
a 0 DET F
paper-and-pencil 0 NOUN F
test 0 NOUN F
. 0 PUNCT F

No 0 DET T
association 0 NOUN F
between 0 ADP F
estrogen B-PHYSICAL NOUN F
and 0 CCONJ F
spatial B-MENTAL ADJ F
ability I-MENTAL NOUN F
was 0 VERB F
found 0 VERB F
; 0 PUNCT F
however 0 ADV F
, 0 PUNCT F
in 0 ADP F
an 0 DET F
additional 0 ADJ F
exploratory 0 ADJ F
data 0 NOUN F
analysis 0 NOUN F
, 0 PUNCT F
high 0 ADJ F
levels 0 NOUN F
of 0 ADP F
testosterone 0 NOUN F
, 0 PUNCT F
LH B-PHYSICAL NOUN T
, 0 PUNCT F
and 0 CCONJ F
FSH B-PHYSICAL NOUN T
correlated 0 VERB F
significantly 0 ADV F
with 0 ADP F
performance 0 NOUN F
in 0 ADP F
the 0 DET F
flexibility B-PHYSICAL NOUN F
of I-PHYSICAL ADP F
closure I-PHYSICAL NOUN F
task 0 NOUN F
. 0 PUNCT F

This 0 DET T
is 0 VERB F
the 0 DET F
very 0 ADJ F
first 0 DET F
study 0 NOUN F
, 0 PUNCT F
based 0 VERB F
on 0 ADP F
estrogen 0 NOUN F
intervention 0 NOUN F
instead 0 ADJ F
of 0 ADP F
physiological 0 ADJ F
hormone 0 NOUN F
changes 0 NOUN F
, 0 PUNCT F
to 0 PART F
examine 0 NOUN F
the 0 DET F
association 0 NOUN F
between 0 ADP F
estrogen B-PHYSICAL NOUN F
and 0 CCONJ F
spatial B-PHYSICAL ADJ F
ability I-PHYSICAL NOUN F
in 0 ADP F
women 0 NOUN F
with 0 ADP F
schizophrenia 0 NOUN F
. 0 PUNCT F

Treatment 0 NOUN T
of 0 ADP F
hypertensive 0 ADJ F
and 0 CCONJ F
hypercholesterolaemic 0 ADJ F
patients 0 NOUN F
in 0 ADP F
general 0 ADJ F
practice 0 NOUN F
. 0 PUNCT F

The 0 DET T
effect 0 NOUN F
of 0 ADP F
captopril 0 NOUN F
, 0 PUNCT F
atenolol 0 NOUN F
and 0 CCONJ F
pravastatin 0 NOUN F
combined 0 VERB F
with 0 ADP F
life 0 NOUN F
style 0 ADJ F
intervention 0 NOUN F
. 0 PUNCT F

OBJECTIVE 0 NOUN T
To 0 PROPN T
elucidate 0 CCONJ F
the 0 DET F
effect 0 NOUN F
on 0 ADP F
blood 0 NOUN F
pressure 0 NOUN F
and 0 CCONJ F
blood 0 NOUN F
lipids 0 NOUN F
of 0 ADP F
an 0 DET F
angiotensin 0 NOUN F
converting 0 VERB F
enzyme 0 NOUN F
inhibitor 0 NOUN F
( 0 PUNCT F
captopril 0 NOUN F
) 0 PUNCT F
, 0 PUNCT F
and 0 CCONJ F
a 0 DET F
beta-receptor 0 NOUN F
blocking 0 DET F
agent 0 NOUN F
( 0 PUNCT F
atenolol 0 NOUN F
) 0 PUNCT F
, 0 PUNCT F
given 0 VERB F
alone 0 ADJ F
or 0 CCONJ F
in 0 ADP F
combination 0 NOUN F
with 0 ADP F
a 0 DET F
cholesterol 0 NOUN F
reducing 0 ADP F
drug 0 NOUN F
, 0 PUNCT F
the 0 DET F
beta-hydroxy-methylglutaryl-coenzyme 0 NOUN F
A 0 DET T
reductase 0 NOUN F
inhibitor 0 NOUN F
pravastatin 0 NOUN F
, 0 PUNCT F
in 0 ADP F
patients 0 NOUN F
who 0 ADP F
were 0 VERB F
also 0 ADV F
encouraged 0 VERB F
to 0 ADP F
improve 0 ADJ F
their 0 PUNCT F
lifestyle 0 NOUN F
. 0 PUNCT F

DESIGN 0 NOUN T
A 0 CCONJ T
longitudinal 0 ADJ F
study 0 NOUN F
consisting 0 DET F
of 0 ADP F
three 0 NUM F
phases 0 NOUN F
. 0 PUNCT F

I 0 NUM T
: 0 PUNCT F
Lifestyle 0 NOUN T
intervention 0 NOUN F
alone 0 ADJ F
. 0 PUNCT F

II 0 NUM T
: 0 PUNCT F
Continued 0 PROPN T
lifestyle 0 NOUN F
intervention 0 NOUN F
combined 0 VERB F
with 0 ADP F
captopril 0 NOUN F
or 0 CCONJ F
atenolol 0 NOUN F
. 0 PUNCT F

III 0 NUM T
: 0 PUNCT F
Continued 0 PROPN T
lifestyle 0 NOUN F
intervention 0 NOUN F
combined 0 VERB F
with 0 ADP F
the 0 DET F
same 0 ADJ F
drugs 0 NOUN F
as 0 PUNCT F
in 0 ADP F
phase 0 NOUN F
II 0 NUM T
and 0 CCONJ F
in 0 ADP F
addition 0 NOUN F
pravastatin 0 NOUN F
or 0 CCONJ F
placebo 0 NOUN F
. 0 PUNCT F

SETTING 0 NUM T
Fifty-four 0 NUM T
general 0 ADJ F
practice 0 NOUN F
surgeries 0 DET F
in 0 ADP F
Norway 0 NOUN T
. 0 PUNCT F

PARTICIPANTS 0 ADP T
Hypertensive 0 ADJ T
patients 0 NOUN F
, 0 PUNCT F
210 0 NUM F
females 0 NOUN F
and 0 CCONJ F
160 0 NUM F
males 0 NOUN F
, 0 PUNCT F
treated 0 DET F
or 0 CCONJ F
untreated 0 VERB F
with 0 ADP F
antihypertensive 0 ADJ F
drugs 0 NOUN F
with 0 ADP F
a 0 DET F
sitting 0 ADP F
diastolic 0 ADJ F
blood 0 NOUN F
pressure 0 NOUN F
between 0 ADP F
95 0 NUM F
and 0 CCONJ F
115 0 NUM F
mmHg 0 NOUN F
and 0 CCONJ F
a 0 DET F
serum 0 NOUN F
total 0 ADJ F
cholesterol 0 NOUN F
between 0 ADP F
6.5 0 NUM F
mmol/l 0 NOUN F
( 0 PUNCT F
7.0 0 NUM F
for 0 ADP F
those 0 PUNCT F
age 0 NOUN F
60-67 0 NUM F
years 0 NOUN F
) 0 PUNCT F
and 0 CCONJ F
9.0 0 NUM F
mmol/l 0 NOUN F
. 0 PUNCT F

RESULTS 0 PUNCT T
The 0 DET T
antihypertensive 0 ADJ F
effect 0 NOUN F
of 0 ADP F
captopril 0 NOUN F
and 0 CCONJ F
atenolol 0 NOUN F
was 0 VERB F
not 0 ADV F
influenced 0 VERB F
by 0 ADP F
concurrent 0 ADJ F
administration 0 NOUN F
of 0 ADP F
pravastatin 0 NOUN F
. 0 PUNCT F

The 0 DET T
effect 0 NOUN F
of 0 ADP F
pravastatin 0 NOUN F
was 0 VERB F
not 0 ADV F
limited 0 VERB F
by 0 ADP F
concurrent 0 ADJ F
medication 0 NOUN F
with 0 ADP F
captopril 0 NOUN F
or 0 CCONJ F
atenolol 0 NOUN F
. 0 PUNCT F

Improvement B-MENTAL NOUN T
in I-MENTAL ADP F
lifestyle I-MENTAL NOUN F
seemed 0 VERB F
to 0 PART F
reduce 0 NOUN F
the 0 DET F
need 0 NOUN F
for 0 ADP F
supplementary B-PHYSICAL ADJ F
treatment 0 NOUN F
with B-PHYSICAL PUNCT F

Long-term 0 NOUN T
survival 0 NOUN F
in 0 ADP F
a 0 DET F
phase 0 NOUN F
III 0 NUM T
, 0 PUNCT F
randomised 0 ADP F
study 0 NOUN F
of 0 ADP F
topotecan 0 PUNCT F
versus 0 CCONJ F
paclitaxel 0 NOUN F
in 0 ADP F
advanced 0 VERB F
epithelial 0 ADJ F
ovarian 0 ADJ F
carcinoma 0 NOUN F
. 0 PUNCT F

BACKGROUND 0 NOUN T
We 0 PRON T
have 0 VERB F
continued 0 NOUN F
to 0 ADJ F
monitor 0 ADP F
the 0 DET F
survival 0 NOUN F
of 0 ADP F
patients 0 NOUN F
randomised 0 ADP F
in 0 ADP F
a 0 DET F
previously 0 ADV F
reported 0 VERB F
multicentre 0 NOUN F
phase 0 NOUN F
III 0 NUM T
study 0 NOUN F
of 0 ADP F
topotecan 0 PUNCT F
versus 0 CCONJ F
paclitaxel 0 NOUN F
in 0 ADP F
patients 0 NOUN F
with 0 ADP F
advanced 0 VERB F
epithelial 0 ADJ F
ovarian 0 ADJ F
cancer 0 NOUN F
who 0 ADP F
had 0 PUNCT F
failed 0 VERB F
one 0 NUM F
prior 0 VERB F
platinum-based 0 ADP F
regimen 0 NOUN F
. 0 PUNCT F

PATIENTS 0 NOUN T
AND 0 CCONJ T
METHODS 0 NOUN T
Patients 0 NOUN T
with 0 ADP F
bidimensionally 0 ADV F
measurable 0 ADJ F
disease 0 NOUN F
were 0 VERB F
randomised 0 VERB F
to 0 ADP F
topotecan 0 PUNCT F
( 0 PUNCT F
1.5 0 NUM F
mg/m 0 NOUN F
( 0 PUNCT F
2 0 NUM F
) 0 PUNCT F
/day 0 NOUN F
for 0 ADP F
5 0 NUM F
days 0 NOUN F
) 0 PUNCT F
or 0 CCONJ F
paclitaxel 0 NOUN F
( 0 PUNCT F
175 0 NUM F
mg/m 0 NOUN F
( 0 PUNCT F
2 0 NUM F
) 0 PUNCT F
/day 0 PUNCT F
as 0 CCONJ F
a 0 DET F
3-h 0 NOUN F
infusion 0 NOUN F
) 0 PUNCT F
every 0 DET F
21 0 NUM F
days 0 NOUN F
. 0 PUNCT F

Patients 0 NOUN T
were 0 VERB F
eligible 0 ADJ F
for 0 ADP F
treatment 0 NOUN F
with 0 ADP F
the 0 DET F
alternate 0 NOUN F
therapy 0 NOUN F
at 0 ADP F
third 0 ADJ F
line 0 NOUN F
. 0 PUNCT F

The 0 DET T
European B-OTHER NOUN T
Organisation I-OTHER NOUN T
for I-OTHER ADP F
Research I-OTHER NOUN T
and I-OTHER CCONJ F
Treatment 0 NOUN T
of B-OTHER ADP F
Cancer I-OTHER NOUN T
Quality 0 NOUN T
of B-OTHER ADP F
Life 0 NOUN T
( 0 PUNCT F
EORTC B-OTHER NOUN T
QOL B-OTHER NOUN T
) 0 PUNCT F
-C30 B-OTHER PUNCT F
questionnaire 0 NOUN F
was 0 VERB F
also 0 ADV F
used 0 VERB F
to 0 PART F
measure 0 PART F
eight 0 ADJ F
symptoms 0 NOUN F
at 0 ADP F
baseline 0 NOUN F
and 0 CCONJ F
during 0 ADP F
each 0 DET F
course 0 NOUN F
( 0 PUNCT F
pain B-PAIN NOUN F
, 0 PUNCT F
anorexia B-PHYSICAL PUNCT F
, 0 PUNCT F
diarrhoea B-PHYSICAL NOUN F
, 0 PUNCT F
fatigue B-PHYSICAL NOUN F
, 0 PUNCT F
nausea B-PHYSICAL NOUN F
and 0 CCONJ F
vomiting B-PHYSICAL PROPN F
, 0 PUNCT F
dyspnea B-PHYSICAL NOUN F
, 0 PUNCT F
constipation B-PHYSICAL NOUN F
and 0 CCONJ F
insomnia B-PHYSICAL NOUN F
) 0 PUNCT F
. 0 PUNCT F

RESULTS 0 NOUN T
A 0 PUNCT T
total 0 NOUN F
of 0 ADP F
226 0 NUM F
patients 0 NOUN F
were 0 VERB F
evaluable 0 ADJ F
for 0 ADP F
response 0 NOUN F
. 0 PUNCT F

Demographic 0 ADJ T
characteristics 0 NOUN F
were 0 VERB F
similar 0 ADJ F
in 0 ADP F
both 0 PUNCT F
treatment 0 NOUN F
groups 0 NOUN F
, 0 PUNCT F
as 0 PUNCT F
were 0 PUNCT F
results 0 CCONJ F
of 0 ADP F
the 0 DET F
EORTC 0 NOUN T
QOL-30 0 NOUN T
questionnaire 0 NOUN F
. 0 PUNCT F

For 0 ADP T
the 0 DET F
topotecan 0 PUNCT F
group 0 NOUN F
, 0 PUNCT F
median 0 ADJ F
time B-PHYSICAL NOUN F
to B-PHYSICAL ADP F
progression I-PHYSICAL NOUN F
was 0 VERB F
18.9 0 DET F
weeks 0 NOUN F
( 0 PUNCT F
range 0 NOUN F
< 0 SYM F
1 0 NUM F
to 0 ADP F
92.6+ 0 PUNCT F
weeks 0 NOUN F
; 0 PUNCT F
25 0 NUM F
% 0 SYM F
censored 0 ADP F
) 0 PUNCT F
, 0 PUNCT F
and 0 CCONJ F
, 0 PUNCT F
for 0 ADP F
paclitaxel 0 NOUN F
, 0 PUNCT F
14.7 0 NUM F
weeks 0 NOUN F
( 0 PUNCT F
range 0 NOUN F
< 0 SYM F
1 0 NUM F
to 0 ADP F
137.3+ 0 NOUN F
weeks 0 NOUN F
; 0 PUNCT F
12.3 0 NUM F
% 0 SYM F
censored 0 ADP F
) 0 PUNCT F
; 0 PUNCT F
P 0 NOUN T
= 0 SYM F
0.076 0 NUM F
. 0 PUNCT F

At 0 ADP T
4 0 NUM F
years 0 NOUN F
post-randomisation 0 NOUN F
, 0 PUNCT F
median 0 ADJ F
survival B-MORTALITY NOUN F
in 0 ADP F
the 0 DET F
topotecan 0 PUNCT F
group 0 NOUN F
was 0 VERB F
63.0 0 NUM F
weeks 0 NOUN F
( 0 PUNCT F
range 0 NOUN F
< 0 SYM F
1 0 NUM F
to 0 ADP F
238.4+ 0 NOUN F
weeks 0 NOUN F
; 0 PUNCT F
20.5 0 NUM F
% 0 SYM F
censored 0 ADP F
) 0 PUNCT F
and 0 CCONJ F
, 0 PUNCT F
for 0 ADP F
paclitaxel 0 NOUN F
, 0 PUNCT F
53.0 0 NUM F
weeks 0 NOUN F
( 0 PUNCT F
range 0 NOUN F
< 0 SYM F
1 0 NUM F
to 0 ADP F
226.3+ 0 PUNCT F
weeks 0 NOUN F
; 0 PUNCT F
12.3 0 NUM F
% 0 SYM F
censored 0 ADP F
) 0 PUNCT F
; 0 PUNCT F
P 0 NOUN T
= 0 SYM F
0.44 0 NUM F
. 0 PUNCT F

CONCLUSION 0 NOUN T
Topotecan 0 NOUN T
continues 0 PROPN F
to 0 ADP F
demonstrate 0 VERB F
comparable 0 ADJ F
efficacy 0 NOUN F
and 0 PUNCT F

[ 0 PUNCT F
Efficacy 0 NOUN T
and 0 CCONJ F
safety B-PHYSICAL NOUN F
of 0 ADP F
extended-release 0 NOUN F
niacin 0 NOUN F
alone 0 ADJ F
or 0 CCONJ F
with 0 ADP F
atorvastatin 0 NOUN F
for 0 ADP F
lipid 0 NOUN F
profile 0 NOUN F
modification 0 NOUN F
] 0 PUNCT F
. 0 PUNCT F

OBJECTIVE 0 NOUN T
To 0 PROPN T
evaluate 0 NOUN F
the 0 DET F
efficacy 0 NOUN F
and 0 CCONJ F
safety B-PHYSICAL NOUN F
of 0 ADP F
extended-release 0 NOUN F
niacin 0 NOUN F
( 0 PUNCT F
niacin 0 NOUN F
ER 0 NOUN T
) 0 PUNCT F
either 0 CCONJ F
alone 0 ADJ F
or 0 CCONJ F
in 0 ADP F
combination 0 NOUN F
with 0 ADP F
atorvastatin 0 NOUN F
for 0 ADP F
the 0 DET F
lipid 0 NOUN F
profile 0 NOUN F
modification 0 NOUN F
in 0 ADP F
the 0 DET F
patients 0 NOUN F
with 0 ADP F
coronary 0 ADJ F
heart 0 NOUN F
disease 0 NOUN F
( 0 PUNCT F
CHD 0 NOUN T
) 0 PUNCT F
and 0 CCONJ F
its 0 DET F
equivalents 0 NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
One 0 NUM T
hundred 0 NUM F
and 0 CCONJ F
ten 0 NUM F
patients 0 NOUN F
with 0 ADP F
CHD 0 NOUN T
and 0 CCONJ F
its 0 ADJ F
equivalents 0 NOUN F
with 0 ADP F
serum 0 NOUN F
total 0 ADJ F
cholesterol 0 NOUN F
( 0 PUNCT F
TC 0 NOUN T
) 0 PUNCT F
> 0 SYM F
or 0 CCONJ F
= 0 SYM F
3.5 0 NUM F
mmol/L 0 NOUN F
were 0 VERB F
randomly 0 ADV F
assigned 0 VERB F
into 0 ADP F
three 0 NUM F
treatment 0 NOUN F
groups 0 NOUN F
: 0 PUNCT F
( 0 PUNCT F
1 0 NUM F
) 0 PUNCT F
atorvastatin 0 NOUN F
group 0 NOUN F
( 0 PUNCT F
n 0 NOUN F
= 0 SYM F
38 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
receiving 0 VERB F
atorvastatin 0 NOUN F
10 0 NUM F
mg/d 0 NOUN F
for 0 ADP F
8 0 NUM F
weeks 0 NOUN F
; 0 PUNCT F
( 0 PUNCT F
2 0 NUM F
) 0 PUNCT F
niacin 0 NOUN F
ER 0 NOUN T
group 0 NOUN F
( 0 PUNCT F
n 0 NOUN F
= 0 SYM F
38 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
given 0 VERB F
niacin 0 NOUN F
ER 0 NOUN T
500 0 NUM F
mg/d 0 NOUN F
for 0 ADP F
4 0 NUM F
weeks 0 NOUN F
and 0 CCONJ F
then 0 ADV F
1000 0 NUM F
mg/d 0 NOUN F
for 0 ADP F
4 0 NUM F
weeks 0 NOUN F
; 0 PUNCT F
( 0 PUNCT F
3 0 NUM F
) 0 PUNCT F
combination 0 NOUN F
treatment 0 NOUN F
group 0 NOUN F
( 0 PUNCT F
n 0 NOUN F
= 0 SYM F
34 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
treated 0 VERB F
with 0 ADP F
atorvastatin 0 NOUN F
( 0 PUNCT F
10 0 ADP F
mg/d 0 NOUN F
) 0 PUNCT F
plus 0 CCONJ F
niacin 0 NOUN F
ER 0 NOUN T
, 0 PUNCT F
with 0 ADP F
the 0 DET F
dose 0 NOUN F
initiating 0 ADJ F
from 0 ADP F
500 0 ADP F
mg/d 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
increasing 0 VERB F
to 0 ADP F
1000 0 NUM F
mg/d 0 NOUN F
after 0 ADP F
4 0 NUM F
weeks 0 NOUN F
, 0 PUNCT F
for 0 ADP F
8 0 NUM F
weeks 0 NOUN F
. 0 PUNCT F

The 0 DET T
serums B-PHYSICAL PUNCT F
lipid I-PHYSICAL NOUN F
profiles I-PHYSICAL NOUN F
and 0 CCONJ F
adverse B-ADVERSE-EFFECTS ADJ F
effects I-ADVERSE-EFFECTS NOUN F
were 0 VERB F
assessed 0 VERB F
in 0 ADP F
all 0 DET F
the 0 DET F
patients 0 NOUN F
before 0 ADP F
treatment 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
4 0 NUM F
and 0 CCONJ F
8 0 NUM F
weeks 0 NOUN F
after 0 ADP F
treatment 0 NOUN F
. 0 PUNCT F

RESULTS 0 NOUN T
( 0 PUNCT F
1 0 NUM F
) 0 PUNCT F
After 0 ADP T
8 0 NUM F
weeks 0 NOUN F
of 0 ADP F
treatment 0 NOUN F
, 0 PUNCT F
the 0 DET F
serum 0 NOUN F
level 0 NOUN F
of 0 ADP F
triglyceride 0 NOUN F
( 0 PUNCT F
TG 0 NOUN T
) 0 PUNCT F
and 0 CCONJ F
high-density B-PHYSICAL NOUN F
lipoprotein I-PHYSICAL NOUN F
cholesterol I-PHYSICAL NOUN F
( I-PHYSICAL PUNCT F
HDL-C I-PHYSICAL NOUN T
) I-PHYSICAL PUNCT F
were 0 VERB F
reduced 0 VERB F
by 0 ADP F
30 0 NUM F
% 0 SYM F
and 0 CCONJ F
16 0 NUM F
% 0 SYM F
respectively 0 ADV F
in 0 ADP F
the 0 DET F
niacin 0 NOUN F
ER 0 NOUN T
group 0 NOUN F
compared 0 VERB F
with 0 ADP F
the 0 DET F
baseline 0 NOUN F
values 0 NOUN F
( 0 PUNCT F
both 0 CCONJ F
P 0 NOUN T
< 0 SYM F
0.05 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

After 0 ADP T
8 0 NUM F
weeks 0 NOUN F
, 0 PUNCT F
the 0 DET F
TC B-PHYSICAL NOUN T
, 0 PUNCT F
low-density B-PHYSICAL NOUN F
lipoprotein I-PHYSICAL NOUN F
cholesterol I-PHYSICAL NOUN F
( I-PHYSICAL PUNCT F
LDL-C I-PHYSICAL NOUN T
) I-PHYSICAL PUNCT F
, 0 PUNCT F
and 0 CCONJ F
TG B-PHYSICAL NOUN T
in 0 ADP F
the 0 DET F
atorvastatin B-PHYSICAL NOUN F
group 0 NOUN F
decreased 0 VERB F
by 0 ADP F
19 0 NUM F
% 0 SYM F
, 0 PUNCT F
26 0 NUM F
% 0 SYM F
, 0 PUNCT F
and 0 CCONJ F
17 0 NUM F
% 0 ADJ F
respectively 0 ADV F
compared 0 VERB F
with 0 ADP F
the 0 DET F
baseline 0 NOUN F
values 0 NOUN F
( 0 PUNCT F
all 0 DET F
P 0 NOUN T
< 0 SYM F
0.05 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Combination 0 NOUN T
treatment 0 NOUN F
decreased 0 VERB F
the 0 DET F
TC B-PHYSICAL NOUN T
, 0 PUNCT F
LDL-C B-PHYSICAL NOUN T
, 0 PUNCT F
and 0 CCONJ F
TG B-PHYSICAL NOUN T
levels I-PHYSICAL NOUN F
by 0 ADP F
28 0 NUM F
% 0 SYM F
, 0 PUNCT F
38 0 NUM F
% 0 SYM F
, 0 PUNCT F
and 0 CCONJ F
39 0 NUM F
% 0 SYM F
respectively 0 ADV F
, 0 PUNCT F
and 0 CCONJ F
increased 0 VERB F
the 0 DET F
HDL-C B-PHYSICAL NOUN T
level I-PHYSICAL NOUN F
by 0 ADP F
23 0 NUM F
% 0 SYM F
( 0 PUNCT F
all 0 DET F
P 0 NOUN T
< 0 SYM F
0.05 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
improvement 0 NOUN F
in 0 ADP F
TC B-PHYSICAL NOUN T
and 0 CCONJ F
LDL-C B-PHYSICAL NOUN T
achieved 0 VERB F
by 0 ADP F
combination 0 NOUN F
treatment 0 NOUN F
was 0 VERB F
superior 0 ADJ F
to 0 ADP F
treatment 0 NOUN F
of 0 ADP F
atorvastatin 0 NOUN F
alone 0 ADJ F
and 0 CCONJ F
treatment 0 NOUN F
of 0 ADP F
niacin 0 NOUN F
ER 0 NOUN T
alone 0 ADJ F
( 0 PUNCT F
all 0 DET F
P 0 NOUN T
< 0 SYM F
0.05 0 NUM F
) 0 PUNCT F
. 0 PUNCT F
( 0 PUNCT F

2 0 NUM F
) 0 PUNCT F
The 0 DET T
rate 0 NOUN F
of 0 ADP F
achieving 0 VERB F
the 0 DET F
LDL-C B-PHYSICAL NOUN T
goal 0 NOUN F
of 0 ADP F
The 0 DET T
National 0 ADJ T
Cholesterol 0 NOUN T
Education 0 NOUN T
Program 0 NOUN T
( 0 PUNCT F
NCEP 0 NOUN T
) 0 PUNCT F
in 0 ADP F
Adult 0 NOUN T
Treatment 0 NOUN T
Panel 0 NOUN T
III 0 NUM T
( 0 PUNCT F
ATP 0 NOUN T
III 0 NUM T
) 0 PUNCT F
in 0 ADP F
the 0 DET F
combination 0 NOUN F
therapy 0 NOUN F
group 0 NOUN F
was 0 VERB F
73.5 0 NUM F
% 0 SYM F
, 0 PUNCT F
significantly 0 ADV F
higher 0 PUNCT F
than 0 PUNCT F
those 0 ADP F
of 0 ADP F
the 0 DET F
atorvastatin 0 NOUN F
and 0 CCONJ F
niacin 0 NOUN F
groups 0 NOUN F
( 0 PUNCT F
47.7 0 NUM F
% 0 SYM F
and 0 CCONJ F
42.1 0 NUM F
% 0 SYM F
respectively 0 ADV F
, 0 PUNCT F
both 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.05 0 NUM F
) 0 PUNCT F
. 0 PUNCT F
( 0 PUNCT F

3 0 NUM F
) 0 PUNCT F
Adverse 0 ADJ T
effect 0 NOUN F
, 0 PUNCT F
such 0 PUNCT F
as 0 ADP F
flushing B-ADVERSE-EFFECTS SYM F
( 0 PUNCT F
15.8 0 NUM F
% 0 SYM F
) 0 PUNCT F
and 0 CCONJ F
gastrointestinal B-ADVERSE-EFFECTS ADJ F
symptoms I-ADVERSE-EFFECTS NOUN F
( 0 PUNCT F
23.7 0 NUM F
% 0 SYM F
) 0 PUNCT F
were 0 VERB F
found 0 VERB F
in 0 ADP F
the 0 DET F
niacin 0 NOUN F
ER 0 NOUN T
group 0 NOUN F
, 0 PUNCT F
however 0 ADV F
, 0 PUNCT F
no 0 DET F
more 0 DET F
adverse 0 ADJ F
effects 0 NOUN F
were 0 VERB F
found 0 VERB F
in 0 ADP F
the 0 DET F
combination 0 NOUN F
therapy 0 NOUN F
group 0 NOUN F
. 0 PUNCT F

There 0 PUNCT T
were 0 VERB F
no 0 DET F
serious 0 ADJ F
adverse 0 ADJ F
events 0 NOUN F
in 0 ADP F
all 0 DET F
groups 0 NOUN F
. 0 PUNCT F

CONCLUSION 0 NOUN T
Niacin 0 NOUN T
ER 0 NOUN T
has 0 PUNCT F
a 0 DET F
favorable 0 ADJ F
effect 0 NOUN F
in 0 ADP F
modulating 0 VERB F
the 0 DET F
blood 0 NOUN F
lipid 0 NOUN F
profile 0 NOUN F
, 0 PUNCT F
especially 0 ADV F
in 0 ADP F
reducing B-OTHER PROPN F
TG B-PHYSICAL NOUN T
and 0 CCONJ F
elevating B-OTHER PUNCT F
HDL-C B-PHYSICAL NOUN T
. 0 PUNCT F

Combined 0 VERB T
statin 0 NOUN F
with 0 ADP F
niacin 0 NOUN F
may 0 VERB F
produce 0 VERB F
a 0 DET F
more 0 ADV F
global B-PHYSICAL ADJ F
and I-PHYSICAL CCONJ F
effective I-PHYSICAL ADJ F
improvement I-PHYSICAL NOUN F
in I-PHYSICAL ADP F
lipid I-PHYSICAL NOUN F
blood I-PHYSICAL NOUN F
levels I-PHYSICAL NOUN F
than 0 CCONJ F
monotherapy 0 NOUN F
and 0 CCONJ F
is 0 VERB F
generally 0 ADV F
safe B-PHYSICAL ADJ F
and 0 CCONJ F
well B-PHYSICAL PUNCT F
tolerable I-PHYSICAL PUNCT F
. 0 PUNCT F

[ 0 PUNCT F
Local 0 ADJ T
therapy 0 NOUN F
of 0 ADP F
grade 0 NOUN F
1 0 NUM F
and 0 CCONJ F
2 0 NUM F
hemorrhoids 0 NOUN F
. 0 PUNCT F

Effectiveness 0 NOUN T
of 0 ADP F
a 0 DET F
combination 0 NOUN F
preparation 0 NOUN F
with 0 ADP F
standardized 0 VERB F
blood 0 NOUN F
leech 0 ADJ F
extract 0 NOUN F
] 0 PUNCT F
. 0 PUNCT F

AIMS 0 NOUN T
Testing 0 PUNCT T
the 0 DET F
effectiveness 0 NOUN F
of 0 ADP F
a 0 DET F
topical 0 ADJ F
combination 0 NOUN F
preparation 0 NOUN F
containing 0 DET F
standardized 0 VERB F
leech 0 ADJ F
extract 0 NOUN F
, 0 PUNCT F
polidocanol 0 ADJ F
and 0 CCONJ F
allantoin 0 NOUN F
. 0 PUNCT F

STUDY 0 NOUN T
DESIGN 0 NOUN T
Placebo-controlled 0 PROPN T
, 0 PUNCT F
double-blind 0 ADJ F
study 0 NOUN F
in 0 ADP F
80 0 NUM F
patients 0 NOUN F
with 0 ADP F
first 0 ADJ F
and 0 CCONJ F
second 0 ADP F
degree 0 NOUN F
hemorrhoids 0 NOUN F
; 0 PUNCT F
duration 0 NOUN F
of 0 ADP F
treatment 0 NOUN F
one 0 NUM F
week 0 NOUN F
; 0 PUNCT F
examinations 0 NOUN F
performed 0 VERB F
on 0 ADP F
admission 0 NOUN F
and 0 CCONJ F
on 0 ADP F
days 0 NOUN F
3 0 NUM F
, 0 PUNCT F
4 0 NUM F
, 0 PUNCT F
5 0 NUM F
and 0 CCONJ F
8 0 NUM F
. 0 PUNCT F

RESULTS 0 DET T
Both 0 CCONJ T
the 0 PUNCT F
subjective B-PHYSICAL ADJ F
and I-PHYSICAL CCONJ F
objective I-PHYSICAL ADJ F
symptoms I-PHYSICAL NOUN F
and I-PHYSICAL CCONJ F
signs I-PHYSICAL NOUN F
improved 0 PRON F
during 0 ADP F
the 0 DET F
one 0 NUM F
week 0 NOUN F
of 0 ADP F
treatment 0 NOUN F
statistically 0 ADJ F
significantly 0 ADV F
more 0 ADV F
rapidly 0 ADV F
under 0 ADP F
the 0 DET F
test 0 ADV F
preparation 0 NOUN F
as 0 PUNCT F
compared 0 VERB F
with 0 ADP F
placebo 0 NOUN F
. 0 PUNCT F

Histologically 0 ADV T
demonstrable 0 VERB F
signs 0 NOUN F
of 0 ADP F
inflammation B-PHYSICAL NOUN F
were 0 VERB F
more 0 ADV F
clearly 0 ADV F
improved 0 VERB F
in 0 ADP F
the 0 DET F
preparation 0 NOUN F
group 0 NOUN F
than 0 PUNCT F
in 0 ADP F
the 0 DET F
placebo 0 NOUN F
group 0 NOUN F
. 0 PUNCT F

No 0 DET T
side 0 NOUN F
effects 0 NOUN F
were 0 VERB F
observed 0 VERB F
. 0 PUNCT F

CONCLUSIONS 0 NOUN T
The 0 DET T
good 0 ADJ F
efficacy 0 NOUN F
and 0 CCONJ F
tolerability 0 NOUN F
of 0 ADP F
a 0 DET F
topical 0 ADJ F
therapeutic 0 ADJ F
preparation 0 NOUN F
in 0 ADP F
first 0 PUNCT F
and 0 CCONJ F
second 0 ADP F
degree 0 NOUN F
hemorrhoids 0 NOUN F
have 0 ADP F
been 0 PUNCT F
convincingly 0 PUNCT F
demonstrated 0 VERB F
. 0 PUNCT F

Green 0 ADJ T
banana-supplemented 0 VERB F
diet 0 NOUN F
in 0 ADP F
the 0 DET F
home 0 NOUN F
management 0 NOUN F
of 0 ADP F
acute B-PHYSICAL ADJ F
and 0 CCONJ F
prolonged B-PHYSICAL VERB F
diarrhoea I-PHYSICAL NOUN F
in I-PHYSICAL ADP F
children I-PHYSICAL NOUN F
: 0 PUNCT F
a 0 DET F
community-based 0 VERB F
trial 0 NOUN F
in 0 ADP F
rural 0 ADJ F
Bangladesh 0 NOUN T
. 0 PUNCT F

SUMMARY 0 NOUN T
OBJECTIVE 0 NOUN T
To 0 PROPN T
determine 0 NOUN F
the 0 DET F
effectiveness 0 NOUN F
of 0 ADP F
green 0 ADJ F
banana 0 NOUN F
in 0 ADP F
the 0 DET F
home 0 NOUN F
management 0 NOUN F
of 0 ADP F
acute B-OTHER ADJ F
( 0 PUNCT F
< 0 PROPN F
7 0 NUM F
days 0 NOUN F
) 0 PUNCT F
or 0 CCONJ F
prolonged B-MORTALITY VERB F
( 0 PUNCT F
? 0 PUNCT F

7 0 DET F
days 0 NOUN F
) 0 PUNCT F
diarrhoea 0 NOUN F
at 0 ADP F
the 0 DET F
community 0 NOUN F
level 0 NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
A 0 PUNCT T
cluster 0 NOUN F
randomized 0 VERB F
field 0 NOUN F
trial 0 NOUN F
was 0 VERB F
conducted 0 VERB F
among 0 ADP F
2968 0 NUM F
Bangladeshi 0 PUNCT T
rural 0 ADJ F
children 0 NOUN F
6-36 0 ADJ F
months 0 NOUN F
old 0 ADJ F
. 0 PUNCT F

Wards 0 NOUN T
( 0 PUNCT F
villages 0 PROPN F
) 0 PUNCT F
were 0 VERB F
randomly 0 ADV F
assigned 0 VERB F
to 0 ADP F
either 0 CCONJ F
a 0 DET F
standard 0 ADJ F
care 0 NOUN F
group 0 NOUN F
or 0 CCONJ F
a 0 DET F
standard 0 ADJ F
care 0 NOUN F
plus 0 CCONJ F
green 0 PUNCT F
banana 0 NOUN F
group 0 NOUN F
where 0 ADP F
mothers 0 NOUN F
were 0 VERB F
instructed 0 VERB F
to 0 ADP F
add 0 PUNCT F
cooked 0 PROPN F
green 0 ADJ F
banana 0 NOUN F
to 0 ADP F
the 0 DET F
diets 0 NOUN F
of 0 ADP F
diarrhoeal 0 ADJ F
children 0 NOUN F
. 0 PUNCT F

Through 0 ADP T
a 0 DET F
village-based 0 ADJ F
surveillance 0 NOUN F
system 0 NOUN F
, 0 PUNCT F
diarrhoeal 0 ADP F
morbidity 0 NOUN F
data 0 NOUN F
( 0 PUNCT F
severity 0 NOUN F
, 0 PUNCT F
duration 0 NOUN F
, 0 PUNCT F
compliance 0 NOUN F
) 0 PUNCT F
were 0 VERB F
collected 0 VERB F
for 0 ADP F
14 0 NUM F
days 0 NOUN F
. 0 PUNCT F

Treatment 0 NOUN T
effects 0 NOUN F
were 0 VERB F
determined 0 VERB F
by 0 ADP F
analysing 0 VERB F
cumulative 0 ADJ F
probability 0 NOUN F
of 0 ADP F
cure 0 NOUN F
by 0 ADP F
testing 0 VERB F
Cox 0 NOUN T
proportional 0 ADJ F
hazards 0 NOUN F
models 0 NOUN F
and 0 CCONJ F
relative 0 ADJ F
risk 0 NOUN F
( 0 PUNCT F
RR 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

RESULTS 0 PUNCT T
The 0 DET T
cumulative 0 ADJ F
probability 0 NOUN F
of 0 ADP F
cure 0 NOUN F
was 0 VERB F
significantly 0 ADV F
( 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.001 0 NUM F
) 0 PUNCT F
different 0 ADJ F
in 0 ADP F
children 0 NOUN F
receiving 0 VERB F
GB 0 NOUN T
for 0 ADP F
both 0 CCONJ F
acute 0 ADJ F
[ 0 PUNCT F
hazard 0 NOUN F
ratio 0 NOUN F
( 0 PUNCT F
HR 0 NOUN T
) 0 PUNCT F
= 0 ADP F
0.63 0 NUM F
( 0 PUNCT F
95 0 NUM F
% 0 SYM F
CI 0 NOUN T
: 0 PUNCT F
0.56-0.67 0 NUM F
) 0 PUNCT F
] 0 PUNCT F
and 0 CCONJ F
prolonged 0 VERB F
diarrhoea 0 NOUN F
[ 0 PUNCT F
HR 0 NOUN T
= 0 SYM F
0.38 0 NUM F
( 0 PUNCT F
95 0 NUM F
% 0 SYM F
CI 0 NOUN T
: 0 PUNCT F
0.26-0.59 0 NUM F
) 0 PUNCT F
] 0 PUNCT F
. 0 PUNCT F

The 0 DET T
recovery 0 NOUN F
rates 0 NOUN F
of 0 ADP F
children 0 NOUN F
with 0 ADP F
acute 0 ADJ F
diarrhoea 0 NOUN F
receiving 0 VERB F
GB 0 NOUN T
( 0 PUNCT F
vs. 0 CCONJ F
control 0 NOUN F
) 0 PUNCT F
were 0 VERB F
significantly 0 ADV F
more 0 DET F
by 0 ADP F
day 0 NOUN F
3 0 NUM F
: 0 PUNCT F
79.9 0 NUM F
% 0 SYM F
vs 0 CCONJ F
. 0 PUNCT F

53.3 0 NUM F
% 0 ADJ F
[ 0 PUNCT F
( 0 PUNCT F
RR 0 NOUN T
) 0 PUNCT F
= 0 SYM F
0.47 0 NUM F
, 0 PUNCT F
95 0 NUM F
% 0 SYM F
CI 0 NOUN T
: 0 PUNCT F
0.41-0.55 0 NUM F
] 0 PUNCT F
, 0 PUNCT F
( 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.001 0 NUM F
) 0 PUNCT F
and 0 CCONJ F
day 0 NOUN F
7 0 NUM F
: 0 PUNCT F
96.6 0 NUM F
% 0 SYM F
vs 0 CCONJ F
. 0 PUNCT F

89.1 0 NUM F
% 0 SYM F
( 0 PUNCT F
RR 0 NOUN T
= 0 SYM F
0.32 0 NUM F
; 0 PUNCT F
0.22-0.46 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
( 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.001 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Children 0 NOUN T
with 0 ADP F
prolonged 0 VERB F
diarrhoea 0 NOUN F
receiving 0 VERB F
green 0 ADJ F
banana 0 NOUN F
had 0 PUNCT F
significantly 0 ADV F
higher 0 PUNCT F
recovery 0 NOUN F
rates 0 NOUN F
by 0 ADP F
day 0 NOUN F
10 0 NUM F
: 0 PUNCT F
79.8 0 NUM F
% 0 SYM F
vs 0 CCONJ F
. 0 PUNCT F

51.9 0 NUM F
% 0 SYM F
( 0 PUNCT F
RR 0 NOUN T
= 0 SYM F
0.42 0 NUM F
; 0 PUNCT F
0.23-0.73 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
( 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.001 0 NUM F
) 0 PUNCT F
and 0 CCONJ F
day 0 NOUN F
14 0 NUM F
: 0 PUNCT F
93.6 0 NUM F
% 0 SYM F
vs 0 CCONJ F
. 0 PUNCT F

67.2 0 NUM F
% 0 SYM F
( 0 PUNCT F
RR 0 NOUN T
= 0 SYM F
0.22 0 NUM F
; 0 PUNCT F
0.08-0.54 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
( 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.001 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

CONCLUSION 0 NOUN T
A 0 PUNCT T
green 0 ADJ F
banana-supplemented 0 VERB F
diet 0 NOUN F
hastened 0 VERB F
recovery 0 NOUN F
of 0 ADP F
acute 0 ADJ F
and 0 CCONJ F
prolonged 0 VERB F
childhood 0 NOUN F
diarrhoea 0 NOUN F
managed 0 DET F
at 0 ADP F
home 0 NOUN F
in 0 ADP F
rural 0 ADJ F
Bangladesh 0 NOUN T
. 0 PUNCT F

Effects 0 NOUN T
of 0 ADP F
glucocorticoids 0 NOUN F
on 0 ADP F
energy B-PHYSICAL NOUN F
metabolism I-PHYSICAL NOUN F
and 0 CCONJ F
food B-MENTAL NOUN F
intake I-MENTAL NOUN F
in 0 ADP F
humans 0 NOUN F
. 0 PUNCT F

The 0 DET T
effect 0 NOUN F
of 0 ADP F
glucocorticoid 0 NOUN F
administration 0 NOUN F
on 0 ADP F
energy B-PHYSICAL NOUN F
metabolism I-PHYSICAL NOUN F
and 0 CCONJ F
food B-MENTAL NOUN F
intake I-MENTAL NOUN F
was 0 VERB F
studied 0 VERB F
in 0 ADP F
20 0 NUM F
healthy 0 ADJ F
, 0 PUNCT F
nondiabetic 0 ADJ F
Caucasian 0 ADJ T
male 0 NOUN F
volunteers 0 NOUN F
[ 0 PUNCT F
27 0 NUM F
+/- 0 SYM F
5 0 NUM F
( 0 PUNCT F
SD 0 NOUN T
) 0 PUNCT F
yr 0 NOUN F
, 0 PUNCT F
72 0 NUM F
+/- 0 SYM F
9 0 NUM F
kg 0 NOUN F
, 0 PUNCT F
20 0 NUM F
+/- 0 SYM F
7 0 NUM F
% 0 SYM F
body 0 NOUN F
fat 0 NOUN F
] 0 PUNCT F
randomly 0 ADV F
and 0 CCONJ F
blindly 0 ADV F
assigned 0 VERB F
to 0 ADP F
glucocorticoid 0 ADJ F
( 0 PUNCT F
methylprednisolone 0 NOUN F
, 0 PUNCT F
METH 0 NOUN T
; 0 PUNCT F
n 0 NOUN F
= 0 SYM F
10 0 NUM F
) 0 PUNCT F
or 0 CCONJ F
placebo 0 NOUN F
( 0 PUNCT F
PLAC 0 NOUN T
; 0 PUNCT F
n 0 NOUN F
= 0 SYM F
10 0 NUM F
) 0 PUNCT F
treatment 0 NOUN F
. 0 PUNCT F

Each 0 DET T
subject 0 NOUN F
was 0 VERB F
studied 0 VERB F
twice 0 ADV F
: 0 PUNCT F
during 0 ADP F
a 0 DET F
weight 0 NOUN F
maintenance 0 NOUN F
diet 0 NOUN F
and 0 CCONJ F
during 0 ADP F
ad 0 PUNCT F
libitum 0 PUNCT F
food 0 NOUN F
intake 0 NOUN F
. 0 PUNCT F

Energy B-PHYSICAL NOUN T
metabolism I-PHYSICAL NOUN F
was 0 VERB F
measured 0 VERB F
by 0 ADP F
indirect 0 ADJ F
calorimetry 0 NOUN F
and 0 CCONJ F
food B-MENTAL NOUN F
intake I-MENTAL NOUN F
by 0 ADP F
an 0 DET F
automated 0 VERB F
food-selection 0 NOUN F
system 0 NOUN F
. 0 PUNCT F

Twenty-four-hour 0 ADV T
urinary B-PHYSICAL ADJ F
norepinephrine I-PHYSICAL NOUN F
excretion I-PHYSICAL NOUN F
( 0 PUNCT F
24-h 0 NOUN F
NE 0 NOUN T
) 0 PUNCT F
was 0 VERB F
used 0 VERB F
as 0 ADP F
an 0 DET F
estimate 0 NOUN F
of 0 ADP F
sympathetic B-PHYSICAL ADJ F
nervous I-PHYSICAL ADJ F
system I-PHYSICAL NOUN F
activity I-PHYSICAL NOUN F
. 0 PUNCT F

During 0 ADP T
weight 0 NOUN F
maintenance 0 NOUN F
, 0 PUNCT F
METH 0 NOUN T
intravenous 0 ADJ F
infusion 0 NOUN F
( 0 PUNCT F
125 0 ADP F
mg/30 0 VERB F
min 0 NOUN F
) 0 PUNCT F
increased 0 ADV F
energy B-PHYSICAL NOUN F
expenditure I-PHYSICAL NOUN F
compared 0 VERB F
with 0 ADP F
PLAC 0 NOUN T
, 0 PUNCT F
and 0 CCONJ F
after 0 ADP F
4 0 NUM F
days 0 NOUN F
of 0 ADP F
oral 0 ADJ F
therapy 0 NOUN F
, 0 PUNCT F
METH 0 NOUN T
( 0 PUNCT F
40 0 NUM F
mg/day 0 NOUN F
) 0 PUNCT F
decreased 0 PUNCT F
24-h B-PHYSICAL NOUN F
NE I-PHYSICAL NOUN T
and 0 CCONJ F
increased 0 VERB F
energy B-PHYSICAL NOUN F
expenditure I-PHYSICAL NOUN F
compared 0 VERB F
with 0 ADP F
PLAC 0 NOUN T
. 0 PUNCT F

During 0 ADP T
ad 0 PUNCT F
libitum 0 PUNCT F
food 0 NOUN F
intake 0 NOUN F
, 0 PUNCT F
after 0 ADP F
4 0 NUM F
days 0 NOUN F
of 0 ADP F
METH 0 NOUN T
( 0 PUNCT F
40 0 NUM F
mg/day 0 NOUN F
) 0 PUNCT F
or 0 CCONJ F
PLAC 0 NOUN T
oral 0 ADJ F
therapy 0 NOUN F
, 0 PUNCT F
both 0 PUNCT F
groups 0 NOUN F
increased 0 VERB F
their 0 PUNCT F
energy B-PHYSICAL NOUN F
intake I-PHYSICAL NOUN F
over 0 ADP F
weight 0 NOUN F
maintenance 0 NOUN F
, 0 PUNCT F
but 0 CCONJ F
the 0 DET F
increase 0 NOUN F
was 0 VERB F
significantly 0 ADV F
larger 0 PUNCT F
in 0 ADP F
the 0 DET F
METH 0 NOUN T
group 0 NOUN F
compared 0 VERB F
with 0 ADP F
the 0 DET F
PLAC 0 NOUN T
group 0 NOUN F
( 0 PUNCT F
4,554 0 NUM F
+/- 0 SYM F
1,857 0 NUM F
vs. 0 CCONJ F
2,867 0 NUM F
+/- 0 SYM F
846 0 NUM F
kcal/day 0 NOUN F
; 0 PUNCT F
P 0 NOUN T
= 0 SYM F
0.04 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Our 0 ADJ T
data 0 NOUN F
suggest 0 VERB F
that 0 ADP F
therapeutic 0 ADJ F
doses 0 NOUN F
of 0 ADP F
glucocorticoids 0 NOUN F
induce 0 VERB F
obesity 0 NOUN F
mostly 0 ADV F
by 0 ADP F
increasing 0 ADJ F
energy B-PHYSICAL NOUN F
intake I-PHYSICAL NOUN F
, 0 PUNCT F
an 0 DET F
effect 0 NOUN F
which 0 DET F
may 0 VERB F
be 0 VERB F
related 0 VERB F
to 0 ADP F
the 0 DET F
ability 0 NOUN F
of 0 ADP F
glucocorticoids 0 NOUN F
to 0 PART F
act 0 NOUN F
directly 0 ADV F
or 0 CCONJ F
indirectly 0 ADV F
on 0 ADP F
the 0 DET F
central 0 ADJ F
regulation 0 NOUN F
of 0 ADP F
appetite 0 NOUN F
. 0 PUNCT F

Preventing 0 ADV T
disability B-PHYSICAL NOUN F
and 0 CCONJ F
managing B-PHYSICAL SYM F
chronic I-PHYSICAL ADJ F
illness I-PHYSICAL NOUN F
in 0 ADP F
frail 0 NOUN F
older 0 CCONJ F
adults 0 NOUN F
: 0 PUNCT F
a 0 DET F
randomized 0 VERB F
trial 0 NOUN F
of 0 ADP F
a 0 DET F
community-based 0 VERB F
partnership 0 NOUN F
with 0 ADP F
primary 0 ADJ F
care 0 NOUN F
. 0 PUNCT F

BACKGROUND 0 NOUN T
Effective 0 ADJ T
new 0 ADJ F
strategies 0 NOUN F
that 0 ADP F
complement 0 NOUN F
primary 0 ADJ F
care 0 NOUN F
are 0 VERB F
needed 0 VERB F
to 0 PART F
reduce 0 NOUN F
disability 0 NOUN F
risks 0 NOUN F
and 0 CCONJ F
improve 0 ADJ F
self-management 0 ADJ F
of 0 ADP F
chronic B-PHYSICAL ADJ F
illness I-PHYSICAL NOUN F
in 0 ADP F
frail 0 NOUN F
older 0 PUNCT F
people 0 NOUN F
living 0 VERB F
in 0 ADP F
the 0 DET F
community 0 NOUN F
. 0 PUNCT F

OBJECTIVE 0 NOUN T
To 0 PROPN T
evaluate 0 NOUN F
the 0 DET F
impact 0 NOUN F
of 0 ADP F
a 0 DET F
1-year 0 NOUN F
, 0 PUNCT F
senior 0 ADJ F
center-based 0 VERB F
chronic B-PHYSICAL ADJ F
illness I-PHYSICAL NOUN F
self-management 0 ADJ F
and 0 CCONJ F
disability 0 NOUN F
prevention 0 NOUN F
program 0 NOUN F
on 0 ADP F
health 0 NOUN F
, 0 PUNCT F
functioning 0 ADP F
, 0 PUNCT F
and 0 CCONJ F
healthcare B-PHYSICAL NOUN F
utilization I-PHYSICAL NOUN F
in 0 ADP F
frail 0 NOUN F
older 0 CCONJ F
adults 0 NOUN F
. 0 PUNCT F

DESIGN 0 NOUN T
A 0 NOUN T
randomized 0 VERB F
controlled 0 VERB F
trial 0 NOUN F
. 0 PUNCT F

SETTING 0 NUM T
A 0 PUNCT T
large 0 ADJ F
senior 0 ADJ F
center 0 NOUN F
located 0 VERB F
in 0 ADP F
a 0 DET F
northeast 0 NOUN F
Seattle 0 PUNCT T
suburb 0 NOUN F
. 0 PUNCT F

The 0 DET T
trial 0 NOUN F
was 0 VERB F
conducted 0 VERB F
in 0 ADP F
collaboration 0 NOUN F
with 0 ADP F
primary 0 ADJ F
care 0 NOUN F
providers 0 ADV F
of 0 ADP F
two 0 NUM F
large 0 ADJ F
managed 0 VERB F
care 0 NOUN F
organizations 0 NOUN F
. 0 PUNCT F

PARTICIPANTS 0 ADP T
A 0 PUNCT T
total 0 NOUN F
of 0 ADP F
201 0 NUM F
chronically 0 ADV F
ill 0 ADJ F
older 0 PUNCT F
adults 0 DET F
seniors 0 NOUN F
aged 0 PROPN F
70 0 NUM F
and 0 CCONJ F
older 0 PUNCT F
recruited 0 VERB F
through 0 ADP F
medical 0 ADJ F
practices 0 NOUN F
. 0 PUNCT F

INTERVENTION 0 NOUN T
A 0 DET T
targeted 0 VERB F
, 0 PUNCT F
multi-component 0 ADJ F
disability 0 NOUN F
prevention 0 NOUN F
and 0 CCONJ F
disease 0 NOUN F
self-management 0 ADJ F
program 0 NOUN F
led 0 PRON F
by 0 ADP F
a 0 DET F
geriatric 0 ADJ F
nurse 0 ADJ F
practitioner 0 NOUN F
( 0 PUNCT F
GNP 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

MEASUREMENTS 0 ADP T
Self-reported 0 PUNCT T
Physical 0 ADJ T
function 0 NOUN F
, 0 PUNCT F
physical 0 ADJ F
performance 0 NOUN F
tests 0 NOUN F
, 0 PUNCT F
health B-PHYSICAL NOUN F
care I-PHYSICAL NOUN F
utilization I-PHYSICAL NOUN F
, 0 PUNCT F
and 0 CCONJ F
health 0 NOUN F
behaviors 0 NOUN F
. 0 PUNCT F

RESULTS 0 NOUN T
Each 0 PUNCT T
of 0 ADP F
101 0 NUM F
intervention 0 NOUN F
participants 0 NOUN F
met 0 ADJ F
with 0 ADP F
the 0 DET F
GNP 0 NOUN T
from 0 ADP F
1 0 NUM F
to 0 ADP F
8 0 NUM F
times 0 NOUN F
( 0 PUNCT F
median 0 ADJ F
= 0 SYM F
3 0 NUM F
) 0 PUNCT F
during 0 ADP F
the 0 DET F
study 0 ADJ F
year 0 NOUN F
. 0 PUNCT F

The 0 DET T
intervention 0 NOUN F
group 0 NOUN F
showed 0 VERB F
less 0 DET F
decline 0 PUNCT F
in 0 ADP F
function B-PHYSICAL NOUN F
, 0 PUNCT F
as 0 PUNCT F
measured 0 VERB F
by 0 ADP F
disability 0 NOUN F
days 0 NOUN F
and 0 CCONJ F
lower 0 PUNCT F
scores 0 NOUN F
on 0 ADP F
the 0 DET F
Health B-PHYSICAL NOUN T
Assessment I-PHYSICAL NOUN T
Questionnaire 0 NOUN T
. 0 PUNCT F

Other 0 ADJ T
measures 0 NOUN F
of 0 ADP F
function 0 NOUN F
, 0 PUNCT F
including 0 VERB F
the 0 DET F
SF-36 B-PHYSICAL NOUN T
and 0 CCONJ F
a 0 DET F
battery 0 NOUN F
of 0 ADP F
physical 0 ADJ F
performance 0 NOUN F
tests 0 NOUN F
, 0 PUNCT F
did 0 CCONJ F
not 0 ADV F
change 0 VERB F
with 0 ADP F
the 0 DET F
intervention 0 NOUN F
. 0 PUNCT F

The 0 DET T
number 0 NOUN F
of 0 ADP F
hospitalized B-OTHER VERB F
participants I-OTHER NOUN F
increased 0 VERB F
by 0 ADP F
69 0 NUM F
% 0 SYM F
among 0 ADP F
the 0 DET F
controls 0 NOUN F
and 0 CCONJ F
decreased 0 PUNCT F
by 0 ADP F
38 0 NUM F
% 0 SYM F
in 0 ADP F
the 0 DET F
intervention 0 NOUN F
group 0 NOUN F
( 0 PUNCT F
P 0 NOUN T
= 0 SYM F
.083 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
total 0 ADJ F
number 0 NOUN F
of 0 ADP F
inpatient B-OTHER NOUN F
hospital I-OTHER NOUN F
days I-OTHER NOUN F
during 0 ADP F
the 0 DET F
study 0 ADJ F
year 0 NOUN F
was 0 VERB F
significantly 0 ADV F
less 0 ADV F
in 0 ADP F
the 0 DET F
intervention 0 NOUN F
group 0 NOUN F
compared 0 VERB F
with 0 ADP F
controls 0 NOUN F
( 0 PUNCT F
total 0 ADJ F
days 0 NOUN F
= 0 SYM F
33 0 NUM F
vs 0 CCONJ F
116 0 NUM F
, 0 PUNCT F
P 0 NOUN T
= 0 SYM F
.049 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
intervention 0 NOUN F
led 0 VERB F
to 0 ADP F
significantly 0 ADV F
higher 0 PUNCT F
levels 0 NOUN F
of 0 ADP F
physical B-PHYSICAL ADJ F
activity I-PHYSICAL NOUN F
and 0 CCONJ F
senior B-MENTAL ADJ F
center I-MENTAL NOUN F
participation I-MENTAL NOUN F
and 0 CCONJ F
significant 0 ADJ F
reductions 0 NOUN F
in 0 ADP F
the 0 DET F
use 0 NOUN F
of 0 ADP F
psychoactive B-PHYSICAL ADJ F
medications I-PHYSICAL NOUN F
. 0 PUNCT F

CONCLUSIONS 0 NOUN T
This 0 PUNCT T
project 0 NOUN F
provides 0 NOUN F
evidence 0 NOUN F
that 0 ADP F
a 0 DET F
community-based 0 VERB F
collaboration 0 NOUN F
with 0 ADP F
primary 0 ADJ F
care 0 NOUN F
providers 0 ADV F
can 0 VERB F
improve 0 VERB F
function B-PHYSICAL NOUN F
and 0 CCONJ F
reduce 0 VERB F
inpatient B-OTHER NOUN F
utilization I-OTHER NOUN F
in 0 ADP F
chronically 0 ADV F
ill 0 ADJ F
older 0 PUNCT F
adults 0 NOUN F
. 0 PUNCT F

Linking 0 ADP T
organized 0 VERB F
medical 0 ADJ F
care 0 NOUN F
with 0 ADP F
complementary 0 ADJ F
community-based 0 VERB F
interventions 0 NOUN F
may 0 VERB F
be 0 ADJ F
a 0 DET F
promising 0 ADV F
direction 0 NOUN F
for 0 ADP F
research 0 NOUN F
and 0 CCONJ F
practice 0 NOUN F
. 0 PUNCT F

Results 0 NOUN T
of 0 ADP F
a 0 DET F
phase 0 NOUN F
I/II 0 NOUN T
trial 0 NOUN F
of 0 ADP F
recombinant 0 ADJ F
human 0 NOUN F
granulocyte-macrophage 0 NOUN F
colony-stimulating 0 VERB F
factor 0 NOUN F
in 0 ADP F
very 0 ADJ F
low 0 ADJ F
birthweight 0 ADP F
neonates 0 NOUN F
: 0 PUNCT F
significant 0 ADJ F
induction 0 NOUN F
of 0 ADP F
circulatory 0 ADJ F
neutrophils 0 NOUN F
, 0 PUNCT F
monocytes 0 NOUN F
, 0 PUNCT F
platelets 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
bone 0 NOUN F
marrow 0 NOUN F
neutrophils 0 NOUN F
. 0 PUNCT F

Neonates 0 NOUN T
, 0 PUNCT F
especially 0 ADV F
those 0 PUNCT F
of 0 ADP F
very 0 ADJ F
low 0 ADJ F
birthweight 0 NOUN F
( 0 PUNCT F
VLBW 0 NOUN T
) 0 PUNCT F
, 0 PUNCT F
have 0 PUNCT F
an 0 DET F
increased 0 VERB F
risk 0 NOUN F
of 0 ADP F
nosocomial 0 ADJ F
infections 0 NOUN F
secondary 0 ADJ F
to 0 ADP F
deficiencies 0 NOUN F
in 0 ADP F
development 0 NOUN F
. 0 PUNCT F

We 0 PRON T
previously 0 ADV F
demonstrated 0 PUNCT F
that 0 ADP F
granulocyte-macrophage 0 NOUN F
colony-stimulating 0 VERB F
factor 0 NOUN F
( 0 PUNCT F
GM-CSF 0 NOUN T
) 0 PUNCT F
production 0 NOUN F
and 0 CCONJ F
mRNA 0 NOUN F
expression 0 NOUN F
from 0 ADP F
stimulated 0 VERB F
neonatal 0 ADJ F
mononuclear 0 ADJ F
cells 0 NOUN F
are 0 VERB F
significantly 0 ADV F
less 0 ADV F
than 0 PUNCT F
that 0 PUNCT F
from 0 ADP F
adult 0 ADJ F
cells 0 NOUN F
. 0 PUNCT F

Recombinant 0 ADJ T
murine 0 ADJ F
GM-CSF 0 NOUN T
administration 0 NOUN F
to 0 ADP F
neonatal 0 ADJ F
rats 0 NOUN F
has 0 PUNCT F
resulted 0 VERB F
in 0 PUNCT F
neutrophilia 0 ADJ F
, 0 PUNCT F
increased 0 VERB F
neutrophil 0 NOUN F
production 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
increased 0 VERB F
survival 0 NOUN F
of 0 ADP F
pups 0 NOUN F
during 0 ADP F
experimental 0 ADJ F
Staphylococcus 0 NOUN T
aureus 0 NOUN F
sepsis 0 NOUN F
. 0 PUNCT F

In 0 ADP T
the 0 DET F
present 0 ADJ F
study 0 NOUN F
, 0 PUNCT F
we 0 PRON F
sought 0 PROPN F
to 0 PART F
determine 0 NOUN F
the 0 DET F
safety 0 NOUN F
and 0 CCONJ F
biologic 0 ADJ F
response 0 NOUN F
of 0 ADP F
recombinant 0 ADJ F
human 0 NOUN F
( 0 PUNCT F
rhu 0 PUNCT F
) 0 PUNCT F
GM-CSF 0 NOUN T
in 0 ADP F
VLBW 0 NOUN T
neonates 0 NOUN F
. 0 PUNCT F

Twenty 0 VERB T
VLBW 0 NOUN T
neonates 0 PUNCT F
( 0 PUNCT F
500 0 NUM F
to 0 ADP F
1,500 0 NUM F
g 0 NOUN F
) 0 PUNCT F
, 0 PUNCT F
aged 0 PUNCT F
< 0 ADP F
72 0 NUM F
hours 0 NOUN F
, 0 PUNCT F
were 0 VERB F
randomized 0 VERB F
to 0 PART F
receive 0 NOUN F
either 0 PUNCT F
placebo 0 NOUN F
( 0 PUNCT F
n 0 NOUN F
= 0 SYM F
5 0 NUM F
) 0 PUNCT F
or 0 CCONJ F
rhuGM-CSF 0 NOUN F
at 0 ADP F
5.0 0 NUM F
micrograms/kg 0 NOUN F
once 0 PUNCT F
per 0 PUNCT F
day 0 NOUN F
( 0 PUNCT F
n 0 NOUN F
= 0 SYM F
5 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
5.0 0 NUM F
micrograms/kg 0 NOUN F
twice 0 ADV F
per 0 ADP F
day 0 NOUN F
( 0 PUNCT F
n 0 NOUN F
= 0 SYM F
5 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
or 0 CCONJ F
10 0 NUM F
micrograms/kg 0 NOUN F
once 0 PUNCT F
per 0 PUNCT F
day 0 NOUN F
( 0 PUNCT F
n 0 NOUN F
= 0 SYM F
5 0 NUM F
) 0 PUNCT F
given 0 VERB F
via 0 ADP F
2-hour 0 NOUN F
intravenous 0 ADJ F
infusion 0 NOUN F
for 0 ADP F
7 0 NUM F
days 0 NOUN F
. 0 PUNCT F

Complete 0 ADJ T
blood 0 NOUN F
counts 0 NOUN F
, 0 PUNCT F
differential 0 ADJ F
, 0 PUNCT F
and 0 CCONJ F
platelet 0 NOUN F
counts 0 NOUN F
were 0 VERB F
obtained 0 VERB F
, 0 PUNCT F
and 0 CCONJ F
tibial 0 ADJ F
bone 0 NOUN F
marrow 0 NOUN F
aspirate 0 NOUN F
was 0 VERB F
performed 0 VERB F
on 0 ADP F
day 0 NOUN F
8 0 NUM F
. 0 PUNCT F

Neutrophil 0 NOUN T
C3bi 0 NOUN T
receptor 0 NOUN F
expression 0 NOUN F
was 0 VERB F
measured 0 VERB F
at 0 ADP F
0 0 NUM F
and 0 CCONJ F
24 0 NUM F
hours 0 NOUN F
. 0 PUNCT F

GM-CSF B-PHYSICAL NOUN T
levels I-PHYSICAL NOUN F
were 0 VERB F
measured 0 VERB F
by 0 ADP F
a 0 DET F
sandwich 0 NOUN F
enzyme-linked 0 VERB F
immunosorbent 0 ADJ F
assay 0 NOUN F
at 0 ADP F
2 0 NUM F
, 0 PUNCT F
4 0 NUM F
, 0 PUNCT F
6 0 NUM F
, 0 PUNCT F
12 0 NUM F
, 0 PUNCT F
and 0 CCONJ F
24 0 NUM F
hours 0 NOUN F
after 0 ADP F
the 0 DET F
first 0 ADJ F
dose 0 NOUN F
of 0 ADP F
rhuGM-CSF 0 NOUN F
. 0 PUNCT F

At 0 ADP T
all 0 DET F
doses 0 NOUN F
, 0 PUNCT F
rhuGM-CSF 0 NOUN F
was 0 VERB F
well 0 VERB F
tolerated 0 ADP F
, 0 PUNCT F
and 0 CCONJ F
there 0 PUNCT F
was 0 VERB F
no 0 DET F
evidence 0 NOUN F
of 0 ADP F
grade 0 NOUN F
III B-PHYSICAL NUM T
or 0 CCONJ F
IV B-PHYSICAL NUM T
toxicity I-PHYSICAL NOUN F
. 0 PUNCT F

Within 0 ADP T
48 0 NUM F
hours 0 NOUN F
of 0 ADP F
administration 0 NOUN F
, 0 PUNCT F
there 0 PUNCT F
was 0 VERB F
a 0 DET F
significant 0 ADJ F
increase 0 NOUN F
in 0 ADP F
the 0 DET F
circulating B-PHYSICAL VERB F
absolute I-PHYSICAL ADJ F
neutrophil I-PHYSICAL NOUN F
count I-PHYSICAL NOUN F
( 0 PUNCT F
ANC B-PHYSICAL NOUN T
) 0 PUNCT F
at 0 ADP F
5.0 0 NUM F
micrograms/kg 0 NOUN F
twice 0 ADV F
per 0 ADP F
day 0 NOUN F
and 0 CCONJ F
10.0 0 NUM F
micrograms/kg 0 NOUN F
once 0 PUNCT F
per 0 PUNCT F
day 0 NOUN F
, 0 PUNCT F
which 0 ADP F
continued 0 VERB F
for 0 ADP F
at 0 ADJ F
least 0 ADV F
24 0 NUM F
hours 0 NOUN F
after 0 ADP F
discontinuation 0 NOUN F
of 0 ADP F
rhuGM-CSF 0 NOUN F
. 0 PUNCT F

When 0 ADP T
the 0 DET F
ANC 0 NOUN T
was 0 VERB F
normalized 0 VERB F
for 0 ADP F
each 0 DET F
patient 0 NOUN F
's 0 PUNCT F
first 0 ADJ F
ANC 0 NOUN T
, 0 PUNCT F
there 0 PUNCT F
was 0 VERB F
a 0 DET F
significant 0 ADJ F
increase 0 NOUN F
in 0 ADP F
the 0 DET F
ANC B-PHYSICAL NOUN T
on 0 ADP F
days 0 NOUN F
6 0 NUM F
and 0 CCONJ F
7 0 NUM F
at 0 ADP F
each 0 DET F
dose 0 NOUN F
level 0 NOUN F
. 0 PUNCT F

By 0 ADP T
day 0 NOUN F
7 0 NUM F
, 0 PUNCT F
all 0 DET F
tested 0 PUNCT F
doses 0 NOUN F
of 0 ADP F
rhuGM-CSF 0 NOUN F
resulted 0 VERB F
in 0 ADP F
an 0 DET F
increase 0 NOUN F
in 0 ADP F
the 0 DET F
absolute B-PHYSICAL ADJ F
monocyte I-PHYSICAL NOUN F
count I-PHYSICAL NOUN F
( I-PHYSICAL PUNCT F
AMC I-PHYSICAL NOUN T
) I-PHYSICAL PUNCT F
compared 0 VERB F
with 0 ADP F
placebo-treated 0 VERB F
neonates 0 NOUN F
. 0 PUNCT F

In 0 ADP T
those 0 PUNCT F
receiving 0 SYM F
rhuGM-CSF 0 NOUN F
5.0 0 NUM F
micrograms/kg 0 NOUN F
twice 0 ADV F
per 0 ADP F
day 0 NOUN F
, 0 PUNCT F
there 0 PUNCT F
was 0 VERB F
additionally 0 ADV F
a 0 DET F
significant 0 ADJ F
increase 0 NOUN F
in 0 ADP F
the 0 DET F
day B-PHYSICAL NOUN F
7 I-PHYSICAL NUM F
and 0 CCONJ F
8 B-PHYSICAL NUM F
platelet I-PHYSICAL NOUN F
count I-PHYSICAL NOUN F
. 0 PUNCT F

Tibial 0 ADJ T
bone 0 NOUN F
marrow 0 NOUN F
aspirates 0 NOUN F
demonstrated 0 VERB F
a 0 DET F
significant 0 ADJ F
increase 0 NOUN F
in 0 ADP F
the 0 DET F
bone B-PHYSICAL NOUN F
marrow I-PHYSICAL NOUN F
neutrophil I-PHYSICAL NOUN F
storage I-PHYSICAL NOUN F
pool I-PHYSICAL NOUN F
( I-PHYSICAL PUNCT F
BM I-PHYSICAL NOUN T
NSP I-PHYSICAL NOUN T
) I-PHYSICAL PUNCT F
at 0 ADP F
5.0 0 NUM F
micrograms/kg 0 NOUN F
twice 0 ADV F
per 0 ADP F
day 0 NOUN F
and 0 CCONJ F
10.0 0 NUM F
micrograms/kg 0 NOUN F
once 0 PUNCT F
per 0 PUNCT F
day 0 NOUN F
. 0 PUNCT F

Neutrophil B-PHYSICAL NOUN T
C3bi I-PHYSICAL NOUN T
receptor I-PHYSICAL NOUN F
expression I-PHYSICAL NOUN F
was 0 VERB F
significantly 0 ADV F
increased 0 VERB F
24 0 NUM F
hours 0 NOUN F
after 0 ADP F
the 0 DET F
first 0 ADJ F
dose 0 NOUN F
of 0 ADP F
rhuGM-CSF 0 NOUN F
at 0 ADP F
5.0 0 NUM F
micrograms/kg 0 NOUN F
once 0 PUNCT F
per 0 PUNCT F
day 0 NOUN F
. 0 PUNCT F

The 0 DET T
elimination 0 NOUN F
half-life 0 NOUN F
( 0 PUNCT F
T1/2 0 NOUN T
) 0 PUNCT F
of 0 ADP F
rhuGM-CSF 0 NOUN F
was 0 VERB F
1.4 0 NUM F
+/- 0 SYM F
0.8 0 NUM F
to 0 ADP F
3.9 0 NUM F
+/- 0 SYM F
2.8 0 NUM F
hours 0 NOUN F
. 0 PUNCT F
( 0 PUNCT F

ABSTRACT 0 ADP T
TRUNCATED 0 PUNCT T
AT 0 ADP T
400 0 NUM F
WORDS 0 NOUN T
) 0 PUNCT F

Patterns 0 NOUN T
of 0 ADP F
management 0 NOUN F
of 0 ADP F
atrial 0 ADJ F
fibrillation 0 NOUN F
complicating 0 SYM F
coronary 0 ADJ F
artery 0 NOUN F
bypass 0 NOUN F
grafting 0 VERB F
: 0 PUNCT F
Results 0 NOUN T
from 0 ADP F
the 0 DET F
PRoject 0 NOUN T
of 0 ADP F
Ex-vivo 0 PUNCT T
Vein 0 NOUN T
graft 0 NOUN F
ENgineering 0 CCONJ T
via 0 ADP F
Transfection 0 NOUN T
IV 0 NUM T
( 0 PUNCT F
PREVENT-IV 0 NOUN T
) 0 PUNCT F
Trial 0 NOUN T
. 0 PUNCT F

BACKGROUND 0 NOUN T
Current 0 ADJ T
practice 0 NOUN F
related 0 VERB F
to 0 ADP F
the 0 DET F
management 0 NOUN F
of 0 ADP F
atrial 0 ADJ F
fibrillation B-PHYSICAL NOUN F
( I-PHYSICAL PUNCT F
AF I-PHYSICAL NOUN T
) I-PHYSICAL PUNCT F
complicating 0 CCONJ F
coronary 0 ADJ F
artery 0 NOUN F
bypass 0 NOUN F
grafting 0 VERB F
( 0 PUNCT F
CABG 0 NOUN T
) 0 PUNCT F
is 0 VERB F
uncertain 0 ADJ F
. 0 PUNCT F

METHODS 0 NOUN T
We 0 PRON T
examined 0 VERB F
management 0 NOUN F
of 0 ADP F
post-CABG 0 NOUN F
AF 0 NOUN T
in 0 ADP F
the 0 DET F
PREVENT-IV 0 NOUN T
trial 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
we 0 NOUN F
explored 0 PUNCT F
patterns 0 NOUN F
of 0 ADP F
use 0 NOUN F
of 0 ADP F
postoperative 0 ADJ F
rhythm 0 NOUN F
versus 0 CCONJ F
rate 0 NOUN F
control 0 NOUN F
and 0 CCONJ F
anticoagulation 0 NOUN F
for 0 ADP F
AF B-PHYSICAL NOUN T
by 0 ADP F
geographic 0 ADJ F
region 0 NOUN F
and 0 CCONJ F
type 0 NOUN F
of 0 ADP F
site 0 NOUN F
. 0 PUNCT F

We 0 PRON T
also 0 ADV F
compared 0 PUNCT F
outcomes 0 NOUN F
of 0 ADP F
patients 0 NOUN F
who 0 ADP F
developed 0 VERB F
post-CABG 0 NOUN F
AF 0 NOUN T
( 0 PUNCT F
663 0 NUM F
) 0 PUNCT F
with 0 ADP F
those 0 ADP F
who 0 PROPN F
did 0 CCONJ F
not 0 ADV F
( 0 PUNCT F
2,131 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

RESULTS 0 PUNCT T
The 0 DET T
incidence 0 NOUN F
of 0 ADP F
AF B-PHYSICAL NOUN T
was 0 VERB F
24 0 NUM F
% 0 SYM F
. 0 PUNCT F

Post-CABG B-PHYSICAL NOUN T
AF I-PHYSICAL NOUN T
was 0 VERB F
treated 0 VERB F
with 0 ADP F
a 0 DET F
rhythm 0 NOUN F
control 0 NOUN F
strategy 0 NOUN F
in 0 ADP F
81 0 NUM F
% 0 SYM F
of 0 ADP F
patients 0 NOUN F
and 0 CCONJ F
with 0 ADP F
warfarin 0 NOUN F
in 0 ADP F
23 0 NUM F
% 0 SYM F
of 0 ADP F
patients 0 NOUN F
. 0 PUNCT F

Although 0 ADP T
there 0 PUNCT F
were 0 VERB F
significant 0 ADJ F
variations 0 NOUN F
across 0 ADP F
sites 0 NOUN F
in 0 ADP F
the 0 DET F
management 0 NOUN F
of 0 ADP F
post-CABG B-PHYSICAL NOUN F
AF I-PHYSICAL NOUN T
, 0 PUNCT F
patterns 0 NOUN F
of 0 ADP F
use 0 NOUN F
of 0 ADP F
postoperative 0 ADJ F
rhythm 0 NOUN F
versus 0 CCONJ F
rate 0 NOUN F
control 0 NOUN F
and 0 CCONJ F
anticoagulation 0 NOUN F
did 0 PUNCT F
not 0 ADV F
differ 0 VERB F
by 0 ADP F
geographic 0 ADJ F
region 0 NOUN F
or 0 CCONJ F
by 0 ADP F
whether 0 PUNCT F
or 0 CCONJ F
not 0 ADV F
the 0 DET F
enrolling 0 PUNCT F
site 0 NOUN F
was 0 VERB F
an 0 DET F
academic 0 ADJ F
institution 0 NOUN F
. 0 PUNCT F

Mortality B-MORTALITY NOUN T
was 0 VERB F
higher 0 PUNCT F
in 0 ADP F
patients 0 NOUN F
with 0 ADP F
post-CABG 0 NOUN F
AF 0 NOUN T
than 0 ADP F
patients 0 NOUN F
without 0 ADP F
AF 0 NOUN T
at 0 ADP F
30 0 NUM F
days 0 NOUN F
( 0 PUNCT F
1.5 0 NUM F
% 0 SYM F
vs 0 CCONJ F
0.7 0 NUM F
% 0 SYM F
, 0 PUNCT F
P 0 NOUN T
= 0 SYM F
.01 0 NUM F
) 0 PUNCT F
but 0 CCONJ F
not 0 ADV F
at 0 ADP F
3 0 NUM F
years 0 NOUN F
( 0 PUNCT F
6.9 0 NUM F
% 0 SYM F
vs 0 CCONJ F
4.9 0 NUM F
% 0 SYM F
, 0 PUNCT F
P 0 NOUN T
= 0 SYM F
.41 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

There 0 PUNCT T
was 0 VERB F
a 0 DET F
trend 0 NOUN F
toward 0 ADP F
a 0 DET F
higher 0 PUNCT F
risk 0 NOUN F
of 0 ADP F
mortality B-MORTALITY NOUN F
or 0 CCONJ F
stroke B-PHYSICAL NOUN F
at 0 ADP F
30 0 NUM F
days 0 NOUN F
in 0 ADP F
patients 0 NOUN F
with 0 ADP F
AF 0 NOUN T
( 0 PUNCT F
2.4 0 NUM F
% 0 SYM F
vs 0 CCONJ F
1.9 0 NUM F
% 0 SYM F
, 0 PUNCT F
P 0 NOUN T
= 0 SYM F
.08 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

CONCLUSION 0 NOUN T
Although 0 ADP T
a 0 DET F
rhythm 0 NOUN F
control 0 NOUN F
strategy 0 NOUN F
was 0 VERB F
used 0 VERB F
in 0 ADP F
most 0 PUNCT F
of 0 ADP F
the 0 DET F
patients 0 NOUN F
in 0 ADP F
this 0 DET F
trial 0 NOUN F
and 0 CCONJ F
the 0 DET F
overall 0 ADJ F
rate 0 NOUN F
of 0 ADP F
use 0 NOUN F
of 0 ADP F
warfarin 0 NOUN F
was 0 VERB F
low 0 ADJ F
, 0 PUNCT F
the 0 DET F
significance 0 NOUN F
of 0 ADP F
these 0 DET F
findings 0 NOUN F
is 0 VERB F
uncertain 0 PUNCT F
because 0 PUNCT F
of 0 ADP F
the 0 DET F
lack 0 NOUN F
of 0 ADP F
data 0 NOUN F
from 0 ADP F
randomized 0 VERB F
clinical 0 ADJ F
trials 0 NOUN F
. 0 PUNCT F

The 0 DET T
substantial 0 ADJ F
variations 0 NOUN F
in 0 ADP F
the 0 DET F
management 0 NOUN F
of 0 ADP F
post-CABG 0 NOUN F
AF 0 NOUN T
across 0 ADP F
sites 0 NOUN F
are 0 VERB F
likely 0 ADJ F
because 0 PUNCT F
of 0 ADP F
definitive 0 ADJ F
data 0 NOUN F
on 0 ADP F
the 0 DET F
most 0 VERB F
effective 0 ADJ F
therapies 0 NOUN F
, 0 PUNCT F
highlighting 0 PUNCT F
the 0 DET F
need 0 NOUN F
for 0 ADP F
clinical 0 ADJ F
trials 0 NOUN F
on 0 ADP F
rate 0 NOUN F
versus 0 CCONJ F
rhythm 0 NOUN F
control 0 NOUN F
and 0 CCONJ F
on 0 ADP F
anticoagulation 0 NOUN F
for 0 ADP F
AF 0 NOUN T
in 0 ADP F
this 0 PUNCT F
setting 0 VERB F
. 0 PUNCT F

Effects 0 NOUN T
of 0 ADP F
clonidine 0 NOUN F
on 0 ADP F
postoperative 0 ADJ F
nausea 0 NOUN F
and 0 CCONJ F
vomiting 0 PUNCT F
in 0 ADP F
breast 0 NOUN F
cancer 0 NOUN F
surgery 0 NOUN F
. 0 PUNCT F

BACKGROUND 0 NOUN T
Postoperative 0 PUNCT T
nausea 0 NOUN F
and 0 CCONJ F
vomiting 0 PROPN F
( 0 PUNCT F
PONV 0 NOUN T
) 0 PUNCT F
is 0 VERB F
still 0 ADV F
common 0 ADJ F
, 0 PUNCT F
especially 0 ADV F
among 0 ADP F
female 0 NOUN F
patients 0 NOUN F
. 0 PUNCT F

Our 0 VERB T
hypothesis 0 NOUN F
is 0 PUNCT F
that 0 ADP F
coinduction 0 NOUN F
with 0 ADP F
clonidine 0 NOUN F
reduces 0 NOUN F
the 0 DET F
incidence 0 NOUN F
of 0 ADP F
PONV 0 NOUN T
in 0 ADP F
adult 0 ADJ F
patients 0 NOUN F
undergoing 0 VERB F
breast 0 NOUN F
cancer 0 NOUN F
surgery 0 NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
Sixty-eight 0 PUNCT T
women 0 NOUN F
premedicated 0 PRON F
with 0 ADP F
midazolam 0 NOUN F
were 0 VERB F
randomly 0 ADV F
allocated 0 VERB F
to 0 ADP F
coinduction 0 NOUN F
with 0 ADP F
intravenous 0 ADJ F
clonidine 0 NOUN F
( 0 PUNCT F
group 0 NOUN F
C 0 NOUN T
) 0 PUNCT F
or 0 CCONJ F
placebo 0 NOUN F
( 0 PUNCT F
group 0 NOUN F
P 0 NOUN T
) 0 PUNCT F
in 0 ADP F
this 0 DET F
prospective 0 ADJ F
, 0 PUNCT F
double-blind 0 ADJ F
study 0 NOUN F
. 0 PUNCT F

Anesthesia 0 NOUN T
was 0 VERB F
standardized 0 VERB F
( 0 PUNCT F
laryngeal 0 ADJ F
mask 0 NOUN F
airway 0 NOUN F
, 0 PUNCT F
fentanyl 0 NOUN F
, 0 PUNCT F
propofol 0 NOUN F
, 0 PUNCT F
sevoflurane 0 NOUN F
, 0 PUNCT F
nitrous 0 ADJ F
oxide 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
oxygen 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

Hemodynamic 0 ADJ T
parameters 0 NOUN F
and 0 CCONJ F
the 0 DET F
requirements 0 NOUN F
for 0 ADP F
propofol 0 NOUN F
, 0 PUNCT F
sevoflurane 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
the 0 DET F
postoperative 0 ADJ F
need 0 NOUN F
for 0 ADP F
ketobemidone 0 NOUN F
were 0 VERB F
noted 0 VERB F
. 0 PUNCT F

The 0 DET T
primary 0 ADJ F
endpoints 0 NOUN F
studied 0 VERB F
were 0 VERB F
the 0 DET F
number 0 NOUN F
of 0 ADP F
PONV-free B-PHYSICAL ADJ T
patients I-PHYSICAL NOUN F
and 0 CCONJ F
patient B-MENTAL NOUN F
satisfaction I-MENTAL NOUN F
with I-MENTAL ADP F
respect I-MENTAL NOUN F
to I-MENTAL ADP F
PONV I-MENTAL NOUN T
. 0 PUNCT F

RESULTS 0 DET T
Patients 0 NOUN T
in 0 ADP F
group 0 NOUN F
C 0 NOUN T
had 0 PUNCT F
a 0 DET F
significantly 0 ADV F
reduced B-OTHER VERB F
need I-OTHER NOUN F
for I-OTHER ADP F
propofol I-OTHER NOUN F
( 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.04 0 NUM F
) 0 PUNCT F
and 0 CCONJ F
sevoflurane 0 NOUN F
( 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.01 0 NUM F
) 0 PUNCT F
and 0 CCONJ F
a 0 DET F
reduced 0 ADJ F
early B-OTHER ADJ F
need I-OTHER NOUN F
for I-OTHER ADP F
ketobemidone I-OTHER NOUN F
( 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.04 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

There 0 PUNCT T
were 0 VERB F
significantly 0 ADV F
more 0 ADV F
PONV-free B-PHYSICAL ADJ T
patients I-PHYSICAL NOUN F
in 0 ADP F
group 0 NOUN F
C 0 NOUN T
compared 0 VERB F
with 0 ADP F
group 0 NOUN F
P 0 NOUN T
( 0 PUNCT F
20 0 NUM F
and 0 CCONJ F
11 0 NUM F
of 0 ADP F
30 0 NUM F
, 0 PUNCT F
respectively 0 ADV F
; 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.04 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
number 0 NOUN F
needed 0 VERB F
to 0 PART F
treat 0 PUNCT F
was 0 VERB F
3.3 0 NUM F
( 0 PUNCT F
95 0 NUM F
% 0 SYM F
confidence 0 NOUN F
interval 0 NOUN F
, 0 PUNCT F
1.8 0 NUM F
, 0 PUNCT F
16.9 0 PUNCT F
) 0 PUNCT F
. 0 PUNCT F

Intraoperative B-PHYSICAL ADJ T
blood I-PHYSICAL NOUN F
pressure I-PHYSICAL NOUN F
, 0 PUNCT F
postoperative B-PHYSICAL ADJ F
heart I-PHYSICAL NOUN F
rate I-PHYSICAL NOUN F
, 0 PUNCT F
and 0 PUNCT F

Phase 0 NOUN T
III 0 NUM T
trial 0 NOUN F
of 0 ADP F
induction 0 NOUN F
gemcitabine 0 NOUN F
or 0 CCONJ F
paclitaxel 0 NOUN F
plus 0 CCONJ F
carboplatin 0 NOUN F
followed 0 VERB F
by 0 ADP F
paclitaxel 0 NOUN F
consolidation 0 NOUN F
in 0 ADP F
ovarian 0 ADJ F
cancer 0 NOUN F
. 0 PUNCT F

OBJECTIVE 0 NOUN T
The 0 DET T
safety 0 NOUN F
and 0 CCONJ F
efficacy 0 NOUN F
of 0 ADP F
gemcitabine 0 NOUN F
plus 0 CCONJ F
carboplatin 0 NOUN F
( 0 PUNCT F
GC 0 NOUN T
) 0 PUNCT F
or 0 CCONJ F
paclitaxel 0 NOUN F
plus 0 CCONJ F
carboplatin 0 NOUN F
( 0 PUNCT F
TC 0 NOUN T
) 0 PUNCT F
induction 0 NOUN F
regimens 0 NOUN F
with 0 ADP F
or 0 CCONJ F
without 0 ADP F
paclitaxel 0 NOUN F
consolidation 0 NOUN F
therapy 0 NOUN F
were 0 VERB F
assessed 0 VERB F
in 0 ADP F
ovarian 0 ADJ F
cancer 0 NOUN F
( 0 PUNCT F
OC 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

METHODS 0 NOUN T
Patients 0 NOUN T
with 0 ADP F
stage 0 NOUN F
IC-IV 0 NOUN T
OC 0 NOUN T
were 0 VERB F
randomized 0 VERB F
to 0 ADP F
either 0 CCONJ F
GC 0 NOUN T
( 0 PUNCT F
gemcitabine 0 NOUN F
1,000 0 NUM F
mg/m 0 NOUN F
( 0 PUNCT F
2 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
days 0 NOUN F
1 0 NUM F
and 0 CCONJ F
8 0 NUM F
, 0 PUNCT F
plus 0 CCONJ F
carboplatin 0 NOUN F
area 0 NOUN F
under 0 ADP F
the 0 DET F
curve 0 NOUN F
[ 0 PUNCT F
AUC 0 NOUN T
] 0 PUNCT F
5 0 NUM F
, 0 PUNCT F
day 0 NOUN F
1 0 NUM F
) 0 PUNCT F
or 0 CCONJ F
TC 0 NOUN T
( 0 PUNCT F
paclitaxel 0 NOUN F
175 0 NUM F
mg/m 0 NOUN F
( 0 PUNCT F
2 0 NUM F
) 0 PUNCT F
plus 0 CCONJ F
carboplatin 0 NOUN F
AUC 0 NOUN T
6 0 NUM F
, 0 PUNCT F
day 0 NOUN F
1 0 NUM F
) 0 PUNCT F
every 0 DET F
21 0 NUM F
days 0 NOUN F
for 0 ADP F
up 0 PUNCT F
to 0 ADV F
six 0 NUM F
cycles 0 NOUN F
. 0 PUNCT F

Patients 0 NOUN T
with 0 ADP F
complete B-PHYSICAL ADJ F
response 0 NOUN F
( B-PHYSICAL PUNCT F
CR I-PHYSICAL PUNCT T

Nebulized 0 VERB T
racemic 0 ADJ F
epinephrine 0 NOUN F
by 0 ADP F
IPPB 0 NOUN T
for 0 ADP F
the 0 DET F
treatment 0 NOUN F
of 0 ADP F
croup 0 NOUN F
: 0 PUNCT F
a 0 DET F
double-blind 0 ADJ F
study 0 NOUN F
. 0 PUNCT F

Racemic 0 ADJ T
epinephrine 0 NOUN F
has 0 PUNCT F
been 0 PUNCT F
advocated 0 VERB F
for 0 ADP F
the 0 DET F
treatment 0 NOUN F
of 0 ADP F
croup 0 NOUN F
, 0 PUNCT F
but 0 CCONJ F
controlled 0 VERB F
studies 0 NOUN F
have 0 ADJ F
not 0 ADV F
proved 0 ADP F
it 0 ADP F
more 0 PUNCT F
effective 0 ADJ F
than 0 PUNCT F
saline 0 NOUN F
. 0 PUNCT F

Twenty 0 NUM T
patients 0 NOUN F
( 0 PUNCT F
aged 0 DET F
4 0 NUM F
months 0 NOUN F
to 0 ADP F
5 0 NUM F
years 0 NOUN F
) 0 PUNCT F
hospitalized 0 VERB F
with 0 ADP F
acute 0 ADJ F
croup 0 NOUN F
and 0 CCONJ F
persistent 0 ADJ F
inspiratory 0 ADJ F
stridor 0 NOUN F
at 0 ADP F
rest 0 NOUN F
were 0 VERB F
randomly 0 ADV F
assigned 0 VERB F
to 0 ADP F
one 0 PUNCT F
of 0 ADP F
two 0 NUM F
treatment 0 NOUN F
groups 0 NOUN F
: 0 PUNCT F
saline 0 ADP F
or 0 CCONJ F
racemic 0 ADJ F
epinephrine 0 NOUN F
, 0 PUNCT F
both 0 CCONJ F
nebulized 0 VERB F
and 0 CCONJ F
delivered 0 VERB F
by 0 ADP F
intermittent 0 ADJ F
positive 0 ADJ F
pressure 0 NOUN F
breathing 0 VERB F
. 0 PUNCT F

Clinical B-PHYSICAL ADJ T
scores I-PHYSICAL NOUN F
were 0 VERB F
significantly 0 ADV F
improved 0 ADP F
( 0 PUNCT F
P 0 NOUN T
less 0 ADV F
than 0 ADP F
.01 0 NUM F
) 0 PUNCT F
at 0 ADP F
ten 0 NUM F
and 0 CCONJ F
30 0 NUM F
minutes 0 NOUN F
following 0 VERB F
the 0 DET F
treatment 0 NOUN F
with 0 ADP F
racemic 0 ADJ F
epinephrine 0 NOUN F
but 0 CCONJ F
not 0 ADV F
at 0 ADP F
120 0 NUM F
minutes 0 NOUN F
. 0 PUNCT F

Racemic 0 ADJ T
epinephrine 0 NOUN F
was 0 VERB F
significantly 0 ADV F
more 0 ADV F
effective 0 ADJ F
than 0 PUNCT F
saline 0 NOUN F
at 0 ADP F
10 0 NUM F
( 0 PUNCT F
P 0 NOUN T
less 0 ADV F
than 0 ADP F
.01 0 NUM F
) 0 PUNCT F
and 0 CCONJ F
30 0 NUM F
minutes 0 NOUN F
( 0 PUNCT F
P 0 NOUN T
less 0 ADV F
than 0 PUNCT F
.05 0 NUM F
) 0 PUNCT F
but 0 CCONJ F
not 0 ADV F
at 0 ADP F
120 0 NUM F
minutes 0 NOUN F
after 0 ADP F
the 0 DET F
treatment 0 NOUN F
. 0 PUNCT F

We 0 PRON T
conclude 0 VERB F
that 0 ADP F
nebulized 0 VERB F
racemic 0 ADJ F
epinephrine 0 NOUN F
is 0 VERB F
effective 0 ADJ F
treatment 0 NOUN F
for 0 ADP F
the 0 DET F
acute 0 ADJ F
signs 0 NOUN F
of 0 ADP F
croup 0 NOUN F
. 0 PUNCT F

An 0 DET T
exploratory 0 ADJ F
study 0 NOUN F
: 0 PUNCT F
the 0 DET F
use 0 NOUN F
of 0 ADP F
paroxetine 0 NOUN F
for 0 ADP F
methamphetamine B-PHYSICAL NOUN F
craving I-PHYSICAL PUNCT F
. 0 PUNCT F

Methamphetamine 0 NOUN T
abuse 0 NOUN F
and 0 CCONJ F
dependence 0 NOUN F
are 0 CCONJ F
growing 0 ADP F
problems 0 NOUN F
nationally 0 ADV F
and 0 CCONJ F
worldwide 0 ADJ F
. 0 PUNCT F

There 0 PUNCT T
are 0 VERB F
currently 0 ADV F
no 0 DET F
effective 0 ADJ F
pharmocologic 0 ADJ F
treatments 0 NOUN F
. 0 PUNCT F

Animal 0 NOUN T
studies 0 NOUN F
with 0 ADP F
SSRI 0 NOUN T
's 0 PUNCT F
suggest 0 VERB F
that 0 ADP F
serotonergic 0 ADJ F
modulation 0 NOUN F
alters 0 VERB F
methamphetamine 0 NOUN F
's 0 PUNCT F
behavioral B-MENTAL ADJ F
effects I-MENTAL NOUN F
. 0 PUNCT F

This 0 DET T
exploratory 0 ADJ F
study 0 NOUN F
is 0 VERB F
a 0 DET F
trial 0 NOUN F
of 0 ADP F
the 0 DET F
effects 0 NOUN F
of 0 ADP F
the 0 DET F
SSRI 0 NOUN T
paroxetine 0 NOUN F
versus 0 CCONJ F
placebo 0 NOUN F
( 0 PUNCT F
in 0 ADP F
a 0 DET F
double 0 ADJ F
blind 0 ADJ F
design 0 NOUN F
) 0 PUNCT F
on 0 ADP F
craving 0 PUNCT F
and 0 CCONJ F
use 0 NOUN F
in 0 ADP F
a 0 DET F
population 0 NOUN F
of 0 ADP F
methamphetamine 0 NOUN F
users 0 NOUN F
. 0 PUNCT F

Many 0 DET T
subjects 0 NOUN F
dropped 0 ADP F
out 0 PUNCT F
of 0 ADP F
the 0 DET F
study 0 NOUN F
, 0 PUNCT F
but 0 CCONJ F
those 0 PUNCT F
in 0 ADP F
active 0 ADJ F
treatment 0 NOUN F
who 0 ADP F
completed 0 PROPN F
the 0 DET F
eight 0 NUM F
week 0 NOUN F
trial 0 NOUN F
had 0 PUNCT F
a 0 DET F
decrease 0 NOUN F
in 0 ADP F
methamphetamine B-PHYSICAL NOUN F
craving I-PHYSICAL PUNCT F
compared 0 VERB F
to 0 ADP F
the 0 DET F
placebo 0 NOUN F
treatment 0 NOUN F
as 0 PUNCT F
measured 0 VERB F
by 0 ADP F
the 0 DET F
OCDS 0 NUM T
modified 0 VERB F
for 0 ADP F
use 0 NOUN F
in 0 ADP F
this 0 DET F
population 0 NOUN F
. 0 PUNCT F

Statistical 0 ADJ T
analyses 0 NOUN F
were 0 NUM F
not 0 ADV F
performed 0 VERB F
due 0 PUNCT F
to 0 ADP F
the 0 DET F
low 0 ADJ F
number 0 NOUN F
of 0 ADP F
subjects 0 NOUN F
. 0 PUNCT F

The 0 DET T
preliminary 0 ADJ F
data 0 NOUN F
suggest 0 VERB F
that 0 ADP F
serotonergic 0 ADJ F
agents 0 NOUN F
may 0 VERB F
play 0 VERB F
a 0 DET F
role 0 NOUN F
in 0 ADP F
the 0 DET F
effective 0 ADJ F
treatment 0 NOUN F
of 0 ADP F
methamphetamine B-PHYSICAL NOUN F
abuse I-PHYSICAL NOUN F
and 0 CCONJ F
dependence B-PHYSICAL NOUN F
within 0 ADP F
the 0 DET F
context 0 NOUN F
of 0 ADP F
other 0 ADJ F
effective 0 ADJ F
behavioral 0 ADJ F
interventions 0 NOUN F
. 0 PUNCT F

A 0 DET T
prospective 0 ADJ F
randomized 0 VERB F
trial 0 NOUN F
of 0 ADP F
Duraflo 0 PUNCT T
II 0 NUM T
heparin-coated 0 VERB F
circuits 0 CCONJ F
in 0 ADP F
cardiac 0 ADJ F
reoperations 0 NOUN F
. 0 PUNCT F

BACKGROUND 0 NOUN T
Heparin-coated 0 VERB T
circuits 0 CCONJ F
in 0 ADP F
cardiopulmonary 0 ADJ F
bypass 0 NOUN F
have 0 ADP F
been 0 PUNCT F
shown 0 VERB F
to 0 PART F
decrease 0 NOUN F
the 0 DET F
systemic 0 ADJ F
inflammatory 0 ADJ F
responses 0 NOUN F
associated 0 VERB F
with 0 ADP F
cardiopulmonary 0 ADJ F
bypass 0 NOUN F
. 0 PUNCT F

Previous 0 ADJ T
clinical 0 ADJ F
studies 0 NOUN F
on 0 ADP F
low-risk 0 NOUN F
patients 0 NOUN F
who 0 PROPN F
had 0 PUNCT F
coronary 0 ADJ F
artery 0 NOUN F
bypass 0 NOUN F
grafting 0 VERB F
( 0 PUNCT F
CABG 0 NOUN T
) 0 PUNCT F
and 0 CCONJ F
received 0 PART F
full-dose 0 NOUN F
systemic 0 ADJ F
heparin 0 NOUN F
did 0 PUNCT F
not 0 ADV F
have 0 PUNCT F
clearly 0 ADV F
improved 0 PUNCT F
clinical 0 ADJ F
outcomes 0 NOUN F
. 0 PUNCT F

We 0 PRON T
hypothesized 0 VERB F
that 0 ADP F
the 0 DET F
beneficial 0 ADJ F
effects 0 NOUN F
of 0 ADP F
heparin-coated 0 VERB F
circuits 0 NOUN F
might 0 VERB F
be 0 VERB F
seen 0 VERB F
in 0 ADP F
patients 0 NOUN F
who 0 ADP F
had 0 PUNCT F
cardiac 0 ADJ F
reoperations 0 NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
Three 0 NUM T
hundred 0 NUM F
fifty 0 ADP F
patients 0 NOUN F
who 0 ADP F
had 0 PUNCT F
reoperation 0 NOUN F
with 0 ADP F
CABG 0 NOUN T
only 0 ADV F
( 0 PUNCT F
58 0 NUM F
% 0 SYM F
) 0 PUNCT F
, 0 PUNCT F
or 0 CCONJ F
with 0 ADP F
valve 0 NOUN F
operations 0 NOUN F
( 0 PUNCT F
42 0 NUM F
% 0 SYM F
) 0 PUNCT F
were 0 VERB F
randomly 0 ADV F
assigned 0 VERB F
to 0 PART F
receive 0 NOUN F
either 0 PUNCT F
a 0 DET F
heparin-coated 0 VERB F
( 0 PUNCT F
Duraflo 0 PUNCT T
II 0 NUM T
; 0 PUNCT F
study 0 PUNCT F
group 0 NOUN F
) 0 PUNCT F
or 0 CCONJ F
uncoated 0 VERB F
( 0 PUNCT F
control 0 NOUN F
group 0 NOUN F
) 0 PUNCT F
circuit 0 NOUN F
. 0 PUNCT F

Clinical 0 ADJ T
outcomes 0 NOUN F
were 0 VERB F
compared 0 VERB F
and 0 CCONJ F
the 0 DET F
variables 0 NOUN F
were 0 VERB F
analyzed 0 VERB F
using 0 VERB F
the 0 DET F
following 0 PUNCT F
three 0 DET F
groups 0 NOUN F
: 0 PUNCT F
entire 0 ADJ F
populations 0 NOUN F
of 0 ADP F
study 0 ADV F
group 0 NOUN F
and 0 CCONJ F
control 0 NOUN F
group 0 NOUN F
, 0 PUNCT F
subgroup 0 NOUN F
of 0 ADP F
patients 0 NOUN F
who 0 ADP F
had 0 PUNCT F
CABG 0 NOUN T
reoperation 0 NOUN F
only 0 ADV F
, 0 PUNCT F
and 0 CCONJ F
a 0 DET F
subgroup 0 NOUN F
who 0 CCONJ F
had 0 ADP F
valve 0 NOUN F
reoperation 0 NOUN F
or 0 CCONJ F
combined 0 VERB F
valve 0 NOUN F
and 0 CCONJ F
CABG 0 NOUN T
reoperation 0 NOUN F
. 0 PUNCT F

RESULTS 0 NOUN T
Preoperative 0 ADJ T
variables 0 NOUN F
were 0 VERB F
the 0 DET F
same 0 ADP F
in 0 ADP F
both 0 CCONJ F
groups 0 NOUN F
. 0 PUNCT F

No 0 DET T
difference 0 NOUN F
in 0 ADP F
clinical 0 ADJ F
outcomes 0 NOUN F
could 0 VERB F
be 0 VERB F
demonstrated 0 VERB F
except 0 ADP F
that 0 CCONJ F
the 0 DET F
percentage 0 NOUN F
of 0 ADP F
patients B-ADVERSE-EFFECTS NOUN F
with I-ADVERSE-EFFECTS ADP F
major I-ADVERSE-EFFECTS ADJ F
bleeding I-ADVERSE-EFFECTS VERB F
episodes I-ADVERSE-EFFECTS NOUN F
was 0 NUM F
significantly 0 ADV F
lower 0 PUNCT F
in 0 ADP F
the 0 DET F
study 0 ADJ F
group 0 NOUN F
( 0 PUNCT F
1.2 0 NUM F
% 0 SYM F
versus 0 CCONJ F
5.4 0 NUM F
% 0 SYM F
, 0 PUNCT F
p 0 NOUN F
= 0 SYM F
0.035 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

In 0 ADP T
the 0 DET F
subgroup 0 NOUN F
analysis 0 NOUN F
of 0 ADP F
patients 0 NOUN F
who 0 ADP F
had 0 ADP F
valve B-PHYSICAL NOUN F
reoperations I-PHYSICAL NOUN F
, 0 PUNCT F
lower 0 PUNCT F
blood B-PHYSICAL NOUN F
transfusion I-PHYSICAL NOUN F
requirements I-PHYSICAL NOUN F
in 0 ADP F
the 0 DET F
intensive 0 ADJ F
care 0 NOUN F
unit 0 NOUN F
( 0 PUNCT F
p 0 NOUN F
= 0 SYM F
0.013 0 NUM F
) 0 PUNCT F
were 0 VERB F
found 0 VERB F
in 0 ADP F
the 0 DET F
study 0 ADJ F
group 0 NOUN F
. 0 PUNCT F

When 0 ADP T
the 0 DET F
subgroup 0 NOUN F
of 0 ADP F
patients 0 NOUN F
who 0 ADP F
had 0 PUNCT F
CABG 0 NOUN T
reoperations 0 NOUN F
was 0 VERB F
analyzed 0 VERB F
separately 0 ADV F
, 0 PUNCT F
there 0 PUNCT F
was 0 VERB F
a 0 DET F
trend 0 NOUN F
toward 0 ADP F
less 0 DET F
reoperation B-PHYSICAL NOUN F
for I-PHYSICAL ADP F
bleeding I-PHYSICAL VERB F
in 0 ADP F
the 0 DET F
study 0 ADJ F
group 0 NOUN F
( 0 PUNCT F
0 0 NUM F
% 0 SYM F
versus 0 CCONJ F
4.0 0 NUM F
% 0 SYM F
, 0 PUNCT F
p 0 NOUN F
= 0 SYM F
0.058 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

CONCLUSIONS 0 NOUN T
We 0 PRON T
conclude 0 VERB F
that 0 ADP F
the 0 DET F
use 0 NOUN F
of 0 ADP F
heparin-coated 0 VERB F
circuits 0 NOUN F
was 0 VERB F
safe 0 ADJ F
and 0 CCONJ F
imparted 0 PUNCT F
protection 0 NOUN F
from 0 ADP F
reoperations 0 NOUN F
for 0 ADP F
bleeding 0 VERB F
and 0 CCONJ F
major 0 ADJ F
bleeding 0 VERB F
episodes 0 NOUN F
. 0 PUNCT F

Material-independent 0 ADJ T
blood 0 NOUN F
activation 0 NOUN F
( 0 PUNCT F
eg 0 ADP F
, 0 PUNCT F
blood-air 0 ADJ F
interface 0 NOUN F
and 0 CCONJ F
cardiotomy 0 NOUN F
suction 0 NOUN F
) 0 PUNCT F
blunted 0 ADP F
the 0 DET F
total 0 ADJ F
effect 0 NOUN F
of 0 ADP F
the 0 DET F
heparin-coated 0 VERB F
surface 0 NOUN F
. 0 PUNCT F

Deliberate 0 ADP T
mild 0 ADJ F
intraoperative 0 ADJ F
hypothermia 0 NOUN F
for 0 ADP F
craniotomy 0 NOUN F
. 0 PUNCT F

BACKGROUND 0 NOUN T
Despite 0 ADP T
enthusiasm 0 NOUN F
for 0 ADP F
the 0 DET F
use 0 NOUN F
of 0 ADP F
mild 0 ADJ F
hypothermia 0 NOUN F
during 0 ADP F
neurosurgical 0 ADJ F
procedures 0 NOUN F
, 0 PUNCT F
this 0 DET F
therapy 0 NOUN F
has 0 VERB F
not 0 ADV F
been 0 PUNCT F
evaluated 0 VERB F
systematically 0 ADV F
. 0 PUNCT F

This 0 DET T
study 0 NOUN F
examined 0 VERB F
the 0 DET F
feasibility 0 NOUN F
and 0 CCONJ F
safety 0 NOUN F
of 0 ADP F
deliberate 0 PUNCT F
mild 0 ADJ F
hypothermia 0 NOUN F
and 0 CCONJ F
rewarming 0 SYM F
. 0 PUNCT F

METHODS 0 NOUN T
Thirty 0 NUM T
patients 0 NOUN F
scheduled 0 VERB F
for 0 ADP F
craniotomy 0 NOUN F
were 0 VERB F
assigned 0 VERB F
to 0 ADP F
either 0 CCONJ F
a 0 DET F
normothermic 0 ADJ F
or 0 CCONJ F
mildly 0 ADJ F
hypothermic 0 PUNCT F
group 0 NOUN F
. 0 PUNCT F

Tympanic 0 ADJ T
membrane 0 NOUN F
temperature 0 NOUN F
was 0 VERB F
monitored 0 VERB F
at 0 ADP F
anesthetic 0 ADJ F
induction 0 NOUN F
, 0 PUNCT F
throughout 0 ADP F
the 0 DET F
isoflurane-fentanyl-N2O-O2 0 PUNCT F
anesthetic 0 ADJ F
, 0 PUNCT F
and 0 CCONJ F
for 0 ADP F
18 0 NUM F
h 0 NOUN F
postoperatively 0 NOUN F
. 0 PUNCT F

Normothermic 0 ADJ T
patients 0 NOUN F
were 0 VERB F
warmed 0 VERB F
to 0 ADP F
36.5-37.0 0 ADJ F
degrees 0 NOUN F
C 0 NUM T
after 0 ADP F
an 0 DET F
initial 0 ADJ F
temperature 0 NOUN F
decrease 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
hypothermic 0 ADJ F
patients 0 NOUN F
were 0 VERB F
cooled 0 VERB F
to 0 ADP F
35 0 NUM F
degrees 0 ADJ F
C. 0 NUM T
In 0 ADP T
the 0 DET F
hypothermic 0 ADJ F
group 0 NOUN F
temperatures 0 NOUN F
were 0 VERB F
allowed 0 VERB F
to 0 PUNCT F
drift 0 PUNCT F
to 0 ADP F
34.5 0 NUM F
degrees 0 NOUN F
C 0 NUM T
before 0 ADP F
rewarming 0 ADP F
was 0 VERB F
initiated 0 VERB F
. 0 PUNCT F

Water 0 NOUN T
blankets 0 NOUN F
and 0 CCONJ F
convective 0 ADJ F
heating 0 ADJ F
devices 0 NOUN F
were 0 VERB F
used 0 VERB F
to 0 ADP F
cool 0 NOUN F
and 0 CCONJ F
rewarm 0 NOUN F
. 0 PUNCT F

RESULTS 0 PUNCT T
The 0 DET T
minimum B-PHYSICAL NOUN F
temperature I-PHYSICAL NOUN F
achieved 0 VERB F
by 0 ADP F
the 0 DET F
hypothermic 0 ADJ F
group 0 NOUN F
was 0 VERB F
34.3 0 NUM F
+/- 0 SYM F
0.4 0 NUM F
degrees 0 ADJ F
C. 0 NUM T
Cooling B-PHYSICAL PUNCT T
occurred 0 VERB F
at 0 ADP F
a 0 DET F
rate 0 NOUN F
of 0 ADP F
1.0 0 NUM F
+/- 0 SYM F
0.4 0 NUM F
degrees 0 ADJ F
C/h 0 NOUN T
. 0 PUNCT F

Rewarming B-OTHER VERB T
took 0 PROPN F
place 0 NOUN F
at 0 ADP F
a 0 DET F
rate 0 NOUN F
of 0 ADP F
0.7 0 NUM F
+/- 0 SYM F
0.6 0 NUM F
degrees 0 ADJ F
C/h 0 NOUN T
( 0 PUNCT F
range 0 NOUN F
0.1-1.8 0 NUM F
) 0 PUNCT F
in 0 ADP F
the 0 DET F
hypothermic 0 ADJ F
group 0 NOUN F
. 0 PUNCT F

Hypothermia B-OTHER NOUN T
did 0 VERB F
not 0 ADV F
delay 0 NUM F
emergence 0 NOUN F
from 0 ADP F
anesthesia B-PHYSICAL NOUN F
( 0 PUNCT F
20 0 NUM F
+/- 0 SYM F
15 0 NUM F
min 0 NOUN F
) 0 PUNCT F
compared 0 VERB F
with 0 ADP F
normothermia 0 NOUN F
( 0 PUNCT F
15 0 NUM F
+/- 0 SYM F
15 0 NUM F
min 0 NOUN F
, 0 PUNCT F
P 0 NOUN T
= 0 SYM F
.45 0 ADP F
) 0 PUNCT F
. 0 PUNCT F

Mean 0 ADJ T
temperature 0 NOUN F
upon 0 ADP F
intensive B-OTHER ADJ F
care I-OTHER NOUN F
unit I-OTHER NOUN F
admission I-OTHER NOUN F
was 0 VERB F
35.8 0 NUM F
+/- 0 SYM F
1.0 0 NUM F
degrees 0 NOUN F
C 0 NUM T
for 0 ADP F
the 0 DET F
hypothermic 0 ADJ F
group 0 NOUN F
and 0 CCONJ F
37.1 0 NUM F
+/- 0 SYM F
0.5 0 NUM F
degrees 0 NOUN F
C 0 NUM T
for 0 ADP F
the 0 DET F
normothermic 0 ADJ F
group 0 NOUN F
( 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.0001 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
hypothermic 0 PUNCT F
patients 0 NOUN F
had 0 PUNCT F
more 0 DET F
postoperative B-OTHER ADJ F
shivering I-OTHER ADP F
. 0 PUNCT F

From 0 ADP T
8 0 NUM F
to 0 ADP F
18 0 NUM F
h 0 NOUN F
postoperatively 0 ADV F
the 0 DET F
temperatures B-PHYSICAL NOUN F
of 0 ADP F
the 0 DET F
two 0 NUM F
groups 0 NOUN F
were 0 VERB F
similar 0 ADJ F
except 0 PUNCT F
for 0 ADP F
a 0 DET F
slightly 0 ADV F
greater 0 PUNCT F
temperature B-OTHER NOUN F
in 0 ADP F
the 0 DET F
hypothermic 0 ADJ F
patients 0 NOUN F
at 0 ADP F
12 0 NUM F
h 0 NOUN F
( 0 PUNCT F
37.6 0 NUM F
+/- 0 SYM F
0.5 0 NUM F
vs. 0 CCONJ F
37.3 0 NUM F
+/- 0 SYM F
0.4 0 NUM F
degrees 0 NOUN F
C 0 NUM T
, 0 PUNCT F
P 0 NOUN T
= 0 SYM F
.029 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

CONCLUSIONS 0 NOUN T
Although 0 PUNCT T
deliberate 0 ADP F
mild 0 ADJ F
hypothermia 0 NOUN F
is 0 VERB F
easily 0 ADV F
achieved 0 VERB F
intraoperatively 0 ADV F
, 0 PUNCT F
complete 0 ADJ F
rewarming 0 ADP F
may 0 ADP F
be 0 VERB F
difficult 0 ADJ F
to 0 ADV F
attain 0 ADP F
during 0 ADP F
craniotomy 0 NOUN F
with 0 ADP F
current 0 ADJ F
methods 0 NOUN F
. 0 PUNCT F

In 0 ADP T
addition 0 NOUN F
to 0 ADP F
the 0 DET F
need 0 NOUN F
for 0 ADP F
determining 0 VERB F
whether 0 PUNCT F
deliberate 0 ADP F
mild 0 ADJ F
hypothermia 0 NOUN F
confers 0 VERB F
cerebral 0 ADJ F
protection 0 NOUN F
in 0 ADP F
humans 0 NOUN F
, 0 PUNCT F
the 0 DET F
potential 0 ADJ F
risks 0 NOUN F
of 0 ADP F
the 0 DET F
therapy 0 NOUN F
need 0 NOUN F
to 0 PART F
be 0 PUNCT F
further 0 ADV F
characterized 0 VERB F
. 0 PUNCT F

Benefits B-OTHER NOUN T
, 0 PUNCT F
morbidity B-PHYSICAL NOUN F
, 0 PUNCT F
and 0 CCONJ F
mortality B-MORTALITY NOUN F
associated 0 VERB F
with 0 ADP F
long-term 0 NOUN F
administration 0 NOUN F
of 0 ADP F
oral 0 ADJ F
anticoagulant 0 NOUN F
therapy 0 NOUN F
to 0 ADP F
patients 0 NOUN F
with 0 ADP F
peripheral 0 ADJ F
arterial 0 ADJ F
bypass 0 NOUN F
procedures 0 NOUN F
: 0 PUNCT F
a 0 DET F
prospective 0 ADJ F
randomized 0 VERB F
study 0 NOUN F
. 0 PUNCT F

BACKGROUND 0 NOUN T
The 0 DET T
benefits 0 NOUN F
of 0 ADP F
the 0 DET F
long-term 0 NOUN F
administration 0 NOUN F
of 0 ADP F
oral 0 ADJ F
anticoagulant 0 NOUN F
therapy 0 NOUN F
remain 0 VERB F
unclear 0 ADJ F
in 0 ADP F
patients 0 NOUN F
with 0 ADP F
lower 0 PUNCT F
extremity 0 NOUN F
arterial 0 ADJ F
bypass 0 NOUN F
surgery 0 NOUN F
. 0 PUNCT F

We 0 PRON T
studied 0 VERB F
the 0 DET F
effect 0 NOUN F
of 0 ADP F
warfarin 0 NOUN F
plus 0 CCONJ F
aspirin 0 NOUN F
therapy 0 NOUN F
( 0 PUNCT F
WASA 0 NOUN T
) 0 PUNCT F
versus 0 CCONJ F
aspirin 0 NOUN F
therapy 0 NOUN F
alone 0 ADJ F
( 0 PUNCT F
ASA 0 NOUN T
) 0 PUNCT F
on 0 ADP F
patient B-MORTALITY NOUN F
mortality I-MORTALITY NOUN F
, 0 PUNCT F
morbidity B-PHYSICAL NOUN F
and 0 CCONJ F
bypass B-PHYSICAL NOUN F
patency I-PHYSICAL NOUN F
rates I-PHYSICAL NOUN F
in 0 ADP F
a 0 DET F
randomized 0 VERB F
clinical 0 ADJ F
trial 0 NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
In 0 ADP T
a 0 DET F
multicenter 0 NOUN F
, 0 PUNCT F
prospective 0 ADJ F
, 0 PUNCT F
nonmasked 0 ADP F
clinical 0 ADJ F
trial 0 NOUN F
, 0 PUNCT F
831 0 NUM F
patients 0 NOUN F
who 0 ADP F
underwent 0 VERB F
peripheral 0 ADJ F
arterial 0 ADJ F
bypass 0 NOUN F
surgery 0 NOUN F
were 0 VERB F
compared 0 VERB F
in 0 ADP F
a 0 DET F
long-term 0 NOUN F
treatment 0 NOUN F
program 0 NOUN F
of 0 ADP F
WASA 0 NOUN T
( 0 PUNCT F
target 0 NOUN F
international 0 ADJ F
normalized 0 VERB F
ratio 0 NOUN F
of 0 ADP F
1.4 0 NUM F
to 0 ADP F
2.8 0 NUM F
; 0 PUNCT F
325 0 NUM F
mg/day 0 NOUN F
) 0 PUNCT F
with 0 ADP F
ASA 0 NOUN T
( 0 PUNCT F
325 0 NUM F
mg/day 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
primary 0 ADJ F
end 0 NOUN F
point 0 NOUN F
was 0 VERB F
bypass B-PHYSICAL NUM F
patency I-PHYSICAL NOUN F
, 0 PUNCT F
and 0 CCONJ F
mortality B-MORTALITY NOUN F
and 0 CCONJ F
morbidity B-PHYSICAL NOUN F
were 0 VERB F
the 0 DET F
secondary 0 ADJ F
endpoints 0 NOUN F
. 0 PUNCT F

RESULTS 0 NOUN T
There 0 CCONJ T
were 0 VERB F
133 0 NUM F
deaths B-MORTALITY NOUN F
in 0 ADP F
the 0 DET F
WASA 0 NOUN T
group 0 NOUN F
( 0 PUNCT F
31.8 0 NUM F
% 0 SYM F
) 0 PUNCT F
and 0 CCONJ F
95 0 NUM F
deaths B-MORTALITY NOUN F
in 0 ADP F
the 0 DET F
ASA 0 NOUN T
group 0 NOUN F
( 0 PUNCT F
23.0 0 NUM F
% 0 SYM F
; 0 PUNCT F
risk 0 NOUN F
ratio 0 NOUN F
, 0 PUNCT F
1.41 0 NUM F
; 0 PUNCT F
95 0 NUM F
% 0 SYM F
confidence 0 NOUN F
interval 0 NOUN F
, 0 PUNCT F
1.09 0 NUM F
to 0 ADP F
1.84 0 ADJ F
; 0 PUNCT F
P 0 NOUN T
=.0001 0 VERB F
) 0 PUNCT F
. 0 PUNCT F

Major B-PHYSICAL ADJ T
hemorrhagic I-PHYSICAL ADJ F
events I-PHYSICAL NOUN F
occurred 0 VERB F
more 0 ADV F
frequently 0 ADV F
in 0 ADP F
the 0 DET F
WASA 0 NOUN T
group 0 NOUN F
( 0 PUNCT F
WASA 0 NOUN T
, 0 PUNCT F
n 0 NOUN F
= 0 SYM F
35 0 NUM F
; 0 PUNCT F
ASA 0 NOUN T
, 0 PUNCT F
n 0 NOUN F
= 0 SYM F
15 0 NUM F
; 0 PUNCT F
P 0 NOUN T
=.02 0 PUNCT F
) 0 PUNCT F
. 0 PUNCT F

In 0 ADP T
the 0 DET F
prosthetic 0 ADJ F
bypass 0 NOUN F
group 0 NOUN F
, 0 PUNCT F
there 0 PUNCT F
was 0 VERB F
no 0 DET F
significant 0 ADJ F
difference 0 NOUN F
in 0 ADP F
patency B-OTHER NOUN F
rate I-OTHER NOUN F
in 0 ADP F
the 0 DET F
8-mm 0 PUNCT F
bypass 0 NOUN F
subgroup 0 NOUN F
, 0 PUNCT F
but 0 CCONJ F
there 0 PUNCT F
was 0 VERB F
a 0 DET F
significant 0 ADJ F
difference 0 NOUN F
in 0 ADP F
patency B-OTHER NOUN F
rate I-OTHER NOUN F
in 0 ADP F
the 0 DET F
6-mm 0 PUNCT F
bypass 0 NOUN F
subgroup 0 NOUN F
( 0 PUNCT F
femoral-popliteal 0 ADJ F
; 0 PUNCT F
71.4 0 NUM F
% 0 SYM F
in 0 ADP F
the 0 DET F
WASA 0 NOUN T
group 0 NOUN F
versus 0 CCONJ F
57.9 0 NUM F
% 0 SYM F
in 0 ADP F
the 0 DET F
ASA 0 NOUN T
group 0 NOUN F
; 0 PUNCT F
P 0 NOUN T
=.02 0 PUNCT F
) 0 PUNCT F
. 0 PUNCT F

In 0 ADP T
the 0 DET F
vein 0 NOUN F
bypass 0 NOUN F
group 0 NOUN F
, 0 PUNCT F
patency B-OTHER NOUN F
rate I-OTHER NOUN F
was 0 VERB F
unaffected 0 VERB F
( 0 PUNCT F
75.3 0 NUM F
% 0 SYM F
in 0 ADP F
the 0 DET F
WASA 0 NOUN T
group 0 NOUN F
versus 0 CCONJ F
74.9 0 NUM F
% 0 SYM F
in 0 ADP F
the 0 DET F
ASA 0 NOUN T
group 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

CONCLUSION 0 NOUN T
The 0 DET T
long-term 0 NOUN F
administration 0 NOUN F
of 0 ADP F
warfarin 0 NOUN F
therapy 0 NOUN F
when 0 ADP F
combined 0 PUNCT F
with 0 ADP F
aspirin 0 NOUN F
therapy 0 NOUN F
has 0 PUNCT F
only 0 ADV F
a 0 DET F
few 0 ADJ F
selected 0 VERB F
indications 0 NOUN F
for 0 ADP F
improvement 0 NOUN F
of 0 ADP F
bypass B-OTHER NOUN F
patency I-OTHER NOUN F
and 0 CCONJ F
is 0 VERB F
associated 0 VERB F
with 0 ADP F
an 0 DET F
increased 0 VERB F
risk 0 NOUN F
of 0 ADP F
morbidity B-PHYSICAL NOUN F
and 0 CCONJ F
mortality B-MORTALITY NOUN F
. 0 PUNCT F

A 0 DET T
comparison 0 NOUN F
of 0 ADP F
seven 0 NUM F
antiarrhythmic 0 ADJ F
drugs 0 NOUN F
in 0 ADP F
patients 0 NOUN F
with 0 ADP F
ventricular 0 ADJ F
tachyarrhythmias 0 NOUN F
. 0 PUNCT F

Electrophysiologic 0 ADJ T
Study 0 NOUN T
versus 0 CCONJ F
Electrocardiographic 0 ADJ T
Monitoring 0 PUNCT T
Investigators 0 NOUN T
. 0 PUNCT F

BACKGROUND 0 NOUN T
The 0 DET T
relative 0 ADJ F
efficacies 0 NOUN F
of 0 ADP F
various 0 ADJ F
antiarrhythmic 0 ADJ F
drugs 0 NOUN F
in 0 ADP F
the 0 DET F
treatment 0 NOUN F
of 0 ADP F
ventricular 0 ADJ F
tachyarrhythmias 0 NOUN F
are 0 VERB F
not 0 VERB F
well 0 VERB F
known 0 CCONJ F
. 0 PUNCT F

This 0 DET T
study 0 NOUN F
examined 0 VERB F
the 0 DET F
effectiveness 0 NOUN F
of 0 ADP F
imipramine 0 NOUN F
, 0 PUNCT F
mexiletine 0 NOUN F
, 0 PUNCT F
pirmenol 0 PUNCT F
, 0 PUNCT F
procainamide 0 NOUN F
, 0 PUNCT F
propafenone 0 NOUN F
, 0 PUNCT F
quinidine 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
sotalol 0 NOUN F
in 0 ADP F
patients 0 NOUN F
with 0 ADP F
ventricular 0 ADJ F
tachyarrhythmias 0 NOUN F
who 0 PROPN F
were 0 VERB F
enrolled 0 VERB F
in 0 ADP F
the 0 DET F
Electrophysiologic 0 ADJ T
Study 0 NOUN T
versus 0 CCONJ F
Electrocardiographic 0 ADJ T
Monitoring 0 PUNCT T
trial 0 NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
Patients 0 NOUN T
were 0 VERB F
randomly 0 ADV F
assigned 0 VERB F
to 0 ADJ F
undergo 0 VERB F
serial 0 ADJ F
testing 0 VERB F
of 0 ADP F
the 0 DET F
efficacy 0 NOUN F
of 0 ADP F
the 0 DET F
seven 0 NUM F
antiarrhythmic 0 ADJ F
drugs 0 NOUN F
by 0 ADP F
one 0 NUM F
of 0 ADP F
two 0 NUM F
strategies 0 NOUN F
: 0 PUNCT F
electrophysiologic 0 ADJ F
study 0 NOUN F
or 0 CCONJ F
Holter 0 NOUN T
monitoring 0 VERB F
together 0 ADV F
with 0 ADP F
exercise 0 NOUN F
testing 0 VERB F
. 0 PUNCT F

The 0 DET T
seven 0 NUM F
drugs 0 NOUN F
were 0 VERB F
then 0 ADV F
tested 0 VERB F
for 0 ADP F
efficacy 0 NOUN F
in 0 ADP F
random 0 ADJ F
order 0 NOUN F
in 0 ADP F
patients 0 NOUN F
who 0 ADP F
were 0 VERB F
eligible 0 ADJ F
to 0 PART F
receive 0 PUNCT F
them 0 PRON F
. 0 PUNCT F

The 0 DET T
frequencies 0 NOUN F
of 0 ADP F
predictions 0 NOUN F
of 0 ADP F
drug 0 NOUN F
efficacy 0 NOUN F
and 0 CCONJ F
of 0 ADP F
adverse 0 ADJ F
drug 0 NOUN F
effects 0 NOUN F
during 0 ADP F
the 0 DET F
initial 0 ADJ F
drug 0 NOUN F
titration 0 NOUN F
were 0 VERB F
tabulated 0 VERB F
for 0 ADP F
all 0 DET F
486 0 NUM F
randomized 0 VERB F
subjects 0 NOUN F
. 0 PUNCT F

Patients 0 NOUN T
received 0 VERB F
long-term 0 NOUN F
treatment 0 NOUN F
with 0 ADP F
the 0 DET F
first 0 ADJ F
antiarrhythmic 0 ADJ F
drug 0 NOUN F
that 0 PUNCT F
was 0 VERB F
predicted 0 VERB F
to 0 PART F
be 0 VERB F
effective 0 ADJ F
on 0 ADP F
the 0 DET F
basis 0 NOUN F
of 0 ADP F
drug 0 NOUN F
testing 0 VERB F
. 0 PUNCT F

Recurrences 0 NOUN T
of 0 ADP F
arrhythmia 0 NOUN F
, 0 PUNCT F
deaths 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
adverse 0 ADJ F
drug 0 NOUN F
effects 0 NOUN F
during 0 ADP F
long-term 0 NOUN F
follow-up 0 NOUN F
were 0 VERB F
recorded 0 VERB F
for 0 ADP F
the 0 DET F
296 0 NUM F
patients 0 NOUN F
in 0 ADP F
whom 0 ADP F
an 0 DET F
antiarrhythmic 0 ADJ F
drug 0 NOUN F
was 0 VERB F
predicted 0 VERB F
to 0 PART F
be 0 VERB F
effective 0 ADJ F
. 0 PUNCT F

RESULTS 0 NOUN T
In 0 ADP T
the 0 DET F
electrophysiologic-study 0 NOUN F
group 0 NOUN F
, 0 PUNCT F
the 0 DET F
percentage 0 NOUN F
of 0 ADP F
patients 0 NOUN F
who 0 ADP F
had 0 ADP F
predictions 0 NOUN F
of 0 ADP F
drug B-MENTAL NOUN F
efficacy I-MENTAL NOUN F
was 0 VERB F
higher B-MENTAL PUNCT F
with 0 ADP F
sotalol 0 NOUN F
( 0 PUNCT F
35 0 NUM F
percent 0 NOUN F
) 0 PUNCT F
than 0 PUNCT F
with 0 ADP F
the 0 DET F
other 0 ADJ F
drugs 0 NOUN F
( 0 PUNCT F
16 0 NUM F
percent 0 NOUN F
, 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.001 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

There 0 PUNCT T
was 0 VERB F
no 0 DET F
significant B-MENTAL ADJ F
difference I-MENTAL NOUN F
among 0 ADP F
the 0 DET F
drugs 0 NOUN F
in 0 ADP F
the 0 DET F
Holter-monitoring 0 ADJ T
group 0 NOUN F
. 0 PUNCT F

The 0 DET T
percentage 0 NOUN F
of 0 ADP F
patients 0 NOUN F
with 0 ADP F
adverse B-MENTAL ADJ F
drug I-MENTAL NOUN F
effects I-MENTAL NOUN F
was 0 VERB F
lowest B-MENTAL PUNCT F
among 0 ADP F
those 0 PUNCT F
receiving 0 ADP F
sotalol 0 NOUN F
. 0 PUNCT F

The 0 DET T
actuarial B-MENTAL ADJ F
probability 0 NOUN F
of B-MENTAL ADP F
a I-MENTAL DET F
recurrence I-MENTAL NOUN F
of I-MENTAL ADP F
arrhythmia B-MENTAL NOUN F
after 0 ADP F
a 0 DET F
prediction 0 NOUN F
of 0 ADP F
drug 0 NOUN F
efficacy 0 NOUN F
by 0 ADP F
either 0 PUNCT F
strategy 0 NOUN F
was 0 VERB F
significantly B-OTHER ADV F
lower B-OTHER PUNCT F
for 0 ADP F
patients 0 NOUN F
treated 0 VERB F
with 0 ADP F
sotalol 0 NOUN F
than 0 PUNCT F
for 0 ADP F
patients 0 NOUN F
treated 0 VERB F
with 0 ADP F
the 0 DET F
other 0 ADJ F
drugs 0 NOUN F
( 0 PUNCT F
risk 0 NOUN F
ratio 0 NOUN F
, 0 PUNCT F
0.43 0 NUM F
; 0 PUNCT F
95 0 NUM F
percent 0 NOUN F
confidence 0 NOUN F
interval 0 NOUN F
, 0 PUNCT F
0.29 0 NUM F
to 0 ADP F
0.62 0 NUM F
; 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.001 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

With 0 ADP T
sotalol 0 NOUN F
, 0 PUNCT F
as 0 PUNCT F
compared 0 VERB F
with 0 ADP F
the 0 DET F
other 0 ADJ F
drugs 0 NOUN F
combined 0 PROPN F
, 0 PUNCT F
there 0 PUNCT F
were 0 VERB F
lower 0 VERB F
risks 0 NOUN F
of 0 PUNCT F

A 0 DET T
double-blind 0 ADJ F
placebo-controlled 0 VERB F
trial 0 NOUN F
of 0 ADP F
zonisamide 0 ADJ F
( 0 PUNCT F
zonegran 0 NOUN F
) 0 PUNCT F
in 0 ADP F
the 0 DET F
treatment 0 NOUN F
of 0 ADP F
essential B-PHYSICAL ADJ F
tremor I-PHYSICAL NOUN F
. 0 PUNCT F

Medical 0 ADJ T
therapy 0 NOUN F
for 0 ADP F
essential B-PHYSICAL ADJ F
tremor I-PHYSICAL NOUN F
( I-PHYSICAL PUNCT F
ET I-PHYSICAL NOUN T
) I-PHYSICAL PUNCT F
, 0 PUNCT F
a 0 DET F
common 0 ADJ F
movement 0 NOUN F
disorder 0 NOUN F
, 0 PUNCT F
is 0 VERB F
often 0 ADV F
inadequate 0 PUNCT F
. 0 PUNCT F

We 0 PRON T
performed 0 VERB F
a 0 DET F
double-blind 0 ADJ F
placebo-controlled 0 VERB F
randomized 0 VERB F
trial 0 NOUN F
to 0 PART F
evaluate 0 NOUN F
the 0 DET F
efficacy 0 NOUN F
and 0 CCONJ F
tolerability B-OTHER NOUN F
of 0 ADP F
zonisamide 0 PUNCT F
( 0 PUNCT F
ZNS 0 NOUN T
) 0 PUNCT F
, 0 PUNCT F
an 0 DET F
antiepileptic 0 ADJ F
agent 0 NOUN F
, 0 PUNCT F
in 0 ADP F
treating 0 VERB F
ET B-PHYSICAL NOUN T
. 0 PUNCT F

Twenty 0 NUM T
patients 0 NOUN F
( 0 PUNCT F
mean 0 NOUN F
age 0 NOUN F
, 0 PUNCT F
60 0 NUM F
+/- 0 SYM F
15 0 NUM F
years 0 NOUN F
) 0 PUNCT F
with 0 ADP F
ET B-PHYSICAL NOUN T
were 0 VERB F
randomized 0 VERB F
to 0 PART F
receive 0 NOUN F
ZNS 0 NOUN T
or 0 CCONJ F
placebo 0 NOUN F
. 0 PUNCT F

ZNS 0 NOUN T
was 0 VERB F
initiated 0 VERB F
at 0 ADP F
a 0 DET F
dosage 0 NOUN F
of 0 ADP F
100 0 NUM F
mg/day 0 NOUN F
and 0 CCONJ F
escalated 0 VERB F
to 0 ADP F
200 0 NUM F
mg/day 0 NOUN F
at 0 ADP F
day 0 NOUN F
14 0 NUM F
. 0 PUNCT F

Patients 0 NOUN T
were 0 VERB F
evaluated 0 VERB F
by 0 ADP F
accelerometry 0 NOUN F
and 0 CCONJ F
the 0 DET F
Fahn-Tolosa-Marin B-OTHER NOUN T
( I-OTHER PUNCT F
FTM I-OTHER NOUN T
) I-OTHER PUNCT F
rating I-OTHER ADP F
scale 0 NOUN F
at 0 ADP F
baseline 0 NOUN F
and 0 CCONJ F
days 0 NOUN F
14 0 NUM F
and 0 CCONJ F
28 0 NUM F
, 0 PUNCT F
as 0 PUNCT F
well 0 PUNCT F
as 0 CCONJ F
the 0 DET F
Clinical B-OTHER ADJ T
Global I-OTHER ADJ T
Impression I-OTHER NOUN T
( I-OTHER PUNCT F
CGI-C I-OTHER NOUN T
) I-OTHER PUNCT F
scale 0 NOUN F
at 0 ADP F
day 0 NOUN F
28 0 NUM F
. 0 PUNCT F

At 0 ADP T
endpoint 0 NOUN F
, 0 PUNCT F
subjects 0 NOUN F
assigned 0 VERB F
to 0 ADP F
ZNS 0 NOUN T
were 0 VERB F
taking 0 CCONJ F
a 0 DET F
mean 0 NOUN F
dosage 0 NOUN F
of 0 ADP F
160 0 NUM F
+/- 0 SYM F
50 0 NUM F
mg/day 0 NOUN F
. 0 PUNCT F

There 0 PUNCT T
were 0 VERB F
no 0 DET F
significant 0 ADJ F
improvements 0 NOUN F
in 0 ADP F
the 0 DET F
FTM B-OTHER NOUN T
total 0 ADJ F
score 0 NOUN F
or B-OTHER CCONJ F
its B-OTHER ADJ F
subsections I-OTHER NOUN F
. 0 PUNCT F

Tremor B-PHYSICAL NOUN T
amplitude B-PHYSICAL ADJ F
as 0 PUNCT F
assessed 0 VERB F
by 0 ADP F
accelerometry 0 NOUN F
significantly 0 ADV F
improved 0 VERB F
in 0 ADP F
the 0 DET F
ZNS 0 NOUN T
group 0 NOUN F
compared 0 VERB F
to 0 ADP F
the 0 DET F
placebo 0 NOUN F
group 0 NOUN F
at 0 ADP F
endpoint 0 NOUN F
relative 0 ADJ F
to 0 ADP F
baseline 0 NOUN F
( 0 PUNCT F
-0.50 0 PUNCT F
+/- 0 SYM F
0.72 0 NUM F
vs. 0 CCONJ F
0.30 0 NUM F
+/- 0 SYM F
0.79 0 NUM F
m/s 0 NOUN F
( 0 PUNCT F
2 0 NUM F
) 0 PUNCT F
; 0 PUNCT F
P 0 NOUN T
= 0 SYM F
0.03 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

On 0 ADP T
the 0 DET F
CGI-C 0 NOUN T
, 0 PUNCT F
60 0 NUM F
% 0 SYM F
( 0 PUNCT F
n 0 NOUN F
= 0 SYM F
6 0 NUM F
) 0 PUNCT F
of 0 ADP F
patients 0 NOUN F
in 0 ADP F
the 0 DET F
ZNS 0 NOUN T
group 0 NOUN F
felt 0 PUNCT F
that 0 CCONJ F
their 0 PUNCT F
tremor B-PHYSICAL NOUN F
was 0 VERB F
unchanged 0 VERB F
, 0 PUNCT F
while 0 ADP F
the 0 DET F
remaining 0 VERB F
patients 0 NOUN F
felt 0 PUNCT F
that 0 CCONJ F
their 0 PUNCT F
tremor B-PHYSICAL NOUN F
was 0 VERB F
minimally 0 ADV F
improved 0 VERB F
. 0 PUNCT F

Thirty 0 NUM T
percent 0 NOUN F
( 0 PUNCT F
n 0 NOUN F
= 0 SYM F
3 0 NUM F
) 0 PUNCT F
of 0 ADP F
patients 0 NOUN F
taking 0 ADJ F
ZNS 0 NOUN T
discontinued 0 VERB F
the 0 DET F
study 0 ADP F
due 0 PUNCT F
to 0 ADP F
side 0 NOUN F
effects 0 NOUN F
( 0 PUNCT F
fatigue B-ADVERSE-EFFECTS NOUN F
, 0 PUNCT F
headache B-ADVERSE-EFFECTS NOUN F
, 0 PUNCT F
paresthesias B-ADVERSE-EFFECTS ADJ F
) 0 PUNCT F
while 0 ADP F
taking 0 ADP F
100 0 NUM F
mg 0 NOUN F
per 0 ADP F
day 0 NOUN F
. 0 PUNCT F

ZNS 0 NOUN T
did 0 PUNCT F
not 0 ADV F
provide 0 VERB F
significant 0 ADJ F
improvements 0 NOUN F
in 0 ADP F
clinical B-OTHER ADJ F
rating B-OTHER ADJ F
scales I-OTHER NOUN F
at 0 ADP F
study 0 NOUN F
endpoint 0 NOUN F
compared 0 VERB F
to 0 ADP F
placebo 0 NOUN F
and 0 CCONJ F
was 0 VERB F
only 0 ADV F
modestly 0 VERB F
well 0 PUNCT F

A 0 DET T
randomized 0 VERB F
, 0 PUNCT F
prospective 0 ADJ F
trial 0 NOUN F
of 0 ADP F
adjuvant 0 NOUN F
chemotherapy 0 NOUN F
in 0 ADP F
adults 0 NOUN F
with 0 ADP F
soft 0 ADJ F
tissue 0 NOUN F
sarcomas 0 NOUN F
of 0 ADP F
the 0 DET F
head 0 NOUN F
and 0 CCONJ F
neck 0 NOUN F
, 0 PUNCT F
breast 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
trunk 0 NOUN F
. 0 PUNCT F

Since 0 ADP T
1977 0 NUM F
, 0 PUNCT F
31 0 NUM F
patients 0 NOUN F
were 0 VERB F
entered 0 VERB F
in 0 ADP F
a 0 DET F
randomized 0 VERB F
, 0 PUNCT F
prospective 0 ADJ F
study 0 NOUN F
testing 0 VERB F
the 0 DET F
efficacy 0 NOUN F
of 0 ADP F
adjuvant 0 NOUN F
chemotherapy 0 NOUN F
after 0 ADP F
aggressive 0 ADJ F
local 0 ADJ F
treatment 0 NOUN F
of 0 ADP F
high-grade 0 NOUN F
sarcomas 0 NOUN F
of 0 ADP F
the 0 DET F
head 0 NOUN F
, 0 PUNCT F
neck 0 NOUN F
, 0 PUNCT F
breast 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
trunk 0 NOUN F
( 0 PUNCT F
excluding 0 CCONJ F
retroperitoneal 0 ADJ F
sarcomas 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

All 0 DET T
patients 0 NOUN F
had 0 PUNCT F
complete 0 ADJ F
resection 0 NOUN F
of 0 ADP F
gross 0 ADJ F
tumor 0 NOUN F
and 0 CCONJ F
underwent 0 PROPN F
postoperative 0 ADJ F
radiotherapy 0 NOUN F
( 0 PUNCT F
6000-6300 0 NUM F
rads 0 NOUN F
over 0 ADP F
7-8 0 VERB F
weeks 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

Seventeen 0 PUNCT T
patients 0 NOUN F
received 0 ADP F
adjuvant 0 NOUN F
chemotherapy 0 NOUN F
consisting 0 VERB F
of 0 ADP F
doxorubicin 0 NOUN F
( 0 PUNCT F
less 0 ADV F
than 0 PUNCT F
or 0 CCONJ F
equal 0 ADJ F
to 0 ADP F
550 0 NUM F
mg/m2 0 ADV F
) 0 PUNCT F
, 0 PUNCT F
cyclophosphamide 0 NOUN F
( 0 PUNCT F
less 0 ADV F
than 0 PUNCT F
or 0 CCONJ F
equal 0 ADJ F
to 0 ADP F
5500 0 NUM F
mg/m2 0 ADV F
) 0 PUNCT F
, 0 PUNCT F
and 0 CCONJ F
methotrexate 0 NOUN F
( 0 PUNCT F
less 0 ADV F
than 0 PUNCT F
or 0 CCONJ F
equal 0 ADJ F
to 0 ADP F
1000 0 NUM F
mg/kg 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

Three-year 0 PUNCT T
actuarial B-MORTALITY ADJ F
disease-free I-MORTALITY ADJ F
survival I-MORTALITY NOUN F
in 0 ADP F
the 0 DET F
chemotherapy 0 NOUN F
arm 0 ADP F
was 0 VERB F
77 0 NUM F
% 0 SYM F
, 0 PUNCT F
compared 0 VERB F
to 0 ADP F
49 0 NUM F
% 0 SYM F
in 0 ADP F
the 0 DET F
no-chemotherapy 0 NOUN F
arm 0 NOUN F
( 0 PUNCT F
P 0 NOUN T
= 0 SYM F
0.075 0 PUNCT F
) 0 PUNCT F
. 0 PUNCT F

Three-year 0 PUNCT T
overall B-MORTALITY ADJ F
actuarial I-MORTALITY ADJ F
survivals I-MORTALITY NOUN F
in 0 ADP F
the 0 DET F
two 0 NUM F
treatment 0 NOUN F
arms 0 NOUN F
, 0 PUNCT F
however 0 ADV F
, 0 PUNCT F
were 0 VERB F
68 0 NUM F
% 0 SYM F
and 0 CCONJ F
58 0 NUM F
% 0 SYM F
, 0 PUNCT F
respectively 0 ADV F
( 0 PUNCT F
P 0 NOUN T
= 0 SYM F
0.38 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Considering 0 ADV T
only 0 ADP F
patients 0 NOUN F
with 0 ADP F
tumors 0 NOUN F
of 0 ADP F
the 0 DET F
trunk 0 NOUN F
( 0 PUNCT F
22 0 NUM F
patients 0 NOUN F
) 0 PUNCT F
, 0 PUNCT F
3-year 0 NOUN F
actuarial 0 ADJ F
disease-free 0 ADJ F
survival 0 NOUN F
in 0 ADP F
the 0 DET F
chemotherapy 0 NOUN F
arm 0 ADP F
was 0 VERB F
92 0 NUM F
% 0 SYM F
, 0 PUNCT F
compared 0 VERB F
to 0 ADP F
47 0 NUM F
% 0 SYM F
in 0 ADP F
the 0 DET F
no-chemotherapy 0 NOUN F
arm 0 NOUN F
( 0 PUNCT F
P 0 NOUN T
= 0 SYM F
0.006 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Actuarial 0 ADJ T
3-year 0 NOUN F
overall 0 ADJ F
survival 0 NOUN F
in 0 ADP F
the 0 DET F
chemotherapy 0 NOUN F
arm 0 ADP F
was 0 VERB F
82 0 NUM F
% 0 SYM F
, 0 PUNCT F
compared 0 VERB F
to 0 ADP F
61 0 NUM F
% 0 SYM F
in 0 ADP F
the 0 DET F
no-chemotherapy 0 NOUN F
arm 0 NOUN F
( 0 PUNCT F
P 0 NOUN T
= 0 SYM F
0.18 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

An 0 DET T
additional 0 ADJ F
26 0 NUM F
patients 0 NOUN F
were 0 VERB F
treated 0 VERB F
in 0 ADP F
an 0 DET F
identical 0 ADJ F
fashion 0 NOUN F
, 0 PUNCT F
but 0 CCONJ F
were 0 VERB F
not 0 ADV F
part 0 NOUN F
of 0 ADP F
the 0 DET F
randomized 0 VERB F
trial 0 NOUN F
because 0 PUNCT F
of 0 ADP F
contraindications 0 NOUN F
to 0 ADP F
chemotherapy 0 NOUN F
, 0 PUNCT F
refusal 0 ADJ F
to 0 PART F
enter 0 NOUN F
the 0 DET F
randomized 0 VERB F
trial 0 NOUN F
, 0 PUNCT F
or 0 CCONJ F
because 0 PUNCT F
they 0 ADP F
were 0 VERB F
treated 0 VERB F
before 0 ADP F
1977 0 NUM F
in 0 ADP F
a 0 DET F
trial 0 NOUN F
in 0 ADP F
which 0 ADP F
all 0 DET F
patients 0 NOUN F
received 0 VERB F
chemotherapy 0 NOUN F
. 0 PUNCT F

Considering 0 ADJ T
the 0 DET F
entire 0 ADJ F
group 0 NOUN F
of 0 ADP F
57 0 NUM F
patients 0 NOUN F
, 0 PUNCT F
follow-up 0 NOUN F
ranged 0 VERB F
from 0 ADP F
10 0 NUM F
to 0 ADP F
86 0 NUM F
months 0 NOUN F
( 0 PUNCT F
median 0 ADJ F
, 0 PUNCT F
35 0 NUM F
months 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

Local B-OTHER ADJ T
control I-OTHER NOUN F
was 0 VERB F
achieved 0 VERB F
in 0 ADP F
46 0 NUM F
patients 0 NOUN F
( 0 PUNCT F
81 0 NUM F
% 0 SYM F
) 0 PUNCT F
; 0 PUNCT F
3-year 0 NOUN F
actuarial B-MORTALITY ADJ F
disease-free I-MORTALITY ADJ F
and I-MORTALITY CCONJ F
overall I-MORTALITY ADJ F
survivals I-MORTALITY NOUN F
were 0 VERB F
67 0 NUM F
% 0 SYM F
and 0 CCONJ F
77 0 NUM F
% 0 SYM F
, 0 PUNCT F
respectively 0 ADV F
. 0 PUNCT F

A 0 DET T
tendency 0 NOUN F
toward 0 ADP F
improved 0 CCONJ F
disease-free B-MORTALITY ADJ F
survival I-MORTALITY NOUN F
was 0 VERB F
apparent 0 ADJ F
among 0 ADP F
patients 0 NOUN F
treated 0 VERB F
with 0 ADP F
chemotherapy 0 NOUN F
( 0 PUNCT F
P 0 NOUN T
= 0 SYM F
0.018 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
but 0 CCONJ F
there 0 PUNCT F
was 0 VERB F
no 0 DET F
statistically 0 ADV F
significant 0 ADJ F
improvement 0 NOUN F
in 0 ADP F
overall B-MORTALITY PUNCT F
actuarial I-MORTALITY ADJ F
survival I-MORTALITY NOUN F
( 0 PUNCT F
P 0 NOUN T
= 0 SYM F
0.46 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
subgroup 0 NOUN F
of 0 ADP F
patients 0 NOUN F
with 0 ADP F
sarcomas 0 NOUN F
of 0 ADP F
the 0 DET F
trunk 0 NOUN F
( 0 PUNCT F
39 0 NUM F
patients 0 NOUN F
) 0 PUNCT F
demonstrated 0 VERB F
the 0 DET F
greatest 0 PUNCT F
benefit 0 CCONJ F
from 0 ADP F
chemotherapy 0 NOUN F
, 0 PUNCT F
with 0 ADP F
regard 0 NOUN F
to 0 ADP F
disease-free B-MORTALITY ADJ F
survival I-MORTALITY NOUN F
( 0 PUNCT F
P 0 NOUN T
less 0 ADV F
than 0 PUNCT F
or 0 CCONJ F
equal 0 ADJ F
to 0 ADP F
0.001 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
most 0 VERB F
significant 0 ADJ F
toxicity B-PHYSICAL NOUN F
associated 0 VERB F
with 0 ADP F
chemotherapy 0 NOUN F
was 0 VERB F
doxorubicin-induced B-ADVERSE-EFFECTS PUNCT F
cardiomyopathy I-ADVERSE-EFFECTS NOUN F
, 0 PUNCT F
which 0 ADP F
resulted 0 VERB F
in 0 ADP F
clinically 0 ADV F
apparent 0 ADJ F
congestive B-PHYSICAL ADJ F
heart I-PHYSICAL NOUN F
failure I-PHYSICAL NOUN F
in 0 ADP F
five 0 NUM F
patients 0 NOUN F
. 0 PUNCT F

Thus 0 ADV T
, 0 PUNCT F
the 0 DET F
use 0 NOUN F
of 0 ADP F
chemotherapy 0 NOUN F
when 0 ADP F
combined 0 PUNCT F
with 0 ADP F
aggressive 0 ADJ F
local 0 ADJ F
measures 0 NOUN F
appears 0 NOUN F
to 0 PART F
improve 0 PUNCT F
disease-free B-MORTALITY ADJ F
survival I-MORTALITY NOUN F
, 0 PUNCT F
but 0 CCONJ F
additional 0 ADJ F
patients 0 NOUN F
and 0 CCONJ F
longer 0 PUNCT F
follow-up 0 NOUN F
are 0 VERB F
necessary 0 ADJ F
to 0 PART F
determine 0 NOUN F
if 0 PUNCT F
improved 0 VERB F
overall B-MORTALITY ADJ F
survival I-MORTALITY NOUN F
will 0 ADV F
result 0 PUNCT F
. 0 PUNCT F

Changing 0 PUNCT T
sodium 0 NOUN F
intake 0 NOUN F
in 0 ADP F
children 0 NOUN F
. 0 PUNCT F

The 0 DET T
Minneapolis 0 NOUN T
Children 0 NOUN T
's 0 PUNCT F
Blood 0 NOUN T
Pressure 0 NOUN T
Study 0 NOUN T
. 0 PUNCT F

To 0 PART T
assess 0 NOUN F
the 0 DET F
effects 0 NOUN F
of 0 ADP F
modifying 0 VERB F
dietary 0 ADJ F
sodium 0 NOUN F
intake 0 NOUN F
, 0 PUNCT F
80 0 NUM F
school 0 NOUN F
children 0 NOUN F
with 0 ADP F
blood 0 NOUN F
pressures 0 NOUN F
above 0 CCONJ F
the 0 DET F
95th 0 ADJ F
percentile 0 NOUN F
for 0 ADP F
age 0 NOUN F
and 0 CCONJ F
sex 0 NOUN F
but 0 CCONJ F
below 0 ADP F
130/90 0 ADJ F
mm 0 NOUN F
Hg 0 NOUN T
at 0 ADP F
school 0 NOUN F
screening 0 PUNCT F
were 0 VERB F
randomized 0 ADP F
to 0 ADP F
a 0 DET F
family 0 NOUN F
intervention 0 NOUN F
program 0 NOUN F
or 0 CCONJ F
a 0 DET F
control 0 NOUN F
group 0 NOUN F
. 0 PUNCT F

Twenty 0 VERB T
children 0 NOUN F
aged 0 PROPN F
6 0 NUM F
to 0 ADP F
9 0 NUM F
years 0 NOUN F
and 0 CCONJ F
their 0 ADP F
families 0 NOUN F
began 0 VERB F
a 0 DET F
program 0 NOUN F
to 0 DET F
modify 0 ADP F
the 0 DET F
family 0 NOUN F
diet 0 NOUN F
toward 0 ADP F
a 0 DET F
goal 0 NOUN F
of 0 ADP F
70 0 NUM F
mEq 0 NOUN F
sodium 0 NOUN F
per 0 ADP F
person 0 NOUN F
per 0 ADP F
day 0 NOUN F
. 0 PUNCT F

Adherence B-MENTAL NOUN T
was 0 VERB F
assessed 0 VERB F
by 0 ADP F
3-day B-OTHER NOUN F
food I-OTHER NOUN F
records I-OTHER NOUN F
and 0 CCONJ F
urine B-OTHER NOUN F
collections I-OTHER NOUN F
in I-OTHER ADP F
children I-OTHER NOUN F
and 0 CCONJ F
adults B-OTHER NOUN F
. 0 PUNCT F

The 0 DET T
sodium B-MENTAL NOUN F
intakes I-MENTAL NOUN F
and 0 CCONJ F
blood B-PHYSICAL NOUN F
pressures I-PHYSICAL NOUN F
of 0 ADP F
the 0 DET F
intervention 0 NOUN F
and 0 CCONJ F
control 0 NOUN F
group 0 NOUN F
were 0 VERB F
compared 0 VERB F
1 0 NUM F
year 0 NOUN F
after 0 ADP F
randomization 0 NOUN F
. 0 PUNCT F

Sodium B-MENTAL NOUN T
intake I-MENTAL NOUN F
was 0 VERB F
significantly 0 ADV F
lower 0 PUNCT F
in 0 ADP F
the 0 DET F
intervention 0 NOUN F
group 0 NOUN F
only 0 ADV F
in 0 ADP F
the 0 DET F
active 0 ADJ F
participants 0 NOUN F
as 0 CCONJ F
compared 0 VERB F
to 0 PUNCT F
dropouts 0 PUNCT F
and 0 CCONJ F
controls 0 NOUN F
( 0 PUNCT F
87 0 NUM F
vs 0 CCONJ F
130 0 NUM F
and 0 CCONJ F
133 0 ADP F
mmoles/24 0 PUNCT F
hr 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

There 0 PUNCT T
were 0 VERB F
no 0 DET F
significant 0 ADJ F
differences 0 NOUN F
between 0 ADP F
the 0 DET F
groups 0 NOUN F
in 0 ADP F
height B-PHYSICAL NOUN F
, 0 PUNCT F
weight 0 NOUN F
, 0 PUNCT F
or 0 CCONJ F
blood B-PHYSICAL NOUN F
pressure I-PHYSICAL NOUN F
. 0 PUNCT F

Blood 0 NOUN T
pressure 0 NOUN F
control 0 NOUN F
during 0 ADP F
weight 0 NOUN F
reduction 0 NOUN F
in 0 ADP F
obese 0 PUNCT F
hypertensive 0 ADJ F
men 0 NOUN F
: 0 PUNCT F
separate 0 ADJ F
effects 0 NOUN F
of 0 ADP F
sodium 0 NOUN F
and 0 CCONJ F
energy 0 NOUN F
restriction 0 NOUN F
. 0 PUNCT F

The 0 DET T
separate 0 ADJ F
and 0 CCONJ F
combined 0 VERB F
effects 0 NOUN F
of 0 ADP F
dietary 0 ADJ F
energy 0 NOUN F
and 0 CCONJ F
sodium 0 NOUN F
restriction 0 NOUN F
on 0 ADP F
regulation 0 NOUN F
of 0 ADP F
blood B-PHYSICAL NOUN F
pressure I-PHYSICAL NOUN F
were 0 VERB F
investigated 0 VERB F
in 0 ADP F
30 0 NUM F
middle 0 ADJ F
aged 0 PUNCT F
obese 0 PUNCT F
men 0 NOUN F
with 0 ADP F
essential 0 ADJ F
hypertension 0 NOUN F
attending 0 VERB F
the 0 DET F
outpatient 0 ADJ F
department 0 NOUN F
. 0 PUNCT F

In 0 ADP T
group 0 NOUN F
1 0 NUM F
( 0 PUNCT F
n 0 NOUN F
= 0 SYM F
15 0 NUM F
) 0 PUNCT F
a 0 DET F
basal 0 ADJ F
period 0 NOUN F
with 0 ADP F
no 0 DET F
dietary 0 ADJ F
restriction 0 NOUN F
was 0 VERB F
followed 0 VERB F
by 0 ADP F
a 0 DET F
period 0 NOUN F
taking 0 PUNCT F
an 0 DET F
energy 0 NOUN F
reduced 0 VERB F
diet 0 NOUN F
( 0 PUNCT F
5.1 0 NUM F
MJ 0 NOUN T
; 0 PUNCT F
1230 0 NUM F
kcal 0 NOUN F
) 0 PUNCT F
, 0 PUNCT F
the 0 DET F
sodium 0 NOUN F
intake 0 NOUN F
being 0 VERB F
supplemented 0 PUNCT F
and 0 CCONJ F
hence 0 ADV F
unchanged 0 PROPN F
( 0 PUNCT F
1 0 NUM F
: 0 PUNCT F
ErSn 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

In 0 ADP T
group 0 NOUN F
2 0 NUM F
( 0 PUNCT F
n 0 NOUN F
= 0 SYM F
15 0 NUM F
) 0 PUNCT F
the 0 DET F
basal 0 ADJ F
period 0 NOUN F
preceded 0 VERB F
a 0 DET F
control 0 NOUN F
period 0 NOUN F
with 0 ADP F
no 0 DET F
intervention 0 NOUN F
, 0 PUNCT F
which 0 ADP F
was 0 VERB F
followed 0 VERB F
by 0 ADP F
taking 0 ADJ F
a 0 DET F
diet 0 NOUN F
restricted 0 PUNCT F
in 0 ADP F
energy 0 NOUN F
( 0 PUNCT F
5.1 0 NUM F
MJ 0 NOUN T
; 0 PUNCT F
1220 0 NUM F
kcal 0 NOUN F
) 0 PUNCT F
and 0 CCONJ F
sodium 0 NOUN F
( 0 PUNCT F
2 0 NUM F
: 0 PUNCT F
ErSr 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

During 0 ADP T
period 0 NOUN F
1 0 NUM F
: 0 PUNCT F
ErSn 0 NOUN T
there 0 PUNCT F
were 0 ADP F
reductions 0 NOUN F
in 0 ADP F
heart B-PHYSICAL NOUN F
rate I-PHYSICAL NOUN F
and 0 CCONJ F
urinary B-PHYSICAL ADJ F
noradrenaline I-PHYSICAL NOUN F
output I-PHYSICAL NOUN F
but 0 CCONJ F
not 0 ADV F
in 0 ADP F
systolic B-PHYSICAL ADJ F
or I-PHYSICAL CCONJ F
diastolic I-PHYSICAL ADJ F
blood I-PHYSICAL NOUN F
pressure I-PHYSICAL NOUN F
. 0 PUNCT F

Body B-PHYSICAL NOUN T
weight I-PHYSICAL NOUN F
decreased 0 PUNCT F
by 0 ADP F
4.9-11.7 0 NUM F
kg 0 NOUN F
and 0 CCONJ F
urinary B-PHYSICAL ADJ F
sodium I-PHYSICAL NOUN F
excretion I-PHYSICAL NOUN F
did 0 PUNCT F
not 0 ADV F
change 0 NUM F
. 0 PUNCT F

In 0 ADP T
period 0 NOUN F
2 0 NUM F
: 0 PUNCT F
ErSr 0 NOUN T
urinary B-PHYSICAL ADJ F
sodium I-PHYSICAL NOUN F
output I-PHYSICAL NOUN F
was 0 VERB F
reduced 0 VERB F
by 0 ADP F
81.4 0 NUM F
( 0 PUNCT F
SEM 0 NOUN T
17.8 0 NUM F
) 0 PUNCT F
mmol 0 NOUN F
( 0 PUNCT F
mEq 0 NOUN F
) 0 PUNCT F
/24 0 PUNCT F
h 0 NOUN F
and 0 CCONJ F
there 0 PUNCT F
was 0 VERB F
a 0 DET F
weight 0 NOUN F
loss B-PHYSICAL NOUN F
of 0 ADP F
8.2 0 NUM F
( 0 PUNCT F
SEM 0 NOUN T
0.7 0 NUM F
) 0 PUNCT F
kg 0 NOUN F
. 0 PUNCT F

Systolic B-PHYSICAL ADJ T
and I-PHYSICAL CCONJ F
diastolic I-PHYSICAL ADJ F
blood I-PHYSICAL NOUN F
pressures I-PHYSICAL NOUN F
fell 0 VERB F
significantly 0 ADV F
, 0 PUNCT F
as 0 PUNCT F
did 0 PUNCT F
the 0 DET F
heart B-PHYSICAL NOUN F
rate I-PHYSICAL NOUN F
and 0 CCONJ F
urinary B-PHYSICAL ADJ F
noradrenaline I-PHYSICAL NOUN F
excretion I-PHYSICAL NOUN F
. 0 PUNCT F

These 0 DET T
results 0 NOUN F
show 0 VERB F
that 0 ADP F
in 0 ADP F
hypertensive 0 ADJ F
obese 0 DET F
men 0 NOUN F
a 0 DET F
moderate 0 ADJ F
weight 0 NOUN F
reducing 0 PUNCT F
diet 0 NOUN F
decreases 0 NOUN F
indices 0 NOUN F
of 0 ADP F
sympathetic B-PHYSICAL ADJ F
nervous I-PHYSICAL ADJ F
system I-PHYSICAL NOUN F
activity I-PHYSICAL NOUN F
. 0 PUNCT F

Reduction 0 NOUN T
of 0 ADP F
blood B-PHYSICAL NOUN F
pressure I-PHYSICAL NOUN F
to 0 ADP F
the 0 DET F
normotensive 0 ADJ F
range 0 NOUN F
was 0 VERB F
observed 0 VERB F
only 0 ADV F
when 0 ADP F
there 0 PUNCT F
was 0 VERB F
a 0 DET F
concomitant 0 ADJ F
restriction 0 NOUN F
of 0 ADP F
sodium 0 NOUN F
intake 0 NOUN F
. 0 PUNCT F

Effects 0 NOUN T
of 0 ADP F
irrigation 0 NOUN F
fluid 0 NOUN F
temperature 0 NOUN F
on 0 ADP F
core 0 NOUN F
body 0 NOUN F
temperature 0 NOUN F
during 0 ADP F
transurethral 0 ADJ F
resection 0 NOUN F
of 0 ADP F
the 0 DET F
prostate 0 NOUN F
. 0 PUNCT F

OBJECTIVES 0 ADP T
To 0 PROPN T
determine 0 NOUN F
the 0 DET F
effect 0 NOUN F
irrigation 0 NOUN F
fluid 0 NOUN F
temperature 0 NOUN F
has 0 PUNCT F
on 0 ADV F
core 0 NOUN F
body 0 NOUN F
temperature 0 NOUN F
changes 0 NOUN F
in 0 ADP F
patients 0 NOUN F
undergoing 0 VERB F
transurethral 0 ADJ F
resection 0 NOUN F
of 0 ADP F
the 0 DET F
prostate 0 NOUN F
( 0 PUNCT F
TURP 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

METHODS 0 NOUN T
Fifty-six 0 ADJ T
male 0 NOUN F
patients 0 NOUN F
( 0 PUNCT F
mean 0 NOUN F
age 0 NOUN F
71.2 0 NUM F
+/- 0 SYM F
8.2 0 NUM F
years 0 NOUN F
) 0 PUNCT F
scheduled 0 VERB F
for 0 ADP F
TURP 0 NOUN T
were 0 VERB F
enrolled 0 VERB F
in 0 ADP F
the 0 DET F
study 0 NOUN F
. 0 PUNCT F

Patients 0 NOUN T
were 0 VERB F
randomized 0 VERB F
to 0 ADP F
one 0 PUNCT F
of 0 ADP F
two 0 NUM F
groups 0 NOUN F
. 0 PUNCT F

Group 0 NOUN T
1 0 NUM F
consisted 0 PRON F
of 0 ADP F
27 0 NUM F
patients 0 NOUN F
who 0 ADP F
received 0 VERB F
room 0 NOUN F
temperature 0 NOUN F
irrigation 0 NOUN F
fluid 0 NOUN F
( 0 PUNCT F
70 0 NUM F
degrees 0 NOUN F
F 0 NOUN T
) 0 PUNCT F
throughout 0 ADP F
TURP 0 NOUN T
; 0 PUNCT F
group 0 NOUN F
2 0 NUM F
consisted 0 VERB F
of 0 ADP F
29 0 NUM F
patients 0 NOUN F
whose 0 DET F
procedure 0 NOUN F
was 0 VERB F
performed 0 VERB F
with 0 ADP F
warmed 0 ADJ F
irrigation 0 NOUN F
fluid 0 NOUN F
( 0 PUNCT F
91.5 0 NUM F
degrees 0 NOUN F
F 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
irrigation 0 NOUN F
fluid 0 NOUN F
used 0 VERB F
for 0 ADP F
both 0 CCONJ F
groups 0 NOUN F
was 0 VERB F
glycine 0 NOUN F
. 0 PUNCT F

The 0 DET T
baseline 0 NOUN F
temperature 0 NOUN F
, 0 PUNCT F
final 0 ADJ F
temperature 0 NOUN F
, 0 PUNCT F
total 0 ADJ F
time 0 NOUN F
in 0 ADP F
the 0 DET F
operating 0 VERB F
room 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
amount 0 NOUN F
of 0 ADP F
irrigation 0 NOUN F
fluid 0 NOUN F
used 0 VERB F
during 0 ADP F
the 0 DET F
procedure 0 NOUN F
were 0 VERB F
recorded 0 VERB F
for 0 ADP F
each 0 DET F
patient 0 NOUN F
. 0 PUNCT F

RESULTS 0 PUNCT T
No 0 DET T
significant 0 ADJ F
difference 0 NOUN F
in 0 ADP F
the 0 DET F
average 0 ADJ F
time B-OTHER NOUN F
spent I-OTHER NUM F
in I-OTHER ADP F
the I-OTHER DET F
operating I-OTHER VERB F
room I-OTHER NOUN F
or 0 CCONJ F
in 0 ADP F
the 0 DET F
total 0 ADJ F
irrigation B-OTHER NOUN F
fluid I-OTHER NOUN F
used 0 VERB F
between 0 ADP F
the 0 DET F
two 0 NUM F
groups 0 NOUN F
was 0 VERB F
observed 0 VERB F
. 0 PUNCT F

Of 0 ADP T
the 0 DET F
27 0 NUM F
patients 0 NOUN F
who 0 ADP F
received 0 VERB F
room B-PHYSICAL NOUN F
temperature I-PHYSICAL NOUN F
irrigation I-PHYSICAL NOUN F
fluid I-PHYSICAL NOUN F
, 0 PUNCT F
15 0 NUM F
( 0 PUNCT F
55.6 0 NUM F
% 0 SYM F
) 0 PUNCT F
had 0 ADP F
a 0 DET F
decrease 0 NOUN F
in 0 ADP F
body B-PHYSICAL NOUN F
temperature I-PHYSICAL NOUN F
. 0 PUNCT F

A 0 DET T
decrease 0 NOUN F
in 0 ADP F
temperature B-PHYSICAL NOUN F
was 0 VERB F
observed 0 VERB F
in 0 ADP F
21 0 NUM F
( 0 PUNCT F
72.4 0 NUM F
% 0 SYM F
) 0 PUNCT F
of 0 ADP F
the 0 DET F
29 0 NUM F
patients 0 NOUN F
who 0 ADP F
received 0 VERB F
warm 0 ADP F
irrigation B-OTHER NOUN F
fluid I-OTHER NOUN F
. 0 PUNCT F

Groups 0 NOUN T
1 0 NUM F
and 0 CCONJ F
2 0 NUM F
had 0 PUNCT F
12 0 NUM F
( 0 PUNCT F
44.4 0 NUM F
% 0 SYM F
) 0 PUNCT F
of 0 ADP F
27 0 NUM F
and 0 CCONJ F
8 0 NUM F
( 0 PUNCT F
27.6 0 NUM F
% 0 SYM F
) 0 PUNCT F
of 0 ADP F
29 0 NUM F
patients 0 NOUN F
, 0 PUNCT F
respectively 0 ADV F
, 0 PUNCT F
who 0 PROPN F
demonstrated 0 VERB F
an 0 DET F
elevation 0 NOUN F
in 0 ADP F
their 0 PUNCT F
core B-PHYSICAL NOUN F
body I-PHYSICAL NOUN F
temperature I-PHYSICAL NOUN F
. 0 PUNCT F

CONCLUSIONS 0 NOUN T
The 0 DET T
results 0 NOUN F
of 0 ADP F
our 0 PUNCT F
study 0 NOUN F
suggest 0 VERB F
that 0 ADP F
irrigation 0 NOUN F
fluid 0 NOUN F
temperature 0 NOUN F
is 0 VERB F
not 0 ADV F
a 0 DET F
factor 0 NOUN F
responsible 0 ADJ F
for 0 ADP F
altering 0 VERB F
the 0 DET F
core 0 NOUN F
body B-PHYSICAL NOUN F
temperature I-PHYSICAL NOUN F
in 0 ADP F
patients 0 NOUN F
undergoing 0 VERB F
TURP 0 NOUN T
. 0 PUNCT F

The 0 DET T
effect 0 NOUN F
of 0 ADP F
case 0 NOUN F
management 0 NOUN F
on 0 ADP F
the 0 DET F
costs 0 NOUN F
of 0 ADP F
health B-OTHER NOUN F
care I-OTHER NOUN F
for 0 ADP F
enrollees 0 NOUN F
in 0 ADP F
Medicare 0 NOUN T
Plus 0 CCONJ T
Choice 0 NOUN T
plans 0 NOUN F
: 0 PUNCT F
a 0 DET F
randomized 0 VERB F
trial 0 NOUN F
. 0 PUNCT F

OBJECTIVE 0 NOUN T
To 0 PROPN T
measure 0 VERB F
the 0 DET F
effects 0 NOUN F
of 0 ADP F
case 0 NOUN F
management 0 NOUN F
on 0 ADP F
an 0 DET F
older 0 PUNCT F
population 0 NOUN F
's 0 PUNCT F
costs 0 NOUN F
of 0 ADP F
health B-OTHER NOUN F
care I-OTHER NOUN F
. 0 PUNCT F

DESIGN 0 NOUN T
A 0 PUNCT T
1-year 0 NOUN F
randomized 0 DET F
controlled 0 VERB F
trial 0 NOUN F
. 0 PUNCT F

SETTING 0 NUM T
Multiple 0 ADJ T
sites 0 NOUN F
of 0 ADP F
care 0 NOUN F
in 0 ADP F
San 0 ADJ T
Francisco 0 NOUN T
, 0 PUNCT F
California 0 PUNCT T
. 0 PUNCT F

PARTICIPANTS 0 ADP T
Patients 0 NOUN T
aged 0 PROPN F
65 0 NUM F
or 0 CCONJ F
older 0 PUNCT F
of 0 ADP F
primary 0 ADJ F
care 0 NOUN F
physicians 0 NOUN F
in 0 ADP F
a 0 DET F
large 0 ADJ F
provider 0 NOUN F
organization 0 NOUN F
bearing 0 SYM F
financial 0 ADJ F
risk 0 NOUN F
for 0 ADP F
their 0 PUNCT F
care 0 NOUN F
( 0 PUNCT F
n 0 NOUN F
= 0 SYM F
6409 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

INTERVENTION 0 NOUN T
Screening 0 PUNCT T
for 0 ADP F
high 0 ADJ F
risk 0 NOUN F
and 0 CCONJ F
provision 0 NOUN F
of 0 ADP F
social 0 ADJ F
work-based 0 VERB F
case 0 NOUN F
management 0 NOUN F
. 0 PUNCT F

OUTCOME 0 NOUN T
MEASURES 0 NOUN T
Volume B-OTHER NOUN T
and 0 CCONJ F
cost B-OTHER NOUN F
of I-OTHER ADP F
hospital I-OTHER NOUN F
, 0 PUNCT F
physician B-OTHER NOUN F
, 0 PUNCT F
case B-OTHER NOUN F
management I-OTHER NOUN F
, 0 PUNCT F
and 0 PUNCT F

Untreated 0 VERB T
silicone 0 NOUN F
breast 0 NOUN F
implant 0 VERB F
rupture 0 NOUN F
. 0 PUNCT F

Implant 0 NOUN T
rupture 0 NOUN F
is 0 ADP F
a 0 DET F
well-known 0 VERB F
complication 0 NOUN F
of 0 ADP F
breast 0 NOUN F
implant 0 VERB F
surgery 0 NOUN F
that 0 ADP F
can 0 PROPN F
pass 0 VERB F
unnoticed 0 PROPN F
by 0 ADP F
both 0 PUNCT F
patient 0 NOUN F
and 0 CCONJ F
physician 0 NOUN F
. 0 PUNCT F

To 0 ADP T
date 0 NOUN F
, 0 PUNCT F
no 0 DET F
prospective 0 ADJ F
study 0 NOUN F
has 0 PUNCT F
addressed 0 ADJ F
the 0 DET F
possible 0 ADJ F
health 0 NOUN F
implications 0 NOUN F
of 0 ADP F
silicone 0 NUM F
breast 0 NOUN F
implant 0 VERB F
rupture 0 NOUN F
. 0 PUNCT F

The 0 DET T
aim 0 NOUN F
of 0 ADP F
the 0 DET F
present 0 ADJ F
study 0 NOUN F
was 0 VERB F
to 0 PART F
evaluate 0 NOUN F
whether 0 ADP F
untreated 0 VERB F
ruptures 0 VERB F
are 0 VERB F
associated 0 VERB F
with 0 ADP F
changes 0 NOUN F
over 0 PUNCT F
time 0 NOUN F
in 0 ADP F
magnetic 0 ADJ F
resonance 0 NOUN F
imaging 0 PROPN F
findings 0 NOUN F
, 0 PUNCT F
serologic 0 ADJ F
markers 0 NOUN F
, 0 PUNCT F
or 0 CCONJ F
self-reported 0 VERB F
breast 0 NOUN F
symptoms 0 NOUN F
. 0 PUNCT F

A 0 DET T
baseline 0 NOUN F
magnetic 0 ADJ F
resonance 0 NOUN F
imaging 0 ADJ F
examination 0 NOUN F
was 0 VERB F
performed 0 VERB F
in 0 ADP F
1999 0 NUM F
on 0 ADP F
271 0 NUM F
women 0 NOUN F
who 0 PROPN F
were 0 VERB F
randomly 0 ADV F
chosen 0 ADP F
from 0 ADP F
a 0 DET F
larger 0 PUNCT F
cohort 0 PUNCT F
of 0 ADP F
women 0 NOUN F
having 0 VERB F
cosmetic 0 ADJ F
breast 0 NOUN F
implants 0 NOUN F
for 0 ADP F
a 0 DET F
median 0 ADJ F
period 0 NOUN F
of 0 ADP F
12 0 NUM F
years 0 NOUN F
( 0 PUNCT F
range 0 NOUN F
, 0 PUNCT F
3 0 NUM F
to 0 ADP F
25 0 NUM F
years 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

A 0 DET T
follow-up 0 NOUN F
magnetic 0 ADJ F
resonance 0 NOUN F
imaging 0 ADJ F
examination 0 NOUN F
was 0 VERB F
carried 0 VERB F
out 0 ADP F
in 0 ADP F
2001 0 NUM F
, 0 PUNCT F
excluding 0 VERB F
women 0 NOUN F
who 0 ADP F
underwent 0 PROPN F
explantation 0 NOUN F
in 0 ADP F
the 0 DET F
period 0 NOUN F
between 0 ADP F
the 0 DET F
two 0 NUM F
magnetic 0 ADJ F
resonance 0 NOUN F
imaging 0 ADJ F
examinations 0 NOUN F
( 0 PUNCT F
n 0 NOUN F
= 0 SYM F
44 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

On 0 ADP T
the 0 DET F
basis 0 NOUN F
of 0 ADP F
these 0 DET F
examinations 0 NOUN F
, 0 PUNCT F
the 0 DET F
authors 0 NOUN F
identified 0 ADJ F
64 0 ADP F
women 0 NOUN F
who 0 ADP F
had 0 PUNCT F
at 0 VERB F
least 0 ADV F
one 0 NUM F
ruptured 0 ADJ F
implant 0 NOUN F
at 0 ADP F
the 0 DET F
first 0 ADJ F
magnetic 0 ADJ F
resonance 0 NOUN F
imaging 0 PUNCT F
examination 0 NOUN F
and 0 CCONJ F
, 0 PUNCT F
for 0 ADP F
comparison 0 NOUN F
, 0 PUNCT F
all 0 DET F
women 0 NOUN F
who 0 ADP F
had 0 ADP F
intact 0 ADJ F
implants 0 NOUN F
at 0 ADP F
both 0 PUNCT F
examinations 0 NOUN F
( 0 PUNCT F
n 0 NOUN F
= 0 SYM F
98 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Magnetic 0 ADJ T
resonance 0 NOUN F
images 0 NOUN F
from 0 ADP F
the 0 DET F
two 0 NUM F
examinations 0 NOUN F
were 0 VERB F
compared 0 VERB F
and 0 CCONJ F
changes 0 NOUN F
in 0 ADP F
rupture 0 NOUN F
configuration 0 NOUN F
were 0 VERB F
evaluated 0 VERB F
. 0 PUNCT F

Comparisons 0 NOUN T
were 0 VERB F
also 0 ADV F
made 0 VERB F
for 0 ADP F
self-reported 0 VERB F
breast 0 NOUN F
symptoms 0 NOUN F
occurring 0 ADJ F
during 0 ADP F
the 0 DET F
study 0 ADV F
period 0 NOUN F
and 0 CCONJ F
for 0 ADP F
changes 0 NOUN F
in 0 ADP F
serum 0 NOUN F
values 0 NOUN F
of 0 ADP F
antinuclear 0 ADP F
antibodies 0 NOUN F
, 0 PUNCT F
rheumatoid 0 ADJ F
factor 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
cardiolipin 0 NOUN F
antibodies 0 NOUN F
immunoglobulin 0 NOUN F
G 0 NOUN T
and 0 CCONJ F
immunoglobulin 0 NOUN F
M. 0 NOUN T
The 0 DET T
majority 0 NOUN F
of 0 ADP F
the 0 DET F
women 0 NOUN F
with 0 ADP F
implant 0 NOUN F
rupture 0 NOUN F
had 0 PUNCT F
no 0 DET F
visible 0 PUNCT F
magnetic B-PHYSICAL ADJ F
resonance I-PHYSICAL NOUN F
imaging I-PHYSICAL ADP F
changes I-PHYSICAL NOUN F
of 0 ADP F
their 0 ADP F
ruptured 0 ADJ F
implants 0 NOUN F
. 0 PUNCT F

For 0 ADP T
11 0 NUM F
implants 0 NOUN F
( 0 PUNCT F
11 0 NUM F
percent 0 NOUN F
) 0 PUNCT F
in 0 ADP F
10 0 NUM F
women 0 NOUN F
, 0 PUNCT F
the 0 DET F
authors 0 NOUN F
observed 0 VERB F
progression 0 NOUN F
of 0 ADP F
silicone B-PHYSICAL PUNCT F
seepage I-PHYSICAL NOUN F
, 0 PUNCT F
either 0 PUNCT F
as 0 VERB F
a 0 DET F
conversion 0 NOUN F
from 0 ADP F
intracapsular 0 ADJ F
into 0 ADP F
extracapsular 0 ADP F
rupture 0 NOUN F
( 0 PUNCT F
n 0 NOUN F
= 0 SYM F
7 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
as 0 PUNCT F
progression 0 NOUN F
of 0 ADP F
extra-capsular 0 ADJ F
silicone 0 NOUN F
( 0 PUNCT F
n 0 NOUN F
= 0 SYM F
3 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
or 0 CCONJ F
as 0 VERB F
increasing 0 ADJ F
herniation 0 NOUN F
of 0 ADP F
the 0 DET F
silicone 0 NUM F
within 0 ADP F
the 0 DET F
fibrous 0 ADJ F
capsule 0 NOUN F
( 0 PUNCT F
n 0 NOUN F
= 0 SYM F
1 0 NUM F
) 0 PUNCT F
; 0 PUNCT F
however 0 ADV F
, 0 PUNCT F
in 0 ADP F
most 0 DET F
cases 0 NOUN F
, 0 PUNCT F
these 0 DET F
changes 0 NOUN F
were 0 VERB F
minor 0 ADJ F
. 0 PUNCT F

Some 0 DET T
changes 0 NOUN F
could 0 VERB F
be 0 VERB F
ascribed 0 VERB F
to 0 ADP F
trauma 0 NOUN F
, 0 PUNCT F
but 0 CCONJ F
others 0 NOUN F
seemed 0 VERB F
spontaneous 0 ADJ F
. 0 PUNCT F

There 0 PUNCT T
was 0 VERB F
no 0 DET F
increase 0 NOUN F
in 0 ADP F
levels B-PHYSICAL NOUN F
of I-PHYSICAL ADP F
autoantibodies I-PHYSICAL NOUN F
during 0 ADP F
the 0 DET F
study 0 ADV F
period 0 NOUN F
in 0 ADP F
either 0 PUNCT F
study 0 ADV F
group 0 NOUN F
. 0 PUNCT F

Women 0 NOUN T
with 0 ADP F
untreated 0 VERB F
implant 0 NOUN F
ruptures 0 NOUN F
reported 0 VERB F
a 0 DET F
significant 0 ADJ F
increase 0 NOUN F
in 0 ADP F
nonspecific B-PHYSICAL ADJ F
breast I-PHYSICAL NOUN F
changes I-PHYSICAL NOUN F
( 0 PUNCT F
odds 0 NOUN F
ratio 0 NOUN F
, 0 PUNCT F
2.1 0 NUM F
; 0 PUNCT F
95 0 NUM F
percent 0 NOUN F
confidence 0 NOUN F
interval 0 NOUN F
, 0 PUNCT F
1.2 0 NUM F
to 0 ADP F
3.8 0 NUM F
) 0 PUNCT F
compared 0 VERB F
with 0 ADP F
women 0 NOUN F
without 0 ADP F
ruptures 0 NOUN F
. 0 PUNCT F

On 0 ADP T
the 0 DET F
basis 0 NOUN F
of 0 ADP F
this 0 DET F
first 0 ADJ F
study 0 NOUN F
of 0 ADP F
women 0 NOUN F
with 0 ADP F
untreated 0 VERB F
silicone 0 NOUN F
breast 0 NOUN F
implant 0 VERB F
rupture 0 NOUN F
, 0 PUNCT F
the 0 DET F
authors 0 NOUN F
conclude 0 VERB F
that 0 ADP F
implant 0 VERB F
rupture 0 NOUN F
is 0 ADP F
a 0 DET F
relatively 0 ADV F
harmless 0 PUNCT F
condition 0 NOUN F
, 0 PUNCT F
which 0 ADP F
only 0 ADV F
rarely 0 ADV F
progresses 0 PUNCT F
and 0 CCONJ F
gives 0 NOUN F
rise 0 NOUN F
to 0 ADP F
notable 0 ADJ F
symptoms 0 NOUN F
. 0 PUNCT F

Even 0 ADV T
so 0 ADP F
, 0 PUNCT F
because 0 PUNCT F
of 0 ADP F
a 0 DET F
small 0 ADJ F
risk 0 NOUN F
of 0 ADP F
silicone 0 NUM F
spread 0 NOUN F
, 0 PUNCT F
the 0 DET F
authors 0 NOUN F
suggest 0 VERB F
that 0 ADP F
women 0 NOUN F
with 0 ADP F
implant 0 VERB F
ruptures 0 NOUN F
be 0 PUNCT F
followed 0 ADV F
clinically 0 ADV F
, 0 PUNCT F
if 0 CCONJ F
not 0 ADV F
operated 0 VERB F
on 0 ADP F
. 0 PUNCT F

Because 0 PUNCT T
implant 0 ADP F
ruptures 0 NOUN F
often 0 ADV F
occur 0 VERB F
asymptomatically 0 ADV F
, 0 PUNCT F
any 0 DET F
woman 0 NOUN F
with 0 ADP F
silicone 0 PUNCT F
implants 0 NOUN F
, 0 PUNCT F
regardless 0 VERB F
of 0 ADP F
rupture 0 NOUN F
status 0 NOUN F
, 0 PUNCT F
should 0 ADP F
be 0 VERB F
evaluated 0 VERB F
at 0 ADP F
regular 0 ADJ F
intervals 0 NOUN F
. 0 PUNCT F

Effects 0 NOUN T
of 0 ADP F
atropine 0 NOUN F
and 0 CCONJ F
scopolamine 0 NOUN F
on 0 ADP F
bradycardia B-PHYSICAL NUM F
and 0 CCONJ F
emetic B-PHYSICAL ADJ F
symptoms I-PHYSICAL NOUN F
in 0 ADP F
otoplasty 0 NOUN F
. 0 PUNCT F

OBJECTIVE 0 NOUN T
To 0 PROPN T
assess 0 NOUN F
the 0 DET F
effects 0 NOUN F
of 0 ADP F
unilateral 0 ADJ F
or 0 CCONJ F
bilateral 0 ADJ F
otoplasty 0 NOUN F
on 0 ADP F
bradycardia B-PHYSICAL NUM F
and 0 CCONJ F
postoperative B-PHYSICAL ADJ F
nausea I-PHYSICAL NOUN F
and I-PHYSICAL CCONJ F
vomiting I-PHYSICAL PROPN F
( 0 PUNCT F
PONV B-PHYSICAL NOUN T
) 0 PUNCT F
and 0 CCONJ F
the 0 DET F
efficiency 0 NOUN F
of 0 ADP F
transdermal 0 ADJ F
scopolamine 0 NOUN F
in 0 ADP F
the 0 DET F
prophylaxis B-PHYSICAL NOUN F
of I-PHYSICAL ADP F
PONV I-PHYSICAL NOUN T
. 0 PUNCT F

STUDY 0 NOUN T
DESIGN 0 NOUN T
Post 0 PUNCT T
hoc 0 CCONJ F
assessment 0 NOUN F
of 0 ADP F
the 0 DET F
data 0 NOUN F
from 0 ADP F
a 0 DET F
double-blind 0 ADJ F
, 0 PUNCT F
randomized 0 ADP F
study 0 NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
Fifty 0 ADJ T
otoplasty 0 NOUN F
patients 0 NOUN F
were 0 VERB F
studied 0 VERB F
; 0 PUNCT F
half 0 NOUN F
of 0 ADP F
them 0 PRON F
received 0 VERB F
randomly 0 ADV F
and 0 CCONJ F
in 0 ADP F
double-blind 0 ADJ F
fashion 0 NOUN F
a 0 DET F
transdermal 0 ADJ F
therapeutic 0 ADJ F
system 0 NOUN F
( 0 PUNCT F
patch 0 NOUN F
) 0 PUNCT F
of 0 ADP F
scopolamine 0 NOUN F
( 0 PUNCT F
TTS-scopolamine 0 NOUN T
) 0 PUNCT F
as 0 ADP F
prophylaxis 0 NOUN F
against 0 ADP F
PONV 0 NOUN T
before 0 PUNCT F
general 0 ADJ F
anesthesia 0 NOUN F
. 0 PUNCT F

The 0 DET T
placebo 0 NOUN F
group 0 NOUN F
received 0 ADP F
atropine 0 PUNCT F
10 0 NUM F
microg 0 NOUN F
x 0 SYM F
kg 0 NOUN F
( 0 PUNCT F
-1 0 NUM F
) 0 PUNCT F
intravenously 0 ADV F
during 0 ADP F
induction 0 NOUN F
. 0 PUNCT F

RESULTS 0 PUNCT T
The 0 DET T
scopolamine-treated 0 VERB F
patients 0 NOUN F
suffered 0 ADJ F
more 0 ADV F
from 0 ADP F
moderate B-PHYSICAL ADJ F
peroperative I-PHYSICAL ADJ F
bradycardia I-PHYSICAL NOUN F
( 0 PUNCT F
8/25 0 NUM F
; 0 PUNCT F
P 0 NOUN T
< 0 SYM F
.05 0 NUM F
) 0 PUNCT F
than 0 PUNCT F
the 0 DET F
atropine-treated 0 VERB F
patients 0 NOUN F
( 0 PUNCT F
1/25 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

Two 0 NUM T
patients 0 NOUN F
wearing 0 VERB F
a 0 DET F
half 0 NOUN F
of 0 ADP F
the 0 DET F
TTS-scopolamine 0 NOUN T
patch 0 NOUN F
needed 0 PUNCT F
intravenous B-PHYSICAL ADJ F
atropine I-PHYSICAL NOUN F
. 0 PUNCT F

After 0 ADP T
unilateral 0 ADJ F
otoplasty 0 NOUN F
, 0 PUNCT F
none 0 NUM F
of 0 ADP F
the 0 DET F
TTS-scopolamine-treated 0 VERB T
patients 0 NOUN F
and 0 CCONJ F
50 0 NUM F
% 0 SYM F
of 0 ADP F
the 0 DET F
atropine-treated 0 VERB F
patients 0 NOUN F
suffered 0 VERB F
from 0 ADP F
PONV B-PHYSICAL NOUN T
. 0 PUNCT F

After 0 ADP T
bilateral 0 ADJ F
operation 0 NOUN F
, 0 PUNCT F
the 0 DET F
respective 0 ADJ F
incidences 0 NOUN F
were 0 VERB F
39 0 NUM F
% 0 SYM F
and 0 CCONJ F
81 0 NUM F
% 0 SYM F
( 0 PUNCT F
P 0 NOUN T
< 0 SYM F
.01 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

After 0 ADP T
unilateral 0 ADJ F
otoplasty 0 NOUN F
no 0 DET F
patient 0 NOUN F
needed 0 PROPN F
droperidol B-OTHER ADV F
, 0 PUNCT F
but 0 CCONJ F
after 0 ADP F
bilateral 0 ADJ F
otoplasty 0 NOUN F
, 0 PUNCT F
12 0 NUM F
of 0 ADP F
19 0 NUM F
of 0 ADP F
the 0 DET F
atropine-treated 0 VERB F
and 0 CCONJ F
4 0 NUM F
of 0 ADP F
18 0 NUM F
( 0 PUNCT F
P 0 NOUN T
< 0 SYM F
.05 0 NUM F
) 0 PUNCT F
of 0 ADP F
the 0 DET F
scopolamine-treated 0 VERB F
patients 0 NOUN F
needed 0 PROPN F
droperidol 0 ADV F
. 0 PUNCT F

The 0 DET T
mean 0 NOUN F
numbers 0 NOUN F
of B-OTHER ADP F
doses I-OTHER NOUN F
of I-OTHER ADP F
droperidol B-OTHER ADV F
were 0 VERB F
0.8+/-0.9 0 PUNCT F
and 0 CCONJ F
0.3+/-0.6 0 PUNCT F
( 0 PUNCT F
P 0 NOUN T
< 0 SYM F
.05 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
respectively 0 ADV F
. 0 PUNCT F

Two 0 NUM T
additional 0 ADJ F
patients 0 NOUN F
, 0 PUNCT F
wearing 0 CCONJ F
half 0 NOUN F
of 0 ADP F
the 0 DET F
TTS-scopolamine 0 NOUN T
patch 0 NOUN F
, 0 PUNCT F
suffered 0 VERB F
from 0 ADP F
mild B-ADVERSE-EFFECTS ADJ F
central B-ADVERSE-EFFECTS ADJ F
anticholinergic I-ADVERSE-EFFECTS ADJ F
syndrome I-ADVERSE-EFFECTS NOUN F
. 0 PUNCT F

CONCLUSION 0 NOUN T
TTS-scopolamine 0 NOUN T
offers 0 ADP F
effective 0 ADJ F
prophylaxis B-OTHER NOUN F
against 0 ADP F
PONV B-PHYSICAL NOUN T
( I-PHYSICAL PUNCT F
auriculoemetic I-PHYSICAL PUNCT F

Randomized 0 VERB T
trial 0 NOUN F
of 0 ADP F
angiotensin 0 NOUN F
II-receptor 0 NOUN T
blocker 0 NOUN F
vs. 0 CCONJ F
dihydropiridine 0 NOUN F
calcium 0 NOUN F
channel 0 NOUN F
blocker 0 NOUN F
in 0 ADP F
the 0 DET F
treatment 0 NOUN F
of 0 ADP F
paroxysmal 0 ADJ F
atrial 0 ADJ F
fibrillation 0 NOUN F
with 0 ADP F
hypertension 0 NOUN F
( 0 PUNCT F
J-RHYTHM 0 NOUN T
II 0 NUM T
study 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

AIMS 0 ADP T
Atrial 0 ADJ T
fibrillation 0 NOUN F
( 0 PUNCT F
AF 0 NOUN T
) 0 PUNCT F
is 0 VERB F
a 0 DET F
common 0 ADJ F
arrhythmia 0 NOUN F
frequently 0 ADV F
associated 0 VERB F
with 0 ADP F
hypertension 0 NOUN F
. 0 PUNCT F

This 0 DET T
study 0 NOUN F
was 0 VERB F
designed 0 VERB F
to 0 ADJ F
test 0 NOUN F
the 0 DET F
hypothesis 0 NOUN F
that 0 ADP F
lowering 0 VERB F
blood 0 NOUN F
pressure 0 NOUN F
by 0 ADP F
angiotensin 0 NOUN F
II-receptor 0 NOUN T
blockers 0 NOUN F
( 0 PUNCT F
ARB 0 NOUN T
) 0 PUNCT F
has 0 PUNCT F
more 0 DET F
beneficial 0 ADJ F
effects 0 NOUN F
than 0 PUNCT F
by 0 ADP F
conventional 0 ADJ F
calcium 0 NOUN F
channel 0 NOUN F
blockers 0 NOUN F
( 0 PUNCT F
CCB 0 NOUN T
) 0 PUNCT F
on 0 ADP F
the 0 DET F
frequency 0 NOUN F
of 0 ADP F
paroxysmal 0 ADJ F
AF 0 NOUN T
with 0 ADP F
hypertension 0 NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
AND 0 CCONJ T
RESULTS 0 PUNCT T
The 0 DET T
Japanese 0 ADJ T
Rhythm 0 NOUN T
Management 0 NOUN T
Trial 0 NOUN T
II 0 NUM T
for 0 ADP F
Atrial 0 ADJ T
Fibrillation 0 NOUN T
( 0 PUNCT F
J-RHYTHM 0 NOUN T
II 0 NUM T
study 0 NOUN F
) 0 PUNCT F
is 0 VERB F
an 0 DET F
open-label 0 NOUN F
randomized 0 VERB F
comparison 0 NOUN F
between 0 ADP F
an 0 DET F
ARB 0 NOUN T
( 0 PUNCT F
candesartan 0 NOUN F
) 0 PUNCT F
and 0 CCONJ F
a 0 DET F
CCB 0 NOUN T
( 0 PUNCT F
amlodipine 0 NOUN F
) 0 PUNCT F
in 0 ADP F
the 0 DET F
treatment 0 NOUN F
of 0 ADP F
paroxysmal 0 ADJ F
AF 0 NOUN T
associated 0 VERB F
with 0 ADP F
hypertension 0 NOUN F
. 0 PUNCT F

Using 0 VERB T
daily 0 ADJ F
transtelephonic 0 ADJ F
monitoring 0 VERB F
, 0 PUNCT F
we 0 NOUN F
examined 0 DET F
asymptomatic 0 ADJ F
and 0 CCONJ F
symptomatic 0 ADJ F
paroxysmal B-PHYSICAL ADJ F
AF I-PHYSICAL NOUN T
episodes 0 NOUN F
during 0 ADP F
a 0 DET F
maximum 0 NOUN F
1 0 NUM F
year 0 NOUN F
treatment 0 NOUN F
. 0 PUNCT F

The 0 DET T
primary 0 ADJ F
endpoint 0 NOUN F
was 0 VERB F
the 0 DET F
difference 0 NOUN F
in 0 ADP F
AF B-OTHER NOUN T
frequency I-OTHER NOUN F
between 0 ADP F
the 0 DET F
pre-treatment 0 NOUN F
period 0 NOUN F
and 0 CCONJ F
the 0 DET F
final 0 ADJ F
month 0 NOUN F
of 0 ADP F
the 0 DET F
follow-up 0 NOUN F
. 0 PUNCT F

The 0 DET T
secondary 0 ADJ F
endpoints 0 NOUN F
included 0 VERB F
cardiovascular B-PHYSICAL ADJ F
events I-PHYSICAL NOUN F
, 0 PUNCT F
development 0 NOUN F
of 0 ADP F
persistent B-PHYSICAL ADJ F
AF I-PHYSICAL NOUN T
, 0 PUNCT F
left B-PHYSICAL PUNCT F
atrial I-PHYSICAL ADJ F
dimension I-PHYSICAL NOUN F
, 0 PUNCT F
and 0 CCONJ F
quality-of-life B-MENTAL NOUN F
( I-MENTAL PUNCT F
QOL I-MENTAL NOUN T
) I-MENTAL PUNCT F
. 0 PUNCT F

The 0 DET T
study 0 NOUN F
enrolled 0 VERB F
318 0 NUM F
patients 0 NOUN F
( 0 PUNCT F
66 0 NUM F
years 0 NOUN F
, 0 PUNCT F
male/female 0 NOUN F
219/99 0 NOUN F
, 0 PUNCT F
158 0 NUM F
in 0 ADP F
the 0 DET F
ARB 0 NOUN T
group 0 NOUN F
and 0 CCONJ F
160 0 NUM F
in 0 ADP F
the 0 DET F
CCB 0 NOUN T
group 0 NOUN F
) 0 PUNCT F
treated 0 VERB F
at 0 ADP F
48 0 NUM F
sites 0 NOUN F
throughout 0 PUNCT F
Japan 0 PUNCT T
. 0 PUNCT F

At 0 ADP T
baseline 0 NOUN F
, 0 PUNCT F
the 0 DET F
frequency 0 NOUN F
of 0 ADP F
AF B-PHYSICAL NOUN T
episodes I-PHYSICAL NOUN F
( 0 PUNCT F
days/month 0 CCONJ F
) 0 PUNCT F
was 0 VERB F
3.8 0 ADJ F
? 0 PUNCT F

5.0 0 NUM F
in 0 ADP F
the 0 DET F
ARB 0 NOUN T
group 0 NOUN F
vs. 0 CCONJ F
4.8 0 NUM F
? 0 PUNCT F

6.3 0 NUM F
in 0 ADP F
the 0 DET F
CCB 0 NOUN T
group 0 NOUN F
( 0 PUNCT F
not 0 ADV F
significant 0 ADJ F
) 0 PUNCT F
. 0 PUNCT F

During 0 ADP T
the 0 DET F
follow-up 0 NOUN F
, 0 PUNCT F
blood 0 NOUN F
pressure 0 NOUN F
was 0 VERB F
significantly 0 ADV F
lower 0 PUNCT F
in 0 ADP F
the 0 DET F
CCB 0 NOUN T
group 0 NOUN F
than 0 PUNCT F
in 0 ADP F
the 0 DET F
ARB 0 NOUN T
group 0 NOUN F
( 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.001 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
AF 0 NOUN T
frequency 0 NOUN F
decreased 0 VERB F
similarly 0 ADV F
in 0 ADP F
both 0 CCONJ F
groups 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
there 0 PUNCT F
was 0 VERB F
no 0 DET F
significant 0 ADJ F
difference 0 NOUN F
in 0 ADP F
the 0 DET F
primary 0 ADJ F
endpoint 0 NOUN F
between 0 ADP F
the 0 DET F
two 0 NUM F
groups 0 NOUN F
. 0 PUNCT F

There 0 PUNCT T
were 0 VERB F
no 0 DET F
significant 0 ADJ F
differences 0 NOUN F
between 0 ADP F
the 0 DET F
two 0 NUM F
groups 0 NOUN F
in 0 ADP F
the 0 DET F
development 0 NOUN F
of 0 ADP F
persistent 0 ADJ F
AF 0 NOUN T
, 0 PUNCT F
changes 0 NOUN F
in 0 ADP F
left 0 PUNCT F
atrial 0 ADJ F
dimension 0 NOUN F
, 0 PUNCT F
occurrence 0 NOUN F
of 0 ADP F
cardiovascular 0 ADJ F
events 0 NOUN F
, 0 PUNCT F
or 0 CCONJ F
changes 0 NOUN F
in 0 ADP F
QOL 0 NOUN T
. 0 PUNCT F

CONCLUSIONS 0 NOUN T
In 0 ADP T
patients 0 NOUN F
with 0 ADP F
paroxysmal 0 ADJ F
AF 0 NOUN T
and 0 CCONJ F
hypertension 0 NOUN F
, 0 PUNCT F
treatment 0 NOUN F
of 0 ADP F
hypertension 0 NOUN F
by 0 ADP F
candesartan 0 NOUN F
did 0 PUNCT F
not 0 ADV F
have 0 PUNCT F
an 0 DET F
advantage 0 NOUN F
over 0 ADP F
amlodipine 0 NOUN F
in 0 ADP F
the 0 DET F
reduction 0 NOUN F
in 0 ADP F
the 0 DET F
frequency 0 NOUN F
of 0 ADP F
paroxysmal 0 ADJ F
AF 0 NOUN T
( 0 PUNCT F
umin 0 NOUN F
CTR 0 NOUN T
C000000427 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
benefit 0 NOUN F
of 0 ADP F
low-dose 0 NOUN F
dopamine 0 NOUN F
during 0 ADP F
vigorous 0 ADJ F
diuresis 0 NOUN F
for 0 ADP F
congestive 0 ADJ F
heart 0 NOUN F
failure 0 NOUN F
associated 0 VERB F
with 0 ADP F
renal 0 ADJ F
insufficiency 0 NOUN F
: 0 PUNCT F
does 0 PUNCT F
it 0 ADJ F
protect 0 VERB F
renal 0 ADJ F
function 0 NOUN F
? 0 PUNCT F

BACKGROUND 0 NOUN T
Low-dose 0 NOUN T
dopamine 0 NOUN F
, 0 PUNCT F
a 0 DET F
renal 0 ADJ F
vasodilator 0 NOUN F
, 0 PUNCT F
has 0 PUNCT F
been 0 PUNCT F
used 0 VERB F
empirically 0 ADV F
to 0 PART F
improve 0 PUNCT F
renal 0 ADJ F
function 0 NOUN F
or 0 CCONJ F
outcome 0 NOUN F
in 0 ADP F
critically 0 ADV F
ill 0 ADJ F
patients 0 NOUN F
with 0 ADP F
oliguria 0 NOUN F
or 0 CCONJ F
acute 0 ADJ F
renal 0 ADJ F
failure 0 NOUN F
. 0 PUNCT F

HYPOTHESIS 0 NOUN T
This 0 DET T
study 0 NOUN F
was 0 VERB F
designed 0 VERB F
to 0 PART F
investigate 0 NOUN F
the 0 DET F
efficacy 0 NOUN F
of 0 ADP F
low-dose 0 NOUN F
dopamine 0 NOUN F
( 0 PUNCT F
2 0 NUM F
micrograms/kg/min 0 NOUN F
) 0 PUNCT F
as 0 ADP F
a 0 DET F
renal-protective 0 ADJ F
agent 0 NOUN F
during 0 ADP F
vigorous 0 ADJ F
diuresis 0 NOUN F
for 0 ADP F
congestive 0 ADJ F
heart 0 NOUN F
failure 0 NOUN F
( 0 PUNCT F
CHF 0 NOUN T
) 0 PUNCT F
associated 0 VERB F
with 0 ADP F
mild 0 ADJ F
or 0 CCONJ F
moderate 0 ADJ F
renal 0 ADJ F
insufficiency 0 NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
Of 0 ADP T
20 0 NUM F
study 0 ADV F
patients 0 NOUN F
( 0 PUNCT F
mean 0 NOUN F
age 0 NOUN F
74.3 0 NUM F
+/- 0 SYM F
15 0 NUM F
years 0 NOUN F
) 0 PUNCT F
with 0 ADP F
severe 0 ADJ F
CHF 0 NOUN T
, 0 PUNCT F
10 0 NUM F
( 0 PUNCT F
Group 0 NOUN T
A 0 NOUN T
) 0 PUNCT F
were 0 VERB F
randomized 0 VERB F
to 0 ADP F
a 0 DET F
treatment 0 NOUN F
strategy 0 NOUN F
of 0 ADP F
intravenous 0 ADJ F
bumetanide 0 NOUN F
( 0 PUNCT F
1 0 NUM F
mg 0 NOUN F
b.i.d 0 PUNCT F
. 0 PUNCT F
) 0 PUNCT F

alone 0 ADJ F
and 0 CCONJ F
another 0 DET F
10 0 ADP F
( 0 PUNCT F
Group 0 NOUN T
B 0 NOUN T
) 0 PUNCT F
to 0 ADP F
low-dose 0 NOUN F
dopamine 0 NOUN F
and 0 CCONJ F
a 0 DET F
similar 0 ADJ F
diuretic 0 NOUN F
regimen 0 NOUN F
for 0 ADP F
a 0 DET F
duration 0 NOUN F
of 0 ADP F
5 0 NUM F
days 0 NOUN F
or 0 CCONJ F
less 0 DET F
if 0 CCONJ F
clinical 0 ADJ F
edema 0 NOUN F
remitted 0 VERB F
. 0 PUNCT F

RESULTS 0 DET T
Group 0 NOUN T
B 0 NOUN T
patients 0 NOUN F
showed 0 VERB F
a 0 DET F
significant 0 ADJ F
improvement 0 NOUN F
in 0 ADP F
renal B-PHYSICAL ADJ F
function I-PHYSICAL NOUN F
and I-PHYSICAL CCONJ F
urinary I-PHYSICAL ADJ F
output I-PHYSICAL NOUN F
: 0 PUNCT F
serum B-PHYSICAL NOUN F
blood I-PHYSICAL NOUN F
urea I-PHYSICAL NOUN F
nitrogen B-PHYSICAL NOUN F
48.9 0 NUM F
+/- 0 SYM F
10.3 0 NUM F
to 0 ADP F
32.1 0 NUM F
+/- 0 SYM F
14.4 0 NUM F
mg/dl 0 NOUN F
( 0 PUNCT F
p 0 NOUN F
< 0 SYM F
0.05 0 NUM F
) 0 PUNCT F
; 0 PUNCT F
serum B-PHYSICAL NOUN F
creatinine I-PHYSICAL NOUN F
1.97 0 NUM F
+/- 0 SYM F
0.24 0 NUM F
to 0 ADP F
1.49 0 NUM F
+/- 0 SYM F
0.39 0 NUM F
mg/dl 0 NOUN F
( 0 PUNCT F
p 0 NOUN F
< 0 SYM F
0.05 0 NUM F
) 0 PUNCT F
; 0 PUNCT F
creatinine B-PHYSICAL NOUN F
clearance I-PHYSICAL NOUN F
35.6 0 NUM F
+/- 0 SYM F
11.6 0 NUM F
to 0 ADP F
48.8 0 ADV F
+/- 0 SYM F
12.3 0 NUM F
ml/min 0 NOUN F
( 0 PUNCT F
p 0 NOUN F
< 0 SYM F
0.05 0 NUM F
) 0 PUNCT F
; 0 PUNCT F
and 0 CCONJ F
indexed B-PHYSICAL VERB F
urinary I-PHYSICAL ADJ F
output I-PHYSICAL NOUN F
0.56 0 NUM F
+/- 0 SYM F
0.16 0 NUM F
to 0 ADP F
2.02 0 NUM F
+/- 0 SYM F
0.72 0 NUM F
ml/kg/h 0 NUM F
( 0 PUNCT F
p 0 NOUN F
< 0 SYM F
0.05 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Group 0 NOUN T
A 0 DET T
patients 0 NOUN F
showed 0 VERB F
a 0 DET F
significant 0 ADJ F
increase 0 NOUN F
in 0 PUNCT F

Short- 0 PUNCT T
and 0 CCONJ F
long-term 0 NOUN F
results 0 CCONJ F
after 0 ADP F
thrombolytic 0 ADJ F
treatment 0 NOUN F
of 0 ADP F
deep 0 ADJ F
venous 0 ADJ F
thrombosis 0 NOUN F
. 0 PUNCT F

OBJECTIVES 0 NOUN T
The 0 DET T
goal 0 NOUN F
of 0 ADP F
this 0 DET F
study 0 NOUN F
was 0 VERB F
to 0 ADV F
assess 0 NOUN F
the 0 DET F
short- 0 ADJ F
and 0 CCONJ F
long-term 0 NOUN F
efficacy 0 NOUN F
of 0 ADP F
different 0 ADJ F
thrombolytic 0 ADJ F
therapy 0 NOUN F
regimens 0 NOUN F
in 0 ADP F
patients 0 NOUN F
with 0 ADP F
leg 0 NOUN F
or 0 CCONJ F
pelvic 0 ADJ F
deep 0 ADJ F
venous 0 ADJ F
thrombosis 0 NOUN F
( 0 PUNCT F
DVT 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

BACKGROUND 0 NOUN T
It 0 PRON T
is 0 VERB F
unclear 0 ADJ F
whether 0 ADP F
locoregional 0 ADJ F
or 0 CCONJ F
systemic 0 ADJ F
thrombolysis 0 NOUN F
is 0 VERB F
superior 0 ADJ F
in 0 ADP F
treating 0 VERB F
acute 0 ADJ F
leg 0 NOUN F
DVT 0 NOUN T
or 0 CCONJ F
even 0 ADV F
whether 0 ADP F
lysis 0 NOUN F
is 0 VERB F
more 0 ADV F
effective 0 ADJ F
than 0 PUNCT F
anticoagulation 0 NOUN F
therapy 0 NOUN F
in 0 ADP F
preventing 0 VERB F
postthrombotic 0 ADJ F
syndrome 0 NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
A 0 PUNCT T
total 0 NOUN F
of 0 ADP F
250 0 NUM F
patients 0 NOUN F
averaging 0 CCONJ F
40 0 NUM F
years 0 NOUN F
of 0 ADP F
age 0 NOUN F
with 0 ADP F
acute 0 ADJ F
DVT 0 NOUN T
were 0 VERB F
randomized 0 VERB F
into 0 ADP F
five 0 NUM F
groups 0 NOUN F
to 0 PART F
receive 0 NOUN F
full 0 ADJ F
heparinization 0 NOUN F
( 0 PUNCT F
1,000 0 NUM F
IU/h 0 NOUN T
) 0 PUNCT F
and 0 CCONJ F
compression 0 NOUN F
treatment 0 NOUN F
, 0 PUNCT F
with 0 ADP F
four 0 NUM F
groups 0 NOUN F
also 0 ADV F
administered 0 VERB F
locoregional 0 ADJ F
tissue 0 NOUN F
plasminogen 0 NOUN F
activator 0 NOUN F
( 0 PUNCT F
20 0 NUM F
mg/day 0 NOUN F
) 0 PUNCT F
or 0 CCONJ F
urokinase 0 NOUN F
( 0 PUNCT F
100,000 0 NUM F
IU/day 0 NOUN T
) 0 PUNCT F
or 0 CCONJ F
systemic 0 ADJ F
streptokinase 0 NOUN F
( 0 PUNCT F
3,000,000 0 NUM F
IU 0 NOUN T
daily 0 ADJ F
) 0 PUNCT F
or 0 CCONJ F
urokinase 0 NOUN F
( 0 PUNCT F
5,000,000 0 ADP F
IU 0 NOUN T
daily 0 ADJ F
) 0 PUNCT F
. 0 PUNCT F

All 0 DET T
groups 0 NOUN F
then 0 ADV F
received 0 PUNCT F
anticoagulation 0 NOUN F
and 0 CCONJ F
compression 0 NOUN F
treatment 0 NOUN F
for 0 ADP F
one 0 NUM F
year 0 NOUN F
. 0 PUNCT F

Primary 0 ADJ T
efficacy 0 NOUN F
criteria 0 NOUN F
included 0 VERB F
the 0 DET F
change 0 NOUN F
after 0 ADP F
one 0 NUM F
year 0 NOUN F
in 0 ADP F
the 0 DET F
number 0 NOUN F
of 0 ADP F
closed B-PHYSICAL VERB F
vein I-PHYSICAL NOUN F
segments I-PHYSICAL NOUN F
and 0 CCONJ F
the 0 DET F
occurrence 0 NOUN F
of 0 ADP F
postthrombotic 0 ADJ F
syndrome 0 NOUN F
. 0 PUNCT F

RESULTS 0 NOUN T
Systemic 0 ADJ T
thrombolytic 0 ADJ F
therapy 0 NOUN F
significantly 0 ADV F
reduced 0 VERB F
the 0 DET F
number 0 NOUN F
of 0 ADP F
closed B-PHYSICAL VERB F
vein I-PHYSICAL NOUN F
segments I-PHYSICAL NOUN F
after 0 ADP F
12 0 NUM F
months 0 NOUN F
in 0 ADP F
patients 0 NOUN F
with 0 ADP F
acute 0 ADJ F
DVT 0 NOUN T
compared 0 VERB F
with 0 ADP F
conventional 0 ADJ F
treatment 0 NOUN F
( 0 PUNCT F
p 0 NOUN F
< 0 SYM F
0.05 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Postthrombotic B-PHYSICAL ADJ T
syndrome I-PHYSICAL NOUN F
also 0 ADV F
occurred 0 VERB F
with 0 ADP F
less 0 DET F
frequency 0 NOUN F
in 0 ADP F
systemically 0 ADV F
treated 0 DET F
patients 0 NOUN F
versus 0 CCONJ F
controls 0 NOUN F
( 0 PUNCT F
p 0 NOUN F
< 0 SYM F
0.001 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

High-dose 0 NOUN T
thrombolysis 0 NOUN F
led 0 VERB F
to 0 PUNCT F
better 0 PUNCT F
rates 0 NOUN F
of 0 ADP F
complete B-PHYSICAL ADJ F
recanalization I-PHYSICAL NOUN F
after 0 ADP F
seven 0 NUM F
days 0 NOUN F
( 0 PUNCT F
p 0 NOUN F
< 0 SYM F
0.01 0 NUM F
) 0 PUNCT F
than 0 ADP F
locoregional 0 ADJ F
lysis 0 NOUN F
. 0 PUNCT F

However 0 ADV T
, 0 PUNCT F
12 0 NUM F
patients 0 NOUN F
receiving 0 VERB F
thrombolysis 0 NOUN F
( 0 PUNCT F
9 0 NUM F
systemic 0 ADJ F
, 0 PUNCT F
3 0 NUM F
local 0 ADJ F
) 0 PUNCT F
suffered 0 ADP F
major B-PHYSICAL ADJ F
bleeding I-PHYSICAL VERB F
complications I-PHYSICAL NOUN F
; 0 PUNCT F
9 0 NUM F
patients 0 NOUN F
on 0 ADP F
systemic 0 ADJ F
treatment 0 NOUN F
developed 0 VERB F
pulmonary B-ADVERSE-EFFECTS ADJ F
emboli I-ADVERSE-EFFECTS NOUN F
. 0 PUNCT F

CONCLUSIONS 0 NOUN T
Systemic 0 ADJ T
thrombolytic 0 ADJ F
treatment 0 NOUN F
for 0 ADP F
acute 0 ADJ F
DVT 0 NOUN T
achieved 0 VERB F
a 0 DET F
significantly 0 ADV F
better 0 PUNCT F
short- 0 ADJ F
and 0 CCONJ F
long-term 0 NOUN F
clinical 0 ADJ F
outcome 0 NOUN F
than 0 PUNCT F
conventional 0 ADJ F
heparin/anticoagulation 0 NOUN F
therapy 0 NOUN F
but 0 CCONJ F
at 0 ADP F
the 0 DET F
expense 0 NOUN F
of 0 ADP F
a 0 DET F
serious 0 ADJ F
increase 0 NOUN F
in 0 ADP F
major 0 ADJ F
bleeding 0 VERB F
and 0 CCONJ F
pulmonary 0 ADJ F
emboli 0 NOUN F
. 0 PUNCT F

Given 0 VERB T
the 0 DET F
inherent 0 ADJ F
risks 0 NOUN F
for 0 ADP F
such 0 CCONJ F
serious 0 ADJ F
complications 0 NOUN F
, 0 PUNCT F
systemic 0 ADJ F
thrombolysis 0 NOUN F
, 0 PUNCT F
although 0 ADP F
effective 0 ADJ F
, 0 PUNCT F
should 0 ADP F
be 0 VERB F
used 0 VERB F
selectively 0 ADV F
in 0 ADP F
limb-threatening 0 ADJ F
thrombotic 0 ADJ F
situations 0 NOUN F
. 0 PUNCT F

A 0 DET T
comparison 0 NOUN F
of 0 ADP F
the 0 DET F
recovery B-OTHER NOUN F
times I-OTHER NOUN F
of 0 ADP F
desflurane 0 NOUN F
and 0 CCONJ F
isoflurane 0 ADJ F
in 0 ADP F
outpatient 0 ADJ F
anesthesia 0 NOUN F
. 0 PUNCT F

The 0 DET T
low 0 ADJ F
solubility 0 NOUN F
of 0 ADP F
desflurane 0 NOUN F
has 0 PUNCT F
been 0 PUNCT F
shown 0 VERB F
to 0 PART F
contribute 0 NOUN F
to 0 ADP F
faster 0 PUNCT F
awakening 0 PUNCT F
from 0 ADP F
anesthesia 0 NOUN F
when 0 ADP F
compared 0 VERB F
with 0 ADP F
other 0 ADJ F
anesthetics 0 NOUN F
in 0 ADP F
common 0 ADJ F
use 0 NOUN F
. 0 PUNCT F

However 0 ADV T
, 0 PUNCT F
research 0 NOUN F
has 0 PUNCT F
failed 0 VERB F
to 0 PUNCT F
consistently 0 ADV F
demonstrate 0 ADJ F
faster 0 PUNCT F
discharge 0 NOUN F
times 0 NOUN F
from 0 ADP F
the 0 DET F
postanesthesia 0 NOUN F
care 0 NOUN F
unit 0 NOUN F
following 0 VERB F
the 0 DET F
use 0 NOUN F
of 0 ADP F
desflurane 0 NOUN F
. 0 PUNCT F

This 0 DET T
study 0 NOUN F
was 0 VERB F
undertaken 0 VERB F
to 0 PART F
compare 0 NOUN F
the 0 DET F
recovery B-OTHER NOUN F
and I-OTHER CCONJ F
discharge I-OTHER NOUN F
times I-OTHER NOUN F
of 0 ADP F
outpatients 0 ADJ F
undergoing 0 PUNCT F
procedures 0 NOUN F
greater 0 PUNCT F
than 0 CCONJ F
2 0 NUM F
hours 0 NOUN F
in 0 ADP F
length 0 NOUN F
. 0 PUNCT F

Thirty-three 0 NUM T
patients 0 NOUN F
aged 0 PROPN F
18 0 NUM F
to 0 ADP F
70 0 NUM F
years 0 NOUN F
were 0 VERB F
randomized 0 VERB F
to 0 PART F
receive 0 NOUN F
either 0 PUNCT F
desflurane 0 NOUN F
or 0 CCONJ F
isoflurane 0 NOUN F
following 0 ADP F
a 0 DET F
standard 0 ADJ F
intravenous 0 ADJ F
induction 0 NOUN F
with 0 ADP F
propofol 0 NOUN F
. 0 PUNCT F

Patients 0 NOUN T
received 0 VERB F
premedication 0 NOUN F
and 0 CCONJ F
opioids 0 NOUN F
consistent 0 ADJ F
with 0 ADP F
institutional 0 ADJ F
practice 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
inhalation 0 NOUN F
agents 0 NOUN F
were 0 VERB F
titrated 0 VERB F
to 0 PUNCT F
effect 0 PUNCT F
during 0 ADP F
anesthetic 0 ADJ F
maintenance 0 NOUN F
. 0 PUNCT F

Following 0 ADP T
surgery 0 NOUN F
, 0 PUNCT F
patients 0 NOUN F
were 0 VERB F
evaluated 0 VERB F
for 0 ADP F
time B-OTHER NOUN F
to I-OTHER ADP F
emergence I-OTHER NOUN F
and I-OTHER CCONJ F
time I-OTHER NOUN F
to I-OTHER ADP F
meeting I-OTHER PUNCT F
discharge I-OTHER NOUN F
criteria I-OTHER NOUN F
. 0 PUNCT F

The 0 DET T
results 0 NOUN F
demonstrated 0 VERB F
no 0 DET F
differences 0 NOUN F
between 0 ADP F
the 0 DET F
emergence 0 NOUN F
or 0 CCONJ F
discharge 0 NOUN F
times 0 NOUN F
following 0 VERB F
desflurane 0 NOUN F
or 0 CCONJ F
isoflurane 0 NOUN F
. 0 PUNCT F

In 0 ADP T
addition 0 NOUN F
, 0 PUNCT F
measured 0 PUNCT F
parameters 0 NOUN F
, 0 PUNCT F
such 0 PUNCT F
as 0 ADP F
intraoperative B-PHYSICAL ADJ F
vital I-PHYSICAL ADJ F
signs I-PHYSICAL NOUN F
and I-PHYSICAL CCONJ F
postoperative I-PHYSICAL ADJ F
emesis I-PHYSICAL NOUN F
and I-PHYSICAL CCONJ F
opioid I-PHYSICAL NOUN F
requirements I-PHYSICAL NOUN F
, 0 PUNCT F
were 0 VERB F
not 0 ADV F
different 0 ADJ F
between 0 ADP F
the 0 DET F
groups 0 NOUN F
. 0 PUNCT F

The 0 DET T
use 0 NOUN F
of 0 ADP F
desflurane 0 NOUN F
as 0 ADP F
part 0 NOUN F
of 0 ADP F
a 0 DET F
balanced 0 ADP F
anesthetic 0 ADJ F
technique 0 NOUN F
did 0 PUNCT F
not 0 PUNCT F
speed 0 CCONJ F
the 0 DET F
emergence 0 NOUN F
or 0 CCONJ F
discharge B-OTHER NOUN F
time I-OTHER NOUN F
when 0 ADP F
compared 0 VERB F
with 0 ADP F
isoflurane 0 NOUN F
. 0 PUNCT F

Acute 0 ADJ T
and 0 CCONJ F
subchronic 0 ADJ F
effects 0 NOUN F
of 0 ADP F
levocetirizine 0 ADJ F
and 0 CCONJ F
diphenhydramine 0 NOUN F
on 0 ADP F
memory 0 NOUN F
functioning 0 PROPN F
, 0 PUNCT F
psychomotor 0 NOUN F
performance 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
mood B-MENTAL NUM F
. 0 PUNCT F

BACKGROUND 0 NOUN T
Central 0 ADJ T
nervous 0 ADJ F
system 0 NOUN F
adverse 0 ADJ F
effects 0 NOUN F
, 0 PUNCT F
such 0 PUNCT F
as 0 ADP F
sedation B-PHYSICAL NOUN F
, 0 PUNCT F
often 0 ADV F
accompany 0 VERB F
the 0 DET F
use 0 NOUN F
of 0 ADP F
first-generation 0 NOUN F
antihistamines 0 ADP F
. 0 PUNCT F

These 0 DET T
effects 0 NOUN F
might 0 VERB F
interfere 0 VERB F
with 0 ADP F
memory 0 NOUN F
functioning 0 PROPN F
and 0 CCONJ F
psychomotor 0 NOUN F
performance 0 NOUN F
. 0 PUNCT F

Levocetirizine 0 NOUN T
was 0 VERB F
recently 0 ADV F
introduced 0 VERB F
as 0 ADP F
a 0 DET F
new 0 ADJ F
antihistamine 0 NOUN F
said 0 PUNCT F
to 0 ADP F
be 0 PUNCT F
free 0 ADJ F
from 0 ADP F
sedative 0 ADJ F
effects 0 NOUN F
. 0 PUNCT F

OBJECTIVE 0 NOUN T
We 0 PRON T
sought 0 PROPN F
to 0 PART F
investigate 0 NOUN F
the 0 DET F
effects 0 NOUN F
of 0 ADP F
levocetirizine 0 NOUN F
( 0 PUNCT F
5 0 NUM F
mg 0 NOUN F
) 0 PUNCT F
, 0 PUNCT F
diphenhydramine 0 NOUN F
( 0 PUNCT F
50 0 NUM F
mg 0 NOUN F
) 0 PUNCT F
, 0 PUNCT F
and 0 CCONJ F
placebo 0 NOUN F
on 0 ADP F
memory B-MENTAL NOUN F
and 0 CCONJ F
psychomotor B-MENTAL NOUN F
performance I-MENTAL NOUN F
after 0 ADP F
acute 0 ADJ F
( 0 PUNCT F
day 0 NOUN F
1 0 NUM F
) 0 PUNCT F
and 0 CCONJ F
subchronic 0 ADJ F
( 0 PUNCT F
day 0 NOUN F
4 0 NUM F
) 0 PUNCT F
daily 0 ADJ F
administration 0 NOUN F
in 0 ADP F
48 0 NUM F
healthy 0 ADJ F
volunteers 0 NOUN F
( 0 PUNCT F
24 0 PUNCT F
men 0 NOUN F
and 0 CCONJ F
24 0 NUM F
women 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

METHODS 0 NOUN T
This 0 PUNCT T
study 0 NOUN F
was 0 VERB F
a 0 DET F
double-blind 0 ADJ F
, 0 PUNCT F
placebo-controlled 0 VERB F
, 0 PUNCT F
randomized 0 VERB F
clinical 0 ADJ F
trial 0 NOUN F
. 0 PUNCT F

Treatments 0 NOUN T
were 0 VERB F
administrated 0 VERB F
on 0 ADP F
days 0 NOUN F
1 0 NUM F
, 0 PUNCT F
2 0 NUM F
, 0 PUNCT F
3 0 NUM F
, 0 PUNCT F
and 0 CCONJ F
4 0 NUM F
, 0 PUNCT F
3 0 NUM F
hours 0 NOUN F
before 0 ADP F
the 0 DET F
start 0 NOUN F
of 0 ADP F
the 0 DET F
laboratory 0 NOUN F
test 0 ADV F
battery 0 NOUN F
( 0 PUNCT F
performed 0 VERB F
on 0 ADP F
days 0 NOUN F
1 0 NUM F
and 0 CCONJ F
4 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
comprising 0 CCONJ F
a 0 DET F
word-learning 0 ADP F
test 0 NOUN F
, 0 PUNCT F
the 0 DET F
Sternberg 0 NOUN T
Memory 0 NOUN T
Scanning 0 PUNCT T
Test 0 NOUN T
, 0 PUNCT F
a 0 DET F
tracking 0 PUNCT F
test 0 NOUN F
( 0 PUNCT F
easy 0 ADP F
and 0 CCONJ F
hard 0 ADJ F
version 0 NOUN F
) 0 PUNCT F
, 0 PUNCT F
and 0 CCONJ F
a 0 DET F
divided 0 VERB F
attention 0 NOUN F
test 0 NOUN F
( 0 PUNCT F
tracking 0 PUNCT F
and 0 CCONJ F
memory 0 NOUN F
scanning 0 VERB F
simultaneously 0 ADV F
) 0 PUNCT F
. 0 PUNCT F

Statistical 0 ADJ T
analyses 0 NOUN F
were 0 VERB F
performed 0 VERB F
separately 0 ADV F
for 0 ADP F
days 0 NOUN F
1 0 NUM F
and 0 CCONJ F
4 0 NUM F
by 0 ADP F
using 0 PUNCT F
analysis 0 NOUN F
of 0 ADP F
variance 0 NOUN F
. 0 PUNCT F

RESULTS 0 NOUN T
On 0 ADP T
day 0 NOUN F
1 0 NUM F
, 0 PUNCT F
diphenhydramine 0 NOUN F
significantly 0 ADV F
impaired 0 VERB F
tracking B-MENTAL PROPN F
performance I-MENTAL NOUN F
( 0 PUNCT F
easy 0 ADP F
: 0 PUNCT F
F 0 NOUN T
( 0 PUNCT F
1,90 0 NUM F
) 0 PUNCT F
= 0 ADP F
25.9 0 NUM F
, 0 PUNCT F
P 0 NOUN T
< 0 SYM F
.0001 0 NUM F
; 0 PUNCT F
hard 0 PUNCT F
: 0 PUNCT F
F 0 NOUN T
( 0 PUNCT F
1,90 0 NUM F
) 0 PUNCT F
= 0 SYM F
20.5 0 NUM F
, 0 PUNCT F
P 0 NOUN T
< 0 SYM F
.0001 0 NUM F
) 0 PUNCT F
and 0 CCONJ F
divided B-PHYSICAL VERB F
attention I-PHYSICAL NOUN F
( 0 PUNCT F
tracking 0 ADP F
: 0 PUNCT F
F 0 NOUN T
( 0 PUNCT F
1,90 0 NUM F
) 0 PUNCT F
= 0 SYM F
23.8 0 NUM F
, 0 PUNCT F
P 0 NOUN T
< 0 SYM F
.0001 0 NUM F
; 0 PUNCT F
memory B-PHYSICAL NOUN F
scanning I-PHYSICAL VERB F
: 0 PUNCT F
F 0 NOUN T
( 0 PUNCT F
1,90 0 NUM F
) 0 PUNCT F
= 0 SYM F
22.0 0 NUM F
, 0 PUNCT F
P 0 NOUN T
< 0 SYM F
.0001 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Results 0 DET T
on 0 ADP F
word-learning B-MENTAL PROPN F
tests I-MENTAL NOUN F
and 0 CCONJ F
Sternberg B-MENTAL NOUN T
Memory I-MENTAL NOUN T
Scanning I-MENTAL DET T
Tests I-MENTAL NOUN T
were 0 VERB F
not 0 ADV F
significantly 0 ADV F
impaired 0 VERB F
. 0 PUNCT F

On 0 ADP T
day 0 NOUN F
4 0 NUM F
, 0 PUNCT F
the 0 DET F
effects 0 NOUN F
of 0 ADP F
diphenhydramine 0 NOUN F
did 0 CCONJ F
not 0 ADV F
reach 0 ADJ F
significance 0 NOUN F
. 0 PUNCT F

In 0 ADP T
contrast 0 NOUN F
, 0 PUNCT F
on 0 ADP F
both 0 PUNCT F
days 0 NOUN F
1 0 NUM F
and 0 CCONJ F
4 0 NUM F
, 0 PUNCT F
levocetirizine 0 NOUN F
did 0 VERB F
not 0 ADV F
significantly 0 ADV F
impair 0 NUM F
laboratory B-OTHER NOUN F
test I-OTHER ADV F
performance I-OTHER NOUN F
. 0 PUNCT F

CONCLUSION 0 NOUN T
The 0 DET T
results 0 ADV F
show 0 VERB F
that 0 ADP F
memory B-MENTAL NOUN F
, 0 PUNCT F
attention B-MENTAL NOUN F
, 0 PUNCT F
and 0 CCONJ F
tracking B-MENTAL PUNCT F
performance I-MENTAL NOUN F
are 0 VERB F
unaffected 0 VERB F
after 0 ADP F
acute 0 ADJ F
and 0 CCONJ F
subchronic 0 ADJ F
administration 0 NOUN F
of 0 ADP F
levocetirizine 0 NOUN F
( 0 PUNCT F
5 0 NUM F
mg 0 NOUN F
) 0 PUNCT F
, 0 PUNCT F
whereas 0 CCONJ F
diphenhydramine 0 NOUN F
( 0 PUNCT F
50 0 NUM F
mg 0 NOUN F
) 0 PUNCT F
significantly 0 ADV F
affected 0 VERB F
divided B-MENTAL VERB F
attention I-MENTAL NOUN F
and 0 CCONJ F
tracking B-MENTAL PUNCT F
after 0 ADP F
acute 0 ADJ F
administration 0 NOUN F
. 0 PUNCT F

Trial 0 NOUN T
design 0 NOUN F
challenges 0 NOUN F
when 0 ADP F
combining 0 ADP F
medication 0 NOUN F
and 0 CCONJ F
parent 0 NOUN F
training 0 VERB F
in 0 ADP F
children 0 NOUN F
with 0 ADP F
pervasive 0 ADJ F
developmental 0 ADJ F
disorders 0 NOUN F
. 0 PUNCT F

This 0 DET T
paper 0 NOUN F
presents 0 NOUN F
the 0 DET F
rationale 0 NOUN F
for 0 ADP F
a 0 DET F
24-week 0 NOUN F
, 0 PUNCT F
randomized 0 VERB F
trial 0 NOUN F
designed 0 VERB F
to 0 PART F
test 0 VERB F
whether 0 ADP F
risperidone 0 NUM F
plus 0 CCONJ F
structured 0 VERB F
parent 0 NOUN F
training 0 ADP F
would 0 VERB F
be 0 VERB F
superior 0 ADJ F
to 0 ADP F
risperidone 0 NUM F
only 0 ADV F
on 0 ADP F
measures 0 NOUN F
of 0 ADP F
noncompliance B-MENTAL NOUN F
, 0 PUNCT F
irritability B-MENTAL NOUN F
and 0 CCONJ F
adaptive B-MENTAL ADJ F
functioning I-MENTAL SYM F
. 0 PUNCT F

In 0 ADP T
this 0 DET F
model 0 NOUN F
, 0 PUNCT F
medication 0 NOUN F
reduces 0 VERB F
tantrums B-MENTAL ADP F
, 0 PUNCT F
aggression B-MENTAL NOUN F
and 0 CCONJ F
self-injury B-MENTAL NOUN F
; 0 PUNCT F
parent 0 NOUN F
training 0 VERB F
promotes 0 NOUN F
improvement 0 NOUN F
in 0 ADP F
noncompliance B-MENTAL NOUN F
and 0 CCONJ F
adaptive B-MENTAL ADJ F
functioning I-MENTAL SYM F
. 0 PUNCT F

Thus 0 ADV T
, 0 PUNCT F
medication 0 NOUN F
and 0 CCONJ F
parent 0 NOUN F
training 0 PUNCT F
target 0 NOUN F
related 0 DET F
, 0 PUNCT F
but 0 CCONJ F
separate 0 PUNCT F
, 0 PUNCT F
outcomes 0 NOUN F
. 0 PUNCT F

At 0 ADP T
week 0 NOUN F
24 0 NUM F
, 0 PUNCT F
the 0 DET F
medication 0 NOUN F
was 0 VERB F
gradually 0 ADV F
withdrawn 0 PUNCT F
to 0 PART F
determine 0 VERB F
whether 0 VERB F
subjects 0 NOUN F
in 0 ADP F
the 0 DET F
combined 0 VERB F
treatment 0 NOUN F
group 0 NOUN F
could 0 VERB F
be 0 VERB F
managed 0 PROPN F
on 0 ADP F
a 0 DET F
lower 0 PUNCT F
dose 0 NOUN F
or 0 CCONJ F
off 0 ADP F
medication 0 NOUN F
without 0 ADP F
relapse 0 NOUN F
. 0 PUNCT F

Both 0 CCONJ T
symptom B-OTHER NOUN F
reduction I-OTHER NOUN F
and 0 CCONJ F
functional B-OTHER ADJ F
improvement I-OTHER NOUN F
are 0 VERB F
important 0 ADJ F
clinical 0 ADJ F
treatment 0 NOUN F
targets 0 NOUN F
. 0 PUNCT F

Thus 0 ADV T
, 0 PUNCT F
experimental 0 ADJ F
evidence 0 NOUN F
on 0 ADP F
the 0 DET F
beneficial 0 ADJ F
effects 0 NOUN F
of 0 ADP F
combining 0 PUNCT F
pharmacotherapy 0 NOUN F
and 0 CCONJ F
exportable 0 ADJ F
behavioral 0 ADJ F
interventions 0 NOUN F
is 0 VERB F
needed 0 VERB F
to 0 PART F
guide 0 NOUN F
clinical 0 ADJ F
practice 0 NOUN F
. 0 PUNCT F

Bacterial 0 ADJ T
ribosomal 0 ADJ F
immunostimulants 0 NOUN F
prime 0 PROPN F
alveolar 0 ADJ F
macrophages 0 NOUN F
in 0 PUNCT F
vivo 0 ADV F
to 0 PART F
produce 0 ADJ F
interleukin 0 NOUN F
1 0 NUM F
in 0 PUNCT F
vitro 0 ADV F
. 0 PUNCT F

Alveolar 0 ADJ T
macrophages 0 NOUN F
( 0 PUNCT F
AMs 0 ADV T
) 0 PUNCT F
may 0 VERB F
play 0 VERB F
a 0 DET F
key 0 ADJ F
role 0 NOUN F
in 0 ADP F
human 0 NOUN F
respiratory 0 ADJ F
immune 0 ADJ F
defenses 0 NOUN F
, 0 PUNCT F
partially 0 ADV F
by 0 ADP F
synthesizing 0 ADJ F
and 0 CCONJ F
releasing 0 PUNCT F
interleukin 0 NOUN F
1 0 NUM F
( 0 PUNCT F
IL 0 NOUN T
= 0 SYM F
1 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

D53 0 ADP T
( 0 PUNCT F
Ribomunyl 0 NOUN T
) 0 PUNCT F
, 0 PUNCT F
a 0 DET F
composite 0 ADJ F
bacterial 0 ADJ F
ribosomal 0 ADJ F
immunostimulant 0 ADJ F
, 0 PUNCT F
has 0 PUNCT F
been 0 PUNCT F
recognized 0 VERB F
as 0 ADP F
an 0 DET F
efficient 0 ADJ F
prevention 0 NOUN F
of 0 ADP F
respiratory B-PHYSICAL ADJ F
tract I-PHYSICAL NOUN F
infections I-PHYSICAL NOUN F
. 0 PUNCT F

In 0 PUNCT T
vitro 0 ADJ F
, 0 PUNCT F
D53 0 NOUN T
enhances 0 ADP F
the 0 DET F
IL-1 B-PHYSICAL NOUN T
production I-PHYSICAL NOUN F
by 0 ADP F
mouse 0 NOUN F
spleen 0 NOUN F
adherent 0 ADJ F
cells 0 NOUN F
. 0 PUNCT F

A 0 DET T
thymocyte 0 NOUN F
proliferative 0 ADJ F
response 0 NOUN F
assay 0 NOUN F
was 0 VERB F
used 0 VERB F
to 0 PART F
evaluate 0 NOUN F
the 0 DET F
in 0 PUNCT F
vitro B-PHYSICAL ADJ F
IL-1 I-PHYSICAL NOUN T
production I-PHYSICAL NOUN F
by 0 ADP F
AMs 0 ADV T
in 0 ADP F
healthy 0 ADJ F
subjects 0 NOUN F
who 0 ADP F
received 0 VERB F
D53 0 NOUN T
immunostimulant 0 ADJ F
. 0 PUNCT F

Twelve 0 NUM T
nonsmoking 0 PUNCT F
healthy 0 ADJ F
subjects 0 NOUN F
took 0 PROPN F
part 0 NOUN F
in 0 ADP F
a 0 DET F
prospective 0 ADJ F
double-blind 0 ADJ F
placebo 0 NOUN F
control 0 NOUN F
study 0 NOUN F
. 0 PUNCT F

On 0 ADP T
day 0 NOUN F
1 0 NUM F
, 0 PUNCT F
a 0 DET F
first 0 ADJ F
bronchoalveolar 0 ADJ F
lavage 0 NOUN F
( 0 PUNCT F
BAL 0 NOUN T
) 0 PUNCT F
was 0 VERB F
performed 0 VERB F
to 0 PART F
assess 0 NOUN F
IL-1 B-PHYSICAL NOUN T
production I-PHYSICAL NOUN F
by 0 ADP F
unstimulated 0 VERB F
and 0 CCONJ F
lipopolysaccharide 0 NOUN F
( 0 PUNCT F
LPS 0 NOUN T
) 0 PUNCT F
stimulated 0 VERB F
AM 0 NOUN T
. 0 PUNCT F

Then 0 ADV T
, 0 PUNCT F
subjects 0 NOUN F
were 0 VERB F
randomized 0 VERB F
to 0 PART F
receive 0 NOUN F
D53 0 ADP T
( 0 PUNCT F
n 0 NOUN F
= 0 SYM F
6 0 NUM F
) 0 PUNCT F
or 0 CCONJ F
its 0 ADP F
placebo 0 NOUN F
( 0 PUNCT F
n 0 NOUN F
= 0 SYM F
6 0 NUM F
) 0 PUNCT F
by 0 ADP F
both 0 CCONJ F
oral 0 ADJ F
and 0 CCONJ F
subcutaneous 0 ADJ F
injection 0 NOUN F
routes 0 CCONJ F
from 0 ADP F
day 0 NOUN F
1 0 NUM F
to 0 ADP F
day 0 NOUN F
15 0 NUM F
. 0 PUNCT F

On 0 ADP T
day 0 NOUN F
15 0 NUM F
, 0 PUNCT F
a 0 DET F
second 0 ADJ F
BAL 0 NOUN T
was 0 VERB F
done 0 PUNCT F
and 0 CCONJ F
AM 0 NOUN T
IL-1 B-PHYSICAL NOUN T
production I-PHYSICAL NOUN F
was 0 VERB F
again 0 ADV F
tested 0 VERB F
. 0 PUNCT F

IL-1 B-PHYSICAL NOUN T
production I-PHYSICAL NOUN F
on 0 ADP F
day 0 NOUN F
15 0 NUM F
did 0 ADP F
not 0 ADV F
significantly 0 ADV F
differ 0 VERB F
from 0 ADP F
day 0 NOUN F
1 0 NUM F
in 0 ADP F
both 0 CCONJ F
D53-treated 0 PUNCT T
and 0 CCONJ F
placebo 0 NOUN F
groups 0 NOUN F
either 0 CCONJ F
when 0 ADP F
AMs 0 ADV T
were 0 VERB F
unstimulated 0 DET F
or 0 CCONJ F
were 0 VERB F
stimulated 0 VERB F
with 0 ADP F
concentrations 0 NOUN F
of 0 ADP F
LPS 0 NOUN T
resulting 0 VERB F
in 0 ADP F
maximal 0 ADJ F
IL-1 B-PHYSICAL NOUN T
production I-PHYSICAL NOUN F
. 0 PUNCT F

However 0 ADV T
, 0 PUNCT F
in 0 ADP F
the 0 DET F
D53-treated 0 NUM T
group 0 NOUN F
, 0 PUNCT F
but 0 CCONJ F
not 0 ADV F
in 0 ADP F
the 0 DET F
placebo 0 NOUN F
group 0 NOUN F
, 0 PUNCT F
IL-1 B-PHYSICAL NOUN T
production I-PHYSICAL NOUN F
induced 0 VERB F
by 0 ADP F
low 0 ADJ F
LPS B-PHYSICAL NOUN T
concentration I-PHYSICAL NOUN F
( 0 PUNCT F
5 0 NUM F
mg/L 0 NOUN F
) 0 PUNCT F
was 0 VERB F
significantly 0 ADV F
higher 0 PUNCT F
( 0 PUNCT F
mean 0 NOUN F
+/- 0 SYM F
SEM 0 NOUN T
: 0 PUNCT F
1,238 0 NUM F
+/- 0 SYM F
287 0 NUM F
U/10 0 NOUN T
( 0 PUNCT F
6 0 NUM F
) 0 PUNCT F
AM 0 NOUN T
) 0 PUNCT F
on 0 ADP F
day 0 NOUN F
15 0 NUM F
in 0 ADP F
comparison 0 NOUN F
with 0 ADP F
day 0 NOUN F
1 0 NUM F
( 0 PUNCT F
577 0 NUM F
+/- 0 SYM F
113 0 NUM F
U/10 0 NOUN T
( 0 PUNCT F
6 0 NUM F
) 0 PUNCT F
AM 0 NOUN T
; 0 PUNCT F
p 0 NOUN F
less 0 ADV F
than 0 ADP F
0.05 0 NUM F
, 0 PUNCT F
Wilcoxon 0 NOUN T
W 0 NOUN T
test 0 NOUN F
) 0 PUNCT F
and 0 CCONJ F
in 0 ADP F
comparison 0 NOUN F
with 0 ADP F
the 0 DET F
control 0 NOUN F
group 0 NOUN F
( 0 PUNCT F
day 0 NOUN F
15 0 NUM F
IL-1 B-PHYSICAL NOUN T
production 0 NOUN F
induced 0 VERB F
by 0 ADP F
5 0 NUM F
mg/L 0 NOUN F
LPS 0 NOUN T
, 0 PUNCT F
758 0 NUM F
+/- 0 SYM F
175 0 NUM F
U/10 0 NOUN T
( 0 PUNCT F
6 0 NUM F
) 0 PUNCT F
AM 0 NOUN T
; 0 PUNCT F
p 0 NOUN F
less 0 ADV F
than 0 ADP F
0.05 0 NUM F
, 0 PUNCT F
Mann-Whitney 0 NOUN T
U 0 NOUN T
test 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

Moreover 0 ADV T
, 0 PUNCT F
in 0 ADP F
the 0 DET F
D53-treated 0 NUM T
group 0 NOUN F
, 0 PUNCT F
the 0 DET F
optimal B-PHYSICAL ADJ F
LPS I-PHYSICAL NOUN T
concentration I-PHYSICAL NOUN F
( 0 PUNCT F
ie 0 ADP F
, 0 PUNCT F
LPS 0 NOUN T
concentration 0 NOUN F
that 0 ADP F
induced 0 ADJ F
maximal 0 ADJ F
IL-1 0 NOUN T
production 0 NOUN F
) 0 PUNCT F
was 0 VERB F
significantly 0 ADV F
lower 0 PUNCT F
on 0 ADP F
day 0 NOUN F
15 0 NUM F
( 0 PUNCT F
mean 0 NOUN F
+/- 0 SYM F
SD 0 NOUN T
: 0 PUNCT F
11 0 NUM F
+/- 0 SYM F
7 0 NUM F
mg/L 0 NOUN F
) 0 PUNCT F
than 0 PUNCT F
on 0 ADP F
day 0 NOUN F
1 0 NUM F
( 0 PUNCT F
16 0 NUM F
+/- 0 SYM F
7 0 NUM F
mg/L 0 NOUN F
; 0 PUNCT F
p 0 NOUN F
less 0 ADV F
than 0 CCONJ F
0.05 0 NUM F
Wilcoxon 0 NOUN T
W 0 NOUN T
test 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

We 0 PRON T
conclude 0 VERB F
that 0 ADP F
D53 0 ADP T
immunostimulant 0 PUNCT F
in 0 ADP F
vivo 0 ADJ F
primes 0 CCONJ F
AM 0 NOUN T
to 0 PART F
produce 0 NOUN F
IL-1 B-PHYSICAL NOUN T
following 0 VERB F
low B-PHYSICAL ADJ F
LPS I-PHYSICAL NOUN T
concentration I-PHYSICAL NOUN F
stimulation 0 NOUN F
. 0 PUNCT F

This 0 PUNCT T
may 0 PART F
partially 0 ADV F
explain 0 VERB F
the 0 DET F
protective 0 ADJ F
effect 0 NOUN F
of 0 ADP F
D53 0 NOUN T
immunostimulant 0 ADJ F
against 0 ADP F
respiratory B-PHYSICAL ADJ F
tract I-PHYSICAL NOUN F
infection I-PHYSICAL NOUN F
. 0 PUNCT F

Post 0 PUNCT T
hoc 0 VERB F
analysis 0 NOUN F
of 0 ADP F
a 0 DET F
single 0 ADJ F
IV 0 NUM T
infusion 0 NOUN F
of 0 ADP F
zoledronic 0 ADJ F
acid 0 NOUN F
versus 0 CCONJ F
daily 0 ADJ F
oral 0 ADJ F
risedronate 0 NOUN F
on 0 ADP F
lumbar 0 ADJ F
spine 0 NOUN F
bone 0 NOUN F
mineral 0 NOUN F
density 0 NOUN F
in 0 ADP F
different 0 ADJ F
subgroups 0 NOUN F
with 0 ADP F
glucocorticoid-induced 0 VERB F
osteoporosis 0 NOUN F
. 0 PUNCT F

This 0 DET T
study 0 NOUN F
summarizes 0 PUNCT F
the 0 DET F
treatment 0 NOUN F
effect 0 NOUN F
of 0 ADP F
zoledronic 0 ADJ F
acid 0 NOUN F
infusion 0 NOUN F
on 0 ADP F
lumbar B-PHYSICAL ADJ F
spine I-PHYSICAL NOUN F
bone I-PHYSICAL NOUN F
mineral I-PHYSICAL NOUN F
density I-PHYSICAL NOUN F
in 0 ADP F
different 0 ADJ F
subgroups 0 NOUN F
with 0 ADP F
glucocorticoid-induced 0 VERB F
osteoporosis 0 NOUN F
. 0 PUNCT F

Zoledronic 0 ADJ T
acid 0 NOUN F
is 0 VERB F
significantly 0 ADV F
more 0 ADV F
effective 0 ADJ F
than 0 VERB F
risedronate 0 NOUN F
in 0 ADP F
increasing 0 PUNCT F
lumbar B-PHYSICAL ADJ F
spine I-PHYSICAL NOUN F
( I-PHYSICAL PUNCT F
LS I-PHYSICAL NOUN T
) I-PHYSICAL PUNCT F
bone I-PHYSICAL NOUN F
mineral I-PHYSICAL NOUN F
density I-PHYSICAL NOUN F
( I-PHYSICAL PUNCT F
BMD I-PHYSICAL NOUN T
) I-PHYSICAL PUNCT F
in 0 ADP F
both 0 CCONJ F
prevention 0 NOUN F
and 0 CCONJ F
treatment 0 NOUN F
of 0 ADP F
glucocorticoid-induced 0 VERB F
osteoporosis 0 NOUN F
. 0 PUNCT F

Introduction 0 NOUN T
In 0 ADP T
patients 0 NOUN F
on 0 ADP F
glucocorticoids 0 NOUN F
, 0 PUNCT F
a 0 DET F
single 0 ADJ F
zoledronic 0 ADJ F
acid 0 NOUN F
infusion 0 NOUN F
significantly 0 ADV F
increased 0 VERB F
BMD B-PHYSICAL NOUN T
versus 0 CCONJ F
daily 0 ADJ F
oral 0 ADJ F
risedronate 0 NOUN F
. 0 PUNCT F

We 0 PRON T
assessed 0 VERB F
treatment 0 NOUN F
effect 0 NOUN F
on 0 ADP F
LS B-PHYSICAL NOUN T
BMD I-PHYSICAL NOUN T
in 0 ADP F
different 0 ADJ F
patient 0 NOUN F
subgroups 0 NOUN F
at 0 ADP F
month 0 NOUN F
12 0 NUM F
that 0 PUNCT F
contributed 0 VERB F
to 0 ADP F
the 0 DET F
risk 0 NOUN F
of 0 ADP F
osteoporosis 0 NOUN F
in 0 ADP F
addition 0 NOUN F
to 0 ADP F
glucocorticoids 0 NOUN F
. 0 PUNCT F

Methods 0 NOUN T
Patients 0 NOUN T
randomized 0 ADP F
to 0 ADP F
a 0 DET F
single 0 ADJ F
IV 0 NUM T
infusion 0 NOUN F
of 0 ADP F
zoledronic 0 ADJ F
acid 0 NOUN F
5 0 NUM F
mg 0 NOUN F
or 0 CCONJ F
risedronate 0 NOUN F
( 0 PUNCT F
5 0 NUM F
mg/day 0 NOUN F
) 0 PUNCT F
and 0 CCONJ F
stratified 0 PUNCT F
based 0 VERB F
on 0 ADP F
glucocorticoids 0 ADJ F
duration 0 NOUN F
[ 0 PUNCT F
treatment 0 NOUN F
( 0 PUNCT F
> 0 PROPN F
3 0 NUM F
months 0 NOUN F
) 0 PUNCT F
and 0 CCONJ F
prevention 0 NOUN F
( 0 PUNCT F
? 0 PUNCT F

3 0 NUM F
months 0 NOUN F
) 0 PUNCT F
subpopulations 0 NOUN F
] 0 PUNCT F
were 0 VERB F
subgrouped 0 VERB F
by 0 ADP F
age 0 NOUN F
; 0 PUNCT F
gender 0 NOUN F
; 0 PUNCT F
menopausal 0 ADJ F
status 0 NOUN F
in 0 ADP F
women 0 NOUN F
; 0 PUNCT F
dose 0 NOUN F
and 0 CCONJ F
duration 0 NOUN F
of 0 ADP F
prednisone 0 NOUN F
during 0 ADP F
the 0 DET F
trial 0 NOUN F
; 0 PUNCT F
and 0 CCONJ F
baseline 0 NOUN F
serum 0 NOUN F
25-OH 0 NOUN F
vitamin 0 NOUN F
D 0 NOUN T
, 0 PUNCT F
LS 0 NOUN T
BMD 0 NOUN T
T-score 0 NOUN T
, 0 PUNCT F
creatinine 0 NOUN F
clearance 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
concomitant 0 ADJ F
medication 0 NOUN F
use 0 NOUN F
. 0 PUNCT F

Results 0 DET T
At 0 ADP T
month 0 NOUN F
12 0 NUM F
, 0 PUNCT F
zoledronic 0 ADJ F
acid 0 NOUN F
significantly 0 ADV F
increased 0 VERB F
LS 0 NOUN T
BMD 0 NOUN T
versus 0 CCONJ F
risedronate 0 NOUN F
in 0 ADP F
patients 0 NOUN F
? 0 PUNCT F

74 0 NUM F
years 0 NOUN F
( 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.05 0 NUM F
) 0 PUNCT F
in 0 ADP F
the 0 DET F
treatment 0 NOUN F
and 0 CCONJ F
65-74 0 NUM F
years 0 NOUN F
( 0 PUNCT F
P 0 NOUN T
= 0 SYM F
0.0008 0 NUM F
) 0 PUNCT F
in 0 ADP F
the 0 DET F
prevention 0 NOUN F
subpopulation 0 NOUN F
. 0 PUNCT F

At 0 ADP T
month 0 NOUN F
12 0 NUM F
, 0 PUNCT F
zoledronic 0 ADJ F
acid 0 NOUN F
significantly 0 ADV F
increased 0 VERB F
LS 0 NOUN T
BMD 0 NOUN T
versus 0 CCONJ F
risedronate 0 NOUN F
in 0 ADP F
both 0 PUNCT F
subpopulations 0 ADJ F
irrespective 0 ADJ F
of 0 ADP F
gender 0 NOUN F
( 0 PUNCT F
all 0 DET F
P 0 NOUN T
< 0 SYM F
0.05 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
cumulative 0 ADJ F
prednisone 0 NOUN F
dose 0 NOUN F
( 0 PUNCT F
all 0 DET F
P 0 NOUN T
< 0 SYM F
0.01 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
and 0 CCONJ F
postmenopausal 0 ADJ F
status 0 NOUN F
( 0 PUNCT F
all 0 DET F
P 0 NOUN T
< 0 SYM F
0.05 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

In 0 ADP T
premenopausal 0 ADJ F
women 0 NOUN F
, 0 PUNCT F
in 0 ADP F
both 0 PUNCT F
subpopulations 0 NOUN F
, 0 PUNCT F
zoledronic 0 ADJ F
acid 0 NOUN F
significantly 0 ADV F
increased 0 CCONJ F
total 0 ADJ F
hip 0 NOUN F
BMD 0 NOUN T
( 0 PUNCT F
all 0 DET F
P 0 NOUN T
< 0 SYM F
0.05 0 NUM F
) 0 PUNCT F
versus 0 CCONJ F
risedronate 0 NOUN F
at 0 ADP F
month 0 NOUN F
12 0 NUM F
but 0 CCONJ F
not 0 ADV F
LS 0 NOUN T
BMD 0 NOUN T
. 0 PUNCT F

Osteoporotic 0 ADJ T
patients 0 NOUN F
in 0 ADP F
the 0 DET F
prevention 0 NOUN F
( 0 PUNCT F
P=0.0189 0 NOUN T
) 0 PUNCT F
and 0 CCONJ F
osteopenic 0 ADJ F
patients 0 NOUN F
in 0 ADP F
the 0 DET F
treatment 0 NOUN F
subpopulation 0 NOUN F
( 0 PUNCT F
P=0.0305 0 NOUN T
) 0 PUNCT F
showed 0 VERB F
significant 0 ADJ F
LS 0 NOUN T
BMD 0 NOUN T
increases 0 NOUN F
with 0 ADP F
zoledronic 0 ADJ F
acid 0 NOUN F
versus 0 CCONJ F
risedronate 0 NOUN F
at 0 ADP F
month 0 NOUN F
12 0 NUM F
. 0 PUNCT F

Conclusions 0 NOUN T
This 0 CCONJ T
post 0 PUNCT F
hoc 0 ADP F
analysis 0 NOUN F
suggests 0 NOUN F
that 0 ADP F
zoledronic 0 ADJ F
acid 0 NOUN F
is 0 VERB F
significantly 0 ADV F
more 0 ADV F
effective 0 ADJ F
than 0 VERB F
risedronate 0 NOUN F
in 0 ADP F
increasing 0 VERB F
LS 0 NOUN T
BMD 0 NOUN T
in 0 ADP F
prevention 0 NOUN F
and 0 CCONJ F
treatment 0 NOUN F
of 0 ADP F
glucocorticoid-induced 0 VERB F
osteoporosis 0 NOUN F
across 0 ADP F
a 0 DET F
wide 0 ADJ F
range 0 NOUN F
of 0 ADP F
patients 0 NOUN F
. 0 PUNCT F

Comparison 0 NOUN T
of 0 ADP F
inhaled 0 VERB F
albuterol 0 NOUN F
powder 0 NOUN F
and 0 CCONJ F
aerosol 0 NOUN F
in 0 ADP F
asthma 0 NOUN F
. 0 PUNCT F

In 0 ADP T
this 0 DET F
multicenter 0 NOUN F
, 0 PUNCT F
randomized 0 VERB F
, 0 PUNCT F
double-blind 0 ADJ F
study 0 NOUN F
comparing 0 VERB F
the 0 DET F
efficacy 0 NOUN F
and 0 CCONJ F
safety 0 NOUN F
of 0 ADP F
aerosolized 0 VERB F
albuterol 0 NOUN F
with 0 ADP F
the 0 DET F
dry 0 ADJ F
powder 0 NOUN F
formulation 0 NOUN F
, 0 PUNCT F
231 0 NUM F
patients 0 NOUN F
with 0 ADP F
chronic 0 ADJ F
reversible 0 ADJ F
obstructive 0 ADJ F
airway 0 NOUN F
disease 0 NOUN F
were 0 VERB F
randomly 0 ADV F
allocated 0 VERB F
to 0 PART F
receive 0 NOUN F
either 0 PUNCT F
placebo 0 NOUN F
albuterol 0 NOUN F
aerosol 0 NOUN F
followed 0 VERB F
immediately 0 ADV F
by 0 ADP F
active 0 ADJ F
albuterol 0 NOUN F
powder 0 NOUN F
( 0 PUNCT F
200 0 NUM F
micrograms 0 NOUN F
) 0 PUNCT F
or 0 CCONJ F
active 0 ADJ F
albuterol 0 NOUN F
aerosol 0 NOUN F
( 0 PUNCT F
two 0 NUM F
puffs 0 VERB F
, 0 PUNCT F
180 0 NUM F
micrograms 0 NOUN F
) 0 PUNCT F
followed 0 ADV F
immediately 0 ADV F
by 0 ADP F
placebo 0 NOUN F
lactose 0 NOUN F
powder 0 NOUN F
four 0 NUM F
times 0 NOUN F
a 0 DET F
day 0 NOUN F
for 0 ADP F
a 0 DET F
period 0 NOUN F
of 0 ADP F
12 0 NUM F
weeks 0 NOUN F
. 0 PUNCT F

No 0 DET T
statistically 0 ADV F
significant 0 ADJ F
differences 0 NOUN F
were 0 VERB F
found 0 VERB F
between 0 ADP F
the 0 DET F
powder 0 NOUN F
and 0 CCONJ F
aerosol 0 NOUN F
formulations 0 NOUN F
with 0 ADP F
respect 0 NOUN F
to 0 ADP F
pulmonary B-PHYSICAL ADJ F
function I-PHYSICAL NOUN F
, 0 PUNCT F
length 0 NOUN F
of 0 ADP F
time 0 NOUN F
mean 0 NOUN F
FEV1 0 NOUN T
remained 0 VERB F
greater 0 PUNCT F
than 0 VERB F
or 0 CCONJ F
equal 0 ADJ F
to 0 ADP F
15 0 NUM F
% 0 SYM F
above 0 ADP F
baseline 0 NOUN F
, 0 PUNCT F
physicians B-PHYSICAL NOUN F
' 0 PUNCT F
assessments B-PHYSICAL NOUN F
of I-PHYSICAL ADP F
patients I-PHYSICAL NOUN F
' 0 PUNCT F
clinical B-PHYSICAL ADJ F
response I-PHYSICAL NOUN F
, 0 PUNCT F
or 0 CCONJ F
patients B-OTHER NOUN F
' 0 PUNCT F
subjective B-OTHER ADJ F
symptom I-OTHER NOUN F
scores 0 NOUN F
. 0 PUNCT F

There 0 PUNCT T
were 0 VERB F
also 0 ADV F
no 0 DET F
significant 0 ADJ F
differences 0 NOUN F
between 0 ADP F
treatment 0 NOUN F
groups 0 NOUN F
in 0 ADP F
cardiovascular B-PHYSICAL ADJ F
effects I-PHYSICAL NOUN F
, 0 PUNCT F
laboratory B-PHYSICAL NOUN F
values I-PHYSICAL NOUN F
, 0 PUNCT F
or 0 PUNCT F
adverse B-ADVERSE-EFFECTS PUNCT F

Granulocyte-macrophage 0 NOUN T
colony-stimulating 0 VERB F
factor 0 NOUN F
( 0 PUNCT F
GM-CSF 0 NOUN T
) 0 PUNCT F
as 0 VERB F
adjunct 0 ADJ F
therapy 0 NOUN F
in 0 ADP F
relapsed 0 VERB F
Hodgkin 0 NOUN T
disease 0 NOUN F
. 0 PUNCT F

OBJECTIVE 0 NOUN T
To 0 PROPN T
determine 0 NOUN F
the 0 DET F
clinical 0 ADJ F
and 0 CCONJ F
economic 0 ADJ F
effects 0 NOUN F
of 0 ADP F
granulocyte 0 NOUN F
macrophage 0 NOUN F
colony-stimulating 0 VERB F
factor 0 NOUN F
( 0 PUNCT F
GM-CSF 0 NOUN T
) 0 PUNCT F
as 0 VERB F
adjunct 0 ADJ F
therapy 0 NOUN F
in 0 ADP F
relapsed 0 VERB F
or 0 CCONJ F
refractory 0 ADJ F
Hodgkin 0 NOUN T
disease 0 NOUN F
. 0 PUNCT F

DESIGN 0 NOUN T
A 0 NOUN T
randomized 0 VERB F
, 0 PUNCT F
double-blind 0 ADJ F
, 0 PUNCT F
phase 0 NOUN F
III 0 NUM T
clinical 0 ADJ F
trial 0 NOUN F
. 0 PUNCT F

SETTING 0 NUM T
A 0 DET T
tertiary 0 ADJ F
referral 0 ADJ F
center 0 NOUN F
. 0 PUNCT F

PATIENTS 0 NOUN T
Twenty-four 0 PUNCT T
patients 0 NOUN F
( 0 PUNCT F
twelve 0 PUNCT F
of 0 ADP F
whom 0 ADP F
were 0 VERB F
controls 0 NOUN F
) 0 PUNCT F
treated 0 VERB F
with 0 ADP F
high-dose 0 NOUN F
chemotherapy 0 NOUN F
and 0 CCONJ F
autologous 0 ADJ F
bone 0 NOUN F
marrow 0 NOUN F
transplantation 0 NOUN F
. 0 PUNCT F

MAIN 0 ADJ T
RESULTS 0 NOUN T
The 0 DET T
12 0 NUM F
patients 0 NOUN F
treated 0 VERB F
with 0 ADP F
GM-CSF 0 NOUN T
, 0 PUNCT F
when 0 ADP F
compared 0 VERB F
with 0 ADP F
placebo 0 NOUN F
recipients 0 NOUN F
, 0 PUNCT F
had 0 VERB F
shorter 0 PUNCT F
periods B-PHYSICAL NOUN F
of I-PHYSICAL ADP F
neutropenia I-PHYSICAL NOUN F
( 0 PUNCT F
median 0 ADJ F
duration 0 NOUN F
of 0 ADP F
an 0 DET F
absolute 0 ADJ F
neutrophil 0 NOUN F
count 0 NOUN F
of 0 ADP F
less 0 ADV F
than 0 PUNCT F
1000 0 NUM F
cells/mm3 0 NOUN F
, 0 PUNCT F
16 0 DET F
days 0 NOUN F
compared 0 VERB F
with 0 ADP F
27 0 NUM F
days 0 NOUN F
; 0 PUNCT F
P 0 NOUN T
= 0 SYM F
0.02 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
shorter 0 PUNCT F
periods 0 NOUN F
of 0 ADP F
platelet-transfusion B-PHYSICAL NOUN F
dependency I-PHYSICAL NOUN F
( 0 PUNCT F
median 0 ADJ F
duration 0 NOUN F
, 0 PUNCT F
13.5 0 NUM F
days 0 NOUN F
compared 0 VERB F
with 0 ADP F
21 0 NUM F
days 0 NOUN F
; 0 PUNCT F
P 0 NOUN T
= 0 SYM F
0.03 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
and 0 CCONJ F
shorter B-OTHER PUNCT F
hospitalizations I-OTHER NOUN F
( 0 PUNCT F
median 0 ADJ F
hospital 0 NOUN F
stay 0 NOUN F
, 0 PUNCT F
32 0 NUM F
days 0 NOUN F
compared 0 VERB F
with 0 ADP F
40.5 0 NUM F
days 0 NOUN F
; 0 PUNCT F
P 0 NOUN T
= 0 SYM F
0.004 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Other 0 ADJ T
clinical 0 ADJ F
outcomes 0 NOUN F
, 0 PUNCT F
such 0 PUNCT F
as 0 ADP F
frequency 0 NOUN F
and 0 CCONJ F
severity B-PHYSICAL NOUN F
of I-PHYSICAL ADP F
toxicities I-PHYSICAL NOUN F
, 0 PUNCT F
development 0 NOUN F
of 0 ADP F
pneumonia B-PHYSICAL NOUN F
or 0 CCONJ F
infection B-PHYSICAL NOUN F
, 0 PUNCT F
in-hospital B-MORTALITY NOUN F
death I-MORTALITY NOUN F
, 0 PUNCT F
and 0 CCONJ F
response 0 NOUN F
rate B-MENTAL NOUN F
were 0 VERB F
similar 0 ADJ F
in 0 ADP F
the 0 DET F
two 0 NUM F
groups 0 NOUN F
. 0 PUNCT F

Actuarial 0 ADJ T
long-term B-MORTALITY NOUN F
disease-free I-MORTALITY ADJ F
survival I-MORTALITY NOUN F
was 0 VERB F
64 0 NUM F
% 0 SYM F
for 0 ADP F
patients 0 NOUN F
treated 0 VERB F
with 0 ADP F
GM-CSF 0 NOUN T
and 0 CCONJ F
58 0 NUM F
% 0 SYM F
for 0 ADP F
patients 0 NOUN F
who 0 ADP F
received 0 VERB F
placebo 0 NOUN F
after 0 ADP F
32 0 NUM F
months 0 NOUN F
of 0 ADP F
follow-up 0 NOUN F
( 0 PUNCT F
P 0 NOUN T
= 0 SYM F
0.15 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
group 0 NOUN F
treated 0 VERB F
with 0 ADP F
GM-CSF 0 NOUN T
had 0 PUNCT F
lower 0 PUNCT F
total 0 ADJ F
charges 0 NOUN F
after 0 ADP F
infusion B-PHYSICAL NOUN F
of I-PHYSICAL ADP F
autologous I-PHYSICAL ADJ F
marrow I-PHYSICAL NOUN F
than 0 PUNCT F
the 0 DET F
placebo 0 NOUN F
group 0 NOUN F
( 0 PUNCT F
median 0 ADJ F
in-hospital 0 NOUN F
charges 0 NOUN F
, 0 PUNCT F
$ 0 PUNCT F
39,800 0 NUM F
compared 0 VERB F
with 0 ADP F
$ 0 PROPN F
62,500 0 NUM F
; 0 PUNCT F
P 0 NOUN T
= 0 SYM F
0.005 0 NUM F
) 0 PUNCT F
because 0 PUNCT F
of 0 ADP F
lower B-PHYSICAL PUNCT F
post-infusion I-PHYSICAL NOUN F
charges I-PHYSICAL NOUN F
for 0 ADP F
room 0 NOUN F
and 0 CCONJ F
board 0 NOUN F
, 0 PUNCT F
antibiotic 0 ADJ F
therapy 0 NOUN F
, 0 PUNCT F
transfusions 0 NOUN F
, 0 PUNCT F
laboratory 0 NOUN F
tests 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
physical 0 ADJ F
therapy 0 NOUN F
visits 0 NOUN F
. 0 PUNCT F

CONCLUSIONS 0 NOUN T
Administration 0 NOUN T
of 0 ADP F
GM-CSF 0 NOUN T
was 0 VERB F
associated 0 VERB F
with 0 ADP F
acceleration 0 NOUN F
of 0 ADP F
myeloid B-PHYSICAL NOUN F
and 0 CCONJ F
platelet B-PHYSICAL NOUN F
recovery I-PHYSICAL NOUN F
and 0 CCONJ F
was 0 ADP F
cost B-OTHER NOUN F
effective I-OTHER ADJ F
in 0 ADP F
the 0 DET F
treatment 0 NOUN F
of 0 ADP F
patients 0 NOUN F
with 0 ADP F
relapsed 0 VERB F
Hodgkin 0 NOUN T
disease 0 NOUN F
who 0 ADP F
received 0 VERB F
intensive 0 ADJ F
chemotherapy 0 NOUN F
. 0 PUNCT F

Prognostic 0 ADJ T
value 0 NOUN F
of 0 ADP F
postoperative 0 ADJ F
CEA 0 NOUN T
clearance 0 NOUN F
in 0 ADP F
rectal 0 ADJ F
cancer 0 NOUN F
patients 0 NOUN F
with 0 ADP F
high 0 ADJ F
preoperative 0 ADJ F
CEA 0 NOUN T
levels 0 NOUN F
. 0 PUNCT F

PURPOSE 0 NOUN T
We 0 PRON T
determined 0 VERB F
the 0 DET F
prognostic 0 ADJ F
value 0 NOUN F
of 0 ADP F
carcinoembryonic 0 ADJ F
antigen 0 NOUN F
( 0 PUNCT F
CEA 0 NOUN T
) 0 PUNCT F
clearance 0 NOUN F
after 0 ADP F
tumor 0 NOUN F
resection 0 NOUN F
with 0 ADP F
serial 0 ADJ F
evaluation 0 NOUN F
of 0 ADP F
postoperative 0 ADJ F
CEA 0 NOUN T
levels 0 NOUN F
in 0 ADP F
rectal 0 ADJ F
cancer 0 NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
Between 0 ADP T
1994 0 NUM F
and 0 CCONJ F
2004 0 NUM F
, 0 PUNCT F
we 0 PRON F
retrospectively 0 ADP F
reviewed 0 ADP F
122 0 NUM F
patients 0 NOUN F
with 0 ADP F
rectal 0 ADJ F
cancer 0 NOUN F
whose 0 ADP F
serum B-PHYSICAL NOUN F
CEA I-PHYSICAL NOUN T
levels I-PHYSICAL NOUN F
were 0 VERB F
measured 0 VERB F
on 0 ADP F
the 0 DET F
preoperative 0 ADJ F
day 0 NOUN F
and 0 CCONJ F
postoperative 0 ADJ F
days 0 NOUN F
7 0 NUM F
and 0 CCONJ F
30 0 NUM F
. 0 PUNCT F

Patients 0 NOUN T
with 0 ADP F
preoperative 0 ADJ F
CEA 0 NOUN T
levels 0 NOUN F
< 0 SYM F
5.0 0 NUM F
ng/ml 0 NOUN F
were 0 VERB F
excluded 0 VERB F
. 0 PUNCT F

An 0 DET T
exponential 0 ADJ F
trend 0 NOUN F
line 0 NOUN F
was 0 VERB F
drawn 0 VERB F
using 0 VERB F
the 0 DET F
three 0 NUM F
CEA 0 NOUN T
values 0 NOUN F
. 0 PUNCT F

Patients 0 NOUN T
were 0 VERB F
categorized 0 VERB F
into 0 ADP F
three 0 NUM F
groups 0 NOUN F
based 0 VERB F
on 0 ADP F
R 0 NOUN T
( 0 PUNCT F
2 0 NUM F
) 0 PUNCT F
values 0 NOUN F
calculated 0 ADP F
through 0 ADP F
trend 0 NOUN F
line 0 NOUN F
, 0 PUNCT F
which 0 ADP F
indicates 0 NOUN F
the 0 DET F
correlation 0 NOUN F
coefficient 0 NOUN F
between 0 ADP F
exponential 0 ADJ F
graph 0 NOUN F
and 0 CCONJ F
measured 0 PUNCT F
CEA B-PHYSICAL NOUN T
values I-PHYSICAL NOUN F
: 0 PUNCT F
exponential 0 ADJ F
decrease 0 NOUN F
group 0 NOUN F
( 0 PUNCT F
group 0 NOUN F
1 0 NUM F
: 0 PUNCT F
0.9 0 NUM F
< 0 SYM F
R 0 NOUN T
( 0 PUNCT F
2 0 NUM F
) 0 PUNCT F
< 0 SYM F
or 0 CCONJ F
= 0 SYM F
1.0 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
nearly 0 PUNCT F
exponential 0 ADJ F
decrease 0 NOUN F
group 0 NOUN F
( 0 PUNCT F
group 0 NOUN F
2 0 NUM F
: 0 PUNCT F
0.5 0 NUM F
< 0 SYM F
R 0 NOUN T
( 0 PUNCT F
2 0 NUM F
) 0 PUNCT F
< 0 SYM F
or 0 CCONJ F
= 0 SYM F
0.9 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
and 0 CCONJ F
randomized 0 VERB F
clearance 0 NOUN F
group 0 NOUN F
( 0 PUNCT F
group 0 NOUN F
3 0 NUM F
: 0 PUNCT F
0.5 0 NUM F
< 0 SYM F
or 0 CCONJ F
= 0 SYM F
R 0 NOUN T
( 0 PUNCT F
2 0 NUM F
) 0 PUNCT F
) 0 PUNCT F
. 0 PUNCT F

We 0 PRON T
then 0 ADV F
analyzed 0 ADP F
the 0 DET F
CEA 0 NOUN T
clearance 0 NOUN F
pattern 0 NOUN F
as 0 ADP F
a 0 DET F
prognostic 0 ADJ F
indicator 0 NOUN F
. 0 PUNCT F

RESULTS 0 NOUN T
With 0 ADP T
a 0 DET F
median 0 ADJ F
follow-up 0 NOUN F
of 0 ADP F
57 0 NUM F
months 0 NOUN F
, 0 PUNCT F
the 0 DET F
5-year B-MORTALITY ADJ F
overall I-MORTALITY ADJ F
survival I-MORTALITY NOUN F
was 0 VERB F
62.3 0 NUM F
% 0 SYM F
vs. 0 CCONJ F
48.1 0 NUM F
% 0 SYM F
vs. 0 CCONJ F
25 0 NUM F
% 0 SYM F
and 0 CCONJ F
the 0 DET F
5-year B-MORTALITY NOUN F
disease-free I-MORTALITY ADJ F
survival I-MORTALITY NOUN F
was 0 VERB F
58.6 0 NUM F
% 0 SYM F
vs. 0 CCONJ F
52.7 0 NUM F
% 0 SYM F
vs. 0 CCONJ F
25 0 NUM F
% 0 SYM F
among 0 ADP F
groups 0 NOUN F
1 0 NUM F
, 0 PUNCT F
2 0 NUM F
, 0 PUNCT F
and 0 CCONJ F
3 0 NUM F
( 0 PUNCT F
P 0 NOUN T
= 0 SYM F
0.014 0 NUM F
, 0 PUNCT F
P 0 NOUN T
= 0 SYM F
0.027 0 NUM F
, 0 PUNCT F
respectively 0 ADV F
) 0 PUNCT F
in 0 ADP F
patients 0 NOUN F
with 0 ADP F
stage 0 NOUN F
III 0 NUM T
rectal 0 ADJ F
cancer 0 NOUN F
. 0 PUNCT F

For 0 ADP T
those 0 PUNCT F
with 0 ADP F
stage 0 NOUN F
II 0 NUM T
rectal 0 ADJ F
cancer 0 NOUN F
, 0 PUNCT F
the 0 DET F
5-year B-MORTALITY ADJ F
overall I-MORTALITY ADJ F
survival I-MORTALITY NOUN F
rate I-MORTALITY NOUN F
of 0 ADP F
group 0 NOUN F
1 0 NUM F
was 0 ADJ F
significantly 0 ADV F
better 0 PUNCT F
than 0 VERB F
groups 0 NOUN F
2 0 NUM F
and 0 CCONJ F
3 0 NUM F
( 0 PUNCT F
88.8 0 NUM F
% 0 SYM F
vs. 0 CCONJ F
74.1 0 NUM F
% 0 SYM F
, 0 PUNCT F
respectively 0 ADV F
, 0 PUNCT F
P 0 NOUN T
= 0 SYM F
0.021 0 PUNCT F
) 0 PUNCT F
. 0 PUNCT F

CONCLUSIONS 0 NOUN T
The 0 DET T
postoperative 0 ADJ F
pattern 0 NOUN F
of 0 ADP F
CEA 0 NOUN T
clearance 0 NOUN F
is 0 VERB F
a 0 DET F
useful 0 ADJ F
prognostic 0 ADJ F
determinant 0 NOUN F
in 0 ADP F
patients 0 NOUN F
with 0 ADP F
rectal 0 ADJ F
cancer 0 NOUN F
. 0 PUNCT F

Patients 0 NOUN T
with 0 ADP F
a 0 DET F
randomized 0 VERB F
pattern 0 NOUN F
of 0 ADP F
CEA B-PHYSICAL NOUN T
clearance I-PHYSICAL NOUN F
after 0 ADP F
tumor 0 NOUN F
resection 0 NOUN F
should 0 VERB F
be 0 VERB F
regarded 0 VERB F
as 0 ADP F
having 0 VERB F
the 0 DET F
possibility 0 NOUN F
of 0 ADP F
a 0 DET F
persistent 0 ADJ F
CEA 0 NOUN T
source 0 NOUN F
and 0 CCONJ F
may 0 VERB F
require 0 VERB F
consideration 0 NOUN F
of 0 ADP F
intensive 0 ADJ F
follow-up 0 NOUN F
or 0 CCONJ F
adjuvant 0 NOUN F
therapy 0 NOUN F
. 0 PUNCT F

Clinical 0 ADJ T
efficacy 0 NOUN F
of 0 ADP F
antazoline 0 NOUN F
in 0 ADP F
rapid B-PHYSICAL ADJ F
cardioversion I-PHYSICAL NOUN F
of I-PHYSICAL ADP F
paroxysmal I-PHYSICAL ADJ F
atrial I-PHYSICAL ADJ F
fibrillation I-PHYSICAL NOUN F
-- I-PHYSICAL PUNCT F
a 0 DET F
protocol 0 NOUN F
of 0 ADP F
a 0 DET F
single 0 ADJ F
center 0 NOUN F
, 0 PUNCT F
randomized 0 VERB F
, 0 PUNCT F
double-blind 0 ADJ F
, 0 PUNCT F
placebo-controlled 0 VERB F
study 0 NOUN F
( 0 PUNCT F
the 0 DET F
AnPAF 0 NOUN T
Study 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

BACKGROUND 0 NOUN T
Rapid B-PHYSICAL ADJ T
conversion I-PHYSICAL NOUN F
of I-PHYSICAL ADP F
atrial I-PHYSICAL ADJ F
fibrillation I-PHYSICAL NOUN F
( 0 PUNCT F
AF B-PHYSICAL NOUN T
) 0 PUNCT F
to B-PHYSICAL ADP F
sinus I-PHYSICAL NOUN F
rhythm B-PHYSICAL NOUN F
may 0 VERB F
be 0 VERB F
achieved 0 VERB F
by 0 ADP F
the 0 DET F
administration 0 NOUN F
of 0 ADP F
class 0 NOUN F
IA 0 NOUN T
, 0 PUNCT F
IC 0 NOUN T
and 0 CCONJ F
III 0 NUM T
antiarrhythmic 0 ADJ F
drugs 0 NOUN F
or 0 CCONJ F
vernakalant 0 ADJ F
hydrochloride 0 NOUN F
. 0 PUNCT F

However 0 ADV T
, 0 PUNCT F
that 0 PUNCT F
treatment 0 NOUN F
may 0 VERB F
be 0 VERB F
related 0 VERB F
to 0 ADP F
potential 0 CCONJ F
pro-arrhythmia 0 NOUN F
, 0 PUNCT F
lack 0 NOUN F
of 0 ADP F
efficacy 0 NOUN F
or 0 CCONJ F
the 0 DET F
exceptionally 0 ADJ F
high 0 ADJ F
cost 0 NOUN F
of 0 ADP F
a 0 DET F
compound 0 NOUN F
used 0 VERB F
. 0 PUNCT F

Antazoline 0 NOUN T
is 0 VERB F
a 0 DET F
first 0 ADJ F
generation 0 NOUN F
antihistaminic 0 ADJ F
agent 0 NOUN F
with 0 ADP F
chinidin-like 0 ADJ F
properties 0 NOUN F
. 0 PUNCT F

When 0 ADP T
administered 0 ADP F
intravenously 0 ADV F
, 0 PUNCT F
antazoline 0 NOUN F
exerts 0 NOUN F
a 0 DET F
strong B-PHYSICAL ADJ F
antiarrhythmic I-PHYSICAL ADJ F
effect 0 NOUN F
on 0 ADP F
supraventricular B-PHYSICAL VERB F
arrhythmia B-PHYSICAL NOUN F
, 0 PUNCT F
especially 0 ADV F
on 0 ADP F
AF B-PHYSICAL NOUN T
, 0 PUNCT F
facilitating 0 CCONJ F
rapid B-PHYSICAL ADJ F
conversion I-PHYSICAL NOUN F
to B-PHYSICAL ADP F
sinus I-PHYSICAL NOUN F
rhythm I-PHYSICAL NOUN F
. 0 PUNCT F

Despite 0 ADP T
a 0 DET F
relative 0 ADJ F
lack 0 NOUN F
of 0 ADP F
published 0 VERB F
data 0 NOUN F
antazoline 0 CCONJ F
has 0 PUNCT F
been 0 PUNCT F
marketed 0 VERB F
in 0 ADP F
Poland 0 PUNCT T
and 0 CCONJ F
widely 0 ADV F
used 0 VERB F
in 0 ADP F
cardiology 0 NOUN F
wards 0 NOUN F
and 0 CCONJ F
emergency 0 NOUN F
rooms 0 NOUN F
for 0 ADP F
many 0 DET F
years 0 NOUN F
due 0 CCONJ F
to 0 ADP F
its 0 PUNCT F
efficacy 0 NOUN F
, 0 PUNCT F
safety 0 NOUN F
and 0 CCONJ F
rapid 0 ADJ F
onset 0 NOUN F
of 0 ADP F
action 0 NOUN F
within 0 ADP F
minutes 0 NOUN F
of 0 ADP F
administration 0 NOUN F
. 0 PUNCT F

METHODS/DESIGN 0 PUNCT T
A 0 NOUN T
randomized 0 VERB F
, 0 PUNCT F
double 0 ADJ F
blind 0 ADJ F
, 0 PUNCT F
placebo-controlled 0 VERB F
, 0 PUNCT F
superiority 0 NOUN F
clinical 0 ADJ F
trial 0 NOUN F
was 0 VERB F
designed 0 VERB F
to 0 PART F
assess 0 NOUN F
clinical B-OTHER ADJ F
efficacy I-OTHER NOUN F
of 0 ADP F
antazoline 0 NOUN F
in 0 ADP F
rapid 0 ADJ F
conversion 0 NOUN F
of 0 ADP F
AF 0 NOUN T
to 0 ADP F
sinus 0 NOUN F
rhythm 0 NOUN F
. 0 PUNCT F

Eligible 0 ADJ T
patients 0 NOUN F
will 0 ADP F
present 0 PUNCT F
AF 0 NOUN T
lasting 0 PROPN F
less 0 ADP F
than 0 PUNCT F
43 0 NUM F
hours 0 NOUN F
, 0 PUNCT F
will 0 VERB F
be 0 ADP F
in 0 ADP F
stable 0 ADJ F
cardio-pulmonary 0 ADJ F
condition 0 NOUN F
and 0 CCONJ F
will 0 PUNCT F
have 0 CCONJ F
no 0 DET F
prior 0 PUNCT F
history 0 NOUN F
of 0 ADP F
advanced 0 VERB F
heart 0 NOUN F
failure 0 NOUN F
or 0 CCONJ F
significant 0 ADJ F
valvular 0 ADJ F
disease 0 NOUN F
. 0 PUNCT F

Long-term 0 NOUN T
antiarrhythmic 0 ADJ F
therapy 0 NOUN F
is 0 VERB F
not 0 ADV F
considered 0 PUNCT F
an 0 DET F
exclusion 0 NOUN F
criterion 0 NOUN F
. 0 PUNCT F

Subjects 0 NOUN T
who 0 NUM F
fulfill 0 PUNCT F
selection 0 NOUN F
criteria 0 NOUN F
will 0 VERB F
be 0 VERB F
randomly 0 ADV F
assigned 0 VERB F
to 0 PART F
receive 0 VERB F
intravenously 0 PUNCT F
either 0 PUNCT F
antazoline 0 NOUN F
or 0 CCONJ F
placebo 0 NOUN F
in 0 ADP F
divided 0 VERB F
doses 0 NOUN F
and 0 CCONJ F
observed 0 VERB F
for 0 ADP F
1.5 0 NUM F
hours 0 NOUN F
after 0 ADP F
conversion 0 NOUN F
to 0 ADP F
sinus 0 NOUN F
rhythm 0 NOUN F
or 0 CCONJ F
after 0 ADP F
the 0 DET F
last 0 ADJ F
i.v 0 NOUN F
. 0 PUNCT F

bolus 0 NOUN F
. 0 PUNCT F

Primary 0 ADJ T
end 0 NOUN F
point 0 NOUN F
will 0 VERB F
be 0 VERB F
the 0 DET F
conversion 0 NOUN F
of 0 PUNCT F

Helicobacter 0 NOUN T
pylori 0 NOUN F
and 0 CCONJ F
gastric 0 ADJ F
cancer 0 NOUN F
: 0 PUNCT F
current 0 ADJ F
status 0 NOUN F
of 0 ADP F
the 0 DET F
Austrain 0 NOUN T
Czech 0 NOUN T
German 0 PUNCT T
gastric 0 ADJ F
cancer 0 NOUN F
prevention 0 NOUN F
trial 0 NOUN F
( 0 PUNCT F
PRISMA 0 NOUN T
Study 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

AIM 0 NOUN T
To 0 ADJ T
test 0 NOUN F
the 0 DET F
hypothesis 0 NOUN F
that 0 ADP F
Helicobacter 0 NOUN T
pylori 0 NOUN F
eradication 0 NOUN F
alone 0 ADJ F
can 0 ADV F
reduce 0 VERB F
the 0 DET F
incidence 0 NOUN F
of 0 ADP F
gastric B-PHYSICAL ADJ F
cancer I-PHYSICAL NOUN F
in 0 ADP F
a 0 DET F
subgroup 0 NOUN F
of 0 ADP F
individuals 0 NOUN F
with 0 ADP F
an 0 DET F
increased 0 VERB F
risk 0 NOUN F
for 0 ADP F
this 0 CCONJ F
fatal 0 ADJ F
disease 0 NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
It 0 ADJ T
is 0 VERB F
a 0 DET F
prospective 0 ADJ F
, 0 PUNCT F
randomized 0 VERB F
, 0 PUNCT F
double 0 ADJ F
blind 0 ADJ F
, 0 PUNCT F
placebo 0 NOUN F
controlled 0 VERB F
multinational 0 ADJ F
multicenter 0 NOUN F
trial 0 NOUN F
. 0 PUNCT F

Men 0 NOUN T
between 0 ADP F
55 0 NUM F
and 0 CCONJ F
65 0 NUM F
years 0 NOUN F
of 0 ADP F
age 0 NOUN F
with 0 ADP F
a 0 DET F
gastric 0 ADJ F
cancer 0 NOUN F
phenotype 0 NOUN F
of 0 ADP F
Helicobacter 0 NOUN T
pylori 0 NOUN F
gastritis 0 NOUN F
are 0 VERB F
randomized 0 VERB F
to 0 PART F
receive 0 NOUN F
a 0 DET F
7 0 NUM F
day 0 NOUN F
course 0 NOUN F
of 0 ADP F
omeprazole 0 NUM F
2 0 NUM F
X 0 ADP T
20mg 0 NOUN F
, 0 PUNCT F
clarithromycin 0 NOUN F
2 0 NUM F
X 0 CCONJ T
500mg 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
amoxicillin 0 NOUN F
2 0 NUM F
X 0 PUNCT T
1g 0 NOUN F
for 0 ADP F
7 0 NUM F
days 0 NOUN F
, 0 PUNCT F
or 0 CCONJ F
omeprazole 0 NUM F
2 0 NUM F
X 0 ADP T
20mg 0 NOUN F
plus 0 CCONJ F
placebo 0 NOUN F
. 0 PUNCT F

Follow-up 0 NOUN T
endoscopy 0 NOUN F
is 0 VERB F
scheduled 0 ADP F
3 0 NUM F
months 0 NOUN F
after 0 ADP F
therapy 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
thereafter 0 ADV F
in 0 ADP F
one-year 0 NOUN F
intervals 0 NOUN F
. 0 PUNCT F

Predefined 0 VERB T
study 0 ADP F
endpoints 0 NOUN F
are 0 VERB F
gastric B-PHYSICAL ADJ F
cancer I-PHYSICAL NOUN F
, 0 PUNCT F
precancerous B-PHYSICAL ADJ F
lesions I-PHYSICAL NOUN F
( 0 PUNCT F
dysplasia B-PHYSICAL NOUN F
, 0 PUNCT F
adenoma B-PHYSICAL NOUN F
) 0 PUNCT F
, 0 PUNCT F

Potential 0 ADJ T
effect 0 NOUN F
of 0 ADP F
the 0 DET F
risk 0 NOUN F
of 0 ADP F
ovarian 0 ADJ F
cancer 0 NOUN F
algorithm 0 NOUN F
( 0 PUNCT F
ROCA 0 NOUN T
) 0 PUNCT F
on 0 ADP F
the 0 DET F
mortality B-MORTALITY NOUN F
outcome I-MORTALITY NOUN F
of 0 ADP F
the 0 DET F
Prostate 0 NOUN T
, 0 PUNCT F
Lung 0 NOUN T
, 0 PUNCT F
Colorectal 0 ADJ T
and 0 CCONJ F
Ovarian 0 PUNCT T
( 0 PUNCT F
PLCO 0 NOUN T
) 0 PUNCT F
trial 0 NOUN F
. 0 PUNCT F

Recently 0 ADV T
, 0 PUNCT F
the 0 DET F
Prostate 0 NOUN T
, 0 PUNCT F
Lung 0 NOUN T
, 0 PUNCT F
Colorectal 0 ADJ T
and 0 CCONJ F
Ovarian 0 PUNCT T
( 0 PUNCT F
PLCO 0 NOUN T
) 0 PUNCT F
Trial 0 NOUN T
reported 0 VERB F
no 0 DET F
mortality 0 NOUN F
benefit 0 NOUN F
for 0 ADP F
annual 0 ADJ F
screening 0 VERB F
with 0 ADP F
CA-125 0 NOUN T
and 0 CCONJ F
transvaginal 0 ADJ F
ultrasound 0 NOUN F
( 0 PUNCT F
TVU 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

Currently 0 ADV T
ongoing 0 PUNCT F
is 0 ADP F
the 0 DET F
UK 0 ADP T
Collaborative 0 ADJ T
Trial 0 NOUN T
of 0 ADP F
Ovarian 0 ADJ T
Cancer 0 NOUN T
Screening 0 PUNCT T
( 0 PUNCT F
UKCTOCS 0 NOUN T
) 0 PUNCT F
, 0 PUNCT F
which 0 ADP F
utilizes 0 VERB F
the 0 DET F
risk 0 NOUN F
of 0 ADP F
ovarian 0 ADJ F
cancer 0 NOUN F
algorithm 0 NOUN F
( 0 PUNCT F
ROCA 0 NOUN T
) 0 PUNCT F
, 0 PUNCT F
a 0 DET F
statistical 0 ADJ F
tool 0 NOUN F
that 0 NUM F
considers 0 PROPN F
current 0 PUNCT F
and 0 CCONJ F
past 0 ADJ F
CA125 0 NOUN T
values 0 NOUN F
to 0 DET F
determine 0 VERB F
ovarian 0 DET F
cancer 0 NOUN F
risk 0 NOUN F
. 0 PUNCT F

In 0 ADP T
contrast 0 NOUN F
, 0 PUNCT F
PLCO 0 NOUN T
used 0 VERB F
a 0 DET F
single 0 ADJ F
cutoff 0 NOUN F
for 0 ADP F
CA125 0 NOUN T
, 0 PUNCT F
based 0 VERB F
on 0 ADP F
current 0 ADJ F
levels 0 NOUN F
alone 0 ADJ F
. 0 PUNCT F

We 0 PRON T
investigated 0 VERB F
whether 0 ADP F
having 0 VERB F
had 0 PUNCT F
used 0 PUNCT F
ROCA 0 NOUN T
in 0 ADP F
PLCO 0 NOUN T
could 0 VERB F
have 0 PUNCT F
, 0 PUNCT F
under 0 ADP F
optimal 0 ADJ F
assumptions 0 NOUN F
, 0 PUNCT F
resulted 0 VERB F
in 0 ADP F
a 0 DET F
significant B-MORTALITY ADJ F
mortality I-MORTALITY NOUN F
benefit I-MORTALITY NOUN F
by 0 ADP F
applying 0 VERB F
ROCA 0 NOUN T
to 0 ADP F
PLCO 0 ADP T
CA125 0 NOUN T
screening 0 VERB F
values 0 NOUN F
. 0 PUNCT F

A 0 DET T
best-case 0 NOUN F
scenario 0 ADJ F
assumed 0 ADP F
that 0 ADP F
all 0 DET F
cancers 0 NOUN F
showing 0 VERB F
a 0 DET F
positive 0 ADJ F
screen 0 NOUN F
result 0 NOUN F
earlier 0 PUNCT F
with 0 ADP F
ROCA 0 NOUN T
than 0 PUNCT F
under 0 ADP F
the 0 DET F
PLCO 0 NOUN T
protocol 0 NOUN F
would 0 ADJ F
have 0 PUNCT F
avoided 0 PUNCT F
mortality B-MORTALITY NOUN F
; 0 PUNCT F
under 0 ADP F
a 0 DET F
stage-shift 0 PUNCT F
scenario 0 ADJ F
, 0 PUNCT F
such 0 DET F
women 0 NOUN F
were 0 VERB F
assigned 0 PUNCT F
survival 0 NOUN F
equivalent 0 ADJ F
to 0 ADP F
Stage 0 NOUN T
I/II 0 NOUN T
screen-detected 0 VERB F
cases 0 NOUN F
. 0 PUNCT F

Updated 0 ADP T
PLCO 0 NOUN T
data 0 NOUN F
show 0 VERB F
132 0 NUM F
intervention 0 NOUN F
arm 0 NOUN F
ovarian 0 ADJ F
cancer 0 NOUN F
deaths 0 NOUN F
versus 0 CCONJ F
119 0 NUM F
in 0 ADP F
usual 0 ADJ F
care 0 NOUN F
( 0 PUNCT F
relative 0 ADJ F
risk 0 NOUN F
, 0 PUNCT F
RR 0 NOUN T
= 0 SYM F
1.11 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Forty-three 0 ADP T
ovarian 0 ADJ F
cancer 0 NOUN F
cases 0 NOUN F
, 0 PUNCT F
25 0 NUM F
fatal 0 ADJ F
, 0 PUNCT F
would 0 PUNCT F
have 0 PUNCT F
been 0 PUNCT F
detected 0 VERB F
earlier 0 PUNCT F
with 0 ADP F
ROCA 0 NOUN T
, 0 PUNCT F
with 0 ADP F
a 0 DET F
median 0 ADJ F
( 0 PUNCT F
minimum 0 NOUN F
) 0 PUNCT F
advance 0 NOUN F
time 0 NOUN F
for 0 ADP F
fatal B-MORTALITY ADJ F
cases I-MORTALITY NOUN F
of 0 ADP F
344 0 NUM F
( 0 PUNCT F
147 0 NUM F
) 0 PUNCT F
days 0 NOUN F
. 0 PUNCT F

Best-case 0 NOUN T
and 0 CCONJ F
stage-shift 0 PUNCT F
scenarios 0 NOUN F
gave 0 VERB F
25 0 NUM F
and 0 CCONJ F
19 0 NUM F
deaths B-MORTALITY NOUN F
prevented 0 ADJ F
with 0 ADP F
ROCA 0 NOUN T
, 0 PUNCT F
for 0 ADP F
RRs 0 NOUN T
of 0 ADP F
0.90 0 NUM F
( 0 PUNCT F
95 0 NUM F
% 0 SYM F
CI 0 NOUN T
: 0 PUNCT F
0.69-1.17 0 NUM F
) 0 PUNCT F
and 0 CCONJ F
0.95 0 NUM F
( 0 PUNCT F
95 0 NUM F
% 0 SYM F
CI 0 NOUN T
: 0 PUNCT F
0.74-1.23 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
respectively 0 ADV F
. 0 PUNCT F

Having 0 DET T
utilized 0 PUNCT F
ROCA 0 NOUN T
in 0 ADP F
PLCO 0 NOUN T
would 0 VERB F
not 0 ADV F
have 0 PUNCT F
led 0 VERB F
to 0 ADP F
a 0 DET F
significant 0 ADJ F
mortality B-MORTALITY NOUN F
benefit I-MORTALITY NOUN F
of 0 ADP F
screening 0 PUNCT F
. 0 PUNCT F

However 0 ADV T
, 0 PUNCT F
ROCA 0 NOUN T
could 0 SYM F
still 0 ADV F
show 0 VERB F
a 0 DET F
significant 0 ADJ F
effect 0 NOUN F
in 0 ADP F
other 0 ADJ F
screening 0 ADP F
trials 0 NOUN F
, 0 PUNCT F
including 0 VERB F
UKCTOCS 0 NOUN T
. 0 PUNCT F

Effect 0 NOUN T
of 0 ADP F
extradural 0 ADJ F
analgesia 0 NOUN F
on 0 ADP F
stress 0 NOUN F
responses B-PHYSICAL NOUN F
to 0 ADP F
abdominal 0 ADJ F
surgery 0 NOUN F
in 0 ADP F
infants 0 NOUN F
. 0 PUNCT F

We 0 PRON T
studied 0 VERB F
40 0 NUM F
children 0 NOUN F
younger 0 PUNCT F
than 0 VERB F
4 0 NUM F
yr 0 NOUN F
having 0 ADJ F
elective 0 ADJ F
abdominal 0 ADJ F
surgery 0 NOUN F
under 0 ADP F
general 0 ADJ F
anaesthesia 0 NOUN F
supplemented 0 ADP F
with 0 ADP F
either 0 CCONJ F
systemic 0 ADJ F
opioids 0 NOUN F
or 0 CCONJ F
extradural 0 ADJ F
bupivacaine 0 NOUN F
. 0 PUNCT F

Venous B-PHYSICAL ADJ T
blood I-PHYSICAL NOUN F
samples I-PHYSICAL NOUN F
were 0 VERB F
obtained 0 VERB F
before 0 ADP F
tracheal 0 ADJ F
intubation 0 NOUN F
to 0 PART F
measure 0 ADJ F
baseline 0 NOUN F
concentrations B-PHYSICAL NOUN F
of I-PHYSICAL ADP F
adrenaline I-PHYSICAL NOUN F
, 0 PUNCT F
noradrenaline B-PHYSICAL NOUN F
, 0 PUNCT F
glucose B-PHYSICAL NOUN F
, 0 PUNCT F
ACTH B-PHYSICAL NOUN T
and 0 CCONJ F
cortisol B-PHYSICAL NOUN F
. 0 PUNCT F

Additional 0 ADJ T
samples 0 NOUN F
were 0 VERB F
obtained 0 VERB F
45 0 NUM F
min 0 NOUN F
after 0 ADP F
the 0 DET F
start 0 NOUN F
of 0 ADP F
surgery 0 NOUN F
, 0 PUNCT F
at 0 ADP F
the 0 DET F
end 0 NOUN F
of 0 ADP F
surgery 0 NOUN F
, 0 PUNCT F
1 0 NUM F
h 0 NOUN F
and 0 CCONJ F
24 0 NUM F
h 0 NOUN F
after 0 ADP F
the 0 DET F
end 0 NOUN F
of 0 ADP F
surgery 0 NOUN F
. 0 PUNCT F

Plasma B-OTHER NOUN T
concentrations I-OTHER NOUN F
of I-OTHER ADP F
bupivacaine I-OTHER NOUN F
were 0 VERB F
measured 0 VERB F
also 0 ADV F
in 0 ADP F
the 0 DET F
extradural 0 ADJ F
group 0 NOUN F
at 0 ADP F
each 0 DET F
sampling 0 DET F
time 0 NOUN F
. 0 PUNCT F

Both 0 DET T
techniques 0 NOUN F
provided 0 VERB F
acceptable 0 ADJ F
analgesia 0 NOUN F
, 0 PUNCT F
but 0 CCONJ F
the 0 DET F
perioperative B-PHYSICAL ADJ F
increases 0 CCONJ F
in B-PHYSICAL ADP F
adrenaline B-PHYSICAL NOUN F
, 0 PUNCT F
glucose B-PHYSICAL NOUN F
and 0 CCONJ F
ACTH B-PHYSICAL NOUN T
were 0 VERB F
significantly 0 ADV F
greater 0 PUNCT F
in 0 ADP F
the 0 DET F
opioid 0 NOUN F
group 0 NOUN F
. 0 PUNCT F

Noradrenaline B-PHYSICAL NOUN T
concentrations I-PHYSICAL NOUN F
decreased 0 NUM F
to 0 ADP F
less 0 ADV F
than 0 PUNCT F
baseline 0 NOUN F
values 0 NOUN F
in 0 ADP F
the 0 DET F
extradural 0 ADJ F
group 0 NOUN F
and 0 CCONJ F
were 0 VERB F
significantly 0 ADV F
less 0 ADV F
than 0 PUNCT F
in 0 ADP F
the 0 DET F
opioid 0 NOUN F
group 0 NOUN F
. 0 PUNCT F

The 0 DET T
perioperative B-PHYSICAL ADJ F
increase 0 NOUN F
in B-PHYSICAL ADP F
cortisol B-PHYSICAL NOUN F
was 0 VERB F
similar 0 ADJ F
in 0 ADP F
the 0 DET F
two 0 NUM F
groups 0 NOUN F
, 0 PUNCT F
despite 0 ADP F
the 0 DET F
differences 0 NOUN F
in 0 ADP F
ACTH 0 NOUN T
responses 0 NOUN F
. 0 PUNCT F

Most 0 PUNCT T
responses 0 NOUN F
returned 0 VERB F
to 0 ADP F
the 0 DET F
baseline 0 NOUN F
values 0 NOUN F
within 0 ADP F
24 0 PUNCT F
h. 0 PUNCT F

Contribution 0 NOUN T
of 0 ADP F
endogenous 0 ADJ F
bradykinin 0 NOUN F
to 0 ADP F
fibrinolysis B-PHYSICAL NOUN F
, 0 PUNCT F
inflammation B-PHYSICAL NOUN F
, 0 PUNCT F
and 0 CCONJ F
blood B-PHYSICAL NOUN F
product I-PHYSICAL NOUN F
transfusion I-PHYSICAL NOUN F
following 0 SYM F
cardiac 0 ADJ F
surgery 0 NOUN F
: 0 PUNCT F
a 0 DET F
randomized 0 VERB F
clinical 0 ADJ F
trial 0 NOUN F
. 0 PUNCT F

Bradykinin 0 NOUN T
increases 0 ADJ F
during 0 ADP F
cardiopulmonary 0 ADJ F
bypass 0 NOUN F
( 0 PUNCT F
CPB 0 NOUN T
) 0 PUNCT F
and 0 CCONJ F
stimulates 0 NOUN F
the 0 DET F
release 0 NOUN F
of 0 ADP F
nitric B-PHYSICAL ADJ F
oxide I-PHYSICAL NOUN F
, 0 PUNCT F
inflammatory 0 ADJ F
cytokines 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
tissue-type 0 NOUN F
plasminogen 0 PUNCT F

Clobazam 0 NOUN T
in 0 ADP F
catamenial 0 ADJ F
epilepsy 0 NOUN F
. 0 PUNCT F

A 0 PUNCT T
model 0 NOUN F
for 0 ADP F
evaluating 0 VERB F
anticonvulsants 0 NOUN F
. 0 PUNCT F

The 0 DET T
cyclical 0 ADJ F
exacerbations 0 NOUN F
of 0 ADP F
epilepsy 0 NOUN F
( 0 PUNCT F
catamenial 0 ADJ F
epilepsy 0 NOUN F
) 0 PUNCT F
were 0 VERB F
used 0 VERB F
to 0 PART F
assess 0 NOUN F
the 0 DET F
antiepileptic 0 ADJ F
effect 0 NOUN F
of 0 ADP F
a 0 DET F
benzodiazepine 0 NOUN F
, 0 PUNCT F
clobazam 0 ADV F
. 0 PUNCT F

Doses 0 NOUN T
of 0 ADP F
20 0 NUM F
mg 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
in 0 ADP F
some 0 DET F
cases 0 NOUN F
30 0 NUM F
mg 0 NOUN F
, 0 PUNCT F
per 0 ADP F
day 0 NOUN F
were 0 VERB F
compared 0 VERB F
with 0 ADP F
placebo 0 NOUN F
over 0 ADP F
predetermined 0 VERB F
ten-day 0 NOUN F
periods 0 NOUN F
in 0 ADP F
a 0 DET F
double-blind 0 ADJ F
cross-over 0 NOUN F
study 0 NOUN F
. 0 PUNCT F

The 0 DET T
results 0 ADV F
were 0 VERB F
evaluated 0 VERB F
by 0 ADP F
preference 0 NOUN F
in 0 ADP F
a 0 DET F
sequential 0 ADJ F
procedure 0 NOUN F
. 0 PUNCT F

In 0 ADP T
14 0 NUM F
of 0 ADP F
18 0 NUM F
patients 0 NOUN F
who 0 ADP F
received 0 VERB F
both 0 PUNCT F
treatments 0 ADJ F
clobazam 0 ADV F
was 0 VERB F
superior 0 ADJ F
to 0 ADP F
placebo 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
in 0 ADP F
4 0 NUM F
patients 0 NOUN F
no 0 DET F
preference 0 NOUN F
was 0 VERB F
established 0 VERB F
. 0 PUNCT F

Clobazam 0 NOUN T
completely 0 ADV F
prevented 0 VERB F
seizures B-PHYSICAL NOUN F
in 0 ADP F
most 0 PUNCT F
of 0 ADP F
the 0 DET F
patients 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
toxic 0 ADJ F
effects 0 NOUN F
were 0 ADJ F
of 0 ADP F
low 0 ADJ F
frequency 0 NOUN F
and 0 CCONJ F
severity B-OTHER NOUN F
. 0 PUNCT F

Diclofenac 0 NOUN T
, 0 PUNCT F
a 0 DET F
nonsteroidal 0 ADJ F
anti-inflammatory 0 ADJ F
drug 0 NOUN F
, 0 PUNCT F
decreases 0 ADJ F
proteinuria 0 NOUN F
in 0 ADP F
some 0 DET F
glomerular 0 ADJ F
diseases 0 NOUN F
: 0 PUNCT F
a 0 DET F
controlled 0 VERB F
study 0 NOUN F
. 0 PUNCT F

Treatment 0 NOUN T
with 0 ADP F
nonsteroidal 0 ADJ F
anti-inflammatory 0 ADJ F
drugs 0 NOUN F
( 0 PUNCT F
NSAIDs 0 NOUN T
) 0 PUNCT F
was 0 VERB F
first 0 ADJ F
used 0 VERB F
in 0 ADP F
glomerulonephritis 0 NOUN F
( 0 PUNCT F
GN 0 NOUN T
) 0 PUNCT F
in 0 ADP F
1966 0 NUM F
but 0 CCONJ F
its 0 PUNCT F
efficiency 0 NOUN F
is 0 VERB F
still 0 ADV F
debated 0 VERB F
. 0 PUNCT F

We 0 PRON T
studied 0 VERB F
the 0 DET F
antiproteinuric B-PHYSICAL ADJ F
effect 0 NOUN F
of 0 ADP F
such 0 CCONJ F
a 0 ADP F
treatment 0 NOUN F
in 0 ADP F
a 0 DET F
double-blind 0 ADJ F
study 0 NOUN F
. 0 PUNCT F

29 0 NUM F
GN 0 NOUN T
patients 0 NOUN F
with 0 ADP F
normal 0 ADJ F
renal 0 ADJ F
function 0 NOUN F
( 0 PUNCT F
17 0 NUM F
membranoproliferative 0 ADJ F
GN 0 NOUN T
, 0 PUNCT F
12 0 NUM F
IgA 0 NOUN T
GN 0 NOUN T
) 0 PUNCT F
were 0 VERB F
randomly 0 ADV F
assigned 0 VERB F
to 0 PART F
receive 0 NOUN F
100 0 NUM F
mg/day 0 NOUN F
of 0 ADP F
diclofenac 0 NOUN F
or 0 CCONJ F
placebo 0 NOUN F
for 0 ADP F
at 0 ADP F
least 0 ADV F
2 0 NUM F
months 0 NOUN F
. 0 PUNCT F

There 0 PUNCT T
was 0 VERB F
a 0 DET F
significant 0 ADJ F
antiproteinuric B-PHYSICAL ADJ F
effect 0 NOUN F
of 0 ADP F
diclofenac 0 NOUN F
versus 0 CCONJ F
placebo 0 NOUN F
with 0 ADP F
a 0 DET F
fall 0 NOUN F
of 0 ADP F
70 0 NUM F
% 0 SYM F
in 0 ADP F
the 0 DET F
diclofenac 0 NOUN F
group 0 NOUN F
versus 0 CCONJ F
6 0 NUM F
% 0 SYM F
in 0 ADP F
the 0 DET F
placebo 0 NOUN F
group 0 NOUN F
( 0 PUNCT F
p 0 NOUN F
less 0 ADV F
than 0 ADP F
0.001 0 NUM F
with 0 ADP F
the 0 DET F
Mann-Whitney 0 NOUN T
test 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
median 0 ADP F
was 0 ADV F
3 0 NUM F
mg/min 0 NOUN F
at 0 ADP F
onset 0 NOUN F
and 0 CCONJ F
2.45 0 NUM F
mg/min 0 NOUN F
after 0 ADP F
2 0 NUM F
months 0 NOUN F
treatment 0 NOUN F
with 0 ADP F
the 0 DET F
placebo 0 NOUN F
. 0 PUNCT F

In 0 ADP T
the 0 DET F
diclofenac 0 NOUN F
group 0 NOUN F
, 0 PUNCT F
it 0 PRON F
was 0 VERB F
2.2 0 NUM F
and 0 CCONJ F
0.95 0 NUM F
mg/min 0 NOUN F
, 0 PUNCT F
respectively 0 ADV F
( 0 PUNCT F
p 0 NOUN F
less 0 ADV F
than 0 PUNCT F
0.01 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Diclofenac 0 NOUN T
did 0 PUNCT F
not 0 ADV F
significantly 0 ADV F
increase 0 ADV F
creatinine B-PHYSICAL NOUN F
levels I-PHYSICAL NOUN F
. 0 PUNCT F

Gastric B-PHYSICAL ADJ T
irritation I-PHYSICAL NOUN F
was 0 VERB F
noted 0 VERB F
only 0 ADV F
once 0 ADP F
. 0 PUNCT F

This 0 DET T
study 0 NOUN F
establishes 0 NOUN F
the 0 DET F
short-term B-PHYSICAL NOUN F
antiproteinuric I-PHYSICAL ADJ F
action I-PHYSICAL NOUN F
of 0 ADP F
diclofenac 0 NOUN F
. 0 PUNCT F

Whether 0 ADP T
this 0 DET F
action 0 NOUN F
affects 0 NOUN F
the 0 DET F
final 0 ADJ F
outcome 0 NOUN F
is 0 VERB F
not 0 ADV F
yet 0 ADV F
determined 0 VERB F
. 0 PUNCT F

Benefit 0 NOUN T
of 0 ADP F
FSH 0 NOUN T
priming 0 VERB F
of 0 ADP F
women 0 NOUN F
with 0 ADP F
PCOS 0 NOUN T
to 0 ADP F
the 0 CCONJ F
in 0 PUNCT F
vitro 0 ADJ F
maturation 0 NOUN F
procedure 0 NOUN F
and 0 CCONJ F
the 0 DET F
outcome 0 NOUN F
: 0 PUNCT F
a 0 DET F
randomized 0 VERB F
prospective 0 ADJ F
study 0 NOUN F
. 0 PUNCT F

The 0 DET T
aim 0 NOUN F
of 0 ADP F
this 0 DET F
study 0 NOUN F
was 0 VERB F
to 0 PART F
determine 0 NOUN F
whether 0 ADP F
the 0 DET F
rates B-PHYSICAL NOUN F
of I-PHYSICAL ADP F
in I-PHYSICAL PUNCT F
vitro I-PHYSICAL ADJ F
oocyte I-PHYSICAL NOUN F
maturation I-PHYSICAL NOUN F
, 0 PUNCT F
fertilization B-PHYSICAL NOUN F
and 0 CCONJ F
cleavage B-PHYSICAL NOUN F
, 0 PUNCT F
as 0 PUNCT F
well 0 PUNCT F
as 0 CCONJ F
implantation B-PHYSICAL NOUN F
rate I-PHYSICAL NOUN F
and 0 CCONJ F
pregnancy B-PHYSICAL NOUN F
rate I-PHYSICAL NOUN F
, 0 PUNCT F
could 0 VERB F
be 0 VERB F
improved 0 VERB F
by 0 ADP F
low-dose 0 NOUN F
priming 0 VERB F
with 0 ADP F
FSH 0 NOUN T
in 0 VERB F
vivo 0 ADV F
before 0 ADP F
retrieval 0 NOUN F
of 0 ADP F
immature 0 ADJ F
oocytes 0 NOUN F
in 0 ADP F
patients 0 NOUN F
with 0 ADP F
polycystic 0 ADJ F
ovary 0 NOUN F
syndrome 0 NOUN F
( 0 PUNCT F
PCOS 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

From 0 ADP T
March 0 NOUN T
1998 0 NUM F
to 0 ADP F
June 0 NOUN T
2000 0 NUM F
, 0 PUNCT F
a 0 DET F
total 0 NOUN F
of 0 ADP F
28 0 NUM F
women 0 NOUN F
underwent 0 VERB F
36 0 NUM F
completed 0 VERB F
treatment 0 NOUN F
cycles 0 NOUN F
, 0 PUNCT F
randomized 0 ADP F
sequentially 0 ADV F
in 0 ADP F
one 0 NUM F
of 0 ADP F
two 0 NUM F
groups 0 NOUN F
. 0 PUNCT F

Women 0 NOUN T
in 0 ADP F
group 0 NOUN F
1 0 NUM F
( 0 PUNCT F
n 0 NOUN F
= 0 SYM F
12 0 NUM F
cycles 0 NOUN F
) 0 PUNCT F
received 0 VERB F
no 0 DET F
stimulation 0 NOUN F
and 0 CCONJ F
women 0 NOUN F
in 0 ADP F
group 0 NOUN F
2 0 NUM F
( 0 PUNCT F
n 0 NOUN F
= 0 SYM F
24 0 NUM F
cycles 0 NOUN F
) 0 PUNCT F
received 0 VERB F
150 0 NUM F
iu 0 PUNCT F
recombinant 0 ADJ F
FSH 0 NOUN T
day 0 NOUN F
( 0 PUNCT F
-1 0 NUM F
) 0 PUNCT F
for 0 ADP F
3 0 NUM F
days 0 NOUN F
, 0 PUNCT F
initiated 0 VERB F
on 0 ADP F
day 0 NOUN F
3 0 NUM F
after 0 ADP F
menstruation 0 NOUN F
. 0 PUNCT F

Aspiration 0 NOUN T
was 0 VERB F
performed 0 VERB F
transvaginally 0 ADV F
between 0 ADP F
day 0 NOUN F
9 0 NUM F
and 0 CCONJ F
day 0 NOUN F
17 0 NUM F
in 0 ADP F
the 0 DET F
unstimulated 0 VERB F
group 0 NOUN F
and 0 CCONJ F
on 0 ADP F
day 0 NOUN F
8 0 NUM F
or 0 CCONJ F
day 0 NOUN F
9 0 NUM F
in 0 ADP F
the 0 DET F
FSH-primed 0 ADJ T
group 0 NOUN F
after 0 ADP F
FSH 0 NOUN T
deprivation 0 NOUN F
for 0 ADP F
2 0 NUM F
or 0 CCONJ F
3 0 NUM F
days 0 NOUN F
. 0 PUNCT F

All 0 DET T
cumulus-enclosed 0 VERB F
oocytes 0 NOUN F
of 0 ADP F
healthy 0 ADJ F
appearance 0 NOUN F
were 0 VERB F
matured 0 ADJ F
in 0 ADP F
culture 0 NOUN F
medium 0 NOUN F
( 0 PUNCT F
TCM-199 0 NOUN T
) 0 PUNCT F
in 0 ADP F
vitro 0 ADJ F
for 0 ADP F
28-36 0 NUM F
h 0 NOUN F
before 0 ADP F
intracytoplasmic 0 ADJ F
sperm 0 NOUN F
injection 0 NOUN F
( 0 PUNCT F
ICSI 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

After 0 ADP T
oocyte 0 NOUN F
retrieval 0 NOUN F
the 0 DET F
women 0 NOUN F
were 0 VERB F
given 0 VERB F
oestradiol 0 NOUN F
( 0 PUNCT F
6 0 NUM F
mg 0 NOUN F
day 0 NOUN F
( 0 PUNCT F
-1 0 NUM F
) 0 PUNCT F
) 0 PUNCT F
and 0 CCONJ F
progesterone 0 NOUN F
administration 0 NOUN F
( 0 PUNCT F
300 0 NUM F
mg 0 NOUN F
day 0 NOUN F
( 0 PUNCT F
-1 0 NUM F
) 0 PUNCT F
) 0 PUNCT F
was 0 VERB F
initiated 0 VERB F
2 0 NUM F
days 0 NOUN F
later 0 ADJ F
. 0 PUNCT F

Suitable 0 ADJ T
embryos 0 NOUN F
( 0 PUNCT F
maximum 0 NOUN F
two 0 NUM F
embryos 0 NOUN F
) 0 PUNCT F
were 0 VERB F
transferred 0 VERB F
on 0 ADP F
day 0 NOUN F
3 0 NUM F
after 0 ADP F
ICSI 0 NOUN T
. 0 PUNCT F

The 0 DET T
percentage 0 NOUN F
of 0 ADP F
oocytes B-OTHER NOUN F
reaching I-OTHER VERB F
metaphase I-OTHER NOUN F
II I-OTHER NUM T
was 0 ADJ F
significantly 0 ADV F
higher 0 PUNCT F
( 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.05 0 NUM F
) 0 PUNCT F
in 0 ADP F
the 0 DET F
FSH-primed 0 ADJ T
group 0 NOUN F
( 0 PUNCT F
59 0 NUM F
% 0 SYM F
, 0 PUNCT F
92/156 0 NOUN F
) 0 PUNCT F
compared 0 VERB F
with 0 ADP F
the 0 DET F
non-primed 0 ADJ F
group 0 NOUN F
( 0 PUNCT F
44 0 NUM F
% 0 SYM F
, 0 PUNCT F
36/81 0 PUNCT F
) 0 PUNCT F
. 0 PUNCT F

There 0 PUNCT T
were 0 VERB F
no 0 DET F
significant 0 ADJ F
differences 0 NOUN F
in 0 ADP F
the 0 DET F
rates 0 NOUN F
of 0 ADP F
oocyte B-OTHER NOUN F
fertilization I-OTHER NOUN F
and 0 CCONJ F
cleavage B-OTHER NOUN F
between 0 ADP F
these 0 DET F
groups 0 NOUN F
. 0 PUNCT F

No 0 DET T
pregnancies B-PHYSICAL NOUN F
were 0 VERB F
obtained 0 VERB F
in 0 ADP F
group 0 NOUN F
1 0 NUM F
( 0 PUNCT F
0 0 NUM F
% 0 SYM F
, 0 PUNCT F
0/12 0 ADP F
) 0 PUNCT F
, 0 PUNCT F
whereas 0 ADP F
seven 0 NUM F
clinical B-OTHER ADJ F
pregnancies I-OTHER NOUN F
were 0 VERB F
obtained 0 VERB F
in 0 ADP F
group 0 NOUN F
2 0 NUM F
( 0 PUNCT F
29 0 NUM F
% 0 SYM F
, 0 PUNCT F
7/24 0 NOUN F
) 0 PUNCT F
( 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.05 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

In 0 ADP T
group 0 NOUN F
2 0 NUM F
, 0 PUNCT F
37 0 NUM F
embryo 0 NOUN F
transfers 0 NOUN F
resulted 0 VERB F
in 0 ADP F
eight 0 NUM F
implantations B-PHYSICAL NOUN F
( 0 PUNCT F
21.6 0 NUM F
% 0 SYM F
) 0 PUNCT F
. 0 PUNCT F

Three 0 NUM T
healthy B-PHYSICAL ADJ F
singleton I-PHYSICAL NOUN F
children I-PHYSICAL NOUN F
have 0 VERB F
been 0 PUNCT F
born B-PHYSICAL VERB F
at 0 ADP F
term 0 NOUN F
; 0 PUNCT F
the 0 DET F
remaining 0 VERB F
pregnancies 0 NOUN F
ended 0 PUNCT F
with 0 ADP F
spontaneous B-ADVERSE-EFFECTS ADJ F
abortions I-ADVERSE-EFFECTS NOUN F
in 0 ADP F
the 0 DET F
first 0 ADJ F
trimester 0 NOUN F
. 0 PUNCT F

These 0 DET T
results 0 NOUN F
indicate 0 VERB F
that 0 ADP F
priming 0 VERB F
with 0 ADP F
recombinant 0 ADJ F
FSH 0 NOUN T
before 0 ADP F
harvesting 0 PUNCT F
of 0 ADP F
immature 0 ADJ F
oocytes 0 NOUN F
from 0 ADP F
patients 0 NOUN F
with 0 ADP F
PCOS 0 NOUN T
may 0 VERB F
improve 0 VERB F
the 0 DET F
maturational B-OTHER ADJ F
potential I-OTHER NOUN F
of I-OTHER ADP F
the I-OTHER DET F
oocytes I-OTHER NOUN F
and I-OTHER CCONJ F
the I-OTHER DET F
implantation I-OTHER NOUN F
rate I-OTHER NOUN F
of I-OTHER ADP F
the I-OTHER DET F
cleaved I-OTHER VERB F
embryos I-OTHER NOUN F
. 0 PUNCT F

Pentoxifylline 0 NOUN T
to 0 PART F
treat 0 NOUN F
radiation 0 NOUN F
proctitis 0 NOUN F
: 0 PUNCT F
a 0 DET F
small 0 ADJ F
and 0 CCONJ F
inconclusive 0 ADJ F
randomised 0 VERB F
trial 0 NOUN F
. 0 PUNCT F

This 0 DET T
prospective 0 ADJ F
randomised 0 VERB F
controlled 0 DET F
study 0 NOUN F
of 0 ADP F
40 0 NUM F
patients 0 NOUN F
could 0 ADP F
not 0 ADV F
show 0 VERB F
a 0 DET F
statistically 0 ADV F
significant 0 ADJ F
advantage 0 NOUN F
with 0 ADP F
6 0 NUM F
months 0 NOUN F
of 0 ADP F
pentoxifylline 0 NOUN F
compared 0 VERB F
with 0 ADP F
standard 0 ADJ F
measures 0 NOUN F
for 0 ADP F
late B-PHYSICAL ADJ F
radiation-induced I-PHYSICAL VERB F
rectal I-PHYSICAL ADJ F
bleeding I-PHYSICAL VERB F
. 0 PUNCT F

However 0 ADV T
, 0 PUNCT F
a 0 DET F
modest 0 ADJ F
benefit 0 NOUN F
can 0 PRON F
not 0 ADV F
be 0 VERB F
excluded 0 VERB F
and 0 CCONJ F
larger 0 PUNCT F
randomised 0 ADP F
placebo-controlled 0 VERB F
trials 0 NOUN F
with 0 ADP F
longer 0 PUNCT F
durations 0 NOUN F
of 0 ADP F
pentoxifylline B-OTHER NOUN F
treatment I-OTHER NOUN F
may 0 VERB F
be 0 VERB F
justified 0 VERB F
. 0 PUNCT F

Effectiveness 0 NOUN T
of 0 ADP F
a 0 DET F
calculus 0 NOUN F
scaling 0 PUNCT F
gel 0 NOUN F
. 0 PUNCT F

This 0 DET T
study 0 NOUN F
evaluated 0 VERB F
the 0 DET F
effect 0 NOUN F
of 0 ADP F
a 0 DET F
calculus 0 NOUN F
scaling 0 PUNCT F
gel 0 NOUN F
( 0 PUNCT F
SofScale 0 NOUN T
) 0 PUNCT F
on 0 ADP F
time B-OTHER NOUN F
and I-OTHER CCONJ F
ease I-OTHER NOUN F
of I-OTHER ADP F
the I-OTHER DET F
scaling I-OTHER ADJ F
procedure I-OTHER NOUN F
in 0 ADP F
a 0 DET F
double-blind 0 ADJ F
, 0 PUNCT F
split-mouth 0 NOUN F
clinical 0 ADJ F
study 0 NOUN F
of 0 ADP F
32 0 NUM F
subjects 0 NOUN F
. 0 PUNCT F

The 0 DET T
Volpe-Manhold B-PHYSICAL ADJ T
calculus I-PHYSICAL NOUN F
index I-PHYSICAL NOUN F
was 0 VERB F
used 0 VERB F
to 0 PART F
quantify 0 NOUN F
the 0 DET F
distribution 0 NOUN F
and 0 CCONJ F
amount 0 NOUN F
of 0 ADP F
calculus 0 NOUN F
deposition 0 NOUN F
on 0 ADP F
the 0 DET F
lingual 0 ADJ F
aspect 0 NOUN F
of 0 ADP F
the 0 DET F
mandibular 0 ADJ F
6 0 NUM F
anterior 0 ADJ F
teeth 0 NOUN F
at 0 ADP F
baseline 0 NOUN F
. 0 PUNCT F

The 0 DET T
gel 0 NOUN F
was 0 VERB F
applied 0 VERB F
directly 0 ADV F
to 0 ADP F
the 0 DET F
calculus 0 NOUN F
and 0 CCONJ F
subgingivally 0 NOUN F
to 0 ADP F
the 0 DET F
area 0 NOUN F
to 0 PART F
be 0 PUNCT F
scaled 0 ADV F
. 0 PUNCT F

Pre- 0 PUNCT T
and 0 CCONJ F
post-treatment 0 NOUN F
gingival 0 ADJ F
and 0 CCONJ F
stain 0 NOUN F
indices 0 NOUN F
were 0 VERB F
taken 0 VERB F
. 0 PUNCT F

Operator B-OTHER NOUN T
and 0 CCONJ F
subject B-OTHER PUNCT F
questionnaires I-OTHER NOUN F
were 0 VERB F
completed 0 VERB F
immediately 0 ADV F
after 0 ADP F
treatment 0 NOUN F
to 0 PART F
determine 0 NOUN F
ease 0 NOUN F
of 0 ADP F
the 0 DET F
scaling 0 ADJ F
procedure 0 NOUN F
. 0 PUNCT F

Results 0 NOUN T
were 0 VERB F
analyzed 0 VERB F
with 0 ADP F
paired 0 VERB F
t-tests 0 NOUN F
. 0 PUNCT F

The 0 DET T
time B-OTHER NOUN F
difference I-OTHER NOUN F
in I-OTHER ADP F
scaling I-OTHER DET F
between 0 ADP F
the 0 DET F
product 0 NOUN F
and 0 CCONJ F
placebo 0 NOUN F
side 0 NOUN F
was 0 VERB F
not 0 ADV F
significant 0 ADJ F
. 0 PUNCT F

This 0 DET T
study 0 NOUN F
found 0 VERB F
that 0 ADP F
SofScale 0 NOUN T
is 0 VERB F
safe 0 ADJ F
to 0 ADP F
gingival B-PHYSICAL ADJ F
tissues I-PHYSICAL NOUN F
and 0 CCONJ F
does 0 PUNCT F
not 0 ADV F
promote 0 VERB F
tooth B-PHYSICAL NOUN F
sensitivity I-PHYSICAL NOUN F
. 0 PUNCT F

However 0 ADV T
, 0 PUNCT F
this 0 DET F
study 0 NOUN F
did 0 PUNCT F
not 0 ADV F
find 0 VERB F
significant 0 ADJ F
differences 0 NOUN F
in 0 ADP F
scaling 0 DET F
time 0 NOUN F
between 0 ADP F
product 0 NOUN F
and 0 CCONJ F
placebo 0 NOUN F
when 0 ADP F
using 0 VERB F
a 0 DET F
2-minute 0 ADJ F
gel 0 NOUN F
contact 0 NOUN F
time 0 NOUN F
. 0 PUNCT F

Acute 0 ADJ T
pressor 0 NOUN F
and 0 CCONJ F
hormonal 0 ADJ F
effects 0 NOUN F
of 0 ADP F
beta-endorphin 0 NOUN F
at 0 ADP F
high 0 ADJ F
doses 0 NOUN F
in 0 ADP F
healthy 0 ADJ F
and 0 CCONJ F
hypertensive 0 ADJ F
subjects 0 NOUN F
: 0 PUNCT F
role 0 NOUN F
of 0 ADP F
opioid 0 NOUN F
receptor 0 NOUN F
agonism 0 NOUN F
. 0 PUNCT F

CONTEXT 0 NOUN T
The 0 DET T
opioid 0 NOUN F
system 0 NOUN F
is 0 VERB F
involved 0 VERB F
in 0 ADP F
blood 0 NOUN F
pressure 0 NOUN F
regulation 0 NOUN F
in 0 ADP F
both 0 CCONJ F
normal 0 ADJ F
humans 0 NOUN F
and 0 CCONJ F
patients 0 NOUN F
with 0 ADP F
essential 0 ADJ F
hypertension 0 NOUN F
. 0 PUNCT F

OBJECTIVE 0 NOUN T
The 0 DET T
objective 0 NOUN F
of 0 ADP F
the 0 DET F
study 0 NOUN F
was 0 VERB F
to 0 PART F
investigate 0 NOUN F
the 0 DET F
effects 0 NOUN F
of 0 ADP F
a 0 DET F
high-dose 0 NOUN F
infusion 0 NOUN F
of 0 ADP F
beta-endorphin 0 NOUN F
, 0 PUNCT F
an 0 DET F
opioid 0 NOUN F
peptide 0 NOUN F
, 0 PUNCT F
on 0 ADP F
blood 0 NOUN F
pressure 0 NOUN F
and 0 CCONJ F
on 0 ADP F
the 0 DET F
hormonal 0 ADJ F
profile 0 NOUN F
in 0 ADP F
healthy 0 ADJ F
subjects 0 NOUN F
and 0 CCONJ F
in 0 ADP F
hypertensive 0 ADJ F
patients 0 NOUN F
and 0 CCONJ F
the 0 DET F
mediation 0 NOUN F
played 0 VERB F
by 0 ADP F
opioid 0 NOUN F
receptor 0 NOUN F
agonism 0 NOUN F
. 0 PUNCT F

DESIGN 0 NOUN T
, 0 PUNCT F
SETTING 0 VERB T
, 0 PUNCT F
AND 0 CCONJ T
PARTICIPANTS 0 ADP T
According 0 PUNCT T
to 0 ADP F
a 0 DET F
randomized 0 VERB F
double-blind 0 ADJ F
design 0 NOUN F
, 0 PUNCT F
11 0 NUM F
healthy 0 ADJ F
subjects 0 NOUN F
( 0 PUNCT F
controls 0 NOUN F
) 0 PUNCT F
and 0 CCONJ F
12 0 NUM F
hypertensive 0 ADJ F
inpatients 0 NOUN F
( 0 PUNCT F
mean 0 NOUN F
age 0 NOUN F
, 0 PUNCT F
38.9 0 NUM F
and 0 CCONJ F
40.4 0 NUM F
yr 0 NOUN F
, 0 PUNCT F
respectively 0 ADV F
) 0 PUNCT F
received 0 VERB F
1-h 0 NOUN F
iv 0 PUNCT F
infusion 0 NOUN F
of 0 ADP F
beta-endorphin 0 NOUN F
( 0 PUNCT F
250 0 NUM F
mug/h 0 PUNCT F
) 0 PUNCT F
and 0 CCONJ F
, 0 PUNCT F
on 0 ADP F
another 0 ADP F
occasion 0 NOUN F
, 0 PUNCT F
the 0 DET F
same 0 ADJ F
infusion 0 NOUN F
protocol 0 NOUN F
preceded 0 VERB F
by 0 ADP F
the 0 DET F
opioid 0 NOUN F
antagonist 0 NOUN F
naloxone 0 NOUN F
( 0 PUNCT F
8 0 NUM F
mg 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

MAIN 0 ADJ T
OUTCOME 0 NOUN T
MEASURES 0 NOUN T
Hemodynamic B-PHYSICAL ADJ T
and I-PHYSICAL CCONJ F
hormonal I-PHYSICAL ADJ F
measurements I-PHYSICAL NOUN F
were 0 VERB F
performed 0 VERB F
at 0 ADP F
established 0 VERB F
times 0 NOUN F
during 0 ADP F
the 0 DET F
infusion 0 NOUN F
protocols 0 NOUN F
. 0 PUNCT F

RESULTS 0 NOUN T
At 0 ADP T
baseline 0 NOUN F
, 0 PUNCT F
circulating 0 VERB F
beta-endorphin 0 NOUN F
, 0 PUNCT F
norepinephrine 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
endothelin-1 0 NOUN F
in 0 ADP F
hypertensive 0 ADJ F
patients 0 NOUN F
were 0 VERB F
significantly 0 ADV F
( 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.05 0 NUM F
) 0 PUNCT F
higher 0 PUNCT F
than 0 CCONJ F
in 0 ADP F
controls 0 NOUN F
. 0 PUNCT F

In 0 ADP T
controls 0 NOUN F
, 0 PUNCT F
beta-endorphin 0 NOUN F
reduced 0 VERB F
blood B-PHYSICAL NOUN F
pressure I-PHYSICAL NOUN F
( 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.01 0 NUM F
) 0 PUNCT F
and 0 CCONJ F
circulating B-PHYSICAL VERB F
norepinephrine I-PHYSICAL NOUN F
( 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.02 0 NUM F
) 0 PUNCT F
and 0 CCONJ F
increased 0 VERB F
plasma 0 NOUN F
atrial 0 ADJ F
natriuretic B-PHYSICAL ADJ F
factor I-PHYSICAL NOUN F
( 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.003 0 NUM F
) 0 PUNCT F
and 0 CCONJ F
GH 0 NOUN T
( 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.0001 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

In 0 ADP T
hypertensive 0 ADJ F
patients 0 NOUN F
, 0 PUNCT F
beta-endorphin 0 NOUN F
decreased 0 VERB F
systemic B-PHYSICAL ADJ F
vascular I-PHYSICAL ADJ F
resistance I-PHYSICAL NOUN F
( 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.0001 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
blood B-PHYSICAL NOUN F
pressure I-PHYSICAL NOUN F
( 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.0001 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
and 0 CCONJ F
plasma B-PHYSICAL NOUN F
norepinephrine I-PHYSICAL NOUN F
( 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.0001 0 NUM F
) 0 PUNCT F
and 0 CCONJ F
endothelin-1 B-PHYSICAL NOUN F
( 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.0001 0 NUM F
) 0 PUNCT F
and 0 CCONJ F
raised 0 VERB F
circulating 0 NUM F
atrial 0 ADJ F
natriuretic B-PHYSICAL ADJ F
factor I-PHYSICAL NOUN F
( 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.0001 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
GH B-PHYSICAL NOUN T
( 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.0001 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
and 0 CCONJ F
IGF-I B-PHYSICAL NOUN T
( 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.0001 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

These 0 DET T
hemodynamic B-PHYSICAL ADJ F
and I-PHYSICAL CCONJ F
hormonal I-PHYSICAL ADJ F
responses I-PHYSICAL NOUN F
to 0 ADP F
beta-endorphin 0 NOUN F
in 0 ADP F
hypertensive 0 ADJ F
patients 0 NOUN F
were 0 VERB F
significantly 0 ADV F
( 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.0001 0 NUM F
) 0 PUNCT F
greater 0 PUNCT F
than 0 CCONJ F
in 0 ADP F
controls 0 NOUN F
but 0 CCONJ F
were 0 VERB F
annulled 0 VERB F
in 0 ADP F
all 0 DET F
individuals 0 NOUN F
when 0 ADP F
naloxone 0 PUNCT F
preceded 0 VERB F
beta-endorphin 0 NOUN F
infusion 0 NOUN F
. 0 PUNCT F

CONCLUSIONS 0 NOUN T
High 0 ADJ T
doses 0 NOUN F
of 0 ADP F
beta-endorphin 0 NOUN F
induce 0 VERB F
hypotensive 0 ADJ F
and 0 CCONJ F
beneficial 0 ADJ F
hormonal 0 ADJ F
effects 0 NOUN F
in 0 ADP F
humans 0 NOUN F
, 0 PUNCT F
which 0 ADP F
are 0 VERB F
enhanced 0 VERB F
in 0 ADP F
essential 0 ADJ F
hypertension 0 NOUN F
and 0 CCONJ F
are 0 VERB F
mediated 0 VERB F
by 0 ADP F
opioid 0 NOUN F
receptors 0 NOUN F
. 0 PUNCT F

Effect 0 NOUN T
of 0 ADP F
pravastatin 0 NOUN F
on 0 ADP F
kidney B-PHYSICAL NOUN F
function I-PHYSICAL NOUN F
and I-PHYSICAL CCONJ F
urinary I-PHYSICAL ADJ F
protein I-PHYSICAL NOUN F
excretion I-PHYSICAL NOUN F
in 0 ADP F
autosomal 0 ADJ F
dominant 0 ADJ F
polycystic 0 ADJ F
kidney 0 NOUN F
disease 0 NOUN F
. 0 PUNCT F

OBJECTIVE 0 NOUN T
Autosomal 0 ADJ T
dominant 0 ADJ F
polycystic 0 ADJ F
kidney 0 NOUN F
disease 0 NOUN F
( 0 PUNCT F
ADPKD 0 NOUN T
) 0 PUNCT F
is 0 VERB F
progressive 0 ADJ F
, 0 PUNCT F
resulting 0 VERB F
in 0 ADP F
end-stage 0 NOUN F
kidney 0 NOUN F
failure 0 NOUN F
in 0 ADP F
most 0 DET F
patients 0 NOUN F
. 0 PUNCT F

Experimental 0 ADJ T
and 0 CCONJ F
clinical 0 ADJ F
studies 0 NOUN F
have 0 CCONJ F
suggested 0 VERB F
that 0 ADP F
statins 0 NOUN F
may 0 DET F
slow 0 CCONJ F
the 0 DET F
progression 0 NOUN F
of 0 ADP F
chronic B-PHYSICAL ADJ F
kidney I-PHYSICAL NOUN F
disease I-PHYSICAL NOUN F
in 0 ADP F
general 0 ADJ F
and 0 CCONJ F
ADPKD 0 NOUN T
specifically 0 ADV F
. 0 PUNCT F

MATERIAL 0 NOUN T
AND 0 CCONJ T
METHODS 0 NOUN T
This 0 PUNCT T
randomized 0 PUNCT F
open-label 0 NOUN F
clinical 0 ADJ F
trial 0 NOUN F
was 0 VERB F
conducted 0 VERB F
to 0 PART F
assess 0 NOUN F
the 0 DET F
effect 0 NOUN F
of 0 ADP F
pravastatin 0 NOUN F
20 0 NUM F
mg 0 NOUN F
on 0 ADP F
kidney 0 NOUN F
function 0 NOUN F
and 0 CCONJ F
urinary 0 ADJ F
protein 0 NOUN F
excretion 0 NOUN F
in 0 ADP F
patients 0 NOUN F
with 0 ADP F
ADPKD 0 NOUN T
. 0 PUNCT F

Sixty 0 NUM T
patients 0 NOUN F
were 0 VERB F
initially 0 ADV F
recruited 0 VERB F
but 0 CCONJ F
49 0 NUM F
of 0 ADP F
these 0 PUNCT F
received 0 VERB F
either 0 CCONJ F
pravastatin 0 NOUN F
20 0 NUM F
mg 0 NOUN F
or 0 CCONJ F
no 0 DET F
treatment 0 NOUN F
for 0 ADP F
2 0 NUM F
years 0 NOUN F
. 0 PUNCT F

Trial 0 NOUN T
visits 0 NOUN F
were 0 VERB F
conducted 0 ADP F
every 0 DET F
3 0 NUM F
months 0 NOUN F
, 0 PUNCT F
assessing 0 ADP F
kidney B-PHYSICAL NOUN F
function I-PHYSICAL NOUN F
by 0 ADP F
estimated 0 ADP F
glomerular B-OTHER ADJ F
filtration I-OTHER NOUN F
rate I-OTHER NOUN F
and 0 CCONJ F
24 0 NUM F
h B-OTHER NOUN F
urine I-OTHER NOUN F
creatinine I-OTHER NOUN F
clearance I-OTHER NOUN F
and 0 CCONJ F
urinary B-OTHER ADJ F
protein I-OTHER NOUN F
excretion I-OTHER NOUN F
. 0 PUNCT F

RESULTS 0 NOUN T
There 0 CCONJ T
were 0 VERB F
no 0 DET F
significant 0 ADJ F
( 0 PUNCT F
p 0 NOUN F
> 0 SYM F
0.05 0 NUM F
) 0 PUNCT F
changes B-OTHER NOUN F
in 0 ADP F
markers 0 NOUN F
of 0 ADP F
kidney B-PHYSICAL NOUN F
function I-PHYSICAL NOUN F
or 0 CCONJ F
urinary B-PHYSICAL ADJ F
protein I-PHYSICAL NOUN F
excretion I-PHYSICAL NOUN F
between 0 ADP F
groups 0 NOUN F
over 0 ADP F
the 0 DET F
2 0 NUM F
years 0 NOUN F
despite 0 ADP F
a 0 DET F
significant 0 ADJ F
fall 0 NOUN F
in 0 ADP F
total 0 ADJ F
serum B-PHYSICAL NOUN F
cholesterol I-PHYSICAL NOUN F
in 0 ADP F
pravastatin-treated 0 VERB F
patients 0 NOUN F
( 0 PUNCT F
p 0 NOUN F
= 0 SYM F
0.029 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

CONCLUSION 0 NOUN T
This 0 DET T
trial 0 NOUN F
found 0 VERB F
that 0 ADP F
taking 0 PUNCT F
20 0 NUM F
mg 0 NOUN F
pravastatin 0 NOUN F
for 0 ADP F
2 0 NUM F
years 0 NOUN F
had 0 VERB F
no 0 DET F
significant 0 ADJ F
effect 0 NOUN F
on 0 ADP F
kidney B-PHYSICAL NOUN F
function I-PHYSICAL NOUN F
or I-PHYSICAL CCONJ F
urinary I-PHYSICAL ADJ F
protein I-PHYSICAL NOUN F
excretion I-PHYSICAL NOUN F
in 0 ADP F
patients 0 NOUN F
with 0 ADP F
ADPKD 0 NOUN T
. 0 PUNCT F

The 0 DET T
lack 0 NOUN F
of 0 ADP F
statistical 0 ADJ F
power 0 NOUN F
limits 0 NOUN F
the 0 DET F
external 0 ADJ F
validity 0 NOUN F
of 0 ADP F
these 0 DET F
findings 0 NOUN F
. 0 PUNCT F

A 0 DET T
larger 0 PUNCT F
, 0 PUNCT F
longer 0 PUNCT F
duration 0 NOUN F
study 0 NOUN F
using 0 VERB F
a 0 DET F
higher 0 PUNCT F
dose 0 NOUN F
of 0 ADP F
a 0 DET F
more 0 ADV F
potent 0 ADJ F
statin 0 NOUN F
is 0 VERB F
required 0 VERB F
. 0 PUNCT F

Are 0 ADJ T
tyrosine 0 NOUN F
kinase 0 NOUN F
inhibitors 0 NOUN F
still 0 ADV F
active 0 ADJ F
in 0 ADP F
patients 0 NOUN F
with 0 ADP F
metastatic 0 ADJ F
renal 0 ADJ F
cell 0 NOUN F
carcinoma 0 NOUN F
previously 0 ADV F
treated 0 VERB F
with 0 ADP F
a 0 DET F
tyrosine 0 NOUN F
kinase 0 NOUN F
inhibitor 0 NOUN F
and 0 CCONJ F
everolimus 0 NOUN F
? 0 PUNCT F

Experience 0 NOUN T
of 0 ADP F
36 0 NUM F
patients 0 NOUN F
treated 0 VERB F
in 0 ADP F
France 0 NOUN T
in 0 ADP F
the 0 DET F
RECORD-1 0 NOUN T
Trial 0 NOUN T
. 0 PUNCT F

BACKGROUND 0 NOUN T
Because 0 PUNCT T
the 0 DET F
response 0 NOUN F
to 0 ADP F
treatment 0 NOUN F
is 0 VERB F
limited 0 VERB F
, 0 PUNCT F
patients 0 NOUN F
with 0 ADP F
metastatic 0 ADJ F
renal 0 ADJ F
cell 0 NOUN F
carcinoma 0 NOUN F
( 0 PUNCT F
mRCC 0 NOUN F
) 0 PUNCT F
typically 0 ADV F
receive 0 VERB F
multiple 0 ADJ F
treatments 0 NOUN F
. 0 PUNCT F

Guidelines 0 PROPN T
recommend 0 VERB F
everolimus 0 NOUN F
for 0 ADP F
patients 0 NOUN F
previously 0 ADV F
treated 0 VERB F
with 0 ADP F
tyrosine 0 NOUN F
kinase 0 NOUN F
inhibitors 0 NOUN F
( 0 PUNCT F
TKI 0 NOUN T
) 0 PUNCT F
sunitinib 0 NOUN F
or 0 CCONJ F
sorafenib 0 NOUN F
. 0 PUNCT F

This 0 DET T
study 0 NOUN F
evaluated 0 VERB F
the 0 DET F
efficacy 0 NOUN F
of 0 ADP F
TKI 0 NOUN T
re-treatment 0 NOUN F
in 0 ADP F
patients 0 NOUN F
with 0 ADP F
disease 0 NOUN F
progression 0 NOUN F
after 0 ADP F
a 0 DET F
TKI-everolimus 0 NOUN T
sequence 0 NOUN F
. 0 PUNCT F

PATIENTS 0 NOUN T
AND 0 CCONJ T
METHODS 0 NOUN T
Data 0 NOUN T
were 0 VERB F
reviewed 0 VERB F
for 0 ADP F
patients 0 NOUN F
enrolled 0 VERB F
in 0 ADP F
RECORD-1 0 NOUN T
( 0 PUNCT F
Renal 0 ADJ T
Cell 0 NOUN T
Cancer 0 NOUN T
Treatment 0 NOUN T
With 0 ADP T
Oral 0 ADJ T
RAD001 0 NOUN T
Given 0 ADP T
Daily 0 CCONJ T
) 0 PUNCT F
at 0 ADP F
French 0 ADJ T
sites 0 NOUN F
. 0 PUNCT F

Response 0 NOUN T
, B-MORTALITY PUNCT F
progression-free I-MORTALITY ADJ F
survival I-MORTALITY NOUN F
( I-MORTALITY PUNCT F
PFS I-MORTALITY NOUN T
) I-MORTALITY PUNCT F
, I-MORTALITY PUNCT F
and I-MORTALITY CCONJ F
overall I-MORTALITY ADJ F
survival B-MORTALITY NOUN F
were 0 VERB F
evaluated 0 VERB F
in 0 ADP F
patients 0 NOUN F
treated 0 VERB F
with 0 ADP F
a 0 DET F
TKI-everolimus-TKI 0 NUM T
sequence 0 NOUN F
. 0 PUNCT F

RESULTS 0 NOUN T
Thirty-six 0 NUM T
patients 0 NOUN F
received 0 VERB F
a 0 DET F
TKI 0 NOUN T
after 0 ADP F
everolimus 0 NOUN F
: 0 PUNCT F
sunitinib 0 NOUN F
in 0 ADP F
17 0 NUM F
patients 0 NOUN F
, 0 PUNCT F
sorafenib 0 NOUN F
in 0 ADP F
15 0 NUM F
, 0 PUNCT F
and 0 CCONJ F
dovitinib 0 NOUN F
( 0 PUNCT F
TKI258 0 NOUN T
) 0 PUNCT F
in 0 ADP F
4 0 NUM F
. 0 PUNCT F

The 0 DET T
response 0 NOUN F
rate B-PHYSICAL NOUN F
with 0 ADP F
TKI 0 NOUN T
re-treatment 0 NOUN F
was 0 VERB F
8 0 NUM F
% 0 SYM F
, 0 PUNCT F
and 0 CCONJ F
the 0 DET F
disease-control B-PHYSICAL NOUN F
rate B-PHYSICAL NOUN F
( I-PHYSICAL PUNCT F
response 0 NOUN F
plus B-PHYSICAL CCONJ F
stable I-PHYSICAL PUNCT F

Effects 0 NOUN T
of 0 ADP F
diet 0 NOUN F
and 0 CCONJ F
Aspergillus 0 NOUN T
oryzae 0 NOUN F
extract 0 NOUN F
or 0 CCONJ F
Saccharomyces 0 NOUN T
cervisiae 0 NOUN F
on 0 ADP F
growth 0 NOUN F
and 0 CCONJ F
carcass 0 NOUN F
characteristics 0 NOUN F
of 0 ADP F
lambs 0 NOUN F
and 0 CCONJ F
steers 0 ADJ F
fed 0 VERB F
to 0 PART F
meet 0 NOUN F
requirements 0 NOUN F
of 0 ADP F
natural 0 ADJ F
markets 0 NOUN F
. 0 PUNCT F

Two 0 NUM T
studies 0 NOUN F
were 0 VERB F
conducted 0 VERB F
to 0 PART F
determine 0 NOUN F
the 0 DET F
effects 0 NOUN F
of 0 ADP F
diet 0 NOUN F
and 0 CCONJ F
feed 0 PUNCT F
additive 0 ADJ F
on 0 ADP F
growth 0 NOUN F
and 0 CCONJ F
carcass 0 NOUN F
characteristics 0 NOUN F
of 0 ADP F
lambs 0 NOUN F
and 0 CCONJ F
cattle 0 NOUN F
destined 0 VERB F
for 0 ADP F
all 0 DET F
natural 0 ADJ F
markets 0 NOUN F
. 0 PUNCT F

In 0 ADP T
Exp 0 NOUN T
. 0 PUNCT F

1 0 NUM F
, 0 PUNCT F
48 0 NUM F
Dorset 0 NOUN T
? 0 PUNCT F

Hampshire 0 PUNCT T
lambs 0 NOUN F
( 0 PUNCT F
initial 0 ADJ F
BW 0 NOUN T
29.4 0 NUM F
? 0 PUNCT F

0.1 0 NUM F
kg 0 NOUN F
) 0 PUNCT F
were 0 VERB F
used 0 VERB F
in 0 ADP F
a 0 DET F
randomized 0 VERB F
complete 0 ADJ F
block 0 ADV F
experiment 0 NOUN F
to 0 PART F
determine 0 NOUN F
the 0 DET F
effects 0 NOUN F
of 0 ADP F
Aspergillus 0 NOUN T
oryzae 0 NOUN F
extract 0 NOUN F
, 0 PUNCT F
Amaferm 0 NOUN T
( 0 PUNCT F
AMF 0 NOUN T
) 0 PUNCT F
supplementation 0 NOUN F
( 0 PUNCT F
1 0 NUM F
g/d 0 NOUN F
) 0 PUNCT F
in 0 ADP F
an 0 DET F
85 0 NUM F
% 0 SYM F
concentrate 0 NOUN F
diet 0 NOUN F
on 0 ADP F
growth 0 NOUN F
and 0 CCONJ F
carcass 0 NOUN F
characteristics 0 NOUN F
. 0 PUNCT F

Lambs 0 ADV T
were 0 VERB F
allotted 0 VERB F
to 0 ADP F
12 0 NUM F
pens 0 NOUN F
( 0 PUNCT F
4 0 NUM F
lambs 0 NOUN F
per 0 ADP F
pen 0 ADP F
) 0 PUNCT F
, 0 PUNCT F
and 0 CCONJ F
blocked 0 VERB F
by 0 ADP F
sex 0 NOUN F
and 0 CCONJ F
BW 0 NOUN T
. 0 PUNCT F

Lambs 0 ADV T
were 0 VERB F
fed 0 VERB F
until 0 ADP F
the 0 DET F
average 0 ADJ F
BW 0 NOUN T
of 0 ADP F
each 0 DET F
pen 0 ADJ F
reached 0 PRON F
a 0 DET F
target 0 NOUN F
BW 0 NOUN T
( 0 PUNCT F
55.4 0 NUM F
kg 0 NOUN F
for 0 ADP F
wethers 0 NOUN F
and 0 CCONJ F
50.0 0 NUM F
kg 0 NOUN F
for 0 ADP F
ewes 0 NOUN F
) 0 PUNCT F
, 0 PUNCT F
at 0 ADP F
which 0 DET F
time 0 VERB F
the 0 DET F
entire 0 ADJ F
pen 0 ADJ F
of 0 ADP F
lambs 0 NOUN F
was 0 VERB F
slaughtered 0 VERB F
. 0 PUNCT F

Amaferm 0 NOUN T
resulted 0 VERB F
in 0 ADP F
a 0 DET F
greater 0 PUNCT F
( 0 PUNCT F
P=0.07 0 NOUN T
) 0 PUNCT F
G 0 NOUN T
: 0 PUNCT F
F. 0 NOUN T
In 0 ADP T
Exp 0 NOUN T
. 0 PUNCT F

2 0 NUM F
, 0 PUNCT F
168 0 NUM F
crossbred 0 ADJ F
steers 0 NOUN F
( 0 PUNCT F
initial 0 ADJ F
BW 0 NOUN T
300 0 NUM F
? 0 PUNCT F

0.7 0 NUM F
kg 0 NOUN F
) 0 PUNCT F
were 0 VERB F
used 0 VERB F
in 0 ADP F
a 0 DET F
trial 0 NOUN F
with 0 ADP F
a 0 DET F
3 0 NUM F
? 0 PUNCT F

2 0 NUM F
factorial 0 ADJ F
arrangement 0 ADJ F
of 0 ADP F
treatments 0 NOUN F
to 0 PART F
examine 0 NOUN F
the 0 DET F
effects 0 NOUN F
of 0 ADP F
0.5 0 NUM F
g/d 0 NOUN F
of 0 ADP F
Saccaromyces 0 PROPN T
cervisiae 0 VERB F
boulardii 0 NOUN F
CNCM 0 NOUN T
1079-Levucell 0 NOUN F
SB 0 NOUN T
( 0 PUNCT F
LEV 0 NOUN T
) 0 PUNCT F
, 0 PUNCT F
or 0 CCONJ F
3 0 NUM F
g/d 0 NOUN F
of 0 ADP F
AMF 0 NOUN T
with 0 ADP F
2 0 NUM F
corn 0 NOUN F
sources 0 NOUN F
, 0 PUNCT F
dry 0 ADJ F
whole-shelled 0 ADV F
corn 0 NOUN F
or 0 CCONJ F
high 0 ADJ F
moisture 0 NOUN F
corn 0 NOUN F
, 0 PUNCT F
on 0 ADP F
growth 0 NOUN F
and 0 CCONJ F
carcass 0 NOUN F
characteristics 0 NOUN F
. 0 PUNCT F

Neither 0 CCONJ T
LEV 0 NOUN T
nor 0 CCONJ F
AMF 0 NOUN T
improved 0 VERB F
( 0 PUNCT F
P 0 NOUN T
> 0 SYM F
0.10 0 NUM F
) 0 PUNCT F
carcass B-PHYSICAL NOUN F
characteristics I-PHYSICAL NOUN F
compared 0 VERB F
with 0 ADP F
control 0 NOUN F
or 0 CCONJ F
non-feed-supplemented 0 PRON F
steers 0 NOUN F
. 0 PUNCT F

Addition 0 NOUN T
of 0 ADP F
LEV 0 NOUN T
to 0 ADP F
high-concentrate 0 ADP F
, 0 PUNCT F
corn-based 0 ADJ F
diets 0 NOUN F
did 0 PUNCT F
not 0 ADV F
improve 0 VERB F
( 0 PUNCT F
P 0 NOUN T
> 0 SYM F
0.10 0 NUM F
) 0 PUNCT F
growth B-PHYSICAL NOUN F
performance I-PHYSICAL NOUN F
of 0 ADP F
feedlot 0 NOUN F
steers 0 NOUN F
. 0 PUNCT F

However 0 ADV T
, 0 PUNCT F
addition 0 NOUN F
of 0 ADP F
AMF 0 NOUN T
to 0 ADP F
a 0 DET F
diet 0 NOUN F
composed 0 VERB F
of 0 ADP F
dry 0 ADJ F
whole-shelled 0 ADV F
corn 0 NOUN F
resulted 0 VERB F
in 0 ADP F
an 0 DET F
improvement 0 NOUN F
( 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.05 0 NUM F
) 0 PUNCT F
in 0 ADP F
G B-PHYSICAL NOUN T
: 0 PUNCT F
F B-PHYSICAL NOUN T
( 0 PUNCT F
0.208 0 ADP F
vs. 0 CCONJ F
0.194 0 PUNCT F
) 0 PUNCT F
. 0 PUNCT F

Results 0 NOUN T
indicate 0 VERB F
that 0 ADP F
at 0 ADP F
the 0 DET F
amounts 0 ADJ F
fed 0 VERB F
, 0 PUNCT F
AMF 0 NOUN T
may 0 PUNCT F
improve 0 PUNCT F

Bridge 0 ADP T
plate 0 NOUN F
osteosynthesis 0 NOUN F
using 0 VERB F
dynamic 0 ADJ F
condylar 0 ADJ F
screw 0 NOUN F
( 0 PUNCT F
DCS 0 NOUN T
) 0 PUNCT F
or 0 CCONJ F
retrograde 0 ADJ F
intramedullary 0 ADJ F
supracondylar 0 ADJ F
nail 0 NOUN F
( 0 PUNCT F
RIMSN 0 NOUN T
) 0 PUNCT F
in 0 ADP F
the 0 DET F
treatment 0 NOUN F
of 0 ADP F
distal 0 ADJ F
femoral 0 ADJ F
fractures 0 NOUN F
: 0 PUNCT F
comparison 0 NOUN F
of 0 ADP F
two 0 NUM F
methods 0 NOUN F
in 0 ADP F
a 0 DET F
prospective 0 ADJ F
randomized 0 VERB F
study 0 NOUN F
. 0 PUNCT F

BACKGROUND 0 NOUN T
The 0 DET T
treatment 0 NOUN F
of 0 ADP F
distal 0 ADJ F
femoral 0 ADJ F
fractures 0 NOUN F
remains 0 ADJ F
a 0 DET F
significant 0 ADJ F
surgical 0 ADJ F
challenge 0 NOUN F
. 0 PUNCT F

With 0 ADP T
the 0 DET F
rigid 0 ADJ F
fixation 0 NOUN F
of 0 ADP F
the 0 DET F
distal 0 ADJ F
femoral 0 ADJ F
fractures 0 NOUN F
, 0 PUNCT F
bone 0 NOUN F
grafting 0 VERB F
is 0 VERB F
frequently 0 ADV F
needed 0 VERB F
. 0 PUNCT F

Biological 0 ADJ T
osteosynthesis 0 NOUN F
using 0 VERB F
dynamic 0 ADJ F
condylar 0 ADJ F
screw 0 NOUN F
( 0 PUNCT F
DCS 0 NOUN T
) 0 PUNCT F
and 0 CCONJ F
retrograde 0 ADJ F
intramedullary 0 ADJ F
supracondylar 0 ADJ F
nail 0 NOUN F
( 0 PUNCT F
RIMSN 0 NOUN T
) 0 PUNCT F
preserve 0 PUNCT F
the 0 DET F
blood 0 NOUN F
supply 0 NOUN F
and 0 CCONJ F
limit 0 ADJ F
the 0 DET F
need 0 NOUN F
for 0 ADP F
bone 0 NOUN F
grafting 0 VERB F
. 0 PUNCT F

METHODS 0 NOUN T
From 0 ADP T
September 0 NOUN T
2002 0 NUM F
to 0 ADP F
December 0 NOUN T
2004 0 NUM F
, 0 PUNCT F
68 0 NUM F
closed 0 VERB F
fractures 0 NOUN F
of 0 ADP F
the 0 DET F
distal 0 ADJ F
femur 0 NOUN F
were 0 VERB F
treated 0 VERB F
by 0 CCONJ F
bridge 0 ADP F
plate 0 NOUN F
osteosynthesis 0 NOUN F
using 0 VERB F
DCS 0 NOUN T
in 0 ADP F
31 0 NUM F
and 0 CCONJ F
RIMSN 0 NOUN T
in 0 ADP F
37 0 NUM F
. 0 PUNCT F

The 0 DET T
patients 0 NOUN F
were 0 VERB F
allocated 0 NUM F
to 0 ADP F
one 0 PUNCT F
of 0 ADP F
the 0 DET F
two 0 NUM F
groups 0 NOUN F
randomly 0 ADV F
and 0 CCONJ F
followed 0 VERB F
for 0 ADP F
24-36 0 NUM F
months 0 NOUN F
( 0 PUNCT F
average 0 NOUN F
: 0 PUNCT F
30 0 NUM F
months 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

RESULTS 0 NOUN T
With 0 ADP T
respect 0 NOUN F
to 0 ADP F
operation 0 NOUN F
time 0 NOUN F
, 0 PUNCT F
the 0 DET F
DCS 0 NOUN T
group 0 NOUN F
presented 0 VERB F
significantly 0 ADV F
better 0 PUNCT F
results 0 PUNCT F
than 0 VERB F
the 0 DET F
RIMSN 0 CCONJ T
group 0 NOUN F
( 0 PUNCT F
p=0.000 0 ADV F
) 0 PUNCT F
. 0 PUNCT F

However 0 ADV T
, 0 PUNCT F
the 0 DET F
blood B-PHYSICAL NOUN F
loss I-PHYSICAL NOUN F
was 0 VERB F
significantly 0 ADV F
more 0 ADV F
in 0 ADP F
the 0 DET F
DCS 0 NOUN T
group 0 NOUN F
( 0 PUNCT F
p=0.000 0 ADV F
) 0 PUNCT F
. 0 PUNCT F

There 0 PUNCT T
were 0 VERB F
no 0 DET F
significant 0 ADJ F
differences 0 NOUN F
in 0 ADP F
terms 0 NOUN F
of 0 ADP F
cumulative B-OTHER ADJ F
rate I-OTHER NOUN F
of I-OTHER ADP F
union I-OTHER NOUN F
( 0 PUNCT F
p=0.855 0 NOUN F
) 0 PUNCT F
, 0 PUNCT F
range 0 NOUN F
of B-PHYSICAL ADP F
motion I-PHYSICAL NOUN F
of I-PHYSICAL ADP F
the I-PHYSICAL DET F
knee B-PHYSICAL NOUN F
( 0 PUNCT F
p=0.727 0 ADV F
) 0 PUNCT F
, 0 PUNCT F
overall B-PHYSICAL PUNCT F

Dysfunctional 0 ADJ T
attitudes 0 ADJ F
as 0 ADP F
a 0 DET F
moderator 0 NOUN F
of 0 ADP F
pharmacotherapy 0 NOUN F
and 0 CCONJ F
psychotherapy 0 NOUN F
for 0 ADP F
chronic 0 ADJ F
depression 0 NOUN F
. 0 PUNCT F

OBJECTIVE 0 NOUN T
Individuals 0 NOUN T
with 0 ADP F
chronic 0 ADJ F
depression 0 NOUN F
exhibit 0 VERB F
heterogeneous 0 ADJ F
responses 0 NOUN F
to 0 ADP F
treatment 0 NOUN F
. 0 PUNCT F

Important 0 ADJ T
individual 0 ADJ F
differences 0 NOUN F
may 0 ADP F
therefore 0 ADV F
exist 0 VERB F
within 0 ADP F
this 0 PUNCT F
particularly 0 ADV F
difficult 0 ADJ F
to 0 PART F
treat 0 NOUN F
population 0 NOUN F
that 0 ADP F
act 0 VERB F
as 0 ADP F
moderators 0 NOUN F
of 0 ADP F
treatment 0 NOUN F
response 0 NOUN F
. 0 PUNCT F

METHOD 0 NOUN T
The 0 DET T
present 0 ADJ F
study 0 NOUN F
examined 0 VERB F
whether 0 ADP F
pretreatment 0 NOUN F
levels 0 NOUN F
of 0 ADP F
dysfunctional 0 ADJ F
attitudes 0 NOUN F
( 0 PUNCT F
DA 0 NOUN T
) 0 PUNCT F
moderated 0 ADJ F
treatment 0 NOUN F
response 0 NOUN F
in 0 ADP F
a 0 DET F
large 0 ADJ F
sample 0 NOUN F
of 0 ADP F
chronically 0 ADV F
depressed 0 VERB F
individuals 0 NOUN F
. 0 PUNCT F

Data 0 NOUN T
were 0 VERB F
taken 0 VERB F
from 0 ADP F
the 0 DET F
Research 0 NOUN T
Evaluating 0 VERB T
the 0 DET F
Value 0 NOUN T
of 0 ADP F
Augmenting 0 ADP T
Medication 0 NOUN T
with 0 ADP F
Psychotherapy 0 NOUN T
( 0 PUNCT F
REVAMP 0 NOUN T
) 0 PUNCT F
treatment 0 NOUN F
study 0 NOUN F
-- 0 PUNCT F
a 0 DET F
multi-site 0 ADJ F
treatment 0 NOUN F
and 0 CCONJ F
augmentation 0 NOUN F
study 0 NOUN F
of 0 ADP F
808 0 NUM F
chronically 0 ADV F
depressed 0 VERB F
individuals 0 NOUN F
. 0 PUNCT F

REVAMP 0 NOUN T
comprised 0 VERB F
two 0 NUM F
phases 0 NOUN F
: 0 PUNCT F
1 0 NUM F
) 0 PUNCT F
a 0 DET F
12-week 0 NOUN F
open-label 0 NOUN F
antidepressant 0 NOUN F
trial 0 NOUN F
and 0 CCONJ F
2 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
a 0 DET F
subsequent 0 ADJ F
phase 0 NOUN F
, 0 PUNCT F
in 0 ADP F
which 0 PUNCT F
phase 0 NOUN F
1 0 NUM F
non-remitters 0 NOUN F
( 0 PUNCT F
N 0 NOUN T
= 0 SYM F
491 0 NUM F
) 0 PUNCT F
were 0 VERB F
randomized 0 VERB F
to 0 ADP F
either 0 PUNCT F
receive 0 ADP F
an 0 DET F
ongoing 0 VERB F
medication 0 NOUN F
algorithm 0 NOUN F
alone 0 ADJ F
, 0 PUNCT F
medication 0 NOUN F
plus 0 CCONJ F
cognitive 0 ADJ F
behavioral 0 ADJ F
analysis 0 NOUN F
system 0 NOUN F
of 0 ADP F
psychotherapy 0 NOUN F
, 0 PUNCT F
or 0 CCONJ F
medication 0 NOUN F
plus 0 CCONJ F
brief 0 ADJ F
supportive 0 ADJ F
psychotherapy 0 NOUN F
. 0 PUNCT F

RESULT 0 NOUN T
In 0 ADP T
phase 0 NOUN F
1 0 NUM F
, 0 PUNCT F
compared 0 VERB F
to 0 ADP F
the 0 DET F
pharmacotherapy B-PHYSICAL NOUN F
response I-PHYSICAL NOUN F
of 0 ADP F
patients 0 NOUN F
with 0 ADP F
lower 0 PUNCT F
DA 0 NOUN T
scores 0 NOUN F
, 0 PUNCT F
the 0 DET F
response 0 NOUN F
for 0 ADP F
patients 0 NOUN F
with 0 ADP F
higher 0 PUNCT F
DA 0 NOUN T
scores 0 NOUN F
was 0 VERB F
steeper 0 PUNCT F
, 0 PUNCT F
but 0 CCONJ F
leveled 0 VERB F
off 0 ADP F
toward 0 ADP F
the 0 DET F
end 0 NOUN F
of 0 ADP F
the 0 DET F
phase 0 NOUN F
. 0 PUNCT F

In 0 ADP T
phase 0 NOUN F
2 0 NUM F
, 0 PUNCT F
DA 0 NOUN T
predicted 0 VERB F
a 0 DET F
differential 0 ADJ F
response 0 NOUN F
in 0 ADP F
the 0 DET F
medication 0 NOUN F
only 0 ADV F
arm 0 NOUN F
, 0 PUNCT F
but 0 CCONJ F
not 0 ADV F
in 0 ADP F
the 0 DET F
two 0 NUM F
psychotherapy 0 NOUN F
+ 0 ADJ F
medication 0 NOUN F
conditions 0 NOUN F
. 0 PUNCT F

Specifically 0 ADV T
, 0 PUNCT F
in 0 ADP F
the 0 DET F
phase 0 NOUN F
2 0 NUM F
medication 0 NOUN F
only 0 PUNCT F
condition 0 NOUN F
, 0 PUNCT F
patients 0 NOUN F
with 0 ADP F
higher 0 PUNCT F
DA 0 NOUN T
improved B-OTHER VERB F
while 0 ADP F
those 0 PUNCT F
with 0 ADP F
lower 0 PUNCT F
DA 0 NOUN T
scores 0 NOUN F
did 0 CCONJ F
not 0 ADV F
. 0 PUNCT F

CONCLUSION 0 NOUN T
These 0 DET T
results 0 NOUN F
indicate 0 VERB F
that 0 ADP F
the 0 DET F
relation 0 NOUN F
between 0 ADP F
DA 0 NOUN T
and 0 CCONJ F
treatment 0 NOUN F
response 0 NOUN F
in 0 ADP F
chronic 0 ADJ F
depression 0 NOUN F
is 0 VERB F
complex 0 CCONJ F
, 0 PUNCT F
but 0 CCONJ F
suggest 0 VERB F
that 0 ADP F
greater 0 PUNCT F
DA 0 NOUN T
may 0 VERB F
be 0 VERB F
associated 0 VERB F
with 0 ADP F
a 0 DET F
steeper 0 PUNCT F
reduction 0 NOUN F
and/or 0 CCONJ F
better 0 PUNCT F
response 0 NOUN F
to 0 ADP F
pharmacotherapy 0 NOUN F
. 0 PUNCT F

Sleep B-PHYSICAL NOUN T
patterns I-PHYSICAL NOUN F
in 0 ADP F
autistic 0 ADJ F
children 0 NOUN F
. 0 PUNCT F

Sleep B-PHYSICAL NOUN T
disturbances I-PHYSICAL NOUN F
are 0 VERB F
regarded 0 VERB F
as 0 ADP F
a 0 DET F
common 0 ADJ F
clinical 0 ADJ F
feature 0 NOUN F
in 0 ADP F
autistic 0 ADJ F
children 0 NOUN F
. 0 PUNCT F

This 0 DET T
concept 0 NOUN F
is 0 PUNCT F
based 0 VERB F
primarily 0 ADV F
on 0 ADP F
informal 0 ADJ F
observations 0 NOUN F
or 0 CCONJ F
studies 0 NOUN F
conducted 0 VERB F
with 0 ADP F
questionnaires 0 NOUN F
. 0 PUNCT F

In 0 ADP T
this 0 DET F
study 0 NOUN F
we 0 PRON F
compared 0 PUNCT F
data 0 NOUN F
obtained 0 VERB F
by 0 ADP F
questionnaires 0 NOUN F
to 0 ADP F
that 0 PUNCT F
obtained 0 VERB F
with 0 ADP F
actigraphy 0 NOUN F
. 0 PUNCT F

Among 0 ADP T
22 0 NUM F
autistic 0 ADJ F
children 0 NOUN F
, 0 PUNCT F
12 0 NUM F
were 0 VERB F
reported 0 VERB F
as 0 PUNCT F
having 0 DET F
sleep 0 ADV F
problems 0 NOUN F
and 0 CCONJ F
8 0 NUM F
patients 0 NOUN F
completed 0 VERB F
72 0 NUM F
hours 0 ADJ F
actigraphy 0 NOUN F
. 0 PUNCT F

While 0 ADP T
the 0 DET F
employment 0 NOUN F
of 0 ADP F
questionnaires 0 NOUN F
disclosed 0 VERB F
that 0 PUNCT F
autistic 0 ADJ F
children 0 NOUN F
had 0 PUNCT F
an 0 DET F
earlier B-PHYSICAL PUNCT F
morning I-PHYSICAL NOUN F
awakening I-PHYSICAL VERB F
time I-PHYSICAL NOUN F
and 0 CCONJ F
multiple B-PHYSICAL ADJ F
and I-PHYSICAL CCONJ F
early I-PHYSICAL ADP F
night I-PHYSICAL NOUN F
arousals I-PHYSICAL NOUN F
, 0 PUNCT F
actigraphic 0 ADJ F
monitoring 0 VERB F
showed 0 VERB F
that 0 ADP F
with 0 ADP F
the 0 DET F
exception 0 NOUN F
of 0 ADP F
an 0 DET F
earlier B-PHYSICAL PUNCT F
morning I-PHYSICAL NOUN F
arousal I-PHYSICAL ADJ F
time I-PHYSICAL NOUN F
( 0 PUNCT F
p 0 NOUN F
= 0 SYM F
.045 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
sleep B-PHYSICAL ADP F
patterns I-PHYSICAL NOUN F
of 0 ADP F
autistic 0 ADJ F
children 0 NOUN F
were 0 VERB F
similar 0 ADJ F
to 0 ADP F
that 0 PUNCT F
of 0 ADP F
normal 0 ADJ F
children 0 NOUN F
. 0 PUNCT F

Parental 0 ADJ T
oversensitivity 0 NOUN F
to 0 ADP F
sleep B-PHYSICAL ADJ F
disturbances I-PHYSICAL ADJ F
of 0 ADP F
the 0 DET F
autistic 0 ADJ F
children 0 NOUN F
may 0 VERB F
explain 0 VERB F
this 0 DET F
phenomenon 0 NOUN F
. 0 PUNCT F

Exhaled 0 VERB T
NO 0 NOUN T
during 0 ADP F
graded 0 NOUN F
changes 0 NOUN F
in 0 ADP F
inhaled 0 VERB F
oxygen 0 NOUN F
in 0 ADP F
man 0 NOUN F
. 0 PUNCT F

BACKGROUND 0 NOUN T
Nitric 0 ADJ T
oxide 0 NOUN F
( 0 PUNCT F
NO 0 NOUN T
) 0 PUNCT F
is 0 VERB F
present 0 ADJ F
in 0 ADP F
the 0 DET F
exhaled 0 VERB F
air 0 NOUN F
of 0 ADP F
animals 0 NOUN F
and 0 CCONJ F
humans 0 NOUN F
. 0 PUNCT F

In 0 ADP T
isolated 0 VERB F
animal 0 NOUN F
lungs 0 CCONJ F
the 0 DET F
amount 0 NOUN F
of 0 ADP F
exhaled 0 NOUN F
NO 0 NOUN T
is 0 VERB F
decreased 0 VERB F
during 0 ADP F
hypoxia 0 NOUN F
. 0 PUNCT F

A 0 DET T
study 0 NOUN F
was 0 VERB F
undertaken 0 VERB F
to 0 PART F
determine 0 NOUN F
whether 0 ADP F
changes 0 NOUN F
in 0 ADP F
arterial 0 ADJ F
oxygen 0 NOUN F
tension 0 NOUN F
affect 0 VERB F
levels 0 NOUN F
of 0 ADP F
exhaled 0 NOUN F
NO 0 NOUN T
in 0 ADP F
humans 0 NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
Sixteen 0 NUM T
healthy 0 ADJ F
subjects 0 NOUN F
were 0 VERB F
randomised 0 VERB F
to 0 ADP F
inhale 0 ADJ F
different 0 ADJ F
gas 0 NOUN F
mixtures 0 NOUN F
of 0 ADP F
oxygen 0 NOUN F
and 0 CCONJ F
nitrogen 0 NOUN F
in 0 ADP F
a 0 DET F
double 0 ADJ F
blind 0 ADJ F
crossover 0 NOUN F
study 0 NOUN F
. 0 PUNCT F

Eight 0 NUM T
gas 0 NOUN F
mixtures 0 NOUN F
of 0 ADP F
oxygen 0 NOUN F
and 0 CCONJ F
nitrogen 0 NOUN F
( 0 PUNCT F
fractional 0 ADJ F
inspired 0 PUNCT F
oxygen 0 NOUN F
concentration 0 NOUN F
( 0 PUNCT F
FiO2 0 NOUN T
) 0 PUNCT F
0.1 0 NUM F
to 0 ADP F
1.0 0 NUM F
) 0 PUNCT F
were 0 VERB F
administered 0 VERB F
. 0 PUNCT F

Exhaled B-PHYSICAL VERB T
NO 0 NOUN T
was 0 VERB F
measured 0 VERB F
with 0 ADP F
a 0 DET F
chemiluminescence 0 NOUN F
detector 0 NOUN F
from 0 ADP F
end 0 NOUN F
expiratory 0 ADJ F
single 0 ADJ F
breath 0 NOUN F
exhalation 0 NOUN F
. 0 PUNCT F

RESULTS 0 NOUN T
A 0 PUNCT T
dose-dependent 0 ADJ F
change 0 NOUN F
in 0 ADP F
exhaled B-PHYSICAL NOUN F
NO 0 NOUN T
during 0 ADP F
graded B-PHYSICAL VERB F
oxygen I-PHYSICAL NOUN F
breathing I-PHYSICAL VERB F
was 0 VERB F
observed 0 VERB F
( 0 PUNCT F
p 0 NOUN F
= 0 SYM F
0.0012 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
mean 0 NOUN F
( 0 PUNCT F
SE B-PHYSICAL NOUN T
) 0 PUNCT F
exhaled B-PHYSICAL PUNCT F
NO I-PHYSICAL NOUN T
concentration I-PHYSICAL NOUN F
was 0 VERB F
31 0 NUM F
( 0 PUNCT F
3 0 NUM F
) 0 PUNCT F
ppb 0 NOUN F
at 0 ADP F
baseline 0 NOUN F
, 0 PUNCT F
39 0 NUM F
( 0 PUNCT F
4 0 NUM F
) 0 PUNCT F
ppb 0 NOUN F
at 0 ADP F
an 0 DET F
FiO2 0 NOUN T
of 0 ADP F
1.0 0 NUM F
, 0 PUNCT F
and 0 CCONJ F
26 0 NUM F
( 0 PUNCT F
3 0 NUM F
) 0 PUNCT F
ppb 0 NOUN F
at 0 ADP F
an 0 DET F
FiO2 0 NOUN T
of 0 ADP F
0.1 0 NUM F
. 0 PUNCT F

CONCLUSIONS 0 NOUN T
The 0 DET T
NO 0 NOUN T
concentration B-PHYSICAL NOUN F
in 0 ADP F
exhaled 0 ADV F
air 0 NOUN F
in 0 ADP F
healthy 0 ADJ F
humans 0 NOUN F
is 0 VERB F
dependent 0 ADJ F
on 0 ADP F
oxygen 0 NOUN F
tension 0 NOUN F
. 0 PUNCT F

Hyperoxia 0 NOUN T
increases 0 PUNCT F
the 0 DET F
level 0 NOUN F
of 0 ADP F
exhaled 0 NOUN F
NO 0 NOUN T
, 0 PUNCT F
which 0 ADP F
indicates 0 ADV F
increased 0 PUNCT F
NO 0 NOUN T
production 0 NOUN F
. 0 PUNCT F

The 0 DET T
mechanism 0 NOUN F
behind 0 ADP F
this 0 DET F
phenomenon 0 NOUN F
remains 0 NOUN F
to 0 PART F
be 0 PUNCT F
elucidated 0 VERB F
. 0 PUNCT F

Late 0 ADJ T
miscarriage 0 NOUN F
and 0 CCONJ F
preterm 0 NOUN F
birth 0 NOUN F
after 0 ADP F
treatment 0 NOUN F
with 0 ADP F
clindamycin 0 NOUN F
: 0 PUNCT F
a 0 DET F
randomised 0 VERB F
consent 0 NOUN F
design 0 NOUN F
study 0 ADP F
according 0 CCONJ F
to 0 ADP F
Zelen 0 NOUN T
. 0 PUNCT F

OBJECTIVE 0 NOUN T
To 0 PART T
screen 0 NOUN F
for 0 ADP F
bacterial 0 ADJ F
vaginosis 0 NOUN F
( 0 PUNCT F
BV 0 NOUN T
) 0 PUNCT F
and 0 CCONJ F
to 0 PART F
investigate 0 NOUN F
the 0 DET F
effect 0 NOUN F
of 0 ADP F
treatment 0 NOUN F
with 0 ADP F
vaginal 0 ADJ F
clindamycin 0 NOUN F
in 0 ADP F
order 0 NOUN F
to 0 PART F
observe 0 NOUN F
the 0 DET F
effect 0 NOUN F
on 0 ADP F
late B-PHYSICAL ADJ F
miscarriage I-PHYSICAL NOUN F
and I-PHYSICAL CCONJ F
delivery I-PHYSICAL NOUN F
prior I-PHYSICAL PUNCT F
to I-PHYSICAL ADP F
37 I-PHYSICAL NUM F
completed I-PHYSICAL VERB F
weeks I-PHYSICAL NOUN F
( 0 PUNCT F
primary 0 ADJ F
outcome 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

DESIGN 0 NOUN T
Randomised 0 VERB T
consent 0 NOUN F
design 0 NOUN F
for 0 ADP F
clinical 0 ADJ F
trials 0 NOUN F
according 0 CCONJ F
to 0 ADP F
Zelen 0 NOUN T
. 0 PUNCT F

SETTING 0 ADJ T
Southeast 0 NOUN T
region 0 NOUN F
of 0 ADP F
Sweden 0 NUM T
. 0 PUNCT F

POPULATION 0 NOUN T
A 0 PUNCT T
total 0 NOUN F
of 0 ADP F
9025 0 NUM F
women 0 NOUN F
were 0 VERB F
screened 0 VERB F
in 0 ADP F
early 0 ADJ F
pregnancy 0 NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
A 0 PUNCT T
total 0 NOUN F
of 0 ADP F
819 0 NUM F
women 0 NOUN F
with 0 ADP F
a 0 DET F
Nugent 0 NOUN T
score 0 NOUN F
of 0 ADP F
6 0 NUM F
and 0 CCONJ F
above 0 PUNCT F
were 0 ADJ F
considered 0 VERB F
to 0 DET F
have 0 PUNCT F
BV 0 NOUN T
and 0 CCONJ F
treated 0 VERB F
according 0 CCONJ F
to 0 ADP F
Zelen 0 NOUN T
allocation 0 NOUN F
. 0 PUNCT F

The 0 DET T
incidence 0 NOUN F
of 0 ADP F
late B-PHYSICAL ADJ F
miscarriage I-PHYSICAL NOUN F
and I-PHYSICAL CCONJ F
spontaneous I-PHYSICAL ADJ F
( I-PHYSICAL PUNCT F
noniatrogenic I-PHYSICAL ADP F
) I-PHYSICAL PUNCT F
preterm I-PHYSICAL NOUN F
birth I-PHYSICAL NOUN F
was 0 VERB F
assessed 0 VERB F
. 0 PUNCT F

MAIN 0 ADJ T
OUTCOME 0 NOUN T
MEASURES 0 NOUN T
Late B-PHYSICAL ADJ T
miscarriage I-PHYSICAL NOUN F
and I-PHYSICAL CCONJ F
spontaneous I-PHYSICAL ADJ F
preterm I-PHYSICAL NOUN F
delivery I-PHYSICAL NOUN F
before I-PHYSICAL ADP F
37 I-PHYSICAL NUM F
weeks I-PHYSICAL NOUN F
. 0 PUNCT F

RESULTS 0 DET T
Therapy 0 NOUN T
with 0 ADP F
vaginal 0 ADJ F
clindamycin 0 NOUN F
had 0 PUNCT F
no 0 DET F
significant 0 ADJ F
impact 0 NOUN F
on 0 ADP F
the 0 DET F
incidence 0 NOUN F
of 0 ADP F
spontaneous B-PHYSICAL ADJ F
preterm I-PHYSICAL NOUN F
delivery I-PHYSICAL NOUN F
prior 0 PUNCT F
to 0 ADP F
37 0 NUM F
completed 0 VERB F
weeks 0 NOUN F
; 0 PUNCT F
OR 0 ADV T
0.90 0 NUM F
, 0 PUNCT F
95 0 NUM F
% 0 SYM F
CI 0 NOUN T
0.40-2.02 0 NUM F
( 0 PUNCT F
primary 0 ADJ F
outcome 0 NOUN F
variable 0 ADJ F
) 0 PUNCT F
. 0 PUNCT F

However 0 ADV T
, 0 PUNCT F
only 0 ADV F
1 0 PUNCT F
of 0 ADP F
11 0 NUM F
women 0 NOUN F
in 0 ADP F
the 0 DET F
treatment 0 NOUN F
group 0 NOUN F
versus 0 CCONJ F
5 0 NUM F
of 0 ADP F
12 0 NUM F
in 0 ADP F
the 0 DET F
control 0 NOUN F
group 0 NOUN F
delivered 0 ADP F
prior 0 PUNCT F
to 0 ADP F
33 0 NUM F
completed 0 VERB F
weeks 0 NOUN F
; 0 PUNCT F
OR 0 ADV T
0.14 0 NUM F
, 0 PUNCT F
95 0 NUM F
% 0 SYM F
CI 0 NOUN T
0.02-0.95 0 NUM F
. 0 PUNCT F

Treatment 0 NOUN T
was 0 VERB F
associated 0 VERB F
with 0 ADP F
32 0 NUM F
days 0 NOUN F
longer B-PHYSICAL PUNCT F
gestation I-PHYSICAL NOUN F
for 0 ADP F
the 0 DET F
23 0 NUM F
participants 0 NOUN F
who 0 ADP F
had 0 PUNCT F
late B-PHYSICAL ADJ F
miscarriage I-PHYSICAL NOUN F
or I-PHYSICAL CCONJ F
spontaneous I-PHYSICAL ADJ F
preterm I-PHYSICAL NOUN F
birth I-PHYSICAL NOUN F
( 0 PUNCT F
P= 0 NOUN T
0.024 0 NUM F
, 0 PUNCT F
Mann-Whitney 0 NOUN T
U 0 NOUN T
test 0 NOUN F
) 0 PUNCT F
and 0 CCONJ F
significantly 0 ADV F
fewer 0 PUNCT F
infants 0 NOUN F
had 0 ADP F
a 0 DET F
birthweight 0 NUM F
below 0 ADP F
2,500 0 NUM F
g B-PHYSICAL NOUN F
( 0 PUNCT F
secondary 0 ADJ F
outcome 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

A 0 PUNCT T
follow 0 PUNCT F
up 0 CCONJ F
of 0 ADP F
infants 0 NOUN F
born 0 VERB F
preterm 0 NOUN F
4 0 NUM F
years 0 NOUN F
postnatally 0 ADV F
indicated 0 PUNCT F
that 0 ADP F
extending 0 CCONJ F
gestational 0 ADJ F
age 0 NOUN F
did 0 PUNCT F
not 0 ADV F
increase 0 VERB F
the 0 DET F
number 0 NOUN F
of 0 ADP F
sequelae 0 NOUN F
. 0 PUNCT F

CONCLUSIONS 0 NOUN T
Clindamycin 0 NOUN T
vaginal 0 ADJ F
cream 0 NOUN F
therapy 0 NOUN F
was 0 VERB F
associated 0 VERB F
with 0 ADP F
significantly 0 ADV F
prolonged 0 VERB F
gestation 0 NOUN F
and 0 CCONJ F
reduced 0 VERB F
cost 0 NOUN F
of 0 ADP F
neonatal 0 ADJ F
care 0 NOUN F
in 0 ADP F
women 0 NOUN F
with 0 ADP F
BV 0 NOUN T
. 0 PUNCT F

Early 0 ADJ T
screening 0 VERB F
for 0 ADP F
BV 0 NOUN T
and 0 CCONJ F
treatment 0 NOUN F
with 0 ADP F
clindamycin 0 NOUN F
saved 0 PUNCT F
approximately 0 ADV F
27 0 NUM F
euro 0 PUNCT F
per 0 ADP F
woman 0 NOUN F
. 0 PUNCT F

Double-blind 0 ADJ T
, 0 PUNCT F
placebo-controlled 0 VERB F
, 0 PUNCT F
dose-ranging 0 ADV F
study 0 NOUN F
of 0 ADP F
new 0 ADJ F
recombinant 0 ADJ F
hypoallergenic 0 ADJ F
Bet 0 ADV T
v 0 CCONJ F
1 0 NUM F
in 0 ADP F
an 0 DET F
environmental 0 ADJ F
exposure 0 NOUN F
chamber 0 NOUN F
. 0 PUNCT F

BACKGROUND 0 NOUN T
Recombinant 0 ADJ T
allergens 0 NOUN F
offer 0 VERB F
a 0 DET F
tool 0 NOUN F
for 0 ADP F
improving 0 VERB F
specific 0 ADJ F
immunotherapy 0 NOUN F
( 0 PUNCT F
SIT 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

OBJECTIVE 0 NOUN T
To 0 PROPN T
find 0 NOUN F
the 0 DET F
optimal 0 ADJ F
dose 0 NOUN F
of 0 ADP F
a 0 DET F
new 0 ADJ F
hypoallergenic 0 ADJ F
folding 0 VERB F
variant 0 NOUN F
of 0 ADP F
recombinant 0 ADJ F
Bet 0 NOUN T
v 0 CCONJ F
1 0 NUM F
( 0 PUNCT F
rBet 0 NOUN F
v 0 NUM F
1-FV 0 NOUN F
) 0 PUNCT F
as 0 ADP F
SIT 0 NOUN T
for 0 ADP F
patients 0 NOUN F
with 0 ADP F
birch 0 NOUN F
pollen 0 VERB F
allergy 0 NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
Before 0 ADP T
SIT 0 NOUN T
, 0 PUNCT F
thirty-seven 0 PUNCT F
adult 0 NOUN F
patients 0 NOUN F
were 0 VERB F
exposed 0 VERB F
for 0 ADP F
eight 0 NUM F
hours 0 NOUN F
in 0 ADP F
an 0 DET F
environmental 0 ADJ F
exposure 0 NOUN F
chamber 0 NOUN F
( 0 PUNCT F
EEC 0 NOUN T
) 0 PUNCT F
to 0 ADP F
birch 0 NOUN F
pollen 0 ADJ F
at 0 ADP F
an 0 DET F
average 0 ADJ F
concentration 0 NOUN F
of 0 ADP F
3500 0 NUM F
? 0 PUNCT F

500 0 NUM F
grains/m 0 NOUN F
( 0 PUNCT F
3 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
then 0 ADV F
randomized 0 VERB F
to 0 ADP F
four 0 NUM F
maintenance 0 NOUN F
dose 0 NOUN F
groups 0 NOUN F
of 0 ADP F
rBet 0 NOUN F
v 0 CCONJ F
1-FV 0 NOUN F
and 0 CCONJ F
one 0 NUM F
placebo 0 NOUN F
group 0 NOUN F
: 0 PUNCT F
20 0 NUM F
?g 0 PUNCT F
( 0 PUNCT F
n 0 NOUN F
= 0 SYM F
7 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
80 0 NUM F
?g 0 PUNCT F
( 0 PUNCT F
n 0 NOUN F
= 0 SYM F
8 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
160 0 NUM F
?g 0 PUNCT F
( 0 PUNCT F
n 0 NOUN F
= 0 SYM F
7 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
320 0 NUM F
?g 0 PUNCT F
( 0 PUNCT F
n 0 NOUN F
= 0 SYM F
8 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
and 0 CCONJ F
placebo 0 NOUN F
( 0 PUNCT F
n 0 NOUN F
= 0 SYM F
7 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Patients 0 NOUN T
were 0 VERB F
treated 0 VERB F
for 0 ADP F
10 0 NUM F
weeks 0 NOUN F
with 0 ADP F
weekly 0 ADV F
injections 0 NOUN F
and 0 CCONJ F
then 0 ADV F
re-exposed 0 VERB F
in 0 ADP F
the 0 DET F
EEC 0 NOUN T
. 0 PUNCT F

The 0 DET T
optimal 0 ADJ F
dose 0 NOUN F
for 0 ADP F
SIT 0 NOUN T
was 0 VERB F
assessed 0 VERB F
using 0 PUNCT F
efficacy 0 NOUN F
results 0 PUNCT F
from 0 ADP F
the 0 DET F
EEC 0 NOUN T
, 0 PUNCT F
IgG 0 NOUN T
responses 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
tolerability 0 NOUN F
. 0 PUNCT F

RESULTS 0 NOUN T
Thirty-six 0 NUM T
patients 0 NOUN F
were 0 VERB F
evaluable 0 ADJ F
for 0 ADP F
efficacy 0 NOUN F
assessment 0 NOUN F
. 0 PUNCT F

The 0 DET T
total 0 ADJ F
symptom 0 NOUN F
score 0 NOUN F
significantly 0 ADV F
decreased 0 NUM F
in 0 ADP F
all 0 DET F
active 0 ADJ F
groups 0 NOUN F
compared 0 VERB F
with 0 ADP F
placebo 0 NOUN F
( 0 PUNCT F
-18.8 0 NUM F
% 0 SYM F
for 0 ADP F
placebo 0 NOUN F
patients 0 NOUN F
; 0 PUNCT F
-71.9 0 NUM F
% 0 SYM F
, 0 PUNCT F
P 0 NOUN T
= 0 SYM F
0.0022 0 NUM F
for 0 ADP F
20 0 NUM F
?g 0 PUNCT F
; 0 PUNCT F
-75.6 0 NUM F
% 0 SYM F
, 0 PUNCT F
P 0 NOUN T
= 0 ADP F
0.0007 0 NUM F
for 0 ADP F
80 0 NUM F
?g 0 PUNCT F
; 0 PUNCT F
-81.8 0 ADV F
% 0 SYM F
, 0 PUNCT F
P 0 NOUN T
= 0 SYM F
0.0009 0 NUM F
for 0 ADP F
160 0 NUM F
?g 0 PUNCT F
; 0 PUNCT F
-78.3 0 NUM F
% 0 SYM F
, 0 PUNCT F
P 0 NOUN T
= 0 SYM F
0.0003 0 NUM F
for 0 ADP F
320 0 NUM F
?g 0 PUNCT F
) 0 PUNCT F
. 0 PUNCT F

IgG1 B-PHYSICAL NOUN T
increased 0 PUNCT F
significantly 0 ADV F
in 0 ADP F
all 0 DET F
active 0 ADJ F
groups 0 NOUN F
compared 0 VERB F
to 0 ADP F
placebo 0 NOUN F
. 0 PUNCT F

All 0 DET T
four 0 NUM F
active 0 ADJ F
doses 0 NOUN F
were 0 VERB F
well 0 VERB F
tolerated 0 ADP F
, 0 PUNCT F
no 0 DET F
serious 0 ADJ F
adverse 0 ADJ F
event 0 NOUN F
occurred 0 ADJ F
; 0 PUNCT F
two 0 NUM F
Grade 0 NOUN T
II B-ADVERSE-EFFECTS NUM T
reactions I-ADVERSE-EFFECTS NOUN F
, 0 PUNCT F
according 0 CCONJ F
to 0 ADP F
EAACI 0 NOUN T
classification 0 NOUN F
, 0 PUNCT F
were 0 VERB F
observed 0 VERB F
, 0 PUNCT F
one 0 NUM F
in 0 ADP F
each 0 PUNCT F
of 0 ADP F
the 0 DET F
160- 0 NOUN F
and 0 CCONJ F
320-?g 0 PUNCT F
groups 0 NOUN F
. 0 PUNCT F

CONCLUSIONS 0 NOUN T
Considering 0 PUNCT T
efficacy 0 NOUN F
, 0 PUNCT F
immunological 0 ADJ F
response 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
tolerability 0 NOUN F
, 0 PUNCT F
a 0 DET F
maintenance 0 NOUN F
dose 0 NOUN F
of 0 ADP F
80 0 NUM F
?g 0 PUNCT F
of 0 ADP F
rBet 0 NOUN F
v 0 NUM F
1-FV 0 NOUN F
appears 0 NOUN F
to 0 PART F
be 0 PUNCT F
the 0 DET F
ideal 0 ADJ F
dose 0 NOUN F
for 0 ADP F
allergen 0 NOUN F
immunotherapy 0 NOUN F
in 0 ADP F
birch 0 NOUN F
pollen 0 ADJ F
allergic 0 ADJ F
patients 0 NOUN F
. 0 PUNCT F

Prophylaxis 0 NOUN T
with 0 ADP F
meropenem 0 NOUN F
of 0 ADP F
septic B-PHYSICAL ADJ F
complications I-PHYSICAL NOUN F
in 0 ADP F
acute 0 ADJ F
pancreatitis 0 NOUN F
: 0 PUNCT F
a 0 DET F
randomized 0 VERB F
, 0 PUNCT F
controlled 0 VERB F
trial 0 NOUN F
versus 0 CCONJ F
imipenem 0 NOUN F
. 0 PUNCT F

OBJECTIVES 0 NOUN T
Prophylactic 0 ADJ T
antibiotics 0 NOUN F
are 0 VERB F
helpful 0 ADJ F
in 0 ADP F
decreasing 0 VERB F
the 0 DET F
incidence 0 NOUN F
of 0 ADP F
septic B-PHYSICAL ADJ F
complications I-PHYSICAL NOUN F
in 0 ADP F
acute 0 ADJ F
pancreatitis 0 NOUN F
. 0 PUNCT F

The 0 DET T
aim 0 NOUN F
of 0 ADP F
this 0 DET F
study 0 NOUN F
was 0 VERB F
to 0 ADV F
compare 0 NOUN F
the 0 DET F
efficacy 0 NOUN F
of 0 ADP F
meropenem 0 NOUN F
, 0 PUNCT F
a 0 DET F
new 0 ADJ F
carbapenem 0 NOUN F
antibiotic 0 NOUN F
, 0 PUNCT F
with 0 ADP F
that 0 PUNCT F
of 0 ADP F
imipenem 0 NOUN F
, 0 PUNCT F
which 0 ADP F
is 0 VERB F
the 0 DET F
standard 0 ADJ F
prophylactic 0 ADJ F
treatment 0 NOUN F
in 0 ADP F
patients 0 NOUN F
with 0 ADP F
severe 0 ADJ F
acute 0 ADJ F
pancreatitis 0 NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
One 0 NUM T
hundred 0 NUM F
seventy-six 0 PUNCT F
patients 0 NOUN F
with 0 ADP F
necrotizing 0 ADP F
pancreatitis 0 NOUN F
were 0 VERB F
prospectively 0 ADV F
randomized 0 PUNCT F
to 0 PUNCT F
prophylactic 0 ADJ F
treatment 0 NOUN F
with 0 ADP F
0.5 0 NUM F
g 0 NOUN F
meropenem 0 NOUN F
t.i.d 0 ADV F
. 0 PUNCT F

intravenously 0 DET F
or 0 CCONJ F
0.5 0 NUM F
g 0 ADP F
imipenem 0 NOUN F
q.i.d 0 ADP F
. 0 PUNCT F

intravenously 0 ADV F
. 0 PUNCT F

The 0 DET T
occurrence 0 NOUN F
of B-PHYSICAL ADP F
infection I-PHYSICAL NOUN F
of I-PHYSICAL ADP F
pancreatic I-PHYSICAL ADJ F
necrosis B-PHYSICAL NOUN F
, 0 PUNCT F
rate 0 NOUN F
of 0 ADP F
extrapancreatic B-PHYSICAL ADJ F
infections I-PHYSICAL NOUN F
, 0 PUNCT F
systemic B-ADVERSE-EFFECTS ADJ F
and B-ADVERSE-EFFECTS CCONJ F
local I-ADVERSE-EFFECTS ADJ F
complications I-ADVERSE-EFFECTS NOUN F
, 0 PUNCT F
need B-OTHER CCONJ F
for I-OTHER ADP F
surgery B-OTHER NOUN F
, 0 PUNCT F
mortality B-MORTALITY NOUN F
rate B-MORTALITY NOUN F
, 0 PUNCT F
and 0 CCONJ F
length B-OTHER NOUN F
of I-OTHER ADP F
hospitalization B-OTHER NOUN F
were 0 VERB F
recorded 0 VERB F
for 0 ADP F
each 0 DET F
group 0 NOUN F
. 0 PUNCT F

When 0 ADP T
a 0 DET F
septic B-PHYSICAL ADJ F
complication I-PHYSICAL NOUN F
of 0 ADP F
pancreatic 0 ADJ F
necrosis 0 NOUN F
was 0 VERB F
suspected 0 VERB F
, 0 PUNCT F
fine 0 PUNCT F
needle 0 NOUN F
aspiration 0 NOUN F
with 0 ADP F
cultures 0 NOUN F
of 0 ADP F
the 0 DET F
sample 0 NOUN F
was 0 VERB F
performed 0 VERB F
. 0 PUNCT F

Surgery 0 NOUN T
was 0 VERB F
performed 0 VERB F
in 0 ADP F
cases 0 NOUN F
of 0 ADP F
verified 0 PUNCT F
infected 0 PUNCT F
necrosis 0 NOUN F
. 0 PUNCT F

CONCLUSION 0 NOUN T
No 0 DET T
difference 0 NOUN F
was 0 VERB F
observed 0 VERB F
between 0 ADP F
patients 0 NOUN F
treated 0 VERB F
with 0 ADP F
meropenem 0 NOUN F
and 0 CCONJ F
those 0 PUNCT F
treated 0 VERB F
with 0 ADP F
imipenem 0 NOUN F
in 0 ADP F
terms 0 NOUN F
of 0 ADP F
incidence 0 NOUN F
of 0 ADP F
pancreatic B-PHYSICAL ADJ F
infection I-PHYSICAL NOUN F
( 0 PUNCT F
11.4 0 NUM F
% 0 SYM F
versus 0 CCONJ F
13.6 0 NUM F
% 0 SYM F
) 0 PUNCT F
and 0 PUNCT F

Effects 0 NOUN T
of 0 ADP F
preoperative 0 ADJ F
intentional 0 ADJ F
hemodilution 0 NOUN F
on 0 ADP F
the 0 DET F
extravasation B-PHYSICAL NOUN F
rate I-PHYSICAL NOUN F
of I-PHYSICAL ADP F
albumin I-PHYSICAL NOUN F
and I-PHYSICAL CCONJ F
fluid I-PHYSICAL NOUN F
. 0 PUNCT F

OBJECTIVE 0 NOUN T
To 0 PROPN T
evaluate 0 NOUN F
the 0 DET F
effects 0 NOUN F
of 0 ADP F
preoperative 0 ADJ F
intentional 0 ADJ F
hemodilution 0 NOUN F
with 0 ADP F
4 0 NUM F
% 0 SYM F
albumin 0 NOUN F
solution 0 NOUN F
on 0 ADP F
the 0 DET F
extravasation 0 NOUN F
rate 0 NOUN F
of 0 ADP F
intravascular 0 PUNCT F
albumin 0 NOUN F
and 0 CCONJ F
fluid 0 NOUN F
in 0 ADP F
surgical 0 ADJ F
patients 0 NOUN F
. 0 PUNCT F

DESIGN 0 NOUN T
A 0 CCONJ T
prospective 0 ADJ F
, 0 PUNCT F
randomized 0 VERB F
, 0 PUNCT F
clinical 0 ADJ F
study 0 NOUN F
. 0 PUNCT F

SETTING 0 ADJ T
University 0 NOUN T
teaching 0 VERB F
hospital 0 NOUN F
. 0 PUNCT F

PATIENTS 0 NOUN T
Two 0 NUM T
groups 0 NOUN F
( 0 PUNCT F
control 0 NOUN F
group 0 NOUN F
[ 0 PUNCT F
group 0 NOUN F
1 0 NUM F
] 0 PUNCT F
and 0 CCONJ F
hemodiluted 0 VERB F
group 0 NOUN F
[ 0 PUNCT F
group 0 NOUN F
2 0 NUM F
] 0 PUNCT F
) 0 PUNCT F
of 0 ADP F
13 0 NUM F
healthy 0 ADJ F
patients 0 NOUN F
were 0 VERB F
studied 0 VERB F
during 0 ADP F
a 0 DET F
long-term 0 NOUN F
( 0 PUNCT F
> 0 PROPN F
4 0 NUM F
hrs 0 NOUN F
) 0 PUNCT F
surgical 0 ADJ F
procedure 0 NOUN F
. 0 PUNCT F

INTERVENTIONS 0 NOUN T
Autologous 0 ADJ T
technetium-99m 0 NOUN F
( 0 PUNCT F
99mTc 0 NOUN F
) 0 PUNCT F
-labeled 0 PUNCT F
red 0 ADJ F
blood 0 NOUN F
cells 0 NOUN F
and 0 CCONJ F
indium-oxine 0 NOUN F
( 0 PUNCT F
( 0 PUNCT F
111 0 NUM F
) 0 PUNCT F
In 0 PUNCT T
) 0 PUNCT F
-labeled 0 NOUN F
human 0 NOUN F
serum 0 NOUN F
albumin 0 NOUN F
were 0 VERB F
injected 0 VERB F
intravenously 0 ADV F
during 0 ADP F
anesthesia 0 NOUN F
at 0 ADP F
T 0 NOUN T
= 0 SYM F
0 0 NUM F
min 0 NOUN F
in 0 ADP F
the 0 DET F
two 0 NUM F
groups 0 NOUN F
for 0 ADP F
the 0 DET F
determination 0 NOUN F
of 0 ADP F
total 0 ADJ F
blood 0 NOUN F
volume 0 NOUN F
and 0 CCONJ F
albumin 0 NOUN F
diffusion 0 NOUN F
space 0 NOUN F
, 0 PUNCT F
respectively 0 ADV F
. 0 PUNCT F

In 0 ADP T
addition 0 NOUN F
, 0 PUNCT F
body 0 NOUN F
tetrapolar 0 ADJ F
electrical 0 ADJ F
impedance 0 NOUN F
was 0 VERB F
used 0 VERB F
to 0 PART F
assess 0 NOUN F
extracellular 0 ADJ F
fluid 0 NOUN F
volume 0 NOUN F
. 0 PUNCT F

In 0 ADP T
the 0 DET F
hemodiluted 0 VERB F
group 0 NOUN F
( 0 PUNCT F
group 0 NOUN F
2 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
15 0 NUM F
mL/kg 0 ADJ F
of 0 ADP F
blood 0 NOUN F
was 0 VERB F
withdrawn 0 CCONJ F
over 0 ADP F
30 0 NUM F
mins 0 NOUN F
( 0 PUNCT F
T 0 NOUN T
= 0 DET F
20 0 NUM F
mins 0 NOUN F
to 0 ADP F
T 0 NOUN T
= 0 SYM F
50 0 NUM F
mins 0 NOUN F
) 0 PUNCT F
and 0 CCONJ F
simultaneously 0 ADV F
replaced 0 VERB F
by 0 ADP F
an 0 DET F
equal 0 ADJ F
volume 0 NOUN F
of 0 ADP F
4 0 NUM F
% 0 SYM F
albumin 0 NOUN F
solution 0 NOUN F
( 0 PUNCT F
0.6 0 NUM F
g/kg 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

MEASUREMENTS 0 ADP T
AND 0 CCONJ T
MAIN 0 ADJ T
RESULTS 0 NOUN T
The 0 DET T
albumin 0 NOUN F
diffusion 0 NOUN F
space 0 NOUN F
, 0 PUNCT F
the 0 DET F
colloid 0 NOUN F
oncotic 0 ADJ F
pressure 0 NOUN F
, 0 PUNCT F
the 0 DET F
plasma B-PHYSICAL NOUN F
albumin I-PHYSICAL NOUN F
concentration I-PHYSICAL NOUN F
and 0 CCONJ F
the 0 DET F
electrical B-PHYSICAL ADJ F
impedance I-PHYSICAL NOUN F
were 0 VERB F
measured 0 VERB F
before 0 PUNCT F
( 0 PUNCT F
T 0 NOUN T
= 0 SYM F
10 0 NUM F
mins 0 NOUN F
) 0 PUNCT F
and 0 CCONJ F
after 0 ADP F
( 0 PUNCT F
T 0 NOUN T
= 0 SYM F
60 0 NUM F
, 0 PUNCT F
120 0 NUM F
, 0 PUNCT F
and 0 CCONJ F
240 0 NUM F
mins 0 NOUN F
) 0 PUNCT F
hemodilution 0 NOUN F
. 0 PUNCT F

Urine B-PHYSICAL NOUN T
was 0 VERB F
collected 0 VERB F
from 0 ADP F
T 0 NOUN T
= 0 SYM F
10 0 NUM F
mins 0 NOUN F
to 0 VERB F
T 0 NOUN T
= 0 SYM F
240 0 NUM F
mins 0 NOUN F
. 0 PUNCT F

The 0 DET T
total 0 ADJ F
blood B-PHYSICAL NOUN F
volume I-PHYSICAL NOUN F
was 0 VERB F
calculated 0 VERB F
at 0 ADP F
T 0 NOUN T
= 0 SYM F
10 0 NUM F
mins 0 NOUN F
. 0 PUNCT F

No 0 DET T
differences 0 NOUN F
in 0 ADP F
the 0 DET F
initial 0 ADJ F
values 0 NOUN F
were 0 VERB F
found 0 VERB F
between 0 ADP F
the 0 DET F
two 0 NUM F
groups 0 NOUN F
. 0 PUNCT F

In 0 ADP T
group 0 NOUN F
2 0 NUM F
, 0 PUNCT F
hemodilution 0 NOUN F
( 0 PUNCT F
hematocrit 0 NOUN F
30 0 NUM F
+/- 0 SYM F
3 0 NUM F
% 0 SYM F
) 0 PUNCT F
resulted 0 VERB F
in 0 ADP F
a 0 DET F
steeper 0 PUNCT F
increase 0 NOUN F
in 0 ADP F
the 0 DET F
albumin B-PHYSICAL NOUN F
diffusion I-PHYSICAL NOUN F
space I-PHYSICAL NOUN F
( 0 PUNCT F
p 0 NOUN F
< 0 SYM F
.05 0 NUM F
) 0 PUNCT F
and 0 CCONJ F
a 0 DET F
progressive 0 ADJ F
decrease 0 NOUN F
in 0 ADP F
the 0 DET F
body B-PHYSICAL NOUN F
electrical I-PHYSICAL ADJ F
impedance I-PHYSICAL NOUN F
( 0 PUNCT F
p 0 NOUN F
< 0 SYM F
.05 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
extravasation B-PHYSICAL NOUN F
rate I-PHYSICAL NOUN F
of I-PHYSICAL ADP F
albumin I-PHYSICAL NOUN F
was 0 VERB F
0.052 0 NUM F
+/- 0 SYM F
0.007 0 NUM F
mL/kg/min 0 NOUN F
in 0 ADP F
group 0 NOUN F
2 0 NUM F
vs. 0 CCONJ F
0.038 0 NUM F
+/- 0 SYM F
0.020 0 NUM F
mL/kg/min 0 NOUN F
in 0 ADP F
group 0 NOUN F
1 0 NUM F
( 0 PUNCT F
p 0 NOUN F
< 0 SYM F
.05 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
value B-PHYSICAL NOUN F
of I-PHYSICAL ADP F
calculated I-PHYSICAL VERB F
plasma I-PHYSICAL NOUN F
volume I-PHYSICAL NOUN F
at 0 ADP F
T 0 NOUN T
= 0 SYM F
0 0 NUM F
min 0 NOUN F
did 0 VERB F
not 0 ADV F
shown 0 VERB F
any 0 DET F
difference 0 NOUN F
between 0 ADP F
the 0 DET F
two 0 NUM F
groups 0 NOUN F
. 0 PUNCT F

This 0 DET T
value 0 NOUN F
was 0 ADJ F
then 0 ADV F
lower 0 PUNCT F
than 0 PUNCT F
expected 0 VERB F
in 0 ADP F
group 0 NOUN F
2 0 NUM F
, 0 PUNCT F
corresponding 0 CCONJ F
to 0 ADP F
a 0 DET F
loss 0 NOUN F
of 0 ADP F
plasma B-PHYSICAL NOUN F
volume I-PHYSICAL NOUN F
of 0 ADP F
> 0 SYM F
3 0 NUM F
mL/kg 0 ADJ F
. 0 PUNCT F

Urine B-PHYSICAL NOUN T
output I-PHYSICAL NOUN F
was 0 ADP F
significantly 0 ADV F
lower 0 PUNCT F
in 0 ADP F
group 0 NOUN F
2 0 NUM F
than 0 PUNCT F
in 0 ADP F
group 0 NOUN F
1 0 NUM F
( 0 PUNCT F
0.7 0 NUM F
+/- 0 SYM F
0.4 0 NUM F
vs. 0 CCONJ F
1.4 0 NUM F
+/- 0 SYM F
1.0 0 NUM F
mL/min 0 NOUN F
, 0 PUNCT F
respectively 0 ADV F
; 0 PUNCT F
p 0 NOUN F
< 0 SYM F
.05 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

A 0 DET T
comparable 0 ADJ F
decrease 0 NOUN F
in 0 ADP F
colloid B-PHYSICAL NOUN F
oncotic I-PHYSICAL ADJ F
pressure I-PHYSICAL NOUN F
and 0 CCONJ F
in B-PHYSICAL ADP F
plasma I-PHYSICAL NOUN F
albumin I-PHYSICAL NOUN F
concentration I-PHYSICAL NOUN F
was 0 VERB F
observed 0 VERB F
in 0 ADP F
both 0 CCONJ F
groups 0 NOUN F
. 0 PUNCT F

CONCLUSIONS 0 NOUN T
These 0 PUNCT T
results 0 CCONJ F
suggest 0 VERB F
that 0 ADP F
preoperative 0 ADJ F
hemodilution 0 NOUN F
using 0 VERB F
4 0 NUM F
% 0 SYM F
albumin 0 NOUN F
on 0 ADP F
a 0 DET F
1:1 0 NUM F
volume 0 NOUN F
basis 0 NOUN F
for 0 ADP F
blood 0 NOUN F
substitution 0 NOUN F
during 0 ADP F
a 0 DET F
prolonged 0 VERB F
surgical 0 ADJ F
procedure 0 NOUN F
with 0 ADP F
reduced 0 VERB F
blood 0 NOUN F
losses 0 NOUN F
enhances 0 NOUN F
the 0 DET F
extravasation 0 NOUN F
rate 0 NOUN F
of 0 ADP F
albumin 0 NOUN F
and 0 CCONJ F
fluid 0 PUNCT F
to 0 ADP F
the 0 DET F
interstitial 0 ADJ F
tissues 0 NOUN F
, 0 PUNCT F
impeding 0 PUNCT F
the 0 DET F
maintenance 0 NOUN F
of 0 ADP F
isovolemia 0 NOUN F
. 0 PUNCT F

These 0 DET T
findings 0 NOUN F
support 0 VERB F
the 0 DET F
use 0 NOUN F
of 0 ADP F
a 0 DET F
volume 0 NOUN F
of 0 ADP F
infused 0 VERB F
colloid 0 NOUN F
solution 0 NOUN F
higher 0 PUNCT F
than 0 CCONJ F
that 0 ADP F
of 0 PUNCT F
withdrawn 0 PUNCT F
blood 0 NOUN F
during 0 ADP F
preoperative 0 ADJ F
hemodilution 0 NOUN F
. 0 PUNCT F

Comparison 0 NOUN T
of 0 ADP F
eltanolone 0 NOUN F
and 0 CCONJ F
thiopental 0 ADJ F
in 0 ADP F
anaesthesia B-PHYSICAL NOUN F
for 0 ADP F
termination 0 NOUN F
of 0 ADP F
pregnancy 0 NOUN F
. 0 PUNCT F

Eltanolone 0 NOUN T
, 0 PUNCT F
a 0 DET F
new 0 ADJ F
steroid 0 NOUN F
hypnotic 0 ADJ F
, 0 PUNCT F
was 0 VERB F
compared 0 VERB F
to 0 ADP F
thiopental 0 ADJ F
in 0 ADP F
short 0 ADJ F
anaesthesia 0 NOUN F
. 0 PUNCT F

Sixty 0 NUM T
unpremedicated 0 ADP F
, 0 PUNCT F
Asa 0 NOUN T
1-2 0 NUM F
women 0 NOUN F
were 0 VERB F
randomized 0 VERB F
to 0 PART F
receive 0 NOUN F
eltanolone 0 NOUN F
0.6 0 NUM F
( 0 PUNCT F
group 0 NOUN F
E1 0 NOUN T
) 0 PUNCT F
or 0 CCONJ F
0.8 0 NUM F
mg.kg-1 0 NOUN F
( 0 PUNCT F
group 0 NOUN F
E2 0 NOUN T
) 0 PUNCT F
or 0 CCONJ F
thiopental 0 ADJ F
4 0 NUM F
mg.kg-1 0 NOUN F
( 0 PUNCT F
group 0 NOUN F
T 0 NOUN T
) 0 PUNCT F
for 0 ADP F
induction 0 NOUN F
of 0 ADP F
anaesthesia 0 NOUN F
. 0 PUNCT F

One 0 NUM T
minute 0 ADJ F
before 0 ADP F
induction 0 NOUN F
glycopyrrolate 0 VERB F
0.2 0 NUM F
mg 0 NOUN F
and 0 CCONJ F
alfentanil 0 NOUN F
15 0 NUM F
micrograms.kg-1 0 NOUN F
i.v 0 NUM F
. 0 PUNCT F

were 0 VERB F
administered 0 VERB F
. 0 PUNCT F

If 0 ADP T
induction 0 NOUN F
failed 0 VERB F
, 0 PUNCT F
additional 0 ADJ F
boluses 0 NOUN F
of 0 ADP F
the 0 DET F
test 0 VERB F
drug 0 NOUN F
were 0 VERB F
given 0 VERB F
. 0 PUNCT F

Anaesthesia 0 NOUN T
was 0 VERB F
maintained 0 VERB F
with 0 ADP F
67 0 NUM F
% 0 SYM F
nitrous 0 ADJ F
oxide 0 NOUN F
in 0 ADP F
oxygen 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
additional 0 ADJ F
bolus 0 NOUN F
doses 0 NOUN F
of 0 ADP F
the 0 DET F
test 0 VERB F
drug 0 NOUN F
were 0 VERB F
given 0 VERB F
in 0 ADP F
a 0 DET F
standardized 0 VERB F
fashion 0 NOUN F
, 0 PUNCT F
if 0 VERB F
needed 0 VERB F
. 0 PUNCT F

Recovery B-MENTAL NOUN T
was 0 VERB F
assessed 0 VERB F
by 0 ADP F
a 0 DET F
research 0 NOUN F
nurse 0 ADJ F
blinded 0 PRON F
to 0 ADP F
the 0 ADP F
agent 0 NOUN F
used 0 VERB F
. 0 PUNCT F

Mean 0 NOUN T
+/- B-PHYSICAL SYM F
s.d 0 ADV F
. 0 PUNCT F

induction 0 NOUN F
doss B-PHYSICAL NOUN F
were 0 VERB F
0.7 0 NUM F
+/- 0 SYM F
0.1 0 NUM F
mg.kg-1 0 NOUN F
( 0 PUNCT F
group 0 NOUN F
E1 0 NOUN T
) 0 PUNCT F
, 0 PUNCT F
0.8 0 NUM F
+/- 0 SYM F
0.1 0 NUM F
mg.kg-1 0 NOUN F
( 0 PUNCT F
group 0 NOUN F
E2 0 NOUN T
) 0 PUNCT F
and 0 CCONJ F
4.0 0 NUM F
+/- 0 SYM F
0.0 0 NUM F
mg.kg-1 0 NOUN F
( 0 PUNCT F
group 0 NOUN F
T 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

Induction 0 NOUN T
time 0 NOUN F
was 0 VERB F
prolonged 0 VERB F
in 0 ADP F
the 0 DET F
group 0 NOUN F
E1 0 NOUN T
compared 0 VERB F
to 0 ADP F
the 0 DET F
other 0 ADJ F
two 0 NUM F
groups 0 NOUN F
( 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.05 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Side 0 NOUN T
effects 0 NOUN F
were 0 VERB F
few 0 ADJ F
in 0 ADP F
all 0 DET F
groups 0 NOUN F
, 0 PUNCT F
but 0 CCONJ F
involuntary B-PHYSICAL ADJ F
muscle I-PHYSICAL NOUN F
movements I-PHYSICAL NOUN F
or I-PHYSICAL CCONJ F
hypertonus I-PHYSICAL NOUN F
occurred 0 VERB F
in 0 ADP F
23 0 NUM F
% 0 SYM F
of 0 ADP F
the 0 DET F
patients 0 NOUN F
in 0 ADP F
the 0 DET F
eltanolone 0 NOUN F
and 0 CCONJ F
in 0 ADP F
3 0 NUM F
% 0 SYM F
in 0 ADP F
the 0 DET F
thiopental 0 ADJ F
groups 0 NOUN F
( 0 PUNCT F
n.s 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

A 0 DET T
comparison 0 NOUN F
of 0 ADP F
recombinant 0 ADJ F
human 0 NOUN F
thyrotropin 0 NOUN F
and 0 CCONJ F
thyroid 0 NOUN F
hormone 0 NOUN F
withdrawal 0 NOUN F
for 0 ADP F
the 0 DET F
detection 0 NOUN F
of 0 ADP F
thyroid 0 NOUN F
remnant 0 ADJ F
or 0 CCONJ F
cancer 0 NOUN F
. 0 PUNCT F

Recombinant 0 ADJ T
human 0 NOUN F
TSH 0 NOUN T
has 0 VERB F
been 0 PUNCT F
developed 0 VERB F
to 0 PART F
facilitate 0 NOUN F
monitoring 0 VERB F
for 0 ADP F
thyroid 0 NOUN F
carcinoma 0 NOUN F
recurrence 0 NOUN F
or 0 CCONJ F
persistence 0 NOUN F
without 0 ADP F
the 0 DET F
attendant 0 PUNCT F
morbidity 0 NOUN F
of 0 ADP F
hypothyroidism 0 NOUN F
seen 0 VERB F
after 0 ADP F
thyroid 0 NOUN F
hormone 0 NOUN F
withdrawal 0 NOUN F
. 0 PUNCT F

The 0 DET T
objectives 0 NOUN F
of 0 ADP F
this 0 DET F
study 0 NOUN F
were 0 VERB F
to 0 PART F
compare 0 NOUN F
the 0 DET F
effect 0 NOUN F
of 0 ADP F
administered 0 VERB F
recombinant 0 ADJ F
human 0 NOUN F
TSH 0 NOUN T
with 0 ADP F
thyroid 0 NOUN F
hormone 0 NOUN F
withdrawal 0 NOUN F
on 0 ADP F
the 0 DET F
results 0 NOUN F
of 0 ADP F
radioiodine 0 NOUN F
whole 0 ADJ F
body 0 NOUN F
scanning 0 PUNCT F
( 0 PUNCT F
WBS 0 NOUN T
) 0 PUNCT F
and 0 CCONJ F
serum 0 NOUN F
thyroglobulin 0 NOUN F
( 0 PUNCT F
Tg 0 NOUN T
) 0 PUNCT F
levels 0 NOUN F
. 0 PUNCT F

Two 0 NUM T
hundred 0 NUM F
and 0 CCONJ F
twenty-nine 0 PUNCT F
adult 0 NOUN F
patients 0 NOUN F
with 0 ADP F
differentiated 0 VERB F
thyroid 0 NOUN F
cancer 0 NOUN F
requiring 0 VERB F
radioiodine 0 NOUN F
WBS 0 NOUN T
were 0 VERB F
studied 0 VERB F
. 0 PUNCT F

Radioiodine 0 NOUN T
WBS 0 NOUN T
and 0 CCONJ F
serum 0 NOUN F
Tg 0 NOUN T
measurements 0 NOUN F
were 0 VERB F
performed 0 VERB F
after 0 ADP F
administration 0 NOUN F
of 0 ADP F
recombinant 0 ADJ F
human 0 NOUN F
TSH 0 NOUN T
and 0 CCONJ F
again 0 ADV F
after 0 ADP F
thyroid 0 NOUN F
hormone 0 NOUN F
withdrawal 0 NOUN F
in 0 ADP F
each 0 DET F
patient 0 NOUN F
. 0 PUNCT F

Radioiodine 0 NOUN T
whole 0 ADJ F
body 0 NOUN F
scans 0 PUNCT F
were 0 VERB F
concordant 0 ADJ F
between 0 ADP F
the 0 DET F
recombinant B-PHYSICAL ADJ F
TSH-stimulated I-PHYSICAL VERB T
and 0 CCONJ F
thyroid B-PHYSICAL NOUN F
hormone I-PHYSICAL NOUN F
withdrawal I-PHYSICAL NOUN F
phases I-PHYSICAL ADP F
in 0 ADP F
195 0 ADJ F
of 0 ADP F
220 0 NUM F
( 0 PUNCT F
89 0 NUM F
% 0 SYM F
) 0 PUNCT F
patients 0 NOUN F
. 0 PUNCT F

Of 0 ADP T
the 0 DET F
discordant 0 ADJ F
scans 0 ADJ F
, 0 PUNCT F
8 0 NUM F
( 0 PUNCT F
4 0 NUM F
% 0 SYM F
) 0 PUNCT F
had 0 PUNCT F
superior 0 ADJ F
scans 0 NOUN F
after 0 ADP F
recombinant 0 ADJ F
human 0 NOUN F
TSH 0 NOUN T
administration 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
17 0 NUM F
( 0 PUNCT F
8 0 NUM F
% 0 SYM F
) 0 PUNCT F
had 0 PUNCT F
superior 0 ADJ F
scans 0 NOUN F
after 0 ADP F
thyroid 0 NOUN F
hormone 0 NOUN F
withdrawal 0 NOUN F
( 0 PUNCT F
P 0 NOUN T
= 0 SYM F
0.108 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Based 0 VERB T
on 0 ADP F
a 0 DET F
serum B-PHYSICAL NOUN F
Tg I-PHYSICAL NOUN T
level I-PHYSICAL NOUN F
of 0 ADP F
2 0 NUM F
ng/mL 0 NOUN F
or 0 CCONJ F
more 0 DET F
, 0 PUNCT F
thyroid 0 NOUN F
tissue 0 NOUN F
or 0 CCONJ F
cancer 0 NOUN F
was 0 VERB F
detected 0 VERB F
during 0 ADP F
thyroid 0 NOUN F
hormone 0 NOUN F
therapy 0 NOUN F
in 0 ADP F
22 0 NUM F
% 0 SYM F
, 0 PUNCT F
after 0 ADP F
recombinant 0 ADJ F
human 0 NOUN F
TSH 0 NOUN T
stimulation 0 NOUN F
in 0 ADP F
52 0 NUM F
% 0 SYM F
, 0 PUNCT F
and 0 CCONJ F
after 0 ADP F
thyroid 0 NOUN F
hormone 0 NOUN F
withdrawal 0 NOUN F
in 0 ADP F
56 0 NUM F
% 0 SYM F
of 0 ADP F
patients 0 NOUN F
with 0 ADP F
disease 0 NOUN F
or 0 CCONJ F
tissue 0 NOUN F
limited 0 VERB F
to 0 ADP F
the 0 DET F
thyroid 0 NOUN F
bed 0 PUNCT F
and 0 CCONJ F
in 0 ADP F
80 0 NUM F
% 0 SYM F
, 0 PUNCT F
100 0 NUM F
% 0 SYM F
, 0 PUNCT F
and 0 CCONJ F
100 0 NUM F
% 0 SYM F
of 0 ADP F
patients 0 NOUN F
, 0 PUNCT F
respectively 0 ADV F
, 0 PUNCT F
with 0 ADP F
metastatic 0 ADJ F
disease 0 NOUN F
. 0 PUNCT F

A 0 DET T
combination 0 NOUN F
of 0 ADP F
radioiodine 0 NOUN F
WBS 0 NOUN T
and 0 CCONJ F
serum 0 NOUN F
Tg 0 NOUN T
after 0 ADP F
recombinant 0 ADJ F
human 0 NOUN F
TSH 0 NOUN T
stimulation 0 NOUN F
detected 0 VERB F
thyroid B-PHYSICAL NOUN F
tissue I-PHYSICAL NOUN F
or 0 CCONJ F
cancer B-PHYSICAL NOUN F
in 0 ADP F
93 0 NUM F
% 0 SYM F
of 0 ADP F
patients 0 NOUN F
with 0 ADP F
disease 0 NOUN F
or 0 CCONJ F
tissue 0 NOUN F
limited 0 VERB F
to 0 ADP F
the 0 DET F
thyroid 0 NOUN F
bed 0 PUNCT F
and 0 CCONJ F
100 0 NUM F
% 0 SYM F
of 0 ADP F
patients 0 NOUN F
with 0 ADP F
metastatic 0 ADJ F
disease 0 NOUN F
. 0 PUNCT F

In 0 ADP T
conclusion 0 NOUN F
, 0 PUNCT F
recombinant 0 ADJ F
human 0 NOUN F
TSH 0 NOUN T
administration 0 NOUN F
is 0 VERB F
a 0 DET F
safe 0 ADJ F
and 0 CCONJ F
effective 0 ADJ F
means 0 NOUN F
of 0 ADP F
stimulating 0 VERB F
radioiodine 0 NOUN F
uptake 0 NOUN F
and 0 CCONJ F
serum 0 NOUN F
Tg 0 NOUN T
levels 0 NOUN F
in 0 ADP F
patients 0 NOUN F
undergoing 0 ADP F
evaluation 0 NOUN F
for 0 ADP F
thyroid 0 NOUN F
cancer 0 NOUN F
persistence 0 NOUN F
and 0 CCONJ F
recurrence 0 NOUN F
. 0 PUNCT F

Prospective 0 ADJ T
randomized 0 VERB F
evaluation 0 NOUN F
of 0 ADP F
diode-laser 0 ADJ F
and 0 CCONJ F
cryotherapy 0 NOUN F
in 0 ADP F
prethreshold B-PHYSICAL NOUN F
retinopathy I-PHYSICAL NOUN F
of 0 ADP F
prematurity 0 NOUN F
. 0 PUNCT F

PURPOSE 0 NOUN T
To 0 ADP T
study 0 NOUN F
the 0 DET F
efficacy 0 NOUN F
of 0 ADP F
indirect 0 ADJ F
diode 0 NOUN F
laser 0 NOUN F
photocoagulation 0 NOUN F
and 0 CCONJ F
cryotherapy 0 NOUN F
in 0 ADP F
prethreshold B-PHYSICAL NOUN F
retinopathy I-PHYSICAL NOUN F
of I-PHYSICAL ADP F
prematurity I-PHYSICAL NOUN F
( I-PHYSICAL PUNCT F
ROP I-PHYSICAL NOUN T
) I-PHYSICAL PUNCT F
. 0 PUNCT F

METHODS 0 NOUN T
Thirty-six 0 NUM T
eyes 0 NOUN F
of 0 ADP F
18 0 NUM F
premature 0 ADJ F
infants 0 NOUN F
less 0 ADV F
than 0 PUNCT F
34 0 NUM F
weeks 0 NOUN F
gestational 0 ADJ F
age 0 NOUN F
and/or 0 CCONJ F
less 0 ADV F
than 0 ADP F
1600 0 NUM F
g 0 NOUN F
birth 0 NOUN F
weight 0 NOUN F
with 0 ADP F
prethreshold 0 NOUN F
ROP 0 NOUN T
were 0 VERB F
prospectively 0 ADV F
randomized 0 PUNCT F
to 0 ADP F
treatment 0 NOUN F
with 0 ADP F
either 0 CCONJ F
indirect 0 ADJ F
laser 0 NOUN F
photocoagulation 0 NOUN F
or 0 CCONJ F
cryotherapy 0 NOUN F
. 0 PUNCT F

Prethreshold 0 NOUN T
ROP 0 NOUN T
was 0 VERB F
defined 0 VERB F
as 0 ADP F
any 0 DET F
stage 0 NOUN F
of 0 ADP F
ROP 0 NOUN T
in 0 ADP F
zone 0 NOUN F
I 0 NUM T
with 0 ADP F
plus 0 CCONJ F
disease 0 NOUN F
; 0 PUNCT F
or 0 CCONJ F
stage 0 NOUN F
3 0 NUM F
with 0 ADP F
three 0 NUM F
or 0 CCONJ F
more 0 DET F
contiguous 0 ADJ F
clock 0 NOUN F
hours 0 NOUN F
or 0 CCONJ F
five 0 NUM F
or 0 CCONJ F
more 0 DET F
total 0 ADJ F
clock 0 NOUN F
hours 0 NOUN F
of 0 ADP F
involvement 0 NOUN F
of 0 ADP F
retina 0 NOUN F
in 0 ADP F
zone 0 NOUN F
II 0 NUM T
with 0 ADP F
plus 0 CCONJ F
disease 0 NOUN F
but 0 CCONJ F
less 0 ADV F
than 0 CCONJ F
threshold 0 NOUN F
disease 0 NOUN F
. 0 PUNCT F

Regression 0 NOUN T
of 0 ADP F
the 0 DET F
ROP B-PHYSICAL NOUN T
was 0 VERB F
assessed 0 VERB F
for 0 ADP F
a 0 DET F
minimum 0 NOUN F
period 0 NOUN F
of 0 ADP F
6 0 NUM F
months 0 NOUN F
. 0 PUNCT F

RESULTS 0 DET T
Regression 0 NOUN T
of 0 ADP F
ROP B-PHYSICAL NOUN T
occurred 0 VERB F
in 0 ADP F
all 0 DET F
36 0 NUM F
eyes 0 NOUN F
( 0 PUNCT F
100 0 NUM F
% 0 SYM F
) 0 PUNCT F
in 0 ADP F
both 0 CCONJ F
groups 0 NOUN F
. 0 PUNCT F

CONCLUSIONS 0 NOUN T
Excellent 0 PUNCT T
results 0 NOUN F
are 0 VERB F
achieved 0 VERB F
if 0 VERB F
ROP B-OTHER NOUN T
is 0 VERB F
treated 0 VERB F
at 0 ADP F
the 0 DET F
prethreshold 0 NOUN F
stage 0 NOUN F
with 0 ADP F
both 0 CCONJ F
indirect 0 ADJ F
laser 0 NOUN F
photocoagulation 0 NOUN F
and 0 CCONJ F
cryotherapy 0 NOUN F
. 0 PUNCT F

Although 0 ADP T
laser 0 NOUN F
has 0 VERB F
definite 0 ADJ F
advantages 0 NOUN F
, 0 PUNCT F
cryotherapy 0 NOUN F
can 0 VERB F
be 0 VERB F
considered 0 VERB F
as 0 ADP F
an 0 DET F
alternative 0 ADJ F
modality 0 NOUN F
of 0 ADP F
treatment 0 NOUN F
in 0 ADP F
developing 0 VERB F
countries 0 NOUN F
due 0 CCONJ F
to 0 ADP F
economic 0 ADJ F
reasons 0 NOUN F
. 0 PUNCT F

Association 0 NOUN T
of 0 ADP F
efavirenz 0 ADP F
hypersusceptibility 0 NOUN F
with 0 ADP F
virologic 0 ADJ F
response 0 NOUN F
in 0 ADP F
ACTG 0 NOUN T
368 0 NUM F
, 0 PUNCT F
a 0 DET F
randomized 0 VERB F
trial 0 NOUN F
of 0 ADP F
abacavir 0 NOUN F
( 0 PUNCT F
ABC 0 NOUN T
) 0 PUNCT F
in 0 ADP F
combination 0 NOUN F
with 0 ADP F
efavirenz 0 NOUN F
( 0 PUNCT F
EFV 0 NOUN T
) 0 PUNCT F
and 0 CCONJ F
indinavir 0 NOUN F
( 0 PUNCT F
IDV 0 NOUN T
) 0 PUNCT F
in 0 ADP F
HIV-infected 0 VERB T
subjects 0 NOUN F
with 0 ADP F
prior 0 PUNCT F
nucleoside 0 NOUN F
analog 0 NOUN F
experience 0 NOUN F
. 0 PUNCT F

PURPOSE 0 NOUN T
To 0 ADJ T
evaluate 0 NOUN F
the 0 DET F
association 0 NOUN F
of 0 ADP F
efavirenz 0 ADP F
hypersusceptibility 0 NOUN F
( 0 PUNCT F
EFV-HS 0 NOUN T
) 0 PUNCT F
with 0 ADP F
clinical 0 ADJ F
outcome 0 NOUN F
in 0 ADP F
a 0 DET F
double-blind 0 ADJ F
, 0 PUNCT F
placebo-controlled 0 VERB F
, 0 PUNCT F
randomized 0 VERB F
trial 0 NOUN F
of 0 ADP F
EFV 0 NOUN T
plus 0 CCONJ F
indinavir 0 NOUN F
( 0 PUNCT F
EFV+IDV 0 NOUN T
) 0 PUNCT F
vs. 0 CCONJ F
EFV+IDV 0 NOUN T
plus 0 CCONJ F
abacavir 0 NOUN F
( 0 PUNCT F
ABC 0 NOUN T
) 0 PUNCT F
in 0 ADP F
283 0 NUM F
nucleoside-experienced 0 VERB F
HIV-infected 0 VERB T
patients 0 NOUN F
. 0 PUNCT F

METHOD 0 NOUN T
AND 0 CCONJ T
RESULTS 0 ADJ T
Rates 0 PUNCT T
of 0 ADP F
virologic B-OTHER ADJ F
failure I-OTHER NOUN F
were 0 VERB F
similar 0 ADJ F
in 0 ADP F
the 0 DET F
2 0 NUM F
arms 0 NOUN F
at 0 ADP F
week 0 NOUN F
16 0 NUM F
( 0 PUNCT F
p 0 NOUN F
= 0 SYM F
.509 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Treatment 0 NOUN T
discontinuations B-OTHER NOUN F
were 0 VERB F
more 0 ADV F
common 0 ADJ F
in 0 ADP F
the 0 DET F
ABC 0 NOUN T
arm 0 NOUN F
( 0 PUNCT F
p 0 NOUN F
= 0 SYM F
.001 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Using 0 PROPN T
logistic 0 ADJ F
regression 0 NOUN F
, 0 PUNCT F
there 0 PUNCT F
was 0 VERB F
no 0 DET F
association 0 NOUN F
between 0 ADP F
virologic B-OTHER ADJ F
failure I-OTHER NOUN F
and 0 CCONJ F
either 0 PUNCT F
baseline 0 NOUN F
ABC B-MENTAL NOUN T
resistance I-MENTAL NOUN F
or 0 CCONJ F
regimen B-OTHER NOUN F
sensitivity I-OTHER NOUN F
score I-OTHER NOUN F
. 0 PUNCT F

Using 0 VERB T
3 0 NUM F
different 0 ADJ F
genotypic 0 ADJ F
scoring 0 VERB F
systems 0 NOUN F
, 0 PUNCT F
EFV-HS 0 PUNCT T
was 0 VERB F
significantly 0 ADV F
associated 0 VERB F
with 0 ADP F
reduced 0 VERB F
virologic 0 ADJ F
failure 0 NOUN F
at 0 ADP F
week 0 NOUN F
16 0 NUM F
, 0 PUNCT F
independent 0 ADJ F
of 0 ADP F
treatment 0 NOUN F
assignment 0 NOUN F
. 0 PUNCT F

In 0 ADP T
some 0 DET F
patients 0 NOUN F
on 0 ADP F
the 0 DET F
nucleoside-sparing 0 PROPN F
arm 0 ADP F
, 0 PUNCT F
the 0 DET F
nucleoside-resistance 0 NOUN F
mutation 0 NOUN F
L74V 0 NOUN T
was 0 VERB F
selected 0 VERB F
for 0 ADP F
in 0 PUNCT F
combination 0 NOUN F
with 0 ADP F
the 0 DET F
uncommonly 0 ADJ F
occurring 0 VERB F
EFV-resistance 0 NOUN T
mutations 0 NOUN F
K103N+L100I 0 NOUN T
; 0 PUNCT F
L74V 0 NOUN T
was 0 VERB F
not 0 ADV F
detected 0 VERB F
as 0 ADP F
a 0 DET F
minority 0 NOUN F
variant 0 NOUN F
, 0 PUNCT F
using 0 SYM F
clonal 0 ADJ F
sequence 0 NOUN F
analysis 0 NOUN F
, 0 PUNCT F
when 0 ADP F
the 0 DET F
nucleoside-sparing 0 PROPN F
regimen 0 NOUN F
was 0 VERB F
initiated 0 VERB F
. 0 PUNCT F

CONCLUSION 0 NOUN T
Premature 0 PUNCT T
treatment 0 NOUN F
discontinuations B-MENTAL NOUN F
in 0 ADP F
the 0 DET F
ABC 0 NOUN T
arm 0 NOUN F
and 0 CCONJ F
the 0 DET F
presence 0 NOUN F
of 0 ADP F
EFV-HS 0 NOUN T
HIV 0 NOUN T
variants 0 NOUN F
in 0 ADP F
this 0 DET F
patient 0 NOUN F
population 0 NOUN F
likely 0 ADJ F
made 0 PUNCT F
it 0 VERB F
difficult 0 ADJ F
to 0 ADJ F
detect 0 NOUN F
a 0 DET F
benefit 0 NOUN F
of 0 ADP F
adding B-OTHER VERB F
ABC I-OTHER NOUN T
to I-OTHER ADP F
EFV+IDV I-OTHER NOUN T
. 0 PUNCT F

In 0 ADP T
addition 0 NOUN F
, 0 PUNCT F
L74V 0 NOUN T
, 0 PUNCT F
when 0 ADP F
combined 0 VERB F
with 0 ADP F
K103N+L100I 0 NOUN T
, 0 PUNCT F
may 0 VERB F
confer 0 VERB F
a 0 DET F
selective 0 ADJ F
advantage 0 PUNCT F
to 0 ADP F
the 0 DET F
virus 0 NOUN F
that 0 ADP F
is 0 VERB F
independent 0 ADJ F
of 0 ADP F
its 0 ADJ F
effects 0 NOUN F
on 0 ADP F
nucleoside B-ADVERSE-EFFECTS NOUN F
resistance I-ADVERSE-EFFECTS NOUN F
. 0 PUNCT F

The 0 DET T
effectiveness 0 NOUN F
of 0 ADP F
single-dose 0 NOUN F
metronidazole 0 NOUN F
therapy 0 NOUN F
for 0 ADP F
patients 0 NOUN F
and 0 CCONJ F
their 0 DET F
partners 0 NOUN F
with 0 ADP F
bacterial 0 ADJ F
vaginosis 0 NOUN F
. 0 PUNCT F

A 0 DET T
randomized 0 VERB F
, 0 PUNCT F
placebo-controlled 0 VERB F
, 0 PUNCT F
double-blind 0 ADJ F
clinical 0 ADJ F
trial 0 NOUN F
was 0 VERB F
performed 0 VERB F
to 0 ADJ F
test 0 NOUN F
the 0 DET F
hypothesis 0 NOUN F
that 0 ADP F
a 0 DET F
2-g 0 NOUN F
single 0 ADJ F
dose 0 NOUN F
of 0 ADP F
metronidazole 0 NOUN F
for 0 ADP F
male 0 NOUN F
partners 0 NOUN F
of 0 ADP F
women 0 NOUN F
with 0 ADP F
bacterial 0 ADJ F
vaginosis 0 NOUN F
was 0 VERB F
more 0 ADV F
effective 0 ADJ F
than 0 PUNCT F
placebo 0 NOUN F
in 0 ADP F
improving 0 VERB F
cure 0 NOUN F
rate 0 NOUN F
and 0 CCONJ F
decreasing 0 VERB F
recurrence 0 NOUN F
rate 0 NOUN F
. 0 PUNCT F

In 0 ADP T
addition 0 NOUN F
, 0 PUNCT F
the 0 DET F
effectiveness 0 NOUN F
of 0 ADP F
a 0 DET F
2-g 0 NOUN F
single 0 ADJ F
dose 0 NOUN F
of 0 ADP F
metronidazole 0 NOUN F
was 0 VERB F
compared 0 VERB F
with 0 ADP F
a 0 DET F
seven-day 0 NOUN F
course 0 NOUN F
of 0 ADP F
500 0 NUM F
mg 0 NOUN F
of 0 ADP F
metronidazole 0 NOUN F
twice 0 ADV F
a 0 DET F
day 0 NOUN F
in 0 ADP F
patients 0 NOUN F
with 0 ADP F
bacterial 0 ADJ F
vaginosis 0 NOUN F
. 0 PUNCT F

Statistically 0 ADV T
significant 0 ADJ F
benefits 0 NOUN F
of 0 ADP F
partner 0 NOUN F
treatment 0 NOUN F
were 0 VERB F
noted 0 VERB F
in 0 ADP F
the 0 DET F
initial 0 ADJ F
cure 0 NOUN F
rate 0 NOUN F
by 0 ADP F
Gram-stained 0 PUNCT T
smear 0 NOUN F
criteria 0 NOUN F
( 0 PUNCT F
P 0 NOUN T
less 0 ADV F
than 0 ADP F
.01 0 NUM F
) 0 PUNCT F
and 0 CCONJ F
in 0 ADP F
percentage 0 NOUN F
of 0 ADP F
women 0 NOUN F
with 0 ADP F
symptoms 0 NOUN F
eight 0 NUM F
weeks 0 NOUN F
after 0 ADP F
initiating 0 VERB F
therapy 0 NOUN F
( 0 PUNCT F
P 0 NOUN T
less 0 ADV F
than 0 PUNCT F
.05 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
seven-day 0 NOUN F
course 0 NOUN F
of 0 ADP F
metronidazole 0 NOUN F
was 0 VERB F
superior 0 ADJ F
to 0 ADP F
the 0 DET F
single-dose 0 NOUN F
regimen 0 NOUN F
in 0 ADP F
the 0 DET F
percentage 0 NOUN F
of 0 ADP F
patients 0 NOUN F
with 0 ADP F
clue 0 ADJ F
cells 0 NOUN F
and 0 CCONJ F
the 0 DET F
percentage 0 NOUN F
of 0 ADP F
patients 0 NOUN F
with 0 ADP F
a 0 DET F
positive 0 ADJ F
sniff 0 NOUN F
test 0 NOUN F
at 0 ADP F
the 0 DET F
first 0 ADJ F
follow-up 0 NOUN F
visit 0 NOUN F
; 0 PUNCT F
however 0 ADV F
, 0 PUNCT F
differences 0 NOUN F
in 0 ADP F
the 0 DET F
initial B-PHYSICAL ADJ F
cure I-PHYSICAL NOUN F
rate I-PHYSICAL NOUN F
assessed I-PHYSICAL VERB F
by I-PHYSICAL ADP F
clinical I-PHYSICAL ADJ F
criteria I-PHYSICAL NOUN F
and 0 CCONJ F
Gram-stained B-PHYSICAL PUNCT T
smear I-PHYSICAL NOUN F
criteria I-PHYSICAL NOUN F
were 0 VERB F
not 0 ADV F
statistically 0 ADV F
significant 0 ADJ F
between 0 ADP F
the 0 DET F
two 0 NUM F
patient 0 NOUN F
treatment 0 NOUN F
regimens 0 NOUN F
. 0 PUNCT F

Recurrence B-PHYSICAL NOUN T
rates I-PHYSICAL NOUN F
by I-PHYSICAL ADP F
Gram-stained I-PHYSICAL PUNCT T
smear I-PHYSICAL NOUN F
criteria I-PHYSICAL NOUN F
between 0 ADP F
patient 0 NOUN F
and 0 CCONJ F
partner 0 NOUN F
treatment 0 NOUN F
groups 0 NOUN F
at 0 ADP F
five 0 NUM F
and 0 CCONJ F
eight 0 NUM F
weeks 0 NOUN F
after 0 ADP F
initiation 0 NOUN F
of 0 ADP F
treatment 0 NOUN F
were 0 VERB F
also 0 ADV F
not 0 ADV F
significantly 0 ADV F
different 0 ADJ F
between 0 ADP F
the 0 DET F
two 0 NUM F
patient 0 NOUN F
regimens 0 NOUN F
. 0 PUNCT F

Single-dose 0 PUNCT T
metronidazole 0 NOUN F
treatment 0 NOUN F
of 0 ADP F
the 0 DET F
sexual 0 ADJ F
partner 0 NOUN F
of 0 ADP F
women 0 NOUN F
with 0 ADP F
bacterial 0 ADJ F
vaginosis 0 NOUN F
improves 0 VERB F
initial 0 ADJ F
bacterial B-PHYSICAL ADJ F
vaginosis I-PHYSICAL NOUN F
cure I-PHYSICAL NOUN F
rates I-PHYSICAL NOUN F
. 0 PUNCT F

The 0 DET T
seven-day 0 NOUN F
course 0 NOUN F
of 0 ADP F
metronidazole 0 NOUN F
was 0 VERB F
not 0 ADV F
found 0 VERB F
by 0 ADP F
statistical 0 ADJ F
analysis 0 NOUN F
to 0 PART F
be 0 PUNCT F
significantly 0 ADV F
superior 0 ADJ F
to 0 ADP F
single-dose 0 NOUN F
therapy 0 NOUN F
when 0 ADP F
considering 0 ADV F
initial 0 ADJ F
cure 0 NOUN F
rates 0 NOUN F
by 0 ADP F
clinical 0 ADJ F
or 0 CCONJ F
Gram-stained 0 PROPN T
smear 0 NOUN F
criteria 0 NOUN F
or 0 CCONJ F
recurrence 0 NOUN F
rates 0 NOUN F
. 0 PUNCT F
( 0 PUNCT F

ABSTRACT 0 ADP T
TRUNCATED 0 PUNCT T
AT 0 ADP T
250 0 NUM F
WORDS 0 NOUN T
) 0 PUNCT F

Long-term 0 NOUN T
treatment 0 NOUN F
with 0 ADP F
atomoxetine 0 NOUN F
for 0 ADP F
attention-deficit/hyperactivity B-MENTAL NOUN F
disorder I-MENTAL NOUN F
symptoms I-MENTAL NOUN F
in 0 ADP F
children 0 NOUN F
and 0 CCONJ F
adolescents 0 NOUN F
with 0 ADP F
autism 0 NOUN F
spectrum 0 NOUN F
disorder 0 NOUN F
: 0 PUNCT F
an 0 DET F
open-label 0 NOUN F
extension 0 NOUN F
study 0 NOUN F
. 0 PUNCT F

OBJECTIVE 0 NOUN T
The 0 DET T
efficacy 0 NOUN F
and 0 CCONJ F
tolerability B-OTHER NOUN F
of 0 ADP F
long-term 0 NOUN F
treatment 0 NOUN F
with 0 ADP F
atomoxetine 0 NOUN F
for 0 ADP F
symptoms 0 NOUN F
of 0 ADP F
attention-deficit/hyperactivity B-MENTAL NOUN F
disorder I-MENTAL NOUN F
( I-MENTAL PUNCT F
ADHD I-MENTAL NOUN T
) I-MENTAL PUNCT F
in 0 ADP F
children 0 NOUN F
with 0 ADP F
autism 0 NOUN F
spectrum 0 NOUN F
disorder 0 NOUN F
( 0 PUNCT F
ASD 0 NOUN T
) 0 PUNCT F
has 0 PUNCT F
not 0 ADV F
been 0 PUNCT F
established 0 VERB F
. 0 PUNCT F

METHODS 0 NOUN T
In 0 ADP T
this 0 DET F
study 0 NOUN F
, 0 PUNCT F
88 0 NUM F
patients 0 NOUN F
6-17 0 NUM F
years 0 NOUN F
of 0 ADP F
age 0 NOUN F
, 0 PUNCT F
with 0 ADP F
ADHD 0 NOUN T
and 0 CCONJ F
ASD 0 NOUN T
, 0 PUNCT F
were 0 VERB F
treated 0 VERB F
with 0 ADP F
1.2 0 NUM F
mg/kg/day 0 PUNCT F
atomoxetine 0 NOUN F
for 0 ADP F
20 0 NUM F
weeks 0 NOUN F
as 0 VERB F
follow-up 0 NOUN F
of 0 ADP F
an 0 DET F
8 0 NUM F
week 0 NOUN F
double-blind 0 ADJ F
placebo-controlled 0 VERB F
period 0 NOUN F
. 0 PUNCT F

Primary 0 ADJ T
endpoint 0 NOUN F
was 0 VERB F
the 0 DET F
ADHD 0 NOUN T
Rating 0 PUNCT T
Scale 0 NOUN T
( 0 PUNCT F
ADHD-RS 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

RESULTS 0 NOUN T
After 0 ADP T
8 0 NUM F
weeks 0 NOUN F
of 0 ADP F
initial 0 ADJ F
treatment 0 NOUN F
, 0 PUNCT F
the 0 DET F
mean 0 ADV F
total 0 ADJ F
, 0 PUNCT F
inattention B-MENTAL NOUN F
, 0 PUNCT F
and 0 CCONJ F
hyperactivity-impulsivity B-MENTAL NOUN F
ADHD-RS I-MENTAL NOUN T
further 0 NOUN F
decreased 0 ADV F
significantly 0 ADV F
from 0 ADP F
34.9 0 NUM F
to 0 ADP F
27.0 0 NUM F
for 0 ADP F
the 0 DET F
total 0 ADJ F
ADHD-RS 0 NOUN T
, 0 PUNCT F
from 0 ADP F
18.3 0 NUM F
to 0 ADP F
14.5 0 NUM F
for 0 ADP F
the 0 DET F
ADHD-RS B-MENTAL NOUN T
inattention I-MENTAL NOUN F
subscale I-MENTAL NOUN F
, 0 PUNCT F
and 0 CCONJ F
from 0 ADP F
16.5 0 NUM F
to 0 ADP F
12.6 0 PUNCT F
for 0 ADP F
the 0 DET F
hyperactivity-impulsivity B-MENTAL NOUN F
subscale I-MENTAL NOUN F
. 0 PUNCT F

Adverse B-ADVERSE-EFFECTS ADJ T
events I-ADVERSE-EFFECTS NOUN F
were 0 VERB F
mild 0 ADJ F
and 0 CCONJ F
tended 0 VERB F
to 0 ADP F
diminish 0 NOUN F
over 0 DET F
time 0 NOUN F
during 0 ADP F
continued 0 VERB F
treatment 0 NOUN F
, 0 PUNCT F
especially 0 ADV F
regarding 0 NUM F
nausea B-ADVERSE-EFFECTS NOUN F
and 0 CCONJ F
fatigue B-ADVERSE-EFFECTS NOUN F
. 0 PUNCT F

There 0 PUNCT T
were 0 VERB F
no 0 DET F
serious B-ADVERSE-EFFECTS ADJ F
adverse I-ADVERSE-EFFECTS ADJ F
events I-ADVERSE-EFFECTS NOUN F
. 0 PUNCT F

CONCLUSIONS 0 NOUN T
The 0 DET T
results 0 NOUN F
of 0 ADP F
the 0 DET F
present 0 ADJ F
analysis 0 NOUN F
suggest 0 VERB F
that 0 ADP F
continued 0 PUNCT F
treatment 0 NOUN F
with 0 ADP F
atomoxetine 0 NOUN F
up 0 PUNCT F
to 0 ADP F
28 0 NUM F
weeks 0 NOUN F
further 0 ADJ F
improve B-MENTAL VERB F
ADHD I-MENTAL NOUN T
symptoms I-MENTAL NOUN F
in 0 ADP F
children 0 NOUN F
and 0 CCONJ F
adolescents 0 NOUN F
with 0 ADP F
ASD 0 NOUN T
, 0 PUNCT F
while 0 CCONJ F
adverse B-ADVERSE-EFFECTS ADJ F
events I-ADVERSE-EFFECTS NOUN F
tend 0 ADP F
to 0 ADP F
subside 0 NOUN F
. 0 PUNCT F

Future 0 ADJ T
studies 0 NOUN F
investigating 0 DET F
the 0 DET F
long-term 0 NOUN F
efficacy 0 NOUN F
of 0 ADP F
atomoxetine 0 NOUN F
in 0 ADP F
children 0 NOUN F
and 0 CCONJ F
adolescents 0 NOUN F
with 0 ADP F
ASD 0 NOUN T
should 0 VERB F
be 0 VERB F
randomized 0 ADP F
and 0 CCONJ F
placebo 0 NOUN F
controlled 0 VERB F
. 0 PUNCT F

This 0 DET T
study 0 NOUN F
has 0 VERB F
been 0 PUNCT F
registered 0 CCONJ F
in 0 ADP F
ClinicalTrials.gov 0 PUNCT T
( 0 PUNCT F
www.clinicaltrials.gov 0 NOUN F
) 0 PUNCT F
under 0 ADP F
registration 0 NOUN F
number 0 NOUN F
NCT00380692 0 PUNCT T
. 0 PUNCT F

Efficacy 0 NOUN T
and 0 CCONJ F
safety B-OTHER NOUN F
of 0 ADP F
selamectin 0 NOUN F
against 0 ADP F
fleas 0 NOUN F
and 0 CCONJ F
heartworms 0 NOUN F
in 0 ADP F
dogs 0 NOUN F
and 0 CCONJ F
cats 0 ADJ F
presented 0 DET F
as 0 PUNCT F
veterinary 0 ADJ F
patients 0 NOUN F
in 0 ADP F
North 0 NOUN T
America 0 ADV T
. 0 PUNCT F

A 0 DET T
series 0 NOUN F
of 0 ADP F
randomized 0 VERB F
, 0 PUNCT F
controlled 0 PUNCT F
, 0 PUNCT F
masked 0 PUNCT F
field 0 NOUN F
studies 0 NOUN F
was 0 VERB F
conducted 0 VERB F
to 0 PART F
assess 0 NOUN F
the 0 DET F
efficacy 0 NOUN F
and 0 CCONJ F
safety B-OTHER NOUN F
of 0 ADP F
selamectin 0 NOUN F
in 0 ADP F
the 0 DET F
treatment 0 NOUN F
of 0 ADP F
flea 0 NOUN F
infestations 0 NOUN F
on 0 ADP F
dogs 0 NOUN F
and 0 CCONJ F
cats 0 ADJ F
, 0 PUNCT F
and 0 CCONJ F
in 0 ADP F
the 0 DET F
prevention 0 NOUN F
of 0 ADP F
heartworm B-PHYSICAL PUNCT F
infection I-PHYSICAL NOUN F
in 0 ADP F
dogs 0 NOUN F
. 0 PUNCT F

In 0 ADP T
addition 0 NOUN F
, 0 PUNCT F
observations 0 NOUN F
were 0 VERB F
made 0 VERB F
on 0 ADP F
the 0 DET F
beneficial 0 ADJ F
effect 0 NOUN F
of 0 ADP F
selamectin 0 NOUN F
treatment 0 NOUN F
on 0 ADP F
dogs 0 NOUN F
and 0 CCONJ F
cats 0 ADJ F
showing 0 VERB F
signs 0 NOUN F
of 0 ADP F
flea 0 NOUN F
allergy 0 NOUN F
dermatitis 0 NOUN F
( 0 PUNCT F
FAD 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

In 0 ADP T
all 0 DET F
studies 0 NOUN F
selamectin 0 NOUN F
was 0 VERB F
applied 0 VERB F
topically 0 ADV F
, 0 PUNCT F
once 0 PUNCT F
per 0 PUNCT F
month 0 NOUN F
, 0 PUNCT F
in 0 ADP F
unit 0 NOUN F
doses 0 NOUN F
providing 0 VERB F
a 0 DET F
minimum 0 NOUN F
dosage 0 NOUN F
of 0 ADP F
6mgkg 0 NOUN F
( 0 PUNCT F
-1 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Dogs 0 NOUN T
and 0 CCONJ F
cats 0 ADJ F
with 0 ADP F
naturally 0 ADV F
occurring 0 DET F
flea 0 NOUN F
infestations 0 NOUN F
, 0 PUNCT F
some 0 ADP F
of 0 ADP F
which 0 ADV F
also 0 ADV F
had 0 PUNCT F
signs 0 NOUN F
associated 0 VERB F
with 0 ADP F
FAD 0 NOUN T
, 0 PUNCT F
were 0 VERB F
assigned 0 VERB F
randomly 0 ADV F
to 0 PART F
receive 0 NOUN F
three 0 NUM F
months 0 NOUN F
of 0 ADP F
topical 0 ADJ F
treatment 0 NOUN F
with 0 ADP F
selamectin 0 NOUN F
( 0 PUNCT F
220 0 NUM F
dogs 0 NOUN F
, 0 PUNCT F
189 0 DET F
cats 0 ADJ F
) 0 PUNCT F
or 0 CCONJ F
a 0 DET F
positive-control 0 NOUN F
product 0 NOUN F
( 0 PUNCT F
dogs 0 NOUN F
: 0 PUNCT F
fenthion 0 NOUN F
, 0 PUNCT F
n=81 0 NOUN F
; 0 PUNCT F
cats 0 ADJ F
: 0 PUNCT F
pyrethrins 0 NOUN F
, 0 PUNCT F
n=66 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

Selamectin 0 NOUN T
was 0 VERB F
administered 0 VERB F
on 0 ADP F
days 0 NOUN F
0 0 NUM F
, 0 PUNCT F
30 0 NUM F
, 0 PUNCT F
and 0 CCONJ F
60 0 NUM F
. 0 PUNCT F

Day 0 NOUN T
0 0 NUM F
was 0 VERB F
defined 0 VERB F
as 0 ADP F
the 0 DET F
day 0 NOUN F
that 0 ADP F
the 0 DET F
animal 0 NOUN F
first 0 NOUN F
received 0 PUNCT F
treatment 0 NOUN F
. 0 PUNCT F

Flea B-PHYSICAL NOUN T
burdens I-PHYSICAL PUNCT F
were 0 VERB F
assessed 0 VERB F
by 0 ADP F
flea 0 NOUN F
comb 0 NOUN F
counts 0 NOUN F
and 0 CCONJ F
clinical 0 ADJ F
evaluations 0 NOUN F
of 0 ADP F
FAD 0 NOUN T
were 0 VERB F
performed 0 VERB F
before 0 ADP F
treatment 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
on 0 ADP F
days 0 NOUN F
14 0 NUM F
, 0 PUNCT F
30 0 NUM F
, 0 PUNCT F
60 0 NUM F
, 0 PUNCT F
and 0 CCONJ F
90 0 NUM F
. 0 PUNCT F

On 0 ADP T
days 0 NOUN F
30 0 NUM F
, 0 PUNCT F
60 0 NUM F
, 0 PUNCT F
and 0 CCONJ F
90 0 NUM F
, 0 PUNCT F
mean 0 NOUN F
flea B-PHYSICAL NOUN F
counts I-PHYSICAL NOUN F
in 0 ADP F
selamectin-treated 0 VERB F
dogs 0 NOUN F
were 0 VERB F
reduced 0 VERB F
by 0 ADP F
92.1 0 NUM F
, 0 PUNCT F
99.0 0 NUM F
, 0 PUNCT F
and 0 CCONJ F
99.8 0 NUM F
% 0 SYM F
, 0 PUNCT F
and 0 CCONJ F
mean 0 NOUN F
flea B-PHYSICAL NOUN F
counts I-PHYSICAL NOUN F
in 0 ADP F
fenthion-treated 0 VERB F
dogs 0 NOUN F
were 0 VERB F
reduced 0 VERB F
by 0 ADP F
81.5 0 NUM F
, 0 PUNCT F
86.8 0 NUM F
, 0 PUNCT F
and 0 CCONJ F
86.1 0 NUM F
% 0 SYM F
, 0 PUNCT F
respectively 0 ADV F
, 0 PUNCT F
compared 0 VERB F
with 0 ADP F
day 0 NOUN F
0 0 NUM F
counts 0 NOUN F
. 0 PUNCT F

Also 0 ADV T
, 0 PUNCT F
on 0 ADP F
days 0 NOUN F
30 0 NUM F
, 0 PUNCT F
60 0 NUM F
, 0 PUNCT F
and 0 CCONJ F
90 0 NUM F
, 0 PUNCT F
mean 0 NOUN F
flea B-PHYSICAL NOUN F
counts I-PHYSICAL NOUN F
in 0 ADP F
selamectin-treated 0 VERB F
cats 0 NOUN F
were 0 VERB F
reduced 0 VERB F
by 0 ADP F
92.5 0 NUM F
, 0 PUNCT F
98.3 0 NUM F
, 0 PUNCT F
and 0 CCONJ F
99.3 0 NUM F
% 0 SYM F
, 0 PUNCT F
and 0 CCONJ F
mean 0 NOUN F
flea B-PHYSICAL NOUN F
counts I-PHYSICAL NOUN F
in 0 ADP F
pyrethrin-treated 0 VERB F
cats 0 NOUN F
were 0 VERB F
reduced 0 VERB F
by 0 ADP F
66.4 0 NUM F
, 0 PUNCT F
73.9 0 NUM F
, 0 PUNCT F
and 0 CCONJ F
81.3 0 NUM F
% 0 SYM F
, 0 PUNCT F
respectively 0 ADV F
, 0 PUNCT F
compared 0 VERB F
with 0 ADP F
day 0 NOUN F
0 0 NUM F
counts 0 NOUN F
. 0 PUNCT F

Selamectin 0 NOUN T
also 0 ADV F
was 0 VERB F
beneficial 0 ADJ F
in 0 ADP F
alleviating 0 VERB F
signs 0 NOUN F
in 0 ADP F
dogs 0 NOUN F
and 0 CCONJ F
cats 0 ADJ F
diagnosed 0 ADV F
clinically 0 ADV F
with 0 ADP F
FAD 0 NOUN T
. 0 PUNCT F

A 0 DET T
total 0 NOUN F
of 0 ADP F
397 0 NUM F
dogs 0 NOUN F
free 0 ADJ F
of 0 ADP F
adult 0 NOUN F
heartworm 0 ADP F
infection 0 NOUN F
from 0 ADP F
four 0 NUM F
heartworm-endemic 0 ADJ F
areas 0 NOUN F
of 0 ADP F
the 0 DET F
USA 0 PUNCT T
were 0 VERB F
allocated 0 VERB F
randomly 0 ADV F
to 0 PUNCT F
six 0 PUNCT F
months 0 NOUN F
of 0 ADP F
treatment 0 NOUN F
with 0 ADP F
selamectin 0 NOUN F
( 0 PUNCT F
n=298 0 PUNCT F
) 0 PUNCT F
or 0 CCONJ F
ivermectin 0 NOUN F
( 0 PUNCT F
n=99 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

Selamectin 0 NOUN T
achieved 0 VERB F
a 0 DET F
heartworm B-PHYSICAL NOUN F
prevention I-PHYSICAL NOUN F
rate I-PHYSICAL NOUN F
of 0 ADP F
100 0 NUM F
% 0 SYM F
, 0 PUNCT F
with 0 ADP F
all 0 DET F
dogs 0 NOUN F
testing 0 VERB F
negative 0 ADJ F
for 0 ADP F
microfilariae 0 ADJ F
and 0 CCONJ F
adult 0 NOUN F
heartworm 0 NOUN F
antigen 0 NOUN F
on 0 ADP F
days 0 NOUN F
180 0 NUM F
and 0 CCONJ F
300 0 NUM F
. 0 PUNCT F

Selamectin 0 NOUN T
was 0 VERB F
administered 0 VERB F
to 0 ADP F
a 0 DET F
total 0 NOUN F
of 0 ADP F
673 0 NUM F
dogs 0 NOUN F
and 0 CCONJ F
347 0 NUM F
cats 0 ADJ F
having 0 VERB F
an 0 DET F
age 0 NOUN F
range 0 NOUN F
of 0 ADP F
6 0 NUM F
weeks 0 NOUN F
to 0 ADP F
19 0 NUM F
years 0 NOUN F
( 0 PUNCT F
3954 0 NUM F
doses 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
animals 0 NOUN F
included 0 VERB F
19 0 NUM F
purebred 0 VERB F
or 0 CCONJ F
crossbred 0 VERB F
Collies 0 PUNCT T
( 0 PUNCT F
Bearded 0 PUNCT T
, 0 PUNCT F
Border 0 NOUN T
, 0 PUNCT F
and 0 CCONJ F
unspecified 0 VERB F
) 0 PUNCT F
. 0 PUNCT F

There 0 PUNCT T
were 0 VERB F
no 0 DET F
serious B-ADVERSE-EFFECTS ADJ F
adverse I-ADVERSE-EFFECTS ADJ F
events I-ADVERSE-EFFECTS NOUN F
. 0 PUNCT F

Results 0 NOUN T
of 0 ADP F
these 0 DET F
studies 0 NOUN F
indicated 0 VERB F
that 0 ADP F
selamectin 0 NOUN F
was 0 VERB F
highly B-OTHER ADV F
effective I-OTHER ADJ F
in 0 ADP F
the 0 DET F
control 0 NOUN F
of 0 ADP F
flea 0 NOUN F
infestations 0 CCONJ F
in 0 ADP F
dogs 0 NOUN F
and 0 CCONJ F
cats 0 ADJ F
without 0 ADP F
the 0 DET F
need 0 NOUN F
for 0 ADP F
simultaneous 0 ADJ F
treatment 0 NOUN F
of 0 ADP F
the 0 DET F
environment 0 NOUN F
or 0 CCONJ F
of 0 ADP F
in-contact 0 PUNCT F
animals 0 NOUN F
and 0 CCONJ F
also 0 ADV F
was 0 VERB F
beneficial 0 ADJ F
in 0 ADP F
alleviating 0 VERB F
signs 0 NOUN F
associated 0 VERB F
with 0 ADP F
FAD 0 NOUN T
. 0 PUNCT F

Selamectin 0 NOUN T
also 0 ADV F
was 0 ADV F
100 0 NUM F
% 0 SYM F
effective 0 ADJ F
in 0 ADP F
preventing 0 VERB F
the 0 DET F
development 0 NOUN F
of 0 ADP F
canine 0 ADJ F
heartworms 0 NOUN F
and 0 CCONJ F
was 0 VERB F
safe B-OTHER ADJ F
for 0 ADP F
topical 0 ADJ F
use 0 NOUN F
in 0 ADP F
dogs 0 NOUN F
and 0 CCONJ F
cats 0 NOUN F
. 0 PUNCT F

Influence 0 NOUN T
of 0 ADP F
sentinel 0 NOUN F
lymph 0 NOUN F
node 0 NOUN F
tumor 0 NOUN F
burden 0 NOUN F
on 0 ADP F
survival 0 NOUN F
in 0 ADP F
melanoma 0 NOUN F
. 0 PUNCT F

BACKGROUND 0 NOUN T
Completion 0 NOUN T
lymph 0 NOUN F
node 0 NOUN F
dissection 0 NOUN F
( 0 PUNCT F
CLND 0 NOUN T
) 0 PUNCT F
is 0 VERB F
the 0 DET F
standard 0 ADJ F
procedure 0 NOUN F
for 0 ADP F
patients 0 NOUN F
with 0 ADP F
positive 0 ADJ F
sentinel 0 NOUN F
lymph 0 NOUN F
nodes 0 NOUN F
( 0 PUNCT F
SLN 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

With 0 ADP T
extensive 0 ADJ F
pathological 0 ADJ F
workup 0 NOUN F
, 0 PUNCT F
increased 0 NOUN F
numbers 0 NOUN F
of 0 ADP F
small 0 ADJ F
metastatic 0 ADJ F
deposits 0 NOUN F
are 0 VERB F
detected 0 VERB F
in 0 ADP F
SLN 0 NOUN T
. 0 PUNCT F

This 0 DET T
study 0 NOUN F
evaluated 0 VERB F
the 0 DET F
prognostic 0 ADJ F
significance 0 NOUN F
of 0 ADP F
SLN 0 NOUN T
metastatic 0 ADJ F
deposits 0 NOUN F
< 0 SYM F
or 0 CCONJ F
= 0 SYM F
0.2 0 NUM F
mm 0 NOUN F
in 0 ADP F
patients 0 NOUN F
treated 0 VERB F
in 0 ADP F
a 0 DET F
referral 0 ADJ F
cancer 0 NOUN F
center 0 NOUN F
in 0 ADP F
Brazil 0 NOUN T
. 0 PUNCT F

METHODS 0 NOUN T
Patients 0 NOUN T
with 0 ADP F
stage 0 NOUN F
I/II 0 NOUN T
melanoma 0 NOUN F
, 0 PUNCT F
consecutively 0 ADV F
submitted 0 VERB F
to 0 ADP F
a 0 DET F
SLN 0 NOUN T
procedure 0 NOUN F
by 0 ADP F
the 0 DET F
same 0 ADJ F
surgeon 0 NOUN F
from 0 ADP F
2000 0 NUM F
to 0 ADP F
2006 0 NUM F
, 0 PUNCT F
were 0 VERB F
evaluated 0 VERB F
. 0 PUNCT F

All 0 DET T
positive 0 ADJ F
SLN 0 NOUN T
and 0 CCONJ F
randomly 0 ADV F
selected 0 PUNCT F
negative 0 ADJ F
cases 0 NOUN F
were 0 VERB F
reviewed 0 VERB F
by 0 ADP F
two 0 NUM F
pathologists 0 NOUN F
. 0 PUNCT F

Different 0 ADJ T
prognostic 0 ADJ F
factors 0 NOUN F
and 0 CCONJ F
SLN 0 NOUN T
tumor 0 NOUN F
burden 0 NOUN F
were 0 VERB F
recorded 0 VERB F
. 0 PUNCT F

Additional 0 ADJ T
positive 0 ADJ F
non-SLN 0 NOUN F
after 0 ADP F
CLND 0 NOUN T
, 0 PUNCT F
and 0 CCONJ F
disease 0 NOUN F
outcome 0 NOUN F
were 0 VERB F
evaluated 0 VERB F
. 0 PUNCT F

RESULTS 0 NOUN T
Of 0 ADP T
381 0 NUM F
patients 0 NOUN F
who 0 ADP F
underwent 0 VERB F
SLN 0 NOUN T
biopsy 0 NOUN F
, 0 PUNCT F
103 0 NUM F
( 0 PUNCT F
27 0 NUM F
% 0 SYM F
) 0 PUNCT F
were 0 VERB F
positive 0 ADJ F
. 0 PUNCT F

The 0 DET T
mean/median 0 ADJ F
Breslow 0 NOUN T
tumor B-PHYSICAL NOUN F
thickness I-PHYSICAL NOUN F
in 0 ADP F
the 0 DET F
overall 0 ADJ F
group 0 NOUN F
was 0 VERB F
3.4/2.0 0 PUNCT F
mm 0 NOUN F
and 0 CCONJ F
in 0 ADP F
the 0 DET F
SLN 0 NOUN T
positive 0 ADJ F
patients 0 NOUN F
was 0 ADP F
5.72/4.0 0 PUNCT F
mm 0 NOUN F
. 0 PUNCT F

Among 0 ADP T
these 0 DET F
patients 0 NOUN F
, 0 PUNCT F
48 0 NUM F
( 0 PUNCT F
47 0 NUM F
% 0 SYM F
) 0 PUNCT F
had 0 PUNCT F
metastatic 0 ADJ F
deposits 0 NOUN F
> 0 SYM F
2 0 NUM F
mm 0 NOUN F
( 0 PUNCT F
macrometastasis 0 NOUN F
) 0 PUNCT F
, 0 PUNCT F
49 0 NUM F
( 0 PUNCT F
47 0 NUM F
% 0 SYM F
) 0 PUNCT F
had 0 PUNCT F
metastatic 0 ADJ F
deposits 0 NOUN F
< 0 SYM F
or 0 CCONJ F
=2 0 NUM F
mm 0 NOUN F
but 0 CCONJ F
> 0 SYM F
0.2 0 NUM F
mm 0 NOUN F
( 0 PUNCT F
micrometastasis 0 NOUN F
) 0 PUNCT F
, 0 PUNCT F
and 0 CCONJ F
6 0 NUM F
( 0 PUNCT F
6 0 NUM F
% 0 SYM F
) 0 PUNCT F
had 0 PUNCT F
metastatic 0 ADJ F
deposits 0 NOUN F
< 0 SYM F
or 0 CCONJ F
=0.2 0 NUM F
mm 0 NOUN F
( 0 PUNCT F
submicrometastasis 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

Additional 0 ADJ T
positive 0 ADJ F
non-SLN 0 NOUN F
were 0 VERB F
detected 0 VERB F
in 0 ADP F
29 0 NUM F
% 0 SYM F
of 0 ADP F
patients 0 NOUN F
with 0 ADP F
macrometastasis 0 NOUN F
, 0 PUNCT F
in 0 ADP F
25 0 NUM F
% 0 SYM F
of 0 ADP F
patients 0 NOUN F
with 0 ADP F
micrometastasis 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
in 0 ADP F
0 0 NUM F
% 0 SYM F
of 0 ADP F
patients 0 NOUN F
with 0 ADP F
submicrometastases 0 NOUN F
. 0 PUNCT F

At 0 ADP T
median 0 ADJ F
follow-up 0 NOUN F
of 0 ADP F
35 0 NUM F
months 0 NOUN F
, 0 PUNCT F
the 0 DET F
estimated 0 VERB F
3-year 0 NOUN F
overall 0 ADJ F
survival 0 NOUN F
was 0 VERB F
92 0 NUM F
% 0 SYM F
for 0 ADP F
negative 0 ADJ F
SLN 0 NOUN T
, 0 PUNCT F
64 0 NUM F
% 0 SYM F
for 0 ADP F
micrometastases 0 NOUN F
, 0 PUNCT F
53 0 NUM F
% 0 SYM F
for 0 ADP F
macrometastases 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
100 0 NUM F
% 0 SYM F
for 0 ADP F
submicrometastases 0 NOUN F
( 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.001 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

CONCLUSION 0 NOUN T
In 0 ADP T
the 0 DET F
present 0 ADJ F
study 0 NOUN F
, 0 PUNCT F
patients 0 NOUN F
with 0 ADP F
SLN 0 NOUN T
metastatic 0 ADJ F
deposits 0 NOUN F
< 0 SYM F
or 0 CCONJ F
=0.2 0 NUM F
mm 0 NOUN F
had 0 PUNCT F
no 0 DET F
additional 0 ADJ F
positive 0 ADJ F
non-SLNs 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
no 0 DET F
recurrences 0 NOUN F
or 0 CCONJ F
deaths 0 NOUN F
were 0 VERB F
recorded 0 VERB F
, 0 PUNCT F
suggesting 0 VERB F
that 0 ADP F
their 0 PUNCT F
prognosis 0 NOUN F
is 0 VERB F
equivalent 0 ADJ F
to 0 ADP F
that 0 PUNCT F
of 0 ADP F
patients 0 NOUN F
with 0 ADP F
negative 0 ADJ F
SLN 0 NOUN T
. 0 PUNCT F

Comparison 0 NOUN T
of 0 ADP F
clinical B-OTHER ADJ F
effectiveness I-OTHER NOUN F
of 0 ADP F
acupuncture 0 ADP F
and 0 CCONJ F
a 0 DET F
Western 0 ADJ T
drug 0 NOUN F
on 0 ADP F
allergic 0 ADJ F
rhinitis 0 NOUN F
: 0 PUNCT F
study 0 ADV F
protocol 0 NOUN F
for 0 ADP F
a 0 DET F
randomized 0 VERB F
controlled 0 VERB F
trial 0 NOUN F
. 0 PUNCT F

OBJECTIVE 0 NOUN T
To 0 PROPN T
compare 0 NOUN F
the 0 DET F
efficacy 0 NOUN F
of 0 ADP F
an 0 DET F
acupuncture 0 ADP F
regimen 0 NOUN F
for 0 ADP F
persistent 0 ADJ F
allergic 0 ADJ F
rhinitis 0 NOUN F
( 0 PUNCT F
PER 0 ADP T
) 0 PUNCT F
, 0 PUNCT F
aimed 0 VERB F
at 0 ADP F
improving 0 VERB F
a 0 DET F
patient 0 NOUN F
's 0 PUNCT F
mind 0 NOUN F
or 0 CCONJ F
Shen 0 NOUN T
in 0 ADP F
Traditional 0 ADJ T
Chinese 0 NOUN T
Medicine 0 NOUN T
, 0 PUNCT F
to 0 ADP F
that 0 PUNCT F
of 0 ADP F
a 0 DET F
second-generation 0 NOUN F
Hi-receptor 0 NOUN T
antagonist 0 NOUN F
, 0 PUNCT F
cetirizine 0 NOUN F
hydrochloride 0 NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
This 0 PUNCT T
multicenter 0 NOUN F
, 0 PUNCT F
randomized 0 VERB F
, 0 PUNCT F
controlled 0 VERB F
clinical 0 ADJ F
trial 0 NOUN F
on 0 ADP F
PER 0 ADP T
will 0 PUNCT F
be 0 VERB F
conducted 0 VERB F
at 0 ADP F
three 0 NUM F
institutions 0 NOUN F
in 0 ADP F
China 0 NOUN T
. 0 PUNCT F

The 0 DET T
total 0 ADJ F
study 0 NOUN F
period 0 NOUN F
will 0 VERB F
be 0 VERB F
9 0 NUM F
weeks 0 NOUN F
. 0 PUNCT F

After 0 ADP T
a 0 DET F
1-week 0 NOUN F
preparatory 0 ADJ F
screening 0 DET F
period 0 NOUN F
, 0 PUNCT F
240 0 NUM F
eligible 0 ADJ F
participants 0 NOUN F
with 0 ADP F
PER 0 ADP T
will 0 PUNCT F
be 0 VERB F
randomized 0 VERB F
to 0 PART F
receive 0 NOUN F
acupuncture 0 ADP F
or 0 CCONJ F
pharmacotherapy 0 NOUN F
( 0 PUNCT F
1:1 0 NUM F
) 0 PUNCT F
for 0 ADP F
4 0 NUM F
weeks 0 NOUN F
with 0 ADP F
a 0 DET F
4-week 0 NOUN F
follow-up 0 NOUN F
. 0 PUNCT F

The 0 DET T
primary 0 ADJ F
outcome 0 NOUN F
will 0 PUNCT F
be 0 ADP F
changes 0 NOUN F
in 0 ADP F
7-day B-OTHER NOUN F
average 0 VERB F
total 0 VERB F
nasal B-OTHER ADJ F
symptom I-OTHER NOUN F
score 0 NOUN F
. 0 PUNCT F

Secondary 0 ADJ T
outcome 0 NOUN F
measures 0 NOUN F
include 0 VERB F
rhinoconjunctivitis B-OTHER NOUN F
quality 0 NOUN F
of 0 ADP F
life 0 NOUN F
questionnaire 0 PUNCT F

Phase 0 NOUN T
III 0 NUM T
trial 0 NOUN F
of 0 ADP F
satraplatin 0 NOUN F
, 0 PUNCT F
an 0 DET F
oral 0 ADJ F
platinum 0 NOUN F
plus 0 CCONJ F
prednisone 0 NOUN F
vs. 0 CCONJ F
prednisone 0 NOUN F
alone 0 ADJ F
in 0 ADP F
patients 0 NOUN F
with 0 ADP F
hormone-refractory 0 ADJ F
prostate 0 NOUN F
cancer 0 NOUN F
. 0 PUNCT F

Satraplatin 0 NOUN T
is 0 VERB F
a 0 DET F
novel 0 ADJ F
oral 0 ADJ F
platinum 0 NOUN F
( 0 PUNCT F
IV 0 NUM T
) 0 PUNCT F
complex 0 NOUN F
that 0 ADP F
shows 0 ADP F
activity 0 NOUN F
against 0 ADP F
hormone-refractory 0 ADJ F
prostate 0 NOUN F
cancer 0 NOUN F
( 0 PUNCT F
HRPC 0 ADP T
) 0 PUNCT F
in 0 ADP F
cisplatin-resistant 0 ADJ F
human 0 NOUN F
tumor 0 NOUN F
lines 0 NOUN F
in 0 ADP F
phase 0 NOUN F
I 0 NUM T
and 0 CCONJ F
phase 0 NOUN F
II 0 NUM T
trials 0 NOUN F
. 0 PUNCT F

A 0 DET T
randomized 0 VERB F
multicenter 0 NOUN F
phase 0 NOUN F
III 0 NUM T
trial 0 NOUN F
with 0 ADP F
a 0 DET F
target 0 NOUN F
sample 0 NOUN F
size 0 NOUN F
of 0 ADP F
380 0 NUM F
patients 0 NOUN F
was 0 VERB F
initiated 0 VERB F
in 0 ADP F
men 0 NOUN F
with 0 ADP F
HRPC 0 CCONJ T
. 0 PUNCT F

After 0 ADP T
50 0 NUM F
randomized 0 VERB F
patients 0 NOUN F
, 0 PUNCT F
the 0 DET F
trial 0 NOUN F
was 0 VERB F
closed 0 VERB F
to 0 PUNCT F
further 0 ADJ F
accrual 0 ADJ F
by 0 ADP F
the 0 DET F
sponsoring 0 ADJ F
company 0 ADV F
. 0 PUNCT F

An 0 DET T
ad 0 ADP F
hoc 0 VERB F
analysis 0 NOUN F
of 0 ADP F
all 0 DET F
available 0 ADJ F
data 0 NOUN F
is 0 VERB F
reported 0 VERB F
here 0 ADV F
. 0 PUNCT F

Eligibility 0 NOUN T
criteria 0 NOUN F
included 0 VERB F
pathological 0 ADJ F
proof 0 NOUN F
of 0 ADP F
prostate 0 NOUN F
cancer 0 NOUN F
, 0 PUNCT F
documented 0 VERB F
progression 0 NOUN F
despite 0 PUNCT F
prior 0 PUNCT F
hormonal 0 ADJ F
manipulation 0 NOUN F
, 0 PUNCT F
WHO 0 NOUN T
PS 0 NOUN T
0-2 0 NUM F
, 0 PUNCT F
and 0 CCONJ F
no 0 DET F
daily 0 ADJ F
intake 0 NOUN F
of 0 ADP F
narcotic 0 ADJ F
analgesics 0 NOUN F
. 0 PUNCT F

Patients 0 NOUN T
were 0 VERB F
randomized 0 PUNCT F
between 0 ADP F
satraplatin 0 NOUN F
100 0 PUNCT F
mg/m 0 NOUN F
( 0 PUNCT F
2 0 NUM F
) 0 PUNCT F
for 0 ADP F
5 0 NUM F
days 0 NOUN F
plus 0 CCONJ F
prednisone 0 NOUN F
10 0 NUM F
mg 0 NOUN F
orally 0 ADV F
BID 0 NOUN T
or 0 CCONJ F
prednisone 0 NOUN F
alone 0 ADJ F
. 0 PUNCT F

Compliance 0 NOUN T
was 0 VERB F
excellent 0 ADJ F
. 0 PUNCT F

48/50 0 PUNCT F
patients 0 NOUN F
have 0 CCONJ F
progressed B-PHYSICAL VERB F
and 0 CCONJ F
42 0 PUNCT F
have 0 PUNCT F
died B-MORTALITY DET F
, 0 PUNCT F
mostly 0 ADV F
due 0 CCONJ F
to 0 ADP F
prostate 0 NOUN F
cancer 0 NOUN F
. 0 PUNCT F

Median 0 ADJ T
overall B-MORTALITY ADJ F
survival I-MORTALITY NOUN F
was 0 VERB F
14.9 0 NUM F
months 0 NOUN F
( 0 PUNCT F
95 0 NUM F
% 0 SYM F
CI 0 NOUN T
: 0 PUNCT F
13.7-28.4 0 NUM F
) 0 PUNCT F
on 0 ADP F
the 0 DET F
satraplatin 0 NOUN F
plus 0 CCONJ F
prednisone 0 NOUN F
arm 0 NOUN F
and 0 CCONJ F
11.9 0 NUM F
months 0 NOUN F
( 0 PUNCT F
95 0 NUM F
% 0 SYM F
CI 0 NOUN T
: 0 PUNCT F
8.4-23.1 0 NUM F
) 0 PUNCT F
on 0 ADP F
prednisone 0 NOUN F
alone 0 ADJ F
( 0 PUNCT F
hazard 0 NOUN F
ratio 0 NOUN F
, 0 PUNCT F
HR 0 NOUN T
= 0 SYM F
0.84 0 NUM F
, 0 PUNCT F
95 0 NUM F
% 0 SYM F
CI 0 NOUN T
: 0 PUNCT F
0.46-1.55 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

A 0 PUNCT T
> 0 PROPN F
50 0 NUM F
% 0 SYM F
decrease 0 NOUN F
in 0 ADP F
prostrate B-PHYSICAL PUNCT F
specific I-PHYSICAL ADJ F
antigen I-PHYSICAL NOUN F
( 0 PUNCT F
PSA 0 NOUN T
) 0 PUNCT F
was 0 VERB F
seen 0 VERB F
in 0 ADP F
9/27 0 NOUN F
( 0 PUNCT F
33.3 0 NUM F
% 0 SYM F
) 0 PUNCT F
in 0 ADP F
the 0 DET F
satraplatin 0 NOUN F
plus 0 CCONJ F
prednisone 0 NOUN F
arm 0 NOUN F
vs. 0 CCONJ F
2/23 0 NOUN F
( 0 PUNCT F
8.7 0 NUM F
% 0 SYM F
) 0 PUNCT F
on 0 ADP F
the 0 DET F
prednisone 0 NOUN F
alone 0 ADJ F
arm 0 ADP F
. 0 PUNCT F

Progression-free B-MORTALITY ADJ T
survival I-MORTALITY NOUN F
was 0 ADV F
5.2 0 NUM F
months 0 NOUN F
( 0 PUNCT F
95 0 NUM F
% 0 SYM F
CI 0 NOUN T
: 0 PUNCT F
2.8-13.7 0 ADV F
) 0 PUNCT F
on 0 ADP F
the 0 DET F
satraplatin 0 NOUN F
plus 0 CCONJ F
prednisone 0 NOUN F
arm 0 NOUN F
as 0 VERB F
compared 0 VERB F
to 0 ADP F
2.5 0 NUM F
months 0 NOUN F
( 0 PUNCT F
95 0 NUM F
% 0 SYM F
CI 0 NOUN T
: 0 PUNCT F
2.1- 0 NUM F
4.7 0 PUNCT F
) 0 PUNCT F
on 0 ADP F
the 0 DET F
prednisone 0 NOUN F
alone 0 ADJ F
arm 0 NOUN F
( 0 PUNCT F
HR 0 NOUN T
= 0 SYM F
0.50 0 NUM F
, 0 PUNCT F
95 0 NUM F
% 0 SYM F
CI 0 NOUN T
: 0 PUNCT F
0.28-0.92 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

This 0 DET T
difference 0 NOUN F
is 0 VERB F
statistically 0 ADV F
significant 0 ADJ F
( 0 PUNCT F
p 0 NOUN F
= 0 SYM F
0.023 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Toxicity B-PHYSICAL NOUN T
was 0 VERB F
generally 0 ADV F
minimal 0 ADJ F
in 0 ADP F
both 0 PUNCT F
arms 0 NOUN F
. 0 PUNCT F

This 0 DET T
randomized 0 VERB F
comparison 0 NOUN F
of 0 ADP F
a 0 DET F
combination 0 NOUN F
of 0 ADP F
satraplatin 0 NOUN F
and 0 CCONJ F
prednisone 0 NOUN F
versus 0 CCONJ F
prednisone 0 NOUN F
alone 0 ADJ F
supports 0 NOUN F
the 0 DET F
antitumor 0 NOUN F
activity 0 NOUN F
of 0 ADP F
the 0 DET F
combination 0 NOUN F
. 0 PUNCT F

Its 0 VERB T
role 0 NOUN F
in 0 ADP F
the 0 DET F
treatment 0 NOUN F
of 0 ADP F
HPRC 0 NOUN T
remains 0 NOUN F
to 0 PART F
be 0 PUNCT F
elucidated 0 VERB F
in 0 ADP F
an 0 DET F
appropriate 0 ADJ F
phase 0 NOUN F
III 0 NUM T
setting 0 VERB F
. 0 PUNCT F

Comparison 0 NOUN T
of 0 ADP F
methods 0 NOUN F
for 0 ADP F
intravenous 0 ADJ F
infusion 0 NOUN F
of 0 ADP F
fat 0 NOUN F
emulsion 0 NOUN F
during 0 ADP F
extracorporeal 0 ADJ F
membrane 0 NOUN F
oxygenation 0 NOUN F
. 0 PUNCT F

STUDY 0 NOUN T
OBJECTIVES 0 NOUN T
To 0 PROPN T
characterize 0 NOUN F
the 0 DET F
effects 0 NOUN F
of 0 ADP F
infusing 0 PROPN F
fat 0 NOUN F
emulsion 0 NOUN F
during 0 ADP F
neonatal 0 ADJ F
extracorporeal 0 ADJ F
membrane 0 NOUN F
oxygenation 0 NOUN F
( 0 PUNCT F
ECMO 0 NOUN T
) 0 PUNCT F
by 0 ADP F
comparing 0 DET F
results 0 ADJ F
from 0 ADP F
patients 0 NOUN F
receiving 0 VERB F
fat 0 NOUN F
emulsion 0 NOUN F
through 0 ADP F
the 0 DET F
ECMO 0 NOUN T
circuit 0 NOUN F
with 0 ADP F
those 0 PUNCT F
receiving 0 VERB F
fat 0 NOUN F
emulsion 0 NOUN F
through 0 ADP F
separate 0 ADJ F
intravenous 0 ADJ F
access 0 NOUN F
. 0 PUNCT F

A 0 DET T
second 0 ADJ F
goal 0 NOUN F
was 0 VERB F
to 0 PART F
identify 0 NOUN F
the 0 DET F
optimal 0 ADJ F
route 0 NOUN F
for 0 ADP F
administration 0 NOUN F
. 0 PUNCT F

DESIGN 0 NOUN T
Prospective 0 ADJ T
, 0 PUNCT F
randomized 0 VERB F
, 0 PUNCT F
open-label 0 NOUN F
trial 0 NOUN F
. 0 PUNCT F

SETTING 0 NUM T
Neonatal 0 ADJ T
intensive 0 ADJ F
care 0 NOUN F
unit 0 NOUN F
in 0 ADP F
a 0 DET F
106-bed 0 PUNCT F
quaternary 0 ADJ F
care 0 NOUN F
pediatric 0 ADJ F
hospital 0 NOUN F
. 0 PUNCT F

SUBJECTS 0 NOUN T
Nine 0 NUM T
neonates 0 NOUN F
receiving 0 VERB F
ECMO 0 NOUN T
who 0 ADP F
required 0 VERB F
intravenous 0 ADJ F
nutrition 0 NOUN F
. 0 PUNCT F

Intervention 0 NOUN T
. 0 PUNCT F

Patients 0 NOUN T
received 0 ADP F
1-3 0 ADP F
g/kg/day 0 NOUN F
of 0 ADP F
fat 0 NOUN F
emulsion 0 NOUN F
into 0 ADP F
either 0 CCONJ F
the 0 DET F
ecmo 0 ADJ F
circuit 0 NOUN F
or 0 CCONJ F
separate 0 ADJ F
intravenous 0 ADJ F
access 0 NOUN F
. 0 PUNCT F

MEASUREMENTS 0 ADP T
AND 0 CCONJ T
MAIN 0 ADJ T
RESULTS 0 NOUN T
The 0 DET T
ECMO 0 NOUN T
circuit 0 NOUN F
and 0 CCONJ F
samples 0 NOUN F
of 0 ADP F
blood 0 NOUN F
were 0 VERB F
evaluated 0 VERB F
hourly 0 NOUN F
for 0 ADP F
phase 0 NOUN F
separation 0 NOUN F
, 0 PUNCT F
layering 0 ADV F
out 0 PUNCT F
of 0 ADP F
the 0 DET F
emulsion 0 NOUN F
from 0 ADP F
blood 0 NOUN F
, 0 PUNCT F
agglutination 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
blood 0 NOUN F
clots 0 NOUN F
. 0 PUNCT F

After 0 ADP T
completion 0 NOUN F
, 0 PUNCT F
the 0 DET F
oxygenators 0 NOUN F
were 0 VERB F
dissected 0 VERB F
and 0 CCONJ F
examined 0 VERB F
. 0 PUNCT F

Data 0 NOUN T
were 0 VERB F
compared 0 VERB F
with 0 ADP F
an 0 DET F
unpaired 0 VERB F
t 0 NOUN F
test 0 NOUN F
. 0 PUNCT F

The 0 DET T
characteristics 0 NOUN F
of 0 ADP F
the 0 DET F
groups 0 NOUN F
were 0 VERB F
similar 0 ADJ F
, 0 PUNCT F
except 0 PUNCT F
for 0 ADP F
a 0 DET F
higher 0 PUNCT F
mean 0 NOUN F
weight 0 NOUN F
in 0 ADP F
the 0 DET F
ECMO 0 NOUN T
circuit 0 NOUN F
group 0 NOUN F
( 0 PUNCT F
3.6 0 NUM F
+/- 0 SYM F
0.3 0 NUM F
kg 0 NOUN F
vs 0 CCONJ F
2.8 0 NUM F
+/- 0 SYM F
0.4 0 NUM F
kg 0 NOUN F
, 0 PUNCT F
p=0.03 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
mean 0 NOUN F
+/- B-PHYSICAL SYM F
SD I-PHYSICAL NOUN T
triglyceride I-PHYSICAL NOUN F
level I-PHYSICAL NOUN F
during 0 ADP F
the 0 DET F
study 0 NOUN F
was 0 ADV F
87 0 NUM F
+/- 0 SYM F
79 0 NUM F
mg/dl 0 NOUN F
, 0 PUNCT F
with 0 ADP F
no 0 DET F
significant 0 ADJ F
difference 0 NOUN F
between 0 ADP F
the 0 DET F
two 0 NUM F
groups 0 NOUN F
. 0 PUNCT F

Two 0 NUM T
patients 0 NOUN F
in 0 ADP F
each 0 DET F
group 0 NOUN F
had 0 PUNCT F
elevated 0 VERB F
triglyceride B-PHYSICAL NOUN F
levels I-PHYSICAL NOUN F
. 0 PUNCT F

No 0 DET T
cases 0 NOUN F
of 0 ADP F
phase 0 NOUN F
separation B-PHYSICAL NOUN F
occurred 0 VERB F
. 0 PUNCT F

In 0 ADP T
the 0 DET F
five 0 NUM F
patients 0 NOUN F
who 0 ADP F
received 0 VERB F
fat 0 NOUN F
emulsion 0 NOUN F
into 0 ADP F
the 0 DET F
ECMO 0 NOUN T
circuit 0 NOUN F
, 0 PUNCT F
three 0 NUM F
had 0 PUNCT F
layering 0 ADP F
out 0 PUNCT F
of 0 ADP F
the 0 DET F
emulsion 0 NOUN F
and 0 CCONJ F
agglutination B-PHYSICAL NOUN F
, 0 PUNCT F
and 0 CCONJ F
all 0 DET F
developed 0 PUNCT F
clots B-PHYSICAL PUNCT F
in 0 ADP F
the 0 DET F
circuit 0 NOUN F
despite 0 ADP F
adequate 0 ADJ F
anticoagulation 0 NOUN F
. 0 PUNCT F

Of 0 ADP T
the 0 DET F
four 0 ADV F
patients 0 NOUN F
in 0 ADP F
the 0 DET F
intravenous-access 0 NOUN F
group 0 NOUN F
, 0 PUNCT F
one 0 NUM F
had 0 PUNCT F
layering 0 ADP F
and 0 CCONJ F
agglutination 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
two 0 NUM F
had 0 PUNCT F
blood 0 NOUN F
clots 0 NOUN F
. 0 PUNCT F

CONCLUSIONS 0 NOUN T
Although 0 ADP T
both 0 CCONJ F
methods 0 NOUN F
were 0 VERB F
associated 0 VERB F
with 0 ADP F
layering B-PHYSICAL ADP F
out I-PHYSICAL PUNCT F
, 0 PUNCT F
agglutination B-PHYSICAL NOUN F
, 0 PUNCT F
and 0 PUNCT F

Cognitive 0 ADJ T
effects 0 NOUN F
of 0 ADP F
risperidone 0 NUM F
in 0 ADP F
children 0 NOUN F
with 0 ADP F
autism 0 NOUN F
and 0 CCONJ F
irritable 0 ADJ F
behavior 0 NOUN F
. 0 PUNCT F

OBJECTIVE 0 NOUN T
The 0 DET T
objective 0 NOUN F
of 0 ADP F
this 0 DET F
research 0 NOUN F
was 0 VERB F
to 0 PART F
explore 0 VERB F
the 0 DET F
effects 0 NOUN F
of 0 ADP F
risperidone 0 NUM F
on 0 ADP F
cognitive B-MENTAL ADJ F
processes I-MENTAL NOUN F
in 0 ADP F
children 0 NOUN F
with 0 ADP F
autism 0 NOUN F
and 0 CCONJ F
irritable 0 ADJ F
behavior 0 NOUN F
. 0 PUNCT F

METHOD 0 NOUN T
Thirty-eight 0 PUNCT T
children 0 NOUN F
, 0 PUNCT F
ages 0 NOUN F
5-17 0 NUM F
years 0 NOUN F
with 0 ADP F
autism 0 NOUN F
and 0 CCONJ F
severe 0 ADJ F
behavioral 0 ADJ F
disturbance 0 NOUN F
, 0 PUNCT F
were 0 VERB F
randomly 0 ADV F
assigned 0 VERB F
to 0 ADP F
risperidone 0 VERB F
( 0 PUNCT F
0.5 0 NUM F
to 0 ADP F
3.5 0 NUM F
mg/day 0 NOUN F
) 0 PUNCT F
or 0 CCONJ F
placebo 0 NOUN F
for 0 ADP F
8 0 NUM F
weeks 0 NOUN F
. 0 PUNCT F

This 0 DET T
sample 0 NOUN F
of 0 ADP F
38 0 NUM F
was 0 VERB F
a 0 DET F
subset 0 NOUN F
of 0 ADP F
101 0 ADJ F
subjects 0 NOUN F
who 0 PROPN F
participated 0 VERB F
in 0 ADP F
the 0 DET F
clinical 0 ADJ F
trial 0 NOUN F
; 0 PUNCT F
63 0 NUM F
were 0 VERB F
unable 0 ADJ F
to 0 PART F
perform 0 NOUN F
the 0 DET F
cognitive 0 ADJ F
tasks 0 NOUN F
. 0 PUNCT F

A 0 DET T
double-blind 0 ADJ F
placebo-controlled 0 DET F
parallel 0 PUNCT F
groups 0 NOUN F
design 0 NOUN F
was 0 VERB F
used 0 VERB F
. 0 PUNCT F

Dependent 0 ADJ T
measures 0 NOUN F
included 0 ADV F
tests B-PHYSICAL NOUN F
of I-PHYSICAL ADP F
sustained I-PHYSICAL VERB F
attention I-PHYSICAL NOUN F
, 0 PUNCT F
verbal B-PHYSICAL ADJ F
learning I-PHYSICAL PROPN F
, 0 PUNCT F
hand-eye B-PHYSICAL NOUN F
coordination I-PHYSICAL NOUN F
, 0 PUNCT F
and 0 CCONJ F
spatial B-PHYSICAL ADJ F
memory I-PHYSICAL NOUN F
assessed I-PHYSICAL VERB F
before 0 CCONJ F
, 0 PUNCT F
during 0 ADP F
, 0 PUNCT F
and 0 CCONJ F
after 0 ADP F
the 0 DET F
8-week B-PHYSICAL NOUN F
treatment I-PHYSICAL NOUN F
. 0 PUNCT F

Changes 0 NOUN T
in 0 ADP F
performance 0 NOUN F
were 0 VERB F
compared 0 VERB F
by 0 ADP F
repeated 0 VERB F
measures 0 NOUN F
ANOVA 0 NOUN T
. 0 PUNCT F

RESULTS 0 NOUN T
Twenty-nine 0 NUM T
boys 0 NOUN F
and 0 CCONJ F
9 0 NUM F
girls 0 NOUN F
with 0 ADP F
autism 0 NOUN F
and 0 CCONJ F
severe 0 ADJ F
behavioral 0 ADJ F
disturbance 0 NOUN F
and 0 CCONJ F
a 0 DET F
mental 0 ADJ F
age 0 NOUN F
> 0 SYM F
or=18 0 NOUN F
months 0 NOUN F
completed 0 PUNCT F
the 0 DET F
cognitive 0 ADJ F
part 0 NOUN F
of 0 ADP F
the 0 DET F
study 0 NOUN F
. 0 PUNCT F

No 0 DET T
decline 0 NOUN F
in 0 ADP F
performance 0 NOUN F
occurred 0 VERB F
with 0 ADP F
risperidone 0 NUM F
. 0 PUNCT F

Performance 0 NOUN T
on 0 ADP F
a 0 DET F
cancellation B-MENTAL NOUN F
task I-MENTAL NOUN F
( I-MENTAL PUNCT F
number I-MENTAL NOUN F
of I-MENTAL ADP F
correct I-MENTAL ADJ F
detections I-MENTAL NOUN F
) 0 PUNCT F
and 0 CCONJ F
a 0 DET F
verbal B-MENTAL ADJ F
learning I-MENTAL VERB F
task I-MENTAL NOUN F
( 0 PUNCT F
word B-MENTAL NOUN F
recognition I-MENTAL NOUN F
) 0 PUNCT F
was 0 VERB F
better 0 PUNCT F
on 0 ADP F
risperidone 0 NUM F
than 0 PUNCT F
on 0 ADP F
placebo 0 NOUN F
( 0 PUNCT F
without 0 ADP F
correction 0 NOUN F
for 0 ADP F
multiplicity 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

Equivocal B-PHYSICAL ADJ T
improvement I-PHYSICAL NOUN F
also 0 ADV F
occurred 0 VERB F
on 0 ADP F
a 0 DET F
spatial B-MENTAL ADJ F
memory I-MENTAL NOUN F
task I-MENTAL NOUN F
. 0 PUNCT F

There 0 PUNCT T
were 0 VERB F
no 0 DET F
significant 0 ADJ F
differences 0 NOUN F
between 0 ADP F
treatment 0 NOUN F
conditions 0 NOUN F
on 0 ADP F
the 0 DET F
Purdue B-MENTAL NOUN T
Pegboard I-MENTAL NOUN T
( I-MENTAL PUNCT F
hand-eye I-MENTAL NOUN F
coordination I-MENTAL NOUN F
) I-MENTAL PUNCT F
task 0 NOUN F
or 0 CCONJ F
the 0 DET F
Analog B-MENTAL NOUN T
Classroom I-MENTAL PUNCT T
Task I-MENTAL NOUN T
( I-MENTAL PUNCT F
timed I-MENTAL PUNCT F
math I-MENTAL ADP F
test I-MENTAL NOUN F
) 0 PUNCT F
. 0 PUNCT F

CONCLUSION 0 NOUN T
Risperidone 0 NUM T
given 0 VERB F
to 0 ADP F
children 0 NOUN F
with 0 ADP F
autism 0 NOUN F
at 0 ADP F
doses 0 NOUN F
up 0 PUNCT F
to 0 DET F
3.5 0 NUM F
mg 0 NOUN F
for 0 ADP F
up 0 PUNCT F
to 0 ADV F
8 0 NUM F
weeks 0 NOUN F
appears 0 NOUN F
to 0 PUNCT F
have 0 PUNCT F
no 0 DET F
detrimental 0 ADJ F
effect 0 NOUN F
on 0 ADP F
cognitive B-MENTAL ADJ F
performance I-MENTAL NOUN F
. 0 PUNCT F

Histamine 0 NOUN T
intolerance-like 0 ADJ F
symptoms 0 NOUN F
in 0 ADP F
healthy 0 ADJ F
volunteers 0 NOUN F
after 0 ADP F
oral 0 ADJ F
provocation 0 NOUN F
with 0 ADP F
liquid 0 ADJ F
histamine 0 NOUN F
. 0 PUNCT F

Histamine 0 NOUN T
in 0 ADP F
food 0 NOUN F
at 0 ADP F
non-toxic 0 ADJ F
doses 0 NOUN F
has 0 PUNCT F
been 0 PUNCT F
proposed 0 VERB F
to 0 PART F
be 0 PUNCT F
a 0 DET F
major 0 ADJ F
cause 0 NOUN F
of 0 ADP F
food 0 NOUN F
intolerance 0 NOUN F
causing 0 ADP F
symptoms 0 NOUN F
like 0 ADP F
diarrhea 0 NOUN F
, 0 PUNCT F
hypotension 0 NOUN F
, 0 PUNCT F
headache 0 NOUN F
, 0 PUNCT F
pruritus 0 NOUN F
and 0 CCONJ F
flush 0 NOUN F
( 0 PUNCT F
histamine 0 NOUN F
intolerance 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

Histamine-rich 0 PUNCT T
foods 0 ADJ F
such 0 CCONJ F
as 0 ADP F
cheese 0 PUNCT F
, 0 PUNCT F
sausages 0 NOUN F
, 0 PUNCT F
sauerkraut 0 PUNCT F
, 0 PUNCT F
tuna 0 ADP F
, 0 PUNCT F
tomatoes 0 ADV F
, 0 PUNCT F
and 0 CCONJ F
alcoholic 0 ADJ F
beverages 0 NOUN F
may 0 VERB F
contain 0 VERB F
histamine 0 NOUN F
up 0 PUNCT F
to 0 ADP F
500 0 NUM F
mg/kg 0 NOUN F
. 0 PUNCT F

We 0 PRON T
conducted 0 VERB F
a 0 DET F
randomized 0 VERB F
, 0 PUNCT F
double-blind 0 ADJ F
, 0 PUNCT F
placebo-controlled 0 VERB F
cross-over 0 NOUN F
study 0 CCONJ F
in 0 ADP F
10 0 NUM F
healthy 0 ADJ F
females 0 NOUN F
( 0 PUNCT F
age 0 NOUN F
range 0 NOUN F
22-36 0 NUM F
years 0 NOUN F
, 0 PUNCT F
mean 0 VERB F
29.1 0 NUM F
+/- 0 SYM F
5.4 0 NUM F
) 0 PUNCT F
who 0 ADP F
were 0 VERB F
hospitalized 0 VERB F
and 0 CCONJ F
challenged 0 VERB F
on 0 ADP F
two 0 NUM F
consecutive 0 ADJ F
days 0 NOUN F
with 0 ADP F
placebo 0 NOUN F
( 0 PUNCT F
peppermint 0 NOUN F
tea 0 NOUN F
) 0 PUNCT F
or 0 CCONJ F
75 0 NUM F
mg 0 NOUN F
of 0 ADP F
pure 0 ADJ F
histamine 0 NOUN F
( 0 PUNCT F
equaling 0 ADJ F
124 0 NUM F
mg 0 NOUN F
histamine 0 NOUN F
dihydrochloride 0 NOUN F
, 0 PUNCT F
dissolved 0 PUNCT F
in 0 ADP F
peppermint 0 NOUN F
tea 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

Objective 0 ADJ T
parameters 0 NOUN F
( 0 PUNCT F
heart 0 NOUN F
rate 0 NOUN F
, 0 PUNCT F
blood 0 NOUN F
pressure 0 NOUN F
, 0 PUNCT F
skin 0 NOUN F
temperature 0 NOUN F
, 0 PUNCT F
peak 0 ADJ F
flow 0 NOUN F
) 0 PUNCT F
as 0 PUNCT F
well 0 PUNCT F
as 0 CCONJ F
a 0 DET F
total 0 ADJ F
clinical 0 ADJ F
symptom 0 NOUN F
score 0 NOUN F
using 0 VERB F
a 0 DET F
standardized 0 VERB F
protocol 0 NOUN F
were 0 VERB F
recorded 0 VERB F
at 0 ADP F
baseline 0 NOUN F
, 0 PUNCT F
10 0 NUM F
, 0 PUNCT F
20 0 NUM F
, 0 PUNCT F
40 0 NUM F
, 0 PUNCT F
80 0 NUM F
minutes 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
24 0 NUM F
hours 0 NOUN F
. 0 PUNCT F

The 0 DET T
subjects 0 NOUN F
received 0 VERB F
a 0 DET F
histamine-free 0 VERB F
diet 0 NOUN F
also 0 ADV F
low 0 ADJ F
in 0 ADP F
allergen 0 NOUN F
24 0 NUM F
hours 0 NOUN F
before 0 PUNCT F
hospitalization 0 NOUN F
and 0 CCONJ F
over 0 ADP F
the 0 DET F
whole 0 ADJ F
observation 0 NOUN F
period 0 NOUN F
. 0 PUNCT F

Blood 0 NOUN T
samples 0 NOUN F
were 0 VERB F
drawn 0 VERB F
at 0 ADP F
baseline 0 NOUN F
, 0 PUNCT F
10 0 NUM F
, 0 PUNCT F
20 0 NUM F
, 0 PUNCT F
40 0 NUM F
, 0 PUNCT F
and 0 CCONJ F
80 0 NUM F
minutes 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
histamine 0 NOUN F
and 0 CCONJ F
the 0 DET F
histamine-degrading 0 ADV F
enzyme 0 NOUN F
diamine 0 NOUN F
oxidase 0 NOUN F
( 0 PUNCT F
DAO 0 NOUN T
) 0 PUNCT F
were 0 VERB F
determined 0 VERB F
. 0 PUNCT F

After 0 ADP T
histamine 0 NOUN F
challenge 0 NOUN F
, 0 PUNCT F
5 0 NUM F
of 0 ADP F
10 0 NUM F
subjects 0 NOUN F
showed 0 VERB F
no 0 DET F
reaction B-PHYSICAL NOUN F
. 0 PUNCT F

One 0 NUM T
individual 0 ADJ F
experienced 0 VERB F
tachycardia B-PHYSICAL NOUN F
, 0 PUNCT F
mild B-PHYSICAL ADJ F
hypotension I-PHYSICAL NOUN F
after I-PHYSICAL ADP F
20 I-PHYSICAL NUM F
minutes I-PHYSICAL NOUN F
, 0 PUNCT F
sneezing B-PHYSICAL PUNCT F
, 0 PUNCT F
itching 0 ADJ F
of 0 ADP F
the 0 DET F
nose 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
rhinorrhea 0 NOUN F
after 0 ADP F
60 B-PHYSICAL NUM F
minutes I-PHYSICAL NOUN F
. 0 PUNCT F

Four 0 NUM T
subjects 0 NOUN F
experienced 0 DET F
delayed 0 VERB F
symptoms 0 NOUN F
like 0 ADP F
diarrhea B-PHYSICAL NOUN F
( I-PHYSICAL PUNCT F
4x I-PHYSICAL NOUN F
) I-PHYSICAL PUNCT F
, 0 PUNCT F
flatulence B-PHYSICAL NOUN F
( I-PHYSICAL PUNCT F
3x I-PHYSICAL NOUN F
) I-PHYSICAL PUNCT F
, 0 PUNCT F
headache B-PHYSICAL ADJ F
( I-PHYSICAL PUNCT F
3x I-PHYSICAL NOUN F
) I-PHYSICAL PUNCT F
, 0 PUNCT F
pruritus B-PHYSICAL NOUN F
( I-PHYSICAL PUNCT F
2x I-PHYSICAL NOUN F
) I-PHYSICAL PUNCT F
and 0 CCONJ F
ocular B-PHYSICAL ADJ F
symptoms I-PHYSICAL NOUN F
( 0 PUNCT F
1x 0 NOUN F
) 0 PUNCT F
starting 0 ADV F
3 0 NUM F
to 0 ADP F
24 0 NUM F
hours 0 NOUN F
after 0 ADP F
provocation 0 NOUN F
. 0 PUNCT F

No 0 DET T
subject 0 NOUN F
reacted 0 VERB F
to 0 ADP F
placebo 0 NOUN F
. 0 PUNCT F

No 0 DET T
changes 0 NOUN F
were 0 VERB F
observed 0 VERB F
in 0 ADP F
histamine B-PHYSICAL NOUN F
and I-PHYSICAL CCONJ F
DAO I-PHYSICAL NOUN T
levels I-PHYSICAL NOUN F
within 0 ADP F
the 0 DET F
first 0 ADJ F
80 0 NUM F
minutes 0 NOUN F
in 0 ADP F
non-reactors 0 NOUN F
as 0 CCONJ F
well 0 PUNCT F
as 0 CCONJ F
reactors 0 NOUN F
. 0 PUNCT F

There 0 PUNCT T
was 0 VERB F
no 0 DET F
difference 0 NOUN F
in 0 ADP F
challenge 0 NOUN F
with 0 ADP F
histamine 0 NOUN F
versus 0 CCONJ F
challenge 0 NOUN F
with 0 ADP F
placebo 0 NOUN F
. 0 PUNCT F

We 0 PRON T
conclude 0 VERB F
that 0 ADP F
75 0 NUM F
mg 0 NOUN F
of 0 ADP F
pure 0 ADJ F
liquid 0 ADJ F
oral 0 ADJ F
histamine 0 NOUN F
-- 0 PUNCT F
a 0 DET F
dose 0 NOUN F
found 0 VERB F
in 0 ADP F
normal 0 ADJ F
meals 0 NOUN F
-- 0 PUNCT F
can 0 VERB F
provoke 0 NOUN F
immediate 0 ADJ F
as 0 PUNCT F
well 0 PUNCT F
as 0 CCONJ F
delayed 0 VERB F
symptoms 0 NOUN F
in 0 ADP F
50 0 NUM F
% 0 SYM F
of 0 ADP F
healthy 0 ADJ F
females 0 NOUN F
without 0 ADP F
a 0 DET F
history 0 NOUN F
of 0 ADP F
food 0 NOUN F
intolerance 0 NOUN F
. 0 PUNCT F

Response 0 NOUN T
prediction 0 NOUN F
in 0 ADP F
metastasised 0 DET F
colorectal 0 ADJ F
cancer 0 NOUN F
using 0 SYM F
intratumoural 0 ADJ F
thymidylate 0 NOUN F
synthase 0 NOUN F
: 0 PUNCT F
results 0 NOUN F
of 0 ADP F
a 0 DET F
randomised 0 VERB F
multicentre 0 NOUN F
trial 0 NOUN F
. 0 PUNCT F

BACKGROUND 0 NOUN T
Molecular 0 ADJ T
markers 0 NOUN F
to 0 PART F
predict 0 NOUN F
response 0 NOUN F
to 0 ADP F
5-fluorouracil 0 NOUN F
( 0 PUNCT F
FU 0 NOUN T
) 0 PUNCT F
-based 0 ADP F
treatment 0 NOUN F
of 0 ADP F
recurrent 0 ADJ F
or 0 CCONJ F
metastasised 0 VERB F
colorectal 0 ADJ F
cancer 0 NOUN F
( 0 PUNCT F
mCRC 0 NOUN F
) 0 PUNCT F
are 0 VERB F
not 0 ADV F
established 0 VERB F
. 0 PUNCT F

The 0 DET T
aim 0 NOUN F
of 0 ADP F
this 0 DET F
trial 0 NOUN F
was 0 VERB F
to 0 PART F
determine 0 NOUN F
the 0 DET F
value 0 NOUN F
of 0 ADP F
thymidylate 0 NOUN F
synthase 0 NOUN F
( 0 PUNCT F
TS 0 NOUN T
) 0 PUNCT F
, 0 PUNCT F
a 0 DET F
key 0 ADJ F
enzyme 0 NOUN F
of 0 ADP F
DNA 0 NOUN T
synthesis 0 NOUN F
and 0 CCONJ F
target 0 NOUN F
of 0 ADP F
5-FU 0 NOUN F
, 0 PUNCT F
to 0 PART F
predict B-PHYSICAL NOUN F
response I-PHYSICAL NOUN F
to 0 ADP F
chemotherapy 0 NOUN F
of 0 ADP F
mCRC 0 NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
Tumour 0 NOUN T
tissue 0 NOUN F
was 0 VERB F
obtained 0 VERB F
from 0 ADP F
168 0 NUM F
patients 0 NOUN F
with 0 ADP F
mCRC 0 NOUN F
for 0 ADP F
relative 0 ADJ F
thymidylate 0 NOUN F
synthase B-PHYSICAL NOUN F
( I-PHYSICAL PUNCT F
TS I-PHYSICAL NOUN T
) I-PHYSICAL PUNCT F
mRNA 0 NOUN F
quantitation 0 NOUN F
. 0 PUNCT F

Patients 0 NOUN T
were 0 VERB F
randomised 0 VERB F
to 0 PART F
receive 0 NOUN F
either 0 PUNCT F
5-FU/folinic 0 ADJ F
acid 0 NOUN F
( 0 PUNCT F
FA 0 NOUN T
, 0 PUNCT F
FUFA 0 NOUN T
) 0 PUNCT F
alone 0 ADJ F
or 0 CCONJ F
in 0 ADP F
combination 0 NOUN F
with 0 ADP F
irinotecan 0 NOUN F
5-fluorouracil/folinic 0 PUNCT F
acid 0 NOUN F
and 0 CCONJ F
irinotecan 0 NOUN F
( 0 PUNCT F
FOLFIRI 0 NOUN T
) 0 PUNCT F
stratified 0 PUNCT F
by 0 ADP F
TS 0 NOUN T
( 0 PUNCT F
low 0 ADJ F
versus 0 CCONJ F
high 0 ADJ F
) 0 PUNCT F
. 0 PUNCT F

Primary 0 ADJ T
end-point 0 NOUN F
was 0 VERB F
overall B-PHYSICAL ADJ F
response 0 NOUN F
to B-PHYSICAL ADP F
first-line I-PHYSICAL NOUN F
treatment B-PHYSICAL NOUN F
among 0 ADP F
TS 0 NOUN T
high 0 ADJ F
patients 0 NOUN F
. 0 PUNCT F

All 0 DET T
parties 0 ADJ F
, 0 PUNCT F
except 0 PUNCT F
for 0 ADP F
the 0 DET F
randomisation 0 NOUN F
centre 0 NOUN F
, 0 PUNCT F
were 0 VERB F
blinded 0 VERB F
for 0 ADP F
TS 0 NOUN T
status 0 NOUN F
. 0 PUNCT F

RESULTS 0 DET T
Biopsies 0 NOUN T
( 0 PUNCT F
n=168 0 NOUN F
) 0 PUNCT F
were 0 VERB F
taken 0 VERB F
without 0 ADP F
complications 0 NOUN F
. 0 PUNCT F

TS B-PHYSICAL NOUN T
levels B-PHYSICAL NOUN F
were 0 VERB F
available 0 ADJ F
for 0 ADP F
147 0 NUM F
patients 0 NOUN F
( 0 PUNCT F
87.5 0 NUM F
% 0 SYM F
) 0 PUNCT F
. 0 PUNCT F

Analysing 0 PROPN T
response 0 NOUN F
to 0 PUNCT F

Effect 0 NOUN T
of 0 ADP F
flurbiprofen 0 PUNCT F
sodium 0 NOUN F
on 0 ADP F
pupillary B-PHYSICAL ADJ F
dilatation I-PHYSICAL NOUN F
during 0 ADP F
scleral 0 ADJ F
buckling 0 ADP F
surgery 0 NOUN F
. 0 PUNCT F

Maintenance 0 NOUN T
of 0 ADP F
pupillary B-PHYSICAL ADJ F
dilatation I-PHYSICAL NOUN F
is 0 VERB F
necessary 0 ADJ F
for 0 ADP F
success 0 NOUN F
of 0 ADP F
scleral 0 ADJ F
buckling 0 ADP F
procedures 0 NOUN F
. 0 PUNCT F

The 0 DET T
efficacy 0 NOUN F
of 0 ADP F
0.03 0 NUM F
% 0 SYM F
flurbiprofen 0 PUNCT F
in 0 ADP F
preventing 0 VERB F
intraoperative 0 ADJ F
miosis 0 NOUN F
was 0 VERB F
evaluated 0 VERB F
by 0 ADP F
a 0 DET F
prospective 0 ADJ F
randomized 0 VERB F
, 0 PUNCT F
double-masked 0 VERB F
controlled 0 VERB F
trial 0 NOUN F
of 0 ADP F
60 0 NUM F
patients 0 NOUN F
. 0 PUNCT F

Thirty 0 NUM T
patients 0 NOUN F
received 0 VERB F
0.03 0 NUM F
% 0 SYM F
flurbiprofen 0 PUNCT F
6 0 NUM F
times 0 NOUN F
at 0 ADP F
15 0 NUM F
minute 0 ADJ F
intervals 0 NOUN F
90 0 NUM F
minutes 0 NOUN F
preoperatively 0 ADV F
in 0 ADP F
addition 0 NOUN F
to 0 ADP F
the 0 DET F
routine 0 ADJ F
dilation 0 NOUN F
regimen 0 NOUN F
. 0 PUNCT F

The 0 DET T
treated 0 DET F
group 0 NOUN F
had 0 PUNCT F
a 0 DET F
mean 0 NOUN F
pupillary B-PHYSICAL ADJ F
decrease 0 NOUN F
of 0 ADP F
1.88 0 NUM F
mm 0 NOUN F
and 0 CCONJ F
the 0 DET F
control 0 NOUN F
group 0 NOUN F
had 0 CCONJ F
a 0 DET F
decrease 0 NOUN F
of 0 ADP F
1.57 0 NUM F
mm 0 NOUN F
( 0 PUNCT F
p 0 NOUN F
> 0 SYM F
0.05 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Flurbiprofen 0 NOUN T
did 0 VERB F
not 0 ADV F
affect 0 VERB F
the 0 DET F
pupillary B-PHYSICAL ADJ F
size I-PHYSICAL NOUN F
at 0 ADP F
any 0 DET F
step 0 NOUN F
of 0 ADP F
the 0 DET F
surgery 0 NOUN F
. 0 PUNCT F

Factors 0 NOUN T
such 0 CCONJ F
as 0 ADP F
age 0 NOUN F
of 0 ADP F
the 0 DET F
patient B-MENTAL NOUN F
, 0 PUNCT F
lens B-PHYSICAL NOUN F
status I-PHYSICAL NOUN F
, 0 PUNCT F
number 0 NOUN F
of 0 ADP F
cryo B-PHYSICAL NOUN F
applications I-PHYSICAL NOUN F
, 0 PUNCT F
duration B-OTHER NOUN F
of I-OTHER ADP F
surgery I-OTHER NOUN F
, 0 PUNCT F
and 0 CCONJ F
the 0 DET F
size 0 NOUN F
and 0 CCONJ F
extent B-OTHER NOUN F
of I-OTHER ADP F
buckle I-OTHER NOUN F
were 0 VERB F
assessed 0 VERB F
. 0 PUNCT F

The 0 DET T
use 0 NOUN F
of 0 ADP F
flurbiprofen 0 NOUN F
did 0 PUNCT F
not 0 ADV F
affect 0 VERB F
the 0 DET F
mean 0 NOUN F
pupillary B-PHYSICAL PUNCT F
change I-PHYSICAL NOUN F
for 0 ADP F
any 0 PUNCT F
of 0 ADP F
these 0 DET F
groups 0 NOUN F
. 0 PUNCT F

Preoperative 0 ADJ T
use 0 NOUN F
of 0 ADP F
flurbiprofen 0 NOUN F
does 0 PUNCT F
not 0 ADV F
significantly 0 ADV F
decrease 0 NOUN F
intraoperative B-PHYSICAL ADJ F
miosis I-PHYSICAL NOUN F
during I-PHYSICAL ADP F
scleral I-PHYSICAL ADJ F
buckling I-PHYSICAL ADP F
procedures I-PHYSICAL NOUN F
. 0 PUNCT F

The 0 DET T
effect 0 NOUN F
of 0 ADP F
visual 0 ADJ F
supports 0 VERB F
on 0 ADP F
performance B-OTHER NOUN F
of 0 ADP F
the 0 DET F
TGMD-2 0 NOUN T
for 0 ADP F
children 0 NOUN F
with 0 ADP F
autism 0 NOUN F
spectrum 0 NOUN F
disorder 0 NOUN F
. 0 PUNCT F

The 0 DET T
purpose 0 NOUN F
of 0 ADP F
this 0 DET F
study 0 NOUN F
was 0 VERB F
to 0 ADV F
examine 0 NOUN F
the 0 DET F
effects 0 NOUN F
of 0 ADP F
visual 0 ADJ F
supports 0 VERB F
on 0 ADP F
the 0 DET F
performance 0 NOUN F
of 0 ADP F
the 0 DET F
Test 0 NOUN T
of 0 ADP F
Gross 0 ADJ T
Motor 0 NOUN T
Development 0 NOUN T
( 0 PUNCT F
TGMD-2 0 NOUN T
) 0 PUNCT F
for 0 ADP F
children 0 NOUN F
with 0 ADP F
autism 0 NOUN F
spectrum 0 NOUN F
disorder 0 NOUN F
( 0 PUNCT F
ASD 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

Participants 0 NOUN T
( 0 PUNCT F
N 0 NOUN T
= 0 SYM F
22 0 NUM F
) 0 PUNCT F
performed 0 VERB F
the 0 DET F
TGMD-2 0 NOUN T
under 0 ADP F
three 0 NUM F
different 0 ADJ F
protocols 0 NOUN F
( 0 PUNCT F
traditional 0 ADJ F
protocol 0 NOUN F
, 0 PUNCT F
picture 0 NOUN F
task 0 NOUN F
card 0 ADJ F
protocol 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
picture 0 NOUN F
activity 0 NOUN F
schedule 0 NOUN F
protocol 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

Gross B-PHYSICAL ADJ T
motor I-PHYSICAL NOUN F
quotient I-PHYSICAL NOUN F
scores 0 NOUN F
on 0 ADP F
the 0 DET F
TGMD-2 0 NOUN T
were 0 VERB F
measured 0 VERB F
and 0 CCONJ F
statistically 0 ADV F
analyzed 0 VERB F
using 0 VERB F
a 0 DET F
within-subjects 0 PUNCT F
repeated-measures 0 VERB F
ANOVA 0 NOUN T
. 0 PUNCT F

Results 0 NOUN T
indicated 0 VERB F
statistically 0 ADP F
significant 0 ADJ F
differences 0 NOUN F
between 0 ADP F
protocols 0 NOUN F
, 0 PUNCT F
while 0 VERB F
post 0 PUNCT F
hoc 0 ADP F
tests 0 NOUN F
indicated 0 VERB F
that 0 ADP F
the 0 DET F
picture 0 NOUN F
task 0 NOUN F
card 0 PUNCT F
condition 0 NOUN F
produced 0 ADJ F
significantly 0 ADV F
higher 0 PUNCT F
gross B-PHYSICAL ADJ F
motor I-PHYSICAL NOUN F
quotient I-PHYSICAL NOUN F
scores 0 ADJ F
than 0 VERB F
the 0 DET F
traditional 0 ADJ F
protocol 0 NOUN F
and 0 CCONJ F
the 0 DET F
picture 0 NOUN F
activity 0 NOUN F
schedule 0 NOUN F
. 0 PUNCT F

The 0 DET T
results 0 CCONJ F
suggest 0 VERB F
that 0 ADP F
more 0 ADV F
accurate 0 ADJ F
gross 0 ADJ F
motor 0 NOUN F
quotient 0 NOUN F
scores 0 NOUN F
on 0 ADP F
the 0 DET F
TGMD-2 B-PHYSICAL NOUN T
by 0 ADP F
children 0 NOUN F
with 0 ADP F
ASD 0 NOUN T
can 0 VERB F
be 0 VERB F
elicited 0 VERB F
using 0 SYM F
the 0 DET F
picture 0 NOUN F
task 0 NOUN F
card 0 ADJ F
protocol 0 NOUN F
. 0 PUNCT F

Hysteroscopic 0 ADJ T
transcervical 0 ADJ F
endometrial 0 ADJ F
resection 0 NOUN F
versus 0 CCONJ F
thermal 0 ADJ F
destruction 0 NOUN F
for 0 ADP F
menorrhagia 0 NOUN F
: 0 PUNCT F
a 0 DET F
prospective 0 ADJ F
randomized 0 VERB F
trial 0 NOUN F
on 0 ADP F
satisfaction 0 NOUN F
rate 0 NOUN F
. 0 PUNCT F

OBJECTIVE 0 NOUN T
The 0 DET T
purpose 0 NOUN F
of 0 ADP F
this 0 DET F
study 0 NOUN F
was 0 VERB F
to 0 ADV F
compare 0 NOUN F
the 0 DET F
satisfaction B-OTHER NOUN F
rate I-OTHER NOUN F
and 0 CCONJ F
the 0 DET F
effectiveness 0 NOUN F
of 0 ADP F
transcervical 0 ADJ F
hysteroscopic 0 ADJ F
endometrial 0 ADJ F
resection 0 NOUN F
and 0 CCONJ F
thermal 0 ADJ F
destruction 0 NOUN F
of 0 ADP F
the 0 DET F
endometrium 0 NOUN F
in 0 ADP F
the 0 DET F
treatment 0 NOUN F
of 0 ADP F
menorrhagia 0 NOUN F
. 0 PUNCT F

STUDY 0 NOUN T
DESIGN 0 NOUN T
A 0 CCONJ T
prospective 0 ADJ F
randomized 0 VERB F
trial 0 NOUN F
with 0 ADP F
2 0 NUM F
years 0 NOUN F
of 0 ADP F
follow-up 0 NOUN F
was 0 VERB F
carried 0 VERB F
out 0 ADP F
in 0 ADP F
the 0 DET F
Department 0 NOUN T
of 0 ADP F
Gynecology 0 NOUN T
of 0 ADP F
the 0 DET F
University 0 NOUN T
of 0 ADP F
Naples 0 NOUN T
. 0 PUNCT F

Eighty-two 0 NUM T
patients 0 NOUN F
who 0 PROPN F
were 0 VERB F
affected 0 VERB F
by 0 ADP F
menorrhagia 0 NOUN F
that 0 ADP F
was 0 VERB F
unresponsive 0 ADJ F
to 0 PUNCT F
medical 0 PUNCT F
treatment 0 NOUN F
were 0 VERB F
respectively 0 ADV F
randomized 0 VERB F
to 0 ADP F
transcervical 0 ADJ F
hysteroscopic 0 ADJ F
endometrial 0 ADJ F
resection 0 NOUN F
or 0 CCONJ F
to 0 ADP F
thermal 0 ADJ F
destruction 0 NOUN F
of 0 ADP F
the 0 DET F
endometrium 0 NOUN F
. 0 PUNCT F

Satisfaction B-OTHER NOUN T
rate I-OTHER NOUN F
, 0 PUNCT F
operative B-OTHER ADJ F
time I-OTHER NOUN F
, 0 PUNCT F
discharge B-OTHER NOUN F
time I-OTHER NOUN F
, 0 PUNCT F
complication B-ADVERSE-EFFECTS NOUN F
rate I-ADVERSE-EFFECTS NOUN F
, 0 PUNCT F
reintervention B-OTHER NOUN F
rate I-OTHER NOUN F
, 0 PUNCT F
and 0 CCONJ F
resumption 0 NOUN F
of 0 ADP F
normal B-OTHER ADJ F
activity I-OTHER NOUN F
were 0 VERB F
evaluated 0 VERB F
in 0 ADP F
each 0 DET F
group 0 NOUN F
. 0 PUNCT F

RESULTS 0 PUNCT T
The 0 DET T
satisfaction B-OTHER NOUN F
rate I-OTHER NOUN F
was 0 VERB F
significantly 0 ADV F
higher 0 PUNCT F
in 0 ADP F
the 0 DET F
thermal 0 ADJ F
destruction 0 NOUN F
group 0 NOUN F
. 0 PUNCT F

Operative B-OTHER ADJ T
time I-OTHER NOUN F
was 0 VERB F
significantly 0 ADV F
shorter 0 PUNCT F
in 0 ADP F
the 0 DET F
thermal 0 ADJ F
destruction 0 NOUN F
group 0 NOUN F
( 0 PUNCT F
24 0 NUM F
+/- 0 SYM F
4 0 NUM F
minutes 0 NOUN F
vs 0 CCONJ F
37 0 NUM F
+/- 0 SYM F
6 0 NUM F
minutes 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

Intraoperative B-ADVERSE-EFFECTS ADJ T
blood I-ADVERSE-EFFECTS NOUN F
loss I-ADVERSE-EFFECTS NOUN F
was 0 VERB F
significantly 0 ADV F
lower 0 PUNCT F
in 0 ADP F
the 0 DET F
thermal 0 ADJ F
destruction 0 NOUN F
group 0 NOUN F
( 0 PUNCT F
7.2 0 NUM F
+/- 0 SYM F
2.8 0 NUM F
mL 0 NOUN F
vs 0 CCONJ F
89 0 NUM F
+/- 0 SYM F
38 0 NUM F
mL 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

Reintervention B-OTHER NOUN T
rates I-OTHER NOUN F
were 0 VERB F
higher 0 PUNCT F
in 0 ADP F
the 0 DET F
transcervical 0 ADJ F
hysteroscopic 0 ADJ F
endometrial 0 ADJ F
resection 0 NOUN F
group 0 NOUN F
, 0 PUNCT F
although 0 ADP F
postoperative 0 ADJ F
pain 0 NOUN F
was 0 VERB F
not 0 ADV F
significantly 0 ADV F
different 0 ADJ F
between 0 ADP F
the 0 DET F
two 0 NUM F
groups 0 NOUN F
. 0 PUNCT F

Discharge B-OTHER NOUN T
time I-OTHER NOUN F
, 0 PUNCT F
complication B-ADVERSE-EFFECTS NOUN F
rate I-ADVERSE-EFFECTS NOUN F
, 0 PUNCT F
and 0 CCONJ F
resumption 0 NOUN F
of 0 ADP F
normal B-OTHER ADJ F
activity I-OTHER NOUN F
were 0 VERB F
not 0 ADV F
significantly 0 ADV F
different 0 ADJ F
between 0 ADP F
the 0 DET F
two 0 NUM F
groups 0 NOUN F
. 0 PUNCT F

CONCLUSION 0 NOUN T
Thermal 0 ADJ T
destruction 0 NOUN F
of 0 ADP F
the 0 DET F
endometrium 0 NOUN F
for 0 ADP F
the 0 DET F
treatment 0 NOUN F
of 0 ADP F
menorrhagia 0 NOUN F
should 0 VERB F
be 0 VERB F
considered 0 VERB F
an 0 DET F
effective 0 ADJ F
therapeutic 0 ADJ F
option 0 NOUN F
because 0 PUNCT F
of 0 ADP F
its 0 ADJ F
acceptability B-OTHER NOUN F
among 0 ADP F
patients 0 NOUN F
, 0 PUNCT F
shorter B-OTHER CCONJ F
operative I-OTHER ADJ F
time I-OTHER NOUN F
, 0 PUNCT F
and 0 CCONJ F
lower B-OTHER VERB F
blood I-OTHER NOUN F
loss I-OTHER NOUN F
. 0 PUNCT F

Repeatability 0 NOUN T
and 0 CCONJ F
protocol 0 NOUN F
comparability 0 NOUN F
of 0 ADP F
presyncopal 0 ADJ F
symptom 0 NOUN F
limited 0 ADP F
lower 0 PUNCT F
body 0 NOUN F
negative 0 ADJ F
pressure 0 NOUN F
exposures 0 NOUN F
. 0 PUNCT F

Data 0 NOUN T
on 0 ADP F
repeatability 0 NOUN F
and 0 CCONJ F
comparability 0 NOUN F
of 0 ADP F
different 0 ADJ F
presyncopal 0 ADJ F
symptom-limited 0 VERB F
lower 0 PUNCT F
body 0 NOUN F
negative 0 ADJ F
pressure 0 NOUN F
( 0 PUNCT F
PSL-LBNP 0 NOUN T
) 0 PUNCT F
exposure 0 NOUN F
protocols 0 NOUN F
, 0 PUNCT F
while 0 ADP F
scarce 0 NOUN F
, 0 PUNCT F
are 0 VERB F
critical 0 ADJ F
to 0 ADP F
the 0 DET F
interpretation 0 NOUN F
of 0 ADP F
studies 0 NOUN F
using 0 VERB F
PSL-LBNP 0 NOUN T
methods 0 NOUN F
. 0 PUNCT F

To 0 PART T
investigate 0 ADP F
if 0 PUNCT F
PSL-LBNP 0 NOUN T
tolerance 0 NOUN F
, 0 PUNCT F
heart 0 NOUN F
rate 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
blood 0 NOUN F
pressure 0 NOUN F
were 0 VERB F
repeatable 0 ADJ F
, 0 PUNCT F
11 0 NUM F
subjects 0 NOUN F
were 0 VERB F
exposed 0 VERB F
to 0 ADP F
4 0 NUM F
PSL-LBNP 0 NOUN T
tests 0 NOUN F
; 0 PUNCT F
each 0 DET F
test 0 NOUN F
occurring 0 ADJ F
at 0 ADP F
the 0 DET F
same 0 ADJ F
time 0 NOUN F
of 0 ADP F
day 0 NOUN F
, 0 PUNCT F
separated 0 VERB F
by 0 ADP F
at 0 ADP F
least 0 ADV F
72 0 NUM F
h 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
using 0 VERB F
the 0 DET F
same 0 ADJ F
protocol 0 NOUN F
. 0 PUNCT F

No 0 DET T
significant 0 ADJ F
differences 0 NOUN F
were 0 VERB F
found 0 VERB F
in 0 ADP F
either 0 CCONJ F
the 0 DET F
heart B-PHYSICAL NOUN F
rate I-PHYSICAL NOUN F
or 0 CCONJ F
blood B-PHYSICAL NOUN F
pressure I-PHYSICAL NOUN F
responses I-PHYSICAL NOUN F
to 0 ADP F
the 0 DET F
PSL-LBNP 0 NOUN T
or 0 CCONJ F
the 0 DET F
tolerance 0 NOUN F
indices B-OTHER NOUN F
( 0 PUNCT F
cumulative 0 ADJ F
stress 0 NOUN F
index 0 NOUN F
; 0 PUNCT F
maximum 0 NOUN F
negative 0 ADJ F
pressure 0 NOUN F
tolerated 0 VERB F
; 0 PUNCT F
and 0 CCONJ F
duration 0 NOUN F
of 0 ADP F
negative 0 ADJ F
pressure 0 NOUN F
exposure 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

To 0 ADJ T
study 0 NOUN F
the 0 DET F
comparability 0 NOUN F
of 0 ADP F
different 0 ADJ F
PSL-LBNP 0 NOUN T
protocols 0 NOUN F
, 0 PUNCT F
nine 0 NUM F
subjects 0 NOUN F
were 0 VERB F
exposed 0 VERB F
randomly 0 ADV F
to 0 PUNCT F
five 0 PUNCT F
PSL-LBNP 0 NOUN T
tests 0 NOUN F
using 0 PROPN F
protocols 0 NOUN F
that 0 ADP F
varied 0 VERB F
in 0 ADP F
stage 0 NOUN F
duration 0 NOUN F
but 0 CCONJ F
not 0 ADV F
pressure 0 NOUN F
profile 0 NOUN F
. 0 PUNCT F

The 0 DET T
protocols 0 NOUN F
had 0 PUNCT F
1- 0 NUM F
, 0 PUNCT F
3- 0 NUM F
, 0 PUNCT F
5- 0 NUM F
, 0 PUNCT F
7- 0 NUM F
, 0 PUNCT F
or 0 CCONJ F
9-min 0 NOUN F
stage 0 NOUN F
durations 0 NOUN F
. 0 PUNCT F

These 0 DET T
PSL-LBNP 0 NOUN T
exposures 0 NOUN F
were 0 VERB F
conducted 0 VERB F
at 0 ADP F
the 0 DET F
same 0 ADJ F
time 0 NOUN F
of 0 ADP F
day 0 NOUN F
and 0 CCONJ F
separated 0 VERB F
by 0 ADP F
at 0 ADP F
least 0 ADV F
72 0 NUM F
h. 0 NOUN F
While 0 ADP T
no 0 DET F
differences 0 NOUN F
were 0 VERB F
noted 0 VERB F
in 0 ADP F
either 0 CCONJ F
the 0 DET F
response 0 NOUN F
pattern 0 NOUN F
or 0 CCONJ F
magnitude 0 NOUN F
of 0 ADP F
heart B-PHYSICAL NOUN F
rate I-PHYSICAL NOUN F
or 0 CCONJ F
blood B-PHYSICAL NOUN F
pressure I-PHYSICAL NOUN F
to 0 ADP F
the 0 DET F
differing 0 VERB F
protocols 0 NOUN F
, 0 PUNCT F
the 0 DET F
cumulative B-OTHER ADJ F
stress 0 NOUN F
index B-OTHER NOUN F
and 0 CCONJ F
the B-PHYSICAL DET F
duration I-PHYSICAL NOUN F
of I-PHYSICAL ADP F
negative 0 PUNCT F

Helicobacter B-PHYSICAL NOUN T
pylori I-PHYSICAL NOUN F
eradication I-PHYSICAL NOUN F
in 0 ADP F
children 0 NOUN F
and 0 CCONJ F
adolescents 0 NOUN F
by 0 ADP F
a 0 PUNCT F
once 0 PUNCT F
daily 0 PUNCT F
6-day 0 CCONJ F
treatment 0 NOUN F
with 0 ADP F
or 0 CCONJ F
without 0 ADP F
a 0 DET F
proton 0 NOUN F
pump 0 NOUN F
inhibitor 0 NOUN F
in 0 ADP F
a 0 DET F
double-blind 0 ADJ F
randomized 0 VERB F
trial 0 NOUN F
. 0 PUNCT F

AIM 0 NOUN T
To 0 ADV T
evaluate 0 NOUN F
two 0 NUM F
simplified 0 VERB F
Helicobacter B-PHYSICAL NOUN T
pylori I-PHYSICAL NOUN F
eradication I-PHYSICAL NOUN F
treatment 0 NOUN F
alternatives 0 VERB F
for 0 ADP F
children 0 NOUN F
and 0 CCONJ F
adolescents 0 NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
Study 0 ADP T
subjects 0 NOUN F
were 0 VERB F
identified 0 VERB F
by 0 ADP F
enzyme-linked 0 VERB F
immunosorbent 0 ADJ F
assay 0 NOUN F
and 0 CCONJ F
immunoblot 0 NOUN F
in 0 ADP F
a 0 DET F
family 0 NOUN F
screening 0 ADJ F
project 0 NOUN F
. 0 PUNCT F

Helicobacter 0 NOUN T
pylori 0 NOUN F
infected 0 ADP F
10-21 0 NUM F
year 0 NOUN F
olds 0 NUM F
were 0 VERB F
offered 0 PUNCT F
treatment 0 NOUN F
, 0 PUNCT F
individuals 0 NOUN F
with 0 ADP F
abdominal 0 ADJ F
pain 0 NOUN F
underwent 0 VERB F
upper 0 ADJ F
endoscopy 0 NOUN F
and 0 CCONJ F
those 0 PUNCT F
with 0 ADP F
peptic 0 ADJ F
ulcers 0 NOUN F
were 0 VERB F
excluded 0 VERB F
. 0 PUNCT F

Participants 0 NOUN T
were 0 VERB F
randomized 0 VERB F
to 0 ADP F
either 0 PUNCT F
azithromycin 0 NOUN F
500 0 NUM F
mg 0 NOUN F
daily 0 ADJ F
and 0 CCONJ F
tinidazole 0 NOUN F
500 0 NUM F
mg 0 NOUN F
two 0 NUM F
tablets 0 ADV F
daily 0 ADP F
in 0 ADP F
combination 0 NOUN F
with 0 ADP F
lansoprasole 0 ADJ F
30 0 NUM F
mg 0 NOUN F
daily 0 ADJ F
for 0 ADP F
6 0 NUM F
days 0 NOUN F
( 0 PUNCT F
ATL-group 0 NOUN T
) 0 PUNCT F
or 0 CCONJ F
with 0 ADP F
placebo 0 NOUN F
( 0 PUNCT F
ATP-group 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

Urea 0 NOUN T
Breath 0 NOUN T
Test 0 NOUN T
was 0 VERB F
performed 0 VERB F
at 0 ADP F
inclusion 0 NOUN F
and 0 CCONJ F
after 0 ADP F
a 0 DET F
minimum 0 NOUN F
of 0 ADP F
6 0 NUM F
weeks 0 NOUN F
after 0 ADP F
end 0 NOUN F
of 0 ADP F
therapy 0 NOUN F
. 0 PUNCT F

RESULTS 0 NOUN T
In 0 ADP T
total 0 NOUN F
, 0 PUNCT F
131 0 NUM F
individuals 0 NOUN F
were 0 VERB F
randomized 0 PROPN F
, 0 PUNCT F
of 0 ADP F
whom 0 ADP F
31 0 NUM F
( 0 PUNCT F
24 0 NUM F
% 0 SYM F
) 0 PUNCT F
had 0 PUNCT F
undergone 0 ADP F
upper 0 ADJ F
endoscopy 0 NOUN F
. 0 PUNCT F

Full B-MENTAL ADJ T
compliance I-MENTAL NOUN F
was 0 VERB F
achieved 0 VERB F
in 0 ADP F
93 0 NUM F
% 0 SYM F
( 0 PUNCT F
122 0 NUM F
of 0 ADP F
131 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
intention-to-treat B-OTHER NOUN F
eradication I-OTHER NOUN F
rate I-OTHER NOUN F
was 0 VERB F
67 0 NUM F
% 0 SYM F
( 0 PUNCT F
44 0 NUM F
of 0 ADP F
66 0 NUM F
) 0 PUNCT F
and 0 CCONJ F
58 0 NUM F
% 0 SYM F
( 0 PUNCT F
38 0 NUM F
of 0 ADP F
65 0 NUM F
) 0 PUNCT F
for 0 ADP F
the 0 DET F
ATL- 0 NOUN T
and 0 CCONJ F
the 0 DET F
ATP-group 0 NOUN T
, 0 PUNCT F
respectively 0 ADV F
. 0 PUNCT F

CONCLUSION 0 NOUN T
The 0 DET T
double-blind 0 ADJ F
randomized 0 VERB F
clinical 0 ADJ F
trial 0 NOUN F
did 0 PUNCT F
not 0 ADV F
identify 0 ADJ F
a 0 ADP F
simplified 0 NOUN F
, 0 PUNCT F
successful 0 ADJ F
once 0 PUNCT F
daily 0 PUNCT F
H. 0 NOUN T
pylori 0 NOUN F
treatment 0 NOUN F
for 0 ADP F
children 0 NOUN F
and 0 CCONJ F
adolescents 0 NOUN F
. 0 PUNCT F

Thus 0 ADV T
, 0 PUNCT F
twice 0 ADV F
daily 0 ADJ F
proton 0 NOUN F
pump 0 NOUN F
inhibitor 0 NOUN F
( 0 PUNCT F
PPI 0 NOUN T
) 0 PUNCT F
-based 0 ADP F
triple 0 ADJ F
therapies 0 NOUN F
for 0 ADP F
7 0 NUM F
days 0 NOUN F
remain 0 VERB F
as 0 ADP F
the 0 DET F
choice 0 NOUN F
of 0 ADP F
treatment 0 NOUN F
in 0 ADP F
children 0 NOUN F
. 0 PUNCT F

Further 0 ADV T
, 0 PUNCT F
powerful 0 ADJ F
and 0 CCONJ F
controlled 0 VERB F
studies 0 NOUN F
are 0 ADV F
needed 0 VERB F
to 0 PART F
elucidate 0 NOUN F
the 0 DET F
best 0 PUNCT F
treatment 0 NOUN F
strategies 0 NOUN F
for 0 ADP F
H. 0 NOUN T
pylori 0 NOUN F
eradication 0 NOUN F
in 0 ADP F
this 0 DET F
age 0 NOUN F
group 0 NOUN F
. 0 PUNCT F

Randomised 0 VERB T
controlled 0 VERB F
trial 0 NOUN F
of 0 ADP F
patient 0 NOUN F
triggered 0 ADP F
and 0 CCONJ F
conventional 0 ADJ F
fast 0 ADJ F
rate 0 NOUN F
ventilation 0 NOUN F
in 0 ADP F
neonatal 0 ADJ F
respiratory 0 ADJ F
distress 0 NOUN F
syndrome 0 NOUN F
. 0 PUNCT F

AIM 0 NOUN T
To 0 ADV T
compare 0 NOUN F
patient 0 NOUN F
triggered 0 ADP F
, 0 PUNCT F
with 0 ADP F
conventional 0 ADJ F
fast 0 ADJ F
rate 0 NOUN F
, 0 PUNCT F
ventilation 0 NOUN F
in 0 ADP F
a 0 DET F
randomised 0 VERB F
controlled 0 VERB F
trial 0 NOUN F
using 0 VERB F
the 0 DET F
incidence 0 NOUN F
of 0 ADP F
chronic B-PHYSICAL ADJ F
lung I-PHYSICAL NOUN F
disease I-PHYSICAL NOUN F
as 0 ADP F
the 0 DET F
primary 0 ADJ F
outcome 0 NOUN F
measure 0 NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
Three 0 NUM T
hundred 0 NUM F
and 0 CCONJ F
eighty 0 PUNCT F
six 0 PUNCT F
preterm 0 NOUN F
infants 0 NOUN F
with 0 ADP F
birthweights 0 NOUN F
from 0 ADP F
1000 0 NUM F
to 0 ADP F
2000 0 NUM F
g 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
requiring 0 PUNCT F
ventilation 0 NOUN F
for 0 ADP F
respiratory 0 ADJ F
distress 0 NOUN F
syndrome 0 NOUN F
within 0 ADP F
24 0 NUM F
hours 0 NOUN F
of 0 ADP F
birth 0 NOUN F
, 0 PUNCT F
were 0 VERB F
randomised 0 VERB F
to 0 PART F
receive 0 ADP F
either 0 PUNCT F
conventional 0 ADJ F
or 0 CCONJ F
trigger 0 PUNCT F
ventilation 0 NOUN F
with 0 ADP F
the 0 DET F
SLE 0 NOUN T
2000 0 NUM F
ventilator 0 NOUN F
. 0 PUNCT F

RESULTS 0 NOUN T
There 0 CCONJ T
were 0 VERB F
no 0 DET F
significant 0 ADJ F
differences 0 NOUN F
in 0 ADP F
the 0 DET F
incidence 0 NOUN F
of 0 ADP F
chronic B-PHYSICAL ADJ F
lung I-PHYSICAL NOUN F
disease I-PHYSICAL NOUN F
( 0 PUNCT F
28 0 NUM F
day 0 NOUN F
and 0 CCONJ F
36 0 NUM F
week 0 NOUN F
definitions 0 NOUN F
) 0 PUNCT F
, 0 PUNCT F
death B-MORTALITY NOUN F
, 0 PUNCT F
pneumothorax 0 NOUN F
, 0 PUNCT F
intraventricular 0 ADJ F
haemorrhage 0 NOUN F
, 0 PUNCT F
number B-OTHER NOUN F
of I-OTHER ADP F
ventilator I-OTHER NOUN F
days I-OTHER NOUN F
, 0 PUNCT F
or 0 PUNCT F

Interventional 0 ADJ T
study 0 NOUN F
to 0 ADP F
strengthen 0 PUNCT F
the 0 DET F
health 0 NOUN F
promoting 0 PUNCT F
behaviours 0 NOUN F
of 0 ADP F
pregnant 0 ADJ F
women 0 NOUN F
to 0 PUNCT F
prevent 0 ADJ F
anaemia 0 PUNCT F
in 0 ADP F
southern 0 PUNCT F
India 0 PUNCT T
. 0 PUNCT F

OBJECTIVES 0 NOUN T
to 0 PART F
determine 0 NOUN F
the 0 DET F
effectiveness 0 NOUN F
of 0 ADP F
a 0 DET F
health 0 NOUN F
information 0 NOUN F
package 0 NOUN F
in 0 ADP F
terms 0 NOUN F
of 0 ADP F
empowering 0 ADJ F
the 0 DET F
pregnant 0 ADJ F
women 0 NOUN F
to 0 PUNCT F
modify 0 ADJ F
their 0 ADP F
health-care 0 NOUN F
behaviour 0 NOUN F
and 0 CCONJ F
take 0 ADV F
appropriate 0 ADJ F
action 0 NOUN F
to 0 ADP F
combat 0 PUNCT F
anaemia 0 NOUN F
in 0 ADP F
pregnancy 0 NOUN F
. 0 PUNCT F

DESIGN 0 NOUN T
the 0 DET F
study 0 NOUN F
was 0 VERB F
conceptualized 0 VERB F
based 0 VERB F
on 0 ADP F
Rosenstock 0 NOUN T
and 0 CCONJ F
Becker 0 NOUN T
's 0 PUNCT F
health 0 NOUN F
belief 0 ADJ F
model 0 NOUN F
. 0 PUNCT F

A 0 DET T
quasi-experimental 0 ADJ F
pretest-posttest 0 NOUN F
control 0 NOUN F
group 0 NOUN F
design 0 NOUN F
was 0 VERB F
used 0 VERB F
. 0 PUNCT F

The 0 DET T
sample 0 NOUN F
consists 0 ADP F
of 0 ADP F
225 0 NUM F
anaemic 0 ADJ F
pregnant 0 ADJ F
women 0 NOUN F
randomly 0 ADV F
allocated 0 VERB F
in 0 ADP F
experimental 0 ADJ F
( 0 PUNCT F
n=75 0 NOUN F
) 0 PUNCT F
, 0 PUNCT F
control 0 NOUN F
group 0 NOUN F
A 0 NOUN T
( 0 PUNCT F
n=75 0 NOUN F
) 0 PUNCT F
and 0 CCONJ F
control 0 NOUN F
group 0 NOUN F
B 0 NOUN T
( 0 PUNCT F
n=75 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
health 0 NOUN F
seeking 0 PUNCT F
behaviour 0 NOUN F
outcome 0 NOUN F
measure 0 NOUN F
included 0 VERB F
knowledge 0 NOUN F
regarding 0 VERB F
anaemia 0 NOUN F
, 0 PUNCT F
food 0 NOUN F
selection 0 NOUN F
ability 0 NOUN F
, 0 PUNCT F
increase 0 CCONJ F
in 0 ADP F
haemoglobin 0 NOUN F
level 0 NOUN F
and 0 CCONJ F
compliance 0 NOUN F
to 0 ADP F
iron 0 NOUN F
supplementation 0 NOUN F
. 0 PUNCT F

Intervention 0 NOUN T
was 0 VERB F
a 0 DET F
validated 0 VERB F
planned 0 PROPN F
educational 0 ADJ F
programme 0 NOUN F
with 0 ADP F
visual 0 ADJ F
aids 0 NOUN F
and 0 CCONJ F
iron 0 NOUN F
supplementation 0 NOUN F
. 0 PUNCT F

FINDINGS 0 NOUN T
the 0 DET F
results 0 CCONJ F
show 0 VERB F
the 0 DET F
mean 0 NOUN F
gain B-OTHER NOUN F
of I-OTHER ADP F
knowledge I-OTHER NOUN F
scores 0 NOUN F
of 0 ADP F
experimental 0 ADJ F
group 0 NOUN F
was 0 VERB F
comparatively 0 ADV F
higher 0 PUNCT F
and 0 CCONJ F
control 0 NOUN F
groups 0 NOUN F
A 0 DET T
and 0 CCONJ F
B 0 NOUN T
showed 0 VERB F
that 0 ADP F
F 0 NOUN T
ratio 0 NOUN F
was 0 VERB F
( 0 PUNCT F
F 0 NOUN T
( 0 PUNCT F
2,190 0 ADP F
) 0 PUNCT F
=11.910 0 PUNCT F
, 0 PUNCT F
p 0 NOUN F
< 0 SYM F
0.01 0 NUM F
) 0 PUNCT F
indicating 0 VERB F
that 0 ADP F
the 0 DET F
pregnant 0 ADJ F
women 0 NOUN F
learned 0 VERB F
more 0 ADV F
about 0 PUNCT F
anaemia 0 NOUN F
prevention 0 NOUN F
than 0 ADP F
others 0 NOUN F
. 0 PUNCT F

With 0 ADP T
regard 0 NOUN F
to 0 ADP F
food 0 NOUN F
selection 0 NOUN F
ability 0 NOUN F
scores 0 NOUN F
of 0 ADP F
experimental 0 ADJ F
, 0 PUNCT F
control 0 NOUN F
groups 0 NOUN F
A 0 DET T
and 0 CCONJ F
B 0 NOUN T
the 0 DET F
F 0 NOUN T
ratio 0 NOUN F
was 0 VERB F
also 0 ADV F
significant 0 ADJ F
( 0 PUNCT F
F 0 NOUN T
( 0 PUNCT F
2,190 0 ADP F
) 0 PUNCT F
=20.92 0 PUNCT F
, 0 PUNCT F
p 0 NOUN F
< 0 SYM F
0.01 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Nearly 0 ADV T
61.2 0 NUM F
% 0 SYM F
of 0 ADP F
the 0 DET F
subjects 0 NOUN F
in 0 ADP F
experimental 0 ADJ F
group 0 NOUN F
became 0 ADP F
non-anaemic B-PHYSICAL ADJ F
after 0 ADP F
the 0 DET F
intervention 0 NOUN F
when 0 ADP F
compared 0 VERB F
to 0 ADP F
control 0 PUNCT F
group 0 NOUN F
A 0 NOUN T
. 0 PUNCT F

This 0 DET T
indicated 0 VERB F
that 0 ADP F
inspite 0 NOUN F
of 0 ADP F
iron 0 NOUN F
supplementation 0 NOUN F
received 0 VERB F
by 0 ADP F
the 0 DET F
three 0 NUM F
groups 0 NOUN F
health 0 NOUN F
education 0 NOUN F
contributed 0 VERB F
significantly 0 ADV F
in 0 ADP F
modifying 0 VERB F
their 0 ADP F
health 0 NOUN F
seeking 0 PUNCT F
behaviour 0 NOUN F
and 0 CCONJ F
their 0 ADJ F
perception 0 NOUN F
about 0 PUNCT F
significance 0 NOUN F
of 0 ADP F
anaemia 0 NOUN F
has 0 PUNCT F
a 0 DET F
problem 0 NOUN F
. 0 PUNCT F

CONCLUSION 0 NOUN T
developing 0 VERB F
countries 0 NOUN F
still 0 ADP F
face 0 ADP F
the 0 DET F
critical 0 ADJ F
problem 0 NOUN F
of 0 ADP F
anaemia 0 NOUN F
in 0 ADP F
pregnancy 0 NOUN F
. 0 PUNCT F

These 0 PUNCT T
are 0 ADJ F
the 0 DET F
socio-cultural 0 PUNCT F
priority 0 NOUN F
problems 0 NOUN F
that 0 PUNCT F
demand 0 ADJ F
immediate 0 ADJ F
attention 0 NOUN F
by 0 ADP F
the 0 DET F
policy 0 NOUN F
makers 0 NOUN F
and 0 CCONJ F
health 0 NOUN F
professionals 0 NOUN F
. 0 PUNCT F

The 0 DET T
national 0 ADJ F
anaemia 0 NOUN F
control 0 NOUN F
programme 0 NOUN F
focuses 0 NOUN F
on 0 ADP F
iron 0 NOUN F
supplementation 0 NOUN F
, 0 PUNCT F
but 0 CCONJ F
nutritional 0 ADJ F
education 0 NOUN F
and 0 CCONJ F
supervision 0 NOUN F
of 0 ADP F
iron 0 NOUN F
supplementation 0 NOUN F
has 0 PUNCT F
failed 0 VERB F
in 0 ADP F
different 0 ADJ F
regions 0 NOUN F
. 0 PUNCT F

The 0 DET T
study 0 NOUN F
implies 0 NOUN F
that 0 PUNCT F
economic 0 ADJ F
empowerment 0 NOUN F
; 0 PUNCT F
strengthening 0 NUM F
health 0 NOUN F
literacy 0 NOUN F
through 0 CCONJ F
planned 0 VERB F
educational 0 ADJ F
programs 0 NOUN F
will 0 ADP F
definitely 0 ADV F
improve 0 VERB F
the 0 DET F
health 0 NOUN F
behaviour 0 NOUN F
of 0 ADP F
individual 0 ADJ F
and 0 CCONJ F
community 0 NOUN F
at 0 ADP F
large 0 ADJ F
. 0 PUNCT F

Effect 0 NOUN T
of 0 ADP F
thermal 0 ADJ F
stress 0 NOUN F
, 0 PUNCT F
restricted 0 VERB F
feeding 0 PROPN F
and 0 CCONJ F
combined 0 VERB F
stresses 0 NOUN F
( 0 PUNCT F
thermal 0 ADJ F
stress 0 NOUN F
and 0 CCONJ F
restricted 0 VERB F
feeding 0 ADV F
) 0 PUNCT F
on 0 ADP F
growth 0 NOUN F
and 0 CCONJ F
plasma 0 NOUN F
reproductive 0 ADJ F
hormone 0 NOUN F
levels 0 NOUN F
of 0 ADP F
Malpura 0 PUNCT T
ewes 0 NOUN F
under 0 ADP F
semi-arid 0 ADJ F
tropical 0 ADJ F
environment 0 NOUN F
. 0 PUNCT F

A 0 DET T
study 0 NOUN F
was 0 VERB F
conducted 0 VERB F
to 0 PART F
assess 0 NOUN F
the 0 DET F
effect 0 NOUN F
of 0 ADP F
thermal 0 ADJ F
, 0 PUNCT F
nutritional 0 ADJ F
and 0 CCONJ F
combined 0 VERB F
stresses 0 NOUN F
( 0 PUNCT F
thermal 0 ADJ F
and 0 CCONJ F
nutritional 0 ADJ F
) 0 PUNCT F
on 0 ADP F
the 0 DET F
growth 0 NOUN F
, 0 PUNCT F
oestradiol 0 NOUN F
and 0 CCONJ F
progesterone 0 NOUN F
levels 0 NOUN F
during 0 ADP F
oestrus 0 NOUN F
cycles 0 NOUN F
in 0 ADP F
Malpura 0 PUNCT T
ewes 0 NOUN F
. 0 PUNCT F

Twenty-eight 0 PUNCT T
adult 0 NOUN F
Malpura 0 PUNCT T
ewes 0 NOUN F
were 0 VERB F
used 0 VERB F
in 0 ADP F
the 0 DET F
present 0 ADJ F
study 0 NOUN F
. 0 PUNCT F

The 0 DET T
ewes 0 NOUN F
were 0 VERB F
randomly 0 ADV F
allocated 0 VERB F
into 0 ADP F
four 0 NUM F
groups 0 NOUN F
, 0 PUNCT F
viz. 0 NOUN F
, 0 PUNCT F
GI 0 NOUN T
( 0 PUNCT F
n=7 0 NOUN F
; 0 PUNCT F
control 0 NOUN F
) 0 PUNCT F
, 0 PUNCT F
GII 0 NOUN T
( 0 PUNCT F
n=7 0 NOUN F
; 0 PUNCT F
thermal 0 ADJ F
stress 0 NOUN F
) 0 PUNCT F
, 0 PUNCT F
GIII 0 ADJ T
( 0 PUNCT F
n=7 0 NOUN F
; 0 PUNCT F
restricted 0 VERB F
feeding 0 ADJ F
) 0 PUNCT F
and 0 CCONJ F
GIV 0 NOUN T
( 0 PUNCT F
n=7 0 NOUN F
; 0 PUNCT F
combined 0 VERB F
stress 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
animals 0 NOUN F
were 0 VERB F
stall 0 NOUN F
fed 0 ADJ F
with 0 ADP F
a 0 DET F
diet 0 NOUN F
consisting 0 VERB F
of 0 ADP F
60 0 NUM F
% 0 ADJ F
roughage 0 NOUN F
and 0 CCONJ F
40 0 NUM F
% 0 SYM F
concentrate 0 NOUN F
. 0 PUNCT F

GI 0 NOUN T
and 0 CCONJ F
GII 0 NOUN T
ewes 0 NOUN F
were 0 VERB F
provided 0 VERB F
with 0 ADP F
ad 0 PUNCT F
libitum 0 PUNCT F
feeding 0 PUNCT F
while 0 ADP F
GIII 0 ADJ T
and 0 CCONJ F
GIV 0 ADJ T
ewes 0 NOUN F
were 0 VERB F
provided 0 VERB F
with 0 ADP F
restricted 0 VERB F
feed 0 NOUN F
( 0 PUNCT F
30 0 NUM F
% 0 SYM F
intake 0 NOUN F
of 0 ADP F
GI 0 NOUN T
and 0 CCONJ F
GII 0 NOUN T
ewes 0 NOUN F
) 0 PUNCT F
to 0 PART F
induce 0 NOUN F
nutritional 0 ADJ F
insufficiency 0 NOUN F
. 0 PUNCT F

GII 0 NOUN T
and 0 CCONJ F
GIV 0 ADJ T
ewes 0 NOUN F
were 0 VERB F
kept 0 PUNCT F
in 0 ADP F
climatic 0 ADJ F
chamber 0 NOUN F
at 0 ADP F
40?C 0 NOUN F
and 0 CCONJ F
55 0 NUM F
% 0 SYM F
RH 0 NOUN T
for 0 ADP F
6 0 NUM F
h 0 NOUN F
a 0 DET F
day 0 NOUN F
between 0 ADP F
10:00 0 NOUN F
and 0 CCONJ F
16:00 0 NOUN F
hours 0 NOUN F
to 0 PART F
induce 0 NOUN F
thermal 0 ADJ F
stress 0 NOUN F
for 0 ADP F
a 0 DET F
period 0 NOUN F
of 0 ADP F
two 0 NUM F
oestrous 0 ADJ F
cycles 0 NOUN F
. 0 PUNCT F

Parameters 0 NOUN T
studied 0 VERB F
were 0 VERB F
body 0 NOUN F
weight 0 NOUN F
, 0 PUNCT F
oestrus 0 NOUN F
incidences 0 NOUN F
, 0 PUNCT F
plasma 0 NOUN F
oestradiol 0 NOUN F
17-? 0 NOUN F
, 0 PUNCT F
plasma 0 NOUN F
progesterone 0 NOUN F
, 0 PUNCT F
conception 0 NOUN F
rate 0 NOUN F
, 0 PUNCT F
gestation 0 NOUN F
period 0 NOUN F
, 0 PUNCT F
lambing 0 ADP F
rate 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
birth 0 NOUN F
weight 0 NOUN F
of 0 ADP F
lambs 0 NOUN F
. 0 PUNCT F

The 0 DET T
results 0 ADV F
indicate 0 VERB F
that 0 ADP F
combined 0 VERB F
stress 0 NOUN F
significantly 0 ADV F
( 0 PUNCT F
p 0 NOUN F
< 0 SYM F
0.05 0 NUM F
) 0 PUNCT F
reduced 0 VERB F
body B-PHYSICAL NOUN F
weight 0 NOUN F
, 0 PUNCT F
oestrus B-PHYSICAL NOUN F
duration I-PHYSICAL NOUN F
, 0 PUNCT F
birth B-PHYSICAL NOUN F
weight 0 NOUN F
of B-PHYSICAL PUNCT F

Erythrocyte B-PHYSICAL NOUN T
deformability I-PHYSICAL NOUN F
, 0 PUNCT F
endothelin B-PHYSICAL NOUN F
levels I-PHYSICAL NOUN F
, 0 PUNCT F
and 0 CCONJ F
renal B-PHYSICAL ADJ F
function I-PHYSICAL NOUN F
in 0 ADP F
cyclosporin-treated 0 VERB F
renal 0 ADJ F
transplant 0 NOUN F
recipients 0 NOUN F
: 0 PUNCT F
effects 0 NOUN F
of 0 ADP F
intervention 0 NOUN F
with 0 ADP F
fish 0 NOUN F
oil 0 NOUN F
and 0 CCONJ F
corn 0 NOUN F
oil 0 NOUN F
. 0 PUNCT F

Twenty 0 NUM T
nine 0 NUM F
stable 0 ADJ F
renal 0 ADJ F
transplant 0 NOUN F
recipients 0 NOUN F
, 0 PUNCT F
10 0 NUM F
receiving 0 VERB F
cyclosporin 0 NOUN F
, 0 PUNCT F
10 0 NUM F
cyclosporin-prednisolone 0 NOUN F
and 0 CCONJ F
nine 0 NUM F
azathioprine-prednisolone 0 NOUN F
were 0 VERB F
supplemented 0 VERB F
in 0 ADP F
a 0 DET F
double 0 ADJ F
blind 0 ADP F
randomization 0 NOUN F
cross-over 0 NOUN F
study 0 CCONJ F
with 0 ADP F
fish 0 NOUN F
oil 0 NOUN F
and 0 CCONJ F
corn 0 NOUN F
oil 0 NOUN F
for 0 ADP F
a 0 DET F
period 0 NOUN F
of 0 ADP F
4 0 NUM F
months 0 NOUN F
each 0 DET F
. 0 PUNCT F

Erythrocyte B-PHYSICAL NOUN T
deformability I-PHYSICAL NOUN F
was 0 VERB F
reduced 0 VERB F
in 0 ADP F
the 0 DET F
cyclosporin-treated 0 VERB F
patients 0 NOUN F
and 0 CCONJ F
returned 0 VERB F
to 0 ADP F
normal 0 ADJ F
values 0 NOUN F
after 0 ADP F
supplementation 0 NOUN F
of 0 ADP F
either 0 CCONJ F
oil 0 NOUN F
. 0 PUNCT F

The 0 DET T
oil 0 NOUN F
supplementation 0 NOUN F
resulted 0 VERB F
in 0 ADP F
an 0 DET F
increased 0 VERB F
polyunsaturated B-PHYSICAL VERB F
fatty I-PHYSICAL ADJ F
acid I-PHYSICAL NOUN F
content I-PHYSICAL NOUN F
in 0 ADP F
the 0 DET F
plasma 0 NOUN F
phospholipids 0 NOUN F
. 0 PUNCT F

An 0 DET T
increased 0 VERB F
erythrocyte 0 NOUN F
membrane 0 NOUN F
polyunsaturated 0 VERB F
fatty 0 ADJ F
acid 0 NOUN F
content 0 NOUN F
might 0 VERB F
correct 0 PUNCT F
the 0 DET F
lower 0 PUNCT F
erythrocyte 0 NOUN F
deformability 0 NOUN F
in 0 ADP F
cyclosporin 0 NOUN F
treated 0 VERB F
patients 0 NOUN F
. 0 PUNCT F

Therefore 0 ADV T
, 0 PUNCT F
it 0 PRON F
is 0 VERB F
probable 0 ADJ F
that 0 ADP F
these 0 DET F
changes 0 NOUN F
are 0 VERB F
membrane-related 0 PROPN F
. 0 PUNCT F

The 0 DET T
oil 0 NOUN F
supplementation 0 NOUN F
had 0 PUNCT F
no 0 DET F
effect 0 NOUN F
on 0 ADP F
glomerular B-PHYSICAL ADJ F
filtration I-PHYSICAL NOUN F
rate I-PHYSICAL NOUN F
, 0 PUNCT F
effective B-PHYSICAL ADJ F
renal I-PHYSICAL ADJ F
plasma I-PHYSICAL NOUN F
flow I-PHYSICAL NOUN F
, 0 PUNCT F
filtration B-PHYSICAL NOUN F
fraction I-PHYSICAL NOUN F
or 0 CCONJ F
blood B-PHYSICAL NOUN F
pressure I-PHYSICAL NOUN F
, 0 PUNCT F
which 0 DET F
does 0 PUNCT F
not 0 ADV F
exclude 0 DET F
effects 0 NOUN F
of 0 ADP F
the 0 DET F
cyclosporin-induced 0 ADP F
rigidified 0 VERB F
erythrocytes 0 NOUN F
in 0 ADP F
the 0 DET F
acute 0 ADJ F
phase 0 NOUN F
of 0 ADP F
renal 0 ADJ F
transplantation 0 NOUN F
. 0 PUNCT F

Decreased 0 VERB T
erythrocyte B-PHYSICAL NOUN F
deformability I-PHYSICAL NOUN F
could 0 VERB F
play 0 VERB F
a 0 DET F
role 0 NOUN F
in 0 ADP F
the 0 DET F
cyclosporin-induced 0 VERB F
deterioration 0 NOUN F
of 0 ADP F
renal 0 ADJ F
haemodynamics 0 NOUN F
. 0 PUNCT F

This 0 PUNCT T
may 0 VERB F
enhance 0 VERB F
the 0 DET F
effects 0 NOUN F
of 0 ADP F
endothelin 0 NOUN F
, 0 PUNCT F
as 0 ADP F
these 0 DET F
patients 0 NOUN F
also 0 ADV F
had 0 PUNCT F
elevated 0 VERB F
endothelin 0 NOUN F
levels 0 NOUN F
. 0 PUNCT F

The 0 DET T
impact 0 NOUN F
of 0 ADP F
fasting 0 ADV F
and 0 CCONJ F
treatment 0 NOUN F
omission 0 NOUN F
on 0 ADP F
susceptibility B-PHYSICAL NOUN F
to I-PHYSICAL ADP F
hypoglycaemia I-PHYSICAL NOUN F
in 0 ADP F
children 0 NOUN F
and 0 CCONJ F
adolescents 0 NOUN F
with 0 ADP F
GH 0 NOUN T
and 0 CCONJ F
cortisol 0 NOUN F
insufficiency 0 NOUN F
. 0 PUNCT F

OBJECTIVE 0 NOUN T
Hypoglycaemia 0 NOUN T
may 0 ADP F
be 0 ADJ F
a 0 DET F
frequent 0 ADJ F
occurrence 0 NOUN F
in 0 ADP F
young 0 ADJ F
GH 0 NOUN T
deficient 0 ADJ F
patients 0 NOUN F
and 0 CCONJ F
so 0 ADP F
we 0 ADP F
studied 0 VERB F
the 0 DET F
response 0 NOUN F
to 0 ADP F
fasting 0 PUNCT F
in 0 ADP F
children 0 NOUN F
and 0 CCONJ F
adolescents 0 NOUN F
with 0 ADP F
GH 0 NOUN T
and/or 0 CCONJ F
cortisol 0 NOUN F
deficiency 0 NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
A 0 PUNCT T
total 0 NOUN F
of 0 ADP F
20 0 NUM F
patients 0 NOUN F
( 0 PUNCT F
2-18 0 NUM F
years 0 NOUN F
) 0 PUNCT F
fasted 0 VERB F
for 0 ADP F
14 0 NUM F
h 0 NOUN F
( 0 PUNCT F
22.00-12.00 0 PUNCT F
h 0 NOUN F
) 0 PUNCT F
on 0 ADP F
two 0 NUM F
occasions 0 NOUN F
as 0 ADP F
part 0 NOUN F
of 0 ADP F
a 0 DET F
randomized 0 VERB F
cross-over 0 NOUN F
study 0 NOUN F
. 0 PUNCT F

Fourteen 0 NUM T
had 0 PUNCT F
pituitary 0 NOUN F
hormone 0 NOUN F
deficiency 0 NOUN F
( 0 PUNCT F
PHD 0 NOUN T
) 0 PUNCT F
including 0 VERB F
GH 0 NOUN T
deficiency 0 NOUN F
( 0 PUNCT F
GHD 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

Of 0 ADP T
the 0 DET F
14 0 NUM F
patients 0 NOUN F
, 0 PUNCT F
seven 0 NUM F
were 0 VERB F
ACTH 0 NOUN T
sufficient 0 ADJ F
( 0 PUNCT F
PHDC+ 0 NOUN T
) 0 PUNCT F
and 0 CCONJ F
seven 0 NUM F
ACTH 0 NOUN T
deficient 0 ADJ F
( 0 PUNCT F
PHDC- 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

Six 0 NUM T
had 0 VERB F
primary 0 ADJ F
adrenal 0 ADJ F
failure 0 NOUN F
( 0 PUNCT F
PAF 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

Subjects 0 NOUN T
administered 0 ADP F
or 0 CCONJ F
omitted 0 PUNCT F
their 0 PUNCT F
normal 0 ADJ F
dose 0 NOUN F
of 0 ADP F
evening 0 PUNCT F
GH 0 NOUN T
and/or 0 CCONJ F
morning 0 NOUN F
hydrocortisone 0 NOUN F
. 0 PUNCT F

Glucose B-PHYSICAL NOUN T
, 0 PUNCT F
insulin B-PHYSICAL NOUN F
, 0 PUNCT F
GH B-PHYSICAL NOUN T
, 0 PUNCT F
cortisol B-PHYSICAL NOUN F
, 0 PUNCT F
ketones B-PHYSICAL NOUN F
and 0 CCONJ F
catecholamines B-PHYSICAL NOUN F
were 0 VERB F
measured 0 VERB F
at 0 ADP F
04.00 0 NUM F
h 0 NOUN F
and 0 CCONJ F
regularly 0 ADV F
from 0 ADP F
07.00 0 NUM F
to 0 ADP F
12.00 0 NUM F
h. 0 NOUN F
Insulin B-PHYSICAL NOUN T
sensitivity I-PHYSICAL NOUN F
was 0 VERB F
assessed 0 VERB F
by 0 ADP F
HOMA B-OTHER NOUN T
and 0 CCONJ F
hypoglycaemia B-PHYSICAL NOUN F
defined 0 PUNCT F
as 0 ADP F
a 0 DET F
blood B-PHYSICAL NOUN F
glucose I-PHYSICAL NOUN F
( 0 PUNCT F
BG 0 NOUN T
) 0 PUNCT F
< 0 SYM F
/= 0 NUM F
3.3 0 NUM F
mmol/l 0 NOUN F
. 0 PUNCT F

RESULTS 0 NOUN T
BG 0 NOUN T
was 0 VERB F
related 0 VERB F
to 0 ADP F
age 0 NOUN F
and 0 CCONJ F
body B-PHYSICAL NOUN F
mass I-PHYSICAL NOUN F
index I-PHYSICAL NOUN F
on 0 ADP F
treatment 0 NOUN F
but 0 CCONJ F
no 0 DET F
subject 0 NOUN F
became 0 ADP F
hypoglycaemic 0 ADJ F
on 0 ADP F
or 0 CCONJ F
off 0 ADP F
therapy 0 NOUN F
prior 0 PUNCT F
to 0 ADP F
07.00 0 NUM F
h. 0 NOUN F
Five 0 NUM T
children 0 NOUN F
( 0 PUNCT F
aged 0 DET F
3 0 NUM F
, 0 PUNCT F
4 0 NUM F
, 0 PUNCT F
7 0 NUM F
, 0 PUNCT F
8 0 NUM F
and 0 CCONJ F
11 0 NUM F
years 0 NOUN F
) 0 PUNCT F
were 0 VERB F
hypoglycaemic B-PHYSICAL ADJ F
between 0 ADP F
07.00 0 NUM F
and 0 CCONJ F
12.00 0 NUM F
h 0 NOUN F
off 0 ADP F
treatment 0 NOUN F
. 0 PUNCT F

There 0 PUNCT T
was 0 VERB F
a 0 DET F
positive 0 ADJ F
relationship 0 NOUN F
between 0 ADP F
GH B-PHYSICAL NOUN T
AUC I-PHYSICAL NOUN T
and 0 CCONJ F
minimum B-PHYSICAL NOUN F
BG I-PHYSICAL NOUN T
in 0 ADP F
patients 0 NOUN F
with 0 ADP F
PHD 0 NOUN T
on 0 ADP F
treatment 0 NOUN F
( 0 PUNCT F
r 0 NOUN F
( 0 PUNCT F
2 0 NUM F
) 0 PUNCT F
= 0 SYM F
0.45 0 NUM F
, 0 PUNCT F
P 0 NOUN T
= 0 SYM F
0.012 0 NUM F
) 0 PUNCT F
with 0 ADP F
increased 0 VERB F
insulin B-PHYSICAL NOUN F
sensitivity I-PHYSICAL NOUN F
off 0 ADP F
treatment 0 NOUN F
. 0 PUNCT F

Increased 0 VERB T
cortisol B-PHYSICAL NOUN F
levels I-PHYSICAL NOUN F
were 0 VERB F
seen 0 VERB F
in 0 ADP F
PHDC+ 0 NOUN T
patients 0 NOUN F
off 0 ADP F
GH 0 NOUN T
( 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.001 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

A 0 DET T
negative 0 ADJ F
relationship 0 NOUN F
was 0 VERB F
observed 0 VERB F
between 0 ADP F
minimum 0 NOUN F
BG B-PHYSICAL NOUN T
and 0 CCONJ F
adrenaline B-PHYSICAL ADJ F
( 0 PUNCT F
r 0 NOUN F
( 0 PUNCT F
2 0 NUM F
) 0 PUNCT F
= 0 ADP F
0.37 0 NUM F
, 0 PUNCT F
P 0 NOUN T
= 0 SYM F
0.01 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
ketone B-PHYSICAL NOUN F
bodies I-PHYSICAL NOUN F
( 0 PUNCT F
r 0 NOUN F
( 0 PUNCT F
2 0 NUM F
) 0 PUNCT F
= 0 ADP F
-0.20 0 PUNCT F
, 0 PUNCT F
P 0 NOUN T
= 0 SYM F
0.05 0 NUM F
) 0 PUNCT F
and 0 CCONJ F
NEFA B-PHYSICAL NOUN T
( 0 PUNCT F
r 0 NOUN F
( 0 PUNCT F
2 0 NUM F
) 0 PUNCT F
= 0 ADP F
-0.35 0 NUM F
, 0 PUNCT F
P 0 NOUN T
= 0 SYM F
0.02 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Noradrenaline B-PHYSICAL NOUN T
levels I-PHYSICAL NOUN F
were 0 VERB F
reduced 0 VERB F
in 0 ADP F
patients 0 NOUN F
with 0 ADP F
PHDC- 0 NOUN T
. 0 PUNCT F

Low 0 ADJ T
BMI 0 NOUN T
( 0 PUNCT F
on 0 ADP F
treatment 0 NOUN F
) 0 PUNCT F
and 0 CCONJ F
young 0 ADJ F
age 0 NOUN F
( 0 PUNCT F
off 0 ADP F
treatment 0 NOUN F
) 0 PUNCT F
were 0 DET F
determinants 0 NOUN F
of 0 ADP F
low B-PHYSICAL ADJ F
BG I-PHYSICAL NOUN T
levels I-PHYSICAL NOUN F
in 0 ADP F
a 0 DET F
multiple 0 ADJ F
regression 0 NOUN F
model 0 NOUN F
. 0 PUNCT F

CONCLUSIONS 0 NOUN T
Unrecognized 0 ADJ T
overnight 0 PROPN F
hypoglycaemia 0 NOUN F
in 0 ADP F
children 0 NOUN F
and 0 CCONJ F
adolescents 0 NOUN F
on 0 ADP F
pituitary 0 NOUN F
hormone 0 NOUN F
replacement 0 NOUN F
is 0 NUM F
uncommon 0 ADJ F
but 0 CCONJ F
BG B-PHYSICAL NOUN T
levels I-PHYSICAL NOUN F
quickly 0 PROPN F
become 0 ADP F
abnormal 0 ADJ F
when 0 ADP F
treatment 0 NOUN F
and 0 CCONJ F
meals 0 NOUN F
are 0 VERB F
omitted 0 VERB F
. 0 PUNCT F

The 0 DET T
insulin B-PHYSICAL NOUN F
antagonistic I-PHYSICAL ADJ F
actions I-PHYSICAL NOUN F
of I-PHYSICAL ADP F
GH I-PHYSICAL NOUN T
are 0 VERB F
important 0 ADJ F
in 0 ADP F
preventing 0 VERB F
hypoglycaemia 0 NOUN F
. 0 PUNCT F

Patients 0 NOUN T
with 0 ADP F
PHD 0 NOUN T
have 0 PUNCT F
altered 0 VERB F
sympathetic B-PHYSICAL ADJ F
nerve I-PHYSICAL NOUN F
activity I-PHYSICAL NOUN F
. 0 PUNCT F

Quantifications 0 NOUN T
of 0 ADP F
the 0 DET F
major 0 ADJ F
urinary B-PHYSICAL ADJ F
metabolite I-PHYSICAL NOUN F
of I-PHYSICAL ADP F
the I-PHYSICAL DET F
E I-PHYSICAL NOUN T
prostaglandins I-PHYSICAL NOUN F
by 0 ADP F
mass 0 NOUN F
spectrometry 0 NOUN F
: 0 PUNCT F
evaluation 0 NOUN F
of 0 ADP F
the 0 DET F
method 0 NOUN F
's 0 PUNCT F
application 0 NOUN F
to 0 ADP F
clinical 0 ADJ F
studies 0 NOUN F
. 0 PUNCT F

Measurement 0 NOUN T
of 0 ADP F
7alpha-hydroxy-5,11-diketotetranoprostane-1,16-dioic 0 ADJ F
acid 0 NOUN F
, 0 PUNCT F
( 0 PUNCT F
PGE-M 0 NOUN T
) 0 PUNCT F
, 0 PUNCT F
the 0 DET F
major 0 ADJ F
urinary 0 ADJ F
metabolite 0 NOUN F
of 0 ADP F
prostaglandin 0 NOUN F
E1 0 NOUN T
and 0 CCONJ F
E2 0 NOUN T
in 0 ADP F
man 0 NOUN F
provides 0 NOUN F
a 0 DET F
useful 0 ADJ F
indicator 0 NOUN F
to 0 ADP F
monitor 0 NOUN F
prostaglandin 0 NOUN F
biosynthesis 0 NOUN F
. 0 PUNCT F

For 0 ADP T
quantitative 0 ADJ F
analysis 0 NOUN F
of 0 ADP F
this 0 DET F
prostaglandin 0 NOUN F
metabolite 0 NOUN F
and 0 CCONJ F
the 0 DET F
stable-isotope 0 PUNCT F
dilution 0 NOUN F
techniqe 0 NOUN F
of 0 ADP F
selected 0 VERB F
ion 0 NOUN F
monitoring 0 VERB F
( 0 PUNCT F
SIM 0 NOUN T
) 0 PUNCT F
is 0 VERB F
employed 0 VERB F
using 0 VERB F
gas-liquid 0 NOUN F
chromatography-mass 0 NOUN F
spectrometry 0 NOUN F
. 0 PUNCT F

The 0 DET T
preparation 0 NOUN F
of 0 ADP F
the 0 DET F
bis 0 ADJ F
( 0 PUNCT F
D3-methyloxime 0 NOUN T
) 0 PUNCT F
, 0 PUNCT F
bis-methyl 0 ADP F
ester 0 NOUN F
of 0 ADP F
PGE-M 0 NOUN T
containing 0 VERB F
a 0 DET F
tritium 0 NOUN F
tracer 0 NOUN F
in 0 ADP F
position 0 NOUN F
2 0 NUM F
which 0 ADP F
was 0 VERB F
used 0 VERB F
as 0 ADP F
internal 0 ADJ F
standard 0 NOUN F
for 0 ADP F
the 0 DET F
SIM 0 NOUN T
method 0 NOUN F
is 0 VERB F
described 0 VERB F
. 0 PUNCT F

The 0 DET T
synthesis 0 NOUN F
of 0 ADP F
this 0 DET F
internal 0 ADJ F
standard 0 PUNCT F
includes 0 ADJ F
the 0 DET F
biosynthetic 0 ADJ F
conversion 0 NOUN F
of 0 ADP F
11-hydroxy-9,15-diketoprostanoic 0 PUNCT F
acid 0 NOUN F
to 0 ADP F
PGE-M 0 NOUN T
by 0 ADP F
the 0 DET F
rabbit 0 NOUN F
. 0 PUNCT F

The 0 DET T
intra-assay 0 NOUN F
coefficient 0 NOUN F
of 0 ADP F
variation 0 NOUN F
of 0 ADP F
this 0 DET F
SIM 0 NOUN T
method 0 NOUN F
ranged 0 VERB F
between 0 ADP F
4.0 0 NUM F
to 0 ADP F
6.7 0 NUM F
percent 0 NOUN F
. 0 PUNCT F

The 0 DET T
recovery 0 NOUN F
of 0 ADP F
authentic 0 ADJ F
, 0 PUNCT F
underivatized 0 VERB F
PGE-M 0 NOUN T
added 0 VERB F
to 0 ADP F
urine 0 NOUN F
was 0 VERB F
93 0 NUM F
+/- 0 SYM F
3 0 NUM F
% 0 SYM F
( 0 PUNCT F
mean 0 NOUN F
+/- 0 SYM F
SEM 0 NOUN T
, 0 PUNCT F
n=17 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
levels B-PHYSICAL NOUN F
of I-PHYSICAL ADP F
PGE-M I-PHYSICAL NOUN T
excreted I-PHYSICAL ADJ F
in 0 ADP F
urine 0 NOUN F
were 0 VERB F
higher 0 PUNCT F
( 0 PUNCT F
p 0 NOUN F
less 0 ADV F
than 0 PUNCT F
0.001 0 NUM F
) 0 PUNCT F
in 0 ADP F
males 0 ADJ F
than 0 PUNCT F
in 0 ADP F
females 0 NOUN F
( 0 PUNCT F
15.2 0 NUM F
+/- 0 SYM F
1.9 0 ADJ F
mug/24 0 PUNCT F
hours 0 NOUN F
( 0 PUNCT F
n=24 0 NOUN F
) 0 PUNCT F
and 0 CCONJ F
3.3 0 NUM F
+/- 0 SYM F
0.3 0 NUM F
mug/24 0 PUNCT F
hours 0 NOUN F
( 0 PUNCT F
n=17 0 NOUN F
) 0 PUNCT F
, 0 PUNCT F
respectively 0 ADV F
. 0 PUNCT F

These 0 DET T
levels 0 NOUN F
were 0 VERB F
in 0 ADP F
close 0 ADJ F
agreement 0 NOUN F
with 0 ADP F
values 0 NOUN F
published 0 VERB F
previously 0 ADV F
. 0 PUNCT F

No 0 DET T
significant 0 ADJ F
difference 0 NOUN F
in 0 ADP F
excretion 0 NOUN F
of 0 ADP F
PGE-M 0 NOUN T
between 0 ADP F
the 0 DET F
sexes 0 NOUN F
was 0 VERB F
observed 0 VERB F
in 0 ADP F
the 0 DET F
pre-pubertal 0 ADJ F
age-grou 0 ADJ F
( 0 PUNCT F
male 0 NOUN F
: 0 PUNCT F
2.9 0 NUM F
+/- 0 SYM F
0.8 0 NUM F
mug/24 0 PUNCT F
hours 0 NOUN F
, 0 PUNCT F
n=5 0 NOUN F
; 0 PUNCT F
female 0 NOUN F
: 0 PUNCT F
3.1 0 NUM F
+/- 0 SYM F
0.9 0 NUM F
mug/24 0 PUNCT F
hours 0 NOUN F
, 0 PUNCT F
n=5 0 NOUN F
) 0 PUNCT F
or 0 CCONJ F
in 0 ADP F
the 0 DET F
age-group 0 NOUN F
of 0 ADP F
45-80 0 NUM F
years 0 NOUN F
( 0 PUNCT F
male 0 NOUN F
: 0 PUNCT F
9.3 0 NUM F
+/- 0 SYM F
1.1 0 ADJ F
mug/24 0 PUNCT F
hours 0 NOUN F
, 0 PUNCT F
n=21 0 NOUN F
; 0 PUNCT F
female 0 NOUN F
: 0 PUNCT F
7.3 0 NUM F
+/- 0 SYM F
0.9 0 NUM F
mug/24 0 PUNCT F
hours 0 NOUN F
, 0 PUNCT F
n=12 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
amount 0 NOUN F
of 0 ADP F
PGE-M 0 NOUN T
excreted 0 ADP F
decreased 0 VERB F
significantly 0 ADV F
after 0 ADP F
administration 0 NOUN F
of 0 ADP F
indomethacin 0 NOUN F
or 0 CCONJ F
acetyl 0 NOUN F
salicylic 0 ADJ F
acid 0 NOUN F
in 0 ADP F
therapeutic 0 ADJ F
doses 0 NOUN F
. 0 PUNCT F

The 0 DET T
concomitant 0 ADJ F
reduction 0 NOUN F
of 0 ADP F
the 0 DET F
urinary 0 ADJ F
excretion 0 NOUN F
of 0 ADP F
PGE-M 0 NOUN T
( 0 PUNCT F
68 0 NUM F
to 0 ADP F
85 0 NUM F
% 0 ADV F
decrease 0 NOUN F
) 0 PUNCT F
and 0 CCONJ F
prostaglandin 0 NOUN F
E 0 NOUN T
( 0 PUNCT F
73 0 NUM F
to 0 ADP F
100 0 NUM F
% 0 SYM F
decrease 0 NOUN F
) 0 PUNCT F
after 0 ADP F
indomethacin 0 NOUN F
treatment 0 NOUN F
in 0 ADP F
each 0 DET F
case 0 NOUN F
( 0 PUNCT F
n=8 0 NOUN F
) 0 PUNCT F
is 0 VERB F
evidence 0 NOUN F
that 0 ADP F
a 0 DET F
diminished 0 VERB F
urinary 0 ADJ F
PGE-M 0 NOUN T
output 0 NOUN F
reflects 0 NOUN F
a 0 DET F
decrease 0 NOUN F
in 0 ADP F
prostaglandin 0 NOUN F
E 0 NOUN T
biosynthesis 0 NOUN F
. 0 PUNCT F

Increasing 0 ADP T
verbal 0 ADJ F
responsiveness 0 NOUN F
in 0 ADP F
parents 0 NOUN F
of 0 ADP F
children 0 NOUN F
with 0 ADP F
autism 0 NOUN F
: 0 PUNCT F
a 0 DET F
pilot 0 NOUN F
study 0 NOUN F
. 0 PUNCT F

Correlational 0 ADJ T
studies 0 NOUN F
have 0 ADP F
revealed 0 VERB F
a 0 DET F
positive 0 ADJ F
relationship 0 NOUN F
between 0 ADP F
parent 0 NOUN F
verbal 0 ADJ F
responsiveness 0 NOUN F
and 0 CCONJ F
language 0 NOUN F
outcomes 0 NOUN F
in 0 ADP F
children 0 NOUN F
with 0 ADP F
autism 0 NOUN F
. 0 PUNCT F

We 0 PRON T
investigated 0 VERB F
whether 0 ADP F
parents 0 NOUN F
of 0 ADP F
young 0 ADJ F
children 0 NOUN F
on 0 ADP F
the 0 DET F
autism 0 NOUN F
spectrum 0 NOUN F
could 0 PUNCT F
learn 0 VERB F
and 0 CCONJ F
implement 0 PUNCT F
the 0 DET F
specific 0 ADJ F
categories 0 NOUN F
of 0 ADP F
verbal 0 ADJ F
responsiveness 0 NOUN F
that 0 PUNCT F
have 0 ADP F
been 0 PUNCT F
suggested 0 VERB F
to 0 PART F
facilitate 0 NOUN F
language 0 NOUN F
development 0 NOUN F
. 0 PUNCT F

Parents 0 NOUN T
were 0 VERB F
taught 0 NOUN F
to 0 ADP F
increase 0 NOUN F
their 0 PUNCT F
verbal 0 ADJ F
responsiveness 0 NOUN F
in 0 ADP F
the 0 DET F
context 0 NOUN F
of 0 ADP F
a 0 DET F
short-term 0 NOUN F
language 0 NOUN F
intervention 0 NOUN F
that 0 PUNCT F
included 0 DET F
group 0 NOUN F
parent 0 NOUN F
education 0 NOUN F
sessions 0 NOUN F
, 0 PUNCT F
as 0 CCONJ F
well 0 PUNCT F
as 0 CCONJ F
individual 0 PUNCT F
and 0 CCONJ F
small-group 0 NOUN F
coaching 0 NUM F
sessions 0 NOUN F
of 0 ADP F
parent-child 0 NOUN F
play 0 NOUN F
interactions 0 NOUN F
. 0 PUNCT F

Parents 0 NOUN T
in 0 ADP F
the 0 DET F
treatment 0 NOUN F
group 0 NOUN F
increased 0 VERB F
their 0 PUNCT F
use 0 NOUN F
of 0 ADP F
comments 0 ADJ F
that 0 ADP F
: 0 PUNCT F
described 0 DET F
their 0 PUNCT F
child B-MENTAL NOUN F
's 0 PUNCT F
focus B-MENTAL NOUN F
of I-MENTAL ADP F
attention I-MENTAL NOUN F
; 0 PUNCT F
interpreted 0 DET F
or 0 CCONJ F
expanded 0 VERB F
child B-MENTAL NOUN F
communication I-MENTAL NOUN F
acts I-MENTAL NOUN F
; 0 PUNCT F
and 0 CCONJ F
prompted 0 PUNCT F
child B-MENTAL NOUN F
communication I-MENTAL NOUN F
. 0 PUNCT F

Preliminary 0 ADJ T
treatment 0 NOUN F
effects 0 NOUN F
were 0 VERB F
also 0 ADV F
noted 0 NUM F
in 0 ADP F
children B-MENTAL NOUN F
's 0 PUNCT F
prompted B-MENTAL VERB F
and 0 CCONJ F
spontaneous B-MENTAL ADJ F
communication I-MENTAL NOUN F
. 0 PUNCT F

These 0 DET T
results 0 NOUN F
support 0 VERB F
the 0 DET F
use 0 NOUN F
of 0 ADP F
parent-mediated 0 NOUN F
interventions 0 NOUN F
targeting 0 VERB F
verbal B-MENTAL ADJ F
responsiveness I-MENTAL NOUN F
to 0 PART F
facilitate 0 ADP F
language B-MENTAL NOUN F
development I-MENTAL NOUN F
and 0 CCONJ F
communication B-MENTAL NOUN F
in 0 ADP F
young 0 ADJ F
children 0 NOUN F
with 0 ADP F
autism 0 NOUN F
. 0 PUNCT F

Prospective 0 ADJ T
comparison 0 NOUN F
of 0 ADP F
the 0 DET F
value 0 NOUN F
of 0 ADP F
brushings 0 NOUN F
before 0 ADP F
and 0 CCONJ F
after 0 ADP F
biopsy 0 NOUN F
in 0 ADP F
the 0 DET F
endoscopic 0 ADJ F
diagnosis 0 NOUN F
of 0 ADP F
gastroesophageal 0 ADJ F
malignancy 0 NOUN F
. 0 PUNCT F

The 0 DET T
hypothesis 0 NOUN F
that 0 ADP F
the 0 DET F
cytodiagnostic 0 ADJ F
results 0 CCONJ F
on 0 ADP F
endoscopic 0 ADJ F
brushings 0 NOUN F
obtained 0 VERB F
before 0 ADP F
biopsy 0 NOUN F
may 0 VERB F
be 0 VERB F
superior 0 ADJ F
to 0 ADP F
those 0 PUNCT F
brushings 0 NOUN F
obtained 0 VERB F
after 0 ADP F
biopsy 0 NOUN F
, 0 PUNCT F
but 0 CCONJ F
with 0 ADP F
the 0 DET F
accuracy 0 NOUN F
of 0 ADP F
the 0 DET F
subsequent 0 ADJ F
biopsy 0 NOUN F
reduced 0 VERB F
, 0 PUNCT F
was 0 VERB F
examined 0 VERB F
for 0 ADP F
300 0 NUM F
consecutive 0 ADJ F
patients 0 NOUN F
, 0 PUNCT F
including 0 VERB F
256 0 NUM F
with 0 ADP F
esophageal 0 ADJ F
or 0 CCONJ F
gastric 0 ADJ F
carcinomas 0 NOUN F
. 0 PUNCT F

Following 0 ADP T
stratification 0 NOUN F
by 0 ADP F
site 0 NOUN F
and 0 CCONJ F
endoscopic 0 ADJ F
appearance 0 NOUN F
of 0 ADP F
their 0 DET F
lesions 0 NOUN F
, 0 PUNCT F
the 0 DET F
patients 0 NOUN F
were 0 VERB F
randomized 0 VERB F
to 0 PUNCT F
undergo 0 NOUN F
brushing 0 PUNCT F
either 0 PUNCT F
before 0 ADP F
or 0 CCONJ F
after 0 ADP F
forceps 0 NOUN F
biopsy 0 NOUN F
. 0 PUNCT F

The 0 DET T
accuracy 0 NOUN F
of 0 ADP F
brushing B-OTHER PUNCT F
cytology I-OTHER NOUN F
in 0 ADP F
patients 0 NOUN F
with 0 ADP F
carcinoma B-PHYSICAL NOUN F
was 0 VERB F
significantly 0 ADV F
higher 0 PUNCT F
when 0 ADP F
the 0 DET F
brushing B-OTHER PUNCT F
was 0 VERB F
performed 0 VERB F
before 0 ADP F
biopsy 0 NOUN F
than 0 PUNCT F
after 0 ADP F
biopsy 0 NOUN F
( 0 PUNCT F
93.5 0 NUM F
% 0 SYM F
versus 0 CCONJ F
82.6 0 NUM F
% 0 SYM F
; 0 PUNCT F
P 0 NOUN T
less 0 ADV F
than 0 ADP F
.01 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
diagnostic B-OTHER ADJ F
yield I-OTHER NOUN F
of 0 ADP F
the 0 DET F
biopsy B-OTHER NOUN F
was 0 VERB F
not 0 ADV F
significantly 0 ADV F
different 0 ADJ F
whether 0 ADP F
the 0 DET F
lesions 0 NOUN F
were 0 VERB F
brushed 0 PROPN F
before 0 ADP F
or 0 CCONJ F
after 0 ADP F
the 0 DET F
biopsy 0 NOUN F
( 0 PUNCT F
92.7 0 NUM F
% 0 SYM F
versus 0 CCONJ F
93.2 0 NUM F
% 0 SYM F
; 0 PUNCT F
P 0 NOUN T
less 0 ADV F
than 0 PUNCT F
.5 0 PUNCT F
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
diagnostic B-OTHER ADJ F
superiority I-OTHER NOUN F
of 0 ADP F
brushings B-OTHER NOUN F
obtained 0 VERB F
before 0 ADP F
biopsy 0 NOUN F
did 0 ADP F
not 0 ADV F
relate 0 VERB F
to 0 ADP F
the 0 DET F
site 0 NOUN F
or 0 CCONJ F
endoscopic 0 ADJ F
appearance 0 NOUN F
of 0 ADP F
the 0 DET F
tumor 0 NOUN F
. 0 PUNCT F

There 0 PUNCT T
were 0 VERB F
no 0 DET F
false-positive B-OTHER ADJ F
cytologic I-OTHER ADJ F
or I-OTHER CCONJ F
histologic I-OTHER ADJ F
reports I-OTHER NOUN F
. 0 PUNCT F

For 0 ADP T
all 0 DET F
256 0 NUM F
carcinomas 0 NOUN F
, 0 PUNCT F
the 0 DET F
cumulative B-OTHER ADJ F
accuracy I-OTHER NOUN F
( 0 PUNCT F
brushing B-OTHER PUNCT F
cytology I-OTHER NOUN F
plus I-OTHER CCONJ F
biopsy I-OTHER NOUN F
) 0 PUNCT F
reached 0 VERB F
98.8 0 NUM F
% 0 SYM F
and 0 CCONJ F
was 0 VERB F
significantly 0 ADV F
better 0 PUNCT F
( 0 PUNCT F
P 0 NOUN T
less 0 ADV F
than 0 PUNCT F
.001 0 NUM F
) 0 PUNCT F
than 0 PUNCT F
that 0 PUNCT F
of 0 ADP F
biopsy B-OTHER NOUN F
alone 0 ADJ F
( 0 PUNCT F
93.9 0 NUM F
% 0 SYM F
) 0 PUNCT F
or 0 CCONJ F
cytology B-OTHER NOUN F
alone 0 ADJ F
( 0 PUNCT F
87.9 0 NUM F
% 0 SYM F
) 0 PUNCT F
. 0 PUNCT F

Apart 0 PUNCT T
from 0 ADP F
reinforcing 0 PUNCT F
the 0 DET F
belief 0 ADP F
that 0 PUNCT F
the 0 DET F
combined B-OTHER VERB F
application I-OTHER NOUN F
of I-OTHER ADP F
brushing I-OTHER PUNCT F
and 0 CCONJ F
biopsy B-OTHER NOUN F
is 0 VERB F
mandatory 0 ADJ F
for 0 ADP F
achieving 0 VERB F
optimal 0 ADJ F
results 0 NOUN F
, 0 PUNCT F
this 0 DET F
study 0 NOUN F
indicated 0 VERB F
that 0 ADP F
the 0 DET F
brushing 0 PUNCT F
should 0 PUNCT F
be 0 VERB F
performed 0 VERB F
before 0 ADP F
the 0 DET F
biopsy 0 NOUN F
. 0 PUNCT F

A 0 DET T
placebo-controlled 0 VERB F
trial 0 NOUN F
of 0 ADP F
maintenance 0 NOUN F
therapy 0 NOUN F
with 0 ADP F
fluconazole 0 NOUN F
after 0 ADP F
treatment 0 NOUN F
of 0 ADP F
cryptococcal 0 ADJ F
meningitis 0 NOUN F
in 0 ADP F
the 0 DET F
acquired 0 VERB F
immunodeficiency 0 NOUN F
syndrome 0 NOUN F
. 0 PUNCT F

California 0 PUNCT T
Collaborative 0 ADJ T
Treatment 0 NOUN T
Group 0 NOUN T
. 0 PUNCT F

BACKGROUND 0 NOUN T
AND 0 CCONJ T
METHODS 0 NOUN T
In 0 ADP T
patients 0 NOUN F
with 0 ADP F
the 0 DET F
acquired 0 VERB F
immunodeficiency 0 NOUN F
syndrome 0 NOUN F
( 0 PUNCT F
AIDS 0 NOUN T
) 0 PUNCT F
, 0 PUNCT F
the 0 DET F
rate 0 NOUN F
of 0 ADP F
relapse 0 NOUN F
after 0 ADP F
primary 0 ADJ F
treatment 0 NOUN F
for 0 ADP F
cryptococcal 0 ADJ F
meningitis 0 NOUN F
remains 0 NOUN F
high 0 ADJ F
. 0 PUNCT F

We 0 PRON T
conducted 0 VERB F
a 0 DET F
controlled 0 VERB F
, 0 PUNCT F
double-blind 0 ADJ F
trial 0 NOUN F
to 0 PART F
evaluate 0 NOUN F
the 0 DET F
efficacy 0 NOUN F
of 0 ADP F
maintenance 0 NOUN F
therapy 0 NOUN F
with 0 ADP F
fluconazole 0 NOUN F
. 0 PUNCT F

At 0 ADP T
entry 0 NOUN F
into 0 ADP F
the 0 DET F
study 0 NOUN F
, 0 PUNCT F
all 0 DET F
participants 0 NOUN F
had 0 PUNCT F
sterile 0 ADJ F
cultures 0 NOUN F
of 0 ADP F
cerebrospinal 0 ADJ F
fluid 0 NOUN F
, 0 PUNCT F
blood 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
urine 0 NOUN F
after 0 ADP F
following 0 PUNCT F
a 0 DET F
standardized 0 VERB F
course 0 NOUN F
of 0 ADP F
therapy 0 NOUN F
for 0 ADP F
culture-proved 0 VERB F
cryptococcal 0 ADJ F
meningitis 0 NOUN F
. 0 PUNCT F

The 0 DET T
patients 0 NOUN F
were 0 VERB F
randomly 0 ADV F
assigned 0 VERB F
to 0 PART F
take 0 NOUN F
either 0 PUNCT F
fluconazole 0 NOUN F
or 0 CCONJ F
placebo 0 NOUN F
as 0 PUNCT F
maintenance 0 NOUN F
therapy 0 NOUN F
. 0 PUNCT F

The 0 DET T
dose 0 NOUN F
of 0 ADP F
fluconazole 0 NOUN F
was 0 VERB F
100 0 NUM F
mg 0 NOUN F
daily 0 ADJ F
in 0 ADP F
the 0 DET F
first 0 ADJ F
phase 0 NOUN F
of 0 ADP F
study 0 NOUN F
and 0 CCONJ F
200 0 NUM F
mg 0 NOUN F
daily 0 ADJ F
in 0 ADP F
the 0 DET F
second 0 ADJ F
phase 0 NOUN F
. 0 PUNCT F

RESULTS 0 NOUN T
Of 0 ADP T
84 0 NUM F
patients 0 NOUN F
initially 0 ADV F
enrolled 0 VERB F
, 0 PUNCT F
16 0 NUM F
( 0 PUNCT F
19 0 NUM F
percent 0 NOUN F
) 0 PUNCT F
were 0 VERB F
found 0 VERB F
to 0 DET F
have 0 PUNCT F
silent 0 PUNCT F
, 0 PUNCT F
persistent 0 ADJ F
infection 0 NOUN F
on 0 ADP F
the 0 DET F
basis 0 NOUN F
of 0 ADP F
cultures 0 NOUN F
that 0 ADP F
became 0 VERB F
positive 0 ADJ F
after 0 ADP F
entry 0 NOUN F
into 0 ADP F
the 0 DET F
study 0 NOUN F
; 0 PUNCT F
7 0 NUM F
other 0 ADJ F
patients 0 NOUN F
were 0 VERB F
lost 0 VERB F
to 0 ADP F
follow-up 0 NOUN F
shortly 0 ADV F
after 0 ADP F
entry 0 NOUN F
. 0 PUNCT F

Of 0 ADP T
the 0 DET F
remaining 0 VERB F
61 0 NUM F
patients 0 NOUN F
, 0 PUNCT F
10 0 NUM F
of 0 ADP F
27 0 NUM F
assigned 0 VERB F
to 0 ADP F
placebo 0 NOUN F
( 0 PUNCT F
37 0 NUM F
percent 0 NOUN F
) 0 PUNCT F
and 0 CCONJ F
1 0 NUM F
of 0 ADP F
34 0 NUM F
assigned 0 VERB F
to 0 PUNCT F
fluconazole 0 NOUN F
( 0 PUNCT F
3 0 NUM F
percent 0 NOUN F
) 0 PUNCT F
had 0 ADP F
a 0 DET F
recurrence 0 NOUN F
of 0 ADP F
cryptococcal B-PHYSICAL ADJ F
infection I-PHYSICAL NOUN F
at I-PHYSICAL ADP F
any I-PHYSICAL DET F
site I-PHYSICAL NOUN F
( 0 PUNCT F
difference 0 NOUN F
in 0 ADP F
risk 0 NOUN F
, 0 PUNCT F
34 0 NUM F
percent 0 NOUN F
; 0 PUNCT F
95 0 NUM F
percent 0 NOUN F
confidence 0 NOUN F
interval 0 NOUN F
, 0 PUNCT F
15 0 NUM F
to 0 ADP F
53 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Of 0 ADP T
the 0 DET F
11 0 NUM F
recurrent 0 ADJ F
infections 0 NOUN F
, 0 PUNCT F
7 0 NUM F
were 0 VERB F
detected 0 VERB F
in 0 ADP F
urine 0 NOUN F
obtained 0 VERB F
after 0 ADP F
prostatic 0 ADJ F
massage 0 NOUN F
. 0 PUNCT F

There 0 PUNCT T
were 0 VERB F
four 0 NUM F
recurrent B-PHYSICAL ADJ F
meningeal I-PHYSICAL ADJ F
infections I-PHYSICAL NOUN F
in 0 ADP F
the 0 DET F
patients 0 NOUN F
taking 0 ADJ F
placebo 0 NOUN F
, 0 PUNCT F
but 0 CCONJ F
none 0 NUM F
in 0 ADP F
those 0 PUNCT F
taking 0 PUNCT F
fluconazole 0 NOUN F
( 0 PUNCT F
mean 0 NOUN F
duration 0 NOUN F
of 0 ADP F
follow-up 0 NOUN F
, 0 PUNCT F
164 0 NUM F
days 0 NOUN F
) 0 PUNCT F
( 0 PUNCT F
P 0 NOUN T
= 0 SYM F
0.03 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

In 0 ADP T
multivariate 0 ADJ F
analyses 0 NOUN F
, 0 PUNCT F
the 0 DET F
best 0 PUNCT F
predictors 0 NOUN F
of 0 ADP F
recurrence-free B-MORTALITY ADJ F
survival I-MORTALITY NOUN F
were 0 VERB F
fluconazole 0 ADJ F
treatment 0 NOUN F
( 0 PUNCT F
P 0 NOUN T
= 0 SYM F
0.02 0 NUM F
; 0 PUNCT F
relative 0 ADJ F
hazard 0 NOUN F
, 0 PUNCT F
13.2 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
a 0 DET F
lower 0 PUNCT F
serum 0 NOUN F
cryptococcal-antigen 0 NOUN F
titer 0 NOUN F
( 0 PUNCT F
P 0 NOUN T
= 0 SYM F
0.05 0 NUM F
; 0 PUNCT F
relative 0 ADJ F
hazard 0 NOUN F
, 0 PUNCT F
1.2 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
and 0 CCONJ F
more 0 DET F
prolonged 0 VERB F
primary 0 ADJ F
therapy 0 NOUN F
with 0 ADP F
flucytosine 0 NOUN F
( 0 PUNCT F
P 0 NOUN T
= 0 SYM F
0.09 0 NUM F
; 0 PUNCT F
relative 0 ADJ F
hazard 0 NOUN F
, 0 PUNCT F
1.1 0 PUNCT F
) 0 PUNCT F
. 0 PUNCT F

Survival B-MORTALITY NOUN T
and 0 CCONJ F
toxicity B-OTHER NOUN F
were 0 VERB F
similar 0 ADJ F
in 0 ADP F
the 0 DET F
two 0 NUM F
maintenance-treatment 0 ADJ F
groups 0 NOUN F
. 0 PUNCT F

CONCLUSIONS 0 NOUN T
In 0 ADP T
patients 0 NOUN F
with 0 ADP F
AIDS 0 NOUN T
, 0 PUNCT F
silent 0 PUNCT F
persistent 0 ADJ F
infection 0 NOUN F
is 0 ADJ F
common 0 ADJ F
after 0 ADP F
clinically 0 ADV F
successful 0 ADJ F
treatment 0 NOUN F
for 0 ADP F
cryptococcal 0 ADJ F
meningitis 0 NOUN F
. 0 PUNCT F

Maintenance 0 NOUN T
therapy 0 NOUN F
with 0 ADP F
fluconazole 0 NOUN F
is 0 VERB F
highly 0 ADV F
effective 0 ADJ F
in 0 ADP F
preventing 0 VERB F
recurrent 0 ADJ F
cryptococcal 0 ADJ F
infection 0 NOUN F
. 0 PUNCT F

Efficacy 0 NOUN T
of 0 ADP F
porcine 0 ADJ F
secretin 0 NOUN F
in 0 ADP F
children 0 NOUN F
with 0 ADP F
autism 0 NOUN F
and 0 CCONJ F
pervasive 0 ADJ F
developmental 0 ADJ F
disorder 0 NOUN F
. 0 PUNCT F

Secretin 0 NOUN T
, 0 PUNCT F
a 0 DET F
gastrointestinal 0 ADJ F
( 0 PUNCT F
GI 0 NOUN T
) 0 PUNCT F
hormone 0 NOUN F
, 0 PUNCT F
was 0 VERB F
reported 0 VERB F
in 0 ADP F
a 0 DET F
preliminary 0 ADJ F
study 0 NOUN F
to 0 PART F
improve 0 PUNCT F
language B-MENTAL NOUN F
and 0 CCONJ F
behavior B-MENTAL NOUN F
in 0 ADP F
children 0 NOUN F
with 0 ADP F
autism/pervasive 0 ADJ F
developmental 0 ADJ F
disorder 0 NOUN F
( 0 PUNCT F
PDD 0 NOUN T
) 0 PUNCT F
and 0 CCONJ F
chronic 0 ADJ F
diarrhea 0 NOUN F
. 0 PUNCT F

To 0 PART T
determine 0 NOUN F
the 0 DET F
efficacy 0 NOUN F
of 0 ADP F
secretin 0 NOUN F
, 0 PUNCT F
we 0 PRON F
completed 0 PROPN F
a 0 DET F
double-blind 0 ADJ F
, 0 PUNCT F
placebo-controlled 0 VERB F
, 0 PUNCT F
crossover 0 NOUN F
( 0 PUNCT F
3 0 NUM F
weeks 0 NOUN F
) 0 PUNCT F
study 0 NOUN F
in 0 ADP F
children 0 NOUN F
with 0 ADP F
autism/PDD 0 NUM F
and 0 CCONJ F
various 0 ADJ F
GI 0 NOUN T
conditions 0 NOUN F
using 0 VERB F
a 0 DET F
single 0 ADJ F
dose 0 NOUN F
of 0 ADP F
intravenous 0 ADJ F
porcine 0 ADJ F
secretin 0 NOUN F
. 0 PUNCT F

Children 0 NOUN T
with 0 ADP F
chronic 0 ADJ F
, 0 PUNCT F
active 0 ADJ F
diarrhea 0 NOUN F
showed 0 VERB F
a 0 DET F
reduction 0 NOUN F
in 0 ADP F
aberrant B-MENTAL ADJ F
behaviors I-MENTAL NOUN F
when 0 ADP F
treated 0 VERB F
with 0 ADP F
the 0 DET F
secretin 0 NOUN F
but 0 CCONJ F
not 0 ADV F
when 0 ADP F
treated 0 VERB F
with 0 ADP F
the 0 DET F
placebo 0 NOUN F
. 0 PUNCT F

Children 0 NOUN T
with 0 ADP F
no 0 DET F
GI 0 NOUN T
problems 0 NOUN F
are 0 VERB F
unaffected 0 VERB F
by 0 ADP F
either 0 CCONJ F
secretin 0 NOUN F
or 0 CCONJ F
placebo 0 NOUN F
. 0 PUNCT F

The 0 DET T
improvement 0 NOUN F
seen 0 VERB F
with 0 ADP F
secretin 0 NOUN F
in 0 ADP F
children 0 NOUN F
with 0 ADP F
autism/PDD 0 NUM F
and 0 CCONJ F
chronic 0 ADJ F
diarrhea 0 NOUN F
suggests 0 NOUN F
that 0 ADP F
there 0 PUNCT F
may 0 VERB F
be 0 ADJ F
a 0 DET F
subtype 0 NOUN F
of 0 ADP F
children 0 NOUN F
with 0 ADP F
autism/PDD 0 NUM F
who 0 ADP F
respond 0 PUNCT F
to 0 ADP F
secretin 0 NOUN F
. 0 PUNCT F

A 0 DET T
randomized 0 VERB F
, 0 PUNCT F
double-blind 0 ADJ F
, 0 PUNCT F
phase 0 NOUN F
II 0 NUM T
study 0 NOUN F
of 0 ADP F
two 0 NUM F
doses 0 NOUN F
of 0 ADP F
pemetrexed 0 PUNCT F
as 0 ADP F
first-line 0 NOUN F
chemotherapy 0 NOUN F
for 0 ADP F
advanced 0 VERB F
breast 0 NOUN F
cancer 0 NOUN F
. 0 PUNCT F

PURPOSE 0 NOUN T
Pemetrexed 0 PUNCT T
has 0 PUNCT F
shown 0 VERB F
varied 0 ADV F
response 0 NOUN F
rates 0 NOUN F
in 0 ADP F
advanced 0 VERB F
breast 0 NOUN F
cancer 0 NOUN F
. 0 PUNCT F

This 0 DET T
randomized 0 VERB F
, 0 PUNCT F
double-blind 0 ADJ F
, 0 PUNCT F
phase 0 NOUN F
II 0 NUM T
study 0 NOUN F
was 0 VERB F
conducted 0 VERB F
to 0 PART F
assess 0 NOUN F
the 0 DET F
efficacy 0 NOUN F
and 0 CCONJ F
safety B-OTHER NOUN F
of 0 ADP F
two 0 NUM F
doses 0 NOUN F
of 0 ADP F
pemetrexed 0 PUNCT F
in 0 ADP F
a 0 DET F
homogeneous 0 ADJ F
population 0 NOUN F
. 0 PUNCT F

A 0 CCONJ T
secondary 0 ADJ F
objective 0 ADJ F
was 0 VERB F
to 0 PART F
identify 0 NOUN F
molecular 0 ADJ F
biomarkers 0 CCONJ F
correlating 0 CCONJ F
with 0 ADP F
response 0 NOUN F
and 0 CCONJ F
toxicity B-ADVERSE-EFFECTS NOUN F
. 0 PUNCT F

EXPERIMENTAL 0 ADJ T
DESIGN 0 NOUN T
Patients 0 NOUN T
with 0 ADP F
newly 0 ADJ F
diagnosed 0 VERB F
metastatic 0 ADJ F
breast 0 NOUN F
cancer 0 NOUN F
or 0 CCONJ F
locally 0 ADV F
recurrent 0 ADJ F
breast 0 NOUN F
cancer 0 NOUN F
received 0 VERB F
600 0 NUM F
mg/m 0 NOUN F
( 0 PUNCT F
2 0 NUM F
) 0 PUNCT F
( 0 PUNCT F
P600 0 NOUN T
arm 0 NOUN F
) 0 PUNCT F
or 0 CCONJ F
900 0 NUM F
mg/m 0 NOUN F
( 0 PUNCT F
2 0 NUM F
) 0 PUNCT F
( 0 PUNCT F
P900 0 NOUN T
arm 0 NOUN F
) 0 PUNCT F
of 0 ADP F
pemetrexed 0 PUNCT F
on 0 ADP F
day 0 NOUN F
1 0 PUNCT F
of 0 ADP F
a 0 DET F
21-day 0 NOUN F
cycle 0 NOUN F
. 0 PUNCT F

All 0 DET T
patients 0 NOUN F
received 0 VERB F
folic 0 ADJ F
acid 0 NOUN F
and 0 CCONJ F
vitamin 0 NOUN F
B 0 NOUN T
( 0 PUNCT F
12 0 NUM F
) 0 PUNCT F
supplementation 0 NOUN F
. 0 PUNCT F

RESULTS 0 PUNCT T
The 0 DET T
P600 0 NOUN T
( 0 PUNCT F
47 0 NUM F
patients 0 NOUN F
) 0 PUNCT F
and 0 CCONJ F
P900 0 NOUN T
( 0 PUNCT F
45 0 NUM F
patients 0 NOUN F
) 0 PUNCT F
arms 0 NOUN F
had 0 PUNCT F
response 0 NOUN F
rates B-OTHER NOUN F
of 0 ADP F
17.0 0 NUM F
% 0 SYM F
( 0 PUNCT F
95 0 NUM F
% 0 SYM F
confidence 0 NOUN F
interval 0 NOUN F
, 0 PUNCT F
7.7-30.8 0 PUNCT F
% 0 SYM F
) 0 PUNCT F
and 0 CCONJ F
15.6 0 NUM F
% 0 SYM F
( 0 PUNCT F
95 0 NUM F
% 0 SYM F
confidence 0 NOUN F
interval 0 NOUN F
, 0 PUNCT F
6.5-29.5 0 VERB F
% 0 SYM F
) 0 PUNCT F
with 0 ADP F
approximately 0 ADV F
50 0 NUM F
% 0 SYM F
stable 0 ADJ F
disease 0 NOUN F
per 0 ADP F
arm 0 NOUN F
, 0 PUNCT F
median 0 ADJ F
progression-free B-MORTALITY NOUN F
survival I-MORTALITY NOUN F
of 0 ADP F
4.2 0 NUM F
and 0 CCONJ F
4.1 0 NUM F
months 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
median 0 ADJ F
times B-PHYSICAL NOUN F
to I-PHYSICAL ADP F
tumor I-PHYSICAL NOUN F
progression I-PHYSICAL NOUN F
of 0 ADP F
4.2 0 NUM F
and 0 CCONJ F
4.6 0 NUM F
months 0 NOUN F
, 0 PUNCT F
respectively 0 ADV F
. 0 PUNCT F

Both 0 CCONJ T
arms 0 NOUN F
exhibited 0 VERB F
minimal B-ADVERSE-EFFECTS ADJ F
toxicity I-ADVERSE-EFFECTS NOUN F
( 0 PUNCT F
grade 0 NOUN F
3/4 0 NUM F
neutropenia B-ADVERSE-EFFECTS NOUN F
< 0 SYM F
20 0 NUM F
% 0 SYM F
, 0 PUNCT F
leukopenia B-ADVERSE-EFFECTS NOUN F
< 0 SYM F
9 0 NUM F
% 0 SYM F
, 0 PUNCT F
and 0 CCONJ F
other 0 ADJ F
toxicities B-ADVERSE-EFFECTS NOUN F
< 0 VERB F
5 0 NUM F
% 0 SYM F
) 0 PUNCT F
. 0 PUNCT F

Tumor 0 NOUN T
samples 0 NOUN F
from 0 ADP F
49 0 NUM F
patients 0 NOUN F
were 0 VERB F
assessed 0 VERB F
for 0 ADP F
the 0 DET F
expression 0 NOUN F
levels 0 NOUN F
of 0 ADP F
12 0 NUM F
pemetrexed-related 0 VERB F
genes 0 NOUN F
. 0 PUNCT F

Folylpolyglutamate 0 ADV T
synthetase 0 NOUN F
and 0 CCONJ F
thymidine 0 NOUN F
phosphorylase 0 NOUN F
correlated 0 VERB F
with 0 ADP F
efficacy 0 NOUN F
. 0 PUNCT F

Best B-OTHER PUNCT T
response 0 NOUN F
rates B-OTHER NOUN F
and 0 CCONJ F
median 0 ADJ F
time B-PHYSICAL NOUN F
to B-PHYSICAL ADP F
tumor B-PHYSICAL NOUN F
progression B-PHYSICAL NOUN F
for 0 ADP F
high 0 ADJ F
versus 0 CCONJ F
low 0 ADJ F
thymidine 0 NOUN F
phosphorylase 0 NOUN F
expression 0 NOUN F
were 0 VERB F
27.6 0 NUM F
% 0 SYM F
versus 0 CCONJ F
6.3 0 NUM F
% 0 SYM F
( 0 PUNCT F
P 0 NOUN T
= 0 SYM F
0.023 0 NUM F
) 0 PUNCT F
and 0 CCONJ F
5.4 0 NUM F
versus 0 CCONJ F
1.9 0 NUM F
months 0 NOUN F
( 0 PUNCT F
P 0 NOUN T
= 0 SYM F
0.076 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
and 0 CCONJ F
for 0 ADP F
folylpolyglutamate 0 NOUN F
synthetase 0 NOUN F
were 0 VERB F
37.5 0 NUM F
% 0 SYM F
versus 0 CCONJ F
10.0 0 NUM F
% 0 SYM F
( 0 PUNCT F
P 0 NOUN T
= 0 SYM F
0.115 0 NUM F
) 0 PUNCT F
and 0 CCONJ F
8.6 0 NUM F
versus 0 CCONJ F
3.0 0 NUM F
months 0 NOUN F
( 0 PUNCT F
P 0 NOUN T
= 0 SYM F
0.019 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
respectively 0 ADV F
. 0 PUNCT F

gamma-Glutamyl 0 ADJ F
hydrolase 0 NOUN F
expression 0 NOUN F
correlated 0 VERB F
with 0 ADP F
grade 0 PUNCT F
3/4 0 PUNCT F

The 0 DET T
effect 0 NOUN F
of 0 ADP F
acupressure 0 NOUN F
at 0 ADP F
the 0 DET F
extra 0 ADJ F
1 0 NUM F
point 0 NOUN F
on 0 ADP F
subjective 0 ADJ F
and 0 CCONJ F
autonomic B-MENTAL ADJ F
responses I-MENTAL NOUN F
to 0 ADP F
needle 0 NOUN F
insertion 0 NOUN F
. 0 PUNCT F

BACKGROUND 0 NOUN T
Premedication 0 NOUN T
with 0 ADP F
sedatives 0 ADV F
can 0 ADV F
decrease 0 VERB F
the 0 DET F
discomfort B-MENTAL NOUN F
associated 0 VERB F
with 0 ADP F
invasive 0 ADJ F
anesthetic 0 ADJ F
procedures 0 NOUN F
. 0 PUNCT F

Some 0 DET T
researchers 0 NOUN F
have 0 CCONJ F
shown 0 VERB F
that 0 ADP F
acupressure 0 NOUN F
on 0 ADP F
the 0 DET F
acupuncture 0 ADP F
extra 0 ADJ F
1 0 NUM F
point 0 NOUN F
is 0 VERB F
effective 0 ADJ F
for 0 ADP F
sedation 0 NOUN F
. 0 PUNCT F

We 0 PRON T
investigated 0 VERB F
whether 0 ADP F
acupressure 0 NOUN F
on 0 ADP F
the 0 DET F
extra 0 ADJ F
1 0 NUM F
point 0 NOUN F
could 0 PUNCT F
alleviate 0 ADP F
the 0 DET F
pain B-PAIN NOUN F
of 0 ADP F
needle 0 NOUN F
insertion 0 NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
We 0 PRON T
investigated 0 VERB F
the 0 DET F
effect 0 NOUN F
of 0 ADP F
acupressure 0 NOUN F
at 0 ADP F
the 0 DET F
extra 0 ADJ F
1 0 NUM F
point 0 NOUN F
or 0 CCONJ F
a 0 DET F
sham 0 ADJ F
point 0 NOUN F
on 0 ADP F
needle 0 NOUN F
insertion 0 NOUN F
using 0 SYM F
verbal B-PAIN ADJ F
rating I-PAIN VERB F
scale I-PAIN NOUN F
( I-PAIN PUNCT F
VRS I-PAIN NOUN T
) I-PAIN PUNCT F
pain I-PAIN NOUN F
scores 0 NOUN F
and 0 CCONJ F
heart B-PHYSICAL NOUN F
rate I-PHYSICAL NOUN F
variability 0 NOUN F
( B-PHYSICAL PUNCT F
HRV I-PHYSICAL NOUN T
) B-PHYSICAL PUNCT F
. 0 PUNCT F

Twenty-two 0 NUM T
healthy 0 ADJ F
female 0 NOUN F
volunteers 0 NOUN F
were 0 VERB F
randomly 0 ADV F
allocated 0 VERB F
to 0 ADP F
two 0 NUM F
groups 0 NOUN F
: 0 PUNCT F
the 0 DET F
extra 0 ADJ F
1 0 NUM F
group 0 NOUN F
received 0 VERB F
acupressure 0 NOUN F
at 0 ADP F
the 0 DET F
extra 0 ADJ F
1 0 NUM F
point 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
the 0 DET F
sham 0 ADJ F
group 0 NOUN F
received 0 VERB F
acupressure 0 NOUN F
at 0 ADP F
a 0 DET F
sham 0 ADJ F
point 0 NOUN F
. 0 PUNCT F

After 0 ADP T
starting 0 VERB F
the 0 DET F
electrocardiogram 0 NOUN F
record 0 NOUN F
, 0 PUNCT F
a 0 DET F
27-gauge 0 NOUN F
needle 0 NOUN F
was 0 VERB F
inserted 0 VERB F
into 0 ADP F
the 0 DET F
skin 0 NOUN F
of 0 ADP F
a 0 DET F
forearm 0 NOUN F
. 0 PUNCT F

Thereafter 0 ADV T
, 0 PUNCT F
another 0 DET F
needle 0 NOUN F
was 0 VERB F
inserted 0 VERB F
into 0 ADP F
the 0 DET F
skin 0 NOUN F
of 0 ADP F
the 0 DET F
other 0 ADJ F
forearm 0 NOUN F
during 0 ADP F
acupressure 0 NOUN F
. 0 PUNCT F

RESULTS 0 NOUN T
Acupressure 0 ADP T
at 0 ADP F
the 0 DET F
extra 0 ADJ F
1 0 NUM F
point 0 NOUN F
significantly 0 ADV F
reduced 0 VERB F
the 0 DET F
VRS B-OTHER NOUN T
, 0 PUNCT F
but 0 CCONJ F
acupressure 0 NOUN F
at 0 ADP F
the 0 DET F
sham 0 ADJ F
increased 0 VERB F
the 0 DET F
VRS B-OTHER NOUN T
. 0 PUNCT F

Acupressure 0 NOUN T
at 0 ADP F
the 0 DET F
extra 0 ADJ F
1 0 NUM F
significantly 0 ADV F
reduced 0 VERB F
the 0 DET F
low B-PHYSICAL ADJ F
frequency/high I-PHYSICAL PUNCT F
frequency 0 NOUN F
ratio 0 NOUN F
of B-PHYSICAL ADP F
HRV I-PHYSICAL NOUN T
responding I-PHYSICAL PUNCT F
to I-PHYSICAL ADP F
needle B-PHYSICAL NOUN F
insertion I-PHYSICAL NOUN F
. 0 PUNCT F

CONCLUSIONS 0 NOUN T
Acupressure 0 NUM T
at 0 ADP F
the 0 DET F
extra 0 ADJ F
1 0 NUM F
point 0 NOUN F
significantly 0 PUNCT F
reduced 0 PUNCT F

Immunogenicity B-PHYSICAL NOUN T
and 0 CCONJ F
reactogenicity B-PHYSICAL NOUN F
of 0 ADP F
a 0 DET F
group 0 NOUN F
C 0 NOUN T
meningococcal 0 ADJ F
conjugate 0 ADJ F
vaccine 0 NOUN F
compared 0 VERB F
with 0 ADP F
a 0 DET F
group 0 NOUN F
A+C 0 NOUN T
meningococcal 0 ADJ F
polysaccharide 0 ADP F
vaccine 0 NOUN F
in 0 ADP F
adolescents 0 NOUN F
in 0 ADP F
a 0 DET F
randomised 0 VERB F
observer-blind 0 NOUN F
controlled 0 VERB F
trial 0 NOUN F
. 0 PUNCT F

This 0 DET T
study 0 NOUN F
evaluated 0 VERB F
the 0 DET F
immunogenicity B-PHYSICAL ADJ F
and 0 CCONJ F
reactogenicity B-PHYSICAL NOUN F
of 0 ADP F
a 0 DET F
group 0 NOUN F
C 0 NOUN T
meningococcal 0 ADJ F
conjugate 0 ADJ F
vaccine 0 NOUN F
( 0 PUNCT F
MenC 0 NOUN T
) 0 PUNCT F
compared 0 VERB F
with 0 ADP F
a 0 DET F
group 0 NOUN F
A+C 0 NOUN T
meningococcal 0 ADJ F
polysaccharide 0 ADP F
vaccine 0 NOUN F
( 0 PUNCT F
MenPS 0 NOUN T
) 0 PUNCT F
in 0 ADP F
healthy 0 ADJ F
adolescents 0 NOUN F
. 0 PUNCT F

Subjects 0 NOUN T
were 0 VERB F
randomised 0 VERB F
to 0 PART F
receive 0 NOUN F
one 0 DET F
dose 0 NOUN F
of 0 ADP F
either 0 CCONJ F
MenC 0 NOUN T
( 0 PUNCT F
n=92 0 NUM F
) 0 PUNCT F
or 0 CCONJ F
MenPS 0 NOUN T
( 0 PUNCT F
n=90 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

Group 0 NOUN T
C 0 NOUN T
meningococcal B-PHYSICAL ADJ F
IgG I-PHYSICAL NOUN T
antibody I-PHYSICAL NOUN F
concentrations I-PHYSICAL NOUN F
and I-PHYSICAL CCONJ F
bactericidal I-PHYSICAL ADJ F
titres I-PHYSICAL NOUN F
were 0 VERB F
higher 0 PUNCT F
in 0 ADP F
the 0 DET F
MenC 0 NOUN T
group 0 NOUN F
than 0 PUNCT F
the 0 DET F
MenPS 0 NOUN T
group 0 NOUN F
at 0 ADP F
1 0 NUM F
month 0 NOUN F
( 0 PUNCT F
22.8 0 NUM F
U/ml 0 NOUN T
vs 0 CCONJ F
4.0 0 NUM F
U/ml 0 NOUN T
, 0 PUNCT F
p 0 NOUN F
< 0 SYM F
0.001 0 NUM F
, 0 PUNCT F
and 0 CCONJ F
87 0 NUM F
vs 0 CCONJ F
20 0 NUM F
, 0 PUNCT F
p 0 NOUN F
< 0 SYM F
0.001 0 NUM F
, 0 PUNCT F
respectively 0 ADV F
) 0 PUNCT F
and 0 CCONJ F
12 0 NUM F
months 0 NOUN F
( 0 PUNCT F
6.1 0 ADP F
U/ml 0 NOUN T
vs 0 CCONJ F
3.0 0 NUM F
U/ml 0 NOUN T
, 0 PUNCT F
p 0 NOUN F
< 0 SYM F
0.001 0 NUM F
, 0 PUNCT F
and 0 CCONJ F
81.3 0 NUM F
vs 0 CCONJ F
20.2 0 NUM F
, 0 PUNCT F
p 0 NOUN F
< 0 SYM F
0.001 0 NUM F
, 0 PUNCT F
respectively 0 ADV F
) 0 PUNCT F
. 0 PUNCT F

No 0 DET T
differences 0 NOUN F
in 0 ADP F
post B-PHYSICAL PUNCT F
immunisation I-PHYSICAL NOUN F
reaction I-PHYSICAL NOUN F
rates I-PHYSICAL NOUN F
were 0 VERB F
noted 0 VERB F
between 0 ADP F
the 0 DET F
two 0 NUM F
vaccinated 0 VERB F
groups 0 NOUN F
. 0 PUNCT F

This 0 DET T
study 0 NOUN F
demonstrated 0 VERB F
the 0 DET F
safety 0 NOUN F
and 0 CCONJ F
enhanced 0 VERB F
immunogenicity B-PHYSICAL NOUN F
of 0 ADP F
the 0 DET F
candidate 0 NOUN F
meningococcal 0 ADJ F
conjugate 0 ADJ F
vaccine 0 NOUN F
as 0 VERB F
compared 0 VERB F
with 0 ADP F
the 0 DET F
licensed 0 PUNCT F
polysaccharide 0 ADP F
vaccine 0 NOUN F
in 0 ADP F
adolescents 0 NOUN F
. 0 PUNCT F

Clinical 0 ADJ T
pathway 0 NOUN F
for 0 ADP F
fractured 0 ADV F
neck 0 NOUN F
of 0 ADP F
femur 0 NOUN F
: 0 PUNCT F
a 0 DET F
prospective 0 ADJ F
, 0 PUNCT F
controlled 0 ADP F
study 0 NOUN F
. 0 PUNCT F

OBJECTIVE 0 NOUN T
To 0 PROPN T
assess 0 NOUN F
outcomes 0 NOUN F
of 0 ADP F
using 0 PUNCT F
a 0 DET F
clinical 0 ADJ F
pathway 0 NOUN F
for 0 ADP F
managing 0 VERB F
patients 0 NOUN F
with 0 ADP F
fractured 0 PUNCT F
neck 0 NOUN F
of 0 ADP F
femur 0 NOUN F
. 0 PUNCT F

DESIGN 0 NOUN T
Prospective 0 ADJ T
, 0 PUNCT F
pseudorandomised 0 PRON F
, 0 PUNCT F
controlled 0 VERB F
trial 0 NOUN F
. 0 PUNCT F

SETTING 0 NUM T
St 0 CCONJ T
Vincent 0 NOUN T
's 0 PUNCT F
Hospital 0 NOUN T
, 0 PUNCT F
Melbourne 0 NOUN T
, 0 PUNCT F
Victoria 0 NOUN T
( 0 PUNCT F
a 0 DET F
tertiary 0 ADJ F
referral 0 NOUN F
, 0 PUNCT F
university 0 NOUN F
teaching 0 VERB F
hospital 0 NOUN F
) 0 PUNCT F
, 0 PUNCT F
1 0 NUM F
October 0 NOUN T
1997 0 NUM F
to 0 ADP F
30 0 NUM F
November 0 NOUN T
1998 0 NUM F
. 0 PUNCT F

PARTICIPANTS 0 ADP T
111 0 NUM F
patients 0 NOUN F
( 0 PUNCT F
80 0 NUM F
women 0 NOUN F
and 0 CCONJ F
31 0 NUM F
men 0 NOUN F
; 0 PUNCT F
mean 0 NOUN F
age 0 NOUN F
, 0 PUNCT F
81 0 NUM F
years 0 NOUN F
) 0 PUNCT F
admitted 0 VERB F
via 0 ADP F
the 0 DET F
emergency 0 NOUN F
department 0 NOUN F
with 0 ADP F
a 0 DET F
primary 0 ADJ F
diagnosis 0 NOUN F
of 0 ADP F
fractured 0 PUNCT F
neck 0 NOUN F
of 0 ADP F
femur 0 NOUN F
. 0 PUNCT F

INTERVENTIONS 0 NOUN T
Management 0 NOUN T
guided 0 PUNCT F
by 0 ADP F
a 0 DET F
clinical 0 ADJ F
pathway 0 NOUN F
( 0 PUNCT F
55 0 NUM F
patients 0 NOUN F
) 0 PUNCT F
or 0 CCONJ F
established 0 VERB F
standard 0 NOUN F
of 0 ADP F
care 0 NOUN F
( 0 PUNCT F
control 0 NOUN F
group 0 NOUN F
, 0 PUNCT F
56 0 NUM F
patients 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

MAIN 0 ADJ T
OUTCOME 0 NOUN T
MEASURES 0 NOUN T
Timing B-OTHER ADJ T
of I-OTHER ADP F
referrals I-OTHER NOUN F
and I-OTHER CCONJ F
discharge I-OTHER NOUN F
planning I-OTHER VERB F
; 0 PUNCT F
total 0 ADJ F
length B-OTHER NOUN F
of B-OTHER ADP F
stay B-OTHER NOUN F
; 0 PUNCT F
and 0 CCONJ F
complication B-ADVERSE-EFFECTS NOUN F
and 0 CCONJ F
readmission B-OTHER ADJ F
rates I-OTHER PUNCT F

Dose-response 0 NOUN T
characteristics 0 NOUN F
during 0 ADP F
long-term 0 NOUN F
inhalation 0 NOUN F
of 0 ADP F
nitric 0 ADJ F
oxide 0 NOUN F
in 0 ADP F
patients 0 NOUN F
with 0 ADP F
severe 0 ADJ F
acute 0 ADJ F
respiratory 0 ADJ F
distress 0 NOUN F
syndrome 0 NOUN F
: 0 PUNCT F
a 0 DET F
prospective 0 ADJ F
, 0 PUNCT F
randomized 0 VERB F
, 0 PUNCT F
controlled 0 ADP F
study 0 NOUN F
. 0 PUNCT F

Inhaled 0 VERB T
nitric 0 ADJ F
oxide 0 NOUN F
( 0 PUNCT F
NO 0 NOUN T
) 0 PUNCT F
improves 0 NOUN F
systemic 0 ADJ F
oxygenation 0 NOUN F
( 0 PUNCT F
PaO2/FIO2 0 NOUN T
) 0 PUNCT F
in 0 ADP F
adult 0 ADJ F
patients 0 NOUN F
with 0 ADP F
acute 0 ADJ F
respiratory 0 ADJ F
distress 0 NOUN F
syndrome 0 NOUN F
( 0 PUNCT F
ARDS 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

However 0 ADV T
, 0 PUNCT F
individual 0 ADJ F
response 0 NOUN F
varies 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
previous 0 ADJ F
trials 0 NOUN F
demonstrated 0 VERB F
no 0 DET F
outcome 0 NOUN F
benefit 0 NOUN F
. 0 PUNCT F

This 0 DET T
prospective 0 ADJ F
, 0 PUNCT F
randomized 0 ADP F
study 0 NOUN F
in 0 ADP F
40 0 NUM F
ARDS 0 NOUN T
patients 0 NOUN F
analyzed 0 VERB F
dose-response B-PHYSICAL NOUN F
( I-PHYSICAL PUNCT F
DR I-PHYSICAL ADV T
) I-PHYSICAL PUNCT F
characteristics I-PHYSICAL NOUN F
during 0 ADP F
long-term 0 NOUN F
inhaled 0 PUNCT F
NO 0 NOUN T
. 0 PUNCT F

Patients 0 NOUN T
were 0 VERB F
randomized 0 VERB F
for 0 ADP F
conventional 0 ADJ F
therapy 0 NOUN F
( 0 PUNCT F
control 0 NOUN F
) 0 PUNCT F
or 0 CCONJ F
continuous 0 ADJ F
treatment 0 NOUN F
with 0 ADP F
10 0 NUM F
parts 0 NOUN F
per 0 ADP F
million 0 NUM F
( 0 PUNCT F
ppm 0 NOUN F
) 0 PUNCT F
inhaled 0 VERB F
NO 0 NOUN T
until 0 ADP F
weaning 0 VERB F
was 0 VERB F
initiated 0 VERB F
. 0 PUNCT F

We 0 PRON T
measured 0 VERB F
DR B-OTHER ADV T
curves I-OTHER NOUN F
of I-OTHER ADP F
PaO2/FIO2 I-OTHER NOUN T
versus I-OTHER CCONJ F
the I-OTHER DET F
inhaled I-OTHER VERB F
NO I-OTHER NOUN T
dose I-OTHER NOUN F
at 0 ADP F
regular 0 ADJ F
intervals 0 NOUN F
. 0 PUNCT F

Before 0 ADP T
treatment 0 NOUN F
( 0 PUNCT F
Day 0 NOUN T
0 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
peak 0 ADJ F
improvement 0 NOUN F
in 0 ADP F
PaO2/FIO2 B-OTHER NOUN T
was 0 VERB F
achieved 0 VERB F
at 0 ADP F
10 0 NUM F
ppm 0 NOUN F
for 0 ADP F
both 0 CCONJ F
control 0 NOUN F
and 0 CCONJ F
NO-treated 0 VERB T
patients 0 NOUN F
. 0 PUNCT F

After 0 ADP T
4 0 NUM F
days 0 NOUN F
, 0 PUNCT F
the 0 DET F
DR 0 ADV T
curve 0 NOUN F
of 0 ADP F
the 0 DET F
NO-treated B-OTHER ADJ T
patients I-OTHER NOUN F
was 0 VERB F
left 0 ADP F
shifted 0 ADJ F
with 0 ADP F
a 0 DET F
peak 0 ADJ F
response 0 NOUN F
at 0 ADP F
1 0 NUM F
ppm 0 NOUN F
. 0 PUNCT F

At 0 ADP T
higher 0 PUNCT F
doses 0 NOUN F
( 0 PUNCT F
10 0 NUM F
and 0 CCONJ F
100 0 NUM F
ppm 0 NOUN F
) 0 PUNCT F
, 0 PUNCT F
oxygenation B-PHYSICAL NOUN F
deteriorated I-PHYSICAL ADP F
, 0 PUNCT F
and 0 CCONJ F
the 0 DET F
response 0 NOUN F
to 0 ADP F
inhaled 0 VERB F
NO 0 NOUN T
disappeared 0 VERB F
in 0 ADP F
several 0 ADJ F
patients 0 NOUN F
. 0 PUNCT F

This 0 DET T
effect 0 NOUN F
was 0 VERB F
not 0 ADV F
observed 0 VERB F
in 0 ADP F
the 0 DET F
control 0 NOUN F
group 0 NOUN F
. 0 PUNCT F

There 0 PUNCT T
was 0 VERB F
no 0 DET F
effect 0 NOUN F
of 0 ADP F
inhaled 0 VERB F
NO 0 NOUN T
on 0 ADP F
duration 0 NOUN F
of 0 ADP F
mechanical B-OTHER ADJ F
ventilation I-OTHER NOUN F
or 0 CCONJ F
stay B-OTHER NOUN F
at I-OTHER ADP F
the I-OTHER DET F
intensive I-OTHER ADJ F
care I-OTHER NOUN F
unit I-OTHER NOUN F
. 0 PUNCT F

In 0 ADP T
conclusion 0 NOUN F
, 0 PUNCT F
long-term 0 NOUN F
inhaled 0 PUNCT F
NO 0 NOUN T
with 0 ADP F
constant 0 ADJ F
doses 0 NOUN F
of 0 ADP F
10 0 NUM F
ppm 0 NOUN F
leads 0 NOUN F
to 0 ADP F
enhanced 0 VERB F
sensitivity 0 NOUN F
after 0 ADP F
several 0 ADJ F
days 0 NOUN F
and 0 CCONJ F
does 0 PUNCT F
do 0 PUNCT F
not 0 ADV F
allow 0 VERB F
reduction 0 NOUN F
of 0 ADP F
ventilation 0 NOUN F
parameters 0 NOUN F
. 0 PUNCT F

Hence 0 ADV T
, 0 PUNCT F
previous 0 ADJ F
trials 0 NOUN F
on 0 ADP F
therapy 0 NOUN F
with 0 ADP F
inhaled 0 VERB F
NO 0 NOUN T
in 0 ADP F
ARDS 0 NOUN T
should 0 PUNCT F
be 0 VERB F
carefully 0 ADV F
interpreted 0 VERB F
, 0 PUNCT F
as 0 PUNCT F
they 0 ADV F
used 0 VERB F
constant 0 ADJ F
NO 0 NOUN T
concentrations 0 NOUN F
, 0 PUNCT F
which 0 ADP F
may 0 VERB F
have 0 CCONJ F
become 0 PUNCT F
overdoses 0 NOUN F
leading 0 VERB F
to 0 ADP F
deterioration 0 NOUN F
of 0 ADP F
oxygenation B-PHYSICAL NOUN F
after 0 ADP F
several 0 ADJ F
days 0 NOUN F
. 0 PUNCT F

The 0 DET T
lunar 0 ADJ F
stent 0 NOUN F
characteristics 0 NOUN F
and 0 CCONJ F
clinical 0 ADJ F
results 0 NOUN F
. 0 PUNCT F

One 0 PUNCT T
of 0 ADP F
the 0 DET F
frequent 0 ADJ F
long-term 0 NOUN F
complications 0 NOUN F
after 0 ADP F
stent 0 NOUN F
implantation 0 NOUN F
is 0 VERB F
restenosis 0 NOUN F
due 0 PUNCT F
to 0 ADP F
the 0 DET F
building 0 ADP F
up 0 PUNCT F
of 0 ADP F
a 0 DET F
neointima 0 NOUN F
within 0 ADP F
the 0 DET F
artery 0 NOUN F
, 0 PUNCT F
as 0 CCONJ F
well 0 PUNCT F
as 0 CCONJ F
endovascular 0 ADJ F
hyperplasia 0 NOUN F
( 0 PUNCT F
tissue 0 NOUN F
growth 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
interesting 0 VERB F
feature 0 NOUN F
of 0 ADP F
the 0 DET F
Lunar 0 ADJ T
stent 0 NOUN F
from 0 ADP F
Inflow 0 NOUN T
Dynamics 0 NOUN T
is 0 VERB F
that 0 ADP F
it 0 PRON F
is 0 VERB F
coated 0 VERB F
with 0 ADP F
a 0 DET F
layer 0 NOUN F
of 0 ADP F
iridium 0 NOUN F
oxide 0 NOUN F
. 0 PUNCT F

The 0 DET T
iridium 0 NOUN F
oxide 0 NOUN F
coating 0 PUNCT F
is 0 VERB F
believed 0 VERB F
to 0 PART F
reduce 0 NOUN F
restenosis B-PHYSICAL NOUN F
by 0 ADP F
decreasing 0 VERB F
the 0 DET F
inflammatory B-PHYSICAL ADJ F
response I-PHYSICAL NOUN F
to 0 ADP F
the 0 DET F
stent 0 NOUN F
via 0 ADP F
its 0 PUNCT F
antioxidant 0 NOUN F
action 0 NOUN F
. 0 PUNCT F

The 0 DET T
MOONLIGHT 0 NOUN T
( 0 PUNCT F
Multicenter 0 NOUN T
Objective 0 ADJ T
ObservatioNal 0 ADV T
Lunar 0 ADJ T
Iridiumoxide 0 NOUN T
intimal 0 ADJ F
GrowtH 0 NOUN T
Trial 0 NOUN T
) 0 PUNCT F
study 0 NOUN F
was 0 VERB F
carried 0 VERB F
out 0 ADP F
to 0 PART F
evaluate 0 NOUN F
the 0 DET F
immediate 0 ADJ F
outcome 0 NOUN F
and 0 CCONJ F
long-term 0 NOUN F
angiographic 0 ADJ F
success 0 NOUN F
after 0 ADP F
implantation 0 NOUN F
of 0 ADP F
Lunar 0 ADJ T
stents 0 NOUN F
. 0 PUNCT F

Between 0 ADP T
March 0 NOUN T
2001 0 NUM F
and 0 CCONJ F
November 0 NOUN T
2001 0 NUM F
, 0 PUNCT F
87 0 NUM F
patients 0 NOUN F
with 0 ADP F
99 0 NUM F
lesions 0 NOUN F
were 0 VERB F
enrolled 0 VERB F
in 0 ADP F
this 0 DET F
study 0 NOUN F
and 0 CCONJ F
were 0 VERB F
treated 0 VERB F
with 0 ADP F
12 0 NUM F
and 0 CCONJ F
16 0 NUM F
mm 0 NOUN F
long 0 ADJ F
iridium-oxide 0 ADJ F
coated 0 ADP F
Lunar 0 ADJ T
stents 0 NOUN F
. 0 PUNCT F

Delivery 0 NOUN T
of 0 ADP F
the 0 DET F
Lunar 0 ADJ T
stent 0 NOUN F
was 0 VERB F
successful 0 ADJ F
in 0 ADP F
most 0 DET F
lesions 0 NOUN F
and 0 CCONJ F
the 0 DET F
optimal 0 ADJ F
radiopacity 0 NOUN F
facilitated 0 ADP F
optimal 0 ADJ F
stent B-PHYSICAL NOUN F
positioning 0 VERB F
with 0 ADP F
optimal 0 ADJ F
immediate 0 ADJ F
clinical 0 ADJ F
and 0 CCONJ F
angiographic 0 ADJ F
results 0 NOUN F
is 0 VERB F
an 0 DET F
unselected 0 VERB F
patient 0 NOUN F
and 0 CCONJ F
lesion 0 NOUN F
population 0 NOUN F
. 0 PUNCT F

Preliminary 0 ADJ T
clinical 0 ADJ F
and 0 CCONJ F
angiographic 0 ADJ F
follow-up 0 NOUN F
show 0 VERB F
a 0 DET F
low 0 ADJ F
rate 0 NOUN F
of 0 ADP F
cardiac B-PHYSICAL ADJ F
events I-PHYSICAL NOUN F
at 0 ADP F
6 0 NUM F
months 0 NOUN F
( 0 PUNCT F
16.1 0 NUM F
% 0 SYM F
MACE 0 NOUN T
) 0 PUNCT F
and 0 CCONJ F
a 0 DET F
moderate 0 ADJ F
hyperplastic B-PHYSICAL ADJ F
response 0 NOUN F
. 0 PUNCT F

Noradrenergic 0 ADJ T
moderation B-OTHER NOUN F
of 0 ADP F
working 0 PUNCT F
memory 0 NOUN F
impairments 0 NOUN F
in 0 ADP F
adults 0 NOUN F
with 0 ADP F
autism 0 NOUN F
spectrum 0 NOUN F
disorder 0 NOUN F
. 0 PUNCT F

In 0 ADP T
addition 0 NOUN F
to 0 ADP F
having 0 PROPN F
difficulties 0 NOUN F
with 0 ADP F
social 0 ADJ F
communications 0 NOUN F
, 0 PUNCT F
individuals 0 NOUN F
with 0 ADP F
an 0 DET F
autism 0 NOUN F
spectrum 0 NOUN F
disorder 0 NOUN F
( 0 PUNCT F
ASD 0 NOUN T
) 0 PUNCT F
often 0 ADV F
also 0 ADV F
experience 0 ADV F
impairment 0 NOUN F
in 0 ADP F
higher-order B-MENTAL NOUN F
, I-MENTAL PUNCT F
executive I-MENTAL ADJ F
skills I-MENTAL NOUN F
. 0 PUNCT F

The 0 DET T
present 0 ADJ F
study 0 NOUN F
examined 0 VERB F
the 0 DET F
effects 0 NOUN F
of 0 ADP F
pharmacological 0 ADJ F
modulation 0 NOUN F
of 0 ADP F
the 0 DET F
norepinephrine 0 NOUN F
system 0 NOUN F
on 0 ADP F
the 0 DET F
severity 0 NOUN F
of 0 ADP F
such 0 ADP F
impairments 0 NOUN F
. 0 PUNCT F

A 0 DET T
sample 0 NOUN F
of 0 ADP F
14 0 NUM F
high-functioning 0 PRON F
adults 0 NOUN F
with 0 ADP F
ASD 0 NOUN T
and 0 CCONJ F
a 0 DET F
demographically-matched 0 ADV F
comparison 0 NOUN F
group 0 NOUN F
of 0 ADP F
13 0 NUM F
typically 0 ADV F
developing 0 NUM F
individuals 0 NOUN F
participated 0 VERB F
. 0 PUNCT F

An 0 DET T
AX 0 NOUN T
continuous 0 ADJ F
performance 0 NOUN F
test 0 NOUN F
( 0 PUNCT F
AX-CPT 0 ADP T
) 0 PUNCT F
was 0 VERB F
used 0 VERB F
to 0 PART F
evaluate 0 NOUN F
working 0 ADP F
memory 0 NOUN F
and 0 CCONJ F
inhibitory 0 ADJ F
control 0 NOUN F
. 0 PUNCT F

AX-CPT B-MENTAL PUNCT T
performance I-MENTAL NOUN F
was 0 VERB F
assessed 0 VERB F
following 0 VERB F
administration 0 NOUN F
of 0 ADP F
a 0 DET F
single 0 ADJ F
dose 0 NOUN F
of 0 ADP F
propranolol 0 NOUN F
( 0 PUNCT F
a 0 DET F
beta 0 NOUN F
adrenergic 0 ADJ F
antagonist 0 NOUN F
) 0 PUNCT F
and 0 CCONJ F
following 0 VERB F
placebo 0 NOUN F
( 0 PUNCT F
sugar 0 NOUN F
pill 0 ADJ F
) 0 PUNCT F
administration 0 NOUN F
. 0 PUNCT F

Individuals 0 NOUN T
with 0 ADP F
ASD 0 NOUN T
performed B-MENTAL PUNCT F
more 0 ADV F
poorly 0 ADV F
than 0 PUNCT F
non-ASD 0 NOUN F
individuals 0 NOUN F
in 0 ADP F
the 0 DET F
working 0 ADJ F
memory 0 NOUN F
condition 0 NOUN F
( 0 PUNCT F
BX 0 ADJ T
trials 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

Importantly 0 ADV T
, 0 PUNCT F
administration 0 NOUN F
of 0 ADP F
propranolol 0 NOUN F
attenuated B-MENTAL VERB F
this I-MENTAL DET F
impairment I-MENTAL NOUN F
, 0 PUNCT F
with 0 ADP F
the 0 DET F
ASD 0 NOUN T
group 0 NOUN F
performing B-MENTAL PUNCT F
significantly 0 ADV F
better 0 PUNCT F
in 0 ADP F
the 0 DET F
propranolol 0 NOUN F
condition 0 NOUN F
than 0 PUNCT F
the 0 DET F
placebo 0 NOUN F
condition 0 NOUN F
. 0 PUNCT F

Working B-MENTAL PUNCT T
memory I-MENTAL NOUN F
performance I-MENTAL NOUN F
of 0 ADP F
the 0 DET F
non-ASD 0 NOUN F
group 0 NOUN F
was 0 VERB F
unaffected 0 VERB F
by 0 ADP F
propranolol/placebo 0 NOUN F
administration 0 NOUN F
. 0 PUNCT F

No 0 DET T
group 0 NOUN F
or 0 CCONJ F
medication 0 NOUN F
effects 0 NOUN F
were 0 VERB F
observed 0 VERB F
for 0 ADP F
the 0 DET F
inhibition B-MENTAL NOUN F
condition I-MENTAL NOUN F
( 0 PUNCT F
AY 0 NUM T
trials 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
present 0 ADJ F
findings 0 NOUN F
suggest 0 VERB F
that 0 ADP F
norepinephrine 0 NOUN F
may 0 PART F
play 0 VERB F
a 0 DET F
role 0 NOUN F
in 0 ADP F
some 0 PUNCT F
, 0 PUNCT F
but 0 CCONJ F
not 0 ADV F
necessarily 0 ADV F
all 0 PUNCT F
, 0 PUNCT F
cognitive B-MENTAL ADJ F
impairments I-MENTAL NOUN F
associated 0 VERB F
with 0 ADP F
ASD 0 NOUN T
. 0 PUNCT F

Additional 0 ADJ T
research 0 NOUN F
is 0 VERB F
needed 0 VERB F
to 0 PUNCT F
fully 0 DET F
understand 0 VERB F
whether 0 ADP F
this 0 DET F
role 0 NOUN F
is 0 VERB F
primarily 0 ADV F
causal 0 PUNCT F
or 0 CCONJ F
compensatory 0 ADJ F
in 0 ADP F
nature 0 NOUN F
. 0 PUNCT F

Exercise 0 NOUN T
for 0 ADP F
methamphetamine 0 NOUN F
dependence 0 NOUN F
: 0 PUNCT F
rationale 0 NOUN F
, 0 PUNCT F
design 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
methodology 0 NOUN F
. 0 PUNCT F

BACKGROUND 0 NOUN T
Effective 0 ADJ T
pharmacotherapies 0 NOUN F
to 0 ADJ F
treat 0 CCONJ F
methamphetamine 0 NOUN F
( 0 PUNCT F
MA 0 NOUN T
) 0 PUNCT F
dependence 0 NOUN F
have 0 PUNCT F
not 0 ADV F
been 0 PUNCT F
identified 0 VERB F
, 0 PUNCT F
and 0 CCONJ F
behavioral 0 ADJ F
therapies 0 NOUN F
are 0 VERB F
marginally 0 ADV F
effective 0 ADJ F
. 0 PUNCT F

Based 0 VERB T
on 0 ADP F
behavioral 0 ADJ F
studies 0 NOUN F
demonstrating 0 VERB F
the 0 DET F
potential 0 ADJ F
efficacy 0 NOUN F
of 0 ADP F
aerobic 0 ADJ F
exercise 0 NOUN F
for 0 ADP F
improving 0 VERB F
depressive B-MENTAL ADJ F
symptoms I-MENTAL NOUN F
, 0 PUNCT F
anxiety B-MENTAL NOUN F
, 0 PUNCT F
cognitive B-MENTAL ADJ F
deficits I-MENTAL NOUN F
, 0 PUNCT F
and 0 PUNCT F

First-line 0 NUM T
cisplatin 0 NOUN F
with 0 ADP F
docetaxel 0 PUNCT F
or 0 CCONJ F
vinorelbine 0 NOUN F
in 0 ADP F
patients 0 NOUN F
with 0 ADP F
advanced 0 VERB F
non-small-cell 0 NOUN F
lung 0 NOUN F
cancer 0 NOUN F
: 0 PUNCT F
a 0 DET F
quality 0 NOUN F
of 0 ADP F
life 0 NOUN F
directed 0 VERB F
phase 0 NOUN F
II 0 NUM T
randomized 0 VERB F
trial 0 NOUN F
of 0 ADP F
Gruppo 0 NOUN T
Oncologico 0 NOUN T
Italia 0 PUNCT T
Meridionale 0 NOUN T
. 0 PUNCT F

BACKGROUND 0 NOUN T
Quality 0 NOUN T
of 0 ADP F
life 0 NOUN F
( B-MENTAL PUNCT F
QoL I-MENTAL NOUN T
) I-MENTAL PUNCT F
has 0 PUNCT F
gained 0 VERB F
greater 0 PUNCT F
importance 0 NOUN F
in 0 ADP F
the 0 DET F
management 0 NOUN F
of 0 ADP F
metastatic 0 ADJ F
non-small-cell 0 NOUN F
lung 0 NOUN F
cancer 0 NOUN F
due 0 CCONJ F
to 0 ADP F
the 0 DET F
palliative 0 ADJ F
nature 0 NOUN F
of 0 ADP F
treatment 0 NOUN F
. 0 PUNCT F

Docetaxel 0 ADV T
( 0 PUNCT F
DCT 0 NOUN T
) 0 PUNCT F
and 0 CCONJ F
cisplatin 0 NOUN F
( 0 PUNCT F
CDDP 0 NOUN T
) 0 PUNCT F
doublet 0 NOUN F
has 0 PUNCT F
been 0 PUNCT F
reported 0 VERB F
to 0 PART F
be 0 PUNCT F
associated 0 VERB F
to 0 ADP F
a 0 DET F
better 0 PUNCT F
QoL 0 NOUN T
than 0 PUNCT F
the 0 DET F
weekly 0 PROPN F
vinorelbine 0 NOUN F
( 0 PUNCT F
VNR 0 NOUN T
) 0 PUNCT F
and 0 CCONJ F
CDDP 0 NOUN T
regimen 0 NOUN F
. 0 PUNCT F

Recently 0 ADV T
a 0 DET F
newer 0 PUNCT F
more 0 DET F
tolerated 0 PUNCT F
schedule 0 NOUN F
of 0 ADP F
the 0 DET F
VNR/CDDP 0 PUNCT T
regimen 0 NOUN F
has 0 PUNCT F
been 0 PUNCT F
published 0 VERB F
and 0 CCONJ F
is 0 NOUN F
widely 0 ADV F
employed 0 VERB F
in 0 ADP F
medical 0 ADJ F
practice 0 NOUN F
. 0 PUNCT F

The 0 DET T
impact 0 NOUN F
of 0 ADP F
these 0 DET F
regimens 0 NOUN F
on 0 ADP F
patients 0 NOUN F
' 0 PUNCT F
QoL 0 NOUN T
as 0 PUNCT F
well 0 PUNCT F
as 0 CCONJ F
symptoms B-PHYSICAL CCONJ F
control I-PHYSICAL NOUN F
and 0 CCONJ F
type 0 NOUN F
and 0 CCONJ F
grading 0 PUNCT F
chemo-related 0 ADJ F
side-effects B-PHYSICAL NOUN F
has 0 PUNCT F
been 0 PUNCT F
compared 0 VERB F
prospectically 0 ADV F
. 0 PUNCT F

METHODS 0 NOUN T
Patients 0 NOUN T
received 0 VERB F
CDDP 0 NOUN T
75 0 NUM F
mg/m 0 NOUN F
( 0 PUNCT F
2 0 NUM F
) 0 PUNCT F
plus 0 CCONJ F
DCT 0 NOUN T
75 0 NUM F
mg/m 0 NOUN F
( 0 PUNCT F
2 0 NUM F
) 0 PUNCT F
on 0 ADP F
day 0 NOUN F
1 0 NUM F
every 0 DET F
weeks 0 NOUN F
( 0 PUNCT F
arm 0 NOUN F
A 0 NOUN T
) 0 PUNCT F
or 0 CCONJ F
CDDP 0 NOUN T
80 0 NUM F
mg/m 0 NOUN F
( 0 PUNCT F
2 0 NUM F
) 0 PUNCT F
on 0 ADP F
day 0 NOUN F
1 0 NUM F
plus 0 CCONJ F
VNR 0 NOUN T
30 0 PUNCT F
mg/m 0 NOUN F
( 0 PUNCT F
2 0 NUM F
) 0 PUNCT F
day 0 NOUN F
1 0 NUM F
and 0 CCONJ F
8 0 NUM F
every 0 DET F
3 0 NUM F
weeks 0 NOUN F
( 0 PUNCT F
arm 0 NOUN F
B 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

G-CSF 0 NOUN T
and/or 0 CCONJ F
EPO 0 NOUN T
were 0 VERB F
employed 0 VERB F
as 0 PUNCT F
needed 0 PUNCT F
. 0 PUNCT F

Health-related B-MENTAL VERB T
QoL I-MENTAL NOUN T
was 0 VERB F
assessed 0 VERB F
at 0 ADP F
entry 0 NOUN F
and 0 CCONJ F
after 0 ADP F
every 0 DET F
cycle 0 NOUN F
by 0 ADP F
the 0 DET F
EORTC-QLQ-C30 0 ADJ T
and 0 CCONJ F
LC13 B-MENTAL NOUN T
questionnaires I-MENTAL NOUN F
, 0 PUNCT F
toxicity B-PHYSICAL NOUN F
by 0 ADP F
the 0 DET F
NCI-NCCN 0 NOUN T
CTC 0 NOUN T
vs 0 CCONJ F
2 0 NUM F
, 0 PUNCT F
and 0 CCONJ F
intent-to-treat 0 NOUN F
objective B-PHYSICAL ADJ F
response I-PHYSICAL NOUN F
by 0 ADP F
the 0 DET F
Recist 0 NOUN T
criteria 0 NOUN F
. 0 PUNCT F

RESULTS 0 PUNCT T
The 0 DET T
QoL B-PHYSICAL NOUN T
questionnaires I-PHYSICAL NOUN F
were 0 VERB F
completed 0 VERB F
by 0 ADP F
37 0 NUM F
pts 0 NOUN F
( 0 PUNCT F
88 0 NUM F
% 0 SYM F
) 0 PUNCT F
in 0 ADP F
the 0 DET F
DCT/CDDP 0 NOUN T
arm 0 NOUN F
and 0 CCONJ F
39 0 NUM F
pts 0 NOUN F
( 0 PUNCT F
87 0 NUM F
% 0 SYM F
) 0 PUNCT F
in 0 ADP F
the 0 DET F
VNR/CDDP 0 PUNCT T
one 0 NUM F
. 0 PUNCT F

Baseline 0 NOUN T
mean 0 NOUN F
scores 0 NOUN F
and 0 CCONJ F
rates 0 NOUN F
at 0 ADP F
which 0 PUNCT F
pts 0 NOUN F
failed 0 VERB F
to 0 ADP F
complete 0 ADJ F
QoL 0 NOUN T
assessment 0 NOUN F
were 0 VERB F
similar 0 ADJ F
in 0 ADP F
the 0 DET F
two 0 NUM F
arms 0 NOUN F
. 0 PUNCT F

Global B-MENTAL ADJ T
health I-MENTAL NOUN F
status I-MENTAL NOUN F
of 0 ADP F
the 0 DET F
EORTC B-PHYSICAL NOUN T
QLQ-C30 I-PHYSICAL NOUN T
scale I-PHYSICAL NOUN F
and 0 CCONJ F
specific 0 ADJ F
symptoms 0 NOUN F
control 0 NOUN F
( 0 PUNCT F
LC13 0 NOUN T
module 0 NOUN F
) 0 PUNCT F
improved 0 PRON F
during 0 ADP F
treatment 0 NOUN F
without 0 ADP F
any 0 DET F
statistically 0 ADV F
significant 0 ADJ F
difference 0 NOUN F
between 0 ADP F
the 0 DET F
two 0 NUM F
arms 0 NOUN F
. 0 PUNCT F

Emotional B-MENTAL ADJ T
functioning I-MENTAL VERB F
remained 0 VERB F
stable 0 ADJ F
in 0 ADP F
both 0 CCONJ F
groups 0 NOUN F
during 0 ADP F
treatment 0 NOUN F
, 0 PUNCT F
whereas 0 ADP F
physical B-MENTAL ADJ F
and 0 CCONJ F
role B-MENTAL NOUN F
improved 0 PUNCT F
slightly 0 ADV F
. 0 PUNCT F

In 0 ADP T
the 0 DET F
DCT/CDDP 0 NOUN T
arm 0 NOUN F
14 0 NUM F
pts 0 NOUN F
( 0 PUNCT F
33 0 NUM F
% 0 SYM F
; 0 PUNCT F
95 0 NUM F
% 0 SYM F
CL 0 NOUN T
24-40 0 NUM F
% 0 SYM F
) 0 PUNCT F
had 0 PUNCT F
PR 0 NOUN T
, 0 PUNCT F
and 0 CCONJ F
10 0 NUM F
( 0 PUNCT F
24 0 NUM F
% 0 SYM F
) 0 PUNCT F
SD 0 NOUN T
for 0 ADP F
a 0 DET F
57 0 NUM F
% 0 SYM F
TGCR 0 NOUN T
. 0 PUNCT F

In 0 ADP T
the 0 DET F
VNR/CDDP 0 PUNCT T
arm 0 NOUN F
12 0 NUM F
pts 0 NOUN F
( 0 PUNCT F
27 0 NUM F
% 0 SYM F
) 0 PUNCT F
achieved 0 VERB F
PR B-PHYSICAL NOUN T
, 0 PUNCT F
18 0 NUM F
( 0 PUNCT F
41 0 NUM F
% 0 SYM F
) 0 PUNCT F
SD 0 NOUN T
a 0 DET F
68 0 NUM F
% 0 SYM F
TGCR 0 NOUN T
. 0 PUNCT F

Differences 0 NOUN T
were 0 VERB F
not 0 ADV F
statistically 0 ADV F
significant 0 ADJ F
. 0 PUNCT F

Median 0 ADJ T
time-to-progression B-PHYSICAL NOUN F
was 0 VERB F
4.2 0 NUM F
months 0 NOUN F
in 0 ADP F
the 0 DET F
DCT/CDDP 0 NOUN T
arm 0 NOUN F
and 0 CCONJ F
4.5 0 NUM F
months 0 NOUN F
in 0 ADP F
the 0 DET F
VNR/CDDP 0 PUNCT T
one 0 NUM F
, 0 PUNCT F
and 0 CCONJ F
median 0 ADJ F
overall B-MORTALITY ADJ F
survival I-MORTALITY NOUN F
was 0 VERB F
12.1 0 NUM F
( 0 PUNCT F
range 0 NOUN F
1-26+ 0 NOUN F
months 0 NOUN F
) 0 PUNCT F
and 0 CCONJ F
12.5 0 NUM F
months 0 NOUN F
( 0 PUNCT F
range 0 NOUN F
1-28+ 0 NOUN F
months 0 NOUN F
) 0 PUNCT F
for 0 ADP F
DCT/CDDP 0 PUNCT T
and 0 CCONJ F
VNR/CDDP 0 PUNCT T
arms 0 NOUN F
, 0 PUNCT F
respectively 0 ADV F
. 0 PUNCT F

Febrile B-PHYSICAL ADJ T
neutropenia I-PHYSICAL NOUN F
rate I-PHYSICAL NOUN F
was 0 VERB F
higher 0 PUNCT F
in 0 ADP F
the 0 DET F
VNR/CDDP 0 PUNCT T
arm 0 NOUN F
( 0 PUNCT F
p=0.02 0 NOUN F
) 0 PUNCT F
as 0 CCONJ F
well 0 PUNCT F
as 0 CCONJ F
G3-4 0 NOUN T
anemia B-PHYSICAL NOUN F
( 0 PUNCT F
p=0.005 0 NOUN F
) 0 PUNCT F
and 0 CCONJ F
G-CSF/EPO 0 PUNCT T
use 0 NOUN F
( 0 PUNCT F
p=0.019 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

CONCLUSIONS 0 NOUN T
Global B-PHYSICAL PUNCT T
and I-PHYSICAL CCONJ F
specific I-PHYSICAL ADJ F
health-related I-PHYSICAL VERB F
QoL I-PHYSICAL NOUN T
data 0 NOUN F
similar 0 ADJ F
in 0 ADP F
both 0 PUNCT F
treatment 0 NOUN F
groups 0 NOUN F
with 0 ADP F
no 0 DET F
statistically 0 ADV F
significant 0 ADJ F
difference 0 NOUN F
. 0 PUNCT F

Efficacy 0 NOUN T
measures B-OTHER NOUN F
, 0 PUNCT F
overall 0 ADJ F
response 0 NOUN F
rate B-PHYSICAL NOUN F
, 0 PUNCT F
time-to-progression B-PHYSICAL NOUN F
and 0 CCONJ F
overall B-MORTALITY ADJ F
survival I-MORTALITY NOUN F
were 0 VERB F
equivalent 0 ADJ F
in 0 ADP F
both 0 PUNCT F
arms 0 NOUN F
. 0 PUNCT F

However 0 ADV T
, 0 PUNCT F
severe B-PHYSICAL ADJ F
anemia I-PHYSICAL NOUN F
and 0 CCONJ F
febrile B-PHYSICAL ADJ F
neutropenia I-PHYSICAL NOUN F
are 0 VERB F
statistically 0 ADV F
more 0 ADV F
frequent 0 ADP F
in 0 ADP F
the 0 DET F
VNR/CDDP 0 PUNCT T
arm 0 NOUN F
than 0 PUNCT F
in 0 ADP F
the 0 DET F
DCT/CDDP 0 NOUN T
one 0 NUM F
. 0 PUNCT F

These 0 DET T
data 0 NOUN F
should 0 VERB F
be 0 VERB F
considered 0 VERB F
in 0 ADP F
treatment 0 NOUN F
decision-making 0 ADJ F
for 0 ADP F
pts 0 NOUN F
with 0 ADP F
advanced 0 VERB F
non-small-cell 0 NOUN F
lung 0 NOUN F
cancer 0 NOUN F
and 0 CCONJ F
for 0 ADP F
the 0 DET F
design 0 NOUN F
of 0 ADP F
future 0 ADJ F
trials 0 NOUN F
with 0 ADP F
chemotherapy 0 NOUN F
plus 0 CCONJ F
biologics 0 NOUN F
. 0 PUNCT F

Pharmacogenetic 0 ADJ T
interaction 0 NOUN F
analysis 0 NOUN F
for 0 ADP F
the 0 DET F
efficacy 0 NOUN F
of 0 ADP F
systemic 0 ADJ F
treatment 0 NOUN F
in 0 ADP F
metastatic 0 ADJ F
colorectal 0 ADJ F
cancer 0 NOUN F
. 0 PUNCT F

BACKGROUND 0 NOUN T
Pharmacogenetic 0 ADJ T
markers 0 NOUN F
related 0 VERB F
to 0 ADP F
drug 0 NOUN F
metabolism 0 NOUN F
and 0 CCONJ F
mechanisms 0 NOUN F
of 0 ADP F
action 0 NOUN F
could 0 VERB F
help 0 VERB F
to 0 PUNCT F
better 0 PUNCT F
select 0 ADP F
patients 0 NOUN F
with 0 ADP F
metastatic 0 ADJ F
colorectal 0 ADJ F
cancer 0 NOUN F
( 0 PUNCT F
mCRC 0 NOUN F
) 0 PUNCT F
for 0 ADP F
treatment 0 NOUN F
. 0 PUNCT F

Genetic 0 ADJ T
interaction 0 NOUN F
analysis 0 NOUN F
is 0 VERB F
used 0 VERB F
as 0 ADP F
a 0 DET F
rational 0 ADJ F
tool 0 NOUN F
to 0 ADP F
study 0 VERB F
the 0 DET F
contribution 0 NOUN F
of 0 ADP F
polygenic 0 ADJ F
variation 0 NOUN F
in 0 ADP F
relation 0 NOUN F
to 0 ADP F
drug 0 NOUN F
response 0 NOUN F
. 0 PUNCT F

PATIENTS 0 NOUN T
AND 0 CCONJ T
METHODS 0 NOUN T
A 0 DET T
selection 0 NOUN F
of 0 ADP F
17 0 NUM F
polymorphisms 0 NOUN F
in 0 ADP F
genes 0 NOUN F
encoding 0 VERB F
drug 0 NOUN F
targets 0 NOUN F
, 0 PUNCT F
pathway B-PHYSICAL NOUN F
molecules I-PHYSICAL NOUN F
and 0 CCONJ F
detoxification B-PHYSICAL NOUN F
enzymes I-PHYSICAL NOUN F
was 0 VERB F
analyzed 0 VERB F
in 0 ADP F
279 0 NUM F
previously 0 ADV F
untreated 0 VERB F
mCRC 0 NOUN F
patients 0 NOUN F
treated 0 VERB F
with 0 ADP F
capecitabine 0 NOUN F
, 0 PUNCT F
oxaliplatin 0 NOUN F
and 0 CCONJ F
bevacizumab 0 PUNCT F
( 0 PUNCT F
CAPOX-B 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

Multifactor 0 NOUN T
dimensionality 0 NOUN F
reduction 0 NOUN F
analysis 0 NOUN F
was 0 VERB F
used 0 VERB F
to 0 PART F
identify 0 NOUN F
a 0 DET F
genetic B-MORTALITY ADJ F
interaction 0 NOUN F
profile B-MORTALITY NOUN F
for I-MORTALITY ADP F
progression-free I-MORTALITY ADJ F
survival I-MORTALITY NOUN F
( I-MORTALITY PUNCT F
PFS I-MORTALITY NOUN T
) B-MORTALITY PUNCT F
. 0 PUNCT F

RESULTS 0 ADJ T
Median 0 ADJ T
PFS B-MORTALITY NOUN T
was 0 VERB F
10.9 0 NUM F
[ 0 PUNCT F
95 0 NUM F
% 0 SYM F
confidence 0 NOUN F
interval 0 NOUN F
( 0 PUNCT F
CI 0 NOUN T
) 0 PUNCT F
9.4-12.4 0 NUM F
] 0 PUNCT F
months 0 NOUN F
. 0 PUNCT F

A 0 DET T
genetic B-PHYSICAL ADJ F
interaction 0 NOUN F
profile B-PHYSICAL NOUN F
consisting 0 DET F
of 0 ADP F
the 0 DET F
TYMS 0 NOUN T
enhancer 0 NOUN F
region 0 NOUN F
and 0 CCONJ F
VEGF 0 NOUN T
+405G 0 PUNCT F
> 0 SYM F
C 0 NOUN T
polymorphisms 0 NOUN F
was 0 VERB F
significantly 0 ADV F
associated 0 VERB F
with 0 ADP F
PFS 0 NOUN T
. 0 PUNCT F

Median 0 ADJ T
PFS B-MORTALITY NOUN T
was 0 VERB F
13.3 0 NUM F
( 0 PUNCT F
95 0 NUM F
% 0 SYM F
CI 0 NOUN T
11.4-15.3 0 PUNCT F
) 0 PUNCT F
and 0 CCONJ F
9.7 0 NUM F
( 0 PUNCT F
95 0 NUM F
% 0 SYM F
CI 0 NOUN T
7.6-11.8 0 NUM F
) 0 PUNCT F
months 0 NOUN F
for 0 ADP F
the 0 DET F
beneficial 0 ADJ F
and 0 CCONJ F
unfavorable 0 ADJ F
genetic B-PHYSICAL ADJ F
profiles I-PHYSICAL NOUN F
, 0 PUNCT F
respectively 0 ADV F
, 0 PUNCT F
corresponding 0 CCONJ F
to 0 ADP F
a 0 DET F
hazards 0 ADJ F
ratio 0 NOUN F
for 0 PUNCT F

Granulocyte-macrophage 0 NOUN T
colony-stimulating 0 VERB F
factor 0 NOUN F
treatment 0 NOUN F
before 0 ADP F
doxorubicin 0 NOUN F
and 0 CCONJ F
cyclophosphamide 0 NOUN F
chemotherapy 0 NOUN F
priming 0 VERB F
in 0 ADP F
women 0 NOUN F
with 0 ADP F
early-stage 0 NOUN F
breast 0 NOUN F
cancer 0 NOUN F
. 0 PUNCT F

PURPOSE 0 NOUN T
To 0 PROPN T
determine 0 NOUN F
if 0 PUNCT F
inhibition 0 NOUN F
of 0 ADP F
stem-cell 0 NOUN F
activity 0 NOUN F
induced 0 VERB F
by 0 ADP F
granulocyte-macrophage 0 NOUN F
colony-stimulating 0 VERB F
factor 0 NOUN F
( 0 PUNCT F
[ 0 PUNCT F
GM-CSF 0 NOUN T
] 0 PUNCT F
; 0 PUNCT F
Sargramostim 0 NOUN T
; 0 PUNCT F
Immunex 0 ADP T
Corporation 0 NOUN T
, 0 PUNCT F
Seattle 0 PUNCT T
, 0 PUNCT F
WA 0 NOUN T
) 0 PUNCT F
withdrawal 0 NOUN F
or 0 CCONJ F
priming 0 PUNCT F
protects 0 VERB F
hematopoietic 0 ADJ F
stem 0 NOUN F
cells 0 NOUN F
from 0 ADP F
the 0 DET F
cytotoxic 0 ADJ F
effects 0 NOUN F
of 0 ADP F
adjuvant 0 NOUN F
chemotherapy 0 NOUN F
for 0 ADP F
early-stage 0 NOUN F
breast 0 NOUN F
cancer 0 NOUN F
. 0 PUNCT F

PATIENTS 0 NOUN T
AND 0 CCONJ T
METHODS 0 NOUN T
Serial 0 PUNCT T
blood 0 NOUN F
counts 0 NOUN F
were 0 VERB F
performed 0 VERB F
in 0 ADP F
20 0 NUM F
women 0 NOUN F
with 0 ADP F
early-stage 0 NOUN F
breast 0 NOUN F
cancer 0 NOUN F
receiving 0 VERB F
four 0 NUM F
courses 0 NOUN F
of 0 ADP F
cyclophosphamide 0 NOUN F
and 0 CCONJ F
doxorubicin 0 NOUN F
chemotherapy 0 NOUN F
. 0 PUNCT F

By 0 ADP T
a 0 DET F
double-blind 0 ADJ F
, 0 PUNCT F
placebo-controlled 0 VERB F
, 0 PUNCT F
balanced 0 ADP F
randomization 0 NOUN F
, 0 PUNCT F
subjects 0 NOUN F
received 0 VERB F
GM-CSF 0 NOUN T
priming 0 VERB F
on 0 ADP F
days 0 NOUN F
5 0 NUM F
to 0 ADP F
1 0 NUM F
for 0 ADP F
courses 0 DET F
1 0 NUM F
and 0 CCONJ F
3 0 NUM F
or 0 CCONJ F
courses 0 ADP F
2 0 NUM F
and 0 CCONJ F
4 0 NUM F
. 0 PUNCT F

RESULTS 0 NOUN T
Compared 0 VERB T
with 0 ADP F
before 0 ADP F
priming 0 VERB F
, 0 PUNCT F
after 0 ADP F
priming 0 PUNCT F
the 0 DET F
times B-PHYSICAL NOUN F
to I-PHYSICAL ADP F
neutrophil I-PHYSICAL NOUN F
nadir I-PHYSICAL NOUN F
( 0 PUNCT F
12.8 0 NUM F
+/- 0 SYM F
2.5 0 NUM F
days 0 NOUN F
v 0 NUM F
14.8 0 NUM F
+/- 0 SYM F
1.5 0 NUM F
days 0 NOUN F
, 0 PUNCT F
respectively 0 ADV F
; 0 PUNCT F
P 0 NOUN T
=.0001 0 VERB F
) 0 PUNCT F
and 0 CCONJ F
platelet B-PHYSICAL NOUN F
nadir I-PHYSICAL NOUN F
( 0 PUNCT F
mean 0 NOUN F
+/- 0 SYM F
SD 0 NOUN T
, 0 PUNCT F
10.1 0 NUM F
+/- 0 SYM F
1.9 0 NUM F
days 0 NOUN F
v 0 CCONJ F
11.1 0 NUM F
+/- 0 SYM F
2.2 0 NUM F
days 0 NOUN F
, 0 PUNCT F
P 0 NOUN T
< 0 SYM F
.05 0 NUM F
) 0 PUNCT F
were 0 VERB F
shorter 0 PUNCT F
, 0 PUNCT F
indicating 0 VERB F
a 0 DET F
shift 0 NOUN F
of 0 ADP F
cytotoxicity 0 NOUN F
to 0 ADP F
later 0 PUNCT F
progenitors 0 NOUN F
. 0 PUNCT F

The 0 DET T
neutrophil B-PHYSICAL NOUN F
nadir I-PHYSICAL NOUN F
was 0 VERB F
similar 0 ADJ F
with 0 ADP F
and 0 CCONJ F
without 0 ADP F
priming 0 VERB F
( 0 PUNCT F
mean 0 NOUN F
+/- 0 SYM F
SD 0 NOUN T
, 0 PUNCT F
490 0 NUM F
+/- 0 SYM F
310/microL 0 NOUN F
v 0 NUM F
550 0 NUM F
+/- 0 SYM F
350/microL 0 ADP F
, 0 PUNCT F
respectively 0 ADV F
; 0 PUNCT F
P 0 NOUN T
=.2 0 PUNCT F
) 0 PUNCT F
; 0 PUNCT F
however 0 ADV F
, 0 PUNCT F
on 0 ADP F
day 0 NOUN F
16 0 PUNCT F
the 0 DET F
mean 0 NOUN F
neutrophil B-PHYSICAL NOUN F
count I-PHYSICAL NOUN F
was 0 VERB F
higher 0 PUNCT F
( 0 PUNCT F
mean 0 NOUN F
+/- 0 SYM F
SD 0 NOUN T
, 0 PUNCT F
1030 0 NUM F
+/- 0 SYM F
580/microL 0 NOUN F
v 0 NUM F
690 0 NUM F
+/- 0 SYM F
370/microL 0 NUM F
, 0 PUNCT F
P 0 NOUN T
=.004 0 PUNCT F
) 0 PUNCT F
, 0 PUNCT F
and 0 CCONJ F
the 0 DET F
proportion 0 NOUN F
of 0 ADP F
patients 0 NOUN F
with 0 ADP F
a 0 DET F
neutrophil B-PHYSICAL NOUN F
count I-PHYSICAL NOUN F
less 0 ADV F
than 0 PUNCT F
500/microL 0 ADP F
was 0 VERB F
lower 0 PUNCT F
after 0 ADP F
priming 0 ADJ F
than 0 VERB F
before 0 PUNCT F
( 0 PUNCT F
six 0 ADJ F
of 0 ADP F
35 0 NUM F
or 0 CCONJ F
17 0 NUM F
. 0 PUNCT F

1 0 NUM F
% 0 SYM F
v 0 NUM F
12 0 NUM F
of 0 ADP F
34 0 NUM F
or 0 CCONJ F
35.3 0 NUM F
% 0 SYM F
, 0 PUNCT F
respectively 0 ADV F
; 0 PUNCT F
P 0 NOUN T
=.04 0 PUNCT F
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
platelet B-PHYSICAL NOUN F
nadir I-PHYSICAL NOUN F
was 0 VERB F
higher 0 PUNCT F
( 0 PUNCT F
mean 0 NOUN F
+/- 0 SYM F
SD 0 NOUN T
, 0 PUNCT F
166,000 0 NUM F
+/- 0 SYM F
51,000/microL 0 NOUN F
after 0 ADP F
priming 0 VERB F
v 0 NUM F
151,000 0 NUM F
+/- 0 SYM F
45,000/microL 0 NOUN F
before 0 ADP F
priming 0 VERB F
, 0 PUNCT F
P 0 NOUN T
=.007 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
and 0 CCONJ F
the 0 DET F
duration B-PHYSICAL NOUN F
of I-PHYSICAL ADP F
thrombocytopenia I-PHYSICAL NOUN F
, 0 PUNCT F
ie 0 ADP F
, 0 PUNCT F
a 0 DET F
platelet 0 NOUN F
count 0 NOUN F
less 0 ADV F
than 0 PUNCT F
150,000/microL 0 ADP F
, 0 PUNCT F
was 0 VERB F
shorter 0 PUNCT F
( 0 PUNCT F
1.5 0 NUM F
+/- 0 SYM F
2.1 0 NUM F
days 0 NOUN F
v 0 NUM F
2.8 0 NUM F
+/- 0 SYM F
2.9 0 NUM F
days 0 NOUN F
, 0 PUNCT F
P 0 PUNCT T
=.0025 0 PUNCT F
) 0 PUNCT F
after 0 ADP F
priming 0 VERB F
. 0 PUNCT F

Episodes 0 NOUN T
of 0 ADP F
fever B-ADVERSE-EFFECTS NOUN F
and 0 CCONJ F
neutropenia B-ADVERSE-EFFECTS NOUN F
were 0 VERB F
not 0 ADV F
observed 0 VERB F
. 0 PUNCT F

CONCLUSIONS 0 NOUN T
GM-CSF 0 NOUN T
priming 0 VERB F
from 0 ADP F
days 0 NOUN F
5 0 NUM F
to 0 ADP F
1 0 NUM F
before 0 ADP F
doxorubicin 0 NOUN F
and 0 CCONJ F
cyclophosphamide 0 NOUN F
chemotherapy 0 NOUN F
was 0 VERB F
associated 0 VERB F
with 0 ADP F
an 0 DET F
earlier 0 PUNCT F
neutrophil B-PHYSICAL NOUN F
and 0 CCONJ F
platelet B-PHYSICAL NOUN F
nadir I-PHYSICAL NOUN F
. 0 PUNCT F

On 0 ADP T
day 0 NOUN F
16 0 NUM F
, 0 PUNCT F
a 0 DET F
higher 0 PUNCT F
mean 0 NOUN F
neutrophil B-PHYSICAL NOUN F
count I-PHYSICAL NOUN F
and 0 CCONJ F
a 0 DET F
lower 0 PUNCT F
proportion 0 NOUN F
of 0 ADP F
patients 0 NOUN F
with 0 ADP F
severe 0 ADJ F
( 0 PUNCT F
< 0 ADP F
500/microL 0 ADP F
) 0 PUNCT F
neutropenia B-ADVERSE-EFFECTS NOUN F
were 0 VERB F
observed 0 VERB F
. 0 PUNCT F

Beneficial 0 ADJ T
effects 0 NOUN F
on 0 ADP F
the 0 DET F
severity 0 NOUN F
and 0 CCONJ F
duration 0 NOUN F
of 0 ADP F
thrombocytopenia B-PHYSICAL NOUN F
were 0 VERB F
also 0 ADV F
noted 0 VERB F
. 0 PUNCT F

These 0 DET T
observations 0 NOUN F
support 0 VERB F
the 0 DET F
hypothesis 0 NOUN F
that 0 ADP F
GM-CSF 0 NOUN T
priming 0 ADP F
protects 0 NOUN F
hematopoietic 0 ADJ F
progenitors 0 NOUN F
from 0 ADP F
the 0 DET F
cytotoxic 0 ADJ F
effects 0 NOUN F
of 0 ADP F
chemotherapy 0 NOUN F
. 0 PUNCT F

Effects 0 NOUN T
of 0 ADP F
ORG-2766 0 NOUN T
on 0 ADP F
brain 0 NOUN F
event-related 0 VERB F
potentials 0 NOUN F
of 0 ADP F
autistic 0 ADJ F
children 0 NOUN F
. 0 PUNCT F

A 0 DET T
double-blind 0 ADJ F
, 0 PUNCT F
placebo-controlled 0 VERB F
study 0 NOUN F
examined 0 VERB F
the 0 DET F
effects 0 NOUN F
of 0 ADP F
6 0 NUM F
weeks 0 NOUN F
of 0 ADP F
treatment 0 NOUN F
with 0 ADP F
the 0 DET F
adrenocorticotropin4-9 0 NOUN F
analogue 0 NOUN F
ORG-2766 0 NOUN T
( 0 PUNCT F
40 0 NUM F
mg/day 0 NOUN F
) 0 PUNCT F
on 0 ADP F
brain 0 NOUN F
event-related 0 VERB F
potentials 0 NOUN F
( 0 PUNCT F
ERPs 0 NOUN T
) 0 PUNCT F
of 0 ADP F
autistic 0 ADJ F
children 0 NOUN F
. 0 PUNCT F

In 0 ADP T
visual 0 ADJ F
and 0 CCONJ F
auditory 0 ADJ F
oddball 0 DET F
paradigms 0 NOUN F
( 0 PUNCT F
with 0 ADP F
task 0 NOUN F
and 0 CCONJ F
nontask 0 PUNCT F
conditions 0 NOUN F
) 0 PUNCT F
, 0 PUNCT F
standard 0 ADJ F
( 0 PUNCT F
80 0 NUM F
% 0 SYM F
) 0 PUNCT F
, 0 PUNCT F
target 0 NOUN F
( 0 PUNCT F
10 0 NUM F
% 0 SYM F
) 0 PUNCT F
, 0 PUNCT F
and 0 CCONJ F
unexpected 0 VERB F
novel 0 ADJ F
stimuli 0 NOUN F
( 0 PUNCT F
10 0 NUM F
% 0 SYM F
) 0 PUNCT F
were 0 VERB F
presented 0 VERB F
. 0 PUNCT F

ORG-2766 0 NOUN T
( 0 PUNCT F
a 0 NOUN F
) 0 PUNCT F
increased 0 VERB F
the B-PHYSICAL DET F
occipital I-PHYSICAL ADJ F
P3 I-PHYSICAL NOUN T
component I-PHYSICAL NOUN F
of I-PHYSICAL ADP F
the I-PHYSICAL DET F
ERP I-PHYSICAL NOUN T
to I-PHYSICAL ADP F
visual I-PHYSICAL ADJ F
targets I-PHYSICAL NOUN F
, 0 PUNCT F
( 0 PUNCT F
b B-PHYSICAL NOUN F
) 0 PUNCT F
decreased 0 VERB F
the B-PHYSICAL DET F
occipital I-PHYSICAL ADJ F
P3 I-PHYSICAL NOUN T
component I-PHYSICAL NOUN F
of I-PHYSICAL ADP F
the I-PHYSICAL DET F
ERP I-PHYSICAL NOUN T
to I-PHYSICAL ADP F
auditory I-PHYSICAL ADJ F
targets B-PHYSICAL NOUN F
, 0 PUNCT F
( B-PHYSICAL PUNCT F
c I-PHYSICAL NOUN F
) I-PHYSICAL PUNCT F
did I-PHYSICAL DET F
not I-PHYSICAL ADV F
affect I-PHYSICAL VERB F
visual I-PHYSICAL ADJ F
and I-PHYSICAL CCONJ F
auditory I-PHYSICAL ADJ F
parietal I-PHYSICAL ADJ F
target I-PHYSICAL NOUN F
P3 B-PHYSICAL NOUN T
components I-PHYSICAL NOUN F
, 0 PUNCT F
and 0 CCONJ F
( 0 PUNCT F
d 0 NOUN F
) 0 PUNCT F
also 0 ADV F
did 0 PUNCT F
not 0 ADV F
affect 0 VERB F
the 0 DET F
A/Pcz/300 0 NOUN T
to 0 ADP F
auditory 0 ADJ F
novel 0 ADJ F
stimuli 0 NOUN F
. 0 PUNCT F

In 0 ADP T
addition 0 NOUN F
, 0 PUNCT F
ORG-2766 0 NOUN T
treatment 0 NOUN F
increased 0 PUNCT F

The 0 DET T
influence 0 NOUN F
of 0 ADP F
epidermal 0 ADJ F
growth 0 NOUN F
factor 0 NOUN F
receptor 0 NOUN F
and 0 CCONJ F
tumor 0 NOUN F
differentiation 0 NOUN F
on 0 ADP F
the 0 DET F
response 0 NOUN F
to 0 ADP F
accelerated 0 PUNCT F
radiotherapy 0 NOUN F
of 0 ADP F
squamous 0 ADJ F
cell 0 NOUN F
carcinomas 0 NOUN F
of 0 ADP F
the 0 DET F
head 0 NOUN F
and 0 CCONJ F
neck 0 NOUN F
in 0 ADP F
the 0 DET F
randomized 0 VERB F
DAHANCA 0 NOUN T
6 0 NUM F
and 0 CCONJ F
7 0 NUM F
study 0 NOUN F
. 0 PUNCT F

BACKGROUND 0 NOUN T
AND 0 CCONJ T
PURPOSE 0 NOUN T
Reduction 0 NOUN T
of 0 ADP F
the 0 DET F
overall 0 ADJ F
treatment 0 NOUN F
time 0 NOUN F
of 0 ADP F
radiotherapy 0 NOUN F
has 0 PUNCT F
increased 0 PUNCT F
locoregional B-PHYSICAL ADJ F
control I-PHYSICAL NOUN F
and 0 CCONJ F
disease B-PHYSICAL NOUN F
specific I-PHYSICAL ADJ F
survival I-PHYSICAL NOUN F
in 0 ADP F
squamous 0 ADJ F
cell 0 NOUN F
carcinomas 0 NOUN F
of 0 ADP F
the 0 DET F
head 0 NOUN F
and 0 CCONJ F
neck 0 NOUN F
( 0 PUNCT F
HNSCC 0 NOUN T
) 0 PUNCT F
, 0 PUNCT F
but 0 CCONJ F
the 0 DET F
response 0 NOUN F
is 0 VERB F
heterogeneous 0 ADJ F
. 0 PUNCT F

EGFr 0 NOUN T
is 0 VERB F
often 0 ADV F
overexpressed 0 VERB F
in 0 ADP F
HNSCC 0 NOUN T
and 0 CCONJ F
has 0 PUNCT F
been 0 PUNCT F
related 0 VERB F
to 0 ADP F
the 0 DET F
repopulation 0 NOUN F
taking 0 PUNCT F
place 0 NOUN F
during 0 ADP F
radiotherapy 0 NOUN F
. 0 PUNCT F

The 0 DET T
aim 0 NOUN F
of 0 ADP F
the 0 DET F
current 0 ADJ F
study 0 NOUN F
was 0 VERB F
to 0 ADV F
address 0 NOUN F
the 0 DET F
influence 0 NOUN F
of 0 ADP F
EGFr 0 NOUN T
and 0 CCONJ F
histopathological B-PHYSICAL ADJ F
differentiation I-PHYSICAL NOUN F
when 0 ADP F
the 0 DET F
overall 0 ADJ F
treatment 0 NOUN F
time 0 NOUN F
of 0 ADP F
radiotherapy 0 NOUN F
was 0 VERB F
moderately 0 ADV F
reduced 0 VERB F
. 0 PUNCT F

PATIENTS 0 NOUN T
AND 0 CCONJ T
METHODS 0 NOUN T
Eight 0 NUM T
hundred 0 NUM F
and 0 CCONJ F
three 0 NUM F
patients 0 NOUN F
with 0 ADP F
representative 0 ADJ F
pretreatment 0 NOUN F
tissue 0 NOUN F
samples 0 NOUN F
from 0 ADP F
the 0 DET F
randomized 0 VERB F
DAHANCA 0 NOUN T
6 0 NUM F
and 0 CCONJ F
7 0 NUM F
study 0 NOUN F
of 0 ADP F
5 0 NUM F
vs. 0 CCONJ F
6 0 NUM F
fx/wk 0 NOUN F
of 0 ADP F
radiotherapy 0 NOUN F
. 0 PUNCT F

EGFr 0 NOUN T
was 0 VERB F
visualized 0 VERB F
using 0 VERB F
immunohistochemistry 0 NOUN F
and 0 CCONJ F
separated 0 VERB F
into 0 ADP F
high 0 ADJ F
and 0 CCONJ F
low 0 ADJ F
expression 0 NOUN F
before 0 ADP F
correlation 0 NOUN F
with 0 ADP F
clinical 0 ADJ F
data 0 NOUN F
. 0 PUNCT F

RESULTS 0 DET T
Tumors 0 NOUN T
with 0 ADP F
high 0 ADJ F
EGFr 0 NOUN T
( 0 PUNCT F
84 0 NUM F
% 0 SYM F
) 0 PUNCT F
responded 0 VERB F
better 0 PUNCT F
to 0 PUNCT F
moderately 0 ADV F
accelerated 0 DET F
radiotherapy 0 NOUN F
, 0 PUNCT F
than 0 PUNCT F
carcinomas 0 NOUN F
with 0 ADP F
low 0 ADJ F
EGFr 0 NOUN T
, 0 PUNCT F
using 0 SYM F
locoregional 0 ADJ F
control 0 NOUN F
as 0 PUNCT F
endpoint 0 ADJ F
and 0 CCONJ F
a 0 DET F
similar 0 ADJ F
pattern 0 NOUN F
was 0 VERB F
seen 0 VERB F
, 0 PUNCT F
stratifying 0 PUNCT F
by 0 ADP F
well/moderate 0 NOUN F
vs. 0 CCONJ F
poor 0 ADJ F
tumor B-PHYSICAL NOUN F
differentiation I-PHYSICAL NOUN F
. 0 PUNCT F

Therefore 0 ADV T
, 0 PUNCT F
a 0 DET F
combined 0 VERB F
parameter 0 NOUN F
was 0 VERB F
constructed 0 VERB F
showing 0 VERB F
a 0 DET F
more 0 ADV F
prominent B-OTHER ADJ F
separation I-OTHER NOUN F
of I-OTHER ADP F
response I-OTHER NOUN F
: 0 PUNCT F
tumors 0 NOUN F
with 0 ADP F
high 0 ADJ F
EGFr 0 NOUN T
and 0 CCONJ F
well/moderate 0 NOUN F
differentiation 0 NOUN F
did 0 PUNCT F
benefit 0 CCONJ F
from 0 ADP F
moderate 0 ADJ F
acceleration 0 NOUN F
of 0 ADP F
treatment 0 NOUN F
regarding 0 VERB F
locoregional 0 ADJ F
control 0 NOUN F
, 0 PUNCT F
HR 0 NOUN T
0.54 0 NUM F
( 0 PUNCT F
0.37-0.78 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
whereas 0 ADP F
such 0 PUNCT F
an 0 DET F
effect 0 NOUN F
was 0 VERB F
not 0 ADV F
seen 0 VERB F
in 0 ADP F
tumors 0 NOUN F
with 0 ADP F
low 0 ADJ F
EGFr 0 NOUN T
and/or 0 CCONJ F
poor 0 ADJ F
differentiation 0 NOUN F
, 0 PUNCT F
HR 0 NOUN T
0.8 0 NUM F
( 0 PUNCT F
0.51-1.25 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

These 0 DET T
results 0 ADP F
reflected 0 VERB F
the 0 DET F
disease B-MORTALITY NOUN F
specific I-MORTALITY ADJ F
survival I-MORTALITY NOUN F
as 0 VERB F
well 0 PUNCT F
and 0 CCONJ F
were 0 VERB F
confirmed 0 VERB F
in 0 ADP F
multivariable 0 ADJ F
analyses 0 NOUN F
. 0 PUNCT F

CONCLUSIONS 0 NOUN T
Moderately 0 ADV T
accelerated 0 VERB F
fractionation 0 NOUN F
is 0 VERB F
superior 0 ADJ F
to 0 ADP F
conventional 0 ADJ F
treatment 0 NOUN F
in 0 ADP F
HNSCC 0 NOUN T
but 0 CCONJ F
the 0 DET F
response 0 NOUN F
is 0 VERB F
heterogeneous 0 ADJ F
and 0 CCONJ F
may 0 PRON F
be 0 VERB F
predicted 0 VERB F
by 0 ADP F
high 0 ADJ F
expression B-PHYSICAL NOUN F
of I-PHYSICAL ADP F
EGFr I-PHYSICAL NOUN T
and 0 CCONJ F
well/moderate 0 NOUN F
tumor B-PHYSICAL NOUN F
differentiation I-PHYSICAL NOUN F
. 0 PUNCT F

Outcomes 0 NOUN T
in 0 ADP F
a 0 DET F
nursing 0 VERB F
home 0 NOUN F
transition 0 NOUN F
case-management 0 NOUN F
program 0 NOUN F
targeting 0 PUNCT F
new 0 ADJ F
admissions 0 NOUN F
. 0 PUNCT F

PURPOSE 0 NOUN T
The 0 DET T
Providing 0 PUNCT T
Assistance 0 NOUN T
to 0 ADP F
Caregivers 0 NOUN T
in 0 ADP F
Transition 0 NOUN T
( 0 PUNCT F
PACT 0 NOUN T
) 0 PUNCT F
program 0 NOUN F
offers 0 NOUN F
nursing 0 VERB F
home 0 NOUN F
discharge 0 NOUN F
planning 0 PROPN F
and 0 CCONJ F
case 0 NOUN F
management 0 NOUN F
for 0 ADP F
individuals 0 NOUN F
in 0 ADP F
the 0 DET F
transitional 0 ADJ F
period 0 NOUN F
following 0 VERB F
a 0 DET F
return 0 NOUN F
to 0 ADP F
the 0 DET F
community 0 NOUN F
. 0 PUNCT F

The 0 DET T
PACT 0 NOUN T
program 0 NOUN F
targeted 0 VERB F
individuals 0 NOUN F
newly 0 ADV F
admitted 0 ADP F
to 0 ADP F
nursing 0 VERB F
homes 0 NOUN F
and 0 CCONJ F
worked 0 VERB F
with 0 ADP F
a 0 DET F
family 0 NOUN F
caregiver 0 NOUN F
to 0 ADJ F
develop 0 NOUN F
and 0 CCONJ F
implement 0 PUNCT F
a 0 DET F
nursing 0 VERB F
home 0 NOUN F
discharge 0 NOUN F
plan 0 NOUN F
. 0 PUNCT F

DESIGN 0 NOUN T
AND 0 CCONJ T
METHOD 0 NOUN T
Reported 0 PUNCT T
are 0 ADP F
the 0 DET F
results 0 CCONJ F
of 0 ADP F
a 0 DET F
randomized 0 VERB F
control 0 NOUN F
design 0 NOUN F
evaluating 0 VERB F
the 0 DET F
program 0 NOUN F
's 0 PUNCT F
effectiveness 0 NOUN F
. 0 PUNCT F

Those 0 ADP T
individuals 0 NOUN F
randomly 0 ADV F
assigned 0 VERB F
to 0 ADP F
the 0 DET F
intervention 0 NOUN F
group 0 NOUN F
( 0 PUNCT F
n 0 NOUN F
= 0 SYM F
33 0 NUM F
) 0 PUNCT F
received 0 VERB F
PACT 0 NOUN T
case 0 NOUN F
management 0 NOUN F
in 0 ADP F
addition 0 NOUN F
to 0 ADP F
their 0 PUNCT F
usual 0 ADJ F
medical 0 ADJ F
and 0 CCONJ F
nursing 0 VERB F
home 0 NOUN F
care 0 NOUN F
. 0 PUNCT F

The 0 DET T
individuals 0 NOUN F
in 0 ADP F
the 0 DET F
control 0 NOUN F
group 0 NOUN F
( 0 PUNCT F
n 0 NOUN F
= 0 SYM F
29 0 NUM F
) 0 PUNCT F
continued 0 ADP F
their 0 ADP F
usual 0 ADJ F
care 0 NOUN F
. 0 PUNCT F

RESULT 0 NOUN T
There 0 PUNCT T
were 0 VERB F
no 0 DET F
statistical 0 ADJ F
differences B-OTHER NOUN F
in I-OTHER ADP F
the I-OTHER DET F
discharge I-OTHER NOUN F
rate I-OTHER NOUN F
( 0 PUNCT F
84 0 NUM F
% 0 SYM F
treatment 0 NOUN F
vs 0 CCONJ F
76 0 NUM F
% 0 SYM F
controls 0 NOUN F
) 0 PUNCT F
or 0 CCONJ F
in 0 ADP F
the B-OTHER DET F
median 0 ADJ F
length B-OTHER NOUN F
of I-OTHER PUNCT F

Effects 0 NOUN T
of 0 ADP F
soy 0 NOUN F
intake 0 NOUN F
on 0 ADP F
sex B-PHYSICAL NOUN F
hormone I-PHYSICAL NOUN F
metabolism I-PHYSICAL NOUN F
in 0 ADP F
premenopausal 0 ADJ F
women 0 NOUN F
. 0 PUNCT F

Studies 0 NOUN T
suggest 0 VERB F
that 0 ADP F
phytoestrogens 0 PUNCT F
in 0 ADP F
soy 0 NOUN F
products 0 NOUN F
may 0 VERB F
impart 0 VERB F
hormonal 0 ADJ F
effects 0 NOUN F
that 0 NUM F
protect 0 DET F
women 0 NOUN F
against 0 ADP F
breast 0 NOUN F
cancer 0 NOUN F
. 0 PUNCT F

Limited 0 VERB T
research 0 NOUN F
suggests 0 NOUN F
that 0 ADP F
intake 0 NOUN F
of 0 ADP F
soy 0 NOUN F
products 0 NOUN F
high 0 ADJ F
in 0 ADP F
isoflavonoid 0 NOUN F
phytoestrogens 0 PUNCT F
affects 0 NOUN F
sex B-PHYSICAL NOUN F
hormone I-PHYSICAL NOUN F
metabolism I-PHYSICAL NOUN F
, 0 PUNCT F
but 0 CCONJ F
it 0 PRON F
is 0 VERB F
unknown 0 VERB F
whether 0 ADP F
phytoestrogens 0 PUNCT F
in 0 ADP F
soy 0 NOUN F
have 0 PUNCT F
any 0 DET F
effect 0 NOUN F
on 0 ADP F
menstrual 0 ADJ F
function 0 NOUN F
or 0 CCONJ F
serum 0 NOUN F
sex 0 NOUN F
hormones 0 NOUN F
in 0 ADP F
women 0 NOUN F
on 0 ADP F
common 0 ADJ F
hormone 0 NOUN F
therapies 0 NOUN F
, 0 PUNCT F
such 0 PUNCT F
as 0 ADP F
oral 0 ADJ F
contraceptives 0 NOUN F
( 0 PUNCT F
OC 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

We 0 PRON T
studied 0 VERB F
the 0 DET F
effects 0 NOUN F
of 0 ADP F
soy 0 NOUN F
in 0 ADP F
36 0 NUM F
premenopausal 0 ADJ F
women 0 NOUN F
, 0 PUNCT F
20 0 NUM F
of 0 ADP F
whom 0 ADP F
used 0 VERB F
OC 0 NOUN T
. 0 PUNCT F

Subjects 0 NOUN T
consumed 0 PUNCT F
their 0 PUNCT F
normal 0 ADJ F
diet 0 NOUN F
for 0 ADP F
two 0 NUM F
menstrual 0 ADJ F
cycles 0 NOUN F
and 0 CCONJ F
added 0 PUNCT F
a 0 DET F
soy 0 NOUN F
beverage 0 NOUN F
containing 0 VERB F
20 0 NUM F
g 0 NOUN F
of 0 ADP F
protein 0 NOUN F
and 0 CCONJ F
38 0 NUM F
mg 0 NOUN F
of 0 ADP F
total 0 ADJ F
isoflavones 0 NOUN F
to 0 ADP F
their 0 PUNCT F
usual 0 ADJ F
diet 0 NOUN F
for 0 ADP F
another 0 DET F
two 0 NUM F
menstrual 0 ADJ F
cycles 0 NOUN F
. 0 PUNCT F

No 0 DET T
significant 0 ADJ F
differences 0 NOUN F
were 0 VERB F
observed 0 VERB F
in 0 ADP F
serum B-PHYSICAL NOUN F
estrone I-PHYSICAL NOUN F
, 0 PUNCT F
estradiol B-PHYSICAL NOUN F
, 0 PUNCT F
sex B-PHYSICAL NOUN F
hormone-binding I-PHYSICAL VERB F
globulin I-PHYSICAL NOUN F
, 0 PUNCT F
dehydroepiandrosterone B-PHYSICAL NOUN F
sulfate I-PHYSICAL NOUN F
, 0 PUNCT F
prolactin B-PHYSICAL NOUN F
, 0 PUNCT F
or 0 CCONJ F
progesterone B-PHYSICAL NOUN F
concentrations I-PHYSICAL NOUN F
with 0 ADP F
soy 0 NOUN F
feeding 0 ADJ F
in 0 ADP F
the 0 DET F
non-OC 0 CCONJ F
or 0 CCONJ F
the 0 DET F
OC 0 NOUN T
group 0 NOUN F
. 0 PUNCT F

No 0 DET T
changes 0 NOUN F
in 0 ADP F
menstrual B-PHYSICAL ADJ F
cycle 0 NOUN F
length B-PHYSICAL NOUN F
or I-PHYSICAL CCONJ F
the I-PHYSICAL DET F
urinary I-PHYSICAL ADJ F
estrogen I-PHYSICAL NOUN F
metabolite I-PHYSICAL NOUN F
ratio 0 NOUN F
of B-PHYSICAL ADP F
2-hydroxyestrone I-PHYSICAL NOUN F
to I-PHYSICAL ADP F
16 B-PHYSICAL NUM F
alpha-hydroxyestrone I-PHYSICAL NOUN F
were 0 VERB F
seen 0 VERB F
with 0 ADP F
soy 0 NOUN F
feeding 0 ADJ F
in 0 ADP F
the 0 DET F
non-OC 0 CCONJ F
or 0 CCONJ F
the 0 DET F
OC 0 NOUN T
group 0 NOUN F
. 0 PUNCT F

Levels B-PHYSICAL NOUN T
of B-PHYSICAL ADP F
urinary I-PHYSICAL ADJ F
estrogen I-PHYSICAL PUNCT F

Promoting 0 VERB T
physical 0 ADJ F
activity 0 NOUN F
in 0 ADP F
patients 0 NOUN F
with 0 ADP F
colon 0 NOUN F
adenomas 0 NOUN F
: 0 PUNCT F
a 0 DET F
randomized 0 VERB F
pilot 0 NOUN F
intervention 0 NOUN F
trial 0 NOUN F
. 0 PUNCT F

BACKGROUND 0 NOUN T
Physical 0 PUNCT T
activity 0 NOUN F
decreases 0 VERB F
risk 0 NOUN F
of 0 ADP F
colon 0 NOUN F
polyps 0 NOUN F
and 0 CCONJ F
colon 0 NOUN F
cancer 0 NOUN F
and 0 CCONJ F
might 0 VERB F
reduce 0 VERB F
risk 0 NOUN F
of 0 ADP F
colon 0 NOUN F
cancer 0 NOUN F
recurrence 0 NOUN F
. 0 PUNCT F

Focusing 0 PUNCT T
on 0 ADP F
recent 0 ADJ F
calls 0 ADJ F
for 0 ADP F
translation 0 NOUN F
of 0 ADP F
epidemiologic 0 ADJ F
evidence 0 NOUN F
into 0 ADP F
clinical 0 ADJ F
care 0 NOUN F
, 0 PUNCT F
our 0 PUNCT F
pilot 0 NOUN F
study 0 VERB F
delivered 0 VERB F
an 0 DET F
evidence-based 0 VERB F
physical 0 ADJ F
activity 0 NOUN F
intervention 0 NOUN F
in 0 ADP F
adults 0 NOUN F
with 0 ADP F
polyps 0 NOUN F
, 0 PUNCT F
who 0 ADP F
are 0 VERB F
thus 0 ADV F
at 0 ADP F
elevated 0 VERB F
risk 0 NOUN F
of 0 ADP F
developing 0 PUNCT F
colon 0 NOUN F
cancer 0 NOUN F
. 0 PUNCT F

The 0 DET T
objective 0 ADJ F
was 0 VERB F
to 0 PART F
evaluate 0 NOUN F
change 0 NOUN F
in 0 ADP F
physical 0 ADJ F
activity 0 NOUN F
, 0 PUNCT F
measured 0 VERB F
by 0 ADP F
steps 0 NOUN F
per 0 ADP F
day 0 NOUN F
and 0 CCONJ F
minutes 0 NOUN F
of 0 ADP F
moderate/vigorous B-MENTAL ADJ F
physical 0 ADJ F
activity 0 NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
Sixteen 0 ADP T
adults 0 NOUN F
with 0 ADP F
adenomas 0 NOUN F
detected 0 ADP F
and 0 CCONJ F
removed 0 VERB F
at 0 ADP F
screening 0 ADJ F
colonoscopy 0 NOUN F
were 0 VERB F
recruited 0 VERB F
to 0 ADP F
a 0 DET F
12-week 0 NOUN F
physical 0 ADJ F
activity 0 NOUN F
intervention 0 NOUN F
. 0 PUNCT F

Participants 0 NOUN T
were 0 VERB F
randomized 0 VERB F
to 0 PART F
receive 0 NOUN F
a 0 DET F
standard 0 ADJ F
( 0 PUNCT F
30 0 NUM F
minutes/day 0 NOUN F
) 0 PUNCT F
or 0 CCONJ F
high 0 ADJ F
( 0 PUNCT F
60 0 NUM F
minutes/day 0 NOUN F
) 0 PUNCT F
walking 0 ADP F
program 0 NOUN F
. 0 PUNCT F

Physical 0 ADJ T
activity 0 NOUN F
was 0 VERB F
measured 0 VERB F
via 0 ADP F
blinded 0 VERB F
pedometer 0 VERB F
and 0 CCONJ F
accelerometer 0 NOUN F
at 0 ADP F
baseline 0 NOUN F
and 0 CCONJ F
follow-up 0 NOUN F
. 0 PUNCT F

Intervention 0 NOUN T
messages 0 NOUN F
focused 0 VERB F
on 0 ADP F
self-monitoring 0 PUNCT F
using 0 VERB F
pedometers 0 NOUN F
and 0 CCONJ F
overcoming 0 PROPN F
barriers 0 NOUN F
to 0 ADP F
engaging 0 PUNCT F
in 0 ADP F
physical 0 ADJ F
activity 0 NOUN F
. 0 PUNCT F

RESULTS 0 PUNCT T
Participants 0 NOUN T
in 0 ADP F
both 0 PUNCT F
arms 0 NOUN F
significantly 0 ADV F
increased 0 VERB F
objectively 0 ADV F
measured 0 PUNCT F
minutes B-MENTAL NOUN F
of I-MENTAL ADP F
moderate/vigorous I-MENTAL ADJ F
physical I-MENTAL ADJ F
activity I-MENTAL NOUN F
over 0 ADP F
the 0 DET F
course 0 NOUN F
of 0 ADP F
the 0 DET F
intervention 0 NOUN F
. 0 PUNCT F

Both 0 CCONJ T
arms 0 NOUN F
exceeded 0 ADP F
the 0 DET F
intervention 0 NOUN F
goal 0 NOUN F
, 0 PUNCT F
but 0 CCONJ F
there 0 PUNCT F
was 0 VERB F
not 0 ADV F
a 0 DET F
significant 0 ADJ F
difference 0 NOUN F
between 0 ADP F
arms 0 NOUN F
at 0 ADP F
follow-up 0 NOUN F
. 0 PUNCT F

Results 0 NOUN T
were 0 VERB F
similar 0 ADJ F
for 0 ADP F
pedometer B-OTHER ADP F
measured I-OTHER ADP F
physical I-OTHER ADJ F
activity I-OTHER NOUN F
, 0 PUNCT F
with 0 ADP F
a 0 DET F
significant 0 ADJ F
overall 0 ADJ F
increase 0 NOUN F
in 0 ADP F
steps/day B-MENTAL NOUN F
from 0 ADP F
baseline 0 NOUN F
to 0 ADP F
follow-up 0 NOUN F
, 0 PUNCT F
but 0 CCONJ F
no 0 ADP F
between 0 ADP F
arm 0 NOUN F
difference 0 NOUN F
in 0 ADP F
change 0 NOUN F
. 0 PUNCT F

CONCLUSION 0 NOUN T
Simple 0 ADJ T
interventions 0 NOUN F
of 0 ADP F
minimal 0 ADJ F
contact 0 NOUN F
time 0 NOUN F
focusing 0 PUNCT F
on 0 ADP F
walking 0 PUNCT F
can 0 PUNCT F
significantly 0 NOUN F
increase 0 NOUN F
physical 0 ADJ F
activity 0 NOUN F
in 0 ADP F
individuals 0 NOUN F
at 0 ADP F
increased 0 VERB F
risk 0 NOUN F
of 0 ADP F
developing 0 PUNCT F
colon 0 NOUN F
cancer 0 NOUN F
. 0 PUNCT F

TRIAL 0 NOUN T
REGISTRATION 0 NOUN T
ClinicalTrials.gov 0 PUNCT T
NCT01476631 0 PUNCT T
. 0 PUNCT F

Measurement 0 NOUN T
of 0 ADP F
health-related B-PHYSICAL VERB F
quality I-PHYSICAL NOUN F
of I-PHYSICAL ADP F
life I-PHYSICAL NOUN F
in 0 ADP F
multiple 0 ADJ F
myeloma 0 NOUN F
. 0 PUNCT F

Nordic 0 ADJ T
Myeloma 0 NOUN T
Study 0 NOUN T
Group 0 NOUN T
. 0 PUNCT F

When 0 ADP T
a 0 DET F
randomized 0 VERB F
trial 0 NOUN F
( 0 PUNCT F
NMSG 0 NOUN T
4/90 0 NOUN F
) 0 PUNCT F
comparing 0 CCONJ F
treatment 0 NOUN F
with 0 ADP F
melphalan/prednisone 0 NOUN F
to 0 ADP F
melphalan/ 0 NOUN F
prednisone 0 NOUN F
+ 0 DET F
interferon 0 NOUN F
alpha-2b 0 NOUN F
in 0 ADP F
newly 0 ADV F
diagnosed 0 VERB F
multiple 0 ADJ F
myeloma 0 NOUN F
was 0 VERB F
initiated 0 VERB F
in 0 ADP F
1990 0 NUM F
, 0 PUNCT F
a 0 DET F
quality-of-life B-OTHER NOUN F
assessment B-PHYSICAL NOUN F
was 0 VERB F
integrated 0 VERB F
into 0 ADP F
the 0 DET F
study 0 NOUN F
. 0 PUNCT F

We 0 PRON T
used 0 VERB F
the 0 DET F
questionnaire 0 NOUN F
( 0 PUNCT F
QLQ-C30 0 NOUN T
) 0 PUNCT F
developed 0 VERB F
by 0 ADP F
the 0 DET F
European 0 NOUN T
Organization 0 NOUN T
of 0 ADP F
Research 0 NOUN T
and 0 CCONJ F
Treatment 0 NOUN T
of 0 ADP F
Cancer 0 NOUN T
( 0 PUNCT F
EORTC 0 NOUN T
) 0 PUNCT F
Study 0 NOUN T
Group 0 NOUN T
on 0 ADP F
Quality 0 NOUN T
of 0 ADP F
Life 0 NOUN T
. 0 PUNCT F

The 0 DET T
QLQ-C30 0 NOUN T
incorporates 0 ADJ F
five 0 NUM F
functional 0 ADJ F
scales 0 NOUN F
, 0 PUNCT F
three 0 NUM F
symptom 0 NOUN F
scales 0 NOUN F
, 0 PUNCT F
a 0 DET F
global 0 ADJ F
health 0 NOUN F
and 0 CCONJ F
quality-of B-OTHER NOUN F
life I-OTHER NOUN F
scale I-OTHER NOUN F
and 0 CCONJ F
some 0 DET F
single 0 ADJ F
symptom 0 NOUN F
measures 0 NOUN F
. 0 PUNCT F

The 0 DET T
questionnaire 0 NOUN F
was 0 VERB F
completed 0 VERB F
prior 0 PUNCT F
to 0 ADP F
treatment 0 NOUN F
and 0 CCONJ F
after 0 ADP F
1 0 NUM F
, 0 PUNCT F
6 0 NUM F
, 0 PUNCT F
12 0 NUM F
, 0 PUNCT F
24 0 NUM F
, 0 PUNCT F
36 0 NUM F
and 0 CCONJ F
48 0 NUM F
months 0 NOUN F
. 0 PUNCT F

524 0 NUM F
( 0 PUNCT F
90.2 0 NUM F
% 0 SYM F
) 0 PUNCT F
of 0 ADP F
581 0 NUM F
patients 0 NOUN F
enrolled 0 VERB F
in 0 ADP F
the 0 DET F
NMSG 0 NOUN T
4/90 0 NOUN F
completed 0 PUNCT F
the 0 DET F
first 0 ADJ F
questionnaire 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
484 0 NUM F
( 0 PUNCT F
83.3 0 NUM F
% 0 SYM F
) 0 PUNCT F
completed 0 DET F
all 0 DET F
questionnaires 0 NOUN F
given 0 VERB F
to 0 ADP F
them 0 PUNCT F
. 0 PUNCT F

All 0 DET T
but 0 CCONJ F
one 0 NUM F
of 0 ADP F
the 0 DET F
scales 0 NOUN F
met 0 VERB F
the 0 DET F
minimum 0 NOUN F
criteria 0 NOUN F
of 0 ADP F
reliability 0 NOUN F
( 0 PUNCT F
Cronbach 0 NOUN T
's 0 PUNCT F
alpha 0 NOUN F
> 0 SYM F
/ 0 SYM F
0.70 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Validity 0 NOUN T
was 0 VERB F
shown 0 VERB F
by 0 ADP F
( 0 PUNCT F
1 0 NUM F
) 0 PUNCT F
the 0 DET F
ability 0 NOUN F
of 0 ADP F
the 0 DET F
scales 0 NOUN F
to 0 ADP F
discriminate 0 NOUN F
clearly 0 ADV F
between 0 ADP F
patients 0 NOUN F
differing 0 PUNCT F
in 0 ADP F
clinical 0 ADJ F
status 0 NOUN F
as 0 PUNCT F
defined 0 VERB F
by 0 ADP F
pretreatment 0 NOUN F
W.H.O 0 NOUN T
. 0 PUNCT F

performance 0 NOUN F
index 0 NOUN F
and 0 CCONJ F
Durie 0 NOUN T
& 0 CCONJ F
Salmon 0 VERB T
stage 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
( 0 PUNCT F
2 0 NUM F
) 0 PUNCT F
the 0 DET F
sensitivity 0 NOUN F
to 0 ADP F
changes 0 NOUN F
in 0 ADP F
objective 0 ADJ F
disease 0 NOUN F
status 0 NOUN F
( 0 PUNCT F
response 0 NOUN F
and 0 CCONJ F
relapse 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

This 0 DET T
is 0 VERB F
the 0 DET F
first 0 ADJ F
report 0 NOUN F
of 0 ADP F
the 0 DET F
measurement 0 NOUN F
of 0 ADP F
health-related B-OTHER VERB F
quality I-OTHER NOUN F
of I-OTHER ADP F
life I-OTHER NOUN F
in 0 ADP F
a 0 DET F
prospective 0 ADJ F
clinical 0 ADJ F
trial 0 NOUN F
in 0 ADP F
multiple 0 ADJ F
myeloma 0 NOUN F
. 0 PUNCT F

The 0 DET T
results 0 ADV F
demonstrate 0 VERB F
that 0 ADP F
the 0 DET F
QLQ-C30 B-OTHER NOUN T
is 0 VERB F
a 0 DET F
reliable 0 ADJ F
and 0 CCONJ F
valid 0 PUNCT F
instrument 0 NOUN F
for 0 ADP F
the 0 DET F
measurement 0 NOUN F
of 0 ADP F
quality 0 NOUN F
of 0 ADP F
life 0 NOUN F
in 0 ADP F
these 0 DET F
patients 0 NOUN F
. 0 PUNCT F

The 0 DET T
data 0 NOUN F
will 0 VERB F
be 0 VERB F
used 0 VERB F
for 0 ADP F
a 0 DET F
cost-utility 0 NOUN F
analysis 0 NOUN F
of 0 ADP F
the 0 DET F
results 0 NOUN F
of 0 ADP F
the 0 DET F
NMSG 0 NOUN T
4/90 0 NOUN F
trial 0 NOUN F
. 0 PUNCT F

Acute 0 ADJ T
cardiac 0 ADJ F
effects 0 NOUN F
of 0 ADP F
nicotine 0 NOUN F
in 0 ADP F
healthy 0 ADJ F
young 0 ADJ F
adults 0 NOUN F
. 0 PUNCT F

BACKGROUND 0 NOUN T
Nicotine 0 NOUN T
is 0 VERB F
known 0 VERB F
to 0 PUNCT F
have 0 PUNCT F
many 0 DET F
physiologic 0 ADJ F
effects 0 NOUN F
. 0 PUNCT F

The 0 DET T
influence 0 NOUN F
of 0 ADP F
nicotine 0 NOUN F
delivered 0 VERB F
in 0 ADP F
chewing 0 ADP F
gum 0 NOUN F
upon 0 ADP F
cardiac 0 ADJ F
hemodynamics 0 NOUN F
and 0 CCONJ F
conduction 0 NOUN F
has 0 VERB F
not 0 ADV F
been 0 PUNCT F
well-characterized 0 VERB F
. 0 PUNCT F

METHODS 0 NOUN T
We 0 PRON T
studied 0 VERB F
the 0 DET F
effects 0 NOUN F
of 0 ADP F
nicotine 0 NOUN F
in 0 ADP F
nonsmoking 0 ADP F
adults 0 NOUN F
( 0 PUNCT F
6 0 ADP F
male 0 NOUN F
, 0 PUNCT F
5 0 NUM F
female 0 NOUN F
; 0 PUNCT F
ages 0 NOUN F
23-36 0 NUM F
years 0 NOUN F
) 0 PUNCT F
using 0 VERB F
a 0 DET F
double-blind 0 ADJ F
, 0 PUNCT F
randomized 0 VERB F
, 0 PUNCT F
cross-over 0 NOUN F
study 0 NOUN F
. 0 PUNCT F

Subjects 0 NOUN T
chewed 0 PUNCT F
nicotine 0 NOUN F
gum 0 NOUN F
( 0 PUNCT F
4 0 NUM F
mg 0 NOUN F
) 0 PUNCT F
or 0 CCONJ F
placebo 0 NOUN F
. 0 PUNCT F

After 0 ADP T
20 0 NUM F
minutes 0 NOUN F
( 0 PUNCT F
approximate 0 ADJ F
time 0 NOUN F
to 0 ADP F
peak 0 ADJ F
nicotine 0 NOUN F
levels 0 NOUN F
) 0 PUNCT F
, 0 PUNCT F
echocardiograms 0 ADJ F
and 0 CCONJ F
signal-averaged 0 NOUN F
electrocardiograms 0 NOUN F
( 0 PUNCT F
SAECG 0 NOUN T
) 0 PUNCT F
were 0 VERB F
obtained 0 VERB F
. 0 PUNCT F

After 0 ADP T
40 0 NUM F
minutes 0 NOUN F
, 0 PUNCT F
subjects 0 NOUN F
were 0 VERB F
again 0 ADV F
given 0 NUM F
nicotine 0 NOUN F
gum 0 NOUN F
or 0 CCONJ F
placebo 0 NOUN F
in 0 ADP F
cross-over 0 NOUN F
fashion 0 NOUN F
. 0 PUNCT F

Standard 0 ADJ T
echocardiographic 0 ADJ F
measurements 0 NOUN F
were 0 VERB F
made 0 VERB F
from 0 ADP F
two-dimensional 0 ADJ F
images 0 NOUN F
. 0 PUNCT F

We 0 PRON T
then 0 ADV F
calculated 0 PUNCT F
end-systolic B-PHYSICAL ADJ F
wall I-PHYSICAL NOUN F
stress 0 NOUN F
( 0 PUNCT F
ESWS B-PHYSICAL NOUN T
) 0 PUNCT F
, 0 PUNCT F
shortening B-PHYSICAL VERB F
fraction B-PHYSICAL NOUN F
( 0 PUNCT F
SF B-PHYSICAL NOUN T
) 0 PUNCT F
, 0 PUNCT F
systemic B-PHYSICAL ADJ F
vascular I-PHYSICAL ADJ F
resistance I-PHYSICAL NOUN F
( 0 PUNCT F
SVR B-PHYSICAL NOUN T
) 0 PUNCT F
, 0 PUNCT F
velocity 0 NOUN F
for B-PHYSICAL ADP F
circumferential B-PHYSICAL ADJ F
fiber I-PHYSICAL NOUN F
shortening B-PHYSICAL PUNCT F
corrected I-PHYSICAL VERB F
for I-PHYSICAL ADP F
heart I-PHYSICAL NOUN F
rate I-PHYSICAL NOUN F
( 0 PUNCT F
Vcfc B-PHYSICAL ADP T
) 0 PUNCT F
, 0 PUNCT F
stroke B-PHYSICAL NOUN F
volume B-PHYSICAL NOUN F
, 0 PUNCT F
and B-PHYSICAL CCONJ F
cardiac I-PHYSICAL ADJ F
output B-PHYSICAL NOUN F
. 0 PUNCT F

P B-PHYSICAL NOUN T
wave I-PHYSICAL NOUN F
and B-PHYSICAL CCONJ F
QRS I-PHYSICAL NOUN T
duration I-PHYSICAL NOUN F
were 0 VERB F
measured 0 VERB F
from 0 ADP F
SAECG 0 NOUN T
. 0 PUNCT F

RESULTS 0 NOUN T
Significant 0 ADJ T
differences 0 NOUN F
( 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.05 0 NUM F
) 0 PUNCT F
from 0 ADP F
control 0 NOUN F
or 0 CCONJ F
placebo 0 NOUN F
were 0 VERB F
found 0 VERB F
for 0 ADP F
ESWS B-OTHER NOUN T
, 0 PUNCT F
mean 0 VERB F
blood B-PHYSICAL NOUN F
pressure I-PHYSICAL NOUN F
, 0 PUNCT F
cardiac B-OTHER ADJ F
output B-OTHER NOUN F
, 0 PUNCT F
SVR B-OTHER NOUN T
, 0 PUNCT F
heart B-OTHER NOUN F
rate I-OTHER NOUN F
, 0 PUNCT F
and 0 CCONJ F
P B-OTHER NOUN T
wave I-OTHER NOUN F
duration B-OTHER NOUN F
. 0 PUNCT F

No 0 DET T
significant 0 ADJ F
changes 0 NOUN F
were 0 VERB F
seen 0 VERB F
in 0 ADP F
left 0 ADJ F
ventricular 0 ADJ F
ejection 0 NOUN F
time 0 NOUN F
( 0 PUNCT F
LVET 0 NOUN T
) 0 PUNCT F
, 0 PUNCT F
LV 0 NOUN T
dimensions 0 NOUN F
, 0 PUNCT F

A 0 ADP T
double 0 ADJ F
blind 0 ADP F
randomized 0 VERB F
study 0 NOUN F
of 0 ADP F
oral 0 ADJ F
clodronate 0 VERB F
in 0 ADP F
the 0 DET F
treatment 0 NOUN F
of 0 ADP F
bone 0 NOUN F
metastases 0 NOUN F
from 0 ADP F
tumors 0 NOUN F
poorly 0 ADV F
responsive 0 ADJ F
to 0 ADP F
chemotherapy 0 NOUN F
. 0 PUNCT F

Bisphosphonates 0 ADP T
are 0 VERB F
used 0 VERB F
in 0 ADP F
oncology 0 NOUN F
as 0 ADP F
a 0 DET F
means 0 NOUN F
of 0 ADP F
decreasing 0 VERB F
complications 0 NOUN F
due 0 CCONJ F
to 0 ADP F
bone 0 NOUN F
metastases 0 NOUN F
, 0 PUNCT F
in 0 ADP F
association 0 NOUN F
with 0 ADP F
anticancer 0 NOUN F
treatment 0 NOUN F
, 0 PUNCT F
especially 0 ADV F
in 0 ADP F
patients 0 NOUN F
with 0 ADP F
breast 0 NOUN F
cancer 0 NOUN F
, 0 PUNCT F
prostate 0 NOUN F
cancer 0 NOUN F
and 0 CCONJ F
myeloma 0 NOUN F
. 0 PUNCT F

Little 0 PUNCT T
is 0 VERB F
known 0 VERB F
about 0 ADP F
the 0 DET F
effects 0 NOUN F
of 0 ADP F
bisphosphonates 0 ADV F
on 0 ADP F
bone 0 NOUN F
metastases 0 NOUN F
from 0 ADP F
other 0 ADJ F
tumors 0 NOUN F
and 0 CCONJ F
in 0 ADP F
particular 0 CCONJ F
from 0 ADP F
tumors 0 NOUN F
for 0 ADP F
which 0 DET F
no 0 DET F
effective 0 ADJ F
treatment 0 NOUN F
is 0 VERB F
available 0 ADJ F
. 0 PUNCT F

We 0 PRON T
conducted 0 VERB F
a 0 DET F
randomized 0 VERB F
, 0 PUNCT F
double-blind 0 ADJ F
placebo-controlled 0 VERB F
trial 0 NOUN F
of 0 ADP F
oral 0 ADJ F
clodronate 0 VERB F
in 0 ADP F
patients 0 NOUN F
with 0 ADP F
bone 0 NOUN F
metastases 0 NOUN F
from 0 ADP F
tumors 0 NOUN F
poorly 0 ADV F
responsive 0 ADJ F
to 0 ADP F
chemotherapy 0 NOUN F
, 0 PUNCT F
with 0 ADP F
the 0 DET F
aims 0 NOUN F
of 0 ADP F
evaluating 0 SYM F
the 0 DET F
effects 0 NOUN F
of 0 ADP F
this 0 DET F
drug B-PHYSICAL NOUN F
on I-PHYSICAL ADP F
symptoms I-PHYSICAL NOUN F
control 0 NOUN F
and 0 CCONJ F
bone B-PHYSICAL NOUN F
metastases I-PHYSICAL NOUN F
evolution I-PHYSICAL NOUN F
. 0 PUNCT F

Sixty-six 0 NUM T
patients 0 NOUN F
with 0 ADP F
poorly 0 ADV F
responsive 0 ADJ F
tumors 0 NOUN F
such 0 ADP F
as 0 ADP F
non-small 0 ADP F
cell 0 NOUN F
lung 0 NOUN F
cancer 0 NOUN F
( 0 PUNCT F
NSCLC 0 NOUN T
) 0 PUNCT F
, 0 PUNCT F
bladder 0 NOUN F
cancer 0 NOUN F
, 0 PUNCT F
gastrointestinal 0 ADJ F
cancers 0 NOUN F
, 0 PUNCT F
kidney 0 NOUN F
cancer 0 NOUN F
, 0 PUNCT F
melanoma 0 NOUN F
and 0 CCONJ F
metastatic 0 ADJ F
carcinoma 0 NOUN F
of 0 ADP F
unknown 0 VERB F
origin 0 NOUN F
entered 0 VERB F
the 0 DET F
study 0 NOUN F
. 0 PUNCT F

Patients 0 NOUN T
were 0 VERB F
randomized 0 VERB F
to 0 PART F
receive 0 ADP F
either 0 PUNCT F
clodronate 0 PUNCT F
1,600 0 NUM F
mg/day 0 NOUN F
for 0 ADP F
one 0 NUM F
year 0 NOUN F
or 0 CCONJ F
identical 0 ADJ F
placebo-containing 0 DET F
tablets 0 ADV F
. 0 PUNCT F

Various 0 ADJ T
parameters 0 NOUN F
such 0 CCONJ F
as 0 ADP F
Karnofsky B-PHYSICAL NOUN T
performance I-PHYSICAL NOUN F
status I-PHYSICAL NOUN F
, 0 PUNCT F
pain 0 NOUN F
score 0 NOUN F
( 0 PUNCT F
measured 0 PROPN F
by 0 ADP F
a 0 DET F
visual-analogue 0 NOUN F
scale 0 NOUN F
) 0 PUNCT F
and 0 CCONJ F
analgesic B-PAIN PUNCT F
requirement B-PHYSICAL NOUN F
were 0 VERB F
recorded 0 VERB F
at 0 ADP F
monthly 0 PUNCT F
intervals 0 NOUN F
. 0 PUNCT F

Of 0 ADP T
the 0 DET F
66 0 NUM F
patients 0 NOUN F
enrolled 0 VERB F
, 0 PUNCT F
9 0 NUM F
were 0 VERB F
observed 0 VERB F
for 0 ADP F
one 0 NUM F
month 0 NOUN F
or 0 CCONJ F
less 0 DET F
; 0 PUNCT F
7 0 NUM F
were 0 VERB F
followed 0 VERB F
for 0 ADP F
two 0 NUM F
months 0 NOUN F
; 0 PUNCT F
only 0 ADV F
50 0 NUM F
patients 0 NOUN F
were 0 VERB F
followed 0 VERB F
for 0 ADP F
more 0 ADV F
than 0 CCONJ F
2 0 NUM F
months 0 NOUN F
and 0 CCONJ F
could 0 VERB F
be 0 VERB F
adequately 0 ADV F
evaluated 0 VERB F
. 0 PUNCT F

At 0 ADP T
3 0 NUM F
months 0 NOUN F
both 0 CCONJ F
clodronate 0 VERB F
and 0 CCONJ F
placebo-treated 0 VERB F
patients 0 NOUN F
had 0 ADP F
a 0 DET F
decrease 0 NOUN F
in 0 ADP F
Karnofsky B-PHYSICAL NOUN T
performance I-PHYSICAL NOUN F
status I-PHYSICAL NOUN F
, 0 PUNCT F
with 0 ADP F
the 0 DET F
decrease 0 NOUN F
being 0 ADP F
more 0 ADV F
evident 0 ADJ F
in 0 ADP F
the 0 DET F
placebo 0 NOUN F
group 0 NOUN F
. 0 PUNCT F

Mean 0 ADJ T
pain B-PAIN NOUN F
scores I-PAIN NOUN F
showed 0 VERB F
an 0 DET F
increase 0 NOUN F
of 0 ADP F
pain B-PAIN NOUN F
in 0 ADP F
patients 0 NOUN F
receiving 0 VERB F
placebo 0 NOUN F
and 0 CCONJ F
a 0 DET F
decrease 0 NOUN F
of 0 ADP F
pain 0 NOUN F
in 0 ADP F
patients 0 NOUN F
receiving 0 CCONJ F
clodronate 0 PUNCT F
, 0 PUNCT F
although 0 ADP F
the 0 DET F
difference 0 NOUN F
failed 0 VERB F
to 0 PART F
be 0 PUNCT F
statistically 0 ADV F
significant 0 ADJ F
. 0 PUNCT F

Analgesics B-PAIN ADJ T
requirement I-PAIN NOUN F
increased 0 VERB F
in 0 ADP F
both 0 CCONJ F
groups 0 NOUN F
, 0 PUNCT F
but 0 CCONJ F
significantly 0 ADV F
more 0 ADV F
in 0 ADP F
patients 0 NOUN F
receiving 0 VERB F
placebo 0 NOUN F
( 0 PUNCT F
p 0 NOUN F
= 0 SYM F
0.042 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
in 0 ADP F
whom 0 ADP F
increase 0 CCONJ F
in 0 ADP F
opioid 0 NOUN F
requirements 0 NOUN F
was 0 VERB F
particularly 0 ADV F
evident 0 ADJ F
. 0 PUNCT F

Toxicity B-ADVERSE-EFFECTS NOUN T
was I-ADVERSE-EFFECTS VERB F
low I-ADVERSE-EFFECTS ADJ F
, 0 PUNCT F
with 0 ADP F
occasional B-ADVERSE-EFFECTS ADJ F
gastroenteric I-ADVERSE-EFFECTS ADJ F
discomfort I-ADVERSE-EFFECTS NOUN F
in 0 ADP F
both 0 CCONJ F
groups 0 NOUN F
. 0 PUNCT F

The 0 DET T
main 0 ADJ F
problem 0 NOUN F
of 0 ADP F
this 0 DET F
study 0 NOUN F
was 0 ADV F
the 0 DET F
difficulty 0 NOUN F
in 0 ADP F
recruiting 0 NOUN F
an 0 DET F
adequate 0 ADJ F
number 0 NOUN F
of 0 ADP F
patients 0 NOUN F
and 0 CCONJ F
following 0 VERB F
them 0 NUM F
for 0 ADP F
a 0 DET F
sufficient 0 ADJ F
period 0 NOUN F
of 0 ADP F
time 0 NOUN F
: 0 PUNCT F
general 0 ADJ F
conditions 0 NOUN F
rapidly 0 ADV F
deteriorated 0 VERB F
in 0 ADP F
many 0 DET F
patients 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
approximately 0 ADV F
25 0 NUM F
% 0 SYM F
of 0 ADP F
the 0 DET F
66 0 NUM F
enrolled 0 VERB F
were 0 VERB F
not 0 ADV F
considered 0 PUNCT F
evaluable 0 ADJ F
; 0 PUNCT F
few 0 ADJ F
patients 0 NOUN F
survived 0 DET F
for 0 ADP F
the 0 DET F
length 0 NOUN F
of 0 ADP F
the 0 DET F
study 0 NOUN F
, 0 PUNCT F
one 0 NUM F
year 0 NOUN F
. 0 PUNCT F

This 0 DET T
might 0 ADP F
partly 0 ADV F
account 0 VERB F
for 0 ADP F
the 0 DET F
lack 0 NOUN F
of 0 ADP F
significance 0 NOUN F
of 0 ADP F
some 0 PUNCT F
of 0 ADP F
the 0 DET F
parameters 0 NOUN F
under 0 ADP F
study 0 NOUN F
. 0 PUNCT F

With 0 ADP T
these 0 DET F
limits 0 NOUN F
, 0 PUNCT F
oral 0 ADJ F
clodronate 0 VERB F
demonstrated 0 VERB F
some 0 DET F
efficacy 0 NOUN F
in 0 ADP F
symptom 0 NOUN F
control 0 NOUN F
and 0 CCONJ F
in 0 ADP F
reducing 0 VERB F
the 0 DET F
need 0 NOUN F
for 0 ADP F
analgesics 0 NOUN F
. 0 PUNCT F

Impact 0 NOUN T
of 0 ADP F
interviewer 0 PUNCT F
's 0 PUNCT F
body 0 NOUN F
mass 0 NOUN F
index 0 NOUN F
on 0 ADP F
underreporting 0 PUNCT F
energy 0 NOUN F
intake 0 NOUN F
in 0 ADP F
overweight 0 ADJ F
and 0 CCONJ F
obese 0 PUNCT F
women 0 NOUN F
. 0 PUNCT F

OBJECTIVE 0 NOUN T
To 0 PROPN T
determine 0 NOUN F
if 0 PUNCT F
overweight 0 VERB F
and 0 CCONJ F
obese 0 PUNCT F
women 0 NOUN F
provide 0 VERB F
more 0 ADV F
accurate 0 ADJ F
reports 0 NOUN F
of 0 ADP F
their 0 PUNCT F
energy 0 NOUN F
intake 0 NOUN F
by 0 ADP F
1 0 NUM F
) 0 PUNCT F
in-person 0 NOUN F
recall 0 ADP F
with 0 ADP F
an 0 DET F
obese 0 ADJ F
interviewer 0 PUNCT F
, 0 PUNCT F
2 0 NUM F
) 0 PUNCT F
in-person 0 NOUN F
recall 0 ADP F
with 0 ADP F
a 0 DET F
lean 0 ADJ F
interviewer 0 PUNCT F
, 0 PUNCT F
or 0 CCONJ F
3 0 NUM F
) 0 PUNCT F
telephone 0 NOUN F
recall 0 PUNCT F
with 0 ADP F
an 0 DET F
unknown 0 VERB F
interviewer 0 PUNCT F
. 0 PUNCT F

RESEARCH 0 NOUN T
METHODS 0 NOUN T
AND 0 CCONJ T
PROCEDURES 0 NOUN T
Eighty-eight 0 PUNCT T
overweight 0 VERB F
and 0 CCONJ F
obese 0 PUNCT F
women 0 NOUN F
participated 0 VERB F
in 0 ADP F
this 0 DET F
study 0 NOUN F
. 0 PUNCT F

Subjects 0 NOUN T
completed 0 DET F
one 0 ADP F
telephone-administered 0 VERB F
multiple-pass 0 NOUN F
24-hour 0 NOUN F
recall 0 NOUN F
( 0 PUNCT F
MP24R 0 NOUN T
) 0 PUNCT F
with 0 ADP F
an 0 DET F
unknown 0 VERB F
interviewer 0 PUNCT F
and 0 CCONJ F
were 0 VERB F
then 0 ADV F
randomly 0 ADV F
assigned 0 VERB F
to 0 ADP F
an 0 DET F
in-person 0 NOUN F
MP24R 0 NOUN T
with 0 ADP F
either 0 CCONJ F
a 0 DET F
lean 0 ADJ F
or 0 CCONJ F
obese 0 DET F
interviewer 0 PUNCT F
to 0 ADP F
gather 0 ADP F
reported B-PHYSICAL VERB F
energy I-PHYSICAL NOUN F
intake I-PHYSICAL NOUN F
( 0 PUNCT F
rEI B-PHYSICAL PUNCT F
) 0 PUNCT F
. 0 PUNCT F

Basal B-PHYSICAL ADJ T
metabolic I-PHYSICAL ADJ F
rate I-PHYSICAL NOUN F
( I-PHYSICAL PUNCT F
BMR I-PHYSICAL PUNCT T
) I-PHYSICAL PUNCT F
was 0 VERB F
measured 0 VERB F
using 0 SYM F
a 0 DET F
Deltrac 0 PUNCT T
monitor 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
physical B-PHYSICAL ADJ F
activity I-PHYSICAL NOUN F
( I-PHYSICAL PUNCT F
EEPA I-PHYSICAL NOUN T
) I-PHYSICAL PUNCT F
was 0 VERB F
estimated 0 VERB F
using 0 VERB F
a 0 DET F
Caltrac 0 NOUN T
accelerometer 0 NOUN F
. 0 PUNCT F

Therefore 0 ADV T
, 0 PUNCT F
estimated 0 ADP F
energy 0 NOUN F
expenditure 0 NOUN F
was 0 VERB F
determined 0 VERB F
by 0 ADP F
: 0 PUNCT F
estTEE 0 NUM F
= 0 ADJ F
( 0 PUNCT F
BMR 0 PUNCT T
+ 0 ADP F
EEPA 0 NOUN T
) 0 PUNCT F
x 0 SYM F
1.10 0 NUM F
. 0 PUNCT F

RESULTS 0 PUNCT T
No 0 DET T
significant 0 ADJ F
differences 0 NOUN F
were 0 VERB F
found 0 VERB F
between 0 ADP F
the 0 DET F
two 0 NUM F
in-person 0 NOUN F
interview 0 NOUN F
modes 0 NOUN F
for 0 ADP F
subject 0 ADJ F
age 0 NOUN F
, 0 PUNCT F
weight 0 NOUN F
, 0 PUNCT F
body 0 NOUN F
mass 0 NOUN F
index 0 NOUN F
, 0 PUNCT F
percentage 0 NOUN F
of 0 ADP F
body 0 NOUN F
fat 0 NOUN F
, 0 PUNCT F
total 0 ADJ F
energy 0 NOUN F
expenditure 0 NOUN F
, 0 PUNCT F
rEI 0 PUNCT F
, 0 PUNCT F
and 0 CCONJ F
misreporting 0 PROPN F
of 0 ADP F
energy 0 NOUN F
intake 0 NOUN F
. 0 PUNCT F

In-person 0 NOUN T
recall 0 PUNCT F
data 0 NOUN F
were 0 VERB F
combined 0 VERB F
for 0 ADP F
comparison 0 NOUN F
with 0 ADP F
the 0 DET F
telephone 0 NOUN F
recalls 0 NOUN F
. 0 PUNCT F

No 0 DET T
significant 0 ADJ F
difference 0 NOUN F
was 0 VERB F
found 0 VERB F
between 0 ADP F
the 0 DET F
in-person 0 NOUN F
and 0 CCONJ F
telephone 0 NOUN F
recalls 0 CCONJ F
for 0 ADP F
rEI B-PHYSICAL PUNCT F
and 0 CCONJ F
misreporting B-OTHER PROPN F
. 0 PUNCT F

Mean 0 NOUN T
reported B-PHYSICAL ADV F
energy I-PHYSICAL NOUN F
intake I-PHYSICAL NOUN F
was 0 VERB F
significantly 0 ADV F
lower 0 PUNCT F
than 0 PUNCT F
estimated 0 DET F
total 0 ADJ F
energy B-PHYSICAL NOUN F
expenditure I-PHYSICAL NOUN F
for 0 ADP F
the 0 DET F
telephone 0 NOUN F
recalls 0 NOUN F
and 0 CCONJ F
combined 0 VERB F
( 0 PUNCT F
lean 0 ADJ F
and 0 CCONJ F
obese 0 DET F
modes 0 NOUN F
) 0 PUNCT F
in-person 0 NOUN F
recalls 0 NOUN F
. 0 PUNCT F

CONCLUSIONS 0 NOUN T
This 0 PUNCT T
study 0 NOUN F
found 0 VERB F
that 0 ADP F
interviewer 0 PUNCT F
body 0 NOUN F
mass 0 NOUN F
index 0 NOUN F
had 0 PUNCT F
no 0 DET F
impact 0 NOUN F
on 0 ADP F
self-reported 0 VERB F
energy 0 NOUN F
intake 0 NOUN F
during 0 ADP F
an 0 DET F
in-person 0 NOUN F
MP24R 0 NOUN T
, 0 PUNCT F
and 0 CCONJ F
that 0 ADP F
telephone 0 NOUN F
recall 0 PUNCT F
data 0 NOUN F
were 0 VERB F
comparable 0 ADJ F
with 0 ADP F
in-person 0 NOUN F
recalls 0 NOUN F
. 0 PUNCT F

Underreporting 0 PUNCT T
was 0 ADP F
a 0 DET F
widespread 0 ADJ F
problem 0 NOUN F
( 0 PUNCT F
approximately 0 ADV F
26 0 NUM F
% 0 SYM F
) 0 PUNCT F
for 0 ADP F
all 0 DET F
modes 0 NOUN F
in 0 ADP F
this 0 DET F
sample 0 NOUN F
. 0 PUNCT F

[ 0 PUNCT F
Postural 0 ADJ T
biofeedback 0 NOUN F
and 0 CCONJ F
locomotion 0 NOUN F
reeducation 0 NOUN F
in 0 ADP F
stroke 0 NOUN F
patients 0 NOUN F
] 0 PUNCT F
. 0 PUNCT F

AIMS 0 NOUN T
To 0 PROPN T
compare 0 ADV F
, 0 PUNCT F
in 0 ADP F
post-acute 0 PUNCT F
hemiparetic 0 ADJ F
patients 0 NOUN F
, 0 PUNCT F
gait B-OTHER NOUN F
improvement I-OTHER NOUN F
after 0 ADP F
conventional 0 ADJ F
physical 0 ADJ F
therapy 0 NOUN F
alone 0 ADJ F
or 0 CCONJ F
with 0 ADP F
a 0 DET F
specialised 0 VERB F
balance 0 NOUN F
retraining 0 ADJ F
program 0 NOUN F
. 0 PUNCT F

PATIENTS 0 NOUN T
Twenty-six 0 NUM T
patients 0 NOUN F
within 0 ADP F
3 0 NUM F
months 0 NOUN F
of 0 ADP F
onset 0 NOUN F
of 0 ADP F
stroke 0 NOUN F
were 0 VERB F
randomised 0 VERB F
to 0 PART F
receive 0 DET F
physical 0 ADJ F
therapy 0 NOUN F
( 0 PUNCT F
control 0 NOUN F
group 0 NOUN F
) 0 PUNCT F
or 0 CCONJ F
therapy 0 NOUN F
and 0 CCONJ F
retraining 0 ADJ F
( 0 PUNCT F
experimental 0 ADJ F
group 0 NOUN F
) 0 PUNCT F
, 0 PUNCT F
most 0 PUNCT F
of 0 ADP F
the 0 DET F
patients 0 NOUN F
in 0 ADP F
both 0 CCONJ F
groups 0 NOUN F
with 0 ADP F
left 0 ADJ F
hemiplegia 0 NOUN F
. 0 PUNCT F

The 0 DET T
experimental 0 ADJ F
group 0 NOUN F
was 0 VERB F
significantly 0 ADV F
older 0 PUNCT F
than 0 PUNCT F
the 0 DET F
control 0 NOUN F
group 0 NOUN F
. 0 PUNCT F

METHOD 0 NOUN T
Thirteen 0 ADP T
patients 0 NOUN F
received 0 ADJ F
early 0 ADJ F
conventional 0 ADJ F
therapy 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
13 0 NUM F
received 0 ADV F
therapy 0 NOUN F
combined 0 VERB F
with 0 ADP F
standing 0 PUNCT F
balance 0 NOUN F
training 0 VERB F
by 0 ADP F
biofeedback 0 NOUN F
( 0 PUNCT F
BPM 0 NOUN T
Monitor 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

Clinical 0 ADJ T
measures 0 NOUN F
were 0 VERB F
collected 0 VERB F
at 0 ADP F
entry 0 NOUN F
( 0 PUNCT F
J0 0 NOUN T
) 0 PUNCT F
, 0 PUNCT F
once 0 PUNCT F
when 0 PUNCT F
subjects 0 NOUN F
began 0 VERB F
to 0 ADP F
walk B-PHYSICAL NOUN F
( 0 PUNCT F
JM 0 NOUN T
) 0 PUNCT F
and 0 CCONJ F
30 0 NUM F
days 0 NOUN F
later 0 ADJ F
( 0 PUNCT F
JM 0 NOUN T
+ 0 SYM F
30 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Gait B-OTHER NOUN T
spatiotemporal I-OTHER ADJ F
parameters I-OTHER NOUN F
were 0 VERB F
collected 0 VERB F
by 0 ADP F
use 0 NOUN F
of 0 ADP F
the 0 DET F
Vicon B-OTHER NOUN T
system I-OTHER NOUN F
at 0 ADP F
JM 0 NOUN T
and 0 CCONJ F
JM 0 NOUN T
+ 0 DET F
30 0 PUNCT F
. 0 PUNCT F

RESULTS 0 NOUN T
Whatever 0 PUNCT T
the 0 DET F
method 0 NOUN F
of 0 ADP F
rehabilitation 0 NOUN F
, 0 PUNCT F
the 0 DET F
clinical B-OTHER ADJ F
scores I-OTHER NOUN F
improved 0 VERB F
significantly 0 ADV F
between 0 ADP F
J0 0 NOUN T
and 0 CCONJ F
JM 0 NOUN T
+ 0 SYM F
30 0 NUM F
, 0 PUNCT F
except 0 PUNCT F
for 0 ADP F
spasticity 0 NOUN F
. 0 PUNCT F

The 0 DET T
time B-OTHER NOUN F
between I-OTHER ADP F
stroke I-OTHER NOUN F
and I-OTHER CCONJ F
the I-OTHER DET F
beginning I-OTHER PUNCT F
of I-OTHER ADP F
walking I-OTHER PUNCT F
was 0 ADV F
not 0 ADV F
significantly 0 ADV F
different 0 ADJ F
between 0 ADP F
both 0 CCONJ F
groups 0 NOUN F
. 0 PUNCT F

Gait B-PHYSICAL NOUN T
velocity I-PHYSICAL NOUN F
increased 0 VERB F
significantly 0 ADV F
between 0 ADP F
JM 0 NOUN T
and 0 CCONJ F
JM 0 NOUN T
+ 0 SYM F
30 0 PUNCT F
in 0 ADP F
both 0 CCONJ F
groups 0 NOUN F
, 0 PUNCT F
with 0 ADP F
no 0 DET F
difference 0 NOUN F
between 0 ADP F
groups 0 NOUN F
. 0 PUNCT F

The 0 DET T
walking B-PHYSICAL VERB F
pattern I-PHYSICAL NOUN F
was 0 VERB F
improved 0 VERB F
for 0 ADP F
both 0 CCONJ F
groups 0 NOUN F
, 0 PUNCT F
with 0 ADP F
a 0 DET F
significant 0 ADJ F
increase 0 NOUN F
of 0 ADP F
the 0 DET F
duration 0 NOUN F
of 0 ADP F
the 0 DET F
paretic B-OTHER ADJ F
limb I-OTHER NOUN F
single I-OTHER ADJ F
stance I-OTHER NOUN F
. 0 PUNCT F

The 0 DET T
experimental 0 ADJ F
group 0 NOUN F
significantly 0 ADV F
improved 0 VERB F
the 0 DET F
duration 0 NOUN F
of 0 ADP F
the B-OTHER DET F
reception I-OTHER NOUN F
double I-OTHER ADJ F
stance I-OTHER ADJ F
on I-OTHER ADP F
the I-OTHER DET F
paretic I-OTHER ADJ F
limb I-OTHER NOUN F
between 0 ADP F
JM 0 NOUN T
and 0 CCONJ F
JM 0 NOUN T
+ 0 SYM F
30 0 NUM F
compared 0 VERB F
with 0 ADP F
the 0 DET F
control 0 NOUN F
group 0 NOUN F
( 0 PUNCT F
P 0 NOUN T
= 0 SYM F
0.03 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

CONCLUSION 0 NOUN T
Both 0 PUNCT T
groups 0 NOUN F
demonstrated 0 VERB F
improvement 0 NOUN F
in 0 ADP F
the 0 DET F
rehabilitation 0 NOUN F
unit 0 NOUN F
. 0 PUNCT F

The 0 DET T
benefits 0 NOUN F
of 0 ADP F
visual 0 ADJ F
biofeedback 0 ADP F
by 0 ADP F
forceplate 0 NOUN F
system 0 NOUN F
training 0 VERB F
suggest 0 DET F
particular 0 CCONJ F
improvement 0 NOUN F
of 0 ADP F
anticipation 0 NOUN F
equilibrium 0 NOUN F
with 0 ADP F
conventional 0 ADJ F
therapy 0 NOUN F
. 0 PUNCT F

Acute 0 ADJ T
effects 0 NOUN F
of 0 ADP F
different 0 ADJ F
stretching 0 PROPN F
durations 0 NOUN F
on 0 ADP F
passive B-PHYSICAL ADJ F
torque I-PHYSICAL NOUN F
, 0 PUNCT F
mobility B-PHYSICAL NOUN F
, 0 PUNCT F
and 0 PUNCT F

Safety B-OTHER NOUN T
, 0 PUNCT F
tolerability B-OTHER NOUN F
, 0 PUNCT F
and 0 CCONJ F
changes 0 NOUN F
in 0 ADP F
amyloid B-PHYSICAL NOUN F
beta I-PHYSICAL NOUN F
concentrations I-PHYSICAL NOUN F
after 0 ADP F
administration 0 NOUN F
of 0 ADP F
a 0 DET F
gamma-secretase 0 NOUN F
inhibitor 0 NOUN F
in 0 ADP F
volunteers 0 NOUN F
. 0 PUNCT F

Amyloid 0 NOUN T
beta 0 NOUN F
( 0 PUNCT F
Abeta 0 NOUN T
) 0 PUNCT F
may 0 VERB F
play 0 VERB F
a 0 DET F
central 0 ADJ F
role 0 NOUN F
in 0 ADP F
the 0 DET F
pathogenesis 0 NOUN F
of 0 ADP F
Alzheimer 0 PUNCT T
disease 0 NOUN F
. 0 PUNCT F

A 0 DET T
functional 0 ADJ F
gamma-secretase 0 NOUN F
inhibitor 0 NOUN F
, 0 PUNCT F
LY450139 0 NOUN T
, 0 PUNCT F
was 0 VERB F
developed 0 ADP F
that 0 ADP F
inhibits 0 NOUN F
Abeta 0 NOUN T
formation 0 NOUN F
in 0 ADP F
whole 0 ADJ F
cell 0 NOUN F
assays 0 NOUN F
, 0 PUNCT F
transgenic 0 ADJ F
mice 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
beagle 0 NOUN F
dogs 0 NOUN F
. 0 PUNCT F

The 0 DET T
authors 0 NOUN F
wished 0 VERB F
to 0 PART F
determine 0 NOUN F
the 0 DET F
safety 0 NOUN F
and 0 CCONJ F
tolerability 0 NOUN F
of 0 ADP F
this 0 DET F
drug 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
the 0 DET F
reduction 0 NOUN F
of 0 ADP F
Abeta 0 NOUN T
in 0 ADP F
plasma 0 NOUN F
and 0 CCONJ F
cerebrospinal 0 ADJ F
fluid 0 NOUN F
( 0 PUNCT F
CSF 0 NOUN T
) 0 PUNCT F
after 0 ADP F
multiple 0 ADJ F
doses 0 NOUN F
. 0 PUNCT F

Volunteer 0 NOUN T
subjects 0 NOUN F
( 0 PUNCT F
N 0 NOUN T
= 0 SYM F
37 0 NUM F
) 0 PUNCT F
were 0 VERB F
studied 0 VERB F
using 0 VERB F
doses 0 NOUN F
from 0 ADP F
5 0 NUM F
to 0 ADP F
50 0 NUM F
mg/day 0 NOUN F
given 0 VERB F
for 0 ADP F
14 0 NUM F
days 0 NOUN F
. 0 PUNCT F

Plasma B-PHYSICAL NOUN T
and I-PHYSICAL CCONJ F
CSF I-PHYSICAL NOUN T
concentrations I-PHYSICAL NOUN F
of I-PHYSICAL ADP F
LY450139 I-PHYSICAL NOUN T
, 0 PUNCT F
Abeta B-PHYSICAL NOUN T
( 0 PUNCT F
1-40 B-PHYSICAL NUM F
) 0 PUNCT F
and 0 CCONJ F
Abeta B-PHYSICAL NOUN T
( I-PHYSICAL PUNCT F
1-X I-PHYSICAL ADP F
) I-PHYSICAL PUNCT F
( I-PHYSICAL PUNCT F
Abeta I-PHYSICAL NOUN T
( I-PHYSICAL PUNCT F
total 0 NOUN F
) B-PHYSICAL PUNCT F
) B-PHYSICAL PUNCT F
were 0 VERB F
determined 0 VERB F
, 0 PUNCT F
and 0 CCONJ F
safety 0 NOUN F
and 0 CCONJ F
tolerability 0 NOUN F
were 0 VERB F
assessed 0 VERB F
. 0 PUNCT F

The 0 DET T
plasma 0 NOUN F
half-life 0 NOUN F
of 0 ADP F
LY450139 0 NOUN T
was 0 VERB F
approximately 0 ADV F
2.5 0 NUM F
hours 0 NOUN F
. 0 PUNCT F

Pharmacokinetic 0 ADJ T
analyses 0 NOUN F
showed 0 VERB F
a 0 DET F
linear 0 ADJ F
relationship 0 NOUN F
between 0 ADP F
dose 0 NOUN F
and 0 CCONJ F
plasma 0 NOUN F
concentrations 0 NOUN F
, 0 PUNCT F
with 0 ADP F
a 0 DET F
Cmax 0 NOUN T
of 0 ADP F
828 0 NUM F
+/- 0 SYM F
19.2 0 NUM F
ng/mL 0 NOUN F
after 0 ADP F
a 0 DET F
50-mg 0 PUNCT F
dose 0 NOUN F
. 0 PUNCT F

Plasma B-PHYSICAL NOUN T
Abeta I-PHYSICAL NOUN T
concentrations B-PHYSICAL NOUN F
decreased 0 VERB F
in 0 ADP F
a 0 DET F
dose-dependent 0 ADJ F
manner 0 NOUN F
over 0 ADP F
a 0 DET F
6-hour 0 NOUN F
interval 0 NOUN F
following 0 PUNCT F
drug 0 NOUN F
administration 0 NOUN F
, 0 PUNCT F
with 0 ADP F
a 0 DET F
maximum 0 NOUN F
decrease 0 NOUN F
of 0 ADP F
approximately 0 ADV F
40 0 NUM F
% 0 ADJ F
relative 0 ADJ F
to 0 ADP F
baseline 0 NOUN F
. 0 PUNCT F

After 0 ADP T
returning 0 ADJ F
to 0 ADP F
baseline 0 NOUN F
, 0 PUNCT F
Abeta B-PHYSICAL NOUN T
concentrations I-PHYSICAL NOUN F
were 0 VERB F
transiently 0 ADV F
increased 0 PUNCT F
. 0 PUNCT F

CSF B-PHYSICAL NOUN T
Abeta I-PHYSICAL NOUN T
concentrations B-PHYSICAL NOUN F
were 0 VERB F
unchanged 0 VERB F
. 0 PUNCT F

Vitamin 0 NOUN T
D 0 NOUN T
supplementation 0 NOUN F
increases 0 NOUN F
calcium B-PHYSICAL NOUN F
absorption I-PHYSICAL NOUN F
without 0 ADP F
a 0 DET F
threshold 0 NOUN F
effect 0 NOUN F
. 0 PUNCT F

BACKGROUND 0 NOUN T
The 0 DET T
maximal 0 ADJ F
calcium 0 NOUN F
absorption 0 NOUN F
in 0 ADP F
response 0 NOUN F
to 0 ADP F
vitamin 0 NOUN F
D 0 NOUN T
has 0 PUNCT F
been 0 PUNCT F
proposed 0 VERB F
as 0 ADP F
a 0 DET F
biomarker 0 NOUN F
for 0 ADP F
vitamin 0 NOUN F
D 0 NOUN T
sufficiency 0 NOUN F
. 0 PUNCT F

OBJECTIVE 0 NOUN T
The 0 DET T
objective 0 ADJ F
was 0 VERB F
to 0 PART F
determine 0 NOUN F
whether 0 ADP F
there 0 PUNCT F
is 0 VERB F
a 0 DET F
threshold 0 NOUN F
beyond 0 ADP F
which 0 PUNCT F
increasing 0 PUNCT F
doses 0 NOUN F
of 0 ADP F
vitamin 0 NOUN F
D 0 NOUN T
, 0 PUNCT F
or 0 CCONJ F
concentrations 0 NOUN F
of 0 ADP F
serum 0 NOUN F
25-hydroxyvitamin 0 NOUN F
D 0 NOUN T
[ 0 PUNCT F
25 0 NUM F
( 0 PUNCT F
OH 0 NOUN T
) 0 PUNCT F
D 0 NOUN T
] 0 PUNCT F
, 0 PUNCT F
no 0 DET F
longer 0 PUNCT F
increase 0 NOUN F
calcium B-PHYSICAL NOUN F
absorption I-PHYSICAL NOUN F
. 0 PUNCT F

DESIGN 0 NOUN T
This 0 PUNCT T
was 0 VERB F
a 0 DET F
placebo-controlled 0 VERB F
, 0 PUNCT F
dose-response 0 NOUN F
, 0 PUNCT F
randomized 0 VERB F
, 0 PUNCT F
double-blind 0 ADJ F
study 0 NOUN F
of 0 ADP F
the 0 DET F
effect 0 NOUN F
of 0 ADP F
vitamin 0 NOUN F
D 0 NOUN T
on 0 ADP F
calcium 0 NOUN F
absorption 0 NOUN F
in 0 ADP F
healthy 0 ADJ F
postmenopausal 0 ADJ F
women 0 NOUN F
. 0 PUNCT F

Seventy-six 0 NUM T
healthy 0 ADJ F
postmenopausal 0 ADJ F
women 0 NOUN F
were 0 VERB F
randomly 0 ADV F
assigned 0 VERB F
to 0 ADP F
placebo 0 NOUN F
or 0 CCONJ F
800 0 NUM F
IU 0 NOUN T
( 0 PUNCT F
20 0 NUM F
?g 0 PUNCT F
) 0 PUNCT F
, 0 PUNCT F
2000 0 NUM F
IU 0 NOUN T
( 0 PUNCT F
50 0 ADP F
?g 0 PUNCT F
) 0 PUNCT F
, 0 PUNCT F
or 0 CCONJ F
4000 0 NUM F
IU 0 NOUN T
( 0 PUNCT F
100 0 ADP F
?g 0 PUNCT F
) 0 PUNCT F
vitamin 0 NOUN F
D? 0 CCONJ T
for 0 ADP F
8 0 NUM F
wk 0 NOUN F
. 0 PUNCT F

The 0 DET T
technique 0 NOUN F
of 0 ADP F
dual 0 ADJ F
isotopes 0 NOUN F
of 0 ADP F
stable 0 ADJ F
calcium 0 NOUN F
was 0 VERB F
used 0 VERB F
with 0 ADP F
a 0 DET F
calcium 0 NOUN F
carrier 0 NOUN F
to 0 PART F
measure 0 VERB F
calcium 0 NOUN F
absorption 0 NOUN F
at 0 ADP F
baseline 0 NOUN F
and 0 CCONJ F
after 0 ADP F
8 0 NUM F
wk 0 NOUN F
. 0 PUNCT F

RESULTS 0 NOUN T
Seventy-one 0 ADJ T
women 0 NOUN F
with 0 ADP F
a 0 DET F
mean 0 NOUN F
? 0 PUNCT F

SD 0 NOUN T
age 0 NOUN F
of 0 ADP F
58.8 0 NUM F
? 0 PUNCT F

4.9 0 NUM F
y 0 NOUN F
completed 0 VERB F
the 0 DET F
study 0 NOUN F
. 0 PUNCT F

The 0 DET T
mean 0 NOUN F
calcium 0 NOUN F
intake 0 NOUN F
was 0 VERB F
1142 0 NUM F
? 0 PUNCT F

509 0 NUM F
mg/d 0 NOUN F
and 0 CCONJ F
serum 0 NOUN F
25 0 NUM F
( 0 PUNCT F
OH 0 NOUN T
) 0 PUNCT F
D 0 NOUN T
was 0 VERB F
63 0 NUM F
? 0 PUNCT F

14 0 NUM F
nmol/L 0 ADJ F
at 0 ADP F
baseline 0 NOUN F
. 0 PUNCT F

A 0 DET T
statistically 0 ADV F
significant 0 ADJ F
linear 0 ADJ F
trend 0 NOUN F
of 0 ADP F
an 0 DET F
increase 0 NOUN F
in 0 ADP F
calcium 0 NOUN F
absorption 0 NOUN F
adjusted 0 PUNCT F
for 0 ADP F
age 0 NOUN F
and 0 CCONJ F
body 0 NOUN F
mass 0 NOUN F
index 0 NOUN F
with 0 ADP F
increasing 0 ADJ F
vitamin 0 NOUN F
D? 0 PUNCT T
dose 0 NOUN F
or 0 CCONJ F
serum 0 NOUN F
25 0 NUM F
( 0 PUNCT F
OH 0 NOUN T
) 0 PUNCT F
D 0 NOUN T
concentration 0 NOUN F
was 0 VERB F
observed 0 VERB F
. 0 PUNCT F

A 0 DET T
6.7 0 NUM F
% 0 SYM F
absolute 0 ADJ F
increase 0 NOUN F
in 0 ADP F
calcium 0 NOUN F
absorption 0 NOUN F
was 0 VERB F
found 0 VERB F
in 0 ADP F
the 0 DET F
highest 0 PUNCT F
vitamin 0 NOUN F
D? 0 PUNCT T
group 0 NOUN F
( 0 PUNCT F
100 0 ADP F
?g 0 PUNCT F
) 0 PUNCT F
. 0 PUNCT F

No 0 DET T
evidence 0 NOUN F
of 0 ADP F
nonlinearity 0 NOUN F
was 0 VERB F
observed 0 VERB F
in 0 ADP F
the 0 DET F
dose-response 0 NOUN F
curve 0 NOUN F
. 0 PUNCT F

CONCLUSIONS 0 NOUN T
No 0 DET T
evidence 0 NOUN F
of 0 ADP F
a 0 DET F
threshold 0 NOUN F
of 0 ADP F
calcium 0 NOUN F
absorption 0 NOUN F
was 0 VERB F
found 0 VERB F
with 0 ADP F
a 0 DET F
serum 0 NOUN F
25 0 NUM F
( 0 PUNCT F
OH 0 NOUN T
) 0 PUNCT F
D 0 NOUN T
range 0 NOUN F
from 0 ADP F
40 0 NUM F
to 0 ADP F
130 0 NUM F
nmol/L 0 ADJ F
. 0 PUNCT F

Calcium 0 NOUN T
absorption 0 NOUN F
in 0 ADP F
this 0 DET F
range 0 NOUN F
is 0 VERB F
not 0 ADV F
a 0 PUNCT F
useful 0 ADJ F
biomarker 0 NOUN F
to 0 PART F
determine 0 VERB F
nutritional 0 ADJ F
recommendations 0 NOUN F
for 0 ADP F
vitamin 0 NOUN F
D 0 NOUN T
. 0 PUNCT F

Impact 0 NOUN T
of 0 ADP F
a 0 DET F
16-community 0 NOUN F
trial 0 NOUN F
to 0 ADJ F
promote 0 NOUN F
judicious 0 ADJ F
antibiotic 0 ADJ F
use 0 NOUN F
in 0 ADP F
Massachusetts 0 NOUN T
. 0 PUNCT F

OBJECTIVES 0 NOUN T
Reducing 0 PUNCT T
unnecessary 0 ADJ F
antibiotic 0 ADJ F
use 0 NOUN F
, 0 PUNCT F
particularly 0 ADV F
among 0 ADP F
children 0 NOUN F
, 0 PUNCT F
continues 0 VERB F
to 0 DET F
be 0 PUNCT F
a 0 DET F
public 0 ADJ F
health 0 NOUN F
priority 0 NOUN F
. 0 PUNCT F

Previous 0 ADJ T
intervention 0 NOUN F
studies 0 NOUN F
have 0 NOUN F
been 0 PUNCT F
limited 0 VERB F
by 0 ADP F
size 0 NOUN F
or 0 CCONJ F
design 0 NOUN F
and 0 CCONJ F
have 0 PUNCT F
shown 0 VERB F
mixed 0 VERB F
results 0 NOUN F
. 0 PUNCT F

The 0 DET T
objective 0 NOUN F
of 0 ADP F
this 0 DET F
study 0 NOUN F
was 0 VERB F
to 0 PART F
determine 0 NOUN F
the 0 DET F
impact 0 NOUN F
of 0 ADP F
a 0 DET F
multifaceted 0 ADP F
, 0 PUNCT F
community-wide 0 NOUN F
intervention 0 NOUN F
on 0 ADP F
overall 0 PUNCT F
antibiotic 0 ADJ F
use 0 NOUN F
for 0 ADP F
young 0 ADJ F
children 0 NOUN F
and 0 CCONJ F
on 0 ADP F
use 0 NOUN F
of 0 ADP F
broad-spectrum 0 NOUN F
agents 0 NOUN F
. 0 PUNCT F

In 0 ADP T
addition 0 NOUN F
, 0 PUNCT F
we 0 PRON F
sought 0 PROPN F
to 0 PART F
compare 0 NOUN F
the 0 DET F
intervention 0 NOUN F
's 0 PUNCT F
impact 0 NOUN F
on 0 ADP F
commercially 0 ADV F
and 0 CCONJ F
Medicaid-insured 0 ADP T
children 0 NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
We 0 PRON T
conducted 0 VERB F
a 0 DET F
controlled 0 VERB F
, 0 PUNCT F
community-level 0 PUNCT F
, 0 PUNCT F
cluster-randomized 0 ADP F
trial 0 NOUN F
in 0 ADP F
16 0 NUM F
nonoverlapping 0 ADV F
Massachusetts 0 NOUN T
communities 0 NOUN F
, 0 PUNCT F
studied 0 VERB F
from 0 ADP F
1998 0 NUM F
to 0 ADP F
2003 0 NUM F
. 0 PUNCT F

During 0 ADP T
3 0 NUM F
years 0 NOUN F
, 0 PUNCT F
we 0 PRON F
implemented 0 VERB F
a 0 DET F
physician 0 NOUN F
behavior-change 0 NOUN F
strategy 0 NOUN F
that 0 ADP F
included 0 VERB F
guideline 0 NOUN F
dissemination 0 NOUN F
, 0 PUNCT F
small-group 0 NOUN F
education 0 NOUN F
, 0 PUNCT F
frequent 0 ADJ F
updates 0 NOUN F
and 0 CCONJ F
educational 0 ADJ F
materials 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
prescribing 0 ADJ F
feedback 0 NOUN F
. 0 PUNCT F

Parents 0 NOUN T
received 0 VERB F
educational 0 ADJ F
materials 0 NOUN F
by 0 ADP F
mail 0 NOUN F
and 0 CCONJ F
in 0 ADP F
primary 0 ADJ F
care 0 NOUN F
practices 0 PROPN F
, 0 PUNCT F
pharmacies 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
child 0 NOUN F
care 0 NOUN F
settings 0 NOUN F
. 0 PUNCT F

Using 0 VERB T
health-plan 0 NOUN F
data 0 NOUN F
, 0 PUNCT F
we 0 PRON F
measured 0 PUNCT F
changes 0 NOUN F
in 0 ADP F
antibiotics 0 NOUN F
dispensed 0 VERB F
per 0 ADP F
person-year 0 ADJ F
of 0 ADP F
observation 0 NOUN F
among 0 ADP F
children 0 NOUN F
who 0 PROPN F
were 0 VERB F
aged 0 VERB F
3 0 NUM F
to 0 PUNCT F
< 0 ADP F
72 0 NUM F
months 0 NOUN F
, 0 PUNCT F
resided 0 VERB F
in 0 ADP F
study 0 VERB F
communities 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
were 0 VERB F
insured 0 NOUN F
by 0 ADP F
a 0 DET F
participating 0 PUNCT F
commercial 0 ADJ F
health 0 NOUN F
plan 0 NOUN F
or 0 CCONJ F
Medicaid 0 NOUN T
. 0 PUNCT F

RESULTS 0 PUNCT T
The 0 DET T
data 0 NOUN F
include 0 VERB F
223,135 0 NUM F
person-years 0 NOUN F
of 0 ADP F
observation 0 NOUN F
. 0 PUNCT F

Antibiotic-use B-MENTAL NUM T
rates I-MENTAL NOUN F
at 0 ADP F
baseline 0 NOUN F
were 0 VERB F
2.8 0 NUM F
, 0 PUNCT F
1.7 0 PUNCT F
, 0 PUNCT F
and 0 CCONJ F
1.4 0 NUM F
antibiotics 0 NOUN F
per 0 ADP F
person-year 0 ADJ F
among 0 ADP F
those 0 PUNCT F
aged 0 VERB F
3 0 NUM F
to 0 PUNCT F
< 0 ADP F
24 0 NUM F
, 0 PUNCT F
24 0 NUM F
to 0 PUNCT F
< 0 ADP F
48 0 NUM F
, 0 PUNCT F
and 0 CCONJ F
48 0 NUM F
to 0 PUNCT F
< 0 ADP F
72 0 NUM F
months 0 NOUN F
, 0 PUNCT F
respectively 0 ADV F
. 0 PUNCT F

We 0 PRON T
observed 0 VERB F
a 0 DET F
substantial 0 ADJ F
downward 0 ADJ F
trend 0 NOUN F
in 0 ADP F
antibiotic B-MENTAL ADJ F
prescribing I-MENTAL VERB F
, 0 PUNCT F
even 0 ADV F
in 0 ADP F
the 0 DET F
absence 0 NOUN F
of 0 ADP F
intervention 0 NOUN F
. 0 PUNCT F

The 0 DET T
intervention 0 NOUN F
had 0 PUNCT F
no 0 DET F
additional 0 ADJ F
effect 0 NOUN F
among 0 ADP F
children 0 ADJ F
aged 0 PROPN F
3 0 NUM F
to 0 PUNCT F
< 0 ADP F
24 0 NUM F
months 0 NOUN F
but 0 CCONJ F
was 0 VERB F
responsible 0 ADJ F
for 0 ADP F
a 0 DET F
4.2 0 ADV F
% 0 ADV F
decrease 0 NOUN F
among 0 ADP F
those 0 PUNCT F
aged 0 PUNCT F
24 0 NUM F
to 0 PUNCT F
< 0 ADP F
48 0 NUM F
months 0 NOUN F
and 0 CCONJ F
a 0 DET F
6.7 0 NUM F
% 0 ADV F
decrease 0 NOUN F
among 0 ADP F
those 0 PUNCT F
aged 0 PROPN F
48 0 NUM F
to 0 PUNCT F
< 0 ADP F
72 0 NUM F
months 0 NOUN F
. 0 PUNCT F

The 0 DET T
intervention 0 NOUN F
effect 0 NOUN F
was 0 VERB F
greater 0 PUNCT F
among 0 ADP F
Medicaid-insured 0 VERB T
children 0 NOUN F
and 0 CCONJ F
for 0 ADP F
broad-spectrum 0 NOUN F
agents 0 NOUN F
. 0 PUNCT F

CONCLUSIONS 0 NOUN T
A 0 CCONJ T
sustained 0 VERB F
, 0 PUNCT F
multifaceted 0 PUNCT F
, 0 PUNCT F
community-level 0 PUNCT F
intervention 0 NOUN F
was 0 VERB F
only 0 ADV F
modestly 0 ADV F
successful 0 ADJ F
at 0 ADP F
decreasing 0 ADP F
overall B-MENTAL ADJ F
antibiotic I-MENTAL ADJ F
use I-MENTAL NOUN F
beyond 0 ADP F
substantial 0 ADJ F
secular 0 ADJ F
trends 0 NOUN F
. 0 PUNCT F

The 0 DET T
more 0 ADV F
robust 0 ADJ F
impact 0 NOUN F
among 0 ADP F
Medicaid-insured 0 ADP T
children 0 NOUN F
and 0 CCONJ F
for 0 ADP F
specific 0 ADJ F
medication 0 NOUN F
classes 0 NOUN F
provides 0 NOUN F
an 0 DET F
argument 0 NOUN F
for 0 ADP F
specific 0 ADJ F
targeting 0 VERB F
of 0 ADP F
resources 0 NOUN F
for 0 ADP F
patient 0 NOUN F
and 0 CCONJ F
physician 0 NOUN F
behavior 0 NOUN F
change 0 NOUN F
. 0 PUNCT F

Comparative B-OTHER ADJ T
effectiveness I-OTHER NOUN F
of 0 ADP F
exercise 0 NOUN F
electrocardiography 0 NOUN F
with 0 ADP F
or 0 CCONJ F
without 0 ADP F
myocardial 0 ADJ F
perfusion 0 NOUN F
single 0 ADJ F
photon 0 ADP F
emission 0 NOUN F
computed 0 VERB F
tomography 0 NOUN F
in 0 ADP F
women 0 NOUN F
with 0 ADP F
suspected 0 VERB F
coronary 0 ADJ F
artery 0 NOUN F
disease 0 NOUN F
: 0 PUNCT F
results 0 DET F
from 0 ADP F
the 0 DET F
What 0 PUNCT T
Is 0 CCONJ T
the 0 PUNCT F
Optimal 0 ADJ T
Method 0 NOUN T
for 0 ADP F
Ischemia 0 NOUN T
Evaluation 0 NOUN T
in 0 ADP F
Women 0 NOUN T
( 0 PUNCT F
WOMEN 0 PUNCT T
) 0 PUNCT F
trial 0 NOUN F
. 0 PUNCT F

BACKGROUND 0 NOUN T
There 0 PUNCT T
is 0 VERB F
a 0 DET F
paucity 0 NOUN F
of 0 ADP F
randomized 0 VERB F
trials 0 NOUN F
regarding 0 VERB F
diagnostic 0 ADJ F
testing 0 VERB F
in 0 ADP F
women 0 NOUN F
with 0 ADP F
suspected 0 VERB F
coronary 0 ADJ F
artery 0 NOUN F
disease 0 NOUN F
( 0 PUNCT F
CAD 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

It 0 PRON T
remains 0 NOUN F
unclear 0 ADJ F
whether 0 ADP F
the 0 DET F
addition 0 NOUN F
of 0 ADP F
myocardial 0 ADJ F
perfusion 0 NOUN F
imaging 0 VERB F
( 0 PUNCT F
MPI 0 NOUN T
) 0 PUNCT F
to 0 ADP F
the 0 DET F
standard 0 ADJ F
ECG 0 NOUN T
exercise 0 NOUN F
treadmill 0 NOUN F
test 0 NOUN F
( 0 PUNCT F
ETT 0 NOUN T
) 0 PUNCT F
provides 0 NOUN F
incremental 0 ADJ F
information 0 NOUN F
to 0 PART F
improve 0 ADJ F
clinical 0 ADJ F
decision 0 NOUN F
making 0 VERB F
in 0 ADP F
women 0 NOUN F
with 0 ADP F
suspected 0 VERB F
CAD 0 NOUN T
. 0 PUNCT F

METHODS 0 NOUN T
AND 0 CCONJ T
RESULTS 0 NOUN T
We 0 PRON T
randomized 0 ADV F
symptomatic 0 ADJ F
women 0 NOUN F
with 0 ADP F
suspected 0 VERB F
CAD 0 NOUN T
, 0 PUNCT F
an 0 DET F
interpretable 0 ADJ F
ECG 0 NOUN T
, 0 PUNCT F
and 0 CCONJ F
?5 0 PUNCT F
metabolic 0 ADJ F
equivalents 0 NOUN F
on 0 ADP F
the 0 DET F
Duke 0 NOUN T
Activity 0 NOUN T
Status 0 NOUN T
Index 0 NOUN T
to 0 ADP F
1 0 PUNCT F
of 0 ADP F
2 0 NUM F
diagnostic 0 ADJ F
strategies 0 NOUN F
: 0 PUNCT F
ETT 0 NOUN T
or 0 CCONJ F
exercise 0 NOUN F
MPI 0 NOUN T
. 0 PUNCT F

The 0 DET T
primary 0 ADJ F
end 0 NOUN F
point 0 NOUN F
was 0 VERB F
2-year 0 NOUN F
incidence 0 NOUN F
of 0 ADP F
major 0 ADJ F
adverse 0 ADJ F
cardiac 0 ADJ F
events 0 NOUN F
, 0 PUNCT F
defined 0 VERB F
as 0 ADP F
CAD 0 NOUN T
death 0 NOUN F
or 0 CCONJ F
hospitalization 0 NOUN F
for 0 ADP F
an 0 DET F
acute 0 ADJ F
coronary 0 ADJ F
syndrome 0 NOUN F
or 0 CCONJ F
heart 0 NOUN F
failure 0 NOUN F
. 0 PUNCT F

A 0 DET T
total 0 NOUN F
of 0 ADP F
824 0 NUM F
women 0 NOUN F
were 0 VERB F
randomized 0 VERB F
to 0 ADP F
ETT 0 NOUN T
or 0 CCONJ F
exercise 0 NOUN F
MPI 0 NOUN T
. 0 PUNCT F

For 0 ADP T
women 0 NOUN F
randomized 0 ADP F
to 0 ADP F
ETT 0 NOUN T
, 0 PUNCT F
ECG 0 NOUN T
results 0 CCONJ F
were 0 VERB F
normal 0 ADJ F
in 0 ADP F
64 0 NUM F
% 0 SYM F
, 0 PUNCT F
indeterminate 0 ADJ F
in 0 ADP F
16 0 NUM F
% 0 SYM F
, 0 PUNCT F
and 0 CCONJ F
abnormal 0 ADJ F
in 0 ADP F
20 0 NUM F
% 0 SYM F
. 0 PUNCT F

By 0 ADP T
comparison 0 NOUN F
, 0 PUNCT F
the 0 DET F
exercise 0 NOUN F
MPI 0 NOUN T
results 0 CCONJ F
were 0 VERB F
normal 0 ADJ F
in 0 ADP F
91 0 NUM F
% 0 SYM F
, 0 PUNCT F
mildly 0 ADV F
abnormal 0 ADJ F
in 0 ADP F
3 0 NUM F
% 0 SYM F
, 0 PUNCT F
and 0 CCONJ F
moderate 0 ADJ F
to 0 ADP F
severely 0 ADV F
abnormal 0 ADJ F
in 0 ADP F
6 0 NUM F
% 0 SYM F
. 0 PUNCT F

At 0 ADP T
2 0 NUM F
years 0 NOUN F
, 0 PUNCT F
there 0 PUNCT F
was 0 VERB F
no 0 DET F
difference 0 NOUN F
in 0 ADP F
major 0 ADJ F
adverse 0 ADJ F
cardiac 0 ADJ F
events 0 NOUN F
( 0 PUNCT F
98.0 0 NUM F
% 0 SYM F
for 0 ADP F
ETT 0 NOUN T
and 0 CCONJ F
97.7 0 NUM F
% 0 SYM F
for 0 ADP F
MPI 0 NOUN T
; 0 PUNCT F
P=0.59 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

Compared 0 VERB T
with 0 ADP F
ETT 0 NOUN T
, 0 PUNCT F
index 0 NOUN F
testing 0 PUNCT F
costs 0 NOUN F
were 0 VERB F
higher 0 PUNCT F
for 0 ADP F
exercise 0 NOUN F
MPI 0 NOUN T
( 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.001 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
whereas 0 ADP F
downstream 0 ADJ F
procedural 0 ADJ F
costs 0 NOUN F
were 0 VERB F
slightly 0 ADV F
lower 0 PUNCT F
( 0 PUNCT F
P=0.0008 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

Overall 0 ADJ T
, 0 PUNCT F
the 0 DET F
cumulative 0 ADJ F
diagnostic 0 ADJ F
cost 0 NOUN F
savings 0 NOUN F
was 0 VERB F
48 0 NUM F
% 0 SYM F
for 0 ADP F
ETT 0 NOUN T
compared 0 VERB F
with 0 ADP F
exercise 0 NOUN F
MPI 0 NOUN T
( 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.001 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

CONCLUSIONS 0 NOUN T
In 0 ADP T
low-risk 0 NOUN F
, 0 PUNCT F
exercising 0 PUNCT F
women 0 NOUN F
, 0 PUNCT F
a 0 DET F
diagnostic 0 ADJ F
strategy 0 NOUN F
that 0 ADP F
uses 0 VERB F
ETT 0 NOUN T
versus 0 CCONJ F
exercise 0 NOUN F
MPI 0 NOUN T
yields 0 ADJ F
similar 0 ADJ F
2-year 0 NOUN F
posttest 0 ADV F
outcomes 0 NOUN F
while 0 ADP F
providing 0 VERB F
significant 0 ADJ F
diagnostic 0 ADJ F
cost 0 NOUN F
savings 0 NOUN F
. 0 PUNCT F

The 0 DET T
ETT 0 NOUN T
with 0 ADP F
selective 0 ADJ F
follow-up 0 NOUN F
testing 0 VERB F
should 0 SYM F
be 0 VERB F
considered 0 VERB F
as 0 ADP F
the 0 DET F
initial 0 ADJ F
diagnostic 0 ADJ F
strategy 0 NOUN F
in 0 ADP F
symptomatic 0 ADJ F
women 0 NOUN F
with 0 ADP F
suspected 0 VERB F
CAD 0 NOUN T
. 0 PUNCT F

CLINICAL 0 ADJ T
TRIAL 0 NOUN T
REGISTRATION 0 NOUN T
http 0 PUNCT F
: 0 PUNCT F
//www.clinicaltrials.gov 0 PUNCT F
. 0 PUNCT F

Unique 0 ADJ T
identifier 0 NOUN F
: 0 PUNCT F
NCT00282711 0 PUNCT T
. 0 PUNCT F

A 0 DET T
comparison 0 NOUN F
of 0 ADP F
lisinopril 0 NOUN F
and 0 CCONJ F
nifedipine 0 NOUN F
in 0 ADP F
the 0 DET F
treatment 0 NOUN F
of 0 ADP F
mild 0 ADJ F
to 0 ADP F
moderate 0 ADJ F
hypertension 0 NOUN F
. 0 PUNCT F

A 0 DET T
multicentre 0 NOUN F
study 0 NOUN F
. 0 PUNCT F

Lisinopril 0 NOUN T
has 0 PUNCT F
been 0 PUNCT F
compared 0 VERB F
with 0 ADP F
slow-release 0 NOUN F
nifedipine 0 NOUN F
in 0 ADP F
a 0 DET F
16-week 0 NOUN F
double-blind 0 ADJ F
, 0 PUNCT F
randomized 0 VERB F
, 0 PUNCT F
parallel-group 0 NOUN F
study 0 NOUN F
involving 0 VERB F
102 0 NUM F
patients 0 NOUN F
with 0 ADP F
mild 0 ADJ F
to 0 ADP F
moderate 0 ADJ F
hypertension 0 NOUN F
. 0 PUNCT F

Sitting B-PHYSICAL ADP T
systolic I-PHYSICAL ADJ F
and 0 CCONJ F
diastolic B-PHYSICAL ADJ F
blood I-PHYSICAL NOUN F
pressures I-PHYSICAL NOUN F
were 0 VERB F
reduced 0 VERB F
6 0 NUM F
and 0 CCONJ F
5 0 NUM F
mmHg 0 NOUN F
more 0 ADV F
by 0 ADP F
lisinopril 0 NOUN F
than 0 PUNCT F
by 0 ADP F
nifedipine 0 NOUN F
over 0 ADP F
12 0 NUM F
weeks 0 NOUN F
monotherapy 0 NOUN F
. 0 PUNCT F

After 0 ADP T
12 0 NUM F
weeks 0 NOUN F
a 0 DET F
greater 0 PUNCT F
proportion 0 NOUN F
of 0 ADP F
patients 0 NOUN F
taking 0 PUNCT F
lisinopril 0 NOUN F
was 0 VERB F
controlled 0 VERB F
( 0 PUNCT F
sitting 0 PUNCT F
diastolic 0 ADJ F
blood 0 NOUN F
pressure 0 NOUN F
below 0 ADP F
95 0 NUM F
mm 0 NOUN F
Hg 0 NOUN T
) 0 PUNCT F
than 0 PUNCT F
in 0 ADP F
those 0 PUNCT F
taking 0 ADJ F
nifedipine 0 NOUN F
. 0 PUNCT F

As 0 ADP T
a 0 DET F
result 0 NOUN F
, 0 PUNCT F
17 0 NUM F
% 0 DET F
of 0 ADP F
those 0 PUNCT F
taking 0 PUNCT F
lisinopril 0 NOUN F
and 0 CCONJ F
38 0 NUM F
% 0 SYM F
of 0 ADP F
those 0 PUNCT F
taking 0 ADJ F
nifedipine 0 NOUN F
required 0 PUNCT F
additional 0 ADJ F
therapy 0 NOUN F
with 0 ADP F
hydrochlorothiazide B-PHYSICAL NOUN F
. 0 PUNCT F

The 0 DET T
addition 0 NOUN F
of 0 ADP F
hydrochlorothiazide 0 PUNCT F
resulted 0 VERB F
in 0 ADP F
similar B-OTHER ADJ F
response 0 NOUN F
rates B-OTHER NOUN F
in 0 ADP F
the 0 DET F
lisinopril 0 NOUN F
and 0 CCONJ F
nifedipine 0 NOUN F
groups 0 NOUN F
( 0 PUNCT F
89 0 NUM F
% 0 SYM F
and 0 CCONJ F
75 0 NUM F
% 0 SYM F
respectively 0 ADV F
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
rate 0 NOUN F
of 0 ADP F
reporting 0 VERB F
of 0 ADP F
adverse B-ADVERSE-EFFECTS ADJ F
events B-ADVERSE-EFFECTS NOUN F
considered 0 VERB F
to 0 PART F
be 0 PUNCT F
drug-related 0 ADV F
and 0 CCONJ F
the 0 DET F
rate 0 NOUN F
of 0 ADP F
withdrawals 0 NOUN F
were 0 VERB F
similar 0 ADJ F
for 0 ADP F
both 0 PUNCT F
treatments 0 NOUN F
. 0 PUNCT F

Cough B-ADVERSE-EFFECTS NOUN T
was 0 VERB F
more 0 ADV F
often 0 ADV F
reported 0 VERB F
with 0 ADP F
lisinopril 0 NOUN F
and 0 CCONJ F
headache B-ADVERSE-EFFECTS NOUN F
, 0 PUNCT F
sweating B-ADVERSE-EFFECTS VERB F
, 0 PUNCT F
and 0 PUNCT F

A 0 DET T
good 0 ADJ F
response 0 NOUN F
to 0 ADP F
oil 0 NOUN F
with 0 ADP F
medium- 0 NOUN F
and 0 CCONJ F
long-chain 0 NOUN F
fatty 0 ADJ F
acids 0 NOUN F
in 0 ADP F
body B-PHYSICAL NOUN F
fat I-PHYSICAL NOUN F
and 0 CCONJ F
blood B-PHYSICAL NOUN F
lipid I-PHYSICAL NOUN F
profiles I-PHYSICAL NOUN F
of 0 ADP F
male 0 NOUN F
hypertriglyceridemic 0 ADJ F
subjects 0 NOUN F
. 0 PUNCT F

A 0 ADP T
double 0 ADJ F
blind 0 ADJ F
clinical 0 ADJ F
trial 0 NOUN F
was 0 VERB F
carried 0 VERB F
out 0 ADP F
to 0 PART F
clarify 0 NOUN F
the 0 DET F
effects 0 NOUN F
of 0 ADP F
oil 0 NOUN F
with 0 ADP F
medium- 0 NOUN F
and 0 CCONJ F
long-chain 0 NOUN F
triglyceride 0 NOUN F
( 0 PUNCT F
MLCT 0 NOUN T
) 0 PUNCT F
on 0 ADP F
body B-PHYSICAL NOUN F
fat I-PHYSICAL NOUN F
and 0 CCONJ F
blood B-PHYSICAL NOUN F
lipid I-PHYSICAL NOUN F
profiles I-PHYSICAL NOUN F
in 0 ADP F
hypertriglyceridemic 0 ADJ F
subjects 0 NOUN F
. 0 PUNCT F

One-hundred-and-twelve 0 PUNCT T
subjects 0 NOUN F
were 0 VERB F
enrolled 0 VERB F
and 0 CCONJ F
divided 0 VERB F
into 0 ADP F
two 0 NUM F
groups 0 NOUN F
; 0 PUNCT F
those 0 ADP F
that 0 PUNCT F
consumed 0 PUNCT F
MLCT 0 NOUN T
oil 0 NOUN F
and 0 CCONJ F
those 0 PUNCT F
that 0 PUNCT F
consumed 0 PUNCT F
long-chain 0 NOUN F
triglyceride 0 NOUN F
( 0 PUNCT F
LCT 0 NOUN T
) 0 PUNCT F
oil 0 NOUN F
for 0 ADP F
8 0 NUM F
weeks 0 NOUN F
. 0 PUNCT F

All 0 DET T
subjects 0 NOUN F
were 0 VERB F
requested 0 VERB F
to 0 ADP F
consume 0 ADJ F
25-30 0 DET F
g 0 NOUN F
of 0 ADP F
the 0 DET F
oils 0 NOUN F
daily 0 ADJ F
and 0 CCONJ F
maintain 0 ADJ F
a 0 DET F
fixed 0 VERB F
level 0 NOUN F
of 0 ADP F
energy 0 NOUN F
intake 0 NOUN F
and 0 CCONJ F
exercise 0 NOUN F
. 0 PUNCT F

Anthropometric B-PHYSICAL ADJ T
and I-PHYSICAL CCONJ F
blood I-PHYSICAL NOUN F
biochemical I-PHYSICAL ADJ F
parameters I-PHYSICAL NOUN F
were 0 VERB F
measured 0 VERB F
when 0 ADP F
the 0 DET F
study 0 NOUN F
was 0 VERB F
initiated 0 VERB F
and 0 CCONJ F
completed 0 NOUN F
. 0 PUNCT F

The 0 DET T
LCT 0 NOUN T
group 0 NOUN F
consisted 0 VERB F
of 0 ADP F
50 0 NUM F
subjects 0 NOUN F
( 0 PUNCT F
34 0 NUM F
men 0 NOUN F
and 0 CCONJ F
16 0 NUM F
women 0 NOUN F
) 0 PUNCT F
, 0 PUNCT F
while 0 ADP F
the 0 DET F
MLCT 0 NOUN T
group 0 NOUN F
consisted 0 VERB F
of 0 ADP F
51 0 NUM F
subjects 0 NOUN F
( 0 PUNCT F
33 0 NUM F
men 0 NOUN F
and 0 CCONJ F
18 0 NUM F
women 0 NOUN F
) 0 PUNCT F
who 0 ADP F
completed 0 PROPN F
the 0 DET F
study 0 NOUN F
. 0 PUNCT F

Larger 0 PUNCT T
decreases 0 CCONJ F
in 0 ADP F
body B-PHYSICAL NOUN F
weight 0 NOUN F
, 0 PUNCT F
body B-PHYSICAL NOUN F
mass 0 NOUN F
index 0 NOUN F
, 0 PUNCT F
waist 0 NOUN F
circumference 0 NOUN F
, 0 PUNCT F
body B-PHYSICAL NOUN F
fat 0 NOUN F
, 0 PUNCT F
total 0 ADJ F
fat 0 NOUN F
area 0 NOUN F
and 0 CCONJ F
subcutaneous 0 ADJ F
fat 0 NOUN F
area 0 NOUN F
in 0 ADP F
the 0 DET F
abdomen 0 NOUN F
and 0 CCONJ F
serum 0 NOUN F
triglycerides 0 NOUN F
, 0 PUNCT F
low-density 0 NOUN F
lipoprotein 0 NOUN F
cholesterol 0 NOUN F
, 0 PUNCT F
apolipoprotein 0 NOUN F
B 0 NOUN T
, 0 PUNCT F
C2 0 NOUN T
, 0 PUNCT F
C3 0 NOUN T
and 0 CCONJ F
E 0 NOUN T
were 0 VERB F
observed 0 VERB F
in 0 ADP F
male 0 NOUN F
subjects 0 NOUN F
in 0 ADP F
the 0 DET F
MLCT 0 NOUN T
group 0 NOUN F
than 0 PUNCT F
those 0 PUNCT F
in 0 ADP F
the 0 DET F
LCT 0 NOUN T
group 0 NOUN F
. 0 PUNCT F

However 0 ADV T
, 0 PUNCT F
no 0 DET F
significant 0 ADJ F
differences 0 NOUN F
in 0 ADP F
these 0 DET F
parameters B-OTHER NOUN F
between 0 ADP F
the 0 DET F
female 0 NOUN F
subjects 0 NOUN F
in 0 ADP F
the 0 DET F
two 0 NUM F
groups 0 NOUN F
were 0 VERB F
observed 0 VERB F
. 0 PUNCT F

Data 0 NOUN T
from 0 ADP F
this 0 DET F
study 0 NOUN F
indicate 0 VERB F
that 0 ADP F
consumption 0 NOUN F
of 0 ADP F
medium-and 0 PUNCT F
long-chain 0 NOUN F
triglycerides 0 NOUN F
can 0 VERB F
reduce 0 VERB F
body B-PHYSICAL NOUN F
weight I-PHYSICAL NOUN F
and 0 CCONJ F
body B-PHYSICAL PUNCT F

Teaching 0 ADJ T
young 0 VERB F
nonverbal 0 ADJ F
children 0 NOUN F
with 0 ADP F
autism 0 NOUN F
useful 0 ADJ F
speech 0 NOUN F
: 0 PUNCT F
a 0 DET F
pilot 0 NOUN F
study 0 NOUN F
of 0 ADP F
the 0 DET F
Denver 0 NOUN T
Model 0 NOUN T
and 0 CCONJ F
PROMPT 0 NOUN T
interventions 0 NOUN F
. 0 PUNCT F

This 0 DET T
single 0 ADJ F
subject 0 NOUN F
design 0 NOUN F
study 0 NOUN F
examined 0 VERB F
two 0 NUM F
models 0 NOUN F
of 0 ADP F
intervention 0 NOUN F
: 0 PUNCT F
Denver 0 NOUN T
Model 0 NOUN T
( 0 PUNCT F
which 0 ADP F
merges 0 PUNCT F
behavioral 0 ADJ F
, 0 PUNCT F
developmental 0 ADJ F
, 0 PUNCT F
and 0 CCONJ F
relationship-oriented 0 VERB F
intervention 0 NOUN F
) 0 PUNCT F
, 0 PUNCT F
and 0 CCONJ F
PROMPT 0 NOUN T
( 0 PUNCT F
a 0 DET F
neuro-developmental 0 ADJ F
approach 0 NOUN F
for 0 ADP F
speech 0 NOUN F
production 0 NOUN F
disorders 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

Ten 0 NUM T
young 0 ADJ F
, 0 PUNCT F
nonverbal 0 ADP F
children 0 NOUN F
with 0 ADP F
autism 0 NOUN F
were 0 VERB F
matched 0 VERB F
in 0 ADP F
pairs 0 NOUN F
and 0 CCONJ F
randomized 0 PUNCT F
to 0 ADP F
treatment 0 NOUN F
. 0 PUNCT F

They 0 PRON T
received 0 ADP F
12 0 NUM F
1-h 0 NOUN F
weekly 0 ADV F
sessions 0 NOUN F
of 0 ADP F
therapy 0 NOUN F
and 0 CCONJ F
daily 0 ADJ F
1-h 0 NOUN F
home 0 NOUN F
intervention 0 NOUN F
delivered 0 VERB F
by 0 ADP F
parents 0 NOUN F
. 0 PUNCT F

Fidelity 0 NOUN T
criteria 0 NOUN F
were 0 VERB F
maintained 0 VERB F
throughout 0 PUNCT F
. 0 PUNCT F

Eight 0 PUNCT T
of 0 ADP F
the 0 DET F
ten 0 NUM F
children 0 NOUN F
used 0 ADJ F
five 0 ADP F
or 0 CCONJ F
more 0 DET F
novel 0 ADJ F
, 0 PUNCT F
functional B-MENTAL ADJ F
words 0 NOUN F
spontaneously 0 ADV F
and 0 CCONJ F
spoke 0 PROPN F
multiple 0 ADJ F
times 0 NOUN F
per 0 ADP F
hour 0 NOUN F
by 0 ADP F
the 0 DET F
conclusion 0 NOUN F
of 0 ADP F
treatment 0 NOUN F
. 0 PUNCT F

There 0 PUNCT T
were 0 VERB F
no 0 DET F
differences 0 NOUN F
in 0 ADP F
acquired B-MENTAL VERB F
language I-MENTAL NOUN F
skills I-MENTAL NOUN F
by 0 ADP F
intervention 0 NOUN F
group 0 NOUN F
. 0 PUNCT F

Initial 0 ADJ T
characteristics 0 NOUN F
of 0 ADP F
the 0 DET F
best 0 PUNCT F
responders 0 NOUN F
were 0 VERB F
mild 0 ADJ F
to 0 ADP F
moderate 0 ADJ F
symptoms 0 NOUN F
of 0 ADP F
autism 0 NOUN F
, 0 PUNCT F
better 0 PUNCT F
motor 0 NOUN F
imitation 0 NOUN F
skills 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
emerging 0 VERB F
joint 0 NOUN F
attention 0 NOUN F
skills 0 NOUN F
. 0 PUNCT F

Clinical 0 ADJ T
evaluation 0 NOUN F
of 0 ADP F
imidapril 0 NOUN F
in 0 ADP F
congestive 0 ADJ F
heart 0 NOUN F
failure 0 NOUN F
in 0 ADP F
dogs 0 NOUN F
: 0 PUNCT F
results 0 NOUN F
of 0 ADP F
the 0 DET F
EFFIC 0 NOUN T
study 0 NOUN F
. 0 PUNCT F

OBJECTIVES 0 NOUN T
The 0 DET T
clinical 0 ADJ F
efficacy 0 NOUN F
and 0 CCONJ F
safety 0 NOUN F
of 0 ADP F
imidapril 0 NOUN F
were 0 VERB F
evaluated 0 VERB F
in 0 ADP F
dogs 0 NOUN F
that 0 PUNCT F
presented 0 VERB F
with 0 ADP F
mild 0 ADJ F
to 0 ADP F
severe 0 ADJ F
congestive 0 ADJ F
heart 0 NOUN F
failure 0 NOUN F
( 0 PUNCT F
New 0 ADJ T
York 0 NOUN T
Heart 0 NOUN T
Association 0 NOUN T
stage 0 NOUN F
II 0 NUM T
to 0 ADP F
IV 0 NUM T
) 0 PUNCT F
by 0 ADP F
comparing 0 DET F
the 0 DET F
success 0 NOUN F
rate 0 NOUN F
of 0 ADP F
imidapril 0 NOUN F
with 0 ADP F
a 0 DET F
positive 0 ADJ F
control 0 NOUN F
by 0 ADP F
a 0 DET F
non-inferiority 0 NOUN F
approach 0 NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
This 0 CCONJ T
good 0 ADJ F
, 0 PUNCT F
clinical 0 ADJ F
practice 0 NOUN F
compliant 0 NOUN F
, 0 PUNCT F
multicentre 0 NOUN F
study 0 NOUN F
( 0 PUNCT F
EFFIC 0 NOUN T
study 0 NOUN F
) 0 PUNCT F
enrolled 0 VERB F
142 0 NUM F
client-owned 0 VERB F
dogs 0 NOUN F
and 0 CCONJ F
was 0 VERB F
conducted 0 VERB F
in 0 ADP F
20 0 NUM F
locations 0 NOUN F
in 0 ADP F
France 0 NOUN T
, 0 PUNCT F
Belgium 0 NOUN T
and 0 CCONJ F
Germany 0 PUNCT T
. 0 PUNCT F

Dogs 0 NOUN T
of 0 ADP F
various 0 ADJ F
breed 0 PUNCT F
, 0 PUNCT F
age 0 NOUN F
and 0 CCONJ F
weight 0 NOUN F
were 0 VERB F
included 0 VERB F
in 0 ADP F
the 0 DET F
study 0 NOUN F
. 0 PUNCT F

These 0 DET T
dogs 0 NOUN F
were 0 VERB F
randomised 0 VERB F
into 0 ADP F
two 0 NUM F
groups 0 NOUN F
that 0 NUM F
were 0 VERB F
treated 0 VERB F
for 0 ADP F
84 0 NUM F
days 0 NOUN F
with 0 ADP F
either 0 CCONJ F
the 0 DET F
test 0 ADV F
product 0 NOUN F
, 0 PUNCT F
imidapril 0 NOUN F
, 0 PUNCT F
or 0 CCONJ F
the 0 DET F
positive 0 ADJ F
control 0 NOUN F
, 0 PUNCT F
benazepril 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
followed 0 VERB F
up 0 PUNCT F
in 0 ADP F
parallel 0 ADJ F
over 0 ADP F
this 0 DET F
period 0 NOUN F
. 0 PUNCT F

Both 0 CCONJ T
treatments 0 NOUN F
were 0 VERB F
administered 0 VERB F
at 0 ADP F
a 0 DET F
dose 0 NOUN F
of 0 ADP F
0.25 0 NUM F
mg/kg 0 NOUN F
once 0 PUNCT F
a 0 DET F
day 0 NOUN F
with 0 ADP F
the 0 DET F
possibility 0 NOUN F
of 0 ADP F
doubling 0 PUNCT F
this 0 DET F
dose 0 NOUN F
to 0 ADP F
0.5 0 NUM F
mg/kg 0 NOUN F
if 0 PUNCT F
considered 0 PUNCT F
necessary 0 ADJ F
from 0 ADP F
a 0 DET F
clinical 0 ADJ F
point 0 NOUN F
of 0 ADP F
view 0 NOUN F
. 0 PUNCT F

In 0 ADP T
addition 0 NOUN F
, 0 PUNCT F
concomitant 0 ADJ F
treatment 0 NOUN F
was 0 VERB F
given 0 VERB F
to 0 ADP F
dogs 0 NOUN F
presenting 0 VERB F
with 0 ADP F
pulmonary 0 ADJ F
oedema 0 NOUN F
and/or 0 CCONJ F
ascites 0 VERB F
, 0 PUNCT F
supraventricular 0 ADP F
tachyarrhythmia 0 NOUN F
and/or 0 CCONJ F
dilated 0 VERB F
cardiomyopathy 0 NOUN F
. 0 PUNCT F

The 0 DET T
evolution B-PHYSICAL NOUN F
of I-PHYSICAL ADP F
the I-PHYSICAL DET F
New I-PHYSICAL ADJ T
York I-PHYSICAL NOUN T
Heart I-PHYSICAL NOUN T
Association 0 NOUN T
stage B-PHYSICAL NOUN F
and 0 CCONJ F
the 0 DET F
functional B-PHYSICAL ADJ F
signs I-PHYSICAL NOUN F
score B-PHYSICAL NOUN F
were 0 VERB F
evaluated 0 VERB F
as 0 ADP F
primary 0 ADJ F
efficacy 0 NOUN F
criteria 0 NOUN F
. 0 PUNCT F

RESULTS 0 PUNCT T
The 0 DET T
success B-OTHER NOUN F
rate I-OTHER NOUN F
in 0 ADP F
the 0 DET F
imidapril 0 NOUN F
group 0 NOUN F
was 0 VERB F
66 0 NUM F
compared 0 VERB F
with 0 ADP F
68 0 NUM F
per 0 ADP F
cent 0 NUM F
in 0 ADP F
the 0 DET F
benazepril 0 NOUN F
group 0 NOUN F
. 0 PUNCT F

Regarding 0 PUNCT T
safety 0 NOUN F
, 0 PUNCT F
35 0 NUM F
dogs 0 NOUN F
in 0 ADP F
each 0 DET F
group 0 NOUN F
experienced 0 PUNCT F
at 0 ADP F
least 0 ADV F
one 0 NUM F
adverse B-ADVERSE-EFFECTS ADJ F
event 0 NOUN F
. 0 PUNCT F

Nine 0 NUM T
dogs 0 NOUN F
in 0 ADP F
each 0 DET F
group 0 NOUN F
experienced 0 PUNCT F
at 0 ADP F
least 0 ADV F
one 0 NUM F
serious B-ADVERSE-EFFECTS PUNCT F

Breast 0 NOUN T
reduction 0 NOUN F
alleviates 0 ADJ F
depression B-MENTAL NOUN F
and 0 CCONJ F
anxiety B-MENTAL NOUN F
and 0 CCONJ F
restores 0 VERB F
self-esteem B-MENTAL CCONJ F
: 0 PUNCT F
a 0 DET F
prospective 0 ADJ F
randomised 0 VERB F
clinical 0 ADJ F
trial 0 NOUN F
. 0 PUNCT F

Of 0 ADP T
women 0 NOUN F
who 0 ADP F
seek 0 VERB F
reduction 0 NOUN F
mammaplasty 0 NOUN F
, 0 PUNCT F
up 0 PUNCT F
to 0 ADP F
a 0 DET F
third 0 PUNCT F
have 0 PUNCT F
pathological 0 ADJ F
degrees 0 PUNCT F
of 0 ADP F
anxiety B-MENTAL NOUN F
or 0 CCONJ F
depression B-MENTAL NOUN F
, 0 PUNCT F
or 0 CCONJ F
both 0 CCONJ F
. 0 PUNCT F

The 0 DET T
psychological B-MENTAL ADJ F
aspect I-MENTAL NOUN F
of 0 ADP F
reduction 0 NOUN F
mammaplasty 0 NOUN F
is 0 VERB F
therefore 0 ADV F
an 0 DET F
important 0 ADJ F
consideration 0 NOUN F
. 0 PUNCT F

We 0 PRON T
did 0 CCONJ F
a 0 DET F
prospective 0 ADJ F
randomised 0 VERB F
clinical 0 ADJ F
trial 0 NOUN F
to 0 PART F
see 0 NOUN F
how 0 ADP F
reduction 0 NOUN F
mammaplasty 0 NOUN F
affected 0 VERB F
macromastia 0 NOUN F
patients 0 NOUN F
' 0 PUNCT F
depression B-MENTAL NOUN F
, 0 PUNCT F
anxiety B-MENTAL NOUN F
, 0 PUNCT F
and 0 CCONJ F
self-esteem B-MENTAL CCONJ F
. 0 PUNCT F

Eighty-two 0 NUM T
patients 0 NOUN F
were 0 VERB F
randomised 0 NUM F
, 0 PUNCT F
40 0 DET F
to 0 ADP F
have 0 PUNCT F
the 0 DET F
operation 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
42 0 NUM F
patients 0 NOUN F
to 0 ADP F
conservative 0 ADJ F
treatment 0 NOUN F
. 0 PUNCT F

Both 0 DET T
groups 0 NOUN F
were 0 VERB F
followed 0 VERB F
for 0 ADP F
six 0 NUM F
months 0 NOUN F
. 0 PUNCT F

The 0 DET T
patients 0 NOUN F
completed 0 VERB F
the 0 DET F
RBDI B-MENTAL NOUN T
questionnaire 0 NOUN F
( B-MENTAL PUNCT F
Raitasalo I-MENTAL NOUN T
's 0 PUNCT F
modification B-MENTAL NOUN F
of I-MENTAL ADP F
the I-MENTAL DET F
short I-MENTAL ADJ F
form I-MENTAL NOUN F
of I-MENTAL ADP F
the I-MENTAL DET F
Beck I-MENTAL NOUN T
Depression I-MENTAL NOUN T
Inventory I-MENTAL PUNCT T
) B-MENTAL PUNCT F
. 0 PUNCT F

Twenty-nine 0 NUM T
patients 0 NOUN F
in 0 ADP F
the 0 DET F
operated 0 ADJ F
group 0 NOUN F
and 0 CCONJ F
35 0 NUM F
patients 0 NOUN F
in 0 ADP F
the 0 DET F
conservative 0 ADJ F
group 0 NOUN F
completed 0 VERB F
the 0 DET F
study 0 NOUN F
. 0 PUNCT F

At 0 ADP T
the 0 DET F
second 0 ADJ F
examination 0 NOUN F
, 0 PUNCT F
the 0 DET F
patients 0 NOUN F
who 0 ADP F
had 0 PUNCT F
been 0 PUNCT F
operated 0 VERB F
on 0 ADP F
, 0 PUNCT F
had 0 PUNCT F
significantly 0 ADV F
less 0 DET F
depression B-MENTAL NOUN F
( 0 PUNCT F
p 0 NOUN F
< 0 SYM F
0.01 0 NUM F
) 0 PUNCT F
and 0 CCONJ F
better B-MENTAL PUNCT F
self-esteem B-MENTAL CCONJ F
( 0 PUNCT F
p=0.03 0 NOUN F
) 0 PUNCT F
than 0 PUNCT F
the 0 DET F
conservative 0 ADJ F
group 0 NOUN F
. 0 PUNCT F

The 0 DET T
proportions 0 NOUN F
of 0 ADP F
depressed B-MENTAL PUNCT F
( 0 PUNCT F
p 0 NOUN F
< 0 SYM F
0.01 0 NUM F
) 0 PUNCT F
and 0 CCONJ F
anxious B-MENTAL ADJ F
( 0 PUNCT F
p=0.04 0 NOUN F
) 0 PUNCT F
patients 0 NOUN F
were 0 VERB F
also 0 ADV F
smaller 0 PUNCT F
in 0 ADP F
the 0 DET F
group 0 NOUN F
who 0 ADP F
were 0 VERB F
operated 0 VERB F
on 0 ADP F
. 0 PUNCT F

There 0 PUNCT T
is 0 VERB F
significantly 0 ADV F
less 0 DET F
depression B-MENTAL NOUN F
and 0 PUNCT F

Comparison 0 NOUN T
of 0 ADP F
ketoconazole 0 NOUN F
and 0 CCONJ F
griseofulvin 0 NOUN F
in 0 ADP F
the 0 DET F
treatment 0 NOUN F
of 0 ADP F
tinea 0 NOUN F
pedis 0 PUNCT F
. 0 PUNCT F

Twenty-nine 0 NUM T
patients 0 NOUN F
with 0 ADP F
mycologically 0 ADJ F
proven 0 VERB F
tinea 0 NOUN F
pedis 0 PUNCT F
were 0 VERB F
randomly 0 ADV F
allocated 0 VERB F
to 0 ADP F
oral 0 ADJ F
treatment 0 NOUN F
with 0 ADP F
either 0 PUNCT F
ketoconazole 0 NOUN F
200 0 NUM F
mg 0 NOUN F
daily 0 ADJ F
or 0 CCONJ F
griseofulvin 0 NOUN F
1 0 NUM F
g 0 ADP F
daily 0 ADJ F
for 0 ADP F
a 0 DET F
period 0 NOUN F
of 0 ADP F
up 0 PUNCT F
to 0 ADP F
8 0 NUM F
weeks 0 NOUN F
. 0 PUNCT F

Mycological B-OTHER ADJ T
cure I-OTHER NOUN F
rate I-OTHER NOUN F
at 0 ADP F
4 0 NUM F
weeks 0 NOUN F
was 0 VERB F
33 0 NUM F
% 0 SYM F
for 0 ADP F
ketoconazole 0 NOUN F
and 0 CCONJ F
29 0 NUM F
% 0 SYM F
for 0 ADP F
griseofulvin 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
at 0 ADP F
8 0 NUM F
weeks 0 NOUN F
was 0 VERB F
53 0 NUM F
% 0 SYM F
and 0 CCONJ F
57 0 NUM F
% 0 SYM F
respectively 0 ADV F
. 0 PUNCT F

The 0 DET T
efficacy 0 NOUN F
of 0 ADP F
both 0 PUNCT F
drugs 0 NOUN F
in 0 ADP F
the 0 DET F
treatment 0 NOUN F
of 0 ADP F
interdigital 0 ADJ F
tinea 0 NOUN F
pedis 0 ADP F
is 0 SYM F
similar 0 ADJ F
, 0 PUNCT F
and 0 CCONJ F
is 0 VERB F
considerably 0 ADV F
lower 0 PUNCT F
than 0 CCONJ F
that 0 PUNCT F
found 0 VERB F
with 0 ADP F
topical 0 ADJ F
imidazole 0 PUNCT F
preparations 0 NOUN F
where 0 ADP F
cure B-OTHER PUNCT F
rates I-OTHER NOUN F
of 0 ADP F
over 0 PUNCT F
70 0 NUM F
% 0 PUNCT F
are 0 VERB F
generally 0 ADV F
expected 0 VERB F
. 0 PUNCT F

Bizzy 0 ADV T
Break 0 NOUN T
! 0 PUNCT F

The 0 DET T
effect 0 NOUN F
of 0 ADP F
a 0 DET F
classroom-based 0 VERB F
activity 0 NOUN F
break 0 NOUN F
on 0 ADP F
in-school B-MENTAL PUNCT F
physical I-MENTAL ADJ F
activity I-MENTAL NOUN F
levels I-MENTAL NOUN F
of 0 ADP F
primary 0 ADJ F
school 0 NOUN F
children 0 NOUN F
. 0 PUNCT F

The 0 DET T
school 0 NOUN F
has 0 PUNCT F
been 0 PUNCT F
identified 0 VERB F
as 0 ADP F
a 0 DET F
key 0 ADJ F
setting 0 VERB F
to 0 PART F
promote 0 PUNCT F
physical 0 ADJ F
activity 0 NOUN F
. 0 PUNCT F

The 0 DET T
purpose 0 NOUN F
of 0 ADP F
this 0 DET F
study 0 NOUN F
was 0 VERB F
to 0 PART F
evaluate 0 NOUN F
the 0 DET F
effect 0 NOUN F
of 0 ADP F
a 0 DET F
classroom-based 0 VERB F
activity 0 NOUN F
break 0 NOUN F
on 0 ADP F
in-school B-MENTAL PUNCT F
step I-MENTAL NOUN F
counts I-MENTAL NOUN F
of 0 ADP F
primary 0 ADJ F
school 0 NOUN F
children 0 NOUN F
. 0 PUNCT F

Data 0 NOUN T
for 0 ADP F
90 0 NUM F
children 0 NOUN F
( 0 PUNCT F
49 0 NUM F
boys 0 NOUN F
, 0 PUNCT F
41 0 NUM F
girls 0 NOUN F
, 0 PUNCT F
9.3 0 NUM F
? 0 PUNCT F

1.4 0 NUM F
years 0 NOUN F
) 0 PUNCT F
from 0 ADP F
three 0 NUM F
Irish 0 NOUN T
primary 0 ADJ F
schools 0 NOUN F
is 0 VERB F
presented 0 VERB F
. 0 PUNCT F

In 0 ADP T
each 0 DET F
school 0 NOUN F
one 0 NUM F
class 0 NOUN F
was 0 ADJ F
randomly 0 ADV F
assigned 0 VERB F
as 0 ADP F
the 0 DET F
intervention 0 NOUN F
group 0 NOUN F
and 0 CCONJ F
another 0 PUNCT F
as 0 PUNCT F
controls 0 VERB F
. 0 PUNCT F

Children 0 PROPN T
's 0 PUNCT F
step 0 NOUN F
counts 0 NOUN F
were 0 VERB F
measured 0 VERB F
for 0 ADP F
five 0 NUM F
consecutive 0 ADJ F
days 0 NOUN F
during 0 ADP F
school 0 NOUN F
hours 0 NOUN F
at 0 ADP F
baseline 0 NOUN F
and 0 CCONJ F
follow-up 0 NOUN F
. 0 PUNCT F

Teachers 0 PUNCT T
of 0 ADP F
the 0 DET F
intervention 0 NOUN F
classes 0 NOUN F
led 0 VERB F
a 0 DET F
10 0 NUM F
min 0 NOUN F
activity 0 NOUN F
break 0 NOUN F
in 0 ADP F
the 0 DET F
classroom 0 PUNCT F
each 0 PUNCT F
day 0 NOUN F
( 0 PUNCT F
Bizzy 0 NOUN T
Break 0 NOUN T
! 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

Mean 0 ADJ T
daily 0 ADJ F
in-school 0 ADJ F
steps 0 NOUN F
for 0 ADP F
the 0 DET F
intervention 0 NOUN F
at 0 ADP F
baseline 0 NOUN F
and 0 CCONJ F
follow-up 0 NOUN F
were 0 VERB F
5351 0 NUM F
and 0 CCONJ F
5054 0 NUM F
. 0 PUNCT F

Corresponding 0 VERB T
values 0 NOUN F
for 0 ADP F
the 0 DET F
control 0 NOUN F
group 0 NOUN F
were 0 VERB F
5469 0 NUM F
and 0 CCONJ F
4246 0 NUM F
. 0 PUNCT F

There 0 PUNCT T
was 0 VERB F
a 0 DET F
significant 0 ADJ F
difference 0 NOUN F
in 0 ADP F
the 0 DET F
change 0 NOUN F
in 0 ADP F
daily 0 ADJ F
steps 0 NOUN F
from 0 ADP F
baseline 0 NOUN F
to 0 ADP F
follow-up 0 NOUN F
between 0 ADP F
groups 0 NOUN F
( 0 PUNCT F
p 0 NOUN F
< 0 SYM F
.05 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

There 0 PUNCT T
was 0 VERB F
no 0 DET F
evidence 0 NOUN F
that 0 ADP F
girls 0 NOUN F
and 0 CCONJ F
boys 0 NOUN F
responded 0 VERB F
differently 0 PUNCT F
to 0 ADP F
the 0 DET F
intervention 0 NOUN F
( 0 PUNCT F
p 0 NOUN F
> 0 SYM F
.05 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Children 0 NOUN T
participating 0 VERB F
in 0 ADP F
a 0 DET F
daily 0 ADJ F
10 0 NUM F
min 0 NOUN F
classroom-based 0 NOUN F
activity 0 NOUN F
break 0 NOUN F
undertake 0 VERB F
more 0 DET F
physical 0 ADJ F
activity 0 NOUN F
during 0 ADP F
school 0 NOUN F
hours 0 NOUN F
than 0 CCONJ F
controls 0 NOUN F
. 0 PUNCT F

Cost-effectiveness B-OTHER NOUN T
of 0 ADP F
collaborative 0 ADJ F
care 0 NOUN F
including 0 PUNCT F
PST 0 NOUN T
and 0 CCONJ F
an 0 DET F
antidepressant 0 NOUN F
treatment 0 NOUN F
algorithm 0 NOUN F
for 0 ADP F
the 0 DET F
treatment 0 NOUN F
of 0 ADP F
major 0 ADJ F
depressive 0 ADJ F
disorder 0 NOUN F
in 0 ADP F
primary 0 ADJ F
care 0 NOUN F
; 0 PUNCT F
a 0 DET F
randomised 0 VERB F
clinical 0 ADJ F
trial 0 NOUN F
. 0 PUNCT F

BACKGROUND 0 NOUN T
Depressive 0 ADJ T
disorder 0 NOUN F
is 0 VERB F
currently 0 ADV F
one 0 NUM F
of 0 ADP F
the 0 DET F
most 0 PUNCT F
burdensome 0 ADJ F
disorders 0 NOUN F
worldwide 0 ADJ F
. 0 PUNCT F

Evidence-based 0 ADJ T
treatments 0 NOUN F
for 0 ADP F
depressive 0 ADJ F
disorder 0 NOUN F
are 0 VERB F
already 0 ADV F
available 0 ADJ F
, 0 PUNCT F
but 0 CCONJ F
these 0 PUNCT F
are 0 VERB F
used 0 VERB F
insufficiently 0 ADV F
, 0 PUNCT F
and 0 CCONJ F
with 0 ADP F
less 0 ADV F
positive 0 ADJ F
results 0 PUNCT F
than 0 VERB F
possible 0 ADJ F
. 0 PUNCT F

Earlier 0 PUNCT T
research 0 NOUN F
in 0 ADP F
the 0 DET F
USA 0 PUNCT T
has 0 PUNCT F
shown 0 VERB F
good 0 ADJ F
results 0 CCONJ F
in 0 ADP F
the 0 DET F
treatment 0 NOUN F
of 0 ADP F
depressive 0 ADJ F
disorder 0 NOUN F
based 0 VERB F
on 0 ADP F
a 0 DET F
collaborative 0 ADJ F
care 0 NOUN F
approach 0 NOUN F
with 0 ADP F
Problem B-PHYSICAL NOUN T
Solving I-PHYSICAL PUNCT T
Treatment I-PHYSICAL NOUN T
and 0 CCONJ F
an 0 DET F
antidepressant 0 NOUN F
treatment 0 NOUN F
algorithm 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
research 0 NOUN F
in 0 ADP F
the 0 DET F
UK 0 NOUN T
has 0 PUNCT F
also 0 ADV F
shown 0 VERB F
good 0 ADJ F
results 0 CCONJ F
with 0 ADP F
Problem 0 NOUN T
Solving 0 PUNCT T
Treatment 0 NOUN T
. 0 PUNCT F

These 0 DET T
treatment 0 NOUN F
strategies 0 NOUN F
may 0 VERB F
also 0 NOUN F
work 0 NOUN F
very 0 VERB F
well 0 VERB F
in 0 PUNCT F
the 0 DET F
Netherlands 0 NOUN T
too 0 ADV F
, 0 PUNCT F
even 0 ADV F
though 0 CCONJ F
health 0 NOUN F
care 0 NOUN F
systems 0 NOUN F
differ 0 VERB F
between 0 ADP F
countries 0 NOUN F
. 0 PUNCT F

METHODS/DESIGN 0 PUNCT T
This 0 DET T
study 0 NOUN F
is 0 VERB F
a 0 DET F
two-armed 0 NOUN F
randomised 0 VERB F
clinical 0 ADJ F
trial 0 NOUN F
, 0 PUNCT F
with 0 ADP F
randomization 0 NOUN F
on 0 ADP F
patient-level 0 NOUN F
. 0 PUNCT F

The 0 DET T
aim 0 NOUN F
of 0 ADP F
the 0 DET F
trial 0 NOUN F
is 0 VERB F
to 0 PART F
evaluate 0 NOUN F
the 0 DET F
treatment 0 NOUN F
of 0 ADP F
depressive 0 ADJ F
disorder 0 NOUN F
in 0 ADP F
primary 0 ADJ F
care 0 NOUN F
in 0 ADP F
the 0 DET F
Netherlands 0 NOUN T
by 0 ADP F
means 0 NOUN F
of 0 ADP F
an 0 DET F
adapted 0 VERB F
collaborative 0 ADJ F
care 0 NOUN F
framework 0 NOUN F
, 0 PUNCT F
including 0 VERB F
contracting 0 VERB F
and 0 CCONJ F
adherence-improving 0 ADJ F
strategies 0 NOUN F
, 0 PUNCT F
combined 0 PUNCT F
with 0 ADP F
Problem 0 NOUN T
Solving 0 PUNCT T
Treatment 0 NOUN T
and 0 CCONJ F
antidepressant 0 NOUN F
medication 0 NOUN F
according 0 ADJ F
to 0 ADP F
a 0 DET F
treatment 0 NOUN F
algorithm 0 NOUN F
. 0 PUNCT F

Forty 0 CCONJ T
general 0 ADJ F
practices 0 NOUN F
will 0 ADP F
be 0 VERB F
randomised 0 VERB F
to 0 ADP F
either 0 CCONJ F
the 0 DET F
intervention 0 NOUN F
group 0 NOUN F
or 0 CCONJ F
the 0 DET F
control 0 NOUN F
group 0 NOUN F
. 0 PUNCT F

Included 0 VERB T
will 0 ADJ F
be 0 DET F
patients 0 NOUN F
who 0 ADP F
are 0 VERB F
diagnosed 0 VERB F
with 0 ADP F
moderate 0 ADJ F
to 0 ADP F
severe 0 ADJ F
depression 0 NOUN F
, 0 PUNCT F
based 0 VERB F
on 0 ADP F
DSM-IV 0 NOUN T
criteria 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
stratified 0 VERB F
according 0 ADP F
to 0 ADP F
comorbid 0 ADJ F
chronic 0 ADJ F
physical 0 ADJ F
illness 0 NOUN F
. 0 PUNCT F

Patients 0 NOUN T
in 0 ADP F
the 0 DET F
intervention 0 NOUN F
group 0 NOUN F
will 0 VERB F
receive 0 VERB F
treatment 0 NOUN F
based 0 VERB F
on 0 ADP F
the 0 DET F
collaborative 0 ADJ F
care 0 NOUN F
approach 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
patients 0 NOUN F
in 0 ADP F
the 0 DET F
control 0 NOUN F
group 0 NOUN F
will 0 VERB F
receive 0 VERB F
care 0 NOUN F
as 0 ADP F
usual 0 ADJ F
. 0 PUNCT F

Baseline 0 NOUN T
measurements 0 NOUN F
and 0 CCONJ F
follow 0 VERB F
up 0 PUNCT F
measures 0 NOUN F
( 0 PUNCT F
3 0 NUM F
, 0 PUNCT F
6 0 NUM F
, 0 PUNCT F
9 0 NUM F
and 0 CCONJ F
12 0 NUM F
months 0 NOUN F
) 0 PUNCT F
are 0 VERB F
assessed 0 VERB F
using 0 PUNCT F
questionnaires 0 NOUN F
and 0 CCONJ F
an 0 DET F
interview 0 NOUN F
. 0 PUNCT F

The 0 DET T
primary 0 ADJ F
outcome 0 NOUN F
measure 0 ADV F
is 0 VERB F
severity 0 NOUN F
of 0 ADP F
depressive B-MENTAL ADJ F
symptoms I-MENTAL NOUN F
, 0 PUNCT F
according 0 CCONJ F
to 0 ADP F
the 0 DET F
PHQ9 B-PHYSICAL NOUN T
. 0 PUNCT F

Secondary 0 ADJ T
outcome 0 NOUN F
measures 0 NOUN F
are 0 VERB F
remission B-PHYSICAL NOUN F
as I-PHYSICAL PUNCT F
measured I-PHYSICAL VERB F
with I-PHYSICAL ADP F
the I-PHYSICAL DET F
PHQ9 I-PHYSICAL NOUN T
and I-PHYSICAL CCONJ F
the I-PHYSICAL DET F
IDS-SR I-PHYSICAL NOUN T
, I-PHYSICAL PUNCT F
and 0 CCONJ F
cost-effectiveness B-OTHER NOUN F
measured 0 VERB F
with 0 ADP F
the 0 DET F
TiC-P B-OTHER NOUN T
, 0 PUNCT F
the 0 DET F
EQ-5D B-OTHER NOUN T
and 0 CCONJ F
the 0 DET F
SF-36 B-OTHER NOUN T
. 0 PUNCT F

DISCUSSION 0 NOUN T
In 0 ADP T
this 0 DET F
study 0 NOUN F
, 0 PUNCT F
an 0 DET F
American 0 ADJ T
model 0 NOUN F
to 0 PART F
enhance 0 ADJ F
care 0 NOUN F
for 0 ADP F
patients 0 NOUN F
with 0 ADP F
a 0 DET F
depressive 0 ADJ F
disorder 0 NOUN F
, 0 PUNCT F
the 0 DET F
collaborative 0 ADJ F
care 0 NOUN F
model 0 NOUN F
, 0 PUNCT F
will 0 VERB F
be 0 VERB F
evaluated 0 VERB F
for 0 ADP F
effectiveness 0 NOUN F
in 0 ADP F
the 0 DET F
primary 0 ADJ F
care 0 NOUN F
setting 0 ADV F
. 0 PUNCT F

If 0 ADP T
effective 0 ADJ F
across 0 ADP F
the 0 DET F
Atlantic 0 ADJ T
and 0 CCONJ F
across 0 ADP F
different 0 ADJ F
health 0 NOUN F
care 0 NOUN F
systems 0 NOUN F
, 0 PUNCT F
it 0 PRON F
is 0 VERB F
also 0 ADV F
likely 0 ADV F
to 0 PART F
be 0 PUNCT F
an 0 DET F
effective 0 ADJ F
strategy 0 NOUN F
to 0 VERB F
implement 0 PUNCT F
in 0 ADP F
the 0 DET F
treatment 0 NOUN F
of 0 ADP F
major 0 ADJ F
depressive 0 ADJ F
disorder 0 NOUN F
in 0 ADP F
the 0 DET F
Netherlands 0 ADV T
. 0 PUNCT F

A 0 DET T
controlled 0 VERB F
study 0 NOUN F
of 0 ADP F
psychiatric 0 ADJ F
hospital 0 NOUN F
versus 0 CCONJ F
community 0 NOUN F
treatment 0 NOUN F
- 0 PUNCT F
the 0 DET F
effect 0 NOUN F
on 0 ADP F
relatives B-MENTAL NOUN F
. 0 PUNCT F

One 0 NUM T
hundred 0 NUM F
and 0 CCONJ F
twenty 0 NUM F
patients 0 NOUN F
presenting 0 VERB F
at 0 ADP F
Macquarie 0 NOUN T
Hospital 0 NOUN T
for 0 ADP F
admission 0 NOUN F
were 0 VERB F
randomly 0 ADV F
allocated 0 VERB F
into 0 ADP F
two 0 NUM F
groups 0 NOUN F
. 0 PUNCT F

The 0 DET T
control 0 NOUN F
group 0 NOUN F
patients 0 NOUN F
received 0 VERB F
standard 0 ADJ F
hospital 0 NOUN F
care 0 NOUN F
and 0 CCONJ F
follow-up 0 NOUN F
. 0 PUNCT F

The 0 DET T
project 0 NOUN F
group 0 NOUN F
patients 0 NOUN F
were 0 VERB F
not 0 ADV F
admitted 0 VERB F
if 0 PUNCT F
this 0 PUNCT F
could 0 VERB F
be 0 VERB F
avoided 0 VERB F
; 0 PUNCT F
instead 0 ADP F
they 0 PUNCT F
were 0 VERB F
taken 0 VERB F
back 0 PUNCT F
to 0 ADP F
the 0 DET F
community 0 NOUN F
by 0 ADP F
the 0 DET F
project 0 NOUN F
team 0 NOUN F
who 0 ADP F
provided 0 VERB F
them 0 ADP F
and 0 CCONJ F
their 0 ADJ F
relatives 0 NOUN F
with 0 ADP F
comprehensive 0 ADJ F
, 0 PUNCT F
assertive 0 ADP F
and 0 CCONJ F
prolonged 0 VERB F
follow-up 0 NOUN F
treatment 0 NOUN F
backed 0 PUNCT F
by 0 ADP F
a 0 DET F
24-hour 0 NOUN F
crisis 0 NOUN F
service 0 NOUN F
. 0 PUNCT F

The 0 DET T
majority 0 NOUN F
( 0 PUNCT F
63 0 NUM F
% 0 SYM F
) 0 PUNCT F
of 0 ADP F
the 0 DET F
project 0 NOUN F
group 0 NOUN F
had 0 VERB F
no 0 DET F
admission 0 NOUN F
during 0 ADP F
the 0 DET F
10 0 NUM F
month 0 NOUN F
study 0 NOUN F
period 0 NOUN F
. 0 PUNCT F

Initially 0 ADV T
, 0 PUNCT F
the 0 DET F
burden B-MENTAL NOUN F
on I-MENTAL ADP F
the I-MENTAL DET F
relatives I-MENTAL NOUN F
of 0 ADP F
the 0 DET F
project 0 NOUN F
group 0 NOUN F
was 0 VERB F
higher 0 PUNCT F
, 0 PUNCT F
but 0 CCONJ F
by 0 ADP F
one 0 NUM F
month 0 NOUN F
it 0 PUNCT F
was 0 ADP F
somewhat 0 ADV F
lower 0 VERB F
and 0 CCONJ F
by 0 ADP F
four 0 NUM F
months 0 NOUN F
it 0 PRON F
was 0 VERB F
significantly 0 ADV F
lower 0 PUNCT F
than 0 PUNCT F
the 0 DET F
burden 0 NOUN F
on 0 ADP F
the 0 DET F
control 0 NOUN F
group 0 NOUN F
relatives 0 NOUN F
. 0 PUNCT F

Relatives 0 NOUN T
of 0 ADP F
the 0 DET F
project 0 NOUN F
group 0 NOUN F
patients 0 NOUN F
were 0 VERB F
significantly 0 ADV F
more 0 ADV F
satisfied B-MENTAL VERB F
with I-MENTAL ADP F
the I-MENTAL DET F
treatment I-MENTAL NOUN F
than 0 PUNCT F
control 0 NOUN F
group 0 NOUN F
relatives 0 NOUN F
. 0 PUNCT F

It 0 PRON T
is 0 VERB F
clearly 0 ADV F
feasible 0 ADJ F
to 0 PART F
treat 0 CCONJ F
most 0 ADP F
psychiatric 0 ADJ F
patients 0 NOUN F
in 0 ADP F
the 0 DET F
community 0 NOUN F
without 0 ADP F
increasing 0 VERB F
the 0 DET F
burden B-MENTAL NOUN F
on I-MENTAL ADP F
their I-MENTAL ADP F
relatives I-MENTAL NOUN F
. 0 PUNCT F

Tubeless 0 PUNCT T
percutaneous 0 ADJ F
nephrolithotomy 0 NOUN F
: 0 PUNCT F
safe 0 ADJ F
even 0 ADV F
in 0 ADP F
supracostal 0 ADJ F
access 0 NOUN F
. 0 PUNCT F

PURPOSE 0 NOUN T
This 0 DET T
study 0 NOUN F
was 0 VERB F
designed 0 VERB F
to 0 PART F
determine 0 NOUN F
the 0 DET F
outcome 0 NOUN F
and 0 CCONJ F
safety B-OTHER NOUN F
of 0 ADP F
tubeless 0 PUNCT F
percutaneous 0 ADJ F
nephrolithotomy 0 NOUN F
( 0 PUNCT F
PCNL 0 NOUN T
) 0 PUNCT F
in 0 ADP F
the 0 DET F
treatment 0 NOUN F
of 0 ADP F
renal 0 ADJ F
calculi 0 NOUN F
. 0 PUNCT F

PATIENTS 0 NOUN T
AND 0 CCONJ T
METHODS 0 NOUN T
Between 0 ADP T
November 0 NOUN T
2005 0 NUM F
and 0 CCONJ F
March 0 NOUN T
2006 0 NUM F
, 0 PUNCT F
48 0 NUM F
patients 0 NOUN F
were 0 VERB F
randomized 0 VERB F
to 0 ADP F
either 0 CCONJ F
an 0 DET F
18F 0 NOUN F
Re-entry 0 NOUN T
nephrostomy 0 NOUN F
tube 0 NOUN F
( 0 PUNCT F
group 0 NOUN F
1 0 NUM F
) 0 PUNCT F
or 0 CCONJ F
a 0 DET F
6F 0 NOUN F
Double-J 0 PUNCT T
stent 0 NOUN F
( 0 PUNCT F
group 0 NOUN F
2 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
two 0 NUM F
groups 0 NOUN F
were 0 VERB F
well 0 VERB F
matched 0 PUNCT F
for 0 ADP F
age 0 NOUN F
, 0 PUNCT F
sex 0 NOUN F
, 0 PUNCT F
stone 0 NOUN F
size 0 NOUN F
, 0 PUNCT F
stone 0 NOUN F
laterality 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
number 0 NOUN F
of 0 ADP F
previous 0 ADJ F
renal 0 ADJ F
procedures 0 NOUN F
. 0 PUNCT F

All 0 DET T
PCNL 0 NOUN T
procedures 0 NOUN F
were 0 VERB F
performed 0 VERB F
by 0 ADP F
the 0 DET F
same 0 ADJ F
surgeon 0 NOUN F
. 0 PUNCT F

Postoperative B-PAIN ADJ T
visual I-PAIN ADJ F
analog I-PAIN NOUN F
pain I-PAIN NOUN F
scale I-PAIN NOUN F
( I-PAIN PUNCT F
VAS 0 NOUN T
) B-PAIN PUNCT F
scores 0 NOUN F
at 0 ADP F
8 0 NUM F
and 0 CCONJ F
24 0 NUM F
hours 0 NOUN F
and 0 CCONJ F
14 0 NUM F
days 0 NOUN F
after 0 ADP F
surgery 0 NOUN F
, 0 PUNCT F
in-hospital B-OTHER NOUN F
analgesic I-OTHER ADJ F
use B-OTHER NOUN F
, I-OTHER PUNCT F
length I-OTHER NOUN F
of B-OTHER ADP F
hospital I-OTHER NOUN F
stay B-OTHER NOUN F
, 0 PUNCT F
success B-OTHER NOUN F
rate I-OTHER NOUN F
, 0 PUNCT F
blood B-OTHER NOUN F
transfusion I-OTHER NOUN F
rate B-OTHER NOUN F
, 0 PUNCT F
and 0 CCONJ F
postoperative B-ADVERSE-EFFECTS ADJ F
complications I-ADVERSE-EFFECTS NOUN F
were 0 VERB F
compared 0 VERB F
for 0 ADP F
the 0 DET F
two 0 NUM F
groups 0 NOUN F
. 0 PUNCT F

RESULTS 0 PUNCT T
The 0 DET T
mean 0 NOUN F
hospital B-OTHER NOUN F
stays I-OTHER NOUN F
in 0 ADP F
groups 0 NOUN F
1 0 NUM F
and 0 CCONJ F
2 0 NUM F
were 0 VERB F
3.1 0 NUM F
and 0 CCONJ F
1.6 0 NUM F
days 0 NOUN F
, 0 PUNCT F
respectively 0 ADV F
( 0 PUNCT F
P 0 NOUN T
= 0 SYM F
0.003 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
mean 0 NOUN F
VAS 0 NOUN T
scores 0 NOUN F
8 0 NUM F
and 0 CCONJ F
24 0 NUM F
hours 0 NOUN F
after 0 ADP F
surgery 0 NOUN F
were 0 VERB F
significantly 0 ADV F
lower 0 PUNCT F
in 0 ADP F
group 0 NOUN F
2 0 NUM F
than 0 PUNCT F
in 0 ADP F
group 0 NOUN F
1 0 NUM F
( 0 PUNCT F
P 0 NOUN T
= 0 SYM F
0.001 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
postoperative B-PAIN ADJ F
analgesic I-PAIN ADP F
requirement I-PAIN NOUN F
( 0 PUNCT F
diclofenac 0 NOUN F
sodium 0 NOUN F
) 0 PUNCT F
was 0 VERB F
significantly 0 ADV F
higher 0 PUNCT F
in 0 ADP F
group 0 NOUN F
1 0 NUM F
( 0 PUNCT F
263 0 NUM F
mg 0 NOUN F
) 0 PUNCT F
than 0 PUNCT F
in 0 ADP F
group 0 NOUN F
2 0 NUM F
( 0 PUNCT F
120 0 NUM F
mg 0 NOUN F
; 0 PUNCT F
P 0 NOUN T
= 0 SYM F
0.02 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
rate 0 NOUN F
of 0 ADP F
blood B-PHYSICAL NOUN F
transfusion I-PHYSICAL NOUN F
in 0 ADP F
the 0 DET F
two 0 NUM F
groups 0 NOUN F
was 0 VERB F
similar 0 ADJ F
( 0 PUNCT F
P 0 NOUN T
= 0 SYM F
NS 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

There 0 PUNCT T
was 0 VERB F
no 0 DET F
difference 0 NOUN F
between 0 ADP F
the 0 DET F
groups 0 NOUN F
in 0 ADP F
VAS 0 NOUN T
scores 0 NOUN F
on 0 ADP F
postoperative 0 ADJ F
day 0 NOUN F
14 0 NUM F
. 0 PUNCT F

The 0 DET T
number 0 NOUN F
of 0 ADP F
supracostal B-PHYSICAL ADJ F
accesses I-PHYSICAL NOUN F
was 0 ADJ F
significantly 0 ADV F
higher 0 PUNCT F
in 0 ADP F
group 0 NOUN F
2 0 NUM F
than 0 PUNCT F
in 0 ADP F
group 0 NOUN F
1 0 NUM F
( 0 PUNCT F
P 0 NOUN T
= 0 SYM F
0.02 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

The 0 PUNCT T

Enhancing 0 ADP T
attitudes B-MENTAL NOUN F
and 0 CCONJ F
intentions B-MENTAL NOUN F
in 0 ADP F
prospective 0 ADJ F
blood 0 NOUN F
donors 0 NOUN F
: 0 PUNCT F
evaluation 0 NOUN F
of 0 ADP F
a 0 DET F
new 0 ADJ F
donor 0 NOUN F
recruitment 0 NOUN F
brochure 0 ADJ F
. 0 PUNCT F

BACKGROUND 0 NOUN T
Although 0 ADP T
little 0 DET F
empiric 0 ADJ F
evidence 0 NOUN F
has 0 PUNCT F
been 0 PUNCT F
published 0 VERB F
concerning 0 VERB F
the 0 DET F
efficacy 0 NOUN F
of 0 ADP F
blood 0 NOUN F
donor 0 NOUN F
recruitment 0 NOUN F
materials 0 NOUN F
, 0 PUNCT F
research 0 NOUN F
suggests 0 NOUN F
that 0 ADP F
simple 0 ADJ F
attempts 0 PUNCT F
to 0 PART F
enhance 0 ADP F
knowledge 0 NOUN F
may 0 VERB F
not 0 ADV F
be 0 VERB F
sufficient 0 ADJ F
to 0 PART F
motivate B-MENTAL ADJ F
donation I-MENTAL NOUN F
. 0 PUNCT F

In 0 ADP T
contrast 0 NOUN F
, 0 PUNCT F
recent 0 ADJ F
donor 0 NOUN F
motivation 0 NOUN F
studies 0 NOUN F
highlight 0 VERB F
the 0 DET F
importance 0 NOUN F
of 0 ADP F
anxiety B-MENTAL NOUN F
, 0 PUNCT F
attitudes B-MENTAL NOUN F
, 0 PUNCT F
and 0 CCONJ F
perceived B-MENTAL VERB F
ability I-MENTAL NOUN F
to I-MENTAL PART F
cope I-MENTAL NOUN F
with I-MENTAL ADP F
donation I-MENTAL NOUN F
( 0 PUNCT F
i.e. 0 CCONJ F
, 0 PUNCT F
self-efficacy 0 NOUN F
) 0 PUNCT F
as 0 ADP F
crucial 0 ADJ F
determinants 0 NOUN F
of 0 ADP F
donation 0 NOUN F
intention 0 NOUN F
. 0 PUNCT F

Therefore 0 ADV T
, 0 PUNCT F
recruitment 0 NOUN F
materials 0 NOUN F
that 0 ADP F
specifically 0 ADV F
address 0 VERB F
these 0 DET F
constructs 0 DET F
have 0 PUNCT F
the 0 DET F
potential 0 ADJ F
to 0 ADP F
outperform 0 PUNCT F
traditional 0 ADJ F
educational 0 ADJ F
brochures 0 NOUN F
. 0 PUNCT F

STUDY 0 NOUN T
DESIGN 0 NOUN T
AND 0 CCONJ T
METHODS 0 NOUN T
Participants 0 PUNCT T
were 0 VERB F
randomly 0 ADV F
assigned 0 VERB F
to 0 PUNCT F
read 0 PUNCT F
one 0 NUM F
of 0 ADP F
three 0 NUM F
brochures 0 NOUN F
: 0 PUNCT F
1 0 NUM F
) 0 PUNCT F
a 0 DET F
new 0 ADJ F
brochure 0 ADJ F
addressing 0 PUNCT F
common 0 ADJ F
donor 0 NOUN F
concerns 0 NOUN F
and 0 CCONJ F
suggesting 0 SYM F
specific 0 ADJ F
coping 0 PUNCT F
strategies 0 NOUN F
, 0 PUNCT F
2 0 NUM F
) 0 PUNCT F
a 0 DET F
standard 0 ADJ F
blood 0 NOUN F
center 0 NOUN F
brochure 0 ADJ F
, 0 PUNCT F
or 0 CCONJ F
3 0 NUM F
) 0 PUNCT F
a 0 DET F
control 0 NOUN F
brochure 0 ADJ F
on 0 ADP F
healthy 0 ADJ F
eating 0 PROPN F
and 0 CCONJ F
exercise 0 NOUN F
. 0 PUNCT F

Standardized 0 VERB T
questionnaires 0 NOUN F
were 0 VERB F
completed 0 VERB F
before 0 ADP F
and 0 CCONJ F
after 0 ADP F
the 0 DET F
brochures 0 PUNCT F
to 0 PART F
assess 0 CCONJ F
change 0 NOUN F
in 0 ADP F
blood B-MENTAL NOUN F
donation I-MENTAL NOUN F
anxiety I-MENTAL NOUN F
, 0 PUNCT F
attitude B-MENTAL NOUN F
, 0 PUNCT F
self-efficacy B-MENTAL NOUN F
, 0 PUNCT F
and 0 CCONJ F
intention B-MENTAL NOUN F
. 0 PUNCT F

RESULTS 0 NOUN T
Although 0 ADP T
no 0 DET F
significant 0 ADJ F
changes 0 NOUN F
were 0 VERB F
noted 0 VERB F
for 0 ADP F
the 0 DET F
control 0 NOUN F
brochure 0 ADJ F
, 0 PUNCT F
after 0 ADP F
reading 0 PUNCT F
the 0 DET F
new 0 ADJ F
brochure 0 PUNCT F
participants 0 NOUN F
reported 0 DET F
significant 0 ADJ F
improvements 0 NOUN F
in 0 ADP F
attitude B-MENTAL NOUN F
, 0 PUNCT F
anxiety B-MENTAL NOUN F
, 0 PUNCT F
self-efficacy B-MENTAL NOUN F
, 0 PUNCT F
and 0 CCONJ F
donation B-MENTAL NOUN F
intention I-MENTAL NOUN F
. 0 PUNCT F

The 0 DET T
standard 0 ADJ F
donation 0 NOUN F
brochure 0 ADJ F
had 0 PUNCT F
an 0 DET F
intermediate 0 ADJ F
effect 0 NOUN F
. 0 PUNCT F

CONCLUSION 0 NOUN T
Efforts 0 NOUN T
to 0 PART F
address 0 NOUN F
common 0 ADJ F
donor 0 NOUN F
fears 0 NOUN F
and 0 CCONJ F
to 0 PART F
provide 0 NOUN F
useful 0 ADJ F
coping 0 PUNCT F
suggestions 0 NOUN F
may 0 VERB F
improve 0 VERB F
the 0 DET F
effectiveness 0 NOUN F
of 0 ADP F
blood B-MENTAL NOUN F
donation I-MENTAL NOUN F
recruitment I-MENTAL NOUN F
materials I-MENTAL NOUN F
. 0 PUNCT F

Effect 0 NOUN T
of 0 ADP F
cervical 0 ADJ F
spine 0 NOUN F
manipulative 0 ADJ F
therapy 0 NOUN F
on 0 ADP F
judo 0 PUNCT F
athletes 0 NOUN F
' 0 PUNCT F
grip 0 NOUN F
strength 0 NOUN F
. 0 PUNCT F

OBJECTIVE 0 NOUN T
The 0 DET T
objective 0 NOUN F
of 0 ADP F
this 0 DET F
study 0 NOUN F
was 0 VERB F
to 0 PART F
perform 0 NOUN F
an 0 DET F
investigation 0 NOUN F
evaluating 0 PUNCT F
if 0 PUNCT F
cervical 0 ADJ F
spinal 0 ADJ F
manipulative 0 ADJ F
therapy 0 NOUN F
( 0 PUNCT F
SMT 0 NOUN T
) 0 PUNCT F
can 0 ADJ F
increase 0 NUM F
grip 0 NOUN F
strength 0 NOUN F
on 0 ADP F
judo 0 PUNCT F
athletes 0 NOUN F
in 0 ADP F
a 0 DET F
top 0 ADJ F
10 0 NUM F
national-ranked 0 DET F
team 0 NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
A 0 NOUN T
single-blinded 0 PUNCT F
, 0 PUNCT F
prospective 0 ADJ F
, 0 PUNCT F
comparative 0 ADJ F
, 0 PUNCT F
pilot 0 NOUN F
, 0 PUNCT F
randomized 0 VERB F
, 0 PUNCT F
clinical 0 ADJ F
trial 0 NOUN F
was 0 VERB F
performed 0 VERB F
with 0 ADP F
18 0 NUM F
athletes 0 NOUN F
of 0 ADP F
both 0 DET F
sexes 0 NOUN F
from 0 ADP F
a 0 DET F
judo 0 PUNCT F
team 0 NOUN F
currently 0 ADP F
competing 0 VERB F
on 0 ADP F
a 0 DET F
national 0 ADJ F
level 0 NOUN F
. 0 PUNCT F

The 0 DET T
athletes 0 NOUN F
were 0 ADJ F
randomly 0 ADV F
assigned 0 VERB F
to 0 ADP F
2 0 NUM F
groups 0 NOUN F
: 0 PUNCT F
chiropractic 0 ADJ F
SMT 0 NOUN T
and 0 CCONJ F
sham 0 PUNCT F
. 0 PUNCT F

Three 0 NUM T
interventions 0 NOUN F
were 0 VERB F
performed 0 VERB F
on 0 ADP F
each 0 PUNCT F
of 0 ADP F
the 0 DET F
athletes 0 NOUN F
at 0 ADP F
different 0 ADJ F
time 0 NOUN F
points 0 NOUN F
. 0 PUNCT F

Force 0 NOUN T
measurements 0 NOUN F
were 0 VERB F
obtained 0 VERB F
by 0 ADP F
a 0 DET F
hydraulic 0 ADJ F
dynamometer 0 ADJ F
immediately 0 ADV F
before 0 PUNCT F
and 0 CCONJ F
after 0 ADP F
each 0 DET F
intervention 0 NOUN F
at 0 ADP F
the 0 DET F
same 0 ADJ F
period 0 NOUN F
before 0 ADP F
training 0 VERB F
up 0 PUNCT F
to 0 ADP F
3 0 NUM F
weeks 0 NOUN F
with 0 ADP F
at 0 ADP F
least 0 ADV F
36 0 NUM F
hours 0 NOUN F
between 0 ADP F
interventions 0 NOUN F
. 0 PUNCT F

RESULTS 0 DET T
Analysis 0 NOUN T
of 0 ADP F
grip B-PHYSICAL NOUN F
strength I-PHYSICAL NOUN F
data 0 NOUN F
revealed 0 VERB F
a 0 DET F
statistically 0 ADV F
significant 0 ADJ F
increase 0 NOUN F
in 0 ADP F
strength B-OTHER NOUN F
within 0 ADP F
the 0 DET F
treatment 0 NOUN F
group 0 NOUN F
after 0 ADP F
the 0 DET F
first 0 ADJ F
intervention 0 NOUN F
( 0 PUNCT F
6.95 0 NUM F
% 0 SYM F
right 0 NOUN F
, 0 PUNCT F
12.61 0 NUM F
% 0 SYM F
left 0 NOUN F
) 0 PUNCT F
as 0 PUNCT F
compared 0 VERB F
with 0 ADP F
the 0 DET F
second 0 ADJ F
( 0 PUNCT F
11.53 0 NUM F
% 0 SYM F
right 0 NOUN F
, 0 PUNCT F
17.02 0 NUM F
% 0 SYM F
left 0 NOUN F
) 0 PUNCT F
and 0 CCONJ F
the 0 DET F
third 0 ADJ F
interventions 0 NOUN F
( 0 PUNCT F
10.53 0 NUM F
% 0 SYM F
right 0 NOUN F
, 0 PUNCT F
16.81 0 NUM F
% 0 SYM F
left 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

No 0 DET T
statistically 0 ADV F
significant 0 ADJ F
differences 0 NOUN F
were 0 VERB F
found 0 VERB F
in 0 ADP F
grip B-OTHER NOUN F
strength I-OTHER NOUN F
comparison I-OTHER NOUN F
within 0 ADP F
the 0 DET F
sham 0 ADJ F
group 0 NOUN F
. 0 PUNCT F

Overall 0 ADJ T
differences B-OTHER NOUN F
in 0 ADP F
strength B-PHYSICAL NOUN F
were 0 VERB F
consistently 0 ADV F
significant 0 ADJ F
between 0 ADP F
the 0 DET F
study 0 ADV F
groups 0 NOUN F
( 0 PUNCT F
P 0 NOUN T
= 0 SYM F
.0025 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

CONCLUSION 0 NOUN T
The 0 DET T
present 0 ADJ F
study 0 NOUN F
suggests 0 NOUN F
that 0 ADP F
the 0 DET F
grip 0 NOUN F
strength 0 NOUN F
of 0 ADP F
national 0 ADJ F
level 0 NOUN F
judo 0 ADP F
athletes 0 NOUN F
receiving 0 VERB F
chiropractic 0 ADJ F
SMT 0 NOUN T
improved 0 DET F
compared 0 VERB F
to 0 ADP F
those 0 PUNCT F
receiving 0 SYM F
sham 0 PUNCT F
. 0 PUNCT F

Fusidic 0 ADJ T
acid 0 NOUN F
prophylaxis 0 NOUN F
before 0 ADP F
cataract 0 NOUN F
surgery 0 NOUN F
: 0 PUNCT F
patient 0 NOUN F
self-administration 0 NOUN F
. 0 PUNCT F

In 0 ADP T
a 0 DET F
placebo-controlled 0 VERB F
, 0 PUNCT F
randomised 0 DET F
, 0 PUNCT F
double-blind 0 ADJ F
clinical 0 ADJ F
trial 0 NOUN F
, 0 PUNCT F
the 0 DET F
authors 0 NOUN F
evaluated 0 VERB F
the 0 DET F
efficacy 0 NOUN F
of 0 ADP F
patient-administered 0 ADJ F
1 0 NUM F
% 0 ADJ F
fusidic 0 ADJ F
acid 0 NOUN F
viscous 0 ADJ F
eye 0 NOUN F
drops 0 PUNCT F
in 0 ADP F
clearing 0 PUNCT F
the 0 DET F
commonest 0 PUNCT F
organisms 0 NOUN F
causing 0 CCONJ F
pseudophakic 0 NOUN F
endophthalmitis 0 NOUN F
( 0 PUNCT F
Staphylococcus 0 NOUN T
epidermidis 0 NOUN F
and 0 CCONJ F
aureus 0 NOUN F
) 0 PUNCT F
from 0 ADP F
the 0 DET F
lids 0 NOUN F
and 0 CCONJ F
conjunctivae 0 PUNCT F
of 0 ADP F
79 0 NUM F
patients 0 NOUN F
before 0 PUNCT F
cataract 0 NOUN F
surgery 0 NOUN F
. 0 PUNCT F

The 0 DET T
treatment 0 NOUN F
group 0 NOUN F
self-administered 0 ADJ F
fusidic 0 ADJ F
acid 0 NOUN F
viscous 0 ADJ F
eye 0 NOUN F
drops 0 ADP F
four 0 NUM F
times 0 NOUN F
daily 0 ADJ F
for 0 ADP F
seven 0 NUM F
days 0 NOUN F
before 0 ADP F
surgery 0 NOUN F
; 0 PUNCT F
the 0 DET F
placebo 0 NOUN F
group 0 NOUN F
received 0 ADP F
inert 0 PUNCT F
ophthalmic 0 ADJ F
drops 0 ADP F
. 0 PUNCT F

Fellow 0 ADJ T
eyes 0 NOUN F
of 0 ADP F
both 0 CCONJ F
groups 0 NOUN F
remained 0 VERB F
untreated 0 VERB F
as 0 ADP F
a 0 DET F
natural 0 ADJ F
control 0 NOUN F
. 0 PUNCT F

Lower 0 PUNCT T
fornix 0 ADP F
and 0 CCONJ F
lid 0 ADJ F
margin 0 NOUN F
cultures 0 NOUN F
were 0 VERB F
taken 0 VERB F
from 0 ADP F
both 0 PUNCT F
eyes 0 NOUN F
before 0 PUNCT F
and 0 CCONJ F
after 0 ADP F
treatment 0 NOUN F
. 0 PUNCT F

Before 0 ADP T
treatment 0 NOUN F
, 0 PUNCT F
there 0 PUNCT F
was 0 VERB F
no 0 DET F
statistical 0 ADJ F
difference 0 NOUN F
in 0 ADP F
organism B-PHYSICAL NOUN F
counts I-PHYSICAL NOUN F
between 0 ADP F
the 0 DET F
groups 0 NOUN F
. 0 PUNCT F

After 0 ADP T
treatment 0 NOUN F
, 0 PUNCT F
eyes 0 NOUN F
receiving 0 VERB F
fusidic 0 PUNCT F
acid 0 NOUN F
were 0 VERB F
more 0 ADV F
likely 0 ADJ F
to 0 PART F
be 0 PUNCT F
free 0 ADJ F
of 0 ADP F
clinically 0 ADV F
relevant 0 ADJ F
Staphylococcus 0 NOUN T
spp 0 NOUN F
. 0 PUNCT F

than 0 PUNCT F
all 0 DET F
pre-treatment 0 NOUN F
eyes 0 NOUN F
( 0 PUNCT F
for 0 ADP F
lids 0 NOUN F
, 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.001 0 NUM F
; 0 PUNCT F
conjunctivae 0 NOUN F
, 0 PUNCT F
P 0 NOUN T
= 0 SYM F
0.02 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

A 0 DET T
highly 0 ADV F
significant 0 ADJ F
( 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.001 0 NUM F
) 0 PUNCT F
number 0 NOUN F
of 0 ADP F
lid B-PHYSICAL ADJ F
margins I-PHYSICAL NOUN F
were 0 VERB F
rendered 0 ADP F
'clinically 0 PUNCT F
clean 0 PUNCT F
' 0 PUNCT F
( 0 PUNCT F
i.e. 0 CCONJ F
, 0 PUNCT F
0-49 0 NUM F
organisms/swab 0 NOUN F
) 0 PUNCT F
by 0 ADP F
fusidic 0 ADJ F
acid 0 NOUN F
when 0 ADP F
compared 0 VERB F
with 0 ADP F
untreated 0 VERB F
eyes 0 NOUN F
. 0 PUNCT F

Treatment 0 NOUN T
also 0 ADV F
effectively 0 ADV F
( 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.05 0 NUM F
) 0 PUNCT F
reduced 0 VERB F
the 0 DET F
numbers 0 NOUN F
of 0 ADP F
bacteria B-PHYSICAL NOUN F
isolated I-PHYSICAL VERB F
from I-PHYSICAL ADP F
conjunctivae I-PHYSICAL NOUN F
. 0 PUNCT F

This 0 DET T
study 0 NOUN F
indicates 0 NOUN F
that 0 ADP F
there 0 PUNCT F
is 0 VERB F
a 0 DET F
highly 0 ADV F
significant 0 ADJ F
reduction 0 NOUN F
of 0 ADP F
Staphylococcus 0 NOUN T
spp 0 NOUN F
. 0 PUNCT F
( 0 PUNCT F

P 0 NOUN T
< 0 SYM F
0.001 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
non-Staphylococcus 0 PUNCT F
spp 0 NOUN F
. 0 PUNCT F
( 0 PUNCT F

P 0 NOUN T
< 0 SYM F
0.001 0 NUM F
) 0 PUNCT F
and 0 CCONJ F
attainment 0 NOUN F
of 0 ADP F
sterile 0 ADJ F
eyes 0 NOUN F
( 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.001 0 NUM F
) 0 PUNCT F
at 0 ADP F
operation 0 NOUN F
gained 0 VERB F
by 0 ADP F
patient 0 NOUN F
self-administration 0 NOUN F
of 0 ADP F
1 0 NUM F
% 0 ADJ F
fusidic 0 ADJ F
acid 0 NOUN F
four 0 NUM F
times 0 NOUN F
daily 0 ADJ F
for 0 ADP F
seven 0 NUM F
days 0 NOUN F
before 0 ADP F
surgery 0 NOUN F
. 0 PUNCT F

Can 0 PUNCT T
incentives 0 PUNCT F
undermine 0 NOUN F
intrinsic B-MENTAL ADJ F
motivation I-MENTAL NOUN F
to 0 PART F
participate 0 NOUN F
in 0 ADP F
epidemiologic 0 ADJ F
surveys 0 NOUN F
? 0 PUNCT F

Response 0 NOUN T
rates 0 NOUN F
to 0 ADP F
surveys 0 NOUN F
are 0 ADP F
decreasing 0 ADP F
. 0 PUNCT F

The 0 DET T
purpose 0 NOUN F
of 0 ADP F
this 0 DET F
study 0 NOUN F
was 0 VERB F
to 0 PART F
evaluate 0 NOUN F
the 0 DET F
use 0 NOUN F
of 0 ADP F
lottery 0 PUNCT F
tickets 0 ADP F
as 0 PUNCT F
incentives 0 DET F
in 0 ADP F
an 0 DET F
epidemiologic 0 ADJ F
control 0 NOUN F
group 0 NOUN F
. 0 PUNCT F

A 0 DET T
self-administered 0 DET F
questionnaire 0 NOUN F
was 0 VERB F
sent 0 NOUN F
to 0 ADP F
parents 0 NOUN F
in 0 ADP F
the 0 DET F
municipality 0 NOUN F
of 0 ADP F
Stockholm 0 NOUN T
, 0 PUNCT F
Sweden 0 PUNCT T
, 0 PUNCT F
who 0 ADP F
were 0 VERB F
to 0 PART F
be 0 PUNCT F
used 0 VERB F
as 0 ADP F
a 0 DET F
control 0 NOUN F
group 0 NOUN F
in 0 ADP F
a 0 DET F
study 0 NOUN F
addressing 0 PUNCT F
stress 0 NOUN F
in 0 ADP F
parents 0 NOUN F
of 0 ADP F
children 0 NOUN F
with 0 ADP F
cancer 0 NOUN F
. 0 PUNCT F

A 0 DET T
stratified 0 VERB F
random 0 ADJ F
sample 0 NOUN F
of 0 ADP F
450 0 NUM F
parents 0 NOUN F
were 0 VERB F
randomized 0 VERB F
into 0 ADP F
three 0 NUM F
incentive 0 ADJ F
groups 0 NOUN F
: 0 PUNCT F
( 0 PUNCT F
a 0 NOUN F
) 0 PUNCT F
no 0 DET F
incentive 0 ADJ F
; 0 PUNCT F
( 0 PUNCT F
b 0 NOUN F
) 0 PUNCT F
a 0 DET F
promised 0 PROPN F
incentive 0 ADJ F
of 0 ADP F
one 0 NUM F
lottery 0 PUNCT F
ticket 0 PUNCT F
to 0 PART F
be 0 PUNCT F
received 0 VERB F
upon 0 ADP F
reply 0 PUNCT F
; 0 PUNCT F
( 0 PUNCT F
c 0 NOUN F
) 0 PUNCT F
a 0 DET F
promised 0 PROPN F
incentive 0 ADJ F
of 0 ADP F
one 0 NUM F
lottery 0 PUNCT F
ticket 0 PUNCT F
to 0 PART F
be 0 PUNCT F
received 0 VERB F
upon 0 ADP F
reply 0 ADV F
and 0 CCONJ F
an 0 DET F
additional 0 ADJ F
lottery 0 PUNCT F
ticket 0 PUNCT F
upon 0 PUNCT F
reply 0 PUNCT F
within 0 ADP F
1 0 NUM F
week 0 NOUN F
. 0 PUNCT F

The 0 DET T
overall 0 ADJ F
response 0 NOUN F
rate B-MENTAL NOUN F
across 0 ADP F
the 0 DET F
three 0 NUM F
groups 0 NOUN F
was 0 VERB F
65.3 0 NUM F
% 0 SYM F
. 0 PUNCT F

The 0 DET T
response 0 NOUN F
rate B-MENTAL NOUN F
was 0 ADV F
highest 0 PUNCT F
in 0 ADP F
the 0 DET F
no 0 DET F
incentive 0 ADJ F
group 0 NOUN F
( 0 PUNCT F
69.3 0 NUM F
% 0 SYM F
) 0 PUNCT F
and 0 CCONJ F
lowest 0 PUNCT F
in 0 ADP F
the 0 DET F
one 0 NUM F
plus 0 CCONJ F
one 0 NUM F
lottery 0 PUNCT F
ticket 0 PUNCT F
group 0 NOUN F
( 0 PUNCT F
62.0 0 NUM F
% 0 SYM F
) 0 PUNCT F
. 0 PUNCT F

In 0 ADP T
a 0 DET F
survival 0 NOUN F
analysis 0 NOUN F
, 0 PUNCT F
the 0 DET F
difference 0 NOUN F
between 0 ADP F
the 0 DET F
two 0 NUM F
response 0 NOUN F
curves 0 NOUN F
was 0 VERB F
significant 0 ADJ F
by 0 ADP F
the 0 DET F
log-rank 0 NOUN F
test 0 NOUN F
( 0 PUNCT F
P 0 NOUN T
= 0 SYM F
0.04 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
with 0 ADP F
the 0 DET F
no 0 DET F
incentive 0 ADJ F
group 0 NOUN F
having 0 VERB F
a 0 DET F
shorter 0 PUNCT F
time 0 NOUN F
to 0 ADP F
response 0 NOUN F
than 0 PUNCT F
the 0 DET F
incentive 0 ADJ F
group 0 NOUN F
. 0 PUNCT F

Our 0 DET T
findings 0 NOUN F
suggest 0 VERB F
that 0 ADP F
the 0 DET F
use 0 NOUN F
of 0 ADP F
lottery 0 PUNCT F
tickets 0 ADP F
as 0 VERB F
incentives 0 DET F
to 0 PART F
increase 0 NOUN F
participation B-MENTAL NOUN F
in 0 ADP F
a 0 DET F
mail B-OTHER NOUN F
questionnaire 0 NOUN F
among 0 ADP F
parents 0 NOUN F
may 0 VERB F
be 0 VERB F
less 0 ADV F
valuable 0 ADJ F
or 0 CCONJ F
even 0 ADV F
harmful 0 ADJ F
. 0 PUNCT F

Incentives 0 NOUN T
may 0 VERB F
undermine 0 PUNCT F
motivation B-MENTAL NOUN F
in 0 ADP F
studies 0 NOUN F
in 0 ADP F
which 0 ADP F
the 0 DET F
intrinsic 0 ADJ F
motivation 0 NOUN F
of 0 ADP F
the 0 DET F
respondents 0 NOUN F
is 0 VERB F
already 0 ADV F
high 0 ADJ F
. 0 PUNCT F

Mending 0 PUNCT T
the 0 DET F
rhythm 0 NOUN F
does 0 PUNCT F
not 0 ADV F
improve 0 VERB F
prognosis 0 NOUN F
in 0 ADP F
patients 0 NOUN F
with 0 ADP F
persistent 0 ADJ F
atrial 0 ADJ F
fibrillation 0 NOUN F
: 0 PUNCT F
a 0 DET F
subanalysis 0 NOUN F
of 0 ADP F
the 0 DET F
RACE 0 NOUN T
study 0 NOUN F
. 0 PUNCT F

AIMS 0 NOUN T
To 0 PROPN T
compare 0 NOUN F
outcome 0 NOUN F
of 0 ADP F
AF 0 NOUN T
patients 0 NOUN F
with 0 ADP F
effective 0 ADJ F
rhythm 0 NOUN F
control 0 NOUN F
with 0 ADP F
patients 0 NOUN F
treated 0 VERB F
with 0 ADP F
rate 0 NOUN F
control 0 NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
AND 0 CCONJ T
RESULTS 0 DET T
Out 0 PUNCT T
of 0 ADP F
the 0 DET F
266 0 NUM F
AF 0 NOUN T
patients 0 NOUN F
randomized 0 VERB F
to 0 ADP F
rhythm 0 NOUN F
control 0 NOUN F
in 0 ADP F
the 0 DET F
RACE 0 NOUN T
study 0 NOUN F
, 0 PUNCT F
49 0 DET F
patients 0 NOUN F
turned 0 ADJ F
to 0 ADP F
long-term 0 NOUN F
sinus 0 NOUN F
rhythm 0 NOUN F
and 0 CCONJ F
were 0 VERB F
continuously 0 ADV F
treated 0 VERB F
with 0 ADP F
oral 0 ADJ F
anticoagulation 0 NOUN F
. 0 PUNCT F

The 0 DET T
incidence 0 NOUN F
of 0 ADP F
the 0 DET F
primary 0 ADJ F
endpoint 0 NOUN F
in 0 ADP F
these 0 DET F
patients 0 NOUN F
was 0 VERB F
compared 0 VERB F
to 0 ADP F
that 0 PUNCT F
in 0 ADP F
178 0 NUM F
patients 0 NOUN F
out 0 PUNCT F
of 0 ADP F
the 0 DET F
initial 0 ADJ F
256 0 NUM F
rate-control 0 NOUN F
patients 0 NOUN F
of 0 ADP F
RACE 0 NOUN T
who 0 ADP F
were 0 VERB F
in 0 ADP F
AF 0 NOUN T
and 0 CCONJ F
using 0 PROPN F
oral 0 ADJ F
anticoagulation 0 NOUN F
continuously 0 ADV F
. 0 PUNCT F

Baseline 0 NOUN T
characteristics 0 NOUN F
of 0 ADP F
both 0 CCONJ F
groups 0 NOUN F
were 0 VERB F
not 0 ADV F
different 0 ADJ F
. 0 PUNCT F

After 0 ADP T
a 0 DET F
mean 0 NOUN F
follow-up 0 NOUN F
of 0 ADP F
2.3+/-0.6 0 DET F
years 0 NOUN F
, 0 PUNCT F
the 0 DET F
primary 0 ADJ F
endpoint 0 NOUN F
( 0 PUNCT F
a 0 DET F
composite B-PHYSICAL NOUN F
of I-PHYSICAL ADP F
cardiovascular I-PHYSICAL ADJ F
mortality I-PHYSICAL NOUN F
, 0 PUNCT F
heart B-PHYSICAL NOUN F
failure I-PHYSICAL NOUN F
, 0 PUNCT F
thrombo-embolic B-PHYSICAL VERB F
complications I-PHYSICAL NOUN F
( I-PHYSICAL PUNCT F
TECs I-PHYSICAL NOUN T
) I-PHYSICAL PUNCT F
, 0 PUNCT F
bleeding B-PHYSICAL VERB F
, 0 PUNCT F
serious B-ADVERSE-EFFECTS ADJ F
adverse I-ADVERSE-EFFECTS ADJ F
effects I-ADVERSE-EFFECTS NOUN F
of I-ADVERSE-EFFECTS ADP F
antiarrhythmic I-ADVERSE-EFFECTS ADJ F
drugs I-ADVERSE-EFFECTS NOUN F
and 0 CCONJ F
pacemaker B-ADVERSE-EFFECTS PUNCT F
implants I-ADVERSE-EFFECTS NOUN F
) 0 PUNCT F
was 0 VERB F
22.4 0 NUM F
% 0 SYM F
in 0 ADP F
the 0 DET F
rhythm-control 0 NOUN F
group 0 NOUN F
vs. 0 CCONJ F
15.2 0 NUM F
% 0 SYM F
in 0 ADP F
the 0 DET F
rate-control 0 NOUN F
group 0 NOUN F
. 0 PUNCT F

Multivariable 0 ADJ T
regression 0 NOUN F
analysis 0 NOUN F
indicated 0 VERB F
coronary B-PHYSICAL ADJ F
artery I-PHYSICAL NOUN F
disease I-PHYSICAL NOUN F
, 0 PUNCT F
heart 0 NOUN F
failure 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
digitalis B-PHYSICAL NOUN F
as 0 PUNCT F
independent 0 ADJ F
risk 0 NOUN F
indicators 0 NOUN F
of 0 ADP F
cardiovascular 0 ADJ F
morbidity 0 NOUN F
and 0 CCONJ F
mortality 0 NOUN F
. 0 PUNCT F

Chronic B-PHYSICAL ADJ T
sinus I-PHYSICAL NOUN F
rhythm I-PHYSICAL NOUN F
did 0 PUNCT F
not 0 ADV F
matter 0 NOUN F
. 0 PUNCT F

CONCLUSION 0 NOUN T
Among 0 ADP T
patients 0 NOUN F
who 0 ADP F
remained 0 VERB F
on 0 ADP F
warfarin 0 NOUN F
, 0 PUNCT F
those 0 ADP F
who 0 ADP F
mostly 0 ADV F
were 0 VERB F
maintained 0 VERB F
in 0 ADP F
sinus 0 NOUN F
rhythm 0 NOUN F
under 0 ADP F
a 0 DET F
rhythm-control 0 NOUN F
strategy 0 NOUN F
did 0 PUNCT F
not 0 ADV F
have 0 PUNCT F
a 0 DET F
superior 0 ADJ F
prognosis 0 NOUN F
compared 0 VERB F
to 0 ADP F
those 0 PUNCT F
who 0 ADP F
remained 0 VERB F
in 0 ADP F
AF 0 NOUN T
under 0 ADP F
a 0 DET F
rate-control 0 NOUN F
strategy 0 NOUN F
. 0 PUNCT F

Total 0 ADJ T
anthelmintic 0 ADJ F
failure 0 NOUN F
to 0 ADP F
control 0 PUNCT F
nematode 0 NOUN F
parasites 0 NOUN F
of 0 ADP F
small 0 ADJ F
ruminants 0 NOUN F
on 0 ADP F
government 0 NOUN F
breeding 0 ADJ F
farms 0 ADP F
in 0 ADP F
Sabah 0 NOUN T
, 0 PUNCT F
East 0 NOUN T
Malaysia 0 NOUN T
. 0 PUNCT F

Government-owned 0 VERB T
small-ruminant 0 ADJ F
breeding 0 SYM F
farms 0 NOUN F
in 0 ADP F
Malaysia 0 NOUN T
provide 0 VERB F
the 0 DET F
source 0 NOUN F
of 0 ADP F
sheep 0 NOUN F
and 0 CCONJ F
goats 0 NOUN F
to 0 ADP F
smallholder 0 ADJ F
farmers 0 NOUN F
in 0 ADP F
the 0 DET F
country 0 NOUN F
. 0 PUNCT F

In 0 ADP T
the 0 DET F
eastern 0 ADJ F
Malaysian 0 ADJ T
state 0 NOUN F
of 0 ADP F
Sabah 0 NOUN T
, 0 PUNCT F
high-level 0 NOUN F
stock 0 NOUN F
losses 0 NOUN F
have 0 ADP F
been 0 PUNCT F
recorded 0 VERB F
on 0 ADP F
these 0 DET F
farms 0 PUNCT F
for 0 ADP F
several 0 ADJ F
years 0 NOUN F
, 0 PUNCT F
frequently 0 ADV F
accompanied 0 VERB F
by 0 ADP F
clinical 0 ADJ F
signs 0 NOUN F
indicating 0 VERB F
pathogenic 0 ADJ F
levels 0 NOUN F
of 0 ADP F
infections 0 NOUN F
with 0 ADP F
the 0 DET F
nematode 0 NOUN F
parasite 0 NOUN F
Haemonchus 0 ADV T
contortus 0 NOUN F
. 0 PUNCT F

This 0 ADJ T
suggests 0 VERB F
that 0 ADP F
their 0 ADP F
dependence 0 NOUN F
on 0 ADP F
chemotherapy 0 NOUN F
to 0 ADP F
control 0 NOUN F
parasite 0 NOUN F
infections 0 NOUN F
had 0 PUNCT F
failed 0 VERB F
. 0 PUNCT F

Accordingly 0 ADV T
, 0 PUNCT F
tests 0 CCONJ F
for 0 ADP F
anthelmintic B-OTHER ADJ F
efficacy I-OTHER NOUN F
using 0 VERB F
the 0 DET F
faecal 0 ADJ F
egg 0 NOUN F
count 0 NOUN F
reduction 0 NOUN F
test 0 NOUN F
( 0 PUNCT F
FECRT 0 NOUN T
) 0 PUNCT F
on 0 ADP F
the 0 DET F
range 0 NOUN F
of 0 ADP F
drugs 0 NOUN F
used 0 VERB F
to 0 PUNCT F
control 0 PUNCT F
nematode 0 NOUN F
parasites 0 NOUN F
were 0 VERB F
carried 0 VERB F
out 0 ADP F
on 0 ADP F
the 0 DET F
five 0 NUM F
government 0 NOUN F
small-ruminant 0 ADJ F
breeding 0 SYM F
farms 0 NOUN F
in 0 ADP F
Sabah 0 NOUN T
. 0 PUNCT F

These 0 DET T
tests 0 NOUN F
showed 0 VERB F
a 0 DET F
total 0 ADJ F
failure 0 NOUN F
of B-OTHER ADP F
the 0 DET F
benzimidazole B-OTHER ADP F
, 0 PUNCT F
imidothiazole B-OTHER NOUN F
, 0 PUNCT F
macrocyclic B-OTHER ADJ F
lactone I-OTHER NOUN F
and 0 PUNCT F
salicylanilide B-OTHER PUNCT F

Scaling 0 ADP T
clinical 0 ADJ F
judgments 0 NOUN F
of 0 ADP F
symptom 0 NOUN F
pathology 0 NOUN F
by 0 ADP F
means 0 NOUN F
of 0 ADP F
the 0 DET F
psychophysiological 0 ADJ F
method 0 NOUN F
of 0 ADP F
magnitude 0 NOUN F
estimation 0 NOUN F
. 0 PUNCT F

Summing 0 PUNCT T
scores 0 NOUN F
across 0 ADP F
heterogeneous 0 ADJ F
symptom 0 NOUN F
items 0 ADJ F
without 0 ADP F
consideration 0 NOUN F
of 0 ADP F
their 0 PUNCT F
differing 0 ADJ F
psychopathological 0 ADJ F
significance 0 NOUN F
has 0 PUNCT F
been 0 PUNCT F
criticized 0 VERB F
as 0 CCONJ F
producing 0 PUNCT F
an 0 DET F
inadequate 0 ADJ F
picture 0 NOUN F
of 0 ADP F
an 0 DET F
individual 0 ADJ F
's 0 PUNCT F
clinical 0 ADJ F
status 0 NOUN F
. 0 PUNCT F

The 0 DET T
purpose 0 NOUN F
of 0 ADP F
this 0 DET F
study 0 NOUN F
was 0 VERB F
to 0 PART F
derive 0 VERB F
symptom 0 NOUN F
item 0 NOUN F
weights 0 NOUN F
representing 0 VERB F
clinically 0 ADV F
judged 0 PUNCT F
seriousness 0 NOUN F
of 0 ADP F
each 0 ADP F
symptom 0 NOUN F
through 0 ADP F
the 0 DET F
application 0 NOUN F
of 0 ADP F
Steven 0 PUNCT T
's 0 PUNCT F
psychophysical 0 ADJ F
method 0 NOUN F
of 0 ADP F
magnitude 0 NOUN F
estimation 0 NOUN F
. 0 PUNCT F

A 0 PUNCT T
nationwide 0 NOUN F
sample 0 NOUN F
of 0 ADP F
129 0 NUM F
clinicians 0 NOUN F
rated 0 VERB F
the 0 DET F
pathological 0 ADJ F
significance 0 NOUN F
of 0 ADP F
221 0 NUM F
symptom 0 NOUN F
items 0 ADJ F
in 0 ADP F
a 0 DET F
design 0 NOUN F
such 0 PUNCT F
that 0 PUNCT F
every 0 DET F
rater 0 ADJ F
rated 0 PUNCT F
121 0 NUM F
items 0 ADJ F
, 0 PUNCT F
21 0 NUM F
of 0 ADP F
which 0 ADP F
were 0 VERB F
rated 0 VERB F
by 0 ADP F
all 0 DET F
raters 0 NOUN F
and 0 CCONJ F
100 0 NUM F
of 0 ADP F
which 0 ADP F
were 0 VERB F
rated 0 VERB F
only 0 ADV F
by 0 ADP F
the 0 DET F
A 0 DET T
or 0 CCONJ F
B 0 NOUN T
subgroup 0 NOUN F
to 0 ADP F
which 0 CCONJ F
each 0 DET F
rater 0 ADV F
was 0 VERB F
randomly 0 ADV F
assigned 0 VERB F
. 0 PUNCT F

Each 0 DET T
item 0 NOUN F
was 0 VERB F
rated 0 VERB F
as 0 PUNCT F
to 0 ADP F
the 0 DET F
seriousness 0 NOUN F
of 0 ADP F
the 0 DET F
pathology 0 NOUN F
it 0 PRON F
would 0 VERB F
represent 0 VERB F
if 0 PUNCT F
manifested 0 VERB F
by 0 ADP F
either 0 PUNCT F
a 0 DET F
boy 0 NOUN F
child 0 NOUN F
, 0 PUNCT F
girl 0 PUNCT F
child 0 NOUN F
, 0 PUNCT F
boy 0 NOUN F
adolescent 0 NOUN F
, 0 PUNCT F
or 0 PUNCT F
girl 0 NOUN F
adolescent 0 NOUN F
, 0 PUNCT F
with 0 ADP F
one-fourth 0 NOUN F
of 0 ADP F
the 0 DET F
raters 0 NOUN F
assigned 0 NUM F
to 0 ADP F
each 0 DET F
condition 0 NOUN F
. 0 PUNCT F

The 0 DET T
results 0 NOUN F
of 0 ADP F
211 0 NUM F
two-way 0 NOUN F
analyses 0 NOUN F
of 0 ADP F
variance 0 NOUN F
revealed 0 VERB F
that 0 ADP F
age 0 NOUN F
and 0 CCONJ F
age 0 NOUN F
and 0 CCONJ F
sex B-MENTAL NOUN F
in 0 ADP F
interaction 0 NOUN F
, 0 PUNCT F
but 0 CCONJ F
not 0 ADV F
sex 0 NOUN F
alone 0 ADJ F
, 0 PUNCT F
significantly 0 ADV F
influenced 0 ADP F
the 0 DET F
clinical 0 ADJ F
ratings 0 NOUN F
. 0 PUNCT F

The 0 DET T
resulting 0 VERB F
magnitude B-MENTAL NOUN F
estimation 0 NOUN F
ratings B-MENTAL NOUN F
of I-MENTAL ADP F
symptom I-MENTAL PUNCT F

The 0 DET T
relationship 0 NOUN F
between 0 ADP F
the 0 DET F
response 0 NOUN F
of 0 ADP F
Plasmodium 0 NOUN T
falciparum 0 NOUN F
malaria 0 NOUN F
to 0 ADP F
mefloquine 0 NOUN F
in 0 ADP F
African 0 ADJ T
children 0 NOUN F
and 0 CCONJ F
its 0 ADJ F
sensitivity 0 NOUN F
in 0 DET F
vitro 0 ADV F
. 0 PUNCT F

The 0 DET T
clinical 0 ADJ F
efficacy 0 NOUN F
of 0 ADP F
two 0 NUM F
doses 0 NOUN F
of 0 ADP F
mefloquine 0 NOUN F
( 0 PUNCT F
15 0 NUM F
and 0 CCONJ F
25 0 NUM F
mg/kg 0 NOUN F
body 0 NOUN F
weight 0 NOUN F
) 0 PUNCT F
was 0 VERB F
evaluated 0 VERB F
in 0 ADP F
85 0 NUM F
children 0 NOUN F
suffering 0 VERB F
from 0 ADP F
acute 0 ADJ F
symptomatic 0 ADJ F
falciparum 0 NOUN F
malaria 0 NOUN F
. 0 PUNCT F

The 0 DET T
cure B-OTHER ADV F
rate I-OTHER NOUN F
on 0 ADP F
day 0 NOUN F
28 0 NUM F
was 0 VERB F
100 0 NUM F
% 0 SYM F
in 0 ADP F
both 0 CCONJ F
groups 0 NOUN F
. 0 PUNCT F

There 0 PUNCT T
was 0 VERB F
no 0 DET F
significant 0 ADJ F
difference 0 NOUN F
( 0 PUNCT F
P 0 NOUN T
> 0 SYM F
0.05 0 NUM F
) 0 PUNCT F
in 0 ADP F
the 0 DET F
mean 0 NOUN F
parasite B-PHYSICAL NOUN F
and I-PHYSICAL CCONJ F
fever I-PHYSICAL NOUN F
clearance I-PHYSICAL NOUN F
times I-PHYSICAL ADP F
in 0 ADP F
both 0 CCONJ F
groups 0 NOUN F
( 0 PUNCT F
48.5 0 NUM F
+/- 0 SYM F
14.6 0 NUM F
and 0 CCONJ F
32.0 0 NUM F
+/- 0 SYM F
12.7 0 NUM F
h 0 NOUN F
respectively 0 ADV F
for 0 ADP F
the 0 DET F
25 0 NUM F
mg/kg 0 NOUN F
group 0 NOUN F
and 0 CCONJ F
49.0 0 NUM F
+/- 0 SYM F
15.1 0 NUM F
and 0 CCONJ F
30.0 0 NUM F
+/- 0 SYM F
13.3 0 NUM F
h 0 NOUN F
respectively 0 ADV F
for 0 ADP F
the 0 DET F
15 0 NUM F
mg/kg 0 ADJ F
group 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

There 0 PUNCT T
was 0 VERB F
also 0 ADV F
no 0 DET F
significant 0 ADJ F
difference 0 NOUN F
( 0 PUNCT F
P 0 NOUN T
> 0 SYM F
0.05 0 NUM F
) 0 PUNCT F
in 0 ADP F
these 0 DET F
values 0 NOUN F
between 0 ADP F
children 0 NOUN F
with 0 ADP F
hyperparasitaemia 0 ADJ F
( 0 PUNCT F
53.6 0 NUM F
+/- 0 SYM F
11.1 0 NUM F
and 0 CCONJ F
36.0 0 NUM F
+/- 0 SYM F
17.0 0 NUM F
h 0 NOUN F
respectively 0 ADV F
) 0 PUNCT F
and 0 CCONJ F
those 0 PUNCT F
without 0 ADP F
hyperparasitaemia 0 ADJ F
( 0 PUNCT F
49.1 0 NUM F
+/- 0 SYM F
13.6 0 NUM F
and 0 CCONJ F
31.8 0 NUM F
+/- 0 SYM F
14.6 0 NUM F
h 0 NOUN F
respectively 0 ADV F
) 0 PUNCT F
. 0 PUNCT F

Recurrence B-PHYSICAL NOUN T
of I-PHYSICAL ADP F
parasitaemia I-PHYSICAL NOUN F
was 0 VERB F
observed 0 NUM F
after 0 ADP F
day 0 NOUN F
30 0 PUNCT F
in 0 ADP F
2 0 NUM F
patients 0 NOUN F
in 0 ADP F
the 0 DET F
15 0 NUM F
mg/kg 0 ADJ F
group 0 NOUN F
and 0 CCONJ F
in 0 ADP F
1 0 NUM F
patient 0 NOUN F
in 0 ADP F
the 0 DET F
25 0 NUM F
mg/kg 0 ADJ F
group 0 NOUN F
. 0 PUNCT F

In 0 PUNCT T
vitro 0 ADJ F
, 0 PUNCT F
3 0 NUM F
of 0 ADP F
21 0 NUM F
isolates 0 NOUN F
showed 0 VERB F
reduced 0 VERB F
susceptibility B-OTHER NOUN F
to I-OTHER ADP F
mefloquine I-OTHER NOUN F
, 0 PUNCT F
with 0 ADP F
minimum 0 NOUN F
inhibitory B-OTHER ADJ F
concentrations I-OTHER NOUN F
( 0 PUNCT F
MIC 0 NOUN T
) 0 PUNCT F
> 0 SYM F
67 0 NUM F
nM/litre 0 NOUN F
. 0 PUNCT F

The 0 DET T
MIC 0 NOUN T
and 0 CCONJ F
50 0 NUM F
% 0 SYM F
, 0 PUNCT F
90 0 NUM F
% 0 SYM F
and 0 CCONJ F
99 0 NUM F
% 0 ADV F
inhibitory 0 ADJ F
concentrations 0 NOUN F
were 0 VERB F
200.8 0 NUM F
, 0 PUNCT F
6.27 0 NUM F
, 0 PUNCT F
31.7 0 NUM F
and 0 CCONJ F
119.6 0 NUM F
nM/litre 0 NOUN F
respectively 0 ADV F
. 0 PUNCT F

Four 0 NUM T
of 0 ADP F
22 0 NUM F
isolates 0 NOUN F
were 0 VERB F
resistant B-OTHER ADJ F
to 0 ADP F
chloroquine 0 NOUN F
( 0 PUNCT F
MIC 0 NOUN T
> 0 SYM F
108 0 NUM F
nM/litre 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

Isolates 0 NOUN T
that 0 NUM F
showed 0 VERB F
low 0 ADJ F
sensitivity B-OTHER NOUN F
to 0 ADP F
mefloquine 0 NOUN F
in 0 DET F
vitro 0 ADV F
were 0 VERB F
sensitive 0 ADJ F
to 0 ADP F
chloroquine 0 NOUN F
in 0 DET F
vitro 0 ADJ F
, 0 PUNCT F
and 0 CCONJ F
the 0 DET F
4 0 NUM F
that 0 VERB F
were 0 VERB F
resistant 0 ADJ F
to 0 ADP F
chloroquine 0 NOUN F
were 0 VERB F
sensitive 0 ADJ F
to 0 ADP F
mefloquine 0 NOUN F
. 0 PUNCT F

Irrespective 0 ADJ T
of 0 ADP F
MIC 0 NOUN T
and 0 CCONJ F
dose 0 NOUN F
of 0 ADP F
mefloquine 0 NOUN F
, 0 PUNCT F
parasitaemia 0 NOUN F
cleared 0 VERB F
in 0 ADP F
all 0 DET F
subjects 0 NOUN F
in 0 ADP F
96 0 NUM F
h 0 NOUN F
or 0 CCONJ F
less 0 DET F
. 0 PUNCT F
( 0 PUNCT F

ABSTRACT 0 ADP T
TRUNCATED 0 PUNCT T
AT 0 ADP T
250 0 NUM F
WORDS 0 NOUN T
) 0 PUNCT F

D-dimer 0 NOUN T
predicts 0 ADV F
outcome 0 NOUN F
after 0 ADP F
aneurysmal 0 ADJ F
subarachnoid 0 NOUN F
hemorrhage 0 NOUN F
: 0 PUNCT F
no 0 DET F
effect 0 NOUN F
of 0 ADP F
thromboprophylaxis 0 NOUN F
on 0 ADP F
coagulation B-PHYSICAL NOUN F
activity I-PHYSICAL NOUN F
. 0 PUNCT F

OBJECTIVE 0 NOUN T
Approximately 0 ADV T
one-third 0 NOUN F
of 0 ADP F
all 0 DET F
patients 0 NOUN F
with 0 ADP F
acute 0 ADJ F
nontraumatic 0 ADJ F
subarachnoid 0 NOUN F
hemorrhage 0 NOUN F
( 0 PUNCT F
SAH 0 NOUN T
) 0 PUNCT F
experience 0 DET F
complications 0 NOUN F
owing 0 PUNCT F
to 0 ADP F
delayed 0 VERB F
ischemic 0 ADJ F
deficit 0 NOUN F
. 0 PUNCT F

We 0 PRON T
reported 0 VERB F
recently 0 ADV F
that 0 ADP F
enoxaparin 0 NOUN F
40 0 NUM F
mg 0 NOUN F
once 0 PUNCT F
daily 0 ADJ F
for 0 ADP F
10 0 NUM F
days 0 NOUN F
seems 0 NOUN F
safe 0 ADJ F
and 0 CCONJ F
demonstrates 0 NOUN F
thromboprophylactic B-OTHER ADJ F
efficacy I-OTHER NOUN F
, 0 PUNCT F
but 0 CCONJ F
it 0 NOUN F
failed 0 VERB F
to 0 ADP F
improve 0 ADP F
outcome 0 NOUN F
in 0 ADP F
a 0 DET F
randomized 0 VERB F
SAH 0 NOUN T
trial 0 NOUN F
. 0 PUNCT F

In 0 ADP T
the 0 DET F
present 0 ADJ F
study 0 NOUN F
, 0 PUNCT F
we 0 NOUN F
assessed 0 VERB F
hemostatic B-PHYSICAL ADJ F
variables I-PHYSICAL NOUN F
associated 0 VERB F
with 0 ADP F
clinical 0 ADJ F
status 0 NOUN F
and 0 CCONJ F
outcome 0 NOUN F
of 0 ADP F
SAH 0 NOUN T
. 0 PUNCT F

We 0 PRON T
also 0 ADV F
monitored 0 PROPN F
the 0 DET F
effect 0 NOUN F
of 0 ADP F
enoxaparin 0 NOUN F
on 0 ADP F
activation 0 NOUN F
of 0 ADP F
coagulation B-PHYSICAL NOUN F
and 0 CCONJ F
fibrinolysis B-PHYSICAL NOUN F
after 0 ADP F
closure 0 NOUN F
of 0 ADP F
the 0 DET F
ruptured 0 VERB F
aneurysm 0 ADV F
. 0 PUNCT F

METHODS 0 NOUN T
Blood B-OTHER NOUN T
samples I-OTHER NOUN F
to 0 PART F
measure 0 VERB F
activation B-PHYSICAL NOUN F
of I-PHYSICAL ADP F
coagulation I-PHYSICAL NOUN F
and 0 CCONJ F
fibrinolysis B-PHYSICAL NOUN F
were 0 VERB F
collected 0 VERB F
from 0 ADP F
42 0 NUM F
patients 0 NOUN F
participating 0 VERB F
in 0 ADP F
the 0 DET F
enoxaparin 0 NOUN F
trial 0 NOUN F
for 0 ADP F
acute 0 ADJ F
aneurysmal 0 ADJ F
SAH 0 NOUN T
at 0 ADP F
four 0 NUM F
time 0 NOUN F
points 0 NOUN F
: 0 PUNCT F
1 0 NUM F
) 0 PUNCT F
at 0 ADP F
hospital 0 NOUN F
admission 0 NOUN F
; 0 PUNCT F
2 0 NUM F
) 0 PUNCT F
12 0 NUM F
to 0 ADP F
24 0 NUM F
hours 0 NOUN F
after 0 ADP F
aneurysm 0 NOUN F
surgery 0 NOUN F
but 0 CCONJ F
before 0 ADP F
initiation 0 NOUN F
of 0 ADP F
enoxaparin 0 NOUN F
therapy 0 NOUN F
; 0 PUNCT F
3 0 NUM F
) 0 PUNCT F
3 0 NUM F
hours 0 NOUN F
after 0 ADP F
the 0 DET F
first 0 ADJ F
dose 0 NOUN F
; 0 PUNCT F
and 0 CCONJ F
4 0 NUM F
) 0 PUNCT F
at 0 ADP F
the 0 DET F
conclusion 0 NOUN F
of 0 ADP F
treatment 0 NOUN F
. 0 PUNCT F

RESULTS 0 NOUN T
At 0 ADP T
admission 0 NOUN F
, 0 PUNCT F
several 0 ADJ F
variables 0 NOUN F
of 0 ADP F
coagulation B-PHYSICAL NOUN F
and 0 CCONJ F
fibrinolysis B-PHYSICAL NOUN F
were 0 VERB F
elevated 0 VERB F
and 0 CCONJ F
correlated 0 VERB F
well 0 VERB F
with 0 CCONJ F
clinical 0 ADJ F
status 0 NOUN F
. 0 PUNCT F

Specifically 0 ADV T
, 0 PUNCT F
D-dimer B-PHYSICAL NOUN T
levels I-PHYSICAL NOUN F
at 0 ADP F
all 0 DET F
four 0 NUM F
time 0 NOUN F
points 0 NOUN F
correlated 0 VERB F
with 0 ADP F
patients 0 NOUN F
' 0 PUNCT F
long-term 0 NOUN F
outcomes 0 NOUN F
. 0 PUNCT F

A 0 DET T
single 0 ADJ F
dose 0 NOUN F
of 0 ADP F
enoxaparin 0 NOUN F
suppressed 0 VERB F
early B-PHYSICAL ADJ F
coagulation I-PHYSICAL NOUN F
activity I-PHYSICAL NOUN F
, 0 PUNCT F
but 0 CCONJ F
thrombin B-PHYSICAL NOUN F
generation I-PHYSICAL NOUN F
was 0 VERB F
not 0 ADV F
inhibited B-OTHER VERB F
during 0 ADP F
thromboprophylaxis 0 NOUN F
. 0 PUNCT F

However 0 ADV T
, 0 PUNCT F
PAI-1 B-PHYSICAL NOUN T
activity I-PHYSICAL NOUN F
was 0 VERB F
suppressed 0 VERB F
. 0 PUNCT F

CONCLUSION 0 NOUN T
D-dimer 0 NOUN T
offers 0 NOUN F
a 0 DET F
useful 0 ADJ F
laboratory 0 NOUN F
tool 0 NOUN F
for 0 ADP F
assessing 0 VERB F
early 0 ADJ F
and 0 CCONJ F
late 0 ADJ F
clinical 0 ADJ F
severity B-PHYSICAL NOUN F
of I-PHYSICAL ADP F
SAH I-PHYSICAL NOUN T
. 0 PUNCT F

A 0 DET T
thromboprophylactic 0 ADJ F
dose 0 NOUN F
of 0 ADP F
enoxaparin 0 NOUN F
inhibited 0 VERB F
PAI-1 B-PHYSICAL NOUN T
activity I-PHYSICAL NOUN F
but 0 CCONJ F
failed 0 VERB F
to 0 PUNCT F
down-regulate 0 PUNCT F
coagulation B-PHYSICAL NOUN F
activity I-PHYSICAL NOUN F
and 0 CCONJ F
D-dimer B-PHYSICAL NOUN T
. 0 PUNCT F

These 0 DET T
findings 0 NOUN F
are 0 VERB F
compatible 0 ADJ F
with 0 ADP F
the 0 DET F
lack 0 NOUN F
of 0 ADP F
efficacy 0 NOUN F
of 0 ADP F
enoxaparin 0 NOUN F
in 0 ADP F
reducing 0 VERB F
ischemic 0 ADJ F
deficit 0 NOUN F
after 0 ADP F
SAH 0 NOUN T
. 0 PUNCT F

A 0 DET T
plaque 0 NOUN F
index 0 NOUN F
for 0 ADP F
occlusal 0 ADJ F
surfaces 0 NOUN F
and 0 CCONJ F
fissures 0 PUNCT F
. 0 PUNCT F

Measurement 0 NOUN T
of 0 ADP F
repeatability 0 NOUN F
and 0 CCONJ F
plaque 0 NOUN F
removal 0 NOUN F
. 0 PUNCT F

Plaque 0 NOUN T
indices 0 NOUN F
have 0 ADJ F
largely 0 ADV F
been 0 PUNCT F
developed 0 VERB F
for 0 ADP F
buccal 0 ADJ F
and 0 CCONJ F
lingual 0 ADJ F
tooth 0 NOUN F
surfaces 0 NOUN F
. 0 PUNCT F

There 0 PUNCT T
has 0 DET F
been 0 PUNCT F
minimal 0 ADJ F
interest 0 NOUN F
in 0 ADP F
plaque 0 NOUN F
accumulation 0 NOUN F
on 0 ADP F
occlusal 0 ADJ F
surfaces 0 NOUN F
despite 0 ADP F
the 0 DET F
predilection 0 NOUN F
for 0 ADP F
caries 0 NOUN F
at 0 ADP F
these 0 DET F
sites 0 NOUN F
. 0 PUNCT F

A 0 DET T
numerical 0 ADJ F
plaque 0 NOUN F
index 0 NOUN F
( 0 PUNCT F
0-5 0 NUM F
) 0 PUNCT F
is 0 VERB F
described 0 VERB F
based 0 VERB F
on 0 ADP F
the 0 DET F
presence 0 NOUN F
and 0 CCONJ F
distribution 0 NOUN F
of 0 ADP F
plaque 0 NOUN F
in 0 ADP F
the 0 DET F
fissures 0 ADV F
and 0 CCONJ F
over 0 ADP F
the 0 DET F
occlusal 0 ADJ F
surfaces 0 NOUN F
of 0 ADP F
permanent 0 ADJ F
molar 0 ADJ F
and 0 CCONJ F
premolar 0 ADP F
teeth 0 NOUN F
. 0 PUNCT F

The 0 DET T
repeatability 0 NOUN F
of 0 ADP F
a 0 DET F
single 0 ADJ F
examiner 0 NOUN F
in 0 ADP F
scoring 0 ADJ F
the 0 DET F
index 0 NOUN F
was 0 VERB F
performed 0 VERB F
using 0 VERB F
4 0 NUM F
groups 0 NOUN F
of 0 ADP F
10 0 NUM F
subjects 0 NOUN F
. 0 PUNCT F

Each 0 DET T
group 0 NOUN F
of 0 ADP F
volunteers 0 NOUN F
suspended 0 DET F
tooth 0 NOUN F
cleaning 0 PROPN F
for 0 ADP F
48 0 NUM F
h 0 NOUN F
and 0 CCONJ F
the 0 DET F
index 0 NOUN F
scored 0 PUNCT F
after 0 ADP F
disclosing 0 PUNCT F
plaque 0 NOUN F
deposits 0 NOUN F
. 0 PUNCT F

The 0 DET T
index 0 NOUN F
was 0 VERB F
rescored 0 ADP F
60-90 0 NUM F
min 0 NOUN F
later 0 ADJ F
. 0 PUNCT F

Plaque 0 NOUN T
area 0 NOUN F
was 0 VERB F
also 0 ADV F
determined 0 VERB F
by 0 ADP F
drawing 0 ADP F
the 0 DET F
outline 0 NOUN F
of 0 ADP F
plaque 0 NOUN F
onto 0 ADP F
grids 0 NOUN F
. 0 PUNCT F

Except 0 PUNCT T
for 0 ADP F
one 0 NUM F
condition 0 NOUN F
of 0 ADP F
repeatability 0 NOUN F
for 0 ADP F
one 0 NUM F
group 0 NOUN F
, 0 PUNCT F
the 0 DET F
4 0 NUM F
conditions 0 NOUN F
of 0 ADP F
repeatability 0 NOUN F
in 0 ADP F
scoring 0 ADJ F
the 0 DET F
index 0 NOUN F
were 0 VERB F
met 0 VERB F
for 0 ADP F
all 0 DET F
4 0 NUM F
groups 0 NOUN F
of 0 ADP F
subjects 0 NOUN F
. 0 PUNCT F

The 0 DET T
sensitivity 0 NOUN F
of 0 ADP F
the 0 DET F
index 0 NOUN F
and 0 CCONJ F
area 0 NOUN F
recordings B-OTHER CCONJ F
to 0 PART F
detect 0 NOUN F
plaque 0 NOUN F
removed 0 VERB F
by 0 ADP F
brushing 0 PUNCT F
was 0 VERB F
then 0 ADV F
evaluated 0 VERB F
. 0 PUNCT F

A 0 DET T
group 0 NOUN F
of 0 ADP F
10 0 NUM F
subjects 0 NOUN F
had 0 PUNCT F
plaque 0 NOUN F
scored 0 VERB F
by 0 ADP F
index 0 NOUN F
and 0 CCONJ F
area 0 NOUN F
after 0 ADP F
suspending 0 ADP F
toothcleaning 0 DET F
for 0 ADP F
48 0 NUM F
h. 0 NOUN F
Subjects 0 NOUN T
were 0 VERB F
then 0 ADV F
randomly 0 ADV F
allocated 0 VERB F
to 0 ADP F
brush 0 NOUN F
or 0 CCONJ F
not 0 ADV F
brush 0 NOUN F
their 0 ADP F
teeth 0 NOUN F
and 0 CCONJ F
plaque 0 NOUN F
rescored 0 ADP F
. 0 PUNCT F

The 0 DET T
experiment 0 NOUN F
was 0 VERB F
then 0 ADV F
repeated 0 VERB F
and 0 CCONJ F
brushing 0 PUNCT F
or 0 CCONJ F
not 0 ADV F
brushing 0 PUNCT F
crossed 0 PUNCT F
over 0 PUNCT F
. 0 PUNCT F

Highly 0 ADV T
significant 0 ADJ F
differences 0 NOUN F
between 0 ADP F
brushing 0 PUNCT F
and 0 CCONJ F
no 0 DET F
brushing 0 PUNCT F
plaque B-OTHER NOUN F
indices I-OTHER NOUN F
and 0 CCONJ F
areas 0 NOUN F
were 0 VERB F
determined 0 VERB F
. 0 PUNCT F

In 0 ADP T
conclusion 0 NOUN F
, 0 PUNCT F
the 0 DET F
occlusal B-OTHER ADJ F
fissure I-OTHER ADJ F
plaque I-OTHER NOUN F
index I-OTHER NOUN F
was 0 DET F
easy 0 PUNCT F
to 0 ADP F
apply 0 ADP F
, 0 PUNCT F
repeatable 0 ADJ F
and 0 CCONJ F
sufficiently 0 ADV F
sensitive 0 ADJ F
to 0 PART F
detect 0 NOUN F
plaque 0 NOUN F
removed 0 VERB F
by 0 ADP F
brushing 0 PUNCT F
. 0 PUNCT F

The 0 DET T
index 0 NOUN F
could 0 PUNCT F
find 0 VERB F
use 0 ADV F
as 0 ADP F
an 0 DET F
additional 0 ADJ F
measure 0 NOUN F
of 0 ADP F
oral 0 ADJ F
hygiene 0 NOUN F
, 0 PUNCT F
in 0 ADP F
clinical 0 ADJ F
trials 0 NOUN F
on 0 ADP F
plaque 0 NOUN F
control 0 NOUN F
and 0 CCONJ F
possibly 0 ADV F
epidemiological 0 ADJ F
studies 0 NOUN F
relating 0 ADJ F
to 0 PUNCT F
caries 0 NOUN F
. 0 PUNCT F

Quitting 0 ADP T
a 0 DET F
weight 0 NOUN F
loss 0 NOUN F
program 0 NOUN F
is 0 VERB F
associated 0 VERB F
with 0 ADP F
anhedonia 0 NOUN F
: 0 PUNCT F
preliminary 0 ADJ F
findings 0 NOUN F
of 0 ADP F
the 0 DET F
Lifestyle 0 NOUN T
Intervention 0 NOUN T
Treatment 0 NOUN T
Evaluation 0 NOUN T
Study 0 NOUN T
in 0 ADP F
northern 0 ADJ F
Finland 0 CCONJ T
. 0 PUNCT F

OBJECTIVES 0 ADP T
To 0 PROPN T
examine 0 NOUN F
whether 0 ADP F
a 0 DET F
diagnosis 0 NOUN F
for 0 ADP F
major 0 ADJ F
depression 0 NOUN F
, 0 PUNCT F
chronic 0 ADJ F
depression 0 NOUN F
or 0 CCONJ F
specific 0 ADJ F
symptoms 0 NOUN F
of 0 ADP F
depression 0 NOUN F
is 0 VERB F
associated 0 VERB F
with 0 ADP F
the 0 DET F
risk 0 NOUN F
of 0 ADP F
quitting 0 NUM F
a 0 DET F
weight 0 NOUN F
loss 0 NOUN F
program 0 NOUN F
. 0 PUNCT F

STUDY 0 NOUN T
DESIGN 0 NOUN T
The 0 DET T
study 0 NOUN F
involved 0 VERB F
82 0 NUM F
overweight 0 VERB F
adults 0 NOUN F
participating 0 PROPN F
in 0 ADP F
the 0 DET F
Lifestyle 0 NOUN T
Intervention 0 NOUN T
Treatment 0 NOUN T
Evaluation 0 NOUN T
( 0 PUNCT F
LITE 0 NOUN T
) 0 PUNCT F
follow-up 0 NOUN F
study 0 NOUN F
at 0 ADP F
Oulu 0 NOUN T
University 0 NOUN T
Hospital 0 NOUN T
in 0 ADP F
northern 0 ADJ F
Finland 0 CCONJ T
. 0 PUNCT F

METHODS 0 NOUN T
Psychiatric B-MENTAL ADJ T
diagnostic I-MENTAL ADJ F
assessments I-MENTAL NOUN F
were 0 VERB F
based 0 VERB F
on 0 ADP F
the 0 DET F
Structured 0 PROPN T
Clinical 0 ADJ T
Interview 0 NOUN T
for 0 ADP F
DSMIV B-PHYSICAL NOUN T
disorders 0 NOUN F
( 0 PUNCT F
SCID-I 0 NOUN T
) 0 PUNCT F
conducted 0 VERB F
by 0 ADP F
a 0 DET F
clinical 0 ADJ F
psychiatrist 0 NOUN F
. 0 PUNCT F

Anhedonia B-MENTAL NOUN T
( I-MENTAL PUNCT F
lack I-MENTAL NOUN F
of I-MENTAL ADP F
pleasure I-MENTAL ADJ F
) I-MENTAL PUNCT F
was 0 VERB F
assessed 0 VERB F
as 0 ADP F
one 0 NUM F
of 0 ADP F
the 0 DET F
core 0 NOUN F
symptoms 0 NOUN F
of 0 ADP F
major 0 ADJ F
depression 0 NOUN F
and 0 CCONJ F
chronic B-PHYSICAL ADJ F
depression 0 NOUN F
( 0 PUNCT F
dysthymia 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

Anhedonia B-MENTAL NOUN T
was 0 VERB F
defined 0 VERB F
to 0 PART F
be 0 PUNCT F
present 0 ADJ F
if 0 PUNCT F
the 0 DET F
participants 0 NOUN F
reported 0 PUNCT F
having 0 SYM F
suffered 0 VERB F
a 0 DET F
major 0 ADJ F
loss 0 NOUN F
of 0 ADP F
interest 0 NOUN F
during 0 ADP F
the 0 DET F
previous 0 ADJ F
month 0 NOUN F
. 0 PUNCT F

RESULTS 0 NOUN T
Twenty 0 PUNCT T
participants 0 NOUN F
( 0 PUNCT F
24.4 0 NUM F
% 0 SYM F
) 0 PUNCT F
quit 0 NOUN F
during 0 ADP F
the 0 DET F
6-month 0 NOUN F
intervention 0 NOUN F
period 0 NOUN F
. 0 PUNCT F

Anhedonia B-MENTAL NOUN T
put 0 PUNCT F
individuals 0 NOUN F
at 0 ADP F
risk 0 NOUN F
of 0 ADP F
quitting 0 PROPN F
the 0 DET F
weight 0 NOUN F
loss 0 NOUN F
program 0 NOUN F
( 0 PUNCT F
bivariate 0 ADJ F
analysis 0 NOUN F
OR 0 CCONJ T
3.1 0 NUM F
, 0 PUNCT F
95 0 NUM F
% 0 SYM F
CI 0 NOUN T
0.8-11.6 0 PUNCT F
, 0 PUNCT F
p=0.091 0 PUNCT F
, 0 PUNCT F
multivariate 0 ADJ F
analysis 0 NOUN F
OR 0 CCONJ T
6.5 0 NUM F
, 0 PUNCT F
95 0 NUM F
% 0 SYM F
CI 0 NOUN T
1.1-38.2 0 PUNCT F
, 0 PUNCT F
p=0.038 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

However 0 ADV T
, 0 PUNCT F
a 0 DET F
diagnosis 0 NOUN F
for 0 ADP F
major B-MENTAL ADJ F
depression I-MENTAL NOUN F
or 0 CCONJ F
chronic B-MENTAL ADJ F
depression I-MENTAL NOUN F
did 0 ADP F
not 0 ADV F
predict 0 VERB F
quitting 0 NOUN F
. 0 PUNCT F

CONCLUSIONS 0 NOUN T
Individual 0 PUNCT T
assessments 0 NOUN F
of 0 ADP F
obesity 0 NOUN F
and 0 CCONJ F
overweight 0 ADV F
should 0 ADP F
also 0 ADV F
include 0 VERB F
an 0 DET F
assessment 0 NOUN F
for 0 ADP F
subthreshold 0 PUNCT F
depression 0 NOUN F
, 0 PUNCT F
mainly 0 ADV F
anhedonia 0 NOUN F
. 0 PUNCT F

The 0 DET T
Randomised 0 ADV T
Intervention 0 NOUN T
Treatment 0 NOUN T
of 0 ADP F
Angina 0 NOUN T
( 0 PUNCT F
RITA 0 NOUN T
) 0 PUNCT F
Trial 0 NOUN T
protocol 0 NOUN F
: 0 PUNCT F
a 0 DET F
long 0 ADJ F
term 0 NOUN F
study 0 NOUN F
of 0 ADP F
coronary 0 ADJ F
angioplasty 0 NOUN F
and 0 CCONJ F
coronary 0 ADJ F
artery 0 NOUN F
bypass 0 NOUN F
surgery 0 NOUN F
in 0 ADP F
patients 0 NOUN F
with 0 ADP F
angina 0 NOUN F
. 0 PUNCT F

The 0 DET T
Randomised 0 ADV T
Intervention 0 NOUN T
Treatment 0 NOUN T
of 0 ADP F
Angina 0 NOUN T
( 0 PUNCT F
RITA 0 NOUN T
) 0 PUNCT F
Trial 0 NOUN T
is 0 VERB F
a 0 DET F
prospective 0 ADJ F
, 0 PUNCT F
randomised 0 ADP F
study 0 NOUN F
to 0 PART F
compare 0 NOUN F
the 0 DET F
short 0 ADJ F
term 0 NOUN F
and 0 CCONJ F
long 0 ADJ F
term 0 NOUN F
effects 0 NOUN F
of 0 ADP F
percutaneous 0 ADJ F
transluminal 0 ADJ F
coronary 0 ADJ F
angioplasty 0 NOUN F
and 0 CCONJ F
coronary 0 ADJ F
artery 0 NOUN F
bypass 0 NOUN F
surgery 0 NOUN F
. 0 PUNCT F

During 0 ADP T
the 0 DET F
study 0 ADV F
a 0 DET F
register 0 NOUN F
of 0 ADP F
patients 0 NOUN F
undergoing 0 VERB F
coronary 0 ADJ F
arteriography 0 NOUN F
at 0 ADP F
the 0 DET F
fourteen 0 ADP F
participating 0 PUNCT F
centres 0 NOUN F
is 0 VERB F
being 0 VERB F
maintained 0 VERB F
to 0 PART F
assess 0 NOUN F
the 0 DET F
overall 0 ADJ F
context 0 NOUN F
of 0 ADP F
patient 0 NOUN F
recruitment 0 NOUN F
. 0 PUNCT F

Patients 0 NOUN T
with 0 ADP F
arteriographically 0 ADV F
proven 0 VERB F
coronary 0 ADJ F
artery 0 NOUN F
disease 0 NOUN F
are 0 VERB F
considered 0 VERB F
for 0 ADP F
the 0 DET F
trial 0 NOUN F
if 0 ADP F
the 0 DET F
participating 0 PUNCT F
cardiologist 0 NOUN F
and 0 CCONJ F
surgeon 0 NOUN F
agree 0 NOUN F
that 0 ADP F
equivalent 0 ADJ F
revascularisation 0 NOUN F
could 0 VERB F
be 0 VERB F
achieved 0 VERB F
by 0 ADP F
either 0 CCONJ F
treatment 0 NOUN F
method 0 NOUN F
. 0 PUNCT F

Patients 0 NOUN T
who 0 ADV F
satisfy 0 ADP F
the 0 DET F
trial 0 NOUN F
entry 0 NOUN F
criteria 0 NOUN F
are 0 VERB F
randomised 0 VERB F
to 0 ADP F
treatment 0 NOUN F
by 0 ADP F
coronary 0 ADJ F
angioplasty 0 NOUN F
or 0 CCONJ F
coronary 0 ADJ F
artery 0 NOUN F
bypass 0 NOUN F
surgery 0 NOUN F
, 0 PUNCT F
with 0 ADP F
prospective 0 ADJ F
stratification 0 NOUN F
into 0 ADP F
groups 0 NOUN F
with 0 ADP F
one 0 NUM F
, 0 PUNCT F
two 0 NUM F
, 0 PUNCT F
or 0 CCONJ F
three 0 NUM F
treatment 0 NOUN F
vessels 0 NOUN F
. 0 PUNCT F

Randomisation 0 NOUN T
implies 0 NOUN F
an 0 DET F
intention 0 NOUN F
to 0 PART F
treat 0 CCONJ F
the 0 DET F
patient 0 NOUN F
by 0 ADP F
the 0 DET F
assigned 0 VERB F
procedure 0 NOUN F
and 0 CCONJ F
the 0 DET F
analysis 0 NOUN F
of 0 ADP F
long 0 ADJ F
term 0 NOUN F
results 0 NOUN F
will 0 VERB F
include 0 VERB F
all 0 DET F
randomised 0 VERB F
cases 0 NOUN F
. 0 PUNCT F

The 0 DET T
trial 0 NOUN F
will 0 VERB F
recruit 0 VERB F
at 0 ADP F
least 0 ADV F
1000 0 NUM F
patients 0 NOUN F
who 0 DET F
will 0 ADP F
be 0 VERB F
followed 0 VERB F
for 0 ADP F
five 0 NUM F
years 0 NOUN F
. 0 PUNCT F

The 0 DET T
major 0 ADJ F
trial 0 NOUN F
end 0 NOUN F
points 0 NOUN F
include 0 VERB F
death B-MORTALITY NOUN F
, 0 PUNCT F
new B-PHYSICAL ADJ F
myocardial I-PHYSICAL ADJ F
infarction I-PHYSICAL NOUN F
, 0 PUNCT F
and 0 CCONJ F
new B-PHYSICAL ADJ F
coronary I-PHYSICAL ADJ F
angioplasty I-PHYSICAL NOUN F
or 0 CCONJ F
coronary B-PHYSICAL ADJ F
artery I-PHYSICAL NOUN F
bypass I-PHYSICAL NOUN F
procedures I-PHYSICAL NOUN F
. 0 PUNCT F

Other 0 ADJ T
outcome 0 NOUN F
measures 0 NOUN F
include 0 VERB F
symptom B-OTHER NOUN F
and 0 CCONJ F
employment B-OTHER ADJ F
status I-OTHER NOUN F
, 0 PUNCT F
quality 0 NOUN F
of 0 ADP F
life 0 NOUN F
, 0 PUNCT F
exercise B-PHYSICAL NOUN F
tolerance I-PHYSICAL NOUN F
, 0 PUNCT F
and 0 CCONJ F
left B-PHYSICAL ADJ F
ventricular I-PHYSICAL ADJ F
function I-PHYSICAL NOUN F
. 0 PUNCT F

Stapled B-OTHER ADP T
hemorrhoidopexy I-OTHER NOUN F
versus 0 CCONJ F
milligan-morgan B-OTHER NOUN F
hemorrhoidectomy I-OTHER NOUN F
: 0 PUNCT F
a 0 DET F
prospective 0 ADJ F
, 0 PUNCT F
randomized 0 VERB F
, 0 PUNCT F
multicenter 0 NOUN F
trial 0 NOUN F
with 0 ADP F
2-year 0 NOUN F
postoperative 0 ADJ F
follow 0 PUNCT F
up 0 ADJ F
. 0 PUNCT F

PURPOSE 0 NOUN T
The 0 DET T
purpose 0 NOUN F
of 0 ADP F
this 0 DET F
study 0 NOUN F
was 0 VERB F
to 0 ADV F
compare 0 NOUN F
the 0 DET F
outcome 0 NOUN F
of 0 ADP F
stapled B-OTHER VERB F
hemorrhoidopexy I-OTHER NOUN F
( 0 PUNCT F
SH 0 NOUN T
group 0 NOUN F
) 0 PUNCT F
performed 0 VERB F
using 0 VERB F
a 0 DET F
circular 0 ADJ F
stapler 0 PUNCT F
with 0 ADP F
that 0 PUNCT F
of 0 ADP F
the 0 DET F
Milligan-Morgan 0 NOUN T
technique 0 NOUN F
( 0 PUNCT F
MM 0 NOUN T
group 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
goals 0 NOUN F
of 0 ADP F
the 0 DET F
study 0 NOUN F
were 0 VERB F
to 0 PART F
evaluate 0 NOUN F
the 0 DET F
efficacy 0 NOUN F
and 0 CCONJ F
reproducibility B-OTHER NOUN F
of 0 ADP F
stapled 0 VERB F
hemorrhoidopexy 0 NOUN F
and 0 CCONJ F
define 0 PUNCT F
its 0 CCONJ F
place 0 NOUN F
among 0 ADP F
conventional 0 ADJ F
techniques 0 NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
A 0 PUNCT T
series 0 NOUN F
of 0 ADP F
134 0 NUM F
patients 0 NOUN F
were 0 VERB F
included 0 VERB F
at 0 ADP F
7 0 NUM F
hospital 0 NOUN F
centers 0 NOUN F
. 0 PUNCT F

They 0 PRON T
were 0 VERB F
randomized 0 VERB F
according 0 CCONJ F
to 0 ADP F
a 0 DET F
single-masked 0 PUNCT F
design 0 NOUN F
and 0 CCONJ F
stratified 0 VERB F
by 0 ADP F
center 0 NOUN F
( 0 PUNCT F
with 0 ADP F
balancing 0 ADP F
every 0 DET F
4 0 NUM F
patients 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

Patients 0 NOUN T
were 0 VERB F
clinically 0 ADV F
evaluated 0 VERB F
preoperatively 0 ADV F
and 0 CCONJ F
at 0 ADP F
6 0 NUM F
weeks 0 NOUN F
, 0 PUNCT F
1 0 NUM F
year 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
a 0 DET F
minimum 0 NOUN F
of 0 ADP F
2 0 NUM F
years 0 NOUN F
after 0 ADP F
treatment 0 NOUN F
. 0 PUNCT F

Patients 0 NOUN T
completed 0 ADV F
a 0 DET F
questionnaire 0 NOUN F
before 0 ADP F
and 0 CCONJ F
1 0 NUM F
year 0 NOUN F
after 0 ADP F
surgery 0 NOUN F
to 0 ADJ F
evaluate 0 ADP F
symptoms 0 NOUN F
, 0 PUNCT F
function 0 ADP F
, 0 PUNCT F
and 0 CCONJ F
overall 0 ADJ F
satisfaction 0 NOUN F
. 0 PUNCT F

RESULTS 0 PUNCT T
The 0 DET T
mean 0 NOUN F
follow-up 0 NOUN F
period 0 NOUN F
was 0 VERB F
2.21 0 NUM F
years 0 NOUN F
+/- 0 SYM F
0.26 0 NUM F
( 0 PUNCT F
1.89-3.07 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Nine 0 NUM T
patients 0 NOUN F
( 0 PUNCT F
7 0 NUM F
% 0 SYM F
) 0 PUNCT F
could 0 VERB F
not 0 ADV F
be 0 VERB F
monitored 0 VERB F
at 0 ADP F
1 0 NUM F
or 0 CCONJ F
2 0 NUM F
years 0 NOUN F
, 0 PUNCT F
but 0 CCONJ F
4 0 NUM F
of 0 ADP F
these 0 DET F
9 0 ADP F
nevertheless 0 ADV F
filled 0 VERB F
in 0 ADP F
the 0 DET F
1-year 0 ADJ F
questionnaire 0 NOUN F
. 0 PUNCT F

The 0 DET T
patients 0 NOUN F
in 0 ADP F
the 0 DET F
SH 0 NOUN T
group 0 NOUN F
experienced 0 VERB F
less 0 ADV F
postoperative B-PAIN ADJ F
pain/discomfort I-PAIN NOUN F
as 0 PUNCT F
scored 0 VERB F
by 0 ADP F
pain 0 NOUN F
during 0 ADP F
bowel B-PAIN NOUN F
movement I-PAIN NOUN F
( 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.001 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
total 0 ADJ F
analgesic B-OTHER ADP F
requirement I-OTHER NOUN F
over I-OTHER ADP F
the I-OTHER DET F
first I-OTHER ADJ F
3 I-OTHER NUM F
days I-OTHER NOUN F
( 0 PUNCT F
according 0 PUNCT F
to 0 ADP F
the 0 DET F
World 0 NOUN T
Health 0 NOUN T
Organization 0 NOUN T
[ 0 PUNCT F
WHO 0 NOUN T
] 0 PUNCT F
class 0 NOUN F
II 0 NUM T
analgesics 0 NOUN F
[ 0 PUNCT F
P 0 NOUN T
= 0 SYM F
0.002 0 NUM F
] 0 PUNCT F
; 0 PUNCT F
class 0 NOUN F
III 0 NUM T
[ 0 PUNCT F
P 0 NOUN T
= 0 SYM F
0.066 0 PUNCT F
] 0 PUNCT F
) 0 PUNCT F
, 0 PUNCT F
and 0 CCONJ F
per-patient 0 PUNCT F
consumption 0 NOUN F
frequency 0 NOUN F
of 0 ADP F
class 0 NOUN F
III 0 NUM T
analgesics 0 NOUN F
( 0 PUNCT F
P 0 NOUN T
= 0 SYM F
0.089 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

A 0 DET T
clear 0 ADJ F
difference 0 NOUN F
in 0 ADP F
morphine B-OTHER NOUN F
requirement I-OTHER NOUN F
became 0 VERB F
evident 0 ADJ F
after 0 ADP F
24 0 NUM F
hours 0 NOUN F
( 0 PUNCT F
P 0 NOUN T
= 0 SYM F
0.010 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Hospital B-PHYSICAL NOUN T
stay I-PHYSICAL NOUN F
was 0 VERB F
significantly 0 ADV F
shorter 0 PUNCT F
in 0 ADP F
the 0 DET F
SH 0 NOUN T
group 0 NOUN F
( 0 PUNCT F
SH 0 NOUN T
2.2 0 NUM F
+/- 0 SYM F
1.2 0 NUM F
[ 0 PUNCT F
0 0 NUM F
; 0 PUNCT F
5.0 0 NUM F
] 0 PUNCT F
versus 0 CCONJ F
MM 0 NOUN T
3.1 0 NUM F
+/- 0 SYM F
1.7 0 NUM F
[ 0 PUNCT F
1 0 NUM F
; 0 PUNCT F
8.0 0 NUM F
] 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.001 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

At 0 ADP T
1 0 NUM F
year 0 NOUN F
, 0 PUNCT F
no 0 DET F
differences 0 NOUN F
in 0 ADP F
the 0 DET F
resolution B-OTHER NOUN F
of I-OTHER ADP F
symptoms I-OTHER NOUN F
were 0 VERB F
observed 0 VERB F
between 0 ADP F
the 0 DET F
2 0 NUM F
groups 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
over 0 ADP F
2 0 NUM F
years 0 NOUN F
, 0 PUNCT F
the 0 DET F
overall B-ADVERSE-EFFECTS ADJ F
incidence 0 NOUN F
of B-ADVERSE-EFFECTS ADP F
complications B-ADVERSE-EFFECTS NOUN F
was 0 VERB F
the 0 DET F
same 0 ADJ F
, 0 PUNCT F
specifically 0 ADV F
fecaloma B-ADVERSE-EFFECTS NOUN F
( 0 PUNCT F
P 0 NOUN T
= 0 SYM F
0.003 0 NUM F
) 0 PUNCT F
in 0 ADP F
the 0 DET F
MM 0 NOUN T
group 0 NOUN F
and 0 CCONJ F
external B-ADVERSE-EFFECTS ADJ F
hemorrhoidal I-ADVERSE-EFFECTS ADJ F
thrombosis I-ADVERSE-EFFECTS NOUN F
( 0 PUNCT F
P 0 NOUN T
= 0 SYM F
0.006 0 NUM F
) 0 PUNCT F
in 0 ADP F
the 0 DET F
SH 0 NOUN T
group 0 NOUN F
. 0 PUNCT F

Impaired B-ADVERSE-EFFECTS VERB T
sphincter I-ADVERSE-EFFECTS NOUN F
function B-ADVERSE-EFFECTS NOUN F
was 0 VERB F
observed 0 VERB F
at 0 ADP F
1 0 NUM F
year 0 NOUN F
with 0 ADP F
no 0 DET F
significant 0 ADJ F
difference 0 NOUN F
between 0 ADP F
the 0 DET F
groups 0 NOUN F
for 0 ADP F
urgency 0 NOUN F
( 0 PUNCT F
12 0 NUM F
% 0 SYM F
) 0 PUNCT F
, 0 PUNCT F
continence 0 ADV F
problems 0 NOUN F
( 0 PUNCT F
10 0 NUM F
% 0 SYM F
) 0 PUNCT F
, 0 PUNCT F
or 0 CCONJ F
tenesmus 0 NOUN F
( 0 PUNCT F
3 0 NUM F
% 0 SYM F
) 0 PUNCT F
. 0 PUNCT F

No 0 DET T
patient 0 NOUN F
needed 0 VERB F
a 0 DET F
second 0 ADJ F
procedure 0 NOUN F
for 0 ADP F
recurrence 0 NOUN F
within 0 ADP F
2 0 NUM F
years 0 NOUN F
, 0 PUNCT F
although 0 ADP F
partial B-ADVERSE-EFFECTS ADJ F
residual 0 ADJ F
prolapse B-ADVERSE-EFFECTS NOUN F
was 0 VERB F
detected 0 VERB F
in 0 ADP F
4 0 NUM F
SH 0 NOUN T
patients 0 NOUN F
( 0 PUNCT F
7.5 0 NUM F
% 0 SYM F
) 0 PUNCT F
versus 0 CCONJ F
1 0 NUM F
MM 0 NOUN T
patient 0 NOUN F
( 0 PUNCT F
1.8 0 NUM F
% 0 SYM F
) 0 PUNCT F
( 0 PUNCT F
P 0 NOUN T
= 0 SYM F
0.194 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

CONCLUSION 0 NOUN T
Stapled 0 PUNCT T
hemorrhoidopexy 0 NOUN F
causes 0 ADV F
significantly 0 ADV F
less 0 PUNCT F

Assisted 0 VERB T
exercise 0 NOUN F
and 0 CCONJ F
bone 0 NOUN F
strength 0 NOUN F
in 0 ADP F
preterm 0 NOUN F
infants 0 NOUN F
. 0 PUNCT F

Studies 0 NOUN T
have 0 ADP F
previously 0 ADV F
demonstrated 0 VERB F
that 0 ADP F
brief 0 ADJ F
( 0 PUNCT F
4 0 NUM F
weeks 0 NOUN F
) 0 PUNCT F
passive 0 ADJ F
range-of-motion 0 NOUN F
exercise 0 NOUN F
is 0 VERB F
beneficial 0 ADJ F
for 0 ADP F
bone 0 NOUN F
development 0 NOUN F
in 0 ADP F
very 0 ADV F
low 0 ADJ F
birth 0 NOUN F
weight 0 NOUN F
( 0 PUNCT F
VLBW 0 NOUN T
) 0 PUNCT F
preterm 0 NOUN F
infants 0 NOUN F
. 0 PUNCT F

However 0 ADV T
, 0 PUNCT F
the 0 DET F
optimal 0 ADJ F
duration 0 NOUN F
of 0 ADP F
exercise 0 NOUN F
for 0 ADP F
bone 0 NOUN F
development 0 NOUN F
in 0 ADP F
preterm 0 NOUN F
infants 0 NOUN F
is 0 ADP F
yet 0 ADV F
unknown 0 VERB F
. 0 PUNCT F

The 0 DET T
aim 0 NOUN F
of 0 ADP F
the 0 DET F
present 0 ADJ F
study 0 NOUN F
was 0 VERB F
to 0 ADV F
examine 0 NOUN F
the 0 DET F
effect 0 NOUN F
of 0 ADP F
8 0 NUM F
weeks 0 NOUN F
of 0 ADP F
assisted 0 VERB F
exercise 0 NOUN F
on 0 ADP F
bone 0 NOUN F
strength 0 NOUN F
and 0 CCONJ F
metabolism 0 NOUN F
in 0 ADP F
VLBW 0 NOUN T
premature 0 ADJ F
infants 0 NOUN F
. 0 PUNCT F

Sixteen 0 NUM T
infants 0 NOUN F
( 0 PUNCT F
mean 0 NOUN F
+/- 0 SYM F
standard 0 ADJ F
error 0 NOUN F
of 0 ADP F
the 0 DET F
mean 0 NOUN F
birth 0 NOUN F
weight 0 NOUN F
1,009 0 NUM F
+/- 0 SYM F
55 0 NUM F
g 0 NOUN F
and 0 CCONJ F
gestational 0 ADJ F
age 0 NOUN F
27.3 0 NUM F
+/- 0 SYM F
0.3 0 NUM F
weeks 0 NOUN F
) 0 PUNCT F
were 0 VERB F
randomly 0 ADV F
assigned 0 VERB F
into 0 ADP F
exercise 0 NOUN F
( 0 PUNCT F
n 0 NOUN F
= 0 SYM F
8 0 NUM F
) 0 PUNCT F
and 0 CCONJ F
control 0 NOUN F
( 0 PUNCT F
n 0 NOUN F
= 0 SYM F
8 0 NUM F
) 0 PUNCT F
groups 0 NOUN F
. 0 PUNCT F

The 0 DET T
intervention 0 NOUN F
started 0 VERB F
at 0 ADP F
the 0 DET F
first 0 ADJ F
week 0 NOUN F
of 0 ADP F
life 0 NOUN F
and 0 CCONJ F
involved 0 ADP F
8 0 NUM F
weeks 0 NOUN F
of 0 ADP F
daily 0 PUNCT F
passive 0 ADJ F
extension 0 NOUN F
and 0 CCONJ F
flexion 0 NOUN F
range-of-motion 0 NOUN F
exercise 0 NOUN F
of 0 ADP F
the 0 DET F
upper 0 ADJ F
and 0 CCONJ F
lower 0 PUNCT F
extremities 0 NOUN F
. 0 PUNCT F

Biochemical B-PHYSICAL ADJ T
markers I-PHYSICAL NOUN F
of I-PHYSICAL ADP F
bone I-PHYSICAL NOUN F
turnover I-PHYSICAL NOUN F
were 0 VERB F
measured 0 VERB F
at 0 ADP F
enrollment 0 NOUN F
and 0 CCONJ F
after 0 ADP F
8 0 NUM F
weeks 0 NOUN F
. 0 PUNCT F

Bone B-PHYSICAL NOUN T
strength I-PHYSICAL NOUN F
was 0 VERB F
measured 0 VERB F
weekly 0 ADV F
by 0 ADP F
quantitative 0 ADJ F
ultrasound 0 NOUN F
measurement 0 NOUN F
of 0 ADP F
tibial B-PHYSICAL ADJ F
bone I-PHYSICAL NOUN F
speed I-PHYSICAL NOUN F
of I-PHYSICAL ADP F
sound I-PHYSICAL ADJ F
( 0 PUNCT F
SOS 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

Bone B-PHYSICAL NOUN T
SOS I-PHYSICAL NOUN T
decreased 0 VERB F
significantly 0 ADV F
in 0 ADP F
the 0 DET F
control 0 NOUN F
group 0 NOUN F
( 0 PUNCT F
-108.1 0 ADJ F
+/- 0 SYM F
33.7 0 NUM F
m/second 0 ADJ F
, 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.0001 0 NUM F
) 0 PUNCT F
during 0 ADP F
the 0 DET F
study 0 ADV F
period 0 NOUN F
, 0 PUNCT F
while 0 CCONJ F
remaining 0 PUNCT F
stable 0 ADJ F
in 0 ADP F
the 0 DET F
exercise 0 NOUN F
group 0 NOUN F
( 0 PUNCT F
11.3 0 NUM F
+/- 0 SYM F
22.8 0 NUM F
m/second 0 CCONJ F
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
main B-PHYSICAL ADJ F
beneficial I-PHYSICAL ADJ F
effect 0 NOUN F
of B-PHYSICAL ADP F
exercise B-PHYSICAL NOUN F
occurred 0 VERB F
in 0 ADP F
the 0 DET F
first 0 ADJ F
4 0 NUM F
weeks 0 NOUN F
of 0 ADP F
the 0 DET F
intervention 0 NOUN F
. 0 PUNCT F

There 0 PUNCT T
were 0 VERB F
no 0 DET F
significant 0 ADJ F
differences 0 NOUN F
in 0 ADP F
the 0 DET F
bone B-PHYSICAL NOUN F
turnover I-PHYSICAL NOUN F
marker I-PHYSICAL NOUN F
changes I-PHYSICAL NOUN F
between 0 ADP F
the 0 DET F
groups 0 NOUN F
. 0 PUNCT F

There 0 PUNCT T
is 0 VERB F
a 0 DET F
significant 0 ADJ F
postnatal B-PHYSICAL ADJ F
decrease 0 NOUN F
in B-PHYSICAL PUNCT F

Investigations 0 NOUN T
into 0 ADP F
the 0 DET F
potential 0 ADJ F
effects 0 NOUN F
of 0 ADP F
multiple 0 ADJ F
dose 0 NOUN F
ketorolac 0 CCONJ F
on 0 ADP F
the 0 DET F
pharmacokinetics B-PHYSICAL NOUN F
and 0 CCONJ F
pharmacodynamics B-PHYSICAL NOUN F
of I-PHYSICAL ADP F
racemic I-PHYSICAL ADJ F
warfarin I-PHYSICAL NOUN F
. 0 PUNCT F

1 0 NUM F
. 0 PUNCT F

The 0 DET T
potential 0 ADJ F
interaction 0 NOUN F
between 0 ADP F
racemic 0 ADJ F
warfarin 0 NOUN F
given 0 VERB F
as 0 ADP F
a 0 DET F
25 0 NUM F
mg 0 NOUN F
single 0 ADJ F
oral 0 ADJ F
dose 0 NOUN F
and 0 CCONJ F
chronically 0 ADV F
administered 0 ADP F
ketorolac 0 NOUN F
was 0 VERB F
studied 0 VERB F
in 0 ADP F
12 0 NUM F
young 0 ADJ F
healthy 0 ADJ F
male 0 NOUN F
volunteers 0 NOUN F
. 0 PUNCT F

2 0 NUM F
. 0 PUNCT F

Ketorolac 0 PUNCT T
produced 0 PUNCT F
no 0 DET F
major B-PHYSICAL ADJ F
change I-PHYSICAL NOUN F
in I-PHYSICAL ADP F
the I-PHYSICAL DET F
pharmacokinetics I-PHYSICAL NOUN F
of I-PHYSICAL ADP F
( 0 PUNCT F
R 0 NOUN T
) 0 PUNCT F
- B-PHYSICAL PUNCT F
or I-PHYSICAL CCONJ F
( 0 PUNCT F
S B-PHYSICAL NOUN T
) 0 PUNCT F
-warfarin B-PHYSICAL NOUN F
. 0 PUNCT F

3 0 NUM F
. 0 PUNCT F

Ketorolac 0 CCONJ T
did 0 PUNCT F
not B-PHYSICAL ADV F
alter I-PHYSICAL VERB F
the I-PHYSICAL PUNCT F

Patient-reported 0 VERB T
outcomes 0 NOUN F
after 0 ADP F
inguinal 0 ADJ F
herniorrhaphy 0 NOUN F
. 0 PUNCT F

BACKGROUND 0 NOUN T
Patient-reported 0 VERB T
outcomes 0 NOUN F
( 0 PUNCT F
PRO 0 NOUN T
) 0 PUNCT F
reflect 0 VERB F
the 0 DET F
functional 0 ADJ F
outcomes 0 NOUN F
of 0 ADP F
inguinal 0 ADJ F
herniorrhaphy 0 NOUN F
. 0 PUNCT F

We 0 PRON T
studied 0 VERB F
the 0 DET F
effect 0 NOUN F
of 0 ADP F
hernia 0 NOUN F
recurrence 0 NOUN F
and 0 CCONJ F
complications 0 NOUN F
on 0 ADP F
PRO 0 NOUN T
for 0 ADP F
participants 0 NOUN F
in 0 ADP F
the 0 DET F
Veterans 0 PUNCT T
Affairs 0 PUNCT T
trial 0 NOUN F
of 0 ADP F
Open 0 ADJ T
or 0 CCONJ F
Laparoscopic 0 ADJ T
Repair 0 NOUN T
of 0 ADP F
Inguinal 0 ADJ T
Hernia 0 NOUN T
. 0 PUNCT F

METHODS 0 NOUN T
Analyzed 0 PUNCT T
PRO 0 NOUN T
included 0 VERB F
( 0 PUNCT F
1 0 NUM F
) 0 PUNCT F
the 0 DET F
Medical 0 ADJ T
Outcomes 0 NOUN T
Study 0 PUNCT T
Short 0 ADJ T
Form 0 NOUN T
36 0 NUM F
, 0 PUNCT F
version 0 ADJ F
2 0 NUM F
, 0 PUNCT F
( 0 PUNCT F
2 0 NUM F
) 0 PUNCT F
the 0 DET F
Surgical 0 ADJ T
Pain 0 NOUN T
Scale 0 NOUN T
, 0 PUNCT F
( 0 PUNCT F
3 0 NUM F
) 0 PUNCT F
the 0 DET F
Activities 0 PUNCT T
Assessment 0 NOUN T
Scale 0 NOUN T
, 0 PUNCT F
and 0 CCONJ F
( 0 PUNCT F
4 0 NUM F
) 0 PUNCT F
patient 0 NOUN F
satisfaction 0 NOUN F
. 0 PUNCT F

Recurrences 0 NOUN T
and 0 CCONJ F
complications 0 NOUN F
were 0 VERB F
recorded 0 VERB F
at 0 ADP F
follow-up 0 NOUN F
visits 0 NOUN F
. 0 PUNCT F

Complications 0 NOUN T
were 0 VERB F
categorized 0 VERB F
by 0 ADP F
( 0 PUNCT F
1 0 NUM F
) 0 PUNCT F
hematoma/seroma B-PHYSICAL NOUN F
, 0 PUNCT F
( 0 PUNCT F
2 0 NUM F
) 0 PUNCT F
orchitis B-PHYSICAL NOUN F
, 0 PUNCT F
( 0 PUNCT F
3 0 NUM F
) 0 PUNCT F
neuralgia B-PHYSICAL NOUN F
, 0 PUNCT F
and 0 CCONJ F
( 0 PUNCT F
4 0 NUM F
) 0 PUNCT F
other 0 PUNCT F
. 0 PUNCT F

Univariate 0 ADJ T
and 0 CCONJ F
multivariable 0 ADJ F
regression 0 NOUN F
analyses 0 NOUN F
identified 0 PUNCT F
variables 0 NOUN F
significantly 0 ADV F
associated 0 VERB F
with 0 ADP F
postoperative 0 ADJ F
PRO 0 NOUN T
. 0 PUNCT F

RESULTS 0 NOUN T
Of 0 ADP T
the 0 DET F
1603 0 NUM F
patients 0 NOUN F
with 0 ADP F
PRO 0 NOUN T
data 0 NOUN F
, 0 PUNCT F
105 0 NUM F
had 0 PUNCT F
a 0 DET F
recurrence 0 NOUN F
and 0 CCONJ F
342 0 NUM F
had 0 VERB F
a 0 DET F
complication 0 NOUN F
at 0 ADP F
2 0 NUM F
years 0 NOUN F
. 0 PUNCT F

Multivariable 0 ADJ T
analyses 0 NOUN F
showed 0 VERB F
neuralgia B-PHYSICAL NOUN F
( 0 PUNCT F
P 0 NOUN T
< 0 SYM F
.0005 0 NUM F
) 0 PUNCT F
adversely 0 ADV F
affected 0 VERB F
all 0 DET F
PRO 0 NOUN T
, 0 PUNCT F
and 0 CCONJ F
recurrence 0 NOUN F
( 0 PUNCT F
P 0 NOUN T
< 0 SYM F
.05 0 NUM F
) 0 PUNCT F
affected 0 VERB F
patient-reported B-PAIN VERB F
pain I-PAIN NOUN F
, 0 PUNCT F
activity B-PHYSICAL NOUN F
, 0 PUNCT F
and 0 CCONJ F
satisfaction B-OTHER NOUN F
, 0 PUNCT F
but 0 CCONJ F
not 0 ADV F
the 0 PUNCT F
score 0 NOUN F
for 0 ADP F
the 0 DET F
Medical B-OTHER ADJ T
Outcomes I-OTHER NOUN T
Study I-OTHER PUNCT T
Short I-OTHER ADJ T
Form I-OTHER NOUN T
3 I-OTHER NUM F
. 0 PUNCT F

Patients 0 NOUN T
with 0 ADP F
a 0 DET F
recurrence 0 NOUN F
after 0 ADP F
open 0 ADJ F
repair 0 NOUN F
had 0 PUNCT F
more 0 DET F
pain B-PAIN NOUN F
than 0 PUNCT F
those 0 PUNCT F
with 0 ADP F
a 0 DET F
recurrence 0 NOUN F
after 0 ADP F
laparoscopic 0 ADJ F
repair 0 NOUN F
( 0 PUNCT F
P 0 NOUN T
= 0 SYM F
.0001 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Patients 0 NOUN T
with 0 ADP F
other 0 ADJ F
complications 0 NOUN F
after 0 ADP F
laparoscopic 0 ADJ F
repair 0 NOUN F
reported 0 DET F
more 0 DET F
pain B-PAIN NOUN F
and 0 CCONJ F
less B-PHYSICAL DET F
activity I-PHYSICAL NOUN F
than 0 PUNCT F
those 0 PUNCT F
with 0 ADP F
other 0 ADJ F
complications 0 NOUN F
after 0 ADP F
open 0 ADJ F
repair 0 NOUN F
( 0 PUNCT F
P 0 NOUN T
= 0 SYM F
.003 0 NUM F
and 0 CCONJ F
P 0 NOUN T
= 0 SYM F
.009 0 NUM F
, 0 PUNCT F
respectively 0 ADV F
) 0 PUNCT F
. 0 PUNCT F

CONCLUSIONS 0 NOUN T
The 0 DET T
effectiveness 0 NOUN F
of 0 ADP F
inguinal 0 ADJ F
herniorrhaphy 0 NOUN F
should 0 VERB F
be 0 VERB F
measured 0 VERB F
by 0 ADP F
the 0 DET F
rate 0 NOUN F
of 0 ADP F
recurrence B-PHYSICAL NOUN F
and 0 CCONJ F
neuralgia B-PHYSICAL NOUN F
. 0 PUNCT F

Postoperative 0 ADJ T
neuralgias 0 PROPN F
have 0 ADP F
a 0 DET F
deleterious 0 ADJ F
effect 0 NOUN F
on 0 ADP F
all 0 ADP F
patient-reported 0 VERB F
outcomes 0 NOUN F
. 0 PUNCT F

Reduced 0 VERB T
cardiotoxicity 0 NOUN F
and 0 CCONJ F
comparable 0 ADJ F
efficacy 0 NOUN F
in 0 ADP F
a 0 DET F
phase 0 NOUN F
III 0 NUM T
trial 0 NOUN F
of 0 ADP F
pegylated 0 VERB F
liposomal 0 ADJ F
doxorubicin 0 NOUN F
HCl 0 NOUN T
( 0 PUNCT F
CAELYX/Doxil 0 NOUN T
) 0 PUNCT F
versus 0 CCONJ F
conventional 0 ADJ F
doxorubicin 0 NOUN F
for 0 ADP F
first-line 0 NOUN F
treatment 0 NOUN F
of 0 ADP F
metastatic 0 ADJ F
breast 0 NOUN F
cancer 0 NOUN F
. 0 PUNCT F

BACKGROUND 0 NOUN T
This 0 DET T
study 0 NOUN F
was 0 VERB F
designed 0 VERB F
to 0 PART F
demonstrate 0 NOUN F
that 0 ADP F
efficacy 0 NOUN F
[ 0 PUNCT F
progression-free B-MORTALITY NOUN F
survival I-MORTALITY NOUN F
( I-MORTALITY PUNCT F
PFS I-MORTALITY NOUN T
) I-MORTALITY PUNCT F
] 0 PUNCT F
of 0 ADP F
CAELYX 0 NOUN T
[ 0 PUNCT F
pegylated 0 PROPN F
liposomal 0 ADJ F
doxorubicin 0 NOUN F
HCl 0 VERB T
( 0 PUNCT F
PLD 0 NOUN T
) 0 PUNCT F
] 0 PUNCT F
is 0 VERB F
non-inferior 0 ADJ F
to 0 ADP F
doxorubicin 0 NOUN F
with 0 ADP F
significantly 0 ADV F
less 0 DET F
cardiotoxicity 0 NOUN F
in 0 ADP F
first-line 0 NOUN F
treatment 0 NOUN F
of 0 ADP F
women 0 NOUN F
with 0 ADP F
metastatic 0 ADJ F
breast 0 NOUN F
cancer 0 NOUN F
( 0 PUNCT F
MBC 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

PATIENTS 0 NOUN T
AND 0 CCONJ T
METHODS 0 NOUN T
Women 0 NOUN T
( 0 PUNCT F
n=509 0 PUNCT F
) 0 PUNCT F
with 0 ADP F
MBC 0 NOUN T
and 0 CCONJ F
normal 0 ADJ F
cardiac 0 ADJ F
function 0 NOUN F
were 0 VERB F
randomized 0 VERB F
to 0 PART F
receive 0 NOUN F
either 0 PUNCT F
PLD 0 NOUN T
50 0 NUM F
mg/m2 0 NOUN F
( 0 PUNCT F
every 0 ADP F
4 0 NUM F
weeks 0 NOUN F
) 0 PUNCT F
or 0 CCONJ F
doxorubicin 0 NOUN F
60 0 PUNCT F
mg/m2 0 NOUN F
( 0 PUNCT F
every 0 ADP F
3 0 NUM F
weeks 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

Cardiac B-ADVERSE-EFFECTS ADJ T
event 0 NOUN F
rates B-ADVERSE-EFFECTS NOUN F
were 0 VERB F
based 0 VERB F
on 0 ADP F
reductions 0 NOUN F
in 0 ADP F
left 0 ADJ F
ventricular 0 ADJ F
ejection 0 NOUN F
fraction 0 NOUN F
as 0 ADP F
a 0 DET F
function 0 NOUN F
of 0 ADP F
cumulative 0 ADJ F
anthracycline 0 NOUN F
dose 0 NOUN F
. 0 PUNCT F

RESULTS 0 NOUN T
PLD 0 NOUN T
and 0 CCONJ F
doxorubicin 0 NOUN F
were 0 VERB F
comparable 0 ADJ F
with 0 ADP F
respect 0 NOUN F
to 0 ADP F
PFS B-MORTALITY NOUN T
[ 0 PUNCT F
6.9 0 ADJ F
versus 0 CCONJ F
7.8 0 NUM F
months 0 NOUN F
, 0 PUNCT F
respectively 0 ADV F
; 0 PUNCT F
hazard 0 NOUN F
ratio 0 NOUN F
( 0 PUNCT F
HR 0 NOUN T
) 0 PUNCT F
=1.00 0 NUM F
; 0 PUNCT F
95 0 NUM F
% 0 SYM F
confidence 0 NOUN F
interval 0 NOUN F
( 0 PUNCT F
CI 0 NOUN T
) 0 PUNCT F
0.82-1.22 0 NUM F
] 0 PUNCT F
. 0 PUNCT F

Subgroup 0 NOUN T
results 0 NOUN F
were 0 VERB F
consistent 0 ADJ F
. 0 PUNCT F

Overall B-ADVERSE-EFFECTS PUNCT T
risk 0 NOUN F
of B-ADVERSE-EFFECTS ADP F
cardiotoxicity B-ADVERSE-EFFECTS NOUN F
was 0 VERB F
significantly 0 ADV F
higher 0 PUNCT F
with 0 ADP F
doxorubicin 0 NOUN F
than 0 PUNCT F
PLD 0 NOUN T
( 0 PUNCT F
HR=3.16 0 NOUN T
; 0 PUNCT F
95 0 NUM F
% 0 SYM F
CI 0 NOUN T
1.58-6.31 0 NUM F
; 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.001 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Overall B-MORTALITY ADJ T
survival B-MORTALITY NOUN F
was 0 VERB F
similar 0 ADJ F
( 0 PUNCT F
21 0 NUM F
and 0 CCONJ F
22 0 NUM F
months 0 NOUN F
for 0 ADP F
PLD 0 NOUN T
and 0 CCONJ F
doxorubicin 0 NOUN F
, 0 PUNCT F
respectively 0 ADV F
; 0 PUNCT F
HR=0.94 0 NOUN T
; 0 PUNCT F
95 0 NUM F
% 0 SYM F
CI 0 NOUN T
0.74-1.19 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Alopecia B-ADVERSE-EFFECTS NOUN T
( 0 PUNCT F
overall 0 ADJ F
, 0 PUNCT F
66 0 NUM F
% 0 SYM F
versus 0 CCONJ F
20 0 NUM F
% 0 SYM F
; 0 PUNCT F
pronounced 0 VERB F
, 0 PUNCT F
54 0 NUM F
% 0 SYM F
versus 0 CCONJ F
7 0 NUM F
% 0 SYM F
) 0 PUNCT F
, 0 PUNCT F
nausea B-ADVERSE-EFFECTS NOUN F
( 0 PUNCT F
53 0 NUM F
% 0 SYM F
versus 0 CCONJ F
37 0 NUM F
% 0 SYM F
) 0 PUNCT F
, 0 PUNCT F
vomiting B-ADVERSE-EFFECTS ADP F
( 0 PUNCT F
31 0 NUM F
% 0 SYM F
versus 0 CCONJ F
19 0 NUM F
% 0 SYM F
) 0 PUNCT F
and 0 CCONJ F
neutropenia B-ADVERSE-EFFECTS NOUN F
( 0 PUNCT F
10 0 NUM F
% 0 SYM F
versus 0 CCONJ F
4 0 NUM F
% 0 SYM F
) 0 PUNCT F
were 0 VERB F
more 0 ADV F
often 0 ADV F
associated 0 VERB F
with 0 ADP F
doxorubicin 0 NOUN F
than 0 PUNCT F
PLD 0 NOUN T
. 0 PUNCT F

Palmar-plantar B-ADVERSE-EFFECTS NOUN T
erythrodysesthesia B-ADVERSE-EFFECTS NOUN F
( 0 PUNCT F
48 0 NUM F
% 0 SYM F
versus 0 CCONJ F
2 0 NUM F
% 0 SYM F
) 0 PUNCT F
, 0 PUNCT F
stomatitis B-ADVERSE-EFFECTS NOUN F
( 0 PUNCT F
22 0 NUM F
% 0 SYM F
versus 0 CCONJ F
15 0 NUM F
% 0 SYM F
) 0 PUNCT F
and 0 PUNCT F

[ 0 PUNCT F
Comparison 0 NOUN T
of 0 ADP F
the 0 DET F
efficacy/tolerability 0 NOUN F
ratio 0 NOUN F
of 0 ADP F
cibenzoline 0 NOUN F
and 0 CCONJ F
propafenone 0 NOUN F
in 0 ADP F
the 0 DET F
treatment 0 NOUN F
of 0 ADP F
ventricular 0 ADJ F
arrhythmia 0 NOUN F
] 0 PUNCT F
. 0 PUNCT F

Cibenzoline 0 NOUN T
( 0 PUNCT F
C 0 NOUN T
) 0 PUNCT F
was 0 VERB F
compared 0 VERB F
with 0 ADP F
propafenone 0 NOUN F
( 0 PUNCT F
P 0 NOUN T
) 0 PUNCT F
in 0 ADP F
18 0 NUM F
adult 0 NOUN F
patients 0 NOUN F
( 0 PUNCT F
7 0 NUM F
women 0 NOUN F
and 0 CCONJ F
11 0 NUM F
men 0 NOUN F
) 0 PUNCT F
aged 0 PUNCT F
50 0 NUM F
+/- 0 SYM F
7 0 NUM F
in 0 ADP F
double-blind 0 ADJ F
, 0 PUNCT F
placebo-controlled 0 VERB F
crossover 0 NOUN F
trial 0 NOUN F
. 0 PUNCT F

After 0 ADP T
a 0 DET F
therapeutic 0 ADJ F
wash-out 0 PUNCT F
period 0 NOUN F
corresponding 0 PUNCT F
to 0 ADP F
5 0 NUM F
times 0 NOUN F
the 0 DET F
half-life 0 NOUN F
of 0 ADP F
previous 0 ADJ F
anti-arrhythmic 0 ADJ F
drugs 0 NOUN F
, 0 PUNCT F
patients 0 NOUN F
with 0 ADP F
more 0 ADV F
than 0 CCONJ F
100 0 NUM F
premature 0 ADJ F
ventricular 0 ADJ F
contractions 0 NOUN F
( 0 PUNCT F
PVC 0 NOUN T
) 0 PUNCT F
per 0 ADP F
hour 0 NOUN F
in 0 ADP F
two 0 NUM F
24 0 NUM F
hour 0 NOUN F
Holter 0 NOUN T
records 0 NOUN F
obtained 0 VERB F
at 0 ADP F
an 0 DET F
interval 0 NOUN F
of 0 ADP F
7 0 NUM F
days 0 NOUN F
were 0 VERB F
treated 0 VERB F
in 0 ADP F
succession 0 NOUN F
and 0 CCONJ F
after 0 ADP F
randomised 0 PUNCT F
by 0 ADP F
C 0 NOUN T
( 0 PUNCT F
390 0 NUM F
mg/day 0 NOUN F
in 0 ADP F
3 0 NUM F
divided 0 VERB F
doses 0 NOUN F
) 0 PUNCT F
and 0 CCONJ F
P 0 NOUN T
( 0 PUNCT F
900 0 NUM F
mg/day 0 NOUN F
in 0 ADP F
3 0 NUM F
divided 0 VERB F
doses 0 NOUN F
) 0 PUNCT F
for 0 ADP F
a 0 DET F
period 0 NOUN F
of 0 ADP F
two 0 NUM F
weeks 0 NOUN F
, 0 PUNCT F
each 0 DET F
active 0 ADJ F
sequence 0 NOUN F
being 0 VERB F
followed 0 VERB F
by 0 ADP F
a 0 DET F
two 0 NUM F
week 0 NOUN F
wash-out 0 PUNCT F
period 0 NOUN F
. 0 PUNCT F

Efficacy 0 NOUN T
( 0 PUNCT F
based 0 ADP F
upon 0 ADP F
the 0 DET F
decrease 0 NOUN F
in 0 ADP F
PVC/hour 0 NOUN T
in 0 ADP F
a 0 DET F
24 0 NUM F
hour 0 NOUN F
Holter 0 NOUN T
) 0 PUNCT F
and 0 CCONJ F
tolerability 0 NOUN F
were 0 VERB F
evaluated 0 VERB F
at 0 ADP F
the 0 DET F
end 0 NOUN F
of 0 ADP F
each 0 DET F
sequence 0 NOUN F
, 0 PUNCT F
with 0 ADP F
samples 0 NOUN F
drawn 0 VERB F
at 0 ADP F
the 0 DET F
same 0 ADJ F
times 0 NOUN F
for 0 ADP F
assay 0 NOUN F
of 0 ADP F
the 0 DET F
study 0 ADJ F
drugs 0 NOUN F
. 0 PUNCT F

Three 0 NUM T
patients 0 NOUN F
dropped 0 NUM F
out 0 PUNCT F
of 0 ADP F
the 0 DET F
trial 0 NOUN F
, 0 PUNCT F
1 0 NUM F
with 0 ADP F
each 0 DET F
active 0 ADJ F
drug 0 NOUN F
( 0 PUNCT F
for 0 ADP F
epigastric B-PAIN ADJ F
pain I-PAIN NOUN F
) I-PAIN PUNCT F
and 0 CCONJ F
1 0 NUM F
with 0 ADP F
dummy 0 NOUN F
. 0 PUNCT F

No 0 DET T
significant 0 ADJ F
difference 0 NOUN F
was 0 VERB F
seen 0 VERB F
between 0 ADP F
the 0 DET F
two 0 NUM F
drugs 0 NOUN F
regarding 0 DET F
the 0 DET F
decrease 0 NOUN F
in 0 ADP F
the 0 DET F
total 0 ADJ F
number B-OTHER NOUN F
of I-OTHER ADP F
PVC/hour I-OTHER NOUN T
in 0 ADP F
the 0 DET F
15 0 NUM F
patients 0 NOUN F
completing 0 VERB F
the 0 DET F
cross-over 0 NOUN F
protocol 0 NOUN F
. 0 PUNCT F

A 0 DET T
reduction B-OTHER NOUN F
in I-OTHER ADP F
PVC/hour I-OTHER NOUN T
of 0 ADP F
more 0 ADV F
than 0 PUNCT F
70 0 NUM F
per 0 ADP F
cent 0 NUM F
was 0 VERB F
seen 0 VERB F
in 0 ADP F
7 0 NUM F
patients 0 NOUN F
with 0 ADP F
C 0 NOUN T
and 0 CCONJ F
in 0 ADP F
9 0 NUM F
patients 0 NOUN F
with 0 ADP F
P. 0 NOUN T
C B-OTHER NOUN T
was I-OTHER VERB F
better I-OTHER PUNCT F
tolerated I-OTHER ADP F
than 0 PUNCT F
P 0 NOUN T
on 0 ADP F
the 0 DET F
basis B-PHYSICAL NOUN F
of I-PHYSICAL ADP F
both I-PHYSICAL CCONJ F
clinical I-PHYSICAL ADJ F
and 0 CCONJ F
electrocardiographic B-PHYSICAL ADJ F
parameters I-PHYSICAL NOUN F
. 0 PUNCT F

One 0 NUM T
patient 0 NOUN F
developed 0 VERB F
troublesome 0 PUNCT F
adverse B-ADVERSE-EFFECTS ADJ F
reactions I-ADVERSE-EFFECTS NOUN F
with 0 ADP F
C 0 NOUN T
as 0 VERB F
compared 0 VERB F
with 0 ADP F
4 0 NUM F
patients 0 NOUN F
in 0 ADP F
the 0 DET F
case 0 NOUN F
of 0 ADP F
P. 0 NOUN T
A 0 NOUN T
more 0 ADV F
than 0 ADP F
20 0 NUM F
per B-PHYSICAL ADP F
cent I-PHYSICAL NUM F
increase 0 NOUN F
in B-PHYSICAL ADP F
QRS B-PHYSICAL NOUN T
was 0 VERB F
seen 0 VERB F
in 0 ADP F
7 0 NUM F
patients 0 NOUN F
with 0 ADP F
C 0 NOUN T
and 0 CCONJ F
in 0 ADP F
10 0 NUM F
patients 0 NOUN F
with 0 ADP F
P 0 NOUN T
, 0 PUNCT F
the 0 DET F
figures 0 NOUN F
for 0 ADP F
PR 0 NOUN T
being 0 ADV F
2 0 NUM F
and 0 CCONJ F
6 0 NUM F
patients 0 NOUN F
respectively 0 ADV F
. 0 PUNCT F

One 0 NUM T
patient 0 NOUN F
showed 0 VERB F
a 0 DET F
proarrhythmic 0 ADJ F
effect 0 NOUN F
with 0 ADP F
P. 0 NOUN T
Plasma 0 NOUN T
levels 0 NOUN F
of 0 ADP F
C 0 NOUN T
were 0 VERB F
significantly 0 ADV F
higher 0 PUNCT F
in 0 ADP F
responders 0 NOUN F
( 0 PUNCT F
328 0 NUM F
+/- 0 SYM F
149 0 NUM F
ng/ml 0 NOUN F
) 0 PUNCT F
than 0 PUNCT F
in 0 ADP F
non-responders 0 NOUN F
( 0 PUNCT F
137 0 NUM F
+/- 0 SYM F
41 0 NUM F
ng/ml 0 NOUN F
, 0 PUNCT F
p 0 NOUN F
less 0 ADV F
than 0 PUNCT F
0.05 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

No 0 DET T
significant 0 ADJ F
difference 0 NOUN F
was 0 VERB F
found 0 VERB F
concerning 0 ADP F
plasma 0 NOUN F
levels 0 NOUN F
of 0 ADP F
P 0 NOUN T
( 0 PUNCT F
578 0 NUM F
+/- 0 SYM F
477 0 NUM F
ng/ml 0 NOUN F
compared 0 VERB F
with 0 ADP F
646 0 NUM F
+/- 0 SYM F
457 0 NUM F
ng/ml 0 NOUN F
, 0 PUNCT F
p 0 NOUN F
greater 0 PUNCT F
than 0 PUNCT F
0.05 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

In 0 ADP T
conclusion 0 NOUN F
, 0 PUNCT F
the 0 PUNCT F

Retrograde 0 ADJ T
tracing 0 ADP F
and 0 CCONJ F
electrophysiological 0 ADJ F
findings 0 NOUN F
of 0 ADP F
collateral 0 ADJ F
sprouting 0 PUNCT F
after 0 PUNCT F
end-to-side 0 NUM F
neurorrhaphy 0 NOUN F
. 0 PUNCT F

The 0 DET T
aim 0 NOUN F
of 0 ADP F
this 0 DET F
study 0 NOUN F
was 0 VERB F
to 0 PART F
seek 0 PROPN F
more 0 DET F
potent 0 ADJ F
evidences 0 NOUN F
of 0 ADP F
collateral 0 ADJ F
sprouting 0 PUNCT F
for 0 ADP F
both 0 PUNCT F
motor 0 NOUN F
and 0 CCONJ F
sensory 0 ADJ F
nerve 0 NOUN F
fibres 0 NOUN F
after 0 ADP F
end-to-side 0 NUM F
neurorrhaphy 0 NOUN F
using 0 VERB F
a 0 DET F
modified 0 VERB F
double-labelling 0 VERB F
retrograde 0 ADJ F
tracing 0 ADP F
method 0 NOUN F
and 0 CCONJ F
to 0 PART F
investigate 0 NOUN F
the 0 DET F
function 0 NOUN F
of 0 ADP F
regenerated 0 PUNCT F
motor 0 NOUN F
axons 0 NOUN F
with 0 ADP F
electrophysiological 0 ADJ F
evaluation 0 NOUN F
. 0 PUNCT F

Four 0 PUNCT T
groups 0 NOUN F
( 0 PUNCT F
n=4 0 NOUN F
for 0 ADP F
each 0 DET F
group 0 NOUN F
) 0 PUNCT F
were 0 VERB F
used 0 VERB F
: 0 PUNCT F
end-to-end 0 NOUN F
coaptation 0 NOUN F
( 0 PUNCT F
six 0 NUM F
months 0 NOUN F
postoperatively 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
end-to-side 0 ADV F
coaptation 0 NOUN F
( 0 PUNCT F
four 0 NUM F
months 0 NOUN F
and 0 CCONJ F
six 0 NUM F
months 0 NOUN F
postoperatively 0 NUM F
) 0 PUNCT F
and 0 CCONJ F
normal 0 ADJ F
control 0 NOUN F
. 0 PUNCT F

Two 0 NUM T
fluorescent 0 ADJ F
tracers 0 NOUN F
( 0 PUNCT F
true 0 ADJ F
blue 0 ADJ F
and 0 CCONJ F
diamidino 0 PUNCT F
yellow 0 NOUN F
) 0 PUNCT F
were 0 VERB F
applied 0 VERB F
to 0 ADP F
the 0 DET F
proximal 0 ADJ F
ends 0 NOUN F
of 0 ADP F
tibial 0 ADJ F
and 0 CCONJ F
common 0 ADJ F
peroneal 0 NOUN F
nerves 0 NOUN F
, 0 PUNCT F
respectively 0 ADV F
after 0 ADP F
four 0 NUM F
or 0 CCONJ F
six 0 NUM F
months 0 NOUN F
of 0 ADP F
nerve 0 NOUN F
coaptation 0 NOUN F
. 0 PUNCT F

Five 0 NUM T
days 0 NOUN F
later 0 ADJ F
, 0 PUNCT F
we 0 ADP F
only 0 ADV F
found 0 PUNCT F
single-labelled B-PHYSICAL ADJ F
motor I-PHYSICAL NOUN F
and I-PHYSICAL CCONJ F
sensory I-PHYSICAL ADJ F
neurons I-PHYSICAL NOUN F
in 0 ADP F
the 0 DET F
normal 0 ADJ F
and 0 CCONJ F
end-to-end 0 NOUN F
coaptation 0 NOUN F
groups 0 NOUN F
, 0 PUNCT F
while 0 ADP F
some 0 DET F
dual-labelled 0 ADV F
neurons 0 NOUN F
can 0 VERB F
be 0 VERB F
identified 0 VERB F
in 0 ADP F
end-to-side 0 NUM F
coaptation 0 NOUN F
groups 0 NOUN F
. 0 PUNCT F

Four 0 NUM T
months 0 NOUN F
after 0 ADP F
surgery 0 NOUN F
, 0 PUNCT F
the 0 DET F
motor B-PHYSICAL NOUN F
nerve I-PHYSICAL NOUN F
conduction I-PHYSICAL NOUN F
velocity I-PHYSICAL NOUN F
in I-PHYSICAL ADP F
end-to-side I-PHYSICAL NOUN F
coaptation 0 NOUN F
was 0 VERB F
significantly 0 ADV F
slower 0 PUNCT F
than 0 CCONJ F
in 0 ADP F
the 0 DET F
normal 0 ADJ F
control 0 NOUN F
. 0 PUNCT F

But 0 CCONJ T
no 0 DET F
difference 0 NOUN F
was 0 VERB F
found 0 VERB F
in 0 ADP F
the 0 DET F
sixth 0 ADJ F
month 0 NOUN F
. 0 PUNCT F

These 0 DET T
results 0 CCONJ F
suggest 0 VERB F
that 0 ADP F
end-to-side 0 NUM F
neurorrhaphy 0 NOUN F
can 0 VERB F
induce 0 VERB F
the 0 DET F
functional 0 ADJ F
collateral 0 ADJ F
sprouting 0 PUNCT F
of 0 ADP F
both 0 PUNCT F
motor 0 NOUN F
and 0 CCONJ F
sensory 0 ADJ F
axons 0 NOUN F
in 0 ADP F
the 0 DET F
peripheral 0 ADJ F
nerve 0 NOUN F
. 0 PUNCT F

The 0 DET T
impact 0 NOUN F
of 0 ADP F
angiotensin 0 NOUN F
II 0 NUM T
receptor 0 NOUN F
blockade 0 NOUN F
and 0 CCONJ F
the 0 DET F
DASH 0 NOUN T
diet 0 NOUN F
on 0 ADP F
markers B-PHYSICAL NOUN F
of 0 ADP F
endogenous 0 ADJ F
fibrinolysis 0 NOUN F
. 0 PUNCT F

Hypertension 0 NOUN T
is 0 VERB F
associated 0 VERB F
with 0 ADP F
impaired 0 VERB F
fibrinolysis 0 NOUN F
. 0 PUNCT F

Both 0 CCONJ T
angiotensin 0 NOUN F
receptor 0 NOUN F
blockers 0 NOUN F
( 0 PUNCT F
ARB 0 NOUN T
) 0 PUNCT F
and 0 CCONJ F
the 0 DET F
DASH 0 NOUN T
( 0 PUNCT F
Dietary 0 ADJ T
Approaches 0 PROPN T
to 0 VERB F
Stop 0 PUNCT T
Hypertension 0 NOUN T
) 0 PUNCT F
diet 0 NOUN F
effectively 0 ADV F
lower 0 ADP F
blood B-PHYSICAL NOUN F
pressure I-PHYSICAL NOUN F
in 0 ADP F
hypertensive 0 ADJ F
patients 0 NOUN F
. 0 PUNCT F

Some 0 DET T
evidence 0 NOUN F
suggests 0 NOUN F
that 0 ADP F
treatment 0 NOUN F
with 0 ADP F
ARBs 0 NOUN T
could 0 VERB F
increase 0 VERB F
fibrinolysis 0 NOUN F
, 0 PUNCT F
however 0 ADV F
, 0 PUNCT F
data 0 NOUN F
is 0 VERB F
conflicting 0 ADJ F
. 0 PUNCT F

The 0 DET T
impact 0 NOUN F
of 0 ADP F
the 0 DET F
DASH 0 NOUN T
diet 0 NOUN F
on 0 ADP F
fibrinolytic B-PHYSICAL ADJ F
parameters I-PHYSICAL NOUN F
is 0 VERB F
not 0 ADV F
known 0 VERB F
. 0 PUNCT F

Fifty-five 0 ADJ T
hypertensive 0 ADJ F
participants 0 NOUN F
( 0 PUNCT F
35 0 NUM F
African-American 0 ADJ T
, 0 PUNCT F
20 0 NUM F
white 0 ADJ F
) 0 PUNCT F
were 0 VERB F
randomly 0 ADV F
assigned 0 VERB F
to 0 PART F
receive 0 NOUN F
8 0 NUM F
weeks 0 NOUN F
of 0 ADP F
either 0 CCONJ F
a 0 DET F
control 0 NOUN F
diet 0 NOUN F
or 0 CCONJ F
the 0 DET F
DASH 0 NOUN T
diet 0 NOUN F
. 0 PUNCT F

The 0 DET T
diets 0 NOUN F
did 0 CCONJ F
not 0 ADV F
differ 0 VERB F
in 0 ADP F
sodium 0 NOUN F
content 0 NOUN F
( 0 PUNCT F
approximately 0 ADV F
3 0 NUM F
g/day 0 PUNCT F
) 0 PUNCT F
. 0 PUNCT F

Within 0 ADP T
each 0 DET F
diet 0 NOUN F
, 0 PUNCT F
individuals 0 NOUN F
were 0 VERB F
randomly 0 ADV F
assigned 0 VERB F
to 0 PART F
receive 0 NOUN F
losartan 0 NOUN F
or 0 CCONJ F
placebo 0 NOUN F
for 0 ADP F
4 0 NUM F
weeks 0 NOUN F
in 0 ADP F
double-blind 0 ADJ F
, 0 PUNCT F
cross-over 0 NOUN F
fashion 0 NOUN F
. 0 PUNCT F

Tissue B-PHYSICAL NOUN T
plasminogen I-PHYSICAL NOUN F
activator I-PHYSICAL NOUN F
( I-PHYSICAL PUNCT F
t-PA I-PHYSICAL NOUN F
) I-PHYSICAL PUNCT F
antigen I-PHYSICAL NOUN F
, 0 PUNCT F
t-PA B-PHYSICAL NOUN F
activity I-PHYSICAL NOUN F
, 0 PUNCT F
plasminogen B-PHYSICAL NOUN F
activator I-PHYSICAL NOUN F
inhibitor-1 I-PHYSICAL NOUN F
( I-PHYSICAL PUNCT F
PAI-1 I-PHYSICAL NOUN T
) I-PHYSICAL PUNCT F
activity I-PHYSICAL NOUN F
and 0 CCONJ F
plasma B-PHYSICAL NOUN F
renin I-PHYSICAL NOUN F
activity I-PHYSICAL NOUN F
( I-PHYSICAL PUNCT F
PRA I-PHYSICAL NOUN T
) I-PHYSICAL PUNCT F
were 0 VERB F
measured 0 VERB F
at 0 ADP F
the 0 DET F
end 0 NOUN F
of 0 ADP F
a 0 DET F
2-week 0 NOUN F
run-in 0 NOUN F
period 0 NOUN F
on 0 ADP F
the 0 DET F
control 0 NOUN F
diet 0 NOUN F
and 0 CCONJ F
after 0 ADP F
each 0 DET F
treatment 0 NOUN F
period 0 NOUN F
. 0 PUNCT F

The 0 DET T
DASH 0 NOUN T
diet 0 NOUN F
did 0 DET F
not 0 ADV F
affect 0 VERB F
markers 0 NOUN F
of 0 ADP F
fibrinolysis 0 NOUN F
. 0 PUNCT F

Losartan 0 NOUN T
significantly 0 ADV F
lowered 0 ADJ F
t-PA B-PHYSICAL NOUN F
antigen I-PHYSICAL NOUN F
levels I-PHYSICAL NOUN F
( 0 PUNCT F
-1.8 0 ADP F
ng/mL 0 NOUN F
, 0 PUNCT F
P 0 NOUN T
= 0 SYM F
0.045 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
but 0 CCONJ F
had 0 VERB F
no 0 DET F
effect 0 NOUN F
on 0 ADP F
t-PA B-PHYSICAL NOUN F
or 0 CCONJ F
PAI-1 B-PHYSICAL NOUN T
activities I-PHYSICAL NOUN F
. 0 PUNCT F

This 0 DET T
effect 0 NOUN F
was 0 VERB F
more 0 ADV F
pronounced 0 VERB F
in 0 ADP F
whites 0 PUNCT F
( 0 PUNCT F
-4.1 0 PUNCT F
ng/mL 0 NOUN F
( 0 PUNCT F
P 0 NOUN T
= 0 SYM F
0.003 0 NUM F
) 0 PUNCT F
) 0 PUNCT F
compared 0 VERB F
with 0 ADP F
African-Americans 0 VERB T
( 0 PUNCT F
-0.3 0 PUNCT F
ng/mL 0 NOUN F
( 0 PUNCT F
P 0 NOUN T
= 0 SYM F
0.7 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
P-interaction 0 NOUN T
= 0 SYM F
0.03 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Results 0 NOUN T
were 0 VERB F
not 0 ADV F
materially 0 PUNCT F
affected 0 VERB F
by 0 ADP F
adjustment 0 NOUN F
for 0 ADP F
basline 0 NOUN F
values 0 NOUN F
or 0 CCONJ F
changes 0 NOUN F
in 0 ADP F
blood B-PHYSICAL NOUN F
pressure I-PHYSICAL NOUN F
. 0 PUNCT F

This 0 DET T
study 0 NOUN F
demonstrates 0 NOUN F
that 0 ADP F
losartan 0 NOUN F
reduces 0 NOUN F
t-PA B-PHYSICAL NOUN F
antigen I-PHYSICAL NOUN F
levels I-PHYSICAL NOUN F
in 0 ADP F
white 0 NOUN F
, 0 PUNCT F
but 0 CCONJ F
not 0 ADV F
African-American 0 ADJ T
hypertensive 0 ADJ F
individuals 0 NOUN F
. 0 PUNCT F

In 0 ADP T
contrast 0 NOUN F
, 0 PUNCT F
the 0 DET F
DASH 0 NOUN T
diet 0 NOUN F
had 0 PUNCT F
no 0 DET F
significant 0 ADJ F
effect 0 NOUN F
on 0 ADP F
markers B-PHYSICAL NOUN F
of I-PHYSICAL ADP F
fibrinolysis I-PHYSICAL NOUN F
in 0 ADP F
whites 0 PUNCT F
or 0 CCONJ F
African-Americans 0 PUNCT T
. 0 PUNCT F

Influence 0 NOUN T
of 0 ADP F
phase-related 0 VERB F
variability 0 NOUN F
in 0 ADP F
premenstrual B-PHYSICAL ADJ F
symptomatology I-PHYSICAL NOUN F
, 0 PUNCT F
mood B-PHYSICAL PUNCT F
, 0 PUNCT F
smoking B-PHYSICAL PUNCT F
withdrawal I-PHYSICAL NOUN F
, 0 PUNCT F
and 0 PUNCT F

Randomized 0 VERB T
clinical 0 ADJ F
trial 0 NOUN F
of 0 ADP F
tamoxifen 0 NOUN F
plus 0 CCONJ F
sequential 0 ADJ F
CMF 0 NOUN T
chemotherapy 0 NOUN F
versus 0 CCONJ F
tamoxifen 0 NOUN F
alone 0 ADJ F
in 0 ADP F
postmenopausal 0 ADJ F
women 0 NOUN F
with 0 ADP F
advanced 0 VERB F
breast 0 NOUN F
cancer 0 NOUN F
. 0 PUNCT F

Eighty-eight 0 PUNCT T
postmenopausal 0 ADJ F
women 0 NOUN F
with 0 ADP F
metastatic 0 ADJ F
breast 0 NOUN F
cancer 0 NOUN F
, 0 PUNCT F
in 0 ADP F
whom 0 ADP F
estrogen 0 NOUN F
receptors 0 NOUN F
( 0 PUNCT F
ER 0 NOUN T
) 0 PUNCT F
were 0 VERB F
positive 0 ADJ F
or 0 CCONJ F
unknown 0 VERB F
, 0 PUNCT F
were 0 VERB F
treated 0 VERB F
on 0 ADP F
a 0 DET F
controlled 0 VERB F
trial 0 NOUN F
to 0 PART F
determine 0 NOUN F
the 0 DET F
effectiveness 0 NOUN F
of 0 ADP F
tamoxifen 0 NOUN F
and 0 CCONJ F
to 0 PART F
assess 0 NOUN F
the 0 DET F
therapeutic B-OTHER ADJ F
advantage I-OTHER NOUN F
of 0 ADP F
sequentially 0 ADV F
adding 0 VERB F
low-dose 0 NOUN F
cyclophosphamide-methotrexate-5-fluorouracil 0 NOUN F
( 0 PUNCT F
CMF 0 NOUN T
) 0 PUNCT F
chemotherapy 0 NOUN F
in 0 ADP F
tamoxifen 0 NOUN F
responders 0 NOUN F
. 0 PUNCT F

Patients 0 NOUN T
with 0 ADP F
known 0 PUNCT F
ER 0 NOUN T
negative 0 ADJ F
status 0 NOUN F
were 0 VERB F
not 0 ADV F
studied 0 VERB F
. 0 PUNCT F

After 0 ADP T
the 0 DET F
initial 0 ADJ F
12-week 0 NOUN F
treatment 0 NOUN F
with 0 ADP F
tamoxifen 0 NOUN F
alone 0 ADJ F
, 0 PUNCT F
60 0 NUM F
% 0 SYM F
of 0 ADP F
ER 0 NOUN T
positive 0 ADJ F
patients 0 NOUN F
achieved 0 ADP F
complete B-OTHER ADJ F
or I-OTHER CCONJ F
partial I-OTHER ADJ F
response I-OTHER NOUN F
as 0 PUNCT F
did 0 PUNCT F
35 0 NUM F
% 0 SYM F
in 0 ADP F
whom 0 ADP F
ER 0 NOUN T
were 0 VERB F
unknown 0 VERB F
. 0 PUNCT F

Response 0 NOUN T
status 0 NOUN F
further 0 ADV F
improved 0 VERB F
in 0 ADP F
18 0 NUM F
% 0 SYM F
randomized 0 VERB F
to 0 PART F
continue 0 PROPN F
tamoxifen 0 NOUN F
alone 0 ADJ F
vs 0 CCONJ F
31 0 NUM F
% 0 SYM F
in 0 ADP F
whom 0 ADP F
CMF 0 NOUN T
was 0 VERB F
added 0 VERB F
to 0 ADP F
tamoxifen 0 NOUN F
. 0 PUNCT F

There 0 PUNCT T
were 0 VERB F
no 0 DET F
statistically 0 ADV F
significant 0 ADJ F
differences 0 NOUN F
in 0 ADP F
time 0 NOUN F
to 0 ADP F
the 0 DET F
development 0 NOUN F
of 0 ADP F
progressive B-PHYSICAL ADJ F
disease I-PHYSICAL NOUN F
or 0 CCONJ F
survival B-MORTALITY NOUN F
between 0 ADP F
the 0 DET F
ER 0 NOUN T
positive 0 ADJ F
and 0 CCONJ F
ER 0 NOUN T
unknown 0 ADJ F
patients 0 NOUN F
or 0 CCONJ F
between 0 ADP F
the 0 DET F
tamoxifen 0 NOUN F
and 0 CCONJ F
tamoxifen 0 NOUN F
plus 0 CCONJ F
CMF 0 NOUN T
groups 0 NOUN F
. 0 PUNCT F

We 0 PRON T
conclude 0 VERB F
that 0 ADP F
inability 0 NOUN F
to 0 PART F
determine 0 NOUN F
ER 0 NOUN T
status 0 NOUN F
should 0 VERB F
not 0 PUNCT F
prejudice 0 PUNCT F
against 0 ADP F
the 0 DET F
use 0 NOUN F
of 0 ADP F
tamoxifen 0 NOUN F
in 0 ADP F
postmenopausal 0 ADJ F
patients 0 NOUN F
with 0 ADP F
advanced 0 VERB F
breast 0 NOUN F
cancer 0 NOUN F
. 0 PUNCT F

No 0 DET T
benefit 0 NOUN F
has 0 PUNCT F
been 0 PUNCT F
demonstrated 0 VERB F
from 0 ADP F
the 0 DET F
addition 0 NOUN F
of 0 ADP F
CMF 0 NOUN T
chemotherapy 0 NOUN F
in 0 ADP F
tamoxifen 0 NOUN F
responders 0 NOUN F
. 0 PUNCT F

A 0 DET T
randomized 0 VERB F
surveillance 0 NOUN F
study 0 NOUN F
of 0 ADP F
patients 0 NOUN F
with 0 ADP F
pedunculated 0 VERB F
and 0 CCONJ F
small 0 ADJ F
sessile 0 ADJ F
tubular 0 ADJ F
and 0 CCONJ F
tubulovillous 0 ADJ F
adenomas 0 NOUN F
. 0 PUNCT F

The 0 DET T
Funen 0 NOUN T
Adenoma 0 NOUN T
Follow-up 0 NOUN T
Study 0 NOUN T
. 0 PUNCT F

BACKGROUND 0 NOUN T
We 0 PRON T
wanted 0 VERB F
to 0 PART F
assess 0 NOUN F
the 0 DET F
influence 0 NOUN F
of 0 ADP F
various 0 ADJ F
surveillance 0 NOUN F
intervals 0 NOUN F
on 0 ADP F
the 0 DET F
risk 0 NOUN F
of 0 ADP F
new B-PHYSICAL ADJ F
neoplasia I-PHYSICAL NOUN F
after 0 ADP F
removal 0 NOUN F
of 0 ADP F
pedunculated 0 ADP F
and 0 CCONJ F
small 0 ADJ F
sessile 0 ADJ F
tubular 0 ADJ F
and 0 CCONJ F
tubulovillous 0 ADJ F
adenomas 0 NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
After 0 ADP T
initial 0 ADJ F
colonoscopic 0 PUNCT F
polypectomy 0 NOUN F
patients 0 NOUN F
were 0 VERB F
randomized 0 VERB F
to 0 ADP F
surveillance 0 NOUN F
with 0 ADP F
either 0 CCONJ F
2 0 NUM F
years 0 NOUN F
( 0 PUNCT F
group 0 NOUN F
A 0 NOUN T
) 0 PUNCT F
or 0 CCONJ F
4 0 NUM F
years 0 NOUN F
( 0 PUNCT F
group 0 NOUN F
B 0 NOUN T
) 0 PUNCT F
between 0 ADP F
colorectal 0 ADJ F
examinations 0 NOUN F
. 0 PUNCT F

RESULTS 0 PUNCT T
The 0 DET T
cumulated 0 PUNCT F
risk 0 NOUN F
of 0 ADP F
a B-PHYSICAL DET F
patient I-PHYSICAL NOUN F
having I-PHYSICAL PUNCT F
new I-PHYSICAL ADJ F
adenomas I-PHYSICAL NOUN F
was 0 VERB F
35.0 0 NUM F
% 0 SYM F
( 0 PUNCT F
28.7-41.4 0 NUM F
% 0 SYM F
) 0 PUNCT F
in 0 ADP F
group 0 NOUN F
A 0 NOUN T
and 0 CCONJ F
35.5 0 NUM F
% 0 SYM F
( 0 PUNCT F
28.4-42.7 0 NUM F
% 0 SYM F
) 0 PUNCT F
in 0 ADP F
group 0 NOUN F
B 0 NOUN T
after 0 ADP F
48 0 NUM F
months 0 NOUN F
. 0 PUNCT F

The 0 DET T
risk 0 NOUN F
increased 0 VERB F
to 0 ADP F
44.9 0 ADV F
% 0 ADJ F
( 0 PUNCT F
36.0-53.9 0 NUM F
% 0 ADP F
) 0 PUNCT F
and 0 CCONJ F
60.1 0 NUM F
% 0 SYM F
( 0 PUNCT F
48.5-71.7 0 NUM F
% 0 SYM F
) 0 PUNCT F
, 0 PUNCT F
respectively 0 ADV F
, 0 PUNCT F
after 0 ADP F
96 0 NUM F
months 0 NOUN F
. 0 PUNCT F

The 0 DET T
risk 0 NOUN F
of 0 ADP F
significant B-PHYSICAL ADJ F
neoplasia I-PHYSICAL NOUN F
( 0 PUNCT F
carcinoma B-PHYSICAL NOUN F
or 0 CCONJ F
adenoma B-PHYSICAL NOUN F
with I-PHYSICAL ADP F
villous I-PHYSICAL ADJ F
structure 0 NOUN F
, 0 PUNCT F
severe B-PHYSICAL ADJ F
dysplasia I-PHYSICAL NOUN F
, 0 PUNCT F
or 0 CCONJ F
diameter 0 NOUN F
> 0 SYM F
10 0 NUM F
mm 0 NOUN F
) 0 PUNCT F
was 0 VERB F
5.2 0 NUM F
% 0 SYM F
( 0 PUNCT F
2.3-8.1 0 NUM F
% 0 SYM F
) 0 PUNCT F
and 0 CCONJ F
8.6 0 NUM F
% 0 SYM F
( 0 PUNCT F
3.8-13.3 0 NUM F
% 0 SYM F
) 0 PUNCT F
after 0 ADP F
48 0 NUM F
months 0 NOUN F
and 0 CCONJ F
8.6 0 NUM F
% 0 SYM F
( 0 PUNCT F
4.2-13.0 0 ADV F
% 0 SYM F
) 0 PUNCT F
and 0 CCONJ F
17.4 0 NUM F
% 0 SYM F
( 0 PUNCT F
7.6-27.2 0 ADP F
% 0 SYM F
) 0 PUNCT F
after 0 ADP F
96 0 NUM F
months 0 NOUN F
. 0 PUNCT F

More 0 DET T
than 0 ADP F
one 0 NUM F
adenoma 0 NOUN F
at 0 ADP F
first 0 ADJ F
examination 0 NOUN F
was 0 VERB F
associated 0 VERB F
with 0 ADP F
higher 0 PUNCT F
risk 0 PUNCT F

Cost-effectiveness 0 NOUN T
of 0 ADP F
clopidogrel 0 NOUN F
in 0 ADP F
acute 0 ADJ F
coronary 0 ADJ F
syndromes 0 NOUN F
in 0 ADP F
Canada 0 PUNCT T
: 0 PUNCT F
a 0 DET F
long-term 0 NOUN F
analysis 0 NOUN F
based 0 VERB F
on 0 ADP F
the 0 DET F
CURE 0 NOUN T
trial 0 NOUN F
. 0 PUNCT F

BACKGROUND 0 NOUN T
Cardiovascular 0 ADJ T
diseases 0 NOUN F
account 0 VERB F
for 0 ADP F
nearly 0 ADV F
20 0 NUM F
% 0 SYM F
of 0 ADP F
all 0 DET F
hospitalizations 0 NOUN F
in 0 ADP F
Canada 0 PUNCT T
and 0 CCONJ F
consume 0 PUNCT F
12 0 NUM F
% 0 SYM F
of 0 ADP F
the 0 DET F
total 0 ADJ F
cost 0 NOUN F
of 0 ADP F
all 0 DET F
illnesses 0 NOUN F
. 0 PUNCT F

With 0 ADP T
increasing 0 ADJ F
trends 0 NOUN F
of 0 ADP F
cardiovascular 0 ADJ F
disease 0 NOUN F
and 0 CCONJ F
increasing 0 PUNCT F
costs 0 NOUN F
of 0 ADP F
care 0 NOUN F
, 0 PUNCT F
development 0 NOUN F
of 0 ADP F
cost-effective 0 ADJ F
strategies 0 NOUN F
is 0 VERB F
vital 0 ADJ F
. 0 PUNCT F

The 0 DET T
Clopidogrel 0 NOUN T
in 0 ADP F
Unstable 0 ADJ T
angina 0 NOUN F
to 0 PART F
prevent 0 VERB F
Recurrent 0 ADJ T
Events 0 NOUN T
( 0 PUNCT F
CURE 0 NOUN T
) 0 PUNCT F
trial 0 NOUN F
demonstrated 0 VERB F
the 0 DET F
effectiveness 0 NOUN F
of 0 ADP F
clopidogrel 0 NOUN F
plus 0 CCONJ F
acetylsalicylic 0 ADJ F
acid 0 NOUN F
( 0 PUNCT F
ASA 0 NOUN T
) 0 PUNCT F
compared 0 VERB F
with 0 ADP F
ASA 0 NOUN T
alone 0 ADJ F
in 0 ADP F
reducing 0 VERB F
cardiovascular 0 ADJ F
events 0 NOUN F
in 0 ADP F
patients 0 NOUN F
with 0 ADP F
acute 0 ADJ F
coronary 0 ADJ F
syndromes 0 NOUN F
and 0 CCONJ F
, 0 PUNCT F
in 0 ADP F
addition 0 NOUN F
, 0 PUNCT F
patients 0 NOUN F
undergoing 0 VERB F
percutaneous 0 ADJ F
coronary 0 ADJ F
intervention 0 NOUN F
in 0 ADP F
the 0 DET F
Percutaneous 0 ADJ T
Coronary 0 ADJ T
Intervention 0 NOUN T
in 0 ADP F
CURE 0 NOUN T
( 0 PUNCT F
PCI-CURE 0 NOUN T
) 0 PUNCT F
trial 0 NOUN F
. 0 PUNCT F

OBJECTIVE 0 NOUN T
To 0 PROPN T
assess 0 NOUN F
the 0 DET F
cost-effectiveness 0 NOUN F
of 0 ADP F
clopidogrel 0 NOUN F
in 0 ADP F
the 0 DET F
Canadian 0 ADJ T
health 0 NOUN F
care 0 NOUN F
system 0 NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
Estimates 0 NOUN T
of 0 ADP F
hospitalization 0 NOUN F
costs 0 NOUN F
were 0 VERB F
based 0 VERB F
on 0 ADP F
the 0 DET F
2003 0 NUM F
cost 0 NOUN F
schedules 0 NOUN F
released 0 VERB F
by 0 ADP F
the 0 DET F
Health 0 NOUN T
Funding 0 PUNCT T
and 0 CCONJ F
Costing 0 PUNCT T
Branch 0 NOUN T
of 0 ADP F
the 0 DET F
Alberta 0 PUNCT T
Health 0 NOUN T
and 0 CCONJ F
Wellness 0 PUNCT T
, 0 PUNCT F
as 0 CCONJ F
well 0 PUNCT F
as 0 CCONJ F
on 0 ADP F
the 0 DET F
Case 0 NOUN T
Mix 0 NOUN T
Group 0 NOUN T
classification 0 NOUN F
system 0 NOUN F
. 0 PUNCT F

Life 0 NOUN T
expectancy 0 NOUN F
beyond 0 ADP F
the 0 DET F
trial 0 NOUN F
was 0 VERB F
estimated 0 VERB F
from 0 ADP F
the 0 DET F
Saskatchewan 0 NOUN T
Health 0 NOUN T
Database 0 NOUN T
. 0 PUNCT F

Cost-effectiveness 0 NOUN T
was 0 VERB F
expressed 0 VERB F
as 0 ADP F
the 0 DET F
incremental 0 ADJ F
cost-effectiveness 0 NOUN F
ratio 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
bootstrap 0 NOUN F
methods 0 NOUN F
were 0 VERB F
used 0 VERB F
to 0 PART F
estimate 0 NOUN F
the 0 DET F
joint 0 NOUN F
distribution 0 NOUN F
of 0 ADP F
costs 0 NOUN F
and 0 CCONJ F
effectiveness 0 NOUN F
. 0 PUNCT F

RESULTS 0 DET T
Clopidogrel 0 NOUN T
was 0 VERB F
shown 0 VERB F
to 0 PART F
be 0 PUNCT F
cost-effective B-OTHER ADJ F
, 0 PUNCT F
with 0 ADP F
incremental 0 ADJ F
cost-effectiveness B-OTHER NOUN F
ratios I-OTHER NOUN F
less 0 ADV F
than 0 VERB F
$ 0 SYM F
10,000 0 NUM F
per 0 ADP F
event 0 NOUN F
prevented B-OTHER ADP F
and 0 CCONJ F
less 0 ADV F
than 0 VERB F
$ 0 SYM F
4,000 0 NUM F
per 0 ADP F
life-year 0 NOUN F
gained B-OTHER VERB F
. 0 PUNCT F

The 0 DET T
probability 0 NOUN F
of 0 ADP F
clopidogrel 0 NOUN F
resulting 0 VERB F
in 0 ADP F
cost 0 NOUN F
per 0 ADP F
life-year B-OTHER NOUN F
gained I-OTHER VERB F
of 0 ADP F
less 0 ADV F
than 0 PUNCT F
$ 0 ADV F
20,000 0 NUM F
was 0 VERB F
0.975 0 PUNCT F
for 0 ADP F
CURE 0 NOUN T
patients 0 NOUN F
and 0 CCONJ F
0.904 0 NUM F
for 0 ADP F
PCI-CURE 0 NOUN T
patients 0 NOUN F
. 0 PUNCT F

CONCLUSIONS 0 NOUN T
The 0 DET T
economic 0 ADJ F
analysis 0 NOUN F
demonstrated 0 VERB F
that 0 ADP F
clopidogrel 0 NOUN F
combination 0 NOUN F
therapy 0 NOUN F
is 0 VERB F
not 0 ADV F
only 0 ADV F
cost-effective 0 ADJ F
as 0 ADP F
antiplatelet 0 NOUN F
therapy 0 NOUN F
compared 0 VERB F
with 0 ADP F
ASA 0 NOUN T
alone 0 ADJ F
, 0 PUNCT F
but 0 CCONJ F
it 0 PRON F
is 0 VERB F
also 0 ADV F
cost-effective 0 ADP F
compared 0 VERB F
with 0 ADP F
other 0 ADJ F
commonly 0 ADV F
used 0 DET F
and 0 CCONJ F
openly 0 ADV F
reimbursed 0 PUNCT F
cardiovascular 0 ADJ F
therapies 0 NOUN F
in 0 ADP F
the 0 DET F
Canadian 0 ADJ T
health 0 NOUN F
care 0 NOUN F
system 0 NOUN F
. 0 PUNCT F

Strategies 0 NOUN T
for 0 ADP F
dietary 0 ADJ F
and 0 CCONJ F
anti-smoking 0 VERB F
advice 0 NOUN F
. 0 PUNCT F

Practical 0 ADJ T
experiences 0 ADJ F
from 0 ADP F
the 0 DET F
Oslo 0 NOUN T
Study 0 NOUN T
. 0 PUNCT F

One 0 PUNCT T
of 0 ADP F
the 0 DET F
2 0 NUM F
controlled 0 VERB F
preventive 0 ADJ F
trials 0 NOUN F
within 0 ADP F
the 0 DET F
Oslo 0 NOUN T
Study 0 NOUN T
was 0 VERB F
a 0 DET F
non-drug 0 NOUN F
trial 0 NOUN F
on 0 ADP F
the 0 DET F
effect 0 NOUN F
of 0 ADP F
diet B-OTHER NOUN F
and 0 CCONJ F
smoking B-OTHER VERB F
intervention I-OTHER NOUN F
on 0 ADP F
coronary 0 ADJ F
heart 0 NOUN F
disease 0 NOUN F
in 0 ADP F
1232 0 NUM F
middleaged 0 PROPN F
, 0 PUNCT F
normotensive 0 ADJ F
, 0 PUNCT F
healthy 0 ADJ F
men 0 NOUN F
. 0 PUNCT F

All 0 DET T
had 0 PUNCT F
elevated 0 VERB F
serum 0 NOUN F
cholesterol 0 NOUN F
and 0 CCONJ F
4 0 NUM F
out 0 PUNCT F
of 0 ADP F
5 0 NUM F
smoked 0 PUNCT F
every 0 DET F
day 0 NOUN F
. 0 PUNCT F

The 0 DET T
participants 0 NOUN F
in 0 ADP F
the 0 DET F
intervention 0 NOUN F
group 0 NOUN F
met 0 VERB F
every 0 DET F
6 0 NUM F
months 0 NOUN F
during 0 ADP F
the 0 DET F
5-year 0 ADJ F
study 0 NOUN F
for 0 ADP F
clinical 0 ADJ F
examination 0 NOUN F
and 0 CCONJ F
for 0 ADP F
dietary 0 ADJ F
and 0 CCONJ F
smoking B-OTHER VERB F
counselling I-OTHER PROPN F
. 0 PUNCT F

The 0 DET T
effect 0 NOUN F
on 0 ADP F
serum B-PHYSICAL NOUN F
cholesterol I-PHYSICAL NOUN F
was 0 VERB F
a 0 DET F
13 0 NUM F
% 0 SYM F
lowering 0 SYM F
( 0 PUNCT F
i.e 0 ADV F
. 0 PUNCT F

10 0 NUM F
% 0 SYM F
net 0 ADJ F
reduction 0 NOUN F
compared 0 VERB F
with 0 ADP F
control 0 NOUN F
group 0 NOUN F
) 0 PUNCT F
, 0 PUNCT F
and 0 CCONJ F
about 0 ADP F
a 0 DET F
50 0 NUM F
% 0 SYM F
reduction 0 NOUN F
in 0 ADP F
cigarette B-MENTAL NOUN F
consumption I-MENTAL NOUN F
. 0 PUNCT F

The 0 DET T
effect 0 NOUN F
on 0 ADP F
coronary B-PHYSICAL ADJ F
heart I-PHYSICAL NOUN F
disease I-PHYSICAL NOUN F
( 0 PUNCT F
fatal 0 ADJ F
and 0 CCONJ F
non-fatal 0 ADJ F
myocardial 0 ADJ F
infarction 0 NOUN F
or 0 CCONJ F
sudden 0 ADJ F
death 0 NOUN F
) 0 PUNCT F
was 0 VERB F
a 0 DET F
47 0 NUM F
% 0 SYM F
lowering 0 DET F
of 0 ADP F
the 0 DET F
5-year 0 ADJ F
incidence 0 NOUN F
in 0 ADP F
the 0 DET F
intervention 0 NOUN F
group 0 NOUN F
compared 0 VERB F
with 0 ADP F
the 0 DET F
control 0 NOUN F
group 0 NOUN F
( 0 PUNCT F
p 0 NOUN F
= 0 SYM F
0.02 0 NUM F
, 0 PUNCT F
2-sided 0 VERB F
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
main 0 ADJ F
intervention 0 NOUN F
strategies 0 NOUN F
were 0 ADJ F
: 0 PUNCT F
information 0 NOUN F
about 0 PUNCT F
the 0 DET F
risk 0 NOUN F
factor 0 NOUN F
concept 0 NOUN F
to 0 ADP F
participant 0 PUNCT F
and 0 CCONJ F
spouse 0 NOUN F
( 0 PUNCT F
in 0 ADP F
groups 0 NOUN F
) 0 PUNCT F
individual 0 ADJ F
diet 0 NOUN F
and 0 CCONJ F
anti-smoking 0 VERB F
counselling 0 VERB F
after 0 ADP F
finishing 0 DET F
an 0 DET F
extensive 0 ADJ F
clinical 0 ADJ F
and 0 CCONJ F
electrocardiographic 0 ADJ F
examination 0 NOUN F
, 0 PUNCT F
including 0 VERB F
exercise-ECG 0 NOUN F
basis 0 NOUN F
and 0 CCONJ F
background 0 NOUN F
for 0 ADP F
the 0 DET F
counselling 0 DET F
strategy 0 NOUN F
: 0 PUNCT F
the 0 DET F
total 0 ADJ F
situation 0 NOUN F
of 0 ADP F
the 0 DET F
participant 0 NOUN F
. 0 PUNCT F

Some 0 PUNCT T
of 0 ADP F
the 0 DET F
most 0 VERB F
important 0 ADJ F
items 0 NOUN F
: 0 PUNCT F
personality 0 NOUN F
, 0 PUNCT F
motivation 0 NOUN F
, 0 PUNCT F
diet 0 NOUN F
history 0 NOUN F
, 0 PUNCT F
bodyweight 0 ADJ F
, 0 PUNCT F
blood 0 NOUN F
lipids 0 NOUN F
and 0 CCONJ F
blood 0 NOUN F
sugar 0 NOUN F
anti-smoking 0 DET F
advice 0 NOUN F
given 0 VERB F
individually 0 ADV F
to 0 ADP F
all 0 DET F
smokers 0 NOUN F
in 0 ADP F
the 0 DET F
intervention 0 NOUN F
group 0 NOUN F
advice 0 NOUN F
that 0 ADP F
smoking 0 ADJ F
cessation 0 NOUN F
was 0 VERB F
expected 0 VERB F
to 0 DET F
be 0 PUNCT F
of 0 ADP F
special 0 ADJ F
importance 0 NOUN F
for 0 ADP F
those 0 PUNCT F
with 0 ADP F
elevated 0 VERB F
blood 0 NOUN F
lipids 0 NOUN F
. 0 PUNCT F

Preventing 0 ADV T
disability B-PHYSICAL NOUN F
and 0 CCONJ F
falls B-PHYSICAL ADJ F
in I-PHYSICAL ADP F
older 0 PUNCT F
adults B-PHYSICAL NOUN F
: 0 PUNCT F
a 0 DET F
population-based 0 VERB F
randomized 0 VERB F
trial 0 NOUN F
. 0 PUNCT F

OBJECTIVES 0 NOUN T
Because 0 PUNCT T
preventing 0 ADP F
disability B-PHYSICAL NOUN F
and 0 CCONJ F
falls B-PHYSICAL ADJ F
in B-PHYSICAL ADP F
older 0 PUNCT F
adults B-PHYSICAL NOUN F
is 0 VERB F
a 0 DET F
national 0 ADJ F
priority 0 NOUN F
, 0 PUNCT F
a 0 DET F
randomized 0 VERB F
controlled 0 VERB F
trial 0 NOUN F
was 0 VERB F
conducted 0 VERB F
to 0 PART F
test 0 NOUN F
a 0 DET F
multicomponent 0 ADJ F
intervention 0 NOUN F
program 0 NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
From 0 ADP T
a 0 DET F
random 0 ADJ F
sample 0 NOUN F
of 0 ADP F
health 0 NOUN F
maintenance 0 NOUN F
organization 0 NOUN F
( 0 PUNCT F
HMO 0 NOUN T
) 0 PUNCT F
enrollees 0 NOUN F
65 0 NUM F
years 0 NOUN F
and 0 CCONJ F
older 0 PUNCT F
, 0 PUNCT F
1559 0 NUM F
ambulatory 0 ADJ F
seniors 0 NOUN F
were 0 VERB F
randomized 0 VERB F
to 0 ADP F
one 0 PUNCT F
of 0 ADP F
three 0 NUM F
groups 0 NOUN F
: 0 PUNCT F
a 0 DET F
nurse 0 ADJ F
assessment 0 NOUN F
visit 0 NOUN F
and 0 CCONJ F
follow-up 0 NOUN F
interventions 0 NOUN F
targeting 0 VERB F
risk 0 NOUN F
factors 0 NOUN F
for 0 ADP F
disability 0 NOUN F
and 0 CCONJ F
falls 0 NOUN F
( 0 PUNCT F
group 0 NOUN F
1 0 NUM F
, 0 PUNCT F
n 0 NOUN F
= 0 SYM F
635 0 NUM F
) 0 PUNCT F
; 0 PUNCT F
a 0 DET F
general 0 ADJ F
health 0 NOUN F
promotion 0 NOUN F
nurse 0 ADJ F
visit 0 NOUN F
( 0 PUNCT F
group 0 NOUN F
2 0 NUM F
, 0 PUNCT F
n 0 NOUN F
= 0 SYM F
317 0 NUM F
) 0 PUNCT F
; 0 PUNCT F
and 0 CCONJ F
usual 0 ADJ F
care 0 NOUN F
( 0 PUNCT F
group 0 NOUN F
3 0 NUM F
, 0 PUNCT F
n 0 NOUN F
= 0 SYM F
607 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Data 0 NOUN T
collection 0 NOUN F
consisted 0 ADJ F
of 0 ADP F
a 0 DET F
baseline 0 NOUN F
and 0 CCONJ F
two 0 NUM F
annual 0 ADJ F
follow-up 0 NOUN F
surveys 0 NOUN F
. 0 PUNCT F

RESULTS 0 NOUN T
After 0 ADP T
1 0 NUM F
year 0 NOUN F
, 0 PUNCT F
group 0 NOUN F
1 0 NUM F
subjects 0 NOUN F
reported 0 VERB F
a 0 DET F
significantly 0 ADV F
lower 0 PUNCT F
incidence 0 NOUN F
of 0 ADP F
declining B-PHYSICAL NUM F
functional B-PHYSICAL ADJ F
status I-PHYSICAL NOUN F
and 0 CCONJ F
a 0 DET F
significantly 0 ADV F
lower 0 PUNCT F
incidence 0 NOUN F
of 0 ADP F
falls B-PHYSICAL CCONJ F
than 0 PUNCT F
group 0 NOUN F
3 0 NUM F
subjects 0 NOUN F
. 0 PUNCT F

Group 0 NOUN T
2 0 NUM F
subjects 0 NOUN F
had 0 VERB F
intermediate 0 ADJ F
levels 0 NOUN F
of 0 ADP F
most 0 DET F
outcomes 0 NOUN F
. 0 PUNCT F

After 0 ADP T
2 0 NUM F
years 0 NOUN F
of 0 ADP F
follow-up 0 NOUN F
, 0 PUNCT F
the 0 DET F
differences 0 NOUN F
narrowed 0 ADJ F
. 0 PUNCT F

CONCLUSIONS 0 NOUN T
The 0 DET T
results 0 CCONJ F
suggest 0 VERB F
that 0 ADP F
a 0 DET F
modest 0 ADJ F
, 0 PUNCT F
one-time 0 ADJ F
prevention 0 NOUN F
program 0 NOUN F
appeared 0 VERB F
to 0 PUNCT F
confer 0 PUNCT F

A 0 DET T
comparative 0 ADJ F
trial 0 NOUN F
of 0 ADP F
fixed 0 VERB F
ratio 0 NOUN F
beta-adrenoceptor 0 NOUN F
blocker 0 NOUN F
and 0 CCONJ F
diuretic 0 NOUN F
combination 0 NOUN F
products 0 NOUN F
in 0 ADP F
moderate 0 ADJ F
hypertension 0 NOUN F
. 0 PUNCT F

Two 0 NUM T
fixed 0 VERB F
ratio 0 NOUN F
combination 0 NOUN F
tablets 0 ADV F
, 0 PUNCT F
10 0 NUM F
mg 0 NOUN F
pindolol 0 NOUN F
combined 0 VERB F
with 0 ADP F
5 0 NUM F
mg 0 NOUN F
clopamide 0 NOUN F
and 0 CCONJ F
100 0 NUM F
mg 0 NOUN F
metoprolol 0 NOUN F
combined 0 PROPN F
with 0 ADP F
12.5 0 NUM F
mg 0 NOUN F
hydrochlorothiazide 0 NOUN F
, 0 PUNCT F
were 0 VERB F
compared 0 VERB F
at 0 ADP F
two 0 NUM F
dose 0 NOUN F
levels 0 NOUN F
in 0 ADP F
a 0 DET F
double-blind 0 ADJ F
crossover 0 ADP F
trial 0 NOUN F
in 0 ADP F
10 0 NUM F
previously 0 ADV F
untreated 0 PUNCT F
hypertensive 0 ADJ F
patients 0 NOUN F
. 0 PUNCT F

No 0 DET T
significant 0 ADJ F
difference 0 NOUN F
was 0 VERB F
observed 0 VERB F
between 0 ADP F
resting B-PHYSICAL VERB F
blood I-PHYSICAL NOUN F
pressure I-PHYSICAL NOUN F
on 0 ADP F
the 0 DET F
two 0 NUM F
combinations 0 NOUN F
at 0 ADP F
either 0 PUNCT F
dose 0 NOUN F
level 0 NOUN F
. 0 PUNCT F

Exercise B-PHYSICAL NOUN T
systolic I-PHYSICAL ADJ F
pressure I-PHYSICAL NOUN F
was 0 VERB F
lower 0 PUNCT F
after 0 ADP F
the 0 DET F
pindolol/clopamide 0 NOUN F
combination 0 NOUN F
at 0 ADP F
low 0 ADJ F
dose 0 NOUN F
( 0 PUNCT F
p 0 NOUN F
less 0 ADV F
than 0 PUNCT F
0.05 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
incidence 0 NOUN F
of 0 ADP F
side-effects B-ADVERSE-EFFECTS NOUN F
in 0 ADP F
this 0 DET F
trial 0 NOUN F
was 0 VERB F
high 0 ADJ F
but 0 CCONJ F
proper 0 ADJ F
comparison 0 NOUN F
of 0 ADP F
the 0 DET F
two 0 NUM F
products 0 NOUN F
could 0 VERB F
not 0 ADV F
be 0 VERB F
made 0 VERB F
because 0 PUNCT F
of 0 ADP F
the 0 DET F
small 0 ADJ F
number 0 NOUN F
of 0 ADP F
patients 0 NOUN F
. 0 PUNCT F

It 0 PRON T
is 0 VERB F
suggested 0 VERB F
that 0 VERB F
combination 0 NOUN F
products 0 NOUN F
should 0 VERB F
be 0 VERB F
used 0 VERB F
only 0 ADV F
after 0 ADP F
patients 0 NOUN F
have 0 PUNCT F
failed 0 VERB F
to 0 PART F
respond 0 NOUN F
adequately 0 ADV F
to 0 ADP F
a 0 DET F
single 0 ADJ F
agent 0 NOUN F
. 0 PUNCT F

Elevated 0 ADP T
concentration 0 NOUN F
of 0 ADP F
placental 0 ADJ F
growth 0 NOUN F
factor 0 NOUN F
( 0 PUNCT F
PlGF 0 NOUN T
) 0 PUNCT F
and 0 CCONJ F
long 0 ADJ F
term 0 NOUN F
risk 0 NOUN F
in 0 ADP F
patients 0 NOUN F
with 0 ADP F
acute 0 ADJ F
coronary 0 ADJ F
syndrome 0 NOUN F
in 0 ADP F
the 0 DET F
PROVE 0 NOUN T
IT-TIMI 0 NOUN T
22 0 NUM F
trial 0 NOUN F
. 0 PUNCT F

Placental B-PHYSICAL ADJ T
growth I-PHYSICAL NOUN F
factor 0 NOUN F
( B-PHYSICAL PUNCT F
PlGF I-PHYSICAL NOUN T
) B-PHYSICAL PUNCT F
, 0 PUNCT F
a 0 DET F
member 0 NOUN F
of 0 ADP F
the 0 DET F
vascular 0 ADJ F
endothelial 0 ADJ F
growth 0 NOUN F
factor 0 NOUN F
( 0 PUNCT F
VEGF 0 NOUN T
) 0 PUNCT F
family 0 NOUN F
, 0 PUNCT F
acts 0 NOUN F
via 0 ADP F
the 0 DET F
flt-1 0 NOUN F
receptor 0 NOUN F
and 0 CCONJ F
promotes 0 ADV F
endothelial 0 ADJ F
activation 0 NOUN F
and 0 CCONJ F
macrophage 0 NOUN F
recruitment 0 NOUN F
into 0 ADP F
atherosclerotic 0 ADJ F
lesions 0 NOUN F
. 0 PUNCT F

We 0 PRON T
investigated 0 VERB F
the 0 DET F
relationship 0 NOUN F
of 0 ADP F
PlGF 0 NOUN T
with 0 ADP F
cardiovascular 0 ADJ F
outcomes 0 NOUN F
in 0 ADP F
a 0 DET F
large 0 ADJ F
cohort 0 NOUN F
of 0 ADP F
patients 0 NOUN F
presenting 0 ADJ F
across 0 ADP F
the 0 DET F
spectrum 0 NOUN F
of 0 ADP F
ACS 0 NOUN T
. 0 PUNCT F

PlGF B-MENTAL NOUN T
was 0 VERB F
measured 0 VERB F
at 0 ADP F
baseline 0 NOUN F
( 0 PUNCT F
n 0 NOUN F
= 0 SYM F
3,761 0 NUM F
) 0 PUNCT F
and 0 CCONJ F
at 0 ADP F
four-months 0 ADP F
( 0 PUNCT F
n 0 NOUN F
= 0 SYM F
3,369 0 NUM F
) 0 PUNCT F
in 0 ADP F
patients 0 NOUN F
randomized 0 VERB F
to 0 ADP F
atorvastatin 0 NOUN F
80 0 NUM F
mg 0 NOUN F
or 0 CCONJ F
pravastatin 0 NOUN F
40 0 NUM F
mg 0 NOUN F
after 0 ADP F
ACS 0 NOUN T
in 0 ADP F
the 0 DET F
PROVE 0 NOUN T
IT-TIMI 0 NOUN T
22 0 NUM F
trial 0 NOUN F
. 0 PUNCT F

The 0 DET T
primary 0 ADJ F
endpoint 0 NOUN F
was 0 VERB F
death B-MORTALITY NOUN F
, 0 PUNCT F
myocardial B-PHYSICAL PUNCT F

EEG 0 NOUN T
mapping 0 PUNCT F
and 0 CCONJ F
psychopharmacological 0 ADJ F
studies 0 NOUN F
with 0 ADP F
denbufylline 0 NOUN F
in 0 ADP F
SDAT 0 NOUN T
and 0 CCONJ F
MID 0 NOUN T
. 0 PUNCT F

Computed 0 VERB T
tomography 0 NOUN F
( 0 PUNCT F
CT 0 NOUN T
) 0 PUNCT F
, 0 PUNCT F
electroencephalograms 0 NOUN F
( 0 PUNCT F
EEG 0 NOUN T
) 0 PUNCT F
, 0 PUNCT F
clinical 0 ADJ F
and 0 CCONJ F
psychometric 0 ADJ F
data 0 NOUN F
were 0 VERB F
obtained 0 VERB F
in 0 ADP F
96 0 NUM F
mildly 0 ADJ F
to 0 PUNCT F
moderately 0 ADV F
demented 0 PUNCT F
patients 0 NOUN F
( 0 PUNCT F
72 0 NUM F
women 0 NOUN F
, 0 PUNCT F
24 0 NUM F
men 0 NOUN F
) 0 PUNCT F
, 0 PUNCT F
aged 0 PUNCT F
61-96 0 NUM F
years 0 NOUN F
( 0 PUNCT F
mean 0 NOUN F
82 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
diagnosed 0 VERB F
according 0 CCONJ F
to 0 ADP F
DSM-III 0 NUM T
criteria 0 NOUN F
. 0 PUNCT F

Patients 0 NOUN T
were 0 VERB F
off 0 ADP F
drugs 0 NOUN F
for 0 ADP F
at 0 ADP F
least 0 ADV F
2 0 NUM F
weeks 0 NOUN F
and 0 CCONJ F
subdiagnosed 0 ADP F
according 0 ADP F
to 0 ADP F
the 0 DET F
modified 0 VERB F
Marshall-Hachinski 0 PUNCT T
ischemic 0 ADJ F
score 0 NOUN F
and 0 CCONJ F
CT 0 NOUN T
in 0 ADP F
45 0 NUM F
senile 0 ADJ F
dementia 0 NOUN F
of 0 ADP F
the 0 DET F
Alzheimer 0 PUNCT T
type 0 NOUN F
( 0 PUNCT F
SDAT 0 NOUN T
) 0 PUNCT F
and 0 CCONJ F
51 0 NUM F
multiinfarct 0 NOUN F
dementia 0 NOUN F
( 0 PUNCT F
MID 0 NOUN T
) 0 PUNCT F
patients 0 NOUN F
. 0 PUNCT F

Evaluations 0 NOUN T
were 0 VERB F
carried 0 VERB F
out 0 ADP F
before 0 ADP F
and 0 CCONJ F
12 0 NUM F
weeks 0 NOUN F
after 0 ADP F
treatment 0 NOUN F
with 0 ADP F
either 0 CCONJ F
100 0 PUNCT F
mg 0 NOUN F
denbufylline 0 NOUN F
BID 0 NOUN T
or 0 CCONJ F
placebo 0 NOUN F
and 0 CCONJ F
included 0 VERB F
EEG 0 NOUN T
mapping 0 PUNCT F
, 0 PUNCT F
the 0 DET F
Sandoz 0 NOUN T
Clinical 0 ADJ T
Assessment 0 NOUN T
Geriatric 0 ADJ T
( 0 PUNCT F
SCAG 0 NOUN T
) 0 PUNCT F
score/factors 0 NOUN F
, 0 PUNCT F
the 0 DET F
Clinical 0 ADJ T
Global 0 ADJ T
Impression 0 NOUN T
( 0 PUNCT F
CGI 0 NOUN T
) 0 PUNCT F
, 0 PUNCT F
the 0 DET F
Digit 0 NOUN T
Symbol 0 NOUN T
Substitution 0 NOUN T
Test 0 NOUN T
( 0 PUNCT F
DSST 0 NOUN T
) 0 PUNCT F
, 0 PUNCT F
the 0 DET F
Trail-Making 0 PUNCT T
Test 0 NOUN T
( 0 PUNCT F
TMT 0 NOUN T
) 0 PUNCT F
and 0 CCONJ F
the 0 DET F
Digit 0 NOUN T
Span 0 NOUN T
Test 0 NOUN T
( 0 PUNCT F
DS 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

Descriptive 0 ADJ T
data 0 NOUN F
analysis 0 NOUN F
including 0 VERB F
confirmatory 0 ADJ F
statements 0 NOUN F
found 0 VERB F
delta/theta B-PHYSICAL NOUN F
activity I-PHYSICAL NOUN F
enhanced 0 VERB F
, 0 PUNCT F
alpha B-PHYSICAL NOUN F
and 0 CCONJ F
beta B-PHYSICAL NOUN F
activity I-PHYSICAL NOUN F
reduced 0 VERB F
, 0 PUNCT F
total 0 ADJ F
power B-PHYSICAL NOUN F
augmented 0 VERB F
, 0 PUNCT F
and 0 CCONJ F
the 0 DET F
centroid B-PHYSICAL NOUN F
slowed 0 DET F
down 0 ADJ F
over 0 ADP F
various 0 ADJ F
brain 0 NOUN F
regions 0 NOUN F
in 0 ADP F
patients 0 NOUN F
as 0 PUNCT F
compared 0 VERB F
with 0 ADP F
controls 0 NOUN F
. 0 PUNCT F

The 0 DET T
two 0 NUM F
subtypes 0 NOUN F
of 0 ADP F
dementia 0 NOUN F
could 0 VERB F
be 0 VERB F
differentiated 0 VERB F
in 0 ADP F
some 0 DET F
conventional 0 ADJ F
EEG 0 NOUN T
variables 0 NOUN F
but 0 CCONJ F
mostly 0 ADV F
by 0 ADP F
means 0 NOUN F
of 0 ADP F
power 0 NOUN F
asymmetry 0 NOUN F
indices 0 NOUN F
. 0 PUNCT F

Denbufylline 0 NOUN T
induced 0 VERB F
a 0 DET F
statistically 0 ADV F
significant 0 ADJ F
and 0 CCONJ F
clinically 0 ADV F
relevant 0 ADJ F
improvement 0 NOUN F
in 0 ADP F
both 0 PUNCT F
SDAT B-OTHER NOUN T
and 0 CCONJ F
MID B-OTHER NOUN T
patients 0 NOUN F
, 0 PUNCT F
whereas 0 CCONJ F
after 0 ADP F
placebo 0 NOUN F
this 0 VERB F
was 0 NUM F
not 0 ADV F
the 0 DET F
case 0 NOUN F
in 0 ADP F
CGI 0 NOUN T
, 0 PUNCT F
the 0 DET F
TMT 0 ADV T
, 0 PUNCT F
and 0 CCONJ F
the 0 DET F
DS 0 NOUN T
, 0 PUNCT F
with 0 ADP F
interdrug 0 NOUN F
differences 0 NOUN F
being 0 VERB F
significant 0 ADJ F
in 0 ADP F
all 0 DET F
primary 0 ADJ F
target 0 NOUN F
variables 0 NOUN F
such 0 CCONJ F
as 0 ADP F
the 0 DET F
CGI 0 NOUN T
, 0 PUNCT F
MMS 0 NOUN T
, 0 PUNCT F
SCAG 0 NOUN T
, 0 PUNCT F
and 0 CCONJ F
DSST 0 NOUN T
. 0 PUNCT F

Thus 0 ADV T
, 0 PUNCT F
both 0 PUNCT F
the 0 DET F
degenerative 0 ADJ F
and 0 CCONJ F
vascular 0 ADJ F
type 0 NOUN F
of 0 ADP F
dementia 0 NOUN F
exhibited 0 VERB F
a 0 DET F
therapeutic 0 ADJ F
benefit 0 NOUN F
that 0 ADP F
could 0 ADP F
be 0 ADP F
objectified 0 VERB F
at 0 ADP F
the 0 DET F
neurophysiological 0 ADJ F
level 0 NOUN F
by 0 ADP F
EEG 0 NOUN T
mapping 0 PUNCT F
in 0 ADP F
an 0 DET F
improvement 0 NOUN F
of 0 ADP F
vigilance 0 NOUN F
. 0 PUNCT F

Alendronate 0 NOUN T
daily 0 ADJ F
, 0 PUNCT F
weekly 0 ADV F
in 0 ADP F
conventional 0 ADJ F
tablets 0 ADV F
and 0 CCONJ F
weekly 0 ADV F
in 0 ADP F
enteric 0 ADJ F
tablets 0 ADV F
: 0 PUNCT F
preliminary 0 ADJ F
study 0 NOUN F
on 0 ADP F
the 0 DET F
effects 0 NOUN F
in 0 ADP F
bone B-PHYSICAL NOUN F
turnover I-PHYSICAL NOUN F
markers I-PHYSICAL NOUN F
and 0 CCONJ F
incidence 0 NOUN F
of 0 ADP F
side B-ADVERSE-EFFECTS NOUN F
effects I-ADVERSE-EFFECTS NOUN F
. 0 PUNCT F

Bisphosphonates 0 ADP T
are 0 NOUN F
now 0 ADV F
in 0 ADP F
the 0 DET F
vanguard 0 PUNCT F
of 0 ADP F
osteoporosis 0 NOUN F
treatment 0 NOUN F
. 0 PUNCT F

Frequently 0 ADV T
, 0 PUNCT F
gastro-oesophageal 0 ADJ F
symptoms 0 NOUN F
are 0 VERB F
associated 0 VERB F
with 0 ADP F
these 0 DET F
drugs 0 NOUN F
. 0 PUNCT F

The 0 DET T
objective 0 NOUN F
of 0 ADP F
this 0 DET F
study 0 NOUN F
was 0 VERB F
to 0 ADV F
compare 0 NOUN F
side 0 NOUN F
effects 0 NOUN F
and 0 CCONJ F
bone 0 NOUN F
turnover 0 NOUN F
markers 0 NOUN F
in 0 ADP F
postmenopausal 0 ADJ F
women 0 NOUN F
who 0 PROPN F
had 0 PUNCT F
received 0 SYM F
alendronate 0 NOUN F
daily 0 ADJ F
or 0 CCONJ F
weekly 0 ADV F
in 0 ADP F
tablets 0 NOUN F
with 0 ADP F
or 0 CCONJ F
without 0 ADP F
enteric 0 ADJ F
coating 0 SYM F
. 0 PUNCT F

We 0 PRON T
conducted 0 VERB F
a 0 DET F
randomised 0 VERB F
, 0 PUNCT F
double-blind 0 ADJ F
, 0 PUNCT F
3-month 0 NOUN F
trial 0 NOUN F
. 0 PUNCT F

The 0 DET T
trial 0 NOUN F
involved 0 VERB F
75 0 NUM F
volunteers 0 NOUN F
, 0 PUNCT F
aged 0 PUNCT F
45-58 0 PUNCT F
with 0 ADP F
moderate 0 ADJ F
to 0 ADP F
severe 0 CCONJ F
osteopenia 0 NOUN F
( 0 PUNCT F
T-score 0 NOUN T
lower 0 PUNCT F
than 0 PUNCT F
-2 0 NUM F
SD 0 NOUN T
) 0 PUNCT F
assessed 0 VERB F
by 0 ADP F
quantitative 0 ADJ F
ultrasound 0 NOUN F
. 0 PUNCT F

Women 0 NOUN T
were 0 VERB F
assigned 0 VERB F
randomly 0 ADV F
to 0 PART F
receive 0 ADP F
: 0 PUNCT F
( 0 PUNCT F
a 0 NOUN F
) 0 PUNCT F
alendronate 0 NOUN F
10mg/day 0 NUM F
: 0 PUNCT F
( 0 PUNCT F
b 0 NOUN F
) 0 PUNCT F
alendronate 0 NOUN F
70 0 NUM F
mg 0 NOUN F
once 0 PUNCT F
a 0 DET F
week 0 NOUN F
: 0 PUNCT F
or 0 CCONJ F
( 0 PUNCT F
c 0 NOUN F
) 0 PUNCT F
enteric 0 ADJ F
alendronate 0 NOUN F
70 0 NUM F
mg 0 NOUN F
per 0 ADP F
week 0 NOUN F
. 0 PUNCT F

We 0 PRON T
recorded 0 PROPN F
side 0 NOUN F
effects 0 NOUN F
, 0 PUNCT F
C-telopeptide B-PHYSICAL NOUN T
, 0 PUNCT F
osteocalcin B-PHYSICAL NOUN F
and 0 CCONJ F
urine B-PHYSICAL NOUN F
hydroxyproline I-PHYSICAL NOUN F
at 0 ADP F
the 0 DET F
start 0 NOUN F
of 0 ADP F
the 0 DET F
study 0 NOUN F
and 0 CCONJ F
at 0 ADP F
3 0 NUM F
months 0 NOUN F
. 0 PUNCT F

After 0 ADP T
3 0 NUM F
months 0 NOUN F
, 0 PUNCT F
pyrosis B-PHYSICAL NOUN F
( I-PHYSICAL PUNCT F
heartburn I-PHYSICAL NOUN F
) I-PHYSICAL PUNCT F
was 0 VERB F
noted 0 VERB F
by 0 ADP F
seven 0 NUM F
women 0 NOUN F
in 0 ADP F
group 0 NOUN F
A 0 NOUN T
( 0 PUNCT F
28 0 NUM F
% 0 SYM F
) 0 PUNCT F
, 0 PUNCT F
three 0 NUM F
in 0 ADP F
group 0 NOUN F
B 0 NOUN T
( 0 PUNCT F
12 0 NUM F
% 0 SYM F
) 0 PUNCT F
and 0 CCONJ F
two 0 NUM F
in 0 ADP F
group 0 NOUN F
C 0 NOUN T
( 0 PUNCT F
8 0 NUM F
% 0 SYM F
) 0 PUNCT F
; 0 PUNCT F
nausea B-PHYSICAL NOUN F
: 0 PUNCT F
by 0 ADP F
one 0 NUM F
woman 0 NOUN F
in 0 ADP F
group 0 NOUN F
B 0 NOUN T
; 0 PUNCT F
and 0 CCONJ F
headache B-PHYSICAL NOUN F
by 0 ADP F
one 0 NUM F
patient 0 NOUN F
in 0 ADP F
each 0 DET F
group 0 NOUN F
. 0 PUNCT F

C-telopeptide B-PHYSICAL NOUN T
( 0 PUNCT F
A 0 NOUN T
: 0 PUNCT F
40.7 0 NUM F
% 0 SYM F
; 0 PUNCT F
B 0 NOUN T
: 0 PUNCT F
34.1 0 NUM F
% 0 SYM F
and 0 CCONJ F
C 0 NOUN T
: 0 PUNCT F
38.5 0 NUM F
% 0 SYM F
) 0 PUNCT F
; 0 PUNCT F
hydroxyproline B-PHYSICAL NOUN F
( 0 PUNCT F
A 0 NOUN T
: 0 PUNCT F
31.1 0 NUM F
% 0 SYM F
; 0 PUNCT F
B 0 NOUN T
: 0 PUNCT F
25.3 0 NUM F
% 0 SYM F
and 0 CCONJ F
C 0 NOUN T
: 0 PUNCT F
31.5 0 NUM F
% 0 SYM F
) 0 PUNCT F
and 0 CCONJ F
osteocalcin B-PHYSICAL NOUN F
( 0 PUNCT F
A 0 NOUN T
: 0 PUNCT F
27.0 0 NUM F
% 0 SYM F
; 0 PUNCT F
B 0 NOUN T
: 0 PUNCT F
25.4 0 NUM F
% 0 SYM F
and 0 CCONJ F
C 0 NOUN T
: 0 PUNCT F
25.1 0 NUM F
% 0 SYM F
) 0 PUNCT F
decreased 0 VERB F
similarly 0 ADV F
in 0 ADP F
the 0 DET F
three 0 NUM F
groups 0 NOUN F
. 0 PUNCT F

Weekly 0 ADV T
intake 0 NOUN F
of 0 ADP F
alendronate 0 NOUN F
, 0 PUNCT F
whether 0 ADP F
conventional 0 ADJ F
or 0 CCONJ F
enteric-coated 0 VERB F
; 0 PUNCT F
is 0 ADV F
associated 0 VERB F
with 0 ADP F
less 0 DET F
heartburn B-PHYSICAL NOUN F
and 0 CCONJ F
nausea B-PHYSICAL NOUN F
. 0 PUNCT F

Enteric 0 ADJ T
alendronate 0 NOUN F
has 0 PUNCT F
a 0 DET F
similar 0 ADJ F
action 0 NOUN F
to 0 ADP F
the 0 DET F
conventional 0 ADJ F
tablets 0 ADV F
on 0 ADP F
biochemical B-PHYSICAL ADJ F
markers I-PHYSICAL NOUN F
. 0 PUNCT F

Impact 0 NOUN T
of 0 ADP F
different 0 ADJ F
platelet 0 NOUN F
glycoprotein 0 NOUN F
IIb/IIIa 0 NOUN T
receptor 0 NOUN F
inhibitors 0 NOUN F
among 0 ADP F
diabetic 0 ADJ F
patients 0 NOUN F
undergoing 0 VERB F
percutaneous 0 ADJ F
coronary 0 ADJ F
intervention 0 NOUN F
: 0 PUNCT F
: 0 PUNCT F
Do 0 PUNCT T
Tirofiban 0 NOUN T
and 0 CCONJ F
ReoPro 0 NOUN T
Give 0 VERB T
Similar 0 ADJ T
Efficacy 0 NOUN T
Outcomes 0 NOUN T
Trial 0 NOUN T
( 0 PUNCT F
TARGET 0 NOUN T
) 0 PUNCT F
1-year 0 NOUN F
follow-up 0 NOUN F
. 0 PUNCT F

BACKGROUND 0 NOUN T
The 0 DET T
platelet 0 NOUN F
glycoprotein 0 NOUN F
IIb/IIIa 0 NOUN T
receptor 0 NOUN F
inhibitor 0 NOUN F
abciximab 0 NOUN F
, 0 PUNCT F
a 0 DET F
monoclonal 0 ADJ F
antibody 0 NOUN F
, 0 PUNCT F
has 0 PUNCT F
been 0 PUNCT F
shown 0 VERB F
to 0 PART F
improve 0 PUNCT F
early 0 ADJ F
and 0 CCONJ F
late 0 ADJ F
outcomes 0 NOUN F
among 0 ADP F
diabetic 0 ADJ F
patients 0 NOUN F
undergoing 0 VERB F
percutaneous 0 ADJ F
coronary 0 ADJ F
intervention 0 NOUN F
( 0 PUNCT F
PCI 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

It 0 PRON T
is 0 VERB F
unknown 0 VERB F
whether 0 ADP F
small-molecule 0 NOUN F
agents 0 NOUN F
confer 0 VERB F
similar 0 ADJ F
benefits 0 NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
AND 0 CCONJ T
RESULTS 0 NOUN T
In 0 ADP T
18 0 NUM F
countries 0 NOUN F
, 0 PUNCT F
4809 0 NUM F
patients 0 NOUN F
undergoing 0 VERB F
PCI 0 NOUN T
with 0 ADP F
stent 0 NOUN F
implantation 0 NOUN F
were 0 VERB F
randomized 0 VERB F
to 0 ADP F
tirofiban 0 NOUN F
or 0 CCONJ F
abciximab 0 NOUN F
. 0 PUNCT F

At 0 ADP T
the 0 DET F
time 0 NOUN F
of 0 ADP F
enrollment 0 NOUN F
, 0 PUNCT F
patients 0 NOUN F
were 0 VERB F
stratified 0 VERB F
according 0 ADP F
to 0 ADP F
diabetes 0 NOUN F
status 0 NOUN F
. 0 PUNCT F

As 0 VERB T
compared 0 VERB F
with 0 ADP F
non-diabetic 0 ADJ F
patients 0 NOUN F
, 0 PUNCT F
patients 0 NOUN F
with 0 ADP F
diabetes 0 NOUN F
( 0 PUNCT F
n=1117 0 NOUN F
) 0 PUNCT F
showed 0 VERB F
similar 0 ADJ F
30-day 0 NOUN F
ischemic 0 ADJ F
outcomes 0 NOUN F
, 0 PUNCT F
an 0 DET F
increased 0 VERB F
incidence 0 NOUN F
of 0 ADP F
any B-PHYSICAL DET F
target I-PHYSICAL NOUN F
vessel I-PHYSICAL NOUN F
revascularization I-PHYSICAL NOUN F
( 0 PUNCT F
TVR B-PHYSICAL NOUN T
) 0 PUNCT F
at 0 ADP F
6 0 NUM F
months 0 NOUN F
( 0 PUNCT F
10.3 0 NUM F
% 0 SYM F
versus 0 CCONJ F
7.8 0 NUM F
% 0 SYM F
; 0 PUNCT F
P= 0 NOUN T
0.008 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
and 0 CCONJ F
a 0 DET F
trend 0 NOUN F
toward 0 ADP F
higher B-MORTALITY PUNCT F
1-year I-MORTALITY NOUN F
mortality I-MORTALITY NOUN F
( 0 PUNCT F
2.5 0 NUM F
% 0 SYM F
versus 0 CCONJ F
1.6 0 NUM F
% 0 SYM F
; 0 PUNCT F
P=0.056 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

Among 0 ADP T
diabetic 0 ADJ F
patients 0 NOUN F
randomized 0 VERB F
to 0 ADP F
tirofiban 0 NOUN F
( 0 PUNCT F
n=560 0 PUNCT F
) 0 PUNCT F
, 0 PUNCT F
the 0 DET F
incidence 0 NOUN F
of 0 ADP F
death B-MORTALITY NOUN F
, 0 PUNCT F
myocardial B-PHYSICAL ADJ F
infarction I-PHYSICAL NOUN F
( 0 PUNCT F
MI B-PHYSICAL NOUN T
) 0 PUNCT F
, 0 PUNCT F
or 0 PUNCT F

[ 0 PUNCT F
Bupivacaine-CO2 0 NOUN T
and 0 CCONJ F
bupivacaine-HCl 0 NOUN F
at 0 ADP F
various 0 ADJ F
injection 0 NOUN F
temperatures 0 NOUN F
in 0 ADP F
peridural 0 ADJ F
anesthesia 0 NOUN F
for 0 ADP F
extracorporeal 0 ADJ F
shock 0 NOUN F
wave 0 NOUN F
lithotripsy 0 NOUN F
] 0 PUNCT F
. 0 PUNCT F

INTRODUCTION 0 NOUN T
The 0 DET T
effect 0 NOUN F
of 0 ADP F
different 0 ADJ F
injection 0 NOUN F
temperatures 0 NOUN F
on 0 ADP F
carbonated 0 VERB F
anesthetics 0 NOUN F
has 0 PUNCT F
been 0 ADP F
controversial 0 ADJ F
since 0 ADP F
1965 0 NUM F
. 0 PUNCT F

The 0 DET T
current 0 ADJ F
study 0 NOUN F
was 0 VERB F
undertaken 0 VERB F
to 0 PART F
determine 0 NOUN F
onset 0 NOUN F
times 0 NOUN F
of 0 ADP F
sensory 0 ADJ F
and 0 CCONJ F
motor 0 NOUN F
blockade 0 NOUN F
after 0 ADP F
epidural 0 ADJ F
anesthesia 0 NOUN F
with 0 ADP F
0.5 0 NUM F
% 0 SYM F
bupivacaine-CO2 0 NOUN F
and 0 CCONJ F
0.5 0 NUM F
% 0 SYM F
bupivacaine-HCl 0 NOUN F
at 0 ADP F
various 0 ADJ F
injection 0 NOUN F
temperatures 0 NOUN F
. 0 PUNCT F

MATERIALS 0 NOUN T
AND 0 CCONJ T
METHODS 0 NOUN T
The 0 DET T
study 0 NOUN F
was 0 VERB F
performed 0 VERB F
on 0 ADP F
90 0 NUM F
ASA 0 NOUN T
class 0 NOUN F
I-II 0 ADV T
urologic 0 ADJ F
patients 0 NOUN F
during 0 ADP F
extracorporeal 0 ADJ F
shock 0 NOUN F
wave 0 NOUN F
lithotripsy 0 NOUN F
. 0 PUNCT F

The 0 DET T
patients 0 NOUN F
were 0 VERB F
randomized 0 VERB F
in 0 ADP F
six 0 DET F
groups 0 NOUN F
to 0 PART F
receive 0 NOUN F
either 0 PUNCT F
0.5 0 NUM F
% 0 SYM F
bupivacaine-CO2 0 NOUN F
or 0 CCONJ F
0.5 0 NUM F
% 0 SYM F
bupivacaine-HCl 0 NOUN F
at 0 ADP F
temperatures 0 NOUN F
of 0 ADP F
4 0 NUM F
degrees 0 NOUN F
, 0 PUNCT F
20 0 NUM F
degrees 0 NOUN F
, 0 PUNCT F
or 0 CCONJ F
36 0 NUM F
degrees 0 ADJ F
C. 0 PUNCT T
The 0 DET T
six 0 NUM F
groups 0 NOUN F
were 0 VERB F
comparable 0 ADJ F
in 0 ADP F
age 0 NOUN F
, 0 PUNCT F
height 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
weight 0 NOUN F
. 0 PUNCT F

Epidural 0 ADJ T
anesthesia 0 NOUN F
was 0 VERB F
performed 0 VERB F
at 0 ADP F
the 0 DET F
L2-3 0 NOUN T
interspace 0 NOUN F
with 0 ADP F
an 0 DET F
18-gauge 0 NOUN F
Tuohy 0 NOUN T
needle 0 NOUN F
using 0 VERB F
loss 0 NOUN F
of 0 ADP F
resistance 0 NOUN F
. 0 PUNCT F

A 0 DET T
catheter 0 NOUN F
was 0 VERB F
advanced 0 VERB F
4 0 NUM F
cm 0 NOUN F
in 0 ADP F
the 0 DET F
epidural 0 ADJ F
space 0 NOUN F
and 0 CCONJ F
4 0 NUM F
ml 0 NOUN F
0.5 0 NUM F
% 0 SYM F
bupivacaine 0 NOUN F
with 0 ADP F
adrenaline 0 PUNCT F
1:200,000 0 ADV F
was 0 VERB F
given 0 VERB F
as 0 ADP F
a 0 DET F
test 0 PUNCT F
dose 0 NOUN F
. 0 PUNCT F

After 0 ADP T
4 0 NUM F
min 0 NOUN F
the 0 DET F
full 0 ADJ F
anesthetic 0 ADJ F
dose 0 NOUN F
, 0 PUNCT F
based 0 VERB F
on 0 ADP F
body 0 NOUN F
size 0 NOUN F
, 0 PUNCT F
was 0 VERB F
injected 0 VERB F
with 0 ADP F
the 0 DET F
patient 0 NOUN F
supine 0 NOUN F
. 0 PUNCT F

Sensory B-OTHER ADJ T
blockade I-OTHER NOUN F
was 0 VERB F
determined 0 VERB F
by 0 ADP F
the 0 DET F
pinprick 0 NOUN F
method 0 NOUN F
and 0 CCONJ F
motor B-OTHER NOUN F
blockade I-OTHER NOUN F
by 0 ADP F
the 0 DET F
Bromage 0 NOUN T
method 0 NOUN F
at 0 ADP F
2-min 0 NOUN F
intervals 0 NOUN F
for 0 ADP F
the 0 DET F
first 0 ADJ F
20 0 NUM F
min 0 NOUN F
, 0 PUNCT F
at 0 ADP F
5-min 0 NOUN F
intervals 0 NOUN F
for 0 ADP F
the 0 DET F
next 0 ADJ F
10 0 NUM F
min 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
then 0 ADP F
every 0 DET F
15 0 NUM F
min 0 NOUN F
to 0 ADP F
a 0 DET F
total 0 NOUN F
of 0 ADP F
240 0 NUM F
min 0 NOUN F
. 0 PUNCT F

Statistical 0 ADJ T
analysis 0 NOUN F
was 0 VERB F
done 0 PUNCT F
by 0 ADP F
the 0 DET F
Mann-Whitney 0 NOUN T
test 0 NOUN F
, 0 PUNCT F
with 0 ADP F
P 0 NOUN T
less 0 ADV F
than 0 ADP F
0.05 0 NUM F
considered 0 PUNCT F
significant 0 ADJ F
. 0 PUNCT F

RESULTS 0 NOUN T
Spread 0 NUM T
of 0 ADP F
sensory B-OTHER ADJ F
blockade I-OTHER NOUN F
was 0 VERB F
significantly 0 ADV F
faster 0 PUNCT F
with 0 ADP F
bupivacaine-CO2 0 NOUN F
and 0 CCONJ F
-HCl 0 NOUN F
at 0 ADP F
a 0 DET F
temperature 0 NOUN F
of 0 ADP F
36 0 NUM F
degrees 0 NOUN F
C 0 NUM T
as 0 VERB F
compared 0 VERB F
to 0 ADP F
4 0 NUM F
degrees 0 NOUN F
or 0 CCONJ F
20 0 NUM F
degrees 0 ADJ F
C 0 NUM T
( 0 PUNCT F
P 0 NOUN T
less 0 ADV F
than 0 PUNCT F
0.05 0 NUM F
) 0 PUNCT F
( 0 PUNCT F
Figs 0 NOUN T
. 0 PUNCT F

1 0 NUM F
, 0 PUNCT F
2 0 NUM F
and 0 CCONJ F
Table 0 PUNCT T
2 0 NUM F
) 0 PUNCT F
. 0 PUNCT F
( 0 PUNCT F

ABSTRACT 0 ADP T
TRUNCATED 0 PUNCT T
AT 0 ADP T
250 0 NUM F
WORDS 0 NOUN T
) 0 PUNCT F

Risk 0 NOUN T
of 0 ADP F
infection 0 NOUN F
after 0 ADP F
penetrating 0 VERB F
abdominal 0 ADJ F
trauma 0 NOUN F
. 0 PUNCT F

To 0 PART T
identify 0 NOUN F
the 0 DET F
risk 0 NOUN F
factors 0 NOUN F
for 0 ADP F
the 0 DET F
development 0 NOUN F
of 0 ADP F
postoperative 0 ADJ F
septic 0 ADJ F
complications 0 NOUN F
in 0 ADP F
patients 0 NOUN F
with 0 ADP F
intestinal 0 ADJ F
perforation 0 NOUN F
after 0 ADP F
abdominal 0 ADJ F
trauma 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
to 0 PART F
compare 0 NOUN F
the 0 DET F
efficacies 0 NOUN F
of 0 ADP F
single-drug 0 NOUN F
and 0 CCONJ F
dual-drug 0 NOUN F
prophylactic 0 ADJ F
antibiotic 0 ADJ F
therapy 0 NOUN F
, 0 PUNCT F
we 0 PRON F
studied 0 VERB F
145 0 NUM F
patients 0 NOUN F
who 0 PROPN F
presented 0 VERB F
with 0 ADP F
abdominal 0 ADJ F
trauma 0 NOUN F
and 0 CCONJ F
intestinal 0 ADJ F
perforation 0 NOUN F
at 0 ADP F
two 0 NUM F
hospitals 0 PROPN F
between 0 ADP F
July 0 NOUN T
1979 0 NUM F
and 0 CCONJ F
June 0 NOUN T
1982 0 NUM F
. 0 PUNCT F

Logistic-regression 0 NOUN T
analysis 0 NOUN F
showed 0 VERB F
that 0 ADP F
a 0 DET F
higher 0 PUNCT F
risk 0 NOUN F
of 0 ADP F
infection 0 NOUN F
( 0 PUNCT F
P 0 NOUN T
less 0 ADV F
than 0 PUNCT F
0.05 0 NUM F
) 0 PUNCT F
was 0 VERB F
associated 0 VERB F
with 0 ADP F
increased 0 VERB F
age 0 NOUN F
, 0 PUNCT F
injury 0 NOUN F
to 0 ADP F
the 0 DET F
left 0 ADJ F
colon 0 NOUN F
necessitating 0 NUM F
colostomy 0 NOUN F
, 0 PUNCT F
a 0 DET F
larger 0 PUNCT F
number 0 NOUN F
of 0 ADP F
units 0 NOUN F
of 0 ADP F
blood 0 NOUN F
or 0 CCONJ F
blood 0 NOUN F
products 0 NOUN F
administered 0 VERB F
at 0 ADP F
surgery 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
a 0 DET F
larger 0 PUNCT F
number 0 NOUN F
of 0 ADP F
injured 0 VERB F
organs 0 NOUN F
. 0 PUNCT F

The 0 DET T
presence 0 NOUN F
of 0 ADP F
shock 0 NOUN F
on 0 ADP F
arrival 0 NOUN F
, 0 PUNCT F
which 0 ADP F
was 0 VERB F
found 0 VERB F
to 0 PART F
increase 0 NOUN F
the 0 DET F
risk 0 NOUN F
of 0 ADP F
infection B-PHYSICAL NOUN F
when 0 ADP F
this 0 DET F
factor 0 NOUN F
was 0 VERB F
analyzed 0 VERB F
individually 0 ADV F
, 0 PUNCT F
did 0 PUNCT F
not 0 ADV F
add 0 PUNCT F
predictive 0 ADJ F
power 0 NOUN F
. 0 PUNCT F

Patients 0 NOUN T
with 0 ADP F
postoperative 0 ADJ F
sepsis 0 NOUN F
were 0 VERB F
hospitalized B-OTHER VERB F
significantly I-OTHER ADV F
longer 0 PUNCT F
than 0 PUNCT F
were 0 DET F
patients 0 NOUN F
without 0 ADP F
infection 0 NOUN F
( 0 PUNCT F
13.8 0 NUM F
vs. 0 CCONJ F
7.7 0 NUM F
days 0 NOUN F
, 0 PUNCT F
P 0 NOUN T
less 0 ADV F
than 0 PUNCT F
0.0001 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Both 0 CCONJ T
treatment 0 NOUN F
regimens 0 NOUN F
-- 0 PUNCT F
cefoxitin 0 NOUN F
given 0 VERB F
alone 0 ADJ F
and 0 CCONJ F
clindamycin 0 NOUN F
and 0 CCONJ F
gentamicin 0 NOUN F
given 0 VERB F
together 0 ADV F
-- 0 PUNCT F
resulted 0 CCONJ F
in 0 ADP F
similar 0 ADJ F
infection B-PHYSICAL NOUN F
rates I-PHYSICAL NOUN F
, 0 PUNCT F
drug B-PHYSICAL NOUN F
toxicity I-PHYSICAL NOUN F
, 0 PUNCT F
duration B-OTHER NOUN F
of I-OTHER ADP F
hospitalization I-OTHER NOUN F
, 0 PUNCT F
and 0 CCONJ F
costs 0 NOUN F
. 0 PUNCT F

Immediately 0 ADV T
restored 0 VERB F
, 0 PUNCT F
single-tapered 0 ADJ F
implants 0 NOUN F
in 0 ADP F
the 0 DET F
anterior 0 ADJ F
maxilla 0 NOUN F
: 0 PUNCT F
prosthodontic 0 ADJ F
and 0 CCONJ F
aesthetic 0 ADJ F
outcomes 0 NOUN F
after 0 ADP F
1 0 NUM F
year 0 NOUN F
. 0 PUNCT F

BACKGROUND 0 NOUN T
Conventional 0 ADJ T
implant 0 NOUN F
protocols 0 NOUN F
advocate 0 NOUN F
a 0 DET F
two-stage 0 ADJ F
technique 0 NOUN F
with 0 ADP F
a 0 DET F
load-free 0 ADP F
, 0 PUNCT F
submerged 0 PUNCT F
healing 0 PROPN F
period 0 NOUN F
. 0 PUNCT F

Recent 0 ADJ T
studies 0 NOUN F
suggest 0 VERB F
that 0 ADP F
immediate 0 ADJ F
restoration 0 NOUN F
of 0 ADP F
single 0 ADJ F
implants 0 NOUN F
may 0 VERB F
be 0 ADJ F
a 0 DET F
viable 0 ADJ F
treatment 0 NOUN F
option 0 NOUN F
. 0 PUNCT F

PURPOSE 0 NOUN T
The 0 DET T
purpose 0 NOUN F
of 0 ADP F
this 0 DET F
study 0 NOUN F
was 0 VERB F
to 0 PART F
evaluate 0 NOUN F
prosthodontic 0 ADJ F
and 0 CCONJ F
aesthetic 0 ADJ F
peri-implant 0 PUNCT F
mucosal 0 ADJ F
outcomes 0 NOUN F
of 0 ADP F
immediately 0 ADV F
restored 0 VERB F
, 0 PUNCT F
Southern 0 NOUN T
single-tapered 0 ADJ F
implants 0 NOUN F
in 0 ADP F
the 0 DET F
anterior 0 ADJ F
maxilla 0 NOUN F
after 0 ADP F
1 0 NUM F
year 0 NOUN F
. 0 PUNCT F

MATERIALS 0 NOUN T
AND 0 CCONJ T
METHODS 0 PROPN T
Participants 0 NOUN T
( 0 PUNCT F
mean 0 NOUN F
age 0 NOUN F
: 0 PUNCT F
43.25 0 NUM F
years 0 NOUN F
; 0 PUNCT F
range 0 NOUN F
: 0 PUNCT F
23-71 0 NUM F
years 0 NOUN F
) 0 PUNCT F
satisfying 0 PUNCT F
specified 0 PUNCT F
inclusion 0 NOUN F
criteria 0 NOUN F
were 0 VERB F
randomly 0 ADV F
allocated 0 VERB F
to 0 ADP F
conventional 0 ADJ F
two-stage 0 ADJ F
restoration 0 NOUN F
( 0 PUNCT F
control 0 NOUN F
group 0 NOUN F
; 0 PUNCT F
n=14 0 NOUN F
) 0 PUNCT F
and 0 CCONJ F
immediate 0 ADJ F
restoration 0 NOUN F
groups 0 NOUN F
( 0 PUNCT F
test 0 ADV F
group 0 NOUN F
; 0 PUNCT F
n 0 NOUN F
=14 0 ADP F
) 0 PUNCT F
in 0 ADP F
a 0 DET F
randomized 0 VERB F
controlled 0 VERB F
clinical 0 ADJ F
trial 0 NOUN F
. 0 PUNCT F

Tapered 0 VERB T
, 0 PUNCT F
roughened-surface 0 NOUN F
Southern 0 ADJ T
implants 0 NOUN F
were 0 VERB F
placed 0 VERB F
using 0 VERB F
a 0 DET F
standardized 0 VERB F
technique 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
implant 0 NOUN F
level 0 NOUN F
bone 0 NOUN F
impressions 0 NOUN F
were 0 VERB F
made 0 VERB F
. 0 PUNCT F

Provisional 0 ADJ T
screw-retained 0 VERB F
crowns 0 NOUN F
, 0 PUNCT F
out 0 PUNCT F
of 0 ADP F
occlusion 0 NOUN F
, 0 PUNCT F
were 0 VERB F
placed 0 VERB F
at 0 ADP F
second-stage 0 NOUN F
surgery 0 NOUN F
after 0 ADP F
26 0 NUM F
weeks 0 NOUN F
for 0 ADP F
the 0 DET F
conventional 0 ADJ F
restoration 0 NOUN F
group 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
within 0 ADP F
4 0 NUM F
hours 0 NOUN F
of 0 ADP F
implant 0 NOUN F
placement 0 NOUN F
for 0 ADP F
the 0 DET F
immediate 0 ADJ F
restoration 0 NOUN F
group 0 NOUN F
. 0 PUNCT F

Both 0 DET T
groups 0 NOUN F
had 0 PUNCT F
definitive 0 ADJ F
screw-retained 0 VERB F
metal-ceramic 0 ADJ F
crowns 0 NOUN F
placed 0 VERB F
in 0 ADP F
occlusion 0 NOUN F
8 0 NUM F
weeks 0 NOUN F
later 0 ADJ F
. 0 PUNCT F

Peri-implant B-PHYSICAL ADJ T
mucosal I-PHYSICAL ADJ F
response 0 NOUN F
and B-PHYSICAL CCONJ F
papilla I-PHYSICAL NOUN F
index B-PHYSICAL NOUN F
were 0 VERB F
recorded 0 VERB F
4 0 NUM F
weeks 0 NOUN F
after 0 ADP F
definitive 0 ADJ F
crown 0 PUNCT F
placement 0 NOUN F
to 0 PART F
allow 0 VERB F
for 0 ADP F
mucosal 0 ADJ F
maturation 0 NOUN F
and 0 CCONJ F
at 0 ADP F
1 0 NUM F
year 0 NOUN F
. 0 PUNCT F

Prosthodontic B-PHYSICAL ADJ T
and 0 CCONJ F
aesthetic B-PHYSICAL ADJ F
outcomes 0 NOUN F
were 0 VERB F
assessed 0 VERB F
using 0 VERB F
established 0 VERB F
criteria 0 NOUN F
. 0 PUNCT F

RESULTS 0 NOUN T
There 0 CCONJ T
were 0 VERB F
no 0 DET F
significant 0 ADJ F
differences 0 NOUN F
within 0 ADP F
, 0 PUNCT F
or 0 CCONJ F
between 0 ADP F
, 0 PUNCT F
the 0 DET F
control 0 NOUN F
and 0 CCONJ F
test 0 ADV F
groups 0 NOUN F
for 0 ADP F
age 0 NOUN F
, 0 PUNCT F
gender 0 NOUN F
, 0 PUNCT F
bone B-OTHER NOUN F
quality B-OTHER NOUN F
or 0 CCONJ F
quantity B-OTHER NOUN F
, 0 PUNCT F
implant 0 VERB F
stability B-OTHER NOUN F
measurements I-OTHER NOUN F
at B-OTHER ADP F
surgery I-OTHER NOUN F
, 0 PUNCT F
or 0 CCONJ F
implant B-OTHER PUNCT F
length I-OTHER NOUN F
. 0 PUNCT F

There 0 PUNCT T
were 0 VERB F
no 0 DET F
significant 0 ADJ F
differences 0 NOUN F
in 0 ADP F
the 0 DET F
implant B-OTHER NOUN F
success I-OTHER NOUN F
rate B-OTHER NOUN F
as 0 PUNCT F
determined 0 VERB F
by 0 ADP F
radiographic 0 PUNCT F

Nitrous 0 ADJ T
oxide 0 NOUN F
diffusion 0 NOUN F
into 0 ADP F
tracheal 0 ADJ F
tube 0 NOUN F
cuffs B-PHYSICAL ADP F
-- 0 PUNCT F
efficacy 0 NOUN F
of 0 ADP F
a 0 DET F
new 0 ADJ F
prototype 0 NOUN F
cuff 0 ADJ F
pressure 0 NOUN F
release 0 NOUN F
valve 0 NOUN F
. 0 PUNCT F

BACKGROUND 0 NOUN T
The 0 DET T
aim 0 NOUN F
of 0 ADP F
this 0 DET F
study 0 NOUN F
was 0 VERB F
to 0 PART F
evaluate 0 NOUN F
the 0 DET F
performance B-OTHER NOUN F
of 0 ADP F
a 0 DET F
new 0 ADJ F
cuff B-PHYSICAL ADJ F
pressure I-PHYSICAL NOUN F
release 0 NOUN F
valve 0 NOUN F
( 0 PUNCT F
CPRV 0 NOUN T
) 0 PUNCT F
, 0 PUNCT F
in 0 ADP F
which 0 ADP F
the 0 DET F
release 0 NOUN F
pressure 0 NOUN F
can 0 VERB F
be 0 VERB F
adjusted 0 VERB F
from 0 ADP F
10 0 NUM F
to 0 ADP F
25 0 NUM F
cmH2O 0 NOUN F
, 0 PUNCT F
particularly 0 ADV F
intended 0 VERB F
to 0 ADP F
control 0 ADP F
pressure 0 NOUN F
in 0 ADP F
paediatric 0 ADJ F
cuffed 0 PUNCT F
tracheal 0 ADJ F
tubes 0 NOUN F
and 0 CCONJ F
to 0 PART F
avoid 0 NOUN F
cuff 0 ADJ F
hyperinflation 0 NOUN F
caused 0 VERB F
by 0 ADP F
N2O 0 NOUN T
diffusion 0 NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
In 0 PUNCT T
vitro 0 ADJ F
: 0 PUNCT F
the 0 DET F
PRV 0 NOUN T
was 0 VERB F
set 0 PUNCT F
to 0 ADP F
10 0 NUM F
, 0 PUNCT F
15 0 NUM F
, 0 PUNCT F
20 0 NUM F
or 0 CCONJ F
25 0 NUM F
cmH2O 0 NOUN F
release 0 NOUN F
pressure 0 NOUN F
and 0 CCONJ F
connected 0 VERB F
to 0 ADP F
a 0 DET F
cuffed 0 ADJ F
tube 0 NOUN F
placed 0 VERB F
into 0 ADP F
a 0 DET F
box 0 NOUN F
flushed 0 PUNCT F
with 0 ADP F
66 0 NUM F
% 0 SYM F
N2O 0 NOUN T
in 0 ADP F
O2 0 NOUN T
. 0 PUNCT F

The 0 DET T
cuff B-PHYSICAL ADJ F
pressure I-PHYSICAL NOUN F
was 0 VERB F
monitored 0 VERB F
with 0 ADP F
and 0 CCONJ F
without 0 ADP F
CPRV 0 NOUN T
for 0 ADP F
60 0 NUM F
min 0 NOUN F
. 0 PUNCT F

Experiments 0 NOUN T
were 0 VERB F
performed 0 VERB F
four 0 NUM F
times 0 NOUN F
using 0 VERB F
two 0 NUM F
different 0 ADJ F
CPRVs 0 NOUN T
. 0 PUNCT F

In 0 ADJ T
vivo 0 ADJ F
: 0 PUNCT F
with 0 ADP F
Institutional 0 ADJ T
Review 0 NOUN T
Board 0 NOUN T
approval 0 PUNCT F
, 0 PUNCT F
CPRV 0 NOUN T
was 0 VERB F
studied 0 VERB F
in 0 ADP F
50 0 NUM F
children 0 NOUN F
undergoing 0 SYM F
general 0 ADJ F
anaesthesia 0 NOUN F
with 0 ADP F
tracheal 0 ADJ F
intubation 0 NOUN F
and 0 CCONJ F
standardized 0 VERB F
anaesthesia 0 NOUN F
technique 0 NOUN F
( 0 PUNCT F
including 0 PROPN F
66 0 NUM F
% 0 SYM F
N2O 0 NOUN T
in 0 ADP F
O2 0 NOUN T
) 0 PUNCT F
and 0 CCONJ F
ventilator 0 NOUN F
settings 0 NOUN F
. 0 PUNCT F

Patients 0 NOUN T
were 0 VERB F
randomized 0 VERB F
into 0 ADP F
two 0 NUM F
groups 0 NOUN F
( 0 PUNCT F
with 0 ADP F
and 0 CCONJ F
without 0 ADP F
CPRV 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
cuff B-PHYSICAL ADJ F
pressure I-PHYSICAL NOUN F
baseline 0 NOUN F
was 0 VERB F
20 0 NUM F
cmH2O 0 NOUN F
and 0 CCONJ F
CPRV 0 NOUN T
was 0 VERB F
set 0 PUNCT F
to 0 ADP F
25 0 NUM F
cmH2O 0 NOUN F
. 0 PUNCT F

If 0 PUNCT T
the 0 DET F
cuff B-PHYSICAL ADJ F
pressure I-PHYSICAL NOUN F
exceeded 0 VERB F
25 0 NUM F
cmH2O 0 NOUN F
, 0 PUNCT F
it 0 PRON F
was 0 VERB F
manually 0 ADV F
released 0 VERB F
to 0 ADP F
20 0 NUM F
cmH2O 0 NOUN F
. 0 PUNCT F

The 0 DET T
numbers 0 NOUN F
of 0 ADP F
deflations 0 NOUN F
in 0 ADP F
both 0 CCONJ F
groups 0 NOUN F
were 0 VERB F
noted 0 VERB F
and 0 CCONJ F
compared 0 VERB F
by 0 ADP F
Mann-Whitney 0 NOUN T
U-test 0 NOUN T
( 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.05 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

RESULTS 0 DET T
In 0 PUNCT T
vitro 0 ADJ F
: 0 PUNCT F
the 0 DET F
cuff B-PHYSICAL ADJ F
pressure I-PHYSICAL NOUN F
exceeded 0 ADP F
50 0 NUM F
cmH2O 0 NOUN F
after 0 ADP F
60 0 NUM F
min 0 NOUN F
without 0 ADP F
CPRV 0 NOUN T
, 0 PUNCT F
but 0 CCONJ F
did 0 PUNCT F
not 0 ADV F
exceed 0 PUNCT F
the 0 DET F
settings 0 NOUN F
with 0 ADP F
CPRV 0 NOUN T
. 0 PUNCT F

In 0 ADJ T
vivo 0 ADJ F
: 0 PUNCT F
there 0 PUNCT F
was 0 VERB F
no 0 DET F
need 0 ADP F
to 0 PUNCT F
manually 0 ADV F
deflate 0 PUNCT F
the 0 DET F
cuff 0 ADJ F
in 0 ADP F
the 0 DET F
CPRV 0 NOUN T
group 0 NOUN F
but 0 CCONJ F
, 0 PUNCT F
in 0 ADP F
every 0 DET F
patient 0 NOUN F
in 0 ADP F
the 0 DET F
control 0 NOUN F
group 0 NOUN F
, 0 PUNCT F
three 0 NUM F
( 0 PUNCT F
two 0 NUM F
to 0 ADP F
seven 0 NUM F
) 0 PUNCT F
deflating 0 VERB F
manoeuvres 0 NOUN F
were 0 VERB F
required 0 VERB F
within 0 ADP F
the 0 DET F
first 0 ADJ F
hour 0 NOUN F
of 0 ADP F
anaesthesia 0 NOUN F
( 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.0001 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

CONCLUSION 0 NOUN T
The 0 DET T
CPRV 0 NOUN T
allows 0 NOUN F
reliable B-PHYSICAL ADJ F
cuff I-PHYSICAL ADJ F
pressure I-PHYSICAL NOUN F
release I-PHYSICAL NOUN F
at 0 ADP F
various 0 ADJ F
pressure 0 NOUN F
levels 0 NOUN F
and 0 CCONJ F
reliably 0 ADV F
prevents 0 NOUN F
cuff B-PHYSICAL ADJ F
pressure I-PHYSICAL NOUN F
increases 0 CCONJ F
caused 0 VERB F
by 0 ADP F
N2O 0 NOUN T
. 0 PUNCT F

Cigarette 0 NOUN T
smoking 0 PUNCT F
is 0 VERB F
associated 0 VERB F
with 0 ADP F
increased 0 VERB F
circulating 0 VERB F
proinflammatory 0 ADJ F
and 0 CCONJ F
procoagulant 0 NOUN F
markers 0 NOUN F
in 0 ADP F
patients 0 NOUN F
with 0 ADP F
chronic 0 ADJ F
coronary 0 ADJ F
artery 0 NOUN F
disease 0 NOUN F
: 0 PUNCT F
effects 0 NOUN F
of 0 ADP F
aspirin 0 NOUN F
treatment 0 NOUN F
. 0 PUNCT F

BACKGROUND 0 NOUN T
Smoking 0 PROPN T
is 0 VERB F
associated 0 VERB F
with 0 ADP F
endothelial 0 ADJ F
dysfunction 0 NOUN F
. 0 PUNCT F

Cytokines 0 NOUN T
released 0 VERB F
by 0 ADP F
injured 0 ADV F
endothelium 0 NOUN F
promote 0 NOUN F
vascular 0 ADJ F
interactions 0 NOUN F
with 0 ADP F
leukocytes 0 NOUN F
and 0 CCONJ F
platelets 0 NOUN F
. 0 PUNCT F

We 0 PRON T
investigated 0 VERB F
whether 0 ADP F
( 0 PUNCT F
a 0 NOUN F
) 0 PUNCT F
cigarette 0 NOUN F
smoking 0 PUNCT F
is 0 VERB F
linked 0 VERB F
to 0 ADP F
increased 0 VERB F
cytokine 0 NOUN F
production 0 NOUN F
, 0 PUNCT F
which 0 DET F
may 0 VERB F
mediate 0 VERB F
platelet 0 NOUN F
activation 0 NOUN F
and 0 CCONJ F
thrombin 0 NOUN F
generation 0 NOUN F
in 0 ADP F
chronic 0 ADJ F
coronary 0 ADJ F
artery 0 NOUN F
disease 0 NOUN F
( 0 PUNCT F
CAD 0 NOUN T
) 0 PUNCT F
, 0 PUNCT F
and 0 CCONJ F
( 0 PUNCT F
b 0 NOUN F
) 0 PUNCT F
aspirin 0 NOUN F
treatment 0 NOUN F
inhibits 0 NOUN F
smoking-related 0 VERB F
changes 0 NOUN F
on 0 ADP F
cytokines 0 NOUN F
, 0 PUNCT F
platelets 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
thrombin 0 NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
AND 0 CCONJ T
RESULTS 0 PROPN T
Plasma 0 NOUN T
macrophage-colony-stimulating 0 ADJ F
factor 0 NOUN F
( 0 PUNCT F
M-CSF 0 NOUN T
) 0 PUNCT F
and 0 CCONJ F
C-reactive 0 ADJ T
protein 0 NOUN F
( 0 PUNCT F
CRP 0 NOUN T
) 0 PUNCT F
were 0 VERB F
measured 0 VERB F
in 0 ADP F
100 0 NUM F
patients 0 NOUN F
with 0 ADP F
chronic 0 ADJ F
CAD 0 NOUN T
, 0 PUNCT F
60 0 NUM F
of 0 ADP F
whom 0 ADP F
were 0 VERB F
chronic 0 ADJ F
smokers 0 NOUN F
. 0 PUNCT F

Prothrombin 0 NOUN T
fragments 0 NOUN F
1+2 0 ADJ F
and 0 CCONJ F
urinary 0 ADJ F
11-dehydro-thromboxane 0 ADJ F
B2 0 NOUN T
( 0 PUNCT F
TXB2 0 NOUN T
) 0 PUNCT F
were 0 VERB F
additionally 0 ADV F
measured 0 VERB F
in 0 ADP F
60 0 NUM F
of 0 ADP F
100 0 NUM F
patients 0 NOUN F
( 0 PUNCT F
30 0 NUM F
of 0 ADP F
whom 0 ADP F
were 0 VERB F
smokers 0 NOUN F
) 0 PUNCT F
and 0 CCONJ F
in 0 ADP F
24 0 NUM F
healthy 0 ADJ F
controls 0 NOUN F
. 0 PUNCT F

Smokers 0 NOUN T
( 0 PUNCT F
n 0 NOUN F
= 0 SYM F
20 0 NUM F
) 0 PUNCT F
matched 0 PROPN F
for 0 ADP F
age 0 NOUN F
, 0 PUNCT F
myocardial 0 ADJ F
ischemia 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
other 0 ADJ F
risk 0 NOUN F
factors 0 NOUN F
with 0 ADP F
20 0 NUM F
nonsmokers 0 NOUN F
entered 0 VERB F
a 0 DET F
double-blind 0 ADJ F
crossover 0 ADP F
trial 0 NOUN F
of 0 ADP F
aspirin 0 NOUN F
( 0 PUNCT F
300 0 ADP F
mg/d 0 NOUN F
for 0 ADP F
3 0 NUM F
weeks 0 NOUN F
) 0 PUNCT F
versus 0 CCONJ F
placebo 0 NOUN F
. 0 PUNCT F

Blood 0 NOUN T
and 0 CCONJ F
urine 0 NOUN F
measurements 0 NOUN F
were 0 VERB F
repeated 0 VERB F
after 0 ADP F
each 0 DET F
treatment 0 NOUN F
. 0 PUNCT F

Compared 0 VERB T
with 0 ADP F
nonsmokers 0 NOUN F
, 0 PUNCT F
smokers 0 NOUN F
had 0 PUNCT F
3-fold B-PHYSICAL NOUN F
median 0 ADJ F
M-CSF B-PHYSICAL NOUN T
( 0 PUNCT F
1499 0 NUM F
vs 0 CCONJ F
476 0 NUM F
pg/mL 0 NOUN F
) 0 PUNCT F
, 0 PUNCT F
2-fold B-PHYSICAL ADP F
CRP B-PHYSICAL NOUN T
( 0 PUNCT F
1.5 0 NUM F
vs 0 CCONJ F
0.8 0 NUM F
mg/L 0 NOUN F
) 0 PUNCT F
, 0 PUNCT F
and 0 CCONJ F
higher 0 PUNCT F
11-dehydro-TXB B-PHYSICAL NUM F
2 0 NUM F
( 0 PUNCT F
3.6 0 NUM F
vs 0 CCONJ F
2.1 0 NUM F
ng/mg 0 NOUN F
creatinine 0 NOUN F
, 0 PUNCT F
P 0 NOUN T
< 0 SYM F
.01 0 PUNCT F
for 0 ADP F
all 0 DET F
comparisons 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

After 0 ADP T
aspirin 0 NOUN F
treatment 0 NOUN F
, 0 PUNCT F
M-CSF B-PHYSICAL NOUN T
, 0 PUNCT F
CRP B-PHYSICAL NOUN T
, 0 PUNCT F
11-dehydro-TXB B-PHYSICAL NOUN F
2 I-PHYSICAL NUM F
, 0 PUNCT F
and 0 PUNCT F

Conjugated 0 VERB T
equine 0 ADJ F
estrogen 0 NOUN F
influence 0 NOUN F
on 0 ADP F
mammographic B-PHYSICAL ADJ F
density I-PHYSICAL NOUN F
in 0 ADP F
postmenopausal 0 ADJ F
women 0 NOUN F
in 0 ADP F
a 0 DET F
substudy 0 NOUN F
of 0 ADP F
the 0 DET F
women 0 NOUN F
's 0 PUNCT F
health 0 NOUN F
initiative 0 NOUN F
randomized 0 VERB F
trial 0 NOUN F
. 0 PUNCT F

PURPOSE 0 NOUN T
Increased 0 PUNCT T
mammographic B-PHYSICAL ADJ F
density I-PHYSICAL NOUN F
is 0 VERB F
associated 0 VERB F
with 0 ADP F
increased 0 VERB F
breast 0 NOUN F
cancer 0 NOUN F
risk 0 NOUN F
and 0 CCONJ F
reduced 0 VERB F
sensitivity 0 NOUN F
of 0 ADP F
screening 0 VERB F
mammography 0 NOUN F
and 0 CCONJ F
is 0 VERB F
related 0 VERB F
to 0 ADP F
hormone 0 NOUN F
exposure 0 NOUN F
. 0 PUNCT F

However 0 ADV T
, 0 PUNCT F
the 0 DET F
effects 0 NOUN F
of 0 ADP F
conjugated 0 PUNCT F
equine 0 ADJ F
estrogens 0 NOUN F
( 0 PUNCT F
CEEs 0 NOUN T
) 0 PUNCT F
alone 0 ADJ F
on 0 ADP F
mammographic B-PHYSICAL ADJ F
density I-PHYSICAL NOUN F
in 0 ADP F
diverse 0 ADJ F
racial/ethnic 0 ADJ F
populations 0 NOUN F
are 0 VERB F
not 0 ADV F
established 0 VERB F
. 0 PUNCT F

We 0 PRON T
examined 0 VERB F
the 0 DET F
effect 0 NOUN F
of 0 ADP F
CEE 0 NOUN T
alone 0 ADJ F
on 0 ADP F
mammographic B-PHYSICAL ADJ F
density I-PHYSICAL NOUN F
in 0 ADP F
a 0 DET F
subsample 0 NOUN F
of 0 ADP F
the 0 DET F
Women 0 NOUN T
's 0 PUNCT F
Health 0 NOUN T
Initiative 0 NOUN T
( 0 PUNCT F
WHI 0 NOUN T
) 0 PUNCT F
clinical 0 ADJ F
trial 0 NOUN F
participants 0 NOUN F
. 0 PUNCT F

PATIENTS 0 NOUN T
AND 0 CCONJ T
METHODS 0 NOUN T
In 0 ADP T
the 0 DET F
WHI 0 PUNCT T
trial 0 NOUN F
, 0 PUNCT F
women 0 NOUN F
were 0 VERB F
randomly 0 ADV F
assigned 0 VERB F
to 0 ADP F
daily 0 ADJ F
CEE 0 NOUN T
0.625 0 NUM F
mg 0 NOUN F
or 0 CCONJ F
placebo 0 NOUN F
. 0 PUNCT F

The 0 DET T
effect 0 NOUN F
of 0 ADP F
CEE 0 NOUN T
on 0 ADP F
mammographic B-PHYSICAL ADJ F
percent I-PHYSICAL NOUN F
density I-PHYSICAL NOUN F
was 0 VERB F
determined 0 VERB F
over 0 ADP F
1 0 NUM F
and 0 CCONJ F
2 0 NUM F
years 0 NOUN F
in 0 ADP F
a 0 DET F
stratified 0 VERB F
random 0 ADJ F
sample 0 NOUN F
of 0 ADP F
435 0 NUM F
racially 0 ADV F
and 0 CCONJ F
ethnically 0 NUM F
diverse 0 ADJ F
participants 0 NOUN F
from 0 ADP F
15 0 NUM F
of 0 ADP F
40 0 NUM F
WHI 0 NOUN T
clinics 0 PROPN F
. 0 PUNCT F

RESULTS 0 DET T
Use 0 NOUN T
of 0 ADP F
CEE 0 NOUN T
resulted 0 VERB F
in 0 ADP F
mean 0 NOUN F
increase 0 NOUN F
in 0 ADP F
mammographic B-PHYSICAL ADJ F
percent I-PHYSICAL NOUN F
density I-PHYSICAL NOUN F
of 0 ADP F
1.6 0 NUM F
percentage 0 NOUN F
points 0 NOUN F
( 0 PUNCT F
95 0 NUM F
% 0 SYM F
CI 0 NOUN T
, 0 PUNCT F
0.8 0 NUM F
to 0 ADP F
2.4 0 NUM F
) 0 PUNCT F
at 0 ADP F
year 0 NOUN F
1 0 NUM F
compared 0 VERB F
with 0 ADP F
a 0 DET F
mean 0 NOUN F
decrease 0 NOUN F
of 0 ADP F
1.0 0 NUM F
percentage 0 NOUN F
point 0 NOUN F
( 0 PUNCT F
95 0 NUM F
% 0 SYM F
CI 0 NOUN T
, 0 PUNCT F
-1.7 0 DET F
to 0 ADP F
-0.4 0 ADP F
) 0 PUNCT F
in 0 ADP F
the 0 DET F
placebo 0 NOUN F
group 0 NOUN F
( 0 PUNCT F
P 0 NOUN T
< 0 SYM F
.001 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
effect 0 NOUN F
persisted 0 VERB F
for 0 ADP F
2 0 NUM F
years 0 NOUN F
, 0 PUNCT F
with 0 ADP F
a 0 DET F
mean 0 NOUN F
increase 0 NOUN F
of 0 ADP F
1.7 0 NUM F
percentage 0 NOUN F
points 0 NOUN F
( 0 PUNCT F
95 0 NUM F
% 0 SYM F
CI 0 NOUN T
, 0 PUNCT F
0.7 0 NUM F
to 0 ADP F
2.7 0 NUM F
) 0 PUNCT F
versus 0 CCONJ F
a 0 DET F
mean 0 NOUN F
decrease 0 NOUN F
of 0 ADP F
1.2 0 NUM F
percentage 0 NOUN F
points 0 NOUN F
( 0 PUNCT F
95 0 NUM F
% 0 SYM F
CI 0 NOUN T
, 0 PUNCT F
-1.8 0 ADJ F
to 0 ADP F
-0.5 0 ADJ F
; 0 PUNCT F
P 0 NOUN T
< 0 SYM F
.001 0 NUM F
) 0 PUNCT F
in 0 ADP F
the 0 DET F
hormone 0 NOUN F
and 0 CCONJ F
placebo 0 NOUN F
groups 0 NOUN F
, 0 PUNCT F
respectively 0 ADV F
. 0 PUNCT F

These 0 DET T
effects 0 NOUN F
were 0 VERB F
greater 0 PUNCT F
in 0 ADP F
women 0 NOUN F
age 0 NOUN F
60 0 NUM F
to 0 ADP F
79 0 NUM F
years 0 NOUN F
( 0 PUNCT F
P 0 NOUN T
= 0 SYM F
.03 0 NUM F
for 0 ADP F
interaction 0 NOUN F
across 0 ADP F
age 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

CONCLUSION 0 NOUN T
Use 0 NOUN T
of 0 ADP F
CEE 0 NOUN T
results 0 ADP F
in 0 ADP F
a 0 DET F
modest 0 ADJ F
but 0 CCONJ F
statistically 0 ADV F
significant 0 ADJ F
increase 0 NOUN F
in 0 ADP F
mammographic B-PHYSICAL ADJ F
density I-PHYSICAL NOUN F
that 0 ADP F
is 0 VERB F
sustained 0 VERB F
over 0 ADP F
at 0 VERB F
least 0 ADV F
a 0 DET F
2-year 0 NOUN F
period 0 NOUN F
. 0 PUNCT F

The 0 DET T
clinical 0 ADJ F
significance 0 NOUN F
of 0 ADP F
the 0 DET F
CEE 0 NOUN T
effect 0 NOUN F
on 0 ADP F
mammographic B-PHYSICAL ADJ F
density I-PHYSICAL NOUN F
remains 0 NOUN F
to 0 PART F
be 0 PUNCT F
determined 0 VERB F
. 0 PUNCT F

Low-dose 0 NOUN T
, 0 PUNCT F
vaginally 0 ADV F
administered 0 ADJ F
estrogens 0 NOUN F
may 0 VERB F
enhance 0 VERB F
local 0 ADJ F
benefits 0 NOUN F
of 0 ADP F
systemic 0 ADJ F
therapy 0 NOUN F
in 0 ADP F
the 0 DET F
treatment 0 NOUN F
of 0 ADP F
urogenital 0 ADJ F
atrophy 0 NOUN F
in 0 ADP F
postmenopausal 0 ADJ F
women 0 NOUN F
on 0 ADP F
hormone 0 NOUN F
therapy 0 NOUN F
. 0 PUNCT F

BACKGROUND 0 NOUN T
When 0 ADP T
genital 0 ADJ F
atrophy 0 NOUN F
exists 0 NOUN F
, 0 PUNCT F
systemic 0 ADJ F
hormone 0 NOUN F
therapy 0 NOUN F
( 0 PUNCT F
HT 0 NOUN T
) 0 PUNCT F
has 0 CCONJ F
a 0 DET F
timing 0 VERB F
until 0 ADP F
to 0 PUNCT F
induce 0 NOUN F
vaginal 0 ADJ F
proliferation 0 NOUN F
and 0 CCONJ F
symptomatic 0 ADJ F
relieve 0 NOUN F
. 0 PUNCT F

Thus 0 ADV T
, 0 PUNCT F
in 0 ADP F
order 0 NOUN F
to 0 PART F
obtain 0 NOUN F
a 0 DET F
prompt 0 NOUN F
improvement 0 NOUN F
, 0 PUNCT F
the 0 DET F
association 0 NOUN F
of 0 ADP F
local 0 ADJ F
therapy 0 NOUN F
acting 0 VERB F
on 0 ADP F
the 0 DET F
genital 0 ADJ F
epithelium 0 NOUN F
to 0 ADP F
the 0 DET F
systemic 0 ADJ F
treatment 0 NOUN F
should 0 VERB F
be 0 VERB F
considered 0 VERB F
. 0 PUNCT F

OBJECTIVE 0 NOUN T
To 0 PROPN T
evaluate 0 NOUN F
the 0 DET F
effects 0 NOUN F
of 0 ADP F
a 0 DET F
combined 0 VERB F
therapy 0 NOUN F
consisting 0 VERB F
of 0 ADP F
vaginal 0 ADJ F
estriol 0 NOUN F
with 0 ADP F
transdermal 0 ADJ F
17-beta-estradiol 0 NOUN F
( 0 PUNCT F
50 0 NUM F
microg/day 0 NOUN F
) 0 PUNCT F
plus 0 CCONJ F
medroxyprogesterone 0 NOUN F
acetate 0 NOUN F
( 0 PUNCT F
5 0 NUM F
mg/day 0 NOUN F
) 0 PUNCT F
per 0 ADP F
os 0 PUNCT F
in 0 ADP F
shortening 0 ADV F
the 0 DET F
period 0 NOUN F
of 0 ADP F
uro-genital 0 ADJ F
symptoms 0 NOUN F
. 0 PUNCT F

SUBJECTS 0 NOUN T
AND 0 CCONJ T
METHODS 0 NOUN T
In 0 ADP T
a 0 DET F
randomized 0 VERB F
, 0 PUNCT F
double 0 ADJ F
blind 0 ADJ F
, 0 PUNCT F
controlled 0 VERB F
with 0 ADP F
placebo 0 NOUN F
study 0 NOUN F
, 0 PUNCT F
27 0 NUM F
women 0 NOUN F
with 0 ADP F
climacteric 0 ADJ F
symptoms 0 NOUN F
and 0 CCONJ F
atrophic 0 ADJ F
vaginitis 0 NOUN F
were 0 VERB F
treated 0 VERB F
for 0 ADP F
4 0 NUM F
months 0 NOUN F
with 0 ADP F
HT 0 NOUN T
plus 0 CCONJ F
vaginal 0 ADJ F
estriol 0 NOUN F
0.5 0 NUM F
mg/day 0 NOUN F
( 0 PUNCT F
group 0 NOUN F
E 0 NOUN T
) 0 PUNCT F
or 0 CCONJ F
placebo 0 NOUN F
( 0 PUNCT F
group 0 NOUN F
P 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

Patients 0 NOUN T
use 0 NUM F
the 0 DET F
local 0 ADJ F
medication 0 NOUN F
daily 0 ADJ F
for 0 ADP F
the 0 DET F
first 0 ADJ F
3 0 NUM F
weeks 0 NOUN F
and 0 CCONJ F
twice-weekly 0 ADP F
thereafter 0 ADV F
. 0 PUNCT F

Before 0 ADP T
entering 0 VERB F
in 0 ADP F
the 0 DET F
study 0 NOUN F
, 0 PUNCT F
patients 0 NOUN F
were 0 VERB F
asked 0 VERB F
about 0 PUNCT F
HT 0 NOUN T
and 0 CCONJ F
selected 0 VERB F
for 0 ADP F
inclusion 0 NOUN F
. 0 PUNCT F

In 0 ADP T
the 0 DET F
first 0 ADJ F
visit 0 NOUN F
, 0 PUNCT F
electible 0 ADJ F
patients 0 NOUN F
after 0 PUNCT F
written 0 PUNCT F
informed 0 VERB F
consent 0 NOUN F
were 0 VERB F
randomized 0 VERB F
to 0 PART F
receive 0 NOUN F
HT 0 NOUN T
plus 0 CCONJ F
local 0 ADJ F
estriol 0 NOUN F
or 0 CCONJ F
placebo 0 NOUN F
. 0 PUNCT F

All 0 DET T
the 0 DET F
subjects 0 NOUN F
had 0 PUNCT F
baseline 0 NOUN F
studies 0 NOUN F
, 0 PUNCT F
including 0 PUNCT F
medical 0 ADJ F
history 0 NOUN F
, 0 PUNCT F
physical 0 ADJ F
examination 0 NOUN F
, 0 PUNCT F
blood 0 NOUN F
and 0 CCONJ F
urine 0 NOUN F
analysis 0 NOUN F
. 0 PUNCT F

In 0 ADP T
order 0 NOUN F
to 0 PART F
evaluate 0 NOUN F
the 0 DET F
effect 0 NOUN F
of 0 ADP F
local 0 ADJ F
treatment 0 NOUN F
on 0 ADP F
urinary 0 ADJ F
and 0 CCONJ F
genital 0 ADJ F
symptoms 0 NOUN F
, 0 PUNCT F
a 0 DET F
score 0 NOUN F
for 0 ADP F
genital 0 ADJ F
, 0 PUNCT F
urinary 0 ADJ F
and 0 CCONJ F
colposcopic 0 ADJ F
complaints 0 NOUN F
( 0 PUNCT F
0 0 NUM F
minimum-100 0 NOUN F
maximum 0 NOUN F
) 0 PUNCT F
was 0 VERB F
developed 0 VERB F
. 0 PUNCT F

This 0 DET T
score 0 NOUN F
and 0 CCONJ F
Blatt-Kuperman 0 NOUN T
were 0 VERB F
recorded 0 VERB F
and 0 CCONJ F
performed 0 VERB F
in 0 ADP F
every 0 DET F
control 0 NOUN F
. 0 PUNCT F

RESULTS 0 NOUN T
There 0 CCONJ T
were 0 VERB F
no 0 DET F
differences 0 NOUN F
on 0 ADP F
climacteric B-OTHER ADJ F
symptoms I-OTHER NOUN F
relief I-OTHER NOUN F
between I-OTHER ADP F
the I-OTHER DET F
two I-OTHER NUM F
groups I-OTHER NOUN F
. 0 PUNCT F

Additionally 0 ADV T
, 0 PUNCT F
the 0 DET F
improvement 0 NOUN F
in 0 ADP F
urinary B-OTHER ADJ F
symptoms I-OTHER NOUN F
at I-OTHER ADP F
the I-OTHER DET F
end I-OTHER NOUN F
of I-OTHER ADP F
the I-OTHER DET F
study I-OTHER NOUN F
was 0 VERB F
similar 0 ADJ F
for 0 ADP F
both 0 CCONJ F
groups 0 NOUN F
( 0 PUNCT F
from 0 ADP F
16.5 0 NUM F
+/- 0 SYM F
6.1 0 NUM F
to 0 ADP F
8.5 0 NUM F
+/- 0 SYM F
2.4 0 NUM F
for 0 ADP F
E 0 NOUN T
group 0 NOUN F
and 0 CCONJ F
from 0 ADP F
15.8 0 NUM F
+/- 0 SYM F
7.8 0 NUM F
to 0 ADP F
8.8 0 NUM F
+/- 0 SYM F
2.7 0 NUM F
for 0 ADP F
P 0 NOUN T
group 0 NOUN F
; 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.01 0 NUM F
versus 0 CCONJ F
basal 0 ADJ F
) 0 PUNCT F
; 0 PUNCT F
however 0 ADV F
, 0 PUNCT F
those 0 ADP F
women 0 NOUN F
in 0 ADP F
group 0 NOUN F
E 0 NOUN T
reached 0 ADP F
significant B-OTHER ADJ F
improvement I-OTHER NOUN F
on I-OTHER ADP F
urinary I-OTHER ADJ F
complaints I-OTHER NOUN F
since 0 ADP F
the 0 DET F
first 0 ADJ F
month 0 NOUN F
of 0 ADP F
treatment 0 NOUN F
. 0 PUNCT F

Additionally 0 ADV T
, 0 PUNCT F
a 0 DET F
significant 0 ADJ F
difference 0 NOUN F
between 0 ADP F
E 0 NOUN T
and 0 CCONJ F
P 0 NOUN T
was 0 VERB F
observed 0 VERB F
at 0 ADP F
months 0 NOUN F
2 0 NUM F
and 0 CCONJ F
3 0 NUM F
, 0 PUNCT F
although 0 ADP F
no 0 DET F
differences 0 NOUN F
were 0 VERB F
detected 0 VERB F
at 0 ADP F
the 0 DET F
end 0 NOUN F
of 0 ADP F
the 0 DET F
study 0 NOUN F
. 0 PUNCT F

Papanicolaou 0 NOUN T
smear 0 NOUN F
showed 0 VERB F
reactive B-OTHER ADJ F
or 0 CCONJ F
reparative B-OTHER ADJ F
changes I-OTHER NOUN F
and 0 CCONJ F
karyopyknotic B-OTHER ADJ F
index 0 NOUN F
exhibited B-OTHER VERB F
a I-OTHER DET F
significant B-OTHER ADJ F
increase 0 NOUN F
in 0 ADP F
superficial B-PHYSICAL ADJ F
cells I-PHYSICAL NOUN F
in 0 ADP F
both B-OTHER CCONJ F
groups I-OTHER NOUN F
and 0 CCONJ F
at B-OTHER ADP F
the I-OTHER DET F
end I-OTHER PUNCT F

Effect 0 NOUN T
of 0 ADP F
ibuprofen 0 NOUN F
on 0 ADP F
cyclooxygenase B-PHYSICAL NOUN F
and 0 CCONJ F
nitric B-PHYSICAL ADJ F
oxide I-PHYSICAL NOUN F
synthase I-PHYSICAL NOUN F
of I-PHYSICAL ADP F
gastric I-PHYSICAL ADJ F
mucosa I-PHYSICAL NOUN F
: 0 PUNCT F
correlation 0 NOUN F
with 0 ADP F
endoscopic B-PHYSICAL ADJ F
lesions I-PHYSICAL NOUN F
and 0 CCONJ F
adverse B-ADVERSE-EFFECTS ADJ F
reactions I-ADVERSE-EFFECTS NOUN F
. 0 PUNCT F

The 0 DET T
aim 0 NOUN F
of 0 ADP F
this 0 DET F
study 0 NOUN F
was 0 VERB F
to 0 PART F
evaluate 0 NOUN F
the 0 DET F
effect 0 NOUN F
of 0 ADP F
ibuprofen 0 NOUN F
on 0 ADP F
gastric B-PHYSICAL ADJ F
mucosa I-PHYSICAL NOUN F
and 0 CCONJ F
enzymes B-PHYSICAL NOUN F
involved I-PHYSICAL VERB F
in I-PHYSICAL ADP F
gastroprotection I-PHYSICAL NOUN F
in 0 ADP F
healthy 0 ADJ F
volunteers 0 NOUN F
. 0 PUNCT F

Twenty-four 0 PUNCT T
Helicobacter 0 NOUN T
pylori-negative 0 ADJ F
subjects 0 NOUN F
were 0 VERB F
randomized 0 VERB F
to 0 ADP F
treatment 0 NOUN F
with 0 ADP F
ibuprofen 0 NOUN F
or 0 CCONJ F
ibuprofen-arginate 0 NOUN F
( 0 PUNCT F
each 0 CCONJ F
600 0 NUM F
mg/6 0 NOUN F
hr 0 NOUN F
during 0 ADP F
3 0 NUM F
days 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

Endoscopies 0 NOUN T
were 0 VERB F
performed 0 VERB F
1 0 NUM F
week 0 NOUN F
before 0 ADP F
and 0 CCONJ F
after 0 ADP F
treatment 0 NOUN F
. 0 PUNCT F

Biopsies 0 NOUN T
were 0 VERB F
taken 0 VERB F
from 0 ADP F
the 0 DET F
gastric 0 ADJ F
antrum 0 NOUN F
and 0 CCONJ F
corpus 0 NOUN F
for 0 ADP F
determination 0 NOUN F
of 0 ADP F
prostaglandin 0 NOUN F
E2 0 NOUN T
( 0 PUNCT F
PGE2 0 NOUN T
) 0 PUNCT F
by 0 ADP F
ELISA 0 NOUN T
and 0 CCONJ F
cyclooxygenase 0 NOUN F
( 0 PUNCT F
COX-1 0 NOUN T
and 0 CCONJ F
COX-2 0 NOUN T
) 0 PUNCT F
and 0 CCONJ F
nitric 0 ADJ F
oxide 0 NOUN F
synthase 0 NOUN F
( 0 PUNCT F
eNOS 0 NOUN F
and 0 CCONJ F
iNOS 0 NOUN F
) 0 PUNCT F
by 0 ADP F
western 0 NOUN F
blot 0 NOUN F
. 0 PUNCT F

All 0 DET T
subjects 0 NOUN F
had 0 PUNCT F
at 0 VERB F
least 0 ADV F
one 0 NUM F
gastric 0 ADJ F
lesion 0 NOUN F
except 0 PUNCT F
for 0 ADP F
two 0 NUM F
individuals 0 NOUN F
taking 0 PUNCT F
ibuprofen-arginate 0 NOUN F
. 0 PUNCT F

Ibuprofen-arginate 0 PUNCT T
caused 0 VERB F
a 0 DET F
lower 0 PUNCT F
rate 0 NOUN F
of 0 ADP F
clinical B-PHYSICAL ADJ F
adverse I-PHYSICAL ADJ F
reactions I-PHYSICAL ADJ F
than 0 ADP F
ibuprofen 0 NOUN F
. 0 PUNCT F

Subjects 0 NOUN T
with 0 ADP F
gastric B-PHYSICAL ADJ F
lesions I-PHYSICAL NOUN F
or 0 CCONJ F
adverse 0 ADJ F
reactions 0 NOUN F
had 0 VERB F
lower 0 PUNCT F
PGE2 0 NOUN T
levels 0 NOUN F
. 0 PUNCT F

COX-1 B-PHYSICAL NOUN T
, 0 PUNCT F
COX-2 B-PHYSICAL NOUN T
, 0 PUNCT F
eNOS B-PHYSICAL NOUN F
, 0 PUNCT F
and 0 CCONJ F
iNOS B-PHYSICAL NOUN F
were 0 VERB F
detectable 0 ADJ F
in 0 ADP F
all 0 DET F
subjects 0 NOUN F
. 0 PUNCT F

The 0 DET T
constitutive 0 ADJ F
enzymes 0 NOUN F
( 0 PUNCT F
COX-1 0 NOUN T
and 0 CCONJ F
eNOS 0 NOUN F
) 0 PUNCT F
did 0 DET F
not 0 ADV F
change 0 VERB F
after 0 ADP F
treatment 0 NOUN F
. 0 PUNCT F

COX-2 0 NOUN T
was 0 VERB F
higher 0 PUNCT F
in 0 ADP F
corpus 0 NOUN F
than 0 PUNCT F
antrum 0 NOUN F
and 0 CCONJ F
it 0 PRON F
increased 0 VERB F
after 0 ADP F
ibuprofen 0 NOUN F
treatment 0 NOUN F
. 0 PUNCT F

iNOS 0 NOUN F
tended 0 VERB F
to 0 PART F
increase 0 VERB F
mildly 0 ADV F
in 0 ADP F
the 0 DET F
corpus 0 NOUN F
in 0 ADP F
subjects 0 NOUN F
with 0 ADP F
adverse 0 ADJ F
reactions 0 NOUN F
or 0 CCONJ F
endoscopic 0 ADJ F
lesions 0 NOUN F
. 0 PUNCT F

There 0 PUNCT T
were 0 VERB F
no 0 DET F
significant 0 ADJ F
differences 0 NOUN F
between 0 ADP F
ibuprofen 0 NOUN F
and 0 CCONJ F
ibuprofen-arginate 0 NOUN F
in 0 ADP F
PGE2 0 NOUN T
, 0 PUNCT F
or 0 CCONJ F
enzymes 0 NOUN F
. 0 PUNCT F

The 0 DET T
patient 0 NOUN F
experience 0 NOUN F
of 0 ADP F
community 0 NOUN F
hospital 0 NOUN F
-- 0 PUNCT F
the 0 DET F
process 0 NOUN F
of 0 ADP F
care 0 NOUN F
as 0 ADP F
a 0 DET F
determinant 0 NOUN F
of 0 ADP F
satisfaction 0 NOUN F
. 0 PUNCT F

AIMS 0 NOUN T
AND 0 CCONJ T
OBJECTIVES 0 NOUN T
We 0 PRON T
report 0 VERB F
findings 0 NOUN F
from 0 ADP F
a 0 DET F
qualitative 0 ADJ F
study 0 NOUN F
to 0 PART F
identify 0 NOUN F
patient 0 NOUN F
views 0 CCONJ F
of 0 ADP F
community 0 NOUN F
hospital 0 NOUN F
care 0 NOUN F
. 0 PUNCT F

We 0 PRON T
consider 0 VERB F
how 0 ADP F
far 0 ADV F
these 0 ADP F
were 0 VERB F
in 0 ADP F
accord 0 NOUN F
with 0 ADP F
the 0 DET F
hospital 0 NOUN F
staffs 0 ADV F
' 0 PUNCT F
views 0 DET F
. 0 PUNCT F

This 0 DET T
constituted 0 ADP F
part 0 NOUN F
of 0 ADP F
a 0 DET F
wider 0 PUNCT F
randomized 0 VERB F
controlled 0 VERB F
trial 0 NOUN F
( 0 PUNCT F
RCT 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
methodological 0 ADJ F
challenges 0 NOUN F
in 0 ADP F
seeking 0 SYM F
to 0 PART F
identify 0 ADJ F
patient 0 NOUN F
satisfaction B-OTHER NOUN F
and 0 CCONJ F
in 0 ADP F
linking 0 VERB F
qualitative B-OTHER ADJ F
findings I-OTHER NOUN F
with 0 ADP F
trial 0 NOUN F
results 0 CCONJ F
are 0 VERB F
explored 0 VERB F
. 0 PUNCT F

DESIGN 0 NOUN T
A 0 CCONJ T
sample 0 NOUN F
of 0 ADP F
13 0 NUM F
patients 0 NOUN F
randomized 0 VERB F
to 0 ADP F
the 0 DET F
community 0 NOUN F
hospital 0 NOUN F
arm 0 NOUN F
of 0 ADP F
the 0 DET F
RCT 0 NOUN T
joined 0 VERB F
the 0 DET F
qualitative 0 ADJ F
study 0 NOUN F
. 0 PUNCT F

Official 0 ADJ T
documentation 0 NOUN F
from 0 ADP F
the 0 DET F
hospital 0 NOUN F
were 0 VERB F
accessed 0 VERB F
and 0 CCONJ F
six 0 NUM F
staff 0 NOUN F
interviewed 0 PUNCT F
to 0 PART F
identify 0 NOUN F
assumptions 0 NOUN F
underlying 0 ADV F
practice 0 NOUN F
. 0 PUNCT F

RESULTS 0 DET T
Analysis 0 NOUN T
of 0 ADP F
interviews 0 NOUN F
identified 0 VERB F
a 0 DET F
complex 0 ADJ F
picture 0 NOUN F
concerning 0 ADV F
expectations 0 PROPN F
These 0 ADV T
could 0 ADJ F
be 0 VERB F
classified 0 VERB F
as 0 ADP F
ideal 0 ADJ F
, 0 PUNCT F
realistic 0 ADJ F
, 0 PUNCT F
normative 0 ADJ F
and 0 CCONJ F
unformed 0 ADP F
. 0 PUNCT F

The 0 DET T
hospital 0 NOUN F
philosophy 0 NOUN F
and 0 CCONJ F
staff B-OTHER NOUN F
views I-OTHER DET F
about 0 PUNCT F
service 0 NOUN F
delivery 0 NOUN F
were 0 VERB F
closely 0 ADV F
in 0 ADP F
harmony 0 PUNCT F
, 0 PUNCT F
they 0 ADV F
delivered 0 PART F
rehabilitation 0 NOUN F
in 0 ADP F
a 0 DET F
home-based 0 VERB F
atmosphere 0 PUNCT F
. 0 PUNCT F

The 0 DET T
formal B-MENTAL ADJ F
, I-MENTAL PUNCT F
or I-MENTAL CCONJ F
'hard 0 PUNCT F
' 0 PUNCT F
, B-MENTAL PUNCT F
process I-MENTAL NOUN F
of I-MENTAL PUNCT F

The 0 DET T
A-V 0 NOUN T
Impulse 0 NOUN T
System 0 NOUN T
reduces 0 NOUN F
deep-vein 0 NOUN F
thrombosis 0 NOUN F
and 0 CCONJ F
swelling 0 VERB F
after 0 ADP F
hemiarthroplasty 0 NOUN F
for 0 ADP F
hip 0 NOUN F
fracture 0 NOUN F
. 0 PUNCT F

We 0 PRON T
performed 0 VERB F
a 0 DET F
prospective 0 ADJ F
randomised 0 VERB F
controlled 0 VERB F
trial 0 NOUN F
of 0 ADP F
the 0 DET F
A-V 0 NOUN T
Impulse 0 NOUN T
System 0 NOUN T
in 0 ADP F
82 0 NUM F
patients 0 NOUN F
treated 0 VERB F
by 0 ADP F
hemiarthroplasty 0 NOUN F
for 0 ADP F
subcapital 0 ADJ F
fracture 0 NOUN F
of 0 ADP F
the 0 DET F
femoral 0 ADJ F
neck 0 NOUN F
. 0 PUNCT F

The 0 DET T
incidence 0 NOUN F
of 0 ADP F
proximal 0 ADJ F
deep-vein 0 NOUN F
thrombosis 0 NOUN F
as 0 PUNCT F
assessed 0 VERB F
by 0 ADP F
Doppler 0 NOUN T
ultrasonography 0 NOUN F
was 0 VERB F
23 0 NUM F
% 0 SYM F
in 0 ADP F
the 0 DET F
control 0 NOUN F
group 0 NOUN F
and 0 CCONJ F
0 0 NUM F
% 0 SYM F
in 0 ADP F
those 0 PUNCT F
using 0 VERB F
the 0 DET F
device 0 NOUN F
( 0 PUNCT F
p 0 NOUN F
less 0 ADV F
than 0 PUNCT F
0.01 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Calf 0 NOUN T
and 0 CCONJ F
thigh 0 DET F
circumferences 0 NOUN F
were 0 VERB F
measured 0 VERB F
in 0 ADP F
both 0 CCONJ F
groups 0 NOUN F
at 0 ADP F
seven 0 NUM F
to 0 ADP F
ten 0 NUM F
days 0 NOUN F
after 0 ADP F
operation 0 NOUN F
. 0 PUNCT F

In 0 ADP T
the 0 DET F
treatment 0 NOUN F
group 0 NOUN F
there 0 PUNCT F
was 0 VERB F
a 0 DET F
mean 0 NOUN F
relative B-OTHER ADJ F
reduction I-OTHER NOUN F
of I-OTHER ADP F
postoperative I-OTHER ADJ F
swelling I-OTHER DET F
of I-OTHER ADP F
the I-OTHER DET F
thigh I-OTHER DET F
by 0 ADP F
3.27 0 NUM F
cm 0 NOUN F
( 0 PUNCT F
p 0 NOUN F
less 0 ADV F
than 0 PUNCT F
0.001 0 NUM F
) 0 PUNCT F
and 0 CCONJ F
of 0 ADP F
the 0 DET F
calf 0 NOUN F
by 0 ADP F
1.55 0 NUM F
cm 0 NOUN F
( 0 PUNCT F
p 0 NOUN F
less 0 ADV F
than 0 PUNCT F
0.001 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
A-V 0 NOUN T
Impulse 0 NOUN T
System 0 NOUN T
appears 0 NOUN F
to 0 PART F
be 0 PUNCT F
a 0 DET F
safe B-OTHER ADJ F
and 0 CCONJ F
effective 0 ADJ F
method 0 NOUN F
of 0 ADP F
reducing 0 VERB F
the 0 DET F
incidence 0 NOUN F
of 0 ADP F
proximal B-PHYSICAL ADJ F
deep-vein I-PHYSICAL NOUN F
thrombosis I-PHYSICAL NOUN F
, 0 PUNCT F
and 0 CCONJ F
of 0 ADP F
postoperative B-ADVERSE-EFFECTS ADJ F
swelling I-ADVERSE-EFFECTS VERB F
. 0 PUNCT F

Uterine 0 ADJ T
incision 0 NOUN F
closure 0 NOUN F
at 0 ADP F
caesarean 0 NOUN F
section 0 NOUN F
: 0 PUNCT F
a 0 DET F
randomised 0 VERB F
comparative 0 ADJ F
study 0 NOUN F
of 0 ADP F
intraperitoneal 0 ADJ F
closure 0 NOUN F
and 0 CCONJ F
closure 0 NOUN F
after 0 ADP F
temporary 0 ADJ F
exteriorisation 0 NOUN F
. 0 PUNCT F

BACKGROUND 0 NOUN T
The 0 DET T
safety 0 NOUN F
of 0 ADP F
the 0 DET F
technique 0 NOUN F
of 0 ADP F
uterine 0 ADJ F
exteriorization 0 NOUN F
at 0 ADP F
caesarean 0 NOUN F
section 0 NOUN F
though 0 ADP F
popular 0 ADJ F
among 0 ADP F
obstetricians 0 NOUN F
, 0 PUNCT F
remains 0 NOUN F
controversial 0 ADJ F
. 0 PUNCT F

OBJECTIVE 0 NOUN T
To 0 PROPN T
evaluate 0 NOUN F
the 0 DET F
influence 0 NOUN F
of 0 ADP F
exteriorization 0 NOUN F
of 0 ADP F
uterus 0 NOUN F
during 0 ADP F
uterine 0 ADJ F
repair 0 NOUN F
on 0 ADP F
caesarean 0 NOUN F
morbidity 0 NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
A 0 CCONJ T
randomized 0 VERB F
comparative 0 ADJ F
study 0 NOUN F
of 0 ADP F
136 0 NUM F
women 0 NOUN F
undergoing 0 VERB F
primary 0 ADJ F
caesarean 0 NOUN F
delivery 0 NOUN F
at 0 ADP F
Havana 0 NOUN T
Specialist 0 NOUN T
Hospital 0 NOUN T
Lagos 0 NOUN T
Nigeria 0 NOUN T
. 0 PUNCT F

Data 0 NOUN T
on 0 ADP F
operation 0 NOUN F
time 0 NOUN F
, 0 PUNCT F
estimated 0 ADP F
blood 0 NOUN F
loss 0 NOUN F
, 0 PUNCT F
postoperative 0 ADJ F
morbidities 0 PUNCT F
were 0 VERB F
collected 0 ADV F
and 0 CCONJ F
analysed 0 VERB F
with 0 ADP F
comparison 0 NOUN F
between 0 ADP F
the 0 DET F
two 0 NUM F
groups 0 NOUN F
using 0 SYM F
chi 0 NOUN F
square 0 PUNCT F
, 0 PUNCT F
Fischer 0 NOUN T
's 0 PUNCT F
exact 0 ADJ F
test 0 NOUN F
and 0 CCONJ F
t-test 0 NOUN F
as 0 PUNCT F
appropriate 0 ADJ F
. 0 PUNCT F

RESULTS 0 PUNCT T
The 0 DET T
mean 0 NOUN F
operative B-OTHER ADJ F
time I-OTHER NOUN F
, 0 PUNCT F
estimated B-PHYSICAL ADP F
blood I-PHYSICAL NOUN F
loss I-PHYSICAL NOUN F
, 0 PUNCT F
transfusion B-PHYSICAL NOUN F
rate I-PHYSICAL NOUN F
and 0 CCONJ F
postoperative B-PHYSICAL ADJ F
anemia I-PHYSICAL NOUN F
rate I-PHYSICAL NOUN F
were 0 VERB F
significantly 0 ADV F
less 0 ADV F
in 0 ADP F
the 0 DET F
exteriorized 0 VERB F
group 0 NOUN F
than 0 PUNCT F
the 0 DET F
intraperitoneal 0 ADJ F
group 0 NOUN F
( 0 PUNCT F
p 0 NOUN F
= 0 SYM F
0.000 0 NUM F
, 0 PUNCT F
0.009,0.048 0 PUNCT F
0.038 0 NUM F
and 0 CCONJ F
0.028 0 NUM F
respectively 0 ADV F
) 0 PUNCT F
, 0 PUNCT F
but 0 CCONJ F
not 0 ADV F
in 0 ADP F
other 0 ADJ F
outcome 0 NOUN F
measures 0 NOUN F
. 0 PUNCT F

CONCLUSION 0 NOUN T
With 0 ADP T
shorter 0 PUNCT F
operative 0 ADJ F
time 0 NOUN F
, 0 PUNCT F
less 0 DET F
blood 0 NOUN F
loss 0 NOUN F
and 0 CCONJ F
similar 0 ADJ F
morbidity 0 NOUN F
profile 0 ADJ F
exteriorization 0 NOUN F
of 0 ADP F
uterus 0 NOUN F
during 0 ADP F
caesarean 0 NOUN F
section 0 NOUN F
seems 0 NOUN F
to 0 PART F
be 0 PUNCT F
preferred 0 VERB F
except 0 ADP F
where 0 ADP F
it 0 PRON F
is 0 VERB F
not 0 ADV F
possible 0 ADJ F
because 0 PUNCT F
of 0 ADP F
adhesions 0 NOUN F
and 0 CCONJ F
surgeons 0 ADJ F
inexperience 0 NOUN F
. 0 PUNCT F

Double-blind 0 ADJ T
placebo-controlled 0 VERB F
administration 0 NOUN F
of 0 ADP F
fluoxetine 0 NOUN F
in 0 ADP F
restricting- 0 ADJ F
and 0 CCONJ F
restricting-purging-type 0 NOUN F
anorexia 0 PUNCT F
nervosa 0 NOUN F
. 0 PUNCT F

BACKGROUND 0 NOUN T
Anorexia 0 NOUN T
nervosa 0 NOUN F
is 0 VERB F
an 0 DET F
often 0 ADV F
chronic 0 ADJ F
disorder 0 NOUN F
with 0 ADP F
high 0 ADJ F
morbidity 0 NOUN F
and 0 CCONJ F
mortality 0 NOUN F
. 0 PUNCT F

Many 0 DET T
people 0 NOUN F
relapse 0 NOUN F
after 0 ADP F
weight 0 NOUN F
restoration 0 NOUN F
. 0 PUNCT F

This 0 DET T
study 0 NOUN F
was 0 VERB F
designed 0 VERB F
to 0 PART F
determine 0 NOUN F
whether 0 ADP F
a 0 DET F
selective 0 ADJ F
serotonin 0 NOUN F
reuptake 0 NOUN F
inhibitor 0 NOUN F
would 0 VERB F
improve 0 VERB F
outcome 0 NOUN F
and 0 CCONJ F
reduce 0 VERB F
relapse 0 NOUN F
after 0 ADP F
weight B-PHYSICAL NOUN F
restoration I-PHYSICAL NOUN F
by I-PHYSICAL ADP F
contributing I-PHYSICAL SYM F
to I-PHYSICAL PUNCT F
maintenance I-PHYSICAL NOUN F
of I-PHYSICAL ADP F
a I-PHYSICAL DET F
healthy I-PHYSICAL ADJ F
normal I-PHYSICAL ADJ F
weight I-PHYSICAL NOUN F
and I-PHYSICAL CCONJ F
a I-PHYSICAL DET F
reduction I-PHYSICAL NOUN F
of I-PHYSICAL ADP F
symptoms B-PHYSICAL NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
We 0 PRON T
administered 0 VERB F
a 0 DET F
double-blind 0 ADJ F
placebo-controlled 0 VERB F
trial 0 NOUN F
of 0 ADP F
fluoxetine 0 NOUN F
to 0 ADP F
35 0 NUM F
patients 0 NOUN F
with 0 ADP F
restricting-type 0 NOUN F
anorexia 0 PUNCT F
nervosa 0 NOUN F
. 0 PUNCT F

Anorexics 0 NOUN T
were 0 VERB F
randomly 0 ADV F
assigned 0 VERB F
to 0 ADP F
fluoxetine 0 NOUN F
( 0 PUNCT F
n 0 NOUN F
= 0 SYM F
16 0 NUM F
) 0 PUNCT F
or 0 CCONJ F
a 0 DET F
placebo 0 NOUN F
( 0 PUNCT F
n 0 NOUN F
= 0 SYM F
19 0 NUM F
) 0 PUNCT F
after 0 ADP F
inpatient 0 NOUN F
weight 0 NOUN F
gain 0 NOUN F
and 0 CCONJ F
then 0 ADV F
were 0 ADJ F
observed 0 VERB F
as 0 ADP F
outpatients 0 VERB F
for 0 ADP F
1 0 NUM F
year 0 NOUN F
. 0 PUNCT F

RESULTS 0 NOUN T
Ten 0 NUM T
of 0 ADP F
16 0 NUM F
( 0 PUNCT F
63 0 NUM F
% 0 SYM F
) 0 PUNCT F
subjects 0 NOUN F
remained 0 VERB F
on 0 ADP F
fluoxetine 0 NOUN F
for 0 ADP F
a 0 DET F
year 0 NOUN F
, 0 PUNCT F
whereas 0 ADP F
only 0 ADV F
three 0 PUNCT F
of 0 ADP F
19 0 NUM F
( 0 PUNCT F
16 0 NUM F
% 0 SYM F
) 0 PUNCT F
remained 0 VERB F
on 0 ADP F
the 0 DET F
placebo 0 NOUN F
for 0 ADP F
a 0 DET F
year 0 NOUN F
( 0 PUNCT F
p 0 NOUN F
=.006 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Those 0 PUNCT T
subjects 0 NOUN F
remaining 0 CCONJ F
on 0 ADP F
fluoxetine 0 NOUN F
for 0 ADP F
a 0 DET F
year 0 NOUN F
had 0 PUNCT F
reduced B-MENTAL CCONJ F
relapse I-MENTAL NOUN F
as 0 PUNCT F
determined 0 VERB F
by 0 ADP F
a 0 DET F
significant B-PHYSICAL ADJ F
increase 0 NOUN F
in B-PHYSICAL ADP F
weight 0 NOUN F
and 0 CCONJ F
reduction B-PHYSICAL PUNCT F

Long-term 0 NOUN T
follow-up 0 NOUN F
of 0 ADP F
the 0 DET F
Stockholm 0 NOUN T
randomized 0 VERB F
trials 0 NOUN F
of 0 ADP F
postoperative 0 ADJ F
radiation 0 NOUN F
therapy 0 NOUN F
versus 0 CCONJ F
adjuvant 0 NOUN F
chemotherapy 0 NOUN F
among 0 ADP F
'high 0 PUNCT F
risk 0 NOUN F
' 0 PUNCT F
pre- 0 ADJ F
and 0 CCONJ F
postmenopausal 0 ADJ F
breast 0 NOUN F
cancer 0 NOUN F
patients 0 NOUN F
. 0 PUNCT F

For 0 ADP T
many 0 DET F
years 0 NOUN F
, 0 PUNCT F
loco-regional 0 ADJ F
radiotherapy 0 NOUN F
was 0 VERB F
the 0 DET F
standard 0 ADJ F
postoperative 0 ADJ F
treatment 0 NOUN F
for 0 ADP F
node 0 NOUN F
positive 0 ADJ F
breast 0 NOUN F
cancer 0 NOUN F
patients 0 NOUN F
in 0 ADP F
Sweden 0 NUM T
. 0 PUNCT F

Because 0 PUNCT T
of 0 ADP F
encouraging 0 VERB F
results 0 CCONJ F
from 0 ADP F
trials 0 NOUN F
of 0 ADP F
adjuvant 0 NOUN F
chemotherapy 0 NOUN F
in 0 ADP F
the 0 DET F
mid 0 NOUN F
1970s 0 ADP F
, 0 PUNCT F
the 0 DET F
Stockholm 0 NOUN T
Breast 0 NOUN T
Cancer 0 NOUN T
Study 0 NOUN T
Group 0 NOUN T
decided 0 VERB F
to 0 PUNCT F
directly 0 ADV F
compare 0 PUNCT F
postoperative 0 ADJ F
radiation 0 NOUN F
( 0 PUNCT F
RT 0 NOUN T
) 0 PUNCT F
with 0 ADP F
adjuvant 0 NOUN F
CMF-type 0 NOUN T
chemotherapy 0 NOUN F
( 0 PUNCT F
CT 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

Long-term 0 NOUN T
results 0 NOUN F
are 0 VERB F
presented 0 VERB F
from 0 ADP F
two 0 NUM F
randomized 0 VERB F
trials 0 NOUN F
of 0 ADP F
RT 0 NOUN T
versus 0 CCONJ F
CT 0 NOUN T
in 0 ADP F
pre- 0 ADJ F
( 0 PUNCT F
n 0 NOUN F
= 0 SYM F
547 0 NUM F
) 0 PUNCT F
and 0 CCONJ F
postmenopausal 0 ADJ F
( 0 PUNCT F
n 0 NOUN F
= 0 SYM F
679 0 NUM F
) 0 PUNCT F
patients 0 NOUN F
, 0 PUNCT F
respectively 0 ADV F
, 0 PUNCT F
with 0 ADP F
node 0 NOUN F
positive 0 ADJ F
disease 0 NOUN F
or 0 CCONJ F
a 0 DET F
tumour 0 NOUN F
diameter 0 NOUN F
> 0 SYM F
30 0 NUM F
mm 0 NOUN F
. 0 PUNCT F

RT 0 NOUN T
substantially 0 ADV F
reduced 0 VERB F
loco-regional B-PHYSICAL ADJ F
recurrences I-PHYSICAL NOUN F
among 0 ADP F
both 0 CCONJ F
pre- 0 ADJ F
and 0 CCONJ F
postmenopausal 0 ADJ F
patients 0 NOUN F
( 0 PUNCT F
relative 0 ADJ F
hazard 0 NOUN F
RT 0 NOUN T
versus 0 CCONJ F
CT 0 NOUN T
: 0 PUNCT F
0.67 0 NUM F
and 0 CCONJ F
0.43 0 NUM F
, 0 PUNCT F
respectively 0 ADV F
) 0 PUNCT F
. 0 PUNCT F

Among 0 ADP T
premenopausal 0 ADJ F
patients 0 NOUN F
distant B-PHYSICAL ADJ F
metastases I-PHYSICAL NOUN F
occurred 0 VERB F
less 0 ADV F
frequently 0 ADV F
in 0 ADP F
the 0 DET F
CT 0 NOUN T
group 0 NOUN F
( 0 PUNCT F
relative 0 ADJ F
hazard 0 NOUN F
: 0 PUNCT F
1.68 0 NUM F
, 0 PUNCT F
p 0 NOUN F
> 0 SYM F
0.001 0 NUM F
) 0 PUNCT F
resulting 0 VERB F
in 0 ADP F
an 0 DET F
improved 0 VERB F
recurrence-free B-MORTALITY ADJ F
survival I-MORTALITY NOUN F
( 0 PUNCT F
p 0 NOUN F
= 0 SYM F
0.04 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Overall B-MORTALITY ADJ T
survival I-MORTALITY NOUN F
was 0 VERB F
also 0 ADV F
better 0 PUNCT F
with 0 ADP F
CT 0 NOUN T
( 0 PUNCT F
cumulative 0 ADJ F
survival 0 NOUN F
at 0 ADP F
15 0 NUM F
years 0 NOUN F
: 0 PUNCT F
50 0 NUM F
% 0 SYM F
and 0 CCONJ F
44 0 NUM F
% 0 SYM F
in 0 ADP F
the 0 DET F
CT 0 NOUN T
and 0 CCONJ F
RT 0 NOUN T
groups 0 NOUN F
, 0 PUNCT F
respectively 0 ADV F
) 0 PUNCT F
but 0 CCONJ F
the 0 DET F
difference 0 NOUN F
was 0 VERB F
not 0 ADV F
statistically 0 ADV F
significant 0 ADJ F
. 0 PUNCT F

Among 0 ADP T
the 0 DET F
postmenopausal 0 ADJ F
patients 0 NOUN F
there 0 ADJ F
were 0 VERB F
no 0 DET F
substantial 0 ADJ F
differences 0 NOUN F
in 0 ADP F
terms 0 NOUN F
of 0 ADP F
recurrence-free B-MORTALITY ADJ F
or I-MORTALITY CCONJ F
overall I-MORTALITY ADJ F
survival I-MORTALITY NOUN F
between 0 ADP F
the 0 DET F
treatment 0 NOUN F
groups 0 NOUN F
. 0 PUNCT F

The 0 DET T
risk 0 NOUN F
of 0 ADP F
a 0 DET F
second 0 ADJ F
primary 0 ADJ F
malignancy 0 NOUN F
, 0 PUNCT F
however 0 ADV F
, 0 PUNCT F
was 0 VERB F
doubled 0 VERB F
in 0 ADP F
the 0 DET F
RT 0 NOUN T
group 0 NOUN F
( 0 PUNCT F
p 0 NOUN F
> 0 SYM F
0.01 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
most 0 CCONJ F
pronounced 0 VERB F
excess 0 ADJ F
concerned 0 VERB F
second B-PHYSICAL ADJ F
lung I-PHYSICAL NOUN F
cancers I-PHYSICAL NOUN F
occurring 0 VERB F
after 0 ADP F
10 0 NUM F
years 0 NOUN F
. 0 PUNCT F

The 0 DET T
cumulative B-PHYSICAL ADJ F
incidence 0 NOUN F
at B-PHYSICAL ADP F
20 I-PHYSICAL NUM F
years B-PHYSICAL NOUN F
was 0 VERB F
estimated 0 VERB F
at 0 ADP F
0.3 0 NUM F
% 0 SYM F
and 0 CCONJ F
3.7 0 NUM F
% 0 SYM F
in 0 ADP F
the 0 DET F
CT 0 NOUN T
and 0 CCONJ F
RT 0 NOUN T
groups 0 NOUN F
, 0 PUNCT F
respectively 0 ADV F
. 0 PUNCT F

The 0 DET T
trials 0 NOUN F
illustrate 0 VERB F
the 0 DET F
role 0 NOUN F
of 0 ADP F
radiotherapy 0 NOUN F
in 0 PUNCT F
preventing 0 PUNCT F

Strength 0 NOUN T
of 0 ADP F
vital 0 ADJ F
force 0 NOUN F
in 0 ADP F
classical 0 ADJ F
homeopathy 0 NOUN F
: 0 PUNCT F
bio-psycho-social-spiritual 0 ADJ F
correlates 0 SYM F
within 0 ADP F
a 0 DET F
complex 0 ADJ F
systems 0 NOUN F
context 0 NOUN F
. 0 PUNCT F

OBJECTIVE 0 NOUN T
To 0 ADJ T
explore 0 NOUN F
associations 0 NOUN F
between 0 ADP F
a 0 DET F
global 0 ADJ F
rating 0 NOUN F
for 0 ADP F
the 0 DET F
classical 0 ADJ F
homeopathic 0 ADJ F
construct 0 NOUN F
of 0 ADP F
vital 0 ADJ F
force 0 NOUN F
and 0 CCONJ F
clinician 0 NOUN F
and 0 CCONJ F
patient 0 NOUN F
ratings 0 NOUN F
on 0 ADP F
previously 0 ADV F
validated 0 PUNCT F
bio-psycho-social-spiritual 0 ADJ F
questionnaires 0 NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
Sixty-two 0 NUM T
( 0 PUNCT F
62 0 NUM F
) 0 PUNCT F
community-recruited 0 VERB F
patients 0 NOUN F
with 0 ADP F
fibromyalgia 0 NOUN F
( 0 PUNCT F
FM 0 NOUN T
) 0 PUNCT F
were 0 VERB F
assessed 0 VERB F
at 0 ADP F
baseline 0 NOUN F
prior 0 PUNCT F
to 0 ADP F
a 0 DET F
clinical 0 ADJ F
trial 0 NOUN F
of 0 ADP F
individualized 0 VERB F
homeopathy 0 NOUN F
. 0 PUNCT F

Two 0 NUM T
homeopaths 0 VERB F
jointly 0 ADV F
performed 0 PUNCT F
case-taking 0 ADJ F
interviews 0 NOUN F
. 0 PUNCT F

A 0 DET T
conventional 0 ADJ F
medical 0 ADJ F
provider 0 NOUN F
independently 0 ADV F
evaluated 0 VERB F
patients 0 NOUN F
with 0 ADP F
a 0 DET F
standardized 0 VERB F
history 0 NOUN F
and 0 CCONJ F
physical 0 ADJ F
examination 0 NOUN F
. 0 PUNCT F

Homeopaths 0 ADJ T
rated 0 DET F
each 0 DET F
patient 0 NOUN F
's 0 PUNCT F
vital 0 ADJ F
force 0 NOUN F
( 0 PUNCT F
five-point 0 NOUN F
Likert 0 PUNCT T
scale 0 NOUN F
, 0 PUNCT F
with 0 ADP F
1 0 NUM F
= 0 SYM F
very 0 ADV F
weak 0 ADJ F
to 0 ADP F
5 0 NUM F
= 0 SYM F
very 0 ADV F
strong 0 ADJ F
) 0 PUNCT F
. 0 PUNCT F

Homeopaths 0 VERB T
and 0 CCONJ F
the 0 DET F
conventional 0 ADJ F
medical 0 ADJ F
provider 0 NOUN F
rated 0 VERB F
their 0 ADP F
Clinical B-PHYSICAL ADJ T
Global I-PHYSICAL ADJ T
Impression I-PHYSICAL NOUN T
( 0 PUNCT F
CGI B-PHYSICAL NOUN T
) 0 PUNCT F
of B-PHYSICAL ADP F
the I-PHYSICAL DET F
severity I-PHYSICAL NOUN F
of I-PHYSICAL ADP F
illness B-PHYSICAL NOUN F
( 0 PUNCT F
1 0 NUM F
= 0 SYM F
normal 0 ADJ F
; 0 PUNCT F
7 0 NUM F
= 0 SYM F
among 0 ADP F
the 0 DET F
most 0 PUNCT F
extremely 0 ADV F
ill 0 ADJ F
) 0 PUNCT F
. 0 PUNCT F

Patients 0 NOUN T
completed 0 ADJ F
self-rating 0 ADJ F
scales 0 NOUN F
on 0 ADP F
pain 0 NOUN F
, 0 PUNCT F
global B-PHYSICAL ADJ F
health B-PHYSICAL NOUN F
, 0 PUNCT F
mood B-MENTAL PUNCT F
, 0 PUNCT F
quality 0 NOUN F
of 0 ADP F
life 0 NOUN F
, 0 PUNCT F
coping B-MENTAL ADP F
style I-MENTAL NOUN F
, 0 PUNCT F
health B-MENTAL NOUN F
locus B-MENTAL NOUN F
of I-MENTAL ADP F
control I-MENTAL NOUN F
, 0 PUNCT F
multidimensional B-MENTAL ADJ F
well-being I-MENTAL DET F
, 0 PUNCT F
spirituality B-MENTAL NOUN F
, 0 PUNCT F
sense B-MENTAL NOUN F
of I-MENTAL ADP F
coherence I-MENTAL NOUN F
, 0 PUNCT F
positive 0 ADJ F
states B-MENTAL NOUN F
of I-MENTAL ADP F
mind B-MENTAL NOUN F
, 0 PUNCT F
and 0 CCONJ F
social B-MENTAL ADJ F
desirability B-MENTAL NOUN F
. 0 PUNCT F

RESULTS 0 PUNCT T
Greater 0 PUNCT T
vital B-PHYSICAL ADJ F
force I-PHYSICAL NOUN F
ratings B-PHYSICAL NOUN F
( 0 PUNCT F
mean 0 NOUN F
2.9 0 NUM F
standard 0 ADJ F
deviation 0 NOUN F
[ 0 PUNCT F
SD 0 NOUN T
] 0 PUNCT F
0.6 0 NUM F
) 0 PUNCT F
correlated 0 VERB F
moderately 0 ADV F
( 0 PUNCT F
p 0 NOUN F
< 0 SYM F
or 0 CCONJ F
= 0 SYM F
0.005 0 NUM F
) 0 PUNCT F
with 0 ADP F
less 0 ADV F
severe 0 ADJ F
CGI B-PHYSICAL NOUN T
illness I-PHYSICAL NOUN F
ratings 0 NOUN F
by 0 ADP F
the 0 DET F
homeopaths 0 NOUN F
( 0 PUNCT F
r 0 NOUN F
=-0.59 0 PUNCT F
) 0 PUNCT F
, 0 PUNCT F
decreased 0 DET F
patient-rated B-MENTAL VERB F
mental B-MENTAL ADJ F
confusion I-MENTAL NOUN F
( 0 PUNCT F
r 0 NOUN F
=-0.43 0 PUNCT F
) 0 PUNCT F
, 0 PUNCT F
higher 0 PUNCT F
vigor B-MENTAL NOUN F
( 0 PUNCT F
r 0 NOUN F
= 0 SYM F
0.38 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
and 0 CCONJ F
greater 0 PUNCT F
positive 0 ADJ F
states B-MENTAL NOUN F
of I-MENTAL ADP F
mind I-MENTAL NOUN F
( 0 PUNCT F
r 0 NOUN F
= 0 SYM F
0.36 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Vital 0 ADJ T
force 0 NOUN F
also 0 ADV F
showed 0 VERB F
correlations 0 NOUN F
( 0 PUNCT F
p 0 NOUN F
< 0 SYM F
0.05 0 NUM F
) 0 PUNCT F
with 0 PUNCT F
lower 0 PUNCT F

Cyclosporine 0 NOUN T
inhibition 0 NOUN F
of 0 ADP F
P-glycoprotein 0 NOUN T
in 0 ADP F
chronic 0 ADJ F
myeloid 0 NOUN F
leukemia 0 NOUN F
blast 0 NOUN F
phase 0 NOUN F
. 0 PUNCT F

Chronic 0 ADJ T
myeloid 0 NOUN F
leukemia 0 NOUN F
blast 0 NOUN F
phase 0 NOUN F
( 0 PUNCT F
CML-BP 0 NOUN T
) 0 PUNCT F
cells 0 NOUN F
commonly 0 ADV F
express 0 VERB F
the 0 DET F
multidrug 0 NOUN F
transporter 0 NOUN F
, 0 PUNCT F
P-glycoprotein 0 NOUN T
( 0 PUNCT F
Pgp 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

To 0 PART T
determine 0 NOUN F
whether 0 ADP F
Pgp 0 NOUN T
inhibition 0 NOUN F
improves 0 NOUN F
treatment 0 NOUN F
outcome 0 NOUN F
in 0 ADP F
CML-BP 0 NOUN T
, 0 PUNCT F
the 0 DET F
Southwest 0 ADV T
Oncology 0 NOUN T
Group 0 NOUN T
performed 0 VERB F
a 0 DET F
randomized 0 VERB F
, 0 PUNCT F
controlled 0 VERB F
trial 0 NOUN F
testing 0 PUNCT F
the 0 DET F
benefit 0 NOUN F
of 0 ADP F
the 0 DET F
Pgp 0 NOUN T
modulator 0 NOUN F
, 0 PUNCT F
cyclosporin 0 NOUN F
A 0 NOUN T
( 0 PUNCT F
CsA 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

Seventy-three 0 NUM T
eligible 0 ADJ F
patients 0 NOUN F
were 0 VERB F
assigned 0 VERB F
to 0 ADP F
treatment 0 NOUN F
with 0 ADP F
cytarabine 0 NOUN F
and 0 CCONJ F
infusional 0 ADJ F
daunorubicin 0 ADV F
with 0 ADP F
or 0 CCONJ F
without 0 ADP F
intravenous 0 ADJ F
CsA 0 NOUN T
. 0 PUNCT F

Treatment 0 NOUN T
with 0 ADP F
CsA 0 NOUN T
yielded 0 VERB F
no 0 DET F
improvement B-OTHER NOUN F
in 0 ADP F
treatment 0 NOUN F
outcome 0 NOUN F
as 0 ADP F
measured 0 VERB F
by 0 ADP F
the 0 DET F
frequency 0 NOUN F
of 0 ADP F
induction 0 NOUN F
resistance B-PHYSICAL NOUN F
( 0 PUNCT F
68 0 NUM F
% 0 SYM F
vs 0 CCONJ F
53 0 NUM F
% 0 SYM F
) 0 PUNCT F
, 0 PUNCT F
rate 0 NOUN F
of 0 ADP F
complete B-PHYSICAL ADJ F
remission I-PHYSICAL NOUN F
or 0 CCONJ F
restored B-PHYSICAL PUNCT F
chronic I-PHYSICAL ADJ F
phase I-PHYSICAL NOUN F
( 0 PUNCT F
CR/CP 0 NOUN T
, 0 PUNCT F
8 0 NUM F
% 0 SYM F
vs 0 CCONJ F
30 0 NUM F
% 0 SYM F
) 0 PUNCT F
, 0 PUNCT F
and 0 CCONJ F
survival B-MORTALITY NOUN F
( 0 PUNCT F
3 0 NUM F
vs 0 CCONJ F
5 0 NUM F
months 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

Blast B-PHYSICAL NOUN T
expression I-PHYSICAL NOUN F
of I-PHYSICAL ADP F
Pgp I-PHYSICAL NOUN T
( 0 PUNCT F
63 0 NUM F
% 0 SYM F
) 0 PUNCT F
and 0 CCONJ F
LRP B-PHYSICAL NOUN T
( 0 PUNCT F
71 0 NUM F
% 0 SYM F
) 0 PUNCT F
was 0 VERB F
common 0 ADJ F
, 0 PUNCT F
whereas 0 ADP F
only 0 DET F
Pgp 0 NOUN T
adversely 0 ADV F
impacted 0 PROPN F
the 0 DET F
rate B-PHYSICAL NOUN F
of I-PHYSICAL ADP F
CR/CP I-PHYSICAL NOUN T
( 0 PUNCT F
P 0 NOUN T
=.025 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

We 0 PRON T
conclude 0 VERB F
that 0 ADP F
Pgp 0 NOUN T
has 0 PUNCT F
prognostic 0 ADJ F
relevance 0 NOUN F
in 0 ADP F
CML-BP 0 NOUN T
but 0 CCONJ F
that 0 ADP F
the 0 DET F
modulation 0 NOUN F
of 0 ADP F
Pgp 0 NOUN T
function 0 NOUN F
with 0 ADP F
CsA 0 NOUN T
as 0 ADP F
applied 0 VERB F
in 0 ADP F
this 0 DET F
trial 0 NOUN F
is 0 VERB F
ineffective 0 ADJ F
. 0 PUNCT F

Effects 0 NOUN T
of 0 ADP F
halothane 0 NOUN F
and 0 CCONJ F
isoflurane 0 NOUN F
on 0 ADP F
transient B-PHYSICAL ADJ F
renal I-PHYSICAL ADJ F
dysfunction I-PHYSICAL NOUN F
associated 0 VERB F
with 0 ADP F
infrarenal 0 ADJ F
aortic 0 ADJ F
cross-clamping 0 PUNCT F
. 0 PUNCT F

Aortic 0 ADJ T
cross-clamping 0 PUNCT F
for 0 ADP F
reconstructive 0 ADJ F
aortic 0 ADJ F
surgery 0 NOUN F
is 0 VERB F
associated 0 VERB F
with 0 ADP F
impairment 0 NOUN F
of 0 ADP F
renal B-PHYSICAL ADJ F
function I-PHYSICAL NOUN F
. 0 PUNCT F

Halothane 0 NOUN T
or 0 CCONJ F
isoflurane 0 NOUN F
was 0 VERB F
used 0 VERB F
to 0 PART F
assess 0 NOUN F
the 0 DET F
influence 0 NOUN F
of 0 ADP F
volatile 0 ADJ F
anesthesia 0 NOUN F
on 0 ADP F
renal B-PHYSICAL ADJ F
hemodynamics I-PHYSICAL NOUN F
during 0 ADP F
aortic 0 ADJ F
surgery 0 NOUN F
. 0 PUNCT F

Nineteen 0 NUM T
patients 0 NOUN F
with 0 ADP F
normal 0 ADJ F
preoperative 0 ADJ F
creatinine 0 NOUN F
clearances 0 ADP F
who 0 ADP F
were 0 VERB F
scheduled 0 VERB F
for 0 ADP F
reconstructive 0 ADJ F
aortic 0 ADJ F
surgery 0 NOUN F
were 0 VERB F
randomly 0 ADV F
divided 0 VERB F
into 0 ADP F
two 0 NUM F
groups 0 NOUN F
: 0 PUNCT F
halothane 0 NOUN F
group 0 NOUN F
( 0 PUNCT F
n 0 NOUN F
= 0 SYM F
9 0 NUM F
) 0 PUNCT F
and 0 CCONJ F
isoflurane 0 ADJ F
group 0 NOUN F
( 0 PUNCT F
n 0 NOUN F
= 0 SYM F
10 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Induction 0 NOUN T
of 0 ADP F
anesthesia 0 NOUN F
consisted 0 VERB F
of 0 ADP F
midazolam 0 NOUN F
, 0 PUNCT F
fentanyl 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
pancuronium 0 NOUN F
. 0 PUNCT F

Anesthesia 0 NOUN T
was 0 VERB F
maintained 0 VERB F
with 0 ADP F
fentanyl 0 NOUN F
and 0 CCONJ F
halothane 0 NOUN F
or 0 CCONJ F
isoflurane 0 NOUN F
in 0 ADP F
nitrous 0 ADJ F
oxide 0 NOUN F
and 0 CCONJ F
oxygen 0 NOUN F
( 0 PUNCT F
50/50 0 PUNCT F
) 0 PUNCT F
. 0 PUNCT F

Systemic B-PHYSICAL ADJ T
hemodynamics I-PHYSICAL NOUN F
were 0 VERB F
similar 0 ADJ F
in 0 ADP F
both 0 CCONJ F
groups 0 NOUN F
throughout 0 ADP F
surgery 0 NOUN F
. 0 PUNCT F

Before 0 PUNCT T
aortic 0 ADJ F
cross-clamping 0 PUNCT F
, 0 PUNCT F
effective B-PHYSICAL ADJ F
renal I-PHYSICAL ADJ F
plasma I-PHYSICAL NOUN F
flow I-PHYSICAL NOUN F
( I-PHYSICAL PUNCT F
ERPF I-PHYSICAL NOUN T
) I-PHYSICAL PUNCT F
( I-PHYSICAL PUNCT F
131I-hippuran I-PHYSICAL NOUN F
clearance I-PHYSICAL NOUN F
) I-PHYSICAL PUNCT F
and 0 CCONJ F
glomerular B-PHYSICAL ADJ F
filtration I-PHYSICAL NOUN F
rate I-PHYSICAL NOUN F
( I-PHYSICAL PUNCT F
GFR I-PHYSICAL NOUN T
) I-PHYSICAL PUNCT F
( I-PHYSICAL PUNCT F
99Tc-DTPA I-PHYSICAL PUNCT F
clearance I-PHYSICAL NOUN F
) I-PHYSICAL PUNCT F
were 0 VERB F
significantly 0 ADV F
lower 0 PUNCT F
in 0 ADP F
the 0 DET F
halothane 0 NOUN F
group 0 NOUN F
( 0 PUNCT F
118.4 0 NUM F
+/- 0 SYM F
25.6 0 NUM F
and 0 CCONJ F
19.7 0 NUM F
+/- 0 SYM F
5.2 0 NUM F
mL/min 0 NOUN F
, 0 PUNCT F
respectively 0 ADV F
) 0 PUNCT F
than 0 PUNCT F
in 0 ADP F
the 0 DET F
isoflurane 0 ADJ F
group 0 NOUN F
( 0 PUNCT F
253.4 0 NUM F
+/- 0 SYM F
51.5 0 NUM F
and 0 CCONJ F
44.9 0 NUM F
+/- 0 SYM F
8.4 0 NUM F
mL/min 0 NOUN F
) 0 PUNCT F
( 0 PUNCT F
P 0 NOUN T
less 0 ADV F
than 0 ADP F
0.05 0 NUM F
for 0 ADP F
both 0 PUNCT F
) 0 PUNCT F
. 0 PUNCT F

During 0 ADP T
cross-clamping 0 PUNCT F
, 0 PUNCT F
the 0 DET F
renal B-PHYSICAL ADJ F
variables I-PHYSICAL NOUN F
were 0 VERB F
not 0 ADV F
markedly 0 ADV F
affected 0 VERB F
in 0 ADP F
either 0 PUNCT F
group 0 NOUN F
and 0 CCONJ F
remained 0 VERB F
higher 0 PUNCT F
in 0 ADP F
the 0 DET F
isoflurane-anesthetized 0 VERB F
patients 0 NOUN F
( 0 PUNCT F
232.9 0 NUM F
+/- 0 SYM F
47.1 0 NUM F
and 0 CCONJ F
49.5 0 NUM F
+/- 0 SYM F
1.2 0 NUM F
mL/min 0 NOUN F
for 0 ADP F
ERPF 0 NOUN T
and 0 CCONJ F
GFR 0 NOUN T
, 0 PUNCT F
respectively 0 ADV F
) 0 PUNCT F
than 0 PUNCT F
in 0 ADP F
the 0 DET F
halothane-anesthetized 0 VERB F
patients 0 NOUN F
( 0 PUNCT F
132.4 0 NUM F
+/- 0 SYM F
31.6 0 NUM F
and 0 CCONJ F
14.8 0 NUM F
+/- 0 SYM F
3.7 0 NUM F
mL/min 0 NOUN F
, 0 PUNCT F
respectively 0 ADV F
) 0 PUNCT F
( 0 PUNCT F
P 0 NOUN T
less 0 ADV F
than 0 PUNCT F
0.05 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

After 0 ADP T
aortic 0 ADJ F
unclamping 0 VERB F
, 0 PUNCT F
ERPF B-PHYSICAL NOUN T
increased 0 VERB F
markedly 0 ADV F
in 0 ADP F
both 0 CCONJ F
groups 0 NOUN F
( 0 PUNCT F
467.8 0 NUM F
+/- 0 SYM F
122 0 NUM F
and 0 CCONJ F
362.5 0 NUM F
+/- 0 SYM F
57.7 0 NUM F
mL/min 0 NOUN F
in 0 ADP F
the 0 DET F
halothane 0 NOUN F
and 0 CCONJ F
isoflurane 0 ADJ F
groups 0 NOUN F
, 0 PUNCT F
respectively 0 ADV F
) 0 PUNCT F
, 0 PUNCT F
as 0 PUNCT F
did 0 PUNCT F
GFR B-PHYSICAL NOUN T
( 0 PUNCT F
74.8 0 NUM F
+/- 0 SYM F
22 0 NUM F
and 0 CCONJ F
71.8 0 NUM F
+/- 0 SYM F
13.1 0 NUM F
mL/min 0 NOUN F
, 0 PUNCT F
respectively 0 ADV F
) 0 PUNCT F
. 0 PUNCT F

These 0 DET T
results 0 CCONJ F
suggest 0 VERB F
that 0 ADP F
anesthesia 0 NOUN F
with 0 ADP F
halothane 0 NOUN F
is 0 VERB F
associated 0 VERB F
with 0 ADP F
transient B-PHYSICAL ADJ F
renal I-PHYSICAL ADJ F
vasoconstriction I-PHYSICAL NOUN F
during 0 ADP F
abdominal 0 ADJ F
surgery 0 NOUN F
. 0 PUNCT F

In 0 ADP T
contrast 0 NOUN F
, 0 PUNCT F
aortic 0 ADJ F
cross-clamping 0 PUNCT F
during 0 ADP F
isoflurane 0 NOUN F
anesthesia 0 NOUN F
was 0 VERB F
not 0 ADV F
associated 0 VERB F
with 0 ADP F
renal B-PHYSICAL ADJ F
hemodynamic I-PHYSICAL ADJ F
impairment I-PHYSICAL NOUN F
. 0 PUNCT F

Lessons 0 ADJ T
learnt 0 NOUN F
in 0 ADP F
conducting 0 PUNCT F
a 0 DET F
clinical 0 ADJ F
drug 0 NOUN F
trial 0 NOUN F
in 0 ADP F
children 0 NOUN F
with 0 ADP F
Asperger 0 ADJ T
Syndrome 0 NOUN T
. 0 PUNCT F

OBJECTIVE 0 NOUN T
To 0 ADJ T
describe 0 PROPN F
the 0 DET F
authors 0 NOUN F
' 0 PUNCT F
experience 0 NOUN F
of 0 ADP F
conducting 0 PUNCT F
a 0 DET F
clinical 0 ADJ F
drug 0 NOUN F
trial 0 NOUN F
in 0 ADP F
children 0 NOUN F
with 0 ADP F
Asperger 0 ADJ T
Syndrome 0 NOUN T
, 0 PUNCT F
including 0 VERB F
the 0 DET F
pitfalls 0 ADV F
encountered 0 ADP F
and 0 CCONJ F
lessons 0 ADJ F
learnt 0 NOUN F
. 0 PUNCT F

CONCLUSIONS 0 NOUN T
The 0 DET T
main 0 ADJ F
barrier 0 NOUN F
encountered 0 PUNCT F
was 0 VERB F
in 0 ADP F
the 0 DET F
recruitment B-OTHER NOUN F
of I-OTHER ADP F
children I-OTHER NOUN F
: 0 PUNCT F
it 0 PRON F
was 0 VERB F
not 0 ADV F
possible 0 ADJ F
to 0 PART F
recruit 0 NOUN F
the 0 DET F
target 0 NOUN F
of 0 ADP F
60 0 NUM F
patients 0 NOUN F
. 0 PUNCT F

The 0 DET T
recruitment B-OTHER NOUN F
of I-OTHER ADP F
children I-OTHER NOUN F
is 0 VERB F
often 0 ADV F
the 0 DET F
major 0 ADJ F
barrier 0 NOUN F
to 0 ADP F
the 0 DET F
progress 0 NOUN F
of 0 ADP F
a 0 DET F
successful 0 ADJ F
clinical 0 ADJ F
trial 0 NOUN F
. 0 PUNCT F

Conducting 0 PUNCT T
the 0 DET F
clinical 0 ADJ F
drug 0 NOUN F
trial 0 NOUN F
was 0 VERB F
greatly 0 ADV F
facilitated 0 VERB F
by 0 ADP F
the 0 DET F
appropriate 0 ADJ F
setting 0 ADP F
and 0 CCONJ F
experienced 0 VERB F
clinical 0 ADJ F
pharmacology 0 NOUN F
staff 0 NOUN F
. 0 PUNCT F

The 0 DET T
tension-free 0 ADJ F
hernioplasty 0 NOUN F
in 0 ADP F
a 0 DET F
randomized 0 VERB F
trial 0 NOUN F
. 0 PUNCT F

BACKGROUND 0 NOUN T
The 0 DET T
tension-free 0 ADJ F
hernioplasty 0 NOUN F
as 0 VERB F
introduced 0 PUNCT F
by 0 ADP F
Lichtenstein 0 NOUN T
has 0 PUNCT F
gained 0 VERB F
increasing 0 ADP F
acceptance 0 NOUN F
during 0 ADP F
the 0 DET F
last 0 ADJ F
decade 0 NOUN F
although 0 ADP F
the 0 DET F
technique 0 NOUN F
has 0 PUNCT F
not 0 ADV F
been 0 PUNCT F
evaluated 0 VERB F
in 0 ADP F
a 0 DET F
randomized 0 VERB F
trial 0 NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
This 0 PUNCT T
randomized 0 NOUN F
study 0 NOUN F
compares 0 PUNCT F
the 0 DET F
2-year 0 NOUN F
follow-up 0 NOUN F
results 0 PUNCT F
after 0 ADP F
102 0 NUM F
tension-free 0 ADJ F
hernioplasties 0 CCONJ F
with 0 ADP F
implantation 0 NOUN F
of 0 ADP F
a 0 DET F
prolene 0 ADJ F
mesh 0 NOUN F
in 0 ADP F
all 0 DET F
groin 0 NOUN F
hernias 0 ADV F
to 0 ADP F
53 0 NUM F
Cooper 0 PUNCT T
ligament 0 NOUN F
repairs 0 VERB F
in 0 ADP F
direct 0 ADJ F
hernias 0 ADV F
and 0 CCONJ F
53 0 NUM F
abdominal 0 ADJ F
ring 0 NOUN F
repairs 0 NOUN F
in 0 ADP F
indirect 0 ADJ F
hernias 0 ADV F
. 0 PUNCT F

RESULTS 0 NOUN T
After 0 ADP T
tension-free 0 VERB F
repairs 0 NOUN F
five 0 NUM F
hernias B-PHYSICAL ADJ F
recurred I-PHYSICAL ADP F
( 0 PUNCT F
5 0 NUM F
% 0 SYM F
) 0 PUNCT F
, 0 PUNCT F
and 0 CCONJ F
after 0 ADP F
either 0 CCONJ F
Cooper 0 PUNCT T
ligament 0 NOUN F
or 0 CCONJ F
abdominal 0 ADJ F
ring 0 NOUN F
repair 0 NOUN F
, 0 PUNCT F
16 0 NUM F
recurrences B-PHYSICAL NOUN F
were 0 VERB F
found 0 VERB F
( 0 PUNCT F
15 0 NUM F
% 0 SYM F
) 0 PUNCT F
( 0 PUNCT F
P 0 NOUN T
= 0 SYM F
0.025 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

No 0 DET T
indirect B-PHYSICAL ADJ F
hernias I-PHYSICAL ADJ F
recurred I-PHYSICAL DET F
after 0 ADP F
a 0 DET F
tension-free 0 ADJ F
repair 0 NOUN F
; 0 PUNCT F
2 0 NUM F
recurred 0 PUNCT F
after 0 ADP F
abdominal 0 ADJ F
ring 0 NOUN F
repair 0 NOUN F
( 0 PUNCT F
4 0 NUM F
% 0 SYM F
; 0 PUNCT F
NS 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
recurrence B-PHYSICAL NOUN F
rate I-PHYSICAL NOUN F
after I-PHYSICAL ADP F
tension-free I-PHYSICAL VERB F
repairs I-PHYSICAL VERB F
for I-PHYSICAL ADP F
primary I-PHYSICAL ADJ F
direct I-PHYSICAL ADJ F
inguinal I-PHYSICAL ADJ F
hernias I-PHYSICAL ADV F
was 0 VERB F
7 0 NUM F
% 0 SYM F
as 0 CCONJ F
compared 0 VERB F
with 0 ADP F
30 0 NUM F
% 0 SYM F
after 0 ADP F
Cooper 0 PUNCT T
ligament 0 NOUN F
repair 0 NOUN F
( 0 PUNCT F
P 0 NOUN T
= 0 SYM F
0.0081 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

No 0 DET T
difference 0 NOUN F
in 0 ADP F
complication B-ADVERSE-EFFECTS NOUN F
rate I-ADVERSE-EFFECTS NOUN F
between 0 ADP F
the 0 DET F
tested 0 ADJ F
methods 0 NOUN F
was 0 VERB F
found 0 VERB F
. 0 PUNCT F

CONCLUSION 0 NOUN T
Recurrence B-PHYSICAL NOUN T
rate I-PHYSICAL NOUN F
is 0 VERB F
reduced 0 VERB F
to 0 ADP F
one-third 0 NOUN F
after 0 ADP F
tension-free 0 VERB F
herniotomies 0 NOUN F
as 0 CCONJ F
compared 0 VERB F
with 0 ADP F
the 0 DET F
conventionel 0 NOUN F
herniotomies 0 NOUN F
without 0 ADP F
increase 0 NOUN F
in 0 ADP F
complication B-ADVERSE-EFFECTS NOUN F
rate I-ADVERSE-EFFECTS NOUN F
. 0 PUNCT F

Comparing 0 ADP T
the 0 DET F
effectiveness 0 NOUN F
of 0 ADP F
copper 0 NOUN F
intrauterine 0 ADJ F
devices 0 NOUN F
available 0 ADJ F
in 0 ADP F
Canada 0 PUNCT T
. 0 PUNCT F

Is 0 PUNCT T
FlexiT 0 PUNCT T
non-inferior 0 ADP F
to 0 ADP F
NovaT 0 NOUN T
when 0 ADP F
inserted 0 ADP F
immediately 0 ADV F
after 0 ADP F
first-trimester 0 NOUN F
abortion 0 NOUN F
? 0 PUNCT F

Study 0 NOUN T
protocol 0 NOUN F
for 0 ADP F
a 0 DET F
randomized 0 VERB F
controlled 0 VERB F
trial 0 NOUN F
. 0 PUNCT F

BACKGROUND 0 NOUN T
We 0 PRON T
describe 0 VERB F
the 0 DET F
rationale 0 NOUN F
and 0 CCONJ F
protocol 0 NOUN F
for 0 ADP F
a 0 DET F
randomized 0 VERB F
noninferiority 0 NOUN F
controlled 0 VERB F
trial 0 NOUN F
( 0 PUNCT F
RCT 0 NOUN T
) 0 PUNCT F
to 0 PART F
determine 0 VERB F
if 0 PUNCT F
the 0 DET F
Flexi-T380 0 NOUN T
( 0 PUNCT F
+ 0 SYM F
) 0 PUNCT F
copper 0 NOUN F
intrauterine 0 ADJ F
contraceptive 0 ADJ F
device 0 NOUN F
( 0 PUNCT F
IUD 0 NOUN T
) 0 PUNCT F
is 0 VERB F
comparable 0 ADJ F
in 0 ADP F
terms 0 NOUN F
of 0 ADP F
effectiveness 0 NOUN F
and 0 CCONJ F
expulsion 0 NOUN F
rates 0 NOUN F
to 0 ADP F
the 0 DET F
most 0 CCONJ F
common 0 ADJ F
Canadian 0 ADJ T
IUD 0 NOUN T
currently 0 ADV F
in 0 ADP F
use 0 NOUN F
, 0 PUNCT F
NovaT-200 0 NOUN T
, 0 PUNCT F
when 0 ADP F
placed 0 ADP F
immediately 0 ADV F
after 0 ADP F
a 0 DET F
first-trimester 0 NOUN F
abortion 0 NOUN F
. 0 PUNCT F

METHODS/DESIGN 0 PUNCT T
Consenting 0 PUNCT T
women 0 VERB F
choosing 0 ADV F
to 0 ADV F
use 0 VERB F
an 0 DET F
IUD 0 NOUN T
after 0 ADP F
an 0 DET F
abortion 0 NOUN F
for 0 ADP F
a 0 DET F
pregnancy 0 NOUN F
of 0 ADP F
less 0 ADV F
than 0 CCONJ F
12 0 NUM F
weeks 0 NOUN F
of 0 ADP F
gestation 0 NOUN F
will 0 VERB F
be 0 VERB F
randomized 0 VERB F
to 0 ADP F
device-type 0 NOUN F
groups 0 NOUN F
to 0 PART F
receive 0 NOUN F
immediate 0 ADJ F
post-abortion 0 NOUN F
placement 0 NOUN F
of 0 ADP F
either 0 CCONJ F
a 0 DET F
Flexi-T380 0 NOUN T
( 0 PUNCT F
+ 0 SYM F
) 0 PUNCT F
IUD 0 NOUN T
, 0 PUNCT F
a 0 DET F
device 0 NOUN F
for 0 ADP F
which 0 DET F
no 0 DET F
current 0 ADJ F
evidence 0 NOUN F
on 0 ADP F
expulsion 0 NOUN F
or 0 CCONJ F
effectiveness 0 NOUN F
rates 0 NOUN F
is 0 VERB F
available 0 ADJ F
, 0 PUNCT F
or 0 CCONJ F
the 0 DET F
Nova-T200 0 PUNCT T
IUD 0 NOUN T
, 0 PUNCT F
the 0 DET F
only 0 ADJ F
other 0 ADJ F
brand 0 NOUN F
of 0 ADP F
copper 0 NOUN F
IUD 0 NOUN T
available 0 ADJ F
in 0 ADP F
Canada 0 PUNCT T
at 0 ADP F
the 0 DET F
time 0 NOUN F
of 0 ADP F
study 0 NOUN F
initiation 0 NOUN F
. 0 PUNCT F

The 0 DET T
primary 0 ADJ F
outcome 0 NOUN F
measure 0 ADV F
is 0 VERB F
IUD B-MENTAL NOUN T
expulsion I-MENTAL NOUN F
rate I-MENTAL NOUN F
at I-MENTAL ADP F
1 I-MENTAL NUM F
year I-MENTAL NOUN F
. 0 PUNCT F

Secondary 0 ADJ T
outcomes 0 NOUN F
include 0 VERB F
: 0 PUNCT F
pregnancy B-MENTAL NOUN F
rate I-MENTAL NOUN F
, 0 PUNCT F
method B-MENTAL NOUN F
continuation I-MENTAL NOUN F
rate I-MENTAL NOUN F
, 0 PUNCT F
complication 0 NOUN F
rates 0 NOUN F
( 0 PUNCT F
infection 0 NOUN F
, 0 PUNCT F
perforation 0 NOUN F
) 0 PUNCT F
, 0 PUNCT F
and 0 CCONJ F
satisfaction B-OTHER NOUN F
with 0 ADP F
contraceptive B-PHYSICAL ADJ F
method I-PHYSICAL NOUN F
. 0 PUNCT F

A 0 DET T
non-intervention 0 NOUN F
group 0 NOUN F
of 0 ADP F
consenting 0 PUNCT F
women 0 NOUN F
choosing 0 PUNCT F
a 0 DET F
range 0 NOUN F
of 0 ADP F
other 0 ADJ F
post-abortion 0 NOUN F
contraception 0 NOUN F
methods 0 NOUN F
, 0 PUNCT F
including 0 VERB F
no 0 DET F
contraception 0 NOUN F
, 0 PUNCT F
will 0 VERB F
be 0 VERB F
included 0 VERB F
for 0 ADP F
comparison 0 NOUN F
of 0 ADP F
secondary 0 ADJ F
outcomes 0 NOUN F
. 0 PUNCT F

Web-based 0 VERB T
contraception 0 NOUN F
satisfaction 0 NOUN F
questionnaires 0 NOUN F
, 0 PUNCT F
clinical 0 ADJ F
records 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
government-linked 0 VERB F
health 0 NOUN F
administrative 0 ADJ F
databases 0 NOUN F
will 0 VERB F
be 0 VERB F
used 0 VERB F
to 0 PART F
assess 0 NOUN F
primary 0 ADJ F
and 0 CCONJ F
secondary 0 ADJ F
outcomes 0 NOUN F
. 0 PUNCT F

DISCUSSION 0 NOUN T
The 0 DET T
RCT 0 NOUN T
design 0 NOUN F
, 0 PUNCT F
combined 0 PUNCT F
with 0 ADP F
access 0 NOUN F
to 0 ADP F
clinical 0 ADJ F
records 0 NOUN F
at 0 ADP F
all 0 DET F
provincial 0 ADJ F
abortion 0 NOUN F
clinics 0 ADP F
, 0 PUNCT F
and 0 CCONJ F
to 0 ADP F
information 0 NOUN F
in 0 ADP F
provincial 0 ADJ F
single-payer 0 NOUN F
linked 0 ADJ F
administrative 0 ADJ F
health 0 NOUN F
databases 0 NOUN F
, 0 PUNCT F
birth 0 NOUN F
registry 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
hospital 0 NOUN F
records 0 NOUN F
, 0 PUNCT F
offers 0 NOUN F
a 0 DET F
unique 0 ADJ F
opportunity 0 NOUN F
to 0 PART F
determine 0 VERB F
if 0 PUNCT F
a 0 DET F
novel 0 ADJ F
IUD 0 NOUN T
has 0 VERB F
a 0 DET F
comparable 0 ADJ F
expulsion B-MENTAL NOUN F
rate I-MENTAL NOUN F
to 0 ADP F
that 0 PUNCT F
of 0 ADP F
the 0 DET F
current 0 ADJ F
standard 0 ADJ F
IUD 0 NOUN T
in 0 ADP F
Canada 0 PUNCT T
, 0 PUNCT F
in 0 ADP F
addition 0 NOUN F
to 0 ADP F
the 0 DET F
first 0 ADJ F
opportunity 0 NOUN F
to 0 PART F
determine 0 NOUN F
pregnancy B-OTHER NOUN F
rate I-OTHER NOUN F
and 0 CCONJ F
method B-OTHER NOUN F
satisfaction I-OTHER NOUN F
at 0 ADP F
1 0 NUM F
year 0 NOUN F
post-abortion 0 NOUN F
for 0 ADP F
women 0 NOUN F
choosing 0 PUNCT F
a 0 DET F
range 0 NOUN F
of 0 ADP F
post-abortion 0 NOUN F
contraceptive 0 ADJ F
options 0 NOUN F
. 0 PUNCT F

We 0 PRON T
highlight 0 PUNCT F
considerations 0 NOUN F
of 0 ADP F
design 0 NOUN F
, 0 PUNCT F
implementation 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
evaluation 0 NOUN F
of 0 ADP F
the 0 DET F
first 0 ADJ F
trial 0 NOUN F
to 0 PART F
provide 0 VERB F
rigorous 0 ADJ F
evidence 0 NOUN F
for 0 ADP F
the 0 DET F
effectiveness 0 NOUN F
of 0 ADP F
current 0 ADJ F
Canadian 0 ADJ T
IUDs 0 NOUN T
when 0 ADP F
inserted 0 VERB F
after 0 ADP F
first-trimester 0 NOUN F
abortion 0 NOUN F
. 0 PUNCT F

TRIAL 0 NOUN T
REGISTRATION 0 NOUN T
ClinicalTrials.gov 0 PUNCT T
Identifier 0 NOUN T
NCT01174225 0 NOUN T
. 0 PUNCT F

Equivalence 0 ADJ T
study 0 NOUN F
of 0 ADP F
a 0 DET F
topical 0 ADJ F
diclofenac 0 NOUN F
solution 0 NOUN F
( 0 PUNCT F
pennsaid 0 NOUN F
) 0 PUNCT F
compared 0 VERB F
with 0 ADP F
oral 0 ADJ F
diclofenac 0 NOUN F
in 0 ADP F
symptomatic 0 ADJ F
treatment 0 NOUN F
of 0 ADP F
osteoarthritis 0 NOUN F
of 0 ADP F
the 0 DET F
knee 0 NOUN F
: 0 PUNCT F
a 0 DET F
randomized 0 VERB F
controlled 0 VERB F
trial 0 NOUN F
. 0 PUNCT F

OBJECTIVE 0 NOUN T
. 0 PUNCT F

To 0 PART T
compare 0 NOUN F
the 0 DET F
safety 0 NOUN F
and 0 CCONJ F
efficacy 0 NOUN F
of 0 ADP F
a 0 DET F
topical 0 ADJ F
diclofenac 0 NOUN F
solution 0 NOUN F
versus 0 CCONJ F
oral 0 ADJ F
diclofenac 0 NOUN F
in 0 ADP F
relieving 0 NUM F
the 0 DET F
symptoms 0 NOUN F
of 0 ADP F
primary 0 ADJ F
osteoarthritis 0 NOUN F
( 0 PUNCT F
OA 0 NOUN T
) 0 PUNCT F
of 0 ADP F
the 0 DET F
knee 0 NOUN F
, 0 PUNCT F
in 0 ADP F
a 0 DET F
randomized 0 VERB F
, 0 PUNCT F
double-blind 0 ADJ F
, 0 PUNCT F
double-dummy 0 NOUN F
equivalence 0 ADJ F
trial 0 NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
A 0 PUNCT T
total 0 NOUN F
of 0 ADP F
622 0 NUM F
men 0 NOUN F
and 0 CCONJ F
women 0 NOUN F
with 0 ADP F
radiological 0 ADJ F
evidence 0 NOUN F
of 0 ADP F
primary 0 ADJ F
knee 0 NOUN F
OA 0 NOUN T
and 0 CCONJ F
mild 0 ADJ F
to 0 ADP F
severe 0 ADJ F
symptoms 0 NOUN F
were 0 VERB F
randomly 0 ADV F
assigned 0 VERB F
to 0 ADP F
treatment 0 NOUN F
with 0 ADP F
a 0 DET F
topical 0 ADJ F
diclofenac 0 NOUN F
solution 0 NOUN F
plus 0 CCONJ F
placebo 0 NOUN F
oral 0 ADJ F
capsules 0 NOUN F
, 0 PUNCT F
or 0 CCONJ F
placebo 0 NOUN F
topical 0 ADJ F
solution 0 NOUN F
plus 0 CCONJ F
oral 0 ADJ F
diclofenac 0 NOUN F
( 0 PUNCT F
50 0 NUM F
mg 0 NOUN F
) 0 PUNCT F
capsules 0 NOUN F
. 0 PUNCT F

Patients 0 NOUN T
applied 0 DET F
50 0 NUM F
drops 0 ADP F
of 0 ADP F
study 0 PUNCT F
solution 0 NOUN F
and 0 CCONJ F
took 0 PROPN F
1 0 NUM F
study 0 ADV F
capsule 0 NOUN F
3 0 NUM F
times 0 NOUN F
daily 0 ADJ F
for 0 ADP F
12 0 NUM F
weeks 0 NOUN F
. 0 PUNCT F

Efficacy 0 NOUN T
variables 0 NOUN F
were 0 VERB F
pain 0 NOUN F
and 0 CCONJ F
physical 0 ADJ F
function 0 NOUN F
, 0 PUNCT F
measured 0 VERB F
by 0 ADP F
the 0 DET F
Western 0 NOUN T
Ontario 0 NOUN T
and 0 CCONJ F
McMaster 0 ADJ T
Universities 0 NOUN T
( 0 PUNCT F
WOMAC 0 NOUN T
) 0 PUNCT F
VA 0 NOUN T
3.1 0 NUM F
OA 0 NOUN T
Index 0 NOUN T
, 0 PUNCT F
and 0 CCONJ F
patient 0 NOUN F
global 0 ADJ F
assessment 0 NOUN F
( 0 PUNCT F
PGA 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

Equivalence 0 NOUN T
in 0 ADP F
the 0 DET F
per-protocol 0 NOUN F
group 0 NOUN F
was 0 VERB F
based 0 VERB F
on 0 ADP F
previously 0 ADV F
defined 0 PUNCT F
ranges 0 PUNCT F
of 0 ADP F
clinically 0 ADV F
significant 0 ADJ F
difference 0 NOUN F
. 0 PUNCT F

Safety 0 NOUN T
was 0 VERB F
assessed 0 VERB F
by 0 ADP F
evaluation 0 NOUN F
of 0 ADP F
adverse 0 ADJ F
events 0 NOUN F
, 0 PUNCT F
vital 0 ADJ F
signs 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
laboratory 0 NOUN F
data 0 NOUN F
. 0 PUNCT F

RESULTS 0 PUNCT T
The 0 DET T
difference 0 NOUN F
in 0 ADP F
mean 0 NOUN F
( 0 PUNCT F
95 0 NUM F
% 0 SYM F
CI 0 NOUN T
) 0 PUNCT F
change 0 DET F
scores 0 NOUN F
( 0 PUNCT F
final 0 ADJ F
minus 0 NOUN F
baseline 0 NOUN F
) 0 PUNCT F
between 0 ADP F
treatments 0 NOUN F
was 0 VERB F
13.3 0 NUM F
mm 0 NOUN F
( 0 PUNCT F
-8.6 0 PUNCT F
to 0 ADP F
35.2 0 NUM F
) 0 PUNCT F
for 0 ADP F
pain 0 NOUN F
( 0 PUNCT F
total 0 ADJ F
scale 0 NOUN F
500 0 NUM F
mm 0 NOUN F
) 0 PUNCT F
, 0 PUNCT F
71.0 0 NUM F
mm 0 NOUN F
( 0 PUNCT F
-2.4 0 NUM F
to 0 ADP F
144.5 0 NUM F
) 0 PUNCT F
for 0 ADP F
physical 0 ADJ F
function 0 NOUN F
( 0 PUNCT F
total 0 ADJ F
scale 0 NOUN F
1700 0 NUM F
mm 0 NOUN F
) 0 PUNCT F
, 0 PUNCT F
and 0 CCONJ F
4.3 0 NUM F
mm 0 NOUN F
( 0 PUNCT F
-1.2 0 ADP F
to 0 ADP F
9.8 0 NUM F
) 0 PUNCT F
for 0 ADP F
PGA 0 NOUN T
( 0 PUNCT F
total 0 ADJ F
scale 0 NOUN F
100 0 NUM F
mm 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
CI 0 NOUN T
for 0 ADP F
each 0 DET F
efficacy 0 NOUN F
variable 0 CCONJ F
fell 0 VERB F
within 0 ADP F
the 0 DET F
predefined 0 ADP F
equivalence 0 NOUN F
ranges 0 ADJ F
( 0 PUNCT F
pain 0 NOUN F
, 0 PUNCT F
+/- 0 ADP F
75 0 NUM F
mm 0 NOUN F
; 0 PUNCT F
physical 0 ADJ F
function 0 NOUN F
, 0 PUNCT F
+/- 0 SYM F
255 0 NUM F
mm 0 NOUN F
; 0 PUNCT F
PGA 0 NOUN T
, 0 PUNCT F
+/- 0 ADP F
20 0 NUM F
mm 0 NOUN F
) 0 PUNCT F
, 0 PUNCT F
indicating 0 VERB F
that 0 ADP F
no 0 DET F
clinically 0 ADV F
relevant 0 ADJ F
difference 0 NOUN F
was 0 VERB F
found 0 VERB F
between 0 ADP F
the 0 DET F
2 0 NUM F
treatment 0 NOUN F
arms 0 NOUN F
. 0 PUNCT F

Safety B-OTHER NOUN T
analyses I-OTHER NOUN F
of 0 ADP F
patients 0 NOUN F
applying 0 VERB F
topical 0 ADJ F
diclofenac 0 NOUN F
solution 0 NOUN F
revealed 0 VERB F
some 0 DET F
minor B-ADVERSE-EFFECTS ADJ F
skin I-ADVERSE-EFFECTS NOUN F
irritation I-ADVERSE-EFFECTS NOUN F
at I-ADVERSE-EFFECTS ADP F
the I-ADVERSE-EFFECTS DET F
application I-ADVERSE-EFFECTS NOUN F
site I-ADVERSE-EFFECTS NOUN F
-- I-ADVERSE-EFFECTS PUNCT F
mostly I-ADVERSE-EFFECTS ADV F
skin 0 NOUN F
dryness 0 NOUN F
in 0 ADP F
83/311 0 NOUN F
( 0 PUNCT F
27 0 NUM F
% 0 SYM F
) 0 PUNCT F
patients 0 NOUN F
-- 0 PUNCT F
but 0 CCONJ F
a 0 DET F
significantly 0 ADV F
reduced 0 DET F
incidence 0 NOUN F
, 0 PUNCT F
relative 0 ADJ F
to 0 ADP F
oral 0 ADJ F
diclofenac 0 NOUN F
, 0 PUNCT F
of 0 ADP F
total 0 ADJ F
and 0 CCONJ F
severe B-ADVERSE-EFFECTS ADJ F
gastrointestinal I-ADVERSE-EFFECTS ADJ F
( I-ADVERSE-EFFECTS PUNCT F
GI I-ADVERSE-EFFECTS NOUN T
) I-ADVERSE-EFFECTS PUNCT F
adverse I-ADVERSE-EFFECTS ADJ F
events I-ADVERSE-EFFECTS NOUN F
, 0 PUNCT F
including 0 VERB F
dyspepsia B-ADVERSE-EFFECTS NOUN F
, 0 PUNCT F
abdominal B-PHYSICAL ADJ F
pain I-PHYSICAL NOUN F
, 0 PUNCT F
diarrhea B-ADVERSE-EFFECTS NOUN F
, 0 PUNCT F
and 0 CCONJ F
nausea B-ADVERSE-EFFECTS NOUN F
. 0 PUNCT F

The 0 DET T
number 0 NOUN F
of 0 ADP F
patients 0 NOUN F
developing 0 PUNCT F
abnormal 0 ADJ F
liver 0 NOUN F
function 0 NOUN F
tests 0 NOUN F
( 0 PUNCT F
including 0 PROPN F
clinically 0 ADV F
significant 0 ADJ F
elevation 0 NOUN F
) 0 PUNCT F
, 0 PUNCT F
hemoglobin 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
creatinine 0 NOUN F
clearance 0 NOUN F
was 0 VERB F
significantly 0 ADV F
higher 0 PUNCT F
in 0 ADP F
the 0 DET F
oral 0 ADJ F
diclofenac 0 NOUN F
group 0 NOUN F
. 0 PUNCT F

CONCLUSION 0 NOUN T
Application 0 NOUN T
of 0 ADP F
this 0 DET F
topical 0 ADJ F
diclofenac 0 NOUN F
solution 0 NOUN F
to 0 ADP F
the 0 DET F
knee 0 NOUN F
of 0 ADP F
patients 0 NOUN F
with 0 ADP F
OA 0 NOUN T
produced 0 ADP F
relief B-PHYSICAL NOUN F
of I-PHYSICAL ADP F
symptoms I-PHYSICAL NOUN F
equivalent 0 ADJ F
to 0 ADP F
oral 0 ADJ F
diclofenac 0 NOUN F
, 0 PUNCT F
with 0 ADP F
minor 0 ADJ F
local 0 ADJ F
skin 0 NOUN F
irritation 0 NOUN F
, 0 PUNCT F
but 0 CCONJ F
significantly 0 ADV F
reduced 0 VERB F
incidence 0 NOUN F
of 0 ADP F
diclofenac-related B-PHYSICAL VERB F
GI I-PHYSICAL NOUN T
complaints I-PHYSICAL NOUN F
and 0 CCONJ F
abnormal B-PHYSICAL ADJ F
laboratory I-PHYSICAL NOUN F
values I-PHYSICAL NOUN F
. 0 PUNCT F

The 0 DET T
efficacy 0 NOUN F
of 0 ADP F
sublingual 0 ADJ F
immunotherapy 0 NOUN F
for 0 ADP F
respiratory 0 ADJ F
allergy 0 NOUN F
is 0 VERB F
not 0 ADV F
affected 0 VERB F
by 0 ADP F
different 0 ADJ F
dosage 0 NOUN F
regimens 0 CCONJ F
in 0 ADP F
the 0 DET F
induction 0 NOUN F
phase 0 NOUN F
. 0 PUNCT F

BACKGROUND 0 NOUN T
Sublingual 0 ADP T
administration 0 NOUN F
of 0 ADP F
allergens 0 NOUN F
is 0 VERB F
a 0 DET F
safe 0 ADJ F
and 0 CCONJ F
effective 0 ADJ F
alternative 0 ADJ F
to 0 ADP F
subcutaneous 0 ADJ F
immunotherapy 0 NOUN F
in 0 ADP F
patients 0 NOUN F
with 0 ADP F
respiratory 0 ADJ F
allergies 0 NOUN F
. 0 PUNCT F

A 0 DET T
drawback 0 NOUN F
to 0 ADP F
this 0 DET F
therapeutic 0 ADJ F
approach 0 NOUN F
is 0 VERB F
the 0 DET F
relatively 0 ADV F
long 0 ADJ F
and 0 CCONJ F
complex 0 ADJ F
management 0 NOUN F
of 0 ADP F
the 0 DET F
induction 0 NOUN F
phase 0 NOUN F
. 0 PUNCT F

AIM 0 NOUN T
OF 0 ADP T
THE 0 DET T
STUDY 0 NOUN T
To 0 PROPN T
determine 0 NOUN F
whether 0 ADP F
different 0 ADJ F
induction 0 NOUN F
regimens 0 NOUN F
affect 0 VERB F
the 0 DET F
outcome 0 NOUN F
of 0 ADP F
sublingual 0 ADJ F
immunotherapy 0 NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
AND 0 CCONJ T
RESULTS 0 NOUN T
Adult 0 ADJ T
and 0 CCONJ F
pediatric 0 ADJ F
patients 0 NOUN F
with 0 ADP F
allergic 0 ADJ F
rhinoconjunctivitis 0 NOUN F
and/or 0 CCONJ F
asthma 0 NOUN F
were 0 VERB F
included 0 VERB F
in 0 ADP F
the 0 DET F
study 0 NOUN F
. 0 PUNCT F

Ten 0 NUM T
subjects 0 NOUN F
served 0 PART F
as 0 ADP F
controls 0 VERB F
and 0 CCONJ F
received 0 VERB F
symptomatic 0 ADJ F
treatments 0 NOUN F
. 0 PUNCT F

Forty-three 0 ADJ T
subjects 0 NOUN F
were 0 VERB F
allocated 0 NUM F
to 0 ADP F
sublingual 0 ADJ F
immunotherapy 0 NOUN F
, 0 PUNCT F
with 0 ADP F
three 0 NUM F
different 0 ADJ F
induction 0 NOUN F
protocols 0 NOUN F
( 0 PUNCT F
8- 0 NUM F
, 0 PUNCT F
15- 0 NUM F
and 0 CCONJ F
20-day 0 NOUN F
, 0 PUNCT F
respectively 0 ADV F
) 0 PUNCT F
. 0 PUNCT F

Symptom B-PHYSICAL NOUN T
and I-PHYSICAL CCONJ F
medication I-PHYSICAL NOUN F
scores 0 NOUN F
, 0 PUNCT F
skin B-PHYSICAL NOUN F
test I-PHYSICAL NOUN F
results I-PHYSICAL DET F
and 0 CCONJ F
( B-PHYSICAL PUNCT F
in I-PHYSICAL ADP F
asthmatic I-PHYSICAL ADJ F
patients I-PHYSICAL NOUN F
) 0 PUNCT F
FEV1 0 NOUN T
values 0 NOUN F
were 0 VERB F
monitored 0 VERB F
for 0 ADP F
two 0 NUM F
years 0 NOUN F
. 0 PUNCT F

Adverse B-ADVERSE-EFFECTS ADJ T
effects I-ADVERSE-EFFECTS NOUN F
were 0 VERB F
recorded 0 VERB F
. 0 PUNCT F

All 0 DET T
induction 0 NOUN F
regimens 0 NOUN F
produced 0 VERB F
a 0 DET F
significant B-PHYSICAL ADJ F
improvement I-PHYSICAL NOUN F
in I-PHYSICAL ADP F
symptom I-PHYSICAL NOUN F
and 0 CCONJ F
medication B-PHYSICAL NOUN F
usage I-PHYSICAL NOUN F
( 0 PUNCT F
p 0 NOUN F
< 0 SYM F
0.0001 0 NUM F
) 0 PUNCT F
; 0 PUNCT F
skin B-PHYSICAL NOUN F
test I-PHYSICAL NOUN F
scores I-PHYSICAL NOUN F
decreased 0 NOUN F
( 0 PUNCT F
p 0 NOUN F
< 0 SYM F
0.0001 0 NUM F
) 0 PUNCT F
and 0 CCONJ F
FEV1 B-PHYSICAL NOUN T
improved I-PHYSICAL NOUN F
( 0 PUNCT F
p 0 NOUN F
< 0 SYM F
0.05 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

In 0 ADP T
contrast 0 NOUN F
, 0 PUNCT F
symptom 0 NOUN F
and 0 CCONJ F
skin 0 NOUN F
test 0 NOUN F
scores 0 NOUN F
did 0 CCONJ F
not 0 ADV F
significantly 0 ADV F
change B-OTHER NUM F
in 0 ADP F
controls 0 NOUN F
. 0 PUNCT F

No 0 DET T
relevant 0 ADJ F
adverse B-ADVERSE-EFFECTS ADJ F
effects I-ADVERSE-EFFECTS NOUN F
were 0 VERB F
observed 0 VERB F
with 0 ADP F
any 0 PUNCT F
of 0 ADP F
the 0 DET F
induction 0 NOUN F
regimens 0 NOUN F
. 0 PUNCT F

CONCLUSIONS 0 NOUN T
For 0 ADP T
patients 0 NOUN F
with 0 ADP F
respiratory 0 ADJ F
allergies 0 NOUN F
, 0 PUNCT F
sublingual 0 ADP F
immunotherapy 0 NOUN F
with 0 ADP F
an 0 DET F
8-day 0 NOUN F
induction 0 NOUN F
protocol 0 NOUN F
is 0 VERB F
safe 0 ADJ F
and 0 CCONJ F
effective 0 ADJ F
. 0 PUNCT F

Our 0 ADJ T
results 0 NOUN F
encourage 0 PUNCT F
the 0 DET F
usage 0 NOUN F
of 0 ADP F
shorter 0 PUNCT F
induction 0 NOUN F
regimens 0 NOUN F
, 0 PUNCT F
which 0 ADP F
produce 0 VERB F
better 0 CCONJ F
compliance 0 NOUN F
with 0 ADP F
this 0 DET F
therapy 0 NOUN F
. 0 PUNCT F

A 0 DET T
randomised 0 VERB F
comparison 0 NOUN F
of 0 ADP F
three 0 NUM F
drainage 0 NOUN F
systems 0 NOUN F
following 0 VERB F
cholecystectomy 0 NOUN F
. 0 PUNCT F

The 0 DET T
efficacy 0 NOUN F
of 0 ADP F
low 0 ADJ F
pressure 0 NOUN F
, 0 PUNCT F
high 0 ADJ F
pressure 0 NOUN F
and 0 CCONJ F
passive 0 ADJ F
drainage 0 NOUN F
systems 0 NOUN F
have 0 PUNCT F
been 0 PUNCT F
compared 0 VERB F
after 0 ADP F
cholecystectomy 0 NOUN F
. 0 PUNCT F

Symptoms B-PAIN NOUN T
of I-PAIN ADP F
pain I-PAIN NOUN F
, 0 PUNCT F
discomfort B-ADVERSE-EFFECTS NOUN F
and 0 CCONJ F
nausea B-ADVERSE-EFFECTS NOUN F
were 0 VERB F
compared 0 VERB F
using 0 SYM F
linear 0 ADJ F
analogue 0 NOUN F
scales 0 NOUN F
and 0 CCONJ F
spirometry 0 NOUN F
was 0 VERB F
used 0 VERB F
to 0 PART F
examine 0 NOUN F
pre-operative 0 ADJ F
and 0 CCONJ F
postoperative 0 ADJ F
respiratory B-PHYSICAL ADJ F
function I-PHYSICAL NOUN F
. 0 PUNCT F

The 0 DET T
low 0 ADJ F
pressure 0 NOUN F
suction 0 NOUN F
drain 0 NOUN F
removed 0 VERB F
an 0 DET F
intraperitoneal 0 ADJ F
marker 0 NOUN F
, 0 PUNCT F
gentamicin 0 NOUN F
, 0 PUNCT F
more 0 ADV F
effectively 0 ADV F
than 0 PUNCT F
the 0 DET F
high 0 ADJ F
pressure 0 NOUN F
suction 0 NOUN F
drain 0 NOUN F
, 0 PUNCT F
but 0 CCONJ F
not 0 ADV F
more 0 ADV F
effectively 0 ADV F
than 0 PUNCT F
the 0 DET F
passive 0 ADJ F
drain 0 NOUN F
. 0 PUNCT F

There 0 PUNCT T
were 0 VERB F
no 0 DET F
differences 0 NOUN F
in 0 ADP F
postoperative B-PHYSICAL ADJ F
respiratory I-PHYSICAL ADJ F
function I-PHYSICAL NOUN F
nor 0 CCONJ F
in 0 ADP F
the 0 DET F
amount 0 NOUN F
of 0 ADP F
pain B-PAIN NOUN F
or 0 CCONJ F
discomfort B-PAIN NOUN F
between 0 ADP F
the 0 DET F
groups 0 NOUN F
. 0 PUNCT F

The 0 DET T
passive 0 ADJ F
drain 0 NOUN F
group 0 NOUN F
reported 0 VERB F
less 0 ADV F
nausea B-PHYSICAL NOUN F
than 0 PUNCT F
the 0 DET F
suction 0 NOUN F
drain 0 NOUN F
groups 0 NOUN F
. 0 PUNCT F

If 0 PUNCT T
a 0 DET F
negative 0 ADJ F
pressure 0 NOUN F
drainage 0 NOUN F
system 0 NOUN F
is 0 VERB F
to 0 PART F
be 0 PUNCT F
used 0 VERB F
, 0 PUNCT F
a 0 DET F
low 0 ADJ F
pressure 0 NOUN F
suction 0 NOUN F
drain 0 NOUN F
should 0 VERB F
be 0 VERB F
used 0 VERB F
in 0 ADP F
preference 0 NOUN F
to 0 ADP F
a 0 DET F
high 0 ADJ F
pressure 0 NOUN F
system 0 NOUN F
. 0 PUNCT F

[ 0 PUNCT F
The 0 DET T
effect 0 NOUN F
of 0 ADP F
losartan 0 NOUN F
versus 0 CCONJ F
atenolol 0 NOUN F
on 0 ADP F
cardiovascular B-MORTALITY ADJ F
morbidity I-MORTALITY NOUN F
and I-MORTALITY CCONJ F
mortality I-MORTALITY NOUN F
in 0 ADP F
patients 0 NOUN F
with 0 ADP F
diabetes 0 NOUN F
mellitus 0 NOUN F
in 0 ADP F
the 0 DET F
LIFE-study 0 NOUN T
] 0 PUNCT F
. 0 PUNCT F

INTRODUCTION 0 NOUN T
The 0 DET T
most 0 PUNCT F
suitable 0 ADJ F
antihypertensive 0 ADJ F
drug 0 NOUN F
to 0 ADJ F
reduce 0 NOUN F
the 0 DET F
risk 0 NOUN F
of 0 ADP F
cardiovascular 0 ADJ F
disease 0 NOUN F
in 0 ADP F
patients 0 NOUN F
with 0 ADP F
hypertension 0 NOUN F
and 0 CCONJ F
diabetes 0 NOUN F
is 0 VERB F
unclear 0 ADJ F
. 0 PUNCT F

In 0 ADP T
a 0 DET F
prespecified 0 ADJ F
analysis 0 NOUN F
of 0 ADP F
the 0 DET F
LIFE-study 0 NOUN T
we 0 ADJ F
compared 0 VERB F
the 0 DET F
effects 0 NOUN F
of 0 ADP F
losartan 0 NOUN F
and 0 CCONJ F
atenolol 0 NOUN F
on 0 ADP F
cardiovascular B-PHYSICAL ADJ F
morbidity I-PHYSICAL NOUN F
and 0 CCONJ F
mortality B-MORTALITY NOUN F
in 0 ADP F
diabetic 0 ADJ F
patients 0 NOUN F
. 0 PUNCT F

MATERIAL 0 NOUN T
AND 0 CCONJ T
METHODS 0 NOUN T
A 0 PUNCT T
total 0 NOUN F
of 0 ADP F
1195 0 NUM F
patients 0 NOUN F
in 0 ADP F
the 0 DET F
LIFE-study 0 NOUN T
had 0 PUNCT F
diabetes 0 NOUN F
at 0 ADP F
the 0 DET F
time 0 NOUN F
of 0 ADP F
the 0 DET F
randomisation 0 NOUN F
. 0 PUNCT F

The 0 DET T
patients 0 NOUN F
were 0 VERB F
randomised 0 VERB F
for 0 ADP F
double-blind 0 ADJ F
treatment 0 NOUN F
with 0 ADP F
losartan 0 NOUN F
versus 0 CCONJ F
atenolol 0 NOUN F
. 0 PUNCT F

The 0 DET T
patients 0 NOUN F
had 0 CCONJ F
ECG-verified 0 VERB T
left 0 ADJ F
ventricular 0 ADJ F
hypertrophy 0 NOUN F
, 0 PUNCT F
mean 0 NOUN F
age 0 NOUN F
67 0 NUM F
years 0 NOUN F
, 0 PUNCT F
blood 0 NOUN F
pressure 0 NOUN F
177/96 0 NOUN F
mmHg 0 NOUN F
after 0 ADP F
two 0 NUM F
weeks 0 NOUN F
placebo 0 NOUN F
run-in 0 NOUN F
period 0 NOUN F
. 0 PUNCT F

Patients 0 NOUN T
were 0 VERB F
followed 0 VERB F
for 0 ADP F
at 0 ADP F
least 0 ADV F
four 0 NUM F
years 0 NOUN F
( 0 PUNCT F
mean 0 NOUN F
4.7 0 NUM F
years 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
primary 0 ADJ F
composite 0 ADJ F
endpoint 0 NOUN F
was 0 VERB F
cardiovascular B-PHYSICAL ADJ F
death I-PHYSICAL NOUN F
, 0 PUNCT F
stroke B-PHYSICAL NOUN F
or 0 CCONJ F
myocardial B-PHYSICAL ADJ F
infarction I-PHYSICAL NOUN F
. 0 PUNCT F

RESULTS 0 ADJ T
Blood B-PHYSICAL NOUN T
pressure I-PHYSICAL NOUN F
was 0 VERB F
reduced 0 VERB F
to 0 ADP F
146/79 0 NOUN F
and 0 CCONJ F
148/79 0 NOUN F
in 0 ADP F
losartan-treated 0 VERB F
patients 0 NOUN F
and 0 CCONJ F
atenolol-treated 0 VERB F
patients 0 NOUN F
, 0 PUNCT F
respectively 0 ADV F
. 0 PUNCT F

The 0 DET T
primary 0 ADJ F
endpoint 0 NOUN F
occurred 0 VERB F
in 0 ADP F
103 0 NUM F
patients 0 NOUN F
assigned 0 DET F
losartan 0 NOUN F
( 0 PUNCT F
n 0 NOUN F
= 0 SYM F
586 0 NUM F
) 0 PUNCT F
and 0 CCONJ F
139 0 NUM F
assigned 0 PUNCT F
atenolol 0 NOUN F
( 0 PUNCT F
n 0 NOUN F
= 0 SYM F
609 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Relative 0 ADJ T
risk 0 NOUN F
reduction B-PHYSICAL NOUN F
24 0 NUM F
% 0 SYM F
( 0 PUNCT F
p 0 NOUN F
< 0 SYM F
0.031 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Cardiovascular B-PHYSICAL ADJ T
mortality I-PHYSICAL NOUN F
was 0 VERB F
reduced 0 VERB F
by 0 ADP F
37 0 NUM F
% 0 SYM F
in 0 ADP F
favour 0 NOUN F
of 0 ADP F
losartan 0 NOUN F
( 0 PUNCT F
p 0 NOUN F
< 0 SYM F
0.028 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
and 0 CCONJ F
all 0 DET F
cause 0 PUNCT F
mortality B-MORTALITY NOUN F
by 0 ADP F
39 0 NUM F
% 0 SYM F
( 0 PUNCT F
p 0 NOUN F
< 0 SYM F
0.002 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

DISCUSSION 0 NOUN T
Losartan 0 NOUN T
was 0 VERB F
very 0 ADV F
effective 0 ADJ F
in 0 ADP F
reducing 0 VERB F
cardiovascular B-PHYSICAL ADJ F
morbidity I-PHYSICAL NOUN F
and 0 CCONJ F
mortality B-MORTALITY NOUN F
as 0 VERB F
compared 0 VERB F
to 0 ADP F
atenolol 0 NOUN F
. 0 PUNCT F

These 0 DET T
results 0 NOUN F
will 0 VERB F
have 0 CCONJ F
a 0 DET F
major 0 ADJ F
impact 0 NOUN F
on 0 ADP F
the 0 DET F
choice 0 NOUN F
of 0 ADP F
anti-hypertensive 0 ADJ F
treatment 0 NOUN F
for 0 ADP F
patients 0 NOUN F
with 0 ADP F
hypertension 0 NOUN F
and 0 CCONJ F
diabetes 0 NOUN F
. 0 PUNCT F

The 0 DET T
effects 0 NOUN F
of 0 ADP F
treatment 0 NOUN F
with 0 ADP F
interleukin-1 0 NOUN F
receptor 0 NOUN F
antagonist 0 NOUN F
on 0 ADP F
the 0 DET F
inflamed 0 ADP F
synovial 0 ADJ F
membrane 0 NOUN F
in 0 ADP F
rheumatoid 0 ADJ F
arthritis 0 NOUN F
. 0 PUNCT F

OBJECTIVE 0 NOUN T
To 0 PROPN T
evaluate 0 NOUN F
the 0 DET F
effects 0 NOUN F
of 0 ADP F
treatment 0 NOUN F
with 0 ADP F
interleukin-1 0 NOUN F
receptor 0 NOUN F
antagonist 0 NOUN F
( 0 PUNCT F
IL-1Ra 0 NOUN T
) 0 PUNCT F
on 0 ADP F
synovial 0 ADJ F
tissue 0 NOUN F
in 0 ADP F
rheumatoid 0 ADJ F
arthritis 0 NOUN F
( 0 PUNCT F
RA 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

METHODS 0 NOUN T
Twelve 0 ADP T
patients 0 NOUN F
with 0 ADP F
RA 0 NOUN T
entering 0 CCONJ F
a 0 DET F
randomized 0 VERB F
clinical 0 ADJ F
trial 0 NOUN F
of 0 ADP F
human 0 NOUN F
recombinant 0 ADJ F
IL-1Ra 0 NOUN T
underwent 0 VERB F
synovial 0 ADJ F
biopsies 0 NOUN F
before 0 ADP F
and 0 CCONJ F
after 0 ADP F
treatment 0 NOUN F
. 0 PUNCT F

Cellular B-PHYSICAL ADJ T
infiltration I-PHYSICAL NOUN F
and I-PHYSICAL CCONJ F
adhesion I-PHYSICAL NOUN F
molecule I-PHYSICAL NOUN F
expression I-PHYSICAL NOUN F
were 0 VERB F
evaluated 0 VERB F
after 0 ADP F
immunohistochemical 0 ADJ F
staining 0 VERB F
. 0 PUNCT F

RESULTS 0 NOUN T
There 0 CCONJ T
was 0 VERB F
a 0 DET F
notable 0 ADJ F
reduction 0 NOUN F
in 0 ADP F
intimal B-PHYSICAL ADJ F
layer I-PHYSICAL NOUN F
macrophages I-PHYSICAL NOUN F
and 0 CCONJ F
subintimal B-PHYSICAL ADJ F
macrophages I-PHYSICAL NOUN F
and 0 CCONJ F
lymphocytes B-PHYSICAL NOUN F
after 0 ADP F
treatment 0 NOUN F
with 0 ADP F
IL-1Ra 0 NOUN T
at 0 ADP F
150 0 NUM F
mg/day 0 NOUN F
( 0 PUNCT F
n=3 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

Increased 0 VERB T
cellular B-PHYSICAL ADJ F
infiltration I-PHYSICAL NOUN F
was 0 VERB F
observed 0 VERB F
in 0 ADP F
all 0 DET F
patients 0 NOUN F
receiving 0 VERB F
placebo 0 NOUN F
( 0 PUNCT F
n=3 0 NOUN F
) 0 PUNCT F
; 0 PUNCT F
variable 0 ADJ F
changes 0 NOUN F
were 0 VERB F
observed 0 NUM F
after 0 ADP F
IL-1Ra 0 NOUN T
30 0 PUNCT F
mg/day 0 NOUN F
( 0 PUNCT F
n=6 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

In 0 ADP T
a 0 DET F
limited 0 PUNCT F
study 0 NOUN F
of 0 ADP F
adhesion 0 NOUN F
molecule 0 NOUN F
expression 0 NOUN F
, 0 PUNCT F
down-regulation 0 NOUN F
of 0 ADP F
E-selectin B-PHYSICAL NOUN T
and 0 CCONJ F
vascular B-PHYSICAL ADJ F
cell I-PHYSICAL NOUN F
adhesion I-PHYSICAL NOUN F
molecule-1 I-PHYSICAL NOUN F
was 0 VERB F
observed 0 NUM F
after 0 ADP F
treatment 0 NOUN F
with 0 ADP F
IL-1Ra 0 NOUN T
150 0 NUM F
mg/day 0 NOUN F
, 0 PUNCT F
but 0 CCONJ F
not 0 ADV F
after 0 ADP F
IL-1Ra 0 NOUN T
30 0 PUNCT F
mg/day 0 NOUN F
or 0 CCONJ F
placebo 0 NOUN F
. 0 PUNCT F

The 0 DET T
apparent 0 ADJ F
arrest 0 NOUN F
of 0 ADP F
progressive B-PHYSICAL ADJ F
joint I-PHYSICAL NOUN F
damage I-PHYSICAL NOUN F
seen 0 VERB F
in 0 ADP F
four 0 NUM F
patients 0 NOUN F
after 0 ADP F
treatment 0 NOUN F
with 0 ADP F
IL-1Ra 0 NOUN T
was 0 VERB F
associated 0 VERB F
with 0 ADP F
reduced 0 ADP F
intimal 0 ADJ F
layer 0 NOUN F
macrophage 0 NOUN F
accumulation 0 NOUN F
in 0 ADP F
all 0 DET F
patients 0 NOUN F
. 0 PUNCT F

CONCLUSION 0 NOUN T
Treatment 0 NOUN T
of 0 ADP F
RA 0 NOUN T
with 0 ADP F
IL-1Ra 0 NOUN T
resulted 0 VERB F
in 0 ADP F
reduced 0 ADP F
mononuclear 0 ADJ F
cell 0 NOUN F
infiltration 0 NOUN F
of 0 ADP F
synovial 0 ADJ F
membrane 0 NOUN F
, 0 PUNCT F
which 0 ADP F
may 0 VERB F
represent 0 VERB F
the 0 DET F
in 0 PUNCT F
vivo 0 ADJ F
inhibition 0 NOUN F
of 0 ADP F
biologically 0 ADV F
relevant 0 ADJ F
IL-1ss-mediated 0 ADJ T
pathogenic 0 ADJ F
effects 0 NOUN F
. 0 PUNCT F

Clinical 0 ADJ T
hypnosis 0 NOUN F
versus 0 CCONJ F
cognitive 0 ADJ F
behavioral 0 ADJ F
training 0 VERB F
for 0 ADP F
pain B-PAIN NOUN F
management I-PAIN NOUN F
with 0 ADP F
pediatric 0 ADJ F
cancer 0 NOUN F
patients 0 NOUN F
undergoing 0 VERB F
bone 0 NOUN F
marrow 0 NOUN F
aspirations 0 NOUN F
. 0 PUNCT F

A 0 DET T
randomized 0 VERB F
controlled 0 VERB F
trial 0 NOUN F
was 0 VERB F
conducted 0 VERB F
to 0 PART F
compare 0 NOUN F
the 0 DET F
efficacy 0 NOUN F
of 0 ADP F
clinical 0 ADJ F
hypnosis 0 NOUN F
versus 0 CCONJ F
cognitive 0 ADJ F
behavioral 0 ADJ F
( 0 PUNCT F
CB 0 NOUN T
) 0 PUNCT F
coping 0 ADJ F
skills 0 NOUN F
training 0 VERB F
in 0 ADP F
alleviating 0 VERB F
the 0 DET F
pain B-PAIN NOUN F
and 0 CCONJ F
distress B-PAIN NOUN F
of 0 ADP F
30 0 NUM F
pediatric 0 ADJ F
cancer 0 NOUN F
patients 0 NOUN F
( 0 PUNCT F
age 0 NOUN F
5 0 NUM F
to 0 ADP F
15 0 NUM F
years 0 NOUN F
) 0 PUNCT F
undergoing 0 VERB F
bone 0 NOUN F
marrow 0 NOUN F
aspirations 0 NOUN F
. 0 PUNCT F

Patients 0 NOUN T
were 0 VERB F
randomized 0 VERB F
to 0 ADP F
one 0 PUNCT F
of 0 ADP F
three 0 NUM F
groups 0 NOUN F
: 0 PUNCT F
hypnosis 0 NOUN F
, 0 PUNCT F
a 0 DET F
package 0 NOUN F
of 0 ADP F
CB 0 NOUN T
coping 0 PROPN F
skills 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
no 0 DET F
intervention 0 NOUN F
. 0 PUNCT F

Patients 0 NOUN T
who 0 PROPN F
received 0 VERB F
either 0 PUNCT F
hypnosis 0 NOUN F
or 0 CCONJ F
CB 0 NOUN T
reported 0 PUNCT F
less 0 DET F
pain B-PAIN NOUN F
and 0 CCONJ F
pain-related B-MENTAL VERB F
anxiety I-MENTAL ADJ F
than 0 PUNCT F
did 0 PUNCT F
control 0 NOUN F
patients 0 NOUN F
and 0 CCONJ F
less 0 DET F
pain B-PAIN NOUN F
and 0 CCONJ F
anxiety B-MENTAL NOUN F
than 0 PUNCT F
at 0 ADP F
their 0 PUNCT F
own 0 ADJ F
baseline 0 NOUN F
. 0 PUNCT F

Hypnosis 0 NOUN T
and 0 CCONJ F
CB 0 NOUN T
were 0 VERB F
similarly 0 ADV F
effective 0 ADJ F
in 0 ADP F
the 0 DET F
relief B-PHYSICAL NOUN F
of I-PHYSICAL ADP F
pain I-PHYSICAL NOUN F
. 0 PUNCT F

Results 0 NOUN T
also 0 ADV F
indicated 0 VERB F
that 0 ADP F
children 0 NOUN F
reported 0 VERB F
more 0 DET F
anxiety B-MENTAL NOUN F
and 0 CCONJ F
exhibited 0 VERB F
more 0 DET F
behavioral B-MENTAL ADJ F
distress I-MENTAL NOUN F
in 0 ADP F
the 0 DET F
CB 0 NOUN T
group 0 NOUN F
than 0 PUNCT F
in 0 ADP F
the 0 DET F
hypnosis 0 NOUN F
group 0 NOUN F
. 0 PUNCT F

It 0 PRON T
is 0 VERB F
concluded 0 NOUN F
that 0 ADP F
hypnosis 0 NOUN F
and 0 CCONJ F
CB 0 NOUN T
coping 0 PUNCT F
skills 0 NOUN F
are 0 PROPN F
effective 0 ADJ F
in 0 ADP F
preparing 0 VERB F
pediatric 0 ADJ F
oncology 0 NOUN F
patients 0 NOUN F
for 0 ADP F
bone 0 NOUN F
marrow 0 NOUN F
aspiration 0 NOUN F
. 0 PUNCT F

Perioperative 0 PUNCT T
blood 0 NOUN F
transfusions 0 NOUN F
, 0 PUNCT F
with 0 ADP F
or 0 CCONJ F
without 0 ADP F
allogeneic 0 ADJ F
leucocytes 0 NOUN F
, 0 PUNCT F
relate 0 VERB F
to 0 ADP F
survival B-MORTALITY NOUN F
, 0 PUNCT F
not 0 ADV F
to 0 ADP F
cancer B-PHYSICAL NOUN F
recurrence I-PHYSICAL NOUN F
. 0 PUNCT F

BACKGROUND 0 NOUN T
Perioperative 0 PUNCT T
blood 0 NOUN F
transfusions 0 NOUN F
are 0 VERB F
reported 0 VERB F
to 0 PART F
be 0 PUNCT F
related 0 VERB F
to 0 ADP F
cancer B-PHYSICAL NOUN F
recurrence I-PHYSICAL NOUN F
and 0 CCONJ F
reduced B-MORTALITY VERB F
survival I-MORTALITY NOUN F
. 0 PUNCT F

Different 0 ADJ T
underlying 0 ADP F
mechanisms 0 NOUN F
have 0 ADP F
been 0 PUNCT F
proposed 0 VERB F
, 0 PUNCT F
and 0 CCONJ F
allogeneic 0 ADJ F
leucocytes 0 NOUN F
in 0 ADP F
transfused 0 DET F
blood 0 NOUN F
have 0 PUNCT F
been 0 PUNCT F
suggested 0 VERB F
to 0 PART F
contribute 0 NOUN F
to 0 ADP F
this 0 DET F
phenomenon 0 NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
Packed 0 PUNCT T
red 0 ADJ F
cells 0 NOUN F
without 0 ADP F
buffy 0 ADJ F
coat 0 NOUN F
( 0 PUNCT F
PC 0 NOUN T
group 0 NOUN F
) 0 PUNCT F
were 0 VERB F
compared 0 VERB F
with 0 ADP F
filtered 0 ADP F
, 0 PUNCT F
leucoreduced 0 PUNCT F
, 0 PUNCT F
red 0 ADJ F
cells 0 NOUN F
( 0 PUNCT F
LD 0 NOUN T
group 0 NOUN F
) 0 PUNCT F
in 0 ADP F
a 0 DET F
randomized 0 VERB F
trial 0 NOUN F
of 0 ADP F
697 0 NUM F
patients 0 NOUN F
with 0 ADP F
colorectal 0 ADJ F
carcinoma 0 NOUN F
. 0 PUNCT F

Five-year B-MORTALITY ADJ T
survival I-MORTALITY NOUN F
and 0 CCONJ F
cancer B-PHYSICAL NOUN F
recurrence I-PHYSICAL NOUN F
rates I-PHYSICAL NOUN F
were 0 VERB F
determined 0 VERB F
, 0 PUNCT F
with 0 ADP F
special 0 ADJ F
emphasis 0 NOUN F
on 0 ADP F
the 0 DET F
location 0 NOUN F
of 0 ADP F
recurrence B-PHYSICAL NOUN F
. 0 PUNCT F

RESULTS 0 PUNCT T
The 0 DET T
intention-to-treat 0 NOUN F
analysis 0 NOUN F
showed 0 VERB F
a 0 DET F
survival B-MORTALITY NOUN F
rate I-MORTALITY NOUN F
of 0 ADP F
63.6 0 NUM F
per 0 ADP F
cent 0 NUM F
in 0 ADP F
the 0 DET F
PC 0 NOUN T
group 0 NOUN F
and 0 CCONJ F
65.3 0 NUM F
per 0 ADP F
cent 0 NUM F
in 0 ADP F
the 0 DET F
LD 0 NOUN T
group 0 NOUN F
( 0 PUNCT F
P 0 NOUN T
= 0 SYM F
0.69 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
with 0 ADP F
recurrence B-PHYSICAL NOUN F
rates I-PHYSICAL NOUN F
of 0 ADP F
27.8 0 NUM F
and 0 CCONJ F
27.9 0 NUM F
per 0 ADP F
cent 0 ADP F
respectively 0 ADV F
. 0 PUNCT F

The 0 DET T
observational 0 ADJ F
analysis 0 NOUN F
showed 0 VERB F
a 0 DET F
significant 0 ADJ F
difference B-MORTALITY NOUN F
in I-MORTALITY ADP F
survival I-MORTALITY NOUN F
between 0 ADP F
transfused 0 VERB F
and 0 CCONJ F
non-transfused 0 ADV F
patients 0 NOUN F
( 0 PUNCT F
59.6 0 ADP F
versus 0 CCONJ F
72.9 0 NUM F
per 0 ADP F
cent 0 NUM F
; 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.001 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
difference 0 NOUN F
in 0 ADP F
cancer B-PHYSICAL NOUN F
recurrence I-PHYSICAL NOUN F
rate I-PHYSICAL NOUN F
between 0 ADP F
transfused 0 VERB F
and 0 CCONJ F
non-transfused 0 ADV F
patients 0 NOUN F
was 0 VERB F
not 0 ADV F
statistically 0 ADV F
significant 0 ADJ F
( 0 PUNCT F
29.8 0 NUM F
versus 0 CCONJ F
24.3 0 NUM F
per 0 ADP F
cent 0 NUM F
; 0 PUNCT F
P 0 NOUN T
= 0 SYM F
0.13 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Local B-PHYSICAL ADJ T
recurrences I-PHYSICAL NOUN F
were 0 VERB F
more 0 ADV F
frequent 0 ADP F
in 0 ADP F
transfused 0 ADP F
than 0 PUNCT F
non-transfused 0 VERB F
patients 0 NOUN F
( 0 PUNCT F
11.9 0 ADP F
versus 0 CCONJ F
7.6 0 NUM F
per 0 ADP F
cent 0 NUM F
; 0 PUNCT F
P 0 NOUN T
= 0 SYM F
0.09 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

CONCLUSION 0 NOUN T
Leucocyte 0 NOUN T
depletion 0 NOUN F
of 0 ADP F
perioperative 0 ADJ F
transfused 0 VERB F
blood 0 NOUN F
has 0 PUNCT F
no 0 DET F
effect 0 NOUN F
on 0 ADP F
long-term B-MORTALITY NOUN F
survival I-MORTALITY NOUN F
and/or 0 CCONJ F
cancer B-PHYSICAL NOUN F
recurrence I-PHYSICAL NOUN F
. 0 PUNCT F

Perioperative 0 PUNCT T
blood 0 NOUN F
transfusions 0 NOUN F
are 0 VERB F
associated 0 VERB F
with 0 ADP F
impaired 0 VERB F
survival 0 NOUN F
, 0 PUNCT F
but 0 CCONJ F
not 0 ADV F
with 0 ADP F
cancer 0 NOUN F
recurrence 0 NOUN F
. 0 PUNCT F

The 0 DET T
slight 0 ADJ F
increase 0 NOUN F
in 0 ADP F
local 0 ADJ F
recurrence B-PHYSICAL NOUN F
rate I-PHYSICAL NOUN F
in 0 ADP F
transfused 0 VERB F
patients 0 NOUN F
appears 0 NOUN F
to 0 PART F
be 0 PUNCT F
related 0 VERB F
to 0 ADP F
complicated 0 PUNCT F
, 0 PUNCT F
in 0 ADP F
particular 0 PUNCT F
rectal 0 ADJ F
, 0 PUNCT F
surgery 0 NOUN F
. 0 PUNCT F

Controlled-release 0 NOUN T
melatonin 0 NOUN F
, 0 PUNCT F
singly 0 ADV F
and 0 CCONJ F
combined 0 VERB F
with 0 ADP F
cognitive 0 ADJ F
behavioural 0 ADJ F
therapy 0 NOUN F
, 0 PUNCT F
for 0 ADP F
persistent 0 ADJ F
insomnia B-PHYSICAL NOUN F
in 0 ADP F
children 0 NOUN F
with 0 ADP F
autism 0 NOUN F
spectrum 0 NOUN F
disorders 0 NOUN F
: 0 PUNCT F
a 0 DET F
randomized 0 VERB F
placebo-controlled 0 VERB F
trial 0 NOUN F
. 0 PUNCT F

Although 0 ADP T
melatonin 0 NOUN F
and 0 CCONJ F
cognitive-behavioural 0 ADJ F
therapy 0 NOUN F
have 0 PUNCT F
shown 0 PUNCT F
efficacy 0 NOUN F
in 0 ADP F
treating 0 VERB F
sleep 0 NOUN F
disorders 0 NOUN F
in 0 ADP F
children 0 NOUN F
with 0 ADP F
autism 0 NOUN F
spectrum 0 NOUN F
disorders 0 NOUN F
, 0 PUNCT F
little 0 PUNCT F
is 0 VERB F
known 0 VERB F
about 0 ADP F
their 0 PUNCT F
relative 0 ADJ F
or 0 CCONJ F
combined 0 VERB F
efficacy 0 NOUN F
. 0 PUNCT F

One 0 NUM T
hundred 0 NUM F
and 0 CCONJ F
sixty 0 PUNCT F
children 0 NOUN F
with 0 ADP F
autism 0 NOUN F
spectrum 0 NOUN F
disorders 0 NOUN F
, 0 PUNCT F
aged 0 VERB F
4-10 0 NUM F
years 0 NOUN F
, 0 PUNCT F
suffering 0 ADP F
from 0 ADP F
sleep 0 NOUN F
onset 0 NOUN F
insomnia 0 ADV F
and 0 CCONJ F
impaired 0 VERB F
sleep 0 NOUN F
maintenance 0 NOUN F
, 0 PUNCT F
were 0 VERB F
assigned 0 VERB F
randomly 0 ADV F
to 0 ADP F
either 0 CCONJ F
( 0 PUNCT F
1 0 NUM F
) 0 PUNCT F
combination 0 NOUN F
of 0 ADP F
controlled-release 0 NOUN F
melatonin 0 NOUN F
and 0 CCONJ F
cognitive-behavioural 0 ADJ F
therapy 0 NOUN F
; 0 PUNCT F
( 0 PUNCT F
2 0 NUM F
) 0 PUNCT F
controlled-release 0 NOUN F
melatonin 0 NOUN F
; 0 PUNCT F
( 0 PUNCT F
3 0 NUM F
) 0 PUNCT F
four 0 NUM F
sessions 0 NOUN F
of 0 ADP F
cognitive-behavioural 0 ADJ F
therapy 0 NOUN F
; 0 PUNCT F
or 0 CCONJ F
( 0 PUNCT F
4 0 NUM F
) 0 PUNCT F
placebo 0 NOUN F
drug 0 NOUN F
treatment 0 NOUN F
condition 0 NOUN F
for 0 ADP F
12 0 NUM F
weeks 0 NOUN F
in 0 ADP F
a 0 DET F
1 0 NUM F
: 0 PUNCT F
1 0 NUM F
: 0 PUNCT F
1 0 NUM F
: 0 PUNCT F
1 0 NUM F
ratio 0 NOUN F
. 0 PUNCT F

Children 0 NOUN T
were 0 VERB F
studied 0 VERB F
at 0 ADP F
baseline 0 NOUN F
and 0 CCONJ F
after 0 ADP F
12 0 NUM F
weeks 0 NOUN F
of 0 ADP F
treatment 0 NOUN F
. 0 PUNCT F

Treatment 0 NOUN T
response 0 NOUN F
was 0 VERB F
assessed 0 VERB F
with 0 ADP F
1-week 0 NOUN F
actigraphic 0 ADJ F
monitoring 0 VERB F
, 0 PUNCT F
sleep 0 ADP F
diary 0 PUNCT F
and 0 CCONJ F
sleep 0 NOUN F
questionnaire 0 NOUN F
. 0 PUNCT F

Main 0 ADJ T
outcome 0 NOUN F
measures 0 NOUN F
, 0 PUNCT F
derived 0 VERB F
actigraphically 0 ADV F
, 0 PUNCT F
were 0 VERB F
sleep 0 NOUN F
latency 0 NOUN F
, 0 PUNCT F
total 0 ADJ F
sleep 0 NOUN F
time 0 NOUN F
, 0 PUNCT F
wake 0 NOUN F
after 0 ADP F
sleep 0 NOUN F
onset 0 NOUN F
and 0 CCONJ F
number 0 NOUN F
of 0 ADP F
awakenings 0 NOUN F
. 0 PUNCT F

The 0 DET T
active 0 ADJ F
treatment 0 NOUN F
groups 0 NOUN F
all 0 DET F
resulted 0 PUNCT F
in 0 ADP F
improvements 0 NOUN F
across 0 ADP F
all 0 DET F
outcome 0 NOUN F
measures 0 NOUN F
, 0 PUNCT F
with 0 ADP F
moderate-to-large 0 PUNCT F
effect 0 NOUN F
sizes 0 NOUN F
from 0 ADP F
baseline 0 NOUN F
to 0 ADP F
a 0 DET F
12-week 0 NOUN F
assessment 0 NOUN F
. 0 PUNCT F

Melatonin 0 NOUN T
treatment 0 NOUN F
was 0 VERB F
mainly 0 ADV F
effective 0 ADJ F
in 0 ADP F
reducing 0 VERB F
insomnia B-PHYSICAL NOUN F
symptoms I-PHYSICAL NOUN F
, 0 PUNCT F
while 0 ADP F
cognitive-behavioural 0 ADJ F
therapy 0 NOUN F
had 0 VERB F
a 0 DET F
light 0 ADJ F
positive 0 ADJ F
impact 0 NOUN F
mainly 0 ADV F
on 0 ADP F
sleep B-PHYSICAL NOUN F
latency I-PHYSICAL NOUN F
, 0 PUNCT F
suggesting 0 VERB F
that 0 ADP F
some 0 DET F
behavioural 0 ADJ F
aspects 0 NOUN F
might 0 VERB F
play 0 VERB F
a 0 DET F
role 0 NOUN F
in 0 ADP F
determining 0 VERB F
initial B-PHYSICAL ADJ F
insomnia I-PHYSICAL NOUN F
. 0 PUNCT F

The 0 DET T
combination 0 NOUN F
treatment 0 NOUN F
group 0 NOUN F
showed 0 VERB F
a 0 DET F
trend 0 NOUN F
to 0 ADP F
outperform 0 PUNCT F
other 0 ADJ F
active 0 ADJ F
treatment 0 NOUN F
groups 0 NOUN F
, 0 PUNCT F
with 0 ADP F
fewer 0 PUNCT F
dropouts 0 ADP F
and 0 CCONJ F
a 0 DET F
greater 0 PUNCT F
proportion 0 NOUN F
of 0 ADP F
treatment 0 NOUN F
responders 0 NOUN F
achieving 0 PUNCT F
clinically 0 ADV F
significant 0 ADJ F
changes 0 NOUN F
( 0 PUNCT F
63.38 0 NUM F
% 0 SYM F
normative 0 ADJ F
sleep 0 NOUN F
efficiency 0 NOUN F
criterion 0 NOUN F
of 0 ADP F
> 0 PROPN F
85 0 NUM F
% 0 SYM F
and 0 CCONJ F
84.62 0 NUM F
% 0 SYM F
, 0 PUNCT F
sleep 0 ADP F
onset 0 NOUN F
latency 0 NOUN F
< 0 SYM F
30 0 NUM F
min 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

This 0 DET T
study 0 NOUN F
demonstrates 0 VERB F
that 0 ADP F
adding 0 VERB F
behavioural 0 ADJ F
intervention 0 NOUN F
to 0 ADP F
melatonin 0 NOUN F
treatment 0 NOUN F
seems 0 NOUN F
to 0 PART F
result 0 NOUN F
in 0 ADP F
a 0 DET F
better 0 PUNCT F
treatment 0 NOUN F
response 0 NOUN F
, 0 PUNCT F
at 0 VERB F
least 0 ADV F
in 0 ADP F
the 0 DET F
short 0 ADJ F
term 0 NOUN F
. 0 PUNCT F

Phase 0 NOUN T
II 0 NUM T
trial 0 NOUN F
of 0 ADP F
nab-paclitaxel 0 NOUN F
compared 0 VERB F
with 0 ADP F
docetaxel 0 PUNCT F
as 0 ADP F
first-line 0 NOUN F
chemotherapy 0 NOUN F
in 0 ADP F
patients 0 NOUN F
with 0 ADP F
metastatic 0 ADJ F
breast 0 NOUN F
cancer 0 NOUN F
: 0 PUNCT F
final 0 ADJ F
analysis 0 NOUN F
of 0 ADP F
overall 0 ADJ F
survival 0 NOUN F
. 0 PUNCT F

BACKGROUND 0 NOUN T
A 0 NOUN T
randomized 0 VERB F
phase 0 NOUN F
II 0 NUM T
study 0 NOUN F
in 0 ADP F
first-line 0 NOUN F
MBC 0 NOUN T
demonstrated 0 VERB F
superior 0 ADJ F
efficacy 0 NOUN F
and 0 CCONJ F
safety B-OTHER NOUN F
of 0 ADP F
weekly 0 ADV F
nab-paclitaxel 0 NOUN F
compared 0 VERB F
with 0 ADP F
docetaxel 0 NOUN F
. 0 PUNCT F

Final 0 ADJ T
survival B-MORTALITY NOUN F
analyses 0 NOUN F
and 0 CCONJ F
updated 0 ADP F
safety B-OTHER NOUN F
results 0 ADJ F
are 0 VERB F
reported 0 VERB F
. 0 PUNCT F

PATIENTS 0 NOUN T
AND 0 CCONJ T
METHODS 0 NOUN T
Three 0 NUM T
hundred 0 NUM F
two 0 NUM F
patients 0 NOUN F
with 0 ADP F
no 0 DET F
previous 0 ADJ F
chemotherapy 0 NOUN F
for 0 ADP F
MBC 0 NOUN T
were 0 VERB F
randomized 0 VERB F
to 0 PART F
receive 0 NOUN F
nab-paclitaxel 0 NOUN F
300 0 NUM F
mg/m 0 NOUN F
( 0 PUNCT F
2 0 NUM F
) 0 PUNCT F
q3w 0 NOUN F
, 0 PUNCT F
nab-paclitaxel 0 NOUN F
100 0 NUM F
mg/m 0 NOUN F
( 0 PUNCT F
2 0 NUM F
) 0 PUNCT F
or 0 CCONJ F
150 0 NUM F
mg/m 0 NOUN F
( 0 PUNCT F
2 0 NUM F
) 0 PUNCT F
the 0 DET F
first 0 ADJ F
3 0 NUM F
of 0 ADP F
4 0 NUM F
weeks 0 NOUN F
( 0 PUNCT F
qw 0 NOUN F
3/4 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
or 0 CCONJ F
docetaxel 0 VERB F
100 0 NUM F
mg/m 0 NOUN F
( 0 PUNCT F
2 0 NUM F
) 0 PUNCT F
q3w 0 ADV F
. 0 PUNCT F

The 0 DET T
trial 0 NOUN F
was 0 VERB F
powered 0 VERB F
for 0 ADP F
analyses 0 NOUN F
of 0 ADP F
antitumor B-OTHER NOUN F
activity I-OTHER NOUN F
and 0 CCONJ F
safety B-OTHER NOUN F
. 0 PUNCT F

RESULTS 0 NOUN T
Treatment 0 NOUN T
with 0 ADP F
nab-paclitaxel 0 NOUN F
150 0 NUM F
mg/m 0 NOUN F
( 0 PUNCT F
2 0 NUM F
) 0 PUNCT F
qw 0 NOUN F
3/4 0 NUM F
resulted 0 VERB F
in 0 ADP F
a 0 DET F
median 0 ADJ F
overall 0 ADJ F
survival B-MORTALITY NOUN F
( 0 PUNCT F
OS 0 NOUN T
) 0 PUNCT F
of 0 ADP F
33.8 0 NUM F
months 0 NOUN F
compared 0 VERB F
with 0 ADP F
22.2 0 NUM F
, 0 PUNCT F
27.7 0 NUM F
, 0 PUNCT F
and 0 CCONJ F
26.6 0 NUM F
months 0 NOUN F
for 0 ADP F
nab-paclitaxel 0 NOUN F
100 0 NUM F
mg/m 0 NOUN F
( 0 PUNCT F
2 0 NUM F
) 0 PUNCT F
qw 0 NOUN F
3/4 0 NUM F
, 0 PUNCT F
nab-paclitaxel 0 NOUN F
300 0 NUM F
mg/m 0 NOUN F
( 0 PUNCT F
2 0 NUM F
) 0 PUNCT F
q3w 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
docetaxel 0 PUNCT F
, 0 PUNCT F
respectively 0 ADV F
( 0 PUNCT F
overall 0 ADJ F
P 0 NOUN T
= 0 SYM F
.047 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Patients 0 NOUN T
receiving 0 VERB F
150 0 NUM F
mg/m 0 NOUN F
( 0 PUNCT F
2 0 NUM F
) 0 PUNCT F
nab-paclitaxel 0 NOUN F
had 0 PUNCT F
prolonged 0 PUNCT F
median 0 ADJ F
OS B-MORTALITY NOUN T
compared 0 VERB F
with 0 ADP F
those 0 PUNCT F
in 0 ADP F
the 0 DET F
100 0 NUM F
mg/m 0 NOUN F
( 0 PUNCT F
2 0 NUM F
) 0 PUNCT F
nab-paclitaxel 0 NOUN F
arm 0 NOUN F
( 0 PUNCT F
hazard 0 NOUN F
ratio 0 NOUN F
, 0 PUNCT F
0.575 0 NUM F
; 0 PUNCT F
P 0 NOUN T
= 0 SYM F
.008 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

A 0 DET T
trend 0 NOUN F
toward 0 ADP F
a 0 DET F
longer 0 PUNCT F
OS B-MORTALITY PUNCT T
was 0 VERB F
noted 0 VERB F
in 0 ADP F
the 0 DET F
150 0 NUM F
mg/m 0 NOUN F
( 0 PUNCT F
2 0 NUM F
) 0 PUNCT F
nab-paclitaxel 0 NOUN F
arm 0 NOUN F
versus 0 CCONJ F
docetaxel 0 DET F
arm 0 NOUN F
( 0 PUNCT F
hazard 0 NOUN F
ratio 0 NOUN F
, 0 PUNCT F
0.688 0 PUNCT F
) 0 PUNCT F
. 0 PUNCT F

Grade 0 NOUN T
3 0 NUM F
or 0 CCONJ F
4 B-PHYSICAL NUM F
fatigue I-PHYSICAL NOUN F
, 0 PUNCT F
neutropenia B-PHYSICAL NOUN F
, 0 PUNCT F
and 0 CCONJ F
febrile B-PHYSICAL ADJ F
neutropenia I-PHYSICAL NOUN F
were 0 VERB F
less 0 ADV F
frequent 0 ADP F
in 0 ADP F
all 0 DET F
nab-paclitaxel 0 NOUN F
arms 0 NOUN F
compared 0 VERB F
with 0 ADP F
docetaxel 0 NOUN F
. 0 PUNCT F

CONCLUSIONS 0 NOUN T
Consistent 0 ADJ T
with 0 ADP F
previously 0 ADV F
published 0 PUNCT F
efficacy 0 NOUN F
results 0 ADJ F
, 0 PUNCT F
these 0 DET F
data 0 NOUN F
suggest 0 VERB F
that 0 ADP F
150 0 NUM F
mg/m 0 NOUN F
( 0 PUNCT F
2 0 NUM F
) 0 PUNCT F
qw 0 NOUN F
3/4 0 NUM F
may 0 VERB F
represent 0 VERB F
the 0 ADP F
most 0 PUNCT F
clinically 0 ADV F
efficacious 0 ADJ F
nab-paclitaxel 0 NOUN F
dosing 0 PUNCT F
regimen 0 NOUN F
for 0 ADP F
patients 0 NOUN F
with 0 ADP F
no 0 DET F
previous 0 ADJ F
chemotherapy 0 NOUN F
for 0 ADP F
MBC 0 NOUN T
. 0 PUNCT F

A 0 DET T
phase 0 NOUN F
III 0 NUM T
trial 0 NOUN F
confirming 0 VERB F
these 0 DET F
results 0 NOUN F
would 0 VERB F
be 0 VERB F
necessary 0 ADJ F
and 0 CCONJ F
prudent 0 ADJ F
before 0 ADP F
widespread 0 ADJ F
adoption 0 NOUN F
of 0 ADP F
the 0 DET F
150 0 NUM F
mg/m 0 NOUN F
( 0 PUNCT F
2 0 NUM F
) 0 PUNCT F
dose 0 NOUN F
in 0 ADP F
clinical 0 ADJ F
practice 0 NOUN F
. 0 PUNCT F

Laser-aided 0 ADJ T
external 0 ADJ F
drainage 0 NOUN F
of 0 ADP F
subretinal 0 ADJ F
fluid 0 NOUN F
: 0 PUNCT F
prospective 0 ADJ F
randomized 0 VERB F
comparison 0 NOUN F
with 0 ADP F
needle 0 NOUN F
drainage 0 NOUN F
. 0 PUNCT F

In 0 ADP T
a 0 DET F
prospective 0 ADJ F
randomized 0 VERB F
study 0 NOUN F
of 0 ADP F
50 0 NUM F
consecutive 0 ADJ F
eyes 0 NOUN F
, 0 PUNCT F
we 0 PRON F
compared 0 VERB F
the 0 DET F
safety B-OTHER NOUN F
and 0 CCONJ F
efficacy 0 NOUN F
of 0 ADP F
draining 0 ADP F
subretinal 0 ADJ F
fluid 0 NOUN F
transchoroidally 0 ADV F
in 0 ADP F
primary 0 ADJ F
scleral 0 ADJ F
buckling 0 PUNCT F
for 0 ADP F
rhegmatogenous 0 ADJ F
retinal 0 ADJ F
detachment 0 NOUN F
using 0 VERB F
a 0 DET F
needle 0 NOUN F
, 0 PUNCT F
with 0 ADP F
the 0 DET F
safety B-PHYSICAL NOUN F
and 0 CCONJ F
efficacy 0 NOUN F
of 0 ADP F
the 0 DET F
same 0 ADJ F
procedure 0 NOUN F
using 0 VERB F
an 0 DET F
angulated 0 VERB F
endolaser 0 ADJ F
probe 0 NOUN F
set 0 ADP F
at 0 ADP F
1 0 NUM F
W 0 NOUN T
for 0 ADP F
0.2 0 NUM F
seconds 0 NOUN F
, 0 PUNCT F
using 0 VERB F
an 0 DET F
average 0 NOUN F
of 0 ADP F
2.4 0 NUM F
laser 0 NOUN F
burns 0 NOUN F
. 0 PUNCT F

There 0 PUNCT T
were 0 VERB F
no 0 DET F
significant 0 ADJ F
complications B-ADVERSE-EFFECTS NOUN F
associated 0 VERB F
with 0 ADP F
the 0 DET F
laser-aided 0 VERB F
drainage 0 NOUN F
procedures 0 NOUN F
( 0 PUNCT F
25 0 PUNCT F
eyes 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

In 0 ADP T
the 0 DET F
transchoroidal 0 ADJ F
needle 0 NOUN F
drainage 0 NOUN F
procedures 0 NOUN F
( 0 PUNCT F
25 0 PUNCT F
eyes 0 NOUN F
) 0 PUNCT F
, 0 PUNCT F
subretinal B-PHYSICAL ADJ F
hemorrhage I-PHYSICAL NOUN F
occurred 0 VERB F
in 0 ADP F
three 0 NUM F
eyes 0 NOUN F
and 0 CCONJ F
retinal 0 ADJ F
incarceration 0 NOUN F
in 0 ADP F
one 0 NUM F
. 0 PUNCT F

Thus 0 ADV T
, 0 PUNCT F
though 0 ADP F
our 0 ADP F
numbers 0 NOUN F
are 0 VERB F
small 0 ADJ F
, 0 PUNCT F
there 0 PUNCT F
appears 0 NOUN F
to 0 PART F
be 0 PUNCT F
some 0 CCONJ F
advantage 0 NOUN F
of 0 ADP F
laser-assisted 0 VERB F
drainage 0 NOUN F
in 0 ADP F
terms 0 NOUN F
of 0 ADP F
a 0 DET F
lower 0 PUNCT F
incidence 0 NOUN F
of 0 ADP F
complications B-ADVERSE-EFFECTS NOUN F
. 0 PUNCT F

Effect 0 NOUN T
of 0 ADP F
topical 0 ADJ F
anesthesia 0 NOUN F
and 0 CCONJ F
age 0 NOUN F
on 0 ADP F
pain B-PAIN NOUN F
scores I-PAIN NOUN F
during 0 ADP F
retinopathy 0 NOUN F
of 0 ADP F
prematurity 0 NOUN F
screening 0 PUNCT F
. 0 PUNCT F

OBJECTIVE 0 NOUN T
The 0 DET T
efficacy 0 NOUN F
of 0 ADP F
topical 0 ADJ F
anesthesia 0 NOUN F
during 0 ADP F
retinopathy 0 NOUN F
of 0 ADP F
prematurity 0 NOUN F
( 0 PUNCT F
ROP 0 NOUN T
) 0 PUNCT F
screening 0 ADP F
has 0 PUNCT F
been 0 PUNCT F
a 0 DET F
controversial 0 ADJ F
issue 0 NOUN F
. 0 PUNCT F

To 0 PART T
determine 0 NOUN F
the 0 DET F
efficacy 0 NOUN F
of 0 ADP F
proparacaine 0 NOUN F
eye 0 NOUN F
drops 0 PUNCT F
( 0 PUNCT F
0.5 0 NUM F
% 0 SYM F
) 0 PUNCT F
, 0 PUNCT F
we 0 PRON F
compared 0 VERB F
the 0 DET F
Premature B-PAIN ADJ T
Infant I-PAIN NOUN T
Pain I-PAIN NOUN T
Profile I-PAIN NOUN T
( 0 PUNCT F
PIPP B-PAIN NOUN T
) 0 PUNCT F
scores 0 NOUN F
in 0 ADP F
40 0 NUM F
preterm 0 NOUN F
infants 0 NOUN F
undergoing 0 VERB F
ROP 0 NOUN T
screening 0 VERB F
. 0 PUNCT F

STUDY 0 NOUN T
DESIGN 0 NOUN T
Prospective 0 ADJ T
randomized 0 VERB F
double 0 PUNCT F
masked 0 CCONJ F
cross-over 0 NOUN F
clinical 0 ADJ F
trial 0 NOUN F
. 0 PUNCT F

The 0 DET T
study 0 NOUN F
was 0 VERB F
conducted 0 VERB F
in 0 ADP F
the 0 DET F
neonatal 0 ADJ F
intensive 0 ADJ F
units 0 NOUN F
for 0 ADP F
infants 0 NOUN F
undergoing 0 VERB F
routine 0 ADJ F
ROP 0 NOUN T
screening 0 VERB F
exams 0 NOUN F
. 0 PUNCT F

Baseline 0 NOUN T
PIPP B-PHYSICAL NOUN T
scores I-PHYSICAL NOUN F
and 0 CCONJ F
post-examination B-PHYSICAL NOUN F
PIPP I-PHYSICAL NOUN T
scores I-PHYSICAL NOUN F
at 0 ADP F
1 0 NUM F
and 0 CCONJ F
5 0 NUM F
min 0 NOUN F
were 0 VERB F
compared 0 VERB F
for 0 ADP F
: 0 PUNCT F
( 0 PUNCT F
1 0 NUM F
) 0 PUNCT F
those 0 PUNCT F
receiving 0 VERB F
saline 0 NOUN F
vs 0 CCONJ F
proparacaine 0 NOUN F
eye 0 NOUN F
drops 0 PUNCT F
( 0 PUNCT F
2 0 NUM F
) 0 PUNCT F
first 0 ADJ F
ROP 0 NOUN T
screening 0 VERB F
vs 0 CCONJ F
second 0 ADJ F
ROP 0 NOUN T
screening 0 VERB F
, 0 PUNCT F
regardless 0 PUNCT F
of 0 ADP F
the 0 DET F
type 0 NOUN F
of 0 ADP F
eye 0 NOUN F
drops 0 PUNCT F
used 0 VERB F
. 0 PUNCT F

Wilcoxon 0 NOUN T
signed-ranks 0 NOUN F
test 0 ADV F
was 0 VERB F
used 0 VERB F
to 0 ADP F
pair 0 PUNCT F
pain 0 NOUN F
scores 0 NOUN F
. 0 PUNCT F

RESULT 0 NOUN T
Forty 0 CCONJ T
preterm 0 NOUN F
infants 0 NOUN F
were 0 VERB F
included 0 VERB F
in 0 ADP F
the 0 DET F
study 0 NOUN F
. 0 PUNCT F

Mean 0 DET T
gestational 0 ADJ F
age 0 NOUN F
( 0 PUNCT F
GA 0 NOUN T
) 0 PUNCT F
at 0 ADP F
first 0 PUNCT F
and 0 CCONJ F
second 0 ADP F
examinations 0 NOUN F
was 0 VERB F
33.3 0 NUM F
and 0 CCONJ F
35.3 0 NUM F
weeks 0 NOUN F
, 0 PUNCT F
respectively 0 ADV F
. 0 PUNCT F

Proparacaine 0 ADJ T
use 0 ADP F
significantly 0 ADV F
lowered 0 CCONJ F
mean 0 NOUN F
PIPP 0 NOUN T
scores 0 NOUN F
( 0 PUNCT F
P=0.027 0 NOUN T
) 0 PUNCT F
and 0 CCONJ F
delta 0 NOUN F
scores 0 NOUN F
( 0 PUNCT F
P=0.013 0 NOUN T
) 0 PUNCT F
at 0 ADP F
1 0 NUM F
min 0 NOUN F
after 0 ADP F
examination 0 NOUN F
, 0 PUNCT F
but 0 CCONJ F
there 0 PUNCT F
was 0 VERB F
no 0 DET F
difference 0 NOUN F
at 0 ADP F
5 0 NUM F
min 0 NOUN F
after 0 ADP F
examination 0 NOUN F
. 0 PUNCT F

Second 0 ADJ T
examinations 0 NOUN F
showed 0 VERB F
significantly 0 ADV F
lower 0 PUNCT F
mean 0 NOUN F
PIPP 0 NOUN T
scores 0 NOUN F
after 0 ADP F
examination 0 NOUN F
( 0 PUNCT F
1 0 NUM F
min 0 NOUN F
( 0 PUNCT F
P=0.003 0 NOUN T
) 0 PUNCT F
and 0 CCONJ F
5 0 NUM F
min 0 NOUN F
( 0 PUNCT F
P=0.025 0 NOUN T
) 0 PUNCT F
) 0 PUNCT F
, 0 PUNCT F
regardless 0 PUNCT F
of 0 ADP F
the 0 DET F
type 0 NOUN F
of 0 ADP F
drop 0 PUNCT F
used 0 PRON F
. 0 PUNCT F

CONCLUSION 0 NOUN T
Proparacaine 0 NOUN T
eye 0 NOUN F
drops 0 PUNCT F
offer 0 VERB F
significant 0 ADJ F
relief 0 NOUN F
of 0 ADP F
pain 0 NOUN F
that 0 ADP F
is 0 VERB F
apparently 0 ADV F
short 0 ADJ F
lived 0 PRON F
. 0 PUNCT F

Significantly 0 ADV T
lower 0 PUNCT F
PIPP 0 NOUN T
scores 0 NOUN F
at 0 ADP F
second 0 ADJ F
ROP 0 NOUN T
examinations 0 NOUN F
suggested 0 VERB F
that 0 ADP F
infants 0 NOUN F
of 0 ADP F
older 0 PUNCT F
GA 0 NOUN T
may 0 VERB F
have 0 PUNCT F
a 0 DET F
greater 0 PUNCT F
ability 0 NOUN F
to 0 VERB F
tolerate 0 NOUN F
ROP 0 NOUN T
screening 0 VERB F
. 0 PUNCT F

We 0 PRON T
recommend 0 VERB F
the 0 DET F
use 0 NOUN F
of 0 ADP F
proparacaine 0 NOUN F
eye 0 NOUN F
drops 0 PUNCT F
for 0 ADP F
the 0 DET F
short 0 ADJ F
term 0 NOUN F
, 0 PUNCT F
immediate 0 ADJ F
relief 0 NOUN F
of 0 ADP F
pain 0 NOUN F
during 0 ADP F
ROP 0 NOUN T
screening 0 NUM F
in 0 ADP F
preterm 0 NOUN F
infants 0 NOUN F
of 0 ADP F
lesser 0 PUNCT F
GA 0 NOUN T
. 0 PUNCT F

Iontophoretic 0 ADJ T
administration 0 NOUN F
of 0 ADP F
dexamethasone 0 NOUN F
sodium 0 NOUN F
phosphate 0 NOUN F
for 0 ADP F
acute 0 ADJ F
epicondylitis 0 NOUN F
. 0 PUNCT F

A 0 DET T
randomized 0 VERB F
, 0 PUNCT F
double-blinded 0 VERB F
, 0 PUNCT F
placebo-controlled 0 VERB F
study 0 NOUN F
. 0 PUNCT F

BACKGROUND 0 NOUN T
A 0 DET T
better 0 PUNCT F
treatment 0 NOUN F
modality 0 NOUN F
is 0 VERB F
needed 0 VERB F
to 0 ADP F
control 0 ADP F
the 0 DET F
pain B-PAIN NOUN F
of 0 ADP F
medial B-PHYSICAL ADJ F
or 0 CCONJ F
lateral B-PHYSICAL ADJ F
epicondylitis I-PHYSICAL NOUN F
( I-PHYSICAL PUNCT F
tennis I-PHYSICAL NOUN F
elbow I-PHYSICAL NOUN F
) I-PHYSICAL PUNCT F
. 0 PUNCT F

HYPOTHESIS 0 ADJ T
Dermal 0 ADJ T
iontophoretic 0 ADJ F
administration 0 NOUN F
of 0 ADP F
dexamethasone 0 NOUN F
sodium 0 NOUN F
phosphate 0 NOUN F
will 0 PUNCT F
be 0 VERB F
significantly 0 ADV F
more 0 ADV F
effective 0 ADJ F
in 0 ADP F
controlling 0 PUNCT F
pain B-PAIN NOUN F
than 0 PUNCT F
a 0 DET F
placebo 0 NOUN F
in 0 ADP F
patients 0 NOUN F
with 0 ADP F
medial 0 ADJ F
or 0 CCONJ F
lateral 0 ADJ F
elbow 0 NOUN F
epicondylitis 0 NOUN F
. 0 PUNCT F

STUDY 0 NOUN T
DESIGN 0 NOUN T
Randomized 0 PROPN T
, 0 PUNCT F
double-blinded 0 VERB F
, 0 PUNCT F
placebo-controlled 0 VERB F
study 0 NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
On 0 ADP T
six 0 NUM F
occasions 0 NOUN F
, 0 PUNCT F
1 0 NUM F
to 0 ADP F
3 0 NUM F
days 0 NOUN F
apart 0 PUNCT F
within 0 ADP F
15 0 NUM F
days 0 NOUN F
, 0 PUNCT F
199 0 NUM F
patients 0 NOUN F
with 0 ADP F
elbow 0 NOUN F
epicondylitis 0 NOUN F
received 0 VERB F
40 0 NUM F
mA-minutes 0 ADP F
of 0 ADP F
either 0 CCONJ F
active 0 ADJ F
or 0 CCONJ F
placebo 0 NOUN F
treatment 0 NOUN F
. 0 PUNCT F

RESULTS 0 NOUN T
Dexamethasone 0 NOUN T
produced 0 VERB F
a 0 DET F
significant 0 ADJ F
23-mm 0 PUNCT F
improvement 0 NOUN F
on 0 ADP F
the 0 DET F
100-mm B-PAIN ADJ F
patient I-PAIN NOUN F
visual 0 ADJ F
analog 0 NOUN F
scale 0 NOUN F
ratings B-PAIN NOUN F
, 0 PUNCT F
compared 0 VERB F
with 0 ADP F
14 0 NUM F
mm 0 NOUN F
for 0 ADP F
placebo 0 NOUN F
at 0 ADP F
2 0 NUM F
days 0 NOUN F
and 0 CCONJ F
24 0 NUM F
mm 0 NOUN F
compared 0 VERB F
with 0 ADP F
19 0 NUM F
mm 0 NOUN F
at 0 ADP F
1 0 NUM F
month 0 NOUN F
. 0 PUNCT F

More 0 DET T
patients 0 NOUN F
treated 0 VERB F
with 0 ADP F
dexamethasone 0 NOUN F
than 0 PUNCT F
those 0 PUNCT F
treated 0 VERB F
with 0 ADP F
placebo 0 NOUN F
scored 0 VERB F
moderate 0 ADJ F
or 0 CCONJ F
better 0 PUNCT F
on 0 ADP F
the 0 DET F
investigator B-PHYSICAL NOUN F
's 0 PUNCT F
global B-PHYSICAL ADJ F
improvement I-PHYSICAL NOUN F
scale 0 NOUN F
( 0 PUNCT F
52 0 NUM F
% 0 SYM F
versus 0 CCONJ F
33 0 NUM F
% 0 SYM F
) 0 PUNCT F
at 0 ADP F
2 0 NUM F
days 0 NOUN F
, 0 PUNCT F
but 0 CCONJ F
the 0 DET F
difference 0 NOUN F
was 0 VERB F
not 0 ADV F
significant 0 ADJ F
at 0 ADP F
1 0 NUM F
month 0 NOUN F
( 0 PUNCT F
54 0 NUM F
% 0 SYM F
versus 0 CCONJ F
49 0 NUM F
% 0 SYM F
) 0 PUNCT F
. 0 PUNCT F

Investigator-rated B-PAIN PUNCT T
pain B-PAIN NOUN F
and I-PAIN CCONJ F
tenderness I-PAIN NOUN F
scores 0 NOUN F
favored 0 VERB F
dexamethasone 0 NOUN F
over 0 ADP F
placebo 0 NOUN F
at 0 ADP F
2 0 NUM F
days 0 NOUN F
. 0 PUNCT F

Patients 0 NOUN T
completing 0 VERB F
six 0 NUM F
treatments 0 NOUN F
in 0 ADP F
10 0 NUM F
days 0 NOUN F
or 0 CCONJ F
less 0 DET F
had 0 PUNCT F
better 0 PUNCT F
results 0 PUNCT F
than 0 PUNCT F
those 0 PUNCT F
treated 0 VERB F
over 0 ADP F
a 0 DET F
longer 0 PUNCT F
period 0 NOUN F
. 0 PUNCT F

CONCLUSIONS 0 NOUN T
Iontophoresis 0 NOUN T
treatment 0 NOUN F
was 0 PUNCT F
well 0 PUNCT F

Long-term 0 NOUN T
retention 0 NOUN F
on 0 ADP F
treatment 0 NOUN F
with 0 ADP F
lumiracoxib 0 NOUN F
100 0 NUM F
mg 0 NOUN F
once 0 PUNCT F
or 0 CCONJ F
twice 0 PUNCT F
daily 0 ADJ F
compared 0 VERB F
with 0 ADP F
celecoxib 0 NOUN F
200 0 NUM F
mg 0 NOUN F
once 0 PUNCT F
daily 0 ADJ F
: 0 PUNCT F
a 0 DET F
randomised 0 VERB F
controlled 0 VERB F
trial 0 NOUN F
in 0 ADP F
patients 0 NOUN F
with 0 ADP F
osteoarthritis 0 NOUN F
. 0 PUNCT F

BACKGROUND 0 NOUN T
The 0 DET T
efficacy 0 NOUN F
, 0 PUNCT F
safety 0 NOUN F
and 0 CCONJ F
tolerability 0 NOUN F
of 0 ADP F
lumiracoxib 0 NOUN F
, 0 PUNCT F
a 0 DET F
novel 0 ADJ F
selective 0 ADJ F
cyclooxygenase-2 0 NOUN F
( 0 PUNCT F
COX-2 0 NOUN T
) 0 PUNCT F
inhibitor 0 NOUN F
, 0 PUNCT F
has 0 PUNCT F
been 0 PUNCT F
demonstrated 0 VERB F
in 0 ADP F
previous 0 ADJ F
studies 0 NOUN F
of 0 ADP F
patients 0 NOUN F
with 0 ADP F
osteoarthritis 0 NOUN F
( 0 PUNCT F
OA 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

As 0 PUNCT T
it 0 DET F
is 0 VERB F
important 0 ADJ F
to 0 PART F
establish 0 ADJ F
the 0 DET F
long-term 0 NOUN F
safety 0 NOUN F
and 0 CCONJ F
efficacy 0 NOUN F
of 0 ADP F
treatments 0 NOUN F
for 0 ADP F
a 0 DET F
chronic 0 ADJ F
disease 0 NOUN F
such 0 PUNCT F
as 0 ADP F
OA 0 NOUN T
, 0 PUNCT F
the 0 DET F
present 0 ADJ F
study 0 NOUN F
compared 0 VERB F
the 0 DET F
effects 0 NOUN F
of 0 ADP F
lumiracoxib 0 NOUN F
at 0 ADP F
doses 0 NOUN F
of 0 ADP F
100 0 NUM F
mg 0 NOUN F
once 0 PUNCT F
daily 0 DET F
( 0 PUNCT F
o.d 0 PUNCT F
. 0 PUNCT F
) 0 PUNCT F

and 0 CCONJ F
100 0 NUM F
mg 0 NOUN F
twice 0 ADV F
daily 0 ADJ F
( 0 PUNCT F
b.i.d 0 ADP F
. 0 PUNCT F
) 0 PUNCT F

with 0 ADP F
those 0 PUNCT F
of 0 ADP F
celecoxib 0 NOUN F
200 0 NUM F
mg 0 NOUN F
o.d 0 PUNCT F
. 0 PUNCT F

on 0 ADP F
retention 0 NOUN F
on 0 ADP F
treatment 0 NOUN F
over 0 ADP F
1 0 NUM F
year 0 NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
In 0 ADP T
this 0 DET F
52-week 0 NOUN F
, 0 PUNCT F
multicentre 0 NOUN F
, 0 PUNCT F
randomised 0 VERB F
, 0 PUNCT F
double-blind 0 ADJ F
, 0 PUNCT F
parallel-group 0 NOUN F
study 0 NOUN F
, 0 PUNCT F
male 0 NOUN F
and 0 CCONJ F
female 0 NOUN F
patients 0 NOUN F
( 0 PUNCT F
aged 0 PROPN F
at 0 DET F
least 0 ADV F
40 0 NUM F
years 0 NOUN F
) 0 PUNCT F
with 0 ADP F
symptomatic 0 ADJ F
primary 0 ADJ F
OA 0 NOUN T
of 0 ADP F
the 0 DET F
hip 0 NOUN F
, 0 PUNCT F
knee 0 NOUN F
, 0 PUNCT F
hand 0 NOUN F
or 0 CCONJ F
spine 0 NOUN F
were 0 VERB F
randomised 0 NUM F
( 0 PUNCT F
1:2:1 0 ADV F
) 0 PUNCT F
to 0 ADP F
lumiracoxib 0 NOUN F
100 0 NUM F
mg 0 NOUN F
o.d 0 PUNCT F
. 0 PUNCT F
( 0 PUNCT F

n 0 NOUN F
= 0 SYM F
755 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
lumiracoxib 0 NOUN F
100 0 NUM F
mg 0 NOUN F
b.i.d 0 PUNCT F
. 0 PUNCT F
( 0 PUNCT F

n 0 NOUN F
= 0 SYM F
1,519 0 NUM F
) 0 PUNCT F
or 0 CCONJ F
celecoxib 0 NOUN F
200 0 NUM F
mg 0 NOUN F
o.d 0 PUNCT F
. 0 PUNCT F
( 0 PUNCT F

n 0 NOUN F
= 0 SYM F
758 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
primary 0 ADJ F
objective 0 NOUN F
of 0 ADP F
the 0 DET F
study 0 NOUN F
was 0 VERB F
to 0 PART F
demonstrate 0 NOUN F
non-inferiority B-PHYSICAL NOUN F
of I-PHYSICAL ADP F
lumiracoxib I-PHYSICAL NOUN F
at 0 ADP F
either 0 PUNCT F
dose 0 NOUN F
compared 0 VERB F
with 0 ADP F
celecoxib 0 NOUN F
200 0 NUM F
mg 0 NOUN F
o.d 0 PUNCT F
. 0 PUNCT F

with 0 ADP F
respect 0 NOUN F
to 0 ADP F
the 0 DET F
1-year B-MENTAL NOUN F
retention I-MENTAL NOUN F
on I-MENTAL ADP F
treatment 0 NOUN F
rate B-MENTAL NOUN F
. 0 PUNCT F

Secondary 0 ADJ T
outcome 0 NOUN F
variables 0 NOUN F
included 0 ADP F
OA 0 NOUN T
pain 0 NOUN F
in 0 ADP F
the 0 DET F
target 0 NOUN F
joint 0 NOUN F
, 0 PUNCT F
patient 0 NOUN F
's 0 PUNCT F
and 0 CCONJ F
physician 0 NOUN F
's 0 PUNCT F
global 0 ADJ F
assessments 0 NOUN F
of 0 ADP F
disease 0 NOUN F
activity 0 NOUN F
, 0 PUNCT F
Short 0 ADJ T
Arthritis 0 NOUN T
assessment 0 NOUN F
Scale 0 NOUN T
( 0 PUNCT F
SAS 0 NOUN T
) 0 PUNCT F
total 0 ADP F
score 0 NOUN F
, 0 PUNCT F
rescue 0 VERB F
medication 0 NOUN F
use 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
safety 0 NOUN F
and 0 CCONJ F
tolerability 0 NOUN F
. 0 PUNCT F

RESULTS 0 NOUN T
Retention B-PHYSICAL NOUN T
rates B-PHYSICAL NOUN F
at 0 ADP F
1 0 NUM F
year 0 NOUN F
were 0 VERB F
similar 0 ADJ F
for 0 ADP F
the 0 DET F
lumiracoxib 0 NOUN F
100 0 NUM F
mg 0 NOUN F
o.d. 0 NOUN F
, 0 PUNCT F
lumiracoxib 0 NOUN F
100 0 NUM F
mg 0 NOUN F
b.i.d 0 ADV F
. 0 PUNCT F

and 0 CCONJ F
celecoxib 0 NOUN F
200 0 NUM F
mg 0 NOUN F
o.d 0 PUNCT F
. 0 PUNCT F

groups 0 NOUN F
( 0 PUNCT F
46.9 0 NUM F
% 0 SYM F
vs 0 CCONJ F
47.5 0 NUM F
% 0 SYM F
vs 0 CCONJ F
45.3 0 NUM F
% 0 SYM F
, 0 PUNCT F
respectively 0 ADV F
) 0 PUNCT F
. 0 PUNCT F

It 0 PRON T
was 0 VERB F
demonstrated 0 VERB F
that 0 ADP F
retention B-OTHER NOUN F
on 0 ADP F
treatment 0 NOUN F
with 0 ADP F
lumiracoxib 0 NOUN F
at 0 ADP F
either 0 PUNCT F
dose 0 NOUN F
was 0 ADP F
non-inferior 0 ADJ F
to 0 ADP F
celecoxib 0 NOUN F
200 0 NUM F
mg 0 NOUN F
o.d 0 PUNCT F
. 0 PUNCT F

Similarly 0 ADV T
, 0 PUNCT F
Kaplan-Meier 0 PUNCT T
curves 0 NOUN F
for 0 ADP F
the 0 DET F
probability 0 NOUN F
of 0 ADP F
premature 0 ADJ F
discontinuation 0 NOUN F
from 0 ADP F
the 0 DET F
study 0 NOUN F
for 0 ADP F
any 0 DET F
reason 0 NOUN F
were 0 VERB F
similar 0 ADJ F
across 0 ADP F
the 0 DET F
treatment 0 NOUN F
groups 0 NOUN F
. 0 PUNCT F

All 0 DET T
three 0 NUM F
treatments 0 NOUN F
generally 0 ADV F
yielded 0 ADV F
comparable 0 ADJ F
results 0 NOUN F
for 0 ADP F
the 0 DET F
secondary 0 ADJ F
efficacy 0 NOUN F
variables 0 NOUN F
and 0 CCONJ F
all 0 DET F
treatments 0 NOUN F
were 0 PUNCT F
well 0 PUNCT F

The 0 DET T
effect 0 NOUN F
of 0 ADP F
knee 0 NOUN F
position 0 NOUN F
on 0 ADP F
blood B-PHYSICAL NOUN F
loss I-PHYSICAL NOUN F
and 0 CCONJ F
range 0 NOUN F
of 0 ADP F
motion B-PHYSICAL NOUN F
following 0 SYM F
total 0 ADJ F
knee 0 NOUN F
arthroplasty 0 NOUN F
. 0 PUNCT F

PURPOSE 0 NOUN T
This 0 DET T
study 0 NOUN F
prospectively 0 ADV F
assessed 0 ADP F
the 0 DET F
effects 0 NOUN F
of 0 ADP F
knee 0 NOUN F
position 0 NOUN F
on 0 ADP F
blood B-PHYSICAL NOUN F
loss I-PHYSICAL NOUN F
and 0 CCONJ F
range 0 NOUN F
of 0 ADP F
motion B-PHYSICAL NOUN F
after 0 ADP F
primary 0 ADJ F
total 0 ADJ F
knee 0 NOUN F
arthroplasty 0 NOUN F
( 0 PUNCT F
TKA 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

METHODS 0 NOUN T
One 0 NUM T
hundred 0 NUM F
and 0 CCONJ F
ten 0 NUM F
consecutive 0 ADJ F
TKA 0 NOUN T
patients 0 NOUN F
were 0 VERB F
randomized 0 VERB F
into 0 ADP F
flexion 0 NOUN F
group 0 NOUN F
and 0 CCONJ F
extension 0 NOUN F
group 0 NOUN F
. 0 PUNCT F

Both 0 DET T
groups 0 NOUN F
had 0 PUNCT F
the 0 DET F
leg 0 NOUN F
elevated 0 ADJ F
30? 0 NOUN F
at 0 ADP F
the 0 DET F
hip 0 NOUN F
over 0 ADP F
an 0 DET F
inactive 0 ADJ F
CPM 0 NOUN T
for 0 ADP F
72 0 NUM F
h 0 NOUN F
postoperatively 0 NOUN F
. 0 PUNCT F

The 0 DET T
flexion 0 NOUN F
group 0 NOUN F
had 0 PUNCT F
the 0 DET F
knee 0 NOUN F
flexed 0 VERB F
to 0 ADP F
30? 0 NUM F
during 0 ADP F
this 0 DET F
period 0 NOUN F
. 0 PUNCT F

The 0 DET T
extension 0 NOUN F
group 0 NOUN F
had 0 PUNCT F
the 0 DET F
knee 0 NOUN F
extended 0 VERB F
fully 0 ADV F
. 0 PUNCT F

Perioperative 0 PUNCT T
blood 0 NOUN F
loss 0 NOUN F
, 0 PUNCT F
hidden 0 PUNCT F
blood 0 NOUN F
loss 0 NOUN F
, 0 PUNCT F
knee 0 NOUN F
swelling 0 VERB F
, 0 PUNCT F
ecchymosis 0 NOUN F
, 0 PUNCT F
analgesia 0 NOUN F
requirements 0 NOUN F
, 0 PUNCT F
range 0 NOUN F
of 0 ADP F
motion 0 NOUN F
( 0 PUNCT F
ROM 0 NOUN T
) 0 PUNCT F
, 0 PUNCT F
fixed 0 VERB F
flexion 0 NOUN F
deformity 0 NOUN F
( 0 PUNCT F
FFD 0 NOUN T
) 0 PUNCT F
, 0 PUNCT F
straight-leg 0 NOUN F
raising 0 SYM F
action 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
postoperative 0 ADJ F
complications 0 NOUN F
within 0 ADP F
6 0 NUM F
weeks 0 NOUN F
of 0 ADP F
surgery 0 NOUN F
were 0 VERB F
measured 0 VERB F
for 0 ADP F
evaluation 0 NOUN F
and 0 CCONJ F
comparison 0 NOUN F
. 0 PUNCT F

RESULTS 0 PUNCT T
The 0 DET T
postoperative 0 ADJ F
hidden 0 PUNCT F
blood 0 NOUN F
loss 0 NOUN F
, 0 PUNCT F
knee 0 NOUN F
swelling 0 VERB F
, 0 PUNCT F
and 0 CCONJ F
scope 0 NOUN F
of 0 ADP F
ecchymosis 0 NOUN F
were 0 VERB F
significantly 0 ADV F
lower 0 PUNCT F
in 0 ADP F
the 0 DET F
flexion 0 NOUN F
group 0 NOUN F
than 0 PUNCT F
in 0 ADP F
the 0 DET F
extension 0 NOUN F
group 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
ROM 0 NOUN T
and 0 CCONJ F
straight-leg 0 NOUN F
raising 0 SYM F
action 0 NOUN F
were 0 VERB F
significantly 0 ADV F
higher 0 PUNCT F
during 0 ADP F
the 0 DET F
early 0 ADJ F
period 0 NOUN F
after 0 ADP F
operation 0 NOUN F
. 0 PUNCT F

No 0 DET T
significant 0 ADJ F
difference 0 NOUN F
was 0 VERB F
observed 0 VERB F
in 0 ADP F
perioperative 0 ADJ F
blood 0 NOUN F
loss 0 NOUN F
, 0 PUNCT F
the 0 DET F
amount 0 NOUN F
of 0 ADP F
morphine 0 NOUN F
used 0 ADP F
, 0 PUNCT F
or 0 CCONJ F
FFD 0 NOUN T
in 0 ADP F
the 0 DET F
early 0 ADJ F
postoperative 0 ADJ F
period 0 NOUN F
or 0 CCONJ F
in 0 ADP F
ROM 0 NOUN T
and 0 CCONJ F
FFD 0 NOUN T
at 0 ADP F
6 0 NUM F
weeks 0 NOUN F
postoperatively 0 ADV F
. 0 PUNCT F

CONCLUSIONS 0 NOUN T
The 0 DET T
findings 0 NOUN F
of 0 ADP F
this 0 DET F
study 0 NOUN F
indicate 0 VERB F
that 0 ADP F
flexion 0 NOUN F
of 0 ADP F
the 0 DET F
knee 0 NOUN F
to 0 ADP F
30? 0 NUM F
with 0 ADP F
the 0 DET F
leg 0 NOUN F
elevated 0 ADJ F
30? 0 NOUN F
at 0 ADP F
the 0 DET F
hip 0 NOUN F
after 0 ADP F
total 0 ADJ F
knee 0 NOUN F
arthroplasty 0 NOUN F
may 0 NOUN F
mitigate 0 PUNCT F
knee 0 NOUN F
swelling 0 VERB F
and 0 CCONJ F
provide 0 PUNCT F
other 0 ADJ F
beneficial 0 ADJ F
results 0 DET F
during 0 ADP F
the 0 DET F
early 0 ADJ F
rehabilitation 0 NOUN F
following 0 VERB F
TKA 0 NOUN T
. 0 PUNCT F

LEVEL 0 NOUN T
OF 0 ADP T
EVIDENCE 0 NOUN T
Prospective 0 ADJ T
comparative 0 ADJ F
study 0 NOUN F
, 0 PUNCT F
Level 0 NOUN T
I 0 NUM T
. 0 PUNCT F

The 0 DET T
effects 0 NOUN F
of 0 ADP F
aerobic 0 ADJ F
exercise 0 NOUN F
on 0 ADP F
academic 0 ADJ F
engagement 0 NOUN F
in 0 ADP F
young 0 ADJ F
children 0 NOUN F
with 0 ADP F
autism 0 NOUN F
spectrum 0 NOUN F
disorder 0 NOUN F
. 0 PUNCT F

PURPOSE 0 NOUN T
To 0 PROPN T
determine 0 NOUN F
whether 0 VERB F
participation 0 NOUN F
in 0 ADP F
aerobic 0 ADJ F
exercise 0 NOUN F
before 0 PUNCT F
classroom 0 PUNCT F
activities 0 NOUN F
improves 0 NOUN F
academic 0 ADJ F
engagement 0 NOUN F
and 0 CCONJ F
reduces 0 VERB F
stereotypic 0 ADJ F
behaviors 0 NOUN F
in 0 ADP F
young 0 ADJ F
children 0 NOUN F
with 0 ADP F
autism 0 NOUN F
spectrum 0 NOUN F
disorder 0 NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
This 0 PUNCT T
study 0 NOUN F
employed 0 VERB F
a 0 DET F
within-subjects 0 VERB F
crossover 0 NOUN F
design 0 NOUN F
, 0 PUNCT F
using 0 VERB F
a 0 DET F
treatment 0 NOUN F
condition 0 NOUN F
( 0 PUNCT F
aerobic 0 ADJ F
exercise 0 NOUN F
) 0 PUNCT F
and 0 CCONJ F
a 0 DET F
control 0 NOUN F
condition 0 NOUN F
, 0 PUNCT F
across 0 ADP F
4 0 NUM F
classrooms 0 PROPN F
. 0 PUNCT F

The 0 DET T
treatment 0 NOUN F
condition 0 NOUN F
included 0 VERB F
15 0 NUM F
minutes 0 NOUN F
of 0 ADP F
running/jogging 0 PUNCT F
followed 0 VERB F
by 0 ADP F
a 0 DET F
classroom 0 PUNCT F
task 0 NOUN F
. 0 PUNCT F

The 0 DET T
control 0 NOUN F
condition 0 NOUN F
included 0 VERB F
a 0 DET F
classroom 0 PUNCT F
task 0 NOUN F
not 0 ADV F
preceded 0 VERB F
by 0 ADP F
exercise 0 NOUN F
. 0 PUNCT F

The 0 DET T
number B-MENTAL NOUN F
of I-MENTAL ADP F
stereotypic I-MENTAL ADJ F
behaviors I-MENTAL NOUN F
, 0 PUNCT F
percentage B-MENTAL NOUN F
of I-MENTAL ADP F
on-task I-MENTAL PUNCT F
behavior I-MENTAL NOUN F
, 0 PUNCT F
and 0 PUNCT F

The 0 DET T
influence 0 NOUN F
of 0 ADP F
pre- 0 ADJ F
and 0 CCONJ F
intraoperative 0 ADJ F
positioning 0 VERB F
of 0 ADP F
the 0 DET F
condyle 0 ADJ F
in 0 ADP F
the 0 DET F
centre 0 NOUN F
of 0 ADP F
the 0 DET F
articular 0 ADJ F
fossa 0 NOUN F
on 0 ADP F
the 0 DET F
position 0 NOUN F
of 0 ADP F
the 0 DET F
disc 0 NOUN F
in 0 ADP F
orthognathic 0 ADJ F
surgery 0 NOUN F
. 0 PUNCT F

A 0 DET T
magnetic 0 ADJ F
resonance 0 NOUN F
study 0 NOUN F
. 0 PUNCT F

OBJECTIVE 0 NOUN T
We 0 PRON T
investigated 0 VERB F
the 0 DET F
changes 0 NOUN F
in 0 ADP F
the 0 DET F
temporomandibular 0 ADJ F
joint 0 NOUN F
( 0 PUNCT F
TMJ 0 NOUN T
) 0 PUNCT F
after 0 ADP F
bilateral 0 ADJ F
sagittal 0 ADJ F
split 0 ADJ F
osteotomy 0 NOUN F
of 0 ADP F
the 0 DET F
mandible 0 ADJ F
for 0 ADP F
orthognathic 0 ADJ F
surgery 0 NOUN F
and 0 CCONJ F
the 0 DET F
influence 0 NOUN F
of 0 ADP F
positioning 0 VERB F
of 0 ADP F
the 0 DET F
condylar 0 ADJ F
process 0 NOUN F
in 0 ADP F
the 0 DET F
centre 0 NOUN F
of 0 ADP F
the 0 DET F
articular 0 ADJ F
fossa 0 NOUN F
before 0 ADP F
and 0 CCONJ F
during 0 ADP F
the 0 DET F
operation 0 NOUN F
for 0 ADP F
preventing 0 VERB F
changes 0 NOUN F
in 0 ADP F
the 0 DET F
TMJ 0 NOUN T
postoperatively 0 NOUN F
. 0 PUNCT F

STUDY 0 NOUN T
DESIGN 0 NOUN T
A 0 PUNCT T
total 0 NOUN F
of 0 ADP F
28 0 NUM F
patients 0 NOUN F
with 0 ADP F
mandibular 0 ADJ F
retrognathism 0 NOUN F
had 0 PUNCT F
bilateral 0 ADJ F
sagittal 0 ADJ F
split 0 ADJ F
osteotomies 0 NOUN F
for 0 ADP F
mandibular 0 ADJ F
advancement 0 ADP F
. 0 PUNCT F

In 0 ADP T
one 0 NUM F
group 0 NOUN F
of 0 ADP F
14 0 NUM F
patients 0 NOUN F
( 0 PUNCT F
28 0 NUM F
TMJ 0 NOUN T
) 0 PUNCT F
, 0 PUNCT F
the 0 DET F
condyles 0 NOUN F
were 0 VERB F
placed 0 VERB F
in 0 ADP F
the 0 DET F
centre 0 NOUN F
of 0 ADP F
the 0 DET F
articular 0 ADJ F
fossa 0 NOUN F
before 0 ADP F
and 0 CCONJ F
during 0 ADP F
the 0 DET F
operation 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
in 0 ADP F
the 0 DET F
other 0 ADJ F
group 0 NOUN F
they 0 PUNCT F
were 0 VERB F
not 0 ADV F
. 0 PUNCT F

Differences B-OTHER NOUN T
on I-OTHER ADP F
magnetic I-OTHER ADJ F
resonance I-OTHER NOUN F
imaging I-OTHER VERB F
( I-OTHER PUNCT F
MRI I-OTHER NOUN T
) I-OTHER PUNCT F
were 0 VERB F
calculated 0 VERB F
and 0 CCONJ F
the 0 DET F
results 0 NOUN F
were 0 VERB F
evaluated 0 VERB F
. 0 PUNCT F

RESULTS 0 PUNCT T
The 0 DET T
main 0 ADJ F
differences 0 NOUN F
were 0 VERB F
found 0 VERB F
at 0 ADP F
maximal B-PHYSICAL ADJ F
mouth I-PHYSICAL NOUN F
opening I-PHYSICAL ADJ F
. 0 PUNCT F

15/28 0 PUNCT F
TMJs 0 NOUN T
( 0 PUNCT F
54 0 NUM F
% 0 SYM F
) 0 PUNCT F
that 0 ADP F
had 0 ADP F
not 0 ADV F
been 0 PUNCT F
positioned 0 VERB F
changed 0 VERB F
the 0 DET F
position 0 NOUN F
of 0 ADP F
the 0 DET F
disc 0 NOUN F
from 0 ADP F
physiological 0 ADJ F
to 0 ADP F
anterior 0 ADJ F
disc 0 NOUN F
derangement 0 VERB F
with 0 ADP F
and 0 CCONJ F
without 0 ADP F
reduction 0 NOUN F
postoperatively 0 NOUN F
. 0 PUNCT F

In 0 ADP T
the 0 DET F
28 0 NUM F
that 0 PUNCT F
had 0 VERB F
been 0 PUNCT F
positioned 0 VERB F
, 0 PUNCT F
changes 0 NOUN F
were 0 VERB F
found 0 VERB F
in 0 ADP F
only 0 ADV F
3 0 NUM F
TMJs B-PHYSICAL NOUN T
( 0 PUNCT F
11 0 NUM F
% 0 SYM F
) 0 PUNCT F
postoperatively 0 ADV F
. 0 PUNCT F

CONCLUSIONS 0 NOUN T
Fixing 0 PUNCT T
the 0 DET F
condylar 0 ADJ F
process 0 NOUN F
in 0 ADP F
the 0 DET F
centre 0 NOUN F
of 0 ADP F
the 0 DET F
articular 0 ADJ F
fossa 0 ADV F
intraoperatively 0 ADV F
before 0 ADP F
bilateral 0 ADJ F
sagittal 0 ADJ F
split 0 ADJ F
osteotomy 0 NOUN F
is 0 VERB F
a 0 DET F
factor 0 NOUN F
in 0 ADP F
preventing 0 VERB F
postoperative 0 ADJ F
structural 0 ADJ F
changes 0 NOUN F
in 0 ADP F
the 0 DET F
temporomandibular 0 ADJ F
joint 0 NOUN F
. 0 PUNCT F

Recombinant 0 ADJ T
human 0 NOUN F
thyrotropin-stimulated 0 VERB F
radioiodine 0 NOUN F
therapy 0 NOUN F
of 0 ADP F
nodular 0 ADJ F
goiter 0 ADJ F
allows 0 ADV F
major 0 ADJ F
reduction 0 NOUN F
of 0 ADP F
the 0 DET F
radiation B-OTHER NOUN F
burden I-OTHER NOUN F
with 0 ADP F
retained 0 VERB F
efficacy 0 NOUN F
. 0 PUNCT F

CONTEXT 0 NOUN T
AND 0 CCONJ T
OBJECTIVE 0 NOUN T
Stimulation 0 NOUN T
with 0 ADP F
recombinant 0 ADJ F
human 0 NOUN F
TSH 0 NOUN T
( 0 PUNCT F
rhTSH 0 NOUN F
) 0 PUNCT F
before 0 ADP F
radioiodine 0 NOUN F
( 0 PUNCT F
131I 0 NOUN F
) 0 PUNCT F
therapy 0 NOUN F
augments 0 NOUN F
goiter B-PHYSICAL ADJ F
volume I-PHYSICAL NOUN F
reduction I-PHYSICAL NOUN F
( I-PHYSICAL PUNCT F
GVR I-PHYSICAL NOUN T
) I-PHYSICAL PUNCT F
. 0 PUNCT F

Observations 0 NOUN T
indicate 0 VERB F
that 0 ADP F
rhTSH 0 NOUN F
has 0 ADP F
a 0 DET F
preconditioning 0 ADV F
effect 0 NOUN F
beyond 0 ADP F
increasing 0 PUNCT F
thyroid 0 NOUN F
( 0 PUNCT F
131 0 NUM F
) 0 PUNCT F
I 0 NUM T
uptake 0 NOUN F
. 0 PUNCT F

We 0 PRON T
test 0 VERB F
the 0 DET F
hypothesis 0 NOUN F
that 0 ADP F
an 0 DET F
equivalent 0 ADJ F
GVR 0 NOUN T
might 0 VERB F
be 0 NOUN F
obtained 0 VERB F
by 0 ADP F
an 0 DET F
absorbed 0 VERB F
thyroid 0 NOUN F
dose 0 VERB F
well 0 VERB F
below 0 PUNCT F
what 0 PUNCT F
has 0 PUNCT F
been 0 PUNCT F
used 0 VERB F
previously 0 ADV F
. 0 PUNCT F

PATIENTS 0 NOUN T
AND 0 CCONJ T
DESIGN 0 NOUN T
In 0 ADP T
a 0 DET F
double-blinded 0 ADV F
setup 0 NOUN F
, 0 PUNCT F
90 0 NUM F
patients 0 NOUN F
( 0 PUNCT F
78 0 NUM F
women 0 NOUN F
; 0 PUNCT F
median 0 ADJ F
age 0 NOUN F
, 0 PUNCT F
52 0 NUM F
yr 0 NOUN F
; 0 PUNCT F
range 0 NOUN F
, 0 PUNCT F
22-83 0 PUNCT F
) 0 PUNCT F
with 0 ADP F
a 0 DET F
nontoxic 0 ADJ F
nodular 0 ADJ F
goiter 0 ADJ F
( 0 PUNCT F
median 0 ADJ F
size 0 NOUN F
, 0 PUNCT F
63 0 NUM F
ml 0 NOUN F
; 0 PUNCT F
range 0 NOUN F
, 0 PUNCT F
25-379 0 NUM F
ml 0 NOUN F
) 0 PUNCT F
were 0 VERB F
randomized 0 VERB F
to 0 ADP F
either 0 CCONJ F
0.1 0 NUM F
mg 0 NOUN F
rhTSH 0 NOUN F
( 0 PUNCT F
n=60 0 NOUN F
) 0 PUNCT F
followed 0 VERB F
by 0 ADP F
a 0 DET F
thyroid 0 NOUN F
dose 0 NOUN F
of 0 ADP F
50 0 NUM F
Gy 0 NOUN T
or 0 CCONJ F
placebo 0 NOUN F
followed 0 VERB F
by 0 ADP F
100 0 NUM F
Gy 0 NOUN T
( 0 PUNCT F
n=30 0 PUNCT F
) 0 PUNCT F
. 0 PUNCT F

RESULTS 0 NOUN T
At 0 ADP T
12 0 NUM F
months 0 NOUN F
, 0 PUNCT F
the 0 DET F
mean 0 NOUN F
relative B-PHYSICAL ADJ F
GVR I-PHYSICAL NOUN T
in 0 ADP F
the 0 DET F
placebo 0 NOUN F
and 0 CCONJ F
the 0 DET F
rhTSH 0 NOUN F
group 0 NOUN F
was 0 VERB F
identical 0 ADJ F
( 0 PUNCT F
35+/-3 0 NOUN F
% 0 SYM F
; 0 PUNCT F
P=0.81 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
median 0 ADJ F
administered 0 VERB F
131I-activity B-PHYSICAL NOUN F
was 0 VERB F
170 0 NUM F
MBq 0 NOUN T
( 0 PUNCT F
45-1269 0 PUNCT F
) 0 PUNCT F
in 0 ADP F
the 0 DET F
rhTSH 0 NOUN F
group 0 NOUN F
and 0 CCONJ F
559 0 NUM F
MBq 0 NOUN T
( 0 PUNCT F
245-3530 0 NOUN F
) 0 PUNCT F
in 0 ADP F
the 0 DET F
placebo 0 NOUN F
group 0 NOUN F
( 0 PUNCT F
70 0 NUM F
% 0 SYM F
reduction 0 NOUN F
, 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.0001 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

According 0 CCONJ T
to 0 ADP F
the 0 DET F
official 0 ADJ F
radiation 0 NOUN F
regulation 0 NOUN F
, 0 PUNCT F
hospitalization B-OTHER NOUN F
was 0 VERB F
required 0 VERB F
in 0 ADP F
14 0 NUM F
patients 0 NOUN F
in 0 ADP F
the 0 DET F
placebo 0 NOUN F
group 0 NOUN F
vs. 0 CCONJ F
one 0 NUM F
patient 0 NOUN F
in 0 ADP F
the 0 DET F
rhTSH 0 NOUN F
group 0 NOUN F
( 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.0001 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

In 0 ADP T
both 0 CCONJ F
groups 0 NOUN F
, 0 PUNCT F
goiter-related B-PHYSICAL VERB F
symptoms I-PHYSICAL NOUN F
were 0 VERB F
effectively 0 ADV F
relieved 0 VERB F
in 0 ADP F
the 0 DET F
majority 0 NOUN F
of 0 ADP F
patients 0 NOUN F
. 0 PUNCT F

The 0 DET T
prevalence 0 NOUN F
of 0 ADP F
myxedema B-PHYSICAL NOUN F
( 0 PUNCT F
10 0 NUM F
% 0 SYM F
) 0 PUNCT F
did 0 DET F
not 0 ADV F
differ 0 VERB F
among 0 DET F
groups 0 NOUN F
. 0 PUNCT F

CONCLUSIONS 0 NOUN T
This 0 PUNCT T
is 0 VERB F
the 0 DET F
first 0 ADJ F
study 0 NOUN F
to 0 DET F
demonstrate 0 NOUN F
that 0 ADP F
rhTSH 0 NOUN F
not 0 ADV F
only 0 ADV F
increases 0 NOUN F
the 0 DET F
thyroid B-PHYSICAL NOUN F
131I I-PHYSICAL NOUN F
uptake I-PHYSICAL NOUN F
, 0 PUNCT F
but 0 CCONJ F
per 0 PUNCT F
se 0 ADV F
potentiates 0 VERB F
the 0 DET F
effect 0 NOUN F
of 0 ADP F
131I-therapy 0 NOUN F
, 0 PUNCT F
allowing 0 VERB F
a 0 DET F
major 0 ADJ F
reduction 0 NOUN F
of 0 ADP F
the 0 DET F
131I-activity B-PHYSICAL NOUN F
without 0 ADP F
compromising 0 PUNCT F
efficacy 0 NOUN F
. 0 PUNCT F

This 0 DET T
approach 0 NOUN F
is 0 VERB F
attractive 0 ADJ F
in 0 ADP F
terms 0 NOUN F
of 0 ADP F
minimizing 0 VERB F
posttherapeutic B-OTHER ADJ F
restrictions I-OTHER NOUN F
and 0 CCONJ F
in 0 ADP F
reducing 0 VERB F
the 0 DET F
potential 0 ADJ F
risk 0 NOUN F
of 0 ADP F
radiation-induced B-PHYSICAL VERB F
malignancy I-PHYSICAL NOUN F
. 0 PUNCT F

Comparison 0 NOUN T
of 0 ADP F
active-learning 0 PROPN F
strategies 0 NOUN F
for 0 ADP F
motivational B-MENTAL ADJ F
interviewing I-MENTAL PUNCT F
skills I-MENTAL NOUN F
, 0 PUNCT F
knowledge B-MENTAL NOUN F
, 0 PUNCT F
and 0 PUNCT F

Intestinal 0 ADJ T
absorption 0 NOUN F
of 0 ADP F
dietary 0 ADJ F
fat 0 NOUN F
in 0 ADP F
patients 0 NOUN F
with 0 ADP F
multiple 0 ADJ F
sclerosis 0 NOUN F
. 0 PUNCT F

Fat B-PHYSICAL NOUN T
absorption I-PHYSICAL NOUN F
was 0 VERB F
studied 0 VERB F
in 0 ADP F
24 0 NUM F
patients 0 NOUN F
with 0 ADP F
clinically 0 ADV F
definite 0 ADJ F
multiple 0 ADJ F
sclerosis 0 NOUN F
and 0 CCONJ F
in 0 ADP F
36 0 NUM F
healthy 0 ADJ F
control 0 NOUN F
subjects 0 NOUN F
. 0 PUNCT F

Beta-carotene B-PHYSICAL NOUN T
and I-PHYSICAL CCONJ F
vitamin I-PHYSICAL NOUN F
A I-PHYSICAL PUNCT T
in I-PHYSICAL ADP F
their I-PHYSICAL ADJ F
plasma I-PHYSICAL NOUN F
were 0 VERB F
also 0 ADV F
measured 0 VERB F
. 0 PUNCT F

This 0 DET T
double-blind 0 ADJ F
and 0 CCONJ F
randomized 0 VERB F
study 0 NOUN F
showed 0 VERB F
no 0 DET F
differences 0 NOUN F
between 0 ADP F
these 0 DET F
two 0 NUM F
populations 0 NOUN F
with 0 ADP F
regard 0 NOUN F
to 0 ADP F
the 0 DET F
three 0 NUM F
parameters 0 NOUN F
. 0 PUNCT F

We 0 PRON T
did 0 CCONJ F
not 0 ADV F
find 0 VERB F
evidence 0 NOUN F
for 0 ADP F
fat 0 NOUN F
malabsorption 0 NOUN F
in 0 ADP F
multiple 0 ADJ F
sclerosis 0 NOUN F
. 0 PUNCT F

Low 0 ADJ T
power 0 NOUN F
Ga-Al-As 0 NOUN T
laser 0 NOUN F
treatment 0 NOUN F
of 0 ADP F
painful B-PAIN ADJ F
osteoarthritis I-PAIN NOUN F
of 0 ADP F
the 0 DET F
knee 0 NOUN F
. 0 PUNCT F

A 0 DET T
double-blind 0 ADJ F
placebo-controlled 0 VERB F
study 0 NOUN F
. 0 PUNCT F

The 0 DET T
aim 0 NOUN F
of 0 ADP F
this 0 DET F
double-blind 0 ADJ F
study 0 NOUN F
was 0 VERB F
to 0 PART F
evaluate 0 NOUN F
the 0 DET F
effect 0 NOUN F
of 0 ADP F
low 0 ADJ F
power 0 NOUN F
Ga-Al-As 0 NOUN T
laser 0 NOUN F
treatment 0 NOUN F
on 0 ADP F
chronic B-PAIN ADJ F
pain I-PAIN NOUN F
related 0 VERB F
to 0 ADP F
osteoarthritis 0 NOUN F
of 0 ADP F
the 0 DET F
knee 0 NOUN F
with 0 ADP F
periarticular 0 ADJ F
tender 0 ADP F
points 0 NOUN F
. 0 PUNCT F

Twenty-nine 0 NUM T
out-patients 0 NOUN F
with 0 ADP F
uni- 0 PUNCT F
or 0 CCONJ F
bilateral 0 ADJ F
osteoarthritis 0 NOUN F
of 0 ADP F
the 0 DET F
knee 0 NOUN F
were 0 VERB F
included 0 VERB F
and 0 CCONJ F
randomly 0 ADV F
assigned 0 VERB F
to 0 ADP F
treatment 0 NOUN F
with 0 ADP F
either 0 CCONJ F
laser 0 NOUN F
or 0 CCONJ F
placebo 0 NOUN F
laser 0 NOUN F
. 0 PUNCT F

Fourteen 0 NUM T
patients 0 NOUN F
received 0 VERB F
active 0 ADJ F
laser 0 NOUN F
treatment 0 NOUN F
and 0 CCONJ F
all 0 DET F
patients 0 NOUN F
included 0 DET F
completed 0 PUNCT F
the 0 DET F
study 0 NOUN F
. 0 PUNCT F

The 0 DET T
effect 0 NOUN F
variables 0 ADP F
were 0 VERB F
daily 0 PUNCT F
levels 0 NOUN F
of 0 ADP F
pain 0 NOUN F
, 0 PUNCT F
analgesic B-PAIN ADP F
requirements I-PAIN NOUN F
, 0 PUNCT F
palpation B-PHYSICAL NOUN F
tenderness I-PHYSICAL NOUN F
and I-PHYSICAL CCONJ F
isokinetic I-PHYSICAL ADJ F
quadriceps I-PHYSICAL NOUN F
strength I-PHYSICAL NOUN F
. 0 PUNCT F

Each 0 DET T
patient 0 NOUN F
participated 0 VERB F
in 0 ADP F
the 0 DET F
study 0 NOUN F
for 0 ADP F
9 0 NUM F
weeks 0 NOUN F
and 0 CCONJ F
registered 0 CCONJ F
daily 0 ADJ F
level 0 NOUN F
of 0 ADP F
pain 0 NOUN F
and 0 CCONJ F
consumption B-PHYSICAL NOUN F
of I-PHYSICAL ADP F
analgesics I-PHYSICAL NOUN F
. 0 PUNCT F

In 0 ADP T
weeks 0 NOUN F
4 0 NUM F
, 0 PUNCT F
5 0 NUM F
and 0 CCONJ F
6 0 NUM F
the 0 DET F
patients 0 NOUN F
received 0 VERB F
a 0 DET F
total 0 NOUN F
of 0 ADP F
nine 0 NUM F
treatments 0 NOUN F
, 0 PUNCT F
each 0 ADP F
of 0 ADP F
15 0 NUM F
min 0 NOUN F
and 0 CCONJ F
administered 0 VERB F
to 0 ADP F
periarticular 0 ADJ F
tender 0 ADP F
points 0 NOUN F
. 0 PUNCT F

The 0 DET T
dose 0 NOUN F
per 0 ADP F
treatment 0 NOUN F
was 0 VERB F
22.5 0 NUM F
joule 0 NOUN F
. 0 PUNCT F

No 0 DET T
significant 0 ADJ F
differences 0 NOUN F
in 0 ADP F
any 0 PUNCT F
of 0 ADP F
the 0 DET F
effect 0 NOUN F
variables 0 NOUN F
were 0 VERB F
found 0 VERB F
between 0 ADP F
the 0 DET F
two 0 NUM F
groups 0 NOUN F
before 0 CCONJ F
, 0 PUNCT F
during 0 ADP F
or 0 CCONJ F
after 0 ADP F
treatment 0 NOUN F
. 0 PUNCT F

With 0 ADP T
regard 0 NOUN F
to 0 ADP F
the 0 DET F
patients 0 NOUN F
' 0 PUNCT F
overall 0 ADJ F
assessment 0 NOUN F
there 0 PUNCT F
was 0 VERB F
a 0 DET F
clearly 0 ADV F
demonstrable 0 VERB F
positive 0 ADJ F
effect 0 NOUN F
of 0 ADP F
treatment 0 NOUN F
in 0 ADP F
both 0 CCONJ F
groups 0 NOUN F
. 0 PUNCT F

This 0 DET T
is 0 VERB F
likely 0 ADJ F
to 0 PART F
be 0 PUNCT F
due 0 CCONJ F
to 0 ADP F
a 0 DET F
placebo 0 NOUN F
effect 0 NOUN F
. 0 PUNCT F

Effects 0 NOUN T
of 0 ADP F
pioglitazone 0 ADJ F
and 0 CCONJ F
glimepiride 0 NOUN F
on 0 ADP F
glycemic 0 ADJ F
control 0 NOUN F
and 0 CCONJ F
insulin 0 NOUN F
sensitivity 0 NOUN F
in 0 ADP F
Mexican 0 ADJ T
patients 0 NOUN F
with 0 ADP F
type 0 NOUN F
2 0 NUM F
diabetes 0 NOUN F
mellitus 0 NOUN F
: 0 PUNCT F
A 0 DET T
multicenter 0 NOUN F
, 0 PUNCT F
randomized 0 VERB F
, 0 PUNCT F
double-blind 0 ADJ F
, 0 PUNCT F
parallel-group 0 NOUN F
trial 0 NOUN F
. 0 PUNCT F

BACKGROUND 0 NOUN T
Pioglitazone 0 NOUN T
and 0 CCONJ F
glimepiride 0 NOUN F
improve 0 ADV F
glycemic 0 ADJ F
control 0 NOUN F
in 0 ADP F
patients 0 NOUN F
with 0 ADP F
type 0 NOUN F
2 0 NUM F
diabetes 0 NOUN F
mellitus 0 NOUN F
by 0 ADP F
different 0 ADJ F
mechanisms 0 NOUN F
. 0 PUNCT F

Pioglitazone 0 NOUN T
is 0 VERB F
a 0 DET F
thiazolidinedione 0 NOUN F
that 0 NUM F
reduces 0 VERB F
insulin 0 NOUN F
resistance 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
glimepiride 0 NOUN F
is 0 VERB F
a 0 DET F
sulfonylurea 0 NOUN F
insulin 0 NOUN F
secretagogue 0 NOUN F
. 0 PUNCT F

OBJECTIVE 0 NOUN T
The 0 DET T
goals 0 NOUN F
of 0 ADP F
this 0 DET F
study 0 NOUN F
were 0 VERB F
to 0 ADV F
compare 0 NOUN F
changes 0 NOUN F
in 0 ADP F
measures 0 NOUN F
of 0 ADP F
glycemic 0 ADJ F
control 0 NOUN F
and 0 CCONJ F
insulin 0 NOUN F
sensitivity 0 NOUN F
in 0 ADP F
Mexican 0 ADJ T
patients 0 NOUN F
with 0 ADP F
type 0 NOUN F
2 0 NUM F
diabetes 0 NOUN F
who 0 ADP F
received 0 VERB F
pioglitazone 0 ADJ F
or 0 CCONJ F
glimepiride 0 NOUN F
for 0 ADP F
1 0 NUM F
year 0 NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
This 0 PUNCT T
was 0 VERB F
a 0 DET F
multicenter 0 NOUN F
, 0 PUNCT F
52-week 0 NOUN F
, 0 PUNCT F
double-blind 0 ADJ F
, 0 PUNCT F
parallel-group 0 NOUN F
trial 0 NOUN F
. 0 PUNCT F

Patients 0 NOUN T
were 0 VERB F
randomized 0 VERB F
to 0 PART F
receive 0 NOUN F
monotherapy 0 NOUN F
with 0 ADP F
either 0 CCONJ F
glimepiride 0 NOUN F
( 0 PUNCT F
2 0 NUM F
mg 0 NOUN F
QD 0 NOUN T
initially 0 ADV F
) 0 PUNCT F
or 0 CCONJ F
pioglitazone 0 ADJ F
( 0 PUNCT F
15 0 NUM F
mg 0 NOUN F
QD 0 NOUN T
initially 0 ADV F
) 0 PUNCT F
. 0 PUNCT F

Doses 0 NOUN T
were 0 VERB F
titrated 0 NOUN F
( 0 PUNCT F
maximal 0 ADJ F
doses 0 NOUN F
: 0 PUNCT F
pioglitazone 0 ADJ F
45 0 NUM F
mg 0 NOUN F
, 0 PUNCT F
glimepiride 0 NOUN F
8 0 NUM F
mg 0 NOUN F
) 0 PUNCT F
to 0 PART F
achieve 0 VERB F
glycemic 0 ADJ F
targets 0 NOUN F
( 0 PUNCT F
fasting 0 PROPN F
blood 0 NOUN F
glucose 0 NOUN F
< 0 SYM F
or 0 CCONJ F
=7 0 NUM F
mmol/L 0 NOUN F
and 0 CCONJ F
1-hour 0 NOUN F
postprandial 0 ADJ F
blood 0 NOUN F
glucose 0 NOUN F
< 0 SYM F
or 0 CCONJ F
=10 0 NUM F
mmol/L 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

Insulin 0 NOUN T
sensitivity 0 NOUN F
( 0 PUNCT F
primary 0 ADJ F
end 0 NOUN F
point 0 NOUN F
) 0 PUNCT F
was 0 VERB F
evaluated 0 VERB F
in 0 ADP F
terms 0 NOUN F
of 0 ADP F
the 0 DET F
Homeostasis 0 NOUN T
Model 0 NOUN T
Assessment 0 NOUN T
for 0 ADP F
Insulin 0 NOUN T
Sensitivity 0 NOUN T
( 0 PUNCT F
HOMA-S 0 NOUN T
) 0 PUNCT F
, 0 PUNCT F
the 0 DET F
Quantitative 0 ADJ T
Insulin 0 NOUN T
Sensitivity 0 NOUN T
Check 0 NOUN T
Index 0 NOUN T
( 0 PUNCT F
QUICKI 0 NOUN T
) 0 PUNCT F
, 0 PUNCT F
and 0 CCONJ F
fasting 0 VERB F
serum 0 NOUN F
insulin 0 NOUN F
( 0 PUNCT F
FSI 0 NOUN T
) 0 PUNCT F
concentrations 0 NOUN F
. 0 PUNCT F

Glycemic 0 ADJ T
control 0 NOUN F
was 0 VERB F
evaluated 0 VERB F
in 0 ADP F
terms 0 NOUN F
of 0 ADP F
glycosylated 0 VERB F
hemoglobin 0 NOUN F
( 0 PUNCT F
HbA 0 NOUN T
( 0 PUNCT F
1c 0 NOUN F
) 0 PUNCT F
) 0 PUNCT F
values 0 NOUN F
and 0 CCONJ F
fasting 0 VERB F
plasma 0 NOUN F
glucose 0 NOUN F
( 0 PUNCT F
FPG 0 NOUN T
) 0 PUNCT F
concentrations 0 NOUN F
. 0 PUNCT F

Patients 0 NOUN T
were 0 VERB F
encouraged 0 VERB F
to 0 ADJ F
maintain 0 NOUN F
their 0 DET F
individual 0 ADJ F
diet 0 NOUN F
and 0 CCONJ F
exercise 0 NOUN F
regimens 0 NOUN F
throughout 0 ADP F
the 0 DET F
study 0 NOUN F
. 0 PUNCT F

RESULTS 0 NOUN T
Two 0 NUM T
hundred 0 NUM F
forty-four 0 ADJ F
patients 0 NOUN F
( 0 PUNCT F
125 0 NUM F
women 0 NOUN F
, 0 PUNCT F
119 0 NUM F
men 0 NOUN F
; 0 PUNCT F
all 0 ADP F
but 0 CCONJ F
1 0 NUM F
Hispanic 0 ADJ T
) 0 PUNCT F
were 0 VERB F
randomized 0 VERB F
to 0 PART F
receive 0 NOUN F
pioglitazone 0 ADJ F
( 0 PUNCT F
n 0 NOUN F
= 0 SYM F
121 0 NUM F
) 0 PUNCT F
or 0 CCONJ F
glimepiride 0 NOUN F
( 0 PUNCT F
n 0 NOUN F
= 0 SYM F
123 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

In 0 ADP T
the 0 DET F
intent-to-treat 0 NOUN F
sample 0 NOUN F
, 0 PUNCT F
pioglitazone 0 ADJ F
and 0 CCONJ F
glimepirede 0 NOUN F
produced 0 PRON F
comparable 0 ADJ F
reductions 0 NOUN F
in 0 ADP F
HbA B-PHYSICAL NOUN T
( I-PHYSICAL PUNCT F
1c I-PHYSICAL NOUN F
) I-PHYSICAL PUNCT F
from 0 ADP F
baseline 0 NOUN F
to 0 ADP F
the 0 DET F
end 0 NOUN F
of 0 ADP F
the 0 DET F
study 0 NOUN F
( 0 PUNCT F
-0.78 0 NUM F
% 0 SYM F
and 0 CCONJ F
-0.68 0 NUM F
% 0 SYM F
, 0 PUNCT F
respectively 0 ADV F
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
pioglitazone 0 ADJ F
group 0 NOUN F
had 0 PUNCT F
significantly 0 ADV F
higher 0 PUNCT F
HbA B-PHYSICAL NOUN T
( I-PHYSICAL PUNCT F
1c I-PHYSICAL NOUN F
) I-PHYSICAL PUNCT F
values 0 NOUN F
compared 0 VERB F
with 0 ADP F
the 0 DET F
glimepiride 0 NOUN F
group 0 NOUN F
after 0 ADP F
12 0 NUM F
weeks 0 NOUN F
of 0 ADP F
therapy 0 NOUN F
( 0 PUNCT F
8.66 0 NUM F
% 0 SYM F
vs 0 CCONJ F
7.80 0 NUM F
% 0 SYM F
; 0 PUNCT F
P 0 NOUN T
= 0 SYM F
0.007 0 NUM F
) 0 PUNCT F
but 0 CCONJ F
had 0 PUNCT F
significantly 0 ADV F
lower 0 PUNCT F
values 0 NOUN F
after 0 ADP F
52 0 NUM F
weeks 0 NOUN F
( 0 PUNCT F
7.46 0 NUM F
% 0 SYM F
vs 0 CCONJ F
7.77 0 NUM F
% 0 SYM F
; 0 PUNCT F
P 0 NOUN T
= 0 SYM F
0.027 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Pioglitazone 0 ADJ T
significantly 0 ADV F
reduced 0 VERB F
FPG B-PHYSICAL NOUN T
compared 0 VERB F
with 0 ADP F
glimepiride 0 NOUN F
( 0 PUNCT F
-0.6 0 ADJ F
vs 0 CCONJ F
0.6 0 NUM F
mmol/L 0 NOUN F
; 0 PUNCT F
P 0 NOUN T
= 0 SYM F
0.01 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Pioglitazone 0 ADJ T
therapy 0 NOUN F
was 0 VERB F
associated 0 VERB F
with 0 ADP F
significant 0 ADJ F
increases 0 NOUN F
in 0 ADP F
insulin B-PHYSICAL NOUN F
sensitivity I-PHYSICAL NOUN F
( 0 PUNCT F
reduced B-PHYSICAL PUNCT F
insulin I-PHYSICAL NOUN F
resistance I-PHYSICAL NOUN F
) 0 PUNCT F
, 0 PUNCT F
whereas 0 ADP F
glimepiride 0 NOUN F
had 0 PUNCT F
no 0 DET F
effect 0 NOUN F
. 0 PUNCT F

HOMA-S B-PHYSICAL NOUN T
values I-PHYSICAL NOUN F
changed 0 VERB F
18.0 0 NUM F
% 0 SYM F
for 0 ADP F
pioglitazone 0 ADJ F
and 0 CCONJ F
-7.9 0 PUNCT F
% 0 SYM F
for 0 ADP F
glimepiride 0 NOUN F
( 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.001 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
QUICKI 0 ADJ T
values 0 NOUN F
changed 0 PRON F
a 0 DET F
respective 0 ADJ F
0.013 0 NUM F
and 0 CCONJ F
-0.007 0 NOUN F
( 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.001 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
and 0 CCONJ F
FSI 0 NOUN T
values 0 NOUN F
were 0 VERB F
-21.1 0 ADJ F
and 0 CCONJ F
15.1 0 NUM F
pmol/L 0 NOUN F
( 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.001 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Both 0 CCONJ T
drugs 0 NOUN F
were 0 VERB F
well 0 VERB F
tolerated B-OTHER ADP F
, 0 PUNCT F
with 0 ADP F
pioglitazone 0 ADJ F
associated 0 VERB F
with 0 ADP F
more 0 DET F
peripheral B-PHYSICAL ADJ F
edema I-PHYSICAL NOUN F
( 0 PUNCT F
number 0 NOUN F
of 0 ADP F
treatment-emergent 0 ADJ F
cases 0 NOUN F
: 0 PUNCT F
35/121 0 NOUN F
[ 0 PUNCT F
28.9 0 NUM F
% 0 SYM F
] 0 PUNCT F
vs 0 CCONJ F
17/123 0 NOUN F
[ 0 PUNCT F
13.8 0 NUM F
% 0 SYM F
] 0 PUNCT F
; 0 PUNCT F
P 0 NOUN T
= 0 SYM F
0.005 0 NUM F
) 0 PUNCT F
and 0 CCONJ F
fewer 0 PUNCT F
hypoglycemic B-PHYSICAL ADJ F
episodes I-PHYSICAL NOUN F
( 0 PUNCT F
19 0 NUM F
[ 0 PUNCT F
15.7 0 NUM F
% 0 SYM F
] 0 PUNCT F
vs 0 CCONJ F
38 0 NUM F
[ 0 PUNCT F
30.9 0 NUM F
% 0 SYM F
] 0 PUNCT F
; 0 PUNCT F
P 0 NOUN T
= 0 SYM F
0.024 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
incidence 0 NOUN F
of 0 ADP F
weight 0 NOUN F
gain B-PHYSICAL NOUN F
was 0 VERB F
not 0 ADV F
significantly 0 ADV F
different 0 ADJ F
between 0 ADP F
treatment 0 NOUN F
groups 0 NOUN F
. 0 PUNCT F

CONCLUSIONS 0 NOUN T
These 0 DET T
data 0 NOUN F
suggest 0 VERB F
that 0 ADP F
long-term 0 NOUN F
treatment 0 NOUN F
with 0 ADP F
pioglitazone 0 ADJ F
enhances 0 VERB F
insulin 0 NOUN F
sensitivity 0 NOUN F
relative 0 ADJ F
to 0 ADP F
glimepiride 0 NOUN F
in 0 ADP F
Mexican 0 ADJ T
patients 0 NOUN F
with 0 ADP F
type 0 NOUN F
2 0 NUM F
diabetes 0 NOUN F
and 0 CCONJ F
that 0 VERB F
pioglitazone 0 NOUN F
may 0 PUNCT F
have 0 PUNCT F
a 0 DET F
more 0 ADV F
sustained 0 ADP F
antihyperglycemic 0 ADJ F
effect 0 NOUN F
. 0 PUNCT F

The 0 DET T
effect 0 NOUN F
of 0 ADP F
Cys 0 NOUN T
LT1 0 NOUN T
receptor 0 NOUN F
blockade 0 NOUN F
on 0 ADP F
airway 0 NOUN F
responses 0 NOUN F
to 0 ADP F
allergen 0 NOUN F
. 0 PUNCT F

STUDY 0 NOUN T
OBJECTIVE 0 NOUN T
To 0 PROPN T
evaluate 0 NOUN F
the 0 DET F
effect 0 NOUN F
of 0 ADP F
a 0 DET F
potent 0 ADJ F
experimental 0 ADJ F
leukotriene 0 NOUN F
receptor 0 NOUN F
antagonist 0 NOUN F
, 0 PUNCT F
MK-571 0 NOUN T
, 0 PUNCT F
on 0 ADP F
airway 0 NOUN F
responses 0 NOUN F
to 0 ADP F
inhaled 0 NOUN F
allergen 0 NOUN F
. 0 PUNCT F

DESIGN 0 NOUN T
Randomized 0 PROPN T
, 0 PUNCT F
double-blind 0 ADJ F
, 0 PUNCT F
placebo-controlled 0 VERB F
, 0 PUNCT F
crossover 0 ADP F
trial 0 NOUN F
. 0 PUNCT F

SETTING 0 NUM T
Clinical 0 ADJ T
research 0 NOUN F
center 0 NOUN F
. 0 PUNCT F

SUBJECTS 0 NOUN T
Eight 0 NUM T
male 0 NOUN F
volunteers 0 NOUN F
with 0 ADP F
allergic 0 ADJ F
asthma 0 NOUN F
. 0 PUNCT F

INTERVENTIONS 0 CCONJ T
An 0 DET T
intravenous 0 ADJ F
loading 0 VERB F
dose 0 NOUN F
was 0 VERB F
followed 0 VERB F
by 0 ADP F
an 0 DET F
8-hour 0 NOUN F
infusion 0 NOUN F
of 0 ADP F
MK-571 0 NOUN T
or 0 CCONJ F
placebo 0 NOUN F
, 0 PUNCT F
with 0 ADP F
a 0 DET F
7- 0 NUM F
to 0 ADP F
14-day 0 NOUN F
washout 0 PUNCT F
between 0 ADP F
treatments 0 NOUN F
. 0 PUNCT F

Allergen 0 NOUN T
challenge 0 NOUN F
was 0 VERB F
performed 0 VERB F
after 0 ADP F
the 0 DET F
loading 0 VERB F
dose 0 NOUN F
and 0 CCONJ F
a 0 DET F
histamine 0 NOUN F
challenge 0 NOUN F
was 0 VERB F
performed 0 VERB F
before 0 ADP F
and 0 CCONJ F
24 0 NUM F
hours 0 NOUN F
after 0 ADP F
allergen 0 NOUN F
. 0 PUNCT F

MEASUREMENTS 0 ADP T
AND 0 CCONJ T
MAIN 0 ADJ T
RESULTS 0 NOUN T
Forced B-PHYSICAL PROPN T
expiratory I-PHYSICAL ADJ F
volume I-PHYSICAL NOUN F
in 0 ADP F
1 0 NUM F
second 0 ADJ F
was 0 VERB F
measured 0 VERB F
serially 0 ADV F
. 0 PUNCT F

MK-571 0 NOUN T
provided 0 VERB F
about 0 PUNCT F
50 0 NUM F
% 0 ADV F
protection 0 NOUN F
during 0 ADP F
maximum 0 NOUN F
early 0 ADJ F
and 0 CCONJ F
late 0 ADJ F
responses 0 NOUN F
compared 0 VERB F
with 0 ADP F
placebo 0 NOUN F
( 0 PUNCT F
p=0.005 0 NOUN F
) 0 PUNCT F
, 0 PUNCT F
but 0 CCONJ F
airway B-PHYSICAL NOUN F
obstruction I-PHYSICAL NOUN F
persisted 0 DET F
8-24 0 NUM F
hours 0 NOUN F
after 0 ADP F
allergen 0 NOUN F
on 0 ADP F
both 0 PUNCT F
treatment 0 NOUN F
days 0 NOUN F
. 0 PUNCT F

Airway B-OTHER NOUN T
responsiveness I-OTHER NOUN F
to 0 ADP F
histamine B-OTHER NOUN F
was 0 VERB F
not 0 ADV F
significantly 0 ADV F
attenuated 0 VERB F
at 0 ADP F
24 0 NUM F
hours 0 NOUN F
. 0 PUNCT F

CONCLUSION 0 NOUN T
Blocking 0 PUNCT T
Cys 0 NOUN T
LT1 0 NOUN T
receptors 0 NOUN F
for 0 ADP F
8 0 NUM F
hours 0 NOUN F
attenuated 0 VERB F
the 0 DET F
early 0 ADJ F
and 0 CCONJ F
late 0 ADJ F
responses 0 NOUN F
but 0 CCONJ F
did 0 PUNCT F
not 0 DET F
interrupt 0 PUNCT F
the 0 DET F
cascade 0 NOUN F
of 0 ADP F
events 0 NOUN F
leading 0 VERB F
to 0 ADP F
subsequent 0 ADJ F
allergen-induced 0 ADJ F
airway 0 NOUN F
obstruction 0 NOUN F
and 0 CCONJ F
hyperreactivity 0 NOUN F
. 0 PUNCT F

Rituximab 0 NOUN T
plus 0 CCONJ F
concurrent 0 ADJ F
infusional 0 ADJ F
EPOCH 0 NOUN T
chemotherapy 0 NOUN F
is 0 VERB F
highly 0 ADV F
effective 0 ADJ F
in 0 ADP F
HIV-associated 0 VERB T
B-cell 0 NOUN T
non-Hodgkin 0 NOUN F
lymphoma 0 NOUN F
. 0 PUNCT F

Rituximab 0 NOUN T
plus 0 CCONJ F
intravenous 0 ADJ F
bolus 0 NOUN F
chemotherapy 0 NOUN F
is 0 VERB F
a 0 DET F
standard 0 ADJ F
treatment 0 NOUN F
for 0 ADP F
immunocompetent 0 ADJ F
patients 0 NOUN F
with 0 ADP F
B-cell 0 NOUN T
non-Hodgkin 0 NOUN F
lymphoma 0 NOUN F
( 0 PUNCT F
NHL 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

Some 0 DET T
studies 0 NOUN F
have 0 ADP F
suggested 0 VERB F
that 0 ADP F
rituximab 0 NOUN F
is 0 VERB F
associated 0 VERB F
with 0 ADP F
excessive B-PHYSICAL ADJ F
toxicity I-PHYSICAL NOUN F
in 0 ADP F
HIV-associated 0 VERB T
NHL 0 NOUN T
, 0 PUNCT F
and 0 CCONJ F
that 0 ADP F
infusional 0 ADJ F
chemotherapy 0 NOUN F
may 0 VERB F
be 0 VERB F
more 0 ADV F
effective 0 ADJ F
. 0 PUNCT F

We 0 PRON T
performed 0 VERB F
a 0 DET F
randomized 0 VERB F
phase 0 NOUN F
2 0 NUM F
trial 0 NOUN F
of 0 ADP F
rituximab 0 NOUN F
( 0 PUNCT F
375 0 NUM F
mg/m 0 NOUN F
( 0 PUNCT F
2 0 NUM F
) 0 PUNCT F
) 0 PUNCT F
given 0 VERB F
either 0 PUNCT F
concurrently 0 ADV F
before 0 ADP F
each 0 DET F
infusional 0 ADJ F
etoposide 0 NOUN F
, 0 PUNCT F
vincristine 0 NOUN F
, 0 PUNCT F
doxorubicin 0 NOUN F
, 0 PUNCT F
cyclophosphamide 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
prednisone 0 NOUN F
( 0 PUNCT F
EPOCH 0 NOUN T
) 0 PUNCT F
chemotherapy 0 NOUN F
cycle 0 NOUN F
or 0 CCONJ F
sequentially 0 ADV F
( 0 PUNCT F
weekly 0 ADV F
for 0 ADP F
6 0 NUM F
weeks 0 NOUN F
) 0 PUNCT F
after 0 ADP F
completion 0 NOUN F
of 0 ADP F
all 0 DET F
chemotherapy 0 NOUN F
in 0 ADP F
HIV-associated 0 VERB T
NHL 0 NOUN T
. 0 PUNCT F

EPOCH 0 NOUN T
consisted 0 PUNCT F
of 0 ADP F
a 0 DET F
96-hour 0 NOUN F
intravenous 0 ADJ F
infusion 0 NOUN F
of 0 ADP F
etoposide 0 NOUN F
, 0 PUNCT F
doxorubicin 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
vincristine 0 NOUN F
plus 0 CCONJ F
oral 0 ADJ F
prednisone 0 NOUN F
followed 0 VERB F
by 0 ADP F
intravenous 0 ADJ F
bolus 0 NOUN F
cyclophosphamide 0 NOUN F
given 0 ADP F
every 0 DET F
21 0 NUM F
days 0 NOUN F
for 0 ADP F
4 0 NUM F
to 0 ADP F
6 0 NUM F
cycles 0 NOUN F
. 0 PUNCT F

In 0 ADP T
the 0 DET F
concurrent 0 ADJ F
arm 0 NOUN F
, 0 PUNCT F
35 0 NUM F
of 0 ADP F
48 0 NUM F
evaluable 0 ADJ F
patients 0 NOUN F
( 0 PUNCT F
73 0 NUM F
% 0 SYM F
; 0 PUNCT F
95 0 NUM F
% 0 SYM F
confidence 0 NOUN F
interval 0 NOUN F
, 0 PUNCT F
58 0 NUM F
% 0 SYM F
-85 0 NUM F
% 0 SYM F
) 0 PUNCT F
had 0 PUNCT F
a 0 DET F
complete B-OTHER ADJ F
response I-OTHER NOUN F
. 0 PUNCT F

In 0 ADP T
the 0 DET F
sequential 0 ADJ F
arm 0 NOUN F
, 0 PUNCT F
29 0 NUM F
of 0 ADP F
53 0 NUM F
evaluable 0 ADJ F
patients 0 NOUN F
( 0 PUNCT F
55 0 NUM F
% 0 SYM F
; 0 PUNCT F
95 0 NUM F
% 0 SYM F
confidence 0 NOUN F
interval 0 NOUN F
, 0 PUNCT F
41 0 NUM F
% 0 SYM F
-68 0 NUM F
% 0 SYM F
) 0 PUNCT F
had 0 PUNCT F
a 0 DET F
complete 0 ADJ F
response 0 NOUN F
. 0 PUNCT F

The 0 DET T
primary 0 ADJ F
efficacy 0 NOUN F
endpoint 0 NOUN F
was 0 VERB F
met 0 VERB F
for 0 ADP F
the 0 DET F
concurrent 0 ADJ F
arm 0 NOUN F
only 0 ADV F
. 0 PUNCT F

Toxicity B-PHYSICAL NOUN T
was 0 VERB F
comparable 0 ADJ F
in 0 ADP F
the 0 DET F
2 0 NUM F
arms 0 NOUN F
, 0 PUNCT F
although 0 ADP F
patients 0 NOUN F
with 0 ADP F
a 0 DET F
baseline 0 NOUN F
CD4 B-PHYSICAL NOUN T
count 0 NOUN F
less 0 ADV F
than 0 PUNCT F
50/microL 0 NOUN F
had 0 PUNCT F
a 0 DET F
high 0 ADJ F
infectious B-MORTALITY ADJ F
death I-MORTALITY NOUN F
rate I-MORTALITY NOUN F
in 0 ADP F
the 0 DET F
concurrent 0 ADJ F
arm 0 NOUN F
. 0 PUNCT F

We 0 PRON T
conclude 0 VERB F
that 0 ADP F
concurrent 0 ADJ F
rituximab 0 NOUN F
plus 0 CCONJ F
infusional 0 ADJ F
EPOCH 0 NOUN T
is 0 VERB F
an 0 DET F
effective 0 ADJ F
regimen 0 NOUN F
for 0 ADP F
HIV-associated 0 VERB T
lymphoma 0 NOUN F
. 0 PUNCT F

Randomized 0 VERB T
controlled 0 VERB F
trial 0 NOUN F
: 0 PUNCT F
Multimodal 0 ADJ T
Anxiety 0 NOUN T
and 0 CCONJ F
Social 0 ADJ T
Skill 0 NOUN T
Intervention 0 NOUN T
for 0 ADP F
adolescents 0 NOUN F
with 0 ADP F
autism 0 NOUN F
spectrum 0 NOUN F
disorder 0 NOUN F
. 0 PUNCT F

Anxiety 0 NOUN T
is 0 VERB F
common 0 ADJ F
among 0 ADP F
adolescents 0 NOUN F
with 0 ADP F
autism 0 NOUN F
spectrum 0 NOUN F
disorders 0 NOUN F
( 0 PUNCT F
ASD 0 NOUN T
) 0 PUNCT F
and 0 CCONJ F
may 0 VERB F
amplify 0 ADP F
the 0 DET F
core 0 NOUN F
social 0 ADJ F
disability 0 NOUN F
, 0 PUNCT F
thus 0 ADV F
necessitating 0 PUNCT F
combined 0 VERB F
treatment 0 NOUN F
approaches 0 NOUN F
. 0 PUNCT F

This 0 DET T
pilot 0 NOUN F
, 0 PUNCT F
randomized 0 VERB F
controlled 0 VERB F
trial 0 NOUN F
evaluated 0 VERB F
the 0 DET F
feasibility B-OTHER NOUN F
and 0 CCONJ F
preliminary B-OTHER ADJ F
outcomes I-OTHER NOUN F
of 0 ADP F
the 0 DET F
Multimodal 0 ADJ T
Anxiety 0 NOUN T
and 0 CCONJ F
Social 0 ADJ T
Skills 0 NOUN T
Intervention 0 NOUN T
( 0 PUNCT F
MASSI 0 NOUN T
) 0 PUNCT F
program 0 NOUN F
in 0 ADP F
a 0 DET F
sample 0 NOUN F
of 0 ADP F
30 0 NUM F
adolescents 0 NOUN F
with 0 ADP F
ASD 0 NOUN T
and 0 CCONJ F
anxiety 0 NOUN F
symptoms 0 NOUN F
of 0 ADP F
moderate 0 ADJ F
or 0 CCONJ F
greater 0 PUNCT F
severity 0 NOUN F
. 0 PUNCT F

The 0 DET T
treatment 0 NOUN F
was 0 VERB F
acceptable 0 ADJ F
to 0 ADP F
families 0 NOUN F
, 0 PUNCT F
subject B-OTHER PUNCT F
adherence I-OTHER NOUN F
was 0 VERB F
high 0 ADJ F
, 0 PUNCT F
and 0 CCONJ F
therapist B-OTHER NOUN F
fidelity I-OTHER NOUN F
was 0 VERB F
high 0 ADJ F
. 0 PUNCT F

A 0 PUNCT T
16 0 NUM F
% 0 SYM F
improvement 0 NOUN F
in 0 ADP F
ASD B-MENTAL NOUN T
social I-MENTAL ADJ F
impairment I-MENTAL NOUN F
( 0 PUNCT F
within-group 0 NOUN F
effect 0 NOUN F
size 0 NOUN F
= 0 SYM F
1.18 0 NUM F
) 0 PUNCT F
was 0 VERB F
observed 0 VERB F
on 0 ADP F
a 0 DET F
parent-reported 0 VERB F
scale 0 NOUN F
. 0 PUNCT F

Although 0 ADP T
anxiety B-MENTAL NOUN F
symptoms I-MENTAL NOUN F
declined 0 VERB F
by 0 ADP F
26 0 NUM F
% 0 SYM F
, 0 PUNCT F
the 0 DET F
change 0 NOUN F
was 0 VERB F
not 0 ADV F
statistically 0 ADV F
significant 0 ADJ F
. 0 PUNCT F

These 0 DET T
findings 0 NOUN F
suggest 0 VERB F
MASSI 0 NOUN T
is 0 VERB F
a 0 DET F
feasible B-OTHER ADJ F
treatment 0 NOUN F
program 0 NOUN F
and 0 CCONJ F
further 0 ADJ F
evaluation 0 NOUN F
is 0 VERB F
warranted 0 VERB F
. 0 PUNCT F

Treatment 0 NOUN T
of 0 ADP F
anal 0 ADJ F
fissures 0 NOUN F
using 0 SYM F
a 0 DET F
combination 0 NOUN F
of 0 ADP F
minoxidil 0 NOUN F
and 0 CCONJ F
lignocaine 0 ADP F
: 0 PUNCT F
a 0 DET F
randomized 0 VERB F
, 0 PUNCT F
double-blind 0 ADJ F
trial 0 NOUN F
. 0 PUNCT F

AIM 0 NOUN T
Anal 0 ADJ T
fissures 0 ADV F
are 0 VERB F
associated 0 VERB F
with 0 ADP F
hypertonia 0 NOUN F
of 0 ADP F
the 0 DET F
internal 0 ADJ F
anal 0 ADJ F
sphincter 0 NOUN F
and 0 CCONJ F
pain 0 NOUN F
. 0 PUNCT F

We 0 PRON T
evaluated 0 VERB F
the 0 DET F
efficacy 0 NOUN F
of 0 ADP F
local 0 ADJ F
application 0 NOUN F
of 0 ADP F
a 0 DET F
combination 0 NOUN F
of 0 ADP F
minoxidil 0 NOUN F
and 0 CCONJ F
lignocaine 0 ADP F
in 0 ADP F
healing 0 VERB F
anal 0 ADJ F
fissures 0 NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
In 0 ADP T
this 0 DET F
prospective 0 ADJ F
, 0 PUNCT F
randomized 0 VERB F
, 0 PUNCT F
double-blind 0 ADJ F
study 0 NOUN F
, 0 PUNCT F
90 0 NUM F
patients 0 NOUN F
with 0 ADP F
anal 0 ADJ F
fissure 0 NOUN F
were 0 VERB F
recruited 0 VERB F
. 0 PUNCT F

Patients 0 NOUN T
received 0 PUNCT F
local 0 ADJ F
applications 0 NOUN F
of 0 ADP F
ointments 0 NOUN F
containing 0 VERB F
5 0 NUM F
% 0 SYM F
lignocaine 0 ADP F
( 0 PUNCT F
n=28 0 NOUN F
) 0 PUNCT F
, 0 PUNCT F
0.5 0 NUM F
% 0 ADV F
minoxidil 0 CCONJ F
( 0 PUNCT F
n=36 0 PUNCT F
) 0 PUNCT F
, 0 PUNCT F
or 0 CCONJ F
both 0 PUNCT F
( 0 PUNCT F
n=26 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

Healing 0 VERB T
of 0 ADP F
anal B-PHYSICAL ADJ F
fissure I-PHYSICAL NOUN F
at 0 ADP F
6 0 NUM F
weeks 0 NOUN F
was 0 VERB F
used 0 VERB F
as 0 ADP F
the 0 DET F
primary 0 ADJ F
end-point 0 NOUN F
. 0 PUNCT F

RESULTS 0 DET T
Rates 0 PUNCT T
of B-PHYSICAL ADP F
complete I-PHYSICAL ADJ F
healing I-PHYSICAL VERB F
of I-PHYSICAL ADP F
fissure B-PHYSICAL ADJ F
were 0 VERB F
similar 0 ADJ F
in 0 ADP F
the 0 DET F
three 0 NUM F
groups 0 NOUN F
( 0 PUNCT F
lignocaine 0 ADP F
alone 0 ADJ F
8/27 0 NOUN F
, 0 PUNCT F
minoxidil 0 PUNCT F
alone 0 ADJ F
10/34 0 PUNCT F
, 0 PUNCT F
combination 0 NOUN F
7/22 0 NOUN F
; 0 PUNCT F
p=ns 0 PUNCT F
) 0 PUNCT F
. 0 PUNCT F

Mean 0 NOUN T
( 0 PUNCT F
SD 0 NOUN T
) 0 PUNCT F
time 0 NOUN F
taken 0 PRON F
for 0 ADP F
complete 0 ADJ F
healing 0 VERB F
with 0 ADP F
combination 0 NOUN F
treatment 0 NOUN F
[ 0 PUNCT F
1.9 0 NUM F
( 0 PUNCT F
0.6 0 NUM F
) 0 PUNCT F
weeks 0 NOUN F
] 0 PUNCT F
was 0 VERB F
significantly 0 ADV F
shorter 0 PUNCT F
than 0 VERB F
that 0 PUNCT F
with 0 ADP F
minoxidil 0 PUNCT F
alone 0 ADJ F
( 0 PUNCT F
3.1 0 NUM F
[ 0 PUNCT F
1.7 0 PUNCT F
] 0 PUNCT F
weeks 0 NOUN F
; 0 PUNCT F
p=0.001 0 NOUN F
) 0 PUNCT F
or 0 CCONJ F
with 0 ADP F
lignocaine 0 ADP F
alone 0 ADJ F
( 0 PUNCT F
3.3 0 NUM F
[ 0 PUNCT F
0.8 0 ADP F
] 0 PUNCT F
weeks 0 NOUN F
; 0 PUNCT F
p=0.002 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

Rates B-PHYSICAL NOUN T
of 0 ADP F
pain B-PAIN NOUN F
relief I-PAIN NOUN F
were 0 VERB F
similar 0 ADJ F
in 0 ADP F
the 0 DET F
three 0 NUM F
groups 0 NOUN F
. 0 PUNCT F

Stoppage B-PHYSICAL NOUN T
of I-PHYSICAL ADP F
bleeding I-PHYSICAL PUNCT F
occurred 0 VERB F
more 0 ADV F
often 0 ADV F
with 0 ADP F
combination 0 NOUN F
treatment 0 NOUN F
than 0 PUNCT F
with 0 ADP F
lignocaine 0 ADP F
alone 0 ADJ F
. 0 PUNCT F

No 0 DET T
patient 0 NOUN F
had 0 PUNCT F

A 0 DET T
double-blind 0 ADJ F
comparison 0 NOUN F
of 0 ADP F
oral 0 ADJ F
ketoprofen 0 NOUN F
'controlled 0 PUNCT F
release 0 NOUN F
' 0 PUNCT F
and 0 CCONJ F
indomethacin 0 NOUN F
suppository 0 ADJ F
in 0 ADP F
the 0 DET F
treatment 0 NOUN F
of 0 ADP F
rheumatoid 0 ADJ F
arthritis 0 NOUN F
with 0 ADP F
special 0 ADJ F
regard 0 NOUN F
to 0 ADP F
morning 0 NOUN F
stiffness 0 NOUN F
and 0 CCONJ F
pain 0 NOUN F
on 0 ADP F
awakening 0 PUNCT F
. 0 PUNCT F

A 0 DET T
double-blind 0 ADJ F
, 0 PUNCT F
double-dummy 0 NOUN F
, 0 PUNCT F
crossover 0 ADP F
study 0 NOUN F
was 0 VERB F
carried 0 VERB F
out 0 ADP F
in 0 ADP F
8 0 NUM F
centres 0 NOUN F
to 0 PART F
compare 0 NOUN F
the 0 DET F
efficacy 0 NOUN F
and 0 CCONJ F
tolerability 0 NOUN F
of 0 ADP F
'controlled-release 0 PUNCT F
' 0 PUNCT F
ketoprofen 0 NOUN F
tablets 0 NOUN F
( 0 PUNCT F
200 0 NUM F
mg 0 NOUN F
) 0 PUNCT F
with 0 ADP F
that 0 PUNCT F
of 0 ADP F
indomethacin 0 NOUN F
suppositories 0 NOUN F
( 0 PUNCT F
100 0 NUM F
mg 0 NOUN F
) 0 PUNCT F
in 0 ADP F
out-patients 0 NOUN F
with 0 ADP F
definite 0 ADJ F
or 0 CCONJ F
classical 0 ADJ F
rheumatoid 0 ADJ F
arthritis 0 NOUN F
. 0 PUNCT F

Patients 0 NOUN T
were 0 VERB F
allocated 0 VERB F
at 0 ADP F
random 0 PUNCT F
to 0 PART F
receive 0 NOUN F
a 0 DET F
daily 0 ADJ F
bedtime 0 NOUN F
dose 0 NOUN F
of 0 ADP F
either 0 CCONJ F
1 0 NUM F
ketoprofen 0 NOUN F
tablet 0 NOUN F
or 0 CCONJ F
1 0 NUM F
indomethacin 0 NOUN F
suppository 0 ADJ F
plus 0 CCONJ F
the 0 DET F
dummy 0 NOUN F
of 0 ADP F
the 0 DET F
other 0 ADJ F
formulation 0 NOUN F
for 0 ADP F
a 0 DET F
period 0 NOUN F
of 0 ADP F
3 0 NUM F
weeks 0 NOUN F
. 0 PUNCT F

They 0 PRON T
were 0 VERB F
then 0 ADV F
crossed 0 VERB F
over 0 PUNCT F
to 0 PUNCT F
the 0 DET F
alternative 0 ADJ F
treatment 0 NOUN F
for 0 ADP F
a 0 DET F
further 0 ADJ F
3 0 NUM F
weeks 0 NOUN F
. 0 PUNCT F

Daily 0 ADJ T
diary 0 ADJ F
records 0 NOUN F
were 0 VERB F
kept 0 PUNCT F
by 0 ADP F
patients 0 NOUN F
of 0 ADP F
the 0 DET F
number 0 NOUN F
of 0 ADP F
night-time 0 NOUN F
awakenings 0 NOUN F
due 0 VERB F
to 0 ADP F
pain 0 NOUN F
, 0 PUNCT F
pain 0 NOUN F
severity 0 NOUN F
at 0 ADP F
awakening 0 ADJ F
in 0 ADP F
the 0 DET F
morning 0 NOUN F
and 0 CCONJ F
the 0 DET F
duration 0 NOUN F
of 0 ADP F
early 0 ADJ F
morning 0 NOUN F
stiffness 0 NOUN F
. 0 PUNCT F

Treatment 0 NOUN T
efficacy 0 NOUN F
was 0 VERB F
also 0 ADV F
assessed 0 VERB F
at 0 ADP F
the 0 DET F
end 0 NOUN F
of 0 ADP F
each 0 DET F
trial 0 NOUN F
period 0 NOUN F
by 0 ADP F
means 0 NOUN F
of 0 ADP F
an 0 DET F
articular 0 ADJ F
index 0 NOUN F
and 0 CCONJ F
by 0 ADP F
physician 0 NOUN F
's 0 PUNCT F
and 0 CCONJ F
patient 0 NOUN F
's 0 PUNCT F
overall 0 ADJ F
evaluation 0 NOUN F
of 0 ADP F
response 0 NOUN F
. 0 PUNCT F

Adverse 0 ADJ T
effects 0 NOUN F
spontaneously 0 ADV F
mentioned 0 PROPN F
by 0 ADP F
the 0 DET F
patients 0 NOUN F
or 0 CCONJ F
elicited 0 VERB F
by 0 ADP F
direct 0 ADJ F
questioning 0 PUNCT F
using 0 ADP F
a 0 DET F
symptom 0 NOUN F
check-list 0 NOUN F
were 0 VERB F
recorded 0 VERB F
. 0 PUNCT F

Statistical 0 ADJ T
analysis 0 NOUN F
of 0 ADP F
the 0 DET F
results 0 ADP F
from 0 ADP F
83 0 NUM F
evaluable 0 ADJ F
patients 0 NOUN F
showed 0 VERB F
that 0 ADP F
the 0 DET F
'controlled-release 0 PUNCT F
' 0 PUNCT F
tablet B-OTHER NOUN F
formulation I-OTHER NOUN F
of I-OTHER ADP F
200 I-OTHER NUM F
mg I-OTHER NOUN F
ketoprofen 0 NOUN F
was 0 VERB F
equally 0 ADV F
as 0 PUNCT F
effective 0 ADJ F
as 0 CCONJ F
the 0 DET F
100 0 NUM F
mg 0 NOUN F
indomethacin B-OTHER NOUN F
suppository I-OTHER ADJ F
in 0 ADP F
the 0 DET F
treatment 0 NOUN F
of 0 ADP F
rheumatoid 0 ADJ F
arthritis 0 NOUN F
, 0 PUNCT F
especially 0 ADV F
with 0 ADP F
regard 0 NOUN F
to 0 ADP F
pain B-PAIN NOUN F
at I-PAIN ADP F
awakening I-PAIN PROPN F
and 0 CCONJ F
morning B-PAIN NOUN F
stiffness I-PAIN NOUN F
. 0 PUNCT F

Side-effects 0 NOUN T
in 0 ADP F
both 0 CCONJ F
groups 0 NOUN F
were 0 VERB F
those 0 PUNCT F
commonly 0 ADV F
seen 0 VERB F
with 0 ADP F
non-steroidal 0 ADJ F
anti-inflammatory 0 ADJ F
drugs 0 NOUN F
and 0 CCONJ F
, 0 PUNCT F
as 0 CCONJ F
expected 0 VERB F
, 0 PUNCT F
gastro-intestinal B-ADVERSE-EFFECTS ADJ F
and I-ADVERSE-EFFECTS CCONJ F
CNS I-ADVERSE-EFFECTS NOUN T
disturbances I-ADVERSE-EFFECTS NOUN F
predominated 0 VERB F
. 0 PUNCT F

Overall 0 ADV T
, 0 PUNCT F
side-effects B-ADVERSE-EFFECTS NOUN F
were 0 VERB F
fewer 0 PUNCT F
with 0 ADP F
ketoprofen B-OTHER NOUN F
than 0 PUNCT F
with 0 ADP F
indomethacin B-OTHER NOUN F
. 0 PUNCT F

Genetic 0 ADJ T
polymorphisms 0 NOUN F
of 0 ADP F
human 0 NOUN F
flavin 0 NOUN F
monooxygenase 0 NOUN F
3 0 NUM F
in 0 ADP F
sulindac-mediated 0 VERB F
primary 0 ADJ F
chemoprevention 0 NOUN F
of 0 ADP F
familial 0 ADJ F
adenomatous 0 ADJ F
polyposis 0 NOUN F
. 0 PUNCT F

PURPOSE 0 NOUN T
Sulindac 0 NOUN T
is 0 VERB F
a 0 DET F
nonsteroidal 0 ADJ F
anti-inflammatory 0 ADJ F
drug 0 NOUN F
( 0 PUNCT F
NSAID 0 NOUN T
) 0 PUNCT F
effective 0 ADJ F
in 0 ADP F
regressing 0 ADJ F
adenomas 0 NOUN F
in 0 ADP F
patients 0 NOUN F
with 0 ADP F
familial 0 ADJ F
adenomatous 0 ADJ F
polyposis 0 NOUN F
( 0 PUNCT F
FAP 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

However 0 ADV T
, 0 PUNCT F
a 0 DET F
recent 0 ADJ F
randomized 0 VERB F
trial 0 NOUN F
showed 0 VERB F
that 0 ADP F
sulindac 0 NOUN F
, 0 PUNCT F
when 0 ADP F
compared 0 VERB F
with 0 ADP F
placebo 0 NOUN F
, 0 PUNCT F
failed 0 VERB F
to 0 PART F
prevent 0 ADJ F
the 0 DET F
development 0 NOUN F
of 0 ADP F
adenomatous 0 ADJ F
polyps 0 NOUN F
in 0 ADP F
genotypically 0 ADV F
positive 0 ADJ F
but 0 CCONJ F
phenotypically 0 ADV F
negative 0 ADJ F
FAP 0 NOUN T
patients 0 NOUN F
. 0 PUNCT F

The 0 DET T
present 0 ADJ F
study 0 NOUN F
determined 0 VERB F
whether 0 ADP F
polymorphisms 0 NOUN F
in 0 ADP F
the 0 DET F
gene 0 NOUN F
encoding 0 VERB F
flavin 0 NOUN F
monooxygenase 0 NOUN F
3 0 NUM F
( 0 PUNCT F
FMO3 0 NOUN T
) 0 PUNCT F
, 0 PUNCT F
a 0 DET F
hepatic 0 ADJ F
microsomal 0 ADJ F
enzyme 0 NOUN F
that 0 PUNCT F
inactivates 0 NOUN F
sulindac 0 NOUN F
, 0 PUNCT F
played 0 VERB F
a 0 DET F
role 0 NOUN F
in 0 ADP F
determining 0 VERB F
the 0 DET F
efficacy 0 NOUN F
of 0 ADP F
sulindac 0 NOUN F
in 0 ADP F
preventing 0 VERB F
polyposis 0 NOUN F
in 0 ADP F
this 0 DET F
cohort 0 NOUN F
of 0 ADP F
FAP 0 NOUN T
patients 0 NOUN F
. 0 PUNCT F

EXPERIMENTAL 0 ADJ T
DESIGN 0 NOUN T
Genotyping 0 PROPN T
was 0 VERB F
performed 0 VERB F
on 0 ADP F
seven 0 NUM F
established 0 ADP F
FMO3 0 NOUN T
polymorphisms 0 NOUN F
previously 0 ADV F
shown 0 VERB F
to 0 DET F
have 0 PUNCT F
functional 0 ADJ F
relevance-M66I 0 NOUN F
, 0 PUNCT F
P153L 0 NOUN T
, 0 PUNCT F
E158K 0 NOUN T
, 0 PUNCT F
V257M 0 NOUN T
, 0 PUNCT F
E305X 0 NOUN T
, 0 PUNCT F
E308G 0 NOUN T
, 0 PUNCT F
and 0 CCONJ F
R492W-in 0 ADJ T
21 0 NUM F
and 0 CCONJ F
20 0 NUM F
FAP 0 NOUN T
patients 0 NOUN F
, 0 PUNCT F
who 0 PROPN F
received 0 VERB F
sulindac 0 NOUN F
and 0 CCONJ F
placebo 0 NOUN F
, 0 PUNCT F
respectively 0 ADV F
. 0 PUNCT F

RESULTS 0 NOUN T
None 0 PUNCT T
of 0 ADP F
the 0 DET F
41 0 NUM F
patients 0 NOUN F
exhibited 0 VERB F
heterozygous B-PHYSICAL ADJ F
or 0 CCONJ F
homozygous B-PHYSICAL ADJ F
M66I I-PHYSICAL NOUN T
and 0 CCONJ F
R492W B-PHYSICAL NOUN T
variant I-PHYSICAL ADJ F
alleles I-PHYSICAL NOUN F
, 0 PUNCT F
or 0 PUNCT F

Determinants 0 NOUN T
of 0 ADP F
the 0 DET F
effect 0 NOUN F
of 0 ADP F
estrogen 0 NOUN F
on 0 ADP F
the 0 DET F
progression 0 NOUN F
of 0 ADP F
subclinical B-PHYSICAL ADJ F
atherosclerosis I-PHYSICAL NOUN F
: 0 PUNCT F
Estrogen 0 NOUN T
in 0 ADP F
the 0 DET F
Prevention 0 NOUN T
of 0 ADP F
Atherosclerosis 0 NOUN T
Trial 0 NOUN T
. 0 PUNCT F

OBJECTIVE 0 NOUN T
To 0 PROPN T
determine 0 NOUN F
the 0 DET F
extent 0 NOUN F
to 0 ADP F
which 0 VERB F
the 0 DET F
estrogen-induced 0 VERB F
changes 0 NOUN F
in 0 ADP F
lipids 0 NOUN F
and 0 CCONJ F
markers 0 NOUN F
of 0 ADP F
carbohydrate 0 NOUN F
metabolism 0 NOUN F
explain 0 VERB F
the 0 DET F
beneficial 0 ADJ F
effect 0 NOUN F
of 0 ADP F
estrogen 0 NOUN F
therapy 0 NOUN F
on 0 ADP F
the 0 DET F
progression 0 NOUN F
of 0 ADP F
carotid B-PHYSICAL ADJ F
artery I-PHYSICAL NOUN F
intima-media I-PHYSICAL ADP F
thickness I-PHYSICAL NOUN F
( I-PHYSICAL PUNCT F
IMT I-PHYSICAL NOUN T
) I-PHYSICAL PUNCT F
in 0 ADP F
postmenopausal 0 ADJ F
women 0 NOUN F
. 0 PUNCT F

DESIGN 0 NOUN T
A 0 NOUN T
randomized 0 VERB F
, 0 PUNCT F
double-blind 0 ADJ F
, 0 PUNCT F
placebo-controlled 0 VERB F
, 0 PUNCT F
single-center 0 ADP F
trial 0 NOUN F
enrolling 0 CCONJ F
222 0 NUM F
postmenopausal 0 ADJ F
women 0 NOUN F
45 0 NUM F
years 0 NOUN F
and 0 CCONJ F
older 0 PUNCT F
without 0 ADP F
cardiovascular 0 ADJ F
disease 0 NOUN F
and 0 CCONJ F
with 0 ADP F
low-density 0 NOUN F
lipoprotein 0 NOUN F
( 0 PUNCT F
LDL 0 NOUN T
) 0 PUNCT F
cholesterol 0 NOUN F
levels 0 NOUN F
of 0 ADP F
3.37 0 NUM F
mmol/L 0 NOUN F
or 0 CCONJ F
greater 0 PUNCT F
( 0 PUNCT F
> 0 PROPN F
or 0 CCONJ F
= 0 SYM F
130 0 NUM F
mg/dL 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

Intervention 0 NOUN T
was 0 VERB F
unopposed 0 VERB F
micronized 0 VERB F
17beta-estradiol 0 NOUN F
versus 0 CCONJ F
placebo 0 NOUN F
. 0 PUNCT F

Measurements 0 NOUN T
were 0 VERB F
made 0 VERB F
using 0 ADP F
high-resolution 0 NOUN F
B-mode 0 NOUN T
ultrasonography 0 NOUN F
to 0 PART F
measure 0 ADJ F
carotid B-PHYSICAL ADJ F
artery I-PHYSICAL NOUN F
IMT I-PHYSICAL NOUN T
at 0 ADP F
baseline 0 NOUN F
and 0 CCONJ F
every 0 DET F
6 0 NUM F
months 0 NOUN F
on-trial 0 ADJ F
. 0 PUNCT F

RESULTS 0 NOUN T
Progression 0 NOUN T
of 0 ADP F
carotid B-PHYSICAL ADJ F
IMT I-PHYSICAL NOUN T
was 0 ADJ F
inversely 0 ADV F
related 0 ADP F
to 0 ADP F
on-trial 0 ADJ F
high-density B-PHYSICAL NOUN F
lipoprotein I-PHYSICAL NOUN F
( I-PHYSICAL PUNCT F
HDL I-PHYSICAL NOUN T
) I-PHYSICAL PUNCT F
cholesterol I-PHYSICAL NOUN F
( 0 PUNCT F
P 0 NOUN T
= 0 SYM F
0.04 0 NUM F
) 0 PUNCT F
and 0 CCONJ F
was 0 VERB F
directly 0 ADV F
related 0 VERB F
to 0 ADP F
on-trial 0 ADJ F
LDL-cholesterol 0 NOUN T
( 0 PUNCT F
P 0 NOUN T
= 0 SYM F
0.005 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Compared 0 VERB T
with 0 ADP F
placebo 0 NOUN F
, 0 PUNCT F
women 0 NOUN F
randomized 0 ADP F
to 0 ADP F
estradiol 0 NOUN F
showed 0 VERB F
a 0 DET F
higher 0 PUNCT F
mean 0 NOUN F
on-trial 0 ADJ F
HDL-cholesterol B-PHYSICAL NOUN T
level I-PHYSICAL NOUN F
and 0 CCONJ F
a 0 DET F
lower 0 PUNCT F
mean 0 NOUN F
on-trial 0 ADJ F
LDL-cholesterol B-PHYSICAL NOUN T
level I-PHYSICAL NOUN F
. 0 PUNCT F

In 0 ADP T
contrast 0 NOUN F
, 0 PUNCT F
fasting B-PHYSICAL VERB F
glucose I-PHYSICAL NOUN F
, 0 PUNCT F
insulin B-PHYSICAL NOUN F
, 0 PUNCT F
and 0 CCONJ F
hemoglobin B-PHYSICAL NOUN F
A1C I-PHYSICAL NOUN T
were 0 VERB F
lowered 0 VERB F
and 0 CCONJ F
insulin 0 NOUN F
sensitivity 0 NOUN F
increased 0 VERB F
with 0 ADP F
estradiol 0 NOUN F
therapy 0 NOUN F
, 0 PUNCT F
but 0 CCONJ F
the 0 DET F
changes 0 NOUN F
were 0 VERB F
not 0 ADV F
related 0 PUNCT F
to 0 ADP F
carotid 0 CCONJ F
IMT 0 NOUN T
progression 0 NOUN F
. 0 PUNCT F

On-trial 0 ADJ T
HDL-cholesterol B-PHYSICAL NOUN T
and 0 CCONJ F
LDL-cholesterol B-PHYSICAL NOUN T
were 0 VERB F
significant 0 ADJ F
independent 0 ADJ F
determinants 0 NOUN F
of 0 ADP F
carotid B-PHYSICAL ADJ F
IMT I-PHYSICAL NOUN T
progression 0 NOUN F
, 0 PUNCT F
jointly 0 ADV F
explaining 0 VERB F
30 0 NUM F
% 0 SYM F
of 0 ADP F
the 0 DET F
treatment 0 NOUN F
effect 0 NOUN F
of 0 ADP F
unopposed 0 VERB F
estrogen 0 NOUN F
on 0 ADP F
the 0 DET F
progression 0 NOUN F
of 0 ADP F
carotid B-PHYSICAL ADJ F
IMT I-PHYSICAL NOUN T
. 0 PUNCT F

CONCLUSION 0 NOUN T
Unopposed 0 NOUN T
17beta-estradiol 0 NOUN F
reduced 0 VERB F
carotid B-PHYSICAL ADJ F
IMT I-PHYSICAL NOUN T
progression 0 NOUN F
in 0 ADP F
postmenopausal 0 ADJ F
women 0 NOUN F
in 0 ADP F
part 0 NOUN F
by 0 ADP F
increasing 0 VERB F
HDL-cholesterol B-PHYSICAL NOUN T
and 0 CCONJ F
decreasing 0 ADJ F
LDL-cholesterol B-PHYSICAL NOUN T
. 0 PUNCT F

Although 0 ADP T
women 0 NOUN F
randomized 0 ADP F
to 0 ADP F
estradiol 0 NOUN F
showed 0 VERB F
improvement 0 NOUN F
in 0 ADP F
all 0 DET F
the 0 DET F
markers 0 NOUN F
of 0 ADP F
carbohydrate 0 NOUN F
metabolism 0 NOUN F
, 0 PUNCT F
these 0 DET F
factors 0 NOUN F
did 0 VERB F
not 0 ADV F
play 0 VERB F
a 0 DET F
significant 0 ADJ F
role 0 NOUN F
in 0 ADP F
carotid B-PHYSICAL ADJ F
IMT I-PHYSICAL NOUN T
progression 0 NOUN F
. 0 PUNCT F

Skin B-PHYSICAL NOUN T
manifestations I-PHYSICAL NOUN F
of I-PHYSICAL ADP F
inhaled I-PHYSICAL VERB F
corticosteroids I-PHYSICAL NOUN F
in 0 ADP F
COPD 0 NOUN T
patients 0 NOUN F
: 0 PUNCT F
results 0 DET F
from 0 ADP F
Lung 0 NOUN T
Health 0 NOUN T
Study 0 NOUN T
II 0 NUM T
. 0 PUNCT F

OBJECTIVE 0 NOUN T
To 0 ADJ T
define 0 NOUN F
the 0 DET F
relationship 0 NOUN F
between 0 ADP F
skin B-ADVERSE-EFFECTS NOUN F
bruising I-ADVERSE-EFFECTS ADJ F
( B-PHYSICAL PUNCT F
as I-PHYSICAL PUNCT F
well I-PHYSICAL PUNCT F
as I-PHYSICAL CCONJ F
other 0 ADJ F
cutaneous B-ADVERSE-EFFECTS ADJ F
manifestations I-ADVERSE-EFFECTS NOUN F
) 0 PUNCT F
and 0 CCONJ F
inhaled 0 DET F
corticosteroid 0 NOUN F
( 0 PUNCT F
ICS 0 NOUN T
) 0 PUNCT F
therapy 0 NOUN F
vs 0 CCONJ F
placebo 0 NOUN F
in 0 ADP F
subjects 0 NOUN F
with 0 ADP F
COPD 0 NOUN T
who 0 ADP F
were 0 VERB F
participating 0 VERB F
in 0 ADP F
a 0 DET F
clinical 0 ADJ F
trial 0 NOUN F
. 0 PUNCT F

To 0 PART T
explore 0 CCONJ F
the 0 DET F
relationship 0 NOUN F
between 0 ADP F
easy B-PHYSICAL CCONJ F
skin I-PHYSICAL NOUN F
bruising I-PHYSICAL ADP F
and 0 CCONJ F
other 0 ADJ F
systemic B-PHYSICAL ADJ F
effects I-PHYSICAL NOUN F
of I-PHYSICAL ADP F
ICS I-PHYSICAL NOUN T
therapy I-PHYSICAL NOUN F
, 0 PUNCT F
including 0 CCONJ F
adrenal B-ADVERSE-EFFECTS ADJ F
suppression I-ADVERSE-EFFECTS NOUN F
and 0 CCONJ F
loss 0 NOUN F
of 0 ADP F
bone B-ADVERSE-EFFECTS NOUN F
mineral I-ADVERSE-EFFECTS NOUN F
density I-ADVERSE-EFFECTS NOUN F
( I-ADVERSE-EFFECTS PUNCT F
BMD I-ADVERSE-EFFECTS NOUN T
) 0 PUNCT F
. 0 PUNCT F

DESIGN 0 NOUN T
Double-blind 0 ADJ T
, 0 PUNCT F
randomized 0 VERB F
, 0 PUNCT F
placebo-controlled 0 VERB F
clinical 0 ADJ F
trial 0 NOUN F
of 0 ADP F
triamcinolone 0 ADV F
acetonide 0 NOUN F
( 0 PUNCT F
1200 0 NUM F
microg 0 NOUN F
daily 0 ADJ F
) 0 PUNCT F
vs 0 CCONJ F
placebo 0 NOUN F
in 0 ADP F
participants 0 NOUN F
with 0 ADP F
mild-to-moderate 0 ADJ F
COPD 0 NOUN T
. 0 PUNCT F

SETTING 0 NUM T
Lung 0 NOUN T
Health 0 NOUN T
Study 0 NOUN T
II 0 NUM T
, 0 PUNCT F
a 0 DET F
clinical 0 ADJ F
trial 0 NOUN F
to 0 PART F
assess 0 NOUN F
the 0 DET F
effect 0 NOUN F
of 0 ADP F
ICS 0 NOUN T
compared 0 VERB F
to 0 ADP F
placebo 0 NOUN F
in 0 ADP F
1,116 0 NUM F
participants 0 NOUN F
in 0 ADP F
10 0 NUM F
centers 0 NOUN F
over 0 ADP F
> 0 ADP F
3.5 0 NUM F
to 0 ADP F
4.5 0 NUM F
years 0 NOUN F
. 0 PUNCT F

PARTICIPANTS 0 ADP T
A 0 PUNCT T
total 0 NOUN F
of 0 ADP F
1,116 0 NUM F
smokers 0 NOUN F
or 0 CCONJ F
recent 0 ADJ F
ex-smokers 0 NOUN F
with 0 ADP F
mild-to-moderate 0 ADJ F
COPD 0 NOUN T
( 0 PUNCT F
age 0 NOUN F
range 0 NOUN F
, 0 PUNCT F
40 0 NUM F
to 0 ADP F
69 0 NUM F
years 0 NOUN F
; 0 PUNCT F
mean 0 NOUN F
age 0 NOUN F
, 0 PUNCT F
56.3 0 NUM F
years 0 NOUN F
; 0 PUNCT F
37.2 0 NUM F
% 0 SYM F
female 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

MEASUREMENTS 0 ADP T
AND 0 CCONJ T
RESULTS 0 PUNCT T
Every 0 DET T
6 0 NUM F
months 0 NOUN F
, 0 PUNCT F
a 0 DET F
structured 0 VERB F
questionnaire 0 NOUN F
was 0 VERB F
administered 0 VERB F
to 0 PUNCT F
elicit 0 ADP F
reports 0 NOUN F
of 0 ADP F
any 0 DET F
bruising B-ADVERSE-EFFECTS PUNCT F
and/or I-ADVERSE-EFFECTS CCONJ F
skin I-ADVERSE-EFFECTS NOUN F
rashes I-ADVERSE-EFFECTS PUNCT F
, 0 PUNCT F
slow B-ADVERSE-EFFECTS ADJ F
healing I-ADVERSE-EFFECTS DET F
of I-ADVERSE-EFFECTS ADP F
cuts I-ADVERSE-EFFECTS ADJ F
or 0 CCONJ F
sores B-ADVERSE-EFFECTS NOUN F
, 0 PUNCT F
or B-PHYSICAL CCONJ F
other 0 ADJ F
skin B-ADVERSE-EFFECTS NOUN F
changes I-ADVERSE-EFFECTS NOUN F
. 0 PUNCT F

Compliance 0 NOUN T
with 0 ADP F
inhaler 0 ADJ F
use 0 NOUN F
was 0 VERB F
assessed 0 VERB F
by 0 ADP F
canister 0 PUNCT F
weighing 0 CCONJ F
. 0 PUNCT F

A 0 PUNCT T
significantly 0 ADV F
higher 0 PUNCT F
proportion 0 NOUN F
of 0 ADP F
ICS 0 NOUN T
than 0 PUNCT F
placebo 0 NOUN F
participants 0 NOUN F
who 0 ADP F
complied 0 PUNCT F
with 0 ADP F
using 0 ADP F
their 0 NOUN F
inhaler 0 ADJ F
reported 0 PUNCT F
easy B-ADVERSE-EFFECTS PUNCT F
bruising I-ADVERSE-EFFECTS ADJ F
( 0 PUNCT F
11.2 0 NUM F
% 0 SYM F
vs 0 CCONJ F
3.5 0 NUM F
% 0 SYM F
, 0 PUNCT F
respectively 0 ADV F
) 0 PUNCT F
and 0 CCONJ F
the 0 DET F
slow B-ADVERSE-EFFECTS ADJ F
healing I-ADVERSE-EFFECTS VERB F
of I-ADVERSE-EFFECTS ADP F
skin I-ADVERSE-EFFECTS NOUN F
cuts I-ADVERSE-EFFECTS PROPN F
or 0 CCONJ F
sores B-ADVERSE-EFFECTS NOUN F
( 0 PUNCT F
2.4 0 NUM F
% 0 SYM F
vs 0 CCONJ F
0.5 0 NUM F
% 0 SYM F
, 0 PUNCT F
respectively 0 ADV F
) 0 PUNCT F
. 0 PUNCT F

Older 0 PUNCT T
men 0 NOUN F
in 0 ADP F
the 0 DET F
ICS 0 NOUN T
group 0 NOUN F
with 0 ADP F
good 0 ADJ F
inhaler 0 ADJ F
compliance 0 NOUN F
appeared 0 VERB F
to 0 PART F
be 0 PUNCT F
at 0 ADP F
the 0 DET F
greatest 0 PUNCT F
risk 0 NOUN F
of 0 ADP F
bruising B-ADVERSE-EFFECTS SYM F
. 0 PUNCT F

In 0 ADP T
those 0 PUNCT F
participants 0 NOUN F
undergoing 0 VERB F
serial 0 ADJ F
measurements 0 NOUN F
of 0 ADP F
adrenal 0 ADJ F
function 0 NOUN F
and 0 CCONJ F
BMD 0 NOUN T
, 0 PUNCT F
no 0 DET F
association 0 NOUN F
was 0 VERB F
noted 0 VERB F
between 0 ADP F
skin B-ADVERSE-EFFECTS NOUN F
bruising I-ADVERSE-EFFECTS ADP F
and 0 CCONJ F
either 0 CCONJ F
the 0 DET F
suppression 0 NOUN F
of 0 ADP F
adrenal B-ADVERSE-EFFECTS ADJ F
function I-ADVERSE-EFFECTS NOUN F
or 0 CCONJ F
the 0 DET F
loss B-ADVERSE-EFFECTS NOUN F
of I-ADVERSE-EFFECTS ADP F
BMD I-ADVERSE-EFFECTS NOUN T
as 0 PUNCT F
systemic 0 ADJ F
complications 0 NOUN F
of 0 ADP F
ICS 0 NOUN T
use 0 NOUN F
. 0 PUNCT F

CONCLUSION 0 NOUN T
These 0 DET T
findings 0 NOUN F
indicate 0 VERB F
that 0 ADP F
moderate-to-high 0 ADJ F
doses 0 NOUN F
of 0 ADP F
ICSs 0 NOUN T
result 0 VERB F
in 0 ADP F
an 0 DET F
increased 0 VERB F
incidence 0 NOUN F
of 0 ADP F
easy B-ADVERSE-EFFECTS ADP F
bruising I-ADVERSE-EFFECTS DET F
and 0 CCONJ F
impairment 0 NOUN F
in 0 ADP F
skin B-ADVERSE-EFFECTS NOUN F
healing I-ADVERSE-EFFECTS VERB F
in 0 ADP F
middle-aged 0 NOUN F
to 0 ADP F
elderly 0 ADP F
persons 0 NOUN F
with 0 ADP F
COPD 0 NOUN T
. 0 PUNCT F

No 0 DET T
association 0 NOUN F
was 0 VERB F
noted 0 VERB F
between 0 ADP F
skin B-ADVERSE-EFFECTS NOUN F
bruising I-ADVERSE-EFFECTS ADP F
and 0 CCONJ F
other 0 ADJ F
markers 0 NOUN F
of 0 ADP F
systemic B-ADVERSE-EFFECTS ADJ F
toxicity I-ADVERSE-EFFECTS NOUN F
from 0 ADP F
the 0 DET F
use 0 NOUN F
of 0 ADP F
ICSs 0 NOUN T
. 0 PUNCT F

A 0 DET T
phase 0 NOUN F
III 0 NUM T
, 0 PUNCT F
double-blind 0 ADJ F
, 0 PUNCT F
placebo-controlled 0 VERB F
, 0 PUNCT F
multicenter 0 NOUN F
study 0 NOUN F
on 0 ADP F
the 0 DET F
efficacy 0 NOUN F
of 0 ADP F
recombinant 0 ADJ F
human 0 NOUN F
antithrombin 0 NOUN F
in 0 ADP F
heparin-resistant 0 ADJ F
patients 0 NOUN F
scheduled 0 DET F
to 0 PART F
undergo 0 VERB F
cardiac 0 ADJ F
surgery 0 NOUN F
necessitating 0 PUNCT F
cardiopulmonary 0 ADJ F
bypass 0 NOUN F
. 0 PUNCT F

BACKGROUND 0 NOUN T
The 0 DET T
study 0 NOUN F
evaluated 0 VERB F
the 0 DET F
efficacy 0 NOUN F
of 0 ADP F
recombinant 0 ADJ F
human 0 NOUN F
antithrombin 0 NOUN F
( 0 PUNCT F
rhAT 0 NOUN F
) 0 PUNCT F
for 0 ADP F
restoring 0 ADV F
heparin B-PHYSICAL NOUN F
responsiveness I-PHYSICAL NOUN F
in 0 ADP F
heparin 0 NOUN F
resistant 0 ADJ F
patients 0 NOUN F
undergoing 0 VERB F
cardiac 0 ADJ F
surgery 0 NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
This 0 PUNCT T
was 0 VERB F
a 0 DET F
multicenter 0 NOUN F
, 0 PUNCT F
randomized 0 VERB F
, 0 PUNCT F
double-blind 0 ADJ F
, 0 PUNCT F
placebo-controlled 0 VERB F
study 0 NOUN F
in 0 ADP F
heparin-resistant 0 ADJ F
patients 0 NOUN F
undergoing 0 VERB F
cardiac 0 ADJ F
surgery 0 NOUN F
with 0 ADP F
cardiopulmonary 0 ADJ F
bypass 0 NOUN F
. 0 PUNCT F

Heparin 0 NOUN T
resistance 0 NOUN F
was 0 VERB F
diagnosed 0 VERB F
when 0 ADP F
the 0 DET F
activated 0 VERB F
clotting 0 DET F
time 0 NOUN F
was 0 VERB F
less 0 ADV F
than 0 PUNCT F
480 0 NUM F
s 0 NOUN F
after 0 ADP F
400 0 NUM F
U/kg 0 ADV T
heparin 0 NOUN F
. 0 PUNCT F

Fifty-four 0 NUM T
heparin-resistant 0 ADJ F
patients 0 NOUN F
were 0 VERB F
randomized 0 VERB F
. 0 PUNCT F

One 0 NUM T
cohort 0 NOUN F
received 0 VERB F
75 0 NUM F
U/kg 0 NOUN T
rhAT 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
the 0 DET F
other 0 ADJ F
received 0 VERB F
normal 0 ADJ F
saline 0 NOUN F
. 0 PUNCT F

If 0 ADP T
the 0 DET F
activated 0 VERB F
clotting 0 DET F
time 0 NOUN F
remained 0 VERB F
less 0 ADV F
than 0 ADP F
480 0 NUM F
s 0 NOUN F
, 0 PUNCT F
this 0 DET F
was 0 NUM F
considered 0 PUNCT F
treatment 0 NOUN F
failure 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
2 0 NUM F
units 0 NOUN F
fresh 0 ADJ F
frozen 0 VERB F
plasma 0 NOUN F
was 0 VERB F
transfused 0 VERB F
. 0 PUNCT F

Patients 0 NOUN T
were 0 VERB F
monitored 0 VERB F
for 0 ADP F
adverse 0 ADJ F
events 0 NOUN F
. 0 PUNCT F

RESULTS 0 NOUN T
Only 0 ADJ T
19 0 NUM F
% 0 SYM F
of 0 ADP F
patients 0 NOUN F
in 0 ADP F
the 0 DET F
rhAT 0 NOUN F
group 0 NOUN F
received 0 ADP F
fresh 0 ADJ F
frozen 0 VERB F
plasma 0 NOUN F
, 0 PUNCT F
compared 0 VERB F
with 0 ADP F
81 0 NUM F
% 0 SYM F
of 0 ADP F
patients 0 NOUN F
in 0 ADP F
the 0 DET F
placebo 0 NOUN F
group 0 NOUN F
( 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.001 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

During 0 ADP T
their 0 PUNCT F
hospitalization 0 NOUN F
, 0 PUNCT F
48 0 NUM F
% 0 SYM F
of 0 ADP F
patients 0 NOUN F
in 0 ADP F
the 0 DET F
rhAT 0 NOUN F
group 0 NOUN F
received 0 ADP F
fresh 0 ADJ F
frozen 0 VERB F
plasma 0 NOUN F
, 0 PUNCT F
compared 0 VERB F
with 0 ADP F
85 0 NUM F
% 0 SYM F
of 0 ADP F
patients 0 NOUN F
in 0 ADP F
the 0 DET F
placebo 0 NOUN F
group 0 NOUN F
( 0 PUNCT F
P 0 NOUN T
= 0 SYM F
0.009 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Patients 0 NOUN T
in 0 ADP F
the 0 DET F
placebo 0 NOUN F
group 0 NOUN F
required 0 VERB F
higher 0 PUNCT F
heparin 0 NOUN F
doses 0 NOUN F
( 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.005 0 NUM F
) 0 PUNCT F
for 0 ADP F
anticoagulation 0 NOUN F
. 0 PUNCT F

There 0 PUNCT T
was 0 VERB F
no 0 DET F
increase 0 NOUN F
in 0 ADP F
serious 0 ADJ F
adverse 0 ADJ F
events 0 NOUN F
associated 0 VERB F
with 0 ADP F
rhAT 0 NOUN F
. 0 PUNCT F

There 0 PUNCT T
was 0 VERB F
increased 0 VERB F
blood B-PHYSICAL NOUN F
loss I-PHYSICAL NOUN F
12 0 NUM F
h 0 NOUN F
postoperatively 0 NOUN F
( 0 PUNCT F
P 0 NOUN T
= 0 SYM F
0.05 0 NUM F
) 0 PUNCT F
with 0 ADP F
a 0 DET F
trend 0 NOUN F
toward 0 ADP F
increased 0 NOUN F
24-h B-PHYSICAL NOUN F
bleeding I-PHYSICAL VERB F
in 0 ADP F
the 0 DET F
rhAT 0 NOUN F
group 0 NOUN F
( 0 PUNCT F
P 0 NOUN T
= 0 SYM F
0.06 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

There 0 PUNCT T
was 0 VERB F
no 0 DET F
difference 0 NOUN F
between 0 ADP F
the 0 DET F
groups 0 NOUN F
in 0 ADP F
blood 0 NOUN F
and 0 CCONJ F
platelet 0 NOUN F
transfusions 0 NOUN F
. 0 PUNCT F

CONCLUSION 0 NOUN T
Treatment 0 NOUN T
with 0 ADP F
75 0 NUM F
U/kg 0 NOUN T
rhAT 0 NOUN F
is 0 VERB F
effective B-PHYSICAL ADJ F
in I-PHYSICAL ADP F
restoring I-PHYSICAL ADV F
heparin I-PHYSICAL NOUN F
responsiveness I-PHYSICAL NOUN F
and 0 CCONJ F
promoting 0 VERB F
therapeutic B-PHYSICAL ADJ F
anticoagulation I-PHYSICAL NOUN F
in 0 ADP F
the 0 DET F
majority 0 NOUN F
of 0 ADP F
heparin-resistant 0 ADJ F
patients 0 NOUN F
. 0 PUNCT F

Treating 0 VERB T
heparin-resistant 0 ADJ F
patients 0 NOUN F
with 0 ADP F
rhAT 0 NOUN F
may 0 ADP F
decrease 0 VERB F
the B-PHYSICAL DET F
requirement I-PHYSICAL NOUN F
for I-PHYSICAL ADP F
heparin I-PHYSICAL NOUN F
and 0 CCONJ F
fresh 0 ADJ F
frozen 0 VERB F
plasma 0 NOUN F
. 0 PUNCT F

